<SEC-DOCUMENT>0000875045-16-000042.txt : 20160203
<SEC-HEADER>0000875045-16-000042.hdr.sgml : 20160203
<ACCEPTANCE-DATETIME>20160203162552
ACCESSION NUMBER:		0000875045-16-000042
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		187
CONFORMED PERIOD OF REPORT:	20151231
FILED AS OF DATE:		20160203
DATE AS OF CHANGE:		20160203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		161385193

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>biib-20151231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>10-K</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s855A4AE682BA56B5D8A2B512B0468886"></a><div></div><br><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:14pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Washington,&#160;D.C. 20549</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:18pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">Form&#160;10-K</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="6%"></td><td width="94%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">For the fiscal year ended December 31, 2015</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">or</font></div><div style="line-height:100%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="6%"></td><td width="94%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Commission file number:&#160;0-19311</font></div><div style="line-height:100%;padding-top:4px;text-align:center;"><img src="biogenlogostandard.jpg" style="height:57px;width:173px;"></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:24pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="1%"></td><td width="50%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">33-0112644</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(State or other jurisdiction of incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(I.R.S. Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">225 Binney Street, Cambridge, Massachusetts 02142</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(617)&#160;679-2000</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices)</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(b) of the Act:</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="1%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Title of Each Class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Name of Each Exchange on Which Registered</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Common Stock, $0.0005&#160;par value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">The Nasdaq Global Select Market</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(g) of the Act:</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">None</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files):&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation&#160;S-K is not contained herein, and will not be contained, to the best of the registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part&#160;III of this Form&#160;10-K or any amendment to this Form&#160;10-K.&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:100%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.81481481481481%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="20%"></td><td width="1%"></td><td width="17%"></td><td width="1%"></td><td width="35%"></td><td width="1%"></td><td width="25%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Large&#160;accelerated&#160;filer&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accelerated&#160;filer </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-accelerated&#160;filer </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Smaller&#160;reporting&#160;company&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(Do&#160;not&#160;check&#160;if&#160;a&#160;smaller&#160;reporting&#160;company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate) computed by reference to the price at which the common stock was last sold as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$94,898,425,323</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">January&#160;29, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the registrant had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218,672,717</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock, $0.0005&#160;par value, outstanding.</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Portions of the definitive proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this report.</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><br><div></div><hr style="page-break-after:always"><a name="sE97C750BE869328FBA03B512B099B381"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">ANNUAL REPORT ON FORM&#160;10-K</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">For the Year Ended December 31, 2015</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">TABLE OF CONTENTS</font></div></div><br><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="9%"></td><td width="76%"></td><td width="15%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#s1FF29E08DDAF0F7C756BB512B13F13FE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;I</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA30F171FDE9DE638C657B512B1605F7B"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA30F171FDE9DE638C657B512B1605F7B"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Business</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA30F171FDE9DE638C657B512B1605F7B">1</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB7A45A12C24CD940C931B512B19484BB"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item&#160;1A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB7A45A12C24CD940C931B512B19484BB"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sB7A45A12C24CD940C931B512B19484BB">32</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s0385BCC5E1B9C0B157E0B512B1B42919"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1B.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s0385BCC5E1B9C0B157E0B512B1B42919"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unresolved Staff Comments</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s0385BCC5E1B9C0B157E0B512B1B42919">43</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sC687E45A6F2B9BCD0321B512B1E5BCA7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sC687E45A6F2B9BCD0321B512B1E5BCA7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Properties</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sC687E45A6F2B9BCD0321B512B1E5BCA7">44</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sBEC0910FD4B23026A848B512B2074C81"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 3.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sBEC0910FD4B23026A848B512B2074C81"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sBEC0910FD4B23026A848B512B2074C81">45</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s873CCF7CF63944374399B512B238B973"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 4.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s873CCF7CF63944374399B512B238B973"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s873CCF7CF63944374399B512B238B973">45</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#s3D24CA0B08FF4F441AECB512B25A6EB0"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;II</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s20BFD3EA5B810DB0EDBDB512946DF050"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 5.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s20BFD3EA5B810DB0EDBDB512946DF050"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s20BFD3EA5B810DB0EDBDB512946DF050">46</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s85C4959389BAE93A2BADB5129E5FAA23"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 6.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s85C4959389BAE93A2BADB5129E5FAA23"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selected Financial Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s85C4959389BAE93A2BADB5129E5FAA23">48</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s362F9929E4D04E9C8998B5129FD6EC34"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 7.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s362F9929E4D04E9C8998B5129FD6EC34"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s362F9929E4D04E9C8998B5129FD6EC34">50</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE3382155A37CE1C4B200B512B6413B7F"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 7A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE3382155A37CE1C4B200B512B6413B7F"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE3382155A37CE1C4B200B512B6413B7F">81</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s81FA614DD88CE6C8E7D8B512B673F865"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 8.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s81FA614DD88CE6C8E7D8B512B673F865"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s81FA614DD88CE6C8E7D8B512B673F865">83</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s3911AF88B9C9E495C2DAB512B69486B0"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 9.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s3911AF88B9C9E495C2DAB512B69486B0"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s3911AF88B9C9E495C2DAB512B69486B0">83</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sDC1FCBC3C831A9733142B512B6C6F1D9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 9A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sDC1FCBC3C831A9733142B512B6C6F1D9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sDC1FCBC3C831A9733142B512B6C6F1D9">84</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s9A1F6C3CE62A468AB47DB512B6E8AB5D"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 9B.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s9A1F6C3CE62A468AB47DB512B6E8AB5D"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s9A1F6C3CE62A468AB47DB512B6E8AB5D">84</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#s8BB64F87AB14E13A6619B512B71A9914"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;III</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s4B0D7A20CE44B30FB528B512B73BB67A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 10.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s4B0D7A20CE44B30FB528B512B73BB67A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Directors, Executive Officers and Corporate Governance</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s4B0D7A20CE44B30FB528B512B73BB67A">86</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s618E8C79488147527486B512B76DAD39"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 11.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s618E8C79488147527486B512B76DAD39"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Compensation</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s618E8C79488147527486B512B76DAD39">86</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s83AD573B8DDA064779F5B512B78E1769"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 12.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s83AD573B8DDA064779F5B512B78E1769"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s83AD573B8DDA064779F5B512B78E1769">86</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s6031CF6B6738C619B0B5B512B7C09D40"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 13.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s6031CF6B6738C619B0B5B512B7C09D40"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s6031CF6B6738C619B0B5B512B7C09D40">86</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s5B43FC771D1AF56BFFCAB512B7E2965A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 14.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s5B43FC771D1AF56BFFCAB512B7E2965A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Principal Accounting Fees and Services</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s5B43FC771D1AF56BFFCAB512B7E2965A">86</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#sC9ADA8D49A749C17E525B512B814F67B"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;IV</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s61A2ACAD8E05C408D812B512B835B78D"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item&#160;15.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s61A2ACAD8E05C408D812B512B835B78D"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exhibits and Financial Statement Schedules</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s61A2ACAD8E05C408D812B512B835B78D">87</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sAB131B415CFDEFD36707B512B8672AA5"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Signatures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sAB131B415CFDEFD36707B512B8672AA5">88</a></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s92F0200CF9E772AC898DB512B8897B88"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s92F0200CF9E772AC898DB512B8897B88">F- 1</a></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sC7CE2221B2FBA0FCC50DB512BFE57186"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exhibit Index</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sC7CE2221B2FBA0FCC50DB512BFE57186">A- 1</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div></div><hr style="page-break-after:always"><a name="sF7A27E44C7FFDAD54F39B512B0BAB59A"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;will&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated amount, timing and accounting of revenues, contingent payments, milestone, royalty and other payments under licensing, collaboration or acquisition agreements, tax positions and contingencies, collectability of receivables, pre-approval inventory, cost of sales, research and development costs, compensation and other selling, general and administrative expenses, amortization of intangible assets, foreign currency exchange risk, estimated fair value of assets and liabilities, and impairment assessments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of increased product competition in the markets in which we compete;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the costs and timing of potential clinical trials, filing and approvals, and the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the drivers for growing our business, including our plans and intent to commit resources relating to business development opportunities and research and development programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated benefits, cost savings, and charges related to our corporate restructuring initiatives; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our manufacturing capacity, use of third-party contract manufacturing organizations and plans and timing relating to the expansion of our manufacturing capabilities, including anticipated investments and activities in new manufacturing facilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe and our collection of accounts receivable in such countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs to constrain the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to finance our operations and business initiatives and obtain funding for such activities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of new laws and accounting standards.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These forward-looking statements involve risks and uncertainties, including those that are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; section of this report, and elsewhere in this report that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</font></div><br><div></div><hr style="page-break-after:always"><a name="sC130EF78A16E5829AC7EB512B0EB8DA3"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Throughout this report, &#8220;Biogen,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. (formerly Biogen Idec Inc.) and its consolidated subsidiaries. References to &#8220;RITUXAN&#8221; refer to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan), and &#8220;ANGIOMAX&#8221; refers to both ANGIOMAX (the trade name for bivalirudin in the U.S., Canada and Latin America) and ANGIOX (the trade name for bivalirudin in Europe).</font></div><a name="s2F7302B09D6E0840D90BB512B10E10E6"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING TRADEMARKS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AVONEX</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, BENEPALI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ELOCTATE</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FLIXABI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, PLEGRIDY</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, RITUXAN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, TECFIDERA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and TYSABRI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;are registered trademarks of Biogen. FUMADERM</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and ZINBRYTA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;are trademarks of Biogen. Other trademarks referenced in this report are the property of their respective owners. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div></div><hr style="page-break-after:always"><a name="s1FF29E08DDAF0F7C756BB512B13F13FE"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;I</font></div><a name="sA30F171FDE9DE638C657B512B1605F7B"></a><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1. &#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-style:italic;font-weight:bold;">Business</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. We also have a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group (Roche Group), which entitles us to certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL, and other potential anti-CD20 therapies.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical expertise and scientific adjacencies. In addition to our innovative drug development efforts, we aim to leverage our manufacturing capabilities and scientific expertise to extend our mission to improve the lives of patients living with serious diseases through the development, manufacture and marketing of biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><a name="sd4f2862689c94e2b975347295f5229b7"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Key Developments</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015 and early 2016, we had a number of key developments affecting our business. </font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Corporate Matters</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Company Name Change</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2015, we changed our name from Biogen Idec Inc. to Biogen Inc.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Corporate Restructuring</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2015, we announced a corporate restructuring, which includes a reduction in workforce and discontinuation of certain programs. We are reinvesting the resulting savings to support key commercial activities and the advancement of our pipeline candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Capital Allocation</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2015, our capital allocation strategy included the following elements:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="14%"></td><td width="2%"></td><td width="84%"></td></tr><tr><td rowspan="2" style="vertical-align:middle;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Share Repurchase Program</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Returned approximately $5.0 billion to our shareholders through our share repurchase program</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Utilized a portion of the proceeds from our $6.0 billion senior unsecured debt offering completed in September 2015 to fund our share repurchase program</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Acquisitions and Collaborations</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired Convergence Pharmaceuticals (Convergence), a clinical-stage biopharmaceutical company with a focus on developing product candidates for neuropathic pain</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Obtained exclusive worldwide license, excluding Asia, from Mitsubishi Tanabe Pharma Corporation (MTPC) to amiselimod (MT-1303), a late stage experimental medicine with potential in multiple autoimmune indications</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Entered into a collaboration agreement with Applied Genetic Technologies Corporation (AGTC) to develop gene-based therapies for multiple ophthalmic diseases</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Investment in Manufacturing</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired land in Solothurn, Switzerland, where we plan to build a biologics manufacturing facility in the Commune of Luterbach over the next several years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired the drug product manufacturing facility and supporting infrastructure of Eisai, Inc. (Eisai) in Research Triangle Park (RTP), North Carolina</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Corporate Responsibility</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="environsustainability.jpg" style="height:152px;width:304px;"></div></td></tr><tr><td style="vertical-align:middle;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Environmental Sustainability</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2015, we were named the biotechnology industry leader on the Dow Jones Sustainability World Index, an index that tracks the economic, environmental and social strategy and performance of the 2,500 largest companies in the S&amp;P Global Broad Market Index.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2015, we announced that we achieved carbon neutrality, meaning we believe we have effectively neutralized all of the carbon emissions associated with our business.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="blooddrop.jpg" style="height:152px;width:101px;"></div></td></tr><tr><td style="vertical-align:middle;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Humanitarian Aid</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2014, we and Swedish Orphan Biovitrum AB (publ) (Sobi) began working with the World Federation of Hemophilia (WFH) to help people with hemophilia in the developing world through our pledge to donate up to one billion international units (IUs) of clotting factor therapy for humanitarian use, of which up to 500 million IUs will be donated to WFH USA over a period of five years. In 2015, we made the first shipments of hemophilia therapy to WFH USA.</font></div></div></div><br><a name="s9dab9244032d49cfb542ac070c065297"></a><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product/Pipeline Developments</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="5%"></td><td width="95%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Multiple Sclerosis</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">ZINBRYTA (daclizumab high yield process)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2015, the European Medicines Agency (EMA) validated our marketing authorization application (MAA) for ZINBRYTA for the treatment of relapsing forms of MS in the European Union (E.U.).</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015, the U.S. Food and Drug Administration (FDA) accepted our Biologics License Application (BLA) for ZINBRYTA for the treatment of relapsing forms of MS in the United States (U.S.).</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">TYSABRI (natalizumab)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015, the results of ACTION, our Phase 2 trial investigating TYSABRI in acute ischemic stroke, did not demonstrate an impact on change in infarct volume, the primary endpoint. Exploratory endpoints suggested that TYSABRI had a beneficial impact on patient functional deficits.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2015, the results of ASCEND, our Phase 3 study evaluating TYSABRI in secondary progressive MS (SPMS), did not achieve its primary and secondary endpoints, and the development of TYSABRI in SPMS was discontinued.</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Anti-LINGO</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2015, we announced top-line results from RENEW, our Phase 2 acute optic neuritis trial.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="5%"></td><td width="95%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#7f160e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Hemophilia</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">ELOCTATE</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">[Antihemophilic Factor (Recombinant), Fc Fusion Protein]</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2015, the European Commission (EC) approved ELOCTA, the approved trade name for ELOCTATE in the E.U., for the treatment of hemophilia A.  </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sobi has assumed final development and commercialization of ELOCTA in their territory, which essentially includes Europe, North Africa, Russia, and certain markets in the Middle East (Sobi Territory).</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">ALPROLIX</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">[Coagulation Factor IX (Recombinant), Fc Fusion Protein]</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015, the EMA validated our MAA for ALPROLIX for the treatment of hemophilia B.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015, Sobi exercised its option to assume final development and commercialization of ALPROLIX in the Sobi Territory.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="5%"></td><td width="95%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#679acb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Neurodegeneration</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Aducanumab (BIIB037)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2015 and July 2015, we announced data from pre-specified interim analyses of PRIME, our Phase 1b study of aducanumab. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015, we enrolled our first patient in our two global Phase 3 studies, ENGAGE and EMERGE, to assess the efficacy and safety of aducanumab in people with early Alzheimer's disease. In October 2015, we announced that we received FDA agreement on a special protocol assessment on the Phase 3 study protocols. Such agreement constitutes FDA&#8217;s concurrence on the design and size of the clinical trials which will form the basis for approval of aducanumab.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="5%"></td><td width="95%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Other Programs</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Nusinersen (ISIS-SMN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015, our collaborator, Ionis Pharmaceuticals, Inc. (Ionis), formerly known as Isis Pharmaceuticals, Inc., announced additional data from two Phase 2 studies of nusinersen for the treatment of SMA in infants and children. There are two ongoing Phase 3 studies of nusinersen.</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="5%"></td><td width="95%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Genentech Relationships</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">GAZYVA (obinutuzumab)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2015, the Roche Group announced positive results from its Phase 3 GADOLIN study of GAZYVA in non-Hodgkin&#8217;s lymphoma.</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Ocrelizumab</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015, the Roche Group announced positive results from two Phase 3 studies evaluating ocrelizumab compared with interferon beta-1a in people with relapsing forms of MS.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015, the Roche Group announced positive results from a Phase 3 study evaluating ocrelizumab in people with primary progressive MS (PPMS).</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under our agreement with Genentech, if ocrelizumab is approved, we will receive tiered royalty payments on sales of ocrelizumab.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="5%"></td><td width="95%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#578196;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Biosimilars (Samsung Bioepis - Biogen's Joint Venture with Samsung Biologics)</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BENEPALI</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2015, Samsung Bioepis received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the MAA for BENEPALI, an etanercept biosimilar referencing ENBREL. In January 2016, the EC approved the MAA for BENEPALI for marketing in the E.U. Under our agreement with Samsung Bioepis, we will manufacture and commercialize BENEPALI in specified E.U. countries.</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">FLIXABI</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2015, the EMA validated and accepted Samsung Bioepis&#8217; MAA for FLIXABI, an infliximab biosimilar candidate referencing REMICADE.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="5%"></td><td width="95%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Discontinued Programs</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015, we discontinued several programs, including our study of Neublastin in neuropathic pain, our Phase 3 program for TECFIDERA in SPMS, our Phase 3 program evaluating TYSABRI in SPMS, the development of anti-TWEAK in lupus nephritis, and certain activities in immunology and fibrosis research.</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><a name="s9175c51e28dd47c89222d9c51b831a3f"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Marketed Products</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following graphs show our product sales and unconsolidated joint business revenues by principal product and geography as a percentage of revenue for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-align:center;"><img src="principalproductschart.jpg" style="height:513px;width:317px;"></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(1) Other includes FAMPYRA, ELOCTATE, ALPROLIX and FUMADERM</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:center;"><img src="geographicsaleschart.jpg" style="height:408px;width:317px;"></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div></div><br><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product sales for TECFIDERA, AVONEX and TYSABRI and unconsolidated joint business revenues for RITUXAN each accounted for more than 10% of our total revenue for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional financial information about our product and other revenues and geographic areas in which we operate, please read Note&#160;24, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements, Item&#160;6. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Selected Financial Data </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and Item 7. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management's Discussion and Analysis of Financial Condition and Results of Operations </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">included in this report. A discussion of the risks attendant to our operations is set forth in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; section of this report. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><a name="s9175c51e28dd47c89222d9c51b831a3f"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We develop, manufacture and market a number of products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, leading to a loss of muscle control, paralysis and, in some cases, death. Patients with active relapsing MS experience an uneven pattern of disease progression characterized by periods of stability that are interrupted by flare-ups of the disease after which the patient returns to a new baseline of functioning. Our MS products and major markets include:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="28%"></td><td width="31%"></td><td width="1%"></td><td width="23%"></td><td width="1%"></td><td width="16%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Collaborator</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Major Markets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="tecfidera.jpg" style="height:37px;width:172px;"></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Relapsing forms of MS in the U.S.</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Relapsing-remitting MS (RRMS) in the E.U.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="avonex.jpg" style="height:49px;width:134px;"></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Relapsing forms of MS</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="plegridy.jpg" style="height:77px;width:128px;"></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Relapsing forms of MS in the U.S.</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RRMS in the E.U.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="tysabri.jpg" style="height:62px;width:114px;"></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Relapsing forms of MS</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Crohn's disease in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="fampyra.jpg" style="height:37px;width:133px;"></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Walking ability for patients with MS</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acorda Therapeutics, Inc. (Acorda)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canada</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><a name="s9175c51e28dd47c89222d9c51b831a3f"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Hemophilia</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We develop, manufacture and market products designed to treat patients with hemophilia A and B. Hemophilia A is caused by having substantially reduced or no Factor VIII activity and hemophilia B is caused by having substantially reduced or no Factor IX activity, each of which is needed for normal blood clotting. People with hemophilia A and B experience bleeding episodes that may cause pain, irreversible joint damage and life-threatening hemorrhages. Prophylactic infusions of Factor VIII or Factor IX, as applicable, temporarily replace clotting factor necessary to control bleeding and help protect against new bleeding episodes. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products for hemophilia and major markets include: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="28%"></td><td width="31%"></td><td width="1%"></td><td width="23%"></td><td width="1%"></td><td width="16%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#7f160e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#7f160e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#7f160e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#7f160e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Collaborator</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#7f160e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#7f160e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Major Markets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="eloctate.jpg" style="height:36px;width:149px;"></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adults and children with hemophilia A for control of bleeding episodes</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sobi</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japan</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="alprolix.jpg" style="height:34px;width:149px;"></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adults and children with hemophilia B for control of bleeding episodes</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sobi</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japan</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2015, the EC approved ELOCTA for the treatment of hemophilia A in the E.U. Under our collaboration agreement with Sobi, Sobi has assumed responsibility for final development and commercialization of ELOCTA in the Sobi Territory.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Genentech that entitles us to certain business and financial rights with respect to RITUXAN, GAZYVA and other anti-CD20 product candidates. Current products include:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="28%"></td><td width="58%"></td><td width="1%"></td><td width="13%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Major Markets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="rituxan.jpg" style="height:46px;width:128px;"></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-Hodgkin's lymphoma</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CLL</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rheumatoid arthritis</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Two forms of ANCA-associated vasculitis</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canada</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="gazyva.jpg" style="height:57px;width:76px;"></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In combination with chlorambucil for previously untreated CLL</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For information about our unconsolidated joint business and agreement with Genentech, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="28%"></td><td width="32%"></td><td width="1%"></td><td width="23%"></td><td width="1%"></td><td width="15%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Collaborator</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Major Market</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="fumaderm.jpg" style="height:45px;width:116px;"></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Moderate to severe plaque psoriasis</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><a name="sa169783af95d491e9e0fd35189bfa8e4"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Marketing and Distribution</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales Force and Marketing</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We promote our products worldwide, including in the U.S., most of the major countries of the E.U. and Japan, primarily through our own sales forces and marketing groups. In some countries, particularly in areas where we continue to expand into new geographic areas, we partner with third parties. We focus our sales and marketing efforts on specialist physicians in private practice or at major medical centers. We use customary pharmaceutical company practices to market our products and to educate physicians, such as sales representatives calling on individual physicians, advertisements, professional symposia, direct mail, public relations and other methods. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Distribution Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We distribute our products in the U.S. principally through wholesale distributors of pharmaceutical products, mail order specialty distributors or shipping service providers. In other countries, the distribution of our products varies from country to country, including through wholesale distributors of pharmaceutical products and third-party distribution partners who are responsible for most marketing and distribution activities.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN and GAZYVA are marketed and distributed by the Roche Group and its sublicensees.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our product sales to two wholesale distributors, AmerisourceBergen and McKesson, each accounted for more than 10% of our total revenues for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and on a combined basis, accounted for approximately 60% of our gross product revenues for such years, respectively. For additional information, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Patient Support and Access</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We interact with patients, advocacy organizations and healthcare societies in order to gain insights into unmet needs. The insights gained from these engagements help us support patients with services, programs and applications that are designed to help patients lead better lives. Among other things, we provide customer service and other related programs for our products, such as disease and product specific websites, insurance research services and order, delivery and fulfillment services. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are dedicated to helping patients obtain access to our therapies. Our patient representatives have access to a comprehensive suite of financial assistance tools. With those tools, we help patients and their caregivers and healthcare professionals understand, compare and select insurance options and programs that are available to them. In the U.S., we have established programs that provide qualified uninsured or underinsured patients with marketed products at no or reduced charge, based on specific eligibility criteria. We also provide charitable contributions that may assist eligible commercially-insured patients with out-of-pocket expenses associated with their costs for our products.</font></div></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><a name="s2874d8ed29d24b4f8976ed9a0f9cce92"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Patents and Other Proprietary Rights</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Patents are important to obtaining and protecting exclusive rights in our products and product candidates. We regularly seek patent protection in the U.S.&#160;and in selected countries outside the U.S.&#160;for inventions originating from our research and development efforts. In addition, we license rights to various patents and patent applications. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.&#160;patents, as well as most foreign patents, are generally effective for 20&#160;years from the date the earliest application was filed; however, U.S.&#160;patents that issue on applications filed before June&#160;8, 1995&#160;may be effective until 17&#160;years from the issue date, if that is later than the 20&#160;year date. In some cases, the patent term may be extended to recapture a portion of the term lost during regulatory review of the claimed therapeutic or, in the case of the U.S., because of U.S.&#160;Patent and Trademark Office (USPTO) delays in prosecuting the application. Specifically, in the U.S., under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, a patent that covers an FDA-approved drug may be eligible for patent term extension (for up to five years, but not beyond a total of 14 years from the date of product approval) as compensation for patent term lost during the FDA regulatory review process. The duration and extension of the term of foreign patents varies, in accordance with local law. For example, supplementary protection certificates (SPCs) on some of our products have been granted in a number of European countries, compensating in part for delays in obtaining marketing approval.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory exclusivity, which may consist of regulatory data protection and market protection, also can provide meaningful protection for our products. Regulatory data protection provides to the holder of a drug or biologic marketing authorization, for a set period of time, the exclusive use of the proprietary pre-clinical and clinical data that it created at significant cost and submitted to the applicable regulatory authority to obtain approval of its product. After the applicable set period of time, third parties are then permitted to rely upon our data to file for approval of their abbreviated applications for, and to market (subject to any applicable market protection), their generic drugs and biosimilars referencing our data. Market protection provides to the holder of a drug or biologic marketing authorization the exclusive right to commercialize its product for a set period of </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">time, thereby preventing the commercialization of another product containing the same active  ingredient(s) during that period. Although the World Trade Organization's agreement on trade-related aspects of intellectual property rights (TRIPS) requires signatory countries to provide regulatory exclusivity to innovative pharmaceutical products, implementation and enforcement varies widely from country to country.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;&#32;We also rely upon other forms of unpatented confidential information to remain competitive. We protect such information principally through confidentiality agreements with our employees, consultants, outside scientific collaborators, scientists whose research we sponsor and other advisers. In the case of our employees, these agreements also provide, in compliance with relevant law, that inventions and other intellectual property conceived by such employees during their employment shall be our exclusive property.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our trademarks are important to us and are generally covered by trademark applications or registrations in the USPTO and the patent or trademark offices of other countries. We also use trademarks licensed from third parties, such as the trademark FAMPYRA which we license from Acorda. Trademark protection varies in accordance with local law, and continues in some countries as long as the trademark is used and in other countries as long as the trademark is registered. Trademark registrations generally are for fixed but renewable terms.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our Patent Portfolio </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table describes our patents in the U.S. and Europe that we currently consider of primary importance to our marketed products, including the territory, patent number, general subject matter and expected expiration dates. Except as otherwise noted, the expected expiration dates include any granted patent term extensions and issued SPCs. In some instances, there are later-expiring patents relating to our products directed to, among other things, particular forms or compositions, methods of manufacturing, or use of the drug in the treatment of particular diseases or conditions. We also continue to pursue additional patents and patent term extensions in the U.S. and other territories covering various aspects of our products that may, if issued, extend exclusivity beyond the expiration of the patents listed in the table.  </font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><a name="s2874d8ed29d24b4f8976ed9a0f9cce92"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td width="12%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="42%"></td><td width="1%"></td><td width="14%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Territory</font></div></td><td style="vertical-align:bottom;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Patent No.</font></div></td><td style="vertical-align:bottom;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">General Subject Matter</font></div></td><td style="vertical-align:bottom;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Patent </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Expiration</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">TECFIDERA</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,619,001</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,803,840</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8,399,514</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2028</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8,524,773</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,509,376</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Formulations of dialkyl fumarates for use in the treatment of autoimmune diseases</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8,759,393</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Formulations</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,320,999</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2020</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1131065</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Formulations of dialkyl fumarates and their use for treating autoimmune diseases</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2137537</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Methods of use</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2028</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">AVONEX and PLEGRIDY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,588,755</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Use of recombinant beta interferon for immunomodulation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2026</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">PLEGRIDY</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,446,173</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Polymer conjugates of interferon beta-1a</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2022</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8,524,660</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8,017,733</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Polymer conjugates of interferon beta-1a</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2025</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1656952</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Polymer conjugates of interferon-beta-1a and uses thereof</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">TYSABRI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,840,299</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Humanized immunoglobulins; nucleic acids; pharmaceutical compositions; methods of use</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,602,503</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Humanized recombinant antibodies; nucleic acids and host cells; processes for production; therapeutic compositions; methods of use</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,807,167</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0804237</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Humanized immunoglobulins; nucleic acids; pharmaceutical compositions; medical uses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1485127</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Methods of use </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">FAMPYRA</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0484186</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Formulations containing aminopyridines, including fampridine</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(4)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1732548</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sustained-release aminopyridine compositions for increasing walking speed in patients with MS</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2025</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(5)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">23775536</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sustained-release aminopyridine compositions for treating MS</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2025</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(6)</sup></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">ELOCTATE and ALPROLIX</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,348,004</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2024</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,862,820</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2024</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8,329,182</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Composition of matter covering rFIXFc and rFVIIIFc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2024</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,404,956</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Composition of matter covering rFIXFc and rFVIIIFc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2025</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1624891</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Composition of matter covering rFIXFc and rFVIIIFc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2024</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1625209</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Composition of matter covering rFIXFc and rFVIIIFc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2024</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2298347</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Composition of matter covering rFIXFc and rFVIIIFc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2024</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">ELOCTATE</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,050,318</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2031</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,241,978</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2031</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">ALPROLIX</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,233,145</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2031</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.91596638655463%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Footnotes follow on next page.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><a name="s2874d8ed29d24b4f8976ed9a0f9cce92"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">In addition to patent protection, certain of our products are entitled to regulatory exclusivity in the U.S. and the E.U. expected until the dates set forth below:</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="20%"></td><td width="2%"></td><td width="21%"></td><td width="2%"></td><td width="55%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Territory</font></div></td><td style="vertical-align:bottom;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Expected Expiration</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">TECFIDERA</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2024</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">PLEGRIDY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2024</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">TYSABRI</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">FAMPYRA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2021</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">ELOCTATE</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">ELOCTA*</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2025</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">ALPROLIX</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">*ELOCTA is commercialized by Sobi per our collaboration agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2024. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2029.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Reflects SPCs granted in most European countries, except for Germany where the application for SPC is pending.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2026.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2026.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The existence of patents does not guarantee our right to practice the patented technology or commercialize the patented product. Patents relating to pharmaceutical, biopharmaceutical and biotechnology products, compounds and processes, such as those that cover our existing compounds, products and processes and those that we will likely file in the future, do not always provide complete or adequate protection. Litigation, interferences, oppositions, inter partes reviews or other proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our patents, regulatory exclusivities or other proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We may also face challenges to our patents, regulatory exclusivities and other proprietary rights covering our products by manufacturers of generics and biosimilars. A discussion of certain risks and uncertainties that may affect our patent position, regulatory exclusivities and other proprietary rights is set forth in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Risk Factors&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;section of this report, and a discussion of legal proceedings related to certain patents described above are set forth in Note&#160;20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><a name="s09ae2b73786546d9885e0c90b3d2274e"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Competition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Competition in the biopharmaceutical industry is intense and comes from many sources, including specialized biotechnology firms and large pharmaceutical companies. Many of our competitors are working to develop products similar to those we are developing or already market and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. Certain of these companies have substantially greater financial, marketing and research and development resources than we do.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that competition and leadership in the industry is based on managerial and technological excellence and innovation as well as establishing patent and other proprietary positions through research and development. The achievement of a leadership position also depends largely upon our ability to maximize the approval, acceptance and use of products resulting from research and the availability of adequate financial resources to fund facilities, equipment, personnel, clinical testing, manufacturing and marketing. Another key aspect of remaining competitive within the industry is recruiting and retaining leading scientists and technicians. We believe that we have been successful in attracting skilled and experienced scientific personnel.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Competition among products approved for sale may be based, among other things, on patent position, product efficacy, safety, convenience/delivery devices, reliability, availability and price. In addition, early entry of a new pharmaceutical product into the market may have important advantages in gaining product acceptance and market share. Accordingly, the relative speed with which we can develop products, complete the testing and approval process and supply commercial quantities of products will have an important impact on our competitive position.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The introduction of new products or technologies, including the development of new processes or technologies by competitors or new information about existing products may result in increased competition for our marketed products or could result in pricing pressure on our products. It is also possible that the development of new or improved treatment options or standards of care or cures for the diseases our products treat could reduce or eliminate the use of our products or may limit the utility and application of ongoing clinical trials for our product candidates. We may also face increased competitive pressures as a result of generics and the emergence of biosimilars in the U.S. and E.U. If a generic or biosimilar version of one of our products were approved, it could reduce our sales of that product.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional information about the competition that our marketed products face is set forth below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TECFIDERA, AVONEX, PLEGRIDY and TYSABRI</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA, AVONEX, PLEGRIDY and TYSABRI each compete with one or more of the following products: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="48%"></td><td width="2%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Competing Product</font></div></td><td style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Competitor</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">COPAXONE </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(glatiramer acetate)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Teva Pharmaceuticals Industries Ltd.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">GLATOPA (glatiramer acetate)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sandoz, a division of Novartis AG</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">REBIF </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(interferon-beta-1)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Merck KGaA (and co-promoted with Pfizer Inc. in the U.S.)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">BETASERON/BETAFERON (interferon-beta-1b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Bayer Group</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">EXTAVIA </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(interferon-beta-1b)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Novartis AG</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">GILENYA (fingolimod)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Novartis AG</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">AUBAGIO (teriflunomide)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sanofi</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">LEMTRADA (alemtuzumab)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sanofi</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Competition in the MS market is intense.&#160;Along with us, a number of companies are working to develop additional treatments for MS that may in the future compete with our MS products. One such product candidate is ocrelizumab, a potential treatment for PPMS being developed by the Roche Group. While we have a financial interest in ocrelizumab, future sales of our MS products may be adversely affected by the commercialization of ocrelizumab, as well as by other MS products we or our competitors are developing</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Future sales may also be negatively impacted</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">by</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of generics, prodrugs of existing therapeutics or biosimilars of existing products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">FAMPYRA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA is indicated as a treatment to improve walking in adult patients with MS who have walking disability and is the first treatment that addresses this unmet medical need with demonstrated efficacy in people with all types of MS. FAMPYRA is currently the only therapy approved to improve walking in patients with MS. </font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><a name="s09ae2b73786546d9885e0c90b3d2274e"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">ELOCTATE and ALPROLIX</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTATE and ALPROLIX compete with recombinant Factor VIII and IX products, respectively, including:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="72%"></td><td width="2%"></td><td width="26%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#7f160e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Competing Product</font></div></td><td style="vertical-align:bottom;background-color:#7f160e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#7f160e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Competitor</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">ELOCTATE:</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">ADVATE </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">[Antihemophilic Factor (Recombinant)]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Baxalta</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">ADYNOVATE</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">[Antihemophilic Factor (Recombinant), PEGylated]</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Baxalta</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">KOGENATE FS </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">[Antihemophilic Factor (Recombinant)]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Bayer</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">HELIXATE FS </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">[Antihemophilic Factor (Recombinant)]</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">CSL Behring</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">RECOMBINATE </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">[Antihemophilic Factor (Recombinant)]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Baxalta</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">XYNTHA </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">[Antihemophilic Factor (Recombinant)], Plasma/Albumin-Free</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Pfizer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">ALPROLIX:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">BENEFIX Coagulation Factor IX (Recombinant)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Pfizer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">IXINITY Coagulation Factor IX (Recombinant)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Emergent Biosolutions</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">RIXUBIS [Coagulation Factor IX (Recombinant)]</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Baxalta</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our hemophilia products also compete with a number of plasma-derived Factor VIII and IX products. We are also aware of other longer-acting products as well as other technologies, such as gene therapies, that are in development, and if successfully developed and approved would compete with our hemophilia products. </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">RITUXAN and GAZYVA in Oncology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN and GAZYVA compete with a number of therapies in the oncology market, including TREANDA (bendamustine HCL), ARZERRA (ofatumumab), IMBRUVICA (ibrutinib) and ZYDELIG (idelalisib). </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also expect that over time GAZYVA will increasingly compete with RITUXAN in the oncology market. In addition, we are aware of other anti-CD20 molecules, including biosimilars, in development that, if successfully developed and approved, may compete with RITUXAN and GAZYVA in the oncology market.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">RITUXAN in Rheumatoid Arthritis</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN competes with several different types of therapies in the rheumatoid arthritis market, including, among others, traditional disease-modifying anti-rheumatic drugs such as steroids, methotrexate and cyclosporine, TNF inhibitors, ORENCIA (abatacept), ACTEMRA (tocilizumab) and XELJANZ (tofacitinib).</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also aware of other products, including biosimilars, in development that, if successfully developed and approved, may compete with RITUXAN in the rheumatoid arthritis market. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">FUMADERM</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM competes with several different types of therapies in the psoriasis market within Germany, including oral systemics such as methotrexate and cyclosporine.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><a name="sdf06da4c17be48f3a8d49973f300a5ad"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Research and Development Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A commitment to research is fundamental to our mission. Our research efforts are focused on better understanding the underlying biology of diseases so we can discover and deliver treatments that have the potential to make a real difference in the lives of patients with high unmet medical needs. By applying our expertise in biologics and our growing capabilities in small molecule, antisense, gene therapy, gene editing and other technologies, we target specific medical needs where we believe new or better treatments are needed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to research and development opportunities.  As part of our ongoing research and development efforts, we have devoted significant resources to conducting clinical studies to advance the development of new pharmaceutical products and technologies and to explore the utility of our existing products in treating disorders beyond those currently approved in their labels.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;"><img src="researchanddevelopment.jpg" style="height:198px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The table below highlights our current research and development programs that are in clinical trials and the current phase of such programs. Drug development involves a high degree of risk and investment, and the status, timing and scope of our development programs are subject to change. Important factors that could adversely affect our drug development efforts are discussed in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; section of this report. </font></div></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td width="17%"></td><td width="19%"></td><td width="15%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product Candidate</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Collaborator</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">PHASE 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">PHASE 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">PHASE 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">FILED</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ZINBRYTA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AbbVie Therapeutics</font></div></td><td colspan="10" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Multiple Sclerosis (MS)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">GAZYVA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Genentech (Roche Group)</font></div></td><td colspan="10" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">RITUXAN-Refractory Indolent Non Hodgkin&#8217;s Lymphoma</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">GAZYVA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Genentech (Roche Group)</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Front-Line Indolent Non Hodgkin&#8217;s Lymphoma</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">GAZYVA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Genentech (Roche Group)</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Front-Line Diffuse Large B-Cell Lymphoma</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Nusinersen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Ionis Pharmaceuticals</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Spinal Muscular Atrophy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Aducanumab</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Neurimmune SubOne AG</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Alzheimer's Disease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Ocrelizumab</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Genentech (Roche Group)</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Primary Progressive &amp; Relapsing Multiple Sclerosis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Anti-LINGO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">None</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Optic Neuritis; Multiple Sclerosis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Amiselimod</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Mitsubishi Tanabe</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Multiple Autoimmune Indications</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BAN2401</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Eisai</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Alzheimer's Disease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">E2609</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Eisai</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Alzheimer's Disease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Raxatrigine</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">None</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Trigeminal Neuralgia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">None</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Acute Ischemic Stroke</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">rAAV-XLRS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AGTC</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">X-linked Juvenile Retinoschisis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BG00011 (STX-100)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">None</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Idiopathic Pulmonary Fibrosis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Dapirolizumab pegol </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">UCB Pharma</font></div></td><td style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">SLE*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BIIB061</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">None</font></div></td><td style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Multiple Sclerosis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">IONIS-DMPK</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Ionis Pharmaceuticals</font></div></td><td style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Myotonic Dystrophy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Anti-BDCA2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">None</font></div></td><td style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">SLE*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Anti-alpha-synuclein</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">None</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Parkinson&#8217;s Disease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BIIB063</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">None</font></div></td><td style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Sjogren&#8217;s Syndrome</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">IONIS-SOD1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;(BIIB067)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Ionis Pharmaceuticals</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">ALS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI (infliximab)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Samsung Bioepis</font></div></td><td colspan="10" style="vertical-align:bottom;background-color:#578196;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Multiple Immunology Indications in Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biosimilar adalimumab</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Samsung Bioepis</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#578196;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Multiple Immunology Indications in Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">* Systemic lupus erythematosus</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><a name="sdf06da4c17be48f3a8d49973f300a5ad"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For information about certain of our agreements with collaborators and other third parties, please see </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Business Relationships&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;below and Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Late Stage Product Candidates</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional information about our late stage product candidates, which includes programs in Phase 3 development or in registration stage, is set forth below. </font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="10%"></td><td width="90%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Multiple Sclerosis</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">ZINBRYTA (daclizumab high yield process)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA is a monoclonal antibody for the treatment of RRMS. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2014, we announced positive top-line results from the Phase 3 DECIDE clinical trial, which investigated ZINBRYTA as a potential once-monthly, subcutaneous treatment for RRMS. Results showed that ZINBRYTA was superior on the study's primary endpoint, demonstrating a statistically significant reduction in annualized relapse rates when compared to interferon beta-1a. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our MAA for ZINBRYTA was validated by the EMA in March 2015, and the BLA was accepted by the FDA in April 2015.</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">TYSABRI (natalizumab)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2013, we completed patient enrollment in a Phase 3 study of TYSABRI in SPMS, known as ASCEND. The study had a duration of approximately two years and involved approximately 875 patients. SPMS is characterized by a steady progression of nerve damage, symptoms and disability. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2015, the results of our Phase 3 ASCEND study did not achieve its primary and secondary endpoints, and the development of TYSABRI in SPMS was discontinued.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="10%"></td><td width="90%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#7f160e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Hemophilia</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">ALPROLIX</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">[Coagulation Factor IX (Recombinant), Fc Fusion Protein]</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2014, ALPROLIX was approved by the FDA for the treatment of hemophilia B. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pediatric data was required as part of the MAA for ALPROLIX that we submitted to the EMA. In February 2015, we and Sobi announced positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of ALPROLIX in children under age 12 with severe hemophilia B. Following these results, we filed a MAA in the E.U., which was validated by the EMA in June 2015.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="10%"></td><td width="90%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Neurodegeneration</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Aducanumab (BIIB037)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015, we enrolled our first patient in our two global Phase 3 studies, ENGAGE and EMERGE. ENGAGE and EMERGE will assess the efficacy and safety of aducanumab in approximately 2,700 people with early Alzheimer's disease. The studies are identical in design and eligibility criteria. Each study will be conducted in more than 20 countries in North America, Europe and Asia. In October 2015, we announced that we received FDA agreement on a special protocol assessment on the Phase 3 study protocols.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="10%"></td><td width="90%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Other Programs</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Nusinersen (IONIS-SMN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2014, Ionis announced the initiation of a pivotal Phase 3 study evaluating nusinersen in infants with SMA, the most common genetic cause of infant mortality. This Phase 3 study, known as ENDEAR, is a randomized, double-blind, sham-procedure controlled thirteen month study in approximately 110 infants diagnosed with SMA.&#160;The study is evaluating the efficacy and safety of a 12mg dose of nusinersen with a primary endpoint of survival or permanent ventilation.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2014, Ionis announced the initiation of a pivotal Phase 3 study evaluating the efficacy and safety of nusinersen in non-ambulatory children with SMA. This Phase 3 study, known as CHERISH, is a randomized, double-blind, sham-procedure controlled fifteen month study in approximately 120 children with SMA. The study is evaluating the efficacy and safety of a 12mg dose of nusinersen with a primary endpoint of a change in the Hammersmith Functional Motor Scale-Expanded, a validated method to measure changes in muscle function in patients with SMA.</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><a name="sdf06da4c17be48f3a8d49973f300a5ad"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="10%"></td><td width="90%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Genentech Relationships</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">GAZYVA (obinutuzumab)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Roche Group is managing the following Phase 3 studies of GAZYVA:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">GOYA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: investigating the efficacy and safety of GAZYVA in combination with CHOP chemotherapy compared to RITUXAN with CHOP chemotherapy in previously untreated patients with CD20-positive diffuse large B-cell lymphoma.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">GALLIUM</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: investigating the efficacy and safety of GAZYVA in combination with chemotherapy followed by maintenance with GAZYVA compared to RITUXAN in combination with chemotherapy followed by maintenance with RITUXAN in previously untreated patients with indolent non-Hodgkin's lymphoma.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">GADOLIN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: investigating the efficacy and safety of GAZYVA plus bendamustine compared with bendamustine alone in patients with RITUXAN-refractory, indolent non-Hodgkin's lymphoma. In February 2015, the Roche Group announced positive results from the Phase 3 GADOLIN study.&#160;At a pre-planned interim analysis, an independent data monitoring committee determined that the study met its primary endpoint early, showing that people lived significantly longer without disease worsening or death (progression-free survival) when treated with GAZYVA plus bendamustine followed by GAZYVA alone, compared to bendamustine alone.</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Ocrelizumab</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015, the Roche Group announced positive results from two Phase 3 studies evaluating ocrelizumab compared with interferon beta-1a in people with relapsing forms of MS. Treatment with ocrelizumab compared with interferon beta-1a significantly reduced the annualized relapse rate over a two-year period; significantly reduced the progression of clinical disability; and led to a significant reduction in the number of lesions in the brain as measured by MRI. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015, the Roche Group announced positive results from a Phase 3 study evaluating ocrelizumab in people with PPMS. Treatment with ocrelizumab significantly reduced the progression of clinical disability compared with placebo, as measured by the Expanded Disability Status Scale.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="10%"></td><td width="90%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#578196;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;font-weight:bold;">Biosimilars (Samsung Bioepis - Biogen's Joint Venture with Samsung Biologics)</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">FLIXABI</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Samsung Bioepis' MAA for FLIXABI, an infliximab biosimilars candidate referencing REMICADE, was validated and accepted by the EMA in March 2015. If approved, under our agreement with Samsung Bioepis, we have commercialization rights to FLIXABI in specified E.U. countries.</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><a name="s2fddc4d2bc1a4be894f81bebcf656161"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Business Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of our business strategy, we establish business relationships, including joint ventures and collaborative arrangements with other companies, universities and medical research institutions to assist in the clinical development and/or commercialization of certain of our products and product candidates and to provide support for our research programs. We also evaluate opportunities for acquiring products or rights to products and technologies that are complementary to our business from other companies, universities and medical research institutions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Below is a brief description of certain business relationships and collaborations that expand our pipeline and provide us with certain rights to existing and potential new products and technologies. For more information regarding certain of these relationships, including their ongoing financial and accounting impact on our business, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie Biotherapeutics, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie Biotherapeutics, Inc. aimed at advancing the development and commercialization of ZINBRYTA in MS.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acorda Therapeutics, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We collaborate with Acorda to develop and commercialize products containing fampridine, such as FAMPYRA, in markets outside the U.S.&#160;We also have responsibility for regulatory activities and the future clinical development of related products in those markets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Applied Genetic Technologies Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2015, we entered into a collaboration agreement with AGTC to develop gene-based therapies for multiple ophthalmic diseases. The collaboration focuses on the development of a clinical-stage candidate for X-linked Retinoschisis (XLRS) and a preclinical candidate for the treatment of X-linked Retinitis Pigmentosa (XLRP), for which we were granted worldwide commercialization rights. The agreement also provides us with options to early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration with Eisai to jointly develop and commercialize E2609 and BAN2401, two Eisai product candidates for the treatment of Alzheimer&#8217;s disease.&#160;Eisai serves as the global operational and regulatory lead for E2609 and BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. Following marketing approval in major markets, we will co-promote E2609 and BAN2401 with Eisai and share profits equally. In smaller markets, Eisai will distribute these products and pay us a royalty.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The agreement also provides Eisai with options to jointly develop and commercialize two of our candidates for Alzheimer&#8217;s disease, aducanumab and an anti-tau monoclonal antibody, upon the exchange or provision of clinical data. Upon exercise of the applicable option, we will execute a separate collaboration agreement with Eisai on terms and conditions that mirror the financial arrangements we have with Eisai with respect to E2609 and BAN2401.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Genentech which entitles us to certain financial and other rights with respect to RITUXAN, GAZYVA and other anti-CD20 product candidates. Additionally, under our agreement with Genentech, if ocrelizumab is approved, we will receive tiered royalty payments on sales of ocrelizumab.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have three separate exclusive, worldwide option and collaboration agreements with Ionis under which both companies will develop and commercialize antisense therapeutics for up to three gene targets, Ionis&#8217; product candidates for the treatment of myotonic dystrophy type 1, and the antisense investigational candidate, nusinersen for the treatment of SMA. We also have a six-year research collaboration agreement with Ionis, which we entered into in 2013, under which both companies perform discovery level research and will develop and commercialize antisense and other therapeutics for the treatment of neurological disorders.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><a name="s2fddc4d2bc1a4be894f81bebcf656161"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Mitsubishi Tanabe Pharma Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2015, we entered into an agreement with MTPC to exclusively license amiselimod, a late stage experimental medicine with potential in multiple autoimmune indications. Amiselimod is an oral compound that targets the sphingosine 1-phosphate receptor. Under the agreement, we obtained worldwide rights to amiselimod, excluding Asia. We are responsible for commercialization and are covering development costs outside of Asia. MTPC has the right to participate in our global clinical trials and has an option to co-promote non-MS indications in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Samsung Biologics established a joint venture, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&#160;In December 2013, we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, anti-TNF biosimilar product candidates in specified E.U. countries, and, in the case of BENEPALI, Japan.&#160;To date, Samsung Bioepis' MAA for BENEPALI, an etanercept biosimilar referencing ENBREL, has been approved by the EC, and the MAA for FLIXABI, an infliximab biosimilars candidate referencing REMICADE, has been validated by the EMA. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our joint venture and commercialization agreement with Samsung Bioepis, we license certain of our proprietary technology to Samsung Bioepis in connection with Samsung Bioepis's development, manufacture and commercialization of its biosimilar products. We also provide technical development and technology transfer services to Samsung Bioepis, and manufacture clinical and commercial quantities of bulk drug substance of Samsung Bioepis' biosimilar products.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sangamo BioSciences, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have an exclusive, worldwide research, development and commercialization collaboration and license agreement with Sangamo BioSciences, Inc. (Sangamo) under which the companies will develop and commercialize product candidates using gene editing technologies for the treatment of two inherited blood disorders, sickle cell disease and beta-thalassemia.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Swedish Orphan Biovitrum AB (publ)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We collaborate with Sobi to jointly develop and commercialize Factor VIII and Factor IX hemophilia products, including ELOCTATE and ALPROLIX. We have commercial rights for North America and for rest of the world markets outside of the Sobi Territory.&#160;Sobi has assumed final development and commercialization of ELOCTA in the Sobi Territory, and, has elected to opt-in to assume final development and commercialization of ALPROLIX if the MAA is approved by the EMA.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><a name="s08b8bb80c7fa4dc6b52d1ca29b65babc"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Regulatory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current and contemplated activities and the products, technologies and processes that result from such activities are subject to substantial government regulation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Regulation of Pharmaceuticals</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Approval and Post-Approval Regulation in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">APPROVAL PROCESS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Before new pharmaceutical products may be sold in the U.S., preclinical studies and clinical trials of the products must be conducted and the results submitted to the FDA for approval. With limited exceptions, the FDA requires companies to register both pre-approval and post-approval clinical trials and disclose clinical trial results in public databases. Failure to register a trial or disclose study results within the required time periods could result in penalties, including civil monetary penalties. Clinical trial programs must establish efficacy, determine an appropriate dose and dosing regimen, and define the conditions for safe use. This is a high-risk process that requires stepwise clinical studies in which the candidate product must successfully meet predetermined endpoints. The results of the preclinical and clinical testing of a product are then submitted to the FDA in the form of a BLA or a New Drug Application (NDA). In response to a BLA or NDA, the FDA may grant marketing approval, request additional information or deny the application if it determines the application does not provide an adequate basis for approval.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development and receipt of regulatory approval takes a number of years, involves the expenditure of substantial resources and depends on a number of factors, including the severity of the disease in question, the availability of alternative treatments, potential safety signals observed in preclinical or clinical tests, and the risks and benefits of the product as demonstrated in clinical trials. The FDA has substantial discretion in the product approval process, and it is impossible to predict with any certainty whether and when the FDA will grant marketing approval. The agency may require the sponsor of a BLA or NDA to conduct additional clinical studies or to provide other scientific or technical information about the product, and these additional requirements may lead to unanticipated delay or expense. Furthermore, even if a product is approved, the approval may be subject to limitations based on the FDA's interpretation of the existing pre-clinical or clinical data. The FDA has developed four distinct approaches intended to make therapeutically important drugs available as rapidly as possible, especially when the drugs are the first available treatment or have advantages over existing treatments: accelerated approval, fast track, breakthrough therapy, and priority review.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Accelerated Approval</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: The FDA may grant &#8220;accelerated approval&#8221; status to products that treat serious or life-threatening illnesses and that provide meaningful therapeutic benefits to patients over existing treatments. Under this pathway, the FDA may approve a product based on surrogate endpoints, or clinical endpoints other than survival or irreversible morbidity. When approval is based on surrogate endpoints or clinical endpoints other than survival or morbidity, the sponsor will be required to conduct additional post-approval clinical studies to verify and describe clinical benefit. Under the agency's accelerated approval regulations, if the FDA concludes that a drug that has been shown to be effective can be safely used only if distribution or use is restricted, it may require certain post-marketing restrictions as necessary to assure safe use. In addition, for products approved under accelerated approval, sponsors may be required to submit all copies of their promotional materials, including advertisements, to the FDA at least thirty days prior to initial dissemination. The FDA may withdraw approval under accelerated approval after a hearing if, for instance, post-marketing studies fail to verify any clinical benefit, it becomes clear that restrictions on the distribution of the product are inadequate to ensure its safe use, or if a sponsor fails to comply with the conditions of the accelerated approval.</font></div></td></tr></table></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><a name="s08b8bb80c7fa4dc6b52d1ca29b65babc"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fast Track Status</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: The FDA may grant &#8220;fast track&#8221; status to products that treat serious diseases or conditions and fill an unmet medical need. Fast track is a process designed to expedite the review of such products by providing, among other things, more frequent meetings with the FDA to discuss the product's development plan, more frequent written correspondence from the FDA about trial design, eligibility for accelerated approval, and rolling review, which allows submission of individually completed sections of a NDA or BLA for FDA review before the entire filing is completed. Fast track status does not ensure that a product will be developed more quickly or receive FDA approval.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Breakthrough Therapy</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: The FDA may grant &#8220;breakthrough therapy&#8221; status to drugs designed to treat, alone or in combination with another drug or drugs, a serious or life-threatening disease or condition and for which preliminary evidence suggests a substantial improvement over existing therapies. Such drugs need not address an unmet need, but are nevertheless eligible for expedited review if they offer the potential for an improvement. Breakthrough therapy status entitles the sponsor to earlier and more frequent meetings with the FDA regarding the development of nonclinical and clinical data and permits the FDA to offer product development or regulatory advice for the purpose of shortening the time to product approval. Breakthrough therapy status does not guarantee that a product will be developed or reviewed more quickly and does not ensure FDA approval.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Priority Review</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: Finally, the FDA may grant &#8220;priority review&#8221; status to products that offer major advances in treatment or provide a treatment where no adequate therapy exists. Priority review is intended to reduce the time it takes for the FDA to review a NDA or BLA.</font></div></td></tr></table></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">POST-MARKETING STUDIES</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of the approval pathway employed, the FDA may require a sponsor to conduct additional post-marketing studies as a condition of approval to provide data on safety and effectiveness. If a sponsor fails to conduct the required studies, the agency may withdraw its approval. In addition, if the FDA concludes that a drug that has been shown to be effective can be safely used only if distribution or use is restricted, it can mandate post-marketing restrictions as necessary to assure safe use. In such a case, the sponsor may be required to establish rigorous systems to assure use of the product under safe conditions. These systems are usually referred to as Risk Evaluation and Mitigation Strategies (REMS). The FDA can impose financial penalties for failing to comply with certain post-marketing commitments, including REMS. In addition, any changes to an approved REMS must be reviewed and approved by the FDA prior to implementation.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">ADVERSE EVENT REPORTING</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor information on side effects and adverse events reported during clinical studies and after marketing approval and report such information and events to regulatory agencies. Non-compliance with the FDA's safety reporting requirements may result in civil or criminal penalties. Side effects or adverse events that are reported during clinical trials can delay, impede, or prevent marketing approval. Based on new safety information that emerges after approval, the FDA can mandate product labeling changes, impose a new REMS or the addition of elements to an existing REMS, require new post-marketing studies (including additional clinical trials), or suspend or withdraw approval of the product. These requirements may affect our ability to maintain marketing approval of our products or require us to make significant expenditures to obtain or maintain such approvals.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">APPROVAL OF CHANGES TO AN APPROVED PRODUCT</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we seek to make certain types of changes to an approved product, such as adding a new indication, making certain manufacturing changes, or changing manufacturers or suppliers of certain ingredients or components, the FDA will need to review and approve such changes in advance. In the case of a new indication, we are required to demonstrate with additional clinical data that the product is safe and effective for a use other than that initially approved. FDA regulatory review may result in denial or modification of the planned changes, or requirements to conduct additional tests or evaluations that can substantially delay or increase the cost of the planned changes.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><a name="s08b8bb80c7fa4dc6b52d1ca29b65babc"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">REGULATION OF PRODUCT ADVERTISING AND PROMOTION</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FDA regulates all advertising and promotion activities and communications for products under its jurisdiction both before and after approval. A company can make only those claims relating to safety and efficacy that are approved by the FDA. However, physicians may prescribe legally available drugs for uses that are not described in the drug's labeling. Such off-label uses are common across medical specialties, and often reflect a physician's belief that the off-label use is the best treatment for patients. The FDA does not regulate the behavior of physicians in their choice of treatments, but FDA regulations do impose stringent restrictions on manufacturers' communications regarding off-label uses. Failure to comply with applicable FDA requirements may subject a company to adverse publicity, enforcement action by the FDA, corrective advertising, and the full range of civil and criminal penalties available to the government.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Regulation of Combination Products</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Combination products are defined by the FDA to include products comprising two or more regulated components (e.g., a biologic and a device). Biologics and devices each have their own regulatory requirements, and combination products may have additional requirements. Some of our marketed products meet this definition and are regulated under this framework and similar regulations outside the U.S., and we expect that some of our pipeline product candidates may be evaluated for regulatory approval under this framework as well. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Approval and Post-Approval Regulation Outside the U.S.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We market our products in numerous jurisdictions outside the U.S. Most of these jurisdictions have product approval and post-approval regulatory processes that are similar in principle to those in the U.S. In Europe, where most of our ex-U.S. efforts are focused, there are several tracks for marketing approval, depending on the type of product for which approval is sought. Under the centralized procedure, a company submits a single application to the EMA. The marketing application is similar to the NDA or BLA in the U.S. and is evaluated by the Committee for Medicinal Products for Human Use (CHMP), the expert scientific committee of the EMA. If the CHMP determines that the marketing application fulfills the requirements for quality, safety, and efficacy, it will submit a favorable opinion to the EC. The CHMP opinion is not binding, but is typically adopted by the EC. A marketing application approved by the EC is valid in all member states. The centralized procedure is required for all biological products, orphan medicinal products, and new </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">treatments for neurodegenerative disorders, and it is available for certain other products, including those which constitute a significant therapeutic, scientific or technical innovation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the centralized procedure, Europe also has: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a nationalized procedure, which requires a separate application to and approval determination by each country; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a decentralized procedure, whereby applicants submit identical applications to several countries and receive simultaneous approval; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a mutual recognition procedure, where applicants submit an application to one country for review and other countries may accept or reject the initial decision. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of the approval process employed, various parties share responsibilities for the monitoring, detection, and evaluation of adverse events post-approval, including national authorities, the EMA, the EC, and the marketing authorization holder. In some regions, it is possible to receive an &#8220;accelerated&#8221; review whereby the national regulatory authority will commit to truncated review timelines for products that meet specific medical needs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Good Manufacturing Practices</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory agencies regulate and inspect equipment, facilities, and processes used in the manufacturing and testing of pharmaceutical and biologic products prior to approving a product. If, after receiving clearance from regulatory agencies, a company makes a material change in manufacturing equipment, location, or process, additional regulatory review and approval may be required. We also must adhere to current Good Manufacturing Practices (cGMP) and product-specific regulations enforced by regulatory agencies following product approval. The FDA, the EMA and other regulatory agencies also conduct periodic visits to re-inspect equipment, facilities, and processes following the initial approval of a product. If, as a result of these inspections, it is determined that our equipment, facilities, or processes do not comply with applicable regulations and conditions of product approval, regulatory agencies may seek civil, criminal, or administrative sanctions or remedies against us, including significant financial penalties and the suspension of our manufacturing operations.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><a name="s08b8bb80c7fa4dc6b52d1ca29b65babc"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Good Clinical Practices</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FDA, the EMA and other regulatory agencies promulgate regulations and standards for designing, conducting, monitoring, auditing and reporting the results of clinical trials to ensure that the data and results are accurate and that the rights and welfare of trial participants are adequately protected (commonly referred to as current Good Clinical Practices (cGCP)). Regulatory agencies enforce cGCP through periodic inspections of trial sponsors, principal investigators and trial sites, contract research organizations (CROs), and institutional review boards. If our studies fail to comply with applicable cGCP, the clinical data generated in our clinical trials may be deemed unreliable and relevant regulatory agencies may require us to perform additional clinical trials before approving our marketing applications. Noncompliance can also result in civil or criminal sanctions. We rely on third parties, including CROs, to carry out many of our clinical trial-related activities. Failure of such third parties to comply with cGCP can likewise result in rejection of our clinical trial data or other sanctions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Approval of Biosimilars </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Affordable Care Act amended the Public Health Service Act (PHSA) to authorize the FDA to approve biological products, referred to as biosimilars or follow-on biologics, that are shown to be highly similar to previously approved biological products based upon potentially abbreviated data packages.&#160;The biosimilar must show it has no clinically meaningful differences in terms of safety and effectiveness from the reference product, and only minor differences in clinically inactive components are allowable in biosimilars products.  The approval pathway for biosimilars does, however, grant a biologics manufacturer a 12-year period of exclusivity from the date of approval of its biological product before biosimilar competition can be introduced. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars legislation has also been in place in the E.U. since 2003. In December 2012, guidelines issued by the EMA for approving biosimilars of marketed monoclonal antibody products became effective. In the E.U., biosimilars have been approved under a specialized pathway of centralized procedures. The pathway allows sponsors of a biosimilar to seek and obtain regulatory approval based in part on the clinical trial data of an innovator product to which the biosimilar has been demonstrated to be &#8220;similar&#8221;. In many cases, this allows biosimilars to be brought to market without conducting the full complement of clinical trials typically required for novel biologic drugs.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Orphan Drug Act</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the U.S.&#160;Orphan Drug Act, the FDA may grant orphan drug designation to drugs or biologics intended to treat a &#8220;rare disease or condition,&#8221; which generally is a disease or condition that affects fewer than 200,000 individuals in the U.S.&#160;If a product which has an orphan drug designation subsequently receives the first FDA approval for the indication for which it has such designation, the product is entitled to orphan exclusivity, i.e., the FDA may not approve any other applications to market the same drug for the same indication for a period of seven years following marketing approval, except in certain very limited circumstances, such as if the later product is shown to be clinically superior to the orphan product. Legislation similar to the U.S.&#160;Orphan Drug Act has been enacted in other countries to encourage the research, development and marketing of medicines to treat, prevent or diagnose rare diseases. In the E.U., medicinal products intended for diagnosis, prevention or treatment of life-threatening or very serious diseases affecting less than five in 10,000 people receive 10-year market exclusivity, protocol assistance, and access to the centralized procedure for marketing authorization.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Regulation Pertaining to Pricing and Reimbursement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In both domestic and foreign markets, sales of our products depend, in part, on the availability and amount of reimbursement by third-party payors, including governments, private health plans and other organizations. Substantial uncertainty exists regarding the pricing reimbursement of our products, and drug prices continue to receive significant scrutiny. Governments may regulate coverage, reimbursement and pricing of our products to control cost or affect utilization of our products. The U.S.&#160;and foreign governments have enacted and regularly consider additional reform measures that affect health care coverage and costs. Private health plans may also seek to manage cost and utilization by implementing coverage and reimbursement limitations. Other payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, and private health insurers, seek price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value.  </font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><a name="s08b8bb80c7fa4dc6b52d1ca29b65babc"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Within the U.S.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Medicaid</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: Medicaid is a joint federal and state program that is administered by the states for low income and disabled beneficiaries. Under the Medicaid Drug Rebate Program, we are required to pay a rebate for each unit of product reimbursed by the state Medicaid programs. For most brand name drugs, the amount of the basic rebate for each product is set by law as the greater of 23.1% (17.1% for clotting factors and certain other products) of the average manufacturer price (AMP) or the difference between AMP and the best price available from us to any customer (with limited exceptions). The rebate amount must be adjusted upward if AMP increases more than inflation (measured by the Consumer Price Index&#160;- Urban). This adjustment can cause the total rebate amount to exceed the minimum 23.1% (or 17.1%) basic rebate amount. The rebate amount is calculated each quarter based on our report of current AMP and best price for each of our products to the Centers for Medicare&#160;&amp; Medicaid Services (CMS). The requirements for calculating AMP and best price are complex. We are required to report any revisions to AMP or best price previously reported within a certain period, which revisions could affect our rebate liability for prior quarters. In addition, if we fail to provide information timely or we are found to have knowingly submitted false information to the government, the statute governing the Medicaid Drug Rebate Program provides for civil monetary penalties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Medicare</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: Medicare is a federal program that is administered by the federal government that covers individuals age&#160;65 and over as well as those with certain disabilities. Medicare Part&#160;B generally covers drugs that must be administered by physicians or other health care practitioners; are provided in connection with certain durable medical equipment; or are certain oral anti-cancer drugs and certain oral immunosuppressive drugs. In addition, clotting factors for hemophilia are typically paid under Medicare Part B. Medicare Part B pays for such drugs under a payment methodology based on the average sales price (ASP) of the drugs. Manufacturers, including us, are required to provide ASP information to the CMS on a quarterly basis. The manufacturer-submitted information is used to calculate Medicare payment rates. The current payment rate for Medicare Part B drugs is ASP plus 6%. The payment rates for drugs in the hospital outpatient setting are subject to periodic adjustment. The CMS also has the statutory authority to adjust payment rates for specific drugs outside the hospital outpatient setting </font></div></td></tr></table></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-left:30px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">based on a comparison of ASP payment rates to widely available market prices or to AMP, which could decrease Medicare payment rates, but the authority has not yet been implemented. If a manufacturer is found to have made a misrepresentation in the reporting of ASP, the governing statute provides for civil monetary penalties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicare Part D provides coverage to enrolled Medicare patients for self-administered drugs (i.e., drugs that are not administered by a physician). Medicare Part D is administered by private prescription drug plans approved by the U.S. government and each drug plan establishes its own Medicare Part D formulary for prescription drug coverage and pricing, which the drug plan may modify from time-to-time. The prescription drug plans negotiate pricing with manufacturers and may condition formulary placement on the availability of manufacturer discounts. In addition, manufacturers, including us, are required to provide to CMS a 50% discount on brand name prescription drugs utilized by Medicare Part D beneficiaries when those beneficiaries reach the coverage gap in their drug benefits.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Federal Agency Discounted Pricing</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: Our products are subject to discounted pricing when purchased by federal agencies via the Federal Supply Schedule (FSS). FSS participation is required for our products to be covered and reimbursed by the Veterans Administration (VA), Department of Defense, Coast Guard, and Public Health Service (PHS). Coverage under Medicaid, Medicare and the PHS pharmaceutical pricing program is also conditioned upon FSS participation. FSS pricing is intended not to exceed the price that we charge our most-favored non-federal customer for a product. In addition, prices for drugs purchased by the VA, Department of Defense (including drugs purchased by military personnel and dependents through the TriCare retail pharmacy program), Coast Guard, and PHS are subject to a cap on pricing equal to 76% of the non-federal average manufacturer price (non-FAMP). An additional discount applies if non-FAMP increases more than inflation (measured by the Consumer Price Index&#160;- Urban). In addition, if we fail to provide information timely or we are found to have knowingly submitted false information to the government, the governing statute provides for civil monetary penalties.</font></div></td></tr></table></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><a name="s08b8bb80c7fa4dc6b52d1ca29b65babc"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">340B Discounted Pricing</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: To maintain coverage of our products under the Medicaid Drug Rebate Program and Medicare Part B, we are required to extend significant discounts to certain covered entities that purchase products under Section 340B of the PHS pharmaceutical pricing program. Purchasers eligible for discounts include hospitals that serve a disproportionate share of financially needy patients, community health clinics, hemophilia treatment centers and other entities that receive certain types of grants under the PHSA. For all of our products, we must agree to charge a price that will not exceed the amount determined under statute (the &#8220;ceiling price&#8221;) when we sell outpatient drugs to these covered entities. In addition, we may, but are not required to, offer these covered entities a price lower than the 340B ceiling price. The 340B discount formula is based on AMP and is generally similar to the level of rebates calculated under the Medicaid Drug Rebate Program. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Outside the U.S.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outside the U.S., the E.U. represents our major market. Within the E.U., our products are paid for by a variety of payors, with governments being the primary source of payment. Governments may determine or influence reimbursement of products. Governments may also set prices or otherwise regulate pricing. Negotiating prices with governmental authorities can delay commercialization of our products. Governments may use a variety of cost-containment measures to control the cost of products, including price cuts, mandatory rebates, value-based pricing, and reference pricing (i.e., referencing prices in other countries and using those reference prices to set a price). Budgetary pressures in many E.U. countries are continuing to cause governments to consider or implement various cost-containment measures, such as price freezes, increased price cuts and rebates, and expanded generic substitution and patient cost-sharing. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Regulation Pertaining to Sales and Marketing</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including anti-kickback laws and false claims laws. Anti-kickback laws generally prohibit a prescription drug manufacturer from soliciting, offering, receiving, or paying any remuneration to generate business, including the purchase or prescription of a particular drug. Although the specific provisions of these laws vary, their scope is generally broad and there may be no regulations, guidance or court decisions that clarify how the laws apply to particular industry practices. There is therefore a possibility that our practices might be challenged under the anti-kickback or similar </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">laws. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented for payment to third-party payors (including Medicare and Medicaid) claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. Our activities relating to the sale and marketing of our products may be subject to scrutiny under these laws. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions, including fines and civil monetary penalties, and exclusion from federal health care programs (including Medicare and Medicaid). In the U.S., federal and state authorities are paying increased attention to enforcement of these laws within the pharmaceutical industry and private individuals have been active in alleging violations of the laws and bringing suits on behalf of the government under the federal civil False Claims Act. If we were subject to allegations concerning, or were convicted of violating, these laws, our business could be harmed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Laws and regulations have been enacted by the federal government and various states to regulate the sales and marketing practices of pharmaceutical manufacturers. The laws and regulations generally limit financial interactions between manufacturers and health care providers or require disclosure to the government and public of such interactions. The laws include federal &#8220;sunshine&#8221; provisions. The sunshine provisions apply to pharmaceutical manufacturers with products reimbursed under certain government programs and require those manufacturers to disclose annually to the federal government (for re-disclosure to the public) certain payments made to physicians and certain other healthcare practitioners or to teaching hospitals. State laws may also require disclosure of pharmaceutical pricing information and marketing expenditures. Many of these laws and regulations contain ambiguous requirements. Given the lack of clarity in laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent federal and state laws and regulations. Outside the U.S., other countries have implemented requirements for disclosure of financial interactions with healthcare providers and additional countries may consider or implement such laws.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><a name="s08b8bb80c7fa4dc6b52d1ca29b65babc"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Regulations</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Foreign Anti-Corruption</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to various federal and foreign laws that govern our international business practices with respect to payments to government officials. Those laws include the U.S.&#160;Foreign Corrupt Practices Act (FCPA), which prohibits U.S.&#160;companies and their representatives from paying, offering to pay, promising, or authorizing the payment of anything of value to any foreign government official, government staff member, political party, or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect their transactions and to devise and maintain an adequate system of internal accounting controls.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The laws to which we are subject also include the U.K. Bribery Act 2010 (Bribery Act) which proscribes giving and receiving bribes in the public and private sectors, bribing a foreign public official, and failing to have adequate procedures to prevent employees and other agents from giving bribes. U.S. companies that conduct business in the United Kingdom generally will be subject to the Bribery Act. Penalties under the Bribery Act include potentially unlimited fines for companies and criminal sanctions for corporate officers under certain circumstances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">NIH Guidelines</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We seek to conduct research at our U.S. facilities in compliance with the current U.S.&#160;National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines). By local ordinance, we are required to, among other things, comply with the NIH Guidelines in relation to our facilities in Cambridge, Massachusetts and RTP, North Carolina and are required to operate pursuant to certain permits.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Laws</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our present and future business has been and will continue to be subject to various other laws and regulations. Various laws, regulations and recommendations relating to data privacy and protection, safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import, export and use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our research work are or may be applicable to our activities. Certain agreements entered into by us involving exclusive license rights may be subject to national or international antitrust regulatory control, the effect of which cannot be predicted. The extent of government regulation, which might result from future legislation or administrative action, cannot accurately be predicted.</font></div><a name="sf6a614e5b2064bf19f8a0fd1f5646cd2"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Environmental Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We strive to comply in all material respects with applicable laws and regulations concerning the environment. While it is impossible to predict accurately the future costs associated with environmental compliance and potential remediation activities, compliance with environmental laws is not expected to require significant capital expenditures and has not had, and is not expected to have, a material adverse effect on our operations or competitive position.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><a name="s566a2b6161144f76ad50cf1cee17cd2d"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Manufacturing</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are committed to ensuring an uninterrupted supply of medicines to patients around the world. To that end, we continually review our manufacturing capacity, capabilities, processes and facilities. We believe that our manufacturing facilities, together with the third-party contract manufacturing organizations we outsource to, currently provide sufficient capacity for our products and the contract manufacturing services we provide to Samsung Bioepis, our joint venture that develops, manufactures and markets biosimilars, and other strategic contract manufacturing partners. In light of the development of our pipeline, we have announced our plans to expand our production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland, which is expected to be operational by the end of the decade.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing Facilities</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our drug substance manufacturing facilities include:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="2%"></td><td width="49%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Facility</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#7cc3e2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Drug Substance Manufactured</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">RTP, North Carolina</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">ALPROLIX</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">AVONEX</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">ELOCTATE</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">PLEGRIDY</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">TYSABRI</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Cambridge, MA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">AVONEX</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">ELOCTATE</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">PLEGRIDY</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Hiller&#248;d, Denmark</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">TYSABRI</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biosimilars</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our drug substance manufacturing facilities, in August 2015, we expanded our capabilities by completing the purchase from Eisai of a drug product manufacturing facility and supporting infrastructure in RTP, North Carolina. This parenteral facility adds capabilities and capacity for filling biologics into vials.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also lease from Eisai an oral solid dose products manufacturing facility in RTP, North Carolina, where we manufacture TECFIDERA and other solid dose products, including products for Eisai. This facility supplements our outsourced small molecule manufacturing capabilities. Under our lease arrangement, Eisai may provide us with packaging services for oral solid dose products. In August 2015, we agreed to purchase this facility following the </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expiration of our current three year lease in the third quarter of 2018.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech is responsible for all worldwide manufacturing activities for bulk RITUXAN and GAZYVA and has sourced the manufacture of certain bulk RITUXAN and GAZYVA requirements to a third party, and Acorda Therapeutics supplies FAMPYRA to us pursuant to its supply agreement with Alkermes, Inc.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Third-Party Suppliers and Manufacturers</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We principally use third parties to manufacture the active pharmaceutical ingredient (API), and to a lesser extent, the final product for our small molecule products and product candidates, including TECFIDERA and FUMADERM, and the final drug product for our large molecule products and product candidates. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We source all of our fill-finish and the majority of final product assembly and storage operations for our products, along with a substantial part of our packaging operations, to a concentrated group of third-party contract manufacturing organizations. We have internal label and packaging capability for clinical and commercial products at our Cambridge and Hiller&#248;d facilities. Raw materials, delivery devices, such as syringes and auto-injectors, and other supplies required for the production of our products and product candidates are procured from various third-party suppliers and manufacturers in quantities adequate to meet our needs. Continuity of supply of such raw materials, devices and supplies is assured using a strategy of dual sourcing where possible or by a risk-based inventory strategy. Our third-party service providers, suppliers and manufacturers may be subject to routine cGMP inspections by the FDA or comparable agencies in other jurisdictions and undergo assessment and certification by our quality management group.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><a name="sc73ecae616d745e6b7d44e8a95819a3a"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Our Employees</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately 7,350 employees worldwide.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Our Executive Officers (as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">February&#160;3, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="30%"></td><td width="1%"></td><td width="56%"></td><td width="1%"></td><td width="4%"></td><td width="1%"></td><td width="7%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Current Position</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Age</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year Joined Biogen</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">George A. Scangos, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2010</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Susan H. Alexander</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Chief Legal Officer and Corporate Secretary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2006</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spyros Artavanis-Tsakonas, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Senior Vice President, Chief Scientific Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2012</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paul J. Clancy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Finance and Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2001</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gregory F. Covino</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vice President, Finance and Chief Accounting Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2012</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">John G. Cox</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Pharmaceutical Operations and Technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2003</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Kenneth DiPietro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Human Resources</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2012</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Steven H. Holtzman</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Corporate Development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2011</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adriana (Andi) Karaboutis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Technology, Business Solutions and Corporate Affairs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adam Koppel, M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Strategy and Business Development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Alfred W. Sandrock, Jr., M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Medical Officer and Executive Vice President of Neurology Discovery and Development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1998</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="5%"></td><td width="5%"></td><td width="90%"></td></tr><tr><td colspan="3" style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">George A. Scangos, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Experience</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dr. Scangos has served as our Chief Executive Officer since July 2010. Prior to that, he served as the President and Chief Executive Officer of Exelixis, Inc., a drug discovery and development company, from 1996 to July 2010. From 1993 to 1996, Dr. Scangos served as President of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer&#8217;s biological products. Before joining Bayer in 1987, Dr. Scangos was a professor of biology at Johns Hopkins University for six years, where he is still an adjunct professor. Dr. Scangos served as non-executive Chairman of Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from 2005 to July 2010 and was a director of the company from 2003 to July 2010. He also served as the Chair of the California Healthcare Institute in 2010 and was a member of the board of the Global Alliance for TB Drug Development until 2010. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Public Company Boards</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Board of Directors of Agilent Technologies, Inc., a provider of instruments, software, services and consumables for laboratories</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Board of Directors of Exelixis, Inc., a drug discovery and development company</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outside Affiliations</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chairman-elect of the Board of Directors of Pharmaceutical Research and Manufacturers of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Board of Trustees of the Boston Museum of Science and the Biomedical Science Careers Program</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">National Board of Visitors of the University of California, Davis School of Medicine</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Education</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cornell University, B.A. in Biology </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">University of Massachusetts, Ph.D. in Microbiology</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Yale University, Jane Coffin Childs Post-Doctoral Fellow</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><a name="sc73ecae616d745e6b7d44e8a95819a3a"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="5%"></td><td width="5%"></td><td width="90%"></td></tr><tr><td colspan="3" style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Susan H. Alexander</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Experience</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ms. Alexander has served as our Executive Vice President, Chief Legal Officer and Corporate Secretary since December 2011. Prior to that, from 2006 to December 2011, Ms. Alexander served as our Executive Vice President, General Counsel and Corporate Secretary. From 2003 to January 2006, Ms.&#160;Alexander served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corporation, a biopharmaceutical services company. From 2001 to 2003, Ms.&#160;Alexander served as General Counsel of IONA Technologies, a software company. From 1995 to 2001, Ms.&#160;Alexander served as Counsel at Cabot Corporation, a specialty chemicals and performance materials company. Prior to that, Ms.&#160;Alexander was a partner at the law firms of Hinckley, Allen&#160;&amp; Snyder and Fine&#160;&amp; Ambrogne. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Education</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Wellesley College, B.A</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Boston University School of Law, J.D.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="5%"></td><td width="5%"></td><td width="90%"></td></tr><tr><td colspan="3" style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spyros Artavanis-Tsakonas, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Experience</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dr. Artavanis-Tsakonas has served as our Senior Vice President, Chief Scientific Officer since May 2013. Prior to that, Dr. Artavanis-Tsakonas served as our interim Chief Scientific Officer while on sabbatical from Harvard Medical School from March 2012 to May 2013. Dr. Artavanis-Tsakonas has been a Professor of Cell Biology at the Harvard Medical School since 1999. From 1999 through 2012, he was Professor, Coll&#232;ge de France, serving as Chair of Biology and Genetics of Development, and from 1999 to 2007, he was also the K.J. Isselbacher- P. Schwartz Professor at the Massachusetts General Hospital Cancer Center and Director of Developmental Biology and Cancer at the Harvard Medical School. Dr. Artavanis-Tsakonas is the scientific co-founder of Exelixis Pharmaceuticals, Inc., a drug discovery and development company, Cellzome, a drug discovery and development company, and Anadys Pharmaceuticals, Inc., a biopharmaceutical company. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Education</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal Institute of Technology, Zurich, M.Sc. in Chemistry</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">University of Cambridge, England, Ph.D. in Molecular Biology</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biozentrum, University of Basel and Stanford University, postdoctoral research</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="5%"></td><td width="5%"></td><td width="90%"></td></tr><tr><td colspan="3" style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Experience</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. Clancy has served as our Executive Vice President, Finance and Chief Financial Officer since August 2007. Mr. Clancy joined Biogen, Inc. in 2001 and has held several senior executive positions with us, including Vice President of Business Planning, Portfolio Management and U.S. Marketing, and Senior Vice President of Finance with responsibilities for leading the Treasury, Tax, Investor Relations and Business Planning groups. Prior to that, he spent 13 years at PepsiCo, a food and beverage company, serving in a range of financial and general management positions. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Public Company Boards</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Board of Directors of Agios Pharmaceuticals, Inc., a biopharmaceutical company</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Board of Directors of Incyte Corporation, a biopharmaceutical company </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Education</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Babson College, B.S. in Finance</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Columbia University, M.B.A.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="5%"></td><td width="5%"></td><td width="90%"></td></tr><tr><td colspan="3" style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gregory F. Covino</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Experience</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. Covino has served as our Vice President, Finance and Chief Accounting Officer since April 2012. Prior to that, Mr. Covino served at Boston Scientific Corporation, a medical device company, as Vice President, Corporate Analysis and Control since March 2010, having responsibility for the company's internal audit function, and as Vice President, Finance, International from February 2008 to March 2010, having responsibility for the financial activities of the company's international division. Prior to that, Mr. Covino held several finance positions at Hubbell Incorporated, an electrical products company, including Vice President, Chief Accounting Officer and Controller from 2002 to January 2008, Interim Chief Financial Officer from 2004 to 2005, and Director, Corporate Accounting from 1999 to 2002. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Education</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bryant University, B.S. in Business Administration</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><a name="sc73ecae616d745e6b7d44e8a95819a3a"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="5%"></td><td width="5%"></td><td width="90%"></td></tr><tr><td colspan="3" style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">John G. Cox</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Experience</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. Cox has served as our Executive Vice President, Pharmaceutical Operations and Technology since June 2010 and has been leading our Global Therapeutic Operations since October 2015. Mr. Cox joined Biogen, Inc. in 2003 and has held several senior executive positions with us, including Senior Vice President of Technical Operations, Senior Vice President of Global Manufacturing, and Vice President of Manufacturing and General Manager of Biogen&#8217;s operations in RTP. Prior to that, Mr. Cox held a number of senior operational roles at Diosynth Inc., a life sciences manufacturing and services company, where he worked in technology transfer, validation and purification. Prior to that, Mr. Cox focused on the same areas at Wyeth Corporation, a life sciences company, from 1993 to 2000. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Public Company Boards</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Board of Directors of Repligen Corporation, a life sciences company</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Education</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Arizona State University, B.S. in Biology</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">University of Michigan, M.B.A. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">California State University, M.S. in Cell Biology</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="5%"></td><td width="5%"></td><td width="90%"></td></tr><tr><td colspan="3" style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Kenneth DiPietro</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Experience</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. DiPietro has served as our Executive Vice President, Human Resources since January 2012. Mr. DiPietro joined Biogen from Lenovo Group, a technology company, where he served as Senior Vice President, Human Resources from 2005 to June 2011. From 2003 to 2005, he served as Corporate Vice President, Human Resources at Microsoft Corporation, a technology company. From 1999 to 2002, Mr. DiPietro worked as Vice President, Human Resources at Dell Inc., a technology company. Prior to that, he spent 17 years at PepsiCo, a food and beverage company, serving in a range of human resource and general management positions.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Public Company Boards</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Board of Directors of InVivo Therapeutics Corporation, a medical device company</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Education</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cornell University, B.S. in Industrial and Labor Relations</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="5%"></td><td width="5%"></td><td width="90%"></td></tr><tr><td colspan="3" style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Steven H. Holtzman</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Experience</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. Holtzman has served as our Executive Vice President, Corporate Development since January 2011. Prior to that, Mr. Holtzman was a founder of Infinity Pharmaceuticals, Inc., a drug discovery and development company, where he served as Chair of the Board of Directors from company inception in 2001 to November 2012, Executive Chair of the Board of Directors in 2010 and as Chief Executive Officer from 2001 to December 2009. From 1994 to 2001, Mr. Holtzman was Chief Business Officer at Millennium Pharmaceuticals Inc., a biopharmaceutical company. From 1986 to 1994, he was a founder, member of the Board of Directors and Executive Vice President of DNX Corporation, a biotechnology company. From 1996 to 2001, Mr. Holtzman served as presidential appointee to the national Bioethics Advisory Commission. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Education</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michigan State University, B.A.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Oxford University, B.Phil. graduate degree, which he attended as a Rhodes Scholar</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><a name="sc73ecae616d745e6b7d44e8a95819a3a"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="5%"></td><td width="5%"></td><td width="90%"></td></tr><tr><td colspan="3" style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adriana (Andi) Karaboutis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Experience</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ms. Karaboutis has served as our Executive Vice President, Technology, Business Solutions and Corporate Affairs since December 2015 and prior to that served as our Executive Vice President, Technology and Business Solutions since joining Biogen in September 2014. Prior to that, Ms. Karaboutis was Vice President and Global Chief Information Officer of Dell, Inc., where she was responsible for leading a global IT organization focused on powering Dell as an end-to-end technology solutions provider. Prior to joining Dell in 2010, Ms. Karaboutis spent over 20 years at General Motors and Ford Motor Company in various international leadership positions including computer-integrated manufacturing, supply chain operations, and information technology. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Public Company Boards</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Board of Directors of Advance Auto Parts, an automotive aftermarket parts provider </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Education</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Wayne State University, B.S. in Computer Science</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="5%"></td><td width="5%"></td><td width="90%"></td></tr><tr><td colspan="3" style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adam Koppel, M.D., Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Experience</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dr. Koppel has served as our Executive Vice President, Strategy and Business Development since November 2015. Prior to that, Dr. Koppel served as our Senior Vice President and Chief Strategy Officer from May 2014 to October 2015, responsible for leading corporate strategy and portfolio management. Prior to joining us, Dr. Koppel served as a Managing Director of Brookside Capital, the public-equity affiliate of Bain Capital, since November 2003. Prior to Brookside Capital, he served as Associate Principal with McKinsey &amp; Company, where he consulted to companies in the pharmaceutical and biotechnology industries. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Public Company Boards</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Board of Directors of PTC Therapeutics, Inc., a biopharmaceutical company </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Board of Directors of Trevena, Inc., a biopharmaceutical company </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Education</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Harvard University, B.A.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Wharton School of the University of Pennsylvania, M.B.A.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">University of Pennsylvania School of Medicine, M.D. and Ph.D.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="5%"></td><td width="5%"></td><td width="90%"></td></tr><tr><td colspan="3" style="vertical-align:middle;border-bottom:2px solid #000000;background-color:#dde5ae;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Alfred W. Sandrock, Jr., M.D., Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Experience</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dr. Sandrock has served as our Chief Medical Officer and Executive Vice President of Neurology Discovery and Development since November 2015. Prior to that, Dr. Sandrock served as our Chief Medical Officer and Group Senior Vice President from May 2013 to October 2015, and as our Chief Medical Officer and Senior Vice President of Development Sciences from February 2012 to April 2013. Prior to that, Dr. Sandrock held several senior executive positions since joining us in 1998, including Senior Vice President of Neurology Research and Development and Vice President of Clinical Development, Neurology. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Public Company Boards</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Board of Directors of Neurocrine Biosciences, Inc., a life sciences company</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Education</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stanford University, B.A. in Human Biology</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Harvard Medical School, M.D. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Harvard University, Ph.D. in Neurobiology</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts General Hospital, internship in Medicine, residency and chief residency in Neurology, and clinical fellowship in Neuromuscular Disease and Clinical Neurophysiology (electromyography)</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><a name="s3f8e520d1b85492c91d442a233a5c4dc"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Available Information</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our principal executive offices are located at 225 Binney Street, Cambridge, MA 02142 and our telephone number is (617)&#160;679-2000. Our website address is www.biogen.com. We make available free of charge through the Investors section of our website our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission (SEC). We include our website address in this report only as an inactive textual reference and do not intend it to be an active link to our website. The contents of our website are not incorporated into this report.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><a name="sB7A45A12C24CD940C931B512B19484BB"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;1A. &#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-style:italic;font-weight:bold;">Risk Factors</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are substantially dependent on revenues from our principal products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current revenues depend upon continued sales of our principal products. We may be substantially dependent on sales from our principal products for many years, including an increasing reliance on sales and growth of TECFIDERA as we further expand into additional markets. Any of the following negative developments relating to any of our principal products may adversely affect our revenues and results of operations or could cause a decline in our stock price: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">safety or efficacy issues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">constraints and additional pressures on product pricing or price increases, due to a number of factors, including governmental or regulatory requirements, increased competition, or changes in reimbursement policies and practices of payors and other third parties; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse legal, administrative, regulatory or legislative developments. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to compete effectively, our business and market position would suffer.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, greater financial and other resources and other technological or competitive advantages. One or more of our competitors may benefit from significantly greater sales and marketing capabilities, may develop products that are accepted more widely than ours or may receive patent protection that dominates, blocks or adversely affects our product development or business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to competition from generics and biosimilars in many markets.&#160;Generic versions of drugs and biosimilars are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of generic or biosimilar versions of our marketed products likely would significantly reduce both the price that we receive for such marketed products and the volume of products that we sell, which may have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the MS market, we face intense competition as the number of products and competitors continues to expand. Due to our significant reliance on sales of our MS products, our business may be harmed if we are unable to successfully compete in the MS market. More specifically, our ability to compete, maintain and grow our share in the MS market may be adversely affected due to a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of more efficacious, safer, less expensive or more convenient alternatives to our MS products, including our own products and products of our collaborators; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of lower-cost biosimilars, follow-on products or generic versions of branded MS products sold by our competitors, and the possibility of future competition from generic versions or prodrugs of existing therapeutics or from off-label use by physicians of therapies indicated for other conditions to treat MS patients; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patient dynamics, including the size of the patient population and our ability to attract new patients to our therapies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">damage to physician and patient confidence in any of our MS products or to our sales and reputation as a result of label changes or adverse experiences or events that may occur with patients treated with our MS products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inability to obtain appropriate pricing and reimbursement for our MS products compared to our competitors in key international markets; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to obtain and maintain patent, data or market exclusivity for our MS products.</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><a name="sB7A45A12C24CD940C931B512B19484BB"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Similarly, the hemophilia treatment market is highly competitive, with current treatments marketed by companies that have substantially greater financial resources and marketing expertise. Our ability to successfully compete in the hemophilia market and gain share in this market may be adversely affected due to a number of reasons, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difficulty in penetrating this market if our therapies are not regarded as offering significant benefits over current treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction by other companies of longer-lasting or more efficacious, safer, less expensive or more convenient treatments than our therapies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our limited marketing experience within the hemophilia treatment market, which may impact our ability to develop relationships with the associated medical and scientific community; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">if one of several companies that are working to develop additional treatments for hemophilia obtains marketing approval of its treatment in the E.U. before we do, our application for ALPROLIX with the EMA could be barred under operation of the EMA&#8217;s orphan medicinal product regulation.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, revenues and results of operations, and could cause a decline in our stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products are dependent, in large part, on the availability and extent of coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pricing and reimbursement for our products may be adversely affected by a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in federal, state or foreign government regulations or private third-party payors' reimbursement policies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pressure by employers on private health insurance plans to reduce costs; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">consolidation and increasing assertiveness of payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value.&#160; </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to set the price for our products can vary significantly from country to country and as a result so can the price of our products.  Certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to secure adequate prices in a particular country may not only limit the marketing of our products within that country, but may also adversely affect our ability to obtain acceptable prices in other markets. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenues.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to maintain adequate coverage, pricing, or reimbursement for our products would have an adverse effect on our business, revenues and results of operation, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products, and could cause a decline in our stock price.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;Drug pricing and other health care costs continue to be subject to intense political and societal pressures which we anticipate will continue and escalate on a global basis.&#160;As a result, our business and reputation may be harmed, our stock price may be adversely impacted and experience periods of volatility, and our results of operations may be adversely impacted.&#160; </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><a name="sB7A45A12C24CD940C931B512B19484BB"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our results of operations may be adversely affected by current and potential future healthcare reforms.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals and enactments to reform health care insurance programs could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the Patient Protection and Affordable Care Act (PPACA) have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for our products. In addition, under the PPACA, as states implement their health care marketplaces or operate under the federal exchange, the impact on drug manufacturers, including us, will depend in part on the formulary and benefit design decisions made by insurance sponsors or plans participating in these programs. It is possible that we may need to provide discounts or rebates to such plans in order to maintain favorable formulary access for our products for this patient population, which could have an adverse impact on our sales and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures to reduce health care costs to constrain their overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possibly retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases, and greater importation of drugs from lower-cost countries to higher-cost countries. These measures have negatively impacted our revenues, and may continue to adversely affect our revenues and results of operations in the future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adverse safety events involving our marketed products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market, and the imposition of fines or criminal penalties. Adverse safety events may also damage physician and patient confidence in our products and our reputation. Any of these could result in liabilities, loss of revenue, material write-offs of inventory, material impairments of intangible assets, goodwill and fixed assets, material restructuring charges and other adverse impacts on our results of operations. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales or stock price to decline or experience periods of volatility. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing progressive multifocal leukoencephalopathy (PML), a serious brain infection, in the label for certain of our products, may significantly reduce expected revenues for those products and require significant expense and management time. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><a name="sB7A45A12C24CD940C931B512B19484BB"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success depends in part on our ability to obtain and defend patent and other intellectual property rights that are important to the commercialization of our products and product candidates. The degree of patent protection that will be afforded to our products and processes in the U.S. and in other important markets remains uncertain and is dependent upon the scope of protection decided upon by the patent offices, courts and lawmakers in these countries. We can provide no assurance that we will successfully obtain or preserve patent protection for the technologies incorporated into our products and processes, or that the protection obtained will be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business. If we cannot prevent others from exploiting our inventions, we will not derive the benefit from them that we currently expect. Furthermore, we can provide no assurance that our products will not infringe patents or other intellectual property rights held by third parties.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also rely on regulatory exclusivity for protection of our products. Implementation and enforcement of regulatory exclusivity, which may consist of regulatory data protection and market protection, varies widely from country to country.&#160;Failure to qualify for regulatory exclusivity, or failure to obtain or maintain the extent or duration of such protections that we expect in each of the markets for our products due to challenges, changes or interpretations in the law or otherwise, could affect our revenue for our products or our decision on whether to market our products in a particular country or countries or could otherwise have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Litigation, interferences, oppositions, inter partes reviews or other proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We may also face challenges to our patent and regulatory protections covering our products by manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity.&#160;Litigation, interference, oppositions, inter partes reviews or other similar types of proceedings are unpredictable and may be protracted, expensive and distracting to management. The outcome of such proceedings could adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our long-term success depends upon the successful development of new products and additional indications for existing products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our long-term viability and growth will depend upon successful development of additional indications for our existing products as well as successful development of new products and technologies from our research and development activities, our biosimilars joint venture with Samsung Biologics or licenses or acquisitions from third parties. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development is very expensive and involves a high degree of risk. Only a small number of research and development programs result in the commercialization of a product. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events, or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm, or significant reduction in the commercial potential of the product candidate.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><a name="sB7A45A12C24CD940C931B512B19484BB"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends in large part on a number of key factors. These factors include protocol design, regulatory and institutional review board approval, patient enrollment rates, and compliance with extensive current Good Clinical Practices. If we or our third-party clinical trial providers or third-party contract research organizations, or CROs, do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have opened clinical sites and are enrolling patients in a number of countries where our experience is more limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for substantially all of our clinical trial related activities and reporting. If this CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs. Although we believe there are a number of other CROs we could engage to continue these activities, the replacement of an existing CRO may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Positive results in a trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. In addition, even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or the processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated. These restrictions may include limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expenses, have an adverse effect on our business, financial condition and results of operations and cause our stock price to decline or experience periods of volatility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we are able to successfully develop new products or indications, sales of new products or products with additional indications may not meet investor expectations.  We may also make a strategic decision to discontinue development of a product or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing issues could substantially increase our costs, limit supply of our products and reduce our revenues.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk of Product Loss.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant. </font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><a name="sB7A45A12C24CD940C931B512B19484BB"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks of Reliance on Third Parties and Single Source Providers.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of several raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Global Bulk Supply Risks.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We rely on our manufacturing facilities in Cambridge, Massachusetts, RTP, North Carolina and Hiller&#248;d, Denmark for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, natural disasters, power failures and numerous other factors.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks Relating to Compliance with cGMP.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenue or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We depend on relationships with collaborators and other third-parties for revenue, and the development, regulatory approval, commercialization and marketing of certain products, which are outside of our full control.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on a number of significant collaborative relationships for revenue, and the development, regulatory approval, commercialization, and marketing of certain of our products and product candidates. Reliance on collaborative relationships subjects us to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">we may be unable to control the resources our collaborator devotes to our programs or products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">disputes may arise with respect to ownership of rights to technology developed with our collaborator, and the underlying contract with our collaborator may fail to provide significant protection or may fail to be effectively enforced if the collaborator fails to perform; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our collaborator&#8217;s interests may not always be aligned with our interests and a collaborator may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">collaborations often require the parties to cooperate, and failure to do so effectively could adversely affect product sales by our collaborator or the clinical development or regulatory approvals of products under joint control or could result in termination of the research, development or commercialization of product candidates or result in litigation or arbitration; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any failure on the part of our collaborator to comply with applicable laws and regulatory requirements in the marketing, sale and maintenance of the market authorization of our products or to fulfill any responsibilities our collaborator may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenues as well as involve us in possible legal proceedings.</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><a name="sB7A45A12C24CD940C931B512B19484BB"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed or revenues from products could decline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may fail to achieve the expected financial and operating benefits of our corporate restructuring and the restructuring may harm our business and financial results. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We face significant risks associated with our corporate restructuring actions that may impair our ability to achieve anticipated savings and operational efficiencies or that may otherwise harm our business. These risks include loss of workforce capabilities, loss of continuity, decreases in employee focus and morale, attrition of necessary or key employees, higher than anticipated separation expenses, litigation and the failure to meet financial and operational targets. In addition, the calculation of the anticipated cost savings and other benefits resulting from our corporate restructuring actions are subject to many estimates and assumptions. These estimates and assumptions are subject to significant business, economic, competitive and other uncertainties and contingencies, many of which are beyond our control. If these estimates and assumptions are incorrect or if we experience delays or unforeseen events, our business and financial results could be adversely affected. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business may be adversely affected if we do not manage our current growth and do not successfully execute our growth initiatives.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate growth through internal development projects, commercial initiatives, and external opportunities, which may include the acquisition, partnering and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations. The availability of high quality development opportunities is limited and competitive, and we are not certain that we will be able to identify candidates that we and our shareholders consider suitable or complete transactions on terms that are acceptable to us and our shareholders. We may fail to complete transactions for other reasons, including if we are unable to obtain desired financing on favorable terms, if at all. Even if we are able to successfully identify and complete acquisitions and other strategic alliances and collaborations, we may face unanticipated costs or liabilities in connection with the transaction or we may not be able to integrate them or take full advantage of them or otherwise realize the benefits that we expect.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To manage our current and future potential growth effectively, we need to continue to enhance our operational, financial and management processes and to expand, train and manage our employee base. Our growth is also dependent upon our ability to attract and retain qualified scientific, information technology, manufacturing, sales and marketing and executive personnel and to develop and maintain relationships with qualified clinical researchers and key distributors in a highly competitive environment. We may face difficulty in attracting and retaining key talent for a number of reasons, such as the underperformance or discontinuation of one or more late stage programs or recruitment by competitors.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supporting our growth initiatives and the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. If we do not successfully manage our current growth and do not successfully execute our growth initiatives, then our business and financial results may be adversely affected and we may incur asset impairment or restructuring charges.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasingly dependent upon technology systems and data. Our computer systems continue to increase in multitude and complexity due to the growth in our business, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Likewise, data privacy or security breaches by individuals authorized to access our technology systems or others may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. Cyber-attacks are increasing in their frequency, sophistication and intensity. While we continue to build and improve our systems and infrastructure and believe we have taken appropriate security measures to reduce these risks to our data and information technology systems, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><a name="sB7A45A12C24CD940C931B512B19484BB"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight both in the U.S.&#160;and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. Our interactions in the U.S.&#160;or abroad with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of the products and place greater restrictions on the marketing practices of health care companies. Health care companies such as ours are facing heightened scrutiny of their relationships with health care providers from anti-corruption enforcement officials. In addition, we along with many other pharmaceutical and biotechnology companies have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations, or violations related to environmental matters. These risks may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have product distribution methods differing from those we currently utilize. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulations governing the health care industry are subject to change, with possibly retroactive effect, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to health care availability, pricing or marketing practices, compliance with wage and hour laws and other employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements, and used product take-back requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA&#8217;s clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action which could harm our business; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use, or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products, or otherwise adversely affect the market for our products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Violations of governmental regulation may be punishable by criminal and civil sanctions against us, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. In addition to penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors, or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increase our vulnerability to general adverse economic and industry conditions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our ability to access capital markets and incur additional debt in the future;</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><a name="sB7A45A12C24CD940C931B512B19484BB"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development and mergers and acquisitions;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to our competitors that have less debt.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our sales and operations are subject to the risks of doing business internationally.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasing our presence in international markets, particularly emerging markets, subjecting us to many risks that could adversely affect our business and revenues, such as:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to obtain necessary foreign regulatory or pricing approvals of products in a timely manner; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">collectability of accounts receivable; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">fluctuations in foreign currency exchange rates, in particular the recent strength of the U.S. dollar versus foreign currencies which has adversely impacted our revenues and net income; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difficulties in staffing and managing international operations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of governmental controls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less favorable intellectual property or other applicable laws; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">compliance with complex import and export control laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">restrictions on direct investments by foreign entities and trade restrictions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">greater political or economic instability; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in tax laws and tariffs.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our international operations are subject to regulation under U.S. law. For example, the Foreign Corrupt Practices Act prohibits U.S. companies and their representatives from offering, promising, authorizing or making payments to foreign officials for the purpose of obtaining or retaining business abroad. In many countries, the health care professionals we regularly interact with may meet the definition of a foreign government official for purposes of the Foreign Corrupt Practices Act. Failure to comply with domestic or foreign laws could result in various adverse consequences, including: possible delay in approval or refusal to approve a product; recalls, seizures or withdrawal of an approved product from the market; disruption in the supply or availability of our products or suspension of export or import privileges; the imposition of civil or criminal sanctions; the prosecution of executives overseeing our international operations; and damage to our reputation.  Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our effective tax rate may fluctuate and we may incur obligations in tax jurisdictions in excess of accrued amounts.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><a name="sB7A45A12C24CD940C931B512B19484BB"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., there are several proposals under consideration to reform tax law, including proposals that may reduce or eliminate the deferral of U.S.&#160;income tax on our unrepatriated earnings, penalize certain transfer pricing structures, and reduce or eliminate certain foreign or domestic tax credits or deductions. Our future reported financial results may be adversely affected by tax law changes which restrict or eliminate certain foreign tax credits or our ability to deduct expenses attributable to foreign earnings, or otherwise affect the treatment of our unrepatriated earnings.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to U.S. tax reform proposals, the adoption of some or all of the recommendations set forth in the Organization for Economic Co-operation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities in the countries in which we operate, could negatively impact our effective tax rate.&#160;These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in a particular country.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our operating results are subject to significant fluctuations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our quarterly revenues, expenses and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Risk Factors&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the cost of restructurings; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">impairments with respect to investments, fixed assets and long-lived assets, including in-process R&amp;D and other intangible assets; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent consideration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">bad debt expenses and increased bad debt reserves; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">milestone payments under license and collaboration agreements; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">payments in connection with acquisitions and other business development activities.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues are also subject to foreign exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and the currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from hedge ineffectiveness or from the termination of a hedge relationship.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are pursuing opportunities to expand our manufacturing capacity for future clinical and commercial requirements for product candidates, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we believe we currently have sufficient manufacturing capacity to meet our near-term manufacturing requirements, it is probable that we would need additional manufacturing capacity to support future clinical and commercial manufacturing requirements for product candidates in our pipeline, if such candidates are successful and approved. We recently announced our intent to build a biologics manufacturing facility in Solothurn, Switzerland and our acquisition of an additional manufacturing facility in RTP, North Carolina. Due to the long lead times necessary for the expansion of manufacturing capacity, we expect to incur significant investment to build or expand our facilities or obtain third-party contract manufacturers with no assurance that such investment will be recouped. If we are unable to adequately and timely manufacture and supply our products and product candidates or if we do not fully utilize our manufacturing facilities, our business may be harmed.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><a name="sB7A45A12C24CD940C931B512B19484BB"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investment in Samsung Bioepis, and our success in commercializing biosimilars developed by Samsung Bioepis, are subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment in Samsung Bioepis, and our success in commercializing biosimilars developed by Samsung Bioepis, are subject to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reliance on Third Parties.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We are dependent on the efforts of Samsung Bioepis and other third parties over whom we have limited or no control in the development and manufacturing of biosimilars products.  If Samsung Bioepis or such other third parties fail to perform successfully, we may not realize the anticipated benefits of our investment in Samsung Bioepis;  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Regulatory Compliance.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intellectual Property and Regulatory Challenges.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions, or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Failure to Gain Market and Patient Acceptance.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Market success of biosimilar products will be adversely affected if patients, physicians and payers do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Competitive Challenges.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products face significant competition, including from innovator products and from biosimilar products offered by other companies.  In some jurisdictions, local tendering processes may restrict biosimilar products from being marketed and sold in those jurisdictions. The number of competitors in a jurisdiction, the timing of approval, and the ability to market biosimilar products successfully in a timely and cost-effective matter are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investments in properties may not be fully realized.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space, and manufacturing operations. For strategic or other operational reasons, we may decide to further consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value we may not realize the full investment in these properties and incur significant impairment charges. If we decide to fully or partially vacate a leased property, we may incur significant cost, including lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements. Any of these events may have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our portfolio of marketable securities is subject to market, interest and credit risk that may reduce its value.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a portfolio of marketable securities for investment of our cash. Changes in the value of our portfolio of marketable securities could adversely affect our earnings. In particular, the value of our investments may decline due to increases in interest rates, downgrades of the bonds and other securities included in our portfolio, instability in the global financial markets that reduces the liquidity of securities included in our portfolio, declines in the value of collateral underlying the securities included in our portfolio, and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">There can be no assurance that we will continue to repurchase stock or that we will repurchase stock at favorable prices.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our Board of Directors has approved stock repurchase programs and may approve additional repurchase programs in the future. The amount and timing of stock repurchases are subject to capital availability and our determination that stock repurchases are in the best interest of our stockholders and are in compliance with all respective laws and our agreements applicable to the repurchase of stock. Our ability to repurchase stock will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, results of operations, financial condition, and other factors beyond our control that we may deem relevant. A reduction in, or the completion or expiration of, our stock repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase stock at favorable prices, if at all.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><a name="sB7A45A12C24CD940C931B512B19484BB"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may not be able to access the capital and credit markets on terms that are favorable to us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may seek access to the capital markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements, and other business initiatives. The capital and credit markets have experienced extreme volatility and disruption which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse capital and credit market conditions, we may be unable to obtain capital market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The illegal distribution and sale by third parties of counterfeit versions of our products or stolen products could have a negative impact on our reputation and business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. Stolen inventory that is not properly stored or sold through unauthorized channels could adversely impact patient safety, our reputation and our business. In addition, thefts of inventory at warehouses, plants or while in-transit, which are not properly stored and which are sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The increasing use of social media platforms presents new risks and challenges.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. &#160;Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.&#160; </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s0385BCC5E1B9C0B157E0B512B1B42919"></a><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;1B. &#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-style:italic;font-weight:bold;">Unresolved Staff Comments</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><a name="sC687E45A6F2B9BCD0321B512B1E5BCA7"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;2. &#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-style:italic;font-weight:bold;">Properties</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Below is a summary of our owned and leased properties as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Massachusetts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In Cambridge, Massachusetts, we own approximately 508,000&#160;square feet of real estate space, consisting of a building that houses a research laboratory and a cogeneration plant totaling approximately 263,000&#160;square feet and a building that contains research, development and quality laboratories which total approximately 245,000&#160;square feet.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we lease a total of approximately 1,312,000&#160;square feet in Massachusetts, which is summarized as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">909,000&#160;square feet in Cambridge, Massachusetts, which is comprised of a 67,000&#160;square foot biologics manufacturing facility and 842,000&#160;square feet for our corporate headquarters, laboratory and additional office space;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">357,000&#160;square feet of office space in Weston, Massachusetts, of which 175,000 square feet has been subleased through the remaining term of our lease agreement; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46,000&#160;square feet of warehouse space in Somerville, Massachusetts.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our Massachusetts lease agreements expire at various dates through the year 2028.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">North Carolina</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In RTP, North Carolina, we own approximately 834,000&#160;square feet of real estate space, which is summarized as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">357,000&#160;square feet of laboratory and office space;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">175,000&#160;square feet related to a large-scale biologics manufacturing facility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">105,000&#160;square feet related to a biologics manufacturing facility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84,000&#160;square feet of warehouse space and utilities;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70,000 square feet related to a parenteral fill-finish facility; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43,000&#160;square feet related to a large-scale purification facility.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we lease 188,000 square feet of a facility in RTP, North Carolina from Eisai to manufacture our and Eisai's oral solid dose products and 10,000 square feet of warehouse space in Durham, North Carolina. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Denmark</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We own a large-scale biologics manufacturing facility totaling approximately 228,000&#160;square feet located in Hiller&#248;d, Denmark. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also own approximately 306,000&#160;square feet of additional space, which is summarized as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">139,000&#160;square feet of warehouse, utilities and support space;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70,000&#160;square feet related to a label and packaging facility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47,000&#160;square feet of administrative space;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50,000&#160;square feet related to a laboratory facility.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Switzerland</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2015, we acquired land in Solothurn, Switzerland, where we plan to build a biologics manufacturing facility in the Commune of Luterbach over the next several years.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><a name="sC687E45A6F2B9BCD0321B512B1E5BCA7"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other International</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We lease office space in Zug, Switzerland, our international headquarters, the United Kingdom, Germany, France, Denmark, and numerous other countries. Our international lease agreements expire at various dates through the year 2023.</font></div><a name="sBEC0910FD4B23026A848B512B2074C81"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;3. &#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of legal matters as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report, which is incorporated into this item by reference.</font></div><a name="s873CCF7CF63944374399B512B238B973"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;4. &#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-style:italic;font-weight:bold;">Mine Safety Disclosures</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Not applicable.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><a name="s3D24CA0B08FF4F441AECB512B25A6EB0"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;II</font></div><a name="s20BFD3EA5B810DB0EDBDB512946DF050"></a><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;5. &#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-style:italic;font-weight:bold;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Market and Stockholder Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our common stock trades on The NASDAQ Global Select Market under the symbol &#8220;BIIB.&#8221; The following table shows the high and low sales price for our common stock as reported by The NASDAQ Global Select Market for each quarter in the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common Stock Price</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Low</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Low</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">480.18</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">334.40</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">358.89</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">270.62</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Second Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">432.88</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">368.88</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">322.25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">272.02</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">412.24</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">265.00</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">349.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">298.31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fourth Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">311.65</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">254.00</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">361.93</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">290.85</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">January&#160;29, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, there were approximately 742 stockholders of record of our common stock.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Dividends</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have not paid cash dividends since our inception. While we historically have not paid cash dividends and do not have a current intention to pay cash dividends, we continually review our capital allocation strategies, including, among other things, payment of cash dividends, stock repurchases, or acquisitions.</font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015, our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2015 Share Repurchase Program). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our common stock repurchase activity under our 2015 Share Repurchase Program during the </font><font style="font-family:inherit;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">fourth</font></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td width="17%"></td><td width="19%"></td><td width="1%"></td><td width="1%"></td><td width="19%"></td><td width="1%"></td><td width="1%"></td><td width="19%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="18%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average&#160;Price</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Paid&#160;per&#160;Share</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">as&#160;Part&#160;of&#160;Publicly</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Announced&#160; Programs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Maximum</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Approximate Dollar Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">of Shares That May Yet Be</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Purchased Under</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Our Programs ($ in millions)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">October&#160;2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,976,270</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">275.87</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,976,270</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">629.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">November&#160;2015</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,131,417</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">295.12</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,131,417</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,107,687</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">281.64</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 2015 Share Repurchase Program was completed and we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011, our Board of Directors authorized a program to repurchase up to 20.0 million shares of our common stock (2011 Share Repurchase Program), which has been used principally to offset common stock issuances under our share-based compensation plans. The 2011 Share Repurchase Program does not have an expiration date. We did not repurchase any shares of common stock under our 2011 Share Repurchase Program during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares remaining available for repurchase under this authorization.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Stock Performance Graph</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The graph below compares the five-year cumulative total stockholder return on our common stock, the S&amp;P 500 Index, the Nasdaq Pharmaceutical Index and the Nasdaq Biotechnology Index assuming the investment of $100.00 on December&#160;31, 2010 with dividends being reinvested. The stock price performance in the graph below is not necessarily indicative of future price performance.</font></div><div style="line-height:120%;text-align:center;"><img src="stockperformancechart.jpg" style="height:480px;width:613px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td width="22%"></td><td width="12%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2010</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2011</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2012</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">164.13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">416.96</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">456.90</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NASDAQ Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">107.59</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">123.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">166.89</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">203.30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">214.35</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">S&amp;P 500 Index</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">102.11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">118.45</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">156.82</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">178.28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">180.75</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NASDAQ Biotechnology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">112.09</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">148.78</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">247.01</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">331.99</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">371.06</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><a name="s85C4959389BAE93A2BADB5129E5FAA23"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;6. &#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-style:italic;font-weight:bold;">Selected Financial Data</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SELECTED FINANCIAL DATA</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td width="36%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2011</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">(3) (4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(1) (2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(1)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Results of Operations</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,188.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,203.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,542.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,166.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,836.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from unconsolidated joint business</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,339.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,126.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,137.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">996.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">236.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">263.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,763.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,703.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,932.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,516.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,048.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,872.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,747.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,441.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,707.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,323.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain on sale of rights</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,891.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,972.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,515.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,855.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,724.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(123.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(25.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(34.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax expense and equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,767.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,946.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,480.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,855.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,711.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,161.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">989.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">601.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">470.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">444.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,593.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,941.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,862.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,380.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,266.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to noncontrolling interests, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">46.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,547.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,862.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,380.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,234.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Diluted Earnings Per Share</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.81</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.76</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.04</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">231.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">239.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">245.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2011</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">(5) (6)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Financial Condition</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,188.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,316.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,848.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,742.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,107.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">19,504.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14,314.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,863.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,130.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,049.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable, line of credit and other financing arrangements, less current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,521.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">592.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">687.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,060.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc. shareholders&#8217; equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,372.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,809.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,620.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,961.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,425.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the following notes, the financial data included within the tables above should be read in conjunction with our consolidated financial statements and related notes and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;sections of this report and our previously filed Form&#160;10-Ks.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of revenues from unconsolidated joint business reflects charges of $50.0 million in 2011 and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$49.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in 2013 for damages and interest awarded to Hoechst in Genentech's arbitration with Hoechst for RITUXAN.</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><a name="s85C4959389BAE93A2BADB5129E5FAA23"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commencing in the second quarter of 2013, product and total revenues include 100% of net revenues related to sales of TYSABRI as a result of our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd (Elan), an affiliate of Elan Corporation, plc. Upon the closing, our collaboration agreement was terminated, and we no longer record collaboration profit sharing expense. We recognized collaboration profit sharing expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$85.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, $317.9 million and $317.8 million during the years ended December 31, 2013, 2012 and 2011, respectively. In addition, product and total revenues includes net revenues related to sales of TECFIDERA. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues reflects a decrease in royalty revenues due to the December 2014 expiration of U.S. patent rights that gave rise to royalty payments related to ANGIOMAX.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Included in total cost and expenses is a restructuring charge of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;incurred in connection with our corporate restructuring announced on October 21, 2015, which included the termination of certain pipeline programs and an 11% reduction in workforce.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable, line of credit and other financing arrangements, less current portion reflects the issuance of our senior unsecured notes for an aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on September 15, 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc.'s shareholders' equity reflects a reduction in additional paid in capital and retained earnings totaling </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;resulting from the repurchase and retirement of our common stock under our 2015 Share Repurchase Program.</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><a name="s362F9929E4D04E9C8998B5129FD6EC34"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;7. &#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following discussion should be read in conjunction with our consolidated financial statements and related notes beginning on page&#160;F-1 of this report. Certain totals may not sum due to rounding.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Executive Summary</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Introduction</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. We also have a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, which entitles us to certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL, and other potential anti-CD20 therapies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current revenues depend upon continued sales of our principal products. We may be substantially dependent on sales from our principal products for many years, including an increasing reliance on sales and growth of TECFIDERA as we continue to expand into additional markets. In the longer term, our revenue growth will be dependent upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products and assets originating from our research and development efforts, and successful execution of external business development opportunities. As part of our ongoing research and development efforts, we have devoted significant resources to conducting clinical studies to advance the development of new pharmaceutical products and to explore the utility of our existing products in treating disorders beyond those currently approved in their labels. In addition to our innovative drug development efforts, we aim to leverage our manufacturing capabilities and scientific expertise to extend our mission to improve the lives of patients living with serious diseases through the development, manufacture and marketing of biosimilars through </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics).</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financial Highlights</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;"><img src="financialhighlightschart.jpg" style="height:426px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc. were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.34</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 24.0% over the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described below under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Results of Operations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,&#8221; our income from operations for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues were </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$10,763.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">10.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$9,188.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">12.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was driven by a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">25.1%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase in worldwide TECFIDERA revenues as well as revenue from our recent product additions PLEGRIDY, ELOCTATE and ALPROLIX, partially offset by a decrease in worldwide AVONEX and TYSABRI revenues. In addition, product revenues, net for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were negatively impacted by foreign currency exchange losses of $388.1 million, partially offset by comparative net gains recognized under our foreign currency hedging program of $166.3 million.</font></div></td></tr></table></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><a name="s362F9929E4D04E9C8998B5129FD6EC34"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN and GAZYVA operating profits totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,339.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">12.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily due to a 4% increase in U.S. product sales of RITUXAN and price increases.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$236.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing a decrease of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">22.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This decrease was driven by a 73.1% decrease in royalty revenues primarily due to the expiration of U.S. patent rights that gave rise to royalty payments related to ANGIOMAX, partially offset by a 47.6% increase in corporate partner revenues primarily due to an increase in contract manufacturing activities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$5,872.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was driven by a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">6.3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase in research and development expense, a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase in cost of sales, losses recognized on fair value remeasurement of contingent consideration as well as the recognition of a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;charge related to our recent corporate restructuring. These increases were partially offset by a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">21.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;decrease in the amortization of acquired intangible assets and a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;decrease in selling, general and administrative expenses. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3,716.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net cash flows from operations for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which were primarily driven by earnings. Cash, cash equivalents and marketable securities totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6,188.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On September 15, 2015, we issued senior unsecured notes for an aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our share repurchase programs. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Restructuring</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On October 21, 2015, we announced a corporate restructuring, which includes the termination of certain pipeline programs and an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction in workforce. For additional information, please read </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Restructuring</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;set forth below in this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management's Discussion and Analysis of Financial Condition and Results of Operations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisitions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 12, 2015, we completed the acquisition of all of the outstanding stock of Convergence Pharmaceuticals (Convergence), a clinical-stage biopharmaceutical company with a focus on developing product candidates for neuropathic pain. For additional information related to this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 2, 2015, we announced a collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases with Applied Genetic Technologies Corporation (AGTC). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On September 9, 2015, we announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to exclusively license amiselimod (MT-1303), a late stage experimental medicine with potential in multiple autoimmune indications. Amiselimod is an oral compound that targets the sphingosine 1-phosphate receptor. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to these transactions, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Environment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing. In addition, the commercialization of certain of our own approved MS products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing MS products. Our products may also face increased competitive pressures from the introduction of generic versions, prodrugs of existing therapeutics or biosimilars of existing products and other technologies, such as gene therapies. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, sales of our products are dependent, in large part, on the availability and extent of coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our competition and pricing risks that could negatively impact our products, please read the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Risk Factors&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;section of this report.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><a name="sEF0F91222DC64509EDEAB5129E6092D9"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td width="35%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015 compared to 2014</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014 compared to 2013</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,545.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,566.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,581.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">17.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,642.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,636.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,961.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,188.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,203.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,542.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,339.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,126.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">236.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">263.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(22.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,763.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,703.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,932.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td width="35%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015 compared to 2014</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014 compared to 2013</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,638.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,909.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">876.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">232.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,968.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,057.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,886.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,959.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,526.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">89.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">319.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">447.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">234.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">208.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">51.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(17.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,188.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,203.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,542.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">* Interferon includes AVONEX and PLEGRIDY.</font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><a name="s77b12d8928874ad794234c07f74212f8"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis (MS)</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA</font></div><div style="line-height:120%;text-align:left;"><img src="tecfiderachart.jpg" style="height:333px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TECFIDERA revenues was primarily due to an increase in unit sales volume of 13% as TECFIDERA penetrated the U.S. market, and increases in gross price partially offset by higher discounts and allowances. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TECFIDERA revenues was primarily due to increases in unit sales volume.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world TECFIDERA revenues was primarily due to increases in unit sales volume in existing markets and in additional markets as we continue to launch the product and expand our presence around the world. These increases were partially offset by pricing reductions in Germany as described below. Rest of world TECFIDERA revenues for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;were negatively impacted by foreign currency exchange losses totaling $74.1 million.&#160;These foreign currency exchange losses were partially offset by comparative net gains recognized under our foreign currency hedging program totaling $47.5 million. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, rest of world TECFIDERA revenues increased as sales in Germany began in the first quarter of 2014. </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under German legislation related to the pricing of new drug products introduced in the German market, pricing is unregulated for the first 12 months after launch. We launched TECFIDERA in Germany in February 2014, and our unregulated pricing ended in the first quarter of 2015, at which time we began recognizing revenue at the fixed price established through our negotiations with the German regulatory authorities. The negotiated annual price is fixed for three years. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we continue to see a strong uptake of TECFIDERA in newly launched territories, total market growth and patient switch rates in our maturing markets, such as the U.S. and Germany, have returned to historical averages for MS. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interferon</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">AVONEX</font></div><div style="line-height:120%;text-align:left;"><img src="avonexchart.jpg" style="height:333px;width:317px;"></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in U.S. AVONEX revenues was primarily due to a decrease in unit sales volume of 17%, which was attributable in part to patients transitioning to PLEGRIDY and oral MS therapies, including TECFIDERA, partially offset by gross price increases. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. AVONEX revenues was primarily due to price increases, partially offset by a decrease in unit sales volume of 10%, which was attributable in part to patients transitioning to PLEGRIDY and oral MS therapies, including TECFIDERA. </font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><a name="s77b12d8928874ad794234c07f74212f8"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world AVONEX revenues was primarily due to a decrease in unit sales volume of 11% primarily in Europe, attributable to patients transitioning to PLEGRIDY and oral MS therapies, including TECFIDERA. Rest of world AVONEX revenues for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were negatively impacted by foreign currency exchange losses of $153.1 million. These foreign currency exchange losses were partially offset by comparative net gains recognized under our foreign currency hedging program of $58.4 million. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world AVONEX revenues was due to a 7% decrease in unit sales volume in Europe primarily attributable to patients transitioning to oral therapies including TECFIDERA, partially offset by a 6% increase in unit demand in the emerging markets region. Rest of world AVONEX revenue for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;also reflects the negative impact of foreign currency exchange rate changes experienced in 2014, partially offset by gains recognized in relation to the settlement of certain cash flow hedge instruments under our foreign currency hedging program. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that AVONEX revenues will continue to decline as a result of competition from our own products, including PLEGRIDY and TECFIDERA, and other MS therapies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">PLEGRIDY</font></div><div style="line-height:120%;text-align:left;"><img src="plegridychart.jpg" style="height:333px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in PLEGRIDY revenues was primarily due to increases in unit sales volume. Sales of PLEGRIDY began in the E.U. and the U.S. in the third and fourth quarters of 2014, respectively.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that PLEGRIDY revenues will increase as PLEGRIDY becomes commercially available in additional markets and as patients transition to PLEGRIDY from AVONEX and other therapies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</font></div><div style="line-height:120%;text-align:left;"><img src="tysabrichart.jpg" style="height:333px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TYSABRI revenues was primarily due to an increase in unit sales volume of 4% and increases in gross price partially offset by higher discounts and allowances. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TYSABRI revenues was primarily due to price increases and our recognition, starting in April 2013, of 100% of net revenues on TYSABRI in-market sales due to our acquisition of the remaining rights to TYSABRI from Elan, partially offset by a 4% decrease in unit sales volume. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on data reported by Elan for 2013 and our sales to third-party customers, total U.S. TYSABRI in-market sales were $958.3 million. For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TYSABRI in-market sales was primarily due to price increases, partially offset by patients transitioning to oral MS therapies, including TECFIDERA. </font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><a name="s77b12d8928874ad794234c07f74212f8"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world TYSABRI revenues was due to pricing reductions in some European countries and the prior year recognition of $53.5 million of revenue previously deferred in Italy relating to the pricing agreement with the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) as discussed below. Rest of world TYSABRI revenues for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;were negatively impacted by foreign currency exchange losses of $136.3 million. These foreign currency exchange losses were partially offset by comparative net gains recognized under our foreign currency hedging program of $45.9 million. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world TYSABRI revenues was primarily due to the recognition of $53.5 million of revenue previously deferred in Italy relating to the pricing agreement with AIFA as discussed below, volume increases in Europe of 10% and in our emerging markets region of 18% and a favorable net price in Germany as the mandatory rebate percentage was reduced. Rest of world TYSABRI revenue for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;also reflects the negative impact of foreign currency exchange rate changes experienced in 2014, partially offset by gains recognized in relation to the settlement of certain cash flow hedge instruments under our foreign currency hedging program. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We remain in discussions with AIFA about a resolution relating to a claim that sales of TYSABRI in Italy exceeded a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006 for the period from mid-February 2009 through January 2013. We could recognize approximately EUR40 million in revenue upon resolution of this matter. For information regarding our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Consolidated Financial Statement Detail</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that TYSABRI revenues will continue to face competition from additional treatments for MS and certain other pipeline products, including ZINBRYTA and ocrelizumab.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Hemophilia</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">ELOCTATE</font></div><div style="line-height:120%;text-align:left;"><img src="eloctatechart.jpg" style="height:333px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in ELOCTATE revenues was primarily due to increases in unit sales volume. Sales of ELOCTATE in the U.S. and Japan began in the third quarter of 2014 and in the first quarter of 2015, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">ALPROLIX</font></div><div style="line-height:120%;text-align:left;"><img src="alprolixchart.jpg" style="height:333px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in ALPROLIX revenues was primarily due to increases in unit sales volume. Sales of ALPROLIX in the U.S. and Japan began in the second and fourth quarters of 2014, respectively.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><a name="s77b12d8928874ad794234c07f74212f8"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect continued growth with ELOCTATE as there remains a significant portion of the patient population that can benefit from long-acting therapies. We also expect moderating patient additions for ALPROLIX.</font></div><a name="s156F7B73AA94BD5326B4B5129E84A84F"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Unconsolidated Joint Business Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from unconsolidated joint business are summarized as follows:</font></div><div style="line-height:120%;"><img src="unconsoljointbusinesschart.jpg" style="height:533px;width:317px;"></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Biogen's share of pre-tax profits includes the reimbursement of selling and development expenses</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a summary of amounts comprising our share of pre-tax profits on RITUXAN and GAZYVA in the U.S.:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="33%"></td><td width="1%"></td><td width="19%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="19%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="19%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,847.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,556.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,425.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">673.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">771.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">615.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax profits in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,174.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,785.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,809.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits*</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,269.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,117.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,087.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S.&#160;product revenues was primarily due to a 4% increase in RITUXAN unit sales volume and price increases, partially offset by higher discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S.&#160;product revenues was primarily due to price increases and an increase in RITUXAN unit sales volume, partially offset by the 2013 recognition of $94.9 million in net revenues resulting from the July 2013 issuance by the Department of Health and Human Services of its final rule on the Exclusion of Orphan Drugs for Certain Covered Entities Under 340B Program. The issuance of the final rule by the Department of Health and Human Services did not have an impact on the amount we recorded as revenues from unconsolidated joint business in our consolidated statements of income because, through June 30, 2013, we had been increasing our share of profits in the U.S. to reflect our interpretation of the proposed 340B rule. The final rule was consistent with our prior interpretation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration costs and expenses for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;decreased primarily due to the 2014 recognition of $53.9 million of additional Branded Pharmaceutical Drug (BPD) fee expense as well as lower RITUXAN cost of sales, partially offset by higher GAZYVA sales and marketing expenses. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;the Internal Revenue Service issued final regulations related to the BPD fee, which had the effect of changing the recognition of the fee for accounting purposes, from the period in which the fee was paid, to the period when the sale occurs. As a result of these final regulations, we recognized an incremental BPD fee in 2014 for the periods 2013 through the end of the third quarter of 2014. The final regulations did not change the timing of payments.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration costs and expenses for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increased primarily due to the recognition of $53.9 million of additional BPD fee expense, as discussed above, as well as GAZYVA sales and marketing and research and development expenses. Upon the first marketing approval of GAZYVA by the FDA in the U.S., we began recognizing all activity, including sales and marketing and research and development expenses related to the GAZYVA program in unconsolidated joint business in our consolidated statements of income. Prior to its first regulatory approval, we recognized our share of GAZYVA development and commercialization expenses as research and development expense and selling, general and administrative expense, respectively, in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect our share of RITUXAN pre-tax profits in the U.S. to decrease to 39% from 40% if GAZYVA is approved by the FDA in RITUXAN-refractory indolent non-Hodgkin&#8217;s lymphoma. For additional information related to our collaboration with Genentech, including information regarding the pre-tax profit sharing formula and its impact on future unconsolidated joint business revenues, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenue on Sales in the Rest of World for RITUXAN</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue on sales in the rest of world for RITUXAN consists of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenue on sales outside the U.S.&#160;and Canada. For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, revenue on sales in the rest of world for RITUXAN decreased as a result of lower pre-tax co-promotion profits on RITUXAN in Canada and patent expirations. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, revenue on sales in the rest of world for RITUXAN increased primarily due to the prior year recognition of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;charge for damages and interest awarded to Hoechst in its arbitration with Genentech. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The royalty period for sales in the rest of world is 11 years from the first commercial sale of such product on a country-by-country basis. The royalty periods for the substantial portion of the royalty-bearing sales in the rest of world markets expired during 2012 and 2013. We expect future revenue on sales of RITUXAN in the rest of world will be limited to our share of pre-tax co-promotion profits in Canada.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><a name="sE8E454D0B9B50477DA81B5129F81E72D"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Revenues</font></div><div style="line-height:120%;text-align:left;"><img src="otherrevenueschart.jpg" style="height:333px;width:317px;"></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalties from net sales on products related to patents that we have out-licensed. Prior to 2015, our most significant source of royalty revenue had been derived from net worldwide sales of ANGIOMAX, which was out-licensed to The Medicines Company. On December 15, 2014 we ceased recognizing royalty revenues from U.S. sales of ANGIOMAX, contemporaneous with the U.S. patent&#8217;s expiration.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, royalty revenues decreased primarily due to the expiration of U.S. patent rights that gave rise to royalty payments related to ANGIOMAX.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, royalty revenues decreased due to a decrease in the net worldwide sales of ANGIOMAX subject to royalty payments. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Corporate Partner Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our corporate partner revenues include amounts earned under contract manufacturing agreements, including revenues related to our arrangements with Samsung Bioepis and other strategic partners.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in corporate partner revenues was primarily due to higher contract manufacturing revenue and the start of product shipments to Sobi in relation to our collaboration agreement as Sobi has assumed final development and commercialization of ALPROLIX and ELOCTATE in Europe, North Africa, Russia, and certain markets in the Middle East.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in corporate partner revenues was primarily due to higher contract manufacturing revenue and increased revenue from our biosimilar arrangements, partially offset by lower revenue associated with our Zevalin supply agreement. Zevalin is a program we sold in 2007 but continued to manufacture in accordance with the amendment to our Zevalin supply agreement. We completed our manufacturing obligation under this amendment in the third quarter of 2014. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationships with Samsung Bioepis and Sobi, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report. </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><a name="s0BF1384AA20FF403F8ADB512A1A89FDB"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of applicable discounts, allowances and other governmental allowances including those associated with the implementation of pricing actions in certain international markets where we operate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves established for these discounts and allowances are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These reserves are based on estimates of the amounts earned or to be claimed on the related sales. Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which will have an effect on earnings in same the period. To date, such adjustments have not been significant.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves for discounts, contractual adjustments and returns that reduced gross product revenues are summarized as follows:</font></div><div style="line-height:120%;text-align:center;"><img src="reserveschart.jpg" style="height:425px;width:317px;"></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves for discounts and allowances increased in each of the past three years due to increased sales associated with launches of TECFIDERA, PLEGRIDY, ELOCTATE and ALPROLIX. In addition, we began recognizing reserves for discounts and allowances for U.S. TYSABRI revenue in the second quarter of 2013 following our acquisition of all remaining rights to TYSABRI from Elan.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Discounts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in discounts was primarily driven by our recent product additions, gross price increases as well as increases in contractual rates. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in discounts was primarily driven by our recent product additions. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Adjustments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments relate to Medicaid and managed care rebates, co-payment assistance (copay), Veterans Administration (VA), Public Health Service (PHS) discounts, specialty pharmacy program fees and other government rebates or applicable allowances. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in contractual adjustments was primarily due to our recent product additions, higher Medicaid and other governmental rebates and allowances in the U.S., and managed care rebates as a result of an increase in contracted business and gross prices.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in contractual adjustments was primarily due to our recent product additions, increases in managed care rebates, U.S. governmental rebates and allowances as a result of price increases and additional managed care contracts. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Returns</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Reserves for product returns are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, return reserves decreased primarily due to a reduction in return rates based on recent experiences of returned products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, return reserves increased primarily due to our acquisition of all remaining rights to TYSABRI, the start of commercial sales of TECFIDERA and increased return rates for prior year AVONEX shipments. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our reserves, please read Note 4, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reserves for Discounts and Allowances</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><br><a name="s91546CFAF1940DAD9A75B5129E7F303F"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Cost and Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of total cost and expenses is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td width="35%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015 compared to 2014</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014 compared to 2013</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization of acquired intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,240.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,171.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">857.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,012.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,893.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,444.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,113.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,232.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,712.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">382.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">489.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">342.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(21.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">93.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit sharing</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(100.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">30.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(38.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(178.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,872.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,747.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,441.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><a name="s419B9A4BBAE015D0F562B512A17B383B"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cost of Sales, Excluding Amortization of Acquired Intangible Assets (Cost of Sales)</font></div><div style="line-height:120%;text-align:left;"><img src="costofsaleschart.jpg" style="height:333px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in product cost of sales was primarily driven by increased contract manufacturing production and higher unit sales volume of our marketed products, including newly launched products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in product cost of sales was driven by higher unit sales volume, including due to recent product launches and our contract and biosimilars manufacturing arrangements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in royalty cost of sales was primarily driven by the increase in royalties due to Sobi on increased sales of our hemophilia products and an increase in the contractual rate of TYSABRI contingent payments due to Perrigo Company plc (Perrigo), which is based on the expected level of annual worldwide net sales of TYSABRI, partially offset by a decrease in TYSABRI revenues and the expiration of certain third-party royalties related to TYSABRI. For additional information on the contingent payments due to Perrigo, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in royalty cost of sales was primarily driven by our acquisition of all remaining rights to TYSABRI, partially offset by the expiration of a third-party royalty related to AVONEX. </font></div><a name="sDC0181E72635235FA955B5129E83A231"></a><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;"><img src="researchanddevelopmentchart.jpg" style="height:730px;width:317px;"></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-align:center;"><img src="rdpiechart2015.jpg" style="height:281px;width:317px;"></div><div style="line-height:120%;text-align:center;"><img src="rdpiechart2014.jpg" style="height:281px;width:317px;"></div><div style="line-height:120%;text-align:center;"><img src="rdpiechart2013.jpg" style="height:281px;width:317px;"></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Other research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs as well as depreciation and other facility-based expenses. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in research and development expense was primarily related to increases in costs incurred in connection with our late and early stage programs and research and discovery, partially offset by a decrease in milestone and upfront expenses and the positive impact of foreign currency translation of $34.0 million.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in spending associated with our late stage programs for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily driven by costs incurred to advance our aducanumab program for Alzheimer's disease and the nusinersen program for the treatment of SMA, partially offset by a decrease in costs related to ZINBRYTA, which is in registration stage, and the approvals of PLEGRIDY and ELOCTATE in 2014.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in spending associated with our early stage programs for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to costs incurred in connection with our aducanumab program for Alzheimer's disease, which advanced to a late stage program during the third quarter of 2015, the BAN2401 program for Alzheimer&#8217;s disease related to our collaboration with Eisai and our Raxatrigine program for trigeminal neuralgia (TGN). These increases were partially offset by a decrease in costs incurred in connection with the nusinersen program for the treatment of SMA as the program advanced to a late stage program during the first quarter of 2015.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in research and development expense was primarily related to increases in costs incurred in connection with our early stage programs, milestone and upfront expenses, research and discovery and marketed products, partially offset by a decrease in costs incurred in connection with our late stage programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense related to our early stage programs increased in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;primarily due to costs incurred in the advancement of our Anti-LINGO program in MS, our aducanumab program for Alzheimer&#8217;s disease, the BAN2401 program for Alzheimer&#8217;s disease related to our collaboration agreement with Eisai and an increase in spending incurred in connection with our development of STX-100 for the treatment of idiopathic pulmonary fibrosis. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in spending associated with marketed products in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is related to ALPROLIX, ELOCTATE and PLEGRIDY, which were approved in 2014, and costs associated with TYSABRI, which previously were shared with Elan prior to our acquisition of all remaining rights to TYSABRI from Elan in April 2013.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in spending associated with our late stage product candidates in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was driven by approvals of ALPROLIX, ELOCTATE and PLEGRIDY in 2014 and GAZYVA in the fourth quarter of 2013, partially offset by costs incurred in the development of nusinersen for the treatment of SMA. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where the drug candidate has the potential to be highly differentiated. Specifically, we intend to continue to invest in our MS pipeline, our aducanumab program, the BAN2401 and E2609 programs, the nusinersen program, the amiselimod program and our Raxatrigine program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Milestone and Upfront Expenses included in Research and Development Expense</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;includes $60.0 million recorded upon entering into our collaboration with MTPC, $48.1 million recorded upon entering into our collaboration with AGTC, $30.0 million recorded as milestones in relation to our collaboration agreements with Ionis and $16.0 million paid to AbbVie related to milestones for the development of ZINBRYTA as a result of filing with the FDA and EMA during the year. For additional information about these transactions, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report. </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;includes $139.3 million recorded in connection with our collaboration agreement with Eisai, $25.0 million recorded as milestones in relation to our collaboration agreements with Ionis and an aggregate of $60.0 million related to upfront payments made to Sangamo and Google Inc. and for other strategic business arrangements. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Included in total research and development expense in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;were charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to an upfront payment made to Ionis in September 2013 upon entering into a six year research collaboration with Ionis under which we both agreed to perform research and then seek to develop and commercialize antisense or other therapeutics for the treatment of neurological disorders, $36.0 million related to upfront and milestone payments made to Samsung Bioepis in December 2013 upon entering into a development and commercialization agreement and a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment made to Ionis related to the selection and advancement of IONIS-DMPK</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to treat mytonic dystrophy (DM1). </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These payments are classified as research and development expense as the programs they relate to have not achieved regulatory approval. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative</font></div><div style="line-height:120%;"><img src="sellinggeneraladminchart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in selling, general and administrative expenses was driven by a decrease in corporate giving, incentive compensation and the positive impact of foreign currency translation of $87.6 million, partially offset by an increase of $38.9 million of BPD fee expense. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in selling, general and administrative expenses was primarily driven by costs associated with developing commercial capabilities for our recent product launches in 2014 along with an increase in sales and marketing activities in support of our MS products. The successful commercialization of new and potential new products requires significant investments, such as sales force build and </font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">development, training, marketing, and other related activities. The increase in selling, general, and administrative expense was also driven by an increase in corporate giving and the recognition of $21.9 million of additional BPD fee expense. </font></div><a name="sC5005016A202D3E6E701B512A1C625A3"></a><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Amortization of Acquired Intangible Assets</font></div><div style="line-height:120%;"><img src="amortizationchart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in amortization of acquired intangible assets was primarily driven by a decrease in AVONEX revenues during the comparative periods and the impact of higher expected lifetime revenues of AVONEX due to a slower than previously expected adoption of PLEGRIDY. Amortization of acquired intangible assets during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included total impairment charges of $50.9 million related to one of our out-licensed patents and one of our in-process research and development (IPR&amp;D) intangible assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in amortization of acquired intangible assets was primarily driven by</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;background-color:#ffffff;">a $60.2 million increase in amortization of a</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">cquired and in-licensed rights and patents </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;background-color:#ffffff;">as we recognized a full year of expense related to our TYSABRI rights in 2014 versus nine months of expense in 2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, total impairment charges of $50.9 million related to one of our out-licensed patents and one of our IPR&amp;D intangible assets, and lower expected lifetime revenues of AVONEX. </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long range planning cycle was completed in the third quarter of 2015. Based upon this analysis,the estimated future amortization of acquired intangible assets is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="68%"></td><td width="1%"></td><td width="30%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">346.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">318.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">291.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">275.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">269.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,500.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenues of the relevant process. The occurrence of an adverse event could substantially increase the amount of amortization expense associated with our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to the amortization of acquired intangible assets, please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Impairment of Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We record charges associated with impairments of intangible assets in amortization of intangible assets. Impairment charges related to our intangible assets during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;were insignificant. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded a charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the impairment of one of our out-licensed patents to reflect a change in its estimated fair value, due to a change in the underlying competitive market for that product. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we updated the probabilities of success related to the early stage programs acquired through our recent acquisitions.&#160;This change in probability of success, combined with a delay in one of the projects, resulted in an impairment loss of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information, please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overall, the value of our acquired IPR&amp;D assets is dependent upon a number of variables, including estimates of future revenues and the effects of competition, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from a clinical trial phase to the next.&#160;We are continually reevaluating our estimates concerning these variables and evaluating industry data regarding the productivity of clinical research and the development process.&#160;Changes in our estimates of items may result in a significant change to our valuation of these assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The field of developing treatments for idiopathic pulmonary fibrosis (IPF) and neuropathic pain, such as TGN, are highly competitive and can be affected by rapid changes to the market. There can be no assurance that we will be able to successfully develop STX-100 for the treatment of IPF or Raxatrigine for the treatment of TGN or that a successfully developed therapy will be able to secure sufficient pricing in a competitive market.&#160;We review amounts capitalized as acquired IPR&amp;D for impairment at least annually, as of October 31, and whenever events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. Our most recent impairment assessment as of October 31, 2015 resulted in no impairments.</font></div><a name="s30822076806d45c8b725f97808eff5f6"></a><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Restructuring Charges</font></div><div style="line-height:120%;"><img src="restructuringchargeschart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On October 21, 2015, we announced a corporate restructuring, which includes the termination of certain pipeline programs and an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction in workforce. These changes are expected to reduce the current annual run rate of operating expenses by approximately $250 million. </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect to reinvest the savings resulting from the restructuring to support the advancement of our high potential pipeline candidates, including our programs in Alzheimer&#8217;s disease, Anti-LINGO for MS, nusinersen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">for SMA, Raxatrigine and amiselimod, an oral S1P modulator, and to support key commercial activities, including TECFIDERA. We also have discontinued several programs, including our Phase 3 program for TECFIDERA in secondary progressive MS (SPMS), the development of anti-TWEAK in lupus nephritis, and certain activities in immunology and fibrosis research. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate making cash payments totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under this program, which includes approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to previously accrued 2015 incentive compensation, for a total net expected restructuring charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$105 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These amounts will be substantially incurred and paid by the end of 2016. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of these charges during the fourth quarter of 2015, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$86.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was related to our workforce reduction and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was related to the pipeline program terminations.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the charges and spending related to our restructuring efforts during 2015:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="15%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="15%"></td><td width="1%"></td><td width="2%"></td><td width="1%"></td><td width="15%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Workforce</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reduction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Pipeline</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges incurred during the fourth quarter of 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">86.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">93.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Previously accrued incentive compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves established</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">102.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">109.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts paid through December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(68.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(72.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><a name="s10c68fe654564a56ba82e7839ce06067"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Collaboration Profit Sharing</font></div><div style="line-height:120%;"><img src="collabprofitsharingchart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon the closing of our acquisition of all remaining rights to TYSABRI, our collaboration agreement with Elan was terminated, and we no longer record collaboration profit sharing. Collaboration profit sharing previously included the portion of rest of world net operating profits to be shared with Elan under the terms of our collaboration agreement for the development, manufacture and commercialization of TYSABRI. The amount also included the reimbursement for our portion of third-party royalties paid by Elan on behalf of the collaboration relating to rest of world sales. For additional information about this collaboration, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><a name="s71922B1F8547C389A9EFB512B47F86AD"></a><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</font></div><div style="line-height:120%;"><img src="gainlossfairvaluechart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular factor or factors. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The loss on fair value remeasurement of contingent consideration for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to changes in the expected timing and probabilities of success related to the achievement of certain developmental milestones and in the discount rate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The gain on fair value remeasurement of contingent consideration for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to an adjustment to the value of our contingent consideration liabilities as we updated the probabilities of success related to the early stage programs acquired through our recent acquisitions. For additional information, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><a name="s90B960AA9A2EA2C5E841B5129ED6CA49"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;"><img src="otherincomeexpensechart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net was primarily due to an increase in interest expense as a result of the issuance of our senior unsecured notes (2015 Senior Notes), higher foreign exchange losses and a decrease in net gains recognized on the sale of our strategic investments and marketable securities. For additional information, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Consolidated Financial Statement Detail</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net was due to lower non-income based state taxes, an increase in interest income due to higher average cash, cash equivalents and marketable securities balances, lower foreign exchange losses and decreased interest expense as we repaid our 6.0% Senior Notes in March 2013, partially offset by lower gains on investments. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect interest expense will continue to increase as a result of our issuance of the 2015 Senior Notes. For additional information related to our 2015 Senior Notes, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><a name="s275A0A262F32520FF3C3B5129EE2EC57"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Tax Provision</font></div><div style="line-height:120%;"><img src="incometaxchart.jpg" style="height:338px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include variability in the allocation of our taxable earnings among multiple jurisdictions, changes in tax laws, the amount and characterization of our research and development expenses, the levels of certain deductions and credits, acquisitions, and licensing transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;benefited from lower anticipated taxes on foreign earnings and reflects a $27.0 million benefit from the 2015 remeasurement of one of our uncertain tax positions, described below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increased primarily as a result of the absence of a benefit related to the 2013 change in our uncertain tax position related to our U.S. federal manufacturing deduction and our unconsolidated joint business described below under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">"Accounting for Uncertainty in Income Taxes"</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, lower current year expenses eligible for the orphan drug credit and a lower relative manufacturing deduction due to unqualified products, partially offset by a higher percentage of our 2014 income being earned outside the U.S.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2013, we received updated technical guidance from the IRS concerning the calculation of our U.S. federal manufacturing deduction and overall tax classification of our unconsolidated joint business for the current and prior year filings.&#160;Based on this guidance we reevaluated the level of our unrecognized benefits related to uncertain tax positions and recorded a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;income tax benefit.&#160;This benefit was for a previously unrecognized position and related to years 2005 through 2012. We recorded an offsetting expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for non-income based state taxes, which was recorded in other income (expense) in our consolidated statements of income. This uncertain tax position was then remeasured in 2015 resulting in a $27.0 million benefit related to the state tax impacts of the IRS technical guidance.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For more information on our uncertain tax positions and income tax rate reconciliation for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note 16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><a name="s712C37A325DECCCE30FAB5129F085BF1"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Share in Equity in Loss of Investee, Net of Tax</font></div><div style="line-height:120%;"><img src="equitinlossofinvesteechart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012, we entered into an agreement with Samsung Biologics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals. We account for this investment under the equity method of accounting. We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our share of losses exceeded the carrying value of our investment. We suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our equity in loss of investee, net of tax, was due to the suspension of equity method investment losses due to our share of losses exceeding the carrying value of our investment in 2015 and a decrease in our ownership interest. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in equity in loss of investee, net of tax was due to the joint venture's clinical trial activity, partially offset by our recognition of a gain as Samsung Bioepis secured additional equity financing from Samsung Biologics from a financing in which we did participate. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to this transaction, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><a name="sCB7699CFC3AF7622BDB0B5129F27B93A"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Noncontrolling Interest</font></div><div style="line-height:120%;"><img src="noncontrollinginterestchart.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in net income (loss) attributable to noncontrolling interests, net of tax, was primarily related to a $60.0 million milestone payment made to Neurimmune SubOne AG (Neurimmune), partially offset by increases in research expenses attributable to noncontrolling interests.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in net income attributable to noncontrolling interests, net of tax, was related to a $10.0 million milestone payment made to Neurimmune and the consolidation of the research activities of Ataxion, Inc. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information about Neurimmune, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><a name="s613F1F660E1DE59F8931B5129F0F2539"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Condition, Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our financial condition is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td width="59%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">%&#160;Change</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015 compared to 2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,308.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,204.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,120.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">640.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,760.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,470.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,188.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,316.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Borrowings:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable and other financing arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,521.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total borrowings</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,526.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">583.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working Capital:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,700.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,535.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,577.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,218.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total working capital</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,122.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,316.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">77.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><a name="s4f2fcba5b67545f693a3c937bf8fac1a"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5,930.5 million in proceeds from the issuance of our 2015 Senior Notes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$3,716.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in net cash flows provided by operating activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for share repurchases;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,674.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total payments for income taxes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$850.0 million in contingent payments made to former shareholders of Fumapharm AG and holders of their rights; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$643.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment, including $104.8 million related to the acquisition of Eisai's drug product manufacturing facility in Research Triangle Park (RTP), North Carolina and $62.5 million related to the acquisition of land in Solothurn, Switzerland;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$198.8 million net cash paid for the acquisition of Convergence;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$184.0 million used for upfront payments made to AGTC and MTPC; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million milestone payment made to Neurimmune.</font></div></td></tr></table></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$2,942.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in net cash flows provided by operating activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,163.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total payments for income taxes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$886.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for share repurchases;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$375.0 million in contingent payments made to former shareholders of Fumapharm AG and holders of their rights; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$287.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$286.3 million used for upfront and milestone payments in collaborative arrangements.</font></div></td></tr></table></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><a name="s4f2fcba5b67545f693a3c937bf8fac1a"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have historically financed our operating and capital expenditures primarily through cash flows earned through our operations. On September 15, 2015, we issued our 2015 Senior Notes for an aggregate principal amount of $6.0 billion. We expect to continue funding our current and planned operating requirements principally through our cash flows from operations, as well as our existing cash resources and proceeds received from our 2015 Senior Notes. We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The undistributed cumulative foreign earnings of certain of our foreign subsidiaries, exclusive of earnings that would result in little or no net income tax expense under current U.S. tax law or which has already been subject to tax under U.S. tax law, are invested indefinitely outside the U.S. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Of the total cash, cash equivalents and marketable securities at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately $3.5 billion was generated in foreign jurisdictions and is primarily intended for use in our foreign operations or in connection with business development transactions outside of the U.S. In managing our day-to-day liquidity in the U.S., we do not rely on the unrepatriated earnings as a source of funds and we have not provided for U.S.&#160;federal or state income taxes on these undistributed foreign earnings. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to certain risks that could negatively impact our financial position or future results of operations, please read the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; sections of this report.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchase Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015, our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2015 Share Repurchase Program). As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 2015 Share Repurchase Program was completed and we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011, our Board of Directors authorized a program to repurchase up to 20.0 million of our common stock (2011 Share Repurchase Program), which has been used principally to offset common stock issuances under our share-based compensation plans. The 2011 Share Repurchase Program does not have an expiration date. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we purchased approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$886.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our 2011 Share Repurchase Program. We did not repurchase any shares of common stock under our 2011 Share Repurchase Program during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares remaining available for repurchase under this authorization.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments and other interest bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity, and investment type. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in cash, cash equivalents and marketable securities at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is primarily due to the issuance of our 2015 Senior Notes and net cash flows provided by operating activities, offset by purchases of our common stock, contingent payments made to former shareholders of Fumapharm AG and holders of their rights, net purchases of property, plant and equipment and the acquisition of Convergence.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><a name="s4f2fcba5b67545f693a3c937bf8fac1a"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Borrowings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On September 15, 2015, we issued senior unsecured notes for an aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2020, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.792%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">3.625%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2022, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.920%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2025, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.764%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15,&#160;2045, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.294%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the 2015 Senior Notes, we have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due March&#160;1, 2018 that were originally priced at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">99.184%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The discounts are amortized as additional interest expense over the period from issuance through maturity.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015, we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;outstanding borrowings and were in compliance with all covenants under this facility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our 2006 distribution agreement with Fumedica, we issued notes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs which were payable to Fumedica in varying amounts from June 2008 through June 2018. Our remaining note payable to Fumedica had a carrying value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a summary of the fair values of our outstanding borrowings as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Working Capital</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We define working capital as current assets less current liabilities. In accordance with ASU No. 2015-17, at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we reclassified </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$137.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our deferred tax assets classified as current to noncurrent and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our deferred tax liabilities classified as current to noncurrent in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;consolidated balance sheet, to conform our prior year presentation to our current year presentation. For additional information related to ASU No. 2015-17, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: New Accounting Pronouncements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in working capital at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reflects an increase in total current assets of $2,165.3 million, partially offset by an increase in current liabilities of $359.6 million. The increase in total current assets was primarily driven by an increase in cash, cash equivalents and marketable securities due to the issuance of our 2015 Senior Notes and an increase in cash from operating activities, partially offset by purchases of our common stock. The increase in total current liabilities primarily resulted from an increase in taxes payable and an increase in accrued expenses and other due to increases in the amount of short-term contingent consideration expected to be paid and revenue-related reserves for discounts and allowances.  </font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><a name="s1a52c9c498264159b51f6c1bf87ff24b"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our cash flow activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td width="35%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015 compared to 2014</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014 compared to 2013</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,716.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,942.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,345.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">26.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in by investing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4,553.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,543.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,604.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">195.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by (used in) financing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">986.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(755.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(716.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(230.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><a name="s8c4bd783061342da83ec39cd560ce5ac"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Operating Activities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating cash flow is derived by adjusting our net income for:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-cash operating items such as depreciation and amortization, impairment charges and share-based compensation charges;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes associated with the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in cash provided by operating activities was primarily driven by higher net income and accounts receivable collections, partially offset by income tax payments.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in cash provided by operating activities was primarily driven by higher net income, partially offset by an increase in accounts receivable resulting from increased product revenue.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Investing Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows used in investing activities was primarily due to an increase in net purchases of marketable securities, an increase in the total amount of contingent consideration paid to the former shareholders of Fumapharm AG, an increase in purchases of property, plant and equipment and cash paid for the acquisition of Convergence. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in net cash flows used in investing activities was primarily due to the prior year acquisition of all remaining rights to TYSABRI from Elan and a decrease in the net purchases of marketable securities, partially offset by the payment of contingent consideration to former shareholders of Fumapharm AG. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Financing Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in net cash flows provided by financing activities was primarily due to the issuance of our 2015 Senior Notes, partially offset by an increase in the amount of common stock we repurchased.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows used in financing activities was primarily due to an increase in the amount of common stock we repurchased, partially offset by the prior year repayment of the aggregate principal amount of our 6.0% Senior Notes.</font></div></div></div><br><a name="s34BC7859EB7994FA6897B5129E8298DE"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Contractual Obligations and Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our contractual obligations as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, TYSABRI contingent payments and contingent consideration related to our business combinations, as described below.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td width="36%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Payments Due by Period</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Less&#160;than</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">1 Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">1 to 3</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">3 to 5</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">After</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">5&#160;Years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capital leases (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">20.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">18.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-cancellable operating leases (2), (3)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">672.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">131.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">117.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">353.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term debt obligations (4)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,563.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">282.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,095.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,983.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,201.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchase and other obligations (5)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">380.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">258.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">79.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">19.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Defined benefit obligation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">70.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">70.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total contractual obligations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11,687.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">611.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,306.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,124.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,644.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><a name="sc9e3323e3f6142e0897101520d8552a3"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015 we amended our existing lease related to Eisai's oral solid dose products manufacturing facility in RTP, North Carolina, where we manufacture our and Eisai's oral solid dose products. Amounts reflected within the table above include the future contractual commitments. For additional information, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, Plant and Equipment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We lease properties and equipment for use in our operations. Amounts reflected within the table above detail future minimum rental commitments under non-cancelable operating leases as of December&#160;31 for each of the periods presented. In addition to the minimum rental commitments, these leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Obligations are presented net of sublease income expected to be received for the vacated portion of our Weston, Massachusetts facility. For additional information, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, Plant and Equipment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term debt obligations are primarily related to our Senior Notes, including principal and interest payments. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchase and other obligations primarily includes our obligations to purchase direct materials and also includes approximately $126.4 million in contractual commitments for the construction of a biologics manufacturing facility in Solothurn, Switzerland and approximately </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$14.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the fair value of net liabilities on derivative contracts.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net liabilities associated with uncertain tax positions.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several on-going clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on our consolidated balance sheet for expenditures incurred by CROs as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$559.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cancellable future commitments based on existing CRO contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones had not occurred as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate that we may pay approximately $150.0&#160;million of milestone payments in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, provided various development, regulatory or commercial milestones are achieved. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TYSABRI Contingent Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013, we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the terms of the acquisition agreement, we are obligated to make contingent payments to Elan of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on annual worldwide net sales up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on annual worldwide net sales that exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo in December 2013. Following that acquisition, we began making these royalty payments to Perrigo.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74</font></div></div><hr style="page-break-after:always"><a name="sc9e3323e3f6142e0897101520d8552a3"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence, Stromedix, Inc. (Stromedix), Biogen International Neuroscience GmbH (formerly Biogen Idec International Neuroscience GmbH) (BIN), Biogen Hemophilia Inc. (formerly Biogen Idec Hemophilia Inc.) (BIH) and Fumapharm AG, we agreed to make additional payments based upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence, Stromedix and BIN, formerly Panima Pharmaceuticals AG, occurred after January&#160;1, 2009, we record contingent consideration liabilities at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in remaining milestones related to these acquisitions. For additional information related to our acquisition of Convergence please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIH</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of BIH, formerly Syntonix, in 2007, we agreed to pay up to an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$80.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;if certain milestone events associated with the development of BIH&#8217;s lead product, ALPROLIX are achieved. The final </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment will occur if, prior to the tenth anniversary of the closing date, a marketing authorization is granted by the EMA for ALPROLIX. This payment will be accounted for as an increase to intangible assets if achieved. In June 2015, the EMA validated our MAA for ALPROLIX for the treatment of hemophilia B.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006, we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We are required to make contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior twelve month period, as defined in the acquisition agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$850.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments as we reached the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2014, second quarter of 2015 and third quarter of 2015, respectively, and accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total cumulative sales of Fumapharm Products in the fourth quarter of 2015.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will owe an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment for every additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, until such time as the cumulative sales level reaches </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments shall be due. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level has been reached. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</font></div><a name="sDF3198729B852CF752CFB512B5EE9470"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Legal Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of legal matters as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Critical Accounting Estimates</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S.&#160;(U.S.&#160;GAAP), requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenue Recognition and Related Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. The timing of distributor orders and shipments can cause variability in earnings.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We establish reserves for trade term discounts, wholesaler incentives, Medicaid rebates, copay, VA and PHS discounts, managed care rebates, product returns and other governmental rebates or applicable allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. If actual results vary, we may need to adjust these estimates, which could have an effect on earnings in the period of the adjustment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the discounts and rebates described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify these payments within selling, general and administrative expenses.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Unconsolidated Joint Business</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from unconsolidated joint business consists of (i)&#160;our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; (ii)&#160;reimbursement of our selling and development expenses in the U.S. for RITUXAN; and (iii)&#160;revenue on sales in the rest of world for RITUXAN, which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales outside the U.S. and Canada by the Roche Group and its sublicensees. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by Genentech in the U.S. and by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less the cost to manufacture, third-party royalty expenses, distribution, selling, and marketing expenses, and joint development expenses incurred by Genentech, the Roche Group and us. We record our share of the pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales outside the U.S. on a cash basis as we do not have the ability to estimate these profits or royalty revenue in the period incurred. Additionally, our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. includes estimates made by Genentech and those estimates are subject to change. Actual results may differ from our estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our receivables arise from product sales in the U.S. and Europe and are primarily due from wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. Credit and economic conditions in the E.U. continue to remain uncertain, which has, from time to time, led to long collection periods for our accounts receivable and greater collection risk in certain countries. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Where our collections continue to be subject to significant payment delays due to government funding and reimbursement practices and a portion of these receivables are routinely being collected beyond our contractual payment terms and over periods in excess of one year, we have discounted our receivables and reduced related revenues based on the period of time that we estimate those amounts will be paid, to the extent such period exceeds one year, using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To date, we have not experienced any significant losses with respect to the collection of our accounts receivable. If economic conditions worsen and/or the financial condition of our customers were to further deteriorate, our risk of collectability may increase, which may result in additional allowances and/or significant bad debts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our concentration of credit risk associated with our accounts receivable balances, please read the subsection entitled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Credit Risk&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Quantitative and Qualitative Disclosures About Market Risk&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;section of this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Capitalization of Inventory Costs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies. All changes in judgment in relation to pre-approval inventory have historically been insignificant.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired Intangible Assets, including In-process Research and Development (IPR&amp;D)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective January&#160;1, 2009, when we purchase a business, the acquired IPR&amp;D is measured at fair value, capitalized as an intangible asset and tested for impairment at least annually, as of October 31, until commercialization, after which time the IPR&amp;D is amortized over its estimated useful life. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have acquired, and expect to continue to acquire, intangible assets through the acquisition of biotechnology companies or through the consolidation of variable interest entities. These intangible assets primarily consist of technology associated with human therapeutic products and IPR&amp;D product candidates. When significant identifiable intangible assets are acquired, we generally engage an independent third-party valuation firm to assist in determining the fair values of these assets as of the acquisition date. Management will determine the fair value of less significant identifiable intangible assets acquired. Discounted cash flow models are typically used in these valuations, and these models require the use of significant estimates and assumptions including but not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">estimating the timing of and expected costs to complete the in-process projects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">projecting regulatory approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">estimating future cash flows from product sales resulting from completed products and in process projects;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">developing appropriate discount rates and probability rates by project.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe the fair values assigned to the intangible assets acquired are based upon reasonable estimates and assumptions given available facts and circumstances as of the acquisition dates.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">77</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If these projects are not successfully developed, the sales and profitability of the company may be adversely affected in future periods. Additionally, the value of the acquired intangible assets may become impaired. We believe that the foregoing assumptions used in the IPR&amp;D analysis were reasonable at the time of the respective acquisition. No assurance can be given, however, that the underlying assumptions used to estimate expected project sales, development costs or profitability, or the events associated with such projects, will transpire as estimated.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certain IPR&amp;D programs have a fair value that is not significantly in excess of carrying value, including our program for the treatment of TGN. Such programs could become impaired if assumptions used in determining the fair value change.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Impairment and Amortization of Long-lived Assets and Accounting for Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Long-lived Assets Other than Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used include property, plant and equipment as well as intangible assets, including IPR&amp;D and trademarks. Property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">"Acquired Intangible Assets, including In-process Research and Development (IPR&amp;D)"</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. If the carrying value of our intangible assets with indefinite lives exceeds its fair value, then the intangible asset is written-down to its fair value. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most significant intangible assets are our acquired and in-licensed rights and patents and developed technology. Acquired and in-licensed rights and patents primarily relates to our acquisition of all remaining rights to TYSABRI from Elan. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TYSABRI and AVONEX using the economic consumption method based on revenue generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TYSABRI and AVONEX is performed annually during our long range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">would significantly affect the anticipated lifetime revenues of TYSABRI or AVONEX. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairment charges related to our long-lived assets during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;were insignificant. For additional information on the impairment charges related to our long-lived assets during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill relates largely to amounts that arose in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003 and amounts that are being paid in connection with the acquisition of Fumapharm AG. Our goodwill balances represent the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess our goodwill balance within our single reporting unit annually, as of October&#160;31, and whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable to determine whether any impairment in this asset may exist and, if so, the extent of such impairment. We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, then we would need to determine the implied fair value of our reporting unit&#8217;s goodwill. If the carrying value of our reporting unit&#8217;s goodwill exceeds its implied fair value, then we would record an impairment loss equal to the difference. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We completed our required annual impairment test in the fourth quarters of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and determined in each of those periods that the carrying value of goodwill was not impaired. In each year, the fair value of our reporting unit, which includes goodwill, was significantly in excess of the carrying value of our reporting unit.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Investments, including Fair Value Measures and Impairments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We invest in various types of securities, including short-term and long-term marketable securities, principally corporate notes, government securities including government sponsored enterprise mortgage-backed securities and credit card and auto loan asset-backed securities, in which our excess cash balances are invested.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In accordance with the accounting standard for fair value measurements, we have classified our financial assets as Level&#160;1, 2 or 3 within the fair value hierarchy. Fair values determined by Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets that we have the ability to access. Fair values determined by Level&#160;2 inputs utilize data points that are observable such as quoted prices, interest rates, yield curves and foreign currency spot rates. Fair values determined by Level&#160;3 inputs utilize unobservable data points for the asset.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As noted in Note&#160;7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements, a majority of our financial assets have been classified as Level&#160;2. These assets have been initially valued at the transaction price and subsequently valued utilizing third-party pricing services. The pricing services use many observable market inputs to determine value, including reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. We validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Impairment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected within earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security and are reflected within earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We make certain assumptions in order to value and record expense associated with awards made under our share-based compensation arrangements. Changes in these assumptions may lead to variability with respect to the amount of expense we recognize in connection with share-based payments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Determining the appropriate valuation model and related assumptions requires judgment, and includes estimating the expected market price of our stock on vesting date and stock price volatility as well as the term of the expected awards. Determining the appropriate amount to expense based on the anticipated achievement of performance targets requires judgment, including forecasting the achievement of future financial targets. The estimate of expense is revised periodically based on the probability of achieving the required performance targets and adjustments are made throughout the performance as appropriate. The cumulative impact of any revision is reflected in the period of change.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also estimate forfeitures over the requisite service period when recognizing share-based compensation expense based on historical rates and forward-looking factors; these estimates are adjusted to the extent that actual forfeitures differ, or are expected to materially differ, from our estimates.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions completed after January&#160;1, 2009, we record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we revalue these obligations and record increases or decreases in their fair value as an adjustment to contingent consideration expense within the consolidated statement of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs including adjustments to the discount rates and achievement and timing of any cumulative sales-based and development milestones, or changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions described above, could have a material impact on the amount of contingent consideration expense we record in any given period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Restructuring Charges</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have made estimates and judgments regarding the amount and timing of our restructuring expense and liability, including current and future period termination benefits, pipeline program termination costs and other exit costs to be incurred when related actions take place. Severance and other related costs are reflected in our consolidated statements of income as a component of total restructuring charges incurred. Actual results may differ from these estimates.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We prepare and file income tax returns based on our interpretation of each jurisdiction&#8217;s tax laws and regulations. In preparing our consolidated financial statements, we estimate our income tax liability in each of the jurisdictions in which we operate by estimating our actual current tax expense together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred tax assets and liabilities, which are included in our consolidated balance sheets. Significant management judgment is required in assessing the realizability of our deferred tax assets. In performing this assessment, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial accounting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income, and the effects of tax planning strategies. Our estimates of future taxable income include, among other items, our estimates of future income tax deductions related to the exercise of stock options. In the event that actual results differ from our estimates, we adjust our estimates in future periods and we may need to establish a valuation allowance, which could materially impact our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All tax effects associated with intercompany transfers of assets within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through the consolidated statement of income when the asset transferred is sold to a third-party or otherwise recovered through amortization of the asset's remaining economic life.&#160;If the asset transferred becomes impaired, for example through the discontinuation of a research program, we will expense any remaining deferred charge or prepaid tax. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total deferred charges and prepaid taxes were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$697.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors, that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Our liabilities for uncertain tax positions can be relieved only if the contingency becomes legally extinguished through either payment to the taxing authority or the expiration of the statute of limitations, the recognition of the benefits associated with the position meet the &#8220;more-likely-than-not&#8221; threshold or the liability becomes effectively settled through the examination process. We consider matters to be effectively settled once the taxing authority has completed all of its required or expected examination procedures, including all appeals and administrative reviews, we have no plans to appeal or litigate any aspect of the tax position, and we believe that it is highly unlikely that the taxing authority would examine or re-examine the related tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We earn a significant amount of our operating income outside the U.S.&#160;As a result, a portion of our cash, cash equivalents, and marketable securities are held by foreign subsidiaries.&#160;We currently do not intend or foresee a need to repatriate these funds. We expect existing domestic cash, cash equivalents, marketable securities and cash flows from operations to continue to be sufficient to fund our domestic operating activities and cash commitments for investing and financing activities for the foreseeable future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our non-U.S. subsidiaries&#8217; undistributed foreign earnings included in consolidated retained earnings and other basis differences aggregated to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;All undistributed foreign earnings of non-U.S.&#160;subsidiaries, exclusive of earnings that would result in little or no net income tax expense or which were previously taxed under current U.S.&#160;tax law, are reinvested indefinitely in operations outside the U.S.&#160;This determination is made on a jurisdiction-by-jurisdiction basis and takes into the account the liquidity requirements in both the U.S. and within our foreign subsidiaries.&#160; </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we decide to repatriate funds in the future to execute our growth initiatives or to fund any other liquidity needs, the resulting tax consequences would negatively impact our results of operations through a higher effective tax rate and dilution of our earnings.&#160;The residual U.S. tax liability, if cumulative amounts were repatriated, would be between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><a name="sD102C7645D3A12459F7FB512B620DFBF"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">New Accounting Standards</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of new accounting standards please read Note&#160;1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Principles</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><a name="sE3382155A37CE1C4B200B512B6413B7F"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;7A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Market Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to certain risks which may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements, pricing pressures worldwide and weak economic conditions in the foreign markets in which we operate. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. Further, we only enter into contracts with counterparties that have at least an "A" (or equivalent) credit rating. The counter-parties to these contracts are major financial institutions and there is no significant concentration of exposure with any one counter-party.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Exchange Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. We have operations or maintain distribution relationships in the U.S., Europe, Canada, Switzerland, Denmark, Japan, Australia, New Zealand and Central and South America. In addition, we receive royalty revenues based on sales of RITUXAN in Canada. As a result, our financial position, results of operations and cash flows can be affected by market fluctuations in foreign exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Danish krone, Japanese yen and Australian dollar.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">81</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenue will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expense which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenue and expenses will increase when reported in U.S. dollars.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by volatility in foreign exchange rates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue and Operating Expense Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenues and operating expenses. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read Note 9, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to mitigate the impact of exchange rate changes on revenues and net income diminishes as significant exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flows from these contracts are reported as operating activities in our consolidated statements of cash flows.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Balance Sheet Risk Management Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets of foreign affiliates. In these instances, we principally utilize currency forward </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">contracts. We have not elected hedge accounting for the balance sheet related items. The cash flows from these contracts are reported as operating activities in our consolidated statement of cash flows.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement in foreign currency rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $185.0 million and $160.0 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $43.0 million and $14.5 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To achieve a desired mix of fixed and floating interest rate debt, we entered into interest rate swap contracts during 2015 for certain of our fixed-rate debt. These derivative contracts effectively converted a fixed-rate interest coupon to a floating-rate LIBOR-based coupon over the life of the respective note. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a 100 basis-point adverse movement (increase in LIBOR) would increase annual interest expense by approximately $6.8&#160;million. </font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">82</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pricing Pressure</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governments in some international markets in which we operate have implemented measures aimed at reducing healthcare costs to constrain the overall level of government expenditures. These implemented measures vary by country and include, among other things, mandatory rebates and discounts, prospective and possible retroactive price reductions and suspensions on price increases of pharmaceuticals. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to secure favorable prices in a particular country may impair our ability to obtain acceptable prices in existing and potential new markets and limit market growth. The continued implementation of pricing actions throughout Europe may also lead to higher levels of parallel trade.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and otherwise have an adverse impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">conditions can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credit and economic conditions in the E.U. continue to remain uncertain, which has, from time to time, led to long collection periods for our accounts receivable and greater collection risk in certain countries. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that our allowance for doubtful accounts was adequate as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</font></div><a name="s81FA614DD88CE6C8E7D8B512B673F865"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The information required by this Item&#160;8 is contained on pages F-1 through F-71 of this report and is incorporated herein by reference.</font></div><a name="s3911AF88B9C9E495C2DAB512B69486B0"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83</font></div></div><hr style="page-break-after:always"><a name="sDC1FCBC3C831A9733142B512B6C6F1D9"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;9A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Disclosure Controls and Procedures and Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Controls and Procedures</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that (a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and (b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were no changes in our internal control over financial reporting during the quarter ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined in Rules&#160;13a-15(f) and 15d-15(f) under the Securities Exchange Act as a process designed by, or under the supervision of, a company&#8217;s principal executive and principal financial officers and effected by a company&#8217;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.&#160;GAAP. Our internal control over financial reporting includes those policies and procedures that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S.&#160;GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our management assessed the effectiveness of our internal control over financial reporting as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its 2013 Internal Control&#160;&#8212; Integrated Framework.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our assessment, our management has concluded that, as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our internal control over financial reporting is effective based on those criteria.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The effectiveness of our internal control over financial reporting as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their attestation report, which is included herein.</font></div><a name="s9A1F6C3CE62A468AB47DB512B6E8AB5D"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;9B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84</font></div></div><hr style="page-break-after:always"><a name="s8BB64F87AB14E13A6619B512B71A9914"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;III</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85</font></div></div><hr style="page-break-after:always"><a name="s4B0D7A20CE44B30FB528B512B73BB67A"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The information concerning our executive officers is set forth under the heading </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Our Executive Officers&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in Part&#160;I of this report. The text of our code of business conduct, which includes the code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions, is posted on our website, www.biogen.com, under the &#8220;Corporate Governance&#8221; subsection of the &#8220;About Us&#8221; section of the site. We intend to make all required disclosures regarding any amendments to, or waivers from, provisions of our code of business conduct at the same location of our website. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to the remainder of this item is incorporated by reference from the discussion responsive thereto in the sections entitled &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Proposal&#160;1&#160;- Election of Directors,&#8221; &#8220;Corporate Governance,&#8221; &#8220;Stock Ownership&#160;- Section&#160;16(a) Beneficial Ownership Reporting Compliance</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Miscellaneous&#160;- Stockholder Proposals</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div><a name="s618E8C79488147527486B512B76DAD39"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive Compensation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Executive Compensation and Related Information</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Corporate Governance&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div><a name="s83AD573B8DDA064779F5B512B78E1769"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Stock Ownership&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Equity Compensation Plan Information&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div><a name="s6031CF6B6738C619B0B5B512B7C09D40"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Certain Relationships and Related Person Transactions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Corporate Governance</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><a name="s5B43FC771D1AF56BFFCAB512B7E2965A"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Principal Accounting Fees and Services</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the section entitled &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Proposal&#160;2&#160;&#8212; Ratification of the Selection of our Independent Registered Public Accounting Firm</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div></div></div><br><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86</font></div></div><hr style="page-break-after:always"><a name="sC9ADA8D49A749C17E525B512B814F67B"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;IV</font></div><a name="s61A2ACAD8E05C408D812B512B835B78D"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;15. &#160;&#160;&#160;&#160;Exhibits and Financial Statement Schedules</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">a. &#160;&#160;&#160;&#160;(1)&#160;Consolidated Financial Statements:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following financial statements are filed as part of this report:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="50%"></td><td width="37%"></td><td width="13%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Financial Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page&#160;Number</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-2</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Comprehensive Income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-3</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Balance Sheets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-4</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Cash Flows</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-5</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-6</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Consolidated Financial Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-9</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-71</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certain totals may not sum due to rounding.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;(2) Financial Statement Schedules</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Schedules are omitted because they are not applicable, or are not required, or because the information is included in the consolidated financial statements and notes thereto.</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">(3) Exhibits</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The exhibits listed on the Exhibit&#160;Index beginning on page&#160;A-1, which is incorporated herein by reference, are filed or furnished as part of this report or are incorporated into this report by reference.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87</font></div></div><hr style="page-break-after:always"><a name="sAB131B415CFDEFD36707B512B8672AA5"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="line-height:120%;font-size:18pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;" align="right"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:316px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="50px"></td><td width="265px"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">BIOGEN INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;G</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">EORGE</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;A. S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">CANGOS</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">George A. Scangos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;3, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88</font></div></div><hr style="page-break-after:always"><a name="sAB131B415CFDEFD36707B512B8672AA5"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="42%"></td><td width="3%"></td><td width="34%"></td><td width="3%"></td><td width="18%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Capacity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;G</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">EORGE</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;A. S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">CANGOS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director&#160;and&#160;Chief&#160;Executive&#160;Officer (principal&#160;executive&#160;officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;3, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">George A. Scangos</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;P</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AUL</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;J. C</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">LANCY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive&#160;Vice&#160;President,&#160;Finance&#160;and Chief Financial Officer (principal financial officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;3, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paul J. Clancy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;G</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">REGORY</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;F. C</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OVINO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vice President, Finance, Chief Accounting Officer (principal accounting officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;3, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gregory F. Covino</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TELIOS</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;P</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">APADOPOULOS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director&#160;and&#160;Chairman&#160;of&#160;the&#160;Board&#160;of Directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;3, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stelios Papadopoulos</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">LEXANDER </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">J</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">D</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ENNER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;3, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Alexander J. Denner</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;C</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AROLINE</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;D. D</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ORSA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;3, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Caroline D. Dorsa</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;N</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ANCY</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;L. L</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">EAMING</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;3, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Nancy L. Leaming</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;R</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ICHARD </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">C</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">M</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ULLIGAN</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;3, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Richard C. Mulligan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;R</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OBERT</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;W. P</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ANGIA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;3, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Robert W. Pangia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">RIAN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;S. P</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OSNER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;3, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Brian S. Posner</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;E</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">RIC</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;K. R</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OWINSKY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;3, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eric K. Rowinsky</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;L</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">YNN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">CHENK</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;3, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Lynn Schenk</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TEPHEN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;A. S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">HERWIN</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;3, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stephen A. Sherwin</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">89</font></div></div><hr style="page-break-after:always"><a name="s92F0200CF9E772AC898DB512B8897B88"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="50%"></td><td width="37%"></td><td width="13%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page&#160;Number</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Comprehensive Income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Balance Sheets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Cash Flows</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-5</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-6</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Consolidated Financial Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-9</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-71</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:300px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 1</font></div></div><hr style="page-break-after:always"><a name="s5D029A8C77133E98449AB51294709005"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions, except per share amounts)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="56%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,188.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,203.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,542.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,339.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,126.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">236.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">263.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,763.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,703.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,932.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,240.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,171.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">857.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,012.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,893.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,444.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,113.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,232.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,712.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">382.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">489.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">342.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">93.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit sharing</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">30.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(38.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,872.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,747.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,441.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain on sale of rights</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,891.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,972.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,515.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(123.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(25.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(34.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax expense and equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,767.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,946.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,480.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,161.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">989.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">601.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,593.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,941.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,862.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to noncontrolling interests, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">46.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,547.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,862.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.38</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.42</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.86</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.81</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">230.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">231.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:120px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 2</font></div></div><hr style="page-break-after:always"><a name="s5E2BE0230B0A4C1D4D7EB5129482FAC6"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="56%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,547.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,862.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on securities available for sale:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: reclassification adjustment for (gains) losses included in net income, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on securities available for sale, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on cash flow hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">110.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(26.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: reclassification adjustment for (gains) losses included in net income, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(172.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on cash flow hedges, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(61.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on pension benefit obligation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Currency translation adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(96.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(109.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(164.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,382.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,903.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,889.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income attributable to noncontrolling interests, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">46.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,428.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,909.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,889.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 3</font></div></div><hr style="page-break-after:always"><a name="s43CD887BD5436D8945F3B51294916402"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions, except per share amounts)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="67%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,308.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,204.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,120.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">640.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,227.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,292.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due from unconsolidated joint business, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">314.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">283.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">893.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">804.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">836.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">309.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,700.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,535.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,760.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,470.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,187.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,765.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,085.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,028.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,663.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,760.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,107.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">754.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">19,504.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14,314.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND EQUITY</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">208.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">168.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">267.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">229.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,096.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,817.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,577.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,218.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable and other financing arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,521.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">124.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">905.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">650.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,129.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,500.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commitments and contingencies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. shareholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Preferred stock, par value $0.001 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock, par value $0.0005 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,196.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(224.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retained earnings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,208.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,283.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Treasury stock, at cost; 22.6 million shares, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc. shareholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,372.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,809.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,374.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,814.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities and equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">19,504.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14,314.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 4</font></div></div><hr style="page-break-after:always"><a name="s79F5B74FBBEE89B1A4A0B51294A121D5"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="62%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,593.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,941.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,862.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to reconcile net income to net cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">600.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">688.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">531.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">161.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">155.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">136.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(145.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(308.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(245.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">82.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(50.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities, net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">29.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(512.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(126.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(174.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(185.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(243.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(156.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(94.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(160.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">74.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">244.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">284.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(410.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">156.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities and taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">93.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">161.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due from unconsolidated joint business</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(30.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,716.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,942.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,345.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from sales and maturities of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,063.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,718.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,190.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6,864.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,583.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,278.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisition of TYSABRI rights</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,262.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration related to Fumapharm AG acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(850.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(375.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(15.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisitions of businesses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(198.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(643.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(287.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(246.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(59.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4,553.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,543.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,604.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchase of treasury stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(886.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(400.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from issuance of stock for share-based compensation arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">54.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Excess tax benefit from share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">78.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">96.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,930.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repayments of borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(452.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(74.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by (used in) financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">986.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(755.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(716.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">148.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">643.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of exchange rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(45.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(40.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, beginning of the year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,204.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">602.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">570.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,308.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,204.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">602.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 5</font></div></div><hr style="page-break-after:always"><a name="s6B2F56CC34EEA4C84790B51294B359B3"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF EQUITY</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td width="10%"></td><td width="4%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="3%"></td><td width="1%"></td><td width="1%"></td><td width="4%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="3%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="5%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="4%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="5%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">257.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,196.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(59.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,283.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(22.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,611.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,809.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,814.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,547.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,547.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">46.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,593.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(164.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(164.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(164.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Distribution to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(60.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(60.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisition of noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock pursuant to the 2015 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retirement of common stock pursuant to the 2015 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4,377.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(622.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock option and stock purchase plans</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">54.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">54.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">54.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock award plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(125.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(125.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(125.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compensation expense related to share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">183.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">183.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">183.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit from share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">241.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(224.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,208.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(22.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,372.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,374.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 6</font></div></div><hr style="page-break-after:always"><a name="s6B2F56CC34EEA4C84790B51294B359B3"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td width="11%"></td><td width="4%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="3%"></td><td width="1%"></td><td width="1%"></td><td width="4%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="3%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="5%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="5%"></td><td width="1%"></td><td width="1%"></td><td width="4%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="5%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">256.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,023.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,349.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,724.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,620.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,620.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,941.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Distribution to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other transactions with noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock for Treasury pursuant to the 2011 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(886.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(886.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(886.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock option and stock purchase plans</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock award plan</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(140.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(140.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(140.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compensation expense related to share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">165.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">165.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">165.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit from share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">257.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,196.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,283.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,809.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,814.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 7</font></div></div><hr style="page-break-after:always"><a name="s6B2F56CC34EEA4C84790B51294B359B3"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td width="11%"></td><td width="4%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="3%"></td><td width="1%"></td><td width="1%"></td><td width="4%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="3%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="5%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="5%"></td><td width="1%"></td><td width="1%"></td><td width="4%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="5%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">254.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,854.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(55.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,486.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,324.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,961.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,963.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,862.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,862.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,862.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deconsolidation of noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock for Treasury pursuant to the 2011 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(400.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(400.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(400.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock option and stock purchase plans</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock award plan</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(89.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(89.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(89.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compensation expense related to share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">146.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">146.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">146.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit from share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">256.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,023.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,349.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,724.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,620.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,620.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 8</font></div></div><hr style="page-break-after:always"><a name="sB06ACEDA9C276ACCC48FB512B9DFEBD6"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><a name="s75C63CBDF334EC139314B5129558CEC6"></a><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">1. &#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. We also have a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, which entitles us to certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL, and other potential anti-CD20 therapies.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our innovative drug development efforts, we aim to leverage our manufacturing capabilities and scientific expertise to extend our mission to improve the lives of patients living with serious diseases through the development, manufacture and marketing of biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. Product revenues are recorded net of applicable reserves for discounts and allowances.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We establish reserves for trade term discounts, wholesaler incentives, Medicaid rebates, co-payment assistance (copay), Veterans Administration (VA) and Public Health Service (PHS) discounts, managed care rebates, product returns and other governmental rebates or applicable allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Reserves established for these discounts and allowances are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These reserves are based on estimates of the amounts earned or to be claimed on the related sales. Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves are categorized as follows: discounts, contractual adjustments and returns.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, patient copay assistance, VA and PHS discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid, and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consists of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Copay represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other governmental rebates or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the discounts, rebates and product returns described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify these payments in selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Unconsolidated Joint Business</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from unconsolidated joint business consists of (i)&#160;our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; (ii)&#160;reimbursement of our selling and development expenses in the U.S. for RITUXAN; and (iii)&#160;revenue on sales in the rest of world for RITUXAN, which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales outside the U.S. and Canada by the Roche Group and its sublicensees. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by Genentech in the U.S. and by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less the cost to manufacture, third-party royalty expenses, distribution, selling, and marketing expenses, and joint development expenses incurred by Genentech, the Roche Group and us. We record our share of the pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales outside the U.S. on a cash basis as we do not have the ability to estimate these profits or royalty revenue in the period incurred. Additionally, our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. includes estimates made by Genentech and those estimates are subject to change. Actual results may differ from our estimates. For additional information related to our collaboration with Genentech, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. If we are unable to reasonably estimate royalty revenue or do not have access to the information, then we record royalty revenues on a cash basis. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Multiple-Element Revenue Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may enter into transactions that involve the sale of products and related services under multiple element arrangements.&#160;In accounting for these transactions, we assess the elements of the contract and whether each element has standalone value and allocate revenue to the various elements based on their estimated selling price as a component of total revenues.&#160;The selling price of a revenue generating element can be based on current selling prices offered by us or another party for current products or management&#8217;s best estimate of a selling price. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;2</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates;&#160;and</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, derivative contracts, marketable debt securities, and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We validate the prices provided by our third-party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources and analyzing pricing data in certain instances. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying amounts reflected in the consolidated balance sheets for current accounts receivable, due from unconsolidated joint business, other current assets, accounts payable, and accrued expenses and other, approximate fair value due to their short-term maturities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consider only those investments which are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, cash equivalents were comprised of money market funds and commercial paper, overnight reverse repurchase agreements, and other debt securities with maturities less than 90 days from the date of purchase.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our consolidated statement of income.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The credit and economic conditions in certain countries in the E.U. continue to remain uncertain and have, from time to time, led to a lengthening of time to collect our accounts receivable in some of these countries. In recent years, our collection efforts in Portugal and select regions of Spain have been subject to significant payment delays due to government funding and reimbursement practices. As a result, a portion of these receivables have been routinely collected beyond our contractual payment terms and over periods in excess of one year. Our accounts receivable collection efforts in Portugal and Spain have improved during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;with our receivables in Spain now expected to be collected within one year. Our net accounts receivable balance from product sales in Portugal and Spain totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;were classified as non-current and included in investments and other assets in our consolidated balance sheets. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives, and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable arise from product sales in the U.S. and Europe and have standard payment terms which generally require payment within </font><font style="font-family:inherit;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 to 90 days</font></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, two wholesale distributors individually accounted for approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.4%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.1%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.4%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of accounts receivable, net, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Marketable Securities and Other Investments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Available-for-sale debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheet. When assessing whether a decline in the fair value of a marketable equity security is other-than-temporary, we consider the fair market value of the security, the duration of the security&#8217;s decline, and prospects for the underlying business, including favorable or adverse clinical trial results, new product initiatives and new collaborative agreements with the companies in which we have invested.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the cost method or the equity method of accounting, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any decline in their value has occurred that would be other-than-temporary, based on the implied value of recent company financings, public market prices of comparable companies, and general market conditions and are included in investments and other assets in our consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Evaluating Investments for Other-than-Temporary Impairments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For equity securities, when assessing whether a decline in value is other-than-temporary, we consider the fair market value of the security, the duration of the security&#8217;s decline, and the financial condition of the issuer. We then consider our intent and ability to hold the equity security for a period of time sufficient to recover our carrying value. Where we have determined that we lack the intent and ability to hold an equity security to its expected recovery, the security&#8217;s decline in fair value is deemed to be other-than-temporary and is reflected in earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Equity Method of Accounting</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In circumstances where we have the ability to exercise significant influence over the operating and financial  policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship.&#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceed the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when selected for use in a clinical manufacturing campaign.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Capitalization of Inventory Costs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Obsolescence and Unmarketable Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring which we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from </font><font style="font-family:inherit;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three to five years</font></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="50%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts on our consolidated balance sheet and include any resulting gain or loss in our consolidated statement of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded as amortization of acquired intangible assets in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd (Elan), an affiliate of Elan Corporation, plc. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TYSABRI and AVONEX using the economic consumption method based on revenue generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TYSABRI and AVONEX is performed annually during our long range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of TYSABRI or AVONEX.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives, however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired In-process Research and Development (IPR&amp;D)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value. The revenue and costs projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology, and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business, then the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Certain IPR&amp;D programs have a fair value that is not significantly in excess of carrying value, including our program for the treatment of TGN. Such programs could become impaired if assumptions used in determining the fair value change.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, then we would need to determine the implied fair value of our reporting unit&#8217;s goodwill. If the carrying value of our reporting unit&#8217;s goodwill exceeds its implied fair value, then we would record an impairment loss equal to the difference. As described in Note&#160;24, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements, we operate in one operating segment which we consider our only reporting unit.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used, including property, plant and equipment and definite-lived intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions that qualify as business combinations completed after January&#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue these contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step, and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Derivative Instruments and Hedging Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of derivatives are recorded each period in current earnings or accumulated other comprehensive income (loss), depending on whether a derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We also assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion to current earnings. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Translation of Foreign Currencies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net, in net income.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Royalty Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Share-Based Compensation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share-based compensation programs grant awards that have included stock options, restricted stock units which vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units which settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units which can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of the Board of Directors and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date on which the employee is retirement eligible.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&#8217; vesting periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures, when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs and PUs and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs and PUs are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price of common stock under our ESPP is equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the lesser of (i)&#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes model. The fair value of the look-back provision plus the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;discount is recognized as compensation expense over the 90 day purchase period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable, and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets on our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of unconsolidated joint business revenues.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For collaborations with commercialized products, if we are the principal, we record revenue and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Advertising costs are expensed as incurred. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, advertising costs totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$108.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$92.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$72.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All tax effects associated with intercompany transfers of assets in our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through the consolidated statement of income when the asset transferred is sold to a third party or otherwise recovered through amortization of the asset's remaining economic life.&#160;If the asset transferred becomes impaired, for example through the discontinuation of a research program, we will expense any remaining deferred charge or prepaid tax.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Earnings per Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2014, the FASB issued ASU No. 2014-11, Transfers and Servicing (Topic 860): Repurchase-to-Maturity Transactions, Repurchase Financings, and Disclosure. The new standard expanded secured borrowing accounting to include repurchase-to-maturity transactions and repurchase financings and set forth new disclosure requirements for repurchase agreements, securities lending transactions, and repurchase-to-maturity transactions that are accounted for as secured borrowings. We adopted this standard on April 1, 2015 and expanded our disclosures presented in Note 8, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. The adoption of this standard did not have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015, the FASB issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The new standard requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU No. 2015-15, Interest - Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements, which clarified that debt issuance costs related to line-of-credit arrangements can be presented in the balance sheet as an asset and amortized over the term of the line-of-credit arrangement. We adopted these standards as of September 30, 2015 with retroactive application. The adoption of these standards did not have a significant impact on our financial position or results of operations. For additional information, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015, the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. Under this standard, if a cloud computing arrangement includes a software license, the software license element of the arrangement should be accounted for consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015, the FASB issued ASU No. 2015-07, Fair Value Measurement (Topic 820): Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent). The new standard removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The new standard will be effective for us on January 1, 2016. Early application is permitted. We maintain investments in certain venture capital funds which primarily invest in small, privately-owned, venture-backed biotechnology companies. The value of our investments in these venture capital funds is estimated using the net asset value of the fund and has been included in the fair value hierarchy disclosure as a Level 3 measurement. These venture capital investments are not material to our financial position or results of operations. We adopted this standard as of June 30, 2015 and our investments in venture capital funds are no longer included in our disclosures reflected in Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The new standard applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The new standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined and sets forth new disclosure requirements related to the adjustments. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. The new standard requires that deferred tax assets and liabilities be classified as noncurrent in a classified statement of financial position. We adopted this standard as of December 31, 2015 with retroactive application. As a result, we reclassified our deferred tax assets classified as current to noncurrent and our deferred tax liabilities classified as current to noncurrent in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;consolidated balance sheet, to conform our prior year presentation to our current year presentation. For additional information, please read Note 16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><a name="sE90257013F8345051316B512956A7957"></a><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Acquisitions</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Convergence Pharmaceuticals</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 12, 2015, we completed our acquisition of all of the outstanding stock of Convergence Pharmaceuticals (Convergence), a clinical-stage biopharmaceutical company with a focus on developing product candidates for neuropathic pain. Convergence&#8217;s lead candidate is a Phase 2 clinical candidate Raxatrigine (CNV1014802), which has demonstrated clinical activity in proof-of-concept studies for trigeminal neuralgia (TGN). Additionally, Raxatrigine has potential applicability in several other neuropathic pain states. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price consisted of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cash payment at closing, plus contingent consideration in the form of development and approval milestones up to a maximum of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$450.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$350.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is associated with the development and approval of Raxatrigine for the treatment of TGN. The acquisition was funded from our existing cash on hand and has been accounted for as the acquisition of a business. In addition to obtaining the rights to Raxatrigine and additional product candidates in preclinical development, we retained the services of key employees of Convergence.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence, we recorded a liability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;representing the fair value of the contingent consideration.&#160;This amount was estimated through a valuation model that incorporates industry-based probability adjusted assumptions relating to the achievement of these milestones and thus the likelihood of making the contingent payments. This fair value measurement is based upon significant inputs not observable in the market and therefore represents a Level 3 measurement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price, as adjusted, consisted of the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="87%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash portion of consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">200.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">274.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">474.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the second quarter of 2015, we adjusted our preliminary estimate of the fair value of the assets acquired and contingent consideration as of the date of acquisition as a result of finalizing the purchase price accounting. This resulted in an increase in the value of our estimated contingent consideration and goodwill by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$36.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our revised purchase price allocation is reflected in the chart below. Our purchase price allocation is substantially complete.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subsequent changes in the fair value of the contingent consideration obligation will be recognized as adjustments to contingent consideration and reflected in our consolidated statements of income. For additional information related to the fair value of this obligation, please read Note 7,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of February&#160;12, 2015, as adjusted:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="87%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">424.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">128.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(84.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">474.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of the IPR&amp;D programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was primarily driven by the value associated with the lead candidate, Raxatrigine, which is in development for the treatment of TGN and is expected to be completed no earlier than 2020, at a remaining cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$145.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value associated with Raxatrigine for the treatment of TGN was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have recorded additional IPR&amp;D assets related to the use of Raxatrigine in two additional neuropathic pain indications, with a total estimated value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$220.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The remaining cost of development for these two indications is approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$415.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with an expected completion date of no earlier than 2021. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have attributed the goodwill recognized to the Convergence workforce's expertise in chronic pain research and clinical development and to establishing a deferred tax liability for the acquired IPR&amp;D intangible assets which have no tax basis. The goodwill is not tax deductible.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pro forma results of operations would not be materially different as a result of the acquisition of Convergence and therefore are not presented. Subsequent to the acquisition date, our results of operations include the results of operations of Convergence.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TYSABRI</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On April 2, 2013, we acquired full ownership of all remaining rights to TYSABRI from Elan that we did not already own or control. Upon the closing of the transaction, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Elan, which was funded from our existing cash, and our collaboration agreement with Elan was terminated. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as the acquisition of an asset as we did not acquire any employees from Elan nor did we acquire any significant processes that we did not previously perform or manage under the collaboration agreement. Under the collaboration agreement, we manufactured TYSABRI and collaborated with Elan on the product's marketing, commercial, regulatory, distribution and ongoing development activities. The collaboration agreement was designed to effect an equal sharing of worldwide profits and losses generated by the activities of the collaboration. For additional information related to this collaboration, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upfront payment was capitalized in the second quarter of 2013 as an intangible asset in our consolidated balance sheet as TYSABRI had reached technological feasibility. We adjusted the value of this intangible asset by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$84.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to deferred revenue from two sales-based milestones previously paid by Elan as well as transaction costs. The net intangible asset capitalized was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.18 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Commencing in the second quarter of 2013, we began amortizing this intangible asset over the estimated useful life using an economic consumption method based on actual and expected revenue generated from the sales of our TYSABRI product. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the April 2, 2013 closing of the transaction, we began recording 100% of U.S. revenues, cost of sales and operating expenses related to TYSABRI in our consolidated statements of income. Under the terms of the acquisition agreement, we continued to share TYSABRI profits with Elan on an equal basis until April 30, 2013. We recorded the profit split for the month ended April 30, 2013, as cost of sales in our consolidated statements of income as we controlled TYSABRI effective April 2, 2013. Between May 1, 2013 and April 30, 2014, we made contingent payments to Elan of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on worldwide net sales of TYSABRI. Commencing May 1, 2014 and thereafter, we will make contingent payments to Elan of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on annual worldwide net sales up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on annual worldwide net sales that exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In 2014, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;threshold was pro-rated for the portion of 2014 remaining after the first 12 months expired. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013. Following that acquisition, we began making these royalty payments to Perrigo. Royalty payments to Perrigo and other third parties are recognized as cost of sales in our consolidated statements of income.</font></div><a name="s27ea271dafa84857bdea4e4a4c54ef97"></a><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Restructuring</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On October 21, 2015, we announced a corporate restructuring, which includes the termination of certain pipeline programs and an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction in workforce. We anticipate making cash payments totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under this program, which includes approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to previously 2015 accrued incentive compensation, for a total net expected restructuring charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$105 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These amounts will be substantially incurred and paid by the end of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of these charges during the fourth quarter of 2015, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$86.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was related to our workforce reduction and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was related to the pipeline program terminations.&#160;Our restructuring reserve is included in accrued expenses and other in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the charges and spending related to our restructuring efforts during 2015:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="53%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Workforce</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reduction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Pipeline</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges incurred during the fourth quarter of 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">86.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">93.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Previously accrued incentive compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves established</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">102.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">109.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts paid through December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(68.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(72.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><a name="sF9B2668139FEE29EE72EB5129583A094"></a><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">4.&#160;&#160;&#160;&#160;Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of our acquisition of all remaining rights to TYSABRI from Elan, we began recognizing reserves for discounts and allowances for U.S. TYSABRI revenue in the second quarter of 2013. In addition, following our recently launched products, we began recognizing reserves for discounts and allowances related to these products' revenue. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="41%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">387.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">49.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">483.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">459.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,732.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,229.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(32.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(405.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,258.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,666.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(44.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(296.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(351.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">56.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">548.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">57.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">662.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="41%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2014</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">345.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">426.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">347.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,265.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,651.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(28.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(299.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(933.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,237.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(46.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(261.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(33.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(341.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">387.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">483.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="41%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2013</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">861.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,120.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(189.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(560.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(750.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(135.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(165.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">345.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">426.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total revenue-related reserves above, included in our consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="67%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">144.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">124.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">518.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">359.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">662.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">483.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><a name="s26245D5139CC8150B99AB51295A1221B"></a><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="67%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">213.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">128.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">577.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">511.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">143.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">164.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">933.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">804.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">893.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">804.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">933.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">804.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory included in investments and other assets in our consolidated balance sheets primarily consisted of work in process.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our inventory included </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with our ZINBRYTA program, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with our BENEPALI program and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with our FLIXABI program, which have been capitalized in advance of regulatory approval. In January 2016, the European Commission (EC) approved the marketing authorization application (MAA) for BENEPALI for marketing in the E.U. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our inventory included </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with our ZINBRYTA program, which has been capitalized in advance of regulatory approval. For information on our pre-approval inventory policy, please read Note 1,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><a name="s9E933F0D0DAE8201CE90B51295A6757C"></a><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td width="21%"></td><td width="17%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(506.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(481.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,552.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">452.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,396.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">608.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">730.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">730.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">314.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">314.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks and tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,303.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(502.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,800.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,280.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(300.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,980.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,646.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3,561.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,085.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,207.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,178.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,028.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$382.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$489.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$342.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Amortization of acquired intangible assets during 2014 included total impairment charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to one of our out-licensed patents and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to one of our IPR&amp;D intangible assets. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Out-licensed Patents</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents to third-parties primarily relate to patents acquired in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. During 2014, we recorded a charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the impairment of one of our out-licensed patents to reflect a change in its estimated fair value, due to a change in the underlying competitive market for that product. The charge was included in amortization of acquired intangible assets. The fair value of the intangible asset was based on a discounted cash flow calculated using Level 3 fair value measurements and inputs including estimated revenues. There were no impairment charges related to our out-licensed patents during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$443.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquire that have not reached technological feasibility at the date of acquisition. Upon commercialization, we determine the estimated useful life. In connection with our acquisition of Convergence in February 2015, we acquired IPR&amp;D programs with an estimated fair value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$424.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This amount has and will be adjusted for foreign exchange rate fluctuations. For a more detailed description of this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of anticipated lifetime revenues and anticipated development costs is performed annually during our long- range planning cycle, which was updated in the third quarter of 2015.&#160;This analysis is based upon certain assumptions that we evaluate on a periodic basis, including anticipated future product sales, the expected impact of changes in the amount of development costs and the probabilities of our programs succeeding, the introduction of new products by our competitors and changes in our commercial and pipeline product candidates.&#160;&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2014, we updated the probabilities of success related to the early stage programs acquired through our recent acquisitions.&#160;The change in probability of success, combined with a delay in one of the projects, resulted in an impairment loss of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in one of our IPR&amp;D assets during 2014.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,742.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For a more detailed description of this transaction, please read Note&#160;2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">&#32;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long range planning cycle was completed in the third quarter of 2015. Based upon this analysis, the estimated future amortization of acquired intangible assets is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="81%"></td><td width="1%"></td><td width="17%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">346.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">318.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">291.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">275.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">269.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,500.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="67%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,760.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,232.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">908.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">527.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,663.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,760.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$900.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$128.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to our acquisition of Convergence. Other includes changes related to foreign exchange rate fluctuations. The increase in goodwill during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$600.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$72.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to future contingent payments to the former shareholders of Fumapharm AG, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. For additional information related to our acquisition of Convergence, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;accumulated impairment losses related to goodwill.</font></div><a name="sAF2F954D9E8AFBCB5217B51295CA8A64"></a><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">909.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">909.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,510.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,510.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,875.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,875.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">494.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">494.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">27.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">27.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,895.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,857.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">520.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">716.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">716.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,063.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,063.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">849.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">849.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,943.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,937.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">220.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third-party pricing services. For a description of our validation procedures related to prices provided by third-party pricing services, refer to Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="67%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">602.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">634.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,497.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,014.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,764.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,757.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,645.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">647.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our notes payable to Fumedica was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable, and corroborated sources. For additional information related to our debt instruments, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="67%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">274.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">30.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(38.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(26.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$301.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;changes in valuation techniques or transfers between fair value measurement levels during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. During the third quarter 2014, we updated the probabilities of success related to the early stage programs acquired through our recent acquisitions. We adjusted the value of our contingent consideration liabilities to reflect these changes. The change in probability of success, combined with a delay in one of the projects, resulted in a net gain of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during 2014, which was&#160;recorded in (gain) loss on fair value remeasurement of contingent consideration and reduced the fair value of our contingent consideration obligations. The fair values of the intangible assets and contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. For additional information related to the valuation techniques and inputs utilized in valuation of our financial assets and liabilities, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence in February 2015, we recorded a liability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing the fair value of the contingent consideration. This valuation was based on probability weighted net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$450.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was the estimated cost of debt financing for market participants. This liability reflects the revised estimate from the date of acquisition for our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. For a more detailed description of this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$297.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$197.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is reflected as a component of accrued expenses and other in our consolidated balance sheets as we expect to make the payment within a year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Stromedix in March 2012, we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$122.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$131.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon probability weighted net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$419.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net increase in the fair value of this obligation was primarily due to changes in the discount rate, partially offset by changes in the expected timing related to the achievement of certain remaining developmental milestones.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon completion of our purchase of the noncontrolling interest in our joint venture investments in Biogen Domp&#233; SRL and Biogen Domp&#233; Switzerland GmbH in September 2011, we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$38.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net decrease in the fair value of this obligation was primarily due to payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of sales-based milestones. Our obligations under this agreement were completed as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Biogen Idec International Neuroscience GmbH (BIN), formerly Panima Pharmaceuticals AG (Panima), in December 2010, we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$81.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$77.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$69.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon probability weighted net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net increase in the fair value of this obligation was primarily due to changes in the probability and expected timing related to the achievement of certain remaining developmental milestones and in the discount rate.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence, we also allocated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$424.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the total purchase price to acquired IPR&amp;D, which was capitalized as an intangible asset. The amount allocated to acquired IPR&amp;D was based on significant inputs not observable in the market and thus represented a Level 3 fair value measurement. This estimate was also adjusted from our preliminary estimate as of the date of acquisition to reflect revised estimates to our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. These assets will be tested for impairment annually until commercialization, after which time the IPR&amp;D will be amortized over its estimated useful life. For a more detailed description of this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><a name="s8E9333A1C0759C54C5D4B51295FCE923"></a><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">8.&#160;&#160;&#160;&#160;Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of </font><font style="font-family:inherit;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less than 90&#160;days</font></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from the date of purchase included in cash and cash equivalents on the accompanying consolidated balance sheet:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="67%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">134.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">305.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">673.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">321.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">79.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">909.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">716.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short term maturities. Our overnight reverse repurchase agreements are collateralized with agency-guaranteed mortgage-backed securities and represent approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of total assets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="41%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">394.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">394.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,116.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,120.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,723.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,724.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,152.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,155.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">491.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">493.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,880.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,891.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">28.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="41%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">370.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">370.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">692.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">693.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">269.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">270.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">579.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,111.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,112.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="41%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,120.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,122.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">640.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">640.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,575.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,583.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,343.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,345.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">184.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">185.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">126.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">126.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,880.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,891.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,111.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,112.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;months and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="53%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,063.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,718.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,190.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of agency mortgage-backed securities and government securities. Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of agency mortgage-backed securities and corporate securities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$96.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 31</font></div></div><hr style="page-break-after:always"><a name="sF1E595466A5F5F957647B5129619B2BE"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">9.&#160;&#160;&#160;&#160;Derivative Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These contracts have been designated as cash flow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and, beginning in the fourth quarter of 2015, in operating expenses when the expense in the currency being hedged is recorded. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="67%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">945.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,174.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss francs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">80.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">76.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Australian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,103.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,302.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$72.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$23.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect all contracts to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments on our consolidated statements of income related to our forecasted revenues:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"></td></tr><tr><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">173.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The effect of foreign currency forward contracts designated as hedging instruments on our consolidated statements of income related to our forecasted operating expenses was immaterial for 2015.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 32</font></div></div><hr style="page-break-after:always"><a name="sF1E595466A5F5F957647B5129619B2BE"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interest Rate Lock Contracts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into treasury rate locks, with an aggregated notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, that were designated as cash flow hedges to hedge against changes in the 10-year and 30-year U.S. treasury interest rates that could have impacted our anticipated debt offering. In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes, as described in Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we settled the treasury rate locks and realized an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;gain. As the hedging relationship was effective, the gain was recorded in AOCI and will be recognized in other income (expense), net over the life of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interest Rate Swap Contracts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes,  as described in Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with one month durations, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$721.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$23.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to these contracts were recognized as a component of other income (expense), net, for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our consolidated balance sheets for our outstanding derivatives including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="54%"></td><td width="27%"></td><td width="1%"></td><td width="17%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance&#160;Sheet&#160;Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Fair Value<br>As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="54%"></td><td width="27%"></td><td width="1%"></td><td width="17%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value<br>As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 33</font></div></div><hr style="page-break-after:always"><a name="sD8CDDEB1E9FCBDA45CC9B5129636CEEE"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">10.&#160;&#160;&#160;&#160;&#160;&#160;Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="67%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">74.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,035.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">947.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">166.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">155.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,079.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,011.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Computer software and hardware</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">647.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">547.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">72.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">441.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">168.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,517.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,952.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,330.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,186.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,187.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,765.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation expense totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$217.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$198.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$187.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we capitalized interest costs related to construction in progress totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research Triangle Park Facility Purchase</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 24, 2015, we purchased from Eisai, Inc. (Eisai) its drug product manufacturing facility and supporting infrastructure in Research Triangle Park (RTP), North Carolina for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$104.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The purchase price consisted of the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="87%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">58.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">104.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 24, 2015, we also amended our existing </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;year lease related to Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. As amended, the lease provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;year term and our agreement to purchase the facility upon expiration of the lease term and Eisai's completion of certain activities. Accordingly, we recorded the assets along with a corresponding financing obligation on our consolidated balance sheet for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net present value of the future minimum lease payments. The assets were recorded as a component of buildings and machinery and equipment. We expect to complete the purchase of the oral solid products manufacturing facility at the end of the lease term in the third quarter of 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 1, 2015, we purchased land in Solothurn, Switzerland for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">). We plan to build a biologics manufacturing facility on this land in the Commune of Luterbach over the next several years. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$99.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;capitalized in construction in progress related to the construction of this facility. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Weston Exit Costs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of our decision to relocate our corporate headquarters to Cambridge, Massachusetts, we vacated part of our Weston, Massachusetts facility in the fourth quarter of 2013. We incurred a charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in connection with this move. This charge represented our remaining lease obligation for the vacated portion of our Weston, Massachusetts facility, net of sublease income expected to be received. The term of our sublease for the </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 34</font></div></div><hr style="page-break-after:always"><a name="sD8CDDEB1E9FCBDA45CC9B5129636CEEE"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">vacated portion of our Weston, Massachusetts facility started in January 2014 and will continue through the remaining term of our lease agreement.</font></div><a name="sC14EB6661025F44149ABB512963EB1A3"></a><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">11.&#160;&#160;&#160;&#160;&#160;Indebtedness</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="67%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing arrangement for the purchase of the RTP facility</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Non-current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">2008 Senior Notes</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">565.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">571.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">2015 Senior Notes</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,485.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">992.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,733.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,721.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing arrangement for the purchase of the RTP facility</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">18.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,521.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary description of our principal indebtedness as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Senior Notes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On September 15, 2015, we issued senior unsecured notes for an aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2020, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.792%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">3.625%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2022, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.920%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2025, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.764%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15,&#160;2045, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.294%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These notes are senior unsecured obligations and may be redeemed at our option at any time at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the principal amount plus accrued interest and a specified make-whole amount. The notes also contain a change of control provision that may require us to purchase the notes at a price equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The costs associated with this offering of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;have been recorded as a reduction to the carrying amount of the debt on our consolidated balance sheet. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. Interest on the notes is payable March 15 and September 15 of each year. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this offering, we also entered into interest rate swaps. The carrying value of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes includes approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to changes in the fair value of the interest rate swaps. For additional information, please read Note 9, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these consolidated financial statements.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2008 Senior Notes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March&#160;4, 2008, we issued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Senior Notes due March&#160;1, 2018 that were originally priced at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">99.184%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par. The discount is amortized as additional interest expense over the period from issuance through maturity. These notes are senior unsecured obligations. Interest on the notes is payable March&#160;1 and September&#160;1 of each year. The notes may be redeemed at our option at any time at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the principal amount plus accrued interest and a specified make-whole amount. The notes contain a change of control provision that may require us to purchase the notes under certain circumstances. There is also an interest rate adjustment feature that requires us to pay interest at an increased rate on the notes if the credit rating on the notes declines below investment grade. In accordance with ASU No. 2015-03, during 2015, we reclassified </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our debt issuance costs related to our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes from an asset to a reduction to the carrying amount of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes in our 2014 consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon the issuance of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Senior Notes due in 2018, we entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. These contracts were terminated in December 2008. Upon termination of these swaps, the carrying amount of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Senior Notes due in 2018 was increased by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and is being amortized using the effective interest rate method over the remaining life of the Senior Notes and is being recognized as a reduction of interest expense. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;remains to be amortized. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Notes Payable to Fumedica</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our 2006 distribution agreement with Fumedica, we issued notes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs which were payable to Fumedica in varying amounts from June 2008 through June 2018. Our remaining note payable to Fumedica had a carrying value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015, we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;outstanding borrowings and were in compliance with all covenants under this facility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2013, we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$750.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">364</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-day senior unsecured revolving credit facility. In March 2014, the revolving credit facility expired and was not renewed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financing Arrangement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015 we recorded a financing obligation in relation to the amendment of our lease agreement of Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the financing obligation totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$19.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, Plant and Equipment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Maturity</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total gross payments, excluding our financing arrangement, due under our debt arrangements are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="80%"></td><td width="1%"></td><td width="18%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">553.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,500.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,500.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,559.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our debt is disclosed in Note&#160;7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 36</font></div></div><hr style="page-break-after:always"><a name="s636D088D40ECF9E2B20BB512964FEF8A"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">12.&#160;&#160;&#160;&#160;&#160; Equity</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares of Preferred Stock authorized, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.75 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares are authorized as Series A, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares are authorized as Series X junior participating and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.25 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares are undesignated. Shares may be issued without a vote or action of stockholders from time to time in classes or series with the designations, powers, preferences, and the relative, participating, optional or other special rights of the shares of each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. No shares of Preferred Stock were issued and outstanding during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table describes the number of shares authorized, issued and outstanding of our common stock as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td width="24%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">241.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">257.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">234.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015, our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2015 Share Repurchase Program). As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 2015 Share Repurchase Program was completed and we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011, our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2011 Share Repurchase Program), which has been used principally to offset common stock issuances under our share-based compensation plans. The 2011 Share Repurchase Program does not have an expiration date. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we purchased approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$886.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our 2011 Share Repurchase Program. We did not repurchase any shares of common stock under our 2011 Share Repurchase Program during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares remaining available for repurchase under this authorization.</font></div><a name="s961CBDC5F2B64FD9A1EDB5129659351A"></a><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">13.&#160;&#160;&#160;&#160;&#160;&#160;Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td width="26%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(99.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(59.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">110.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(96.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(172.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(171.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(61.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(96.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(164.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(37.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(195.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(224.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td width="26%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(109.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(109.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(99.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td width="26%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(55.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(26.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td width="28%"></td><td width="25%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">173.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">171.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 38</font></div></div><hr style="page-break-after:always"><a name="sE1647DAD450EBE8F4722B5129684A15C"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">14.&#160;&#160;&#160;&#160;&#160;&#160;Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="53%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,547.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,862.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">230.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">231.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Earnings per share for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects, on a weighted average basis, the repurchase of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares, respectively, of our common stock under our share repurchase authorizations.</font></div><a name="s89B3FE40BD0BDB277F2DB512968CB1A6"></a><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">15.&#160;&#160;&#160;&#160;&#160;Share-based Payments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="55%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">88.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">102.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">127.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">160.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reversal of previously accrued incentive compensation included in restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(8.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">207.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">252.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">255.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">196.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">246.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(55.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(72.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(73.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">140.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">172.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="55%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">38.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">119.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">115.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">103.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">109.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">207.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">252.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">255.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">196.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">246.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Windfall tax benefits from vesting of stock awards, exercises of stock options and ESPP participation were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$78.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$96.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$73.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These amounts have been calculated under the alternative transition method.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, unrecognized compensation cost related to unvested share-based compensation was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$184.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;years.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-Based Compensation Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share-based compensation plans pursuant to which awards are currently being made: (i)&#160;the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006&#160;Directors Plan); (ii)&#160;the Biogen Inc. 2008 Amended and Restated Omnibus Equity Plan (2008 Omnibus Plan); and (iii)&#160;the Biogen Inc. 2015 Employee Stock Purchase Plan (ESPP). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Directors Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2006, our stockholders approved the 2006&#160;Directors Plan for share-based awards to our directors. Awards granted from the 2006&#160;Directors Plan may include stock options, shares of restricted stock, restricted stock units, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. We have reserved a total of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock for issuance under the 2006&#160;Directors Plan. The 2006&#160;Directors Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a </font><font style="font-family:inherit;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5-to-1</font></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;ratio. In June 2015, our stockholders approved an amendment to extend the term of the 2006 Directors Plan until June 10, 2025.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Omnibus Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2008, our stockholders approved the 2008 Omnibus Plan for share-based awards to our employees. Awards granted from the 2008 Omnibus Plan may include stock options, shares of restricted stock, restricted stock units, performance shares, shares of phantom stock, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for issuance under the 2008 Omnibus Plan consist of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares reserved for this purpose, plus shares of common stock that remained available for issuance under our 2005 Omnibus Equity Plan on the date that our stockholders approved the 2008 Omnibus Plan, plus shares that were subject to awards under the 2005 Omnibus Equity Plan which remain unissued upon the cancellation, surrender, exchange or termination of such awards. The 2008 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a </font><font style="font-family:inherit;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5-to-1</font></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;ratio.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have not made any awards pursuant to the 2005 Omnibus Equity Plan since our stockholders approved the 2008 Omnibus Plan, and do not intend to make any awards pursuant to the 2005 Omnibus Equity Plan in the future, except that unused shares under the 2005 Omnibus Equity Plan have been carried over for use under the 2008 Omnibus Plan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We currently do not grant stock options to our employees or directors. Outstanding stock options previously granted to our employees and directors generally have a ten-year term and vest over a period of between one and four years, provided the individual continues to serve at Biogen through the vesting dates. Options granted under all plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the options&#8217; vesting periods. The fair value of the stock options granted in 2010 was estimated as of the date of grant using a Black-Scholes option valuation model. There were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;grants of stock options made in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, all outstanding options were exercisable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The expected life of options granted is derived using assumed exercise rates based on historical exercise patterns and represents the period of time that options granted are expected to be outstanding. Expected stock price volatility is based upon implied volatility for our exchange-traded options and other factors, including historical volatility. After assessing all available information on either historical volatility, implied volatility, or both, we have concluded that a combination of both historical and implied volatility provides the best estimate of expected volatility. The risk-free interest rate used is determined by the market yield curve based upon risk-free interest rates established by the Federal Reserve, or non-coupon bonds that have maturities equal to the expected term. The dividend yield of zero is based upon the fact that we have not historically granted cash dividends, and do not expect to issue dividends in the foreseeable future. Stock options granted prior to January&#160;1, 2006 were valued based on the grant date fair value of those awards, using the Black-Scholes option pricing model, as previously calculated for pro-forma disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our stock option activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="67%"></td><td width="15%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">221,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">56.98</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(114,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">59.82</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">107,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.94</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total intrinsic values of options exercised in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$38.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$86.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The aggregate intrinsic values of options outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The weighted average remaining contractual term for options outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;years. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="53%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit realized for stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received from the exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Market Stock Units (MSUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees prior to 2014 vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">four</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of units granted based on actual stock performance. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees in 2014 and 2015 vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of units granted based on actual stock performance. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our MSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="67%"></td><td width="15%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">403,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">219.29</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">185,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">493.43</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(277,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">165.63</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(42,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">294.85</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">269,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">339.89</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">MSUs granted in 2015 include approximately </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">8,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">19,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">24,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;and </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">34,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;MSUs issued in 2015 based upon the attainment of performance criteria set for 2014, 2013, 2012 and 2011, respectively, in relation to awards granted in those years. The remainder of MSUs granted during 2015 include awards granted in conjunction with our annual awards made in February 2015 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, including the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price on grant date for MSUs awarded prior to 2014, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price on the date of grant for MSUs awarded in 2014 and 2015, expected volatility of our stock price, risk-free rates of return and expected dividend yield. The assumptions used in our valuation are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="44%"></td><td width="18%"></td><td width="1%"></td><td width="18%"></td><td width="1%"></td><td width="18%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of expected stock price volatility</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">31.0% - 33.2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.7% - 35.1%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.7% - 25.7%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of risk-free interest rates</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2% - 1.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1% - 0.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1% - 0.7%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 calendar day average stock price on grant date</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$277.35 - $426.27</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$280.88 - $335.65</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60 calendar day average stock price on grant date</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.33 - $240.14</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average per share grant date fair value</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$493.43</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$395.22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$193.45</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total fair values of MSUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$109.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$117.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Settled Performance Units (CSPUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CSPUs awarded to employees vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December&#160;31 of each year. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs awarded prior to 2014 are settled in cash based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. CSPUs awarded in 2014 and 2015 will be settled in cash based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our CSPU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="82%"></td><td width="17%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">335,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">115,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(222,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(36,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">192,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">CSPUs granted in 2015 include approximately </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">48,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;CSPUs issued in 2015 based upon the attainment of performance criteria set for 2014 in relation to awards granted in 2014. The remainder of the CSPUs granted in 2015 include awards granted in conjunction with our annual awards made in February 2015 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total cash paid in settlement of CSPUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$79.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$92.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Performance-vested Restricted Stock Units (PUs)</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning in the first quarter of 2014, we revised our long term incentive program to include a new type of award granted to certain employees in the form of restricted stock units that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the cash settled performance units, and vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="82%"></td><td width="17%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">57,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">89,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(33,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">103,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">PUs granted in 2015 include approximately </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">42,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;PUs issued in 2015 based upon the attainment of performance criteria set for 2014 in relation to awards granted in 2014. The remainder of the PUs granted in 2015 include awards granted in conjunction with our annual awards made in February 2015 and PUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;PUs were converted to share settlements, of which approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares were vested and issued. All other PUs that vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;were settled in cash totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Time-Vested Restricted Stock Units (RSUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs awarded to employees generally vest no sooner than </font><font style="font-family:inherit;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one-third per year over three years</font></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes. The fair value of all RSUs is based on the market value of our stock on the date of grant. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our RSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td width="67%"></td><td width="15%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,137,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">221.01</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">459,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">388.88</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(626,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">190.65</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(160,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">302.35</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">810,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">323.87</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">RSUs granted in 2015 primarily represent RSUs granted in conjunction with our annual awards made in February 2015 and awards made in conjunction with the hiring of new employees. RSUs granted in 2015 also include approximately </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">7,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;RSUs granted to our Board of Directors.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs granted in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;had weighted average grant date fair values of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$321.72</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$176.53</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total fair values of RSUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$239.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$281.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$209.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan (ESPP)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015, our stockholders approved the Biogen Inc. 2015 ESPP (2015 ESPP). The 2015 ESPP, which became effective on July 1, 2015, replaced the Biogen Idec Inc. 1995 ESPP (1995 ESPP), which expired on June&#160;30, 2015. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our ESPP activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="53%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 2015 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">78,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 1995 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">98,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">180,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">245,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 2015 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">19.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 1995 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">30.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 44</font></div></div><hr style="page-break-after:always"><a name="s03F2BF8951CBFA892756B51296D998C6"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">16.&#160;&#160;&#160;&#160;&#160;&#160;Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Tax Expense</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax provision and the income tax expense consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="53%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income before income taxes (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,386.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,557.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,953.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,380.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,389.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">527.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,767.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,946.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,480.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income tax expense (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,214.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,159.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">700.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">38.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">54.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,307.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,298.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">846.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(129.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(280.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(200.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(35.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(145.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(308.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(245.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,161.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">989.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">601.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Tax Assets and Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Significant components of our deferred tax assets and liabilities are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="67%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">189.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory, other reserves, and accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">243.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">217.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangibles, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">328.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">251.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">63.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">871.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">693.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(440.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(432.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(102.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(107.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(542.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(539.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In accordance with ASU No. 2015-17, at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we reclassified </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$137.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our deferred tax assets classified as current to noncurrent and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our deferred tax liabilities classified as current to noncurrent in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;consolidated balance sheet, to conform our prior year presentation to our current year presentation.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to deferred tax assets and liabilities, we have recorded prepaid tax and deferred charges related to intercompany transactions. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total deferred charges and prepaid taxes were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$697.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$238.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 45</font></div></div><hr style="page-break-after:always"><a name="s03F2BF8951CBFA892756B51296D998C6"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2013, we recorded a deferred charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$203.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in connection with an intercompany transfer of the intellectual property for ZINBRYTA. The net book value of this deferred charge as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$166.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$179.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The deferred charge will be amortized to income tax expense over the economic life of the ZINBRYTA program. Our regulatory submissions in Europe and the U.S. have been accepted for review by the relevant authorities. If the ZINBRYTA applications are not approved, we may have to accelerate the amortization of this deferred charge and record an expense equal to its remaining net book value.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td width="55%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration and other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;benefited from lower anticipated taxes on foreign earnings and reflects a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;benefit from the 2015 remeasurement of one of our uncertain tax positions, described below under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">"Accounting for Uncertainty in Income Taxes"</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increased primarily as a result of the absence of a benefit related to the 2013 change in our uncertain tax position related to our U.S. federal manufacturing deduction and our unconsolidated joint business described below under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">"Accounting for Uncertainty in Income Taxes"</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, lower current year expenses eligible for the orphan drug credit and a lower relative manufacturing deduction due to unqualified products, partially offset by a higher percentage of our 2014 income being earned outside the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had net operating losses and general business credit carry forwards for federal income tax purposes of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$127.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which begin to expire in 2020. Additionally, for state income tax purposes, we had net operating loss carry forwards of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$91.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which begin to expire in 2016. For state income tax purposes, we also had research and investment credit carry forwards of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$125.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which begin to expire in 2016. For foreign income tax purposes, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net operating loss carryforwards, which begin to expire in 2021.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. Our estimates of future taxable income take into consideration, among other items, our estimates of future income tax deductions related to the exercise of stock options. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax assets are utilizable, we believe it is more likely than not that we will realize the benefits of the deferred tax assets of our wholly owned subsidiaries. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to establish a valuation allowance, which could materially impact our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, undistributed foreign earnings of non-U.S.&#160;subsidiaries included in consolidated retained earnings and other basis differences aggregated approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We intend to reinvest these earnings indefinitely in operations outside the U.S.&#160;The residual U.S. tax liability, if cumulative amounts were repatriated, would be between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 46</font></div></div><hr style="page-break-after:always"><a name="s03F2BF8951CBFA892756B51296D998C6"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="56%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at January&#160;1,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">131.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">110.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">125.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions based on tax positions related to the current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">19.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reductions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(49.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(92.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statute expirations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(42.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(60.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at December&#160;31,</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">67.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">110.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in the U.S.&#160;federal jurisdiction, various U.S. states, and foreign jurisdictions. With few exceptions, including the proposed disallowance we discuss below, we are no longer subject to U.S.&#160;federal tax examination for years before 2013 or state, local, or non-U.S.&#160;income tax examinations for years before 2004. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Included in the balance of unrecognized tax benefits as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;are </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$32.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize potential interest and penalties accrued related to unrecognized tax benefits in income tax expense. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net interest expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net interest expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net interest expense of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have accrued approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the payment of interest as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2015, we received a final assessment from the Danish Tax Authority (SKAT) for fiscal 2009, regarding withholding taxes and the treatment of certain intercompany transactions involving our Danish affiliate and another of our affiliates.&#160;The audits of our tax filings for 2010 through 2013 are not completed but have been prepared in a manner consistent with prior filings, with similar transactions. In December 2015, we received draft assessments for these periods.&#160;The total amount assessed for all periods is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including interest.&#160;For all periods potentially under dispute, we believe that positions taken in our tax filings are valid and we are contesting the assessment vigorously.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Federal Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2013, we received updated technical guidance from the IRS concerning our current and prior year filings and calculation of our U.S. federal manufacturing deduction and overall tax classification of our unconsolidated joint business.&#160;Based on this guidance we reevaluated the level of our unrecognized benefits related to uncertain tax positions, and recorded a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;income tax benefit.&#160;This benefit is for a previously unrecognized position and relates to years 2005 through 2012. We recorded an offsetting expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for non-income based state taxes, which is recorded in other income (expense) in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2011, in conjunction with our examination, the IRS proposed a disallowance of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in deductions for tax years 2007, 2008 and 2009 related to payments for services provided by our wholly owned Danish subsidiary located in Hiller&#248;d, Denmark. We believe that these items represent valid deductible business expenses and are vigorously defending our position. We have initiated a mutual agreement procedure between the IRS and SKAT for the years 2001 through 2009, in an attempt to reach agreement on the issue. In addition, we have applied for a bilateral advanced pricing agreement for the years 2010 through 2014 to resolve similar issues for the subsequent years.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 47</font></div></div><hr style="page-break-after:always"><a name="s03F2BF8951CBFA892756B51296D998C6"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net effect of adjustments to our uncertain tax positions was a net benefit of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. It is reasonably possible that we will adjust the value of our uncertain tax positions related to our unconsolidated joint business and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with the authorities. In addition, the IRS and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</font></div><a name="sDACC159EE6054EEA9DCEB5129703AE1D"></a><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">17.&#160;&#160;&#160;&#160;&#160;&#160;Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Supplemental Cash Flow Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="51%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid during the year for:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,674.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,163.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">643.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-cash Investing and Financing Activity</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2015, we accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total cumulative sales of Fumapharm Products. The amount, net of tax benefit, was accounted for as an increase to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm and is expected to be paid in the first quarter of 2016. For additional information related to this transaction, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitment and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the construction of our manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$59.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in our consolidated balance sheet. For additional information related to this transaction, please read Note 10,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Property, Plant and Equipment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2015, upon completion of our acquisition of Convergence, we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as part of the purchase price. For additional information related to this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July and November 2013, the construction of two office buildings in Cambridge, Massachusetts was completed and we started leasing the facilities.&#160;Upon completion of the construction of the buildings, we determined that we were no longer considered the owner of the buildings because we did not have any unusual or significant continuing involvement.&#160;Consequently, we derecognized the buildings and their associated financing obligation of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$161.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from our consolidated balance sheet.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="53%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(95.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(29.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairments on investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(32.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(15.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(13.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(123.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(25.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(34.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Current Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets includes prepaid taxes totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$57.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="67%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">518.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">359.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">504.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">265.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">270.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">393.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">167.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">172.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">579.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">505.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,096.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,817.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Long-Term Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="67%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="14%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">301.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">369.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">249.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other long-term liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">905.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">650.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Pricing of TYSABRI in Italy - AIFA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011, Biogen Italia SRL (formerly Biogen Idec Italia SRL), our Italian subsidiary,&#160;received a notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 through mid-February 2011 exceeded by EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006. In December 2011, we filed an appeal against AIFA in administrative court in Rome, Italy seeking a ruling that the reimbursement limit in the Price Determination Resolution should apply as written to only &#8220;the first 24 months&#8221; of TYSABRI sales, which ended in mid-February 2009. That appeal is still pending. Since being notified in the fourth quarter of 2011 that AIFA believed a reimbursement limit was still in effect, we deferred revenue on sales of TYSABRI as if the reimbursement limit were in effect for each biannual period beginning in mid-February 2009. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2013, we negotiated an agreement in principle with AIFA's Price and Reimbursement Committee that would have resolved all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for the periods from February 2009 through January 2013 for an aggregate repayment of EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The agreement was sent to the Avvocatura Generale dello Stato (Attorney General) for its opinion. As a result of this agreement in principle, we recorded a liability and reduction to revenue of EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;at June 30, 2013, which approximated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the claim related to the period from mid-February 2009 through mid-February 2011. In October 2014, we proposed a revised settlement for the period from February 2009 through January 2013 of EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to be paid in one payment. AIFA and Biogen Italia SRL are still discussing a possible resolution for the period from February 2009 through January 2013.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2014, AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. As a result, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of TYSABRI revenues related to the periods beginning February 2013 that were previously deferred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have approximately EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;recorded as accrued expenses and long-term deferred revenue in our consolidated balance sheets for this matter as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 49</font></div></div><hr style="page-break-after:always"><a name="s38A78711A30B25258101B512971A784E"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">18.&#160;&#160;&#160;&#160;&#160;Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2007, we entered into a collaboration agreement with Neurimmune SubOne AG (Neurimmune), a subsidiary of Neurimmune AG, for the development and commercialization of antibodies for the treatment of Alzheimer&#8217;s disease. Neurimmune conducts research to identify potential therapeutic antibodies and we are responsible for the development, manufacturing and commercialization of all products. Our anti-amyloid beta antibody, aducanumab (BIIB037), for the treatment of Alzheimer&#8217;s disease resulted from this collaboration. In September 2015, we announced that the first patient had been enrolled in a Phase 3 trial for aducanumab, which triggered a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment due to Neurimmune. As we consolidate the financial results of Neurimmune, we recognized this payment as a charge to noncontrolling interest in the third quarter of 2015. Based upon our current development plans for aducanumab, we may pay Neurimmune up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$275.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in remaining milestone payments. We may also pay royalties in the low-to-mid-teens on sales of any resulting commercial products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and are required to fund </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the research and development costs incurred in support of the collaboration agreement. Accordingly, we consolidate the results of Neurimmune.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts that are incurred by Neurimmune for research and development expenses in support of the collaboration that we reimburse are reflected in research and development expense in our consolidated statements of income.  During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, these amounts were immaterial. Future milestone payments and royalties, if any, will be reflected in our consolidated statements of income as a charge to noncontrolling interest, net of tax, when such milestones are achieved. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Rodin Therapeutics, Inc. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2015, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for preferred stock in Rodin Therapeutics, Inc. (Rodin) and entered into an option and collaboration agreement which gives us the right to purchase all remaining outstanding shares of Rodin, at any time until 35 days after acceptance of an Investigational New Drug (IND) application by the FDA. Rodin is a discovery-stage biotechnology company developing novel therapeutics for neurological disorders. We committed to make additional investments in Rodin&#8217;s preferred shares of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, if certain development milestones are achieved. If we exercise our option to purchase the outstanding shares of Rodin, we could pay additional amounts upon achievement of clinical and commercial milestones. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Through our fixed price option to purchase Rodin, purchases of equity, our collaboration and presence on the program advisory committee and Rodin Board of Directors, we are deemed to be the primary beneficiary of Rodin, a variable interest entity. Therefore, we consolidate the results of Rodin. As part of the initial consolidation of Rodin, we recorded an IPR&amp;D intangible asset of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and assigned approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to minority interest in our stockholder's equity. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Rodin are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Rodin other than contractually required amounts. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 50</font></div></div><hr style="page-break-after:always"><a name="s38A78711A30B25258101B512971A784E"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total carrying value of our investments in biotechnology companies totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income, as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </font></div><a name="s503C33353B4365FB7507B5129723A2A0"></a><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">19.&#160;&#160;&#160;&#160;&#160;&#160;Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our business strategy, we have entered into various collaboration agreements which provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depending on the collaborative arrangement, we may record funding receivables or payable balances with our partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaboration arrangements are discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We collaborate with Genentech on the development and commercialization of RITUXAN. In addition, in the U.S., we share operating profits and losses relating to GAZYVA with Genentech. The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacturing and commercialization of GAZYVA in the U.S. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our collaboration agreement will continue in effect until we mutually agree to terminate the collaboration, except that if we undergo a change in control, as defined in the collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech&#8217;s offer or purchase Genentech&#8217;s rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to any other anti-CD20 products in development in exchange for a royalty and our rights to GAZYVA in exchange for the compensation described in the table below. Our collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">RITUXAN</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech is responsible for the worldwide manufacturing of RITUXAN. Development and commercialization rights and responsibilities under this collaboration are divided as follows:</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">U.S.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share with Genentech co-exclusive rights to develop, commercialize and market RITUXAN in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Canada</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Genentech have assigned our rights under our collaboration agreement with respect to Canada to the Roche Group.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Outside the U.S. and Canada</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have granted Genentech exclusive rights to develop, commercialize and market RITUXAN outside the U.S. and Canada. Under the terms of separate sublicense agreements between Genentech and the Roche Group, development and commercialization of RITUXAN outside the U.S. and Canada is the responsibility of the Roche Group and its sublicensees. We do not have any direct contractual arrangements with the Roche Group or it sublicensees.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the collaboration agreement, the Roche Group pays us royalties between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on sales of RITUXAN outside the U.S. and Canada, with the royalty period lasting </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11 years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from the first commercial sale of RITUXAN on a country-by-country basis. The royalty periods for the substantial portion of the royalty-bearing sales in the rest of world markets expired during 2012 and 2013. We expect future revenue on sales of RITUXAN in the rest of world will be limited to our share of pre-tax co-promotion profits in Canada.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to FDA approval of GAZYVA, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the development and commercialization expenses as research and development expense and selling, general and administrative expense, respectively, in our consolidated statements of income. After GAZYVA was approved by the FDA in the fourth quarter of 2013, we began to recognize our share of the development and commercialization expenses as a reduction of our share of pre-tax profits in revenues from unconsolidated joint business. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercialization of GAZYVA will impact our percentage of the co-promotion profits for RITUXAN, as summarized in the table below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Ocrelizumab</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech is solely responsible for development and commercialization of ocrelizumab, a humanized anti-CD20 monoclonal antibody currently in development for MS, and funding future costs. Genentech cannot develop ocrelizumab in CLL, NHL or RA. We will receive tiered royalties between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on U.S. net sales of ocrelizumab if approved for commercial sale by the FDA. There will be a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction to these royalties if a biosimilar to ocrelizumab is approved in the U.S. In addition, we will receive a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;royalty on worldwide net sales of ocrelizumab outside the U.S., with the royalty period lasting </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11 years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from the first commercial sale of ocrelizumab on a country-by-country basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercialization of ocrelizumab will not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Profit-sharing Formulas</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">RITUXAN Profit Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax co-promotion profit-sharing formula for RITUXAN provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share on the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of co-promotion operating profits earned each calendar year. Our share of annual co-promotion profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="82%"></td><td width="17%"></td><td width="1%"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until GAZYVA First Non-CLL FDA Approval</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First Non-CLL GAZYVA FDA Approval</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;means the FDA&#8217;s first approval of GAZYVA in an indication other than CLL.</font></div><div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;means the earlier of (1)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12 month period were at least </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;or (2)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12 month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">Second GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12 month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$500.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect our share of RITUXAN pre-tax profits in the U.S. to decrease to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;if GAZYVA is approved by the FDA in RITUXAN-refractory indolent non-Hodgkin&#8217;s lymphoma. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, should the FDA approve an anti-CD20 product other than ocrelizumab or GAZYVA that is acquired or developed by Genentech and subject to the collaboration agreement, our share of the co-promotion operating profits would be between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;based on certain events.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">GAZYVA Profit Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax profit-sharing formula for GAZYVA provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share on the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of operating profits earned each calendar year. Our share of annual profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="82%"></td><td width="17%"></td><td width="1%"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our share of operating losses on GAZYVA was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Unconsolidated Joint Business Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2013, we reduced our share of RITUXAN revenues from unconsolidated joint business by approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which revenue on sales in the rest of world for RITUXAN was reduced by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and pre-tax profits in the U.S. were reduced by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to reflect our share of the royalties and interest awarded to Hoechst in its arbitration with Genentech. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from unconsolidated joint business are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="53%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,269.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,117.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,087.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue on sales in the rest of world for RITUXAN</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total unconsolidated joint business revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,339.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,126.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1) GAZYVA sales began in the fourth quarter of 2013.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;profit-sharing threshold was met during the first quarter.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to regulatory approval, we record our share of the expenses incurred by the collaboration for the development of anti-CD20 products in research and development expense in our consolidated statements of income. We incurred </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in development expense for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. After an anti-CD20 product is approved, we record our share of the development expenses related to that product as a reduction of our share of pre-tax profits in revenues from unconsolidated joint business. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Elan</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On April 2, 2013, we acquired full ownership of all remaining rights to TYSABRI from Elan that we did not already own or control. Upon the closing of the transaction, our collaboration agreement with Elan was terminated. For additional information related to this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We previously collaborated with Elan on the development, manufacture and commercialization of TYSABRI. Under the terms of our collaboration agreement, we manufactured TYSABRI and collaborated with Elan on the product&#8217;s marketing, commercial distribution and ongoing development activities. The agreement was designed to effect an equal sharing of profits and losses generated by the activities of our collaboration. Under the agreement, however, once sales of TYSABRI exceeded specific thresholds, Elan was required to make milestone payments to us in order to continue sharing equally in the collaboration&#8217;s results. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., we previously sold TYSABRI to Elan who then sold the product to third-party distributors. Our sales price to Elan in the U.S. was set prior to the beginning of each quarterly period to effect an approximate equal sharing of the gross profit between Elan and us. We recognized revenue for sales in the U.S. of TYSABRI upon Elan&#8217;s shipment of the product to the third-party distributors, at which time all revenue recognition criteria had been met. We incurred manufacturing and distribution costs, research and development expenses, commercial expenses, and general and administrative expenses related to TYSABRI. We recorded these expenses to their respective line items in our consolidated statements of income when they were incurred. Research and development and sales and marketing expenses were shared equally with Elan and the reimbursement of these expenses was recorded as </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">reductions of the respective expense categories. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as a reduction of research and development expense resulting from reimbursements from Elan. In addition, for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as a reduction of selling, general and administrative expense resulting from reimbursements from Elan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the rest of world, we previously were responsible for distributing TYSABRI to customers and were primarily responsible for all operating activities. Generally, we recognized revenue for sales of TYSABRI in the rest of world at the time of product delivery to our customers. We made payments to Elan which effected an equal sharing of rest of world collaboration operating profits. These payments also included the reimbursement we paid to Elan for half of the third-party royalties that Elan paid on behalf of the collaboration relating to rest of world sales. These amounts were reflected in the collaboration profit sharing line in our consolidated statements of income. For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$85.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was reflected in the collaboration profit sharing line for our collaboration with Elan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acorda</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2009, we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine in markets outside the U.S.&#160;We also have responsibility for regulatory activities and the future clinical development of related products in those markets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the collaboration and license agreement, we pay Acorda tiered royalties based on the level of ex-U.S. net sales. We may pay up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$375.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of additional milestone payments to Acorda, based on the successful achievement of certain regulatory and commercial milestones. The next expected milestone would be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, due if ex-U.S. net sales reach </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over a period of four consecutive quarters. We will capitalize these additional milestones as intangible assets upon achievement of the milestone which will then be amortized utilizing an economic consumption model and recognized as amortization of acquired intangible assets. Royalty payments are recognized as a cost of goods sold.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the collaboration and license agreement, we have also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement is a sublicense arrangement of an existing agreement between Acorda and Alkermes, who acquired Elan Drug Technologies, the original party to the license with Acorda. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, total cost of sales related to royalties and commercial supply of FAMPRYA reflected in our consolidated statement of income were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Swedish Orphan Biovitrum AB (publ)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2007, we acquired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the stock of Syntonix. Syntonix had previously entered into a collaboration agreement with Swedish Orphan Biovitrum AB (publ) (Sobi) to jointly develop and commercialize Factor VIII and Factor IX hemophilia products, including ELOCTATE and ALPROLIX. In February 2010, we restructured the collaboration agreement and assumed full development responsibilities and costs, as well as manufacturing rights. In addition, the cross-royalty rates were reduced and commercial rights for certain territories were changed. As a result, we have commercial rights for North America (the Biogen North America Territory) and for rest of the world markets outside of, essentially, Europe, North Africa, Russia and certain countries in the Middle East (the Biogen Direct Territory).&#160;Subject to the exercise of an option right that Sobi controls, Sobi will have commercial rights in, essentially, Europe, North Africa, Russia and certain countries in the Middle East (the Sobi Territory). The collaboration agreement was amended and restated in April 2014. (References to the collaboration agreement refer to the amended and restated collaboration agreement).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2014, Sobi exercised its option to assume final development and commercialization activities in the Sobi Territory for ELOCTA (the trade name for ELOCTATE in the E.U.). In July 2015, Sobi exercised its option to assume final development and commercialization of ALPROLIX within the Sobi Territory. Upon each exercise of opt-in right under the terms of the collaboration agreement, Sobi made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;payment in escrow. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon EMA regulatory approval of each such product, Sobi will be liable to reimburse us </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the sum of all shared manufacturing and development expenses incurred by us from October 1, 2009 through the earlier of the date on which Sobi is registered as the marketing authorization holder for the applicable product or 90 days post-regulatory approval, as well as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of certain development expenses incurred exclusively for the benefit of the Sobi Territory (the Opt-In Consideration).&#160;This reimbursement will be recognized in proportion to collaboration revenues, over a ten year period, consistent with the initial patent terms of the products.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTA was approved by the EC in November 2015. Through </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in expenditures for ELOCTA, net of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;escrow payment discussed above, are reimbursable by Sobi under the collaboration agreement due to its election to assume final development and commercialization of ELOCTA within the Sobi Territory. Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$175 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in expenditures for ALPROLIX may be reimbursable by Sobi under the collaboration agreement due to its election to assume final development and commercialization of ALPROLIX within the Sobi Territory. The escrow payment made with respect to ALPROLIX will be applied to the amount of the Opt-In Consideration to be reimbursed by Sobi upon EMA regulatory approval. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To effect Sobi&#8217;s reimbursement to us for the Opt-In Consideration exceeding the escrow payment for the applicable product, the cross-royalty cash payment structure for direct sales in each company&#8217;s respective territories will be adjusted until the Opt-In Consideration is paid in full (the Reimbursement Period). The mechanism for reimbursement is outlined in the table below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the collaboration agreement, cash payments are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="35%"></td><td width="13%"></td><td width="1%"></td><td width="15%"></td><td width="1%"></td><td width="18%"></td><td width="1%"></td><td width="16%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rates post Sobi Opt-In</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Royalty and Net Revenue Share Rates:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Method</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rate prior to 1st</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">commercial sale in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">the&#160;Sobi&#160;Territory:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Base Rate following</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">1st&#160;commercial&#160;sale&#160;in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">the Sobi Territory:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rate during the</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reimbursement</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period:</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sobi rate to Biogen on net sales in the Sobi Territory</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10&#160;or&#160;12%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base&#160;Rate<br>plus 5%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net sales in the Biogen North America Territory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10&#160;or&#160;12%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br>less 5%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net sales in the Biogen Direct Territory</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15&#160;or&#160;17%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br>less 5%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net revenue</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">from the Biogen Distributor Territory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Net<br>Revenue<br>Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br>less 15%</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net revenue represents Biogen&#8217;s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If the reimbursement of the Opt-in Consideration has not been achieved within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the first commercial sale of such product, we maintain the right to require Sobi to pay any remaining balances due to us within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90 days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the six year anniversary date of the first commercial sale.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect to recognize the effect of the cash reimbursement as an adjustment to the Base Rate in the table above.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Should Sobi terminate the collaboration agreement with respect to ALPROLIX, we will obtain full worldwide development and commercialization rights and we will be obligated to pay royalties to Sobi subject to separate terms, as defined in the collaboration agreement.&#160;In addition, if EMA approval for ALPROLIX is not granted within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the filing date, Sobi shall have the right to require that the escrow payment be refunded and revoke its option right for such product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie Biotherapeutics, Inc. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie Biotherapeutics, Inc., a subsidiary of AbbVie, Inc. (AbbVie) aimed at advancing the development and commercialization of ZINBRYTA in MS. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the agreement, we and AbbVie will conduct ZINBRYTA co-promotion activities in the E.U., U.S. and Canada territories (Collaboration Territory), where development and commercialization costs and profits are shared equally. We are responsible for all manufacturing activities in the Collaboration Territory.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., AbbVie will recognize revenues on sales to third parties and we will recognize our 50% share of the co-promotion profits or losses as a component of total revenues in our consolidated statements of income.  </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and Canada, we will reflect revenues on sales to third parties in product revenues, net in our consolidated statements of income. We will record the related cost of revenues and sales and marketing expenses to their respective line items in our consolidated statements of income when these costs are incurred. The reimbursement with AbbVie for the 50% sharing of the co-promotion profits or losses in the E.U. and Canada will be recognized in our total costs and expenses. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outside of the Collaboration Territory, we are solely responsible for development and commercialization where we will pay a tiered royalty to AbbVie on net sales in the low to high teens.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are the responsible party for manufacturing and research and development activities in both the Collaboration Territory and outside the Collaboration Territory and will record these activities to their respective lines in our consolidated statements of income, net of any reimbursement of research and development expenditures from AbbVie.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we made milestone payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the development of ZINBRYTA as a result of filing for regulatory approval in the U.S. and E.U. during the year. These payments were recorded as research and development expense in our consolidated statements of income. We may incur up to an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$32.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of milestone payments related to the development of ZINBRYTA, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is due upon regulatory approval in the U.S. and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is due upon regulatory approval in the E.U. These future payments will be capitalized as an intangible asset in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of activity related to this collaboration is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="56%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">113.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">117.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">133.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of development expense reflected in our consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Long-Term Strategic Research Collaboration</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2013, we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;year research collaboration with Ionis Pharmaceuticals, Inc. (Ionis), formerly known as Isis Pharmaceuticals Inc. under which both companies collaborate to perform discovery level research and then develop and commercialize antisense or other therapeutics for the treatment of neurological disorders.&#160;Under the collaboration, Ionis will perform research on a set of neurological targets identified within the agreement. Once the research has reached a specific stage of development, we will make the determination whether antisense is the preferred approach to develop a therapeutic candidate or whether another modality is preferred. If antisense is selected, Ionis will continue development and identify a product candidate. If another modality is used, we will assume the responsibility for identifying a product candidate and developing it. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of this agreement, we paid Ionis an upfront amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;Of this payment, we recorded prepaid research and discovery services of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing the value of the Ionis full time equivalent employee resources which are required by the collaboration to provide research and discovery services to us over the next six years.&#160;The remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the upfront payment was recorded as research and development expense as it represented the purchase of intellectual property that had not reached technological feasibility.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ionis is also eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we triggered milestones of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to the advancement of IONIS-SOD1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the treatment of ALS and other neurological targets identified.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For non-ALS antisense product candidates, Ionis will be responsible for global development through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise. &#160;&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For product candidates using a different modality, we will be responsible for global development through all stages and will pay Ionis up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon the achievement of certain regulatory milestones and royalties on future sales if we successfully develop the product candidate. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Collaborations </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December, June and January 2012, we entered into three separate exclusive, worldwide option and collaboration agreements with Ionis under which both companies will develop and commercialize antisense therapeutics for up to three gene targets, Ionis&#8217; product candidates for the treatment of myotonic dystrophy type 1 (DM1), and the antisense investigational candidate nusinersen (ISIS-SMN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for the treatment of spinal muscular atrophy (SMA), respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Antisense Therapeutics</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the December 2012 agreement relating to the development and commercialization of up to three gene targets we provided Ionis with an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and will make potential additional payments, prior to licensing, of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;based on the development of the selected product candidate as well as a mark-up of the cost estimate of the Phase 1 and Phase 2 trials. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we triggered a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment. Ionis will be responsible for global development of any product candidate</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive up to another </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">if we successfully develop the product candidate after option exercise. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">IONIS-DMPK</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub>&#160;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the June 2012 agreement for the DM1 candidate, we provided Ionis with an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and agreed to make potential additional payments, prior to licensing, of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$59.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;based on the development of the selected product candidate. During 2015, we amended the agreement to adjust the amount of potential additional payments by an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;due to changes in the clinical trial design. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we triggered milestones of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to the selection and advancement of IONIS-DMPK</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to treat DM1. Ionis will be responsible for global development of any product candidate through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We also have an option to license the product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive up to another </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales if we successfully develop the product candidate after option exercise. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, were reflected in research and development expense in our consolidated statements of income. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Nusinersen</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the January 2012 agreement for the antisense investigational drug candidate, nusinersen, we paid Ionis </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as an upfront payment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2014, we amended the agreement to adjust the amount of potential additional payments and terms of the exercise of our opt-in right to license nusinersen. Consistent with the initial agreement, Ionis remains responsible for conducting the pivotal/Phase 3 trials.&#160;We are providing input on the clinical trial design and regulatory strategy for the development of nusinersen. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we triggered clinical trial payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$57.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the advancement of the program. We are recognizing these payments as research and development expenses as the trial costs are incurred. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015, we amended the agreement and may pay up to an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$92.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;due to changes in the clinical trial design. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may exercise our opt-in right upon&#160;completion of and data review of the first successful Phase 2/3 trial or completion of both Phase 2/3 trials.&#160;An amendment in December 2014 provided for additional opt-in scenarios, based on the filing or the acceptance of a new drug application or marketing authorization application with the FDA or EMA. Under the amended collaboration agreement, we may pay Ionis up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$325.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in a license fee and payments, including </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in payments associated with the clinical development of nusinersen prior to licensing, a license fee and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales of nusinersen if we successfully develop nusinersen after option exercise.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$13.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, were reflected in research and development expense in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and E2609 Collaboration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March 4, 2014, we entered into a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize two Eisai product candidates for the treatment of Alzheimer&#8217;s disease, BAN2401, a monoclonal antibody that targets amyloid-beta aggregates, and E2609, a BACE inhibitor, (Eisai Collaboration Agreement).&#160;Under the Eisai Collaboration Agreement, Eisai serves as the global operational and regulatory lead for both compounds and all costs, including research, development, sales and marketing expenses, will be shared equally by us and Eisai. Following marketing approval in major markets, such as the U.S., the E.U. and Japan, we will co-promote BAN2401 and E2609 with Eisai and share profits equally. In smaller markets, Eisai will distribute these products and pay us a royalty. The Eisai Collaboration Agreement also provides the parties with certain rights and obligations in the event of a change in control of either party.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Eisai Collaboration Agreement also provides Eisai an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for Alzheimer&#8217;s disease (Aducanumab Option) and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). Upon exercise of each of the Aducanumab Option and the Anti-Tau Option, we will execute a separate collaboration agreement with Eisai on terms and conditions that mirror the Eisai Collaboration Agreement.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Option</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai may exercise the Aducanumab Option after either (i) completion of both the current Phase 1b clinical trial for aducanumab and the current Phase 2 clinical trial for BAN2401 (Post-Phase 2 Aducanumab Option), or (ii) completion of the Phase 3 clinical trial for aducanumab (Post-Phase 3 Aducanumab Option) under certain conditions. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration we will receive if Eisai exercises the Post-Phase 2 Aducanumab Option depends on the development status of BAN2401. If BAN2401 is then determined to advance to Phase 3, we will be entitled to receive a single payment from Eisai upon regulatory approval of aducanumab and we will no longer be required to pay Eisai any milestone payments for products containing BAN2401 under the Eisai Collaboration Agreement. If the development of BAN2401 has instead been terminated, we will receive development and commercial milestone payments from Eisai (Post-Phase 2 Aducanumab Milestone Payments). If Eisai does not exercise its Post-Phase 2 Aducanumab Option, we may elect to terminate the Eisai Collaboration Agreement with respect to BAN2401 but, under certain conditions, will have the option to reinstate the Eisai Collaboration Agreement after completion of a BAN2401 Phase 3 clinical trial.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If Eisai exercises its Post-Phase 3 Aducanumab Option, Eisai will be required to pay us all Phase 3 development and commercialization costs plus a mark-up and an amount equal to any unpaid Post-Phase 2 Aducanumab Milestone Payments that would have been payable if Eisai had exercised its Post-Phase 2 Aducanumab Option. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Anti-Tau Option</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon the effective date of the Eisai Collaboration Agreement, we paid Eisai </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflecting the fair value of the options granted under the Eisai Collaboration Agreement, both of which were classified as research and development expense in our consolidated statements of income. During the second quarter of 2014, Eisai exercised its option under the Eisai Collaboration Agreement to expand the joint development and commercialization activities to include Japan. Upon such exercise, we paid Eisai an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as research and development expense in our consolidated statements of income, which represented the difference between the payment made upon exercise of the option and the fair value of that option recorded as research and development expense upon closing of the agreement in the first quarter of 2014. We could pay Eisai up to an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under the Eisai Collaboration Agreement based on the future achievement of certain development, regulatory and commercial milestones.&#160;  </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our arrangements with Eisai, Neurimmune is entitled to milestone and royalty payments related to the development and commercialization of aducanumab and certain anti-tau antibodies. For additional information regarding our agreement with Neurimmune, please see Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of activity related to this collaboration is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="56%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">84.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of development expense, excluding upfront and milestone payments, reflected in our consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sangamo BioSciences, Inc. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 22, 2014, we completed an exclusive worldwide research, development and commercialization collaboration and license agreement with Sangamo BioSciences, Inc. (Sangamo) under which both companies will develop and commercialize product candidates for the treatment of two inherited blood disorders, sickle cell disease and beta-thalassemia.&#160;The collaboration is currently in the research stage of development.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the agreement, we paid Sangamo an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cash, with additional payments of up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;based on the achievement of certain development, regulatory and commercial milestones, plus royalties based on sales.&#160;We recorded the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upfront payment as research and development expense. Under this arrangement, Sangamo will be responsible for identifying a product candidate for the treatment of beta-thalassemia and advancing that candidate through a completed Phase 1 human clinical trial, at which point we would assume responsibility for development.&#160;We will jointly develop a sickle cell disease candidate through the potential filing of an investigative new drug application, after which we would assume clinical responsibilities. We will lead the global development and commercialization efforts and Sangamo will have the option to assume co-promotion responsibilities in the U.S.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$13.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of expense was reflected in our consolidated statements of income.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Applied Genetic Technologies Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 2, 2015, we announced a collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases with Applied Genetic Technologies Corporation (AGTC). The collaboration will focus on the development of a portfolio of AGTC&#8217;s therapeutic programs, including both a clinical-stage candidate for X-linked Retinoschisis (XLRS) and a pre-clinical candidate for the treatment of X-Linked Retinitis Pigmentosa (XLRP). The agreement also includes options for early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition, as well as an equity investment in AGTC.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2015, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$124.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which included a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equity investment in AGTC, prepaid research and development expenditures of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and total licensing and other fees of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of prepaid research and development expenditures were recorded in investments and other assets in our consolidated balance sheets and will be expensed as the services are provided. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$54.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as research and development expense associated with AGTC in our consolidated statements of income, including the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;total licensing and other fees, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in research and development services, a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;premium on our equity investment and a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;clinical development milestone related to XLRS. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AGTC is eligible to receive development, regulatory and commercial milestone payments aggregating in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which includes up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$472.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;collectively for the two lead programs and up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$592.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;across the discovery programs. AGTC is also eligible to receive royalties in the mid-single digit to mid-teen percentages of annual net sales. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We were granted worldwide commercialization rights for the XLRS and XLRP programs. AGTC has an option to share development costs and profits after the initial clinical trial data are available, and an option to co-promote the second of these products to be approved in the U.S. AGTC will lead the clinical development programs of XLRS through product approval and of XLRP through the completion of first-in-human trials. We will support the clinical development costs, subject to certain conditions, following the first-in-human study for XLRS and IND-enabling studies for XLRP. Under the manufacturing license, we have received an exclusive license to use AGTC&#8217;s proprietary technology platform to make AAV vectors for up to six genes, three of which are in AGTC&#8217;s discretion, in exchange for payment of milestones and royalties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Mitsubishi Tanabe Pharma Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On September 9, 2015, we announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to exclusively license amiselimod (MT-1303), a late stage experimental medicine with potential in multiple autoimmune indications. Amiselimod is an oral compound that targets the sphingosine 1-phosphate receptor. Under the terms of the agreement, we will receive worldwide rights to amiselimod, excluding Asia. We will be responsible for global commercialization and development costs except for costs related to the Asian territories, which are the responsibility of MTPC. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2015, the agreement became effective and we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was recorded as research and development expense in our consolidated statements of income. In the future we may pay up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$484.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in milestone payments for multiple indications and territories, along with average royalties in the mid- to high-teen percentages of annual net sales. MTPC has the right to participate in our global clinical trials related to amiselimod and has an option to co-promote non-MS indications in the U.S. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into several research, discovery and other related arrangements that resulted in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$40.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, recorded as research and development expense in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These additional arrangements include the potential for future milestone payments based on clinical and commercial development over a period of several years. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012, we entered into a joint venture agreement with Samsung BioLogics Co. Ltd. (Samsung Biologics), establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&#160;Samsung Biologics contributed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;stake in Samsung Bioepis and we contributed approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for the remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;ownership interest.&#160;Under the joint venture agreement, we have no obligation to provide any additional funding and our ownership interest may be diluted due to financings in which we do not participate. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership interest is approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects our additional contribution of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.3 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) in the first quarter of 2015 and the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;The exercise of this option is within our control and is based on paying for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the total investment made by Samsung Biologics into Samsung Bioepis in excess of what we have already contributed under the agreement plus a rate that will represent their return on capital.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Samsung Biologics has the power to direct the activities of Samsung Bioepis which will most significantly and directly impact its economic performance.&#160;We account for this investment under the equity method of accounting as we maintain the ability to exercise significant influence over Samsung Bioepis through a presence on the entity&#8217;s Board of Directors and our contractual relationship.&#160;Under the equity method, we recorded our original investment at cost and subsequently adjust the carrying value of our investment for our share of equity in the entity&#8217;s income or losses according to our percentage of ownership. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our share of losses exceed the carrying value of our investment. We suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), which was classified as a component of investments and other assets in our consolidated balance sheets. We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our consolidated statements of income. During the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a loss on our investment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 17, 2013, pursuant to our rights under the joint venture agreement with Samsung Biologics, we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of one anti-TNF biosimilar, Japan.&#160;Under the terms of this agreement, we have paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$46.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which has been recorded as a research and development expense in our consolidated statements of income as the programs they relate to had not achieved regulatory approval. Samsung Bioepis is eligible to receive an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional milestones, including </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon the regulatory approval of each anti-TNF biosimilar product candidate in the E.U. In January 2016, the EC approved the MAA for BENEPALI for marketing in the E.U. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon commercialization, we will reflect revenues on sales to third parties in product revenues, net in our consolidated statements of income. We will record the related cost of revenues and sales and marketing expenses in our consolidated statements of income to their respective line items when these costs are incurred. A </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;profit share with Samsung Bioepis will be recognized in costs and expenses. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">License Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we entered into a license agreement with Samsung Bioepis. Under the terms of the agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture, and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we will receive single digit royalties on all biosimilar products developed and commercialized by Samsung Bioepis. </font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we entered into a technical development services agreement and a manufacturing agreement with Samsung Bioepis. Under the terms of the technical development services agreement, we provide Samsung Bioepis technical development and technology transfer services, which include, but are not limited to, cell culture development, purification process development, formulation development, and analytical development. Under the terms of our manufacturing agreement, we manufacture clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis pursuant to contractual terms.&#160;Under limited circumstances, we may also supply Samsung Bioepis with quantities of drug product of biosimilar products for use in clinical trials through arrangements with third-party contract manufacturers. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$43.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues in relation to these services, which is reflected as a component of other revenues in our consolidated statement of income. </font></div><a name="s9E3E60C0E4B1367D5E19B512977C0A85"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">20.&#160;&#160;&#160;&#160;Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies regarding contingencies, see Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Patent Matters </font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Forward Pharma German Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On November 18, 2014 Forward Pharma A/S (Forward Pharma) filed suit against us in the Regional Court of Dusseldorf, Germany alleging that TECFIDERA infringes German Utility Model DE&#160;20 2005 022 112&#160;U1, which was issued in April 2014 and expired in October 2015. Forward Pharma subsequently&#160;extended its allegations&#160;to assert that TECFIDERA infringes Forward Pharma's European Patent No. 2,801,355, which was issued in May 2015 and expires in October 2025. Forward Pharma seeks declarations of infringement and damages for our sales of TECFIDERA in Germany. Under German law, disgorgement of profits on infringing sales is a measure of damages. A hearing has been scheduled for early 2016.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interference Proceeding with Forward Pharma</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015, the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of multiple sclerosis with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. A hearing has been scheduled for early 2017.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Inter Partes Review Proceeding</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On September 28, 2015, the Coalition for Affordable Drugs V LLC, an entity associated with a hedge fund, filed a petition with the USPTO for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;review of the '514 patent, which we opposed. The USPTO has not yet decided whether to institute review. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Several parties have filed oppositions in the European Patent Office requesting revocation of our European patent number 2 137 537 (the '537 patent), which includes claims covering the treatment of multiple sclerosis with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. The '537 patent expires in 2028.&#160;A hearing has been scheduled for early 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Patent Licensing Matter </font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are in discussions with Pfizer regarding its proposal that we take a license to its U.S. Patent No. 8,603,777&#160;(Expression of Factor VII and IX Activities in Mammalian Cells) and pay&#160;royalties on sales of ALPROLIX. </font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An estimate of the possible loss or range of loss cannot be made at this time.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Patent Revocation Matter</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2015, Swiss Pharma International AG brought an action in the Patents Court of the United Kingdom to revoke the UK counterpart of our European Patent Number 1 485 127&#160;(&#8220;Administration of agents to treat inflammation&#8221;) (the '127 patent), which was issued in June 2011 and concerns administration of natalizumab (TYSABRI) to treat multiple sclerosis. The patent expires in February 2023.&#160;On January 11, 2016 the same entity brought an action in the District Court of The Hague seeking to revoke the Dutch counterpart of the '127 patent. A hearing has been scheduled in the Dutch action for early 2017. No hearing has yet been scheduled in the UK action.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On May&#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (manufacturer, marketer and seller of REBIF), Pfizer Inc. (co-marketer of REBIF), and Novartis Pharmaceuticals Corp. (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. The court has consolidated the two lawsuits, and we refer to the two actions as the &#8220;Consolidated '755 Patent Actions.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims in the Consolidated '755 Patent Actions seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees, and EMD Serono and Bayer have each filed a counterclaim seeking a declaratory judgment that the '755 Patent is unenforceable based on alleged inequitable conduct. Bayer has also amended its complaint to seek such a declaration. No trial date has been set.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Italian National Medicines Agency</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011, Biogen Italia SRL&#160;received notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in December 2006. On December&#160;23, 2011, we filed an appeal in the Regional Administrative Tribunal of Lazio (Il Tribunale Amministrativo Regionale per il Lazio) in Rome, Italy seeking a ruling that the reimbursement limit in the Price Resolution should apply as written to only &#8220;the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months&#8221; of TYSABRI sales, which ended in mid-February 2009. The appeal is still pending. In June 2014, AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. AIFA and Biogen Italia SRL are discussing a possible resolution for the period from February 2009 through January 2013.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government in this matter. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also received a subpoena from the federal government for documents relating to our relationship with certain pharmacy benefit managers, with which we cooperated. We do not anticipate any further involvement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 6, 2015, four qui tam actions filed against us by relators suing on behalf of the United States and certain states were unsealed by the U.S. District Court for the District of Massachusetts. The actions, which have been administratively consolidated, allege sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seek single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. The United States declined to intervene in two of the actions, both of which have since been voluntarily dismissed, and has not made an intervention decision in the other two actions, which we have moved to dismiss. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in In re Biogen Inc. Securities Litigation, filed by a shareholder on August 18, 2015 in the U.S. District Court for the District of Massachusetts. The amended complaint alleges violations of federal securities laws under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5. The lead plaintiff seeks a declaration of the action as a class action, certification as a representative of the class and its counsel as class counsel, and an award of damages, interest, and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div><a name="s0D72587900F55F9B3400B512977E1532"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">21.&#160;&#160;&#160;&#160;Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rent laboratory and office space and certain equipment under non-cancelable operating leases. These lease agreements contain various clauses for renewal at our option and, in certain cases, escalation clauses typically linked to rates of inflation. Rental expense under these leases, net of amounts recognized in relation to exiting our Weston, Massachusetts facility, which terminate at various dates through 2028, amounted to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Rent expense was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$56.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition to rent, the leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td width="24%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">75.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">75.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">67.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">63.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">382.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">732.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(28.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(59.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">61.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">56.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">353.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">672.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">As a result of our decision to relocate our corporate headquarters to Cambridge, Massachusetts, we vacated part of our Weston, Massachusetts facility in the fourth quarter of 2013. We incurred a charge of </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">$27.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;in connection with this move. This charge represented our remaining lease obligation for the vacated portion of our Weston, Massachusetts facility, net of sublease income expected to be received. The term of our sublease to the vacated portion of our Weston, Massachusetts facility started in January 2014 and will continue through the remaining term of our lease agreement.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under certain of our lease agreements, we are contractually obligated to return leased space to its original condition upon termination of the lease agreement. At the inception of a lease with such conditions, we record an asset retirement obligation liability and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. In subsequent periods, for each such lease, we record interest expense to accrete the asset retirement obligation liability to full value and depreciate each capitalized asset retirement obligation asset, both over the term of the associated lease agreement. Our asset retirement obligations were not significant as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Financing Arrangement</font></div><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015 we amended our existing lease related to Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. For additional information, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, Plant and Equipment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net present value of the future minimum lease payments were as follows:</font></div><div style="line-height:120%;padding-left:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="79%"></td><td width="1%"></td><td width="19%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">20.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net present value of the future minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">19.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net liabilities associated with uncertain tax positions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several on-going clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on our consolidated balance sheet for expenditures incurred by CROs as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$559.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cancellable future commitments based on existing CRO contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones had not occurred as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing Commitments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 1, 2015, we purchased land in Solothurn, Switzerland where we plan to build a biologics manufacturing facility over the next several years. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$126.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the construction of this facility.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TYSABRI Contingent Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013, we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the terms of the acquisition agreement, we are obligated to make contingent payments to Elan of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on annual worldwide net sales up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on annual worldwide net sales that exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo in December 2013. Following that acquisition, we began making these royalty payments to Perrigo.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence, Stromedix, Inc. (Stromedix), Biogen International Neuroscience GmbH (formerly Biogen Idec International Neuroscience GmbH) (BIN), Biogen Hemophilia Inc. (formerly Biogen Idec Hemophilia Inc.) (BIH) and Fumapharm AG, we agreed to make additional payments based upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence, Stromedix and BIN, formerly Panima Pharmaceuticals AG, occurred after January&#160;1, 2009, we record contingent consideration liabilities at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in remaining milestones related to these acquisitions. For additional information related to our acquisition of Convergence please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIH</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of BIH, formerly Syntonix, in 2007, we agreed to pay up to an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$80.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;if certain milestone events associated with the development of BIH&#8217;s lead product, ALPROLIX are achieved. The first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$40.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment was achieved in 2010. We paid an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the second quarter of 2014 as ALPROLIX was approved for the treatment of hemophilia B. A second </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment will occur if, prior to the tenth anniversary of the closing date, a marketing authorization is granted by the EMA for ALPROLIX. This payment will be accounted for as an increase to intangible assets if achieved. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006, we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$220.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon closing of the transaction and agreed to pay an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;if a Fumapharm Product was approved for MS in the U.S.&#160;or E.U. In the second quarter of 2013, we paid this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment as TECFIDERA was approved in the U.S. for MS by the FDA. We are also required to make additional contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior twelve month period, as defined in the acquisition agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$850.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments as we reached the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2014, second quarter of 2015 and third quarter of 2015, respectively, and accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total cumulative sales of Fumapharm Products in the fourth quarter of 2015.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will owe an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment for every additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, until such time as the cumulative sales level reaches </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments shall be due. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level has been reached. </font></div><a name="s67098E3E1AEAC1E15D9FB512979720F0"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">22.&#160;&#160;&#160;&#160;&#160;&#160;Guarantees</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we did not have significant liabilities recorded for guarantees.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 66</font></div></div><hr style="page-break-after:always"><a name="s9E274AFC5D39A12D1FA2B512979773A2"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">23.&#160;&#160;&#160;&#160;&#160;&#160;Employee Benefit Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We sponsor various retirement and pension plans. Our estimates of liabilities and expenses for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">401(k) Savings Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a 401(k) Savings Plan which is available to substantially all regular employees in the U.S. over the age of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan&#8217;s matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense related to our 401(k) Savings Plan totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$51.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Compensation Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees, which are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$126.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$105.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pension Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries in which we maintain an operating presence.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by Swiss government and was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.75%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#8217;s contribution. Minimum employee contributions are based on the respective employee&#8217;s age, salary, and gender. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the the Swiss plan had an unfunded net pension obligation of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and plan assets which totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$63.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$43.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized expense totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to our Swiss plan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The obligations under the German plans are unfunded and totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net periodic pension cost related to the German plans totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 67</font></div></div><hr style="page-break-after:always"><a name="sAE5CD40363980AF407ECB51297A38343"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">24.&#160;&#160;&#160;&#160;&#160;&#160;Segment Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;operating segment, which is discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders, and, therefore, our chief operating decision-maker manages the operations of our company as a single operating segment. Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area and information relating to major customers are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue by product is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="36"></td></tr><tr><td width="18%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,908.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">730.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">3,638.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,426.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">482.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,909.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">864.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">11.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">876.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AVONEX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,790.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">840.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,630.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,956.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,056.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,013.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,902.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,103.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,005.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">PLEGRIDY</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">227.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">111.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">338.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">27.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">16.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">44.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,103.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">783.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,886.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,025.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">934.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,959.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">814.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">712.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,526.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">89.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">89.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">80.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">80.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">74.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">74.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">308.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">11.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">319.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">58.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">58.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">208.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">25.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">234.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">72.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">76.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">51.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">51.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">62.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">62.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">60.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">60.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">6,545.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,642.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">9,188.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">5,566.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,636.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">8,203.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,581.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,961.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">5,542.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Geographic Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables contain certain financial information by geographic area:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td width="29%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Germany</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,545.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,497.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">668.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">143.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">333.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,188.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,269.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">65.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,339.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">142.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">29.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">62.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">236.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,296.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">879.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,187.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2014 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Germany</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,566.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,383.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">811.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">112.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">328.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,203.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,117.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,055.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">701.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,765.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2013 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Germany</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,581.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,170.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">417.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,542.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,087.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,126.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">193.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">263.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">984.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">758.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,750.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Represents amounts related to Europe less those attributable to Germany.</font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 68</font></div></div><hr style="page-break-after:always"><a name="sAE5CD40363980AF407ECB51297A38343"></a><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenues from Unconsolidated Joint Business</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our total revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, are derived from our joint business arrangement with Genentech. For additional information related to our collaboration with Genentech, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Significant Customers</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recorded revenue from two wholesalers accounting for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$684.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$731.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our long-lived assets were related to our manufacturing facilities in Denmark. </font></div><a name="sBFFAB0D68C2A39AC7131B51297FB0B29"></a><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">25.&#160;&#160;&#160;&#160;&#160;&#160;Quarterly Financial Data (Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td width="36%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(c) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,172.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,198.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,391.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,425.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,188.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">330.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">337.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">337.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">333.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,339.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">52.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">49.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">79.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">236.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,555.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,591.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,777.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,839.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,763.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,242.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,305.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,467.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,507.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,523.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">820.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">924.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,019.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">828.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,593.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">822.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">927.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">965.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">831.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,547.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.50</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.94</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.16</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.77</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.38</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.49</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.93</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.15</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.77</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.34</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">232.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">220.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">230.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">232.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">220.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">231.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td width="36%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2014</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(f) (g)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(f)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(f)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,742.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,056.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,117.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,287.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,203.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">296.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">303.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">290.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">103.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,129.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,421.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,511.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,640.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,703.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,850.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,129.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,208.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,343.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,532.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">479.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">723.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">856.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">882.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,941.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">480.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">714.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">856.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">883.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.02</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.63</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.75</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.02</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.01</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.62</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.74</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)  Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc., for the third quarter of 2015, include a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$48.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;recorded upon entering into the collaboration agreement with AGTC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc., for the third quarter of 2015, reflects the attribution of a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;charge to noncontrolling interests, net of tax, related to a milestone payment due Neurimmune upon the enrollment of the first patient in a Phase 3 trial for aducanumab.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc., for the fourth quarter of 2015, include a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;recorded upon entering into the collaboration agreement with MTPC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc., for the fourth quarter of 2015, include pre-tax restructuring charges totaling </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc., for the first quarter of 2014, include pre-tax charges to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$117.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;recorded upon entering into the collaboration agreement with Eisai.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net and total revenues for the second, third and fourth quarters of 2014 include net revenues related to ALPROLIX as commercial sales of ALPROLIX commenced in the second quarter of 2014.  Product revenues, net and total revenues for the third and fourth quarters of 2014 include net revenues related to ELOCTATE and PLEGRIDY as commercial sales of ELOCTATE and PLEGRIDY commenced in the third quarter of 2014.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net and total revenues for the second quarter of 2014 include the recognition of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$53.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of revenue previously deferred in Italy relating to the pricing agreement with AIFA. </font></div></td></tr></table><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 70</font></div></div><hr style="page-break-after:always"><a name="s2C45CF52C15E6CBBEE6FB512BFC98380"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">To the Board of Directors and Shareholders of Biogen Inc.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of income, comprehensive income, equity and cash flows present fairly, in all material respects, the financial position of Biogen Inc. and its subsidiaries at December 31, 2015 and December 31, 2014, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2015 in conformity with accounting principles generally accepted in the United States of America.  Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2015, based on criteria established in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Internal Control - Integrated Framework</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).  The Company's management is responsible for these financial statements, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Report on Internal Control over Financial Reporting under item 9A.  Our responsibility is to express opinions on these financial statements and on the Company's internal control over financial reporting based on our integrated audits.  We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects.  Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation.  Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk.  Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As discussed in Note 16 to the consolidated financial statements, the Company changed the manner in which it classifies deferred taxes in 2015 and 2014 due to the adoption of Accounting Standards Update 2015-17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification of Deferred Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.  A company&#8217;s internal control over financial reporting includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ PricewaterhouseCoopers LLP</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Boston, Massachusetts</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;3, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 71</font></div></div><hr style="page-break-after:always"><a name="sC7CE2221B2FBA0FCC50DB512BFE57186"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="16%"></td><td width="7%"></td><td width="77%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset Purchase Agreement among Biogen Idec International Holding Ltd., Elan Pharma International Limited and Elan Pharmaceuticals, Inc., dated as of February 5, 2013. Filed as Exhibit 2.1 to our Current Report on Form 8-K/A filed on February 12, 2013.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amended and Restated Certificate of Incorporation, as amended. Filed as Exhibit 3.1 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2012.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certificate of Amendment to the Certificate of Incorporation. Filed as Exhibit 3.1 to our Current Report on Form 8-K filed on March 27, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third Amended and Restated Bylaws. Filed as Exhibit 3.2 to our Current Report on Form 8-K filed on March 27, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reference is made to Exhibit 3.1 for a description of the rights, preferences and privileges of our Series A Preferred Stock and Series X Junior Participating Preferred Stock.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indenture between Biogen Idec and The Bank of New York Trust Company, N.A. dated as of February 26, 2008. Filed as Exhibit 4.1 to our Registration Statement on Form S-3 (File No. 333-149379).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">First Supplemental Indenture between Biogen Idec and The Bank of New York Trust Company, N.A. dated as of March 4, 2008. Filed as Exhibit 4.1 to our Current Report on Form 8-K filed on March 4, 2008.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indenture, dated September 15, 2015, between Biogen Inc. and U.S. Bank National Association. Filed as Exhibit 4.1 to our Current Report on Form 8-K filed on September 16, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">First Supplemental Indenture, dated September 15, 2015, between Biogen Inc. and U.S. Bank National Association. Filed as Exhibit 4.2 to our Current Report on Form 8-K filed on September 16, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credit Agreement, dated August 28, 2015, between Biogen Inc., Bank of America, N.A., as administrative agent, swing line lender and an L/C issuer, and the other lenders party thereto. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on September 1, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expression Technology Agreement between Biogen Idec and Genentech. Inc. dated March 16, 1995. Filed as an exhibit to Biogen Idec&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 1995.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter Agreement between Biogen Idec and Genentech, Inc. dated May 21, 1996. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on June 6, 1996.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.4&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Second Amended and Restated Collaboration Agreement between Biogen Idec and Genentech, Inc. dated as of October 18, 2010. Filed as Exhibit 10.5 to our Annual Report on Form 10-K for the year ended December 31, 2010.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.5&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter agreement regarding GA101 financial terms between Biogen Idec and Genentech, Inc. dated October 18, 2010. Filed as Exhibit 10.6 to our Annual Report on Form 10-K for the year ended December 31, 2010.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.6*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. 2008 Amended and Restated Omnibus Equity Plan. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.7*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan.  Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.8*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of market stock unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan.  Filed as Exhibit 10.3 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.9*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of restricted stock unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on August 1, 2008.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.10*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of nonqualified stock option award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Current Report on Form 8-K filed on August 1, 2008.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.11*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of cash-settled performance shares award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2010.</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A- 1</font></div></div><hr style="page-break-after:always"><a name="sC7CE2221B2FBA0FCC50DB512BFE57186"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="16%"></td><td width="7%"></td><td width="77%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.12*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance shares award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan.  Filed as Exhibit 10.12 to our Annual Report on Form 10-K for the year ended December 31, 2013.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.13*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of market stock unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2010.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.14*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. 2006 Non-Employee Directors Equity Plan, as amended. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.15*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. 2005 Omnibus Equity Plan. Filed as Appendix A to our Definitive Proxy Statement on Schedule 14A filed on April 15, 2005.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.16*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amendment No. 1 to the Biogen Idec Inc. 2005 Omnibus Equity Plan dated April 4, 2006. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2007.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.17*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amendment No. 2 to the Biogen Idec Inc. 2005 Omnibus Equity Plan dated February 12, 2007. Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2007.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.18*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amendment to the Biogen Idec Inc. 2005 Omnibus Equity Plan dated April 18, 2008. Filed as Exhibit 10.7 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2008.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.19*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amendment to Biogen Idec Inc. 2005 Omnibus Equity Plan dated October 13, 2008. Filed as Exhibit 10.30 to our Annual Report on Form 10-K for the year ended December 31, 2008.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.20*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. 2015 Employee Stock Purchase Plan. Filed as Appendix A to Biogen's Definitive Proxy Statement on Schedule 14A filed on April 30, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.21*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. 2008 Performance-Based Management Incentive Plan. Filed as Appendix B to Biogen Idec&#8217;s Definitive Proxy Statement on Schedule 14A filed on May 8, 2008.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.22*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Voluntary Executive Supplemental Savings Plan, as amended and restated effective January 1, 2004. Filed as Exhibit 10.13 to our Annual Report on Form 10-K for the year ended December 31, 2003.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.23*+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental Savings Plan, as amended.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.24*+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Voluntary Board of Directors Savings Plan, as amended.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.25*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Executive Severance Policy &#8212; U.S. Executive Vice President, as amended effective January 1, 2014. Filed as Exhibit 10.39 to our Annual Report on Form 10-K for the year ended December 31, 2013.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.26*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Executive Severance Policy &#8212; International Executive Vice President, as amended effective January 1, 2014. Filed as Exhibit 10.40 Annual Report on Form 10-K for the year ended December 31, 2013.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.27*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Executive Severance Policy &#8212; U.S. Senior Vice President, as amended effective October 13, 2008. Filed as Exhibit 10.53 to our Annual Report on Form 10-K for the year ended December 31, 2008.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.28*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Executive Severance Policy &#8212; International Senior Vice President, as amended effective October 13, 2008. Filed as Exhibit 10.54 to our Annual Report on Form 10-K for the year ended December 31, 2008.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.29*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Annual Retainer Summary for Board of Directors. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2014.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.30*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of indemnification agreement for directors and executive officers. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on June 7, 2011.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.31*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employment Agreement between Biogen Idec and George A. Scangos amended as of August 23, 2013. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on August 26, 2013.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.32*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Paul J. Clancy dated August 17, 2007. Filed as Exhibit 10.49 to our Annual Report on Form 10-K for the year ended December 31, 2007.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.33*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Douglas E. Williams dated December 7, 2010. Filed as Exhibit 10.57 to our Annual Report on Form 10-K for the year ended December 31, 2011.</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A- 2</font></div></div><hr style="page-break-after:always"><a name="sC7CE2221B2FBA0FCC50DB512BFE57186"></a><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#sE97C750BE869328FBA03B512B099B381"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><br><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="17%"></td><td width="6%"></td><td width="77%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.34*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Steven H. Holtzman dated November 19, 2010. Filed as Exhibit 10.58 to our Annual Report on Form 10-K for the year ended December 31, 2011.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.35*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Kenneth DiPietro dated December 12, 2011. Filed as Exhibit 10.49 to our Annual Report on Form 10-K for the year ended December 31, 2012.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.36*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Alfred Sandrock dated May 7, 2013. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2013.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.37*+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Alfred Sandrock dated October 19, 2015. </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.38*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Adam Koppel dated January 10, 2014. Filed as Exhibit 10.43 to our Annual Report on Form 10-K for the year ended December 31, 2014.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.39*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Susan Alexander dated December&#160;13, 2005. Filed as Exhibit&#160;10.58 to our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2009.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.40*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Adriana Karaboutis dated August 7, 2014. Filed as Exhibit 10.44 to our Annual Report on Form 10-K for the year ended December 31, 2014.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.41*+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of John Cox dated September 7, 2010.  </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.42*+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding separation arrangement of Tony Kingsley dated November 12, 2015.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subsidiaries. </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consent of PricewaterhouseCoopers LLP, an Independent Registered Public Accounting Firm.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.1+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.1++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following materials from Biogen Inc.&#8217;s Annual Report on Form 10-K for the year ended December 31, 2015, formatted in XBRL (Extensible Business Reporting Language): (i) the Consolidated Statements of Income, (ii) the Consolidated Statements of Comprehensive Income, (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statements of Cash Flows, (v) the Consolidated Statements of Equity and (vi) Notes to Consolidated Financial Statements.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="6%"></td><td width="94%"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">^</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References to &#8220;our&#8221; filings mean filings made by Biogen Inc. (formerly Biogen Idec Inc.) and filings made by IDEC Pharmaceuticals Corporation prior to the merger with Biogen, Inc. Unless otherwise indicated, exhibits were previously filed with the Securities and Exchange Commission under Commission File Number 0-19311 and are incorporated herein by reference.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="6%"></td><td width="94%"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Management contract or compensatory plan or arrangement.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="6%"></td><td width="94%"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Confidential treatment has been granted or requested with respect to portions of this exhibit.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="6%"></td><td width="94%"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Filed herewith.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="2%"></td><td width="4%"></td><td width="94%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furnished herewith.</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A- 3</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>2
<FILENAME>biib-20151231xex1023.htm
<DESCRIPTION>EXHIBIT 10.23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s348a7fc1ab934bfb9919640c34e4dd6a"></a><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:center;padding-left:158px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BIOGEN IDEC INC.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:158px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SUPPLEMENTAL SAVINGS PLAN</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:158px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Plan Provisions as in Effect on January 1, 2012)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><hr style="page-break-after:always"><a name="s348a7fc1ab934bfb9919640c34e4dd6a"></a><br><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="10%"></td><td width="1%"></td><td width="4%"></td><td width="79%"></td><td width="5%"></td><td width="1%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ARTICLE I</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">INTRODUCTION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Purpose and Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ARTICLE 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DEFINITIONS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">401(k) restoration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Applicable compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Base salary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Biogen Idec</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Biogen SERP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Board</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Change in Control</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Code</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Compensation Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Disability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Employee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Employer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ERISA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Excess applicable compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Non-recurring bonus amounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Participant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Plan year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Prior plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Recurring bonus amounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Savings Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Service</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Transition credit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Voluntary deferred compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Years of service</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ARTICLE 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PARTICIPATION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Eligibility and Participation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">End of Participation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ARTICLE 4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">VOLUNTARY DEFERRALS BY PARTICIPANTS; EMPLOYER CREDITS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">401(k) Restoration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Voluntary Deferrals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Transition Credit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Election Procedures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ARTICLE 5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PARTICIPANT ACCOUNTS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Participant Accounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Participant's Account Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><hr style="page-break-after:always"><a name="s348a7fc1ab934bfb9919640c34e4dd6a"></a><br><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="10%"></td><td width="1%"></td><td width="4%"></td><td width="79%"></td><td width="5%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Vesting</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ARTICLE 6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DISTRIBUTIONS TO PARTICIPANT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Distributions for Unforeseeable Emergency</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Distributions Upon Change in Control</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In-Service Distribution(s) at a Time Specified Participant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Distribution upon Death of a Participant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Distribution upon Participant's Termination of Employment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Installment Distributions in Certain Cases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain Other Distributions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delay in Distributions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Compliance with Code Section 409A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ARTICLE 7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">MISCELLANEOUS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Amendment or Termination of Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Benefits Not Currently Funded</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No Assignment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effect of Change in Control</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Responsibilities and Authority of Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Limitation on Rights Created by Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Tax Withholding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Text Controls</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Applicable State Law</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Paperless Administration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">APPENDIX A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A-1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">APPENDIX B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">B-1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><hr style="page-break-after:always"><a name="s8fb786935a3f46f190c10b7b5b19e69d"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:3px;text-align:center;padding-left:269px;text-indent:1px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ARTICLE 1 INTRODUCTION</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.1</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Purpose and Effective Date. </font><font style="font-family:Arial;font-size:10pt;">The purpose of this plan is to provide certain key executives and managers of Biogen Idec (or its subsidiaries) with additional tax-deferred savings opportunities supplementing those available under the Savings Plan. This plan allows certain eligible participants to make voluntary deferrals from base salary or recurring and/or non-recurring bonus amounts, if elected by a participant in accordance with the terms of the plan. In addition, certain participants whose compensation exceeds the Code Section 401(a)(17) limit applicable to the Savings Plan will receive an employer 401(k) restoration credit in accordance with Section 4.1. and certain participants received transition credits in accordance with Section 4.3.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This plan also contains certain account balances or benefits previously maintained under the amended and restated IDEC Pharmaceuticals Corporation Deferred Compensation Plan, the Biogen, Inc. Voluntary Executive Supplemental Savings Plan, and the Biogen. Inc. Supplemental Executive Retirement Plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The plan was amended and restated effective January 1, 2005 to comply with Code Section 409A and restated again effective February 1, 2008, October 1, 2008 and January 1, 2010. This amended and restated plan document is effective as of January 1, 2012 to expand the tax-deferred savings opportunities by allowing eligible participants to defer certain equity based awards granted under the Biogen Idec Inc. 2008 Omnibus Equity Plan (or successor long term incentive plan) whereby such awards are considered non-recurring bonus amounts hereunder. Certain historical information about the plan and any amendments thereto is set forth in Appendix A.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:276px;text-indent:1px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ARTICLE 2 DEFINITIONS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This section contains definitions of certain terms used in the plan. Where the context so requires, the masculine includes the feminine, the singular includes the plural, and the plural includes the singular.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.1&#160;&#160;&#160;&#160;401(k) restoration </font><font style="font-family:Arial;font-size:10pt;">means that component of the plan under which an eligible participant's account will receive an employer 401(k) restoration credit under Section 4.1 with respect to applicable compensation in excess of the limit imposed by Section 401(a)(17) of the Code.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.2&#160;&#160;&#160;&#160;Applicable compensation </font><font style="font-family:Arial;font-size:10pt;">shall have the same meaning as in the Savings Plan except that applicable compensation under this plan shall also include voluntary deferrals made under Section 4.2 in addition to other salary reductions included in applicable compensation under the Savings Plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.3&#160;&#160;&#160;&#160;Base salary </font><font style="font-family:Arial;font-size:10pt;">means the base salary established for any participant by his employer as in effect from time to time: the entire amount of a participant's base salary will be taken into account in accordance with the terms of this plan without regard to any dollar limitation on applicable compensation that may be imposed under the Savings Plan: base salary includes all components of a participant's applicable compensation other than recurring and non&#173; recurring bonus amounts.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.4&#160;&#160;&#160;&#160;Biogen Idec </font><font style="font-family:Arial;font-size:10pt;">means Biogen Idec Inc., a Delaware corporation, or any successor to it or to all or the major portion of its assets or business which assumes the obligations of Biogen Idec Inc. under this plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.5&#160;&#160;&#160;&#160;Biogen SERP </font><font style="font-family:Arial;font-size:10pt;">means the Biogen, Inc. Supplemental Executive Retirement Plan, as in effect immediately prior to January 1, 2004 (or other date of transfer referred to in Section 3.1(c)).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.6&#160;&#160;&#160;&#160;Board </font><font style="font-family:Arial;font-size:10pt;">means the Board of Directors of Biogen Idec,</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.7&#160;&#160;&#160;&#160;Change in Control</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:54px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:41px;">(a)</font><font style="font-family:Arial;font-size:10pt;">For purposes of Section 5.3(f) and Section 7.4. a change in control means a "Corporate Change in Control" or a "Corporate Transaction" as each is defined in the Biogen Idec Inc. 2008 Omnibus Equity Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><a name="s8fb786935a3f46f190c10b7b5b19e69d"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:57px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:38px;">(b)</font><font style="font-family:Arial;font-size:10pt;">For purposes of Section 4.4(b) and Section 6.2, a change in control means (i) the acquisition by a person or group of stock of Biogen Idec that, together with stock previously held by such person or group, constitutes more than 50 percent of the total fair market value or total voting power of the stock of Biogen Idec; (ii) a change in the effective control of Biogen Idec resulting from either the acquisition by any person or group during a 12-month period of stock of Biogen Idec possessing 30 percent or more of the total voting power of Biogen Idec stock; or the replacement of a majority of the members of the Board during any 12-month period by directors whose appointment or election was not endorsed by a majority of the members of the Board in office immediately before the start of such 12-month period; or (iii) the acquisition by any person or group (during any 12-month period) of assets having a gross fair market value equal to or greater than 40 percent of the total gross fair market value of all assets of Biogen Idec. This subsection (b) and terms used herein will be interpreted in accordance with the regulations under Code Section 409A relating to a change in the ownership or effective control of a corporation or a change in the ownership of a substantial portion of the assets of a corporation.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:57px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This subsection 2.8(b) is effective as of the date of execution of this amended and restated plan document.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.8&#160;&#160;&#160;&#160;Code</font><font style="font-family:Arial;font-size:10pt;">&#32;means the Internal Revenue Code of 1986, as amended, or any successor statute enacted in its place. Reference to any provision of the Code includes reference to any successor provision thereto.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.9&#160;&#160;&#160;&#160;Committee</font><font style="font-family:Arial;font-size:10pt;">&#32;means the Retirement Committee, or such other committee designated by the Board to administer this Plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.10&#160;&#160;&#160;&#160;Compensation Committee</font><font style="font-family:Arial;font-size:10pt;">&#32;means the Compensation and Management Development Committee of the Board (or any successor committee, however named, carrying out its functions).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.11&#160;&#160;&#160;&#160;Disability</font><font style="font-family:Arial;font-size:10pt;">&#32;means "disability" as defined under the long-term disability program of Biogen Idec or another employer covering a participant, or, if no such program is in effect with respect to such participant, then "disability" means ''total and permanent disability" as defined in Code Section 22(e)(3).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.12&#160;&#160;&#160;&#160;Employee</font><font style="font-family:Arial;font-size:10pt;">&#32;means a person who is classified as a regular, common law employee of Biogen Idec (or other employer) under the regular personnel classifications and practices of his employer. An individual will not be considered an employee for purposes of this plan if the individual is classified as a consultant or contractor under Biogen Idec's (or other employer's) regular personnel classifications and practices or he is a party to an agreement to provide services to Biogen Idec (or other employer) without participating in this plan, notwithstanding that such individual may be treated as a common law employee for payroll tax or other legal purposes.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.13&#160;&#160;&#160;&#160;Employer</font><font style="font-family:Arial;font-size:10pt;">&#32;means Biogen Idec and each direct or indirect subsidiary or other affiliate of Biogen Idec that employs persons who are or may be eligible to participate in this plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.14&#160;&#160;&#160;&#160;ERISA</font><font style="font-family:Arial;font-size:10pt;">&#32;means the Employee Retirement Income Security Act of 1974, as amended, or any successor statute enacted in its place. Reference to any provision of ERISA includes reference to any successor provision thereto.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.15&#160;&#160;&#160;&#160;Excess applicable compensation</font><font style="font-family:Arial;font-size:10pt;">&#32;means, for any plan year, the amount of a participant's applicable compensation in excess of the limit under Section 401(a)(17) of the Code applicable to such year and which therefore could not be considered under the Savings Plan, plus, if applicable, the amount by which a participant's applicable compensation is reduced below such Code Section 401(a)(17) limit by reason of an election to reduce base salary or recurring and/or non-recurring bonus amounts under Section 4.2.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.16&#160;&#160;&#160;&#160;Non-recurring bonus</font><font style="font-family:Arial;font-size:10pt;">&#32;amounts means any portion(s) of a participant's compensation which constitutes a bonus payable in cash (including any equity-based compensation awards that are settled in cash) other than a bonus amount. Effective January 1, 20 l 2, non-recurring bonus amounts shall also include any restricted     stock units, market stock units, or other&#160;&#160;&#160;&#160;equity-based awards that may be granted under the Biogen Idec Inc. 2008 Omnibus Equity Plan (or successor long term incentive plan) on and after such date. Any component of a participant's compensation which is a non-recurring bonus amount will be designated as such by&#160;&#160;&#160;&#160;the </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><a name="s8fb786935a3f46f190c10b7b5b19e69d"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">committee. The entire amount of any such non-recurring bonus amount will be taken into account in accordance with the terms of this plan without regard to any dollar limitation on applicable compensation that may be imposed under the Savings Plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.17&#160;&#160;&#160;&#160;Participant </font><font style="font-family:Arial;font-size:10pt;">means an employee of Biogen Idec (or other employer) who is eligible to participate in this plan in accordance with Section 3.1 and who has an account described in Section 5.1 or for whom an amount has been transferred to this plan from a prior plan or from the Biogen SERP.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.18&#160;&#160;&#160;&#160;Plan </font><font style="font-family:Arial;font-size:10pt;">means the Biogen Idec Inc. Supplemental Savings Plan. as set forth in this plan instrument, and as it may be amended from time to time.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.19&#160;&#160;&#160;&#160;Plan year </font><font style="font-family:Arial;font-size:10pt;">means the 12-month periods commencing on January 1, 2005 and on each subsequent January 1 while the plan remains in effect.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.20&#160;&#160;&#160;&#160;Prior plan </font><font style="font-family:Arial;font-size:10pt;">means the amended and restated IDEC Pharmaceuticals Corporation Deferred Compensation Plan and the Biogen, Inc. Voluntary Executive Supplemental Savings Plan. each as in effect immediately prior to January 1, 2004 (or other date of transfer referred to in Section 3. 1(c)).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.21&#160;&#160;&#160;&#160;Recurring bonus amounts </font><font style="font-family:Arial;font-size:10pt;">means any portion(s) of a participant's compensation which is (i) not base salary, (ii) is payable in cash (excluding any equity-based compensation awards that are settled in cash). and (iii) is a recurring and/or predictable component of the participant's compensation for a calendar year such that the participant will know before the start of such calendar year that he is or may be eligible to receive such bonus if the criteria applicable to such bonus are satisfied (in full or in part). Recurring bonus amounts include (but are not limited to) a participant's annual bonus, sales incentive compensation plan bonuses (if applicable to a participant), and similar bonuses (if any) but does not include any long term incentive award payments. The entire amount of any such recurring bonus amount will be taken into account in accordance with the terms of this plan without regard to any dollar limitation on applicable compensation that may be imposed under the Savings Plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.22&#160;&#160;&#160;&#160;Savings Plan </font><font style="font-family:Arial;font-size:10pt;">means the Biogen Idec 401(k) Savings Plan, as amended from time to time. Any term defined in the Savings Plan will have the same meaning when used in this plan unless otherwise defined herein.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.23&#160;&#160;&#160;&#160;Service </font><font style="font-family:Arial;font-size:10pt;">means the sum of a participant's employment (a) with Biogen Idec since November 12, 2003 and (b) with either Biogen, Inc. or IDEC Pharmaceuticals Corporation prior to November 12, 2003 (including in each case service with any subsidiary or other affiliate of such entity).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.24&#160;&#160;&#160;&#160;Transition credit </font><font style="font-family:Arial;font-size:10pt;">means an amount credited by Biogen Idec to a participant's account under this plan that is equal to (a) the additional amount that would be contributed on behalf of the participant under the Savings Plan, as determined under Appendix C of the Savings Plan but without regard to the nondiscrimination limits or the Code Section 401(a)(17) or Code Section 415 limits that restrict additions to the participant's account(s) under the Savings Plan, reduced by (b) the amount of the actual additional contribution on the participant's behalf to the Savings Plan in accordance with Appendix C thereof.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.25&#160;&#160;&#160;&#160;Voluntary deferred compensation </font><font style="font-family:Arial;font-size:10pt;">means that component of the plan which permits an eligible participant to defer from 1% to 80% of his base salary and from 1 % to 100% of his recurring bonus and/or non-recurring bonus amounts in accordance with Section 4.2.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.26&#160;&#160;&#160;&#160;Years of service </font><font style="font-family:Arial;font-size:10pt;">means full years of completed continuous service as a regular employee, determined in accordance with the personnel policies and practices of a participant's employer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:265px;text-indent:2px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ARTICLE 3 PARTICIPATION</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.1   Eligibility and Participation.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Voluntary Deferred Compensation</font><font style="font-family:Arial;font-size:10pt;">. An employee (i) who has the job title of Senior Director or Vice President or more senior officer of Biogen Idec (or other employer which is participating hereunder) or (ii) </font></div></td></tr></table><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><a name="s8fb786935a3f46f190c10b7b5b19e69d"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="font-family:Arial;font-size:10pt;">who is designated as eligible by the Compensation Committee will be eligible to be a participant in the voluntary deferred compensation component of the plan. Participation in this component of the plan is voluntary and no eligible employee will be required to participate.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Transition Credit</font><font style="font-family:Arial;font-size:10pt;">. An employee (i) whose ''additional employer contribution" as determined under Appendix C of the Savings Plan was limited because of limits on compensation, limits on annual additions or nondiscrimination requirements applicable to qualified plans under the Code and (ii) who was designated by the committee (either individually or by class) is eligible to be a participant in the transition contribution component of this plan (see Section 4.3).</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Prior Plans and Biogen SERP</font><font style="font-family:Arial;font-size:10pt;">. Each employee who is not eligible to be a participant under subsection (a) or (b) above or (d) below, or who is eligible but declines to participate under subsection (a) above, but who was a prior plan participant and/or Biogen SERP participant and whose prior plan and/or Biogen SERP account balance (or supplemental pension formula benefit under Section 4.1 of the Biogen SERP, if applicable) was transferred to this plan effective as of January 1, 2004 (or such later date as the committee specified) is a participant solely with respect to such transferred prior plan and/or Biogen SERP account balance (or supplemental pension formula benefit, if applicable). This will not include a person who is a vested participant under the Biogen SERP but not an employee (i.e., a person who terminated employment from Biogen, Inc. or from Biogen Idec on or before the date of transfer referred to in the preceding sentence); such a person's benefits under the Biogen SERP are governed by the provisions of Section 5.1(f) and Appendix B.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">401(k) Restoration</font><font style="font-family:Arial;font-size:10pt;">. An employee who satisfies the requirements of Section 4.1(a) below will be eligible to be a participant with respect to the employer 401(k) restoration component of the plan.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Time of Eligibility and Participation</font><font style="font-family:Arial;font-size:10pt;">. An employee who is newly hired or promoted into a position described in subsection (a)(i) above, or who is newly designated as eligible under subsection (a)(ii) above, will be deemed to be eligible on the date the committee (or its delegatee) sends him an enrollment form (see Section 4.4).</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">An eligible employee under subsection (a) above will become a participant hereunder when he makes a voluntary deferral under this plan. An eligible employee under subsection (b), (c) or (d) above will become a participant hereunder when Biogen Idec (or other employer) credits an amount to his account(s) hereunder.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Top Hat Plan</font><font style="font-family:Arial;font-size:10pt;">. Notwithstanding the preceding subsections (or any other provisions of the plan), no employee will be eligible to participate in any component of this plan at any time when he or she is not a member of a select group of management or highly compensated employees (within the meaning of ERISA Sections 201(2), 301(a)(3) and 401(a)(1)), as determined by the committee.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.2&#160;&#160;&#160;&#160;End of Participation. </font><font style="font-family:Arial;font-size:10pt;">A participant's participation in this plan (or a particular component of this plan) will end upon the termination of his service as an employee of Biogen Idec (or other employer) because of death or any other reason, or upon his transfer to or reclassification as an employee who is not eligible to participate in the plan (or in such component).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, in the case of a participant who was designated as eligible for a component of the plan by the Compensation Committee, his participation in such component will end upon the Compensation Committee's specifying that he is no longer eligible to participate. In such event, his participation will end effective as of the later of the date of the Compensation Committee's action or the date specified by the Compensation Committee; provided that no such action will retroactively deprive a participant of any amount credited to his account or any amount he was entitled to under this plan determined as of the effective date of his termination of participation.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upon the termination of a participant's participation in this plan (or in a particular component of this plan) in accordance with this section, there will be no additional voluntary deferrals or employer credits to such participant's account(s) (or the account(s) related to such component), except to the extent required by Code Section 409A or the regulations or any rulings thereunder with respect to the balance of the plan year in which such termination of participation occurred. However. the participant will be entitled to receive amounts credited </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><a name="s8fb786935a3f46f190c10b7b5b19e69d"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to his account(s) in accordance with this plan.</font></div><div style="line-height:120%;padding-top:3px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:3px;text-align:center;text-indent:288px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ARTICLE 4</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">VOLUNTARY DEFERRALS BY PARTICIPANTS; EMPLOYER CREDITS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4.1&#160;&#160;&#160;&#160;401(k) Restoration.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:42px;">(a)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Eligibility</font><font style="font-family:Arial;font-size:10pt;">. Each employee who has excess applicable compensation during a plan year will receive employer credits under this section, but only if the individual is still an employee as of the end of the plan year (or other period-for example, quarterly) for which an amount is to be credited under subsection (c) below.</font></div><div style="line-height:120%;text-align:left;padding-left:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Amount of Employer 401(k) Restoration Credits</font><font style="font-family:Arial;font-size:10pt;">. For each plan year (or a shorter period of time specified by the committee), each employer will credit a 401(k) restoration amount to the account of each eligible participant (under subsection (a) above) employed by such employer who has excess applicable compensation during such plan year (or such shorter period of time). The employer's credits on behalf of such a participant will be equal to six percent of his excess applicable compensation during the plan year (or such shorter period of time).</font></div><div style="line-height:120%;text-align:left;padding-left:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(c)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Time for Making Employer 401(k) Restoration Credits</font><font style="font-family:Arial;font-size:10pt;">. Employer credit amounts under subsection (b) will be credited to participants' accounts at such time(s) as the committee determines after the end of each plan year (or such shorter periods of time-for example, quarterly-specified by the committee).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4.2&#160;&#160;&#160;&#160;Voluntary Deferrals. </font><font style="font-family:Arial;font-size:10pt;">Each eligible employee (under Section 3.1(a)) may make voluntary deferrals under the plan from his base salary in any whole percentage of his base salary from a minimum of 1% to a maximum of 80% by electing to reduce his base salary by such amount. In addition, each such eligible employee may make voluntary deferrals under the plan from his recurring bonus amounts (as defined in Section 2.21) in any whole percentage of his recurring bonus amounts from a minimum of 1% to a maximum of 100% by electing to reduce his recurring bonus amounts by such amount. Elections to reduce base salary and/or recurring bonus amounts will be in accordance with the requirements of Section 4.4(a)(i). Finally, each such eligible employee may make voluntary deferrals under the plan from his non-recurring bonus amounts (as defined in Section 2.16), if any, in any whole percentage of his non-recurring bonus amounts from a minimum of 1% to a maximum of 100%, by electing to reduce his non-recurring bonus amounts by such amount. Deferrals of any equity based awards shall not include any partial shares of common stock of Biogen Idec. Elections to reduce non-recurring bonus amounts must be made in accordance with the requirements of Section 4.4(a)(ii).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Notwithstanding the first sentence of the preceding paragraph, the committee (or its designee) may reduce the maximum base salary deferral an eligible employee may elect from 80% to such smaller percentage as the committee (or its designee) deems advisable, in the case of any participant or group of participants, so that all employee contributions (by salary reduction or otherwise) for benefit plan coverages applicable to such participant(s), withholding tax obligations applicable to such participant(s), and any other elective or non-elective application of the base salary of such participant(s) (such as, by way of illustration and not by way of limitation, charitable deductions) will be accommodated. Any such reduction applicable to a participant for a plan year will be made before the start of such plan year.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4.3&#160;&#160;&#160;&#160;Transition Credit. </font><font style="font-family:Arial;font-size:10pt;">Each eligible employee (under Section 3.1(b)) will receive a transition credit hereunder. The amount of such credit will be the amount the participant would have received under the terms and conditions of Appendix C of the Savings Plan if Code Section 401(a) nondiscrimination requirements and/or Code Section 401(a)(17) or 415 limits did not apply, reduced by any amount actually contributed to the Savings Plan on his behalf under such Appendix C. Any such transition credit amount hereunder will be credited at a time determined by the committee.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4.4&#160;&#160;&#160;&#160;Election Procedures.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Voluntary Deferrals from Base Salary or Recurring Bonus Amounts.</font><font style="font-family:Arial;font-size:10pt;">&#32;An eligible employee under Section 3.1(a) who wishes to reduce his base salary and/or recurring bonus amounts to be earned during a particular plan year in order to make voluntary deferrals under Section 4.2 must complete an enrollment form specifying the amount of his voluntary deferrals (with separate percentages for his base salary and recurring </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><a name="s8fb786935a3f46f190c10b7b5b19e69d"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">bonus amounts, if desired, agreeing to reduce his base salary and/or recurring bonus amounts by the amount(s) he specifies, and providing such other information as the committee may require.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A participant's enrollment form electing such voluntary deferrals for any plan year must be filed with the committee by such deadline as the committee specifies, but in any event before the start of such plan year. A participant may change the amount of his voluntary deferrals with respect to any subsequent plan year by filing a new enrollment form before the start of such subsequent plan year, and the change will become effective as of the first day of such subsequent plan year. Once a participant has elected to defer base salary and/or recurring bonus amounts, his enrollment form will remain in effect for future plan years unless the participant changes or terminates his prior elections by filing a new enrollment form in accordance with the preceding sentence.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">An individual who first becomes eligible under Section 3.1(a) during a plan year may make an initial election by filing an enrollment form with the committee not later than 30 days after the committee (or its delegatee) sends him an enrollment form. However, such a newly eligible employee may elect to defer only base salary and/or that portion of any recurring bonus amounts to be earned after the date of filing his completed enrollment form. An individual is considered first eligible only if either: (i) he had not during the preceding 24-month period been eligible to make voluntary deferrals under this plan or under another non-qualified deferred compensation plan maintained by Biogen Idec (or another employer or other subsidiary or affiliate of Biogen Idec): or (ii) he had received a complete distribution of his entire interest under the plan and subsequently, through rehi re. promotion, transfer or designation, again becomes eligible to participate in this plan under Section 3.1.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">After a plan year has begun, a participant may not change the amount of voluntary deferrals of base salary and/or recurring bonus amounts (if any) he had elected for such plan year. However, if during a plan year a participant either (i) has an unforeseeable emergency (as defined in Section 6.1) and receives a distribution under Section 6.1 or (ii) has a financial hardship (as defined in the Savings Plan) and receives a financial hardship withdrawal from the Savings Plan, the participant's deferral election will automatically be cancelled. For distributions referred to in (i) above, deferrals shall be cancelled for the balance of the year in which any such distribution is made. For distributions referred to in (ii) above, deferrals shall be cancelled through the end of the year in which falls the six-month anniversary of the hardship withdrawal.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(ii)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Voluntary Deferrals From Non-Recurring Bonus Amounts</font><font style="font-family:Arial;font-size:10pt;">. If an eligible employee (under Section 3.1(a)becomes eligible to receive a non-recurring bonus amount (as designated by the committee in accordance with Section 2.16), such eligible employee may elect to make voluntary deferrals under Section 4.2 equal to all or a specified portion of such non-recurring bonus amount in accordance with such procedures as established by the committee. Elections made with respect to equity based awards shall apply to all tranches of such awards regardless of the date such award becomes nonforfeitable and shall apply with respect to any and all dividends or dividend equivalents provided with respect to such awards. All deferral elections hereunder must be made on an enrollment form approved by the committee, specifying the amount he elects to defer, agreeing to reduce his non-recurring bonus amount(s) by such amount, and providing such other information as the committee may require. If an eligible employee elects to defer restricted stock or market stock unit awards, such employee shall not be permitted to diversify the investment of such awards other than in Biogen Idec stock or stock equivalent.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A participant's enrollment form must be filed with the committee by such deadline as the committee specifies in written procedures approved by the committee (or its delegatee) governing deferral elections for non&#173; recurring bonus amounts. Any filing deadline will comply with the timing of elections requirements of the regulations under Code Section 409A. Accordingly, if the committee determines that a particular non-recurring bonus amount constitutes "performance-based compensation" the timing requirements for electing to defer performance-based compensation may be applied. Furthermore, with respect to the initial election to defer payment of any equity based awards such as restricted stock unit awards, market stock unit awards or any other forfeitable rights that requires the participant to provide services for at least 12 months from the date the award is granted, the election to defer such compensation may be made within 30 days after the date of grant or, if earlier. 12 months in advance of the date such award or right becomes nonforfeitable provided that if death, disability or a change in control occurs which accelerates the vesting before the end of such 12-month period, the deferral election will not be effective. The committee's written procedures will be deemed to constitute part of this plan for purposes of the written plan document requirements of the regulations under Code Section 409A.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If an individual first becomes eligible under Section 3.1(a) during a plan year and after the deadline </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><a name="s8fb786935a3f46f190c10b7b5b19e69d"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">provided in the preceding paragraph, he may make an election to defer his non-recurring bonus amounts (if any for such plan year in accordance with the rules specified in the third paragraph of subsection (i) above. In addition, the rules in the fourth paragraph of subsection (i) above will apply to any non-recurring bonus amounts deferral election the participant made for any plan year in which he receives a distribution under Section 6.1 or a financial hardship withdrawal from the Savings Plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:54px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Form and Time of Payment</font><font style="font-family:Arial;font-size:10pt;">.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:54px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:41px;">(i)</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Initial Election. </font><font style="font-family:Arial;font-size:10pt;">Each participant must specify the form of payment (lump sum or installments in accordance with Section 6.4(a), 6.5(a) and/or Section 6.6(a) below. as applicable) of his accounts hereunder in the event of the participant's death or other termination of employment (including as a result of disability). The time and form of payments under the plan are governed by the provisions of Article 6 and participant elections must conform to the requirements of such provisions. Any election as to medium of payment with respect to equity based awards (i.e. whether such award will be settled in stock or cash) shall be subject to the terms of the Biogen Idec Inc. 2008 Omnibus Equity Plan (or successor long term incentive plan) and/or award agreement thereunder. Any such election shall not be considered an election as to time or form of payment and shall not be subject to the restrictions under this Section.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:54px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, a participant may elect payment of his accounts under Section 6.2 in the event of a change in control (as defined in Section 2.7(b)).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:54px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, a participant who is an active Employee may (but is not required to) specify one or more in-service distributions to the participant in accordance with Section 6.3 if desired by the participant. A participant who declines to elect such an in-service distribution is deemed to have elected payment only after death (Section 6.4) or termination of employment (Section 6.5) or, if applicable, a change in control (Section 6.2); such a participant may not thereafter make a change of election under subsection (ii) with respect to an in-service distribution from the plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:54px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A participant's initial election of a time and form of payment hereunder must be made by whichever of the following dates applies to the participant (or the earlier of such dates, if both apply to a particular participant): (A) the deadline for filing the participant's initial enrollment form under subsection</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:53px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a) above; or (B) January 30 of the year following the year for which an amount is first credited to the participant under Section 3.1(c), Section 4.1 or Section 4.3 (provided that this clause (B) will not apply to a participant if he was previously eligible for employer credits or contributions (as opposed to voluntary deferrals) under this plan or under any other account balance non-qualified deferred compensation plan maintained by Biogen Idec (or another employer or other subsidiary or affiliate of Biogen Idec).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:53px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:42px;">(ii)</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Change of Election </font><font style="font-family:Arial;font-size:10pt;">Notwithstanding subsection (i) above, the following changes of election will be permitted. If such a subsequent election becomes effective as provided below, then the participant's account(s) will be payable at the time and in the form specified in his subsequent election.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:148px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:98px;"><font style="font-family:Arial;font-size:10pt;">(A)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">In-Service Distributions</font><font style="font-family:Arial;font-size:10pt;">. In the case of an eligible participant who elected an in-service distribution, at any time that is at least one year prior to the date for payment originally elected by the participant, if the participant is still an employee of Biogen Idec (or another employer or other subsidiary or affiliate) at such time, the participant may make one subsequent election to defer the time when any previously elected in-service distribution under Section 6.3 from his account(s) would otherwise be payable (or installment payments would otherwise begin) to a subsequent date specified by him, and/or may elect another form of payment or a different number of installments with respect to the in-service distribution of his account(s), subject in all cases to the requirements of this section and to the requirements of Section 6.3.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:146px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:97px;"><font style="font-family:Arial;font-size:10pt;">(B)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Death or Termination of Employment</font><font style="font-family:Arial;font-size:10pt;">. A participant who is still an employee of Biogen Idec (or another employer or other subsidiary or affiliate) may make one subsequent election to change the form of payment hereunder that will be used following his death </font></div></td></tr></table><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><a name="s8fb786935a3f46f190c10b7b5b19e69d"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:146px;text-align:left;"><font style="font-family:Arial;font-size:10pt;">or other termination of employment. Such an election must comply with the applicable requirements of Sections 6.4(a), 6.5(a) and 6.6(a) (as applicable).</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:Arial;font-size:10pt;">(C)</font></div></td><td style="vertical-align:top;padding-left:54px;"><div style="line-height:120%;text-align:left;font-size:10pt;text-indent:-54px;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Effectiveness of Subsequent Election</font><font style="font-family:Arial;font-size:10pt;">. A participant's subsequent election under this subsection (ii) will become effective only if the following requirements are satisfied: (1) the subsequent election does not take effect until one year after the date of the subsequent election and the participant remains an employee of Biogen Idec (or another employer or other subsidiary or affiliate) during such one year period, (2) the election extends the date for payment, or the start date for installment payments, by at least five years, and (3) in the case of a subsequent election to defer a previously elected in-service distribution (under subsection (A) above), the subsequent election is made at least 12 months before the date previously elected for such in-service distribution.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:60px;text-indent:45px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No election under this subsection (ii) may operate to accelerate any payment or distribution hereunder or violate any requirement of Code Section 409A or the regulations and rulings thereunder.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:60px;text-indent:45px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A participant may make only one subsequent election under subsection (ii)(A) and only one subsequent election under subsection (ii)(B). Such subsequent election(s) may be made at the same or at different times. Also, the committee may permit additional election opportunities (in accordance with the transition or other rules under the regulations or other Internal Revenue Service guidance under Code Section 409A or in such other circumstances as the committee deems appropriate). Any such additional subsequent elections under subsection (ii) must satisfy all the requirements of this section and any other applicable requirements under the plan or, alternatively, must satisfy such requirements as the committee may impose in connection with a new election under a Code Section 409A transition or other rule.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:236px;text-indent:49px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ARTICLE 5</font></div><div style="line-height:120%;text-align:center;text-indent:49px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PARTICIPANT ACCOUNTS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.1&#160;&#160;&#160;&#160;Participant Accounts.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Employer 401(k) Restoration Accounts</font><font style="font-family:Arial;font-size:10pt;">. Employer credits on a participant's behalf under Section 4.1 will be credited to an account in the name of such participant. Such account will be called his employer 401(k) restoration account.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Voluntary Deferred Compensation Accounts</font><font style="font-family:Arial;font-size:10pt;">. Voluntary deferrals by a participant under Section 4.2 will be credited to an account in the name of such participant. Such account will be called his voluntary deferred compensation account.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Transition Accounts</font><font style="font-family:Arial;font-size:10pt;">. Transition credits on a participant's behalf under Section 4.3 will be credited to an account in the name of such participant. Such account will be called his transition account.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Prior Plan Account</font><font style="font-family:Arial;font-size:10pt;">. Account balances as of December 31, 2003 (or such later date as the committee specified) for a participant in a prior plan were transferred to this plan from such prior plan and the transferred amount was credited to an account in the name of such participant. Such account is called his prior plan account.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Biogen SERP Account</font><font style="font-family:Arial;font-size:10pt;">. Amounts transferred to this plan from the Biogen SERP on behalf of a participant were credited to an account in the name of such participant. Such account is called his Biogen SERP account. The amount so transferred on behalf of a participant in the excess benefit formulas in Section 4.2 of the Biogen SERP was the amount credited to such participant's Biogen SERP cash balance account as of December 31, 2003 (or such later date of transfer as the committee specified). The amount so transferred on behalf of a participant in the supplemental pension formula in Section 4.1 of the SERP was the present value as of December 31, 2003 such later date of transfer as the committee specified) of the participant's SERP accrued supplemental pension as of such date (calculated in accordance with the terms of the SERP in effect on such date).</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Certain Special Provisions</font><font style="font-family:Arial;font-size:10pt;">. Participants' prior plan accounts and Biogen SERP accounts will be governed </font></div></td></tr></table><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><a name="s8fb786935a3f46f190c10b7b5b19e69d"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="font-family:Arial;font-size:10pt;">by the applicable provisions of this plan as in effect from time to time.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For persons who were participants in the Biogen SERP before the transfer date referred to in subsection (e) above and are entitled to a vested SERP benefit thereunder, but who are not active participants under this plan and therefore do not have an account hereunder, the amount transferred to this plan in respect of their Biogen SERP benefit will be governed by Appendix B hereto, as in effect from time to time.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">409A</font><font style="font-family:Arial;font-size:10pt;">. For purposes of applying Code Section 409A, as provided in the regulations thereunder, a participant's voluntary deferred compensation account is disaggregated from his or her other accounts hereunder.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.2&#160;&#160;&#160;&#160;Participant's Account Value.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Deemed Investment Results</font><font style="font-family:Arial;font-size:10pt;">. Except as otherwise provided below, a participant's accounts will be credited with deemed investment results as if the amounts credited to his accounts were invested in one or more designated investment funds (as described below) and all dividends and distributions on shares or other interests of a particular investment fund were reinvested in such fund. The investment funds available for this purpose will be those from time to time available as investment options for participants' accounts under the Savings Plan, plus the investment funds specified in subsections (b) and (c) below (in the case of eligible participants). Notwithstanding the foregoing, with respect to the portion of a participant's voluntary deferred compensation account attributable to restricted stock or market stock units or other equity based awards, such portion will be deemed to be invested in shares of common stock of Biogen Idec as described in the long term incentive plan sponsored by Biogen Idec. Investment funds hereunder are for the sole purpose of providing the basis for crediting deemed investment results to participants' accounts, and do not represent any actual funds or assets held hereunder for the benefit of participants.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Each participant will indicate with his initial enrollment form (or another form specified by the committee)the investment fund or funds (and the proportion in each fund when the participant designates more than one) he wishes to designate for this purpose. Thereafter. a participant may change his designation with respect to either the deemed investment of future credits to his account(s) hereunder or the deemed transfer of amounts from a previously designated investment fund to another fund. The committee shall establish the frequency with which such a change may be made, the method of making such a change. and the effective date of such a change, and shall prescribe such other rules and procedures as it deems appropriate. Such designation will remain in effect until subsequently changed by the participant in accordance with this paragraph. Following a participant's death and before the payment of any amount due to the participant's beneficiary hereunder has been completed, the beneficiary will exercise the participant's designation powers under this section.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Notwithstanding the preceding paragraph, the committee may establish one or more default investment funds that will be used to determine deemed investment results in the case of any participant or group of participants who have not made a designation under the preceding paragraph. Such default investment fund(s) will be used to determine deemed investment results applicable to the account of such participant or participants until any such participant makes a designation of investment fund(s) in accordance with the plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deemed investment results under this subsection will be credited to a participant's accounts effective as of the last day of each plan year (and as of such other valuation dates during a plan year as the committee may establish).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The value of a participant's accounts at any point in time will be his voluntary deferrals, employer 401(k) restoration credits, transition credits on his behalf, and prior plan and/or Biogen SERP transfer amounts, increased or decreased by deemed investment results as provided in this section through the most recent valuation date. and reduced by any distributions from the participant's accounts.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Fixed Rate Option</font><font style="font-family:Arial;font-size:10pt;">. In addition to the investment funds offered under the Savings Plan as described in (a)&#160;&#160;&#160;&#160;above, a participant who is an active Employee may elect to have his accounts credited with the deemed investment results as if they were invested in a fixed rate option earning a rate of return specified by the committee. The rate of return under the fixed rate option will be 8% for the 2008 plan year. The rate of return of future plan years will be determined each year by the committee.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><a name="s8fb786935a3f46f190c10b7b5b19e69d"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(c)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Exception for Certain Prior Plan Accounts</font><font style="font-family:Arial;font-size:10pt;">. Former participants in the IDEC Pharmaceuticals Corporation Deferred Compensation Plan whose accounts were credited with interest under the fixed rate option available under that plan immediately prior to the date such account was transferred to this plan may continue to have such transferred amount credited with deemed investment results equal to the interest rate under that fixed rate option. Any additional contributions made under this plan will be credited with deemed investment results as described in subsection (a) or (b) above. Amounts being credited with interest under this subsection (c) may be transferred to an option described in subsection (a) or (b) above, but no amounts credited to a participant's accounts may be transferred into the fixed rate option under this subsection (c) (even if such amounts had previously been invested in such investment fund and then transferred to another investment fund).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(d)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Special Rule for Transferred Prior Plan Accounts and Transferred Biogen SERP Accounts</font><font style="font-family:Arial;font-size:10pt;">. In connection with the transfer of participants' prior plan account balances and Biogen SERP account balances to this plan, transferred account balances were initially credited with deemed investment results as if the participant had selected the money market fund investment option under the Savings Plan. Deemed investment results in accordance with the preceding sentence will apply to such transferred account balances until a participant changes such designation in accordance with subsection (a) above.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(e)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Bookkeeping Accounts</font><font style="font-family:Arial;font-size:10pt;">. Participants' accounts and subaccounts will be maintained on the books of the participant's employer for bookkeeping purposes only: such accounts will not represent any property or any secured or priority interest in any trust or in any segregated asset.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In order to facilitate the administration of the plan, the committee may arrange for a participant's account to be divided for recordkeeping purposes into two or more subaccounts, in accordance with procedures established by the committee.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.3&#160;&#160;&#160;&#160;Vesting.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:49px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:40px;">(a)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Employer 40l (k) Restoration Account</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:57px;text-align:left;text-indent:45px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:41px;">(i)</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Before January 1, 2008. </font><font style="font-family:Arial;font-size:10pt;">This subsection (i) will apply to participants who incur a termination of employment before January 1, 2008.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:57px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A participant who is an active employee will have a fully vested interest in his employer 401(k) restoration account at all times on and after his 55th birthday. Before that date, such a participant will have a vested interest in that percentage of his employer 401(k) restoration account specified in the following table based upon his number of years of service under the plan:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:40.511307767944935%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="55%"></td><td width="45%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Years of Service</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Vested Percentage</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Less than 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">25%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">50%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">75%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4 or more</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">100%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:56px;text-indent:46px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">On or After January 1</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">2008. </font><font style="font-family:Arial;font-size:10pt;">This subsection (ii) will apply to participants who are active employees on or after January 1, 2008 (i.e., have not incurred a termination of employment with Biogen Idec, or another employer or other subsidiary or affiliate of Biogen Idec, before January 1, 2008). Each such participant will have a fully vested interest in his employer 401(k) restoration account at all times.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:41px;">(b)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Voluntary Deferred Compensation Account</font><font style="font-family:Arial;font-size:10pt;">. A participant will have a fully vested interest in his voluntary deferred compensation account at all times except that any equity based awards deferred hereunder shall be subject to such vesting requirements as provided under the Biogen Idec Inc. 2008 Omnibus Equity Plan (or successor long term incentive plan) and/or any award agreement applicable to such award.</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><a name="s8fb786935a3f46f190c10b7b5b19e69d"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:41px;">(c)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Transition Account</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:54px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:41px;">(i)</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Before January 1, 2008</font><font style="font-family:Arial;font-size:10pt;">. This subsection (i) will apply to participants who incur a termination of employment before January 1, 2008.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A participant who is an active employee will have a fully vested interest in his transition account at all times on and after his 65th birthday. Before that date, such a participant will have a vested interest in that percentage of his transition contribution account specified in the following table based upon his number of years of service under the plan:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:40.511307767944935%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="55%"></td><td width="45%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Years of Service</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Vested Percentage</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Less than 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">0%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">20%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">50%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">60%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">70%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">80%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7 or more</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">100%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:58px;text-indent:46px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">On or After January 1</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">2008. </font><font style="font-family:Arial;font-size:10pt;">This subsection (ii) will apply to participants who are active employees on or after January 1, 2008 (i.e., have not incurred a termination of employment with Biogen Idec, or another employer or other subsidiary or affiliate of Biogen Idec, before January 1, 2008). Each such participant will have a fully vested interest in his transition account at all times.</font></div><div style="line-height:120%;text-align:left;padding-left:58px;text-indent:46px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:42px;">(d)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Prior Plan Account</font><font style="font-family:Arial;font-size:10pt;">. A participant will have a fully vested interest in his prior plan account at all times.</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:42px;">(e)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Biogen SERP Account</font><font style="font-family:Arial;font-size:10pt;">. A participant who is an active employee will have a fully vested interest in his Biogen SERP account at all times effective January 1, 2004.</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:42px;">(f)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Full Vesting upon Death, Disability or Change in Control</font><font style="font-family:Arial;font-size:10pt;">. Notwithstanding subsections (a)(i) and (c)(i) above (for participants to whom such subsections apply):</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:57px;text-align:left;text-indent:45px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:41px;">(i)</font><font style="font-family:Arial;font-size:10pt;">If a participant's employment by his employer (or another Biogen Idec subsidiary or affiliate) is terminated because of the participant's death or disability, all his accounts hereunder will be fully vested regardless of his number of years of service.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:57px;text-indent:45px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;In the event of a change in control (as defined in Section 2.7(a)), all accounts of all participants still employed by Biogen Idec at such time will be fully vested regardless of a participant's number of years of service.</font></div><div style="line-height:120%;text-align:left;padding-left:57px;text-indent:45px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:54px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:42px;">(g)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Forfeiture of Non-Vested Account Balances</font><font style="font-family:Arial;font-size:10pt;">. If a participant terminates employment with his employer (and all other Biogen Idec subsidiaries or affiliates) under circumstances such that he is not fully vested in one or more accounts in accordance with the preceding subsections, the non-vested balance(s) as of the date of termination of employment will be forfeited and cancelled.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:54px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:42px;">(h)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Meaning of "Fully Vested</font><font style="font-family:Arial;font-size:10pt;">.'' Reference to any account of a participant as "fully vested" means that such account is not subject to forfeiture; however, all participant accounts, including fully vested accounts, are subject to (i) fluctuation as a result of the crediting of deemed investment results (including&#160;&#160;&#160;&#160;to such accounts as provided in the plan and (ii) the possibility of the insolvency or bankruptcy of Biogen Idec (or other employer) (see Section 7.2(a)).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:76px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ARTICLE 6 </font></div><div style="line-height:120%;text-align:center;text-indent:76px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">DISTRIBUTIONS TO PARTICIPANT</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.1&#160;&#160;&#160;&#160;Distributions for Unforeseeable Emergency. I</font><font style="font-family:Arial;font-size:10pt;">f a participant has an unforeseeable emergency prior to his termination of employment with his employer he may apply to the committee for a distribution from the plan. If </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><a name="s8fb786935a3f46f190c10b7b5b19e69d"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">such application for an unforeseeable emergency distribution is approved by the committee, distribution of the approved amount will be made on the date of approval by the committee. The amount of the distribution will be the amount reasonably needed to alleviate the participant's unforeseeable emergency (including the amount necessary to pay any federal, state or local income taxes and penalties reasonably anticipated to result from the distribution), as determined by the committee, up to a maximum of the participant's vested account balances. Such a distribution will be made from the participant's vested accounts in a single lump sum payment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">An unforeseeable emergency is a severe financial hardship affecting the participant resulting from illness or accident of the participant or the participant's spouse, dependent or designated beneficiary, the need to rebuild the participant's principal residence following damage not covered by insurance, or other similar extraordinary and unforeseeable circumstances arising as a result of events beyond the participant's control. A circumstance or of the participant does not constitute an unforeseeable emergency to the extent that the participant's financial need is or may be relieved through reimbursement or compensation by insurance or otherwise, or by liquidation of assets (to the extent that such liquidation would not itself cause severe hardship).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The committee will determine whether a participant has incurred an unforeseeable emergency and the amount needed to alleviate the unforeseeable emergency. A participant is not entitled to a distribution under this section regardless of the participant's circumstances or exigencies, and all such distributions and the amounts thereof are subject to the determination of the committee.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.2&#160;&#160;&#160;&#160;Distribution Upon a Change in Control. </font><font style="font-family:Arial;font-size:10pt;">In the event of a change in control (as defined in Section 2.7(b)), a participant who elected payment of his accounts under the second paragraph of Section 4.4(b)(i) will  receive a lump sum payment equal to the amount credited to his accounts hereunder. Such payment will be made 30 days after the occurrence of the change in control (but not before January 1, 2008 in the case of a change in control that occurs during 2007). This Section 6.2 is effective as of December 26, 2007.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.3&#160;&#160;&#160;&#160;In-Service Distribution(s) at a Time Specified by Participant. </font><font style="font-family:Arial;font-size:10pt;">A participant who is an active Employee may, in accordance with this section and Section 4.4, elect an in-service distribution at a specified future date (but not earlier than five years after the time the participant is making such election) of all or any portion of his vested accounts. If, in his initial enrollment or subsequent change of election form, the participant designated payment of all or any portion of his vested account(s) at a specified time(s) and he is still an employee of Biogen Idec (or another employer or other subsidiary or affiliate) at such time(s), the participant will receive payment of the amount elected, payable on the designated date(s). A participant's election for in-service distributions under this Section 6.3 may be for a single payment or up to five annual payments (with the first payment on the date specified by the participant and subsequent payments made in each subsequent calendar year until all such annual payments have been distributed), in each case in an amount or portion specified by the participant in his initial enrollment or other subsequent change of election form (whichever applies). Each payment will be the amount specified (or the entire vested balance remaining in the participant's accounts, if less). Payments with respect to an in-service distribution election of a flat dollar amount (as opposed to a percentage of the participant's vested account) by a participant who has deferred equity based awards shall be paid from the portion of the participant's vested account that is not attributable to such equity based awards.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Any amount in a participant's accounts hereunder not distributed to the participant under this Section 6.3 will be distributed under Section 6.2 or under Section 6.4 or 6.5, whichever may be applicable, and Section 6.6, if applicable. If a participant is receiving multiple payments under this Section 6.3 and dies or otherwise terminates employment, or (if applicable) there is a change in control, payments under this subsection will cease and subsequent&#160;&#160;&#160;&#160;will be governed by Section 6.4 or 6.5, or Section 6.2, as the case may be.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.4&#160;&#160;&#160;&#160;Distribution upon Death of a Participant.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">In general</font><font style="font-family:Arial;font-size:10pt;">. If a participant dies while still an employee of Biogen Idec (or another employer or other subsidiary&#160;&#160;&#160;&#160;or affiliate) or after termination of such employment, but before the complete distribution of his vested accounts hereunder, his beneficiary will receive the total amount remaining in his vested accounts,&#160;&#160;&#160;&#160;as otherwise provided in Section 6.6, distribution will be made in a single sum payment within 90 days of the date of death.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><a name="s8fb786935a3f46f190c10b7b5b19e69d"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Beneficiary</font><font style="font-family:Arial;font-size:10pt;">. Each participant may designate one or more beneficiaries to receive a distribution payable under subsection (a) above and may revoke or change such a designation at any time. If the participant names two or more beneficiaries, distribution to them will be in such proportions as the participant designates, or if the participant does not so designate, in equal shares. Any such designation of beneficiary will be made in accordance with such procedures or in such form as the committee may prescribe or deem acceptable.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Any portion of a distribution payable upon the death of a participant that is not disposed of by a designation of beneficiary under the preceding paragraph, for any reason whatsoever, will be paid to the beneficiary determined under the following rules:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:57px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:Arial;font-size:10pt;padding-right:38px;">(i)</font><font style="font-family:Arial;font-size:10pt;">If at the participant's death the participant has an account under the Savings Plan and there is a valid designation of beneficiary under the Savings Plan, the beneficiary(ies) will be the same person(s) who is (are) the Savings Plan beneficiary(ies) (in the same proportions, if more than one).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:57px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:38px;">(ii)</font><font style="font-family:Arial;font-size:10pt;">If subsection (a) does not apply, the participant's account(s) hereunder will be paid to the participant's spouse if living at his death, otherwise equally to the participant's natural and adopted children living at his death (and the issue of a deceased child by right of representation), otherwise to the participant's estate. For purposes of the preceding sentence, a spouse includes a spouse of the same gender as the participant if the marriage occurred in a jurisdiction that recognizes as valid marriages between persons of the same gender.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The committee may direct payment in accordance with a prior designation of beneficiary (and will be fully protected in so doing) if such direction (i) is given before a later designation is received, or (ii) is due to the committee's inability to verify the authenticity of a later designation. Such a distribution will discharge all liability therefor under the plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.5&#160;&#160;&#160;&#160;Distribution upon Participant's Termination of Employment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Time and Form of Payment</font><font style="font-family:Arial;font-size:10pt;">. Following a participant's termination of employment (including as a result of disability) for any reason other than death, except as otherwise provided in Section 6.6, the participant will receive a single sum payment equal to his vested account balance, payable on the first business day following the six-month anniversary of the participant's termination of employment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Termination of Employment</font><font style="font-family:Arial;font-size:10pt;">. For purposes of this plan, a participant will have a termination of employment only if the provisions of the regulations under Code Section 409A defining "separation from service" are satisfied.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.6&#160;&#160;&#160;&#160;Installment Distributions in Certain Cases.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Participant</font><font style="font-family:Arial;font-size:10pt;">. Notwithstanding the provisions of Section 6.5, a participant may, at the time of filing his initial enrollment form under Section 4.4(b)(i) (or, if applicable, in a subsequent election under Section 4.4(b)(ii)), designate that the amount payable to him hereunder upon termination of employment will be paid in a number (minimum of two and maximum of fifteen) of annual installment payments, as specified by the participant. However, in the event the participant's vested account balance as of the date that installment distributions would begin in accordance with Section 6.5 is equal to or less than the limit under Code Section 402(g)(1)(B) and (g)(4) (as in effect at such time-for example, $15,500 during 2008), such vested account balance will be automatically paid in the form of a lump sum payment to the extent not prohibited by the regulations under Code Section 409A.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Beneficiary</font><font style="font-family:Arial;font-size:10pt;">. Notwithstanding Section 6.4, a participant may at the time of&#160;&#160;&#160;&#160;his initial enrollment form under Section 4.4 (or, if applicable, in a subsequent election), designate that, if the participant dies before&#160;&#160;&#160;&#160;the entire amount payable to him hereunder, the beneficiary will receive either:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:60px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:36px;">(i)</font><font style="font-family:Arial;font-size:10pt;">A number of annual installment payments equal to:</font></div><div style="line-height:120%;text-align:left;padding-left:60px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:108px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:36px;">(A)</font><font style="font-family:Arial;font-size:10pt;">the number the participant elected for himself under subsection (a) above (if the participant dies before any installment payments), or</font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><a name="s8fb786935a3f46f190c10b7b5b19e69d"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:108px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:36px;">(B)</font><font style="font-family:Arial;font-size:10pt;">the number of remaining installment payments due to the participant under subsection (a) above (if the participant dies after receiving one or more installment payments) or</font></div><div style="line-height:120%;text-align:left;padding-left:108px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:60px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:36px;">(ii)</font><font style="font-family:Arial;font-size:10pt;">A</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:10pt;">single payment.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Payment to the beneficiary (or the first installment) will be made at the time provided in Section 6.4(a).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If the participant fails to designate the form of payment to the beneficiary, the default form of payment will payment under (ii) above.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(c)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Installment payments</font><font style="font-family:Arial;font-size:10pt;">. Where installment payments are due, the first annual installment payment will be made on the date specified in Section 6.4 or 6.5 (whichever is applicable) and subsequent annual installments will be made in each subsequent calendar year until all such annual payments have been distributed. The amount of each annual installment payment will be determined by multiplying the then amount of the participant's vested account balances by a fraction whose numerator is one and whose denominator is the number of remaining annual installment payments. Installment payments with respect to equity based awards shall be made in shares and shall not include any fractional shares.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(d)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Death of Beneficiary</font><font style="font-family:Arial;font-size:10pt;">. If a participant's designated beneficiary is receiving installment payments and dies before receiving payment of all the annual installments, the deceased beneficiary's estate will receive a lump sum payment of the amount remaining to be distributed to such beneficiary. Such payment will be made within 90 days of the date of death.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(e)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Deemed Single Payment</font><font style="font-family:Arial;font-size:10pt;">. As provided in the regulations under Code Section 409A, installment payments to a participant will be deemed a single payment on the date of the first installment for purposes of the anti-acceleration rule (Section 4.4(b) and Section 6.9) and the rules governing the timing of changes in elections with respect to time and form of payment hereunder (Section 4.4(b)).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.7&#160;&#160;&#160;&#160;Certain Other Distributions. </font><font style="font-family:Arial;font-size:10pt;">In addition to the distributions provided for in the preceding sections of this Article 6, the committee may provide for a distribution from a participant's account(s) under the following circumstances:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Domestic Relations Order</font><font style="font-family:Arial;font-size:10pt;">. Distribution of the amount necessary to fulfill the requirements of a domestic relations order (as defined in Code Section 414(p)) requiring the payment of all or a portion of the participant's vested account(s) to another individual (see Section 7.3(b)).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Conflicts of Interest</font><font style="font-family:Arial;font-size:10pt;">. Distribution to the extent reasonably necessary to comply with a federal government ethics agreement or a federal, state, local or foreign ethics or conflicts of interest law (as described in the regulations under Code Section 409A).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(c)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Violation of Code Section 409A</font><font style="font-family:Arial;font-size:10pt;">. In the event that, notwithstanding the intent that this plan satisfy in form and operation the requirements of Code Section 409A, it is determined that the requirements of Code Section 409A have been violated with respect to one or more accounts of any participant or group of participants, distribution of the amount determined to be includable in taxable income of such participant or participants as a result of such a violation of Code Section 409A shall be made to such participant(s).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(d)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Other Circumstances</font><font style="font-family:Arial;font-size:10pt;">. Distribution of any amount specifically permitted by Code Section 409A and the regulations thereunder.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.8&#160;&#160;&#160;&#160;Delay in Distributions. </font><font style="font-family:Arial;font-size:10pt;">Notwithstanding the provisions of any of the foregoing sections in this Article 6, the committee may delay the making of any payment due to a subsequent date, provided that the delayed payment is made not later than the latest time permitted under Code Section 409</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">A </font><font style="font-family:Arial;font-size:10pt;">and the regulations and rulings thereunder (generally, the later of the end of the calendar year in which the specified payment date occurs or the 15th day of the third month after the specified payment date).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.9&#160;&#160;&#160;&#160;Compliance with Code Section 409A. </font><font style="font-family:Arial;font-size:10pt;">Notwithstanding any</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:10pt;">other provision</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Arial;font-size:10pt;">of this plan (including, without limitation, Section 6.7(c)), distributions and elections respecting distributions are intended to be and will </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><a name="s8fb786935a3f46f190c10b7b5b19e69d"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">be administered in accordance with the&#160;&#160;&#160;&#160;of Code Section 409A and the regulations and rulings thereunder(including the provisions prohibiting acceleration of payment unless specifically permitted by such regulations and rulings).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:261px;text-indent:1px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ARTICLE 7 MISCELLANEOUS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.1</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Amendment or Termination of Plan. </font><font style="font-family:Arial;font-size:10pt;">Biogen Idec, by action of the Board or of the Compensation Committee (or such other committee thereof or officer or officers of Biogen Idec to whom the Board or Compensation Committee has delegated this authority), at any time and from time to time, may amend or modify any or all of the provisions of this plan or may terminate this plan without the consent of any participant (or beneficiary or other person claiming through a participant). In addition, any amendment may be made by the committee, or by the Executive Vice President - Chief Financial Officer, or the Executive Vice President - Human Resources of Biogen Idec except for an amendment that would materially increase or reduce the benefits of the plan to participants or materially increase the cost of maintaining the plan to the employers; such committee or specified officer(s) may not terminate the plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Notwithstanding the preceding paragraph, no termination or amendment of the plan may reduce the amounts credited to the accounts of any participant under the plan (including a participant whose employment with the employer was terminated before such plan termination or amendment) or the vested percentages of such accounts. However, Biogen Idec may change the deemed investment options under Section 5.2, and Biogen Idec may upon termination of this plan pay participants' account balances to the participants regardless of the times elected for payment (or the start of installment payments) elected by the participants and may pay such amounts in single sum payments regardless of whether installment distributions would otherwise be payable under Section 6.6; provided that any such distributions upon plan termination must be permitted by Code Section 409A and the regulations and rulings thereunder. In addition, Biogen Idec may, from time to time, make any amendment that it deems necessary or desirable to satisfy the applicable requirements of the tax laws and rulings and regulations thereunder in order to preserve, if possible, the tax deferral features of this plan for participants. No diminution or restriction on a participant's opportunity to make elections or withdrawals, or exercise other privileges or rights hereunder, pursuant to the preceding sentence will be deemed to violate the rights of any participant or beneficiary hereunder so long as such change does not effect a forfeiture of any of a participant's account balances hereunder or render an account balance (or portion thereof) which previously was nonforfeitable forfeitable. Any amendment that is required by Code Section 409A and the regulations and rulings thereunder to have a delayed effective date will be effective no earlier than such required date.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.2&#160;&#160;&#160;&#160;Benefits Not Currently Funded.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;">Nothing in this plan will be construed to create a trust or to obligate Biogen Idec to segregate a fund, purchase an insurance contract or other investment, or in any other way currently to fund the future payment of any benefits hereunder, nor will anything herein be construed to give any participant or any other person rights to any specific assets of Biogen Idec or any other entity. However, in order to make provision for its obligations hereunder, Biogen Idec (or other employer) may in its discretion purchase an insurance contract or other investment; any such contract or investment will be a general asset belonging to Biogen Idec (or other employer), and no participant or beneficiary will have any rights to any such asset. The rights of a participant or beneficiary hereunder will be solely those of a general, unsecured creditor of his employer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:42px;">(b)</font><font style="font-family:Arial;font-size:10pt;">Notwithstanding subsection (a) above, Biogen Idec or other employer) in its sole discretion may establish a grantor trust of which it is treated as the owner under Code Section 671 to provide for the payment of benefits hereunder, subject to such terms and conditions as Biogen Idec (or other employer) may deem necessary or advisable to ensure that trust assets and benefit payments are not includable, by reason of the trust, in the taxable income of trust beneficiaries before actual distribution and that the existence of the trust does not cause the plan or any other arrangement to be considered funded for purposes of Title I of ERISA. Biogen Idec may terminate any such trust in accordance with its terms.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><a name="s8fb786935a3f46f190c10b7b5b19e69d"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.3&#160;&#160;&#160;&#160;No Assignment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:42px;">(a)</font><font style="font-family:Arial;font-size:10pt;">No participant or beneficiary will have any power or right to transfer, assign, anticipate or otherwise encumber any benefit or amount payable under this plan, nor shall any such benefit or amount payable be subject to seizure or attachment by any creditor of a participant or a beneficiary, or to any other legal, equitable or other process, or be liable for, or subject to, the debts, liabilities or other obligations of a participant or beneficiary except as otherwise required by law.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:42px;">(b)</font><font style="font-family:Arial;font-size:10pt;">Notwithstanding subsection (a)</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:10pt;">above, all or a portion of a participant's account balances may be assigned to the participant's spouse, former spouse, or other dependent (for purposes of this section, an ''alternate recipient") in connection with a domestic relations order (as defined in Code Section 414(p)) awarding such portion(s) to the alternate recipient. However, no such order may award to an alternate recipient greater rights than the participant has with respect to his account. If any portion of an account so assigned is not fully vested at such time, such portion will vest only in accordance with the applicable provisions of this plan based upon the participant's years of service. Upon receipt of a copy of the relevant provisions of any such order or property settlement agreement, certified or represented to the committee's satisfaction to be accurate and in effect, and an acknowledgment by the alternate recipient that such alternate recipient will be responsible for income taxes on such amounts when distributed or made available to such alternate recipient and that such amounts are subject to income tax withholding as provided in this plan, and such other information (including the alternate recipient's social security number) as the committee may reasonably request, the committee will assign such amount to a separate account hereunder and will distribute such account to the alternate recipient in the form of a single sum payment as soon as administratively possible, as permitted by Reg. 1.409A-3(j)(4)(ii) (except for any unvested amounts) as provided in Section 6.7(a).</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.4&#160;&#160;&#160;&#160;Effect of Change in Control.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Amendments</font><font style="font-family:Arial;font-size:10pt;">. Notwithstanding Section 7.1, following the occurrence of a change in control (as defined in Section 2.7(a)): no amendment will be made following a change in control without the consent of the affected participant (or beneficiary or other person claiming through a participant) that adversely affects the rights of a participant (or beneficiary or other person claiming through a participant) under the plan as in effect immediately before such change in control, including (i) the right to make elections concerning the form and time of payment of distributions in accordance with Section 4.4(b) and the right to receive distributions in the form elected by the participant thereunder; and (ii) the right to the investment funds or options specified herein for the determination of deemed investment results applicable to participants' accounts, as in effect immediately before such change in control. In particular, for purposes of clause (ii) of the preceding sentence: (i) the committee may not set the rate of return under Section 5.2(b) at a rate lower than that available under life insurance or annuity contracts obtained by a vendor or service provider (currently, The Newport Group) for purposes of the plan; and (ii) the committee will maintain a menu of investment funds under Section 5.2(a) that is substantially similar (in terms of investment styles and ability to position account(s) on a risk/reward spectrum) to the array of funds available immediately prior to the change in control.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Termination</font><font style="font-family:Arial;font-size:10pt;">. The plan will not be terminated before the payment of all benefits hereunder in accordance with the terms of the plan as in effect immediately before such change in control without the consent of a majority of the participants (including, in the case of the deceased participant, the beneficiary or other person claiming through such deceased participant). This subsection (b) will not preclude the merger of this plan into a nonqualified deferred compensation plan maintained by a successor to Biogen Idec provided that the benefits and rights of participants hereunder (including this Section 7.4) are preserved in such successor plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:54px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Effective Date</font><font style="font-family:Arial;font-size:10pt;">. This Section 7.4 is effective as of December 26, 2007.</font></div><div style="line-height:120%;text-align:left;padding-left:54px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.5&#160;&#160;&#160;&#160;Responsibilities and Authority of Committee. </font><font style="font-family:Arial;font-size:10pt;">The committee will control and manage the operation and administration of the plan except to the extent that such responsibilities are specifically assigned hereunder to Biogen Idec, the Board or the Compensation Committee, or to a specified officer of Biogen Idec.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The committee will have all powers and authority necessary or appropriate to carry out its responsibilities for the operation and administration of the plan. It will have discretionary authority to interpret and apply all plan provisions and may correct any defect, supply any omission or reconcile any inconsistency or ambiguity in such manner as it deems advisable. It will make all final determinations concerning eligibility, </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><a name="s8fb786935a3f46f190c10b7b5b19e69d"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">benefits and rights hereunder, and all other matters concerning plan administration and interpretation. All determinations and actions of the committee will be conclusive and binding upon all persons, except as otherwise provided herein or by law, and except that the committee may revoke or modify a determination or action previously made in error. It is intended that any action or inaction by the committee will be given the maximum possible deference by any reviewing body (whether a court or other reviewing body), and will be reversed by such reviewing court or other body only if found to be arbitrary and capricious.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:56px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Biogen Idec will be the "plan administrator" and the "named fiduciary" for purposes of ERISA.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.6</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Limitation on Rights Created by Plan. </font><font style="font-family:Arial;font-size:10pt;">Nothing appearing in the plan will be construed (a) to give any person any benefit, right or interest except as expressly provided herein, or (b) to create a contract of employment or to give any employee the right to continue as an employee or to affect or modify his terms of employment in any way.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.7&#160;&#160;&#160;&#160;Tax Withholding. </font><font style="font-family:Arial;font-size:10pt;">Any payment hereunder to a participant, beneficiary or alternate recipient will be subject to withholding of income and other taxes to the extent required by law. In addition, amounts that were owed as FICA or other withholding on amounts previously credited to a participant's account hereunder, but that were not correctly paid at the time owed, may in the discretion of the committee be deducted from the participant's account.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.8&#160;&#160;&#160;&#160;Text Controls.   </font><font style="font-family:Arial;font-size:10pt;">Headings and titles are for convenience only, and the text will control in all matters.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.9&#160;&#160;&#160;&#160;Applicable State Law. </font><font style="font-family:Arial;font-size:10pt;">To the extent that state law applies, the provisions of the plan will be construed, enforced and administered according to the laws of the Commonwealth of Massachusetts.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.10&#160;&#160;&#160;&#160;Paperless Administration. </font><font style="font-family:Arial;font-size:10pt;">The committee may establish procedures whereby an electronic, internet or voice recognized authorization or election will or may be utilized under the plan in lieu a written form or document otherwise required by the terms of the plan. In such event, any reference herein to a written election. authorization or other form shall be deemed to include such other authorization or election.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:432px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">BIOGEN IDEC INC.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:432px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"></font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">/s/ Paul Clancy</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:432px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:432px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dated: December 13, 2011</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><a name="sdca593381158460eb4872801273ccbdb"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:5px;text-align:center;padding-left:172px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">APPENDIX A</font></div><div style="line-height:120%;padding-top:5px;text-align:center;padding-left:172px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:center;padding-left:172px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Historical Information; Amendments</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">A.1&#160;&#160;&#160;&#160;Adoption of Plan Document. </font><font style="font-family:Arial;font-size:10pt;">This plan document, effective as of January 1, 2004, was approved by the Corporation (Biogen Idec Inc.) under the initial name of "Biogen Idec Inc. Voluntary Executive Supplemental Savings Plan." Prior to execution of the plan document, the name of the plan was changed to "Biogen Idec Inc. Supplemental Savings Plan."</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By appropriate votes, (i) the lDEC Pharmaceuticals Corporation Deferred Compensation Plan maintained by IDEC Pharmaceuticals Corporation, (ii) the Biogen, Inc. Voluntary Executive Supplemental Savings Plan maintained by Biogen, Inc.. and (iii) the Biogen, Inc. Supplemental Executive Retirement Plan maintained by Biogen, Inc. prior to the merger transaction, were merged into this plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">A.2&#160;&#160;&#160;&#160;2005 Amendment and Restatement. </font><font style="font-family:Arial;font-size:10pt;">The plan was amended and restated in its entirety, effective as of January 1, 2005 (except as otherwise specified), primarily to comply with the requirements of Code Section 409A and regulations thereunder. During the period from January 1, 2005 until the date of execution of this amended and restated plan document, the plan was interpreted and administered in accordance with a good faith interpretation of the requirements of Code Section 409A and applicable guidance of the Internal Revenue Service thereunder.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The provisions herein relating to distributions and other changes upon the occurrence of a change in control (primarily Sections 2.7(b), 4.4(b), 6.2 and 7.4) are effective as of the date of execution of this amended and restated plan document. The provisions relating to full vesting of all accounts (subsections 5.3(a) and (c)) and the increase in the threshold for the payment of a lump sum in place of installments from $10,000 to the Code Section 402(g)(1)(B) and (g)(4) limit (the last sentence of subsection 6.6(a)) are effective as of January 1, 2008.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">A.3&#160;&#160;&#160;&#160;February 2008 Restatement.  </font><font style="font-family:Arial;font-size:10pt;">The plan was amended and restated in its entirety effective as of February 1, 2008, primarily to provide for the deferral of non-recurring bonus amounts.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">A.4&#160;&#160;&#160;&#160;October 2008 Restatement. </font><font style="font-family:Arial;font-size:10pt;">The plan was amended and restated in its entirety effective October 1, 2008, to update the reference in the Change in Control definition to the 2008 Omnibus Equity Plan and to modify the distribution provisions applicable to inactive participants with Biogen SERP accounts whereby distributions shall be made as of July 1, 2009 in either a lump sum payment or in installments. For a participant who elects installments, the participant's account shall no longer be credited with interest credits under Section 8.3 but shall be invested in the same manner as other plan participants.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">A.5&#160;&#160;&#160;&#160;January 2010 Restatement. </font><font style="font-family:Arial;font-size:10pt;">The plan was amended and restated in its entirety effective January 1, 2010, to allow an employee who is eligible under Section 3.1(a) to elect to defer payments made under Biogen Idec's long term incentive award program which are settled in cash. Such amounts are considered non-recurring bonus amounts hereunder.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">A.6&#160;&#160;&#160;&#160;January 2012 Restatement. </font><font style="font-family:Arial;font-size:10pt;">The plan was amended and restated in its entirety effective as of January 1, 2012 to expand the tax-deferred savings opportunities by allowing eligible participants to defer certain equity based awards granted under the Biogen Idec lnc. 2008 Omnibus Equity Plan (or successor long term incentive plan) whether or not settled in cash or shares. Such amounts are considered non-recurring bonus amounts  hereunder.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="font-family:Times New Roman;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A-1</font></div></div><hr style="page-break-after:always"><a name="s8de2c213ba644524b59342b4dc843b5a"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:10px;text-align:center;padding-left:177px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">APPENDIX B</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:177px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Biogen, Inc. Supplemental Executive Retirement Plan</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">B.1&#160;&#160;&#160;&#160;Applicability.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(a)&#160;&#160;&#160;&#160;The provisions of this Appendix B will govern the treatment of transferred Biogen SERP account balances (or supplemental pension benefit formula benefit under Section 4.1(a) of the Biogen SERP, if applicable) of persons who were entitled to a benefit under the Biogen SERP but who were not active employees of Biogen Idec or any of its subsidiaries or other affiliates as of the date of transfer. To the extent that the provisions of this Appendix B are applicable, they will govern over any other provisions of this plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:102px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A participant whose Biogen SERP account (or supplemental pension formula benefit, if applicable) is governed by this Appendix will be referred to as an "Appendix B participant."</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:10pt;">This Appendix B will not apply to any transferred Biogen SERP account balances of any person who was an active employee of Biogen Idec (or any of its subsidiaries or other affiliates) as of the date of transfer as described in Section 3.1(c) and 5.1(e). The other provisions of this plan (including, without limitation, the crediting of deemed investment experience and the distribution provisions) will govern such transferred SERP account balance.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(c)</font><font style="font-family:Arial;font-size:10pt;">For purposes of Code Section 409A, prior to the changes made to this Appendix B effective October 1, 2008, this Appendix B will be treated as a separate grandfathered non-qualified deferred compensation plan not subject to the requirements of such section.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">B.2&#160;&#160;&#160;&#160;Amount Transferred.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For an Appendix B participant in the excess benefit formulas in Section 4.2 of the Biogen SERP, the  amount transferred from the Biogen SERP to this plan on behalf of an Appendix B participant was the vested amount in the Appendix B participant's Biogen SERP account as of his or her date of termination of employment, with subsequent interest credits on such amounts in accordance with the terms of the Biogen SERP. The full vesting provisions of Section 5.3(e) of this plan will not apply to an Appendix B  participant.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">B.3&#160;&#160;&#160;&#160;Interest Credits.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For periods prior to July 1, 2009, interest credits shall continue to be added to each Appendix B participant's Biogen SERP account as of the last day of the plan year based on the amount of the participant's Biogen SERP account balance as of the first day of the plan year in the same manner as interest credits were added before such transfer.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The annual rate of interest used to determine the interest credit shall be the annual average of the yield on the one-year Treasury Bill constant maturity rate for the preceding plan year plus 100 basis points. However, in no event shall the annual interest rate be less than 5.25% or more than 10.0%.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Notwithstanding the foregoing, for any plan year in which a plan benefit commences, an interest credit shall be added on the amount of the participant's Biogen SERP account balance as of the first day of the plan year for the period from the first day of such plan year until the participant's expected date of distribution. The interest rate shall be the annual interest rate as described above multiplied by the number of complete months since the end of the prior plan year divided by 12. Interest credits shall continue to be made during any period in which payment of an Appendix B participant 's benefit is being deferred. In no event will interest credits be made after benefits have commenced.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effective July 1, 2009. for any Appendix B participant who elects to receive his distribution in installments rather than a lump sum payment commencing as of such date in accordance with Section B.4, the participant's Biogen SERP account balance shall no longer be credited with interest credits under this Section B.3 but shall be invested in accordance with Section 5.2.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="font-family:Times New Roman;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">B-</font><font style="font-family:Arial;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><a name="s8de2c213ba644524b59342b4dc843b5a"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">B.4&#160;&#160;&#160;&#160;Distributions.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;">With respect to an Appendix B participant who has not commenced distribution of his Biogen SERP account by October 1, 2008, distribution of such participant's Biogen SERP account shall be made, or commence, as of July 1, 2009. Such a participant shall be furnished a distribution election form whereby the participant may elect to receive his Biogen SERP account as of such date in either a single lump sum payment or in installments as prescribed in Section 6.6. If a participant fails to make an election, the default form of payment will be a single lump sum payment. The lump sum payment amount shall be the amount credited to the participant's account as of such date of payment including interest credits, as described in Section B.3, to such date. If the participant elects payment of his Biogen SERP account in installments, Section 6.6 shall apply in determining the amount and timing of the annual installments and payment in the event of death.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:10pt;">Prior to October 1, 2008, an Appendix B participant's Biogen SERP account (or supplemental pension formula benefit, if applicable) will be paid in the same form and beginning at approximately the same time that his benefit under the Retirement Plan is payable, subject to the following rules. Notwithstanding the preceding sentence, if a participant elects a lump sum form of payment under the Retirement Plan, payment in such form under this plan will be subject to the approval of the  committee.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(i)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Annuity Options</font><font style="font-family:Arial;font-size:10pt;">. If an Appendix B participant's Biogen SERP account balance (or supplemental pension formula benefit, if applicable) is payable in any form other than a lump sum, the actuarial factors used to convert his Biogen SERP account balance to such other form of payment will be the same as the factors used for such purpose in the Retirement  Plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(ii)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Lump Sum</font><font style="font-family:Arial;font-size:10pt;">. If an Appendix B participant's Biogen SERP account is payable in a single sum, the payment amount is the amount credited to the participant's account as of the date of payment, with interest credits hereunder to such date (or as close thereto as is practicable). For a participant with a supplemental pension benefit under Section 4.1(a) of the Biogen SERP, the amount of lump sum payment shall be the supplemental pension amount converted to a single lump sum using the assumptions set forth in the Biogen Retirement Plan for such purpose.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(iii)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Lump Sum Override.</font><font style="font-family:Arial;font-size:10pt;">&#32;Notwithstanding the preceding provisions of this section, if an Appendix B participant's Biogen SERP account balance (or lump sum value of his supplemental pension benefit, if applicable) is $10,000 or less as of the date that distribution would be made, such amount will be paid in the form of a lump sum payment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">B.5&#160;&#160;&#160;&#160;Death Benefits.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Applicability of this Section</font><font style="font-family:Arial;font-size:10pt;">. This section specifies the benefits payable upon the death of an Appendix B participant, either before or after the date his benefit payments hereunder begin. Except as specified in this section, no benefits are payable upon the death of an Appendix B participant.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Preretirement Death Benefits</font><font style="font-family:Arial;font-size:10pt;">. If an Appendix B participant dies before the date when his Biogen SERP account balance is converted to an annuity (or installments) or paid to such participant, his beneficiary will receive payment of the participant's Biogen SERP account balance (or value of supplemental pension benefit, if applicable). Such amount will be paid in a single payment to the beneficiary.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;If a participant dies while receiving installment payments hereunder, his beneficiary will receive the death benefit as described in Section 6.6.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="font-family:Times New Roman;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">B-</font><font style="font-family:Arial;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><a name="s08c5a613f3d648dab7928026dd269ce9"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:3px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;font-weight:bold;">Biogen Idec Inc. </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;font-weight:bold;">Supplemental Savings </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;font-weight:bold;">Plan</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">First Amendment </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">to </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">the January </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">1, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">2012 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Amended </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">and </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Restated </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Document</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;padding-left:10px;text-indent:46px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">WHEREAS, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Idec </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Inc. (the </font><font style="font-family:Arial;font-size:10pt;color:#414141;">"Em</font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">ployer</font><font style="font-family:Arial;font-size:10pt;color:#414141;">") </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">established </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the Biogen </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Idec </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Inc</font><font style="font-family:Arial;font-size:10pt;color:#414141;">. </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Supplemental Savings </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Plan</font><font style="font-family:Arial;font-size:10pt;color:#414141;">, </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">most recently </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">amended and </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">restated </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">effective as </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">of </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">January </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">1, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">2012 (the </font><font style="font-family:Arial;font-size:10pt;color:#414141;">"</font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Plan");</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">WHEREAS, </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Section </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">7.1 of </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Plan provides the Employer the </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">right to amend </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">or </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">modify </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">any </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">and all </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">provisions of the </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Plan by </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">action of </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Board or of </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Compensation Committee </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">(</font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">or </font><font style="font-family:Arial;font-size:10pt;color:#414141;">s</font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">uch </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">other </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">committee thereof </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">or </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">officer or </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">officers of </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Biogen </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Idec to whom the </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Board </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">or Compensation Committee </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">has delegated this </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">authority); and further, </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">that </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">any amendment </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">may </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">be made by </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Committee or </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">by the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Executive Vice </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">President </font><font style="font-family:Arial;font-size:10pt;color:#777777;">- </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Chief </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Financial </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Officer, or Executive Vice </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Presid</font><font style="font-family:Arial;font-size:10pt;color:#414141;">e</font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">nt - Human </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Resources, except for an amendment </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">that </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">would </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">materially increase </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">or </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">reduce the benefits of the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Plan </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">to participants </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">or materially </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">incr</font><font style="font-family:Arial;font-size:10pt;color:#414141;">e</font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">ase the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">cost </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">of maintaining the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Plan </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">to the Employer</font><font style="font-family:Arial;font-size:10pt;color:#414141;">; </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">WHEREAS</font><font style="font-family:Arial;font-size:10pt;color:#414141;">, </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Employer </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">d</font><font style="font-family:Arial;font-size:10pt;color:#414141;">esi</font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">res </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">to amend </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Plan to eliminate the ability </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">to defer </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">any </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">restricted </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">stock units, market stock </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">units, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">or other equity </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">based </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">awards </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">that may be </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">granted </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">beginning </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">on </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">or </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">after </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">January 1, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">2015 under the Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Idec Inc. </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Amended and </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Restated </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">2008 </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Omnibus </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Equity </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">NOW, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">THEREFORE, </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the Plan is </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">amended </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">effective </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">as </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">of January 1, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">2015 as </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">set forth below:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Section </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">2.16, </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the definition </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">of </font><font style="font-family:Arial;font-size:10pt;color:#414141;">"</font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">non-recurring </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">bonus amounts", </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">is </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">amended </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">by deleting the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">second sentence </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">thereof and </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">substituting </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">following sentence therefor:</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">"For </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">th</font><font style="font-family:Arial;font-size:10pt;color:#414141;">e </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">period beginning January 1, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">2012 </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">and </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">ending on December </font><font style="font-family:Arial;font-size:10pt;color:#414141;">3</font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">1, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">2014 only, </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">non-recurring bonus </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">amounts shall include any restricted stock units, </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">market </font><font style="font-family:Arial;font-size:10pt;color:#414141;">s</font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">tock units</font><font style="font-family:Arial;font-size:10pt;color:#414141;">, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">or other equity </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">based </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">awards that </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">may be </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">granted </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">during </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">such </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">period under </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">the </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Biogen Idec Inc</font><font style="font-family:Arial;font-size:10pt;color:#414141;">. </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Amended and </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Restated </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">2008 </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Omnibus </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Equity Plan."</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Section 4.4(a)(ii) </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">(Voluntary Deferrals </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">from </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Non-Recurring Bonu</font><font style="font-family:Arial;font-size:10pt;color:#414141;">s </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Amounts) </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">is </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">amended </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">by adding the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">following </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">new paragraph to the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">end </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">thereof:</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#414141;">"No</font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">twithstanding anything in this plan to the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">contrary, </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">no </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">eligible employee shall </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">be permitted to </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">elect </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">to defer </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">equity grants, </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">including restricted </font><font style="font-family:Arial;font-size:10pt;color:#414141;">stock </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">or market stock </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">unit awards </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">that are granted under </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Idec Inc</font><font style="font-family:Arial;font-size:10pt;">. </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Amended and </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Restated </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">2008 Omnibus </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Equity Plan beginning </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">on or after January </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">1, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">2015."</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Section 6.4 (Distribution </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">upon Death </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">of a Participant) </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">is </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">amended by deleting </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">second </font><font style="font-family:Arial;font-size:10pt;color:#414141;">se</font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">ntence of </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">subsection (b)(ii) </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">thereof </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">and </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">replacing it </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">with </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the following:</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">"For all </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">purpo</font><font style="font-family:Arial;font-size:10pt;color:#414141;">se</font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">s under the plan</font><font style="font-family:Arial;font-size:10pt;color:#414141;">, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">"spouse" shall </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">have the same </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">meaning as </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">under the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Savings </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Plan."</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#363636;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;">Appendix </font><font style="font-family:Arial;font-size:10pt;color:#262626;">A, </font><font style="font-family:Arial;font-size:10pt;color:#363636;">"Historical </font><font style="font-family:Arial;font-size:10pt;color:#262626;">Information; Amendments"</font><font style="font-family:Arial;font-size:10pt;color:#545454;">, </font><font style="font-family:Arial;font-size:10pt;color:#262626;">is </font><font style="font-family:Arial;font-size:10pt;color:#363636;">amended </font><font style="font-family:Arial;font-size:10pt;color:#262626;">by </font><font style="font-family:Arial;font-size:10pt;color:#363636;">adding a </font><font style="font-family:Arial;font-size:10pt;color:#262626;">new Sect</font><font style="font-family:Arial;font-size:10pt;color:#0a0a0a;">i</font><font style="font-family:Arial;font-size:10pt;color:#363636;">on </font><font style="font-family:Arial;font-size:10pt;color:#262626;">A.7 to read </font><font style="font-family:Arial;font-size:10pt;color:#363636;">as follows:</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;">"A.7</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#363636;font-weight:bold;">2015 </font><font style="font-family:Arial;font-size:10pt;color:#262626;font-weight:bold;">Amendment. </font><font style="font-family:Arial;font-size:10pt;color:#262626;">The plan </font><font style="font-family:Arial;font-size:10pt;color:#363636;">was amended to </font><font style="font-family:Arial;font-size:10pt;color:#262626;">eliminate the </font><font style="font-family:Arial;font-size:10pt;color:#363636;">ability </font><font style="font-family:Arial;font-size:10pt;color:#262626;">to defer </font><font style="font-family:Arial;font-size:10pt;color:#363636;">any restricted stock </font><font style="font-family:Arial;font-size:10pt;color:#262626;">units</font><font style="font-family:Arial;font-size:10pt;color:#545454;">, </font><font style="font-family:Arial;font-size:10pt;color:#262626;">market </font><font style="font-family:Arial;font-size:10pt;color:#363636;">stock </font><font style="font-family:Arial;font-size:10pt;color:#262626;">units, </font><font style="font-family:Arial;font-size:10pt;color:#363636;">or </font><font style="font-family:Arial;font-size:10pt;color:#262626;">other equity based awards t</font><font style="font-family:Arial;font-size:10pt;color:#0a0a0a;">h</font><font style="font-family:Arial;font-size:10pt;color:#262626;">at may be granted b</font><font style="font-family:Arial;font-size:10pt;color:#545454;">e</font><font style="font-family:Arial;font-size:10pt;color:#262626;">ginning </font><font style="font-family:Arial;font-size:10pt;color:#363636;">on or </font><font style="font-family:Arial;font-size:10pt;color:#262626;">after January </font><font style="font-family:Arial;font-size:10pt;color:#0a0a0a;">1</font><font style="font-family:Arial;font-size:10pt;color:#363636;">, 2015 </font><font style="font-family:Arial;font-size:10pt;color:#262626;">under </font><font style="font-family:Arial;font-size:10pt;color:#363636;">the </font><font style="font-family:Arial;font-size:10pt;color:#262626;">Biogen Idec Inc</font><font style="font-family:Arial;font-size:10pt;color:#0a0a0a;">. </font><font style="font-family:Arial;font-size:10pt;color:#363636;">Amended </font><font style="font-family:Arial;font-size:10pt;color:#262626;">and Restated </font><font style="font-family:Arial;font-size:10pt;color:#363636;">2008 </font><font style="font-family:Arial;font-size:10pt;color:#262626;">Omnibus </font><font style="font-family:Arial;font-size:10pt;color:#363636;">Equity </font><font style="font-family:Arial;font-size:10pt;color:#262626;">P</font><font style="font-family:Arial;font-size:10pt;color:#0a0a0a;">l</font><font style="font-family:Arial;font-size:10pt;color:#262626;">an."</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#363636;">IN </font><font style="font-family:Arial;font-size:10pt;color:#262626;">WITNESS WHEREOF, the Employe</font><font style="font-family:Arial;font-size:10pt;color:#545454;">r </font><font style="font-family:Arial;font-size:10pt;color:#262626;">has caused</font><font style="font-family:Arial;font-size:10pt;color:#363636;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#262626;">this instrument to be</font><font style="font-family:Arial;font-size:10pt;color:#363636;">&#32;executed by </font><font style="font-family:Arial;font-size:10pt;color:#262626;">an authorized </font><font style="font-family:Arial;font-size:10pt;color:#363636;">officer on </font><font style="font-family:Arial;font-size:10pt;color:#262626;">behalf of the </font><font style="font-family:Arial;font-size:10pt;color:#363636;">Employer</font><font style="font-family:Arial;font-size:10pt;color:#545454;">, </font><font style="font-family:Arial;font-size:10pt;color:#262626;">as </font><font style="font-family:Arial;font-size:10pt;color:#363636;">of </font><font style="font-family:Arial;font-size:10pt;color:#262626;">the</font><font style="font-family:Arial;font-size:10pt;">&#32;15th </font><font style="font-family:Arial;font-size:10pt;color:#262626;">day of </font><font style="font-family:Arial;font-size:10pt;">October, 2014</font><font style="font-family:Arial;font-size:10pt;color:#363636;">,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:432px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#262626;">BIOGEN IDEC INC.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:432px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#262626;">By: </font><font style="font-family:Arial;font-size:10pt;color:#262626;text-decoration:underline;">/s/ Paul Clancy</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><a name="s64112d3ee0164ff48df6af7d77466601"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;font-weight:bold;">Biogen Inc. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">Supplemental </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;font-weight:bold;">Savings Plan</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Second </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Amendment </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">to the January 1, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">2012</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Amended and </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Re</font><font style="font-family:Arial;font-size:10pt;color:#424242;">s</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">tated </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Plan </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Document</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">WHEREAS</font><font style="font-family:Arial;font-size:10pt;color:#424242;">, </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Biogen Idec </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Inc., a </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Delaware </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">corporation, </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">is the plan </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">sponsor of, and a participating employer </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">under</font><font style="font-family:Arial;font-size:10pt;color:#565656;">, </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the Biogen Idec Inc. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Supplemental </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Savings Plan </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(the "Plan"); and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">WHEREAS, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">effective </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">March </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">23, 2015, Biogen Idec </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Inc</font><font style="font-family:Arial;font-size:10pt;color:#424242;">. </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">changed </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">its name </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">to </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Inc</font><font style="font-family:Arial;font-size:10pt;color:#424242;">. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(the </font><font style="font-family:Arial;font-size:10pt;color:#424242;">"Em</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">ployer"); </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">WHEREAS, </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Employer established the </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Plan</font><font style="font-family:Arial;font-size:10pt;color:#424242;">, </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">and most </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">recently amended and restated </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the Plan effecti</font><font style="font-family:Arial;font-size:10pt;color:#424242;">ve </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">as of January </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">1, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">2012; and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">WHEREAS, Section 7.1 </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">of the Plan provides the </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Employer the </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">right to </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">amend the </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Plan; </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">and </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">WHEREAS</font><font style="font-family:Arial;font-size:10pt;color:#424242;">, </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Employer </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">desires to amend the Plan effective March </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">23, 2015 to change </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">name </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">of the </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Plan </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">from the Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Idec Inc. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Supplemental </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Saving</font><font style="font-family:Arial;font-size:10pt;color:#424242;">s </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Plan </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">to the Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Inc. Supplemental Saving</font><font style="font-family:Arial;font-size:10pt;color:#424242;">s </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Plan and to </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">reflect </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Employer's name change.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">NOW, THEREFORE, </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Plan </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">is amended </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">effective </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">as </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">of March 23, 2015 </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">as </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">set forth </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">below:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Section </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">1.1, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">"Purpose and Effective Date", </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">is amended b</font><font style="font-family:Arial;font-size:10pt;color:#424242;">y </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">deleting the reference to </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Idec" in the </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">first sentence of </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the first paragraph </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">and substituting </font><font style="font-family:Arial;font-size:10pt;color:#424242;">"B</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">iogen" therefor, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">and </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">by deleting the reference to th</font><font style="font-family:Arial;font-size:10pt;color:#424242;">e </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Idec Inc. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">2008 </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Omnibus </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Equity </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Plan</font><font style="font-family:Arial;font-size:10pt;color:#424242;">" </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">in the </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">second sentence </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">of </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">the </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">third paragraph </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">and substituting </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">"Biogen (formerly </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Biogen Idec) Amended </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">and </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Restated </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">2008 </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Omnibus </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Equity P</font><font style="font-family:Arial;font-size:10pt;color:#080808;">l</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">an" </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Section </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">2.4, </font><font style="font-family:Arial;font-size:10pt;color:#424242;">"B</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">iogen Idec</font><font style="font-family:Arial;font-size:10pt;color:#424242;">", </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">is </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">amended </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">by deleting it in its entirety and </font><font style="font-family:Arial;font-size:10pt;color:#424242;">s</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">ubstituting the following ther</font><font style="font-family:Arial;font-size:10pt;color:#424242;">e</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">for:</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">"2.4</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;font-weight:bold;">Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">means Biogen Inc., a Delaware corporation</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">, </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">or </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">any successor to </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">it or to </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">all </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">or the </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">major </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">portion </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">of </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">it</font><font style="font-family:Arial;font-size:10pt;color:#424242;">s </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">assets </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">or </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">bu</font><font style="font-family:Arial;font-size:10pt;color:#424242;">s</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">ines</font><font style="font-family:Arial;font-size:10pt;color:#424242;">s </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">which assumes the obligations of Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Inc. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">under </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">thi</font><font style="font-family:Arial;font-size:10pt;color:#424242;">s </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">plan."</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Section </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">2.6, "Board", </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">is </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">amended by </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">deleting </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">it </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">in </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">its entirety and substituting the following </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">therefor:</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">"2</font><font style="font-family:Arial;font-size:10pt;color:#080808;font-weight:bold;">.6</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;font-weight:bold;">Board </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">means the Board of Directors of Biogen.</font><font style="font-family:Arial;font-size:10pt;color:#424242;">"</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Section </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">2.7, "Change </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">in </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Control", is amended </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">by deleting the </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">reference </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">to </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">the "Biogen Idec </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Inc. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">2008 </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Omnibus </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Equity </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Plan" </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">in subsection (a) </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">thereof </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">and substituting </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the </font><font style="font-family:Arial;font-size:10pt;color:#424242;">"</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Biogen </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(formerly </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Biogen </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Idec) Amended and </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Restated </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">2008 </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Omnibus </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Equity P</font><font style="font-family:Arial;font-size:10pt;color:#080808;">l</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">an" therefor; by </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">deleting all references to </font><font style="font-family:Arial;font-size:10pt;color:#424242;">"</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Biogen Idec" </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">in </font><font style="font-family:Arial;font-size:10pt;color:#424242;">s</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">ubsection </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">(b) thereof </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">and </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">substituting </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">"Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">therefor; and </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">by del</font><font style="font-family:Arial;font-size:10pt;color:#424242;">et</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">ing the reference to </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">"2.8(b</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">)" in </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">subsection </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">(b) thereof </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">and substituting </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">"2.</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">7(b)" </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Section </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">2.11, </font><font style="font-family:Arial;font-size:10pt;color:#424242;">"</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Disability"</font><font style="font-family:Arial;font-size:10pt;color:#424242;">, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">is amended </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">by deleting the reference </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">to </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">"Biogen Idec" </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">and substituting "Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#282828;">Section 2.12, "Employee", is amended </font><font style="font-family:Arial;font-size:10pt;color:#151515;">by </font><font style="font-family:Arial;font-size:10pt;color:#282828;">deleting all references to "Biogen Idec" and </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">substitut</font><font style="font-family:Arial;font-size:10pt;color:#151515;">in</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">g "Biogen" t</font><font style="font-family:Arial;font-size:10pt;color:#151515;">h</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">erefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#282828;">Section 2.13</font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;">, </font><font style="font-family:Arial;font-size:10pt;color:#282828;">"Employer", is </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">amended </font><font style="font-family:Arial;font-size:10pt;color:#282828;">by deleting all references </font><font style="font-family:Arial;font-size:10pt;color:#151515;">to </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"B</font><font style="font-family:Arial;font-size:10pt;color:#151515;">i</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">ogen </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Idec" </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and s</font><font style="font-family:Arial;font-size:10pt;color:#151515;">ubstitutin</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">g </font><font style="font-family:Arial;font-size:10pt;color:#282828;">"Biogen" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#282828;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#282828;">Section 2.16, </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Non-recurring </font><font style="font-family:Arial;font-size:10pt;color:#282828;">bonus </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">amo</font><font style="font-family:Arial;font-size:10pt;color:#151515;">unts"</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">, </font><font style="font-family:Arial;font-size:10pt;color:#151515;">is </font><font style="font-family:Arial;font-size:10pt;color:#282828;">amended by deleting the reference to </font><font style="font-family:Arial;font-size:10pt;color:#151515;">th</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">e "Bioge</font><font style="font-family:Arial;font-size:10pt;color:#151515;">n </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Idec Inc. 2008 Omnibus Equity Plan" and </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">subst</font><font style="font-family:Arial;font-size:10pt;color:#151515;">ituting </font><font style="font-family:Arial;font-size:10pt;color:#282828;">the "Biogen (formerly Biogen </font><font style="font-family:Arial;font-size:10pt;color:#151515;">Ide</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">c) Amended and </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Restated </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">2008 </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Omnibus Equity Plan" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#282828;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#282828;">Section </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">2.17, "Participant", </font><font style="font-family:Arial;font-size:10pt;color:#282828;">is </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">amended </font><font style="font-family:Arial;font-size:10pt;color:#282828;">by deleting the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">reference </font><font style="font-family:Arial;font-size:10pt;color:#282828;">to </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#151515;">Idec</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"and substituting "Biogen" </font></div></td></tr></table><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><a name="s64112d3ee0164ff48df6af7d77466601"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="font-family:Arial;font-size:10pt;color:#282828;">therefor.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#282828;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#282828;">Section 2.18, </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"P</font><font style="font-family:Arial;font-size:10pt;color:#151515;">lan</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">", </font><font style="font-family:Arial;font-size:10pt;color:#282828;">is </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">amended </font><font style="font-family:Arial;font-size:10pt;color:#282828;">by deleting it in its entirety </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and </font><font style="font-family:Arial;font-size:10pt;color:#282828;">substituting the following therefor:</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;font-weight:bold;">"2.18</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#282828;font-weight:bold;">Plan </font><font style="font-family:Arial;font-size:10pt;color:#282828;">means </font><font style="font-family:Arial;font-size:10pt;color:#151515;">the </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Biogen Inc. Supplemental Savings Plan</font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;">, </font><font style="font-family:Arial;font-size:10pt;color:#282828;">as </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">set </font><font style="font-family:Arial;font-size:10pt;color:#282828;">forth in </font><font style="font-family:Arial;font-size:10pt;color:#151515;">thi</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">s </font><font style="font-family:Arial;font-size:10pt;color:#282828;">plan instrument, and as it may be amended from </font><font style="font-family:Arial;font-size:10pt;color:#151515;">time </font><font style="font-family:Arial;font-size:10pt;color:#282828;">to time."</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#282828;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#282828;">Section </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">2</font><font style="font-family:Arial;font-size:10pt;color:#151515;">.22</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">, "Savings </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Plan", is amended by deleting the reference to the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"B</font><font style="font-family:Arial;font-size:10pt;color:#151515;">io</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">ge</font><font style="font-family:Arial;font-size:10pt;color:#151515;">n </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Idec 401(k) Savings Plan" and </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">substituting the "Biogen </font><font style="font-family:Arial;font-size:10pt;color:#282828;">401(k) Savings Plan" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#282828;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#282828;">Section 2.23, </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Service", </font><font style="font-family:Arial;font-size:10pt;color:#282828;">is amended by deleting </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">the </font><font style="font-family:Arial;font-size:10pt;color:#282828;">reference to </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#151515;">Idec</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">" </font><font style="font-family:Arial;font-size:10pt;color:#282828;">in </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">subsection (a) </font><font style="font-family:Arial;font-size:10pt;color:#282828;">thereof and substituting "Biogen" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#282828;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#282828;">Section 2.24, </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Transition </font><font style="font-family:Arial;font-size:10pt;color:#282828;">credit", is amended by deleting the reference to "Biogen Idec" and substituting </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"B</font><font style="font-family:Arial;font-size:10pt;color:#151515;">i</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">ogen" </font><font style="font-family:Arial;font-size:10pt;color:#282828;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#282828;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#282828;">Section 3.1(a), "Voluntary Deferred Compensation", is </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">amended </font><font style="font-family:Arial;font-size:10pt;color:#282828;">by deleting the </font><font style="font-family:Arial;font-size:10pt;color:#151515;">referen</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">ce to "Biogen </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Idec" </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and substituting "Biogen" t</font><font style="font-family:Arial;font-size:10pt;color:#151515;">h</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">erefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#282828;">Section 3</font><font style="font-family:Arial;font-size:10pt;color:#151515;">.1</font><font style="font-family:Arial;font-size:10pt;color:#282828;">(c), "Prior Plans and Biogen SERP", </font><font style="font-family:Arial;font-size:10pt;color:#151515;">is </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">amended </font><font style="font-family:Arial;font-size:10pt;color:#282828;">by deleting the reference to </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"B</font><font style="font-family:Arial;font-size:10pt;color:#151515;">io</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">gen </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Idec" and </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">substituting "Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#151515;">the</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">refor</font><font style="font-family:Arial;font-size:10pt;color:#151515;">.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#151515;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#282828;">Section </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">3</font><font style="font-family:Arial;font-size:10pt;color:#282828;">.1(</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">e), </font><font style="font-family:Arial;font-size:10pt;color:#282828;">"Time of Eligibility and Participation", is </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">amended </font><font style="font-family:Arial;font-size:10pt;color:#282828;">by deleting the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">reference </font><font style="font-family:Arial;font-size:10pt;color:#282828;">to </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Idec" and substituting </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#282828;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#282828;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#282828;">Section 4.2</font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;">, </font><font style="font-family:Arial;font-size:10pt;color:#282828;">"Voluntary Deferrals", is </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">amended </font><font style="font-family:Arial;font-size:10pt;color:#282828;">by deleting the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">reference </font><font style="font-family:Arial;font-size:10pt;color:#282828;">to </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Idec" </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and </font><font style="font-family:Arial;font-size:10pt;color:#282828;">substituting </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"B</font><font style="font-family:Arial;font-size:10pt;color:#151515;">iog</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">e</font><font style="font-family:Arial;font-size:10pt;color:#151515;">n" </font><font style="font-family:Arial;font-size:10pt;color:#282828;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#282828;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#282828;">Section 4.4(a)(i), </font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;">"</font><font style="font-family:Arial;font-size:10pt;color:#282828;">Voluntary Deferrals from Base </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Salary </font><font style="font-family:Arial;font-size:10pt;color:#282828;">or Recurring Bonus Amounts", is amended by deleting </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">a</font><font style="font-family:Arial;font-size:10pt;color:#151515;">ll </font><font style="font-family:Arial;font-size:10pt;color:#282828;">references to "Biogen Idec" </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and </font><font style="font-family:Arial;font-size:10pt;color:#282828;">substituting </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"B</font><font style="font-family:Arial;font-size:10pt;color:#151515;">iogen</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">" </font><font style="font-family:Arial;font-size:10pt;color:#282828;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#282828;">19.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#282828;">Section 4.4(a)(ii), </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Voluntary </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Deferrals from Non-Recurring Bonus Amounts", is </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">amended </font><font style="font-family:Arial;font-size:10pt;color:#282828;">by deleting the reference to "Biogen Idec" and substituting "Biogen" therefor, and by deleting the reference to the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"B</font><font style="font-family:Arial;font-size:10pt;color:#151515;">io</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">gen </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Idec Inc. Amended and Restated </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">2008 </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Omnibus Equity Plan" </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and substituting the </font><font style="font-family:Arial;font-size:10pt;color:#282828;">"Biogen (formerly Biogen Idec) Amended </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Restated </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">2008 </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Omnibus Equity Plan" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#282828;">20.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">Section 4.4(b)(i), </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Initial </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Election", is amended by deleting the reference to the </font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">"</font><font style="font-family:Arial;font-size:10pt;color:#212121;">Biogen Idec Inc. </font><font style="font-family:Arial;font-size:10pt;color:#343434;">2008 </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Omnibus Equity Plan" and </font><font style="font-family:Arial;font-size:10pt;color:#343434;">substituting </font><font style="font-family:Arial;font-size:10pt;color:#212121;">the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#212121;">(formerly Biogen Idec) Amended </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Restated 2008 Omnibus Equity Plan" therefor</font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">, </font><font style="font-family:Arial;font-size:10pt;color:#212121;">and by deleting all references to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Idec" </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and </font><font style="font-family:Arial;font-size:10pt;color:#212121;">substituting </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#212121;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#212121;">21.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">Section 4.4(b)(ii)(A), "In-Service Distributions", is amended by deleting the reference to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Idec" and </font><font style="font-family:Arial;font-size:10pt;color:#343434;">substituting "Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#212121;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#212121;">22.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">Section 4.4(b)(ii)(B)</font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Death </font><font style="font-family:Arial;font-size:10pt;color:#212121;">or Termination of </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Employment", </font><font style="font-family:Arial;font-size:10pt;color:#212121;">is amended by deleting the reference to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Biogen Idec" </font><font style="font-family:Arial;font-size:10pt;color:#212121;">and </font><font style="font-family:Arial;font-size:10pt;color:#343434;">substituting </font><font style="font-family:Arial;font-size:10pt;color:#212121;">"Biogen" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#212121;">23.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">Section 4.4(b)(ii)(C), </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Effectiveness </font><font style="font-family:Arial;font-size:10pt;color:#212121;">of Subsequent Election", is amended by deleting </font><font style="font-family:Arial;font-size:10pt;color:#343434;">the </font><font style="font-family:Arial;font-size:10pt;color:#212121;">reference to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Idec" </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and </font><font style="font-family:Arial;font-size:10pt;color:#212121;">substituting </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#212121;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#212121;">24.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">Section </font><font style="font-family:Arial;font-size:10pt;color:#343434;">5.2(a), </font><font style="font-family:Arial;font-size:10pt;color:#212121;">"Deemed Investment Results", is </font><font style="font-family:Arial;font-size:10pt;color:#343434;">amended </font><font style="font-family:Arial;font-size:10pt;color:#212121;">by deleting all references to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Idec" and </font><font style="font-family:Arial;font-size:10pt;color:#343434;">substituting "Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#212121;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#212121;">25.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">Section 5.3(a)(ii), </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"On </font><font style="font-family:Arial;font-size:10pt;color:#212121;">or After January 1, 2008", is amended by deleting all references to "Biogen Idec" and substituting </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#212121;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#212121;">26.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#343434;">Section </font><font style="font-family:Arial;font-size:10pt;color:#212121;">5.3(b), </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Voluntary </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Deferred </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Compensation </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Account", is </font><font style="font-family:Arial;font-size:10pt;color:#343434;">amended </font><font style="font-family:Arial;font-size:10pt;color:#212121;">by deleting the reference to the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Idec Inc. 2008 Omnibus </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Equity </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Plan" and substituting the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#212121;">(formerly Biogen Idec) Amended and </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Restated 2008 Omnibus</font><font style="font-family:Arial;font-size:10pt;color:#212121;">&#32;Equity Plan" therefor.</font></div></td></tr></table><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><a name="s64112d3ee0164ff48df6af7d77466601"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#212121;">27.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">Section 5.3(c)(ii)</font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">, "</font><font style="font-family:Arial;font-size:10pt;color:#212121;">On or After January 1, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">2008", </font><font style="font-family:Arial;font-size:10pt;color:#212121;">is amended by deleting all references to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Idec" and substituting </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#212121;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#212121;">28.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">Section </font><font style="font-family:Arial;font-size:10pt;color:#343434;">5.3(f), "Full </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Vesting upon Death, Disability or Change in Control", is amended by d</font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">e</font><font style="font-family:Arial;font-size:10pt;color:#212121;">leting all references to "Biogen Idec" in </font><font style="font-family:Arial;font-size:10pt;color:#343434;">subsections </font><font style="font-family:Arial;font-size:10pt;color:#212121;">(i) and (ii) thereof and substituting </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Biogen"  </font><font style="font-family:Arial;font-size:10pt;color:#212121;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#212121;">29.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">Section 5.3(g), </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Forfeiture of Non-Vested </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Account Balances", is amended by deleting the reference to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Idec" </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and substituting </font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">"</font><font style="font-family:Arial;font-size:10pt;color:#212121;">Biogen" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#212121;">30.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">Section 5.3(h), </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Meaning </font><font style="font-family:Arial;font-size:10pt;color:#212121;">of 'Fully Vested"</font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">'</font><font style="font-family:Arial;font-size:10pt;color:#212121;">, is </font><font style="font-family:Arial;font-size:10pt;color:#343434;">amended </font><font style="font-family:Arial;font-size:10pt;color:#212121;">by deleting </font><font style="font-family:Arial;font-size:10pt;color:#343434;">the </font><font style="font-family:Arial;font-size:10pt;color:#212121;">reference to </font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">"</font><font style="font-family:Arial;font-size:10pt;color:#212121;">Biogen Idec" and </font><font style="font-family:Arial;font-size:10pt;color:#343434;">substituting </font><font style="font-family:Arial;font-size:10pt;color:#212121;">"Biogen" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#212121;">31.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">Section </font><font style="font-family:Arial;font-size:10pt;color:#343434;">6.3, "In-Service </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Distribution(s) at a </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Time </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Specified by Participant", is amended by deleting the reference to "Biogen Idec" and </font><font style="font-family:Arial;font-size:10pt;color:#343434;">substituting "Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#212121;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#212121;">32.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">Section </font><font style="font-family:Arial;font-size:10pt;color:#343434;">6.4(a), </font><font style="font-family:Arial;font-size:10pt;color:#212121;">"In </font><font style="font-family:Arial;font-size:10pt;color:#343434;">general", </font><font style="font-family:Arial;font-size:10pt;color:#212121;">is amended by deleting the reference to "Biogen Idec" and </font><font style="font-family:Arial;font-size:10pt;color:#343434;">substituting "Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#212121;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#212121;">33.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">Section </font><font style="font-family:Arial;font-size:10pt;color:#343434;">7.1, </font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">"A</font><font style="font-family:Arial;font-size:10pt;color:#212121;">mendment or Termination of Plan", is amended by deleting all references to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Idec" </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and substituting "Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#212121;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#212121;">34.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">Section </font><font style="font-family:Arial;font-size:10pt;color:#343434;">7.2, </font><font style="font-family:Arial;font-size:10pt;color:#212121;">"Benefits </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Not Currently </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Funded", is </font><font style="font-family:Arial;font-size:10pt;color:#343434;">amended </font><font style="font-family:Arial;font-size:10pt;color:#212121;">by deleting all references to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Idec" in subsections (a) </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and </font><font style="font-family:Arial;font-size:10pt;color:#212121;">(b) thereof </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and substituting "Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#212121;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#212121;">35.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">Section 7.4(b)</font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">, </font><font style="font-family:Arial;font-size:10pt;color:#212121;">"Termination"</font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">, </font><font style="font-family:Arial;font-size:10pt;color:#212121;">is </font><font style="font-family:Arial;font-size:10pt;color:#343434;">amended </font><font style="font-family:Arial;font-size:10pt;color:#212121;">by deleting the reference to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Idec" </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and </font><font style="font-family:Arial;font-size:10pt;color:#212121;">substituting </font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">"</font><font style="font-family:Arial;font-size:10pt;color:#212121;">Biogen" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#212121;">36.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Section </font><font style="font-family:Arial;font-size:10pt;color:#313131;">7.5, "Responsibilities and Authority of Committee", </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">is </font><font style="font-family:Arial;font-size:10pt;color:#313131;">amended </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">by deleting </font><font style="font-family:Arial;font-size:10pt;color:#313131;">all references </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">to </font><font style="font-family:Arial;font-size:10pt;color:#313131;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Idec" </font><font style="font-family:Arial;font-size:10pt;color:#313131;">and substituting "Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">37.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Section </font><font style="font-family:Arial;font-size:10pt;color:#313131;">A.5, "January 2010 Restatement", of Appendix A</font><font style="font-family:Arial;font-size:10pt;color:#59595b;">, </font><font style="font-family:Arial;font-size:10pt;color:#313131;">"Historical Information</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">; </font><font style="font-family:Arial;font-size:10pt;color:#313131;">Amendments", is amended </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">by deleting the </font><font style="font-family:Arial;font-size:10pt;color:#313131;">reference to "Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Idec" </font><font style="font-family:Arial;font-size:10pt;color:#313131;">and substituting "Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">38.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#313131;">Section A.7, "2015 Amendment", of Appendix A, </font><font style="font-family:Arial;font-size:10pt;color:#59595b;">"</font><font style="font-family:Arial;font-size:10pt;color:#313131;">Historica</font><font style="font-family:Arial;font-size:10pt;color:#0f0f0f;">l </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Information; </font><font style="font-family:Arial;font-size:10pt;color:#313131;">Amendments", </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">is </font><font style="font-family:Arial;font-size:10pt;color:#313131;">amended </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">by </font><font style="font-family:Arial;font-size:10pt;color:#313131;">de</font><font style="font-family:Arial;font-size:10pt;color:#0f0f0f;">l</font><font style="font-family:Arial;font-size:10pt;color:#313131;">eting </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">it in its </font><font style="font-family:Arial;font-size:10pt;color:#313131;">entirety and substituting the following therefor:</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#313131;">"A.7</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#313131;font-weight:bold;">2015 Amendments </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;font-weight:bold;">to the January </font><font style="font-family:Arial;font-size:10pt;color:#313131;font-weight:bold;">2012 </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;font-weight:bold;">Restatement. </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">The </font><font style="font-family:Arial;font-size:10pt;color:#313131;">January 2012 Restatement of </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the </font><font style="font-family:Arial;font-size:10pt;color:#313131;">plan </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">was </font><font style="font-family:Arial;font-size:10pt;color:#313131;">amended </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">by </font><font style="font-family:Arial;font-size:10pt;color:#313131;">the First Amendment </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">thereto to </font><font style="font-family:Arial;font-size:10pt;color:#313131;">eliminate the abi</font><font style="font-family:Arial;font-size:10pt;color:#0f0f0f;">l</font><font style="font-family:Arial;font-size:10pt;color:#313131;">ity </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">to defer any </font><font style="font-family:Arial;font-size:10pt;color:#313131;">restricted stock </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">units, </font><font style="font-family:Arial;font-size:10pt;color:#313131;">market stock units</font><font style="font-family:Arial;font-size:10pt;color:#59595b;">, </font><font style="font-family:Arial;font-size:10pt;color:#313131;">or other equity based awards that may </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">be </font><font style="font-family:Arial;font-size:10pt;color:#313131;">granted </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">beginning </font><font style="font-family:Arial;font-size:10pt;color:#313131;">on or after January 1, 2015 under the Biogen (formerly Biogen Idec) Amended and Restated 2008 Omnibus Equity Plan. The January 2012 Restatement of </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the </font><font style="font-family:Arial;font-size:10pt;color:#313131;">plan was further amended by </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the </font><font style="font-family:Arial;font-size:10pt;color:#313131;">Second Amendme</font><font style="font-family:Arial;font-size:10pt;color:#0f0f0f;">n</font><font style="font-family:Arial;font-size:10pt;color:#313131;">t thereto, effective March 23, 2015, to reflect </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the </font><font style="font-family:Arial;font-size:10pt;color:#313131;">change </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">in </font><font style="font-family:Arial;font-size:10pt;color:#313131;">the name of </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the </font><font style="font-family:Arial;font-size:10pt;color:#313131;">plan from </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the </font><font style="font-family:Arial;font-size:10pt;color:#313131;">'Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Idec </font><font style="font-family:Arial;font-size:10pt;color:#313131;">Inc. Supplemental Savings Plan' </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">to </font><font style="font-family:Arial;font-size:10pt;color:#313131;">the 'Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Inc. </font><font style="font-family:Arial;font-size:10pt;color:#313131;">Supp</font><font style="font-family:Arial;font-size:10pt;color:#0f0f0f;">l</font><font style="font-family:Arial;font-size:10pt;color:#313131;">emental Savings P</font><font style="font-family:Arial;font-size:10pt;color:#0f0f0f;">l</font><font style="font-family:Arial;font-size:10pt;color:#313131;">an' and </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">to </font><font style="font-family:Arial;font-size:10pt;color:#313131;">reflect the </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Employer's </font><font style="font-family:Arial;font-size:10pt;color:#313131;">change of </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">name from </font><font style="font-family:Arial;font-size:10pt;color:#313131;">'Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Idec </font><font style="font-family:Arial;font-size:10pt;color:#313131;">Inc.' to </font><font style="font-family:Arial;font-size:10pt;color:#0f0f0f;">'B</font><font style="font-family:Arial;font-size:10pt;color:#313131;">iogen Inc."'</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#313131;">39.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#313131;">Section B.1</font><font style="font-family:Arial;font-size:10pt;color:#59595b;">, </font><font style="font-family:Arial;font-size:10pt;color:#313131;">"Applicability", of Appendix B</font><font style="font-family:Arial;font-size:10pt;color:#59595b;">, </font><font style="font-family:Arial;font-size:10pt;color:#313131;">"Biogen</font><font style="font-family:Arial;font-size:10pt;color:#59595b;">, </font><font style="font-family:Arial;font-size:10pt;color:#313131;">Inc. Supplemental Executive Retirement Plan"</font><font style="font-family:Arial;font-size:10pt;color:#59595b;">, </font><font style="font-family:Arial;font-size:10pt;color:#313131;">is amended </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">by deleting </font><font style="font-family:Arial;font-size:10pt;color:#313131;">all references to "Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Idec" </font><font style="font-family:Arial;font-size:10pt;color:#313131;">in subsections (a) and (b) thereof and substituting "Biogen" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">IN </font><font style="font-family:Arial;font-size:10pt;color:#313131;">WITNESS WHEREOF, the Emp</font><font style="font-family:Arial;font-size:10pt;color:#0f0f0f;">l</font><font style="font-family:Arial;font-size:10pt;color:#313131;">oyer </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">has </font><font style="font-family:Arial;font-size:10pt;color:#313131;">caused this </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">instrument </font><font style="font-family:Arial;font-size:10pt;color:#313131;">to </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">be </font><font style="font-family:Arial;font-size:10pt;color:#313131;">executed by an authorized officer on behalf of </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the </font><font style="font-family:Arial;font-size:10pt;color:#313131;">Emp</font><font style="font-family:Arial;font-size:10pt;color:#0f0f0f;">l</font><font style="font-family:Arial;font-size:10pt;color:#313131;">oyer, as of </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the 15th day of May, 2015.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:480px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:left;text-indent:480px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:480px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">By: </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;text-decoration:underline;">/s/ Paul Clancy</font></div><div style="line-height:120%;text-align:left;text-indent:480px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:480px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Title: </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;text-decoration:underline;">EVP and CFO</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>3
<FILENAME>biib-20151231xex1024.htm
<DESCRIPTION>EXHIBIT 10.24
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s053e1bc2af8f4a80a17c9ec8be69b9e4"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BIOGEN IDEC INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">VOLUNTARY BOARD OF DIRECTORS SAVINGS PLAN</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(Plan Provisions as in Effect on January l. 2012)</font></div><br><div></div><hr style="page-break-after:always"><a name="s053e1bc2af8f4a80a17c9ec8be69b9e4"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="12%"></td><td width="1%"></td><td width="4%"></td><td width="77%"></td><td width="5%"></td><td width="1%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ARTICLE 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">INTRODUCTION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Purpose and Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ARTICLE 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DEFINITIONS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Biogen Idec</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Board</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Change in Control</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Equity Plan Award</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Participant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Plan Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Retainer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2.12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Savings Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ARTICLE 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PARTICIPATION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Eligibility and Participation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">End of Participation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ARTICLE 4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">VOLUNTARY DEFERRALS BY PARTICIPANTS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Voluntary Deferrals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Election Procedures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ARTICLE 5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PARTICIPANT ACCOUNTS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Participant Accounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Vesting</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ARTICLE 6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">DISTRIBUTIONS TO PARTICIPANT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Distributions for Unforeseeable Emergency</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In-Service Distribution(s) at a Time Specified by Participant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Distribution Upon a Change in Control</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Distribution Upon Death of a Participant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other Distributions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Installment Distributions in Certain Cases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain Other Distributions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delay in Distributions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Compliance with Code Section 409A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ARTICLE 7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">MISCELLANEOUS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Amendment or Termination of Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Benefits Not Currently Funded</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div></div><hr style="page-break-after:always"><a name="s053e1bc2af8f4a80a17c9ec8be69b9e4"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="12%"></td><td width="1%"></td><td width="4%"></td><td width="77%"></td><td width="5%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No Assignment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Effect of Change in Control</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Responsibilities and Authority of Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Limitation on Rights Created by Plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Tax Withholding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Text Controls</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Applicable State Law</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7.10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Paperless Administration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">APPENDIX A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A-1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div></div><hr style="page-break-after:always"><a name="scb2ea42d4fbc4dc68ce8aab11c4dd156"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:3px;text-align:center;padding-left:268px;text-indent:2px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ARTICLE 1 INTRODUCTION</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">1.1&#160;&#160;&#160;&#160;Purpose and Effective Date</font><font style="font-family:Arial;font-size:10pt;">. The purpose of this plan is to provide members of the Board of Directors of Biogen Idec with a tax-deferred savings opportunity. This plan allows participants to defer all or a portion of their cash directors' fees and retainer by so electing before such fees and retainer have been earned.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This amended and restated plan is effective as of January 1, 2012 to expand the tax-deferred savings opportunities by allowing members of the Board of Directors to defer certain equity based awards granted under the Biogen Idec Inc. 2006 Non-Employee Directors Equity Plan (or successor plan). Certain historical information about the plan and any amendments thereto is set forth in Appendix A.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:277px;text-indent:1px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">ARTICLE 2 DEFINITIONS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This section contains definitions of terms used in the plan. Where the context so requires, the masculine includes the feminine, the singular includes the plural, and the plural includes the singular.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.1&#160;&#160;&#160;&#160;Biogen Idec</font><font style="font-family:Arial;font-size:10pt;">&#32;means Biogen Idec Inc., a Delaware corporation, or any successor to all or the major portion of its assets or business which assumes the obligations of Biogen Idec Inc. under this plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.2&#160;&#160;&#160;&#160;Board</font><font style="font-family:Arial;font-size:10pt;">&#32;means the Board of Directors of Biogen Idec.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.3&#160;&#160;&#160;&#160;Change in Control</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;">For purposes of Section 7.4: a change in control means a "Corporate Change in Control" or a "Corporate Transaction" as each is defined in the Biogen Idec Inc. 2008 Omnibus Equity Plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:10pt;">For purposes of Section 4.2(b) and Section 6.3: a change in control means (i) the acquisition by a person or group of stock of Biogen Idec that, together with stock previously held by such person or group,</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">constitutes more than 50 percent of the total fair market value or total voting power of the stock of Biogen Idec; (ii) a change in the effective control of Biogen Idec resulting from either the acquisition by any person or group during a 12-month period of stock of Biogen Idec possessing 30 percent or more of the total voting power of Biogen Idec stock; or the replacement of a majority of the members of the Board during any 12-month period by directors whose appointment or election was not endorsed by a majority of the members of the Board in office immediately before the start of such 12-month period; or (iii)</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:10pt;">the acquisition by any person or group (during any 12-month period) of assets having a gross fair market value equal to or greater than 40 percent of the total gross fair market value of all assets of Biogen Idec. This subsection (b)</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:10pt;">and terms used herein will be interpreted in accordance with the regulations under Code Section 409A relating to a change in the ownership or effective control of a corporation or a change in the ownership of a substantial portion of the assets of a corporation.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This subsection 2.3(b) is effective as of the date of execution of this amended and restated plan document.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.4&#160;&#160;&#160;&#160;Committee</font><font style="font-family:Arial;font-size:10pt;">&#32;means the Retirement Committee, or such other committee designated by the Board to administer this Plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.5&#160;&#160;&#160;&#160;Director</font><font style="font-family:Arial;font-size:10pt;">&#32;means an individual serving as a non-employee director of Biogen Idec in accordance with its</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">articles and by-laws.</font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.6&#160;&#160;&#160;&#160;Equity Plan Award</font><font style="font-family:Arial;font-size:10pt;">&#32;means an award granted pursuant to the Biogen Idec lnc. 2006 Non-Employee Directors Equity Plan, or successor plan thereto.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.7&#160;&#160;&#160;&#160;Fees</font><font style="font-family:Arial;font-size:10pt;">&#32;means the cash amounts payable to a director or compensation for his or her attendance at a meeting of the Board or a committee of the Board or for other special services.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.8&#160;&#160;&#160;&#160;Participant </font><font style="font-family:Arial;font-size:10pt;">means a director who has made a voluntary deferral hereunder or for whom an amount has been transferred to this plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><a name="scb2ea42d4fbc4dc68ce8aab11c4dd156"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.9&#160;&#160;&#160;&#160;Plan </font><font style="font-family:Arial;font-size:10pt;">means the Biogen Idec Inc. Voluntary Board of Directors Savings Plan, as set forth in this plan instrument, and as it may be amended from time to time.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.10&#160;&#160;&#160;&#160;Plan Year </font><font style="font-family:Arial;font-size:10pt;">means the 12-month periods commencing on January 1, 2005 and on each subsequent January 1 while this plan remains in effect.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.11&#160;&#160;&#160;&#160;Retainer </font><font style="font-family:Arial;font-size:10pt;">means the cash amount payable to a director as an annual retainer for service in such capacity, as in effect from time to time.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">2.12&#160;&#160;&#160;&#160;Savings Plan </font><font style="font-family:Arial;font-size:10pt;">means the Biogen Idec 401(k) Savings Plan, as amended from time to time. Any term defined in the Savings Plan will have the same meaning when used in this plan unless otherwise defined herein.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:266px;text-indent:1px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ARTICLE 3 PARTICIPATION</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.1&#160;&#160;&#160;&#160;Eligibility and Participation. </font><font style="font-family:Arial;font-size:10pt;">Each director will be eligible to be a participant in this plan as long as he is a director. A director will become a participant hereunder when he makes a voluntary deferral to this plan or when his account balance under the Biogen, Inc. Voluntary Board of Directors Savings Plan (the "Biogen Directors Plan") is transferred to this plan. Voluntary deferrals under this plan are voluntary and no director will be required to make such deferrals.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">3.2&#160;&#160;&#160;&#160;End of Participation. </font><font style="font-family:Arial;font-size:10pt;">A participant's participation in this plan will end upon the termination of his service as a director of Biogen Idec because of death, retirement, resignation, failure of reelection, or any other reason. Upon the termination of a participant's participation in this plan in accordance with this section, the participant may make no further voluntary deferrals hereunder. However, the participant will be entitled to receive any amounts in his account in accordance with this plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:5px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ARTICLE 4</font></div><div style="line-height:120%;text-align:center;padding-left:5px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">VOLUNTARY DEFERRALS BY PARTICIPANTS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4.1&#160;&#160;&#160;&#160;Voluntary Deferrals. </font><font style="font-family:Arial;font-size:10pt;">Each director may make voluntary deferrals to the plan from his fees, retainer, or equity plan award in any whole percentage of such fees. retainer, and/or equity plan award from a minimum of 1% to a maximum of 100%, by electing to reduce his fees, retainer, and/or equity plan award by such amount in accordance with this plan. If a director's fees include separately identified types of fees (for example, meeting fees or special service fees), the committee may permit separate elections to defer with respect to different categories of fees. Deferrals of any equity plan awards shall not include any partial shares of common stock of Biogen Idec.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All amounts by which a participant reduces his fees, retainer, and/or equity plan award hereunder are referred to herein as the participant's </font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">voluntary deferrals</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">4.2&#160;&#160;&#160;&#160;Election Procedures</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Voluntary Deferrals</font><font style="font-family:Arial;font-size:10pt;">. A director who wishes to reduce his fees, retainer, and or equity plan award to be earned during a particular plan year in order to make voluntary deferrals under Section 4.1 must complete an enrollment form specifying the amount of his voluntary deferrals (with separate percentages for his meeting fees, special service fees (if any) and/or retainer, if desired), agreeing to reduce such fees, retainer, and/or equity plan award by the amount(s) he specifies, and providing such other information as the committee may require. Elections made with respect to equity plan awards shall apply to all tranches of such awards regardless of the date such award becomes nonforfeitable and shall apply with respect to any and all dividends or dividend equivalents provided with respect to such awards. All deferral elections hereunder must be made on an enrollment form approved by the committee, specifying the amount he elects to defer, agreeing to reduce his&#160;&#160;&#160;&#160;fees, retainer, and/or equity plan award by such amount and providing such other information as the committee may require. If a director elects to defer an equity plan award, he or she shall not be permitted to diversify the investment of such awards other than in Biogen Idec stock or stock equivalent.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A director's enrollment form electing voluntary deferrals for any plan year must be filed with the committee by such deadline as the committee specifies, but in any event before the start of such plan year. In addition, in the case of an individual who anticipates being elected as a director during a plan year, such person may make an </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><a name="scb2ea42d4fbc4dc68ce8aab11c4dd156"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">election hereunder in anticipation of his or her election and such election will be effective with respect to fees, retainer, and/or equity plan award to be earned after the date of such election; such an election will be effective as of the date when it is made but will be subject to such individual's actual election as a director. Further, in the case of a newly elected director, who did not make an election under the preceding sentence, such person may elect to defer his fees, retainer, and/or equity plan award for the plan year of his election to office, within 30 days after the committee sends him an enrollment form, provided that such election will relate only to fees, retainer, and equity plan award to be earned after the date of filing his completed enrollment form, and provided further that such person had not previously been eligible to make voluntary deferrals under this plan for a period of at least 24 months. Any filing deadline will comply with the timing of elections requirements of the regulations under Code Section 409A. Accordingly, with respect to the initial election to defer payment of any equity plan awards or any other forfeitable rights that requires the participant to provide services for at least 12 months from the date the award is granted, the election to defer such compensation may be made within 30 days after the date of grant or, if earlier, 12 months in advance of the date such award or right becomes nonforfeitable provided that if death, disability or a change in control occurs which accelerates the vesting before the end of such 12-month period, the deferral election will not be effective. The committee's written procedures will be deemed to constitute part of this plan for purposes of the written plan document requirements of the regulations under Code Section 409A. A participant may change the amount of his voluntary deferrals with respect to any subsequent plan year by filing a new enrollment form before the start of such subsequent plan year, and the change will become effective as of the first day of such subsequent plan year. Once a participant has elected to defer fees, retainer, and/or equity plan awards his enrollment form will remain in effect for future plan years unless the participant changes or terminates his prior elections by filing a new enrollment form in accordance with the preceding sentence.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">After a plan year has begun, a participant may not change the amount of voluntary deferrals (if any) he had elected for such plan year. However, if during a plan year a participant has an unforeseeable emergency (as defined in Section 6.1) and receives a distribution under Section 6.1, the participant's voluntary deferral election for the balance of that year will automatically be cancelled.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Form and Time of Payment.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(i)</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Initial Election. </font><font style="font-family:Arial;font-size:10pt;">Each participant in the initial enrollment form filed hereunder or another form designated by the committee must specify the form of payment (lump sum or installments in accordance with Section 6.4(a), 6.5 and/or 6.6(a) below, as applicable) of his account hereunder in the event of the participant's death or other termination of service as a director (including as a result of disability). In addition, effective as of the date of execution of this amended and restated plan document, a participant may elect payment of his account under Section 6.3 in the event of a change in control (as defined in Section 2.3(b)).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:50px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, a participant may (but is not required to) specify one or more in-service distributions to the participant in accordance with Section 6.2 if desired by the participant.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:50px;text-indent:49px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The time and form payments under the plan are governed by the provisions of Article 6 and participant elections must conform to the requirements of such provisions. Any election as to medium of payment with respect to equity plan award (i.e. whether such award will be settled in stock or cash) shall be subject to the terms of the Biogen Idec Inc. 2006 Non-Employee Directors Equity Plan&#160;&#160;&#160;&#160;successor plan) and/or award agreement thereunder. Any such election shall not be considered an election as to time or form of payment and shall not be subject to the restrictions under this Section.</font></div><div style="line-height:120%;text-align:left;padding-left:50px;text-indent:49px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:50px;text-align:left;text-indent:49px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:44px;">(ii)</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Change of Election</font><font style="font-family:Arial;font-size:10pt;">. Notwithstanding subsection (i) above, the following changes of election will be permitted. If such a subsequent election becomes effective as provided below, then the participant's account will be payable at the time and in the form specified in his subsequent election.</font></div><div style="line-height:120%;text-align:left;padding-left:50px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:Arial;font-size:10pt;">(A)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">In-Service Distributions</font><font style="font-family:Arial;font-size:10pt;">. In the case of a participant who elected an in-service distribution, at any time that is at least one year prior to the date for payment originally elected by the participant, if the participant is still a director of Biogen Idec at such time, the participant may make one subsequent election to defer the time when any previously elected in-service distribution under Section 6.2 from his account would otherwise be payable (or installment payments would otherwise begin) to a subsequent date specified by him, and/or may elect another form of payment or a different number of installments with respect to the </font></div></td></tr></table><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><a name="scb2ea42d4fbc4dc68ce8aab11c4dd156"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:144px;text-align:left;"><font style="font-family:Arial;font-size:10pt;">in-service distribution of his account, subject in all cases to the requirements of this section and to the requirements of Section 6.2.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:Arial;font-size:10pt;">(B)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Death or Termination of Employment.</font><font style="font-family:Arial;font-size:10pt;">&#32;A participant who is still a director of Biogen Idec may make one subsequent election to change the form of payment hereunder that will be used following his death or other termination of employment. Such an election must comply with the applicable requirements of Sections 6.4, 6.5 and 6.6 (as applicable).</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:Arial;font-size:10pt;">(C)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Effectiveness of Subsequent Election</font><font style="font-family:Arial;font-size:10pt;">. A participant's subsequent election under this subsection (ii) will become effective only if the following requirements are satisfied: (1) the subsequent election does not take effect until one year after the date of the subsequent election and the participant remains a director of Biogen Idec during such one year period, (2) the election extends the date for payment, or the start date for installment payments, by at least five years, and (3) in the case of a subsequent election to defer a previously elected in-service distribution (under subsection (A) above), the subsequent election is made at least 12 months before the date previously elected for such in-service distribution.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No election under this subsection (ii) may operate to accelerate any payment or distribution hereunder or violate any requirement of Code Section 409A or the regulations and rulings thereunder.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A participant may make only one subsequent election under subsection (ii) (A) and only one subsequent election under subsection (ii)(B). Such subsequent election(s) may be made at the same or at different times. Also, the committee may permit additional election opportunities (in accordance with the transition or other rules under the regulations or other Internal Revenue Service guidance under Code Section 409A or in such other circumstances as the committee deems appropriate). Any such additional subsequent elections under subsection (ii) must satisfy all the requirements of this section and any other applicable requirements under the plan or, alternatively, must satisfy such requirements as the committee may impose in connection with a new election under a Code Section 409A transition or other rule.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ARTICLE 5 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PARTICIPANT ACCOUNTS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.1&#160;&#160;&#160;&#160;Participant Accounts.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Voluntary Deferrals Account</font><font style="font-family:Arial;font-size:10pt;">. Voluntary deferrals by a participant from his fees and/or retainer hereunder will be credited to an account in the name of such participant. Such account will be called his voluntary deferrals account.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Participant's Account Value</font><font style="font-family:Arial;font-size:10pt;">. Except as otherwise provided below, a participant's account will be credited with deemed investment results as if his voluntary deferrals account were invested in one or more designated investment funds and all dividends and distributions on shares of a particular investment fund were reinvested in shares of such fund. The investment funds available for this purpose will be those from time to time available as investment options under the Savings Plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to the investment funds offered under the Savings Plan as described in the preceding paragraph, a participant may elect to have his account credited with the deemed investment results as if such amounts were invested in a fixed income option&#160;&#160;&#160;&#160; earnings a rate of return specified by the committee. The rate of return under the fixed income option will be 8% for the 2008 plan year. The rate of return of future plan years will be determined by the committee.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Notwithstanding the foregoing, with respect to the portion of a participant's voluntary deferred compensation account attributable to the equity plan awards, such portion will be deemed to be invested in shares of common stock of Biogen Idec. and the participant shall not be permitted to designate any other investment fund for this purpose.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Investment funds hereunder are for the sole purpose of providing a basis for crediting deemed investment results to participants' accounts, and do not represent any actual funds or assets held hereunder for the benefit of </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><a name="scb2ea42d4fbc4dc68ce8aab11c4dd156"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">participants.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Each participant will indicate with his initial enrollment form (or other form specified by the committee) the investment fund or funds (and the proportion in each fund when the participant designates more than one) he wishes to designate for this purpose. Thereafter, a participant may change his designation either with respect to the deemed investment of future voluntary deferrals or the deemed transfer of amounts from a previously designated investment fund to another fund. The committee shall establish the frequency by which such a change may be made, the method of making such a change, and the effective date of such a change and shall prescribe such other rules and procedures as it deems appropriate. Such designation will remain in effect until subsequently changed by the participant in accordance with this paragraph. Following a participant's death and before the payment of any amount due to the participant's beneficiary hereunder has been completed, the beneficiary will exercise the participant's designation powers under this section.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Notwithstanding the preceding paragraph, the committee may establish one or more default investment funds that will be used to determine deemed investment results in the case of any participant or group of participants who have not made a designation under the preceding paragraph. Such default investment fund(s) will be used to determine deemed investment results applicable to the account of such participant or participants until any such participant makes a designation of investment fund(s) in accordance with the plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deemed investment results under this subsection will be credited to a participant's account effective as of the last day of each plan year (and as of such other valuation dates during a plan year as the committee may establish).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The value of a participant's account at any point in time will be his voluntary deferrals (plus, if applicable, his transferred account balance from the Biogen Directors Plan), increased or decreased by deemed investment results as provided in this subsection (b) through the end of the most recent valuation date, and reduced by any distributions from the participant's account.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Notwithstanding the foregoing, in connection with the transfer of participants' Biogen Directors Plan account balances to this plan, transferred account balances will be initially credited with deemed investment results as if the participant had selected the money market fund investment option under the Savings Plan. Deemed investment results in accordance with the preceding sentence will apply to such transferred account balances until a participant changes such designation in accordance with this section.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(c)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Bookkeeping Accounts</font><font style="font-family:Arial;font-size:10pt;">. Participants' accounts and subaccounts will be maintained on Biogen Idec's books for bookkeeping purposes only; such accounts will not represent any property or any secured or priority interest in any trust or in any segregated asset.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In order to facilitate the administration of the plan, the committee may arrange for a participant's voluntary deferrals account to be divided for recordkeeping purposes into two or more subaccounts, in accordance with procedures established by the committee.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">5.2&#160;&#160;&#160;&#160;Vesting. </font><font style="font-family:Arial;font-size:10pt;">A participant will have a fully vested interest in his voluntary deferrals account at all times except that any equity plan awards deferred hereunder shall be subject to such vesting requirements as provided under the Biogen Idec Inc. 2006 Non-Employee Directors Equity Plan (or successor plan) and/or award agreement applicable to such award. For this purpose, "fully vested" means that such account is not subject to forfeiture: however, all participant accounts are subject to (i) fluctuation as result of the crediting of deemed investment results (including losses) to such accounts as provided in the plan and (ii) the possibility of the insolvency or bankruptcy of Biogen Idec (see Section 7.2(a)).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ARTICLE 6 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">DISTRIBUTIONS TO PARTICIPANT</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.1&#160;&#160;&#160;&#160;Distributions for Unforeseeable Emergency. </font><font style="font-family:Arial;font-size:10pt;">If a participant has an unforeseeable emergency prior to his termination of service as a director, he may apply to the committee for a distribution from his vested account. If such application for an unforeseeable emergency distribution is approved by the committee, distribution of the approved amount will be made on the date of approval by the committee. The amount of the distribution will be the amount reasonably needed to alleviate the participant's unforeseeable emergency (including the amount necessary to pay </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><a name="scb2ea42d4fbc4dc68ce8aab11c4dd156"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">any federal, state or local income taxes and penalties reasonably anticipated to result from the distribution), as determined by the committee, up to a maximum of the participant's account balance. Such a distribution will be made from the participant's account in a single lump sum payment. If such a participant's account has two or more subaccounts, the committee will determine which subaccount(s) will be debited to reflect the unforeseeable emergency distribution.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">An unforeseeable emergency is a severe financial hardship affecting the participant resulting from illness of the participant or spouse, dependent or designated beneficiary, need to rebuild the participant's principal residence following damage not covered by insurance, or other similar extraordinary and unforeseeable circumstances arising as a result of events beyond the participant's control. A circumstance or exigency of the participant does not constitute an unforeseeable emergency to the extent that the participant's financial need is or may be relieved through reimbursement or compensation by insurance or otherwise, by liquidation of assets (to the extent that such liquidation would not itself cause severe hardship), or by cessation of voluntary deferrals in accordance with Section 4.1.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The committee will determine whether a participant has incurred an unforeseeable emergency and the amount needed to alleviate the unforeseeable emergency. A participant is not entitled to a distribution under this section regardless of the participant's circumstances or exigencies, and all such distributions and the amounts thereof are subject to the determination of the committee.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.2&#160;&#160;&#160;&#160;In-Service Distribution(s) at a Time Specified by Participant. </font><font style="font-family:Arial;font-size:10pt;">A participant shall be permitted, in accordance with this section, to elect an in-service distribution at a specified date (but not earlier than five years after the date he is making such election) of the portion of his vested account that is not invested in the fixed income option described in the second paragraph of Section 5.1(b). If, in his initial enrollment or other election form (or, if applicable, a subsequent election under Section 4.2(b)(ii)), the participant elected payment of such portion of his vested account (or a specified part of such portion) at a specified time(s) and he is still a director at such time(s), the participant will receive payment of the amount elected, payable on the designated date(s). A participant's election for in-service distributions under this Section 6.2 may be for a single payment or up to five annual payments (with the first payment on the date specified by the participant and subsequent payments on anniversaries of such date), in each case in an amount or portion specified by the participant in his enrollment or other election form. Each payment will be the amount specified (or the entire balance remaining in the participant's account, if less). Payments with respect to an in-service distribution election of a flat dollar amount (as opposed to a percentage of the participant's vested account) by a participant who has deferred equity plan awards shall be paid from the portion of the participant's vested account that is not attributable to such equity based awards.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Any amount in a participant's vested account hereunder not distributed to the participant under this Section 6.2 will be distributed under Section 6.3, 6.4 or 6.5. whichever may be applicable, and Section 6.6 (if applicable). If a participant is receiving multiple payments under this Section 6.2 and dies or otherwise terminates service as a director, payments under this subsection will cease and subsequent payments will be&#160;&#160;&#160;&#160;by Section 6.4 or 6.5, as the case may be.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.3&#160;&#160;&#160;&#160;Distribution Upon a Change in Control. </font><font style="font-family:Arial;font-size:10pt;">In the event of a change in control (as defined in Section 2.3(b), a participant who elected payment of his account under Section 4.2(b)(i) will receive a lump sum payment equal to the amount credited to his account hereunder. Such payment will be made 30 days after the occurrence of the change in control (but not before January 1, 2008 in the case of a change in control that occurs during 2007). This Section 6.2 is effective as of the date of execution of this amended and restated plan document.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.4&#160;&#160;&#160;&#160;Distribution upon Death of a Participant.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">In general</font><font style="font-family:Arial;font-size:10pt;">. If a participant dies before his entire vested account balance has been distributed, his beneficiary will receive the amount remaining in the participant's vested account. Except as provided in Section 6.6. distribution will be made in a single sum payment on the first day of the month after the committee receives appropriate evidence of the participant's death and of the right of any beneficiary to receive such payment (and in the case of payment to the participant's estate, the appointment of a personal representative).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Beneficiary</font><font style="font-family:Arial;font-size:10pt;">. A participant may designate one or more beneficiaries to receive a distribution payable under subsection (a) above and may revoke or change such a designation at any time. If the participant names two or more beneficiaries, distribution to them will be in such proportions as the participant designates or, if the </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><a name="scb2ea42d4fbc4dc68ce8aab11c4dd156"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">participant does not so designate, in equal shares. Any designation of beneficiary will be made in accordance with such procedures or in such form as the committee may prescribe or deem acceptable.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Any portion of a distribution payable upon the death of a participant that is not disposed of by a designation of beneficiary under the preceding paragraph, for any reason whatsoever, will be paid to the participant's spouse if living at his death, otherwise equally to the participant's natural and adopted children (and the issue of a deceased child by right of representation), otherwise to the participant's estate.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The committee may direct payment in accordance with a prior designation of beneficiary (and will be fully protected in so doing) if such direction (i) is given before a later designation is received, or (ii) is due to the committee's inability to verify the authenticity of a later designation. Such a distribution will discharge all liability therefor under the plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.5&#160;&#160;&#160;&#160;Other Distributions. </font><font style="font-family:Arial;font-size:10pt;">Except in the case of the participant's death (in which case distribution is made in accordance with Section 6.4), distribution of a participant's account will be made at the time elected by the participant in accordance with Section 4.2. In the absence of such an election, distribution of the participant's account will be made on the first day of the month after the participant's termination of service as a director. Distribution will be made in a single lump sum payment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In applying the distribution provisions of this Article 6, in the case of a participant who terminates service as a director but thereupon becomes an employee of Biogen Idec (or a subsidiary or other affiliate of Biogen Idec), such participant will be deemed not to have a termination of service as a director until he terminates employment with Biogen Idec (or subsidiary or other affiliate).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.6&#160;&#160;&#160;&#160;Installment Distributions in Certain Cases.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Participant</font><font style="font-family:Arial;font-size:10pt;">. Notwithstanding the provisions of Section 6.5, a participant may, at the time of filing his initial enrollment form under Section 4.2(b)(i) (or. if applicable, in a subsequent election under Section 4.2(b)(ii)), designate that the amount payable to him hereunder upon termination of service as a director will be paid in a number (minimum of two and maximum of fifteen) of annual installment payments, as specified by the participant. However, in the event the participant's account balance as of the date that installment distribution would begin in accordance with Section 6.5 is equal to or less than the limit under Code Section 402(g)(1)(B) and (g)(4) as in effect when installments would begin (for example, $15,500 for 2008)), such account balance will automatically be paid in the form of a lump sum payment to the extent not prohibited by the regulations under Code Section 409A.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Beneficiary</font><font style="font-family:Arial;font-size:10pt;">. Notwithstanding Section 6.4, a participant may at the time of filing his initial enrollment form under Section 4.2 (or, if applicable, in a subsequent election) designate that, if the participant dies before receiving the entire amount payable to him hereunder, the beneficiary will receive either:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:96px;text-align:left;text-indent:0px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(i)</font><font style="font-family:Arial;font-size:10pt;">A number of annual installment payments equal to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:Arial;font-size:10pt;">(A)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the number the participant elected for himself under subsection (a) above (if the participant dies before receiving any installment payments), or</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:3px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:Arial;font-size:10pt;">(B)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the number of remaining installment payments due to the participant under subsection (a) above (if the participant dies after receiving one or more installment payments); or</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:192px;text-indent:-48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:Arial;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a single payment.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Payment to the beneficiary (or the first installment) will be made or begin as provided in Section 6.4(a).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">lf the participant fails to designate the form of payment to the beneficiary, the default form of payment will be a single payment under (ii)</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:10pt;">above.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(c)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Installment Payments</font><font style="font-family:Arial;font-size:10pt;">. Where installment payments are due, the first annual installment payment will be made on the date specified in Section 6.4 or 6.5 (whichever is applicable) and subsequent annual installments will be paid on succeeding anniversaries of the first payment date. The amount of each annual </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><a name="scb2ea42d4fbc4dc68ce8aab11c4dd156"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="font-family:Arial;font-size:10pt;">installment payment will be determined by multiplying the amount then remaining to be paid by a fraction whose numerator is one and whose denominator is the number of remaining annual installment payments. Installment payments with respect to the portion of a participant's vested account equity based awards shall be made in shares and shall not include any fractional shares</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(d)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Death of a Beneficiary</font><font style="font-family:Arial;font-size:10pt;">. If a participant's designated beneficiary is receiving installment payments and dies before receiving payment of all the annual installments, the designated beneficiary's estate will receive a lump sum payment of the amount remaining to the distributed to such deceased beneficiary. Such payment will be made on the first day of the month next following the committee's receipt of satisfactory evidence of the death of the designated beneficiary and the appointment of a personal representative.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(e)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Deemed Single Payment</font><font style="font-family:Arial;font-size:10pt;">. As provided in the regulations under Code Section 409A, installment payments to a participant will be deemed a single payment on the date of the first installment for purposes of the anti-acceleration rule (Section 4.2(b) and Section 6.9) and the rules governing the timing of changes in elections with respect to time and form of payment hereunder (Section 4.2(b)).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.7&#160;&#160;&#160;&#160;Certain Other Distributions. </font><font style="font-family:Arial;font-size:10pt;">In addition to the distributions provided for in the preceding sections of this Article 6, the committee may provide for a distribution from a participant's account under the following circumstances:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Domestic Relations Order</font><font style="font-family:Arial;font-size:10pt;">. Distribution of the amount necessary to fulfill the requirements of a domestic relations order (as defined in Code Section 414(p)) requiring the payment of all or a portion of participant's account to another individual (see Section 7.3(b)).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Conflicts of Interest</font><font style="font-family:Arial;font-size:10pt;">. Distribution to the extent reasonably necessary to comply with a federal government ethics agreement or a federal, state, local or foreign ethics or conflicts of interest law (as described in the regulations under Code Section 409A.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(c)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Violations of Code Section 409A</font><font style="font-family:Arial;font-size:10pt;">. In the event that, notwithstanding the intent that this plan satisfy in form and operation the requirements of Code Section 409A, it is determined that the requirements of Code Section 409A have been violated with respect to any participant or group of participants, distribution of the amount determined to be includable in taxable income of such participant or participants as a result of such violation of Code Section 409A.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(d)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Other Circumstances</font><font style="font-family:Arial;font-size:10pt;">. Distribution of any amount specifically permitted by Code Section 409A and the regulations thereunder.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.8&#160;&#160;&#160;&#160;Delay in Distributions. </font><font style="font-family:Arial;font-size:10pt;">Notwithstanding the provisions of any of the foregoing sections in this Article 6, the committee may delay the making of any payment to a subsequent date, provided that the delayed payment is made not later than the latest time permitted under Code Section 409A and the&#160;&#160;&#160;&#160;regulations and rulings thereunder (generally, the later of the end of the calendar year in which the specified payment date occurs or the 15th day of the third month after the specified payment date).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">6.9&#160;&#160;&#160;&#160;Compliance with Code Section 409A. </font><font style="font-family:Arial;font-size:10pt;">Notwithstanding any other provision of this plan (including, without limitation, Section 6.7(c)), distributions and elections respecting distributions are intended to be and will be administered in accordance with the provisions of Code Section 409A and the regulations and rulings thereunder (including the provisions prohibiting acceleration of payment unless specifically permitted by such regulations and rulings).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:264px;text-indent:1px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ARTICLE 7 MISCELLANEOUS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.1&#160;&#160;&#160;&#160;Amendment or Termination of Plan. </font><font style="font-family:Arial;font-size:10pt;">Biogen Idec, by action of the Board or of the Compensation Committee (or such committee thereof or officer or officers of Biogen Idec to whom the Board has delegated this authority), at any time and from time to time, may amend or modify any or all of the provisions of this plan or may terminate this plan without the consent of any participant (or beneficiary or other person claiming through a participant). In addition, any amendment may be made by the committee, or the Executive Vice President - Chief Financial Officer, or the Executive Vice President - Human Resources of Biogen Idec except for an amendment that </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><a name="scb2ea42d4fbc4dc68ce8aab11c4dd156"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">would materially increase or reduce the benefits of the plan to participants or materially increase the cost of maintaining the plan to Biogen Idec: such committee or specified officers may not terminate the plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">No termination or amendment of the plan may reduce the amount credited to the account of any participant under the plan (including a participant whose service as a director terminated before such plan termination or amendment). However, Biogen Idec may change the deemed investment options under Section 5.1(b), and Biogen Idec may upon termination of this plan pay participants' account balances to the participants regardless of the times elected for payment (or the start of installment payments) elected by the participants and may pay such amounts in single sum payments regardless of whether installment distributions would otherwise be payable under Section 6.6; provided that any such distributions upon plan termination must be permitted by Code Section 409A and the regulations and rulings thereunder. In addition, Biogen Idec may, from time to time, make any amendment that it deems necessary or desirable to satisfy the applicable requirements of the tax laws and rulings and regulations thereunder in order to preserve, if possible, the tax deferral features of this plan for participants. No diminution or restriction on a participant's opportunity to make elections or withdrawals, or exercise other privileges or rights hereunder pursuant to the preceding sentence will be deemed to violate the rights of any participant or beneficiary hereunder so long as such change does not render a participant's account balance forfeitable. Any amendment that is required by Code Section 409A and the regulations and rulings thereunder to have a delayed effective date will be effective no earlier than such required date.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.2&#160;&#160;&#160;&#160;Benefits Not Currently Funded.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;">Nothing in this plan will be construed to create a trust or to obligate Biogen ldec to segregate a fund, purchase an insurance contract or other investment, or in any other way currently to fund the future payment of any benefits hereunder, nor will anything herein be construed to give any participant or any other person rights to any specific assets of Biogen Idec or any other entity. However, in order to make provision for its obligations hereunder, Biogen Idec may in its discretion purchase an insurance contract or other investment; any such contract or investment will be a general asset belonging to Biogen Idec, and no participant or beneficiary will have any rights to any such asset. The rights of a participant or beneficiary hereunder will be solely those of a general, unsecured creditor of Biogen Idec.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:10pt;">Notwithstanding subsection (a) above, Biogen Idec in its sole discretion may establish a grantor trust of which it is treated as the owner under Code Section 671 to provide for the payment of benefits hereunder, subject to such terms and conditions as Biogen Idec may deem necessary or advisable to ensure that trust assets and benefit payments hereunder are nor includable, by reason of the trust, in the taxable income of trust beneficiaries before actual distribution and that the existence of the trust does not cause the plan or any other arrangement to be considered funded for purposes of Title I of the Employee Retirement Income Security Act of 1974, as amended ("ERISA") or for purposes of the Internal Revenue Code of 1986. as amended. Biogen Idec may terminate any such trust in accordance with its terms.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.3&#160;&#160;&#160;&#160;No Assignment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;">No participant or beneficiary will have any power or right to transfer, assign, anticipate or  otherwise encumber any benefit or amount payable under this plan, nor shall any such benefit or amount payable be subject to seizure or attachment by any creditor of a participant or a beneficiary, or to any other legal, equitable or other process, or be liable for, or subject to, the debts, liabilities or other obligations of a participant or beneficiary except as otherwise required by law.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:10pt;">Notwithstanding subsection (a) above, all or a portion of a participant's account balance may be assigned to the participant's spouse, former spouse, or other dependent (for purposes of this section, an "alternate recipient") in connection with a domestic relations order (as defined in Code Section 414(p)) awarding such portion to the alternate recipient. However, no such order may award an alternate recipient greater rights than the participant has with respect to his account. Upon receipt of a copy of the relevant provisions of any such order or property settlement agreement, certified to be accurate and in effect by the participant, and an acknowledgment by the alternate recipient that such alternate recipient will be responsible for income taxes on such amounts when distributed or made available to such alternate recipient and that such amounts are subject to income tax withholding as provided in this plan, and such other information (including the alternate recipient's social security number) as the committee may reasonably request, the committee will assign such amount to a separate account hereunder and will distribute such account to the alternate recipient in the form of a single sum payment as soon as </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><a name="scb2ea42d4fbc4dc68ce8aab11c4dd156"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="font-family:Arial;font-size:10pt;">administratively possible, as permitted by Reg. 1.409A-3(j)(4)(ii) (except for any unvested amounts).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.4&#160;&#160;&#160;&#160;Effect of Change in Control.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:42px;">(a)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Amendments</font><font style="font-family:Arial;font-size:10pt;">. Notwithstanding Section 7.1, following the occurrence of a change in control (as defined in Section 2.3(a)); No amendment will be made following a change in control without the consent of the affected participant (or beneficiary or other person claiming through a participant) that adversely affects the rights of a participant (or beneficiary or other person claiming through a participant) under the plan as in effect immediately before such change in control, including (i) the right to make elections concerning the form and time of payment of distributions in accordance with Section 4.2(b) and the right to receive distributions in the form elected by the participant thereunder; and (ii) the right to the investment funds or options specified herein for the determination of deemed investment results applicable to participants' accounts, as in effect immediately before such change in control. In particular, for purposes of clause (ii) of the preceding sentence (i) the committee may not set the rate of return of the fixed income option under Section 5.1(b)</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Arial;font-size:10pt;">at a rate lower than that available under life insurance or annuity contracts obtained by a vendor or service provider (currently, The Todd Organization) for purposes of the plan; and (ii) the committee will maintain a menu of investment funds under Section 5.1(b) that is substantially similar (in terms of investment styles and ability to position an account on a risk/reward spectrum) to the array of funds available immediately prior to the change in control.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Termination.</font><font style="font-family:Arial;font-size:10pt;">&#32;The plan will not be terminated before the payment of all benefits hereunder in accordance with the terms of the plan as in effect immediately before such change in control without the consent of a majority of the participants (including, in the case of the deceased participant, the beneficiary or other person claiming through such deceased participant). This subsection (b) will not preclude the merger of this plan into a nonqualified deferred compensation plan maintained by a successor to Biogen Idec provided that the benefits and rights of participants hereunder (including this Section 7.4) are preserved in such successor plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Effective Date</font><font style="font-family:Arial;font-size:10pt;">. This Section 7.4 is effective as of the date of execution of this amended and restated plan document.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.5&#160;&#160;&#160;&#160;Responsibilities and Authority of Committee. </font><font style="font-family:Arial;font-size:10pt;">The committee will control and manage the operation and administration of the plan except to the extent that such responsibilities are specifically assigned hereunder to Biogen Idec, the Board, the Compensation Committee (or a delegatee of the Board or the Compensation Committee).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The committee will have all powers and authority necessary or appropriate to carry out its responsibilities for the operation and administration of the plan. It will have discretionary authority to interpret and apply all plan provisions and to correct any defect, supply any omission or reconcile any inconsistency or ambiguity in such manner as it deems advisable.  It will make all final determinations concerning eligibility, benefits and rights hereunder, and all other matters concerning plan administration and interpretation.  All determinations and actions of the committee will be conclusive and binding upon all persons, except as otherwise provided herein or by law, and except that the committee may revoke or modify a determination or action previously made in error. It is intended that any action or inaction by the committee will be given the maximum possible deference by any reviewing body (whether a court or other reviewing body), and will be reversed by such reviewing court or other body only if found to be arbitrary and capricious.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Biogen Idec will be the "plan administrator" and the "named fiduciary" for purposes of ERISA.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.6&#160;&#160;&#160;&#160;Limitation on Rights Created by Plan. </font><font style="font-family:Arial;font-size:10pt;">Nothing appearing in the plan will be construed (a) to give any person any benefit, right or interest except as expressly provided herein, or (b) to create a contract of employment or to give any director the right to continue in such capacity or to affect or modify the terms of his service as a director in any way.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.7&#160;&#160;&#160;&#160;Tax Withholding. </font><font style="font-family:Arial;font-size:10pt;">Any payment hereunder to a participant, beneficiary or alternate recipient will be subject to withholding of income and other taxes to the extent required by law.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.8&#160;&#160;&#160;&#160;Text Controls. </font><font style="font-family:Arial;font-size:10pt;">Headings and titles are for convenience only, and the text will control in all matters.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.9&#160;&#160;&#160;&#160;Applicable State Law. </font><font style="font-family:Arial;font-size:10pt;">To the extent that state law applies, the provisions of the plan will be construed, </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><a name="scb2ea42d4fbc4dc68ce8aab11c4dd156"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">enforced and administered according to the laws of the Commonwealth of Massachusetts.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">7.10&#160;&#160;&#160;&#160;Paperless Administration. </font><font style="font-family:Arial;font-size:10pt;">The committee may establish procedures whereby an electronic, internet or voice recognized authorization or election will or may be utilized under the plan in lieu a written form or document otherwise required by the terms of the plan. In such event, any reference herein to a written election, authorization or other form shall be deemed to include such other authorization or election.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:432px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">BIOGEN IDEC INC.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:432px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By: </font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">/s/ Paul Clancy</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:432px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dated: December 13, 2011</font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><a name="sc3bb50ae40784d7aae01320f4a8d9f27"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">APPENDIX A</font></div><div style="line-height:120%;padding-top:5px;text-align:center;padding-left:220px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Historical Information: Amendments</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">A.1&#160;&#160;&#160;&#160;Adoption of Plan Document.  </font><font style="font-family:Arial;font-size:10pt;">This plan document was approved by the Board of Directors of the Corporation (Biogen Idec Inc.), effective as of January 1, 2004.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">By appropriate votes, the account balances of certain directors who previously were participants under the Biogen, Inc. Voluntary Board of Directors Savings Plan, maintained by Biogen, Inc. prior to the merger transaction, were transferred to and merged into this plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">A.2&#160;&#160;&#160;&#160;2005 Amendment and Restatement. </font><font style="font-family:Arial;font-size:10pt;">The plan was amended and restated in its entirety, effective as of January 1, 2005 (except as otherwise specified), primarily to comply with the requirements of Code Section 409A and regulations thereunder. During the period from January 1, 2005 until the date of execution of this amended and restated plan document, the plan was interpreted and administered in accordance with a good faith interpretation of the requirements of Code Section 409A and applicable guidance of the Internal Revenue Service thereunder.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The provisions herein relating to distributions and other changes upon the occurrence of a change in control (primarily Sections 2.3, 4.2(b), 6.3 and 7.4) are effective as of the date of execution of this amended and restated plan document. The provisions relating to the increase in the threshold for the payment of a lump sum in place of installments from $10,000 to the Code Section 402(g)(1)(B) and (g)(4) limit (the last sentence of Section 6.6(a)) are effective as of January 1, 2008.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">A.3&#160;&#160;&#160;&#160;2012 Amendment and Restatement. </font><font style="font-family:Arial;font-size:10pt;">The plan was amended and restated in its entirety, effective as of January 1, 2012 to expand the tax-deferred savings opportunities by allowing members of the Board of Directors to defer certain equity based awards granted under the Biogen Idec Inc. 2006 Non-Employee Directors Equity Plan (or successor plan).</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div style="font-family:Times New Roman;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A-1</font></div></div><hr style="page-break-after:always"><a name="s46fe58244c744b97a7e3016214231210"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#232323;font-weight:bold;">Biogen Idec Inc. Voluntary Board of Directors </font><font style="font-family:Arial;font-size:10pt;color:#343434;font-weight:bold;">Savings </font><font style="font-family:Arial;font-size:10pt;color:#232323;font-weight:bold;">Plan</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#232323;">First Amendment to the January 1, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">20</font><font style="font-family:Arial;font-size:10pt;color:#111111;">12 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#232323;">Amended and Restated Document</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#232323;">WHEREAS</font><font style="font-family:Arial;font-size:10pt;color:#494949;">, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Biogen Idec Inc. (the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Employer") established t</font><font style="font-family:Arial;font-size:10pt;color:#111111;">he </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Biogen Idec Inc. Voluntary Board of Directors Savings Plan, most recently amended and restated effective as of January </font><font style="font-family:Arial;font-size:10pt;color:#343434;">1, 2012 (the "Plan");</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#232323;">WHEREAS, Section 7.1 of the Plan provides the Employer the right to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">amend or </font><font style="font-family:Arial;font-size:10pt;color:#232323;">modify any and all provisions </font><font style="font-family:Arial;font-size:10pt;color:#343434;">of </font><font style="font-family:Arial;font-size:10pt;color:#232323;">the Plan by action </font><font style="font-family:Arial;font-size:10pt;color:#343434;">of </font><font style="font-family:Arial;font-size:10pt;color:#232323;">the Board or </font><font style="font-family:Arial;font-size:10pt;color:#343434;">of </font><font style="font-family:Arial;font-size:10pt;color:#111111;">the </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Compensation </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Committee </font><font style="font-family:Arial;font-size:10pt;color:#232323;">(or </font><font style="font-family:Arial;font-size:10pt;color:#343434;">such </font><font style="font-family:Arial;font-size:10pt;color:#232323;">other </font><font style="font-family:Arial;font-size:10pt;color:#343434;">committee </font><font style="font-family:Arial;font-size:10pt;color:#232323;">thereof </font><font style="font-family:Arial;font-size:10pt;color:#343434;">or </font><font style="font-family:Arial;font-size:10pt;color:#232323;">officer </font><font style="font-family:Arial;font-size:10pt;color:#343434;">or </font><font style="font-family:Arial;font-size:10pt;color:#232323;">officers of Biog</font><font style="font-family:Arial;font-size:10pt;color:#494949;">e</font><font style="font-family:Arial;font-size:10pt;color:#232323;">n Idec to whom the Board or </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Compensa</font><font style="font-family:Arial;font-size:10pt;color:#111111;">tion </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Committee has delegated this </font><font style="font-family:Arial;font-size:10pt;color:#343434;">author</font><font style="font-family:Arial;font-size:10pt;color:#111111;">it</font><font style="font-family:Arial;font-size:10pt;color:#343434;">y); a</font><font style="font-family:Arial;font-size:10pt;color:#111111;">nd </font><font style="font-family:Arial;font-size:10pt;color:#232323;">further</font><font style="font-family:Arial;font-size:10pt;color:#494949;">, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">that any amendment may be made by the Committee or by </font><font style="font-family:Arial;font-size:10pt;color:#343434;">the </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Executive Vice President - Chief Financial Officer, or Executive Vice President - Human Resources, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">except </font><font style="font-family:Arial;font-size:10pt;color:#232323;">for an amendment that would materially increase </font><font style="font-family:Arial;font-size:10pt;color:#343434;">or </font><font style="font-family:Arial;font-size:10pt;color:#232323;">reduce the benefits of </font><font style="font-family:Arial;font-size:10pt;color:#111111;">the </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Plan to participants or materially increase the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">cost of </font><font style="font-family:Arial;font-size:10pt;color:#232323;">maintaining the Plan to the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Employer; </font><font style="font-family:Arial;font-size:10pt;color:#232323;">and</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#232323;">WHEREAS, the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Employer </font><font style="font-family:Arial;font-size:10pt;color:#232323;">desires to amend </font><font style="font-family:Arial;font-size:10pt;color:#343434;">the </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Plan to eliminate the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">ability to </font><font style="font-family:Arial;font-size:10pt;color:#232323;">defer any </font><font style="font-family:Arial;font-size:10pt;color:#343434;">equity </font><font style="font-family:Arial;font-size:10pt;color:#232323;">based awards that may be </font><font style="font-family:Arial;font-size:10pt;color:#343434;">granted </font><font style="font-family:Arial;font-size:10pt;color:#232323;">beginning on or after January 1, 2015 under the Biogen </font><font style="font-family:Arial;font-size:10pt;color:#111111;">Id</font><font style="font-family:Arial;font-size:10pt;color:#343434;">ec </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Inc</font><font style="font-family:Arial;font-size:10pt;">. </font><font style="font-family:Arial;font-size:10pt;color:#232323;">2006 Non-Employee Directors </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Equ</font><font style="font-family:Arial;font-size:10pt;color:#111111;">i</font><font style="font-family:Arial;font-size:10pt;color:#343434;">ty </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#343434;">NOW, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">THEREFORE, the Plan is amended </font><font style="font-family:Arial;font-size:10pt;color:#343434;">effective </font><font style="font-family:Arial;font-size:10pt;color:#232323;">as of January 1, 2015 as </font><font style="font-family:Arial;font-size:10pt;color:#343434;">se</font><font style="font-family:Arial;font-size:10pt;color:#111111;">t </font><font style="font-family:Arial;font-size:10pt;color:#232323;">forth below:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#232323;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#232323;">Section 4.1, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Voluntary </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Deferrals"</font><font style="font-family:Arial;font-size:10pt;color:#494949;">, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">is amended by adding the following new paragraph to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">the </font><font style="font-family:Arial;font-size:10pt;color:#232323;">end </font><font style="font-family:Arial;font-size:10pt;color:#343434;">the</font><font style="font-family:Arial;font-size:10pt;color:#111111;">reof</font><font style="font-family:Arial;font-size:10pt;color:#343434;">:</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#343434;">"Notwithstanding </font><font style="font-family:Arial;font-size:10pt;color:#232323;">anything in this plan </font><font style="font-family:Arial;font-size:10pt;color:#343434;">to the </font><font style="font-family:Arial;font-size:10pt;color:#232323;">contrary, no director may elect </font><font style="font-family:Arial;font-size:10pt;color:#343434;">to </font><font style="font-family:Arial;font-size:10pt;color:#232323;">defer to this plan any </font><font style="font-family:Arial;font-size:10pt;color:#343434;">equity </font><font style="font-family:Arial;font-size:10pt;color:#232323;">plan </font><font style="font-family:Arial;font-size:10pt;color:#343434;">award granted </font><font style="font-family:Arial;font-size:10pt;color:#232323;">on or after January </font><font style="font-family:Arial;font-size:10pt;color:#111111;">1</font><font style="font-family:Arial;font-size:10pt;color:#343434;">, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">2015 under the Biogen Idec Inc. 2006 Non&#173; Employee Directors </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Equity </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Plan.</font><font style="font-family:Arial;font-size:10pt;color:#494949;">"</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#232323;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#232323;">Section 4.2(a), </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Voluntary </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Deferrals", is amended by adding the following new paragraph to the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">end </font><font style="font-family:Arial;font-size:10pt;color:#232323;">thereof:</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#343434;">"Notwithstandi</font><font style="font-family:Arial;font-size:10pt;color:#111111;">ng </font><font style="font-family:Arial;font-size:10pt;color:#232323;">anything in this </font><font style="font-family:Arial;font-size:10pt;color:#343434;">p</font><font style="font-family:Arial;font-size:10pt;color:#111111;">l</font><font style="font-family:Arial;font-size:10pt;color:#343434;">an </font><font style="font-family:Arial;font-size:10pt;color:#232323;">to the contrary, no director may </font><font style="font-family:Arial;font-size:10pt;color:#343434;">elect </font><font style="font-family:Arial;font-size:10pt;color:#232323;">to defer to this plan any equity plan </font><font style="font-family:Arial;font-size:10pt;color:#343434;">award granted </font><font style="font-family:Arial;font-size:10pt;color:#232323;">on or after January 1, 2015 under the Biogen Idec Inc. </font><font style="font-family:Arial;font-size:10pt;color:#343434;">2006 </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Non&#173; </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Emp</font><font style="font-family:Arial;font-size:10pt;color:#111111;">l</font><font style="font-family:Arial;font-size:10pt;color:#343434;">oyee </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Directors Equity Plan."</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#232323;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#232323;">Appendix A, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">"Historical </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Information; Amendments", is amended by adding a new Section A.4 to read as follows:</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#343434;">"A.4 </font><font style="font-family:Arial;font-size:10pt;color:#232323;font-weight:bold;">2015 Amendment</font><font style="font-family:Arial;font-size:10pt;color:#232323;">. The plan </font><font style="font-family:Arial;font-size:10pt;color:#343434;">was </font><font style="font-family:Arial;font-size:10pt;color:#232323;">amended to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">eliminate </font><font style="font-family:Arial;font-size:10pt;color:#232323;">the ability to defer </font><font style="font-family:Arial;font-size:10pt;color:#343434;">any </font><font style="font-family:Arial;font-size:10pt;color:#232323;">equity based </font><font style="font-family:Arial;font-size:10pt;color:#343434;">awa</font><font style="font-family:Arial;font-size:10pt;color:#111111;">rd</font><font style="font-family:Arial;font-size:10pt;color:#343434;">s </font><font style="font-family:Arial;font-size:10pt;color:#232323;">that may be granted beginning on or after January 1, 2015 under the Biogen Idec Inc. </font><font style="font-family:Arial;font-size:10pt;color:#343434;">2006 </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Non-Employee Directors Equity Plan Amended and Restated 2008 Omnibus Equity Plan.</font><font style="font-family:Arial;font-size:10pt;color:#494949;">"</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#232323;">IN </font><font style="font-family:Arial;font-size:10pt;color:#313131;">WITNESS WHEREOF, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">the </font><font style="font-family:Arial;font-size:10pt;color:#313131;">Employer has </font><font style="font-family:Arial;font-size:10pt;color:#232323;">caused </font><font style="font-family:Arial;font-size:10pt;color:#313131;">t</font><font style="font-family:Arial;font-size:10pt;color:#131313;">hi</font><font style="font-family:Arial;font-size:10pt;color:#424242;">s </font><font style="font-family:Arial;font-size:10pt;color:#232323;">in</font><font style="font-family:Arial;font-size:10pt;color:#424242;">st</font><font style="font-family:Arial;font-size:10pt;color:#131313;">rum</font><font style="font-family:Arial;font-size:10pt;color:#313131;">e</font><font style="font-family:Arial;font-size:10pt;color:#131313;">nt to be executed by an </font><font style="font-family:Arial;font-size:10pt;color:#313131;">author</font><font style="font-family:Arial;font-size:10pt;color:#131313;">i</font><font style="font-family:Arial;font-size:10pt;color:#313131;">zed officer on beha</font><font style="font-family:Arial;font-size:10pt;color:#131313;">l</font><font style="font-family:Arial;font-size:10pt;color:#313131;">f of the Emp</font><font style="font-family:Arial;font-size:10pt;color:#131313;">l</font><font style="font-family:Arial;font-size:10pt;color:#313131;">oye</font><font style="font-family:Arial;font-size:10pt;color:#131313;">r</font><font style="font-family:Arial;font-size:10pt;color:#313131;">, as of </font><font style="font-family:Arial;font-size:10pt;color:#232323;">the 15th day of October, 2014.</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:432px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#232323;">BIOGEN IDEC INC.</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:432px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#232323;">By: </font><font style="font-family:Arial;font-size:10pt;color:#232323;text-decoration:underline;">/s/ Paul Clancy</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><a name="sefa62d779a1647798bd1086876288714"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;font-weight:bold;">Biogen Inc</font><font style="font-family:Arial;font-size:10pt;color:#676767;font-weight:bold;">.</font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;font-weight:bold;">Voluntary Board of </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;font-weight:bold;">Directors </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;font-weight:bold;">Savings </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;font-weight:bold;">Plan</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Second Amendment </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">to the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">January </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">1, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">2012 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Amended and </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Restated Plan </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Document</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">WHEREAS, </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Biogen Idec Inc., a </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Delaware corporation</font><font style="font-family:Arial;font-size:10pt;color:#464646;">, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">is the plan sponsor </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">of the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Biogen Idec </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Inc. </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Voluntary </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Board </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">of </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Directors </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Savings </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Plan (the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">"Plan")</font><font style="font-family:Arial;font-size:10pt;color:#464646;">; </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">and</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">WHEREAS, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">effective </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">March </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">23, 2015, Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Idec Inc. </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">changed </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">its name </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">to </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Biogen Inc. </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">("Biogen")</font><font style="font-family:Arial;font-size:10pt;color:#464646;">; </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">and</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">WHEREAS</font><font style="font-family:Arial;font-size:10pt;color:#464646;">, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Biogen established the Plan</font><font style="font-family:Arial;font-size:10pt;color:#464646;">, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">amended and </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">restat</font><font style="font-family:Arial;font-size:10pt;color:#464646;">e</font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">d </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Plan eff</font><font style="font-family:Arial;font-size:10pt;color:#464646;">e</font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">ctive as of January </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">1</font><font style="font-family:Arial;font-size:10pt;color:#565656;">, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">2012; and</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">WHEREAS</font><font style="font-family:Arial;font-size:10pt;color:#464646;">, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Section 7.1 of </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the Plan provides </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">th</font><font style="font-family:Arial;font-size:10pt;color:#464646;">e </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">right to </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">amend </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the Plan; </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">and </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">WHEREAS, </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Biogen </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">desires </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">to </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">amend </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Plan effective </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">March </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">23, 2015 </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">to </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">change </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the name </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">of the </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Plan from the Biogen Idec Inc. </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Voluntary </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Board </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">of Dir</font><font style="font-family:Arial;font-size:10pt;color:#464646;">e</font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">ctors Savings Plan </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">to </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">the </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Biogen Inc. </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Voluntary Board of Directors Savings Plan </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">and </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">to </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">reflect Biogen </font><font style="font-family:Arial;font-size:10pt;color:#464646;">'</font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">s </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">name </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">change.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">NOW, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">THEREFORE, </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Plan is amended </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">effective </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">as of </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">March </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">23, 2015 as set forth </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">below:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Section </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">1.1, "Purpose and </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Effective </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Date", is </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">amended </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">by deleting </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">the </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">reference to </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Idec</font><font style="font-family:Arial;font-size:10pt;color:#464646;">" </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">in the first </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">sentence of </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the first paragraph </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">and substituting "Biogen" therefor</font><font style="font-family:Arial;font-size:10pt;color:#464646;">, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">and by deleting the reference to </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the </font><font style="font-family:Arial;font-size:10pt;color:#565656;">"</font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Biogen Idec Inc. </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">2006 Non-Employee </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Directors </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Equity Plan" </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">in the first </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">sentence of the second paragraph and substituting </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the </font><font style="font-family:Arial;font-size:10pt;color:#464646;">"</font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Biogen Inc. </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">2006 Non-Employee </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Directors </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Equity </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Plan" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Section 2</font><font style="font-family:Arial;font-size:10pt;color:#030303;">.1</font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">, "Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Idec", is </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">amended </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">by deleting it </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">in </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">its </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">entirety and substituting the following therefor:</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">"2.1</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;font-weight:bold;">Biogen</font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">&#32;means Biogen Inc</font><font style="font-family:Arial;font-size:10pt;color:#464646;">.</font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">, a </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Delaware </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">corporation, or any successor </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">to all </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">or </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the major </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">portion of </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">its </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">assets or business which assumes the obligations of </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Biogen Inc. </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">under this plan."</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Section 2.2, "Board", </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">i</font><font style="font-family:Arial;font-size:10pt;color:#464646;">s </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">amended by </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">deleting it in </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">its </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">entirety </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">and substituting </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the following therefor:</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">"2.2</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;font-weight:bold;">Board</font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">&#32;means the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Board </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">of Directors </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">of Biogen."</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Section 2.3, </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">"Change in </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Control </font><font style="font-family:Arial;font-size:10pt;color:#464646;">"</font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">, </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">is </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">amended </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">by deleting the reference to the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Idec Inc. </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">2008 Omnibus Equity </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Plan" in </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">subsection (a) </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">thereof </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">and substituting the "Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">(formerly </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Idec) Amended and </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Restated 2008 Omnibus Equity </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Plan" </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">therefor, and </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">by deleting </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">all references </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">to </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">"Biogen Idec" </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">in </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">subsection (b) </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">thereof </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">and substituting "Biogen" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Section 2.5, "Director", </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">is </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">amended by deleting </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">reference </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">to </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">Idec" </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">and substituting </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">"Biogen</font><font style="font-family:Arial;font-size:10pt;color:#464646;">" </font><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#1c1c1c;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Section </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">2.6, </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">"Equity Plan Award", is amended by deleting the reference to </font><font style="font-family:Arial;font-size:10pt;color:#161616;">the </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Idec </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Inc. </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">2006 </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Non-Employee Directors </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Equity </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Plan" </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">substituting the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Inc. 2006 </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">No</font><font style="font-family:Arial;font-size:10pt;color:#161616;">n&#173; </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Employee Directors Equity Plan" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Section </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">2.9, </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"P</font><font style="font-family:Arial;font-size:10pt;color:#161616;">lan</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">", </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">is amended by deleting it in its entirety and </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">substituting the fo</font><font style="font-family:Arial;font-size:10pt;color:#161616;">llowin</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">g </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">therefor:</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">"2.9</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;font-weight:bold;">Plan </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">means </font><font style="font-family:Arial;font-size:10pt;color:#161616;">the </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Biogen Inc. Voluntary Board of Directors </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Savings </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Plan, as </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">set </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">forth in this plan </font><font style="font-family:Arial;font-size:10pt;color:#161616;">in</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">strument, </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">and as it may be amended from time to </font><font style="font-family:Arial;font-size:10pt;color:#161616;">time.</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Section </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">2.12, "Savings </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Plan", is amended by deleting the reference to the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"B</font><font style="font-family:Arial;font-size:10pt;color:#161616;">iog</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">e</font><font style="font-family:Arial;font-size:10pt;color:#161616;">n </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Idec 401(k) Savings Plan" and substituting the "Biogen 401(k) Savings Plan" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Section </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">3.2, </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">"End </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">of </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Participation", is amended by deleting the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">reference </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">to "Biogen Idec" </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and s</font><font style="font-family:Arial;font-size:10pt;color:#161616;">ubstituting </font></div></td></tr></table><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><a name="sefa62d779a1647798bd1086876288714"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen</font><font style="font-family:Arial;font-size:10pt;color:#545454;">" </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">therefor.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Section 4.1, </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Vo</font><font style="font-family:Arial;font-size:10pt;color:#161616;">lun</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">tary </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Deferrals</font><font style="font-family:Arial;font-size:10pt;color:#545454;">"</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">, </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">is amended by deleting the reference </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">to "Biogen </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Idec" </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">substituting </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">therefor, and by deleting the </font><font style="font-family:Arial;font-size:10pt;color:#161616;">re</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">fere</font><font style="font-family:Arial;font-size:10pt;color:#161616;">nc</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">e </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">to the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Idec Inc. 2006 </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">No</font><font style="font-family:Arial;font-size:10pt;color:#161616;">n&#173; </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Emp</font><font style="font-family:Arial;font-size:10pt;color:#161616;">loyee </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Directors Equity Plan" </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and substituting the "Biogen </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Inc. </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">2006 </font><font style="font-family:Arial;font-size:10pt;color:#161616;">Non-Emplo</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">yee </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Directors </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Equity Plan" </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Section </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">4.2(a), "Volun</font><font style="font-family:Arial;font-size:10pt;color:#161616;">ta</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">ry </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Deferrals"</font><font style="font-family:Arial;font-size:10pt;color:#545454;">, </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">is amended </font><font style="font-family:Arial;font-size:10pt;color:#161616;">by </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">deleting the reference to </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Idec" and </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">substi</font><font style="font-family:Arial;font-size:10pt;color:#161616;">tuting </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">therefor, and by deleting the </font><font style="font-family:Arial;font-size:10pt;color:#161616;">r</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">efere</font><font style="font-family:Arial;font-size:10pt;color:#161616;">nc</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">e </font><font style="font-family:Arial;font-size:10pt;color:#161616;">to </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">the "Biogen Idec </font><font style="font-family:Arial;font-size:10pt;color:#161616;">Inc. </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">2006 </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Non&#173; </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Emp</font><font style="font-family:Arial;font-size:10pt;color:#161616;">lo</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">yee </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Directors </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Equity </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Plan" and substituting the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Inc. </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">2006 </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Non-Employee Directors Equity Plan" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Section 4.2(b)(i), </font><font style="font-family:Arial;font-size:10pt;color:#545454;">"</font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Initial </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Election", </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">is amended by deleting the reference to the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"B</font><font style="font-family:Arial;font-size:10pt;color:#161616;">iog</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">en </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Idec Inc. </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">2006 </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Non-Employee Directors </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Equ</font><font style="font-family:Arial;font-size:10pt;color:#161616;">it</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">y </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Plan" </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and substitu</font><font style="font-family:Arial;font-size:10pt;color:#161616;">ting </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Inc. </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">2006 </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Non&#173; Employee Directors Equity Plan" therefor</font><font style="font-family:Arial;font-size:10pt;color:#545454;">, </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">and by deleting all references to </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Idec" and substituting </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Section 4.2(b)(ii)(A), "In-Service Distributions", </font><font style="font-family:Arial;font-size:10pt;color:#161616;">is </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">amended by deleting </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">t</font><font style="font-family:Arial;font-size:10pt;color:#161616;">he re</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">ference to "Bioge</font><font style="font-family:Arial;font-size:10pt;color:#161616;">n </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Idec" and </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">substitut</font><font style="font-family:Arial;font-size:10pt;color:#161616;">in</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">g "Biogen" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Section </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">4.2(b)(ii)(B), "Death or Termination of </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Employment", </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">is amended by deleting the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">reference </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">to </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Idec" </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and s</font><font style="font-family:Arial;font-size:10pt;color:#161616;">ub</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">st</font><font style="font-family:Arial;font-size:10pt;color:#161616;">itutin</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">g </font><font style="font-family:Arial;font-size:10pt;color:#545454;">"</font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Biogen" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Section </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">4.2(b)(ii)(C)</font><font style="font-family:Arial;font-size:10pt;color:#545454;">, </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">"Effectiveness of Subsequent </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Elect</font><font style="font-family:Arial;font-size:10pt;color:#161616;">ion</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"</font><font style="font-family:Arial;font-size:10pt;color:#545454;">, </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">is amended by deleting the </font><font style="font-family:Arial;font-size:10pt;color:#161616;">r</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">efe</font><font style="font-family:Arial;font-size:10pt;color:#161616;">rence </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">to </font><font style="font-family:Arial;font-size:10pt;color:#545454;">"</font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Biogen Idec" </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">a</font><font style="font-family:Arial;font-size:10pt;color:#161616;">nd </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">substitut</font><font style="font-family:Arial;font-size:10pt;color:#161616;">in</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">g </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">"Biogen" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Section </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">5.1(b), </font><font style="font-family:Arial;font-size:10pt;color:#545454;">"</font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Participant's </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Account </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Value</font><font style="font-family:Arial;font-size:10pt;color:#545454;">"</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">, </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">is amended by deleting the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">reference </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">to </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Idec" and substituting </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Bioge</font><font style="font-family:Arial;font-size:10pt;color:#161616;">n</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"</font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Section 5.1(c), </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Bookkeeping </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Accounts", </font><font style="font-family:Arial;font-size:10pt;color:#161616;">is </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">amended by deleting the </font><font style="font-family:Arial;font-size:10pt;color:#161616;">r</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">efe</font><font style="font-family:Arial;font-size:10pt;color:#161616;">renc</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">e </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">to "Biogen Idec" and substituting </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">18.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Section 5.2</font><font style="font-family:Arial;font-size:10pt;color:#545454;">, </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Vesting", </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">is amended by deleting the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">refe</font><font style="font-family:Arial;font-size:10pt;color:#161616;">r</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">ence </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">to the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#161616;">Idec </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Inc. </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">2006 </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Non&#173; </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Employee </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Directors </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Equity </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Plan" and </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">substituting </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Biogen </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Inc. </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">2006 </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Non-Employee Directors </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Equ</font><font style="font-family:Arial;font-size:10pt;color:#161616;">it</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">y </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Plan" therefor, and by deleting the reference to </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"B</font><font style="font-family:Arial;font-size:10pt;color:#161616;">io</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">gen </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">Idec" in </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">subsect</font><font style="font-family:Arial;font-size:10pt;color:#161616;">ion </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">(ii) thereof and </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">s</font><font style="font-family:Arial;font-size:10pt;color:#161616;">ubstitu</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">t</font><font style="font-family:Arial;font-size:10pt;color:#161616;">in</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">g "Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2a2a2a;">19.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Section 6.5, "Other Distributions", is amended </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">by deleting </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">all </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">references </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">to </font><font style="font-family:Arial;font-size:10pt;color:#424242;">"B</font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">iogen Idec" and </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">substituting "Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">20.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Section 7</font><font style="font-family:Arial;font-size:10pt;color:#050505;">.</font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">1</font><font style="font-family:Arial;font-size:10pt;color:#424242;">, </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">"Amendment </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">or </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Termination </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">of Plan", is amended </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">by deleting all references </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">to "Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Idec</font><font style="font-family:Arial;font-size:10pt;color:#424242;">" </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">and </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">substituting </font><font style="font-family:Arial;font-size:10pt;color:#424242;">"Bioge</font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">n</font><font style="font-family:Arial;font-size:10pt;color:#424242;">" </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">21.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Section </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">7.2, </font><font style="font-family:Arial;font-size:10pt;color:#424242;">"</font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Benefits </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Not Currently Funded", is amended </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">by </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">deleting all </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">references </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">to "Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Idec" in </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">subsections (a) and (b) thereof and substituting "Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">ther</font><font style="font-family:Arial;font-size:10pt;color:#424242;">e</font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">for.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">22.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Section 7.4(b), "Termination", </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">i</font><font style="font-family:Arial;font-size:10pt;color:#424242;">s </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">amended </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">by </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">deleting </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">the </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">reference to "Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Idec" </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">and substituting "Biogen" </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">th</font><font style="font-family:Arial;font-size:10pt;color:#424242;">e</font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">r</font><font style="font-family:Arial;font-size:10pt;color:#424242;">efo</font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">r.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">23.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Sect</font><font style="font-family:Arial;font-size:10pt;color:#050505;">ion </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">7.5, </font><font style="font-family:Arial;font-size:10pt;color:#424242;">"Responsi</font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">bilitie</font><font style="font-family:Arial;font-size:10pt;color:#424242;">s </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">and Authority </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">of </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Committee", is amended </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">by del</font><font style="font-family:Arial;font-size:10pt;color:#424242;">e</font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">ting </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">all </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">references </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">to "Biogen </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Id</font><font style="font-family:Arial;font-size:10pt;color:#424242;">ec" </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">and </font><font style="font-family:Arial;font-size:10pt;color:#424242;">s</font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">ubstituting </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">"Biogen" therefor.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">24.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Section A.3, </font><font style="font-family:Arial;font-size:10pt;color:#424242;">"2</font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">012 Amendment and </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Restatement", of </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Appendix A</font><font style="font-family:Arial;font-size:10pt;color:#424242;">, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">"Historical </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Information; Amendments", is </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">amended by deleting the </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">reference to </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">the </font><font style="font-family:Arial;font-size:10pt;color:#424242;">"</font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Biogen Idec </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Inc</font><font style="font-family:Arial;font-size:10pt;color:#050505;">. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">2006 </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Non&#173; </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Employee </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Directors </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Equity </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Plan</font><font style="font-family:Arial;font-size:10pt;color:#424242;">" </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">and substituting </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">"Biogen Inc</font><font style="font-family:Arial;font-size:10pt;color:#424242;">. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">2006 Non-Employee </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Directors Equity Plan" th</font><font style="font-family:Arial;font-size:10pt;color:#424242;">e</font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">r</font><font style="font-family:Arial;font-size:10pt;color:#424242;">efo</font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">r.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">25.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Section A.4, </font><font style="font-family:Arial;font-size:10pt;color:#424242;">"2</font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">015 </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Amendment", of Appendix </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">A, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">"Historical </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Information</font><font style="font-family:Arial;font-size:10pt;color:#424242;">; </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Amendments", is amended by </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">deleting it </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">in its entirety </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">and </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">substituting the following therefor:</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">"A.4</font><font style="font-family:Arial;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">2015 </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;font-weight:bold;">Amendments to the </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;font-weight:bold;">2012 Amendment </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;font-weight:bold;">and Restatement.  </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">The 2012 Amendment and </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Restatement </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">of </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">the plan </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">was </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">amended by the </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">First Amendment thereto </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">to </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">eliminate </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">the </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">ability </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">to defer </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">any </font><font style="font-family:Arial;font-size:10pt;color:#424242;">e</font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">quity </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">based </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">awards that may </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">be granted </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">beginning on or </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">after </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">January 1, </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">2015 under </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">the Biogen Idec Inc</font><font style="font-family:Arial;font-size:10pt;color:#424242;">. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">2006 Non-Employee </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Directors </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Equity </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Plan. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">The 2012 </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Amendment and </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Restateme</font><font style="font-family:Arial;font-size:10pt;color:#bfbfbf;">'</font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">nt of the plan was </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">further </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><a name="sefa62d779a1647798bd1086876288714"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">amended by th</font><font style="font-family:Arial;font-size:10pt;color:#424242;">e </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Second </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Amendment </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">thereto, effective </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">March </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">23, 2015, </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">to reflect </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">the change </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">in the name of th</font><font style="font-family:Arial;font-size:10pt;color:#424242;">e </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">plan from the 'Biogen Idec Inc. </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Voluntary Board of Directors Savings Plan' </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">to the </font><font style="font-family:Arial;font-size:10pt;color:#424242;">'</font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Biogen Inc</font><font style="font-family:Arial;font-size:10pt;color:#424242;">. </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Voluntary </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Board of </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Directors </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Savings </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">Plan."</font><font style="font-family:Arial;font-size:10pt;color:#424242;">'</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">IN WITNESS WHEREOF</font><font style="font-family:Arial;font-size:10pt;color:#424242;">, </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">the </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Employer </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">has </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">caused </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">this instrument to be executed </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">by an </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">authorized </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">officer on </font><font style="font-family:Arial;font-size:10pt;color:#1d1d1d;">behalf of the </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Employer, as of the 15th day of May, 2015.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:480px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:480px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">By: </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;text-decoration:underline;">/s/ Paul Clancy</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:480px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;">Title: </font><font style="font-family:Arial;font-size:10pt;color:#2f2f2f;text-decoration:underline;">EVP and CFO</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">3</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>4
<FILENAME>biib-20151231xex1037.htm
<DESCRIPTION>EXHIBIT 10.37
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sf673f7180c494f4a894fc575bdec1cd7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#161616;">October 19, 2015 </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#161616;">Al Sandrock</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#161616;">Dear Al,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#161616;">I am pleased </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">to extend </font><font style="font-family:Arial;font-size:10pt;color:#161616;">you the promotion offer detailed on the attached term sheet. Your promotion will be effective on the first payroll date following your written acceptance of this offer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#161616;">Upon your acceptance of this offer, you will continue to be a member of the G8 and an Executive Officer of the company. You will also continue to be subject to all disclosure and share ownership requirements of 3x </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">salary </font><font style="font-family:Arial;font-size:10pt;color:#161616;">related to Executive Officer </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">status </font><font style="font-family:Arial;font-size:10pt;color:#161616;">as an Executive Vice President.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#161616;">Al, once again, we are all very excited about your appointment to this important position, and look forward to continuing a great future together</font><font style="font-family:Times New Roman;font-size:10pt;color:#3d3d3d;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#161616;">To confirm your acceptance of this offer, please sign and return this letter and keep a copy for your records.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#161616;">Sincerely,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#161616;">George Scangos,</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#161616;">Chief Executive Officer</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#161616;font-weight:bold;">ACCEPTED:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="60%"></td><td width="1%"></td><td width="39%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">/s/ Alfred Sandrock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">October 20, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Alfred Sandrock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Signature Date</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sf673f7180c494f4a894fc575bdec1cd7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td width="17%"></td><td width="1%"></td><td width="16%"></td><td width="1%"></td><td width="19%"></td><td width="1%"></td><td width="17%"></td><td width="1%"></td><td width="27%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">New Level</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">New Bonus Target</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">70% of salary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">New Position</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">EVP, CMO, Neurology &amp; Neurodegeneration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Reports to</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">CEO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#333399;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#333399;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#333399;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#333399;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#333399;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#333399;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#333399;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#333399;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#333399;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">New</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">% Difference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(New vs. Current)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Comments</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Salary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$591,993</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$700,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Target Bonus</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$500,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$490,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(2)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Bonus guarantee removed</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(%)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">(guaranteed min)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">70%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Target Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$1,091,993</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$1,190,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">9%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">LTI Grant Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$1,500,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$0 - $2.15m - $4.8m</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">na</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">EVP LTI follows a range (no target)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">(guaranteed min)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">LTI guarantee removed</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Total Compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$2,591,993</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">$3,340,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">29%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Assumes $2.15m annual LTI</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">BIIB Summary of Promotion Elements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Promotion to L24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">EVP, CMO, Neurology &amp; Neurodegeneration</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Annual Bonus</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">70% bonus target; Bonus guarantee removed starting in the 2016 performance year</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Salary Increase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">18% increase</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Annual LTI</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Eligible for EVP LTI range; LTI guarantee removed; All future grants are eligible for retirement acceleration according to the terms of 2008 Omnibus Equity Plan</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.41
<SEQUENCE>5
<FILENAME>biib-20151231xex1041.htm
<DESCRIPTION>EXHIBIT 10.41
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="se40b12aabec04b4581bda27bb93b2e21"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:2px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">September 7, 2010</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">John Cox</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">106 Grey Bridge Row</font></div><div style="line-height:120%;padding-top:1px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cary, NC 27513</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dear John,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">I am pleased to confirm your current position and compensation.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Job Title: </font><font style="font-family:Arial;font-size:10pt;">Your current job title is EVP, Pharmaceutical Operations &amp; Technology.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Reporting Relationship: </font><font style="font-family:Arial;font-size:10pt;">In this position, you report to George Scangos, Chief Executive Officer.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Work Location: </font><font style="font-family:Arial;font-size:10pt;">Your position is based at our Weston, Massachusetts facility.</font></div><div style="line-height:120%;padding-top:1px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Base Salary: </font><font style="font-family:Arial;font-size:10pt;">Effective September 6, 2010, your biweekly salary is $17,307.70, equivalent to an annual salary of</font></div><div style="line-height:120%;padding-top:1px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">$450,000.20, and paid in accordance with our standard payroll policies.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Annual Bonus Plan: </font><font style="font-family:Arial;font-size:10pt;">Your target bonus opportunity under the Biogen Idec Annual Bonus Plan is 55% of your annualized base salary. Please refer to the Plan documents for further details about eligibility and payment provisions.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Stock Trading Plan: </font><font style="font-family:Arial;font-size:10pt;">As an Executive Vice President of the Company, you are required to enter into a 10b5-1 stock trading plan for all open market trades in Biogen Idec stock. A 10b5-1 plan allows you to buy or sell Biogen Idec securities at pre-defined times and/or prices and provides an affirmative defense against insider trading liability. More information on 1Ob5-1 trading plans is available on iNet.</font></div><div style="line-height:120%;padding-top:1px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Relocation: </font><font style="font-family:Arial;font-size:10pt;">Biogen Idec will provide relocation benefits to facilitate your move from Cary, N.C. to the Boston area. The relocation benefits and payments will be provided to you after you sign the enclosed U.S. Domestic Relocation Policy Acknowledgment and Relocation Repayment Agreement, which detail the terms and conditions of your relocation package. Payments and reimbursements will be made in accordance with Biogen Idec's relocation policy, which is enclosed and to which you should refer for more details on your relocation benefits.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Additional Executive Benefits</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Vacation: </font><font style="font-family:Arial;font-size:10pt;">You are entitled to 25 vacation days per year, accrued on a per pay period basis.</font></div><div style="line-height:120%;padding-top:1px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Supplemental Savings Plan: </font><font style="font-family:Arial;font-size:10pt;">You are entitled to participate in Biogen Idec's Supplemental Savings Plan (SSP). This plan allows you to make pre-tax deferrals of up to 80% of your base salary and up to 100% of your Annual Bonus payment and certain other eligible incentive payments. Your contributions to this plan may be limited by your contributions towards other plans (e.g., 401(k), ESPP, medical, etc.).</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Life Insurance: </font><font style="font-family:Arial;font-size:10pt;">You will be provided life insurance coverage equal to three times your annual base salary, subject to meeting the medical standards stated in the group term life insurance policy for U.S. employees. Biogen Idec pays the premium for this insurance. The IRS requires employers to impute the value of company-paid life insurance for coverage over $50,000. This imputed income will be displayed on your pay stub.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Severance: </font><font style="font-family:Arial;font-size:10pt;">Under certain circumstances, you will be entitled to receive severance benefits. Your severance benefits are explained in detail in the attached executive severance document.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Tax Preparation, Financial and Estate Planning: </font><font style="font-family:Arial;font-size:10pt;">You are entitled to reimbursement of up to $7,500 per calendar year (January 1 - December 31) for expenses incurred due to tax preparation, financial and/or estate planning services, as well as the purchase of tax preparation and/or financial planning software. Reimbursement must be made no later than the end of the calendar year following the year in which the expense is incurred, and must be requested within the deadlines and processes established in the policy.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="se40b12aabec04b4581bda27bb93b2e21"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Your employment at Biogen Idec continues to be employment at-will. This means that just as you are free to leave your employment at any time, with or without cause or notice, Biogen Idec also has the same right to terminate your employment at any time, with or without cause or notice.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Regards,</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;text-decoration:underline;">/s/ Susan Stemper</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Susan Stemper</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Senior Director, Global Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">cc: Maura Bullock</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.42
<SEQUENCE>6
<FILENAME>biib-20151231xex1042.htm
<DESCRIPTION>EXHIBIT 10.42
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sb3a4c86066b2489d858bf55395c7995b"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:20px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;font-weight:bold;text-decoration:underline;">BY HAND DELIVERY</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">October 19</font><font style="font-family:Arial;font-size:10pt;color:#444444;">, </font><font style="font-family:Arial;font-size:10pt;color:#212121;">2015</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">[Revised November 12, 2015]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">Tony Kingsley</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">152 Chestnut Street</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">West Newton </font><font style="font-family:Arial;font-size:10pt;color:#444444;">, </font><font style="font-family:Arial;font-size:10pt;color:#212121;">MA 02465</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;text-decoration:underline;">Re:</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;color:#212121;text-decoration:underline;">Separation Agreement </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">Dear Tony:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">Biogen is implementing a corporate restructuring which includes a global reduction in force. As a result, your employment will be terminated. The purpose of this Separation Agreement (the "Agreement") is to confirm the terms of your separation from Biogen Inc. or one of its subsidiaries ("Biogen" or the "Company"). The specific severance pay and benefits being offered to you, and the terms on which they are being offered</font><font style="font-family:Arial;font-size:10pt;color:#444444;">, </font><font style="font-family:Arial;font-size:10pt;color:#212121;">are described below. This consideration is conditioned on you timely signing and not revoking this Agreement, and complying with all of its provisions.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#212121;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;text-decoration:underline;">Transition Period and Separation.</font><font style="font-family:Arial;font-size:10pt;color:#212121;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#212121;">Your employment with the Company will end on February 29, 2016 (the "Separation Date"), provided that you comply with Company rules and policies (as determined by the Company) from the date you received this Agreement through your Separation Date ("Transition Employment Period").</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;">Provided that you comply with Company rules and policies (as determined by the Company) during the Transition Employment Period, you will continue working as at present, will continue to receive your regular base pay and any 2015 annual bonus determined by the Company in accordance with the Company's annual bonus plan for executive vice presidents, subject to applicable payroll withholdings</font><font style="font-family:Arial;font-size:10pt;color:#444444;">, </font><font style="font-family:Arial;font-size:10pt;color:#212121;">and will continue to receive benefits for which you are eligible under the Company's benefit plans, including the accrual of vacation days. Upon your Separation Date</font><font style="font-family:Arial;font-size:10pt;color:#444444;">, </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Biogen will pay you all unpaid wages due through that date, including all accrued but unused vacation</font><font style="font-family:Arial;font-size:10pt;color:#545454;">. </font><font style="font-family:Arial;font-size:10pt;color:#212121;">Unless otherwise provided for in this Agreement, benefits which have vested under any other employee benefit plan of the Company on or before the Separation Date will be managed in accordance with and subject to the terms and conditions of such plans. Your last day of required work (your "Last Work Day") is the date on which you will be required to turn in your Company property.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#212121;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#212121;text-decoration:underline;">Severance Pay and Benefits.</font><font style="font-family:Arial;font-size:10pt;color:#212121;">&#32;In exchange for the mutual promises set forth in this Agreement</font><font style="font-family:Arial;font-size:10pt;color:#545454;">, </font><font style="font-family:Arial;font-size:10pt;color:#212121;">including the release of claims, and pursuant to the Severance Plan for U.S. Executive Vice Presidents effective January 1, 2014, Biogen agrees to provide you with the following severance pay and benefits (the "Severance Pay and Benefits"), provided you comply with the requirements set forth below:</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;text-decoration:underline;">Outplacement Services.</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">&#32;If you sign this Agreement and return it within 45 days to HR Operations at Biogen, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">225 </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Binney St.</font><font style="font-family:Arial;font-size:10pt;color:#424242;">, </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Cambridge, MA 02142, and do not revoke your acceptance pursuant to Section </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">7 </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">below, the Company will provide you with up to 12 months of outplacement services from a recognized provider of such services selected by the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;text-decoration:underline;">Supplemental Severance Pay and Benefits:</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">&#32;At the conclusion of the Transition </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Employment </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Period and after the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Separation </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Date, if you accept and do not revoke your </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">acceptance </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">of the Reaffirmation of Release of Claims </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">attached </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">to this Agreement as </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;text-decoration:underline;">Exhibit</font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;text-decoration:underline;">B</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">&#32;("Reaffirmation Agreement"), you will receive </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">from </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Biogen additional </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">severance </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">benefits described below ("Supplemental Severance Pay and Benefits"). Payment of the Supplemental Severance Pay </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">and </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Benefits is expressly conditioned upon</font><font style="font-family:Arial;font-size:10pt;color:#424242;">: </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">(a) your signing and not revoking the Reaffirmation Agreement by the later of the 14-day period after you</font><font style="font-family:Arial;font-size:10pt;color:#424242;">r </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Separation Date or 45 days from </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">your </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">receipt of this Agreement; </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">and </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">(b) the termination of </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">your </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">employment. The Supplemental Severance Pay and Benefits include:</font></div></td></tr></table><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sb3a4c86066b2489d858bf55395c7995b"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">The </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Company </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">will provide you </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">with </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">a lump sum payment in the amount of $2,096,031, less lawful deductions, payable within fifteen (15) business days of </font><font style="font-family:Arial;font-size:10pt;color:#0e0e0e;">th</font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">e </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">effective date of the Reaffirmation Agreement. This amount represents 21 months of pay at your base salary and target bonus.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:144px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">If </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">you </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">currently participate in the Company's group health benefits, the Company will </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">subsidize your </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">current level of participation in Biogen </font><font style="font-family:Arial;font-size:10pt;color:#424242;">'</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">s group medical, vision and dental insurance plans through November 30, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">2017 </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">("COBRA Subsidy Period"), provided </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">that </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">you complete and timely submit </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">your </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">COBRA election form. In particular, during the COBRA Subsidy Period, you will be </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">required </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">timely to pay the employee portion </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">of </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the premiums and the Company will pay the employer portion of the premiums </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">at </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the same rate as paid on behalf of current employees, as long as you do not become eligible to participate in another medical, vision and/or dental insurance plan. After the COBRA Subsidy Period, </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">you </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">may continue </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">your </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">group health benefits through COBRA for the period permitted by law, by timely paying the full premiums </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">at your </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">sole expense. A notice regarding your COBRA rights and benefits will be mailed separately by ADP, Biogen </font><font style="font-family:Arial;font-size:10pt;color:#424242;">'</font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">s COBRA administrator. Irrespective of </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">whether </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">you </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">accept </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">the offer of Outplacement Services and/or Supplemental Severance Pay and Benefits, the benefit period under </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">COBRA </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">will commence on the Separation Date. You agree to promptly notify the Company if you become eligible to participate </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">in another </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">medical</font><font style="font-family:Arial;font-size:10pt;color:#424242;">, </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">vision </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">and/or </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">dental insurance plan during the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">COBRA </font><font style="font-family:Arial;font-size:10pt;color:#1f1f1f;">Subsidy Period.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#343434;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#343434;text-decoration:underline;">Employee Affirmations</font><font style="font-family:Arial;font-size:10pt;color:#707070;">. </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Biogen will </font><font style="font-family:Arial;font-size:10pt;color:#232323;">pay </font><font style="font-family:Arial;font-size:10pt;color:#343434;">you all </font><font style="font-family:Arial;font-size:10pt;color:#232323;">unpaid </font><font style="font-family:Arial;font-size:10pt;color:#343434;">wages </font><font style="font-family:Arial;font-size:10pt;color:#232323;">due </font><font style="font-family:Arial;font-size:10pt;color:#343434;">through your Separation </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Date, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">including all accrued </font><font style="font-family:Arial;font-size:10pt;color:#232323;">but unused </font><font style="font-family:Arial;font-size:10pt;color:#343434;">vacation. You affirm and agree </font><font style="font-family:Arial;font-size:10pt;color:#232323;">that, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">with the </font><font style="font-family:Arial;font-size:10pt;color:#232323;">payments </font><font style="font-family:Arial;font-size:10pt;color:#343434;">set forth </font><font style="font-family:Arial;font-size:10pt;color:#232323;">in this </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Agreement, you will </font><font style="font-family:Arial;font-size:10pt;color:#232323;">have received </font><font style="font-family:Arial;font-size:10pt;color:#343434;">all </font><font style="font-family:Arial;font-size:10pt;color:#232323;">leave </font><font style="font-family:Arial;font-size:10pt;color:#343434;">(paid or unpaid), compensation, wages, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">bonuses, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">commissions</font><font style="font-family:Arial;font-size:10pt;color:#525252;">, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and</font><font style="font-family:Arial;font-size:10pt;color:#525252;">/</font><font style="font-family:Arial;font-size:10pt;color:#343434;">or </font><font style="font-family:Arial;font-size:10pt;color:#232323;">benefits </font><font style="font-family:Arial;font-size:10pt;color:#343434;">to which you may be entitled and </font><font style="font-family:Arial;font-size:10pt;color:#232323;">that </font><font style="font-family:Arial;font-size:10pt;color:#343434;">no </font><font style="font-family:Arial;font-size:10pt;color:#232323;">other leave (paid </font><font style="font-family:Arial;font-size:10pt;color:#343434;">or unpaid), compensation, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">wages, bonuses</font><font style="font-family:Arial;font-size:10pt;color:#525252;">, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">commissions and</font><font style="font-family:Arial;font-size:10pt;color:#525252;">/</font><font style="font-family:Arial;font-size:10pt;color:#232323;">or benefits </font><font style="font-family:Arial;font-size:10pt;color:#343434;">are </font><font style="font-family:Arial;font-size:10pt;color:#232323;">due to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">you. </font><font style="font-family:Arial;font-size:10pt;color:#232323;">You </font><font style="font-family:Arial;font-size:10pt;color:#343434;">furthermore affirm </font><font style="font-family:Arial;font-size:10pt;color:#232323;">that </font><font style="font-family:Arial;font-size:10pt;color:#343434;">you </font><font style="font-family:Arial;font-size:10pt;color:#232323;">have no known </font><font style="font-family:Arial;font-size:10pt;color:#343434;">workplace </font><font style="font-family:Arial;font-size:10pt;color:#232323;">injuries </font><font style="font-family:Arial;font-size:10pt;color:#343434;">or occupational diseases and have </font><font style="font-family:Arial;font-size:10pt;color:#232323;">been </font><font style="font-family:Arial;font-size:10pt;color:#343434;">provided and</font><font style="font-family:Arial;font-size:10pt;color:#525252;">/</font><font style="font-family:Arial;font-size:10pt;color:#343434;">or </font><font style="font-family:Arial;font-size:10pt;color:#232323;">have not </font><font style="font-family:Arial;font-size:10pt;color:#343434;">been </font><font style="font-family:Arial;font-size:10pt;color:#232323;">denied </font><font style="font-family:Arial;font-size:10pt;color:#343434;">any leave requested under the Family and Medical Leave </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Act. You </font><font style="font-family:Arial;font-size:10pt;color:#343434;">also affirm </font><font style="font-family:Arial;font-size:10pt;color:#232323;">that </font><font style="font-family:Arial;font-size:10pt;color:#343434;">you </font><font style="font-family:Arial;font-size:10pt;color:#232323;">have not been retaliated  </font><font style="font-family:Arial;font-size:10pt;color:#343434;">against for </font><font style="font-family:Arial;font-size:10pt;color:#232323;">reporting </font><font style="font-family:Arial;font-size:10pt;color:#343434;">any allegations of </font><font style="font-family:Arial;font-size:10pt;color:#232323;">wrongdoing by the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Company or its officers, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">including </font><font style="font-family:Arial;font-size:10pt;color:#343434;">without </font><font style="font-family:Arial;font-size:10pt;color:#232323;">limitation, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">any allegations of corporate fraud. </font><font style="font-family:Arial;font-size:10pt;color:#232323;">In </font><font style="font-family:Arial;font-size:10pt;color:#343434;">addition, you affirm </font><font style="font-family:Arial;font-size:10pt;color:#232323;">that </font><font style="font-family:Arial;font-size:10pt;color:#343434;">all </font><font style="font-family:Arial;font-size:10pt;color:#232323;">decisions </font><font style="font-family:Arial;font-size:10pt;color:#343434;">regarding your </font><font style="font-family:Arial;font-size:10pt;color:#232323;">pay and benefits through the date </font><font style="font-family:Arial;font-size:10pt;color:#343434;">of your execution of this </font><font style="font-family:Arial;font-size:10pt;color:#232323;">letter </font><font style="font-family:Arial;font-size:10pt;color:#343434;">agreement and general </font><font style="font-family:Arial;font-size:10pt;color:#232323;">release </font><font style="font-family:Arial;font-size:10pt;color:#343434;">were </font><font style="font-family:Arial;font-size:10pt;color:#232323;">not discriminatory based on age, disability, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">race, color, sex religion</font><font style="font-family:Arial;font-size:10pt;color:#525252;">, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">national </font><font style="font-family:Arial;font-size:10pt;color:#343434;">origin or any other classification </font><font style="font-family:Arial;font-size:10pt;color:#232323;">protected </font><font style="font-family:Arial;font-size:10pt;color:#343434;">by </font><font style="font-family:Arial;font-size:10pt;color:#232323;">law.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#343434;">You </font><font style="font-family:Arial;font-size:10pt;color:#232323;">represent </font><font style="font-family:Arial;font-size:10pt;color:#343434;">that, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">based </font><font style="font-family:Arial;font-size:10pt;color:#343434;">on your current </font><font style="font-family:Arial;font-size:10pt;color:#232323;">knowledge </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and </font><font style="font-family:Arial;font-size:10pt;color:#232323;">understanding, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">you </font><font style="font-family:Arial;font-size:10pt;color:#232323;">have </font><font style="font-family:Arial;font-size:10pt;color:#343434;">complied with </font><font style="font-family:Arial;font-size:10pt;color:#232323;">all laws, regulations, rules </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and </font><font style="font-family:Arial;font-size:10pt;color:#232323;">policies </font><font style="font-family:Arial;font-size:10pt;color:#343434;">pertaining </font><font style="font-family:Arial;font-size:10pt;color:#232323;">to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Medicare, Medicaid, or any other </font><font style="font-family:Arial;font-size:10pt;color:#232323;">federal health </font><font style="font-family:Arial;font-size:10pt;color:#343434;">care </font><font style="font-family:Arial;font-size:10pt;color:#232323;">program </font><font style="font-family:Arial;font-size:10pt;color:#343434;">while employed </font><font style="font-family:Arial;font-size:10pt;color:#232323;">at Biogen</font><font style="font-family:Arial;font-size:10pt;color:#050505;">. </font><font style="font-family:Arial;font-size:10pt;color:#343434;">You further affirm that </font><font style="font-family:Arial;font-size:10pt;color:#232323;">either (i) </font><font style="font-family:Arial;font-size:10pt;color:#343434;">you are </font><font style="font-family:Arial;font-size:10pt;color:#232323;">unaware </font><font style="font-family:Arial;font-size:10pt;color:#343434;">of any non-compliant conduct </font><font style="font-family:Arial;font-size:10pt;color:#232323;">by Biogen or its </font><font style="font-family:Arial;font-size:10pt;color:#343434;">employees; or (ii) you have provided Biogen with any and all </font><font style="font-family:Arial;font-size:10pt;color:#232323;">information </font><font style="font-family:Arial;font-size:10pt;color:#343434;">you </font><font style="font-family:Arial;font-size:10pt;color:#232323;">have</font><font style="font-family:Arial;font-size:10pt;color:#525252;">, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">whether based on direct or indirect </font><font style="font-family:Arial;font-size:10pt;color:#232323;">information, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">of </font><font style="font-family:Arial;font-size:10pt;color:#232323;">any wrongdoing, irregularities, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">improprieties or </font><font style="font-family:Arial;font-size:10pt;color:#232323;">illegalities </font><font style="font-family:Arial;font-size:10pt;color:#343434;">regarding </font><font style="font-family:Arial;font-size:10pt;color:#232323;">the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">ordering or </font><font style="font-family:Arial;font-size:10pt;color:#232323;">delivery </font><font style="font-family:Arial;font-size:10pt;color:#343434;">of any item or </font><font style="font-family:Arial;font-size:10pt;color:#232323;">performance </font><font style="font-family:Arial;font-size:10pt;color:#343434;">of any service by Biogen </font><font style="font-family:Arial;font-size:10pt;color:#232323;">that </font><font style="font-family:Arial;font-size:10pt;color:#343434;">is reimbursable </font><font style="font-family:Arial;font-size:10pt;color:#232323;">by </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Medicare, Medicaid, or any other federal </font><font style="font-family:Arial;font-size:10pt;color:#232323;">health </font><font style="font-family:Arial;font-size:10pt;color:#343434;">care program.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#343434;">You acknowledge and agree that, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">but </font><font style="font-family:Arial;font-size:10pt;color:#343434;">for executing </font><font style="font-family:Arial;font-size:10pt;color:#232323;">this </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Agreement and the Reaffirmation Agreement, you would </font><font style="font-family:Arial;font-size:10pt;color:#232323;">not be </font><font style="font-family:Arial;font-size:10pt;color:#343434;">receiving the </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Severance Pay </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Benefits </font><font style="font-family:Arial;font-size:10pt;color:#343434;">described </font><font style="font-family:Arial;font-size:10pt;color:#232323;">herein. If </font><font style="font-family:Arial;font-size:10pt;color:#343434;">you apply </font><font style="font-family:Arial;font-size:10pt;color:#232323;">for </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and accept </font><font style="font-family:Arial;font-size:10pt;color:#232323;">a position </font><font style="font-family:Arial;font-size:10pt;color:#343434;">at Biogen (in any capacity, including employee, supplemental staff, contractor, consultant, etc.) either </font><font style="font-family:Arial;font-size:10pt;color:#232323;">before </font><font style="font-family:Arial;font-size:10pt;color:#343434;">or within 21 </font><font style="font-family:Arial;font-size:10pt;color:#232323;">months </font><font style="font-family:Arial;font-size:10pt;color:#343434;">following your Separation Date, you agree </font><font style="font-family:Arial;font-size:10pt;color:#232323;">to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">repay </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Biogen </font><font style="font-family:Arial;font-size:10pt;color:#343434;">a </font><font style="font-family:Arial;font-size:10pt;color:#232323;">prorated </font><font style="font-family:Arial;font-size:10pt;color:#343434;">amount of </font><font style="font-family:Arial;font-size:10pt;color:#232323;">the Severance Pay </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Benefits </font><font style="font-family:Arial;font-size:10pt;color:#343434;">you received.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#232323;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#232323;text-decoration:underline;">Long-Term</font><font style="font-family:Arial;font-size:10pt;color:#232323;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#343434;text-decoration:underline;">Incentive</font><font style="font-family:Arial;font-size:10pt;color:#343434;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#232323;text-decoration:underline;">(LTI) Awards</font><font style="font-family:Arial;font-size:10pt;color:#232323;">. </font><font style="font-family:Arial;font-size:10pt;color:#343434;">You acknowledge and agree that all LTI awards that are </font><font style="font-family:Arial;font-size:10pt;color:#232323;">unvested </font><font style="font-family:Arial;font-size:10pt;color:#343434;">as of </font><font style="font-family:Arial;font-size:10pt;color:#232323;">the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Separation </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Date </font><font style="font-family:Arial;font-size:10pt;color:#343434;">will </font><font style="font-family:Arial;font-size:10pt;color:#232323;">be </font><font style="font-family:Arial;font-size:10pt;color:#343434;">forfeited </font><font style="font-family:Arial;font-size:10pt;color:#232323;">and </font><font style="font-family:Arial;font-size:10pt;color:#343434;">revert to </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Biogen </font><font style="font-family:Arial;font-size:10pt;color:#343434;">on the Separation </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Date </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and you </font><font style="font-family:Arial;font-size:10pt;color:#232323;">will have no further </font><font style="font-family:Arial;font-size:10pt;color:#343434;">or future </font><font style="font-family:Arial;font-size:10pt;color:#232323;">rights </font><font style="font-family:Arial;font-size:10pt;color:#343434;">to any of those forfeited and reverted </font><font style="font-family:Arial;font-size:10pt;color:#232323;">LTI </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Awards. If you are </font><font style="font-family:Arial;font-size:10pt;color:#232323;">55 </font><font style="font-family:Arial;font-size:10pt;color:#343434;">years of age </font><font style="font-family:Arial;font-size:10pt;color:#232323;">or </font><font style="font-family:Arial;font-size:10pt;color:#343434;">older with </font><font style="font-family:Arial;font-size:10pt;color:#232323;">10 </font><font style="font-family:Arial;font-size:10pt;color:#343434;">years of consecutive service with </font><font style="font-family:Arial;font-size:10pt;color:#232323;">the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Company, you </font><font style="font-family:Arial;font-size:10pt;color:#232323;">will be </font><font style="font-family:Arial;font-size:10pt;color:#343434;">entitled </font><font style="font-family:Arial;font-size:10pt;color:#232323;">to accelerated </font><font style="font-family:Arial;font-size:10pt;color:#343434;">vesting as of the Separation Date of certain of </font><font style="font-family:Arial;font-size:10pt;color:#232323;">your </font><font style="font-family:Arial;font-size:10pt;color:#343434;">LTI Awards </font><font style="font-family:Arial;font-size:10pt;color:#232323;">in </font><font style="font-family:Arial;font-size:10pt;color:#343434;">accordance with </font><font style="font-family:Arial;font-size:10pt;color:#232323;">the terms </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and conditions of the Biogen Inc. Amended and Restated 2008 Omnibus Equity Plan, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">as </font><font style="font-family:Arial;font-size:10pt;color:#343434;">amended </font><font style="font-family:Arial;font-size:10pt;color:#232323;">to date.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sb3a4c86066b2489d858bf55395c7995b"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#232323;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#343434;text-decoration:underline;">Release of Claims.</font><font style="font-family:Arial;font-size:10pt;color:#343434;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#232323;">In </font><font style="font-family:Arial;font-size:10pt;color:#343434;">consideration for the </font><font style="font-family:Arial;font-size:10pt;color:#232323;">promises </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and representations of </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Biogen </font><font style="font-family:Arial;font-size:10pt;color:#343434;">as described in this Agreement, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">you hereby agree to forever release </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and </font><font style="font-family:Arial;font-size:10pt;color:#232323;">discharge </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Biogen and any of </font><font style="font-family:Arial;font-size:10pt;color:#232323;">its divisions, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">affiliates, subsidiaries, related entities, and its and their current and former directors, officers, employees, attorneys, agents</font><font style="font-family:Arial;font-size:10pt;color:#525252;">, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">insurers</font><font style="font-family:Arial;font-size:10pt;color:#525252;">, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">successors and assigns, in their individual and official capacities, as </font><font style="font-family:Arial;font-size:10pt;color:#232323;">well as their health, welfare </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and benefits </font><font style="font-family:Arial;font-size:10pt;color:#232323;">plans </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and programs or the administrators or trustees </font><font style="font-family:Arial;font-size:10pt;color:#232323;">of </font><font style="font-family:Arial;font-size:10pt;color:#343434;">the </font><font style="font-family:Arial;font-size:10pt;color:#232323;">plans </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and programs (collectively </font><font style="font-family:Arial;font-size:10pt;color:#525252;">"</font><font style="font-family:Arial;font-size:10pt;color:#343434;">Releasees")</font><font style="font-family:Arial;font-size:10pt;color:#525252;">, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">from any and all claim</font><font style="font-family:Arial;font-size:10pt;color:#525252;">s</font><font style="font-family:Arial;font-size:10pt;color:#343434;">, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">demands</font><font style="font-family:Arial;font-size:10pt;color:#525252;">, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">actions</font><font style="font-family:Arial;font-size:10pt;color:#525252;">, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">liabilities, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">obligations, accounts, expenses, attorneys' fees and causes of action, of every </font><font style="font-family:Arial;font-size:10pt;color:#232323;">kind and nature, in law, equity or </font><font style="font-family:Arial;font-size:10pt;color:#343434;">otherwise, whether </font><font style="font-family:Arial;font-size:10pt;color:#232323;">known </font><font style="font-family:Arial;font-size:10pt;color:#343434;">or </font><font style="font-family:Arial;font-size:10pt;color:#232323;">unknown, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">asserted or unasserted, which you ever had</font><font style="font-family:Arial;font-size:10pt;color:#565656;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">now have</font><font style="font-family:Arial;font-size:10pt;color:#565656;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">or which may hereafter accrue in connection with </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">any </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">event, act or occurrence arising prior to the date that you </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">execute </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">this Agreement</font><font style="font-family:Arial;font-size:10pt;color:#565656;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">including but not limited </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">to all </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">matters that arise in any way </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">out of </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">your </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">employment </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">or </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">separatio</font><font style="font-family:Arial;font-size:10pt;color:#181818;">n </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">from employment with Biogen.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">This release is to be interpreted broadly and is intended to include, without limitation, </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">any and </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">all claims </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">you </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">may have against Releasees under federal, state or local statutes, ordinances, regulations or rules, including without limitation the following:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Any and all federal statutory or regulatory claims </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">such </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">as </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">claims </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">under the Age Discrimination in Employment Act, </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">29 </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">U.S</font><font style="font-family:Arial;font-size:10pt;color:#565656;">.</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">C. &#167; 621 </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">et</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;text-decoration:underline;">seq</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">., </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Title VII of the Civil Rights Act of 1964, 42 U.S.C. &#167; 2000e </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">et</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;text-decoration:underline;">seq</font><font style="font-family:Arial;font-size:10pt;color:#181818;text-decoration:underline;">.</font><font style="font-family:Arial;font-size:10pt;color:#181818;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">the Americans </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">with </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Disabilities Act of 1990, 42 U.S.C. &#167; 12101 </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;text-decoration:underline;">et</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">seq</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">., the Family and Medical Leave Act</font><font style="font-family:Arial;font-size:10pt;color:#565656;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">29 U.S.C. </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">&#167; 260 </font><font style="font-family:Arial;font-size:10pt;color:#181818;">1 </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">et seq</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">., the Worker Adjustment </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">and </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Retraining </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">Notification </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Act (</font><font style="font-family:Arial;font-size:10pt;color:#565656;">"</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">WARN"), 29 U.S.C. </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">&#167; </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">2101 </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">et seq</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">.</font><font style="font-family:Arial;font-size:10pt;color:#565656;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">and the Rehabilitation Act of 1973, 29 </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">U.S.C. &#167; </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">701 </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">et seq</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">., all as amended; all </font><font style="font-family:Arial;font-size:10pt;color:#181818;">claims </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">arising out of the Fair Credit Reporting Act, 15 U.S.C. </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">&#167; 168</font><font style="font-family:Arial;font-size:10pt;color:#181818;">1 </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">et seq</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">., the Employee Retirement Income Security Act </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">of </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">1974 ("BRISA"), 29 </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">U</font><font style="font-family:Arial;font-size:10pt;color:#181818;">.S</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">.C. &#167; 1001 </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">et seq</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">., the Sarbanes-Oxley Act of 2002, the Immigration Reform and </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">Contro</font><font style="font-family:Arial;font-size:10pt;color:#181818;">l </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Act</font><font style="font-family:Arial;font-size:10pt;color:#565656;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">the Equal Pay Act, Sections </font><font style="font-family:Arial;font-size:10pt;color:#181818;">1981 </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">thorough </font><font style="font-family:Arial;font-size:10pt;color:#181818;">19</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">88 of </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Title 42 if the United States Code and the Genetic </font><font style="font-family:Arial;font-size:10pt;color:#181818;">information </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Nondiscrimination  Act.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Any and all state statutory or regulatory claims </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">such as </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">claims under </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">the </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Massachusetts Fair Employment Practices Law, M.G.L. ch. </font><font style="font-family:Arial;font-size:10pt;color:#181818;">15</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">lB; the Massachusetts Wage Payment Statute, G.L. c. 149, &#167;&#167; </font><font style="font-family:Arial;font-size:10pt;color:#181818;">148</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">, </font><font style="font-family:Arial;font-size:10pt;color:#181818;">148A, 14</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">8B, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">149, 150</font><font style="font-family:Arial;font-size:10pt;color:#565656;">,</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">150A-150C, 151, 152, </font><font style="font-family:Arial;font-size:10pt;color:#181818;">152A, </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;text-decoration:underline;">et seq</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">.; a</font><font style="font-family:Arial;font-size:10pt;color:#181818;">nd </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">the Massachusetts Wage and Hour laws, G.L. </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">c. </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">151&#167;1A </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;text-decoration:underline;">et seq</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">.; t</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">he North Carolina Equal Employment </font><font style="font-family:Arial;font-size:10pt;color:#181818;">Practi</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">ces Act </font><font style="font-family:Arial;font-size:10pt;color:#808080;">-</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">N.C. Gen</font><font style="font-family:Arial;font-size:10pt;color:#565656;">. </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Stat. </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">&#167;143</font><font style="font-family:Arial;font-size:10pt;color:#181818;">-</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">422.1 </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;text-decoration:underline;">et</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">seq</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">.; the North Carolina Persons With Disabilities Protection Act </font><font style="font-family:Arial;font-size:10pt;color:#808080;">-</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">N.C. Gen. Stat. </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">&#167;</font><font style="font-family:Arial;font-size:10pt;color:#181818;">16</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">8A- </font><font style="font-family:Arial;font-size:10pt;color:#181818;">l </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">et seq</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">.; the North Carolina Retaliatory </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">Employment </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Discrimination Law </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">-</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">N.C. Gen. Stat. </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">&#167;95-240 </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">et</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;text-decoration:underline;">seq</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">.; </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">the North Carolina Wage and Hour Act, as amended, including N.C. Gen</font><font style="font-family:Arial;font-size:10pt;color:#565656;">. </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Stat. </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">&#167;95-25.2 </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">et</font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;text-decoration:underline;">seq</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">., </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">and </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">&#167;95-25.14 </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;text-decoration:underline;">et seq</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Any and all other claims under public policy, </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">contract, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">tort </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">or common </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">law </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">such </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">as claims for breach of contract, detrimental </font><font style="font-family:Arial;font-size:10pt;color:#181818;">reliance</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">breach of the covenant of good faith and fair </font><font style="font-family:Arial;font-size:10pt;color:#181818;">dealing, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">wrongful discharge, employment discrimination, harassment, or retaliation, infliction of </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">emotiona</font><font style="font-family:Arial;font-size:10pt;color:#181818;">l </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">distress, negligence, defamation </font><font style="font-family:Arial;font-size:10pt;color:#565656;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">fraud, </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">and </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">non&#173; payment of wages </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">or </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">benefits.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Any and all claims for </font><font style="font-family:Arial;font-size:10pt;color:#181818;">recover</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">y </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">of costs, fees, or </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">other expenses </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">including attorneys' fees incurred in any matter.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Notwithstanding the foregoing or the following, by </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">signing </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">this Agreement, </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">you are </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">not waiving any rights you may have to: (i) your own vested accrued employee benefits under </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">the Company's </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">health, welfare</font><font style="font-family:Arial;font-size:10pt;color:#565656;">, </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">or retirement benefit plans as of </font><font style="font-family:Arial;font-size:10pt;color:#181818;">th</font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">e </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">Separation Date or any of </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">your </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">LTI awards that </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">are </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">vested as </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">of </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">the Separation Date; (ii) benefits </font><font style="font-family:Arial;font-size:10pt;color:#3f3f3f;">and/or </font><font style="font-family:Arial;font-size:10pt;color:#2b2b2b;">the right to seek benefits under applicable workers' compensation and/or unemployment compensation statutes; (iii) pursue </font><font style="font-family:Arial;font-size:10pt;color:#282828;">claims which by law cannot be waived by signing this Agreement; </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">(iv) enforce </font><font style="font-family:Arial;font-size:10pt;color:#282828;">this Agreement; </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">(v) </font><font style="font-family:Arial;font-size:10pt;color:#282828;">challenge the validity </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">of </font><font style="font-family:Arial;font-size:10pt;color:#282828;">this Agreement; and/or (vi) indemnification pursuant to that certain Indemnification Agreement between you and the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Company </font><font style="font-family:Arial;font-size:10pt;color:#282828;">effective as of </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">November </font><font style="font-family:Arial;font-size:10pt;color:#282828;">7, </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">2011 </font><font style="font-family:Arial;font-size:10pt;color:#282828;">(the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">"Indemnification </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Agreement") or any indemnification rights </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">you may </font><font style="font-family:Arial;font-size:10pt;color:#282828;">have pursuant to the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Company's </font><font style="font-family:Arial;font-size:10pt;color:#282828;">bylaws or any applicable insurance policy.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Nothing </font><font style="font-family:Arial;font-size:10pt;color:#282828;">in this release or </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">elsewhere </font><font style="font-family:Arial;font-size:10pt;color:#282828;">in </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">this </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Agreement </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">shall </font><font style="font-family:Arial;font-size:10pt;color:#282828;">be deemed </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">to </font><font style="font-family:Arial;font-size:10pt;color:#282828;">prohibit </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">you from </font><font style="font-family:Arial;font-size:10pt;color:#282828;">filing a </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">charge </font><font style="font-family:Arial;font-size:10pt;color:#282828;">or complaint of </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">employment </font><font style="font-family:Arial;font-size:10pt;color:#282828;">related discrimination with the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Equal Employment Opportunity Commission </font><font style="font-family:Arial;font-size:10pt;color:#282828;">("EEOC") </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">or </font><font style="font-family:Arial;font-size:10pt;color:#282828;">equivalent </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">state </font><font style="font-family:Arial;font-size:10pt;color:#282828;">agency, or </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">from </font><font style="font-family:Arial;font-size:10pt;color:#282828;">participating in any investigation or proceeding conducted by the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">EEOC or </font><font style="font-family:Arial;font-size:10pt;color:#282828;">equivalent </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">state </font><font style="font-family:Arial;font-size:10pt;color:#282828;">agency. Notwithstanding </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">your </font><font style="font-family:Arial;font-size:10pt;color:#282828;">right to file a charge or complaint with </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and</font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;">/</font><font style="font-family:Arial;font-size:10pt;color:#282828;">or </font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sb3a4c86066b2489d858bf55395c7995b"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#282828;">participate in any investigation or proceeding by the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">EEOC </font><font style="font-family:Arial;font-size:10pt;color:#282828;">or </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">equivalent state agency, to </font><font style="font-family:Arial;font-size:10pt;color:#282828;">the fullest </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">extent permitted </font><font style="font-family:Arial;font-size:10pt;color:#282828;">by law, </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">you expressly waive your </font><font style="font-family:Arial;font-size:10pt;color:#282828;">right to recover </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">any </font><font style="font-family:Arial;font-size:10pt;color:#282828;">individual monetary relief or </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">other </font><font style="font-family:Arial;font-size:10pt;color:#282828;">individual remedies from Biogen or any </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">other </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Releasees, in any administrative </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">action </font><font style="font-family:Arial;font-size:10pt;color:#282828;">or proceeding, whether </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">state </font><font style="font-family:Arial;font-size:10pt;color:#282828;">or </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">federal, </font><font style="font-family:Arial;font-size:10pt;color:#282828;">and </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">whether </font><font style="font-family:Arial;font-size:10pt;color:#282828;">brought by </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">you or on your behalf </font><font style="font-family:Arial;font-size:10pt;color:#282828;">by an </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">administrative </font><font style="font-family:Arial;font-size:10pt;color:#282828;">agency, related in any </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">way </font><font style="font-family:Arial;font-size:10pt;color:#282828;">to the matters released herein. Likewise, nothing in this release </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">or </font><font style="font-family:Arial;font-size:10pt;color:#282828;">elsewhere in this Agreement (including without limitation </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">any confidentiality </font><font style="font-family:Arial;font-size:10pt;color:#282828;">or non-disparagement obligations below) </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">shall </font><font style="font-family:Arial;font-size:10pt;color:#282828;">be construed to prevent you </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">from </font><font style="font-family:Arial;font-size:10pt;color:#282828;">responding truthfully </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and </font><font style="font-family:Arial;font-size:10pt;color:#282828;">completely to any lawfully issued </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">court </font><font style="font-family:Arial;font-size:10pt;color:#282828;">order </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">or subpoena </font><font style="font-family:Arial;font-size:10pt;color:#282828;">or from communicating with </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">a government </font><font style="font-family:Arial;font-size:10pt;color:#282828;">agency.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;text-decoration:underline;">Consideration</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#282828;text-decoration:underline;">Period and Applicable Data</font><font style="font-family:Arial;font-size:10pt;color:#282828;">. In </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">signing this </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Agreement, </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">you acknowledge that </font><font style="font-family:Arial;font-size:10pt;color:#282828;">you understand its provisions, that </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">your </font><font style="font-family:Arial;font-size:10pt;color:#282828;">agreement is knowing and voluntary, that are hereby </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">afforded an </font><font style="font-family:Arial;font-size:10pt;color:#282828;">opportunity to take up to forty-five </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">(45) </font><font style="font-family:Arial;font-size:10pt;color:#282828;">days to </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">consider </font><font style="font-family:Arial;font-size:10pt;color:#282828;">its terms </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and </font><font style="font-family:Arial;font-size:10pt;color:#282828;">consult </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">with or seek </font><font style="font-family:Arial;font-size:10pt;color:#282828;">advice from </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">any </font><font style="font-family:Arial;font-size:10pt;color:#282828;">person of </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">your choosing, and that </font><font style="font-family:Arial;font-size:10pt;color:#282828;">you are hereby </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">advised </font><font style="font-family:Arial;font-size:10pt;color:#282828;">by the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Company </font><font style="font-family:Arial;font-size:10pt;color:#282828;">to consult with </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">an </font><font style="font-family:Arial;font-size:10pt;color:#282828;">attorney prior to </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">executing </font><font style="font-family:Arial;font-size:10pt;color:#282828;">the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Agreement. </font><font style="font-family:Arial;font-size:10pt;color:#282828;">You further </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">acknowledge </font><font style="font-family:Arial;font-size:10pt;color:#282828;">that </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Biogen </font><font style="font-family:Arial;font-size:10pt;color:#282828;">has provided you with, in the form of </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;text-decoration:underline;">OWBPA</font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#282828;text-decoration:underline;">Attachment</font><font style="font-family:Arial;font-size:10pt;color:#282828;">&#32;to this Agreement, certain information regarding </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">individuals employed </font><font style="font-family:Arial;font-size:10pt;color:#282828;">by the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Company who </font><font style="font-family:Arial;font-size:10pt;color:#282828;">were </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">selected </font><font style="font-family:Arial;font-size:10pt;color:#282828;">and not </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">selected </font><font style="font-family:Arial;font-size:10pt;color:#282828;">for the Global Reduction in Force Program </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">(the "Program"). </font><font style="font-family:Arial;font-size:10pt;color:#282828;">The decisional unit for the Program in the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">US </font><font style="font-family:Arial;font-size:10pt;color:#282828;">consists </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">of </font><font style="font-family:Arial;font-size:10pt;color:#282828;">employees </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">in </font><font style="font-family:Arial;font-size:10pt;color:#282828;">the Pharma Operations and Technology, Research </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Development, Commercial, and </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Corporate </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Functions </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">organizations, </font><font style="font-family:Arial;font-size:10pt;color:#282828;">with the following departments </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">excluded </font><font style="font-family:Arial;font-size:10pt;color:#282828;">from consideration</font><font style="font-family:Arial;font-size:10pt;color:#5b5b5b;">: </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Compliance, </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Legal, and US </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Commercial Field </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Operations, US Market Access </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Reimbursement, </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and US </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Marketing. Factors used in selecting </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">eligible </font><font style="font-family:Arial;font-size:10pt;color:#282828;">individuals included one </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">or </font><font style="font-family:Arial;font-size:10pt;color:#282828;">more of the following criteria: skills, leadership </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">and </font><font style="font-family:Arial;font-size:10pt;color:#282828;">functional competencies, prior performance </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">ratings, </font><font style="font-family:Arial;font-size:10pt;color:#282828;">discipline </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">or </font><font style="font-family:Arial;font-size:10pt;color:#282828;">corrective </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">action, </font><font style="font-family:Arial;font-size:10pt;color:#282828;">redundancy of job functions, and business need. You </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">acknowledge </font><font style="font-family:Arial;font-size:10pt;color:#282828;">that, if </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">you choose </font><font style="font-family:Arial;font-size:10pt;color:#282828;">to </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">sign </font><font style="font-family:Arial;font-size:10pt;color:#282828;">this </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Agreement </font><font style="font-family:Arial;font-size:10pt;color:#282828;">before the end of the 45-day </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">consideration </font><font style="font-family:Arial;font-size:10pt;color:#282828;">period, </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">you </font><font style="font-family:Arial;font-size:10pt;color:#282828;">have had </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">a fully adequate </font><font style="font-family:Arial;font-size:10pt;color:#282828;">opportunity to review the Agreement. You agree </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">that any </font><font style="font-family:Arial;font-size:10pt;color:#282828;">modifications, material </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">or </font><font style="font-family:Arial;font-size:10pt;color:#282828;">otherwise, do not restart </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">or affect </font><font style="font-family:Arial;font-size:10pt;color:#282828;">in any manner the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">original </font><font style="font-family:Arial;font-size:10pt;color:#282828;">45-day consideration period.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#282828;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#282828;text-decoration:underline;">Revocation Period</font><font style="font-family:Arial;font-size:10pt;color:#282828;">. You further understand that </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">for a </font><font style="font-family:Arial;font-size:10pt;color:#282828;">period </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">of seven (7) </font><font style="font-family:Arial;font-size:10pt;color:#282828;">days </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">following your execution </font><font style="font-family:Arial;font-size:10pt;color:#282828;">of </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">this </font><font style="font-family:Arial;font-size:10pt;color:#282828;">Agreement, you may revoke </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">the Agreement, and </font><font style="font-family:Arial;font-size:10pt;color:#282828;">this Agreement shall not become </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">effective </font><font style="font-family:Arial;font-size:10pt;color:#282828;">or enforceable until this </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">seven (7) </font><font style="font-family:Arial;font-size:10pt;color:#282828;">day revocation period has </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">expired, </font><font style="font-family:Arial;font-size:10pt;color:#282828;">therefore making </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">the effective </font><font style="font-family:Arial;font-size:10pt;color:#282828;">date the eighth (8th) day </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">after </font><font style="font-family:Arial;font-size:10pt;color:#282828;">this </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">Agreement </font><font style="font-family:Arial;font-size:10pt;color:#282828;">is </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">signed </font><font style="font-family:Arial;font-size:10pt;color:#282828;">by </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">you, </font><font style="font-family:Arial;font-size:10pt;color:#282828;">provided that you do not revoke this Agreement during the </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">seven (7) </font><font style="font-family:Arial;font-size:10pt;color:#282828;">day revocation period (the "Effective Date"). Any </font><font style="font-family:Arial;font-size:10pt;color:#3b3b3b;">revocation within the seven (7) </font><font style="font-family:Arial;font-size:10pt;color:#282828;">day revocation </font><font style="font-family:Arial;font-size:10pt;color:#343434;">period </font><font style="font-family:Arial;font-size:10pt;color:#232323;">must </font><font style="font-family:Arial;font-size:10pt;color:#343434;">be </font><font style="font-family:Arial;font-size:10pt;color:#232323;">personally delivered </font><font style="font-family:Arial;font-size:10pt;color:#343434;">or </font><font style="font-family:Arial;font-size:10pt;color:#232323;">mailed </font><font style="font-family:Arial;font-size:10pt;color:#343434;">by Federal Express or Express Mail </font><font style="font-family:Arial;font-size:10pt;color:#232323;">to HR </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Operations at </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Biogen</font><font style="font-family:Arial;font-size:10pt;color:#5d5d5d;">, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">225 </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Binney </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Street, Cambridge, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">MA 02142, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">within seven (7) </font><font style="font-family:Arial;font-size:10pt;color:#232323;">days of </font><font style="font-family:Arial;font-size:10pt;color:#343434;">your execution of this Agreement. This Agreement shall </font><font style="font-family:Arial;font-size:10pt;color:#232323;">not become </font><font style="font-family:Arial;font-size:10pt;color:#343434;">effective </font><font style="font-family:Arial;font-size:10pt;color:#232323;">or </font><font style="font-family:Arial;font-size:10pt;color:#343434;">enforceable </font><font style="font-family:Arial;font-size:10pt;color:#232323;">until the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">revocation </font><font style="font-family:Arial;font-size:10pt;color:#232323;">period has </font><font style="font-family:Arial;font-size:10pt;color:#343434;">expired. If </font><font style="font-family:Arial;font-size:10pt;color:#232323;">the last day of the revocation period </font><font style="font-family:Arial;font-size:10pt;color:#343434;">is a Saturday, Sunday, or </font><font style="font-family:Arial;font-size:10pt;color:#232323;">legal holiday in Massachusetts </font><font style="font-family:Arial;font-size:10pt;color:#343434;">or </font><font style="font-family:Arial;font-size:10pt;color:#232323;">the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">state </font><font style="font-family:Arial;font-size:10pt;color:#232323;">in which </font><font style="font-family:Arial;font-size:10pt;color:#343434;">you </font><font style="font-family:Arial;font-size:10pt;color:#232323;">reside, then the revocation period </font><font style="font-family:Arial;font-size:10pt;color:#343434;">shall </font><font style="font-family:Arial;font-size:10pt;color:#232323;">not </font><font style="font-family:Arial;font-size:10pt;color:#343434;">expire </font><font style="font-family:Arial;font-size:10pt;color:#232323;">until the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">next </font><font style="font-family:Arial;font-size:10pt;color:#232323;">following day which is not </font><font style="font-family:Arial;font-size:10pt;color:#343434;">a Saturday, Sunday, or legal holiday.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#343434;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#343434;text-decoration:underline;">No Pending</font><font style="font-family:Arial;font-size:10pt;color:#343434;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#232323;text-decoration:underline;">Suits</font><font style="font-family:Arial;font-size:10pt;color:#232323;">. </font><font style="font-family:Arial;font-size:10pt;color:#343434;">You acknowledge and agree that you </font><font style="font-family:Arial;font-size:10pt;color:#232323;">have no </font><font style="font-family:Arial;font-size:10pt;color:#343434;">pending </font><font style="font-family:Arial;font-size:10pt;color:#232323;">lawsuit or </font><font style="font-family:Arial;font-size:10pt;color:#343434;">complaint against Biogen or any of </font><font style="font-family:Arial;font-size:10pt;color:#232323;">the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">other </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Releasees in </font><font style="font-family:Arial;font-size:10pt;color:#343434;">any court of </font><font style="font-family:Arial;font-size:10pt;color:#232323;">law. </font><font style="font-family:Arial;font-size:10pt;color:#343434;">You further waive the right </font><font style="font-family:Arial;font-size:10pt;color:#232323;">to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">seek or </font><font style="font-family:Arial;font-size:10pt;color:#232323;">receive </font><font style="font-family:Arial;font-size:10pt;color:#343434;">any </font><font style="font-family:Arial;font-size:10pt;color:#232323;">money damage</font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">s </font><font style="font-family:Arial;font-size:10pt;color:#232323;">based upon </font><font style="font-family:Arial;font-size:10pt;color:#343434;">any claim that might </font><font style="font-family:Arial;font-size:10pt;color:#232323;">be </font><font style="font-family:Arial;font-size:10pt;color:#343434;">asserted arising </font><font style="font-family:Arial;font-size:10pt;color:#232323;">out </font><font style="font-family:Arial;font-size:10pt;color:#343434;">of your employment </font><font style="font-family:Arial;font-size:10pt;color:#232323;">against </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Biogen or </font><font style="font-family:Arial;font-size:10pt;color:#232323;">any of </font><font style="font-family:Arial;font-size:10pt;color:#343434;">the other Releasees.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#343434;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#343434;text-decoration:underline;">Return of</font><font style="font-family:Arial;font-size:10pt;color:#343434;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#232323;text-decoration:underline;">Property</font><font style="font-family:Arial;font-size:10pt;color:#232323;">. </font><font style="font-family:Arial;font-size:10pt;color:#343434;">You agree </font><font style="font-family:Arial;font-size:10pt;color:#232323;">to return </font><font style="font-family:Arial;font-size:10pt;color:#343434;">(and </font><font style="font-family:Arial;font-size:10pt;color:#232323;">not destroy) </font><font style="font-family:Arial;font-size:10pt;color:#343434;">all property and documents of </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Biogen in </font><font style="font-family:Arial;font-size:10pt;color:#343434;">your custody and </font><font style="font-family:Arial;font-size:10pt;color:#232323;">possession upon the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">earlier of your Separation </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Date </font><font style="font-family:Arial;font-size:10pt;color:#343434;">or your </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Last Work Day</font><font style="font-family:Arial;font-size:10pt;color:#5d5d5d;">. </font><font style="font-family:Arial;font-size:10pt;color:#232323;">This includes, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">without </font><font style="font-family:Arial;font-size:10pt;color:#232323;">limitation, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">all Biogen-related </font><font style="font-family:Arial;font-size:10pt;color:#232323;">documents, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">both </font><font style="font-family:Arial;font-size:10pt;color:#232323;">in </font><font style="font-family:Arial;font-size:10pt;color:#343434;">paper and </font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">e</font><font style="font-family:Arial;font-size:10pt;color:#232323;">lectronic </font><font style="font-family:Arial;font-size:10pt;color:#343434;">form, all </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Biogen </font><font style="font-family:Arial;font-size:10pt;color:#343434;">equipment and other property such as </font><font style="font-family:Arial;font-size:10pt;color:#232323;">laptop </font><font style="font-family:Arial;font-size:10pt;color:#343434;">or other portable computers, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">lab notebooks, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">proprietary </font><font style="font-family:Arial;font-size:10pt;color:#232323;">and/or </font><font style="font-family:Arial;font-size:10pt;color:#343434;">confidential company </font><font style="font-family:Arial;font-size:10pt;color:#232323;">information</font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">cell </font><font style="font-family:Arial;font-size:10pt;color:#232323;">phones</font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">parking passes, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">your </font><font style="font-family:Arial;font-size:10pt;color:#232323;">office </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and </font><font style="font-family:Arial;font-size:10pt;color:#232323;">building </font><font style="font-family:Arial;font-size:10pt;color:#343434;">keys and/or security </font><font style="font-family:Arial;font-size:10pt;color:#232323;">card</font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">s, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and your identification </font><font style="font-family:Arial;font-size:10pt;color:#232323;">badge</font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#343434;text-decoration:underline;">Confidentiality of Company Information</font><font style="font-family:Arial;font-size:10pt;color:#343434;">. You agree to abide </font><font style="font-family:Arial;font-size:10pt;color:#232323;">by </font><font style="font-family:Arial;font-size:10pt;color:#343434;">all common </font><font style="font-family:Arial;font-size:10pt;color:#232323;">law </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and statutory obligations </font><font style="font-family:Arial;font-size:10pt;color:#232323;">relating to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">the protection and </font><font style="font-family:Arial;font-size:10pt;color:#232323;">non-di</font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">sclosure </font><font style="font-family:Arial;font-size:10pt;color:#343434;">of </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Biogen' </font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">s </font><font style="font-family:Arial;font-size:10pt;color:#343434;">trade secrets and confidential and </font><font style="font-family:Arial;font-size:10pt;color:#232323;">proprietary </font><font style="font-family:Arial;font-size:10pt;color:#343434;">documents and information. In addition, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">by </font><font style="font-family:Arial;font-size:10pt;color:#343434;">accepting </font><font style="font-family:Arial;font-size:10pt;color:#232323;">this </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Agreement, you </font><font style="font-family:Arial;font-size:10pt;color:#232323;">hereby </font><font style="font-family:Arial;font-size:10pt;color:#343434;">confirm that you have </font><font style="font-family:Arial;font-size:10pt;color:#232323;">previou</font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">s</font><font style="font-family:Arial;font-size:10pt;color:#232323;">ly </font><font style="font-family:Arial;font-size:10pt;color:#343434;">executed Biogen's </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Proprietary Information and Inventions </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Dispute </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Resolution </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Agreement </font><font style="font-family:Arial;font-size:10pt;color:#343434;">("PU Agreement") </font><font style="font-family:Arial;font-size:10pt;color:#232323;">in </font><font style="font-family:Arial;font-size:10pt;color:#343434;">the form attached </font><font style="font-family:Arial;font-size:10pt;color:#232323;">hereto as </font><font style="font-family:Arial;font-size:10pt;color:#343434;text-decoration:underline;">Exhibit A</font><font style="font-family:Arial;font-size:10pt;color:#343434;">&#32;and </font><font style="font-family:Arial;font-size:10pt;color:#232323;">that </font><font style="font-family:Arial;font-size:10pt;color:#343434;">certain U.S. Noncompetition Agreement dated November </font><font style="font-family:Arial;font-size:10pt;color:#232323;">11, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">2011 (the "Noncompete Agreement") attached </font><font style="font-family:Arial;font-size:10pt;color:#232323;">hereto </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and incorporated herein </font><font style="font-family:Arial;font-size:10pt;color:#232323;">by </font><font style="font-family:Arial;font-size:10pt;color:#343434;">this </font><font style="font-family:Arial;font-size:10pt;color:#232323;">reference</font><font style="font-family:Arial;font-size:10pt;color:#5d5d5d;">, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and you </font><font style="font-family:Arial;font-size:10pt;color:#232323;">hereby </font><font style="font-family:Arial;font-size:10pt;color:#343434;">reaffirm and/or </font><font style="font-family:Arial;font-size:10pt;color:#232323;">agree </font><font style="font-family:Arial;font-size:10pt;color:#343434;">to all obligations </font><font style="font-family:Arial;font-size:10pt;color:#232323;">under the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">PU Agreement </font><font style="font-family:Arial;font-size:10pt;color:#232323;">and </font><font style="font-family:Arial;font-size:10pt;color:#343434;">the Noncompete Agreement </font><font style="font-family:Arial;font-size:10pt;color:#232323;">that </font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">s</font><font style="font-family:Arial;font-size:10pt;color:#232323;">urvive the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">termination of your employment.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sb3a4c86066b2489d858bf55395c7995b"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#343434;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#343434;text-decoration:underline;">Confidentiality of</font><font style="font-family:Arial;font-size:10pt;color:#343434;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#232323;text-decoration:underline;">This</font><font style="font-family:Arial;font-size:10pt;color:#232323;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#343434;text-decoration:underline;">Agreement</font><font style="font-family:Arial;font-size:10pt;color:#343434;">. Except as required by law or </font><font style="font-family:Arial;font-size:10pt;color:#232323;">to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">enforce </font><font style="font-family:Arial;font-size:10pt;color:#232323;">this </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Agreement, you </font><font style="font-family:Arial;font-size:10pt;color:#232323;">agree </font><font style="font-family:Arial;font-size:10pt;color:#343434;">not to </font><font style="font-family:Arial;font-size:10pt;color:#232323;">disclose the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">existence or content of this Agreement </font><font style="font-family:Arial;font-size:10pt;color:#232323;">to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">any </font><font style="font-family:Arial;font-size:10pt;color:#232323;">person</font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">firm or entity, except </font><font style="font-family:Arial;font-size:10pt;color:#232323;">to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">your </font><font style="font-family:Arial;font-size:10pt;color:#232323;">accountant(s), financial </font><font style="font-family:Arial;font-size:10pt;color:#343434;">planner(s), attorney</font><font style="font-family:Arial;font-size:10pt;color:#232323;">(s)</font><font style="font-family:Arial;font-size:10pt;color:#5d5d5d;">, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">and </font><font style="font-family:Arial;font-size:10pt;color:#232323;">member</font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">s </font><font style="font-family:Arial;font-size:10pt;color:#343434;">of your immediate family, and to them only if </font><font style="font-family:Arial;font-size:10pt;color:#232323;">they </font><font style="font-family:Arial;font-size:10pt;color:#343434;">agree </font><font style="font-family:Arial;font-size:10pt;color:#232323;">to </font><font style="font-family:Arial;font-size:10pt;color:#343434;">keep this Agreement confidential. Notwithstanding anything </font><font style="font-family:Arial;font-size:10pt;color:#232323;">in the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">foregoing sentence </font><font style="font-family:Arial;font-size:10pt;color:#232323;">to the contrary</font><font style="font-family:Arial;font-size:10pt;color:#343434;">, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">in </font><font style="font-family:Arial;font-size:10pt;color:#343434;">connection with securing future employment you </font><font style="font-family:Arial;font-size:10pt;color:#232323;">may disclose </font><font style="font-family:Arial;font-size:10pt;color:#343434;">that your </font><font style="font-family:Arial;font-size:10pt;color:#232323;">being </font><font style="font-family:Arial;font-size:10pt;color:#343434;">employed through February 29, 2016 is </font><font style="font-family:Arial;font-size:10pt;color:#232323;">required </font><font style="font-family:Arial;font-size:10pt;color:#343434;">in order for you </font><font style="font-family:Arial;font-size:10pt;color:#232323;">to receive </font><font style="font-family:Arial;font-size:10pt;color:#343434;">certain </font><font style="font-family:Arial;font-size:10pt;color:#232323;">financial and other </font><font style="font-family:Arial;font-size:10pt;color:#343434;">benefits.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#343434;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#343434;text-decoration:underline;">Breach.</font><font style="font-family:Arial;font-size:10pt;color:#343434;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#232323;">In </font><font style="font-family:Arial;font-size:10pt;color:#343434;">the event of your material </font><font style="font-family:Arial;font-size:10pt;color:#232323;">breach </font><font style="font-family:Arial;font-size:10pt;color:#343434;">of </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Paragraphs </font><font style="font-family:Arial;font-size:10pt;color:#343434;">9, 10, </font><font style="font-family:Arial;font-size:10pt;color:#232323;">11, </font><font style="font-family:Arial;font-size:10pt;color:#343434;">13, or 14 of this Agreement or of </font><font style="font-family:Arial;font-size:10pt;color:#232323;">any provision of the PU </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Agreement or </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Noncompete </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Agreement: (a) all of Biogen's obligations </font><font style="font-family:Arial;font-size:10pt;color:#232323;">under this </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Agreement shall cease; (b) you agree to repay Biogen (i) all compensation paid to you </font><font style="font-family:Arial;font-size:10pt;color:#232323;">under </font><font style="font-family:Arial;font-size:10pt;color:#343434;">this Agreement other than wages and </font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">accrued </font><font style="font-family:Arial;font-size:10pt;color:#343434;">vacation earned through your Separation </font><font style="font-family:Arial;font-size:10pt;color:#232323;">Date, and (ii) the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">value of </font><font style="font-family:Arial;font-size:10pt;color:#232323;">all benefits </font><font style="font-family:Arial;font-size:10pt;color:#343434;">you received under </font><font style="font-family:Arial;font-size:10pt;color:#232323;">thi</font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">s </font><font style="font-family:Arial;font-size:10pt;color:#343434;">Agreement; and </font><font style="font-family:Arial;font-size:10pt;color:#232323;">(c) the </font><font style="font-family:Arial;font-size:10pt;color:#343434;">general </font><font style="font-family:Arial;font-size:10pt;color:#232323;">release </font><font style="font-family:Arial;font-size:10pt;color:#343434;">set forth </font><font style="font-family:Arial;font-size:10pt;color:#232323;">in paragraph </font><font style="font-family:Arial;font-size:10pt;color:#343434;">5 remains </font><font style="font-family:Arial;font-size:10pt;color:#232323;">in </font><font style="font-family:Arial;font-size:10pt;color:#343434;">full force and </font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">effect. </font><font style="font-family:Arial;font-size:10pt;color:#343434;">This </font><font style="font-family:Arial;font-size:10pt;color:#232323;">provi</font><font style="font-family:Arial;font-size:10pt;color:#4b4b4b;">s</font><font style="font-family:Arial;font-size:10pt;color:#232323;">ion </font><font style="font-family:Arial;font-size:10pt;color:#343434;">shall </font><font style="font-family:Arial;font-size:10pt;color:#232323;">in no </font><font style="font-family:Arial;font-size:10pt;color:#343434;">way affect Biogen's ability to </font><font style="font-family:Arial;font-size:10pt;color:#232323;">recover </font><font style="font-family:Arial;font-size:10pt;color:#343434;">other damages, or obtain any </font><font style="font-family:Arial;font-size:10pt;">other form of relief, otherwise available as a result of your breach of the PII Agreement or the Noncompete Agreement.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Cooperation.</font><font style="font-family:Arial;font-size:10pt;">&#32;You agree that you will make yourself available to Biogen, upon reasonable notice, either by telephone or in person to assist Biogen in any matter relating to the services performed by you during your employment with Biogen. You also agree that you will cooperate fully with Biogen in the defense or prosecution of any claims or actions now in existence or which may be brought in the future or on behalf of Biogen or its agents. Your full cooperation in connection with such claims or actions shall include, but not be limited to, your being available to meet with Biogen's counsel to prepare for trial or discovery or an administrative hearing and to act as a witness when requested by Biogen at reasonable times designated by Biogen. Nothing in this section is intended or should be construed as requiring anything other than your cooperation in providing truthful and accurate information.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Non-Disparagement</font><font style="font-family:Arial;font-size:10pt;">. You agree not to make any statements that are, or could reasonably be interpreted to be, disparaging about, or adverse to the business interests of Biogen, its directors, officers, and employees, including but not limited to, any statements that disparage any product, service, finances, capability or any other aspect of the business of Biogen. Breach of this provision shall constitute a material breach of this Agreement and cause substantial, irreparable harm to Biogen, for which you acknowledge there would be no adequate remedy at law.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Indemnification</font><font style="font-family:Arial;font-size:10pt;">. You shall be entitled after the Separation Date to indemnification in accordance with and subject to the terms of the Indemnification Agreement for actions taken while employed by the Company. Likewise, nothing in this Agreement constitutes a waiver of any indemnification rights you may have pursuant to the Company&#8217;s bylaws or any applicable insurance policy.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">16.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Miscellaneous</font><font style="font-family:Arial;font-size:10pt;">. Except for the Indemnification Agreement and any agreement or document expressly incorporated herein, this Agreement supersedes any and all prior oral or written agreements and sets forth the entire agreement between Biogen and you with respect to your separation from Biogen, including without limitation, any severance plan or policy. Notwithstanding anything in the foregoing sentence to the contrary, your obligations under the PII, the Noncompete Agreement and the Indemnification Agreement shall continue in full force and effect. No variations or modifications may be effective unless reduced to writing and signed by both parties.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">This Agreement shall be deemed to have been made in Massachusetts and shall take effect as an instrument under seal within Massachusetts. The validity, interpretation and performance of this Agreement, shall be governed by, and construed in accordance with, the internal laws of Massachusetts, without giving effect to conflict of law principles. Any action, demand, claim or counterclaim arising under this Agreement shall be commenced in Massachusetts and both parties acknowledge that material witnesses and documents would be located within Massachusetts. </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Both you and Biogen waive the right to a trial by jury with respect to any such action or proceeding.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">The provisions </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">of this Agreement are severable, and </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">if </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">for any </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">rea</font><font style="font-family:Arial;font-size:10pt;color:#414141;">so</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">n </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">any part </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">hereof </font><font style="font-family:Arial;font-size:10pt;color:#414141;">s</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">hall be </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">found </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">to </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">be </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">unenforceable, the remaining </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">provisions shall </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">be </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">enforced in </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">full. </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">This </font><font style="font-family:Arial;font-size:10pt;color:#414141;">Ag</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">reement may b</font><font style="font-family:Arial;font-size:10pt;color:#414141;">e </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">executed </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">in </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">counterparts, each of which shall </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">be </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">an original, </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">but all </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">of </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">which togeth</font><font style="font-family:Arial;font-size:10pt;color:#414141;">er </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">shall constitute one </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">agreem</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ent. </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Execution of </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">a facsimile </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">copy of this </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">Agreement </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">shall </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">hav</font><font style="font-family:Arial;font-size:10pt;color:#414141;">e </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">the same force and effect as </font><font style="font-family:Arial;font-size:10pt;color:#414141;">exec</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">ution </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">of </font><font style="font-family:Arial;font-size:10pt;color:#414141;">a</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">n </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">original, and a facsimile </font><font style="font-family:Arial;font-size:10pt;color:#414141;">s</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">ignature </font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sb3a4c86066b2489d858bf55395c7995b"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">shall </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">be d</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ee</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">m</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ed </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">an original and valid signature.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">lt is </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Biogen's desire </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">and intent </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">to make certain that you fully </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">understand the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">provisions and </font><font style="font-family:Arial;font-size:10pt;color:#414141;">effects </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">of this Agreement. To that end, you are encouraged and given an opportunity </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">to </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">consult with </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">legal </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">counsel. By executing </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">this </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Agreement, you are acknowledging </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">that </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">you </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">have b</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ee</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">n </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">afforded </font><font style="font-family:Arial;font-size:10pt;color:#414141;">s</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">ufficient </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">time </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">to understand the provisions </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">and effects of </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">thi</font><font style="font-family:Arial;font-size:10pt;color:#414141;">s </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Agreement and to consult </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">with l</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ega</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">l </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">counsel, </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">that </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">your agreements </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">and </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">obligations </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">under thi</font><font style="font-family:Arial;font-size:10pt;color:#414141;">s </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Agreement </font><font style="font-family:Arial;font-size:10pt;color:#414141;">a</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">re </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">made voluntarily, </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">knowingly </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">and </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">without </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">duress and </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">that n</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ei</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">ther Biogen nor its ag</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ents </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">or representatives </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">have m</font><font style="font-family:Arial;font-size:10pt;color:#414141;">a</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">d</font><font style="font-family:Arial;font-size:10pt;color:#414141;">e </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">any </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">repre</font><font style="font-family:Arial;font-size:10pt;color:#414141;">se</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">ntation</font><font style="font-family:Arial;font-size:10pt;color:#414141;">s </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">inconsistent with this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">17.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;text-decoration:underline;">No</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;text-decoration:underline;">&#32;</font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;text-decoration:underline;">Admissions</font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">. The parties agree that </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">neith</font><font style="font-family:Arial;font-size:10pt;color:#414141;">er </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">this </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Agreement nor </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">furnishing of </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">th</font><font style="font-family:Arial;font-size:10pt;color:#414141;">e co</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">nsideration </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">for this Agreement and the </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">r</font><font style="font-family:Arial;font-size:10pt;color:#414141;">e</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">l</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ease </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">shall </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">be deemed </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">or construed at any </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">time </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">for any purpose as an admission </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">by </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Releasees of any </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">liability </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">or wrongdoing.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;"></font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;font-weight:bold;">Nothing in this Agreement or the Reaffirmation Agreement </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;font-weight:bold;">shall </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;font-weight:bold;">be construed to prevent you from responding truthfully </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;font-weight:bold;">and </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;font-weight:bold;">completely to </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;font-weight:bold;">any </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;font-weight:bold;">lawfully issued </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;font-weight:bold;">court </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;font-weight:bold;">order or </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;font-weight:bold;">subpoena </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;font-weight:bold;">or </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;font-weight:bold;">any </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;font-weight:bold;">internal investigation </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;font-weight:bold;">by </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;font-weight:bold;">the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;font-weight:bold;">Company </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;font-weight:bold;">or from communicating with a </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;font-weight:bold;">government a</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;font-weight:bold;">gency.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">If </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">the </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">foregoing correctly </font><font style="font-family:Arial;font-size:10pt;color:#414141;">se</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">ts </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">forth our </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">agreement, please </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">sign, date and return the original of this Agreement </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">to HR </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">Operations </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">no later than 45 days </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">after </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">your rec</font><font style="font-family:Arial;font-size:10pt;color:#414141;">e</font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">ipt </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">of this Agreement. </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">Pl</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ease </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">ke</font><font style="font-family:Arial;font-size:10pt;color:#414141;">ep </font><font style="font-family:Arial;font-size:10pt;color:#2d2d2d;">the enclosed copy of the Agreement for your </font><font style="font-family:Arial;font-size:10pt;color:#1a1a1a;">records.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:432px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Very truly yours,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:432px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"></font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">/s/ Ken DiPietro</font></div><div style="line-height:120%;text-align:left;text-indent:432px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ken DiPietro</font></div><div style="line-height:120%;text-align:left;text-indent:432px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">EVP, Human Resources</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The foregoing Separation Agreement is agreed to and accepted by me on November 13, 2015.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:432px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"></font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">/s/ Tony Kingsley</font></div><div style="line-height:120%;text-align:left;text-indent:432px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Tony Kingsley</font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>7
<FILENAME>biib-20151231xex21.htm
<DESCRIPTION>EXHIBIT 21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s88bcb867eb704419a9e0c67e3904c882"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 21</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a list of subsidiaries of Biogen Inc. as of December 31, 2015, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="1%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">SUBSIDIARY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen MA Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Realty Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Realty Limited Partnership</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. Limited Partnership</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Foundation Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (RTP) Realty LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Hemophilia Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Holding I LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Holding II LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Nobel Research Center, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Manufacturing Holding LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen New Ventures Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen SRO Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Therapeutics Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. Pacific LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. West Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conforma Therapeutics Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stromedix, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Argentina) SRL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Argentina</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Australia PTY Ltd</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Australia</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Austria GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Austria</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Belgium N.V./S.A.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Belgium</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen International Holding Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bermuda</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Brasil Produtos Farmaceuticos LTDA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Brazil</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Canada Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canada</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Chile Spa</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chile</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Pharmaceutical Consultancy (Shanghai) Co., Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">China</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Czech Republic) s.r.o.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Czech Republic</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Denmark) A/S</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Denmark) Manufacturing ApS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Holding APS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Denmark) New Manufacturing ApS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Finland OY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen France S.A.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec (Hong Kong) Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hong Kong</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Hungary KFT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hungary</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Biotech India Pvt. Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">India</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec (Ireland) Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Italia SRL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div></td></tr></table></div></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s88bcb867eb704419a9e0c67e3904c882"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="1%"></td><td width="50%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Japan Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japan</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Luxembourg Holding SARL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Luxembourg</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Mexico S. DE R.L. DE C.V.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mexico</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen NZ Biopharma Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">New Zealand</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Norway AS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Norway</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Poland Sp. z.o.o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Poland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Portugal Sociedade Farmaceutica, Unipessoal, Lda.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Portugal</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Singapore) Pte Ltd</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Singapore</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Slovakia s.r.o.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Slovak Republic</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Pharma, farmacevtska in biotehnoloska druzba d.o.o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Slovenia</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Spain, S.L.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fundacion Biogen</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Sweden AB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sweden</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen International GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen International Neuroscience GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Management Services GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Swiss Manufacturing GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Switzerland AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Switzerland Holdings GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eidetica Biopharma GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen B.V.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Netherlands</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Netherlands B.V.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Netherlands</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">UK</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Research Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">UK</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Convergence Pharmaceuticals Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">UK</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Convergence Pharmaceuticals Holdings Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">UK</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Old Convergence Pharmaceuticals Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">UK</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Panion Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">UK</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Silver Acquisition Co. Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">UK</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Uruguay SA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Uruguay</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>8
<FILENAME>biib-20151231xex23.htm
<DESCRIPTION>EXHIBIT 23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s434C50E96854729229ECB512A5DCE8A2"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 23</font></div><div style="line-height:120%;padding-bottom:32px;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-206799) and Registration Statements on Forms S-8 (Nos. 333-205254, 333-110432, 333-128339, 333-152456, 333-140817 and 333-170133) of Biogen Inc. of our report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">dated February 3, 2016 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10&#8209;K.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ PricewaterhouseCoopers LLP</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Boston, Massachusetts</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February 3, 2016</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>biib-20151231xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s096455997B60F05F26B9B512A6818DAC"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, George A. Scangos, certify that:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this annual report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">c) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="76%"></td><td width="24%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: February&#160;3, 2016</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ George A. Scangos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">George A. Scangos</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>biib-20151231xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s3223EF3F9508108F9662B512A7274F51"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Paul J. Clancy, certify that:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this annual report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">d) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="75%"></td><td width="25%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: February&#160;3, 2016</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>biib-20151231xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sDAACB57B8622E9BCCB98B512A7CD136F"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Annual Report on Form 10-K for the year ended December&#160;31, 2015 (the &#8220;Form 10-K&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="75%"></td><td width="25%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: February&#160;3, 2016</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ George A. Scangos &#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">George A. Scangos</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal executive officer]</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="75%"></td><td width="25%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: February 3, 2016</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paul J. Clancy</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal financial officer]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>12
<FILENAME>biib-20151231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:912cefa20ac44a8888600957576de383,x:9aae7204255541f48329f4ff23d10725-->
<xbrli:xbrl xmlns:biib="http://www.biogenidec.com/20151231" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2015-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-roles="http://fasb.org/us-roles/2015-01-31" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="biib-20151231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2015Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4SharesOutstanding">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_biib_SpainandPortugalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SpainandPortugalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementGeographicalAxis_biib_SpainandPortugalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SpainandPortugalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-02-01</xbrli:startDate>
			<xbrli:endDate>2015-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-04-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_RaxatrigineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RaxatrigineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-04-01</xbrli:startDate>
			<xbrli:endDate>2013-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_NeuropathicpainindicationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:NeuropathicpainindicationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_RaxatrigineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RaxatrigineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-02-01</xbrli:startDate>
			<xbrli:endDate>2015-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q3Restructuring">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-10-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q3Restructuring_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-10-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q3Restructuring_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-10-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_biib_AVONEXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NotesPayableToFumedicaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NotesPayableToFumedicaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2011Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_CorporateJointVentureInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:CorporateJointVentureInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-07-01</xbrli:startDate>
			<xbrli:endDate>2011-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_CorporateJointVentureInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:CorporateJointVentureInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_BusinessAcquisitionAxis_biib_CorporateJointVentureInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:CorporateJointVentureInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_CorporateJointVentureInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:CorporateJointVentureInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2010Q4QTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-10-01</xbrli:startDate>
			<xbrli:endDate>2010-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_DerivativeByNatureAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:SalesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DerivativeByNatureAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:SalesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_DerivativeByNatureAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:SalesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DerivativeByNatureAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:SalesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_DerivativeByNatureAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:SalesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_DerivativeByNatureAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:SalesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CurrencyAxis_currency_JPY_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CurrencyAxis_currency_AUD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_CurrencyAxis_currency_AUD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_CurrencyAxis_currency_JPY_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD_biib_FacilityLocationAxis_biib_SolothurnMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_biib_FacilityLocationAxis_biib_CambridgeLeasesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:CambridgeLeasesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_biib_FacilityLocationAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:EisaiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:EisaiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:EisaiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2008Q1SD_us-gaap_LongtermDebtTypeAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2008-03-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_LongtermDebtTypeAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2006Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2006-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_LongtermDebtTypeAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2008Q1SD_us-gaap_LongtermDebtTypeAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2008-12-01</xbrli:startDate>
			<xbrli:endDate>2008-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2011Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_biib_UndesignatedPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">biib:UndesignatedPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_biib_SeriesXPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">biib:SeriesXPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_PlanNameAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_PlanNameAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_AttainmentOfPerformanceCriteriain2013Member_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ShareBasedCompensationPlanAxis">biib:AttainmentOfPerformanceCriteriain2013Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_AttainmentOfPerformanceCriteriain2011Member_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ShareBasedCompensationPlanAxis">biib:AttainmentOfPerformanceCriteriain2011Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_AttainmentOfPerformanceCriteriain2014Member_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ShareBasedCompensationPlanAxis">biib:AttainmentOfPerformanceCriteriain2014Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_AttainmentOfPerformanceCriteriain2014Member_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ShareBasedCompensationPlanAxis">biib:AttainmentOfPerformanceCriteriain2014Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_DirectorsPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ShareBasedCompensationPlanAxis">biib:DirectorsPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_AttainmentOfPerformanceCriteriain2012Member_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ShareBasedCompensationPlanAxis">biib:AttainmentOfPerformanceCriteriain2012Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_AttainmentOfPerformanceCriteriain2014Member_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ShareBasedCompensationPlanAxis">biib:AttainmentOfPerformanceCriteriain2014Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember_us-gaap_TitleOfIndividualAxis_us-gaap_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_OmnibusPlansMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ShareBasedCompensationPlanAxis">biib:OmnibusPlansMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A1995ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A1995ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A1995ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2011Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-10-01</xbrli:startDate>
			<xbrli:endDate>2011-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_biib_CumulativeSalesLevelAxis_biib_SevenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:SevenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q2_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_biib_FacilityLocationAxis_biib_CambridgeLeasesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:CambridgeLeasesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD_biib_CumulativeSalesLevelAxis_biib_SevenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:SevenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2011Q4_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_RodinTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:RodinTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_RodinTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:RodinTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IsisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SwedishOrphanBiovitrumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IsisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IsisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SangamoBioSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoBioSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_LeadprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:LeadprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_NewAntiCd20Member_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q1_us-gaap_TypeOfArrangementAxis_biib_SangamoBioSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoBioSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-02-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-02-01</xbrli:startDate>
			<xbrli:endDate>2012-02-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SMNRxMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SMNRxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IsisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ProductOrServiceAxis_biib_SMNRxMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SMNRxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IsisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_TypeOfArrangementAxis_biib_SangamoBioSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoBioSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q3_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IsisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_TypeOfArrangementAxis_biib_ElanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:ElanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD_us-gaap_TypeOfArrangementAxis_biib_MitsubishiTanabePharmaCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-10-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_OcrelizumabMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:OcrelizumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_OcrelizumabMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:OcrelizumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_TypeOfArrangementAxis_biib_AbbvieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbvieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:DMPKMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IsisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:DMPKMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IsisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SangamoBioSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoBioSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:DMPKMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IsisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_TypeOfArrangementAxis_biib_GenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:GenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q4QTD_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IsisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-10-01</xbrli:startDate>
			<xbrli:endDate>2012-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SwedishOrphanBiovitrumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_BiosimilarsMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IsisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_DiscoveryprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:DiscoveryprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_SMNRxMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SMNRxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IsisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:DMPKMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IsisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q1_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_OcrelizumabMember_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:OcrelizumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_SMNRxMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SMNRxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IsisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_biib_AdditionalProductsAxis_biib_NewAntiCd20Member_us-gaap_ProductOrServiceAxis_biib_ThirdPartyAntiCdTwentyMember_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:AdditionalProductsAxis">biib:NewAntiCd20Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ThirdPartyAntiCdTwentyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_OcrelizumabMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:OcrelizumabMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_LossContingenciesByNatureOfContingencyAxis_biib_HoechstMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">biib:HoechstMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_TypeOfArrangementAxis_biib_MitsubishiTanabePharmaCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SwedishOrphanBiovitrumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbvieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbvieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_biib_AbbvieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbvieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_LeadprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:LeadprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q3QTD_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IsisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-07-01</xbrli:startDate>
			<xbrli:endDate>2013-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q2_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:DMPKMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IsisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q1_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_SMNRxMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SMNRxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IsisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_NewAntiCd20Member_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q1QTD_us-gaap_ProductOrServiceAxis_biib_SMNRxMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SMNRxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IsisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2007Q1SD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecHemophiliaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecHemophiliaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2007-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q2QTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:DMPKMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IsisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-04-01</xbrli:startDate>
			<xbrli:endDate>2012-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbvieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbvieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SobiTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:SobiRateToBiogenOnNetSalesInSobiTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SobiTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SobiTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbvieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbvieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbvieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbvieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:SobiRateToBiogenOnNetSalesInSobiTerritoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:SobiRateToBiogenOnNetSalesInSobiTerritoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2011Q4QTD_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-10-01</xbrli:startDate>
			<xbrli:endDate>2011-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:EachAdditionalOneBillionUpToTwentyBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q2_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_biib_CumulativeSalesLevelAxis_biib_FivebillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:FivebillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecHemophiliaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecHemophiliaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_biib_CumulativeSalesLevelAxis_biib_OneBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:OneBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2010Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecHemophiliaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecHemophiliaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-01-01</xbrli:startDate>
			<xbrli:endDate>2010-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_biib_CumulativeSalesLevelAxis_biib_SixbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:SixbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:EachAdditionalOneBillionUpToTwentyBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_CumulativeSalesLevelAxis_biib_SixbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:SixbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_biib_CumulativeSalesLevelAxis_biib_ThreeBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:ThreeBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2006Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2006-01-01</xbrli:startDate>
			<xbrli:endDate>2006-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_biib_CumulativeSalesLevelAxis_biib_FourbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:FourbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SwissplanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">biib:SwissplanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_GermanPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">biib:GermanPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_GermanPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">biib:GermanPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_GermanPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">biib:GermanPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_GermanPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">biib:GermanPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_DeferredCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">biib:DeferredCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_DeferredCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">biib:DeferredCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SwissplanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">biib:SwissplanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SwissplanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">biib:SwissplanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SavingsPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">biib:SavingsPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SwissplanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">biib:SwissplanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SavingsPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">biib:SavingsPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SwissplanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">biib:SwissplanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SavingsPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">biib:SavingsPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_GermanPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis">biib:GermanPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementGeographicalAxis_country_DE">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementGeographicalAxis_country_DK">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementGeographicalAxis_country_DK">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementGeographicalAxis_country_DK">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-10-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="Plan">
		<xbrli:measure>biib:Plan</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="Increment">
		<xbrli:measure>biib:Increment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="chf">
		<xbrli:measure>iso4217:CHF</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="EUR">
		<xbrli:measure>iso4217:EUR</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>biib:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="KRW">
		<xbrli:measure>iso4217:KRW</xbrli:measure>
	</xbrli:unit>
	<biib:AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch contextRef="FI2015Q4" decimals="-5" id="Fact-B8190886FA8E1F1FD27438A291306FDC" unitRef="usd">25000000</biib:AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch>
	<biib:AdditionalMilestonePayment contextRef="FI2012Q2_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-E30448C65FFE92D4290C38A29134CE01" unitRef="usd">59000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2014Q4_us-gaap_ProductOrServiceAxis_biib_SMNRxMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-13F5F4B52053F72828A138A2913437F6" unitRef="usd">100000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_BiosimilarsMember_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-94A68503F048619C0C4038A2911DBEE9" unitRef="usd">25000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-EEAF13D662F9C864722E93B3A2FE7675" unitRef="usd">4200000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_DiscoveryprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-7298305A858051B803C438A29133C22F" unitRef="usd">592500000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_LeadprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-8592DCE06C035A13D7CA38A2911EC540" unitRef="usd">472500000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_SMNRxMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-04ACC1F0B95D4227885293B45E159069" unitRef="usd">92000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2015Q4_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-909170F41D7F2F3795AF38A2913448BB" unitRef="usd">75000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2015Q4_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-8" id="Fact-107EBD41ECBB7FF60AD838A29120CDCF" unitRef="usd">1100000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2015Q4_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-8" id="Fact-37ABC7798A82C34DF0BD38A29119AD2C" unitRef="usd">1000000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2015Q4_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-B8C09115E44779526D4938A2911CB59F" unitRef="usd">10000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2015Q4_us-gaap_TypeOfArrangementAxis_biib_MitsubishiTanabePharmaCorporationMember" decimals="-5" id="Fact-F5437FFA9F51FE20CA5838A2911C4F63" unitRef="usd">484000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2015Q4_us-gaap_TypeOfArrangementAxis_biib_SangamoBioSciencesMember" decimals="-5" id="Fact-9A882525425494B9633038A2911DEC3A" unitRef="usd">300000000</biib:AdditionalMilestonePayment>
	<biib:Additionalmilestonepaymentsforproductcandidateusingadifferentmodality contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-BDD26B1D7E261763BEDC38A291336509" unitRef="usd">90000000</biib:Additionalmilestonepaymentsforproductcandidateusingadifferentmodality>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2013Q4YTD" decimals="-5" id="Fact-04EEAF6AFB23E98DC85A38A2913F398F" unitRef="usd">16000000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2013Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-D888747705B549F759F938A2912BDEB2" unitRef="usd">16400000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2013Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-879C893515BFFC337CCD38A29124CBB3" unitRef="usd">700000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2013Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-8C2968F06A161C9B72B838A2913F3093" unitRef="usd">-1100000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2014Q4YTD" decimals="-5" id="Fact-1A408BD76B67772801E338A29139384F" unitRef="usd">16000000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-DA1ECE686087DB10F3B738A29139028B" unitRef="usd">28500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-2F8C7CF4966C5C8419D838A29139FAF6" unitRef="usd">1000000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-BE39871B66DFE5CAF86038A29139623D" unitRef="usd">-13500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2015Q4YTD" decimals="-5" id="Fact-DFB478244C43FAB8FD0438A291214A5B" unitRef="usd">32300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-703536E6E56C23F8CA0038A29124A997" unitRef="usd">16300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-BA1377505C0A83C102D738A291223663" unitRef="usd">1300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-067BFBCE17C9037841C638A29122B840" unitRef="usd">14700000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AmountReflectedInCollaborationProfitSharingLineForCollaboration contextRef="FD2013Q4YTD_us-gaap_TypeOfArrangementAxis_biib_ElanMember" decimals="-5" id="Fact-94E0C851740677B09C2638A2911DC454" unitRef="usd">85400000</biib:AmountReflectedInCollaborationProfitSharingLineForCollaboration>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2014Q4" decimals="-5" id="Fact-6E5F42AC233F7EB19B0738A291400D18" unitRef="usd">126800000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2015Q4" decimals="-5" id="Fact-358444EB4A9BDA1E065038A291405CDE" unitRef="usd">185300000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2014Q4" decimals="-5" id="Fact-E37450A7E5D660612EED38A291402E1E" unitRef="usd">126900000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2015Q4" decimals="-5" id="Fact-EAEB6F6B7C09C808AC3938A2914016E0" unitRef="usd">184500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AverageMaturityOfMarketableSecurities contextRef="FD2014Q4YTD" id="Fact-CE0508177BC8783DA3E038A29136205E">P15M</biib:AverageMaturityOfMarketableSecurities>
	<biib:AverageMaturityOfMarketableSecurities contextRef="FD2015Q4YTD" id="Fact-79DD7CEC0DC24B5531BE38A29135E86C">P16M</biib:AverageMaturityOfMarketableSecurities>
	<biib:AverageStockPriceOnGrantDateInDollarsMaximum contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-4D4546B880595BE429E338A2912F4101" unitRef="usd">240.14</biib:AverageStockPriceOnGrantDateInDollarsMaximum>
	<biib:AverageStockPriceOnGrantDateInDollarsMaximum contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-63DA2149213F218BC57038A291301DBB" unitRef="usd">335.65</biib:AverageStockPriceOnGrantDateInDollarsMaximum>
	<biib:AverageStockPriceOnGrantDateInDollarsMaximum contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-19210B8D43F445305A1538A29130F1A8" unitRef="usd">426.27</biib:AverageStockPriceOnGrantDateInDollarsMaximum>
	<biib:AverageStockPriceOnGrantDateInDollarsMinimum contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-3E2E170513D77EF471C338A2912F3C3E" unitRef="usd">150.33</biib:AverageStockPriceOnGrantDateInDollarsMinimum>
	<biib:AverageStockPriceOnGrantDateInDollarsMinimum contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-4A54675A22239F41A9EF38A2912FA1AB" unitRef="usd">280.88</biib:AverageStockPriceOnGrantDateInDollarsMinimum>
	<biib:AverageStockPriceOnGrantDateInDollarsMinimum contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-6E75B91556B27B410A5938A29130607A" unitRef="usd">227.35</biib:AverageStockPriceOnGrantDateInDollarsMinimum>
	<biib:BaseRateAfterFirstCommercialSale contextRef="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember" decimals="2" id="Fact-9316F7915C13B7AE401138A29121BA6D" unitRef="number">0.50</biib:BaseRateAfterFirstCommercialSale>
	<biib:BaseRateAfterFirstCommercialSale contextRef="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-94D5069B8965EB09B0BC38A2912E0E40" unitRef="number">0.17</biib:BaseRateAfterFirstCommercialSale>
	<biib:BaseRateAfterFirstCommercialSale contextRef="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-A9333838AF33BF1FE55E38A2912DFF1E" unitRef="number">0.15</biib:BaseRateAfterFirstCommercialSale>
	<biib:BaseRateAfterFirstCommercialSale contextRef="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-604CBF9D8E02CFB50F5D38A2912EA239" unitRef="number">0.12</biib:BaseRateAfterFirstCommercialSale>
	<biib:BaseRateAfterFirstCommercialSale contextRef="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-7A39385437E5F2632AB838A2912DB911" unitRef="number">0.10</biib:BaseRateAfterFirstCommercialSale>
	<biib:BaseRateAfterFirstCommercialSale contextRef="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-BFCBA7566FBCF73F36ED38A29132D4C4" unitRef="number">0.12</biib:BaseRateAfterFirstCommercialSale>
	<biib:BaseRateAfterFirstCommercialSale contextRef="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-1908941470A3AFD1FCD638A2912E054C" unitRef="number">0.10</biib:BaseRateAfterFirstCommercialSale>
	<biib:Chargesrecognizedtovacatebuilding contextRef="FD2013Q4YTD_biib_FacilityLocationAxis_biib_CambridgeLeasesMember" decimals="-5" id="Fact-9AF643F6ED8B2521A61438A2912D2ECF" unitRef="usd">27200000</biib:Chargesrecognizedtovacatebuilding>
	<biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="-5" id="Fact-941F31C959F41648133038A2911FFBEA" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
	<biib:CollaborationProfitSharing contextRef="FD2013Q4YTD" decimals="-5" id="Fact-FCCA267C611CFDB0D79338A2913FB0B1" unitRef="usd">85400000</biib:CollaborationProfitSharing>
	<biib:CollaborationProfitSharing contextRef="FD2014Q4YTD" decimals="-5" id="Fact-9378B29685F71E1FEAC038A2913675D4" unitRef="usd">0</biib:CollaborationProfitSharing>
	<biib:CollaborationProfitSharing contextRef="FD2015Q4YTD" decimals="-5" id="Fact-F06D99B2CD81B0CC123038A2913F1A69" unitRef="usd">0</biib:CollaborationProfitSharing>
	<biib:CompensationExpenseOverPurchasePeriod contextRef="FD2015Q4YTD" id="Fact-C08EF435BCFCF2D6B41338A291370850">The fair value of the look-back provision plus the 15% discount</biib:CompensationExpenseOverPurchasePeriod>
	<biib:ComputerSoftwareAndHardware contextRef="FI2014Q4" decimals="-5" id="Fact-DFC2AC59C62BC380A23A38A2913E5351" unitRef="usd">547800000</biib:ComputerSoftwareAndHardware>
	<biib:ComputerSoftwareAndHardware contextRef="FI2015Q4" decimals="-5" id="Fact-92BFE6C5162EC0C7F9F738A2913C1F14" unitRef="usd">647100000</biib:ComputerSoftwareAndHardware>
	<biib:ConsiderationPerProductDeveloped contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" decimals="-5" id="Fact-26EBAE8FA932D0FC37D293B0F42E3CA7" unitRef="usd">10000000</biib:ConsiderationPerProductDeveloped>
	<biib:CumulativeSalesLevel contextRef="FI2015Q4_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-8C88B750C1EC9802AEA238A2913012EF" unitRef="usd">20000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2015Q4_biib_CumulativeSalesLevelAxis_biib_FivebillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-37E538317CD9FC459ACC38A2913291CC" unitRef="usd">5000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2015Q4_biib_CumulativeSalesLevelAxis_biib_FourbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-1D0C7BB9B135A92BF36838A2913263AE" unitRef="usd">4000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2015Q4_biib_CumulativeSalesLevelAxis_biib_OneBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-34C29668B345C49BB4FA38A29131213C" unitRef="usd">1000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2015Q4_biib_CumulativeSalesLevelAxis_biib_SevenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-485CCC46D0B89E4D22C738A2913032BC" unitRef="usd">7000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2015Q4_biib_CumulativeSalesLevelAxis_biib_SixbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-72FA7E41D77CFB033EFD38A29132D05C" unitRef="usd">6000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2015Q4_biib_CumulativeSalesLevelAxis_biib_ThreeBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-8" id="Fact-2F1387E70A6F887C8C7238A29130E8D0" unitRef="usd">3000000000</biib:CumulativeSalesLevel>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2013Q4YTD" decimals="-5" id="Fact-330188D90B01083C4D1738A29124C7BC" unitRef="usd">1120500000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2013Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-4D7757AB6FCB71CC7CA338A2912C21DC" unitRef="usd">861300000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2013Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-71C405229C93B62347F438A2913F45BF" unitRef="usd">236300000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2013Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-0211F33912A21E66C59C38A29123BFD3" unitRef="usd">22900000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2014Q4YTD" decimals="-5" id="Fact-C85F6150BDCB2FC8BF7538A2913815F2" unitRef="usd">1651800000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-085914F1CB9E0759155938A291392DDE" unitRef="usd">1265400000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-20F22C89FECC05F6E03138A291397603" unitRef="usd">347300000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-9474F390542427039F2E38A29139F207" unitRef="usd">39100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2015Q4YTD" decimals="-5" id="Fact-6AE32E09394FAE4BAD4B38A2912AA3E7" unitRef="usd">2229400000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-88303F129ABCEE97BB0338A29132431A" unitRef="usd">1732100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-3DEF99608FCFB8F41DCD38A29123290C" unitRef="usd">459700000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-200C4F60D2CAD4DA975938A291239C66" unitRef="usd">37600000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage contextRef="FD2015Q4YTD" decimals="INF" id="Fact-65C86A4187D9C1B189B538A29127AE22" unitRef="number">1.01</biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage>
	<biib:DebtInstrumentUnamortizedInterestOnDebt contextRef="FI2015Q4_us-gaap_LongtermDebtTypeAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-2EE584FE60FCACDB484A38A2911FD4CA" unitRef="usd">17800000</biib:DebtInstrumentUnamortizedInterestOnDebt>
	<biib:DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages contextRef="FD2013Q4YTD_us-gaap_LossContingenciesByNatureOfContingencyAxis_biib_HoechstMember" decimals="-5" id="Fact-2BE48571761419F389C638A291344870" unitRef="usd">49700000</biib:DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages>
	<biib:DeferredTaxLiabilitiesDepreciationAmortizationOther contextRef="FI2014Q4" decimals="-5" id="Fact-DF1E2ED738A672E1003538A291283DA9" unitRef="usd">107000000</biib:DeferredTaxLiabilitiesDepreciationAmortizationOther>
	<biib:DeferredTaxLiabilitiesDepreciationAmortizationOther contextRef="FI2015Q4" decimals="-5" id="Fact-B36664BE919E86C649F438A2912E7C53" unitRef="usd">102700000</biib:DeferredTaxLiabilitiesDepreciationAmortizationOther>
	<biib:DeferredTaxLiabilityRecognized contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-C8C5B81D3812311D875638A291319DEB" unitRef="usd">203700000</biib:DeferredTaxLiabilityRecognized>
	<biib:Deferredtaxassetreclassification contextRef="FI2015Q4" decimals="-5" id="Fact-7095E98F079FC30B947838A29134B6F8" unitRef="usd">137100000</biib:Deferredtaxassetreclassification>
	<biib:Deferredtaxliabilityreclassification contextRef="FI2015Q4" decimals="-5" id="Fact-5BA404D0F68849CE66CF38A291310EBF" unitRef="usd">1600000</biib:Deferredtaxliabilityreclassification>
	<biib:DerecognitionOfConstructionInProgressAssets contextRef="FI2013Q4_biib_FacilityLocationAxis_biib_CambridgeLeasesMember" decimals="-5" id="Fact-B72FA6705FA1F22FB72138A2913015F0" unitRef="usd">161500000</biib:DerecognitionOfConstructionInProgressAssets>
	<biib:DiscountRateRecognizedInCompensationExpense contextRef="FD2015Q4YTD" decimals="2" id="Fact-C65387A9FE44D2B4727738A29141D6EB" unitRef="number">0.15</biib:DiscountRateRecognizedInCompensationExpense>
	<biib:DueFromUnconsolidatedJointBusiness contextRef="FI2014Q4" decimals="-5" id="Fact-B58B240680976798323638A2912324C2" unitRef="usd">283400000</biib:DueFromUnconsolidatedJointBusiness>
	<biib:DueFromUnconsolidatedJointBusiness contextRef="FI2015Q4" decimals="-5" id="Fact-60FFDC6594237EC0CCD938A29131F420" unitRef="usd">314500000</biib:DueFromUnconsolidatedJointBusiness>
	<biib:EffectiveIncomeTaxRateReconciliationContingentConsideration contextRef="FD2013Q4YTD" decimals="3" id="Fact-D6B5FBB3C1754E1A7B9B38A291399618" unitRef="number">-0.003</biib:EffectiveIncomeTaxRateReconciliationContingentConsideration>
	<biib:EffectiveIncomeTaxRateReconciliationContingentConsideration contextRef="FD2014Q4YTD" decimals="3" id="Fact-0360A66DE729E220D35738A291398A66" unitRef="number">-0.004</biib:EffectiveIncomeTaxRateReconciliationContingentConsideration>
	<biib:EffectiveIncomeTaxRateReconciliationContingentConsideration contextRef="FD2015Q4YTD" decimals="3" id="Fact-829970F5EEA92F8FB3AB38A2912FD337" unitRef="number">0.003</biib:EffectiveIncomeTaxRateReconciliationContingentConsideration>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2013Q4YTD" decimals="3" id="Fact-6774210AB81ADD5DF28438A2913A8F8D" unitRef="number">-0.066</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2014Q4YTD" decimals="3" id="Fact-DA76841E3B7045BB980838A2913949AA" unitRef="number">-0.018</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2015Q4YTD" decimals="3" id="Fact-AF5D0EA6F956192A837E38A2912EC509" unitRef="number">-0.018</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="0" id="Fact-4BCEBC9ECC9E90245FFD98CB1075ADE5" unitRef="shares">32000</biib:EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards>
	<biib:EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" decimals="0" id="Fact-CFA8C109AB54C5DC93CA98CCBF0CD515" unitRef="shares">11000</biib:EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards>
	<biib:Employeerelatedliabilitiesnoncurrent contextRef="FI2014Q4" decimals="-5" id="Fact-4352611A80FC4905030E38A2913F077B" unitRef="usd">200700000</biib:Employeerelatedliabilitiesnoncurrent>
	<biib:Employeerelatedliabilitiesnoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-DF6D0A3C458F46185DB138A2913FF36F" unitRef="usd">235400000</biib:Employeerelatedliabilitiesnoncurrent>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2013Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="2" id="Fact-95426F36B60B8E54D5EE38A2913313BF" unitRef="number">0.32</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2013Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="2" id="Fact-2B41B73597FF7AC7731438A2913A33CC" unitRef="number">0.24</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2014Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="2" id="Fact-C5D02E0F5A289CB2B91238A2913A0A26" unitRef="number">0.33</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2014Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="2" id="Fact-4817798197F059AACDB038A2913F3270" unitRef="number">0.27</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2015Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="2" id="Fact-C854193C46639915253538A29133374A" unitRef="number">0.34</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2015Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="2" id="Fact-FC530D286F53638E09C038A29133EA2B" unitRef="number">0.26</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EquityMethodInvestmentOwnershipPercentageMaximum contextRef="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-91C82ECE420806D48A1038A29133ADF4" unitRef="number">0.499</biib:EquityMethodInvestmentOwnershipPercentageMaximum>
	<biib:EquityMethodInvestmentsExpectedProfitShare contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-5FF06AECE7CE61315CD438A2913C41C2" unitRef="number">0.5</biib:EquityMethodInvestmentsExpectedProfitShare>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="FI2014Q4_us-gaap_ProductOrServiceAxis_biib_SMNRxMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-ADD50D9A2930AC2BE0CC38A2911DE5E9" unitRef="usd">325000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbvieMember" decimals="-5" id="Fact-4D23C99245DFFF66A21638A2911E5E53" unitRef="usd">20000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_biib_AbbvieMember" decimals="-5" id="Fact-D83B8AEEEA8489C8BE0438A2911F202E" unitRef="usd">12000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="FI2015Q4_us-gaap_TypeOfArrangementAxis_biib_AbbvieMember" decimals="-5" id="Fact-7C88B4914065806AEEBE38A29119C3EE" unitRef="usd">32000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries contextRef="FI2015Q4_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="-8" id="Fact-37A05EB55C00755F93B938A291338E4A" unitRef="usd">2000000000</biib:EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries>
	<biib:EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries contextRef="FI2015Q4_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="-8" id="Fact-6CE49D7BFC18B268A6A438A2913498E1" unitRef="usd">1500000000</biib:EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries>
	<biib:EstimatedUsefulLivesOfLeaseholdImprovements contextRef="FD2015Q4YTD" id="Fact-52C18CB3AB810C9E11BE38A2913783BB">Lesser of the useful life or the term of the respective lease</biib:EstimatedUsefulLivesOfLeaseholdImprovements>
	<biib:ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones contextRef="FI2015Q4_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-63B1585DC3A0944A9ACE38A2911E8B6E" unitRef="usd">375000000</biib:ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones>
	<biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold contextRef="FI2015Q4_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-72AB0DE644FF49A7059838A29120678A" unitRef="usd">15000000</biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold>
	<biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments contextRef="FI2014Q4_us-gaap_ProductOrServiceAxis_biib_SMNRxMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-7AA7E374AEE8334BF25938A291339178" unitRef="usd">150000000</biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments>
	<biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-8CE1432D9CC4426A2C4238A291348890" unitRef="usd">130000000</biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments>
	<biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments contextRef="FI2015Q4_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-6AB116E86CCF429C981E38A2911E6FA4" unitRef="usd">130000000</biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments>
	<biib:ExpenseForNonIncomeBasedStateTaxes contextRef="FI2013Q4" decimals="-5" id="Fact-AA6F99B3D3D3B86CDE8B38A29134236A" unitRef="usd">11300000</biib:ExpenseForNonIncomeBasedStateTaxes>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2013Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbvieMember" decimals="-5" id="Fact-2C6B36F2955169517E3838A291298474" unitRef="usd">133400000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2013Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-F0E746612C47842B57C838A29141450E" unitRef="usd">0</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbvieMember" decimals="-5" id="Fact-C1B9494EB23A049D347238A29129E944" unitRef="usd">117800000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-8FA9CE7EEB68EBF1565C38A2911D2634" unitRef="usd">57500000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbvieMember" decimals="-5" id="Fact-B02A46BA2C9A2BF312B538A291297316" unitRef="usd">113800000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-FECC38CF1599245F6F8C38A29140874E" unitRef="usd">84100000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-FA1437B41DC007DA422C38A2912ED6C1" unitRef="usd">11200000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_SMNRxMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-89272E4F77DE875D91A538A291219CEC" unitRef="usd">13600000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2013Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbvieMember" decimals="-5" id="Fact-E8628239D9E517A2716538A2912958D8" unitRef="usd">71000000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2013Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-A0D524CFC0D1DBE2796838A2911DD230" unitRef="usd">24300000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2013Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-2A872010CA77FEBAD9B238A2914184B1" unitRef="usd">0</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-370E54AE21DE2FCA671738A29134968A" unitRef="usd">10900000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_SMNRxMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-DC965EFDFCA43EA8F67F38A2911D5573" unitRef="usd">27700000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbvieMember" decimals="-5" id="Fact-2175F01B96AA664366CE38A29129646D" unitRef="usd">67400000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-EF2B3AE75BBAD17AAF8138A2913316A9" unitRef="usd">29200000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-7086319CFA8DD14648F238A291413770" unitRef="usd">29100000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SangamoBioSciencesMember" decimals="-5" id="Fact-4337963FA60B5B8197F938A29133F15D" unitRef="usd">28900000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-605D1FFF53CD2C78DFD338A2911A3957" unitRef="usd">9000000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SMNRxMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-35E9F97537ED3CB46B0638A2911F42BE" unitRef="usd">74900000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbvieMember" decimals="-5" id="Fact-D3E3CD9CFF268E6DE09038A2912937C1" unitRef="usd">60800000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-7FCE2C6A2D7A04CC6D2D38A291340453" unitRef="usd">30600000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-F50D8A1C89F5E67AAD6038A29140632F" unitRef="usd">40400000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:ExpenseReflectedWithinStatementsOfIncome contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SangamoBioSciencesMember" decimals="-5" id="Fact-4E5EB08693D6132E2E9538A2911BCB2E" unitRef="usd">13600000</biib:ExpenseReflectedWithinStatementsOfIncome>
	<biib:Finitelivedintangibleassetsfutureamortization contextRef="FI2015Q4" decimals="-5" id="Fact-AB2A69D72315FBF3FAA938A29125DE27" unitRef="usd">1500200000</biib:Finitelivedintangibleassetsfutureamortization>
	<biib:ForeignSalesRequiredToTriggerMilestone contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-A85DEC3DA5EFCD6E880638A2911B02D9" unitRef="usd">100000000</biib:ForeignSalesRequiredToTriggerMilestone>
	<biib:FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" decimals="2" id="Fact-65D335C0A2D111D6893F38A2912D27C4" unitRef="number">0.25</biib:FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion>
	<biib:FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" decimals="2" id="Fact-A77AB442F7CEBAFE94F138A2912DD87D" unitRef="number">0.18</biib:FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion>
	<biib:FutureContingentPaymentForFirst12Months contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" decimals="2" id="Fact-14E3A8528D54A56A7AA938A2912CF931" unitRef="number">0.12</biib:FutureContingentPaymentForFirst12Months>
	<biib:FutureContingentPaymentThreshold contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" decimals="-8" id="Fact-EEC871F13FC21AC38DDA38A291319B50" unitRef="usd">2000000000</biib:FutureContingentPaymentThreshold>
	<biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_OcrelizumabMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-39E4CFBFFF0B8BE7A1E638A2911DC80E" unitRef="number">0.24</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
	<biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_OcrelizumabMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-D626DA4314C65207EF5538A2911DA6C4" unitRef="number">0.135</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
	<biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_OcrelizumabMember_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember" decimals="2" id="Fact-9546D4A4421BD0221DE238A2911CCDB8" unitRef="number">0.03</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
	<biib:Futurepercentageofcopromotionoperatingprofits contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_NewAntiCd20Member_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-3D5118D38F6C4C697CED38A291345F7B" unitRef="number">0.38</biib:Futurepercentageofcopromotionoperatingprofits>
	<biib:Futurepercentageofcopromotionoperatingprofits contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_NewAntiCd20Member_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-954A3522DCFF685FBB6438A29133F8E5" unitRef="number">0.30</biib:Futurepercentageofcopromotionoperatingprofits>
	<biib:GainOnSaleOfRights contextRef="FD2013Q4YTD" decimals="-5" id="Fact-92C680B033A6B02CF2F338A291367DB2" unitRef="usd">24900000</biib:GainOnSaleOfRights>
	<biib:GainOnSaleOfRights contextRef="FD2014Q4YTD" decimals="-5" id="Fact-E5A0464CAAE061677D6938A2912DE85B" unitRef="usd">16800000</biib:GainOnSaleOfRights>
	<biib:GainOnSaleOfRights contextRef="FD2015Q4YTD" decimals="-5" id="Fact-10A26E4C0C36735A74C738A29131D5C8" unitRef="usd">0</biib:GainOnSaleOfRights>
	<biib:IncreasedCarryingAmountOfSeniorNotes contextRef="D2008Q1SD_us-gaap_LongtermDebtTypeAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-6F39D091EC72A2A952A938A29122C30B" unitRef="usd">62800000</biib:IncreasedCarryingAmountOfSeniorNotes>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2015Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact-01EAFA033E77078A31E738A2913E42AC">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2015Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" id="Fact-911E5F59FAA70353BF4438A2913E8DC1">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:InterestInSubsidiary contextRef="FD2015Q4YTD" decimals="2" id="Fact-2C0F04A9DDB9694D0D9138A2913C8C02" unitRef="number">1.00</biib:InterestInSubsidiary>
	<biib:Inventorynetcurrentandnoncurrent contextRef="FI2014Q4" decimals="-5" id="Fact-22B7B97AA6427B00542938A29139B8CD" unitRef="usd">804000000</biib:Inventorynetcurrentandnoncurrent>
	<biib:Inventorynetcurrentandnoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-C547BE31CEF735AD00D638A2912BC8C2" unitRef="usd">933600000</biib:Inventorynetcurrentandnoncurrent>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2014Q4" decimals="-5" id="Fact-D9CF9C36A316263C367938A29133842C" unitRef="usd">7900000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2015Q4" decimals="-5" id="Fact-ECFAA1B4D832392C285C38A2913205B8" unitRef="usd">29200000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-96A3FF55E69396C99F9238A2911D2244" unitRef="KRW">280500000000</biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement>
	<biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-1D33108612F8EE2BAB1D38A2911DC4FE" unitRef="usd">250000000</biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement>
	<biib:JointVentureOwnerShipPercentageByThirdParty contextRef="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="2" id="Fact-A6D8DC4E8D1675F1B37638A2911FF2BB" unitRef="number">0.85</biib:JointVentureOwnerShipPercentageByThirdParty>
	<biib:LiabilityForFairValueOfOptionsGrantedUnderAgreement contextRef="FI2014Q1_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-051E549A9AD8EBCA7ABD38A2911BD0B8" unitRef="usd">17700000</biib:LiabilityForFairValueOfOptionsGrantedUnderAgreement>
	<biib:LicenseFee contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-BB7E11ECC73E070A9E8A38A29120A66D" unitRef="usd">70000000</biib:LicenseFee>
	<biib:LicenseFee contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-B544537875FE90E5367A38A2911FC084" unitRef="usd">70000000</biib:LicenseFee>
	<biib:LossContingencyAdjustmentRelatedToClaimAmountPercent contextRef="FI2013Q2_us-gaap_StatementGeographicalAxis_country_IT" decimals="INF" id="Fact-5A5FA9F072EBD69757C838A2913125BC" unitRef="number">0.5</biib:LossContingencyAdjustmentRelatedToClaimAmountPercent>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-2314F22E7814A8921D3438A2913E58E9" unitRef="number">1.50</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="2" id="Fact-A70B618348934858431038A2913E26C2" unitRef="number">2.00</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-0ABBC4115A82F3E2D16D38A29137D7BC" unitRef="number">2.00</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="2" id="Fact-88DAF941ABB7D231729538A2912E758E" unitRef="number">2.00</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MilestonePaymentsMadeDuringPeriod contextRef="D2010Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecHemophiliaMember" decimals="-5" id="Fact-722DD45A30A1A210E65638A291318038" unitRef="usd">40000000</biib:MilestonePaymentsMadeDuringPeriod>
	<biib:MilestonePaymentsMadeDuringPeriod contextRef="FD2014Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecHemophiliaMember" decimals="-5" id="Fact-CA6BC0B72EF077B54C8638A29130E75D" unitRef="usd">20000000</biib:MilestonePaymentsMadeDuringPeriod>
	<biib:MilestonePaymentsMadeDuringPeriod contextRef="FD2014Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-5181905C4147A931C22938A291340AF3" unitRef="usd">35000000</biib:MilestonePaymentsMadeDuringPeriod>
	<biib:MilestonePaymentsMadeDuringPeriod contextRef="FD2015Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_CorporateJointVentureInvestmentsMember" decimals="-5" id="Fact-04B9EE6C55444091151738A2913FB247" unitRef="usd">14500000</biib:MilestonePaymentsMadeDuringPeriod>
	<biib:MinimumQualifyingAgeForEmployeeBenefitPlan contextRef="FD2015Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SavingsPlanMember" id="Fact-5AB372F7D9CD1CAE63DE38A291348665">P21Y</biib:MinimumQualifyingAgeForEmployeeBenefitPlan>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-1A63A3E1CC8CF3AAF38F38A2913CD3E1" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="2" id="Fact-B7D331FA99D1B9DA5A3A38A2913C25BA" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-95B96D89F2EA4D68980838A2913F1409" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="2" id="Fact-1BFECB16C032CEC089F338A2913EB6A3" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:NetBenefitForPreviouslyUnrecognizedPosition contextRef="FI2013Q4" decimals="-5" id="Fact-0EF70D439DDD99F3FFEA38A29131743F" unitRef="usd">49800000</biib:NetBenefitForPreviouslyUnrecognizedPosition>
	<biib:NetBenefitForPreviouslyUnrecognizedPosition contextRef="FI2015Q4" decimals="-5" id="Fact-F840CF14FA8656C11C66939E5C6C17EC" unitRef="usd">27000000</biib:NetBenefitForPreviouslyUnrecognizedPosition>
	<biib:NetMinimumLeasePayments contextRef="FI2015Q4" decimals="-5" id="Fact-75CDFB1E03F2C704E57738A2913CD369" unitRef="usd">672300000</biib:NetMinimumLeasePayments>
	<biib:NetMinimumLeasePaymentsThereafter contextRef="FI2015Q4" decimals="-5" id="Fact-6E3077ACED89A685EE8B38A291379992" unitRef="usd">353800000</biib:NetMinimumLeasePaymentsThereafter>
	<biib:NetMinimumLeasePaymentsWithInFiveYear contextRef="FI2015Q4" decimals="-5" id="Fact-E9FB2EA1C697EE2738F838A2913C88FF" unitRef="usd">56900000</biib:NetMinimumLeasePaymentsWithInFiveYear>
	<biib:NetMinimumLeasePaymentsWithInFourYear contextRef="FI2015Q4" decimals="-5" id="Fact-6C40200042DAB7FFEBB338A291387B19" unitRef="usd">60400000</biib:NetMinimumLeasePaymentsWithInFourYear>
	<biib:NetMinimumLeasePaymentsWithInOneYear contextRef="FI2015Q4" decimals="-5" id="Fact-547C9F759D47F58B5C8138A291361BB2" unitRef="usd">69900000</biib:NetMinimumLeasePaymentsWithInOneYear>
	<biib:NetMinimumLeasePaymentsWithInThreeYear contextRef="FI2015Q4" decimals="-5" id="Fact-BE3DC79C13B5F3CE3CE138A291367933" unitRef="usd">61600000</biib:NetMinimumLeasePaymentsWithInThreeYear>
	<biib:NetMinimumLeasePaymentsWithInTwoYear contextRef="FI2015Q4" decimals="-5" id="Fact-B60A02620193E306980238A29134E149" unitRef="usd">69700000</biib:NetMinimumLeasePaymentsWithInTwoYear>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" id="Fact-19C7B48F514AD39F5C9038A29139A71A">P60D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" id="Fact-CD5BC50A32D3E052E30138A2913C8294">P60D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" id="Fact-306C61A56F5DDB7E1DF638A2912E7EA0">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" id="Fact-F09D5850FBCF0430AA8438A2913C0BCA">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" id="Fact-BB67462A61DF9C99505338A2913CFB2F">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:NumberOfEqualAnnualIncrements contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-F2A97BBA4B453B1B1BB138A2913C32E9" unitRef="Increment">4</biib:NumberOfEqualAnnualIncrements>
	<biib:NumberOfEqualAnnualIncrements contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-461F670E3EA1E595DE3038A2912D9349" unitRef="Increment">3</biib:NumberOfEqualAnnualIncrements>
	<biib:NumberOfEqualAnnualIncrements contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-F429B8DBEBFE96A7D3DE38A2913ED56B" unitRef="Increment">3</biib:NumberOfEqualAnnualIncrements>
	<biib:NumberOfEqualAnnualIncrements contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-A1DC8BE260A40450B4B338A2913EF947" unitRef="Increment">3</biib:NumberOfEqualAnnualIncrements>
	<biib:NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade contextRef="FD2015Q4YTD" decimals="INF" id="Fact-F1A99F56006F1B91098B38A2913FF461" unitRef="Plan">3</biib:NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade>
	<biib:NumberOfSharesOfCommonStockForIssuance contextRef="FD2015Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_DirectorsPlanMember" decimals="-5" id="Fact-BE4813789AD6BF9FDB5C38A2913F31F6" unitRef="shares">1600000</biib:NumberOfSharesOfCommonStockForIssuance>
	<biib:NumberOfSharesOfCommonStockForIssuance contextRef="FD2015Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_OmnibusPlansMember" decimals="-5" id="Fact-017CFAF413DC9F3317CC38A2912D522D" unitRef="shares">15000000</biib:NumberOfSharesOfCommonStockForIssuance>
	<biib:OtherIncomeExpenseNet contextRef="FD2013Q4YTD" decimals="-5" id="Fact-E2A034A6AFCBA1C5053A38A2913A7C0B" unitRef="usd">-14900000</biib:OtherIncomeExpenseNet>
	<biib:OtherIncomeExpenseNet contextRef="FD2014Q4YTD" decimals="-5" id="Fact-C6374FF052F6C68B55B138A291349BC4" unitRef="usd">-8700000</biib:OtherIncomeExpenseNet>
	<biib:OtherIncomeExpenseNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-8A5B7A62587629DC283F38A2913A04AB" unitRef="usd">-13800000</biib:OtherIncomeExpenseNet>
	<biib:Overnightreverserepurchaseagreementspercentoftotalassets contextRef="FI2014Q4" decimals="INF" id="Fact-C0434920E7B27C73B5FC38A29136FF74" unitRef="number">0.021</biib:Overnightreverserepurchaseagreementspercentoftotalassets>
	<biib:Overnightreverserepurchaseagreementspercentoftotalassets contextRef="FI2015Q4" decimals="INF" id="Fact-B39F0158020814CD700C38A291362785" unitRef="number">0.0071</biib:Overnightreverserepurchaseagreementspercentoftotalassets>
	<biib:ParValueOfNotesPayable contextRef="FI2014Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-6E09467444796E1E534638A291218FB4" unitRef="chf">11600000</biib:ParValueOfNotesPayable>
	<biib:ParValueOfNotesPayable contextRef="FI2014Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-A3EC1A9D2275F92776F838A29120E2F7" unitRef="usd">11700000</biib:ParValueOfNotesPayable>
	<biib:ParValueOfNotesPayable contextRef="FI2015Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-30A09FE97B9E7E1899B738A29120E857" unitRef="usd">9000000</biib:ParValueOfNotesPayable>
	<biib:ParValueOfNotesPayable contextRef="FI2015Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-564FFDDCC88C08D5BC2E38A2912D42D9" unitRef="chf">8900000</biib:ParValueOfNotesPayable>
	<biib:PaymentTermsOfAccountsReceivable contextRef="FD2015Q4YTD" id="Fact-69150DF48268AE24456738A29136C7DE">30 to 90 days</biib:PaymentTermsOfAccountsReceivable>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2013Q4YTD" decimals="-5" id="Fact-8054384594F08533D7D438A2912A4A7F" unitRef="usd">750100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2013Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-E590AE4C9F487566190338A2913FAD61" unitRef="usd">560400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2013Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-8AC038FD6207C1C8338938A2913F1632" unitRef="usd">189700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2013Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-1C7FF2A37E57321E7DF538A2912B192F" unitRef="usd">0</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2014Q4YTD" decimals="-5" id="Fact-EBAEDC74262CD64D73CF38A29139A6C0" unitRef="usd">1237200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-86B13678424CB2E4DC6D38A2913970F7" unitRef="usd">933400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-AC64F2AA471ED73D2F4A38A291399567" unitRef="usd">299700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-1D3C6794C30D9841BBD138A2912A2C86" unitRef="usd">4100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2015Q4YTD" decimals="-5" id="Fact-CB673592DB6E2279541938A2912124B2" unitRef="usd">1666600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-4C46513C50CF3FDD884D38A291331FD1" unitRef="usd">1258100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-F6FC04A8B8DC2515B71E38A29123B7B4" unitRef="usd">405900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-12002E8744BB03DE313738A291223DCD" unitRef="usd">2600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2013Q4YTD" decimals="-5" id="Fact-19E6F5E84FDE48FBEECA38A2913F125C" unitRef="usd">165300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2013Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-D6D990DDF8FEF86D474338A29121662A" unitRef="usd">135000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2013Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-FD903DA4AB77AEED424138A2912B2FA8" unitRef="usd">13200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2013Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-29E2167898F8480ED44638A2912CED61" unitRef="usd">17100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2014Q4YTD" decimals="-5" id="Fact-3285CA70C2B42C997DAB38A29139214C" unitRef="usd">341000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-9BC4496DB164305F740F38A29139257F" unitRef="usd">261900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-C07B0D125446027AAC7C38A2913922A3" unitRef="usd">46000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2014Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-9C4834D6DFC8681693E138A29139C236" unitRef="usd">33100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2015Q4YTD" decimals="-5" id="Fact-784472D6CDAD91171DE038A2912A8545" unitRef="usd">351600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-987C2032E39E84CAD20C38A291250076" unitRef="usd">296100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-F71740091AC3EA0057C038A2912A277F" unitRef="usd">44000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2015Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-05DD65D371FD1711D72038A291259982" unitRef="usd">11500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PercentageOfCoPromotionOperatingLosses contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="2" id="Fact-04579483E9EE1B7EB04C38A2911BB034" unitRef="number">0.35</biib:PercentageOfCoPromotionOperatingLosses>
	<biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="2" id="Fact-3EE9A2C1EF4D473B79F138A2911FF425" unitRef="number">0.35</biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion>
	<biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="2" id="Fact-C8F860E9B89D4B5D855F38A2911D7227" unitRef="number">0.30</biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion contextRef="FI2013Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="2" id="Fact-89B746ECC9998B40145638A291317C58" unitRef="number">0.40</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion contextRef="FI2014Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="2" id="Fact-91B20C8A2509A64F11B438A29131FB2F" unitRef="number">0.40</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="2" id="Fact-3DE9DB3767E3F2EE822C38A2911CACED" unitRef="number">0.40</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="3" id="Fact-2EE180DE89D2975248DB93AEC9ABC3F3" unitRef="number">0.400</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="3" id="Fact-414A821AEFAC8843526438A2912C08CB" unitRef="number">0.390</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="3" id="Fact-6DF3632706C71285054793AF059D5A58" unitRef="number">0.390</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="3" id="Fact-B5E2F9D5512C933AEC9038A2912CF462" unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="3" id="Fact-24D7502E9F7E47EE6EAB38A2912B0715" unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="3" id="Fact-67EA1A3525DB84E91F0D38A2912C801F" unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_RituxanMember" decimals="3" id="Fact-6866B9FC7459E6DA238538A29137BE97" unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
	<biib:PercentageOfDevelopmentAndCommercializationExpensesPayableRelated contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="2" id="Fact-528A93CE6E1C094A2E4D38A29133695E" unitRef="number">0.35</biib:PercentageOfDevelopmentAndCommercializationExpensesPayableRelated>
	<biib:PercentageOfDevelopmentReimbursementExpenses contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" decimals="2" id="Fact-4D844276E903DAD616F438A2911BC7B7" unitRef="number">1.00</biib:PercentageOfDevelopmentReimbursementExpenses>
	<biib:PercentageOfMarketValuePerShareOfCommonStock contextRef="FD2015Q4YTD" decimals="2" id="Fact-B03F511DF6D5E288075138A2913C8E89" unitRef="number">0.85</biib:PercentageOfMarketValuePerShareOfCommonStock>
	<biib:PercentageOfMinimumInvestmentReturn contextRef="FD2013Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SwissplanMember" decimals="3" id="Fact-D7FF440C0F20FEC85D7E38A2913ED939" unitRef="number">0.015</biib:PercentageOfMinimumInvestmentReturn>
	<biib:PercentageOfMinimumInvestmentReturn contextRef="FD2014Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SwissplanMember" decimals="4" id="Fact-B998A9A6FBC6AB3C513438A2913440D6" unitRef="number">0.0175</biib:PercentageOfMinimumInvestmentReturn>
	<biib:PercentageOfMinimumInvestmentReturn contextRef="FD2015Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SwissplanMember" decimals="4" id="Fact-6F57F418BB7BE482AA9438A291340397" unitRef="number">0.0175</biib:PercentageOfMinimumInvestmentReturn>
	<biib:PercentageOfRedemptionOfNotes contextRef="FD2015Q4YTD_us-gaap_LongtermDebtTypeAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="INF" id="Fact-1A743FDF7BF31FFFE31338A2913A3B23" unitRef="number">1</biib:PercentageOfRedemptionOfNotes>
	<biib:PercentageOfReimbursementExpenses contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" decimals="2" id="Fact-5294FCE3ED9251BDCDD138A291335AD3" unitRef="number">0.50</biib:PercentageOfReimbursementExpenses>
	<biib:PercentageOfRoyaltiesAsPerCollaboration contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-B7135F109EAC08DA349538A2911B1622" unitRef="number">0.12</biib:PercentageOfRoyaltiesAsPerCollaboration>
	<biib:PercentageOfRoyaltiesAsPerCollaboration contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-59F74E55B50E289D8E9A38A2911D4594" unitRef="number">0.10</biib:PercentageOfRoyaltiesAsPerCollaboration>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="INF" id="Fact-2118D5F00E4ABAA7DEE338A2912BFFE7" unitRef="number">0.99294</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="INF" id="Fact-E3492E4F69C1F41D246C38A29121A8EF" unitRef="number">0.99764</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="INF" id="Fact-B29BA0C6DB3B2F63B8E638A29120AD99" unitRef="number">0.9992</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="INF" id="Fact-5C92CB70427C815A51FB38A2912DD72A" unitRef="number">0.99792</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageParValueOfSeniorNotes contextRef="I2008Q1SD_us-gaap_LongtermDebtTypeAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="INF" id="Fact-29A60EDD70DB953B35A838A291218471" unitRef="number">0.99184</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables contextRef="FI2014Q4_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="3" id="Fact-569A3539E624D681DEB538A29135E3CC" unitRef="number">0.344</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
	<biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables contextRef="FI2014Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="3" id="Fact-5BE72830EE8517DA8CCC38A29135B9E6" unitRef="number">0.233</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
	<biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables contextRef="FI2015Q4_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="3" id="Fact-68CBA93213261F266D3338A29135BCCD" unitRef="number">0.354</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
	<biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables contextRef="FI2015Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="3" id="Fact-A24DBDB74FCA7CF3ADAA38A2913D8BB4" unitRef="number">0.231</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
	<biib:PeriodForGrantingOfApprovalByApprovingAuthority contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" id="Fact-FB4BCBF67B70E614E62938A2911E0721">P18M</biib:PeriodForGrantingOfApprovalByApprovingAuthority>
	<biib:PeriodOfCollaborationAgreement contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember" id="Fact-D8DD36DC710DCFF3ED9638A29133E496">P11Y</biib:PeriodOfCollaborationAgreement>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2E1F5A404630383F4ED838A29119F14F" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D07ED6AACE3224C00C4E38A2912C71C6" unitRef="usd">36900000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-AA36D15732BFC75EF68938A2911B1BF2" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-241E120F092BF00ECD1438A2912C02B5" unitRef="usd">36900000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1747285BBBCBD4A75A7F38A291321368" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-58A2C5EF4FAE7D29331D38A291325EEF" unitRef="usd">40100000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-982E0F84742DC92BA24438A2913632F8" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F777743E70AC2F56303538A291366AFC" unitRef="usd">40100000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2015Q4" decimals="-8" id="Fact-00FA21C608A7D8E170AF38A291316D28" unitRef="usd">2800000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-442BB8F36180A7696F0A38A2912B80B6" unitRef="usd">450000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_RaxatrigineMember" decimals="-5" id="Fact-1A5A93184A229578FDC538A2912BEFEE" unitRef="usd">350000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:Preapprovalinventory contextRef="FI2014Q4_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-263E7D6275C443BE293538A2913FDE36" unitRef="usd">6300000</biib:Preapprovalinventory>
	<biib:Preapprovalinventory contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember" decimals="-5" id="Fact-A2BC433AE92EC9B9F18938A2912A219D" unitRef="usd">18400000</biib:Preapprovalinventory>
	<biib:Preapprovalinventory contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember" decimals="-5" id="Fact-643AC84B8B138D0FC7209349513078E9" unitRef="usd">24200000</biib:Preapprovalinventory>
	<biib:Preapprovalinventory contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-E0AA786AFFF0E748830238A2913E30AE" unitRef="usd">24700000</biib:Preapprovalinventory>
	<biib:Premiumonequityinvestment contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-DCC02D4A541A17EBA58038A2913465FA" unitRef="usd">7500000</biib:Premiumonequityinvestment>
	<biib:ProposedDisallowanceByTaxAuthoritiesForPaymentForServices contextRef="FD2011Q4QTD" decimals="-6" id="Fact-C136C3D8245AD090E33638A291342A9E" unitRef="usd">130000000</biib:ProposedDisallowanceByTaxAuthoritiesForPaymentForServices>
	<biib:PurchasePriceOfCommonStockUnderEspp contextRef="FD2015Q4YTD" id="Fact-9FECCBF0C78956F853B438A291361994">85% of the lower of (i) the market value per share of the common stock on the participant's entry date into an offering period or (ii) the market value per share of the common stock on the purchase date</biib:PurchasePriceOfCommonStockUnderEspp>
	<biib:Purchaseofcommonstock contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-857658530C40DCE0D44B38A2911BE3F2" unitRef="usd">30000000</biib:Purchaseofcommonstock>
	<biib:RateDuringReimbursementPeriod contextRef="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" id="Fact-F14CEACFDFE6656720C538A291388D35">Base Rate
less 15%</biib:RateDuringReimbursementPeriod>
	<biib:RateDuringReimbursementPeriod contextRef="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" id="Fact-12146B5BBD1DB59BB14D38A2912104E3">Base Rate
less 5%</biib:RateDuringReimbursementPeriod>
	<biib:RateDuringReimbursementPeriod contextRef="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" id="Fact-BAFD6D39A3899CED72B138A29121478C">Base Rate
less 5%</biib:RateDuringReimbursementPeriod>
	<biib:RateDuringReimbursementPeriod contextRef="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" id="Fact-C01E03ADBF935D3A9D3238A29121C9C0">Base&#160;Rate
plus 5%</biib:RateDuringReimbursementPeriod>
	<biib:RatePriorToFirstCommercialSale contextRef="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember" decimals="2" id="Fact-F8A1824328F441EE3AFA38A291210002" unitRef="number">0.10</biib:RatePriorToFirstCommercialSale>
	<biib:RatePriorToFirstCommercialSale contextRef="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember" decimals="2" id="Fact-C4A8F932E0D5DD2571B538A291214E32" unitRef="number">0.02</biib:RatePriorToFirstCommercialSale>
	<biib:RatePriorToFirstCommercialSale contextRef="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember" decimals="2" id="Fact-4EC38C2CB9B2674A1DA938A29138EB26" unitRef="number">0.02</biib:RatePriorToFirstCommercialSale>
	<biib:RatioOfNumberOfSharesReservedUnderPlan contextRef="FD2015Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_DirectorsPlanMember" id="Fact-616FD3488912B33B82C338A2912DCA52">1.5-to-1</biib:RatioOfNumberOfSharesReservedUnderPlan>
	<biib:RatioOfNumberOfSharesReservedUnderPlan contextRef="FD2015Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_OmnibusPlansMember" id="Fact-D7010CFFBFBF7106F30838A2912EBA0E">1.5-to-1</biib:RatioOfNumberOfSharesReservedUnderPlan>
	<biib:Reductioninroyaltyrate contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_OcrelizumabMember" decimals="INF" id="Fact-3B3264CEFD7F96F7141C38A2911CDC08" unitRef="number">0.5</biib:Reductioninroyaltyrate>
	<biib:ReimbursementCostAchievingPeriod contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" id="Fact-5F6A84F66D281034AFC438A29134C84C">P6Y</biib:ReimbursementCostAchievingPeriod>
	<biib:ReimbursementLimitStatedInResolution contextRef="FD2011Q4QTD_us-gaap_StatementGeographicalAxis_country_IT" id="Fact-D3EA384ECE37EE594A3738A2913445F6">P24M</biib:ReimbursementLimitStatedInResolution>
	<biib:ReimbursementUnderAmendedAgreementMethod contextRef="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" id="Fact-71944A427C85961E42CF38A291380D45">Net
Revenue
Share</biib:ReimbursementUnderAmendedAgreementMethod>
	<biib:ReimbursementUnderAmendedAgreementMethod contextRef="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" id="Fact-BEED716B5BA20D04249938A29138D073">Royalty</biib:ReimbursementUnderAmendedAgreementMethod>
	<biib:ReimbursementUnderAmendedAgreementMethod contextRef="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" id="Fact-FBC97B85CACB320C6FEA38A2912182E6">Royalty</biib:ReimbursementUnderAmendedAgreementMethod>
	<biib:ReimbursementUnderAmendedAgreementMethod contextRef="FD2015Q4YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" id="Fact-777BD028E0A48A80328C38A291382848">Royalty</biib:ReimbursementUnderAmendedAgreementMethod>
	<biib:ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner contextRef="FD2013Q4YTD_us-gaap_TypeOfArrangementAxis_biib_ElanMember" decimals="-5" id="Fact-146A72CC361B50DE0AFA38A2911E6B01" unitRef="usd">11700000</biib:ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner>
	<biib:ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner contextRef="FD2013Q4YTD_us-gaap_TypeOfArrangementAxis_biib_ElanMember" decimals="-5" id="Fact-0FF2D8D8A5196FF0098F38A2911FAAFB" unitRef="usd">20600000</biib:ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner>
	<biib:RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement contextRef="FD2015Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-D1BA9534484AF6233C3F38A29134299D" unitRef="usd">275000000</biib:RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement>
	<biib:ResearchAndDevelopmentCostInSupportOfCollaborationAgreement contextRef="FD2015Q4YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="2" id="Fact-595E16EF55A884089AEA38A291331D04" unitRef="number">1.00</biib:ResearchAndDevelopmentCostInSupportOfCollaborationAgreement>
	<biib:Researchanddevelopmentservices contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-B81D836357E3CFA0E53F38A2911F3A4E" unitRef="usd">6500000</biib:Researchanddevelopmentservices>
	<biib:RestructuringandRelatedCostExpectedCashPayments contextRef="FI2015Q4" decimals="-6" id="Fact-E858982E789B791F1B4A38A2913B2314" unitRef="usd">120000000</biib:RestructuringandRelatedCostExpectedCashPayments>
	<biib:Restructuringandrelatedcostexpectedpercentageofpositionseliminated contextRef="FD2015Q4QTD" decimals="2" id="Fact-724AFE5BF4F0AB5DF42F38A2913C5A8E" unitRef="number">0.11</biib:Restructuringandrelatedcostexpectedpercentageofpositionseliminated>
	<biib:RevenuesFromUnconsolidatedJointBusiness contextRef="FD2013Q4YTD" decimals="-5" id="Fact-D590FE067B150FCBB83038A2912F4A13" unitRef="usd">1126000000</biib:RevenuesFromUnconsolidatedJointBusiness>
	<biib:RevenuesFromUnconsolidatedJointBusiness contextRef="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-7B6721E59CD43C5BB35C38A2912DD077" unitRef="usd">33900000</biib:RevenuesFromUnconsolidatedJointBusiness>
	<biib:RevenuesFromUnconsolidatedJointBusiness contextRef="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-5F397781E7E1EE8AB13C38A2912E8BEE" unitRef="usd">0</biib:RevenuesFromUnconsolidatedJointBusiness>
	<biib:RevenuesFromUnconsolidatedJointBusiness contextRef="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-04D6E02E0F38E12C5B0C38A2912E0147" unitRef="usd">1087300000</biib:RevenuesFromUnconsolidatedJointBusiness>
	<biib:RevenuesFromUnconsolidatedJointBusiness contextRef="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-54B9BD11ECE39B1631AB38A291301BE1" unitRef="usd">3200000</biib:RevenuesFromUnconsolidatedJointBusiness>
	<biib:RevenuesFromUnconsolidatedJointBusiness contextRef="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-B5AB874D6D25D47743A238A2912EA95F" unitRef="usd">1600000</biib:RevenuesFromUnconsolidatedJointBusiness>
	<biib:RevenuesFromUnconsolidatedJointBusiness contextRef="FD2014Q4YTD" decimals="-5" id="Fact-67F275BD9629C6C13DE438A2912FD90A" unitRef="usd">1195400000</biib:RevenuesFromUnconsolidatedJointBusiness>
	<biib:RevenuesFromUnconsolidatedJointBusiness contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-17FE1A4028FD8C2B534638A2912E0B5C" unitRef="usd">70600000</biib:RevenuesFromUnconsolidatedJointBusiness>
	<biib:RevenuesFromUnconsolidatedJointBusiness contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-73B2C4DE5CC8603D518138A2912FBA04" unitRef="usd">0</biib:RevenuesFromUnconsolidatedJointBusiness>
	<biib:RevenuesFromUnconsolidatedJointBusiness contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-5EB4A76905D2AF0D932F38A2912F70CC" unitRef="usd">1117100000</biib:RevenuesFromUnconsolidatedJointBusiness>
	<biib:RevenuesFromUnconsolidatedJointBusiness contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-B5C2E8B56835CB5D413238A2912EE631" unitRef="usd">0</biib:RevenuesFromUnconsolidatedJointBusiness>
	<biib:RevenuesFromUnconsolidatedJointBusiness contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-EF9AB3638B3487DB052938A2912F0660" unitRef="usd">7700000</biib:RevenuesFromUnconsolidatedJointBusiness>
	<biib:RevenuesFromUnconsolidatedJointBusiness contextRef="FD2015Q4YTD" decimals="-5" id="Fact-44A1DF5FCF0DAA5B7E2538A2912FA701" unitRef="usd">1339200000</biib:RevenuesFromUnconsolidatedJointBusiness>
	<biib:RevenuesFromUnconsolidatedJointBusiness contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-E1B2548868C4C417E85738A2912E3721" unitRef="usd">65900000</biib:RevenuesFromUnconsolidatedJointBusiness>
	<biib:RevenuesFromUnconsolidatedJointBusiness contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-C3D45F95B382144CF9A338A2912FB55A" unitRef="usd">0</biib:RevenuesFromUnconsolidatedJointBusiness>
	<biib:RevenuesFromUnconsolidatedJointBusiness contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-B086E47F6C234195787238A2912E6EEA" unitRef="usd">1269800000</biib:RevenuesFromUnconsolidatedJointBusiness>
	<biib:RevenuesFromUnconsolidatedJointBusiness contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-D1C4459A3E86CB1AA9B938A2912F3C69" unitRef="usd">0</biib:RevenuesFromUnconsolidatedJointBusiness>
	<biib:RevenuesFromUnconsolidatedJointBusiness contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-4F145BA4AC0DC589E60038A2912EC482" unitRef="usd">3500000</biib:RevenuesFromUnconsolidatedJointBusiness>
	<biib:RevenuesInPercentageFromUnconsolidatedJointBusiness contextRef="FD2013Q4YTD" decimals="2" id="Fact-87E7296CD77DC8DD1CF638A291333071" unitRef="number">0.16</biib:RevenuesInPercentageFromUnconsolidatedJointBusiness>
	<biib:RevenuesInPercentageFromUnconsolidatedJointBusiness contextRef="FD2014Q4YTD" decimals="2" id="Fact-40912AE818E79046B03038A29133FD46" unitRef="number">0.12</biib:RevenuesInPercentageFromUnconsolidatedJointBusiness>
	<biib:RevenuesInPercentageFromUnconsolidatedJointBusiness contextRef="FD2015Q4YTD" decimals="2" id="Fact-7BF2E541C52C09EF1C9338A2913F5461" unitRef="number">0.12</biib:RevenuesInPercentageFromUnconsolidatedJointBusiness>
	<biib:RoyaltiesTermsOfCollaborationAgreement contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember" id="Fact-325415A22422A30D761B38A2912FDDEF">10% and 12% on sales of RITUXAN outside the U.S. and Canada, with the royalty period lasting 11 years </biib:RoyaltiesTermsOfCollaborationAgreement>
	<biib:RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember" id="Fact-BC9B32488996D5BC37DC38A2913D4751">expire through 2012</biib:RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld>
	<biib:SalesTriggerGrossSalesThreshold contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="-5" id="Fact-8CD4094FD5D7F57EA9EB38A2911C335C" unitRef="usd">500000000</biib:SalesTriggerGrossSalesThreshold>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2013Q4YTD" decimals="-5" id="Fact-F5B873BF53F79C6AB37338A29140630C" unitRef="usd">246100000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2014Q4YTD" decimals="-5" id="Fact-6634E77106BB2739305838A29140C093" unitRef="usd">242400000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2015Q4YTD" decimals="-5" id="Fact-92DAE092C22BC4B0FA4038A2914021B6" unitRef="usd">196300000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareOfCoPromotionProfits contextRef="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-471CB8FEA78E3D4D85CC38A29133A075" unitRef="usd">1087300000</biib:ShareOfCoPromotionProfits>
	<biib:ShareOfCoPromotionProfits contextRef="FD2013Q4YTD_us-gaap_TypeOfArrangementAxis_biib_GenentechMember" decimals="-5" id="Fact-0B02598E8472E52BB8DE38A291351513" unitRef="usd">8500000</biib:ShareOfCoPromotionProfits>
	<biib:ShareOfCoPromotionProfits contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-BA164586355AED98F59138A291365F92" unitRef="usd">1117100000</biib:ShareOfCoPromotionProfits>
	<biib:ShareOfCoPromotionProfits contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-7C5287515EA83A08BB0438A291335DAC" unitRef="usd">1269800000</biib:ShareOfCoPromotionProfits>
	<biib:StrategicInvestmentPortfolio contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-E4BF8C92F0205B9C6C9138A29136F7B9" unitRef="usd">47800000</biib:StrategicInvestmentPortfolio>
	<biib:StrategicInvestmentPortfolio contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-08DF4B42D644BAF70D4638A29136C6A5" unitRef="usd">96000000</biib:StrategicInvestmentPortfolio>
	<biib:TermOfLease contextRef="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember" id="Fact-BD630D0D33B8F8F1342C38A2912D0E3A">P3Y</biib:TermOfLease>
	<biib:Termofcollaborationagreement contextRef="FD2013Q3QTD_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" id="Fact-C1657376F740E005A9AF38A2913482FB">P6Y</biib:Termofcollaborationagreement>
	<biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="-5" id="Fact-B02072E7E1E79565E01738A2911AAD42" unitRef="usd">150000000</biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne>
	<biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_GAZYVAMember" decimals="-5" id="Fact-6F10620678ACD00AEE5A38A2911CA4B0" unitRef="usd">150000000</biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne>
	<biib:TimePeriodForPayingRemainingBalanceDue contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" id="Fact-40F00668E537F688FCD838A29133CF5B">P90D</biib:TimePeriodForPayingRemainingBalanceDue>
	<biib:Totaldeferredchargesandprepaidtaxes contextRef="FI2014Q4" decimals="-5" id="Fact-BA2209E680C2B031F71A38A291342159" unitRef="usd">238900000</biib:Totaldeferredchargesandprepaidtaxes>
	<biib:Totaldeferredchargesandprepaidtaxes contextRef="FI2015Q4" decimals="-5" id="Fact-67E8D9E54F161591B72F38A29131CC0B" unitRef="usd">697900000</biib:Totaldeferredchargesandprepaidtaxes>
	<biib:UnconsolidatedJointBusiness contextRef="FD2013Q4YTD" decimals="-5" id="Fact-407E7A2BF80D84ABCF9438A2913FDE76" unitRef="usd">1126000000</biib:UnconsolidatedJointBusiness>
	<biib:UnconsolidatedJointBusiness contextRef="FD2013Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-74CE8EEDA5CFEC8E526938A2913328E1" unitRef="usd">1126000000</biib:UnconsolidatedJointBusiness>
	<biib:UnconsolidatedJointBusiness contextRef="FD2014Q1QTD" decimals="-5" id="Fact-3C0C72F055DB5EE0947A38A2911A0901" unitRef="usd">296900000</biib:UnconsolidatedJointBusiness>
	<biib:UnconsolidatedJointBusiness contextRef="FD2014Q2QTD" decimals="-5" id="Fact-E4C2AB9EEC61BDB3550B38A2911B49EF" unitRef="usd">303300000</biib:UnconsolidatedJointBusiness>
	<biib:UnconsolidatedJointBusiness contextRef="FD2014Q3QTD" decimals="-5" id="Fact-D2BCDCFB6DADC6FAE66C38A29142B7D8" unitRef="usd">290700000</biib:UnconsolidatedJointBusiness>
	<biib:UnconsolidatedJointBusiness contextRef="FD2014Q4QTD" decimals="-5" id="Fact-EF9D889F3084114E8F2938A2911B878B" unitRef="usd">304500000</biib:UnconsolidatedJointBusiness>
	<biib:UnconsolidatedJointBusiness contextRef="FD2014Q4YTD" decimals="-5" id="Fact-8811F2CF78BFD2F89F0738A291423CA6" unitRef="usd">1195400000</biib:UnconsolidatedJointBusiness>
	<biib:UnconsolidatedJointBusiness contextRef="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-45E93060A253D184965F38A29132383A" unitRef="usd">1195400000</biib:UnconsolidatedJointBusiness>
	<biib:UnconsolidatedJointBusiness contextRef="FD2015Q1QTD" decimals="-5" id="Fact-B7C6C449F0EA208AFA3E38A29132EF51" unitRef="usd">330600000</biib:UnconsolidatedJointBusiness>
	<biib:UnconsolidatedJointBusiness contextRef="FD2015Q2QTD" decimals="-5" id="Fact-E4B2676309BF52BBD50138A291322A33" unitRef="usd">337500000</biib:UnconsolidatedJointBusiness>
	<biib:UnconsolidatedJointBusiness contextRef="FD2015Q3QTD" decimals="-5" id="Fact-5B2D99B14EB7FF0336EA38A2913D9939" unitRef="usd">337200000</biib:UnconsolidatedJointBusiness>
	<biib:UnconsolidatedJointBusiness contextRef="FD2015Q4QTD" decimals="-5" id="Fact-C8E903FBC7A2658B942D38A2913FB1A5" unitRef="usd">333900000</biib:UnconsolidatedJointBusiness>
	<biib:UnconsolidatedJointBusiness contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E5CDA8BF087BA66C7C8D38A29140D8A4" unitRef="usd">1339200000</biib:UnconsolidatedJointBusiness>
	<biib:UnconsolidatedJointBusiness contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-B111E4F82A1D71613FF238A2913620FA" unitRef="usd">1339200000</biib:UnconsolidatedJointBusiness>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="FI2013Q3_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-5C4E994A850877705DB838A29134C0E0" unitRef="usd">100000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="FI2014Q1_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-61D377352E6B949FBDFC38A2911A846E" unitRef="usd">100000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="FI2014Q1_us-gaap_TypeOfArrangementAxis_biib_SangamoBioSciencesMember" decimals="-5" id="Fact-2A6C8D30D5E8B1E810D238A29133FDB7" unitRef="usd">20000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-DBFF27CF50A8B25333D738A29133A45B" unitRef="usd">124000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<biib:WeightedAveragePeriodToRecognizeCostOfNonvestedAwards contextRef="FD2015Q4YTD" id="Fact-6429AE4F1E532DE6F1F338A2913E2EF5">P1Y9M</biib:WeightedAveragePeriodToRecognizeCostOfNonvestedAwards>
	<biib:WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation contextRef="FD2013Q4YTD" decimals="-5" id="Fact-51F37872994560FBDD4738A29139FEFD" unitRef="usd">73500000</biib:WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation>
	<biib:WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation contextRef="FD2014Q4YTD" decimals="-5" id="Fact-6BD4108640638AF414C538A291345DB0" unitRef="usd">96400000</biib:WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation>
	<biib:WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation contextRef="FD2015Q4YTD" decimals="-5" id="Fact-7AD144C42501A2E9947138A291347C26" unitRef="usd">78200000</biib:WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation>
	<dei:AmendmentFlag contextRef="FD2015Q4YTD" id="Fact-44C6721ED8E2D204DF5038A2912C0733">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2015Q4YTD" id="Fact-7AD2658050A10BB9701D38A2912781FD">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2015Q4YTD" id="Fact-822058743BE3B66987BA38A291385510">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2015Q4YTD" id="Fact-FBC0CC883D6B5CF76ED338A291398135">2015</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2015Q4YTD" id="Fact-67B0E1C58522FDB737CC38A291380F6E">2015-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2015Q4YTD" id="Fact-98CF83D402E638E67EA138A29137EB52">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2015Q4YTD" id="Fact-AD87DC12879DFFFDDA1B38A2913826AE">0000875045</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2015Q4SharesOutstanding" decimals="0" id="Fact-9B02CEA3852981F3113638A2913A594B" unitRef="shares">218672717</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2015Q4YTD" id="Fact-B1C620B63440D3CA27F138A291405210">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityFilerCategory contextRef="FD2015Q4YTD" id="Fact-BBF9E8B3368EAEF8834C38A291400695">Large Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2015Q2" decimals="0" id="Fact-A77174E4FCCD896489C738A291205245" unitRef="usd">94898425323</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2015Q4YTD" id="Fact-BDC0DDEB750073F7947138A29126E516">BIOGEN INC.</dei:EntityRegistrantName>
	<dei:EntityVoluntaryFilers contextRef="FD2015Q4YTD" id="Fact-F47BF8A5294C5C5D79CD38A2912D843F">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2015Q4YTD" id="Fact-04DA615B767AF1F08BC438A2913A3B19">Yes</dei:EntityWellKnownSeasonedIssuer>
	<invest:DerivativeNotionalAmount contextRef="FI2014Q4_us-gaap_CurrencyAxis_currency_AUD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-055F9BD2A6E7BA702A2338A2911CCE2A" unitRef="usd">19900000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2014Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-D7FD6E8017C3A808583B38A2912C4E4A" unitRef="usd">56700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2014Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-2FD42A3200B6D566EC9F38A29124E003" unitRef="usd">0</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2014Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-4BCCAB0034BA79C4262B38A29131AFDB" unitRef="usd">1174600000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2014Q4_us-gaap_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-DE54CFCD561D52A7395038A29139FB0A" unitRef="usd">34500000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2014Q4_us-gaap_CurrencyAxis_currency_JPY_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-311E0BA188E526A4F56938A2913D5A41" unitRef="usd">16600000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2014Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-5ABDD93AE7121518D97938A2911B9891" unitRef="usd">1302300000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2014Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-7759BEE12498EB36571D38A2912C1E56" unitRef="usd">365200000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_CurrencyAxis_currency_AUD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-9BE399830F5B8826F9A538A2912B8F7E" unitRef="usd">0</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-94963E878F98902C71C838A29136134B" unitRef="usd">76700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-5607A5FD29D1768648C038A29135D56D" unitRef="usd">80800000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-2A9EFBE91B265D45114A38A2913643B5" unitRef="usd">945500000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-8714689F3A735189CB7638A2913AA438" unitRef="usd">0</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_CurrencyAxis_currency_JPY_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-83E38B43620B376AC78738A2911BBC0A" unitRef="usd">0</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-8" id="Fact-D1F6162175BC390CC26693617AEA55F8" unitRef="usd">1100000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-42256CBF381B91176DAD38A2912BA45B" unitRef="usd">675000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-F2D6F2E269FFC76BBF5F38A29137A92D" unitRef="usd">1103000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-BF32019B631201F1F8DF38A2912DC6F9" unitRef="usd">721000000</invest:DerivativeNotionalAmount>
	<us-gaap:AccountsPayableCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-37AFA58058D867DB89AA38A29131B88D" unitRef="usd">229200000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-45CC7F4B8C8AE1CF99FC38A291245595" unitRef="usd">267400000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-4638516ECD4C671B916F38A2912F8C2A" unitRef="usd">1292400000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2014Q4_us-gaap_StatementGeographicalAxis_biib_SpainandPortugalMember" decimals="-5" id="Fact-775B2BB5158452AA498C38A29135972B" unitRef="usd">90200000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-D374D169C7361EF6C0F538A29126F990" unitRef="usd">1227000000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_biib_SpainandPortugalMember" decimals="-5" id="Fact-B97AAD6169758D88B26738A29137804F" unitRef="usd">62400000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetNoncurrent contextRef="FI2014Q4_us-gaap_StatementGeographicalAxis_biib_SpainandPortugalMember" decimals="-5" id="Fact-E9E6BD4C07783AB821F938A291371DBE" unitRef="usd">12600000</us-gaap:AccountsReceivableNetNoncurrent>
	<us-gaap:AccountsReceivableNetNoncurrent contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_biib_SpainandPortugalMember" decimals="-5" id="Fact-2DAE56CB31F8934D1FAA38A29135584A" unitRef="usd">6100000</us-gaap:AccountsReceivableNetNoncurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-B81DFC7D14C59CAA98D038A2913AA8C3" unitRef="usd">172400000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-ED73826518F23C3C7F0438A2913A0AAD" unitRef="usd">167900000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2014Q4" decimals="-5" id="Fact-7FD6ECD08B1F0DA2764738A2913EC10E" unitRef="usd">1186400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2015Q4" decimals="-5" id="Fact-20D8E8EE3D9AC31D9DB838A2913EB4C4" unitRef="usd">1330100000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2012Q4" decimals="-5" id="Fact-B0376977E0EF642D15FC38A29126C529" unitRef="usd">-55300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-60349245E6B93FBFCCFC38A29126EB26" unitRef="usd">-21700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-C25CCC20941B24ED8C3F38A291273702" unitRef="usd">-10700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-4889DAE7D0205E9C6ECC38A29127621C" unitRef="usd">4200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-9E1A55DB305BAE93CCAE38A29127E5DE" unitRef="usd">-27100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2013Q4" decimals="-5" id="Fact-76A006EC78B1D054D4A038A291270D7A" unitRef="usd">-27700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-68C8861F9A7E232C79F338A29126BD62" unitRef="usd">-19600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-08AD3DB4BCADF91D5B5838A29127A0A7" unitRef="usd">-23700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-09235D2D08162B93BD7438A29127BE5F" unitRef="usd">5600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-5B1EF0249F8A38473EE038A29127627C" unitRef="usd">10000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4" decimals="-5" id="Fact-6DBCDECF6E146269210038A29131EFA4" unitRef="usd">-59500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-92FA195FA5CBD9CE6F1038A29133636D" unitRef="usd">-31600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-DBD5416F3D77A5BAB1C738A2913312A5" unitRef="usd">71700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-806A18CEA1755B4A1CD438A2913369EC" unitRef="usd">-400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-9AF35FD7F61FB0B1FE8538A29133E1A4" unitRef="usd">-99200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4" decimals="-5" id="Fact-9323B330430F0AE820A438A291246E55" unitRef="usd">-224000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-E0D5DC0BA9CADB1B2FC838A2912ECA16" unitRef="usd">-37800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-E18B3A55CF7E6498D52F38A291342696" unitRef="usd">10200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-80D847CE833252EC561C38A2912D37E3" unitRef="usd">-800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-7EB4870FF26584DCFF1D38A2912D16E6" unitRef="usd">-195600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2014Q4" decimals="-5" id="Fact-B5D0D61F7AE119C4E73A38A291253438" unitRef="usd">4196200000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2015Q4" decimals="-5" id="Fact-07CA644296A72F6FCC7A38A29130F71C" unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2013Q4YTD" decimals="-5" id="Fact-1438D556B280031A505B38A291357664" unitRef="usd">45900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-0D7B4185839D96485E8138A291389660" unitRef="usd">45900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-7AEE20778EF033E53ED638A2913769AE" unitRef="usd">45900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2014Q4YTD" decimals="-5" id="Fact-54609A63E07BC44CF1A838A2913B6CE5" unitRef="usd">93000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-054C80F40B1F8BA6761F38A2913A4C67" unitRef="usd">93000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-14C4C6EEBD229D5673D538A2913B281E" unitRef="usd">93000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-5" id="Fact-80158A6C9D2429C0B78138A2912BFD85" unitRef="usd">69000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-0684A17E28FCD7E4D81138A29126AF98" unitRef="usd">69000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-DE4BE481692EF071B88A38A2912BF568" unitRef="usd">69000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdvertisingExpense contextRef="FD2013Q4YTD" decimals="-5" id="Fact-76BB9DE268DD382DD8A638A29135D98B" unitRef="usd">72700000</us-gaap:AdvertisingExpense>
	<us-gaap:AdvertisingExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-C21707380A3E0C37881938A291354E48" unitRef="usd">92900000</us-gaap:AdvertisingExpense>
	<us-gaap:AdvertisingExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-A611A4C785BCCD97D7CE38A2913722B3" unitRef="usd">108600000</us-gaap:AdvertisingExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2013Q4YTD" decimals="-5" id="Fact-8A2DC96E8B60B1BA7B8738A29136F2EC" unitRef="usd">146200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2013Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-E78F51F38BFA8D7F87BC38A29141BEDA" unitRef="usd">172800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2013Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-323999B1A5623D0F865238A2914154DF" unitRef="usd">95600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2013Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-36E5C8C694274C07550B93799D5C8361" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2013Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-789E4CC0ADA96C4FE59A38A291418B51" unitRef="usd">160300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-FE30308C8F5195D9D4EA38A29140D5B5" unitRef="usd">109800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-B818692D6B6E75CD398D38A291402C08" unitRef="usd">9200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-742B7376ECBA22C43B4838A2913EBD18" unitRef="usd">32800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-63F797DF7D5B0F5E1C0538A29140EC0A" unitRef="usd">103500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-AB473E9148FF4563BA1A38A2914118D7" unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-AAFF46C97BF52D50044738A2914142B3" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-1BF87962114E46182A3B38A29136D60C" unitRef="usd">146200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-E4400AA54CBDB93FDCBC38A29123DABE" unitRef="usd">146200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-C7D5F846628DAFE67DE338A2913BEF54" unitRef="usd">165000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-0342B8973EDB3F87791A38A29141BC7B" unitRef="usd">170200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-EDD275F08BD534FB9ED238A291410E05" unitRef="usd">102100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-753BD8FE899EE12BF2C09379627943CD" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-78BE5D03CDE0CE9D1C2B38A29141982C" unitRef="usd">150300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-F55A2C40E115DAAE2E7C38A291404B0E" unitRef="usd">65500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-CCACBBAC6DCBC3774C7638A2914103B7" unitRef="usd">12200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-732B31F2847763C47DB338A2913268D2" unitRef="usd">37400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-A1D5D873669F25C8C6F938A2914100EF" unitRef="usd">115400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-509637AC4F5DFF9B15C238A29140AE1B" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-A6DDDC7C2C8F9FE737FF38A291408242" unitRef="usd">21900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-7B5EC3DA5EDEE8EFCFFF38A2913A8C37" unitRef="usd">165000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-AD29563C46971DDB7CE838A29121F5A5" unitRef="usd">165000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-0590804AAC2738A4910838A29123D45B" unitRef="usd">183200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-44B3DBD5E42BE01CBE3A38A29141D5D9" unitRef="usd">140500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-9C3C0904C4724B46642738A291411B68" unitRef="usd">88600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-9BA46C263E9DE15246C29378A8932FCC" unitRef="usd">8600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-C69D728972B6A34AEAB538A291426D51" unitRef="usd">127300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-6AA302DFE6CC22CA30A738A2913E3C28" unitRef="usd">22400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-041CFC60B4B48F98D17838A2914121CE" unitRef="usd">13900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-587573799A90D6E1CDB838A2913D8517" unitRef="usd">38100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-4A0BB9FA37FBFB30D29538A291401FE9" unitRef="usd">119000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-0ED93D2E70C1FFFA590938A29140B1B7" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-90729553F7BDFBEBB29338A291406FF0" unitRef="usd">13900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-EFF9746F59F32D70AA1938A29137576B" unitRef="usd">183200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-24C5DDED0BBCF4A82C1E38A29126DE9B" unitRef="usd">183200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2013Q4YTD" decimals="-5" id="Fact-3B588E8102917DB7D41038A2913FFB00" unitRef="usd">255900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-C0E971B86FBD1718C3A338A29141A49D" unitRef="usd">252400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-316C4A5270E1AB4D370738A291417F0E" unitRef="usd">207300000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2013Q4YTD" decimals="-5" id="Fact-F8467968252191A8571938A29131043F" unitRef="usd">342900000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2014Q4YTD" decimals="-5" id="Fact-147918E2F3FA0DD90B8638A2914061B5" unitRef="usd">489800000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2015Q4YTD" decimals="-5" id="Fact-ED6F964680733EFF0DA338A29140DF8F" unitRef="usd">382600000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:Assets contextRef="FI2014Q4" decimals="-5" id="Fact-63D356FC2557A1F8F32D38A291229345" unitRef="usd">14314700000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2015Q4" decimals="-5" id="Fact-F5ABA541A78E8D385BD938A2912F2F79" unitRef="usd">19504800000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-DE855BDEBED2ACAC884538A291308102" unitRef="usd">4535000000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-7DECBEE90321A0D0F12E38A2912F3E95" unitRef="usd">6700300000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9E19948B7CD246F21F1F38A2912C6984" unitRef="usd">6900000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-49C50482E14C7F6DAD7D38A2911A9DBE" unitRef="usd">2937000000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A849D80DAA56836832B938A2912C638B" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F1077819FCB60809F96F38A2912D150B" unitRef="usd">2943900000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-EB9292B2D152527E629238A29137CDD4" unitRef="usd">37500000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E48F5C02ED1415D7BD7E38A2913512BD" unitRef="usd">5857700000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C6F2D8E5D6AAA79BCE0638A291387EF3" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5F07EDFA6B12C4DC9A2038A29137FDA5" unitRef="usd">5895200000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2014Q4" decimals="-5" id="Fact-4E5128D66BC1AB4F318338A2914060F9" unitRef="usd">2112800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2015Q4" decimals="-5" id="Fact-4EC7900D4FCA6635328738A29140AFC2" unitRef="usd">4891200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4" decimals="-5" id="Fact-C0C6A2FEB3B79C1EAC9B38A29140C445" unitRef="usd">2111100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-912C47BA74B823277EDF38A2911920D6" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D940B4CB5B50BC77106338A2911B2993" unitRef="usd">198300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6A97DDC6A06C6B7B2F6538A2912C224F" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5ED38BE9CADCE0CD42C438A2912CC11A" unitRef="usd">198300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D2CD37A8DBD73052B00A38A2912C2849" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D03A763983F9658CC58B38A2912C4CD8" unitRef="usd">1063000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4627627BAC37C2CA503D38A2912C927A" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FC03CC6A860B85C9029838A2912C7BF4" unitRef="usd">1063000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-BC1D7DAAADAC23FB258538A2912C1999" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C5E669B06F3BAC4E626038A2912CFD2C" unitRef="usd">849800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-668002A888BCBA046F5138A2912CCE9D" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8F9025617528CCE467DE38A2912C8BFE" unitRef="usd">849800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-47AB020AE074EEC8B92438A2914259E0" unitRef="usd">370400000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-1A834F4135763E31DE9538A2913CD240" unitRef="usd">692600000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-C9550A0C75060390ED2B38A2913B0DD8" unitRef="usd">269900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-9FC4AAC28D0F9C0695BEA2C249293FF6" unitRef="usd">579900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember" decimals="-5" id="Fact-43328AAC0F2BD726DFC638A2913CE3F1" unitRef="usd">6900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-BBF454EE02500E7E025538A29142665E" unitRef="usd">200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-8A5FF9D8D3C2E0EFC2F938A2913B23D1" unitRef="usd">198100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4" decimals="-5" id="Fact-CEC0CC9D76A7B6DD731E38A291402ED3" unitRef="usd">4880900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-14ECCED8225CD2A7A4AD38A29135B669" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4B8CC21B10213D69C3C838A29132440C" unitRef="usd">494100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0E3738A5BF44166D045138A2913C877A" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B0E9C5A75ED7E1B468AA38A29135CB1F" unitRef="usd">494100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A4849538FAA1F6EC4D8638A29137862B" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C59737505A0D57ADCD8938A291352F64" unitRef="usd">1510900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-13EA5CD90E948828BD6F38A291376AC3" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FC6EBD82C8F9831B2FB638A29132A8E6" unitRef="usd">1510900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6B18B21137AE99ED0A3A38A291376895" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0D39CE97A12749840E4938A29138B1D8" unitRef="usd">2875900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-07F16E587A0AF201BC3238A291379377" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-300B122D1A4A743FB0A238A291351CE9" unitRef="usd">2875900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-C030000F173081B95F2138A291403BA7" unitRef="usd">394300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-E6DC292505764661835038A291428D9B" unitRef="usd">1116600000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-ED58CB0B483F66005E5B38A29140960B" unitRef="usd">1723400000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-18027BB9B228D3F7335D38A29119F6E2" unitRef="usd">1152500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember" decimals="-5" id="Fact-D90FFBD7F0BF327866A338A291407629" unitRef="usd">37500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-B8808CB57FD954669E1A38A291428D87" unitRef="usd">2800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-D6FE25DE2B0EB9D4745138A291425491" unitRef="usd">491300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4" decimals="-5" id="Fact-2439C19E95697E40FA7C935BC3BEA008" unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-736A5ADA396CD2BE8AD738A2913B6F17" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-A4D0049283030056161338A2913C6035" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-77334F16D194887B320938A2913B70F9" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-A1DCC6C7847023AB98E638A29119D21F" unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember" decimals="-5" id="Fact-C43DBA2DD7EC012304E938A29142EC5E" unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-F7FD78B74E89B460436738A2913B59B0" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-0B7BA159FF6B6492A1A038A2913B46A2" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4" decimals="-5" id="Fact-EC32506DD29AF2CA29AE935B4020B449" unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-A93E41A41FB4742CA3CB38A29140AD12" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-0DB03D61D7DA222BBD8B38A291406482" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-BB6604E8CA2ED0D3977938A2914275C6" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-19E9A818052B595ACF5038A291400D7B" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember" decimals="-5" id="Fact-9C20867A3DEB82D4EEFF38A29142CD64" unitRef="usd">9200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-96EA497BE1202EE4A4D938A29140A6E1" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-126795755E09FDB8F5D538A291410992" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4" decimals="-5" id="Fact-12B72432C0B9C67BB555935BDA541A87" unitRef="usd">2400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-AE24F328B7F3553F257338A2913CA35F" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-3D7F2B0D3CF10836F62738A2913B24E2" unitRef="usd">1500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-BF1CA44B15A39B267236A2C2492A1209" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-0DC706E3DC3983B52BBDA2C24925EDBD" unitRef="usd">400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember" decimals="-5" id="Fact-6B881F690E8E15BE28B738A2913BC3B0" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-FFB4A751F825448C00B038A29119E2DB" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-BBC9EA0DA3FDC343D04F38A2911AEFE4" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4" decimals="-5" id="Fact-CE417D141B989B50AEE4935B57E4D46E" unitRef="usd">10600000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-9BF777AFEF5CBB2F3F6838A29140CD13" unitRef="usd">500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-5A83E31D220F46F2F30C38A2914073F6" unitRef="usd">4100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-DE035E9E4F61C8C9BFFA38A291408C59" unitRef="usd">1100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-C94FCCBC2D6EAE35395D38A29142189B" unitRef="usd">3100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember" decimals="-5" id="Fact-CBED284E48173B6C501738A2914203A4" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-339C6ED42634777802E438A2914270CC" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-45A9A241022CC5BAF6FA38A291413615" unitRef="usd">1800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4" decimals="-5" id="Fact-8A9F8582B98A199C7B31935BFDA46D8F" unitRef="usd">2112800000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-78BF22E3837D985FFDE438A29142E08F" unitRef="usd">370600000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-B4F2E0E127991173B20C38A2911B1318" unitRef="usd">693900000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-721BB80EF6F50BA0F7EF38A2913B247D" unitRef="usd">270000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-63E9E51B96BF581D33DB38A2913C8A2A" unitRef="usd">580000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember" decimals="-5" id="Fact-5650D38B93901C1A8F0938A2913CCC92" unitRef="usd">5900000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-7746682114EEDC84F4E338A29142DB65" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2014Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-BD0E9CBF26EE8B581E8938A291424B85" unitRef="usd">198100000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4" decimals="-5" id="Fact-81AE2364C0C1C20A8B14935B718FC323" unitRef="usd">4891200000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-AF4D746DF0F21F0D7EAA38A29142BE6C" unitRef="usd">394800000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-07C836FBFF772EC65F7F38A29142406A" unitRef="usd">1120600000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-649EB16177CF8E5B438838A291406E69" unitRef="usd">1724400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-50A1A2B09A294C05FDC638A291405427" unitRef="usd">1155600000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MarketableEquitySecuritiesMember" decimals="-5" id="Fact-F6271CE25FC0B630E81C38A29140322E" unitRef="usd">28300000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-B71C049C632E313F71A838A291324C83" unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-988535C95F27B5B9EDF738A29142B4DE" unitRef="usd">493000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-C2585B25C184FC51391038A291212DA0" unitRef="usd">640500000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-6C9BA3D79E06923AA99138A291316947" unitRef="usd">2120500000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2014Q4" decimals="-5" id="Fact-7D4155430CAA50A7545A38A29140CE8A" unitRef="usd">1345200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2015Q4" decimals="-5" id="Fact-50DA001B6CD199031A3938A29140FC29" unitRef="usd">2583900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2014Q4" decimals="-5" id="Fact-73EA8ADEC3652399C08C38A291405A18" unitRef="usd">1343700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2015Q4" decimals="-5" id="Fact-0F443B7A4F47E4AFEB0F38A291404A0E" unitRef="usd">2575900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2014Q4" decimals="-5" id="Fact-889192D50025236DD5F338A291405139" unitRef="usd">640800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2015Q4" decimals="-5" id="Fact-CD8F9DFB101FAFB6CCB338A291401B77" unitRef="usd">2122000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2014Q4" decimals="-5" id="Fact-34C0E4DCB6E46C503CC838A29140B3CF" unitRef="usd">640500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2015Q4" decimals="-5" id="Fact-1F94ABCCE29553883E1338A2914008CD" unitRef="usd">2120500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2013Q4YTD" decimals="-5" id="Fact-AFE55518A0B457D4B27538A291384F09" unitRef="usd">6600000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2014Q4YTD" decimals="-5" id="Fact-AFD78E40512BB8C17F8F38A29139C859" unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2015Q4YTD" decimals="-5" id="Fact-058EF9314F257F6A594C38A2913B8278" unitRef="usd">1500000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2013Q4YTD" decimals="-5" id="Fact-DE72A29D8F0CA2CF160238A29138C6C2" unitRef="usd">2100000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2014Q4YTD" decimals="-5" id="Fact-B6789D8B383D305A75E938A2913B7F78" unitRef="usd">500000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2015Q4YTD" decimals="-5" id="Fact-02CCF5FD3A2D444D392A38A29138A9EA" unitRef="usd">3500000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2014Q4" decimals="-5" id="Fact-B2BEC24D7B52F30BB82138A2912F4CE5" unitRef="usd">1470700000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-A1F716BD08DE79A7177A38A2912F65A9" unitRef="usd">2760400000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:BuildingsAndImprovementsGross contextRef="FI2014Q4" decimals="-5" id="Fact-FFD2D00F91F8960FFBCA38A2913C5D54" unitRef="usd">947700000</us-gaap:BuildingsAndImprovementsGross>
	<us-gaap:BuildingsAndImprovementsGross contextRef="FI2015Q4" decimals="-5" id="Fact-A12F0E28449C2C862B6838A2913D00EB" unitRef="usd">1035600000</us-gaap:BuildingsAndImprovementsGross>
	<us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="I2007Q1SD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecHemophiliaMember" decimals="2" id="Fact-BE2512617E50295C94A738A291336602" unitRef="number">1.00</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
	<us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-BA45B2A20241DD30A8B338A2913CBD2A" unitRef="usd">474600000</us-gaap:BusinessCombinationConsiderationTransferred1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-243CC94B893E2D1A004B38A2912ED50A" unitRef="usd">36000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2013Q2_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-8E78795E21FEA7350B5038A2913293C6" unitRef="usd">15000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2015Q4" decimals="-8" id="Fact-F8275D1D989A05E5CE9F38A291318055" unitRef="usd">1300000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="-5" id="Fact-B7E2881B13E65FA817D338A291201C1D" unitRef="usd">365000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="-5" id="Fact-24293D45762D01C348AD38A29122191E" unitRef="usd">419000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="I2007Q1SD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecHemophiliaMember" decimals="-5" id="Fact-09CDBF69248263C4F75D38A29131E081" unitRef="usd">80000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_NeuropathicpainindicationsMember" decimals="-5" id="Fact-61849DF4A51D576E136438A2912CF690" unitRef="usd">415000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_RaxatrigineMember" decimals="-5" id="Fact-CD41E7CB71B3AE3C670D38A29130675E" unitRef="usd">145000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2013Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1720EC4D6245DAB49E6A38A29126292E" unitRef="usd">280900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2014Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="-5" id="Fact-82ACDE2A59118819409438A2911F528F" unitRef="usd">69500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2014Q4_us-gaap_BusinessAcquisitionAxis_biib_CorporateJointVentureInvestmentsMember" decimals="-5" id="Fact-C78CE1D85BF10CE90A5F38A2911E2419" unitRef="usd">15500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2014Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="-5" id="Fact-1953E217308747FA4AEF38A2913F9566" unitRef="usd">130500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F4BD6425DC7ACBB8598438A2912CA9B3" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F3C00B5D67881785EDCD38A291199832" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C3B460F4B62581AA088238A2911BAA42" unitRef="usd">215500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-28CD32F3B2D388E2CA9538A2913EC901" unitRef="usd">215500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="-5" id="Fact-6A3CF6CC9D48DF90259438A2911F77E9" unitRef="usd">77000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-B68EDC1425FA4A32B46566051CA6C681" unitRef="usd">297500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember" decimals="-5" id="Fact-34C5F340DCB5FCB4B9A938A2911F4856" unitRef="usd">197200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_CorporateJointVentureInvestmentsMember" decimals="-5" id="Fact-A8A4F3E23FA8BED33FA238A2912BE187" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="-5" id="Fact-733773893291E077FDE038A2911EE284" unitRef="usd">131500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4C111010BD54196D3CC238A2913576DA" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F2A2358E1EB17EB4077D38A291358589" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4E06407C07CDB89E8FF838A2913794A8" unitRef="usd">506000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4923FA2060AFD7611D1C38A2913E7BBA" unitRef="usd">506000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-CFB2228D7E2CB265061638A2913AFE13" unitRef="usd">265500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-99A62C86CE4B09579E9238A2913A3DB6" unitRef="usd">504700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2014Q4" decimals="-5" id="Fact-6BA41464FCDBD97F3C8D38A2913F40A6" unitRef="usd">200000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2014Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember" decimals="-5" id="Fact-A5518AFE94A5B8B1230B38A2911FDB0C" unitRef="usd">200000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-8F8A6B2C763A5BC0779C38A2913F2ACF" unitRef="usd">301300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2015Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember" decimals="-5" id="Fact-DFB53C79DB7C5C665DEA38A29126BF8D" unitRef="usd">301300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-352D5495A34ADCB2F93F38A2911E6A5F" unitRef="usd">84900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-617E284BEA550855F5C738A2911BAD7B" unitRef="usd">424600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_NeuropathicpainindicationsMember" decimals="-5" id="Fact-E1195DF3424324C30AA938A2912F2F86" unitRef="usd">220000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_RaxatrigineMember" decimals="-5" id="Fact-5A1018152C6D306A78CF38A2912D20D2" unitRef="usd">200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" decimals="-7" id="Fact-F8349821D1EEA28DDB9338A29131B845" unitRef="usd">3180000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-C27056683079D025266538A291365983" unitRef="usd">7600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-322FFD6C6EF6CEA4672038A2911D1C39" unitRef="usd">474600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-C57C832DA0347B0FE99D38A2911E7D1F" unitRef="usd">1000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets>
	<us-gaap:CapitalLeaseObligations contextRef="FI2015Q3_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember" decimals="-5" id="Fact-B751083588B9778F026E38A2912D567D" unitRef="usd">20300000</us-gaap:CapitalLeaseObligations>
	<us-gaap:CapitalLeaseObligations contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember" decimals="-5" id="Fact-3E6D679B761681EDAEBE38A2912D6E76" unitRef="usd">19800000</us-gaap:CapitalLeaseObligations>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="FI2015Q4" decimals="-5" id="Fact-CBADE583A9FB0A88875238A291343E60" unitRef="usd">20700000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-DFA1F7B11C2C9A486A1C38A2912E53C4" unitRef="usd">2000000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears contextRef="FI2015Q4" decimals="-5" id="Fact-BB18ACE92E53D6303E5538A2913A2C4B" unitRef="usd">0</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2015Q4" decimals="-5" id="Fact-11E3B9C81249042EC9EA38A2913567E8" unitRef="usd">0</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2015Q4" decimals="-5" id="Fact-814AC36D8E0DAF19DC9938A2913E25C0" unitRef="usd">16700000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2015Q4" decimals="-5" id="Fact-2705A7AAE775D1969B4D38A2913D2022" unitRef="usd">2000000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter contextRef="FI2015Q4" decimals="-5" id="Fact-25A41F4D806D5C1B450F38A2913FA4DE" unitRef="usd">0</us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments contextRef="FI2015Q4" decimals="-5" id="Fact-5A26F54C966B1816586738A2912D090D" unitRef="usd">900000</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments contextRef="FI2015Q4" decimals="-5" id="Fact-D02058070B0E49A9924B38A2913FD6BD" unitRef="usd">19800000</us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2012Q4" decimals="-5" id="Fact-4EFF29B3DA3390C1D23738A291417E97" unitRef="usd">570700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2013Q4" decimals="-5" id="Fact-955BC9968E24BCF5101038A291410072" unitRef="usd">602600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-5" id="Fact-4FEDBD29A956EA2E786838A291225CB4" unitRef="usd">1204900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-5" id="Fact-28E7F19E7FAE7C1EC45238A29123A2F4" unitRef="usd">1308000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8950E2F1A23A7C2E36E138A2912C9FB2" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FC40DA151BEEA2D745F938A2912C16D4" unitRef="usd">716300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-CF4DCC3DB8D2D5E3653A38A2912D2D72" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D71CE3072AE537BEA97B38A2912D3DB2" unitRef="usd">716300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D1E393CB119AB4E5B94138A291352460" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-518FE677BD0281A72B1D38A29137D660" unitRef="usd">909500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-92C6A61646C517C7EBE738A29132C6C0" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4A4BA3F1A2D9978EBF4938A29132ADE8" unitRef="usd">909500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2013Q4YTD" decimals="-5" id="Fact-07C1936E9856EA43E26A38A29141991E" unitRef="usd">23900000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2014Q4YTD" decimals="-5" id="Fact-6A6F47C2E31AE04F11CC38A2914272FF" unitRef="usd">643200000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2015Q4YTD" decimals="-5" id="Fact-EB166612D6D21962A22E38A291412D0F" unitRef="usd">148900000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-5" id="Fact-3E2B524B3F42F95F59DE38A2912D363A" unitRef="usd">716300000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2014Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-1F9FB414EF9DAE42A00C38A29121C9B5" unitRef="usd">54200000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2014Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-32B2CC4D3447617BA02238A2911E9DCD" unitRef="usd">35900000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2014Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-DAEAB8BB0B5A47AAFECB38A29120B115" unitRef="usd">321200000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2014Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" decimals="-5" id="Fact-A415D119FA8DB7ED48A738A291218ED4" unitRef="usd">305000000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-5" id="Fact-F42ECCCCB4431CC0969938A2912C6E9B" unitRef="usd">909500000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-A9CB692AFFD471F3740438A2913F1DBF" unitRef="usd">21900000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-C8DB61BDD09BD4DAF18E38A2911FF95B" unitRef="usd">79100000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-73554C3836628F5247E038A2911EDF9B" unitRef="usd">673800000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" decimals="-5" id="Fact-CA69AB404933D11B399F38A29120FFBE" unitRef="usd">134700000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2014Q4" id="Fact-D6C46108C1B81E4F6C0738A2912F113C" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2015Q4" id="Fact-E6D58DD10391A4D4E7FA38A291229455" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2014Q4" decimals="4" id="Fact-4F66B29286ABBB53DF0D38A29140B65E" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2015Q4" decimals="4" id="Fact-FB2FB7BB7A28F61F779238A29139BAAC" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2014Q4" decimals="-5" id="Fact-AB04026D922E985D639438A2912FBD82" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2015Q4" decimals="-5" id="Fact-304A0ECF94BD9095918638A2912F9ADE" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2014Q4" decimals="-5" id="Fact-1859FE7C476476B2336738A2912FDD36" unitRef="shares">257100000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2015Q4" decimals="-5" id="Fact-E723DA5BB1CB3885F12338A2912FF55E" unitRef="shares">241200000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2014Q4" decimals="-5" id="Fact-A3B2545AF348D100385938A2912FA394" unitRef="shares">234600000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4" decimals="-5" id="Fact-FC8760DB763EB658085438A2912F9C81" unitRef="shares">218600000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2014Q4" decimals="-5" id="Fact-7CB4FB6EA209C072DE9F38A291244E75" unitRef="usd">100000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2015Q4" decimals="-5" id="Fact-7E0555B4A0C51665424438A29121C2E2" unitRef="usd">100000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2013Q4YTD" decimals="-5" id="Fact-2E89EF2FEA653D8D93A538A2912EDE11" unitRef="usd">1889900000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-2E0E30B401DB6828A02538A29135D82F" unitRef="usd">2903000000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-B40C374FEC7D2ABB08BC38A2912EBCAD" unitRef="usd">3382500000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2013Q4YTD" decimals="-5" id="Fact-A201461F78FB919E39A438A29123869B" unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2014Q4YTD" decimals="-5" id="Fact-FFA247CE72750679B78038A2913AB1AB" unitRef="usd">-6800000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2015Q4YTD" decimals="-5" id="Fact-1DF3E2043866644782B938A291313C8E" unitRef="usd">-46200000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2013Q4YTD" decimals="-5" id="Fact-AEE32B3ECA1877736BB238A29138A26C" unitRef="usd">1889900000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2014Q4YTD" decimals="-5" id="Fact-CEF77AEB182105D4D6BD38A291203420" unitRef="usd">2909800000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2015Q4YTD" decimals="-5" id="Fact-F26C8D6124C7015D397E38A291421B90" unitRef="usd">3428700000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ConstructionInProgressGross contextRef="FI2014Q4" decimals="-5" id="Fact-F2C37AE8428BBC00C2D338A2913C7F8E" unitRef="usd">168600000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionInProgressGross contextRef="FI2015Q4" decimals="-5" id="Fact-B95C60C313F8E2DB9E4338A2913C4847" unitRef="usd">441200000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionInProgressGross contextRef="FI2015Q4_biib_FacilityLocationAxis_biib_SolothurnMember" decimals="-5" id="Fact-D93F35A207E2FDB172FE9365933AE272" unitRef="usd">99000000</us-gaap:ConstructionInProgressGross>
	<us-gaap:CostOfGoodsSold contextRef="FD2013Q4YTD" decimals="-5" id="Fact-04AC16DA6CD6E0376A4538A29131E35B" unitRef="usd">857700000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2014Q4YTD" decimals="-5" id="Fact-245D14782584A05742CD38A29142E049" unitRef="usd">1171000000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2015Q4YTD" decimals="-5" id="Fact-A02EF892DA66E0D3BB7338A29141DE0C" unitRef="usd">1240400000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostsAndExpenses contextRef="FD2013Q4YTD" decimals="-5" id="Fact-EDFCD9CE27437EA071E238A2912CEFE8" unitRef="usd">4441600000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2014Q4YTD" decimals="-5" id="Fact-F621BCDD6E0A78D7090738A2913427B2" unitRef="usd">5747700000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2015Q4YTD" decimals="-5" id="Fact-9118EF9359795D0B048238A29131626B" unitRef="usd">5872800000</us-gaap:CostsAndExpenses>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2013Q4YTD" decimals="-5" id="Fact-AF8BBA3F1561A359B57338A2913EEA11" unitRef="usd">700900000</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-5" id="Fact-8C917F388C578DF79B5338A2913D5728" unitRef="usd">1159500000</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-377F373C9565BFB5CD3B38A2913F47D6" unitRef="usd">1214100000</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2013Q4YTD" decimals="-5" id="Fact-FD8DB986FAB83FC8154438A2913E32DD" unitRef="usd">46800000</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-5" id="Fact-F7AE830EC53B5A7AB3C838A2913D4C03" unitRef="usd">73400000</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-C7600068D37049814F3638A29132678C" unitRef="usd">54500000</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2013Q4YTD" decimals="-5" id="Fact-3E0DE5E824620BFE4EF238A29132437C" unitRef="usd">846100000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-5" id="Fact-A8449838ADE646227A0238A2913EDC4C" unitRef="usd">1298100000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-8FD2B13B2A5933663A2238A2913D3AF6" unitRef="usd">1307200000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2013Q4YTD" decimals="-5" id="Fact-48DF06EB96730D9E67DD38A2912ECBA0" unitRef="usd">98400000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-5" id="Fact-7235BE699C8DBF5DA40238A291319817" unitRef="usd">65200000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-3A52C2945B8CBF613A5938A2913371CB" unitRef="usd">38600000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:DebtCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-A6A79E3C26920EB0C43938A291301988" unitRef="usd">3100000</us-gaap:DebtCurrent>
	<us-gaap:DebtCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-8A2897A4A899BEEE20F638A29130F30C" unitRef="usd">4800000</us-gaap:DebtCurrent>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q4" decimals="-8" id="Fact-787CC4496E5563FB98FE38A29120C9B2" unitRef="usd">6000000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-7" id="Fact-9541162B23B53130CAEB38A291273950" unitRef="usd">1750000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-7" id="Fact-EFEFF9970B0B15A60F8138A2912030F7" unitRef="usd">1750000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-8" id="Fact-0461FE150D80C36FEF8338A2911E862A" unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-8" id="Fact-19A97C3E64281A2C5E1638A2911E97F9" unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2008Q1SD_us-gaap_LongtermDebtTypeAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-0D0CC71648B0AABB0A4238A29120422E" unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2014Q4" decimals="-5" id="Fact-48F5F8BF820679AA47C338A29137C0C9" unitRef="usd">647200000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2015Q4" decimals="-5" id="Fact-89239C07ECE093763D0238A291378451" unitRef="usd">6645900000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="INF" id="Fact-77745AE73C0E261B628638A29136D0D7" unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="4" id="Fact-686A9EE9B840CADA194438A291278F08" unitRef="number">0.0520</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="4" id="Fact-37F19A6BB01DD4335AE238A2913C6A09" unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="INF" id="Fact-E2663EB9BDB5947E96D938A29136D07B" unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="5" id="Fact-E2652190A0B491E34A1A38A2912572EC" unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="INF" id="Fact-A7B08355BDD6A7AD97D738A291364EB4" unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="INF" id="Fact-6BB75B1F41BD0510D1E538A2913601D8" unitRef="number">0.029</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="4" id="Fact-20C3EDB242205AD8854F38A291289288" unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2008Q1SD_us-gaap_LongtermDebtTypeAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="INF" id="Fact-2292B07A2A0E8082246B38A29120B4D1" unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentMaturityDateDescription contextRef="FD2015Q4YTD" id="Fact-149EF42309813B20E2A938A29135C4DA">less than 90&#160;days</us-gaap:DebtInstrumentMaturityDateDescription>
	<us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="FD2015Q4YTD" decimals="INF" id="Fact-FD9202904E291B26E3DA38A29120DAD9" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
	<us-gaap:DebtIssuanceCosts contextRef="FD2015Q4YTD" decimals="-5" id="Fact-A2DFA4944AB0854C464538A291204C40" unitRef="usd">47500000</us-gaap:DebtIssuanceCosts>
	<us-gaap:DebtIssuanceCosts contextRef="FD2015Q4YTD_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-0849A49FC1FC154F042A38A2913F86E2" unitRef="usd">1800000</us-gaap:DebtIssuanceCosts>
	<us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="FI2014Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_DeferredCompensationPlanMember" decimals="-5" id="Fact-D5BAA4FF32DB5CC7A13F38A29134D570" unitRef="usd">105200000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
	<us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="FI2015Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_DeferredCompensationPlanMember" decimals="-5" id="Fact-4C51A4F40EA029E89EFD38A29133F9CA" unitRef="usd">126900000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2013Q4YTD" decimals="-5" id="Fact-82945D699C6A6A731ABE38A2913C7052" unitRef="usd">-200600000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-5" id="Fact-A9E3A734EA434C71ED7138A2913DECE4" unitRef="usd">-280900000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E4FED5840743665029F038A2912E5025" unitRef="usd">-129600000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2013Q4YTD" decimals="-5" id="Fact-39E767D783B4383FB90438A2913DDA65" unitRef="usd">-8600000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-5" id="Fact-19C735DE33C927EDB41738A291341A4B" unitRef="usd">-6300000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E879BFE83434AFA0C23538A29130DA07" unitRef="usd">-14100000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2013Q4YTD" decimals="-5" id="Fact-6057B8ED848C379C2C4A38A291406B38" unitRef="usd">-245100000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-5" id="Fact-B20E7AFE9671ADE507AE38A29140CD05" unitRef="usd">-308200000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D2C372C5ED7CFECA95C738A29142A40F" unitRef="usd">-145600000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-269956115D80C5A5D22138A2913A27DC" unitRef="usd">120900000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-E786F2828DF35D213D2738A2913AE7CF" unitRef="usd">55700000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" decimals="-5" id="Fact-38996910884021A17D7538A2912FC041" unitRef="usd">84400000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2013Q4YTD" decimals="-5" id="Fact-175321F41A654496A5E638A2913F68B4" unitRef="usd">-35900000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-5" id="Fact-59AB933CD520291C6F9B38A2913318AE" unitRef="usd">-21000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-7D057A7A873202F5050738A2913E2712" unitRef="usd">-1900000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="FI2014Q4" decimals="-5" id="Fact-23C20A0A1195F57363E938A2912EEC21" unitRef="usd">251700000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
	<us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="FI2015Q4" decimals="-5" id="Fact-6E8994A79CD393E0CF8438A2912E4929" unitRef="usd">328300000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
	<us-gaap:DeferredTaxAssetsInventory contextRef="FI2014Q4" decimals="-5" id="Fact-AF96140732C98D53E5FA38A2912DEF80" unitRef="usd">217300000</us-gaap:DeferredTaxAssetsInventory>
	<us-gaap:DeferredTaxAssetsInventory contextRef="FI2015Q4" decimals="-5" id="Fact-89C040CEAE4B44FF7A1138A2912D2F59" unitRef="usd">243900000</us-gaap:DeferredTaxAssetsInventory>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2014Q4" decimals="-5" id="Fact-F2D124FC1A9035C088FB38A2912E23C8" unitRef="usd">693100000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2015Q4" decimals="-5" id="Fact-3291D6C108C31C5ED42738A2912F1ECC" unitRef="usd">871700000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2014Q4" decimals="-5" id="Fact-19C4608324059128201E38A2912EEF84" unitRef="usd">20600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2015Q4" decimals="-5" id="Fact-BDBF4D4EE22D8A06AF5838A29128F375" unitRef="usd">24700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" decimals="-5" id="Fact-5488E2B584588839001738A291317510" unitRef="usd">91700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2014Q4" decimals="-5" id="Fact-255E67C7402749D2A3D038A291258971" unitRef="usd">60000000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2015Q4" decimals="-5" id="Fact-1C97171D42BB8F4C888838A29125B06E" unitRef="usd">35800000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="FI2014Q4" decimals="-5" id="Fact-03D06EDCFE373D79A76F38A2912EA221" unitRef="usd">69000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="FI2015Q4" decimals="-5" id="Fact-C7DF41933D474DBC0DB138A2912EF586" unitRef="usd">189300000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2014Q4" decimals="-5" id="Fact-E28CBE7DCC8EC2CFB55238A29125C43B" unitRef="usd">86000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2015Q4" decimals="-5" id="Fact-0988C40D796717A3625838A29125FACA" unitRef="usd">63800000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2014Q4" decimals="-5" id="Fact-12ABD15193E6ECACA48938A29123ACA9" unitRef="usd">11500000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2015Q4" decimals="-5" id="Fact-D169D437DC695024A91738A2912E98DA" unitRef="usd">14100000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2014Q4" decimals="-5" id="Fact-B297F678D4E1381ABCE538A2912D9533" unitRef="usd">539800000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2014Q4_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-5EB6D075260D57518CE238A29134AFAA" unitRef="usd">179900000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2015Q4" decimals="-5" id="Fact-2877406B686CAECA117738A2912E825A" unitRef="usd">542800000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-FC2EB7D98EC8EEFBF0F138A2913330AD" unitRef="usd">166300000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="FI2014Q4" decimals="-5" id="Fact-CB1D661292C7704F0B3D38A2912EA625" unitRef="usd">432800000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
	<us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="FI2015Q4" decimals="-5" id="Fact-DE684D8E55661161601038A2912D6B01" unitRef="usd">440100000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2014Q4" decimals="-5" id="Fact-495357A365A8A90EE65C38A29131F67E" unitRef="usd">52200000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-96D4B937C3F919DA189538A291313563" unitRef="usd">124900000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DefinedBenefitPlanBenefitObligation contextRef="FI2014Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_GermanPlanMember" decimals="-5" id="Fact-4849A0ACC8331773C81E38A291340CF2" unitRef="usd">24800000</us-gaap:DefinedBenefitPlanBenefitObligation>
	<us-gaap:DefinedBenefitPlanBenefitObligation contextRef="FI2014Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SwissplanMember" decimals="-5" id="Fact-A5886BC8C3FA125E52F238A2913427A3" unitRef="usd">43900000</us-gaap:DefinedBenefitPlanBenefitObligation>
	<us-gaap:DefinedBenefitPlanBenefitObligation contextRef="FI2015Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_GermanPlanMember" decimals="-5" id="Fact-2DFC9CDFD8AEB38F5FEB38A2913466E1" unitRef="usd">27600000</us-gaap:DefinedBenefitPlanBenefitObligation>
	<us-gaap:DefinedBenefitPlanBenefitObligation contextRef="FI2015Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SwissplanMember" decimals="-5" id="Fact-72D85F358578749FA26F38A2913489C0" unitRef="usd">63900000</us-gaap:DefinedBenefitPlanBenefitObligation>
	<us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="FI2014Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SwissplanMember" decimals="-5" id="Fact-E0F7CACF8EE1C5C0D48938A29134649B" unitRef="usd">31900000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
	<us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="FI2015Q4_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SwissplanMember" decimals="-5" id="Fact-28A06D7D4D328D451BE938A291348481" unitRef="usd">42400000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
	<us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="FD2013Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_GermanPlanMember" decimals="-5" id="Fact-9AC5FA9117980D4B0C1A38A29134D283" unitRef="usd">3300000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
	<us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="FD2014Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_GermanPlanMember" decimals="-5" id="Fact-6C5472FF071A7A75D62738A29134A638" unitRef="usd">3500000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
	<us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="FD2015Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_GermanPlanMember" decimals="-5" id="Fact-6605BCE7C86F90F045EE38A291342FC6" unitRef="usd">4000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2013Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SavingsPlanMember" decimals="-5" id="Fact-EBE80592BB478C1BAC6238A291343961" unitRef="usd">39300000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2014Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SavingsPlanMember" decimals="-5" id="Fact-C9E84AC04B6D1AF7376D38A29135104D" unitRef="usd">49300000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2015Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SavingsPlanMember" decimals="-5" id="Fact-D29E2E7333C111081D7738A29134FAAD" unitRef="usd">51800000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:Depreciation contextRef="FD2013Q4YTD" decimals="-5" id="Fact-AAD0567D347F86F142F938A29129BD67" unitRef="usd">187800000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2014Q4YTD" decimals="-5" id="Fact-59DAB710BC9744C42F2338A291295DAD" unitRef="usd">198400000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2015Q4YTD" decimals="-5" id="Fact-96081A0BC6FB689A263C38A291294FC2" unitRef="usd">217900000</us-gaap:Depreciation>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2013Q4YTD" decimals="-5" id="Fact-4CB63F8A7F241FA55B1838A291425026" unitRef="usd">531700000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2014Q4YTD" decimals="-5" id="Fact-0CAF7CC7E0A783A9C00138A291387CA9" unitRef="usd">688100000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2015Q4YTD" decimals="-5" id="Fact-7564957A24905609561D38A291388E56" unitRef="usd">600400000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-201D6BFDF40C08A1A76938A29125A3AF" unitRef="usd">69500000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-15BE6E06A88771E1F09938A29139E19C" unitRef="usd">1300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-BE97ECD295AD2C886E3338A2913BAEE7" unitRef="usd">1900000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-9AED901054AE4E6174AD38A2913FAD64" unitRef="usd">16600000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-5A24C3456909941BF8AB38A29123485F" unitRef="usd">10300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-38B42B52FA731C2B9F9038A2913F8FBD" unitRef="usd">300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" decimals="-5" id="Fact-28A6E914F0BF9DD2C70A38A2912071B5" unitRef="usd">1800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-9556187E7F9F34E03EF138A29129C27B" unitRef="usd">5400000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-F231E06C56C3549302D538A2913F19FA" unitRef="usd">10200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-786A19D1A84798E7016F38A2913FF556" unitRef="usd">2000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-E9D1DC54BCB0A360F1B638A2913F4A6B" unitRef="usd">2500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeHigherRemainingMaturityRange1 contextRef="FD2014Q4YTD" id="Fact-832ECCCD098BA16AE6B838A291275D36">P15M</us-gaap:DerivativeHigherRemainingMaturityRange1>
	<us-gaap:DerivativeHigherRemainingMaturityRange1 contextRef="FD2015Q4YTD" id="Fact-32D7AF2339DD04FEE77838A2912D8A81">P18M</us-gaap:DerivativeHigherRemainingMaturityRange1>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2013Q4YTD_us-gaap_DerivativeByNatureAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-2C951208F2251024F90738A2913DACF2" unitRef="usd">-13200000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2014Q4YTD_us-gaap_DerivativeByNatureAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-B24C631F0164F361BE7638A2913D86CD" unitRef="usd">6800000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2015Q4YTD_us-gaap_DerivativeByNatureAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-27971C2568D34B0F19D638A2913DD179" unitRef="usd">173200000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2013Q4YTD_us-gaap_DerivativeByNatureAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-EBA741C1CF80DB970A8A38A2913DE283" unitRef="usd">-200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2014Q4YTD_us-gaap_DerivativeByNatureAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-6FE9DD336A17B2F4592438A2913DB7E9" unitRef="usd">-1500000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2015Q4YTD_us-gaap_DerivativeByNatureAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-85C31221342E663D4B8238A2913D2347" unitRef="usd">4900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeLowerRemainingMaturityRange1 contextRef="FD2014Q4YTD" id="Fact-42A6C935462E1814A94938A2912953EC">P1M</us-gaap:DerivativeLowerRemainingMaturityRange1>
	<us-gaap:DerivativeLowerRemainingMaturityRange1 contextRef="FD2015Q4YTD" id="Fact-23004A259BDFD24275CA38A2912C1062">P1M</us-gaap:DerivativeLowerRemainingMaturityRange1>
	<us-gaap:EarningsPerShareBasic contextRef="FD2013Q4YTD" decimals="2" id="Fact-6DB8B6FBF11F39D62F6A38A29141DAFC" unitRef="usdPerShare">7.86</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2014Q1QTD" decimals="2" id="Fact-1096AC4CC73D0CA707AE38A2913ABC92" unitRef="usdPerShare">2.03</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2014Q2QTD" decimals="2" id="Fact-E5EF4A6B0FB341FF8D8938A291412A5B" unitRef="usdPerShare">3.02</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2014Q3QTD" decimals="2" id="Fact-77816F6183FB01ACEED138A29139ABB8" unitRef="usdPerShare">3.63</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2014Q4QTD" decimals="2" id="Fact-9619E4B9C32E5590994938A2914108CB" unitRef="usdPerShare">3.75</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2014Q4YTD" decimals="2" id="Fact-249EA9E05376FDFC881038A2912FFB25" unitRef="usdPerShare">12.42</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q1QTD" decimals="2" id="Fact-18FF750545802E85DEBA38A2912F8C95" unitRef="usdPerShare">3.50</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q2QTD" decimals="2" id="Fact-1AD0A34650D13FF96ECD38A2913F2896" unitRef="usdPerShare">3.94</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q3QTD" decimals="2" id="Fact-43711D69C861BCC9334738A2912D5D8E" unitRef="usdPerShare">4.16</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q4QTD" decimals="2" id="Fact-1FA811715E7585BACE9538A291320F1A" unitRef="usdPerShare">3.77</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q4YTD" decimals="2" id="Fact-1871C77DBAE52E814BB738A2912C82AF" unitRef="usdPerShare">15.38</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2013Q4YTD" decimals="2" id="Fact-CC479E4BC6E781237D2A38A2913F3E25" unitRef="usdPerShare">7.81</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2014Q1QTD" decimals="2" id="Fact-9C171A3076F03A0A5BCF38A29131F5B9" unitRef="usdPerShare">2.02</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2014Q2QTD" decimals="2" id="Fact-E0D884A6BDA1D171601338A29130E5C7" unitRef="usdPerShare">3.01</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2014Q3QTD" decimals="2" id="Fact-8F9E156AEBC748B32F5138A2912FF54B" unitRef="usdPerShare">3.62</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2014Q4QTD" decimals="2" id="Fact-82EDAFA5D7D95594421A38A2913A657C" unitRef="usdPerShare">3.74</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2014Q4YTD" decimals="2" id="Fact-74AD4C59A2A1CEEEB65C38A2912F997A" unitRef="usdPerShare">12.37</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q1QTD" decimals="2" id="Fact-58FCB973C9EB58E3859138A291359673" unitRef="usdPerShare">3.49</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q2QTD" decimals="2" id="Fact-A135522C57D9154A0C7238A291350C47" unitRef="usdPerShare">3.93</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q3QTD" decimals="2" id="Fact-E28B566808CC66429C6838A291409E86" unitRef="usdPerShare">4.15</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q4QTD" decimals="2" id="Fact-73F0484FE156284B949638A291397CBC" unitRef="usdPerShare">3.77</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q4YTD" decimals="2" id="Fact-DAEBDA2614B862EF72D138A2913F2DB3" unitRef="usdPerShare">15.34</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2013Q4YTD" decimals="-5" id="Fact-1388557743B4891CB4FE38A2914293BB" unitRef="usd">8000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2014Q4YTD" decimals="-5" id="Fact-49804CC1E0A1B082BA8138A291428A3E" unitRef="usd">-40900000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2015Q4YTD" decimals="-5" id="Fact-F32E395E34928ABB431E38A291393FCD" unitRef="usd">-45800000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2013Q4YTD" decimals="3" id="Fact-6C19E1F4BED587A0699238A2912D888F" unitRef="number">0.242</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2014Q4YTD" decimals="3" id="Fact-03BC4CF1D57C953F479838A29139CEDE" unitRef="number">0.251</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2015Q4YTD" decimals="3" id="Fact-5B884D90016CBD70317638A29138E19A" unitRef="number">0.244</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2013Q4YTD" decimals="3" id="Fact-9A025CF4C14908C1CE8238A2912DDE39" unitRef="number">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2014Q4YTD" decimals="3" id="Fact-7E593C8005260AD2E64838A291386744" unitRef="number">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2015Q4YTD" decimals="3" id="Fact-062C2A82C529388070DB38A29139660E" unitRef="number">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2013Q4YTD" decimals="3" id="Fact-D127E52988C27BD8AE0238A29139272B" unitRef="number">-0.067</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2014Q4YTD" decimals="3" id="Fact-E11E3BF70B803560B69338A2912D0AC0" unitRef="number">-0.095</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2015Q4YTD" decimals="3" id="Fact-99E2A46D45D3EC85A36B38A2913AC8EB" unitRef="number">-0.100</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2013Q4YTD" decimals="3" id="Fact-9596A28193A01939625338A291381EC6" unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2014Q4YTD" decimals="3" id="Fact-12CAAC0420811FE1ADAC38A2912E304F" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2015Q4YTD" decimals="3" id="Fact-0CB534B5C61DB8CA5FAA38A2913AC1A0" unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2013Q4YTD" decimals="3" id="Fact-3B710775C69BFD9B6B9338A29138E1DD" unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2014Q4YTD" decimals="3" id="Fact-D233F739572B564C2C8138A2913899F4" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2015Q4YTD" decimals="3" id="Fact-8D9F7BC8B851B5FE7EE838A291399CB7" unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2013Q4YTD" decimals="3" id="Fact-B4CAEA80513C4EAFC07938A2912E3B26" unitRef="number">0.031</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2014Q4YTD" decimals="3" id="Fact-814F960A6E4CBB563F2738A29139B16F" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2015Q4YTD" decimals="3" id="Fact-B1CF1710775B5A894AF238A2912EF43D" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2013Q4YTD" decimals="3" id="Fact-FB822A3A2AD6EFDB5D9F38A2912E63F1" unitRef="number">-0.026</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2014Q4YTD" decimals="3" id="Fact-8E2BE9F3BB4E4250363638A2912E4725" unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2015Q4YTD" decimals="3" id="Fact-2CAB8C13CCFB7AB0879D38A2913953BE" unitRef="number">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-209E5D97BFE151291D2438A2913AE98C" unitRef="usd">393800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-85CAA1FF58F63E9D75ED38A29139D218" unitRef="usd">270800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2013Q4YTD" decimals="-5" id="Fact-FFB76C04E82CEC45220A38A2913D7C8F" unitRef="usd">-9800000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2014Q4YTD" decimals="-5" id="Fact-4A4680B733110FC92BE638A29141E246" unitRef="usd">-10000000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2015Q4YTD" decimals="-5" id="Fact-236A03385460906942A638A291411336" unitRef="usd">-11000000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-B172E429F15C7B64709B38A2913F4FFF" unitRef="usd">48300000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-8A1FF67B488FD49B246B38A29139BC01" unitRef="usd">92800000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-F654F7979781E9D1456038A2913FC8FF" unitRef="usd">79800000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-83C46B1C11E11BBD2A1993912B4C2229" unitRef="usd">12400000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions contextRef="FD2013Q4YTD" decimals="-5" id="Fact-49411DFD2CD6FB250E7438A2913A62AB" unitRef="usd">28100000</us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions>
	<us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions contextRef="FD2014Q4YTD" decimals="-5" id="Fact-16C6BA5D0051FBDF031138A2913AC68E" unitRef="usd">8500000</us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions>
	<us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D889BD3B631231A8F20238A2913AEBB6" unitRef="usd">6300000</us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2015Q4" decimals="-5" id="Fact-D10F27839E131A637F5538A291341E07" unitRef="usd">184300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2013Q4YTD" decimals="-5" id="Fact-227B422C623FC25ACAF738A2914281C3" unitRef="usd">73300000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-A7773DEDCAC8DA9DAAF638A291425308" unitRef="usd">72200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-7644BB06A21E4869FFB238A29141BC70" unitRef="usd">55800000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions contextRef="FD2013Q4YTD" decimals="-5" id="Fact-B0EC8796C14EC9B86DC738A2913A89B7" unitRef="usd">29400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions contextRef="FD2014Q4YTD" decimals="-5" id="Fact-9459DAC5EFA59B8B709D38A2913ABA78" unitRef="usd">13000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions contextRef="FD2015Q4YTD" decimals="-5" id="Fact-9C9ECEBB61D75F542A1438A2913A6B83" unitRef="usd">11900000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="FI2015Q4_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="2" id="Fact-A523A499D5D13B8F2A6E38A2911C8169" unitRef="number">0.09</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="2" id="Fact-975BF279DB16ECE6DAE938A2911FB455" unitRef="number">0.15</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquityMethodInvestments contextRef="FI2014Q4_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-BDC1C01AE8572657610F38A2911BF014" unitRef="usd">8600000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="FI2014Q4_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-E5D7BA933222CA417E3838A2911F44B1" unitRef="KRW">9100000000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="FI2015Q4_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-A0E69D5E4F7F5EFDBB7038A291346555" unitRef="KRW">6300000000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="FI2015Q4_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-E73C78BD0233CCFB106A38A2911CA934" unitRef="usd">5700000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-C73FE4623DBEA1AD995F38A2911DAFC6" unitRef="KRW">49500000000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-730D068A4C8FE1D1C0D238A2911E0214" unitRef="usd">45000000</us-gaap:EquityMethodInvestments>
	<us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="FD2013Q4YTD" decimals="-5" id="Fact-DD757C8643FE878709F038A29119538C" unitRef="usd">73500000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
	<us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-28FC2A0A4D1E019FE0E638A291388A16" unitRef="usd">96400000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
	<us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-92E2598ECCC6860C51CA38A291411772" unitRef="usd">78200000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
	<us-gaap:FairValueInputsDiscountRate contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="INF" id="Fact-1486D2CA70AB97772D7838A2913EA60D" unitRef="number">0.02</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueInputsDiscountRate contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ProductOrServiceAxis_biib_RaxatrigineMember" decimals="INF" id="Fact-943108A9FEA8D8194C8B38A2912EF29A" unitRef="number">0.11</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueInputsDiscountRate contextRef="FD2015Q4QTD_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="INF" id="Fact-612CA9C69CF1A136BBD7660724A43C7D" unitRef="number">0.03</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueInputsDiscountRate contextRef="FD2015Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="2" id="Fact-F3E7CDEE8C008348242338A2912DBE77" unitRef="number">0.03</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueInputsDiscountRate contextRef="FD2015Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="INF" id="Fact-6BE04B4B664246CE9B1538A2913FD246" unitRef="number">0.02</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2013Q4YTD" decimals="-5" id="Fact-9F91DF03F59277483B4E38A291409C8D" unitRef="usd">500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2014Q3QTD" decimals="-5" id="Fact-0CD939B347AB1B4CA6D16602E0223EB8" unitRef="usd">49400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2014Q4YTD" decimals="-5" id="Fact-1635F9ED2C31986CB0FF38A29135D217" unitRef="usd">38900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2015Q4YTD" decimals="-5" id="Fact-587E969FB8C3CD1C78AE38A2913957B7" unitRef="usd">-30500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-F5C49580BDD80B683BA438A2913B9F03" unitRef="usd">274500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2010Q4QTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="-5" id="Fact-8019E5C9D5A4E5CC5E9D38A2913FD48E" unitRef="usd">81200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2011Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_CorporateJointVentureInvestmentsMember" decimals="-5" id="Fact-7F00DA0380269257928338A2911EA864" unitRef="usd">38800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2012Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="-5" id="Fact-B8C1A423D818D9A6F8B638A2913F7482" unitRef="usd">122200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2014Q4YTD" decimals="-5" id="Fact-F4691E9D42B415E8FAA038A2913D88FA" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2015Q4YTD" decimals="-5" id="Fact-6A25C9BC16F2AADAC00D38A2913E3A3E" unitRef="usd">274500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2014Q4YTD" decimals="-5" id="Fact-5589B8EF31AA8E8F2A8738A291294788" unitRef="usd">26500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2015Q4YTD" decimals="-5" id="Fact-A68CB1091E081BA1F3CD38A2913EFA22" unitRef="usd">14500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementsChangesInValuationTechniques contextRef="FD2014Q4YTD" id="Fact-AD1131F3AD30EF8C8F0438A291331AEE">0</us-gaap:FairValueMeasurementsChangesInValuationTechniques>
	<us-gaap:FairValueMeasurementsChangesInValuationTechniques contextRef="FD2015Q4YTD" id="Fact-BE3DA22A79CE71C62A8638A2913F2A34">0</us-gaap:FairValueMeasurementsChangesInValuationTechniques>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2015Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-1BF9F0644A2E95B36C7238A291422C3E">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2015Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-19EB969D2754646EA08838A29142B0B0">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2015Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-5320998B8E80AFA9E7DC38A2913EA040">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2015Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-D9FA2D51D35985921DB138A2913E1B65">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2015Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-3B23F977B9982213AF8138A29142FECD">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2015Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-F3D0783587008DCB56FD38A2913E5589">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2014Q4" decimals="-5" id="Fact-C3A7C2DA4BC70725F62C38A2912ABB8E" unitRef="usd">3178600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-7F06E35512914462BA6738A2912B8E26" unitRef="usd">300100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-3AFD287FE3A3C037A77738A2912C2C49" unitRef="usd">481700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-AABAA30819FC375C5CBE38A2912C4E4A" unitRef="usd">2396800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2014Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-D7C275319A4107A9ACBB38A2912B0209" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2014Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-15DA79DDB717922150AD38A2912BFCBD" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q4" decimals="-5" id="Fact-C1258F90979A710B0F6B38A2912B7A58" unitRef="usd">3561200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-077FFDA120E9A20EC3CB38A2912BCC7B" unitRef="usd">502300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-F06DBA39E855F28A711138A2912BFEA6" unitRef="usd">506000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-E7395425DF9316BD452438A2912CD6D2" unitRef="usd">2552900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-10975058E6B564DBA51838A2912B3E81" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-7BCA07E355DC0AFFFC0438A2912C861C" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="FI2015Q4" decimals="-5" id="Fact-5F784EB10EBE25F6381138A29124CBC6" unitRef="usd">346400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="FI2015Q4" decimals="-5" id="Fact-059E712031AC8885DC1F38A29123B364" unitRef="usd">269100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="FI2015Q4" decimals="-5" id="Fact-C2B13F155E6B8D6F81E938A29124625A" unitRef="usd">275100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="FI2015Q4" decimals="-5" id="Fact-50CF5D55EB6FC6384E4038A291230D20" unitRef="usd">291000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="FI2015Q4" decimals="-5" id="Fact-4D463482EE7CCA6F484D38A2912435B5" unitRef="usd">318600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-81BCF698D9118F29D90938A2912C4C0F" unitRef="usd">3280400000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-ED0BD37915CD7E98A34338A2912B5963" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-FCFB99F582EFF7A7219F38A2912C7376" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-93791DA306FB7FC5267638A2912C0807" unitRef="usd">3303200000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-38B6B8FBD643E2169DC838A29129E93C" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-D375DFB2BF005ED12BB338A2912AC085" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-C25A996C4649B24D3E9738A2912C0D92" unitRef="usd">2980300000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-C0F30A80722F4F3000B238A2912C3831" unitRef="usd">61600000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2014Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-9FD97208AF6C3477D57538A2912A8787" unitRef="usd">608500000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-7F047A6D8BF04D2DA82C38A2912BBEAC" unitRef="usd">2800900000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_TysabriProductMember" decimals="-5" id="Fact-B41F86746CA7AED47B8338A2912DA02A" unitRef="usd">2742900000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-D74FEAB43D319A6E4B9A38A2912B88C7" unitRef="usd">37300000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-60C362B9619C0C04C72D38A2912B0393" unitRef="usd">452400000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_biib_AVONEXMember" decimals="-5" id="Fact-FDC3B0C2542225B5C4BE38A29128AA3F" unitRef="usd">443900000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2AF11F426DCD2F00693938A29119C753" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A1A9D332832712D6F43738A2912C1665" unitRef="usd">72700000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-87BCD0900B345094F54338A2912D282A" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-CCB3E57043688618733638A2911BBCD4" unitRef="usd">72700000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5555FB81944B1B709CA738A29137B8F0" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-54497A67DD856392597338A291326414" unitRef="usd">27200000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4099B3207A3912450D0638A29132846A" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4F85BDD2290B86862B1C38A291369F2F" unitRef="usd">27200000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C546BE557240B8978B8C38A2911AA058" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2255400CE6A7D7F866D638A2912C953D" unitRef="usd">5400000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2DBEBF0C63D71D32D73838A2912CBFDB" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5A86EDFDF410308A3D8638A291199E89" unitRef="usd">5400000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C4159EA5CEB6DFFF955A38A29132D65E" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A1E210802B4598E15A2738A29138DDC7" unitRef="usd">14700000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B6C01431C7136993589D38A291372997" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-98954BF9B5AE5EF6768138A29138EB31" unitRef="usd">14700000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2013Q4YTD" decimals="-5" id="Fact-357048B8FC3D2E754D3338A291340ADB" unitRef="usd">-15200000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-7F6F01B5933CE114DF0538A2913D2EB8" unitRef="usd">-11600000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-C3CA173282D1AA44615D38A2913C9601" unitRef="usd">-32700000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:FurnitureAndFixturesGross contextRef="FI2014Q4" decimals="-5" id="Fact-C7648769D9313F11FED438A2913C4559" unitRef="usd">64300000</us-gaap:FurnitureAndFixturesGross>
	<us-gaap:FurnitureAndFixturesGross contextRef="FI2015Q4" decimals="-5" id="Fact-7D768EF49F2DE7E3F99938A2913E7BD8" unitRef="usd">72900000</us-gaap:FurnitureAndFixturesGross>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions contextRef="FI2015Q4" decimals="-5" id="Fact-F2D877B0A187A750E54238A2913C88DF" unitRef="usd">59800000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter contextRef="FI2015Q4" decimals="-5" id="Fact-D08AAF8336E4603AA2AE38A2913C4105" unitRef="usd">28900000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears contextRef="FI2015Q4" decimals="-5" id="Fact-00C6DBEE7A81DA14D43338A29134ED20" unitRef="usd">6300000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears contextRef="FI2015Q4" decimals="-5" id="Fact-E5C3C3E7803C2991465838A2913E3CCC" unitRef="usd">6300000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear contextRef="FI2015Q4" decimals="-5" id="Fact-841405BC154464FE3A4838A29138F8DA" unitRef="usd">6000000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears contextRef="FI2015Q4" decimals="-5" id="Fact-E5C492A71B96CA7EBA3138A291381988" unitRef="usd">6300000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears contextRef="FI2015Q4" decimals="-5" id="Fact-3B5562465D2DD50B5D4438A29134DFC9" unitRef="usd">6000000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2013Q4YTD" decimals="-5" id="Fact-7896CFF3EBC60A6AB1CB38A2912CA72B" unitRef="usd">5200000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2014Q4YTD" decimals="-5" id="Fact-CDABE9691B05657F072938A2912D463A" unitRef="usd">15500000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2015Q4YTD" decimals="-5" id="Fact-1EFD81D445C616D21ADE38A2913E1DAD" unitRef="usd">23800000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2013Q4YTD" decimals="-5" id="Fact-18C48402A3B4B6E9A00338A291342F77" unitRef="usd">21700000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2014Q4YTD" decimals="-5" id="Fact-8B725640A36935D70DD038A29134E70E" unitRef="usd">11800000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2015Q4YTD" decimals="-5" id="Fact-BDFB6418BB482035473C38A291320F90" unitRef="usd">-3800000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:Goodwill contextRef="FI2013Q4" decimals="-5" id="Fact-2C9C57C80E8DC0F8A14A38A291283D9E" unitRef="usd">1232900000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2014Q4" decimals="-5" id="Fact-D2EF40D4FD8F113BE92D38A29130B401" unitRef="usd">1760200000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2015Q4" decimals="-5" id="Fact-5BFFCDBE7FEE3573304F38A29130C92D" unitRef="usd">2663800000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-CED280A288F9B8ED5B9538A2911BE148" unitRef="usd">128300000</us-gaap:Goodwill>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2014Q4YTD" decimals="-5" id="Fact-5E7FB7B48803F4A2138438A2912985C7" unitRef="usd">527300000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2014Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-564153921FE62A0C39DA934E0F890C0D" unitRef="usd">600000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2015Q4QTD_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-690954A95A2644D190A038A29132F608" unitRef="usd">300000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2015Q4QTD_biib_CumulativeSalesLevelAxis_biib_SevenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-D8FD9D8F44DC3EB15E5A38A29130293F" unitRef="usd">300000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2015Q4YTD" decimals="-5" id="Fact-83D4DA44CD572BC0F32E38A2912AA476" unitRef="usd">908100000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2015Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-6885F82AA166F210D18438A2912A298F" unitRef="usd">900000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="FI2015Q4" decimals="-6" id="Fact-0B82808FDD8C90E0AACC38A291284D4A" unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
	<us-gaap:GoodwillOtherChanges contextRef="FD2014Q4YTD" decimals="-5" id="Fact-13D8F45BCBABC2223DCC38A291291804" unitRef="usd">0</us-gaap:GoodwillOtherChanges>
	<us-gaap:GoodwillOtherChanges contextRef="FD2015Q4YTD" decimals="-5" id="Fact-DA370A1D6CF3FC39E0EB38A2912A85BD" unitRef="usd">-4500000</us-gaap:GoodwillOtherChanges>
	<us-gaap:GoodwillPeriodIncreaseDecrease contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-DA1A41FCBCB4952C2D4938A291238D6E" unitRef="usd">36000000</us-gaap:GoodwillPeriodIncreaseDecrease>
	<us-gaap:GrossProfit contextRef="FD2014Q1QTD" decimals="-5" id="Fact-F74719305B53C64CC48838A2913A2EBE" unitRef="usd">1850500000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2014Q2QTD" decimals="-5" id="Fact-BA551EC43FFDC49B8C3338A2911BCBEF" unitRef="usd">2129600000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2014Q3QTD" decimals="-5" id="Fact-42803C3611D868B497AC38A2913A5F84" unitRef="usd">2208800000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2014Q4QTD" decimals="-5" id="Fact-DE9CFFBA1B47652098DB38A2911B0589" unitRef="usd">2343400000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2014Q4YTD" decimals="-5" id="Fact-A1C08975785CC6BEDCC438A2913F026F" unitRef="usd">8532300000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2015Q1QTD" decimals="-5" id="Fact-9FFA1428C30B2E0EE9C938A2913F83B3" unitRef="usd">2242600000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2015Q2QTD" decimals="-5" id="Fact-2743E7883471645A9B3438A291359E45" unitRef="usd">2305500000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2015Q3QTD" decimals="-5" id="Fact-C1217E9EDB8E95808FFF38A2914146BB" unitRef="usd">2467900000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2015Q4QTD" decimals="-5" id="Fact-1911035BC8BA10EF45B538A2912E546C" unitRef="usd">2507500000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-DF91792A0252AA6099B038A2912FB49A" unitRef="usd">9523400000</us-gaap:GrossProfit>
	<us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="FD2014Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-ADB4DF97DDC5E2A1FEE838A2912CA4F1" unitRef="usd">34700000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
	<us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="FD2014Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-726F6BDA09930979C0CC38A29123019F" unitRef="usd">16200000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
	<us-gaap:ImpairmentOfInvestments contextRef="FD2013Q4YTD" decimals="-5" id="Fact-956F0A68377C666E9FAB38A2913A654F" unitRef="usd">2800000</us-gaap:ImpairmentOfInvestments>
	<us-gaap:ImpairmentOfInvestments contextRef="FD2014Q4YTD" decimals="-5" id="Fact-C0012326D7D581EA156138A2912EFC02" unitRef="usd">0</us-gaap:ImpairmentOfInvestments>
	<us-gaap:ImpairmentOfInvestments contextRef="FD2015Q4YTD" decimals="-5" id="Fact-24A09ACE0722E9A1004138A291300A69" unitRef="usd">0</us-gaap:ImpairmentOfInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2013Q4YTD" decimals="-5" id="Fact-E1DD9A2325583E5C8CFA38A2913DE9FF" unitRef="usd">1953000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2014Q4YTD" decimals="-5" id="Fact-9C49B7B9280A6D7FCF4838A2913C71A4" unitRef="usd">2557400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2015Q4YTD" decimals="-5" id="Fact-EAA87D8A7BF23BE18FF638A291357807" unitRef="usd">3386700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2013Q4YTD" decimals="-5" id="Fact-DFC33C677F3CF5DB5EB638A29134E0CB" unitRef="usd">527600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2014Q4YTD" decimals="-5" id="Fact-060BEFDC3E60FFAC2DC838A2913E2EEA" unitRef="usd">1389200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2015Q4YTD" decimals="-5" id="Fact-FEC310B71D15DFF4527538A2913C0642" unitRef="usd">1380600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2013Q4YTD" decimals="-5" id="Fact-423D91B49570D125ADC838A2913004C5" unitRef="usd">2480600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2014Q4YTD" decimals="-5" id="Fact-A27911DD23C633EEF0E138A2912C77D9" unitRef="usd">3946600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2015Q4YTD" decimals="-5" id="Fact-664DA41C8342F162F19938A29132F756" unitRef="usd">4767300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2013Q4YTD" decimals="-5" id="Fact-F75B939B8DF2DAB567DE38A29133E903" unitRef="usd">-17200000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2014Q4YTD" decimals="-5" id="Fact-B4AE25FD14F171E9F8A938A2911D3997" unitRef="usd">-15100000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2015Q4YTD" decimals="-5" id="Fact-2B2CF9776BB07F66B23938A2911D56DA" unitRef="usd">-12500000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="FI2015Q4" decimals="-5" id="Fact-FB7DBE70DEFA4C9A99D838A291346A8E" unitRef="usd">60900000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2013Q4YTD" decimals="-5" id="Fact-66C2F54C8877C2E49A1138A2914061AD" unitRef="usd">601000000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2013Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-29087137527013B9645638A2913B1C30" unitRef="usd">-500000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2013Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-949466566892EC51B0AD38A2912E957D" unitRef="usd">-5500000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-5" id="Fact-8FED439D55FC7973428B38A29141C430" unitRef="usd">989900000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-3DC7D3E39300A2D4B61F934E4EE67328" unitRef="usd">72700000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-863B453CE20F616226D538A29130F650" unitRef="usd">-500000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-F2BE8FE9D15369BED1C938A2913B5412" unitRef="usd">-3500000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-5" id="Fact-DCC94986771BEBB1DEA438A2913299F9" unitRef="usd">1161600000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-549EEC87BB1B8C56D70238A291224276" unitRef="usd">120200000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-893F9C6A05403A20DC7938A2913869DA" unitRef="usd">-800000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-BB3BB0917EB5EB18138138A2913A9BB9" unitRef="usd">700000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxesPaidNet contextRef="FD2013Q4YTD" decimals="-5" id="Fact-CAEF3D56D12ACB590A6D38A291323D42" unitRef="usd">643200000</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncomeTaxesPaidNet contextRef="FD2014Q4YTD" decimals="-5" id="Fact-CA023731CAD2AE1C447038A2913155E3" unitRef="usd">1163200000</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncomeTaxesPaidNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-6869903124740BB1410B38A291314DC5" unitRef="usd">1674800000</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2013Q4YTD" decimals="-5" id="Fact-F117481A9295BA4B560738A2913997A5" unitRef="usd">126700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2014Q4YTD" decimals="-5" id="Fact-16BD44121D96832B5C9B38A29142EA89" unitRef="usd">512400000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2015Q4YTD" decimals="-5" id="Fact-C309A65DAF517D87761938A29142E86D" unitRef="usd">-29000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2013Q4YTD" decimals="-5" id="Fact-0E6AE3317A81CF127F8165C9A2699C31" unitRef="usd">156800000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2014Q4YTD" decimals="-5" id="Fact-63BDEFD7BD302126F89765C9906CD06D" unitRef="usd">61000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2015Q4YTD" decimals="-5" id="Fact-B4833E02318E1FFDB2CE65C952641677" unitRef="usd">-410200000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2013Q4YTD" decimals="-5" id="Fact-E8E08ED78B0F3DBC5CD038A291424B67" unitRef="usd">284100000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-E032BBE4C4EFCA380A8838A2911C6389" unitRef="usd">244300000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-CFBA133D37BDB6534A9538A2914128A6" unitRef="usd">74200000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2013Q4YTD" decimals="-5" id="Fact-04E913C76C3B1FB6399C38A291195413" unitRef="usd">243900000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2014Q4YTD" decimals="-5" id="Fact-E0161344B75CDE5EAEFB38A29141AB9A" unitRef="usd">185900000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2015Q4YTD" decimals="-5" id="Fact-759AA62C653D195F0EA238A291427622" unitRef="usd">174400000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2013Q4YTD" decimals="-5" id="Fact-7F072820D8C51339E78238A29138CF23" unitRef="usd">160200000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2014Q4YTD" decimals="-5" id="Fact-B12FF63B150EAF4C1B9738A29139B3CE" unitRef="usd">94500000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2015Q4YTD" decimals="-5" id="Fact-195FA36D4A671197034938A29142BB4F" unitRef="usd">156600000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2013Q4YTD" decimals="-5" id="Fact-3E6F7E38D4BBAD41E58C38A29139DD72" unitRef="usd">-15700000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2014Q4YTD" decimals="-5" id="Fact-0164CB8828F006792DA138A2914123AC" unitRef="usd">30700000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-225E351D32B17B91F8F038A29142F6A5" unitRef="usd">31100000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2013Q4YTD" decimals="-5" id="Fact-A630FD7606BE839FDB7E38A29142ADEF" unitRef="usd">161700000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-9B24D223CC674E8543AC38A29142D2E2" unitRef="usd">33800000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-583E57FA6FB059F0022838A291421F8D" unitRef="usd">93600000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2013Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-9D8F50895299F36AFD9638A2913170D1" unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2013Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-4EA663B810985940222238A2913172B7" unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2013Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-4394967E003834C1604638A2913C4717" unitRef="shares">800000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2014Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-FACD38E1BDF80219338538A2913BFB29" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2014Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-A7BB19A796CB9C4A66A338A29131EEE0" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2014Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-CAED843C0D7962C6D5BF38A2913C4448" unitRef="shares">500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-4AA9E4C29740F2386BD638A2913B8ED0" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-E987CEFB3340404C600438A2913B77AD" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-5FF3DC923D6937254F9738A2913169D7" unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2014Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-240E15B52E788189E64938A2912C2D23" unitRef="usd">314100000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2014Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-A20086ADEB45220FD5EA38A2912CB301" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2015Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-90AC11C08DA9C227F56338A2912CF4B1" unitRef="usd">730500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2015Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-BF332D0F12DD6AA8400438A2912950E8" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2014Q4" decimals="-5" id="Fact-93A9DCA43DEB0E5A054D38A291292248" unitRef="usd">7207100000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2015Q4" decimals="-5" id="Fact-018638E10AE1ACB862A538A2912C8F8F" unitRef="usd">7646300000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2014Q4" decimals="-5" id="Fact-1C476DC221EF3145813238A291236256" unitRef="usd">4028500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2015Q4" decimals="-5" id="Fact-464B8F4A329A6416C87638A291302DCD" unitRef="usd">4085100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:InterestCostsCapitalized contextRef="FD2013Q4YTD" decimals="-5" id="Fact-9D4DB10FB27DDF9393CD38A2912C02E2" unitRef="usd">7800000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestCostsCapitalized contextRef="FD2014Q4YTD" decimals="-5" id="Fact-6D1A327C82DF3798FA1838A291272917" unitRef="usd">6400000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestCostsCapitalized contextRef="FD2015Q4YTD" decimals="-5" id="Fact-3FF3867E29C78B22D63138A291288113" unitRef="usd">10400000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestExpense contextRef="FD2013Q4YTD" decimals="-5" id="Fact-5AC73720774AEF9B4BF738A29130AD6C" unitRef="usd">31900000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-30EB8D7FC872AE7C5AA438A2912FDC2F" unitRef="usd">29500000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-DB895E5CDD07751D35A838A2913D5201" unitRef="usd">95500000</us-gaap:InterestExpense>
	<us-gaap:InterestPaidNet contextRef="FD2013Q4YTD" decimals="-5" id="Fact-47D346A9425A398A101E38A2913125CD" unitRef="usd">53600000</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2014Q4YTD" decimals="-5" id="Fact-2B2D87D874CC2738CF9438A29131E143" unitRef="usd">41200000</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-37A7F5CD40CABD9AE2AC38A29131687D" unitRef="usd">39100000</us-gaap:InterestPaidNet>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2014Q4" decimals="-5" id="Fact-33FCAF88C051A53420FD38A2913E538E" unitRef="usd">164200000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2015Q4" decimals="-5" id="Fact-0DF08B727FDAF32BA93238A2913EF90D" unitRef="usd">143000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryNet contextRef="FI2014Q4" decimals="-5" id="Fact-75B116D898AFE71BB8A838A291316BE1" unitRef="usd">804000000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2015Q4" decimals="-5" id="Fact-4C365538BA3FBBD3BA1838A29131061D" unitRef="usd">893400000</us-gaap:InventoryNet>
	<us-gaap:InventoryNoncurrent contextRef="FI2014Q4" decimals="-5" id="Fact-B2AFB81964DA1B57BE9638A2912B401F" unitRef="usd">0</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryNoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-B580651A7F7F2E1DDB1C38A2913EC7B7" unitRef="usd">40200000</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2014Q4" decimals="-5" id="Fact-57C96571B8F155D0C4B738A2912B8FC6" unitRef="usd">128300000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2015Q4" decimals="-5" id="Fact-7DCA47BC32EBF53E919E38A2912B198C" unitRef="usd">213000000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2014Q4" decimals="-5" id="Fact-D2BC2B7CBE516E07D53938A2913D767E" unitRef="usd">511500000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2015Q4" decimals="-5" id="Fact-8E9F7EB1E27337EE43B438A2912B9243" unitRef="usd">577600000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InventoryWriteDown contextRef="FD2013Q4YTD" decimals="-5" id="Fact-9A9B24C564DF2F0612B138A2911DDCC2" unitRef="usd">47300000</us-gaap:InventoryWriteDown>
	<us-gaap:InventoryWriteDown contextRef="FD2014Q4YTD" decimals="-5" id="Fact-4D4703A1FD0E6400E5E138A291328DAA" unitRef="usd">50600000</us-gaap:InventoryWriteDown>
	<us-gaap:InventoryWriteDown contextRef="FD2015Q4YTD" decimals="-5" id="Fact-8E595C3982B5E6D290BE38A29129F0B0" unitRef="usd">41900000</us-gaap:InventoryWriteDown>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2013Q4YTD" decimals="-5" id="Fact-E39F24690ABB17DAF07C38A2912EBD5F" unitRef="usd">8200000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2014Q4YTD" decimals="-5" id="Fact-CDC66A77D63140B0340538A2913CF7FC" unitRef="usd">12200000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2015Q4YTD" decimals="-5" id="Fact-868686651E9F0A564B4738A2913DEC55" unitRef="usd">22100000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C60AA837B2EAEAD2B09938A2911BDC91" unitRef="usd">6900000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3109C82B167EE0ADD12A38A2912CC534" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3DDD61F1DF4958F8337838A2912C13AA" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DB109046297A818713FC38A29119242F" unitRef="usd">6900000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C36E7B6484B90301E4B838A29137FE94" unitRef="usd">37500000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-18828B62ED62AAD5204738A29132A3DA" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6379EC5391C4F02E822738A291354DDA" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-55ACCC465CF7D1F1F33C38A291359A3E" unitRef="usd">37500000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:Land contextRef="FI2014Q4" decimals="-5" id="Fact-535EA2204BBB20DCC35E38A2913C767B" unitRef="usd">56900000</us-gaap:Land>
	<us-gaap:Land contextRef="FI2015Q4" decimals="-5" id="Fact-84CC3E88CB6FEC01F5F538A2913D1F5C" unitRef="usd">74700000</us-gaap:Land>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2013Q4YTD" decimals="-5" id="Fact-5C84F65B9ACD0AAAE49238A2912F0B90" unitRef="usd">56100000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-35A088A42B88C19FA7A738A29131A4C2" unitRef="usd">62400000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-1B23F742607085ABBD9D38A291312EA0" unitRef="usd">68600000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseholdImprovementsGross contextRef="FI2014Q4" decimals="-5" id="Fact-54C35847ED2C9E77FE4538A2913DF521" unitRef="usd">155500000</us-gaap:LeaseholdImprovementsGross>
	<us-gaap:LeaseholdImprovementsGross contextRef="FI2015Q4" decimals="-5" id="Fact-F84FC6F73CC3585A46A038A2913CC7D0" unitRef="usd">166600000</us-gaap:LeaseholdImprovementsGross>
	<us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember" id="Fact-1336EEB62FAE6FEB0BF638A291298574">P10Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
	<us-gaap:Liabilities contextRef="FI2014Q4" decimals="-5" id="Fact-6577BBACEC95BBADF3A738A2912F4D1B" unitRef="usd">3500700000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2015Q4" decimals="-5" id="Fact-2EF2FCC28B550088AEA238A29122DFA5" unitRef="usd">10129900000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2014Q4" decimals="-5" id="Fact-2FB983314CFF879BAFA538A29125BAF0" unitRef="usd">14314700000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2015Q4" decimals="-5" id="Fact-A4F9224342DDEFE1CB2638A29123B04F" unitRef="usd">19504800000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-1099FD8E591791FD425E38A2912592AB" unitRef="usd">2218100000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-5121C7952BF605E8C4B238A2912FA82E" unitRef="usd">2577700000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E54FC6B7A2193229CB3F38A2912C7EB8" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-236810E8AC7751A09D0F38A2912C7108" unitRef="usd">5400000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A2ECE054C3019E0E940038A2912C4C41" unitRef="usd">215500000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D64316AE9D36ABFA0B3238A2912C217F" unitRef="usd">220900000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FF6F61A3823F9792CBD038A2913709B1" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-AF9026B4B8BF45DC427238A291357D0A" unitRef="usd">14700000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-AD1473AC26363315386738A29137140A" unitRef="usd">506000000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6BD6A72EBF1B40BBD87538A29136A05D" unitRef="usd">520700000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-79B70BFD53C62F57309938A29131F296" unitRef="usd">45400000</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
	<us-gaap:LicenseCosts contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-938FBD7BE09822190C1F38A2911F6ECE" unitRef="usd">35600000</us-gaap:LicenseCosts>
	<us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="FD2013Q4YTD" id="Fact-012D67511A89A050FB07936A9E208141">P364D</us-gaap:LineOfCreditFacilityExpirationPeriod>
	<us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="FD2015Q4YTD" id="Fact-1A33AEF8765C07349FF2936A23AAADED">P5Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
	<us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding contextRef="FI2015Q4" decimals="0" id="Fact-79A46ABF0E110CE6893238A29120B235" unitRef="usd">0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="FI2013Q4" decimals="-5" id="Fact-184899DFD09CFE5AA42238A2912D63D9" unitRef="usd">750000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="FI2015Q4" decimals="-8" id="Fact-D96CE3BE22C95075FBC038A2912DF4A7" unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LongTermDebt contextRef="FI2014Q4" decimals="-5" id="Fact-061856735F07E863F24838A291301E8D" unitRef="usd">580300000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2015Q4" decimals="-5" id="Fact-A238D8E089E8605A624538A291260773" unitRef="usd">6521500000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="FI2014Q4" decimals="-5" id="Fact-DCBF2CF354350647748338A291391B2C" unitRef="usd">0</us-gaap:LongTermDebtAndCapitalLeaseObligations>
	<us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="FI2015Q4" decimals="-5" id="Fact-FABE2BACEE26EC80A7B638A2913A4D52" unitRef="usd">18100000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
	<us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-A8905932BD73EE51752E38A2913981A1" unitRef="usd">0</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
	<us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-77DC2836005224CA5C6338A2913918B5" unitRef="usd">1700000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="FI2015Q4" decimals="-5" id="Fact-8DD5F42D2AF40C04F52E38A2913561D2" unitRef="usd">4500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="FI2015Q4" decimals="-5" id="Fact-C33606E8F86365171CA738A291416A37" unitRef="usd">3200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="FI2015Q4" decimals="-5" id="Fact-F3272FB88A38E099BEF138A2913465C0" unitRef="usd">1500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="FI2015Q4" decimals="-5" id="Fact-C079F9A53DFEAA09039238A29119DC64" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="FI2015Q4" decimals="-5" id="Fact-140D57289A261EF48C0B38A2913B5ABD" unitRef="usd">553200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="FI2015Q4" decimals="-5" id="Fact-5163CB7992705EE2C61438A2913BB7F1" unitRef="usd">3200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
	<us-gaap:LongTermNotesPayable contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-97795CC62D5F32F4AAE138A2913A55F7" unitRef="usd">0</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-E57BDC0F177B6CA6CBD038A291395DE6" unitRef="usd">0</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-20F8229C8CDC641C5B2738A291399323" unitRef="usd">571700000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-40940B4C9A9AA9FA286A38A2913993D4" unitRef="usd">0</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-BAE5A361C0BE1616741838A2913935C0" unitRef="usd">0</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2014Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-1F0494FF8C1A4BB2FA4238A2913918B7" unitRef="usd">8600000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2015Q4" decimals="-5" id="Fact-EDA57A83387EEE71C16938A29138B6E6" unitRef="usd">6559600000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-F0FF49AE4393FF52BAA338A291396EA4" unitRef="usd">1721100000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-F616129A10B67A980CF938A29139274A" unitRef="usd">1733400000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-E5C5DB3BA4FF1AE416B038A291399D0D" unitRef="usd">565300000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-98C56B21D0BDD91ACC8A38A2913AA046" unitRef="usd">992200000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-0A32575B82553C466BB038A29139D243" unitRef="usd">1485500000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2015Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-74EED29D53F682D6A71138A2913AB790" unitRef="usd">5900000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="I2006Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-A1FED017FB615A077A3138A2912063AB" unitRef="chf">61400000</us-gaap:LongTermNotesPayable>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2013Q2_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-C7B0A92D61845BD27A7B38A291303B6D" unitRef="EUR">15400000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="FI2011Q4_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-E63AD5540F7EE6A7F3F938A291308C8B" unitRef="EUR">30700000</us-gaap:LossContingencyEstimateOfPossibleLoss>
	<us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="FI2013Q2_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-A84F59F46AEF67FF34FE38A291301A6D" unitRef="EUR">33300000</us-gaap:LossContingencyEstimateOfPossibleLoss>
	<us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="FI2014Q4_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-157845DAD7C6A495A38338A2913006D4" unitRef="EUR">35600000</us-gaap:LossContingencyEstimateOfPossibleLoss>
	<us-gaap:MachineryAndEquipmentGross contextRef="FI2014Q4" decimals="-5" id="Fact-309ABB17AA2F2AB1378E38A2913D6E73" unitRef="usd">1011300000</us-gaap:MachineryAndEquipmentGross>
	<us-gaap:MachineryAndEquipmentGross contextRef="FI2015Q4" decimals="-5" id="Fact-06A8FEAA9182D272489238A2913CD594" unitRef="usd">1079600000</us-gaap:MachineryAndEquipmentGross>
	<us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1 contextRef="FD2015Q4YTD" id="Fact-1F88665FB8288F2789B638A2912B9637">P18M</us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1>
	<us-gaap:MinorityInterest contextRef="FI2014Q4" decimals="-5" id="Fact-A806272E3A803F6E5AFE38A29130671E" unitRef="usd">5000000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2015Q4" decimals="-5" id="Fact-DC6C2037CBF0C808966F38A29124C249" unitRef="usd">2100000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2014Q4YTD" decimals="-5" id="Fact-07CCB37DA13E0AE76D1C38A2913B21AE" unitRef="usd">9100000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-16485337EB07C103BD9538A29122B052" unitRef="usd">9100000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-F3918264A84F85543D8438A2913BD50C" unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2015Q4YTD" decimals="-5" id="Fact-22556DD316F00DA38A1238A2913647CD" unitRef="usd">60000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-48518F2CAB4B6FC0B2A538A2913E9D65" unitRef="usd">60000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-0F63F5E99A7DDE92172E38A2913FD1BC" unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2013Q4YTD" decimals="-5" id="Fact-1694A335B0F67726B97038A29119D557" unitRef="usd">-716500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-0CCC76BC9159192EC0EB38A2913975C6" unitRef="usd">-755900000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-DAEE3613C7C164D55FC638A29142B1C4" unitRef="usd">986400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2013Q4YTD" decimals="-5" id="Fact-A1BA35385A70D3F5B8DE38A291422AC9" unitRef="usd">-1604700000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-4C294E1272DECBFED7C838A29141A7B9" unitRef="usd">-1543000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-FE49DF8C34654D45E29438A291381337" unitRef="usd">-4553600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2013Q4YTD" decimals="-5" id="Fact-5C813A5D3E9A098A047638A291406EEE" unitRef="usd">2345100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-0F659B0316B2C74A44B838A291418808" unitRef="usd">2942100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D05C75A37A486002EB7938A291419389" unitRef="usd">3716100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q4YTD" decimals="-5" id="Fact-63E01FD16AF1545FE83638A2912E24B3" unitRef="usd">1862300000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-293DE65A1C5F3E7778CE38A2912FC523" unitRef="usd">-3300000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q1QTD" decimals="-5" id="Fact-3768710039BD87BD45C538A29140224B" unitRef="usd">480000000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q2QTD" decimals="-5" id="Fact-AE5C516A8BB603EF38C538A29139B24E" unitRef="usd">714500000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q3QTD" decimals="-5" id="Fact-F8B86D285A4A68C988F838A2912F49CA" unitRef="usd">856900000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4QTD" decimals="-5" id="Fact-7DE1184A0C63DD556ADB38A29140BE8A" unitRef="usd">883500000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD" decimals="-5" id="Fact-7D965F08FEE886A777FE38A2913555C0" unitRef="usd">2934800000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-BF045F7EB0FC797186F338A2913AAA3A" unitRef="usd">12700000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q1QTD" decimals="-5" id="Fact-B5DE55463428189B357838A29132BDB1" unitRef="usd">822500000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q2QTD" decimals="-5" id="Fact-7356358C6A9818E321D138A2912FAA7F" unitRef="usd">927300000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q3QTD" decimals="-5" id="Fact-A4EB5C969BEB0FBD299438A29138221E" unitRef="usd">965600000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4QTD" decimals="-5" id="Fact-126D71D130122B168F6038A29134663B" unitRef="usd">831600000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD" decimals="-5" id="Fact-7098013DF6993B8D882138A29141F22A" unitRef="usd">3547000000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-8677BC7763A32943875538A29134A1C8" unitRef="usd">171000000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2013Q4YTD" decimals="-5" id="Fact-5AE294444C873F36260538A2913203D7" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2014Q4YTD" decimals="-5" id="Fact-FA876682700F9B89EDFF38A2912B9280" unitRef="usd">6800000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2015Q3QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-9D4F24E5556CAC774A8838A29132A9F9" unitRef="usd">60000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2015Q4YTD" decimals="-5" id="Fact-9664222A042179FD5AD538A291327108" unitRef="usd">46200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="FD2013Q4YTD" decimals="-5" id="Fact-FBF4DE90F187BDA4252C38A291369E82" unitRef="usd">1700000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
	<us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-A8DD27ADF8BFD4F1240E38A29135321A" unitRef="usd">1700000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
	<us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-989563DC942B7A4A035A38A29137AAF1" unitRef="usd">0</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
	<us-gaap:NoncontrollingInterestInVariableInterestEntity contextRef="FI2015Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_RodinTherapeuticsMember" decimals="-5" id="Fact-034AA43B159279CF12A038A291324719" unitRef="usd">10900000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2014Q4YTD" decimals="-5" id="Fact-6E006D259AA45867592038A291214106" unitRef="usd">6700000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-A1AEA62B80B0BA5269D738A2913A9A5E" unitRef="usd">6700000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-2168171BCB3B0FCF4D2138A29122B31D" unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2015Q4YTD" decimals="-5" id="Fact-7C08DA61BDB5C54B913C65CF8101ADD1" unitRef="usd">10900000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-B60FB0D198C492443B9B65CF365ABA43" unitRef="usd">10900000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-9598BAA7F6CA0EA027F865CEE2AB23F1" unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncurrentAssets contextRef="FI2013Q4" decimals="-5" id="Fact-1EE5C448774F32DA785138A29131C837" unitRef="usd">1750700000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2013Q4_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-D3FC7A114EC206AF402A38A2912EB82E" unitRef="usd">3300000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2013Q4_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-B0306D9B415C7817119538A291323043" unitRef="usd">2500000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2013Q4_us-gaap_StatementGeographicalAxis_country_DK" decimals="-5" id="Fact-1C3006E89FEB2AA7DFA438A291332595" unitRef="usd">731100000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2013Q4_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-AB4270FCFBB9BB78F07138A2912D3FCC" unitRef="usd">984400000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2013Q4_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-68359C3EFAB4C34C5DCF38A291322CF5" unitRef="usd">2100000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2013Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-76FC6555B70974A94EA238A2912EF5F1" unitRef="usd">758300000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2014Q4" decimals="-5" id="Fact-616C8F77D4351B1F21E038A2912E8549" unitRef="usd">1765700000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2014Q4_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-4AA071CF22926496224238A2912F551F" unitRef="usd">3200000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2014Q4_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-A690B21B01C85867648338A2912EDBBF" unitRef="usd">2500000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2014Q4_us-gaap_StatementGeographicalAxis_country_DK" decimals="-5" id="Fact-28E6DD0F52D609DAFB7B38A29132E97A" unitRef="usd">676000000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2014Q4_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-38227BD3BF086A3B0CE138A2912E0F40" unitRef="usd">1055500000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2014Q4_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-B4C8DB0A1210ECE49DD438A2912F7514" unitRef="usd">2600000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2014Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-CF7175C0F3DB20B1BE8038A2913243F6" unitRef="usd">701900000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4" decimals="-5" id="Fact-53A5D9E45F1AF2C22D8538A29130DEF2" unitRef="usd">2187600000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-EA94D56E5F20AE6CD18438A2912DD981" unitRef="usd">1700000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-1213880B40419D8261E738A2912D9E14" unitRef="usd">2300000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_country_DK" decimals="-5" id="Fact-3EEAFFAD0C139049225338A291330AEE" unitRef="usd">684900000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-92F3A671EAC0CC48FF6B38A2912EE62A" unitRef="usd">1296500000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-D1C0801C8C7F8CF5A88D38A2912F6BE5" unitRef="usd">7700000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-2EA8C86F01AB6A5401DC38A2912F805D" unitRef="usd">879400000</us-gaap:NoncurrentAssets>
	<us-gaap:NotesPayableCurrent contextRef="FI2014Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-B6AEA453E73513E4E0C838A2913A64AB" unitRef="usd">3100000</us-gaap:NotesPayableCurrent>
	<us-gaap:NotesPayableCurrent contextRef="FI2015Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-5934713CAFEAF79943C838A2913929DC" unitRef="usd">3100000</us-gaap:NotesPayableCurrent>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-E7F59768BF5706D74CB538A29132B9DF" unitRef="usd">12600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-449524E62FA358740C2738A29137A37F" unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-0B61A95274561A4AAFBD38A29138EA4C" unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-D77BEE1E038C9692DB8038A29137F7D0" unitRef="usd">634600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-0F0D5EFF2EA066E40E0B38A291354956" unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2014Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-203193E143E05F2CFD8B38A29135D4CC" unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-200F6FA2F96505473BFD38A29138D7B7" unitRef="usd">9400000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-C32AABBD1CB45C6BE3FE38A291380D6B" unitRef="usd">1757600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-A6BA695465AEC373DC8338A2913620E9" unitRef="usd">1764600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-6530AD51B928AEBEDBF238A291387847" unitRef="usd">602600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-1153CF9DE55AC0786D0438A291359B32" unitRef="usd">1014200000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-3F955F202CC7F0BDFD9338A2913880A6" unitRef="usd">1497500000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NumberOfReportableSegments contextRef="FD2015Q4YTD" decimals="0" id="Fact-815ADD2FCD9A46514B0138A29139DCF2" unitRef="segment">1</us-gaap:NumberOfReportableSegments>
	<us-gaap:OperatingIncomeLoss contextRef="FD2013Q4YTD" decimals="-5" id="Fact-D7F23B8D855202AF58BF38A29131B702" unitRef="usd">2515500000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q4YTD" decimals="-5" id="Fact-BCF1BEDEDE38CD73EC2F38A2914130B3" unitRef="usd">3972400000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q4YTD" decimals="-5" id="Fact-839172FB7470C6E579EC38A291400B00" unitRef="usd">4891000000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2015Q4" decimals="-5" id="Fact-FF2D985F55465E4FE31D38A29136CB20" unitRef="usd">732100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-FA3C2F713F90921E546638A2913701E0" unitRef="usd">75900000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="FI2015Q4" decimals="-5" id="Fact-10295FA48EB105A523EE38A29134AD19" unitRef="usd">63200000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2015Q4" decimals="-5" id="Fact-93C7EDBD0DB6D78B3AFA38A29135241B" unitRef="usd">66700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2015Q4" decimals="-5" id="Fact-A67C723F5C3DF173B3C038A29134289C" unitRef="usd">67900000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2015Q4" decimals="-5" id="Fact-6A59BBB5030C3282166F38A2913C082C" unitRef="usd">75700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="FI2015Q4" decimals="-5" id="Fact-E25538B9A6089FDAF17438A29137AE76" unitRef="usd">382700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" decimals="-5" id="Fact-401D2CFAFF0A28643F4A38A2913477B2" unitRef="usd">25300000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" decimals="-5" id="Fact-0513ABB6A9A9B215C16738A29131043F" unitRef="usd">53400000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-6D1BEDD94E239AD9BF0D38A2913A7C70" unitRef="usd">505900000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-9014D51B72ECDBA3706238A2912EF5ED" unitRef="usd">579600000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="FI2014Q4" decimals="-5" id="Fact-8E63EFA9FE573F97C92A38A2913F9962" unitRef="usd">249400000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
	<us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-5F302EC9581C638CFD4538A2913F701B" unitRef="usd">369100000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-CB5B050347AD3243A9FA38A2912FED98" unitRef="usd">309800000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-7B45CBE045F46B7EF5CB38A29126752B" unitRef="usd">836900000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2014Q4" decimals="-5" id="Fact-93904C8E351E2AC75F3A38A291314816" unitRef="usd">754600000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-74A3FDC63F0006AC33AE38A29126BD3A" unitRef="usd">1107600000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherCommitment contextRef="FI2015Q4" decimals="-5" id="Fact-CAAADB2BACC6E7D3443C38A291313292" unitRef="usd">559000000</us-gaap:OtherCommitment>
	<us-gaap:OtherCommitment contextRef="FI2015Q4_biib_FacilityLocationAxis_biib_SolothurnMember" decimals="-5" id="Fact-9900B19B7D17151C169793B7CEC82B73" unitRef="usd">126400000</us-gaap:OtherCommitment>
	<us-gaap:OtherCommitment contextRef="FI2015Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_RodinTherapeuticsMember" decimals="-5" id="Fact-DC577146A0156F9ECD4A38A29133F756" unitRef="usd">4000000</us-gaap:OtherCommitment>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2013Q4YTD" decimals="-5" id="Fact-6B76835E9304AD30239738A2912B9DB0" unitRef="usd">1400000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-FE370FF5BD7780F127F938A2913FE184" unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-A8B00FBD86E2A4CB288138A2911D0608" unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2013Q4YTD" decimals="-5" id="Fact-5BAD76593C6A6A37D08138A2912E0F46" unitRef="usd">24300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-0814E76F1ECC787453C138A2912E1F83" unitRef="usd">2100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-40C388E161BAE7B7CC9E38A2912684AA" unitRef="usd">-26700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-EBB49CDB25F3330E481238A291269F3D" unitRef="usd">11800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-D43A2B21CB12CA1B341938A29127CB0B" unitRef="usd">37100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-BA30E469DD011D2DFF1538A291330AA1" unitRef="usd">-19100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-A2B658D00CE214F9432738A2913306F5" unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-D19E86A8AE281B8D3EB538A291330DBD" unitRef="usd">101700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-C5BABDEC2E5E93D2DBFD38A291333D63" unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-866C722265093CA5452D38A29133FF49" unitRef="usd">-109200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-1289426BBAFAD768097B38A291327AEE" unitRef="usd">6500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember" decimals="-5" id="Fact-9AFE1E38BFF73EDA179838A29127D810" unitRef="usd">8500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-4DEA7A17B2C98802B88538A2912D0BC3" unitRef="usd">-6200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-797103729BEF14BC93F138A2912D5162" unitRef="usd">110800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-0CD84CCDC4D0CA9DCE3B38A2912D261C" unitRef="usd">-1700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-09556A9B51BE1C253E0738A2912D1A4E" unitRef="usd">-96400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2013Q4YTD" decimals="-5" id="Fact-AF8FD719DF48779A1B7738A291345EFB" unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-5F6443C597444681544E38A29140FE61" unitRef="usd">95400000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-9861596983D2F68F3B0338A2911A7AC1" unitRef="usd">-61500000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2013Q4YTD" decimals="-5" id="Fact-39008464DBE691707CC238A2912CEBB4" unitRef="usd">37100000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-AF59749E8EADF20A685638A2912E0282" unitRef="usd">-109200000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-29CBF572F85AD191BC5E38A2914184D7" unitRef="usd">-96400000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2013Q4YTD" decimals="-5" id="Fact-A0D95B2EACCBF1ADCB1838A2913635E3" unitRef="usd">-27600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-D1C727E2D2D55D15908A38A29127A3DC" unitRef="usd">2100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-062C13604F1F379FA78338A291271855" unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-CC1ED246B4CD2CDF485738A2912E56FE" unitRef="usd">1400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-5D360E8574974729B3D038A29136A884" unitRef="usd">-27600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-64687F2F6768FD3A6E6138A291254482" unitRef="usd">37100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-269767B4FB8BAD6D120838A291357665" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-062BAFAB869FA867D77438A29136A7F5" unitRef="usd">-27600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-D3CCB970ED405A11951238A2913BD982" unitRef="usd">-31800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-464EC2542E969304802838A29133FA3E" unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-2F5B7EB9C207CAACF7DE38A2913398E6" unitRef="usd">95400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-293E3E0E505BE67E9F7D38A2913329A6" unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-56C7ECF63AD6E883A8AE38A29121DDD8" unitRef="usd">-31800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-5C900519968367B0865738A291338304" unitRef="usd">-109200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-44F8CE0788FE7ECCD46738A2913BE085" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-2E7681A0CEF85AFE83D438A2913AA50A" unitRef="usd">-31800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-C700AF790E596D5B1BCD38A2913C8304" unitRef="usd">164500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-29462CB38BF9239058E038A2912D7404" unitRef="usd">-6200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-4269D26EB3A6CA173C9538A2912DBB0F" unitRef="usd">-61500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-C359FDA5EA30239DDBE638A2912D32D4" unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-A5BC672FB3068148638638A2912CF445" unitRef="usd">164500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-409924604805BB6390E338A2912D62C1" unitRef="usd">-96400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-42651DCE45A1C5FEA19C38A2913747F3" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-534E309731CE0C92EA8238A2913FAE1C" unitRef="usd">164500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2013Q4YTD" decimals="-5" id="Fact-105766C4E746CCD625A738A29130638C" unitRef="usd">27600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2014Q4YTD" decimals="-5" id="Fact-5ED606B013871937721738A2913154BD" unitRef="usd">-31800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2015Q4YTD" decimals="-5" id="Fact-4A03F00C16FB46A9809138A2913828BE" unitRef="usd">-164500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2013Q4YTD" decimals="-5" id="Fact-BD526B8EA204DC56818538A2913147D7" unitRef="usd">-2100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-E2E4B76578F57890F1E138A29140122B" unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-B57930BDB233367F4B2738A2913516E6" unitRef="usd">6200000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="FD2013Q4YTD" decimals="-5" id="Fact-857FC37FBCA8FEC4593338A291317934" unitRef="usd">10400000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-8DA62E3AB31D5F53AC1438A2913B8F4B" unitRef="usd">6400000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-6B8E324217039B00D7AE38A291408B69" unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax contextRef="FD2013Q4YTD" decimals="-5" id="Fact-33816E6C35E33621105B38A2911E3378" unitRef="usd">-13700000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-ED39CC312B3F08D1625438A2912E6E19" unitRef="usd">6300000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-CCB5D012DEE334BCC2B738A291317222" unitRef="usd">172300000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax contextRef="FD2013Q4YTD" decimals="-5" id="Fact-B39D8CE0B3E8DB1DBE2138A2913502A5" unitRef="usd">-26700000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-DFD256428564C226510038A291313C98" unitRef="usd">101700000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-6AD5BC9DF9B5B580521E38A29132985F" unitRef="usd">110800000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2013Q4YTD" decimals="-5" id="Fact-BB4F7BBDD639D84BE4BE38A2912D09FC" unitRef="usd">11800000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-020B4B3E5F933AF7EC4F38A29132A81F" unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-848F9D11490AE69943CE38A2913C5755" unitRef="usd">-1700000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-7ADF1A55DA9A23E5919338A29122340B" unitRef="usd">1817700000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-7AF1D11CB3A1F6411D7838A29127A12C" unitRef="usd">2096800000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_biib_SolothurnMember" decimals="-5" id="Fact-0C8D74A20903B8220FCB93A5040E008F" unitRef="usd">59100000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2014Q4" decimals="-5" id="Fact-C6CAF982D4F1668E682D38A29130B6DE" unitRef="usd">650100000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-B2DD8379C1C916A254E638A2913026A8" unitRef="usd">905800000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2015Q4_us-gaap_StatementGeographicalAxis_country_IT" decimals="-6" id="Fact-5D0E5FC4FED2B279D59793A838CE8443" unitRef="EUR">75000000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2013Q4YTD" decimals="-5" id="Fact-E837ED6470C9DA423EA438A29142D635" unitRef="usd">27600000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-CE033330553B8BAFBD0738A291411CBB" unitRef="usd">50300000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-DE2464EF97AC2A9A1A4F38A29142D53E" unitRef="usd">-82200000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2013Q4YTD" decimals="-5" id="Fact-713C1AAC1938EDD1992438A29141C2AB" unitRef="usd">-34900000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2013Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-ED316E4C2277E44DE79638A2913B3008" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2013Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-8A21A651A5D31BF53D1F38A2912F0B33" unitRef="usd">15900000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-D72CD16FF893798C04D338A291409343" unitRef="usd">-25800000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2014Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-B19DE5FAC7AD1D816EE038A2912F622A" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2014Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-C2A8367F1DCB449DF59138A29139DF10" unitRef="usd">9900000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-262310A28804CF304CDC38A29130728B" unitRef="usd">-123700000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-7F78E6184A5D440D0A9538A29134F443" unitRef="usd">-100000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-71261DD65376925B61A038A2913A4711" unitRef="usd">-2000000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2013Q4YTD" decimals="-5" id="Fact-F491D62C61D48E83ADB338A2911CF9FB" unitRef="usd">263900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2013Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-BFA15A577E4101CD162F38A2911F1398" unitRef="usd">43100000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-F914C7B4228123F1AD5538A2912DAE6D" unitRef="usd">0</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-688B9B2C1B3FF1F36D3638A2912E0C80" unitRef="usd">1200000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-EF5AB977D42C12D9CCA138A2912E525D" unitRef="usd">193500000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-69AF21F4360028D6E49038A29132F6F8" unitRef="usd">43100000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-3EA7806752AE63C1833938A2913254F5" unitRef="usd">26100000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q1QTD" decimals="-5" id="Fact-E48D35C31B469EF430C538A2913A89DE" unitRef="usd">90100000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q2QTD" decimals="-5" id="Fact-CD9834519E70C23DE3E138A2914110F7" unitRef="usd">61900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q3QTD" decimals="-5" id="Fact-663CD09387BB0045898D38A29139F9FA" unitRef="usd">103400000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q4QTD" decimals="-5" id="Fact-111821CA1D78940C3C8338A29141BD5B" unitRef="usd">49200000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q4YTD" decimals="-5" id="Fact-6FC4DB4AC327D9255DD038A2913F6C07" unitRef="usd">304500000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-29A9843C67C3E350514E38A29119C2A5" unitRef="usd">58500000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-316ABF961330B905868D38A29132E334" unitRef="usd">0</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-021FFFAAF7C41EDB527738A2912FF93B" unitRef="usd">1800000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-D445E5F7345C6864C66038A291323CDB" unitRef="usd">212600000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-6C2E1DE3A761366CCFF438A291320A87" unitRef="usd">58500000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-DEA553A0BC7A0F5B3C5B38A2912E6CF9" unitRef="usd">31600000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q1QTD" decimals="-5" id="Fact-AAA8E8267A0CF5822F7C38A29141CCC5" unitRef="usd">52000000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q2QTD" decimals="-5" id="Fact-A51725D9495C120EC45538A2913D8CAA" unitRef="usd">55600000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q3QTD" decimals="-5" id="Fact-9E9C98FB48FA75C7009938A2912E4F59" unitRef="usd">49000000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4QTD" decimals="-5" id="Fact-07344B0358BC3B10391038A2913D0612" unitRef="usd">79500000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D47A1C932216FF870A2E38A2913F687A" unitRef="usd">236100000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-999B497344DCCE92E52838A2911CFDB5" unitRef="usd">62900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-D3B73C3925F213BDF87438A291325743" unitRef="usd">0</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-59663FD12A9CDB7854DC38A2912F9844" unitRef="usd">1600000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-51BDDB3982B11E9C139838A2912EEAA8" unitRef="usd">142000000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-1F264E86AD22FDFAAE4E38A291325C2B" unitRef="usd">62900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-67AB0487CE282AA796B638A2912E6A8A" unitRef="usd">29600000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2013Q4YTD" decimals="-5" id="Fact-06F9095F937D3C6C422F38A29142E5A9" unitRef="usd">-7300000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-C1F24F4E374D7F1F79DA38A291423488" unitRef="usd">16000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-AD3E2E2023188397217E38A29141452E" unitRef="usd">59900000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2013Q4YTD" decimals="-5" id="Fact-DB853D424717FF3F598F38A291382E60" unitRef="usd">400300000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2014Q4YTD" decimals="-5" id="Fact-FE31EAF4793EFCFDFC8D38A291424359" unitRef="usd">886800000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2015Q4YTD" decimals="-5" id="Fact-84E8DB8E6C3793B5FE4538A291419470" unitRef="usd">5000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRestructuring contextRef="FD2015Q4QTD" decimals="-5" id="Fact-2C0A7A85E09066639E3238A29128DD93" unitRef="usd">72000000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsForRestructuring contextRef="FD2015Q4QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-5" id="Fact-B7EB9EFD4878B4BDEA5A38A2913D0E1C" unitRef="usd">3600000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsForRestructuring contextRef="FD2015Q4QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-5" id="Fact-A2075BAF59B0A3A0779938A2913E8843" unitRef="usd">68400000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2013Q4YTD" decimals="-5" id="Fact-AE356693EA22A368795C38A291384E3D" unitRef="usd">3278100000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-014F921B0D2134CDE1AF38A29141B49E" unitRef="usd">3583100000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-2D0B9CBFE41E2825D46238A2914176D6" unitRef="usd">6864900000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="D2006Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-5" id="Fact-E1D4841CE309EB11D30938A29135529D" unitRef="usd">220000000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-7DC7CFE835017736CDF138A2913C3AA2" unitRef="usd">200100000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="FD2015Q4YTD_biib_CumulativeSalesLevelAxis_biib_SixbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-A4520038D7A9330A2EF738A291320AAC" unitRef="usd">850000000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="FD2013Q4YTD" decimals="-5" id="Fact-FE8DFA8F8AEEDBE658CB38A291406196" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
	<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="FD2014Q4YTD" decimals="-5" id="Fact-F8810FCDC490AD7CD35A38A29139162B" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
	<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="FD2015Q4YTD" decimals="-5" id="Fact-376EE38E9B7B5C1C5C6B38A29139308A" unitRef="usd">198800000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2013Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" decimals="-7" id="Fact-6D6F286BDD083380A80638A291301949" unitRef="usd">3250000000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2013Q4YTD" decimals="-5" id="Fact-773FE2E62758C0FF8AA038A291397181" unitRef="usd">3262700000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2014Q4YTD" decimals="-5" id="Fact-B703DBC3B62C8ACD532D38A2914250A8" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2015Q4YTD" decimals="-5" id="Fact-4D2062018C66CBEE01D238A291385230" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates contextRef="FD2015Q4QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_RodinTherapeuticsMember" decimals="-5" id="Fact-D97363732BE6DCFC7AD838A291341D74" unitRef="usd">8000000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2013Q4YTD" decimals="-5" id="Fact-EBA0AE96A9953D2A82DC38A29142821C" unitRef="usd">15000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2014Q4YTD" decimals="-5" id="Fact-09A5A35E0B0040A9EB8E38A2914108AE" unitRef="usd">375000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E9AAC74DD05C7246BA8B38A291421235" unitRef="usd">850000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2013Q4YTD" decimals="-5" id="Fact-419488C85B7E422E9D5538A29139B30C" unitRef="usd">246300000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2014Q4YTD" decimals="-5" id="Fact-41C2B977D98E0457912738A29138E185" unitRef="usd">287800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q4YTD" decimals="-5" id="Fact-51D57242AFD1FCC03B0338A2911A5416" unitRef="usd">643000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PensionExpense contextRef="FD2013Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SwissplanMember" decimals="-5" id="Fact-9A49D3603F24E85F2E6738A291346203" unitRef="usd">10900000</us-gaap:PensionExpense>
	<us-gaap:PensionExpense contextRef="FD2014Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SwissplanMember" decimals="-5" id="Fact-95E1D9FC8AA0C8C30E4C38A29134EC29" unitRef="usd">9800000</us-gaap:PensionExpense>
	<us-gaap:PensionExpense contextRef="FD2015Q4YTD_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_biib_SwissplanMember" decimals="-5" id="Fact-CC8AEC07CD9ED09F758638A29134B725" unitRef="usd">12900000</us-gaap:PensionExpense>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2014Q4" decimals="3" id="Fact-364332DE47FCC53BA91138A291406DC6" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2015Q4" decimals="3" id="Fact-24FF1E1499F434B5997538A29140087E" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2015Q4" decimals="-5" id="Fact-8C7D732C508D29551F5038A2913E4C9B" unitRef="shares">8000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_biib_SeriesXPreferredStockMember" decimals="-5" id="Fact-DD9D425CAC102B0CA30338A2913EBC27" unitRef="shares">1000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_biib_UndesignatedPreferredStockMember" decimals="-4" id="Fact-AAA2FBFD5E50504792D338A2913E0239" unitRef="shares">5250000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-4" id="Fact-45AAB4537511E32E0CC738A2913E300A" unitRef="shares">1750000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockValue contextRef="FI2014Q4" decimals="-5" id="Fact-CAADBBDEF81E4EE552C938A291311EBC" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2015Q4" decimals="-5" id="Fact-1A041E4C9439ED658F1738A2912174EC" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssets contextRef="FI2013Q3_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-55D10E3D2CB7CDDEFFC538A291349DDF" unitRef="usd">25000000</us-gaap:PrepaidExpenseAndOtherAssets>
	<us-gaap:PrepaidExpenseAndOtherAssets contextRef="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-12FDC83D73193BA99CCC38A2911BA8C9" unitRef="usd">58400000</us-gaap:PrepaidExpenseAndOtherAssets>
	<us-gaap:PrepaidTaxes contextRef="FI2014Q4" decimals="-5" id="Fact-D3D623B88641A7667A4793A734758E32" unitRef="usd">57600000</us-gaap:PrepaidTaxes>
	<us-gaap:PrepaidTaxes contextRef="FI2015Q4" decimals="-5" id="Fact-E7317E8714E72A7B1B9093A701EA0410" unitRef="usd">550600000</us-gaap:PrepaidTaxes>
	<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="FD2013Q4YTD" decimals="-5" id="Fact-7E11985DF46B6C714E4F38A291414B76" unitRef="usd">66800000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
	<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="FD2014Q4YTD" decimals="-5" id="Fact-C84A794BEC368281DE5238A2914176B7" unitRef="usd">54900000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
	<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="FD2015Q4YTD" decimals="-5" id="Fact-FB24E830811A786426EF38A2911965CE" unitRef="usd">54200000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
	<us-gaap:ProceedsFromNotesPayable contextRef="FD2013Q4YTD" decimals="-5" id="Fact-B04CC15BAC66760FA3C465CD2FC372F2" unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
	<us-gaap:ProceedsFromNotesPayable contextRef="FD2014Q4YTD" decimals="-5" id="Fact-3679EE6DCEC7895F382C65CD20909E2E" unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
	<us-gaap:ProceedsFromNotesPayable contextRef="FD2015Q4YTD" decimals="-5" id="Fact-C374D6E4349DD23FB14E65CCECFFA8B2" unitRef="usd">5930500000</us-gaap:ProceedsFromNotesPayable>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2013Q4YTD" decimals="-5" id="Fact-5EC7DBC220A19155E82238A29139F43E" unitRef="usd">-4100000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-1644ED5FA2DB53CD275C38A29138C278" unitRef="usd">-17700000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E138705D8F9B4ECA8A6A38A2911923F2" unitRef="usd">-74400000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2013Q4YTD" decimals="-5" id="Fact-4126A2F762DBF49AFC9938A291425601" unitRef="usd">5190100000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-5E7A23BFEAB21276FF0938A291393F21" unitRef="usd">2718900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-5E361A7DBAB87BC2A56B38A29119987E" unitRef="usd">4063000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProfitLoss contextRef="FD2013Q4YTD" decimals="-5" id="Fact-E465C90A3549713C264238A2912E4261" unitRef="usd">1862300000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-83747AE349BF6C767CE938A29136F48F" unitRef="usd">0</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-FDFE8E4C4CA615D99F8638A291351753" unitRef="usd">1862300000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-7B268294A2E5F21BF81938A291350CB6" unitRef="usd">1862300000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2014Q1QTD" decimals="-5" id="Fact-E171291189CDD236682B38A2911CDBD8" unitRef="usd">479700000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2014Q2QTD" decimals="-5" id="Fact-1DDE964C96D64A3DA02B38A29132A4E5" unitRef="usd">723100000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2014Q3QTD" decimals="-5" id="Fact-94DE791E85619E439C3338A2913E88FA" unitRef="usd">856100000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2014Q4QTD" decimals="-5" id="Fact-DB77BE5DB6B490A69FD538A2913F024C" unitRef="usd">882600000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2014Q4YTD" decimals="-5" id="Fact-FBAA6580E4FADBB3E0A738A291408592" unitRef="usd">2941600000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-94BE266C1DC23A186C0F38A2913A9F0C" unitRef="usd">6800000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-1C0B6D609F1EC0C22F9838A29122B16B" unitRef="usd">2934800000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-BB5885940EE9D6E8084538A2913AE56C" unitRef="usd">2934800000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2015Q1QTD" decimals="-5" id="Fact-ED7899674FF86C51930338A2912EF32E" unitRef="usd">820200000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2015Q2QTD" decimals="-5" id="Fact-4263C74CB89A69356A3038A2913A0F7D" unitRef="usd">924800000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2015Q3QTD" decimals="-5" id="Fact-D26DB3C54D0E856965BB38A29138C209" unitRef="usd">1019500000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2015Q4QTD" decimals="-5" id="Fact-F66D4A230D5AE80FF47238A291329633" unitRef="usd">828700000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2015Q4YTD" decimals="-5" id="Fact-3C563C53D72A2EDA4A1F38A29131ED34" unitRef="usd">3593200000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-E15EB1E2AB1598B96AFC38A29122551B" unitRef="usd">46200000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-E755AC6603248C66252D38A2912B3E95" unitRef="usd">3547000000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-D852F24C277A3AF6141438A2913FEEEC" unitRef="usd">3547000000</us-gaap:ProfitLoss>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember" decimals="-5" id="Fact-A36E70C2AEACED3B625B38A2912B10CC" unitRef="usd">104800000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" decimals="-5" id="Fact-561D569447593455266138A29138536A" unitRef="usd">58600000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" decimals="-5" id="Fact-219FE16287FBC8A37E8738A291373D78" unitRef="usd">20300000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_EisaiMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" decimals="-5" id="Fact-45933974A4F271ACDA4138A29137A608" unitRef="usd">25900000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q4QTD_biib_FacilityLocationAxis_biib_SolothurnMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" decimals="-5" id="Fact-B86C3ACBCAE937A9AADA38A291222802" unitRef="usd">62500000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q4QTD_biib_FacilityLocationAxis_biib_SolothurnMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" decimals="-5" id="Fact-42FECA761EE95A6F1EC538A29127E073" unitRef="chf">64400000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2014Q4" decimals="-5" id="Fact-D2008CF7250DF78630F138A2913E8BEF" unitRef="usd">2952100000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4" decimals="-5" id="Fact-72BFBFD44716EED8217A38A2913CD807" unitRef="usd">3517700000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2014Q4" decimals="-5" id="Fact-AEF7DE9C9064BA59D6FF38A29131BE39" unitRef="usd">1765700000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2015Q4" decimals="-5" id="Fact-35E560FA99F1929742C038A291235085" unitRef="usd">2187600000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-4009E32A3758D3DDC0E038A29136D3A5">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-6A0EFE45912AB250C50138A2913755A0">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-BA766BA10B6689D56CC038A291389349">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-BE3780BBFC8B88BD00BF38A291383439">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-ECFAA23748050566691438A29138BA66">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-0815530DCD33598F2A2B38A29138F583">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-3F2275F18C572E8259F538A29138FC4B">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-A954F479A8D2EE72B7F838A291381ACE">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2013Q4YTD" decimals="-5" id="Fact-6310F642E24E324B3BD038A291271086" unitRef="usd">3300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-2E2FAE5CA1E845F4A2DD38A29125634C" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-E5E319C7F99779B2F01438A29126E28E" unitRef="usd">13700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-5B1B85AC9D15E9294E4A38A291263158" unitRef="usd">-10400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-D52FE6FCBFCAA890510C38A29128675D" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-6F667D22E71B38F0AC8638A29133EF45" unitRef="usd">-12700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-20FE390149162D704FE738A29133C394" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-5A430926AE308C3D8A0138A2913378B0" unitRef="usd">-6300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-FDD8FDFED91C71CA885638A29133E03A" unitRef="usd">-6400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-B8287C24CC9DAC92043F38A291331B9B" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-206C48289CD697454EC838A2912E96B0" unitRef="usd">-171000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-9DA36B888FEB86E340D238A2912D65EC" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-8407BEAD2F5F8B0211E938A291326935" unitRef="usd">-172300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-980CF2D3C9A8A0D50AFB38A2912D28BF" unitRef="usd">1300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-60DC4DBFC229A223C09F38A2912AE8B4" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:RepaymentsOfDebt contextRef="FD2013Q4YTD" decimals="-5" id="Fact-9A962884D9577095028138A291393899" unitRef="usd">452400000</us-gaap:RepaymentsOfDebt>
	<us-gaap:RepaymentsOfDebt contextRef="FD2014Q4YTD" decimals="-5" id="Fact-5C0A9BB9F676EFBC3EAD38A291411B74" unitRef="usd">2700000</us-gaap:RepaymentsOfDebt>
	<us-gaap:RepaymentsOfDebt contextRef="FD2015Q4YTD" decimals="-5" id="Fact-EC763A4F583DE1311A3738A29142FF73" unitRef="usd">2100000</us-gaap:RepaymentsOfDebt>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2012Q1QTD_us-gaap_ProductOrServiceAxis_biib_SMNRxMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-1347D0309D0FB0A0854038A2911A6CCC" unitRef="usd">29000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2012Q2QTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-268C1B1986DC365B9D7838A291197898" unitRef="usd">12000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2012Q4QTD_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-330EFB00A8887101C3A038A2911F1004" unitRef="usd">30000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2013Q3QTD_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-198DC60F12C2BDC63DE738A2911CD114" unitRef="usd">75000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2013Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-D837198336EC757AB54E38A2912087C9" unitRef="usd">46000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2013Q4YTD" decimals="-5" id="Fact-E82F93B91FF1B37157D738A29130B78E" unitRef="usd">1444100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2013Q4YTD_biib_AdditionalProductsAxis_biib_NewAntiCd20Member_us-gaap_ProductOrServiceAxis_biib_ThirdPartyAntiCdTwentyMember_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-797313DE214AF83AAED638A2911D90AC" unitRef="usd">25700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-27C5385697ECC69F5C9238A2911F96FE" unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2014Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-76FA20A3173A4911B02538A2913A9EC3" unitRef="usd">117700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2014Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-BF3538037A6BD526980838A2913398A8" unitRef="usd">21600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2014Q4YTD" decimals="-5" id="Fact-5056903B90CE8DAF686A38A29140E2D1" unitRef="usd">1893400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-0F2C5FA14E65B571C2D438A2913319EF" unitRef="usd">14000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_SMNRxMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-15B03FD37F4FE7DA91CF38A2911CE691" unitRef="usd">57300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-62C0814788C4D3A269D538A2911E10EA" unitRef="usd">20000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2014Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember" decimals="-5" id="Fact-91A902A378C4478C8EBD38A2913B27FB" unitRef="usd">40000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-3699DCE37A99EC85472B38A291398C34" unitRef="usd">48100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4QTD_us-gaap_TypeOfArrangementAxis_biib_MitsubishiTanabePharmaCorporationMember" decimals="-5" id="Fact-108A1D54ACA758E5476B38A2911DA522" unitRef="usd">60000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD" decimals="-5" id="Fact-77417F7123FF48546C6F38A29130C169" unitRef="usd">2012800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" decimals="-6" id="Fact-DE83F837E33DF70999C238A2913B6A31" unitRef="usd">175000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_DMPKMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-0E1635886A7B80A950DA38A2911CB2C7" unitRef="usd">2800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" decimals="-6" id="Fact-D8D9CDEDDAC6C34938C238A29134CBC4" unitRef="usd">200000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_LeadprogramsMember_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-D48C63CF65542FF8B21738A2911F3726" unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SMNRxMember_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-04C9A45A7B73337BD05538A2911C2636" unitRef="usd">42800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-DE38303D04A0C90AACF193B2B5BAED0E" unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-42D5EB1C01DB32A00DDE38A2911EFDD5" unitRef="usd">54500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbvieMember" decimals="-5" id="Fact-BCAEF0B2E1757545D2A038A2911DAA29" unitRef="usd">16000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IsisPharmaceuticalsMember" decimals="-5" id="Fact-4826557AE25E5080951D38A2911DCE5C" unitRef="usd">20000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember" decimals="-5" id="Fact-56087A15B4CFACE5791F38A2911FE6AA" unitRef="usd">9700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2015Q4QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_RodinTherapeuticsMember" decimals="-5" id="Fact-3DE73F366FC045E03EC138A29132F9E3" unitRef="usd">8700000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="FI2015Q4" decimals="-6" id="Fact-5AD39F8EF59CF1B77E9B38A2913EA2EC" unitRef="usd">105000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
	<us-gaap:RestructuringCharges contextRef="FD2013Q4YTD" decimals="-5" id="Fact-79A3D052D304E76463EB38A2912F8940" unitRef="usd">0</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2014Q4YTD" decimals="-5" id="Fact-4A42D460562548848C8738A2914235D6" unitRef="usd">0</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2015Q4QTD" decimals="-5" id="Fact-A637B578518EEDC4F88F38A291266077" unitRef="usd">93400000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2015Q4QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-5" id="Fact-BB9FD4712E5D1ACFE30738A2913DBD0E" unitRef="usd">7200000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2015Q4QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-5" id="Fact-8FBD063674698B61AB8938A291419A10" unitRef="usd">86200000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2015Q4YTD" decimals="-5" id="Fact-7F8D51E0A7CC15AC33DC38A2914078AC" unitRef="usd">93400000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringReserve contextRef="FI2015Q4" decimals="-5" id="Fact-C3D8FE36217BD1F8790938A291282F70" unitRef="usd">37300000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-5" id="Fact-44BD1902987247C5AB9838A29127C061" unitRef="usd">3600000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-5" id="Fact-8D9DCC56CB8E339D0A2E38A2913D79C7" unitRef="usd">33700000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="I2015Q3Restructuring" decimals="-5" id="Fact-EC41AAA76AB148A6423993438ACC186A" unitRef="usd">109300000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="I2015Q3Restructuring_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-5" id="Fact-C126CD8D2680E7903E5193434E57A52F" unitRef="usd">7200000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="I2015Q3Restructuring_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-5" id="Fact-D46C020B7AAD14C6552E9341AEC2F044" unitRef="usd">102100000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserveAccrualAdjustment contextRef="FD2015Q4QTD" decimals="-5" id="Fact-62732361FE5AE7ED684A9344BD6CD8F8" unitRef="usd">15900000</us-gaap:RestructuringReserveAccrualAdjustment>
	<us-gaap:RestructuringReserveAccrualAdjustment contextRef="FD2015Q4QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-5" id="Fact-6511C4CD8D749FE12EE4933CF6E17D73" unitRef="usd">0</us-gaap:RestructuringReserveAccrualAdjustment>
	<us-gaap:RestructuringReserveAccrualAdjustment contextRef="FD2015Q4QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-5" id="Fact-CF19E191F637294F9ACA9339881959B9" unitRef="usd">15900000</us-gaap:RestructuringReserveAccrualAdjustment>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2014Q4" decimals="-5" id="Fact-90AD4451148ECDEECE3B38A291306E4B" unitRef="usd">9283900000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2015Q4" decimals="-5" id="Fact-6EB8C061477C3E3B1F7238A29131361B" unitRef="usd">12208400000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:Revenues contextRef="FD2013Q4YTD" decimals="-5" id="Fact-C4E4C1B7563F31B0E9FC38A291317F71" unitRef="usd">6932200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2014Q1QTD" decimals="-5" id="Fact-9DDBF36505F5C8C9BB6338A2914144B9" unitRef="usd">2129800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2014Q2QTD" decimals="-5" id="Fact-0B8DCF3D9E4726B07CBB38A2913A70E5" unitRef="usd">2421500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2014Q3QTD" decimals="-5" id="Fact-6933233FACDBC24B628838A2913F3BB1" unitRef="usd">2511400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2014Q4QTD" decimals="-5" id="Fact-2BF4F3D728E0A139A25A38A2911B6421" unitRef="usd">2640700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2014Q4YTD" decimals="-5" id="Fact-E53F2A0CE0F551284E9A38A291416E16" unitRef="usd">9703300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q1QTD" decimals="-5" id="Fact-18BB5109F004E191483838A2912EB014" unitRef="usd">2555000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q2QTD" decimals="-5" id="Fact-E5F8C14E19C8E49FE0EE38A2911BE172" unitRef="usd">2591600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q3QTD" decimals="-5" id="Fact-84BC42DAD862B1999B0338A291305B78" unitRef="usd">2777900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q4QTD" decimals="-5" id="Fact-AD1D609F64731F364C2038A2913500CA" unitRef="usd">2839300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q4YTD" decimals="-5" id="Fact-F64521ECA8D7078EA80538A2912F7772" unitRef="usd">10763800000</us-gaap:Revenues>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD" decimals="-5" id="Fact-88044D3F16D992AB801E38A2912F8472" unitRef="usd">5542300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember" decimals="-5" id="Fact-C89870801F56DA7DF27938A291373175" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-623C2C0785F17A3910A138A29136624F" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-8AFB96BCBF60C5049DD938A2913654D3" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember" decimals="-5" id="Fact-6223FEAB57D8EF2773C593BE3D2D1BA9" unitRef="usd">3005500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-EAAAFC947CA8EA94953093BE3D307F20" unitRef="usd">1103100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-13E20E57088EBC7B531D93BE3D2A156E" unitRef="usd">1902400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember" decimals="-5" id="Fact-9B7234AFE5DD42217E1E38A291382921" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-20AEF238617AF82BCFCA38A29136EEE7" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-49B2F55FD527C3BB6B7F38A29136C31E" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember" decimals="-5" id="Fact-D5A5E72E5E17086002F738A29136AAC9" unitRef="usd">74000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-1FB189A036C4E8634C2C38A29136233A" unitRef="usd">74000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-7F52D398AB0742DAE16138A2913712A8" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember" decimals="-5" id="Fact-AAF4AE9AF79F6321999938A29136F705" unitRef="usd">60200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-B8D6082D855FA5C99E6138A29136888F" unitRef="usd">60200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-92CAF083620DF7F22C0D38A291377617" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember" decimals="-5" id="Fact-218ADBFD668724A27EA593C243D6769C" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-43F62987247EF662500193C1821CCAA1" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-880FF18522F4D2004A4493C0E389B13B" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-FD747C7C29F5E134B54638A29133746A" unitRef="usd">38700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-54480DF06B8A3F42494338A291379391" unitRef="usd">876100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-4C1F81D39D7CE4A7F7F338A29136EF3E" unitRef="usd">11700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-586AC31E663F606A529238A29139851E" unitRef="usd">864400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember" decimals="-5" id="Fact-12F5C0CCD4FFE106F50F38A29136FEC8" unitRef="usd">1526500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-ABE38E950115916DCC4938A291356EF9" unitRef="usd">712300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-C8428E9BE82E2E9DC24B38A2913716B5" unitRef="usd">814200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-5249787EBC1DF5DA6CF738A2912F99C7" unitRef="usd">13200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-9E8BA46E3D6B6F00D3AF38A29136E1B4" unitRef="usd">1961300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-2DF3100E9CC7370CA9CE38A29138885E" unitRef="usd">3581000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-64CC1F68C880346A268F38A2913281C0" unitRef="usd">280200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-853CC503C11F4291FF4F38A2912E9ABC" unitRef="usd">417700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-B9BC685C8358AF23A0E938A2912DE7D2" unitRef="usd">3581000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-D2F2B98B8226A8C0DC2738A2912E9612" unitRef="usd">93200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-2353CAF4AEB5F72553BA38A2912F7688" unitRef="usd">1170200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2013Q4YTD_us-gaap_TypeOfArrangementAxis_biib_GenentechMember" decimals="-5" id="Fact-76B64C58A9CEBC45786038A2911E2386" unitRef="usd">41200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q1QTD" decimals="-5" id="Fact-227C0106D861ACD9921D38A29119C61F" unitRef="usd">1742800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q2QTD" decimals="-5" id="Fact-819730C4FA7517C949A238A2913F8EA6" unitRef="usd">2056300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q2QTD_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-4479395673A23D5623A538A29132E145" unitRef="usd">53500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q3QTD" decimals="-5" id="Fact-CC771C77791DDAD5A9A238A2914180C9" unitRef="usd">2117300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4QTD" decimals="-5" id="Fact-302E804AEDF7A9EB72DD38A29140AA6E" unitRef="usd">2287000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD" decimals="-5" id="Fact-A0A116E0003A24F00D8438A2912E9620" unitRef="usd">8203400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember" decimals="-5" id="Fact-9E4415A747446088EE6B38A291382E36" unitRef="usd">76000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-B77EA8497CA377D18AA138A291371234" unitRef="usd">3900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-622F5685E68B6A5CABA038A29136AA18" unitRef="usd">72100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember" decimals="-5" id="Fact-4CDB9B2B5F4B257BA62E93BE3D340C6B" unitRef="usd">3013100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-076FA2F7AED27EDA7A9393BE3D2E6793" unitRef="usd">1056400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-A8E6F2C327298C173A1C93BE3D354A1E" unitRef="usd">1956700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember" decimals="-5" id="Fact-561551EC7F77C9D6E9BC38A29136805D" unitRef="usd">58400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-1B6CB3A0AE96764DA92E38A291379A1D" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-BABB81CE78CFD0E9E7A738A29137AE77" unitRef="usd">58400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember" decimals="-5" id="Fact-1C24799484872CE187E438A291355905" unitRef="usd">80200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-FF148E775918D8C6002838A291367AEA" unitRef="usd">80200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-705C0D1AE2525C3B8A2A38A29137357E" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember" decimals="-5" id="Fact-1B71BDF50EA7AFA770B738A291360604" unitRef="usd">62500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-3815153E336E6A1CDE8438A29137926C" unitRef="usd">62500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-8AF09BF93D8B42B54D4E38A2913986A4" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember" decimals="-5" id="Fact-F7C65900121B9F717D5893C214CEC3B6" unitRef="usd">44500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-AEFD327DD854ABDFB8AB93C15D748ACC" unitRef="usd">16700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-458596CAFC39779C48A993C0BFC32880" unitRef="usd">27800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-59007241EE75271D016938A291334BFA" unitRef="usd">78300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-D6F950B3103E2A3B759738A29136C8F5" unitRef="usd">2909200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-0955096368A76A5D426B38A29136879E" unitRef="usd">482600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-A7858C0186AFB5D38CE438A29138F0AA" unitRef="usd">2426600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember" decimals="-5" id="Fact-4BD42A00643E1D02FA2038A29137652E" unitRef="usd">1959500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-B4496C7BF15792B4E37E38A2913868C4" unitRef="usd">934400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-15664F2FC06CFB218B5638A29139CB2E" unitRef="usd">1025100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-77C838AA05ECEC0CD0C838A291392D43" unitRef="usd">6800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-DC375876F6BFE918C2B138A291365F52" unitRef="usd">2636700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-B8526BE8CC51BD4A9D5D38A291365815" unitRef="usd">5566700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-D0326E20E6B5480109B938A2912F016B" unitRef="usd">328200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-AD4239C811F0BA9F5E9B38A2912D2062" unitRef="usd">811800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-836CD84FEF3F2F23C03A38A2912EC02D" unitRef="usd">5566700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-1D6125D7E2C81A620DE738A2912D168D" unitRef="usd">112800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-BF4CAACC373459A960A638A29132B896" unitRef="usd">1383900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q1QTD" decimals="-5" id="Fact-B8BCC9CC13063C415F1738A2912FCFCB" unitRef="usd">2172300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q2QTD" decimals="-5" id="Fact-A9369CB11A43779ABF6538A291383788" unitRef="usd">2198600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q3QTD" decimals="-5" id="Fact-D19C354C9E51320DE59E38A291320E38" unitRef="usd">2391700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4QTD" decimals="-5" id="Fact-616C7C9E03BC3A0A771238A2912EFF53" unitRef="usd">2425900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-AF66D3FE2CE0BBE1188B38A291304FB3" unitRef="usd">9188500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember" decimals="-5" id="Fact-6EED23E8085E71FD321038A29138E6C3" unitRef="usd">234500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-EEAE288813D1347D356738A29138D922" unitRef="usd">25600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXProductMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-82D9D6260066D4682CBB38A2913733D5" unitRef="usd">208900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember" decimals="-5" id="Fact-C49E345F048935A2D91B93BE3D3984E2" unitRef="usd">2630200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-EDAC1046DC2340F9F55393BE3D3247D2" unitRef="usd">840000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-7A20C3794A1FCE56D7B293BE3D374B79" unitRef="usd">1790200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember" decimals="-5" id="Fact-EE8071041362FB97055C38A29135D682" unitRef="usd">319700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-C577404D1A3DF70FD94338A29135F73F" unitRef="usd">11400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-18BE0AA4A8D00D7993E738A291353949" unitRef="usd">308300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember" decimals="-5" id="Fact-6774CF89756124B44F4538A29136662C" unitRef="usd">89700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-55B475861080FE47B51538A2913870A9" unitRef="usd">89700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-051506D6EEB3EBAFAFF538A291381432" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember" decimals="-5" id="Fact-6F250B62032F6AB31AFB38A29137A5F9" unitRef="usd">51400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-5E3E0AF367200862DECF38A291382E1B" unitRef="usd">51400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-8042CEE190EAFE9EFFD038A291365FDD" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember" decimals="-5" id="Fact-F8997A45A51F695477AB93C1B21BC31B" unitRef="usd">338500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-BBD6DB84512CC0BA5DF393C117396AE3" unitRef="usd">111400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_PLEGRIDYMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-BF179DFC66404626DB9693BDC7E73E66" unitRef="usd">227100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_RituxanMember_us-gaap_StatementGeographicalAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-F88A04815AA237B0890B38A291335EB2" unitRef="usd">69400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-7BF9BB723C7A669917E338A291371632" unitRef="usd">3638400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-EC3B7654067E075F899538A29136651F" unitRef="usd">730200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-F85EEB54D2E4A39593BB38A291362D02" unitRef="usd">2908200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember" decimals="-5" id="Fact-3E7657E55B826653BFD938A29137B191" unitRef="usd">1886100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-A09DB29708134188792638A29135145B" unitRef="usd">783000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_biib_TysabriMember_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-3EE62B526D529D53CE3738A291376B47" unitRef="usd">1103100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-A02751ACED7C78A37F1938A291308ABC" unitRef="usd">173200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementBusinessSegmentsAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-5F0EEAE8A2D60390A8F238A291362DA6" unitRef="usd">2642700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementBusinessSegmentsAxis_country_US" decimals="-5" id="Fact-D4458B16904F176DC68938A291351402" unitRef="usd">6545800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-67246CD7AB585060FD4E38A2912FC4A5" unitRef="usd">333300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_DE" decimals="-5" id="Fact-1163DD97BC4B2785401938A291326443" unitRef="usd">668100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-27AF2D781CAAE80DDA4138A2912DEAF6" unitRef="usd">6545800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_AsiaMember" decimals="-5" id="Fact-9D7DC2797AE11FFFEB4B38A2912E52DF" unitRef="usd">143700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q4YTD_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-5" id="Fact-C44A0781623878CED8CD38A2912F4A48" unitRef="usd">1497600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2013Q4YTD" decimals="-5" id="Fact-B26C9909896030CCC27A38A2913F3F75" unitRef="usd">1712100000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-B34D2A1D5C1C8EAA70CC38A2913123B2" unitRef="usd">2232300000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-24B649349E5D8499915338A29142CACA" unitRef="usd">2113100000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2013Q4YTD" decimals="-5" id="Fact-ECFC19E3033B659D775138A291399FDD" unitRef="usd">136300000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2014Q4YTD" decimals="-5" id="Fact-A4233B50E2B471D16B3038A29142C411" unitRef="usd">155300000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-5" id="Fact-13E5BF9E84DBE9B7043638A291397755" unitRef="usd">161400000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-D5AA78D8C91CEFD4829A38A29130408F" unitRef="shares">36000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-EBA19242972582604F0938A2912F07F8" unitRef="shares">42000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-DA8794BD21D0DA128F3638A29130EDEB" unitRef="shares">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-4759D3632D75DEFEE16F38A2913DF038" unitRef="shares">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-DEA462F0344647DE4E8D38A2912F2E5D" unitRef="usdPerShare">294.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-36041031D2A5B4AEC04638A2913156F7" unitRef="usdPerShare">302.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_AttainmentOfPerformanceCriteriain2011Member_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-22BB62EB3BBFDA1ED52F98BD2C380C26" unitRef="shares">34000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_AttainmentOfPerformanceCriteriain2012Member_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-FF26E9737114775FDCA698BC0DE150AB" unitRef="shares">24000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_AttainmentOfPerformanceCriteriain2013Member_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-28F9E49D98045AB0432198B8D5F2DCC8" unitRef="shares">19000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_AttainmentOfPerformanceCriteriain2014Member_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="0" id="Fact-3865CA8147F6E33CE2B498BF5C0BD813" unitRef="shares">48000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_AttainmentOfPerformanceCriteriain2014Member_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-4F4289884853C522F17B98B537B7D401" unitRef="shares">8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q4YTD_biib_ShareBasedCompensationPlanAxis_biib_AttainmentOfPerformanceCriteriain2014Member_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="0" id="Fact-7C9E5EFFA0C7386F44BC98C66E67255B" unitRef="shares">42000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-8C24D273E3021AA7BE1838A2912F421B" unitRef="shares">115000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-24E033551F39C18EB70838A291303583" unitRef="shares">185000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-F83B25C507A520C53C6638A29131EC9D" unitRef="shares">459000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember_us-gaap_TitleOfIndividualAxis_us-gaap_DirectorMember" decimals="INF" id="Fact-DC7F0E124CF3ECF81CE698CED754BFF3" unitRef="shares">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-16C0BB3AD2DC25F79D0538A2913DF7D3" unitRef="shares">89000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-0D049BC5098E8E681BDE38A2913DC5F7" unitRef="usdPerShare">193.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-6375AE1748C03E6EB6D538A2913926D2" unitRef="usdPerShare">176.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-870AFA9636F4986FBBE238A2913C7F76" unitRef="usdPerShare">395.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-4EA8D4D2A33C68CD6A5B38A29139C8D5" unitRef="usdPerShare">321.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-5B0C2393AC0BBE84B1F038A2913DD9A6" unitRef="usdPerShare">493.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-2342104CD4C8D09B0FF038A291306DFA" unitRef="usdPerShare">388.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2014Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-15D894659E64E292A75838A29130B779" unitRef="shares">335000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2014Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-0F9E4FFE98B44A41D3BE38A291309554" unitRef="shares">403000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2014Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-3D0643A5EC683E741E6338A29130F54F" unitRef="shares">1137000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2014Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-4103BEE0B75316B6E1B438A2913CE3B0" unitRef="shares">57000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2015Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-B01EEFB4C9F7C86E9CC438A291309408" unitRef="shares">192000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2015Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-4D9BFACE4424D6CCD81E38A2913169EF" unitRef="shares">269000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2015Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-618342C4D43584646C2038A291307D0C" unitRef="shares">810000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-19AF0A65DDAA22DE194D38A2913CEC08" unitRef="shares">103000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2014Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-F7179A079781CF5471A638A2912F2627" unitRef="usdPerShare">219.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2014Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-F8EE673BD1DE6C291E7C38A29130161F" unitRef="usdPerShare">221.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2015Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-A6416230B3681706451938A2912F3051" unitRef="usdPerShare">339.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2015Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-7C6023EF1FDE59802E8B38A29130DDBD" unitRef="usdPerShare">323.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-D996274A9128B28FCF3438A2912FE73B" unitRef="shares">222000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-37CB1EFED170388514A438A29132FE22" unitRef="shares">277000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-32C547DDB944AF94E81A38A291316E94" unitRef="shares">626000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-D5E3D0FB0E27B02E35F838A2913C44D0" unitRef="shares">33000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-E6A5CF30CB7750D4265238A2913CA945" unitRef="usd">50900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-4F8390A9781708BD3BB138A2912DBC47" unitRef="usd">209700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-E3299D14338712B204BA38A2913CF81C" unitRef="usd">117400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-030F6E49ED494680C2B538A2913F3AD4" unitRef="usd">281100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-D5A7887F4211D07B7A2938A2913E3A77" unitRef="usd">109000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-27238D8B875001AD839238A2913E2A8B" unitRef="usd">239700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-857DFDFB366F0738B40938A2912FEE34" unitRef="usdPerShare">165.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-6E511559ED71CBE309D138A291312A98" unitRef="usdPerShare">190.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-136DD5C19C61F8FD63B038A2913C415D" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-6718EDDB40F60977DDFA38A2913CC3B2" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-1F548B73366D777C569C38A2913CC515" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-1D56AC7148BAC7FB086638A2912FE56D" unitRef="number">0.257</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-05C3F2194DB3D974450438A29130AB8B" unitRef="number">0.217</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-50DBD77450878218F3AD38A291307E51" unitRef="number">0.351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-1F498B964D95092BD88838A2912FDBAB" unitRef="number">0.317</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-DE9212619F9DF96F618738A291307C8D" unitRef="number">0.332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-01478A32F96DA832493538A29130AED1" unitRef="number">0.310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-F2CE2C859E540A966BE438A29130BFB3" unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-65F4E540C190E131C0CF38A2912F90DD" unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-9B6CEC5BA2A025118DFC38A2912FF75F" unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-3F5C805DF982CBBCFC9E38A29130A9D8" unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-7BDCBEFD6724E161E78C38A291308F13" unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-FDCAF78F8DBB7B5F603038A29130E53F" unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2013Q4" decimals="INF" id="Fact-21DA787F9FED1806C24738A2913D8746" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2014Q4" decimals="INF" id="Fact-EADF23A9E9AFC23BB59F38A2913D63C2" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2015Q4" decimals="INF" id="Fact-40A7CC89892B69907A6438A2913C7687" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2013Q4YTD" decimals="-5" id="Fact-467880BE1F6620C8726738A291326506" unitRef="usd">86200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2014Q4YTD" decimals="-5" id="Fact-9CCAC6AD52DCECA14B5238A2913FDA10" unitRef="usd">42700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2015Q4YTD" decimals="-5" id="Fact-34F990BC96AA605AA6F138A2912ED7C2" unitRef="usd">38000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2015Q4YTD" decimals="INF" id="Fact-EA5B791A20AD67AB893338A29132604F" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2015Q4YTD" decimals="INF" id="Fact-84478BA8E03F4B2B483D38A29132780B" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2015Q4" decimals="-5" id="Fact-0FD29F92D835F7B4A99638A2913EED42" unitRef="usd">27000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2014Q4" decimals="INF" id="Fact-19F280F5C9C30CCFAB5438A29132E5CF" unitRef="shares">221000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4" decimals="INF" id="Fact-5909396B2EEA793F617838A291324739" unitRef="shares">107000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2014Q4" decimals="2" id="Fact-39D643B4131A1EA20EE938A291322744" unitRef="usdPerShare">56.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4" decimals="2" id="Fact-DD316078E149408E81C838A2913250F7" unitRef="usdPerShare">53.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD" decimals="2" id="Fact-824AF0A56502540A335438A291320ED4" unitRef="usdPerShare">59.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD" decimals="2" id="Fact-992C4AB8E54FD08F59D038A291323D40" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD" decimals="2" id="Fact-FD78B55434A24F4B717D38A29132DA96" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2015Q4YTD" id="Fact-A56465344426ABEE5DD138A2913A22DD">P3Y2M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharesIssued contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-6B60CD6219B33BD6783338A291364DB7" unitRef="shares">254200000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-49CC418E7EC1C4D00E1838A29137448C" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-4D22CA544CB8B4D7315F38A29136314C" unitRef="shares">17700000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-745C04D34F3988438BC438A29135CCF1" unitRef="shares">256000000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-EF42638069FA5CC677A238A2913597BD" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-B3E0F3D8AB440AD4ACA138A29135777E" unitRef="shares">19700000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-53ABAE6D1136270991D338A29127B366" unitRef="shares">257100000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-FF1D1108FD06691F745E38A2912B9D64" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-E17FB60987955F3838A138A291236385" unitRef="shares">22600000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-8FB665A8E49B498EE3E338A2912BCD91" unitRef="shares">241200000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-8BE3FF374672BD50F35438A29128B69E" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-9C1FB940D9A75D90985A38A2912A55A3" unitRef="shares">22600000</us-gaap:SharesIssued>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="INF" id="Fact-BB0ADD8FAA6901995C6738A2913F6698" unitRef="shares">245000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="INF" id="Fact-35A4BFEDEC7C7F9FE70338A2913E54A3" unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2015Q4YTD" decimals="-5" id="Fact-396A94225C203253EFAB38A2912DE3A9" unitRef="shares">6200000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="INF" id="Fact-21F2DA7A5E0005FDA88738A2913E4DA3" unitRef="shares">98000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="INF" id="Fact-86453070E6A7145D62ED38A2913EA3F7" unitRef="shares">78000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-D86C5B6EF45A842D6F1F38A291375CAD" unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-A1C4AD55C8A2720F11BB38A2913AD1E9" unitRef="shares">800000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD" decimals="INF" id="Fact-0925296C053AB524EEB638A29133A3B7" unitRef="shares">114000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-DF7B38D8B335D71A8A7938A2913F2164" unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-8A0EDC3575761AA10FE538A291372CD7" unitRef="shares">800000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-69FC5BDEAB8F3643433D38A2913AB883" unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-355066DAA4B803BD727F38A2913F299F" unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="-5" id="Fact-6FFFB80EFFBDB710641938A2913E4534" unitRef="usd">38700000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="-5" id="Fact-D38D27D9AA1FB2C2AE7238A2913EBEFF" unitRef="usd">46400000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="-5" id="Fact-D3813BD9CD916F85F36C38A2913EFA5A" unitRef="usd">30000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="-5" id="Fact-46203705F4E5C0D2953A38A2913E3D29" unitRef="usd">19300000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2013Q4YTD" decimals="-5" id="Fact-FFC31B8A5989C42424B038A2913687CF" unitRef="usd">89700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-F3EA90397C98DC7FFEA338A29135ADD4" unitRef="usd">89700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-6B1910C332DE1369C0C638A29138C6C8" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-1715CF0A369E52D8ACAC38A2913510AE" unitRef="usd">89700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2014Q4YTD" decimals="-5" id="Fact-7AD620260F3596860FC538A2913B94B1" unitRef="usd">140300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-F8F52752C32E828E9CA238A2913B156E" unitRef="usd">140300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-7C64A935072CF76AEA8938A29121E8A4" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-3C00F76E6DBB67F964E638A2913BE2CC" unitRef="usd">140300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD" decimals="-5" id="Fact-EB763548BAB7F42352B138A29129206D" unitRef="usd">125100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-B054A7915B26BF5BA69738A291388772" unitRef="usd">125100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-3712A69B1B5AADC44B7738A291378947" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-242A52C36F184B53F34838A291427BDB" unitRef="usd">125100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2013Q4YTD" decimals="-5" id="Fact-AD8F99C12E15A6FB44D038A29137DC80" unitRef="usd">66700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-FCD58FCDF375B13C59CE38A2913FCEBA" unitRef="usd">66700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-EAFE942D68EEBE309EA138A2913628D2" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-BD38AEB5E1414524198A38A291350142" unitRef="usd">66700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2014Q4YTD" decimals="-5" id="Fact-C923C2E62EBEA9AD09C738A2913B9861" unitRef="usd">54900000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-0C0C079D8B936960366C38A2913AB087" unitRef="usd">54900000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-2EF2996DFD7544CD85CF38A2913B5B50" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-7B4389A052D4F092258F38A2913AD9A8" unitRef="usd">54900000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2015Q4YTD" decimals="-5" id="Fact-A8B4012F6B20999C46FB38A291412AD1" unitRef="usd">54200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-E4DF8183035C0202A7F938A2912806C5" unitRef="usd">54200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-E7B646FAAF870447452438A291297A77" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-B28D8EB863FC72642EB538A2913F5AC5" unitRef="usd">54200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="FI2015Q2" decimals="-8" id="Fact-2A931D94C76282A624A838A2913ED2E1" unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
	<us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased contextRef="FI2011Q1" decimals="-5" id="Fact-74E78E4111778F86997838A2913EF237" unitRef="shares">20000000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
	<us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased contextRef="FI2015Q4" decimals="-5" id="Fact-9E09E208223D6FE5D84738A2913E5481" unitRef="shares">1300000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-65A339B31F3BE1AE9B9438A291381E70" unitRef="shares">16800000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-B91CEA40EEC9A3BEB1E038A291388212" unitRef="shares">16800000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4" decimals="-5" id="Fact-7640DD5FB411ACBA3EBF38A291255556" unitRef="usd">10809000000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4" decimals="-5" id="Fact-1725B590F8ACB3E8DF9F38A29131934B" unitRef="usd">9372800000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2012Q4" decimals="-5" id="Fact-2493ED87346C26AAD35838A2913634E4" unitRef="usd">6963800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-24C9E17319A7B7C9103E38A291368F61" unitRef="usd">-55300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-525B64698E6B558CA9AF38A291356DEB" unitRef="usd">3854500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-DFF0F5615EA5043B915D38A29127FD34" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-C8145D0BEA7F160DFD3F38A291225065" unitRef="usd">2300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-A84497A8B24E547185F838A29136C030" unitRef="usd">6961500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-0FC17FC7F6A9E7C708B538A2913F1A9E" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-9C9368EAD28105B19C9B38A29136ED42" unitRef="usd">4486800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-BB30FFA389C3AAC6211D38A29136E6B3" unitRef="usd">1324600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4" decimals="-5" id="Fact-AB26535416CA13231E6038A291350084" unitRef="usd">8620800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-7C32B81D4C3724F5121A38A29137441E" unitRef="usd">27700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-BE617EE6CF28C146BA2C38A29135D871" unitRef="usd">4023600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-FC22A83379497A483D4138A291361EC9" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-8177167C24944CEB10E038A29137770B" unitRef="usd">600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-D214512ABCAD0560A10038A2913BA734" unitRef="usd">8620200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-3A5B9D79EE393D7856B338A29136EC21" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-6D6BBA88D23DA4699A4338A2913513BA" unitRef="usd">6349100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-24E7860820F24443DB9238A2913731C3" unitRef="usd">1724900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4" decimals="-5" id="Fact-47268B446204FDCA69A838A29125CB3B" unitRef="usd">10814000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-B5156408D1A1E7B5641238A291376060" unitRef="usd">59500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-6201631BC5B4BFC864DA38A291224311" unitRef="usd">4196200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-52C81F7C3ADF03DED02638A2913D7826" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-00801CA87D4C445C932938A29135097E" unitRef="usd">5000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-BCCD8D930F5FEBEE189C38A2912A98F5" unitRef="usd">10809000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-A04211EB48B6B7FB202238A29135C856" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-9C484D426B5440B2102538A2912B46A7" unitRef="usd">9283900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-84DDA55E8C261A7F488138A2912A5D8C" unitRef="usd">2611700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4" decimals="-5" id="Fact-97F1CFCBB77AF5D6C96738A2912F1B87" unitRef="usd">9374900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-85AE6A4CEDBAB8C72CFD38A2912A8BB5" unitRef="usd">224000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-1D75A6B14A4AE8554B5738A29123488E" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-4F1A2EEA1AE8C0061B4738A29137DE53" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-567EB2EA3374DADC334E38A2912BCBA6" unitRef="usd">2100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-FD0E6BDEA853A5C7691738A2912B651A" unitRef="usd">9372800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-F683015720906981558338A291386E14" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-285CA7595DB56CABBAF538A291286A34" unitRef="usd">12208400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-5F6DD3EDE617C642882F38A29125A2B7" unitRef="usd">2611700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" decimals="-5" id="Fact-D469C387478DE0B3C32238A29131E72D" unitRef="usd">127600000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-BBA784C4BFDF7883CAF438A291312598" unitRef="usd">125500000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxesPayableCurrent contextRef="FI2014Q4" decimals="-5" id="Fact-38AE7F1CA961307DFB0838A291313C63" unitRef="usd">168100000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TaxesPayableCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-1B6EF5856208F5AFEE2038A291243960" unitRef="usd">208700000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2015Q4YTD" decimals="-5" id="Fact-080120CD84352DC7EF0C38A2913545EB" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-7E86AFED9B096174B3E238A291233BF1" unitRef="usd">4377500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-2C85841E77ED311D8D8838A2913C0990" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-E1BE5DE9F947B5C9D31938A29128F978" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-2ECCFC7771E7B6648CA165D13B98AD01" unitRef="usd">622500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-57222E1C2542D9F6CD4F38A29128F971" unitRef="usd">5000000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockShares contextRef="FI2014Q4" decimals="-5" id="Fact-1A2B646FF8CADA4FD30E38A291402424" unitRef="shares">22600000</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockShares contextRef="FI2015Q4" decimals="-5" id="Fact-50E86B55D1DE4CA9F15D38A29140DC13" unitRef="shares">22600000</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-F03FE2CA2CA3E139C52238A2913612AB" unitRef="shares">2000000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2014Q4YTD" decimals="-5" id="Fact-659D4FC61839A00C71E238A2913E80D1" unitRef="shares">2900000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-EAA5DAF35CA0C47CB78F38A2913B4324" unitRef="shares">2900000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2015Q4YTD" decimals="-5" id="Fact-5DC060C8D2C8709D344638A2913EEF30" unitRef="shares">16800000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-4EB579483189F39271C638A2913D1E78" unitRef="shares">16800000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockValue contextRef="FI2014Q4" decimals="-5" id="Fact-55DBBE765F856A61148D38A2912FA7D6" unitRef="usd">2611700000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="FI2015Q4" decimals="-5" id="Fact-FC7394539F077E52248E38A291312CD7" unitRef="usd">2611700000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2013Q4YTD" decimals="-5" id="Fact-3FED099BB59E4491698B38A2913694ED" unitRef="usd">400300000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-F1A6AA34835A2F190B6738A291377A09" unitRef="usd">400300000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-EF31DA30555D34A30E5E38A291362DAB" unitRef="usd">400300000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2014Q4YTD" decimals="-5" id="Fact-F67010BDD670DD3B1FE838A2913BBD34" unitRef="usd">886800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-5421CAEF5CD673B6C82838A29122AF05" unitRef="usd">886800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-6A46EB922A4D47149A4638A2913B48E9" unitRef="usd">886800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2015Q4YTD" decimals="-5" id="Fact-CD58402F99847A97365D38A2912CC4D1" unitRef="usd">5000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentCompanyMember" decimals="-5" id="Fact-A19A9163D63249BCEDC038A291367187" unitRef="usd">5000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-65336E792F62D5B5374138A291358B65" unitRef="usd">5000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:UndistributedEarningsOfForeignSubsidiaries contextRef="FI2015Q4" decimals="-8" id="Fact-96BE7FC20EE47746E73138A2913E945A" unitRef="usd">6000000000</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
	<us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax contextRef="FD2013Q4YTD" decimals="-5" id="Fact-F68684EFEF18DC37D75338A291261610" unitRef="usd">23600000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
	<us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax contextRef="FD2014Q4YTD" decimals="-5" id="Fact-0D07A6E49283FEA1899D38A2912921D6" unitRef="usd">-72100000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
	<us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax contextRef="FD2015Q4YTD" decimals="-5" id="Fact-82616710D2836D72072A38A29128F1CE" unitRef="usd">1800000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2012Q4" decimals="-5" id="Fact-24F71B058F5CCF99C4A638A2913D79B0" unitRef="usd">125900000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2013Q4" decimals="-5" id="Fact-04448AD5C60E0CEE4F9A38A2913D2352" unitRef="usd">110100000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2014Q4" decimals="-5" id="Fact-3D7EF55ACEEDE9AC092738A2913D9F17" unitRef="usd">131500000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2015Q4" decimals="-5" id="Fact-2FE2E99C485F63B41AE038A2913DF2D7" unitRef="usd">67900000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2015Q4YTD" decimals="-5" id="Fact-B36F7C08491BB9000AEE38A291349FA6" unitRef="usd">25000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2013Q4YTD" decimals="-5" id="Fact-3AC05F70193F1079284E38A2913DBE4D" unitRef="usd">92100000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2014Q4YTD" decimals="-5" id="Fact-E10143C75953C5940CD038A2913DB116" unitRef="usd">23400000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2015Q4YTD" decimals="-5" id="Fact-E6D5380E7E5BC8B5B43538A2913DC29D" unitRef="usd">49900000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="FD2013Q4YTD" decimals="-5" id="Fact-1F9FE9FC560E094B573838A2913C0250" unitRef="usd">5400000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="FD2014Q4YTD" decimals="-5" id="Fact-A03BAE540FCE011164FF38A2913C8528" unitRef="usd">60500000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="FD2015Q4YTD" decimals="-5" id="Fact-92F2D6807E0BBA901E3938A2913D7F88" unitRef="usd">42500000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="FD2013Q4YTD" decimals="-5" id="Fact-58D4FD5D826F9150129938A29130FC5C" unitRef="usd">4500000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="FD2014Q4YTD" decimals="-5" id="Fact-5837CCE6279C70360B8638A2913362B0" unitRef="usd">4100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="FD2015Q4YTD" decimals="-5" id="Fact-EFA7D8D9A294845DC15E38A29134E6B0" unitRef="usd">3100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2013Q4YTD" decimals="-5" id="Fact-6AA62458C95612C3A05F38A2913D5D26" unitRef="usd">11900000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2014Q4YTD" decimals="-5" id="Fact-BD6B78A00701E301710938A2913C366B" unitRef="usd">20800000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D21F9BD5D2FD5DC161AD38A2913D9343" unitRef="usd">10500000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2013Q4YTD" decimals="-5" id="Fact-C7336EC4C439C0FC77BE38A2913C4C11" unitRef="usd">71700000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2014Q4YTD" decimals="-5" id="Fact-540EA18A35D002CFDE6838A2913DC08B" unitRef="usd">86100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2015Q4YTD" decimals="-5" id="Fact-39865F56127314F796FF38A2913D0C2C" unitRef="usd">19500000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued contextRef="FI2014Q4" decimals="-5" id="Fact-3CABD53DFB8049BD968238A29133612C" unitRef="usd">17600000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
	<us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued contextRef="FI2015Q4" decimals="-5" id="Fact-D77B27B7E16251510DB338A29131C952" unitRef="usd">12500000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="FD2013Q4YTD" decimals="-5" id="Fact-C3D1D780BB7E8AD3523438A2913C0FE6" unitRef="usd">1900000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="FD2014Q4YTD" decimals="-5" id="Fact-95520A15DCE10F8150D738A2913D0516" unitRef="usd">1600000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="FD2015Q4YTD" decimals="-5" id="Fact-751B3E2187A12EE684F338A2913D8CA1" unitRef="usd">1200000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2013Q4" decimals="-5" id="Fact-AD023F616553CB47EE6438A2913E20BB" unitRef="usd">32500000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2014Q4" decimals="-5" id="Fact-BE086CDC9F868B96CBE238A291341FE0" unitRef="usd">53600000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2015Q4" decimals="-5" id="Fact-BFD5A8EC4F878DE0B38A38A291342314" unitRef="usd">15700000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2012Q4" decimals="-5" id="Fact-5E8CD443BABD37764B8A38A29124C7CB" unitRef="usd">237100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2012Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-6DCD653E99E01662C7B738A2913F7EF7" unitRef="usd">196000000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2012Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-EC6563D89DE0DB05B7A938A291382E10" unitRef="usd">14300000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2012Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-FCBCBB48D6DAA30E75F838A29125DFE5" unitRef="usd">26800000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2013Q4" decimals="-5" id="Fact-9476DF75EE12F501D87E38A2912C72CB" unitRef="usd">426200000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2013Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-F2407BA9C1C2A3989C2538A2913E5774" unitRef="usd">345500000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2013Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-C7EFE2FC77C5EC4B973D38A291221FD5" unitRef="usd">47000000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2013Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-2ADEAF6B1DF9F8302BA338A2912CF92A" unitRef="usd">33700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4" decimals="-5" id="Fact-15F65904B391F3F1396438A29132E73B" unitRef="usd">483800000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-FB7DD2523AB5361AC2D338A291245FE1" unitRef="usd">124600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-24B008D1354682FF2D7D38A2912470AC" unitRef="usd">359200000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-4DD0D78C166ED5F3909C38A291234811" unitRef="usd">387100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-C228D28CEA2FE06E6F5338A291249F30" unitRef="usd">47600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2014Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-AF4132C073A599BEB65338A29125B7FB" unitRef="usd">49100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4" decimals="-5" id="Fact-B11439635F932C8B9FD738A2912A9527" unitRef="usd">662700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-E4F9CB5790A22B09B2F138A291243662" unitRef="usd">144600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-0596189BE511CFEBC7A238A29125A46C" unitRef="usd">518100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-F88E355ABE5344410B2638A291404B9B" unitRef="usd">548700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-56728057EAD3CC51722538A29125A4D6" unitRef="usd">56100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-5A7E91D2F1BA3B4150C338A2912329FD" unitRef="usd">57900000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2013Q4YTD" decimals="-5" id="Fact-70BF9725A7A1978A170138A2913B2488" unitRef="shares">1400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2014Q4YTD" decimals="-5" id="Fact-30C82027EB6FE365814138A2913BDB12" unitRef="shares">800000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2015Q4YTD" decimals="-5" id="Fact-EBCBEC1FA469342BB9CC38A291311FA6" unitRef="shares">500000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2013Q4YTD" decimals="-5" id="Fact-6906C72D3E8CAEC88A8C38A29140E9D4" unitRef="shares">238300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2014Q1QTD" decimals="-5" id="Fact-F038CFA0F7661763573F93CAF0DFBD67" unitRef="shares">237800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2014Q2QTD" decimals="-5" id="Fact-A22C77673F58183EEE2993CB09D01836" unitRef="shares">237400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2014Q3QTD" decimals="-5" id="Fact-2DC3C9D7B3FC568EA68193CB18B62CBE" unitRef="shares">237000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2014Q4QTD" decimals="-5" id="Fact-E042F8FF7BC9341C7B6093CB26DBA24F" unitRef="shares">236300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2014Q4YTD" decimals="-5" id="Fact-7C573C69C461C8C85C2B38A291318D35" unitRef="shares">237200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q1QTD" decimals="-5" id="Fact-FF9DEBA6CDA3D9ED23DA93C5E22BCA00" unitRef="shares">235600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q2QTD" decimals="-5" id="Fact-942D6C5BA334F8B0A3A993CAB5ADFDF6" unitRef="shares">235700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q3QTD" decimals="-5" id="Fact-BB873D6811BB33792DEF93CAC3AB28E2" unitRef="shares">232600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q4QTD" decimals="-5" id="Fact-4A54E73D389C4E58380393CAD1FA6898" unitRef="shares">220800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q4YTD" decimals="-5" id="Fact-6F5C660BBA7B7C1F009438A29142B81D" unitRef="shares">231200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="FD2013Q4YTD" decimals="-5" id="Fact-15C4A49CA35AA0260E1A38A2913C136A" unitRef="shares">900000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
	<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="FD2014Q4YTD" decimals="-5" id="Fact-FB6C5CBE5B1E1F1B579438A2913C2F74" unitRef="shares">1000000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
	<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="FD2015Q4YTD" decimals="-5" id="Fact-AC2B4B04BC8972E2B5D638A2913DC008" unitRef="shares">4600000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2013Q4YTD" decimals="-5" id="Fact-FFF5A75B0E4E09C3079F38A291407CD6" unitRef="shares">236900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2014Q1QTD" decimals="-5" id="Fact-F19936FCE27936609BF593C7E72A176D" unitRef="shares">236800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2014Q2QTD" decimals="-5" id="Fact-4B27362C4800D9089E0F93C7FDF21161" unitRef="shares">236700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2014Q3QTD" decimals="-5" id="Fact-9481E7663243B40FC95C93C812E71E15" unitRef="shares">236200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2014Q4QTD" decimals="-5" id="Fact-93860A26AF91ABC5DBFB93C82CFFB5F7" unitRef="shares">235500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2014Q4YTD" decimals="-5" id="Fact-AE1EFC9B443287C7086238A2913FD93A" unitRef="shares">236400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q1QTD" decimals="-5" id="Fact-9302F73EA435BA94525593C4F520C367" unitRef="shares">235000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q2QTD" decimals="-5" id="Fact-C119659A1556B6F7237393C795CA7956" unitRef="shares">235300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q3QTD" decimals="-5" id="Fact-B7069A7A24B15E3270F693C7A41E3ED8" unitRef="shares">232200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q4QTD" decimals="-5" id="Fact-B38448C72474F9DD719393C7BD7CCF79" unitRef="shares">220400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q4YTD" decimals="-5" id="Fact-2D6434FB06773CFBD25538A291307DA4" unitRef="shares">230700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock contextRef="FD2015Q4YTD" id="Fact-A7ED10D555BE4F6DC89638A2912CEC76">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;387.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;49.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;483.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;459.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,732.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(16.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(32.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(405.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,258.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,666.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(44.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(296.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(351.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;56.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;548.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;57.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;345.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;426.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;347.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,265.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,651.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(299.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(933.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,237.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(46.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(261.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(33.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(341.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;387.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;483.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;196.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;237.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;861.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,120.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(189.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(560.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(750.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(13.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(135.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(17.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(165.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;345.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;426.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
	<biib:AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock contextRef="FD2015Q4YTD" id="Fact-0C7E557B62E7D052B70138A291391C90">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="44%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="18%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="18%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="18%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of expected stock price volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;31.0% - 33.2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.7% - 35.1%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.7% - 25.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of risk-free interest rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2% - 1.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1% - 0.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1% - 0.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 calendar day average stock price on grant date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$277.35 - $426.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$280.88 - $335.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;60 calendar day average stock price on grant date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.33 - $240.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average per share grant date fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$493.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$395.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$193.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock>
	<biib:BusinessOverviewPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-04EA050FDF2ED4D9BEC138A2913C52F4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. We also have a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, which entitles us to certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL, and other potential anti-CD20 therapies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to our innovative drug development efforts, we aim to leverage our manufacturing capabilities and scientific expertise to extend our mission to improve the lives of patients living with serious diseases through the development, manufacture and marketing of biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
	<biib:CoPromotionProfitSharingFormulaTableTextBlock contextRef="FD2015Q4YTD" id="Fact-9277D41FE75B40192A6338A29135DA75">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="82%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="17%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until GAZYVA First Non-CLL FDA Approval&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First Non-CLL GAZYVA FDA Approval&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the FDA&amp;#8217;s first approval of GAZYVA in an indication other than CLL.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First GAZYVA Threshold Date&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the earlier of (1)&amp;#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12 month period were at least &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; or (2)&amp;#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12 month period have reached &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;Second GAZYVA Threshold Date&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12 month period have reached &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$500.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:CoPromotionProfitSharingFormulaTableTextBlock>
	<biib:IntangibleAssetsExcludingGoodwillTableTextBlock contextRef="FD2015Q4YTD" id="Fact-930E12752ABB1DC5B1CE38A29127F0FC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="21%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="17%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(481.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2,552.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;452.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,396.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;608.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;730.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;730.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks and tradenames&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6-18 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,303.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(502.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,800.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,280.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(300.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,980.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7,646.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3,561.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,085.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,207.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3,178.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,028.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
	<biib:PerformanceunitsactivityTableTextBlock contextRef="FD2015Q4YTD" id="Fact-A12C374A3630E8B8E49B38A2913D727A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="82%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="17%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;57,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;89,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(33,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;103,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:PerformanceunitsactivityTableTextBlock>
	<biib:PretaxProfitSharingFormulaTableTextBlock contextRef="FD2015Q4YTD" id="Fact-6F8AE69F9A5DF3BAC39338A29133C8B0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="82%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="17%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until First GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:PretaxProfitSharingFormulaTableTextBlock>
	<biib:PropertyplantandequipmentpurchasepriceallocationTableTextBlock contextRef="FD2015Q4YTD" id="Fact-99492FB12B9EF4DE32EB38A291285880">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;58.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;25.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;104.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:PropertyplantandequipmentpurchasepriceallocationTableTextBlock>
	<biib:ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock contextRef="FD2015Q4YTD" id="Fact-8722C871046CC333A65738A2911C1415">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="35%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="18%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="16%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rates post Sobi Opt-In&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(3)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Royalty and Net Revenue Share Rates:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Method&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rate prior to 1st&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;commercial sale in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;the&amp;#160;Sobi&amp;#160;Territory:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Base Rate following&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;1st&amp;#160;commercial&amp;#160;sale&amp;#160;in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;the Sobi Territory:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rate during the&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reimbursement&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Period:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Sobi rate to Biogen on net sales in the Sobi Territory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10&amp;#160;or&amp;#160;12%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base&amp;#160;Rate&lt;br clear="none"/&gt;plus 5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Biogen rate to Sobi on net sales in the Biogen North America Territory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10&amp;#160;or&amp;#160;12%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base Rate&lt;br clear="none"/&gt;less 5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Biogen rate to Sobi on net sales in the Biogen Direct Territory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15&amp;#160;or&amp;#160;17%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base Rate&lt;br clear="none"/&gt;less 5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Biogen rate to Sobi on net revenue&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;from the Biogen Distributor Territory&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Net&lt;br clear="none"/&gt;Revenue&lt;br clear="none"/&gt;Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base Rate&lt;br clear="none"/&gt;less 15%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;Net revenue represents Biogen&amp;#8217;s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock>
	<biib:RevenuesFromUnconsolidatedJointBusinessTableTextBlock contextRef="FD2015Q4YTD" id="Fact-1AA8D3E0DE268D57435838A2911B52BF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="53%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,269.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,117.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,087.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue on sales in the rest of world for RITUXAN&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;69.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;78.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total unconsolidated joint business revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,339.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,195.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,126.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:RevenuesFromUnconsolidatedJointBusinessTableTextBlock>
	<biib:RoyaltyCostofSalesPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-ECA9877853829F98D99B38A2913D537B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&amp;#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:RoyaltyCostofSalesPolicyTextBlock>
	<biib:ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock contextRef="FD2015Q4YTD" id="Fact-D8FF17CAAB8DD402D7B138A2913E3FCD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="82%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="17%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;335,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;115,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(222,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(36,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;192,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock>
	<biib:ScheduleOfMarketStockUnitsActivityTableTextBlock contextRef="FD2015Q4YTD" id="Fact-6A17B85EE01BC5B4AADB38A2912EA571">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;403,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;219.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;185,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;493.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(277,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;165.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(42,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;294.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;269,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;339.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ScheduleOfMarketStockUnitsActivityTableTextBlock>
	<biib:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock contextRef="FD2015Q4YTD" id="Fact-80101FE366BD26A6B70F38A29141E999">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="50%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="50%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Useful Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Not depreciated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15 to 40&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Leasehold Improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Lesser of the useful life or the term of the respective lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Furniture and Fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 7&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Machinery and Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 20&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Computer&amp;#160;Software&amp;#160;and&amp;#160;Hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3 to 5&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock>
	<biib:SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock contextRef="FD2015Q4YTD" id="Fact-4D9E15E5A2F76DC819A138A2913EEC9E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="53%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares issued under the 2015 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;78,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares issued under the 1995 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;98,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;180,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;245,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received under the 2015 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;19.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received under the 1995 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;30.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;46.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock>
	<biib:SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock contextRef="FD2015Q4YTD" id="Fact-115C309BB9FA2EFD79E438A29133DFF8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="56%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;84.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen&amp;#8217;s share of development expense, excluding upfront and milestone payments, reflected in our consolidated statements of income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;29.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock>
	<biib:SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock contextRef="FD2015Q4YTD" id="Fact-CFE73901E9021F03056F38A2913393DB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="56%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;113.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;117.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;133.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen&amp;#8217;s share of development expense reflected in our consolidated statements of income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;60.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;67.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock>
	<biib:SummaryOfCommonStockTableTextBlock contextRef="FD2015Q4YTD" id="Fact-0D64AC7427DA137212D838A2913EF767">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="24%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;241.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;218.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;257.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;234.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfCommonStockTableTextBlock>
	<biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock contextRef="FD2015Q4YTD" id="Fact-1C165CC6E0BC01DA357938A2912C6B0A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;144.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;124.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;518.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;359.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenue-related reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;483.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
	<biib:TimeVestedRestrictedStockUnitsActivityTableTextBlock contextRef="FD2015Q4YTD" id="Fact-66430549682581F80CF138A2912D8120">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,137,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;221.01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;459,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;388.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(626,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;190.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(160,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;302.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;810,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;323.87&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:TimeVestedRestrictedStockUnitsActivityTableTextBlock>
	<us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-DF28CFE24DA8CA55C06138A29130CED7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Other Consolidated Financial Statement Detail&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Supplemental Cash Flow Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Supplemental disclosure of cash flow information for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="51%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash paid during the year for:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;41.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;53.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,674.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,163.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;643.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Non-cash Investing and Financing Activity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the fourth quarter of 2015, we accrued &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon reaching &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in total cumulative sales of Fumapharm Products. The amount, net of tax benefit, was accounted for as an increase to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm and is expected to be paid in the first quarter of 2016. For additional information related to this transaction, please read Note 21, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitment and Contingencies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the construction of our manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$59.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our consolidated balance sheet. For additional information related to this transaction, please read Note 10,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Property, Plant and Equipment&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2015, upon completion of our acquisition of Convergence, we recorded a contingent consideration obligation of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$274.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as part of the purchase price. For additional information related to this transaction, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July and November 2013, the construction of two office buildings in Cambridge, Massachusetts was completed and we started leasing the facilities.&amp;#160;Upon completion of the construction of the buildings, we determined that we were no longer considered the owner of the buildings because we did not have any unusual or significant continuing involvement.&amp;#160;Consequently, we derecognized the buildings and their associated financing obligation of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$161.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from our consolidated balance sheet.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Income (Expense), Net&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="53%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;22.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(95.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(29.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(31.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Impairments on investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(15.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(13.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(123.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(25.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(34.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Current Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets includes prepaid taxes totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$550.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$57.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accrued Expenses and Other&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;518.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;359.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;504.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;265.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;270.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;393.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;167.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;172.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;55.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;120.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;579.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;505.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,096.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,817.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Long-Term Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;301.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;235.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;369.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;249.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;905.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;650.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Pricing of TYSABRI in Italy - AIFA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the fourth quarter of 2011, Biogen Italia SRL (formerly Biogen Idec Italia SRL), our Italian subsidiary,&amp;#160;received a notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 through mid-February 2011 exceeded by EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006. In December 2011, we filed an appeal against AIFA in administrative court in Rome, Italy seeking a ruling that the reimbursement limit in the Price Determination Resolution should apply as written to only &amp;#8220;the first 24 months&amp;#8221; of TYSABRI sales, which ended in mid-February 2009. That appeal is still pending. Since being notified in the fourth quarter of 2011 that AIFA believed a reimbursement limit was still in effect, we deferred revenue on sales of TYSABRI as if the reimbursement limit were in effect for each biannual period beginning in mid-February 2009. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2013, we negotiated an agreement in principle with AIFA's Price and Reimbursement Committee that would have resolved all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for the periods from February 2009 through January 2013 for an aggregate repayment of EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The agreement was sent to the Avvocatura Generale dello Stato (Attorney General) for its opinion. As a result of this agreement in principle, we recorded a liability and reduction to revenue of EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; at June 30, 2013, which approximated &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the claim related to the period from mid-February 2009 through mid-February 2011. In October 2014, we proposed a revised settlement for the period from February 2009 through January 2013 of EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to be paid in one payment. AIFA and Biogen Italia SRL are still discussing a possible resolution for the period from February 2009 through January 2013.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2014, AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. As a result, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$53.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of TYSABRI revenues related to the periods beginning February 2013 that were previously deferred. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have approximately EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;75 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; recorded as accrued expenses and long-term deferred revenue in our consolidated balance sheets for this matter as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
	<us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="FD2015Q4YTD" id="Fact-EE48CFC1A546C70117C038A291363945">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;394.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;394.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,116.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,120.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,723.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,724.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,152.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,155.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;491.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;493.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,880.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,891.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;28.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2014 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;370.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;370.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;692.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;693.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;269.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;270.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;579.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;580.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;198.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;198.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,111.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,112.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
	<us-gaap:BusinessCombinationsPolicy contextRef="FD2015Q4YTD" id="Fact-76E82E3AAE0DD4D7B94138A29141161F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions that qualify as business combinations completed after January&amp;#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue these contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step, and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-4A0E741DCCC5F88FD78138A2913D3401">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consider only those investments which are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, cash equivalents were comprised of money market funds and commercial paper, overnight reverse repurchase agreements, and other debt securities with maturities less than 90 days from the date of purchase.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="FD2015Q4YTD" id="Fact-770E099A64A118E542A038A29135CCD5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;less than 90&amp;#160;days&lt;/font&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from the date of purchase included in cash and cash equivalents on the accompanying consolidated balance sheet:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;54.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;134.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;305.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;673.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;321.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;79.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;909.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;716.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short term maturities. Our overnight reverse repurchase agreements are collateralized with agency-guaranteed mortgage-backed securities and represent approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of total assets as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize our marketable debt and equity securities:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;394.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;394.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,116.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,120.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,723.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,724.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,152.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,155.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;491.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;493.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,880.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,891.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;28.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2014 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;370.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;370.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;692.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;693.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;269.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;270.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;579.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;580.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;198.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;198.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,111.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,112.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Contractual Maturities: Available-for-Sale Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160; Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160; Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,120.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,122.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;640.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;640.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,575.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,583.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,343.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,345.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;184.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;185.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;126.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;126.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,880.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,891.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,111.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,112.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The average maturity of our marketable debt securities available-for-sale as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;months and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proceeds from Marketable Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="53%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,063.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,718.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,190.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, primarily relate to sales of agency mortgage-backed securities and government securities. Realized losses for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, primarily relate to sales of agency mortgage-backed securities and corporate securities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Strategic Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our strategic investment portfolio was comprised of investments totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$96.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$47.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which are included in investments and other assets in our consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-4F36B2538B510A1C5F2438A2911EE868">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our business strategy, we have entered into various collaboration agreements which provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depending on the collaborative arrangement, we may record funding receivables or payable balances with our partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaboration arrangements are discussed below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Genentech (Roche Group)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We collaborate with Genentech on the development and commercialization of RITUXAN. In addition, in the U.S., we share operating profits and losses relating to GAZYVA with Genentech. The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacturing and commercialization of GAZYVA in the U.S. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our collaboration agreement will continue in effect until we mutually agree to terminate the collaboration, except that if we undergo a change in control, as defined in the collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech&amp;#8217;s offer or purchase Genentech&amp;#8217;s rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to any other anti-CD20 products in development in exchange for a royalty and our rights to GAZYVA in exchange for the compensation described in the table below. Our collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;RITUXAN&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Genentech is responsible for the worldwide manufacturing of RITUXAN. Development and commercialization rights and responsibilities under this collaboration are divided as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We share with Genentech co-exclusive rights to develop, commercialize and market RITUXAN in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Canada&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and Genentech have assigned our rights under our collaboration agreement with respect to Canada to the Roche Group.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Outside the U.S. and Canada&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have granted Genentech exclusive rights to develop, commercialize and market RITUXAN outside the U.S. and Canada. Under the terms of separate sublicense agreements between Genentech and the Roche Group, development and commercialization of RITUXAN outside the U.S. and Canada is the responsibility of the Roche Group and its sublicensees. We do not have any direct contractual arrangements with the Roche Group or it sublicensees.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of the collaboration agreement, the Roche Group pays us royalties between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on sales of RITUXAN outside the U.S. and Canada, with the royalty period lasting &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11 years&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from the first commercial sale of RITUXAN on a country-by-country basis. The royalty periods for the substantial portion of the royalty-bearing sales in the rest of world markets expired during 2012 and 2013. We expect future revenue on sales of RITUXAN in the rest of world will be limited to our share of pre-tax co-promotion profits in Canada.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;GAZYVA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Prior to FDA approval of GAZYVA, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the development and commercialization expenses as research and development expense and selling, general and administrative expense, respectively, in our consolidated statements of income. After GAZYVA was approved by the FDA in the fourth quarter of 2013, we began to recognize our share of the development and commercialization expenses as a reduction of our share of pre-tax profits in revenues from unconsolidated joint business. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercialization of GAZYVA will impact our percentage of the co-promotion profits for RITUXAN, as summarized in the table below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Ocrelizumab&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Genentech is solely responsible for development and commercialization of ocrelizumab, a humanized anti-CD20 monoclonal antibody currently in development for MS, and funding future costs. Genentech cannot develop ocrelizumab in CLL, NHL or RA. We will receive tiered royalties between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on U.S. net sales of ocrelizumab if approved for commercial sale by the FDA. There will be a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction to these royalties if a biosimilar to ocrelizumab is approved in the U.S. In addition, we will receive a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; royalty on worldwide net sales of ocrelizumab outside the U.S., with the royalty period lasting &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11 years&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from the first commercial sale of ocrelizumab on a country-by-country basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercialization of ocrelizumab will not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Profit-sharing Formulas&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;RITUXAN Profit Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our current pretax co-promotion profit-sharing formula for RITUXAN provides for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share on the first &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of co-promotion operating profits earned each calendar year. Our share of annual co-promotion profits in excess of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; varies, as summarized in the table below, upon the following events:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="82%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="17%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until GAZYVA First Non-CLL FDA Approval&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First Non-CLL GAZYVA FDA Approval&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the FDA&amp;#8217;s first approval of GAZYVA in an indication other than CLL.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First GAZYVA Threshold Date&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the earlier of (1)&amp;#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12 month period were at least &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; or (2)&amp;#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12 month period have reached &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;Second GAZYVA Threshold Date&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12 month period have reached &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$500.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We expect our share of RITUXAN pre-tax profits in the U.S. to decrease to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; if GAZYVA is approved by the FDA in RITUXAN-refractory indolent non-Hodgkin&amp;#8217;s lymphoma. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, should the FDA approve an anti-CD20 product other than ocrelizumab or GAZYVA that is acquired or developed by Genentech and subject to the collaboration agreement, our share of the co-promotion operating profits would be between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; based on certain events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;GAZYVA Profit Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our current pretax profit-sharing formula for GAZYVA provides for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share on the first &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of operating profits earned each calendar year. Our share of annual profits in excess of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; varies, as summarized in the table below, upon the following events:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="82%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="17%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until First GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our share of operating losses on GAZYVA was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Unconsolidated Joint Business Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the first quarter of 2013, we reduced our share of RITUXAN revenues from unconsolidated joint business by approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$49.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which revenue on sales in the rest of world for RITUXAN was reduced by &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$41.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and pre-tax profits in the U.S. were reduced by &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to reflect our share of the royalties and interest awarded to Hoechst in its arbitration with Genentech. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from unconsolidated joint business are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="53%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,269.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,117.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,087.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue on sales in the rest of world for RITUXAN&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;69.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;78.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total unconsolidated joint business revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,339.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,195.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,126.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1) GAZYVA sales began in the fourth quarter of 2013.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; profit-sharing threshold was met during the first quarter.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Prior to regulatory approval, we record our share of the expenses incurred by the collaboration for the development of anti-CD20 products in research and development expense in our consolidated statements of income. We incurred &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in development expense for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. After an anti-CD20 product is approved, we record our share of the development expenses related to that product as a reduction of our share of pre-tax profits in revenues from unconsolidated joint business. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Elan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On April 2, 2013, we acquired full ownership of all remaining rights to TYSABRI from Elan that we did not already own or control. Upon the closing of the transaction, our collaboration agreement with Elan was terminated. For additional information related to this transaction, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We previously collaborated with Elan on the development, manufacture and commercialization of TYSABRI. Under the terms of our collaboration agreement, we manufactured TYSABRI and collaborated with Elan on the product&amp;#8217;s marketing, commercial distribution and ongoing development activities. The agreement was designed to effect an equal sharing of profits and losses generated by the activities of our collaboration. Under the agreement, however, once sales of TYSABRI exceeded specific thresholds, Elan was required to make milestone payments to us in order to continue sharing equally in the collaboration&amp;#8217;s results. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the U.S., we previously sold TYSABRI to Elan who then sold the product to third-party distributors. Our sales price to Elan in the U.S. was set prior to the beginning of each quarterly period to effect an approximate equal sharing of the gross profit between Elan and us. We recognized revenue for sales in the U.S. of TYSABRI upon Elan&amp;#8217;s shipment of the product to the third-party distributors, at which time all revenue recognition criteria had been met. We incurred manufacturing and distribution costs, research and development expenses, commercial expenses, and general and administrative expenses related to TYSABRI. We recorded these expenses to their respective line items in our consolidated statements of income when they were incurred. Research and development and sales and marketing expenses were shared equally with Elan and the reimbursement of these expenses was recorded as reductions of the respective expense categories. During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$11.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as a reduction of research and development expense resulting from reimbursements from Elan. In addition, for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as a reduction of selling, general and administrative expense resulting from reimbursements from Elan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the rest of world, we previously were responsible for distributing TYSABRI to customers and were primarily responsible for all operating activities. Generally, we recognized revenue for sales of TYSABRI in the rest of world at the time of product delivery to our customers. We made payments to Elan which effected an equal sharing of rest of world collaboration operating profits. These payments also included the reimbursement we paid to Elan for half of the third-party royalties that Elan paid on behalf of the collaboration relating to rest of world sales. These amounts were reflected in the collaboration profit sharing line in our consolidated statements of income. For &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$85.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was reflected in the collaboration profit sharing line for our collaboration with Elan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Acorda&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2009, we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine in markets outside the U.S.&amp;#160;We also have responsibility for regulatory activities and the future clinical development of related products in those markets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of the collaboration and license agreement, we pay Acorda tiered royalties based on the level of ex-U.S. net sales. We may pay up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$375.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of additional milestone payments to Acorda, based on the successful achievement of certain regulatory and commercial milestones. The next expected milestone would be &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, due if ex-U.S. net sales reach &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; over a period of four consecutive quarters. We will capitalize these additional milestones as intangible assets upon achievement of the milestone which will then be amortized utilizing an economic consumption model and recognized as amortization of acquired intangible assets. Royalty payments are recognized as a cost of goods sold.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the collaboration and license agreement, we have also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement is a sublicense arrangement of an existing agreement between Acorda and Alkermes, who acquired Elan Drug Technologies, the original party to the license with Acorda. During the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, total cost of sales related to royalties and commercial supply of FAMPRYA reflected in our consolidated statement of income were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$30.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$29.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$24.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Swedish Orphan Biovitrum AB (publ)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2007, we acquired &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the stock of Syntonix. Syntonix had previously entered into a collaboration agreement with Swedish Orphan Biovitrum AB (publ) (Sobi) to jointly develop and commercialize Factor VIII and Factor IX hemophilia products, including ELOCTATE and ALPROLIX. In February 2010, we restructured the collaboration agreement and assumed full development responsibilities and costs, as well as manufacturing rights. In addition, the cross-royalty rates were reduced and commercial rights for certain territories were changed. As a result, we have commercial rights for North America (the Biogen North America Territory) and for rest of the world markets outside of, essentially, Europe, North Africa, Russia and certain countries in the Middle East (the Biogen Direct Territory).&amp;#160;Subject to the exercise of an option right that Sobi controls, Sobi will have commercial rights in, essentially, Europe, North Africa, Russia and certain countries in the Middle East (the Sobi Territory). The collaboration agreement was amended and restated in April 2014. (References to the collaboration agreement refer to the amended and restated collaboration agreement).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2014, Sobi exercised its option to assume final development and commercialization activities in the Sobi Territory for ELOCTA (the trade name for ELOCTATE in the E.U.). In July 2015, Sobi exercised its option to assume final development and commercialization of ALPROLIX within the Sobi Territory. Upon each exercise of opt-in right under the terms of the collaboration agreement, Sobi made a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; payment in escrow. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon EMA regulatory approval of each such product, Sobi will be liable to reimburse us &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the sum of all shared manufacturing and development expenses incurred by us from October 1, 2009 through the earlier of the date on which Sobi is registered as the marketing authorization holder for the applicable product or 90 days post-regulatory approval, as well as &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of certain development expenses incurred exclusively for the benefit of the Sobi Territory (the Opt-In Consideration).&amp;#160;This reimbursement will be recognized in proportion to collaboration revenues, over a ten year period, consistent with the initial patent terms of the products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ELOCTA was approved by the EC in November 2015. Through &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$200 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in expenditures for ELOCTA, net of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; escrow payment discussed above, are reimbursable by Sobi under the collaboration agreement due to its election to assume final development and commercialization of ELOCTA within the Sobi Territory. Approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$175 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in expenditures for ALPROLIX may be reimbursable by Sobi under the collaboration agreement due to its election to assume final development and commercialization of ALPROLIX within the Sobi Territory. The escrow payment made with respect to ALPROLIX will be applied to the amount of the Opt-In Consideration to be reimbursed by Sobi upon EMA regulatory approval. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;To effect Sobi&amp;#8217;s reimbursement to us for the Opt-In Consideration exceeding the escrow payment for the applicable product, the cross-royalty cash payment structure for direct sales in each company&amp;#8217;s respective territories will be adjusted until the Opt-In Consideration is paid in full (the Reimbursement Period). The mechanism for reimbursement is outlined in the table below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the collaboration agreement, cash payments are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="35%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="18%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="16%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rates post Sobi Opt-In&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(3)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Royalty and Net Revenue Share Rates:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Method&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rate prior to 1st&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;commercial sale in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;the&amp;#160;Sobi&amp;#160;Territory:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Base Rate following&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;1st&amp;#160;commercial&amp;#160;sale&amp;#160;in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;the Sobi Territory:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rate during the&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reimbursement&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Period:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Sobi rate to Biogen on net sales in the Sobi Territory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10&amp;#160;or&amp;#160;12%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base&amp;#160;Rate&lt;br clear="none"/&gt;plus 5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Biogen rate to Sobi on net sales in the Biogen North America Territory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10&amp;#160;or&amp;#160;12%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base Rate&lt;br clear="none"/&gt;less 5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Biogen rate to Sobi on net sales in the Biogen Direct Territory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15&amp;#160;or&amp;#160;17%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base Rate&lt;br clear="none"/&gt;less 5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Biogen rate to Sobi on net revenue&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;from the Biogen Distributor Territory&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Net&lt;br clear="none"/&gt;Revenue&lt;br clear="none"/&gt;Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base Rate&lt;br clear="none"/&gt;less 15%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;Net revenue represents Biogen&amp;#8217;s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;If the reimbursement of the Opt-in Consideration has not been achieved within &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six years&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the first commercial sale of such product, we maintain the right to require Sobi to pay any remaining balances due to us within &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;90 days&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the six year anniversary date of the first commercial sale.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We expect to recognize the effect of the cash reimbursement as an adjustment to the Base Rate in the table above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Should Sobi terminate the collaboration agreement with respect to ALPROLIX, we will obtain full worldwide development and commercialization rights and we will be obligated to pay royalties to Sobi subject to separate terms, as defined in the collaboration agreement.&amp;#160;In addition, if EMA approval for ALPROLIX is not granted within &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the filing date, Sobi shall have the right to require that the escrow payment be refunded and revoke its option right for such product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;AbbVie Biotherapeutics, Inc. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration agreement with AbbVie Biotherapeutics, Inc., a subsidiary of AbbVie, Inc. (AbbVie) aimed at advancing the development and commercialization of ZINBRYTA in MS. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the agreement, we and AbbVie will conduct ZINBRYTA co-promotion activities in the E.U., U.S. and Canada territories (Collaboration Territory), where development and commercialization costs and profits are shared equally. We are responsible for all manufacturing activities in the Collaboration Territory.&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the U.S., AbbVie will recognize revenues on sales to third parties and we will recognize our 50% share of the co-promotion profits or losses as a component of total revenues in our consolidated statements of income.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the E.U. and Canada, we will reflect revenues on sales to third parties in product revenues, net in our consolidated statements of income. We will record the related cost of revenues and sales and marketing expenses to their respective line items in our consolidated statements of income when these costs are incurred. The reimbursement with AbbVie for the 50% sharing of the co-promotion profits or losses in the E.U. and Canada will be recognized in our total costs and expenses. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outside of the Collaboration Territory, we are solely responsible for development and commercialization where we will pay a tiered royalty to AbbVie on net sales in the low to high teens.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are the responsible party for manufacturing and research and development activities in both the Collaboration Territory and outside the Collaboration Territory and will record these activities to their respective lines in our consolidated statements of income, net of any reimbursement of research and development expenditures from AbbVie.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we made milestone payments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the development of ZINBRYTA as a result of filing for regulatory approval in the U.S. and E.U. during the year. These payments were recorded as research and development expense in our consolidated statements of income. We may incur up to an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$32.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of milestone payments related to the development of ZINBRYTA, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is due upon regulatory approval in the U.S. and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is due upon regulatory approval in the E.U. These future payments will be capitalized as an intangible asset in our consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of activity related to this collaboration is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="56%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;113.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;117.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;133.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen&amp;#8217;s share of development expense reflected in our consolidated statements of income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;60.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;67.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Ionis Pharmaceuticals, Inc. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Long-Term Strategic Research Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2013, we entered into a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; year research collaboration with Ionis Pharmaceuticals, Inc. (Ionis), formerly known as Isis Pharmaceuticals Inc. under which both companies collaborate to perform discovery level research and then develop and commercialize antisense or other therapeutics for the treatment of neurological disorders.&amp;#160;Under the collaboration, Ionis will perform research on a set of neurological targets identified within the agreement. Once the research has reached a specific stage of development, we will make the determination whether antisense is the preferred approach to develop a therapeutic candidate or whether another modality is preferred. If antisense is selected, Ionis will continue development and identify a product candidate. If another modality is used, we will assume the responsibility for identifying a product candidate and developing it. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of this agreement, we paid Ionis an upfront amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&amp;#160;Of this payment, we recorded prepaid research and discovery services of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, representing the value of the Ionis full time equivalent employee resources which are required by the collaboration to provide research and discovery services to us over the next six years.&amp;#160;The remaining &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the upfront payment was recorded as research and development expense as it represented the purchase of intellectual property that had not reached technological feasibility.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ionis is also eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us. During the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we triggered milestones of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to the advancement of IONIS-SOD1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt;Rx&lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the treatment of ALS and other neurological targets identified.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For non-ALS antisense product candidates, Ionis will be responsible for global development through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$70.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$130.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise. &amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For product candidates using a different modality, we will be responsible for global development through all stages and will pay Ionis up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$90.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon the achievement of certain regulatory milestones and royalties on future sales if we successfully develop the product candidate. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Product Collaborations &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December, June and January 2012, we entered into three separate exclusive, worldwide option and collaboration agreements with Ionis under which both companies will develop and commercialize antisense therapeutics for up to three gene targets, Ionis&amp;#8217; product candidates for the treatment of myotonic dystrophy type 1 (DM1), and the antisense investigational candidate nusinersen (ISIS-SMN&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt;Rx&lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) for the treatment of spinal muscular atrophy (SMA), respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Antisense Therapeutics&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of the December 2012 agreement relating to the development and commercialization of up to three gene targets we provided Ionis with an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and will make potential additional payments, prior to licensing, of up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; based on the development of the selected product candidate as well as a mark-up of the cost estimate of the Phase 1 and Phase 2 trials. During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we triggered a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment. Ionis will be responsible for global development of any product candidate&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt; &lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt; &lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$70.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive up to another &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$130.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt; &lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;if we successfully develop the product candidate after option exercise. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;IONIS-DMPK&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt;Rx&lt;/sub&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of the June 2012 agreement for the DM1 candidate, we provided Ionis with an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and agreed to make potential additional payments, prior to licensing, of up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$59.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; based on the development of the selected product candidate. During 2015, we amended the agreement to adjust the amount of potential additional payments by an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; due to changes in the clinical trial design. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we triggered milestones of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$14.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to the selection and advancement of IONIS-DMPK&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt;Rx&lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to treat DM1. Ionis will be responsible for global development of any product candidate through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We also have an option to license the product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$70.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive up to another &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$130.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales if we successfully develop the product candidate after option exercise. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$9.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$11.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, were reflected in research and development expense in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Nusinersen&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of the January 2012 agreement for the antisense investigational drug candidate, nusinersen, we paid Ionis &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$29.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as an upfront payment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During 2014, we amended the agreement to adjust the amount of potential additional payments and terms of the exercise of our opt-in right to license nusinersen. Consistent with the initial agreement, Ionis remains responsible for conducting the pivotal/Phase 3 trials.&amp;#160;We are providing input on the clinical trial design and regulatory strategy for the development of nusinersen. During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we triggered clinical trial payments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$42.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$57.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the advancement of the program. We are recognizing these payments as research and development expenses as the trial costs are incurred. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During 2015, we amended the agreement and may pay up to an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$92.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; due to changes in the clinical trial design. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We may exercise our opt-in right upon&amp;#160;completion of and data review of the first successful Phase 2/3 trial or completion of both Phase 2/3 trials.&amp;#160;An amendment in December 2014 provided for additional opt-in scenarios, based on the filing or the acceptance of a new drug application or marketing authorization application with the FDA or EMA. Under the amended collaboration agreement, we may pay Ionis up to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$325.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in a license fee and payments, including &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in payments associated with the clinical development of nusinersen prior to licensing, a license fee and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales of nusinersen if we successfully develop nusinersen after option exercise.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$74.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$27.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$13.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, were reflected in research and development expense in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Eisai Co., Ltd. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;BAN2401 and E2609 Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On March 4, 2014, we entered into a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize two Eisai product candidates for the treatment of Alzheimer&amp;#8217;s disease, BAN2401, a monoclonal antibody that targets amyloid-beta aggregates, and E2609, a BACE inhibitor, (Eisai Collaboration Agreement).&amp;#160;Under the Eisai Collaboration Agreement, Eisai serves as the global operational and regulatory lead for both compounds and all costs, including research, development, sales and marketing expenses, will be shared equally by us and Eisai. Following marketing approval in major markets, such as the U.S., the E.U. and Japan, we will co-promote BAN2401 and E2609 with Eisai and share profits equally. In smaller markets, Eisai will distribute these products and pay us a royalty. The Eisai Collaboration Agreement also provides the parties with certain rights and obligations in the event of a change in control of either party.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The Eisai Collaboration Agreement also provides Eisai an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for Alzheimer&amp;#8217;s disease (Aducanumab Option) and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). Upon exercise of each of the Aducanumab Option and the Anti-Tau Option, we will execute a separate collaboration agreement with Eisai on terms and conditions that mirror the Eisai Collaboration Agreement.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Aducanumab Option&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Eisai may exercise the Aducanumab Option after either (i) completion of both the current Phase 1b clinical trial for aducanumab and the current Phase 2 clinical trial for BAN2401 (Post-Phase 2 Aducanumab Option), or (ii) completion of the Phase 3 clinical trial for aducanumab (Post-Phase 3 Aducanumab Option) under certain conditions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The consideration we will receive if Eisai exercises the Post-Phase 2 Aducanumab Option depends on the development status of BAN2401. If BAN2401 is then determined to advance to Phase 3, we will be entitled to receive a single payment from Eisai upon regulatory approval of aducanumab and we will no longer be required to pay Eisai any milestone payments for products containing BAN2401 under the Eisai Collaboration Agreement. If the development of BAN2401 has instead been terminated, we will receive development and commercial milestone payments from Eisai (Post-Phase 2 Aducanumab Milestone Payments). If Eisai does not exercise its Post-Phase 2 Aducanumab Option, we may elect to terminate the Eisai Collaboration Agreement with respect to BAN2401 but, under certain conditions, will have the option to reinstate the Eisai Collaboration Agreement after completion of a BAN2401 Phase 3 clinical trial.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;If Eisai exercises its Post-Phase 3 Aducanumab Option, Eisai will be required to pay us all Phase 3 development and commercialization costs plus a mark-up and an amount equal to any unpaid Post-Phase 2 Aducanumab Milestone Payments that would have been payable if Eisai had exercised its Post-Phase 2 Aducanumab Option. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Anti-Tau Option&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon the effective date of the Eisai Collaboration Agreement, we paid Eisai &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$17.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, reflecting the fair value of the options granted under the Eisai Collaboration Agreement, both of which were classified as research and development expense in our consolidated statements of income. During the second quarter of 2014, Eisai exercised its option under the Eisai Collaboration Agreement to expand the joint development and commercialization activities to include Japan. Upon such exercise, we paid Eisai an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$21.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as research and development expense in our consolidated statements of income, which represented the difference between the payment made upon exercise of the option and the fair value of that option recorded as research and development expense upon closing of the agreement in the first quarter of 2014. We could pay Eisai up to an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under the Eisai Collaboration Agreement based on the future achievement of certain development, regulatory and commercial milestones.&amp;#160;  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to our arrangements with Eisai, Neurimmune is entitled to milestone and royalty payments related to the development and commercialization of aducanumab and certain anti-tau antibodies. For additional information regarding our agreement with Neurimmune, please see Note 18, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Investments in Variable Interest Entities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of activity related to this collaboration is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="56%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;84.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen&amp;#8217;s share of development expense, excluding upfront and milestone payments, reflected in our consolidated statements of income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;29.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Sangamo BioSciences, Inc. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On February 22, 2014, we completed an exclusive worldwide research, development and commercialization collaboration and license agreement with Sangamo BioSciences, Inc. (Sangamo) under which both companies will develop and commercialize product candidates for the treatment of two inherited blood disorders, sickle cell disease and beta-thalassemia.&amp;#160;The collaboration is currently in the research stage of development.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of the agreement, we paid Sangamo an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash, with additional payments of up to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; based on the achievement of certain development, regulatory and commercial milestones, plus royalties based on sales.&amp;#160;We recorded the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment as research and development expense. Under this arrangement, Sangamo will be responsible for identifying a product candidate for the treatment of beta-thalassemia and advancing that candidate through a completed Phase 1 human clinical trial, at which point we would assume responsibility for development.&amp;#160;We will jointly develop a sickle cell disease candidate through the potential filing of an investigative new drug application, after which we would assume clinical responsibilities. We will lead the global development and commercialization efforts and Sangamo will have the option to assume co-promotion responsibilities in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$13.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$28.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of expense was reflected in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Applied Genetic Technologies Corporation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On July 2, 2015, we announced a collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases with Applied Genetic Technologies Corporation (AGTC). The collaboration will focus on the development of a portfolio of AGTC&amp;#8217;s therapeutic programs, including both a clinical-stage candidate for X-linked Retinoschisis (XLRS) and a pre-clinical candidate for the treatment of X-Linked Retinitis Pigmentosa (XLRP). The agreement also includes options for early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition, as well as an equity investment in AGTC.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the third quarter of 2015, we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$124.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which included a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equity investment in AGTC, prepaid research and development expenditures of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$58.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and total licensing and other fees of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$58.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of prepaid research and development expenditures were recorded in investments and other assets in our consolidated balance sheets and will be expensed as the services are provided. During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$54.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as research and development expense associated with AGTC in our consolidated statements of income, including the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; total licensing and other fees, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$6.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in research and development services, a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; premium on our equity investment and a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; clinical development milestone related to XLRS. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;AGTC is eligible to receive development, regulatory and commercial milestone payments aggregating in excess of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.1 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which includes up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$472.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; collectively for the two lead programs and up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$592.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; across the discovery programs. AGTC is also eligible to receive royalties in the mid-single digit to mid-teen percentages of annual net sales. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We were granted worldwide commercialization rights for the XLRS and XLRP programs. AGTC has an option to share development costs and profits after the initial clinical trial data are available, and an option to co-promote the second of these products to be approved in the U.S. AGTC will lead the clinical development programs of XLRS through product approval and of XLRP through the completion of first-in-human trials. We will support the clinical development costs, subject to certain conditions, following the first-in-human study for XLRS and IND-enabling studies for XLRP. Under the manufacturing license, we have received an exclusive license to use AGTC&amp;#8217;s proprietary technology platform to make AAV vectors for up to six genes, three of which are in AGTC&amp;#8217;s discretion, in exchange for payment of milestones and royalties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Mitsubishi Tanabe Pharma Corporation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On September 9, 2015, we announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to exclusively license amiselimod (MT-1303), a late stage experimental medicine with potential in multiple autoimmune indications. Amiselimod is an oral compound that targets the sphingosine 1-phosphate receptor. Under the terms of the agreement, we will receive worldwide rights to amiselimod, excluding Asia. We will be responsible for global commercialization and development costs except for costs related to the Asian territories, which are the responsibility of MTPC. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the fourth quarter of 2015, the agreement became effective and we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which was recorded as research and development expense in our consolidated statements of income. In the future we may pay up to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$484.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in milestone payments for multiple indications and territories, along with average royalties in the mid- to high-teen percentages of annual net sales. MTPC has the right to participate in our global clinical trials related to amiselimod and has an option to co-promote non-MS indications in the U.S. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Research and Discovery Arrangements &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we entered into several research, discovery and other related arrangements that resulted in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$9.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$40.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, recorded as research and development expense in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These additional arrangements include the potential for future milestone payments based on clinical and commercial development over a period of several years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Samsung Bioepis&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012, we entered into a joint venture agreement with Samsung BioLogics Co. Ltd. (Samsung Biologics), establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&amp;#160;Samsung Biologics contributed &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;280.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$250.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) for an &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; stake in Samsung Bioepis and we contributed approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$45.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) for the remaining &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; ownership interest.&amp;#160;Under the joint venture agreement, we have no obligation to provide any additional funding and our ownership interest may be diluted due to financings in which we do not participate. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our ownership interest is approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which reflects our additional contribution of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.3 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) in the first quarter of 2015 and the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&amp;#160;The exercise of this option is within our control and is based on paying for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the total investment made by Samsung Biologics into Samsung Bioepis in excess of what we have already contributed under the agreement plus a rate that will represent their return on capital.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Samsung Biologics has the power to direct the activities of Samsung Bioepis which will most significantly and directly impact its economic performance.&amp;#160;We account for this investment under the equity method of accounting as we maintain the ability to exercise significant influence over Samsung Bioepis through a presence on the entity&amp;#8217;s Board of Directors and our contractual relationship.&amp;#160;Under the equity method, we recorded our original investment at cost and subsequently adjust the carrying value of our investment for our share of equity in the entity&amp;#8217;s income or losses according to our percentage of ownership. During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our share of losses exceed the carrying value of our investment. We suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investment in Samsung Bioepis totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.1 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;), which was classified as a component of investments and other assets in our consolidated balance sheets. We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our consolidated statements of income. During the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a loss on our investment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$17.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Commercial Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On December 17, 2013, pursuant to our rights under the joint venture agreement with Samsung Biologics, we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of one anti-TNF biosimilar, Japan.&amp;#160;Under the terms of this agreement, we have paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$46.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which has been recorded as a research and development expense in our consolidated statements of income as the programs they relate to had not achieved regulatory approval. Samsung Bioepis is eligible to receive an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestones, including &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon the regulatory approval of each anti-TNF biosimilar product candidate in the E.U. In January 2016, the EC approved the MAA for BENEPALI for marketing in the E.U. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon commercialization, we will reflect revenues on sales to third parties in product revenues, net in our consolidated statements of income. We will record the related cost of revenues and sales and marketing expenses in our consolidated statements of income to their respective line items when these costs are incurred. A &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; profit share with Samsung Bioepis will be recognized in costs and expenses. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;License Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Simultaneous with the formation of Samsung Bioepis, we entered into a license agreement with Samsung Bioepis. Under the terms of the agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture, and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we will receive single digit royalties on all biosimilar products developed and commercialized by Samsung Bioepis. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Services&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we entered into a technical development services agreement and a manufacturing agreement with Samsung Bioepis. Under the terms of the technical development services agreement, we provide Samsung Bioepis technical development and technology transfer services, which include, but are not limited to, cell culture development, purification process development, formulation development, and analytical development. Under the terms of our manufacturing agreement, we manufacture clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis pursuant to contractual terms.&amp;#160;Under limited circumstances, we may also supply Samsung Bioepis with quantities of drug product of biosimilar products for use in clinical trials through arrangements with third-party contract manufacturers. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$62.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$58.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$43.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in revenues in relation to these services, which is reflected as a component of other revenues in our consolidated statement of income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-4C352C2CA2B044FE1FD438A2913196E0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We rent laboratory and office space and certain equipment under non-cancelable operating leases. These lease agreements contain various clauses for renewal at our option and, in certain cases, escalation clauses typically linked to rates of inflation. Rental expense under these leases, net of amounts recognized in relation to exiting our Weston, Massachusetts facility, which terminate at various dates through 2028, amounted to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$68.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$62.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Rent expense was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$56.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In addition to rent, the leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="24%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Minimum lease payments (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;75.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;75.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;67.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;66.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;63.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;382.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;732.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: income from subleases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(28.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(59.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;69.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;69.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;61.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;60.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;56.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;353.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;672.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;As a result of our decision to relocate our corporate headquarters to Cambridge, Massachusetts, we vacated part of our Weston, Massachusetts facility in the fourth quarter of 2013. We incurred a charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:9pt;"&gt;$27.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt; in connection with this move. This charge represented our remaining lease obligation for the vacated portion of our Weston, Massachusetts facility, net of sublease income expected to be received. The term of our sublease to the vacated portion of our Weston, Massachusetts facility started in January 2014 and will continue through the remaining term of our lease agreement.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under certain of our lease agreements, we are contractually obligated to return leased space to its original condition upon termination of the lease agreement. At the inception of a lease with such conditions, we record an asset retirement obligation liability and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. In subsequent periods, for each such lease, we record interest expense to accrete the asset retirement obligation liability to full value and depreciate each capitalized asset retirement obligation asset, both over the term of the associated lease agreement. Our asset retirement obligations were not significant as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Eisai Financing Arrangement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During 2015 we amended our existing lease related to Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. For additional information, please read Note 10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net present value of the future minimum lease payments were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="79%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="19%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;20.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net present value of the future minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;19.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Related Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$45.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of net liabilities associated with uncertain tax positions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Funding Commitments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have several on-going clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on our consolidated balance sheet for expenditures incurred by CROs as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We have approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$559.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cancellable future commitments based on existing CRO contracts as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Development, Regulatory and Commercial Milestone Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based on our development plans as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we could make potential future milestone payments to third parties of up to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.8 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones had not occurred as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Manufacturing Commitments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On December 1, 2015, we purchased land in Solothurn, Switzerland where we plan to build a biologics manufacturing facility over the next several years. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had contractual commitments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$126.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the construction of this facility.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;TYSABRI Contingent Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2013, we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the terms of the acquisition agreement, we are obligated to make contingent payments to Elan of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on annual worldwide net sales up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on annual worldwide net sales that exceed &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo in December 2013. Following that acquisition, we began making these royalty payments to Perrigo.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration related to Business Combinations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisitions of Convergence, Stromedix, Inc. (Stromedix), Biogen International Neuroscience GmbH (formerly Biogen Idec International Neuroscience GmbH) (BIN), Biogen Hemophilia Inc. (formerly Biogen Idec Hemophilia Inc.) (BIH) and Fumapharm AG, we agreed to make additional payments based upon the achievement of certain milestone events. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As the acquisitions of Convergence, Stromedix and BIN, formerly Panima Pharmaceuticals AG, occurred after January&amp;#160;1, 2009, we record contingent consideration liabilities at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.3 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in remaining milestones related to these acquisitions. For additional information related to our acquisition of Convergence please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;BIH&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of BIH, formerly Syntonix, in 2007, we agreed to pay up to an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$80.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; if certain milestone events associated with the development of BIH&amp;#8217;s lead product, ALPROLIX are achieved. The first &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$40.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; contingent payment was achieved in 2010. We paid an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the second quarter of 2014 as ALPROLIX was approved for the treatment of hemophilia B. A second &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; contingent payment will occur if, prior to the tenth anniversary of the closing date, a marketing authorization is granted by the EMA for ALPROLIX. This payment will be accounted for as an increase to intangible assets if achieved. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Fumapharm AG&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2006, we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$220.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon closing of the transaction and agreed to pay an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; if a Fumapharm Product was approved for MS in the U.S.&amp;#160;or E.U. In the second quarter of 2013, we paid this &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; contingent payment as TECFIDERA was approved in the U.S. for MS by the FDA. We are also required to make additional contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior twelve month period, as defined in the acquisition agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$850.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in contingent payments as we reached the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$6.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2014, second quarter of 2015 and third quarter of 2015, respectively, and accrued &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon reaching &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in total cumulative sales of Fumapharm Products in the fourth quarter of 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We will owe an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; contingent payment for every additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, until such time as the cumulative sales level reaches &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, at which time no further contingent payments shall be due. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&amp;#160;days following the end of the quarter in which the applicable cumulative sales level has been reached.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-7FEF924B7AB1D753CD4838A2913DFC72">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&amp;#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&amp;#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
	<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-A1CBCE86CC22552D606038A291358D8F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share-based compensation programs grant awards that have included stock options, restricted stock units which vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units which settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units which can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of the Board of Directors and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date on which the employee is retirement eligible.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&amp;#8217; vesting periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures, when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs and PUs and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs and PUs are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The purchase price of common stock under our ESPP is equal to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the lesser of (i)&amp;#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&amp;#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes model. The fair value of the look-back provision plus the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; discount is recognized as compensation expense over the 90 day purchase period. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
	<us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="FD2015Q4YTD" id="Fact-D79CB763912D89AFCA6A38A2912E01CE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="26%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(99.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(59.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;110.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(96.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(172.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(171.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(61.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(96.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(164.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(195.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(224.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="26%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(23.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(19.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(27.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;101.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(12.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(109.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(19.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(12.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;95.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(12.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(109.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(31.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(99.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(59.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="26%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(21.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(27.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(55.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(26.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(13.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;27.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(23.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(19.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(27.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="28%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="25%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;173.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(13.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;171.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2015Q4YTD" id="Fact-009A8299C766A8FC4F3B38A291357D14">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives, and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable arise from product sales in the U.S. and Europe and have standard payment terms which generally require payment within &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 to 90 days&lt;/font&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, two wholesale distributors individually accounted for approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.4%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;23.1%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.4%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;23.3%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of accounts receivable, net, respectively. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-FB54CE956091A82F435538A2913C9E7A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-EB7B0E15727F41E81A5138A2911DD512">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Indebtedness&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our indebtedness is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Current portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financing arrangement for the purchase of the RTP facility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of notes payable and other financing arrangements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Non-current portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;2008 Senior Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;565.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;571.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;2015 Senior Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,485.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;992.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,733.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,721.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financing arrangement for the purchase of the RTP facility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;18.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current portion of notes payable and other financing arrangements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,521.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;580.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following is a summary description of our principal indebtedness as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;2015 Senior Notes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On September 15, 2015, we issued senior unsecured notes for an aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$6.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, consisting of the following:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2020, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.792%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;3.625%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2022, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.920%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.75 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;4.05%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2025, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.764%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.75 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;5.20%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15,&amp;#160;2045, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.294%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These notes are senior unsecured obligations and may be redeemed at our option at any time at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the principal amount plus accrued interest and a specified make-whole amount. The notes also contain a change of control provision that may require us to purchase the notes at a price equal to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;101%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The costs associated with this offering of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$47.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; have been recorded as a reduction to the carrying amount of the debt on our consolidated balance sheet. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. Interest on the notes is payable March 15 and September 15 of each year. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with this offering, we also entered into interest rate swaps. The carrying value of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes includes approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to changes in the fair value of the interest rate swaps. For additional information, please read Note 9, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative Instruments, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;2008 Senior Notes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On March&amp;#160;4, 2008, we issued &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$550.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;Senior Notes due March&amp;#160;1, 2018 that were originally priced at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;99.184%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par. The discount is amortized as additional interest expense over the period from issuance through maturity. These notes are senior unsecured obligations. Interest on the notes is payable March&amp;#160;1 and September&amp;#160;1 of each year. The notes may be redeemed at our option at any time at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the principal amount plus accrued interest and a specified make-whole amount. The notes contain a change of control provision that may require us to purchase the notes under certain circumstances. There is also an interest rate adjustment feature that requires us to pay interest at an increased rate on the notes if the credit rating on the notes declines below investment grade. In accordance with ASU No. 2015-03, during 2015, we reclassified &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our debt issuance costs related to our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes from an asset to a reduction to the carrying amount of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes in our 2014 consolidated balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon the issuance of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;Senior Notes due in 2018, we entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. These contracts were terminated in December 2008. Upon termination of these swaps, the carrying amount of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;Senior Notes due in 2018 was increased by &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$62.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and is being amortized using the effective interest rate method over the remaining life of the Senior Notes and is being recognized as a reduction of interest expense. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$17.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; remains to be amortized. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Notes Payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our 2006 distribution agreement with Fumedica, we issued notes totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Swiss Francs which were payable to Fumedica in varying amounts from June 2008 through June 2018. Our remaining note payable to Fumedica had a carrying value of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Swiss Francs (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$9.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Swiss Francs (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$11.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Credit Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2015, we entered into a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; outstanding borrowings and were in compliance with all covenants under this facility.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2013, we entered into a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$750.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;364&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-day senior unsecured revolving credit facility. In March 2014, the revolving credit facility expired and was not renewed.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Financing Arrangement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During 2015 we recorded a financing obligation in relation to the amendment of our lease agreement of Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the financing obligation totaled approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$19.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For additional information, please read Note 10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Maturity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total gross payments, excluding our financing arrangement, due under our debt arrangements are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="80%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="18%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;553.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,500.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021 and thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,500.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,559.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair value of our debt is disclosed in Note&amp;#160;7, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-981F8EDE13E77E20849038A29127ACE7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Derivative Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&amp;#160;dollar. The value of revenues and operating expenses measured in U.S.&amp;#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign currency forward contracts in effect as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, had durations of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. These contracts have been designated as cash flow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and, beginning in the fourth quarter of 2015, in operating expenses when the expense in the currency being hedged is recorded. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and expenses is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;945.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,174.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss francs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;80.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;76.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;56.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound sterling&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Australian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Japanese yen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,103.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,302.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$72.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$23.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We expect all contracts to be settled over the next &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&amp;#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, credit risk did not change the fair value of our foreign currency forward contracts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments on our consolidated statements of income related to our forecasted revenues:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="27" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Effective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Ineffective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;173.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(13.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The effect of foreign currency forward contracts designated as hedging instruments on our consolidated statements of income related to our forecasted operating expenses was immaterial for 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Interest Rate Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Interest Rate Lock Contracts&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we entered into treasury rate locks, with an aggregated notional amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.1 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, that were designated as cash flow hedges to hedge against changes in the 10-year and 30-year U.S. treasury interest rates that could have impacted our anticipated debt offering. In connection with the issuance of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.05%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.20%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes, as described in Note 11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we settled the treasury rate locks and realized an &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; gain. As the hedging relationship was effective, the gain was recorded in AOCI and will be recognized in other income (expense), net over the life of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.05%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.20%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Interest Rate Swap Contracts&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the issuance of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes,  as described in Note 11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we entered into interest rate swaps with an aggregate notional amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$675.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Other Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also enter into other foreign currency forward contracts, usually with one month durations, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The aggregate notional amount of these outstanding foreign currency contracts was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$721.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$365.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Net losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$23.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and net gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to these contracts were recognized as a component of other income (expense), net, for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our consolidated balance sheets for our outstanding derivatives including those designated as hedging instruments:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="54%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="27%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="17%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance&amp;#160;Sheet&amp;#160;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;16.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="54%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="27%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="17%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;69.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
	<us-gaap:DerivativesPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-0190F834FCE7DE95F0CD38A29135BC0E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of derivatives are recorded each period in current earnings or accumulated other comprehensive income (loss), depending on whether a derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We also assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion to current earnings. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2015Q4YTD" id="Fact-1606DF0750511C23AD5238A2913E1600">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Share-based Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-based Compensation Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="55%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;88.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;102.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;95.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;127.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;150.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;160.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reversal of previously accrued incentive compensation included in restructuring charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;207.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;252.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;255.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;196.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;242.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;246.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(55.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(72.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(73.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;140.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;170.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;172.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="55%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;38.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;32.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;119.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;115.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;103.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;22.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;109.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;13.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;13.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;207.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;252.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;255.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;196.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;242.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;246.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Windfall tax benefits from vesting of stock awards, exercises of stock options and ESPP participation were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$78.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$96.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$73.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. These amounts have been calculated under the alternative transition method.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, unrecognized compensation cost related to unvested share-based compensation was approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$184.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.8&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-Based Compensation Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share-based compensation plans pursuant to which awards are currently being made: (i)&amp;#160;the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006&amp;#160;Directors Plan); (ii)&amp;#160;the Biogen Inc. 2008 Amended and Restated Omnibus Equity Plan (2008 Omnibus Plan); and (iii)&amp;#160;the Biogen Inc. 2015 Employee Stock Purchase Plan (ESPP). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Directors Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2006, our stockholders approved the 2006&amp;#160;Directors Plan for share-based awards to our directors. Awards granted from the 2006&amp;#160;Directors Plan may include stock options, shares of restricted stock, restricted stock units, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. We have reserved a total of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock for issuance under the 2006&amp;#160;Directors Plan. The 2006&amp;#160;Directors Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5-to-1&lt;/font&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; ratio. In June 2015, our stockholders approved an amendment to extend the term of the 2006 Directors Plan until June 10, 2025.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Omnibus Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2008, our stockholders approved the 2008 Omnibus Plan for share-based awards to our employees. Awards granted from the 2008 Omnibus Plan may include stock options, shares of restricted stock, restricted stock units, performance shares, shares of phantom stock, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for issuance under the 2008 Omnibus Plan consist of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares reserved for this purpose, plus shares of common stock that remained available for issuance under our 2005 Omnibus Equity Plan on the date that our stockholders approved the 2008 Omnibus Plan, plus shares that were subject to awards under the 2005 Omnibus Equity Plan which remain unissued upon the cancellation, surrender, exchange or termination of such awards. The 2008 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5-to-1&lt;/font&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; ratio.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have not made any awards pursuant to the 2005 Omnibus Equity Plan since our stockholders approved the 2008 Omnibus Plan, and do not intend to make any awards pursuant to the 2005 Omnibus Equity Plan in the future, except that unused shares under the 2005 Omnibus Equity Plan have been carried over for use under the 2008 Omnibus Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We currently do not grant stock options to our employees or directors. Outstanding stock options previously granted to our employees and directors generally have a ten-year term and vest over a period of between one and four years, provided the individual continues to serve at Biogen through the vesting dates. Options granted under all plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the options&amp;#8217; vesting periods. The fair value of the stock options granted in 2010 was estimated as of the date of grant using a Black-Scholes option valuation model. There were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; grants of stock options made in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, all outstanding options were exercisable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The expected life of options granted is derived using assumed exercise rates based on historical exercise patterns and represents the period of time that options granted are expected to be outstanding. Expected stock price volatility is based upon implied volatility for our exchange-traded options and other factors, including historical volatility. After assessing all available information on either historical volatility, implied volatility, or both, we have concluded that a combination of both historical and implied volatility provides the best estimate of expected volatility. The risk-free interest rate used is determined by the market yield curve based upon risk-free interest rates established by the Federal Reserve, or non-coupon bonds that have maturities equal to the expected term. The dividend yield of zero is based upon the fact that we have not historically granted cash dividends, and do not expect to issue dividends in the foreseeable future. Stock options granted prior to January&amp;#160;1, 2006 were valued based on the grant date fair value of those awards, using the Black-Scholes option pricing model, as previously calculated for pro-forma disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our stock option activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;221,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;56.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(114,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;59.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;107,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total intrinsic values of options exercised in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$38.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$42.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$86.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. The aggregate intrinsic values of options outstanding as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$27.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The weighted average remaining contractual term for options outstanding as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="53%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax benefit realized for stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;29.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received from the exercise of stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Market Stock Units (MSUs)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;MSUs awarded to employees prior to 2014 vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;150%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on actual stock performance. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;MSUs awarded to employees in 2014 and 2015 vest in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on actual stock performance. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The vesting of these awards is subject to the respective employee&amp;#8217;s continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our MSU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;403,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;219.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;185,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;493.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(277,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;165.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(42,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;294.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;269,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;339.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;MSUs granted in 2015 include approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:9pt;"&gt;8,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:9pt;"&gt;19,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:9pt;"&gt;24,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:9pt;"&gt;34,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt; MSUs issued in 2015 based upon the attainment of performance criteria set for 2014, 2013, 2012 and 2011, respectively, in relation to awards granted in those years. The remainder of MSUs granted during 2015 include awards granted in conjunction with our annual awards made in February 2015 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, including the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price on grant date for MSUs awarded prior to 2014, the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price on the date of grant for MSUs awarded in 2014 and 2015, expected volatility of our stock price, risk-free rates of return and expected dividend yield. The assumptions used in our valuation are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="44%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="18%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="18%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="18%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of expected stock price volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;31.0% - 33.2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.7% - 35.1%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.7% - 25.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of risk-free interest rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2% - 1.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1% - 0.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1% - 0.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 calendar day average stock price on grant date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$277.35 - $426.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$280.88 - $335.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;60 calendar day average stock price on grant date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.33 - $240.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average per share grant date fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$493.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$395.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$193.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total fair values of MSUs vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$109.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$117.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Cash Settled Performance Units (CSPUs)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;CSPUs awarded to employees vest in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee&amp;#8217;s continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December&amp;#160;31 of each year. Participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs awarded prior to 2014 are settled in cash based on the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. CSPUs awarded in 2014 and 2015 will be settled in cash based on the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our CSPU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="82%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="17%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;335,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;115,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(222,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(36,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;192,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;CSPUs granted in 2015 include approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:9pt;"&gt;48,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt; CSPUs issued in 2015 based upon the attainment of performance criteria set for 2014 in relation to awards granted in 2014. The remainder of the CSPUs granted in 2015 include awards granted in conjunction with our annual awards made in February 2015 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total cash paid in settlement of CSPUs vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$79.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$92.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$48.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Performance-vested Restricted Stock Units (PUs)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning in the first quarter of 2014, we revised our long term incentive program to include a new type of award granted to certain employees in the form of restricted stock units that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the cash settled performance units, and vest in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our PU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="82%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="17%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;57,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;89,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(33,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;103,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;PUs granted in 2015 include approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:9pt;"&gt;42,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt; PUs issued in 2015 based upon the attainment of performance criteria set for 2014 in relation to awards granted in 2014. The remainder of the PUs granted in 2015 include awards granted in conjunction with our annual awards made in February 2015 and PUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;32,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; PUs were converted to share settlements, of which approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares were vested and issued. All other PUs that vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; were settled in cash totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Time-Vested Restricted Stock Units (RSUs)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;RSUs awarded to employees generally vest no sooner than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one-third per year over three years&lt;/font&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes. The fair value of all RSUs is based on the market value of our stock on the date of grant. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our RSU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,137,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;221.01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;459,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;388.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(626,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;190.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(160,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;302.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;810,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;323.87&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;RSUs granted in 2015 primarily represent RSUs granted in conjunction with our annual awards made in February 2015 and awards made in conjunction with the hiring of new employees. RSUs granted in 2015 also include approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:9pt;"&gt;7,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt; RSUs granted to our Board of Directors.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;RSUs granted in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; had weighted average grant date fair values of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$321.72&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$176.53&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total fair values of RSUs vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$239.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$281.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$209.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan (ESPP)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2015, our stockholders approved the Biogen Inc. 2015 ESPP (2015 ESPP). The 2015 ESPP, which became effective on July 1, 2015, replaced the Biogen Idec Inc. 1995 ESPP (1995 ESPP), which expired on June&amp;#160;30, 2015. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our ESPP activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="53%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares issued under the 2015 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;78,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares issued under the 1995 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;98,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;180,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;245,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received under the 2015 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;19.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received under the 1995 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;30.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;46.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-E1179A9CE8A0C317C9D838A2913C294A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2015Q4YTD" id="Fact-FBA23D19363AB21AE77538A2913D3B95">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Earnings&amp;#160;per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="53%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,547.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,934.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,862.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;230.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;231.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;237.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;238.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Earnings per share for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, reflects, on a weighted average basis, the repurchase of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares, respectively, of our common stock under our share repurchase authorizations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:EquityMethodInvestmentsPolicy contextRef="FD2015Q4YTD" id="Fact-18DE6C335133749AD3A738A291355B05">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In circumstances where we have the ability to exercise significant influence over the operating and financial  policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&amp;#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship.&amp;#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceed the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
	<us-gaap:FairValueByBalanceSheetGroupingTextBlock contextRef="FD2015Q4YTD" id="Fact-19151B81C63868E1D23138A2913E6ADD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;602.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;634.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,497.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,014.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,764.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,757.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,645.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;647.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2015Q4YTD" id="Fact-49E56ACF914D35AA37AE38A2913A91A8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;909.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;909.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,510.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,510.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,875.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,875.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;494.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;494.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;27.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;27.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,895.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,857.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;520.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in&amp;#160;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;716.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;716.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,063.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,063.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;849.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;849.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;198.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;198.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;72.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;72.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;36.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;36.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,943.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,937.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;220.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third-party pricing services. For a description of our validation procedures related to prices provided by third-party pricing services, refer to Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies: Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our debt instruments, which are Level&amp;#160;2 liabilities, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;602.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;634.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,497.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,014.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,764.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,757.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,645.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;647.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair value of our notes payable to Fumedica was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable, and corroborated sources. For additional information related to our debt instruments, please read Note 11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the fair values of our contingent consideration obligations which includes Level 3 measurements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;280.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;274.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;30.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(38.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(14.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(26.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$301.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$200.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;There were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; changes in valuation techniques or transfers between fair value measurement levels during the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. During the third quarter 2014, we updated the probabilities of success related to the early stage programs acquired through our recent acquisitions. We adjusted the value of our contingent consideration liabilities to reflect these changes. The change in probability of success, combined with a delay in one of the projects, resulted in a net gain of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$49.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during 2014, which was&amp;#160;recorded in (gain) loss on fair value remeasurement of contingent consideration and reduced the fair value of our contingent consideration obligations. The fair values of the intangible assets and contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. For additional information related to the valuation techniques and inputs utilized in valuation of our financial assets and liabilities, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Convergence in February 2015, we recorded a liability of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$274.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, representing the fair value of the contingent consideration. This valuation was based on probability weighted net cash outflow projections of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$450.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, discounted using a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which was the estimated cost of debt financing for market participants. This liability reflects the revised estimate from the date of acquisition for our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. For a more detailed description of this transaction, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the fair value of this contingent consideration obligation was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$297.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, discounted using a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$197.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is reflected as a component of accrued expenses and other in our consolidated balance sheets as we expect to make the payment within a year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Stromedix in March 2012, we recorded a contingent consideration obligation of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$122.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the fair value of this contingent consideration obligation was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$131.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$130.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our most recent valuation was determined based upon probability weighted net cash outflow projections of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$419.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, discounted using a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which is a measure of the credit risk associated with settling the liability. For &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net increase in the fair value of this obligation was primarily due to changes in the discount rate, partially offset by changes in the expected timing related to the achievement of certain remaining developmental milestones.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon completion of our purchase of the noncontrolling interest in our joint venture investments in Biogen Domp&amp;#233; SRL and Biogen Domp&amp;#233; Switzerland GmbH in September 2011, we recorded a contingent consideration obligation of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$38.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the fair value of this contingent consideration obligation was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. For &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net decrease in the fair value of this obligation was primarily due to payments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$14.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of sales-based milestones. Our obligations under this agreement were completed as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Biogen Idec International Neuroscience GmbH (BIN), formerly Panima Pharmaceuticals AG (Panima), in December 2010, we recorded a contingent consideration obligation of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$81.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the fair value of this contingent consideration obligation was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$77.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$69.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our most recent valuation was determined based upon probability weighted net cash outflow projections of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$365.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, discounted using a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which is a measure of the credit risk associated with settling the liability. For &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net increase in the fair value of this obligation was primarily due to changes in the probability and expected timing related to the achievement of certain remaining developmental milestones and in the discount rate.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Acquired IPR&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Convergence, we also allocated &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$424.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the total purchase price to acquired IPR&amp;amp;D, which was capitalized as an intangible asset. The amount allocated to acquired IPR&amp;amp;D was based on significant inputs not observable in the market and thus represented a Level 3 fair value measurement. This estimate was also adjusted from our preliminary estimate as of the date of acquisition to reflect revised estimates to our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. These assets will be tested for impairment annually until commercialization, after which time the IPR&amp;amp;D will be amortized over its estimated useful life. For a more detailed description of this transaction, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2015Q4YTD" id="Fact-5F39C63073CC36A6B77638A2911F6AD9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;280.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;274.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;30.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(38.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(14.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(26.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2015Q4YTD" id="Fact-583A3FD2BD0703019D2538A2913570B4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have certain financial assets and liabilities recorded at fair value which have been classified as Level&amp;#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates;&amp;#160;and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our financial assets have been classified as Level&amp;#160;2. Our financial assets (which include our cash equivalents, derivative contracts, marketable debt securities, and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We validate the prices provided by our third-party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources and analyzing pricing data in certain instances. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying amounts reflected in the consolidated balance sheets for current accounts receivable, due from unconsolidated joint business, other current assets, accounts payable, and accrued expenses and other, approximate fair value due to their short-term maturities.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-830F7F66498E0E1D7F3138A29142908A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&amp;#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net, in net income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-BB7F112679BDAA5FB8D738A291281361">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Intangible Assets and Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="21%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="17%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(481.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2,552.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;452.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,396.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;608.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;730.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;730.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks and tradenames&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6-18 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,303.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(502.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,800.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,280.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(300.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,980.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7,646.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3,561.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,085.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,207.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3,178.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,028.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization of acquired intangible assets totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$382.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$489.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$342.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Amortization of acquired intangible assets during 2014 included total impairment charges of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$34.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to one of our out-licensed patents and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to one of our IPR&amp;amp;D intangible assets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Out-licensed Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents to third-parties primarily relate to patents acquired in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. During 2014, we recorded a charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$34.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the impairment of one of our out-licensed patents to reflect a change in its estimated fair value, due to a change in the underlying competitive market for that product. The charge was included in amortization of acquired intangible assets. The fair value of the intangible asset was based on a discounted cash flow calculated using Level 3 fair value measurements and inputs including estimated revenues. There were no impairment charges related to our out-licensed patents during &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Developed Technology&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$443.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;IPR&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IPR&amp;amp;D represents the fair value assigned to research and development assets that we acquire that have not reached technological feasibility at the date of acquisition. Upon commercialization, we determine the estimated useful life. In connection with our acquisition of Convergence in February 2015, we acquired IPR&amp;amp;D programs with an estimated fair value of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$424.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This amount has and will be adjusted for foreign exchange rate fluctuations. For a more detailed description of this transaction, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of anticipated lifetime revenues and anticipated development costs is performed annually during our long- range planning cycle, which was updated in the third quarter of 2015.&amp;#160;This analysis is based upon certain assumptions that we evaluate on a periodic basis, including anticipated future product sales, the expected impact of changes in the amount of development costs and the probabilities of our programs succeeding, the introduction of new products by our competitors and changes in our commercial and pipeline product candidates.&amp;#160;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the third quarter of 2014, we updated the probabilities of success related to the early stage programs acquired through our recent acquisitions.&amp;#160;The change in probability of success, combined with a delay in one of the projects, resulted in an impairment loss of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in one of our IPR&amp;amp;D assets during 2014.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Acquired and In-licensed Rights and Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan. The net book value of this asset as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2,742.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For a more detailed description of this transaction, please read Note&amp;#160;2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Estimated Future Amortization of Intangible Assets&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our most recent long range planning cycle was completed in the third quarter of 2015. Based upon this analysis, the estimated future amortization of acquired intangible assets is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="81%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="17%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;346.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;318.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;291.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;275.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;269.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,500.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,760.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,232.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;908.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;527.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,760.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The increase in goodwill during &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was related to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$900.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in contingent milestones achieved (exclusive of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$120.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$128.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to our acquisition of Convergence. Other includes changes related to foreign exchange rate fluctuations. The increase in goodwill during &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was related to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$600.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in contingent milestones achieved (exclusive of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$72.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to future contingent payments to the former shareholders of Fumapharm AG, please read Note 21, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. For additional information related to our acquisition of Convergence, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; accumulated impairment losses related to goodwill.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="FD2015Q4YTD" id="Fact-A930D60DF28089B3EC3F38A2913E0BCB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&amp;#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, then we would need to determine the implied fair value of our reporting unit&amp;#8217;s goodwill. If the carrying value of our reporting unit&amp;#8217;s goodwill exceeds its implied fair value, then we would record an impairment loss equal to the difference. As described in Note&amp;#160;24, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Segment Information&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements, we operate in one operating segment which we consider our only reporting unit.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
	<us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="FD2015Q4YTD" id="Fact-D89A6A367806526ED0D838A2913D27A4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&amp;#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded as amortization of acquired intangible assets in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd (Elan), an affiliate of Elan Corporation, plc. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TYSABRI and AVONEX using the economic consumption method based on revenue generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TYSABRI and AVONEX is performed annually during our long range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of TYSABRI or AVONEX.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives, however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&amp;#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
	<us-gaap:GuaranteesTextBlock contextRef="FD2015Q4YTD" id="Fact-EFE684B40234089FD14438A2913D5557">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Guarantees&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we did not have significant liabilities recorded for guarantees.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GuaranteesTextBlock>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-93214877B2AF215997BC38A29135948F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets to be held and used, including property, plant and equipment and definite-lived intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="FD2015Q4YTD" id="Fact-499DBB761AE25CCBB4A638A29142715A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired IPR&amp;amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value. The revenue and costs projections used to value acquired IPR&amp;amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology, and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business, then the acquired IPR&amp;amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Certain IPR&amp;amp;D programs have a fair value that is not significantly in excess of carrying value, including our program for the treatment of TGN. Such programs could become impaired if assumptions used in determining the fair value change.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-B28741816C5EB98644D838A291340CEB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Income Tax Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income before income tax provision and the income tax expense consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="53%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income before income taxes (benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Domestic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,386.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,557.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,953.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,380.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,389.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;527.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,767.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,946.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,480.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income tax expense (benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,214.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,159.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;700.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;38.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;98.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;54.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;73.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;46.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,307.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,298.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;846.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(129.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(280.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(200.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(35.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(14.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(145.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(308.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(245.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total income tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,161.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;989.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;601.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Deferred Tax Assets and Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Significant components of our deferred tax assets and liabilities are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;189.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;69.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory, other reserves, and accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;243.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;217.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangibles, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;328.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;251.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net operating loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;63.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;86.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;60.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(14.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;693.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(440.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(432.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depreciation, amortization and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(102.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(107.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(542.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(539.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In accordance with ASU No. 2015-17, at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we reclassified &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$137.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our deferred tax assets classified as current to noncurrent and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our deferred tax liabilities classified as current to noncurrent in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; consolidated balance sheet, to conform our prior year presentation to our current year presentation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to deferred tax assets and liabilities, we have recorded prepaid tax and deferred charges related to intercompany transactions. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the total deferred charges and prepaid taxes were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$697.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$238.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During 2013, we recorded a deferred charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$203.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in connection with an intercompany transfer of the intellectual property for ZINBRYTA. The net book value of this deferred charge as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$166.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$179.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. The deferred charge will be amortized to income tax expense over the economic life of the ZINBRYTA program. Our regulatory submissions in Europe and the U.S. have been accepted for review by the relevant authorities. If the ZINBRYTA applications are not approved, we may have to accelerate the amortization of this deferred charge and record an expense equal to its remaining net book value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Rate&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&amp;#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="55%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our effective tax rate for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; benefited from lower anticipated taxes on foreign earnings and reflects a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$27.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; benefit from the 2015 remeasurement of one of our uncertain tax positions, described below under &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;"Accounting for Uncertainty in Income Taxes"&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our effective tax rate for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; increased primarily as a result of the absence of a benefit related to the 2013 change in our uncertain tax position related to our U.S. federal manufacturing deduction and our unconsolidated joint business described below under &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;"Accounting for Uncertainty in Income Taxes"&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, lower current year expenses eligible for the orphan drug credit and a lower relative manufacturing deduction due to unqualified products, partially offset by a higher percentage of our 2014 income being earned outside the U.S.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had net operating losses and general business credit carry forwards for federal income tax purposes of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$127.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which begin to expire in 2020. Additionally, for state income tax purposes, we had net operating loss carry forwards of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$91.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which begin to expire in 2016. For state income tax purposes, we also had research and investment credit carry forwards of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$125.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which begin to expire in 2016. For foreign income tax purposes, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$53.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of net operating loss carryforwards, which begin to expire in 2021.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. Our estimates of future taxable income take into consideration, among other items, our estimates of future income tax deductions related to the exercise of stock options. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax assets are utilizable, we believe it is more likely than not that we will realize the benefits of the deferred tax assets of our wholly owned subsidiaries. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to establish a valuation allowance, which could materially impact our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, undistributed foreign earnings of non-U.S.&amp;#160;subsidiaries included in consolidated retained earnings and other basis differences aggregated approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$6.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We intend to reinvest these earnings indefinitely in operations outside the U.S.&amp;#160;The residual U.S. tax liability, if cumulative amounts were repatriated, would be between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Uncertainty in Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="56%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at January&amp;#160;1,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;131.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;110.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;125.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions based on tax positions related to the current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions for tax positions of prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;19.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;86.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reductions for tax positions of prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(49.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(23.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(92.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statute expirations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Settlements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(42.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(60.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;67.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;131.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;110.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in the U.S.&amp;#160;federal jurisdiction, various U.S. states, and foreign jurisdictions. With few exceptions, including the proposed disallowance we discuss below, we are no longer subject to U.S.&amp;#160;federal tax examination for years before 2013 or state, local, or non-U.S.&amp;#160;income tax examinations for years before 2004. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Included in the balance of unrecognized tax benefits as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; are &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$53.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$32.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize potential interest and penalties accrued related to unrecognized tax benefits in income tax expense. In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a net interest expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized net interest expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a net interest expense of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We have accrued approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$17.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the payment of interest as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2015, we received a final assessment from the Danish Tax Authority (SKAT) for fiscal 2009, regarding withholding taxes and the treatment of certain intercompany transactions involving our Danish affiliate and another of our affiliates.&amp;#160;The audits of our tax filings for 2010 through 2013 are not completed but have been prepared in a manner consistent with prior filings, with similar transactions. In December 2015, we received draft assessments for these periods.&amp;#160;The total amount assessed for all periods is &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, including interest.&amp;#160;For all periods potentially under dispute, we believe that positions taken in our tax filings are valid and we are contesting the assessment vigorously.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Federal Uncertain Tax Positions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During 2013, we received updated technical guidance from the IRS concerning our current and prior year filings and calculation of our U.S. federal manufacturing deduction and overall tax classification of our unconsolidated joint business.&amp;#160;Based on this guidance we reevaluated the level of our unrecognized benefits related to uncertain tax positions, and recorded a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$49.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; income tax benefit.&amp;#160;This benefit is for a previously unrecognized position and relates to years 2005 through 2012. We recorded an offsetting expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$11.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for non-income based state taxes, which is recorded in other income (expense) in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2011, in conjunction with our examination, the IRS proposed a disallowance of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$130 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in deductions for tax years 2007, 2008 and 2009 related to payments for services provided by our wholly owned Danish subsidiary located in Hiller&amp;#248;d, Denmark. We believe that these items represent valid deductible business expenses and are vigorously defending our position. We have initiated a mutual agreement procedure between the IRS and SKAT for the years 2001 through 2009, in an attempt to reach agreement on the issue. In addition, we have applied for a bilateral advanced pricing agreement for the years 2010 through 2014 to resolve similar issues for the subsequent years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net effect of adjustments to our uncertain tax positions was a net benefit of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. It is reasonably possible that we will adjust the value of our uncertain tax positions related to our unconsolidated joint business and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with the authorities. In addition, the IRS and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-70A4CDEB8639F8CD17DA38A29136DC27">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;All tax effects associated with intercompany transfers of assets in our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through the consolidated statement of income when the asset transferred is sold to a third party or otherwise recovered through amortization of the asset's remaining economic life.&amp;#160;If the asset transferred becomes impaired, for example through the discontinuation of a research program, we will expense any remaining deferred charge or prepaid tax.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We account for uncertain tax positions using a &amp;#8220;more-likely-than-not&amp;#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-554E4654752A46E1F3B638A291407413">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;213.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;128.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;577.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;511.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;143.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;164.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;933.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;804.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;893.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;804.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;933.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;804.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory included in investments and other assets in our consolidated balance sheets primarily consisted of work in process.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our inventory included &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$24.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with our ZINBRYTA program, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$18.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with our BENEPALI program and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$24.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with our FLIXABI program, which have been capitalized in advance of regulatory approval. In January 2016, the European Commission (EC) approved the marketing authorization application (MAA) for BENEPALI for marketing in the E.U. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our inventory included &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$6.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with our ZINBRYTA program, which has been capitalized in advance of regulatory approval. For information on our pre-approval inventory policy, please read Note 1,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$41.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$47.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-935D06FDFD02BDA52A5838A2913C4CCA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when selected for use in a clinical manufacturing campaign.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Capitalization of Inventory Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&amp;#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Obsolescence and Unmarketable Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring which we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:InvestmentPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-226041A26F892037FA3038A29137FDB5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Available-for-sale debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Equity Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheet. When assessing whether a decline in the fair value of a marketable equity security is other-than-temporary, we consider the fair market value of the security, the duration of the security&amp;#8217;s decline, and prospects for the underlying business, including favorable or adverse clinical trial results, new product initiatives and new collaborative agreements with the companies in which we have invested.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Non-Marketable Equity Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the cost method or the equity method of accounting, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any decline in their value has occurred that would be other-than-temporary, based on the implied value of recent company financings, public market prices of comparable companies, and general market conditions and are included in investments and other assets in our consolidated balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Evaluating Investments for Other-than-Temporary Impairments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&amp;#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For equity securities, when assessing whether a decline in value is other-than-temporary, we consider the fair market value of the security, the duration of the security&amp;#8217;s decline, and the financial condition of the issuer. We then consider our intent and ability to hold the equity security for a period of time sufficient to recover our carrying value. Where we have determined that we lack the intent and ability to hold an equity security to its expected recovery, the security&amp;#8217;s decline in fair value is deemed to be other-than-temporary and is reflected in earnings as an impairment loss.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
	<us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="FD2015Q4YTD" id="Fact-7FED0F03E2EAE700B5D838A29135D188">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160; Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160; Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,120.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,122.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;640.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;640.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,575.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,583.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,343.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,345.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;184.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;185.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;126.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;126.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,880.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,891.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,111.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,112.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
	<us-gaap:LegalMattersAndContingenciesTextBlock contextRef="FD2015Q4YTD" id="Fact-C7640CF1F3AE2BBBB63638A291346185">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies regarding contingencies, see Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Patent Matters &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Forward Pharma German Patent Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On November 18, 2014 Forward Pharma A/S (Forward Pharma) filed suit against us in the Regional Court of Dusseldorf, Germany alleging that TECFIDERA infringes German Utility Model DE&amp;#160;20 2005 022 112&amp;#160;U1, which was issued in April 2014 and expired in October 2015. Forward Pharma subsequently&amp;#160;extended its allegations&amp;#160;to assert that TECFIDERA infringes Forward Pharma's European Patent No. 2,801,355, which was issued in May 2015 and expires in October 2025. Forward Pharma seeks declarations of infringement and damages for our sales of TECFIDERA in Germany. Under German law, disgorgement of profits on infringing sales is a measure of damages. A hearing has been scheduled for early 2016.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Interference Proceeding with Forward Pharma&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2015, the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&amp;#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of multiple sclerosis with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. A hearing has been scheduled for early 2017.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Inter Partes Review Proceeding&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On September 28, 2015, the Coalition for Affordable Drugs V LLC, an entity associated with a hedge fund, filed a petition with the USPTO for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;inter partes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; review of the '514 patent, which we opposed. The USPTO has not yet decided whether to institute review. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;European Patent Office Oppositions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Several parties have filed oppositions in the European Patent Office requesting revocation of our European patent number 2 137 537 (the '537 patent), which includes claims covering the treatment of multiple sclerosis with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. The '537 patent expires in 2028.&amp;#160;A hearing has been scheduled for early 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Patent Licensing Matter &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are in discussions with Pfizer regarding its proposal that we take a license to its U.S. Patent No. 8,603,777&amp;#160;(Expression of Factor VII and IX Activities in Mammalian Cells) and pay&amp;#160;royalties on sales of ALPROLIX. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Patent Revocation Matter&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2015, Swiss Pharma International AG brought an action in the Patents Court of the United Kingdom to revoke the UK counterpart of our European Patent Number 1 485 127&amp;#160;(&amp;#8220;Administration of agents to treat inflammation&amp;#8221;) (the '127 patent), which was issued in June 2011 and concerns administration of natalizumab (TYSABRI) to treat multiple sclerosis. The patent expires in February 2023.&amp;#160;On January 11, 2016 the same entity brought an action in the District Court of The Hague seeking to revoke the Dutch counterpart of the '127 patent. A hearing has been scheduled in the Dutch action for early 2017. No hearing has yet been scheduled in the UK action.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;'755 Patent Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On May&amp;#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&amp;#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (manufacturer, marketer and seller of REBIF), Pfizer Inc. (co-marketer of REBIF), and Novartis Pharmaceuticals Corp. (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. The court has consolidated the two lawsuits, and we refer to the two actions as the &amp;#8220;Consolidated '755 Patent Actions.&amp;#8221;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims in the Consolidated '755 Patent Actions seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees, and EMD Serono and Bayer have each filed a counterclaim seeking a declaratory judgment that the '755 Patent is unenforceable based on alleged inequitable conduct. Bayer has also amended its complaint to seek such a declaration. No trial date has been set.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Italian National Medicines Agency&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the fourth quarter of 2011, Biogen Italia SRL&amp;#160;received notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in December 2006. On December&amp;#160;23, 2011, we filed an appeal in the Regional Administrative Tribunal of Lazio (Il Tribunale Amministrativo Regionale per il Lazio) in Rome, Italy seeking a ruling that the reimbursement limit in the Price Resolution should apply as written to only &amp;#8220;the first &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months&amp;#8221; of TYSABRI sales, which ended in mid-February 2009. The appeal is still pending. In June 2014, AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. AIFA and Biogen Italia SRL are discussing a possible resolution for the period from February 2009 through January 2013.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Government Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government in this matter. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also received a subpoena from the federal government for documents relating to our relationship with certain pharmacy benefit managers, with which we cooperated. We do not anticipate any further involvement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Qui Tam Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On July 6, 2015, four qui tam actions filed against us by relators suing on behalf of the United States and certain states were unsealed by the U.S. District Court for the District of Massachusetts. The actions, which have been administratively consolidated, allege sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seek single and treble damages, civil penalties, interest, attorneys&amp;#8217; fees and costs. The United States declined to intervene in two of the actions, both of which have since been voluntarily dismissed, and has not made an intervention decision in the other two actions, which we have moved to dismiss. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Securities Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and certain current and former officers are defendants in In re Biogen Inc. Securities Litigation, filed by a shareholder on August 18, 2015 in the U.S. District Court for the District of Massachusetts. The amended complaint alleges violations of federal securities laws under 15 U.S.C. &amp;#167;78j(b) and &amp;#167;78t(a) and 17 C.F.R. &amp;#167;240.10b-5. The lead plaintiff seeks a declaration of the action as a class action, certification as a representative of the class and its counsel as class counsel, and an award of damages, interest, and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Product Liability and Other Legal Proceedings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
	<us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="FD2015Q4YTD" id="Fact-A078A66B6E55A2691DF438A2912D9914">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Acquisitions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Convergence Pharmaceuticals&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On February 12, 2015, we completed our acquisition of all of the outstanding stock of Convergence Pharmaceuticals (Convergence), a clinical-stage biopharmaceutical company with a focus on developing product candidates for neuropathic pain. Convergence&amp;#8217;s lead candidate is a Phase 2 clinical candidate Raxatrigine (CNV1014802), which has demonstrated clinical activity in proof-of-concept studies for trigeminal neuralgia (TGN). Additionally, Raxatrigine has potential applicability in several other neuropathic pain states. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The purchase price consisted of a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$200.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; cash payment at closing, plus contingent consideration in the form of development and approval milestones up to a maximum of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$450.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$350.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is associated with the development and approval of Raxatrigine for the treatment of TGN. The acquisition was funded from our existing cash on hand and has been accounted for as the acquisition of a business. In addition to obtaining the rights to Raxatrigine and additional product candidates in preclinical development, we retained the services of key employees of Convergence.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Convergence, we recorded a liability of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$274.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; representing the fair value of the contingent consideration.&amp;#160;This amount was estimated through a valuation model that incorporates industry-based probability adjusted assumptions relating to the achievement of these milestones and thus the likelihood of making the contingent payments. This fair value measurement is based upon significant inputs not observable in the market and therefore represents a Level 3 measurement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The purchase price, as adjusted, consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash portion of consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;200.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;274.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;474.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the second quarter of 2015, we adjusted our preliminary estimate of the fair value of the assets acquired and contingent consideration as of the date of acquisition as a result of finalizing the purchase price accounting. This resulted in an increase in the value of our estimated contingent consideration and goodwill by &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$36.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our revised purchase price allocation is reflected in the chart below. Our purchase price allocation is substantially complete.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subsequent changes in the fair value of the contingent consideration obligation will be recognized as adjustments to contingent consideration and reflected in our consolidated statements of income. For additional information related to the fair value of this obligation, please read Note 7,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of February&amp;#160;12, 2015, as adjusted:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;424.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;128.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(84.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;474.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our estimate of the fair value of the IPR&amp;amp;D programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This valuation was primarily driven by the value associated with the lead candidate, Raxatrigine, which is in development for the treatment of TGN and is expected to be completed no earlier than 2020, at a remaining cost of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$145.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The fair value associated with Raxatrigine for the treatment of TGN was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$200.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We have recorded additional IPR&amp;amp;D assets related to the use of Raxatrigine in two additional neuropathic pain indications, with a total estimated value of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$220.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The remaining cost of development for these two indications is approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$415.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, with an expected completion date of no earlier than 2021. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have attributed the goodwill recognized to the Convergence workforce's expertise in chronic pain research and clinical development and to establishing a deferred tax liability for the acquired IPR&amp;amp;D intangible assets which have no tax basis. The goodwill is not tax deductible.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pro forma results of operations would not be materially different as a result of the acquisition of Convergence and therefore are not presented. Subsequent to the acquisition date, our results of operations include the results of operations of Convergence.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;TYSABRI&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On April 2, 2013, we acquired full ownership of all remaining rights to TYSABRI from Elan that we did not already own or control. Upon the closing of the transaction, we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.25 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Elan, which was funded from our existing cash, and our collaboration agreement with Elan was terminated. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We accounted for this transaction as the acquisition of an asset as we did not acquire any employees from Elan nor did we acquire any significant processes that we did not previously perform or manage under the collaboration agreement. Under the collaboration agreement, we manufactured TYSABRI and collaborated with Elan on the product's marketing, commercial, regulatory, distribution and ongoing development activities. The collaboration agreement was designed to effect an equal sharing of worldwide profits and losses generated by the activities of the collaboration. For additional information related to this collaboration, please read Note&amp;#160;19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.25 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment was capitalized in the second quarter of 2013 as an intangible asset in our consolidated balance sheet as TYSABRI had reached technological feasibility. We adjusted the value of this intangible asset by &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$84.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to deferred revenue from two sales-based milestones previously paid by Elan as well as transaction costs. The net intangible asset capitalized was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.18 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Commencing in the second quarter of 2013, we began amortizing this intangible asset over the estimated useful life using an economic consumption method based on actual and expected revenue generated from the sales of our TYSABRI product. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Following the April 2, 2013 closing of the transaction, we began recording 100% of U.S. revenues, cost of sales and operating expenses related to TYSABRI in our consolidated statements of income. Under the terms of the acquisition agreement, we continued to share TYSABRI profits with Elan on an equal basis until April 30, 2013. We recorded the profit split for the month ended April 30, 2013, as cost of sales in our consolidated statements of income as we controlled TYSABRI effective April 2, 2013. Between May 1, 2013 and April 30, 2014, we made contingent payments to Elan of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on worldwide net sales of TYSABRI. Commencing May 1, 2014 and thereafter, we will make contingent payments to Elan of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on annual worldwide net sales up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on annual worldwide net sales that exceed &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In 2014, the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; threshold was pro-rated for the portion of 2014 remaining after the first 12 months expired. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013. Following that acquisition, we began making these royalty payments to Perrigo. Royalty payments to Perrigo and other third parties are recognized as cost of sales in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-9B9EFE96ACF14415EF2738A291351D8D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2014, the FASB issued ASU No. 2014-11, Transfers and Servicing (Topic 860): Repurchase-to-Maturity Transactions, Repurchase Financings, and Disclosure. The new standard expanded secured borrowing accounting to include repurchase-to-maturity transactions and repurchase financings and set forth new disclosure requirements for repurchase agreements, securities lending transactions, and repurchase-to-maturity transactions that are accounted for as secured borrowings. We adopted this standard on April 1, 2015 and expanded our disclosures presented in Note 8, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. The adoption of this standard did not have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2015, the FASB issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The new standard requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU No. 2015-15, Interest - Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements, which clarified that debt issuance costs related to line-of-credit arrangements can be presented in the balance sheet as an asset and amortized over the term of the line-of-credit arrangement. We adopted these standards as of September 30, 2015 with retroactive application. The adoption of these standards did not have a significant impact on our financial position or results of operations. For additional information, please read Note 11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2015, the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. Under this standard, if a cloud computing arrangement includes a software license, the software license element of the arrangement should be accounted for consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2015, the FASB issued ASU No. 2015-07, Fair Value Measurement (Topic 820): Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent). The new standard removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The new standard will be effective for us on January 1, 2016. Early application is permitted. We maintain investments in certain venture capital funds which primarily invest in small, privately-owned, venture-backed biotechnology companies. The value of our investments in these venture capital funds is estimated using the net asset value of the fund and has been included in the fair value hierarchy disclosure as a Level 3 measurement. These venture capital investments are not material to our financial position or results of operations. We adopted this standard as of June 30, 2015 and our investments in venture capital funds are no longer included in our disclosures reflected in Note 7, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The new standard applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The new standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined and sets forth new disclosure requirements related to the adjustments. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. The new standard requires that deferred tax assets and liabilities be classified as noncurrent in a classified statement of financial position. We adopted this standard as of December 31, 2015 with retroactive application. As a result, we reclassified our deferred tax assets classified as current to noncurrent and our deferred tax liabilities classified as current to noncurrent in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; consolidated balance sheet, to conform our prior year presentation to our current year presentation. For additional information, please read Note 16, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="FD2015Q4YTD" id="Fact-A684694048A972EEC31138A2913C809B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Business Overview&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. We also have a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, which entitles us to certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL, and other potential anti-CD20 therapies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to our innovative drug development efforts, we aim to leverage our manufacturing capabilities and scientific expertise to extend our mission to improve the lives of patients living with serious diseases through the development, manufacture and marketing of biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. Product revenues are recorded net of applicable reserves for discounts and allowances.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Reserves for Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We establish reserves for trade term discounts, wholesaler incentives, Medicaid rebates, co-payment assistance (copay), Veterans Administration (VA) and Public Health Service (PHS) discounts, managed care rebates, product returns and other governmental rebates or applicable allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Reserves established for these discounts and allowances are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These reserves are based on estimates of the amounts earned or to be claimed on the related sales. Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenue reserves are categorized as follows: discounts, contractual adjustments and returns.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contractual adjustments primarily relate to Medicaid and managed care rebates, patient copay assistance, VA and PHS discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid, and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consists of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&amp;#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Copay represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other governmental rebates or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to the discounts, rebates and product returns described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify these payments in selling, general and administrative expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Revenues from Unconsolidated Joint Business&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from unconsolidated joint business consists of (i)&amp;#160;our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; (ii)&amp;#160;reimbursement of our selling and development expenses in the U.S. for RITUXAN; and (iii)&amp;#160;revenue on sales in the rest of world for RITUXAN, which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales outside the U.S. and Canada by the Roche Group and its sublicensees. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by Genentech in the U.S. and by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less the cost to manufacture, third-party royalty expenses, distribution, selling, and marketing expenses, and joint development expenses incurred by Genentech, the Roche Group and us. We record our share of the pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales outside the U.S. on a cash basis as we do not have the ability to estimate these profits or royalty revenue in the period incurred. Additionally, our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. includes estimates made by Genentech and those estimates are subject to change. Actual results may differ from our estimates. For additional information related to our collaboration with Genentech, please read Note&amp;#160;19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Royalty Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. If we are unable to reasonably estimate royalty revenue or do not have access to the information, then we record royalty revenues on a cash basis. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Multiple-Element Revenue Arrangements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We may enter into transactions that involve the sale of products and related services under multiple element arrangements.&amp;#160;In accounting for these transactions, we assess the elements of the contract and whether each element has standalone value and allocate revenue to the various elements based on their estimated selling price as a component of total revenues.&amp;#160;The selling price of a revenue generating element can be based on current selling prices offered by us or another party for current products or management&amp;#8217;s best estimate of a selling price. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have certain financial assets and liabilities recorded at fair value which have been classified as Level&amp;#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates;&amp;#160;and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our financial assets have been classified as Level&amp;#160;2. Our financial assets (which include our cash equivalents, derivative contracts, marketable debt securities, and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We validate the prices provided by our third-party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources and analyzing pricing data in certain instances. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying amounts reflected in the consolidated balance sheets for current accounts receivable, due from unconsolidated joint business, other current assets, accounts payable, and accrued expenses and other, approximate fair value due to their short-term maturities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consider only those investments which are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, cash equivalents were comprised of money market funds and commercial paper, overnight reverse repurchase agreements, and other debt securities with maturities less than 90 days from the date of purchase.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounts Receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&amp;#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&amp;#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our consolidated statement of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The credit and economic conditions in certain countries in the E.U. continue to remain uncertain and have, from time to time, led to a lengthening of time to collect our accounts receivable in some of these countries. In recent years, our collection efforts in Portugal and select regions of Spain have been subject to significant payment delays due to government funding and reimbursement practices. As a result, a portion of these receivables have been routinely collected beyond our contractual payment terms and over periods in excess of one year. Our accounts receivable collection efforts in Portugal and Spain have improved during &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; with our receivables in Spain now expected to be collected within one year. Our net accounts receivable balance from product sales in Portugal and Spain totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$62.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$90.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$6.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; were classified as non-current and included in investments and other assets in our consolidated balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives, and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable arise from product sales in the U.S. and Europe and have standard payment terms which generally require payment within &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 to 90 days&lt;/font&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, two wholesale distributors individually accounted for approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.4%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;23.1%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.4%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;23.3%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of accounts receivable, net, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Marketable Securities and Other Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Available-for-sale debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Equity Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheet. When assessing whether a decline in the fair value of a marketable equity security is other-than-temporary, we consider the fair market value of the security, the duration of the security&amp;#8217;s decline, and prospects for the underlying business, including favorable or adverse clinical trial results, new product initiatives and new collaborative agreements with the companies in which we have invested.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Non-Marketable Equity Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the cost method or the equity method of accounting, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any decline in their value has occurred that would be other-than-temporary, based on the implied value of recent company financings, public market prices of comparable companies, and general market conditions and are included in investments and other assets in our consolidated balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Evaluating Investments for Other-than-Temporary Impairments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&amp;#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For equity securities, when assessing whether a decline in value is other-than-temporary, we consider the fair market value of the security, the duration of the security&amp;#8217;s decline, and the financial condition of the issuer. We then consider our intent and ability to hold the equity security for a period of time sufficient to recover our carrying value. Where we have determined that we lack the intent and ability to hold an equity security to its expected recovery, the security&amp;#8217;s decline in fair value is deemed to be other-than-temporary and is reflected in earnings as an impairment loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Equity Method of Accounting&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In circumstances where we have the ability to exercise significant influence over the operating and financial  policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&amp;#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship.&amp;#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceed the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when selected for use in a clinical manufacturing campaign.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Capitalization of Inventory Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&amp;#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Obsolescence and Unmarketable Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring which we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three to five years&lt;/font&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="50%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="50%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Useful Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Not depreciated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15 to 40&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Leasehold Improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Lesser of the useful life or the term of the respective lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Furniture and Fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 7&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Machinery and Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 20&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Computer&amp;#160;Software&amp;#160;and&amp;#160;Hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3 to 5&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts on our consolidated balance sheet and include any resulting gain or loss in our consolidated statement of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&amp;#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded as amortization of acquired intangible assets in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd (Elan), an affiliate of Elan Corporation, plc. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TYSABRI and AVONEX using the economic consumption method based on revenue generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TYSABRI and AVONEX is performed annually during our long range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of TYSABRI or AVONEX.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives, however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&amp;#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Acquired In-process Research and Development (IPR&amp;amp;D)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired IPR&amp;amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value. The revenue and costs projections used to value acquired IPR&amp;amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology, and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business, then the acquired IPR&amp;amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Certain IPR&amp;amp;D programs have a fair value that is not significantly in excess of carrying value, including our program for the treatment of TGN. Such programs could become impaired if assumptions used in determining the fair value change.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&amp;#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, then we would need to determine the implied fair value of our reporting unit&amp;#8217;s goodwill. If the carrying value of our reporting unit&amp;#8217;s goodwill exceeds its implied fair value, then we would record an impairment loss equal to the difference. As described in Note&amp;#160;24, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Segment Information&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements, we operate in one operating segment which we consider our only reporting unit.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets to be held and used, including property, plant and equipment and definite-lived intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions that qualify as business combinations completed after January&amp;#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue these contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step, and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Derivative Instruments and Hedging Activities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of derivatives are recorded each period in current earnings or accumulated other comprehensive income (loss), depending on whether a derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We also assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion to current earnings. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Translation of Foreign Currencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&amp;#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net, in net income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Royalty Cost of Sales&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&amp;#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Share-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share-based compensation programs grant awards that have included stock options, restricted stock units which vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units which settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units which can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of the Board of Directors and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date on which the employee is retirement eligible.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&amp;#8217; vesting periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures, when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs and PUs and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs and PUs are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The purchase price of common stock under our ESPP is equal to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the lesser of (i)&amp;#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&amp;#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes model. The fair value of the look-back provision plus the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; discount is recognized as compensation expense over the 90 day purchase period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable, and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets on our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&amp;#160;19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of unconsolidated joint business revenues.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For collaborations with commercialized products, if we are the principal, we record revenue and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Selling, General and Administrative Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Advertising costs are expensed as incurred. For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, advertising costs totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$108.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$92.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$72.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;All tax effects associated with intercompany transfers of assets in our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through the consolidated statement of income when the asset transferred is sold to a third party or otherwise recovered through amortization of the asset's remaining economic life.&amp;#160;If the asset transferred becomes impaired, for example through the discontinuation of a research program, we will expense any remaining deferred charge or prepaid tax.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We account for uncertain tax positions using a &amp;#8220;more-likely-than-not&amp;#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&amp;#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&amp;#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Earnings per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2014, the FASB issued ASU No. 2014-11, Transfers and Servicing (Topic 860): Repurchase-to-Maturity Transactions, Repurchase Financings, and Disclosure. The new standard expanded secured borrowing accounting to include repurchase-to-maturity transactions and repurchase financings and set forth new disclosure requirements for repurchase agreements, securities lending transactions, and repurchase-to-maturity transactions that are accounted for as secured borrowings. We adopted this standard on April 1, 2015 and expanded our disclosures presented in Note 8, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. The adoption of this standard did not have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2015, the FASB issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The new standard requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU No. 2015-15, Interest - Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements, which clarified that debt issuance costs related to line-of-credit arrangements can be presented in the balance sheet as an asset and amortized over the term of the line-of-credit arrangement. We adopted these standards as of September 30, 2015 with retroactive application. The adoption of these standards did not have a significant impact on our financial position or results of operations. For additional information, please read Note 11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2015, the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. Under this standard, if a cloud computing arrangement includes a software license, the software license element of the arrangement should be accounted for consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2015, the FASB issued ASU No. 2015-07, Fair Value Measurement (Topic 820): Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent). The new standard removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The new standard will be effective for us on January 1, 2016. Early application is permitted. We maintain investments in certain venture capital funds which primarily invest in small, privately-owned, venture-backed biotechnology companies. The value of our investments in these venture capital funds is estimated using the net asset value of the fund and has been included in the fair value hierarchy disclosure as a Level 3 measurement. These venture capital investments are not material to our financial position or results of operations. We adopted this standard as of June 30, 2015 and our investments in venture capital funds are no longer included in our disclosures reflected in Note 7, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The new standard applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The new standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined and sets forth new disclosure requirements related to the adjustments. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. The new standard requires that deferred tax assets and liabilities be classified as noncurrent in a classified statement of financial position. We adopted this standard as of December 31, 2015 with retroactive application. As a result, we reclassified our deferred tax assets classified as current to noncurrent and our deferred tax liabilities classified as current to noncurrent in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; consolidated balance sheet, to conform our prior year presentation to our current year presentation. For additional information, please read Note 16, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
	<us-gaap:OtherNoncurrentLiabilitiesTableTextBlock contextRef="FD2015Q4YTD" id="Fact-DA2714947282C0EB386438A29130423C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;301.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;235.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;369.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;249.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;905.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;650.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
	<us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-5CA81E116FF2B4F2AA2E38A29134A03B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Employee Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We sponsor various retirement and pension plans. Our estimates of liabilities and expenses for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;401(k) Savings Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We maintain a 401(k) Savings Plan which is available to substantially all regular employees in the U.S. over the age of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan&amp;#8217;s matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expense related to our 401(k) Savings Plan totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$51.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$49.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$39.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Deferred Compensation Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees, which are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$126.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$105.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Pension Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries in which we maintain an operating presence.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by Swiss government and was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.75%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&amp;#8217;s contribution. Minimum employee contributions are based on the respective employee&amp;#8217;s age, salary, and gender. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the the Swiss plan had an unfunded net pension obligation of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$42.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$31.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and plan assets which totaled approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$63.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$43.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized expense totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$9.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to our Swiss plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The obligations under the German plans are unfunded and totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$27.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$24.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Net periodic pension cost related to the German plans totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-897B1DAA6A59B24678E638A2912D51AF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;74.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;56.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,035.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;947.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;166.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;155.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,079.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,011.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Computer software and hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;647.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;547.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;72.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;441.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;168.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,517.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,952.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,330.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,186.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,187.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,765.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depreciation expense totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$217.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$198.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$187.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we capitalized interest costs related to construction in progress totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$6.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Research Triangle Park Facility Purchase&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On August 24, 2015, we purchased from Eisai, Inc. (Eisai) its drug product manufacturing facility and supporting infrastructure in Research Triangle Park (RTP), North Carolina for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$104.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The purchase price consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;58.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;25.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;104.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On August 24, 2015, we also amended our existing &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; year lease related to Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. As amended, the lease provides for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; year term and our agreement to purchase the facility upon expiration of the lease term and Eisai's completion of certain activities. Accordingly, we recorded the assets along with a corresponding financing obligation on our consolidated balance sheet for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net present value of the future minimum lease payments. The assets were recorded as a component of buildings and machinery and equipment. We expect to complete the purchase of the oral solid products manufacturing facility at the end of the lease term in the third quarter of 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On December 1, 2015, we purchased land in Solothurn, Switzerland for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Swiss Francs (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$62.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;). We plan to build a biologics manufacturing facility on this land in the Commune of Luterbach over the next several years. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$99.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; capitalized in construction in progress related to the construction of this facility. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Weston Exit Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As a result of our decision to relocate our corporate headquarters to Cambridge, Massachusetts, we vacated part of our Weston, Massachusetts facility in the fourth quarter of 2013. We incurred a charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$27.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in connection with this move. This charge represented our remaining lease obligation for the vacated portion of our Weston, Massachusetts facility, net of sublease income expected to be received. The term of our sublease for the vacated portion of our Weston, Massachusetts facility started in January 2014 and will continue through the remaining term of our lease agreement.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-AD7EB8B9FC3E7DA02BAD38A2913D4F9D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three to five years&lt;/font&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="50%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="50%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Useful Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Not depreciated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15 to 40&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Leasehold Improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Lesser of the useful life or the term of the respective lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Furniture and Fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 7&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Machinery and Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 20&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Computer&amp;#160;Software&amp;#160;and&amp;#160;Hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3 to 5&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts on our consolidated balance sheet and include any resulting gain or loss in our consolidated statement of income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2015Q4YTD" id="Fact-EA83E9EF39B569779ACE38A291394F39">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;74.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;56.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,035.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;947.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;166.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;155.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,079.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,011.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Computer software and hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;647.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;547.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;72.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;441.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;168.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,517.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,952.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,330.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,186.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,187.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,765.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:QuarterlyFinancialInformationTextBlock contextRef="FD2015Q4YTD" id="Fact-A2A82CB5A750904F5F5738A2913AA883">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Quarterly Financial Data (Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="36%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a) (b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(c) (d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,172.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,198.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,391.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,425.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9,188.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unconsolidated joint business revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;330.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;337.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;337.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;333.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,339.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;52.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;55.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;49.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;79.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;236.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,555.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,591.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,777.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,839.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10,763.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,242.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,305.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,467.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,507.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9,523.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;820.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;924.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,019.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;828.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,593.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;822.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;927.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;965.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;831.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,547.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;235.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;235.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;232.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;220.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;230.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;235.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;235.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;232.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;220.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;231.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="36%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(f) (g)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(f)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(f)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,742.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,056.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,117.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,287.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8,203.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unconsolidated joint business revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;296.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;303.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;290.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;304.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,195.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;90.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;103.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;304.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,129.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,421.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,511.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,640.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9,703.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,850.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,129.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,208.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,343.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8,532.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;479.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;723.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;856.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;882.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,941.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;480.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;714.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;856.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;883.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,934.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;235.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;237.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;237.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;237.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;237.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1)  Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc., for the third quarter of 2015, include a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$48.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; recorded upon entering into the collaboration agreement with AGTC.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc., for the third quarter of 2015, reflects the attribution of a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; charge to noncontrolling interests, net of tax, related to a milestone payment due Neurimmune upon the enrollment of the first patient in a Phase 3 trial for aducanumab.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc., for the fourth quarter of 2015, include a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; recorded upon entering into the collaboration agreement with MTPC.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc., for the fourth quarter of 2015, include pre-tax restructuring charges totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$93.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc., for the first quarter of 2014, include pre-tax charges to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$117.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; recorded upon entering into the collaboration agreement with Eisai.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(f)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net and total revenues for the second, third and fourth quarters of 2014 include net revenues related to ALPROLIX as commercial sales of ALPROLIX commenced in the second quarter of 2014.  Product revenues, net and total revenues for the third and fourth quarters of 2014 include net revenues related to ELOCTATE and PLEGRIDY as commercial sales of ELOCTATE and PLEGRIDY commenced in the third quarter of 2014.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(g)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net and total revenues for the second quarter of 2014 include the recognition of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$53.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of revenue previously deferred in Italy relating to the pricing agreement with AIFA.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
	<us-gaap:RealizedGainLossOnInvestmentsTableTextBlock contextRef="FD2015Q4YTD" id="Fact-239A78948405E4B6DB4B38A29136BD3B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="53%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,063.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,718.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,190.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
	<us-gaap:ReceivablesPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-CA689CFF3EA4F88A7C8F38A291356BB2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&amp;#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&amp;#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our consolidated statement of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The credit and economic conditions in certain countries in the E.U. continue to remain uncertain and have, from time to time, led to a lengthening of time to collect our accounts receivable in some of these countries. In recent years, our collection efforts in Portugal and select regions of Spain have been subject to significant payment delays due to government funding and reimbursement practices. As a result, a portion of these receivables have been routinely collected beyond our contractual payment terms and over periods in excess of one year. Our accounts receivable collection efforts in Portugal and Spain have improved during &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; with our receivables in Spain now expected to be collected within one year. Our net accounts receivable balance from product sales in Portugal and Spain totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$62.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$90.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$6.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; were classified as non-current and included in investments and other assets in our consolidated balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
	<us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock contextRef="FD2015Q4YTD" id="Fact-E4D177DD37150E3F4A7238A2912D6841">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="28%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="25%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;173.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(13.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;171.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
	<us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-FE7E9EC699F5A96F09FC38A29135E8E6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable, and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets on our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&amp;#160;19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of unconsolidated joint business revenues.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For collaborations with commercialized products, if we are the principal, we record revenue and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
	<us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-0707A73CD891569010E438A2913E5A14">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Restructuring&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On October 21, 2015, we announced a corporate restructuring, which includes the termination of certain pipeline programs and an &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in workforce. We anticipate making cash payments totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$120 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under this program, which includes approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to previously 2015 accrued incentive compensation, for a total net expected restructuring charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$105 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. These amounts will be substantially incurred and paid by the end of 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$93.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of these charges during the fourth quarter of 2015, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$86.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was related to our workforce reduction and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was related to the pipeline program terminations.&amp;#160;Our restructuring reserve is included in accrued expenses and other in our consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the charges and spending related to our restructuring efforts during 2015:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="53%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Workforce&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Pipeline&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring charges incurred during the fourth quarter of 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;86.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;93.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Previously accrued incentive compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reserves established&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;102.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;109.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts paid through December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(68.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(72.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring reserve as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;33.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-06742B97F1F1BA5AB6A738A2913D7159">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. Product revenues are recorded net of applicable reserves for discounts and allowances.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Reserves for Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We establish reserves for trade term discounts, wholesaler incentives, Medicaid rebates, co-payment assistance (copay), Veterans Administration (VA) and Public Health Service (PHS) discounts, managed care rebates, product returns and other governmental rebates or applicable allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Reserves established for these discounts and allowances are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These reserves are based on estimates of the amounts earned or to be claimed on the related sales. Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenue reserves are categorized as follows: discounts, contractual adjustments and returns.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contractual adjustments primarily relate to Medicaid and managed care rebates, patient copay assistance, VA and PHS discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid, and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consists of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&amp;#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Copay represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other governmental rebates or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to the discounts, rebates and product returns described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify these payments in selling, general and administrative expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Revenues from Unconsolidated Joint Business&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from unconsolidated joint business consists of (i)&amp;#160;our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; (ii)&amp;#160;reimbursement of our selling and development expenses in the U.S. for RITUXAN; and (iii)&amp;#160;revenue on sales in the rest of world for RITUXAN, which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales outside the U.S. and Canada by the Roche Group and its sublicensees. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by Genentech in the U.S. and by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less the cost to manufacture, third-party royalty expenses, distribution, selling, and marketing expenses, and joint development expenses incurred by Genentech, the Roche Group and us. We record our share of the pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales outside the U.S. on a cash basis as we do not have the ability to estimate these profits or royalty revenue in the period incurred. Additionally, our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. includes estimates made by Genentech and those estimates are subject to change. Actual results may differ from our estimates. For additional information related to our collaboration with Genentech, please read Note&amp;#160;19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Royalty Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. If we are unable to reasonably estimate royalty revenue or do not have access to the information, then we record royalty revenues on a cash basis. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Multiple-Element Revenue Arrangements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We may enter into transactions that involve the sale of products and related services under multiple element arrangements.&amp;#160;In accounting for these transactions, we assess the elements of the contract and whether each element has standalone value and allocate revenue to the various elements based on their estimated selling price as a component of total revenues.&amp;#160;The selling price of a revenue generating element can be based on current selling prices offered by us or another party for current products or management&amp;#8217;s best estimate of a selling price. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2015Q4YTD" id="Fact-29C3B1E119E7678599C038A291300551">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;518.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;359.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;504.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;265.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;270.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;393.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;167.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;172.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;55.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;120.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;579.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;505.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,096.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,817.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="FD2015Q4YTD" id="Fact-B28FB21EC83EA9E0BE1C38A2912D996C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="26%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(99.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(59.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;110.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(96.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(172.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(171.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(61.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(96.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(164.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(195.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(224.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="26%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(23.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(19.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(27.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;101.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(12.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(109.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(19.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(12.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;95.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(12.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(109.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(31.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(99.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(59.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="26%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(21.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(27.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(55.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(26.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(13.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;27.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(23.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(19.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(27.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
	<us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="FD2015Q4YTD" id="Fact-86E46235F226F1AA3F7838A2912B5F74">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash portion of consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;200.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;274.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;474.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
	<us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="FD2015Q4YTD" id="Fact-4CA325AA0330A68EF5FB38A291367ED7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;54.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;134.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;305.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;673.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;321.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;79.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;909.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;716.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
	<us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="FD2015Q4YTD" id="Fact-779554DF9A87B77179F038A29130216D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="51%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash paid during the year for:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;41.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;53.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,674.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,163.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;643.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
	<us-gaap:ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock contextRef="FD2015Q4YTD" id="Fact-243EDB147EEA95F7C27838A2913E56A2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="53%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax benefit realized for stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;29.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received from the exercise of stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock>
	<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="FD2015Q4YTD" id="Fact-B026404E0AF8F3553BC138A2913FD89C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="55%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;38.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;32.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;119.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;115.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;103.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;22.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;109.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;13.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;13.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;207.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;252.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;255.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;196.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;242.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;246.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="FD2015Q4YTD" id="Fact-77896FD1675350A8CCAE38A2913306FF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="53%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income before income taxes (benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Domestic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,386.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,557.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,953.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,380.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,389.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;527.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,767.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,946.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,480.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income tax expense (benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,214.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,159.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;700.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;38.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;98.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;54.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;73.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;46.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,307.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,298.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;846.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(129.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(280.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(200.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(35.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(14.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(145.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(308.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(245.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total income tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,161.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;989.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;601.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfDebtTableTextBlock contextRef="FD2015Q4YTD" id="Fact-189E3252ED86C8F3EC4338A291398BB3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Current portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financing arrangement for the purchase of the RTP facility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of notes payable and other financing arrangements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Non-current portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;2008 Senior Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;565.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;571.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;2015 Senior Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,485.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;992.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,733.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,721.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financing arrangement for the purchase of the RTP facility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;18.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current portion of notes payable and other financing arrangements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,521.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;580.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2015Q4YTD" id="Fact-31318B0637534E763D4438A291330586">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;189.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;69.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory, other reserves, and accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;243.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;217.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangibles, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;328.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;251.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net operating loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;63.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;86.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;60.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(14.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;693.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(440.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(432.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depreciation, amortization and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(102.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(107.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(542.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(539.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="FD2015Q4YTD" id="Fact-6135CFB9B92C8250675138A2912757CA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="27" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Effective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Ineffective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;173.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(13.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="FD2015Q4YTD" id="Fact-6991A035368016AA6D4638A29124DC38">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="54%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="27%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="17%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance&amp;#160;Sheet&amp;#160;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;16.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="54%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="27%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="17%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;69.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2015Q4YTD" id="Fact-FF23522D1F38DF40017238A2913C0936">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="53%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,547.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,934.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,862.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;230.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;231.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;237.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;238.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2015Q4YTD" id="Fact-C3978F5B8ED24133039538A2913388C8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="55%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2015Q4YTD" id="Fact-D4A46D12EA810932627038A2913929B8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="55%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;88.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;102.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;95.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;127.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;150.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;160.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reversal of previously accrued incentive compensation included in restructuring charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;207.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;252.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;255.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;196.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;242.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;246.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(55.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(72.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(73.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;140.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;170.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;172.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="FD2015Q4YTD" id="Fact-869F53AF6DA42DCC14A338A2913A7698">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="36" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="18%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Multiple Sclerosis (MS):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TECFIDERA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;2,908.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;730.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;3,638.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,426.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;482.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,909.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;864.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;11.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;876.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;AVONEX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,790.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;840.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;2,630.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,956.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,056.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,013.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,902.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,103.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,005.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;PLEGRIDY&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;227.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;111.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;338.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;27.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;44.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TYSABRI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,103.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;783.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,886.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,025.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;934.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,959.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;814.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;712.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,526.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FAMPYRA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;89.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;89.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;80.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;80.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;74.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;74.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Hemophilia:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ELOCTATE&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;308.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;11.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;319.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;58.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;58.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ALPROLIX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;208.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;25.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;234.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;72.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;76.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other product revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FUMADERM&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;51.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;51.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;62.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;62.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;60.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;60.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;6,545.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;2,642.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;9,188.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;5,566.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,636.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;8,203.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,581.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,961.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;5,542.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2015Q4YTD" id="Fact-857EEFDF1074182C105538A2913EAC00">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;909.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;909.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,510.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,510.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,875.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,875.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;494.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;494.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;27.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;27.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,895.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,857.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;520.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in&amp;#160;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;716.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;716.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,063.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,063.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;849.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;849.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;198.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;198.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;72.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;72.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;36.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;36.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,943.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,937.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;220.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="FD2015Q4YTD" id="Fact-BDEFE29E145D17BB3F5838A291326E81">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="79%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="19%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;20.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net present value of the future minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;19.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2015Q4YTD" id="Fact-5E7AF661751EF3B684B138A291321706">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="24%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Minimum lease payments (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;75.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;75.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;67.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;66.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;63.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;382.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;732.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: income from subleases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(28.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(59.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;69.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;69.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;61.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;60.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;56.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;353.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;672.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;As a result of our decision to relocate our corporate headquarters to Cambridge, Massachusetts, we vacated part of our Weston, Massachusetts facility in the fourth quarter of 2013. We incurred a charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:9pt;"&gt;$27.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt; in connection with this move. This charge represented our remaining lease obligation for the vacated portion of our Weston, Massachusetts facility, net of sublease income expected to be received. The term of our sublease to the vacated portion of our Weston, Massachusetts facility started in January 2014 and will continue through the remaining term of our lease agreement.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfGoodwillTextBlock contextRef="FD2015Q4YTD" id="Fact-1937ED0967B964702F3638A29125348F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,760.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,232.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;908.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;527.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,760.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="FD2015Q4YTD" id="Fact-978A0323555961CFAF7E38A2913BDD7B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;213.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;128.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;577.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;511.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;143.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;164.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;933.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;804.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;893.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;804.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;933.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;804.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="FD2015Q4YTD" id="Fact-04DF53B40A836576BF8738A29120DAAD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="80%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="18%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;553.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,500.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021 and thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,500.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,559.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
	<us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock contextRef="FD2015Q4YTD" id="Fact-04BB8E3290ED63C5A89938A291292096">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;945.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,174.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss francs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;80.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;76.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;56.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound sterling&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Australian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Japanese yen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,103.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,302.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
	<us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="FD2015Q4YTD" id="Fact-01A9345ED45639A7E62838A29131C345">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="53%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;22.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(95.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(29.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(31.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Impairments on investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(15.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(13.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(123.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(25.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(34.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
	<us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="FD2015Q4YTD" id="Fact-6AE44F4CF8FDADBFD1C938A2912FE68C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="36%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a) (b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(c) (d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,172.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,198.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,391.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,425.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9,188.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unconsolidated joint business revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;330.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;337.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;337.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;333.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,339.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;52.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;55.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;49.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;79.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;236.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,555.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,591.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,777.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,839.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10,763.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,242.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,305.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,467.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,507.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9,523.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;820.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;924.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,019.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;828.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,593.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;822.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;927.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;965.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;831.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,547.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;235.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;235.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;232.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;220.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;230.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;235.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;235.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;232.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;220.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;231.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="36%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(f) (g)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(f)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(f)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,742.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,056.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,117.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,287.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8,203.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unconsolidated joint business revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;296.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;303.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;290.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;304.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,195.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;90.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;103.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;304.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,129.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,421.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,511.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,640.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9,703.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,850.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,129.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,208.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,343.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8,532.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;479.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;723.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;856.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;882.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,941.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;480.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;714.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;856.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;883.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,934.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;235.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;237.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;237.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;237.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;237.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1)  Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc., for the third quarter of 2015, include a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$48.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; recorded upon entering into the collaboration agreement with AGTC.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc., for the third quarter of 2015, reflects the attribution of a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; charge to noncontrolling interests, net of tax, related to a milestone payment due Neurimmune upon the enrollment of the first patient in a Phase 3 trial for aducanumab.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc., for the fourth quarter of 2015, include a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; recorded upon entering into the collaboration agreement with MTPC.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc., for the fourth quarter of 2015, include pre-tax restructuring charges totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$93.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc., for the first quarter of 2014, include pre-tax charges to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$117.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; recorded upon entering into the collaboration agreement with Eisai.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(f)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net and total revenues for the second, third and fourth quarters of 2014 include net revenues related to ALPROLIX as commercial sales of ALPROLIX commenced in the second quarter of 2014.  Product revenues, net and total revenues for the third and fourth quarters of 2014 include net revenues related to ELOCTATE and PLEGRIDY as commercial sales of ELOCTATE and PLEGRIDY commenced in the third quarter of 2014.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(g)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net and total revenues for the second quarter of 2014 include the recognition of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$53.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of revenue previously deferred in Italy relating to the pricing agreement with AIFA. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
	<us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="FD2015Q4YTD" id="Fact-9339A71D05D41F00F61B38A2912EAFE8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;424.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;128.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(84.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total purchase price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;474.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
	<us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="FD2015Q4YTD" id="Fact-D14D57F0D2B53540B88738A2913D904E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="53%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Workforce&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Pipeline&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring charges incurred during the fourth quarter of 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;86.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;93.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Previously accrued incentive compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reserves established&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;102.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;109.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts paid through December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(68.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(72.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring reserve as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;33.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
	<us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock contextRef="FD2015Q4YTD" id="Fact-995D34AE014D0ACD7C9538A29133B155">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="29%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;December 31, 2015 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Germany&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,545.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,497.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;668.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;143.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;333.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9,188.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unconsolidated joint business revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,269.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;65.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,339.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;142.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;29.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;62.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;236.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,296.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;879.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,187.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2014 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Germany&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,566.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,383.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;811.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;112.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;328.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8,203.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unconsolidated joint business revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,117.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;70.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,195.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;212.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;58.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;304.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,055.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;701.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,765.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2013 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Germany&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,581.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,170.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;417.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;93.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;280.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,542.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unconsolidated joint business revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,087.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,126.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;193.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;43.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;263.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;984.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;758.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,750.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2015Q4YTD" id="Fact-9CC6C7C9D09C8D47412538A2913DEF9D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="15%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;221,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;56.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(114,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;59.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;107,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="FD2015Q4YTD" id="Fact-8B929D88C7EAB7CD6CD038A291341C98">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="56%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at January&amp;#160;1,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;131.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;110.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;125.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions based on tax positions related to the current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions for tax positions of prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;19.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;86.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reductions for tax positions of prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(49.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(23.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(92.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statute expirations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Settlements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(42.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(60.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;67.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;131.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;110.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
	<us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-151698D80E89A340B8EF38A2912C62CB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Reserves for Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As a result of our acquisition of all remaining rights to TYSABRI from Elan, we began recognizing reserves for discounts and allowances for U.S. TYSABRI revenue in the second quarter of 2013. In addition, following our recently launched products, we began recognizing reserves for discounts and allowances related to these products' revenue. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;387.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;49.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;483.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;459.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,732.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(16.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(32.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(405.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,258.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,666.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(44.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(296.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(351.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;56.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;548.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;57.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;345.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;426.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;347.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,265.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,651.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(299.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(933.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,237.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(46.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(261.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(33.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(341.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;387.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;483.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="41%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;196.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;237.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;236.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;861.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,120.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(189.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(560.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(750.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(13.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(135.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(17.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(165.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;345.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;426.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total revenue-related reserves above, included in our consolidated balance sheets, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="67%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="14%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;144.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;124.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;518.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;359.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenue-related reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;483.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
	<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="FD2015Q4YTD" id="Fact-A76D115AFD412B6D50A438A29124D9B9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="81%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="17%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;346.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;318.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;291.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;275.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;269.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,500.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
	<us-gaap:SegmentReportingDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-0BFDF9D3C7576999C80D38A291329E94">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Segment Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, which is discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders, and, therefore, our chief operating decision-maker manages the operations of our company as a single operating segment. Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area and information relating to major customers are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue by product is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="36" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="18%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Multiple Sclerosis (MS):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TECFIDERA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;2,908.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;730.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;3,638.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,426.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;482.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,909.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;864.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;11.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;876.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;AVONEX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,790.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;840.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;2,630.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,956.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,056.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,013.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,902.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,103.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,005.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;PLEGRIDY&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;227.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;111.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;338.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;27.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;44.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TYSABRI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,103.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;783.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,886.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,025.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;934.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,959.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;814.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;712.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,526.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FAMPYRA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;89.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;89.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;80.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;80.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;74.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;74.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Hemophilia:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ELOCTATE&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;308.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;11.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;319.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;58.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;58.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ALPROLIX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;208.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;25.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;234.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;72.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;76.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other product revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FUMADERM&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;51.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;51.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;62.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;62.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;60.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;60.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;6,545.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;2,642.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;9,188.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;5,566.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,636.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;8,203.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,581.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,961.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;5,542.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Geographic Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables contain certain financial information by geographic area:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="29%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;December 31, 2015 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Germany&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,545.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,497.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;668.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;143.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;333.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9,188.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unconsolidated joint business revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,269.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;65.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,339.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;142.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;29.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;62.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;236.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,296.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;879.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,187.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2014 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Germany&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,566.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,383.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;811.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;112.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;328.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8,203.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unconsolidated joint business revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,117.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;70.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,195.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;212.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;58.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;304.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,055.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;701.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,765.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2013 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Germany&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,581.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,170.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;417.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;93.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;280.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,542.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unconsolidated joint business revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,087.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,126.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;193.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;43.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;263.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;984.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;758.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,750.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;Represents amounts related to Europe less those attributable to Germany.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Revenues from Unconsolidated Joint Business&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our total revenues in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, are derived from our joint business arrangement with Genentech. For additional information related to our collaboration with Genentech, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Significant Customers&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recorded revenue from two wholesalers accounting for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;27%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;32%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$684.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$676.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$731.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of our long-lived assets were related to our manufacturing facilities in Denmark.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
	<us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-27583FAEAFF075F8F8CE38A291375C48">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Advertising costs are expensed as incurred. For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, advertising costs totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$108.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$92.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$72.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-D942C65492F153845DB638A2913E983C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;shares of Preferred Stock authorized, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.75 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares are authorized as Series A, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares are authorized as Series X junior participating and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.25 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares are undesignated. Shares may be issued without a vote or action of stockholders from time to time in classes or series with the designations, powers, preferences, and the relative, participating, optional or other special rights of the shares of each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. No shares of Preferred Stock were issued and outstanding during &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table describes the number of shares authorized, issued and outstanding of our common stock as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="24%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;241.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;218.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;257.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;234.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share Repurchases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2015, our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2015 Share Repurchase Program). As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the 2015 Share Repurchase Program was completed and we repurchased and retired approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2011, our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2011 Share Repurchase Program), which has been used principally to offset common stock issuances under our share-based compensation plans. The 2011 Share Repurchase Program does not have an expiration date. During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we purchased approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$886.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under our 2011 Share Repurchase Program. We did not repurchase any shares of common stock under our 2011 Share Repurchase Program during the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and have approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares remaining available for repurchase under this authorization.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2015Q4YTD" id="Fact-BE825F7FBE330E9795F338A2911BF54C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-D7D4253B2A000B80B90838A29133192E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Investments in Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Neurimmune SubOne AG&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2007, we entered into a collaboration agreement with Neurimmune SubOne AG (Neurimmune), a subsidiary of Neurimmune AG, for the development and commercialization of antibodies for the treatment of Alzheimer&amp;#8217;s disease. Neurimmune conducts research to identify potential therapeutic antibodies and we are responsible for the development, manufacturing and commercialization of all products. Our anti-amyloid beta antibody, aducanumab (BIIB037), for the treatment of Alzheimer&amp;#8217;s disease resulted from this collaboration. In September 2015, we announced that the first patient had been enrolled in a Phase 3 trial for aducanumab, which triggered a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment due to Neurimmune. As we consolidate the financial results of Neurimmune, we recognized this payment as a charge to noncontrolling interest in the third quarter of 2015. Based upon our current development plans for aducanumab, we may pay Neurimmune up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$275.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in remaining milestone payments. We may also pay royalties in the low-to-mid-teens on sales of any resulting commercial products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&amp;#8217;s economic performance and are required to fund &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the research and development costs incurred in support of the collaboration agreement. Accordingly, we consolidate the results of Neurimmune.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts that are incurred by Neurimmune for research and development expenses in support of the collaboration that we reimburse are reflected in research and development expense in our consolidated statements of income.  During the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, these amounts were immaterial. Future milestone payments and royalties, if any, will be reflected in our consolidated statements of income as a charge to noncontrolling interest, net of tax, when such milestones are achieved. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assets and liabilities of Neurimmune are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Rodin Therapeutics, Inc. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2015, we paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for preferred stock in Rodin Therapeutics, Inc. (Rodin) and entered into an option and collaboration agreement which gives us the right to purchase all remaining outstanding shares of Rodin, at any time until 35 days after acceptance of an Investigational New Drug (IND) application by the FDA. Rodin is a discovery-stage biotechnology company developing novel therapeutics for neurological disorders. We committed to make additional investments in Rodin&amp;#8217;s preferred shares of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, if certain development milestones are achieved. If we exercise our option to purchase the outstanding shares of Rodin, we could pay additional amounts upon achievement of clinical and commercial milestones. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Through our fixed price option to purchase Rodin, purchases of equity, our collaboration and presence on the program advisory committee and Rodin Board of Directors, we are deemed to be the primary beneficiary of Rodin, a variable interest entity. Therefore, we consolidate the results of Rodin. As part of the initial consolidation of Rodin, we recorded an IPR&amp;amp;D intangible asset of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and assigned approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to minority interest in our stockholder's equity. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assets and liabilities of Rodin are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Rodin other than contractually required amounts. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Unconsolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the total carrying value of our investments in biotechnology companies totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$29.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income, as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
		<link:loc xlink:href="#Fact-10295FA48EB105A523EE38A29134AD19" xlink:label="Fact-10295FA48EB105A523EE38A29134AD19_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-12146B5BBD1DB59BB14D38A2912104E3" xlink:label="Fact-12146B5BBD1DB59BB14D38A2912104E3_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-16C0BB3AD2DC25F79D0538A2913DF7D3" xlink:label="Fact-16C0BB3AD2DC25F79D0538A2913DF7D3_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-1908941470A3AFD1FCD638A2912E054C" xlink:label="Fact-1908941470A3AFD1FCD638A2912E054C_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-22BB62EB3BBFDA1ED52F98BD2C380C26" xlink:label="Fact-22BB62EB3BBFDA1ED52F98BD2C380C26_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2342104CD4C8D09B0FF038A291306DFA" xlink:label="Fact-2342104CD4C8D09B0FF038A291306DFA_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2353CAF4AEB5F72553BA38A2912F7688" xlink:label="Fact-2353CAF4AEB5F72553BA38A2912F7688_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-24E033551F39C18EB70838A291303583" xlink:label="Fact-24E033551F39C18EB70838A291303583_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-28F9E49D98045AB0432198B8D5F2DCC8" xlink:label="Fact-28F9E49D98045AB0432198B8D5F2DCC8_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2EA8C86F01AB6A5401DC38A2912F805D" xlink:label="Fact-2EA8C86F01AB6A5401DC38A2912F805D_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-3865CA8147F6E33CE2B498BF5C0BD813" xlink:label="Fact-3865CA8147F6E33CE2B498BF5C0BD813_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-3EA7806752AE63C1833938A2913254F5" xlink:label="Fact-3EA7806752AE63C1833938A2913254F5_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-4F145BA4AC0DC589E60038A2912EC482" xlink:label="Fact-4F145BA4AC0DC589E60038A2912EC482_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-4F4289884853C522F17B98B537B7D401" xlink:label="Fact-4F4289884853C522F17B98B537B7D401_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-5B0C2393AC0BBE84B1F038A2913DD9A6" xlink:label="Fact-5B0C2393AC0BBE84B1F038A2913DD9A6_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-604CBF9D8E02CFB50F5D38A2912EA239" xlink:label="Fact-604CBF9D8E02CFB50F5D38A2912EA239_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-67AB0487CE282AA796B638A2912E6A8A" xlink:label="Fact-67AB0487CE282AA796B638A2912E6A8A_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-6A59BBB5030C3282166F38A2913C082C" xlink:label="Fact-6A59BBB5030C3282166F38A2913C082C_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-71944A427C85961E42CF38A291380D45" xlink:label="Fact-71944A427C85961E42CF38A291380D45_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-76FC6555B70974A94EA238A2912EF5F1" xlink:label="Fact-76FC6555B70974A94EA238A2912EF5F1_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-7A39385437E5F2632AB838A2912DB911" xlink:label="Fact-7A39385437E5F2632AB838A2912DB911_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-7C9E5EFFA0C7386F44BC98C66E67255B" xlink:label="Fact-7C9E5EFFA0C7386F44BC98C66E67255B_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-8C24D273E3021AA7BE1838A2912F421B" xlink:label="Fact-8C24D273E3021AA7BE1838A2912F421B_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-9316F7915C13B7AE401138A29121BA6D" xlink:label="Fact-9316F7915C13B7AE401138A29121BA6D_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-93C7EDBD0DB6D78B3AFA38A29135241B" xlink:label="Fact-93C7EDBD0DB6D78B3AFA38A29135241B_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-94D5069B8965EB09B0BC38A2912E0E40" xlink:label="Fact-94D5069B8965EB09B0BC38A2912E0E40_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-A67C723F5C3DF173B3C038A29134289C" xlink:label="Fact-A67C723F5C3DF173B3C038A29134289C_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-A9333838AF33BF1FE55E38A2912DFF1E" xlink:label="Fact-A9333838AF33BF1FE55E38A2912DFF1E_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-B5AB874D6D25D47743A238A2912EA95F" xlink:label="Fact-B5AB874D6D25D47743A238A2912EA95F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-BAFD6D39A3899CED72B138A29121478C" xlink:label="Fact-BAFD6D39A3899CED72B138A29121478C_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-BF4CAACC373459A960A638A29132B896" xlink:label="Fact-BF4CAACC373459A960A638A29132B896_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-BFCBA7566FBCF73F36ED38A29132D4C4" xlink:label="Fact-BFCBA7566FBCF73F36ED38A29132D4C4_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-C01E03ADBF935D3A9D3238A29121C9C0" xlink:label="Fact-C01E03ADBF935D3A9D3238A29121C9C0_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-C44A0781623878CED8CD38A2912F4A48" xlink:label="Fact-C44A0781623878CED8CD38A2912F4A48_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-CF7175C0F3DB20B1BE8038A2913243F6" xlink:label="Fact-CF7175C0F3DB20B1BE8038A2913243F6_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-DC7F0E124CF3ECF81CE698CED754BFF3" xlink:label="Fact-DC7F0E124CF3ECF81CE698CED754BFF3_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-DEA553A0BC7A0F5B3C5B38A2912E6CF9" xlink:label="Fact-DEA553A0BC7A0F5B3C5B38A2912E6CF9_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-E25538B9A6089FDAF17438A29137AE76" xlink:label="Fact-E25538B9A6089FDAF17438A29137AE76_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-EF9AB3638B3487DB052938A2912F0660" xlink:label="Fact-EF9AB3638B3487DB052938A2912F0660_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-F14CEACFDFE6656720C538A291388D35" xlink:label="Fact-F14CEACFDFE6656720C538A291388D35_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-F83B25C507A520C53C6638A29131EC9D" xlink:label="Fact-F83B25C507A520C53C6638A29131EC9D_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-F8A1824328F441EE3AFA38A291210002" xlink:label="Fact-F8A1824328F441EE3AFA38A291210002_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-FA3C2F713F90921E546638A2913701E0" xlink:label="Fact-FA3C2F713F90921E546638A2913701E0_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-FF26E9737114775FDCA698BC0DE150AB" xlink:label="Fact-FF26E9737114775FDCA698BC0DE150AB_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-FF2D985F55465E4FE31D38A29136CB20" xlink:label="Fact-FF2D985F55465E4FE31D38A29136CB20_lbl" xlink:type="locator" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-10295FA48EB105A523EE38A29134AD19_lbl" xlink:to="Footnote-5962320E525B80D1F9E038A2914718E6_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-12146B5BBD1DB59BB14D38A2912104E3_lbl" xlink:to="Footnote-4690D039884801B0736238A29146709A_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-16C0BB3AD2DC25F79D0538A2913DF7D3_lbl" xlink:to="Footnote-410087F1484F83249B9C38A29147C558_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-1908941470A3AFD1FCD638A2912E054C_lbl" xlink:to="Footnote-4690D039884801B0736238A29146709A_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-22BB62EB3BBFDA1ED52F98BD2C380C26_lbl" xlink:to="Footnote-EB5533545B98174FD42338A29147BAEB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2342104CD4C8D09B0FF038A291306DFA_lbl" xlink:to="Footnote-38EF3ED0C972D0E3664438A291474D47_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2353CAF4AEB5F72553BA38A2912F7688_lbl" xlink:to="Footnote-8C1F4813A77BF593543A38A291475EAF_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-24E033551F39C18EB70838A291303583_lbl" xlink:to="Footnote-EB5533545B98174FD42338A29147BAEB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-28F9E49D98045AB0432198B8D5F2DCC8_lbl" xlink:to="Footnote-EB5533545B98174FD42338A29147BAEB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2EA8C86F01AB6A5401DC38A2912F805D_lbl" xlink:to="Footnote-8C1F4813A77BF593543A38A291475EAF_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-3865CA8147F6E33CE2B498BF5C0BD813_lbl" xlink:to="Footnote-410087F1484F83249B9C38A29147C558_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-3EA7806752AE63C1833938A2913254F5_lbl" xlink:to="Footnote-8C1F4813A77BF593543A38A291475EAF_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-4F145BA4AC0DC589E60038A2912EC482_lbl" xlink:to="Footnote-8C1F4813A77BF593543A38A291475EAF_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-4F4289884853C522F17B98B537B7D401_lbl" xlink:to="Footnote-EB5533545B98174FD42338A29147BAEB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-5B0C2393AC0BBE84B1F038A2913DD9A6_lbl" xlink:to="Footnote-EB5533545B98174FD42338A29147BAEB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-604CBF9D8E02CFB50F5D38A2912EA239_lbl" xlink:to="Footnote-4690D039884801B0736238A29146709A_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-67AB0487CE282AA796B638A2912E6A8A_lbl" xlink:to="Footnote-8C1F4813A77BF593543A38A291475EAF_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-6A59BBB5030C3282166F38A2913C082C_lbl" xlink:to="Footnote-5962320E525B80D1F9E038A2914718E6_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-71944A427C85961E42CF38A291380D45_lbl" xlink:to="Footnote-014E3409DEA3BE3A6ABC38A29146BA98_lbl" xlink:type="arc" />
		<link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-71944A427C85961E42CF38A291380D45_lbl" xlink:to="Footnote-05CA652A7E79DC5C682D38A29146DA70_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-76FC6555B70974A94EA238A2912EF5F1_lbl" xlink:to="Footnote-8C1F4813A77BF593543A38A291475EAF_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-7A39385437E5F2632AB838A2912DB911_lbl" xlink:to="Footnote-4690D039884801B0736238A29146709A_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-7C9E5EFFA0C7386F44BC98C66E67255B_lbl" xlink:to="Footnote-410087F1484F83249B9C38A29147C558_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-8C24D273E3021AA7BE1838A2912F421B_lbl" xlink:to="Footnote-410087F1484F83249B9C38A29147C558_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-9316F7915C13B7AE401138A29121BA6D_lbl" xlink:to="Footnote-014E3409DEA3BE3A6ABC38A29146BA98_lbl" xlink:type="arc" />
		<link:footnoteArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-9316F7915C13B7AE401138A29121BA6D_lbl" xlink:to="Footnote-05CA652A7E79DC5C682D38A29146DA70_lbl" xlink:type="arc" />
		<link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-9316F7915C13B7AE401138A29121BA6D_lbl" xlink:to="Footnote-4690D039884801B0736238A29146709A_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-93C7EDBD0DB6D78B3AFA38A29135241B_lbl" xlink:to="Footnote-5962320E525B80D1F9E038A2914718E6_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-94D5069B8965EB09B0BC38A2912E0E40_lbl" xlink:to="Footnote-4690D039884801B0736238A29146709A_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-A67C723F5C3DF173B3C038A29134289C_lbl" xlink:to="Footnote-5962320E525B80D1F9E038A2914718E6_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-A9333838AF33BF1FE55E38A2912DFF1E_lbl" xlink:to="Footnote-4690D039884801B0736238A29146709A_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-B5AB874D6D25D47743A238A2912EA95F_lbl" xlink:to="Footnote-8C1F4813A77BF593543A38A291475EAF_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-BAFD6D39A3899CED72B138A29121478C_lbl" xlink:to="Footnote-4690D039884801B0736238A29146709A_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-BF4CAACC373459A960A638A29132B896_lbl" xlink:to="Footnote-8C1F4813A77BF593543A38A291475EAF_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-BFCBA7566FBCF73F36ED38A29132D4C4_lbl" xlink:to="Footnote-4690D039884801B0736238A29146709A_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-C01E03ADBF935D3A9D3238A29121C9C0_lbl" xlink:to="Footnote-4690D039884801B0736238A29146709A_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-C44A0781623878CED8CD38A2912F4A48_lbl" xlink:to="Footnote-8C1F4813A77BF593543A38A291475EAF_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-CF7175C0F3DB20B1BE8038A2913243F6_lbl" xlink:to="Footnote-8C1F4813A77BF593543A38A291475EAF_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-DC7F0E124CF3ECF81CE698CED754BFF3_lbl" xlink:to="Footnote-38EF3ED0C972D0E3664438A291474D47_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-DEA553A0BC7A0F5B3C5B38A2912E6CF9_lbl" xlink:to="Footnote-8C1F4813A77BF593543A38A291475EAF_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-E25538B9A6089FDAF17438A29137AE76_lbl" xlink:to="Footnote-5962320E525B80D1F9E038A2914718E6_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-EF9AB3638B3487DB052938A2912F0660_lbl" xlink:to="Footnote-8C1F4813A77BF593543A38A291475EAF_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-F14CEACFDFE6656720C538A291388D35_lbl" xlink:to="Footnote-014E3409DEA3BE3A6ABC38A29146BA98_lbl" xlink:type="arc" />
		<link:footnoteArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-F14CEACFDFE6656720C538A291388D35_lbl" xlink:to="Footnote-05CA652A7E79DC5C682D38A29146DA70_lbl" xlink:type="arc" />
		<link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-F14CEACFDFE6656720C538A291388D35_lbl" xlink:to="Footnote-4690D039884801B0736238A29146709A_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-F83B25C507A520C53C6638A29131EC9D_lbl" xlink:to="Footnote-38EF3ED0C972D0E3664438A291474D47_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-F8A1824328F441EE3AFA38A291210002_lbl" xlink:to="Footnote-014E3409DEA3BE3A6ABC38A29146BA98_lbl" xlink:type="arc" />
		<link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-F8A1824328F441EE3AFA38A291210002_lbl" xlink:to="Footnote-05CA652A7E79DC5C682D38A29146DA70_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-FA3C2F713F90921E546638A2913701E0_lbl" xlink:to="Footnote-5962320E525B80D1F9E038A2914718E6_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-FF26E9737114775FDCA698BC0DE150AB_lbl" xlink:to="Footnote-EB5533545B98174FD42338A29147BAEB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-FF2D985F55465E4FE31D38A29136CB20_lbl" xlink:to="Footnote-5962320E525B80D1F9E038A2914718E6_lbl" xlink:type="arc" />
		<link:footnote xlink:label="Footnote-014E3409DEA3BE3A6ABC38A29146BA98_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor.</link:footnote>
		<link:footnote xlink:label="Footnote-05CA652A7E79DC5C682D38A29146DA70_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Net revenue represents Biogen&#8217;s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities.</link:footnote>
		<link:footnote xlink:label="Footnote-38EF3ED0C972D0E3664438A291474D47_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">RSUs granted in 2015 primarily represent RSUs granted in conjunction with our annual awards made in February 2015 and awards made in conjunction with the hiring of new employees. RSUs granted in 2015 also include approximately 7,000 RSUs granted to our Board of Directors.</link:footnote>
		<link:footnote xlink:label="Footnote-410087F1484F83249B9C38A29147C558_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">CSPUs granted in 2015 include approximately 48,000 CSPUs issued in 2015 based upon the attainment of performance criteria set for 2014 in relation to awards granted in 2014. The remainder of the CSPUs granted in 2015 include awards granted in conjunction with our annual awards made in February 2015 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</link:footnote>
		<link:footnote xlink:label="Footnote-4690D039884801B0736238A29146709A_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.</link:footnote>
		<link:footnote xlink:label="Footnote-5962320E525B80D1F9E038A2914718E6_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As a result of our decision to relocate our corporate headquarters to Cambridge, Massachusetts, we vacated part of our Weston, Massachusetts facility in the fourth quarter of 2013. We incurred a charge of $27.2 million in connection with this move. This charge represented our remaining lease obligation for the vacated portion of our Weston, Massachusetts facility, net of sublease income expected to be received. The term of our sublease to the vacated portion of our Weston, Massachusetts facility started in January 2014 and will continue through the remaining term of our lease agreement.</link:footnote>
		<link:footnote xlink:label="Footnote-8C1F4813A77BF593543A38A291475EAF_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents amounts related to Europe less those attributable to Germany.</link:footnote>
		<link:footnote xlink:label="Footnote-EB5533545B98174FD42338A29147BAEB_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">MSUs granted in 2015 include approximately 8,000, 19,000, 24,000 and 34,000 MSUs issued in 2015 based upon the attainment of performance criteria set for 2014, 2013, 2012 and 2011, respectively, in relation to awards granted in those years. The remainder of MSUs granted during 2015 include awards granted in conjunction with our annual awards made in February 2015 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</link:footnote>
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>biib-20151231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20151231" xmlns:biib="http://www.biogenidec.com/20151231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-roles-2015-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2015-01-31" schemaLocation="http://xbrl.sec.gov/exch/2015/exch-2015-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20151231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20151231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20151231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20151231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss">
        <link:definition>2116100 - Disclosure - Accumulated Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2416402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails1" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1">
        <link:definition>2416403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2316301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>2102100 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAcquisitionsDetails" roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails">
        <link:definition>2402402 - Disclosure - Acquisitions Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAcquisitionsDetails1" roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1">
        <link:definition>2402403 - Disclosure - Acquisitions Acquisitions (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAcquisitionsTables" roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables">
        <link:definition>2302301 - Disclosure - Acquisitions Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDetailsTextual" roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual">
        <link:definition>2402404 - Disclosure - Acquisitions (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships">
        <link:definition>2122100 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3">
        <link:definition>2422405 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails">
        <link:definition>2422402 - Disclosure - Collaborative and Other Relationships (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsDetails1" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1">
        <link:definition>2422403 - Disclosure - Collaborative and Other Relationships (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsDetails2" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails2">
        <link:definition>2422404 - Disclosure - Collaborative and Other Relationships (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsDetailsTextual" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual">
        <link:definition>2422406 - Disclosure - Collaborative and Other Relationships (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables">
        <link:definition>2322301 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies">
        <link:definition>2124100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1">
        <link:definition>2424403 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetails" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails">
        <link:definition>2424402 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual">
        <link:definition>2424404 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2324301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets">
        <link:definition>1003000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1003501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncome" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome">
        <link:definition>1002000 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfEquity" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity">
        <link:definition>1005000 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfIncome" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome">
        <link:definition>1001000 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2112100 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2412402 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1">
        <link:definition>2412403 - Disclosure - Derivative Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual">
        <link:definition>2412404 - Disclosure - Derivative Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2312301 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.biogenidec.com/role/EarningsPerShare">
        <link:definition>2117100 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails">
        <link:definition>2417402 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.biogenidec.com/role/EarningsPerShareTables">
        <link:definition>2317301 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans">
        <link:definition>2126100 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails" roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails">
        <link:definition>2426401 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2115100 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetails" roleURI="http://www.biogenidec.com/role/EquityDetails">
        <link:definition>2415402 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetailsTextual" roleURI="http://www.biogenidec.com/role/EquityDetailsTextual">
        <link:definition>2415403 - Disclosure - Equity (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.biogenidec.com/role/EquityTables">
        <link:definition>2315301 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2110100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2410402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2410403 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2410404 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2410405 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2310301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2111100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2411402 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2411403 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2411404 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2411405 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1">
        <link:definition>2411406 - Disclosure - Financial Instruments (Details Textual 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2">
        <link:definition>2411407 - Disclosure - Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2311301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Guarantees" roleURI="http://www.biogenidec.com/role/Guarantees">
        <link:definition>2125100 - Disclosure - Guarantees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2119100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2419402 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails1" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1">
        <link:definition>2419403 - Disclosure - Income Taxes (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails2" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2">
        <link:definition>2419404 - Disclosure - Income Taxes (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails3" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3">
        <link:definition>2419405 - Disclosure - Income Taxes (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2419406 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2319301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Indebtedness" roleURI="http://www.biogenidec.com/role/Indebtedness">
        <link:definition>2114100 - Disclosure - Indebtedness</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails" roleURI="http://www.biogenidec.com/role/IndebtednessDetails">
        <link:definition>2414402 - Disclosure - Indebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails1" roleURI="http://www.biogenidec.com/role/IndebtednessDetails1">
        <link:definition>2414403 - Disclosure - Indebtedness (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetailsTextual" roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual">
        <link:definition>2414404 - Disclosure - Indebtedness (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessTables" roleURI="http://www.biogenidec.com/role/IndebtednessTables">
        <link:definition>2314301 - Disclosure - Indebtedness (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill">
        <link:definition>2109100 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails">
        <link:definition>2409402 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1">
        <link:definition>2409403 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables">
        <link:definition>2309301 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2108100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryDetails">
        <link:definition>2408402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetailsTextual" roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual">
        <link:definition>2408403 - Disclosure - Inventory (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2308301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities">
        <link:definition>2121100 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails">
        <link:definition>2421401 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2123100 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>2423401 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2120100 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2420402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual">
        <link:definition>2420403 - Disclosure - Other Consolidated Financial Statement Detail (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2320301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment">
        <link:definition>2113100 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails">
        <link:definition>2413402 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentDetailsTextual" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual">
        <link:definition>2413404 - Disclosure - Property, Plant and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails1" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails1">
        <link:definition>2413403 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentTables" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables">
        <link:definition>2313301 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnaudited" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited">
        <link:definition>2128100 - Disclosure - Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedDetails" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails">
        <link:definition>2428402 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedDetailsTextual" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual">
        <link:definition>2428403 - Disclosure - Quarterly Financial Data (Unaudited) (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedTables" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables">
        <link:definition>2328301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuring" roleURI="http://www.biogenidec.com/role/RestructuringRestructuring">
        <link:definition>2106100 - Disclosure - Restructuring Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuringDetails" roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetails">
        <link:definition>2406402 - Disclosure - Restructuring Restructuring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuringDetailsTextual" roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual">
        <link:definition>2406403 - Disclosure - Restructuring Restructuring (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuringTables" roleURI="http://www.biogenidec.com/role/RestructuringRestructuringTables">
        <link:definition>2306301 - Disclosure - Restructuring Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueReserves" roleURI="http://www.biogenidec.com/role/RevenueReserves">
        <link:definition>2107100 - Disclosure - Revenue Reserves</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueReservesDetails" roleURI="http://www.biogenidec.com/role/RevenueReservesDetails">
        <link:definition>2407402 - Disclosure - Revenue Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueReservesDetails1" roleURI="http://www.biogenidec.com/role/RevenueReservesDetails1">
        <link:definition>2407403 - Disclosure - Revenue Reserves (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueReservesTables" roleURI="http://www.biogenidec.com/role/RevenueReservesTables">
        <link:definition>2307301 - Disclosure - Revenue Reserves (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.biogenidec.com/role/SegmentInformation">
        <link:definition>2127100 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetails" roleURI="http://www.biogenidec.com/role/SegmentInformationDetails">
        <link:definition>2427402 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetails1" roleURI="http://www.biogenidec.com/role/SegmentInformationDetails1">
        <link:definition>2427403 - Disclosure - Segment Information (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetailsTextual" roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual">
        <link:definition>2427404 - Disclosure - Segment Information (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.biogenidec.com/role/SegmentInformationTables">
        <link:definition>2327301 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.biogenidec.com/role/ShareBasedPayments">
        <link:definition>2118100 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2418402 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2418403 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails2" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2">
        <link:definition>2418404 - Disclosure - Share-Based Payments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails3" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3">
        <link:definition>2418405 - Disclosure - Share-Based Payments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails4" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4">
        <link:definition>2418406 - Disclosure - Share-Based Payments (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails5" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5">
        <link:definition>2418407 - Disclosure - Share-Based Payments (Details 5)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails6" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6">
        <link:definition>2418408 - Disclosure - Share-Based Payments (Details 6)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails8" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8">
        <link:definition>2418410 - Disclosure - Share-Based Payments (Details 8)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails9" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9">
        <link:definition>2418411 - Disclosure - Share-Based Payments (Details 9)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetailsTextual" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual">
        <link:definition>2418412 - Disclosure - Share-Based Payments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsShareBasedPaymentsDetails7" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7">
        <link:definition>2418409 - Disclosure - Share-based Payments Share-Based Payments (Details 7)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2318301 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2401403 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2301302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="biib_A1995ESPPMember" name="A1995ESPPMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2015ESPPMember" name="A2015ESPPMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AGTCMember" name="AGTCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ALPROLIXMember" name="ALPROLIXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ALPROLIXProductMember" name="ALPROLIXProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AVONEXMember" name="AVONEXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AbbvieMember" name="AbbvieMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" name="AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_AcordaMember" name="AcordaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdditionalMilestonePayment" name="AdditionalMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_AdditionalProductsAxis" name="AdditionalProductsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AdditionalProductsDomain" name="AdditionalProductsDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality" name="Additionalmilestonepaymentsforproductcandidateusingadifferentmodality" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration" name="AmountReflectedInCollaborationProfitSharingLineForCollaboration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" name="AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AttainmentOfPerformanceCriteriain2011Member" name="AttainmentOfPerformanceCriteriain2011Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AttainmentOfPerformanceCriteriain2012Member" name="AttainmentOfPerformanceCriteriain2012Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AttainmentOfPerformanceCriteriain2013Member" name="AttainmentOfPerformanceCriteriain2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AttainmentOfPerformanceCriteriain2014Member" name="AttainmentOfPerformanceCriteriain2014Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AverageMaturityOfMarketableSecurities" name="AverageMaturityOfMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AverageStockPriceOnGrantDateInDollarsMaximum" name="AverageStockPriceOnGrantDateInDollarsMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_AverageStockPriceOnGrantDateInDollarsMinimum" name="AverageStockPriceOnGrantDateInDollarsMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BENEPALIMember" name="BENEPALIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BaseRateAfterFirstCommercialSale" name="BaseRateAfterFirstCommercialSale" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BasicAndDilutedEarningsPerShareAbstract" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BiogenIdecHemophiliaMember" name="BiogenIdecHemophiliaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BiogenIdecInternationalNeuroscienceMember" name="BiogenIdecInternationalNeuroscienceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" name="BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" name="BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" name="BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiosimilarsMember" name="BiosimilarsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BusinessOverviewPolicyTextBlock" name="BusinessOverviewPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BusinessTextualAbstract" name="BusinessTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CambridgeLeasesMember" name="CambridgeLeasesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesAbstract" name="CashSettledPerformanceSharesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesMember" name="CashSettledPerformanceSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Chargesrecognizedtovacatebuilding" name="Chargesrecognizedtovacatebuilding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" name="CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_CoPromotionProfitSharingFormulaAbstract" name="CoPromotionProfitSharingFormulaAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CoPromotionProfitSharingFormulaTableTextBlock" name="CoPromotionProfitSharingFormulaTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CollaborationProfitSharing" name="CollaborationProfitSharing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CollaborationsTextualAbstract" name="CollaborationsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CommitmentsAndContingenciesTextualAbstract" name="CommitmentsAndContingenciesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CompensationExpenseOverPurchasePeriod" name="CompensationExpenseOverPurchasePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ComputerSoftwareAndHardware" name="ComputerSoftwareAndHardware" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_ConsiderationPerProductDeveloped" name="ConsiderationPerProductDeveloped" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ContractualAdjustmentsMember" name="ContractualAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ConvergencePharmaceuticalsMember" name="ConvergencePharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesCurrentMember" name="CorporateDebtSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesNonCurrentMember" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CorporateJointVentureInvestmentsMember" name="CorporateJointVentureInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CumulativeSalesLevel" name="CumulativeSalesLevel" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_CumulativeSalesLevelAxis" name="CumulativeSalesLevelAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CumulativeSalesLevelDomain" name="CumulativeSalesLevelDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DMPKMember" name="DMPKMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" name="DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DebtInstrumentUnamortizedInterestOnDebt" name="DebtInstrumentUnamortizedInterestOnDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages" name="DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DeferredCompensationPlanMember" name="DeferredCompensationPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" name="DeferredTaxLiabilitiesDepreciationAmortizationOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_DeferredTaxLiabilityRecognized" name="DeferredTaxLiabilityRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_Deferredtaxassetreclassification" name="Deferredtaxassetreclassification" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_Deferredtaxliabilityreclassification" name="Deferredtaxliabilityreclassification" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_DenominatorAbstract" name="DenominatorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DerecognitionOfConstructionInProgressAssets" name="DerecognitionOfConstructionInProgressAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_DirectorsPlanMember" name="DirectorsPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DiscountRateRecognizedInCompensationExpense" name="DiscountRateRecognizedInCompensationExpense" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DiscoveryprogramsMember" name="DiscoveryprogramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DistributorOneMember" name="DistributorOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DistributorTwoMember" name="DistributorTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DueFromUnconsolidatedJointBusiness" name="DueFromUnconsolidatedJointBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_ELOCTATEMember" name="ELOCTATEMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EachAdditionalOneBillionUpToTwentyBillionMember" name="EachAdditionalOneBillionUpToTwentyBillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EarningsPerShareTextualAbstract" name="EarningsPerShareTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveIncomeTaxRateReconciliationContingentConsideration" name="EffectiveIncomeTaxRateReconciliationContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" name="EffectiveIncomeTaxRateReconciliationManufacturingDeduction" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EisaiMember" name="EisaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ElanMember" name="ElanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeBenefitPlansTextualAbstract" name="EmployeeBenefitPlansTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards" name="EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Employeerelatedliabilitiesnoncurrent" name="Employeerelatedliabilitiesnoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentOwnershipPercentageMaximum" name="EquityMethodInvestmentOwnershipPercentageMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentsExpectedProfitShare" name="EquityMethodInvestmentsExpectedProfitShare" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EquityTextualAbstract" name="EquityTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries" name="EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_EstimatedUsefulLivesOfLeaseholdImprovements" name="EstimatedUsefulLivesOfLeaseholdImprovements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones" name="ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" name="ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" name="ExpectedLicenseFeeAndRegulatoryMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_ExpenseForNonIncomeBasedStateTaxes" name="ExpenseForNonIncomeBasedStateTaxes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_ExpenseIncurredByCollaboration" name="ExpenseIncurredByCollaboration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_ExpenseReflectedWithinStatementsOfIncome" name="ExpenseReflectedWithinStatementsOfIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FAMPYRAMember" name="FAMPYRAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FLIXABIMember" name="FLIXABIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FUMADERMMember" name="FUMADERMMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationAxis" name="FacilityLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationDomain" name="FacilityLocationDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FinancialInstrumentsTextualAbstract" name="FinancialInstrumentsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Finitelivedintangibleassetsfutureamortization" name="Finitelivedintangibleassetsfutureamortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_FivebillionMember" name="FivebillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ForeignSalesRequiredToTriggerMilestone" name="ForeignSalesRequiredToTriggerMilestone" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FourbillionMember" name="FourbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FumapharmAgMember" name="FumapharmAgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" name="FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" name="FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_FutureContingentPaymentForFirst12Months" name="FutureContingentPaymentForFirst12Months" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_FutureContingentPaymentThreshold" name="FutureContingentPaymentThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" name="FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Futurepercentageofcopromotionoperatingprofits" name="Futurepercentageofcopromotionoperatingprofits" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GAZYVAMember" name="GAZYVAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_GainOnSaleOfRights" name="GainOnSaleOfRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GenentechMember" name="GenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GermanPlanMember" name="GermanPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesCurrentMember" name="GovernmentSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesNonCurrentMember" name="GovernmentSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_HoechstMember" name="HoechstMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InLicensedPatentsMember" name="InLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IncomeTaxesTextualAbstract" name="IncomeTaxesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IncreasedCarryingAmountOfSeniorNotes" name="IncreasedCarryingAmountOfSeniorNotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_IndefiniteLivedIntangibleAssetsUsefulLife" name="IndefiniteLivedIntangibleAssetsUsefulLife" nillable="true" substitutionGroup="xbrli:item" type="us-types:durationStringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" name="IntangibleAssetsAndGoodwillAdditionalTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InterestInSubsidiary" name="InterestInSubsidiary" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Inventorynetcurrentandnoncurrent" name="Inventorynetcurrentandnoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentInVariableInterestEntitiesTextualAbstract" name="InvestmentInVariableInterestEntitiesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" name="InvestmentsByThirdPartyInJointVentureAsPerAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentsInVariableInterestEntitiesAbstract" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IsisPharmaceuticalsMember" name="IsisPharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_JointVentureOwnerShipPercentageByThirdParty" name="JointVentureOwnerShipPercentageByThirdParty" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_LeadprogramsMember" name="LeadprogramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement" name="LiabilityForFairValueOfOptionsGrantedUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_LicenseFee" name="LicenseFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_LossContingencyAdjustmentRelatedToClaimAmountPercent" name="LossContingencyAdjustmentRelatedToClaimAmountPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_MajorDistributorAxis" name="MajorDistributorAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MajorDistributorDomain" name="MajorDistributorDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsActivityAbstract" name="MarketStockUnitsActivityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsMember" name="MarketStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketableEquitySecuritiesMember" name="MarketableEquitySecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" name="MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_MilestonePaymentsMadeDuringPeriod" name="MilestonePaymentsMadeDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_MinimumQualifyingAgeForEmployeeBenefitPlan" name="MinimumQualifyingAgeForEmployeeBenefitPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract" name="MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" name="MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MitsubishiTanabePharmaCorporationMember" name="MitsubishiTanabePharmaCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NetBenefitForPreviouslyUnrecognizedPosition" name="NetBenefitForPreviouslyUnrecognizedPosition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePayments" name="NetMinimumLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsThereafter" name="NetMinimumLeasePaymentsThereafter" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInFiveYear" name="NetMinimumLeasePaymentsWithInFiveYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInFourYear" name="NetMinimumLeasePaymentsWithInFourYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInOneYear" name="NetMinimumLeasePaymentsWithInOneYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInThreeYear" name="NetMinimumLeasePaymentsWithInThreeYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInTwoYear" name="NetMinimumLeasePaymentsWithInTwoYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_NeurimmuneMember" name="NeurimmuneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NeuropathicpainindicationsMember" name="NeuropathicpainindicationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NewAntiCd20Member" name="NewAntiCd20Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NotesPayableToFumedicaMember" name="NotesPayableToFumedicaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" name="NumberOfDaysForCalculationOfAverageClosingStockPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfEqualAnnualIncrements" name="NumberOfEqualAnnualIncrements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" name="NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfSharesOfCommonStockForIssuance" name="NumberOfSharesOfCommonStockForIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NumeratorAbstract" name="NumeratorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OcrelizumabMember" name="OcrelizumabMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OmnibusPlansMember" name="OmnibusPlansMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OneBillionMember" name="OneBillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OtherIncomeExpenseNet" name="OtherIncomeExpenseNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OtherresearchanddiscoveryMember" name="OtherresearchanddiscoveryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OutLicensedPatentsMember" name="OutLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Overnightreverserepurchaseagreementspercentoftotalassets" name="Overnightreverserepurchaseagreementspercentoftotalassets" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_PLEGRIDYMember" name="PLEGRIDYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ParValueOfNotesPayable" name="ParValueOfNotesPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_PaymentTermsOfAccountsReceivable" name="PaymentTermsOfAccountsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingLosses" name="PercentageOfCoPromotionOperatingLosses" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" name="PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated" name="PercentageOfDevelopmentAndCommercializationExpensesPayableRelated" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfDevelopmentReimbursementExpenses" name="PercentageOfDevelopmentReimbursementExpenses" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfMarketValuePerShareOfCommonStock" name="PercentageOfMarketValuePerShareOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfMinimumInvestmentReturn" name="PercentageOfMinimumInvestmentReturn" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfRedemptionOfNotes" name="PercentageOfRedemptionOfNotes" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfReimbursementExpenses" name="PercentageOfReimbursementExpenses" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfRoyaltiesAsPerCollaboration" name="PercentageOfRoyaltiesAsPerCollaboration" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageParValueOfSeniorNotes" name="PercentageParValueOfSeniorNotes" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" name="PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PerformanceunitsactivityTableTextBlock" name="PerformanceunitsactivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PeriodForGrantingOfApprovalByApprovingAuthority" name="PeriodForGrantingOfApprovalByApprovingAuthority" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PeriodOfCollaborationAgreement" name="PeriodOfCollaborationAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Preapprovalinventory" name="Preapprovalinventory" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_Premiumonequityinvestment" name="Premiumonequityinvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PretaxProfitSharingFormulaTableTextBlock" name="PretaxProfitSharingFormulaTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ProceedsFromMarketableDebtSecuritiesAbstract" name="ProceedsFromMarketableDebtSecuritiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock" name="PropertyplantandequipmentpurchasepriceallocationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices" name="ProposedDisallowanceByTaxAuthoritiesForPaymentForServices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PurchasePriceOfCommonStockUnderEspp" name="PurchasePriceOfCommonStockUnderEspp" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Purchaseofcommonstock" name="Purchaseofcommonstock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_RateDuringReimbursementPeriod" name="RateDuringReimbursementPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RatePriorToFirstCommercialSale" name="RatePriorToFirstCommercialSale" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RatioOfNumberOfSharesReservedUnderPlan" name="RatioOfNumberOfSharesReservedUnderPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RaxatrigineMember" name="RaxatrigineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Reductioninroyaltyrate" name="Reductioninroyaltyrate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReimbursementCostAchievingPeriod" name="ReimbursementCostAchievingPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReimbursementLimitStatedInResolution" name="ReimbursementLimitStatedInResolution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract" name="ReimbursementUnderAmendedAgreementAmountsPayableAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock" name="ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReimbursementUnderAmendedAgreementMethod" name="ReimbursementUnderAmendedAgreementMethod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner" name="ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner" name="ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" name="RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" name="ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Researchanddevelopmentservices" name="Researchanddevelopmentservices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ReservesForDiscountsAndAllowancesAbstract" name="ReservesForDiscountsAndAllowancesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RestOfWorldMember" name="RestOfWorldMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RestrictedStockUnitsActivityAbstract" name="RestrictedStockUnitsActivityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RestructuringandRelatedCostExpectedCashPayments" name="RestructuringandRelatedCostExpectedCashPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated" name="Restructuringandrelatedcostexpectedpercentageofpositionseliminated" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesFromUnconsolidatedJointBusiness" name="RevenuesFromUnconsolidatedJointBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RevenuesFromUnconsolidatedJointBusinessAbstract" name="RevenuesFromUnconsolidatedJointBusinessAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock" name="RevenuesFromUnconsolidatedJointBusinessTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesInPercentageFromUnconsolidatedJointBusiness" name="RevenuesInPercentageFromUnconsolidatedJointBusiness" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RituxanMember" name="RituxanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RocheGroupGenentechMember" name="RocheGroupGenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RodinTherapeuticsMember" name="RodinTherapeuticsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RoyaltiesTermsOfCollaborationAgreement" name="RoyaltiesTermsOfCollaborationAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis" name="RoyaltyAndNetRevenueShareRatesByTerritoryAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain" name="RoyaltyAndNetRevenueShareRatesByTerritoryDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RoyaltyCostofSalesPolicyTextBlock" name="RoyaltyCostofSalesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld" name="RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SMNRxMember" name="SMNRxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SOD1Member" name="SOD1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SalesTriggerGrossSalesThreshold" name="SalesTriggerGrossSalesThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SamsungBiosimilarAgreementMember" name="SamsungBiosimilarAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SangamoBioSciencesMember" name="SangamoBioSciencesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SavingsPlanMember" name="SavingsPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" name="ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" name="ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" name="ScheduleOfDevelopmentMilestoneAndCollaborationTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" name="ScheduleOfMarketStockUnitsActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" name="SegmentGeographicalGroupsOfCountriesGroupOtherMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SegmentInformationTextualAbstract" name="SegmentInformationTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" name="SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SeriesXPreferredStockMember" name="SeriesXPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SevenbillionMember" name="SevenbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ShareBasedCompensationPlanAxis" name="ShareBasedCompensationPlanAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ShareBasedCompensationPlanDomain" name="ShareBasedCompensationPlanDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ShareBasedPaymentsTextualAbstract" name="ShareBasedPaymentsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareOfCoPromotionProfits" name="ShareOfCoPromotionProfits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" name="SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SixbillionMember" name="SixbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" name="SobiRateToBiogenOnNetSalesInSobiTerritoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SobiTerritoryMember" name="SobiTerritoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SolothurnMember" name="SolothurnMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SpainandPortugalMember" name="SpainandPortugalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StockOptionActivityAbstract" name="StockOptionActivityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StockOptionsAndEmployeeStockPurchasePlanMember" name="StockOptionsAndEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_StrategicInvestmentPortfolio" name="StrategicInvestmentPortfolio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_StrategicInvestmentsMember" name="StrategicInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StromedixMember" name="StromedixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" name="SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock" name="SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfCommonStockTableTextBlock" name="SummaryOfCommonStockTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract" name="SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SwedishOrphanBiovitrumMember" name="SwedishOrphanBiovitrumMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SwissplanMember" name="SwissplanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TaxBenefitAndCashReceivedFromStockOptionAbstract" name="TaxBenefitAndCashReceivedFromStockOptionAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TecfideraMember" name="TecfideraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_TermOfLease" name="TermOfLease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Termofcollaborationagreement" name="Termofcollaborationagreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ThirdPartyAntiCdTwentyMember" name="ThirdPartyAntiCdTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ThreeBillionMember" name="ThreeBillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" name="ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" name="ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_TimePeriodForPayingRemainingBalanceDue" name="TimePeriodForPayingRemainingBalanceDue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" name="TimeVestedRestrictedStockUnitsActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TimeVestedRestrictedStockUnitsMember" name="TimeVestedRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Totaldeferredchargesandprepaidtaxes" name="Totaldeferredchargesandprepaidtaxes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_TysabriMember" name="TysabriMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TysabriProductMember" name="TysabriProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UnconsolidatedJointBusiness" name="UnconsolidatedJointBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_UndesignatedPreferredStockMember" name="UndesignatedPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_ValuationOfGrantedStockUnitsAbstract" name="ValuationOfGrantedStockUnitsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" name="WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation" name="WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ZINBRYTAMember" name="ZINBRYTAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>biib-20151231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20151231.xsd#AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20151231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20151231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20151231.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20151231.xsd#Acquisitions" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:href="biib-20151231.xsd#AcquisitionsAcquisitionsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1" xlink:href="biib-20151231.xsd#AcquisitionsAcquisitionsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables" xlink:href="biib-20151231.xsd#AcquisitionsAcquisitionsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20151231.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationshipsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationshipsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails2" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationshipsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20151231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:href="biib-20151231.xsd#CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:href="biib-20151231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="biib-20151231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:href="biib-20151231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:href="biib-20151231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="biib-20151231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="biib-20151231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:href="biib-20151231.xsd#ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:href="biib-20151231.xsd#ConsolidatedStatementsOfEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:href="biib-20151231.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20151231.xsd#DerivativeInstruments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20151231.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1" xlink:href="biib-20151231.xsd#DerivativeInstrumentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:href="biib-20151231.xsd#DerivativeInstrumentsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20151231.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20151231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20151231.xsd#EarningsPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20151231.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20151231.xsd#EarningsPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:href="biib-20151231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails" xlink:href="biib-20151231.xsd#EmployeeBenefitPlansDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20151231.xsd#Equity" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20151231.xsd#EquityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20151231.xsd#EquityDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20151231.xsd#EquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20151231.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20151231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20151231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20151231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20151231.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20151231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20151231.xsd#FinancialInstruments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20151231.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20151231.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20151231.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20151231.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:href="biib-20151231.xsd#FinancialInstrumentsDetailsTextual1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:href="biib-20151231.xsd#FinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20151231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Guarantees" xlink:href="biib-20151231.xsd#Guarantees" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20151231.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20151231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:href="biib-20151231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:href="biib-20151231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:href="biib-20151231.xsd#IncomeTaxesDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20151231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20151231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:href="biib-20151231.xsd#Indebtedness" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:href="biib-20151231.xsd#IndebtednessDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:href="biib-20151231.xsd#IndebtednessDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:href="biib-20151231.xsd#IndebtednessDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTables" xlink:href="biib-20151231.xsd#IndebtednessTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20151231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20151231.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20151231.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20151231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20151231.xsd#Inventory" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20151231.xsd#InventoryDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20151231.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20151231.xsd#InventoryTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20151231.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20151231.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20151231.xsd#Litigation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20151231.xsd#LitigationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20151231.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20151231.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:href="biib-20151231.xsd#OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20151231.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:href="biib-20151231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20151231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:href="biib-20151231.xsd#PropertyPlantAndEquipmentDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails1" xlink:href="biib-20151231.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:href="biib-20151231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:href="biib-20151231.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="biib-20151231.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:href="biib-20151231.xsd#QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="biib-20151231.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:href="biib-20151231.xsd#RestructuringRestructuring" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:href="biib-20151231.xsd#RestructuringRestructuringDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:href="biib-20151231.xsd#RestructuringRestructuringDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:href="biib-20151231.xsd#RestructuringRestructuringTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RevenueReserves" xlink:href="biib-20151231.xsd#RevenueReserves" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesDetails" xlink:href="biib-20151231.xsd#RevenueReservesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesDetails1" xlink:href="biib-20151231.xsd#RevenueReservesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesTables" xlink:href="biib-20151231.xsd#RevenueReservesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SegmentInformation" xlink:href="biib-20151231.xsd#SegmentInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:href="biib-20151231.xsd#SegmentInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails1" xlink:href="biib-20151231.xsd#SegmentInformationDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:href="biib-20151231.xsd#SegmentInformationDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationTables" xlink:href="biib-20151231.xsd#SegmentInformationTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20151231.xsd#ShareBasedPayments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails4" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails5" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails6" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails8" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails9" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:href="biib-20151231.xsd#ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20151231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20151231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20151231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20151231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="biib-20151231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails" xlink:type="extended">
    <loc xlink:href="biib-20151231.xsd#biib_UnconsolidatedJointBusiness" xlink:label="loc_biib_UnconsolidatedJointBusiness_9d7213e3-e33d-5fcd-5a5d-d4ecccc4667d" xlink:type="locator" />
    <loc xlink:href="biib-20151231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_5002e734-2733-e541-5a61-38a2cc29a533" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_UnconsolidatedJointBusiness_9d7213e3-e33d-5fcd-5a5d-d4ecccc4667d" xlink:to="loc_biib_ShareOfCoPromotionProfits_5002e734-2733-e541-5a61-38a2cc29a533" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_ca646ab3-5159-77d2-80af-f70eebc0f27d" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_UnconsolidatedJointBusiness_9d7213e3-e33d-5fcd-5a5d-d4ecccc4667d" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_ca646ab3-5159-77d2-80af-f70eebc0f27d" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails2" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_5247fda4-8b88-6e22-1a65-38a2c7ef19f4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8a0692b4-cb50-1eeb-12b4-1509099841b7" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_5247fda4-8b88-6e22-1a65-38a2c7ef19f4" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8a0692b4-cb50-1eeb-12b4-1509099841b7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_671cd179-ca82-2856-ce52-e703bb5ea364" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_5247fda4-8b88-6e22-1a65-38a2c7ef19f4" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_671cd179-ca82-2856-ce52-e703bb5ea364" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_f32f6b0b-c05b-5b48-7f87-38a2c8bb1793" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_c48f63ae-e409-59ce-5794-cc7ae6139c21" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_f32f6b0b-c05b-5b48-7f87-38a2c8bb1793" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_c48f63ae-e409-59ce-5794-cc7ae6139c21" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_5c4f13b4-a2e8-045c-ecae-e7a536a799fc" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_f32f6b0b-c05b-5b48-7f87-38a2c8bb1793" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_5c4f13b4-a2e8-045c-ecae-e7a536a799fc" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_4262d7d2-7c42-ed1c-e111-38a2c7c32765" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_baee32aa-bbe2-ead3-1f78-a80f542a97a2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_4262d7d2-7c42-ed1c-e111-38a2c7c32765" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_baee32aa-bbe2-ead3-1f78-a80f542a97a2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_8cd900c1-2e0a-7994-be52-f185e493e8a0" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_4262d7d2-7c42-ed1c-e111-38a2c7c32765" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_8cd900c1-2e0a-7994-be52-f185e493e8a0" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_6fe55797-22c2-e385-c3ac-38a2c9163126" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_6adcb5b9-fb65-97ee-8a5b-2e780c178728" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_6fe55797-22c2-e385-c3ac-38a2c9163126" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_6adcb5b9-fb65-97ee-8a5b-2e780c178728" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_0e8ae422-d6d8-a751-2fa0-62b3339c3840" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_6fe55797-22c2-e385-c3ac-38a2c9163126" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_0e8ae422-d6d8-a751-2fa0-62b3339c3840" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_936e5946-55b1-4a7a-c6a1-38a2c885f91f" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5e342c11-473b-4170-d672-935adcfdb463" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_936e5946-55b1-4a7a-c6a1-38a2c885f91f" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5e342c11-473b-4170-d672-935adcfdb463" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_4f1b9318-9314-9f1a-0326-798bf98e1b56" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_936e5946-55b1-4a7a-c6a1-38a2c885f91f" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_4f1b9318-9314-9f1a-0326-798bf98e1b56" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_e523faff-7da3-a19c-8019-38a2cae158da" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_4c8190eb-f692-81f2-35bc-182f11d12444" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_e523faff-7da3-a19c-8019-38a2cae158da" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_4c8190eb-f692-81f2-35bc-182f11d12444" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_6b9c4322-60b6-ce19-69fe-2f0557c52073" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_e523faff-7da3-a19c-8019-38a2cae158da" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_6b9c4322-60b6-ce19-69fe-2f0557c52073" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_e2627738-9e68-6fd4-c9fe-38a2cb557f32" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6282e4c0-b0bd-9c84-bf43-857ac02b98fc" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePayments_e2627738-9e68-6fd4-c9fe-38a2cb557f32" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6282e4c0-b0bd-9c84-bf43-857ac02b98fc" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_443d77dd-8193-26c0-c24c-8020f9bb1890" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePayments_e2627738-9e68-6fd4-c9fe-38a2cb557f32" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_443d77dd-8193-26c0-c24c-8020f9bb1890" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_effc14df-fd72-eec8-ede9-64e0071b91bc" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_effc14df-fd72-eec8-ede9-64e0071b91bc" xlink:to="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_eae794c2-73ec-cd91-efb3-99a2ff1f24cf" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:to="loc_us-gaap_InventoryNet_eae794c2-73ec-cd91-efb3-99a2ff1f24cf" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd34decb-53b6-e0a9-28d5-0a9741c4b0f8" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd34decb-53b6-e0a9-28d5-0a9741c4b0f8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_222b5a74-9526-7448-da46-fccf1775d7c0" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_222b5a74-9526-7448-da46-fccf1775d7c0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4d24e56f-a5cb-07ba-0508-f5f1533ae24e" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4d24e56f-a5cb-07ba-0508-f5f1533ae24e" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DueFromUnconsolidatedJointBusiness" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_cf573ba9-04a8-7ac8-507a-d4ecccd56637" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:to="loc_biib_DueFromUnconsolidatedJointBusiness_cf573ba9-04a8-7ac8-507a-d4ecccd56637" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_33278e4f-d71c-924a-f185-bd5aaa288d0b" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_39eaeb62-7ee3-5503-48f5-08c2dff05e50" xlink:to="loc_us-gaap_OtherAssetsCurrent_33278e4f-d71c-924a-f185-bd5aaa288d0b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_392a46ef-05fd-68f8-e487-35e85a8f15a1" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_effc14df-fd72-eec8-ede9-64e0071b91bc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_392a46ef-05fd-68f8-e487-35e85a8f15a1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7ce178a4-245f-fa78-36a1-552609a67554" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_effc14df-fd72-eec8-ede9-64e0071b91bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7ce178a4-245f-fa78-36a1-552609a67554" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_894a128f-2068-d267-1e3e-64c93d0ed5ca" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_effc14df-fd72-eec8-ede9-64e0071b91bc" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_894a128f-2068-d267-1e3e-64c93d0ed5ca" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_b108d604-1348-4e65-3817-2944b734c65a" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_effc14df-fd72-eec8-ede9-64e0071b91bc" xlink:to="loc_us-gaap_Goodwill_b108d604-1348-4e65-3817-2944b734c65a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9b98e689-e6db-3e5b-e5c3-3324fffb4edf" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_effc14df-fd72-eec8-ede9-64e0071b91bc" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9b98e689-e6db-3e5b-e5c3-3324fffb4edf" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4a314f0d-c6fa-5cf2-0be1-add747465af3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a5c5aff-ee63-a4f2-571a-3515b5d26a3b" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4a314f0d-c6fa-5cf2-0be1-add747465af3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a5c5aff-ee63-a4f2-571a-3515b5d26a3b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a5c5aff-ee63-a4f2-571a-3515b5d26a3b" xlink:to="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_359b0ac4-80ce-a291-f73b-cff103b81eae" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:to="loc_us-gaap_PreferredStockValue_359b0ac4-80ce-a291-f73b-cff103b81eae" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_ce40a301-9b6b-9fc3-bfb6-dfbb8fcdf29b" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:to="loc_us-gaap_CommonStockValue_ce40a301-9b6b-9fc3-bfb6-dfbb8fcdf29b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9158c8ad-1189-2464-9c41-553e6a22df6c" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9158c8ad-1189-2464-9c41-553e6a22df6c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dd6b7206-c19f-4dd5-339b-1369c57cfe0f" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dd6b7206-c19f-4dd5-339b-1369c57cfe0f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1d565cd0-d7bf-de89-4dbe-a484007b1fe8" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1d565cd0-d7bf-de89-4dbe-a484007b1fe8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_0b2a392d-b5d5-0c30-4a0c-bcaab86d8160" xlink:type="locator" />
    <calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d0f349aa-18e3-6323-86ad-665f8773c064" xlink:to="loc_us-gaap_TreasuryStockValue_0b2a392d-b5d5-0c30-4a0c-bcaab86d8160" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_be52b263-dda5-21e0-250c-b71c8efa5893" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a5c5aff-ee63-a4f2-571a-3515b5d26a3b" xlink:to="loc_us-gaap_MinorityInterest_be52b263-dda5-21e0-250c-b71c8efa5893" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_4e70462c-e5f6-e2d9-0cf5-7f1332ddbc05" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4a314f0d-c6fa-5cf2-0be1-add747465af3" xlink:to="loc_us-gaap_Liabilities_4e70462c-e5f6-e2d9-0cf5-7f1332ddbc05" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4e70462c-e5f6-e2d9-0cf5-7f1332ddbc05" xlink:to="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_22caddf9-3843-6329-6e39-dc458323b572" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:to="loc_us-gaap_AccountsPayableCurrent_22caddf9-3843-6329-6e39-dc458323b572" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_7432ef68-60ae-faca-f534-19eb617f5674" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:to="loc_us-gaap_TaxesPayableCurrent_7432ef68-60ae-faca-f534-19eb617f5674" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0d8009a1-9f3a-b52e-6afc-03d7b3b4df06" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0d8009a1-9f3a-b52e-6afc-03d7b3b4df06" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_e290f5d1-6cff-e2db-d278-97a30e8ccd78" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1de50dbc-01a9-6657-f83f-d1e74edfdf18" xlink:to="loc_us-gaap_DebtCurrent_e290f5d1-6cff-e2db-d278-97a30e8ccd78" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_9210187e-cdda-2312-446f-000237db141c" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4e70462c-e5f6-e2d9-0cf5-7f1332ddbc05" xlink:to="loc_us-gaap_LongTermDebt_9210187e-cdda-2312-446f-000237db141c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_d3900b70-6aae-8c94-5a39-4a06f81c5d62" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4e70462c-e5f6-e2d9-0cf5-7f1332ddbc05" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_d3900b70-6aae-8c94-5a39-4a06f81c5d62" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7f5c7cfd-4659-429c-35ab-266d67961421" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_4e70462c-e5f6-e2d9-0cf5-7f1332ddbc05" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7f5c7cfd-4659-429c-35ab-266d67961421" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ff5db18e-7b91-5a5d-e914-0527b02a8012" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ff5db18e-7b91-5a5d-e914-0527b02a8012" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_5f8983ec-dfa4-10d0-f53d-c0676300a16f" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_ProfitLoss_5f8983ec-dfa4-10d0-f53d-c0676300a16f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_783b94c5-664a-4bc7-f813-8c258cc934b7" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_783b94c5-664a-4bc7-f813-8c258cc934b7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_d4c99b59-c44a-c4ac-309f-0bddfdb944a5" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_ShareBasedCompensation_d4c99b59-c44a-c4ac-309f-0bddfdb944a5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8b437d2d-6bbf-1f71-a341-6d3ac2b36703" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8b437d2d-6bbf-1f71-a341-6d3ac2b36703" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_8a9fbf97-3c14-4351-6d6b-553e136a9df1" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_8a9fbf97-3c14-4351-6d6b-553e136a9df1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_91d80b53-6368-7466-a11d-02030d33de5c" xlink:type="locator" />
    <calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_91d80b53-6368-7466-a11d-02030d33de5c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_bfab8b08-4541-18e9-28b5-5802fef422a3" xlink:type="locator" />
    <calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_bfab8b08-4541-18e9-28b5-5802fef422a3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_59947135-2495-391e-9e35-ed6effebb894" xlink:type="locator" />
    <calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_59947135-2495-391e-9e35-ed6effebb894" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6726a997-b874-a6f6-d79f-e0a4bde49905" xlink:type="locator" />
    <calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6726a997-b874-a6f6-d79f-e0a4bde49905" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1ea297cc-8653-7155-6fa9-a3af7df49950" xlink:type="locator" />
    <calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1ea297cc-8653-7155-6fa9-a3af7df49950" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_70b3d080-1749-085d-dc6b-2028c07db0f3" xlink:type="locator" />
    <calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_70b3d080-1749-085d-dc6b-2028c07db0f3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3eb22aca-47ee-3290-8d2e-e73a1c67010e" xlink:type="locator" />
    <calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_916e1eb7-21fa-e5f0-a15f-0b05ed633776" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3eb22aca-47ee-3290-8d2e-e73a1c67010e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58a5bd26-e5f4-de8f-6118-f713733148b8" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ff5db18e-7b91-5a5d-e914-0527b02a8012" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58a5bd26-e5f4-de8f-6118-f713733148b8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_198988d2-2f05-3f47-d4f0-bce81f98eaf0" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58a5bd26-e5f4-de8f-6118-f713733148b8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_198988d2-2f05-3f47-d4f0-bce81f98eaf0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_11bab1ef-563b-9c08-d855-5223ff2c6591" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58a5bd26-e5f4-de8f-6118-f713733148b8" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_11bab1ef-563b-9c08-d855-5223ff2c6591" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4852d3ee-c33e-1b07-798c-41e651367343" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58a5bd26-e5f4-de8f-6118-f713733148b8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4852d3ee-c33e-1b07-798c-41e651367343" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_386292ff-155c-0309-455a-2b91b395b3da" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58a5bd26-e5f4-de8f-6118-f713733148b8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_386292ff-155c-0309-455a-2b91b395b3da" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_bf382864-695e-2d3a-3151-198ef5847742" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58a5bd26-e5f4-de8f-6118-f713733148b8" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_bf382864-695e-2d3a-3151-198ef5847742" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0ff68e79-9d67-8dd3-0a29-1b2e1239e793" xlink:type="locator" />
    <calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58a5bd26-e5f4-de8f-6118-f713733148b8" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0ff68e79-9d67-8dd3-0a29-1b2e1239e793" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_b6ed717f-2ece-aa81-6051-41cf1a876a59" xlink:type="locator" />
    <calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58a5bd26-e5f4-de8f-6118-f713733148b8" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_b6ed717f-2ece-aa81-6051-41cf1a876a59" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a678c20d-a481-ef6a-800a-4bd566075d81" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ff5db18e-7b91-5a5d-e914-0527b02a8012" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a678c20d-a481-ef6a-800a-4bd566075d81" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4c2e87e5-41d0-b35b-6dfd-e3ab5b253709" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a678c20d-a481-ef6a-800a-4bd566075d81" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4c2e87e5-41d0-b35b-6dfd-e3ab5b253709" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_fdef3cb2-ec10-67c4-c0cc-b6e268faa4f7" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a678c20d-a481-ef6a-800a-4bd566075d81" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_fdef3cb2-ec10-67c4-c0cc-b6e268faa4f7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_bcbb7beb-ea8a-f0cb-eb3f-4769f26a96db" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a678c20d-a481-ef6a-800a-4bd566075d81" xlink:to="loc_us-gaap_RepaymentsOfDebt_bcbb7beb-ea8a-f0cb-eb3f-4769f26a96db" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_03b01b21-9333-5ba7-dbad-c8702c225fae" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a678c20d-a481-ef6a-800a-4bd566075d81" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_03b01b21-9333-5ba7-dbad-c8702c225fae" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_9dbeb004-67a9-1b19-c357-8b5cbf0013ee" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a678c20d-a481-ef6a-800a-4bd566075d81" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_9dbeb004-67a9-1b19-c357-8b5cbf0013ee" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_ae38354d-77f5-8db7-0abd-f1fc628a19a0" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a678c20d-a481-ef6a-800a-4bd566075d81" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_ae38354d-77f5-8db7-0abd-f1fc628a19a0" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_038f4602-9abc-1f60-05a2-6f69306a77ae" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_640557c9-9806-6bef-9084-9cc792948f77" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_038f4602-9abc-1f60-05a2-6f69306a77ae" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_640557c9-9806-6bef-9084-9cc792948f77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e62ce8b8-4401-2622-8598-3e644745e95e" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_640557c9-9806-6bef-9084-9cc792948f77" xlink:to="loc_us-gaap_NetIncomeLoss_e62ce8b8-4401-2622-8598-3e644745e95e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_58e3e908-4af5-683d-5a7a-0ca47c8e456d" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_640557c9-9806-6bef-9084-9cc792948f77" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_58e3e908-4af5-683d-5a7a-0ca47c8e456d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8449f638-e094-e8fc-6726-9e09a5f21c54" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_58e3e908-4af5-683d-5a7a-0ca47c8e456d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8449f638-e094-e8fc-6726-9e09a5f21c54" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7a0c4985-9166-79eb-6063-d5e6ffb820df" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8449f638-e094-e8fc-6726-9e09a5f21c54" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7a0c4985-9166-79eb-6063-d5e6ffb820df" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1c4a86dc-184f-b6a9-3882-e4b9077e09ca" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8449f638-e094-e8fc-6726-9e09a5f21c54" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1c4a86dc-184f-b6a9-3882-e4b9077e09ca" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7443b8c0-35a8-1f56-7e6b-5e71bdbce930" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_58e3e908-4af5-683d-5a7a-0ca47c8e456d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7443b8c0-35a8-1f56-7e6b-5e71bdbce930" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_57f718b6-d463-a1a8-7fd5-83810f6bedf1" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7443b8c0-35a8-1f56-7e6b-5e71bdbce930" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_57f718b6-d463-a1a8-7fd5-83810f6bedf1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_65cbf966-17f1-6b91-ff34-d36adae843af" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7443b8c0-35a8-1f56-7e6b-5e71bdbce930" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_65cbf966-17f1-6b91-ff34-d36adae843af" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_a8fa6c6f-a6dd-0012-f55c-e82fc2a06223" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_58e3e908-4af5-683d-5a7a-0ca47c8e456d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_a8fa6c6f-a6dd-0012-f55c-e82fc2a06223" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_fbd5cad0-09ca-a68e-f9d5-77ff2ba61ae4" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_58e3e908-4af5-683d-5a7a-0ca47c8e456d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_fbd5cad0-09ca-a68e-f9d5-77ff2ba61ae4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_560dfcb1-0fb6-5ffa-6e3b-8257ed923a94" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_038f4602-9abc-1f60-05a2-6f69306a77ae" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_560dfcb1-0fb6-5ffa-6e3b-8257ed923a94" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e62ce8b8-4401-2622-8598-3e644745e95e" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_5f8983ec-dfa4-10d0-f53d-c0676300a16f" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e62ce8b8-4401-2622-8598-3e644745e95e" xlink:to="loc_us-gaap_ProfitLoss_5f8983ec-dfa4-10d0-f53d-c0676300a16f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f0ea1b66-a9f7-f42c-6882-4cca5faefea1" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5f8983ec-dfa4-10d0-f53d-c0676300a16f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f0ea1b66-a9f7-f42c-6882-4cca5faefea1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_0ea1551e-1643-5e21-4c6e-6431fd87aa68" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f0ea1b66-a9f7-f42c-6882-4cca5faefea1" xlink:to="loc_us-gaap_OperatingIncomeLoss_0ea1551e-1643-5e21-4c6e-6431fd87aa68" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_ba59260a-e348-d7f8-5375-fde11baf79c1" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0ea1551e-1643-5e21-4c6e-6431fd87aa68" xlink:to="loc_us-gaap_Revenues_ba59260a-e348-d7f8-5375-fde11baf79c1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_ca646ab3-5159-77d2-80af-f70eebc0f27d" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_ba59260a-e348-d7f8-5375-fde11baf79c1" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_ca646ab3-5159-77d2-80af-f70eebc0f27d" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_UnconsolidatedJointBusiness" xlink:label="loc_biib_UnconsolidatedJointBusiness_9d7213e3-e33d-5fcd-5a5d-d4ecccc4667d" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_ba59260a-e348-d7f8-5375-fde11baf79c1" xlink:to="loc_biib_UnconsolidatedJointBusiness_9d7213e3-e33d-5fcd-5a5d-d4ecccc4667d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_104a708e-80a2-fec9-83a4-0bfbe74de8c9" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_ba59260a-e348-d7f8-5375-fde11baf79c1" xlink:to="loc_us-gaap_OtherSalesRevenueNet_104a708e-80a2-fec9-83a4-0bfbe74de8c9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0ea1551e-1643-5e21-4c6e-6431fd87aa68" xlink:to="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_47bf16bc-113d-838a-56d3-e154f0f2a154" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:to="loc_us-gaap_CostOfGoodsSold_47bf16bc-113d-838a-56d3-e154f0f2a154" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ec32a100-932a-145a-1c30-859c3cf9ce96" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ec32a100-932a-145a-1c30-859c3cf9ce96" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_37d23128-e0be-7b8b-d6c6-f3d1ac14cac9" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_37d23128-e0be-7b8b-d6c6-f3d1ac14cac9" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_a1d2a501-1cbe-4da5-95ed-38a2ca47cff5" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:to="loc_biib_CollaborationProfitSharing_a1d2a501-1cbe-4da5-95ed-38a2ca47cff5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_682e13ed-74ef-f976-16fa-3796f1bc898f" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_682e13ed-74ef-f976-16fa-3796f1bc898f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_9eeada2d-bc9c-ffca-e02d-8e9d67d5416e" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:to="loc_us-gaap_RestructuringCharges_9eeada2d-bc9c-ffca-e02d-8e9d67d5416e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8d928bd0-3555-e21c-4646-ebe154fbdd5d" xlink:type="locator" />
    <calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8281466b-86c7-ec9c-c7fc-3723705ba526" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8d928bd0-3555-e21c-4646-ebe154fbdd5d" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_GainOnSaleOfRights" xlink:label="loc_biib_GainOnSaleOfRights_c3d7f6e7-1c4d-b587-6955-d4ecccf10a0d" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0ea1551e-1643-5e21-4c6e-6431fd87aa68" xlink:to="loc_biib_GainOnSaleOfRights_c3d7f6e7-1c4d-b587-6955-d4ecccf10a0d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_51486ac3-3cfb-dff4-43ca-0d3980775a1d" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f0ea1b66-a9f7-f42c-6882-4cca5faefea1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_51486ac3-3cfb-dff4-43ca-0d3980775a1d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b8dcf191-083d-828d-7b9f-e2d2969b89f4" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5f8983ec-dfa4-10d0-f53d-c0676300a16f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b8dcf191-083d-828d-7b9f-e2d2969b89f4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b71b86f8-adb0-6f61-c3a9-37e1e67b4d68" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5f8983ec-dfa4-10d0-f53d-c0676300a16f" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b71b86f8-adb0-6f61-c3a9-37e1e67b4d68" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6e1329dd-9911-a537-956e-8ca9c6805be6" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e62ce8b8-4401-2622-8598-3e644745e95e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6e1329dd-9911-a537-956e-8ca9c6805be6" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ca9bebe4-4073-b721-7b75-1a0086593d58" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8afbf9ec-40f2-ac04-dde9-64f96fdfbf74" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ca9bebe4-4073-b721-7b75-1a0086593d58" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8afbf9ec-40f2-ac04-dde9-64f96fdfbf74" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_58a1745d-db2b-3ff9-104d-4b3f9664d3ce" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ca9bebe4-4073-b721-7b75-1a0086593d58" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_58a1745d-db2b-3ff9-104d-4b3f9664d3ce" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0449447d-2475-b5e7-892e-ced6d0229840" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_58a1745d-db2b-3ff9-104d-4b3f9664d3ce" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0449447d-2475-b5e7-892e-ced6d0229840" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_190f7f5c-4b8c-bf2f-74c0-cab5f1deb02f" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0fe5317b-bdcf-7a27-121f-55fe035264d7" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_190f7f5c-4b8c-bf2f-74c0-cab5f1deb02f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0fe5317b-bdcf-7a27-121f-55fe035264d7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_72dfc996-2bdc-a5c2-43c9-885b6330f5bb" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_190f7f5c-4b8c-bf2f-74c0-cab5f1deb02f" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_72dfc996-2bdc-a5c2-43c9-885b6330f5bb" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_a6e76a34-fa42-d66f-a2a4-5865ce92446b" xlink:type="locator" />
    <loc xlink:href="biib-20151231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_bf13782d-1724-0c45-a352-d4ecccf5eb0b" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_a6e76a34-fa42-d66f-a2a4-5865ce92446b" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_bf13782d-1724-0c45-a352-d4ecccf5eb0b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_73b022da-9054-5e1b-96dd-04e339313a48" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_a6e76a34-fa42-d66f-a2a4-5865ce92446b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_73b022da-9054-5e1b-96dd-04e339313a48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_465ba6e6-2b33-45fe-3e73-c5293643fc38" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_a6e76a34-fa42-d66f-a2a4-5865ce92446b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_465ba6e6-2b33-45fe-3e73-c5293643fc38" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9361d00b-bf28-09e2-175e-2f8c5c8d39ac" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0c84ece3-1f8c-2bb3-6d4d-e7a215e4c9c1" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9361d00b-bf28-09e2-175e-2f8c5c8d39ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0c84ece3-1f8c-2bb3-6d4d-e7a215e4c9c1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0936fe34-b1c6-5f4e-1eee-fa338ed8b930" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9361d00b-bf28-09e2-175e-2f8c5c8d39ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0936fe34-b1c6-5f4e-1eee-fa338ed8b930" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_a142b19a-8793-4b19-f90e-d4ecccce4f97" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9361d00b-bf28-09e2-175e-2f8c5c8d39ac" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_a142b19a-8793-4b19-f90e-d4ecccce4f97" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/Guarantees" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b8dcf191-083d-828d-7b9f-e2d2969b89f4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_34234baa-d101-3f73-2c90-9ccf83248ac9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b8dcf191-083d-828d-7b9f-e2d2969b89f4" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_34234baa-d101-3f73-2c90-9ccf83248ac9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_bbeff925-a146-2078-8abf-f4cd97255735" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_34234baa-d101-3f73-2c90-9ccf83248ac9" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_bbeff925-a146-2078-8abf-f4cd97255735" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2ac2b83b-7587-ac08-d667-af95bd01fbb2" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_34234baa-d101-3f73-2c90-9ccf83248ac9" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2ac2b83b-7587-ac08-d667-af95bd01fbb2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1be7a3a1-cbc3-8ffe-f157-edb51cd26a68" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_34234baa-d101-3f73-2c90-9ccf83248ac9" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1be7a3a1-cbc3-8ffe-f157-edb51cd26a68" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8b437d2d-6bbf-1f71-a341-6d3ac2b36703" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b8dcf191-083d-828d-7b9f-e2d2969b89f4" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8b437d2d-6bbf-1f71-a341-6d3ac2b36703" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0a099f0c-8f61-7b47-fb6f-d9dfccab6a2b" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8b437d2d-6bbf-1f71-a341-6d3ac2b36703" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0a099f0c-8f61-7b47-fb6f-d9dfccab6a2b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_01bd828d-ff2f-1258-4ecb-6afd711760b6" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8b437d2d-6bbf-1f71-a341-6d3ac2b36703" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_01bd828d-ff2f-1258-4ecb-6afd711760b6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_de4150a6-31ba-55b3-12d4-35cb377c9ca2" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8b437d2d-6bbf-1f71-a341-6d3ac2b36703" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_de4150a6-31ba-55b3-12d4-35cb377c9ca2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f0ea1b66-a9f7-f42c-6882-4cca5faefea1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e8c93fd8-b953-0fac-1368-bda1875af048" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f0ea1b66-a9f7-f42c-6882-4cca5faefea1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e8c93fd8-b953-0fac-1368-bda1875af048" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6a037740-99db-8b3b-3911-f1b1e7885e0c" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f0ea1b66-a9f7-f42c-6882-4cca5faefea1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6a037740-99db-8b3b-3911-f1b1e7885e0c" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_f790ef08-9e64-0989-2e62-f1a00cb26d64" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_371df7bd-8911-dc61-e047-ba9703021545" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f790ef08-9e64-0989-2e62-f1a00cb26d64" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_371df7bd-8911-dc61-e047-ba9703021545" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:label="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_710ba9ee-0a98-8a02-ed3f-38a2c82c084c" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f790ef08-9e64-0989-2e62-f1a00cb26d64" xlink:to="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_710ba9ee-0a98-8a02-ed3f-38a2c82c084c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c9103802-e01c-0411-2da8-2206c8e6cbaf" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_351e9f9c-f3e3-2db3-110c-394de97ab52e" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c9103802-e01c-0411-2da8-2206c8e6cbaf" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_351e9f9c-f3e3-2db3-110c-394de97ab52e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_5f4f401a-b6c0-85a8-5abe-7ae5899d7ce1" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c9103802-e01c-0411-2da8-2206c8e6cbaf" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_5f4f401a-b6c0-85a8-5abe-7ae5899d7ce1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_537e4665-5eba-ae94-5fa7-7d9f8b4fe9eb" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c9103802-e01c-0411-2da8-2206c8e6cbaf" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_537e4665-5eba-ae94-5fa7-7d9f8b4fe9eb" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2388bf7d-bac3-63e4-7ea0-6e9febb628dd" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c9103802-e01c-0411-2da8-2206c8e6cbaf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2388bf7d-bac3-63e4-7ea0-6e9febb628dd" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_11af201b-713a-e639-e3e5-2a2e9be5b0c6" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c9103802-e01c-0411-2da8-2206c8e6cbaf" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_11af201b-713a-e639-e3e5-2a2e9be5b0c6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_d2894808-c556-546c-7bdb-cf4d5d84446f" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c9103802-e01c-0411-2da8-2206c8e6cbaf" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_d2894808-c556-546c-7bdb-cf4d5d84446f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_43429341-a7f8-3d28-8300-64e1feef8fa0" xlink:type="locator" />
    <calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c9103802-e01c-0411-2da8-2206c8e6cbaf" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_43429341-a7f8-3d28-8300-64e1feef8fa0" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_037594ef-c95d-7169-0f2c-0d9bf9c6587e" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_acf5d13d-61d7-58c0-7f7b-a5c0f7cb7066" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_037594ef-c95d-7169-0f2c-0d9bf9c6587e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_acf5d13d-61d7-58c0-7f7b-a5c0f7cb7066" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4b3be44f-5687-e783-ac34-c53c5c3f10e0" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_037594ef-c95d-7169-0f2c-0d9bf9c6587e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4b3be44f-5687-e783-ac34-c53c5c3f10e0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_79b52493-ed4b-fb62-5daf-e1982275e67b" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_037594ef-c95d-7169-0f2c-0d9bf9c6587e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_79b52493-ed4b-fb62-5daf-e1982275e67b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_b7dc579f-e75c-078b-3163-aa7cbf10455d" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_037594ef-c95d-7169-0f2c-0d9bf9c6587e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_b7dc579f-e75c-078b-3163-aa7cbf10455d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_9c55f220-92b5-d322-b264-8565d6f98283" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_037594ef-c95d-7169-0f2c-0d9bf9c6587e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_9c55f220-92b5-d322-b264-8565d6f98283" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_decf3e7b-8400-73a7-9168-2d6d4804b247" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_037594ef-c95d-7169-0f2c-0d9bf9c6587e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_decf3e7b-8400-73a7-9168-2d6d4804b247" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EffectiveIncomeTaxRateReconciliationContingentConsideration" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_6b362912-d49e-3558-c643-38a2cc15334d" xlink:type="locator" />
    <calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_037594ef-c95d-7169-0f2c-0d9bf9c6587e" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_6b362912-d49e-3558-c643-38a2cc15334d" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_827805f6-6e2a-818b-c1dc-d4eccd3a9153" xlink:type="locator" />
    <calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_037594ef-c95d-7169-0f2c-0d9bf9c6587e" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_827805f6-6e2a-818b-c1dc-d4eccd3a9153" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_c196df40-1c93-aa9e-08cb-64f83b0b3872" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b123dc5b-f642-4c2e-fe3e-7f92b8b51b2a" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_c196df40-1c93-aa9e-08cb-64f83b0b3872" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b123dc5b-f642-4c2e-fe3e-7f92b8b51b2a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3535a701-94d8-c323-4675-b61ad499142b" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_c196df40-1c93-aa9e-08cb-64f83b0b3872" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3535a701-94d8-c323-4675-b61ad499142b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_84624c36-fd7f-cb7d-c9b6-303206ca1c9e" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_c196df40-1c93-aa9e-08cb-64f83b0b3872" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_84624c36-fd7f-cb7d-c9b6-303206ca1c9e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e96c6294-18bd-4972-ec5b-a1eb9894f000" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_c196df40-1c93-aa9e-08cb-64f83b0b3872" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e96c6294-18bd-4972-ec5b-a1eb9894f000" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_3d2a581f-6caf-0baf-d854-5ffca65542bd" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_c196df40-1c93-aa9e-08cb-64f83b0b3872" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_3d2a581f-6caf-0baf-d854-5ffca65542bd" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_656a3a31-335a-3d32-fffb-b3602e789d7a" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_c196df40-1c93-aa9e-08cb-64f83b0b3872" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_656a3a31-335a-3d32-fffb-b3602e789d7a" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d1f67248-e9b5-f4cc-7b0f-6057f1a3d17a" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_37242da4-8bd9-8845-4f04-4d33ee3aa769" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d1f67248-e9b5-f4cc-7b0f-6057f1a3d17a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_37242da4-8bd9-8845-4f04-4d33ee3aa769" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5fad788a-33b8-6ace-c3c4-7d91cd9f63e4" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d1f67248-e9b5-f4cc-7b0f-6057f1a3d17a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5fad788a-33b8-6ace-c3c4-7d91cd9f63e4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0b66a991-68b5-43d2-3cb3-4ea68bba2b7e" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d1f67248-e9b5-f4cc-7b0f-6057f1a3d17a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0b66a991-68b5-43d2-3cb3-4ea68bba2b7e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_894a128f-2068-d267-1e3e-64c93d0ed5ca" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ba3ee58c-a1d2-0b1b-d8ba-aeea5e112c4e" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_894a128f-2068-d267-1e3e-64c93d0ed5ca" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ba3ee58c-a1d2-0b1b-d8ba-aeea5e112c4e" xlink:type="arc" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_894a128f-2068-d267-1e3e-64c93d0ed5ca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5fad788a-33b8-6ace-c3c4-7d91cd9f63e4" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <loc xlink:href="biib-20151231.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_6fedbe30-eedd-0f68-be8d-38a2c7d5d99b" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_52e0aebe-a03f-09bd-b0a5-024dc9cc6bc5" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_6fedbe30-eedd-0f68-be8d-38a2c7d5d99b" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_52e0aebe-a03f-09bd-b0a5-024dc9cc6bc5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_8162f0c6-3901-3410-efb8-4a460fb9898c" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_6fedbe30-eedd-0f68-be8d-38a2c7d5d99b" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_8162f0c6-3901-3410-efb8-4a460fb9898c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_67158a47-96e7-9b0f-c6d4-8e2f09cc69df" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_6fedbe30-eedd-0f68-be8d-38a2c7d5d99b" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_67158a47-96e7-9b0f-c6d4-8e2f09cc69df" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7f5c7cfd-4659-429c-35ab-266d67961421" xlink:type="locator" />
    <loc xlink:href="biib-20151231.xsd#biib_Employeerelatedliabilitiesnoncurrent" xlink:label="loc_biib_Employeerelatedliabilitiesnoncurrent_f92e99ca-128a-38fa-2b71-d4ecccd8d600" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_7f5c7cfd-4659-429c-35ab-266d67961421" xlink:to="loc_biib_Employeerelatedliabilitiesnoncurrent_f92e99ca-128a-38fa-2b71-d4ecccd8d600" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_966acde3-4f37-c9e4-23af-34b57d61d82f" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_7f5c7cfd-4659-429c-35ab-266d67961421" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_966acde3-4f37-c9e4-23af-34b57d61d82f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_c1cdcecb-6358-aee2-3913-b09d3829a3a8" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_7f5c7cfd-4659-429c-35ab-266d67961421" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_c1cdcecb-6358-aee2-3913-b09d3829a3a8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_51486ac3-3cfb-dff4-43ca-0d3980775a1d" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f41ffc72-ebad-5797-e151-38939dd37877" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_51486ac3-3cfb-dff4-43ca-0d3980775a1d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f41ffc72-ebad-5797-e151-38939dd37877" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_8d3aa4ad-dbea-9eba-4578-5d3b83ba3bc6" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_51486ac3-3cfb-dff4-43ca-0d3980775a1d" xlink:to="loc_us-gaap_InterestExpense_8d3aa4ad-dbea-9eba-4578-5d3b83ba3bc6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="loc_us-gaap_ImpairmentOfInvestments_85b28f39-559e-204f-e377-e6ef8c2d638d" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_51486ac3-3cfb-dff4-43ca-0d3980775a1d" xlink:to="loc_us-gaap_ImpairmentOfInvestments_85b28f39-559e-204f-e377-e6ef8c2d638d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_a9b00820-766d-4f93-08eb-06a6be9e0e6b" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_51486ac3-3cfb-dff4-43ca-0d3980775a1d" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_a9b00820-766d-4f93-08eb-06a6be9e0e6b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7d95006c-ae0a-39bc-bb82-9715342e9a83" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_51486ac3-3cfb-dff4-43ca-0d3980775a1d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7d95006c-ae0a-39bc-bb82-9715342e9a83" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_OtherIncomeExpenseNet" xlink:label="loc_biib_OtherIncomeExpenseNet_c5650fd7-777e-5e6a-f6f7-d4eccd41658d" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_51486ac3-3cfb-dff4-43ca-0d3980775a1d" xlink:to="loc_biib_OtherIncomeExpenseNet_c5650fd7-777e-5e6a-f6f7-d4eccd41658d" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7ce178a4-245f-fa78-36a1-552609a67554" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6591f040-08b3-69a1-a560-c70736475ada" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_7ce178a4-245f-fa78-36a1-552609a67554" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6591f040-08b3-69a1-a560-c70736475ada" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_5f113b74-55d3-328d-c134-0ba25c366a34" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_6591f040-08b3-69a1-a560-c70736475ada" xlink:to="loc_us-gaap_Land_5f113b74-55d3-328d-c134-0ba25c366a34" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_687d5c44-0ff0-a374-7249-2d0457f747d0" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_6591f040-08b3-69a1-a560-c70736475ada" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_687d5c44-0ff0-a374-7249-2d0457f747d0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_e0b7ea08-053f-5432-d792-3b4214a3d7ab" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_6591f040-08b3-69a1-a560-c70736475ada" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_e0b7ea08-053f-5432-d792-3b4214a3d7ab" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_5ebe2673-c7bd-8813-b08b-ccdafddcf93d" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_6591f040-08b3-69a1-a560-c70736475ada" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_5ebe2673-c7bd-8813-b08b-ccdafddcf93d" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ComputerSoftwareAndHardware" xlink:label="loc_biib_ComputerSoftwareAndHardware_cbe2a92c-bdd2-ba99-53c9-38a2c99d77ba" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_6591f040-08b3-69a1-a560-c70736475ada" xlink:to="loc_biib_ComputerSoftwareAndHardware_cbe2a92c-bdd2-ba99-53c9-38a2c99d77ba" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_d63fd3fd-4444-a091-d95a-6eb67f429c4c" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_6591f040-08b3-69a1-a560-c70736475ada" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_d63fd3fd-4444-a091-d95a-6eb67f429c4c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_e52c88f9-b25a-e353-24f6-ceda52000430" xlink:type="locator" />
    <calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_6591f040-08b3-69a1-a560-c70736475ada" xlink:to="loc_us-gaap_ConstructionInProgressGross_e52c88f9-b25a-e353-24f6-ceda52000430" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b84a1570-30ad-4e3a-2391-9767a64e15fd" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_7ce178a4-245f-fa78-36a1-552609a67554" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b84a1570-30ad-4e3a-2391-9767a64e15fd" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/RevenueReserves" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/RevenueReservesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/RevenueReservesDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/RevenueReservesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <loc xlink:href="biib-20151231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_33deb27f-5bc5-f719-f29b-d4eccd282105" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_ed55a377-3e01-611f-cd7f-0fbe24ab1ea8" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_33deb27f-5bc5-f719-f29b-d4eccd282105" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_ed55a377-3e01-611f-cd7f-0fbe24ab1ea8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_7668125b-8e16-a6bf-5206-b61c4942c5e3" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_33deb27f-5bc5-f719-f29b-d4eccd282105" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_7668125b-8e16-a6bf-5206-b61c4942c5e3" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>biib-20151231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20151231.xsd#AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20151231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20151231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20151231.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20151231.xsd#Acquisitions" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:href="biib-20151231.xsd#AcquisitionsAcquisitionsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1" xlink:href="biib-20151231.xsd#AcquisitionsAcquisitionsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables" xlink:href="biib-20151231.xsd#AcquisitionsAcquisitionsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20151231.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationshipsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationshipsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails2" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationshipsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20151231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:href="biib-20151231.xsd#CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:href="biib-20151231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="biib-20151231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:href="biib-20151231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:href="biib-20151231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="biib-20151231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="biib-20151231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:href="biib-20151231.xsd#ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:href="biib-20151231.xsd#ConsolidatedStatementsOfEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:href="biib-20151231.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20151231.xsd#DerivativeInstruments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20151231.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1" xlink:href="biib-20151231.xsd#DerivativeInstrumentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:href="biib-20151231.xsd#DerivativeInstrumentsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20151231.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20151231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20151231.xsd#EarningsPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20151231.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20151231.xsd#EarningsPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:href="biib-20151231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails" xlink:href="biib-20151231.xsd#EmployeeBenefitPlansDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20151231.xsd#Equity" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20151231.xsd#EquityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20151231.xsd#EquityDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20151231.xsd#EquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20151231.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20151231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20151231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20151231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20151231.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20151231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20151231.xsd#FinancialInstruments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20151231.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20151231.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20151231.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20151231.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:href="biib-20151231.xsd#FinancialInstrumentsDetailsTextual1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:href="biib-20151231.xsd#FinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20151231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Guarantees" xlink:href="biib-20151231.xsd#Guarantees" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20151231.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20151231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:href="biib-20151231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:href="biib-20151231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:href="biib-20151231.xsd#IncomeTaxesDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20151231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20151231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:href="biib-20151231.xsd#Indebtedness" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:href="biib-20151231.xsd#IndebtednessDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:href="biib-20151231.xsd#IndebtednessDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:href="biib-20151231.xsd#IndebtednessDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTables" xlink:href="biib-20151231.xsd#IndebtednessTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20151231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20151231.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20151231.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20151231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20151231.xsd#Inventory" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20151231.xsd#InventoryDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20151231.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20151231.xsd#InventoryTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20151231.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20151231.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20151231.xsd#Litigation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20151231.xsd#LitigationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20151231.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20151231.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:href="biib-20151231.xsd#OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20151231.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:href="biib-20151231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20151231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:href="biib-20151231.xsd#PropertyPlantAndEquipmentDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails1" xlink:href="biib-20151231.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:href="biib-20151231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:href="biib-20151231.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="biib-20151231.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:href="biib-20151231.xsd#QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="biib-20151231.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:href="biib-20151231.xsd#RestructuringRestructuring" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:href="biib-20151231.xsd#RestructuringRestructuringDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:href="biib-20151231.xsd#RestructuringRestructuringDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:href="biib-20151231.xsd#RestructuringRestructuringTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RevenueReserves" xlink:href="biib-20151231.xsd#RevenueReserves" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesDetails" xlink:href="biib-20151231.xsd#RevenueReservesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesDetails1" xlink:href="biib-20151231.xsd#RevenueReservesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesTables" xlink:href="biib-20151231.xsd#RevenueReservesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SegmentInformation" xlink:href="biib-20151231.xsd#SegmentInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:href="biib-20151231.xsd#SegmentInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails1" xlink:href="biib-20151231.xsd#SegmentInformationDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:href="biib-20151231.xsd#SegmentInformationDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationTables" xlink:href="biib-20151231.xsd#SegmentInformationTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20151231.xsd#ShareBasedPayments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails4" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails5" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails6" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails8" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails9" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:href="biib-20151231.xsd#ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20151231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20151231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20151231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20151231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="biib-20151231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_F367701BAC9B5C4E1E7938A3517510B9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404" xlink:to="loc_us-gaap_StatementTable_F367701BAC9B5C4E1E7938A3517510B9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_35EF3E62B0FEFD161CAE38A351757A2E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_F367701BAC9B5C4E1E7938A3517510B9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_35EF3E62B0FEFD161CAE38A351757A2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D08DD666831095457F6D38A3517533FB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_35EF3E62B0FEFD161CAE38A351757A2E" xlink:to="loc_us-gaap_EquityComponentDomain_D08DD666831095457F6D38A3517533FB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D08DD666831095457F6D38A3517533FB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_35EF3E62B0FEFD161CAE38A351757A2E" xlink:to="loc_us-gaap_EquityComponentDomain_D08DD666831095457F6D38A3517533FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_4E9EBCBBEA4C0F47856B38A35175DE26" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_D08DD666831095457F6D38A3517533FB" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_4E9EBCBBEA4C0F47856B38A35175DE26" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_52B8760C6E948BB127DC38A351759E97" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_D08DD666831095457F6D38A3517533FB" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_52B8760C6E948BB127DC38A351759E97" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B32F9CA4C5D75A635EEC38A35175DB81" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_D08DD666831095457F6D38A3517533FB" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B32F9CA4C5D75A635EEC38A35175DB81" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9990C88D179E86E82ECF38A351752411" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_D08DD666831095457F6D38A3517533FB" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9990C88D179E86E82ECF38A351752411" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9CDE9C9203C719405EC138A35175CF30" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9CDE9C9203C719405EC138A35175CF30" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1A6766F0BBAE99D698FA38A351764483" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1A6766F0BBAE99D698FA38A351764483" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7D1D700EF560D4EE171838A35176923C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7D1D700EF560D4EE171838A35176923C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B3EE7F07332C2FD20DC38A35176A287" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B3EE7F07332C2FD20DC38A35176A287" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_277C06FF2DF5065E96A9A32AB8B8CD99" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_9BB201B91433480EF93DA32AB8B79A47" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_277C06FF2DF5065E96A9A32AB8B8CD99" xlink:to="loc_us-gaap_StatementTable_9BB201B91433480EF93DA32AB8B79A47" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_927D80F05A693AEB0221A32AB8B7EA06" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9BB201B91433480EF93DA32AB8B79A47" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_927D80F05A693AEB0221A32AB8B7EA06" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_24A298292EEA86A62B4AA32AB8B760D6_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_927D80F05A693AEB0221A32AB8B7EA06" xlink:to="loc_us-gaap_EquityComponentDomain_24A298292EEA86A62B4AA32AB8B760D6_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_24A298292EEA86A62B4AA32AB8B760D6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_927D80F05A693AEB0221A32AB8B7EA06" xlink:to="loc_us-gaap_EquityComponentDomain_24A298292EEA86A62B4AA32AB8B760D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E7F3341A93C7485FD0C0A32AB8B8BA61" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_24A298292EEA86A62B4AA32AB8B760D6" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E7F3341A93C7485FD0C0A32AB8B8BA61" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_717DB635D96594086B23A32AB8B84639" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_24A298292EEA86A62B4AA32AB8B760D6" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_717DB635D96594086B23A32AB8B84639" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_4085589AEFE4C3D47979A32AB8B83CCA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9BB201B91433480EF93DA32AB8B79A47" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_4085589AEFE4C3D47979A32AB8B83CCA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_D5DB919A12A1E3100A64A32AB8B8EBB5_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_4085589AEFE4C3D47979A32AB8B83CCA" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_D5DB919A12A1E3100A64A32AB8B8EBB5_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_D5DB919A12A1E3100A64A32AB8B8EBB5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_4085589AEFE4C3D47979A32AB8B83CCA" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_D5DB919A12A1E3100A64A32AB8B8EBB5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_870F6DCF66B42EFC83BDA32AB8B851AD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_D5DB919A12A1E3100A64A32AB8B8EBB5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_870F6DCF66B42EFC83BDA32AB8B851AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1C915A4C86FE38E85B05A32AB8B84C0C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_277C06FF2DF5065E96A9A32AB8B8CD99" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1C915A4C86FE38E85B05A32AB8B84C0C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_01BEA23D64A5F84CDDB9A32AB8B840AA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_277C06FF2DF5065E96A9A32AB8B8CD99" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_01BEA23D64A5F84CDDB9A32AB8B840AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_B2003F153C8493AD1985A32AB8B85FAC" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_277C06FF2DF5065E96A9A32AB8B8CD99" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_B2003F153C8493AD1985A32AB8B85FAC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_38261C774CF9A59A46F9A32AB8B89003" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_277C06FF2DF5065E96A9A32AB8B8CD99" xlink:to="loc_us-gaap_NetIncomeLoss_38261C774CF9A59A46F9A32AB8B89003" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4B0D1102F508681F589493224D3C3E85" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4C69EB01C1EA5F6171A193224D3C60D8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B0D1102F508681F589493224D3C3E85" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4C69EB01C1EA5F6171A193224D3C60D8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9761638C0CA7F8673A4993224D3CE278" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4C69EB01C1EA5F6171A193224D3C60D8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9761638C0CA7F8673A4993224D3CE278" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9A12111ADD3A9D02671793224D3C4C6B_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9761638C0CA7F8673A4993224D3CE278" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9A12111ADD3A9D02671793224D3C4C6B_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9A12111ADD3A9D02671793224D3C4C6B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9761638C0CA7F8673A4993224D3CE278" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9A12111ADD3A9D02671793224D3C4C6B" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_584D5A2C868F0CD1228393224D3C5B79" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9A12111ADD3A9D02671793224D3C4C6B" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_584D5A2C868F0CD1228393224D3C5B79" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_E01CD3F64172105EF56C93224D3C6D7B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B0D1102F508681F589493224D3C3E85" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_E01CD3F64172105EF56C93224D3C6D7B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_E6E156F93A07B676308793224D3CEBDE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B0D1102F508681F589493224D3C3E85" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_E6E156F93A07B676308793224D3CEBDE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_26E9A90E23F7C3CBD8BC93224D3C32E8" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B0D1102F508681F589493224D3C3E85" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_26E9A90E23F7C3CBD8BC93224D3C32E8" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_05EC6EDFE30C861BF48293224D39A961" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A92E498CFC50F86900993224D3843DE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05EC6EDFE30C861BF48293224D39A961" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A92E498CFC50F86900993224D3843DE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_605C477E7E9F5A673FF293224D395267" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A92E498CFC50F86900993224D3843DE" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_605C477E7E9F5A673FF293224D395267" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BDBBB50B85EEBBED801793224D3900CA_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_605C477E7E9F5A673FF293224D395267" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BDBBB50B85EEBBED801793224D3900CA_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BDBBB50B85EEBBED801793224D3900CA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_605C477E7E9F5A673FF293224D395267" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BDBBB50B85EEBBED801793224D3900CA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_31A9E723ECE4DF4F8DCE93224D399891" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BDBBB50B85EEBBED801793224D3900CA" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_31A9E723ECE4DF4F8DCE93224D399891" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_B8540C3E76381D3FAD5493224D39FBBC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05EC6EDFE30C861BF48293224D39A961" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_B8540C3E76381D3FAD5493224D39FBBC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_89103FACF1D0D4B9C26293224D3994E7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05EC6EDFE30C861BF48293224D39A961" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_89103FACF1D0D4B9C26293224D3994E7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_198DB2409DE54C383EF293224D39048B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05EC6EDFE30C861BF48293224D39A961" xlink:to="loc_us-gaap_Goodwill_198DB2409DE54C383EF293224D39048B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_F0EAA334FFC051ADE0DC93224D39758D" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05EC6EDFE30C861BF48293224D39A961" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_F0EAA334FFC051ADE0DC93224D39758D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_99C58519B10AC5892C5793224D39EA53" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05EC6EDFE30C861BF48293224D39A961" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_99C58519B10AC5892C5793224D39EA53" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7D38838342A7A24D505A93224D391B19" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05EC6EDFE30C861BF48293224D39A961" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7D38838342A7A24D505A93224D391B19" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25626C3330FCFFA8EF0B65DB84EF7F09" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25626C3330FCFFA8EF0B65DB84EF7F09" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_A43E2990F525B65B424E65DB84EF4D1A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25626C3330FCFFA8EF0B65DB84EF7F09" xlink:to="loc_us-gaap_ProductOrServiceAxis_A43E2990F525B65B424E65DB84EF4D1A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_01B3E61721E4222A7A4C65DB84EF29D9_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_A43E2990F525B65B424E65DB84EF4D1A" xlink:to="loc_us-gaap_ProductsAndServicesDomain_01B3E61721E4222A7A4C65DB84EF29D9_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_01B3E61721E4222A7A4C65DB84EF29D9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_A43E2990F525B65B424E65DB84EF4D1A" xlink:to="loc_us-gaap_ProductsAndServicesDomain_01B3E61721E4222A7A4C65DB84EF29D9" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RaxatrigineMember" xlink:label="loc_biib_RaxatrigineMember_914C5EE36A52C7A9F7CB65DB84EF5DC9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_01B3E61721E4222A7A4C65DB84EF29D9" xlink:to="loc_biib_RaxatrigineMember_914C5EE36A52C7A9F7CB65DB84EF5DC9" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NeuropathicpainindicationsMember" xlink:label="loc_biib_NeuropathicpainindicationsMember_F45DC58CC17DFC3574FF65DB84EF4DCD" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_01B3E61721E4222A7A4C65DB84EF29D9" xlink:to="loc_biib_NeuropathicpainindicationsMember_F45DC58CC17DFC3574FF65DB84EF4DCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_C50877112869C6B94EFC65DB84EF81BA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25626C3330FCFFA8EF0B65DB84EF7F09" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_C50877112869C6B94EFC65DB84EF81BA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D4A9A1AEC81489672A1765DB84EF19A1_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C50877112869C6B94EFC65DB84EF81BA" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D4A9A1AEC81489672A1765DB84EF19A1_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D4A9A1AEC81489672A1765DB84EF19A1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C50877112869C6B94EFC65DB84EF81BA" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D4A9A1AEC81489672A1765DB84EF19A1" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_582A8FF708C55581F95865DB84EF3854" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D4A9A1AEC81489672A1765DB84EF19A1" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_582A8FF708C55581F95865DB84EF3854" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_E1851822BCC3BA1FFC2765DB84EF889F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D4A9A1AEC81489672A1765DB84EF19A1" xlink:to="loc_biib_TysabriProductMember_E1851822BCC3BA1FFC2765DB84EF889F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8A0481D00C4A318D2C7165DB84F0C04E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8A0481D00C4A318D2C7165DB84F0C04E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0986DFF09A228A13CCCB65DB84F08FCE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0986DFF09A228A13CCCB65DB84F08FCE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_A7F685AA14D7DAD78E7A65DB84F03FC0" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_A7F685AA14D7DAD78E7A65DB84F03FC0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_88E6E843AF55C281FAC465DB84F0C24E" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_88E6E843AF55C281FAC465DB84F0C24E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_9222F5B584599A22563D65DB84F0001C" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_9222F5B584599A22563D65DB84F0001C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_35EFFC671EFCA996157865DB84F0BE00" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_35EFFC671EFCA996157865DB84F0BE00" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_FF9E8217E2B35FBBF3C365DB84F0088D" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_FF9E8217E2B35FBBF3C365DB84F0088D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4F9D94BC92C21F1B02F065DB84F0DA89" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4F9D94BC92C21F1B02F065DB84F0DA89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7EDF24EA0B9F59FCB40E65DB84F02611" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7EDF24EA0B9F59FCB40E65DB84F02611" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_C78F65BF68E23F5486C465DB84F0AAEC" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_DeferredRevenueCurrent_C78F65BF68E23F5486C465DB84F0AAEC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_B9030EBAEF2F879AA62065DB84F0B1BE" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_B9030EBAEF2F879AA62065DB84F0B1BE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FutureContingentPaymentForFirst12Months" xlink:label="loc_biib_FutureContingentPaymentForFirst12Months_2D28165EC5D48327DA2065DB84F0CC40" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_biib_FutureContingentPaymentForFirst12Months_2D28165EC5D48327DA2065DB84F0CC40" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_1207F3F98AB356C20B4C65DB84F0F103" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_1207F3F98AB356C20B4C65DB84F0F103" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FutureContingentPaymentThreshold" xlink:label="loc_biib_FutureContingentPaymentThreshold_EB879259F15D73B381E465DB84F0F05E" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_biib_FutureContingentPaymentThreshold_EB879259F15D73B381E465DB84F0F05E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_EFAF0F346EBA5B8C8E9265DB84F0ABFE" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_EFAF0F346EBA5B8C8E9265DB84F0ABFE" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53FC471D714412EA7E8A38A3548A9B26" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5FC91CF438B82F485A0F38A3548A6CD5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53FC471D714412EA7E8A38A3548A9B26" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5FC91CF438B82F485A0F38A3548A6CD5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_FFB27D0F59D4CED4C6FC38A3548AADBA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5FC91CF438B82F485A0F38A3548A6CD5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_FFB27D0F59D4CED4C6FC38A3548AADBA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2D19567CFFB86C539F9138A3548AD7B2_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FFB27D0F59D4CED4C6FC38A3548AADBA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2D19567CFFB86C539F9138A3548AD7B2_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2D19567CFFB86C539F9138A3548AD7B2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FFB27D0F59D4CED4C6FC38A3548AADBA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2D19567CFFB86C539F9138A3548AD7B2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_C03D2A42EDD6CF4C9D5038A3548A08BE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2D19567CFFB86C539F9138A3548AD7B2" xlink:to="loc_biib_EisaiMember_C03D2A42EDD6CF4C9D5038A3548A08BE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_74516694506A14A50B1638A3548AED0F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53FC471D714412EA7E8A38A3548A9B26" xlink:to="loc_biib_ExpenseIncurredByCollaboration_74516694506A14A50B1638A3548AED0F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ExpenseReflectedWithinStatementsOfIncome" xlink:label="loc_biib_ExpenseReflectedWithinStatementsOfIncome_09F9C30431555CF33A0538A3548ACB3B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53FC471D714412EA7E8A38A3548A9B26" xlink:to="loc_biib_ExpenseReflectedWithinStatementsOfIncome_09F9C30431555CF33A0538A3548ACB3B" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D8C144561649DB2ECD838A351246275" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9D19A7F2EE1D8D14503B38A35123599E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D8C144561649DB2ECD838A351246275" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9D19A7F2EE1D8D14503B38A35123599E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_E26700D2162DB73CB57E38A35123EC02" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9D19A7F2EE1D8D14503B38A35123599E" xlink:to="loc_us-gaap_ProductOrServiceAxis_E26700D2162DB73CB57E38A35123EC02" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_62664D6ADAD3E0E0ABAE38A35123B590_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_E26700D2162DB73CB57E38A35123EC02" xlink:to="loc_us-gaap_ProductsAndServicesDomain_62664D6ADAD3E0E0ABAE38A35123B590_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_62664D6ADAD3E0E0ABAE38A35123B590" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_E26700D2162DB73CB57E38A35123EC02" xlink:to="loc_us-gaap_ProductsAndServicesDomain_62664D6ADAD3E0E0ABAE38A35123B590" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_4B5AB1A8264A4795196038A351239DF5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_62664D6ADAD3E0E0ABAE38A35123B590" xlink:to="loc_biib_GAZYVAMember_4B5AB1A8264A4795196038A351239DF5" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_AD753FB0C5B56224770138A35123CCDB" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_62664D6ADAD3E0E0ABAE38A35123B590" xlink:to="loc_biib_RituxanMember_AD753FB0C5B56224770138A35123CCDB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_10CB0B1E14F88F18A83438A35123DA8F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9D19A7F2EE1D8D14503B38A35123599E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_10CB0B1E14F88F18A83438A35123DA8F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A146D3511E62A4D85B6538A351232432_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_10CB0B1E14F88F18A83438A35123DA8F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A146D3511E62A4D85B6538A351232432_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A146D3511E62A4D85B6538A351232432" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_10CB0B1E14F88F18A83438A35123DA8F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A146D3511E62A4D85B6538A351232432" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_0455D84FED67B7FE19E538A351230557" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A146D3511E62A4D85B6538A351232432" xlink:to="loc_biib_RocheGroupGenentechMember_0455D84FED67B7FE19E538A351230557" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_14EABB81BBBEB19A7E7038A351241832" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9D19A7F2EE1D8D14503B38A35123599E" xlink:to="loc_us-gaap_StatementGeographicalAxis_14EABB81BBBEB19A7E7038A351241832" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_6CD0A72A268074DD74C438A35124E129_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_14EABB81BBBEB19A7E7038A351241832" xlink:to="loc_us-gaap_SegmentGeographicalDomain_6CD0A72A268074DD74C438A35124E129_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_6CD0A72A268074DD74C438A35124E129" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_14EABB81BBBEB19A7E7038A351241832" xlink:to="loc_us-gaap_SegmentGeographicalDomain_6CD0A72A268074DD74C438A35124E129" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="loc_country_US_86F3ADC7D5DA419BC79638A351241BF8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_6CD0A72A268074DD74C438A35124E129" xlink:to="loc_country_US_86F3ADC7D5DA419BC79638A351241BF8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_CB1D8BCDC01573BF6C4538A351245DB5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_6CD0A72A268074DD74C438A35124E129" xlink:to="loc_us-gaap_ForeignCountryMember_CB1D8BCDC01573BF6C4538A351245DB5" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CoPromotionProfitSharingFormulaAbstract" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract_206A2574F36DEAD5BCA138A35124F55F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D8C144561649DB2ECD838A351246275" xlink:to="loc_biib_CoPromotionProfitSharingFormulaAbstract_206A2574F36DEAD5BCA138A35124F55F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_72EE9E256276BFF1F78038A3512435E4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_206A2574F36DEAD5BCA138A35124F55F" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_72EE9E256276BFF1F78038A3512435E4" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_7F908F1E8E6DEE52357238A351243863" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_206A2574F36DEAD5BCA138A35124F55F" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_7F908F1E8E6DEE52357238A351243863" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_A76C1526278DB1FF798538A35124809F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_7F908F1E8E6DEE52357238A351243863" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_A76C1526278DB1FF798538A35124809F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_519A267EE42F8895C1BC38A3512402A2" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_7F908F1E8E6DEE52357238A351243863" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_519A267EE42F8895C1BC38A3512402A2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_E9C77CA29E45AC9E23B338A35124FAED" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_7F908F1E8E6DEE52357238A351243863" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_E9C77CA29E45AC9E23B338A35124FAED" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RevenuesFromUnconsolidatedJointBusinessAbstract" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_2FB19097E477B7D598A538A351249A93" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D8C144561649DB2ECD838A351246275" xlink:to="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_2FB19097E477B7D598A538A351249A93" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_4DE6DEB5D896A1DE17C638A351248B06" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_2FB19097E477B7D598A538A351249A93" xlink:to="loc_biib_ShareOfCoPromotionProfits_4DE6DEB5D896A1DE17C638A351248B06" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_B0981BC5E19E2FE7BFA838A35124AA59" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_2FB19097E477B7D598A538A351249A93" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_B0981BC5E19E2FE7BFA838A35124AA59" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_UnconsolidatedJointBusiness" xlink:label="loc_biib_UnconsolidatedJointBusiness_271FB402D617EEE48A4B38A3512419F5" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_2FB19097E477B7D598A538A351249A93" xlink:to="loc_biib_UnconsolidatedJointBusiness_271FB402D617EEE48A4B38A3512419F5" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9049014DA4092D3573CF38A356D66046" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D7BDD709A11BAD29E44F38A356D5C0FC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9049014DA4092D3573CF38A356D66046" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D7BDD709A11BAD29E44F38A356D5C0FC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="biib-20151231.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_6670AF6F06670508869B38A356D52A32" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D7BDD709A11BAD29E44F38A356D5C0FC" xlink:to="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_6670AF6F06670508869B38A356D52A32" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_6670AF6F06670508869B38A356D52A32" xlink:to="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390_default" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_6670AF6F06670508869B38A356D52A32" xlink:to="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" xlink:label="loc_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_52C2DFB5E9A28A552DED38A356D5F208" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390" xlink:to="loc_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_52C2DFB5E9A28A552DED38A356D5F208" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_2C7188067A5169ADEEA038A356D5894D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390" xlink:to="loc_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_2C7188067A5169ADEEA038A356D5894D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_712C86F78E572F826D5338A356D6A5FF" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390" xlink:to="loc_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_712C86F78E572F826D5338A356D6A5FF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_11FB6B83DBE4F62E20DF38A356D69B96" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390" xlink:to="loc_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_11FB6B83DBE4F62E20DF38A356D69B96" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_6665FAF73F4F26F9EAE838A356D62AAF" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D7BDD709A11BAD29E44F38A356D5C0FC" xlink:to="loc_us-gaap_StatementGeographicalAxis_6665FAF73F4F26F9EAE838A356D62AAF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_104DC06FFE042F1A6F7B38A356D63DAA_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_6665FAF73F4F26F9EAE838A356D62AAF" xlink:to="loc_us-gaap_SegmentGeographicalDomain_104DC06FFE042F1A6F7B38A356D63DAA_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_104DC06FFE042F1A6F7B38A356D63DAA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_6665FAF73F4F26F9EAE838A356D62AAF" xlink:to="loc_us-gaap_SegmentGeographicalDomain_104DC06FFE042F1A6F7B38A356D63DAA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SobiTerritoryMember" xlink:label="loc_biib_SobiTerritoryMember_E5973DF826CE8783512A38A356D6CB0F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_104DC06FFE042F1A6F7B38A356D63DAA" xlink:to="loc_biib_SobiTerritoryMember_E5973DF826CE8783512A38A356D6CB0F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_131869F99B4F0E33119E38A356D62707" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D7BDD709A11BAD29E44F38A356D5C0FC" xlink:to="loc_us-gaap_RangeAxis_131869F99B4F0E33119E38A356D62707" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1ED4A051FC1C3729297D38A356D66081_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_131869F99B4F0E33119E38A356D62707" xlink:to="loc_us-gaap_RangeMember_1ED4A051FC1C3729297D38A356D66081_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1ED4A051FC1C3729297D38A356D66081" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_131869F99B4F0E33119E38A356D62707" xlink:to="loc_us-gaap_RangeMember_1ED4A051FC1C3729297D38A356D66081" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_6A4B51C7F202BD4CD99938A356D6EF75" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_1ED4A051FC1C3729297D38A356D66081" xlink:to="loc_us-gaap_MaximumMember_6A4B51C7F202BD4CD99938A356D6EF75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4C45755CB3F0AA55400C38A356D6CA5A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_1ED4A051FC1C3729297D38A356D66081" xlink:to="loc_us-gaap_MinimumMember_4C45755CB3F0AA55400C38A356D6CA5A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9049014DA4092D3573CF38A356D66046" xlink:to="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ReimbursementUnderAmendedAgreementMethod" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementMethod_6CD61DAD54FED3715B6938A356D63F4E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70" xlink:to="loc_biib_ReimbursementUnderAmendedAgreementMethod_6CD61DAD54FED3715B6938A356D63F4E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RatePriorToFirstCommercialSale" xlink:label="loc_biib_RatePriorToFirstCommercialSale_BED538263F231440DA2838A356D69282" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70" xlink:to="loc_biib_RatePriorToFirstCommercialSale_BED538263F231440DA2838A356D69282" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BaseRateAfterFirstCommercialSale" xlink:label="loc_biib_BaseRateAfterFirstCommercialSale_3FCE01CF9E6E97B5A99D38A356D6B9FC" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70" xlink:to="loc_biib_BaseRateAfterFirstCommercialSale_3FCE01CF9E6E97B5A99D38A356D6B9FC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RateDuringReimbursementPeriod" xlink:label="loc_biib_RateDuringReimbursementPeriod_DFF6B8226D1DC8A5BC0838A356D67522" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70" xlink:to="loc_biib_RateDuringReimbursementPeriod_DFF6B8226D1DC8A5BC0838A356D67522" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC56B109C48B1665FBC038A355A8607A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2F92622CF27BF1C4800938A355A84869" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC56B109C48B1665FBC038A355A8607A" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2F92622CF27BF1C4800938A355A84869" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8D8EE0D3A0B271C016D238A355A82CF0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2F92622CF27BF1C4800938A355A84869" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8D8EE0D3A0B271C016D238A355A82CF0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28E947ABD46F94A083B38A355A8D0CB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8D8EE0D3A0B271C016D238A355A82CF0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28E947ABD46F94A083B38A355A8D0CB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28E947ABD46F94A083B38A355A8D0CB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8D8EE0D3A0B271C016D238A355A82CF0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28E947ABD46F94A083B38A355A8D0CB" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AbbvieMember" xlink:label="loc_biib_AbbvieMember_E617B6CC3C877B4351AB38A355A81BD1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28E947ABD46F94A083B38A355A8D0CB" xlink:to="loc_biib_AbbvieMember_E617B6CC3C877B4351AB38A355A81BD1" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_FE5E24C5E6FFF8154E4438A355A861D8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC56B109C48B1665FBC038A355A8607A" xlink:to="loc_biib_ExpenseIncurredByCollaboration_FE5E24C5E6FFF8154E4438A355A861D8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ExpenseReflectedWithinStatementsOfIncome" xlink:label="loc_biib_ExpenseReflectedWithinStatementsOfIncome_B78A52685CDE4A5814A338A355A865CA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC56B109C48B1665FBC038A355A8607A" xlink:to="loc_biib_ExpenseReflectedWithinStatementsOfIncome_B78A52685CDE4A5814A338A355A865CA" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_E0912BB6DDFEB12549C693D5C96EB6F6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="loc_us-gaap_StatementGeographicalAxis_E0912BB6DDFEB12549C693D5C96EB6F6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_AEECFD82D62299124D9793D5C96E5FA6_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_E0912BB6DDFEB12549C693D5C96EB6F6" xlink:to="loc_us-gaap_SegmentGeographicalDomain_AEECFD82D62299124D9793D5C96E5FA6_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_AEECFD82D62299124D9793D5C96E5FA6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_E0912BB6DDFEB12549C693D5C96EB6F6" xlink:to="loc_us-gaap_SegmentGeographicalDomain_AEECFD82D62299124D9793D5C96E5FA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_80AE7224E0EC5D14079E93D5C96E6C84" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_AEECFD82D62299124D9793D5C96E5FA6" xlink:to="loc_us-gaap_ForeignCountryMember_80AE7224E0EC5D14079E93D5C96E6C84" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="loc_country_US_02D07D2C9CEA6EF4DBD693D5C96E1867" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_AEECFD82D62299124D9793D5C96E5FA6" xlink:to="loc_country_US_02D07D2C9CEA6EF4DBD693D5C96E1867" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C3349773AA0D57BEB8B993D5C96EC538" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_C3349773AA0D57BEB8B993D5C96EC538" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_FE8730FCE8FA2CC590FD93D5C96FB578_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C3349773AA0D57BEB8B993D5C96EC538" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_FE8730FCE8FA2CC590FD93D5C96FB578_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_FE8730FCE8FA2CC590FD93D5C96FB578" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C3349773AA0D57BEB8B993D5C96EC538" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_FE8730FCE8FA2CC590FD93D5C96FB578" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E0FFB83D9FE6FB03368793D5C96F1696" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_FE8730FCE8FA2CC590FD93D5C96FB578" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E0FFB83D9FE6FB03368793D5C96F1696" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_353E77C6D02DCF8B951893D5C96FF734" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_353E77C6D02DCF8B951893D5C96FF734" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_46A8009752A5B984C18893D5C96FEE7D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_353E77C6D02DCF8B951893D5C96FF734" xlink:to="loc_us-gaap_LossContingencyNatureDomain_46A8009752A5B984C18893D5C96FEE7D_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_46A8009752A5B984C18893D5C96FEE7D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_353E77C6D02DCF8B951893D5C96FF734" xlink:to="loc_us-gaap_LossContingencyNatureDomain_46A8009752A5B984C18893D5C96FEE7D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_HoechstMember" xlink:label="loc_biib_HoechstMember_9787FDBA9337F3760D3E93D5C96FA543" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_46A8009752A5B984C18893D5C96FEE7D" xlink:to="loc_biib_HoechstMember_9787FDBA9337F3760D3E93D5C96FA543" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AdditionalProductsAxis" xlink:label="loc_biib_AdditionalProductsAxis_E3851D105C85384660D593D5C96F98D6" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="loc_biib_AdditionalProductsAxis_E3851D105C85384660D593D5C96F98D6" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AdditionalProductsDomain" xlink:label="loc_biib_AdditionalProductsDomain_06DD47C969E3A03571D493D5C96F6545_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_AdditionalProductsAxis_E3851D105C85384660D593D5C96F98D6" xlink:to="loc_biib_AdditionalProductsDomain_06DD47C969E3A03571D493D5C96F6545_default" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AdditionalProductsDomain" xlink:label="loc_biib_AdditionalProductsDomain_06DD47C969E3A03571D493D5C96F6545" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_AdditionalProductsAxis_E3851D105C85384660D593D5C96F98D6" xlink:to="loc_biib_AdditionalProductsDomain_06DD47C969E3A03571D493D5C96F6545" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NewAntiCd20Member" xlink:label="loc_biib_NewAntiCd20Member_6AC8E63DCEFFC5DC6C6393D5C96F77F1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AdditionalProductsDomain_06DD47C969E3A03571D493D5C96F6545" xlink:to="loc_biib_NewAntiCd20Member_6AC8E63DCEFFC5DC6C6393D5C96F77F1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72D9824CCE950F40F21093D5C96F399E" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72D9824CCE950F40F21093D5C96F399E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_B0FA555C1F86CE910CA193D5C96FEAEE_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72D9824CCE950F40F21093D5C96F399E" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_B0FA555C1F86CE910CA193D5C96FEAEE_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_B0FA555C1F86CE910CA193D5C96FEAEE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72D9824CCE950F40F21093D5C96F399E" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_B0FA555C1F86CE910CA193D5C96FEAEE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_1FF89E58852BA33785A993D5C96F87C1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_B0FA555C1F86CE910CA193D5C96FEAEE" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_1FF89E58852BA33785A993D5C96F87C1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_C1CC42211F03E706987B93D5C96FD83E" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="loc_us-gaap_ProductOrServiceAxis_C1CC42211F03E706987B93D5C96FD83E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_C1CC42211F03E706987B93D5C96FD83E" xlink:to="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_C1CC42211F03E706987B93D5C96FD83E" xlink:to="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_5ABFC98D8F2F43AB5C1D93D5C96FA970" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_RituxanMember_5ABFC98D8F2F43AB5C1D93D5C96FA970" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_7148DE974A124A82D98893D5C96F3750" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_GAZYVAMember_7148DE974A124A82D98893D5C96F3750" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NewAntiCd20Member" xlink:label="loc_biib_NewAntiCd20Member_8EA4B6907A83B7811DF393D5C96F8D5C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_NewAntiCd20Member_8EA4B6907A83B7811DF393D5C96F8D5C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ThirdPartyAntiCdTwentyMember" xlink:label="loc_biib_ThirdPartyAntiCdTwentyMember_3114A1838DD1F322077B93D5C9701C93" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_ThirdPartyAntiCdTwentyMember_3114A1838DD1F322077B93D5C9701C93" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_BABCFA279ECCB60FEE6993D5C9709290" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_ELOCTATEMember_BABCFA279ECCB60FEE6993D5C9709290" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_34C73C20FB27CAFA6C3793D5C9702889" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_ALPROLIXMember_34C73C20FB27CAFA6C3793D5C9702889" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_OcrelizumabMember" xlink:label="loc_biib_OcrelizumabMember_8DC2C6B53A41932DDAEF93D5C97034B0" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_OcrelizumabMember_8DC2C6B53A41932DDAEF93D5C97034B0" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SOD1Member" xlink:label="loc_biib_SOD1Member_EB60A87A0FB3E1E02A2793DFA04EC495" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_SOD1Member_EB60A87A0FB3E1E02A2793DFA04EC495" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DMPKMember" xlink:label="loc_biib_DMPKMember_DF85E0ED1B849170CEEE93D5C9704FCA" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_DMPKMember_DF85E0ED1B849170CEEE93D5C9704FCA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SMNRxMember" xlink:label="loc_biib_SMNRxMember_7A78831878BA77DB329293D5C970ADF0" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_SMNRxMember_7A78831878BA77DB329293D5C970ADF0" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_LeadprogramsMember" xlink:label="loc_biib_LeadprogramsMember_753B73C00DCDB9A4950A93D5C970D598" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_LeadprogramsMember_753B73C00DCDB9A4950A93D5C970D598" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DiscoveryprogramsMember" xlink:label="loc_biib_DiscoveryprogramsMember_30C901FB7EE2418F69A693D5C97076E5" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_DiscoveryprogramsMember_30C901FB7EE2418F69A693D5C97076E5" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_10197333C26473E38D5093D5C970D2A4" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_BiosimilarsMember_10197333C26473E38D5093D5C970D2A4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A0B789E254BBE740009A93D5C97095FA" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A0B789E254BBE740009A93D5C97095FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A0B789E254BBE740009A93D5C97095FA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A0B789E254BBE740009A93D5C97095FA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_1C2551141E3D2D79B80C93D5C97023A7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_RocheGroupGenentechMember_1C2551141E3D2D79B80C93D5C97023A7" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_GenentechMember" xlink:label="loc_biib_GenentechMember_3A76385BB3F92D60E76093D5C970B6CF" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_GenentechMember_3A76385BB3F92D60E76093D5C970B6CF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ElanMember" xlink:label="loc_biib_ElanMember_F8C67C8905D242E26AE793D5C970525E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_ElanMember_F8C67C8905D242E26AE793D5C970525E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AcordaMember" xlink:label="loc_biib_AcordaMember_4E92B1A6BF7AF627891893D5C9700BB8" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_AcordaMember_4E92B1A6BF7AF627891893D5C9700BB8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SwedishOrphanBiovitrumMember" xlink:label="loc_biib_SwedishOrphanBiovitrumMember_E18976E6EAC193F1670B93D5C9705535" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_SwedishOrphanBiovitrumMember_E18976E6EAC193F1670B93D5C9705535" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AbbvieMember" xlink:label="loc_biib_AbbvieMember_7603D7708BE1A05A352693D5C9705C45" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_AbbvieMember_7603D7708BE1A05A352693D5C9705C45" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_IsisPharmaceuticalsMember" xlink:label="loc_biib_IsisPharmaceuticalsMember_F94324D1F70DE576704793D5C97041A4" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_IsisPharmaceuticalsMember_F94324D1F70DE576704793D5C97041A4" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_21827AB91F12B494258D93D5C970E8A6" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_EisaiMember_21827AB91F12B494258D93D5C970E8A6" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SangamoBioSciencesMember" xlink:label="loc_biib_SangamoBioSciencesMember_B99A805243157ABB445893D5C9702A6C" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_SangamoBioSciencesMember_B99A805243157ABB445893D5C9702A6C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AGTCMember" xlink:label="loc_biib_AGTCMember_887AF927DE7A493B429793D5C971730D" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_AGTCMember_887AF927DE7A493B429793D5C971730D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MitsubishiTanabePharmaCorporationMember" xlink:label="loc_biib_MitsubishiTanabePharmaCorporationMember_FA9176EC03F833D8912793D5C97104E5" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_MitsubishiTanabePharmaCorporationMember_FA9176EC03F833D8912793D5C97104E5" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_OtherresearchanddiscoveryMember" xlink:label="loc_biib_OtherresearchanddiscoveryMember_3566344DF130A66F861E93D5C971A63B" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_OtherresearchanddiscoveryMember_3566344DF130A66F861E93D5C971A63B" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_20F2750B592D1418D04293D5C9719874" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_20F2750B592D1418D04293D5C9719874" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_B6420F58A851EB781E3A93D5C9715D0C" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="loc_us-gaap_RangeAxis_B6420F58A851EB781E3A93D5C9715D0C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8652B90BD740441D6AED93D5C971512E_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_B6420F58A851EB781E3A93D5C9715D0C" xlink:to="loc_us-gaap_RangeMember_8652B90BD740441D6AED93D5C971512E_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8652B90BD740441D6AED93D5C971512E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_B6420F58A851EB781E3A93D5C9715D0C" xlink:to="loc_us-gaap_RangeMember_8652B90BD740441D6AED93D5C971512E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_656BB3D2295C575E68A193D5C971258A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_8652B90BD740441D6AED93D5C971512E" xlink:to="loc_us-gaap_MaximumMember_656BB3D2295C575E68A193D5C971258A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_AAA47C9143B57245747D93D5C9712C99" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_8652B90BD740441D6AED93D5C971512E" xlink:to="loc_us-gaap_MinimumMember_AAA47C9143B57245747D93D5C9712C99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_22B6E6E4936353D6FF5293D5C9710618" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_22B6E6E4936353D6FF5293D5C9710618" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FA3860EAF9C54F9DD19493D5C971DFEC_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_22B6E6E4936353D6FF5293D5C9710618" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FA3860EAF9C54F9DD19493D5C971DFEC_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FA3860EAF9C54F9DD19493D5C971DFEC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_22B6E6E4936353D6FF5293D5C9710618" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FA3860EAF9C54F9DD19493D5C971DFEC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BiogenIdecHemophiliaMember" xlink:label="loc_biib_BiogenIdecHemophiliaMember_C08125830F1C7595D31293D5C9712332" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FA3860EAF9C54F9DD19493D5C971DFEC" xlink:to="loc_biib_BiogenIdecHemophiliaMember_C08125830F1C7595D31293D5C9712332" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RoyaltiesTermsOfCollaborationAgreement" xlink:label="loc_biib_RoyaltiesTermsOfCollaborationAgreement_190F8FE5707A045C034493D5C971DC9F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_RoyaltiesTermsOfCollaborationAgreement_190F8FE5707A045C034493D5C971DC9F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CollaborationsTextualAbstract" xlink:label="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_5D0093F9D4DD7378419593D5C971DF0C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_5D0093F9D4DD7378419593D5C971DF0C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PeriodOfCollaborationAgreement" xlink:label="loc_biib_PeriodOfCollaborationAgreement_AEE58ED468B795DC264293D5C971CEE0" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_PeriodOfCollaborationAgreement_AEE58ED468B795DC264293D5C971CEE0" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated" xlink:label="loc_biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated_795C0D84F80A6CD7D7F393D5C9728756" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated_795C0D84F80A6CD7D7F393D5C9728756" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_F3F53D5CCF40D2AD5B8E93D5C972EB47" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_F3F53D5CCF40D2AD5B8E93D5C972EB47" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Reductioninroyaltyrate" xlink:label="loc_biib_Reductioninroyaltyrate_F00621A5F66C87870CA493D5C97288EC" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_Reductioninroyaltyrate_F00621A5F66C87870CA493D5C97288EC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_17C1BBA894D5D67B299C93D5C9720751" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_17C1BBA894D5D67B299C93D5C9720751" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CB87872C91EF7EEFD73D93D5C9728092" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CB87872C91EF7EEFD73D93D5C9728092" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_7B25B94EF1114380917793D5C9727750" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_7B25B94EF1114380917793D5C9727750" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_24C275EF6FD786E9805A93D5C972B925" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_24C275EF6FD786E9805A93D5C972B925" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SalesTriggerGrossSalesThreshold" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_396FA6F8703B8821032293D5C9726CE2" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_396FA6F8703B8821032293D5C9726CE2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Futurepercentageofcopromotionoperatingprofits" xlink:label="loc_biib_Futurepercentageofcopromotionoperatingprofits_4F8D1CC7249F45D2C2E093D5C97230D8" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_Futurepercentageofcopromotionoperatingprofits_4F8D1CC7249F45D2C2E093D5C97230D8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingLosses" xlink:label="loc_biib_PercentageOfCoPromotionOperatingLosses_CBE5308D32EBE93A422993D5C97284B2" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_PercentageOfCoPromotionOperatingLosses_CBE5308D32EBE93A422993D5C97284B2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages" xlink:label="loc_biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages_A1ADDE750FB90CB8FCEE93D5C972FA4E" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages_A1ADDE750FB90CB8FCEE93D5C972FA4E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_B3C06B5FC540DDDAEAE893D5C972A9FB" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_B3C06B5FC540DDDAEAE893D5C972A9FB" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_3029BCADED57FD2474BD93D5C9721F45" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ShareOfCoPromotionProfits_3029BCADED57FD2474BD93D5C9721F45" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_C9F22A32CB29E8F0B5E693D5C9720162" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_C9F22A32CB29E8F0B5E693D5C9720162" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_CD79E9D32061DEF323FE93D5C9725630" xlink:type="locator" />
    <definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_CD79E9D32061DEF323FE93D5C9725630" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner" xlink:label="loc_biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner_97B8FE85B2AEDD3DAF9293D5C9720ADB" xlink:type="locator" />
    <definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner_97B8FE85B2AEDD3DAF9293D5C9720ADB" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner" xlink:label="loc_biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner_FE328A3348C9C093511393D5C9720EAE" xlink:type="locator" />
    <definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner_FE328A3348C9C093511393D5C9720EAE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration" xlink:label="loc_biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration_FFBC347447608196092A93D5C972D40B" xlink:type="locator" />
    <definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration_FFBC347447608196092A93D5C972D40B" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_F48F09B0AFFAB4FA899293D5C972A015" xlink:type="locator" />
    <definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_F48F09B0AFFAB4FA899293D5C972A015" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4B9B23ABEA0867C9DA9893D5C9722ACA" xlink:type="locator" />
    <definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4B9B23ABEA0867C9DA9893D5C9722ACA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ForeignSalesRequiredToTriggerMilestone" xlink:label="loc_biib_ForeignSalesRequiredToTriggerMilestone_198B74121E8F20EF985A93D5C97358CA" xlink:type="locator" />
    <definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ForeignSalesRequiredToTriggerMilestone_198B74121E8F20EF985A93D5C97358CA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ExpenseReflectedWithinStatementsOfIncome" xlink:label="loc_biib_ExpenseReflectedWithinStatementsOfIncome_5547D39B607D618C287793D5C97373E3" xlink:type="locator" />
    <definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ExpenseReflectedWithinStatementsOfIncome_5547D39B607D618C287793D5C97373E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9F98DD455CC00E73D81E93D5C973E83A" xlink:type="locator" />
    <definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9F98DD455CC00E73D81E93D5C973E83A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ConsiderationPerProductDeveloped" xlink:label="loc_biib_ConsiderationPerProductDeveloped_C8BE94CD385ADF5704AA93D5C973BB12" xlink:type="locator" />
    <definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ConsiderationPerProductDeveloped_C8BE94CD385ADF5704AA93D5C973BB12" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfReimbursementExpenses" xlink:label="loc_biib_PercentageOfReimbursementExpenses_E61E4789BF2BDEB75F5893D5C9736524" xlink:type="locator" />
    <definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_PercentageOfReimbursementExpenses_E61E4789BF2BDEB75F5893D5C9736524" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfDevelopmentReimbursementExpenses" xlink:label="loc_biib_PercentageOfDevelopmentReimbursementExpenses_75E6598CDC58E09E045693D5C973C3FE" xlink:type="locator" />
    <definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_PercentageOfDevelopmentReimbursementExpenses_75E6598CDC58E09E045693D5C973C3FE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ReimbursementCostAchievingPeriod" xlink:label="loc_biib_ReimbursementCostAchievingPeriod_AAB9D4EB8A2B433D4F9493D5C973CA35" xlink:type="locator" />
    <definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ReimbursementCostAchievingPeriod_AAB9D4EB8A2B433D4F9493D5C973CA35" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TimePeriodForPayingRemainingBalanceDue" xlink:label="loc_biib_TimePeriodForPayingRemainingBalanceDue_3E75520ADE0C7484C0D293D5C9733DEF" xlink:type="locator" />
    <definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_TimePeriodForPayingRemainingBalanceDue_3E75520ADE0C7484C0D293D5C9733DEF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PeriodForGrantingOfApprovalByApprovingAuthority" xlink:label="loc_biib_PeriodForGrantingOfApprovalByApprovingAuthority_D71C2BE170A37B6EA15C93D5C97374F9" xlink:type="locator" />
    <definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_PeriodForGrantingOfApprovalByApprovingAuthority_D71C2BE170A37B6EA15C93D5C97374F9" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_7F4E7355A9FDD2E7AE0E93D5C9733222" xlink:type="locator" />
    <definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_7F4E7355A9FDD2E7AE0E93D5C9733222" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_7E0327C69FC6C80503DF93D5C9731F57" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_Termofcollaborationagreement_7E0327C69FC6C80503DF93D5C9731F57" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_84EFF9834D509D0D282793D5C97361D5" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_84EFF9834D509D0D282793D5C97361D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_411A5AE1D8A305ED569B93D5C9733210" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_411A5AE1D8A305ED569B93D5C9733210" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_DDEAF86502DABC80A2FB93D5C9739A03" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_LicenseFee_DDEAF86502DABC80A2FB93D5C9739A03" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:label="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_9633E8F995FFE31AA99993D5C97379DF" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_9633E8F995FFE31AA99993D5C97379DF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality" xlink:label="loc_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_00B7CFB4A6D8E7A5580593D5C973B44B" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_00B7CFB4A6D8E7A5580593D5C973B44B" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_5359E696D056AAD6845793D5C9731824" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_AdditionalMilestonePayment_5359E696D056AAD6845793D5C9731824" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement" xlink:label="loc_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_9F898B3FFB2A3EAC7BD493D5C97397E4" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_9F898B3FFB2A3EAC7BD493D5C97397E4" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_D2B92E233CAF715D8E3793D5C9742C8D" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_MilestonePaymentsMadeDuringPeriod_D2B92E233CAF715D8E3793D5C9742C8D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_204914CB0D936E5B606693D5C974358A" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_Purchaseofcommonstock_204914CB0D936E5B606693D5C974358A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_D75559A20C8EF99E5F3393D5C9749A05" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_us-gaap_LicenseCosts_D75559A20C8EF99E5F3393D5C9749A05" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Researchanddevelopmentservices" xlink:label="loc_biib_Researchanddevelopmentservices_99B74768AB0842EC7AA893D5C9743B14" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_Researchanddevelopmentservices_99B74768AB0842EC7AA893D5C9743B14" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Premiumonequityinvestment" xlink:label="loc_biib_Premiumonequityinvestment_7AEA0BC77BF1919BC72293D5C974F0CC" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_Premiumonequityinvestment_7AEA0BC77BF1919BC72293D5C974F0CC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_E0F9354CB30B46E83DE193D5C974B15F" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_E0F9354CB30B46E83DE193D5C974B15F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_2239FEA998EFAF28783E93D5C9741605" xlink:type="locator" />
    <definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_JointVentureOwnerShipPercentageByThirdParty_2239FEA998EFAF28783E93D5C9741605" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_0C18E13973A6B1AD86FA93D5C974E26B" xlink:type="locator" />
    <definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_us-gaap_EquityMethodInvestments_0C18E13973A6B1AD86FA93D5C974E26B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_DC7C146A501F502454A893D5C97432DC" xlink:type="locator" />
    <definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_DC7C146A501F502454A893D5C97432DC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_A88B55D3DDC16EA67F2D93D5C974E09E" xlink:type="locator" />
    <definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_A88B55D3DDC16EA67F2D93D5C974E09E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_A282151B713A4322109E93D5C974EA68" xlink:type="locator" />
    <definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_A282151B713A4322109E93D5C974EA68" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_796C264D3983462D515093D5C9741242" xlink:type="locator" />
    <definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_796C264D3983462D515093D5C9741242" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_C68E69952778AA89647293D5C974B18D" xlink:type="locator" />
    <definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_us-gaap_OtherSalesRevenueNet_C68E69952778AA89647293D5C974B18D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld" xlink:label="loc_biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld_728B22946A7477DD245893D5C974B7D0" xlink:type="locator" />
    <definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld_728B22946A7477DD245893D5C974B7D0" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_431E97FB34007EC5370993D5C974754E" xlink:type="locator" />
    <definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_431E97FB34007EC5370993D5C974754E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_BC08D65BB20D6B1C7C0C93D5C9742013" xlink:type="locator" />
    <definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_BC08D65BB20D6B1C7C0C93D5C9742013" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1C46867B73668FB9751B93582DC72426" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C62F48C8E07A30171AF393582DC6626F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C46867B73668FB9751B93582DC72426" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C62F48C8E07A30171AF393582DC6626F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="biib-20151231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_2D27C0052C808E3564BF93582DC6DE0F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C62F48C8E07A30171AF393582DC6626F" xlink:to="loc_biib_CumulativeSalesLevelAxis_2D27C0052C808E3564BF93582DC6DE0F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_CumulativeSalesLevelAxis_2D27C0052C808E3564BF93582DC6DE0F" xlink:to="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46_default" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_CumulativeSalesLevelAxis_2D27C0052C808E3564BF93582DC6DE0F" xlink:to="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SixbillionMember" xlink:label="loc_biib_SixbillionMember_525EE520AF11727B08BD93582DC65ED0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46" xlink:to="loc_biib_SixbillionMember_525EE520AF11727B08BD93582DC65ED0" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FourbillionMember" xlink:label="loc_biib_FourbillionMember_9BB0B81D90F32132B1D193582DC64433" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46" xlink:to="loc_biib_FourbillionMember_9BB0B81D90F32132B1D193582DC64433" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FivebillionMember" xlink:label="loc_biib_FivebillionMember_65191D8793EC1EC4B4BF93582DC6E83D" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46" xlink:to="loc_biib_FivebillionMember_65191D8793EC1EC4B4BF93582DC6E83D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SevenbillionMember" xlink:label="loc_biib_SevenbillionMember_1170AA26EF39E5EEA2E393582DC6D036" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46" xlink:to="loc_biib_SevenbillionMember_1170AA26EF39E5EEA2E393582DC6D036" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_OneBillionMember" xlink:label="loc_biib_OneBillionMember_566EFD185CD9CD9BBF9093582DC69A60" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46" xlink:to="loc_biib_OneBillionMember_566EFD185CD9CD9BBF9093582DC69A60" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_BAA88DF10D1FC6C4164E93582DC6F1C7" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_BAA88DF10D1FC6C4164E93582DC6F1C7" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ThreeBillionMember" xlink:label="loc_biib_ThreeBillionMember_C4E5C0E49873C4DC9E4F93582DC6C38E" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46" xlink:to="loc_biib_ThreeBillionMember_C4E5C0E49873C4DC9E4F93582DC6C38E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_7596968419A326AEE05A93582DC633AF" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C62F48C8E07A30171AF393582DC6626F" xlink:to="loc_us-gaap_ProductOrServiceAxis_7596968419A326AEE05A93582DC633AF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_AD967973D1B3FFB37ED593582DC6AFB7_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_7596968419A326AEE05A93582DC633AF" xlink:to="loc_us-gaap_ProductsAndServicesDomain_AD967973D1B3FFB37ED593582DC6AFB7_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_AD967973D1B3FFB37ED593582DC6AFB7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_7596968419A326AEE05A93582DC633AF" xlink:to="loc_us-gaap_ProductsAndServicesDomain_AD967973D1B3FFB37ED593582DC6AFB7" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_F57DD1017638A9AFC55393582DC68F35" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_AD967973D1B3FFB37ED593582DC6AFB7" xlink:to="loc_biib_TecfideraMember_F57DD1017638A9AFC55393582DC68F35" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_A7C5474E32473F2F37C493582DC6E73E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C62F48C8E07A30171AF393582DC6626F" xlink:to="loc_biib_FacilityLocationAxis_A7C5474E32473F2F37C493582DC6E73E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_BC5EAA10C947B3F27B7393582DC63B37_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_A7C5474E32473F2F37C493582DC6E73E" xlink:to="loc_biib_FacilityLocationDomain_BC5EAA10C947B3F27B7393582DC63B37_default" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_BC5EAA10C947B3F27B7393582DC63B37" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_A7C5474E32473F2F37C493582DC6E73E" xlink:to="loc_biib_FacilityLocationDomain_BC5EAA10C947B3F27B7393582DC63B37" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CambridgeLeasesMember" xlink:label="loc_biib_CambridgeLeasesMember_2E4B3E3607F704D2635A93582DC79948" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_BC5EAA10C947B3F27B7393582DC63B37" xlink:to="loc_biib_CambridgeLeasesMember_2E4B3E3607F704D2635A93582DC79948" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_300FE7AFB8AB7FE0F77793582DC70F1E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_BC5EAA10C947B3F27B7393582DC63B37" xlink:to="loc_biib_SolothurnMember_300FE7AFB8AB7FE0F77793582DC70F1E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3D4976770DC48C8E9C7493582DC7A8C3" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C62F48C8E07A30171AF393582DC6626F" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3D4976770DC48C8E9C7493582DC7A8C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C0AB5D493CE2C1801CCC93582DC7F628_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3D4976770DC48C8E9C7493582DC7A8C3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C0AB5D493CE2C1801CCC93582DC7F628_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C0AB5D493CE2C1801CCC93582DC7F628" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3D4976770DC48C8E9C7493582DC7A8C3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C0AB5D493CE2C1801CCC93582DC7F628" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_CDD6F4F3C468F56F8C9493582DC758C6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C0AB5D493CE2C1801CCC93582DC7F628" xlink:to="loc_biib_TysabriProductMember_CDD6F4F3C468F56F8C9493582DC758C6" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BiogenIdecHemophiliaMember" xlink:label="loc_biib_BiogenIdecHemophiliaMember_6AD528A5AAD4B1DDE81893582DC735FE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C0AB5D493CE2C1801CCC93582DC7F628" xlink:to="loc_biib_BiogenIdecHemophiliaMember_6AD528A5AAD4B1DDE81893582DC735FE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_092129E2A285AA2512BF93582DC73C7E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C0AB5D493CE2C1801CCC93582DC7F628" xlink:to="loc_biib_FumapharmAgMember_092129E2A285AA2512BF93582DC73C7E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Chargesrecognizedtovacatebuilding" xlink:label="loc_biib_Chargesrecognizedtovacatebuilding_E099AAB2ADD0765AF52793582DC7F358" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C46867B73668FB9751B93582DC72426" xlink:to="loc_biib_Chargesrecognizedtovacatebuilding_E099AAB2ADD0765AF52793582DC7F358" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_42202F7006C2C3AA256093582DC7908F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C46867B73668FB9751B93582DC72426" xlink:to="loc_us-gaap_OtherCommitment_42202F7006C2C3AA256093582DC7908F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_E7B5D6A3E1F1E8567E5993582DC7ACD2" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C46867B73668FB9751B93582DC72426" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_E7B5D6A3E1F1E8567E5993582DC7ACD2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_9112320EAD59CF89DF6393582DC79CD0" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C46867B73668FB9751B93582DC72426" xlink:to="loc_biib_MilestonePaymentsMadeDuringPeriod_9112320EAD59CF89DF6393582DC79CD0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1B4201E56846CE7A3E1393582DC762AF" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C46867B73668FB9751B93582DC72426" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1B4201E56846CE7A3E1393582DC762AF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_3C87651AC57DB8E9970E93582DC760FF" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C46867B73668FB9751B93582DC72426" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_3C87651AC57DB8E9970E93582DC760FF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_DECAA53444CC975EA80893582DC79AFD" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C46867B73668FB9751B93582DC72426" xlink:to="loc_biib_CumulativeSalesLevel_DECAA53444CC975EA80893582DC79AFD" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_B842F67491A086C87A04A34B6AEB890F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_StatementTable_B842F67491A086C87A04A34B6AEB890F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7E353E4C27E42D2F33B9A34B6AEB3683" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_B842F67491A086C87A04A34B6AEB890F" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7E353E4C27E42D2F33B9A34B6AEB3683" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7E353E4C27E42D2F33B9A34B6AEB3683" xlink:to="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7E353E4C27E42D2F33B9A34B6AEB3683" xlink:to="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="loc_us-gaap_ParentCompanyMember_A7A7B90EFBE226DA8327A34B6AEB5B78" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:to="loc_us-gaap_ParentCompanyMember_A7A7B90EFBE226DA8327A34B6AEB5B78" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_5FF835D36D07DC1FF096A34B6AEB7B24" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:to="loc_us-gaap_PreferredStockMember_5FF835D36D07DC1FF096A34B6AEB7B24" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_C6B088FECEF4DDF46ACBA34B6AEB3F29" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:to="loc_us-gaap_CommonStockMember_C6B088FECEF4DDF46ACBA34B6AEB3F29" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4F03A9D50C43526FD55CA34B6AEB881F" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4F03A9D50C43526FD55CA34B6AEB881F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9DB159D9B7D49CB877C7A34B6AEBCDE5" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9DB159D9B7D49CB877C7A34B6AEBCDE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_BDE4C6F4CE32ECB82C74A34B6AEBF67D" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:to="loc_us-gaap_RetainedEarningsMember_BDE4C6F4CE32ECB82C74A34B6AEBF67D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_C24894674BFCFA3ED127A34B6AEB6162" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:to="loc_us-gaap_TreasuryStockMember_C24894674BFCFA3ED127A34B6AEB6162" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_EA06B0336302B1C3190FA34B6AEB4F94" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:to="loc_us-gaap_NoncontrollingInterestMember_EA06B0336302B1C3190FA34B6AEB4F94" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_97BC60DE6EF5DD36733CA34B6AEB83B4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_97BC60DE6EF5DD36733CA34B6AEB83B4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_B1A61E954B94C94DC3FCA34B6AEC3001" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_SharesIssued_B1A61E954B94C94DC3FCA34B6AEC3001" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_183DB335637CF53E5443A34B6AECC9C2" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_ProfitLoss_183DB335637CF53E5443A34B6AECC9C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D0170E653F0CA6910A35A34B6AEC0ABE" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D0170E653F0CA6910A35A34B6AEC0ABE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_276E7416052B33694D7BA34B6AEC456E" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_276E7416052B33694D7BA34B6AEC456E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C5A74CDEA1B97BF22C3DA34B6AEC35E1" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C5A74CDEA1B97BF22C3DA34B6AEC35E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_89D028E32038AECE1805A34B6AEC6801" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_89D028E32038AECE1805A34B6AEC6801" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_8641BFE0E2D04EA1E77BA34B6AECADA1" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_8641BFE0E2D04EA1E77BA34B6AECADA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_0A9B30088B8475F83E89A34B6AECD0D7" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_0A9B30088B8475F83E89A34B6AECD0D7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_3DC274BAF9B69CB6ACDFA34B6AEC0028" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_3DC274BAF9B69CB6ACDFA34B6AEC0028" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_511A1E90666A9443AFE9A34B6AECCD8C" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_511A1E90666A9443AFE9A34B6AECCD8C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63DF82B7E187B57D09D2A34B6AECB6A5" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63DF82B7E187B57D09D2A34B6AECB6A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_444971711DD9519B8472A34B6AEC721A" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_444971711DD9519B8472A34B6AEC721A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_DE49D532E3538C2C52C9A34B6AECA296" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_DE49D532E3538C2C52C9A34B6AECA296" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9FDBD3B7B97FA1B6DF09A34B6AEC9B7B" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9FDBD3B7B97FA1B6DF09A34B6AEC9B7B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6027D8B5BBF741A18224A34B6AECACF7" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6027D8B5BBF741A18224A34B6AECACF7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F5B3AF00556D11CA4EEA34B6AEC3519" xlink:type="locator" />
    <definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F5B3AF00556D11CA4EEA34B6AEC3519" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_157E95E22652ACDA14A493582EE0E2E3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8FD40407D73CE268ABD093582EDEA6EA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_157E95E22652ACDA14A493582EE0E2E3" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8FD40407D73CE268ABD093582EDEA6EA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_34E4B5A01D850AE75F9493582EDEC52D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8FD40407D73CE268ABD093582EDEA6EA" xlink:to="loc_us-gaap_CurrencyAxis_34E4B5A01D850AE75F9493582EDEC52D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CurrencyAxis_34E4B5A01D850AE75F9493582EDEC52D" xlink:to="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CurrencyAxis_34E4B5A01D850AE75F9493582EDEC52D" xlink:to="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_612C5E3C929BEF4D334E93582EDEC642" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:to="loc_currency_EUR_612C5E3C929BEF4D334E93582EDEC642" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_5EF1605A2DA90172BADB935EC0DFE4FF" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:to="loc_currency_CHF_5EF1605A2DA90172BADB935EC0DFE4FF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_78095A2F2D20A72CCD5793582EDF0AE0" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:to="loc_currency_CAD_78095A2F2D20A72CCD5793582EDF0AE0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_E07E6C181EF3F8FADBD593582EDF7E4F" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:to="loc_currency_GBP_E07E6C181EF3F8FADBD593582EDF7E4F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AUD" xlink:label="loc_currency_AUD_6C55CFF9B350EFAF89DD93582EDF343F" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:to="loc_currency_AUD_6C55CFF9B350EFAF89DD93582EDF343F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_071D806A25A2A7139E0393582EDFEDAA" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:to="loc_currency_JPY_071D806A25A2A7139E0393582EDFEDAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_B0B6A67A2896B380B69393582EDF815B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8FD40407D73CE268ABD093582EDEA6EA" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_B0B6A67A2896B380B69393582EDF815B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_C9136B57B7C2A4FD16E493582EDFF4E7_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_B0B6A67A2896B380B69393582EDF815B" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_C9136B57B7C2A4FD16E493582EDFF4E7_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_C9136B57B7C2A4FD16E493582EDFF4E7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_B0B6A67A2896B380B69393582EDF815B" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_C9136B57B7C2A4FD16E493582EDFF4E7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_899718E16A049BEF310893582EDFBBF5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_C9136B57B7C2A4FD16E493582EDFF4E7" xlink:to="loc_us-gaap_ForeignExchangeContractMember_899718E16A049BEF310893582EDFBBF5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1200A372C26E388D187F93582EDF1456" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8FD40407D73CE268ABD093582EDEA6EA" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1200A372C26E388D187F93582EDF1456" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1200A372C26E388D187F93582EDF1456" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1200A372C26E388D187F93582EDF1456" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_B7C1AC47A03184B37ECD93582EDFCF64" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_B7C1AC47A03184B37ECD93582EDFCF64" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_89342B8C8348CA322A2793582EDF6256" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3" xlink:to="loc_us-gaap_OtherInvestmentsMember_89342B8C8348CA322A2793582EDF6256" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_4F31AD62251905C135E593582EDFC242" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_4F31AD62251905C135E593582EDFC242" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_5A4422CDF2BE8DD6C3CD93582EDF645D" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_5A4422CDF2BE8DD6C3CD93582EDF645D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_FF04858B8D713FB2EDAE93582EDF45CA" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8FD40407D73CE268ABD093582EDEA6EA" xlink:to="loc_us-gaap_HedgingDesignationAxis_FF04858B8D713FB2EDAE93582EDF45CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_2CA42FBE5EB08EF0480A93582EDFA815_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_FF04858B8D713FB2EDAE93582EDF45CA" xlink:to="loc_us-gaap_HedgingDesignationDomain_2CA42FBE5EB08EF0480A93582EDFA815_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_2CA42FBE5EB08EF0480A93582EDFA815" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_FF04858B8D713FB2EDAE93582EDF45CA" xlink:to="loc_us-gaap_HedgingDesignationDomain_2CA42FBE5EB08EF0480A93582EDFA815" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_C06494185A7F5FCBC6D793582EDFF51C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_2CA42FBE5EB08EF0480A93582EDFA815" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_C06494185A7F5FCBC6D793582EDFF51C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_68564F20C6283362111193582EE0335F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_2CA42FBE5EB08EF0480A93582EDFA815" xlink:to="loc_us-gaap_NondesignatedMember_68564F20C6283362111193582EE0335F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_2493643E075823EA649A93582EE0A13B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_157E95E22652ACDA14A493582EE0E2E3" xlink:to="loc_invest_DerivativeNotionalAmount_2493643E075823EA649A93582EE0A13B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_BA0D55B3BD94999B81A893582EE0EAE5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_157E95E22652ACDA14A493582EE0E2E3" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_BA0D55B3BD94999B81A893582EE0EAE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_E3C988842006D5EC77CF93582EE04BF1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_BA0D55B3BD94999B81A893582EE0EAE5" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_E3C988842006D5EC77CF93582EE04BF1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_471E4D3FF4D07150885593582EE0ACCC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_BA0D55B3BD94999B81A893582EE0EAE5" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_471E4D3FF4D07150885593582EE0ACCC" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_573609C0E7606F68E9E293582ED84B77" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8BCD211E255AEAE9C10D93582ED7C6E1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_573609C0E7606F68E9E293582ED84B77" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8BCD211E255AEAE9C10D93582ED7C6E1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaap_DerivativeByNatureAxis_23A0F49B692869B696EC93582ED75CFB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8BCD211E255AEAE9C10D93582ED7C6E1" xlink:to="loc_us-gaap_DerivativeByNatureAxis_23A0F49B692869B696EC93582ED75CFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_C843415E3C92A6777ADC93582ED75625_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeByNatureAxis_23A0F49B692869B696EC93582ED75CFB" xlink:to="loc_us-gaap_DerivativeNameDomain_C843415E3C92A6777ADC93582ED75625_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_C843415E3C92A6777ADC93582ED75625" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeByNatureAxis_23A0F49B692869B696EC93582ED75CFB" xlink:to="loc_us-gaap_DerivativeNameDomain_C843415E3C92A6777ADC93582ED75625" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_D5FE4A484447B39E723993582ED8DBD5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeNameDomain_C843415E3C92A6777ADC93582ED75625" xlink:to="loc_us-gaap_SalesMember_D5FE4A484447B39E723993582ED8DBD5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_106AC38E187C97465AD493582ED80981" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8BCD211E255AEAE9C10D93582ED7C6E1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_106AC38E187C97465AD493582ED80981" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5B8DB93FCF69B13C7AB493582ED82CCC_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_106AC38E187C97465AD493582ED80981" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5B8DB93FCF69B13C7AB493582ED82CCC_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5B8DB93FCF69B13C7AB493582ED82CCC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_106AC38E187C97465AD493582ED80981" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5B8DB93FCF69B13C7AB493582ED82CCC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_67D4C0FC526B5368136793582ED8ECB1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5B8DB93FCF69B13C7AB493582ED82CCC" xlink:to="loc_us-gaap_ForeignExchangeContractMember_67D4C0FC526B5368136793582ED8ECB1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_259B476FFD90E4F44B6393582ED8C989" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8BCD211E255AEAE9C10D93582ED7C6E1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_259B476FFD90E4F44B6393582ED8C989" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3095240D889CC37EF20393582ED863FB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_259B476FFD90E4F44B6393582ED8C989" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3095240D889CC37EF20393582ED863FB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3095240D889CC37EF20393582ED863FB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_259B476FFD90E4F44B6393582ED8C989" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3095240D889CC37EF20393582ED863FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_B9E94AB3F9E6CEE6F28B93582ED88A38" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3095240D889CC37EF20393582ED863FB" xlink:to="loc_us-gaap_SalesMember_B9E94AB3F9E6CEE6F28B93582ED88A38" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8F59E3D0669AD13C1DD093582ED8C574" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3095240D889CC37EF20393582ED863FB" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8F59E3D0669AD13C1DD093582ED8C574" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_CA99F4236C15B27CE53D93582ED84AB4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_573609C0E7606F68E9E293582ED84B77" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_CA99F4236C15B27CE53D93582ED84AB4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_CB23975FDAC09B0BA47593582ED80148" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_CA99F4236C15B27CE53D93582ED84AB4" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_CB23975FDAC09B0BA47593582ED80148" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_3038DD34BF4CB6913BD793582ED84CBF" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_CA99F4236C15B27CE53D93582ED84AB4" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_3038DD34BF4CB6913BD793582ED84CBF" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_4B0719102212A6FE38C193582ED3EAC4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_B251B83F4A59DAA4B37293582ED2C099" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_4B0719102212A6FE38C193582ED3EAC4" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_B251B83F4A59DAA4B37293582ED2C099" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_87AA4E43DD1805A0DE4C93582ED2479D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_B251B83F4A59DAA4B37293582ED2C099" xlink:to="loc_us-gaap_DebtInstrumentAxis_87AA4E43DD1805A0DE4C93582ED2479D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7D4BC042658495E595CF93582ED2F9A8_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_87AA4E43DD1805A0DE4C93582ED2479D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7D4BC042658495E595CF93582ED2F9A8_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7D4BC042658495E595CF93582ED2F9A8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_87AA4E43DD1805A0DE4C93582ED2479D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7D4BC042658495E595CF93582ED2F9A8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_7BBA6CD71E88B7C1192493582ED28147" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7D4BC042658495E595CF93582ED2F9A8" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_7BBA6CD71E88B7C1192493582ED28147" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_3B588C655EF07FBB87B293582ED26018" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7D4BC042658495E595CF93582ED2F9A8" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_3B588C655EF07FBB87B293582ED26018" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_28A83B8F9AF16314F04593582ED29F43" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7D4BC042658495E595CF93582ED2F9A8" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_28A83B8F9AF16314F04593582ED29F43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_595557D31D62610900DA93582ED2654A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_B251B83F4A59DAA4B37293582ED2C099" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_595557D31D62610900DA93582ED2654A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_B31B3EE9E3303C95075593582ED26427_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_595557D31D62610900DA93582ED2654A" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_B31B3EE9E3303C95075593582ED26427_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_B31B3EE9E3303C95075593582ED26427" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_595557D31D62610900DA93582ED2654A" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_B31B3EE9E3303C95075593582ED26427" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_D9B0A01FFF8BB388A7BB93582ED25D7F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_B31B3EE9E3303C95075593582ED26427" xlink:to="loc_us-gaap_InterestRateContractMember_D9B0A01FFF8BB388A7BB93582ED25D7F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_4236ED4A89FC2A66A3BB93582ED228F3" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_B31B3EE9E3303C95075593582ED26427" xlink:to="loc_us-gaap_InterestRateSwapMember_4236ED4A89FC2A66A3BB93582ED228F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_401544A4EFD6E694D1D393582ED3867F" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_B251B83F4A59DAA4B37293582ED2C099" xlink:to="loc_us-gaap_HedgingDesignationAxis_401544A4EFD6E694D1D393582ED3867F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_D753A0AFA9C471F95C3193582ED3AE95_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_401544A4EFD6E694D1D393582ED3867F" xlink:to="loc_us-gaap_HedgingDesignationDomain_D753A0AFA9C471F95C3193582ED3AE95_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_D753A0AFA9C471F95C3193582ED3AE95" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_401544A4EFD6E694D1D393582ED3867F" xlink:to="loc_us-gaap_HedgingDesignationDomain_D753A0AFA9C471F95C3193582ED3AE95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3BBDC99CA2A4A196E85B93582ED3DECF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_D753A0AFA9C471F95C3193582ED3AE95" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3BBDC99CA2A4A196E85B93582ED3DECF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_298685895F2BA95A8D5893582ED379C2" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_D753A0AFA9C471F95C3193582ED3AE95" xlink:to="loc_us-gaap_NondesignatedMember_298685895F2BA95A8D5893582ED379C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_C1FEDE170CF0343B4AB993582ED3969A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_4B0719102212A6FE38C193582ED3EAC4" xlink:to="loc_invest_DerivativeNotionalAmount_C1FEDE170CF0343B4AB993582ED3969A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_DC15059F0ED68DC4508E93582ED33FA3" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_4B0719102212A6FE38C193582ED3EAC4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_DC15059F0ED68DC4508E93582ED33FA3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3426D062DABB67CA998D93582ED31D7A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_4B0719102212A6FE38C193582ED3EAC4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3426D062DABB67CA998D93582ED31D7A" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_05AE7F98B990A61A310038A3550A28F2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4500351C8C6B01A0B0DB38A35509ABCD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_05AE7F98B990A61A310038A3550A28F2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4500351C8C6B01A0B0DB38A35509ABCD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8D1435F0F78793BAD56838A3550926BA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4500351C8C6B01A0B0DB38A35509ABCD" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8D1435F0F78793BAD56838A3550926BA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89E7E1DE0CD38BB57CDE38A3550AE632_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8D1435F0F78793BAD56838A3550926BA" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89E7E1DE0CD38BB57CDE38A3550AE632_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89E7E1DE0CD38BB57CDE38A3550AE632" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8D1435F0F78793BAD56838A3550926BA" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89E7E1DE0CD38BB57CDE38A3550AE632" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E596138FF9D1D90C6D6A38A3550A36AA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89E7E1DE0CD38BB57CDE38A3550AE632" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E596138FF9D1D90C6D6A38A3550A36AA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_63D2FFB0AC774D77F74938A3550A5AD8" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89E7E1DE0CD38BB57CDE38A3550AE632" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_63D2FFB0AC774D77F74938A3550A5AD8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_B9E9C06845B8A899EDD738A3550A8F26" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89E7E1DE0CD38BB57CDE38A3550AE632" xlink:to="loc_biib_MarketStockUnitsMember_B9E9C06845B8A899EDD738A3550A8F26" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_83E3F9FD4944AE8A5F0B38A3550ACC14" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_05AE7F98B990A61A310038A3550A28F2" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_83E3F9FD4944AE8A5F0B38A3550ACC14" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NumeratorAbstract" xlink:label="loc_biib_NumeratorAbstract_30D2DD904D2C85047A8738A3550A4CA9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_83E3F9FD4944AE8A5F0B38A3550ACC14" xlink:to="loc_biib_NumeratorAbstract_30D2DD904D2C85047A8738A3550A4CA9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E275DC2B1441440C473B38A3550A3BCE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_NumeratorAbstract_30D2DD904D2C85047A8738A3550A4CA9" xlink:to="loc_us-gaap_NetIncomeLoss_E275DC2B1441440C473B38A3550A3BCE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DenominatorAbstract" xlink:label="loc_biib_DenominatorAbstract_1F4BA4D7D4AAB2A7604738A3550A9883" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_83E3F9FD4944AE8A5F0B38A3550ACC14" xlink:to="loc_biib_DenominatorAbstract_1F4BA4D7D4AAB2A7604738A3550A9883" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1D7ED7FBDA70998A596A38A3550A57E4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DenominatorAbstract_1F4BA4D7D4AAB2A7604738A3550A9883" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1D7ED7FBDA70998A596A38A3550A57E4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_B133058C18B4E730717938A3550A2979" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DenominatorAbstract_1F4BA4D7D4AAB2A7604738A3550A9883" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_B133058C18B4E730717938A3550A2979" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5497B723E5308EBCC12138A3550A1A87" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_B133058C18B4E730717938A3550A2979" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5497B723E5308EBCC12138A3550A1A87" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_830CEFE18602F71ECCD738A3550ADD37" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_B133058C18B4E730717938A3550A2979" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_830CEFE18602F71ECCD738A3550ADD37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A2D107C5C7675DF3390238A3550AF32F" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DenominatorAbstract_1F4BA4D7D4AAB2A7604738A3550A9883" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A2D107C5C7675DF3390238A3550AF32F" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A16AB03A2A829C39D57F93582DBBCB7F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7EC1F275AD1483AD62AD93582DBAC85A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A16AB03A2A829C39D57F93582DBBCB7F" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7EC1F275AD1483AD62AD93582DBAC85A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis" xlink:label="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_1DEAD1AADAA6F1577D3193582DBAD285" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7EC1F275AD1483AD62AD93582DBAC85A" xlink:to="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_1DEAD1AADAA6F1577D3193582DBAD285" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlansDomain" xlink:label="loc_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_1DEAD1AADAA6F1577D3193582DBAD285" xlink:to="loc_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlansDomain" xlink:label="loc_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_1DEAD1AADAA6F1577D3193582DBAD285" xlink:to="loc_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SavingsPlanMember" xlink:label="loc_biib_SavingsPlanMember_10CEA71099B8F7DE07F593582DBAA4F3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6" xlink:to="loc_biib_SavingsPlanMember_10CEA71099B8F7DE07F593582DBAA4F3" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DeferredCompensationPlanMember" xlink:label="loc_biib_DeferredCompensationPlanMember_1CCEB4031C08B6E21A7193582DBA9373" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6" xlink:to="loc_biib_DeferredCompensationPlanMember_1CCEB4031C08B6E21A7193582DBA9373" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SwissplanMember" xlink:label="loc_biib_SwissplanMember_24CD85770BCA10B6692993582DBABFFC" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6" xlink:to="loc_biib_SwissplanMember_24CD85770BCA10B6692993582DBABFFC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_GermanPlanMember" xlink:label="loc_biib_GermanPlanMember_DFED4B345FF92402935293582DBABF76" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6" xlink:to="loc_biib_GermanPlanMember_DFED4B345FF92402935293582DBABF76" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:label="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_5000C4E6886F72532E8593582DBB65A2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A16AB03A2A829C39D57F93582DBBCB7F" xlink:to="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_5000C4E6886F72532E8593582DBB65A2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EmployeeBenefitPlansTextualAbstract" xlink:label="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A16AB03A2A829C39D57F93582DBBCB7F" xlink:to="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_C4FB52C1B1F1E463BE5A93582DBB1CBA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_C4FB52C1B1F1E463BE5A93582DBB1CBA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_287186BE44A245B4438B93582DBBF320" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_287186BE44A245B4438B93582DBBF320" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfMinimumInvestmentReturn" xlink:label="loc_biib_PercentageOfMinimumInvestmentReturn_6DE96913D428B52E056393582DBBF643" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:to="loc_biib_PercentageOfMinimumInvestmentReturn_6DE96913D428B52E056393582DBBF643" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9710048810DB5A6A65CA93582DBB20E4" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9710048810DB5A6A65CA93582DBB20E4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_FACFAE28B6BFCC147B9493582DBBD6BC" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_FACFAE28B6BFCC147B9493582DBBD6BC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionExpense" xlink:label="loc_us-gaap_PensionExpense_56ACAC55FE31D81D312D93582DBB2D3B" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:to="loc_us-gaap_PensionExpense_56ACAC55FE31D81D312D93582DBB2D3B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8CB8E5E71EA19683EDD693582DBB0AD2" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8CB8E5E71EA19683EDD693582DBB0AD2" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_F84558E38180F726A7EA38A350DEB4A0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_854F01725EA5CFD6635B38A350DDB069" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_F84558E38180F726A7EA38A350DEB4A0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_854F01725EA5CFD6635B38A350DDB069" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2843337B39C3D9FECCE238A350DE9A92" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_854F01725EA5CFD6635B38A350DDB069" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2843337B39C3D9FECCE238A350DE9A92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_DEFD71EB7ACBCE2603C538A350DE68DB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2843337B39C3D9FECCE238A350DE9A92" xlink:to="loc_us-gaap_ClassOfStockDomain_DEFD71EB7ACBCE2603C538A350DE68DB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_DEFD71EB7ACBCE2603C538A350DE68DB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2843337B39C3D9FECCE238A350DE9A92" xlink:to="loc_us-gaap_ClassOfStockDomain_DEFD71EB7ACBCE2603C538A350DE68DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_BD57FD73F04BCC7EB89338A350DE9BB3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_DEFD71EB7ACBCE2603C538A350DE68DB" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_BD57FD73F04BCC7EB89338A350DE9BB3" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeriesXPreferredStockMember" xlink:label="loc_biib_SeriesXPreferredStockMember_9E44739AFBD5045646AD38A350DE9E9A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_DEFD71EB7ACBCE2603C538A350DE68DB" xlink:to="loc_biib_SeriesXPreferredStockMember_9E44739AFBD5045646AD38A350DE9E9A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_UndesignatedPreferredStockMember" xlink:label="loc_biib_UndesignatedPreferredStockMember_8D0FB545910F61E0CEC138A350DE495E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_DEFD71EB7ACBCE2603C538A350DE68DB" xlink:to="loc_biib_UndesignatedPreferredStockMember_8D0FB545910F61E0CEC138A350DE495E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9E3B50CEA26AE16D8BC538A350DE82FA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_F84558E38180F726A7EA38A350DEB4A0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9E3B50CEA26AE16D8BC538A350DE82FA" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_CB0BBE2DA7A3AE99178C38A356B4AC68" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_57E469E45496C534E1E238A356B3D278" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_CB0BBE2DA7A3AE99178C38A356B4AC68" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_57E469E45496C534E1E238A356B3D278" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2A61573EE6301817F85C38A356B37F89" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_57E469E45496C534E1E238A356B3D278" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2A61573EE6301817F85C38A356B37F89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54A9AE8BE9B847EC449A38A356B37002_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2A61573EE6301817F85C38A356B37F89" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54A9AE8BE9B847EC449A38A356B37002_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54A9AE8BE9B847EC449A38A356B37002" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2A61573EE6301817F85C38A356B37F89" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54A9AE8BE9B847EC449A38A356B37002" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_912A5211016B15994A0938A356B34CDE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54A9AE8BE9B847EC449A38A356B37002" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_912A5211016B15994A0938A356B34CDE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_BDFEAE4247B6DF7DD91238A356B39C45" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54A9AE8BE9B847EC449A38A356B37002" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_BDFEAE4247B6DF7DD91238A356B39C45" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_83B9CD8CEE450A8E474738A356B3CF17" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54A9AE8BE9B847EC449A38A356B37002" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_83B9CD8CEE450A8E474738A356B3CF17" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A65656DC19C1972C9C6E38A356B34244" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_57E469E45496C534E1E238A356B3D278" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A65656DC19C1972C9C6E38A356B34244" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_BBCE05DE2CB3CCB047C638A356B35715_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A65656DC19C1972C9C6E38A356B34244" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_BBCE05DE2CB3CCB047C638A356B35715_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_BBCE05DE2CB3CCB047C638A356B35715" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A65656DC19C1972C9C6E38A356B34244" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_BBCE05DE2CB3CCB047C638A356B35715" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_DEEABE05639E36828F0238A356B3C7E4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_BBCE05DE2CB3CCB047C638A356B35715" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_DEEABE05639E36828F0238A356B3C7E4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2A58EF54765ACD13352738A356B3EBD9" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_57E469E45496C534E1E238A356B3D278" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2A58EF54765ACD13352738A356B3EBD9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5E70717DD42DCEF281BB38A356B3B66C_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2A58EF54765ACD13352738A356B3EBD9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5E70717DD42DCEF281BB38A356B3B66C_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5E70717DD42DCEF281BB38A356B3B66C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2A58EF54765ACD13352738A356B3EBD9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5E70717DD42DCEF281BB38A356B3B66C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_BE4A1FACA42DC4D6EE1F38A356B37E0C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5E70717DD42DCEF281BB38A356B3B66C" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_BE4A1FACA42DC4D6EE1F38A356B37E0C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_0955D638C7816BCB216138A356B324DD" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5E70717DD42DCEF281BB38A356B3B66C" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_0955D638C7816BCB216138A356B324DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_362E30C5F20DCB9149B138A356B31269" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5E70717DD42DCEF281BB38A356B3B66C" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_362E30C5F20DCB9149B138A356B31269" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_785FFD586FB922C5947B38A356B43DC6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_CB0BBE2DA7A3AE99178C38A356B4AC68" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_785FFD586FB922C5947B38A356B43DC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_785FFD586FB922C5947B38A356B43DC6" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2435279020FE517F5D0138A356B4D467" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2435279020FE517F5D0138A356B4D467" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_339DCBB7E8ECF5E073B938A356B40CFE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:to="loc_us-gaap_AvailableForSaleSecurities_339DCBB7E8ECF5E073B938A356B40CFE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_29DB9608F328A6EBD47338A356B44497" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_29DB9608F328A6EBD47338A356B44497" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_71DF90912EC9A7A3F03838A356B42724" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_71DF90912EC9A7A3F03838A356B42724" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_D6613B9F2C7F5BDDD6E138A356B409F6" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_D6613B9F2C7F5BDDD6E138A356B409F6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_21703CC0597A5CED4AE638A356B4FA34" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_21703CC0597A5CED4AE638A356B4FA34" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_D14D031534A103A6E7E638A356B40464" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_785FFD586FB922C5947B38A356B43DC6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_D14D031534A103A6E7E638A356B40464" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_7F68FAB9F50E8E82BD0E38A356B41F5E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_D14D031534A103A6E7E638A356B40464" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_7F68FAB9F50E8E82BD0E38A356B41F5E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_FB8E4292A1916FDF3A7538A356B48513" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_D14D031534A103A6E7E638A356B40464" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_FB8E4292A1916FDF3A7538A356B48513" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_69ADC2C3331D96F2CC4238A356B46C0C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_D14D031534A103A6E7E638A356B40464" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_69ADC2C3331D96F2CC4238A356B46C0C" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_630C7362783DF34BE27A38A35498CE3C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_6B0BBD99BA996D8DB29438A35497542E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_630C7362783DF34BE27A38A35498CE3C" xlink:to="loc_us-gaap_DebtInstrumentTable_6B0BBD99BA996D8DB29438A35497542E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_EFD5E184E353765869CC38A35497BE6C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6B0BBD99BA996D8DB29438A35497542E" xlink:to="loc_us-gaap_DebtInstrumentAxis_EFD5E184E353765869CC38A35497BE6C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_517C6EF63E9ECD2D30A338A35497F912_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_EFD5E184E353765869CC38A35497BE6C" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_517C6EF63E9ECD2D30A338A35497F912_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_517C6EF63E9ECD2D30A338A35497F912" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_EFD5E184E353765869CC38A35497BE6C" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_517C6EF63E9ECD2D30A338A35497F912" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_71EA1F8EA9FE10FDD1C038A3549791B8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_517C6EF63E9ECD2D30A338A35497F912" xlink:to="loc_biib_NotesPayableToFumedicaMember_71EA1F8EA9FE10FDD1C038A3549791B8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C12B3F15C51547BDAA8738A3549866D0" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_517C6EF63E9ECD2D30A338A35497F912" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C12B3F15C51547BDAA8738A3549866D0" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_AD25EC3E4CBB2845468038A354980258" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_517C6EF63E9ECD2D30A338A35497F912" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_AD25EC3E4CBB2845468038A354980258" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_C738D8D8E6C8932BFDE838A354987F33" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_517C6EF63E9ECD2D30A338A35497F912" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_C738D8D8E6C8932BFDE838A354987F33" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_465F76B6DF0CCE4A281A38A354984590" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_517C6EF63E9ECD2D30A338A35497F912" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_465F76B6DF0CCE4A281A38A354984590" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E41D70EC4F87B067298238A3549879BF" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_517C6EF63E9ECD2D30A338A35497F912" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E41D70EC4F87B067298238A3549879BF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract" xlink:label="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_14600032C3BE18CC2F1038A3549810F8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_630C7362783DF34BE27A38A35498CE3C" xlink:to="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_14600032C3BE18CC2F1038A3549810F8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_105FE6420C89276F94F038A3549888B0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_14600032C3BE18CC2F1038A3549810F8" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_105FE6420C89276F94F038A3549888B0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_9D00D83E8762E71ED67B38A354984735" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_14600032C3BE18CC2F1038A3549810F8" xlink:to="loc_us-gaap_DebtInstrumentFairValue_9D00D83E8762E71ED67B38A354984735" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3B80226A0DFCABA8904838A35390EFA6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3B80226A0DFCABA8904838A35390EFA6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4CC7EB0562C3C980D6DF38A3539002C8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3B80226A0DFCABA8904838A35390EFA6" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4CC7EB0562C3C980D6DF38A3539002C8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_66B27713F238BFA3C9A938A3539081C5_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4CC7EB0562C3C980D6DF38A3539002C8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_66B27713F238BFA3C9A938A3539081C5_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_66B27713F238BFA3C9A938A3539081C5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4CC7EB0562C3C980D6DF38A3539002C8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_66B27713F238BFA3C9A938A3539081C5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_FA6549F79D91B65A085638A35390C55E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_66B27713F238BFA3C9A938A3539081C5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_FA6549F79D91B65A085638A35390C55E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1A2FCB21FDEE8350B30038A35390A4A1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1A2FCB21FDEE8350B30038A35390A4A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_63998FE40E5274EEAC9A38A35390E1CE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_63998FE40E5274EEAC9A38A35390E1CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD0563565BF61C4A021438A35390F2A1" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD0563565BF61C4A021438A35390F2A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8C89FC9EA4F9BD38911438A353904E5B" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8C89FC9EA4F9BD38911438A353904E5B" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_371F0C070B7EB1C4C87293D5CA9946FA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_371F0C070B7EB1C4C87293D5CA9946FA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_011018B3FCBF4C97908B93D5CA9908E8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_371F0C070B7EB1C4C87293D5CA9946FA" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_011018B3FCBF4C97908B93D5CA9908E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_B03F8C62B7525987D5D493D5CA991520_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_011018B3FCBF4C97908B93D5CA9908E8" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_B03F8C62B7525987D5D493D5CA991520_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_B03F8C62B7525987D5D493D5CA991520" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_011018B3FCBF4C97908B93D5CA9908E8" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_B03F8C62B7525987D5D493D5CA991520" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0BDD28D1B7E85ADF522193D5CA99AAFB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_B03F8C62B7525987D5D493D5CA991520" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0BDD28D1B7E85ADF522193D5CA99AAFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_CBCBC09117C58495F53C93D5CA9E8C09" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_B03F8C62B7525987D5D493D5CA991520" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_CBCBC09117C58495F53C93D5CA9E8C09" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0F0C2663004B22C4142193D5CA9E1234" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_371F0C070B7EB1C4C87293D5CA9946FA" xlink:to="loc_us-gaap_DebtInstrumentAxis_0F0C2663004B22C4142193D5CA9E1234" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7ADBF1A4268D19C0129A93D5CA9E8459_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0F0C2663004B22C4142193D5CA9E1234" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7ADBF1A4268D19C0129A93D5CA9E8459_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7ADBF1A4268D19C0129A93D5CA9E8459" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0F0C2663004B22C4142193D5CA9E1234" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7ADBF1A4268D19C0129A93D5CA9E8459" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_891970B7B1B2F196C32893D5CA9EB28D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7ADBF1A4268D19C0129A93D5CA9E8459" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_891970B7B1B2F196C32893D5CA9EB28D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_A15A67A2E253C06460EE93D5CA9EB2F1" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7ADBF1A4268D19C0129A93D5CA9E8459" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_A15A67A2E253C06460EE93D5CA9EB2F1" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_E6357CE5393A7D4B39D093D5CA9EDE2A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7ADBF1A4268D19C0129A93D5CA9E8459" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_E6357CE5393A7D4B39D093D5CA9EDE2A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_44E05FF9C983FA23756F93D5CA9EB9FB" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7ADBF1A4268D19C0129A93D5CA9E8459" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_44E05FF9C983FA23756F93D5CA9EB9FB" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_3928BDE4280506A0979193D5CA9E5BB3" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7ADBF1A4268D19C0129A93D5CA9E8459" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_3928BDE4280506A0979193D5CA9E5BB3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_BA3F4BEDB33E43386CE193D5CA9ED476" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_371F0C070B7EB1C4C87293D5CA9946FA" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_BA3F4BEDB33E43386CE193D5CA9ED476" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F15C026E217607F45D5993D5CA9EC938_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_BA3F4BEDB33E43386CE193D5CA9ED476" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F15C026E217607F45D5993D5CA9EC938_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F15C026E217607F45D5993D5CA9EC938" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_BA3F4BEDB33E43386CE193D5CA9ED476" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F15C026E217607F45D5993D5CA9EC938" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_2A5FB2D3C2E5B8F5459793D5CA9FA548" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F15C026E217607F45D5993D5CA9EC938" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_2A5FB2D3C2E5B8F5459793D5CA9FA548" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_StromedixMember" xlink:label="loc_biib_StromedixMember_4695609B053A40CEF97393D5CA9FD1C2" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F15C026E217607F45D5993D5CA9EC938" xlink:to="loc_biib_StromedixMember_4695609B053A40CEF97393D5CA9FD1C2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CorporateJointVentureInvestmentsMember" xlink:label="loc_biib_CorporateJointVentureInvestmentsMember_6888F403EE1C785E636B93D5CA9F477B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F15C026E217607F45D5993D5CA9EC938" xlink:to="loc_biib_CorporateJointVentureInvestmentsMember_6888F403EE1C785E636B93D5CA9F477B" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BiogenIdecInternationalNeuroscienceMember" xlink:label="loc_biib_BiogenIdecInternationalNeuroscienceMember_D68BD599A551A3C2E0AC93D5CA9FF945" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F15C026E217607F45D5993D5CA9EC938" xlink:to="loc_biib_BiogenIdecInternationalNeuroscienceMember_D68BD599A551A3C2E0AC93D5CA9FF945" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_43A07A945E07D0A6A79F93E6AD7F3521" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_43A07A945E07D0A6A79F93E6AD7F3521" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_AA3113422E0AEFCC3A5493D5CA9FECD2" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_AA3113422E0AEFCC3A5493D5CA9FECD2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_AC1C63097055A9DB3E2393D5CA9F7F39" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_AC1C63097055A9DB3E2393D5CA9F7F39" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D5A8B9B9728864F5162D93D5CA9F51CB" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D5A8B9B9728864F5162D93D5CA9F51CB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_B817FAC06C684443C72293D5CA9FF8AD" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_B817FAC06C684443C72293D5CA9FF8AD" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_CCC28E552FB78D57D8F493D5CA9FCA52" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_CCC28E552FB78D57D8F493D5CA9FCA52" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_88BF551DE420FD3ACD0E93D5CA9F35CE" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_88BF551DE420FD3ACD0E93D5CA9F35CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5C23C7655E1A30EF6DF793D5CA9F3953" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5C23C7655E1A30EF6DF793D5CA9F3953" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_1861DDB7767BB75CD97793D5CA9F02B8" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_1861DDB7767BB75CD97793D5CA9F02B8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_E249EF1B31AEDBE4277593D5CA9FF1CA" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_biib_MilestonePaymentsMadeDuringPeriod_E249EF1B31AEDBE4277593D5CA9FF1CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_EE8FAFA4F99938EC1F9893D5CA9FE032" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_EE8FAFA4F99938EC1F9893D5CA9FE032" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_50DD7BB047E4D5B9B12693224C0B772D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_36E61ABCE67E4925BCF293224C0627A6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_50DD7BB047E4D5B9B12693224C0B772D" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_36E61ABCE67E4925BCF293224C0627A6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_D1C96879004D120A41FE93224C06599E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_36E61ABCE67E4925BCF293224C0627A6" xlink:to="loc_us-gaap_InvestmentTypeAxis_D1C96879004D120A41FE93224C06599E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_D1C96879004D120A41FE93224C06599E" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_D1C96879004D120A41FE93224C06599E" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_FB6ADD8CC68CBD351F4593224C0B7A70" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B" xlink:to="loc_us-gaap_CommercialPaperMember_FB6ADD8CC68CBD351F4593224C0B7A70" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_38931A31A77E907C2C0993224C0B2699" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_38931A31A77E907C2C0993224C0B2699" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_AA07445EBD9ED8B52AA693224C0BD230" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B" xlink:to="loc_us-gaap_MoneyMarketFundsMember_AA07445EBD9ED8B52AA693224C0BD230" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_6476AC24DF8547A4DD6693224C0BB051" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B" xlink:to="loc_us-gaap_DebtSecuritiesMember_6476AC24DF8547A4DD6693224C0BB051" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_63BF7DA00FA8964CBBB893224C0B33E0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_50DD7BB047E4D5B9B12693224C0B772D" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_63BF7DA00FA8964CBBB893224C0B33E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_EC9F04072C2FDE4678D193224C0B82E7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_63BF7DA00FA8964CBBB893224C0B33E0" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_EC9F04072C2FDE4678D193224C0B82E7" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0C3587EC485D2B006E78A34B6A135499" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EF589FF997A39165DD75A34B6A0E8844" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0C3587EC485D2B006E78A34B6A135499" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EF589FF997A39165DD75A34B6A0E8844" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_C204162746A8575AAA92A34B6A0E945D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EF589FF997A39165DD75A34B6A0E8844" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_C204162746A8575AAA92A34B6A0E945D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_C204162746A8575AAA92A34B6A0E945D" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_C204162746A8575AAA92A34B6A0E945D" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_48035EC16EEEB30D3517A34B6A13F018" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_48035EC16EEEB30D3517A34B6A13F018" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_2FF5B4F3834FFCFF8AA0A34B6A13A1CE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_2FF5B4F3834FFCFF8AA0A34B6A13A1CE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_73E250A0607C282E86CBA34B6A13AE74" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_73E250A0607C282E86CBA34B6A13AE74" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_377740B18487722700FEA34B6A138831" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_377740B18487722700FEA34B6A138831" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E5DC0C2F9CBEE4A11A78A34B6A1384CD" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E5DC0C2F9CBEE4A11A78A34B6A1384CD" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_F3A6F99A8C8A7626A270A34B6A13EEE9" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_F3A6F99A8C8A7626A270A34B6A13EEE9" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MarketableEquitySecuritiesMember" xlink:label="loc_biib_MarketableEquitySecuritiesMember_5940B366C07C79E18A29A34B6A1362C2" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7" xlink:to="loc_biib_MarketableEquitySecuritiesMember_5940B366C07C79E18A29A34B6A1362C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_EFA3EA49F348A33DDDE6A34B6A149E38" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0C3587EC485D2B006E78A34B6A135499" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_EFA3EA49F348A33DDDE6A34B6A149E38" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_345C9693A6544936BD96A34B6A14597A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_EFA3EA49F348A33DDDE6A34B6A149E38" xlink:to="loc_us-gaap_AvailableForSaleSecurities_345C9693A6544936BD96A34B6A14597A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_06818972C6A31812A1C7A34B6A14BED5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_EFA3EA49F348A33DDDE6A34B6A149E38" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_06818972C6A31812A1C7A34B6A14BED5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C63AC6000C4B847B010A34B6A14D008" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_EFA3EA49F348A33DDDE6A34B6A149E38" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C63AC6000C4B847B010A34B6A14D008" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B67596B5771210779D01A34B6A14B966" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_EFA3EA49F348A33DDDE6A34B6A149E38" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B67596B5771210779D01A34B6A14B966" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_BDE54CDFD747302D705F38A356F6A244" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_01718A016490CF9071EF38A356F6DFC5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BDE54CDFD747302D705F38A356F6A244" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_01718A016490CF9071EF38A356F6DFC5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6C47C226576F7437020938A356F6744F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_01718A016490CF9071EF38A356F6DFC5" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6C47C226576F7437020938A356F6744F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_047044B7E1D20A20F63038A356F650DA_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6C47C226576F7437020938A356F6744F" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_047044B7E1D20A20F63038A356F650DA_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_047044B7E1D20A20F63038A356F650DA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6C47C226576F7437020938A356F6744F" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_047044B7E1D20A20F63038A356F650DA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_AEB935940F11C0E90BF838A356F691D4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_047044B7E1D20A20F63038A356F650DA" xlink:to="loc_biib_StrategicInvestmentsMember_AEB935940F11C0E90BF838A356F691D4" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_10B6954D7E10E83B4BE538A356F6B8A1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BDE54CDFD747302D705F38A356F6A244" xlink:to="loc_biib_StrategicInvestmentPortfolio_10B6954D7E10E83B4BE538A356F6B8A1" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/Guarantees" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_30208D169A56F678697293582E2E43A1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219" xlink:to="loc_us-gaap_ProductOrServiceAxis_30208D169A56F678697293582E2E43A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_3CF9F316829008BD64D393582E2EAB17_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_30208D169A56F678697293582E2E43A1" xlink:to="loc_us-gaap_ProductsAndServicesDomain_3CF9F316829008BD64D393582E2EAB17_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_3CF9F316829008BD64D393582E2EAB17" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_30208D169A56F678697293582E2E43A1" xlink:to="loc_us-gaap_ProductsAndServicesDomain_3CF9F316829008BD64D393582E2EAB17" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_FE71A339EB72CED89E6493582E2FC7D1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3CF9F316829008BD64D393582E2EAB17" xlink:to="loc_biib_ZINBRYTAMember_FE71A339EB72CED89E6493582E2FC7D1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_A5B08BDDEE98876A464C93582E2F90CF" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_A5B08BDDEE98876A464C93582E2F90CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_575ED5D5599A1FCF6F9793582E2FFE6B_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_A5B08BDDEE98876A464C93582E2F90CF" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_575ED5D5599A1FCF6F9793582E2FFE6B_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_575ED5D5599A1FCF6F9793582E2FFE6B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_A5B08BDDEE98876A464C93582E2F90CF" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_575ED5D5599A1FCF6F9793582E2FFE6B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="loc_us-gaap_GeneralBusinessMember_458EA3DD02696E6BC4A593582E2F9887" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_575ED5D5599A1FCF6F9793582E2FFE6B" xlink:to="loc_us-gaap_GeneralBusinessMember_458EA3DD02696E6BC4A593582E2F9887" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_0B1F15C996EB5CAA454A93582E2F0700" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_575ED5D5599A1FCF6F9793582E2FFE6B" xlink:to="loc_us-gaap_ResearchMember_0B1F15C996EB5CAA454A93582E2F0700" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_E2C9DF5FDC5648AEF1D993582E2FED5F" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_E2C9DF5FDC5648AEF1D993582E2FED5F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_BCDACC1F98F82E9B295093582E2F95DB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_E2C9DF5FDC5648AEF1D993582E2FED5F" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_BCDACC1F98F82E9B295093582E2F95DB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_BCDACC1F98F82E9B295093582E2F95DB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_E2C9DF5FDC5648AEF1D993582E2FED5F" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_BCDACC1F98F82E9B295093582E2F95DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_9DEDB3D54181BB5FE67493582E2F70DE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_BCDACC1F98F82E9B295093582E2F95DB" xlink:to="loc_us-gaap_DomesticCountryMember_9DEDB3D54181BB5FE67493582E2F70DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_6CD246E861244F85738493582E2F83F8" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_BCDACC1F98F82E9B295093582E2F95DB" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_6CD246E861244F85738493582E2F83F8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_DDEB699653B5CD04C67F93582E2F085C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_BCDACC1F98F82E9B295093582E2F95DB" xlink:to="loc_us-gaap_ForeignCountryMember_DDEB699653B5CD04C67F93582E2F085C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_AF2ABAA69DA13ADA5B8E93582E2FA19E" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219" xlink:to="loc_us-gaap_RangeAxis_AF2ABAA69DA13ADA5B8E93582E2FA19E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_47E465FC7CF20C97943793582E2F4D39_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_AF2ABAA69DA13ADA5B8E93582E2FA19E" xlink:to="loc_us-gaap_RangeMember_47E465FC7CF20C97943793582E2F4D39_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_47E465FC7CF20C97943793582E2F4D39" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_AF2ABAA69DA13ADA5B8E93582E2FA19E" xlink:to="loc_us-gaap_RangeMember_47E465FC7CF20C97943793582E2F4D39" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_6EE46D63C2C0CC8CD46A93582E2F9A75" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_47E465FC7CF20C97943793582E2F4D39" xlink:to="loc_us-gaap_MinimumMember_6EE46D63C2C0CC8CD46A93582E2F9A75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_44B069374FAB56861C8393582E2F21C7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_47E465FC7CF20C97943793582E2F4D39" xlink:to="loc_us-gaap_MaximumMember_44B069374FAB56861C8393582E2F21C7" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Deferredtaxassetreclassification" xlink:label="loc_biib_Deferredtaxassetreclassification_71964BE76E996AC4AD4093582E2FA8D3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_biib_Deferredtaxassetreclassification_71964BE76E996AC4AD4093582E2FA8D3" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Deferredtaxliabilityreclassification" xlink:label="loc_biib_Deferredtaxliabilityreclassification_6A5C72435CE5DD42FC7B93582E3017EC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_biib_Deferredtaxliabilityreclassification_6A5C72435CE5DD42FC7B93582E3017EC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Totaldeferredchargesandprepaidtaxes" xlink:label="loc_biib_Totaldeferredchargesandprepaidtaxes_EA60536622BE4B7406B293582E30371D" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_biib_Totaldeferredchargesandprepaidtaxes_EA60536622BE4B7406B293582E30371D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DeferredTaxLiabilityRecognized" xlink:label="loc_biib_DeferredTaxLiabilityRecognized_6B65C37FCB1267FE2A6193582E30DC4E" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_biib_DeferredTaxLiabilityRecognized_6B65C37FCB1267FE2A6193582E30DC4E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_6860946B2A527EB06C4C93582E30FD61" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_us-gaap_DeferredTaxLiabilities_6860946B2A527EB06C4C93582E30FD61" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NetBenefitForPreviouslyUnrecognizedPosition" xlink:label="loc_biib_NetBenefitForPreviouslyUnrecognizedPosition_DD80BE9FFC638ED526F693582E3022D2" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_biib_NetBenefitForPreviouslyUnrecognizedPosition_DD80BE9FFC638ED526F693582E3022D2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2BBAB2DD33D107A563DD93582E305729" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2BBAB2DD33D107A563DD93582E305729" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_9A6C248890E77AD4A08D93582E30F101" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_9A6C248890E77AD4A08D93582E30F101" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75D824E7D34A092D851E93582E306473" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75D824E7D34A092D851E93582E306473" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries" xlink:label="loc_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_5E0956CDF5D7981A279393582E307943" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_5E0956CDF5D7981A279393582E307943" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ExpenseForNonIncomeBasedStateTaxes" xlink:label="loc_biib_ExpenseForNonIncomeBasedStateTaxes_95D1E705EE20C1C39CE893582E3018DA" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_biib_ExpenseForNonIncomeBasedStateTaxes_95D1E705EE20C1C39CE893582E3018DA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices" xlink:label="loc_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_F872C17DCA650D15FD5493582E30CEE8" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_F872C17DCA650D15FD5493582E30CEE8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_3DC2598769BB2AB1F3C093582E3006B8" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_3DC2598769BB2AB1F3C093582E3006B8" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3057976B1A522670D18C38A351EB09DD" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5433ADC4A08143DA0D6138A351EA686B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3057976B1A522670D18C38A351EB09DD" xlink:to="loc_us-gaap_DebtInstrumentTable_5433ADC4A08143DA0D6138A351EA686B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B373CDA1FBCD5A8B70EF38A351EAF208" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5433ADC4A08143DA0D6138A351EA686B" xlink:to="loc_us-gaap_DebtInstrumentAxis_B373CDA1FBCD5A8B70EF38A351EAF208" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_808CADC0DADEE4DCB89538A351EAC0D6_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_B373CDA1FBCD5A8B70EF38A351EAF208" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_808CADC0DADEE4DCB89538A351EAC0D6_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_808CADC0DADEE4DCB89538A351EAC0D6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_B373CDA1FBCD5A8B70EF38A351EAF208" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_808CADC0DADEE4DCB89538A351EAC0D6" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_0085337D8828E67DD0B738A351EB7C2C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_808CADC0DADEE4DCB89538A351EAC0D6" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_0085337D8828E67DD0B738A351EB7C2C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_45FC4FB67ECBF578E4D838A351EB8A22" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_808CADC0DADEE4DCB89538A351EAC0D6" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_45FC4FB67ECBF578E4D838A351EB8A22" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D55CF4FD3D9015E6E4A938A351EBBEEF" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_808CADC0DADEE4DCB89538A351EAC0D6" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D55CF4FD3D9015E6E4A938A351EBBEEF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_3824910742301AA8119A38A351EB4C4A" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_808CADC0DADEE4DCB89538A351EAC0D6" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_3824910742301AA8119A38A351EB4C4A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_6311357ECD8FFF8D30F238A351EBDDD6" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_808CADC0DADEE4DCB89538A351EAC0D6" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_6311357ECD8FFF8D30F238A351EBDDD6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_99BEF29C1FC75DF8F48C38A351EB2C1E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5433ADC4A08143DA0D6138A351EA686B" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_99BEF29C1FC75DF8F48C38A351EB2C1E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_911BE02EA1DEC33112F438A351EBC542_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_99BEF29C1FC75DF8F48C38A351EB2C1E" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_911BE02EA1DEC33112F438A351EBC542_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_911BE02EA1DEC33112F438A351EBC542" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_99BEF29C1FC75DF8F48C38A351EB2C1E" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_911BE02EA1DEC33112F438A351EBC542" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_A604064A0E08FC5D609138A351EB6099" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_911BE02EA1DEC33112F438A351EBC542" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_A604064A0E08FC5D609138A351EB6099" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtCurrentAbstract_FCE66CB076C27EB71CED38A351EB3587" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3057976B1A522670D18C38A351EB09DD" xlink:to="loc_us-gaap_LongTermDebtCurrentAbstract_FCE66CB076C27EB71CED38A351EB3587" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_22F8762A23417647460B38A351EB50BE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_FCE66CB076C27EB71CED38A351EB3587" xlink:to="loc_us-gaap_NotesPayableCurrent_22F8762A23417647460B38A351EB50BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_FCE98FB685D4F612AE8B38A351EBA7EF" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_FCE66CB076C27EB71CED38A351EB3587" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_FCE98FB685D4F612AE8B38A351EBA7EF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_19E5A1ACA121766BC13B38A351ECDBFA" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_FCE66CB076C27EB71CED38A351EB3587" xlink:to="loc_us-gaap_DebtCurrent_19E5A1ACA121766BC13B38A351ECDBFA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_3B1F0C555BE913E113CE38A351EC4DB5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3057976B1A522670D18C38A351EB09DD" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_3B1F0C555BE913E113CE38A351EC4DB5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_A0BD62888ED5C8C9B0F038A351ECFFA1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_3B1F0C555BE913E113CE38A351EC4DB5" xlink:to="loc_us-gaap_LongTermNotesPayable_A0BD62888ED5C8C9B0F038A351ECFFA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_26C4BB6C887D4582936A38A351ECFEC7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_3B1F0C555BE913E113CE38A351EC4DB5" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_26C4BB6C887D4582936A38A351ECFEC7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_8C310E52827A95BA75AE38A351EC474D" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_3B1F0C555BE913E113CE38A351EC4DB5" xlink:to="loc_us-gaap_LongTermDebt_8C310E52827A95BA75AE38A351EC474D" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0589111E6C67C78E40C993D5CA1FA6E3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0589111E6C67C78E40C993D5CA1FA6E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_971902D456D20355A82D93D5CA1F7ED8_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0589111E6C67C78E40C993D5CA1FA6E3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_971902D456D20355A82D93D5CA1F7ED8_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_971902D456D20355A82D93D5CA1F7ED8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0589111E6C67C78E40C993D5CA1FA6E3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_971902D456D20355A82D93D5CA1F7ED8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_89F59F815B7C310F4BEF93D5CA1F2C71" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_971902D456D20355A82D93D5CA1F7ED8" xlink:to="loc_biib_EisaiMember_89F59F815B7C310F4BEF93D5CA1F2C71" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_EFBC1D8220BAA09FD98B93D5CA1F7987" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_EFBC1D8220BAA09FD98B93D5CA1F7987" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_85DABEB888190B9427AD93D5CA1F67E7_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_EFBC1D8220BAA09FD98B93D5CA1F7987" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_85DABEB888190B9427AD93D5CA1F67E7_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_85DABEB888190B9427AD93D5CA1F67E7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_EFBC1D8220BAA09FD98B93D5CA1F7987" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_85DABEB888190B9427AD93D5CA1F67E7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_D4288B47E7D0BA66F49693D5CA1F6CC5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_85DABEB888190B9427AD93D5CA1F67E7" xlink:to="loc_us-gaap_InterestRateSwapMember_D4288B47E7D0BA66F49693D5CA1F6CC5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_860325E6506CC6C3943A93D5CA1FB26F" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D" xlink:to="loc_us-gaap_DebtInstrumentAxis_860325E6506CC6C3943A93D5CA1FB26F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_860325E6506CC6C3943A93D5CA1FB26F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_860325E6506CC6C3943A93D5CA1FB26F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_59B31C7C9A3A736B503F93D5CA1F47BF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_59B31C7C9A3A736B503F93D5CA1F47BF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8AFD80790EA34399A7BA93D5CA1FFD4F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8AFD80790EA34399A7BA93D5CA1FFD4F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_767C61E63B4356C4011693D5CA1F163E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_767C61E63B4356C4011693D5CA1F163E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_DEA3CD82BFBCDA2F38BC93D5CA1F67F6" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_DEA3CD82BFBCDA2F38BC93D5CA1F67F6" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7CE22C1F69C1430DA9BA93E5A6FBC5A4" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7CE22C1F69C1430DA9BA93E5A6FBC5A4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_FADA9BCA25F556DE271F93D5CA1FCF31" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_FADA9BCA25F556DE271F93D5CA1FCF31" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9493788F303D7B1E086E93D5CA1F73A4_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_FADA9BCA25F556DE271F93D5CA1FCF31" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9493788F303D7B1E086E93D5CA1F73A4_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9493788F303D7B1E086E93D5CA1F73A4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_FADA9BCA25F556DE271F93D5CA1FCF31" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9493788F303D7B1E086E93D5CA1F73A4" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_697EC9037B3D3D886D3693D5CA1F5B18" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9493788F303D7B1E086E93D5CA1F73A4" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_697EC9037B3D3D886D3693D5CA1F5B18" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_206CD114F4E55150E50993D5CA1F8118" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9493788F303D7B1E086E93D5CA1F73A4" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_206CD114F4E55150E50993D5CA1F8118" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_25F082A9E4EAC6D4D61293D5CA204531" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_25F082A9E4EAC6D4D61293D5CA204531" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_907BBD8298F21D66CE4C93D5CA20B3BB" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_907BBD8298F21D66CE4C93D5CA20B3BB" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_CCD183A70709537A1B9D93D5CA20E814" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_CCD183A70709537A1B9D93D5CA20E814" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_12BE5EA91E95F29E8E3993D5CA202D58" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_12BE5EA91E95F29E8E3993D5CA202D58" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E11A275EB3E843B967F493D5CA202D6C" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E11A275EB3E843B967F493D5CA202D6C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_us-gaap_DebtIssuanceCosts_05703242317BF7C5967593D5CA203251" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_DebtIssuanceCosts_05703242317BF7C5967593D5CA203251" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_CF427481D02137E93E6D93D5CA202BC3" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_CF427481D02137E93E6D93D5CA202BC3" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfRedemptionOfNotes" xlink:label="loc_biib_PercentageOfRedemptionOfNotes_062780907191105FBFFA93D5CA20127C" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_biib_PercentageOfRedemptionOfNotes_062780907191105FBFFA93D5CA20127C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_IncreasedCarryingAmountOfSeniorNotes" xlink:label="loc_biib_IncreasedCarryingAmountOfSeniorNotes_5A186CE6CBA86C55210093D5CA205B87" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_biib_IncreasedCarryingAmountOfSeniorNotes_5A186CE6CBA86C55210093D5CA205B87" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DebtInstrumentUnamortizedInterestOnDebt" xlink:label="loc_biib_DebtInstrumentUnamortizedInterestOnDebt_86E476B5EBA1CC28D41B93D5CA209F6F" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_biib_DebtInstrumentUnamortizedInterestOnDebt_86E476B5EBA1CC28D41B93D5CA209F6F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_FCAD46566DF217E0C03393D5CA2042CC" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_LongTermNotesPayable_FCAD46566DF217E0C03393D5CA2042CC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ParValueOfNotesPayable" xlink:label="loc_biib_ParValueOfNotesPayable_2CF1812C49CEF134DB3593D5CA2051E8" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_biib_ParValueOfNotesPayable_2CF1812C49CEF134DB3593D5CA2051E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_C5DC1A416C14521A7A8A93D5CA2078C9" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_C5DC1A416C14521A7A8A93D5CA2078C9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_C79F9AE510112EA1414793D5CA20FF9F" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_C79F9AE510112EA1414793D5CA20FF9F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_5D983F76332D71EF5F3B93D5CA207AC7" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_5D983F76332D71EF5F3B93D5CA207AC7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_17EE439A728C6C5E108793D5CA205A26" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_CapitalLeaseObligations_17EE439A728C6C5E108793D5CA205A26" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_35BF1C14C20E9719E31393224CD481C4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_35BF1C14C20E9719E31393224CD481C4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0F3C0CCD51380D04CA1193224CD48751_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_35BF1C14C20E9719E31393224CD481C4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0F3C0CCD51380D04CA1193224CD48751_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0F3C0CCD51380D04CA1193224CD48751" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_35BF1C14C20E9719E31393224CD481C4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0F3C0CCD51380D04CA1193224CD48751" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_78DBEEC366214FD9AF0A93224CD44D99" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0F3C0CCD51380D04CA1193224CD48751" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_78DBEEC366214FD9AF0A93224CD44D99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_1CB2691B3700402EF03693224CD4597E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:to="loc_us-gaap_ProductOrServiceAxis_1CB2691B3700402EF03693224CD4597E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_E0C8DEEBB7E02923633193224CD493EF_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_1CB2691B3700402EF03693224CD4597E" xlink:to="loc_us-gaap_ProductsAndServicesDomain_E0C8DEEBB7E02923633193224CD493EF_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_E0C8DEEBB7E02923633193224CD493EF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_1CB2691B3700402EF03693224CD4597E" xlink:to="loc_us-gaap_ProductsAndServicesDomain_E0C8DEEBB7E02923633193224CD493EF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_967F1C1E8B6DE26A06AB93224CD58816" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E0C8DEEBB7E02923633193224CD493EF" xlink:to="loc_biib_AVONEXMember_967F1C1E8B6DE26A06AB93224CD58816" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_3C18AE78F81848CE4FF693224CD5BB9D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E0C8DEEBB7E02923633193224CD493EF" xlink:to="loc_biib_TysabriProductMember_3C18AE78F81848CE4FF693224CD5BB9D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_631D0E0BAEC2B363B14693224CD5D7F9" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_631D0E0BAEC2B363B14693224CD5D7F9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBEA22071E45F6D0A56993224CD50159_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_631D0E0BAEC2B363B14693224CD5D7F9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBEA22071E45F6D0A56993224CD50159_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBEA22071E45F6D0A56993224CD50159" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_631D0E0BAEC2B363B14693224CD5D7F9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBEA22071E45F6D0A56993224CD50159" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_EE3FBB42D063C2CAF29193224CD53EDC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBEA22071E45F6D0A56993224CD50159" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_EE3FBB42D063C2CAF29193224CD53EDC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_F579532BF40DE32380B693224CDADD1B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBEA22071E45F6D0A56993224CD50159" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_F579532BF40DE32380B693224CDADD1B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A3EF29F06427E7FFB3F093224CDAA2AC" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A3EF29F06427E7FFB3F093224CDAA2AC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448862C0974759741B993224CDA8DC8_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A3EF29F06427E7FFB3F093224CDAA2AC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448862C0974759741B993224CDA8DC8_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448862C0974759741B993224CDA8DC8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A3EF29F06427E7FFB3F093224CDAA2AC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448862C0974759741B993224CDA8DC8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_029BDACC881DC6EEA47093224CDAD84A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448862C0974759741B993224CDA8DC8" xlink:to="loc_biib_OutLicensedPatentsMember_029BDACC881DC6EEA47093224CDAD84A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_6253A9E80E7FC0196DD993224CDAB87C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448862C0974759741B993224CDA8DC8" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_6253A9E80E7FC0196DD993224CDAB87C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_541EEB822EE2F808604893224CDA2BFB" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448862C0974759741B993224CDA8DC8" xlink:to="loc_biib_InLicensedPatentsMember_541EEB822EE2F808604893224CDA2BFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_F484C7AB99B3F86138D593224CDA6C84" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:to="loc_us-gaap_RangeAxis_F484C7AB99B3F86138D593224CDA6C84" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_73C1DCED6391BC31BBF893224CDBF21B_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_F484C7AB99B3F86138D593224CDA6C84" xlink:to="loc_us-gaap_RangeMember_73C1DCED6391BC31BBF893224CDBF21B_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_73C1DCED6391BC31BBF893224CDBF21B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_F484C7AB99B3F86138D593224CDA6C84" xlink:to="loc_us-gaap_RangeMember_73C1DCED6391BC31BBF893224CDBF21B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_C2B1ED635F518B2F805493224CDB7841" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_73C1DCED6391BC31BBF893224CDBF21B" xlink:to="loc_us-gaap_MinimumMember_C2B1ED635F518B2F805493224CDB7841" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_EC541F2B77398883C1B993224CDB19D0" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_73C1DCED6391BC31BBF893224CDBF21B" xlink:to="loc_us-gaap_MaximumMember_EC541F2B77398883C1B993224CDB19D0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_550A17DC156B1EA5351493224CDB34A3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:to="loc_us-gaap_Goodwill_550A17DC156B1EA5351493224CDB34A3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6AAA18418CECF4AC42FE93224CDB60C5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6AAA18418CECF4AC42FE93224CDB60C5" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EE6B94DAA428326B583493224CDB4832" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EE6B94DAA428326B583493224CDB4832" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_67E1D80199CD61F45DDE93224CDBD485" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_67E1D80199CD61F45DDE93224CDBD485" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_580BAF5F95D2553B699E93224CDB2C1D" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_580BAF5F95D2553B699E93224CDB2C1D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FE91F4D170521E3001BE93224CDB46F5" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FE91F4D170521E3001BE93224CDB46F5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_62401F5858547C75BE6993224CDBEEA6" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_62401F5858547C75BE6993224CDBEEA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7FDBD5F4A46A832C49B293224CDB6FBC" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7FDBD5F4A46A832C49B293224CDB6FBC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9447849594F2FEFEB52A93224CDB0E46" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9447849594F2FEFEB52A93224CDB0E46" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" xlink:label="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:to="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C23F119A34CE854FFD0893224CDB2BEB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C23F119A34CE854FFD0893224CDB2BEB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0BF8322266308215EE8593224CDBDCC2" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0BF8322266308215EE8593224CDBDCC2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3803DBFEB22501377C4C93224CDC7239" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3803DBFEB22501377C4C93224CDC7239" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_39EF1AE3183A43A1795293224CDCB194" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_39EF1AE3183A43A1795293224CDCB194" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_D4C188C6827958A0554693224CDC1327" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_D4C188C6827958A0554693224CDC1327" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Finitelivedintangibleassetsfutureamortization" xlink:label="loc_biib_Finitelivedintangibleassetsfutureamortization_1CE2EFA9D1B450CBAFA793224CDC9A14" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:to="loc_biib_Finitelivedintangibleassetsfutureamortization_1CE2EFA9D1B450CBAFA793224CDC9A14" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_D901030EFCADAFC40D1F93224CDC563F" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_D901030EFCADAFC40D1F93224CDC563F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9F7308450AECCEBFC24C93224CDCB2C2" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9F7308450AECCEBFC24C93224CDCB2C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_73600D0315A83E03C4F193224CDC9F24" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_73600D0315A83E03C4F193224CDC9F24" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_DDDE86A3DE7CC7DAD0F493224CDCFC0D" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_DDDE86A3DE7CC7DAD0F493224CDCFC0D" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_6937FB604D575D7DA65693224CACA0C2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5DFEA886036FE17FC47193224CAB9C9B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_6937FB604D575D7DA65693224CACA0C2" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5DFEA886036FE17FC47193224CAB9C9B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6137E3E4E4C5197F9D9693224CAB9CF7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5DFEA886036FE17FC47193224CAB9C9B" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6137E3E4E4C5197F9D9693224CAB9CF7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0DB72D01F24E9E1496A93224CAB8541_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6137E3E4E4C5197F9D9693224CAB9CF7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0DB72D01F24E9E1496A93224CAB8541_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0DB72D01F24E9E1496A93224CAB8541" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6137E3E4E4C5197F9D9693224CAB9CF7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0DB72D01F24E9E1496A93224CAB8541" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_17F00435A67785A555ED93224CAC203F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0DB72D01F24E9E1496A93224CAB8541" xlink:to="loc_biib_FumapharmAgMember_17F00435A67785A555ED93224CAC203F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_3A2855E2A30F57572D5893224CAC2502" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0DB72D01F24E9E1496A93224CAB8541" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_3A2855E2A30F57572D5893224CAC2502" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_F625A013400BE92F078393224CAC107E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5DFEA886036FE17FC47193224CAB9C9B" xlink:to="loc_us-gaap_ProductOrServiceAxis_F625A013400BE92F078393224CAC107E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_2BE34A7DEA59CAA7FE5193224CAC1CC9_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_F625A013400BE92F078393224CAC107E" xlink:to="loc_us-gaap_ProductsAndServicesDomain_2BE34A7DEA59CAA7FE5193224CAC1CC9_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_2BE34A7DEA59CAA7FE5193224CAC1CC9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_F625A013400BE92F078393224CAC107E" xlink:to="loc_us-gaap_ProductsAndServicesDomain_2BE34A7DEA59CAA7FE5193224CAC1CC9" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_362DBCE9D8CB4B86AB0493224CAC2725" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_2BE34A7DEA59CAA7FE5193224CAC1CC9" xlink:to="loc_biib_TecfideraMember_362DBCE9D8CB4B86AB0493224CAC2725" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_230C835D6A19260E000293224CAC7E07" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_6937FB604D575D7DA65693224CACA0C2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_230C835D6A19260E000293224CAC7E07" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_71B1D94AC2E8E3844CAF93224CB11877" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_6937FB604D575D7DA65693224CACA0C2" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_71B1D94AC2E8E3844CAF93224CB11877" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_A319C20CA67DB99B8C0F93224CFEEAC5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_63832FB8ECD162BE35FB93224CFDA2AD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_A319C20CA67DB99B8C0F93224CFEEAC5" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_63832FB8ECD162BE35FB93224CFDA2AD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_BDDBD00F820312A6FEAB93224CFE1142" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_63832FB8ECD162BE35FB93224CFDA2AD" xlink:to="loc_us-gaap_ProductOrServiceAxis_BDDBD00F820312A6FEAB93224CFE1142" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_9260D1A09B45C728FDEB93224CFED462_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_BDDBD00F820312A6FEAB93224CFE1142" xlink:to="loc_us-gaap_ProductsAndServicesDomain_9260D1A09B45C728FDEB93224CFED462_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_9260D1A09B45C728FDEB93224CFED462" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_BDDBD00F820312A6FEAB93224CFE1142" xlink:to="loc_us-gaap_ProductsAndServicesDomain_9260D1A09B45C728FDEB93224CFED462" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_51B9B2FDC7A334F8F90093224CFE83EE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9260D1A09B45C728FDEB93224CFED462" xlink:to="loc_biib_ZINBRYTAMember_51B9B2FDC7A334F8F90093224CFE83EE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_F1CDA2889F89AFDEA4F39348C760D985" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9260D1A09B45C728FDEB93224CFED462" xlink:to="loc_biib_BENEPALIMember_F1CDA2889F89AFDEA4F39348C760D985" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_7ED2C1D896193DA9B4DE9349E8DD90CE" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9260D1A09B45C728FDEB93224CFED462" xlink:to="loc_biib_FLIXABIMember_7ED2C1D896193DA9B4DE9349E8DD90CE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Preapprovalinventory" xlink:label="loc_biib_Preapprovalinventory_C2E4723CC87A5104ACE593224CFEEB95" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_A319C20CA67DB99B8C0F93224CFEEAC5" xlink:to="loc_biib_Preapprovalinventory_C2E4723CC87A5104ACE593224CFEEB95" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_CF0C9258BAA90ED184D993582E12A7E6" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ACAA23A49FE96951D3D993582E116794" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_CF0C9258BAA90ED184D993582E12A7E6" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ACAA23A49FE96951D3D993582E116794" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_95BC0FB58538605DFA5893582E11C4A5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ACAA23A49FE96951D3D993582E116794" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_95BC0FB58538605DFA5893582E11C4A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_EDB337D64A68833E396F93582E11B77D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_95BC0FB58538605DFA5893582E11C4A5" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_EDB337D64A68833E396F93582E11B77D_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_EDB337D64A68833E396F93582E11B77D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_95BC0FB58538605DFA5893582E11C4A5" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_EDB337D64A68833E396F93582E11B77D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_E451959490AEA52B965C93582E12DEEE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_EDB337D64A68833E396F93582E11B77D" xlink:to="loc_biib_NeurimmuneMember_E451959490AEA52B965C93582E12DEEE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RodinTherapeuticsMember" xlink:label="loc_biib_RodinTherapeuticsMember_67FD71452ABDB315E16293582E12A9CD" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_EDB337D64A68833E396F93582E11B77D" xlink:to="loc_biib_RodinTherapeuticsMember_67FD71452ABDB315E16293582E12A9CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D0E71C59F74910FA3AB893582E12B471" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_CF0C9258BAA90ED184D993582E12A7E6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D0E71C59F74910FA3AB893582E12B471" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_CF0C9258BAA90ED184D993582E12A7E6" xlink:to="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" xlink:label="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_7AC122855F0F1564806893582E12EDBF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:to="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_7AC122855F0F1564806893582E12EDBF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" xlink:label="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E18D82267E8A1717B8D793582E1216D6" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:to="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E18D82267E8A1717B8D793582E1216D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_4161E02A52751C889D4F93582E12C6E0" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_4161E02A52751C889D4F93582E12C6E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_C00A27608CF68B15FA9093582E128A66" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:to="loc_us-gaap_OtherCommitment_C00A27608CF68B15FA9093582E128A66" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_FD50110CA21A4198118293582E12CD34" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_FD50110CA21A4198118293582E12CD34" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_2F033F03E873A4E04A6D93582E120BB6" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:to="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_2F033F03E873A4E04A6D93582E120BB6" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_0F6EA27E012A1106F31093582E12B6B9" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_0F6EA27E012A1106F31093582E12B6B9" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_6681F07F45EA49BE213938A352087500" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_222F11C1B7136752E23638A352086ACA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_6681F07F45EA49BE213938A352087500" xlink:to="loc_us-gaap_LossContingenciesTable_222F11C1B7136752E23638A352086ACA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_E6609F50E3182813128638A35208D6B4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_222F11C1B7136752E23638A352086ACA" xlink:to="loc_us-gaap_StatementGeographicalAxis_E6609F50E3182813128638A35208D6B4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_D6765D53F81CCC261F9038A352085D92_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_E6609F50E3182813128638A35208D6B4" xlink:to="loc_us-gaap_SegmentGeographicalDomain_D6765D53F81CCC261F9038A352085D92_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_D6765D53F81CCC261F9038A352085D92" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_E6609F50E3182813128638A35208D6B4" xlink:to="loc_us-gaap_SegmentGeographicalDomain_D6765D53F81CCC261F9038A352085D92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IT" xlink:label="loc_country_IT_7A40A3C9EF397CD27DBB38A3520882F1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_D6765D53F81CCC261F9038A352085D92" xlink:to="loc_country_IT_7A40A3C9EF397CD27DBB38A3520882F1" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ReimbursementLimitStatedInResolution" xlink:label="loc_biib_ReimbursementLimitStatedInResolution_1A30F955400C20011CC238A352087B44" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6681F07F45EA49BE213938A352087500" xlink:to="loc_biib_ReimbursementLimitStatedInResolution_1A30F955400C20011CC238A352087B44" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_F1501C35B3A715D8DC7193582E229042" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_02D32A0E4C21C40BDAA993582E2291E1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_F1501C35B3A715D8DC7193582E229042" xlink:to="loc_us-gaap_StatementTable_02D32A0E4C21C40BDAA993582E2291E1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_C771E0094C40EA166EAC93582E22B326" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_02D32A0E4C21C40BDAA993582E2291E1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_C771E0094C40EA166EAC93582E22B326" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0DCA0D6CC1F077A8C5EF93582E227B95_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_C771E0094C40EA166EAC93582E22B326" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0DCA0D6CC1F077A8C5EF93582E227B95_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0DCA0D6CC1F077A8C5EF93582E227B95" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_C771E0094C40EA166EAC93582E22B326" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0DCA0D6CC1F077A8C5EF93582E227B95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_88964426E76164C547D793582E22DA3E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0DCA0D6CC1F077A8C5EF93582E227B95" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_88964426E76164C547D793582E22DA3E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1A3F21360DF7A429BC4993582E2211A8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_F1501C35B3A715D8DC7193582E229042" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_1A3F21360DF7A429BC4993582E2211A8" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_854C756DFB8ABBD1471F93582E1AAA5E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_854C756DFB8ABBD1471F93582E1AAA5E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_CECA1ACFBEFB6A00B7DF93582E1AD795" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_854C756DFB8ABBD1471F93582E1AAA5E" xlink:to="loc_us-gaap_StatementGeographicalAxis_CECA1ACFBEFB6A00B7DF93582E1AD795" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_BD4C99E8B1F5084D352F93582E1A3421_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_CECA1ACFBEFB6A00B7DF93582E1AD795" xlink:to="loc_us-gaap_SegmentGeographicalDomain_BD4C99E8B1F5084D352F93582E1A3421_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_BD4C99E8B1F5084D352F93582E1A3421" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_CECA1ACFBEFB6A00B7DF93582E1AD795" xlink:to="loc_us-gaap_SegmentGeographicalDomain_BD4C99E8B1F5084D352F93582E1A3421" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IT" xlink:label="loc_country_IT_538F9BEC69198083C6EC93582E1A3640" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_BD4C99E8B1F5084D352F93582E1A3421" xlink:to="loc_country_IT_538F9BEC69198083C6EC93582E1A3640" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_115EE47B89E8256D1F0793582E1A0F25" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_854C756DFB8ABBD1471F93582E1AAA5E" xlink:to="loc_us-gaap_ProductOrServiceAxis_115EE47B89E8256D1F0793582E1A0F25" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_D13EF9936227009823C693582E1BCAE2_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_115EE47B89E8256D1F0793582E1A0F25" xlink:to="loc_us-gaap_ProductsAndServicesDomain_D13EF9936227009823C693582E1BCAE2_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_D13EF9936227009823C693582E1BCAE2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_115EE47B89E8256D1F0793582E1A0F25" xlink:to="loc_us-gaap_ProductsAndServicesDomain_D13EF9936227009823C693582E1BCAE2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_299D3CDE1A69CD4A0FBC93582E1BF245" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D13EF9936227009823C693582E1BCAE2" xlink:to="loc_biib_TecfideraMember_299D3CDE1A69CD4A0FBC93582E1BF245" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_A7C4C764F6D4CD8D1D2093582E1B15DE" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_854C756DFB8ABBD1471F93582E1AAA5E" xlink:to="loc_biib_CumulativeSalesLevelAxis_A7C4C764F6D4CD8D1D2093582E1B15DE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_81C67463153D48212EA393582E1B86CE_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_CumulativeSalesLevelAxis_A7C4C764F6D4CD8D1D2093582E1B15DE" xlink:to="loc_biib_CumulativeSalesLevelDomain_81C67463153D48212EA393582E1B86CE_default" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_81C67463153D48212EA393582E1B86CE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_CumulativeSalesLevelAxis_A7C4C764F6D4CD8D1D2093582E1B15DE" xlink:to="loc_biib_CumulativeSalesLevelDomain_81C67463153D48212EA393582E1B86CE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SevenbillionMember" xlink:label="loc_biib_SevenbillionMember_567169C21EE3568D5BFA93582E1BBB75" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_81C67463153D48212EA393582E1B86CE" xlink:to="loc_biib_SevenbillionMember_567169C21EE3568D5BFA93582E1BBB75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_71775D7C5777969FB1C093582E1BB749" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_854C756DFB8ABBD1471F93582E1AAA5E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_71775D7C5777969FB1C093582E1BB749" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44B3BB169B8FBE0C617393582E1B1347_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_71775D7C5777969FB1C093582E1BB749" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44B3BB169B8FBE0C617393582E1B1347_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44B3BB169B8FBE0C617393582E1B1347" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_71775D7C5777969FB1C093582E1BB749" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44B3BB169B8FBE0C617393582E1B1347" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_E8FE24E5BAE042A22F0D93582E1B825F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44B3BB169B8FBE0C617393582E1B1347" xlink:to="loc_biib_FumapharmAgMember_E8FE24E5BAE042A22F0D93582E1B825F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_EC7DDEC790CBD9C1540A93A5AB807D46" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44B3BB169B8FBE0C617393582E1B1347" xlink:to="loc_biib_SolothurnMember_EC7DDEC790CBD9C1540A93A5AB807D46" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_C32F9DFF6253F09DB7AC93582E1BC9C7" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44B3BB169B8FBE0C617393582E1B1347" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_C32F9DFF6253F09DB7AC93582E1BC9C7" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_C5362AF692EB0190BB2F93582E1B6084" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_854C756DFB8ABBD1471F93582E1AAA5E" xlink:to="loc_biib_FacilityLocationAxis_C5362AF692EB0190BB2F93582E1B6084" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_D366C70A71587103385893582E1B3AD8_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_C5362AF692EB0190BB2F93582E1B6084" xlink:to="loc_biib_FacilityLocationDomain_D366C70A71587103385893582E1B3AD8_default" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_D366C70A71587103385893582E1B3AD8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_C5362AF692EB0190BB2F93582E1B6084" xlink:to="loc_biib_FacilityLocationDomain_D366C70A71587103385893582E1B3AD8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CambridgeLeasesMember" xlink:label="loc_biib_CambridgeLeasesMember_68646E544EEDF91D34DF93582E1B92AB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_D366C70A71587103385893582E1B3AD8" xlink:to="loc_biib_CambridgeLeasesMember_68646E544EEDF91D34DF93582E1B92AB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_E5F49049122DC812941193582E1B2405" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_E5F49049122DC812941193582E1B2405" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_401908750E8A9FABA4A693582E1BD155" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_biib_CumulativeSalesLevel_401908750E8A9FABA4A693582E1BD155" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_DFEB40D38CAA2B365F9B93A5D37497DD" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_DFEB40D38CAA2B365F9B93A5D37497DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_FA5731EB42A753379F0A93582E1C51AF" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_FA5731EB42A753379F0A93582E1C51AF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DerecognitionOfConstructionInProgressAssets" xlink:label="loc_biib_DerecognitionOfConstructionInProgressAssets_F0271AC9C526803ED86493582E1C5DEC" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_biib_DerecognitionOfConstructionInProgressAssets_F0271AC9C526803ED86493582E1C5DEC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_3B74A10E7B2101F964E193A7016DA739" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_us-gaap_PrepaidTaxes_3B74A10E7B2101F964E193A7016DA739" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_17F8F9CCD5C2093E03C493582E1C4B0D" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_17F8F9CCD5C2093E03C493582E1C4B0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_C15660B4201AC26AAC9893582E1C052C" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_C15660B4201AC26AAC9893582E1C052C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_LossContingencyAdjustmentRelatedToClaimAmountPercent" xlink:label="loc_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_C553290695048CF5AA6F93582E1CB1D5" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_C553290695048CF5AA6F93582E1CB1D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_202C99E7DD9851F899EE93582E1CD17E" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_202C99E7DD9851F899EE93582E1CD17E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_75B5C5DFFA579B5507F293A8926B620D" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_75B5C5DFFA579B5507F293A8926B620D" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_526149A3AD8A06D3698493582EBFD06E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_526149A3AD8A06D3698493582EBFD06E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B9739312139686999FA893582EC036EB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_526149A3AD8A06D3698493582EBFD06E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B9739312139686999FA893582EC036EB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_12E3CEB31452D6B5582B93582EC0A160_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B9739312139686999FA893582EC036EB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_12E3CEB31452D6B5582B93582EC0A160_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_12E3CEB31452D6B5582B93582EC0A160" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B9739312139686999FA893582EC036EB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_12E3CEB31452D6B5582B93582EC0A160" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_0B6E8E89E7C515A8D1B693582EC09A02" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_12E3CEB31452D6B5582B93582EC0A160" xlink:to="loc_us-gaap_LandMember_0B6E8E89E7C515A8D1B693582EC09A02" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_604B2B699C19D89521E393582EC0F757" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_526149A3AD8A06D3698493582EBFD06E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_604B2B699C19D89521E393582EC0F757" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_03A68F34153EEF2BC6C993582EC0FD48_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_604B2B699C19D89521E393582EC0F757" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_03A68F34153EEF2BC6C993582EC0FD48_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_03A68F34153EEF2BC6C993582EC0FD48" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_604B2B699C19D89521E393582EC0F757" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_03A68F34153EEF2BC6C993582EC0FD48" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_18C747C4DBA60D6AE48A93582EC0DD50" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_03A68F34153EEF2BC6C993582EC0FD48" xlink:to="loc_biib_EisaiMember_18C747C4DBA60D6AE48A93582EC0DD50" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_FB29CD8146A6A876232193582EC05A13" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_526149A3AD8A06D3698493582EBFD06E" xlink:to="loc_biib_FacilityLocationAxis_FB29CD8146A6A876232193582EC05A13" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_1CD8E2999E95A83BAC0C93582EC0204D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_FB29CD8146A6A876232193582EC05A13" xlink:to="loc_biib_FacilityLocationDomain_1CD8E2999E95A83BAC0C93582EC0204D_default" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_1CD8E2999E95A83BAC0C93582EC0204D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_FB29CD8146A6A876232193582EC05A13" xlink:to="loc_biib_FacilityLocationDomain_1CD8E2999E95A83BAC0C93582EC0204D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_653BCD04F283A92AF96893582EC05621" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_1CD8E2999E95A83BAC0C93582EC0204D" xlink:to="loc_biib_SolothurnMember_653BCD04F283A92AF96893582EC05621" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CambridgeLeasesMember" xlink:label="loc_biib_CambridgeLeasesMember_0F9D636F62E40B76FC2D93582EC0A22B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_1CD8E2999E95A83BAC0C93582EC0204D" xlink:to="loc_biib_CambridgeLeasesMember_0F9D636F62E40B76FC2D93582EC0A22B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_50379A40152691BDA69F93582EC0FC45" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:to="loc_us-gaap_Depreciation_50379A40152691BDA69F93582EC0FC45" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_96C5DC5019D5689310B093582EC0EED1" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:to="loc_us-gaap_InterestCostsCapitalized_96C5DC5019D5689310B093582EC0EED1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_2760805C27537E3F935E93582EC04F73" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_2760805C27537E3F935E93582EC04F73" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_4332A13B17E127473DD6936629FA14AA" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:to="loc_us-gaap_ConstructionInProgressGross_4332A13B17E127473DD6936629FA14AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_E8FA4A619E63B8DA1C8693582EC0AC40" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_E8FA4A619E63B8DA1C8693582EC0AC40" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TermOfLease" xlink:label="loc_biib_TermOfLease_27CF5E8D36D42AA6B9D493582EC1BA5E" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:to="loc_biib_TermOfLease_27CF5E8D36D42AA6B9D493582EC1BA5E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_573043FDF49FC9F474AF93582EC14D0D" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:to="loc_us-gaap_CapitalLeaseObligations_573043FDF49FC9F474AF93582EC14D0D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Chargesrecognizedtovacatebuilding" xlink:label="loc_biib_Chargesrecognizedtovacatebuilding_CF1F1466AA378E4E574293582EC15DA5" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:to="loc_biib_Chargesrecognizedtovacatebuilding_CF1F1466AA378E4E574293582EC15DA5" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5D5E26F77EEAC39FFD2B38A356E2D447" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3B3E4E4C503D9CA450BD38A356E18A04" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5D5E26F77EEAC39FFD2B38A356E2D447" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3B3E4E4C503D9CA450BD38A356E18A04" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_336D62827DE4C50E343C38A356E1FC44" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3B3E4E4C503D9CA450BD38A356E18A04" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_336D62827DE4C50E343C38A356E1FC44" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8EA6F7EC1FB455A4F58938A356E15C7C_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_336D62827DE4C50E343C38A356E1FC44" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8EA6F7EC1FB455A4F58938A356E15C7C_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8EA6F7EC1FB455A4F58938A356E15C7C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_336D62827DE4C50E343C38A356E1FC44" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8EA6F7EC1FB455A4F58938A356E15C7C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_0D2966C5C8A73F89A58F38A356E111A8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8EA6F7EC1FB455A4F58938A356E15C7C" xlink:to="loc_biib_EisaiMember_0D2966C5C8A73F89A58F38A356E111A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F67D6A61CD46EB7F55138A356E2C76B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3B3E4E4C503D9CA450BD38A356E18A04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F67D6A61CD46EB7F55138A356E2C76B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_138DB7B5C6001BC6FD5D38A356E2F9E9_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F67D6A61CD46EB7F55138A356E2C76B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_138DB7B5C6001BC6FD5D38A356E2F9E9_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_138DB7B5C6001BC6FD5D38A356E2F9E9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F67D6A61CD46EB7F55138A356E2C76B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_138DB7B5C6001BC6FD5D38A356E2F9E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_C5ED73E78CACC366017438A356E2887E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_138DB7B5C6001BC6FD5D38A356E2F9E9" xlink:to="loc_us-gaap_BuildingMember_C5ED73E78CACC366017438A356E2887E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_4BE491E57AE73834EEAE38A356E267AB" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_138DB7B5C6001BC6FD5D38A356E2F9E9" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_4BE491E57AE73834EEAE38A356E267AB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_8BAE76D781F1A88E70A538A356E2A46E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_138DB7B5C6001BC6FD5D38A356E2F9E9" xlink:to="loc_us-gaap_LandMember_8BAE76D781F1A88E70A538A356E2A46E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_F471BED0362C729C95BD38A356E2E24D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5D5E26F77EEAC39FFD2B38A356E2D447" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_F471BED0362C729C95BD38A356E2E24D" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="extended">
    <loc xlink:href="biib-20151231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4" xlink:type="locator" />
    <loc xlink:href="biib-20151231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4" xlink:to="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_C9BCCA5614887BE79AEA93582D8E9ABC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F" xlink:to="loc_us-gaap_StatementGeographicalAxis_C9BCCA5614887BE79AEA93582D8E9ABC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_6D719E95E1A6D8BA33F893582D8EBA99_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_C9BCCA5614887BE79AEA93582D8E9ABC" xlink:to="loc_us-gaap_SegmentGeographicalDomain_6D719E95E1A6D8BA33F893582D8EBA99_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_6D719E95E1A6D8BA33F893582D8EBA99" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_C9BCCA5614887BE79AEA93582D8E9ABC" xlink:to="loc_us-gaap_SegmentGeographicalDomain_6D719E95E1A6D8BA33F893582D8EBA99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IT" xlink:label="loc_country_IT_EBB14A246D001B1F915493582D8EDE6D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_6D719E95E1A6D8BA33F893582D8EBA99" xlink:to="loc_country_IT_EBB14A246D001B1F915493582D8EDE6D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_E66BD1B2C4C2F5FD784893582D8E5CF1" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_E66BD1B2C4C2F5FD784893582D8E5CF1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_40EBD9636490F1323CEF93582D8EEB41_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_E66BD1B2C4C2F5FD784893582D8E5CF1" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_40EBD9636490F1323CEF93582D8EEB41_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_40EBD9636490F1323CEF93582D8EEB41" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_E66BD1B2C4C2F5FD784893582D8E5CF1" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_40EBD9636490F1323CEF93582D8EEB41" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_CD6DD8CDA6E45A21F96C93582D8E1A8F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_40EBD9636490F1323CEF93582D8EEB41" xlink:to="loc_biib_NeurimmuneMember_CD6DD8CDA6E45A21F96C93582D8E1A8F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0291529BB1210B62A8B693582D8ECEC3" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0291529BB1210B62A8B693582D8ECEC3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386DB671ECFC303CA27593582D8FF132_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0291529BB1210B62A8B693582D8ECEC3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386DB671ECFC303CA27593582D8FF132_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386DB671ECFC303CA27593582D8FF132" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0291529BB1210B62A8B693582D8ECEC3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386DB671ECFC303CA27593582D8FF132" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AGTCMember" xlink:label="loc_biib_AGTCMember_B48193D647AD3D5A7D1593582D8FDE14" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386DB671ECFC303CA27593582D8FF132" xlink:to="loc_biib_AGTCMember_B48193D647AD3D5A7D1593582D8FDE14" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MitsubishiTanabePharmaCorporationMember" xlink:label="loc_biib_MitsubishiTanabePharmaCorporationMember_7941860A9B32CF4299F093582D8F5B73" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386DB671ECFC303CA27593582D8FF132" xlink:to="loc_biib_MitsubishiTanabePharmaCorporationMember_7941860A9B32CF4299F093582D8F5B73" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_72D93DF27F2045653BB993582D8F3A17" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386DB671ECFC303CA27593582D8FF132" xlink:to="loc_biib_EisaiMember_72D93DF27F2045653BB993582D8F3A17" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0982A2008736AE2F497A93582D8F3304" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0982A2008736AE2F497A93582D8F3304" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_93C44E2EF15B0D6F10A193582D8F5120" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_93C44E2EF15B0D6F10A193582D8F5120" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_4C6FDBBFDB4990C670C093582D8F8B57" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4" xlink:to="loc_us-gaap_RestructuringCharges_4C6FDBBFDB4990C670C093582D8F8B57" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_7BD2FD44548E7769BF6393582D8F1D6F" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_7BD2FD44548E7769BF6393582D8F1D6F" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_D0D228F95C32351A1526A34B6AB86200" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4793816C3B7775B0D6ECA34B6AB886B4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_D0D228F95C32351A1526A34B6AB86200" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4793816C3B7775B0D6ECA34B6AB886B4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_58A37B23AFBEB876F54BA34B6AB86DDF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4793816C3B7775B0D6ECA34B6AB886B4" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_58A37B23AFBEB876F54BA34B6AB86DDF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_FC9038997F7E17DB835AA34B6AB86FBC_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_58A37B23AFBEB876F54BA34B6AB86DDF" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_FC9038997F7E17DB835AA34B6AB86FBC_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_FC9038997F7E17DB835AA34B6AB86FBC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_58A37B23AFBEB876F54BA34B6AB86DDF" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_FC9038997F7E17DB835AA34B6AB86FBC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_6D6CEBFF9E17820C928EA34B6AB8677A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_FC9038997F7E17DB835AA34B6AB86FBC" xlink:to="loc_us-gaap_EmployeeSeveranceMember_6D6CEBFF9E17820C928EA34B6AB8677A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_AACDEB13A404D3499DD1A34B6AB86691" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_FC9038997F7E17DB835AA34B6AB86FBC" xlink:to="loc_us-gaap_ContractTerminationMember_AACDEB13A404D3499DD1A34B6AB86691" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_403A5AC5D36027E1FC56A34B6AB82CE9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_D0D228F95C32351A1526A34B6AB86200" xlink:to="loc_us-gaap_RestructuringCharges_403A5AC5D36027E1FC56A34B6AB82CE9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment_8D70FC9AFF553E31F148A34B6AB8E3A6" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_D0D228F95C32351A1526A34B6AB86200" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment_8D70FC9AFF553E31F148A34B6AB8E3A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_24842824D18CF28086C3A34B6AB90DFB" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_D0D228F95C32351A1526A34B6AB86200" xlink:to="loc_us-gaap_PaymentsForRestructuring_24842824D18CF28086C3A34B6AB90DFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_83ADDA779D2D596CCC80A34B6AB92AD9" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_D0D228F95C32351A1526A34B6AB86200" xlink:to="loc_us-gaap_RestructuringReserve_83ADDA779D2D596CCC80A34B6AB92AD9" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9BE33509E755ABE8F0BA93582F4699DE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9BE33509E755ABE8F0BA93582F4699DE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_609773673EE18F66158593582F462080" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9BE33509E755ABE8F0BA93582F4699DE" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_609773673EE18F66158593582F462080" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1E36BCB41A357200179593582F46BFF8_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_609773673EE18F66158593582F462080" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1E36BCB41A357200179593582F46BFF8_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1E36BCB41A357200179593582F46BFF8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_609773673EE18F66158593582F462080" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1E36BCB41A357200179593582F46BFF8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_D2972B22204C90579FFA93582F46BD6A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1E36BCB41A357200179593582F46BFF8" xlink:to="loc_us-gaap_EmployeeSeveranceMember_D2972B22204C90579FFA93582F46BD6A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_6FCAACD5BC492B1364FE93582F46FE6C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1E36BCB41A357200179593582F46BFF8" xlink:to="loc_us-gaap_ContractTerminationMember_6FCAACD5BC492B1364FE93582F46FE6C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated" xlink:label="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_36D6F8AC4923455F7EC993582F461A06" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2" xlink:to="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_36D6F8AC4923455F7EC993582F461A06" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RestructuringandRelatedCostExpectedCashPayments" xlink:label="loc_biib_RestructuringandRelatedCostExpectedCashPayments_4575AF495F5D1800146C93582F466615" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2" xlink:to="loc_biib_RestructuringandRelatedCostExpectedCashPayments_4575AF495F5D1800146C93582F466615" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment_5997A996DD1B835C326993582F467471" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment_5997A996DD1B835C326993582F467471" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_F342CD5793A41DDC243393582F478DA5" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_F342CD5793A41DDC243393582F478DA5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_EFE58B1659EFBA5A79CB93582F4755B0" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2" xlink:to="loc_us-gaap_RestructuringCharges_EFE58B1659EFBA5A79CB93582F4755B0" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/RevenueReserves" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/RevenueReservesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_54B09DAD77CB1B68BDCC38A353FA8B23" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_4A82E3FAF26B9C2426AA38A353FA2915" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_54B09DAD77CB1B68BDCC38A353FA8B23" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_4A82E3FAF26B9C2426AA38A353FA2915" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_D63BD7385AC0963A5CF438A353FA98D9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_4A82E3FAF26B9C2426AA38A353FA2915" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_D63BD7385AC0963A5CF438A353FA98D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_391120911795C250B1AB38A353FA9369_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_D63BD7385AC0963A5CF438A353FA98D9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_391120911795C250B1AB38A353FA9369_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_391120911795C250B1AB38A353FA9369" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_D63BD7385AC0963A5CF438A353FA98D9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_391120911795C250B1AB38A353FA9369" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_9B39ED37AD49D9E3576E38A353FA262F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_391120911795C250B1AB38A353FA9369" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_9B39ED37AD49D9E3576E38A353FA262F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_2E81D210CC743515AB0738A353FA56E9" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_391120911795C250B1AB38A353FA9369" xlink:to="loc_biib_ContractualAdjustmentsMember_2E81D210CC743515AB0738A353FA56E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_01521B5C408E1FB9D9AE38A353FA74BE" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_391120911795C250B1AB38A353FA9369" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_01521B5C408E1FB9D9AE38A353FA74BE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_54B09DAD77CB1B68BDCC38A353FA8B23" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_A147B12175580DE2D9E338A353FB4288" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_A147B12175580DE2D9E338A353FB4288" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_598CD8A6A3AF9491FA9C38A353FBF800" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_598CD8A6A3AF9491FA9C38A353FBF800" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_7D00426613B4B1CD174538A353FB7C9F" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_7D00426613B4B1CD174538A353FB7C9F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_3E28DF57E223BD46E27A38A353FBAEB4" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_3E28DF57E223BD46E27A38A353FBAEB4" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_28A04DE65941BC15A7F638A353FB4373" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_28A04DE65941BC15A7F638A353FB4373" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/RevenueReservesDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_F6554C06906DA44A828038A35231C877" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_25EC4D3ED1308FF50F2A38A352302AA4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_F6554C06906DA44A828038A35231C877" xlink:to="loc_us-gaap_StatementTable_25EC4D3ED1308FF50F2A38A352302AA4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_FB22A40FE463D17A446C38A352309989" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_25EC4D3ED1308FF50F2A38A352302AA4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_FB22A40FE463D17A446C38A352309989" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7D5F37C75F539828EA6E38A3523078A3_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_FB22A40FE463D17A446C38A352309989" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7D5F37C75F539828EA6E38A3523078A3_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7D5F37C75F539828EA6E38A3523078A3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_FB22A40FE463D17A446C38A352309989" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7D5F37C75F539828EA6E38A3523078A3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_E579D86953A3E58406EC38A352318966" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7D5F37C75F539828EA6E38A3523078A3" xlink:to="loc_us-gaap_AccountsReceivableMember_E579D86953A3E58406EC38A352318966" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_6AEE8694837B9CC8E91A38A352317981" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7D5F37C75F539828EA6E38A3523078A3" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_6AEE8694837B9CC8E91A38A352317981" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_41E31A5F12D66E79D11038A35231E128" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_F6554C06906DA44A828038A35231C877" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_41E31A5F12D66E79D11038A35231E128" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/RevenueReservesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_1C649AE38FC47A6ED53B93582DB1C1D7" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_69288E60D2271F348B9B93582DB12F54" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_1C649AE38FC47A6ED53B93582DB1C1D7" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_69288E60D2271F348B9B93582DB12F54" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_E4BD828DD45D0414430593582DB10077" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_69288E60D2271F348B9B93582DB12F54" xlink:to="loc_us-gaap_ProductOrServiceAxis_E4BD828DD45D0414430593582DB10077" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_E4BD828DD45D0414430593582DB10077" xlink:to="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_E4BD828DD45D0414430593582DB10077" xlink:to="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_AA323686622737C15D7993582DB1F6EB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:to="loc_biib_TecfideraMember_AA323686622737C15D7993582DB1F6EB" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_51A775E1F2D69C848B0293BDFED76FA3" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:to="loc_biib_AVONEXMember_51A775E1F2D69C848B0293BDFED76FA3" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PLEGRIDYMember" xlink:label="loc_biib_PLEGRIDYMember_4FF1B60F70EA75C024E593BF1760193D" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:to="loc_biib_PLEGRIDYMember_4FF1B60F70EA75C024E593BF1760193D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TysabriMember" xlink:label="loc_biib_TysabriMember_9E74EB0A8F1143A5102693582DB111AA" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:to="loc_biib_TysabriMember_9E74EB0A8F1143A5102693582DB111AA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_E4159D68FB4AE8AA37FE93582DB17627" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:to="loc_biib_FAMPYRAMember_E4159D68FB4AE8AA37FE93582DB17627" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_C939844255E3DA7EA53C93582DB1250A" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:to="loc_biib_ELOCTATEMember_C939844255E3DA7EA53C93582DB1250A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ALPROLIXProductMember" xlink:label="loc_biib_ALPROLIXProductMember_4B031756E9332D9CBFA993582DB16CB2" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:to="loc_biib_ALPROLIXProductMember_4B031756E9332D9CBFA993582DB16CB2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_2644BCB933B4CD111AF393582DB100DE" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:to="loc_biib_FUMADERMMember_2644BCB933B4CD111AF393582DB100DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0D8B1A8B504FEB2113BC93582DB1F72D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_69288E60D2271F348B9B93582DB12F54" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0D8B1A8B504FEB2113BC93582DB1F72D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_FA29F4DA416A7E8A095B93582DB11FFC_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0D8B1A8B504FEB2113BC93582DB1F72D" xlink:to="loc_us-gaap_SegmentDomain_FA29F4DA416A7E8A095B93582DB11FFC_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_FA29F4DA416A7E8A095B93582DB11FFC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0D8B1A8B504FEB2113BC93582DB1F72D" xlink:to="loc_us-gaap_SegmentDomain_FA29F4DA416A7E8A095B93582DB11FFC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="loc_country_US_ED064019BF23D178BFFB93582DB1DA08" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_FA29F4DA416A7E8A095B93582DB11FFC" xlink:to="loc_country_US_ED064019BF23D178BFFB93582DB1DA08" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RestOfWorldMember" xlink:label="loc_biib_RestOfWorldMember_6104F7C6E215BA8B5F8593582DB1F25C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_FA29F4DA416A7E8A095B93582DB11FFC" xlink:to="loc_biib_RestOfWorldMember_6104F7C6E215BA8B5F8593582DB1F25C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNetAbstract" xlink:label="loc_us-gaap_SalesRevenueGoodsNetAbstract_F0F14FB3439325F9222893582DB271E0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_1C649AE38FC47A6ED53B93582DB1C1D7" xlink:to="loc_us-gaap_SalesRevenueGoodsNetAbstract_F0F14FB3439325F9222893582DB271E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_FC3BACCB842A6E5D605193582DB28ADD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SalesRevenueGoodsNetAbstract_F0F14FB3439325F9222893582DB271E0" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_FC3BACCB842A6E5D605193582DB28ADD" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_AAC54936E48FB1EA8CDC38A3526AEAA8" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_41189C1D1B76EC0A46E438A3526A6553" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_AAC54936E48FB1EA8CDC38A3526AEAA8" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_41189C1D1B76EC0A46E438A3526A6553" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_311969CF7FB375C66B5238A3526A3C62" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_41189C1D1B76EC0A46E438A3526A6553" xlink:to="loc_us-gaap_StatementGeographicalAxis_311969CF7FB375C66B5238A3526A3C62" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_38C3F2E633AC5085F23038A3526A21BB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_311969CF7FB375C66B5238A3526A3C62" xlink:to="loc_us-gaap_SegmentGeographicalDomain_38C3F2E633AC5085F23038A3526A21BB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_38C3F2E633AC5085F23038A3526A21BB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_311969CF7FB375C66B5238A3526A3C62" xlink:to="loc_us-gaap_SegmentGeographicalDomain_38C3F2E633AC5085F23038A3526A21BB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="loc_country_US_583278D6AB2DE841CEFF38A3526A41C7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_38C3F2E633AC5085F23038A3526A21BB" xlink:to="loc_country_US_583278D6AB2DE841CEFF38A3526A41C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_22DA1AF86DCCC1149D0438A3526A5D05" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_38C3F2E633AC5085F23038A3526A21BB" xlink:to="loc_us-gaap_EuropeMember_22DA1AF86DCCC1149D0438A3526A5D05" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_DE" xlink:label="loc_country_DE_BB7ABBF54FFCA885765238A3526ABF89" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_38C3F2E633AC5085F23038A3526A21BB" xlink:to="loc_country_DE_BB7ABBF54FFCA885765238A3526ABF89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AsiaMember" xlink:label="loc_us-gaap_AsiaMember_37EDA8542BEF8885EA7C38A3526A278D" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_38C3F2E633AC5085F23038A3526A21BB" xlink:to="loc_us-gaap_AsiaMember_37EDA8542BEF8885EA7C38A3526A278D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:label="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_78A5D0860C9F0B41068D38A3526AE776" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_38C3F2E633AC5085F23038A3526A21BB" xlink:to="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_78A5D0860C9F0B41068D38A3526AE776" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_354E0164C1BB8CC0F85638A3526AD552" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_AAC54936E48FB1EA8CDC38A3526AEAA8" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_354E0164C1BB8CC0F85638A3526AD552" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_13E3187695FAB6D75BC538A3526ABA23" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_354E0164C1BB8CC0F85638A3526AD552" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_13E3187695FAB6D75BC538A3526ABA23" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RevenuesFromUnconsolidatedJointBusiness" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusiness_F2EB0BEC9C01139352A838A3526BB69A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_354E0164C1BB8CC0F85638A3526AD552" xlink:to="loc_biib_RevenuesFromUnconsolidatedJointBusiness_F2EB0BEC9C01139352A838A3526BB69A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_2082A334E47ECC84D18A38A3526B420A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_354E0164C1BB8CC0F85638A3526AD552" xlink:to="loc_us-gaap_OtherSalesRevenueNet_2082A334E47ECC84D18A38A3526B420A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_4270173758342207655B38A3526B85F2" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_354E0164C1BB8CC0F85638A3526AD552" xlink:to="loc_us-gaap_NoncurrentAssets_4270173758342207655B38A3526B85F2" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_EFCF28BE687BE3AEA68F38A3565ADC02" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_F3A7F53566CAABF32CC338A3565ABC80" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_EFCF28BE687BE3AEA68F38A3565ADC02" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_F3A7F53566CAABF32CC338A3565ABC80" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_E956AC05C35633591A1438A3565AC747" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_F3A7F53566CAABF32CC338A3565ABC80" xlink:to="loc_us-gaap_StatementGeographicalAxis_E956AC05C35633591A1438A3565AC747" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_81706E1B9664BF36C56838A3565A2D15_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_E956AC05C35633591A1438A3565AC747" xlink:to="loc_us-gaap_SegmentGeographicalDomain_81706E1B9664BF36C56838A3565A2D15_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_81706E1B9664BF36C56838A3565A2D15" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_E956AC05C35633591A1438A3565AC747" xlink:to="loc_us-gaap_SegmentGeographicalDomain_81706E1B9664BF36C56838A3565A2D15" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_DK" xlink:label="loc_country_DK_5E7BC962BE53087A9B5A38A3565AA832" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_81706E1B9664BF36C56838A3565A2D15" xlink:to="loc_country_DK_5E7BC962BE53087A9B5A38A3565AA832" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_00507505375E9ADAC02E38A3565A9BAF" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_F3A7F53566CAABF32CC338A3565ABC80" xlink:to="loc_biib_MajorDistributorAxis_00507505375E9ADAC02E38A3565A9BAF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_9A07EE8DA25FE78A384738A3565A5067_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_MajorDistributorAxis_00507505375E9ADAC02E38A3565A9BAF" xlink:to="loc_biib_MajorDistributorDomain_9A07EE8DA25FE78A384738A3565A5067_default" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_9A07EE8DA25FE78A384738A3565A5067" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_MajorDistributorAxis_00507505375E9ADAC02E38A3565A9BAF" xlink:to="loc_biib_MajorDistributorDomain_9A07EE8DA25FE78A384738A3565A5067" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_5AD69CCFD0D67FE4E3DF38A3565A54FD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MajorDistributorDomain_9A07EE8DA25FE78A384738A3565A5067" xlink:to="loc_biib_DistributorOneMember_5AD69CCFD0D67FE4E3DF38A3565A54FD" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_EF1B70F2C2B319385F2838A3565A0282" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MajorDistributorDomain_9A07EE8DA25FE78A384738A3565A5067" xlink:to="loc_biib_DistributorTwoMember_EF1B70F2C2B319385F2838A3565A0282" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RevenuesInPercentageFromUnconsolidatedJointBusiness" xlink:label="loc_biib_RevenuesInPercentageFromUnconsolidatedJointBusiness_55E7AC59066BF8A147BC38A3565A0207" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_EFCF28BE687BE3AEA68F38A3565ADC02" xlink:to="loc_biib_RevenuesInPercentageFromUnconsolidatedJointBusiness_55E7AC59066BF8A147BC38A3565A0207" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D5EC9ED7E6822D2ABBF238A3565A66E0" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_EFCF28BE687BE3AEA68F38A3565ADC02" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D5EC9ED7E6822D2ABBF238A3565A66E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_33051466D157CF1100BE38A3565A596F" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_EFCF28BE687BE3AEA68F38A3565ADC02" xlink:to="loc_us-gaap_NoncurrentAssets_33051466D157CF1100BE38A3565A596F" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CB93F131642F96A37C8C93D5C9F6BBAD" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A3200CB417915E39AC4193D5C9F54B54" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CB93F131642F96A37C8C93D5C9F6BBAD" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A3200CB417915E39AC4193D5C9F54B54" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8D19CD154CC2BC16542C93D5C9F594D6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A3200CB417915E39AC4193D5C9F54B54" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8D19CD154CC2BC16542C93D5C9F594D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1631EB288E4E0F0D45BB93D5C9F585CC_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8D19CD154CC2BC16542C93D5C9F594D6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1631EB288E4E0F0D45BB93D5C9F585CC_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1631EB288E4E0F0D45BB93D5C9F585CC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8D19CD154CC2BC16542C93D5C9F594D6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1631EB288E4E0F0D45BB93D5C9F585CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_83FBAD2106C8946A03CF93D5C9F69F16" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1631EB288E4E0F0D45BB93D5C9F585CC" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_83FBAD2106C8946A03CF93D5C9F69F16" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4A50D7796B3A3D60369A93D5C9F65EB1" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1631EB288E4E0F0D45BB93D5C9F585CC" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4A50D7796B3A3D60369A93D5C9F65EB1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_0EC24D24F01A41296D6393D5C9F6F696" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1631EB288E4E0F0D45BB93D5C9F585CC" xlink:to="loc_us-gaap_RestructuringChargesMember_0EC24D24F01A41296D6393D5C9F6F696" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_D31ED573CC1379AE2E6793D5C9F6B956" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1631EB288E4E0F0D45BB93D5C9F585CC" xlink:to="loc_us-gaap_ParentMember_D31ED573CC1379AE2E6793D5C9F6B956" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CB93F131642F96A37C8C93D5C9F6BBAD" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_E7FED733DC3A15639D6293D5C9F61454" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_E7FED733DC3A15639D6293D5C9F61454" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4FF3132759B6BE9EDA1C93D5C9F60A6E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4FF3132759B6BE9EDA1C93D5C9F60A6E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_A21069CFFFA1F1609C8C93D5C9F6B956" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_A21069CFFFA1F1609C8C93D5C9F6B956" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_5D606F6D385779F6C91F93D5C9F6313F" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_5D606F6D385779F6C91F93D5C9F6313F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_17E570DCFB9764669A0893D5C9F6209F" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_17E570DCFB9764669A0893D5C9F6209F" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_DDBA53D56B3C9E0B722E38A351C42815" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A1260F14EA75B6FC484738A351C3902A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_DDBA53D56B3C9E0B722E38A351C42815" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A1260F14EA75B6FC484738A351C3902A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D62D6EECD38B98DB398D38A351C33F43" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A1260F14EA75B6FC484738A351C3902A" xlink:to="loc_us-gaap_PlanNameAxis_D62D6EECD38B98DB398D38A351C33F43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_D62D6EECD38B98DB398D38A351C33F43" xlink:to="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_D62D6EECD38B98DB398D38A351C33F43" xlink:to="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5FB678B51102E88068F138A351C43F1A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5FB678B51102E88068F138A351C43F1A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_47C8FB953AAFDF7742FB38A351C4910E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:to="loc_biib_MarketStockUnitsMember_47C8FB953AAFDF7742FB38A351C4910E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_60E4AEE4672C29A51E9B38A351C4099C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_60E4AEE4672C29A51E9B38A351C4099C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_9B089081790B1CE751F338A351C4E383" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:to="loc_biib_CashSettledPerformanceSharesMember_9B089081790B1CE751F338A351C4E383" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_7D8B76DBC0E4EAFCF18638A351C49BAF" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:to="loc_us-gaap_PerformanceSharesMember_7D8B76DBC0E4EAFCF18638A351C49BAF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_3708315C2599A53C59E338A351C41D8D" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_3708315C2599A53C59E338A351C41D8D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_DDBA53D56B3C9E0B722E38A351C42815" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7223C27190003AE1DAE138A351C40567" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7223C27190003AE1DAE138A351C40567" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_166B2321EEC6FA7D93A638A351C445C7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_166B2321EEC6FA7D93A638A351C445C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_B75367DC93997B4D31F438A351C47ED8" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_B75367DC93997B4D31F438A351C47ED8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1541A7E48B0D186FA5EA38A351C42A33" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1541A7E48B0D186FA5EA38A351C42A33" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B56BCEE5AC256ABAA97E38A3534B9F13" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BE9ECD4F99F22768B6F38A3534AF239" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B56BCEE5AC256ABAA97E38A3534B9F13" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BE9ECD4F99F22768B6F38A3534AF239" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5734004D80954E4494DB38A3534B51B9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BE9ECD4F99F22768B6F38A3534AF239" xlink:to="loc_us-gaap_AwardTypeAxis_5734004D80954E4494DB38A3534B51B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5FA16734B2850DF100E938A3534BF2C1_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5734004D80954E4494DB38A3534B51B9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5FA16734B2850DF100E938A3534BF2C1_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5FA16734B2850DF100E938A3534BF2C1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5734004D80954E4494DB38A3534B51B9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5FA16734B2850DF100E938A3534BF2C1" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_F7AA432E10402D1CC16738A3534B8D5F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5FA16734B2850DF100E938A3534BF2C1" xlink:to="loc_biib_MarketStockUnitsMember_F7AA432E10402D1CC16738A3534B8D5F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MarketStockUnitsActivityAbstract" xlink:label="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B56BCEE5AC256ABAA97E38A3534B9F13" xlink:to="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_42665CAE190FBEDAE6D538A3534BA65F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_42665CAE190FBEDAE6D538A3534BA65F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55F6DF417BE4B009718238A3534BA6FB" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55F6DF417BE4B009718238A3534BA6FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_238769352ABA1FBB41E338A3534BBCC6" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_238769352ABA1FBB41E338A3534BBCC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_659CF0CEEDAE07E529F038A3534BA9A8" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_659CF0CEEDAE07E529F038A3534BA9A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5E13630B2D751574DA8B38A3534B9FF8" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5E13630B2D751574DA8B38A3534B9FF8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9868E37B9AF59CAA3AF538A3534B6E47" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9868E37B9AF59CAA3AF538A3534B6E47" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6ECF9E36B3754DF6EB7C38A3534BAFB9" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6ECF9E36B3754DF6EB7C38A3534BAFB9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E0FE6EB810CF938AEC9F38A3534B3DA7" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E0FE6EB810CF938AEC9F38A3534B3DA7" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5F92934CDBECD2F9C64C93D5C9E14F20" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6F072C14B4E6B655C7AE93D5C9E1A820" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5F92934CDBECD2F9C64C93D5C9E14F20" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6F072C14B4E6B655C7AE93D5C9E1A820" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4646B8E800F75C5057C093D5C9E11548" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6F072C14B4E6B655C7AE93D5C9E1A820" xlink:to="loc_us-gaap_AwardTypeAxis_4646B8E800F75C5057C093D5C9E11548" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E4E07DE9E60B90A723593D5C9E18AB3_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4646B8E800F75C5057C093D5C9E11548" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E4E07DE9E60B90A723593D5C9E18AB3_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E4E07DE9E60B90A723593D5C9E18AB3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4646B8E800F75C5057C093D5C9E11548" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E4E07DE9E60B90A723593D5C9E18AB3" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_A9C3B692A59FE7947DAD93D5C9E14B6F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E4E07DE9E60B90A723593D5C9E18AB3" xlink:to="loc_biib_MarketStockUnitsMember_A9C3B692A59FE7947DAD93D5C9E14B6F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_0618DEEF8496D620823393D5C9E1931A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6F072C14B4E6B655C7AE93D5C9E1A820" xlink:to="loc_us-gaap_RangeAxis_0618DEEF8496D620823393D5C9E1931A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F998FCEF3B2980031D9993D5C9E1BBE6_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_0618DEEF8496D620823393D5C9E1931A" xlink:to="loc_us-gaap_RangeMember_F998FCEF3B2980031D9993D5C9E1BBE6_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F998FCEF3B2980031D9993D5C9E1BBE6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_0618DEEF8496D620823393D5C9E1931A" xlink:to="loc_us-gaap_RangeMember_F998FCEF3B2980031D9993D5C9E1BBE6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_E0820DB682165630461C93D5C9E116D7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F998FCEF3B2980031D9993D5C9E1BBE6" xlink:to="loc_us-gaap_MinimumMember_E0820DB682165630461C93D5C9E116D7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_E3FD526013C6FD21D34793D5C9E19420" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F998FCEF3B2980031D9993D5C9E1BBE6" xlink:to="loc_us-gaap_MaximumMember_E3FD526013C6FD21D34793D5C9E19420" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ValuationOfGrantedStockUnitsAbstract" xlink:label="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5F92934CDBECD2F9C64C93D5C9E14F20" xlink:to="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_98FA3713CB727EDBB9EE93D5C9E1707A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_98FA3713CB727EDBB9EE93D5C9E1707A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_C0B74D6A2907A7BEA38093D5C9E15A2A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_C0B74D6A2907A7BEA38093D5C9E15A2A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9270EAF2B76108E47E8C93D5C9E10421" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9270EAF2B76108E47E8C93D5C9E10421" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8CE6724163294A70034E93D5C9E15626" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8CE6724163294A70034E93D5C9E15626" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_B5A4A55E29F678A7735293D5C9E1359A" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_B5A4A55E29F678A7735293D5C9E1359A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_9F2EBAFAD48B0C56739193D5C9E17280" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_9F2EBAFAD48B0C56739193D5C9E17280" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2AA64739946C70DB114393D5C9E2EF6C" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2AA64739946C70DB114393D5C9E2EF6C" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E8652754D1C974B2E2AF38A3556C6FD0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_413BFD79D095683FAD3E38A3556C5795" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E8652754D1C974B2E2AF38A3556C6FD0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_413BFD79D095683FAD3E38A3556C5795" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B8875B37C21458C1430438A3556C2AAF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_413BFD79D095683FAD3E38A3556C5795" xlink:to="loc_us-gaap_AwardTypeAxis_B8875B37C21458C1430438A3556C2AAF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0A07D03EA37D677884BF38A3556C6667_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_B8875B37C21458C1430438A3556C2AAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0A07D03EA37D677884BF38A3556C6667_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0A07D03EA37D677884BF38A3556C6667" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_B8875B37C21458C1430438A3556C2AAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0A07D03EA37D677884BF38A3556C6667" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_C046B76FB400E76AC39E38A3556C91BA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0A07D03EA37D677884BF38A3556C6667" xlink:to="loc_biib_CashSettledPerformanceSharesMember_C046B76FB400E76AC39E38A3556C91BA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CashSettledPerformanceSharesAbstract" xlink:label="loc_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E8652754D1C974B2E2AF38A3556C6FD0" xlink:to="loc_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64F6BE16BF74B554900338A3556D80C1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64F6BE16BF74B554900338A3556D80C1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17D4B97A6D6C18A618FD38A3556DFDFC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17D4B97A6D6C18A618FD38A3556DFDFC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_AD5E5843647D156230CE38A3556D13FA" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_AD5E5843647D156230CE38A3556D13FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6B5AAE4E80BE17FDE6DD38A3556D823E" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6B5AAE4E80BE17FDE6DD38A3556D823E" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A3CD57A145C20D0736C438A3524BE4F4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1897B6E0300D4C20A7BB38A3524A9159" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A3CD57A145C20D0736C438A3524BE4F4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1897B6E0300D4C20A7BB38A3524A9159" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_59E0525AD706CEB260BD38A3524B7F42" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1897B6E0300D4C20A7BB38A3524A9159" xlink:to="loc_us-gaap_AwardTypeAxis_59E0525AD706CEB260BD38A3524B7F42" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8C0A09213216E1AB6E7438A3524B468F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_59E0525AD706CEB260BD38A3524B7F42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8C0A09213216E1AB6E7438A3524B468F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8C0A09213216E1AB6E7438A3524B468F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_59E0525AD706CEB260BD38A3524B7F42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8C0A09213216E1AB6E7438A3524B468F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_4A05EAD367A6A271607B38A3524BFEF4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8C0A09213216E1AB6E7438A3524B468F" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_4A05EAD367A6A271607B38A3524BFEF4" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RestrictedStockUnitsActivityAbstract" xlink:label="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A3CD57A145C20D0736C438A3524BE4F4" xlink:to="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6D7B6A169ABDF8D8F7D038A3524B74CE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6D7B6A169ABDF8D8F7D038A3524B74CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8161A1F63DB5C454795C38A3524B1BE2" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8161A1F63DB5C454795C38A3524B1BE2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2BC356A55B151B1810F838A3524B28E1" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2BC356A55B151B1810F838A3524B28E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8D47E8E0566C2AE700DE38A3524B62C2" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8D47E8E0566C2AE700DE38A3524B62C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_34C8CE9B59A99EF230E538A3524B445C" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_34C8CE9B59A99EF230E538A3524B445C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B9A9B37B33E9939DECB238A3524B5F72" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B9A9B37B33E9939DECB238A3524B5F72" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3FE41D41256140F5B38F38A3524B6B25" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3FE41D41256140F5B38F38A3524B6B25" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_80095C700D997D1936B038A3524B20A8" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_80095C700D997D1936B038A3524B20A8" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_F1F2DFF925DD78279ABB38A3553E6A73" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_06DA34F5BA55FD26713C38A3553EE0D6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_F1F2DFF925DD78279ABB38A3553E6A73" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_06DA34F5BA55FD26713C38A3553EE0D6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_61F0B20E9C75EB6848DB38A3553E4689" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_06DA34F5BA55FD26713C38A3553EE0D6" xlink:to="loc_us-gaap_PlanNameAxis_61F0B20E9C75EB6848DB38A3553E4689" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_057C8AD5FD561AA629E338A3553E4247_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_61F0B20E9C75EB6848DB38A3553E4689" xlink:to="loc_us-gaap_PlanNameDomain_057C8AD5FD561AA629E338A3553E4247_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_057C8AD5FD561AA629E338A3553E4247" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_61F0B20E9C75EB6848DB38A3553E4689" xlink:to="loc_us-gaap_PlanNameDomain_057C8AD5FD561AA629E338A3553E4247" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_2F37A9AA31DCE4F00E7238A3553E5983" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_057C8AD5FD561AA629E338A3553E4247" xlink:to="loc_biib_A2015ESPPMember_2F37A9AA31DCE4F00E7238A3553E5983" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_A1995ESPPMember" xlink:label="loc_biib_A1995ESPPMember_50181B306D5DD784FDB938A3553ED876" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_057C8AD5FD561AA629E338A3553E4247" xlink:to="loc_biib_A1995ESPPMember_50181B306D5DD784FDB938A3553ED876" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_29FD4852B22FC9A7A0DE38A3553E5ED0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_F1F2DFF925DD78279ABB38A3553E6A73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_29FD4852B22FC9A7A0DE38A3553E5ED0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E14C1F0C38DEF3E95CAD38A3553E388F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_F1F2DFF925DD78279ABB38A3553E6A73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E14C1F0C38DEF3E95CAD38A3553E388F" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98E427C7314B6526C91B98B5C4EA7F3A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98E427C7314B6526C91B98B5C4EA7F3A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_40E8C87B70D34F424B0198B5C4EBBA46" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98E427C7314B6526C91B98B5C4EA7F3A" xlink:to="loc_us-gaap_VestingAxis_40E8C87B70D34F424B0198B5C4EBBA46" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_13260DB5A6AF6849214F98B5C4EBD1D1_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_40E8C87B70D34F424B0198B5C4EBBA46" xlink:to="loc_us-gaap_VestingDomain_13260DB5A6AF6849214F98B5C4EBD1D1_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_13260DB5A6AF6849214F98B5C4EBD1D1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_40E8C87B70D34F424B0198B5C4EBBA46" xlink:to="loc_us-gaap_VestingDomain_13260DB5A6AF6849214F98B5C4EBD1D1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_D42223038A32C35DD0E198B5C4EBBD43" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_13260DB5A6AF6849214F98B5C4EBD1D1" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_D42223038A32C35DD0E198B5C4EBBD43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_41167DC81BCD8DB47F6998B5C4EC6B0D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98E427C7314B6526C91B98B5C4EA7F3A" xlink:to="loc_us-gaap_TitleOfIndividualAxis_41167DC81BCD8DB47F6998B5C4EC6B0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_DFE56EFFA4168C169F0698B5C4ECD2D6_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_41167DC81BCD8DB47F6998B5C4EC6B0D" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_DFE56EFFA4168C169F0698B5C4ECD2D6_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_DFE56EFFA4168C169F0698B5C4ECD2D6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_41167DC81BCD8DB47F6998B5C4EC6B0D" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_DFE56EFFA4168C169F0698B5C4ECD2D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_BA32105F96DE220C366598B5C4ECA349" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_DFE56EFFA4168C169F0698B5C4ECD2D6" xlink:to="loc_us-gaap_DirectorMember_BA32105F96DE220C366598B5C4ECA349" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ShareBasedCompensationPlanAxis" xlink:label="loc_biib_ShareBasedCompensationPlanAxis_4063594AD7691594A39498B5C4EC7522" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98E427C7314B6526C91B98B5C4EA7F3A" xlink:to="loc_biib_ShareBasedCompensationPlanAxis_4063594AD7691594A39498B5C4EC7522" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ShareBasedCompensationPlanDomain" xlink:label="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ShareBasedCompensationPlanAxis_4063594AD7691594A39498B5C4EC7522" xlink:to="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49_default" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ShareBasedCompensationPlanDomain" xlink:label="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ShareBasedCompensationPlanAxis_4063594AD7691594A39498B5C4EC7522" xlink:to="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DirectorsPlanMember" xlink:label="loc_biib_DirectorsPlanMember_A3EE5948A54486A74ECF98B5C4EC55DA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:to="loc_biib_DirectorsPlanMember_A3EE5948A54486A74ECF98B5C4EC55DA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_OmnibusPlansMember" xlink:label="loc_biib_OmnibusPlansMember_4DEFADDA318BD6DB40B098B5C4EDB1C7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:to="loc_biib_OmnibusPlansMember_4DEFADDA318BD6DB40B098B5C4EDB1C7" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AttainmentOfPerformanceCriteriain2014Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2014Member_159C56D155D476E1AB1398B5C4ED79D9" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:to="loc_biib_AttainmentOfPerformanceCriteriain2014Member_159C56D155D476E1AB1398B5C4ED79D9" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AttainmentOfPerformanceCriteriain2013Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2013Member_FD04B19BDA389B0E466398B5C4EDF891" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:to="loc_biib_AttainmentOfPerformanceCriteriain2013Member_FD04B19BDA389B0E466398B5C4EDF891" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AttainmentOfPerformanceCriteriain2012Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2012Member_EDEA18D7F463F31C5E9B98B5C4EDACEC" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:to="loc_biib_AttainmentOfPerformanceCriteriain2012Member_EDEA18D7F463F31C5E9B98B5C4EDACEC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AttainmentOfPerformanceCriteriain2011Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2011Member_1ADE04A9800A9514912B98B5C4EDD51D" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:to="loc_biib_AttainmentOfPerformanceCriteriain2011Member_1ADE04A9800A9514912B98B5C4EDD51D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E91EEEBCAE1706E488B498B5C4EDF6CC" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98E427C7314B6526C91B98B5C4EA7F3A" xlink:to="loc_us-gaap_AwardTypeAxis_E91EEEBCAE1706E488B498B5C4EDF6CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08CA3F9AB21918A8179098B5C4EDCAC6_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_E91EEEBCAE1706E488B498B5C4EDF6CC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08CA3F9AB21918A8179098B5C4EDCAC6_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08CA3F9AB21918A8179098B5C4EDCAC6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_E91EEEBCAE1706E488B498B5C4EDF6CC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08CA3F9AB21918A8179098B5C4EDCAC6" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_191DD044B4A36E54C5D898B5C4ED9AFC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08CA3F9AB21918A8179098B5C4EDCAC6" xlink:to="loc_biib_MarketStockUnitsMember_191DD044B4A36E54C5D898B5C4ED9AFC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_992B527D01AE4C4F8C4E98B5C4ED6301" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08CA3F9AB21918A8179098B5C4EDCAC6" xlink:to="loc_biib_CashSettledPerformanceSharesMember_992B527D01AE4C4F8C4E98B5C4ED6301" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_D04701A8F3E67C2FC84B98B5C4EDDD87" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08CA3F9AB21918A8179098B5C4EDCAC6" xlink:to="loc_us-gaap_PerformanceSharesMember_D04701A8F3E67C2FC84B98B5C4EDDD87" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_4FD05C4E37D1A693148498B5C4EE526F" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08CA3F9AB21918A8179098B5C4EDCAC6" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_4FD05C4E37D1A693148498B5C4EE526F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NumberOfSharesOfCommonStockForIssuance" xlink:label="loc_biib_NumberOfSharesOfCommonStockForIssuance_2B0DF2A4D268F276B56198B5C4EEC811" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_biib_NumberOfSharesOfCommonStockForIssuance_2B0DF2A4D268F276B56198B5C4EEC811" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_597416A45ACED01D19E098B5C4EE28E8" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_597416A45ACED01D19E098B5C4EE28E8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NumberOfEqualAnnualIncrements" xlink:label="loc_biib_NumberOfEqualAnnualIncrements_B9A834D8514C3AE51A7998B5C4EEB50B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_biib_NumberOfEqualAnnualIncrements_B9A834D8514C3AE51A7998B5C4EEB50B" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_8258BA110B8D8B04771798B5C4EE0DAE" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_8258BA110B8D8B04771798B5C4EE0DAE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_E5BEAF446BB760BEDF6598B5C4EE3FBF" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_E5BEAF446BB760BEDF6598B5C4EE3FBF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3D581C856263EF9AA89598B5C4EE478F" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3D581C856263EF9AA89598B5C4EE478F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards" xlink:label="loc_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_83EEACD96D8765AC10D898B5C4EED193" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_83EEACD96D8765AC10D898B5C4EED193" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_10B5CF33AA88725F456F98B5C4EED138" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_10B5CF33AA88725F456F98B5C4EED138" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_E94502BB5C80D2F277FE98B5C4EF806D" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_E94502BB5C80D2F277FE98B5C4EF806D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_EDB9D6FB8745EEB108DA98B5C4EF9473" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_EDB9D6FB8745EEB108DA98B5C4EF9473" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6A9F40DE69AF084A27698B5C4EF1576" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6A9F40DE69AF084A27698B5C4EF1576" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7F41815A59F143F8271398B5C4EF2D52" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7F41815A59F143F8271398B5C4EF2D52" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C9E22B40D2ADEE8BB4BB38A35154A97C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932C68CAA782F08C66EE38A351549FD9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C9E22B40D2ADEE8BB4BB38A35154A97C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932C68CAA782F08C66EE38A351549FD9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D5D8B9FFCA6354DF295038A35154763A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932C68CAA782F08C66EE38A351549FD9" xlink:to="loc_us-gaap_AwardTypeAxis_D5D8B9FFCA6354DF295038A35154763A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_228D3EE77ED713BCC6F838A35154F445_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_D5D8B9FFCA6354DF295038A35154763A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_228D3EE77ED713BCC6F838A35154F445_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_228D3EE77ED713BCC6F838A35154F445" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_D5D8B9FFCA6354DF295038A35154763A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_228D3EE77ED713BCC6F838A35154F445" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_0E29942217448DF67B7538A351548072" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_228D3EE77ED713BCC6F838A35154F445" xlink:to="loc_us-gaap_PerformanceSharesMember_0E29942217448DF67B7538A351548072" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5F8E4546BD0D78A908B438A35154DFA9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C9E22B40D2ADEE8BB4BB38A35154A97C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5F8E4546BD0D78A908B438A35154DFA9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_47110D444F01E346372D38A35154C7A5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C9E22B40D2ADEE8BB4BB38A35154A97C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_47110D444F01E346372D38A35154C7A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_81819268573DF887430D38A351541C6B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C9E22B40D2ADEE8BB4BB38A35154A97C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_81819268573DF887430D38A351541C6B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8B55A0CC777ADA4C928038A351549415" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C9E22B40D2ADEE8BB4BB38A35154A97C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8B55A0CC777ADA4C928038A351549415" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_46A962654E2245A594B393224D476A77" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B4CCB43E4070121DA97493224D467AD5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_46A962654E2245A594B393224D476A77" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B4CCB43E4070121DA97493224D467AD5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_EF24D297BC275530EFE293224D466DA8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B4CCB43E4070121DA97493224D467AD5" xlink:to="loc_us-gaap_StatementGeographicalAxis_EF24D297BC275530EFE293224D466DA8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_B6E7172E9FB6C9D7012793224D46E44E_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_EF24D297BC275530EFE293224D466DA8" xlink:to="loc_us-gaap_SegmentGeographicalDomain_B6E7172E9FB6C9D7012793224D46E44E_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_B6E7172E9FB6C9D7012793224D46E44E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_EF24D297BC275530EFE293224D466DA8" xlink:to="loc_us-gaap_SegmentGeographicalDomain_B6E7172E9FB6C9D7012793224D46E44E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SpainandPortugalMember" xlink:label="loc_biib_SpainandPortugalMember_7382CD86A808443C9CD093224D468088" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_B6E7172E9FB6C9D7012793224D46E44E" xlink:to="loc_biib_SpainandPortugalMember_7382CD86A808443C9CD093224D468088" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_CF05B3CB6FB3E1AFF4E493224D461A39" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B4CCB43E4070121DA97493224D467AD5" xlink:to="loc_biib_MajorDistributorAxis_CF05B3CB6FB3E1AFF4E493224D461A39" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_D19608FF0747B56D040093224D469412_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_MajorDistributorAxis_CF05B3CB6FB3E1AFF4E493224D461A39" xlink:to="loc_biib_MajorDistributorDomain_D19608FF0747B56D040093224D469412_default" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_D19608FF0747B56D040093224D469412" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_MajorDistributorAxis_CF05B3CB6FB3E1AFF4E493224D461A39" xlink:to="loc_biib_MajorDistributorDomain_D19608FF0747B56D040093224D469412" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_1B9F233B92ECCA027B4893224D46F4D4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MajorDistributorDomain_D19608FF0747B56D040093224D469412" xlink:to="loc_biib_DistributorOneMember_1B9F233B92ECCA027B4893224D46F4D4" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_BE97007B48D86CCBC8C593224D46DDB5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MajorDistributorDomain_D19608FF0747B56D040093224D469412" xlink:to="loc_biib_DistributorTwoMember_BE97007B48D86CCBC8C593224D46DDB5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_3ED29BDE91B0021A2F6493224D472B91" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B4CCB43E4070121DA97493224D467AD5" xlink:to="loc_us-gaap_RangeAxis_3ED29BDE91B0021A2F6493224D472B91" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1D50EB45A40490755A2393224D47B0F8_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_3ED29BDE91B0021A2F6493224D472B91" xlink:to="loc_us-gaap_RangeMember_1D50EB45A40490755A2393224D47B0F8_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1D50EB45A40490755A2393224D47B0F8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_3ED29BDE91B0021A2F6493224D472B91" xlink:to="loc_us-gaap_RangeMember_1D50EB45A40490755A2393224D47B0F8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_DC21457430B0BED56D2593224D477B76" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_1D50EB45A40490755A2393224D47B0F8" xlink:to="loc_us-gaap_MinimumMember_DC21457430B0BED56D2593224D477B76" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_A5452D4CF061D8C7CF0893224D4715E1" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_1D50EB45A40490755A2393224D47B0F8" xlink:to="loc_us-gaap_MaximumMember_A5452D4CF061D8C7CF0893224D4715E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3FAF792965252BA5FD8993224D476AA5" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B4CCB43E4070121DA97493224D467AD5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3FAF792965252BA5FD8993224D476AA5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D80420BD8E99199C49DD93224D47ABCA_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3FAF792965252BA5FD8993224D476AA5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D80420BD8E99199C49DD93224D47ABCA_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D80420BD8E99199C49DD93224D47ABCA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3FAF792965252BA5FD8993224D476AA5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D80420BD8E99199C49DD93224D47ABCA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_F6FC6A92C38C6118E51193224D47BE04" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D80420BD8E99199C49DD93224D47ABCA" xlink:to="loc_us-gaap_BuildingMember_F6FC6A92C38C6118E51193224D47BE04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_592C85B726B8154E5E3893224D47D094" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D80420BD8E99199C49DD93224D47ABCA" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_592C85B726B8154E5E3893224D47D094" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_74A7217FED99D99C460E93224D47991A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D80420BD8E99199C49DD93224D47ABCA" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_74A7217FED99D99C460E93224D47991A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_C77E064D4342DB0D363093224D47B055" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D80420BD8E99199C49DD93224D47ABCA" xlink:to="loc_us-gaap_ComputerEquipmentMember_C77E064D4342DB0D363093224D47B055" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8FDE3AC732279BA4AB8493224D47304D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_46A962654E2245A594B393224D476A77" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8FDE3AC732279BA4AB8493224D47304D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetNoncurrent" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_D86F647C9562E54C0D4E93224D47F020" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_46A962654E2245A594B393224D476A77" xlink:to="loc_us-gaap_AccountsReceivableNetNoncurrent_D86F647C9562E54C0D4E93224D47F020" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:label="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_F58901727424061506FF93224D47386C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_46A962654E2245A594B393224D476A77" xlink:to="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_F58901727424061506FF93224D47386C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4F13D15A1F955C16DAD693224D474E44" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_46A962654E2245A594B393224D476A77" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4F13D15A1F955C16DAD693224D474E44" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>biib-20151231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_346ED35A627C7073473638A3549F4021_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_346ED35A627C7073473638A3549F4021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_346ED35A627C7073473638A3549F4021" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_346ED35A627C7073473638A3549F4021" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_346ED35A627C7073473638A3549F4021" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNetAbstract_DB67E59AA88314167F1938A3549F74B9_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_DB67E59AA88314167F1938A3549F74B9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_DB67E59AA88314167F1938A3549F74B9_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_DB67E59AA88314167F1938A3549F74B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_DB67E59AA88314167F1938A3549F74B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract_DB67E59AA88314167F1938A3549F74B9" xlink:to="lab_us-gaap_InventoryNetAbstract_DB67E59AA88314167F1938A3549F74B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_13CB605F5C1F398D87F738A3549F7F26_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_13CB605F5C1F398D87F738A3549F7F26" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_13CB605F5C1F398D87F738A3549F7F26_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_13CB605F5C1F398D87F738A3549F7F26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_13CB605F5C1F398D87F738A3549F7F26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_13CB605F5C1F398D87F738A3549F7F26" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_13CB605F5C1F398D87F738A3549F7F26" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_0D723282EE03CD352C5E38A3549FBAA4_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_0D723282EE03CD352C5E38A3549FBAA4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_0D723282EE03CD352C5E38A3549FBAA4_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_0D723282EE03CD352C5E38A3549FBAA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0D723282EE03CD352C5E38A3549FBAA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0D723282EE03CD352C5E38A3549FBAA4" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_0D723282EE03CD352C5E38A3549FBAA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_06F483F5DC2966864D3638A3549F6568_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_06F483F5DC2966864D3638A3549F6568" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_06F483F5DC2966864D3638A3549F6568_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_06F483F5DC2966864D3638A3549F6568" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_06F483F5DC2966864D3638A3549F6568" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_06F483F5DC2966864D3638A3549F6568" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_06F483F5DC2966864D3638A3549F6568" xlink:type="arc" />
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_87A8ECAD4E5FE7FE83FC38A3549FC45F_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_87A8ECAD4E5FE7FE83FC38A3549FC45F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_87A8ECAD4E5FE7FE83FC38A3549FC45F_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_87A8ECAD4E5FE7FE83FC38A3549FC45F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_87A8ECAD4E5FE7FE83FC38A3549FC45F_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_87A8ECAD4E5FE7FE83FC38A3549FC45F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_87A8ECAD4E5FE7FE83FC38A3549FC45F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_87A8ECAD4E5FE7FE83FC38A3549FC45F" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent_87A8ECAD4E5FE7FE83FC38A3549FC45F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_B75DA26F7B52FC1C1CD338A354A0F2B7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_B75DA26F7B52FC1C1CD338A354A0F2B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_B75DA26F7B52FC1C1CD338A354A0F2B7_label_en-US" xlink:label="lab_us-gaap_InventoryNet_B75DA26F7B52FC1C1CD338A354A0F2B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_B75DA26F7B52FC1C1CD338A354A0F2B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_B75DA26F7B52FC1C1CD338A354A0F2B7" xlink:to="lab_us-gaap_InventoryNet_B75DA26F7B52FC1C1CD338A354A0F2B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNoncurrent_DA371DDE556D6381F35538A354A04BF3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_DA371DDE556D6381F35538A354A04BF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_DA371DDE556D6381F35538A354A04BF3_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_DA371DDE556D6381F35538A354A04BF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_DA371DDE556D6381F35538A354A04BF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent_DA371DDE556D6381F35538A354A04BF3" xlink:to="lab_us-gaap_InventoryNoncurrent_DA371DDE556D6381F35538A354A04BF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_91F796198C4500D72DBA93582EBF30F7_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_91F796198C4500D72DBA93582EBF30F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_91F796198C4500D72DBA93582EBF30F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_91F796198C4500D72DBA93582EBF30F7" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_91F796198C4500D72DBA93582EBF30F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_526149A3AD8A06D3698493582EBFD06E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_526149A3AD8A06D3698493582EBFD06E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_526149A3AD8A06D3698493582EBFD06E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_526149A3AD8A06D3698493582EBFD06E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_526149A3AD8A06D3698493582EBFD06E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_526149A3AD8A06D3698493582EBFD06E" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_526149A3AD8A06D3698493582EBFD06E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B9739312139686999FA893582EC036EB_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B9739312139686999FA893582EC036EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B9739312139686999FA893582EC036EB_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B9739312139686999FA893582EC036EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B9739312139686999FA893582EC036EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B9739312139686999FA893582EC036EB" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B9739312139686999FA893582EC036EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_12E3CEB31452D6B5582B93582EC0A160_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_12E3CEB31452D6B5582B93582EC0A160" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_12E3CEB31452D6B5582B93582EC0A160_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_12E3CEB31452D6B5582B93582EC0A160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_12E3CEB31452D6B5582B93582EC0A160" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_12E3CEB31452D6B5582B93582EC0A160" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_12E3CEB31452D6B5582B93582EC0A160" xlink:type="arc" />
    <link:label id="lab_us-gaap_LandMember_0B6E8E89E7C515A8D1B693582EC09A02_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember_0B6E8E89E7C515A8D1B693582EC09A02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_0B6E8E89E7C515A8D1B693582EC09A02_label_en-US" xlink:label="lab_us-gaap_LandMember_0B6E8E89E7C515A8D1B693582EC09A02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_0B6E8E89E7C515A8D1B693582EC09A02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember_0B6E8E89E7C515A8D1B693582EC09A02" xlink:to="lab_us-gaap_LandMember_0B6E8E89E7C515A8D1B693582EC09A02" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_604B2B699C19D89521E393582EC0F757_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_604B2B699C19D89521E393582EC0F757" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_604B2B699C19D89521E393582EC0F757_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_604B2B699C19D89521E393582EC0F757" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_604B2B699C19D89521E393582EC0F757" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_604B2B699C19D89521E393582EC0F757" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_604B2B699C19D89521E393582EC0F757" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_03A68F34153EEF2BC6C993582EC0FD48_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_03A68F34153EEF2BC6C993582EC0FD48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_03A68F34153EEF2BC6C993582EC0FD48_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_03A68F34153EEF2BC6C993582EC0FD48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_03A68F34153EEF2BC6C993582EC0FD48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_03A68F34153EEF2BC6C993582EC0FD48" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_03A68F34153EEF2BC6C993582EC0FD48" xlink:type="arc" />
    <link:label id="lab_biib_EisaiMember_18C747C4DBA60D6AE48A93582EC0DD50_terseLabel_en-US" xlink:label="lab_biib_EisaiMember_18C747C4DBA60D6AE48A93582EC0DD50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_18C747C4DBA60D6AE48A93582EC0DD50_label_en-US" xlink:label="lab_biib_EisaiMember_18C747C4DBA60D6AE48A93582EC0DD50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_18C747C4DBA60D6AE48A93582EC0DD50_documentation_en-US" xlink:label="lab_biib_EisaiMember_18C747C4DBA60D6AE48A93582EC0DD50" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_18C747C4DBA60D6AE48A93582EC0DD50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember_18C747C4DBA60D6AE48A93582EC0DD50" xlink:to="lab_biib_EisaiMember_18C747C4DBA60D6AE48A93582EC0DD50" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationAxis_FB29CD8146A6A876232193582EC05A13_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis_FB29CD8146A6A876232193582EC05A13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_FB29CD8146A6A876232193582EC05A13_label_en-US" xlink:label="lab_biib_FacilityLocationAxis_FB29CD8146A6A876232193582EC05A13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_FB29CD8146A6A876232193582EC05A13_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis_FB29CD8146A6A876232193582EC05A13" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_FB29CD8146A6A876232193582EC05A13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis_FB29CD8146A6A876232193582EC05A13" xlink:to="lab_biib_FacilityLocationAxis_FB29CD8146A6A876232193582EC05A13" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationDomain_1CD8E2999E95A83BAC0C93582EC0204D_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain_1CD8E2999E95A83BAC0C93582EC0204D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_1CD8E2999E95A83BAC0C93582EC0204D_label_en-US" xlink:label="lab_biib_FacilityLocationDomain_1CD8E2999E95A83BAC0C93582EC0204D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_1CD8E2999E95A83BAC0C93582EC0204D_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain_1CD8E2999E95A83BAC0C93582EC0204D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_1CD8E2999E95A83BAC0C93582EC0204D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain_1CD8E2999E95A83BAC0C93582EC0204D" xlink:to="lab_biib_FacilityLocationDomain_1CD8E2999E95A83BAC0C93582EC0204D" xlink:type="arc" />
    <link:label id="lab_biib_SolothurnMember_653BCD04F283A92AF96893582EC05621_terseLabel_en-US" xlink:label="lab_biib_SolothurnMember_653BCD04F283A92AF96893582EC05621" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Solothurn</link:label>
    <link:label id="lab_biib_SolothurnMember_653BCD04F283A92AF96893582EC05621_label_en-US" xlink:label="lab_biib_SolothurnMember_653BCD04F283A92AF96893582EC05621" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solothurn [Member]</link:label>
    <link:label id="lab_biib_SolothurnMember_653BCD04F283A92AF96893582EC05621_documentation_en-US" xlink:label="lab_biib_SolothurnMember_653BCD04F283A92AF96893582EC05621" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Solothurn [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_653BCD04F283A92AF96893582EC05621" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnMember_653BCD04F283A92AF96893582EC05621" xlink:to="lab_biib_SolothurnMember_653BCD04F283A92AF96893582EC05621" xlink:type="arc" />
    <link:label id="lab_biib_CambridgeLeasesMember_0F9D636F62E40B76FC2D93582EC0A22B_terseLabel_en-US" xlink:label="lab_biib_CambridgeLeasesMember_0F9D636F62E40B76FC2D93582EC0A22B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cambridge Leases</link:label>
    <link:label id="lab_biib_CambridgeLeasesMember_0F9D636F62E40B76FC2D93582EC0A22B_label_en-US" xlink:label="lab_biib_CambridgeLeasesMember_0F9D636F62E40B76FC2D93582EC0A22B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cambridge Leases [Member]</link:label>
    <link:label id="lab_biib_CambridgeLeasesMember_0F9D636F62E40B76FC2D93582EC0A22B_documentation_en-US" xlink:label="lab_biib_CambridgeLeasesMember_0F9D636F62E40B76FC2D93582EC0A22B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cambridge leases.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_CambridgeLeasesMember" xlink:label="loc_biib_CambridgeLeasesMember_0F9D636F62E40B76FC2D93582EC0A22B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CambridgeLeasesMember_0F9D636F62E40B76FC2D93582EC0A22B" xlink:to="lab_biib_CambridgeLeasesMember_0F9D636F62E40B76FC2D93582EC0A22B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_50379A40152691BDA69F93582EC0FC45_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_50379A40152691BDA69F93582EC0FC45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_50379A40152691BDA69F93582EC0FC45_label_en-US" xlink:label="lab_us-gaap_Depreciation_50379A40152691BDA69F93582EC0FC45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_50379A40152691BDA69F93582EC0FC45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_50379A40152691BDA69F93582EC0FC45" xlink:to="lab_us-gaap_Depreciation_50379A40152691BDA69F93582EC0FC45" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestCostsCapitalized_96C5DC5019D5689310B093582EC0EED1_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized_96C5DC5019D5689310B093582EC0EED1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest cost capitalization related to construction in progress</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_96C5DC5019D5689310B093582EC0EED1_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized_96C5DC5019D5689310B093582EC0EED1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_96C5DC5019D5689310B093582EC0EED1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized_96C5DC5019D5689310B093582EC0EED1" xlink:to="lab_us-gaap_InterestCostsCapitalized_96C5DC5019D5689310B093582EC0EED1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_2760805C27537E3F935E93582EC04F73_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions_2760805C27537E3F935E93582EC04F73" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland land purchase</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_2760805C27537E3F935E93582EC04F73_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions_2760805C27537E3F935E93582EC04F73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_2760805C27537E3F935E93582EC04F73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions_2760805C27537E3F935E93582EC04F73" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions_2760805C27537E3F935E93582EC04F73" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressGross_4332A13B17E127473DD6936629FA14AA_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_4332A13B17E127473DD6936629FA14AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_4332A13B17E127473DD6936629FA14AA_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_4332A13B17E127473DD6936629FA14AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_4332A13B17E127473DD6936629FA14AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross_4332A13B17E127473DD6936629FA14AA" xlink:to="lab_us-gaap_ConstructionInProgressGross_4332A13B17E127473DD6936629FA14AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_E8FA4A619E63B8DA1C8693582EC0AC40_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_E8FA4A619E63B8DA1C8693582EC0AC40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of original lease</link:label>
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_E8FA4A619E63B8DA1C8693582EC0AC40_label_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_E8FA4A619E63B8DA1C8693582EC0AC40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_E8FA4A619E63B8DA1C8693582EC0AC40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_E8FA4A619E63B8DA1C8693582EC0AC40" xlink:to="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_E8FA4A619E63B8DA1C8693582EC0AC40" xlink:type="arc" />
    <link:label id="lab_biib_TermOfLease_27CF5E8D36D42AA6B9D493582EC1BA5E_terseLabel_en-US" xlink:label="lab_biib_TermOfLease_27CF5E8D36D42AA6B9D493582EC1BA5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of amended lease</link:label>
    <link:label id="lab_biib_TermOfLease_27CF5E8D36D42AA6B9D493582EC1BA5E_label_en-US" xlink:label="lab_biib_TermOfLease_27CF5E8D36D42AA6B9D493582EC1BA5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Of Lease</link:label>
    <link:label id="lab_biib_TermOfLease_27CF5E8D36D42AA6B9D493582EC1BA5E_documentation_en-US" xlink:label="lab_biib_TermOfLease_27CF5E8D36D42AA6B9D493582EC1BA5E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Of Lease.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_TermOfLease" xlink:label="loc_biib_TermOfLease_27CF5E8D36D42AA6B9D493582EC1BA5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TermOfLease_27CF5E8D36D42AA6B9D493582EC1BA5E" xlink:to="lab_biib_TermOfLease_27CF5E8D36D42AA6B9D493582EC1BA5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeaseObligations_573043FDF49FC9F474AF93582EC14D0D_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligations_573043FDF49FC9F474AF93582EC14D0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital lease obligation</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligations_573043FDF49FC9F474AF93582EC14D0D_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligations_573043FDF49FC9F474AF93582EC14D0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_573043FDF49FC9F474AF93582EC14D0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligations_573043FDF49FC9F474AF93582EC14D0D" xlink:to="lab_us-gaap_CapitalLeaseObligations_573043FDF49FC9F474AF93582EC14D0D" xlink:type="arc" />
    <link:label id="lab_biib_Chargesrecognizedtovacatebuilding_CF1F1466AA378E4E574293582EC15DA5_terseLabel_en-US" xlink:label="lab_biib_Chargesrecognizedtovacatebuilding_CF1F1466AA378E4E574293582EC15DA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges recognized to vacate building</link:label>
    <link:label id="lab_biib_Chargesrecognizedtovacatebuilding_CF1F1466AA378E4E574293582EC15DA5_label_en-US" xlink:label="lab_biib_Chargesrecognizedtovacatebuilding_CF1F1466AA378E4E574293582EC15DA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Charges recognized to vacate building</link:label>
    <link:label id="lab_biib_Chargesrecognizedtovacatebuilding_CF1F1466AA378E4E574293582EC15DA5_documentation_en-US" xlink:label="lab_biib_Chargesrecognizedtovacatebuilding_CF1F1466AA378E4E574293582EC15DA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Charges recognized to vacate building</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_Chargesrecognizedtovacatebuilding" xlink:label="loc_biib_Chargesrecognizedtovacatebuilding_CF1F1466AA378E4E574293582EC15DA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Chargesrecognizedtovacatebuilding_CF1F1466AA378E4E574293582EC15DA5" xlink:to="lab_biib_Chargesrecognizedtovacatebuilding_CF1F1466AA378E4E574293582EC15DA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_CBAA42770409FBD6B7B338A353D8A18C_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_CBAA42770409FBD6B7B338A353D8A18C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_CBAA42770409FBD6B7B338A353D8A18C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CBAA42770409FBD6B7B338A353D8A18C" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_CBAA42770409FBD6B7B338A353D8A18C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_10918401BC3356F9359638A353D8DCE0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_10918401BC3356F9359638A353D8DCE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_10918401BC3356F9359638A353D8DCE0_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_10918401BC3356F9359638A353D8DCE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_10918401BC3356F9359638A353D8DCE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_10918401BC3356F9359638A353D8DCE0" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_10918401BC3356F9359638A353D8DCE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_51826887EBB926618A7193582DD58E3F_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_51826887EBB926618A7193582DD58E3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_51826887EBB926618A7193582DD58E3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_51826887EBB926618A7193582DD58E3F" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_51826887EBB926618A7193582DD58E3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C4C993CC7A5EB330630693582DD59AFE_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C4C993CC7A5EB330630693582DD59AFE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum rental commitments under non-cancelable leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C4C993CC7A5EB330630693582DD59AFE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C4C993CC7A5EB330630693582DD59AFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C4C993CC7A5EB330630693582DD59AFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C4C993CC7A5EB330630693582DD59AFE" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C4C993CC7A5EB330630693582DD59AFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_40530E79315E3DC4CF3E93582DD5F30D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_40530E79315E3DC4CF3E93582DD5F30D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_40530E79315E3DC4CF3E93582DD5F30D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_40530E79315E3DC4CF3E93582DD5F30D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_40530E79315E3DC4CF3E93582DD5F30D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_40530E79315E3DC4CF3E93582DD5F30D" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_40530E79315E3DC4CF3E93582DD5F30D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_7B73AD0AF76D2F05468B38A3564D4745_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_7B73AD0AF76D2F05468B38A3564D4745" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7B73AD0AF76D2F05468B38A3564D4745" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7B73AD0AF76D2F05468B38A3564D4745" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_7B73AD0AF76D2F05468B38A3564D4745" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_145A673660996FAA320F38A3564D2AD9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_145A673660996FAA320F38A3564D2AD9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_145A673660996FAA320F38A3564D2AD9_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_145A673660996FAA320F38A3564D2AD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_145A673660996FAA320F38A3564D2AD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_145A673660996FAA320F38A3564D2AD9" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_145A673660996FAA320F38A3564D2AD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GuaranteesAbstract_057AC7E20C99DD45FD0738A352164A35_label_en-US" xlink:label="lab_us-gaap_GuaranteesAbstract_057AC7E20C99DD45FD0738A352164A35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantees [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GuaranteesAbstract" xlink:label="loc_us-gaap_GuaranteesAbstract_057AC7E20C99DD45FD0738A352164A35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesAbstract_057AC7E20C99DD45FD0738A352164A35" xlink:to="lab_us-gaap_GuaranteesAbstract_057AC7E20C99DD45FD0738A352164A35" xlink:type="arc" />
    <link:label id="lab_us-gaap_GuaranteesTextBlock_1FA39F706AFE3990E40138A352164574_verboseLabel_en-US" xlink:label="lab_us-gaap_GuaranteesTextBlock_1FA39F706AFE3990E40138A352164574" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Guarantees</link:label>
    <link:label id="lab_us-gaap_GuaranteesTextBlock_1FA39F706AFE3990E40138A352164574_label_en-US" xlink:label="lab_us-gaap_GuaranteesTextBlock_1FA39F706AFE3990E40138A352164574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantees [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GuaranteesTextBlock" xlink:label="loc_us-gaap_GuaranteesTextBlock_1FA39F706AFE3990E40138A352164574" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesTextBlock_1FA39F706AFE3990E40138A352164574" xlink:to="lab_us-gaap_GuaranteesTextBlock_1FA39F706AFE3990E40138A352164574" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_85316B7F84AA0A1BF6BC38A35514016F_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_85316B7F84AA0A1BF6BC38A35514016F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the beginning and ending of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_85316B7F84AA0A1BF6BC38A35514016F_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_85316B7F84AA0A1BF6BC38A35514016F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_85316B7F84AA0A1BF6BC38A35514016F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_85316B7F84AA0A1BF6BC38A35514016F" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_85316B7F84AA0A1BF6BC38A35514016F" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_41D0666A9491239B319C38A355140A61_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_41D0666A9491239B319C38A355140A61" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at January 1</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_41D0666A9491239B319C38A355140A61_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_41D0666A9491239B319C38A355140A61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_41D0666A9491239B319C38A355140A61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_41D0666A9491239B319C38A355140A61" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_41D0666A9491239B319C38A355140A61" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_EF2AFDB55DB70FC3832B38A35515B62F_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_EF2AFDB55DB70FC3832B38A35515B62F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions based on tax positions related to the current period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_EF2AFDB55DB70FC3832B38A35515B62F_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_EF2AFDB55DB70FC3832B38A35515B62F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_EF2AFDB55DB70FC3832B38A35515B62F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_EF2AFDB55DB70FC3832B38A35515B62F" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_EF2AFDB55DB70FC3832B38A35515B62F" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_93CEE4CE358F6FCFBA7738A35515B05C_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_93CEE4CE358F6FCFBA7738A35515B05C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions for tax positions of prior periods</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_93CEE4CE358F6FCFBA7738A35515B05C_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_93CEE4CE358F6FCFBA7738A35515B05C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_93CEE4CE358F6FCFBA7738A35515B05C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_93CEE4CE358F6FCFBA7738A35515B05C" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_93CEE4CE358F6FCFBA7738A35515B05C" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6ADB5166546C0EDA733138A35515522B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6ADB5166546C0EDA733138A35515522B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reductions for tax positions of prior periods</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6ADB5166546C0EDA733138A35515522B_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6ADB5166546C0EDA733138A35515522B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6ADB5166546C0EDA733138A35515522B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6ADB5166546C0EDA733138A35515522B" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6ADB5166546C0EDA733138A35515522B" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_A00E62265025C45EEC8D38A35515FF62_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_A00E62265025C45EEC8D38A35515FF62" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Statute expirations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_A00E62265025C45EEC8D38A35515FF62_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_A00E62265025C45EEC8D38A35515FF62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_A00E62265025C45EEC8D38A35515FF62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_A00E62265025C45EEC8D38A35515FF62" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_A00E62265025C45EEC8D38A35515FF62" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_95C1C0F2BD67988E9B8638A35515DBC6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_95C1C0F2BD67988E9B8638A35515DBC6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_95C1C0F2BD67988E9B8638A35515DBC6_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_95C1C0F2BD67988E9B8638A35515DBC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_95C1C0F2BD67988E9B8638A35515DBC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_95C1C0F2BD67988E9B8638A35515DBC6" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_95C1C0F2BD67988E9B8638A35515DBC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_58C019F2AC5B2AD0661438A3551511BD_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_58C019F2AC5B2AD0661438A3551511BD" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at December 31</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_58C019F2AC5B2AD0661438A3551511BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_58C019F2AC5B2AD0661438A3551511BD" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_58C019F2AC5B2AD0661438A3551511BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_36A4DB193A1C37364A6738A3539344CC_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_36A4DB193A1C37364A6738A3539344CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_36A4DB193A1C37364A6738A3539344CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_36A4DB193A1C37364A6738A3539344CC" xlink:to="lab_us-gaap_EarningsPerShareAbstract_36A4DB193A1C37364A6738A3539344CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_B5AC7967F09420D3E49538A353938CFF_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_B5AC7967F09420D3E49538A353938CFF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_B5AC7967F09420D3E49538A353938CFF_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_B5AC7967F09420D3E49538A353938CFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_B5AC7967F09420D3E49538A353938CFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_B5AC7967F09420D3E49538A353938CFF" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_B5AC7967F09420D3E49538A353938CFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_47EE2DE5B02E4E077DB038A35363956D_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_47EE2DE5B02E4E077DB038A35363956D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Retirement Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_47EE2DE5B02E4E077DB038A35363956D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_47EE2DE5B02E4E077DB038A35363956D" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_47EE2DE5B02E4E077DB038A35363956D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_844112BF2686B9C834D738A353638835_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_844112BF2686B9C834D738A353638835" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_844112BF2686B9C834D738A353638835_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_844112BF2686B9C834D738A353638835" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_844112BF2686B9C834D738A353638835" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_844112BF2686B9C834D738A353638835" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_844112BF2686B9C834D738A353638835" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E21F9FE9955F71E8071138A353D14B45_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E21F9FE9955F71E8071138A353D14B45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E21F9FE9955F71E8071138A353D14B45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E21F9FE9955F71E8071138A353D14B45" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E21F9FE9955F71E8071138A353D14B45" xlink:type="arc" />
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_D08499F73CDF3341533D38A353D144B1_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_D08499F73CDF3341533D38A353D144B1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_D08499F73CDF3341533D38A353D144B1_label_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_D08499F73CDF3341533D38A353D144B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Profit Sharing Formula [Table Text Block]</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_D08499F73CDF3341533D38A353D144B1_documentation_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_D08499F73CDF3341533D38A353D144B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_D08499F73CDF3341533D38A353D144B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_D08499F73CDF3341533D38A353D144B1" xlink:to="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_D08499F73CDF3341533D38A353D144B1" xlink:type="arc" />
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_1831D0B73257747BA65E38A353D1614F_terseLabel_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock_1831D0B73257747BA65E38A353D1614F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pretax profit sharing formula</link:label>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_1831D0B73257747BA65E38A353D1614F_label_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock_1831D0B73257747BA65E38A353D1614F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pretax Profit Sharing Formula [Table Text Block]</link:label>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_1831D0B73257747BA65E38A353D1614F_documentation_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock_1831D0B73257747BA65E38A353D1614F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pretax Profit Sharing Formula [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PretaxProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_PretaxProfitSharingFormulaTableTextBlock_1831D0B73257747BA65E38A353D1614F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PretaxProfitSharingFormulaTableTextBlock_1831D0B73257747BA65E38A353D1614F" xlink:to="lab_biib_PretaxProfitSharingFormulaTableTextBlock_1831D0B73257747BA65E38A353D1614F" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_1787874D463057EA6A6C38A353D1433C_verboseLabel_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_1787874D463057EA6A6C38A353D1433C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business</link:label>
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_1787874D463057EA6A6C38A353D1433C_label_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_1787874D463057EA6A6C38A353D1433C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues From Unconsolidated Joint Business [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_1787874D463057EA6A6C38A353D1433C_documentation_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_1787874D463057EA6A6C38A353D1433C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_1787874D463057EA6A6C38A353D1433C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_1787874D463057EA6A6C38A353D1433C" xlink:to="lab_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_1787874D463057EA6A6C38A353D1433C" xlink:type="arc" />
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_F6514BF493ED2FB2988138A353D18675_verboseLabel_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_F6514BF493ED2FB2988138A353D18675" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mechanism for reimbursement, under the amended agreement amounts payable</link:label>
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_F6514BF493ED2FB2988138A353D18675_label_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_F6514BF493ED2FB2988138A353D18675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Under The Amended Agreement Amounts Payable [Table Text Block]</link:label>
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_F6514BF493ED2FB2988138A353D18675_documentation_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_F6514BF493ED2FB2988138A353D18675" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mechanism for reimbursement, under the amended agreement amounts payable.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_F6514BF493ED2FB2988138A353D18675" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_F6514BF493ED2FB2988138A353D18675" xlink:to="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_F6514BF493ED2FB2988138A353D18675" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_68FBB4AFB59D3F3B3C4138A353D1AA1B_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_68FBB4AFB59D3F3B3C4138A353D1AA1B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of activity related to collaboration with AbbVie Inc.</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_68FBB4AFB59D3F3B3C4138A353D1AA1B_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_68FBB4AFB59D3F3B3C4138A353D1AA1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Activity Related To Collaboration With Company Seven [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_68FBB4AFB59D3F3B3C4138A353D1AA1B_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_68FBB4AFB59D3F3B3C4138A353D1AA1B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of activity related to collaboration with company seven.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_68FBB4AFB59D3F3B3C4138A353D1AA1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_68FBB4AFB59D3F3B3C4138A353D1AA1B" xlink:to="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_68FBB4AFB59D3F3B3C4138A353D1AA1B" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_CCB53B66A8501048A59938A353D13691_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_CCB53B66A8501048A59938A353D13691" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of activity related to collaboration with Eisai</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_CCB53B66A8501048A59938A353D13691_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_CCB53B66A8501048A59938A353D13691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_CCB53B66A8501048A59938A353D13691_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_CCB53B66A8501048A59938A353D13691" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_CCB53B66A8501048A59938A353D13691" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_CCB53B66A8501048A59938A353D13691" xlink:to="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_CCB53B66A8501048A59938A353D13691" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_CA9E6BBC4214D566D13238A351F133C4_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_CA9E6BBC4214D566D13238A351F133C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_CA9E6BBC4214D566D13238A351F133C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_CA9E6BBC4214D566D13238A351F133C4" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_CA9E6BBC4214D566D13238A351F133C4" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_E2E05ADBFD9D943BC04C38A351F1D517_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_E2E05ADBFD9D943BC04C38A351F1D517" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_E2E05ADBFD9D943BC04C38A351F1D517_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_E2E05ADBFD9D943BC04C38A351F1D517" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_E2E05ADBFD9D943BC04C38A351F1D517_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_E2E05ADBFD9D943BC04C38A351F1D517" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_E2E05ADBFD9D943BC04C38A351F1D517" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_E2E05ADBFD9D943BC04C38A351F1D517" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_E2E05ADBFD9D943BC04C38A351F1D517" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_A7007905ECD08E3A3B7638A351F12408_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_A7007905ECD08E3A3B7638A351F12408" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_A7007905ECD08E3A3B7638A351F12408_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_A7007905ECD08E3A3B7638A351F12408" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_A7007905ECD08E3A3B7638A351F12408" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_A7007905ECD08E3A3B7638A351F12408" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_A7007905ECD08E3A3B7638A351F12408" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_E6E695B0EFDB5FE2B74C38A351F1F603_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_E6E695B0EFDB5FE2B74C38A351F1F603" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_E6E695B0EFDB5FE2B74C38A351F1F603_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_E6E695B0EFDB5FE2B74C38A351F1F603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_E6E695B0EFDB5FE2B74C38A351F1F603" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_E6E695B0EFDB5FE2B74C38A351F1F603" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_E6E695B0EFDB5FE2B74C38A351F1F603" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_B39FDB53CCC7F03D641638A356F6802A_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_B39FDB53CCC7F03D641638A356F6802A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_B39FDB53CCC7F03D641638A356F6802A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_B39FDB53CCC7F03D641638A356F6802A" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_B39FDB53CCC7F03D641638A356F6802A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_01718A016490CF9071EF38A356F6DFC5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_01718A016490CF9071EF38A356F6DFC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_01718A016490CF9071EF38A356F6DFC5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_01718A016490CF9071EF38A356F6DFC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_01718A016490CF9071EF38A356F6DFC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_01718A016490CF9071EF38A356F6DFC5" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_01718A016490CF9071EF38A356F6DFC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6C47C226576F7437020938A356F6744F_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6C47C226576F7437020938A356F6744F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6C47C226576F7437020938A356F6744F_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6C47C226576F7437020938A356F6744F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6C47C226576F7437020938A356F6744F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6C47C226576F7437020938A356F6744F" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6C47C226576F7437020938A356F6744F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_047044B7E1D20A20F63038A356F650DA_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_047044B7E1D20A20F63038A356F650DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_047044B7E1D20A20F63038A356F650DA_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_047044B7E1D20A20F63038A356F650DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_047044B7E1D20A20F63038A356F650DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_047044B7E1D20A20F63038A356F650DA" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_047044B7E1D20A20F63038A356F650DA" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentsMember_AEB935940F11C0E90BF838A356F691D4_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_AEB935940F11C0E90BF838A356F691D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_AEB935940F11C0E90BF838A356F691D4_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_AEB935940F11C0E90BF838A356F691D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_AEB935940F11C0E90BF838A356F691D4_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_AEB935940F11C0E90BF838A356F691D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_AEB935940F11C0E90BF838A356F691D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember_AEB935940F11C0E90BF838A356F691D4" xlink:to="lab_biib_StrategicInvestmentsMember_AEB935940F11C0E90BF838A356F691D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_BDE54CDFD747302D705F38A356F6A244_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_BDE54CDFD747302D705F38A356F6A244" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_BDE54CDFD747302D705F38A356F6A244_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_BDE54CDFD747302D705F38A356F6A244" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_BDE54CDFD747302D705F38A356F6A244" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BDE54CDFD747302D705F38A356F6A244" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_BDE54CDFD747302D705F38A356F6A244" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentPortfolio_10B6954D7E10E83B4BE538A356F6B8A1_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_10B6954D7E10E83B4BE538A356F6B8A1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_10B6954D7E10E83B4BE538A356F6B8A1_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_10B6954D7E10E83B4BE538A356F6B8A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_10B6954D7E10E83B4BE538A356F6B8A1_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_10B6954D7E10E83B4BE538A356F6B8A1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_10B6954D7E10E83B4BE538A356F6B8A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio_10B6954D7E10E83B4BE538A356F6B8A1" xlink:to="lab_biib_StrategicInvestmentPortfolio_10B6954D7E10E83B4BE538A356F6B8A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_6D87CF4ADFC9AACE3E5938A35390E7C0_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_6D87CF4ADFC9AACE3E5938A35390E7C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6D87CF4ADFC9AACE3E5938A35390E7C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6D87CF4ADFC9AACE3E5938A35390E7C0" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_6D87CF4ADFC9AACE3E5938A35390E7C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3B80226A0DFCABA8904838A35390EFA6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3B80226A0DFCABA8904838A35390EFA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3B80226A0DFCABA8904838A35390EFA6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3B80226A0DFCABA8904838A35390EFA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3B80226A0DFCABA8904838A35390EFA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3B80226A0DFCABA8904838A35390EFA6" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3B80226A0DFCABA8904838A35390EFA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4CC7EB0562C3C980D6DF38A3539002C8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4CC7EB0562C3C980D6DF38A3539002C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4CC7EB0562C3C980D6DF38A3539002C8_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4CC7EB0562C3C980D6DF38A3539002C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4CC7EB0562C3C980D6DF38A3539002C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4CC7EB0562C3C980D6DF38A3539002C8" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4CC7EB0562C3C980D6DF38A3539002C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_66B27713F238BFA3C9A938A3539081C5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_66B27713F238BFA3C9A938A3539081C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_66B27713F238BFA3C9A938A3539081C5_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_66B27713F238BFA3C9A938A3539081C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_66B27713F238BFA3C9A938A3539081C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_66B27713F238BFA3C9A938A3539081C5" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_66B27713F238BFA3C9A938A3539081C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_FA6549F79D91B65A085638A35390C55E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_FA6549F79D91B65A085638A35390C55E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_FA6549F79D91B65A085638A35390C55E_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_FA6549F79D91B65A085638A35390C55E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_FA6549F79D91B65A085638A35390C55E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_FA6549F79D91B65A085638A35390C55E" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_FA6549F79D91B65A085638A35390C55E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_1A2FCB21FDEE8350B30038A35390A4A1_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_1A2FCB21FDEE8350B30038A35390A4A1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_1A2FCB21FDEE8350B30038A35390A4A1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_1A2FCB21FDEE8350B30038A35390A4A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1A2FCB21FDEE8350B30038A35390A4A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1A2FCB21FDEE8350B30038A35390A4A1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_1A2FCB21FDEE8350B30038A35390A4A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_63998FE40E5274EEAC9A38A35390E1CE_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_63998FE40E5274EEAC9A38A35390E1CE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_63998FE40E5274EEAC9A38A35390E1CE_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_63998FE40E5274EEAC9A38A35390E1CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_63998FE40E5274EEAC9A38A35390E1CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_63998FE40E5274EEAC9A38A35390E1CE" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_63998FE40E5274EEAC9A38A35390E1CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD0563565BF61C4A021438A35390F2A1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD0563565BF61C4A021438A35390F2A1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD0563565BF61C4A021438A35390F2A1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD0563565BF61C4A021438A35390F2A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD0563565BF61C4A021438A35390F2A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD0563565BF61C4A021438A35390F2A1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD0563565BF61C4A021438A35390F2A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8C89FC9EA4F9BD38911438A353904E5B_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8C89FC9EA4F9BD38911438A353904E5B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8C89FC9EA4F9BD38911438A353904E5B_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8C89FC9EA4F9BD38911438A353904E5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8C89FC9EA4F9BD38911438A353904E5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8C89FC9EA4F9BD38911438A353904E5B" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8C89FC9EA4F9BD38911438A353904E5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_AD8C210E8E34226368E938A3539078E4_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_AD8C210E8E34226368E938A3539078E4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_AD8C210E8E34226368E938A3539078E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_AD8C210E8E34226368E938A3539078E4" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_AD8C210E8E34226368E938A3539078E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9589EB5A6A04C5AB139C93582D8E7415_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9589EB5A6A04C5AB139C93582D8E7415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9589EB5A6A04C5AB139C93582D8E7415" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9589EB5A6A04C5AB139C93582D8E7415" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9589EB5A6A04C5AB139C93582D8E7415" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Table]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F_label_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Table]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F_documentation_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of development milestone and collaboration.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F" xlink:to="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementGeographicalAxis_C9BCCA5614887BE79AEA93582D8E9ABC_terseLabel_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_C9BCCA5614887BE79AEA93582D8E9ABC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementGeographicalAxis_C9BCCA5614887BE79AEA93582D8E9ABC_label_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_C9BCCA5614887BE79AEA93582D8E9ABC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_C9BCCA5614887BE79AEA93582D8E9ABC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementGeographicalAxis_C9BCCA5614887BE79AEA93582D8E9ABC" xlink:to="lab_us-gaap_StatementGeographicalAxis_C9BCCA5614887BE79AEA93582D8E9ABC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_6D719E95E1A6D8BA33F893582D8EBA99_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_6D719E95E1A6D8BA33F893582D8EBA99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_6D719E95E1A6D8BA33F893582D8EBA99_label_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_6D719E95E1A6D8BA33F893582D8EBA99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_6D719E95E1A6D8BA33F893582D8EBA99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentGeographicalDomain_6D719E95E1A6D8BA33F893582D8EBA99" xlink:to="lab_us-gaap_SegmentGeographicalDomain_6D719E95E1A6D8BA33F893582D8EBA99" xlink:type="arc" />
    <link:label id="lab_country_IT_EBB14A246D001B1F915493582D8EDE6D_terseLabel_en-US" xlink:label="lab_country_IT_EBB14A246D001B1F915493582D8EDE6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ITALY</link:label>
    <link:label id="lab_country_IT_EBB14A246D001B1F915493582D8EDE6D_label_en-US" xlink:label="lab_country_IT_EBB14A246D001B1F915493582D8EDE6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ITALY</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IT" xlink:label="loc_country_IT_EBB14A246D001B1F915493582D8EDE6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IT_EBB14A246D001B1F915493582D8EDE6D" xlink:to="lab_country_IT_EBB14A246D001B1F915493582D8EDE6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_E66BD1B2C4C2F5FD784893582D8E5CF1_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_E66BD1B2C4C2F5FD784893582D8E5CF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_E66BD1B2C4C2F5FD784893582D8E5CF1_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_E66BD1B2C4C2F5FD784893582D8E5CF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_E66BD1B2C4C2F5FD784893582D8E5CF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_E66BD1B2C4C2F5FD784893582D8E5CF1" xlink:to="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_E66BD1B2C4C2F5FD784893582D8E5CF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_40EBD9636490F1323CEF93582D8EEB41_terseLabel_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_40EBD9636490F1323CEF93582D8EEB41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_40EBD9636490F1323CEF93582D8EEB41_label_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_40EBD9636490F1323CEF93582D8EEB41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_40EBD9636490F1323CEF93582D8EEB41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_40EBD9636490F1323CEF93582D8EEB41" xlink:to="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_40EBD9636490F1323CEF93582D8EEB41" xlink:type="arc" />
    <link:label id="lab_biib_NeurimmuneMember_CD6DD8CDA6E45A21F96C93582D8E1A8F_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember_CD6DD8CDA6E45A21F96C93582D8E1A8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_CD6DD8CDA6E45A21F96C93582D8E1A8F_label_en-US" xlink:label="lab_biib_NeurimmuneMember_CD6DD8CDA6E45A21F96C93582D8E1A8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_CD6DD8CDA6E45A21F96C93582D8E1A8F_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember_CD6DD8CDA6E45A21F96C93582D8E1A8F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_CD6DD8CDA6E45A21F96C93582D8E1A8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember_CD6DD8CDA6E45A21F96C93582D8E1A8F" xlink:to="lab_biib_NeurimmuneMember_CD6DD8CDA6E45A21F96C93582D8E1A8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_0291529BB1210B62A8B693582D8ECEC3_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_0291529BB1210B62A8B693582D8ECEC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_0291529BB1210B62A8B693582D8ECEC3_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_0291529BB1210B62A8B693582D8ECEC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0291529BB1210B62A8B693582D8ECEC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0291529BB1210B62A8B693582D8ECEC3" xlink:to="lab_us-gaap_TypeOfArrangementAxis_0291529BB1210B62A8B693582D8ECEC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386DB671ECFC303CA27593582D8FF132_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386DB671ECFC303CA27593582D8FF132" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386DB671ECFC303CA27593582D8FF132_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386DB671ECFC303CA27593582D8FF132" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386DB671ECFC303CA27593582D8FF132" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386DB671ECFC303CA27593582D8FF132" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386DB671ECFC303CA27593582D8FF132" xlink:type="arc" />
    <link:label id="lab_biib_AGTCMember_B48193D647AD3D5A7D1593582D8FDE14_terseLabel_en-US" xlink:label="lab_biib_AGTCMember_B48193D647AD3D5A7D1593582D8FDE14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGTC</link:label>
    <link:label id="lab_biib_AGTCMember_B48193D647AD3D5A7D1593582D8FDE14_label_en-US" xlink:label="lab_biib_AGTCMember_B48193D647AD3D5A7D1593582D8FDE14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGTC [Member]</link:label>
    <link:label id="lab_biib_AGTCMember_B48193D647AD3D5A7D1593582D8FDE14_documentation_en-US" xlink:label="lab_biib_AGTCMember_B48193D647AD3D5A7D1593582D8FDE14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGTC [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AGTCMember" xlink:label="loc_biib_AGTCMember_B48193D647AD3D5A7D1593582D8FDE14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AGTCMember_B48193D647AD3D5A7D1593582D8FDE14" xlink:to="lab_biib_AGTCMember_B48193D647AD3D5A7D1593582D8FDE14" xlink:type="arc" />
    <link:label id="lab_biib_MitsubishiTanabePharmaCorporationMember_7941860A9B32CF4299F093582D8F5B73_terseLabel_en-US" xlink:label="lab_biib_MitsubishiTanabePharmaCorporationMember_7941860A9B32CF4299F093582D8F5B73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation</link:label>
    <link:label id="lab_biib_MitsubishiTanabePharmaCorporationMember_7941860A9B32CF4299F093582D8F5B73_label_en-US" xlink:label="lab_biib_MitsubishiTanabePharmaCorporationMember_7941860A9B32CF4299F093582D8F5B73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation [Member]</link:label>
    <link:label id="lab_biib_MitsubishiTanabePharmaCorporationMember_7941860A9B32CF4299F093582D8F5B73_documentation_en-US" xlink:label="lab_biib_MitsubishiTanabePharmaCorporationMember_7941860A9B32CF4299F093582D8F5B73" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mitsubishi Tanabe Pharmaceutical Corporation [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_MitsubishiTanabePharmaCorporationMember" xlink:label="loc_biib_MitsubishiTanabePharmaCorporationMember_7941860A9B32CF4299F093582D8F5B73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MitsubishiTanabePharmaCorporationMember_7941860A9B32CF4299F093582D8F5B73" xlink:to="lab_biib_MitsubishiTanabePharmaCorporationMember_7941860A9B32CF4299F093582D8F5B73" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Line Items]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4_label_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Line Items]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4_documentation_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4" xlink:to="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0982A2008736AE2F497A93582D8F3304_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0982A2008736AE2F497A93582D8F3304" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0982A2008736AE2F497A93582D8F3304_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0982A2008736AE2F497A93582D8F3304" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0982A2008736AE2F497A93582D8F3304" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0982A2008736AE2F497A93582D8F3304" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0982A2008736AE2F497A93582D8F3304" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_93C44E2EF15B0D6F10A193582D8F5120_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_93C44E2EF15B0D6F10A193582D8F5120" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_93C44E2EF15B0D6F10A193582D8F5120_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_93C44E2EF15B0D6F10A193582D8F5120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_93C44E2EF15B0D6F10A193582D8F5120" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_93C44E2EF15B0D6F10A193582D8F5120" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_93C44E2EF15B0D6F10A193582D8F5120" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_4C6FDBBFDB4990C670C093582D8F8B57_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_4C6FDBBFDB4990C670C093582D8F8B57" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_4C6FDBBFDB4990C670C093582D8F8B57_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_4C6FDBBFDB4990C670C093582D8F8B57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_4C6FDBBFDB4990C670C093582D8F8B57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_4C6FDBBFDB4990C670C093582D8F8B57" xlink:to="lab_us-gaap_RestructuringCharges_4C6FDBBFDB4990C670C093582D8F8B57" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_7BD2FD44548E7769BF6393582D8F1D6F_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_7BD2FD44548E7769BF6393582D8F1D6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_7BD2FD44548E7769BF6393582D8F1D6F_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_7BD2FD44548E7769BF6393582D8F1D6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_7BD2FD44548E7769BF6393582D8F1D6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_7BD2FD44548E7769BF6393582D8F1D6F" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_7BD2FD44548E7769BF6393582D8F1D6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_80AE7224E0EC5D14079E93D5C96E6C84_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_80AE7224E0EC5D14079E93D5C96E6C84" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outside the U.S</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_80AE7224E0EC5D14079E93D5C96E6C84_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_80AE7224E0EC5D14079E93D5C96E6C84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_80AE7224E0EC5D14079E93D5C96E6C84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_80AE7224E0EC5D14079E93D5C96E6C84" xlink:to="lab_us-gaap_ForeignCountryMember_80AE7224E0EC5D14079E93D5C96E6C84" xlink:type="arc" />
    <link:label id="lab_country_US_02D07D2C9CEA6EF4DBD693D5C96E1867_terseLabel_en-US" xlink:label="lab_country_US_02D07D2C9CEA6EF4DBD693D5C96E1867" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S</link:label>
    <link:label id="lab_country_US_02D07D2C9CEA6EF4DBD693D5C96E1867_label_en-US" xlink:label="lab_country_US_02D07D2C9CEA6EF4DBD693D5C96E1867" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="loc_country_US_02D07D2C9CEA6EF4DBD693D5C96E1867" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_02D07D2C9CEA6EF4DBD693D5C96E1867" xlink:to="lab_country_US_02D07D2C9CEA6EF4DBD693D5C96E1867" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_C3349773AA0D57BEB8B993D5C96EC538_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_C3349773AA0D57BEB8B993D5C96EC538" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_C3349773AA0D57BEB8B993D5C96EC538_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_C3349773AA0D57BEB8B993D5C96EC538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C3349773AA0D57BEB8B993D5C96EC538" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C3349773AA0D57BEB8B993D5C96EC538" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_C3349773AA0D57BEB8B993D5C96EC538" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_FE8730FCE8FA2CC590FD93D5C96FB578_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_FE8730FCE8FA2CC590FD93D5C96FB578" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_FE8730FCE8FA2CC590FD93D5C96FB578_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_FE8730FCE8FA2CC590FD93D5C96FB578" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_FE8730FCE8FA2CC590FD93D5C96FB578" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_FE8730FCE8FA2CC590FD93D5C96FB578" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_FE8730FCE8FA2CC590FD93D5C96FB578" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E0FFB83D9FE6FB03368793D5C96F1696_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E0FFB83D9FE6FB03368793D5C96F1696" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E0FFB83D9FE6FB03368793D5C96F1696_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E0FFB83D9FE6FB03368793D5C96F1696" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E0FFB83D9FE6FB03368793D5C96F1696" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E0FFB83D9FE6FB03368793D5C96F1696" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E0FFB83D9FE6FB03368793D5C96F1696" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_353E77C6D02DCF8B951893D5C96FF734_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_353E77C6D02DCF8B951893D5C96FF734" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies by Nature of Contingency [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_353E77C6D02DCF8B951893D5C96FF734_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_353E77C6D02DCF8B951893D5C96FF734" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_353E77C6D02DCF8B951893D5C96FF734" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_353E77C6D02DCF8B951893D5C96FF734" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_353E77C6D02DCF8B951893D5C96FF734" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_46A8009752A5B984C18893D5C96FEE7D_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_46A8009752A5B984C18893D5C96FEE7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_46A8009752A5B984C18893D5C96FEE7D_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_46A8009752A5B984C18893D5C96FEE7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_46A8009752A5B984C18893D5C96FEE7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain_46A8009752A5B984C18893D5C96FEE7D" xlink:to="lab_us-gaap_LossContingencyNatureDomain_46A8009752A5B984C18893D5C96FEE7D" xlink:type="arc" />
    <link:label id="lab_biib_HoechstMember_9787FDBA9337F3760D3E93D5C96FA543_terseLabel_en-US" xlink:label="lab_biib_HoechstMember_9787FDBA9337F3760D3E93D5C96FA543" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hoechst</link:label>
    <link:label id="lab_biib_HoechstMember_9787FDBA9337F3760D3E93D5C96FA543_label_en-US" xlink:label="lab_biib_HoechstMember_9787FDBA9337F3760D3E93D5C96FA543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hoechst [Member]</link:label>
    <link:label id="lab_biib_HoechstMember_9787FDBA9337F3760D3E93D5C96FA543_documentation_en-US" xlink:label="lab_biib_HoechstMember_9787FDBA9337F3760D3E93D5C96FA543" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hoechst [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_HoechstMember" xlink:label="loc_biib_HoechstMember_9787FDBA9337F3760D3E93D5C96FA543" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_HoechstMember_9787FDBA9337F3760D3E93D5C96FA543" xlink:to="lab_biib_HoechstMember_9787FDBA9337F3760D3E93D5C96FA543" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalProductsAxis_E3851D105C85384660D593D5C96F98D6_terseLabel_en-US" xlink:label="lab_biib_AdditionalProductsAxis_E3851D105C85384660D593D5C96F98D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Products [Axis]</link:label>
    <link:label id="lab_biib_AdditionalProductsAxis_E3851D105C85384660D593D5C96F98D6_label_en-US" xlink:label="lab_biib_AdditionalProductsAxis_E3851D105C85384660D593D5C96F98D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Products [Axis]</link:label>
    <link:label id="lab_biib_AdditionalProductsAxis_E3851D105C85384660D593D5C96F98D6_documentation_en-US" xlink:label="lab_biib_AdditionalProductsAxis_E3851D105C85384660D593D5C96F98D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional products.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AdditionalProductsAxis" xlink:label="loc_biib_AdditionalProductsAxis_E3851D105C85384660D593D5C96F98D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalProductsAxis_E3851D105C85384660D593D5C96F98D6" xlink:to="lab_biib_AdditionalProductsAxis_E3851D105C85384660D593D5C96F98D6" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalProductsDomain_06DD47C969E3A03571D493D5C96F6545_terseLabel_en-US" xlink:label="lab_biib_AdditionalProductsDomain_06DD47C969E3A03571D493D5C96F6545" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Products [Domain]</link:label>
    <link:label id="lab_biib_AdditionalProductsDomain_06DD47C969E3A03571D493D5C96F6545_label_en-US" xlink:label="lab_biib_AdditionalProductsDomain_06DD47C969E3A03571D493D5C96F6545" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Products [Domain]</link:label>
    <link:label id="lab_biib_AdditionalProductsDomain_06DD47C969E3A03571D493D5C96F6545_documentation_en-US" xlink:label="lab_biib_AdditionalProductsDomain_06DD47C969E3A03571D493D5C96F6545" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional products.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AdditionalProductsDomain" xlink:label="loc_biib_AdditionalProductsDomain_06DD47C969E3A03571D493D5C96F6545" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalProductsDomain_06DD47C969E3A03571D493D5C96F6545" xlink:to="lab_biib_AdditionalProductsDomain_06DD47C969E3A03571D493D5C96F6545" xlink:type="arc" />
    <link:label id="lab_biib_NewAntiCd20Member_6AC8E63DCEFFC5DC6C6393D5C96F77F1_verboseLabel_en-US" xlink:label="lab_biib_NewAntiCd20Member_6AC8E63DCEFFC5DC6C6393D5C96F77F1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">New Anti-CD20</link:label>
    <link:label id="lab_biib_NewAntiCd20Member_6AC8E63DCEFFC5DC6C6393D5C96F77F1_label_en-US" xlink:label="lab_biib_NewAntiCd20Member_6AC8E63DCEFFC5DC6C6393D5C96F77F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Anti Cd20 [Member]</link:label>
    <link:label id="lab_biib_NewAntiCd20Member_6AC8E63DCEFFC5DC6C6393D5C96F77F1_documentation_en-US" xlink:label="lab_biib_NewAntiCd20Member_6AC8E63DCEFFC5DC6C6393D5C96F77F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New Anti-CD20.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_NewAntiCd20Member" xlink:label="loc_biib_NewAntiCd20Member_6AC8E63DCEFFC5DC6C6393D5C96F77F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NewAntiCd20Member_6AC8E63DCEFFC5DC6C6393D5C96F77F1" xlink:to="lab_biib_NewAntiCd20Member_6AC8E63DCEFFC5DC6C6393D5C96F77F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72D9824CCE950F40F21093D5C96F399E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72D9824CCE950F40F21093D5C96F399E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72D9824CCE950F40F21093D5C96F399E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72D9824CCE950F40F21093D5C96F399E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72D9824CCE950F40F21093D5C96F399E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72D9824CCE950F40F21093D5C96F399E" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72D9824CCE950F40F21093D5C96F399E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_B0FA555C1F86CE910CA193D5C96FEAEE_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_B0FA555C1F86CE910CA193D5C96FEAEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_B0FA555C1F86CE910CA193D5C96FEAEE_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_B0FA555C1F86CE910CA193D5C96FEAEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_B0FA555C1F86CE910CA193D5C96FEAEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_B0FA555C1F86CE910CA193D5C96FEAEE" xlink:to="lab_us-gaap_EquityMethodInvesteeNameDomain_B0FA555C1F86CE910CA193D5C96FEAEE" xlink:type="arc" />
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_1FF89E58852BA33785A993D5C96F87C1_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_1FF89E58852BA33785A993D5C96F87C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_1FF89E58852BA33785A993D5C96F87C1_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_1FF89E58852BA33785A993D5C96F87C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_1FF89E58852BA33785A993D5C96F87C1_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_1FF89E58852BA33785A993D5C96F87C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_1FF89E58852BA33785A993D5C96F87C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember_1FF89E58852BA33785A993D5C96F87C1" xlink:to="lab_biib_SamsungBiosimilarAgreementMember_1FF89E58852BA33785A993D5C96F87C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductOrServiceAxis_C1CC42211F03E706987B93D5C96FD83E_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_C1CC42211F03E706987B93D5C96FD83E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_C1CC42211F03E706987B93D5C96FD83E_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_C1CC42211F03E706987B93D5C96FD83E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_C1CC42211F03E706987B93D5C96FD83E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis_C1CC42211F03E706987B93D5C96FD83E" xlink:to="lab_us-gaap_ProductOrServiceAxis_C1CC42211F03E706987B93D5C96FD83E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="lab_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:type="arc" />
    <link:label id="lab_biib_RituxanMember_5ABFC98D8F2F43AB5C1D93D5C96FA970_verboseLabel_en-US" xlink:label="lab_biib_RituxanMember_5ABFC98D8F2F43AB5C1D93D5C96FA970" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RITUXAN</link:label>
    <link:label id="lab_biib_RituxanMember_5ABFC98D8F2F43AB5C1D93D5C96FA970_label_en-US" xlink:label="lab_biib_RituxanMember_5ABFC98D8F2F43AB5C1D93D5C96FA970" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RITUXAN [Member]</link:label>
    <link:label id="lab_biib_RituxanMember_5ABFC98D8F2F43AB5C1D93D5C96FA970_documentation_en-US" xlink:label="lab_biib_RituxanMember_5ABFC98D8F2F43AB5C1D93D5C96FA970" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RITUXAN.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_5ABFC98D8F2F43AB5C1D93D5C96FA970" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RituxanMember_5ABFC98D8F2F43AB5C1D93D5C96FA970" xlink:to="lab_biib_RituxanMember_5ABFC98D8F2F43AB5C1D93D5C96FA970" xlink:type="arc" />
    <link:label id="lab_biib_GAZYVAMember_7148DE974A124A82D98893D5C96F3750_terseLabel_en-US" xlink:label="lab_biib_GAZYVAMember_7148DE974A124A82D98893D5C96F3750" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GAZYVA</link:label>
    <link:label id="lab_biib_GAZYVAMember_7148DE974A124A82D98893D5C96F3750_label_en-US" xlink:label="lab_biib_GAZYVAMember_7148DE974A124A82D98893D5C96F3750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:label id="lab_biib_GAZYVAMember_7148DE974A124A82D98893D5C96F3750_documentation_en-US" xlink:label="lab_biib_GAZYVAMember_7148DE974A124A82D98893D5C96F3750" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_7148DE974A124A82D98893D5C96F3750" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GAZYVAMember_7148DE974A124A82D98893D5C96F3750" xlink:to="lab_biib_GAZYVAMember_7148DE974A124A82D98893D5C96F3750" xlink:type="arc" />
    <link:label id="lab_biib_ThirdPartyAntiCdTwentyMember_3114A1838DD1F322077B93D5C9701C93_verboseLabel_en-US" xlink:label="lab_biib_ThirdPartyAntiCdTwentyMember_3114A1838DD1F322077B93D5C9701C93" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Third Party Anti CD-20</link:label>
    <link:label id="lab_biib_ThirdPartyAntiCdTwentyMember_3114A1838DD1F322077B93D5C9701C93_label_en-US" xlink:label="lab_biib_ThirdPartyAntiCdTwentyMember_3114A1838DD1F322077B93D5C9701C93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third Party Anti CD Twenty [Member]</link:label>
    <link:label id="lab_biib_ThirdPartyAntiCdTwentyMember_3114A1838DD1F322077B93D5C9701C93_documentation_en-US" xlink:label="lab_biib_ThirdPartyAntiCdTwentyMember_3114A1838DD1F322077B93D5C9701C93" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Third Party Anti CD 20.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ThirdPartyAntiCdTwentyMember" xlink:label="loc_biib_ThirdPartyAntiCdTwentyMember_3114A1838DD1F322077B93D5C9701C93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThirdPartyAntiCdTwentyMember_3114A1838DD1F322077B93D5C9701C93" xlink:to="lab_biib_ThirdPartyAntiCdTwentyMember_3114A1838DD1F322077B93D5C9701C93" xlink:type="arc" />
    <link:label id="lab_biib_ELOCTATEMember_BABCFA279ECCB60FEE6993D5C9709290_terseLabel_en-US" xlink:label="lab_biib_ELOCTATEMember_BABCFA279ECCB60FEE6993D5C9709290" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ELOCTATE</link:label>
    <link:label id="lab_biib_ELOCTATEMember_BABCFA279ECCB60FEE6993D5C9709290_label_en-US" xlink:label="lab_biib_ELOCTATEMember_BABCFA279ECCB60FEE6993D5C9709290" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ELOCTATE [Member]</link:label>
    <link:label id="lab_biib_ELOCTATEMember_BABCFA279ECCB60FEE6993D5C9709290_documentation_en-US" xlink:label="lab_biib_ELOCTATEMember_BABCFA279ECCB60FEE6993D5C9709290" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ELOCTATE [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_BABCFA279ECCB60FEE6993D5C9709290" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ELOCTATEMember_BABCFA279ECCB60FEE6993D5C9709290" xlink:to="lab_biib_ELOCTATEMember_BABCFA279ECCB60FEE6993D5C9709290" xlink:type="arc" />
    <link:label id="lab_biib_ALPROLIXMember_34C73C20FB27CAFA6C3793D5C9702889_terseLabel_en-US" xlink:label="lab_biib_ALPROLIXMember_34C73C20FB27CAFA6C3793D5C9702889" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ALPROLIX</link:label>
    <link:label id="lab_biib_ALPROLIXMember_34C73C20FB27CAFA6C3793D5C9702889_label_en-US" xlink:label="lab_biib_ALPROLIXMember_34C73C20FB27CAFA6C3793D5C9702889" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ALPROLIX [Member]</link:label>
    <link:label id="lab_biib_ALPROLIXMember_34C73C20FB27CAFA6C3793D5C9702889_documentation_en-US" xlink:label="lab_biib_ALPROLIXMember_34C73C20FB27CAFA6C3793D5C9702889" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ALPROLIX [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_34C73C20FB27CAFA6C3793D5C9702889" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ALPROLIXMember_34C73C20FB27CAFA6C3793D5C9702889" xlink:to="lab_biib_ALPROLIXMember_34C73C20FB27CAFA6C3793D5C9702889" xlink:type="arc" />
    <link:label id="lab_biib_OcrelizumabMember_8DC2C6B53A41932DDAEF93D5C97034B0_verboseLabel_en-US" xlink:label="lab_biib_OcrelizumabMember_8DC2C6B53A41932DDAEF93D5C97034B0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Ocrelizumab</link:label>
    <link:label id="lab_biib_OcrelizumabMember_8DC2C6B53A41932DDAEF93D5C97034B0_label_en-US" xlink:label="lab_biib_OcrelizumabMember_8DC2C6B53A41932DDAEF93D5C97034B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ocrelizumab [Member]</link:label>
    <link:label id="lab_biib_OcrelizumabMember_8DC2C6B53A41932DDAEF93D5C97034B0_documentation_en-US" xlink:label="lab_biib_OcrelizumabMember_8DC2C6B53A41932DDAEF93D5C97034B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ocrelizumab.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_OcrelizumabMember" xlink:label="loc_biib_OcrelizumabMember_8DC2C6B53A41932DDAEF93D5C97034B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OcrelizumabMember_8DC2C6B53A41932DDAEF93D5C97034B0" xlink:to="lab_biib_OcrelizumabMember_8DC2C6B53A41932DDAEF93D5C97034B0" xlink:type="arc" />
    <link:label id="lab_biib_SOD1Member_EB60A87A0FB3E1E02A2793DFA04EC495_terseLabel_en-US" xlink:label="lab_biib_SOD1Member_EB60A87A0FB3E1E02A2793DFA04EC495" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SOD1</link:label>
    <link:label id="lab_biib_SOD1Member_EB60A87A0FB3E1E02A2793DFA04EC495_label_en-US" xlink:label="lab_biib_SOD1Member_EB60A87A0FB3E1E02A2793DFA04EC495" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SOD1 [Member]</link:label>
    <link:label id="lab_biib_SOD1Member_EB60A87A0FB3E1E02A2793DFA04EC495_documentation_en-US" xlink:label="lab_biib_SOD1Member_EB60A87A0FB3E1E02A2793DFA04EC495" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SOD1 [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SOD1Member" xlink:label="loc_biib_SOD1Member_EB60A87A0FB3E1E02A2793DFA04EC495" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SOD1Member_EB60A87A0FB3E1E02A2793DFA04EC495" xlink:to="lab_biib_SOD1Member_EB60A87A0FB3E1E02A2793DFA04EC495" xlink:type="arc" />
    <link:label id="lab_biib_DMPKMember_DF85E0ED1B849170CEEE93D5C9704FCA_terseLabel_en-US" xlink:label="lab_biib_DMPKMember_DF85E0ED1B849170CEEE93D5C9704FCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DMPK</link:label>
    <link:label id="lab_biib_DMPKMember_DF85E0ED1B849170CEEE93D5C9704FCA_label_en-US" xlink:label="lab_biib_DMPKMember_DF85E0ED1B849170CEEE93D5C9704FCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DMPK [Member]</link:label>
    <link:label id="lab_biib_DMPKMember_DF85E0ED1B849170CEEE93D5C9704FCA_documentation_en-US" xlink:label="lab_biib_DMPKMember_DF85E0ED1B849170CEEE93D5C9704FCA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DMPK [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_DMPKMember" xlink:label="loc_biib_DMPKMember_DF85E0ED1B849170CEEE93D5C9704FCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DMPKMember_DF85E0ED1B849170CEEE93D5C9704FCA" xlink:to="lab_biib_DMPKMember_DF85E0ED1B849170CEEE93D5C9704FCA" xlink:type="arc" />
    <link:label id="lab_biib_SMNRxMember_7A78831878BA77DB329293D5C970ADF0_terseLabel_en-US" xlink:label="lab_biib_SMNRxMember_7A78831878BA77DB329293D5C970ADF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SMNRx</link:label>
    <link:label id="lab_biib_SMNRxMember_7A78831878BA77DB329293D5C970ADF0_label_en-US" xlink:label="lab_biib_SMNRxMember_7A78831878BA77DB329293D5C970ADF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SMNRx [Member]</link:label>
    <link:label id="lab_biib_SMNRxMember_7A78831878BA77DB329293D5C970ADF0_documentation_en-US" xlink:label="lab_biib_SMNRxMember_7A78831878BA77DB329293D5C970ADF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SMNRx [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SMNRxMember" xlink:label="loc_biib_SMNRxMember_7A78831878BA77DB329293D5C970ADF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SMNRxMember_7A78831878BA77DB329293D5C970ADF0" xlink:to="lab_biib_SMNRxMember_7A78831878BA77DB329293D5C970ADF0" xlink:type="arc" />
    <link:label id="lab_biib_LeadprogramsMember_753B73C00DCDB9A4950A93D5C970D598_terseLabel_en-US" xlink:label="lab_biib_LeadprogramsMember_753B73C00DCDB9A4950A93D5C970D598" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lead programs</link:label>
    <link:label id="lab_biib_LeadprogramsMember_753B73C00DCDB9A4950A93D5C970D598_label_en-US" xlink:label="lab_biib_LeadprogramsMember_753B73C00DCDB9A4950A93D5C970D598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lead programs [Member]</link:label>
    <link:label id="lab_biib_LeadprogramsMember_753B73C00DCDB9A4950A93D5C970D598_documentation_en-US" xlink:label="lab_biib_LeadprogramsMember_753B73C00DCDB9A4950A93D5C970D598" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lead programs [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_LeadprogramsMember" xlink:label="loc_biib_LeadprogramsMember_753B73C00DCDB9A4950A93D5C970D598" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LeadprogramsMember_753B73C00DCDB9A4950A93D5C970D598" xlink:to="lab_biib_LeadprogramsMember_753B73C00DCDB9A4950A93D5C970D598" xlink:type="arc" />
    <link:label id="lab_biib_DiscoveryprogramsMember_30C901FB7EE2418F69A693D5C97076E5_terseLabel_en-US" xlink:label="lab_biib_DiscoveryprogramsMember_30C901FB7EE2418F69A693D5C97076E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discovery programs</link:label>
    <link:label id="lab_biib_DiscoveryprogramsMember_30C901FB7EE2418F69A693D5C97076E5_label_en-US" xlink:label="lab_biib_DiscoveryprogramsMember_30C901FB7EE2418F69A693D5C97076E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discovery programs [Member]</link:label>
    <link:label id="lab_biib_DiscoveryprogramsMember_30C901FB7EE2418F69A693D5C97076E5_documentation_en-US" xlink:label="lab_biib_DiscoveryprogramsMember_30C901FB7EE2418F69A693D5C97076E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discovery programs [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_DiscoveryprogramsMember" xlink:label="loc_biib_DiscoveryprogramsMember_30C901FB7EE2418F69A693D5C97076E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DiscoveryprogramsMember_30C901FB7EE2418F69A693D5C97076E5" xlink:to="lab_biib_DiscoveryprogramsMember_30C901FB7EE2418F69A693D5C97076E5" xlink:type="arc" />
    <link:label id="lab_biib_BiosimilarsMember_10197333C26473E38D5093D5C970D2A4_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember_10197333C26473E38D5093D5C970D2A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_10197333C26473E38D5093D5C970D2A4_label_en-US" xlink:label="lab_biib_BiosimilarsMember_10197333C26473E38D5093D5C970D2A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_10197333C26473E38D5093D5C970D2A4_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember_10197333C26473E38D5093D5C970D2A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_10197333C26473E38D5093D5C970D2A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember_10197333C26473E38D5093D5C970D2A4" xlink:to="lab_biib_BiosimilarsMember_10197333C26473E38D5093D5C970D2A4" xlink:type="arc" />
    <link:label id="lab_biib_RocheGroupGenentechMember_1C2551141E3D2D79B80C93D5C97023A7_verboseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_1C2551141E3D2D79B80C93D5C97023A7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Roche Group - Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_1C2551141E3D2D79B80C93D5C97023A7_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_1C2551141E3D2D79B80C93D5C97023A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_1C2551141E3D2D79B80C93D5C97023A7_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_1C2551141E3D2D79B80C93D5C97023A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_1C2551141E3D2D79B80C93D5C97023A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember_1C2551141E3D2D79B80C93D5C97023A7" xlink:to="lab_biib_RocheGroupGenentechMember_1C2551141E3D2D79B80C93D5C97023A7" xlink:type="arc" />
    <link:label id="lab_biib_GenentechMember_3A76385BB3F92D60E76093D5C970B6CF_verboseLabel_en-US" xlink:label="lab_biib_GenentechMember_3A76385BB3F92D60E76093D5C970B6CF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_GenentechMember_3A76385BB3F92D60E76093D5C970B6CF_label_en-US" xlink:label="lab_biib_GenentechMember_3A76385BB3F92D60E76093D5C970B6CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genentech [Member]</link:label>
    <link:label id="lab_biib_GenentechMember_3A76385BB3F92D60E76093D5C970B6CF_documentation_en-US" xlink:label="lab_biib_GenentechMember_3A76385BB3F92D60E76093D5C970B6CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Genentech.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_GenentechMember" xlink:label="loc_biib_GenentechMember_3A76385BB3F92D60E76093D5C970B6CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GenentechMember_3A76385BB3F92D60E76093D5C970B6CF" xlink:to="lab_biib_GenentechMember_3A76385BB3F92D60E76093D5C970B6CF" xlink:type="arc" />
    <link:label id="lab_biib_ElanMember_F8C67C8905D242E26AE793D5C970525E_verboseLabel_en-US" xlink:label="lab_biib_ElanMember_F8C67C8905D242E26AE793D5C970525E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Elan</link:label>
    <link:label id="lab_biib_ElanMember_F8C67C8905D242E26AE793D5C970525E_label_en-US" xlink:label="lab_biib_ElanMember_F8C67C8905D242E26AE793D5C970525E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Elan [Member]</link:label>
    <link:label id="lab_biib_ElanMember_F8C67C8905D242E26AE793D5C970525E_documentation_en-US" xlink:label="lab_biib_ElanMember_F8C67C8905D242E26AE793D5C970525E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Elan.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ElanMember" xlink:label="loc_biib_ElanMember_F8C67C8905D242E26AE793D5C970525E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ElanMember_F8C67C8905D242E26AE793D5C970525E" xlink:to="lab_biib_ElanMember_F8C67C8905D242E26AE793D5C970525E" xlink:type="arc" />
    <link:label id="lab_biib_AcordaMember_4E92B1A6BF7AF627891893D5C9700BB8_terseLabel_en-US" xlink:label="lab_biib_AcordaMember_4E92B1A6BF7AF627891893D5C9700BB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acorda</link:label>
    <link:label id="lab_biib_AcordaMember_4E92B1A6BF7AF627891893D5C9700BB8_label_en-US" xlink:label="lab_biib_AcordaMember_4E92B1A6BF7AF627891893D5C9700BB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acorda [Member]</link:label>
    <link:label id="lab_biib_AcordaMember_4E92B1A6BF7AF627891893D5C9700BB8_documentation_en-US" xlink:label="lab_biib_AcordaMember_4E92B1A6BF7AF627891893D5C9700BB8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acorda.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AcordaMember" xlink:label="loc_biib_AcordaMember_4E92B1A6BF7AF627891893D5C9700BB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AcordaMember_4E92B1A6BF7AF627891893D5C9700BB8" xlink:to="lab_biib_AcordaMember_4E92B1A6BF7AF627891893D5C9700BB8" xlink:type="arc" />
    <link:label id="lab_biib_SwedishOrphanBiovitrumMember_E18976E6EAC193F1670B93D5C9705535_verboseLabel_en-US" xlink:label="lab_biib_SwedishOrphanBiovitrumMember_E18976E6EAC193F1670B93D5C9705535" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum</link:label>
    <link:label id="lab_biib_SwedishOrphanBiovitrumMember_E18976E6EAC193F1670B93D5C9705535_label_en-US" xlink:label="lab_biib_SwedishOrphanBiovitrumMember_E18976E6EAC193F1670B93D5C9705535" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum [Member]</link:label>
    <link:label id="lab_biib_SwedishOrphanBiovitrumMember_E18976E6EAC193F1670B93D5C9705535_documentation_en-US" xlink:label="lab_biib_SwedishOrphanBiovitrumMember_E18976E6EAC193F1670B93D5C9705535" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Swedish orphan biovitrum.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SwedishOrphanBiovitrumMember" xlink:label="loc_biib_SwedishOrphanBiovitrumMember_E18976E6EAC193F1670B93D5C9705535" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SwedishOrphanBiovitrumMember_E18976E6EAC193F1670B93D5C9705535" xlink:to="lab_biib_SwedishOrphanBiovitrumMember_E18976E6EAC193F1670B93D5C9705535" xlink:type="arc" />
    <link:label id="lab_biib_AbbvieMember_7603D7708BE1A05A352693D5C9705C45_verboseLabel_en-US" xlink:label="lab_biib_AbbvieMember_7603D7708BE1A05A352693D5C9705C45" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:label id="lab_biib_AbbvieMember_7603D7708BE1A05A352693D5C9705C45_label_en-US" xlink:label="lab_biib_AbbvieMember_7603D7708BE1A05A352693D5C9705C45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AbbVie Member</link:label>
    <link:label id="lab_biib_AbbvieMember_7603D7708BE1A05A352693D5C9705C45_documentation_en-US" xlink:label="lab_biib_AbbvieMember_7603D7708BE1A05A352693D5C9705C45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AbbvieMember" xlink:label="loc_biib_AbbvieMember_7603D7708BE1A05A352693D5C9705C45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AbbvieMember_7603D7708BE1A05A352693D5C9705C45" xlink:to="lab_biib_AbbvieMember_7603D7708BE1A05A352693D5C9705C45" xlink:type="arc" />
    <link:label id="lab_biib_IsisPharmaceuticalsMember_F94324D1F70DE576704793D5C97041A4_terseLabel_en-US" xlink:label="lab_biib_IsisPharmaceuticalsMember_F94324D1F70DE576704793D5C97041A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals</link:label>
    <link:label id="lab_biib_IsisPharmaceuticalsMember_F94324D1F70DE576704793D5C97041A4_label_en-US" xlink:label="lab_biib_IsisPharmaceuticalsMember_F94324D1F70DE576704793D5C97041A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Isis Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_IsisPharmaceuticalsMember_F94324D1F70DE576704793D5C97041A4_documentation_en-US" xlink:label="lab_biib_IsisPharmaceuticalsMember_F94324D1F70DE576704793D5C97041A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Isis Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_IsisPharmaceuticalsMember" xlink:label="loc_biib_IsisPharmaceuticalsMember_F94324D1F70DE576704793D5C97041A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IsisPharmaceuticalsMember_F94324D1F70DE576704793D5C97041A4" xlink:to="lab_biib_IsisPharmaceuticalsMember_F94324D1F70DE576704793D5C97041A4" xlink:type="arc" />
    <link:label id="lab_biib_SangamoBioSciencesMember_B99A805243157ABB445893D5C9702A6C_terseLabel_en-US" xlink:label="lab_biib_SangamoBioSciencesMember_B99A805243157ABB445893D5C9702A6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sangamo BioSciences</link:label>
    <link:label id="lab_biib_SangamoBioSciencesMember_B99A805243157ABB445893D5C9702A6C_label_en-US" xlink:label="lab_biib_SangamoBioSciencesMember_B99A805243157ABB445893D5C9702A6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sangamo BioSciences [Member]</link:label>
    <link:label id="lab_biib_SangamoBioSciencesMember_B99A805243157ABB445893D5C9702A6C_documentation_en-US" xlink:label="lab_biib_SangamoBioSciencesMember_B99A805243157ABB445893D5C9702A6C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sangamo BioSciences [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SangamoBioSciencesMember" xlink:label="loc_biib_SangamoBioSciencesMember_B99A805243157ABB445893D5C9702A6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoBioSciencesMember_B99A805243157ABB445893D5C9702A6C" xlink:to="lab_biib_SangamoBioSciencesMember_B99A805243157ABB445893D5C9702A6C" xlink:type="arc" />
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_3566344DF130A66F861E93D5C971A63B_terseLabel_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember_3566344DF130A66F861E93D5C971A63B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other research and discovery</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_3566344DF130A66F861E93D5C971A63B_label_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember_3566344DF130A66F861E93D5C971A63B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_3566344DF130A66F861E93D5C971A63B_documentation_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember_3566344DF130A66F861E93D5C971A63B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_OtherresearchanddiscoveryMember" xlink:label="loc_biib_OtherresearchanddiscoveryMember_3566344DF130A66F861E93D5C971A63B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherresearchanddiscoveryMember_3566344DF130A66F861E93D5C971A63B" xlink:to="lab_biib_OtherresearchanddiscoveryMember_3566344DF130A66F861E93D5C971A63B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_B6420F58A851EB781E3A93D5C9715D0C_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_B6420F58A851EB781E3A93D5C9715D0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_B6420F58A851EB781E3A93D5C9715D0C_label_en-US" xlink:label="lab_us-gaap_RangeAxis_B6420F58A851EB781E3A93D5C9715D0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_B6420F58A851EB781E3A93D5C9715D0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_B6420F58A851EB781E3A93D5C9715D0C" xlink:to="lab_us-gaap_RangeAxis_B6420F58A851EB781E3A93D5C9715D0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_8652B90BD740441D6AED93D5C971512E_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_8652B90BD740441D6AED93D5C971512E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_8652B90BD740441D6AED93D5C971512E_label_en-US" xlink:label="lab_us-gaap_RangeMember_8652B90BD740441D6AED93D5C971512E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8652B90BD740441D6AED93D5C971512E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_8652B90BD740441D6AED93D5C971512E" xlink:to="lab_us-gaap_RangeMember_8652B90BD740441D6AED93D5C971512E" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_656BB3D2295C575E68A193D5C971258A_verboseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_656BB3D2295C575E68A193D5C971258A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_656BB3D2295C575E68A193D5C971258A_label_en-US" xlink:label="lab_us-gaap_MaximumMember_656BB3D2295C575E68A193D5C971258A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_656BB3D2295C575E68A193D5C971258A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_656BB3D2295C575E68A193D5C971258A" xlink:to="lab_us-gaap_MaximumMember_656BB3D2295C575E68A193D5C971258A" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_AAA47C9143B57245747D93D5C9712C99_verboseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_AAA47C9143B57245747D93D5C9712C99" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_AAA47C9143B57245747D93D5C9712C99_label_en-US" xlink:label="lab_us-gaap_MinimumMember_AAA47C9143B57245747D93D5C9712C99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_AAA47C9143B57245747D93D5C9712C99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_AAA47C9143B57245747D93D5C9712C99" xlink:to="lab_us-gaap_MinimumMember_AAA47C9143B57245747D93D5C9712C99" xlink:type="arc" />
    <link:label id="lab_biib_BiogenIdecHemophiliaMember_C08125830F1C7595D31293D5C9712332_terseLabel_en-US" xlink:label="lab_biib_BiogenIdecHemophiliaMember_C08125830F1C7595D31293D5C9712332" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen Hemophilia</link:label>
    <link:label id="lab_biib_BiogenIdecHemophiliaMember_C08125830F1C7595D31293D5C9712332_label_en-US" xlink:label="lab_biib_BiogenIdecHemophiliaMember_C08125830F1C7595D31293D5C9712332" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen Idec Hemophilia [Member]</link:label>
    <link:label id="lab_biib_BiogenIdecHemophiliaMember_C08125830F1C7595D31293D5C9712332_documentation_en-US" xlink:label="lab_biib_BiogenIdecHemophiliaMember_C08125830F1C7595D31293D5C9712332" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen Idec Hemophilia.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_BiogenIdecHemophiliaMember" xlink:label="loc_biib_BiogenIdecHemophiliaMember_C08125830F1C7595D31293D5C9712332" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiogenIdecHemophiliaMember_C08125830F1C7595D31293D5C9712332" xlink:to="lab_biib_BiogenIdecHemophiliaMember_C08125830F1C7595D31293D5C9712332" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangements and non-collaborative arrangement transactions</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:type="arc" />
    <link:label id="lab_biib_RoyaltiesTermsOfCollaborationAgreement_190F8FE5707A045C034493D5C971DC9F_terseLabel_en-US" xlink:label="lab_biib_RoyaltiesTermsOfCollaborationAgreement_190F8FE5707A045C034493D5C971DC9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties Terms Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_RoyaltiesTermsOfCollaborationAgreement_190F8FE5707A045C034493D5C971DC9F_label_en-US" xlink:label="lab_biib_RoyaltiesTermsOfCollaborationAgreement_190F8FE5707A045C034493D5C971DC9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalties Terms Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_RoyaltiesTermsOfCollaborationAgreement_190F8FE5707A045C034493D5C971DC9F_documentation_en-US" xlink:label="lab_biib_RoyaltiesTermsOfCollaborationAgreement_190F8FE5707A045C034493D5C971DC9F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalties terms of collaboration agreement.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RoyaltiesTermsOfCollaborationAgreement" xlink:label="loc_biib_RoyaltiesTermsOfCollaborationAgreement_190F8FE5707A045C034493D5C971DC9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltiesTermsOfCollaborationAgreement_190F8FE5707A045C034493D5C971DC9F" xlink:to="lab_biib_RoyaltiesTermsOfCollaborationAgreement_190F8FE5707A045C034493D5C971DC9F" xlink:type="arc" />
    <link:label id="lab_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429_verboseLabel_en-US" xlink:label="lab_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships (Textual)</link:label>
    <link:label id="lab_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429_label_en-US" xlink:label="lab_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborations (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429_documentation_en-US" xlink:label="lab_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborations.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_CollaborationsTextualAbstract" xlink:label="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="lab_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_5D0093F9D4DD7378419593D5C971DF0C_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_5D0093F9D4DD7378419593D5C971DF0C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of royalties as per collaboration</link:label>
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_5D0093F9D4DD7378419593D5C971DF0C_label_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_5D0093F9D4DD7378419593D5C971DF0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Royalties As Per Collaboration</link:label>
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_5D0093F9D4DD7378419593D5C971DF0C_documentation_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_5D0093F9D4DD7378419593D5C971DF0C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of royalties as per collaboration.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_5D0093F9D4DD7378419593D5C971DF0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_5D0093F9D4DD7378419593D5C971DF0C" xlink:to="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_5D0093F9D4DD7378419593D5C971DF0C" xlink:type="arc" />
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_AEE58ED468B795DC264293D5C971CEE0_verboseLabel_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement_AEE58ED468B795DC264293D5C971CEE0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Period of collaboration agreement</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_AEE58ED468B795DC264293D5C971CEE0_label_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement_AEE58ED468B795DC264293D5C971CEE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_AEE58ED468B795DC264293D5C971CEE0_documentation_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement_AEE58ED468B795DC264293D5C971CEE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of collaboration agreement.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PeriodOfCollaborationAgreement" xlink:label="loc_biib_PeriodOfCollaborationAgreement_AEE58ED468B795DC264293D5C971CEE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PeriodOfCollaborationAgreement_AEE58ED468B795DC264293D5C971CEE0" xlink:to="lab_biib_PeriodOfCollaborationAgreement_AEE58ED468B795DC264293D5C971CEE0" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated_795C0D84F80A6CD7D7F393D5C9728756_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated_795C0D84F80A6CD7D7F393D5C9728756" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of future development and commercialization expenses payable related to GAZYVA</link:label>
    <link:label id="lab_biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated_795C0D84F80A6CD7D7F393D5C9728756_label_en-US" xlink:label="lab_biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated_795C0D84F80A6CD7D7F393D5C9728756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Development And Commercialization Expenses Payable Related</link:label>
    <link:label id="lab_biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated_795C0D84F80A6CD7D7F393D5C9728756_documentation_en-US" xlink:label="lab_biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated_795C0D84F80A6CD7D7F393D5C9728756" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of development and commercialization expenses payable related.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated" xlink:label="loc_biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated_795C0D84F80A6CD7D7F393D5C9728756" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated_795C0D84F80A6CD7D7F393D5C9728756" xlink:to="lab_biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated_795C0D84F80A6CD7D7F393D5C9728756" xlink:type="arc" />
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_F3F53D5CCF40D2AD5B8E93D5C972EB47_verboseLabel_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_F3F53D5CCF40D2AD5B8E93D5C972EB47" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Future royalties percentage to be received on sale of ocrelizumab</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_F3F53D5CCF40D2AD5B8E93D5C972EB47_label_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_F3F53D5CCF40D2AD5B8E93D5C972EB47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Royalties Percentage To Be Received On Sale Of Product</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_F3F53D5CCF40D2AD5B8E93D5C972EB47_documentation_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_F3F53D5CCF40D2AD5B8E93D5C972EB47" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future royalties percentage to be received on sale of product.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_F3F53D5CCF40D2AD5B8E93D5C972EB47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_F3F53D5CCF40D2AD5B8E93D5C972EB47" xlink:to="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_F3F53D5CCF40D2AD5B8E93D5C972EB47" xlink:type="arc" />
    <link:label id="lab_biib_Reductioninroyaltyrate_F00621A5F66C87870CA493D5C97288EC_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyrate_F00621A5F66C87870CA493D5C97288EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_F00621A5F66C87870CA493D5C97288EC_label_en-US" xlink:label="lab_biib_Reductioninroyaltyrate_F00621A5F66C87870CA493D5C97288EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_F00621A5F66C87870CA493D5C97288EC_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyrate_F00621A5F66C87870CA493D5C97288EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_Reductioninroyaltyrate" xlink:label="loc_biib_Reductioninroyaltyrate_F00621A5F66C87870CA493D5C97288EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyrate_F00621A5F66C87870CA493D5C97288EC" xlink:to="lab_biib_Reductioninroyaltyrate_F00621A5F66C87870CA493D5C97288EC" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_17C1BBA894D5D67B299C93D5C9720751_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_17C1BBA894D5D67B299C93D5C9720751" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Co promotion Operating Profits first fifty million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_17C1BBA894D5D67B299C93D5C9720751_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_17C1BBA894D5D67B299C93D5C9720751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits First Fifty Million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_17C1BBA894D5D67B299C93D5C9720751_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_17C1BBA894D5D67B299C93D5C9720751" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits first fifty million.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_17C1BBA894D5D67B299C93D5C9720751" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_17C1BBA894D5D67B299C93D5C9720751" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_17C1BBA894D5D67B299C93D5C9720751" xlink:type="arc" />
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CB87872C91EF7EEFD73D93D5C9728092_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CB87872C91EF7EEFD73D93D5C9728092" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion operating profit threshold for Rituxan in U S and Canada to determine share of co promotion operating profit prior to amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CB87872C91EF7EEFD73D93D5C9728092_label_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CB87872C91EF7EEFD73D93D5C9728092" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Operating Profit Threshold To Determine Share Of Co Promotion Operating Profit Prior To Amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CB87872C91EF7EEFD73D93D5C9728092_documentation_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CB87872C91EF7EEFD73D93D5C9728092" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CB87872C91EF7EEFD73D93D5C9728092" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CB87872C91EF7EEFD73D93D5C9728092" xlink:to="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CB87872C91EF7EEFD73D93D5C9728092" xlink:type="arc" />
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_7B25B94EF1114380917793D5C9727750_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_7B25B94EF1114380917793D5C9727750" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_7B25B94EF1114380917793D5C9727750_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_7B25B94EF1114380917793D5C9727750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_7B25B94EF1114380917793D5C9727750_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_7B25B94EF1114380917793D5C9727750" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_7B25B94EF1114380917793D5C9727750" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_7B25B94EF1114380917793D5C9727750" xlink:to="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_7B25B94EF1114380917793D5C9727750" xlink:type="arc" />
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_24C275EF6FD786E9805A93D5C972B925_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_24C275EF6FD786E9805A93D5C972B925" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_24C275EF6FD786E9805A93D5C972B925_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_24C275EF6FD786E9805A93D5C972B925" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Of Gross Sales To Be Achieved In Any Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_24C275EF6FD786E9805A93D5C972B925_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_24C275EF6FD786E9805A93D5C972B925" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold of gross sales to be achieved in any twelve consecutive months under option one.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_24C275EF6FD786E9805A93D5C972B925" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_24C275EF6FD786E9805A93D5C972B925" xlink:to="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_24C275EF6FD786E9805A93D5C972B925" xlink:type="arc" />
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_396FA6F8703B8821032293D5C9726CE2_terseLabel_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold_396FA6F8703B8821032293D5C9726CE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Trigger Gross Sales Threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_396FA6F8703B8821032293D5C9726CE2_label_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold_396FA6F8703B8821032293D5C9726CE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Trigger Gross Sales Threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_396FA6F8703B8821032293D5C9726CE2_documentation_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold_396FA6F8703B8821032293D5C9726CE2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales trigger gross sales threshold.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SalesTriggerGrossSalesThreshold" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_396FA6F8703B8821032293D5C9726CE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SalesTriggerGrossSalesThreshold_396FA6F8703B8821032293D5C9726CE2" xlink:to="lab_biib_SalesTriggerGrossSalesThreshold_396FA6F8703B8821032293D5C9726CE2" xlink:type="arc" />
    <link:label id="lab_biib_Futurepercentageofcopromotionoperatingprofits_4F8D1CC7249F45D2C2E093D5C97230D8_terseLabel_en-US" xlink:label="lab_biib_Futurepercentageofcopromotionoperatingprofits_4F8D1CC7249F45D2C2E093D5C97230D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future percentage of co-promotion operating profits</link:label>
    <link:label id="lab_biib_Futurepercentageofcopromotionoperatingprofits_4F8D1CC7249F45D2C2E093D5C97230D8_label_en-US" xlink:label="lab_biib_Futurepercentageofcopromotionoperatingprofits_4F8D1CC7249F45D2C2E093D5C97230D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future percentage of co-promotion operating profits</link:label>
    <link:label id="lab_biib_Futurepercentageofcopromotionoperatingprofits_4F8D1CC7249F45D2C2E093D5C97230D8_documentation_en-US" xlink:label="lab_biib_Futurepercentageofcopromotionoperatingprofits_4F8D1CC7249F45D2C2E093D5C97230D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future percentage of co-promotion operating profits</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_Futurepercentageofcopromotionoperatingprofits" xlink:label="loc_biib_Futurepercentageofcopromotionoperatingprofits_4F8D1CC7249F45D2C2E093D5C97230D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Futurepercentageofcopromotionoperatingprofits_4F8D1CC7249F45D2C2E093D5C97230D8" xlink:to="lab_biib_Futurepercentageofcopromotionoperatingprofits_4F8D1CC7249F45D2C2E093D5C97230D8" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingLosses_CBE5308D32EBE93A422993D5C97284B2_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingLosses_CBE5308D32EBE93A422993D5C97284B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Losses</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingLosses_CBE5308D32EBE93A422993D5C97284B2_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingLosses_CBE5308D32EBE93A422993D5C97284B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Losses</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingLosses_CBE5308D32EBE93A422993D5C97284B2_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingLosses_CBE5308D32EBE93A422993D5C97284B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Losses</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingLosses" xlink:label="loc_biib_PercentageOfCoPromotionOperatingLosses_CBE5308D32EBE93A422993D5C97284B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingLosses_CBE5308D32EBE93A422993D5C97284B2" xlink:to="lab_biib_PercentageOfCoPromotionOperatingLosses_CBE5308D32EBE93A422993D5C97284B2" xlink:type="arc" />
    <link:label id="lab_biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages_A1ADDE750FB90CB8FCEE93D5C972FA4E_terseLabel_en-US" xlink:label="lab_biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages_A1ADDE750FB90CB8FCEE93D5C972FA4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease In Share Of Co Promotion Profits Due To Estimated Compensation Damages</link:label>
    <link:label id="lab_biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages_A1ADDE750FB90CB8FCEE93D5C972FA4E_label_en-US" xlink:label="lab_biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages_A1ADDE750FB90CB8FCEE93D5C972FA4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease In Share Of Co Promotion Profits Due To Estimated Compensation Damages</link:label>
    <link:label id="lab_biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages_A1ADDE750FB90CB8FCEE93D5C972FA4E_documentation_en-US" xlink:label="lab_biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages_A1ADDE750FB90CB8FCEE93D5C972FA4E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Decrease in share of co-promotion profits due to estimated compensation damages.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages" xlink:label="loc_biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages_A1ADDE750FB90CB8FCEE93D5C972FA4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages_A1ADDE750FB90CB8FCEE93D5C972FA4E" xlink:to="lab_biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages_A1ADDE750FB90CB8FCEE93D5C972FA4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_B3C06B5FC540DDDAEAE893D5C972A9FB_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_B3C06B5FC540DDDAEAE893D5C972A9FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue on sales in the rest of world for RITUXAN</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_B3C06B5FC540DDDAEAE893D5C972A9FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_B3C06B5FC540DDDAEAE893D5C972A9FB" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_B3C06B5FC540DDDAEAE893D5C972A9FB" xlink:type="arc" />
    <link:label id="lab_biib_ShareOfCoPromotionProfits_3029BCADED57FD2474BD93D5C9721F45_verboseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_3029BCADED57FD2474BD93D5C9721F45" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_3029BCADED57FD2474BD93D5C9721F45_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_3029BCADED57FD2474BD93D5C9721F45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_3029BCADED57FD2474BD93D5C9721F45_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_3029BCADED57FD2474BD93D5C9721F45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_3029BCADED57FD2474BD93D5C9721F45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits_3029BCADED57FD2474BD93D5C9721F45" xlink:to="lab_biib_ShareOfCoPromotionProfits_3029BCADED57FD2474BD93D5C9721F45" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_C9F22A32CB29E8F0B5E693D5C9720162_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_C9F22A32CB29E8F0B5E693D5C9720162" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of share of Co promotion profits exceeding $50 million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_C9F22A32CB29E8F0B5E693D5C9720162_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_C9F22A32CB29E8F0B5E693D5C9720162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_C9F22A32CB29E8F0B5E693D5C9720162_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_C9F22A32CB29E8F0B5E693D5C9720162" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_C9F22A32CB29E8F0B5E693D5C9720162" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_C9F22A32CB29E8F0B5E693D5C9720162" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_C9F22A32CB29E8F0B5E693D5C9720162" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_CD79E9D32061DEF323FE93D5C9725630_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_CD79E9D32061DEF323FE93D5C9725630" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_CD79E9D32061DEF323FE93D5C9725630" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_CD79E9D32061DEF323FE93D5C9725630" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_CD79E9D32061DEF323FE93D5C9725630" xlink:type="arc" />
    <link:label id="lab_biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner_97B8FE85B2AEDD3DAF9293D5C9720ADB_verboseLabel_en-US" xlink:label="lab_biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner_97B8FE85B2AEDD3DAF9293D5C9720ADB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reimbursements of research and developments expense from Elan</link:label>
    <link:label id="lab_biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner_97B8FE85B2AEDD3DAF9293D5C9720ADB_label_en-US" xlink:label="lab_biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner_97B8FE85B2AEDD3DAF9293D5C9720ADB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursements Of Research And Developments Expense From Collaboration Partner</link:label>
    <link:label id="lab_biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner_97B8FE85B2AEDD3DAF9293D5C9720ADB_documentation_en-US" xlink:label="lab_biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner_97B8FE85B2AEDD3DAF9293D5C9720ADB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursements of research and developments expense from collaboration partner.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner" xlink:label="loc_biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner_97B8FE85B2AEDD3DAF9293D5C9720ADB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner_97B8FE85B2AEDD3DAF9293D5C9720ADB" xlink:to="lab_biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner_97B8FE85B2AEDD3DAF9293D5C9720ADB" xlink:type="arc" />
    <link:label id="lab_biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner_FE328A3348C9C093511393D5C9720EAE_verboseLabel_en-US" xlink:label="lab_biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner_FE328A3348C9C093511393D5C9720EAE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reimbursements of selling general and administrative expenses from Elan</link:label>
    <link:label id="lab_biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner_FE328A3348C9C093511393D5C9720EAE_label_en-US" xlink:label="lab_biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner_FE328A3348C9C093511393D5C9720EAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursements Of Selling General And Administrative Expenses From Collaboration Partner</link:label>
    <link:label id="lab_biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner_FE328A3348C9C093511393D5C9720EAE_documentation_en-US" xlink:label="lab_biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner_FE328A3348C9C093511393D5C9720EAE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursements of selling general and administrative expenses from collaboration partner.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner" xlink:label="loc_biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner_FE328A3348C9C093511393D5C9720EAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner_FE328A3348C9C093511393D5C9720EAE" xlink:to="lab_biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner_FE328A3348C9C093511393D5C9720EAE" xlink:type="arc" />
    <link:label id="lab_biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration_FFBC347447608196092A93D5C972D40B_verboseLabel_en-US" xlink:label="lab_biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration_FFBC347447608196092A93D5C972D40B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amount reflected in collaboration profit sharing line for collaboration</link:label>
    <link:label id="lab_biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration_FFBC347447608196092A93D5C972D40B_label_en-US" xlink:label="lab_biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration_FFBC347447608196092A93D5C972D40B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount Reflected In Collaboration Profit Sharing Line For Collaboration</link:label>
    <link:label id="lab_biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration_FFBC347447608196092A93D5C972D40B_documentation_en-US" xlink:label="lab_biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration_FFBC347447608196092A93D5C972D40B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount reflected in collaboration profit sharing line for collaboration.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration" xlink:label="loc_biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration_FFBC347447608196092A93D5C972D40B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration_FFBC347447608196092A93D5C972D40B" xlink:to="lab_biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration_FFBC347447608196092A93D5C972D40B" xlink:type="arc" />
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_F48F09B0AFFAB4FA899293D5C972A015_verboseLabel_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_F48F09B0AFFAB4FA899293D5C972A015" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected additional milestone payments for successful achievement of regulatory and commercial sales milestones</link:label>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_F48F09B0AFFAB4FA899293D5C972A015_label_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_F48F09B0AFFAB4FA899293D5C972A015" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Additional Milestone Payments On Successful Achievement Of Regulatory And Commercial Sales Milestones</link:label>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_F48F09B0AFFAB4FA899293D5C972A015_documentation_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_F48F09B0AFFAB4FA899293D5C972A015" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected additional milestone payments on successful achievement of regulatory and commercial sales milestones.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_F48F09B0AFFAB4FA899293D5C972A015" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_F48F09B0AFFAB4FA899293D5C972A015" xlink:to="lab_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_F48F09B0AFFAB4FA899293D5C972A015" xlink:type="arc" />
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4B9B23ABEA0867C9DA9893D5C9722ACA_verboseLabel_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4B9B23ABEA0867C9DA9893D5C9722ACA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected additional milestone payments when certain sales threshold is met</link:label>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4B9B23ABEA0867C9DA9893D5C9722ACA_label_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4B9B23ABEA0867C9DA9893D5C9722ACA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Additional Milestone Payments When Meeting Certain Sales Threshold</link:label>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4B9B23ABEA0867C9DA9893D5C9722ACA_documentation_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4B9B23ABEA0867C9DA9893D5C9722ACA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected additional milestone payments when meeting certain sales threshold.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4B9B23ABEA0867C9DA9893D5C9722ACA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4B9B23ABEA0867C9DA9893D5C9722ACA" xlink:to="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4B9B23ABEA0867C9DA9893D5C9722ACA" xlink:type="arc" />
    <link:label id="lab_biib_ForeignSalesRequiredToTriggerMilestone_198B74121E8F20EF985A93D5C97358CA_verboseLabel_en-US" xlink:label="lab_biib_ForeignSalesRequiredToTriggerMilestone_198B74121E8F20EF985A93D5C97358CA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign sales required to trigger milestone</link:label>
    <link:label id="lab_biib_ForeignSalesRequiredToTriggerMilestone_198B74121E8F20EF985A93D5C97358CA_label_en-US" xlink:label="lab_biib_ForeignSalesRequiredToTriggerMilestone_198B74121E8F20EF985A93D5C97358CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Sales Required To Trigger Milestone</link:label>
    <link:label id="lab_biib_ForeignSalesRequiredToTriggerMilestone_198B74121E8F20EF985A93D5C97358CA_documentation_en-US" xlink:label="lab_biib_ForeignSalesRequiredToTriggerMilestone_198B74121E8F20EF985A93D5C97358CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign sales required to trigger milestone.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ForeignSalesRequiredToTriggerMilestone" xlink:label="loc_biib_ForeignSalesRequiredToTriggerMilestone_198B74121E8F20EF985A93D5C97358CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignSalesRequiredToTriggerMilestone_198B74121E8F20EF985A93D5C97358CA" xlink:to="lab_biib_ForeignSalesRequiredToTriggerMilestone_198B74121E8F20EF985A93D5C97358CA" xlink:type="arc" />
    <link:label id="lab_biib_ExpenseReflectedWithinStatementsOfIncome_5547D39B607D618C287793D5C97373E3_terseLabel_en-US" xlink:label="lab_biib_ExpenseReflectedWithinStatementsOfIncome_5547D39B607D618C287793D5C97373E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of expense reflected within our consolidation statements of income</link:label>
    <link:label id="lab_biib_ExpenseReflectedWithinStatementsOfIncome_5547D39B607D618C287793D5C97373E3_label_en-US" xlink:label="lab_biib_ExpenseReflectedWithinStatementsOfIncome_5547D39B607D618C287793D5C97373E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Reflected Within Statements Of Income</link:label>
    <link:label id="lab_biib_ExpenseReflectedWithinStatementsOfIncome_5547D39B607D618C287793D5C97373E3_documentation_en-US" xlink:label="lab_biib_ExpenseReflectedWithinStatementsOfIncome_5547D39B607D618C287793D5C97373E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen Idec's share of expense reflected within our consolidated statements of income.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ExpenseReflectedWithinStatementsOfIncome" xlink:label="loc_biib_ExpenseReflectedWithinStatementsOfIncome_5547D39B607D618C287793D5C97373E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseReflectedWithinStatementsOfIncome_5547D39B607D618C287793D5C97373E3" xlink:to="lab_biib_ExpenseReflectedWithinStatementsOfIncome_5547D39B607D618C287793D5C97373E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9F98DD455CC00E73D81E93D5C973E83A_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9F98DD455CC00E73D81E93D5C973E83A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock acquired in acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9F98DD455CC00E73D81E93D5C973E83A_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9F98DD455CC00E73D81E93D5C973E83A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9F98DD455CC00E73D81E93D5C973E83A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9F98DD455CC00E73D81E93D5C973E83A" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9F98DD455CC00E73D81E93D5C973E83A" xlink:type="arc" />
    <link:label id="lab_biib_ConsiderationPerProductDeveloped_C8BE94CD385ADF5704AA93D5C973BB12_verboseLabel_en-US" xlink:label="lab_biib_ConsiderationPerProductDeveloped_C8BE94CD385ADF5704AA93D5C973BB12" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consideration per product</link:label>
    <link:label id="lab_biib_ConsiderationPerProductDeveloped_C8BE94CD385ADF5704AA93D5C973BB12_label_en-US" xlink:label="lab_biib_ConsiderationPerProductDeveloped_C8BE94CD385ADF5704AA93D5C973BB12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration Per Product Developed</link:label>
    <link:label id="lab_biib_ConsiderationPerProductDeveloped_C8BE94CD385ADF5704AA93D5C973BB12_documentation_en-US" xlink:label="lab_biib_ConsiderationPerProductDeveloped_C8BE94CD385ADF5704AA93D5C973BB12" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consideration per product developed.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ConsiderationPerProductDeveloped" xlink:label="loc_biib_ConsiderationPerProductDeveloped_C8BE94CD385ADF5704AA93D5C973BB12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ConsiderationPerProductDeveloped_C8BE94CD385ADF5704AA93D5C973BB12" xlink:to="lab_biib_ConsiderationPerProductDeveloped_C8BE94CD385ADF5704AA93D5C973BB12" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfReimbursementExpenses_E61E4789BF2BDEB75F5893D5C9736524_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfReimbursementExpenses_E61E4789BF2BDEB75F5893D5C9736524" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of reimbursement expenses</link:label>
    <link:label id="lab_biib_PercentageOfReimbursementExpenses_E61E4789BF2BDEB75F5893D5C9736524_label_en-US" xlink:label="lab_biib_PercentageOfReimbursementExpenses_E61E4789BF2BDEB75F5893D5C9736524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Reimbursement Expenses</link:label>
    <link:label id="lab_biib_PercentageOfReimbursementExpenses_E61E4789BF2BDEB75F5893D5C9736524_documentation_en-US" xlink:label="lab_biib_PercentageOfReimbursementExpenses_E61E4789BF2BDEB75F5893D5C9736524" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of reimbursement expenses.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PercentageOfReimbursementExpenses" xlink:label="loc_biib_PercentageOfReimbursementExpenses_E61E4789BF2BDEB75F5893D5C9736524" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfReimbursementExpenses_E61E4789BF2BDEB75F5893D5C9736524" xlink:to="lab_biib_PercentageOfReimbursementExpenses_E61E4789BF2BDEB75F5893D5C9736524" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfDevelopmentReimbursementExpenses_75E6598CDC58E09E045693D5C973C3FE_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfDevelopmentReimbursementExpenses_75E6598CDC58E09E045693D5C973C3FE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of development reimbursement expenses</link:label>
    <link:label id="lab_biib_PercentageOfDevelopmentReimbursementExpenses_75E6598CDC58E09E045693D5C973C3FE_label_en-US" xlink:label="lab_biib_PercentageOfDevelopmentReimbursementExpenses_75E6598CDC58E09E045693D5C973C3FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Development Reimbursement Expenses</link:label>
    <link:label id="lab_biib_PercentageOfDevelopmentReimbursementExpenses_75E6598CDC58E09E045693D5C973C3FE_documentation_en-US" xlink:label="lab_biib_PercentageOfDevelopmentReimbursementExpenses_75E6598CDC58E09E045693D5C973C3FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of development reimbursement expenses.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PercentageOfDevelopmentReimbursementExpenses" xlink:label="loc_biib_PercentageOfDevelopmentReimbursementExpenses_75E6598CDC58E09E045693D5C973C3FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfDevelopmentReimbursementExpenses_75E6598CDC58E09E045693D5C973C3FE" xlink:to="lab_biib_PercentageOfDevelopmentReimbursementExpenses_75E6598CDC58E09E045693D5C973C3FE" xlink:type="arc" />
    <link:label id="lab_biib_ReimbursementCostAchievingPeriod_AAB9D4EB8A2B433D4F9493D5C973CA35_verboseLabel_en-US" xlink:label="lab_biib_ReimbursementCostAchievingPeriod_AAB9D4EB8A2B433D4F9493D5C973CA35" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement cost achieving period</link:label>
    <link:label id="lab_biib_ReimbursementCostAchievingPeriod_AAB9D4EB8A2B433D4F9493D5C973CA35_label_en-US" xlink:label="lab_biib_ReimbursementCostAchievingPeriod_AAB9D4EB8A2B433D4F9493D5C973CA35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Cost Achieving Period</link:label>
    <link:label id="lab_biib_ReimbursementCostAchievingPeriod_AAB9D4EB8A2B433D4F9493D5C973CA35_documentation_en-US" xlink:label="lab_biib_ReimbursementCostAchievingPeriod_AAB9D4EB8A2B433D4F9493D5C973CA35" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement cost achieving period.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ReimbursementCostAchievingPeriod" xlink:label="loc_biib_ReimbursementCostAchievingPeriod_AAB9D4EB8A2B433D4F9493D5C973CA35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReimbursementCostAchievingPeriod_AAB9D4EB8A2B433D4F9493D5C973CA35" xlink:to="lab_biib_ReimbursementCostAchievingPeriod_AAB9D4EB8A2B433D4F9493D5C973CA35" xlink:type="arc" />
    <link:label id="lab_biib_TimePeriodForPayingRemainingBalanceDue_3E75520ADE0C7484C0D293D5C9733DEF_verboseLabel_en-US" xlink:label="lab_biib_TimePeriodForPayingRemainingBalanceDue_3E75520ADE0C7484C0D293D5C9733DEF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time period for paying remaining balance due</link:label>
    <link:label id="lab_biib_TimePeriodForPayingRemainingBalanceDue_3E75520ADE0C7484C0D293D5C9733DEF_label_en-US" xlink:label="lab_biib_TimePeriodForPayingRemainingBalanceDue_3E75520ADE0C7484C0D293D5C9733DEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Period For Paying Remaining Balance Due</link:label>
    <link:label id="lab_biib_TimePeriodForPayingRemainingBalanceDue_3E75520ADE0C7484C0D293D5C9733DEF_documentation_en-US" xlink:label="lab_biib_TimePeriodForPayingRemainingBalanceDue_3E75520ADE0C7484C0D293D5C9733DEF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time period for paying remaining balance due.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_TimePeriodForPayingRemainingBalanceDue" xlink:label="loc_biib_TimePeriodForPayingRemainingBalanceDue_3E75520ADE0C7484C0D293D5C9733DEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimePeriodForPayingRemainingBalanceDue_3E75520ADE0C7484C0D293D5C9733DEF" xlink:to="lab_biib_TimePeriodForPayingRemainingBalanceDue_3E75520ADE0C7484C0D293D5C9733DEF" xlink:type="arc" />
    <link:label id="lab_biib_PeriodForGrantingOfApprovalByApprovingAuthority_D71C2BE170A37B6EA15C93D5C97374F9_verboseLabel_en-US" xlink:label="lab_biib_PeriodForGrantingOfApprovalByApprovingAuthority_D71C2BE170A37B6EA15C93D5C97374F9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Term for revocation option right</link:label>
    <link:label id="lab_biib_PeriodForGrantingOfApprovalByApprovingAuthority_D71C2BE170A37B6EA15C93D5C97374F9_label_en-US" xlink:label="lab_biib_PeriodForGrantingOfApprovalByApprovingAuthority_D71C2BE170A37B6EA15C93D5C97374F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period For Granting Of Approval By Approving Authority</link:label>
    <link:label id="lab_biib_PeriodForGrantingOfApprovalByApprovingAuthority_D71C2BE170A37B6EA15C93D5C97374F9_documentation_en-US" xlink:label="lab_biib_PeriodForGrantingOfApprovalByApprovingAuthority_D71C2BE170A37B6EA15C93D5C97374F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period for granting of approval by approving authority.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PeriodForGrantingOfApprovalByApprovingAuthority" xlink:label="loc_biib_PeriodForGrantingOfApprovalByApprovingAuthority_D71C2BE170A37B6EA15C93D5C97374F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PeriodForGrantingOfApprovalByApprovingAuthority_D71C2BE170A37B6EA15C93D5C97374F9" xlink:to="lab_biib_PeriodForGrantingOfApprovalByApprovingAuthority_D71C2BE170A37B6EA15C93D5C97374F9" xlink:type="arc" />
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_7F4E7355A9FDD2E7AE0E93D5C9733222_verboseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_7F4E7355A9FDD2E7AE0E93D5C9733222" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_7F4E7355A9FDD2E7AE0E93D5C9733222_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_7F4E7355A9FDD2E7AE0E93D5C9733222" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_7F4E7355A9FDD2E7AE0E93D5C9733222_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_7F4E7355A9FDD2E7AE0E93D5C9733222" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_7F4E7355A9FDD2E7AE0E93D5C9733222" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_7F4E7355A9FDD2E7AE0E93D5C9733222" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_7F4E7355A9FDD2E7AE0E93D5C9733222" xlink:type="arc" />
    <link:label id="lab_biib_Termofcollaborationagreement_7E0327C69FC6C80503DF93D5C9731F57_terseLabel_en-US" xlink:label="lab_biib_Termofcollaborationagreement_7E0327C69FC6C80503DF93D5C9731F57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_7E0327C69FC6C80503DF93D5C9731F57_label_en-US" xlink:label="lab_biib_Termofcollaborationagreement_7E0327C69FC6C80503DF93D5C9731F57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_7E0327C69FC6C80503DF93D5C9731F57_documentation_en-US" xlink:label="lab_biib_Termofcollaborationagreement_7E0327C69FC6C80503DF93D5C9731F57" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_7E0327C69FC6C80503DF93D5C9731F57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Termofcollaborationagreement_7E0327C69FC6C80503DF93D5C9731F57" xlink:to="lab_biib_Termofcollaborationagreement_7E0327C69FC6C80503DF93D5C9731F57" xlink:type="arc" />
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_84EFF9834D509D0D282793D5C97361D5_terseLabel_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_84EFF9834D509D0D282793D5C97361D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_84EFF9834D509D0D282793D5C97361D5_label_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_84EFF9834D509D0D282793D5C97361D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_84EFF9834D509D0D282793D5C97361D5_documentation_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_84EFF9834D509D0D282793D5C97361D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_84EFF9834D509D0D282793D5C97361D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_84EFF9834D509D0D282793D5C97361D5" xlink:to="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_84EFF9834D509D0D282793D5C97361D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_411A5AE1D8A305ED569B93D5C9733210_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_411A5AE1D8A305ED569B93D5C9733210" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and discovery services</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_411A5AE1D8A305ED569B93D5C9733210_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_411A5AE1D8A305ED569B93D5C9733210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_411A5AE1D8A305ED569B93D5C9733210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_411A5AE1D8A305ED569B93D5C9733210" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets_411A5AE1D8A305ED569B93D5C9733210" xlink:type="arc" />
    <link:label id="lab_biib_LicenseFee_DDEAF86502DABC80A2FB93D5C9739A03_terseLabel_en-US" xlink:label="lab_biib_LicenseFee_DDEAF86502DABC80A2FB93D5C9739A03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_biib_LicenseFee_DDEAF86502DABC80A2FB93D5C9739A03_label_en-US" xlink:label="lab_biib_LicenseFee_DDEAF86502DABC80A2FB93D5C9739A03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_biib_LicenseFee_DDEAF86502DABC80A2FB93D5C9739A03_documentation_en-US" xlink:label="lab_biib_LicenseFee_DDEAF86502DABC80A2FB93D5C9739A03" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_DDEAF86502DABC80A2FB93D5C9739A03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LicenseFee_DDEAF86502DABC80A2FB93D5C9739A03" xlink:to="lab_biib_LicenseFee_DDEAF86502DABC80A2FB93D5C9739A03" xlink:type="arc" />
    <link:label id="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_9633E8F995FFE31AA99993D5C97379DF_terseLabel_en-US" xlink:label="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_9633E8F995FFE31AA99993D5C97379DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected License Fee And Regulatory Milestone Payments</link:label>
    <link:label id="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_9633E8F995FFE31AA99993D5C97379DF_label_en-US" xlink:label="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_9633E8F995FFE31AA99993D5C97379DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected License Fee And Regulatory Milestone Payments</link:label>
    <link:label id="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_9633E8F995FFE31AA99993D5C97379DF_documentation_en-US" xlink:label="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_9633E8F995FFE31AA99993D5C97379DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected license fee and regulatory milestone payments.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:label="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_9633E8F995FFE31AA99993D5C97379DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_9633E8F995FFE31AA99993D5C97379DF" xlink:to="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_9633E8F995FFE31AA99993D5C97379DF" xlink:type="arc" />
    <link:label id="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_00B7CFB4A6D8E7A5580593D5C973B44B_terseLabel_en-US" xlink:label="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_00B7CFB4A6D8E7A5580593D5C973B44B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional milestone payments for product candidate using a different modality</link:label>
    <link:label id="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_00B7CFB4A6D8E7A5580593D5C973B44B_label_en-US" xlink:label="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_00B7CFB4A6D8E7A5580593D5C973B44B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional milestone payments for product candidate using a different modality</link:label>
    <link:label id="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_00B7CFB4A6D8E7A5580593D5C973B44B_documentation_en-US" xlink:label="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_00B7CFB4A6D8E7A5580593D5C973B44B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional milestone payments for product candidate using a different modality</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality" xlink:label="loc_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_00B7CFB4A6D8E7A5580593D5C973B44B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_00B7CFB4A6D8E7A5580593D5C973B44B" xlink:to="lab_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_00B7CFB4A6D8E7A5580593D5C973B44B" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalMilestonePayment_5359E696D056AAD6845793D5C9731824_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_5359E696D056AAD6845793D5C9731824" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_5359E696D056AAD6845793D5C9731824_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_5359E696D056AAD6845793D5C9731824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_5359E696D056AAD6845793D5C9731824_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_5359E696D056AAD6845793D5C9731824" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_5359E696D056AAD6845793D5C9731824" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment_5359E696D056AAD6845793D5C9731824" xlink:to="lab_biib_AdditionalMilestonePayment_5359E696D056AAD6845793D5C9731824" xlink:type="arc" />
    <link:label id="lab_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_9F898B3FFB2A3EAC7BD493D5C97397E4_terseLabel_en-US" xlink:label="lab_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_9F898B3FFB2A3EAC7BD493D5C97397E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount recorded to reflect fair value of options granted</link:label>
    <link:label id="lab_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_9F898B3FFB2A3EAC7BD493D5C97397E4_label_en-US" xlink:label="lab_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_9F898B3FFB2A3EAC7BD493D5C97397E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability For Fair Value Of Options Granted Under Agreement</link:label>
    <link:label id="lab_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_9F898B3FFB2A3EAC7BD493D5C97397E4_documentation_en-US" xlink:label="lab_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_9F898B3FFB2A3EAC7BD493D5C97397E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability For Fair Value Of Options Granted Under Agreement</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement" xlink:label="loc_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_9F898B3FFB2A3EAC7BD493D5C97397E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_9F898B3FFB2A3EAC7BD493D5C97397E4" xlink:to="lab_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_9F898B3FFB2A3EAC7BD493D5C97397E4" xlink:type="arc" />
    <link:label id="lab_biib_MilestonePaymentsMadeDuringPeriod_D2B92E233CAF715D8E3793D5C9742C8D_terseLabel_en-US" xlink:label="lab_biib_MilestonePaymentsMadeDuringPeriod_D2B92E233CAF715D8E3793D5C9742C8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payments Made During Period</link:label>
    <link:label id="lab_biib_MilestonePaymentsMadeDuringPeriod_D2B92E233CAF715D8E3793D5C9742C8D_label_en-US" xlink:label="lab_biib_MilestonePaymentsMadeDuringPeriod_D2B92E233CAF715D8E3793D5C9742C8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments Made During Period</link:label>
    <link:label id="lab_biib_MilestonePaymentsMadeDuringPeriod_D2B92E233CAF715D8E3793D5C9742C8D_documentation_en-US" xlink:label="lab_biib_MilestonePaymentsMadeDuringPeriod_D2B92E233CAF715D8E3793D5C9742C8D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payments Made During Period.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_D2B92E233CAF715D8E3793D5C9742C8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MilestonePaymentsMadeDuringPeriod_D2B92E233CAF715D8E3793D5C9742C8D" xlink:to="lab_biib_MilestonePaymentsMadeDuringPeriod_D2B92E233CAF715D8E3793D5C9742C8D" xlink:type="arc" />
    <link:label id="lab_biib_Purchaseofcommonstock_204914CB0D936E5B606693D5C974358A_terseLabel_en-US" xlink:label="lab_biib_Purchaseofcommonstock_204914CB0D936E5B606693D5C974358A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:label id="lab_biib_Purchaseofcommonstock_204914CB0D936E5B606693D5C974358A_label_en-US" xlink:label="lab_biib_Purchaseofcommonstock_204914CB0D936E5B606693D5C974358A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:label id="lab_biib_Purchaseofcommonstock_204914CB0D936E5B606693D5C974358A_documentation_en-US" xlink:label="lab_biib_Purchaseofcommonstock_204914CB0D936E5B606693D5C974358A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_204914CB0D936E5B606693D5C974358A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Purchaseofcommonstock_204914CB0D936E5B606693D5C974358A" xlink:to="lab_biib_Purchaseofcommonstock_204914CB0D936E5B606693D5C974358A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseCosts_D75559A20C8EF99E5F3393D5C9749A05_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseCosts_D75559A20C8EF99E5F3393D5C9749A05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total licensing and other fees</link:label>
    <link:label id="lab_us-gaap_LicenseCosts_D75559A20C8EF99E5F3393D5C9749A05_label_en-US" xlink:label="lab_us-gaap_LicenseCosts_D75559A20C8EF99E5F3393D5C9749A05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_D75559A20C8EF99E5F3393D5C9749A05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseCosts_D75559A20C8EF99E5F3393D5C9749A05" xlink:to="lab_us-gaap_LicenseCosts_D75559A20C8EF99E5F3393D5C9749A05" xlink:type="arc" />
    <link:label id="lab_biib_Researchanddevelopmentservices_99B74768AB0842EC7AA893D5C9743B14_terseLabel_en-US" xlink:label="lab_biib_Researchanddevelopmentservices_99B74768AB0842EC7AA893D5C9743B14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development services</link:label>
    <link:label id="lab_biib_Researchanddevelopmentservices_99B74768AB0842EC7AA893D5C9743B14_label_en-US" xlink:label="lab_biib_Researchanddevelopmentservices_99B74768AB0842EC7AA893D5C9743B14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development services</link:label>
    <link:label id="lab_biib_Researchanddevelopmentservices_99B74768AB0842EC7AA893D5C9743B14_documentation_en-US" xlink:label="lab_biib_Researchanddevelopmentservices_99B74768AB0842EC7AA893D5C9743B14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development services</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_Researchanddevelopmentservices" xlink:label="loc_biib_Researchanddevelopmentservices_99B74768AB0842EC7AA893D5C9743B14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Researchanddevelopmentservices_99B74768AB0842EC7AA893D5C9743B14" xlink:to="lab_biib_Researchanddevelopmentservices_99B74768AB0842EC7AA893D5C9743B14" xlink:type="arc" />
    <link:label id="lab_biib_Premiumonequityinvestment_7AEA0BC77BF1919BC72293D5C974F0CC_terseLabel_en-US" xlink:label="lab_biib_Premiumonequityinvestment_7AEA0BC77BF1919BC72293D5C974F0CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premium on equity investment</link:label>
    <link:label id="lab_biib_Premiumonequityinvestment_7AEA0BC77BF1919BC72293D5C974F0CC_label_en-US" xlink:label="lab_biib_Premiumonequityinvestment_7AEA0BC77BF1919BC72293D5C974F0CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Premium on equity investment</link:label>
    <link:label id="lab_biib_Premiumonequityinvestment_7AEA0BC77BF1919BC72293D5C974F0CC_documentation_en-US" xlink:label="lab_biib_Premiumonequityinvestment_7AEA0BC77BF1919BC72293D5C974F0CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Premium on equity investment</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_Premiumonequityinvestment" xlink:label="loc_biib_Premiumonequityinvestment_7AEA0BC77BF1919BC72293D5C974F0CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Premiumonequityinvestment_7AEA0BC77BF1919BC72293D5C974F0CC" xlink:to="lab_biib_Premiumonequityinvestment_7AEA0BC77BF1919BC72293D5C974F0CC" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_E0F9354CB30B46E83DE193D5C974B15F_terseLabel_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_E0F9354CB30B46E83DE193D5C974B15F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments By Third Party In Joint Venture As Per Agreement.</link:label>
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_E0F9354CB30B46E83DE193D5C974B15F_label_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_E0F9354CB30B46E83DE193D5C974B15F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments By Third Party In Joint Venture As Per Agreement.</link:label>
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_E0F9354CB30B46E83DE193D5C974B15F_documentation_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_E0F9354CB30B46E83DE193D5C974B15F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments by third party in joint venture as per agreement</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_E0F9354CB30B46E83DE193D5C974B15F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_E0F9354CB30B46E83DE193D5C974B15F" xlink:to="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_E0F9354CB30B46E83DE193D5C974B15F" xlink:type="arc" />
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_2239FEA998EFAF28783E93D5C9741605_terseLabel_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_2239FEA998EFAF28783E93D5C9741605" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Joint Venture Owner Ship Percentage By Third Party.</link:label>
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_2239FEA998EFAF28783E93D5C9741605_label_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_2239FEA998EFAF28783E93D5C9741605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Joint Venture Owner Ship Percentage By Third Party.</link:label>
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_2239FEA998EFAF28783E93D5C9741605_documentation_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_2239FEA998EFAF28783E93D5C9741605" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Joint venture owner ship percentage by third party.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_2239FEA998EFAF28783E93D5C9741605" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_JointVentureOwnerShipPercentageByThirdParty_2239FEA998EFAF28783E93D5C9741605" xlink:to="lab_biib_JointVentureOwnerShipPercentageByThirdParty_2239FEA998EFAF28783E93D5C9741605" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_0C18E13973A6B1AD86FA93D5C974E26B_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_0C18E13973A6B1AD86FA93D5C974E26B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_0C18E13973A6B1AD86FA93D5C974E26B_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_0C18E13973A6B1AD86FA93D5C974E26B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_0C18E13973A6B1AD86FA93D5C974E26B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_0C18E13973A6B1AD86FA93D5C974E26B" xlink:to="lab_us-gaap_EquityMethodInvestments_0C18E13973A6B1AD86FA93D5C974E26B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_DC7C146A501F502454A893D5C97432DC_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_DC7C146A501F502454A893D5C97432DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of equity interest to the portion of total capital stock</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_DC7C146A501F502454A893D5C97432DC_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_DC7C146A501F502454A893D5C97432DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_DC7C146A501F502454A893D5C97432DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_DC7C146A501F502454A893D5C97432DC" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_DC7C146A501F502454A893D5C97432DC" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_A88B55D3DDC16EA67F2D93D5C974E09E_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_A88B55D3DDC16EA67F2D93D5C974E09E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment Ownership Percentage Maximum</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_A88B55D3DDC16EA67F2D93D5C974E09E_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_A88B55D3DDC16EA67F2D93D5C974E09E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment Ownership Percentage Maximum</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_A88B55D3DDC16EA67F2D93D5C974E09E_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_A88B55D3DDC16EA67F2D93D5C974E09E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity method investment ownership percentage maximum.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_A88B55D3DDC16EA67F2D93D5C974E09E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_A88B55D3DDC16EA67F2D93D5C974E09E" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_A88B55D3DDC16EA67F2D93D5C974E09E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_A282151B713A4322109E93D5C974EA68_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_A282151B713A4322109E93D5C974EA68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_A282151B713A4322109E93D5C974EA68_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_A282151B713A4322109E93D5C974EA68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_A282151B713A4322109E93D5C974EA68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_A282151B713A4322109E93D5C974EA68" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_A282151B713A4322109E93D5C974EA68" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_796C264D3983462D515093D5C9741242_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_796C264D3983462D515093D5C9741242" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_796C264D3983462D515093D5C9741242_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_796C264D3983462D515093D5C9741242" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_796C264D3983462D515093D5C9741242_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_796C264D3983462D515093D5C9741242" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_796C264D3983462D515093D5C9741242" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentsExpectedProfitShare_796C264D3983462D515093D5C9741242" xlink:to="lab_biib_EquityMethodInvestmentsExpectedProfitShare_796C264D3983462D515093D5C9741242" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_C68E69952778AA89647293D5C974B18D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_C68E69952778AA89647293D5C974B18D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues from external customers</link:label>
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_C68E69952778AA89647293D5C974B18D_label_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_C68E69952778AA89647293D5C974B18D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Revenue, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_C68E69952778AA89647293D5C974B18D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSalesRevenueNet_C68E69952778AA89647293D5C974B18D" xlink:to="lab_us-gaap_OtherSalesRevenueNet_C68E69952778AA89647293D5C974B18D" xlink:type="arc" />
    <link:label id="lab_biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld_728B22946A7477DD245893D5C974B7D0_terseLabel_en-US" xlink:label="lab_biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld_728B22946A7477DD245893D5C974B7D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Period For Substantially All Remaining Royalty Bearing Sales Rest Of World</link:label>
    <link:label id="lab_biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld_728B22946A7477DD245893D5C974B7D0_label_en-US" xlink:label="lab_biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld_728B22946A7477DD245893D5C974B7D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Period For Substantially All Remaining Royalty Bearing Sales Rest Of World</link:label>
    <link:label id="lab_biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld_728B22946A7477DD245893D5C974B7D0_documentation_en-US" xlink:label="lab_biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld_728B22946A7477DD245893D5C974B7D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty period for substantially all of the remaining royalty-bearing sales of RITUXAN in the rest of world.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld" xlink:label="loc_biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld_728B22946A7477DD245893D5C974B7D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld_728B22946A7477DD245893D5C974B7D0" xlink:to="lab_biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld_728B22946A7477DD245893D5C974B7D0" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_431E97FB34007EC5370993D5C974754E_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_431E97FB34007EC5370993D5C974754E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option One</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_431E97FB34007EC5370993D5C974754E_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_431E97FB34007EC5370993D5C974754E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option One</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_431E97FB34007EC5370993D5C974754E_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_431E97FB34007EC5370993D5C974754E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option one.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_431E97FB34007EC5370993D5C974754E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_431E97FB34007EC5370993D5C974754E" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_431E97FB34007EC5370993D5C974754E" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_BC08D65BB20D6B1C7C0C93D5C9742013_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_BC08D65BB20D6B1C7C0C93D5C9742013" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option One</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_BC08D65BB20D6B1C7C0C93D5C9742013_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_BC08D65BB20D6B1C7C0C93D5C9742013" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option One</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_BC08D65BB20D6B1C7C0C93D5C9742013_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_BC08D65BB20D6B1C7C0C93D5C9742013" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option one.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_BC08D65BB20D6B1C7C0C93D5C9742013" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_BC08D65BB20D6B1C7C0C93D5C9742013" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_BC08D65BB20D6B1C7C0C93D5C9742013" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9A676344B12ADB0924B338A3534AE650_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9A676344B12ADB0924B338A3534AE650" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9A676344B12ADB0924B338A3534AE650" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9A676344B12ADB0924B338A3534AE650" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9A676344B12ADB0924B338A3534AE650" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BE9ECD4F99F22768B6F38A3534AF239_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BE9ECD4F99F22768B6F38A3534AF239" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BE9ECD4F99F22768B6F38A3534AF239_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BE9ECD4F99F22768B6F38A3534AF239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BE9ECD4F99F22768B6F38A3534AF239" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BE9ECD4F99F22768B6F38A3534AF239" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BE9ECD4F99F22768B6F38A3534AF239" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_5734004D80954E4494DB38A3534B51B9_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_5734004D80954E4494DB38A3534B51B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_5734004D80954E4494DB38A3534B51B9_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_5734004D80954E4494DB38A3534B51B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5734004D80954E4494DB38A3534B51B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_5734004D80954E4494DB38A3534B51B9" xlink:to="lab_us-gaap_AwardTypeAxis_5734004D80954E4494DB38A3534B51B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5FA16734B2850DF100E938A3534BF2C1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5FA16734B2850DF100E938A3534BF2C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5FA16734B2850DF100E938A3534BF2C1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5FA16734B2850DF100E938A3534BF2C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5FA16734B2850DF100E938A3534BF2C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5FA16734B2850DF100E938A3534BF2C1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5FA16734B2850DF100E938A3534BF2C1" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsMember_F7AA432E10402D1CC16738A3534B8D5F_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember_F7AA432E10402D1CC16738A3534B8D5F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_F7AA432E10402D1CC16738A3534B8D5F_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember_F7AA432E10402D1CC16738A3534B8D5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_F7AA432E10402D1CC16738A3534B8D5F_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember_F7AA432E10402D1CC16738A3534B8D5F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_F7AA432E10402D1CC16738A3534B8D5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember_F7AA432E10402D1CC16738A3534B8D5F" xlink:to="lab_biib_MarketStockUnitsMember_F7AA432E10402D1CC16738A3534B8D5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B56BCEE5AC256ABAA97E38A3534B9F13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B56BCEE5AC256ABAA97E38A3534B9F13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B56BCEE5AC256ABAA97E38A3534B9F13_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B56BCEE5AC256ABAA97E38A3534B9F13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B56BCEE5AC256ABAA97E38A3534B9F13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B56BCEE5AC256ABAA97E38A3534B9F13" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B56BCEE5AC256ABAA97E38A3534B9F13" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units activity</link:label>
    <link:label id="lab_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6_label_en-US" xlink:label="lab_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units Activity [Abstract]</link:label>
    <link:label id="lab_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units activity.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_MarketStockUnitsActivityAbstract" xlink:label="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:to="lab_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_42665CAE190FBEDAE6D538A3534BA65F_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_42665CAE190FBEDAE6D538A3534BA65F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Unvested, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_42665CAE190FBEDAE6D538A3534BA65F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_42665CAE190FBEDAE6D538A3534BA65F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_42665CAE190FBEDAE6D538A3534BA65F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_42665CAE190FBEDAE6D538A3534BA65F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_42665CAE190FBEDAE6D538A3534BA65F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55F6DF417BE4B009718238A3534BA6FB_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55F6DF417BE4B009718238A3534BA6FB" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55F6DF417BE4B009718238A3534BA6FB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55F6DF417BE4B009718238A3534BA6FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55F6DF417BE4B009718238A3534BA6FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55F6DF417BE4B009718238A3534BA6FB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55F6DF417BE4B009718238A3534BA6FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_238769352ABA1FBB41E338A3534BBCC6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_238769352ABA1FBB41E338A3534BBCC6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_238769352ABA1FBB41E338A3534BBCC6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_238769352ABA1FBB41E338A3534BBCC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_238769352ABA1FBB41E338A3534BBCC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_238769352ABA1FBB41E338A3534BBCC6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_238769352ABA1FBB41E338A3534BBCC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_659CF0CEEDAE07E529F038A3534BA9A8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_659CF0CEEDAE07E529F038A3534BA9A8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_659CF0CEEDAE07E529F038A3534BA9A8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_659CF0CEEDAE07E529F038A3534BA9A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_659CF0CEEDAE07E529F038A3534BA9A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_659CF0CEEDAE07E529F038A3534BA9A8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_659CF0CEEDAE07E529F038A3534BA9A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5E13630B2D751574DA8B38A3534B9FF8_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5E13630B2D751574DA8B38A3534B9FF8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5E13630B2D751574DA8B38A3534B9FF8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5E13630B2D751574DA8B38A3534B9FF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5E13630B2D751574DA8B38A3534B9FF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5E13630B2D751574DA8B38A3534B9FF8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5E13630B2D751574DA8B38A3534B9FF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9868E37B9AF59CAA3AF538A3534B6E47_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9868E37B9AF59CAA3AF538A3534B6E47" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9868E37B9AF59CAA3AF538A3534B6E47_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9868E37B9AF59CAA3AF538A3534B6E47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9868E37B9AF59CAA3AF538A3534B6E47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9868E37B9AF59CAA3AF538A3534B6E47" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9868E37B9AF59CAA3AF538A3534B6E47" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6ECF9E36B3754DF6EB7C38A3534BAFB9_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6ECF9E36B3754DF6EB7C38A3534BAFB9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6ECF9E36B3754DF6EB7C38A3534BAFB9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6ECF9E36B3754DF6EB7C38A3534BAFB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6ECF9E36B3754DF6EB7C38A3534BAFB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6ECF9E36B3754DF6EB7C38A3534BAFB9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6ECF9E36B3754DF6EB7C38A3534BAFB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E0FE6EB810CF938AEC9F38A3534B3DA7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E0FE6EB810CF938AEC9F38A3534B3DA7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E0FE6EB810CF938AEC9F38A3534B3DA7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E0FE6EB810CF938AEC9F38A3534B3DA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E0FE6EB810CF938AEC9F38A3534B3DA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E0FE6EB810CF938AEC9F38A3534B3DA7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E0FE6EB810CF938AEC9F38A3534B3DA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_74261960BC5FBC08F7FB38A3534C4637_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_74261960BC5FBC08F7FB38A3534C4637" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Unvested, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_74261960BC5FBC08F7FB38A3534C4637" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_74261960BC5FBC08F7FB38A3534C4637" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_74261960BC5FBC08F7FB38A3534C4637" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08CDFF9167F552A654F638A3534CA634_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08CDFF9167F552A654F638A3534CA634" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08CDFF9167F552A654F638A3534CA634" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08CDFF9167F552A654F638A3534CA634" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08CDFF9167F552A654F638A3534CA634" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_5DFEBB826A9105720C7638A35323E187_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_5DFEBB826A9105720C7638A35323E187" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5DFEBB826A9105720C7638A35323E187" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5DFEBB826A9105720C7638A35323E187" xlink:to="lab_us-gaap_DebtDisclosureAbstract_5DFEBB826A9105720C7638A35323E187" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_0748F7758406A3AA4BC538A35323C0B4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_0748F7758406A3AA4BC538A35323C0B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Indebtedness</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_0748F7758406A3AA4BC538A35323C0B4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_0748F7758406A3AA4BC538A35323C0B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_0748F7758406A3AA4BC538A35323C0B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_0748F7758406A3AA4BC538A35323C0B4" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_0748F7758406A3AA4BC538A35323C0B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ED7EDDC26192065C824E38A35323994E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ED7EDDC26192065C824E38A35323994E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total debt maturities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ED7EDDC26192065C824E38A35323994E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ED7EDDC26192065C824E38A35323994E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ED7EDDC26192065C824E38A35323994E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ED7EDDC26192065C824E38A35323994E" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ED7EDDC26192065C824E38A35323994E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_0E29942217448DF67B7538A351548072_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_0E29942217448DF67B7538A351548072" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_0E29942217448DF67B7538A351548072_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_0E29942217448DF67B7538A351548072" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_0E29942217448DF67B7538A351548072" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_0E29942217448DF67B7538A351548072" xlink:to="lab_us-gaap_PerformanceSharesMember_0E29942217448DF67B7538A351548072" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_D270D06C326C0657E8EE38A35385B1D2_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_D270D06C326C0657E8EE38A35385B1D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_D270D06C326C0657E8EE38A35385B1D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_D270D06C326C0657E8EE38A35385B1D2" xlink:to="lab_us-gaap_EquityAbstract_D270D06C326C0657E8EE38A35385B1D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_EB9A661A817F3AAB72BD38A3538553F7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_EB9A661A817F3AAB72BD38A3538553F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_EB9A661A817F3AAB72BD38A3538553F7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_EB9A661A817F3AAB72BD38A3538553F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_EB9A661A817F3AAB72BD38A3538553F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_EB9A661A817F3AAB72BD38A3538553F7" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_EB9A661A817F3AAB72BD38A3538553F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_E4BA5C1F703708988DC338A3538529AD_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_E4BA5C1F703708988DC338A3538529AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_E4BA5C1F703708988DC338A3538529AD_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_E4BA5C1F703708988DC338A3538529AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_E4BA5C1F703708988DC338A3538529AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_E4BA5C1F703708988DC338A3538529AD" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_E4BA5C1F703708988DC338A3538529AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4500351C8C6B01A0B0DB38A35509ABCD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4500351C8C6B01A0B0DB38A35509ABCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4500351C8C6B01A0B0DB38A35509ABCD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4500351C8C6B01A0B0DB38A35509ABCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4500351C8C6B01A0B0DB38A35509ABCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4500351C8C6B01A0B0DB38A35509ABCD" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4500351C8C6B01A0B0DB38A35509ABCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8D1435F0F78793BAD56838A3550926BA_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8D1435F0F78793BAD56838A3550926BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8D1435F0F78793BAD56838A3550926BA_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8D1435F0F78793BAD56838A3550926BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8D1435F0F78793BAD56838A3550926BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8D1435F0F78793BAD56838A3550926BA" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8D1435F0F78793BAD56838A3550926BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_89E7E1DE0CD38BB57CDE38A3550AE632_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_89E7E1DE0CD38BB57CDE38A3550AE632" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_89E7E1DE0CD38BB57CDE38A3550AE632_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_89E7E1DE0CD38BB57CDE38A3550AE632" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89E7E1DE0CD38BB57CDE38A3550AE632" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89E7E1DE0CD38BB57CDE38A3550AE632" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_89E7E1DE0CD38BB57CDE38A3550AE632" xlink:type="arc" />
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E596138FF9D1D90C6D6A38A3550A36AA_verboseLabel_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E596138FF9D1D90C6D6A38A3550A36AA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E596138FF9D1D90C6D6A38A3550A36AA_label_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E596138FF9D1D90C6D6A38A3550A36AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan [Member]</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E596138FF9D1D90C6D6A38A3550A36AA_documentation_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E596138FF9D1D90C6D6A38A3550A36AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E596138FF9D1D90C6D6A38A3550A36AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E596138FF9D1D90C6D6A38A3550A36AA" xlink:to="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E596138FF9D1D90C6D6A38A3550A36AA" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_63D2FFB0AC774D77F74938A3550A5AD8_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_63D2FFB0AC774D77F74938A3550A5AD8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_63D2FFB0AC774D77F74938A3550A5AD8_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_63D2FFB0AC774D77F74938A3550A5AD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_63D2FFB0AC774D77F74938A3550A5AD8_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_63D2FFB0AC774D77F74938A3550A5AD8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_63D2FFB0AC774D77F74938A3550A5AD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember_63D2FFB0AC774D77F74938A3550A5AD8" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember_63D2FFB0AC774D77F74938A3550A5AD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_05AE7F98B990A61A310038A3550A28F2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_05AE7F98B990A61A310038A3550A28F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_05AE7F98B990A61A310038A3550A28F2_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_05AE7F98B990A61A310038A3550A28F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_05AE7F98B990A61A310038A3550A28F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_05AE7F98B990A61A310038A3550A28F2" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_05AE7F98B990A61A310038A3550A28F2" xlink:type="arc" />
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_83E3F9FD4944AE8A5F0B38A3550ACC14_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_83E3F9FD4944AE8A5F0B38A3550ACC14" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_83E3F9FD4944AE8A5F0B38A3550ACC14_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_83E3F9FD4944AE8A5F0B38A3550ACC14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_83E3F9FD4944AE8A5F0B38A3550ACC14_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_83E3F9FD4944AE8A5F0B38A3550ACC14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_83E3F9FD4944AE8A5F0B38A3550ACC14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_83E3F9FD4944AE8A5F0B38A3550ACC14" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract_83E3F9FD4944AE8A5F0B38A3550ACC14" xlink:type="arc" />
    <link:label id="lab_biib_NumeratorAbstract_30D2DD904D2C85047A8738A3550A4CA9_verboseLabel_en-US" xlink:label="lab_biib_NumeratorAbstract_30D2DD904D2C85047A8738A3550A4CA9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_biib_NumeratorAbstract_30D2DD904D2C85047A8738A3550A4CA9_label_en-US" xlink:label="lab_biib_NumeratorAbstract_30D2DD904D2C85047A8738A3550A4CA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_biib_NumeratorAbstract_30D2DD904D2C85047A8738A3550A4CA9_documentation_en-US" xlink:label="lab_biib_NumeratorAbstract_30D2DD904D2C85047A8738A3550A4CA9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_NumeratorAbstract" xlink:label="loc_biib_NumeratorAbstract_30D2DD904D2C85047A8738A3550A4CA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumeratorAbstract_30D2DD904D2C85047A8738A3550A4CA9" xlink:to="lab_biib_NumeratorAbstract_30D2DD904D2C85047A8738A3550A4CA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_E275DC2B1441440C473B38A3550A3BCE_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_E275DC2B1441440C473B38A3550A3BCE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Idec Inc</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_E275DC2B1441440C473B38A3550A3BCE_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_E275DC2B1441440C473B38A3550A3BCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E275DC2B1441440C473B38A3550A3BCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_E275DC2B1441440C473B38A3550A3BCE" xlink:to="lab_us-gaap_NetIncomeLoss_E275DC2B1441440C473B38A3550A3BCE" xlink:type="arc" />
    <link:label id="lab_biib_DenominatorAbstract_1F4BA4D7D4AAB2A7604738A3550A9883_verboseLabel_en-US" xlink:label="lab_biib_DenominatorAbstract_1F4BA4D7D4AAB2A7604738A3550A9883" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_biib_DenominatorAbstract_1F4BA4D7D4AAB2A7604738A3550A9883_label_en-US" xlink:label="lab_biib_DenominatorAbstract_1F4BA4D7D4AAB2A7604738A3550A9883" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_biib_DenominatorAbstract_1F4BA4D7D4AAB2A7604738A3550A9883_documentation_en-US" xlink:label="lab_biib_DenominatorAbstract_1F4BA4D7D4AAB2A7604738A3550A9883" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_DenominatorAbstract" xlink:label="loc_biib_DenominatorAbstract_1F4BA4D7D4AAB2A7604738A3550A9883" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenominatorAbstract_1F4BA4D7D4AAB2A7604738A3550A9883" xlink:to="lab_biib_DenominatorAbstract_1F4BA4D7D4AAB2A7604738A3550A9883" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1D7ED7FBDA70998A596A38A3550A57E4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1D7ED7FBDA70998A596A38A3550A57E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1D7ED7FBDA70998A596A38A3550A57E4_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1D7ED7FBDA70998A596A38A3550A57E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1D7ED7FBDA70998A596A38A3550A57E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1D7ED7FBDA70998A596A38A3550A57E4" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1D7ED7FBDA70998A596A38A3550A57E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_B133058C18B4E730717938A3550A2979_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_B133058C18B4E730717938A3550A2979" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_B133058C18B4E730717938A3550A2979_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_B133058C18B4E730717938A3550A2979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_B133058C18B4E730717938A3550A2979" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_B133058C18B4E730717938A3550A2979" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_B133058C18B4E730717938A3550A2979" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5497B723E5308EBCC12138A3550A1A87_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5497B723E5308EBCC12138A3550A1A87" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5497B723E5308EBCC12138A3550A1A87_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5497B723E5308EBCC12138A3550A1A87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5497B723E5308EBCC12138A3550A1A87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5497B723E5308EBCC12138A3550A1A87" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5497B723E5308EBCC12138A3550A1A87" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_830CEFE18602F71ECCD738A3550ADD37_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_830CEFE18602F71ECCD738A3550ADD37" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_830CEFE18602F71ECCD738A3550ADD37_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_830CEFE18602F71ECCD738A3550ADD37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_830CEFE18602F71ECCD738A3550ADD37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_830CEFE18602F71ECCD738A3550ADD37" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_830CEFE18602F71ECCD738A3550ADD37" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A2D107C5C7675DF3390238A3550AF32F_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A2D107C5C7675DF3390238A3550AF32F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A2D107C5C7675DF3390238A3550AF32F_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A2D107C5C7675DF3390238A3550AF32F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A2D107C5C7675DF3390238A3550AF32F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A2D107C5C7675DF3390238A3550AF32F" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A2D107C5C7675DF3390238A3550AF32F" xlink:type="arc" />
    <link:label id="lab_biib_EarningsPerShareTextualAbstract_AF9170BB876C6D73878B38A3550AB7FC_terseLabel_en-US" xlink:label="lab_biib_EarningsPerShareTextualAbstract_AF9170BB876C6D73878B38A3550AB7FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share (Textual)</link:label>
    <link:label id="lab_biib_EarningsPerShareTextualAbstract_AF9170BB876C6D73878B38A3550AB7FC_label_en-US" xlink:label="lab_biib_EarningsPerShareTextualAbstract_AF9170BB876C6D73878B38A3550AB7FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_EarningsPerShareTextualAbstract_AF9170BB876C6D73878B38A3550AB7FC_documentation_en-US" xlink:label="lab_biib_EarningsPerShareTextualAbstract_AF9170BB876C6D73878B38A3550AB7FC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings per share.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_EarningsPerShareTextualAbstract" xlink:label="loc_biib_EarningsPerShareTextualAbstract_AF9170BB876C6D73878B38A3550AB7FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EarningsPerShareTextualAbstract_AF9170BB876C6D73878B38A3550AB7FC" xlink:to="lab_biib_EarningsPerShareTextualAbstract_AF9170BB876C6D73878B38A3550AB7FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_ACA1A86020D252DE7C3638A3550A45E0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_ACA1A86020D252DE7C3638A3550A45E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_ACA1A86020D252DE7C3638A3550A45E0_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_ACA1A86020D252DE7C3638A3550A45E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_ACA1A86020D252DE7C3638A3550A45E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_ACA1A86020D252DE7C3638A3550A45E0" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_ACA1A86020D252DE7C3638A3550A45E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_F33D9BAF6B3E4D6A7D1D93224D3C542B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_F33D9BAF6B3E4D6A7D1D93224D3C542B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_F33D9BAF6B3E4D6A7D1D93224D3C542B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_F33D9BAF6B3E4D6A7D1D93224D3C542B" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_F33D9BAF6B3E4D6A7D1D93224D3C542B" xlink:type="arc" />
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_584D5A2C868F0CD1228393224D3C5B79_terseLabel_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember_584D5A2C868F0CD1228393224D3C5B79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convergence Pharmaceuticals</link:label>
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_584D5A2C868F0CD1228393224D3C5B79_label_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember_584D5A2C868F0CD1228393224D3C5B79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convergence Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_584D5A2C868F0CD1228393224D3C5B79_documentation_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember_584D5A2C868F0CD1228393224D3C5B79" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convergence Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_584D5A2C868F0CD1228393224D3C5B79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ConvergencePharmaceuticalsMember_584D5A2C868F0CD1228393224D3C5B79" xlink:to="lab_biib_ConvergencePharmaceuticalsMember_584D5A2C868F0CD1228393224D3C5B79" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_E01CD3F64172105EF56C93224D3C6D7B_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_E01CD3F64172105EF56C93224D3C6D7B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash portion of consideration</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_E01CD3F64172105EF56C93224D3C6D7B_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_E01CD3F64172105EF56C93224D3C6D7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_E01CD3F64172105EF56C93224D3C6D7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_E01CD3F64172105EF56C93224D3C6D7B" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_E01CD3F64172105EF56C93224D3C6D7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_E6E156F93A07B676308793224D3CEBDE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_E6E156F93A07B676308793224D3CEBDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_E6E156F93A07B676308793224D3CEBDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_E6E156F93A07B676308793224D3CEBDE" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_E6E156F93A07B676308793224D3CEBDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_26E9A90E23F7C3CBD8BC93224D3C32E8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_26E9A90E23F7C3CBD8BC93224D3C32E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_26E9A90E23F7C3CBD8BC93224D3C32E8_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_26E9A90E23F7C3CBD8BC93224D3C32E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_26E9A90E23F7C3CBD8BC93224D3C32E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_26E9A90E23F7C3CBD8BC93224D3C32E8" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_26E9A90E23F7C3CBD8BC93224D3C32E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_3520DD9E865A936770F0A34B6AEAC8BE_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_3520DD9E865A936770F0A34B6AEAC8BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3520DD9E865A936770F0A34B6AEAC8BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3520DD9E865A936770F0A34B6AEAC8BE" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_3520DD9E865A936770F0A34B6AEAC8BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_B842F67491A086C87A04A34B6AEB890F_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_B842F67491A086C87A04A34B6AEB890F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_B842F67491A086C87A04A34B6AEB890F_label_en-US" xlink:label="lab_us-gaap_StatementTable_B842F67491A086C87A04A34B6AEB890F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_B842F67491A086C87A04A34B6AEB890F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_B842F67491A086C87A04A34B6AEB890F" xlink:to="lab_us-gaap_StatementTable_B842F67491A086C87A04A34B6AEB890F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7E353E4C27E42D2F33B9A34B6AEB3683_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_7E353E4C27E42D2F33B9A34B6AEB3683" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7E353E4C27E42D2F33B9A34B6AEB3683_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_7E353E4C27E42D2F33B9A34B6AEB3683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7E353E4C27E42D2F33B9A34B6AEB3683" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7E353E4C27E42D2F33B9A34B6AEB3683" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_7E353E4C27E42D2F33B9A34B6AEB3683" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:to="lab_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentCompanyMember_A7A7B90EFBE226DA8327A34B6AEB5B78_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentCompanyMember_A7A7B90EFBE226DA8327A34B6AEB5B78" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total Biogen Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_ParentCompanyMember_A7A7B90EFBE226DA8327A34B6AEB5B78_label_en-US" xlink:label="lab_us-gaap_ParentCompanyMember_A7A7B90EFBE226DA8327A34B6AEB5B78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="loc_us-gaap_ParentCompanyMember_A7A7B90EFBE226DA8327A34B6AEB5B78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentCompanyMember_A7A7B90EFBE226DA8327A34B6AEB5B78" xlink:to="lab_us-gaap_ParentCompanyMember_A7A7B90EFBE226DA8327A34B6AEB5B78" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_5FF835D36D07DC1FF096A34B6AEB7B24_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_5FF835D36D07DC1FF096A34B6AEB7B24" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_5FF835D36D07DC1FF096A34B6AEB7B24_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_5FF835D36D07DC1FF096A34B6AEB7B24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_5FF835D36D07DC1FF096A34B6AEB7B24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_5FF835D36D07DC1FF096A34B6AEB7B24" xlink:to="lab_us-gaap_PreferredStockMember_5FF835D36D07DC1FF096A34B6AEB7B24" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_C6B088FECEF4DDF46ACBA34B6AEB3F29_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_C6B088FECEF4DDF46ACBA34B6AEB3F29" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_C6B088FECEF4DDF46ACBA34B6AEB3F29_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_C6B088FECEF4DDF46ACBA34B6AEB3F29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_C6B088FECEF4DDF46ACBA34B6AEB3F29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_C6B088FECEF4DDF46ACBA34B6AEB3F29" xlink:to="lab_us-gaap_CommonStockMember_C6B088FECEF4DDF46ACBA34B6AEB3F29" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4F03A9D50C43526FD55CA34B6AEB881F_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_4F03A9D50C43526FD55CA34B6AEB881F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4F03A9D50C43526FD55CA34B6AEB881F_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_4F03A9D50C43526FD55CA34B6AEB881F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4F03A9D50C43526FD55CA34B6AEB881F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_4F03A9D50C43526FD55CA34B6AEB881F" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_4F03A9D50C43526FD55CA34B6AEB881F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9DB159D9B7D49CB877C7A34B6AEBCDE5_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9DB159D9B7D49CB877C7A34B6AEBCDE5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9DB159D9B7D49CB877C7A34B6AEBCDE5_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9DB159D9B7D49CB877C7A34B6AEBCDE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9DB159D9B7D49CB877C7A34B6AEBCDE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9DB159D9B7D49CB877C7A34B6AEBCDE5" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9DB159D9B7D49CB877C7A34B6AEBCDE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_BDE4C6F4CE32ECB82C74A34B6AEBF67D_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_BDE4C6F4CE32ECB82C74A34B6AEBF67D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_BDE4C6F4CE32ECB82C74A34B6AEBF67D_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_BDE4C6F4CE32ECB82C74A34B6AEBF67D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_BDE4C6F4CE32ECB82C74A34B6AEBF67D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_BDE4C6F4CE32ECB82C74A34B6AEBF67D" xlink:to="lab_us-gaap_RetainedEarningsMember_BDE4C6F4CE32ECB82C74A34B6AEBF67D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_C24894674BFCFA3ED127A34B6AEB6162_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_C24894674BFCFA3ED127A34B6AEB6162" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_C24894674BFCFA3ED127A34B6AEB6162_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_C24894674BFCFA3ED127A34B6AEB6162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_C24894674BFCFA3ED127A34B6AEB6162" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_C24894674BFCFA3ED127A34B6AEB6162" xlink:to="lab_us-gaap_TreasuryStockMember_C24894674BFCFA3ED127A34B6AEB6162" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_EA06B0336302B1C3190FA34B6AEB4F94_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_EA06B0336302B1C3190FA34B6AEB4F94" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_EA06B0336302B1C3190FA34B6AEB4F94_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_EA06B0336302B1C3190FA34B6AEB4F94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_EA06B0336302B1C3190FA34B6AEB4F94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_EA06B0336302B1C3190FA34B6AEB4F94" xlink:to="lab_us-gaap_NoncontrollingInterestMember_EA06B0336302B1C3190FA34B6AEB4F94" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="lab_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_97BC60DE6EF5DD36733CA34B6AEB83B4_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_97BC60DE6EF5DD36733CA34B6AEB83B4" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_97BC60DE6EF5DD36733CA34B6AEB83B4_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_97BC60DE6EF5DD36733CA34B6AEB83B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_97BC60DE6EF5DD36733CA34B6AEB83B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_97BC60DE6EF5DD36733CA34B6AEB83B4" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_97BC60DE6EF5DD36733CA34B6AEB83B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_B1A61E954B94C94DC3FCA34B6AEC3001_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_B1A61E954B94C94DC3FCA34B6AEC3001" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, shares</link:label>
    <link:label id="lab_us-gaap_SharesIssued_B1A61E954B94C94DC3FCA34B6AEC3001_label_en-US" xlink:label="lab_us-gaap_SharesIssued_B1A61E954B94C94DC3FCA34B6AEC3001" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_B1A61E954B94C94DC3FCA34B6AEC3001" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_B1A61E954B94C94DC3FCA34B6AEC3001" xlink:to="lab_us-gaap_SharesIssued_B1A61E954B94C94DC3FCA34B6AEC3001" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_183DB335637CF53E5443A34B6AECC9C2_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_183DB335637CF53E5443A34B6AECC9C2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_183DB335637CF53E5443A34B6AECC9C2_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_183DB335637CF53E5443A34B6AECC9C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_183DB335637CF53E5443A34B6AECC9C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_183DB335637CF53E5443A34B6AECC9C2" xlink:to="lab_us-gaap_ProfitLoss_183DB335637CF53E5443A34B6AECC9C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D0170E653F0CA6910A35A34B6AEC0ABE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D0170E653F0CA6910A35A34B6AEC0ABE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D0170E653F0CA6910A35A34B6AEC0ABE_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D0170E653F0CA6910A35A34B6AEC0ABE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D0170E653F0CA6910A35A34B6AEC0ABE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D0170E653F0CA6910A35A34B6AEC0ABE" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D0170E653F0CA6910A35A34B6AEC0ABE" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_276E7416052B33694D7BA34B6AEC456E_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_276E7416052B33694D7BA34B6AEC456E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Distribution to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_276E7416052B33694D7BA34B6AEC456E_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_276E7416052B33694D7BA34B6AEC456E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_276E7416052B33694D7BA34B6AEC456E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_276E7416052B33694D7BA34B6AEC456E" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_276E7416052B33694D7BA34B6AEC456E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C5A74CDEA1B97BF22C3DA34B6AEC35E1_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C5A74CDEA1B97BF22C3DA34B6AEC35E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C5A74CDEA1B97BF22C3DA34B6AEC35E1_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C5A74CDEA1B97BF22C3DA34B6AEC35E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C5A74CDEA1B97BF22C3DA34B6AEC35E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C5A74CDEA1B97BF22C3DA34B6AEC35E1" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C5A74CDEA1B97BF22C3DA34B6AEC35E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_89D028E32038AECE1805A34B6AEC6801_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_89D028E32038AECE1805A34B6AEC6801" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deconsolidation of noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_89D028E32038AECE1805A34B6AEC6801_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_89D028E32038AECE1805A34B6AEC6801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Deconsolidation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_89D028E32038AECE1805A34B6AEC6801" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_89D028E32038AECE1805A34B6AEC6801" xlink:to="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_89D028E32038AECE1805A34B6AEC6801" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_8641BFE0E2D04EA1E77BA34B6AECADA1_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_8641BFE0E2D04EA1E77BA34B6AECADA1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_8641BFE0E2D04EA1E77BA34B6AECADA1_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_8641BFE0E2D04EA1E77BA34B6AECADA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_8641BFE0E2D04EA1E77BA34B6AECADA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_8641BFE0E2D04EA1E77BA34B6AECADA1" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_8641BFE0E2D04EA1E77BA34B6AECADA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_0A9B30088B8475F83E89A34B6AECD0D7_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_0A9B30088B8475F83E89A34B6AECD0D7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_0A9B30088B8475F83E89A34B6AECD0D7_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_0A9B30088B8475F83E89A34B6AECD0D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_0A9B30088B8475F83E89A34B6AECD0D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_0A9B30088B8475F83E89A34B6AECD0D7" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_0A9B30088B8475F83E89A34B6AECD0D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_3DC274BAF9B69CB6ACDFA34B6AEC0028_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_3DC274BAF9B69CB6ACDFA34B6AEC0028" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to the 2015 Share Repurchase Program, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_3DC274BAF9B69CB6ACDFA34B6AEC0028_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_3DC274BAF9B69CB6ACDFA34B6AEC0028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_3DC274BAF9B69CB6ACDFA34B6AEC0028" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_3DC274BAF9B69CB6ACDFA34B6AEC0028" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_3DC274BAF9B69CB6ACDFA34B6AEC0028" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_511A1E90666A9443AFE9A34B6AECCD8C_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_511A1E90666A9443AFE9A34B6AECCD8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to the 2015 Share Repurchase Program, at cost, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_511A1E90666A9443AFE9A34B6AECCD8C_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_511A1E90666A9443AFE9A34B6AECCD8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_511A1E90666A9443AFE9A34B6AECCD8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_511A1E90666A9443AFE9A34B6AECCD8C" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_511A1E90666A9443AFE9A34B6AECCD8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63DF82B7E187B57D09D2A34B6AECB6A5_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63DF82B7E187B57D09D2A34B6AECB6A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63DF82B7E187B57D09D2A34B6AECB6A5_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63DF82B7E187B57D09D2A34B6AECB6A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63DF82B7E187B57D09D2A34B6AECB6A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63DF82B7E187B57D09D2A34B6AECB6A5" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63DF82B7E187B57D09D2A34B6AECB6A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_444971711DD9519B8472A34B6AEC721A_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_444971711DD9519B8472A34B6AEC721A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_444971711DD9519B8472A34B6AEC721A_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_444971711DD9519B8472A34B6AEC721A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_444971711DD9519B8472A34B6AEC721A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_444971711DD9519B8472A34B6AEC721A" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_444971711DD9519B8472A34B6AEC721A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_DE49D532E3538C2C52C9A34B6AECA296_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_DE49D532E3538C2C52C9A34B6AECA296" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_DE49D532E3538C2C52C9A34B6AECA296_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_DE49D532E3538C2C52C9A34B6AECA296" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_DE49D532E3538C2C52C9A34B6AECA296" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_DE49D532E3538C2C52C9A34B6AECA296" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_DE49D532E3538C2C52C9A34B6AECA296" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9FDBD3B7B97FA1B6DF09A34B6AEC9B7B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9FDBD3B7B97FA1B6DF09A34B6AEC9B7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9FDBD3B7B97FA1B6DF09A34B6AEC9B7B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9FDBD3B7B97FA1B6DF09A34B6AEC9B7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9FDBD3B7B97FA1B6DF09A34B6AEC9B7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9FDBD3B7B97FA1B6DF09A34B6AEC9B7B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9FDBD3B7B97FA1B6DF09A34B6AEC9B7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6027D8B5BBF741A18224A34B6AECACF7_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_6027D8B5BBF741A18224A34B6AECACF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense related to share-based payments</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6027D8B5BBF741A18224A34B6AECACF7_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_6027D8B5BBF741A18224A34B6AECACF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6027D8B5BBF741A18224A34B6AECACF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_6027D8B5BBF741A18224A34B6AECACF7" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_6027D8B5BBF741A18224A34B6AECACF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F5B3AF00556D11CA4EEA34B6AEC3519_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F5B3AF00556D11CA4EEA34B6AEC3519" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit from share-based payments</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F5B3AF00556D11CA4EEA34B6AEC3519_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F5B3AF00556D11CA4EEA34B6AEC3519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F5B3AF00556D11CA4EEA34B6AEC3519" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F5B3AF00556D11CA4EEA34B6AEC3519" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F5B3AF00556D11CA4EEA34B6AEC3519" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80F7ED959DA509C35ED8A34B6AEC248D_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80F7ED959DA509C35ED8A34B6AEC248D" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80F7ED959DA509C35ED8A34B6AEC248D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80F7ED959DA509C35ED8A34B6AEC248D" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80F7ED959DA509C35ED8A34B6AEC248D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_6709E0A8D6B1D9BAA840A34B6AED444C_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_6709E0A8D6B1D9BAA840A34B6AED444C" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_6709E0A8D6B1D9BAA840A34B6AED444C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_6709E0A8D6B1D9BAA840A34B6AED444C" xlink:to="lab_us-gaap_SharesIssued_6709E0A8D6B1D9BAA840A34B6AED444C" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_951E4458524A97CA750D38A3522922DF_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_951E4458524A97CA750D38A3522922DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_951E4458524A97CA750D38A3522922DF_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_951E4458524A97CA750D38A3522922DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_951E4458524A97CA750D38A3522922DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_951E4458524A97CA750D38A3522922DF" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_951E4458524A97CA750D38A3522922DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_DE993325C757D86932F193582ED7CC93_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_DE993325C757D86932F193582ED7CC93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_DE993325C757D86932F193582ED7CC93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_DE993325C757D86932F193582ED7CC93" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_DE993325C757D86932F193582ED7CC93" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8BCD211E255AEAE9C10D93582ED7C6E1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8BCD211E255AEAE9C10D93582ED7C6E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8BCD211E255AEAE9C10D93582ED7C6E1_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8BCD211E255AEAE9C10D93582ED7C6E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8BCD211E255AEAE9C10D93582ED7C6E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8BCD211E255AEAE9C10D93582ED7C6E1" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8BCD211E255AEAE9C10D93582ED7C6E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeByNatureAxis_23A0F49B692869B696EC93582ED75CFB_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeByNatureAxis_23A0F49B692869B696EC93582ED75CFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, by Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeByNatureAxis_23A0F49B692869B696EC93582ED75CFB_label_en-US" xlink:label="lab_us-gaap_DerivativeByNatureAxis_23A0F49B692869B696EC93582ED75CFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, by Nature [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaap_DerivativeByNatureAxis_23A0F49B692869B696EC93582ED75CFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeByNatureAxis_23A0F49B692869B696EC93582ED75CFB" xlink:to="lab_us-gaap_DerivativeByNatureAxis_23A0F49B692869B696EC93582ED75CFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeNameDomain_C843415E3C92A6777ADC93582ED75625_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNameDomain_C843415E3C92A6777ADC93582ED75625" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeNameDomain_C843415E3C92A6777ADC93582ED75625_label_en-US" xlink:label="lab_us-gaap_DerivativeNameDomain_C843415E3C92A6777ADC93582ED75625" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_C843415E3C92A6777ADC93582ED75625" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNameDomain_C843415E3C92A6777ADC93582ED75625" xlink:to="lab_us-gaap_DerivativeNameDomain_C843415E3C92A6777ADC93582ED75625" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesMember_D5FE4A484447B39E723993582ED8DBD5_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember_D5FE4A484447B39E723993582ED8DBD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_D5FE4A484447B39E723993582ED8DBD5_label_en-US" xlink:label="lab_us-gaap_SalesMember_D5FE4A484447B39E723993582ED8DBD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_D5FE4A484447B39E723993582ED8DBD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember_D5FE4A484447B39E723993582ED8DBD5" xlink:to="lab_us-gaap_SalesMember_D5FE4A484447B39E723993582ED8DBD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_106AC38E187C97465AD493582ED80981_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_106AC38E187C97465AD493582ED80981" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument Risk [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_106AC38E187C97465AD493582ED80981_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_106AC38E187C97465AD493582ED80981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_106AC38E187C97465AD493582ED80981" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_106AC38E187C97465AD493582ED80981" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_106AC38E187C97465AD493582ED80981" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_5B8DB93FCF69B13C7AB493582ED82CCC_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_5B8DB93FCF69B13C7AB493582ED82CCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract Type [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_5B8DB93FCF69B13C7AB493582ED82CCC_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_5B8DB93FCF69B13C7AB493582ED82CCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5B8DB93FCF69B13C7AB493582ED82CCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5B8DB93FCF69B13C7AB493582ED82CCC" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_5B8DB93FCF69B13C7AB493582ED82CCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_67D4C0FC526B5368136793582ED8ECB1_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_67D4C0FC526B5368136793582ED8ECB1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_67D4C0FC526B5368136793582ED8ECB1_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_67D4C0FC526B5368136793582ED8ECB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_67D4C0FC526B5368136793582ED8ECB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember_67D4C0FC526B5368136793582ED8ECB1" xlink:to="lab_us-gaap_ForeignExchangeContractMember_67D4C0FC526B5368136793582ED8ECB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_259B476FFD90E4F44B6393582ED8C989_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_259B476FFD90E4F44B6393582ED8C989" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_259B476FFD90E4F44B6393582ED8C989" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_259B476FFD90E4F44B6393582ED8C989" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_259B476FFD90E4F44B6393582ED8C989" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3095240D889CC37EF20393582ED863FB_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_3095240D889CC37EF20393582ED863FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3095240D889CC37EF20393582ED863FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3095240D889CC37EF20393582ED863FB" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_3095240D889CC37EF20393582ED863FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesMember_B9E94AB3F9E6CEE6F28B93582ED88A38_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesMember_B9E94AB3F9E6CEE6F28B93582ED88A38" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_B9E94AB3F9E6CEE6F28B93582ED88A38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember_B9E94AB3F9E6CEE6F28B93582ED88A38" xlink:to="lab_us-gaap_SalesMember_B9E94AB3F9E6CEE6F28B93582ED88A38" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_8F59E3D0669AD13C1DD093582ED8C574_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_8F59E3D0669AD13C1DD093582ED8C574" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_8F59E3D0669AD13C1DD093582ED8C574_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_8F59E3D0669AD13C1DD093582ED8C574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8F59E3D0669AD13C1DD093582ED8C574" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8F59E3D0669AD13C1DD093582ED8C574" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_8F59E3D0669AD13C1DD093582ED8C574" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_573609C0E7606F68E9E293582ED84B77_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_573609C0E7606F68E9E293582ED84B77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_573609C0E7606F68E9E293582ED84B77_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_573609C0E7606F68E9E293582ED84B77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_573609C0E7606F68E9E293582ED84B77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_573609C0E7606F68E9E293582ED84B77" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_573609C0E7606F68E9E293582ED84B77" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_CA99F4236C15B27CE53D93582ED84AB4_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_CA99F4236C15B27CE53D93582ED84AB4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_CA99F4236C15B27CE53D93582ED84AB4_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_CA99F4236C15B27CE53D93582ED84AB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_CA99F4236C15B27CE53D93582ED84AB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_CA99F4236C15B27CE53D93582ED84AB4" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_CA99F4236C15B27CE53D93582ED84AB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_CB23975FDAC09B0BA47593582ED80148_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_CB23975FDAC09B0BA47593582ED80148" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amount Reclassified from Accumulated Other Comprehensive Income into Income Gain/(Loss) (Effective Portion)</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_CB23975FDAC09B0BA47593582ED80148_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_CB23975FDAC09B0BA47593582ED80148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_CB23975FDAC09B0BA47593582ED80148" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_CB23975FDAC09B0BA47593582ED80148" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_CB23975FDAC09B0BA47593582ED80148" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_3038DD34BF4CB6913BD793582ED84CBF_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_3038DD34BF4CB6913BD793582ED84CBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) in earnings of foreign currency forward contracts due to hedge ineffectiveness</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_3038DD34BF4CB6913BD793582ED84CBF_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_3038DD34BF4CB6913BD793582ED84CBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_3038DD34BF4CB6913BD793582ED84CBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_3038DD34BF4CB6913BD793582ED84CBF" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_3038DD34BF4CB6913BD793582ED84CBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_186DC61E0EF52BA7A28138A3510E0F6F_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_186DC61E0EF52BA7A28138A3510E0F6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_186DC61E0EF52BA7A28138A3510E0F6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_186DC61E0EF52BA7A28138A3510E0F6F" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_186DC61E0EF52BA7A28138A3510E0F6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_30193E1793E9C7CF9E8338A3510EF028_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_30193E1793E9C7CF9E8338A3510EF028" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_30193E1793E9C7CF9E8338A3510EF028_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_30193E1793E9C7CF9E8338A3510EF028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_30193E1793E9C7CF9E8338A3510EF028" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_30193E1793E9C7CF9E8338A3510EF028" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_30193E1793E9C7CF9E8338A3510EF028" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_A1BBFD7E13EE3B33784393224C28AE50_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_A1BBFD7E13EE3B33784393224C28AE50" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_A1BBFD7E13EE3B33784393224C28AE50_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_A1BBFD7E13EE3B33784393224C28AE50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_A1BBFD7E13EE3B33784393224C28AE50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_A1BBFD7E13EE3B33784393224C28AE50" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_A1BBFD7E13EE3B33784393224C28AE50" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_8120F952666FD93F1A7193224C2879E0_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_8120F952666FD93F1A7193224C2879E0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities including strategic investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_8120F952666FD93F1A7193224C2879E0_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_8120F952666FD93F1A7193224C2879E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_8120F952666FD93F1A7193224C2879E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_8120F952666FD93F1A7193224C2879E0" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_8120F952666FD93F1A7193224C2879E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_004FB68E1322EAC2C03893224C284056_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_004FB68E1322EAC2C03893224C284056" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of contractual maturities: Available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_004FB68E1322EAC2C03893224C284056_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_004FB68E1322EAC2C03893224C284056" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_004FB68E1322EAC2C03893224C284056" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_004FB68E1322EAC2C03893224C284056" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_004FB68E1322EAC2C03893224C284056" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_F54D2529A9762E2BAB6493224C28982B_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_F54D2529A9762E2BAB6493224C28982B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from marketable securities, excluding strategic investments</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_F54D2529A9762E2BAB6493224C28982B_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_F54D2529A9762E2BAB6493224C28982B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_F54D2529A9762E2BAB6493224C28982B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_F54D2529A9762E2BAB6493224C28982B" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_F54D2529A9762E2BAB6493224C28982B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingAbstract_20DD24D3739D1488703438A3526AE61E_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract_20DD24D3739D1488703438A3526AE61E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_20DD24D3739D1488703438A3526AE61E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_20DD24D3739D1488703438A3526AE61E" xlink:to="lab_us-gaap_SegmentReportingAbstract_20DD24D3739D1488703438A3526AE61E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_41189C1D1B76EC0A46E438A3526A6553_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_41189C1D1B76EC0A46E438A3526A6553" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_41189C1D1B76EC0A46E438A3526A6553_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_41189C1D1B76EC0A46E438A3526A6553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_41189C1D1B76EC0A46E438A3526A6553" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_41189C1D1B76EC0A46E438A3526A6553" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_41189C1D1B76EC0A46E438A3526A6553" xlink:type="arc" />
    <link:label id="lab_country_US_583278D6AB2DE841CEFF38A3526A41C7_verboseLabel_en-US" xlink:label="lab_country_US_583278D6AB2DE841CEFF38A3526A41C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="loc_country_US_583278D6AB2DE841CEFF38A3526A41C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_583278D6AB2DE841CEFF38A3526A41C7" xlink:to="lab_country_US_583278D6AB2DE841CEFF38A3526A41C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EuropeMember_22DA1AF86DCCC1149D0438A3526A5D05_verboseLabel_en-US" xlink:label="lab_us-gaap_EuropeMember_22DA1AF86DCCC1149D0438A3526A5D05" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_us-gaap_EuropeMember_22DA1AF86DCCC1149D0438A3526A5D05_label_en-US" xlink:label="lab_us-gaap_EuropeMember_22DA1AF86DCCC1149D0438A3526A5D05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_22DA1AF86DCCC1149D0438A3526A5D05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeMember_22DA1AF86DCCC1149D0438A3526A5D05" xlink:to="lab_us-gaap_EuropeMember_22DA1AF86DCCC1149D0438A3526A5D05" xlink:type="arc" />
    <link:label id="lab_country_DE_BB7ABBF54FFCA885765238A3526ABF89_verboseLabel_en-US" xlink:label="lab_country_DE_BB7ABBF54FFCA885765238A3526ABF89" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_BB7ABBF54FFCA885765238A3526ABF89_label_en-US" xlink:label="lab_country_DE_BB7ABBF54FFCA885765238A3526ABF89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_DE" xlink:label="loc_country_DE_BB7ABBF54FFCA885765238A3526ABF89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE_BB7ABBF54FFCA885765238A3526ABF89" xlink:to="lab_country_DE_BB7ABBF54FFCA885765238A3526ABF89" xlink:type="arc" />
    <link:label id="lab_us-gaap_AsiaMember_37EDA8542BEF8885EA7C38A3526A278D_verboseLabel_en-US" xlink:label="lab_us-gaap_AsiaMember_37EDA8542BEF8885EA7C38A3526A278D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Asia</link:label>
    <link:label id="lab_us-gaap_AsiaMember_37EDA8542BEF8885EA7C38A3526A278D_label_en-US" xlink:label="lab_us-gaap_AsiaMember_37EDA8542BEF8885EA7C38A3526A278D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asia [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AsiaMember" xlink:label="loc_us-gaap_AsiaMember_37EDA8542BEF8885EA7C38A3526A278D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AsiaMember_37EDA8542BEF8885EA7C38A3526A278D" xlink:to="lab_us-gaap_AsiaMember_37EDA8542BEF8885EA7C38A3526A278D" xlink:type="arc" />
    <link:label id="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_78A5D0860C9F0B41068D38A3526AE776_verboseLabel_en-US" xlink:label="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_78A5D0860C9F0B41068D38A3526AE776" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_78A5D0860C9F0B41068D38A3526AE776_label_en-US" xlink:label="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_78A5D0860C9F0B41068D38A3526AE776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Geographical Groups Of Countries Group Other [Member]</link:label>
    <link:label id="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_78A5D0860C9F0B41068D38A3526AE776_documentation_en-US" xlink:label="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_78A5D0860C9F0B41068D38A3526AE776" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Segment geographical groups of countries group other.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:label="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_78A5D0860C9F0B41068D38A3526AE776" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_78A5D0860C9F0B41068D38A3526AE776" xlink:to="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_78A5D0860C9F0B41068D38A3526AE776" xlink:type="arc" />
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_AAC54936E48FB1EA8CDC38A3526AEAA8_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_AAC54936E48FB1EA8CDC38A3526AEAA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_AAC54936E48FB1EA8CDC38A3526AEAA8_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_AAC54936E48FB1EA8CDC38A3526AEAA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_AAC54936E48FB1EA8CDC38A3526AEAA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_AAC54936E48FB1EA8CDC38A3526AEAA8" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_AAC54936E48FB1EA8CDC38A3526AEAA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_354E0164C1BB8CC0F85638A3526AD552_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract_354E0164C1BB8CC0F85638A3526AD552" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Geographic information</link:label>
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_354E0164C1BB8CC0F85638A3526AD552_label_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract_354E0164C1BB8CC0F85638A3526AD552" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments, Geographical Areas [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_354E0164C1BB8CC0F85638A3526AD552" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_354E0164C1BB8CC0F85638A3526AD552" xlink:to="lab_us-gaap_SegmentsGeographicalAreasAbstract_354E0164C1BB8CC0F85638A3526AD552" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusiness_F2EB0BEC9C01139352A838A3526BB69A_verboseLabel_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusiness_F2EB0BEC9C01139352A838A3526BB69A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business</link:label>
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusiness_F2EB0BEC9C01139352A838A3526BB69A_label_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusiness_F2EB0BEC9C01139352A838A3526BB69A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues From Unconsolidated Joint Business</link:label>
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusiness_F2EB0BEC9C01139352A838A3526BB69A_documentation_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusiness_F2EB0BEC9C01139352A838A3526BB69A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RevenuesFromUnconsolidatedJointBusiness" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusiness_F2EB0BEC9C01139352A838A3526BB69A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusiness_F2EB0BEC9C01139352A838A3526BB69A" xlink:to="lab_biib_RevenuesFromUnconsolidatedJointBusiness_F2EB0BEC9C01139352A838A3526BB69A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncurrentAssets_4270173758342207655B38A3526B85F2_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets_4270173758342207655B38A3526B85F2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_4270173758342207655B38A3526B85F2_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets_4270173758342207655B38A3526B85F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_4270173758342207655B38A3526B85F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets_4270173758342207655B38A3526B85F2" xlink:to="lab_us-gaap_NoncurrentAssets_4270173758342207655B38A3526B85F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_Land_1728B4EF26D2F167348C38A3542A9B98_terseLabel_en-US" xlink:label="lab_us-gaap_Land_1728B4EF26D2F167348C38A3542A9B98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_1728B4EF26D2F167348C38A3542A9B98_label_en-US" xlink:label="lab_us-gaap_Land_1728B4EF26D2F167348C38A3542A9B98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_1728B4EF26D2F167348C38A3542A9B98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land_1728B4EF26D2F167348C38A3542A9B98" xlink:to="lab_us-gaap_Land_1728B4EF26D2F167348C38A3542A9B98" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_18F8522E9A10EDDC789A38A3542B0A73_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross_18F8522E9A10EDDC789A38A3542B0A73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_18F8522E9A10EDDC789A38A3542B0A73_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross_18F8522E9A10EDDC789A38A3542B0A73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_18F8522E9A10EDDC789A38A3542B0A73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross_18F8522E9A10EDDC789A38A3542B0A73" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross_18F8522E9A10EDDC789A38A3542B0A73" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_EE9D475C4ABCD5F2288E38A3542B811B_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross_EE9D475C4ABCD5F2288E38A3542B811B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_EE9D475C4ABCD5F2288E38A3542B811B_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross_EE9D475C4ABCD5F2288E38A3542B811B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_EE9D475C4ABCD5F2288E38A3542B811B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross_EE9D475C4ABCD5F2288E38A3542B811B" xlink:to="lab_us-gaap_LeaseholdImprovementsGross_EE9D475C4ABCD5F2288E38A3542B811B" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_C53F29B189BA00A4B1A438A3542B7749_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross_C53F29B189BA00A4B1A438A3542B7749" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_C53F29B189BA00A4B1A438A3542B7749_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross_C53F29B189BA00A4B1A438A3542B7749" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_C53F29B189BA00A4B1A438A3542B7749" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross_C53F29B189BA00A4B1A438A3542B7749" xlink:to="lab_us-gaap_MachineryAndEquipmentGross_C53F29B189BA00A4B1A438A3542B7749" xlink:type="arc" />
    <link:label id="lab_biib_ComputerSoftwareAndHardware_A7BF2E3506C865064D4938A3542B6EC6_terseLabel_en-US" xlink:label="lab_biib_ComputerSoftwareAndHardware_A7BF2E3506C865064D4938A3542B6EC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer software and hardware</link:label>
    <link:label id="lab_biib_ComputerSoftwareAndHardware_A7BF2E3506C865064D4938A3542B6EC6_label_en-US" xlink:label="lab_biib_ComputerSoftwareAndHardware_A7BF2E3506C865064D4938A3542B6EC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer software and hardware</link:label>
    <link:label id="lab_biib_ComputerSoftwareAndHardware_A7BF2E3506C865064D4938A3542B6EC6_documentation_en-US" xlink:label="lab_biib_ComputerSoftwareAndHardware_A7BF2E3506C865064D4938A3542B6EC6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer software and hardware</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ComputerSoftwareAndHardware" xlink:label="loc_biib_ComputerSoftwareAndHardware_A7BF2E3506C865064D4938A3542B6EC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ComputerSoftwareAndHardware_A7BF2E3506C865064D4938A3542B6EC6" xlink:to="lab_biib_ComputerSoftwareAndHardware_A7BF2E3506C865064D4938A3542B6EC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_1E5F7C746DCFEF0B3B7B38A3542B4502_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross_1E5F7C746DCFEF0B3B7B38A3542B4502" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_1E5F7C746DCFEF0B3B7B38A3542B4502_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross_1E5F7C746DCFEF0B3B7B38A3542B4502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_1E5F7C746DCFEF0B3B7B38A3542B4502" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesGross_1E5F7C746DCFEF0B3B7B38A3542B4502" xlink:to="lab_us-gaap_FurnitureAndFixturesGross_1E5F7C746DCFEF0B3B7B38A3542B4502" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_490677C1401B4B94EC1838A3542B3046_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_490677C1401B4B94EC1838A3542B3046" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_490677C1401B4B94EC1838A3542B3046_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_490677C1401B4B94EC1838A3542B3046" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_490677C1401B4B94EC1838A3542B3046" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_490677C1401B4B94EC1838A3542B3046" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_490677C1401B4B94EC1838A3542B3046" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7A26695DBC2C279B6DAD38A3542B24A0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7A26695DBC2C279B6DAD38A3542B24A0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7A26695DBC2C279B6DAD38A3542B24A0_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7A26695DBC2C279B6DAD38A3542B24A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7A26695DBC2C279B6DAD38A3542B24A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7A26695DBC2C279B6DAD38A3542B24A0" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7A26695DBC2C279B6DAD38A3542B24A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2CA922BB08054997476838A3542B63D3_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_2CA922BB08054997476838A3542B63D3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2CA922BB08054997476838A3542B63D3_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_2CA922BB08054997476838A3542B63D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2CA922BB08054997476838A3542B63D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2CA922BB08054997476838A3542B63D3" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_2CA922BB08054997476838A3542B63D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D" xlink:to="lab_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateSwapMember_D4288B47E7D0BA66F49693D5CA1F6CC5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_D4288B47E7D0BA66F49693D5CA1F6CC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_D4288B47E7D0BA66F49693D5CA1F6CC5_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_D4288B47E7D0BA66F49693D5CA1F6CC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_D4288B47E7D0BA66F49693D5CA1F6CC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember_D4288B47E7D0BA66F49693D5CA1F6CC5" xlink:to="lab_us-gaap_InterestRateSwapMember_D4288B47E7D0BA66F49693D5CA1F6CC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_860325E6506CC6C3943A93D5CA1FB26F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_860325E6506CC6C3943A93D5CA1FB26F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_860325E6506CC6C3943A93D5CA1FB26F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_860325E6506CC6C3943A93D5CA1FB26F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_860325E6506CC6C3943A93D5CA1FB26F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_860325E6506CC6C3943A93D5CA1FB26F" xlink:to="lab_us-gaap_DebtInstrumentAxis_860325E6506CC6C3943A93D5CA1FB26F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_59B31C7C9A3A736B503F93D5CA1F47BF_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_59B31C7C9A3A736B503F93D5CA1F47BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.90% Senior Notes due 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_59B31C7C9A3A736B503F93D5CA1F47BF_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_59B31C7C9A3A736B503F93D5CA1F47BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_59B31C7C9A3A736B503F93D5CA1F47BF_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_59B31C7C9A3A736B503F93D5CA1F47BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_59B31C7C9A3A736B503F93D5CA1F47BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_59B31C7C9A3A736B503F93D5CA1F47BF" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_59B31C7C9A3A736B503F93D5CA1F47BF" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8AFD80790EA34399A7BA93D5CA1FFD4F_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8AFD80790EA34399A7BA93D5CA1FFD4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8AFD80790EA34399A7BA93D5CA1FFD4F_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8AFD80790EA34399A7BA93D5CA1FFD4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8AFD80790EA34399A7BA93D5CA1FFD4F_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8AFD80790EA34399A7BA93D5CA1FFD4F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8AFD80790EA34399A7BA93D5CA1FFD4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8AFD80790EA34399A7BA93D5CA1FFD4F" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8AFD80790EA34399A7BA93D5CA1FFD4F" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_767C61E63B4356C4011693D5CA1F163E_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_767C61E63B4356C4011693D5CA1F163E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.05% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_767C61E63B4356C4011693D5CA1F163E_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_767C61E63B4356C4011693D5CA1F163E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_767C61E63B4356C4011693D5CA1F163E_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_767C61E63B4356C4011693D5CA1F163E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_767C61E63B4356C4011693D5CA1F163E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_767C61E63B4356C4011693D5CA1F163E" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_767C61E63B4356C4011693D5CA1F163E" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_DEA3CD82BFBCDA2F38BC93D5CA1F67F6_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_DEA3CD82BFBCDA2F38BC93D5CA1F67F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.20% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_DEA3CD82BFBCDA2F38BC93D5CA1F67F6_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_DEA3CD82BFBCDA2F38BC93D5CA1F67F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_DEA3CD82BFBCDA2F38BC93D5CA1F67F6_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_DEA3CD82BFBCDA2F38BC93D5CA1F67F6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_DEA3CD82BFBCDA2F38BC93D5CA1F67F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_DEA3CD82BFBCDA2F38BC93D5CA1F67F6" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_DEA3CD82BFBCDA2F38BC93D5CA1F67F6" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7CE22C1F69C1430DA9BA93E5A6FBC5A4_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7CE22C1F69C1430DA9BA93E5A6FBC5A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.875% Senior Notes due 2018</link:label>
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7CE22C1F69C1430DA9BA93E5A6FBC5A4_label_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7CE22C1F69C1430DA9BA93E5A6FBC5A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Six Point Eight Seven Five Percent Due Twenty Eighteen [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7CE22C1F69C1430DA9BA93E5A6FBC5A4_documentation_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7CE22C1F69C1430DA9BA93E5A6FBC5A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Six Point Eight Seven Five Percent Due Twenty Eighteen.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7CE22C1F69C1430DA9BA93E5A6FBC5A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7CE22C1F69C1430DA9BA93E5A6FBC5A4" xlink:to="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7CE22C1F69C1430DA9BA93E5A6FBC5A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_FADA9BCA25F556DE271F93D5CA1FCF31_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_FADA9BCA25F556DE271F93D5CA1FCF31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_FADA9BCA25F556DE271F93D5CA1FCF31_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_FADA9BCA25F556DE271F93D5CA1FCF31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_FADA9BCA25F556DE271F93D5CA1FCF31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_FADA9BCA25F556DE271F93D5CA1FCF31" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_FADA9BCA25F556DE271F93D5CA1FCF31" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_9493788F303D7B1E086E93D5CA1F73A4_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_9493788F303D7B1E086E93D5CA1F73A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_9493788F303D7B1E086E93D5CA1F73A4_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_9493788F303D7B1E086E93D5CA1F73A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9493788F303D7B1E086E93D5CA1F73A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9493788F303D7B1E086E93D5CA1F73A4" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_9493788F303D7B1E086E93D5CA1F73A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_206CD114F4E55150E50993D5CA1F8118_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember_206CD114F4E55150E50993D5CA1F8118" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note payable to Fumedica</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_206CD114F4E55150E50993D5CA1F8118_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember_206CD114F4E55150E50993D5CA1F8118" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_206CD114F4E55150E50993D5CA1F8118" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember_206CD114F4E55150E50993D5CA1F8118" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember_206CD114F4E55150E50993D5CA1F8118" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="lab_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_25F082A9E4EAC6D4D61293D5CA204531_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_25F082A9E4EAC6D4D61293D5CA204531" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount of senior notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_25F082A9E4EAC6D4D61293D5CA204531_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_25F082A9E4EAC6D4D61293D5CA204531" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_25F082A9E4EAC6D4D61293D5CA204531" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_25F082A9E4EAC6D4D61293D5CA204531" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_25F082A9E4EAC6D4D61293D5CA204531" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_907BBD8298F21D66CE4C93D5CA20B3BB_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_907BBD8298F21D66CE4C93D5CA20B3BB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on senior notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_907BBD8298F21D66CE4C93D5CA20B3BB_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_907BBD8298F21D66CE4C93D5CA20B3BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_907BBD8298F21D66CE4C93D5CA20B3BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_907BBD8298F21D66CE4C93D5CA20B3BB" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_907BBD8298F21D66CE4C93D5CA20B3BB" xlink:type="arc" />
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_CCD183A70709537A1B9D93D5CA20E814_terseLabel_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_CCD183A70709537A1B9D93D5CA20E814" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption percentage par value of senior notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_CCD183A70709537A1B9D93D5CA20E814_label_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_CCD183A70709537A1B9D93D5CA20E814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_CCD183A70709537A1B9D93D5CA20E814_documentation_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_CCD183A70709537A1B9D93D5CA20E814" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_CCD183A70709537A1B9D93D5CA20E814" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageParValueOfSeniorNotes_CCD183A70709537A1B9D93D5CA20E814" xlink:to="lab_biib_PercentageParValueOfSeniorNotes_CCD183A70709537A1B9D93D5CA20E814" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_12BE5EA91E95F29E8E3993D5CA202D58_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_12BE5EA91E95F29E8E3993D5CA202D58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemptions percentage of 2015 notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_12BE5EA91E95F29E8E3993D5CA202D58_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_12BE5EA91E95F29E8E3993D5CA202D58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_12BE5EA91E95F29E8E3993D5CA202D58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_12BE5EA91E95F29E8E3993D5CA202D58" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_12BE5EA91E95F29E8E3993D5CA202D58" xlink:type="arc" />
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E11A275EB3E843B967F493D5CA202D6C_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E11A275EB3E843B967F493D5CA202D6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption percentage for change in control provision on the 2015 Senior Notes</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E11A275EB3E843B967F493D5CA202D6C_label_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E11A275EB3E843B967F493D5CA202D6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E11A275EB3E843B967F493D5CA202D6C_documentation_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E11A275EB3E843B967F493D5CA202D6C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E11A275EB3E843B967F493D5CA202D6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E11A275EB3E843B967F493D5CA202D6C" xlink:to="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E11A275EB3E843B967F493D5CA202D6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtIssuanceCosts_05703242317BF7C5967593D5CA203251_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCosts_05703242317BF7C5967593D5CA203251" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCosts_05703242317BF7C5967593D5CA203251_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCosts_05703242317BF7C5967593D5CA203251" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_us-gaap_DebtIssuanceCosts_05703242317BF7C5967593D5CA203251" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCosts_05703242317BF7C5967593D5CA203251" xlink:to="lab_us-gaap_DebtIssuanceCosts_05703242317BF7C5967593D5CA203251" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_CF427481D02137E93E6D93D5CA202BC3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_CF427481D02137E93E6D93D5CA202BC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of the interest rate swaps</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_CF427481D02137E93E6D93D5CA202BC3_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_CF427481D02137E93E6D93D5CA202BC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_CF427481D02137E93E6D93D5CA202BC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_CF427481D02137E93E6D93D5CA202BC3" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_CF427481D02137E93E6D93D5CA202BC3" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfRedemptionOfNotes_062780907191105FBFFA93D5CA20127C_terseLabel_en-US" xlink:label="lab_biib_PercentageOfRedemptionOfNotes_062780907191105FBFFA93D5CA20127C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of redemption of notes</link:label>
    <link:label id="lab_biib_PercentageOfRedemptionOfNotes_062780907191105FBFFA93D5CA20127C_label_en-US" xlink:label="lab_biib_PercentageOfRedemptionOfNotes_062780907191105FBFFA93D5CA20127C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Redemption Of Notes</link:label>
    <link:label id="lab_biib_PercentageOfRedemptionOfNotes_062780907191105FBFFA93D5CA20127C_documentation_en-US" xlink:label="lab_biib_PercentageOfRedemptionOfNotes_062780907191105FBFFA93D5CA20127C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of redemption of notes.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PercentageOfRedemptionOfNotes" xlink:label="loc_biib_PercentageOfRedemptionOfNotes_062780907191105FBFFA93D5CA20127C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfRedemptionOfNotes_062780907191105FBFFA93D5CA20127C" xlink:to="lab_biib_PercentageOfRedemptionOfNotes_062780907191105FBFFA93D5CA20127C" xlink:type="arc" />
    <link:label id="lab_biib_IncreasedCarryingAmountOfSeniorNotes_5A186CE6CBA86C55210093D5CA205B87_terseLabel_en-US" xlink:label="lab_biib_IncreasedCarryingAmountOfSeniorNotes_5A186CE6CBA86C55210093D5CA205B87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increased carrying amount of interest rate swap</link:label>
    <link:label id="lab_biib_IncreasedCarryingAmountOfSeniorNotes_5A186CE6CBA86C55210093D5CA205B87_label_en-US" xlink:label="lab_biib_IncreasedCarryingAmountOfSeniorNotes_5A186CE6CBA86C55210093D5CA205B87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increased Carrying Amount Of Senior Notes</link:label>
    <link:label id="lab_biib_IncreasedCarryingAmountOfSeniorNotes_5A186CE6CBA86C55210093D5CA205B87_documentation_en-US" xlink:label="lab_biib_IncreasedCarryingAmountOfSeniorNotes_5A186CE6CBA86C55210093D5CA205B87" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increased carrying amount of senior notes.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_IncreasedCarryingAmountOfSeniorNotes" xlink:label="loc_biib_IncreasedCarryingAmountOfSeniorNotes_5A186CE6CBA86C55210093D5CA205B87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncreasedCarryingAmountOfSeniorNotes_5A186CE6CBA86C55210093D5CA205B87" xlink:to="lab_biib_IncreasedCarryingAmountOfSeniorNotes_5A186CE6CBA86C55210093D5CA205B87" xlink:type="arc" />
    <link:label id="lab_biib_DebtInstrumentUnamortizedInterestOnDebt_86E476B5EBA1CC28D41B93D5CA209F6F_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentUnamortizedInterestOnDebt_86E476B5EBA1CC28D41B93D5CA209F6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest to be amortized on debt</link:label>
    <link:label id="lab_biib_DebtInstrumentUnamortizedInterestOnDebt_86E476B5EBA1CC28D41B93D5CA209F6F_label_en-US" xlink:label="lab_biib_DebtInstrumentUnamortizedInterestOnDebt_86E476B5EBA1CC28D41B93D5CA209F6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Unamortized Interest On Debt</link:label>
    <link:label id="lab_biib_DebtInstrumentUnamortizedInterestOnDebt_86E476B5EBA1CC28D41B93D5CA209F6F_documentation_en-US" xlink:label="lab_biib_DebtInstrumentUnamortizedInterestOnDebt_86E476B5EBA1CC28D41B93D5CA209F6F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instrument unamortized interest on debt.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_DebtInstrumentUnamortizedInterestOnDebt" xlink:label="loc_biib_DebtInstrumentUnamortizedInterestOnDebt_86E476B5EBA1CC28D41B93D5CA209F6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentUnamortizedInterestOnDebt_86E476B5EBA1CC28D41B93D5CA209F6F" xlink:to="lab_biib_DebtInstrumentUnamortizedInterestOnDebt_86E476B5EBA1CC28D41B93D5CA209F6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermNotesPayable_FCAD46566DF217E0C03393D5CA2042CC_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_FCAD46566DF217E0C03393D5CA2042CC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable and other financing arrangements</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_FCAD46566DF217E0C03393D5CA2042CC_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_FCAD46566DF217E0C03393D5CA2042CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_FCAD46566DF217E0C03393D5CA2042CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable_FCAD46566DF217E0C03393D5CA2042CC" xlink:to="lab_us-gaap_LongTermNotesPayable_FCAD46566DF217E0C03393D5CA2042CC" xlink:type="arc" />
    <link:label id="lab_biib_ParValueOfNotesPayable_2CF1812C49CEF134DB3593D5CA2051E8_terseLabel_en-US" xlink:label="lab_biib_ParValueOfNotesPayable_2CF1812C49CEF134DB3593D5CA2051E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Par value of notes payable</link:label>
    <link:label id="lab_biib_ParValueOfNotesPayable_2CF1812C49CEF134DB3593D5CA2051E8_label_en-US" xlink:label="lab_biib_ParValueOfNotesPayable_2CF1812C49CEF134DB3593D5CA2051E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Par Value Of Notes Payable</link:label>
    <link:label id="lab_biib_ParValueOfNotesPayable_2CF1812C49CEF134DB3593D5CA2051E8_documentation_en-US" xlink:label="lab_biib_ParValueOfNotesPayable_2CF1812C49CEF134DB3593D5CA2051E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Par value of notes payable.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ParValueOfNotesPayable" xlink:label="loc_biib_ParValueOfNotesPayable_2CF1812C49CEF134DB3593D5CA2051E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ParValueOfNotesPayable_2CF1812C49CEF134DB3593D5CA2051E8" xlink:to="lab_biib_ParValueOfNotesPayable_2CF1812C49CEF134DB3593D5CA2051E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_C5DC1A416C14521A7A8A93D5CA2078C9_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_C5DC1A416C14521A7A8A93D5CA2078C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior unsecured revolving credit facility maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_C5DC1A416C14521A7A8A93D5CA2078C9_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_C5DC1A416C14521A7A8A93D5CA2078C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_C5DC1A416C14521A7A8A93D5CA2078C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_C5DC1A416C14521A7A8A93D5CA2078C9" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_C5DC1A416C14521A7A8A93D5CA2078C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_C79F9AE510112EA1414793D5CA20FF9F_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_C79F9AE510112EA1414793D5CA20FF9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_C79F9AE510112EA1414793D5CA20FF9F_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_C79F9AE510112EA1414793D5CA20FF9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_C79F9AE510112EA1414793D5CA20FF9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_C79F9AE510112EA1414793D5CA20FF9F" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_C79F9AE510112EA1414793D5CA20FF9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_5D983F76332D71EF5F3B93D5CA207AC7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_5D983F76332D71EF5F3B93D5CA207AC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount outstanding under the credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_5D983F76332D71EF5F3B93D5CA207AC7_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_5D983F76332D71EF5F3B93D5CA207AC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_5D983F76332D71EF5F3B93D5CA207AC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_5D983F76332D71EF5F3B93D5CA207AC7" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_5D983F76332D71EF5F3B93D5CA207AC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4086C5F20151E36D53EA38A351D948D2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4086C5F20151E36D53EA38A351D948D2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue by product</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4086C5F20151E36D53EA38A351D948D2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4086C5F20151E36D53EA38A351D948D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4086C5F20151E36D53EA38A351D948D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4086C5F20151E36D53EA38A351D948D2" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4086C5F20151E36D53EA38A351D948D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_DE9417008471803C30A738A351D9B00F_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_DE9417008471803C30A738A351D9B00F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Geographic information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_DE9417008471803C30A738A351D9B00F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_DE9417008471803C30A738A351D9B00F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_DE9417008471803C30A738A351D9B00F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_DE9417008471803C30A738A351D9B00F" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_DE9417008471803C30A738A351D9B00F" xlink:type="arc" />
    <link:label id="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_6670AF6F06670508869B38A356D52A32_terseLabel_en-US" xlink:label="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_6670AF6F06670508869B38A356D52A32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty And Net Revenue Share Rates By Territory [Axis]</link:label>
    <link:label id="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_6670AF6F06670508869B38A356D52A32_label_en-US" xlink:label="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_6670AF6F06670508869B38A356D52A32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty And Net Revenue Share Rates By Territory [Axis]</link:label>
    <link:label id="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_6670AF6F06670508869B38A356D52A32_documentation_en-US" xlink:label="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_6670AF6F06670508869B38A356D52A32" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty and net revenue share rates by territory.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_6670AF6F06670508869B38A356D52A32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_6670AF6F06670508869B38A356D52A32" xlink:to="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_6670AF6F06670508869B38A356D52A32" xlink:type="arc" />
    <link:label id="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390_terseLabel_en-US" xlink:label="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty And Net Revenue Share Rates By Territory [Domain]</link:label>
    <link:label id="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390_label_en-US" xlink:label="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty And Net Revenue Share Rates By Territory [Domain]</link:label>
    <link:label id="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390_documentation_en-US" xlink:label="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty and net revenue share rates by territory.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390" xlink:to="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390" xlink:type="arc" />
    <link:label id="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_52C2DFB5E9A28A552DED38A356D5F208_verboseLabel_en-US" xlink:label="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_52C2DFB5E9A28A552DED38A356D5F208" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sobi rate to Biogen on net sales in the Sobi Territory [Member]</link:label>
    <link:label id="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_52C2DFB5E9A28A552DED38A356D5F208_label_en-US" xlink:label="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_52C2DFB5E9A28A552DED38A356D5F208" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sobi Rate To Biogen On Net Sales In The Sobi Territory [Member]</link:label>
    <link:label id="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_52C2DFB5E9A28A552DED38A356D5F208_documentation_en-US" xlink:label="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_52C2DFB5E9A28A552DED38A356D5F208" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sobi rate to Biogen on net sales in the sobi territory.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" xlink:label="loc_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_52C2DFB5E9A28A552DED38A356D5F208" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_52C2DFB5E9A28A552DED38A356D5F208" xlink:to="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_52C2DFB5E9A28A552DED38A356D5F208" xlink:type="arc" />
    <link:label id="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_2C7188067A5169ADEEA038A356D5894D_verboseLabel_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_2C7188067A5169ADEEA038A356D5894D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen rate to sobi on net sales in the Biogen North America Territory [Member]</link:label>
    <link:label id="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_2C7188067A5169ADEEA038A356D5894D_label_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_2C7188067A5169ADEEA038A356D5894D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen Rate To Sobi On Net Sales In The Biogen North America Territory [Member]</link:label>
    <link:label id="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_2C7188067A5169ADEEA038A356D5894D_documentation_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_2C7188067A5169ADEEA038A356D5894D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen rate to sobi on net sales in the Biogen North America territory.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_2C7188067A5169ADEEA038A356D5894D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_2C7188067A5169ADEEA038A356D5894D" xlink:to="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_2C7188067A5169ADEEA038A356D5894D" xlink:type="arc" />
    <link:label id="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_712C86F78E572F826D5338A356D6A5FF_verboseLabel_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_712C86F78E572F826D5338A356D6A5FF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen rate to sobi on net sales in the Biogen direct Territory [Member]</link:label>
    <link:label id="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_712C86F78E572F826D5338A356D6A5FF_label_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_712C86F78E572F826D5338A356D6A5FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen Rate To Sobi On Net Sales In The Biogen Direct Territory [Member]</link:label>
    <link:label id="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_712C86F78E572F826D5338A356D6A5FF_documentation_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_712C86F78E572F826D5338A356D6A5FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen rate to sobi on net sales in the Biogen direct Territory.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_712C86F78E572F826D5338A356D6A5FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_712C86F78E572F826D5338A356D6A5FF" xlink:to="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_712C86F78E572F826D5338A356D6A5FF" xlink:type="arc" />
    <link:label id="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_11FB6B83DBE4F62E20DF38A356D69B96_verboseLabel_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_11FB6B83DBE4F62E20DF38A356D69B96" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen rate to Sobi on net revenue from the Biogen distributor Territory [Member]</link:label>
    <link:label id="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_11FB6B83DBE4F62E20DF38A356D69B96_label_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_11FB6B83DBE4F62E20DF38A356D69B96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen Rate To Sobi On Net Revenue From The Biogen Distributor Territory Member</link:label>
    <link:label id="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_11FB6B83DBE4F62E20DF38A356D69B96_documentation_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_11FB6B83DBE4F62E20DF38A356D69B96" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen rate to Sobi on net revenue(1) from the Biogen distributor territory(2).</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_11FB6B83DBE4F62E20DF38A356D69B96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_11FB6B83DBE4F62E20DF38A356D69B96" xlink:to="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_11FB6B83DBE4F62E20DF38A356D69B96" xlink:type="arc" />
    <link:label id="lab_biib_SobiTerritoryMember_E5973DF826CE8783512A38A356D6CB0F_verboseLabel_en-US" xlink:label="lab_biib_SobiTerritoryMember_E5973DF826CE8783512A38A356D6CB0F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sobi Territory [Member]</link:label>
    <link:label id="lab_biib_SobiTerritoryMember_E5973DF826CE8783512A38A356D6CB0F_label_en-US" xlink:label="lab_biib_SobiTerritoryMember_E5973DF826CE8783512A38A356D6CB0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sobi Territory [Member]</link:label>
    <link:label id="lab_biib_SobiTerritoryMember_E5973DF826CE8783512A38A356D6CB0F_documentation_en-US" xlink:label="lab_biib_SobiTerritoryMember_E5973DF826CE8783512A38A356D6CB0F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sobi territory.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SobiTerritoryMember" xlink:label="loc_biib_SobiTerritoryMember_E5973DF826CE8783512A38A356D6CB0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SobiTerritoryMember_E5973DF826CE8783512A38A356D6CB0F" xlink:to="lab_biib_SobiTerritoryMember_E5973DF826CE8783512A38A356D6CB0F" xlink:type="arc" />
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70_verboseLabel_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mechanism for reimbursement, under the amended agreement amounts payable</link:label>
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70_label_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Under The Amended Agreement Amounts Payable [Abstract]</link:label>
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70_documentation_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mechanism for reimbursement, under the amended agreement amounts payable.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70" xlink:to="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70" xlink:type="arc" />
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementMethod_6CD61DAD54FED3715B6938A356D63F4E_verboseLabel_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementMethod_6CD61DAD54FED3715B6938A356D63F4E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement, under the amended agreement, Method</link:label>
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementMethod_6CD61DAD54FED3715B6938A356D63F4E_label_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementMethod_6CD61DAD54FED3715B6938A356D63F4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Under The Amended Agreement Method</link:label>
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementMethod_6CD61DAD54FED3715B6938A356D63F4E_documentation_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementMethod_6CD61DAD54FED3715B6938A356D63F4E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement, under the amended agreement, method.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ReimbursementUnderAmendedAgreementMethod" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementMethod_6CD61DAD54FED3715B6938A356D63F4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementMethod_6CD61DAD54FED3715B6938A356D63F4E" xlink:to="lab_biib_ReimbursementUnderAmendedAgreementMethod_6CD61DAD54FED3715B6938A356D63F4E" xlink:type="arc" />
    <link:label id="lab_biib_RatePriorToFirstCommercialSale_BED538263F231440DA2838A356D69282_verboseLabel_en-US" xlink:label="lab_biib_RatePriorToFirstCommercialSale_BED538263F231440DA2838A356D69282" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Rate prior to first commercial sale in the territory</link:label>
    <link:label id="lab_biib_RatePriorToFirstCommercialSale_BED538263F231440DA2838A356D69282_label_en-US" xlink:label="lab_biib_RatePriorToFirstCommercialSale_BED538263F231440DA2838A356D69282" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rate Prior To First Commercial Sale</link:label>
    <link:label id="lab_biib_RatePriorToFirstCommercialSale_BED538263F231440DA2838A356D69282_documentation_en-US" xlink:label="lab_biib_RatePriorToFirstCommercialSale_BED538263F231440DA2838A356D69282" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rate prior to first commercial sale.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RatePriorToFirstCommercialSale" xlink:label="loc_biib_RatePriorToFirstCommercialSale_BED538263F231440DA2838A356D69282" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RatePriorToFirstCommercialSale_BED538263F231440DA2838A356D69282" xlink:to="lab_biib_RatePriorToFirstCommercialSale_BED538263F231440DA2838A356D69282" xlink:type="arc" />
    <link:label id="lab_biib_BaseRateAfterFirstCommercialSale_3FCE01CF9E6E97B5A99D38A356D6B9FC_verboseLabel_en-US" xlink:label="lab_biib_BaseRateAfterFirstCommercialSale_3FCE01CF9E6E97B5A99D38A356D6B9FC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Base rate following first commercial sale in the territory</link:label>
    <link:label id="lab_biib_BaseRateAfterFirstCommercialSale_3FCE01CF9E6E97B5A99D38A356D6B9FC_label_en-US" xlink:label="lab_biib_BaseRateAfterFirstCommercialSale_3FCE01CF9E6E97B5A99D38A356D6B9FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Rate After First Commercial Sale</link:label>
    <link:label id="lab_biib_BaseRateAfterFirstCommercialSale_3FCE01CF9E6E97B5A99D38A356D6B9FC_documentation_en-US" xlink:label="lab_biib_BaseRateAfterFirstCommercialSale_3FCE01CF9E6E97B5A99D38A356D6B9FC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Base rate after first commercial sale.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_BaseRateAfterFirstCommercialSale" xlink:label="loc_biib_BaseRateAfterFirstCommercialSale_3FCE01CF9E6E97B5A99D38A356D6B9FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BaseRateAfterFirstCommercialSale_3FCE01CF9E6E97B5A99D38A356D6B9FC" xlink:to="lab_biib_BaseRateAfterFirstCommercialSale_3FCE01CF9E6E97B5A99D38A356D6B9FC" xlink:type="arc" />
    <link:label id="lab_biib_RateDuringReimbursementPeriod_DFF6B8226D1DC8A5BC0838A356D67522_verboseLabel_en-US" xlink:label="lab_biib_RateDuringReimbursementPeriod_DFF6B8226D1DC8A5BC0838A356D67522" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Rate during the reimbursement period</link:label>
    <link:label id="lab_biib_RateDuringReimbursementPeriod_DFF6B8226D1DC8A5BC0838A356D67522_label_en-US" xlink:label="lab_biib_RateDuringReimbursementPeriod_DFF6B8226D1DC8A5BC0838A356D67522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rate During Reimbursement Period</link:label>
    <link:label id="lab_biib_RateDuringReimbursementPeriod_DFF6B8226D1DC8A5BC0838A356D67522_documentation_en-US" xlink:label="lab_biib_RateDuringReimbursementPeriod_DFF6B8226D1DC8A5BC0838A356D67522" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rate during the reimbursement period.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RateDuringReimbursementPeriod" xlink:label="loc_biib_RateDuringReimbursementPeriod_DFF6B8226D1DC8A5BC0838A356D67522" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RateDuringReimbursementPeriod_DFF6B8226D1DC8A5BC0838A356D67522" xlink:to="lab_biib_RateDuringReimbursementPeriod_DFF6B8226D1DC8A5BC0838A356D67522" xlink:type="arc" />
    <link:label id="lab_biib_ReservesForDiscountsAndAllowancesAbstract_038ECE832DA189AF821C38A354F7EB44_label_en-US" xlink:label="lab_biib_ReservesForDiscountsAndAllowancesAbstract_038ECE832DA189AF821C38A354F7EB44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserves for Discounts and Allowances [Abstract]</link:label>
    <link:label id="lab_biib_ReservesForDiscountsAndAllowancesAbstract_038ECE832DA189AF821C38A354F7EB44_documentation_en-US" xlink:label="lab_biib_ReservesForDiscountsAndAllowancesAbstract_038ECE832DA189AF821C38A354F7EB44" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue reserves.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ReservesForDiscountsAndAllowancesAbstract" xlink:label="loc_biib_ReservesForDiscountsAndAllowancesAbstract_038ECE832DA189AF821C38A354F7EB44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReservesForDiscountsAndAllowancesAbstract_038ECE832DA189AF821C38A354F7EB44" xlink:to="lab_biib_ReservesForDiscountsAndAllowancesAbstract_038ECE832DA189AF821C38A354F7EB44" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_0D48A8E336C5DC79FF8838A354F7BA7F_verboseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_0D48A8E336C5DC79FF8838A354F7BA7F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Analysis of the change in reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_0D48A8E336C5DC79FF8838A354F7BA7F_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_0D48A8E336C5DC79FF8838A354F7BA7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_0D48A8E336C5DC79FF8838A354F7BA7F_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_0D48A8E336C5DC79FF8838A354F7BA7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_0D48A8E336C5DC79FF8838A354F7BA7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_0D48A8E336C5DC79FF8838A354F7BA7F" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_0D48A8E336C5DC79FF8838A354F7BA7F" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_F5C3D19B8B1A40A41B4638A354F757A8_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_F5C3D19B8B1A40A41B4638A354F757A8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total reserves, included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_F5C3D19B8B1A40A41B4638A354F757A8_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_F5C3D19B8B1A40A41B4638A354F757A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_F5C3D19B8B1A40A41B4638A354F757A8_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_F5C3D19B8B1A40A41B4638A354F757A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_F5C3D19B8B1A40A41B4638A354F757A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_F5C3D19B8B1A40A41B4638A354F757A8" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_F5C3D19B8B1A40A41B4638A354F757A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726_terseLabel_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726_label_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726" xlink:to="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726" xlink:type="arc" />
    <link:label id="lab_biib_UnconsolidatedJointBusiness_1B10BFCE2EE413672FC893582D9B5CDF_terseLabel_en-US" xlink:label="lab_biib_UnconsolidatedJointBusiness_1B10BFCE2EE413672FC893582D9B5CDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unconsolidated joint business revenues</link:label>
    <link:label id="lab_biib_UnconsolidatedJointBusiness_1B10BFCE2EE413672FC893582D9B5CDF_label_en-US" xlink:label="lab_biib_UnconsolidatedJointBusiness_1B10BFCE2EE413672FC893582D9B5CDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unconsolidated Joint Business</link:label>
    <link:label id="lab_biib_UnconsolidatedJointBusiness_1B10BFCE2EE413672FC893582D9B5CDF_documentation_en-US" xlink:label="lab_biib_UnconsolidatedJointBusiness_1B10BFCE2EE413672FC893582D9B5CDF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_UnconsolidatedJointBusiness" xlink:label="loc_biib_UnconsolidatedJointBusiness_1B10BFCE2EE413672FC893582D9B5CDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnconsolidatedJointBusiness_1B10BFCE2EE413672FC893582D9B5CDF" xlink:to="lab_biib_UnconsolidatedJointBusiness_1B10BFCE2EE413672FC893582D9B5CDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_56AA72CE474834ABF1B293582D9BD0FC_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_56AA72CE474834ABF1B293582D9BD0FC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_56AA72CE474834ABF1B293582D9BD0FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSalesRevenueNet_56AA72CE474834ABF1B293582D9BD0FC" xlink:to="lab_us-gaap_OtherSalesRevenueNet_56AA72CE474834ABF1B293582D9BD0FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_A8DADB8D19FB2033327B93582D9BF23D_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues_A8DADB8D19FB2033327B93582D9BF23D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_A8DADB8D19FB2033327B93582D9BF23D_label_en-US" xlink:label="lab_us-gaap_Revenues_A8DADB8D19FB2033327B93582D9BF23D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_A8DADB8D19FB2033327B93582D9BF23D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_A8DADB8D19FB2033327B93582D9BF23D" xlink:to="lab_us-gaap_Revenues_A8DADB8D19FB2033327B93582D9BF23D" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_A2D04CDF022762A8766B93582D9B3F4E_verboseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_A2D04CDF022762A8766B93582D9B3F4E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_A2D04CDF022762A8766B93582D9B3F4E_label_en-US" xlink:label="lab_us-gaap_GrossProfit_A2D04CDF022762A8766B93582D9B3F4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_A2D04CDF022762A8766B93582D9B3F4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_A2D04CDF022762A8766B93582D9B3F4E" xlink:to="lab_us-gaap_GrossProfit_A2D04CDF022762A8766B93582D9B3F4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_1DA9BDE5E4F094A840A293582D9CB992_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_1DA9BDE5E4F094A840A293582D9CB992" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_1DA9BDE5E4F094A840A293582D9CB992_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_1DA9BDE5E4F094A840A293582D9CB992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1DA9BDE5E4F094A840A293582D9CB992" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_1DA9BDE5E4F094A840A293582D9CB992" xlink:to="lab_us-gaap_EarningsPerShareBasic_1DA9BDE5E4F094A840A293582D9CB992" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_C27BBA342994DCDBFEB393582D9C834A_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_C27BBA342994DCDBFEB393582D9C834A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_C27BBA342994DCDBFEB393582D9C834A_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_C27BBA342994DCDBFEB393582D9C834A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_C27BBA342994DCDBFEB393582D9C834A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_C27BBA342994DCDBFEB393582D9C834A" xlink:to="lab_us-gaap_EarningsPerShareDiluted_C27BBA342994DCDBFEB393582D9C834A" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1AA297A5EE12D6AA844E93C4F82C3C19_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1AA297A5EE12D6AA844E93C4F82C3C19" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1AA297A5EE12D6AA844E93C4F82C3C19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1AA297A5EE12D6AA844E93C4F82C3C19" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1AA297A5EE12D6AA844E93C4F82C3C19" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F2C674E48064BFC050A393C5E215DD72_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F2C674E48064BFC050A393C5E215DD72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F2C674E48064BFC050A393C5E215DD72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F2C674E48064BFC050A393C5E215DD72" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F2C674E48064BFC050A393C5E215DD72" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_95CBA1430F0AC8E35D2093582E399BC1_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_95CBA1430F0AC8E35D2093582E399BC1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_95CBA1430F0AC8E35D2093582E399BC1_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_95CBA1430F0AC8E35D2093582E399BC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_95CBA1430F0AC8E35D2093582E399BC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_95CBA1430F0AC8E35D2093582E399BC1" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_95CBA1430F0AC8E35D2093582E399BC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_22A1F0B2278A60B4DA3D93582E39D1EC_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_22A1F0B2278A60B4DA3D93582E39D1EC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_22A1F0B2278A60B4DA3D93582E39D1EC_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_22A1F0B2278A60B4DA3D93582E39D1EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_22A1F0B2278A60B4DA3D93582E39D1EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_22A1F0B2278A60B4DA3D93582E39D1EC" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_22A1F0B2278A60B4DA3D93582E39D1EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_62E4B0D58F073D1CC5EF93582E39D96D_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_62E4B0D58F073D1CC5EF93582E39D96D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_62E4B0D58F073D1CC5EF93582E39D96D_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_62E4B0D58F073D1CC5EF93582E39D96D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_62E4B0D58F073D1CC5EF93582E39D96D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_62E4B0D58F073D1CC5EF93582E39D96D" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_62E4B0D58F073D1CC5EF93582E39D96D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_04014512EAEFD515F57A93582E399A9E_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_04014512EAEFD515F57A93582E399A9E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_04014512EAEFD515F57A93582E399A9E_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_04014512EAEFD515F57A93582E399A9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_04014512EAEFD515F57A93582E399A9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_04014512EAEFD515F57A93582E399A9E" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_04014512EAEFD515F57A93582E399A9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_292843187CE435D8391C93582E39D871_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_292843187CE435D8391C93582E39D871" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_292843187CE435D8391C93582E39D871_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_292843187CE435D8391C93582E39D871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_292843187CE435D8391C93582E39D871" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_292843187CE435D8391C93582E39D871" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_292843187CE435D8391C93582E39D871" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_632606BF7532872A26D693582E39599A_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_632606BF7532872A26D693582E39599A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_632606BF7532872A26D693582E39599A_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_632606BF7532872A26D693582E39599A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_632606BF7532872A26D693582E39599A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_632606BF7532872A26D693582E39599A" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_632606BF7532872A26D693582E39599A" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_63AC2ABC460E7DCBCA7F93582E3A71D2_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_63AC2ABC460E7DCBCA7F93582E3A71D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_63AC2ABC460E7DCBCA7F93582E3A71D2_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_63AC2ABC460E7DCBCA7F93582E3A71D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_63AC2ABC460E7DCBCA7F93582E3A71D2_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_63AC2ABC460E7DCBCA7F93582E3A71D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_63AC2ABC460E7DCBCA7F93582E3A71D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_63AC2ABC460E7DCBCA7F93582E3A71D2" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_63AC2ABC460E7DCBCA7F93582E3A71D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_EE3B56C609C29AEC727093582E3AF6CF_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_EE3B56C609C29AEC727093582E3AF6CF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_EE3B56C609C29AEC727093582E3AF6CF_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_EE3B56C609C29AEC727093582E3AF6CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_EE3B56C609C29AEC727093582E3AF6CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_EE3B56C609C29AEC727093582E3AF6CF" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_EE3B56C609C29AEC727093582E3AF6CF" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_16935FD513FCE8AEE0A093582E3AC82A_verboseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_16935FD513FCE8AEE0A093582E3AC82A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_16935FD513FCE8AEE0A093582E3AC82A_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_16935FD513FCE8AEE0A093582E3AC82A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Contingent Consideration</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_16935FD513FCE8AEE0A093582E3AC82A_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_16935FD513FCE8AEE0A093582E3AC82A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation contingent consideration.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_EffectiveIncomeTaxRateReconciliationContingentConsideration" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_16935FD513FCE8AEE0A093582E3AC82A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_16935FD513FCE8AEE0A093582E3AC82A" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_16935FD513FCE8AEE0A093582E3AC82A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_50C70A03FA880DD8054793582E3A31DE_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_50C70A03FA880DD8054793582E3A31DE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_50C70A03FA880DD8054793582E3A31DE_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_50C70A03FA880DD8054793582E3A31DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_50C70A03FA880DD8054793582E3A31DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_50C70A03FA880DD8054793582E3A31DE" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_50C70A03FA880DD8054793582E3A31DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3054232819F8C4676C0138A3541D2A1B_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3054232819F8C4676C0138A3541D2A1B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3054232819F8C4676C0138A3541D2A1B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3054232819F8C4676C0138A3541D2A1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3054232819F8C4676C0138A3541D2A1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3054232819F8C4676C0138A3541D2A1B" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3054232819F8C4676C0138A3541D2A1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_F03D6EE68A08BF31C35A38A35716C2EB_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_F03D6EE68A08BF31C35A38A35716C2EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_F03D6EE68A08BF31C35A38A35716C2EB_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_F03D6EE68A08BF31C35A38A35716C2EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_F03D6EE68A08BF31C35A38A35716C2EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_F03D6EE68A08BF31C35A38A35716C2EB" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_F03D6EE68A08BF31C35A38A35716C2EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_A61EA0E17042BE5E834793D5C9457882_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_A61EA0E17042BE5E834793D5C9457882" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital leases, future minimum payments due in 2016</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_A61EA0E17042BE5E834793D5C9457882_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_A61EA0E17042BE5E834793D5C9457882" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_A61EA0E17042BE5E834793D5C9457882" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_A61EA0E17042BE5E834793D5C9457882" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_A61EA0E17042BE5E834793D5C9457882" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_AA3DA792A059CA068F7193D5C945B470_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_AA3DA792A059CA068F7193D5C945B470" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital leases, future minimum payments due in 2017</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_AA3DA792A059CA068F7193D5C945B470_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_AA3DA792A059CA068F7193D5C945B470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_AA3DA792A059CA068F7193D5C945B470" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_AA3DA792A059CA068F7193D5C945B470" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_AA3DA792A059CA068F7193D5C945B470" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_3605E78D4FC9FB3901BB93D5C9456D13_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_3605E78D4FC9FB3901BB93D5C9456D13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital leases, future minimum payments due in 2018</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_3605E78D4FC9FB3901BB93D5C9456D13_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_3605E78D4FC9FB3901BB93D5C9456D13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_3605E78D4FC9FB3901BB93D5C9456D13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_3605E78D4FC9FB3901BB93D5C9456D13" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_3605E78D4FC9FB3901BB93D5C9456D13" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_54BA260D7E4BFF015DFA93D5C94570F7_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_54BA260D7E4BFF015DFA93D5C94570F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital leases, future minimum payments due in 2019</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_54BA260D7E4BFF015DFA93D5C94570F7_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_54BA260D7E4BFF015DFA93D5C94570F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_54BA260D7E4BFF015DFA93D5C94570F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_54BA260D7E4BFF015DFA93D5C94570F7" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_54BA260D7E4BFF015DFA93D5C94570F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_C55F649F16005DCED58293D5C945B922_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_C55F649F16005DCED58293D5C945B922" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital leases, future minimum payments due in 2020</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_C55F649F16005DCED58293D5C945B922_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_C55F649F16005DCED58293D5C945B922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_C55F649F16005DCED58293D5C945B922" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_C55F649F16005DCED58293D5C945B922" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_C55F649F16005DCED58293D5C945B922" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_1596F88FFA9CC286B53593D5C946973C_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_1596F88FFA9CC286B53593D5C946973C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital leases, future minimum payments due thereafter</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_1596F88FFA9CC286B53593D5C946973C_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_1596F88FFA9CC286B53593D5C946973C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_1596F88FFA9CC286B53593D5C946973C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_1596F88FFA9CC286B53593D5C946973C" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_1596F88FFA9CC286B53593D5C946973C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_FAF9EEA341D6A1F403EA93D5C9469829_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_FAF9EEA341D6A1F403EA93D5C9469829" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital leases, future minimum payments due total</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_FAF9EEA341D6A1F403EA93D5C9469829_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_FAF9EEA341D6A1F403EA93D5C9469829" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_FAF9EEA341D6A1F403EA93D5C9469829" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_FAF9EEA341D6A1F403EA93D5C9469829" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_FAF9EEA341D6A1F403EA93D5C9469829" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_501556FE96CDACACBA1C93D5C9466605_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_501556FE96CDACACBA1C93D5C9466605" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: interest on capital lease</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_501556FE96CDACACBA1C93D5C9466605_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_501556FE96CDACACBA1C93D5C9466605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments, Interest Included in Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_501556FE96CDACACBA1C93D5C9466605" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_501556FE96CDACACBA1C93D5C9466605" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_501556FE96CDACACBA1C93D5C9466605" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_FE9CC181B7092B87632993D5C94618C2_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_FE9CC181B7092B87632993D5C94618C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net present value of the future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_FE9CC181B7092B87632993D5C94618C2_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_FE9CC181B7092B87632993D5C94618C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_FE9CC181B7092B87632993D5C94618C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_FE9CC181B7092B87632993D5C94618C2" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_FE9CC181B7092B87632993D5C94618C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_E589638E95C720984EC138A35725420C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_E589638E95C720984EC138A35725420C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplementary cash flow information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_E589638E95C720984EC138A35725420C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_E589638E95C720984EC138A35725420C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_E589638E95C720984EC138A35725420C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_E589638E95C720984EC138A35725420C" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_E589638E95C720984EC138A35725420C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_63ACD14FD7057F93DAF338A3572562E9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_63ACD14FD7057F93DAF338A3572562E9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_63ACD14FD7057F93DAF338A3572562E9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_63ACD14FD7057F93DAF338A3572562E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_63ACD14FD7057F93DAF338A3572562E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_63ACD14FD7057F93DAF338A3572562E9" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_63ACD14FD7057F93DAF338A3572562E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_228B2591DA4255421C9038A35725CD1A_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_228B2591DA4255421C9038A35725CD1A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_228B2591DA4255421C9038A35725CD1A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_228B2591DA4255421C9038A35725CD1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_228B2591DA4255421C9038A35725CD1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_228B2591DA4255421C9038A35725CD1A" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_228B2591DA4255421C9038A35725CD1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_F7E4CF0F44B87602EEE738A35725AC39_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_F7E4CF0F44B87602EEE738A35725AC39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_F7E4CF0F44B87602EEE738A35725AC39_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_F7E4CF0F44B87602EEE738A35725AC39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_F7E4CF0F44B87602EEE738A35725AC39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_F7E4CF0F44B87602EEE738A35725AC39" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_F7E4CF0F44B87602EEE738A35725AC39" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_BEEB9B902591B8B318B493582F463DE7_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_BEEB9B902591B8B318B493582F463DE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_BEEB9B902591B8B318B493582F463DE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_BEEB9B902591B8B318B493582F463DE7" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_BEEB9B902591B8B318B493582F463DE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9BE33509E755ABE8F0BA93582F4699DE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9BE33509E755ABE8F0BA93582F4699DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9BE33509E755ABE8F0BA93582F4699DE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9BE33509E755ABE8F0BA93582F4699DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9BE33509E755ABE8F0BA93582F4699DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9BE33509E755ABE8F0BA93582F4699DE" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9BE33509E755ABE8F0BA93582F4699DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_609773673EE18F66158593582F462080_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_609773673EE18F66158593582F462080" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_609773673EE18F66158593582F462080_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_609773673EE18F66158593582F462080" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_609773673EE18F66158593582F462080" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_609773673EE18F66158593582F462080" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis_609773673EE18F66158593582F462080" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_1E36BCB41A357200179593582F46BFF8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_1E36BCB41A357200179593582F46BFF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_1E36BCB41A357200179593582F46BFF8_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_1E36BCB41A357200179593582F46BFF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1E36BCB41A357200179593582F46BFF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1E36BCB41A357200179593582F46BFF8" xlink:to="lab_us-gaap_TypeOfRestructuringDomain_1E36BCB41A357200179593582F46BFF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_D2972B22204C90579FFA93582F46BD6A_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember_D2972B22204C90579FFA93582F46BD6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Workforce reduction</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_D2972B22204C90579FFA93582F46BD6A_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember_D2972B22204C90579FFA93582F46BD6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_D2972B22204C90579FFA93582F46BD6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember_D2972B22204C90579FFA93582F46BD6A" xlink:to="lab_us-gaap_EmployeeSeveranceMember_D2972B22204C90579FFA93582F46BD6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractTerminationMember_6FCAACD5BC492B1364FE93582F46FE6C_terseLabel_en-US" xlink:label="lab_us-gaap_ContractTerminationMember_6FCAACD5BC492B1364FE93582F46FE6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pipeline programs</link:label>
    <link:label id="lab_us-gaap_ContractTerminationMember_6FCAACD5BC492B1364FE93582F46FE6C_label_en-US" xlink:label="lab_us-gaap_ContractTerminationMember_6FCAACD5BC492B1364FE93582F46FE6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Termination [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_6FCAACD5BC492B1364FE93582F46FE6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractTerminationMember_6FCAACD5BC492B1364FE93582F46FE6C" xlink:to="lab_us-gaap_ContractTerminationMember_6FCAACD5BC492B1364FE93582F46FE6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2" xlink:type="arc" />
    <link:label id="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_36D6F8AC4923455F7EC993582F461A06_terseLabel_en-US" xlink:label="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_36D6F8AC4923455F7EC993582F461A06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, expected percentage of positions eliminated</link:label>
    <link:label id="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_36D6F8AC4923455F7EC993582F461A06_label_en-US" xlink:label="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_36D6F8AC4923455F7EC993582F461A06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, expected percentage of positions eliminated</link:label>
    <link:label id="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_36D6F8AC4923455F7EC993582F461A06_documentation_en-US" xlink:label="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_36D6F8AC4923455F7EC993582F461A06" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, expected percentage of positions eliminated</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated" xlink:label="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_36D6F8AC4923455F7EC993582F461A06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_36D6F8AC4923455F7EC993582F461A06" xlink:to="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_36D6F8AC4923455F7EC993582F461A06" xlink:type="arc" />
    <link:label id="lab_biib_RestructuringandRelatedCostExpectedCashPayments_4575AF495F5D1800146C93582F466615_terseLabel_en-US" xlink:label="lab_biib_RestructuringandRelatedCostExpectedCashPayments_4575AF495F5D1800146C93582F466615" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Previously accrued incentive compensation</link:label>
    <link:label id="lab_biib_RestructuringandRelatedCostExpectedCashPayments_4575AF495F5D1800146C93582F466615_label_en-US" xlink:label="lab_biib_RestructuringandRelatedCostExpectedCashPayments_4575AF495F5D1800146C93582F466615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cash Payments</link:label>
    <link:label id="lab_biib_RestructuringandRelatedCostExpectedCashPayments_4575AF495F5D1800146C93582F466615_documentation_en-US" xlink:label="lab_biib_RestructuringandRelatedCostExpectedCashPayments_4575AF495F5D1800146C93582F466615" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cash Payments</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RestructuringandRelatedCostExpectedCashPayments" xlink:label="loc_biib_RestructuringandRelatedCostExpectedCashPayments_4575AF495F5D1800146C93582F466615" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RestructuringandRelatedCostExpectedCashPayments_4575AF495F5D1800146C93582F466615" xlink:to="lab_biib_RestructuringandRelatedCostExpectedCashPayments_4575AF495F5D1800146C93582F466615" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment_5997A996DD1B835C326993582F467471_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment_5997A996DD1B835C326993582F467471" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Previously accrued incentive compensation</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment_5997A996DD1B835C326993582F467471_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment_5997A996DD1B835C326993582F467471" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Accrual Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment_5997A996DD1B835C326993582F467471" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAccrualAdjustment_5997A996DD1B835C326993582F467471" xlink:to="lab_us-gaap_RestructuringReserveAccrualAdjustment_5997A996DD1B835C326993582F467471" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_F342CD5793A41DDC243393582F478DA5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_F342CD5793A41DDC243393582F478DA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total restructuring charges expected</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_F342CD5793A41DDC243393582F478DA5_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_F342CD5793A41DDC243393582F478DA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_F342CD5793A41DDC243393582F478DA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_F342CD5793A41DDC243393582F478DA5" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_F342CD5793A41DDC243393582F478DA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A3200CB417915E39AC4193D5C9F54B54_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A3200CB417915E39AC4193D5C9F54B54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A3200CB417915E39AC4193D5C9F54B54_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A3200CB417915E39AC4193D5C9F54B54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A3200CB417915E39AC4193D5C9F54B54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A3200CB417915E39AC4193D5C9F54B54" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A3200CB417915E39AC4193D5C9F54B54" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_83FBAD2106C8946A03CF93D5C9F69F16_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_83FBAD2106C8946A03CF93D5C9F69F16" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_83FBAD2106C8946A03CF93D5C9F69F16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_83FBAD2106C8946A03CF93D5C9F69F16" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_83FBAD2106C8946A03CF93D5C9F69F16" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4A50D7796B3A3D60369A93D5C9F65EB1_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4A50D7796B3A3D60369A93D5C9F65EB1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4A50D7796B3A3D60369A93D5C9F65EB1_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4A50D7796B3A3D60369A93D5C9F65EB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4A50D7796B3A3D60369A93D5C9F65EB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4A50D7796B3A3D60369A93D5C9F65EB1" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4A50D7796B3A3D60369A93D5C9F65EB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringChargesMember_0EC24D24F01A41296D6393D5C9F6F696_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember_0EC24D24F01A41296D6393D5C9F6F696" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_0EC24D24F01A41296D6393D5C9F6F696_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember_0EC24D24F01A41296D6393D5C9F6F696" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_0EC24D24F01A41296D6393D5C9F6F696" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember_0EC24D24F01A41296D6393D5C9F6F696" xlink:to="lab_us-gaap_RestructuringChargesMember_0EC24D24F01A41296D6393D5C9F6F696" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_D31ED573CC1379AE2E6793D5C9F6B956_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_D31ED573CC1379AE2E6793D5C9F6B956" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_D31ED573CC1379AE2E6793D5C9F6B956_label_en-US" xlink:label="lab_us-gaap_ParentMember_D31ED573CC1379AE2E6793D5C9F6B956" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_D31ED573CC1379AE2E6793D5C9F6B956" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_D31ED573CC1379AE2E6793D5C9F6B956" xlink:to="lab_us-gaap_ParentMember_D31ED573CC1379AE2E6793D5C9F6B956" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CB93F131642F96A37C8C93D5C9F6BBAD_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CB93F131642F96A37C8C93D5C9F6BBAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CB93F131642F96A37C8C93D5C9F6BBAD_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CB93F131642F96A37C8C93D5C9F6BBAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CB93F131642F96A37C8C93D5C9F6BBAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CB93F131642F96A37C8C93D5C9F6BBAD" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CB93F131642F96A37C8C93D5C9F6BBAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_E7FED733DC3A15639D6293D5C9F61454_negatedLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_E7FED733DC3A15639D6293D5C9F61454" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_E7FED733DC3A15639D6293D5C9F61454" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_E7FED733DC3A15639D6293D5C9F61454" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_E7FED733DC3A15639D6293D5C9F61454" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4FF3132759B6BE9EDA1C93D5C9F60A6E_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4FF3132759B6BE9EDA1C93D5C9F60A6E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4FF3132759B6BE9EDA1C93D5C9F60A6E_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4FF3132759B6BE9EDA1C93D5C9F60A6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4FF3132759B6BE9EDA1C93D5C9F60A6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4FF3132759B6BE9EDA1C93D5C9F60A6E" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4FF3132759B6BE9EDA1C93D5C9F60A6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_A21069CFFFA1F1609C8C93D5C9F6B956_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_A21069CFFFA1F1609C8C93D5C9F6B956" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_A21069CFFFA1F1609C8C93D5C9F6B956_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_A21069CFFFA1F1609C8C93D5C9F6B956" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_A21069CFFFA1F1609C8C93D5C9F6B956" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_A21069CFFFA1F1609C8C93D5C9F6B956" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_A21069CFFFA1F1609C8C93D5C9F6B956" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_5D606F6D385779F6C91F93D5C9F6313F_totalLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_5D606F6D385779F6C91F93D5C9F6313F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_5D606F6D385779F6C91F93D5C9F6313F_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_5D606F6D385779F6C91F93D5C9F6313F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_5D606F6D385779F6C91F93D5C9F6313F_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_5D606F6D385779F6C91F93D5C9F6313F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_5D606F6D385779F6C91F93D5C9F6313F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_5D606F6D385779F6C91F93D5C9F6313F" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_5D606F6D385779F6C91F93D5C9F6313F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_17E570DCFB9764669A0893D5C9F6209F_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_17E570DCFB9764669A0893D5C9F6209F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_17E570DCFB9764669A0893D5C9F6209F_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_17E570DCFB9764669A0893D5C9F6209F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Tax Benefit from Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_17E570DCFB9764669A0893D5C9F6209F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_17E570DCFB9764669A0893D5C9F6209F" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_17E570DCFB9764669A0893D5C9F6209F" xlink:type="arc" />
    <link:label id="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C_verboseLabel_en-US" xlink:label="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum rental commitments under non-cancelable leases</link:label>
    <link:label id="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C_label_en-US" xlink:label="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Rental Commitments Under Noncancellable Leases [Abstract]</link:label>
    <link:label id="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C_documentation_en-US" xlink:label="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum rental commitments under noncancellable leases.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract" xlink:label="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_522412E745D570E5CCC438A3513D872C_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_522412E745D570E5CCC438A3513D872C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2016</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_522412E745D570E5CCC438A3513D872C_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_522412E745D570E5CCC438A3513D872C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_522412E745D570E5CCC438A3513D872C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_522412E745D570E5CCC438A3513D872C" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_522412E745D570E5CCC438A3513D872C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1724AEFD8DA873FDD30938A3513DD947_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1724AEFD8DA873FDD30938A3513DD947" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2017</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1724AEFD8DA873FDD30938A3513DD947_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1724AEFD8DA873FDD30938A3513DD947" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1724AEFD8DA873FDD30938A3513DD947" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1724AEFD8DA873FDD30938A3513DD947" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1724AEFD8DA873FDD30938A3513DD947" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_9F9073170E6498BB71B038A3513D13A3_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_9F9073170E6498BB71B038A3513D13A3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2018</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_9F9073170E6498BB71B038A3513D13A3_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_9F9073170E6498BB71B038A3513D13A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_9F9073170E6498BB71B038A3513D13A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_9F9073170E6498BB71B038A3513D13A3" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_9F9073170E6498BB71B038A3513D13A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_CE32293352F2ABAB108438A3513D6C58_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_CE32293352F2ABAB108438A3513D6C58" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_CE32293352F2ABAB108438A3513D6C58_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_CE32293352F2ABAB108438A3513D6C58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_CE32293352F2ABAB108438A3513D6C58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_CE32293352F2ABAB108438A3513D6C58" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_CE32293352F2ABAB108438A3513D6C58" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_3B68A5A057ED2CEFC06E38A3513D5390_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_3B68A5A057ED2CEFC06E38A3513D5390" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_3B68A5A057ED2CEFC06E38A3513D5390_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_3B68A5A057ED2CEFC06E38A3513D5390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_3B68A5A057ED2CEFC06E38A3513D5390" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_3B68A5A057ED2CEFC06E38A3513D5390" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_3B68A5A057ED2CEFC06E38A3513D5390" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_80205E621442A32B550938A3513D5865_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_80205E621442A32B550938A3513D5865" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_80205E621442A32B550938A3513D5865_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_80205E621442A32B550938A3513D5865" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_80205E621442A32B550938A3513D5865" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_80205E621442A32B550938A3513D5865" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_80205E621442A32B550938A3513D5865" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_65A12BA9F501A1F1010A38A3513D5574_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_65A12BA9F501A1F1010A38A3513D5574" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_65A12BA9F501A1F1010A38A3513D5574_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_65A12BA9F501A1F1010A38A3513D5574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_65A12BA9F501A1F1010A38A3513D5574" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_65A12BA9F501A1F1010A38A3513D5574" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_65A12BA9F501A1F1010A38A3513D5574" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_7689BD0E6CD7AD6C281538A3513E9A31_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_7689BD0E6CD7AD6C281538A3513E9A31" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2016</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_7689BD0E6CD7AD6C281538A3513E9A31_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_7689BD0E6CD7AD6C281538A3513E9A31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_7689BD0E6CD7AD6C281538A3513E9A31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_7689BD0E6CD7AD6C281538A3513E9A31" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_7689BD0E6CD7AD6C281538A3513E9A31" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_33EB4CDFE04E7616674438A3513EFD1C_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_33EB4CDFE04E7616674438A3513EFD1C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2017</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_33EB4CDFE04E7616674438A3513EFD1C_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_33EB4CDFE04E7616674438A3513EFD1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_33EB4CDFE04E7616674438A3513EFD1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_33EB4CDFE04E7616674438A3513EFD1C" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_33EB4CDFE04E7616674438A3513EFD1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_92B2954622190F025CC538A3513E569F_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_92B2954622190F025CC538A3513E569F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2018</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_92B2954622190F025CC538A3513E569F_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_92B2954622190F025CC538A3513E569F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_92B2954622190F025CC538A3513E569F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_92B2954622190F025CC538A3513E569F" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_92B2954622190F025CC538A3513E569F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_212C93D4552DA61D0A0238A3513E8532_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_212C93D4552DA61D0A0238A3513E8532" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2019</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_212C93D4552DA61D0A0238A3513E8532_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_212C93D4552DA61D0A0238A3513E8532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_212C93D4552DA61D0A0238A3513E8532" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_212C93D4552DA61D0A0238A3513E8532" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_212C93D4552DA61D0A0238A3513E8532" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_6B3E67C3621F3BF14A0F38A3513E67CD_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_6B3E67C3621F3BF14A0F38A3513E67CD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2020</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_6B3E67C3621F3BF14A0F38A3513E67CD_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_6B3E67C3621F3BF14A0F38A3513E67CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_6B3E67C3621F3BF14A0F38A3513E67CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_6B3E67C3621F3BF14A0F38A3513E67CD" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_6B3E67C3621F3BF14A0F38A3513E67CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B158A0B6533A767E59C638A3513E2F8E_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B158A0B6533A767E59C638A3513E2F8E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, Thereafter</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B158A0B6533A767E59C638A3513E2F8E_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B158A0B6533A767E59C638A3513E2F8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B158A0B6533A767E59C638A3513E2F8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B158A0B6533A767E59C638A3513E2F8E" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B158A0B6533A767E59C638A3513E2F8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_2F864E5AF1DDB9DC2F0A38A3513E0534_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_2F864E5AF1DDB9DC2F0A38A3513E0534" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, Total</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_2F864E5AF1DDB9DC2F0A38A3513E0534_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_2F864E5AF1DDB9DC2F0A38A3513E0534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_2F864E5AF1DDB9DC2F0A38A3513E0534" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_2F864E5AF1DDB9DC2F0A38A3513E0534" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_2F864E5AF1DDB9DC2F0A38A3513E0534" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_14F06C4209227824F1D038A3513E3471_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_14F06C4209227824F1D038A3513E3471" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2016</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_14F06C4209227824F1D038A3513E3471_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_14F06C4209227824F1D038A3513E3471" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In One Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_14F06C4209227824F1D038A3513E3471_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_14F06C4209227824F1D038A3513E3471" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in one year.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_14F06C4209227824F1D038A3513E3471" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_14F06C4209227824F1D038A3513E3471" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInOneYear_14F06C4209227824F1D038A3513E3471" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_485F945D2E5837F0AF9D38A3513E94E0_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_485F945D2E5837F0AF9D38A3513E94E0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2017</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_485F945D2E5837F0AF9D38A3513E94E0_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_485F945D2E5837F0AF9D38A3513E94E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Two Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_485F945D2E5837F0AF9D38A3513E94E0_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_485F945D2E5837F0AF9D38A3513E94E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in two year.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_485F945D2E5837F0AF9D38A3513E94E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_485F945D2E5837F0AF9D38A3513E94E0" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_485F945D2E5837F0AF9D38A3513E94E0" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_368C594D1BA80D7768E438A3513E19C4_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_368C594D1BA80D7768E438A3513E19C4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2018</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_368C594D1BA80D7768E438A3513E19C4_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_368C594D1BA80D7768E438A3513E19C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Three Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_368C594D1BA80D7768E438A3513E19C4_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_368C594D1BA80D7768E438A3513E19C4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in three year.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_368C594D1BA80D7768E438A3513E19C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_368C594D1BA80D7768E438A3513E19C4" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_368C594D1BA80D7768E438A3513E19C4" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_64E27CF29ABE5CC3144A38A3513E6354_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_64E27CF29ABE5CC3144A38A3513E6354" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2019</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_64E27CF29ABE5CC3144A38A3513E6354_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_64E27CF29ABE5CC3144A38A3513E6354" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Four Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_64E27CF29ABE5CC3144A38A3513E6354_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_64E27CF29ABE5CC3144A38A3513E6354" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in four year.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_64E27CF29ABE5CC3144A38A3513E6354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_64E27CF29ABE5CC3144A38A3513E6354" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInFourYear_64E27CF29ABE5CC3144A38A3513E6354" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_4EB3268F36B6E026ED5D38A3513E4DAC_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_4EB3268F36B6E026ED5D38A3513E4DAC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2020</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_4EB3268F36B6E026ED5D38A3513E4DAC_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_4EB3268F36B6E026ED5D38A3513E4DAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Five Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_4EB3268F36B6E026ED5D38A3513E4DAC_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_4EB3268F36B6E026ED5D38A3513E4DAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in five year.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_4EB3268F36B6E026ED5D38A3513E4DAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_4EB3268F36B6E026ED5D38A3513E4DAC" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_4EB3268F36B6E026ED5D38A3513E4DAC" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_FF240E4161FE06AEEAF338A3513ECA41_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_FF240E4161FE06AEEAF338A3513ECA41" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, Thereafter</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_FF240E4161FE06AEEAF338A3513ECA41_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_FF240E4161FE06AEEAF338A3513ECA41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments Thereafter</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_FF240E4161FE06AEEAF338A3513ECA41_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_FF240E4161FE06AEEAF338A3513ECA41" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments thereafter.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_FF240E4161FE06AEEAF338A3513ECA41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_FF240E4161FE06AEEAF338A3513ECA41" xlink:to="lab_biib_NetMinimumLeasePaymentsThereafter_FF240E4161FE06AEEAF338A3513ECA41" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePayments_84FC89E02D8A559D99FB38A3513E542A_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_84FC89E02D8A559D99FB38A3513E542A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, Total</link:label>
    <link:label id="lab_biib_NetMinimumLeasePayments_84FC89E02D8A559D99FB38A3513E542A_label_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_84FC89E02D8A559D99FB38A3513E542A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments</link:label>
    <link:label id="lab_biib_NetMinimumLeasePayments_84FC89E02D8A559D99FB38A3513E542A_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_84FC89E02D8A559D99FB38A3513E542A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments total.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_84FC89E02D8A559D99FB38A3513E542A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePayments_84FC89E02D8A559D99FB38A3513E542A" xlink:to="lab_biib_NetMinimumLeasePayments_84FC89E02D8A559D99FB38A3513E542A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0F3FEB34EDC49283AB9A38A3524F5ECE_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0F3FEB34EDC49283AB9A38A3524F5ECE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0F3FEB34EDC49283AB9A38A3524F5ECE_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0F3FEB34EDC49283AB9A38A3524F5ECE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0F3FEB34EDC49283AB9A38A3524F5ECE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0F3FEB34EDC49283AB9A38A3524F5ECE" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0F3FEB34EDC49283AB9A38A3524F5ECE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_B251B83F4A59DAA4B37293582ED2C099_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_B251B83F4A59DAA4B37293582ED2C099" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_B251B83F4A59DAA4B37293582ED2C099_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_B251B83F4A59DAA4B37293582ED2C099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_B251B83F4A59DAA4B37293582ED2C099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_B251B83F4A59DAA4B37293582ED2C099" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_B251B83F4A59DAA4B37293582ED2C099" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateContractMember_D9B0A01FFF8BB388A7BB93582ED25D7F_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember_D9B0A01FFF8BB388A7BB93582ED25D7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate lock</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_D9B0A01FFF8BB388A7BB93582ED25D7F_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember_D9B0A01FFF8BB388A7BB93582ED25D7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_D9B0A01FFF8BB388A7BB93582ED25D7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember_D9B0A01FFF8BB388A7BB93582ED25D7F" xlink:to="lab_us-gaap_InterestRateContractMember_D9B0A01FFF8BB388A7BB93582ED25D7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_401544A4EFD6E694D1D393582ED3867F_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_401544A4EFD6E694D1D393582ED3867F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_401544A4EFD6E694D1D393582ED3867F_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_401544A4EFD6E694D1D393582ED3867F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_401544A4EFD6E694D1D393582ED3867F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_401544A4EFD6E694D1D393582ED3867F" xlink:to="lab_us-gaap_HedgingDesignationAxis_401544A4EFD6E694D1D393582ED3867F" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_D753A0AFA9C471F95C3193582ED3AE95_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_D753A0AFA9C471F95C3193582ED3AE95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_D753A0AFA9C471F95C3193582ED3AE95_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_D753A0AFA9C471F95C3193582ED3AE95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_D753A0AFA9C471F95C3193582ED3AE95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_D753A0AFA9C471F95C3193582ED3AE95" xlink:to="lab_us-gaap_HedgingDesignationDomain_D753A0AFA9C471F95C3193582ED3AE95" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_3BBDC99CA2A4A196E85B93582ED3DECF_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_3BBDC99CA2A4A196E85B93582ED3DECF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_3BBDC99CA2A4A196E85B93582ED3DECF_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_3BBDC99CA2A4A196E85B93582ED3DECF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3BBDC99CA2A4A196E85B93582ED3DECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3BBDC99CA2A4A196E85B93582ED3DECF" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_3BBDC99CA2A4A196E85B93582ED3DECF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NondesignatedMember_298685895F2BA95A8D5893582ED379C2_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember_298685895F2BA95A8D5893582ED379C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_298685895F2BA95A8D5893582ED379C2_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember_298685895F2BA95A8D5893582ED379C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_298685895F2BA95A8D5893582ED379C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember_298685895F2BA95A8D5893582ED379C2" xlink:to="lab_us-gaap_NondesignatedMember_298685895F2BA95A8D5893582ED379C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_4B0719102212A6FE38C193582ED3EAC4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_4B0719102212A6FE38C193582ED3EAC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_4B0719102212A6FE38C193582ED3EAC4_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_4B0719102212A6FE38C193582ED3EAC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_4B0719102212A6FE38C193582ED3EAC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_4B0719102212A6FE38C193582ED3EAC4" xlink:to="lab_us-gaap_DerivativesFairValueLineItems_4B0719102212A6FE38C193582ED3EAC4" xlink:type="arc" />
    <link:label id="lab_invest_DerivativeNotionalAmount_C1FEDE170CF0343B4AB993582ED3969A_terseLabel_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_C1FEDE170CF0343B4AB993582ED3969A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate notional amount</link:label>
    <link:label id="lab_invest_DerivativeNotionalAmount_C1FEDE170CF0343B4AB993582ED3969A_label_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_C1FEDE170CF0343B4AB993582ED3969A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_C1FEDE170CF0343B4AB993582ED3969A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_DerivativeNotionalAmount_C1FEDE170CF0343B4AB993582ED3969A" xlink:to="lab_invest_DerivativeNotionalAmount_C1FEDE170CF0343B4AB993582ED3969A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_DC15059F0ED68DC4508E93582ED33FA3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_DC15059F0ED68DC4508E93582ED33FA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on senior notes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_DC15059F0ED68DC4508E93582ED33FA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_DC15059F0ED68DC4508E93582ED33FA3" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_DC15059F0ED68DC4508E93582ED33FA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3426D062DABB67CA998D93582ED31D7A_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3426D062DABB67CA998D93582ED31D7A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain on treasury rate lock settlement</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3426D062DABB67CA998D93582ED31D7A_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3426D062DABB67CA998D93582ED31D7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3426D062DABB67CA998D93582ED31D7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3426D062DABB67CA998D93582ED31D7A" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3426D062DABB67CA998D93582ED31D7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLowerRemainingMaturityRange1_CDEC9630565D8F1BAEE593582ED38C6C_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLowerRemainingMaturityRange1_CDEC9630565D8F1BAEE593582ED38C6C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lower range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeLowerRemainingMaturityRange1_CDEC9630565D8F1BAEE593582ED38C6C_label_en-US" xlink:label="lab_us-gaap_DerivativeLowerRemainingMaturityRange1_CDEC9630565D8F1BAEE593582ED38C6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Lower Remaining Maturity Range</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLowerRemainingMaturityRange1" xlink:label="loc_us-gaap_DerivativeLowerRemainingMaturityRange1_CDEC9630565D8F1BAEE593582ED38C6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLowerRemainingMaturityRange1_CDEC9630565D8F1BAEE593582ED38C6C" xlink:to="lab_us-gaap_DerivativeLowerRemainingMaturityRange1_CDEC9630565D8F1BAEE593582ED38C6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeHigherRemainingMaturityRange1_79341B948E81B7E246BA93582ED32E21_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeHigherRemainingMaturityRange1_79341B948E81B7E246BA93582ED32E21" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Higher range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeHigherRemainingMaturityRange1_79341B948E81B7E246BA93582ED32E21_label_en-US" xlink:label="lab_us-gaap_DerivativeHigherRemainingMaturityRange1_79341B948E81B7E246BA93582ED32E21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Higher Remaining Maturity Range</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeHigherRemainingMaturityRange1" xlink:label="loc_us-gaap_DerivativeHigherRemainingMaturityRange1_79341B948E81B7E246BA93582ED32E21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeHigherRemainingMaturityRange1_79341B948E81B7E246BA93582ED32E21" xlink:to="lab_us-gaap_DerivativeHigherRemainingMaturityRange1_79341B948E81B7E246BA93582ED32E21" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4225067F62877F12E47C93582ED3BAB3_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4225067F62877F12E47C93582ED3BAB3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4225067F62877F12E47C93582ED3BAB3_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4225067F62877F12E47C93582ED3BAB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4225067F62877F12E47C93582ED3BAB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4225067F62877F12E47C93582ED3BAB3" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4225067F62877F12E47C93582ED3BAB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_62283ADD7B837B2485DA93582ED31F14_verboseLabel_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_62283ADD7B837B2485DA93582ED31F14" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected settlement time for contracts, in months</link:label>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_62283ADD7B837B2485DA93582ED31F14_label_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_62283ADD7B837B2485DA93582ED31F14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Remaining Maturity of Foreign Currency Derivatives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_62283ADD7B837B2485DA93582ED31F14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_62283ADD7B837B2485DA93582ED31F14" xlink:to="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_62283ADD7B837B2485DA93582ED31F14" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6117269FAB8C630EE0ED93582ED32F65_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6117269FAB8C630EE0ED93582ED32F65" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) of other income (expense) related to foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6117269FAB8C630EE0ED93582ED32F65_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6117269FAB8C630EE0ED93582ED32F65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6117269FAB8C630EE0ED93582ED32F65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6117269FAB8C630EE0ED93582ED32F65" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6117269FAB8C630EE0ED93582ED32F65" xlink:type="arc" />
    <link:label id="lab_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB_verboseLabel_en-US" xlink:label="lab_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB_label_en-US" xlink:label="lab_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Activity [Abstract]</link:label>
    <link:label id="lab_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB_documentation_en-US" xlink:label="lab_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock option activity.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_StockOptionActivityAbstract" xlink:label="loc_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB" xlink:to="lab_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E99F9720CE3452ED1C4338A356EF8AA3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E99F9720CE3452ED1C4338A356EF8AA3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Outstanding shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E99F9720CE3452ED1C4338A356EF8AA3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E99F9720CE3452ED1C4338A356EF8AA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E99F9720CE3452ED1C4338A356EF8AA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E99F9720CE3452ED1C4338A356EF8AA3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E99F9720CE3452ED1C4338A356EF8AA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8E8388EAD292C0A2500538A356EF167E_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8E8388EAD292C0A2500538A356EF167E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8E8388EAD292C0A2500538A356EF167E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8E8388EAD292C0A2500538A356EF167E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8E8388EAD292C0A2500538A356EF167E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8E8388EAD292C0A2500538A356EF167E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8E8388EAD292C0A2500538A356EF167E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_BAAC7B6779AEAFBB0E7738A356EF385E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_BAAC7B6779AEAFBB0E7738A356EF385E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_BAAC7B6779AEAFBB0E7738A356EF385E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_BAAC7B6779AEAFBB0E7738A356EF385E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_BAAC7B6779AEAFBB0E7738A356EF385E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_BAAC7B6779AEAFBB0E7738A356EF385E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_BAAC7B6779AEAFBB0E7738A356EF385E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_883BE8EB1666179DCB7338A356EF554C_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_883BE8EB1666179DCB7338A356EF554C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_883BE8EB1666179DCB7338A356EF554C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_883BE8EB1666179DCB7338A356EF554C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_883BE8EB1666179DCB7338A356EF554C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_883BE8EB1666179DCB7338A356EF554C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_883BE8EB1666179DCB7338A356EF554C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3EB45271EA8E436DF3EC38A356EF121F_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3EB45271EA8E436DF3EC38A356EF121F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3EB45271EA8E436DF3EC38A356EF121F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3EB45271EA8E436DF3EC38A356EF121F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3EB45271EA8E436DF3EC38A356EF121F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F150C42883376695334C38A356EFE1C2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F150C42883376695334C38A356EFE1C2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F150C42883376695334C38A356EFE1C2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F150C42883376695334C38A356EFE1C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F150C42883376695334C38A356EFE1C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F150C42883376695334C38A356EFE1C2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F150C42883376695334C38A356EFE1C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9901323551C0CA7F7BD838A356EF690B_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9901323551C0CA7F7BD838A356EF690B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9901323551C0CA7F7BD838A356EF690B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9901323551C0CA7F7BD838A356EF690B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9901323551C0CA7F7BD838A356EF690B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9901323551C0CA7F7BD838A356EF690B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9901323551C0CA7F7BD838A356EF690B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_189A685FA7BCAFD8158F38A356EF3710_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_189A685FA7BCAFD8158F38A356EF3710" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_189A685FA7BCAFD8158F38A356EF3710_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_189A685FA7BCAFD8158F38A356EF3710" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_189A685FA7BCAFD8158F38A356EF3710" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_189A685FA7BCAFD8158F38A356EF3710" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_189A685FA7BCAFD8158F38A356EF3710" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13625644266ADCFBAD6638A356EF73D8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13625644266ADCFBAD6638A356EF73D8" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Outstanding shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13625644266ADCFBAD6638A356EF73D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13625644266ADCFBAD6638A356EF73D8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13625644266ADCFBAD6638A356EF73D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_89826D6523E695C592A738A356EFC8C5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_89826D6523E695C592A738A356EFC8C5" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_89826D6523E695C592A738A356EFC8C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_89826D6523E695C592A738A356EFC8C5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_89826D6523E695C592A738A356EFC8C5" xlink:type="arc" />
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06_label_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06_documentation_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:to="lab_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_07E684D9ADDEB240FAA338A354EC04F9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_07E684D9ADDEB240FAA338A354EC04F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_07E684D9ADDEB240FAA338A354EC04F9_label_en-US" xlink:label="lab_dei_EntityRegistrantName_07E684D9ADDEB240FAA338A354EC04F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_07E684D9ADDEB240FAA338A354EC04F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_07E684D9ADDEB240FAA338A354EC04F9" xlink:to="lab_dei_EntityRegistrantName_07E684D9ADDEB240FAA338A354EC04F9" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_13740DE2C15346834B2438A354ECC7C8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_13740DE2C15346834B2438A354ECC7C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_13740DE2C15346834B2438A354ECC7C8_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_13740DE2C15346834B2438A354ECC7C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_13740DE2C15346834B2438A354ECC7C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_13740DE2C15346834B2438A354ECC7C8" xlink:to="lab_dei_EntityCentralIndexKey_13740DE2C15346834B2438A354ECC7C8" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_C619CC7A44565DE4209938A354EC2E42_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_C619CC7A44565DE4209938A354EC2E42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_C619CC7A44565DE4209938A354EC2E42_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_C619CC7A44565DE4209938A354EC2E42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_C619CC7A44565DE4209938A354EC2E42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_C619CC7A44565DE4209938A354EC2E42" xlink:to="lab_dei_CurrentFiscalYearEndDate_C619CC7A44565DE4209938A354EC2E42" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_2869DE61A99CFA88919D38A354EC5EAD_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_2869DE61A99CFA88919D38A354EC5EAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_2869DE61A99CFA88919D38A354EC5EAD_label_en-US" xlink:label="lab_dei_EntityFilerCategory_2869DE61A99CFA88919D38A354EC5EAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_2869DE61A99CFA88919D38A354EC5EAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_2869DE61A99CFA88919D38A354EC5EAD" xlink:to="lab_dei_EntityFilerCategory_2869DE61A99CFA88919D38A354EC5EAD" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_C8A6EA61820A82D4174038A354ECA1C7_terseLabel_en-US" xlink:label="lab_dei_DocumentType_C8A6EA61820A82D4174038A354ECA1C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_C8A6EA61820A82D4174038A354ECA1C7_label_en-US" xlink:label="lab_dei_DocumentType_C8A6EA61820A82D4174038A354ECA1C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_C8A6EA61820A82D4174038A354ECA1C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_C8A6EA61820A82D4174038A354ECA1C7" xlink:to="lab_dei_DocumentType_C8A6EA61820A82D4174038A354ECA1C7" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_55AF593F73C9759BAB0138A354EC7487_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_55AF593F73C9759BAB0138A354EC7487" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_55AF593F73C9759BAB0138A354EC7487_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_55AF593F73C9759BAB0138A354EC7487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_55AF593F73C9759BAB0138A354EC7487" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_55AF593F73C9759BAB0138A354EC7487" xlink:to="lab_dei_DocumentPeriodEndDate_55AF593F73C9759BAB0138A354EC7487" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_45D12785D820C1D377E538A354ECD75D_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_45D12785D820C1D377E538A354ECD75D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_45D12785D820C1D377E538A354ECD75D_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_45D12785D820C1D377E538A354ECD75D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_45D12785D820C1D377E538A354ECD75D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_45D12785D820C1D377E538A354ECD75D" xlink:to="lab_dei_DocumentFiscalYearFocus_45D12785D820C1D377E538A354ECD75D" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0AA210AD9CA830E9CBC638A354EC199C_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0AA210AD9CA830E9CBC638A354EC199C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0AA210AD9CA830E9CBC638A354EC199C_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0AA210AD9CA830E9CBC638A354EC199C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0AA210AD9CA830E9CBC638A354EC199C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_0AA210AD9CA830E9CBC638A354EC199C" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0AA210AD9CA830E9CBC638A354EC199C" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_79A3C61A01773FFD8C9538A354EC86DF_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_79A3C61A01773FFD8C9538A354EC86DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_79A3C61A01773FFD8C9538A354EC86DF_label_en-US" xlink:label="lab_dei_AmendmentFlag_79A3C61A01773FFD8C9538A354EC86DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_79A3C61A01773FFD8C9538A354EC86DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_79A3C61A01773FFD8C9538A354EC86DF" xlink:to="lab_dei_AmendmentFlag_79A3C61A01773FFD8C9538A354EC86DF" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_5C8D08D788B8080F0DE638A354EC3144_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_5C8D08D788B8080F0DE638A354EC3144" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_5C8D08D788B8080F0DE638A354EC3144_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_5C8D08D788B8080F0DE638A354EC3144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5C8D08D788B8080F0DE638A354EC3144" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_5C8D08D788B8080F0DE638A354EC3144" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_5C8D08D788B8080F0DE638A354EC3144" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_ECF5EFDBC39201113CE638A354ECE0C9_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_ECF5EFDBC39201113CE638A354ECE0C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_ECF5EFDBC39201113CE638A354ECE0C9_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_ECF5EFDBC39201113CE638A354ECE0C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_ECF5EFDBC39201113CE638A354ECE0C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_ECF5EFDBC39201113CE638A354ECE0C9" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_ECF5EFDBC39201113CE638A354ECE0C9" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_536B7AE381630C30C31838A354EC9214_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_536B7AE381630C30C31838A354EC9214" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_536B7AE381630C30C31838A354EC9214_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_536B7AE381630C30C31838A354EC9214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_536B7AE381630C30C31838A354EC9214" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_536B7AE381630C30C31838A354EC9214" xlink:to="lab_dei_EntityVoluntaryFilers_536B7AE381630C30C31838A354EC9214" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_9AFB69203786BA54FAA238A354ECCF3A_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_9AFB69203786BA54FAA238A354ECCF3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_9AFB69203786BA54FAA238A354ECCF3A_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_9AFB69203786BA54FAA238A354ECCF3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_9AFB69203786BA54FAA238A354ECCF3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_9AFB69203786BA54FAA238A354ECCF3A" xlink:to="lab_dei_EntityCurrentReportingStatus_9AFB69203786BA54FAA238A354ECCF3A" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_6EE87082F489B18D8BC738A354EC823B_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_6EE87082F489B18D8BC738A354EC823B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_6EE87082F489B18D8BC738A354EC823B_label_en-US" xlink:label="lab_dei_EntityPublicFloat_6EE87082F489B18D8BC738A354EC823B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_6EE87082F489B18D8BC738A354EC823B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_6EE87082F489B18D8BC738A354EC823B" xlink:to="lab_dei_EntityPublicFloat_6EE87082F489B18D8BC738A354EC823B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_9DE81DD06BBF8335201B38A35168EE9A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_9DE81DD06BBF8335201B38A35168EE9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_9DE81DD06BBF8335201B38A35168EE9A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_9DE81DD06BBF8335201B38A35168EE9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_9DE81DD06BBF8335201B38A35168EE9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_9DE81DD06BBF8335201B38A35168EE9A" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_9DE81DD06BBF8335201B38A35168EE9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_A163740B1414684357E738A35168F539_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_A163740B1414684357E738A35168F539" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair values of separately identifiable assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_A163740B1414684357E738A35168F539_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_A163740B1414684357E738A35168F539" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_A163740B1414684357E738A35168F539" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_A163740B1414684357E738A35168F539" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_A163740B1414684357E738A35168F539" xlink:type="arc" />
    <link:label id="lab_biib_SpainandPortugalMember_7382CD86A808443C9CD093224D468088_terseLabel_en-US" xlink:label="lab_biib_SpainandPortugalMember_7382CD86A808443C9CD093224D468088" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Spain and Portugal</link:label>
    <link:label id="lab_biib_SpainandPortugalMember_7382CD86A808443C9CD093224D468088_label_en-US" xlink:label="lab_biib_SpainandPortugalMember_7382CD86A808443C9CD093224D468088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spain and Portugal [Member]</link:label>
    <link:label id="lab_biib_SpainandPortugalMember_7382CD86A808443C9CD093224D468088_documentation_en-US" xlink:label="lab_biib_SpainandPortugalMember_7382CD86A808443C9CD093224D468088" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Spain and Portugal [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SpainandPortugalMember" xlink:label="loc_biib_SpainandPortugalMember_7382CD86A808443C9CD093224D468088" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SpainandPortugalMember_7382CD86A808443C9CD093224D468088" xlink:to="lab_biib_SpainandPortugalMember_7382CD86A808443C9CD093224D468088" xlink:type="arc" />
    <link:label id="lab_biib_MajorDistributorAxis_CF05B3CB6FB3E1AFF4E493224D461A39_terseLabel_en-US" xlink:label="lab_biib_MajorDistributorAxis_CF05B3CB6FB3E1AFF4E493224D461A39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Distributor [Axis]</link:label>
    <link:label id="lab_biib_MajorDistributorAxis_CF05B3CB6FB3E1AFF4E493224D461A39_label_en-US" xlink:label="lab_biib_MajorDistributorAxis_CF05B3CB6FB3E1AFF4E493224D461A39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Distributor [Axis]</link:label>
    <link:label id="lab_biib_MajorDistributorAxis_CF05B3CB6FB3E1AFF4E493224D461A39_documentation_en-US" xlink:label="lab_biib_MajorDistributorAxis_CF05B3CB6FB3E1AFF4E493224D461A39" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Major Distributor.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_CF05B3CB6FB3E1AFF4E493224D461A39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MajorDistributorAxis_CF05B3CB6FB3E1AFF4E493224D461A39" xlink:to="lab_biib_MajorDistributorAxis_CF05B3CB6FB3E1AFF4E493224D461A39" xlink:type="arc" />
    <link:label id="lab_biib_MajorDistributorDomain_D19608FF0747B56D040093224D469412_terseLabel_en-US" xlink:label="lab_biib_MajorDistributorDomain_D19608FF0747B56D040093224D469412" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Distributor [Domain]</link:label>
    <link:label id="lab_biib_MajorDistributorDomain_D19608FF0747B56D040093224D469412_label_en-US" xlink:label="lab_biib_MajorDistributorDomain_D19608FF0747B56D040093224D469412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Distributor [Domain]</link:label>
    <link:label id="lab_biib_MajorDistributorDomain_D19608FF0747B56D040093224D469412_documentation_en-US" xlink:label="lab_biib_MajorDistributorDomain_D19608FF0747B56D040093224D469412" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Major Distributor.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_D19608FF0747B56D040093224D469412" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MajorDistributorDomain_D19608FF0747B56D040093224D469412" xlink:to="lab_biib_MajorDistributorDomain_D19608FF0747B56D040093224D469412" xlink:type="arc" />
    <link:label id="lab_biib_DistributorOneMember_1B9F233B92ECCA027B4893224D46F4D4_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember_1B9F233B92ECCA027B4893224D46F4D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_1B9F233B92ECCA027B4893224D46F4D4_label_en-US" xlink:label="lab_biib_DistributorOneMember_1B9F233B92ECCA027B4893224D46F4D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_1B9F233B92ECCA027B4893224D46F4D4_documentation_en-US" xlink:label="lab_biib_DistributorOneMember_1B9F233B92ECCA027B4893224D46F4D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_1B9F233B92ECCA027B4893224D46F4D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember_1B9F233B92ECCA027B4893224D46F4D4" xlink:to="lab_biib_DistributorOneMember_1B9F233B92ECCA027B4893224D46F4D4" xlink:type="arc" />
    <link:label id="lab_biib_DistributorTwoMember_BE97007B48D86CCBC8C593224D46DDB5_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember_BE97007B48D86CCBC8C593224D46DDB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_BE97007B48D86CCBC8C593224D46DDB5_label_en-US" xlink:label="lab_biib_DistributorTwoMember_BE97007B48D86CCBC8C593224D46DDB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_BE97007B48D86CCBC8C593224D46DDB5_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember_BE97007B48D86CCBC8C593224D46DDB5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_BE97007B48D86CCBC8C593224D46DDB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember_BE97007B48D86CCBC8C593224D46DDB5" xlink:to="lab_biib_DistributorTwoMember_BE97007B48D86CCBC8C593224D46DDB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingMember_F6FC6A92C38C6118E51193224D47BE04_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember_F6FC6A92C38C6118E51193224D47BE04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_F6FC6A92C38C6118E51193224D47BE04_label_en-US" xlink:label="lab_us-gaap_BuildingMember_F6FC6A92C38C6118E51193224D47BE04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_F6FC6A92C38C6118E51193224D47BE04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember_F6FC6A92C38C6118E51193224D47BE04" xlink:to="lab_us-gaap_BuildingMember_F6FC6A92C38C6118E51193224D47BE04" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_592C85B726B8154E5E3893224D47D094_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_592C85B726B8154E5E3893224D47D094" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_592C85B726B8154E5E3893224D47D094_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_592C85B726B8154E5E3893224D47D094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_592C85B726B8154E5E3893224D47D094" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_592C85B726B8154E5E3893224D47D094" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_592C85B726B8154E5E3893224D47D094" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_74A7217FED99D99C460E93224D47991A_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_74A7217FED99D99C460E93224D47991A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_74A7217FED99D99C460E93224D47991A_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_74A7217FED99D99C460E93224D47991A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_74A7217FED99D99C460E93224D47991A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_74A7217FED99D99C460E93224D47991A" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_74A7217FED99D99C460E93224D47991A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_C77E064D4342DB0D363093224D47B055_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_C77E064D4342DB0D363093224D47B055" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_C77E064D4342DB0D363093224D47B055_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_C77E064D4342DB0D363093224D47B055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_C77E064D4342DB0D363093224D47B055" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_C77E064D4342DB0D363093224D47B055" xlink:to="lab_us-gaap_ComputerEquipmentMember_C77E064D4342DB0D363093224D47B055" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_8FDE3AC732279BA4AB8493224D47304D_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_8FDE3AC732279BA4AB8493224D47304D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current balance included within accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_8FDE3AC732279BA4AB8493224D47304D_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_8FDE3AC732279BA4AB8493224D47304D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8FDE3AC732279BA4AB8493224D47304D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_8FDE3AC732279BA4AB8493224D47304D" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_8FDE3AC732279BA4AB8493224D47304D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetNoncurrent_D86F647C9562E54C0D4E93224D47F020_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetNoncurrent_D86F647C9562E54C0D4E93224D47F020" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current balance included within investments and other assets</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetNoncurrent_D86F647C9562E54C0D4E93224D47F020_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetNoncurrent_D86F647C9562E54C0D4E93224D47F020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetNoncurrent" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_D86F647C9562E54C0D4E93224D47F020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetNoncurrent_D86F647C9562E54C0D4E93224D47F020" xlink:to="lab_us-gaap_AccountsReceivableNetNoncurrent_D86F647C9562E54C0D4E93224D47F020" xlink:type="arc" />
    <link:label id="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_F58901727424061506FF93224D47386C_terseLabel_en-US" xlink:label="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_F58901727424061506FF93224D47386C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage receivables of wholesale distributor accounted in consolidated receivables</link:label>
    <link:label id="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_F58901727424061506FF93224D47386C_label_en-US" xlink:label="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_F58901727424061506FF93224D47386C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Receivables Of Wholesale Distributor Accounted In Consolidated Receivables</link:label>
    <link:label id="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_F58901727424061506FF93224D47386C_documentation_en-US" xlink:label="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_F58901727424061506FF93224D47386C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage receivables of wholesale distributor accounted in consolidated receivables.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:label="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_F58901727424061506FF93224D47386C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_F58901727424061506FF93224D47386C" xlink:to="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_F58901727424061506FF93224D47386C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_4F13D15A1F955C16DAD693224D474E44_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_4F13D15A1F955C16DAD693224D474E44" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_4F13D15A1F955C16DAD693224D474E44_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_4F13D15A1F955C16DAD693224D474E44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4F13D15A1F955C16DAD693224D474E44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4F13D15A1F955C16DAD693224D474E44" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_4F13D15A1F955C16DAD693224D474E44" xlink:type="arc" />
    <link:label id="lab_biib_BusinessTextualAbstract_6C798F31A1A8CD1A91EF93224D47614A_terseLabel_en-US" xlink:label="lab_biib_BusinessTextualAbstract_6C798F31A1A8CD1A91EF93224D47614A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business (Textual)</link:label>
    <link:label id="lab_biib_BusinessTextualAbstract_6C798F31A1A8CD1A91EF93224D47614A_label_en-US" xlink:label="lab_biib_BusinessTextualAbstract_6C798F31A1A8CD1A91EF93224D47614A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_BusinessTextualAbstract_6C798F31A1A8CD1A91EF93224D47614A_documentation_en-US" xlink:label="lab_biib_BusinessTextualAbstract_6C798F31A1A8CD1A91EF93224D47614A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_BusinessTextualAbstract" xlink:label="loc_biib_BusinessTextualAbstract_6C798F31A1A8CD1A91EF93224D47614A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessTextualAbstract_6C798F31A1A8CD1A91EF93224D47614A" xlink:to="lab_biib_BusinessTextualAbstract_6C798F31A1A8CD1A91EF93224D47614A" xlink:type="arc" />
    <link:label id="lab_biib_InterestInSubsidiary_E0108D6025BBFE911F2E93224D470401_terseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary_E0108D6025BBFE911F2E93224D470401" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_E0108D6025BBFE911F2E93224D470401_label_en-US" xlink:label="lab_biib_InterestInSubsidiary_E0108D6025BBFE911F2E93224D470401" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_E0108D6025BBFE911F2E93224D470401_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary_E0108D6025BBFE911F2E93224D470401" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_E0108D6025BBFE911F2E93224D470401" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary_E0108D6025BBFE911F2E93224D470401" xlink:to="lab_biib_InterestInSubsidiary_E0108D6025BBFE911F2E93224D470401" xlink:type="arc" />
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_62CE54EA96E9EED23ED693224D470737_verboseLabel_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable_62CE54EA96E9EED23ED693224D470737" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payment terms of accounts receivable arising from product sales</link:label>
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_62CE54EA96E9EED23ED693224D470737_label_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable_62CE54EA96E9EED23ED693224D470737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Terms Of Accounts Receivable</link:label>
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_62CE54EA96E9EED23ED693224D470737_documentation_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable_62CE54EA96E9EED23ED693224D470737" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment  terms of accounts receivable.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PaymentTermsOfAccountsReceivable" xlink:label="loc_biib_PaymentTermsOfAccountsReceivable_62CE54EA96E9EED23ED693224D470737" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentTermsOfAccountsReceivable_62CE54EA96E9EED23ED693224D470737" xlink:to="lab_biib_PaymentTermsOfAccountsReceivable_62CE54EA96E9EED23ED693224D470737" xlink:type="arc" />
    <link:label id="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_ECA68A6D3C7BE9DE91C493224D47638D_terseLabel_en-US" xlink:label="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_ECA68A6D3C7BE9DE91C493224D47638D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives of leasehold improvements</link:label>
    <link:label id="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_ECA68A6D3C7BE9DE91C493224D47638D_label_en-US" xlink:label="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_ECA68A6D3C7BE9DE91C493224D47638D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives Of Leasehold Improvements</link:label>
    <link:label id="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_ECA68A6D3C7BE9DE91C493224D47638D_documentation_en-US" xlink:label="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_ECA68A6D3C7BE9DE91C493224D47638D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated useful lives of leasehold improvements.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_EstimatedUsefulLivesOfLeaseholdImprovements" xlink:label="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_ECA68A6D3C7BE9DE91C493224D47638D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_ECA68A6D3C7BE9DE91C493224D47638D" xlink:to="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_ECA68A6D3C7BE9DE91C493224D47638D" xlink:type="arc" />
    <link:label id="lab_biib_PurchasePriceOfCommonStockUnderEspp_72B7744049EC244E761493224D48744A_terseLabel_en-US" xlink:label="lab_biib_PurchasePriceOfCommonStockUnderEspp_72B7744049EC244E761493224D48744A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price of common stock under ESPP</link:label>
    <link:label id="lab_biib_PurchasePriceOfCommonStockUnderEspp_72B7744049EC244E761493224D48744A_label_en-US" xlink:label="lab_biib_PurchasePriceOfCommonStockUnderEspp_72B7744049EC244E761493224D48744A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Price Of Common Stock Under ESPP</link:label>
    <link:label id="lab_biib_PurchasePriceOfCommonStockUnderEspp_72B7744049EC244E761493224D48744A_documentation_en-US" xlink:label="lab_biib_PurchasePriceOfCommonStockUnderEspp_72B7744049EC244E761493224D48744A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Price Of Common Stock Under ESPP.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PurchasePriceOfCommonStockUnderEspp" xlink:label="loc_biib_PurchasePriceOfCommonStockUnderEspp_72B7744049EC244E761493224D48744A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PurchasePriceOfCommonStockUnderEspp_72B7744049EC244E761493224D48744A" xlink:to="lab_biib_PurchasePriceOfCommonStockUnderEspp_72B7744049EC244E761493224D48744A" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_1DE036031D00C4126EA993224D48556A_terseLabel_en-US" xlink:label="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_1DE036031D00C4126EA993224D48556A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of market value per share of common stock</link:label>
    <link:label id="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_1DE036031D00C4126EA993224D48556A_label_en-US" xlink:label="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_1DE036031D00C4126EA993224D48556A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Market Value Per Share Of Common Stock</link:label>
    <link:label id="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_1DE036031D00C4126EA993224D48556A_documentation_en-US" xlink:label="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_1DE036031D00C4126EA993224D48556A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of market value per share of common stock.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PercentageOfMarketValuePerShareOfCommonStock" xlink:label="loc_biib_PercentageOfMarketValuePerShareOfCommonStock_1DE036031D00C4126EA993224D48556A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfMarketValuePerShareOfCommonStock_1DE036031D00C4126EA993224D48556A" xlink:to="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_1DE036031D00C4126EA993224D48556A" xlink:type="arc" />
    <link:label id="lab_biib_CompensationExpenseOverPurchasePeriod_1905BF3F3EFC83956A4693224D486D5E_terseLabel_en-US" xlink:label="lab_biib_CompensationExpenseOverPurchasePeriod_1905BF3F3EFC83956A4693224D486D5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense over purchase period</link:label>
    <link:label id="lab_biib_CompensationExpenseOverPurchasePeriod_1905BF3F3EFC83956A4693224D486D5E_label_en-US" xlink:label="lab_biib_CompensationExpenseOverPurchasePeriod_1905BF3F3EFC83956A4693224D486D5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Expense Over Purchase Period</link:label>
    <link:label id="lab_biib_CompensationExpenseOverPurchasePeriod_1905BF3F3EFC83956A4693224D486D5E_documentation_en-US" xlink:label="lab_biib_CompensationExpenseOverPurchasePeriod_1905BF3F3EFC83956A4693224D486D5E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compensation expense over purchase period.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_CompensationExpenseOverPurchasePeriod" xlink:label="loc_biib_CompensationExpenseOverPurchasePeriod_1905BF3F3EFC83956A4693224D486D5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CompensationExpenseOverPurchasePeriod_1905BF3F3EFC83956A4693224D486D5E" xlink:to="lab_biib_CompensationExpenseOverPurchasePeriod_1905BF3F3EFC83956A4693224D486D5E" xlink:type="arc" />
    <link:label id="lab_biib_DiscountRateRecognizedInCompensationExpense_3B692CDCE560E41116CF93224D487FE4_terseLabel_en-US" xlink:label="lab_biib_DiscountRateRecognizedInCompensationExpense_3B692CDCE560E41116CF93224D487FE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate recognized in compensation expense</link:label>
    <link:label id="lab_biib_DiscountRateRecognizedInCompensationExpense_3B692CDCE560E41116CF93224D487FE4_label_en-US" xlink:label="lab_biib_DiscountRateRecognizedInCompensationExpense_3B692CDCE560E41116CF93224D487FE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discount Rate Recognized In Compensation Expense</link:label>
    <link:label id="lab_biib_DiscountRateRecognizedInCompensationExpense_3B692CDCE560E41116CF93224D487FE4_documentation_en-US" xlink:label="lab_biib_DiscountRateRecognizedInCompensationExpense_3B692CDCE560E41116CF93224D487FE4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discount rate recognized in compensation expense.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_DiscountRateRecognizedInCompensationExpense" xlink:label="loc_biib_DiscountRateRecognizedInCompensationExpense_3B692CDCE560E41116CF93224D487FE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DiscountRateRecognizedInCompensationExpense_3B692CDCE560E41116CF93224D487FE4" xlink:to="lab_biib_DiscountRateRecognizedInCompensationExpense_3B692CDCE560E41116CF93224D487FE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdvertisingExpense_AB848642F67A41E571A893224D482081_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_AB848642F67A41E571A893224D482081" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_AB848642F67A41E571A893224D482081_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_AB848642F67A41E571A893224D482081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_AB848642F67A41E571A893224D482081" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense_AB848642F67A41E571A893224D482081" xlink:to="lab_us-gaap_AdvertisingExpense_AB848642F67A41E571A893224D482081" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_444C0081B3CBB555CB3138A354D5316F_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_444C0081B3CBB555CB3138A354D5316F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_444C0081B3CBB555CB3138A354D5316F_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_444C0081B3CBB555CB3138A354D5316F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_444C0081B3CBB555CB3138A354D5316F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_444C0081B3CBB555CB3138A354D5316F" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_444C0081B3CBB555CB3138A354D5316F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_854F01725EA5CFD6635B38A350DDB069_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_854F01725EA5CFD6635B38A350DDB069" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_854F01725EA5CFD6635B38A350DDB069_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_854F01725EA5CFD6635B38A350DDB069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_854F01725EA5CFD6635B38A350DDB069" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_854F01725EA5CFD6635B38A350DDB069" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_854F01725EA5CFD6635B38A350DDB069" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_2843337B39C3D9FECCE238A350DE9A92_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_2843337B39C3D9FECCE238A350DE9A92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_2843337B39C3D9FECCE238A350DE9A92_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_2843337B39C3D9FECCE238A350DE9A92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2843337B39C3D9FECCE238A350DE9A92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2843337B39C3D9FECCE238A350DE9A92" xlink:to="lab_us-gaap_StatementClassOfStockAxis_2843337B39C3D9FECCE238A350DE9A92" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_DEFD71EB7ACBCE2603C538A350DE68DB_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_DEFD71EB7ACBCE2603C538A350DE68DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_DEFD71EB7ACBCE2603C538A350DE68DB_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_DEFD71EB7ACBCE2603C538A350DE68DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_DEFD71EB7ACBCE2603C538A350DE68DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_DEFD71EB7ACBCE2603C538A350DE68DB" xlink:to="lab_us-gaap_ClassOfStockDomain_DEFD71EB7ACBCE2603C538A350DE68DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_BD57FD73F04BCC7EB89338A350DE9BB3_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_BD57FD73F04BCC7EB89338A350DE9BB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_BD57FD73F04BCC7EB89338A350DE9BB3_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_BD57FD73F04BCC7EB89338A350DE9BB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_BD57FD73F04BCC7EB89338A350DE9BB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_BD57FD73F04BCC7EB89338A350DE9BB3" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_BD57FD73F04BCC7EB89338A350DE9BB3" xlink:type="arc" />
    <link:label id="lab_biib_SeriesXPreferredStockMember_9E44739AFBD5045646AD38A350DE9E9A_terseLabel_en-US" xlink:label="lab_biib_SeriesXPreferredStockMember_9E44739AFBD5045646AD38A350DE9E9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series X junior participating</link:label>
    <link:label id="lab_biib_SeriesXPreferredStockMember_9E44739AFBD5045646AD38A350DE9E9A_label_en-US" xlink:label="lab_biib_SeriesXPreferredStockMember_9E44739AFBD5045646AD38A350DE9E9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series X Preferred Stock [Member]</link:label>
    <link:label id="lab_biib_SeriesXPreferredStockMember_9E44739AFBD5045646AD38A350DE9E9A_documentation_en-US" xlink:label="lab_biib_SeriesXPreferredStockMember_9E44739AFBD5045646AD38A350DE9E9A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series X preferred stock.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SeriesXPreferredStockMember" xlink:label="loc_biib_SeriesXPreferredStockMember_9E44739AFBD5045646AD38A350DE9E9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeriesXPreferredStockMember_9E44739AFBD5045646AD38A350DE9E9A" xlink:to="lab_biib_SeriesXPreferredStockMember_9E44739AFBD5045646AD38A350DE9E9A" xlink:type="arc" />
    <link:label id="lab_biib_UndesignatedPreferredStockMember_8D0FB545910F61E0CEC138A350DE495E_terseLabel_en-US" xlink:label="lab_biib_UndesignatedPreferredStockMember_8D0FB545910F61E0CEC138A350DE495E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated</link:label>
    <link:label id="lab_biib_UndesignatedPreferredStockMember_8D0FB545910F61E0CEC138A350DE495E_label_en-US" xlink:label="lab_biib_UndesignatedPreferredStockMember_8D0FB545910F61E0CEC138A350DE495E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:label id="lab_biib_UndesignatedPreferredStockMember_8D0FB545910F61E0CEC138A350DE495E_documentation_en-US" xlink:label="lab_biib_UndesignatedPreferredStockMember_8D0FB545910F61E0CEC138A350DE495E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_UndesignatedPreferredStockMember" xlink:label="loc_biib_UndesignatedPreferredStockMember_8D0FB545910F61E0CEC138A350DE495E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UndesignatedPreferredStockMember_8D0FB545910F61E0CEC138A350DE495E" xlink:to="lab_biib_UndesignatedPreferredStockMember_8D0FB545910F61E0CEC138A350DE495E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_F84558E38180F726A7EA38A350DEB4A0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_F84558E38180F726A7EA38A350DEB4A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_F84558E38180F726A7EA38A350DEB4A0_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_F84558E38180F726A7EA38A350DEB4A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_F84558E38180F726A7EA38A350DEB4A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_F84558E38180F726A7EA38A350DEB4A0" xlink:to="lab_us-gaap_ClassOfStockLineItems_F84558E38180F726A7EA38A350DEB4A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_9E3B50CEA26AE16D8BC538A350DE82FA_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_9E3B50CEA26AE16D8BC538A350DE82FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_9E3B50CEA26AE16D8BC538A350DE82FA_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_9E3B50CEA26AE16D8BC538A350DE82FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9E3B50CEA26AE16D8BC538A350DE82FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_9E3B50CEA26AE16D8BC538A350DE82FA" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_9E3B50CEA26AE16D8BC538A350DE82FA" xlink:type="arc" />
    <link:label id="lab_biib_EquityTextualAbstract_F87ECFB602EB42CA914938A350DE9D8F_verboseLabel_en-US" xlink:label="lab_biib_EquityTextualAbstract_F87ECFB602EB42CA914938A350DE9D8F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity (Textual)</link:label>
    <link:label id="lab_biib_EquityTextualAbstract_F87ECFB602EB42CA914938A350DE9D8F_label_en-US" xlink:label="lab_biib_EquityTextualAbstract_F87ECFB602EB42CA914938A350DE9D8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_EquityTextualAbstract_F87ECFB602EB42CA914938A350DE9D8F_documentation_en-US" xlink:label="lab_biib_EquityTextualAbstract_F87ECFB602EB42CA914938A350DE9D8F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_EquityTextualAbstract" xlink:label="loc_biib_EquityTextualAbstract_F87ECFB602EB42CA914938A350DE9D8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityTextualAbstract_F87ECFB602EB42CA914938A350DE9D8F" xlink:to="lab_biib_EquityTextualAbstract_F87ECFB602EB42CA914938A350DE9D8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7B2B93DD03F0D7831E3738A350DE788E_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7B2B93DD03F0D7831E3738A350DE788E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized amount of share repurchases under the 2015 Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7B2B93DD03F0D7831E3738A350DE788E_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7B2B93DD03F0D7831E3738A350DE788E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7B2B93DD03F0D7831E3738A350DE788E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7B2B93DD03F0D7831E3738A350DE788E" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7B2B93DD03F0D7831E3738A350DE788E" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_909116DA1E0DCC7849A838A350DE5077_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_909116DA1E0DCC7849A838A350DE5077" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_909116DA1E0DCC7849A838A350DE5077" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_909116DA1E0DCC7849A838A350DE5077" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_909116DA1E0DCC7849A838A350DE5077" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_075C26D731D2B793C7E238A350DEE530_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_075C26D731D2B793C7E238A350DEE530" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, value</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_075C26D731D2B793C7E238A350DEE530_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_075C26D731D2B793C7E238A350DEE530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_075C26D731D2B793C7E238A350DEE530" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_075C26D731D2B793C7E238A350DEE530" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_075C26D731D2B793C7E238A350DEE530" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_21D57D72931BD08D5BE738A350DEC7B9_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_21D57D72931BD08D5BE738A350DEC7B9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares authorized for repurchase</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_21D57D72931BD08D5BE738A350DEC7B9_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_21D57D72931BD08D5BE738A350DEC7B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_21D57D72931BD08D5BE738A350DEC7B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_21D57D72931BD08D5BE738A350DEC7B9" xlink:to="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_21D57D72931BD08D5BE738A350DEC7B9" xlink:type="arc" />
    <link:label id="lab_biib_FinancialInstrumentsTextualAbstract_FB9A795AA5BF0794AF0A93582EE982EC_terseLabel_en-US" xlink:label="lab_biib_FinancialInstrumentsTextualAbstract_FB9A795AA5BF0794AF0A93582EE982EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments (Textual)</link:label>
    <link:label id="lab_biib_FinancialInstrumentsTextualAbstract_FB9A795AA5BF0794AF0A93582EE982EC_label_en-US" xlink:label="lab_biib_FinancialInstrumentsTextualAbstract_FB9A795AA5BF0794AF0A93582EE982EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_FinancialInstrumentsTextualAbstract_FB9A795AA5BF0794AF0A93582EE982EC_documentation_en-US" xlink:label="lab_biib_FinancialInstrumentsTextualAbstract_FB9A795AA5BF0794AF0A93582EE982EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Instruments.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_FinancialInstrumentsTextualAbstract" xlink:label="loc_biib_FinancialInstrumentsTextualAbstract_FB9A795AA5BF0794AF0A93582EE982EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FinancialInstrumentsTextualAbstract_FB9A795AA5BF0794AF0A93582EE982EC" xlink:to="lab_biib_FinancialInstrumentsTextualAbstract_FB9A795AA5BF0794AF0A93582EE982EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_A0654D043CA9BBCCFB6193582EE93F68_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription_A0654D043CA9BBCCFB6193582EE93F68" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Original maturities of commercial paper and short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_A0654D043CA9BBCCFB6193582EE93F68_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription_A0654D043CA9BBCCFB6193582EE93F68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date, Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_A0654D043CA9BBCCFB6193582EE93F68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateDescription_A0654D043CA9BBCCFB6193582EE93F68" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateDescription_A0654D043CA9BBCCFB6193582EE93F68" xlink:type="arc" />
    <link:label id="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_24C36EC46210EE76709693582EE91895_terseLabel_en-US" xlink:label="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_24C36EC46210EE76709693582EE91895" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements, percent of total assets</link:label>
    <link:label id="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_24C36EC46210EE76709693582EE91895_label_en-US" xlink:label="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_24C36EC46210EE76709693582EE91895" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements, percent of total assets</link:label>
    <link:label id="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_24C36EC46210EE76709693582EE91895_documentation_en-US" xlink:label="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_24C36EC46210EE76709693582EE91895" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements, percent of total assets</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_Overnightreverserepurchaseagreementspercentoftotalassets" xlink:label="loc_biib_Overnightreverserepurchaseagreementspercentoftotalassets_24C36EC46210EE76709693582EE91895" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Overnightreverserepurchaseagreementspercentoftotalassets_24C36EC46210EE76709693582EE91895" xlink:to="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_24C36EC46210EE76709693582EE91895" xlink:type="arc" />
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_B54632D1302A69B236B293582EE98EA4_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_B54632D1302A69B236B293582EE98EA4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_B54632D1302A69B236B293582EE98EA4_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_B54632D1302A69B236B293582EE98EA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_B54632D1302A69B236B293582EE98EA4_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_B54632D1302A69B236B293582EE98EA4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_B54632D1302A69B236B293582EE98EA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities_B54632D1302A69B236B293582EE98EA4" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities_B54632D1302A69B236B293582EE98EA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_69288E60D2271F348B9B93582DB12F54_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_69288E60D2271F348B9B93582DB12F54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_69288E60D2271F348B9B93582DB12F54_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_69288E60D2271F348B9B93582DB12F54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_69288E60D2271F348B9B93582DB12F54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_69288E60D2271F348B9B93582DB12F54" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_69288E60D2271F348B9B93582DB12F54" xlink:type="arc" />
    <link:label id="lab_biib_TecfideraMember_AA323686622737C15D7993582DB1F6EB_terseLabel_en-US" xlink:label="lab_biib_TecfideraMember_AA323686622737C15D7993582DB1F6EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TecfideraMember_AA323686622737C15D7993582DB1F6EB_label_en-US" xlink:label="lab_biib_TecfideraMember_AA323686622737C15D7993582DB1F6EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TecfideraMember_AA323686622737C15D7993582DB1F6EB_documentation_en-US" xlink:label="lab_biib_TecfideraMember_AA323686622737C15D7993582DB1F6EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_AA323686622737C15D7993582DB1F6EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TecfideraMember_AA323686622737C15D7993582DB1F6EB" xlink:to="lab_biib_TecfideraMember_AA323686622737C15D7993582DB1F6EB" xlink:type="arc" />
    <link:label id="lab_biib_AVONEXMember_51A775E1F2D69C848B0293BDFED76FA3_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember_51A775E1F2D69C848B0293BDFED76FA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_51A775E1F2D69C848B0293BDFED76FA3_label_en-US" xlink:label="lab_biib_AVONEXMember_51A775E1F2D69C848B0293BDFED76FA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_51A775E1F2D69C848B0293BDFED76FA3_documentation_en-US" xlink:label="lab_biib_AVONEXMember_51A775E1F2D69C848B0293BDFED76FA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_51A775E1F2D69C848B0293BDFED76FA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember_51A775E1F2D69C848B0293BDFED76FA3" xlink:to="lab_biib_AVONEXMember_51A775E1F2D69C848B0293BDFED76FA3" xlink:type="arc" />
    <link:label id="lab_biib_PLEGRIDYMember_4FF1B60F70EA75C024E593BF1760193D_terseLabel_en-US" xlink:label="lab_biib_PLEGRIDYMember_4FF1B60F70EA75C024E593BF1760193D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PLEGRIDY</link:label>
    <link:label id="lab_biib_PLEGRIDYMember_4FF1B60F70EA75C024E593BF1760193D_label_en-US" xlink:label="lab_biib_PLEGRIDYMember_4FF1B60F70EA75C024E593BF1760193D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PLEGRIDY [Member]</link:label>
    <link:label id="lab_biib_PLEGRIDYMember_4FF1B60F70EA75C024E593BF1760193D_documentation_en-US" xlink:label="lab_biib_PLEGRIDYMember_4FF1B60F70EA75C024E593BF1760193D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PLEGRIDY [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PLEGRIDYMember" xlink:label="loc_biib_PLEGRIDYMember_4FF1B60F70EA75C024E593BF1760193D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PLEGRIDYMember_4FF1B60F70EA75C024E593BF1760193D" xlink:to="lab_biib_PLEGRIDYMember_4FF1B60F70EA75C024E593BF1760193D" xlink:type="arc" />
    <link:label id="lab_biib_TysabriMember_9E74EB0A8F1143A5102693582DB111AA_verboseLabel_en-US" xlink:label="lab_biib_TysabriMember_9E74EB0A8F1143A5102693582DB111AA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriMember_9E74EB0A8F1143A5102693582DB111AA_label_en-US" xlink:label="lab_biib_TysabriMember_9E74EB0A8F1143A5102693582DB111AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI [Member]</link:label>
    <link:label id="lab_biib_TysabriMember_9E74EB0A8F1143A5102693582DB111AA_documentation_en-US" xlink:label="lab_biib_TysabriMember_9E74EB0A8F1143A5102693582DB111AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tysabri.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_TysabriMember" xlink:label="loc_biib_TysabriMember_9E74EB0A8F1143A5102693582DB111AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriMember_9E74EB0A8F1143A5102693582DB111AA" xlink:to="lab_biib_TysabriMember_9E74EB0A8F1143A5102693582DB111AA" xlink:type="arc" />
    <link:label id="lab_biib_FAMPYRAMember_E4159D68FB4AE8AA37FE93582DB17627_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember_E4159D68FB4AE8AA37FE93582DB17627" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_E4159D68FB4AE8AA37FE93582DB17627_label_en-US" xlink:label="lab_biib_FAMPYRAMember_E4159D68FB4AE8AA37FE93582DB17627" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_E4159D68FB4AE8AA37FE93582DB17627_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember_E4159D68FB4AE8AA37FE93582DB17627" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_E4159D68FB4AE8AA37FE93582DB17627" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember_E4159D68FB4AE8AA37FE93582DB17627" xlink:to="lab_biib_FAMPYRAMember_E4159D68FB4AE8AA37FE93582DB17627" xlink:type="arc" />
    <link:label id="lab_biib_ALPROLIXProductMember_4B031756E9332D9CBFA993582DB16CB2_terseLabel_en-US" xlink:label="lab_biib_ALPROLIXProductMember_4B031756E9332D9CBFA993582DB16CB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ALPROLIX</link:label>
    <link:label id="lab_biib_ALPROLIXProductMember_4B031756E9332D9CBFA993582DB16CB2_label_en-US" xlink:label="lab_biib_ALPROLIXProductMember_4B031756E9332D9CBFA993582DB16CB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ALPROLIX Product [Member]</link:label>
    <link:label id="lab_biib_ALPROLIXProductMember_4B031756E9332D9CBFA993582DB16CB2_documentation_en-US" xlink:label="lab_biib_ALPROLIXProductMember_4B031756E9332D9CBFA993582DB16CB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ALPROLIX Product [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ALPROLIXProductMember" xlink:label="loc_biib_ALPROLIXProductMember_4B031756E9332D9CBFA993582DB16CB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ALPROLIXProductMember_4B031756E9332D9CBFA993582DB16CB2" xlink:to="lab_biib_ALPROLIXProductMember_4B031756E9332D9CBFA993582DB16CB2" xlink:type="arc" />
    <link:label id="lab_biib_FUMADERMMember_2644BCB933B4CD111AF393582DB100DE_terseLabel_en-US" xlink:label="lab_biib_FUMADERMMember_2644BCB933B4CD111AF393582DB100DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FUMADERM</link:label>
    <link:label id="lab_biib_FUMADERMMember_2644BCB933B4CD111AF393582DB100DE_label_en-US" xlink:label="lab_biib_FUMADERMMember_2644BCB933B4CD111AF393582DB100DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMMember_2644BCB933B4CD111AF393582DB100DE_documentation_en-US" xlink:label="lab_biib_FUMADERMMember_2644BCB933B4CD111AF393582DB100DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_2644BCB933B4CD111AF393582DB100DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMMember_2644BCB933B4CD111AF393582DB100DE" xlink:to="lab_biib_FUMADERMMember_2644BCB933B4CD111AF393582DB100DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_0D8B1A8B504FEB2113BC93582DB1F72D_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_0D8B1A8B504FEB2113BC93582DB1F72D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Business Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_0D8B1A8B504FEB2113BC93582DB1F72D_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_0D8B1A8B504FEB2113BC93582DB1F72D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0D8B1A8B504FEB2113BC93582DB1F72D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0D8B1A8B504FEB2113BC93582DB1F72D" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis_0D8B1A8B504FEB2113BC93582DB1F72D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentDomain_FA29F4DA416A7E8A095B93582DB11FFC_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain_FA29F4DA416A7E8A095B93582DB11FFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_FA29F4DA416A7E8A095B93582DB11FFC_label_en-US" xlink:label="lab_us-gaap_SegmentDomain_FA29F4DA416A7E8A095B93582DB11FFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_FA29F4DA416A7E8A095B93582DB11FFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain_FA29F4DA416A7E8A095B93582DB11FFC" xlink:to="lab_us-gaap_SegmentDomain_FA29F4DA416A7E8A095B93582DB11FFC" xlink:type="arc" />
    <link:label id="lab_biib_RestOfWorldMember_6104F7C6E215BA8B5F8593582DB1F25C_verboseLabel_en-US" xlink:label="lab_biib_RestOfWorldMember_6104F7C6E215BA8B5F8593582DB1F25C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_biib_RestOfWorldMember_6104F7C6E215BA8B5F8593582DB1F25C_label_en-US" xlink:label="lab_biib_RestOfWorldMember_6104F7C6E215BA8B5F8593582DB1F25C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:label id="lab_biib_RestOfWorldMember_6104F7C6E215BA8B5F8593582DB1F25C_documentation_en-US" xlink:label="lab_biib_RestOfWorldMember_6104F7C6E215BA8B5F8593582DB1F25C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rest of world.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RestOfWorldMember" xlink:label="loc_biib_RestOfWorldMember_6104F7C6E215BA8B5F8593582DB1F25C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RestOfWorldMember_6104F7C6E215BA8B5F8593582DB1F25C" xlink:to="lab_biib_RestOfWorldMember_6104F7C6E215BA8B5F8593582DB1F25C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_1C649AE38FC47A6ED53B93582DB1C1D7_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_1C649AE38FC47A6ED53B93582DB1C1D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_1C649AE38FC47A6ED53B93582DB1C1D7_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_1C649AE38FC47A6ED53B93582DB1C1D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_1C649AE38FC47A6ED53B93582DB1C1D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_1C649AE38FC47A6ED53B93582DB1C1D7" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_1C649AE38FC47A6ED53B93582DB1C1D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetAbstract_F0F14FB3439325F9222893582DB271E0_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetAbstract_F0F14FB3439325F9222893582DB271E0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue by product</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetAbstract_F0F14FB3439325F9222893582DB271E0_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetAbstract_F0F14FB3439325F9222893582DB271E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNetAbstract" xlink:label="loc_us-gaap_SalesRevenueGoodsNetAbstract_F0F14FB3439325F9222893582DB271E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNetAbstract_F0F14FB3439325F9222893582DB271E0" xlink:to="lab_us-gaap_SalesRevenueGoodsNetAbstract_F0F14FB3439325F9222893582DB271E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_50A474CBB5FADD48127238A3518E3CCB_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_50A474CBB5FADD48127238A3518E3CCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_50A474CBB5FADD48127238A3518E3CCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_50A474CBB5FADD48127238A3518E3CCB" xlink:to="lab_us-gaap_IncomeStatementAbstract_50A474CBB5FADD48127238A3518E3CCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_8B3F2BE4195F7DAF90A138A3518E1355_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_8B3F2BE4195F7DAF90A138A3518E1355" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_8B3F2BE4195F7DAF90A138A3518E1355_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_8B3F2BE4195F7DAF90A138A3518E1355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_8B3F2BE4195F7DAF90A138A3518E1355" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_8B3F2BE4195F7DAF90A138A3518E1355" xlink:to="lab_us-gaap_RevenuesAbstract_8B3F2BE4195F7DAF90A138A3518E1355" xlink:type="arc" />
    <link:label id="lab_biib_UnconsolidatedJointBusiness_4D35A74A59EA2BFE8D1F38A3518E6A14_verboseLabel_en-US" xlink:label="lab_biib_UnconsolidatedJointBusiness_4D35A74A59EA2BFE8D1F38A3518E6A14" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unconsolidated joint business</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_UnconsolidatedJointBusiness" xlink:label="loc_biib_UnconsolidatedJointBusiness_4D35A74A59EA2BFE8D1F38A3518E6A14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnconsolidatedJointBusiness_4D35A74A59EA2BFE8D1F38A3518E6A14" xlink:to="lab_biib_UnconsolidatedJointBusiness_4D35A74A59EA2BFE8D1F38A3518E6A14" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_82EAD47E4758E299061638A3518FCDC9_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_82EAD47E4758E299061638A3518FCDC9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_82EAD47E4758E299061638A3518FCDC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_82EAD47E4758E299061638A3518FCDC9" xlink:to="lab_us-gaap_Revenues_82EAD47E4758E299061638A3518FCDC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_6653B7D1F9F5D4F0C60738A3518FE778_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_6653B7D1F9F5D4F0C60738A3518FE778" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_6653B7D1F9F5D4F0C60738A3518FE778_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_6653B7D1F9F5D4F0C60738A3518FE778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_6653B7D1F9F5D4F0C60738A3518FE778" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_6653B7D1F9F5D4F0C60738A3518FE778" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_6653B7D1F9F5D4F0C60738A3518FE778" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_3DCD6125D6751DA6C08938A3518F46F3_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_3DCD6125D6751DA6C08938A3518F46F3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales, excluding amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsSold_3DCD6125D6751DA6C08938A3518F46F3_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_3DCD6125D6751DA6C08938A3518F46F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_3DCD6125D6751DA6C08938A3518F46F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_3DCD6125D6751DA6C08938A3518F46F3" xlink:to="lab_us-gaap_CostOfGoodsSold_3DCD6125D6751DA6C08938A3518F46F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_9107D774D44AA6879FBB38A3518F1062_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_9107D774D44AA6879FBB38A3518F1062" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_9107D774D44AA6879FBB38A3518F1062_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_9107D774D44AA6879FBB38A3518F1062" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9107D774D44AA6879FBB38A3518F1062" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9107D774D44AA6879FBB38A3518F1062" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_9107D774D44AA6879FBB38A3518F1062" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_05BB3780013DFDFAF05C38A3518F8A05_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_05BB3780013DFDFAF05C38A3518F8A05" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_05BB3780013DFDFAF05C38A3518F8A05_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_05BB3780013DFDFAF05C38A3518F8A05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_05BB3780013DFDFAF05C38A3518F8A05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_05BB3780013DFDFAF05C38A3518F8A05" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_05BB3780013DFDFAF05C38A3518F8A05" xlink:type="arc" />
    <link:label id="lab_biib_CollaborationProfitSharing_C4265855BA7AC8F9288638A3518F407F_verboseLabel_en-US" xlink:label="lab_biib_CollaborationProfitSharing_C4265855BA7AC8F9288638A3518F407F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaboration profit sharing</link:label>
    <link:label id="lab_biib_CollaborationProfitSharing_C4265855BA7AC8F9288638A3518F407F_label_en-US" xlink:label="lab_biib_CollaborationProfitSharing_C4265855BA7AC8F9288638A3518F407F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration profit sharing</link:label>
    <link:label id="lab_biib_CollaborationProfitSharing_C4265855BA7AC8F9288638A3518F407F_documentation_en-US" xlink:label="lab_biib_CollaborationProfitSharing_C4265855BA7AC8F9288638A3518F407F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_C4265855BA7AC8F9288638A3518F407F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationProfitSharing_C4265855BA7AC8F9288638A3518F407F" xlink:to="lab_biib_CollaborationProfitSharing_C4265855BA7AC8F9288638A3518F407F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_6ABE525194BC8E4A416138A3518F8608_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_6ABE525194BC8E4A416138A3518F8608" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_6ABE525194BC8E4A416138A3518F8608_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_6ABE525194BC8E4A416138A3518F8608" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_6ABE525194BC8E4A416138A3518F8608" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_6ABE525194BC8E4A416138A3518F8608" xlink:to="lab_us-gaap_CostsAndExpenses_6ABE525194BC8E4A416138A3518F8608" xlink:type="arc" />
    <link:label id="lab_biib_GainOnSaleOfRights_B60F7F2944B1ABD28E1038A3518FB2FB_terseLabel_en-US" xlink:label="lab_biib_GainOnSaleOfRights_B60F7F2944B1ABD28E1038A3518FB2FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of rights</link:label>
    <link:label id="lab_biib_GainOnSaleOfRights_B60F7F2944B1ABD28E1038A3518FB2FB_label_en-US" xlink:label="lab_biib_GainOnSaleOfRights_B60F7F2944B1ABD28E1038A3518FB2FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on sale of rights</link:label>
    <link:label id="lab_biib_GainOnSaleOfRights_B60F7F2944B1ABD28E1038A3518FB2FB_documentation_en-US" xlink:label="lab_biib_GainOnSaleOfRights_B60F7F2944B1ABD28E1038A3518FB2FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain on sale of our royalty and other rights related to future sales of BENLYSTA recognized in our consolidated statement of income.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_GainOnSaleOfRights" xlink:label="loc_biib_GainOnSaleOfRights_B60F7F2944B1ABD28E1038A3518FB2FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GainOnSaleOfRights_B60F7F2944B1ABD28E1038A3518FB2FB" xlink:to="lab_biib_GainOnSaleOfRights_B60F7F2944B1ABD28E1038A3518FB2FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_FD8DD347948E1ECF42C338A3518FC2AE_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_FD8DD347948E1ECF42C338A3518FC2AE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_FD8DD347948E1ECF42C338A3518FC2AE_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_FD8DD347948E1ECF42C338A3518FC2AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_FD8DD347948E1ECF42C338A3518FC2AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_FD8DD347948E1ECF42C338A3518FC2AE" xlink:to="lab_us-gaap_OperatingIncomeLoss_FD8DD347948E1ECF42C338A3518FC2AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_E4BA1C049B99CE03AC6C38A3518F2DF8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_E4BA1C049B99CE03AC6C38A3518F2DF8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_E4BA1C049B99CE03AC6C38A3518F2DF8_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_E4BA1C049B99CE03AC6C38A3518F2DF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_E4BA1C049B99CE03AC6C38A3518F2DF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_E4BA1C049B99CE03AC6C38A3518F2DF8" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_E4BA1C049B99CE03AC6C38A3518F2DF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E94ECC88CC9ED284892138A351901F6C_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E94ECC88CC9ED284892138A351901F6C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E94ECC88CC9ED284892138A351901F6C_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E94ECC88CC9ED284892138A351901F6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E94ECC88CC9ED284892138A351901F6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E94ECC88CC9ED284892138A351901F6C" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E94ECC88CC9ED284892138A351901F6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_E8A9ED9AB733602D484038A351901884_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_E8A9ED9AB733602D484038A351901884" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_E8A9ED9AB733602D484038A351901884_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_E8A9ED9AB733602D484038A351901884" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E8A9ED9AB733602D484038A351901884" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_E8A9ED9AB733602D484038A351901884" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_E8A9ED9AB733602D484038A351901884" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_E862D1C36D8E85564B8338A35190E4CE_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_E862D1C36D8E85564B8338A35190E4CE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity in loss of investee, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_E862D1C36D8E85564B8338A35190E4CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_E862D1C36D8E85564B8338A35190E4CE" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_E862D1C36D8E85564B8338A35190E4CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_8EA0D0C97C8801CB62E538A351902893_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_8EA0D0C97C8801CB62E538A351902893" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8EA0D0C97C8801CB62E538A351902893" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_8EA0D0C97C8801CB62E538A351902893" xlink:to="lab_us-gaap_ProfitLoss_8EA0D0C97C8801CB62E538A351902893" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_A0A44558248CA663417438A3519096FC_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_A0A44558248CA663417438A3519096FC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A0A44558248CA663417438A3519096FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_A0A44558248CA663417438A3519096FC" xlink:to="lab_us-gaap_NetIncomeLoss_A0A44558248CA663417438A3519096FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_471817362E66FFC53D9838A35190489B_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_471817362E66FFC53D9838A35190489B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_471817362E66FFC53D9838A35190489B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_471817362E66FFC53D9838A35190489B" xlink:to="lab_us-gaap_EarningsPerShareAbstract_471817362E66FFC53D9838A35190489B" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B8A2ADD740B9F06CE98338A351902403_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B8A2ADD740B9F06CE98338A351902403" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B8A2ADD740B9F06CE98338A351902403_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B8A2ADD740B9F06CE98338A351902403" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B8A2ADD740B9F06CE98338A351902403" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B8A2ADD740B9F06CE98338A351902403" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B8A2ADD740B9F06CE98338A351902403" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrentAbstract_FCE66CB076C27EB71CED38A351EB3587_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrentAbstract_FCE66CB076C27EB71CED38A351EB3587" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion:</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrentAbstract_FCE66CB076C27EB71CED38A351EB3587_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrentAbstract_FCE66CB076C27EB71CED38A351EB3587" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtCurrentAbstract_FCE66CB076C27EB71CED38A351EB3587" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_FCE66CB076C27EB71CED38A351EB3587" xlink:to="lab_us-gaap_LongTermDebtCurrentAbstract_FCE66CB076C27EB71CED38A351EB3587" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableCurrent_22F8762A23417647460B38A351EB50BE_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_22F8762A23417647460B38A351EB50BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable to Fumedica</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_22F8762A23417647460B38A351EB50BE_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_22F8762A23417647460B38A351EB50BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_22F8762A23417647460B38A351EB50BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent_22F8762A23417647460B38A351EB50BE" xlink:to="lab_us-gaap_NotesPayableCurrent_22F8762A23417647460B38A351EB50BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_FCE98FB685D4F612AE8B38A351EBA7EF_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_FCE98FB685D4F612AE8B38A351EBA7EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing arrangement for the purchase of the RTP facility</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_FCE98FB685D4F612AE8B38A351EBA7EF_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_FCE98FB685D4F612AE8B38A351EBA7EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt and Capital Lease Obligations, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_FCE98FB685D4F612AE8B38A351EBA7EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_FCE98FB685D4F612AE8B38A351EBA7EF" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_FCE98FB685D4F612AE8B38A351EBA7EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_19E5A1ACA121766BC13B38A351ECDBFA_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_19E5A1ACA121766BC13B38A351ECDBFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable and other financing arrangements</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_19E5A1ACA121766BC13B38A351ECDBFA_label_en-US" xlink:label="lab_us-gaap_DebtCurrent_19E5A1ACA121766BC13B38A351ECDBFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_19E5A1ACA121766BC13B38A351ECDBFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_19E5A1ACA121766BC13B38A351ECDBFA" xlink:to="lab_us-gaap_DebtCurrent_19E5A1ACA121766BC13B38A351ECDBFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_3B1F0C555BE913E113CE38A351EC4DB5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract_3B1F0C555BE913E113CE38A351EC4DB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion:</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_3B1F0C555BE913E113CE38A351EC4DB5_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract_3B1F0C555BE913E113CE38A351EC4DB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_3B1F0C555BE913E113CE38A351EC4DB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_3B1F0C555BE913E113CE38A351EC4DB5" xlink:to="lab_us-gaap_LongTermDebtNoncurrentAbstract_3B1F0C555BE913E113CE38A351EC4DB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermNotesPayable_A0BD62888ED5C8C9B0F038A351ECFFA1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_A0BD62888ED5C8C9B0F038A351ECFFA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current notes payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_A0BD62888ED5C8C9B0F038A351ECFFA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable_A0BD62888ED5C8C9B0F038A351ECFFA1" xlink:to="lab_us-gaap_LongTermNotesPayable_A0BD62888ED5C8C9B0F038A351ECFFA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_26C4BB6C887D4582936A38A351ECFEC7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_26C4BB6C887D4582936A38A351ECFEC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing arrangement for the purchase of the RTP facility</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_26C4BB6C887D4582936A38A351ECFEC7_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_26C4BB6C887D4582936A38A351ECFEC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt and Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_26C4BB6C887D4582936A38A351ECFEC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_26C4BB6C887D4582936A38A351ECFEC7" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_26C4BB6C887D4582936A38A351ECFEC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_8C310E52827A95BA75AE38A351EC474D_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_8C310E52827A95BA75AE38A351EC474D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion of notes payable and other financing arrangements</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_8C310E52827A95BA75AE38A351EC474D_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_8C310E52827A95BA75AE38A351EC474D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_8C310E52827A95BA75AE38A351EC474D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_8C310E52827A95BA75AE38A351EC474D" xlink:to="lab_us-gaap_LongTermDebt_8C310E52827A95BA75AE38A351EC474D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B49F459DA6FCB32B38C738A35201F1FD_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B49F459DA6FCB32B38C738A35201F1FD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B49F459DA6FCB32B38C738A35201F1FD_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B49F459DA6FCB32B38C738A35201F1FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B49F459DA6FCB32B38C738A35201F1FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B49F459DA6FCB32B38C738A35201F1FD" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B49F459DA6FCB32B38C738A35201F1FD" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_1D270AB6FC568E3C9F8D38A3542013BE_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_1D270AB6FC568E3C9F8D38A3542013BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_1D270AB6FC568E3C9F8D38A3542013BE_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_1D270AB6FC568E3C9F8D38A3542013BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_1D270AB6FC568E3C9F8D38A3542013BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_1D270AB6FC568E3C9F8D38A3542013BE" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_1D270AB6FC568E3C9F8D38A3542013BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_8EFCA35DEECF2C92CC8838A354205A43_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_8EFCA35DEECF2C92CC8838A354205A43" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_8EFCA35DEECF2C92CC8838A354205A43_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_8EFCA35DEECF2C92CC8838A354205A43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_8EFCA35DEECF2C92CC8838A354205A43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_8EFCA35DEECF2C92CC8838A354205A43" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_8EFCA35DEECF2C92CC8838A354205A43" xlink:type="arc" />
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_21B7804BD0481162920838A353669AB9_verboseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_21B7804BD0481162920838A353669AB9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_21B7804BD0481162920838A353669AB9_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_21B7804BD0481162920838A353669AB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_21B7804BD0481162920838A353669AB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_21B7804BD0481162920838A353669AB9" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_21B7804BD0481162920838A353669AB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_D2BB5002400E09AE009038A35613759A_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_D2BB5002400E09AE009038A35613759A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_D2BB5002400E09AE009038A35613759A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_D2BB5002400E09AE009038A35613759A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_D2BB5002400E09AE009038A35613759A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_D2BB5002400E09AE009038A35613759A" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_D2BB5002400E09AE009038A35613759A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_CE691A86335070181CCB38A3561364CE_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_CE691A86335070181CCB38A3561364CE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_CE691A86335070181CCB38A3561364CE_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_CE691A86335070181CCB38A3561364CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_CE691A86335070181CCB38A3561364CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_CE691A86335070181CCB38A3561364CE" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_CE691A86335070181CCB38A3561364CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_779CA10DAB9BC42AD07A38A35613F274_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_779CA10DAB9BC42AD07A38A35613F274" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_779CA10DAB9BC42AD07A38A35613F274_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_779CA10DAB9BC42AD07A38A35613F274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_779CA10DAB9BC42AD07A38A35613F274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_779CA10DAB9BC42AD07A38A35613F274" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_779CA10DAB9BC42AD07A38A35613F274" xlink:type="arc" />
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_63832FB8ECD162BE35FB93224CFDA2AD_terseLabel_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable_63832FB8ECD162BE35FB93224CFDA2AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_63832FB8ECD162BE35FB93224CFDA2AD_label_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable_63832FB8ECD162BE35FB93224CFDA2AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_63832FB8ECD162BE35FB93224CFDA2AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_63832FB8ECD162BE35FB93224CFDA2AD" xlink:to="lab_us-gaap_AirlineProductsAndServicesTable_63832FB8ECD162BE35FB93224CFDA2AD" xlink:type="arc" />
    <link:label id="lab_biib_ZINBRYTAMember_51B9B2FDC7A334F8F90093224CFE83EE_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember_51B9B2FDC7A334F8F90093224CFE83EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_51B9B2FDC7A334F8F90093224CFE83EE_label_en-US" xlink:label="lab_biib_ZINBRYTAMember_51B9B2FDC7A334F8F90093224CFE83EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_51B9B2FDC7A334F8F90093224CFE83EE_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember_51B9B2FDC7A334F8F90093224CFE83EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_51B9B2FDC7A334F8F90093224CFE83EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember_51B9B2FDC7A334F8F90093224CFE83EE" xlink:to="lab_biib_ZINBRYTAMember_51B9B2FDC7A334F8F90093224CFE83EE" xlink:type="arc" />
    <link:label id="lab_biib_BENEPALIMember_F1CDA2889F89AFDEA4F39348C760D985_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember_F1CDA2889F89AFDEA4F39348C760D985" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_F1CDA2889F89AFDEA4F39348C760D985_label_en-US" xlink:label="lab_biib_BENEPALIMember_F1CDA2889F89AFDEA4F39348C760D985" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_F1CDA2889F89AFDEA4F39348C760D985_documentation_en-US" xlink:label="lab_biib_BENEPALIMember_F1CDA2889F89AFDEA4F39348C760D985" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_F1CDA2889F89AFDEA4F39348C760D985" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember_F1CDA2889F89AFDEA4F39348C760D985" xlink:to="lab_biib_BENEPALIMember_F1CDA2889F89AFDEA4F39348C760D985" xlink:type="arc" />
    <link:label id="lab_biib_FLIXABIMember_7ED2C1D896193DA9B4DE9349E8DD90CE_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember_7ED2C1D896193DA9B4DE9349E8DD90CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_7ED2C1D896193DA9B4DE9349E8DD90CE_label_en-US" xlink:label="lab_biib_FLIXABIMember_7ED2C1D896193DA9B4DE9349E8DD90CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_7ED2C1D896193DA9B4DE9349E8DD90CE_documentation_en-US" xlink:label="lab_biib_FLIXABIMember_7ED2C1D896193DA9B4DE9349E8DD90CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_7ED2C1D896193DA9B4DE9349E8DD90CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember_7ED2C1D896193DA9B4DE9349E8DD90CE" xlink:to="lab_biib_FLIXABIMember_7ED2C1D896193DA9B4DE9349E8DD90CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryLineItems_A319C20CA67DB99B8C0F93224CFEEAC5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems_A319C20CA67DB99B8C0F93224CFEEAC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_A319C20CA67DB99B8C0F93224CFEEAC5_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems_A319C20CA67DB99B8C0F93224CFEEAC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_A319C20CA67DB99B8C0F93224CFEEAC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems_A319C20CA67DB99B8C0F93224CFEEAC5" xlink:to="lab_us-gaap_InventoryLineItems_A319C20CA67DB99B8C0F93224CFEEAC5" xlink:type="arc" />
    <link:label id="lab_biib_Preapprovalinventory_C2E4723CC87A5104ACE593224CFEEB95_terseLabel_en-US" xlink:label="lab_biib_Preapprovalinventory_C2E4723CC87A5104ACE593224CFEEB95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-approval inventory</link:label>
    <link:label id="lab_biib_Preapprovalinventory_C2E4723CC87A5104ACE593224CFEEB95_label_en-US" xlink:label="lab_biib_Preapprovalinventory_C2E4723CC87A5104ACE593224CFEEB95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-approval inventory</link:label>
    <link:label id="lab_biib_Preapprovalinventory_C2E4723CC87A5104ACE593224CFEEB95_documentation_en-US" xlink:label="lab_biib_Preapprovalinventory_C2E4723CC87A5104ACE593224CFEEB95" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-approval inventory</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_Preapprovalinventory" xlink:label="loc_biib_Preapprovalinventory_C2E4723CC87A5104ACE593224CFEEB95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Preapprovalinventory_C2E4723CC87A5104ACE593224CFEEB95" xlink:to="lab_biib_Preapprovalinventory_C2E4723CC87A5104ACE593224CFEEB95" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWriteDown_30CCC3E10DFBACD9149593224CFEC0AC_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_30CCC3E10DFBACD9149593224CFEC0AC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Write-downs on excess, obsolete, unmarketable or other inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_30CCC3E10DFBACD9149593224CFEC0AC_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_30CCC3E10DFBACD9149593224CFEC0AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_30CCC3E10DFBACD9149593224CFEC0AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown_30CCC3E10DFBACD9149593224CFEC0AC" xlink:to="lab_us-gaap_InventoryWriteDown_30CCC3E10DFBACD9149593224CFEC0AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_03A66E4528CB90EA059338A351CA3A66_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_03A66E4528CB90EA059338A351CA3A66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_03A66E4528CB90EA059338A351CA3A66_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_03A66E4528CB90EA059338A351CA3A66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_03A66E4528CB90EA059338A351CA3A66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_03A66E4528CB90EA059338A351CA3A66" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_03A66E4528CB90EA059338A351CA3A66" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_DD8C516FD16A0CB7AC0238A351CADE09_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_DD8C516FD16A0CB7AC0238A351CADE09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_DD8C516FD16A0CB7AC0238A351CADE09_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_DD8C516FD16A0CB7AC0238A351CADE09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_DD8C516FD16A0CB7AC0238A351CADE09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_DD8C516FD16A0CB7AC0238A351CADE09" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_DD8C516FD16A0CB7AC0238A351CADE09" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1678CCF4AA1498B67AA838A351CA0984_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_1678CCF4AA1498B67AA838A351CA0984" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1678CCF4AA1498B67AA838A351CA0984_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_1678CCF4AA1498B67AA838A351CA0984" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1678CCF4AA1498B67AA838A351CA0984" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_1678CCF4AA1498B67AA838A351CA0984" xlink:to="lab_us-gaap_CommonStockSharesIssued_1678CCF4AA1498B67AA838A351CA0984" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3AF0B849A682D9B9E3A438A351CA3032_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_3AF0B849A682D9B9E3A438A351CA3032" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3AF0B849A682D9B9E3A438A351CA3032_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_3AF0B849A682D9B9E3A438A351CA3032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3AF0B849A682D9B9E3A438A351CA3032" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_3AF0B849A682D9B9E3A438A351CA3032" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_3AF0B849A682D9B9E3A438A351CA3032" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_767247D19448D0B5D9FE38A3531F6E5B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_767247D19448D0B5D9FE38A3531F6E5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges and spending related to our restructuring efforts</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_767247D19448D0B5D9FE38A3531F6E5B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_767247D19448D0B5D9FE38A3531F6E5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_767247D19448D0B5D9FE38A3531F6E5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_767247D19448D0B5D9FE38A3531F6E5B" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_767247D19448D0B5D9FE38A3531F6E5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_9B21AB9E33C6BEDB7ACD38A355180598_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_9B21AB9E33C6BEDB7ACD38A355180598" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_9B21AB9E33C6BEDB7ACD38A355180598_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_9B21AB9E33C6BEDB7ACD38A355180598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_9B21AB9E33C6BEDB7ACD38A355180598" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_9B21AB9E33C6BEDB7ACD38A355180598" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_9B21AB9E33C6BEDB7ACD38A355180598" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_C3FB4E3324BD5356489338A3565D9319_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_C3FB4E3324BD5356489338A3565D9319" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_C3FB4E3324BD5356489338A3565D9319_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_C3FB4E3324BD5356489338A3565D9319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_C3FB4E3324BD5356489338A3565D9319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_C3FB4E3324BD5356489338A3565D9319" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_C3FB4E3324BD5356489338A3565D9319" xlink:type="arc" />
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaAbstract_206A2574F36DEAD5BCA138A35124F55F_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaAbstract_206A2574F36DEAD5BCA138A35124F55F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaAbstract_206A2574F36DEAD5BCA138A35124F55F_label_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaAbstract_206A2574F36DEAD5BCA138A35124F55F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Profit Sharing Formula [Abstract]</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaAbstract_206A2574F36DEAD5BCA138A35124F55F_documentation_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaAbstract_206A2574F36DEAD5BCA138A35124F55F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_CoPromotionProfitSharingFormulaAbstract" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract_206A2574F36DEAD5BCA138A35124F55F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_206A2574F36DEAD5BCA138A35124F55F" xlink:to="lab_biib_CoPromotionProfitSharingFormulaAbstract_206A2574F36DEAD5BCA138A35124F55F" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_72EE9E256276BFF1F78038A3512435E4_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_72EE9E256276BFF1F78038A3512435E4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Until GAZYVA First Non-CLL FDA Approval</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_72EE9E256276BFF1F78038A3512435E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_72EE9E256276BFF1F78038A3512435E4" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_72EE9E256276BFF1F78038A3512435E4" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_7F908F1E8E6DEE52357238A351243863_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_7F908F1E8E6DEE52357238A351243863" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">After First GA101 Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_7F908F1E8E6DEE52357238A351243863_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_7F908F1E8E6DEE52357238A351243863" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two [Abstract]</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_7F908F1E8E6DEE52357238A351243863_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_7F908F1E8E6DEE52357238A351243863" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_7F908F1E8E6DEE52357238A351243863" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_7F908F1E8E6DEE52357238A351243863" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_7F908F1E8E6DEE52357238A351243863" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_A76C1526278DB1FF798538A35124809F_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_A76C1526278DB1FF798538A35124809F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Until First GAZYVA Threshold Date</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_A76C1526278DB1FF798538A35124809F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_A76C1526278DB1FF798538A35124809F" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_A76C1526278DB1FF798538A35124809F" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_519A267EE42F8895C1BC38A3512402A2_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_519A267EE42F8895C1BC38A3512402A2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">After First Threshold Date and until Second Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_519A267EE42F8895C1BC38A3512402A2_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_519A267EE42F8895C1BC38A3512402A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Two</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_519A267EE42F8895C1BC38A3512402A2_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_519A267EE42F8895C1BC38A3512402A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option two.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_519A267EE42F8895C1BC38A3512402A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_519A267EE42F8895C1BC38A3512402A2" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_519A267EE42F8895C1BC38A3512402A2" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_E9C77CA29E45AC9E23B338A35124FAED_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_E9C77CA29E45AC9E23B338A35124FAED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">After Second Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_E9C77CA29E45AC9E23B338A35124FAED_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_E9C77CA29E45AC9E23B338A35124FAED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Three</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_E9C77CA29E45AC9E23B338A35124FAED_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_E9C77CA29E45AC9E23B338A35124FAED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option three.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_E9C77CA29E45AC9E23B338A35124FAED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_E9C77CA29E45AC9E23B338A35124FAED" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_E9C77CA29E45AC9E23B338A35124FAED" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_2FB19097E477B7D598A538A351249A93_verboseLabel_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_2FB19097E477B7D598A538A351249A93" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business</link:label>
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_2FB19097E477B7D598A538A351249A93_label_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_2FB19097E477B7D598A538A351249A93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues From Unconsolidated Joint Business [Abstract]</link:label>
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_2FB19097E477B7D598A538A351249A93_documentation_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_2FB19097E477B7D598A538A351249A93" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RevenuesFromUnconsolidatedJointBusinessAbstract" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_2FB19097E477B7D598A538A351249A93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_2FB19097E477B7D598A538A351249A93" xlink:to="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_2FB19097E477B7D598A538A351249A93" xlink:type="arc" />
    <link:label id="lab_biib_UnconsolidatedJointBusiness_271FB402D617EEE48A4B38A3512419F5_totalLabel_en-US" xlink:label="lab_biib_UnconsolidatedJointBusiness_271FB402D617EEE48A4B38A3512419F5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total unconsolidated joint business revenues</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_UnconsolidatedJointBusiness" xlink:label="loc_biib_UnconsolidatedJointBusiness_271FB402D617EEE48A4B38A3512419F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnconsolidatedJointBusiness_271FB402D617EEE48A4B38A3512419F5" xlink:to="lab_biib_UnconsolidatedJointBusiness_271FB402D617EEE48A4B38A3512419F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_011018B3FCBF4C97908B93D5CA9908E8_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis_011018B3FCBF4C97908B93D5CA9908E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_011018B3FCBF4C97908B93D5CA9908E8_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis_011018B3FCBF4C97908B93D5CA9908E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_011018B3FCBF4C97908B93D5CA9908E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_011018B3FCBF4C97908B93D5CA9908E8" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis_011018B3FCBF4C97908B93D5CA9908E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_B03F8C62B7525987D5D493D5CA991520_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain_B03F8C62B7525987D5D493D5CA991520" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_B03F8C62B7525987D5D493D5CA991520_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain_B03F8C62B7525987D5D493D5CA991520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_B03F8C62B7525987D5D493D5CA991520" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_B03F8C62B7525987D5D493D5CA991520" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain_B03F8C62B7525987D5D493D5CA991520" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_0BDD28D1B7E85ADF522193D5CA99AAFB_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_0BDD28D1B7E85ADF522193D5CA99AAFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_0BDD28D1B7E85ADF522193D5CA99AAFB_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_0BDD28D1B7E85ADF522193D5CA99AAFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0BDD28D1B7E85ADF522193D5CA99AAFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0BDD28D1B7E85ADF522193D5CA99AAFB" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_0BDD28D1B7E85ADF522193D5CA99AAFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_CBCBC09117C58495F53C93D5CA9E8C09_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_CBCBC09117C58495F53C93D5CA9E8C09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_CBCBC09117C58495F53C93D5CA9E8C09_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_CBCBC09117C58495F53C93D5CA9E8C09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_CBCBC09117C58495F53C93D5CA9E8C09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember_CBCBC09117C58495F53C93D5CA9E8C09" xlink:to="lab_us-gaap_AccruedLiabilitiesMember_CBCBC09117C58495F53C93D5CA9E8C09" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_891970B7B1B2F196C32893D5CA9EB28D_verboseLabel_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_891970B7B1B2F196C32893D5CA9EB28D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">6.875% Senior Notes due 2018</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_891970B7B1B2F196C32893D5CA9EB28D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_891970B7B1B2F196C32893D5CA9EB28D" xlink:to="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_891970B7B1B2F196C32893D5CA9EB28D" xlink:type="arc" />
    <link:label id="lab_biib_StromedixMember_4695609B053A40CEF97393D5CA9FD1C2_verboseLabel_en-US" xlink:label="lab_biib_StromedixMember_4695609B053A40CEF97393D5CA9FD1C2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stromedix, Inc.</link:label>
    <link:label id="lab_biib_StromedixMember_4695609B053A40CEF97393D5CA9FD1C2_label_en-US" xlink:label="lab_biib_StromedixMember_4695609B053A40CEF97393D5CA9FD1C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stromedix [Member]</link:label>
    <link:label id="lab_biib_StromedixMember_4695609B053A40CEF97393D5CA9FD1C2_documentation_en-US" xlink:label="lab_biib_StromedixMember_4695609B053A40CEF97393D5CA9FD1C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stromedix.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_StromedixMember" xlink:label="loc_biib_StromedixMember_4695609B053A40CEF97393D5CA9FD1C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StromedixMember_4695609B053A40CEF97393D5CA9FD1C2" xlink:to="lab_biib_StromedixMember_4695609B053A40CEF97393D5CA9FD1C2" xlink:type="arc" />
    <link:label id="lab_biib_CorporateJointVentureInvestmentsMember_6888F403EE1C785E636B93D5CA9F477B_terseLabel_en-US" xlink:label="lab_biib_CorporateJointVentureInvestmentsMember_6888F403EE1C785E636B93D5CA9F477B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen Dompe SRL and Biogen Dompe Switzerland GmbH</link:label>
    <link:label id="lab_biib_CorporateJointVentureInvestmentsMember_6888F403EE1C785E636B93D5CA9F477B_label_en-US" xlink:label="lab_biib_CorporateJointVentureInvestmentsMember_6888F403EE1C785E636B93D5CA9F477B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Joint Venture Investments Member</link:label>
    <link:label id="lab_biib_CorporateJointVentureInvestmentsMember_6888F403EE1C785E636B93D5CA9F477B_documentation_en-US" xlink:label="lab_biib_CorporateJointVentureInvestmentsMember_6888F403EE1C785E636B93D5CA9F477B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Joint Venture Investments.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_CorporateJointVentureInvestmentsMember" xlink:label="loc_biib_CorporateJointVentureInvestmentsMember_6888F403EE1C785E636B93D5CA9F477B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateJointVentureInvestmentsMember_6888F403EE1C785E636B93D5CA9F477B" xlink:to="lab_biib_CorporateJointVentureInvestmentsMember_6888F403EE1C785E636B93D5CA9F477B" xlink:type="arc" />
    <link:label id="lab_biib_BiogenIdecInternationalNeuroscienceMember_D68BD599A551A3C2E0AC93D5CA9FF945_terseLabel_en-US" xlink:label="lab_biib_BiogenIdecInternationalNeuroscienceMember_D68BD599A551A3C2E0AC93D5CA9FF945" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec International Neuroscience GmbH</link:label>
    <link:label id="lab_biib_BiogenIdecInternationalNeuroscienceMember_D68BD599A551A3C2E0AC93D5CA9FF945_label_en-US" xlink:label="lab_biib_BiogenIdecInternationalNeuroscienceMember_D68BD599A551A3C2E0AC93D5CA9FF945" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen Idec International Neuroscience Member</link:label>
    <link:label id="lab_biib_BiogenIdecInternationalNeuroscienceMember_D68BD599A551A3C2E0AC93D5CA9FF945_documentation_en-US" xlink:label="lab_biib_BiogenIdecInternationalNeuroscienceMember_D68BD599A551A3C2E0AC93D5CA9FF945" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen idec international neuroscience.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_BiogenIdecInternationalNeuroscienceMember" xlink:label="loc_biib_BiogenIdecInternationalNeuroscienceMember_D68BD599A551A3C2E0AC93D5CA9FF945" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiogenIdecInternationalNeuroscienceMember_D68BD599A551A3C2E0AC93D5CA9FF945" xlink:to="lab_biib_BiogenIdecInternationalNeuroscienceMember_D68BD599A551A3C2E0AC93D5CA9FF945" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_AA3113422E0AEFCC3A5493D5CA9FECD2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_AA3113422E0AEFCC3A5493D5CA9FECD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_AA3113422E0AEFCC3A5493D5CA9FECD2_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_AA3113422E0AEFCC3A5493D5CA9FECD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_AA3113422E0AEFCC3A5493D5CA9FECD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_AA3113422E0AEFCC3A5493D5CA9FECD2" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_AA3113422E0AEFCC3A5493D5CA9FECD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_AC1C63097055A9DB3E2393D5CA9F7F39_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_AC1C63097055A9DB3E2393D5CA9F7F39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements, changes in valuation techniques</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_AC1C63097055A9DB3E2393D5CA9F7F39_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_AC1C63097055A9DB3E2393D5CA9F7F39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Changes in Valuation Techniques</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_AC1C63097055A9DB3E2393D5CA9F7F39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_AC1C63097055A9DB3E2393D5CA9F7F39" xlink:to="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_AC1C63097055A9DB3E2393D5CA9F7F39" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D5A8B9B9728864F5162D93D5CA9F51CB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D5A8B9B9728864F5162D93D5CA9F51CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D5A8B9B9728864F5162D93D5CA9F51CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D5A8B9B9728864F5162D93D5CA9F51CB" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D5A8B9B9728864F5162D93D5CA9F51CB" xlink:type="arc" />
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_CCC28E552FB78D57D8F493D5CA9FCA52_terseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_CCC28E552FB78D57D8F493D5CA9FCA52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential future milestone payments</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_CCC28E552FB78D57D8F493D5CA9FCA52_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_CCC28E552FB78D57D8F493D5CA9FCA52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_CCC28E552FB78D57D8F493D5CA9FCA52_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_CCC28E552FB78D57D8F493D5CA9FCA52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_CCC28E552FB78D57D8F493D5CA9FCA52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_CCC28E552FB78D57D8F493D5CA9FCA52" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_CCC28E552FB78D57D8F493D5CA9FCA52" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_88BF551DE420FD3ACD0E93D5CA9F35CE_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_88BF551DE420FD3ACD0E93D5CA9F35CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_88BF551DE420FD3ACD0E93D5CA9F35CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_88BF551DE420FD3ACD0E93D5CA9F35CE" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_88BF551DE420FD3ACD0E93D5CA9F35CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5C23C7655E1A30EF6DF793D5CA9F3953_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5C23C7655E1A30EF6DF793D5CA9F3953" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum contingent consideration in the form of development and approval milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5C23C7655E1A30EF6DF793D5CA9F3953_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5C23C7655E1A30EF6DF793D5CA9F3953" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5C23C7655E1A30EF6DF793D5CA9F3953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5C23C7655E1A30EF6DF793D5CA9F3953" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5C23C7655E1A30EF6DF793D5CA9F3953" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsDiscountRate_1861DDB7767BB75CD97793D5CA9F02B8_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsDiscountRate_1861DDB7767BB75CD97793D5CA9F02B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discount rate used for net cash outflow projections for fair value measurement</link:label>
    <link:label id="lab_us-gaap_FairValueInputsDiscountRate_1861DDB7767BB75CD97793D5CA9F02B8_label_en-US" xlink:label="lab_us-gaap_FairValueInputsDiscountRate_1861DDB7767BB75CD97793D5CA9F02B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Inputs, Discount Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_1861DDB7767BB75CD97793D5CA9F02B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsDiscountRate_1861DDB7767BB75CD97793D5CA9F02B8" xlink:to="lab_us-gaap_FairValueInputsDiscountRate_1861DDB7767BB75CD97793D5CA9F02B8" xlink:type="arc" />
    <link:label id="lab_biib_MilestonePaymentsMadeDuringPeriod_E249EF1B31AEDBE4277593D5CA9FF1CA_verboseLabel_en-US" xlink:label="lab_biib_MilestonePaymentsMadeDuringPeriod_E249EF1B31AEDBE4277593D5CA9FF1CA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments made during period</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_E249EF1B31AEDBE4277593D5CA9FF1CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MilestonePaymentsMadeDuringPeriod_E249EF1B31AEDBE4277593D5CA9FF1CA" xlink:to="lab_biib_MilestonePaymentsMadeDuringPeriod_E249EF1B31AEDBE4277593D5CA9FF1CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_EE8FAFA4F99938EC1F9893D5CA9FE032_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_EE8FAFA4F99938EC1F9893D5CA9FE032" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_EE8FAFA4F99938EC1F9893D5CA9FE032_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_EE8FAFA4F99938EC1F9893D5CA9FE032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_EE8FAFA4F99938EC1F9893D5CA9FE032" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_EE8FAFA4F99938EC1F9893D5CA9FE032" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_EE8FAFA4F99938EC1F9893D5CA9FE032" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_927D80F05A693AEB0221A32AB8B7EA06_netLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_927D80F05A693AEB0221A32AB8B7EA06" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_927D80F05A693AEB0221A32AB8B7EA06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_927D80F05A693AEB0221A32AB8B7EA06" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_927D80F05A693AEB0221A32AB8B7EA06" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E7F3341A93C7485FD0C0A32AB8B8BA61_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E7F3341A93C7485FD0C0A32AB8B8BA61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Net Unrealized Investment Gain (Loss) [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E7F3341A93C7485FD0C0A32AB8B8BA61_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E7F3341A93C7485FD0C0A32AB8B8BA61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E7F3341A93C7485FD0C0A32AB8B8BA61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E7F3341A93C7485FD0C0A32AB8B8BA61" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E7F3341A93C7485FD0C0A32AB8B8BA61" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_717DB635D96594086B23A32AB8B84639_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_717DB635D96594086B23A32AB8B84639" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_717DB635D96594086B23A32AB8B84639_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_717DB635D96594086B23A32AB8B84639" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_717DB635D96594086B23A32AB8B84639" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_717DB635D96594086B23A32AB8B84639" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_717DB635D96594086B23A32AB8B84639" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_4085589AEFE4C3D47979A32AB8B83CCA_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_4085589AEFE4C3D47979A32AB8B83CCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_4085589AEFE4C3D47979A32AB8B83CCA_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_4085589AEFE4C3D47979A32AB8B83CCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_4085589AEFE4C3D47979A32AB8B83CCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_4085589AEFE4C3D47979A32AB8B83CCA" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_4085589AEFE4C3D47979A32AB8B83CCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_D5DB919A12A1E3100A64A32AB8B8EBB5_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_D5DB919A12A1E3100A64A32AB8B8EBB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_D5DB919A12A1E3100A64A32AB8B8EBB5_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_D5DB919A12A1E3100A64A32AB8B8EBB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_D5DB919A12A1E3100A64A32AB8B8EBB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_D5DB919A12A1E3100A64A32AB8B8EBB5" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_D5DB919A12A1E3100A64A32AB8B8EBB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_870F6DCF66B42EFC83BDA32AB8B851AD_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_870F6DCF66B42EFC83BDA32AB8B851AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_870F6DCF66B42EFC83BDA32AB8B851AD_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_870F6DCF66B42EFC83BDA32AB8B851AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_870F6DCF66B42EFC83BDA32AB8B851AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_870F6DCF66B42EFC83BDA32AB8B851AD" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_870F6DCF66B42EFC83BDA32AB8B851AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_277C06FF2DF5065E96A9A32AB8B8CD99_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_277C06FF2DF5065E96A9A32AB8B8CD99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_277C06FF2DF5065E96A9A32AB8B8CD99_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_277C06FF2DF5065E96A9A32AB8B8CD99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_277C06FF2DF5065E96A9A32AB8B8CD99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_277C06FF2DF5065E96A9A32AB8B8CD99" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_277C06FF2DF5065E96A9A32AB8B8CD99" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_1C915A4C86FE38E85B05A32AB8B84C0C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_1C915A4C86FE38E85B05A32AB8B84C0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1C915A4C86FE38E85B05A32AB8B84C0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_1C915A4C86FE38E85B05A32AB8B84C0C" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_1C915A4C86FE38E85B05A32AB8B84C0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_01BEA23D64A5F84CDDB9A32AB8B840AA_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_01BEA23D64A5F84CDDB9A32AB8B840AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_01BEA23D64A5F84CDDB9A32AB8B840AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_01BEA23D64A5F84CDDB9A32AB8B840AA" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_01BEA23D64A5F84CDDB9A32AB8B840AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_B2003F153C8493AD1985A32AB8B85FAC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_B2003F153C8493AD1985A32AB8B85FAC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_B2003F153C8493AD1985A32AB8B85FAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_B2003F153C8493AD1985A32AB8B85FAC" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_B2003F153C8493AD1985A32AB8B85FAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_38261C774CF9A59A46F9A32AB8B89003_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_38261C774CF9A59A46F9A32AB8B89003" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_38261C774CF9A59A46F9A32AB8B89003" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_38261C774CF9A59A46F9A32AB8B89003" xlink:to="lab_us-gaap_NetIncomeLoss_38261C774CF9A59A46F9A32AB8B89003" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_89103FACF1D0D4B9C26293224D3994E7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_89103FACF1D0D4B9C26293224D3994E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_89103FACF1D0D4B9C26293224D3994E7_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_89103FACF1D0D4B9C26293224D3994E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_89103FACF1D0D4B9C26293224D3994E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_89103FACF1D0D4B9C26293224D3994E7" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_89103FACF1D0D4B9C26293224D3994E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_198DB2409DE54C383EF293224D39048B_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_198DB2409DE54C383EF293224D39048B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_198DB2409DE54C383EF293224D39048B_label_en-US" xlink:label="lab_us-gaap_Goodwill_198DB2409DE54C383EF293224D39048B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_198DB2409DE54C383EF293224D39048B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_198DB2409DE54C383EF293224D39048B" xlink:to="lab_us-gaap_Goodwill_198DB2409DE54C383EF293224D39048B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_F0EAA334FFC051ADE0DC93224D39758D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_F0EAA334FFC051ADE0DC93224D39758D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_F0EAA334FFC051ADE0DC93224D39758D_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_F0EAA334FFC051ADE0DC93224D39758D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_F0EAA334FFC051ADE0DC93224D39758D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_F0EAA334FFC051ADE0DC93224D39758D" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_F0EAA334FFC051ADE0DC93224D39758D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_99C58519B10AC5892C5793224D39EA53_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_99C58519B10AC5892C5793224D39EA53" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_99C58519B10AC5892C5793224D39EA53_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_99C58519B10AC5892C5793224D39EA53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_99C58519B10AC5892C5793224D39EA53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_99C58519B10AC5892C5793224D39EA53" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_99C58519B10AC5892C5793224D39EA53" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7D38838342A7A24D505A93224D391B19_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7D38838342A7A24D505A93224D391B19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7D38838342A7A24D505A93224D391B19_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7D38838342A7A24D505A93224D391B19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7D38838342A7A24D505A93224D391B19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7D38838342A7A24D505A93224D391B19" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7D38838342A7A24D505A93224D391B19" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevelAxis_A7C4C764F6D4CD8D1D2093582E1B15DE_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_A7C4C764F6D4CD8D1D2093582E1B15DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelAxis_A7C4C764F6D4CD8D1D2093582E1B15DE_label_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_A7C4C764F6D4CD8D1D2093582E1B15DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelAxis_A7C4C764F6D4CD8D1D2093582E1B15DE_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_A7C4C764F6D4CD8D1D2093582E1B15DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_A7C4C764F6D4CD8D1D2093582E1B15DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevelAxis_A7C4C764F6D4CD8D1D2093582E1B15DE" xlink:to="lab_biib_CumulativeSalesLevelAxis_A7C4C764F6D4CD8D1D2093582E1B15DE" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevelDomain_81C67463153D48212EA393582E1B86CE_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_81C67463153D48212EA393582E1B86CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Domain]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelDomain_81C67463153D48212EA393582E1B86CE_label_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_81C67463153D48212EA393582E1B86CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Domain]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelDomain_81C67463153D48212EA393582E1B86CE_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_81C67463153D48212EA393582E1B86CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Cumulative sales level [Axis]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_81C67463153D48212EA393582E1B86CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevelDomain_81C67463153D48212EA393582E1B86CE" xlink:to="lab_biib_CumulativeSalesLevelDomain_81C67463153D48212EA393582E1B86CE" xlink:type="arc" />
    <link:label id="lab_biib_SevenbillionMember_567169C21EE3568D5BFA93582E1BBB75_terseLabel_en-US" xlink:label="lab_biib_SevenbillionMember_567169C21EE3568D5BFA93582E1BBB75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Seven billion</link:label>
    <link:label id="lab_biib_SevenbillionMember_567169C21EE3568D5BFA93582E1BBB75_label_en-US" xlink:label="lab_biib_SevenbillionMember_567169C21EE3568D5BFA93582E1BBB75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seven billion [Member]</link:label>
    <link:label id="lab_biib_SevenbillionMember_567169C21EE3568D5BFA93582E1BBB75_documentation_en-US" xlink:label="lab_biib_SevenbillionMember_567169C21EE3568D5BFA93582E1BBB75" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Seven billion [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SevenbillionMember" xlink:label="loc_biib_SevenbillionMember_567169C21EE3568D5BFA93582E1BBB75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SevenbillionMember_567169C21EE3568D5BFA93582E1BBB75" xlink:to="lab_biib_SevenbillionMember_567169C21EE3568D5BFA93582E1BBB75" xlink:type="arc" />
    <link:label id="lab_biib_FumapharmAgMember_E8FE24E5BAE042A22F0D93582E1B825F_terseLabel_en-US" xlink:label="lab_biib_FumapharmAgMember_E8FE24E5BAE042A22F0D93582E1B825F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fumapharm AG</link:label>
    <link:label id="lab_biib_FumapharmAgMember_E8FE24E5BAE042A22F0D93582E1B825F_label_en-US" xlink:label="lab_biib_FumapharmAgMember_E8FE24E5BAE042A22F0D93582E1B825F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:label id="lab_biib_FumapharmAgMember_E8FE24E5BAE042A22F0D93582E1B825F_documentation_en-US" xlink:label="lab_biib_FumapharmAgMember_E8FE24E5BAE042A22F0D93582E1B825F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_E8FE24E5BAE042A22F0D93582E1B825F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumapharmAgMember_E8FE24E5BAE042A22F0D93582E1B825F" xlink:to="lab_biib_FumapharmAgMember_E8FE24E5BAE042A22F0D93582E1B825F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_E5F49049122DC812941193582E1B2405_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_E5F49049122DC812941193582E1B2405" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_E5F49049122DC812941193582E1B2405_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_E5F49049122DC812941193582E1B2405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_E5F49049122DC812941193582E1B2405" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_E5F49049122DC812941193582E1B2405" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_E5F49049122DC812941193582E1B2405" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevel_401908750E8A9FABA4A693582E1BD155_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevel_401908750E8A9FABA4A693582E1BD155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:label id="lab_biib_CumulativeSalesLevel_401908750E8A9FABA4A693582E1BD155_label_en-US" xlink:label="lab_biib_CumulativeSalesLevel_401908750E8A9FABA4A693582E1BD155" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:label id="lab_biib_CumulativeSalesLevel_401908750E8A9FABA4A693582E1BD155_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevel_401908750E8A9FABA4A693582E1BD155" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_401908750E8A9FABA4A693582E1BD155" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevel_401908750E8A9FABA4A693582E1BD155" xlink:to="lab_biib_CumulativeSalesLevel_401908750E8A9FABA4A693582E1BD155" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_DFEB40D38CAA2B365F9B93A5D37497DD_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_DFEB40D38CAA2B365F9B93A5D37497DD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_DFEB40D38CAA2B365F9B93A5D37497DD_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_DFEB40D38CAA2B365F9B93A5D37497DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_DFEB40D38CAA2B365F9B93A5D37497DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_DFEB40D38CAA2B365F9B93A5D37497DD" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_DFEB40D38CAA2B365F9B93A5D37497DD" xlink:type="arc" />
    <link:label id="lab_biib_DerecognitionOfConstructionInProgressAssets_F0271AC9C526803ED86493582E1C5DEC_terseLabel_en-US" xlink:label="lab_biib_DerecognitionOfConstructionInProgressAssets_F0271AC9C526803ED86493582E1C5DEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derecognition of construction in progress assets</link:label>
    <link:label id="lab_biib_DerecognitionOfConstructionInProgressAssets_F0271AC9C526803ED86493582E1C5DEC_label_en-US" xlink:label="lab_biib_DerecognitionOfConstructionInProgressAssets_F0271AC9C526803ED86493582E1C5DEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derecognition of construction in progress assets</link:label>
    <link:label id="lab_biib_DerecognitionOfConstructionInProgressAssets_F0271AC9C526803ED86493582E1C5DEC_documentation_en-US" xlink:label="lab_biib_DerecognitionOfConstructionInProgressAssets_F0271AC9C526803ED86493582E1C5DEC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derecognition of construction in progress assets</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_DerecognitionOfConstructionInProgressAssets" xlink:label="loc_biib_DerecognitionOfConstructionInProgressAssets_F0271AC9C526803ED86493582E1C5DEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerecognitionOfConstructionInProgressAssets_F0271AC9C526803ED86493582E1C5DEC" xlink:to="lab_biib_DerecognitionOfConstructionInProgressAssets_F0271AC9C526803ED86493582E1C5DEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidTaxes_3B74A10E7B2101F964E193A7016DA739_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes_3B74A10E7B2101F964E193A7016DA739" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_3B74A10E7B2101F964E193A7016DA739_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes_3B74A10E7B2101F964E193A7016DA739" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_3B74A10E7B2101F964E193A7016DA739" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes_3B74A10E7B2101F964E193A7016DA739" xlink:to="lab_us-gaap_PrepaidTaxes_3B74A10E7B2101F964E193A7016DA739" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_17F8F9CCD5C2093E03C493582E1C4B0D_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_17F8F9CCD5C2093E03C493582E1C4B0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proposed settlement</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_17F8F9CCD5C2093E03C493582E1C4B0D_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_17F8F9CCD5C2093E03C493582E1C4B0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_17F8F9CCD5C2093E03C493582E1C4B0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_17F8F9CCD5C2093E03C493582E1C4B0D" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_17F8F9CCD5C2093E03C493582E1C4B0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_C15660B4201AC26AAC9893582E1C052C_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_C15660B4201AC26AAC9893582E1C052C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_C15660B4201AC26AAC9893582E1C052C_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_C15660B4201AC26AAC9893582E1C052C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_C15660B4201AC26AAC9893582E1C052C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue_C15660B4201AC26AAC9893582E1C052C" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue_C15660B4201AC26AAC9893582E1C052C" xlink:type="arc" />
    <link:label id="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_C553290695048CF5AA6F93582E1CB1D5_terseLabel_en-US" xlink:label="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_C553290695048CF5AA6F93582E1CB1D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, adjustment related to claim amount, percent</link:label>
    <link:label id="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_C553290695048CF5AA6F93582E1CB1D5_label_en-US" xlink:label="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_C553290695048CF5AA6F93582E1CB1D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Adjustment Related To Claim Amount, Percent</link:label>
    <link:label id="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_C553290695048CF5AA6F93582E1CB1D5_documentation_en-US" xlink:label="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_C553290695048CF5AA6F93582E1CB1D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Adjustment Related To Claim Amount, Percent</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_LossContingencyAdjustmentRelatedToClaimAmountPercent" xlink:label="loc_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_C553290695048CF5AA6F93582E1CB1D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_C553290695048CF5AA6F93582E1CB1D5" xlink:to="lab_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_C553290695048CF5AA6F93582E1CB1D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_75B5C5DFFA579B5507F293A8926B620D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_75B5C5DFFA579B5507F293A8926B620D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other long-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_75B5C5DFFA579B5507F293A8926B620D_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_75B5C5DFFA579B5507F293A8926B620D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_75B5C5DFFA579B5507F293A8926B620D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_75B5C5DFFA579B5507F293A8926B620D" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_75B5C5DFFA579B5507F293A8926B620D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7EC1F275AD1483AD62AD93582DBAC85A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7EC1F275AD1483AD62AD93582DBAC85A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7EC1F275AD1483AD62AD93582DBAC85A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7EC1F275AD1483AD62AD93582DBAC85A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7EC1F275AD1483AD62AD93582DBAC85A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7EC1F275AD1483AD62AD93582DBAC85A" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7EC1F275AD1483AD62AD93582DBAC85A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_1DEAD1AADAA6F1577D3193582DBAD285_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_1DEAD1AADAA6F1577D3193582DBAD285" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_1DEAD1AADAA6F1577D3193582DBAD285_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_1DEAD1AADAA6F1577D3193582DBAD285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis" xlink:label="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_1DEAD1AADAA6F1577D3193582DBAD285" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_1DEAD1AADAA6F1577D3193582DBAD285" xlink:to="lab_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_1DEAD1AADAA6F1577D3193582DBAD285" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans [Domain]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan and Other Postretirement Benefit Plan [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlansDomain" xlink:label="loc_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6" xlink:to="lab_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6" xlink:type="arc" />
    <link:label id="lab_biib_SavingsPlanMember_10CEA71099B8F7DE07F593582DBAA4F3_verboseLabel_en-US" xlink:label="lab_biib_SavingsPlanMember_10CEA71099B8F7DE07F593582DBAA4F3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Savings plan [Member]</link:label>
    <link:label id="lab_biib_SavingsPlanMember_10CEA71099B8F7DE07F593582DBAA4F3_label_en-US" xlink:label="lab_biib_SavingsPlanMember_10CEA71099B8F7DE07F593582DBAA4F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Savings Plan [Member]</link:label>
    <link:label id="lab_biib_SavingsPlanMember_10CEA71099B8F7DE07F593582DBAA4F3_documentation_en-US" xlink:label="lab_biib_SavingsPlanMember_10CEA71099B8F7DE07F593582DBAA4F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Savings plan.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SavingsPlanMember" xlink:label="loc_biib_SavingsPlanMember_10CEA71099B8F7DE07F593582DBAA4F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SavingsPlanMember_10CEA71099B8F7DE07F593582DBAA4F3" xlink:to="lab_biib_SavingsPlanMember_10CEA71099B8F7DE07F593582DBAA4F3" xlink:type="arc" />
    <link:label id="lab_biib_DeferredCompensationPlanMember_1CCEB4031C08B6E21A7193582DBA9373_verboseLabel_en-US" xlink:label="lab_biib_DeferredCompensationPlanMember_1CCEB4031C08B6E21A7193582DBA9373" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred compensation plan [Member]</link:label>
    <link:label id="lab_biib_DeferredCompensationPlanMember_1CCEB4031C08B6E21A7193582DBA9373_label_en-US" xlink:label="lab_biib_DeferredCompensationPlanMember_1CCEB4031C08B6E21A7193582DBA9373" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Plan [Member]</link:label>
    <link:label id="lab_biib_DeferredCompensationPlanMember_1CCEB4031C08B6E21A7193582DBA9373_documentation_en-US" xlink:label="lab_biib_DeferredCompensationPlanMember_1CCEB4031C08B6E21A7193582DBA9373" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred compensation plan.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_DeferredCompensationPlanMember" xlink:label="loc_biib_DeferredCompensationPlanMember_1CCEB4031C08B6E21A7193582DBA9373" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredCompensationPlanMember_1CCEB4031C08B6E21A7193582DBA9373" xlink:to="lab_biib_DeferredCompensationPlanMember_1CCEB4031C08B6E21A7193582DBA9373" xlink:type="arc" />
    <link:label id="lab_biib_SwissplanMember_24CD85770BCA10B6692993582DBABFFC_terseLabel_en-US" xlink:label="lab_biib_SwissplanMember_24CD85770BCA10B6692993582DBABFFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss plan [Member]</link:label>
    <link:label id="lab_biib_SwissplanMember_24CD85770BCA10B6692993582DBABFFC_label_en-US" xlink:label="lab_biib_SwissplanMember_24CD85770BCA10B6692993582DBABFFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Swiss plan [Member]</link:label>
    <link:label id="lab_biib_SwissplanMember_24CD85770BCA10B6692993582DBABFFC_documentation_en-US" xlink:label="lab_biib_SwissplanMember_24CD85770BCA10B6692993582DBABFFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Swiss plan [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SwissplanMember" xlink:label="loc_biib_SwissplanMember_24CD85770BCA10B6692993582DBABFFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SwissplanMember_24CD85770BCA10B6692993582DBABFFC" xlink:to="lab_biib_SwissplanMember_24CD85770BCA10B6692993582DBABFFC" xlink:type="arc" />
    <link:label id="lab_biib_GermanPlanMember_DFED4B345FF92402935293582DBABF76_verboseLabel_en-US" xlink:label="lab_biib_GermanPlanMember_DFED4B345FF92402935293582DBABF76" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">German plan [Member]</link:label>
    <link:label id="lab_biib_GermanPlanMember_DFED4B345FF92402935293582DBABF76_label_en-US" xlink:label="lab_biib_GermanPlanMember_DFED4B345FF92402935293582DBABF76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">German Plan [Member]</link:label>
    <link:label id="lab_biib_GermanPlanMember_DFED4B345FF92402935293582DBABF76_documentation_en-US" xlink:label="lab_biib_GermanPlanMember_DFED4B345FF92402935293582DBABF76" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">German plan.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_GermanPlanMember" xlink:label="loc_biib_GermanPlanMember_DFED4B345FF92402935293582DBABF76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GermanPlanMember_DFED4B345FF92402935293582DBABF76" xlink:to="lab_biib_GermanPlanMember_DFED4B345FF92402935293582DBABF76" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_A16AB03A2A829C39D57F93582DBBCB7F_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_A16AB03A2A829C39D57F93582DBBCB7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_A16AB03A2A829C39D57F93582DBBCB7F_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_A16AB03A2A829C39D57F93582DBBCB7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A16AB03A2A829C39D57F93582DBBCB7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A16AB03A2A829C39D57F93582DBBCB7F" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_A16AB03A2A829C39D57F93582DBBCB7F" xlink:type="arc" />
    <link:label id="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_5000C4E6886F72532E8593582DBB65A2_terseLabel_en-US" xlink:label="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_5000C4E6886F72532E8593582DBB65A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum Qualifying Age For Employee Benefit Plan</link:label>
    <link:label id="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_5000C4E6886F72532E8593582DBB65A2_label_en-US" xlink:label="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_5000C4E6886F72532E8593582DBB65A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Qualifying Age For Employee Benefit Plan</link:label>
    <link:label id="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_5000C4E6886F72532E8593582DBB65A2_documentation_en-US" xlink:label="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_5000C4E6886F72532E8593582DBB65A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum qualifying age for employee benefit plan.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:label="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_5000C4E6886F72532E8593582DBB65A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_5000C4E6886F72532E8593582DBB65A2" xlink:to="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_5000C4E6886F72532E8593582DBB65A2" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC_verboseLabel_en-US" xlink:label="lab_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC_label_en-US" xlink:label="lab_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC_documentation_en-US" xlink:label="lab_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee benefit plans.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_EmployeeBenefitPlansTextualAbstract" xlink:label="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:to="lab_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_C4FB52C1B1F1E463BE5A93582DBB1CBA_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_C4FB52C1B1F1E463BE5A93582DBB1CBA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expenses related to savings plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_C4FB52C1B1F1E463BE5A93582DBB1CBA_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_C4FB52C1B1F1E463BE5A93582DBB1CBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_C4FB52C1B1F1E463BE5A93582DBB1CBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized_C4FB52C1B1F1E463BE5A93582DBB1CBA" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized_C4FB52C1B1F1E463BE5A93582DBB1CBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_287186BE44A245B4438B93582DBBF320_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_287186BE44A245B4438B93582DBBF320" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred compensation related to Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_287186BE44A245B4438B93582DBBF320_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_287186BE44A245B4438B93582DBBF320" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_287186BE44A245B4438B93582DBBF320" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_287186BE44A245B4438B93582DBBF320" xlink:to="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_287186BE44A245B4438B93582DBBF320" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfMinimumInvestmentReturn_6DE96913D428B52E056393582DBBF643_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfMinimumInvestmentReturn_6DE96913D428B52E056393582DBBF643" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of minimum investment return</link:label>
    <link:label id="lab_biib_PercentageOfMinimumInvestmentReturn_6DE96913D428B52E056393582DBBF643_label_en-US" xlink:label="lab_biib_PercentageOfMinimumInvestmentReturn_6DE96913D428B52E056393582DBBF643" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Minimum Investment Return</link:label>
    <link:label id="lab_biib_PercentageOfMinimumInvestmentReturn_6DE96913D428B52E056393582DBBF643_documentation_en-US" xlink:label="lab_biib_PercentageOfMinimumInvestmentReturn_6DE96913D428B52E056393582DBBF643" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of minimum investment return.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PercentageOfMinimumInvestmentReturn" xlink:label="loc_biib_PercentageOfMinimumInvestmentReturn_6DE96913D428B52E056393582DBBF643" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfMinimumInvestmentReturn_6DE96913D428B52E056393582DBBF643" xlink:to="lab_biib_PercentageOfMinimumInvestmentReturn_6DE96913D428B52E056393582DBBF643" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9710048810DB5A6A65CA93582DBB20E4_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9710048810DB5A6A65CA93582DBB20E4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unfunded net pension</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9710048810DB5A6A65CA93582DBB20E4_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9710048810DB5A6A65CA93582DBB20E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Funded Status of Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9710048810DB5A6A65CA93582DBB20E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9710048810DB5A6A65CA93582DBB20E4" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9710048810DB5A6A65CA93582DBB20E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_FACFAE28B6BFCC147B9493582DBBD6BC_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation_FACFAE28B6BFCC147B9493582DBBD6BC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_FACFAE28B6BFCC147B9493582DBBD6BC_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation_FACFAE28B6BFCC147B9493582DBBD6BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_FACFAE28B6BFCC147B9493582DBBD6BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation_FACFAE28B6BFCC147B9493582DBBD6BC" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation_FACFAE28B6BFCC147B9493582DBBD6BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionExpense_56ACAC55FE31D81D312D93582DBB2D3B_terseLabel_en-US" xlink:label="lab_us-gaap_PensionExpense_56ACAC55FE31D81D312D93582DBB2D3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Expense</link:label>
    <link:label id="lab_us-gaap_PensionExpense_56ACAC55FE31D81D312D93582DBB2D3B_label_en-US" xlink:label="lab_us-gaap_PensionExpense_56ACAC55FE31D81D312D93582DBB2D3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionExpense" xlink:label="loc_us-gaap_PensionExpense_56ACAC55FE31D81D312D93582DBB2D3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionExpense_56ACAC55FE31D81D312D93582DBB2D3B" xlink:to="lab_us-gaap_PensionExpense_56ACAC55FE31D81D312D93582DBB2D3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8CB8E5E71EA19683EDD693582DBB0AD2_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8CB8E5E71EA19683EDD693582DBB0AD2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Periodic pension cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8CB8E5E71EA19683EDD693582DBB0AD2_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8CB8E5E71EA19683EDD693582DBB0AD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8CB8E5E71EA19683EDD693582DBB0AD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8CB8E5E71EA19683EDD693582DBB0AD2" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8CB8E5E71EA19683EDD693582DBB0AD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:type="arc" />
    <link:label id="lab_biib_TysabriProductMember_3C18AE78F81848CE4FF693224CD5BB9D_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember_3C18AE78F81848CE4FF693224CD5BB9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI product</link:label>
    <link:label id="lab_biib_TysabriProductMember_3C18AE78F81848CE4FF693224CD5BB9D_label_en-US" xlink:label="lab_biib_TysabriProductMember_3C18AE78F81848CE4FF693224CD5BB9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_3C18AE78F81848CE4FF693224CD5BB9D_documentation_en-US" xlink:label="lab_biib_TysabriProductMember_3C18AE78F81848CE4FF693224CD5BB9D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_3C18AE78F81848CE4FF693224CD5BB9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember_3C18AE78F81848CE4FF693224CD5BB9D" xlink:to="lab_biib_TysabriProductMember_3C18AE78F81848CE4FF693224CD5BB9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_631D0E0BAEC2B363B14693224CD5D7F9_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_631D0E0BAEC2B363B14693224CD5D7F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_631D0E0BAEC2B363B14693224CD5D7F9_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_631D0E0BAEC2B363B14693224CD5D7F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_631D0E0BAEC2B363B14693224CD5D7F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_631D0E0BAEC2B363B14693224CD5D7F9" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_631D0E0BAEC2B363B14693224CD5D7F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBEA22071E45F6D0A56993224CD50159_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBEA22071E45F6D0A56993224CD50159" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBEA22071E45F6D0A56993224CD50159_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBEA22071E45F6D0A56993224CD50159" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBEA22071E45F6D0A56993224CD50159" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBEA22071E45F6D0A56993224CD50159" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBEA22071E45F6D0A56993224CD50159" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_EE3FBB42D063C2CAF29193224CD53EDC_verboseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_EE3FBB42D063C2CAF29193224CD53EDC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_EE3FBB42D063C2CAF29193224CD53EDC_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_EE3FBB42D063C2CAF29193224CD53EDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_EE3FBB42D063C2CAF29193224CD53EDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_EE3FBB42D063C2CAF29193224CD53EDC" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_EE3FBB42D063C2CAF29193224CD53EDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_F579532BF40DE32380B693224CDADD1B_verboseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_F579532BF40DE32380B693224CDADD1B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and trade names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_F579532BF40DE32380B693224CDADD1B_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_F579532BF40DE32380B693224CDADD1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_F579532BF40DE32380B693224CDADD1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember_F579532BF40DE32380B693224CDADD1B" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember_F579532BF40DE32380B693224CDADD1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A3EF29F06427E7FFB3F093224CDAA2AC_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A3EF29F06427E7FFB3F093224CDAA2AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A3EF29F06427E7FFB3F093224CDAA2AC_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A3EF29F06427E7FFB3F093224CDAA2AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A3EF29F06427E7FFB3F093224CDAA2AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A3EF29F06427E7FFB3F093224CDAA2AC" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A3EF29F06427E7FFB3F093224CDAA2AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448862C0974759741B993224CDA8DC8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448862C0974759741B993224CDA8DC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448862C0974759741B993224CDA8DC8_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448862C0974759741B993224CDA8DC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448862C0974759741B993224CDA8DC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448862C0974759741B993224CDA8DC8" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448862C0974759741B993224CDA8DC8" xlink:type="arc" />
    <link:label id="lab_biib_OutLicensedPatentsMember_029BDACC881DC6EEA47093224CDAD84A_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_029BDACC881DC6EEA47093224CDAD84A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Out-licensed patents</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_029BDACC881DC6EEA47093224CDAD84A_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_029BDACC881DC6EEA47093224CDAD84A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_029BDACC881DC6EEA47093224CDAD84A_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_029BDACC881DC6EEA47093224CDAD84A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_029BDACC881DC6EEA47093224CDAD84A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember_029BDACC881DC6EEA47093224CDAD84A" xlink:to="lab_biib_OutLicensedPatentsMember_029BDACC881DC6EEA47093224CDAD84A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_6253A9E80E7FC0196DD993224CDAB87C_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_6253A9E80E7FC0196DD993224CDAB87C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_6253A9E80E7FC0196DD993224CDAB87C_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_6253A9E80E7FC0196DD993224CDAB87C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_6253A9E80E7FC0196DD993224CDAB87C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember_6253A9E80E7FC0196DD993224CDAB87C" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember_6253A9E80E7FC0196DD993224CDAB87C" xlink:type="arc" />
    <link:label id="lab_biib_InLicensedPatentsMember_541EEB822EE2F808604893224CDA2BFB_terseLabel_en-US" xlink:label="lab_biib_InLicensedPatentsMember_541EEB822EE2F808604893224CDA2BFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_541EEB822EE2F808604893224CDA2BFB_label_en-US" xlink:label="lab_biib_InLicensedPatentsMember_541EEB822EE2F808604893224CDA2BFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_541EEB822EE2F808604893224CDA2BFB_documentation_en-US" xlink:label="lab_biib_InLicensedPatentsMember_541EEB822EE2F808604893224CDA2BFB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-licensed patents.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_541EEB822EE2F808604893224CDA2BFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InLicensedPatentsMember_541EEB822EE2F808604893224CDA2BFB" xlink:to="lab_biib_InLicensedPatentsMember_541EEB822EE2F808604893224CDA2BFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6AAA18418CECF4AC42FE93224CDB60C5_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6AAA18418CECF4AC42FE93224CDB60C5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated life, (In Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6AAA18418CECF4AC42FE93224CDB60C5_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6AAA18418CECF4AC42FE93224CDB60C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6AAA18418CECF4AC42FE93224CDB60C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6AAA18418CECF4AC42FE93224CDB60C5" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6AAA18418CECF4AC42FE93224CDB60C5" xlink:type="arc" />
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EE6B94DAA428326B583493224CDB4832_terseLabel_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EE6B94DAA428326B583493224CDB4832" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EE6B94DAA428326B583493224CDB4832_label_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EE6B94DAA428326B583493224CDB4832" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite Lived Intangible Assets Useful Life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EE6B94DAA428326B583493224CDB4832_documentation_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EE6B94DAA428326B583493224CDB4832" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EE6B94DAA428326B583493224CDB4832" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EE6B94DAA428326B583493224CDB4832" xlink:to="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EE6B94DAA428326B583493224CDB4832" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_67E1D80199CD61F45DDE93224CDBD485_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_67E1D80199CD61F45DDE93224CDBD485" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_67E1D80199CD61F45DDE93224CDBD485_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_67E1D80199CD61F45DDE93224CDBD485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_67E1D80199CD61F45DDE93224CDBD485" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_67E1D80199CD61F45DDE93224CDBD485" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_67E1D80199CD61F45DDE93224CDBD485" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_580BAF5F95D2553B699E93224CDB2C1D_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_580BAF5F95D2553B699E93224CDB2C1D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_580BAF5F95D2553B699E93224CDB2C1D_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_580BAF5F95D2553B699E93224CDB2C1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_580BAF5F95D2553B699E93224CDB2C1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_580BAF5F95D2553B699E93224CDB2C1D" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_580BAF5F95D2553B699E93224CDB2C1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FE91F4D170521E3001BE93224CDB46F5_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FE91F4D170521E3001BE93224CDB46F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FE91F4D170521E3001BE93224CDB46F5_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FE91F4D170521E3001BE93224CDB46F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FE91F4D170521E3001BE93224CDB46F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FE91F4D170521E3001BE93224CDB46F5" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FE91F4D170521E3001BE93224CDB46F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_62401F5858547C75BE6993224CDBEEA6_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_62401F5858547C75BE6993224CDBEEA6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_62401F5858547C75BE6993224CDBEEA6_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_62401F5858547C75BE6993224CDBEEA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_62401F5858547C75BE6993224CDBEEA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_62401F5858547C75BE6993224CDBEEA6" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_62401F5858547C75BE6993224CDBEEA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7FDBD5F4A46A832C49B293224CDB6FBC_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7FDBD5F4A46A832C49B293224CDB6FBC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7FDBD5F4A46A832C49B293224CDB6FBC_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7FDBD5F4A46A832C49B293224CDB6FBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7FDBD5F4A46A832C49B293224CDB6FBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7FDBD5F4A46A832C49B293224CDB6FBC" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7FDBD5F4A46A832C49B293224CDB6FBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9447849594F2FEFEB52A93224CDB0E46_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9447849594F2FEFEB52A93224CDB0E46" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9447849594F2FEFEB52A93224CDB0E46_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9447849594F2FEFEB52A93224CDB0E46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9447849594F2FEFEB52A93224CDB0E46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9447849594F2FEFEB52A93224CDB0E46" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9447849594F2FEFEB52A93224CDB0E46" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill (Additional Textual)</link:label>
    <link:label id="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5_label_en-US" xlink:label="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets And Goodwill (Additional Textual) [Abstract]</link:label>
    <link:label id="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill additional.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" xlink:label="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:to="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C23F119A34CE854FFD0893224CDB2BEB_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C23F119A34CE854FFD0893224CDB2BEB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2016</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C23F119A34CE854FFD0893224CDB2BEB_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C23F119A34CE854FFD0893224CDB2BEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C23F119A34CE854FFD0893224CDB2BEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C23F119A34CE854FFD0893224CDB2BEB" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C23F119A34CE854FFD0893224CDB2BEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0BF8322266308215EE8593224CDBDCC2_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0BF8322266308215EE8593224CDBDCC2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2017</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0BF8322266308215EE8593224CDBDCC2_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0BF8322266308215EE8593224CDBDCC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0BF8322266308215EE8593224CDBDCC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0BF8322266308215EE8593224CDBDCC2" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0BF8322266308215EE8593224CDBDCC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3803DBFEB22501377C4C93224CDC7239_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3803DBFEB22501377C4C93224CDC7239" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2018</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3803DBFEB22501377C4C93224CDC7239_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3803DBFEB22501377C4C93224CDC7239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3803DBFEB22501377C4C93224CDC7239" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3803DBFEB22501377C4C93224CDC7239" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3803DBFEB22501377C4C93224CDC7239" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_39EF1AE3183A43A1795293224CDCB194_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_39EF1AE3183A43A1795293224CDCB194" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2019</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_39EF1AE3183A43A1795293224CDCB194_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_39EF1AE3183A43A1795293224CDCB194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_39EF1AE3183A43A1795293224CDCB194" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_39EF1AE3183A43A1795293224CDCB194" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_39EF1AE3183A43A1795293224CDCB194" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_D4C188C6827958A0554693224CDC1327_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_D4C188C6827958A0554693224CDC1327" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_D4C188C6827958A0554693224CDC1327_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_D4C188C6827958A0554693224CDC1327" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_D4C188C6827958A0554693224CDC1327" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_D4C188C6827958A0554693224CDC1327" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_D4C188C6827958A0554693224CDC1327" xlink:type="arc" />
    <link:label id="lab_biib_Finitelivedintangibleassetsfutureamortization_1CE2EFA9D1B450CBAFA793224CDC9A14_terseLabel_en-US" xlink:label="lab_biib_Finitelivedintangibleassetsfutureamortization_1CE2EFA9D1B450CBAFA793224CDC9A14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FiniteLivedIntangibleAssetsFutureAmortization</link:label>
    <link:label id="lab_biib_Finitelivedintangibleassetsfutureamortization_1CE2EFA9D1B450CBAFA793224CDC9A14_label_en-US" xlink:label="lab_biib_Finitelivedintangibleassetsfutureamortization_1CE2EFA9D1B450CBAFA793224CDC9A14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FiniteLivedIntangibleAssetsFutureAmortization</link:label>
    <link:label id="lab_biib_Finitelivedintangibleassetsfutureamortization_1CE2EFA9D1B450CBAFA793224CDC9A14_documentation_en-US" xlink:label="lab_biib_Finitelivedintangibleassetsfutureamortization_1CE2EFA9D1B450CBAFA793224CDC9A14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FiniteLivedIntangibleAssetsFutureAmortization</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_Finitelivedintangibleassetsfutureamortization" xlink:label="loc_biib_Finitelivedintangibleassetsfutureamortization_1CE2EFA9D1B450CBAFA793224CDC9A14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Finitelivedintangibleassetsfutureamortization_1CE2EFA9D1B450CBAFA793224CDC9A14" xlink:to="lab_biib_Finitelivedintangibleassetsfutureamortization_1CE2EFA9D1B450CBAFA793224CDC9A14" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9F7308450AECCEBFC24C93224CDCB2C2_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9F7308450AECCEBFC24C93224CDCB2C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of out-licensed patent</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9F7308450AECCEBFC24C93224CDCB2C2_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9F7308450AECCEBFC24C93224CDCB2C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9F7308450AECCEBFC24C93224CDCB2C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9F7308450AECCEBFC24C93224CDCB2C2" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9F7308450AECCEBFC24C93224CDCB2C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_73600D0315A83E03C4F193224CDC9F24_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_73600D0315A83E03C4F193224CDC9F24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of in-process research and development asset</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_73600D0315A83E03C4F193224CDC9F24_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_73600D0315A83E03C4F193224CDC9F24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_73600D0315A83E03C4F193224CDC9F24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_73600D0315A83E03C4F193224CDC9F24" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_73600D0315A83E03C4F193224CDC9F24" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrencyAxis_34E4B5A01D850AE75F9493582EDEC52D_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencyAxis_34E4B5A01D850AE75F9493582EDEC52D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_us-gaap_CurrencyAxis_34E4B5A01D850AE75F9493582EDEC52D_label_en-US" xlink:label="lab_us-gaap_CurrencyAxis_34E4B5A01D850AE75F9493582EDEC52D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_34E4B5A01D850AE75F9493582EDEC52D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencyAxis_34E4B5A01D850AE75F9493582EDEC52D" xlink:to="lab_us-gaap_CurrencyAxis_34E4B5A01D850AE75F9493582EDEC52D" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:to="lab_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:type="arc" />
    <link:label id="lab_currency_EUR_612C5E3C929BEF4D334E93582EDEC642_verboseLabel_en-US" xlink:label="lab_currency_EUR_612C5E3C929BEF4D334E93582EDEC642" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_612C5E3C929BEF4D334E93582EDEC642_label_en-US" xlink:label="lab_currency_EUR_612C5E3C929BEF4D334E93582EDEC642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_612C5E3C929BEF4D334E93582EDEC642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_612C5E3C929BEF4D334E93582EDEC642" xlink:to="lab_currency_EUR_612C5E3C929BEF4D334E93582EDEC642" xlink:type="arc" />
    <link:label id="lab_currency_CHF_5EF1605A2DA90172BADB935EC0DFE4FF_terseLabel_en-US" xlink:label="lab_currency_CHF_5EF1605A2DA90172BADB935EC0DFE4FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss francs</link:label>
    <link:label id="lab_currency_CHF_5EF1605A2DA90172BADB935EC0DFE4FF_label_en-US" xlink:label="lab_currency_CHF_5EF1605A2DA90172BADB935EC0DFE4FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_5EF1605A2DA90172BADB935EC0DFE4FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF_5EF1605A2DA90172BADB935EC0DFE4FF" xlink:to="lab_currency_CHF_5EF1605A2DA90172BADB935EC0DFE4FF" xlink:type="arc" />
    <link:label id="lab_currency_CAD_78095A2F2D20A72CCD5793582EDF0AE0_verboseLabel_en-US" xlink:label="lab_currency_CAD_78095A2F2D20A72CCD5793582EDF0AE0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_78095A2F2D20A72CCD5793582EDF0AE0_label_en-US" xlink:label="lab_currency_CAD_78095A2F2D20A72CCD5793582EDF0AE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_78095A2F2D20A72CCD5793582EDF0AE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD_78095A2F2D20A72CCD5793582EDF0AE0" xlink:to="lab_currency_CAD_78095A2F2D20A72CCD5793582EDF0AE0" xlink:type="arc" />
    <link:label id="lab_currency_GBP_E07E6C181EF3F8FADBD593582EDF7E4F_terseLabel_en-US" xlink:label="lab_currency_GBP_E07E6C181EF3F8FADBD593582EDF7E4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">British pound sterling</link:label>
    <link:label id="lab_currency_GBP_E07E6C181EF3F8FADBD593582EDF7E4F_label_en-US" xlink:label="lab_currency_GBP_E07E6C181EF3F8FADBD593582EDF7E4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_E07E6C181EF3F8FADBD593582EDF7E4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP_E07E6C181EF3F8FADBD593582EDF7E4F" xlink:to="lab_currency_GBP_E07E6C181EF3F8FADBD593582EDF7E4F" xlink:type="arc" />
    <link:label id="lab_currency_AUD_6C55CFF9B350EFAF89DD93582EDF343F_terseLabel_en-US" xlink:label="lab_currency_AUD_6C55CFF9B350EFAF89DD93582EDF343F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Australian dollar</link:label>
    <link:label id="lab_currency_AUD_6C55CFF9B350EFAF89DD93582EDF343F_label_en-US" xlink:label="lab_currency_AUD_6C55CFF9B350EFAF89DD93582EDF343F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Australia, Dollars</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AUD" xlink:label="loc_currency_AUD_6C55CFF9B350EFAF89DD93582EDF343F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AUD_6C55CFF9B350EFAF89DD93582EDF343F" xlink:to="lab_currency_AUD_6C55CFF9B350EFAF89DD93582EDF343F" xlink:type="arc" />
    <link:label id="lab_currency_JPY_071D806A25A2A7139E0393582EDFEDAA_terseLabel_en-US" xlink:label="lab_currency_JPY_071D806A25A2A7139E0393582EDFEDAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japanese yen</link:label>
    <link:label id="lab_currency_JPY_071D806A25A2A7139E0393582EDFEDAA_label_en-US" xlink:label="lab_currency_JPY_071D806A25A2A7139E0393582EDFEDAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_071D806A25A2A7139E0393582EDFEDAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY_071D806A25A2A7139E0393582EDFEDAA" xlink:to="lab_currency_JPY_071D806A25A2A7139E0393582EDFEDAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_1200A372C26E388D187F93582EDF1456_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_1200A372C26E388D187F93582EDF1456" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_1200A372C26E388D187F93582EDF1456_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_1200A372C26E388D187F93582EDF1456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1200A372C26E388D187F93582EDF1456" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1200A372C26E388D187F93582EDF1456" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_1200A372C26E388D187F93582EDF1456" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_B7C1AC47A03184B37ECD93582EDFCF64_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_B7C1AC47A03184B37ECD93582EDFCF64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_B7C1AC47A03184B37ECD93582EDFCF64_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_B7C1AC47A03184B37ECD93582EDFCF64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_B7C1AC47A03184B37ECD93582EDFCF64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_B7C1AC47A03184B37ECD93582EDFCF64" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_B7C1AC47A03184B37ECD93582EDFCF64" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherInvestmentsMember_89342B8C8348CA322A2793582EDF6256_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_89342B8C8348CA322A2793582EDF6256" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_89342B8C8348CA322A2793582EDF6256_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_89342B8C8348CA322A2793582EDF6256" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_89342B8C8348CA322A2793582EDF6256" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember_89342B8C8348CA322A2793582EDF6256" xlink:to="lab_us-gaap_OtherInvestmentsMember_89342B8C8348CA322A2793582EDF6256" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_C06494185A7F5FCBC6D793582EDFF51C_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_C06494185A7F5FCBC6D793582EDFF51C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_C06494185A7F5FCBC6D793582EDFF51C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_C06494185A7F5FCBC6D793582EDFF51C" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_C06494185A7F5FCBC6D793582EDFF51C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_BA0D55B3BD94999B81A893582EE0EAE5_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_BA0D55B3BD94999B81A893582EE0EAE5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of derivatives designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_BA0D55B3BD94999B81A893582EE0EAE5_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_BA0D55B3BD94999B81A893582EE0EAE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Amount Not Offset Against Collateral [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_BA0D55B3BD94999B81A893582EE0EAE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_BA0D55B3BD94999B81A893582EE0EAE5" xlink:to="lab_us-gaap_DerivativeAssetFairValueNetAbstract_BA0D55B3BD94999B81A893582EE0EAE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_E3C988842006D5EC77CF93582EE04BF1_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_E3C988842006D5EC77CF93582EE04BF1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Asset derivatives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_E3C988842006D5EC77CF93582EE04BF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_E3C988842006D5EC77CF93582EE04BF1" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_E3C988842006D5EC77CF93582EE04BF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_471E4D3FF4D07150885593582EE0ACCC_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_471E4D3FF4D07150885593582EE0ACCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_471E4D3FF4D07150885593582EE0ACCC_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_471E4D3FF4D07150885593582EE0ACCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_471E4D3FF4D07150885593582EE0ACCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_471E4D3FF4D07150885593582EE0ACCC" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_471E4D3FF4D07150885593582EE0ACCC" xlink:type="arc" />
    <link:label id="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_82723F04026CA76799F438A3559C8E9D_verboseLabel_en-US" xlink:label="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_82723F04026CA76799F438A3559C8E9D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Marketable Debt Securities</link:label>
    <link:label id="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_82723F04026CA76799F438A3559C8E9D_label_en-US" xlink:label="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_82723F04026CA76799F438A3559C8E9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Marketable Debt Securities [Abstract]</link:label>
    <link:label id="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_82723F04026CA76799F438A3559C8E9D_documentation_en-US" xlink:label="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_82723F04026CA76799F438A3559C8E9D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from marketable debt securities.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ProceedsFromMarketableDebtSecuritiesAbstract" xlink:label="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_82723F04026CA76799F438A3559C8E9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_82723F04026CA76799F438A3559C8E9D" xlink:to="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_82723F04026CA76799F438A3559C8E9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B77162956A3CBFE0E7C338A3559CC730_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B77162956A3CBFE0E7C338A3559CC730" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B77162956A3CBFE0E7C338A3559CC730_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B77162956A3CBFE0E7C338A3559CC730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B77162956A3CBFE0E7C338A3559CC730" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B77162956A3CBFE0E7C338A3559CC730" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B77162956A3CBFE0E7C338A3559CC730" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_83E1F4A4E85BB302C8A338A3559CC6C7_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_83E1F4A4E85BB302C8A338A3559CC6C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_83E1F4A4E85BB302C8A338A3559CC6C7_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_83E1F4A4E85BB302C8A338A3559CC6C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Gains</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_83E1F4A4E85BB302C8A338A3559CC6C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_83E1F4A4E85BB302C8A338A3559CC6C7" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_83E1F4A4E85BB302C8A338A3559CC6C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_E8550B69D6ABF5BDFA5A38A3559C362A_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_E8550B69D6ABF5BDFA5A38A3559C362A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_E8550B69D6ABF5BDFA5A38A3559C362A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_E8550B69D6ABF5BDFA5A38A3559C362A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_E8550B69D6ABF5BDFA5A38A3559C362A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_E8550B69D6ABF5BDFA5A38A3559C362A" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_E8550B69D6ABF5BDFA5A38A3559C362A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_36E61ABCE67E4925BCF293224C0627A6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_36E61ABCE67E4925BCF293224C0627A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_36E61ABCE67E4925BCF293224C0627A6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_36E61ABCE67E4925BCF293224C0627A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_36E61ABCE67E4925BCF293224C0627A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_36E61ABCE67E4925BCF293224C0627A6" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_36E61ABCE67E4925BCF293224C0627A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_D1C96879004D120A41FE93224C06599E_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_D1C96879004D120A41FE93224C06599E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_D1C96879004D120A41FE93224C06599E_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_D1C96879004D120A41FE93224C06599E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_D1C96879004D120A41FE93224C06599E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_D1C96879004D120A41FE93224C06599E" xlink:to="lab_us-gaap_InvestmentTypeAxis_D1C96879004D120A41FE93224C06599E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_FB6ADD8CC68CBD351F4593224C0B7A70_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_FB6ADD8CC68CBD351F4593224C0B7A70" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_FB6ADD8CC68CBD351F4593224C0B7A70_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_FB6ADD8CC68CBD351F4593224C0B7A70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_FB6ADD8CC68CBD351F4593224C0B7A70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_FB6ADD8CC68CBD351F4593224C0B7A70" xlink:to="lab_us-gaap_CommercialPaperMember_FB6ADD8CC68CBD351F4593224C0B7A70" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_38931A31A77E907C2C0993224C0B2699_verboseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_38931A31A77E907C2C0993224C0B2699" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overnight Reverse Repurchase Agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_38931A31A77E907C2C0993224C0B2699_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_38931A31A77E907C2C0993224C0B2699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_38931A31A77E907C2C0993224C0B2699" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember_38931A31A77E907C2C0993224C0B2699" xlink:to="lab_us-gaap_RepurchaseAgreementsMember_38931A31A77E907C2C0993224C0B2699" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_AA07445EBD9ED8B52AA693224C0BD230_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_AA07445EBD9ED8B52AA693224C0BD230" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_AA07445EBD9ED8B52AA693224C0BD230_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_AA07445EBD9ED8B52AA693224C0BD230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_AA07445EBD9ED8B52AA693224C0BD230" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_AA07445EBD9ED8B52AA693224C0BD230" xlink:to="lab_us-gaap_MoneyMarketFundsMember_AA07445EBD9ED8B52AA693224C0BD230" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesMember_6476AC24DF8547A4DD6693224C0BB051_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_6476AC24DF8547A4DD6693224C0BB051" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_6476AC24DF8547A4DD6693224C0BB051_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_6476AC24DF8547A4DD6693224C0BB051" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_6476AC24DF8547A4DD6693224C0BB051" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember_6476AC24DF8547A4DD6693224C0BB051" xlink:to="lab_us-gaap_DebtSecuritiesMember_6476AC24DF8547A4DD6693224C0BB051" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_50DD7BB047E4D5B9B12693224C0B772D_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_50DD7BB047E4D5B9B12693224C0B772D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_50DD7BB047E4D5B9B12693224C0B772D_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_50DD7BB047E4D5B9B12693224C0B772D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_50DD7BB047E4D5B9B12693224C0B772D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_50DD7BB047E4D5B9B12693224C0B772D" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_50DD7BB047E4D5B9B12693224C0B772D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_63BF7DA00FA8964CBBB893224C0B33E0_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_63BF7DA00FA8964CBBB893224C0B33E0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_63BF7DA00FA8964CBBB893224C0B33E0_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_63BF7DA00FA8964CBBB893224C0B33E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_63BF7DA00FA8964CBBB893224C0B33E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_63BF7DA00FA8964CBBB893224C0B33E0" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_63BF7DA00FA8964CBBB893224C0B33E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_EC9F04072C2FDE4678D193224C0B82E7_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_EC9F04072C2FDE4678D193224C0B82E7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_EC9F04072C2FDE4678D193224C0B82E7_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_EC9F04072C2FDE4678D193224C0B82E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_EC9F04072C2FDE4678D193224C0B82E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_EC9F04072C2FDE4678D193224C0B82E7" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_EC9F04072C2FDE4678D193224C0B82E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_D62D6EECD38B98DB398D38A351C33F43_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_D62D6EECD38B98DB398D38A351C33F43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_D62D6EECD38B98DB398D38A351C33F43_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_D62D6EECD38B98DB398D38A351C33F43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D62D6EECD38B98DB398D38A351C33F43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_D62D6EECD38B98DB398D38A351C33F43" xlink:to="lab_us-gaap_PlanNameAxis_D62D6EECD38B98DB398D38A351C33F43" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:to="lab_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5FB678B51102E88068F138A351C43F1A_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_5FB678B51102E88068F138A351C43F1A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5FB678B51102E88068F138A351C43F1A_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_5FB678B51102E88068F138A351C43F1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5FB678B51102E88068F138A351C43F1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_5FB678B51102E88068F138A351C43F1A" xlink:to="lab_us-gaap_EmployeeStockOptionMember_5FB678B51102E88068F138A351C43F1A" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_9B089081790B1CE751F338A351C4E383_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_9B089081790B1CE751F338A351C4E383" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance units</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_9B089081790B1CE751F338A351C4E383_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_9B089081790B1CE751F338A351C4E383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_9B089081790B1CE751F338A351C4E383_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_9B089081790B1CE751F338A351C4E383" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_9B089081790B1CE751F338A351C4E383" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember_9B089081790B1CE751F338A351C4E383" xlink:to="lab_biib_CashSettledPerformanceSharesMember_9B089081790B1CE751F338A351C4E383" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_3708315C2599A53C59E338A351C41D8D_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_3708315C2599A53C59E338A351C41D8D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_3708315C2599A53C59E338A351C41D8D_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_3708315C2599A53C59E338A351C41D8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_3708315C2599A53C59E338A351C41D8D_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_3708315C2599A53C59E338A351C41D8D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_3708315C2599A53C59E338A351C41D8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember_3708315C2599A53C59E338A351C41D8D" xlink:to="lab_biib_EmployeeStockPurchasePlanMember_3708315C2599A53C59E338A351C41D8D" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7223C27190003AE1DAE138A351C40567_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_7223C27190003AE1DAE138A351C40567" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7223C27190003AE1DAE138A351C40567" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_7223C27190003AE1DAE138A351C40567" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_7223C27190003AE1DAE138A351C40567" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1541A7E48B0D186FA5EA38A351C42A33_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1541A7E48B0D186FA5EA38A351C42A33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1541A7E48B0D186FA5EA38A351C42A33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1541A7E48B0D186FA5EA38A351C42A33" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1541A7E48B0D186FA5EA38A351C42A33" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_34187F5CBC964022305F38A3532ADDB5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_34187F5CBC964022305F38A3532ADDB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before income tax provision and the income tax expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_34187F5CBC964022305F38A3532ADDB5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_34187F5CBC964022305F38A3532ADDB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_34187F5CBC964022305F38A3532ADDB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_34187F5CBC964022305F38A3532ADDB5" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_34187F5CBC964022305F38A3532ADDB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7BC52D96E8D8FB975A0C38A3532ABB50_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7BC52D96E8D8FB975A0C38A3532ABB50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7BC52D96E8D8FB975A0C38A3532ABB50_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7BC52D96E8D8FB975A0C38A3532ABB50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7BC52D96E8D8FB975A0C38A3532ABB50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7BC52D96E8D8FB975A0C38A3532ABB50" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7BC52D96E8D8FB975A0C38A3532ABB50" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E50EBA0223105569169938A3532AC416_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E50EBA0223105569169938A3532AC416" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E50EBA0223105569169938A3532AC416_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E50EBA0223105569169938A3532AC416" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E50EBA0223105569169938A3532AC416" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E50EBA0223105569169938A3532AC416" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E50EBA0223105569169938A3532AC416" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_E50D04939079CE96C4A438A3532A27D9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_E50D04939079CE96C4A438A3532A27D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of beginning and ending amount of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_E50D04939079CE96C4A438A3532A27D9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_E50D04939079CE96C4A438A3532A27D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_E50D04939079CE96C4A438A3532A27D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_E50D04939079CE96C4A438A3532A27D9" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_E50D04939079CE96C4A438A3532A27D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_018B74EFB64F37D4459493582E3E18A5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_018B74EFB64F37D4459493582E3E18A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_018B74EFB64F37D4459493582E3E18A5_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_018B74EFB64F37D4459493582E3E18A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_018B74EFB64F37D4459493582E3E18A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_018B74EFB64F37D4459493582E3E18A5" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_018B74EFB64F37D4459493582E3E18A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_7BDBBFC108ADE200428F93582E3EC1B6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory_7BDBBFC108ADE200428F93582E3EC1B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, other reserves, and accruals</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_7BDBBFC108ADE200428F93582E3EC1B6_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory_7BDBBFC108ADE200428F93582E3EC1B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_7BDBBFC108ADE200428F93582E3EC1B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory_7BDBBFC108ADE200428F93582E3EC1B6" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory_7BDBBFC108ADE200428F93582E3EC1B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_23CD29C92C42AB11E7E293582E3E553F_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_23CD29C92C42AB11E7E293582E3E553F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_23CD29C92C42AB11E7E293582E3E553F_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_23CD29C92C42AB11E7E293582E3E553F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_23CD29C92C42AB11E7E293582E3E553F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_23CD29C92C42AB11E7E293582E3E553F" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_23CD29C92C42AB11E7E293582E3E553F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_37B7387852F12BF33DB093582E3E9B02_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_37B7387852F12BF33DB093582E3E9B02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_37B7387852F12BF33DB093582E3E9B02_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_37B7387852F12BF33DB093582E3E9B02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_37B7387852F12BF33DB093582E3E9B02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_37B7387852F12BF33DB093582E3E9B02" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_37B7387852F12BF33DB093582E3E9B02" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7D0419C1BBA276180BFF93582E3E7C2C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7D0419C1BBA276180BFF93582E3E7C2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7D0419C1BBA276180BFF93582E3E7C2C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7D0419C1BBA276180BFF93582E3E7C2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7D0419C1BBA276180BFF93582E3E7C2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7D0419C1BBA276180BFF93582E3E7C2C" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7D0419C1BBA276180BFF93582E3E7C2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_3B8BAE78F21F8F9E0B0393582E3FDD3D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_3B8BAE78F21F8F9E0B0393582E3FDD3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_3B8BAE78F21F8F9E0B0393582E3FDD3D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_3B8BAE78F21F8F9E0B0393582E3FDD3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3B8BAE78F21F8F9E0B0393582E3FDD3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_3B8BAE78F21F8F9E0B0393582E3FDD3D" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_3B8BAE78F21F8F9E0B0393582E3FDD3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5548D027B1E5A76B388593582E3F98C1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5548D027B1E5A76B388593582E3F98C1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5548D027B1E5A76B388593582E3F98C1_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5548D027B1E5A76B388593582E3F98C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5548D027B1E5A76B388593582E3F98C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5548D027B1E5A76B388593582E3F98C1" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5548D027B1E5A76B388593582E3F98C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_42B59245F83957EEB15993582E3F411F_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_42B59245F83957EEB15993582E3F411F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_42B59245F83957EEB15993582E3F411F_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_42B59245F83957EEB15993582E3F411F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_42B59245F83957EEB15993582E3F411F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_42B59245F83957EEB15993582E3F411F" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_42B59245F83957EEB15993582E3F411F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9E53C289CD853F1FB96093582E3FE98D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9E53C289CD853F1FB96093582E3FE98D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9E53C289CD853F1FB96093582E3FE98D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9E53C289CD853F1FB96093582E3FE98D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9E53C289CD853F1FB96093582E3FE98D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9E53C289CD853F1FB96093582E3FE98D" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9E53C289CD853F1FB96093582E3FE98D" xlink:type="arc" />
    <link:label id="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_1CD75B86169DA9CD7DD393582E3F2D89_negatedTerseLabel_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_1CD75B86169DA9CD7DD393582E3F2D89" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and other</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_1CD75B86169DA9CD7DD393582E3F2D89_label_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_1CD75B86169DA9CD7DD393582E3F2D89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities Depreciation Amortization Other</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_1CD75B86169DA9CD7DD393582E3F2D89_documentation_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_1CD75B86169DA9CD7DD393582E3F2D89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities depreciation amortization other.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:label="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_1CD75B86169DA9CD7DD393582E3F2D89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_1CD75B86169DA9CD7DD393582E3F2D89" xlink:to="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_1CD75B86169DA9CD7DD393582E3F2D89" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_082127298C323BC8258C93582E3F1CC8_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_082127298C323BC8258C93582E3F1CC8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_082127298C323BC8258C93582E3F1CC8_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_082127298C323BC8258C93582E3F1CC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_082127298C323BC8258C93582E3F1CC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_082127298C323BC8258C93582E3F1CC8" xlink:to="lab_us-gaap_DeferredTaxLiabilities_082127298C323BC8258C93582E3F1CC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_6BCB731984D2BCCFD03A38A3535C2029_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_6BCB731984D2BCCFD03A38A3535C2029" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_6BCB731984D2BCCFD03A38A3535C2029_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_6BCB731984D2BCCFD03A38A3535C2029" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_6BCB731984D2BCCFD03A38A3535C2029" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_6BCB731984D2BCCFD03A38A3535C2029" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_6BCB731984D2BCCFD03A38A3535C2029" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1471D4BB1A7C87F1021838A3535CF9C7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1471D4BB1A7C87F1021838A3535CF9C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes (benefit):</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1471D4BB1A7C87F1021838A3535CF9C7_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1471D4BB1A7C87F1021838A3535CF9C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1471D4BB1A7C87F1021838A3535CF9C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1471D4BB1A7C87F1021838A3535CF9C7" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1471D4BB1A7C87F1021838A3535CF9C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5F030EA4BE1A7601759A38A3535C796D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5F030EA4BE1A7601759A38A3535C796D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5F030EA4BE1A7601759A38A3535C796D_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5F030EA4BE1A7601759A38A3535C796D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5F030EA4BE1A7601759A38A3535C796D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5F030EA4BE1A7601759A38A3535C796D" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5F030EA4BE1A7601759A38A3535C796D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_FD730E58320F97B3154038A3535C59CF_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_FD730E58320F97B3154038A3535C59CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_FD730E58320F97B3154038A3535C59CF_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_FD730E58320F97B3154038A3535C59CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_FD730E58320F97B3154038A3535C59CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_FD730E58320F97B3154038A3535C59CF" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_FD730E58320F97B3154038A3535C59CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_B8379CB2EE878FC46B4C38A3535C1318_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_B8379CB2EE878FC46B4C38A3535C1318" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit):</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_B8379CB2EE878FC46B4C38A3535C1318_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_B8379CB2EE878FC46B4C38A3535C1318" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_B8379CB2EE878FC46B4C38A3535C1318" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_B8379CB2EE878FC46B4C38A3535C1318" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_B8379CB2EE878FC46B4C38A3535C1318" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_38CBD550C84D00F7F1F838A3535C78B3_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_38CBD550C84D00F7F1F838A3535C78B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_38CBD550C84D00F7F1F838A3535C78B3_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_38CBD550C84D00F7F1F838A3535C78B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_38CBD550C84D00F7F1F838A3535C78B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_38CBD550C84D00F7F1F838A3535C78B3" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_38CBD550C84D00F7F1F838A3535C78B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_9221D17A9F54FFE355AA38A3535C3C04_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_9221D17A9F54FFE355AA38A3535C3C04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_9221D17A9F54FFE355AA38A3535C3C04_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_9221D17A9F54FFE355AA38A3535C3C04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_9221D17A9F54FFE355AA38A3535C3C04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_9221D17A9F54FFE355AA38A3535C3C04" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_9221D17A9F54FFE355AA38A3535C3C04" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_691EC02E4D948D49CE7E38A3535C8588_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_691EC02E4D948D49CE7E38A3535C8588" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_691EC02E4D948D49CE7E38A3535C8588_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_691EC02E4D948D49CE7E38A3535C8588" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_691EC02E4D948D49CE7E38A3535C8588" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_691EC02E4D948D49CE7E38A3535C8588" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_691EC02E4D948D49CE7E38A3535C8588" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_B1871714E69B944A140C38A3535CC99E_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_B1871714E69B944A140C38A3535CC99E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_B1871714E69B944A140C38A3535CC99E_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_B1871714E69B944A140C38A3535CC99E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_B1871714E69B944A140C38A3535CC99E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit_B1871714E69B944A140C38A3535CC99E" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit_B1871714E69B944A140C38A3535CC99E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_2E24F8F6D1798AD5408D38A3535C2ADA_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_2E24F8F6D1798AD5408D38A3535C2ADA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_2E24F8F6D1798AD5408D38A3535C2ADA_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_2E24F8F6D1798AD5408D38A3535C2ADA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2E24F8F6D1798AD5408D38A3535C2ADA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2E24F8F6D1798AD5408D38A3535C2ADA" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_2E24F8F6D1798AD5408D38A3535C2ADA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_384FD5E7F55CCC660D9938A3535C7280_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_384FD5E7F55CCC660D9938A3535C7280" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_384FD5E7F55CCC660D9938A3535C7280_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_384FD5E7F55CCC660D9938A3535C7280" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_384FD5E7F55CCC660D9938A3535C7280" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_384FD5E7F55CCC660D9938A3535C7280" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_384FD5E7F55CCC660D9938A3535C7280" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2815B96E2BDACB7C2F6B38A3535CD9D7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2815B96E2BDACB7C2F6B38A3535CD9D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2815B96E2BDACB7C2F6B38A3535CD9D7_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2815B96E2BDACB7C2F6B38A3535CD9D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2815B96E2BDACB7C2F6B38A3535CD9D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2815B96E2BDACB7C2F6B38A3535CD9D7" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2815B96E2BDACB7C2F6B38A3535CD9D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_89D74B87F20CAE64EE3938A3535D4C6D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_89D74B87F20CAE64EE3938A3535D4C6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_89D74B87F20CAE64EE3938A3535D4C6D_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_89D74B87F20CAE64EE3938A3535D4C6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_89D74B87F20CAE64EE3938A3535D4C6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_89D74B87F20CAE64EE3938A3535D4C6D" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_89D74B87F20CAE64EE3938A3535D4C6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1426DEC074D5E107035D38A3535DDAD2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1426DEC074D5E107035D38A3535DDAD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1426DEC074D5E107035D38A3535DDAD2_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1426DEC074D5E107035D38A3535DDAD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1426DEC074D5E107035D38A3535DDAD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1426DEC074D5E107035D38A3535DDAD2" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1426DEC074D5E107035D38A3535DDAD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C0108610C5BD479EAC3538A3535D9C58_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C0108610C5BD479EAC3538A3535D9C58" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C0108610C5BD479EAC3538A3535D9C58_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C0108610C5BD479EAC3538A3535D9C58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_C0108610C5BD479EAC3538A3535D9C58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_C0108610C5BD479EAC3538A3535D9C58" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_C0108610C5BD479EAC3538A3535D9C58" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3CD8383F628292B84BB138A3535D71D9_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_3CD8383F628292B84BB138A3535D71D9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3CD8383F628292B84BB138A3535D71D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3CD8383F628292B84BB138A3535D71D9" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_3CD8383F628292B84BB138A3535D71D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_222F11C1B7136752E23638A352086ACA_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_222F11C1B7136752E23638A352086ACA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_222F11C1B7136752E23638A352086ACA_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_222F11C1B7136752E23638A352086ACA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_222F11C1B7136752E23638A352086ACA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_222F11C1B7136752E23638A352086ACA" xlink:to="lab_us-gaap_LossContingenciesTable_222F11C1B7136752E23638A352086ACA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_6681F07F45EA49BE213938A352087500_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_6681F07F45EA49BE213938A352087500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_6681F07F45EA49BE213938A352087500_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_6681F07F45EA49BE213938A352087500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_6681F07F45EA49BE213938A352087500" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_6681F07F45EA49BE213938A352087500" xlink:to="lab_us-gaap_LossContingenciesLineItems_6681F07F45EA49BE213938A352087500" xlink:type="arc" />
    <link:label id="lab_biib_ReimbursementLimitStatedInResolution_1A30F955400C20011CC238A352087B44_terseLabel_en-US" xlink:label="lab_biib_ReimbursementLimitStatedInResolution_1A30F955400C20011CC238A352087B44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement Limit Stated In Resolution</link:label>
    <link:label id="lab_biib_ReimbursementLimitStatedInResolution_1A30F955400C20011CC238A352087B44_label_en-US" xlink:label="lab_biib_ReimbursementLimitStatedInResolution_1A30F955400C20011CC238A352087B44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Limit Stated In Resolution</link:label>
    <link:label id="lab_biib_ReimbursementLimitStatedInResolution_1A30F955400C20011CC238A352087B44_documentation_en-US" xlink:label="lab_biib_ReimbursementLimitStatedInResolution_1A30F955400C20011CC238A352087B44" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement limit stated in the resolution.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ReimbursementLimitStatedInResolution" xlink:label="loc_biib_ReimbursementLimitStatedInResolution_1A30F955400C20011CC238A352087B44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReimbursementLimitStatedInResolution_1A30F955400C20011CC238A352087B44" xlink:to="lab_biib_ReimbursementLimitStatedInResolution_1A30F955400C20011CC238A352087B44" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_EE34DEFF3CB7C3653DED38A3514593F2_verboseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_EE34DEFF3CB7C3653DED38A3514593F2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_EE34DEFF3CB7C3653DED38A3514593F2_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_EE34DEFF3CB7C3653DED38A3514593F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_EE34DEFF3CB7C3653DED38A3514593F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_EE34DEFF3CB7C3653DED38A3514593F2" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_EE34DEFF3CB7C3653DED38A3514593F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C5F909778E938E81299538A352A32F5C_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C5F909778E938E81299538A352A32F5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C5F909778E938E81299538A352A32F5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C5F909778E938E81299538A352A32F5C" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C5F909778E938E81299538A352A32F5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5DB7C0198308F2FEC29338A352A4416E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5DB7C0198308F2FEC29338A352A4416E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) recognized during the period, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5DB7C0198308F2FEC29338A352A4416E_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5DB7C0198308F2FEC29338A352A4416E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5DB7C0198308F2FEC29338A352A4416E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5DB7C0198308F2FEC29338A352A4416E" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5DB7C0198308F2FEC29338A352A4416E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_B6D472236AD4A9B284E938A352A48FCF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_B6D472236AD4A9B284E938A352A48FCF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: reclassification adjustment for (gains) losses included in net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_B6D472236AD4A9B284E938A352A48FCF_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_B6D472236AD4A9B284E938A352A48FCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_B6D472236AD4A9B284E938A352A48FCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_B6D472236AD4A9B284E938A352A48FCF" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_B6D472236AD4A9B284E938A352A48FCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0E698620DE2CE9FE3D2538A352A45310_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0E698620DE2CE9FE3D2538A352A45310" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0E698620DE2CE9FE3D2538A352A45310_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0E698620DE2CE9FE3D2538A352A45310" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0E698620DE2CE9FE3D2538A352A45310" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0E698620DE2CE9FE3D2538A352A45310" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0E698620DE2CE9FE3D2538A352A45310" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_EAA6979F914A34E4D73738A352A4F33C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_EAA6979F914A34E4D73738A352A4F33C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) recognized during the period, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_EAA6979F914A34E4D73738A352A4F33C_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_EAA6979F914A34E4D73738A352A4F33C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_EAA6979F914A34E4D73738A352A4F33C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_EAA6979F914A34E4D73738A352A4F33C" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_EAA6979F914A34E4D73738A352A4F33C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_76554DB606B6A4C687B338A352A59258_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_76554DB606B6A4C687B338A352A59258" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: reclassification adjustment for (gains) losses included in net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_76554DB606B6A4C687B338A352A59258_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_76554DB606B6A4C687B338A352A59258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_76554DB606B6A4C687B338A352A59258" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_76554DB606B6A4C687B338A352A59258" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_76554DB606B6A4C687B338A352A59258" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_225F61223B6BC8C6B48938A352A52E07_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_225F61223B6BC8C6B48938A352A52E07" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_225F61223B6BC8C6B48938A352A52E07_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_225F61223B6BC8C6B48938A352A52E07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_225F61223B6BC8C6B48938A352A52E07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_225F61223B6BC8C6B48938A352A52E07" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_225F61223B6BC8C6B48938A352A52E07" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_567FFE5EB34C706F923A38A352A5B539_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_567FFE5EB34C706F923A38A352A5B539" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_567FFE5EB34C706F923A38A352A5B539_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_567FFE5EB34C706F923A38A352A5B539" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_567FFE5EB34C706F923A38A352A5B539" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_567FFE5EB34C706F923A38A352A5B539" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_567FFE5EB34C706F923A38A352A5B539" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_63BF46E44125E7E0E50938A352A57557_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_63BF46E44125E7E0E50938A352A57557" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_63BF46E44125E7E0E50938A352A57557_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_63BF46E44125E7E0E50938A352A57557" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_63BF46E44125E7E0E50938A352A57557" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_63BF46E44125E7E0E50938A352A57557" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_63BF46E44125E7E0E50938A352A57557" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8CCCA88C8D2E9153B07A38A352A5DB6D_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8CCCA88C8D2E9153B07A38A352A5DB6D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8CCCA88C8D2E9153B07A38A352A5DB6D_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8CCCA88C8D2E9153B07A38A352A5DB6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8CCCA88C8D2E9153B07A38A352A5DB6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8CCCA88C8D2E9153B07A38A352A5DB6D" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8CCCA88C8D2E9153B07A38A352A5DB6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_F62EB71AE46113110F5738A352A5D2A9_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_F62EB71AE46113110F5738A352A5D2A9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_F62EB71AE46113110F5738A352A5D2A9_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_F62EB71AE46113110F5738A352A5D2A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_F62EB71AE46113110F5738A352A5D2A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_F62EB71AE46113110F5738A352A5D2A9" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_F62EB71AE46113110F5738A352A5D2A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_C9977A74310C72802CFD38A352A55D00_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_C9977A74310C72802CFD38A352A55D00" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_C9977A74310C72802CFD38A352A55D00_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_C9977A74310C72802CFD38A352A55D00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_C9977A74310C72802CFD38A352A55D00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_C9977A74310C72802CFD38A352A55D00" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_C9977A74310C72802CFD38A352A55D00" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_E4E40221CC845C6DD06E38A352A5DE10_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_E4E40221CC845C6DD06E38A352A5DE10" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_E4E40221CC845C6DD06E38A352A5DE10_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_E4E40221CC845C6DD06E38A352A5DE10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_E4E40221CC845C6DD06E38A352A5DE10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_E4E40221CC845C6DD06E38A352A5DE10" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_E4E40221CC845C6DD06E38A352A5DE10" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_E579D86953A3E58406EC38A352318966_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_E579D86953A3E58406EC38A352318966" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_E579D86953A3E58406EC38A352318966_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_E579D86953A3E58406EC38A352318966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_E579D86953A3E58406EC38A352318966" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_E579D86953A3E58406EC38A352318966" xlink:to="lab_us-gaap_AccountsReceivableMember_E579D86953A3E58406EC38A352318966" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_6AEE8694837B9CC8E91A38A352317981_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_6AEE8694837B9CC8E91A38A352317981" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_6AEE8694837B9CC8E91A38A352317981_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_6AEE8694837B9CC8E91A38A352317981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_6AEE8694837B9CC8E91A38A352317981" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_6AEE8694837B9CC8E91A38A352317981" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_6AEE8694837B9CC8E91A38A352317981" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_41E31A5F12D66E79D11038A35231E128_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_41E31A5F12D66E79D11038A35231E128" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total reserves</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_41E31A5F12D66E79D11038A35231E128_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_41E31A5F12D66E79D11038A35231E128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves, Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_41E31A5F12D66E79D11038A35231E128" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_41E31A5F12D66E79D11038A35231E128" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_41E31A5F12D66E79D11038A35231E128" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfCommonStockTableTextBlock_DD14AC70FEFEB2EB1B7438A355F8A8C7_terseLabel_en-US" xlink:label="lab_biib_SummaryOfCommonStockTableTextBlock_DD14AC70FEFEB2EB1B7438A355F8A8C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of common stock</link:label>
    <link:label id="lab_biib_SummaryOfCommonStockTableTextBlock_DD14AC70FEFEB2EB1B7438A355F8A8C7_label_en-US" xlink:label="lab_biib_SummaryOfCommonStockTableTextBlock_DD14AC70FEFEB2EB1B7438A355F8A8C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Common Stock [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfCommonStockTableTextBlock_DD14AC70FEFEB2EB1B7438A355F8A8C7_documentation_en-US" xlink:label="lab_biib_SummaryOfCommonStockTableTextBlock_DD14AC70FEFEB2EB1B7438A355F8A8C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of common stock.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SummaryOfCommonStockTableTextBlock" xlink:label="loc_biib_SummaryOfCommonStockTableTextBlock_DD14AC70FEFEB2EB1B7438A355F8A8C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfCommonStockTableTextBlock_DD14AC70FEFEB2EB1B7438A355F8A8C7" xlink:to="lab_biib_SummaryOfCommonStockTableTextBlock_DD14AC70FEFEB2EB1B7438A355F8A8C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_5DFEA886036FE17FC47193224CAB9C9B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_5DFEA886036FE17FC47193224CAB9C9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_5DFEA886036FE17FC47193224CAB9C9B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_5DFEA886036FE17FC47193224CAB9C9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5DFEA886036FE17FC47193224CAB9C9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5DFEA886036FE17FC47193224CAB9C9B" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable_5DFEA886036FE17FC47193224CAB9C9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillLineItems_6937FB604D575D7DA65693224CACA0C2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_6937FB604D575D7DA65693224CACA0C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_6937FB604D575D7DA65693224CACA0C2_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_6937FB604D575D7DA65693224CACA0C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_6937FB604D575D7DA65693224CACA0C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems_6937FB604D575D7DA65693224CACA0C2" xlink:to="lab_us-gaap_GoodwillLineItems_6937FB604D575D7DA65693224CACA0C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_71B1D94AC2E8E3844CAF93224CB11877_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_71B1D94AC2E8E3844CAF93224CB11877" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_71B1D94AC2E8E3844CAF93224CB11877_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_71B1D94AC2E8E3844CAF93224CB11877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_71B1D94AC2E8E3844CAF93224CB11877" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_71B1D94AC2E8E3844CAF93224CB11877" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_71B1D94AC2E8E3844CAF93224CB11877" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_4A363181A0D3DCAAF89B93224CB1D4F8_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_4A363181A0D3DCAAF89B93224CB1D4F8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_4A363181A0D3DCAAF89B93224CB1D4F8_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_4A363181A0D3DCAAF89B93224CB1D4F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_4A363181A0D3DCAAF89B93224CB1D4F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_4A363181A0D3DCAAF89B93224CB1D4F8" xlink:to="lab_us-gaap_GoodwillRollForward_4A363181A0D3DCAAF89B93224CB1D4F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_8F41510ECF3EBB1A711D93224CB12E14_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_8F41510ECF3EBB1A711D93224CB12E14" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_8F41510ECF3EBB1A711D93224CB12E14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_8F41510ECF3EBB1A711D93224CB12E14" xlink:to="lab_us-gaap_Goodwill_8F41510ECF3EBB1A711D93224CB12E14" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_78339B434249F34814BA93224CB19E92_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_78339B434249F34814BA93224CB19E92" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase to goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_78339B434249F34814BA93224CB19E92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_78339B434249F34814BA93224CB19E92" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_78339B434249F34814BA93224CB19E92" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillOtherChanges_7904C7F3D7BD07C4415393224CB11FF5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherChanges_7904C7F3D7BD07C4415393224CB11FF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other goodwill adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherChanges_7904C7F3D7BD07C4415393224CB11FF5_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherChanges_7904C7F3D7BD07C4415393224CB11FF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Changes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillOtherChanges" xlink:label="loc_us-gaap_GoodwillOtherChanges_7904C7F3D7BD07C4415393224CB11FF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherChanges_7904C7F3D7BD07C4415393224CB11FF5" xlink:to="lab_us-gaap_GoodwillOtherChanges_7904C7F3D7BD07C4415393224CB11FF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_D17956BB60917D52180E93224CB1F2B5_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_D17956BB60917D52180E93224CB1F2B5" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_D17956BB60917D52180E93224CB1F2B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_D17956BB60917D52180E93224CB1F2B5" xlink:to="lab_us-gaap_Goodwill_D17956BB60917D52180E93224CB1F2B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_9DF5E621B9C7707D03FD65C9FE74F75B_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_9DF5E621B9C7707D03FD65C9FE74F75B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9DF5E621B9C7707D03FD65C9FE74F75B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9DF5E621B9C7707D03FD65C9FE74F75B" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_9DF5E621B9C7707D03FD65C9FE74F75B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_B6AAD5B947851D1B2CD665C9FE74D0ED_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_B6AAD5B947851D1B2CD665C9FE74D0ED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_B6AAD5B947851D1B2CD665C9FE74D0ED_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_B6AAD5B947851D1B2CD665C9FE74D0ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_B6AAD5B947851D1B2CD665C9FE74D0ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_B6AAD5B947851D1B2CD665C9FE74D0ED" xlink:to="lab_us-gaap_AssetsAbstract_B6AAD5B947851D1B2CD665C9FE74D0ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_546530D569491F4EE4E265C9FE740182_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_546530D569491F4EE4E265C9FE740182" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_546530D569491F4EE4E265C9FE740182_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_546530D569491F4EE4E265C9FE740182" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_546530D569491F4EE4E265C9FE740182" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_546530D569491F4EE4E265C9FE740182" xlink:to="lab_us-gaap_AssetsCurrentAbstract_546530D569491F4EE4E265C9FE740182" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A858A3B8B806F31E21AC65C9FE79BB6D_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A858A3B8B806F31E21AC65C9FE79BB6D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A858A3B8B806F31E21AC65C9FE79BB6D_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A858A3B8B806F31E21AC65C9FE79BB6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A858A3B8B806F31E21AC65C9FE79BB6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A858A3B8B806F31E21AC65C9FE79BB6D" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A858A3B8B806F31E21AC65C9FE79BB6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_21384ABF87069619BB9565C9FE79549C_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_21384ABF87069619BB9565C9FE79549C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_21384ABF87069619BB9565C9FE79549C_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_21384ABF87069619BB9565C9FE79549C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_21384ABF87069619BB9565C9FE79549C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent_21384ABF87069619BB9565C9FE79549C" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent_21384ABF87069619BB9565C9FE79549C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_87CCCD86C59D9F0F11E365C9FE79C88F_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_87CCCD86C59D9F0F11E365C9FE79C88F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_87CCCD86C59D9F0F11E365C9FE79C88F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_87CCCD86C59D9F0F11E365C9FE79C88F" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_87CCCD86C59D9F0F11E365C9FE79C88F" xlink:type="arc" />
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_65541EAD4407BB1B0F0565C9FE79F047_verboseLabel_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness_65541EAD4407BB1B0F0565C9FE79F047" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due from unconsolidated joint business, net</link:label>
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_65541EAD4407BB1B0F0565C9FE79F047_label_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness_65541EAD4407BB1B0F0565C9FE79F047" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from unconsolidated joint business</link:label>
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_65541EAD4407BB1B0F0565C9FE79F047_documentation_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness_65541EAD4407BB1B0F0565C9FE79F047" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivable from unconsolidated joint business for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_DueFromUnconsolidatedJointBusiness" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_65541EAD4407BB1B0F0565C9FE79F047" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DueFromUnconsolidatedJointBusiness_65541EAD4407BB1B0F0565C9FE79F047" xlink:to="lab_biib_DueFromUnconsolidatedJointBusiness_65541EAD4407BB1B0F0565C9FE79F047" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_2DE82226962B4CDFEB7965C9FE7A929E_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_2DE82226962B4CDFEB7965C9FE7A929E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_2DE82226962B4CDFEB7965C9FE7A929E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_2DE82226962B4CDFEB7965C9FE7A929E" xlink:to="lab_us-gaap_InventoryNet_2DE82226962B4CDFEB7965C9FE7A929E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_00A28E5C2C969319D5AD65C9FE7A035F_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_00A28E5C2C969319D5AD65C9FE7A035F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_00A28E5C2C969319D5AD65C9FE7A035F_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_00A28E5C2C969319D5AD65C9FE7A035F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_00A28E5C2C969319D5AD65C9FE7A035F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_00A28E5C2C969319D5AD65C9FE7A035F" xlink:to="lab_us-gaap_OtherAssetsCurrent_00A28E5C2C969319D5AD65C9FE7A035F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_C5B68464D16C2A6EE76265C9FE7AA736_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_C5B68464D16C2A6EE76265C9FE7AA736" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_C5B68464D16C2A6EE76265C9FE7AA736_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_C5B68464D16C2A6EE76265C9FE7AA736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_C5B68464D16C2A6EE76265C9FE7AA736" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_C5B68464D16C2A6EE76265C9FE7AA736" xlink:to="lab_us-gaap_AssetsCurrent_C5B68464D16C2A6EE76265C9FE7AA736" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_D48628E8C8FBA497389865C9FE7A54E9_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_D48628E8C8FBA497389865C9FE7A54E9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_D48628E8C8FBA497389865C9FE7A54E9_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_D48628E8C8FBA497389865C9FE7A54E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_D48628E8C8FBA497389865C9FE7A54E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_D48628E8C8FBA497389865C9FE7A54E9" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_D48628E8C8FBA497389865C9FE7A54E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_84D6468F9D614FA2DA8D65C9FE7ACA83_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_84D6468F9D614FA2DA8D65C9FE7ACA83" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_84D6468F9D614FA2DA8D65C9FE7ACA83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_84D6468F9D614FA2DA8D65C9FE7ACA83" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_84D6468F9D614FA2DA8D65C9FE7ACA83" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_811B1CCD538FDD0E1A0665C9FE7AD5FB_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_811B1CCD538FDD0E1A0665C9FE7AD5FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_811B1CCD538FDD0E1A0665C9FE7AD5FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_811B1CCD538FDD0E1A0665C9FE7AD5FB" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_811B1CCD538FDD0E1A0665C9FE7AD5FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_2C9DA785D5AADFF8803165C9FE7AEAF9_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_2C9DA785D5AADFF8803165C9FE7AEAF9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_2C9DA785D5AADFF8803165C9FE7AEAF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_2C9DA785D5AADFF8803165C9FE7AEAF9" xlink:to="lab_us-gaap_Goodwill_2C9DA785D5AADFF8803165C9FE7AEAF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_00A057A980D77102AF4765C9FE7A4FDE_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_00A057A980D77102AF4765C9FE7A4FDE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_00A057A980D77102AF4765C9FE7A4FDE_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_00A057A980D77102AF4765C9FE7A4FDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_00A057A980D77102AF4765C9FE7A4FDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_00A057A980D77102AF4765C9FE7A4FDE" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_00A057A980D77102AF4765C9FE7A4FDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_DDD8D6BD3F8D6A4A77B765C9FE7A1DE4_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_DDD8D6BD3F8D6A4A77B765C9FE7A1DE4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_DDD8D6BD3F8D6A4A77B765C9FE7A1DE4_label_en-US" xlink:label="lab_us-gaap_Assets_DDD8D6BD3F8D6A4A77B765C9FE7A1DE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_DDD8D6BD3F8D6A4A77B765C9FE7A1DE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_DDD8D6BD3F8D6A4A77B765C9FE7A1DE4" xlink:to="lab_us-gaap_Assets_DDD8D6BD3F8D6A4A77B765C9FE7A1DE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AA8ABA66073B65B3C0EB65C9FE7AA8F3_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AA8ABA66073B65B3C0EB65C9FE7AA8F3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AA8ABA66073B65B3C0EB65C9FE7AA8F3_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AA8ABA66073B65B3C0EB65C9FE7AA8F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AA8ABA66073B65B3C0EB65C9FE7AA8F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AA8ABA66073B65B3C0EB65C9FE7AA8F3" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AA8ABA66073B65B3C0EB65C9FE7AA8F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1B32DDF94F16B146B9B865C9FE7A342D_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1B32DDF94F16B146B9B865C9FE7A342D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1B32DDF94F16B146B9B865C9FE7A342D_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1B32DDF94F16B146B9B865C9FE7A342D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1B32DDF94F16B146B9B865C9FE7A342D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1B32DDF94F16B146B9B865C9FE7A342D" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_1B32DDF94F16B146B9B865C9FE7A342D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_76AC069D30752DC5F5F565C9FE7AF9AD_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_76AC069D30752DC5F5F565C9FE7AF9AD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable and other financing arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_76AC069D30752DC5F5F565C9FE7AF9AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_76AC069D30752DC5F5F565C9FE7AF9AD" xlink:to="lab_us-gaap_DebtCurrent_76AC069D30752DC5F5F565C9FE7AF9AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_61511834F6CF72EFC4A665C9FE7B1C8D_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_61511834F6CF72EFC4A665C9FE7B1C8D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_61511834F6CF72EFC4A665C9FE7B1C8D_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_61511834F6CF72EFC4A665C9FE7B1C8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_61511834F6CF72EFC4A665C9FE7B1C8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_61511834F6CF72EFC4A665C9FE7B1C8D" xlink:to="lab_us-gaap_TaxesPayableCurrent_61511834F6CF72EFC4A665C9FE7B1C8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_CE886FFCB94047E5833165C9FE7B88D4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_CE886FFCB94047E5833165C9FE7B88D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_CE886FFCB94047E5833165C9FE7B88D4_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_CE886FFCB94047E5833165C9FE7B88D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_CE886FFCB94047E5833165C9FE7B88D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_CE886FFCB94047E5833165C9FE7B88D4" xlink:to="lab_us-gaap_AccountsPayableCurrent_CE886FFCB94047E5833165C9FE7B88D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_974D1FCDEF0F26CF4F6765C9FE7BA08E_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_974D1FCDEF0F26CF4F6765C9FE7BA08E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_974D1FCDEF0F26CF4F6765C9FE7BA08E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_974D1FCDEF0F26CF4F6765C9FE7BA08E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_974D1FCDEF0F26CF4F6765C9FE7BA08E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_974D1FCDEF0F26CF4F6765C9FE7BA08E" xlink:to="lab_us-gaap_LiabilitiesCurrent_974D1FCDEF0F26CF4F6765C9FE7BA08E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_324EB57CF6E52DE154AB65C9FE7B69E4_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_324EB57CF6E52DE154AB65C9FE7B69E4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable and other financing arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_324EB57CF6E52DE154AB65C9FE7B69E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_324EB57CF6E52DE154AB65C9FE7B69E4" xlink:to="lab_us-gaap_LongTermDebt_324EB57CF6E52DE154AB65C9FE7B69E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_FF225CC051D31A75D37765C9FE805F99_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_FF225CC051D31A75D37765C9FE805F99" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_FF225CC051D31A75D37765C9FE805F99_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_FF225CC051D31A75D37765C9FE805F99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_FF225CC051D31A75D37765C9FE805F99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_FF225CC051D31A75D37765C9FE805F99" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_FF225CC051D31A75D37765C9FE805F99" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8E04BDD82C59CC17940365C9FE80AFBF_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_8E04BDD82C59CC17940365C9FE80AFBF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8E04BDD82C59CC17940365C9FE80AFBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_8E04BDD82C59CC17940365C9FE80AFBF" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_8E04BDD82C59CC17940365C9FE80AFBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_5D04B319A3D8C1578E7D65C9FE80614E_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_5D04B319A3D8C1578E7D65C9FE80614E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_5D04B319A3D8C1578E7D65C9FE80614E_label_en-US" xlink:label="lab_us-gaap_Liabilities_5D04B319A3D8C1578E7D65C9FE80614E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_5D04B319A3D8C1578E7D65C9FE80614E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_5D04B319A3D8C1578E7D65C9FE80614E" xlink:to="lab_us-gaap_Liabilities_5D04B319A3D8C1578E7D65C9FE80614E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_A77FD073E02E781A525465C9FE809DED_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_A77FD073E02E781A525465C9FE809DED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_A77FD073E02E781A525465C9FE809DED_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_A77FD073E02E781A525465C9FE809DED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_A77FD073E02E781A525465C9FE809DED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_A77FD073E02E781A525465C9FE809DED" xlink:to="lab_us-gaap_CommitmentsAndContingencies_A77FD073E02E781A525465C9FE809DED" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FE8093A6A79CC3DDA04865C9FE8086FC_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FE8093A6A79CC3DDA04865C9FE8086FC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FE8093A6A79CC3DDA04865C9FE8086FC_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FE8093A6A79CC3DDA04865C9FE8086FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FE8093A6A79CC3DDA04865C9FE8086FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FE8093A6A79CC3DDA04865C9FE8086FC" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FE8093A6A79CC3DDA04865C9FE8086FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_A2E12E159450DB48C38B65C9FE803C04_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_A2E12E159450DB48C38B65C9FE803C04" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_A2E12E159450DB48C38B65C9FE803C04_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_A2E12E159450DB48C38B65C9FE803C04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_A2E12E159450DB48C38B65C9FE803C04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A2E12E159450DB48C38B65C9FE803C04" xlink:to="lab_us-gaap_StockholdersEquityAbstract_A2E12E159450DB48C38B65C9FE803C04" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_19021014AF38AD9B828865C9FE80AA7A_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_19021014AF38AD9B828865C9FE80AA7A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_19021014AF38AD9B828865C9FE80AA7A_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_19021014AF38AD9B828865C9FE80AA7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_19021014AF38AD9B828865C9FE80AA7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_19021014AF38AD9B828865C9FE80AA7A" xlink:to="lab_us-gaap_PreferredStockValue_19021014AF38AD9B828865C9FE80AA7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_FB977526109751B4766865C9FE81C90B_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_FB977526109751B4766865C9FE81C90B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_FB977526109751B4766865C9FE81C90B_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_FB977526109751B4766865C9FE81C90B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_FB977526109751B4766865C9FE81C90B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_FB977526109751B4766865C9FE81C90B" xlink:to="lab_us-gaap_CommonStockValue_FB977526109751B4766865C9FE81C90B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_DB13BFBF027130922E9C65C9FE81ED92_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_DB13BFBF027130922E9C65C9FE81ED92" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_DB13BFBF027130922E9C65C9FE81ED92_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_DB13BFBF027130922E9C65C9FE81ED92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_DB13BFBF027130922E9C65C9FE81ED92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_DB13BFBF027130922E9C65C9FE81ED92" xlink:to="lab_us-gaap_AdditionalPaidInCapital_DB13BFBF027130922E9C65C9FE81ED92" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75E9455C68C7C01AA3AF65C9FE819CF2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75E9455C68C7C01AA3AF65C9FE819CF2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75E9455C68C7C01AA3AF65C9FE819CF2_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75E9455C68C7C01AA3AF65C9FE819CF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75E9455C68C7C01AA3AF65C9FE819CF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75E9455C68C7C01AA3AF65C9FE819CF2" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75E9455C68C7C01AA3AF65C9FE819CF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_EB0F39592E8CC6881D5E65C9FE8122DC_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_EB0F39592E8CC6881D5E65C9FE8122DC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_EB0F39592E8CC6881D5E65C9FE8122DC_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_EB0F39592E8CC6881D5E65C9FE8122DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_EB0F39592E8CC6881D5E65C9FE8122DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_EB0F39592E8CC6881D5E65C9FE8122DC" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_EB0F39592E8CC6881D5E65C9FE8122DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_80EF6C9E35673F630BB065C9FE811F41_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_80EF6C9E35673F630BB065C9FE811F41" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost; 22.6 million shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_80EF6C9E35673F630BB065C9FE811F41_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_80EF6C9E35673F630BB065C9FE811F41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_80EF6C9E35673F630BB065C9FE811F41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_80EF6C9E35673F630BB065C9FE811F41" xlink:to="lab_us-gaap_TreasuryStockValue_80EF6C9E35673F630BB065C9FE811F41" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_D2D3D02D36B72021C9C365C9FE8122C6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_D2D3D02D36B72021C9C365C9FE8122C6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_D2D3D02D36B72021C9C365C9FE8122C6_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_D2D3D02D36B72021C9C365C9FE8122C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_D2D3D02D36B72021C9C365C9FE8122C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_D2D3D02D36B72021C9C365C9FE8122C6" xlink:to="lab_us-gaap_StockholdersEquity_D2D3D02D36B72021C9C365C9FE8122C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_C94EB9D770C6B678497D65C9FE81761C_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_C94EB9D770C6B678497D65C9FE81761C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_C94EB9D770C6B678497D65C9FE81761C_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_C94EB9D770C6B678497D65C9FE81761C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_C94EB9D770C6B678497D65C9FE81761C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_C94EB9D770C6B678497D65C9FE81761C" xlink:to="lab_us-gaap_MinorityInterest_C94EB9D770C6B678497D65C9FE81761C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78EF6F6F13273144D52965C9FE812C49_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78EF6F6F13273144D52965C9FE812C49" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78EF6F6F13273144D52965C9FE812C49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78EF6F6F13273144D52965C9FE812C49" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78EF6F6F13273144D52965C9FE812C49" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_CEFF1AE575898508403D65C9FE81CBDA_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_CEFF1AE575898508403D65C9FE81CBDA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_CEFF1AE575898508403D65C9FE81CBDA_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_CEFF1AE575898508403D65C9FE81CBDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_CEFF1AE575898508403D65C9FE81CBDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_CEFF1AE575898508403D65C9FE81CBDA" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_CEFF1AE575898508403D65C9FE81CBDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EF589FF997A39165DD75A34B6A0E8844_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EF589FF997A39165DD75A34B6A0E8844" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EF589FF997A39165DD75A34B6A0E8844_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EF589FF997A39165DD75A34B6A0E8844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EF589FF997A39165DD75A34B6A0E8844" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EF589FF997A39165DD75A34B6A0E8844" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EF589FF997A39165DD75A34B6A0E8844" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_48035EC16EEEB30D3517A34B6A13F018_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_48035EC16EEEB30D3517A34B6A13F018" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_48035EC16EEEB30D3517A34B6A13F018_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_48035EC16EEEB30D3517A34B6A13F018" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_48035EC16EEEB30D3517A34B6A13F018_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_48035EC16EEEB30D3517A34B6A13F018" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_48035EC16EEEB30D3517A34B6A13F018" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember_48035EC16EEEB30D3517A34B6A13F018" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember_48035EC16EEEB30D3517A34B6A13F018" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_2FF5B4F3834FFCFF8AA0A34B6A13A1CE_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_2FF5B4F3834FFCFF8AA0A34B6A13A1CE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_2FF5B4F3834FFCFF8AA0A34B6A13A1CE_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_2FF5B4F3834FFCFF8AA0A34B6A13A1CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_2FF5B4F3834FFCFF8AA0A34B6A13A1CE_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_2FF5B4F3834FFCFF8AA0A34B6A13A1CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_2FF5B4F3834FFCFF8AA0A34B6A13A1CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember_2FF5B4F3834FFCFF8AA0A34B6A13A1CE" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember_2FF5B4F3834FFCFF8AA0A34B6A13A1CE" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_73E250A0607C282E86CBA34B6A13AE74_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_73E250A0607C282E86CBA34B6A13AE74" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_73E250A0607C282E86CBA34B6A13AE74_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_73E250A0607C282E86CBA34B6A13AE74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_73E250A0607C282E86CBA34B6A13AE74_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_73E250A0607C282E86CBA34B6A13AE74" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_73E250A0607C282E86CBA34B6A13AE74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember_73E250A0607C282E86CBA34B6A13AE74" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember_73E250A0607C282E86CBA34B6A13AE74" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_377740B18487722700FEA34B6A138831_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_377740B18487722700FEA34B6A138831" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_377740B18487722700FEA34B6A138831_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_377740B18487722700FEA34B6A138831" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_377740B18487722700FEA34B6A138831_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_377740B18487722700FEA34B6A138831" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_377740B18487722700FEA34B6A138831" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember_377740B18487722700FEA34B6A138831" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember_377740B18487722700FEA34B6A138831" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E5DC0C2F9CBEE4A11A78A34B6A1384CD_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E5DC0C2F9CBEE4A11A78A34B6A1384CD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E5DC0C2F9CBEE4A11A78A34B6A1384CD_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E5DC0C2F9CBEE4A11A78A34B6A1384CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E5DC0C2F9CBEE4A11A78A34B6A1384CD_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E5DC0C2F9CBEE4A11A78A34B6A1384CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E5DC0C2F9CBEE4A11A78A34B6A1384CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E5DC0C2F9CBEE4A11A78A34B6A1384CD" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E5DC0C2F9CBEE4A11A78A34B6A1384CD" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_F3A6F99A8C8A7626A270A34B6A13EEE9_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_F3A6F99A8C8A7626A270A34B6A13EEE9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_F3A6F99A8C8A7626A270A34B6A13EEE9_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_F3A6F99A8C8A7626A270A34B6A13EEE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_F3A6F99A8C8A7626A270A34B6A13EEE9_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_F3A6F99A8C8A7626A270A34B6A13EEE9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_F3A6F99A8C8A7626A270A34B6A13EEE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_F3A6F99A8C8A7626A270A34B6A13EEE9" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_F3A6F99A8C8A7626A270A34B6A13EEE9" xlink:type="arc" />
    <link:label id="lab_biib_MarketableEquitySecuritiesMember_5940B366C07C79E18A29A34B6A1362C2_verboseLabel_en-US" xlink:label="lab_biib_MarketableEquitySecuritiesMember_5940B366C07C79E18A29A34B6A1362C2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_biib_MarketableEquitySecuritiesMember_5940B366C07C79E18A29A34B6A1362C2_label_en-US" xlink:label="lab_biib_MarketableEquitySecuritiesMember_5940B366C07C79E18A29A34B6A1362C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Equity Securities [Member]</link:label>
    <link:label id="lab_biib_MarketableEquitySecuritiesMember_5940B366C07C79E18A29A34B6A1362C2_documentation_en-US" xlink:label="lab_biib_MarketableEquitySecuritiesMember_5940B366C07C79E18A29A34B6A1362C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketable equity securities.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_MarketableEquitySecuritiesMember" xlink:label="loc_biib_MarketableEquitySecuritiesMember_5940B366C07C79E18A29A34B6A1362C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketableEquitySecuritiesMember_5940B366C07C79E18A29A34B6A1362C2" xlink:to="lab_biib_MarketableEquitySecuritiesMember_5940B366C07C79E18A29A34B6A1362C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0C3587EC485D2B006E78A34B6A135499_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0C3587EC485D2B006E78A34B6A135499" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0C3587EC485D2B006E78A34B6A135499_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0C3587EC485D2B006E78A34B6A135499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0C3587EC485D2B006E78A34B6A135499" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0C3587EC485D2B006E78A34B6A135499" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0C3587EC485D2B006E78A34B6A135499" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_EFA3EA49F348A33DDDE6A34B6A149E38_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_EFA3EA49F348A33DDDE6A34B6A149E38" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_EFA3EA49F348A33DDDE6A34B6A149E38_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_EFA3EA49F348A33DDDE6A34B6A149E38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_EFA3EA49F348A33DDDE6A34B6A149E38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_EFA3EA49F348A33DDDE6A34B6A149E38" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract_EFA3EA49F348A33DDDE6A34B6A149E38" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_345C9693A6544936BD96A34B6A14597A_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_345C9693A6544936BD96A34B6A14597A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_345C9693A6544936BD96A34B6A14597A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_345C9693A6544936BD96A34B6A14597A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_345C9693A6544936BD96A34B6A14597A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_345C9693A6544936BD96A34B6A14597A" xlink:to="lab_us-gaap_AvailableForSaleSecurities_345C9693A6544936BD96A34B6A14597A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_06818972C6A31812A1C7A34B6A14BED5_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_06818972C6A31812A1C7A34B6A14BED5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_06818972C6A31812A1C7A34B6A14BED5_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_06818972C6A31812A1C7A34B6A14BED5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_06818972C6A31812A1C7A34B6A14BED5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_06818972C6A31812A1C7A34B6A14BED5" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_06818972C6A31812A1C7A34B6A14BED5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C63AC6000C4B847B010A34B6A14D008_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C63AC6000C4B847B010A34B6A14D008" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C63AC6000C4B847B010A34B6A14D008_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C63AC6000C4B847B010A34B6A14D008" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C63AC6000C4B847B010A34B6A14D008" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C63AC6000C4B847B010A34B6A14D008" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C63AC6000C4B847B010A34B6A14D008" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B67596B5771210779D01A34B6A14B966_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B67596B5771210779D01A34B6A14B966" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B67596B5771210779D01A34B6A14B966_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B67596B5771210779D01A34B6A14B966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B67596B5771210779D01A34B6A14B966" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B67596B5771210779D01A34B6A14B966" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B67596B5771210779D01A34B6A14B966" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50_verboseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Settled Performance Shares [Abstract]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_CashSettledPerformanceSharesAbstract" xlink:label="loc_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50" xlink:to="lab_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50" xlink:type="arc" />
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_A06720D624E707D68D8B38A354C9CDD4_terseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_A06720D624E707D68D8B38A354C9CDD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_A06720D624E707D68D8B38A354C9CDD4_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_A06720D624E707D68D8B38A354C9CDD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_A06720D624E707D68D8B38A354C9CDD4_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_A06720D624E707D68D8B38A354C9CDD4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_A06720D624E707D68D8B38A354C9CDD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock_A06720D624E707D68D8B38A354C9CDD4" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock_A06720D624E707D68D8B38A354C9CDD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_B1EB8A03646326DEC51C38A354C9CE4A_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_B1EB8A03646326DEC51C38A354C9CE4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_B1EB8A03646326DEC51C38A354C9CE4A_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_B1EB8A03646326DEC51C38A354C9CE4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_B1EB8A03646326DEC51C38A354C9CE4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_B1EB8A03646326DEC51C38A354C9CE4A" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_B1EB8A03646326DEC51C38A354C9CE4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_FCCE7650F0E3A88C262438A354C95A11_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_FCCE7650F0E3A88C262438A354C95A11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_FCCE7650F0E3A88C262438A354C95A11_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_FCCE7650F0E3A88C262438A354C95A11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_FCCE7650F0E3A88C262438A354C95A11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_FCCE7650F0E3A88C262438A354C95A11" xlink:to="lab_us-gaap_UseOfEstimates_FCCE7650F0E3A88C262438A354C95A11" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_7A590073499F1CEAA33838A354C91654_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_7A590073499F1CEAA33838A354C91654" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_7A590073499F1CEAA33838A354C91654_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_7A590073499F1CEAA33838A354C91654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_7A590073499F1CEAA33838A354C91654" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_7A590073499F1CEAA33838A354C91654" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_7A590073499F1CEAA33838A354C91654" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_8AD5E14C3EEB5DD0F0EC38A354CAA3D9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_8AD5E14C3EEB5DD0F0EC38A354CAA3D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_8AD5E14C3EEB5DD0F0EC38A354CAA3D9_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_8AD5E14C3EEB5DD0F0EC38A354CAA3D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_8AD5E14C3EEB5DD0F0EC38A354CAA3D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_8AD5E14C3EEB5DD0F0EC38A354CAA3D9" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_8AD5E14C3EEB5DD0F0EC38A354CAA3D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32C6B715D7F4B49514BA38A354CA7278_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32C6B715D7F4B49514BA38A354CA7278" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32C6B715D7F4B49514BA38A354CA7278_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32C6B715D7F4B49514BA38A354CA7278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32C6B715D7F4B49514BA38A354CA7278" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32C6B715D7F4B49514BA38A354CA7278" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32C6B715D7F4B49514BA38A354CA7278" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_A2FBF6D5A6BAFFD38E5E38A354CA722F_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_A2FBF6D5A6BAFFD38E5E38A354CA722F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_A2FBF6D5A6BAFFD38E5E38A354CA722F_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_A2FBF6D5A6BAFFD38E5E38A354CA722F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_A2FBF6D5A6BAFFD38E5E38A354CA722F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock_A2FBF6D5A6BAFFD38E5E38A354CA722F" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock_A2FBF6D5A6BAFFD38E5E38A354CA722F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_63592F92384D82EFE17D38A354CA93D0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_63592F92384D82EFE17D38A354CA93D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_63592F92384D82EFE17D38A354CA93D0_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_63592F92384D82EFE17D38A354CA93D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_63592F92384D82EFE17D38A354CA93D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_63592F92384D82EFE17D38A354CA93D0" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_63592F92384D82EFE17D38A354CA93D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_C6DB3090E890EB7A471E38A354CBC414_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_C6DB3090E890EB7A471E38A354CBC414" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities and Other Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_C6DB3090E890EB7A471E38A354CBC414_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_C6DB3090E890EB7A471E38A354CBC414" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_C6DB3090E890EB7A471E38A354CBC414" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock_C6DB3090E890EB7A471E38A354CBC414" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock_C6DB3090E890EB7A471E38A354CBC414" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_0455DA74069A8F606FD238A354CB75EC_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy_0455DA74069A8F606FD238A354CB75EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method of Accounting</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_0455DA74069A8F606FD238A354CB75EC_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy_0455DA74069A8F606FD238A354CB75EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_0455DA74069A8F606FD238A354CB75EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy_0455DA74069A8F606FD238A354CB75EC" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy_0455DA74069A8F606FD238A354CB75EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_DE0CB3B15C4A9518F15D38A354CB4DB1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_DE0CB3B15C4A9518F15D38A354CB4DB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_DE0CB3B15C4A9518F15D38A354CB4DB1_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_DE0CB3B15C4A9518F15D38A354CB4DB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_DE0CB3B15C4A9518F15D38A354CB4DB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_DE0CB3B15C4A9518F15D38A354CB4DB1" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_DE0CB3B15C4A9518F15D38A354CB4DB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6DBBD3DA5E82D6EB407D38A354CB6FC0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6DBBD3DA5E82D6EB407D38A354CB6FC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6DBBD3DA5E82D6EB407D38A354CB6FC0_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6DBBD3DA5E82D6EB407D38A354CB6FC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6DBBD3DA5E82D6EB407D38A354CB6FC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6DBBD3DA5E82D6EB407D38A354CB6FC0" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6DBBD3DA5E82D6EB407D38A354CB6FC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_64269D44B4861E5987FC38A354CBD803_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_64269D44B4861E5987FC38A354CBD803" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_64269D44B4861E5987FC38A354CBD803_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_64269D44B4861E5987FC38A354CBD803" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_64269D44B4861E5987FC38A354CBD803" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_64269D44B4861E5987FC38A354CBD803" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_64269D44B4861E5987FC38A354CBD803" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_172A747579B8A25CDF3038A354CB0395_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_172A747579B8A25CDF3038A354CB0395" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired In-process Research and Development (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_172A747579B8A25CDF3038A354CB0395_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_172A747579B8A25CDF3038A354CB0395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_172A747579B8A25CDF3038A354CB0395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_172A747579B8A25CDF3038A354CB0395" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_172A747579B8A25CDF3038A354CB0395" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1F632CE067E4ECFF0A6538A354CB24EF_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1F632CE067E4ECFF0A6538A354CB24EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1F632CE067E4ECFF0A6538A354CB24EF_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1F632CE067E4ECFF0A6538A354CB24EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1F632CE067E4ECFF0A6538A354CB24EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1F632CE067E4ECFF0A6538A354CB24EF" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1F632CE067E4ECFF0A6538A354CB24EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_C72C1E92E44241FCA47938A354CB0E98_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_C72C1E92E44241FCA47938A354CB0E98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_C72C1E92E44241FCA47938A354CB0E98_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_C72C1E92E44241FCA47938A354CB0E98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_C72C1E92E44241FCA47938A354CB0E98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_C72C1E92E44241FCA47938A354CB0E98" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_C72C1E92E44241FCA47938A354CB0E98" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_9744106FBB21A853AF5838A354CBC9A2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_9744106FBB21A853AF5838A354CBC9A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_9744106FBB21A853AF5838A354CBC9A2_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_9744106FBB21A853AF5838A354CBC9A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_9744106FBB21A853AF5838A354CBC9A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy_9744106FBB21A853AF5838A354CBC9A2" xlink:to="lab_us-gaap_BusinessCombinationsPolicy_9744106FBB21A853AF5838A354CBC9A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_A09D858852F4C53ECC1E38A354CB5DF4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_A09D858852F4C53ECC1E38A354CB5DF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_A09D858852F4C53ECC1E38A354CB5DF4_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_A09D858852F4C53ECC1E38A354CB5DF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_A09D858852F4C53ECC1E38A354CB5DF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_A09D858852F4C53ECC1E38A354CB5DF4" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_A09D858852F4C53ECC1E38A354CB5DF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_7A052EDE2DB3901B1AFE38A354CB4DFF_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_7A052EDE2DB3901B1AFE38A354CB4DFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation of Foreign Currencies</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_7A052EDE2DB3901B1AFE38A354CB4DFF_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_7A052EDE2DB3901B1AFE38A354CB4DFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_7A052EDE2DB3901B1AFE38A354CB4DFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_7A052EDE2DB3901B1AFE38A354CB4DFF" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_7A052EDE2DB3901B1AFE38A354CB4DFF" xlink:type="arc" />
    <link:label id="lab_biib_RoyaltyCostofSalesPolicyTextBlock_6F150555ADA2AF5352B738A354CBF881_terseLabel_en-US" xlink:label="lab_biib_RoyaltyCostofSalesPolicyTextBlock_6F150555ADA2AF5352B738A354CBF881" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Cost of Sales</link:label>
    <link:label id="lab_biib_RoyaltyCostofSalesPolicyTextBlock_6F150555ADA2AF5352B738A354CBF881_label_en-US" xlink:label="lab_biib_RoyaltyCostofSalesPolicyTextBlock_6F150555ADA2AF5352B738A354CBF881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Cost of Sales [Policy Text Block]</link:label>
    <link:label id="lab_biib_RoyaltyCostofSalesPolicyTextBlock_6F150555ADA2AF5352B738A354CBF881_documentation_en-US" xlink:label="lab_biib_RoyaltyCostofSalesPolicyTextBlock_6F150555ADA2AF5352B738A354CBF881" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Cost of Sales [Policy Text Block]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RoyaltyCostofSalesPolicyTextBlock" xlink:label="loc_biib_RoyaltyCostofSalesPolicyTextBlock_6F150555ADA2AF5352B738A354CBF881" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltyCostofSalesPolicyTextBlock_6F150555ADA2AF5352B738A354CBF881" xlink:to="lab_biib_RoyaltyCostofSalesPolicyTextBlock_6F150555ADA2AF5352B738A354CBF881" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_16202B3F198C4D57647138A354CB0B3A_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_16202B3F198C4D57647138A354CB0B3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting for Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_16202B3F198C4D57647138A354CB0B3A_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_16202B3F198C4D57647138A354CB0B3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_16202B3F198C4D57647138A354CB0B3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_16202B3F198C4D57647138A354CB0B3A" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_16202B3F198C4D57647138A354CB0B3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_5A0F705F87901A5DA53938A354CB64D9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_5A0F705F87901A5DA53938A354CB64D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_5A0F705F87901A5DA53938A354CB64D9_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_5A0F705F87901A5DA53938A354CB64D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_5A0F705F87901A5DA53938A354CB64D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_5A0F705F87901A5DA53938A354CB64D9" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_5A0F705F87901A5DA53938A354CB64D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_D2C5813874BB18C9D08138A354CB1A02_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_D2C5813874BB18C9D08138A354CB1A02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_D2C5813874BB18C9D08138A354CB1A02_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_D2C5813874BB18C9D08138A354CB1A02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_D2C5813874BB18C9D08138A354CB1A02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_D2C5813874BB18C9D08138A354CB1A02" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_D2C5813874BB18C9D08138A354CB1A02" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_2125F2319C41BC03CD8838A354CBFB90_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_2125F2319C41BC03CD8838A354CBFB90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_2125F2319C41BC03CD8838A354CBFB90_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_2125F2319C41BC03CD8838A354CBFB90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_2125F2319C41BC03CD8838A354CBFB90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_2125F2319C41BC03CD8838A354CBFB90" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_2125F2319C41BC03CD8838A354CBFB90" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_2EE2B2EC0A7626FE3A7238A354CB16EF_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_2EE2B2EC0A7626FE3A7238A354CB16EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_2EE2B2EC0A7626FE3A7238A354CB16EF_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_2EE2B2EC0A7626FE3A7238A354CB16EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_2EE2B2EC0A7626FE3A7238A354CB16EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_2EE2B2EC0A7626FE3A7238A354CB16EF" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_2EE2B2EC0A7626FE3A7238A354CB16EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_E8EC518AA4888EE77E3C38A354CB51CD_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_E8EC518AA4888EE77E3C38A354CB51CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_E8EC518AA4888EE77E3C38A354CB51CD_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_E8EC518AA4888EE77E3C38A354CB51CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_E8EC518AA4888EE77E3C38A354CB51CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_E8EC518AA4888EE77E3C38A354CB51CD" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_E8EC518AA4888EE77E3C38A354CB51CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_B98C0FFB093AC41D542638A354CCCDA6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_B98C0FFB093AC41D542638A354CCCDA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_B98C0FFB093AC41D542638A354CCCDA6_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_B98C0FFB093AC41D542638A354CCCDA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_B98C0FFB093AC41D542638A354CCCDA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_B98C0FFB093AC41D542638A354CCCDA6" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_B98C0FFB093AC41D542638A354CCCDA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0807D66A1150EC4ABF2838A353B23143_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0807D66A1150EC4ABF2838A353B23143" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0807D66A1150EC4ABF2838A353B23143_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0807D66A1150EC4ABF2838A353B23143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0807D66A1150EC4ABF2838A353B23143" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0807D66A1150EC4ABF2838A353B23143" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0807D66A1150EC4ABF2838A353B23143" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_57E469E45496C534E1E238A356B3D278_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_57E469E45496C534E1E238A356B3D278" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_57E469E45496C534E1E238A356B3D278_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_57E469E45496C534E1E238A356B3D278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_57E469E45496C534E1E238A356B3D278" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_57E469E45496C534E1E238A356B3D278" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_57E469E45496C534E1E238A356B3D278" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2A61573EE6301817F85C38A356B37F89_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2A61573EE6301817F85C38A356B37F89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2A61573EE6301817F85C38A356B37F89_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2A61573EE6301817F85C38A356B37F89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2A61573EE6301817F85C38A356B37F89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2A61573EE6301817F85C38A356B37F89" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2A61573EE6301817F85C38A356B37F89" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54A9AE8BE9B847EC449A38A356B37002_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54A9AE8BE9B847EC449A38A356B37002" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54A9AE8BE9B847EC449A38A356B37002_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54A9AE8BE9B847EC449A38A356B37002" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54A9AE8BE9B847EC449A38A356B37002" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54A9AE8BE9B847EC449A38A356B37002" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54A9AE8BE9B847EC449A38A356B37002" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_912A5211016B15994A0938A356B34CDE_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_912A5211016B15994A0938A356B34CDE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_912A5211016B15994A0938A356B34CDE_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_912A5211016B15994A0938A356B34CDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_912A5211016B15994A0938A356B34CDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_912A5211016B15994A0938A356B34CDE" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_912A5211016B15994A0938A356B34CDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_BDFEAE4247B6DF7DD91238A356B39C45_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_BDFEAE4247B6DF7DD91238A356B39C45" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_BDFEAE4247B6DF7DD91238A356B39C45_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_BDFEAE4247B6DF7DD91238A356B39C45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_BDFEAE4247B6DF7DD91238A356B39C45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_BDFEAE4247B6DF7DD91238A356B39C45" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_BDFEAE4247B6DF7DD91238A356B39C45" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_83B9CD8CEE450A8E474738A356B3CF17_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_83B9CD8CEE450A8E474738A356B3CF17" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_83B9CD8CEE450A8E474738A356B3CF17_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_83B9CD8CEE450A8E474738A356B3CF17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_83B9CD8CEE450A8E474738A356B3CF17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_83B9CD8CEE450A8E474738A356B3CF17" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_83B9CD8CEE450A8E474738A356B3CF17" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_DEEABE05639E36828F0238A356B3C7E4_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_DEEABE05639E36828F0238A356B3C7E4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_DEEABE05639E36828F0238A356B3C7E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_DEEABE05639E36828F0238A356B3C7E4" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_DEEABE05639E36828F0238A356B3C7E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_2A58EF54765ACD13352738A356B3EBD9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_2A58EF54765ACD13352738A356B3EBD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_2A58EF54765ACD13352738A356B3EBD9_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_2A58EF54765ACD13352738A356B3EBD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2A58EF54765ACD13352738A356B3EBD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2A58EF54765ACD13352738A356B3EBD9" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_2A58EF54765ACD13352738A356B3EBD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5E70717DD42DCEF281BB38A356B3B66C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5E70717DD42DCEF281BB38A356B3B66C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, by Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5E70717DD42DCEF281BB38A356B3B66C_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5E70717DD42DCEF281BB38A356B3B66C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5E70717DD42DCEF281BB38A356B3B66C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5E70717DD42DCEF281BB38A356B3B66C" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5E70717DD42DCEF281BB38A356B3B66C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_BE4A1FACA42DC4D6EE1F38A356B37E0C_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_BE4A1FACA42DC4D6EE1F38A356B37E0C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_BE4A1FACA42DC4D6EE1F38A356B37E0C_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_BE4A1FACA42DC4D6EE1F38A356B37E0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_BE4A1FACA42DC4D6EE1F38A356B37E0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_BE4A1FACA42DC4D6EE1F38A356B37E0C" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_BE4A1FACA42DC4D6EE1F38A356B37E0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_0955D638C7816BCB216138A356B324DD_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_0955D638C7816BCB216138A356B324DD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_0955D638C7816BCB216138A356B324DD_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_0955D638C7816BCB216138A356B324DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_0955D638C7816BCB216138A356B324DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_0955D638C7816BCB216138A356B324DD" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_0955D638C7816BCB216138A356B324DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_362E30C5F20DCB9149B138A356B31269_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_362E30C5F20DCB9149B138A356B31269" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_362E30C5F20DCB9149B138A356B31269_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_362E30C5F20DCB9149B138A356B31269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_362E30C5F20DCB9149B138A356B31269" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_362E30C5F20DCB9149B138A356B31269" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_362E30C5F20DCB9149B138A356B31269" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_CB0BBE2DA7A3AE99178C38A356B4AC68_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_CB0BBE2DA7A3AE99178C38A356B4AC68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_CB0BBE2DA7A3AE99178C38A356B4AC68_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_CB0BBE2DA7A3AE99178C38A356B4AC68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_CB0BBE2DA7A3AE99178C38A356B4AC68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_CB0BBE2DA7A3AE99178C38A356B4AC68" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_CB0BBE2DA7A3AE99178C38A356B4AC68" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_785FFD586FB922C5947B38A356B43DC6_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_785FFD586FB922C5947B38A356B43DC6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_785FFD586FB922C5947B38A356B43DC6_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_785FFD586FB922C5947B38A356B43DC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_785FFD586FB922C5947B38A356B43DC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_785FFD586FB922C5947B38A356B43DC6" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_785FFD586FB922C5947B38A356B43DC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2435279020FE517F5D0138A356B4D467_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2435279020FE517F5D0138A356B4D467" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2435279020FE517F5D0138A356B4D467_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2435279020FE517F5D0138A356B4D467" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2435279020FE517F5D0138A356B4D467" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2435279020FE517F5D0138A356B4D467" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2435279020FE517F5D0138A356B4D467" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_339DCBB7E8ECF5E073B938A356B40CFE_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_339DCBB7E8ECF5E073B938A356B40CFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_339DCBB7E8ECF5E073B938A356B40CFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_339DCBB7E8ECF5E073B938A356B40CFE" xlink:to="lab_us-gaap_AvailableForSaleSecurities_339DCBB7E8ECF5E073B938A356B40CFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_29DB9608F328A6EBD47338A356B44497_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_29DB9608F328A6EBD47338A356B44497" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_29DB9608F328A6EBD47338A356B44497_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_29DB9608F328A6EBD47338A356B44497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_29DB9608F328A6EBD47338A356B44497" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_29DB9608F328A6EBD47338A356B44497" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_29DB9608F328A6EBD47338A356B44497" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_71DF90912EC9A7A3F03838A356B42724_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_71DF90912EC9A7A3F03838A356B42724" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_71DF90912EC9A7A3F03838A356B42724_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_71DF90912EC9A7A3F03838A356B42724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_71DF90912EC9A7A3F03838A356B42724" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_71DF90912EC9A7A3F03838A356B42724" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_71DF90912EC9A7A3F03838A356B42724" xlink:type="arc" />
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_D6613B9F2C7F5BDDD6E138A356B409F6_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_D6613B9F2C7F5BDDD6E138A356B409F6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_D6613B9F2C7F5BDDD6E138A356B409F6_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_D6613B9F2C7F5BDDD6E138A356B409F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_D6613B9F2C7F5BDDD6E138A356B409F6_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_D6613B9F2C7F5BDDD6E138A356B409F6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_D6613B9F2C7F5BDDD6E138A356B409F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_D6613B9F2C7F5BDDD6E138A356B409F6" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_D6613B9F2C7F5BDDD6E138A356B409F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_21703CC0597A5CED4AE638A356B4FA34_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_21703CC0597A5CED4AE638A356B4FA34" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_21703CC0597A5CED4AE638A356B4FA34_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_21703CC0597A5CED4AE638A356B4FA34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_21703CC0597A5CED4AE638A356B4FA34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_21703CC0597A5CED4AE638A356B4FA34" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_21703CC0597A5CED4AE638A356B4FA34" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_D14D031534A103A6E7E638A356B40464_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_D14D031534A103A6E7E638A356B40464" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_D14D031534A103A6E7E638A356B40464_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_D14D031534A103A6E7E638A356B40464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_D14D031534A103A6E7E638A356B40464" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_D14D031534A103A6E7E638A356B40464" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_D14D031534A103A6E7E638A356B40464" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_7F68FAB9F50E8E82BD0E38A356B41F5E_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_7F68FAB9F50E8E82BD0E38A356B41F5E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_7F68FAB9F50E8E82BD0E38A356B41F5E_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_7F68FAB9F50E8E82BD0E38A356B41F5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_7F68FAB9F50E8E82BD0E38A356B41F5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_7F68FAB9F50E8E82BD0E38A356B41F5E" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_7F68FAB9F50E8E82BD0E38A356B41F5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_FB8E4292A1916FDF3A7538A356B48513_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_FB8E4292A1916FDF3A7538A356B48513" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_FB8E4292A1916FDF3A7538A356B48513" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_FB8E4292A1916FDF3A7538A356B48513" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_FB8E4292A1916FDF3A7538A356B48513" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_69ADC2C3331D96F2CC4238A356B46C0C_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_69ADC2C3331D96F2CC4238A356B46C0C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_69ADC2C3331D96F2CC4238A356B46C0C_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_69ADC2C3331D96F2CC4238A356B46C0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_69ADC2C3331D96F2CC4238A356B46C0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_69ADC2C3331D96F2CC4238A356B46C0C" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_69ADC2C3331D96F2CC4238A356B46C0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_E448DD3DC4E6E476E03A38A3521B051D_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_E448DD3DC4E6E476E03A38A3521B051D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_E448DD3DC4E6E476E03A38A3521B051D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_E448DD3DC4E6E476E03A38A3521B051D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_E448DD3DC4E6E476E03A38A3521B051D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_E448DD3DC4E6E476E03A38A3521B051D" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_E448DD3DC4E6E476E03A38A3521B051D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_84D06638AC9F8380998338A3521C7A22_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_84D06638AC9F8380998338A3521C7A22" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as hedging instruments on our consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_84D06638AC9F8380998338A3521C7A22_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_84D06638AC9F8380998338A3521C7A22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_84D06638AC9F8380998338A3521C7A22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_84D06638AC9F8380998338A3521C7A22" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_84D06638AC9F8380998338A3521C7A22" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_831E845CB835245C770938A3521CC6B7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_831E845CB835245C770938A3521CC6B7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the fair value for our outstanding derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_831E845CB835245C770938A3521CC6B7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_831E845CB835245C770938A3521CC6B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_831E845CB835245C770938A3521CC6B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_831E845CB835245C770938A3521CC6B7" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_831E845CB835245C770938A3521CC6B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_3A080AABFA8A8DC6211238A3560EEC50_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_3A080AABFA8A8DC6211238A3560EEC50" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_3A080AABFA8A8DC6211238A3560EEC50_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_3A080AABFA8A8DC6211238A3560EEC50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_3A080AABFA8A8DC6211238A3560EEC50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_3A080AABFA8A8DC6211238A3560EEC50" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_3A080AABFA8A8DC6211238A3560EEC50" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EF01E040FA752695E61238A351FC5C6A_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EF01E040FA752695E61238A351FC5C6A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EF01E040FA752695E61238A351FC5C6A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EF01E040FA752695E61238A351FC5C6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EF01E040FA752695E61238A351FC5C6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EF01E040FA752695E61238A351FC5C6A" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EF01E040FA752695E61238A351FC5C6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6BE19F29BC142591D08938A351FC9620_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6BE19F29BC142591D08938A351FC9620" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6BE19F29BC142591D08938A351FC9620_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6BE19F29BC142591D08938A351FC9620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6BE19F29BC142591D08938A351FC9620" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6BE19F29BC142591D08938A351FC9620" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6BE19F29BC142591D08938A351FC9620" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_E4C0230BAC9593C40AD238A351FCB052_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_E4C0230BAC9593C40AD238A351FCB052" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_E4C0230BAC9593C40AD238A351FCB052_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_E4C0230BAC9593C40AD238A351FCB052" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_E4C0230BAC9593C40AD238A351FCB052" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_E4C0230BAC9593C40AD238A351FCB052" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_E4C0230BAC9593C40AD238A351FCB052" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8D38CBD45DEDA3BCA97538A351FC691C_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8D38CBD45DEDA3BCA97538A351FC691C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8D38CBD45DEDA3BCA97538A351FC691C_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8D38CBD45DEDA3BCA97538A351FC691C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8D38CBD45DEDA3BCA97538A351FC691C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8D38CBD45DEDA3BCA97538A351FC691C" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8D38CBD45DEDA3BCA97538A351FC691C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_CA13F1811A3D713F326A38A351FC1C0C_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_CA13F1811A3D713F326A38A351FC1C0C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_CA13F1811A3D713F326A38A351FC1C0C_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_CA13F1811A3D713F326A38A351FC1C0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_CA13F1811A3D713F326A38A351FC1C0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_CA13F1811A3D713F326A38A351FC1C0C" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_CA13F1811A3D713F326A38A351FC1C0C" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3D57C402E984713838A838A351FC5996_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3D57C402E984713838A838A351FC5996" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, Estimated Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3D57C402E984713838A838A351FC5996_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3D57C402E984713838A838A351FC5996" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3D57C402E984713838A838A351FC5996_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3D57C402E984713838A838A351FC5996" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3D57C402E984713838A838A351FC5996" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3D57C402E984713838A838A351FC5996" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3D57C402E984713838A838A351FC5996" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_DBDADBF79C3EA111C15238A351FC9CC2_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_DBDADBF79C3EA111C15238A351FC9CC2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_DBDADBF79C3EA111C15238A351FC9CC2_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_DBDADBF79C3EA111C15238A351FC9CC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_DBDADBF79C3EA111C15238A351FC9CC2_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_DBDADBF79C3EA111C15238A351FC9CC2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_DBDADBF79C3EA111C15238A351FC9CC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_DBDADBF79C3EA111C15238A351FC9CC2" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_DBDADBF79C3EA111C15238A351FC9CC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_C06D06D52618DE93D0C138A351FCC0B8_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_C06D06D52618DE93D0C138A351FCC0B8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_C06D06D52618DE93D0C138A351FCC0B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_C06D06D52618DE93D0C138A351FCC0B8" xlink:to="lab_us-gaap_AvailableForSaleSecurities_C06D06D52618DE93D0C138A351FCC0B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D7164B12F5430C52F56238A351FC93EB_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D7164B12F5430C52F56238A351FC93EB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D7164B12F5430C52F56238A351FC93EB_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D7164B12F5430C52F56238A351FC93EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D7164B12F5430C52F56238A351FC93EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D7164B12F5430C52F56238A351FC93EB" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D7164B12F5430C52F56238A351FC93EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_66AA109B483A91BB8A9D38A355BD7E3A_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_66AA109B483A91BB8A9D38A355BD7E3A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_66AA109B483A91BB8A9D38A355BD7E3A_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_66AA109B483A91BB8A9D38A355BD7E3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_66AA109B483A91BB8A9D38A355BD7E3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_66AA109B483A91BB8A9D38A355BD7E3A" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_66AA109B483A91BB8A9D38A355BD7E3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_434012B3355A71DBF87E38A355BDEA98_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_434012B3355A71DBF87E38A355BDEA98" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_434012B3355A71DBF87E38A355BDEA98_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_434012B3355A71DBF87E38A355BDEA98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_434012B3355A71DBF87E38A355BDEA98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_434012B3355A71DBF87E38A355BDEA98" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_434012B3355A71DBF87E38A355BDEA98" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockShares_87C478E331ED820A9B3438A355BD6D6A_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_87C478E331ED820A9B3438A355BD6D6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_87C478E331ED820A9B3438A355BD6D6A_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_87C478E331ED820A9B3438A355BD6D6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_87C478E331ED820A9B3438A355BD6D6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_87C478E331ED820A9B3438A355BD6D6A" xlink:to="lab_us-gaap_TreasuryStockShares_87C478E331ED820A9B3438A355BD6D6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_F471BED0362C729C95BD38A356E2E24D_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions_F471BED0362C729C95BD38A356E2E24D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Triangle Park facility purchase</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_F471BED0362C729C95BD38A356E2E24D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions_F471BED0362C729C95BD38A356E2E24D" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions_F471BED0362C729C95BD38A356E2E24D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_BE19AAFE1837CFBA8E3538A3559FA0C2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_BE19AAFE1837CFBA8E3538A3559FA0C2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reserves for Discounts and Allowances</link:label>
    <link:label id="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_BE19AAFE1837CFBA8E3538A3559FA0C2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_BE19AAFE1837CFBA8E3538A3559FA0C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_BE19AAFE1837CFBA8E3538A3559FA0C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_BE19AAFE1837CFBA8E3538A3559FA0C2" xlink:to="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_BE19AAFE1837CFBA8E3538A3559FA0C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0A3D4999315E6FBDE7B738A35337B497_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0A3D4999315E6FBDE7B738A35337B497" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0A3D4999315E6FBDE7B738A35337B497_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0A3D4999315E6FBDE7B738A35337B497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0A3D4999315E6FBDE7B738A35337B497" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0A3D4999315E6FBDE7B738A35337B497" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0A3D4999315E6FBDE7B738A35337B497" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8308648ACADD6FDDEB9B38A35337A635_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8308648ACADD6FDDEB9B38A35337A635" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8308648ACADD6FDDEB9B38A35337A635_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8308648ACADD6FDDEB9B38A35337A635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8308648ACADD6FDDEB9B38A35337A635" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8308648ACADD6FDDEB9B38A35337A635" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8308648ACADD6FDDEB9B38A35337A635" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_93ACC9B4D340EDA02A2938A35337A575_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_93ACC9B4D340EDA02A2938A35337A575" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_93ACC9B4D340EDA02A2938A35337A575_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_93ACC9B4D340EDA02A2938A35337A575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_93ACC9B4D340EDA02A2938A35337A575" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_93ACC9B4D340EDA02A2938A35337A575" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_93ACC9B4D340EDA02A2938A35337A575" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock_E0CAC3CDE8862A85A4E838A35337E024_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock_E0CAC3CDE8862A85A4E838A35337E024" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit and cash received from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock_E0CAC3CDE8862A85A4E838A35337E024_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock_E0CAC3CDE8862A85A4E838A35337E024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Proceeds Received from Share-based Payment Awards [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock_E0CAC3CDE8862A85A4E838A35337E024" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock_E0CAC3CDE8862A85A4E838A35337E024" xlink:to="lab_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock_E0CAC3CDE8862A85A4E838A35337E024" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_1176190B842E78BCEF9438A35337932F_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_1176190B842E78BCEF9438A35337932F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market stock units activity</link:label>
    <link:label id="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_1176190B842E78BCEF9438A35337932F_label_en-US" xlink:label="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_1176190B842E78BCEF9438A35337932F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Market Stock Units Activity [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_1176190B842E78BCEF9438A35337932F_documentation_en-US" xlink:label="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_1176190B842E78BCEF9438A35337932F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Market Stock Units Activity.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_1176190B842E78BCEF9438A35337932F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_1176190B842E78BCEF9438A35337932F" xlink:to="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_1176190B842E78BCEF9438A35337932F" xlink:type="arc" />
    <link:label id="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F621CC2E288380B2A6238A35337141B_terseLabel_en-US" xlink:label="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F621CC2E288380B2A6238A35337141B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions used in valuation of market based stock units</link:label>
    <link:label id="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F621CC2E288380B2A6238A35337141B_label_en-US" xlink:label="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F621CC2E288380B2A6238A35337141B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assumptions Used In Valuation Of Market Based Stock Units [Table Text Block]</link:label>
    <link:label id="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F621CC2E288380B2A6238A35337141B_documentation_en-US" xlink:label="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F621CC2E288380B2A6238A35337141B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assumptions used in valuation of market based stock units.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" xlink:label="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F621CC2E288380B2A6238A35337141B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F621CC2E288380B2A6238A35337141B" xlink:to="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F621CC2E288380B2A6238A35337141B" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_7F191088F1D189683E0A38A3533795C4_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_7F191088F1D189683E0A38A3533795C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares activity</link:label>
    <link:label id="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_7F191088F1D189683E0A38A3533795C4_label_en-US" xlink:label="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_7F191088F1D189683E0A38A3533795C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Cash Settled Performance Shares Activity [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_7F191088F1D189683E0A38A3533795C4_documentation_en-US" xlink:label="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_7F191088F1D189683E0A38A3533795C4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Cash Settled Performance Shares Activity.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_7F191088F1D189683E0A38A3533795C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_7F191088F1D189683E0A38A3533795C4" xlink:to="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_7F191088F1D189683E0A38A3533795C4" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceunitsactivityTableTextBlock_BBB1B5A845E01B63B77D38A353378611_terseLabel_en-US" xlink:label="lab_biib_PerformanceunitsactivityTableTextBlock_BBB1B5A845E01B63B77D38A353378611" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units activity</link:label>
    <link:label id="lab_biib_PerformanceunitsactivityTableTextBlock_BBB1B5A845E01B63B77D38A353378611_label_en-US" xlink:label="lab_biib_PerformanceunitsactivityTableTextBlock_BBB1B5A845E01B63B77D38A353378611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance units activity [Table Text Block]</link:label>
    <link:label id="lab_biib_PerformanceunitsactivityTableTextBlock_BBB1B5A845E01B63B77D38A353378611_documentation_en-US" xlink:label="lab_biib_PerformanceunitsactivityTableTextBlock_BBB1B5A845E01B63B77D38A353378611" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance units activity [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PerformanceunitsactivityTableTextBlock" xlink:label="loc_biib_PerformanceunitsactivityTableTextBlock_BBB1B5A845E01B63B77D38A353378611" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceunitsactivityTableTextBlock_BBB1B5A845E01B63B77D38A353378611" xlink:to="lab_biib_PerformanceunitsactivityTableTextBlock_BBB1B5A845E01B63B77D38A353378611" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_5BDF64A4DE698C6828E238A3533701D4_terseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_5BDF64A4DE698C6828E238A3533701D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units activity</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_5BDF64A4DE698C6828E238A3533701D4_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_5BDF64A4DE698C6828E238A3533701D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_5BDF64A4DE698C6828E238A3533701D4_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_5BDF64A4DE698C6828E238A3533701D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units Activity.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_5BDF64A4DE698C6828E238A3533701D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_5BDF64A4DE698C6828E238A3533701D4" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_5BDF64A4DE698C6828E238A3533701D4" xlink:type="arc" />
    <link:label id="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_33DADADAB25D4EE39B7838A3533745B4_terseLabel_en-US" xlink:label="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_33DADADAB25D4EE39B7838A3533745B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under employee stock purchase plan</link:label>
    <link:label id="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_33DADADAB25D4EE39B7838A3533745B4_label_en-US" xlink:label="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_33DADADAB25D4EE39B7838A3533745B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued Under Employee Stock Purchase Plan [Table Text Block]</link:label>
    <link:label id="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_33DADADAB25D4EE39B7838A3533745B4_documentation_en-US" xlink:label="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_33DADADAB25D4EE39B7838A3533745B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares issued under employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" xlink:label="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_33DADADAB25D4EE39B7838A3533745B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_33DADADAB25D4EE39B7838A3533745B4" xlink:to="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_33DADADAB25D4EE39B7838A3533745B4" xlink:type="arc" />
    <link:label id="lab_biib_RaxatrigineMember_914C5EE36A52C7A9F7CB65DB84EF5DC9_terseLabel_en-US" xlink:label="lab_biib_RaxatrigineMember_914C5EE36A52C7A9F7CB65DB84EF5DC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raxatrigine</link:label>
    <link:label id="lab_biib_RaxatrigineMember_914C5EE36A52C7A9F7CB65DB84EF5DC9_label_en-US" xlink:label="lab_biib_RaxatrigineMember_914C5EE36A52C7A9F7CB65DB84EF5DC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Raxatrigine [Member]</link:label>
    <link:label id="lab_biib_RaxatrigineMember_914C5EE36A52C7A9F7CB65DB84EF5DC9_documentation_en-US" xlink:label="lab_biib_RaxatrigineMember_914C5EE36A52C7A9F7CB65DB84EF5DC9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Raxatrigine [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RaxatrigineMember" xlink:label="loc_biib_RaxatrigineMember_914C5EE36A52C7A9F7CB65DB84EF5DC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RaxatrigineMember_914C5EE36A52C7A9F7CB65DB84EF5DC9" xlink:to="lab_biib_RaxatrigineMember_914C5EE36A52C7A9F7CB65DB84EF5DC9" xlink:type="arc" />
    <link:label id="lab_biib_NeuropathicpainindicationsMember_F45DC58CC17DFC3574FF65DB84EF4DCD_terseLabel_en-US" xlink:label="lab_biib_NeuropathicpainindicationsMember_F45DC58CC17DFC3574FF65DB84EF4DCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neuropathic pain indications</link:label>
    <link:label id="lab_biib_NeuropathicpainindicationsMember_F45DC58CC17DFC3574FF65DB84EF4DCD_label_en-US" xlink:label="lab_biib_NeuropathicpainindicationsMember_F45DC58CC17DFC3574FF65DB84EF4DCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neuropathic pain indications [Member]</link:label>
    <link:label id="lab_biib_NeuropathicpainindicationsMember_F45DC58CC17DFC3574FF65DB84EF4DCD_documentation_en-US" xlink:label="lab_biib_NeuropathicpainindicationsMember_F45DC58CC17DFC3574FF65DB84EF4DCD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neuropathic pain indications [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_NeuropathicpainindicationsMember" xlink:label="loc_biib_NeuropathicpainindicationsMember_F45DC58CC17DFC3574FF65DB84EF4DCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeuropathicpainindicationsMember_F45DC58CC17DFC3574FF65DB84EF4DCD" xlink:to="lab_biib_NeuropathicpainindicationsMember_F45DC58CC17DFC3574FF65DB84EF4DCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_88E6E843AF55C281FAC465DB84F0C24E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_88E6E843AF55C281FAC465DB84F0C24E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_88E6E843AF55C281FAC465DB84F0C24E_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_88E6E843AF55C281FAC465DB84F0C24E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_88E6E843AF55C281FAC465DB84F0C24E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_88E6E843AF55C281FAC465DB84F0C24E" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_88E6E843AF55C281FAC465DB84F0C24E" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_9222F5B584599A22563D65DB84F0001C_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease_9222F5B584599A22563D65DB84F0001C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_9222F5B584599A22563D65DB84F0001C_label_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease_9222F5B584599A22563D65DB84F0001C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_9222F5B584599A22563D65DB84F0001C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPeriodIncreaseDecrease_9222F5B584599A22563D65DB84F0001C" xlink:to="lab_us-gaap_GoodwillPeriodIncreaseDecrease_9222F5B584599A22563D65DB84F0001C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsDiscountRate_35EFFC671EFCA996157865DB84F0BE00_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsDiscountRate_35EFFC671EFCA996157865DB84F0BE00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_35EFFC671EFCA996157865DB84F0BE00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsDiscountRate_35EFFC671EFCA996157865DB84F0BE00" xlink:to="lab_us-gaap_FairValueInputsDiscountRate_35EFFC671EFCA996157865DB84F0BE00" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_7EDF24EA0B9F59FCB40E65DB84F02611_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_7EDF24EA0B9F59FCB40E65DB84F02611" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of TYSABRI rights</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_7EDF24EA0B9F59FCB40E65DB84F02611_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_7EDF24EA0B9F59FCB40E65DB84F02611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7EDF24EA0B9F59FCB40E65DB84F02611" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7EDF24EA0B9F59FCB40E65DB84F02611" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_7EDF24EA0B9F59FCB40E65DB84F02611" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_C78F65BF68E23F5486C465DB84F0AAEC_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_C78F65BF68E23F5486C465DB84F0AAEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_C78F65BF68E23F5486C465DB84F0AAEC_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_C78F65BF68E23F5486C465DB84F0AAEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_C78F65BF68E23F5486C465DB84F0AAEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_C78F65BF68E23F5486C465DB84F0AAEC" xlink:to="lab_us-gaap_DeferredRevenueCurrent_C78F65BF68E23F5486C465DB84F0AAEC" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentPaymentForFirst12Months_2D28165EC5D48327DA2065DB84F0CC40_terseLabel_en-US" xlink:label="lab_biib_FutureContingentPaymentForFirst12Months_2D28165EC5D48327DA2065DB84F0CC40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future contingent payment for the first 12 months</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForFirst12Months_2D28165EC5D48327DA2065DB84F0CC40_label_en-US" xlink:label="lab_biib_FutureContingentPaymentForFirst12Months_2D28165EC5D48327DA2065DB84F0CC40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future contingent payment for the first 12 months</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForFirst12Months_2D28165EC5D48327DA2065DB84F0CC40_documentation_en-US" xlink:label="lab_biib_FutureContingentPaymentForFirst12Months_2D28165EC5D48327DA2065DB84F0CC40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future contingent payment for the first 12 months</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_FutureContingentPaymentForFirst12Months" xlink:label="loc_biib_FutureContingentPaymentForFirst12Months_2D28165EC5D48327DA2065DB84F0CC40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentPaymentForFirst12Months_2D28165EC5D48327DA2065DB84F0CC40" xlink:to="lab_biib_FutureContingentPaymentForFirst12Months_2D28165EC5D48327DA2065DB84F0CC40" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_1207F3F98AB356C20B4C65DB84F0F103_terseLabel_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_1207F3F98AB356C20B4C65DB84F0F103" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales up to $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_1207F3F98AB356C20B4C65DB84F0F103_label_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_1207F3F98AB356C20B4C65DB84F0F103" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales up to $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_1207F3F98AB356C20B4C65DB84F0F103_documentation_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_1207F3F98AB356C20B4C65DB84F0F103" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales up to $2.0 billion</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_1207F3F98AB356C20B4C65DB84F0F103" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_1207F3F98AB356C20B4C65DB84F0F103" xlink:to="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_1207F3F98AB356C20B4C65DB84F0F103" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentPaymentThreshold_EB879259F15D73B381E465DB84F0F05E_terseLabel_en-US" xlink:label="lab_biib_FutureContingentPaymentThreshold_EB879259F15D73B381E465DB84F0F05E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future contingent payment threshold</link:label>
    <link:label id="lab_biib_FutureContingentPaymentThreshold_EB879259F15D73B381E465DB84F0F05E_label_en-US" xlink:label="lab_biib_FutureContingentPaymentThreshold_EB879259F15D73B381E465DB84F0F05E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future contingent payment threshold</link:label>
    <link:label id="lab_biib_FutureContingentPaymentThreshold_EB879259F15D73B381E465DB84F0F05E_documentation_en-US" xlink:label="lab_biib_FutureContingentPaymentThreshold_EB879259F15D73B381E465DB84F0F05E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future contingent payment threshold</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_FutureContingentPaymentThreshold" xlink:label="loc_biib_FutureContingentPaymentThreshold_EB879259F15D73B381E465DB84F0F05E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentPaymentThreshold_EB879259F15D73B381E465DB84F0F05E" xlink:to="lab_biib_FutureContingentPaymentThreshold_EB879259F15D73B381E465DB84F0F05E" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_EFAF0F346EBA5B8C8E9265DB84F0ABFE_terseLabel_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_EFAF0F346EBA5B8C8E9265DB84F0ABFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_EFAF0F346EBA5B8C8E9265DB84F0ABFE_label_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_EFAF0F346EBA5B8C8E9265DB84F0ABFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_EFAF0F346EBA5B8C8E9265DB84F0ABFE_documentation_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_EFAF0F346EBA5B8C8E9265DB84F0ABFE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_EFAF0F346EBA5B8C8E9265DB84F0ABFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_EFAF0F346EBA5B8C8E9265DB84F0ABFE" xlink:to="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_EFAF0F346EBA5B8C8E9265DB84F0ABFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_6E2297FA4DAE033A4C9638A35128886A_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_6E2297FA4DAE033A4C9638A35128886A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_6E2297FA4DAE033A4C9638A35128886A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_6E2297FA4DAE033A4C9638A35128886A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_6E2297FA4DAE033A4C9638A35128886A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_6E2297FA4DAE033A4C9638A35128886A" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_6E2297FA4DAE033A4C9638A35128886A" xlink:type="arc" />
    <link:label id="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_A5718F1CAD6250C4B26338A3520DA6C8_verboseLabel_en-US" xlink:label="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_A5718F1CAD6250C4B26338A3520DA6C8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit and cash received from stock option</link:label>
    <link:label id="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_A5718F1CAD6250C4B26338A3520DA6C8_label_en-US" xlink:label="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_A5718F1CAD6250C4B26338A3520DA6C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Benefit And Cash Received From Stock Option [Abstract]</link:label>
    <link:label id="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_A5718F1CAD6250C4B26338A3520DA6C8_documentation_en-US" xlink:label="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_A5718F1CAD6250C4B26338A3520DA6C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax benefit and cash received from stock option.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_TaxBenefitAndCashReceivedFromStockOptionAbstract" xlink:label="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_A5718F1CAD6250C4B26338A3520DA6C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_A5718F1CAD6250C4B26338A3520DA6C8" xlink:to="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_A5718F1CAD6250C4B26338A3520DA6C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions_663A10335DC630C2A8CE38A3520E3A2D_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions_663A10335DC630C2A8CE38A3520E3A2D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit realized for stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions_663A10335DC630C2A8CE38A3520E3A2D_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions_663A10335DC630C2A8CE38A3520E3A2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions_663A10335DC630C2A8CE38A3520E3A2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions_663A10335DC630C2A8CE38A3520E3A2D" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions_663A10335DC630C2A8CE38A3520E3A2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_60430BCC7299E5C08BEE38A3520EF38F_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_60430BCC7299E5C08BEE38A3520EF38F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash received from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_60430BCC7299E5C08BEE38A3520EF38F_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_60430BCC7299E5C08BEE38A3520EF38F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_60430BCC7299E5C08BEE38A3520EF38F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_60430BCC7299E5C08BEE38A3520EF38F" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_60430BCC7299E5C08BEE38A3520EF38F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_1A3F21360DF7A429BC4993582E2211A8_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_1A3F21360DF7A429BC4993582E2211A8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue-related rebates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1A3F21360DF7A429BC4993582E2211A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_1A3F21360DF7A429BC4993582E2211A8" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_1A3F21360DF7A429BC4993582E2211A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_222548CC92E403F117FB93582E232390_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_222548CC92E403F117FB93582E232390" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Paid During the Year</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_222548CC92E403F117FB93582E232390_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_222548CC92E403F117FB93582E232390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_222548CC92E403F117FB93582E232390" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_222548CC92E403F117FB93582E232390" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_222548CC92E403F117FB93582E232390" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_238A61B74532B4F9BA1E93582E23D7FA_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_238A61B74532B4F9BA1E93582E23D7FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_238A61B74532B4F9BA1E93582E23D7FA_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_238A61B74532B4F9BA1E93582E23D7FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_238A61B74532B4F9BA1E93582E23D7FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_238A61B74532B4F9BA1E93582E23D7FA" xlink:to="lab_us-gaap_InterestPaidNet_238A61B74532B4F9BA1E93582E23D7FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_110627A1A8A89C33CEFC93582E23938F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_110627A1A8A89C33CEFC93582E23938F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_110627A1A8A89C33CEFC93582E23938F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_110627A1A8A89C33CEFC93582E23938F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_110627A1A8A89C33CEFC93582E23938F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_110627A1A8A89C33CEFC93582E23938F" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_110627A1A8A89C33CEFC93582E23938F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0BD9BBB6E1BDEFDBF72993582E236AF2_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0BD9BBB6E1BDEFDBF72993582E236AF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0BD9BBB6E1BDEFDBF72993582E236AF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0BD9BBB6E1BDEFDBF72993582E236AF2" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0BD9BBB6E1BDEFDBF72993582E236AF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_604DB9E231D85549B11893582E23CFFC_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_604DB9E231D85549B11893582E23CFFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_604DB9E231D85549B11893582E23CFFC_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_604DB9E231D85549B11893582E23CFFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_604DB9E231D85549B11893582E23CFFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_604DB9E231D85549B11893582E23CFFC" xlink:to="lab_us-gaap_InvestmentIncomeInterest_604DB9E231D85549B11893582E23CFFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_4DE51CC62B8B256F782293582E2379F6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_4DE51CC62B8B256F782293582E2379F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_4DE51CC62B8B256F782293582E2379F6_label_en-US" xlink:label="lab_us-gaap_InterestExpense_4DE51CC62B8B256F782293582E2379F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_4DE51CC62B8B256F782293582E2379F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_4DE51CC62B8B256F782293582E2379F6" xlink:to="lab_us-gaap_InterestExpense_4DE51CC62B8B256F782293582E2379F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfInvestments_2939AF52705A4DBF276893582E2375A0_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfInvestments_2939AF52705A4DBF276893582E2375A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment on investments</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfInvestments_2939AF52705A4DBF276893582E2375A0_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfInvestments_2939AF52705A4DBF276893582E2375A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other than Temporary Impairment Losses, Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="loc_us-gaap_ImpairmentOfInvestments_2939AF52705A4DBF276893582E2375A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfInvestments_2939AF52705A4DBF276893582E2375A0" xlink:to="lab_us-gaap_ImpairmentOfInvestments_2939AF52705A4DBF276893582E2375A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_288877178BCEBB704C2493582E23ED93_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_288877178BCEBB704C2493582E23ED93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investments, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_288877178BCEBB704C2493582E23ED93_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_288877178BCEBB704C2493582E23ED93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_288877178BCEBB704C2493582E23ED93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments_288877178BCEBB704C2493582E23ED93" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments_288877178BCEBB704C2493582E23ED93" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_F188918C5724DE74B65993582E23D370_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_F188918C5724DE74B65993582E23D370" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_F188918C5724DE74B65993582E23D370_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_F188918C5724DE74B65993582E23D370" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_F188918C5724DE74B65993582E23D370" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_F188918C5724DE74B65993582E23D370" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_F188918C5724DE74B65993582E23D370" xlink:type="arc" />
    <link:label id="lab_biib_OtherIncomeExpenseNet_0281F8BA3E70210713E793582E2358CE_terseLabel_en-US" xlink:label="lab_biib_OtherIncomeExpenseNet_0281F8BA3E70210713E793582E2358CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_biib_OtherIncomeExpenseNet_0281F8BA3E70210713E793582E2358CE_label_en-US" xlink:label="lab_biib_OtherIncomeExpenseNet_0281F8BA3E70210713E793582E2358CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income Expense Net</link:label>
    <link:label id="lab_biib_OtherIncomeExpenseNet_0281F8BA3E70210713E793582E2358CE_documentation_en-US" xlink:label="lab_biib_OtherIncomeExpenseNet_0281F8BA3E70210713E793582E2358CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of other nonoperating income and expense, which does not qualify for separate disclosure on the income statement.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_OtherIncomeExpenseNet" xlink:label="loc_biib_OtherIncomeExpenseNet_0281F8BA3E70210713E793582E2358CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherIncomeExpenseNet_0281F8BA3E70210713E793582E2358CE" xlink:to="lab_biib_OtherIncomeExpenseNet_0281F8BA3E70210713E793582E2358CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ACC5DA418C4D53EE0E5193582E239A84_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_ACC5DA418C4D53EE0E5193582E239A84" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ACC5DA418C4D53EE0E5193582E239A84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_ACC5DA418C4D53EE0E5193582E239A84" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_ACC5DA418C4D53EE0E5193582E239A84" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_CE8D61A651B403C51C9A93582E233898_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_CE8D61A651B403C51C9A93582E233898" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_CE8D61A651B403C51C9A93582E233898" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_CE8D61A651B403C51C9A93582E233898" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_CE8D61A651B403C51C9A93582E233898" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E62B544CAB7DFC29B5D293582E23C10F_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E62B544CAB7DFC29B5D293582E23C10F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E62B544CAB7DFC29B5D293582E23C10F_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E62B544CAB7DFC29B5D293582E23C10F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E62B544CAB7DFC29B5D293582E23C10F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E62B544CAB7DFC29B5D293582E23C10F" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E62B544CAB7DFC29B5D293582E23C10F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C813ADDE284AFCAA1DE793582E23F52F_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C813ADDE284AFCAA1DE793582E23F52F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C813ADDE284AFCAA1DE793582E23F52F_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C813ADDE284AFCAA1DE793582E23F52F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_C813ADDE284AFCAA1DE793582E23F52F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_C813ADDE284AFCAA1DE793582E23F52F" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_C813ADDE284AFCAA1DE793582E23F52F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_32CAE7C9EBA7A97C630E93582E234E90_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_32CAE7C9EBA7A97C630E93582E234E90" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_32CAE7C9EBA7A97C630E93582E234E90_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_32CAE7C9EBA7A97C630E93582E234E90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_32CAE7C9EBA7A97C630E93582E234E90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_32CAE7C9EBA7A97C630E93582E234E90" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_32CAE7C9EBA7A97C630E93582E234E90" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_1DEBF0B17BE10B2DDE6493582E234E71_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_1DEBF0B17BE10B2DDE6493582E234E71" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_1DEBF0B17BE10B2DDE6493582E234E71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_1DEBF0B17BE10B2DDE6493582E234E71" xlink:to="lab_us-gaap_DeferredRevenueCurrent_1DEBF0B17BE10B2DDE6493582E234E71" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_6AC91033AB2BCAC8593593582E2356C3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_6AC91033AB2BCAC8593593582E2356C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_6AC91033AB2BCAC8593593582E2356C3_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_6AC91033AB2BCAC8593593582E2356C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6AC91033AB2BCAC8593593582E2356C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6AC91033AB2BCAC8593593582E2356C3" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_6AC91033AB2BCAC8593593582E2356C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_F8ED9A7F0A46E116A5A493582E232C76_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_F8ED9A7F0A46E116A5A493582E232C76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Long-Term Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_F8ED9A7F0A46E116A5A493582E232C76_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_F8ED9A7F0A46E116A5A493582E232C76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Other than Long-term Debt, Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_F8ED9A7F0A46E116A5A493582E232C76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_F8ED9A7F0A46E116A5A493582E232C76" xlink:to="lab_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_F8ED9A7F0A46E116A5A493582E232C76" xlink:type="arc" />
    <link:label id="lab_biib_Employeerelatedliabilitiesnoncurrent_FF763D22D1C5F8ED9F0293582E247D2A_terseLabel_en-US" xlink:label="lab_biib_Employeerelatedliabilitiesnoncurrent_FF763D22D1C5F8ED9F0293582E247D2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_biib_Employeerelatedliabilitiesnoncurrent_FF763D22D1C5F8ED9F0293582E247D2A_label_en-US" xlink:label="lab_biib_Employeerelatedliabilitiesnoncurrent_FF763D22D1C5F8ED9F0293582E247D2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee related liabilities noncurrent</link:label>
    <link:label id="lab_biib_Employeerelatedliabilitiesnoncurrent_FF763D22D1C5F8ED9F0293582E247D2A_documentation_en-US" xlink:label="lab_biib_Employeerelatedliabilitiesnoncurrent_FF763D22D1C5F8ED9F0293582E247D2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee related liabilities noncurrent</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_Employeerelatedliabilitiesnoncurrent" xlink:label="loc_biib_Employeerelatedliabilitiesnoncurrent_FF763D22D1C5F8ED9F0293582E247D2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Employeerelatedliabilitiesnoncurrent_FF763D22D1C5F8ED9F0293582E247D2A" xlink:to="lab_biib_Employeerelatedliabilitiesnoncurrent_FF763D22D1C5F8ED9F0293582E247D2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent_3B82A3F4BD54501DBA3993582E24CCD4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent_3B82A3F4BD54501DBA3993582E24CCD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent_3B82A3F4BD54501DBA3993582E24CCD4_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent_3B82A3F4BD54501DBA3993582E24CCD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_3B82A3F4BD54501DBA3993582E24CCD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_3B82A3F4BD54501DBA3993582E24CCD4" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesNoncurrent_3B82A3F4BD54501DBA3993582E24CCD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_5D56CA29519EB1CCCB5B93582E247C54_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_5D56CA29519EB1CCCB5B93582E247C54" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other long-term liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5D56CA29519EB1CCCB5B93582E247C54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_5D56CA29519EB1CCCB5B93582E247C54" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_5D56CA29519EB1CCCB5B93582E247C54" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_35EF3E62B0FEFD161CAE38A351757A2E_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_35EF3E62B0FEFD161CAE38A351757A2E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_35EF3E62B0FEFD161CAE38A351757A2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_35EF3E62B0FEFD161CAE38A351757A2E" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_35EF3E62B0FEFD161CAE38A351757A2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B32F9CA4C5D75A635EEC38A35175DB81_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B32F9CA4C5D75A635EEC38A35175DB81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B32F9CA4C5D75A635EEC38A35175DB81_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B32F9CA4C5D75A635EEC38A35175DB81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B32F9CA4C5D75A635EEC38A35175DB81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B32F9CA4C5D75A635EEC38A35175DB81" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B32F9CA4C5D75A635EEC38A35175DB81" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_9990C88D179E86E82ECF38A351752411_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_9990C88D179E86E82ECF38A351752411" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Translation Adjustment [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_9990C88D179E86E82ECF38A351752411_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_9990C88D179E86E82ECF38A351752411" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9990C88D179E86E82ECF38A351752411" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9990C88D179E86E82ECF38A351752411" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_9990C88D179E86E82ECF38A351752411" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9CDE9C9203C719405EC138A35175CF30_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9CDE9C9203C719405EC138A35175CF30" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9CDE9C9203C719405EC138A35175CF30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9CDE9C9203C719405EC138A35175CF30" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9CDE9C9203C719405EC138A35175CF30" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1A6766F0BBAE99D698FA38A351764483_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1A6766F0BBAE99D698FA38A351764483" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), before reclassifications</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1A6766F0BBAE99D698FA38A351764483" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1A6766F0BBAE99D698FA38A351764483" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1A6766F0BBAE99D698FA38A351764483" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7D1D700EF560D4EE171838A35176923C_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7D1D700EF560D4EE171838A35176923C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7D1D700EF560D4EE171838A35176923C_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7D1D700EF560D4EE171838A35176923C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7D1D700EF560D4EE171838A35176923C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7D1D700EF560D4EE171838A35176923C" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7D1D700EF560D4EE171838A35176923C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B3EE7F07332C2FD20DC38A35176A287_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B3EE7F07332C2FD20DC38A35176A287" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net current period other comprehensive income (loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B3EE7F07332C2FD20DC38A35176A287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B3EE7F07332C2FD20DC38A35176A287" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B3EE7F07332C2FD20DC38A35176A287" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_899395873859DBA9C3E838A351762877_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_899395873859DBA9C3E838A351762877" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_899395873859DBA9C3E838A351762877" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_899395873859DBA9C3E838A351762877" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_899395873859DBA9C3E838A351762877" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_B1E27C984FFFFF45886638A351B4B44E_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_B1E27C984FFFFF45886638A351B4B44E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_B1E27C984FFFFF45886638A351B4B44E_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_B1E27C984FFFFF45886638A351B4B44E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_B1E27C984FFFFF45886638A351B4B44E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_B1E27C984FFFFF45886638A351B4B44E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_B1E27C984FFFFF45886638A351B4B44E" xlink:type="arc" />
    <link:label id="lab_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_F088AD9D3BD381EB4DC838A351B53412_terseLabel_en-US" xlink:label="lab_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_F088AD9D3BD381EB4DC838A351B53412" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property plant and equipment purchase price allocation [Table Text Block]</link:label>
    <link:label id="lab_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_F088AD9D3BD381EB4DC838A351B53412_label_en-US" xlink:label="lab_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_F088AD9D3BD381EB4DC838A351B53412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property plant and equipment purchase price allocation [Table Text Block]</link:label>
    <link:label id="lab_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_F088AD9D3BD381EB4DC838A351B53412_documentation_en-US" xlink:label="lab_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_F088AD9D3BD381EB4DC838A351B53412" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property plant and equipment purchase price allocation [Table]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock" xlink:label="loc_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_F088AD9D3BD381EB4DC838A351B53412" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_F088AD9D3BD381EB4DC838A351B53412" xlink:to="lab_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_F088AD9D3BD381EB4DC838A351B53412" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_4B2E274F4AF5243FE1A538A3510905A2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract_4B2E274F4AF5243FE1A538A3510905A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total debt maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_4B2E274F4AF5243FE1A538A3510905A2_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract_4B2E274F4AF5243FE1A538A3510905A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_4B2E274F4AF5243FE1A538A3510905A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_4B2E274F4AF5243FE1A538A3510905A2" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract_4B2E274F4AF5243FE1A538A3510905A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_E8B53D895249DA0EDA0C38A35109A549_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_E8B53D895249DA0EDA0C38A35109A549" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_E8B53D895249DA0EDA0C38A35109A549_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_E8B53D895249DA0EDA0C38A35109A549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_E8B53D895249DA0EDA0C38A35109A549" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_E8B53D895249DA0EDA0C38A35109A549" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_E8B53D895249DA0EDA0C38A35109A549" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D8991833D6408D99041D38A351092E96_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D8991833D6408D99041D38A351092E96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D8991833D6408D99041D38A351092E96_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D8991833D6408D99041D38A351092E96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D8991833D6408D99041D38A351092E96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D8991833D6408D99041D38A351092E96" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D8991833D6408D99041D38A351092E96" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_E882102FA59C9D3FA2EA38A3510AB87F_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_E882102FA59C9D3FA2EA38A3510AB87F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_E882102FA59C9D3FA2EA38A3510AB87F_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_E882102FA59C9D3FA2EA38A3510AB87F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_E882102FA59C9D3FA2EA38A3510AB87F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_E882102FA59C9D3FA2EA38A3510AB87F" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_E882102FA59C9D3FA2EA38A3510AB87F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_46DD3E297225D26EDD7538A3510A7181_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_46DD3E297225D26EDD7538A3510A7181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_46DD3E297225D26EDD7538A3510A7181_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_46DD3E297225D26EDD7538A3510A7181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_46DD3E297225D26EDD7538A3510A7181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_46DD3E297225D26EDD7538A3510A7181" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_46DD3E297225D26EDD7538A3510A7181" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_9585C127DF209CBF318C38A3510A13F5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_9585C127DF209CBF318C38A3510A13F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_9585C127DF209CBF318C38A3510A13F5_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_9585C127DF209CBF318C38A3510A13F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_9585C127DF209CBF318C38A3510A13F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_9585C127DF209CBF318C38A3510A13F5" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_9585C127DF209CBF318C38A3510A13F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3283CF2DFED37B1E42F538A3510AE4C4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3283CF2DFED37B1E42F538A3510AE4C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 and thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3283CF2DFED37B1E42F538A3510AE4C4_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3283CF2DFED37B1E42F538A3510AE4C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3283CF2DFED37B1E42F538A3510AE4C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3283CF2DFED37B1E42F538A3510AE4C4" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3283CF2DFED37B1E42F538A3510AE4C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermNotesPayable_A129968542F722367FB238A3510A6D54_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_A129968542F722367FB238A3510A6D54" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_A129968542F722367FB238A3510A6D54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable_A129968542F722367FB238A3510A6D54" xlink:to="lab_us-gaap_LongTermNotesPayable_A129968542F722367FB238A3510A6D54" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_451E17E765EA24C1C59E38A35698133C_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_451E17E765EA24C1C59E38A35698133C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_451E17E765EA24C1C59E38A35698133C_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_451E17E765EA24C1C59E38A35698133C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_451E17E765EA24C1C59E38A35698133C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_451E17E765EA24C1C59E38A35698133C" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_451E17E765EA24C1C59E38A35698133C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3EA9BF6C42C36C78617238A355359A0F_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_3EA9BF6C42C36C78617238A355359A0F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3EA9BF6C42C36C78617238A355359A0F_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_3EA9BF6C42C36C78617238A355359A0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_3EA9BF6C42C36C78617238A355359A0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_3EA9BF6C42C36C78617238A355359A0F" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_3EA9BF6C42C36C78617238A355359A0F" xlink:type="arc" />
    <link:label id="lab_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587_verboseLabel_en-US" xlink:label="lab_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587_label_en-US" xlink:label="lab_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units Activity [Abstract]</link:label>
    <link:label id="lab_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587_documentation_en-US" xlink:label="lab_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted stock units activity.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RestrictedStockUnitsActivityAbstract" xlink:label="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:to="lab_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_D235947EBAD0641F828438A3569C80DC_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_D235947EBAD0641F828438A3569C80DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment estimated useful lives</link:label>
    <link:label id="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_D235947EBAD0641F828438A3569C80DC_label_en-US" xlink:label="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_D235947EBAD0641F828438A3569C80DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Property Plant And Equipment Useful Lives [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_D235947EBAD0641F828438A3569C80DC_documentation_en-US" xlink:label="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_D235947EBAD0641F828438A3569C80DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of property plant and equipment useful lives.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_D235947EBAD0641F828438A3569C80DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_D235947EBAD0641F828438A3569C80DC" xlink:to="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_D235947EBAD0641F828438A3569C80DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8AB29F9E7C5B82AF06C538A353D58AE9_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8AB29F9E7C5B82AF06C538A353D58AE9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8AB29F9E7C5B82AF06C538A353D58AE9_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8AB29F9E7C5B82AF06C538A353D58AE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8AB29F9E7C5B82AF06C538A353D58AE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8AB29F9E7C5B82AF06C538A353D58AE9" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8AB29F9E7C5B82AF06C538A353D58AE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingAxis_40E8C87B70D34F424B0198B5C4EBBA46_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis_40E8C87B70D34F424B0198B5C4EBBA46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_40E8C87B70D34F424B0198B5C4EBBA46_label_en-US" xlink:label="lab_us-gaap_VestingAxis_40E8C87B70D34F424B0198B5C4EBBA46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_40E8C87B70D34F424B0198B5C4EBBA46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_40E8C87B70D34F424B0198B5C4EBBA46" xlink:to="lab_us-gaap_VestingAxis_40E8C87B70D34F424B0198B5C4EBBA46" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingDomain_13260DB5A6AF6849214F98B5C4EBD1D1_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain_13260DB5A6AF6849214F98B5C4EBD1D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_13260DB5A6AF6849214F98B5C4EBD1D1_label_en-US" xlink:label="lab_us-gaap_VestingDomain_13260DB5A6AF6849214F98B5C4EBD1D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_13260DB5A6AF6849214F98B5C4EBD1D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_13260DB5A6AF6849214F98B5C4EBD1D1" xlink:to="lab_us-gaap_VestingDomain_13260DB5A6AF6849214F98B5C4EBD1D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_D42223038A32C35DD0E198B5C4EBBD43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_D42223038A32C35DD0E198B5C4EBBD43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement of PUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_D42223038A32C35DD0E198B5C4EBBD43_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_D42223038A32C35DD0E198B5C4EBBD43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_D42223038A32C35DD0E198B5C4EBBD43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_D42223038A32C35DD0E198B5C4EBBD43" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_D42223038A32C35DD0E198B5C4EBBD43" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_41167DC81BCD8DB47F6998B5C4EC6B0D_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_41167DC81BCD8DB47F6998B5C4EC6B0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_41167DC81BCD8DB47F6998B5C4EC6B0D_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_41167DC81BCD8DB47F6998B5C4EC6B0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_41167DC81BCD8DB47F6998B5C4EC6B0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis_41167DC81BCD8DB47F6998B5C4EC6B0D" xlink:to="lab_us-gaap_TitleOfIndividualAxis_41167DC81BCD8DB47F6998B5C4EC6B0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_DFE56EFFA4168C169F0698B5C4ECD2D6_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_DFE56EFFA4168C169F0698B5C4ECD2D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_DFE56EFFA4168C169F0698B5C4ECD2D6_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_DFE56EFFA4168C169F0698B5C4ECD2D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_DFE56EFFA4168C169F0698B5C4ECD2D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_DFE56EFFA4168C169F0698B5C4ECD2D6" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_DFE56EFFA4168C169F0698B5C4ECD2D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DirectorMember_BA32105F96DE220C366598B5C4ECA349_terseLabel_en-US" xlink:label="lab_us-gaap_DirectorMember_BA32105F96DE220C366598B5C4ECA349" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:label id="lab_us-gaap_DirectorMember_BA32105F96DE220C366598B5C4ECA349_label_en-US" xlink:label="lab_us-gaap_DirectorMember_BA32105F96DE220C366598B5C4ECA349" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_BA32105F96DE220C366598B5C4ECA349" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectorMember_BA32105F96DE220C366598B5C4ECA349" xlink:to="lab_us-gaap_DirectorMember_BA32105F96DE220C366598B5C4ECA349" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationPlanAxis_4063594AD7691594A39498B5C4EC7522_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationPlanAxis_4063594AD7691594A39498B5C4EC7522" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Plan [Axis]</link:label>
    <link:label id="lab_biib_ShareBasedCompensationPlanAxis_4063594AD7691594A39498B5C4EC7522_label_en-US" xlink:label="lab_biib_ShareBasedCompensationPlanAxis_4063594AD7691594A39498B5C4EC7522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Plan [Axis]</link:label>
    <link:label id="lab_biib_ShareBasedCompensationPlanAxis_4063594AD7691594A39498B5C4EC7522_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationPlanAxis_4063594AD7691594A39498B5C4EC7522" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation plan.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ShareBasedCompensationPlanAxis" xlink:label="loc_biib_ShareBasedCompensationPlanAxis_4063594AD7691594A39498B5C4EC7522" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationPlanAxis_4063594AD7691594A39498B5C4EC7522" xlink:to="lab_biib_ShareBasedCompensationPlanAxis_4063594AD7691594A39498B5C4EC7522" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Plan [Domain]</link:label>
    <link:label id="lab_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49_label_en-US" xlink:label="lab_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Plan [Domain]</link:label>
    <link:label id="lab_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation plan.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ShareBasedCompensationPlanDomain" xlink:label="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:to="lab_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:type="arc" />
    <link:label id="lab_biib_DirectorsPlanMember_A3EE5948A54486A74ECF98B5C4EC55DA_verboseLabel_en-US" xlink:label="lab_biib_DirectorsPlanMember_A3EE5948A54486A74ECF98B5C4EC55DA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Directors Plan</link:label>
    <link:label id="lab_biib_DirectorsPlanMember_A3EE5948A54486A74ECF98B5C4EC55DA_label_en-US" xlink:label="lab_biib_DirectorsPlanMember_A3EE5948A54486A74ECF98B5C4EC55DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Directors Plan [Member]</link:label>
    <link:label id="lab_biib_DirectorsPlanMember_A3EE5948A54486A74ECF98B5C4EC55DA_documentation_en-US" xlink:label="lab_biib_DirectorsPlanMember_A3EE5948A54486A74ECF98B5C4EC55DA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Directors plan.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_DirectorsPlanMember" xlink:label="loc_biib_DirectorsPlanMember_A3EE5948A54486A74ECF98B5C4EC55DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DirectorsPlanMember_A3EE5948A54486A74ECF98B5C4EC55DA" xlink:to="lab_biib_DirectorsPlanMember_A3EE5948A54486A74ECF98B5C4EC55DA" xlink:type="arc" />
    <link:label id="lab_biib_OmnibusPlansMember_4DEFADDA318BD6DB40B098B5C4EDB1C7_terseLabel_en-US" xlink:label="lab_biib_OmnibusPlansMember_4DEFADDA318BD6DB40B098B5C4EDB1C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Omnibus Plans</link:label>
    <link:label id="lab_biib_OmnibusPlansMember_4DEFADDA318BD6DB40B098B5C4EDB1C7_label_en-US" xlink:label="lab_biib_OmnibusPlansMember_4DEFADDA318BD6DB40B098B5C4EDB1C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Omnibus Plans [Member]</link:label>
    <link:label id="lab_biib_OmnibusPlansMember_4DEFADDA318BD6DB40B098B5C4EDB1C7_documentation_en-US" xlink:label="lab_biib_OmnibusPlansMember_4DEFADDA318BD6DB40B098B5C4EDB1C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Omnibus plans.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_OmnibusPlansMember" xlink:label="loc_biib_OmnibusPlansMember_4DEFADDA318BD6DB40B098B5C4EDB1C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OmnibusPlansMember_4DEFADDA318BD6DB40B098B5C4EDB1C7" xlink:to="lab_biib_OmnibusPlansMember_4DEFADDA318BD6DB40B098B5C4EDB1C7" xlink:type="arc" />
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2014Member_159C56D155D476E1AB1398B5C4ED79D9_terseLabel_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2014Member_159C56D155D476E1AB1398B5C4ED79D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2014</link:label>
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2014Member_159C56D155D476E1AB1398B5C4ED79D9_label_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2014Member_159C56D155D476E1AB1398B5C4ED79D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2014 [Member]</link:label>
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2014Member_159C56D155D476E1AB1398B5C4ED79D9_documentation_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2014Member_159C56D155D476E1AB1398B5C4ED79D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Attainment of performance criteria in 2014</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AttainmentOfPerformanceCriteriain2014Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2014Member_159C56D155D476E1AB1398B5C4ED79D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AttainmentOfPerformanceCriteriain2014Member_159C56D155D476E1AB1398B5C4ED79D9" xlink:to="lab_biib_AttainmentOfPerformanceCriteriain2014Member_159C56D155D476E1AB1398B5C4ED79D9" xlink:type="arc" />
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2013Member_FD04B19BDA389B0E466398B5C4EDF891_terseLabel_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2013Member_FD04B19BDA389B0E466398B5C4EDF891" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2013</link:label>
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2013Member_FD04B19BDA389B0E466398B5C4EDF891_label_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2013Member_FD04B19BDA389B0E466398B5C4EDF891" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2013 [Member]</link:label>
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2013Member_FD04B19BDA389B0E466398B5C4EDF891_documentation_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2013Member_FD04B19BDA389B0E466398B5C4EDF891" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2013</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AttainmentOfPerformanceCriteriain2013Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2013Member_FD04B19BDA389B0E466398B5C4EDF891" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AttainmentOfPerformanceCriteriain2013Member_FD04B19BDA389B0E466398B5C4EDF891" xlink:to="lab_biib_AttainmentOfPerformanceCriteriain2013Member_FD04B19BDA389B0E466398B5C4EDF891" xlink:type="arc" />
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2012Member_EDEA18D7F463F31C5E9B98B5C4EDACEC_terseLabel_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2012Member_EDEA18D7F463F31C5E9B98B5C4EDACEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2012</link:label>
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2012Member_EDEA18D7F463F31C5E9B98B5C4EDACEC_label_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2012Member_EDEA18D7F463F31C5E9B98B5C4EDACEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2012 [Member]</link:label>
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2012Member_EDEA18D7F463F31C5E9B98B5C4EDACEC_documentation_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2012Member_EDEA18D7F463F31C5E9B98B5C4EDACEC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2012 [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AttainmentOfPerformanceCriteriain2012Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2012Member_EDEA18D7F463F31C5E9B98B5C4EDACEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AttainmentOfPerformanceCriteriain2012Member_EDEA18D7F463F31C5E9B98B5C4EDACEC" xlink:to="lab_biib_AttainmentOfPerformanceCriteriain2012Member_EDEA18D7F463F31C5E9B98B5C4EDACEC" xlink:type="arc" />
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2011Member_1ADE04A9800A9514912B98B5C4EDD51D_terseLabel_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2011Member_1ADE04A9800A9514912B98B5C4EDD51D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2011</link:label>
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2011Member_1ADE04A9800A9514912B98B5C4EDD51D_label_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2011Member_1ADE04A9800A9514912B98B5C4EDD51D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2011 [Member]</link:label>
    <link:label id="lab_biib_AttainmentOfPerformanceCriteriain2011Member_1ADE04A9800A9514912B98B5C4EDD51D_documentation_en-US" xlink:label="lab_biib_AttainmentOfPerformanceCriteriain2011Member_1ADE04A9800A9514912B98B5C4EDD51D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Attainment Of Performance Criteria in 2011 [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AttainmentOfPerformanceCriteriain2011Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2011Member_1ADE04A9800A9514912B98B5C4EDD51D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AttainmentOfPerformanceCriteriain2011Member_1ADE04A9800A9514912B98B5C4EDD51D" xlink:to="lab_biib_AttainmentOfPerformanceCriteriain2011Member_1ADE04A9800A9514912B98B5C4EDD51D" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfSharesOfCommonStockForIssuance_2B0DF2A4D268F276B56198B5C4EEC811_verboseLabel_en-US" xlink:label="lab_biib_NumberOfSharesOfCommonStockForIssuance_2B0DF2A4D268F276B56198B5C4EEC811" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total number of shares of common stock for issuance</link:label>
    <link:label id="lab_biib_NumberOfSharesOfCommonStockForIssuance_2B0DF2A4D268F276B56198B5C4EEC811_label_en-US" xlink:label="lab_biib_NumberOfSharesOfCommonStockForIssuance_2B0DF2A4D268F276B56198B5C4EEC811" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Of Common Stock For Issuance</link:label>
    <link:label id="lab_biib_NumberOfSharesOfCommonStockForIssuance_2B0DF2A4D268F276B56198B5C4EEC811_documentation_en-US" xlink:label="lab_biib_NumberOfSharesOfCommonStockForIssuance_2B0DF2A4D268F276B56198B5C4EEC811" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total number of shares of common stock for issuance.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_NumberOfSharesOfCommonStockForIssuance" xlink:label="loc_biib_NumberOfSharesOfCommonStockForIssuance_2B0DF2A4D268F276B56198B5C4EEC811" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfSharesOfCommonStockForIssuance_2B0DF2A4D268F276B56198B5C4EEC811" xlink:to="lab_biib_NumberOfSharesOfCommonStockForIssuance_2B0DF2A4D268F276B56198B5C4EEC811" xlink:type="arc" />
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_597416A45ACED01D19E098B5C4EE28E8_verboseLabel_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_597416A45ACED01D19E098B5C4EE28E8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Ratio of total number of shares reserved under the plan</link:label>
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_597416A45ACED01D19E098B5C4EE28E8_label_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_597416A45ACED01D19E098B5C4EE28E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ratio Of Number Of Shares Reserved Under Plan</link:label>
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_597416A45ACED01D19E098B5C4EE28E8_documentation_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_597416A45ACED01D19E098B5C4EE28E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ratio of total number of shares reserved under the plan.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_597416A45ACED01D19E098B5C4EE28E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_597416A45ACED01D19E098B5C4EE28E8" xlink:to="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_597416A45ACED01D19E098B5C4EE28E8" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfEqualAnnualIncrements_B9A834D8514C3AE51A7998B5C4EEB50B_verboseLabel_en-US" xlink:label="lab_biib_NumberOfEqualAnnualIncrements_B9A834D8514C3AE51A7998B5C4EEB50B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of equal annual increments</link:label>
    <link:label id="lab_biib_NumberOfEqualAnnualIncrements_B9A834D8514C3AE51A7998B5C4EEB50B_label_en-US" xlink:label="lab_biib_NumberOfEqualAnnualIncrements_B9A834D8514C3AE51A7998B5C4EEB50B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Equal Annual Increments</link:label>
    <link:label id="lab_biib_NumberOfEqualAnnualIncrements_B9A834D8514C3AE51A7998B5C4EEB50B_documentation_en-US" xlink:label="lab_biib_NumberOfEqualAnnualIncrements_B9A834D8514C3AE51A7998B5C4EEB50B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of equal annual increments.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_NumberOfEqualAnnualIncrements" xlink:label="loc_biib_NumberOfEqualAnnualIncrements_B9A834D8514C3AE51A7998B5C4EEB50B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfEqualAnnualIncrements_B9A834D8514C3AE51A7998B5C4EEB50B" xlink:to="lab_biib_NumberOfEqualAnnualIncrements_B9A834D8514C3AE51A7998B5C4EEB50B" xlink:type="arc" />
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_8258BA110B8D8B04771798B5C4EE0DAE_verboseLabel_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_8258BA110B8D8B04771798B5C4EE0DAE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</link:label>
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_8258BA110B8D8B04771798B5C4EE0DAE_label_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_8258BA110B8D8B04771798B5C4EE0DAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent</link:label>
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_8258BA110B8D8B04771798B5C4EE0DAE_documentation_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_8258BA110B8D8B04771798B5C4EE0DAE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum target number of market stock units granted based on stock performance in percent.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_8258BA110B8D8B04771798B5C4EE0DAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_8258BA110B8D8B04771798B5C4EE0DAE" xlink:to="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_8258BA110B8D8B04771798B5C4EE0DAE" xlink:type="arc" />
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_E5BEAF446BB760BEDF6598B5C4EE3FBF_verboseLabel_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_E5BEAF446BB760BEDF6598B5C4EE3FBF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</link:label>
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_E5BEAF446BB760BEDF6598B5C4EE3FBF_label_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_E5BEAF446BB760BEDF6598B5C4EE3FBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent</link:label>
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_E5BEAF446BB760BEDF6598B5C4EE3FBF_documentation_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_E5BEAF446BB760BEDF6598B5C4EE3FBF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum target number of market stock units granted based on stock performance in percent.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_E5BEAF446BB760BEDF6598B5C4EE3FBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_E5BEAF446BB760BEDF6598B5C4EE3FBF" xlink:to="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_E5BEAF446BB760BEDF6598B5C4EE3FBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3D581C856263EF9AA89598B5C4EE478F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3D581C856263EF9AA89598B5C4EE478F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3D581C856263EF9AA89598B5C4EE478F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3D581C856263EF9AA89598B5C4EE478F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3D581C856263EF9AA89598B5C4EE478F" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_83EEACD96D8765AC10D898B5C4EED193_terseLabel_en-US" xlink:label="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_83EEACD96D8765AC10D898B5C4EED193" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PUs converted to share settlements</link:label>
    <link:label id="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_83EEACD96D8765AC10D898B5C4EED193_label_en-US" xlink:label="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_83EEACD96D8765AC10D898B5C4EED193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Shares Used to Settle Awards</link:label>
    <link:label id="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_83EEACD96D8765AC10D898B5C4EED193_documentation_en-US" xlink:label="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_83EEACD96D8765AC10D898B5C4EED193" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Shares Used to Settle Awards</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards" xlink:label="loc_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_83EEACD96D8765AC10D898B5C4EED193" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_83EEACD96D8765AC10D898B5C4EED193" xlink:to="lab_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_83EEACD96D8765AC10D898B5C4EED193" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_10B5CF33AA88725F456F98B5C4EED138_verboseLabel_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_10B5CF33AA88725F456F98B5C4EED138" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of days for calculation of average closing stock price</link:label>
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_10B5CF33AA88725F456F98B5C4EED138_label_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_10B5CF33AA88725F456F98B5C4EED138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Days For Calculation Of Average Closing Stock Price</link:label>
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_10B5CF33AA88725F456F98B5C4EED138_documentation_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_10B5CF33AA88725F456F98B5C4EED138" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of days for calculation of average closing stock price.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_10B5CF33AA88725F456F98B5C4EED138" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_10B5CF33AA88725F456F98B5C4EED138" xlink:to="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_10B5CF33AA88725F456F98B5C4EED138" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_E94502BB5C80D2F277FE98B5C4EF806D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_E94502BB5C80D2F277FE98B5C4EF806D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of vested awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_E94502BB5C80D2F277FE98B5C4EF806D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_E94502BB5C80D2F277FE98B5C4EF806D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_E94502BB5C80D2F277FE98B5C4EF806D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_E94502BB5C80D2F277FE98B5C4EF806D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_E94502BB5C80D2F277FE98B5C4EF806D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_EDB9D6FB8745EEB108DA98B5C4EF9473_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_EDB9D6FB8745EEB108DA98B5C4EF9473" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash in settlement of CSPS awards upon vesting</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_EDB9D6FB8745EEB108DA98B5C4EF9473_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_EDB9D6FB8745EEB108DA98B5C4EF9473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Cash Flow Effect, Cash Used to Settle Awards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_EDB9D6FB8745EEB108DA98B5C4EF9473" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_EDB9D6FB8745EEB108DA98B5C4EF9473" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_EDB9D6FB8745EEB108DA98B5C4EF9473" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6A9F40DE69AF084A27698B5C4EF1576_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6A9F40DE69AF084A27698B5C4EF1576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6A9F40DE69AF084A27698B5C4EF1576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6A9F40DE69AF084A27698B5C4EF1576" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6A9F40DE69AF084A27698B5C4EF1576" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7F41815A59F143F8271398B5C4EF2D52_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7F41815A59F143F8271398B5C4EF2D52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7F41815A59F143F8271398B5C4EF2D52_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7F41815A59F143F8271398B5C4EF2D52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7F41815A59F143F8271398B5C4EF2D52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7F41815A59F143F8271398B5C4EF2D52" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7F41815A59F143F8271398B5C4EF2D52" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedPaymentsTextualAbstract_026AEF02AE5EB0D6961F98B5C4EFC49B_terseLabel_en-US" xlink:label="lab_biib_ShareBasedPaymentsTextualAbstract_026AEF02AE5EB0D6961F98B5C4EFC49B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payments (Textual)</link:label>
    <link:label id="lab_biib_ShareBasedPaymentsTextualAbstract_026AEF02AE5EB0D6961F98B5C4EFC49B_label_en-US" xlink:label="lab_biib_ShareBasedPaymentsTextualAbstract_026AEF02AE5EB0D6961F98B5C4EFC49B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_ShareBasedPaymentsTextualAbstract_026AEF02AE5EB0D6961F98B5C4EFC49B_documentation_en-US" xlink:label="lab_biib_ShareBasedPaymentsTextualAbstract_026AEF02AE5EB0D6961F98B5C4EFC49B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Payments.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ShareBasedPaymentsTextualAbstract" xlink:label="loc_biib_ShareBasedPaymentsTextualAbstract_026AEF02AE5EB0D6961F98B5C4EFC49B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_026AEF02AE5EB0D6961F98B5C4EFC49B" xlink:to="lab_biib_ShareBasedPaymentsTextualAbstract_026AEF02AE5EB0D6961F98B5C4EFC49B" xlink:type="arc" />
    <link:label id="lab_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_24C44461E8AFE0F2C2A398B5C4EFDAB2_verboseLabel_en-US" xlink:label="lab_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_24C44461E8AFE0F2C2A398B5C4EFDAB2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Windfall tax benefits from vesting of stock awards, exercises of stock options and ESPP participation</link:label>
    <link:label id="lab_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_24C44461E8AFE0F2C2A398B5C4EFDAB2_label_en-US" xlink:label="lab_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_24C44461E8AFE0F2C2A398B5C4EFDAB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Windfall Tax Benefits From Vesting Of Stock Awards Exercises Of Stock Options And ESPP Participation</link:label>
    <link:label id="lab_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_24C44461E8AFE0F2C2A398B5C4EFDAB2_documentation_en-US" xlink:label="lab_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_24C44461E8AFE0F2C2A398B5C4EFDAB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Windfall tax benefits from vesting of stock awards, exercises of stock options and ESPP participation.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation" xlink:label="loc_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_24C44461E8AFE0F2C2A398B5C4EFDAB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_24C44461E8AFE0F2C2A398B5C4EFDAB2" xlink:to="lab_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_24C44461E8AFE0F2C2A398B5C4EFDAB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FF0BC73D19B3F6F7DDB198B5C4EFDCEF_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FF0BC73D19B3F6F7DDB198B5C4EFDCEF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to unvested share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FF0BC73D19B3F6F7DDB198B5C4EFDCEF_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FF0BC73D19B3F6F7DDB198B5C4EFDCEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FF0BC73D19B3F6F7DDB198B5C4EFDCEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FF0BC73D19B3F6F7DDB198B5C4EFDCEF" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FF0BC73D19B3F6F7DDB198B5C4EFDCEF" xlink:type="arc" />
    <link:label id="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_280FEC9EB7B28E1E5EF198B5C4EFC7D1_verboseLabel_en-US" xlink:label="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_280FEC9EB7B28E1E5EF198B5C4EFC7D1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period to recognize the cost of unvested awards</link:label>
    <link:label id="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_280FEC9EB7B28E1E5EF198B5C4EFC7D1_label_en-US" xlink:label="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_280FEC9EB7B28E1E5EF198B5C4EFC7D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Period To Recognize Cost Of Nonvested Awards</link:label>
    <link:label id="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_280FEC9EB7B28E1E5EF198B5C4EFC7D1_documentation_en-US" xlink:label="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_280FEC9EB7B28E1E5EF198B5C4EFC7D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted-average period to recognize the cost of nonvested awards.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" xlink:label="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_280FEC9EB7B28E1E5EF198B5C4EFC7D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_280FEC9EB7B28E1E5EF198B5C4EFC7D1" xlink:to="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_280FEC9EB7B28E1E5EF198B5C4EFC7D1" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_C2302BB5CDC4AA90C00898B5C4EF91F0_verboseLabel_en-US" xlink:label="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_C2302BB5CDC4AA90C00898B5C4EF91F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of share-based compensation plans pursuant to which awards are currently being made</link:label>
    <link:label id="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_C2302BB5CDC4AA90C00898B5C4EF91F0_label_en-US" xlink:label="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_C2302BB5CDC4AA90C00898B5C4EF91F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Share Based Compensation Plans Pursuant To Which Awards Are Currently Being Made</link:label>
    <link:label id="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_C2302BB5CDC4AA90C00898B5C4EF91F0_documentation_en-US" xlink:label="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_C2302BB5CDC4AA90C00898B5C4EF91F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of share-based compensation plans pursuant to which awards are currently being made.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" xlink:label="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_C2302BB5CDC4AA90C00898B5C4EF91F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_C2302BB5CDC4AA90C00898B5C4EF91F0" xlink:to="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_C2302BB5CDC4AA90C00898B5C4EF91F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_22B354F8EB2930830FC098B5C4F0E1EF_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_22B354F8EB2930830FC098B5C4F0E1EF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares granted under stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_22B354F8EB2930830FC098B5C4F0E1EF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_22B354F8EB2930830FC098B5C4F0E1EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_22B354F8EB2930830FC098B5C4F0E1EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_22B354F8EB2930830FC098B5C4F0E1EF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_22B354F8EB2930830FC098B5C4F0E1EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F641DF2680CA9F2F3EF398B5C4F0C5D3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F641DF2680CA9F2F3EF398B5C4F0C5D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F641DF2680CA9F2F3EF398B5C4F0C5D3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F641DF2680CA9F2F3EF398B5C4F0C5D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F641DF2680CA9F2F3EF398B5C4F0C5D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F641DF2680CA9F2F3EF398B5C4F0C5D3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F641DF2680CA9F2F3EF398B5C4F0C5D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_349163CFF10125BAEBED98B5C4F0EFDF_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_349163CFF10125BAEBED98B5C4F0EFDF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic values of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_349163CFF10125BAEBED98B5C4F0EFDF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_349163CFF10125BAEBED98B5C4F0EFDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_349163CFF10125BAEBED98B5C4F0EFDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_349163CFF10125BAEBED98B5C4F0EFDF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_349163CFF10125BAEBED98B5C4F0EFDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_06B83798BF11C9CD584198B5C4F004E1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_06B83798BF11C9CD584198B5C4F004E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term for options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_06B83798BF11C9CD584198B5C4F004E1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_06B83798BF11C9CD584198B5C4F004E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_06B83798BF11C9CD584198B5C4F004E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_06B83798BF11C9CD584198B5C4F004E1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_06B83798BF11C9CD584198B5C4F004E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_83BCE1E4616C1C2FF999A29B5EE28886_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_83BCE1E4616C1C2FF999A29B5EE28886" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_83BCE1E4616C1C2FF999A29B5EE28886" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_83BCE1E4616C1C2FF999A29B5EE28886" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_83BCE1E4616C1C2FF999A29B5EE28886" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AB1E557C2D037660306CA29B5EE2D229_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AB1E557C2D037660306CA29B5EE2D229" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AB1E557C2D037660306CA29B5EE2D229_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AB1E557C2D037660306CA29B5EE2D229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AB1E557C2D037660306CA29B5EE2D229" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AB1E557C2D037660306CA29B5EE2D229" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AB1E557C2D037660306CA29B5EE2D229" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E95DA9E364CCB18E743AA29B5EE24028_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E95DA9E364CCB18E743AA29B5EE24028" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E95DA9E364CCB18E743AA29B5EE24028_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E95DA9E364CCB18E743AA29B5EE24028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E95DA9E364CCB18E743AA29B5EE24028" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E95DA9E364CCB18E743AA29B5EE24028" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E95DA9E364CCB18E743AA29B5EE24028" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8F27E467BB7AB7D5C316A29B5EE296D6_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_8F27E467BB7AB7D5C316A29B5EE296D6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8F27E467BB7AB7D5C316A29B5EE296D6_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_8F27E467BB7AB7D5C316A29B5EE296D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8F27E467BB7AB7D5C316A29B5EE296D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_8F27E467BB7AB7D5C316A29B5EE296D6" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_8F27E467BB7AB7D5C316A29B5EE296D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_1FCB23A1AFEFF481D03BA29B5EE2E1C0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_1FCB23A1AFEFF481D03BA29B5EE2E1C0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_1FCB23A1AFEFF481D03BA29B5EE2E1C0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_1FCB23A1AFEFF481D03BA29B5EE2E1C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1FCB23A1AFEFF481D03BA29B5EE2E1C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_1FCB23A1AFEFF481D03BA29B5EE2E1C0" xlink:to="lab_us-gaap_ShareBasedCompensation_1FCB23A1AFEFF481D03BA29B5EE2E1C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_673AC5C2F69F77163642A29B5EE2D64B_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_673AC5C2F69F77163642A29B5EE2D64B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_673AC5C2F69F77163642A29B5EE2D64B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_673AC5C2F69F77163642A29B5EE2D64B" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_673AC5C2F69F77163642A29B5EE2D64B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_DFF825361B734D7C476EA29B5EE2BAD7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_DFF825361B734D7C476EA29B5EE2BAD7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_DFF825361B734D7C476EA29B5EE2BAD7_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_DFF825361B734D7C476EA29B5EE2BAD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_DFF825361B734D7C476EA29B5EE2BAD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_DFF825361B734D7C476EA29B5EE2BAD7" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_DFF825361B734D7C476EA29B5EE2BAD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9AF78B1E1679CA03983CA29B5EE2DDF2_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9AF78B1E1679CA03983CA29B5EE2DDF2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9AF78B1E1679CA03983CA29B5EE2DDF2_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9AF78B1E1679CA03983CA29B5EE2DDF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9AF78B1E1679CA03983CA29B5EE2DDF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9AF78B1E1679CA03983CA29B5EE2DDF2" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9AF78B1E1679CA03983CA29B5EE2DDF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_CF077F558243CCDDD5C7A29B5EE22054_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_CF077F558243CCDDD5C7A29B5EE22054" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_CF077F558243CCDDD5C7A29B5EE22054_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_CF077F558243CCDDD5C7A29B5EE22054" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_CF077F558243CCDDD5C7A29B5EE22054" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_CF077F558243CCDDD5C7A29B5EE22054" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_CF077F558243CCDDD5C7A29B5EE22054" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4B0381D252BCB31D35C4A29B5EE2B33A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_4B0381D252BCB31D35C4A29B5EE2B33A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4B0381D252BCB31D35C4A29B5EE2B33A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_4B0381D252BCB31D35C4A29B5EE2B33A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4B0381D252BCB31D35C4A29B5EE2B33A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_4B0381D252BCB31D35C4A29B5EE2B33A" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_4B0381D252BCB31D35C4A29B5EE2B33A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_381EEF8A77B615B85FEEA29B5EE2E702_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_381EEF8A77B615B85FEEA29B5EE2E702" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_381EEF8A77B615B85FEEA29B5EE2E702_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_381EEF8A77B615B85FEEA29B5EE2E702" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_381EEF8A77B615B85FEEA29B5EE2E702" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_381EEF8A77B615B85FEEA29B5EE2E702" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_381EEF8A77B615B85FEEA29B5EE2E702" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_BDB5F0234FAE4966F3F2A29B5EE262E5_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_BDB5F0234FAE4966F3F2A29B5EE262E5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_BDB5F0234FAE4966F3F2A29B5EE262E5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_BDB5F0234FAE4966F3F2A29B5EE262E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_BDB5F0234FAE4966F3F2A29B5EE262E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_BDB5F0234FAE4966F3F2A29B5EE262E5" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_BDB5F0234FAE4966F3F2A29B5EE262E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7A1058DE700082F8BEA3A29B5EE2FC40_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7A1058DE700082F8BEA3A29B5EE2FC40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7A1058DE700082F8BEA3A29B5EE2FC40_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7A1058DE700082F8BEA3A29B5EE2FC40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7A1058DE700082F8BEA3A29B5EE2FC40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7A1058DE700082F8BEA3A29B5EE2FC40" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7A1058DE700082F8BEA3A29B5EE2FC40" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9108244451B1D5DCFD35A29B5EE20AB9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9108244451B1D5DCFD35A29B5EE20AB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities and taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9108244451B1D5DCFD35A29B5EE20AB9_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9108244451B1D5DCFD35A29B5EE20AB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9108244451B1D5DCFD35A29B5EE20AB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9108244451B1D5DCFD35A29B5EE20AB9" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9108244451B1D5DCFD35A29B5EE20AB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1E1AEAB733C7FB172909A29B5EE37457_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1E1AEAB733C7FB172909A29B5EE37457" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Due from unconsolidated joint business</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1E1AEAB733C7FB172909A29B5EE37457_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1E1AEAB733C7FB172909A29B5EE37457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1E1AEAB733C7FB172909A29B5EE37457" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1E1AEAB733C7FB172909A29B5EE37457" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1E1AEAB733C7FB172909A29B5EE37457" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4C8C38B2CA728B42C189A29B5EE3D623_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4C8C38B2CA728B42C189A29B5EE3D623" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4C8C38B2CA728B42C189A29B5EE3D623_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4C8C38B2CA728B42C189A29B5EE3D623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4C8C38B2CA728B42C189A29B5EE3D623" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4C8C38B2CA728B42C189A29B5EE3D623" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4C8C38B2CA728B42C189A29B5EE3D623" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0C0DB1F3C9844C57AD08A29B5EE3CEF7_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0C0DB1F3C9844C57AD08A29B5EE3CEF7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0C0DB1F3C9844C57AD08A29B5EE3CEF7_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0C0DB1F3C9844C57AD08A29B5EE3CEF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0C0DB1F3C9844C57AD08A29B5EE3CEF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0C0DB1F3C9844C57AD08A29B5EE3CEF7" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0C0DB1F3C9844C57AD08A29B5EE3CEF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_C24FC773F35A84ADBDF1A29B5EE3583B_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_C24FC773F35A84ADBDF1A29B5EE3583B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_C24FC773F35A84ADBDF1A29B5EE3583B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_C24FC773F35A84ADBDF1A29B5EE3583B" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_C24FC773F35A84ADBDF1A29B5EE3583B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_F8CD4762E715A60A5468A29B5EE35134_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_F8CD4762E715A60A5468A29B5EE35134" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_F8CD4762E715A60A5468A29B5EE35134_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_F8CD4762E715A60A5468A29B5EE35134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_F8CD4762E715A60A5468A29B5EE35134" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_F8CD4762E715A60A5468A29B5EE35134" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_F8CD4762E715A60A5468A29B5EE35134" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_BB92FCA184E81777E321A29B5EE36ED5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_BB92FCA184E81777E321A29B5EE36ED5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of TYSABRI rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_BB92FCA184E81777E321A29B5EE36ED5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_BB92FCA184E81777E321A29B5EE36ED5" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_BB92FCA184E81777E321A29B5EE36ED5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_98CA5807ACF979A82C13A29B5EE3461A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_98CA5807ACF979A82C13A29B5EE3461A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration related to Fumapharm AG acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_98CA5807ACF979A82C13A29B5EE3461A_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_98CA5807ACF979A82C13A29B5EE3461A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_98CA5807ACF979A82C13A29B5EE3461A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_98CA5807ACF979A82C13A29B5EE3461A" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_98CA5807ACF979A82C13A29B5EE3461A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_DD935B3279D3CA94AF44A29B5EE32A35_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_DD935B3279D3CA94AF44A29B5EE32A35" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of businesses</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_DD935B3279D3CA94AF44A29B5EE32A35_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_DD935B3279D3CA94AF44A29B5EE32A35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_DD935B3279D3CA94AF44A29B5EE32A35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_DD935B3279D3CA94AF44A29B5EE32A35" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_DD935B3279D3CA94AF44A29B5EE32A35" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8DD43832294B4DA57DEAA29B5EE30CF4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8DD43832294B4DA57DEAA29B5EE30CF4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8DD43832294B4DA57DEAA29B5EE30CF4_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8DD43832294B4DA57DEAA29B5EE30CF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8DD43832294B4DA57DEAA29B5EE30CF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8DD43832294B4DA57DEAA29B5EE30CF4" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8DD43832294B4DA57DEAA29B5EE30CF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EDA805EC0887681CDAB4A29B5EE382F3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EDA805EC0887681CDAB4A29B5EE382F3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EDA805EC0887681CDAB4A29B5EE382F3_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EDA805EC0887681CDAB4A29B5EE382F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EDA805EC0887681CDAB4A29B5EE382F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EDA805EC0887681CDAB4A29B5EE382F3" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EDA805EC0887681CDAB4A29B5EE382F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ACBED5A7C08A556D83EA29B5EE3B0EF_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ACBED5A7C08A556D83EA29B5EE3B0EF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ACBED5A7C08A556D83EA29B5EE3B0EF_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ACBED5A7C08A556D83EA29B5EE3B0EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ACBED5A7C08A556D83EA29B5EE3B0EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ACBED5A7C08A556D83EA29B5EE3B0EF" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ACBED5A7C08A556D83EA29B5EE3B0EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8498A9F9E449D9CECE60A29B5EE3CD09_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8498A9F9E449D9CECE60A29B5EE3CD09" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8498A9F9E449D9CECE60A29B5EE3CD09_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8498A9F9E449D9CECE60A29B5EE3CD09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8498A9F9E449D9CECE60A29B5EE3CD09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8498A9F9E449D9CECE60A29B5EE3CD09" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8498A9F9E449D9CECE60A29B5EE3CD09" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_549D5D24DCD8C51D7A49A29B5EE351CF_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_549D5D24DCD8C51D7A49A29B5EE351CF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_549D5D24DCD8C51D7A49A29B5EE351CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_549D5D24DCD8C51D7A49A29B5EE351CF" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_549D5D24DCD8C51D7A49A29B5EE351CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0AB2485F08E944312FC6A29B5EE305F0_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0AB2485F08E944312FC6A29B5EE305F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of stock for share-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0AB2485F08E944312FC6A29B5EE305F0_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0AB2485F08E944312FC6A29B5EE305F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0AB2485F08E944312FC6A29B5EE305F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0AB2485F08E944312FC6A29B5EE305F0" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0AB2485F08E944312FC6A29B5EE305F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_2EC574553DDB828B2389A29B5EE368CD_terseLabel_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_2EC574553DDB828B2389A29B5EE368CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess tax benefit from share-based compensation</link:label>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_2EC574553DDB828B2389A29B5EE368CD_label_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_2EC574553DDB828B2389A29B5EE368CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_2EC574553DDB828B2389A29B5EE368CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_2EC574553DDB828B2389A29B5EE368CD" xlink:to="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_2EC574553DDB828B2389A29B5EE368CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_6F2326BA8B62770B5221A29B5EE3EFDA_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_6F2326BA8B62770B5221A29B5EE3EFDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_6F2326BA8B62770B5221A29B5EE3EFDA_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_6F2326BA8B62770B5221A29B5EE3EFDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_6F2326BA8B62770B5221A29B5EE3EFDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable_6F2326BA8B62770B5221A29B5EE3EFDA" xlink:to="lab_us-gaap_ProceedsFromNotesPayable_6F2326BA8B62770B5221A29B5EE3EFDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfDebt_B92DAEF195297AD9E3E0A29B5EE411B1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_B92DAEF195297AD9E3E0A29B5EE411B1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_B92DAEF195297AD9E3E0A29B5EE411B1_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_B92DAEF195297AD9E3E0A29B5EE411B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_B92DAEF195297AD9E3E0A29B5EE411B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_B92DAEF195297AD9E3E0A29B5EE411B1" xlink:to="lab_us-gaap_RepaymentsOfDebt_B92DAEF195297AD9E3E0A29B5EE411B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9A64B3FED209C77E9592A29B5EE46E9B_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9A64B3FED209C77E9592A29B5EE46E9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9A64B3FED209C77E9592A29B5EE46E9B_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9A64B3FED209C77E9592A29B5EE46E9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9A64B3FED209C77E9592A29B5EE46E9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9A64B3FED209C77E9592A29B5EE46E9B" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9A64B3FED209C77E9592A29B5EE46E9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BBE1F9F11CF7F0E853C8A29B5EE4F743_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BBE1F9F11CF7F0E853C8A29B5EE4F743" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BBE1F9F11CF7F0E853C8A29B5EE4F743_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BBE1F9F11CF7F0E853C8A29B5EE4F743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BBE1F9F11CF7F0E853C8A29B5EE4F743" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BBE1F9F11CF7F0E853C8A29B5EE4F743" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BBE1F9F11CF7F0E853C8A29B5EE4F743" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_42FC4590105C14E160D5A29B5EE446BF_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_42FC4590105C14E160D5A29B5EE446BF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_42FC4590105C14E160D5A29B5EE446BF_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_42FC4590105C14E160D5A29B5EE446BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_42FC4590105C14E160D5A29B5EE446BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_42FC4590105C14E160D5A29B5EE446BF" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_42FC4590105C14E160D5A29B5EE446BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_64FA4221A6A18BB1519CA29B5EE47C96_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_64FA4221A6A18BB1519CA29B5EE47C96" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_64FA4221A6A18BB1519CA29B5EE47C96_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_64FA4221A6A18BB1519CA29B5EE47C96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_64FA4221A6A18BB1519CA29B5EE47C96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_64FA4221A6A18BB1519CA29B5EE47C96" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_64FA4221A6A18BB1519CA29B5EE47C96" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9E77036E22356843AB8DA29B5EE4CD03_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9E77036E22356843AB8DA29B5EE4CD03" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of the year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9E77036E22356843AB8DA29B5EE4CD03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9E77036E22356843AB8DA29B5EE4CD03" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9E77036E22356843AB8DA29B5EE4CD03" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_69388F7AF1250408BDCEA29B5EE40412_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_69388F7AF1250408BDCEA29B5EE40412" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of the year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_69388F7AF1250408BDCEA29B5EE40412" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_69388F7AF1250408BDCEA29B5EE40412" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_69388F7AF1250408BDCEA29B5EE40412" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_ACAA23A49FE96951D3D993582E116794_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_ACAA23A49FE96951D3D993582E116794" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_ACAA23A49FE96951D3D993582E116794_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_ACAA23A49FE96951D3D993582E116794" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ACAA23A49FE96951D3D993582E116794" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ACAA23A49FE96951D3D993582E116794" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_ACAA23A49FE96951D3D993582E116794" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_95BC0FB58538605DFA5893582E11C4A5_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_95BC0FB58538605DFA5893582E11C4A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities by Classification of Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_95BC0FB58538605DFA5893582E11C4A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_95BC0FB58538605DFA5893582E11C4A5" xlink:to="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_95BC0FB58538605DFA5893582E11C4A5" xlink:type="arc" />
    <link:label id="lab_biib_NeurimmuneMember_E451959490AEA52B965C93582E12DEEE_verboseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember_E451959490AEA52B965C93582E12DEEE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_E451959490AEA52B965C93582E12DEEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember_E451959490AEA52B965C93582E12DEEE" xlink:to="lab_biib_NeurimmuneMember_E451959490AEA52B965C93582E12DEEE" xlink:type="arc" />
    <link:label id="lab_biib_RodinTherapeuticsMember_67FD71452ABDB315E16293582E12A9CD_terseLabel_en-US" xlink:label="lab_biib_RodinTherapeuticsMember_67FD71452ABDB315E16293582E12A9CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rodin Therapeutics</link:label>
    <link:label id="lab_biib_RodinTherapeuticsMember_67FD71452ABDB315E16293582E12A9CD_label_en-US" xlink:label="lab_biib_RodinTherapeuticsMember_67FD71452ABDB315E16293582E12A9CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rodin Therapeutics [Member]</link:label>
    <link:label id="lab_biib_RodinTherapeuticsMember_67FD71452ABDB315E16293582E12A9CD_documentation_en-US" xlink:label="lab_biib_RodinTherapeuticsMember_67FD71452ABDB315E16293582E12A9CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rodin Therapeutics [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RodinTherapeuticsMember" xlink:label="loc_biib_RodinTherapeuticsMember_67FD71452ABDB315E16293582E12A9CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RodinTherapeuticsMember_67FD71452ABDB315E16293582E12A9CD" xlink:to="lab_biib_RodinTherapeuticsMember_67FD71452ABDB315E16293582E12A9CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_CF0C9258BAA90ED184D993582E12A7E6_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_CF0C9258BAA90ED184D993582E12A7E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_CF0C9258BAA90ED184D993582E12A7E6_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_CF0C9258BAA90ED184D993582E12A7E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_CF0C9258BAA90ED184D993582E12A7E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_CF0C9258BAA90ED184D993582E12A7E6" xlink:to="lab_us-gaap_VariableInterestEntityLineItems_CF0C9258BAA90ED184D993582E12A7E6" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual)</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B_label_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B_documentation_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:to="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:type="arc" />
    <link:label id="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_7AC122855F0F1564806893582E12EDBF_verboseLabel_en-US" xlink:label="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_7AC122855F0F1564806893582E12EDBF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Remaining potential development milestone payments and royalties on commercial sales under the terms of collaboration agreement</link:label>
    <link:label id="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_7AC122855F0F1564806893582E12EDBF_label_en-US" xlink:label="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_7AC122855F0F1564806893582E12EDBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining Potential Development Milestone Payments And Royalties On Commercial Sales Under Terms Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_7AC122855F0F1564806893582E12EDBF_documentation_en-US" xlink:label="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_7AC122855F0F1564806893582E12EDBF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected total payments including upfront and milestone payments as well as the greater of an annual maintenance fee or usage-based royalty payments under the terms of collaboration agreement.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" xlink:label="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_7AC122855F0F1564806893582E12EDBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_7AC122855F0F1564806893582E12EDBF" xlink:to="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_7AC122855F0F1564806893582E12EDBF" xlink:type="arc" />
    <link:label id="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E18D82267E8A1717B8D793582E1216D6_verboseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E18D82267E8A1717B8D793582E1216D6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of funding for R&amp;D cost required in support of the collaboration agreement</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E18D82267E8A1717B8D793582E1216D6_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E18D82267E8A1717B8D793582E1216D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Cost In Support Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E18D82267E8A1717B8D793582E1216D6_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E18D82267E8A1717B8D793582E1216D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development cost in support of the collaboration agreement.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" xlink:label="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E18D82267E8A1717B8D793582E1216D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E18D82267E8A1717B8D793582E1216D6" xlink:to="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E18D82267E8A1717B8D793582E1216D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_4161E02A52751C889D4F93582E12C6E0_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_4161E02A52751C889D4F93582E12C6E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire interest in peferred stock of an affiliates</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_4161E02A52751C889D4F93582E12C6E0_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_4161E02A52751C889D4F93582E12C6E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_4161E02A52751C889D4F93582E12C6E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_4161E02A52751C889D4F93582E12C6E0" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_4161E02A52751C889D4F93582E12C6E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitment_C00A27608CF68B15FA9093582E128A66_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment_C00A27608CF68B15FA9093582E128A66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional investments committed to if certain development milestones are achieved</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_C00A27608CF68B15FA9093582E128A66_label_en-US" xlink:label="lab_us-gaap_OtherCommitment_C00A27608CF68B15FA9093582E128A66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_C00A27608CF68B15FA9093582E128A66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment_C00A27608CF68B15FA9093582E128A66" xlink:to="lab_us-gaap_OtherCommitment_C00A27608CF68B15FA9093582E128A66" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_FD50110CA21A4198118293582E12CD34_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_FD50110CA21A4198118293582E12CD34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_FD50110CA21A4198118293582E12CD34_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_FD50110CA21A4198118293582E12CD34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_FD50110CA21A4198118293582E12CD34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess_FD50110CA21A4198118293582E12CD34" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess_FD50110CA21A4198118293582E12CD34" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_2F033F03E873A4E04A6D93582E120BB6_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_2F033F03E873A4E04A6D93582E120BB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minority interest in our stockholder's equity</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_2F033F03E873A4E04A6D93582E120BB6_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_2F033F03E873A4E04A6D93582E120BB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest in Variable Interest Entity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_2F033F03E873A4E04A6D93582E120BB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_2F033F03E873A4E04A6D93582E120BB6" xlink:to="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_2F033F03E873A4E04A6D93582E120BB6" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_0F6EA27E012A1106F31093582E12B6B9_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_0F6EA27E012A1106F31093582E12B6B9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_0F6EA27E012A1106F31093582E12B6B9_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_0F6EA27E012A1106F31093582E12B6B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_0F6EA27E012A1106F31093582E12B6B9_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_0F6EA27E012A1106F31093582E12B6B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_0F6EA27E012A1106F31093582E12B6B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_0F6EA27E012A1106F31093582E12B6B9" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_0F6EA27E012A1106F31093582E12B6B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_4A82E3FAF26B9C2426AA38A353FA2915_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_4A82E3FAF26B9C2426AA38A353FA2915" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_4A82E3FAF26B9C2426AA38A353FA2915_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_4A82E3FAF26B9C2426AA38A353FA2915" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_4A82E3FAF26B9C2426AA38A353FA2915" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_4A82E3FAF26B9C2426AA38A353FA2915" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_4A82E3FAF26B9C2426AA38A353FA2915" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_D63BD7385AC0963A5CF438A353FA98D9_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_D63BD7385AC0963A5CF438A353FA98D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_D63BD7385AC0963A5CF438A353FA98D9_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_D63BD7385AC0963A5CF438A353FA98D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_D63BD7385AC0963A5CF438A353FA98D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_D63BD7385AC0963A5CF438A353FA98D9" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_D63BD7385AC0963A5CF438A353FA98D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_391120911795C250B1AB38A353FA9369_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_391120911795C250B1AB38A353FA9369" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_391120911795C250B1AB38A353FA9369_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_391120911795C250B1AB38A353FA9369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_391120911795C250B1AB38A353FA9369" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_391120911795C250B1AB38A353FA9369" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_391120911795C250B1AB38A353FA9369" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_9B39ED37AD49D9E3576E38A353FA262F_verboseLabel_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_9B39ED37AD49D9E3576E38A353FA262F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_9B39ED37AD49D9E3576E38A353FA262F_label_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_9B39ED37AD49D9E3576E38A353FA262F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discount [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_9B39ED37AD49D9E3576E38A353FA262F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReserveForCashDiscountMember_9B39ED37AD49D9E3576E38A353FA262F" xlink:to="lab_us-gaap_ReserveForCashDiscountMember_9B39ED37AD49D9E3576E38A353FA262F" xlink:type="arc" />
    <link:label id="lab_biib_ContractualAdjustmentsMember_2E81D210CC743515AB0738A353FA56E9_verboseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_2E81D210CC743515AB0738A353FA56E9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contractual Adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_2E81D210CC743515AB0738A353FA56E9_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_2E81D210CC743515AB0738A353FA56E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_2E81D210CC743515AB0738A353FA56E9_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_2E81D210CC743515AB0738A353FA56E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_2E81D210CC743515AB0738A353FA56E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember_2E81D210CC743515AB0738A353FA56E9" xlink:to="lab_biib_ContractualAdjustmentsMember_2E81D210CC743515AB0738A353FA56E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_01521B5C408E1FB9D9AE38A353FA74BE_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_01521B5C408E1FB9D9AE38A353FA74BE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_01521B5C408E1FB9D9AE38A353FA74BE_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_01521B5C408E1FB9D9AE38A353FA74BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_01521B5C408E1FB9D9AE38A353FA74BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember_01521B5C408E1FB9D9AE38A353FA74BE" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember_01521B5C408E1FB9D9AE38A353FA74BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_54B09DAD77CB1B68BDCC38A353FA8B23_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_54B09DAD77CB1B68BDCC38A353FA8B23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_54B09DAD77CB1B68BDCC38A353FA8B23_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_54B09DAD77CB1B68BDCC38A353FA8B23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_54B09DAD77CB1B68BDCC38A353FA8B23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_54B09DAD77CB1B68BDCC38A353FA8B23" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_54B09DAD77CB1B68BDCC38A353FA8B23" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F_verboseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Analysis of the amount of, and change in, reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Abstract]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of the amount of, and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_A147B12175580DE2D9E338A353FB4288_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_A147B12175580DE2D9E338A353FB4288" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_A147B12175580DE2D9E338A353FB4288" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_A147B12175580DE2D9E338A353FB4288" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_A147B12175580DE2D9E338A353FB4288" xlink:type="arc" />
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_598CD8A6A3AF9491FA9C38A353FBF800_verboseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_598CD8A6A3AF9491FA9C38A353FBF800" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current provisions relating to sales in current year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_598CD8A6A3AF9491FA9C38A353FBF800_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_598CD8A6A3AF9491FA9C38A353FBF800" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_598CD8A6A3AF9491FA9C38A353FBF800_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_598CD8A6A3AF9491FA9C38A353FBF800" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_598CD8A6A3AF9491FA9C38A353FBF800" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_598CD8A6A3AF9491FA9C38A353FBF800" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_598CD8A6A3AF9491FA9C38A353FBF800" xlink:type="arc" />
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_7D00426613B4B1CD174538A353FB7C9F_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_7D00426613B4B1CD174538A353FB7C9F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustments relating to prior years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_7D00426613B4B1CD174538A353FB7C9F_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_7D00426613B4B1CD174538A353FB7C9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_7D00426613B4B1CD174538A353FB7C9F_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_7D00426613B4B1CD174538A353FB7C9F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_7D00426613B4B1CD174538A353FB7C9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_7D00426613B4B1CD174538A353FB7C9F" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_7D00426613B4B1CD174538A353FB7C9F" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_3E28DF57E223BD46E27A38A353FBAEB4_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_3E28DF57E223BD46E27A38A353FBAEB4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/returns relating to sales in current year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_3E28DF57E223BD46E27A38A353FBAEB4_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_3E28DF57E223BD46E27A38A353FBAEB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_3E28DF57E223BD46E27A38A353FBAEB4_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_3E28DF57E223BD46E27A38A353FBAEB4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_3E28DF57E223BD46E27A38A353FBAEB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_3E28DF57E223BD46E27A38A353FBAEB4" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_3E28DF57E223BD46E27A38A353FBAEB4" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_28A04DE65941BC15A7F638A353FB4373_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_28A04DE65941BC15A7F638A353FB4373" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/returns relating to sales in prior years</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_28A04DE65941BC15A7F638A353FB4373_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_28A04DE65941BC15A7F638A353FB4373" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_28A04DE65941BC15A7F638A353FB4373_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_28A04DE65941BC15A7F638A353FB4373" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_28A04DE65941BC15A7F638A353FB4373" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_28A04DE65941BC15A7F638A353FB4373" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_28A04DE65941BC15A7F638A353FB4373" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_3114512F5F1E1621943638A353FB02C5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_3114512F5F1E1621943638A353FB02C5" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_3114512F5F1E1621943638A353FB02C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_3114512F5F1E1621943638A353FB02C5" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_3114512F5F1E1621943638A353FB02C5" xlink:type="arc" />
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_FE5E24C5E6FFF8154E4438A355A861D8_verboseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_FE5E24C5E6FFF8154E4438A355A861D8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total expense incurred by collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_FE5E24C5E6FFF8154E4438A355A861D8_label_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_FE5E24C5E6FFF8154E4438A355A861D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_FE5E24C5E6FFF8154E4438A355A861D8_documentation_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_FE5E24C5E6FFF8154E4438A355A861D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total expense incurred by collaboration.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_FE5E24C5E6FFF8154E4438A355A861D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration_FE5E24C5E6FFF8154E4438A355A861D8" xlink:to="lab_biib_ExpenseIncurredByCollaboration_FE5E24C5E6FFF8154E4438A355A861D8" xlink:type="arc" />
    <link:label id="lab_biib_ExpenseReflectedWithinStatementsOfIncome_B78A52685CDE4A5814A338A355A865CA_verboseLabel_en-US" xlink:label="lab_biib_ExpenseReflectedWithinStatementsOfIncome_B78A52685CDE4A5814A338A355A865CA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of expense reflected within our consolidation statements of income</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ExpenseReflectedWithinStatementsOfIncome" xlink:label="loc_biib_ExpenseReflectedWithinStatementsOfIncome_B78A52685CDE4A5814A338A355A865CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseReflectedWithinStatementsOfIncome_B78A52685CDE4A5814A338A355A865CA" xlink:to="lab_biib_ExpenseReflectedWithinStatementsOfIncome_B78A52685CDE4A5814A338A355A865CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_4A42491BA05A7C047DCF38A35149BD0E_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_4A42491BA05A7C047DCF38A35149BD0E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_4A42491BA05A7C047DCF38A35149BD0E_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_4A42491BA05A7C047DCF38A35149BD0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4A42491BA05A7C047DCF38A35149BD0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_4A42491BA05A7C047DCF38A35149BD0E" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_4A42491BA05A7C047DCF38A35149BD0E" xlink:type="arc" />
    <link:label id="lab_biib_NotesPayableToFumedicaMember_71EA1F8EA9FE10FDD1C038A3549791B8_verboseLabel_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_71EA1F8EA9FE10FDD1C038A3549791B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable to Fumedica</link:label>
    <link:label id="lab_biib_NotesPayableToFumedicaMember_71EA1F8EA9FE10FDD1C038A3549791B8_label_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_71EA1F8EA9FE10FDD1C038A3549791B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable To Fumedica [Member]</link:label>
    <link:label id="lab_biib_NotesPayableToFumedicaMember_71EA1F8EA9FE10FDD1C038A3549791B8_documentation_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_71EA1F8EA9FE10FDD1C038A3549791B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes payable.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_71EA1F8EA9FE10FDD1C038A3549791B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NotesPayableToFumedicaMember_71EA1F8EA9FE10FDD1C038A3549791B8" xlink:to="lab_biib_NotesPayableToFumedicaMember_71EA1F8EA9FE10FDD1C038A3549791B8" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_14600032C3BE18CC2F1038A3549810F8_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_14600032C3BE18CC2F1038A3549810F8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_14600032C3BE18CC2F1038A3549810F8_label_en-US" xlink:label="lab_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_14600032C3BE18CC2F1038A3549810F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_14600032C3BE18CC2F1038A3549810F8_documentation_en-US" xlink:label="lab_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_14600032C3BE18CC2F1038A3549810F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract" xlink:label="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_14600032C3BE18CC2F1038A3549810F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_14600032C3BE18CC2F1038A3549810F8" xlink:to="lab_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_14600032C3BE18CC2F1038A3549810F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_105FE6420C89276F94F038A3549888B0_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_105FE6420C89276F94F038A3549888B0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_105FE6420C89276F94F038A3549888B0_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_105FE6420C89276F94F038A3549888B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_105FE6420C89276F94F038A3549888B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_105FE6420C89276F94F038A3549888B0" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_105FE6420C89276F94F038A3549888B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_9D00D83E8762E71ED67B38A354984735_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_9D00D83E8762E71ED67B38A354984735" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_9D00D83E8762E71ED67B38A354984735_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_9D00D83E8762E71ED67B38A354984735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_9D00D83E8762E71ED67B38A354984735" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_9D00D83E8762E71ED67B38A354984735" xlink:to="lab_us-gaap_DebtInstrumentFairValue_9D00D83E8762E71ED67B38A354984735" xlink:type="arc" />
    <link:label id="lab_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD_verboseLabel_en-US" xlink:label="lab_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assumptions used in valuation of market based stock units</link:label>
    <link:label id="lab_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD_label_en-US" xlink:label="lab_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation of Granted Stock Units [Abstract]</link:label>
    <link:label id="lab_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD_documentation_en-US" xlink:label="lab_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation of granted stock units.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ValuationOfGrantedStockUnitsAbstract" xlink:label="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:to="lab_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_98FA3713CB727EDBB9EE93D5C9E1707A_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_98FA3713CB727EDBB9EE93D5C9E1707A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_98FA3713CB727EDBB9EE93D5C9E1707A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_98FA3713CB727EDBB9EE93D5C9E1707A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_98FA3713CB727EDBB9EE93D5C9E1707A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_98FA3713CB727EDBB9EE93D5C9E1707A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_98FA3713CB727EDBB9EE93D5C9E1707A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_C0B74D6A2907A7BEA38093D5C9E15A2A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_C0B74D6A2907A7BEA38093D5C9E15A2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_C0B74D6A2907A7BEA38093D5C9E15A2A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_C0B74D6A2907A7BEA38093D5C9E15A2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_C0B74D6A2907A7BEA38093D5C9E15A2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_C0B74D6A2907A7BEA38093D5C9E15A2A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_C0B74D6A2907A7BEA38093D5C9E15A2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9270EAF2B76108E47E8C93D5C9E10421_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9270EAF2B76108E47E8C93D5C9E10421" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum range of risk-free interest rates</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9270EAF2B76108E47E8C93D5C9E10421_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9270EAF2B76108E47E8C93D5C9E10421" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9270EAF2B76108E47E8C93D5C9E10421" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9270EAF2B76108E47E8C93D5C9E10421" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9270EAF2B76108E47E8C93D5C9E10421" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8CE6724163294A70034E93D5C9E15626_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8CE6724163294A70034E93D5C9E15626" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum range of risk-free interest rates</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8CE6724163294A70034E93D5C9E15626_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8CE6724163294A70034E93D5C9E15626" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8CE6724163294A70034E93D5C9E15626" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8CE6724163294A70034E93D5C9E15626" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8CE6724163294A70034E93D5C9E15626" xlink:type="arc" />
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_B5A4A55E29F678A7735293D5C9E1359A_verboseLabel_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_B5A4A55E29F678A7735293D5C9E1359A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average stock price on grant date minimum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_B5A4A55E29F678A7735293D5C9E1359A_label_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_B5A4A55E29F678A7735293D5C9E1359A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Stock Price On Grant Date In Dollars Minimum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_B5A4A55E29F678A7735293D5C9E1359A_documentation_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_B5A4A55E29F678A7735293D5C9E1359A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average stock price on grant date in dollars minimum.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_B5A4A55E29F678A7735293D5C9E1359A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_B5A4A55E29F678A7735293D5C9E1359A" xlink:to="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_B5A4A55E29F678A7735293D5C9E1359A" xlink:type="arc" />
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_9F2EBAFAD48B0C56739193D5C9E17280_verboseLabel_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_9F2EBAFAD48B0C56739193D5C9E17280" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average stock price on grant date maximum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_9F2EBAFAD48B0C56739193D5C9E17280_label_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_9F2EBAFAD48B0C56739193D5C9E17280" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Stock Price On Grant Date In Dollars Maximum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_9F2EBAFAD48B0C56739193D5C9E17280_documentation_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_9F2EBAFAD48B0C56739193D5C9E17280" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average stock price on grant date in dollars maximum.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_9F2EBAFAD48B0C56739193D5C9E17280" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_9F2EBAFAD48B0C56739193D5C9E17280" xlink:to="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_9F2EBAFAD48B0C56739193D5C9E17280" xlink:type="arc" />
    <link:label id="lab_biib_SixbillionMember_525EE520AF11727B08BD93582DC65ED0_terseLabel_en-US" xlink:label="lab_biib_SixbillionMember_525EE520AF11727B08BD93582DC65ED0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Six billion</link:label>
    <link:label id="lab_biib_SixbillionMember_525EE520AF11727B08BD93582DC65ED0_label_en-US" xlink:label="lab_biib_SixbillionMember_525EE520AF11727B08BD93582DC65ED0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Six billion [Member]</link:label>
    <link:label id="lab_biib_SixbillionMember_525EE520AF11727B08BD93582DC65ED0_documentation_en-US" xlink:label="lab_biib_SixbillionMember_525EE520AF11727B08BD93582DC65ED0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Six billion [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SixbillionMember" xlink:label="loc_biib_SixbillionMember_525EE520AF11727B08BD93582DC65ED0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SixbillionMember_525EE520AF11727B08BD93582DC65ED0" xlink:to="lab_biib_SixbillionMember_525EE520AF11727B08BD93582DC65ED0" xlink:type="arc" />
    <link:label id="lab_biib_FourbillionMember_9BB0B81D90F32132B1D193582DC64433_terseLabel_en-US" xlink:label="lab_biib_FourbillionMember_9BB0B81D90F32132B1D193582DC64433" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Four billion</link:label>
    <link:label id="lab_biib_FourbillionMember_9BB0B81D90F32132B1D193582DC64433_label_en-US" xlink:label="lab_biib_FourbillionMember_9BB0B81D90F32132B1D193582DC64433" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Four billion [Member]</link:label>
    <link:label id="lab_biib_FourbillionMember_9BB0B81D90F32132B1D193582DC64433_documentation_en-US" xlink:label="lab_biib_FourbillionMember_9BB0B81D90F32132B1D193582DC64433" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Four billion [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_FourbillionMember" xlink:label="loc_biib_FourbillionMember_9BB0B81D90F32132B1D193582DC64433" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FourbillionMember_9BB0B81D90F32132B1D193582DC64433" xlink:to="lab_biib_FourbillionMember_9BB0B81D90F32132B1D193582DC64433" xlink:type="arc" />
    <link:label id="lab_biib_FivebillionMember_65191D8793EC1EC4B4BF93582DC6E83D_terseLabel_en-US" xlink:label="lab_biib_FivebillionMember_65191D8793EC1EC4B4BF93582DC6E83D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Five billion</link:label>
    <link:label id="lab_biib_FivebillionMember_65191D8793EC1EC4B4BF93582DC6E83D_label_en-US" xlink:label="lab_biib_FivebillionMember_65191D8793EC1EC4B4BF93582DC6E83D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Five billion [Member]</link:label>
    <link:label id="lab_biib_FivebillionMember_65191D8793EC1EC4B4BF93582DC6E83D_documentation_en-US" xlink:label="lab_biib_FivebillionMember_65191D8793EC1EC4B4BF93582DC6E83D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Five billion [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_FivebillionMember" xlink:label="loc_biib_FivebillionMember_65191D8793EC1EC4B4BF93582DC6E83D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FivebillionMember_65191D8793EC1EC4B4BF93582DC6E83D" xlink:to="lab_biib_FivebillionMember_65191D8793EC1EC4B4BF93582DC6E83D" xlink:type="arc" />
    <link:label id="lab_biib_OneBillionMember_566EFD185CD9CD9BBF9093582DC69A60_terseLabel_en-US" xlink:label="lab_biib_OneBillionMember_566EFD185CD9CD9BBF9093582DC69A60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One billion</link:label>
    <link:label id="lab_biib_OneBillionMember_566EFD185CD9CD9BBF9093582DC69A60_label_en-US" xlink:label="lab_biib_OneBillionMember_566EFD185CD9CD9BBF9093582DC69A60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One billion [Member]</link:label>
    <link:label id="lab_biib_OneBillionMember_566EFD185CD9CD9BBF9093582DC69A60_documentation_en-US" xlink:label="lab_biib_OneBillionMember_566EFD185CD9CD9BBF9093582DC69A60" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One billion [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_OneBillionMember" xlink:label="loc_biib_OneBillionMember_566EFD185CD9CD9BBF9093582DC69A60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OneBillionMember_566EFD185CD9CD9BBF9093582DC69A60" xlink:to="lab_biib_OneBillionMember_566EFD185CD9CD9BBF9093582DC69A60" xlink:type="arc" />
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_BAA88DF10D1FC6C4164E93582DC6F1C7_terseLabel_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_BAA88DF10D1FC6C4164E93582DC6F1C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion</link:label>
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_BAA88DF10D1FC6C4164E93582DC6F1C7_label_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_BAA88DF10D1FC6C4164E93582DC6F1C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion [Member]</link:label>
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_BAA88DF10D1FC6C4164E93582DC6F1C7_documentation_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_BAA88DF10D1FC6C4164E93582DC6F1C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_BAA88DF10D1FC6C4164E93582DC6F1C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_BAA88DF10D1FC6C4164E93582DC6F1C7" xlink:to="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_BAA88DF10D1FC6C4164E93582DC6F1C7" xlink:type="arc" />
    <link:label id="lab_biib_ThreeBillionMember_C4E5C0E49873C4DC9E4F93582DC6C38E_terseLabel_en-US" xlink:label="lab_biib_ThreeBillionMember_C4E5C0E49873C4DC9E4F93582DC6C38E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Three billion</link:label>
    <link:label id="lab_biib_ThreeBillionMember_C4E5C0E49873C4DC9E4F93582DC6C38E_label_en-US" xlink:label="lab_biib_ThreeBillionMember_C4E5C0E49873C4DC9E4F93582DC6C38E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three billion [Member]</link:label>
    <link:label id="lab_biib_ThreeBillionMember_C4E5C0E49873C4DC9E4F93582DC6C38E_documentation_en-US" xlink:label="lab_biib_ThreeBillionMember_C4E5C0E49873C4DC9E4F93582DC6C38E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Three billion [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ThreeBillionMember" xlink:label="loc_biib_ThreeBillionMember_C4E5C0E49873C4DC9E4F93582DC6C38E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThreeBillionMember_C4E5C0E49873C4DC9E4F93582DC6C38E" xlink:to="lab_biib_ThreeBillionMember_C4E5C0E49873C4DC9E4F93582DC6C38E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitment_42202F7006C2C3AA256093582DC7908F_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment_42202F7006C2C3AA256093582DC7908F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cancellable future commitments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_42202F7006C2C3AA256093582DC7908F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment_42202F7006C2C3AA256093582DC7908F" xlink:to="lab_us-gaap_OtherCommitment_42202F7006C2C3AA256093582DC7908F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_1B4201E56846CE7A3E1393582DC762AF_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_1B4201E56846CE7A3E1393582DC762AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount paid in cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1B4201E56846CE7A3E1393582DC762AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_1B4201E56846CE7A3E1393582DC762AF" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_1B4201E56846CE7A3E1393582DC762AF" xlink:type="arc" />
    <link:label id="lab_biib_CommitmentsAndContingenciesTextualAbstract_C3E60C5AF87F1042D77893582DC75D05_terseLabel_en-US" xlink:label="lab_biib_CommitmentsAndContingenciesTextualAbstract_C3E60C5AF87F1042D77893582DC75D05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies (Textual)</link:label>
    <link:label id="lab_biib_CommitmentsAndContingenciesTextualAbstract_C3E60C5AF87F1042D77893582DC75D05_label_en-US" xlink:label="lab_biib_CommitmentsAndContingenciesTextualAbstract_C3E60C5AF87F1042D77893582DC75D05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_CommitmentsAndContingenciesTextualAbstract_C3E60C5AF87F1042D77893582DC75D05_documentation_en-US" xlink:label="lab_biib_CommitmentsAndContingenciesTextualAbstract_C3E60C5AF87F1042D77893582DC75D05" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_biib_CommitmentsAndContingenciesTextualAbstract_C3E60C5AF87F1042D77893582DC75D05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_C3E60C5AF87F1042D77893582DC75D05" xlink:to="lab_biib_CommitmentsAndContingenciesTextualAbstract_C3E60C5AF87F1042D77893582DC75D05" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_335010E79A3DD0031F4F93582DC7FABB_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_335010E79A3DD0031F4F93582DC7FABB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease rent expense which terminates at various dates through 2028</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_335010E79A3DD0031F4F93582DC7FABB_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_335010E79A3DD0031F4F93582DC7FABB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_335010E79A3DD0031F4F93582DC7FABB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_335010E79A3DD0031F4F93582DC7FABB" xlink:to="lab_us-gaap_LeaseAndRentalExpense_335010E79A3DD0031F4F93582DC7FABB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_F57853CC9EA002EF6DDF93582DC7A6D8_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_F57853CC9EA002EF6DDF93582DC7A6D8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities associated with uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_F57853CC9EA002EF6DDF93582DC7A6D8_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_F57853CC9EA002EF6DDF93582DC7A6D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Uncertain Tax Positions, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_F57853CC9EA002EF6DDF93582DC7A6D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_F57853CC9EA002EF6DDF93582DC7A6D8" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_F57853CC9EA002EF6DDF93582DC7A6D8" xlink:type="arc" />
    <link:label id="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F41C98432D67381C37393582DC70370_verboseLabel_en-US" xlink:label="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F41C98432D67381C37393582DC70370" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F41C98432D67381C37393582DC70370_label_en-US" xlink:label="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F41C98432D67381C37393582DC70370" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses On Funding Commitment Related To Clinical Research</link:label>
    <link:label id="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F41C98432D67381C37393582DC70370_documentation_en-US" xlink:label="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F41C98432D67381C37393582DC70370" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued expenses on funding commitment related to clinical research.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" xlink:label="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F41C98432D67381C37393582DC70370" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F41C98432D67381C37393582DC70370" xlink:to="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F41C98432D67381C37393582DC70370" xlink:type="arc" />
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_29A3385DFFFC26D2C78593582DC8E6F1_verboseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_29A3385DFFFC26D2C78593582DC8E6F1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Potential future milestone payments commitment, approximately</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_29A3385DFFFC26D2C78593582DC8E6F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_29A3385DFFFC26D2C78593582DC8E6F1" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_29A3385DFFFC26D2C78593582DC8E6F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_06DA34F5BA55FD26713C38A3553EE0D6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_06DA34F5BA55FD26713C38A3553EE0D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_06DA34F5BA55FD26713C38A3553EE0D6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_06DA34F5BA55FD26713C38A3553EE0D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_06DA34F5BA55FD26713C38A3553EE0D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_06DA34F5BA55FD26713C38A3553EE0D6" xlink:to="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_06DA34F5BA55FD26713C38A3553EE0D6" xlink:type="arc" />
    <link:label id="lab_biib_A2015ESPPMember_2F37A9AA31DCE4F00E7238A3553E5983_terseLabel_en-US" xlink:label="lab_biib_A2015ESPPMember_2F37A9AA31DCE4F00E7238A3553E5983" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 ESPP</link:label>
    <link:label id="lab_biib_A2015ESPPMember_2F37A9AA31DCE4F00E7238A3553E5983_label_en-US" xlink:label="lab_biib_A2015ESPPMember_2F37A9AA31DCE4F00E7238A3553E5983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2015 ESPP [Member]</link:label>
    <link:label id="lab_biib_A2015ESPPMember_2F37A9AA31DCE4F00E7238A3553E5983_documentation_en-US" xlink:label="lab_biib_A2015ESPPMember_2F37A9AA31DCE4F00E7238A3553E5983" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2015 ESPP [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_2F37A9AA31DCE4F00E7238A3553E5983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2015ESPPMember_2F37A9AA31DCE4F00E7238A3553E5983" xlink:to="lab_biib_A2015ESPPMember_2F37A9AA31DCE4F00E7238A3553E5983" xlink:type="arc" />
    <link:label id="lab_biib_A1995ESPPMember_50181B306D5DD784FDB938A3553ED876_terseLabel_en-US" xlink:label="lab_biib_A1995ESPPMember_50181B306D5DD784FDB938A3553ED876" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1995 ESPP</link:label>
    <link:label id="lab_biib_A1995ESPPMember_50181B306D5DD784FDB938A3553ED876_label_en-US" xlink:label="lab_biib_A1995ESPPMember_50181B306D5DD784FDB938A3553ED876" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1995 ESPP [Member]</link:label>
    <link:label id="lab_biib_A1995ESPPMember_50181B306D5DD784FDB938A3553ED876_documentation_en-US" xlink:label="lab_biib_A1995ESPPMember_50181B306D5DD784FDB938A3553ED876" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1995 ESPP [Member]</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_A1995ESPPMember" xlink:label="loc_biib_A1995ESPPMember_50181B306D5DD784FDB938A3553ED876" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A1995ESPPMember_50181B306D5DD784FDB938A3553ED876" xlink:to="lab_biib_A1995ESPPMember_50181B306D5DD784FDB938A3553ED876" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_F1F2DFF925DD78279ABB38A3553E6A73_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_F1F2DFF925DD78279ABB38A3553E6A73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_F1F2DFF925DD78279ABB38A3553E6A73_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_F1F2DFF925DD78279ABB38A3553E6A73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_F1F2DFF925DD78279ABB38A3553E6A73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_F1F2DFF925DD78279ABB38A3553E6A73" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_F1F2DFF925DD78279ABB38A3553E6A73" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E14C1F0C38DEF3E95CAD38A3553E388F_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E14C1F0C38DEF3E95CAD38A3553E388F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash received under ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E14C1F0C38DEF3E95CAD38A3553E388F_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E14C1F0C38DEF3E95CAD38A3553E388F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E14C1F0C38DEF3E95CAD38A3553E388F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E14C1F0C38DEF3E95CAD38A3553E388F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E14C1F0C38DEF3E95CAD38A3553E388F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_A5B08BDDEE98876A464C93582E2F90CF_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_A5B08BDDEE98876A464C93582E2F90CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_A5B08BDDEE98876A464C93582E2F90CF_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_A5B08BDDEE98876A464C93582E2F90CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_A5B08BDDEE98876A464C93582E2F90CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_A5B08BDDEE98876A464C93582E2F90CF" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis_A5B08BDDEE98876A464C93582E2F90CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_575ED5D5599A1FCF6F9793582E2FFE6B_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_575ED5D5599A1FCF6F9793582E2FFE6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_575ED5D5599A1FCF6F9793582E2FFE6B_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_575ED5D5599A1FCF6F9793582E2FFE6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_575ED5D5599A1FCF6F9793582E2FFE6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_575ED5D5599A1FCF6F9793582E2FFE6B" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain_575ED5D5599A1FCF6F9793582E2FFE6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralBusinessMember_458EA3DD02696E6BC4A593582E2F9887_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralBusinessMember_458EA3DD02696E6BC4A593582E2F9887" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General Business</link:label>
    <link:label id="lab_us-gaap_GeneralBusinessMember_458EA3DD02696E6BC4A593582E2F9887_label_en-US" xlink:label="lab_us-gaap_GeneralBusinessMember_458EA3DD02696E6BC4A593582E2F9887" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General Business Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="loc_us-gaap_GeneralBusinessMember_458EA3DD02696E6BC4A593582E2F9887" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralBusinessMember_458EA3DD02696E6BC4A593582E2F9887" xlink:to="lab_us-gaap_GeneralBusinessMember_458EA3DD02696E6BC4A593582E2F9887" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchMember_0B1F15C996EB5CAA454A93582E2F0700_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember_0B1F15C996EB5CAA454A93582E2F0700" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research</link:label>
    <link:label id="lab_us-gaap_ResearchMember_0B1F15C996EB5CAA454A93582E2F0700_label_en-US" xlink:label="lab_us-gaap_ResearchMember_0B1F15C996EB5CAA454A93582E2F0700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_0B1F15C996EB5CAA454A93582E2F0700" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember_0B1F15C996EB5CAA454A93582E2F0700" xlink:to="lab_us-gaap_ResearchMember_0B1F15C996EB5CAA454A93582E2F0700" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_E2C9DF5FDC5648AEF1D993582E2FED5F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_E2C9DF5FDC5648AEF1D993582E2FED5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_E2C9DF5FDC5648AEF1D993582E2FED5F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_E2C9DF5FDC5648AEF1D993582E2FED5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_E2C9DF5FDC5648AEF1D993582E2FED5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_E2C9DF5FDC5648AEF1D993582E2FED5F" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_E2C9DF5FDC5648AEF1D993582E2FED5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_BCDACC1F98F82E9B295093582E2F95DB_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_BCDACC1F98F82E9B295093582E2F95DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_BCDACC1F98F82E9B295093582E2F95DB_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_BCDACC1F98F82E9B295093582E2F95DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_BCDACC1F98F82E9B295093582E2F95DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_BCDACC1F98F82E9B295093582E2F95DB" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_BCDACC1F98F82E9B295093582E2F95DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_9DEDB3D54181BB5FE67493582E2F70DE_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_9DEDB3D54181BB5FE67493582E2F70DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Country</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_9DEDB3D54181BB5FE67493582E2F70DE_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_9DEDB3D54181BB5FE67493582E2F70DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_9DEDB3D54181BB5FE67493582E2F70DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_9DEDB3D54181BB5FE67493582E2F70DE" xlink:to="lab_us-gaap_DomesticCountryMember_9DEDB3D54181BB5FE67493582E2F70DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_6CD246E861244F85738493582E2F83F8_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_6CD246E861244F85738493582E2F83F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_6CD246E861244F85738493582E2F83F8_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_6CD246E861244F85738493582E2F83F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_6CD246E861244F85738493582E2F83F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_6CD246E861244F85738493582E2F83F8" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_6CD246E861244F85738493582E2F83F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_DDEB699653B5CD04C67F93582E2F085C_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_DDEB699653B5CD04C67F93582E2F085C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_DDEB699653B5CD04C67F93582E2F085C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_DDEB699653B5CD04C67F93582E2F085C" xlink:to="lab_us-gaap_ForeignCountryMember_DDEB699653B5CD04C67F93582E2F085C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:type="arc" />
    <link:label id="lab_biib_Deferredtaxassetreclassification_71964BE76E996AC4AD4093582E2FA8D3_terseLabel_en-US" xlink:label="lab_biib_Deferredtaxassetreclassification_71964BE76E996AC4AD4093582E2FA8D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset, reclassification</link:label>
    <link:label id="lab_biib_Deferredtaxassetreclassification_71964BE76E996AC4AD4093582E2FA8D3_label_en-US" xlink:label="lab_biib_Deferredtaxassetreclassification_71964BE76E996AC4AD4093582E2FA8D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax asset, reclassification</link:label>
    <link:label id="lab_biib_Deferredtaxassetreclassification_71964BE76E996AC4AD4093582E2FA8D3_documentation_en-US" xlink:label="lab_biib_Deferredtaxassetreclassification_71964BE76E996AC4AD4093582E2FA8D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax asset, reclassification</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_Deferredtaxassetreclassification" xlink:label="loc_biib_Deferredtaxassetreclassification_71964BE76E996AC4AD4093582E2FA8D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Deferredtaxassetreclassification_71964BE76E996AC4AD4093582E2FA8D3" xlink:to="lab_biib_Deferredtaxassetreclassification_71964BE76E996AC4AD4093582E2FA8D3" xlink:type="arc" />
    <link:label id="lab_biib_Deferredtaxliabilityreclassification_6A5C72435CE5DD42FC7B93582E3017EC_terseLabel_en-US" xlink:label="lab_biib_Deferredtaxliabilityreclassification_6A5C72435CE5DD42FC7B93582E3017EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability, reclassification</link:label>
    <link:label id="lab_biib_Deferredtaxliabilityreclassification_6A5C72435CE5DD42FC7B93582E3017EC_label_en-US" xlink:label="lab_biib_Deferredtaxliabilityreclassification_6A5C72435CE5DD42FC7B93582E3017EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability, reclassification</link:label>
    <link:label id="lab_biib_Deferredtaxliabilityreclassification_6A5C72435CE5DD42FC7B93582E3017EC_documentation_en-US" xlink:label="lab_biib_Deferredtaxliabilityreclassification_6A5C72435CE5DD42FC7B93582E3017EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liability, reclassification</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_Deferredtaxliabilityreclassification" xlink:label="loc_biib_Deferredtaxliabilityreclassification_6A5C72435CE5DD42FC7B93582E3017EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Deferredtaxliabilityreclassification_6A5C72435CE5DD42FC7B93582E3017EC" xlink:to="lab_biib_Deferredtaxliabilityreclassification_6A5C72435CE5DD42FC7B93582E3017EC" xlink:type="arc" />
    <link:label id="lab_biib_Totaldeferredchargesandprepaidtaxes_EA60536622BE4B7406B293582E30371D_terseLabel_en-US" xlink:label="lab_biib_Totaldeferredchargesandprepaidtaxes_EA60536622BE4B7406B293582E30371D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total deferred charges and prepaid taxes</link:label>
    <link:label id="lab_biib_Totaldeferredchargesandprepaidtaxes_EA60536622BE4B7406B293582E30371D_label_en-US" xlink:label="lab_biib_Totaldeferredchargesandprepaidtaxes_EA60536622BE4B7406B293582E30371D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total deferred charges and prepaid taxes</link:label>
    <link:label id="lab_biib_Totaldeferredchargesandprepaidtaxes_EA60536622BE4B7406B293582E30371D_documentation_en-US" xlink:label="lab_biib_Totaldeferredchargesandprepaidtaxes_EA60536622BE4B7406B293582E30371D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total deferred charges and prepaid taxes</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_Totaldeferredchargesandprepaidtaxes" xlink:label="loc_biib_Totaldeferredchargesandprepaidtaxes_EA60536622BE4B7406B293582E30371D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Totaldeferredchargesandprepaidtaxes_EA60536622BE4B7406B293582E30371D" xlink:to="lab_biib_Totaldeferredchargesandprepaidtaxes_EA60536622BE4B7406B293582E30371D" xlink:type="arc" />
    <link:label id="lab_biib_DeferredTaxLiabilityRecognized_6B65C37FCB1267FE2A6193582E30DC4E_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxLiabilityRecognized_6B65C37FCB1267FE2A6193582E30DC4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability recognized</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilityRecognized_6B65C37FCB1267FE2A6193582E30DC4E_label_en-US" xlink:label="lab_biib_DeferredTaxLiabilityRecognized_6B65C37FCB1267FE2A6193582E30DC4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability recognized</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilityRecognized_6B65C37FCB1267FE2A6193582E30DC4E_documentation_en-US" xlink:label="lab_biib_DeferredTaxLiabilityRecognized_6B65C37FCB1267FE2A6193582E30DC4E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liability recognized</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_DeferredTaxLiabilityRecognized" xlink:label="loc_biib_DeferredTaxLiabilityRecognized_6B65C37FCB1267FE2A6193582E30DC4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxLiabilityRecognized_6B65C37FCB1267FE2A6193582E30DC4E" xlink:to="lab_biib_DeferredTaxLiabilityRecognized_6B65C37FCB1267FE2A6193582E30DC4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_6860946B2A527EB06C4C93582E30FD61_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_6860946B2A527EB06C4C93582E30FD61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net book value of deferred charge</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_6860946B2A527EB06C4C93582E30FD61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_6860946B2A527EB06C4C93582E30FD61" xlink:to="lab_us-gaap_DeferredTaxLiabilities_6860946B2A527EB06C4C93582E30FD61" xlink:type="arc" />
    <link:label id="lab_biib_NetBenefitForPreviouslyUnrecognizedPosition_DD80BE9FFC638ED526F693582E3022D2_terseLabel_en-US" xlink:label="lab_biib_NetBenefitForPreviouslyUnrecognizedPosition_DD80BE9FFC638ED526F693582E3022D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net benefit for a previously unrecognized position</link:label>
    <link:label id="lab_biib_NetBenefitForPreviouslyUnrecognizedPosition_DD80BE9FFC638ED526F693582E3022D2_label_en-US" xlink:label="lab_biib_NetBenefitForPreviouslyUnrecognizedPosition_DD80BE9FFC638ED526F693582E3022D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net benefit for a previously unrecognized position</link:label>
    <link:label id="lab_biib_NetBenefitForPreviouslyUnrecognizedPosition_DD80BE9FFC638ED526F693582E3022D2_documentation_en-US" xlink:label="lab_biib_NetBenefitForPreviouslyUnrecognizedPosition_DD80BE9FFC638ED526F693582E3022D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net benefit for a previously unrecognized position</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_NetBenefitForPreviouslyUnrecognizedPosition" xlink:label="loc_biib_NetBenefitForPreviouslyUnrecognizedPosition_DD80BE9FFC638ED526F693582E3022D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetBenefitForPreviouslyUnrecognizedPosition_DD80BE9FFC638ED526F693582E3022D2" xlink:to="lab_biib_NetBenefitForPreviouslyUnrecognizedPosition_DD80BE9FFC638ED526F693582E3022D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_2BBAB2DD33D107A563DD93582E305729_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_2BBAB2DD33D107A563DD93582E305729" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_2BBAB2DD33D107A563DD93582E305729_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_2BBAB2DD33D107A563DD93582E305729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2BBAB2DD33D107A563DD93582E305729" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_2BBAB2DD33D107A563DD93582E305729" xlink:to="lab_us-gaap_OperatingLossCarryforwards_2BBAB2DD33D107A563DD93582E305729" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_9A6C248890E77AD4A08D93582E30F101_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_9A6C248890E77AD4A08D93582E30F101" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_9A6C248890E77AD4A08D93582E30F101_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_9A6C248890E77AD4A08D93582E30F101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_9A6C248890E77AD4A08D93582E30F101" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_9A6C248890E77AD4A08D93582E30F101" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_9A6C248890E77AD4A08D93582E30F101" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75D824E7D34A092D851E93582E306473_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75D824E7D34A092D851E93582E306473" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75D824E7D34A092D851E93582E306473_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75D824E7D34A092D851E93582E306473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75D824E7D34A092D851E93582E306473" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75D824E7D34A092D851E93582E306473" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75D824E7D34A092D851E93582E306473" xlink:type="arc" />
    <link:label id="lab_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_5E0956CDF5D7981A279393582E307943_terseLabel_en-US" xlink:label="lab_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_5E0956CDF5D7981A279393582E307943" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Tax Liability On Undistributed Earnings Of Foreign Subsidiaries</link:label>
    <link:label id="lab_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_5E0956CDF5D7981A279393582E307943_label_en-US" xlink:label="lab_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_5E0956CDF5D7981A279393582E307943" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Tax Liability On Undistributed Earnings Of Foreign Subsidiaries</link:label>
    <link:label id="lab_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_5E0956CDF5D7981A279393582E307943_documentation_en-US" xlink:label="lab_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_5E0956CDF5D7981A279393582E307943" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated tax liability on undistributed earnings of foreign subsidiaries.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries" xlink:label="loc_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_5E0956CDF5D7981A279393582E307943" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_5E0956CDF5D7981A279393582E307943" xlink:to="lab_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_5E0956CDF5D7981A279393582E307943" xlink:type="arc" />
    <link:label id="lab_biib_ExpenseForNonIncomeBasedStateTaxes_95D1E705EE20C1C39CE893582E3018DA_terseLabel_en-US" xlink:label="lab_biib_ExpenseForNonIncomeBasedStateTaxes_95D1E705EE20C1C39CE893582E3018DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense for non-income based state taxes</link:label>
    <link:label id="lab_biib_ExpenseForNonIncomeBasedStateTaxes_95D1E705EE20C1C39CE893582E3018DA_label_en-US" xlink:label="lab_biib_ExpenseForNonIncomeBasedStateTaxes_95D1E705EE20C1C39CE893582E3018DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense for non-income based state taxes</link:label>
    <link:label id="lab_biib_ExpenseForNonIncomeBasedStateTaxes_95D1E705EE20C1C39CE893582E3018DA_documentation_en-US" xlink:label="lab_biib_ExpenseForNonIncomeBasedStateTaxes_95D1E705EE20C1C39CE893582E3018DA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense for non-income based state taxes</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ExpenseForNonIncomeBasedStateTaxes" xlink:label="loc_biib_ExpenseForNonIncomeBasedStateTaxes_95D1E705EE20C1C39CE893582E3018DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseForNonIncomeBasedStateTaxes_95D1E705EE20C1C39CE893582E3018DA" xlink:to="lab_biib_ExpenseForNonIncomeBasedStateTaxes_95D1E705EE20C1C39CE893582E3018DA" xlink:type="arc" />
    <link:label id="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_F872C17DCA650D15FD5493582E30CEE8_terseLabel_en-US" xlink:label="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_F872C17DCA650D15FD5493582E30CEE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proposed Disallowance By Tax Authorities For Payment For Services</link:label>
    <link:label id="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_F872C17DCA650D15FD5493582E30CEE8_label_en-US" xlink:label="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_F872C17DCA650D15FD5493582E30CEE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proposed Disallowance By Tax Authorities For Payment For Services</link:label>
    <link:label id="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_F872C17DCA650D15FD5493582E30CEE8_documentation_en-US" xlink:label="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_F872C17DCA650D15FD5493582E30CEE8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proposed disallowance by tax authorities for payment for services.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices" xlink:label="loc_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_F872C17DCA650D15FD5493582E30CEE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_F872C17DCA650D15FD5493582E30CEE8" xlink:to="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_F872C17DCA650D15FD5493582E30CEE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_3DC2598769BB2AB1F3C093582E3006B8_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_3DC2598769BB2AB1F3C093582E3006B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net effect of adjustments to our uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_3DC2598769BB2AB1F3C093582E3006B8_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_3DC2598769BB2AB1F3C093582E3006B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_3DC2598769BB2AB1F3C093582E3006B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_3DC2598769BB2AB1F3C093582E3006B8" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_3DC2598769BB2AB1F3C093582E3006B8" xlink:type="arc" />
    <link:label id="lab_biib_IncomeTaxesTextualAbstract_DDF5556B851A446A52B893582E3083F0_verboseLabel_en-US" xlink:label="lab_biib_IncomeTaxesTextualAbstract_DDF5556B851A446A52B893582E3083F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes (Textual)</link:label>
    <link:label id="lab_biib_IncomeTaxesTextualAbstract_DDF5556B851A446A52B893582E3083F0_label_en-US" xlink:label="lab_biib_IncomeTaxesTextualAbstract_DDF5556B851A446A52B893582E3083F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_IncomeTaxesTextualAbstract_DDF5556B851A446A52B893582E3083F0_documentation_en-US" xlink:label="lab_biib_IncomeTaxesTextualAbstract_DDF5556B851A446A52B893582E3083F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_IncomeTaxesTextualAbstract" xlink:label="loc_biib_IncomeTaxesTextualAbstract_DDF5556B851A446A52B893582E3083F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncomeTaxesTextualAbstract_DDF5556B851A446A52B893582E3083F0" xlink:to="lab_biib_IncomeTaxesTextualAbstract_DDF5556B851A446A52B893582E3083F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_2961CF035B3E9B48377193582E305ECB_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_2961CF035B3E9B48377193582E305ECB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undistributed Foreign Earnings Of Non Us Subsidiaries</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_2961CF035B3E9B48377193582E305ECB_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_2961CF035B3E9B48377193582E305ECB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings of Foreign Subsidiaries</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_2961CF035B3E9B48377193582E305ECB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_2961CF035B3E9B48377193582E305ECB" xlink:to="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_2961CF035B3E9B48377193582E305ECB" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_BEB80068861D98EA92FD93582E30E457_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_BEB80068861D98EA92FD93582E30E457" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefit</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_BEB80068861D98EA92FD93582E30E457_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_BEB80068861D98EA92FD93582E30E457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_BEB80068861D98EA92FD93582E30E457" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_BEB80068861D98EA92FD93582E30E457" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_BEB80068861D98EA92FD93582E30E457" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_07221CB8A51997043B2993582E3041C1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_07221CB8A51997043B2993582E3041C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net interest expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_07221CB8A51997043B2993582E3041C1_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_07221CB8A51997043B2993582E3041C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_07221CB8A51997043B2993582E3041C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_07221CB8A51997043B2993582E3041C1" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_07221CB8A51997043B2993582E3041C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_F196ADB78AB94A78DB2F93582E305441_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_F196ADB78AB94A78DB2F93582E305441" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_F196ADB78AB94A78DB2F93582E305441_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_F196ADB78AB94A78DB2F93582E305441" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_F196ADB78AB94A78DB2F93582E305441" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_F196ADB78AB94A78DB2F93582E305441" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_F196ADB78AB94A78DB2F93582E305441" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_BF89ED8191646BB680DF93582E30760B_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_BF89ED8191646BB680DF93582E30760B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notice of assessment of corporate withholding tax including penalties and interest</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_BF89ED8191646BB680DF93582E30760B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_BF89ED8191646BB680DF93582E30760B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_BF89ED8191646BB680DF93582E30760B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_BF89ED8191646BB680DF93582E30760B" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_BF89ED8191646BB680DF93582E30760B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_8F0FDADFE6E659B93D0338A3560A902C_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_8F0FDADFE6E659B93D0338A3560A902C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_8F0FDADFE6E659B93D0338A3560A902C_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_8F0FDADFE6E659B93D0338A3560A902C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_8F0FDADFE6E659B93D0338A3560A902C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_8F0FDADFE6E659B93D0338A3560A902C" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_8F0FDADFE6E659B93D0338A3560A902C" xlink:type="arc" />
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_74516694506A14A50B1638A3548AED0F_terseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_74516694506A14A50B1638A3548AED0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total expense incurred by collaboration</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_74516694506A14A50B1638A3548AED0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration_74516694506A14A50B1638A3548AED0F" xlink:to="lab_biib_ExpenseIncurredByCollaboration_74516694506A14A50B1638A3548AED0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_F2FB395B5BB712B5B76638A354EF368E_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_F2FB395B5BB712B5B76638A354EF368E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_F2FB395B5BB712B5B76638A354EF368E_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_F2FB395B5BB712B5B76638A354EF368E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_F2FB395B5BB712B5B76638A354EF368E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_F2FB395B5BB712B5B76638A354EF368E" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_F2FB395B5BB712B5B76638A354EF368E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_56F1C3A22CDC1B1683B038A354F369FF_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_56F1C3A22CDC1B1683B038A354F369FF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_56F1C3A22CDC1B1683B038A354F369FF_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_56F1C3A22CDC1B1683B038A354F369FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_56F1C3A22CDC1B1683B038A354F369FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_56F1C3A22CDC1B1683B038A354F369FF" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_56F1C3A22CDC1B1683B038A354F369FF" xlink:type="arc" />
    <link:label id="lab_country_DK_5E7BC962BE53087A9B5A38A3565AA832_terseLabel_en-US" xlink:label="lab_country_DK_5E7BC962BE53087A9B5A38A3565AA832" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DENMARK</link:label>
    <link:label id="lab_country_DK_5E7BC962BE53087A9B5A38A3565AA832_label_en-US" xlink:label="lab_country_DK_5E7BC962BE53087A9B5A38A3565AA832" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DENMARK</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_DK" xlink:label="loc_country_DK_5E7BC962BE53087A9B5A38A3565AA832" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DK_5E7BC962BE53087A9B5A38A3565AA832" xlink:to="lab_country_DK_5E7BC962BE53087A9B5A38A3565AA832" xlink:type="arc" />
    <link:label id="lab_biib_DistributorOneMember_5AD69CCFD0D67FE4E3DF38A3565A54FD_verboseLabel_en-US" xlink:label="lab_biib_DistributorOneMember_5AD69CCFD0D67FE4E3DF38A3565A54FD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Distributor One</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_5AD69CCFD0D67FE4E3DF38A3565A54FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember_5AD69CCFD0D67FE4E3DF38A3565A54FD" xlink:to="lab_biib_DistributorOneMember_5AD69CCFD0D67FE4E3DF38A3565A54FD" xlink:type="arc" />
    <link:label id="lab_biib_DistributorTwoMember_EF1B70F2C2B319385F2838A3565A0282_verboseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember_EF1B70F2C2B319385F2838A3565A0282" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Distributor Two</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_EF1B70F2C2B319385F2838A3565A0282" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember_EF1B70F2C2B319385F2838A3565A0282" xlink:to="lab_biib_DistributorTwoMember_EF1B70F2C2B319385F2838A3565A0282" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesInPercentageFromUnconsolidatedJointBusiness_55E7AC59066BF8A147BC38A3565A0207_verboseLabel_en-US" xlink:label="lab_biib_RevenuesInPercentageFromUnconsolidatedJointBusiness_55E7AC59066BF8A147BC38A3565A0207" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business in percentage</link:label>
    <link:label id="lab_biib_RevenuesInPercentageFromUnconsolidatedJointBusiness_55E7AC59066BF8A147BC38A3565A0207_label_en-US" xlink:label="lab_biib_RevenuesInPercentageFromUnconsolidatedJointBusiness_55E7AC59066BF8A147BC38A3565A0207" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues In Percentage From Unconsolidated Joint Business</link:label>
    <link:label id="lab_biib_RevenuesInPercentageFromUnconsolidatedJointBusiness_55E7AC59066BF8A147BC38A3565A0207_documentation_en-US" xlink:label="lab_biib_RevenuesInPercentageFromUnconsolidatedJointBusiness_55E7AC59066BF8A147BC38A3565A0207" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues in percentage from unconsolidated joint business.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_RevenuesInPercentageFromUnconsolidatedJointBusiness" xlink:label="loc_biib_RevenuesInPercentageFromUnconsolidatedJointBusiness_55E7AC59066BF8A147BC38A3565A0207" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesInPercentageFromUnconsolidatedJointBusiness_55E7AC59066BF8A147BC38A3565A0207" xlink:to="lab_biib_RevenuesInPercentageFromUnconsolidatedJointBusiness_55E7AC59066BF8A147BC38A3565A0207" xlink:type="arc" />
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D5EC9ED7E6822D2ABBF238A3565A66E0_verboseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D5EC9ED7E6822D2ABBF238A3565A66E0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity wide percentage of revenue from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D5EC9ED7E6822D2ABBF238A3565A66E0_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D5EC9ED7E6822D2ABBF238A3565A66E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D5EC9ED7E6822D2ABBF238A3565A66E0_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D5EC9ED7E6822D2ABBF238A3565A66E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D5EC9ED7E6822D2ABBF238A3565A66E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D5EC9ED7E6822D2ABBF238A3565A66E0" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D5EC9ED7E6822D2ABBF238A3565A66E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncurrentAssets_33051466D157CF1100BE38A3565A596F_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets_33051466D157CF1100BE38A3565A596F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived assets related to operations in Denmark</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_33051466D157CF1100BE38A3565A596F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets_33051466D157CF1100BE38A3565A596F" xlink:to="lab_us-gaap_NoncurrentAssets_33051466D157CF1100BE38A3565A596F" xlink:type="arc" />
    <link:label id="lab_biib_SegmentInformationTextualAbstract_B24ABE778F825795043438A3565A9868_verboseLabel_en-US" xlink:label="lab_biib_SegmentInformationTextualAbstract_B24ABE778F825795043438A3565A9868" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_SegmentInformationTextualAbstract_B24ABE778F825795043438A3565A9868_label_en-US" xlink:label="lab_biib_SegmentInformationTextualAbstract_B24ABE778F825795043438A3565A9868" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Information (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_SegmentInformationTextualAbstract_B24ABE778F825795043438A3565A9868_documentation_en-US" xlink:label="lab_biib_SegmentInformationTextualAbstract_B24ABE778F825795043438A3565A9868" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Segment Information.</link:label>
    <link:loc xlink:href="biib-20151231.xsd#biib_SegmentInformationTextualAbstract" xlink:label="loc_biib_SegmentInformationTextualAbstract_B24ABE778F825795043438A3565A9868" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SegmentInformationTextualAbstract_B24ABE778F825795043438A3565A9868" xlink:to="lab_biib_SegmentInformationTextualAbstract_B24ABE778F825795043438A3565A9868" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_65EB1D3A7BA25FD343E538A3565ADC60_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_65EB1D3A7BA25FD343E538A3565ADC60" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segment</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_65EB1D3A7BA25FD343E538A3565ADC60_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_65EB1D3A7BA25FD343E538A3565ADC60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_65EB1D3A7BA25FD343E538A3565ADC60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_65EB1D3A7BA25FD343E538A3565ADC60" xlink:to="lab_us-gaap_NumberOfReportableSegments_65EB1D3A7BA25FD343E538A3565ADC60" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRestructuring_24842824D18CF28086C3A34B6AB90DFB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring_24842824D18CF28086C3A34B6AB90DFB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Restructuring amounts paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_24842824D18CF28086C3A34B6AB90DFB_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring_24842824D18CF28086C3A34B6AB90DFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_24842824D18CF28086C3A34B6AB90DFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring_24842824D18CF28086C3A34B6AB90DFB" xlink:to="lab_us-gaap_PaymentsForRestructuring_24842824D18CF28086C3A34B6AB90DFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_83ADDA779D2D596CCC80A34B6AB92AD9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_83ADDA779D2D596CCC80A34B6AB92AD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring reserve</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_83ADDA779D2D596CCC80A34B6AB92AD9_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve_83ADDA779D2D596CCC80A34B6AB92AD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_83ADDA779D2D596CCC80A34B6AB92AD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_83ADDA779D2D596CCC80A34B6AB92AD9" xlink:to="lab_us-gaap_RestructuringReserve_83ADDA779D2D596CCC80A34B6AB92AD9" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>biib-20151231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20151231.xsd#AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20151231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20151231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20151231.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20151231.xsd#Acquisitions" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:href="biib-20151231.xsd#AcquisitionsAcquisitionsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1" xlink:href="biib-20151231.xsd#AcquisitionsAcquisitionsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables" xlink:href="biib-20151231.xsd#AcquisitionsAcquisitionsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20151231.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationshipsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationshipsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails2" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationshipsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20151231.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20151231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:href="biib-20151231.xsd#CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:href="biib-20151231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="biib-20151231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:href="biib-20151231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:href="biib-20151231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="biib-20151231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="biib-20151231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:href="biib-20151231.xsd#ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:href="biib-20151231.xsd#ConsolidatedStatementsOfEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:href="biib-20151231.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20151231.xsd#DerivativeInstruments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20151231.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1" xlink:href="biib-20151231.xsd#DerivativeInstrumentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:href="biib-20151231.xsd#DerivativeInstrumentsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20151231.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20151231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20151231.xsd#EarningsPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20151231.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20151231.xsd#EarningsPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:href="biib-20151231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails" xlink:href="biib-20151231.xsd#EmployeeBenefitPlansDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20151231.xsd#Equity" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20151231.xsd#EquityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20151231.xsd#EquityDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20151231.xsd#EquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20151231.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20151231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20151231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20151231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20151231.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20151231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20151231.xsd#FinancialInstruments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20151231.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20151231.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20151231.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20151231.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:href="biib-20151231.xsd#FinancialInstrumentsDetailsTextual1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:href="biib-20151231.xsd#FinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20151231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Guarantees" xlink:href="biib-20151231.xsd#Guarantees" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20151231.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20151231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:href="biib-20151231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:href="biib-20151231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:href="biib-20151231.xsd#IncomeTaxesDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20151231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20151231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:href="biib-20151231.xsd#Indebtedness" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:href="biib-20151231.xsd#IndebtednessDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:href="biib-20151231.xsd#IndebtednessDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:href="biib-20151231.xsd#IndebtednessDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTables" xlink:href="biib-20151231.xsd#IndebtednessTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20151231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20151231.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20151231.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20151231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20151231.xsd#Inventory" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20151231.xsd#InventoryDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20151231.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20151231.xsd#InventoryTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20151231.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20151231.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20151231.xsd#Litigation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20151231.xsd#LitigationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20151231.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20151231.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:href="biib-20151231.xsd#OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20151231.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:href="biib-20151231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20151231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:href="biib-20151231.xsd#PropertyPlantAndEquipmentDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails1" xlink:href="biib-20151231.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:href="biib-20151231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:href="biib-20151231.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="biib-20151231.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:href="biib-20151231.xsd#QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="biib-20151231.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:href="biib-20151231.xsd#RestructuringRestructuring" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:href="biib-20151231.xsd#RestructuringRestructuringDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:href="biib-20151231.xsd#RestructuringRestructuringDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:href="biib-20151231.xsd#RestructuringRestructuringTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RevenueReserves" xlink:href="biib-20151231.xsd#RevenueReserves" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesDetails" xlink:href="biib-20151231.xsd#RevenueReservesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesDetails1" xlink:href="biib-20151231.xsd#RevenueReservesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RevenueReservesTables" xlink:href="biib-20151231.xsd#RevenueReservesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SegmentInformation" xlink:href="biib-20151231.xsd#SegmentInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:href="biib-20151231.xsd#SegmentInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails1" xlink:href="biib-20151231.xsd#SegmentInformationDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:href="biib-20151231.xsd#SegmentInformationDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationTables" xlink:href="biib-20151231.xsd#SegmentInformationTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20151231.xsd#ShareBasedPayments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails4" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails5" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails6" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails8" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetails9" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20151231.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:href="biib-20151231.xsd#ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20151231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20151231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20151231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20151231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="biib-20151231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_B4BA18EFCC136C4A8A3038A356981527" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_451E17E765EA24C1C59E38A35698133C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_B4BA18EFCC136C4A8A3038A356981527" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_451E17E765EA24C1C59E38A35698133C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_E50ABE1FDBFC1FE0339B38A35175E6E8" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_F367701BAC9B5C4E1E7938A3517510B9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_E50ABE1FDBFC1FE0339B38A35175E6E8" xlink:to="loc_us-gaap_StatementTable_F367701BAC9B5C4E1E7938A3517510B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_35EF3E62B0FEFD161CAE38A351757A2E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_F367701BAC9B5C4E1E7938A3517510B9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_35EF3E62B0FEFD161CAE38A351757A2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D08DD666831095457F6D38A3517533FB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_35EF3E62B0FEFD161CAE38A351757A2E" xlink:to="loc_us-gaap_EquityComponentDomain_D08DD666831095457F6D38A3517533FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_4E9EBCBBEA4C0F47856B38A35175DE26" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_D08DD666831095457F6D38A3517533FB" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_4E9EBCBBEA4C0F47856B38A35175DE26" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_52B8760C6E948BB127DC38A351759E97" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_D08DD666831095457F6D38A3517533FB" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_52B8760C6E948BB127DC38A351759E97" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B32F9CA4C5D75A635EEC38A35175DB81" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_D08DD666831095457F6D38A3517533FB" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B32F9CA4C5D75A635EEC38A35175DB81" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9990C88D179E86E82ECF38A351752411" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_D08DD666831095457F6D38A3517533FB" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_9990C88D179E86E82ECF38A351752411" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_F367701BAC9B5C4E1E7938A3517510B9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9CDE9C9203C719405EC138A35175CF30" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9CDE9C9203C719405EC138A35175CF30" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1A6766F0BBAE99D698FA38A351764483" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1A6766F0BBAE99D698FA38A351764483" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7D1D700EF560D4EE171838A35176923C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7D1D700EF560D4EE171838A35176923C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B3EE7F07332C2FD20DC38A35176A287" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B3EE7F07332C2FD20DC38A35176A287" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_899395873859DBA9C3E838A351762877" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E9D425F48F453E7322C638A35175E404" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_899395873859DBA9C3E838A351762877" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_91AC0ED94286E3675336A32AB8B72449" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_9BB201B91433480EF93DA32AB8B79A47" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_91AC0ED94286E3675336A32AB8B72449" xlink:to="loc_us-gaap_StatementTable_9BB201B91433480EF93DA32AB8B79A47" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_927D80F05A693AEB0221A32AB8B7EA06" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9BB201B91433480EF93DA32AB8B79A47" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_927D80F05A693AEB0221A32AB8B7EA06" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_24A298292EEA86A62B4AA32AB8B760D6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_927D80F05A693AEB0221A32AB8B7EA06" xlink:to="loc_us-gaap_EquityComponentDomain_24A298292EEA86A62B4AA32AB8B760D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E7F3341A93C7485FD0C0A32AB8B8BA61" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_24A298292EEA86A62B4AA32AB8B760D6" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E7F3341A93C7485FD0C0A32AB8B8BA61" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_717DB635D96594086B23A32AB8B84639" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_24A298292EEA86A62B4AA32AB8B760D6" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_717DB635D96594086B23A32AB8B84639" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_4085589AEFE4C3D47979A32AB8B83CCA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9BB201B91433480EF93DA32AB8B79A47" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_4085589AEFE4C3D47979A32AB8B83CCA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_D5DB919A12A1E3100A64A32AB8B8EBB5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_4085589AEFE4C3D47979A32AB8B83CCA" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_D5DB919A12A1E3100A64A32AB8B8EBB5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_870F6DCF66B42EFC83BDA32AB8B851AD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_D5DB919A12A1E3100A64A32AB8B8EBB5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_870F6DCF66B42EFC83BDA32AB8B851AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_277C06FF2DF5065E96A9A32AB8B8CD99" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9BB201B91433480EF93DA32AB8B79A47" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_277C06FF2DF5065E96A9A32AB8B8CD99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1C915A4C86FE38E85B05A32AB8B84C0C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_277C06FF2DF5065E96A9A32AB8B8CD99" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1C915A4C86FE38E85B05A32AB8B84C0C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_01BEA23D64A5F84CDDB9A32AB8B840AA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_277C06FF2DF5065E96A9A32AB8B8CD99" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_01BEA23D64A5F84CDDB9A32AB8B840AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_B2003F153C8493AD1985A32AB8B85FAC" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_277C06FF2DF5065E96A9A32AB8B8CD99" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_B2003F153C8493AD1985A32AB8B85FAC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_38261C774CF9A59A46F9A32AB8B89003" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_277C06FF2DF5065E96A9A32AB8B8CD99" xlink:to="loc_us-gaap_NetIncomeLoss_38261C774CF9A59A46F9A32AB8B89003" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_D270D06C326C0657E8EE38A35385B1D2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_EB9A661A817F3AAB72BD38A3538553F7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_D270D06C326C0657E8EE38A35385B1D2" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_EB9A661A817F3AAB72BD38A3538553F7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_E4BA5C1F703708988DC338A3538529AD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_D270D06C326C0657E8EE38A35385B1D2" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_E4BA5C1F703708988DC338A3538529AD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_88320DF799DCDD13E59238A35366CC93" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_21B7804BD0481162920838A353669AB9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_88320DF799DCDD13E59238A35366CC93" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_21B7804BD0481162920838A353669AB9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_F33D9BAF6B3E4D6A7D1D93224D3C542B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4C69EB01C1EA5F6171A193224D3C60D8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_F33D9BAF6B3E4D6A7D1D93224D3C542B" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4C69EB01C1EA5F6171A193224D3C60D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9761638C0CA7F8673A4993224D3CE278" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4C69EB01C1EA5F6171A193224D3C60D8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9761638C0CA7F8673A4993224D3CE278" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9A12111ADD3A9D02671793224D3C4C6B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9761638C0CA7F8673A4993224D3CE278" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9A12111ADD3A9D02671793224D3C4C6B" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_584D5A2C868F0CD1228393224D3C5B79" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9A12111ADD3A9D02671793224D3C4C6B" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_584D5A2C868F0CD1228393224D3C5B79" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4B0D1102F508681F589493224D3C3E85" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4C69EB01C1EA5F6171A193224D3C60D8" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_4B0D1102F508681F589493224D3C3E85" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_E01CD3F64172105EF56C93224D3C6D7B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B0D1102F508681F589493224D3C3E85" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_E01CD3F64172105EF56C93224D3C6D7B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_E6E156F93A07B676308793224D3CEBDE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B0D1102F508681F589493224D3C3E85" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_E6E156F93A07B676308793224D3CEBDE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_26E9A90E23F7C3CBD8BC93224D3C32E8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4B0D1102F508681F589493224D3C3E85" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_26E9A90E23F7C3CBD8BC93224D3C32E8" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_192DEF1E497428A42DB493224D384790" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A92E498CFC50F86900993224D3843DE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_192DEF1E497428A42DB493224D384790" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A92E498CFC50F86900993224D3843DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_605C477E7E9F5A673FF293224D395267" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A92E498CFC50F86900993224D3843DE" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_605C477E7E9F5A673FF293224D395267" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BDBBB50B85EEBBED801793224D3900CA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_605C477E7E9F5A673FF293224D395267" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BDBBB50B85EEBBED801793224D3900CA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_31A9E723ECE4DF4F8DCE93224D399891" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BDBBB50B85EEBBED801793224D3900CA" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_31A9E723ECE4DF4F8DCE93224D399891" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_05EC6EDFE30C861BF48293224D39A961" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A92E498CFC50F86900993224D3843DE" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_05EC6EDFE30C861BF48293224D39A961" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_B8540C3E76381D3FAD5493224D39FBBC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05EC6EDFE30C861BF48293224D39A961" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_B8540C3E76381D3FAD5493224D39FBBC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_89103FACF1D0D4B9C26293224D3994E7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05EC6EDFE30C861BF48293224D39A961" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_89103FACF1D0D4B9C26293224D3994E7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_198DB2409DE54C383EF293224D39048B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05EC6EDFE30C861BF48293224D39A961" xlink:to="loc_us-gaap_Goodwill_198DB2409DE54C383EF293224D39048B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_F0EAA334FFC051ADE0DC93224D39758D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05EC6EDFE30C861BF48293224D39A961" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_F0EAA334FFC051ADE0DC93224D39758D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_99C58519B10AC5892C5793224D39EA53" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05EC6EDFE30C861BF48293224D39A961" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_99C58519B10AC5892C5793224D39EA53" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7D38838342A7A24D505A93224D391B19" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05EC6EDFE30C861BF48293224D39A961" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7D38838342A7A24D505A93224D391B19" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3322FC218E6F590D6F1938A3516854E6" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_9DE81DD06BBF8335201B38A35168EE9A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3322FC218E6F590D6F1938A3516854E6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_9DE81DD06BBF8335201B38A35168EE9A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_A163740B1414684357E738A35168F539" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3322FC218E6F590D6F1938A3516854E6" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_A163740B1414684357E738A35168F539" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_0B713D766D888C9E9F4365DB84EE55B4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25626C3330FCFFA8EF0B65DB84EF7F09" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_0B713D766D888C9E9F4365DB84EE55B4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25626C3330FCFFA8EF0B65DB84EF7F09" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_A43E2990F525B65B424E65DB84EF4D1A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25626C3330FCFFA8EF0B65DB84EF7F09" xlink:to="loc_us-gaap_ProductOrServiceAxis_A43E2990F525B65B424E65DB84EF4D1A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_01B3E61721E4222A7A4C65DB84EF29D9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_A43E2990F525B65B424E65DB84EF4D1A" xlink:to="loc_us-gaap_ProductsAndServicesDomain_01B3E61721E4222A7A4C65DB84EF29D9" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RaxatrigineMember" xlink:label="loc_biib_RaxatrigineMember_914C5EE36A52C7A9F7CB65DB84EF5DC9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_01B3E61721E4222A7A4C65DB84EF29D9" xlink:to="loc_biib_RaxatrigineMember_914C5EE36A52C7A9F7CB65DB84EF5DC9" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NeuropathicpainindicationsMember" xlink:label="loc_biib_NeuropathicpainindicationsMember_F45DC58CC17DFC3574FF65DB84EF4DCD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_01B3E61721E4222A7A4C65DB84EF29D9" xlink:to="loc_biib_NeuropathicpainindicationsMember_F45DC58CC17DFC3574FF65DB84EF4DCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_C50877112869C6B94EFC65DB84EF81BA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25626C3330FCFFA8EF0B65DB84EF7F09" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_C50877112869C6B94EFC65DB84EF81BA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D4A9A1AEC81489672A1765DB84EF19A1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C50877112869C6B94EFC65DB84EF81BA" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D4A9A1AEC81489672A1765DB84EF19A1" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_582A8FF708C55581F95865DB84EF3854" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D4A9A1AEC81489672A1765DB84EF19A1" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_582A8FF708C55581F95865DB84EF3854" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_E1851822BCC3BA1FFC2765DB84EF889F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D4A9A1AEC81489672A1765DB84EF19A1" xlink:to="loc_biib_TysabriProductMember_E1851822BCC3BA1FFC2765DB84EF889F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25626C3330FCFFA8EF0B65DB84EF7F09" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8A0481D00C4A318D2C7165DB84F0C04E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8A0481D00C4A318D2C7165DB84F0C04E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0986DFF09A228A13CCCB65DB84F08FCE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0986DFF09A228A13CCCB65DB84F08FCE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_A7F685AA14D7DAD78E7A65DB84F03FC0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_A7F685AA14D7DAD78E7A65DB84F03FC0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_88E6E843AF55C281FAC465DB84F0C24E" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_88E6E843AF55C281FAC465DB84F0C24E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_9222F5B584599A22563D65DB84F0001C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_9222F5B584599A22563D65DB84F0001C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_35EFFC671EFCA996157865DB84F0BE00" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_35EFFC671EFCA996157865DB84F0BE00" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_FF9E8217E2B35FBBF3C365DB84F0088D" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_FF9E8217E2B35FBBF3C365DB84F0088D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4F9D94BC92C21F1B02F065DB84F0DA89" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4F9D94BC92C21F1B02F065DB84F0DA89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7EDF24EA0B9F59FCB40E65DB84F02611" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7EDF24EA0B9F59FCB40E65DB84F02611" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_C78F65BF68E23F5486C465DB84F0AAEC" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_DeferredRevenueCurrent_C78F65BF68E23F5486C465DB84F0AAEC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_B9030EBAEF2F879AA62065DB84F0B1BE" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_B9030EBAEF2F879AA62065DB84F0B1BE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FutureContingentPaymentForFirst12Months" xlink:label="loc_biib_FutureContingentPaymentForFirst12Months_2D28165EC5D48327DA2065DB84F0CC40" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_biib_FutureContingentPaymentForFirst12Months_2D28165EC5D48327DA2065DB84F0CC40" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_1207F3F98AB356C20B4C65DB84F0F103" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_1207F3F98AB356C20B4C65DB84F0F103" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FutureContingentPaymentThreshold" xlink:label="loc_biib_FutureContingentPaymentThreshold_EB879259F15D73B381E465DB84F0F05E" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_biib_FutureContingentPaymentThreshold_EB879259F15D73B381E465DB84F0F05E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_EFAF0F346EBA5B8C8E9265DB84F0ABFE" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_67F598EDA763D9EA59EE65DB84EFFC00" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_EFAF0F346EBA5B8C8E9265DB84F0ABFE" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3CF3815DB1B6967BE64538A354D5FD23" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_444C0081B3CBB555CB3138A354D5316F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3CF3815DB1B6967BE64538A354D5FD23" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_444C0081B3CBB555CB3138A354D5316F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FF53B6DD8D509AAB6D0238A3548962F9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5FC91CF438B82F485A0F38A3548A6CD5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FF53B6DD8D509AAB6D0238A3548962F9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5FC91CF438B82F485A0F38A3548A6CD5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_FFB27D0F59D4CED4C6FC38A3548AADBA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5FC91CF438B82F485A0F38A3548A6CD5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_FFB27D0F59D4CED4C6FC38A3548AADBA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2D19567CFFB86C539F9138A3548AD7B2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FFB27D0F59D4CED4C6FC38A3548AADBA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2D19567CFFB86C539F9138A3548AD7B2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_C03D2A42EDD6CF4C9D5038A3548A08BE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2D19567CFFB86C539F9138A3548AD7B2" xlink:to="loc_biib_EisaiMember_C03D2A42EDD6CF4C9D5038A3548A08BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53FC471D714412EA7E8A38A3548A9B26" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5FC91CF438B82F485A0F38A3548A6CD5" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53FC471D714412EA7E8A38A3548A9B26" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_74516694506A14A50B1638A3548AED0F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53FC471D714412EA7E8A38A3548A9B26" xlink:to="loc_biib_ExpenseIncurredByCollaboration_74516694506A14A50B1638A3548AED0F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ExpenseReflectedWithinStatementsOfIncome" xlink:label="loc_biib_ExpenseReflectedWithinStatementsOfIncome_09F9C30431555CF33A0538A3548ACB3B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53FC471D714412EA7E8A38A3548A9B26" xlink:to="loc_biib_ExpenseReflectedWithinStatementsOfIncome_09F9C30431555CF33A0538A3548ACB3B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B5792217B54C82C81D2538A35123068D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9D19A7F2EE1D8D14503B38A35123599E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B5792217B54C82C81D2538A35123068D" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9D19A7F2EE1D8D14503B38A35123599E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_E26700D2162DB73CB57E38A35123EC02" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9D19A7F2EE1D8D14503B38A35123599E" xlink:to="loc_us-gaap_ProductOrServiceAxis_E26700D2162DB73CB57E38A35123EC02" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_62664D6ADAD3E0E0ABAE38A35123B590" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_E26700D2162DB73CB57E38A35123EC02" xlink:to="loc_us-gaap_ProductsAndServicesDomain_62664D6ADAD3E0E0ABAE38A35123B590" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_4B5AB1A8264A4795196038A351239DF5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_62664D6ADAD3E0E0ABAE38A35123B590" xlink:to="loc_biib_GAZYVAMember_4B5AB1A8264A4795196038A351239DF5" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_AD753FB0C5B56224770138A35123CCDB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_62664D6ADAD3E0E0ABAE38A35123B590" xlink:to="loc_biib_RituxanMember_AD753FB0C5B56224770138A35123CCDB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_10CB0B1E14F88F18A83438A35123DA8F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9D19A7F2EE1D8D14503B38A35123599E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_10CB0B1E14F88F18A83438A35123DA8F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A146D3511E62A4D85B6538A351232432" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_10CB0B1E14F88F18A83438A35123DA8F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A146D3511E62A4D85B6538A351232432" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_0455D84FED67B7FE19E538A351230557" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A146D3511E62A4D85B6538A351232432" xlink:to="loc_biib_RocheGroupGenentechMember_0455D84FED67B7FE19E538A351230557" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_14EABB81BBBEB19A7E7038A351241832" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9D19A7F2EE1D8D14503B38A35123599E" xlink:to="loc_us-gaap_StatementGeographicalAxis_14EABB81BBBEB19A7E7038A351241832" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_6CD0A72A268074DD74C438A35124E129" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_14EABB81BBBEB19A7E7038A351241832" xlink:to="loc_us-gaap_SegmentGeographicalDomain_6CD0A72A268074DD74C438A35124E129" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="loc_country_US_86F3ADC7D5DA419BC79638A351241BF8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_6CD0A72A268074DD74C438A35124E129" xlink:to="loc_country_US_86F3ADC7D5DA419BC79638A351241BF8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_CB1D8BCDC01573BF6C4538A351245DB5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_6CD0A72A268074DD74C438A35124E129" xlink:to="loc_us-gaap_ForeignCountryMember_CB1D8BCDC01573BF6C4538A351245DB5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D8C144561649DB2ECD838A351246275" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9D19A7F2EE1D8D14503B38A35123599E" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D8C144561649DB2ECD838A351246275" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CoPromotionProfitSharingFormulaAbstract" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract_206A2574F36DEAD5BCA138A35124F55F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D8C144561649DB2ECD838A351246275" xlink:to="loc_biib_CoPromotionProfitSharingFormulaAbstract_206A2574F36DEAD5BCA138A35124F55F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_72EE9E256276BFF1F78038A3512435E4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_206A2574F36DEAD5BCA138A35124F55F" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_72EE9E256276BFF1F78038A3512435E4" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_7F908F1E8E6DEE52357238A351243863" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_206A2574F36DEAD5BCA138A35124F55F" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_7F908F1E8E6DEE52357238A351243863" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_A76C1526278DB1FF798538A35124809F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_7F908F1E8E6DEE52357238A351243863" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_A76C1526278DB1FF798538A35124809F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_519A267EE42F8895C1BC38A3512402A2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_7F908F1E8E6DEE52357238A351243863" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_519A267EE42F8895C1BC38A3512402A2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_E9C77CA29E45AC9E23B338A35124FAED" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_7F908F1E8E6DEE52357238A351243863" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_E9C77CA29E45AC9E23B338A35124FAED" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RevenuesFromUnconsolidatedJointBusinessAbstract" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_2FB19097E477B7D598A538A351249A93" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6D8C144561649DB2ECD838A351246275" xlink:to="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_2FB19097E477B7D598A538A351249A93" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_4DE6DEB5D896A1DE17C638A351248B06" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_2FB19097E477B7D598A538A351249A93" xlink:to="loc_biib_ShareOfCoPromotionProfits_4DE6DEB5D896A1DE17C638A351248B06" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_B0981BC5E19E2FE7BFA838A35124AA59" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_2FB19097E477B7D598A538A351249A93" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_B0981BC5E19E2FE7BFA838A35124AA59" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_UnconsolidatedJointBusiness" xlink:label="loc_biib_UnconsolidatedJointBusiness_271FB402D617EEE48A4B38A3512419F5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_2FB19097E477B7D598A538A351249A93" xlink:to="loc_biib_UnconsolidatedJointBusiness_271FB402D617EEE48A4B38A3512419F5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6CF0E333888ED7A0C8EB38A356D5E9EF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D7BDD709A11BAD29E44F38A356D5C0FC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6CF0E333888ED7A0C8EB38A356D5E9EF" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D7BDD709A11BAD29E44F38A356D5C0FC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_6670AF6F06670508869B38A356D52A32" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D7BDD709A11BAD29E44F38A356D5C0FC" xlink:to="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_6670AF6F06670508869B38A356D52A32" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_6670AF6F06670508869B38A356D52A32" xlink:to="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" xlink:label="loc_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_52C2DFB5E9A28A552DED38A356D5F208" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390" xlink:to="loc_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_52C2DFB5E9A28A552DED38A356D5F208" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_2C7188067A5169ADEEA038A356D5894D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390" xlink:to="loc_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_2C7188067A5169ADEEA038A356D5894D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_712C86F78E572F826D5338A356D6A5FF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390" xlink:to="loc_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_712C86F78E572F826D5338A356D6A5FF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_11FB6B83DBE4F62E20DF38A356D69B96" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_697FE10B46032A5F048D38A356D5C390" xlink:to="loc_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_11FB6B83DBE4F62E20DF38A356D69B96" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_6665FAF73F4F26F9EAE838A356D62AAF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D7BDD709A11BAD29E44F38A356D5C0FC" xlink:to="loc_us-gaap_StatementGeographicalAxis_6665FAF73F4F26F9EAE838A356D62AAF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_104DC06FFE042F1A6F7B38A356D63DAA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_6665FAF73F4F26F9EAE838A356D62AAF" xlink:to="loc_us-gaap_SegmentGeographicalDomain_104DC06FFE042F1A6F7B38A356D63DAA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SobiTerritoryMember" xlink:label="loc_biib_SobiTerritoryMember_E5973DF826CE8783512A38A356D6CB0F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_104DC06FFE042F1A6F7B38A356D63DAA" xlink:to="loc_biib_SobiTerritoryMember_E5973DF826CE8783512A38A356D6CB0F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_131869F99B4F0E33119E38A356D62707" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D7BDD709A11BAD29E44F38A356D5C0FC" xlink:to="loc_us-gaap_RangeAxis_131869F99B4F0E33119E38A356D62707" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1ED4A051FC1C3729297D38A356D66081" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_131869F99B4F0E33119E38A356D62707" xlink:to="loc_us-gaap_RangeMember_1ED4A051FC1C3729297D38A356D66081" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_6A4B51C7F202BD4CD99938A356D6EF75" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_1ED4A051FC1C3729297D38A356D66081" xlink:to="loc_us-gaap_MaximumMember_6A4B51C7F202BD4CD99938A356D6EF75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4C45755CB3F0AA55400C38A356D6CA5A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_1ED4A051FC1C3729297D38A356D66081" xlink:to="loc_us-gaap_MinimumMember_4C45755CB3F0AA55400C38A356D6CA5A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9049014DA4092D3573CF38A356D66046" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D7BDD709A11BAD29E44F38A356D5C0FC" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9049014DA4092D3573CF38A356D66046" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9049014DA4092D3573CF38A356D66046" xlink:to="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ReimbursementUnderAmendedAgreementMethod" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementMethod_6CD61DAD54FED3715B6938A356D63F4E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70" xlink:to="loc_biib_ReimbursementUnderAmendedAgreementMethod_6CD61DAD54FED3715B6938A356D63F4E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RatePriorToFirstCommercialSale" xlink:label="loc_biib_RatePriorToFirstCommercialSale_BED538263F231440DA2838A356D69282" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70" xlink:to="loc_biib_RatePriorToFirstCommercialSale_BED538263F231440DA2838A356D69282" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BaseRateAfterFirstCommercialSale" xlink:label="loc_biib_BaseRateAfterFirstCommercialSale_3FCE01CF9E6E97B5A99D38A356D6B9FC" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70" xlink:to="loc_biib_BaseRateAfterFirstCommercialSale_3FCE01CF9E6E97B5A99D38A356D6B9FC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RateDuringReimbursementPeriod" xlink:label="loc_biib_RateDuringReimbursementPeriod_DFF6B8226D1DC8A5BC0838A356D67522" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract_7C67588696D31E7D1F9938A356D68E70" xlink:to="loc_biib_RateDuringReimbursementPeriod_DFF6B8226D1DC8A5BC0838A356D67522" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FAE5EFFE925CFAD3759038A355A72DA8" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2F92622CF27BF1C4800938A355A84869" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FAE5EFFE925CFAD3759038A355A72DA8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2F92622CF27BF1C4800938A355A84869" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8D8EE0D3A0B271C016D238A355A82CF0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2F92622CF27BF1C4800938A355A84869" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8D8EE0D3A0B271C016D238A355A82CF0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28E947ABD46F94A083B38A355A8D0CB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8D8EE0D3A0B271C016D238A355A82CF0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28E947ABD46F94A083B38A355A8D0CB" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AbbvieMember" xlink:label="loc_biib_AbbvieMember_E617B6CC3C877B4351AB38A355A81BD1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_E28E947ABD46F94A083B38A355A8D0CB" xlink:to="loc_biib_AbbvieMember_E617B6CC3C877B4351AB38A355A81BD1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC56B109C48B1665FBC038A355A8607A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2F92622CF27BF1C4800938A355A84869" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC56B109C48B1665FBC038A355A8607A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_FE5E24C5E6FFF8154E4438A355A861D8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC56B109C48B1665FBC038A355A8607A" xlink:to="loc_biib_ExpenseIncurredByCollaboration_FE5E24C5E6FFF8154E4438A355A861D8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ExpenseReflectedWithinStatementsOfIncome" xlink:label="loc_biib_ExpenseReflectedWithinStatementsOfIncome_B78A52685CDE4A5814A338A355A865CA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CC56B109C48B1665FBC038A355A8607A" xlink:to="loc_biib_ExpenseReflectedWithinStatementsOfIncome_B78A52685CDE4A5814A338A355A865CA" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F24141132A3AFA4420B993D5C96E0B74" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F24141132A3AFA4420B993D5C96E0B74" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_E0912BB6DDFEB12549C693D5C96EB6F6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="loc_us-gaap_StatementGeographicalAxis_E0912BB6DDFEB12549C693D5C96EB6F6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_AEECFD82D62299124D9793D5C96E5FA6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_E0912BB6DDFEB12549C693D5C96EB6F6" xlink:to="loc_us-gaap_SegmentGeographicalDomain_AEECFD82D62299124D9793D5C96E5FA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_80AE7224E0EC5D14079E93D5C96E6C84" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_AEECFD82D62299124D9793D5C96E5FA6" xlink:to="loc_us-gaap_ForeignCountryMember_80AE7224E0EC5D14079E93D5C96E6C84" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="loc_country_US_02D07D2C9CEA6EF4DBD693D5C96E1867" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_AEECFD82D62299124D9793D5C96E5FA6" xlink:to="loc_country_US_02D07D2C9CEA6EF4DBD693D5C96E1867" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C3349773AA0D57BEB8B993D5C96EC538" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_C3349773AA0D57BEB8B993D5C96EC538" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_FE8730FCE8FA2CC590FD93D5C96FB578" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C3349773AA0D57BEB8B993D5C96EC538" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_FE8730FCE8FA2CC590FD93D5C96FB578" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E0FFB83D9FE6FB03368793D5C96F1696" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_FE8730FCE8FA2CC590FD93D5C96FB578" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E0FFB83D9FE6FB03368793D5C96F1696" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_353E77C6D02DCF8B951893D5C96FF734" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_353E77C6D02DCF8B951893D5C96FF734" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_46A8009752A5B984C18893D5C96FEE7D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_353E77C6D02DCF8B951893D5C96FF734" xlink:to="loc_us-gaap_LossContingencyNatureDomain_46A8009752A5B984C18893D5C96FEE7D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_HoechstMember" xlink:label="loc_biib_HoechstMember_9787FDBA9337F3760D3E93D5C96FA543" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_46A8009752A5B984C18893D5C96FEE7D" xlink:to="loc_biib_HoechstMember_9787FDBA9337F3760D3E93D5C96FA543" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AdditionalProductsAxis" xlink:label="loc_biib_AdditionalProductsAxis_E3851D105C85384660D593D5C96F98D6" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="loc_biib_AdditionalProductsAxis_E3851D105C85384660D593D5C96F98D6" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AdditionalProductsDomain" xlink:label="loc_biib_AdditionalProductsDomain_06DD47C969E3A03571D493D5C96F6545" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AdditionalProductsAxis_E3851D105C85384660D593D5C96F98D6" xlink:to="loc_biib_AdditionalProductsDomain_06DD47C969E3A03571D493D5C96F6545" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NewAntiCd20Member" xlink:label="loc_biib_NewAntiCd20Member_6AC8E63DCEFFC5DC6C6393D5C96F77F1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AdditionalProductsDomain_06DD47C969E3A03571D493D5C96F6545" xlink:to="loc_biib_NewAntiCd20Member_6AC8E63DCEFFC5DC6C6393D5C96F77F1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72D9824CCE950F40F21093D5C96F399E" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72D9824CCE950F40F21093D5C96F399E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_B0FA555C1F86CE910CA193D5C96FEAEE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72D9824CCE950F40F21093D5C96F399E" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_B0FA555C1F86CE910CA193D5C96FEAEE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_1FF89E58852BA33785A993D5C96F87C1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_B0FA555C1F86CE910CA193D5C96FEAEE" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_1FF89E58852BA33785A993D5C96F87C1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_C1CC42211F03E706987B93D5C96FD83E" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="loc_us-gaap_ProductOrServiceAxis_C1CC42211F03E706987B93D5C96FD83E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_C1CC42211F03E706987B93D5C96FD83E" xlink:to="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_5ABFC98D8F2F43AB5C1D93D5C96FA970" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_RituxanMember_5ABFC98D8F2F43AB5C1D93D5C96FA970" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_7148DE974A124A82D98893D5C96F3750" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_GAZYVAMember_7148DE974A124A82D98893D5C96F3750" xlink:type="arc" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_NewAntiCd20Member_6AC8E63DCEFFC5DC6C6393D5C96F77F1" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ThirdPartyAntiCdTwentyMember" xlink:label="loc_biib_ThirdPartyAntiCdTwentyMember_3114A1838DD1F322077B93D5C9701C93" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_ThirdPartyAntiCdTwentyMember_3114A1838DD1F322077B93D5C9701C93" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_BABCFA279ECCB60FEE6993D5C9709290" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_ELOCTATEMember_BABCFA279ECCB60FEE6993D5C9709290" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_34C73C20FB27CAFA6C3793D5C9702889" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_ALPROLIXMember_34C73C20FB27CAFA6C3793D5C9702889" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_OcrelizumabMember" xlink:label="loc_biib_OcrelizumabMember_8DC2C6B53A41932DDAEF93D5C97034B0" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_OcrelizumabMember_8DC2C6B53A41932DDAEF93D5C97034B0" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SOD1Member" xlink:label="loc_biib_SOD1Member_EB60A87A0FB3E1E02A2793DFA04EC495" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_SOD1Member_EB60A87A0FB3E1E02A2793DFA04EC495" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DMPKMember" xlink:label="loc_biib_DMPKMember_DF85E0ED1B849170CEEE93D5C9704FCA" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_DMPKMember_DF85E0ED1B849170CEEE93D5C9704FCA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SMNRxMember" xlink:label="loc_biib_SMNRxMember_7A78831878BA77DB329293D5C970ADF0" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_SMNRxMember_7A78831878BA77DB329293D5C970ADF0" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_LeadprogramsMember" xlink:label="loc_biib_LeadprogramsMember_753B73C00DCDB9A4950A93D5C970D598" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_LeadprogramsMember_753B73C00DCDB9A4950A93D5C970D598" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DiscoveryprogramsMember" xlink:label="loc_biib_DiscoveryprogramsMember_30C901FB7EE2418F69A693D5C97076E5" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_DiscoveryprogramsMember_30C901FB7EE2418F69A693D5C97076E5" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_10197333C26473E38D5093D5C970D2A4" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8EE24C88724AAB062E5593D5C96F1D99" xlink:to="loc_biib_BiosimilarsMember_10197333C26473E38D5093D5C970D2A4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A0B789E254BBE740009A93D5C97095FA" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A0B789E254BBE740009A93D5C97095FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A0B789E254BBE740009A93D5C97095FA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_1C2551141E3D2D79B80C93D5C97023A7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_RocheGroupGenentechMember_1C2551141E3D2D79B80C93D5C97023A7" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_GenentechMember" xlink:label="loc_biib_GenentechMember_3A76385BB3F92D60E76093D5C970B6CF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_GenentechMember_3A76385BB3F92D60E76093D5C970B6CF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ElanMember" xlink:label="loc_biib_ElanMember_F8C67C8905D242E26AE793D5C970525E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_ElanMember_F8C67C8905D242E26AE793D5C970525E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AcordaMember" xlink:label="loc_biib_AcordaMember_4E92B1A6BF7AF627891893D5C9700BB8" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_AcordaMember_4E92B1A6BF7AF627891893D5C9700BB8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SwedishOrphanBiovitrumMember" xlink:label="loc_biib_SwedishOrphanBiovitrumMember_E18976E6EAC193F1670B93D5C9705535" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_SwedishOrphanBiovitrumMember_E18976E6EAC193F1670B93D5C9705535" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AbbvieMember" xlink:label="loc_biib_AbbvieMember_7603D7708BE1A05A352693D5C9705C45" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_AbbvieMember_7603D7708BE1A05A352693D5C9705C45" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_IsisPharmaceuticalsMember" xlink:label="loc_biib_IsisPharmaceuticalsMember_F94324D1F70DE576704793D5C97041A4" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_IsisPharmaceuticalsMember_F94324D1F70DE576704793D5C97041A4" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_21827AB91F12B494258D93D5C970E8A6" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_EisaiMember_21827AB91F12B494258D93D5C970E8A6" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SangamoBioSciencesMember" xlink:label="loc_biib_SangamoBioSciencesMember_B99A805243157ABB445893D5C9702A6C" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_SangamoBioSciencesMember_B99A805243157ABB445893D5C9702A6C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AGTCMember" xlink:label="loc_biib_AGTCMember_887AF927DE7A493B429793D5C971730D" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_AGTCMember_887AF927DE7A493B429793D5C971730D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MitsubishiTanabePharmaCorporationMember" xlink:label="loc_biib_MitsubishiTanabePharmaCorporationMember_FA9176EC03F833D8912793D5C97104E5" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_MitsubishiTanabePharmaCorporationMember_FA9176EC03F833D8912793D5C97104E5" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_OtherresearchanddiscoveryMember" xlink:label="loc_biib_OtherresearchanddiscoveryMember_3566344DF130A66F861E93D5C971A63B" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_OtherresearchanddiscoveryMember_3566344DF130A66F861E93D5C971A63B" xlink:type="arc" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D2F342F8F0B489F4CD093D5C970CC01" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_1FF89E58852BA33785A993D5C96F87C1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_B6420F58A851EB781E3A93D5C9715D0C" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="loc_us-gaap_RangeAxis_B6420F58A851EB781E3A93D5C9715D0C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8652B90BD740441D6AED93D5C971512E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_B6420F58A851EB781E3A93D5C9715D0C" xlink:to="loc_us-gaap_RangeMember_8652B90BD740441D6AED93D5C971512E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_656BB3D2295C575E68A193D5C971258A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_8652B90BD740441D6AED93D5C971512E" xlink:to="loc_us-gaap_MaximumMember_656BB3D2295C575E68A193D5C971258A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_AAA47C9143B57245747D93D5C9712C99" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_8652B90BD740441D6AED93D5C971512E" xlink:to="loc_us-gaap_MinimumMember_AAA47C9143B57245747D93D5C9712C99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_22B6E6E4936353D6FF5293D5C9710618" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_22B6E6E4936353D6FF5293D5C9710618" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FA3860EAF9C54F9DD19493D5C971DFEC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_22B6E6E4936353D6FF5293D5C9710618" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FA3860EAF9C54F9DD19493D5C971DFEC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BiogenIdecHemophiliaMember" xlink:label="loc_biib_BiogenIdecHemophiliaMember_C08125830F1C7595D31293D5C9712332" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FA3860EAF9C54F9DD19493D5C971DFEC" xlink:to="loc_biib_BiogenIdecHemophiliaMember_C08125830F1C7595D31293D5C9712332" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1305351AE2995F0C0B1B93D5C96E7A2E" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RoyaltiesTermsOfCollaborationAgreement" xlink:label="loc_biib_RoyaltiesTermsOfCollaborationAgreement_190F8FE5707A045C034493D5C971DC9F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_RoyaltiesTermsOfCollaborationAgreement_190F8FE5707A045C034493D5C971DC9F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CollaborationsTextualAbstract" xlink:label="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_5D0093F9D4DD7378419593D5C971DF0C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_5D0093F9D4DD7378419593D5C971DF0C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PeriodOfCollaborationAgreement" xlink:label="loc_biib_PeriodOfCollaborationAgreement_AEE58ED468B795DC264293D5C971CEE0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_PeriodOfCollaborationAgreement_AEE58ED468B795DC264293D5C971CEE0" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated" xlink:label="loc_biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated_795C0D84F80A6CD7D7F393D5C9728756" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated_795C0D84F80A6CD7D7F393D5C9728756" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_F3F53D5CCF40D2AD5B8E93D5C972EB47" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_F3F53D5CCF40D2AD5B8E93D5C972EB47" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Reductioninroyaltyrate" xlink:label="loc_biib_Reductioninroyaltyrate_F00621A5F66C87870CA493D5C97288EC" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_Reductioninroyaltyrate_F00621A5F66C87870CA493D5C97288EC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_17C1BBA894D5D67B299C93D5C9720751" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_17C1BBA894D5D67B299C93D5C9720751" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CB87872C91EF7EEFD73D93D5C9728092" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CB87872C91EF7EEFD73D93D5C9728092" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_7B25B94EF1114380917793D5C9727750" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_7B25B94EF1114380917793D5C9727750" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_24C275EF6FD786E9805A93D5C972B925" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_24C275EF6FD786E9805A93D5C972B925" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SalesTriggerGrossSalesThreshold" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_396FA6F8703B8821032293D5C9726CE2" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_396FA6F8703B8821032293D5C9726CE2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Futurepercentageofcopromotionoperatingprofits" xlink:label="loc_biib_Futurepercentageofcopromotionoperatingprofits_4F8D1CC7249F45D2C2E093D5C97230D8" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_Futurepercentageofcopromotionoperatingprofits_4F8D1CC7249F45D2C2E093D5C97230D8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingLosses" xlink:label="loc_biib_PercentageOfCoPromotionOperatingLosses_CBE5308D32EBE93A422993D5C97284B2" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_PercentageOfCoPromotionOperatingLosses_CBE5308D32EBE93A422993D5C97284B2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages" xlink:label="loc_biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages_A1ADDE750FB90CB8FCEE93D5C972FA4E" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages_A1ADDE750FB90CB8FCEE93D5C972FA4E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_B3C06B5FC540DDDAEAE893D5C972A9FB" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_B3C06B5FC540DDDAEAE893D5C972A9FB" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_3029BCADED57FD2474BD93D5C9721F45" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ShareOfCoPromotionProfits_3029BCADED57FD2474BD93D5C9721F45" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_C9F22A32CB29E8F0B5E693D5C9720162" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion_C9F22A32CB29E8F0B5E693D5C9720162" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_CD79E9D32061DEF323FE93D5C9725630" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_CD79E9D32061DEF323FE93D5C9725630" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner" xlink:label="loc_biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner_97B8FE85B2AEDD3DAF9293D5C9720ADB" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner_97B8FE85B2AEDD3DAF9293D5C9720ADB" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner" xlink:label="loc_biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner_FE328A3348C9C093511393D5C9720EAE" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner_FE328A3348C9C093511393D5C9720EAE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration" xlink:label="loc_biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration_FFBC347447608196092A93D5C972D40B" xlink:type="locator" />
    <presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration_FFBC347447608196092A93D5C972D40B" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_F48F09B0AFFAB4FA899293D5C972A015" xlink:type="locator" />
    <presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones_F48F09B0AFFAB4FA899293D5C972A015" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4B9B23ABEA0867C9DA9893D5C9722ACA" xlink:type="locator" />
    <presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_4B9B23ABEA0867C9DA9893D5C9722ACA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ForeignSalesRequiredToTriggerMilestone" xlink:label="loc_biib_ForeignSalesRequiredToTriggerMilestone_198B74121E8F20EF985A93D5C97358CA" xlink:type="locator" />
    <presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ForeignSalesRequiredToTriggerMilestone_198B74121E8F20EF985A93D5C97358CA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ExpenseReflectedWithinStatementsOfIncome" xlink:label="loc_biib_ExpenseReflectedWithinStatementsOfIncome_5547D39B607D618C287793D5C97373E3" xlink:type="locator" />
    <presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ExpenseReflectedWithinStatementsOfIncome_5547D39B607D618C287793D5C97373E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9F98DD455CC00E73D81E93D5C973E83A" xlink:type="locator" />
    <presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9F98DD455CC00E73D81E93D5C973E83A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ConsiderationPerProductDeveloped" xlink:label="loc_biib_ConsiderationPerProductDeveloped_C8BE94CD385ADF5704AA93D5C973BB12" xlink:type="locator" />
    <presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ConsiderationPerProductDeveloped_C8BE94CD385ADF5704AA93D5C973BB12" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfReimbursementExpenses" xlink:label="loc_biib_PercentageOfReimbursementExpenses_E61E4789BF2BDEB75F5893D5C9736524" xlink:type="locator" />
    <presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_PercentageOfReimbursementExpenses_E61E4789BF2BDEB75F5893D5C9736524" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfDevelopmentReimbursementExpenses" xlink:label="loc_biib_PercentageOfDevelopmentReimbursementExpenses_75E6598CDC58E09E045693D5C973C3FE" xlink:type="locator" />
    <presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_PercentageOfDevelopmentReimbursementExpenses_75E6598CDC58E09E045693D5C973C3FE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ReimbursementCostAchievingPeriod" xlink:label="loc_biib_ReimbursementCostAchievingPeriod_AAB9D4EB8A2B433D4F9493D5C973CA35" xlink:type="locator" />
    <presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_ReimbursementCostAchievingPeriod_AAB9D4EB8A2B433D4F9493D5C973CA35" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TimePeriodForPayingRemainingBalanceDue" xlink:label="loc_biib_TimePeriodForPayingRemainingBalanceDue_3E75520ADE0C7484C0D293D5C9733DEF" xlink:type="locator" />
    <presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_TimePeriodForPayingRemainingBalanceDue_3E75520ADE0C7484C0D293D5C9733DEF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PeriodForGrantingOfApprovalByApprovingAuthority" xlink:label="loc_biib_PeriodForGrantingOfApprovalByApprovingAuthority_D71C2BE170A37B6EA15C93D5C97374F9" xlink:type="locator" />
    <presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_PeriodForGrantingOfApprovalByApprovingAuthority_D71C2BE170A37B6EA15C93D5C97374F9" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_7F4E7355A9FDD2E7AE0E93D5C9733222" xlink:type="locator" />
    <presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_2F0FFAEDB2DCA5BD97B993D5C971B429" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_7F4E7355A9FDD2E7AE0E93D5C9733222" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_7E0327C69FC6C80503DF93D5C9731F57" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_Termofcollaborationagreement_7E0327C69FC6C80503DF93D5C9731F57" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_84EFF9834D509D0D282793D5C97361D5" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_84EFF9834D509D0D282793D5C97361D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_411A5AE1D8A305ED569B93D5C9733210" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_411A5AE1D8A305ED569B93D5C9733210" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_DDEAF86502DABC80A2FB93D5C9739A03" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_LicenseFee_DDEAF86502DABC80A2FB93D5C9739A03" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:label="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_9633E8F995FFE31AA99993D5C97379DF" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_9633E8F995FFE31AA99993D5C97379DF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality" xlink:label="loc_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_00B7CFB4A6D8E7A5580593D5C973B44B" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality_00B7CFB4A6D8E7A5580593D5C973B44B" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_5359E696D056AAD6845793D5C9731824" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_AdditionalMilestonePayment_5359E696D056AAD6845793D5C9731824" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement" xlink:label="loc_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_9F898B3FFB2A3EAC7BD493D5C97397E4" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement_9F898B3FFB2A3EAC7BD493D5C97397E4" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_D2B92E233CAF715D8E3793D5C9742C8D" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_MilestonePaymentsMadeDuringPeriod_D2B92E233CAF715D8E3793D5C9742C8D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_204914CB0D936E5B606693D5C974358A" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_Purchaseofcommonstock_204914CB0D936E5B606693D5C974358A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_D75559A20C8EF99E5F3393D5C9749A05" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_us-gaap_LicenseCosts_D75559A20C8EF99E5F3393D5C9749A05" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Researchanddevelopmentservices" xlink:label="loc_biib_Researchanddevelopmentservices_99B74768AB0842EC7AA893D5C9743B14" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_Researchanddevelopmentservices_99B74768AB0842EC7AA893D5C9743B14" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Premiumonequityinvestment" xlink:label="loc_biib_Premiumonequityinvestment_7AEA0BC77BF1919BC72293D5C974F0CC" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_Premiumonequityinvestment_7AEA0BC77BF1919BC72293D5C974F0CC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_E0F9354CB30B46E83DE193D5C974B15F" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_E0F9354CB30B46E83DE193D5C974B15F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_2239FEA998EFAF28783E93D5C9741605" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_JointVentureOwnerShipPercentageByThirdParty_2239FEA998EFAF28783E93D5C9741605" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_0C18E13973A6B1AD86FA93D5C974E26B" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_us-gaap_EquityMethodInvestments_0C18E13973A6B1AD86FA93D5C974E26B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_DC7C146A501F502454A893D5C97432DC" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_DC7C146A501F502454A893D5C97432DC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_A88B55D3DDC16EA67F2D93D5C974E09E" xlink:type="locator" />
    <presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_A88B55D3DDC16EA67F2D93D5C974E09E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_A282151B713A4322109E93D5C974EA68" xlink:type="locator" />
    <presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_A282151B713A4322109E93D5C974EA68" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_796C264D3983462D515093D5C9741242" xlink:type="locator" />
    <presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_796C264D3983462D515093D5C9741242" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_C68E69952778AA89647293D5C974B18D" xlink:type="locator" />
    <presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_us-gaap_OtherSalesRevenueNet_C68E69952778AA89647293D5C974B18D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld" xlink:label="loc_biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld_728B22946A7477DD245893D5C974B7D0" xlink:type="locator" />
    <presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld_728B22946A7477DD245893D5C974B7D0" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_431E97FB34007EC5370993D5C974754E" xlink:type="locator" />
    <presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_431E97FB34007EC5370993D5C974754E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_BC08D65BB20D6B1C7C0C93D5C9742013" xlink:type="locator" />
    <presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_02333A722653C772BFA993D5C9710F0D" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_BC08D65BB20D6B1C7C0C93D5C9742013" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E21F9FE9955F71E8071138A353D14B45" xlink:type="locator" />
    <loc xlink:href="biib-20151231.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_D08499F73CDF3341533D38A353D144B1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E21F9FE9955F71E8071138A353D14B45" xlink:to="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_D08499F73CDF3341533D38A353D144B1" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PretaxProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_PretaxProfitSharingFormulaTableTextBlock_1831D0B73257747BA65E38A353D1614F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E21F9FE9955F71E8071138A353D14B45" xlink:to="loc_biib_PretaxProfitSharingFormulaTableTextBlock_1831D0B73257747BA65E38A353D1614F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_1787874D463057EA6A6C38A353D1433C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E21F9FE9955F71E8071138A353D14B45" xlink:to="loc_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock_1787874D463057EA6A6C38A353D1433C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_F6514BF493ED2FB2988138A353D18675" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E21F9FE9955F71E8071138A353D14B45" xlink:to="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_F6514BF493ED2FB2988138A353D18675" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_68FBB4AFB59D3F3B3C4138A353D1AA1B" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E21F9FE9955F71E8071138A353D14B45" xlink:to="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_68FBB4AFB59D3F3B3C4138A353D1AA1B" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_CCB53B66A8501048A59938A353D13691" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E21F9FE9955F71E8071138A353D14B45" xlink:to="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_CCB53B66A8501048A59938A353D13691" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2A8DA2A696E2EE86670438A353D54C8F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8AB29F9E7C5B82AF06C538A353D58AE9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2A8DA2A696E2EE86670438A353D54C8F" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8AB29F9E7C5B82AF06C538A353D58AE9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B343609630F2D9051F5F93D5C94543D0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_A61EA0E17042BE5E834793D5C9457882" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B343609630F2D9051F5F93D5C94543D0" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_A61EA0E17042BE5E834793D5C9457882" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_AA3DA792A059CA068F7193D5C945B470" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B343609630F2D9051F5F93D5C94543D0" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_AA3DA792A059CA068F7193D5C945B470" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_3605E78D4FC9FB3901BB93D5C9456D13" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B343609630F2D9051F5F93D5C94543D0" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_3605E78D4FC9FB3901BB93D5C9456D13" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_54BA260D7E4BFF015DFA93D5C94570F7" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B343609630F2D9051F5F93D5C94543D0" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_54BA260D7E4BFF015DFA93D5C94570F7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_C55F649F16005DCED58293D5C945B922" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B343609630F2D9051F5F93D5C94543D0" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_C55F649F16005DCED58293D5C945B922" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_1596F88FFA9CC286B53593D5C946973C" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B343609630F2D9051F5F93D5C94543D0" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_1596F88FFA9CC286B53593D5C946973C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_FAF9EEA341D6A1F403EA93D5C9469829" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B343609630F2D9051F5F93D5C94543D0" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_FAF9EEA341D6A1F403EA93D5C9469829" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_501556FE96CDACACBA1C93D5C9466605" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B343609630F2D9051F5F93D5C94543D0" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_501556FE96CDACACBA1C93D5C9466605" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_FE9CC181B7092B87632993D5C94618C2" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B343609630F2D9051F5F93D5C94543D0" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_FE9CC181B7092B87632993D5C94618C2" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_09780AB191E648455CB638A3513D7830" xlink:type="locator" />
    <loc xlink:href="biib-20151231.xsd#biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract" xlink:label="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_09780AB191E648455CB638A3513D7830" xlink:to="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_522412E745D570E5CCC438A3513D872C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_522412E745D570E5CCC438A3513D872C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1724AEFD8DA873FDD30938A3513DD947" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1724AEFD8DA873FDD30938A3513DD947" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_9F9073170E6498BB71B038A3513D13A3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_9F9073170E6498BB71B038A3513D13A3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_CE32293352F2ABAB108438A3513D6C58" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_CE32293352F2ABAB108438A3513D6C58" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_3B68A5A057ED2CEFC06E38A3513D5390" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_3B68A5A057ED2CEFC06E38A3513D5390" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_80205E621442A32B550938A3513D5865" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_80205E621442A32B550938A3513D5865" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_65A12BA9F501A1F1010A38A3513D5574" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_65A12BA9F501A1F1010A38A3513D5574" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_7689BD0E6CD7AD6C281538A3513E9A31" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_7689BD0E6CD7AD6C281538A3513E9A31" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_33EB4CDFE04E7616674438A3513EFD1C" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_33EB4CDFE04E7616674438A3513EFD1C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_92B2954622190F025CC538A3513E569F" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_92B2954622190F025CC538A3513E569F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_212C93D4552DA61D0A0238A3513E8532" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_212C93D4552DA61D0A0238A3513E8532" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_6B3E67C3621F3BF14A0F38A3513E67CD" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_6B3E67C3621F3BF14A0F38A3513E67CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B158A0B6533A767E59C638A3513E2F8E" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_B158A0B6533A767E59C638A3513E2F8E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_2F864E5AF1DDB9DC2F0A38A3513E0534" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_2F864E5AF1DDB9DC2F0A38A3513E0534" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_14F06C4209227824F1D038A3513E3471" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInOneYear_14F06C4209227824F1D038A3513E3471" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_485F945D2E5837F0AF9D38A3513E94E0" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_485F945D2E5837F0AF9D38A3513E94E0" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_368C594D1BA80D7768E438A3513E19C4" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_368C594D1BA80D7768E438A3513E19C4" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_64E27CF29ABE5CC3144A38A3513E6354" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFourYear_64E27CF29ABE5CC3144A38A3513E6354" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_4EB3268F36B6E026ED5D38A3513E4DAC" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_4EB3268F36B6E026ED5D38A3513E4DAC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_FF240E4161FE06AEEAF338A3513ECA41" xlink:type="locator" />
    <presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_biib_NetMinimumLeasePaymentsThereafter_FF240E4161FE06AEEAF338A3513ECA41" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_84FC89E02D8A559D99FB38A3513E542A" xlink:type="locator" />
    <presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_30113E9B55D99A92107438A3513D8E6C" xlink:to="loc_biib_NetMinimumLeasePayments_84FC89E02D8A559D99FB38A3513E542A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1E9FCC3EF0C4C4975F8C93582DC54AF7" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C62F48C8E07A30171AF393582DC6626F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1E9FCC3EF0C4C4975F8C93582DC54AF7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C62F48C8E07A30171AF393582DC6626F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_2D27C0052C808E3564BF93582DC6DE0F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C62F48C8E07A30171AF393582DC6626F" xlink:to="loc_biib_CumulativeSalesLevelAxis_2D27C0052C808E3564BF93582DC6DE0F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelAxis_2D27C0052C808E3564BF93582DC6DE0F" xlink:to="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SixbillionMember" xlink:label="loc_biib_SixbillionMember_525EE520AF11727B08BD93582DC65ED0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46" xlink:to="loc_biib_SixbillionMember_525EE520AF11727B08BD93582DC65ED0" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FourbillionMember" xlink:label="loc_biib_FourbillionMember_9BB0B81D90F32132B1D193582DC64433" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46" xlink:to="loc_biib_FourbillionMember_9BB0B81D90F32132B1D193582DC64433" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FivebillionMember" xlink:label="loc_biib_FivebillionMember_65191D8793EC1EC4B4BF93582DC6E83D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46" xlink:to="loc_biib_FivebillionMember_65191D8793EC1EC4B4BF93582DC6E83D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SevenbillionMember" xlink:label="loc_biib_SevenbillionMember_1170AA26EF39E5EEA2E393582DC6D036" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46" xlink:to="loc_biib_SevenbillionMember_1170AA26EF39E5EEA2E393582DC6D036" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_OneBillionMember" xlink:label="loc_biib_OneBillionMember_566EFD185CD9CD9BBF9093582DC69A60" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46" xlink:to="loc_biib_OneBillionMember_566EFD185CD9CD9BBF9093582DC69A60" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_BAA88DF10D1FC6C4164E93582DC6F1C7" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_BAA88DF10D1FC6C4164E93582DC6F1C7" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ThreeBillionMember" xlink:label="loc_biib_ThreeBillionMember_C4E5C0E49873C4DC9E4F93582DC6C38E" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_BE417A4D8A937975330293582DC66C46" xlink:to="loc_biib_ThreeBillionMember_C4E5C0E49873C4DC9E4F93582DC6C38E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_7596968419A326AEE05A93582DC633AF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C62F48C8E07A30171AF393582DC6626F" xlink:to="loc_us-gaap_ProductOrServiceAxis_7596968419A326AEE05A93582DC633AF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_AD967973D1B3FFB37ED593582DC6AFB7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_7596968419A326AEE05A93582DC633AF" xlink:to="loc_us-gaap_ProductsAndServicesDomain_AD967973D1B3FFB37ED593582DC6AFB7" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_F57DD1017638A9AFC55393582DC68F35" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_AD967973D1B3FFB37ED593582DC6AFB7" xlink:to="loc_biib_TecfideraMember_F57DD1017638A9AFC55393582DC68F35" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_A7C5474E32473F2F37C493582DC6E73E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C62F48C8E07A30171AF393582DC6626F" xlink:to="loc_biib_FacilityLocationAxis_A7C5474E32473F2F37C493582DC6E73E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_BC5EAA10C947B3F27B7393582DC63B37" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_A7C5474E32473F2F37C493582DC6E73E" xlink:to="loc_biib_FacilityLocationDomain_BC5EAA10C947B3F27B7393582DC63B37" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CambridgeLeasesMember" xlink:label="loc_biib_CambridgeLeasesMember_2E4B3E3607F704D2635A93582DC79948" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_BC5EAA10C947B3F27B7393582DC63B37" xlink:to="loc_biib_CambridgeLeasesMember_2E4B3E3607F704D2635A93582DC79948" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_300FE7AFB8AB7FE0F77793582DC70F1E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_BC5EAA10C947B3F27B7393582DC63B37" xlink:to="loc_biib_SolothurnMember_300FE7AFB8AB7FE0F77793582DC70F1E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3D4976770DC48C8E9C7493582DC7A8C3" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C62F48C8E07A30171AF393582DC6626F" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3D4976770DC48C8E9C7493582DC7A8C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C0AB5D493CE2C1801CCC93582DC7F628" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3D4976770DC48C8E9C7493582DC7A8C3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C0AB5D493CE2C1801CCC93582DC7F628" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_CDD6F4F3C468F56F8C9493582DC758C6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C0AB5D493CE2C1801CCC93582DC7F628" xlink:to="loc_biib_TysabriProductMember_CDD6F4F3C468F56F8C9493582DC758C6" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BiogenIdecHemophiliaMember" xlink:label="loc_biib_BiogenIdecHemophiliaMember_6AD528A5AAD4B1DDE81893582DC735FE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C0AB5D493CE2C1801CCC93582DC7F628" xlink:to="loc_biib_BiogenIdecHemophiliaMember_6AD528A5AAD4B1DDE81893582DC735FE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_092129E2A285AA2512BF93582DC73C7E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_C0AB5D493CE2C1801CCC93582DC7F628" xlink:to="loc_biib_FumapharmAgMember_092129E2A285AA2512BF93582DC73C7E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1C46867B73668FB9751B93582DC72426" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C62F48C8E07A30171AF393582DC6626F" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1C46867B73668FB9751B93582DC72426" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Chargesrecognizedtovacatebuilding" xlink:label="loc_biib_Chargesrecognizedtovacatebuilding_E099AAB2ADD0765AF52793582DC7F358" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C46867B73668FB9751B93582DC72426" xlink:to="loc_biib_Chargesrecognizedtovacatebuilding_E099AAB2ADD0765AF52793582DC7F358" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_42202F7006C2C3AA256093582DC7908F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C46867B73668FB9751B93582DC72426" xlink:to="loc_us-gaap_OtherCommitment_42202F7006C2C3AA256093582DC7908F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_E7B5D6A3E1F1E8567E5993582DC7ACD2" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C46867B73668FB9751B93582DC72426" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_E7B5D6A3E1F1E8567E5993582DC7ACD2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_9112320EAD59CF89DF6393582DC79CD0" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C46867B73668FB9751B93582DC72426" xlink:to="loc_biib_MilestonePaymentsMadeDuringPeriod_9112320EAD59CF89DF6393582DC79CD0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1B4201E56846CE7A3E1393582DC762AF" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C46867B73668FB9751B93582DC72426" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1B4201E56846CE7A3E1393582DC762AF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_3C87651AC57DB8E9970E93582DC760FF" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C46867B73668FB9751B93582DC72426" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_3C87651AC57DB8E9970E93582DC760FF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_DECAA53444CC975EA80893582DC79AFD" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1C46867B73668FB9751B93582DC72426" xlink:to="loc_biib_CumulativeSalesLevel_DECAA53444CC975EA80893582DC79AFD" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_biib_CommitmentsAndContingenciesTextualAbstract_C3E60C5AF87F1042D77893582DC75D05" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1E9FCC3EF0C4C4975F8C93582DC54AF7" xlink:to="loc_biib_CommitmentsAndContingenciesTextualAbstract_C3E60C5AF87F1042D77893582DC75D05" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_335010E79A3DD0031F4F93582DC7FABB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_C3E60C5AF87F1042D77893582DC75D05" xlink:to="loc_us-gaap_LeaseAndRentalExpense_335010E79A3DD0031F4F93582DC7FABB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_F57853CC9EA002EF6DDF93582DC7A6D8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_C3E60C5AF87F1042D77893582DC75D05" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_F57853CC9EA002EF6DDF93582DC7A6D8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" xlink:label="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F41C98432D67381C37393582DC70370" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_C3E60C5AF87F1042D77893582DC75D05" xlink:to="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_0F41C98432D67381C37393582DC70370" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_29A3385DFFFC26D2C78593582DC8E6F1" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_C3E60C5AF87F1042D77893582DC75D05" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_29A3385DFFFC26D2C78593582DC8E6F1" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_8DDEA201BBD796E3703A93582DC8D75F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_C3E60C5AF87F1042D77893582DC75D05" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_8DDEA201BBD796E3703A93582DC8D75F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FutureContingentPaymentThreshold" xlink:label="loc_biib_FutureContingentPaymentThreshold_F01B614AFC1E975D122293582DC8AFF2" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_C3E60C5AF87F1042D77893582DC75D05" xlink:to="loc_biib_FutureContingentPaymentThreshold_F01B614AFC1E975D122293582DC8AFF2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_4A3C97FF91953F38138693582DC89818" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_C3E60C5AF87F1042D77893582DC75D05" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_4A3C97FF91953F38138693582DC89818" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_51826887EBB926618A7193582DD58E3F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C4C993CC7A5EB330630693582DD59AFE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_51826887EBB926618A7193582DD58E3F" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C4C993CC7A5EB330630693582DD59AFE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_40530E79315E3DC4CF3E93582DD5F30D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_51826887EBB926618A7193582DD58E3F" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_40530E79315E3DC4CF3E93582DD5F30D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9DF5E621B9C7707D03FD65C9FE74F75B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_B6AAD5B947851D1B2CD665C9FE74D0ED" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9DF5E621B9C7707D03FD65C9FE74F75B" xlink:to="loc_us-gaap_AssetsAbstract_B6AAD5B947851D1B2CD665C9FE74D0ED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_546530D569491F4EE4E265C9FE740182" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_B6AAD5B947851D1B2CD665C9FE74D0ED" xlink:to="loc_us-gaap_AssetsCurrentAbstract_546530D569491F4EE4E265C9FE740182" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A858A3B8B806F31E21AC65C9FE79BB6D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_546530D569491F4EE4E265C9FE740182" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A858A3B8B806F31E21AC65C9FE79BB6D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_21384ABF87069619BB9565C9FE79549C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_546530D569491F4EE4E265C9FE740182" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_21384ABF87069619BB9565C9FE79549C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_87CCCD86C59D9F0F11E365C9FE79C88F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_546530D569491F4EE4E265C9FE740182" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_87CCCD86C59D9F0F11E365C9FE79C88F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DueFromUnconsolidatedJointBusiness" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_65541EAD4407BB1B0F0565C9FE79F047" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_546530D569491F4EE4E265C9FE740182" xlink:to="loc_biib_DueFromUnconsolidatedJointBusiness_65541EAD4407BB1B0F0565C9FE79F047" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_2DE82226962B4CDFEB7965C9FE7A929E" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_546530D569491F4EE4E265C9FE740182" xlink:to="loc_us-gaap_InventoryNet_2DE82226962B4CDFEB7965C9FE7A929E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_00A28E5C2C969319D5AD65C9FE7A035F" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_546530D569491F4EE4E265C9FE740182" xlink:to="loc_us-gaap_OtherAssetsCurrent_00A28E5C2C969319D5AD65C9FE7A035F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_C5B68464D16C2A6EE76265C9FE7AA736" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_546530D569491F4EE4E265C9FE740182" xlink:to="loc_us-gaap_AssetsCurrent_C5B68464D16C2A6EE76265C9FE7AA736" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_D48628E8C8FBA497389865C9FE7A54E9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_B6AAD5B947851D1B2CD665C9FE74D0ED" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_D48628E8C8FBA497389865C9FE7A54E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_84D6468F9D614FA2DA8D65C9FE7ACA83" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_B6AAD5B947851D1B2CD665C9FE74D0ED" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_84D6468F9D614FA2DA8D65C9FE7ACA83" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_811B1CCD538FDD0E1A0665C9FE7AD5FB" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_B6AAD5B947851D1B2CD665C9FE74D0ED" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_811B1CCD538FDD0E1A0665C9FE7AD5FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_2C9DA785D5AADFF8803165C9FE7AEAF9" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_B6AAD5B947851D1B2CD665C9FE74D0ED" xlink:to="loc_us-gaap_Goodwill_2C9DA785D5AADFF8803165C9FE7AEAF9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_00A057A980D77102AF4765C9FE7A4FDE" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_B6AAD5B947851D1B2CD665C9FE74D0ED" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_00A057A980D77102AF4765C9FE7A4FDE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_DDD8D6BD3F8D6A4A77B765C9FE7A1DE4" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_B6AAD5B947851D1B2CD665C9FE74D0ED" xlink:to="loc_us-gaap_Assets_DDD8D6BD3F8D6A4A77B765C9FE7A1DE4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AA8ABA66073B65B3C0EB65C9FE7AA8F3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9DF5E621B9C7707D03FD65C9FE74F75B" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AA8ABA66073B65B3C0EB65C9FE7AA8F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1B32DDF94F16B146B9B865C9FE7A342D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AA8ABA66073B65B3C0EB65C9FE7AA8F3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1B32DDF94F16B146B9B865C9FE7A342D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_76AC069D30752DC5F5F565C9FE7AF9AD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1B32DDF94F16B146B9B865C9FE7A342D" xlink:to="loc_us-gaap_DebtCurrent_76AC069D30752DC5F5F565C9FE7AF9AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_61511834F6CF72EFC4A665C9FE7B1C8D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1B32DDF94F16B146B9B865C9FE7A342D" xlink:to="loc_us-gaap_TaxesPayableCurrent_61511834F6CF72EFC4A665C9FE7B1C8D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_CE886FFCB94047E5833165C9FE7B88D4" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1B32DDF94F16B146B9B865C9FE7A342D" xlink:to="loc_us-gaap_AccountsPayableCurrent_CE886FFCB94047E5833165C9FE7B88D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_D41946ACE8EBE381101565C9FE7B646C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1B32DDF94F16B146B9B865C9FE7A342D" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_D41946ACE8EBE381101565C9FE7B646C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_974D1FCDEF0F26CF4F6765C9FE7BA08E" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1B32DDF94F16B146B9B865C9FE7A342D" xlink:to="loc_us-gaap_LiabilitiesCurrent_974D1FCDEF0F26CF4F6765C9FE7BA08E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_324EB57CF6E52DE154AB65C9FE7B69E4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AA8ABA66073B65B3C0EB65C9FE7AA8F3" xlink:to="loc_us-gaap_LongTermDebt_324EB57CF6E52DE154AB65C9FE7B69E4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_FF225CC051D31A75D37765C9FE805F99" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AA8ABA66073B65B3C0EB65C9FE7AA8F3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_FF225CC051D31A75D37765C9FE805F99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8E04BDD82C59CC17940365C9FE80AFBF" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AA8ABA66073B65B3C0EB65C9FE7AA8F3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8E04BDD82C59CC17940365C9FE80AFBF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_5D04B319A3D8C1578E7D65C9FE80614E" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AA8ABA66073B65B3C0EB65C9FE7AA8F3" xlink:to="loc_us-gaap_Liabilities_5D04B319A3D8C1578E7D65C9FE80614E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_A77FD073E02E781A525465C9FE809DED" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AA8ABA66073B65B3C0EB65C9FE7AA8F3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_A77FD073E02E781A525465C9FE809DED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FE8093A6A79CC3DDA04865C9FE8086FC" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AA8ABA66073B65B3C0EB65C9FE7AA8F3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FE8093A6A79CC3DDA04865C9FE8086FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_A2E12E159450DB48C38B65C9FE803C04" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FE8093A6A79CC3DDA04865C9FE8086FC" xlink:to="loc_us-gaap_StockholdersEquityAbstract_A2E12E159450DB48C38B65C9FE803C04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_19021014AF38AD9B828865C9FE80AA7A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A2E12E159450DB48C38B65C9FE803C04" xlink:to="loc_us-gaap_PreferredStockValue_19021014AF38AD9B828865C9FE80AA7A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_FB977526109751B4766865C9FE81C90B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A2E12E159450DB48C38B65C9FE803C04" xlink:to="loc_us-gaap_CommonStockValue_FB977526109751B4766865C9FE81C90B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_DB13BFBF027130922E9C65C9FE81ED92" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A2E12E159450DB48C38B65C9FE803C04" xlink:to="loc_us-gaap_AdditionalPaidInCapital_DB13BFBF027130922E9C65C9FE81ED92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75E9455C68C7C01AA3AF65C9FE819CF2" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A2E12E159450DB48C38B65C9FE803C04" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75E9455C68C7C01AA3AF65C9FE819CF2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_EB0F39592E8CC6881D5E65C9FE8122DC" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A2E12E159450DB48C38B65C9FE803C04" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_EB0F39592E8CC6881D5E65C9FE8122DC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_80EF6C9E35673F630BB065C9FE811F41" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A2E12E159450DB48C38B65C9FE803C04" xlink:to="loc_us-gaap_TreasuryStockValue_80EF6C9E35673F630BB065C9FE811F41" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_D2D3D02D36B72021C9C365C9FE8122C6" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A2E12E159450DB48C38B65C9FE803C04" xlink:to="loc_us-gaap_StockholdersEquity_D2D3D02D36B72021C9C365C9FE8122C6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_C94EB9D770C6B678497D65C9FE81761C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FE8093A6A79CC3DDA04865C9FE8086FC" xlink:to="loc_us-gaap_MinorityInterest_C94EB9D770C6B678497D65C9FE81761C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78EF6F6F13273144D52965C9FE812C49" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_FE8093A6A79CC3DDA04865C9FE8086FC" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78EF6F6F13273144D52965C9FE812C49" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_CEFF1AE575898508403D65C9FE81CBDA" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AA8ABA66073B65B3C0EB65C9FE7AA8F3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_CEFF1AE575898508403D65C9FE81CBDA" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_840D78FA73538859AA6138A355BD8C71" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_66AA109B483A91BB8A9D38A355BD7E3A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_840D78FA73538859AA6138A355BD8C71" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_66AA109B483A91BB8A9D38A355BD7E3A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_434012B3355A71DBF87E38A355BDEA98" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_840D78FA73538859AA6138A355BD8C71" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_434012B3355A71DBF87E38A355BDEA98" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_87C478E331ED820A9B3438A355BD6D6A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_840D78FA73538859AA6138A355BD8C71" xlink:to="loc_us-gaap_TreasuryStockShares_87C478E331ED820A9B3438A355BD6D6A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_83BCE1E4616C1C2FF999A29B5EE28886" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AB1E557C2D037660306CA29B5EE2D229" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_83BCE1E4616C1C2FF999A29B5EE28886" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AB1E557C2D037660306CA29B5EE2D229" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_2FB4C0261D5DE0F55D85A29B5EE2B198" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AB1E557C2D037660306CA29B5EE2D229" xlink:to="loc_us-gaap_ProfitLoss_2FB4C0261D5DE0F55D85A29B5EE2B198" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E95DA9E364CCB18E743AA29B5EE24028" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_AB1E557C2D037660306CA29B5EE2D229" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E95DA9E364CCB18E743AA29B5EE24028" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8F27E467BB7AB7D5C316A29B5EE296D6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E95DA9E364CCB18E743AA29B5EE24028" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8F27E467BB7AB7D5C316A29B5EE296D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1FCB23A1AFEFF481D03BA29B5EE2E1C0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E95DA9E364CCB18E743AA29B5EE24028" xlink:to="loc_us-gaap_ShareBasedCompensation_1FCB23A1AFEFF481D03BA29B5EE2E1C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_673AC5C2F69F77163642A29B5EE2D64B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E95DA9E364CCB18E743AA29B5EE24028" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_673AC5C2F69F77163642A29B5EE2D64B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_DFF825361B734D7C476EA29B5EE2BAD7" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E95DA9E364CCB18E743AA29B5EE24028" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_DFF825361B734D7C476EA29B5EE2BAD7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9AF78B1E1679CA03983CA29B5EE2DDF2" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E95DA9E364CCB18E743AA29B5EE24028" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9AF78B1E1679CA03983CA29B5EE2DDF2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_CF077F558243CCDDD5C7A29B5EE22054" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9AF78B1E1679CA03983CA29B5EE2DDF2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_CF077F558243CCDDD5C7A29B5EE22054" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4B0381D252BCB31D35C4A29B5EE2B33A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9AF78B1E1679CA03983CA29B5EE2DDF2" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4B0381D252BCB31D35C4A29B5EE2B33A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_381EEF8A77B615B85FEEA29B5EE2E702" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9AF78B1E1679CA03983CA29B5EE2DDF2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_381EEF8A77B615B85FEEA29B5EE2E702" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_BDB5F0234FAE4966F3F2A29B5EE262E5" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9AF78B1E1679CA03983CA29B5EE2DDF2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_BDB5F0234FAE4966F3F2A29B5EE262E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7A1058DE700082F8BEA3A29B5EE2FC40" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9AF78B1E1679CA03983CA29B5EE2DDF2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7A1058DE700082F8BEA3A29B5EE2FC40" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9108244451B1D5DCFD35A29B5EE20AB9" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9AF78B1E1679CA03983CA29B5EE2DDF2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9108244451B1D5DCFD35A29B5EE20AB9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1E1AEAB733C7FB172909A29B5EE37457" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9AF78B1E1679CA03983CA29B5EE2DDF2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1E1AEAB733C7FB172909A29B5EE37457" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4C8C38B2CA728B42C189A29B5EE3D623" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E95DA9E364CCB18E743AA29B5EE24028" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4C8C38B2CA728B42C189A29B5EE3D623" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0C0DB1F3C9844C57AD08A29B5EE3CEF7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_83BCE1E4616C1C2FF999A29B5EE28886" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0C0DB1F3C9844C57AD08A29B5EE3CEF7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_C24FC773F35A84ADBDF1A29B5EE3583B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0C0DB1F3C9844C57AD08A29B5EE3CEF7" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_C24FC773F35A84ADBDF1A29B5EE3583B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_F8CD4762E715A60A5468A29B5EE35134" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0C0DB1F3C9844C57AD08A29B5EE3CEF7" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_F8CD4762E715A60A5468A29B5EE35134" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_BB92FCA184E81777E321A29B5EE36ED5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0C0DB1F3C9844C57AD08A29B5EE3CEF7" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_BB92FCA184E81777E321A29B5EE36ED5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_98CA5807ACF979A82C13A29B5EE3461A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0C0DB1F3C9844C57AD08A29B5EE3CEF7" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_98CA5807ACF979A82C13A29B5EE3461A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_DD935B3279D3CA94AF44A29B5EE32A35" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0C0DB1F3C9844C57AD08A29B5EE3CEF7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_DD935B3279D3CA94AF44A29B5EE32A35" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8DD43832294B4DA57DEAA29B5EE30CF4" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0C0DB1F3C9844C57AD08A29B5EE3CEF7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8DD43832294B4DA57DEAA29B5EE30CF4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EDA805EC0887681CDAB4A29B5EE382F3" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0C0DB1F3C9844C57AD08A29B5EE3CEF7" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_EDA805EC0887681CDAB4A29B5EE382F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ACBED5A7C08A556D83EA29B5EE3B0EF" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0C0DB1F3C9844C57AD08A29B5EE3CEF7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ACBED5A7C08A556D83EA29B5EE3B0EF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8498A9F9E449D9CECE60A29B5EE3CD09" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_83BCE1E4616C1C2FF999A29B5EE28886" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8498A9F9E449D9CECE60A29B5EE3CD09" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_549D5D24DCD8C51D7A49A29B5EE351CF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8498A9F9E449D9CECE60A29B5EE3CD09" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_549D5D24DCD8C51D7A49A29B5EE351CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0AB2485F08E944312FC6A29B5EE305F0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8498A9F9E449D9CECE60A29B5EE3CD09" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0AB2485F08E944312FC6A29B5EE305F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_2EC574553DDB828B2389A29B5EE368CD" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8498A9F9E449D9CECE60A29B5EE3CD09" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_2EC574553DDB828B2389A29B5EE368CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_6F2326BA8B62770B5221A29B5EE3EFDA" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8498A9F9E449D9CECE60A29B5EE3CD09" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_6F2326BA8B62770B5221A29B5EE3EFDA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_B92DAEF195297AD9E3E0A29B5EE411B1" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8498A9F9E449D9CECE60A29B5EE3CD09" xlink:to="loc_us-gaap_RepaymentsOfDebt_B92DAEF195297AD9E3E0A29B5EE411B1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9A64B3FED209C77E9592A29B5EE46E9B" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8498A9F9E449D9CECE60A29B5EE3CD09" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9A64B3FED209C77E9592A29B5EE46E9B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BBE1F9F11CF7F0E853C8A29B5EE4F743" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8498A9F9E449D9CECE60A29B5EE3CD09" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BBE1F9F11CF7F0E853C8A29B5EE4F743" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_42FC4590105C14E160D5A29B5EE446BF" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_83BCE1E4616C1C2FF999A29B5EE28886" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_42FC4590105C14E160D5A29B5EE446BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_64FA4221A6A18BB1519CA29B5EE47C96" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_83BCE1E4616C1C2FF999A29B5EE28886" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_64FA4221A6A18BB1519CA29B5EE47C96" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9E77036E22356843AB8DA29B5EE4CD03" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_83BCE1E4616C1C2FF999A29B5EE28886" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9E77036E22356843AB8DA29B5EE4CD03" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_69388F7AF1250408BDCEA29B5EE40412" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_83BCE1E4616C1C2FF999A29B5EE28886" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_69388F7AF1250408BDCEA29B5EE40412" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C5F909778E938E81299538A352A32F5C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0EA04C6EDD60982506D438A352A4DE34" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C5F909778E938E81299538A352A32F5C" xlink:to="loc_us-gaap_NetIncomeLoss_0EA04C6EDD60982506D438A352A4DE34" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C5F909778E938E81299538A352A32F5C" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5DB7C0198308F2FEC29338A352A4416E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5DB7C0198308F2FEC29338A352A4416E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_B6D472236AD4A9B284E938A352A48FCF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_B6D472236AD4A9B284E938A352A48FCF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0E698620DE2CE9FE3D2538A352A45310" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0E698620DE2CE9FE3D2538A352A45310" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_EAA6979F914A34E4D73738A352A4F33C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_EAA6979F914A34E4D73738A352A4F33C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_76554DB606B6A4C687B338A352A59258" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_76554DB606B6A4C687B338A352A59258" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_225F61223B6BC8C6B48938A352A52E07" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_225F61223B6BC8C6B48938A352A52E07" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_567FFE5EB34C706F923A38A352A5B539" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_567FFE5EB34C706F923A38A352A5B539" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_63BF46E44125E7E0E50938A352A57557" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_63BF46E44125E7E0E50938A352A57557" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8CCCA88C8D2E9153B07A38A352A5DB6D" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8CCCA88C8D2E9153B07A38A352A5DB6D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_F62EB71AE46113110F5738A352A5D2A9" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_F62EB71AE46113110F5738A352A5D2A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_C9977A74310C72802CFD38A352A55D00" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_C9977A74310C72802CFD38A352A55D00" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_E4E40221CC845C6DD06E38A352A5DE10" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_DAB24AEF6A56B89F861438A352A4E2AD" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_E4E40221CC845C6DD06E38A352A5DE10" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3520DD9E865A936770F0A34B6AEAC8BE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_B842F67491A086C87A04A34B6AEB890F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3520DD9E865A936770F0A34B6AEAC8BE" xlink:to="loc_us-gaap_StatementTable_B842F67491A086C87A04A34B6AEB890F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7E353E4C27E42D2F33B9A34B6AEB3683" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_B842F67491A086C87A04A34B6AEB890F" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7E353E4C27E42D2F33B9A34B6AEB3683" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7E353E4C27E42D2F33B9A34B6AEB3683" xlink:to="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="loc_us-gaap_ParentCompanyMember_A7A7B90EFBE226DA8327A34B6AEB5B78" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:to="loc_us-gaap_ParentCompanyMember_A7A7B90EFBE226DA8327A34B6AEB5B78" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_5FF835D36D07DC1FF096A34B6AEB7B24" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:to="loc_us-gaap_PreferredStockMember_5FF835D36D07DC1FF096A34B6AEB7B24" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_C6B088FECEF4DDF46ACBA34B6AEB3F29" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:to="loc_us-gaap_CommonStockMember_C6B088FECEF4DDF46ACBA34B6AEB3F29" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4F03A9D50C43526FD55CA34B6AEB881F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4F03A9D50C43526FD55CA34B6AEB881F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9DB159D9B7D49CB877C7A34B6AEBCDE5" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9DB159D9B7D49CB877C7A34B6AEBCDE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_BDE4C6F4CE32ECB82C74A34B6AEBF67D" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:to="loc_us-gaap_RetainedEarningsMember_BDE4C6F4CE32ECB82C74A34B6AEBF67D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_C24894674BFCFA3ED127A34B6AEB6162" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:to="loc_us-gaap_TreasuryStockMember_C24894674BFCFA3ED127A34B6AEB6162" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_EA06B0336302B1C3190FA34B6AEB4F94" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_DC163B6140C2F8BAEC3DA34B6AEB39F4" xlink:to="loc_us-gaap_NoncontrollingInterestMember_EA06B0336302B1C3190FA34B6AEB4F94" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_B842F67491A086C87A04A34B6AEB890F" xlink:to="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_97BC60DE6EF5DD36733CA34B6AEB83B4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_97BC60DE6EF5DD36733CA34B6AEB83B4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_B1A61E954B94C94DC3FCA34B6AEC3001" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_SharesIssued_B1A61E954B94C94DC3FCA34B6AEC3001" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_183DB335637CF53E5443A34B6AECC9C2" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_ProfitLoss_183DB335637CF53E5443A34B6AECC9C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D0170E653F0CA6910A35A34B6AEC0ABE" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D0170E653F0CA6910A35A34B6AEC0ABE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_276E7416052B33694D7BA34B6AEC456E" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_276E7416052B33694D7BA34B6AEC456E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C5A74CDEA1B97BF22C3DA34B6AEC35E1" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C5A74CDEA1B97BF22C3DA34B6AEC35E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_89D028E32038AECE1805A34B6AEC6801" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_89D028E32038AECE1805A34B6AEC6801" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_8641BFE0E2D04EA1E77BA34B6AECADA1" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_8641BFE0E2D04EA1E77BA34B6AECADA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_0A9B30088B8475F83E89A34B6AECD0D7" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_0A9B30088B8475F83E89A34B6AECD0D7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_3DC274BAF9B69CB6ACDFA34B6AEC0028" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_3DC274BAF9B69CB6ACDFA34B6AEC0028" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_511A1E90666A9443AFE9A34B6AECCD8C" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_511A1E90666A9443AFE9A34B6AECCD8C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63DF82B7E187B57D09D2A34B6AECB6A5" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_63DF82B7E187B57D09D2A34B6AECB6A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_444971711DD9519B8472A34B6AEC721A" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_444971711DD9519B8472A34B6AEC721A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_DE49D532E3538C2C52C9A34B6AECA296" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_DE49D532E3538C2C52C9A34B6AECA296" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9FDBD3B7B97FA1B6DF09A34B6AEC9B7B" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9FDBD3B7B97FA1B6DF09A34B6AEC9B7B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6027D8B5BBF741A18224A34B6AECACF7" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6027D8B5BBF741A18224A34B6AECACF7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F5B3AF00556D11CA4EEA34B6AEC3519" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_8F5B3AF00556D11CA4EEA34B6AEC3519" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80F7ED959DA509C35ED8A34B6AEC248D" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80F7ED959DA509C35ED8A34B6AEC248D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_6709E0A8D6B1D9BAA840A34B6AED444C" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31E80DA6C29CDB423988A34B6AEBF915" xlink:to="loc_us-gaap_SharesIssued_6709E0A8D6B1D9BAA840A34B6AED444C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_50A474CBB5FADD48127238A3518E3CCB" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_8B3F2BE4195F7DAF90A138A3518E1355" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_50A474CBB5FADD48127238A3518E3CCB" xlink:to="loc_us-gaap_RevenuesAbstract_8B3F2BE4195F7DAF90A138A3518E1355" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_869D3AC56BC3C66B675A38A3518E6F5F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8B3F2BE4195F7DAF90A138A3518E1355" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_869D3AC56BC3C66B675A38A3518E6F5F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_UnconsolidatedJointBusiness" xlink:label="loc_biib_UnconsolidatedJointBusiness_4D35A74A59EA2BFE8D1F38A3518E6A14" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8B3F2BE4195F7DAF90A138A3518E1355" xlink:to="loc_biib_UnconsolidatedJointBusiness_4D35A74A59EA2BFE8D1F38A3518E6A14" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_C1F20AB001010606800B38A3518EA53F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8B3F2BE4195F7DAF90A138A3518E1355" xlink:to="loc_us-gaap_OtherSalesRevenueNet_C1F20AB001010606800B38A3518EA53F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_82EAD47E4758E299061638A3518FCDC9" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8B3F2BE4195F7DAF90A138A3518E1355" xlink:to="loc_us-gaap_Revenues_82EAD47E4758E299061638A3518FCDC9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_6653B7D1F9F5D4F0C60738A3518FE778" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_50A474CBB5FADD48127238A3518E3CCB" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_6653B7D1F9F5D4F0C60738A3518FE778" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_3DCD6125D6751DA6C08938A3518F46F3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_6653B7D1F9F5D4F0C60738A3518FE778" xlink:to="loc_us-gaap_CostOfGoodsSold_3DCD6125D6751DA6C08938A3518F46F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_810A4B41B8B68F268FDB38A3518F46A2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_6653B7D1F9F5D4F0C60738A3518FE778" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_810A4B41B8B68F268FDB38A3518F46A2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9107D774D44AA6879FBB38A3518F1062" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_6653B7D1F9F5D4F0C60738A3518FE778" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9107D774D44AA6879FBB38A3518F1062" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_05BB3780013DFDFAF05C38A3518F8A05" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_6653B7D1F9F5D4F0C60738A3518FE778" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_05BB3780013DFDFAF05C38A3518F8A05" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_653AC797E9FE4325AD7B38A3518FF563" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_6653B7D1F9F5D4F0C60738A3518FE778" xlink:to="loc_us-gaap_RestructuringCharges_653AC797E9FE4325AD7B38A3518FF563" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_C4265855BA7AC8F9288638A3518F407F" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_6653B7D1F9F5D4F0C60738A3518FE778" xlink:to="loc_biib_CollaborationProfitSharing_C4265855BA7AC8F9288638A3518F407F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3355AE382BF904250AEC38A3518F6C86" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_6653B7D1F9F5D4F0C60738A3518FE778" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3355AE382BF904250AEC38A3518F6C86" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_6ABE525194BC8E4A416138A3518F8608" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_6653B7D1F9F5D4F0C60738A3518FE778" xlink:to="loc_us-gaap_CostsAndExpenses_6ABE525194BC8E4A416138A3518F8608" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_GainOnSaleOfRights" xlink:label="loc_biib_GainOnSaleOfRights_B60F7F2944B1ABD28E1038A3518FB2FB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_50A474CBB5FADD48127238A3518E3CCB" xlink:to="loc_biib_GainOnSaleOfRights_B60F7F2944B1ABD28E1038A3518FB2FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_FD8DD347948E1ECF42C338A3518FC2AE" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_50A474CBB5FADD48127238A3518E3CCB" xlink:to="loc_us-gaap_OperatingIncomeLoss_FD8DD347948E1ECF42C338A3518FC2AE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_E4BA1C049B99CE03AC6C38A3518F2DF8" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_50A474CBB5FADD48127238A3518E3CCB" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_E4BA1C049B99CE03AC6C38A3518F2DF8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E94ECC88CC9ED284892138A351901F6C" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_50A474CBB5FADD48127238A3518E3CCB" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E94ECC88CC9ED284892138A351901F6C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E8A9ED9AB733602D484038A351901884" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_50A474CBB5FADD48127238A3518E3CCB" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_E8A9ED9AB733602D484038A351901884" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_E862D1C36D8E85564B8338A35190E4CE" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_50A474CBB5FADD48127238A3518E3CCB" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_E862D1C36D8E85564B8338A35190E4CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8EA0D0C97C8801CB62E538A351902893" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_50A474CBB5FADD48127238A3518E3CCB" xlink:to="loc_us-gaap_ProfitLoss_8EA0D0C97C8801CB62E538A351902893" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3304A423BC364D0E6D8138A351909E1B" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_50A474CBB5FADD48127238A3518E3CCB" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3304A423BC364D0E6D8138A351909E1B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A0A44558248CA663417438A3519096FC" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_50A474CBB5FADD48127238A3518E3CCB" xlink:to="loc_us-gaap_NetIncomeLoss_A0A44558248CA663417438A3519096FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_471817362E66FFC53D9838A35190489B" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_50A474CBB5FADD48127238A3518E3CCB" xlink:to="loc_us-gaap_EarningsPerShareAbstract_471817362E66FFC53D9838A35190489B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_B727C8D0215EA371217238A351903C20" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_471817362E66FFC53D9838A35190489B" xlink:to="loc_us-gaap_EarningsPerShareBasic_B727C8D0215EA371217238A351903C20" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_878C539293EDCA26CFEB38A35190FF04" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_471817362E66FFC53D9838A35190489B" xlink:to="loc_us-gaap_EarningsPerShareDiluted_878C539293EDCA26CFEB38A35190FF04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B8A2ADD740B9F06CE98338A351902403" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_50A474CBB5FADD48127238A3518E3CCB" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B8A2ADD740B9F06CE98338A351902403" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C352EECB11CD3D3C26B838A351901196" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B8A2ADD740B9F06CE98338A351902403" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C352EECB11CD3D3C26B838A351901196" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CBBEED463A4A4229CB6B38A3519084F1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B8A2ADD740B9F06CE98338A351902403" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CBBEED463A4A4229CB6B38A3519084F1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1910C6D0978064FD774738A35201517D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B49F459DA6FCB32B38C738A35201F1FD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1910C6D0978064FD774738A35201517D" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_B49F459DA6FCB32B38C738A35201F1FD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8D85B93CF411F5FC4E9C93582EDE6DA8" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8FD40407D73CE268ABD093582EDEA6EA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8D85B93CF411F5FC4E9C93582EDE6DA8" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8FD40407D73CE268ABD093582EDEA6EA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_34E4B5A01D850AE75F9493582EDEC52D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8FD40407D73CE268ABD093582EDEA6EA" xlink:to="loc_us-gaap_CurrencyAxis_34E4B5A01D850AE75F9493582EDEC52D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrencyAxis_34E4B5A01D850AE75F9493582EDEC52D" xlink:to="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_612C5E3C929BEF4D334E93582EDEC642" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:to="loc_currency_EUR_612C5E3C929BEF4D334E93582EDEC642" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_5EF1605A2DA90172BADB935EC0DFE4FF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:to="loc_currency_CHF_5EF1605A2DA90172BADB935EC0DFE4FF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_78095A2F2D20A72CCD5793582EDF0AE0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:to="loc_currency_CAD_78095A2F2D20A72CCD5793582EDF0AE0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_E07E6C181EF3F8FADBD593582EDF7E4F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:to="loc_currency_GBP_E07E6C181EF3F8FADBD593582EDF7E4F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_AUD" xlink:label="loc_currency_AUD_6C55CFF9B350EFAF89DD93582EDF343F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:to="loc_currency_AUD_6C55CFF9B350EFAF89DD93582EDF343F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_071D806A25A2A7139E0393582EDFEDAA" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_A79DF33D46A98A3728AD93582EDE675D" xlink:to="loc_currency_JPY_071D806A25A2A7139E0393582EDFEDAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_B0B6A67A2896B380B69393582EDF815B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8FD40407D73CE268ABD093582EDEA6EA" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_B0B6A67A2896B380B69393582EDF815B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_C9136B57B7C2A4FD16E493582EDFF4E7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_B0B6A67A2896B380B69393582EDF815B" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_C9136B57B7C2A4FD16E493582EDFF4E7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_899718E16A049BEF310893582EDFBBF5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_C9136B57B7C2A4FD16E493582EDFF4E7" xlink:to="loc_us-gaap_ForeignExchangeContractMember_899718E16A049BEF310893582EDFBBF5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1200A372C26E388D187F93582EDF1456" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8FD40407D73CE268ABD093582EDEA6EA" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1200A372C26E388D187F93582EDF1456" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1200A372C26E388D187F93582EDF1456" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_B7C1AC47A03184B37ECD93582EDFCF64" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_B7C1AC47A03184B37ECD93582EDFCF64" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_89342B8C8348CA322A2793582EDF6256" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3" xlink:to="loc_us-gaap_OtherInvestmentsMember_89342B8C8348CA322A2793582EDF6256" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_4F31AD62251905C135E593582EDFC242" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_4F31AD62251905C135E593582EDFC242" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_5A4422CDF2BE8DD6C3CD93582EDF645D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7B907FA064D48EC8DA8093582EDFE5D3" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_5A4422CDF2BE8DD6C3CD93582EDF645D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_FF04858B8D713FB2EDAE93582EDF45CA" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8FD40407D73CE268ABD093582EDEA6EA" xlink:to="loc_us-gaap_HedgingDesignationAxis_FF04858B8D713FB2EDAE93582EDF45CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_2CA42FBE5EB08EF0480A93582EDFA815" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_FF04858B8D713FB2EDAE93582EDF45CA" xlink:to="loc_us-gaap_HedgingDesignationDomain_2CA42FBE5EB08EF0480A93582EDFA815" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_C06494185A7F5FCBC6D793582EDFF51C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_2CA42FBE5EB08EF0480A93582EDFA815" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_C06494185A7F5FCBC6D793582EDFF51C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_68564F20C6283362111193582EE0335F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_2CA42FBE5EB08EF0480A93582EDFA815" xlink:to="loc_us-gaap_NondesignatedMember_68564F20C6283362111193582EE0335F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_157E95E22652ACDA14A493582EE0E2E3" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8FD40407D73CE268ABD093582EDEA6EA" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_157E95E22652ACDA14A493582EE0E2E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_2493643E075823EA649A93582EE0A13B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_157E95E22652ACDA14A493582EE0E2E3" xlink:to="loc_invest_DerivativeNotionalAmount_2493643E075823EA649A93582EE0A13B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_BA0D55B3BD94999B81A893582EE0EAE5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_157E95E22652ACDA14A493582EE0E2E3" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_BA0D55B3BD94999B81A893582EE0EAE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_E3C988842006D5EC77CF93582EE04BF1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_BA0D55B3BD94999B81A893582EE0EAE5" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_E3C988842006D5EC77CF93582EE04BF1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_471E4D3FF4D07150885593582EE0ACCC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_BA0D55B3BD94999B81A893582EE0EAE5" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_471E4D3FF4D07150885593582EE0ACCC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_DE993325C757D86932F193582ED7CC93" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8BCD211E255AEAE9C10D93582ED7C6E1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_DE993325C757D86932F193582ED7CC93" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8BCD211E255AEAE9C10D93582ED7C6E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaap_DerivativeByNatureAxis_23A0F49B692869B696EC93582ED75CFB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8BCD211E255AEAE9C10D93582ED7C6E1" xlink:to="loc_us-gaap_DerivativeByNatureAxis_23A0F49B692869B696EC93582ED75CFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaap_DerivativeNameDomain_C843415E3C92A6777ADC93582ED75625" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeByNatureAxis_23A0F49B692869B696EC93582ED75CFB" xlink:to="loc_us-gaap_DerivativeNameDomain_C843415E3C92A6777ADC93582ED75625" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_D5FE4A484447B39E723993582ED8DBD5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeNameDomain_C843415E3C92A6777ADC93582ED75625" xlink:to="loc_us-gaap_SalesMember_D5FE4A484447B39E723993582ED8DBD5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_106AC38E187C97465AD493582ED80981" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8BCD211E255AEAE9C10D93582ED7C6E1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_106AC38E187C97465AD493582ED80981" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5B8DB93FCF69B13C7AB493582ED82CCC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_106AC38E187C97465AD493582ED80981" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5B8DB93FCF69B13C7AB493582ED82CCC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_67D4C0FC526B5368136793582ED8ECB1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5B8DB93FCF69B13C7AB493582ED82CCC" xlink:to="loc_us-gaap_ForeignExchangeContractMember_67D4C0FC526B5368136793582ED8ECB1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_259B476FFD90E4F44B6393582ED8C989" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8BCD211E255AEAE9C10D93582ED7C6E1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_259B476FFD90E4F44B6393582ED8C989" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3095240D889CC37EF20393582ED863FB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_259B476FFD90E4F44B6393582ED8C989" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3095240D889CC37EF20393582ED863FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_B9E94AB3F9E6CEE6F28B93582ED88A38" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3095240D889CC37EF20393582ED863FB" xlink:to="loc_us-gaap_SalesMember_B9E94AB3F9E6CEE6F28B93582ED88A38" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8F59E3D0669AD13C1DD093582ED8C574" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3095240D889CC37EF20393582ED863FB" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8F59E3D0669AD13C1DD093582ED8C574" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_573609C0E7606F68E9E293582ED84B77" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_8BCD211E255AEAE9C10D93582ED7C6E1" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_573609C0E7606F68E9E293582ED84B77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_CA99F4236C15B27CE53D93582ED84AB4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_573609C0E7606F68E9E293582ED84B77" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_CA99F4236C15B27CE53D93582ED84AB4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_CB23975FDAC09B0BA47593582ED80148" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_CA99F4236C15B27CE53D93582ED84AB4" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_CB23975FDAC09B0BA47593582ED80148" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_3038DD34BF4CB6913BD793582ED84CBF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract_CA99F4236C15B27CE53D93582ED84AB4" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_3038DD34BF4CB6913BD793582ED84CBF" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_220A0CD6063C768860E093582ED25407" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_B251B83F4A59DAA4B37293582ED2C099" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_220A0CD6063C768860E093582ED25407" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_B251B83F4A59DAA4B37293582ED2C099" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_87AA4E43DD1805A0DE4C93582ED2479D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_B251B83F4A59DAA4B37293582ED2C099" xlink:to="loc_us-gaap_DebtInstrumentAxis_87AA4E43DD1805A0DE4C93582ED2479D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7D4BC042658495E595CF93582ED2F9A8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_87AA4E43DD1805A0DE4C93582ED2479D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7D4BC042658495E595CF93582ED2F9A8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_7BBA6CD71E88B7C1192493582ED28147" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7D4BC042658495E595CF93582ED2F9A8" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_7BBA6CD71E88B7C1192493582ED28147" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_3B588C655EF07FBB87B293582ED26018" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7D4BC042658495E595CF93582ED2F9A8" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_3B588C655EF07FBB87B293582ED26018" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_28A83B8F9AF16314F04593582ED29F43" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7D4BC042658495E595CF93582ED2F9A8" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_28A83B8F9AF16314F04593582ED29F43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_595557D31D62610900DA93582ED2654A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_B251B83F4A59DAA4B37293582ED2C099" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_595557D31D62610900DA93582ED2654A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_B31B3EE9E3303C95075593582ED26427" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_595557D31D62610900DA93582ED2654A" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_B31B3EE9E3303C95075593582ED26427" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_D9B0A01FFF8BB388A7BB93582ED25D7F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_B31B3EE9E3303C95075593582ED26427" xlink:to="loc_us-gaap_InterestRateContractMember_D9B0A01FFF8BB388A7BB93582ED25D7F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_4236ED4A89FC2A66A3BB93582ED228F3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_B31B3EE9E3303C95075593582ED26427" xlink:to="loc_us-gaap_InterestRateSwapMember_4236ED4A89FC2A66A3BB93582ED228F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_401544A4EFD6E694D1D393582ED3867F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_B251B83F4A59DAA4B37293582ED2C099" xlink:to="loc_us-gaap_HedgingDesignationAxis_401544A4EFD6E694D1D393582ED3867F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_D753A0AFA9C471F95C3193582ED3AE95" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_401544A4EFD6E694D1D393582ED3867F" xlink:to="loc_us-gaap_HedgingDesignationDomain_D753A0AFA9C471F95C3193582ED3AE95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3BBDC99CA2A4A196E85B93582ED3DECF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_D753A0AFA9C471F95C3193582ED3AE95" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3BBDC99CA2A4A196E85B93582ED3DECF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_298685895F2BA95A8D5893582ED379C2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_D753A0AFA9C471F95C3193582ED3AE95" xlink:to="loc_us-gaap_NondesignatedMember_298685895F2BA95A8D5893582ED379C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_4B0719102212A6FE38C193582ED3EAC4" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_B251B83F4A59DAA4B37293582ED2C099" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_4B0719102212A6FE38C193582ED3EAC4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_C1FEDE170CF0343B4AB993582ED3969A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_4B0719102212A6FE38C193582ED3EAC4" xlink:to="loc_invest_DerivativeNotionalAmount_C1FEDE170CF0343B4AB993582ED3969A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_DC15059F0ED68DC4508E93582ED33FA3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_4B0719102212A6FE38C193582ED3EAC4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_DC15059F0ED68DC4508E93582ED33FA3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3426D062DABB67CA998D93582ED31D7A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_4B0719102212A6FE38C193582ED3EAC4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3426D062DABB67CA998D93582ED31D7A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLowerRemainingMaturityRange1" xlink:label="loc_us-gaap_DerivativeLowerRemainingMaturityRange1_CDEC9630565D8F1BAEE593582ED38C6C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_220A0CD6063C768860E093582ED25407" xlink:to="loc_us-gaap_DerivativeLowerRemainingMaturityRange1_CDEC9630565D8F1BAEE593582ED38C6C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeHigherRemainingMaturityRange1" xlink:label="loc_us-gaap_DerivativeHigherRemainingMaturityRange1_79341B948E81B7E246BA93582ED32E21" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_220A0CD6063C768860E093582ED25407" xlink:to="loc_us-gaap_DerivativeHigherRemainingMaturityRange1_79341B948E81B7E246BA93582ED32E21" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4225067F62877F12E47C93582ED3BAB3" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_220A0CD6063C768860E093582ED25407" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_4225067F62877F12E47C93582ED3BAB3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_62283ADD7B837B2485DA93582ED31F14" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_220A0CD6063C768860E093582ED25407" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_62283ADD7B837B2485DA93582ED31F14" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6117269FAB8C630EE0ED93582ED32F65" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_220A0CD6063C768860E093582ED25407" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6117269FAB8C630EE0ED93582ED32F65" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_40AD36CC49BC219CD5BF38A3521B0B57" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_E448DD3DC4E6E476E03A38A3521B051D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_40AD36CC49BC219CD5BF38A3521B0B57" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_E448DD3DC4E6E476E03A38A3521B051D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_84D06638AC9F8380998338A3521C7A22" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_40AD36CC49BC219CD5BF38A3521B0B57" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_84D06638AC9F8380998338A3521C7A22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_831E845CB835245C770938A3521CC6B7" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_40AD36CC49BC219CD5BF38A3521B0B57" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_831E845CB835245C770938A3521CC6B7" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:href="biib-20151231.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:type="locator" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_07E684D9ADDEB240FAA338A354EC04F9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:to="loc_dei_EntityRegistrantName_07E684D9ADDEB240FAA338A354EC04F9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_13740DE2C15346834B2438A354ECC7C8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:to="loc_dei_EntityCentralIndexKey_13740DE2C15346834B2438A354ECC7C8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_C619CC7A44565DE4209938A354EC2E42" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:to="loc_dei_CurrentFiscalYearEndDate_C619CC7A44565DE4209938A354EC2E42" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_2869DE61A99CFA88919D38A354EC5EAD" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:to="loc_dei_EntityFilerCategory_2869DE61A99CFA88919D38A354EC5EAD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_C8A6EA61820A82D4174038A354ECA1C7" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:to="loc_dei_DocumentType_C8A6EA61820A82D4174038A354ECA1C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_55AF593F73C9759BAB0138A354EC7487" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:to="loc_dei_DocumentPeriodEndDate_55AF593F73C9759BAB0138A354EC7487" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_45D12785D820C1D377E538A354ECD75D" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:to="loc_dei_DocumentFiscalYearFocus_45D12785D820C1D377E538A354ECD75D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0AA210AD9CA830E9CBC638A354EC199C" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0AA210AD9CA830E9CBC638A354EC199C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_79A3C61A01773FFD8C9538A354EC86DF" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:to="loc_dei_AmendmentFlag_79A3C61A01773FFD8C9538A354EC86DF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5C8D08D788B8080F0DE638A354EC3144" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5C8D08D788B8080F0DE638A354EC3144" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_ECF5EFDBC39201113CE638A354ECE0C9" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_ECF5EFDBC39201113CE638A354ECE0C9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_536B7AE381630C30C31838A354EC9214" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:to="loc_dei_EntityVoluntaryFilers_536B7AE381630C30C31838A354EC9214" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_9AFB69203786BA54FAA238A354ECCF3A" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:to="loc_dei_EntityCurrentReportingStatus_9AFB69203786BA54FAA238A354ECCF3A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_6EE87082F489B18D8BC738A354EC823B" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_88888A082ED10138A11638A354EB4D06" xlink:to="loc_dei_EntityPublicFloat_6EE87082F489B18D8BC738A354EC823B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_36A4DB193A1C37364A6738A3539344CC" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_B5AC7967F09420D3E49538A353938CFF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_36A4DB193A1C37364A6738A3539344CC" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_B5AC7967F09420D3E49538A353938CFF" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_DA0F6C322D786E75F46D38A355099325" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4500351C8C6B01A0B0DB38A35509ABCD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_DA0F6C322D786E75F46D38A355099325" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4500351C8C6B01A0B0DB38A35509ABCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8D1435F0F78793BAD56838A3550926BA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4500351C8C6B01A0B0DB38A35509ABCD" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8D1435F0F78793BAD56838A3550926BA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89E7E1DE0CD38BB57CDE38A3550AE632" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8D1435F0F78793BAD56838A3550926BA" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89E7E1DE0CD38BB57CDE38A3550AE632" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E596138FF9D1D90C6D6A38A3550A36AA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89E7E1DE0CD38BB57CDE38A3550AE632" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_E596138FF9D1D90C6D6A38A3550A36AA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_63D2FFB0AC774D77F74938A3550A5AD8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89E7E1DE0CD38BB57CDE38A3550AE632" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_63D2FFB0AC774D77F74938A3550A5AD8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_B9E9C06845B8A899EDD738A3550A8F26" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89E7E1DE0CD38BB57CDE38A3550AE632" xlink:to="loc_biib_MarketStockUnitsMember_B9E9C06845B8A899EDD738A3550A8F26" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_05AE7F98B990A61A310038A3550A28F2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4500351C8C6B01A0B0DB38A35509ABCD" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_05AE7F98B990A61A310038A3550A28F2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_83E3F9FD4944AE8A5F0B38A3550ACC14" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_05AE7F98B990A61A310038A3550A28F2" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_83E3F9FD4944AE8A5F0B38A3550ACC14" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NumeratorAbstract" xlink:label="loc_biib_NumeratorAbstract_30D2DD904D2C85047A8738A3550A4CA9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_83E3F9FD4944AE8A5F0B38A3550ACC14" xlink:to="loc_biib_NumeratorAbstract_30D2DD904D2C85047A8738A3550A4CA9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E275DC2B1441440C473B38A3550A3BCE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_NumeratorAbstract_30D2DD904D2C85047A8738A3550A4CA9" xlink:to="loc_us-gaap_NetIncomeLoss_E275DC2B1441440C473B38A3550A3BCE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DenominatorAbstract" xlink:label="loc_biib_DenominatorAbstract_1F4BA4D7D4AAB2A7604738A3550A9883" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_83E3F9FD4944AE8A5F0B38A3550ACC14" xlink:to="loc_biib_DenominatorAbstract_1F4BA4D7D4AAB2A7604738A3550A9883" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1D7ED7FBDA70998A596A38A3550A57E4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DenominatorAbstract_1F4BA4D7D4AAB2A7604738A3550A9883" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1D7ED7FBDA70998A596A38A3550A57E4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_B133058C18B4E730717938A3550A2979" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DenominatorAbstract_1F4BA4D7D4AAB2A7604738A3550A9883" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_B133058C18B4E730717938A3550A2979" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5497B723E5308EBCC12138A3550A1A87" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_B133058C18B4E730717938A3550A2979" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5497B723E5308EBCC12138A3550A1A87" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_830CEFE18602F71ECCD738A3550ADD37" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_B133058C18B4E730717938A3550A2979" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_830CEFE18602F71ECCD738A3550ADD37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A2D107C5C7675DF3390238A3550AF32F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DenominatorAbstract_1F4BA4D7D4AAB2A7604738A3550A9883" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_A2D107C5C7675DF3390238A3550AF32F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EarningsPerShareTextualAbstract" xlink:label="loc_biib_EarningsPerShareTextualAbstract_AF9170BB876C6D73878B38A3550AB7FC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_DA0F6C322D786E75F46D38A355099325" xlink:to="loc_biib_EarningsPerShareTextualAbstract_AF9170BB876C6D73878B38A3550AB7FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_ACA1A86020D252DE7C3638A3550A45E0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EarningsPerShareTextualAbstract_AF9170BB876C6D73878B38A3550AB7FC" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_ACA1A86020D252DE7C3638A3550A45E0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3E85070B61326C3FFF9738A3541D7020" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3054232819F8C4676C0138A3541D2A1B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3E85070B61326C3FFF9738A3541D7020" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3054232819F8C4676C0138A3541D2A1B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_47EE2DE5B02E4E077DB038A35363956D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_844112BF2686B9C834D738A353638835" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_47EE2DE5B02E4E077DB038A35363956D" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_844112BF2686B9C834D738A353638835" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_763C8EDE0CF4149FD3AB93582DBA3E78" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7EC1F275AD1483AD62AD93582DBAC85A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_763C8EDE0CF4149FD3AB93582DBA3E78" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7EC1F275AD1483AD62AD93582DBAC85A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis" xlink:label="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_1DEAD1AADAA6F1577D3193582DBAD285" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7EC1F275AD1483AD62AD93582DBAC85A" xlink:to="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_1DEAD1AADAA6F1577D3193582DBAD285" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlansDomain" xlink:label="loc_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis_1DEAD1AADAA6F1577D3193582DBAD285" xlink:to="loc_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SavingsPlanMember" xlink:label="loc_biib_SavingsPlanMember_10CEA71099B8F7DE07F593582DBAA4F3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6" xlink:to="loc_biib_SavingsPlanMember_10CEA71099B8F7DE07F593582DBAA4F3" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DeferredCompensationPlanMember" xlink:label="loc_biib_DeferredCompensationPlanMember_1CCEB4031C08B6E21A7193582DBA9373" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6" xlink:to="loc_biib_DeferredCompensationPlanMember_1CCEB4031C08B6E21A7193582DBA9373" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SwissplanMember" xlink:label="loc_biib_SwissplanMember_24CD85770BCA10B6692993582DBABFFC" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6" xlink:to="loc_biib_SwissplanMember_24CD85770BCA10B6692993582DBABFFC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_GermanPlanMember" xlink:label="loc_biib_GermanPlanMember_DFED4B345FF92402935293582DBABF76" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansDomain_4870CE80E049CFA57E8393582DBA03F6" xlink:to="loc_biib_GermanPlanMember_DFED4B345FF92402935293582DBABF76" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A16AB03A2A829C39D57F93582DBBCB7F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_7EC1F275AD1483AD62AD93582DBAC85A" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A16AB03A2A829C39D57F93582DBBCB7F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:label="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_5000C4E6886F72532E8593582DBB65A2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A16AB03A2A829C39D57F93582DBBCB7F" xlink:to="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_5000C4E6886F72532E8593582DBB65A2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EmployeeBenefitPlansTextualAbstract" xlink:label="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A16AB03A2A829C39D57F93582DBBCB7F" xlink:to="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_C4FB52C1B1F1E463BE5A93582DBB1CBA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_C4FB52C1B1F1E463BE5A93582DBB1CBA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_287186BE44A245B4438B93582DBBF320" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_287186BE44A245B4438B93582DBBF320" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfMinimumInvestmentReturn" xlink:label="loc_biib_PercentageOfMinimumInvestmentReturn_6DE96913D428B52E056393582DBBF643" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:to="loc_biib_PercentageOfMinimumInvestmentReturn_6DE96913D428B52E056393582DBBF643" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9710048810DB5A6A65CA93582DBB20E4" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9710048810DB5A6A65CA93582DBB20E4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_FACFAE28B6BFCC147B9493582DBBD6BC" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_FACFAE28B6BFCC147B9493582DBBD6BC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionExpense" xlink:label="loc_us-gaap_PensionExpense_56ACAC55FE31D81D312D93582DBB2D3B" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:to="loc_us-gaap_PensionExpense_56ACAC55FE31D81D312D93582DBB2D3B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8CB8E5E71EA19683EDD693582DBB0AD2" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_7D0C0DD42B8582825D8393582DBBE1EC" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8CB8E5E71EA19683EDD693582DBB0AD2" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_63C40ACA9FCFC6C62C1F38A3565D670D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_C3FB4E3324BD5356489338A3565D9319" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_63C40ACA9FCFC6C62C1F38A3565D670D" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_C3FB4E3324BD5356489338A3565D9319" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_91C863015BDAC20D385E38A351CA72B0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_03A66E4528CB90EA059338A351CA3A66" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_91C863015BDAC20D385E38A351CA72B0" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_03A66E4528CB90EA059338A351CA3A66" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_DD8C516FD16A0CB7AC0238A351CADE09" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_03A66E4528CB90EA059338A351CA3A66" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_DD8C516FD16A0CB7AC0238A351CADE09" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1678CCF4AA1498B67AA838A351CA0984" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_03A66E4528CB90EA059338A351CA3A66" xlink:to="loc_us-gaap_CommonStockSharesIssued_1678CCF4AA1498B67AA838A351CA0984" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3AF0B849A682D9B9E3A438A351CA3032" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_03A66E4528CB90EA059338A351CA3A66" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3AF0B849A682D9B9E3A438A351CA3032" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_02A60B63A0E94D369D1C38A350DD83DF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_854F01725EA5CFD6635B38A350DDB069" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_02A60B63A0E94D369D1C38A350DD83DF" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_854F01725EA5CFD6635B38A350DDB069" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2843337B39C3D9FECCE238A350DE9A92" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_854F01725EA5CFD6635B38A350DDB069" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2843337B39C3D9FECCE238A350DE9A92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_DEFD71EB7ACBCE2603C538A350DE68DB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2843337B39C3D9FECCE238A350DE9A92" xlink:to="loc_us-gaap_ClassOfStockDomain_DEFD71EB7ACBCE2603C538A350DE68DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_BD57FD73F04BCC7EB89338A350DE9BB3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_DEFD71EB7ACBCE2603C538A350DE68DB" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_BD57FD73F04BCC7EB89338A350DE9BB3" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeriesXPreferredStockMember" xlink:label="loc_biib_SeriesXPreferredStockMember_9E44739AFBD5045646AD38A350DE9E9A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_DEFD71EB7ACBCE2603C538A350DE68DB" xlink:to="loc_biib_SeriesXPreferredStockMember_9E44739AFBD5045646AD38A350DE9E9A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_UndesignatedPreferredStockMember" xlink:label="loc_biib_UndesignatedPreferredStockMember_8D0FB545910F61E0CEC138A350DE495E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_DEFD71EB7ACBCE2603C538A350DE68DB" xlink:to="loc_biib_UndesignatedPreferredStockMember_8D0FB545910F61E0CEC138A350DE495E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_F84558E38180F726A7EA38A350DEB4A0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_854F01725EA5CFD6635B38A350DDB069" xlink:to="loc_us-gaap_ClassOfStockLineItems_F84558E38180F726A7EA38A350DEB4A0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9E3B50CEA26AE16D8BC538A350DE82FA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_F84558E38180F726A7EA38A350DEB4A0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9E3B50CEA26AE16D8BC538A350DE82FA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EquityTextualAbstract" xlink:label="loc_biib_EquityTextualAbstract_F87ECFB602EB42CA914938A350DE9D8F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_02A60B63A0E94D369D1C38A350DD83DF" xlink:to="loc_biib_EquityTextualAbstract_F87ECFB602EB42CA914938A350DE9D8F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7B2B93DD03F0D7831E3738A350DE788E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EquityTextualAbstract_F87ECFB602EB42CA914938A350DE9D8F" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7B2B93DD03F0D7831E3738A350DE788E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_909116DA1E0DCC7849A838A350DE5077" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EquityTextualAbstract_F87ECFB602EB42CA914938A350DE9D8F" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_909116DA1E0DCC7849A838A350DE5077" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_075C26D731D2B793C7E238A350DEE530" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EquityTextualAbstract_F87ECFB602EB42CA914938A350DE9D8F" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_075C26D731D2B793C7E238A350DEE530" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_21D57D72931BD08D5BE738A350DEC7B9" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EquityTextualAbstract_F87ECFB602EB42CA914938A350DE9D8F" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_21D57D72931BD08D5BE738A350DEC7B9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_6C4E53838E2F1C4338B638A355F8B163" xlink:type="locator" />
    <loc xlink:href="biib-20151231.xsd#biib_SummaryOfCommonStockTableTextBlock" xlink:label="loc_biib_SummaryOfCommonStockTableTextBlock_DD14AC70FEFEB2EB1B7438A355F8A8C7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6C4E53838E2F1C4338B638A355F8B163" xlink:to="loc_biib_SummaryOfCommonStockTableTextBlock_DD14AC70FEFEB2EB1B7438A355F8A8C7" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_38759CE5B9793036942F38A35535EC4D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_3EA9BF6C42C36C78617238A355359A0F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_38759CE5B9793036942F38A35535EC4D" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_3EA9BF6C42C36C78617238A355359A0F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E5228490EF556AC24BBA38A356B36A7C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_57E469E45496C534E1E238A356B3D278" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E5228490EF556AC24BBA38A356B36A7C" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_57E469E45496C534E1E238A356B3D278" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2A61573EE6301817F85C38A356B37F89" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_57E469E45496C534E1E238A356B3D278" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2A61573EE6301817F85C38A356B37F89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54A9AE8BE9B847EC449A38A356B37002" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2A61573EE6301817F85C38A356B37F89" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54A9AE8BE9B847EC449A38A356B37002" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_912A5211016B15994A0938A356B34CDE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54A9AE8BE9B847EC449A38A356B37002" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_912A5211016B15994A0938A356B34CDE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_BDFEAE4247B6DF7DD91238A356B39C45" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54A9AE8BE9B847EC449A38A356B37002" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_BDFEAE4247B6DF7DD91238A356B39C45" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_83B9CD8CEE450A8E474738A356B3CF17" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54A9AE8BE9B847EC449A38A356B37002" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_83B9CD8CEE450A8E474738A356B3CF17" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A65656DC19C1972C9C6E38A356B34244" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_57E469E45496C534E1E238A356B3D278" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A65656DC19C1972C9C6E38A356B34244" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_BBCE05DE2CB3CCB047C638A356B35715" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A65656DC19C1972C9C6E38A356B34244" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_BBCE05DE2CB3CCB047C638A356B35715" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_DEEABE05639E36828F0238A356B3C7E4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_BBCE05DE2CB3CCB047C638A356B35715" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_DEEABE05639E36828F0238A356B3C7E4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2A58EF54765ACD13352738A356B3EBD9" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_57E469E45496C534E1E238A356B3D278" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2A58EF54765ACD13352738A356B3EBD9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5E70717DD42DCEF281BB38A356B3B66C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2A58EF54765ACD13352738A356B3EBD9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5E70717DD42DCEF281BB38A356B3B66C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_BE4A1FACA42DC4D6EE1F38A356B37E0C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5E70717DD42DCEF281BB38A356B3B66C" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_BE4A1FACA42DC4D6EE1F38A356B37E0C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_0955D638C7816BCB216138A356B324DD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5E70717DD42DCEF281BB38A356B3B66C" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_0955D638C7816BCB216138A356B324DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_362E30C5F20DCB9149B138A356B31269" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5E70717DD42DCEF281BB38A356B3B66C" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_362E30C5F20DCB9149B138A356B31269" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_CB0BBE2DA7A3AE99178C38A356B4AC68" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_57E469E45496C534E1E238A356B3D278" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_CB0BBE2DA7A3AE99178C38A356B4AC68" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_785FFD586FB922C5947B38A356B43DC6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_CB0BBE2DA7A3AE99178C38A356B4AC68" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_785FFD586FB922C5947B38A356B43DC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_785FFD586FB922C5947B38A356B43DC6" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2435279020FE517F5D0138A356B4D467" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2435279020FE517F5D0138A356B4D467" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_339DCBB7E8ECF5E073B938A356B40CFE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:to="loc_us-gaap_AvailableForSaleSecurities_339DCBB7E8ECF5E073B938A356B40CFE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_29DB9608F328A6EBD47338A356B44497" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_29DB9608F328A6EBD47338A356B44497" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_71DF90912EC9A7A3F03838A356B42724" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_71DF90912EC9A7A3F03838A356B42724" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_D6613B9F2C7F5BDDD6E138A356B409F6" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_D6613B9F2C7F5BDDD6E138A356B409F6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_21703CC0597A5CED4AE638A356B4FA34" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_DE4D7BD92C6C798AC39F38A356B4AC02" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_21703CC0597A5CED4AE638A356B4FA34" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_D14D031534A103A6E7E638A356B40464" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_785FFD586FB922C5947B38A356B43DC6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_D14D031534A103A6E7E638A356B40464" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_7F68FAB9F50E8E82BD0E38A356B41F5E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_D14D031534A103A6E7E638A356B40464" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_7F68FAB9F50E8E82BD0E38A356B41F5E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_FB8E4292A1916FDF3A7538A356B48513" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_D14D031534A103A6E7E638A356B40464" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_FB8E4292A1916FDF3A7538A356B48513" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_69ADC2C3331D96F2CC4238A356B46C0C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_D14D031534A103A6E7E638A356B40464" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_69ADC2C3331D96F2CC4238A356B46C0C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_B425E1323AEF1A844F7238A35497C02D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_6B0BBD99BA996D8DB29438A35497542E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_B425E1323AEF1A844F7238A35497C02D" xlink:to="loc_us-gaap_DebtInstrumentTable_6B0BBD99BA996D8DB29438A35497542E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_EFD5E184E353765869CC38A35497BE6C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6B0BBD99BA996D8DB29438A35497542E" xlink:to="loc_us-gaap_DebtInstrumentAxis_EFD5E184E353765869CC38A35497BE6C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_517C6EF63E9ECD2D30A338A35497F912" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_EFD5E184E353765869CC38A35497BE6C" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_517C6EF63E9ECD2D30A338A35497F912" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_71EA1F8EA9FE10FDD1C038A3549791B8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_517C6EF63E9ECD2D30A338A35497F912" xlink:to="loc_biib_NotesPayableToFumedicaMember_71EA1F8EA9FE10FDD1C038A3549791B8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C12B3F15C51547BDAA8738A3549866D0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_517C6EF63E9ECD2D30A338A35497F912" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C12B3F15C51547BDAA8738A3549866D0" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_AD25EC3E4CBB2845468038A354980258" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_517C6EF63E9ECD2D30A338A35497F912" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_AD25EC3E4CBB2845468038A354980258" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_C738D8D8E6C8932BFDE838A354987F33" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_517C6EF63E9ECD2D30A338A35497F912" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_C738D8D8E6C8932BFDE838A354987F33" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_465F76B6DF0CCE4A281A38A354984590" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_517C6EF63E9ECD2D30A338A35497F912" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_465F76B6DF0CCE4A281A38A354984590" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E41D70EC4F87B067298238A3549879BF" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_517C6EF63E9ECD2D30A338A35497F912" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E41D70EC4F87B067298238A3549879BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_630C7362783DF34BE27A38A35498CE3C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6B0BBD99BA996D8DB29438A35497542E" xlink:to="loc_us-gaap_DebtInstrumentLineItems_630C7362783DF34BE27A38A35498CE3C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract" xlink:label="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_14600032C3BE18CC2F1038A3549810F8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_630C7362783DF34BE27A38A35498CE3C" xlink:to="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_14600032C3BE18CC2F1038A3549810F8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_105FE6420C89276F94F038A3549888B0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_14600032C3BE18CC2F1038A3549810F8" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_105FE6420C89276F94F038A3549888B0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_9D00D83E8762E71ED67B38A354984735" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract_14600032C3BE18CC2F1038A3549810F8" xlink:to="loc_us-gaap_DebtInstrumentFairValue_9D00D83E8762E71ED67B38A354984735" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6D87CF4ADFC9AACE3E5938A35390E7C0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3B80226A0DFCABA8904838A35390EFA6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6D87CF4ADFC9AACE3E5938A35390E7C0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3B80226A0DFCABA8904838A35390EFA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4CC7EB0562C3C980D6DF38A3539002C8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3B80226A0DFCABA8904838A35390EFA6" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4CC7EB0562C3C980D6DF38A3539002C8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_66B27713F238BFA3C9A938A3539081C5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4CC7EB0562C3C980D6DF38A3539002C8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_66B27713F238BFA3C9A938A3539081C5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_FA6549F79D91B65A085638A35390C55E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_66B27713F238BFA3C9A938A3539081C5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_FA6549F79D91B65A085638A35390C55E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3B80226A0DFCABA8904838A35390EFA6" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1A2FCB21FDEE8350B30038A35390A4A1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1A2FCB21FDEE8350B30038A35390A4A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_63998FE40E5274EEAC9A38A35390E1CE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_63998FE40E5274EEAC9A38A35390E1CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD0563565BF61C4A021438A35390F2A1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BD0563565BF61C4A021438A35390F2A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8C89FC9EA4F9BD38911438A353904E5B" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8C89FC9EA4F9BD38911438A353904E5B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_AD8C210E8E34226368E938A3539078E4" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_F8B4E65F98953E8080C638A353909564" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_AD8C210E8E34226368E938A3539078E4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_A49BBEF51637E65ED42593D5CA993D46" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_371F0C070B7EB1C4C87293D5CA9946FA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_A49BBEF51637E65ED42593D5CA993D46" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_371F0C070B7EB1C4C87293D5CA9946FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_011018B3FCBF4C97908B93D5CA9908E8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_371F0C070B7EB1C4C87293D5CA9946FA" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_011018B3FCBF4C97908B93D5CA9908E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_B03F8C62B7525987D5D493D5CA991520" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_011018B3FCBF4C97908B93D5CA9908E8" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_B03F8C62B7525987D5D493D5CA991520" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0BDD28D1B7E85ADF522193D5CA99AAFB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_B03F8C62B7525987D5D493D5CA991520" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_0BDD28D1B7E85ADF522193D5CA99AAFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_CBCBC09117C58495F53C93D5CA9E8C09" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_B03F8C62B7525987D5D493D5CA991520" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_CBCBC09117C58495F53C93D5CA9E8C09" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0F0C2663004B22C4142193D5CA9E1234" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_371F0C070B7EB1C4C87293D5CA9946FA" xlink:to="loc_us-gaap_DebtInstrumentAxis_0F0C2663004B22C4142193D5CA9E1234" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7ADBF1A4268D19C0129A93D5CA9E8459" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0F0C2663004B22C4142193D5CA9E1234" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7ADBF1A4268D19C0129A93D5CA9E8459" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_891970B7B1B2F196C32893D5CA9EB28D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7ADBF1A4268D19C0129A93D5CA9E8459" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_891970B7B1B2F196C32893D5CA9EB28D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_A15A67A2E253C06460EE93D5CA9EB2F1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7ADBF1A4268D19C0129A93D5CA9E8459" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_A15A67A2E253C06460EE93D5CA9EB2F1" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_E6357CE5393A7D4B39D093D5CA9EDE2A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7ADBF1A4268D19C0129A93D5CA9E8459" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_E6357CE5393A7D4B39D093D5CA9EDE2A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_44E05FF9C983FA23756F93D5CA9EB9FB" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7ADBF1A4268D19C0129A93D5CA9E8459" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_44E05FF9C983FA23756F93D5CA9EB9FB" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_3928BDE4280506A0979193D5CA9E5BB3" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7ADBF1A4268D19C0129A93D5CA9E8459" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_3928BDE4280506A0979193D5CA9E5BB3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_BA3F4BEDB33E43386CE193D5CA9ED476" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_371F0C070B7EB1C4C87293D5CA9946FA" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_BA3F4BEDB33E43386CE193D5CA9ED476" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F15C026E217607F45D5993D5CA9EC938" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_BA3F4BEDB33E43386CE193D5CA9ED476" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F15C026E217607F45D5993D5CA9EC938" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_2A5FB2D3C2E5B8F5459793D5CA9FA548" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F15C026E217607F45D5993D5CA9EC938" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_2A5FB2D3C2E5B8F5459793D5CA9FA548" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_StromedixMember" xlink:label="loc_biib_StromedixMember_4695609B053A40CEF97393D5CA9FD1C2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F15C026E217607F45D5993D5CA9EC938" xlink:to="loc_biib_StromedixMember_4695609B053A40CEF97393D5CA9FD1C2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CorporateJointVentureInvestmentsMember" xlink:label="loc_biib_CorporateJointVentureInvestmentsMember_6888F403EE1C785E636B93D5CA9F477B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F15C026E217607F45D5993D5CA9EC938" xlink:to="loc_biib_CorporateJointVentureInvestmentsMember_6888F403EE1C785E636B93D5CA9F477B" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BiogenIdecInternationalNeuroscienceMember" xlink:label="loc_biib_BiogenIdecInternationalNeuroscienceMember_D68BD599A551A3C2E0AC93D5CA9FF945" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F15C026E217607F45D5993D5CA9EC938" xlink:to="loc_biib_BiogenIdecInternationalNeuroscienceMember_D68BD599A551A3C2E0AC93D5CA9FF945" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_371F0C070B7EB1C4C87293D5CA9946FA" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_43A07A945E07D0A6A79F93E6AD7F3521" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_43A07A945E07D0A6A79F93E6AD7F3521" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_AA3113422E0AEFCC3A5493D5CA9FECD2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_AA3113422E0AEFCC3A5493D5CA9FECD2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_AC1C63097055A9DB3E2393D5CA9F7F39" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_AC1C63097055A9DB3E2393D5CA9F7F39" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D5A8B9B9728864F5162D93D5CA9F51CB" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D5A8B9B9728864F5162D93D5CA9F51CB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_B817FAC06C684443C72293D5CA9FF8AD" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_B817FAC06C684443C72293D5CA9FF8AD" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_CCC28E552FB78D57D8F493D5CA9FCA52" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_CCC28E552FB78D57D8F493D5CA9FCA52" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_88BF551DE420FD3ACD0E93D5CA9F35CE" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_88BF551DE420FD3ACD0E93D5CA9F35CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5C23C7655E1A30EF6DF793D5CA9F3953" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5C23C7655E1A30EF6DF793D5CA9F3953" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_1861DDB7767BB75CD97793D5CA9F02B8" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_1861DDB7767BB75CD97793D5CA9F02B8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MilestonePaymentsMadeDuringPeriod" xlink:label="loc_biib_MilestonePaymentsMadeDuringPeriod_E249EF1B31AEDBE4277593D5CA9FF1CA" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_biib_MilestonePaymentsMadeDuringPeriod_E249EF1B31AEDBE4277593D5CA9FF1CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_EE8FAFA4F99938EC1F9893D5CA9FE032" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1FBD8BC1CDE875E6BFEA93D5CA9FE238" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_EE8FAFA4F99938EC1F9893D5CA9FE032" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1D58E8B3164B7BE9639438A356121CBA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_D2BB5002400E09AE009038A35613759A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1D58E8B3164B7BE9639438A356121CBA" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_D2BB5002400E09AE009038A35613759A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_CE691A86335070181CCB38A3561364CE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1D58E8B3164B7BE9639438A356121CBA" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_CE691A86335070181CCB38A3561364CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_779CA10DAB9BC42AD07A38A35613F274" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1D58E8B3164B7BE9639438A356121CBA" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_779CA10DAB9BC42AD07A38A35613F274" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_F4BA7F8E0EA3E92112C638A354EFE18F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_F2FB395B5BB712B5B76638A354EF368E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_F4BA7F8E0EA3E92112C638A354EFE18F" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_F2FB395B5BB712B5B76638A354EF368E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_18548A0D87E80629F85893224C05E959" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_36E61ABCE67E4925BCF293224C0627A6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_18548A0D87E80629F85893224C05E959" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_36E61ABCE67E4925BCF293224C0627A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_D1C96879004D120A41FE93224C06599E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_36E61ABCE67E4925BCF293224C0627A6" xlink:to="loc_us-gaap_InvestmentTypeAxis_D1C96879004D120A41FE93224C06599E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_D1C96879004D120A41FE93224C06599E" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_FB6ADD8CC68CBD351F4593224C0B7A70" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B" xlink:to="loc_us-gaap_CommercialPaperMember_FB6ADD8CC68CBD351F4593224C0B7A70" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_38931A31A77E907C2C0993224C0B2699" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_38931A31A77E907C2C0993224C0B2699" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_AA07445EBD9ED8B52AA693224C0BD230" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B" xlink:to="loc_us-gaap_MoneyMarketFundsMember_AA07445EBD9ED8B52AA693224C0BD230" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_6476AC24DF8547A4DD6693224C0BB051" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_79BF02278F6C17B128A093224C06A66B" xlink:to="loc_us-gaap_DebtSecuritiesMember_6476AC24DF8547A4DD6693224C0BB051" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_50DD7BB047E4D5B9B12693224C0B772D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_36E61ABCE67E4925BCF293224C0627A6" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_50DD7BB047E4D5B9B12693224C0B772D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_63BF7DA00FA8964CBBB893224C0B33E0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_50DD7BB047E4D5B9B12693224C0B772D" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_63BF7DA00FA8964CBBB893224C0B33E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_EC9F04072C2FDE4678D193224C0B82E7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_63BF7DA00FA8964CBBB893224C0B33E0" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_EC9F04072C2FDE4678D193224C0B82E7" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_37FF85B41493BCD212A2A34B6A0D6BF6" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EF589FF997A39165DD75A34B6A0E8844" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_37FF85B41493BCD212A2A34B6A0D6BF6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EF589FF997A39165DD75A34B6A0E8844" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_C204162746A8575AAA92A34B6A0E945D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EF589FF997A39165DD75A34B6A0E8844" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_C204162746A8575AAA92A34B6A0E945D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_C204162746A8575AAA92A34B6A0E945D" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_48035EC16EEEB30D3517A34B6A13F018" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_48035EC16EEEB30D3517A34B6A13F018" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_2FF5B4F3834FFCFF8AA0A34B6A13A1CE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_2FF5B4F3834FFCFF8AA0A34B6A13A1CE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_73E250A0607C282E86CBA34B6A13AE74" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_73E250A0607C282E86CBA34B6A13AE74" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_377740B18487722700FEA34B6A138831" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_377740B18487722700FEA34B6A138831" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E5DC0C2F9CBEE4A11A78A34B6A1384CD" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_E5DC0C2F9CBEE4A11A78A34B6A1384CD" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_F3A6F99A8C8A7626A270A34B6A13EEE9" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_F3A6F99A8C8A7626A270A34B6A13EEE9" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MarketableEquitySecuritiesMember" xlink:label="loc_biib_MarketableEquitySecuritiesMember_5940B366C07C79E18A29A34B6A1362C2" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_6D063C990EE30D370992A34B6A0E93E7" xlink:to="loc_biib_MarketableEquitySecuritiesMember_5940B366C07C79E18A29A34B6A1362C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0C3587EC485D2B006E78A34B6A135499" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EF589FF997A39165DD75A34B6A0E8844" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0C3587EC485D2B006E78A34B6A135499" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_EFA3EA49F348A33DDDE6A34B6A149E38" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0C3587EC485D2B006E78A34B6A135499" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_EFA3EA49F348A33DDDE6A34B6A149E38" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_345C9693A6544936BD96A34B6A14597A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_EFA3EA49F348A33DDDE6A34B6A149E38" xlink:to="loc_us-gaap_AvailableForSaleSecurities_345C9693A6544936BD96A34B6A14597A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_06818972C6A31812A1C7A34B6A14BED5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_EFA3EA49F348A33DDDE6A34B6A149E38" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_06818972C6A31812A1C7A34B6A14BED5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C63AC6000C4B847B010A34B6A14D008" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_EFA3EA49F348A33DDDE6A34B6A149E38" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7C63AC6000C4B847B010A34B6A14D008" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B67596B5771210779D01A34B6A14B966" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_EFA3EA49F348A33DDDE6A34B6A149E38" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B67596B5771210779D01A34B6A14B966" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3AED1CD857AB2726079A38A351FC3575" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EF01E040FA752695E61238A351FC5C6A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3AED1CD857AB2726079A38A351FC3575" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EF01E040FA752695E61238A351FC5C6A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6BE19F29BC142591D08938A351FC9620" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EF01E040FA752695E61238A351FC5C6A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6BE19F29BC142591D08938A351FC9620" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_E4C0230BAC9593C40AD238A351FCB052" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EF01E040FA752695E61238A351FC5C6A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_E4C0230BAC9593C40AD238A351FCB052" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8D38CBD45DEDA3BCA97538A351FC691C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EF01E040FA752695E61238A351FC5C6A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8D38CBD45DEDA3BCA97538A351FC691C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_CA13F1811A3D713F326A38A351FC1C0C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EF01E040FA752695E61238A351FC5C6A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_CA13F1811A3D713F326A38A351FC1C0C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3D57C402E984713838A838A351FC5996" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EF01E040FA752695E61238A351FC5C6A" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3D57C402E984713838A838A351FC5996" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_DBDADBF79C3EA111C15238A351FC9CC2" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EF01E040FA752695E61238A351FC5C6A" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_DBDADBF79C3EA111C15238A351FC9CC2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_C06D06D52618DE93D0C138A351FCC0B8" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EF01E040FA752695E61238A351FC5C6A" xlink:to="loc_us-gaap_AvailableForSaleSecurities_C06D06D52618DE93D0C138A351FCC0B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D7164B12F5430C52F56238A351FC93EB" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EF01E040FA752695E61238A351FC5C6A" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D7164B12F5430C52F56238A351FC93EB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_BF0A9B4E646DDE11309E38A3559CDCC5" xlink:type="locator" />
    <loc xlink:href="biib-20151231.xsd#biib_ProceedsFromMarketableDebtSecuritiesAbstract" xlink:label="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_82723F04026CA76799F438A3559C8E9D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_BF0A9B4E646DDE11309E38A3559CDCC5" xlink:to="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_82723F04026CA76799F438A3559C8E9D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B77162956A3CBFE0E7C338A3559CC730" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_82723F04026CA76799F438A3559C8E9D" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_B77162956A3CBFE0E7C338A3559CC730" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_83E1F4A4E85BB302C8A338A3559CC6C7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_82723F04026CA76799F438A3559C8E9D" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_83E1F4A4E85BB302C8A338A3559CC6C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_E8550B69D6ABF5BDFA5A38A3559C362A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_82723F04026CA76799F438A3559C8E9D" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_E8550B69D6ABF5BDFA5A38A3559C362A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_4EF8BC4D7E8361724AA993582EE9A516" xlink:type="locator" />
    <loc xlink:href="biib-20151231.xsd#biib_FinancialInstrumentsTextualAbstract" xlink:label="loc_biib_FinancialInstrumentsTextualAbstract_FB9A795AA5BF0794AF0A93582EE982EC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_4EF8BC4D7E8361724AA993582EE9A516" xlink:to="loc_biib_FinancialInstrumentsTextualAbstract_FB9A795AA5BF0794AF0A93582EE982EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_A0654D043CA9BBCCFB6193582EE93F68" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FinancialInstrumentsTextualAbstract_FB9A795AA5BF0794AF0A93582EE982EC" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_A0654D043CA9BBCCFB6193582EE93F68" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Overnightreverserepurchaseagreementspercentoftotalassets" xlink:label="loc_biib_Overnightreverserepurchaseagreementspercentoftotalassets_24C36EC46210EE76709693582EE91895" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FinancialInstrumentsTextualAbstract_FB9A795AA5BF0794AF0A93582EE982EC" xlink:to="loc_biib_Overnightreverserepurchaseagreementspercentoftotalassets_24C36EC46210EE76709693582EE91895" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_B54632D1302A69B236B293582EE98EA4" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FinancialInstrumentsTextualAbstract_FB9A795AA5BF0794AF0A93582EE982EC" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_B54632D1302A69B236B293582EE98EA4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_B39FDB53CCC7F03D641638A356F6802A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_01718A016490CF9071EF38A356F6DFC5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_B39FDB53CCC7F03D641638A356F6802A" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_01718A016490CF9071EF38A356F6DFC5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6C47C226576F7437020938A356F6744F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_01718A016490CF9071EF38A356F6DFC5" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6C47C226576F7437020938A356F6744F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_047044B7E1D20A20F63038A356F650DA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6C47C226576F7437020938A356F6744F" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_047044B7E1D20A20F63038A356F650DA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_AEB935940F11C0E90BF838A356F691D4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_047044B7E1D20A20F63038A356F650DA" xlink:to="loc_biib_StrategicInvestmentsMember_AEB935940F11C0E90BF838A356F691D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_BDE54CDFD747302D705F38A356F6A244" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_01718A016490CF9071EF38A356F6DFC5" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_BDE54CDFD747302D705F38A356F6A244" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_10B6954D7E10E83B4BE538A356F6B8A1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_BDE54CDFD747302D705F38A356F6A244" xlink:to="loc_biib_StrategicInvestmentPortfolio_10B6954D7E10E83B4BE538A356F6B8A1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_205521AF271716A9CF8693224C287677" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_A1BBFD7E13EE3B33784393224C28AE50" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_205521AF271716A9CF8693224C287677" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_A1BBFD7E13EE3B33784393224C28AE50" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_8120F952666FD93F1A7193224C2879E0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_205521AF271716A9CF8693224C287677" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_8120F952666FD93F1A7193224C2879E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_004FB68E1322EAC2C03893224C284056" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_205521AF271716A9CF8693224C287677" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_004FB68E1322EAC2C03893224C284056" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_F54D2529A9762E2BAB6493224C28982B" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_205521AF271716A9CF8693224C287677" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_F54D2529A9762E2BAB6493224C28982B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/Guarantees" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GuaranteesAbstract" xlink:label="loc_us-gaap_GuaranteesAbstract_057AC7E20C99DD45FD0738A352164A35" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GuaranteesTextBlock" xlink:label="loc_us-gaap_GuaranteesTextBlock_1FA39F706AFE3990E40138A352164574" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteesAbstract_057AC7E20C99DD45FD0738A352164A35" xlink:to="loc_us-gaap_GuaranteesTextBlock_1FA39F706AFE3990E40138A352164574" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7B73AD0AF76D2F05468B38A3564D4745" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_145A673660996FAA320F38A3564D2AD9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7B73AD0AF76D2F05468B38A3564D4745" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_145A673660996FAA320F38A3564D2AD9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_B639858080BAC02CA76338A3535C0A8E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_6BCB731984D2BCCFD03A38A3535C2029" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B639858080BAC02CA76338A3535C0A8E" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_6BCB731984D2BCCFD03A38A3535C2029" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1471D4BB1A7C87F1021838A3535CF9C7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_6BCB731984D2BCCFD03A38A3535C2029" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1471D4BB1A7C87F1021838A3535CF9C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5F030EA4BE1A7601759A38A3535C796D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1471D4BB1A7C87F1021838A3535CF9C7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5F030EA4BE1A7601759A38A3535C796D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_FD730E58320F97B3154038A3535C59CF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1471D4BB1A7C87F1021838A3535CF9C7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_FD730E58320F97B3154038A3535C59CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_18DE3ED27B2BCC158DDE38A3535CCD9F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1471D4BB1A7C87F1021838A3535CF9C7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_18DE3ED27B2BCC158DDE38A3535CCD9F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_B8379CB2EE878FC46B4C38A3535C1318" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_6BCB731984D2BCCFD03A38A3535C2029" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_B8379CB2EE878FC46B4C38A3535C1318" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_38CBD550C84D00F7F1F838A3535C78B3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_B8379CB2EE878FC46B4C38A3535C1318" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_38CBD550C84D00F7F1F838A3535C78B3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_9221D17A9F54FFE355AA38A3535C3C04" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_38CBD550C84D00F7F1F838A3535C78B3" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_9221D17A9F54FFE355AA38A3535C3C04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_691EC02E4D948D49CE7E38A3535C8588" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_38CBD550C84D00F7F1F838A3535C78B3" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_691EC02E4D948D49CE7E38A3535C8588" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_B1871714E69B944A140C38A3535CC99E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_38CBD550C84D00F7F1F838A3535C78B3" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_B1871714E69B944A140C38A3535CC99E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2E24F8F6D1798AD5408D38A3535C2ADA" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_38CBD550C84D00F7F1F838A3535C78B3" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2E24F8F6D1798AD5408D38A3535C2ADA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_384FD5E7F55CCC660D9938A3535C7280" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_B8379CB2EE878FC46B4C38A3535C1318" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_384FD5E7F55CCC660D9938A3535C7280" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2815B96E2BDACB7C2F6B38A3535CD9D7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_384FD5E7F55CCC660D9938A3535C7280" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2815B96E2BDACB7C2F6B38A3535CD9D7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_89D74B87F20CAE64EE3938A3535D4C6D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_384FD5E7F55CCC660D9938A3535C7280" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_89D74B87F20CAE64EE3938A3535D4C6D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1426DEC074D5E107035D38A3535DDAD2" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_384FD5E7F55CCC660D9938A3535C7280" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1426DEC074D5E107035D38A3535DDAD2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_C0108610C5BD479EAC3538A3535D9C58" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_384FD5E7F55CCC660D9938A3535C7280" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_C0108610C5BD479EAC3538A3535D9C58" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3CD8383F628292B84BB138A3535D71D9" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_6BCB731984D2BCCFD03A38A3535C2029" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3CD8383F628292B84BB138A3535D71D9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_D6EEFCA1FF45B4649DA393582E3E2E82" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D6EEFCA1FF45B4649DA393582E3E2E82" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_018B74EFB64F37D4459493582E3E18A5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_018B74EFB64F37D4459493582E3E18A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_7BDBBFC108ADE200428F93582E3EC1B6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_7BDBBFC108ADE200428F93582E3EC1B6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_23CD29C92C42AB11E7E293582E3E553F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_23CD29C92C42AB11E7E293582E3E553F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_37B7387852F12BF33DB093582E3E9B02" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_37B7387852F12BF33DB093582E3E9B02" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7D0419C1BBA276180BFF93582E3E7C2C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7D0419C1BBA276180BFF93582E3E7C2C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3B8BAE78F21F8F9E0B0393582E3FDD3D" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_3B8BAE78F21F8F9E0B0393582E3FDD3D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5548D027B1E5A76B388593582E3F98C1" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5548D027B1E5A76B388593582E3F98C1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_42B59245F83957EEB15993582E3F411F" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_42B59245F83957EEB15993582E3F411F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9E53C289CD853F1FB96093582E3FE98D" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9E53C289CD853F1FB96093582E3FE98D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:label="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_1CD75B86169DA9CD7DD393582E3F2D89" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B" xlink:to="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_1CD75B86169DA9CD7DD393582E3F2D89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_082127298C323BC8258C93582E3F1CC8" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_CCEBCB5F1E93E36603ED93582E3E5D2B" xlink:to="loc_us-gaap_DeferredTaxLiabilities_082127298C323BC8258C93582E3F1CC8" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_AA29D32EC4464B4F6CCB93582E39136E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_95CBA1430F0AC8E35D2093582E399BC1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_AA29D32EC4464B4F6CCB93582E39136E" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_95CBA1430F0AC8E35D2093582E399BC1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_22A1F0B2278A60B4DA3D93582E39D1EC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_95CBA1430F0AC8E35D2093582E399BC1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_22A1F0B2278A60B4DA3D93582E39D1EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_62E4B0D58F073D1CC5EF93582E39D96D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_95CBA1430F0AC8E35D2093582E399BC1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_62E4B0D58F073D1CC5EF93582E39D96D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_04014512EAEFD515F57A93582E399A9E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_95CBA1430F0AC8E35D2093582E399BC1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_04014512EAEFD515F57A93582E399A9E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_292843187CE435D8391C93582E39D871" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_95CBA1430F0AC8E35D2093582E399BC1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_292843187CE435D8391C93582E39D871" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_632606BF7532872A26D693582E39599A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_95CBA1430F0AC8E35D2093582E399BC1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_632606BF7532872A26D693582E39599A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_63AC2ABC460E7DCBCA7F93582E3A71D2" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_95CBA1430F0AC8E35D2093582E399BC1" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_63AC2ABC460E7DCBCA7F93582E3A71D2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_EE3B56C609C29AEC727093582E3AF6CF" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_95CBA1430F0AC8E35D2093582E399BC1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_EE3B56C609C29AEC727093582E3AF6CF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EffectiveIncomeTaxRateReconciliationContingentConsideration" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_16935FD513FCE8AEE0A093582E3AC82A" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_95CBA1430F0AC8E35D2093582E399BC1" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration_16935FD513FCE8AEE0A093582E3AC82A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_50C70A03FA880DD8054793582E3A31DE" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_95CBA1430F0AC8E35D2093582E399BC1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_50C70A03FA880DD8054793582E3A31DE" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2BBEE5D5EEC54AD1AE0038A355141E69" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_85316B7F84AA0A1BF6BC38A35514016F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2BBEE5D5EEC54AD1AE0038A355141E69" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_85316B7F84AA0A1BF6BC38A35514016F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_41D0666A9491239B319C38A355140A61" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_85316B7F84AA0A1BF6BC38A35514016F" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_41D0666A9491239B319C38A355140A61" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_EF2AFDB55DB70FC3832B38A35515B62F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_85316B7F84AA0A1BF6BC38A35514016F" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_EF2AFDB55DB70FC3832B38A35515B62F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_93CEE4CE358F6FCFBA7738A35515B05C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_85316B7F84AA0A1BF6BC38A35514016F" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_93CEE4CE358F6FCFBA7738A35515B05C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6ADB5166546C0EDA733138A35515522B" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_85316B7F84AA0A1BF6BC38A35514016F" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6ADB5166546C0EDA733138A35515522B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_A00E62265025C45EEC8D38A35515FF62" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_85316B7F84AA0A1BF6BC38A35514016F" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_A00E62265025C45EEC8D38A35515FF62" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_95C1C0F2BD67988E9B8638A35515DBC6" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_85316B7F84AA0A1BF6BC38A35514016F" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_95C1C0F2BD67988E9B8638A35515DBC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_58C019F2AC5B2AD0661438A3551511BD" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_85316B7F84AA0A1BF6BC38A35514016F" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_58C019F2AC5B2AD0661438A3551511BD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_AFD99AC8151C729FF87693582E2E17DA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_AFD99AC8151C729FF87693582E2E17DA" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_30208D169A56F678697293582E2E43A1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219" xlink:to="loc_us-gaap_ProductOrServiceAxis_30208D169A56F678697293582E2E43A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_3CF9F316829008BD64D393582E2EAB17" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_30208D169A56F678697293582E2E43A1" xlink:to="loc_us-gaap_ProductsAndServicesDomain_3CF9F316829008BD64D393582E2EAB17" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_FE71A339EB72CED89E6493582E2FC7D1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3CF9F316829008BD64D393582E2EAB17" xlink:to="loc_biib_ZINBRYTAMember_FE71A339EB72CED89E6493582E2FC7D1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_A5B08BDDEE98876A464C93582E2F90CF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_A5B08BDDEE98876A464C93582E2F90CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_575ED5D5599A1FCF6F9793582E2FFE6B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_A5B08BDDEE98876A464C93582E2F90CF" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_575ED5D5599A1FCF6F9793582E2FFE6B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="loc_us-gaap_GeneralBusinessMember_458EA3DD02696E6BC4A593582E2F9887" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_575ED5D5599A1FCF6F9793582E2FFE6B" xlink:to="loc_us-gaap_GeneralBusinessMember_458EA3DD02696E6BC4A593582E2F9887" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_0B1F15C996EB5CAA454A93582E2F0700" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_575ED5D5599A1FCF6F9793582E2FFE6B" xlink:to="loc_us-gaap_ResearchMember_0B1F15C996EB5CAA454A93582E2F0700" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_E2C9DF5FDC5648AEF1D993582E2FED5F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_E2C9DF5FDC5648AEF1D993582E2FED5F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_BCDACC1F98F82E9B295093582E2F95DB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_E2C9DF5FDC5648AEF1D993582E2FED5F" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_BCDACC1F98F82E9B295093582E2F95DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_9DEDB3D54181BB5FE67493582E2F70DE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_BCDACC1F98F82E9B295093582E2F95DB" xlink:to="loc_us-gaap_DomesticCountryMember_9DEDB3D54181BB5FE67493582E2F70DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_6CD246E861244F85738493582E2F83F8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_BCDACC1F98F82E9B295093582E2F95DB" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_6CD246E861244F85738493582E2F83F8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_DDEB699653B5CD04C67F93582E2F085C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_BCDACC1F98F82E9B295093582E2F95DB" xlink:to="loc_us-gaap_ForeignCountryMember_DDEB699653B5CD04C67F93582E2F085C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_AF2ABAA69DA13ADA5B8E93582E2FA19E" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219" xlink:to="loc_us-gaap_RangeAxis_AF2ABAA69DA13ADA5B8E93582E2FA19E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_47E465FC7CF20C97943793582E2F4D39" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_AF2ABAA69DA13ADA5B8E93582E2FA19E" xlink:to="loc_us-gaap_RangeMember_47E465FC7CF20C97943793582E2F4D39" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_6EE46D63C2C0CC8CD46A93582E2F9A75" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_47E465FC7CF20C97943793582E2F4D39" xlink:to="loc_us-gaap_MinimumMember_6EE46D63C2C0CC8CD46A93582E2F9A75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_44B069374FAB56861C8393582E2F21C7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_47E465FC7CF20C97943793582E2F4D39" xlink:to="loc_us-gaap_MaximumMember_44B069374FAB56861C8393582E2F21C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_B2C2EAED4AE128D95DD093582E2E2219" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Deferredtaxassetreclassification" xlink:label="loc_biib_Deferredtaxassetreclassification_71964BE76E996AC4AD4093582E2FA8D3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_biib_Deferredtaxassetreclassification_71964BE76E996AC4AD4093582E2FA8D3" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Deferredtaxliabilityreclassification" xlink:label="loc_biib_Deferredtaxliabilityreclassification_6A5C72435CE5DD42FC7B93582E3017EC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_biib_Deferredtaxliabilityreclassification_6A5C72435CE5DD42FC7B93582E3017EC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Totaldeferredchargesandprepaidtaxes" xlink:label="loc_biib_Totaldeferredchargesandprepaidtaxes_EA60536622BE4B7406B293582E30371D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_biib_Totaldeferredchargesandprepaidtaxes_EA60536622BE4B7406B293582E30371D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DeferredTaxLiabilityRecognized" xlink:label="loc_biib_DeferredTaxLiabilityRecognized_6B65C37FCB1267FE2A6193582E30DC4E" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_biib_DeferredTaxLiabilityRecognized_6B65C37FCB1267FE2A6193582E30DC4E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_6860946B2A527EB06C4C93582E30FD61" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_us-gaap_DeferredTaxLiabilities_6860946B2A527EB06C4C93582E30FD61" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NetBenefitForPreviouslyUnrecognizedPosition" xlink:label="loc_biib_NetBenefitForPreviouslyUnrecognizedPosition_DD80BE9FFC638ED526F693582E3022D2" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_biib_NetBenefitForPreviouslyUnrecognizedPosition_DD80BE9FFC638ED526F693582E3022D2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2BBAB2DD33D107A563DD93582E305729" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2BBAB2DD33D107A563DD93582E305729" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_9A6C248890E77AD4A08D93582E30F101" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_9A6C248890E77AD4A08D93582E30F101" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75D824E7D34A092D851E93582E306473" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75D824E7D34A092D851E93582E306473" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries" xlink:label="loc_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_5E0956CDF5D7981A279393582E307943" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries_5E0956CDF5D7981A279393582E307943" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ExpenseForNonIncomeBasedStateTaxes" xlink:label="loc_biib_ExpenseForNonIncomeBasedStateTaxes_95D1E705EE20C1C39CE893582E3018DA" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_biib_ExpenseForNonIncomeBasedStateTaxes_95D1E705EE20C1C39CE893582E3018DA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices" xlink:label="loc_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_F872C17DCA650D15FD5493582E30CEE8" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_F872C17DCA650D15FD5493582E30CEE8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_3DC2598769BB2AB1F3C093582E3006B8" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_BDD0A2C79602BB59D0C193582E2FC505" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_3DC2598769BB2AB1F3C093582E3006B8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_IncomeTaxesTextualAbstract" xlink:label="loc_biib_IncomeTaxesTextualAbstract_DDF5556B851A446A52B893582E3083F0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_AFD99AC8151C729FF87693582E2E17DA" xlink:to="loc_biib_IncomeTaxesTextualAbstract_DDF5556B851A446A52B893582E3083F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_2961CF035B3E9B48377193582E305ECB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_DDF5556B851A446A52B893582E3083F0" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_2961CF035B3E9B48377193582E305ECB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_BEB80068861D98EA92FD93582E30E457" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_DDF5556B851A446A52B893582E3083F0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_BEB80068861D98EA92FD93582E30E457" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_07221CB8A51997043B2993582E3041C1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_DDF5556B851A446A52B893582E3083F0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_07221CB8A51997043B2993582E3041C1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_F196ADB78AB94A78DB2F93582E305441" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_DDF5556B851A446A52B893582E3083F0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_F196ADB78AB94A78DB2F93582E305441" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_BF89ED8191646BB680DF93582E30760B" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_DDF5556B851A446A52B893582E3083F0" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_BF89ED8191646BB680DF93582E30760B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2C970D1D31F10C9CF8FF38A3532A199B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_34187F5CBC964022305F38A3532ADDB5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2C970D1D31F10C9CF8FF38A3532A199B" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_34187F5CBC964022305F38A3532ADDB5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7BC52D96E8D8FB975A0C38A3532ABB50" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2C970D1D31F10C9CF8FF38A3532A199B" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7BC52D96E8D8FB975A0C38A3532ABB50" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E50EBA0223105569169938A3532AC416" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2C970D1D31F10C9CF8FF38A3532A199B" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E50EBA0223105569169938A3532AC416" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_E50D04939079CE96C4A438A3532A27D9" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2C970D1D31F10C9CF8FF38A3532A199B" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_E50D04939079CE96C4A438A3532A27D9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_DA74DD498B88824EC00938A351489FC1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4A42491BA05A7C047DCF38A35149BD0E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_DA74DD498B88824EC00938A351489FC1" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4A42491BA05A7C047DCF38A35149BD0E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_F9D81721EF46DA65C9C838A351EA10E1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5433ADC4A08143DA0D6138A351EA686B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_F9D81721EF46DA65C9C838A351EA10E1" xlink:to="loc_us-gaap_DebtInstrumentTable_5433ADC4A08143DA0D6138A351EA686B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B373CDA1FBCD5A8B70EF38A351EAF208" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5433ADC4A08143DA0D6138A351EA686B" xlink:to="loc_us-gaap_DebtInstrumentAxis_B373CDA1FBCD5A8B70EF38A351EAF208" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_808CADC0DADEE4DCB89538A351EAC0D6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_B373CDA1FBCD5A8B70EF38A351EAF208" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_808CADC0DADEE4DCB89538A351EAC0D6" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_0085337D8828E67DD0B738A351EB7C2C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_808CADC0DADEE4DCB89538A351EAC0D6" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_0085337D8828E67DD0B738A351EB7C2C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_45FC4FB67ECBF578E4D838A351EB8A22" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_808CADC0DADEE4DCB89538A351EAC0D6" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_45FC4FB67ECBF578E4D838A351EB8A22" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D55CF4FD3D9015E6E4A938A351EBBEEF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_808CADC0DADEE4DCB89538A351EAC0D6" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_D55CF4FD3D9015E6E4A938A351EBBEEF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_3824910742301AA8119A38A351EB4C4A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_808CADC0DADEE4DCB89538A351EAC0D6" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_3824910742301AA8119A38A351EB4C4A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_6311357ECD8FFF8D30F238A351EBDDD6" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_808CADC0DADEE4DCB89538A351EAC0D6" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_6311357ECD8FFF8D30F238A351EBDDD6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_99BEF29C1FC75DF8F48C38A351EB2C1E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5433ADC4A08143DA0D6138A351EA686B" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_99BEF29C1FC75DF8F48C38A351EB2C1E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_911BE02EA1DEC33112F438A351EBC542" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_99BEF29C1FC75DF8F48C38A351EB2C1E" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_911BE02EA1DEC33112F438A351EBC542" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_A604064A0E08FC5D609138A351EB6099" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_911BE02EA1DEC33112F438A351EBC542" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_A604064A0E08FC5D609138A351EB6099" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3057976B1A522670D18C38A351EB09DD" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5433ADC4A08143DA0D6138A351EA686B" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3057976B1A522670D18C38A351EB09DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtCurrentAbstract_FCE66CB076C27EB71CED38A351EB3587" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3057976B1A522670D18C38A351EB09DD" xlink:to="loc_us-gaap_LongTermDebtCurrentAbstract_FCE66CB076C27EB71CED38A351EB3587" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_22F8762A23417647460B38A351EB50BE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_FCE66CB076C27EB71CED38A351EB3587" xlink:to="loc_us-gaap_NotesPayableCurrent_22F8762A23417647460B38A351EB50BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_FCE98FB685D4F612AE8B38A351EBA7EF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_FCE66CB076C27EB71CED38A351EB3587" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_FCE98FB685D4F612AE8B38A351EBA7EF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_19E5A1ACA121766BC13B38A351ECDBFA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_FCE66CB076C27EB71CED38A351EB3587" xlink:to="loc_us-gaap_DebtCurrent_19E5A1ACA121766BC13B38A351ECDBFA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_3B1F0C555BE913E113CE38A351EC4DB5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3057976B1A522670D18C38A351EB09DD" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_3B1F0C555BE913E113CE38A351EC4DB5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_A0BD62888ED5C8C9B0F038A351ECFFA1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_3B1F0C555BE913E113CE38A351EC4DB5" xlink:to="loc_us-gaap_LongTermNotesPayable_A0BD62888ED5C8C9B0F038A351ECFFA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_26C4BB6C887D4582936A38A351ECFEC7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_3B1F0C555BE913E113CE38A351EC4DB5" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_26C4BB6C887D4582936A38A351ECFEC7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_8C310E52827A95BA75AE38A351EC474D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_3B1F0C555BE913E113CE38A351EC4DB5" xlink:to="loc_us-gaap_LongTermDebt_8C310E52827A95BA75AE38A351EC474D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_89929CC8C2C367CE825838A35109EB7C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_4B2E274F4AF5243FE1A538A3510905A2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_89929CC8C2C367CE825838A35109EB7C" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_4B2E274F4AF5243FE1A538A3510905A2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_E8B53D895249DA0EDA0C38A35109A549" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_4B2E274F4AF5243FE1A538A3510905A2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_E8B53D895249DA0EDA0C38A35109A549" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D8991833D6408D99041D38A351092E96" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_4B2E274F4AF5243FE1A538A3510905A2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_D8991833D6408D99041D38A351092E96" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_E882102FA59C9D3FA2EA38A3510AB87F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_4B2E274F4AF5243FE1A538A3510905A2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_E882102FA59C9D3FA2EA38A3510AB87F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_46DD3E297225D26EDD7538A3510A7181" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_4B2E274F4AF5243FE1A538A3510905A2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_46DD3E297225D26EDD7538A3510A7181" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_9585C127DF209CBF318C38A3510A13F5" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_4B2E274F4AF5243FE1A538A3510905A2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_9585C127DF209CBF318C38A3510A13F5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3283CF2DFED37B1E42F538A3510AE4C4" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_4B2E274F4AF5243FE1A538A3510905A2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3283CF2DFED37B1E42F538A3510AE4C4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_A129968542F722367FB238A3510A6D54" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_4B2E274F4AF5243FE1A538A3510905A2" xlink:to="loc_us-gaap_LongTermNotesPayable_A129968542F722367FB238A3510A6D54" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6D2C0AF188D6A58DFDBB93D5CA1E8E67" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6D2C0AF188D6A58DFDBB93D5CA1E8E67" xlink:to="loc_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0589111E6C67C78E40C993D5CA1FA6E3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0589111E6C67C78E40C993D5CA1FA6E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_971902D456D20355A82D93D5CA1F7ED8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0589111E6C67C78E40C993D5CA1FA6E3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_971902D456D20355A82D93D5CA1F7ED8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_89F59F815B7C310F4BEF93D5CA1F2C71" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_971902D456D20355A82D93D5CA1F7ED8" xlink:to="loc_biib_EisaiMember_89F59F815B7C310F4BEF93D5CA1F2C71" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_EFBC1D8220BAA09FD98B93D5CA1F7987" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_EFBC1D8220BAA09FD98B93D5CA1F7987" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_85DABEB888190B9427AD93D5CA1F67E7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_EFBC1D8220BAA09FD98B93D5CA1F7987" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_85DABEB888190B9427AD93D5CA1F67E7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_D4288B47E7D0BA66F49693D5CA1F6CC5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_85DABEB888190B9427AD93D5CA1F67E7" xlink:to="loc_us-gaap_InterestRateSwapMember_D4288B47E7D0BA66F49693D5CA1F6CC5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_860325E6506CC6C3943A93D5CA1FB26F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D" xlink:to="loc_us-gaap_DebtInstrumentAxis_860325E6506CC6C3943A93D5CA1FB26F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_860325E6506CC6C3943A93D5CA1FB26F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_59B31C7C9A3A736B503F93D5CA1F47BF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_59B31C7C9A3A736B503F93D5CA1F47BF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8AFD80790EA34399A7BA93D5CA1FFD4F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8AFD80790EA34399A7BA93D5CA1FFD4F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_767C61E63B4356C4011693D5CA1F163E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_767C61E63B4356C4011693D5CA1F163E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_DEA3CD82BFBCDA2F38BC93D5CA1F67F6" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_DEA3CD82BFBCDA2F38BC93D5CA1F67F6" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_697EC9037B3D3D886D3693D5CA1F5B18" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5AC65E919D0FF2004BFA93D5CA1FFBD3" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_697EC9037B3D3D886D3693D5CA1F5B18" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_FADA9BCA25F556DE271F93D5CA1FCF31" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_FADA9BCA25F556DE271F93D5CA1FCF31" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9493788F303D7B1E086E93D5CA1F73A4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_FADA9BCA25F556DE271F93D5CA1FCF31" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9493788F303D7B1E086E93D5CA1F73A4" xlink:type="arc" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9493788F303D7B1E086E93D5CA1F73A4" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_697EC9037B3D3D886D3693D5CA1F5B18" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_206CD114F4E55150E50993D5CA1F8118" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9493788F303D7B1E086E93D5CA1F73A4" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_206CD114F4E55150E50993D5CA1F8118" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_EE972E59E1273D03648D93D5CA1E2D2D" xlink:to="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_25F082A9E4EAC6D4D61293D5CA204531" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_25F082A9E4EAC6D4D61293D5CA204531" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_907BBD8298F21D66CE4C93D5CA20B3BB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_907BBD8298F21D66CE4C93D5CA20B3BB" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_CCD183A70709537A1B9D93D5CA20E814" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_CCD183A70709537A1B9D93D5CA20E814" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_12BE5EA91E95F29E8E3993D5CA202D58" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_12BE5EA91E95F29E8E3993D5CA202D58" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E11A275EB3E843B967F493D5CA202D6C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_E11A275EB3E843B967F493D5CA202D6C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_us-gaap_DebtIssuanceCosts_05703242317BF7C5967593D5CA203251" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_DebtIssuanceCosts_05703242317BF7C5967593D5CA203251" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_CF427481D02137E93E6D93D5CA202BC3" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_CF427481D02137E93E6D93D5CA202BC3" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfRedemptionOfNotes" xlink:label="loc_biib_PercentageOfRedemptionOfNotes_062780907191105FBFFA93D5CA20127C" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_biib_PercentageOfRedemptionOfNotes_062780907191105FBFFA93D5CA20127C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_IncreasedCarryingAmountOfSeniorNotes" xlink:label="loc_biib_IncreasedCarryingAmountOfSeniorNotes_5A186CE6CBA86C55210093D5CA205B87" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_biib_IncreasedCarryingAmountOfSeniorNotes_5A186CE6CBA86C55210093D5CA205B87" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DebtInstrumentUnamortizedInterestOnDebt" xlink:label="loc_biib_DebtInstrumentUnamortizedInterestOnDebt_86E476B5EBA1CC28D41B93D5CA209F6F" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_biib_DebtInstrumentUnamortizedInterestOnDebt_86E476B5EBA1CC28D41B93D5CA209F6F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_FCAD46566DF217E0C03393D5CA2042CC" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_LongTermNotesPayable_FCAD46566DF217E0C03393D5CA2042CC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ParValueOfNotesPayable" xlink:label="loc_biib_ParValueOfNotesPayable_2CF1812C49CEF134DB3593D5CA2051E8" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_biib_ParValueOfNotesPayable_2CF1812C49CEF134DB3593D5CA2051E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_C5DC1A416C14521A7A8A93D5CA2078C9" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_C5DC1A416C14521A7A8A93D5CA2078C9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_C79F9AE510112EA1414793D5CA20FF9F" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_C79F9AE510112EA1414793D5CA20FF9F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_5D983F76332D71EF5F3B93D5CA207AC7" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_5D983F76332D71EF5F3B93D5CA207AC7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_17EE439A728C6C5E108793D5CA205A26" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_BED839B79D6DD366DEC793D5CA206518" xlink:to="loc_us-gaap_CapitalLeaseObligations_17EE439A728C6C5E108793D5CA205A26" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5DFEBB826A9105720C7638A35323E187" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_0748F7758406A3AA4BC538A35323C0B4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5DFEBB826A9105720C7638A35323E187" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_0748F7758406A3AA4BC538A35323C0B4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ED7EDDC26192065C824E38A35323994E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5DFEBB826A9105720C7638A35323E187" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ED7EDDC26192065C824E38A35323994E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_65CBDDF5E8B227FC797C38A35229D0EE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_951E4458524A97CA750D38A3522922DF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_65CBDDF5E8B227FC797C38A35229D0EE" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_951E4458524A97CA750D38A3522922DF" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7202C44C677B1A03A34D93224CD4E5C0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7202C44C677B1A03A34D93224CD4E5C0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_35BF1C14C20E9719E31393224CD481C4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_35BF1C14C20E9719E31393224CD481C4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0F3C0CCD51380D04CA1193224CD48751" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_35BF1C14C20E9719E31393224CD481C4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0F3C0CCD51380D04CA1193224CD48751" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_78DBEEC366214FD9AF0A93224CD44D99" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0F3C0CCD51380D04CA1193224CD48751" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_78DBEEC366214FD9AF0A93224CD44D99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_1CB2691B3700402EF03693224CD4597E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:to="loc_us-gaap_ProductOrServiceAxis_1CB2691B3700402EF03693224CD4597E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_E0C8DEEBB7E02923633193224CD493EF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_1CB2691B3700402EF03693224CD4597E" xlink:to="loc_us-gaap_ProductsAndServicesDomain_E0C8DEEBB7E02923633193224CD493EF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_967F1C1E8B6DE26A06AB93224CD58816" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E0C8DEEBB7E02923633193224CD493EF" xlink:to="loc_biib_AVONEXMember_967F1C1E8B6DE26A06AB93224CD58816" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_3C18AE78F81848CE4FF693224CD5BB9D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E0C8DEEBB7E02923633193224CD493EF" xlink:to="loc_biib_TysabriProductMember_3C18AE78F81848CE4FF693224CD5BB9D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_631D0E0BAEC2B363B14693224CD5D7F9" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_631D0E0BAEC2B363B14693224CD5D7F9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBEA22071E45F6D0A56993224CD50159" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_631D0E0BAEC2B363B14693224CD5D7F9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBEA22071E45F6D0A56993224CD50159" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_EE3FBB42D063C2CAF29193224CD53EDC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBEA22071E45F6D0A56993224CD50159" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_EE3FBB42D063C2CAF29193224CD53EDC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_F579532BF40DE32380B693224CDADD1B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_EBEA22071E45F6D0A56993224CD50159" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_F579532BF40DE32380B693224CDADD1B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A3EF29F06427E7FFB3F093224CDAA2AC" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A3EF29F06427E7FFB3F093224CDAA2AC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448862C0974759741B993224CDA8DC8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A3EF29F06427E7FFB3F093224CDAA2AC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448862C0974759741B993224CDA8DC8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_029BDACC881DC6EEA47093224CDAD84A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448862C0974759741B993224CDA8DC8" xlink:to="loc_biib_OutLicensedPatentsMember_029BDACC881DC6EEA47093224CDAD84A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_6253A9E80E7FC0196DD993224CDAB87C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448862C0974759741B993224CDA8DC8" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_6253A9E80E7FC0196DD993224CDAB87C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_541EEB822EE2F808604893224CDA2BFB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6448862C0974759741B993224CDA8DC8" xlink:to="loc_biib_InLicensedPatentsMember_541EEB822EE2F808604893224CDA2BFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_F484C7AB99B3F86138D593224CDA6C84" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:to="loc_us-gaap_RangeAxis_F484C7AB99B3F86138D593224CDA6C84" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_73C1DCED6391BC31BBF893224CDBF21B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_F484C7AB99B3F86138D593224CDA6C84" xlink:to="loc_us-gaap_RangeMember_73C1DCED6391BC31BBF893224CDBF21B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_C2B1ED635F518B2F805493224CDB7841" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_73C1DCED6391BC31BBF893224CDBF21B" xlink:to="loc_us-gaap_MinimumMember_C2B1ED635F518B2F805493224CDB7841" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_EC541F2B77398883C1B993224CDB19D0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_73C1DCED6391BC31BBF893224CDBF21B" xlink:to="loc_us-gaap_MaximumMember_EC541F2B77398883C1B993224CDB19D0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4F9063EB5D934C02A9FA93224CD4DC78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_550A17DC156B1EA5351493224CDB34A3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:to="loc_us-gaap_Goodwill_550A17DC156B1EA5351493224CDB34A3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6AAA18418CECF4AC42FE93224CDB60C5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6AAA18418CECF4AC42FE93224CDB60C5" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EE6B94DAA428326B583493224CDB4832" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_EE6B94DAA428326B583493224CDB4832" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_67E1D80199CD61F45DDE93224CDBD485" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_67E1D80199CD61F45DDE93224CDBD485" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_580BAF5F95D2553B699E93224CDB2C1D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_580BAF5F95D2553B699E93224CDB2C1D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FE91F4D170521E3001BE93224CDB46F5" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_FE91F4D170521E3001BE93224CDB46F5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_62401F5858547C75BE6993224CDBEEA6" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_62401F5858547C75BE6993224CDBEEA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7FDBD5F4A46A832C49B293224CDB6FBC" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7FDBD5F4A46A832C49B293224CDB6FBC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9447849594F2FEFEB52A93224CDB0E46" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_22C90D6029C542C0215C93224CDB4ABD" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9447849594F2FEFEB52A93224CDB0E46" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" xlink:label="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:to="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C23F119A34CE854FFD0893224CDB2BEB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C23F119A34CE854FFD0893224CDB2BEB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0BF8322266308215EE8593224CDBDCC2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0BF8322266308215EE8593224CDBDCC2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3803DBFEB22501377C4C93224CDC7239" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3803DBFEB22501377C4C93224CDC7239" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_39EF1AE3183A43A1795293224CDCB194" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_39EF1AE3183A43A1795293224CDCB194" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_D4C188C6827958A0554693224CDC1327" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_D4C188C6827958A0554693224CDC1327" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Finitelivedintangibleassetsfutureamortization" xlink:label="loc_biib_Finitelivedintangibleassetsfutureamortization_1CE2EFA9D1B450CBAFA793224CDC9A14" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_E0CFE1D677D4628385DD93224CDBCDA5" xlink:to="loc_biib_Finitelivedintangibleassetsfutureamortization_1CE2EFA9D1B450CBAFA793224CDC9A14" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_D901030EFCADAFC40D1F93224CDC563F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_D901030EFCADAFC40D1F93224CDC563F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9F7308450AECCEBFC24C93224CDCB2C2" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9F7308450AECCEBFC24C93224CDCB2C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_73600D0315A83E03C4F193224CDC9F24" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_73600D0315A83E03C4F193224CDC9F24" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_DDDE86A3DE7CC7DAD0F493224CDCFC0D" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DD0FB3BAB9D03498142F93224CDBA5FA" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_DDDE86A3DE7CC7DAD0F493224CDCFC0D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3B974F133C2D2316D52D93224CAB63E2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5DFEA886036FE17FC47193224CAB9C9B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3B974F133C2D2316D52D93224CAB63E2" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5DFEA886036FE17FC47193224CAB9C9B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6137E3E4E4C5197F9D9693224CAB9CF7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5DFEA886036FE17FC47193224CAB9C9B" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6137E3E4E4C5197F9D9693224CAB9CF7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0DB72D01F24E9E1496A93224CAB8541" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6137E3E4E4C5197F9D9693224CAB9CF7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0DB72D01F24E9E1496A93224CAB8541" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_17F00435A67785A555ED93224CAC203F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0DB72D01F24E9E1496A93224CAB8541" xlink:to="loc_biib_FumapharmAgMember_17F00435A67785A555ED93224CAC203F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_3A2855E2A30F57572D5893224CAC2502" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F0DB72D01F24E9E1496A93224CAB8541" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_3A2855E2A30F57572D5893224CAC2502" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_F625A013400BE92F078393224CAC107E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5DFEA886036FE17FC47193224CAB9C9B" xlink:to="loc_us-gaap_ProductOrServiceAxis_F625A013400BE92F078393224CAC107E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_2BE34A7DEA59CAA7FE5193224CAC1CC9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_F625A013400BE92F078393224CAC107E" xlink:to="loc_us-gaap_ProductsAndServicesDomain_2BE34A7DEA59CAA7FE5193224CAC1CC9" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_362DBCE9D8CB4B86AB0493224CAC2725" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_2BE34A7DEA59CAA7FE5193224CAC1CC9" xlink:to="loc_biib_TecfideraMember_362DBCE9D8CB4B86AB0493224CAC2725" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_6937FB604D575D7DA65693224CACA0C2" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5DFEA886036FE17FC47193224CAB9C9B" xlink:to="loc_us-gaap_GoodwillLineItems_6937FB604D575D7DA65693224CACA0C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_230C835D6A19260E000293224CAC7E07" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_6937FB604D575D7DA65693224CACA0C2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_230C835D6A19260E000293224CAC7E07" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_71B1D94AC2E8E3844CAF93224CB11877" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_6937FB604D575D7DA65693224CACA0C2" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_71B1D94AC2E8E3844CAF93224CB11877" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_4A363181A0D3DCAAF89B93224CB1D4F8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3B974F133C2D2316D52D93224CAB63E2" xlink:to="loc_us-gaap_GoodwillRollForward_4A363181A0D3DCAAF89B93224CB1D4F8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_8F41510ECF3EBB1A711D93224CB12E14" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_4A363181A0D3DCAAF89B93224CB1D4F8" xlink:to="loc_us-gaap_Goodwill_8F41510ECF3EBB1A711D93224CB12E14" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_78339B434249F34814BA93224CB19E92" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_4A363181A0D3DCAAF89B93224CB1D4F8" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_78339B434249F34814BA93224CB19E92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillOtherChanges" xlink:label="loc_us-gaap_GoodwillOtherChanges_7904C7F3D7BD07C4415393224CB11FF5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_4A363181A0D3DCAAF89B93224CB1D4F8" xlink:to="loc_us-gaap_GoodwillOtherChanges_7904C7F3D7BD07C4415393224CB11FF5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_D17956BB60917D52180E93224CB1F2B5" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_4A363181A0D3DCAAF89B93224CB1D4F8" xlink:to="loc_us-gaap_Goodwill_D17956BB60917D52180E93224CB1F2B5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_CA9E6BBC4214D566D13238A351F133C4" xlink:type="locator" />
    <loc xlink:href="biib-20151231.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_E2E05ADBFD9D943BC04C38A351F1D517" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_CA9E6BBC4214D566D13238A351F133C4" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_E2E05ADBFD9D943BC04C38A351F1D517" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_A7007905ECD08E3A3B7638A351F12408" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_CA9E6BBC4214D566D13238A351F133C4" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_A7007905ECD08E3A3B7638A351F12408" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_E6E695B0EFDB5FE2B74C38A351F1F603" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_CA9E6BBC4214D566D13238A351F133C4" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_E6E695B0EFDB5FE2B74C38A351F1F603" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_748FEEFA7283427BCD2B38A35716EC38" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_F03D6EE68A08BF31C35A38A35716C2EB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_748FEEFA7283427BCD2B38A35716EC38" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_F03D6EE68A08BF31C35A38A35716C2EB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_346ED35A627C7073473638A3549F4021" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_DB67E59AA88314167F1938A3549F74B9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_346ED35A627C7073473638A3549F4021" xlink:to="loc_us-gaap_InventoryNetAbstract_DB67E59AA88314167F1938A3549F74B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_13CB605F5C1F398D87F738A3549F7F26" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_DB67E59AA88314167F1938A3549F74B9" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_13CB605F5C1F398D87F738A3549F7F26" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0D723282EE03CD352C5E38A3549FBAA4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_DB67E59AA88314167F1938A3549F74B9" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0D723282EE03CD352C5E38A3549FBAA4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_06F483F5DC2966864D3638A3549F6568" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_DB67E59AA88314167F1938A3549F74B9" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_06F483F5DC2966864D3638A3549F6568" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_87A8ECAD4E5FE7FE83FC38A3549FC45F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_DB67E59AA88314167F1938A3549F74B9" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_87A8ECAD4E5FE7FE83FC38A3549FC45F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_B75DA26F7B52FC1C1CD338A354A0F2B7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_346ED35A627C7073473638A3549F4021" xlink:to="loc_us-gaap_InventoryNet_B75DA26F7B52FC1C1CD338A354A0F2B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_DA371DDE556D6381F35538A354A04BF3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_346ED35A627C7073473638A3549F4021" xlink:to="loc_us-gaap_InventoryNoncurrent_DA371DDE556D6381F35538A354A04BF3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2406AD47B03074F33B8093224CF8AD9D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_63832FB8ECD162BE35FB93224CFDA2AD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2406AD47B03074F33B8093224CF8AD9D" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_63832FB8ECD162BE35FB93224CFDA2AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_BDDBD00F820312A6FEAB93224CFE1142" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_63832FB8ECD162BE35FB93224CFDA2AD" xlink:to="loc_us-gaap_ProductOrServiceAxis_BDDBD00F820312A6FEAB93224CFE1142" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_9260D1A09B45C728FDEB93224CFED462" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_BDDBD00F820312A6FEAB93224CFE1142" xlink:to="loc_us-gaap_ProductsAndServicesDomain_9260D1A09B45C728FDEB93224CFED462" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_51B9B2FDC7A334F8F90093224CFE83EE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9260D1A09B45C728FDEB93224CFED462" xlink:to="loc_biib_ZINBRYTAMember_51B9B2FDC7A334F8F90093224CFE83EE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_F1CDA2889F89AFDEA4F39348C760D985" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9260D1A09B45C728FDEB93224CFED462" xlink:to="loc_biib_BENEPALIMember_F1CDA2889F89AFDEA4F39348C760D985" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_7ED2C1D896193DA9B4DE9349E8DD90CE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9260D1A09B45C728FDEB93224CFED462" xlink:to="loc_biib_FLIXABIMember_7ED2C1D896193DA9B4DE9349E8DD90CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_A319C20CA67DB99B8C0F93224CFEEAC5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_63832FB8ECD162BE35FB93224CFDA2AD" xlink:to="loc_us-gaap_InventoryLineItems_A319C20CA67DB99B8C0F93224CFEEAC5" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Preapprovalinventory" xlink:label="loc_biib_Preapprovalinventory_C2E4723CC87A5104ACE593224CFEEB95" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_A319C20CA67DB99B8C0F93224CFEEAC5" xlink:to="loc_biib_Preapprovalinventory_C2E4723CC87A5104ACE593224CFEEB95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_30CCC3E10DFBACD9149593224CFEC0AC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2406AD47B03074F33B8093224CF8AD9D" xlink:to="loc_us-gaap_InventoryWriteDown_30CCC3E10DFBACD9149593224CFEC0AC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5FDE81E9A89AA047A6C438A353B2790E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0807D66A1150EC4ABF2838A353B23143" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5FDE81E9A89AA047A6C438A353B2790E" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0807D66A1150EC4ABF2838A353B23143" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended">
    <loc xlink:href="biib-20151231.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_1D270AB6FC568E3C9F8D38A3542013BE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_8EFCA35DEECF2C92CC8838A354205A43" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_1D270AB6FC568E3C9F8D38A3542013BE" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_8EFCA35DEECF2C92CC8838A354205A43" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <loc xlink:href="biib-20151231.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_FAA7F1457DFAF78594E993582E1113F1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ACAA23A49FE96951D3D993582E116794" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_FAA7F1457DFAF78594E993582E1113F1" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ACAA23A49FE96951D3D993582E116794" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_95BC0FB58538605DFA5893582E11C4A5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ACAA23A49FE96951D3D993582E116794" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_95BC0FB58538605DFA5893582E11C4A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_EDB337D64A68833E396F93582E11B77D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_95BC0FB58538605DFA5893582E11C4A5" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_EDB337D64A68833E396F93582E11B77D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_E451959490AEA52B965C93582E12DEEE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_EDB337D64A68833E396F93582E11B77D" xlink:to="loc_biib_NeurimmuneMember_E451959490AEA52B965C93582E12DEEE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RodinTherapeuticsMember" xlink:label="loc_biib_RodinTherapeuticsMember_67FD71452ABDB315E16293582E12A9CD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_EDB337D64A68833E396F93582E11B77D" xlink:to="loc_biib_RodinTherapeuticsMember_67FD71452ABDB315E16293582E12A9CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_CF0C9258BAA90ED184D993582E12A7E6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_ACAA23A49FE96951D3D993582E116794" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_CF0C9258BAA90ED184D993582E12A7E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D0E71C59F74910FA3AB893582E12B471" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_CF0C9258BAA90ED184D993582E12A7E6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_D0E71C59F74910FA3AB893582E12B471" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_CF0C9258BAA90ED184D993582E12A7E6" xlink:to="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" xlink:label="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_7AC122855F0F1564806893582E12EDBF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:to="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_7AC122855F0F1564806893582E12EDBF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" xlink:label="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E18D82267E8A1717B8D793582E1216D6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:to="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E18D82267E8A1717B8D793582E1216D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_4161E02A52751C889D4F93582E12C6E0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_4161E02A52751C889D4F93582E12C6E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_C00A27608CF68B15FA9093582E128A66" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:to="loc_us-gaap_OtherCommitment_C00A27608CF68B15FA9093582E128A66" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_FD50110CA21A4198118293582E12CD34" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_FD50110CA21A4198118293582E12CD34" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_2F033F03E873A4E04A6D93582E120BB6" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:to="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_2F033F03E873A4E04A6D93582E120BB6" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_0F6EA27E012A1106F31093582E12B6B9" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_9CBED96917F637D416B593582E12BF1B" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_0F6EA27E012A1106F31093582E12B6B9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_186DC61E0EF52BA7A28138A3510E0F6F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_30193E1793E9C7CF9E8338A3510EF028" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_186DC61E0EF52BA7A28138A3510E0F6F" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_30193E1793E9C7CF9E8338A3510EF028" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_4FACBF6C79F1FA7F661738A35208A443" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_222F11C1B7136752E23638A352086ACA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_4FACBF6C79F1FA7F661738A35208A443" xlink:to="loc_us-gaap_LossContingenciesTable_222F11C1B7136752E23638A352086ACA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_E6609F50E3182813128638A35208D6B4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_222F11C1B7136752E23638A352086ACA" xlink:to="loc_us-gaap_StatementGeographicalAxis_E6609F50E3182813128638A35208D6B4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_D6765D53F81CCC261F9038A352085D92" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_E6609F50E3182813128638A35208D6B4" xlink:to="loc_us-gaap_SegmentGeographicalDomain_D6765D53F81CCC261F9038A352085D92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IT" xlink:label="loc_country_IT_7A40A3C9EF397CD27DBB38A3520882F1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_D6765D53F81CCC261F9038A352085D92" xlink:to="loc_country_IT_7A40A3C9EF397CD27DBB38A3520882F1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_6681F07F45EA49BE213938A352087500" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_222F11C1B7136752E23638A352086ACA" xlink:to="loc_us-gaap_LossContingenciesLineItems_6681F07F45EA49BE213938A352087500" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ReimbursementLimitStatedInResolution" xlink:label="loc_biib_ReimbursementLimitStatedInResolution_1A30F955400C20011CC238A352087B44" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6681F07F45EA49BE213938A352087500" xlink:to="loc_biib_ReimbursementLimitStatedInResolution_1A30F955400C20011CC238A352087B44" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81D8EF02C0394DC584CB38A3560AB161" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_8F0FDADFE6E659B93D0338A3560A902C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81D8EF02C0394DC584CB38A3560AB161" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_8F0FDADFE6E659B93D0338A3560A902C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A580F9570AA6ED3579AA93582E22DC0C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_02D32A0E4C21C40BDAA993582E2291E1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A580F9570AA6ED3579AA93582E22DC0C" xlink:to="loc_us-gaap_StatementTable_02D32A0E4C21C40BDAA993582E2291E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_C771E0094C40EA166EAC93582E22B326" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_02D32A0E4C21C40BDAA993582E2291E1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_C771E0094C40EA166EAC93582E22B326" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0DCA0D6CC1F077A8C5EF93582E227B95" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_C771E0094C40EA166EAC93582E22B326" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0DCA0D6CC1F077A8C5EF93582E227B95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_88964426E76164C547D793582E22DA3E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0DCA0D6CC1F077A8C5EF93582E227B95" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_88964426E76164C547D793582E22DA3E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_F1501C35B3A715D8DC7193582E229042" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_02D32A0E4C21C40BDAA993582E2291E1" xlink:to="loc_us-gaap_StatementLineItems_F1501C35B3A715D8DC7193582E229042" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1A3F21360DF7A429BC4993582E2211A8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_F1501C35B3A715D8DC7193582E229042" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_1A3F21360DF7A429BC4993582E2211A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_222548CC92E403F117FB93582E232390" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A580F9570AA6ED3579AA93582E22DC0C" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_222548CC92E403F117FB93582E232390" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_238A61B74532B4F9BA1E93582E23D7FA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_222548CC92E403F117FB93582E232390" xlink:to="loc_us-gaap_InterestPaidNet_238A61B74532B4F9BA1E93582E23D7FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_110627A1A8A89C33CEFC93582E23938F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_222548CC92E403F117FB93582E232390" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_110627A1A8A89C33CEFC93582E23938F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0BD9BBB6E1BDEFDBF72993582E236AF2" xlink:type="locator" />
    <presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A580F9570AA6ED3579AA93582E22DC0C" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0BD9BBB6E1BDEFDBF72993582E236AF2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_604DB9E231D85549B11893582E23CFFC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0BD9BBB6E1BDEFDBF72993582E236AF2" xlink:to="loc_us-gaap_InvestmentIncomeInterest_604DB9E231D85549B11893582E23CFFC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_4DE51CC62B8B256F782293582E2379F6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0BD9BBB6E1BDEFDBF72993582E236AF2" xlink:to="loc_us-gaap_InterestExpense_4DE51CC62B8B256F782293582E2379F6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="loc_us-gaap_ImpairmentOfInvestments_2939AF52705A4DBF276893582E2375A0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0BD9BBB6E1BDEFDBF72993582E236AF2" xlink:to="loc_us-gaap_ImpairmentOfInvestments_2939AF52705A4DBF276893582E2375A0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_288877178BCEBB704C2493582E23ED93" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0BD9BBB6E1BDEFDBF72993582E236AF2" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_288877178BCEBB704C2493582E23ED93" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_F188918C5724DE74B65993582E23D370" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0BD9BBB6E1BDEFDBF72993582E236AF2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_F188918C5724DE74B65993582E23D370" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_OtherIncomeExpenseNet" xlink:label="loc_biib_OtherIncomeExpenseNet_0281F8BA3E70210713E793582E2358CE" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0BD9BBB6E1BDEFDBF72993582E236AF2" xlink:to="loc_biib_OtherIncomeExpenseNet_0281F8BA3E70210713E793582E2358CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ACC5DA418C4D53EE0E5193582E239A84" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0BD9BBB6E1BDEFDBF72993582E236AF2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ACC5DA418C4D53EE0E5193582E239A84" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_CE8D61A651B403C51C9A93582E233898" xlink:type="locator" />
    <presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A580F9570AA6ED3579AA93582E22DC0C" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_CE8D61A651B403C51C9A93582E233898" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E62B544CAB7DFC29B5D293582E23C10F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_CE8D61A651B403C51C9A93582E233898" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_E62B544CAB7DFC29B5D293582E23C10F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_C813ADDE284AFCAA1DE793582E23F52F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_CE8D61A651B403C51C9A93582E233898" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_C813ADDE284AFCAA1DE793582E23F52F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_32CAE7C9EBA7A97C630E93582E234E90" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_CE8D61A651B403C51C9A93582E233898" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_32CAE7C9EBA7A97C630E93582E234E90" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_1DEBF0B17BE10B2DDE6493582E234E71" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_CE8D61A651B403C51C9A93582E233898" xlink:to="loc_us-gaap_DeferredRevenueCurrent_1DEBF0B17BE10B2DDE6493582E234E71" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6AC91033AB2BCAC8593593582E2356C3" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_CE8D61A651B403C51C9A93582E233898" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6AC91033AB2BCAC8593593582E2356C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4ED9B4B4BE34C49B247193582E2362A2" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_CE8D61A651B403C51C9A93582E233898" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4ED9B4B4BE34C49B247193582E2362A2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_F8ED9A7F0A46E116A5A493582E232C76" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A580F9570AA6ED3579AA93582E22DC0C" xlink:to="loc_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_F8ED9A7F0A46E116A5A493582E232C76" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_DAC97E2F29D6DDBD56EC93582E24CEFA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_F8ED9A7F0A46E116A5A493582E232C76" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_DAC97E2F29D6DDBD56EC93582E24CEFA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Employeerelatedliabilitiesnoncurrent" xlink:label="loc_biib_Employeerelatedliabilitiesnoncurrent_FF763D22D1C5F8ED9F0293582E247D2A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_F8ED9A7F0A46E116A5A493582E232C76" xlink:to="loc_biib_Employeerelatedliabilitiesnoncurrent_FF763D22D1C5F8ED9F0293582E247D2A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_3B82A3F4BD54501DBA3993582E24CCD4" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_F8ED9A7F0A46E116A5A493582E232C76" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_3B82A3F4BD54501DBA3993582E24CCD4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5D56CA29519EB1CCCB5B93582E247C54" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_F8ED9A7F0A46E116A5A493582E232C76" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5D56CA29519EB1CCCB5B93582E247C54" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BD033BEC7EFE1442698E93582E1AE6C9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_854C756DFB8ABBD1471F93582E1AAA5E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BD033BEC7EFE1442698E93582E1AE6C9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_854C756DFB8ABBD1471F93582E1AAA5E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_CECA1ACFBEFB6A00B7DF93582E1AD795" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_854C756DFB8ABBD1471F93582E1AAA5E" xlink:to="loc_us-gaap_StatementGeographicalAxis_CECA1ACFBEFB6A00B7DF93582E1AD795" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_BD4C99E8B1F5084D352F93582E1A3421" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_CECA1ACFBEFB6A00B7DF93582E1AD795" xlink:to="loc_us-gaap_SegmentGeographicalDomain_BD4C99E8B1F5084D352F93582E1A3421" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IT" xlink:label="loc_country_IT_538F9BEC69198083C6EC93582E1A3640" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_BD4C99E8B1F5084D352F93582E1A3421" xlink:to="loc_country_IT_538F9BEC69198083C6EC93582E1A3640" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_115EE47B89E8256D1F0793582E1A0F25" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_854C756DFB8ABBD1471F93582E1AAA5E" xlink:to="loc_us-gaap_ProductOrServiceAxis_115EE47B89E8256D1F0793582E1A0F25" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_D13EF9936227009823C693582E1BCAE2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_115EE47B89E8256D1F0793582E1A0F25" xlink:to="loc_us-gaap_ProductsAndServicesDomain_D13EF9936227009823C693582E1BCAE2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_299D3CDE1A69CD4A0FBC93582E1BF245" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D13EF9936227009823C693582E1BCAE2" xlink:to="loc_biib_TecfideraMember_299D3CDE1A69CD4A0FBC93582E1BF245" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_A7C4C764F6D4CD8D1D2093582E1B15DE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_854C756DFB8ABBD1471F93582E1AAA5E" xlink:to="loc_biib_CumulativeSalesLevelAxis_A7C4C764F6D4CD8D1D2093582E1B15DE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_81C67463153D48212EA393582E1B86CE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelAxis_A7C4C764F6D4CD8D1D2093582E1B15DE" xlink:to="loc_biib_CumulativeSalesLevelDomain_81C67463153D48212EA393582E1B86CE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SevenbillionMember" xlink:label="loc_biib_SevenbillionMember_567169C21EE3568D5BFA93582E1BBB75" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_81C67463153D48212EA393582E1B86CE" xlink:to="loc_biib_SevenbillionMember_567169C21EE3568D5BFA93582E1BBB75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_71775D7C5777969FB1C093582E1BB749" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_854C756DFB8ABBD1471F93582E1AAA5E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_71775D7C5777969FB1C093582E1BB749" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44B3BB169B8FBE0C617393582E1B1347" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_71775D7C5777969FB1C093582E1BB749" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44B3BB169B8FBE0C617393582E1B1347" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_E8FE24E5BAE042A22F0D93582E1B825F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44B3BB169B8FBE0C617393582E1B1347" xlink:to="loc_biib_FumapharmAgMember_E8FE24E5BAE042A22F0D93582E1B825F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_EC7DDEC790CBD9C1540A93A5AB807D46" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44B3BB169B8FBE0C617393582E1B1347" xlink:to="loc_biib_SolothurnMember_EC7DDEC790CBD9C1540A93A5AB807D46" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_C32F9DFF6253F09DB7AC93582E1BC9C7" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44B3BB169B8FBE0C617393582E1B1347" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_C32F9DFF6253F09DB7AC93582E1BC9C7" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_C5362AF692EB0190BB2F93582E1B6084" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_854C756DFB8ABBD1471F93582E1AAA5E" xlink:to="loc_biib_FacilityLocationAxis_C5362AF692EB0190BB2F93582E1B6084" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_D366C70A71587103385893582E1B3AD8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_C5362AF692EB0190BB2F93582E1B6084" xlink:to="loc_biib_FacilityLocationDomain_D366C70A71587103385893582E1B3AD8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CambridgeLeasesMember" xlink:label="loc_biib_CambridgeLeasesMember_68646E544EEDF91D34DF93582E1B92AB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_D366C70A71587103385893582E1B3AD8" xlink:to="loc_biib_CambridgeLeasesMember_68646E544EEDF91D34DF93582E1B92AB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_854C756DFB8ABBD1471F93582E1AAA5E" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_E5F49049122DC812941193582E1B2405" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_E5F49049122DC812941193582E1B2405" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_401908750E8A9FABA4A693582E1BD155" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_biib_CumulativeSalesLevel_401908750E8A9FABA4A693582E1BD155" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_DFEB40D38CAA2B365F9B93A5D37497DD" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_DFEB40D38CAA2B365F9B93A5D37497DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_FA5731EB42A753379F0A93582E1C51AF" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_FA5731EB42A753379F0A93582E1C51AF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DerecognitionOfConstructionInProgressAssets" xlink:label="loc_biib_DerecognitionOfConstructionInProgressAssets_F0271AC9C526803ED86493582E1C5DEC" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_biib_DerecognitionOfConstructionInProgressAssets_F0271AC9C526803ED86493582E1C5DEC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_3B74A10E7B2101F964E193A7016DA739" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_us-gaap_PrepaidTaxes_3B74A10E7B2101F964E193A7016DA739" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_17F8F9CCD5C2093E03C493582E1C4B0D" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_17F8F9CCD5C2093E03C493582E1C4B0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_C15660B4201AC26AAC9893582E1C052C" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_C15660B4201AC26AAC9893582E1C052C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_LossContingencyAdjustmentRelatedToClaimAmountPercent" xlink:label="loc_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_C553290695048CF5AA6F93582E1CB1D5" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent_C553290695048CF5AA6F93582E1CB1D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_202C99E7DD9851F899EE93582E1CD17E" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_202C99E7DD9851F899EE93582E1CD17E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_75B5C5DFFA579B5507F293A8926B620D" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C47B1C3089049980425F93582E1B51FA" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_75B5C5DFFA579B5507F293A8926B620D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B836CB7E51F89E7D90138A357252EE0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_E589638E95C720984EC138A35725420C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B836CB7E51F89E7D90138A357252EE0" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_E589638E95C720984EC138A35725420C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_63ACD14FD7057F93DAF338A3572562E9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B836CB7E51F89E7D90138A357252EE0" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_63ACD14FD7057F93DAF338A3572562E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_228B2591DA4255421C9038A35725CD1A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B836CB7E51F89E7D90138A357252EE0" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_228B2591DA4255421C9038A35725CD1A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_F7E4CF0F44B87602EEE738A35725AC39" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B836CB7E51F89E7D90138A357252EE0" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_F7E4CF0F44B87602EEE738A35725AC39" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4750AC91EB6533B6CA3538A354F357FC" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_56F1C3A22CDC1B1683B038A354F369FF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4750AC91EB6533B6CA3538A354F357FC" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_56F1C3A22CDC1B1683B038A354F369FF" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2D36083958FCA98F511538A3542A5F8E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_1728B4EF26D2F167348C38A3542A9B98" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2D36083958FCA98F511538A3542A5F8E" xlink:to="loc_us-gaap_Land_1728B4EF26D2F167348C38A3542A9B98" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_18F8522E9A10EDDC789A38A3542B0A73" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2D36083958FCA98F511538A3542A5F8E" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_18F8522E9A10EDDC789A38A3542B0A73" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_EE9D475C4ABCD5F2288E38A3542B811B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2D36083958FCA98F511538A3542A5F8E" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_EE9D475C4ABCD5F2288E38A3542B811B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_C53F29B189BA00A4B1A438A3542B7749" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2D36083958FCA98F511538A3542A5F8E" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_C53F29B189BA00A4B1A438A3542B7749" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ComputerSoftwareAndHardware" xlink:label="loc_biib_ComputerSoftwareAndHardware_A7BF2E3506C865064D4938A3542B6EC6" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2D36083958FCA98F511538A3542A5F8E" xlink:to="loc_biib_ComputerSoftwareAndHardware_A7BF2E3506C865064D4938A3542B6EC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_1E5F7C746DCFEF0B3B7B38A3542B4502" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2D36083958FCA98F511538A3542A5F8E" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_1E5F7C746DCFEF0B3B7B38A3542B4502" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_795EA26B53CBDDE8462B38A3542B0CF2" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2D36083958FCA98F511538A3542A5F8E" xlink:to="loc_us-gaap_ConstructionInProgressGross_795EA26B53CBDDE8462B38A3542B0CF2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_490677C1401B4B94EC1838A3542B3046" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2D36083958FCA98F511538A3542A5F8E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_490677C1401B4B94EC1838A3542B3046" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7A26695DBC2C279B6DAD38A3542B24A0" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2D36083958FCA98F511538A3542A5F8E" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7A26695DBC2C279B6DAD38A3542B24A0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2CA922BB08054997476838A3542B63D3" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2D36083958FCA98F511538A3542A5F8E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2CA922BB08054997476838A3542B63D3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_91F796198C4500D72DBA93582EBF30F7" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_526149A3AD8A06D3698493582EBFD06E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_91F796198C4500D72DBA93582EBF30F7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_526149A3AD8A06D3698493582EBFD06E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B9739312139686999FA893582EC036EB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_526149A3AD8A06D3698493582EBFD06E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B9739312139686999FA893582EC036EB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_12E3CEB31452D6B5582B93582EC0A160" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B9739312139686999FA893582EC036EB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_12E3CEB31452D6B5582B93582EC0A160" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_0B6E8E89E7C515A8D1B693582EC09A02" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_12E3CEB31452D6B5582B93582EC0A160" xlink:to="loc_us-gaap_LandMember_0B6E8E89E7C515A8D1B693582EC09A02" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_604B2B699C19D89521E393582EC0F757" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_526149A3AD8A06D3698493582EBFD06E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_604B2B699C19D89521E393582EC0F757" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_03A68F34153EEF2BC6C993582EC0FD48" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_604B2B699C19D89521E393582EC0F757" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_03A68F34153EEF2BC6C993582EC0FD48" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_18C747C4DBA60D6AE48A93582EC0DD50" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_03A68F34153EEF2BC6C993582EC0FD48" xlink:to="loc_biib_EisaiMember_18C747C4DBA60D6AE48A93582EC0DD50" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_FB29CD8146A6A876232193582EC05A13" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_526149A3AD8A06D3698493582EBFD06E" xlink:to="loc_biib_FacilityLocationAxis_FB29CD8146A6A876232193582EC05A13" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_1CD8E2999E95A83BAC0C93582EC0204D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_FB29CD8146A6A876232193582EC05A13" xlink:to="loc_biib_FacilityLocationDomain_1CD8E2999E95A83BAC0C93582EC0204D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_653BCD04F283A92AF96893582EC05621" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_1CD8E2999E95A83BAC0C93582EC0204D" xlink:to="loc_biib_SolothurnMember_653BCD04F283A92AF96893582EC05621" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CambridgeLeasesMember" xlink:label="loc_biib_CambridgeLeasesMember_0F9D636F62E40B76FC2D93582EC0A22B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_1CD8E2999E95A83BAC0C93582EC0204D" xlink:to="loc_biib_CambridgeLeasesMember_0F9D636F62E40B76FC2D93582EC0A22B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_526149A3AD8A06D3698493582EBFD06E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_50379A40152691BDA69F93582EC0FC45" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:to="loc_us-gaap_Depreciation_50379A40152691BDA69F93582EC0FC45" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_96C5DC5019D5689310B093582EC0EED1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:to="loc_us-gaap_InterestCostsCapitalized_96C5DC5019D5689310B093582EC0EED1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_2760805C27537E3F935E93582EC04F73" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_2760805C27537E3F935E93582EC04F73" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_4332A13B17E127473DD6936629FA14AA" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:to="loc_us-gaap_ConstructionInProgressGross_4332A13B17E127473DD6936629FA14AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_E8FA4A619E63B8DA1C8693582EC0AC40" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_E8FA4A619E63B8DA1C8693582EC0AC40" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TermOfLease" xlink:label="loc_biib_TermOfLease_27CF5E8D36D42AA6B9D493582EC1BA5E" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:to="loc_biib_TermOfLease_27CF5E8D36D42AA6B9D493582EC1BA5E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_573043FDF49FC9F474AF93582EC14D0D" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:to="loc_us-gaap_CapitalLeaseObligations_573043FDF49FC9F474AF93582EC14D0D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Chargesrecognizedtovacatebuilding" xlink:label="loc_biib_Chargesrecognizedtovacatebuilding_CF1F1466AA378E4E574293582EC15DA5" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78463B4BD7E3FA4AC96193582EC07344" xlink:to="loc_biib_Chargesrecognizedtovacatebuilding_CF1F1466AA378E4E574293582EC15DA5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F0B168FF1C9A8958C95F38A356E10607" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3B3E4E4C503D9CA450BD38A356E18A04" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F0B168FF1C9A8958C95F38A356E10607" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3B3E4E4C503D9CA450BD38A356E18A04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_336D62827DE4C50E343C38A356E1FC44" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3B3E4E4C503D9CA450BD38A356E18A04" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_336D62827DE4C50E343C38A356E1FC44" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8EA6F7EC1FB455A4F58938A356E15C7C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_336D62827DE4C50E343C38A356E1FC44" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8EA6F7EC1FB455A4F58938A356E15C7C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_0D2966C5C8A73F89A58F38A356E111A8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8EA6F7EC1FB455A4F58938A356E15C7C" xlink:to="loc_biib_EisaiMember_0D2966C5C8A73F89A58F38A356E111A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F67D6A61CD46EB7F55138A356E2C76B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3B3E4E4C503D9CA450BD38A356E18A04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F67D6A61CD46EB7F55138A356E2C76B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_138DB7B5C6001BC6FD5D38A356E2F9E9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F67D6A61CD46EB7F55138A356E2C76B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_138DB7B5C6001BC6FD5D38A356E2F9E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_C5ED73E78CACC366017438A356E2887E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_138DB7B5C6001BC6FD5D38A356E2F9E9" xlink:to="loc_us-gaap_BuildingMember_C5ED73E78CACC366017438A356E2887E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_4BE491E57AE73834EEAE38A356E267AB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_138DB7B5C6001BC6FD5D38A356E2F9E9" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_4BE491E57AE73834EEAE38A356E267AB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_8BAE76D781F1A88E70A538A356E2A46E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_138DB7B5C6001BC6FD5D38A356E2F9E9" xlink:to="loc_us-gaap_LandMember_8BAE76D781F1A88E70A538A356E2A46E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5D5E26F77EEAC39FFD2B38A356E2D447" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3B3E4E4C503D9CA450BD38A356E18A04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5D5E26F77EEAC39FFD2B38A356E2D447" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_F471BED0362C729C95BD38A356E2E24D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5D5E26F77EEAC39FFD2B38A356E2D447" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_F471BED0362C729C95BD38A356E2E24D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6C1C7C68354EB3E0C5A738A351B470C3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_B1E27C984FFFFF45886638A351B4B44E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6C1C7C68354EB3E0C5A738A351B470C3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_B1E27C984FFFFF45886638A351B4B44E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock" xlink:label="loc_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_F088AD9D3BD381EB4DC838A351B53412" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6C1C7C68354EB3E0C5A738A351B470C3" xlink:to="loc_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock_F088AD9D3BD381EB4DC838A351B53412" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_14C4DCA98946DF862FBA38A35145532A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_EE34DEFF3CB7C3653DED38A3514593F2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_14C4DCA98946DF862FBA38A35145532A" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_EE34DEFF3CB7C3653DED38A3514593F2" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_D5F7DBE60553D66C116C93582D9B8DF3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_D5F7DBE60553D66C116C93582D9B8DF3" xlink:to="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_3C991DBA003DBF20073093582D9B7E60" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_3C991DBA003DBF20073093582D9B7E60" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_UnconsolidatedJointBusiness" xlink:label="loc_biib_UnconsolidatedJointBusiness_1B10BFCE2EE413672FC893582D9B5CDF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726" xlink:to="loc_biib_UnconsolidatedJointBusiness_1B10BFCE2EE413672FC893582D9B5CDF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_56AA72CE474834ABF1B293582D9BD0FC" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726" xlink:to="loc_us-gaap_OtherSalesRevenueNet_56AA72CE474834ABF1B293582D9BD0FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_A8DADB8D19FB2033327B93582D9BF23D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726" xlink:to="loc_us-gaap_Revenues_A8DADB8D19FB2033327B93582D9BF23D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_A2D04CDF022762A8766B93582D9B3F4E" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726" xlink:to="loc_us-gaap_GrossProfit_A2D04CDF022762A8766B93582D9B3F4E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_05E3559F98CED01FC93993582D9BD9E6" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726" xlink:to="loc_us-gaap_ProfitLoss_05E3559F98CED01FC93993582D9BD9E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6A41E2CB4F0D3835438893582D9BAAE5" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726" xlink:to="loc_us-gaap_NetIncomeLoss_6A41E2CB4F0D3835438893582D9BAAE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1DA9BDE5E4F094A840A293582D9CB992" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726" xlink:to="loc_us-gaap_EarningsPerShareBasic_1DA9BDE5E4F094A840A293582D9CB992" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_C27BBA342994DCDBFEB393582D9C834A" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726" xlink:to="loc_us-gaap_EarningsPerShareDiluted_C27BBA342994DCDBFEB393582D9C834A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1AA297A5EE12D6AA844E93C4F82C3C19" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1AA297A5EE12D6AA844E93C4F82C3C19" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F2C674E48064BFC050A393C5E215DD72" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_682D3BDBA34920F8580593582D9B1726" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F2C674E48064BFC050A393C5E215DD72" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9589EB5A6A04C5AB139C93582D8E7415" xlink:type="locator" />
    <loc xlink:href="biib-20151231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9589EB5A6A04C5AB139C93582D8E7415" xlink:to="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_C9BCCA5614887BE79AEA93582D8E9ABC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F" xlink:to="loc_us-gaap_StatementGeographicalAxis_C9BCCA5614887BE79AEA93582D8E9ABC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_6D719E95E1A6D8BA33F893582D8EBA99" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_C9BCCA5614887BE79AEA93582D8E9ABC" xlink:to="loc_us-gaap_SegmentGeographicalDomain_6D719E95E1A6D8BA33F893582D8EBA99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_IT" xlink:label="loc_country_IT_EBB14A246D001B1F915493582D8EDE6D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_6D719E95E1A6D8BA33F893582D8EBA99" xlink:to="loc_country_IT_EBB14A246D001B1F915493582D8EDE6D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_E66BD1B2C4C2F5FD784893582D8E5CF1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_E66BD1B2C4C2F5FD784893582D8E5CF1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_40EBD9636490F1323CEF93582D8EEB41" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_E66BD1B2C4C2F5FD784893582D8E5CF1" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_40EBD9636490F1323CEF93582D8EEB41" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_CD6DD8CDA6E45A21F96C93582D8E1A8F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_40EBD9636490F1323CEF93582D8EEB41" xlink:to="loc_biib_NeurimmuneMember_CD6DD8CDA6E45A21F96C93582D8E1A8F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0291529BB1210B62A8B693582D8ECEC3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0291529BB1210B62A8B693582D8ECEC3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386DB671ECFC303CA27593582D8FF132" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0291529BB1210B62A8B693582D8ECEC3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386DB671ECFC303CA27593582D8FF132" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AGTCMember" xlink:label="loc_biib_AGTCMember_B48193D647AD3D5A7D1593582D8FDE14" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386DB671ECFC303CA27593582D8FF132" xlink:to="loc_biib_AGTCMember_B48193D647AD3D5A7D1593582D8FDE14" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MitsubishiTanabePharmaCorporationMember" xlink:label="loc_biib_MitsubishiTanabePharmaCorporationMember_7941860A9B32CF4299F093582D8F5B73" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386DB671ECFC303CA27593582D8FF132" xlink:to="loc_biib_MitsubishiTanabePharmaCorporationMember_7941860A9B32CF4299F093582D8F5B73" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_72D93DF27F2045653BB993582D8F3A17" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386DB671ECFC303CA27593582D8FF132" xlink:to="loc_biib_EisaiMember_72D93DF27F2045653BB993582D8F3A17" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_7562D6F7CE86A7E34D2293582D8EF61F" xlink:to="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0982A2008736AE2F497A93582D8F3304" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0982A2008736AE2F497A93582D8F3304" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_93C44E2EF15B0D6F10A193582D8F5120" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_93C44E2EF15B0D6F10A193582D8F5120" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_4C6FDBBFDB4990C670C093582D8F8B57" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4" xlink:to="loc_us-gaap_RestructuringCharges_4C6FDBBFDB4990C670C093582D8F8B57" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_7BD2FD44548E7769BF6393582D8F1D6F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_7CDF5BEB9B3A677577A893582D8F5DA4" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_7BD2FD44548E7769BF6393582D8F1D6F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_3BEC3EA087746E87EB0038A35128AC9E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_6E2297FA4DAE033A4C9638A35128886A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_3BEC3EA087746E87EB0038A35128AC9E" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_6E2297FA4DAE033A4C9638A35128886A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_D7B66166887E67A17AF138A35518E020" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_9B21AB9E33C6BEDB7ACD38A355180598" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_D7B66166887E67A17AF138A35518E020" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_9B21AB9E33C6BEDB7ACD38A355180598" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6D453F14BF90FF403549A34B6AB8D206" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4793816C3B7775B0D6ECA34B6AB886B4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6D453F14BF90FF403549A34B6AB8D206" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4793816C3B7775B0D6ECA34B6AB886B4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_58A37B23AFBEB876F54BA34B6AB86DDF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4793816C3B7775B0D6ECA34B6AB886B4" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_58A37B23AFBEB876F54BA34B6AB86DDF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_FC9038997F7E17DB835AA34B6AB86FBC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_58A37B23AFBEB876F54BA34B6AB86DDF" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_FC9038997F7E17DB835AA34B6AB86FBC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_6D6CEBFF9E17820C928EA34B6AB8677A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_FC9038997F7E17DB835AA34B6AB86FBC" xlink:to="loc_us-gaap_EmployeeSeveranceMember_6D6CEBFF9E17820C928EA34B6AB8677A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_AACDEB13A404D3499DD1A34B6AB86691" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_FC9038997F7E17DB835AA34B6AB86FBC" xlink:to="loc_us-gaap_ContractTerminationMember_AACDEB13A404D3499DD1A34B6AB86691" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_D0D228F95C32351A1526A34B6AB86200" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4793816C3B7775B0D6ECA34B6AB886B4" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_D0D228F95C32351A1526A34B6AB86200" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_403A5AC5D36027E1FC56A34B6AB82CE9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_D0D228F95C32351A1526A34B6AB86200" xlink:to="loc_us-gaap_RestructuringCharges_403A5AC5D36027E1FC56A34B6AB82CE9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment_8D70FC9AFF553E31F148A34B6AB8E3A6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_D0D228F95C32351A1526A34B6AB86200" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment_8D70FC9AFF553E31F148A34B6AB8E3A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_24842824D18CF28086C3A34B6AB90DFB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_D0D228F95C32351A1526A34B6AB86200" xlink:to="loc_us-gaap_PaymentsForRestructuring_24842824D18CF28086C3A34B6AB90DFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_83ADDA779D2D596CCC80A34B6AB92AD9" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_D0D228F95C32351A1526A34B6AB86200" xlink:to="loc_us-gaap_RestructuringReserve_83ADDA779D2D596CCC80A34B6AB92AD9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_BEEB9B902591B8B318B493582F463DE7" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9BE33509E755ABE8F0BA93582F4699DE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_BEEB9B902591B8B318B493582F463DE7" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9BE33509E755ABE8F0BA93582F4699DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_609773673EE18F66158593582F462080" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9BE33509E755ABE8F0BA93582F4699DE" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_609773673EE18F66158593582F462080" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1E36BCB41A357200179593582F46BFF8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_609773673EE18F66158593582F462080" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1E36BCB41A357200179593582F46BFF8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_D2972B22204C90579FFA93582F46BD6A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1E36BCB41A357200179593582F46BFF8" xlink:to="loc_us-gaap_EmployeeSeveranceMember_D2972B22204C90579FFA93582F46BD6A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_6FCAACD5BC492B1364FE93582F46FE6C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1E36BCB41A357200179593582F46BFF8" xlink:to="loc_us-gaap_ContractTerminationMember_6FCAACD5BC492B1364FE93582F46FE6C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9BE33509E755ABE8F0BA93582F4699DE" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated" xlink:label="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_36D6F8AC4923455F7EC993582F461A06" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2" xlink:to="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_36D6F8AC4923455F7EC993582F461A06" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RestructuringandRelatedCostExpectedCashPayments" xlink:label="loc_biib_RestructuringandRelatedCostExpectedCashPayments_4575AF495F5D1800146C93582F466615" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2" xlink:to="loc_biib_RestructuringandRelatedCostExpectedCashPayments_4575AF495F5D1800146C93582F466615" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment_5997A996DD1B835C326993582F467471" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment_5997A996DD1B835C326993582F467471" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_F342CD5793A41DDC243393582F478DA5" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_F342CD5793A41DDC243393582F478DA5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_EFE58B1659EFBA5A79CB93582F4755B0" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_100D276A9E1606774F4293582F46EAF2" xlink:to="loc_us-gaap_RestructuringCharges_EFE58B1659EFBA5A79CB93582F4755B0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_F99AAEE7C2BC521B979F38A3531F58F1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_767247D19448D0B5D9FE38A3531F6E5B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_F99AAEE7C2BC521B979F38A3531F58F1" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_767247D19448D0B5D9FE38A3531F6E5B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/RevenueReserves" xlink:type="extended">
    <loc xlink:href="biib-20151231.xsd#biib_ReservesForDiscountsAndAllowancesAbstract" xlink:label="loc_biib_ReservesForDiscountsAndAllowancesAbstract_AFA851BFE7232666E86D38A3559F64BD" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_BE19AAFE1837CFBA8E3538A3559FA0C2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReservesForDiscountsAndAllowancesAbstract_AFA851BFE7232666E86D38A3559F64BD" xlink:to="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_BE19AAFE1837CFBA8E3538A3559FA0C2" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/RevenueReservesDetails" xlink:type="extended">
    <loc xlink:href="biib-20151231.xsd#biib_ReservesForDiscountsAndAllowancesAbstract" xlink:label="loc_biib_ReservesForDiscountsAndAllowancesAbstract_26AA13E8CBB938BAFFB238A353FA352A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_4A82E3FAF26B9C2426AA38A353FA2915" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReservesForDiscountsAndAllowancesAbstract_26AA13E8CBB938BAFFB238A353FA352A" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_4A82E3FAF26B9C2426AA38A353FA2915" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_D63BD7385AC0963A5CF438A353FA98D9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_4A82E3FAF26B9C2426AA38A353FA2915" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_D63BD7385AC0963A5CF438A353FA98D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_391120911795C250B1AB38A353FA9369" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_D63BD7385AC0963A5CF438A353FA98D9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_391120911795C250B1AB38A353FA9369" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_9B39ED37AD49D9E3576E38A353FA262F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_391120911795C250B1AB38A353FA9369" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_9B39ED37AD49D9E3576E38A353FA262F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_2E81D210CC743515AB0738A353FA56E9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_391120911795C250B1AB38A353FA9369" xlink:to="loc_biib_ContractualAdjustmentsMember_2E81D210CC743515AB0738A353FA56E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_01521B5C408E1FB9D9AE38A353FA74BE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_391120911795C250B1AB38A353FA9369" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_01521B5C408E1FB9D9AE38A353FA74BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_54B09DAD77CB1B68BDCC38A353FA8B23" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_4A82E3FAF26B9C2426AA38A353FA2915" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_54B09DAD77CB1B68BDCC38A353FA8B23" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_54B09DAD77CB1B68BDCC38A353FA8B23" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_A147B12175580DE2D9E338A353FB4288" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_A147B12175580DE2D9E338A353FB4288" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_598CD8A6A3AF9491FA9C38A353FBF800" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_598CD8A6A3AF9491FA9C38A353FBF800" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_7D00426613B4B1CD174538A353FB7C9F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_7D00426613B4B1CD174538A353FB7C9F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_3E28DF57E223BD46E27A38A353FBAEB4" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_3E28DF57E223BD46E27A38A353FBAEB4" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_28A04DE65941BC15A7F638A353FB4373" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_28A04DE65941BC15A7F638A353FB4373" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_3114512F5F1E1621943638A353FB02C5" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_875F345D9EAA1C17E2DB38A353FA7C1F" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_3114512F5F1E1621943638A353FB02C5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/RevenueReservesDetails1" xlink:type="extended">
    <loc xlink:href="biib-20151231.xsd#biib_ReservesForDiscountsAndAllowancesAbstract" xlink:label="loc_biib_ReservesForDiscountsAndAllowancesAbstract_38F34E167D3F4630D20A38A352307970" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_25EC4D3ED1308FF50F2A38A352302AA4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReservesForDiscountsAndAllowancesAbstract_38F34E167D3F4630D20A38A352307970" xlink:to="loc_us-gaap_StatementTable_25EC4D3ED1308FF50F2A38A352302AA4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_FB22A40FE463D17A446C38A352309989" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_25EC4D3ED1308FF50F2A38A352302AA4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_FB22A40FE463D17A446C38A352309989" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7D5F37C75F539828EA6E38A3523078A3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_FB22A40FE463D17A446C38A352309989" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7D5F37C75F539828EA6E38A3523078A3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_E579D86953A3E58406EC38A352318966" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7D5F37C75F539828EA6E38A3523078A3" xlink:to="loc_us-gaap_AccountsReceivableMember_E579D86953A3E58406EC38A352318966" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_6AEE8694837B9CC8E91A38A352317981" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7D5F37C75F539828EA6E38A3523078A3" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_6AEE8694837B9CC8E91A38A352317981" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_F6554C06906DA44A828038A35231C877" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_25EC4D3ED1308FF50F2A38A352302AA4" xlink:to="loc_us-gaap_StatementLineItems_F6554C06906DA44A828038A35231C877" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_41E31A5F12D66E79D11038A35231E128" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_F6554C06906DA44A828038A35231C877" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_41E31A5F12D66E79D11038A35231E128" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/RevenueReservesTables" xlink:type="extended">
    <loc xlink:href="biib-20151231.xsd#biib_ReservesForDiscountsAndAllowancesAbstract" xlink:label="loc_biib_ReservesForDiscountsAndAllowancesAbstract_038ECE832DA189AF821C38A354F7EB44" xlink:type="locator" />
    <loc xlink:href="biib-20151231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_0D48A8E336C5DC79FF8838A354F7BA7F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReservesForDiscountsAndAllowancesAbstract_038ECE832DA189AF821C38A354F7EB44" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_0D48A8E336C5DC79FF8838A354F7BA7F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_F5C3D19B8B1A40A41B4638A354F757A8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReservesForDiscountsAndAllowancesAbstract_038ECE832DA189AF821C38A354F7EB44" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_F5C3D19B8B1A40A41B4638A354F757A8" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformation" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_F606E234DF5D0AF105D438A3560EB801" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_3A080AABFA8A8DC6211238A3560EEC50" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_F606E234DF5D0AF105D438A3560EB801" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_3A080AABFA8A8DC6211238A3560EEC50" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_5355D5984C3CD39F26B393582DB1B7B6" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_69288E60D2271F348B9B93582DB12F54" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5355D5984C3CD39F26B393582DB1B7B6" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_69288E60D2271F348B9B93582DB12F54" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_E4BD828DD45D0414430593582DB10077" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_69288E60D2271F348B9B93582DB12F54" xlink:to="loc_us-gaap_ProductOrServiceAxis_E4BD828DD45D0414430593582DB10077" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_E4BD828DD45D0414430593582DB10077" xlink:to="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_AA323686622737C15D7993582DB1F6EB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:to="loc_biib_TecfideraMember_AA323686622737C15D7993582DB1F6EB" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_51A775E1F2D69C848B0293BDFED76FA3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:to="loc_biib_AVONEXMember_51A775E1F2D69C848B0293BDFED76FA3" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PLEGRIDYMember" xlink:label="loc_biib_PLEGRIDYMember_4FF1B60F70EA75C024E593BF1760193D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:to="loc_biib_PLEGRIDYMember_4FF1B60F70EA75C024E593BF1760193D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TysabriMember" xlink:label="loc_biib_TysabriMember_9E74EB0A8F1143A5102693582DB111AA" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:to="loc_biib_TysabriMember_9E74EB0A8F1143A5102693582DB111AA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_E4159D68FB4AE8AA37FE93582DB17627" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:to="loc_biib_FAMPYRAMember_E4159D68FB4AE8AA37FE93582DB17627" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_C939844255E3DA7EA53C93582DB1250A" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:to="loc_biib_ELOCTATEMember_C939844255E3DA7EA53C93582DB1250A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ALPROLIXProductMember" xlink:label="loc_biib_ALPROLIXProductMember_4B031756E9332D9CBFA993582DB16CB2" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:to="loc_biib_ALPROLIXProductMember_4B031756E9332D9CBFA993582DB16CB2" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_2644BCB933B4CD111AF393582DB100DE" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_385D02028F6774F8A9DA93582DB18F63" xlink:to="loc_biib_FUMADERMMember_2644BCB933B4CD111AF393582DB100DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0D8B1A8B504FEB2113BC93582DB1F72D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_69288E60D2271F348B9B93582DB12F54" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0D8B1A8B504FEB2113BC93582DB1F72D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_FA29F4DA416A7E8A095B93582DB11FFC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0D8B1A8B504FEB2113BC93582DB1F72D" xlink:to="loc_us-gaap_SegmentDomain_FA29F4DA416A7E8A095B93582DB11FFC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="loc_country_US_ED064019BF23D178BFFB93582DB1DA08" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_FA29F4DA416A7E8A095B93582DB11FFC" xlink:to="loc_country_US_ED064019BF23D178BFFB93582DB1DA08" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RestOfWorldMember" xlink:label="loc_biib_RestOfWorldMember_6104F7C6E215BA8B5F8593582DB1F25C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_FA29F4DA416A7E8A095B93582DB11FFC" xlink:to="loc_biib_RestOfWorldMember_6104F7C6E215BA8B5F8593582DB1F25C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_1C649AE38FC47A6ED53B93582DB1C1D7" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_69288E60D2271F348B9B93582DB12F54" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_1C649AE38FC47A6ED53B93582DB1C1D7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNetAbstract" xlink:label="loc_us-gaap_SalesRevenueGoodsNetAbstract_F0F14FB3439325F9222893582DB271E0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_1C649AE38FC47A6ED53B93582DB1C1D7" xlink:to="loc_us-gaap_SalesRevenueGoodsNetAbstract_F0F14FB3439325F9222893582DB271E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_FC3BACCB842A6E5D605193582DB28ADD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesRevenueGoodsNetAbstract_F0F14FB3439325F9222893582DB271E0" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_FC3BACCB842A6E5D605193582DB28ADD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_20DD24D3739D1488703438A3526AE61E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_41189C1D1B76EC0A46E438A3526A6553" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_20DD24D3739D1488703438A3526AE61E" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_41189C1D1B76EC0A46E438A3526A6553" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_311969CF7FB375C66B5238A3526A3C62" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_41189C1D1B76EC0A46E438A3526A6553" xlink:to="loc_us-gaap_StatementGeographicalAxis_311969CF7FB375C66B5238A3526A3C62" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_38C3F2E633AC5085F23038A3526A21BB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_311969CF7FB375C66B5238A3526A3C62" xlink:to="loc_us-gaap_SegmentGeographicalDomain_38C3F2E633AC5085F23038A3526A21BB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="loc_country_US_583278D6AB2DE841CEFF38A3526A41C7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_38C3F2E633AC5085F23038A3526A21BB" xlink:to="loc_country_US_583278D6AB2DE841CEFF38A3526A41C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_22DA1AF86DCCC1149D0438A3526A5D05" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_38C3F2E633AC5085F23038A3526A21BB" xlink:to="loc_us-gaap_EuropeMember_22DA1AF86DCCC1149D0438A3526A5D05" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_DE" xlink:label="loc_country_DE_BB7ABBF54FFCA885765238A3526ABF89" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_38C3F2E633AC5085F23038A3526A21BB" xlink:to="loc_country_DE_BB7ABBF54FFCA885765238A3526ABF89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AsiaMember" xlink:label="loc_us-gaap_AsiaMember_37EDA8542BEF8885EA7C38A3526A278D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_38C3F2E633AC5085F23038A3526A21BB" xlink:to="loc_us-gaap_AsiaMember_37EDA8542BEF8885EA7C38A3526A278D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:label="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_78A5D0860C9F0B41068D38A3526AE776" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_38C3F2E633AC5085F23038A3526A21BB" xlink:to="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_78A5D0860C9F0B41068D38A3526AE776" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_AAC54936E48FB1EA8CDC38A3526AEAA8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_41189C1D1B76EC0A46E438A3526A6553" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_AAC54936E48FB1EA8CDC38A3526AEAA8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_354E0164C1BB8CC0F85638A3526AD552" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_AAC54936E48FB1EA8CDC38A3526AEAA8" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_354E0164C1BB8CC0F85638A3526AD552" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_13E3187695FAB6D75BC538A3526ABA23" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_354E0164C1BB8CC0F85638A3526AD552" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_13E3187695FAB6D75BC538A3526ABA23" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RevenuesFromUnconsolidatedJointBusiness" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusiness_F2EB0BEC9C01139352A838A3526BB69A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_354E0164C1BB8CC0F85638A3526AD552" xlink:to="loc_biib_RevenuesFromUnconsolidatedJointBusiness_F2EB0BEC9C01139352A838A3526BB69A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_2082A334E47ECC84D18A38A3526B420A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_354E0164C1BB8CC0F85638A3526AD552" xlink:to="loc_us-gaap_OtherSalesRevenueNet_2082A334E47ECC84D18A38A3526B420A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_4270173758342207655B38A3526B85F2" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_354E0164C1BB8CC0F85638A3526AD552" xlink:to="loc_us-gaap_NoncurrentAssets_4270173758342207655B38A3526B85F2" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_74D207D15672E614ED9838A3565AB4D7" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_F3A7F53566CAABF32CC338A3565ABC80" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_74D207D15672E614ED9838A3565AB4D7" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_F3A7F53566CAABF32CC338A3565ABC80" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_E956AC05C35633591A1438A3565AC747" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_F3A7F53566CAABF32CC338A3565ABC80" xlink:to="loc_us-gaap_StatementGeographicalAxis_E956AC05C35633591A1438A3565AC747" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_81706E1B9664BF36C56838A3565A2D15" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_E956AC05C35633591A1438A3565AC747" xlink:to="loc_us-gaap_SegmentGeographicalDomain_81706E1B9664BF36C56838A3565A2D15" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_DK" xlink:label="loc_country_DK_5E7BC962BE53087A9B5A38A3565AA832" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_81706E1B9664BF36C56838A3565A2D15" xlink:to="loc_country_DK_5E7BC962BE53087A9B5A38A3565AA832" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_00507505375E9ADAC02E38A3565A9BAF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_F3A7F53566CAABF32CC338A3565ABC80" xlink:to="loc_biib_MajorDistributorAxis_00507505375E9ADAC02E38A3565A9BAF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_9A07EE8DA25FE78A384738A3565A5067" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorAxis_00507505375E9ADAC02E38A3565A9BAF" xlink:to="loc_biib_MajorDistributorDomain_9A07EE8DA25FE78A384738A3565A5067" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_5AD69CCFD0D67FE4E3DF38A3565A54FD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorDomain_9A07EE8DA25FE78A384738A3565A5067" xlink:to="loc_biib_DistributorOneMember_5AD69CCFD0D67FE4E3DF38A3565A54FD" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_EF1B70F2C2B319385F2838A3565A0282" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorDomain_9A07EE8DA25FE78A384738A3565A5067" xlink:to="loc_biib_DistributorTwoMember_EF1B70F2C2B319385F2838A3565A0282" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_EFCF28BE687BE3AEA68F38A3565ADC02" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_F3A7F53566CAABF32CC338A3565ABC80" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_EFCF28BE687BE3AEA68F38A3565ADC02" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RevenuesInPercentageFromUnconsolidatedJointBusiness" xlink:label="loc_biib_RevenuesInPercentageFromUnconsolidatedJointBusiness_55E7AC59066BF8A147BC38A3565A0207" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_EFCF28BE687BE3AEA68F38A3565ADC02" xlink:to="loc_biib_RevenuesInPercentageFromUnconsolidatedJointBusiness_55E7AC59066BF8A147BC38A3565A0207" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D5EC9ED7E6822D2ABBF238A3565A66E0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_EFCF28BE687BE3AEA68F38A3565ADC02" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_D5EC9ED7E6822D2ABBF238A3565A66E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_33051466D157CF1100BE38A3565A596F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_EFCF28BE687BE3AEA68F38A3565ADC02" xlink:to="loc_us-gaap_NoncurrentAssets_33051466D157CF1100BE38A3565A596F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SegmentInformationTextualAbstract" xlink:label="loc_biib_SegmentInformationTextualAbstract_B24ABE778F825795043438A3565A9868" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_74D207D15672E614ED9838A3565AB4D7" xlink:to="loc_biib_SegmentInformationTextualAbstract_B24ABE778F825795043438A3565A9868" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_65EB1D3A7BA25FD343E538A3565ADC60" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SegmentInformationTextualAbstract_B24ABE778F825795043438A3565A9868" xlink:to="loc_us-gaap_NumberOfReportableSegments_65EB1D3A7BA25FD343E538A3565ADC60" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_2B54497B69E2F4C33F7A38A351D9C26A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4086C5F20151E36D53EA38A351D948D2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2B54497B69E2F4C33F7A38A351D9C26A" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4086C5F20151E36D53EA38A351D948D2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_DE9417008471803C30A738A351D9B00F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2B54497B69E2F4C33F7A38A351D9C26A" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_DE9417008471803C30A738A351D9B00F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EDF2A2A2B297DD9747E438A3524F5D26" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0F3FEB34EDC49283AB9A38A3524F5ECE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_EDF2A2A2B297DD9747E438A3524F5D26" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0F3FEB34EDC49283AB9A38A3524F5ECE" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2C58102DDB9838FE315093D5C9F52614" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A3200CB417915E39AC4193D5C9F54B54" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2C58102DDB9838FE315093D5C9F52614" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A3200CB417915E39AC4193D5C9F54B54" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8D19CD154CC2BC16542C93D5C9F594D6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A3200CB417915E39AC4193D5C9F54B54" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8D19CD154CC2BC16542C93D5C9F594D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1631EB288E4E0F0D45BB93D5C9F585CC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8D19CD154CC2BC16542C93D5C9F594D6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1631EB288E4E0F0D45BB93D5C9F585CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_83FBAD2106C8946A03CF93D5C9F69F16" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1631EB288E4E0F0D45BB93D5C9F585CC" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_83FBAD2106C8946A03CF93D5C9F69F16" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4A50D7796B3A3D60369A93D5C9F65EB1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1631EB288E4E0F0D45BB93D5C9F585CC" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4A50D7796B3A3D60369A93D5C9F65EB1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_0EC24D24F01A41296D6393D5C9F6F696" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1631EB288E4E0F0D45BB93D5C9F585CC" xlink:to="loc_us-gaap_RestructuringChargesMember_0EC24D24F01A41296D6393D5C9F6F696" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_D31ED573CC1379AE2E6793D5C9F6B956" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1631EB288E4E0F0D45BB93D5C9F585CC" xlink:to="loc_us-gaap_ParentMember_D31ED573CC1379AE2E6793D5C9F6B956" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CB93F131642F96A37C8C93D5C9F6BBAD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A3200CB417915E39AC4193D5C9F54B54" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CB93F131642F96A37C8C93D5C9F6BBAD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CB93F131642F96A37C8C93D5C9F6BBAD" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_E7FED733DC3A15639D6293D5C9F61454" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_E7FED733DC3A15639D6293D5C9F61454" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4FF3132759B6BE9EDA1C93D5C9F60A6E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4FF3132759B6BE9EDA1C93D5C9F60A6E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_A21069CFFFA1F1609C8C93D5C9F6B956" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_A21069CFFFA1F1609C8C93D5C9F6B956" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_5D606F6D385779F6C91F93D5C9F6313F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_5D606F6D385779F6C91F93D5C9F6313F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_17E570DCFB9764669A0893D5C9F6209F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_3DB9C423B012BFA135C293D5C9F61DA3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_17E570DCFB9764669A0893D5C9F6209F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ACBB028238ECCF6B20C338A351C35C70" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A1260F14EA75B6FC484738A351C3902A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ACBB028238ECCF6B20C338A351C35C70" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A1260F14EA75B6FC484738A351C3902A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D62D6EECD38B98DB398D38A351C33F43" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A1260F14EA75B6FC484738A351C3902A" xlink:to="loc_us-gaap_PlanNameAxis_D62D6EECD38B98DB398D38A351C33F43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_D62D6EECD38B98DB398D38A351C33F43" xlink:to="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5FB678B51102E88068F138A351C43F1A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5FB678B51102E88068F138A351C43F1A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_47C8FB953AAFDF7742FB38A351C4910E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:to="loc_biib_MarketStockUnitsMember_47C8FB953AAFDF7742FB38A351C4910E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_60E4AEE4672C29A51E9B38A351C4099C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_60E4AEE4672C29A51E9B38A351C4099C" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_9B089081790B1CE751F338A351C4E383" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:to="loc_biib_CashSettledPerformanceSharesMember_9B089081790B1CE751F338A351C4E383" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_7D8B76DBC0E4EAFCF18638A351C49BAF" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:to="loc_us-gaap_PerformanceSharesMember_7D8B76DBC0E4EAFCF18638A351C49BAF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_3708315C2599A53C59E338A351C41D8D" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4EC1B390895D7D88578138A351C40C0A" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_3708315C2599A53C59E338A351C41D8D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_DDBA53D56B3C9E0B722E38A351C42815" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_A1260F14EA75B6FC484738A351C3902A" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_DDBA53D56B3C9E0B722E38A351C42815" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_DDBA53D56B3C9E0B722E38A351C42815" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7223C27190003AE1DAE138A351C40567" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7223C27190003AE1DAE138A351C40567" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_166B2321EEC6FA7D93A638A351C445C7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_166B2321EEC6FA7D93A638A351C445C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_B75367DC93997B4D31F438A351C47ED8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_B75367DC93997B4D31F438A351C47ED8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1541A7E48B0D186FA5EA38A351C42A33" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_33D34398B8C811D73C5738A351C48C32" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1541A7E48B0D186FA5EA38A351C42A33" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DD8E3252200624876DC938A356EED9FA" xlink:type="locator" />
    <loc xlink:href="biib-20151231.xsd#biib_StockOptionActivityAbstract" xlink:label="loc_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DD8E3252200624876DC938A356EED9FA" xlink:to="loc_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E99F9720CE3452ED1C4338A356EF8AA3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E99F9720CE3452ED1C4338A356EF8AA3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8E8388EAD292C0A2500538A356EF167E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8E8388EAD292C0A2500538A356EF167E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_BAAC7B6779AEAFBB0E7738A356EF385E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_BAAC7B6779AEAFBB0E7738A356EF385E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_883BE8EB1666179DCB7338A356EF554C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_883BE8EB1666179DCB7338A356EF554C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3EB45271EA8E436DF3EC38A356EF121F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3EB45271EA8E436DF3EC38A356EF121F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F150C42883376695334C38A356EFE1C2" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_F150C42883376695334C38A356EFE1C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9901323551C0CA7F7BD838A356EF690B" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9901323551C0CA7F7BD838A356EF690B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_189A685FA7BCAFD8158F38A356EF3710" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_189A685FA7BCAFD8158F38A356EF3710" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13625644266ADCFBAD6638A356EF73D8" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13625644266ADCFBAD6638A356EF73D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_89826D6523E695C592A738A356EFC8C5" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_85865750E9440026C87D38A356EF3CAB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_89826D6523E695C592A738A356EFC8C5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0C5014A4968E89495D6C38A3520D0115" xlink:type="locator" />
    <loc xlink:href="biib-20151231.xsd#biib_TaxBenefitAndCashReceivedFromStockOptionAbstract" xlink:label="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_A5718F1CAD6250C4B26338A3520DA6C8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0C5014A4968E89495D6C38A3520D0115" xlink:to="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_A5718F1CAD6250C4B26338A3520DA6C8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions_663A10335DC630C2A8CE38A3520E3A2D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_A5718F1CAD6250C4B26338A3520DA6C8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions_663A10335DC630C2A8CE38A3520E3A2D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_60430BCC7299E5C08BEE38A3520EF38F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_A5718F1CAD6250C4B26338A3520DA6C8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_60430BCC7299E5C08BEE38A3520EF38F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9A676344B12ADB0924B338A3534AE650" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BE9ECD4F99F22768B6F38A3534AF239" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9A676344B12ADB0924B338A3534AE650" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BE9ECD4F99F22768B6F38A3534AF239" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5734004D80954E4494DB38A3534B51B9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BE9ECD4F99F22768B6F38A3534AF239" xlink:to="loc_us-gaap_AwardTypeAxis_5734004D80954E4494DB38A3534B51B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5FA16734B2850DF100E938A3534BF2C1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5734004D80954E4494DB38A3534B51B9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5FA16734B2850DF100E938A3534BF2C1" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_F7AA432E10402D1CC16738A3534B8D5F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5FA16734B2850DF100E938A3534BF2C1" xlink:to="loc_biib_MarketStockUnitsMember_F7AA432E10402D1CC16738A3534B8D5F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B56BCEE5AC256ABAA97E38A3534B9F13" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1BE9ECD4F99F22768B6F38A3534AF239" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B56BCEE5AC256ABAA97E38A3534B9F13" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MarketStockUnitsActivityAbstract" xlink:label="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B56BCEE5AC256ABAA97E38A3534B9F13" xlink:to="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_42665CAE190FBEDAE6D538A3534BA65F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_42665CAE190FBEDAE6D538A3534BA65F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55F6DF417BE4B009718238A3534BA6FB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55F6DF417BE4B009718238A3534BA6FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_238769352ABA1FBB41E338A3534BBCC6" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_238769352ABA1FBB41E338A3534BBCC6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_659CF0CEEDAE07E529F038A3534BA9A8" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_659CF0CEEDAE07E529F038A3534BA9A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5E13630B2D751574DA8B38A3534B9FF8" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5E13630B2D751574DA8B38A3534B9FF8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9868E37B9AF59CAA3AF538A3534B6E47" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9868E37B9AF59CAA3AF538A3534B6E47" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6ECF9E36B3754DF6EB7C38A3534BAFB9" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6ECF9E36B3754DF6EB7C38A3534BAFB9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E0FE6EB810CF938AEC9F38A3534B3DA7" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E0FE6EB810CF938AEC9F38A3534B3DA7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_74261960BC5FBC08F7FB38A3534C4637" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_74261960BC5FBC08F7FB38A3534C4637" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08CDFF9167F552A654F638A3534CA634" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_9CF96C04B9EBB2BF39A838A3534B4AD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08CDFF9167F552A654F638A3534CA634" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48394F721EED32EA537793D5C9E01606" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6F072C14B4E6B655C7AE93D5C9E1A820" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48394F721EED32EA537793D5C9E01606" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6F072C14B4E6B655C7AE93D5C9E1A820" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4646B8E800F75C5057C093D5C9E11548" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6F072C14B4E6B655C7AE93D5C9E1A820" xlink:to="loc_us-gaap_AwardTypeAxis_4646B8E800F75C5057C093D5C9E11548" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E4E07DE9E60B90A723593D5C9E18AB3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4646B8E800F75C5057C093D5C9E11548" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E4E07DE9E60B90A723593D5C9E18AB3" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_A9C3B692A59FE7947DAD93D5C9E14B6F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3E4E07DE9E60B90A723593D5C9E18AB3" xlink:to="loc_biib_MarketStockUnitsMember_A9C3B692A59FE7947DAD93D5C9E14B6F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_0618DEEF8496D620823393D5C9E1931A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6F072C14B4E6B655C7AE93D5C9E1A820" xlink:to="loc_us-gaap_RangeAxis_0618DEEF8496D620823393D5C9E1931A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F998FCEF3B2980031D9993D5C9E1BBE6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_0618DEEF8496D620823393D5C9E1931A" xlink:to="loc_us-gaap_RangeMember_F998FCEF3B2980031D9993D5C9E1BBE6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_E0820DB682165630461C93D5C9E116D7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F998FCEF3B2980031D9993D5C9E1BBE6" xlink:to="loc_us-gaap_MinimumMember_E0820DB682165630461C93D5C9E116D7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_E3FD526013C6FD21D34793D5C9E19420" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F998FCEF3B2980031D9993D5C9E1BBE6" xlink:to="loc_us-gaap_MaximumMember_E3FD526013C6FD21D34793D5C9E19420" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5F92934CDBECD2F9C64C93D5C9E14F20" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6F072C14B4E6B655C7AE93D5C9E1A820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5F92934CDBECD2F9C64C93D5C9E14F20" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ValuationOfGrantedStockUnitsAbstract" xlink:label="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5F92934CDBECD2F9C64C93D5C9E14F20" xlink:to="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_98FA3713CB727EDBB9EE93D5C9E1707A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_98FA3713CB727EDBB9EE93D5C9E1707A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_C0B74D6A2907A7BEA38093D5C9E15A2A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_C0B74D6A2907A7BEA38093D5C9E15A2A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9270EAF2B76108E47E8C93D5C9E10421" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_9270EAF2B76108E47E8C93D5C9E10421" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8CE6724163294A70034E93D5C9E15626" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8CE6724163294A70034E93D5C9E15626" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_B5A4A55E29F678A7735293D5C9E1359A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_B5A4A55E29F678A7735293D5C9E1359A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_9F2EBAFAD48B0C56739193D5C9E17280" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_9F2EBAFAD48B0C56739193D5C9E17280" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2AA64739946C70DB114393D5C9E2EF6C" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_ADC40861B43B3A805F5293D5C9E134BD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2AA64739946C70DB114393D5C9E2EF6C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B2165F08EDF6A53871DB38A3556C27DC" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_413BFD79D095683FAD3E38A3556C5795" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B2165F08EDF6A53871DB38A3556C27DC" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_413BFD79D095683FAD3E38A3556C5795" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B8875B37C21458C1430438A3556C2AAF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_413BFD79D095683FAD3E38A3556C5795" xlink:to="loc_us-gaap_AwardTypeAxis_B8875B37C21458C1430438A3556C2AAF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0A07D03EA37D677884BF38A3556C6667" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_B8875B37C21458C1430438A3556C2AAF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0A07D03EA37D677884BF38A3556C6667" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_C046B76FB400E76AC39E38A3556C91BA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0A07D03EA37D677884BF38A3556C6667" xlink:to="loc_biib_CashSettledPerformanceSharesMember_C046B76FB400E76AC39E38A3556C91BA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E8652754D1C974B2E2AF38A3556C6FD0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_413BFD79D095683FAD3E38A3556C5795" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E8652754D1C974B2E2AF38A3556C6FD0" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CashSettledPerformanceSharesAbstract" xlink:label="loc_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E8652754D1C974B2E2AF38A3556C6FD0" xlink:to="loc_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64F6BE16BF74B554900338A3556D80C1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64F6BE16BF74B554900338A3556D80C1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17D4B97A6D6C18A618FD38A3556DFDFC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17D4B97A6D6C18A618FD38A3556DFDFC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_AD5E5843647D156230CE38A3556D13FA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_AD5E5843647D156230CE38A3556D13FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6B5AAE4E80BE17FDE6DD38A3556D823E" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6B5AAE4E80BE17FDE6DD38A3556D823E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_D5C48F826260BF89E5F638A3556D5D91" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_C34FCB5137F8B48C707E38A3556CDB50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_D5C48F826260BF89E5F638A3556D5D91" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FA818C6774E69F464BDB38A3524A8802" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1897B6E0300D4C20A7BB38A3524A9159" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FA818C6774E69F464BDB38A3524A8802" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1897B6E0300D4C20A7BB38A3524A9159" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_59E0525AD706CEB260BD38A3524B7F42" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1897B6E0300D4C20A7BB38A3524A9159" xlink:to="loc_us-gaap_AwardTypeAxis_59E0525AD706CEB260BD38A3524B7F42" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8C0A09213216E1AB6E7438A3524B468F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_59E0525AD706CEB260BD38A3524B7F42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8C0A09213216E1AB6E7438A3524B468F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_4A05EAD367A6A271607B38A3524BFEF4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8C0A09213216E1AB6E7438A3524B468F" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_4A05EAD367A6A271607B38A3524BFEF4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A3CD57A145C20D0736C438A3524BE4F4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1897B6E0300D4C20A7BB38A3524A9159" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A3CD57A145C20D0736C438A3524BE4F4" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RestrictedStockUnitsActivityAbstract" xlink:label="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A3CD57A145C20D0736C438A3524BE4F4" xlink:to="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6D7B6A169ABDF8D8F7D038A3524B74CE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6D7B6A169ABDF8D8F7D038A3524B74CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8161A1F63DB5C454795C38A3524B1BE2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8161A1F63DB5C454795C38A3524B1BE2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2BC356A55B151B1810F838A3524B28E1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2BC356A55B151B1810F838A3524B28E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8D47E8E0566C2AE700DE38A3524B62C2" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8D47E8E0566C2AE700DE38A3524B62C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_34C8CE9B59A99EF230E538A3524B445C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_34C8CE9B59A99EF230E538A3524B445C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B9A9B37B33E9939DECB238A3524B5F72" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B9A9B37B33E9939DECB238A3524B5F72" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3FE41D41256140F5B38F38A3524B6B25" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3FE41D41256140F5B38F38A3524B6B25" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_80095C700D997D1936B038A3524B20A8" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_80095C700D997D1936B038A3524B20A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AB6FC5E827D7B42EB71538A3524BF47E" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_AB6FC5E827D7B42EB71538A3524BF47E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_600EF3758444FA1FD0D838A3524B957F" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_5D250F23F9EC1873D96C38A3524B4587" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_600EF3758444FA1FD0D838A3524B957F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A24C753FAA5006E939FD38A3553E1388" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_06DA34F5BA55FD26713C38A3553EE0D6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A24C753FAA5006E939FD38A3553E1388" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_06DA34F5BA55FD26713C38A3553EE0D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_61F0B20E9C75EB6848DB38A3553E4689" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_06DA34F5BA55FD26713C38A3553EE0D6" xlink:to="loc_us-gaap_PlanNameAxis_61F0B20E9C75EB6848DB38A3553E4689" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_057C8AD5FD561AA629E338A3553E4247" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_61F0B20E9C75EB6848DB38A3553E4689" xlink:to="loc_us-gaap_PlanNameDomain_057C8AD5FD561AA629E338A3553E4247" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_2F37A9AA31DCE4F00E7238A3553E5983" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_057C8AD5FD561AA629E338A3553E4247" xlink:to="loc_biib_A2015ESPPMember_2F37A9AA31DCE4F00E7238A3553E5983" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_A1995ESPPMember" xlink:label="loc_biib_A1995ESPPMember_50181B306D5DD784FDB938A3553ED876" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_057C8AD5FD561AA629E338A3553E4247" xlink:to="loc_biib_A1995ESPPMember_50181B306D5DD784FDB938A3553ED876" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_F1F2DFF925DD78279ABB38A3553E6A73" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_06DA34F5BA55FD26713C38A3553EE0D6" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_F1F2DFF925DD78279ABB38A3553E6A73" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_29FD4852B22FC9A7A0DE38A3553E5ED0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_F1F2DFF925DD78279ABB38A3553E6A73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_29FD4852B22FC9A7A0DE38A3553E5ED0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E14C1F0C38DEF3E95CAD38A3553E388F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_F1F2DFF925DD78279ABB38A3553E6A73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E14C1F0C38DEF3E95CAD38A3553E388F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C7C80240BDED6C2E0A9898B5C4E82675" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98E427C7314B6526C91B98B5C4EA7F3A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C7C80240BDED6C2E0A9898B5C4E82675" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98E427C7314B6526C91B98B5C4EA7F3A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_40E8C87B70D34F424B0198B5C4EBBA46" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98E427C7314B6526C91B98B5C4EA7F3A" xlink:to="loc_us-gaap_VestingAxis_40E8C87B70D34F424B0198B5C4EBBA46" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_13260DB5A6AF6849214F98B5C4EBD1D1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_40E8C87B70D34F424B0198B5C4EBBA46" xlink:to="loc_us-gaap_VestingDomain_13260DB5A6AF6849214F98B5C4EBD1D1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_D42223038A32C35DD0E198B5C4EBBD43" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_13260DB5A6AF6849214F98B5C4EBD1D1" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_D42223038A32C35DD0E198B5C4EBBD43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_41167DC81BCD8DB47F6998B5C4EC6B0D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98E427C7314B6526C91B98B5C4EA7F3A" xlink:to="loc_us-gaap_TitleOfIndividualAxis_41167DC81BCD8DB47F6998B5C4EC6B0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_DFE56EFFA4168C169F0698B5C4ECD2D6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_41167DC81BCD8DB47F6998B5C4EC6B0D" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_DFE56EFFA4168C169F0698B5C4ECD2D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_BA32105F96DE220C366598B5C4ECA349" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_DFE56EFFA4168C169F0698B5C4ECD2D6" xlink:to="loc_us-gaap_DirectorMember_BA32105F96DE220C366598B5C4ECA349" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ShareBasedCompensationPlanAxis" xlink:label="loc_biib_ShareBasedCompensationPlanAxis_4063594AD7691594A39498B5C4EC7522" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98E427C7314B6526C91B98B5C4EA7F3A" xlink:to="loc_biib_ShareBasedCompensationPlanAxis_4063594AD7691594A39498B5C4EC7522" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ShareBasedCompensationPlanDomain" xlink:label="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedCompensationPlanAxis_4063594AD7691594A39498B5C4EC7522" xlink:to="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DirectorsPlanMember" xlink:label="loc_biib_DirectorsPlanMember_A3EE5948A54486A74ECF98B5C4EC55DA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:to="loc_biib_DirectorsPlanMember_A3EE5948A54486A74ECF98B5C4EC55DA" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_OmnibusPlansMember" xlink:label="loc_biib_OmnibusPlansMember_4DEFADDA318BD6DB40B098B5C4EDB1C7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:to="loc_biib_OmnibusPlansMember_4DEFADDA318BD6DB40B098B5C4EDB1C7" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AttainmentOfPerformanceCriteriain2014Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2014Member_159C56D155D476E1AB1398B5C4ED79D9" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:to="loc_biib_AttainmentOfPerformanceCriteriain2014Member_159C56D155D476E1AB1398B5C4ED79D9" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AttainmentOfPerformanceCriteriain2013Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2013Member_FD04B19BDA389B0E466398B5C4EDF891" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:to="loc_biib_AttainmentOfPerformanceCriteriain2013Member_FD04B19BDA389B0E466398B5C4EDF891" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AttainmentOfPerformanceCriteriain2012Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2012Member_EDEA18D7F463F31C5E9B98B5C4EDACEC" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:to="loc_biib_AttainmentOfPerformanceCriteriain2012Member_EDEA18D7F463F31C5E9B98B5C4EDACEC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AttainmentOfPerformanceCriteriain2011Member" xlink:label="loc_biib_AttainmentOfPerformanceCriteriain2011Member_1ADE04A9800A9514912B98B5C4EDD51D" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedCompensationPlanDomain_BC0AED3A0F6D643197DE98B5C4EC3F49" xlink:to="loc_biib_AttainmentOfPerformanceCriteriain2011Member_1ADE04A9800A9514912B98B5C4EDD51D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E91EEEBCAE1706E488B498B5C4EDF6CC" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98E427C7314B6526C91B98B5C4EA7F3A" xlink:to="loc_us-gaap_AwardTypeAxis_E91EEEBCAE1706E488B498B5C4EDF6CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08CA3F9AB21918A8179098B5C4EDCAC6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_E91EEEBCAE1706E488B498B5C4EDF6CC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08CA3F9AB21918A8179098B5C4EDCAC6" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_191DD044B4A36E54C5D898B5C4ED9AFC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08CA3F9AB21918A8179098B5C4EDCAC6" xlink:to="loc_biib_MarketStockUnitsMember_191DD044B4A36E54C5D898B5C4ED9AFC" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_992B527D01AE4C4F8C4E98B5C4ED6301" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08CA3F9AB21918A8179098B5C4EDCAC6" xlink:to="loc_biib_CashSettledPerformanceSharesMember_992B527D01AE4C4F8C4E98B5C4ED6301" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_D04701A8F3E67C2FC84B98B5C4EDDD87" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08CA3F9AB21918A8179098B5C4EDCAC6" xlink:to="loc_us-gaap_PerformanceSharesMember_D04701A8F3E67C2FC84B98B5C4EDDD87" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_4FD05C4E37D1A693148498B5C4EE526F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08CA3F9AB21918A8179098B5C4EDCAC6" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_4FD05C4E37D1A693148498B5C4EE526F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98E427C7314B6526C91B98B5C4EA7F3A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NumberOfSharesOfCommonStockForIssuance" xlink:label="loc_biib_NumberOfSharesOfCommonStockForIssuance_2B0DF2A4D268F276B56198B5C4EEC811" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_biib_NumberOfSharesOfCommonStockForIssuance_2B0DF2A4D268F276B56198B5C4EEC811" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_597416A45ACED01D19E098B5C4EE28E8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_597416A45ACED01D19E098B5C4EE28E8" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NumberOfEqualAnnualIncrements" xlink:label="loc_biib_NumberOfEqualAnnualIncrements_B9A834D8514C3AE51A7998B5C4EEB50B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_biib_NumberOfEqualAnnualIncrements_B9A834D8514C3AE51A7998B5C4EEB50B" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_8258BA110B8D8B04771798B5C4EE0DAE" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_8258BA110B8D8B04771798B5C4EE0DAE" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_E5BEAF446BB760BEDF6598B5C4EE3FBF" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_E5BEAF446BB760BEDF6598B5C4EE3FBF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3D581C856263EF9AA89598B5C4EE478F" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3D581C856263EF9AA89598B5C4EE478F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards" xlink:label="loc_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_83EEACD96D8765AC10D898B5C4EED193" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards_83EEACD96D8765AC10D898B5C4EED193" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_10B5CF33AA88725F456F98B5C4EED138" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_10B5CF33AA88725F456F98B5C4EED138" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_E94502BB5C80D2F277FE98B5C4EF806D" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_E94502BB5C80D2F277FE98B5C4EF806D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_EDB9D6FB8745EEB108DA98B5C4EF9473" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_EDB9D6FB8745EEB108DA98B5C4EF9473" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6A9F40DE69AF084A27698B5C4EF1576" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6A9F40DE69AF084A27698B5C4EF1576" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7F41815A59F143F8271398B5C4EF2D52" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C24DC59B85D36B98D0D398B5C4EED878" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7F41815A59F143F8271398B5C4EF2D52" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ShareBasedPaymentsTextualAbstract" xlink:label="loc_biib_ShareBasedPaymentsTextualAbstract_026AEF02AE5EB0D6961F98B5C4EFC49B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C7C80240BDED6C2E0A9898B5C4E82675" xlink:to="loc_biib_ShareBasedPaymentsTextualAbstract_026AEF02AE5EB0D6961F98B5C4EFC49B" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation" xlink:label="loc_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_24C44461E8AFE0F2C2A398B5C4EFDAB2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_026AEF02AE5EB0D6961F98B5C4EFC49B" xlink:to="loc_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation_24C44461E8AFE0F2C2A398B5C4EFDAB2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FF0BC73D19B3F6F7DDB198B5C4EFDCEF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_026AEF02AE5EB0D6961F98B5C4EFC49B" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FF0BC73D19B3F6F7DDB198B5C4EFDCEF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" xlink:label="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_280FEC9EB7B28E1E5EF198B5C4EFC7D1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_026AEF02AE5EB0D6961F98B5C4EFC49B" xlink:to="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_280FEC9EB7B28E1E5EF198B5C4EFC7D1" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" xlink:label="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_C2302BB5CDC4AA90C00898B5C4EF91F0" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_026AEF02AE5EB0D6961F98B5C4EFC49B" xlink:to="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_C2302BB5CDC4AA90C00898B5C4EF91F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_22B354F8EB2930830FC098B5C4F0E1EF" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_026AEF02AE5EB0D6961F98B5C4EFC49B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_22B354F8EB2930830FC098B5C4F0E1EF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F641DF2680CA9F2F3EF398B5C4F0C5D3" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_026AEF02AE5EB0D6961F98B5C4EFC49B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F641DF2680CA9F2F3EF398B5C4F0C5D3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_349163CFF10125BAEBED98B5C4F0EFDF" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_026AEF02AE5EB0D6961F98B5C4EFC49B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_349163CFF10125BAEBED98B5C4F0EFDF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_06B83798BF11C9CD584198B5C4F004E1" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_026AEF02AE5EB0D6961F98B5C4EFC49B" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_06B83798BF11C9CD584198B5C4F004E1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C92389E9AED6E066EEF638A35154F3F4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932C68CAA782F08C66EE38A351549FD9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C92389E9AED6E066EEF638A35154F3F4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932C68CAA782F08C66EE38A351549FD9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D5D8B9FFCA6354DF295038A35154763A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932C68CAA782F08C66EE38A351549FD9" xlink:to="loc_us-gaap_AwardTypeAxis_D5D8B9FFCA6354DF295038A35154763A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_228D3EE77ED713BCC6F838A35154F445" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_D5D8B9FFCA6354DF295038A35154763A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_228D3EE77ED713BCC6F838A35154F445" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_0E29942217448DF67B7538A351548072" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_228D3EE77ED713BCC6F838A35154F445" xlink:to="loc_us-gaap_PerformanceSharesMember_0E29942217448DF67B7538A351548072" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C9E22B40D2ADEE8BB4BB38A35154A97C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932C68CAA782F08C66EE38A351549FD9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C9E22B40D2ADEE8BB4BB38A35154A97C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5F8E4546BD0D78A908B438A35154DFA9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C9E22B40D2ADEE8BB4BB38A35154A97C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5F8E4546BD0D78A908B438A35154DFA9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_47110D444F01E346372D38A35154C7A5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C9E22B40D2ADEE8BB4BB38A35154A97C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_47110D444F01E346372D38A35154C7A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_81819268573DF887430D38A351541C6B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C9E22B40D2ADEE8BB4BB38A35154A97C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_81819268573DF887430D38A351541C6B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8B55A0CC777ADA4C928038A351549415" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C9E22B40D2ADEE8BB4BB38A35154A97C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8B55A0CC777ADA4C928038A351549415" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00B2774E8C31B8B4A22338A351543B5D" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C9E22B40D2ADEE8BB4BB38A35154A97C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00B2774E8C31B8B4A22338A351543B5D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5990BD96691471771B9238A3533714A9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0A3D4999315E6FBDE7B738A35337B497" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5990BD96691471771B9238A3533714A9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0A3D4999315E6FBDE7B738A35337B497" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8308648ACADD6FDDEB9B38A35337A635" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5990BD96691471771B9238A3533714A9" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8308648ACADD6FDDEB9B38A35337A635" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_93ACC9B4D340EDA02A2938A35337A575" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5990BD96691471771B9238A3533714A9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_93ACC9B4D340EDA02A2938A35337A575" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock_E0CAC3CDE8862A85A4E838A35337E024" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5990BD96691471771B9238A3533714A9" xlink:to="loc_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock_E0CAC3CDE8862A85A4E838A35337E024" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_1176190B842E78BCEF9438A35337932F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5990BD96691471771B9238A3533714A9" xlink:to="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_1176190B842E78BCEF9438A35337932F" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" xlink:label="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F621CC2E288380B2A6238A35337141B" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5990BD96691471771B9238A3533714A9" xlink:to="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_4F621CC2E288380B2A6238A35337141B" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_7F191088F1D189683E0A38A3533795C4" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5990BD96691471771B9238A3533714A9" xlink:to="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_7F191088F1D189683E0A38A3533795C4" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PerformanceunitsactivityTableTextBlock" xlink:label="loc_biib_PerformanceunitsactivityTableTextBlock_BBB1B5A845E01B63B77D38A353378611" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5990BD96691471771B9238A3533714A9" xlink:to="loc_biib_PerformanceunitsactivityTableTextBlock_BBB1B5A845E01B63B77D38A353378611" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_5BDF64A4DE698C6828E238A3533701D4" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5990BD96691471771B9238A3533714A9" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_5BDF64A4DE698C6828E238A3533701D4" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" xlink:label="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_33DADADAB25D4EE39B7838A3533745B4" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5990BD96691471771B9238A3533714A9" xlink:to="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_33DADADAB25D4EE39B7838A3533745B4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_CBAA42770409FBD6B7B338A353D8A18C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_10918401BC3356F9359638A353D8DCE0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CBAA42770409FBD6B7B338A353D8A18C" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_10918401BC3356F9359638A353D8DCE0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_16D7B5CD516D0326970193224D467E38" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B4CCB43E4070121DA97493224D467AD5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_16D7B5CD516D0326970193224D467E38" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B4CCB43E4070121DA97493224D467AD5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_EF24D297BC275530EFE293224D466DA8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B4CCB43E4070121DA97493224D467AD5" xlink:to="loc_us-gaap_StatementGeographicalAxis_EF24D297BC275530EFE293224D466DA8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_B6E7172E9FB6C9D7012793224D46E44E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_EF24D297BC275530EFE293224D466DA8" xlink:to="loc_us-gaap_SegmentGeographicalDomain_B6E7172E9FB6C9D7012793224D46E44E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_SpainandPortugalMember" xlink:label="loc_biib_SpainandPortugalMember_7382CD86A808443C9CD093224D468088" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_B6E7172E9FB6C9D7012793224D46E44E" xlink:to="loc_biib_SpainandPortugalMember_7382CD86A808443C9CD093224D468088" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_CF05B3CB6FB3E1AFF4E493224D461A39" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B4CCB43E4070121DA97493224D467AD5" xlink:to="loc_biib_MajorDistributorAxis_CF05B3CB6FB3E1AFF4E493224D461A39" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_D19608FF0747B56D040093224D469412" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorAxis_CF05B3CB6FB3E1AFF4E493224D461A39" xlink:to="loc_biib_MajorDistributorDomain_D19608FF0747B56D040093224D469412" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_1B9F233B92ECCA027B4893224D46F4D4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorDomain_D19608FF0747B56D040093224D469412" xlink:to="loc_biib_DistributorOneMember_1B9F233B92ECCA027B4893224D46F4D4" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_BE97007B48D86CCBC8C593224D46DDB5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorDomain_D19608FF0747B56D040093224D469412" xlink:to="loc_biib_DistributorTwoMember_BE97007B48D86CCBC8C593224D46DDB5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_3ED29BDE91B0021A2F6493224D472B91" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B4CCB43E4070121DA97493224D467AD5" xlink:to="loc_us-gaap_RangeAxis_3ED29BDE91B0021A2F6493224D472B91" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1D50EB45A40490755A2393224D47B0F8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_3ED29BDE91B0021A2F6493224D472B91" xlink:to="loc_us-gaap_RangeMember_1D50EB45A40490755A2393224D47B0F8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_DC21457430B0BED56D2593224D477B76" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_1D50EB45A40490755A2393224D47B0F8" xlink:to="loc_us-gaap_MinimumMember_DC21457430B0BED56D2593224D477B76" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_A5452D4CF061D8C7CF0893224D4715E1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_1D50EB45A40490755A2393224D47B0F8" xlink:to="loc_us-gaap_MaximumMember_A5452D4CF061D8C7CF0893224D4715E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3FAF792965252BA5FD8993224D476AA5" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B4CCB43E4070121DA97493224D467AD5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3FAF792965252BA5FD8993224D476AA5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D80420BD8E99199C49DD93224D47ABCA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3FAF792965252BA5FD8993224D476AA5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D80420BD8E99199C49DD93224D47ABCA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_F6FC6A92C38C6118E51193224D47BE04" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D80420BD8E99199C49DD93224D47ABCA" xlink:to="loc_us-gaap_BuildingMember_F6FC6A92C38C6118E51193224D47BE04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_592C85B726B8154E5E3893224D47D094" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D80420BD8E99199C49DD93224D47ABCA" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_592C85B726B8154E5E3893224D47D094" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_74A7217FED99D99C460E93224D47991A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D80420BD8E99199C49DD93224D47ABCA" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_74A7217FED99D99C460E93224D47991A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_C77E064D4342DB0D363093224D47B055" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D80420BD8E99199C49DD93224D47ABCA" xlink:to="loc_us-gaap_ComputerEquipmentMember_C77E064D4342DB0D363093224D47B055" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_46A962654E2245A594B393224D476A77" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B4CCB43E4070121DA97493224D467AD5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_46A962654E2245A594B393224D476A77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8FDE3AC732279BA4AB8493224D47304D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_46A962654E2245A594B393224D476A77" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8FDE3AC732279BA4AB8493224D47304D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetNoncurrent" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_D86F647C9562E54C0D4E93224D47F020" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_46A962654E2245A594B393224D476A77" xlink:to="loc_us-gaap_AccountsReceivableNetNoncurrent_D86F647C9562E54C0D4E93224D47F020" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:label="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_F58901727424061506FF93224D47386C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_46A962654E2245A594B393224D476A77" xlink:to="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_F58901727424061506FF93224D47386C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4F13D15A1F955C16DAD693224D474E44" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_46A962654E2245A594B393224D476A77" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4F13D15A1F955C16DAD693224D474E44" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_BusinessTextualAbstract" xlink:label="loc_biib_BusinessTextualAbstract_6C798F31A1A8CD1A91EF93224D47614A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_16D7B5CD516D0326970193224D467E38" xlink:to="loc_biib_BusinessTextualAbstract_6C798F31A1A8CD1A91EF93224D47614A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_E0108D6025BBFE911F2E93224D470401" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_6C798F31A1A8CD1A91EF93224D47614A" xlink:to="loc_biib_InterestInSubsidiary_E0108D6025BBFE911F2E93224D470401" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PaymentTermsOfAccountsReceivable" xlink:label="loc_biib_PaymentTermsOfAccountsReceivable_62CE54EA96E9EED23ED693224D470737" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_6C798F31A1A8CD1A91EF93224D47614A" xlink:to="loc_biib_PaymentTermsOfAccountsReceivable_62CE54EA96E9EED23ED693224D470737" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_EstimatedUsefulLivesOfLeaseholdImprovements" xlink:label="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_ECA68A6D3C7BE9DE91C493224D47638D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_6C798F31A1A8CD1A91EF93224D47614A" xlink:to="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_ECA68A6D3C7BE9DE91C493224D47638D" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PurchasePriceOfCommonStockUnderEspp" xlink:label="loc_biib_PurchasePriceOfCommonStockUnderEspp_72B7744049EC244E761493224D48744A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_6C798F31A1A8CD1A91EF93224D47614A" xlink:to="loc_biib_PurchasePriceOfCommonStockUnderEspp_72B7744049EC244E761493224D48744A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_PercentageOfMarketValuePerShareOfCommonStock" xlink:label="loc_biib_PercentageOfMarketValuePerShareOfCommonStock_1DE036031D00C4126EA993224D48556A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_6C798F31A1A8CD1A91EF93224D47614A" xlink:to="loc_biib_PercentageOfMarketValuePerShareOfCommonStock_1DE036031D00C4126EA993224D48556A" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_CompensationExpenseOverPurchasePeriod" xlink:label="loc_biib_CompensationExpenseOverPurchasePeriod_1905BF3F3EFC83956A4693224D486D5E" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_6C798F31A1A8CD1A91EF93224D47614A" xlink:to="loc_biib_CompensationExpenseOverPurchasePeriod_1905BF3F3EFC83956A4693224D486D5E" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_DiscountRateRecognizedInCompensationExpense" xlink:label="loc_biib_DiscountRateRecognizedInCompensationExpense_3B692CDCE560E41116CF93224D487FE4" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_6C798F31A1A8CD1A91EF93224D47614A" xlink:to="loc_biib_DiscountRateRecognizedInCompensationExpense_3B692CDCE560E41116CF93224D487FE4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_AB848642F67A41E571A893224D482081" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_6C798F31A1A8CD1A91EF93224D47614A" xlink:to="loc_us-gaap_AdvertisingExpense_AB848642F67A41E571A893224D482081" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:type="locator" />
    <loc xlink:href="biib-20151231.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_A06720D624E707D68D8B38A354C9CDD4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_A06720D624E707D68D8B38A354C9CDD4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_B1EB8A03646326DEC51C38A354C9CE4A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_B1EB8A03646326DEC51C38A354C9CE4A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_FCCE7650F0E3A88C262438A354C95A11" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_UseOfEstimates_FCCE7650F0E3A88C262438A354C95A11" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_7A590073499F1CEAA33838A354C91654" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_7A590073499F1CEAA33838A354C91654" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_8AD5E14C3EEB5DD0F0EC38A354CAA3D9" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_8AD5E14C3EEB5DD0F0EC38A354CAA3D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32C6B715D7F4B49514BA38A354CA7278" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32C6B715D7F4B49514BA38A354CA7278" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_A2FBF6D5A6BAFFD38E5E38A354CA722F" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_A2FBF6D5A6BAFFD38E5E38A354CA722F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_63592F92384D82EFE17D38A354CA93D0" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_63592F92384D82EFE17D38A354CA93D0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_C6DB3090E890EB7A471E38A354CBC414" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_C6DB3090E890EB7A471E38A354CBC414" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_0455DA74069A8F606FD238A354CB75EC" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_0455DA74069A8F606FD238A354CB75EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_DE0CB3B15C4A9518F15D38A354CB4DB1" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_DE0CB3B15C4A9518F15D38A354CB4DB1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6DBBD3DA5E82D6EB407D38A354CB6FC0" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6DBBD3DA5E82D6EB407D38A354CB6FC0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_64269D44B4861E5987FC38A354CBD803" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_64269D44B4861E5987FC38A354CBD803" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_172A747579B8A25CDF3038A354CB0395" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_172A747579B8A25CDF3038A354CB0395" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1F632CE067E4ECFF0A6538A354CB24EF" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1F632CE067E4ECFF0A6538A354CB24EF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_C72C1E92E44241FCA47938A354CB0E98" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_C72C1E92E44241FCA47938A354CB0E98" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_9744106FBB21A853AF5838A354CBC9A2" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_9744106FBB21A853AF5838A354CBC9A2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_A09D858852F4C53ECC1E38A354CB5DF4" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_A09D858852F4C53ECC1E38A354CB5DF4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_7A052EDE2DB3901B1AFE38A354CB4DFF" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_7A052EDE2DB3901B1AFE38A354CB4DFF" xlink:type="arc" />
    <loc xlink:href="biib-20151231.xsd#biib_RoyaltyCostofSalesPolicyTextBlock" xlink:label="loc_biib_RoyaltyCostofSalesPolicyTextBlock_6F150555ADA2AF5352B738A354CBF881" xlink:type="locator" />
    <presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_biib_RoyaltyCostofSalesPolicyTextBlock_6F150555ADA2AF5352B738A354CBF881" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_16202B3F198C4D57647138A354CB0B3A" xlink:type="locator" />
    <presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_16202B3F198C4D57647138A354CB0B3A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_5A0F705F87901A5DA53938A354CB64D9" xlink:type="locator" />
    <presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_5A0F705F87901A5DA53938A354CB64D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_D2C5813874BB18C9D08138A354CB1A02" xlink:type="locator" />
    <presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_D2C5813874BB18C9D08138A354CB1A02" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_2125F2319C41BC03CD8838A354CBFB90" xlink:type="locator" />
    <presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_2125F2319C41BC03CD8838A354CBFB90" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_2EE2B2EC0A7626FE3A7238A354CB16EF" xlink:type="locator" />
    <presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_2EE2B2EC0A7626FE3A7238A354CB16EF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_E8EC518AA4888EE77E3C38A354CB51CD" xlink:type="locator" />
    <presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_E8EC518AA4888EE77E3C38A354CB51CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_B98C0FFB093AC41D542638A354CCCDA6" xlink:type="locator" />
    <presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05919BA5820E3D64170B38A354C9BD64" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_B98C0FFB093AC41D542638A354CCCDA6" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6F62B0DE6FD5F290D98338A3569CE8C5" xlink:type="locator" />
    <loc xlink:href="biib-20151231.xsd#biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_D235947EBAD0641F828438A3569C80DC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6F62B0DE6FD5F290D98338A3569CE8C5" xlink:to="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_D235947EBAD0641F828438A3569C80DC" xlink:type="arc" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>alprolix.jpg
<TEXT>
begin 644 alprolix.jpg
M_]C_X  02D9)1@ ! 0$ CP".  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !? 9(# 2(  A$! Q$!_\0
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M-N"S(?-1,Y*CC'3WIUQX/UO2]<U"_P##%_:Q1ZCS-%<J?D;^\I&?6FYJ[U]
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= YQZU/,I+E7D!X')_K'^IHI7&YV/J:*]:Q9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>alprolixchart.jpg
<TEXT>
begin 644 alprolixchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
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M"\'?LH_$[XB_M?\ Q!35;SP'/\2/&OAOQIX.\!_!/1_$&@ZO\/\ PHUCJGB
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MQ^T7\<O%'QK\._!_X,Z/\%_@G#%\._AWX%TGP%9:&?AVUAX^U+P[!9^*-/\
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M[S5_$%SJNM:AH_&;]D;4OC=XOC?Q9\</'+_".X\=_#?XEZA\+$\.>!7O=/\
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M>ZSX(@^'GA/XC>.=:U7Q;\-/BCX=T+5?"?PANXK/XHZYX(UW5_!MGI/Q$LO
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M7Q&OASX@W]WHOA7P;X?^'^A^(O$OP_T;Q/X;A\9^'8_^$>\2ZG%WW[(7PO\
MC#X#\?:4;CPC\;/A1\']!^ FA^!O$_@GXY?M$V'Q^N?%?Q?TC5_#T'A[Q;\-
M9++Q=XW@\+^%?#7@W2_%6BZYJEN?AC;^/I/$?A24?";0IO",LZ 'Z144W>G]
MY?\ OH?XT;T_O+_WT/\ &@!U%-WI_>7_ +Z'^-&]/[R_]]#_ !H =13=Z?WE
M_P"^A_C1O3^\O_?0_P : '44W>G]Y?\ OH?XT;T_O+_WT/\ &@!U%-WI_>7_
M +Z'^-&]/[R_]]#_ !H =13=Z?WE_P"^A_C1O3^\O_?0_P : '44W>G]Y?\
MOH?XT;T_O+_WT/\ &@!U%-WI_>7_ +Z'^-&]/[R_]]#_ !H =13=Z?WE_P"^
MA_C1O3^\O_?0_P : '44W>G]Y?\ OH?XT;T_O+_WT/\ &@!U%-WI_>7_ +Z'
M^-*"#T(/T(/\J %HHHH **** "BBB@ HHHH **** /P[_P""EL$-S_P4?_X(
M5PW$,4\+_M6_M/;XIHTEB?;^QW\0&7=&X9&VLJL,@X8 CD U]]?M=?M ^$_V
M3OAQX?\ ']Y\+;+QS'K?B^P\(+I=G<Z3H$MN]YHFM:P+]KNZT?4TE2,:,UN;
M<0([-<+()0(V1_@K_@I/_P I)/\ @A3_ -G6_M0?^L<_$&O4/^"Q'_)MWP__
M .RRZ#_ZA/C>N/'U:E#!UZM*7+4A"\964K/F2O:2:>CZIGN\,X+#9CG^5X+&
M4_:X;$XJ-.M3YYT^>#C)M<]*4*D=4G>,D_.QXC_P^$\ _P#1K4O_ (6WAO\
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M HHHH **** "BBB@#\._^"ETK0_\%'_^"%DBP37++^U;^T_B&W$1F?/['?Q
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MLBEX09,G=9IF2;23:A@TVEJEIA]DW)KM?UO_ $;?\-,_L\_]%I^'7_A0P_\
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M<U>LKR:[\WS=.OK#R]FW[8+,>;NW9\O[+>W?W-HW^9Y?WEV[N=M^B@ HHHH
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MI5C::9IFFVL%CI^G6%O%:65C8VL:P6EI:6L*I#;6UO D<4%O$B1P1(L2*J*
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M_P#QBK5M8V5EO^QVEK:^9M\S[-;PP;]N=N_RD3=MW-MW9QDXQDYMT4 %%%%
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M_M34?^A;U7_P*T'_ .7%;=% &)_:FH_]"WJO_@5H/_RXH_M34?\ H6]5_P#
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MVVG06MA;RW<JO/)#9VT%M$TA2")(U50 ?B?_ ,%)_P#E))_P0I_[.M_:@_\
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MH5)XFDZ=6AB8RC5P>+KX*O:^9Q<J;K8>HZ-1Q@ZM%TZCA#GY%_I=:)_P6O\
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M& D$HJG!(!(S@D+Q\HQ];_\ !2?_ )22?\$*?^SK?VH/_6.?B#7R=_P=1?\
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MA_\ !TO=W=Q^P7\%TGTF\L$7]J[P:1+<7&F3(S#X3?%\!%6RO;F3+ E@Q0(
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M'\66#Z'\C1@^A_(U_?#_ ,0F_P#P31_Z*/\ MP?^),M_\P5'_$)O_P $T?\
MHH_[<'_B3+?_ #!4?\0RQW_0UPG_ ((K>7GYO[O,/^)NN'?^B.SS_P +\O\
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M9+2S.G56,KX>NZ[Q\L!*#IN@ERJG]3ES*6_/&VS/VFR/?\C_ (49'O\ D?\
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M:XC%NPN(0\)*[PZ_Q_>-K*\/C;QJ19WA!\:^,2#]CNN1_P )/JW/^IK]G_\
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MC[Q%\4OV?_A#\1/%LME-XE\9> ]!\0:Y+IUF-/L9-2U"V,MRUK8K+.+6 O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>amortizationchart.jpg
<TEXT>
begin 644 amortizationchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MKI_FFV$X\W9O\Z\O;O[F[;M^V7-QY?WCGR]F[C=NPN "_1110 4444 %%%%
M!1110 4444 ?B!_P4G_Y22?\$*?^SK?VH/\ UCGX@U^WD?\ JX_]Q?\ T$5^
M(?\ P4G_ .4DG_!"G_LZW]J#_P!8Y^(-?MY'_JX_]Q?_ $$4 /HHHH ****
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M[9X1?PL^_P"OF6_^DXT?1>K_ $,'[)XA_P"@U8_^"-O_ )<4?9/$/_0:L?\
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MK5O<^2?AY^S[XY\*_##0?@[K?B3X._\ "N[J\^*6E_%CP_X(^&/Q!L;KXF^
M_B;X)UW2-4@D\7_$'XR_$#QCI_Q5U?QYXAU'QUX_^+GB#5O&FI^.XI[G2KK2
M=.U.Z?Q%'A?L\?LB2_!#Q5X)\2:IXX\/^)E^$W[.UA^RU\,[7PG\,+#X9W%S
M\+[#Q)X7\2QZW\6[ZS\3^(Q\1?B.;CP;H5O;:E8VWA;PMH\]SXSU[2?#4&M>
M/]<DM_M.BL7F.,E&O!U5RXEN5?\ =TKU)/VG--SY.=3FJLXSFI*<X-0DW",8
MQ+OO_2_K^KA7UU\$O^1+;_L-:E_[0KY%KZE^#]WJ4'A%DM-+^V1?VOJ#>=]O
MMK;YR8=R>5*C/\N!\V<-GCI7V_A?_P E._\ L6XO_P!.X4.C]5^4CW.OBCXJ
M?\C]XA_ZZV/_ *:[&OK?^T=;_P"@#_Y5K+_XW7R#\2Y)I?&^NR7$'V69I+$R
M0>='<>6?[,L@!YT06-]R@-\H&W=L;+*37WGBQ_R(,#_V.*/_ *A8\1PM%%%?
MS^ 4444 %%%% %[3/^0EIW_80L/_ $L@K]"J_/3321J-@5&YA?V15<A=S"[A
M(7<>%W' W'@9R>!7W7_:.M_] '_RKV7_ ,;K]L\(OX6??]?,M_\ 2<:/HO5_
ME$@\::C>:3X4U[4M/E\B]L].GGMIMD<OERH!M?RY5>-\9^ZZ,I[@U\K'XL^/
M@2/[<'!Q_P @W2__ )"KZ"\>WNK2>#?$<<^C>1"VEW DF_M.TE\I<#+^6D8>
M3''R*0S= :^-FZGZG^=<_B=FN:8#-LOIX',<=@J<\N4YPPN+Q&'A.?UFO'GE
M&E4A&4N5*/,TW9)7LD@Z+U?Z?YA\5_VM]/\ @7X$UKXF_&#XK>&OAUX"\/)
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M7B*^*KSJ8U3KXBK4KUIJ.-Q$8J52K*4Y*,4HQO)VBDE9)(1H4445]B 4444
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M2_#'Q*U'XJ^,O!G@C4_ OC_5?#$FAZIXNT>YNM7FTRS\3WOA[-^)G_!1_P
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MH/ASP_<:WK$VFOJ5U[I110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>avonex.jpg
<TEXT>
begin 644 avonex.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !5 .(# 2(  A$! Q$!_\0
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M0JJ.PJ6N&M5=27,Q-B8HI:*R$(.E+2#I6=X@U-='T.ZO6(!B0E<]V[4TFW9
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M*** $'2O./BUJVV"TTN-N7/G2 >@X'ZYKT?M7.:OX$TK6]0>\O?/:5@!Q)@
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M&JS<?$;48,7;>'[A=-)XF?()'KTQ6TJ4IPAR]@/0**Q7\5Z:GAO^V_,)M2.
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>avonexchart.jpg
<TEXT>
begin 644 avonexchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
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M"\'?LH_$[XB_M?\ Q!35;SP'/\2/&OAOQIX.\!_!/1_$&@ZO\/\ PHUCJGB
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MQ^T7\<O%'QK\._!_X,Z/\%_@G#%\._AWX%TGP%9:&?AVUAX^U+P[!9^*-/\
M'WQ%$?PL\(Z5+>>+)+GP<WAM_%/AV/P5#8>,O$1O #ZSU3]NG]FK1=$M-8U7
MQ=XILKNXU/Q5I5[X-E^$GQ?;XF^&YO 6B>'?$WCN]\9_"N'P++\1/!6@^"_#
M'B[PGXF\2>)O%/AK2O#NG>'_ !9X2U9M4DM/%?AR35'ZS^W5^RYX?E^(3:O\
M3/L>E?#'P[\2O$OB;Q8_@_QV? =S9_!OP_>>*OBQIWA#X@+X9/@KX@>)OAUX
M>T^_U3QAX3\#:]XA\2:+#INL1W.F"YT'78=,\(\(_P#!.+2?AM%X9\0_"7XJ
M_P#"E?BIID7Q1T/7/&OP<^!_P,^'_A_5/!/QCC^%D?C'P]IGPVTSPA)X:TG5
M+"Y^"GPUUSP=XUU2?Q3XHT37=#G35KOQ-X5U!_"4'!ZQ_P $B?@E?#]HNQTK
M6['0=-^/G@O]IW0?[9MO@Y\&+[XK>%?$O[6?AWQIHOQ1\3M\:]0\(S?$;Q/;
M6U]\0O%^M^%O#NH:MI\-B^N7>@ZSJFO^%;?2]$TT ]\\4?\ !1C]F;2++Q3:
M:)XMU/6O&F@W>M>'+7PGJ7@7XF>%$N/'J?#B_P#BCX$\(:YXAUSP1!H_@]OB
M]X2LEU;X1ZWXAFM-)^)UA*9O %QXEN8C9MG?"+_@I#^SO\1_A!X$^(VN:OK7
M@WQ1XP^%_P !/B-_PK!_!/Q,UCQ=JI_:$T47?@BP^%&E)X$L-?\ CEI>H:_9
M^(O#&G>)_AGH&MZ7>7GAG6+JZ&F6EI-)'PWQ#_X)D>"/B)JWQ*U34/BIXVL?
M^%E?%C]F/XJZC:VVD^')8K"\_9G^%EM\+-'T6U>>$R2Z?XML+8:MKEQ<$WEE
M?L8]+>.W50.$US_@D7\+_%WAGP'I'C_XDZ]\3=5^!?@;X1_#']G?4?B-X ^&
M?BK1/A]X#^#]GJ-EI^D>,/!%WH,?AKXMW?CFSU673?B+J?B:#3I-1T_2_#TO
MA2#P9X@TN;Q!J(!]N^$/VP/V??'WCOPG\,_!OC6^\0^.?&?A&Y\=Z3X<L/!'
MC[^T+'PGIWBOQ?X#UO5O%J7'AB!? 0\->._ OB3P/XKL?'#>'M2\,>-+2U\)
MZY9V/B#5-,T^[\P^-G[7?B;X+_&KP!\.-2^'7@34-!^(?Q ^&GP]\*6DGQT\
M/6/QZ\?2>/\ 7] T#Q!XY^%OP$@\,ZG>>*OA[\'7UN76?BMJFM>,_">LZ1X3
M\.^-/%5AHMWI/A[3Y/$LO[/_ .PWX(_9[^)VD_$OPMXCD,FG?L_6GP*;PGH_
M@;X>^ /!H0_&KQ_\<]7\5:5X;^'N@>'-&T*[U+Q3\1-8LQI&G:<+6/3X+>\O
M[S5_$%SJNM:AH_&;]D;4OC=XOC?Q9\</'+_".X\=_#?XEZA\+$\.>!7O=/\
M$_PK\0^#_%GAO3_ OQ0718/'7@7PAJ7B7P/HVM>*-(LKC4M;O;N\\01Z!XJ\
M,6>LM:6P!>^ G[5FH?&WX]?M.?!6_P#A#XF^&:?L]_\ "H)M+UCQ?K6CS:YX
M_P!)^*VC>--1M]>E\):0+QO!-C#<^"[Q-'T[6M;NO$6JZ1=V.LZMI'AF2ZBT
MH>R_%KQ=\5O#</A?3OA#\+-/^)/B/Q+K5SI]Y=^)_'$?P]\!>"=(L]&U#4Y_
M$/C#Q!:^'O&GB>2*[O+:Q\/Z)I'A/P1XDU/4-:U:V>_&BZ%::IK=E\A>#/V.
M?C[X%^-7[2?QVTS]JZ*_\3_M">"--\-2:._P%\"Z7IWA+5_ 'A7QKX?^#NNZ
M1J/]O:S-<R^#[KQC)J6NVNMZ;J]CXNDT^WM[BTTVSDN+:;UG]IG]G+XJ?M _
M"GP?\,=*_:(U;X<16MUIK?%F\T_X>^']=T_XWZ':Z&]AJO@GQ=IHUCPYJ&A^
M"?%&LNFL>*='\':_H<VO:=$W@W4;V;P?J6N:/JH!\Q:=_P %,]5\5_#W5_B5
MX#^ ;:WH'PD^!%Q^T3^T=#JGQ7T/3;SPEX MOB#\:/AXJ?!R?3?#.NZ9\:+[
M7_\ AGKXN>/O ^K7MW\-_"'C#X>Z3X.U:T\06=[\0=-LM*^C='_:_.N_M:Z;
M^S?8_"OQ%#X-UO\ 9N\>_M!^&OC;?ZYHL.C^.(/ GBOX(Z!=Z/X(\'6C7VO:
MEH4]E\;='O!XUUR;PY:W&K:7?:)H>D:U';W^K6/G?B']@K4/%?AXZ/J'QPU;
MPS/XZ^"&F?LT_M!1_#3X8_#SP5X8^+'P-\.ZGX[E\(^%- \)S6_B&V^$.K>%
M/#/Q(\9^!=&\2>"]0GEMO#'B;51'IL>L67A+5/"FQK/['OQ/N_VL?!?[2&A?
MM%1>%_#'@+X;^)?@GX<^$6F?!7PD;&R^$7CCQ%\)_%/BWP\GC=O$D>O)KTNK
M?"#PZOASQ-'8+'X;L+G4+9="U.5X+J( 9^Q5^V7JW[5!O9=<C^ 6@2S^ _"'
MQ!T3PG\-_C!XW^('CF#1/%L<=PMSK^G>*_@S\,=$N=)TLW-OHEYXH\ Z[XY\
M,_\ "5QWVA'5(IK>)[CWSXZ?$[XM_#^.Q/PO^$OACQS:P^'?%OB[Q?XO^(_Q
M:L?@[\.?!^C>$8M-N3IE_P")%\)^/M8E\3>)H;R^FT7?X6M?!VD:7H.OZUXP
M\8:#':Z58:[X_'^RQ\7;2?7O&;?M1>,O%'Q@T/X0>.?@U\"/'WB;X?\ PMMH
M_AAHWC[5O ^N:YXH\0>']#\,6FA?$GQIJ.J?#;P)/JVHZOIVE>');;PX+71?
M!^@R:QK5U?:/[7O[+GQ"_:=3P%HVB_'4_#SX>^&[S5=3\<_"K5OA5X8^)OP_
M^,>H.VFOX6A^)&FZOK?AS4M8\->$9[6^U&+P,^JOX+\4ZM>6EUXWT+Q%;:)I
M=C$ >"_\/,;+6/!FH_&/PC\(KNY^"7PS^$/[./QD_:$UWQ;XUMO"OQ#^&>@?
MM&^%M*^(-GI.B?#^U\.>(-/\6:_\+/AKKFC^/?B?9ZMXR\%PC2=1M]+\"W'B
M_P 0+<Z?#]$>"_VL+WQ9^US\4_V7M0^$?B;P78?#CX,^&OB[IWQ'\5ZUHUJO
MCJSUOXG>/?AI>MH?@^Q-]J&E>%+"]\"7-]I/BSQ'J>F7?BB"ZFNK+PS9Z%:Z
M?KNM\%XV_80M_B)J&N3^*/B[XCCTCXR^%?A9X;_:P\*^'O"/A/1_#WQ^E^$T
M2P:9J,$=PFK:I\,!XNTH+X*^(%EX:U34H]=^'=II?AS3)] U;3D\428_B']A
M;QCXW_:;^)OQQ\>_'Q?$WP\^+OP<O?V<?&_P03X2:)H-AJ/P)FUSXA>(;;PE
M!\1]"\86?C;3O$(OOB/K4&H>--.>TOKZPAM$MM/TR_0ZE0!Z#^S'^V/#^TK\
M7OVC_ &E^ 9_#G@_X-CX,:Q\/?'MQXA&H3?%_P "?&3P?KOB71/'*>&O[%L9
M/!NF7D_AV_E\,V-UJNLWWB#PC>>'_%ETNB2:T-$L]7QC^WM^R[\.[GQW#X_\
M>ZSX(@^'GA/XC>.=:U7Q;\-/BCX=T+5?"?PANXK/XHZYX(UW5_!MGI/Q$LO
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M/XOU33_#NF(M_P")-5LM#FTOP[9S6UQK5Y8QW5J9OQMT;]AG]K+P/\$OB/\
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MX*C:4.!\%-5 ]!X[T[_YG*_(2BOZL_XA#X??]"*7_ATSGR_ZF'D_O\C^9/\
MB*?'7_0ZC_X;<J_^8?+\^[/U[_X>CZ5_T135?_"[T_\ ^9RC_AZ/I7_1%-5_
M\+O3_P#YG*_(2BC_ (A#X??]"*7_ (=,Y\O^IAY/[_(/^(I\=?\ 0ZC_ .&W
M*O\ YA\OS[L_7O\ X>CZ5_T135?_  N]/_\ F<H_X>CZ5_T135?_  N]/_\
MF<K\A**/^(0^'W_0BE_X=,Y\O^IAY/[_ "#_ (BGQU_T.H_^&W*O_F'R_/NS
M]>_^'H^E?]$4U7_PN]/_ /F<K[G_ &=_C?!^T!\/CX]MO#<_A6,:_J^A?V7<
MZI#J\F[23; W7VN"SLDVS_:1B+R=T>PY=]PQ_,[7[P_\$XO^3=F_[*#XQ_\
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MO_!2W_DAO@W_ +*9H_\ ZB_BJOM_#?\ Y+GAK_L8Q_\ 354^.\0?^2,XA_[
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M8VFF:9IMK!8Z?IUA;Q6EE8V-K&L%I:6EK"J0VUM;P)'%!;Q(D<$2+$BJB@
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ML<H2<8RL_;T5?EDG%Z-Z--'X:?\ #<GAK_HG/B3_ ,*#1?\ Y#H_X;D\-?\
M1.?$G_A0:+_\AU^<M%?Z3?ZMY1_T#S_\**_E_P!//+\7W/\ /+_63-_^@F'_
M (3X?_Y5Y?GW9^C7_#<GAK_HG/B3_P *#1?_ )#H_P"&Y/#7_1.?$G_A0:+_
M /(=?G+11_JWE'_0//\ \**_E_T\\OQ?</\ 63-_^@F'_A/A_P#Y5Y?GW9^C
M7_#<GAK_ *)SXD_\*#1?_D.C_AN3PU_T3GQ)_P"%!HO_ ,AU^<M%'^K>4?\
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M. .>I%?P5/\ ?;_>;^9KZSZ*_P#R2/$/_91R_P#59EY\M])G_DK,A_[)]?\
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M6)R?^%=?$KDY)YY//7D^IKHO^"D__*23_@A3_P!G6_M0?^L<_$&N=_X.!?\
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MF@_"S_LX?PO_ .JY^)-?I7@]_P G.X,_['%/_P!,UC\[\6?^3<<6_P#8K?\
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M+^R\O9C[;#%%YF_=GR_*N)]VS;\^[;C<N,YX_EO_ .#=O_DH7[4W_8E_"/\
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MK>6WOM.U"RN)K/4-/NK6]MI7AG1C_81_P0:_Y,7D_P"RW_%/_P!"\.U_'_\
M$7Q+<^,O'WC+Q=>>)]?\:7GB?Q%J>O7GBSQ5IECHOB/Q#>:I,;J[U36-'TS4
M]9TS2KN>XDD4:=INJ7FGV5M';VUB\5K%#;0?UV_\$)[C5(OV&Y%LM,BO(O\
MA=OQ1/FOJ4=J=Q;P]N7RFM)C@8 W;\'K@9%?EOTC)5Y>%>%EBG3>)EG61RQ+
MHPJTJ+KO"8UUG2IUTJ].FZG-[.G67M81M&I[ZD?I?T?HT8^)F*CAO:+#QR?.
M%A_;3IU*OL%C,"J*JU*%Z,ZGL^53G2_=2G>5/W&C]MVZ'Z'^5?PD_P#!77_E
M(I^TC_V$_A]_ZJ;P'7]RQO?$.#_Q(;?H?^8W$/\ W'U_#'_P5M>>3_@H=^T:
M]S MM.=2^'_F0K.MPJ$?"?P(%Q,L<0?<H5\>6NPML.XJ6/XO]%K_ )+S.O\
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M_P"O&1_^J'+#_0;P%_Y-?D'_ &$9W_ZN\P"BBBOQ0_8@HHHH **** "BBB@
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M_2'$/B/G&H:)C<^/^)/?YQO;K_Q/1SZ]L].*_P WGX9_\E+^&O\ V4CX??\
MJ9Z'7^E O0_[S_\ H;5_&7TK_P#>^"/^O'$'_I>2G]=_1>_W;C+_ *_Y'_Z;
MS0^ _P#@I9%KB_L%?M6FYO=)E@'P:\5>8D&EWD$S+LM]P2635[A$;&<,T,@!
MQ\I&0?X)W^^W^\W\S7]]O_!3/_DP7]K#_LC'BO\ ]%V]?P)/]]O]YOYFOK/H
MK_\ )(\0_P#91R_]5F7GRWTF?^2LR'_LGU_ZL<8-HHHK^H3^;0HHHH ****
M/Z+/^#>9-0?X@?M1_8)[*!AX+^$OF&\M)[M6'_"0^/=@007UD4(^;<6,@;*X
M"!6W?U/6::DGF?VA<V-QG;Y7V.RGM-F-V_S#/?WOF;OEV[1%MPV=^X;?Y;?^
M#=O_ )*%^U-_V)?PC_\ 4A\?U_5!7^<7TA?^3K<0_P#7C(__ %0Y8?Z#> O_
M ":_(/\ L(SO_P!7>8!1117XH?L04444 %%%% !1110 4444 ?B!_P %)_\
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M]8_^8RC_ (A>/V#O^B__ /!0[_Q+O6/_ )C*_K/_ (FKX?\ ^B4SK_PLP/\
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M%_\ ^"AW_B7>L?\ S&4?\0O'[!W_ $7_ /X*'?\ B7>L?_,97]$?\35\/_\
M1*9U_P"%F!_K_AGY7_ O^)8L]_Z*G*/_  BQO^?]6?E?^6^BOZCV_P"#7G]@
MY0#_ ,+^_P""AQ^9!C_AKO6/XF"_]"9[]L'T(ZU\X_L@_P#!N=^QA\<_V8?@
M7\7_ !=\?OV^_P#A)_B+\-?#7BO7CHO[6>KVFDMJFJV?G7;:=:KX2G%O:&7)
MAA$\PCC*IYCD%V/^)J^'O^B3SK_PLP/]?GU\KG_$L6>_]%3E'_A'C?+S]?N]
M#^?ZBOZD/^(7C]@[_HO_ /P4._\ $N]8_P#F,H_XA>/V#O\ HO\ _P %#O\
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MRZG@LM6!E2Q6'Q%6<Y_6J]?VD946HJ/+54;/WKQ?2U_Y;Z*_J0_XA>/V#O\
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MQ9\;?%>K^+/$>N>*?@Q::1\2='\,ZUX%T'4M,\1:B/!%MX*EMXGF]/\ "O\
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M3:987TK>"KW7-*;QU)X9L;DWD>5^S7^R#XP_9X^)^N^/;OXY:K\7(O'WP+^
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+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>biogenlogostandard.jpg
<TEXT>
begin 644 biogenlogostandard.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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MQQMEM;KJT---(4XZZXI*&VVT)-2UK6HR2A"$D9F9GH1#Z 7$-:*N*^$@"IV
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MC)(CTM-?,>D'L-"L[%<JI 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MIH;9K7%C2 YW$]K-A.S>ZOF4*_\ 2'=FOF[;G?QIQ7^]#87]E74'TK9_BY%
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MUOC/M9\HF/";O#S[T[+U-S[!ZAKGY[LKSUUO[9BI!#HNN?R B B B B B B
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M_81+HOR9]V6)]5)[>52("*E)Z B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B BYYY4[4KWEV+SK#H;'CWZ*\K_%2)*ENG
MDF/J_",",P23Z.6R&G()F9'VHE*/34B&4:,S0P.H[:_D-+;BX)/5O]%Q/VM0
M_P K5CFK<0<W@+BR8*W'#QQ_;L]( ?;;6^1RK!,S5MJ-"^Y"TF:5)41I4E23
MT4E23T-)I/74O48W =&"*C<M5@\C8=Z^^FQ/3WWH+[/NCR,07IWB^%VQZ'[7
MV>D?IL2_)D7@RY^B5&:B)):F9F>A$7K,SZ:=!4LC7B^1:UOLQB0R6B,E4Y\B
M/0FS)+"5%_9OGKK_ .82OND*MK"T;0J4O!.Q:*R.RN;U2BFR%%'UU3#8U:BI
MZZEW-D9FZI/J-9J,NNF@\I YVP[EZ,+6[1O6"/5/]K^D*<Q+V$B^D=1_:_U!
M^.Z7[,E%_:*C^U'T1+X9.E>FQ4]2]GW/4/V(E^"]=,;$<6MUM^K1$;",><12
MLR$,VF86Z7H&+5/5/B$]8FTLYLMM"B/X-%0_)T/7L).JBP377,S1_+JS,^H;
MD?/2VL=M'1]Q)OIPQU'"TD$=Y(61UV<5=BOV!TQF=2S=WCHCW -'2NV1MZZN
MIM/V+:N[**>CCEPSVOX\QXUNAE.8[B^"12LTMXK9*@..-&V^QB]:I3S5'&6E
M:DFX2G);B5&2W>PR0GGWS1YZ:JYC.?8 FQTQ79:QN/I@&H-Q)L,IK0\-&QM(
M!#.(<1V%TMH3$Z::+BG?Y2FV5P^+U]VW;P#MVN/2:;%UBZ[Z>OZGZH@M[UG*
MYMW'V9A7*W[C%4,5]JM2W9-;[+,">M7M*4P?1$*4M7I]#2S/KVGJHX_S^E(;
MPF[QW#'<G:6[FN[1]:?J'LWJAGLP_P!.+8[JZ#^\N495?-K)CT*QBOPY<=9H
M>CR&U-NH47NI41:I474C+4E%U(S(1I+!-;RF&=I9*#M!&W_3ZBMA:6GA<*%?
M<CH]'V?='HP+]A9'$;] K8VKU:LKA->]Z"XQ-7NT+,H#7O1<X6JH:%M+"\=D
MY)>5=)$+1VPDMLJ<[343#):KD25EZ31'82I9EZR2,KTYAI\[E[?$VW\[/(&U
MW\+=[G'L:T%Q\B]QZ(JI,(4./7PXD"(V346%&8B1FB]#;$=I++2"]'O6T$0W
MIM+6&RM8[.V'#;Q1M8T=36@- \P"IR:FIWK[0J$0$447G6?1Z[K?&?:SY1,>
M$W>'GWIV7J;GV#U#7/SW97GKK?VS%2"'1=<_D!$!%/+Q/\DC\Z#CUMIOQ^<U
M_ ?_ #B5EI9?P5_S,?PE_ _X-R*XH/!_#G^=C'_PAXWX)\7N^!L=OB=NA]O<
M>L^M_$5^ANJKS3/YG^<_-'M;WGSON^/BC8^O!\V?PTXJ?'.ZO31;&:,Y ?I=
MIFTU'^=OF_SICG=W\U[SAX7N93C^<,XJ\-?BC?3HJNB/Z.9_]8W_ -O?_P \
M!BO[6'_T'_KO_9K)_P!EW_[S_P!%_P"[3^CF?_6-_P#;W_\ / /VL/\ Z#_U
MW_LT_9=_^\_]%_[M/Z.9_P#6-_\ ;W_\\ _:P_\ H/\ UW_LT_9=_P#O/_1?
M^[7QN_5S72:<-CF&VX\3:S9;=X_J9:6Z23-M#CR-ZWUM-J7H1J)"S274DGZ!
M];XL!4<6 (;7;2]K]3YH*_"/*OA\+IH>'. NIL_Y.GU?G1_<*YJW9\@KE5AT
M&39[8YQMCN^U&2M2:1N988'E<PR2:D%"AY"S(Q8]>TR/QKEDR4:="41F:<OP
M?B=T5?RB',VUY8./RZ-FB'E+")/@B/3NZ<4S/AOUC8QF;$7%I?-'R*NAD/D#
MP8_AE'GZ(;MS]IMS-E<MFX)NQ@V3;?9=7D3C]'E%5)JY;D93CC;-A!4^@F+.
MJE*95X$N,MV,^DNYMQ1=1/N&SF'U#8MR6#N8;JQ=N?&X.%>EIIM:X5VM< X=
M("@O+X7+8"]=CLU;RVUZW>R1I::=!%=CFFFQS26GH)6O!=5;$!$!%*GY07*N
M7QNY9XSCMO8.L[:;[/UNV6915OFB##N[&;X> 94XVI:&"?I<BEE%<>69)9KK
M*6KJ?:0A7GOHIFKM#S7<# <OC0ZXB--I8T?AX^NCXQQ #?)'&.M3%R1UB_2N
MM(K6=Q&)R);!**[ ]Q_ R=56O/"2=S'O*O#CG(N@B BCO\V#Z/7DM\6,7^43
M#A*O)'WIX?UTGL)5&'.;W99;U4?MXE0U'3!<Z$!$!%?*\I_Z/7C3\6,H^43,
M1S/YW>]/,>NC]A$NB_)GW98GU4GMY5(@(J4GH"("("("("("("("("("("("
M("("("("("("("("("("("("("("("("("("("("("("("("("("("("("("
M("("("("("("("("("("("("("("("("("("("("("*MQS]V07LSO=/NJF"J
M/A&YQR\KH%MM&B'"MUO)/*J)M1$EI*H5E(3);;21):BS64%[TQM?RSU",_IY
MMO.ZN1LZ1OV[2VGX-_G:.$G>7-<3O6LO,+!'"9UT\+:6-U61G4'5_"-\SCQ
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M>V9ME0EXR"U[6]>U7K6D>,_A1NF_]-G(WFGRK0LV]&ZX?L[?J%>T/B@MG?\
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MJZZZ^ZX^^XX\\\XMUYYU:G'777%&MQQQQ9FM;BUF9F9F9F9ZF)3:T- :T -
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M;3#'3W>/?/9MWR6Y$[:=)+6?A6@;R71M%.G?22]/<X.7^I'M@M;]D%V[='<
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M6S;N9$QK&^4AH%2>EQJ2=I)*U?R>6RF:NG7V7N)KF\=O?(]SW>0%Q- .@"@
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MCY.\.'3#DC[K,/ZF3V\JYS\Y?>;EO71^QB4=XE51B@(KE_D+?R'[;_3KGO\
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M>J'$NQW'F'(^YB<N<)S$PQL,@!'D8P3!<  OB?\ 4XHW?+C)HX;06O#7#/-
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M"*RTN::TG.I-*3-,9E]6BR,M=%]OOC_$#RNOY.Z??26[R:#O8)6@_P )K'M
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MH.:&;K<D^;4FHV-TGJ22N<C9^ E<=MPQHVM>>F9@VUWR,!)]-KB^? :QK8]
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M]KFU-*KFD9>L40$4AOEB<JY_%/E=@M[-LE1=M]Q)\';?=*(ZZ2(!8YD4]B-
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M6.4V2YTJ.I78:6)DV46&1DOH(U$OP?A#9*3HE:R/N* \EXI],P3%F*QM[<1
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M/.YSYWN+G.<27.<34N<3M))VDG:3M*WXBBB@B;#"UK(6-#6M: &M:!0  ;
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MCJ=):QLH'8XJ ?$7A(\AH9N6#1\XL+ICN*FT1S'NGM[ Y[HB>UH5-D;^K1=
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M+*,/<=[I(QW;W'[9["?.N9?,/$1X+7&4Q<(#;>.\D+ -S6//>,:/(UP'F7*
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M /@KOI_R6 ?CB+3^RSJ_Z1QO_'_JE=/VF=)_^0R/_!_K4_I"?&?_ ,%=]/\
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MI_+UQ_\ T8[D?Y.AB!?$A[LI?[9!_**G#P]^\>+^R3_R0KJPYZ+?9 1 1 1
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M_P XB_PUVMAO#3_WU=_Y3+_B+57"!H8MX$!$!$!$!%1<\X[Z1_D9_JB^0C;
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MQ)FRW&X[*W%$VA1DA"E'T(S$F\F[NUL>9F*N[V6.&U9-(7/>X,8VL,H%7.(
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M)\1QY:42K1Y"'GTH2W'CQ^>?-;FOD^9&1;&UKK?3EN\F&&NUQW=[+389"W8
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M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(HT>=_P#@3OT;?^"L?RX?^*1^P?\
MZ?\ \T2_RT_G!_W=\8__ (C_ %__ .7G44<Q?YL_]J[A_P#EO)T?ZO,JE')O
M_"+7^15_<OY,G^#_ /O*'_[J_P#2_P#9O$&\FCOBL_[AZ?\ \AO^*?C?ZOLJ
M+2W5OQG_ /X#^X;OC#XO^GQ:KBH2$L"0$0$6Q-KO^M\#_N\_N?\ WH_]4/\
M#(G^'_\ I?\  ^(+5F?^@=_U?]W_ )W<?B_Z;Z*YXC_KF_\ 2_WC^:WC?_IN
MJK,? S_"<?\ H9_\*K_^I'_?S^QI_9O_ &K_ -1_PWBC3_F9\27W@;G?SW_1
M>;LZ^SA6V/+GX\?_ &)O;_-?]9Y^WJ[:JQ<Q^PL_L7[$W^P?L/O"_8?^"_L?
MM#5%WQCOW]._S]JVA;\4;MW1N\R^4?E?4!$!$!$!$!$!$!$!$!$!$!$!$!$!
C$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>blooddrop.jpg
<TEXT>
begin 644 blooddrop.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0HX17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    D    <@$R  (    4    EH=I  0    !    J@   -8 +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-#(#(P,34@*$UA8VEN=&]S:"D
M,C Q-CHP,3HP-2 Q,CHT-CHT,0   Z !  ,    !__\  * "  0    !   #
MM* #  0    !   %C0         & 0,  P    $ !@   1H !0    $   $D
M 1L !0    $   $L 2@  P    $  @   @$ !     $   $T @( !     $
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M71/">I7K2/&RPE(V3[P=OE4CZ$@_A63\,M374/!L,88L]I(T+$D'(SN&/;#
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M #A"24T$!       %QP!6@ #&R5'' %:  ,;)4<< @   @   #A"24T$)0
M    $,==%^5TM6[UV[XYE,#I>5PX0DE-!#H      0L    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585    !0 0P!! $T 4 !2 $D 3@!4 #$ +0!& $\ 3 !, $\
M5P M $( 5P      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\
M9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M
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M9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M"G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M    3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M        4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN
M9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,
M969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!2
M96-T5&]P;&]N9P      .$))30/M       0 2P    !  $!+     $  3A"
M24T$)@      #@             _@   .$))30/R       *  #_______\
M #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M           ! #A"24TG$       "@ !          $X0DE- _4      $@
M+V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@
M  8       $ -0    $ +0    8       $X0DE- _@      '   /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z   .$))300        "   X0DE-! (       (  #A"
M24T$,        0$ .$))300M       &  $    ".$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      U$    &
M              6-   #M     X : !H &$ 7P!B &P ;P!O &0 7P!D '(
M;P!P     0                         !              .T   %C0
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   %C0
M  !29VAT;&]N9P   [0    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P  !8T     4F=H=&QO;F<   .T
M     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%
M6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-
M3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N
M=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y
M<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T
M<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U
M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3004       $     CA"24T$#      +<P
M  $   !K    H    40  ,J    +5P 8  '_V/_M  Q!9&]B95]#30 "_^X
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M22G_V0 X0DE-!"$      %T    ! 0    \ 00!D &\ 8@!E "  4 !H &\
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M10
M    "F1E<V,   #\    =&-P<G0   %P    *W=T<'0   &<    %$$R0C
M  &P  "B!D$R0C(   &P  "B!D$R0C$  *.X  "B!D(R03   47   (XM$(R
M03$  WYT  (XM$(R03( !;<H  (XM&=A;70 !^_<  "0D61E<V,
M&E4N4RX@5V5B($-O871E9" H4U=/4"D@=C(
M
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M:D)K4FQ>;6=N<6]Z<(-QC'*4<YQTHW6J=K%WMWB]><-ZR'O-?,Y]S7[,?\N
MR8''@L6#PH2_A;N&MX>SB*Z)J8JDBYZ,F(V1CH:/>Y!PD6226)-,E$"5,Y8F
MEQF8#)C_F?*:Y)O6G,B=NYZMGY^@CJ%\HFJC5Z1%I3.F(*<.I_RHZJG7JL6K
MLZRAK8^N?:]KL%FQ1[(VLR2T$K4 M>VVVK?(N+6YH[J0NWZ\:[U9OD>_-< B
MP1#!_L+LP]K$Q\6UQJ/'D<A^R6S*6<M$S"[-&,X!SNO/U="^T:?2D--YU&'5
M2=8QUQC8 -CFV<W:LMN8W'W=8MY'WRS@$.#TX=CBN^.>Y'OE5^8SYP[GZ.C!
MZ9KJ<>M([!WL\.W#[I;O=O!5\3/R#_+J\\/TG/5S]DGW'O?S^,;YE?IA^RG[
MZ_RG_5S^"_ZT_UK__P   >@#IP4L!H0'OPCG"@0+%@P<#1X.' \9$!<1%!(0
M$PL4!!3\%?,6YA?8&,P9UAK>&^$<X1W?'ML?UB#1(<LBQ".^)+@ELR:N)ZHH
MIBFB*J KGBR=+9HNE2^1,(TQB3*&,X,T@35_-G\W?SB .8(Z?SM^/'P]?#Y\
M/WU ?T&"0H5#B42-19)&F$>:2)M)G4J?2Z-,IDVJ3J]/M%"Z4<!2QU/.5-55
MUU;95]M8WEG@6N-;YUSJ7>U>\5_U8/AA_&, 9 -E 67_9OQG^FCX:?5J\VOP
M;.YMZV[H;^5PX7'><MISUG3-=<-VN7>O>*5YFWJ0>X5\>GUO?F1_6(!-@4&"
M-8,IA!R%$(7^ANV'VXC*B;B*IHN5C(.-<8Y@CTZ0/9$LDAN3"I/ZE.F5V9;)
ME[J8IYF3FH";;9Q:G4B>-I\EH!2A!*'UHN:CV*3*I;VFL:>FJ)NID:J'JW^L
M=ZUOKF>O8+!:L52R3[-,M$FU1K9%MT2X1;E&NDB[2KQ.O5*^5[]=P&/!:L)R
MPWO$A,6*QI#'ELB=R:7*K<NVS+_-R,[2S]S0YM'QTOO4!M42UA[7*M@WV43:
M4=M>W&O=>=Z&WY3@G.&BXJCCK>2RY;;FNN>]Z,#IP^K4Z^7L]>X$[Q+P(/$L
M\CCS0_1.]5GV8_=J^&[Y;_IL^V3\5OU$_B__%___   "!0/8!6@&Q@@&"3(*
M4@ME#'(-> YZ#WH0>A%Y$G43<!1H%5X64A=%&#<9*1HT&ST<0!T_'CH?-" L
M(2,B&2,/) 0D^27N)N,GV"C,*<$JMBNK+)\MDRZ'+WPP<#%D,EDS331!-38V
M*S<A.!8Y"SH .O8[[3SC/=L^TS_+0,1!O4*W0[)$K$6F1J%'G$B7291*D$N.
M3(M-BDZ)3XA0B%&)4HA3B%2(58A6B5>*6(M9C5J/6Y%<DUV67IA?FV"=89]B
MH&.A9*-EI&:F9Z=HJ&FI:JIKJFRK;:MNJV^K<*EQJ'*E<Z-TH'6==IEWE7B1
M>8QZAWN"?'Q]=GYO?VF 88%:@E&#2(0^A36&*X<AB!>)#(H"BO>+[8SBC=B.
MS8_#D+F1KY*EDYR4DI6)EH"7>)APF6J:8YM>G%F=59Y2GU"@3Z%/HE"C4J15
MI5FF7Z=FJ&ZI>*J"JXZLG*VKKKNOS+#?L?.S";0@M3BV4;=LN(>YI+K"N^&]
M ;XAOT/ 9<&'PJK#SL3QQA7'.<A>R8+*ILO*S.W.$,\RT%31=-*4T[+4S]7K
MUP;8'MDVVDS;8=QTW8?>F-^GX+/AON+'X\WDT>72YM#GS.C$Z;KJK.N;[(?M
M;^Y8[USP6_%6\DSS/?0J]1+U]O;6][/XC?EB^B_Z]/NQ_&;]$?VS_DW^X?]Q
M__\   '9 XT%"094!W\(E@FA"J0+GPR3#8(.< ]?$$P1-Q(A$PD3\!36%;L6
MGQ>#&($9?1IT&V8<51U!'BP?%R  (.HATR*](Z8DD"5Z)F0G3B@Y*24J$"K]
M*^HLURW$+K$OGC",,7DR9S-5-$0U,C8B-Q$X 3CQ.>(ZTSO$/+4]ICZ8/XI
M?4%O0F)#541)13Q&,$<C2!=)"TG_2O-+Z$S<3=!.Q4^Y4*U1H5*54XA4>E5M
M5E]745A#635:)EL87 E<^EWK7MQ?S&"]8:QBFV.)9'AE9F949T)H,&D>:@MJ
M^&OE;-)MOFZJ;Y9P@G%L<E9S0'0I=1)U^W;D=\UXMGF>>H9[;GQ6?3Y^)7\-
M?_2 VX'"@JB#C81RA5>&.X<@B 6(ZHG/BK.+F(Q]C6*.1X\MD!*0^)'>DL23
MJI21E7B68)='F"^9&)H!FNJ;U)R_G:J>EI^#H'&A7Z)/HS^D,*4BIA6G"*?]
MJ/.IZJKBJ]NLU:W0KLNOQ[#$L<*RP;/!M,*UQ;;(M\VXT[G;NN.[[;SXO@2_
M$< @P3#"0,-2Q&;%>L:/QZ;(OLG6RO',#,TJSD?/8]" T9_2O]/@U0/6)]=,
MV'/9F]K$V^_=&MY&WW/@H>'/XP+D3>69YN?H-NF&ZMCL*^V [M?P,?&0\N_T
M3?6J]P3X6OFK^O;\.OU[_KO___\ @ "  .6T?\U_5,P_?Z5^P[*,?Y1^:9A_
M?YY^3'WC?\%^8V)!?_Y^DD1A@']_!1]D@?Z '/RX?G2+>>0/?E>)LLK;?D^(
M%+$^?ER&M)<O?H*%FWR3?KZ$NF#I?P^#]$, ?Y:#>!VB@.2#W_JC?267".)(
M?1R4,<E8?261>J_.?4N/'I76?8:-#7M.?=>+/%^T?C>)B4'+?L"(+1P$?\^(
M$?B_?!>BL.""?!>>R<>R?"N;%*Y%?%N7HY1S?*N4IGH.?0R1YEZ5?7>/3T"V
M??^-+1J,?L2+R?<)>T>N==[:>T2I>L8;>UVDQ*S2>Y:@9I,0>^J<6GC:?%N8
MNUV(?,^533^Y?5*2BQD\?<:.\/6%>JJZ7=U9>I^T2,2G>K.NBZM\>O"I/9'B
M>TRD3G>R>\"?NER+?#V;CS[3?+R8=A@7?-N02?0X>B_&<MP->AN_.\-B>B>X
M<ZI->F2R-I#?>LFL<7;2>T2G$%NN>\"B,#X,?#N?#Q<<? >/H/,=>='2R-KQ
M>;3*8<))>;C"C:D_>?"[88_G>EFTSG8&>MVNQEL&>UZIASUC>]"DTQ9)>U*/
M$?(J>8S?A-G]>6;5T\%5>6#,[JA6>93$XH\3>?Z]DG5+>H:W!UII>PRQW#S:
M>WJI)16>>LB.G>WMB1-^*]9^B !]L;[-AP5]5Z:UAC!],XX:A81]2'30A/Q]
MC%IKA)M]Z#V.A)]^BQB+AGJ  >O)AZZ)"-4 AJ.'?;V-A;F&(:5^A/B% XS0
MA&2$*G-]@_2#B%D/@ZB#!SPY@[B"X!;YA7>$ ^G[AG"3^--3A7>1=;P0A)R/
M&:04@_6-$XN)@W6+5G)5@Q>)U5?_@MB(?#LL@NN'E!6(A'N'J.A2A7.>^-&R
MA(.;@;I_@[*8.Z*A@PZ5.HHX@J"2H7$I@E"00U;W@AN.'#HT@BZ,EA0X@XF*
MR>;(A*JJ&- R@[NEK;D&@O&A@J$_@E6=I(CN@>.:$G +@:.6YU8"@763_SE3
M@8:2#!,5@IJ,Y^5CA RU8L[6@QVP [>U@E*JZJ %@;FF+H?5@4ZAQF[]@0F=
MO%4?@..:,SB)@/.8.!(?@;R,0>0O@XO VLVL@IRZ@K:2@<ZT>I[T@3:NWX;H
M@-.IL&XQ@).D[51<@&6@V#?=@'2>6!%4@0.+M^,I@R3,E<RO@C;%.[68@66^
M0YX#@,JWRX8)@&FQW6UW@#.LC5/&@ BH5C=-@ JC7!"N@&R+1^).@M#8N\O:
M@>;03K3$@1/(89TU@'3!%(5.@!*Z>FS5?]^TS5,\?[JP2#;1?[RE$! J?_2*
M[MT\DF%\F,=KD'I\0[%6CK)\$)K'C1I\$8.7B[=\26N>BH)\L5)UB8A],C:.
MB2=^ 1$RB]9_WMM&D2V&R\8%CT*%A+ JC8.$;YFRB_R#D(*#BJV"\FJ,B8V"
MB%%>B*."0#5ZB$F"8! $BIB#AMFSD "1),2=CB*.[:[]C&.,WYB BO&+)H%5
MB;.)LFEJB*:(?%!*A\N'=C1VAWF'!0[ZB5:&N]A'CPB;DL,NC3*8>ZV!BX:5
MEY<>BA.2_8 7B.B0OFA3A^:.O$];AQ.,_S.=AL*,'0X4B"B)A-;ICDJF%<'1
MC'BB)JPDBM2><Y72B6B;"G[FB#*7ZF=+ASZ5+4Y]AF^2S#+9AAR1P0U.AR6(
M_]6GC;&PQ\";B^*L *KVBCZG=Y2TB-:C07WBAZ2?7&98AJ>;VDVUA=V8^3(L
MA8J7\@RHADN(C]20C3.[I;^2BV>V!:GRB<*PII.^B%NKI'T*AS"G"&6>AC:B
MYTT,A5^?KS&=A0N=/PP>A9>(,=.CC,O&Q[ZSBP/ 2:D6B5ZZ%)+GA_2T27Q"
MALRO!&3VA=RJ=TR'A06G93$DA**A.@NNA02'YM+@C'+25[W[BK#*\:A=B0W#
MX9(QAZ.]4WN=AGJW?&1IA8NRQTP-A+VN9S"WA%R@\ M5A(Z'J<S[F_)[6[B3
MF4=[(:/VEKA["8[>E&![)GD5DD5[>&)ID&5[^4IRCMI\DR]CCC5]?@I^D!]_
MP,LZFN*$_;=FF".#YZ,!E9F"_(WZDTV"2W@KD4.!V&%\CW6!FDE^C?>!@2YY
MC5>!XPG/CIN#",G3F=^.K;8<ER6,PJ'EE)B*^(SADEN)B7<AD%Z(5&"#CIZ'
M7DB8C2J&H"VGC(R&G0DUC4>%Z,BHF.>8CK3CECV5SJ"GD[V3-(N[D7*0[78#
MCX:._U]_C=*-4D>QC&:+^RS>B\R+S0BOC!^%W\=\F"RBAK/&E82>^I][DPN;
MK(J$D-*8JG3LCMF5]%Z/C3&3H$;NB\61Q"P[BR>1O@@\BR&%D<9?EYNLI;*R
ME/6H69YLDGZD2HF$D$J@C70!CE.=(UVXC)V:)T9!BS27]RNNBI27.P?;BDR%
M4,5FER:V[+')E("QWIV)D@BM#HBJC]6HFG- C>6DCUT3C#"A$T6QBK2>TRLZ
MBA*;R >+B9N%&L22EL/!>+$'E!Z[I9S)D:>V%H?NCW*P[G*/C86L55Q]B]JH
MF44^BERF02K9B:B<^0=*B0N$[L/BEF[,>;!GD\K%V)PHD5:_A8=.CR.YLW'^
MC3:TJEP#BXVQ$T35BAJL0BI\B6F<N@<6B)F$R[T_I=!Z>JH<HFAZ39;1GQQZ
M18,4G AZ<FZ=F3AZU%DLEK)[9$)3E*)\"B?SD_-\_02JDW]_IKNSI.*#E*DJ
MH5J"G)85G@J!T()@FOV!/FW;F#J ZUACE<* SD&"D[R VR<TDPN!=01HD@."
MFKJ(H^N,PJ@7H&B+ 94DG16);H%KFA>(*6SQEUV')U>*E.^&9D"\DNZ%Z":.
MDCB&6P0OD+2"U+E\HQN5]:;]GZ.3>I/_G%F1.8!?F4Z/,VOUEIV-D5:ME#2,
M,4 "DC2+.27YD7>+V0/]CY*"LKB6HE6?:*8*GNF<,Y+^FZJ9/W]6F*:6BVL$
ME=B4+E79DWR2/S]2D7Z0["5ND+^15@/3CIF"EK>CH<BI J4UGE6E%9(NFQ&A
M:WZ"F!&>&6HYE5:;(E4BDNN8K#[#D.R7/R4!D">6"P.OC<B"?;;+H5>RO:1M
MG>&N'I%LFIVIQGW*EZ"ET6F6E.NB4E26DH"?@SY/D&R>5"2LCZ"8S .1C1J"
M:;8/H/Z\MJ/&G8*W89#*FCVR7'TLES^MS&D!E(ZIX%07DBVG#3WOD!*DPR1E
MCS"8FP-YC(V"6;5QH*_'+*,\G2W!%Y!!F>J[7WREEO"V/VB(E$"R$E.SD>"O
M1SV;C]*IJ"0?CO28; -EC!V"3*X>K_YYY)PIJ]YYMHH0I]YYLG>*I!=YYF1'
MH)AZ4$_YG7-ZYCH?FO9[C2 IFIA\<0  E=-_RJS.KRB"@YMHJN2!F8E^IMJ
MX';[HQ. 8V.HGYN )D]3G'^ (SETF@6 3!^AF9:!%P  E(Z  *O?KCV++IJ*
MJ?Z)C8B]I>V(&G8QHC"&^V+DGKR&($Z?FZ:%CCC5F2R%2Q\NF*N&1@  DW"
M *L2K6J3YYFJJ3>1FH?,I3"/A'50H6B-O6(2G?R,44WHFNB+.#A!F&J*HA[*
ME]>+LP  DGB  *I!K,J<M)C:J)B9PH;SI)27%W1UH,^4P&%-G4N2L$U"FCV1
M*#>_E[B0:QYUEQ2080 +D9* !ZF0K"RES)@OI_RB,89(H_F>XG/*H#6;[V"J
MG+*97$ROF8^7:S=-EPJ6Y1XHEE^46  ;D,2 $JCBJ[FO Y>BIWVJN(7"HW*F
MPW- GZRC0V IG#:@3TQ!F1R>.S;VEH"=?1WSE<B40  HD!F &ZA"JV&X=)<9
MIQNS>X5#HPVNYW+(GTBJY%^[F]:GJ4OAF,6EXS:PEB.BZQW,E4^4)@ SCX^
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MLP^/YWP:KE*-^VJJJ<Z,8UA]I:N++459H?:*5S"5GQ.*+!=<GQR*L   CSZ
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ML'2X@WH.JZ&SMFBLIQNOXU:RHN^MH$/?GSBJIR^1G"^@*1<?F[:/H@  C8Z
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MO%N5M7"2MO"3=& +L;N1E4[HK-:0)CS#J)*/:2C7I6.0&Q $I>&*U   C%Z
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MREEX@V:NQ&]X6U<1OM9X?4:SN9-XVC4'M0AY6"#VLG=YK@?KLME[10  B?F
M (1BSY^ ;G6;R7Y_9V9PPXQ^K5;.O=9^1$9QN'1^*339L\Q^4"#VL/Y^GPAG
ML.I_YP  BA:  (1*SH6'Q75OR'R&069#PH6$^E:9O+V$(48_MTN#GC2^LI&#
M@2$+KY6#^ CFKRB#_@  BB^  (1&S7R/%G5?QVR-&68@P7*+9U9VNYN*&D8D
MMBB)2#2UL6:(_B$LKDF)Y E=K9N&50  BD6  (0YS)B6A758QGB4!V8=P'"1
M\%9JNI>0248AM16/)#3$L%6.WR%:K2"/>PG,K$*&H   BEB  (0=R]2>(750
MQ:2;&F8HOXZ8D%:#N:^6F48XM"^52S3CKUV52B&2K!B40 HTJQN&Y@  BFB
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M>@>#Z,%Q>H"#!*D5>OZ"3I =>X6!R'9Y?!>!9%NZ?+*!"CZ7?6> U!EU?E^
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MF.Z?T8JIECB<OG?@D[R9Y61CD7V75T__CXJ5/3HXC?Z4$B"IC;>2X #6BF.
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MI>=\FX(DHG!\<W!VGS1\<%W:G#E\ETHBF9M\WC2_EZU]+1K0F#5]F   C&R
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MH@6E9WYWGHJB!FS(FT:>\UINF$Z<6T<JE;*:DS)BDYV:$!E0DZ*1'0  B'R
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MKL.#-'6PJI."963\IJF!V%-OHP>!?T"]G^"!6RPOG;2!9Q(_GS^""0  B"&
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MJVRJ>',FIRRFXV)XHQ^CR5$=GVVAC3[.G#V@NBK:F<J<^1('FEV,,0  AAF
M )'[KWJW;(+*JQ>S$7+5IM"N\6(JHK^K?%#<GPFI<SZ>F]2FS2J\F62<Y1(&
MF>:,,   A>*  (AVO^5S47GANO5SK6K9MD-T*ULGL<ITS$J*K9YUASB3JA1V
M1B12J"MVMPI8J@=W%P  A@R  (@>OP5[+GFYN@AZU&JNM3QZK%KTL*MZMDI/
MK&YZ[CA?J-5[0R0TIL=[@0J?J"Y\8@  A;:  (?>O?*"Z7EBN/V!]&I>M":!
M+EJ6KX^ M4GVJTR =#@:IZR ;"03I8& E K?IH.!)@  A6N  (>7O.>*F'D!
MM_6)&VGGLR*'U%HLKH&&UTF4JD&&+3?/IIV%U2/RI%N&& L7I0>%40  A2F
M (<^O J28'BEMQ:08FF$LD&.IEG K9Z-,TD_J4Z,'#>/I:R+EB/7HU:,/@M*
MH[F'H@  A/&  (;?NV*:4WA0MF>7UFDUL8B5G%EUK-^3O4CYJ(R253==I-.1
MQB/#HFN1Z MTHI2'OP  A,*  (:'NMZB7W@)M=J?9&CUL.^<KEDYK#Z::TC"
MI^R8VS<YI"R8JB.ZH9B6HPN<H92'V0  A)J  (9-NF*JE7?5M5JG'FC&L&NC
M]ED/J[.A94B:IUZ?Y3<4HZ:?"B.JH/R8'0O H+2'\@  A'N  (8-NA&S/G?
MM/BO.6BWK_.K@UCUJR.HJ$B(IKVG.3<3HOVD#R/"H&"8+0OQH!V($P  A&&
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MP7".@%[^O 2,Z% "ML*+I4!/L=^*SR]0K=R*K!O?J]"+, 6!J22#N0  @QZ
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MD^R1HX/+D="/XG'VC]R.,U]&CA:,LTM^C*6+?38JBXR*KAR/B]"*XP  A3"
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MV2]BE =^Z!54E7A_"   A 2  )A*H66(2HD-GF.'1'D8FX:&4VA.F-F%A%:
MEG.$XT.3E&2$:B[>DO^$*Q4'E#Z$@   @RB  )=^H'R0W8A#G7R/0GA'FJ&-
MO6=TE_>,6%71E8&+&D+\DWN*-2YLD@R)T13*DQN)0   @FR  );7G["9JX>7
MG+F7>G>7F=^55V;)ER^34U4OE+>1C4)[DIN00"X,D2>0#A22DA2-1@  @<Z
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MJGIVCF\ INUV\E\:HY5W;$XKH(-W^SOHG?1XC">$G)EXY TZGN)XT0  @<6
M (NZK0U^77USJ5A]_VY\I<)]NUZ+HFE]HDVGGU9]J#MYG,=]QB<SFU=]W@T_
MG39^.P  @2&  (LPJ^J&9WS/J#J%=VW#I*N$HEWKH4V#^4T1GD.#@3L F[2#
M-B;@FC6#+0T_F[6#$0  @).  (J;JOF.@WPTITV-#6T>H\&+M%U!H&**@4R)
MG4R)B3J-FL&([":4F3&(_PT_FER'/0  @!J  (H0JD&6Q'NNII:4S6R8HP62
M[%RZGZ&1.4P)G(6/T3HRF=V.]"9;F#^/6PU"F2>(]P  @ "  (FHJ9Z?('M
MI?B<JVPFHF2:1EQ(GOV8&$NAF]Z67#GCF2Z5AB8VEUZ4W U*F!&(_   @ "
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MLY]\G6-%KV=\7E0SJVA\5$0JI\)\:S*VI-5\EAZYH[5\H09RHS9]HP  @ "
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MKXZA4&&0JSV>S5*&IQN<J4*LHUR;<#&<H$J:XAYFGGR4C0=YG':%#@  @ "
M 'TVLYNL1V_0KRNI5F&$JL&F75)DIH*CZT*0HJVBPS&4GX^?\QYVG<F4F0>@
MF\6%*   @ "  '*OQ4ALWF6EP*QMM%@=O#ENGTG3M^QOE3IUM %P@2E3L31Q
M+126L>EPN   JRET>P  @ "  '*BQ'=T<&7#O[%TBU@ZNP1TU4GQMH9U0#J6
MLG9UORF-KW]V(145K\1UNP /J>EXYP  @ "  '*CPSI[N&6JOG)[15@FN;5Z
M_4G6M21Z]SJ(L0-[$BF>K?)[.!5NK=Y[! "CI]-]+@  @ "  '*5P>V"VF6
MO2:!^%?GN&J!0DFHL]* S#IFKZV EBF<K(J D!6OK#" S $AI?B Q   @ "
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MN5"EHE>[M$.C*$EKKW>A:SI%JRF@42G0I\J<11:HIH^/4@*ZG_.!V   @ "
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M@KZINH3X@>>F)G+A@2:BC& 2@)>?5DQ3@#F<V3<W?]^;M1WX?Z>41   @ "
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MCPN#LWSVC7Z#-6P)C!""N%GZBM:"6$;.B=.""3'EB3"!S1@1BA*!V0  @ "
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MBWNN\7E6B=RK.6A.B%*GD%:1AP:DE$/5A@2B]B^&A3B?'19KA4B/*   @ "
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MEUF)N7"TE1V(QV"TDP>'WD_6D1R'##V;CZ"&>BEWCL&&/@^MD!:%>P  @ "
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MI?9IX&@5HQYK>%CBH'AL_DB+G@YN<C:RG#5OMR)>F^-P6@A8G:]P(   @ "
M (,2I_)P9W7>I-9Q1V>MH>=R+%B!GR=S%D@PG*MS_C9GFL-TRR(KFD=U'@B
MFW1U,0  @ "  (*6II9X:'4_HXAXHF<BH)-XY5?OG=)Y/4>PFU1YH#8 F6=Y
M_B'KF,QZ%0B=F6=ZIP  @ "  (( I4* 4'20HCJ  &9?GTY_ME=.G(Q_@D<<
MFAA_:36+F"E_7R&AEW5_6 BNEXM_DP  @ "  (%DI"6(1W/PH22'>&6UGCR&
MK5:?FWF%\4:6F/J%7#4;EP^% B%:ED*%% B\E=^#T0  @ "  (#8HTN07W-H
MH$Z/&64NG6&-RU85FIB,CT83F!*+B#3(E@>*\2$KE22+8@C,E&"%\P  @ "
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MKRAP'5Q7JZ9P^4WYJ%1QW3YPI5YRO"TZHTES:ACCHZ=S1@'^H#=U80  @ "
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MJ<&3REINIB.20TP8HJV0WCS4GYJ/[BPPG3N0!QC:G)6.60-6EVJ"0@  @ "
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MN-IU@%#5M,]UN$,FL.UV&311K9!V?".1JXAVK@\<K,AV)@  G(E\(@  @ "
M &FHNW)\:UUAMV9\'E"'LUU[Z4+RKW=[WC0MK!1[\".3J?)[^ ]GJN)[V
MFVA_H0  @ "  &EZNC&#?UTUMB."VE!6LA6"2T*TKBN!US04JK>!FB.4J(6!
MG@^IJ3"!K@  FFR     @ "  &E.N3R*NUT>M1R)R5!$L0"(W$*>K0V($#/\
MJ9&'DB.=ISJ'P _FIZN&N   F9"     @ "  &DIN'^1_ET4M$>0R% _L!B/
M@D*4K!N.;#/QJ)N-X2.GIC*.11 BIEF*Z0  F-^     @ "  &D-M_.965T7
MLYZ7YE!$KUF654*2JTV5"#/DI\>4MB.<I5Z3S! _I5F*_   F$B     @ "
M &CZMX^@ZUTCLQ.?25!1KK6=?$*6JIN<)3/IIPN;;B.QI)28(A!6I(.+#
ME[*     @ "  ,U0;&UF1+GG;C!H=:73;]AJD)#@<6-LE'L.<M]NC615=$]P
M?4QL=:1R4#&M=JESU@W'>#%SMLM<:>YQ5+A8:^=R9Z1M;;9S=X^?;V=TAGGC
M<09UEV,^<I9VI4MA<_IWFS"Q=-QX50SF=G1WY<F(9\E\8+:1:=Q\7*+A:\M\
M7XXF;9E\?7B1;U9\JF(2</]\WDI9<F]]!"_&<RM]! PA=.Y\@\>[9>*'4+3"
M: J&4*$;:@N%8(R::_*$AW<J;<V#TV#;;XR#+TE4<06"C2[I<9F!ZPMV<YN
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M=0.4>(C1=9&2EG:D=B.0J6.A=L&.UD^2=V.--SH9=]^+^2"_=YB+M@#]?E6
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M?(:::7T]?%>8+FPF?#25Y%HT?"Z3R4<T?#B2"C*E?"N1)AEQ>\>.V0  @ "
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MBDUV#G88B4AVQ&74B&1W<%1]AY]X&D'7AQ-XN2U)ANYY'Q,#B']XF@  @ "
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MA-F?EG'I@^&=&V',@O2:BU#5@C>86CZY@;*6]"KP@3J61A&R@1&+]P  @ "
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MD?Q\3&G,D%U\<UJFCMI\ETI+C8Q\P#B1C)1\Y22<C%A\Y@L!C+Q]#   @ "
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MC<ZD6V;+C!>AQU>1BF>?+T>$B/>=4C8\A^6<<"+NASF7G@J5AD:'*   @ "
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MFG*!N5X>F#6!=D_(EA.!+4!HE#2 ^"]DDN^ W!NUDO6 V 2.C_V G0  @ "
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MJEUCDE4ZI[=E@T=II3MG5SA-HQUH]R<VHA=J&Q(JI']IIP  F--N8@  @ "
M &V#K!!I/V&ZJ1MJCU3]ID9KX4= HZ!M*C@WH6!N4R<_H#%O&Q)QHBUNB@
MERUS:0  @ "  &T7JH%PLV$YIY-Q<U28I+1R-T;>H@-S 3?MG[ESNB<;GG)T
M+A*2H!-SF   E:!X,   @ "  &RAJ.IX"&"OI@-X4U/]HRQXG$9JH'IX[S>)
MGC-Y02;=G-QY;!*7GC)X]0  E#!\8P  @ "  &PHIY!_;& XI*]_4%.!H=E_
M*T7CGR9_!#<QG-!^]":=FW!^\A*2G(9^XP  DNB     @ "  &N]IH>&\E_9
MHZ6&=U,EH,>%Y$6%G@N%4#;8FZN$Y29OFBB$U1*2FP.$N   D<:     @ "
M &MDI;>.?5^1HM*-KU+?G^>,LD4ZG1Z+NS:&FKR+&R8[F26+2A*EF:B)H0
MD-N     @ "  &LDI0^6$%]4HB:4]5*<GS.3GT3SG%^2639 F?21LR7IF&&1
MO!*"F*V,@P  D">     @ "  &KPI*&=XU]6H:2<J%*9GIB:]T38FZ*95C8S
MF1>8SR7\EVJ6YQ*JEZF,G@ +CXJ "   @ "  &&SN'Q@B57TM7QB4DFALI!D
M&#QAK\-EPRV[K8QG)1R2K41GN A<KJ1G:P  DUARV   @ "  &$PMY%GVU7'
MM$]I DF2L15J.#QOK@MK9BWEJY]L9!SPJPILN@CQK EL:0  DA=W;@  @ "
M &#JM@MN[%5WLK]ODDE=KW)P13Q#K%%Q!RW6J<YQIQT4J05QR0E<J:5QG0
MD.%[@   @ "  &"JM&1UV%4EL1IV&4C]K=!V83P$JJMVNBVJJ"!W"QT7IS)W
M!@FHIWIW.   C[]_%@  @ "  &!HLO5\TE3IKZQ\OTB^K%U\K3NYJ31\G"V.
MII5\HAT9I8Y\F0GJI8A]&0  CL&     @ "  & NL=J#\53'KH&#ETBCJR2#
M*CN;I_&"P2UOI4B"@QTEI!""H HGH\R".0  C>.     @ "  %_]L/R+%%2U
MK8V*?4B8JA^)O#N+IN&)""U=I#&(MATKHMZ)( IEHDJ&B   C3.     @ "
M %_9L%>21E2RK,N1?DB8J4B0=CN%I?F/B2U+HT&/91T8H>R.O I\H1^'%P
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M;UJ%.X$(<'6$MV_4<8.$'UVT<I2#D$I5<Y^#%S5\=$V"K1QJ<X6";P  @ "
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M=B:+AW6$=I>*D658=P:)@U0Z=WZ(@T'@=_:'KBW&>#"'+12!=\:&I@  @ "
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M?<R1!FI'?8V/MUL-?4Z.4$K<?2F-#SEF?1:,+"7U?..,.@SJ?3*(E@  @ "
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MC,5O(V+DB[QP8E1.BM!QCD2+B@URHS,NB:ESAA\VBB-SS 9WB9]T*P  @ "
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MAE25L5]=A5F4)U#UA%62?$&:@X.1,3#4@OB0R!VX@IN/U@:)@>6$:P  @ "
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ME)9TK5<KDP=U94F-D8]V$CJ9D%MVJ"GEC\%W"17>D-EVK0"BC&MY1   @ "
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MCWV9^%2YC=287T<0C""6L3ARBK&5T2@YB<65)Q3\B<F., $GA@. R   @ "
M &5BIE=;L%H2I!]>%4WPHB-@94"KH%MBC3'RGP5D:"#GGQ-EB@O[H;ME&@
MC91MT@  @ "  &2SI,QC)UFFHHYD\4V3H&UFL$!LGGMH5C'2G/]IOR#SG-5J
MB@Q/GOII_0  B_MRS   @ "  &0KHNAJ=5D,H+AKN$T9GI1L\3_XG)IN'C%_
MFQ%O&B#0FL%OE0Q]G&QO!@  BGMWH@  @ "  &.=H0=QJUAKGN)R>DQHG,ES
M/#]UFM%S]3$1F4ATC2"0F-YTPPR.FAET50  B11[Y0  @ "  &,.GVYX\%?A
MG5-Y6$O>FSMYK3[CF3]Y[#"TEZEZ)R!-ERUZ,0R.F %Z*@  A]%_G   @ "
M &*0GBR 5E=QG!: 84MUF?B 2#Y\E_. &C!5EDY_^B EE:)_^ R5EAZ $0
MAK2     @ "  &(FG2V'OU<9FQB'>4LDF/"&^#XHEMR&9B_ZE3*&#A_FE&V&
M1 RLE'2%#0  A<Z     @ "  &'5G%Z/*U;,FDJ.FTK3F!R-OCW8E?V,VR^N
ME$2,=A^+DWZ,KPR)DR6(>@  A2&     @ "  &&5F\N6S5:_F:Z6)$K%EVR4
M[SV]E2B3K"^KDTJ39Q^QDEN1[PR_D>R(GP  A)R     @ "  %DCL:U:9$X:
MKU)<C4)DK1E>JC6<JQA@GB<LJ>-B(Q63JV%B: -%J;9C6@  B.=Q_0  @ "
M %APL&=A?4VZK>)C&T(CJVIDN35_J2YF.B<ZI[UG8!7JJ,]G< /2IK]H40
MAZ!VL@  @ "  %@(KI)H:$U*K MID$'0J8EJM#4XISAKSB<8I:QLFA8*IG-L
M? 0YH_-M>   AF=ZW0  @ "  %>NK*=O.DS?JB9O_4%7IZAPN33GI55Q;2;?
MH[QQ[!8*I$YQJP2$H5QR_   A4%^B@  @ "  %=2JOUV'$R*J()VBD$$I?]V
MZC2*HZ9W,R:ZH?5W;18)HEUW*03"GP9XX0  A#Z     @ "  %;_J:U](TQ0
MIRI]2D#5I)U]3C1>HC=]/R:2H'1],Q8;H)=]%@3_G.]^%@  @UZ     @ "
M %:ZJ*"$+4PIIA*$%D"YHW6#QS1!H0*#;"9TGS2#1Q8=GRV#AP4^FR&">@
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M:IUZX0#]?E1\9J&H77^!?9)@8!F!78(M8GR!)G#^9+B XE[H9N& I$N7:-2
M=S;H:@. 2QYK:'2 '0#J?G5_U*!C6Y"+>Y$K7D**EH$)8+B)DF_I8PF(@UWF
M94"'@DK)9S6&HS9#:%B%^!WN9JN%V@#9?I& DY]?6?F5=) R7+R3S( :7SZ1
M^V\&89N0)%T18^*.;TH39=R,\S6_9N6+X1V/93.+C #,?JB BIZ=6+N?88]S
M6XB<]W]97@V:6VY*8&R7OUQ:8KB584EH9+F3:34W9;*2-QTZ9 20-@#!?KJ
M@IX=5]BI-H[J6J6F#'[#72.BIVVR7WN?3EO08<2<6$CU8\*:!S3#9**8Y1S+
M8PV3> "X?LF ?)LV<+)8]XS5<<Q<8'UG<O%?D&R\=!MBC%KA=41E9$?!=F=H
M$S+R=VAJ8!E>=\UK6@  @ !R'9GA;8=BC8NC;NYE#WPQ<$%G:6NC<8QIH5GE
M<M%KOD;F= =MNC(X=/5O8!C2=,EOW   @ !VR)B%:J%L((H_;$!MQWL1;;UO
M56J%;R9PQECN<(-R*$88<<ES=#&9<J5T?!AC<B9TDP  @ !ZXI<$: 5UF8C!
M:<MV?GF#:V=W1FDZ;.QW^5>^;FQXHT46;\)Y03#'<(EYMQ?*;^QYC   @ !^
M<96@9<9_#H=G9Z9_/'@S:5Y_1F?X:OE_.5;&;(A_+$0Y;>U_*# :;IY_'A=2
M;@9^\   @ "  )1[8^J(DH9,9=^("G<F9Z:'5F;W:5.&C%76:NV%S$-_;$Z%
M*R^(;.>$OQ;I;'*$P   @ "  )./8F*2$H5E9&:0V'9&9C:/9F8A9^V-XE4-
M:9*,?4+6:O2+5B\5:VJ*K!:=:R.)QP  @ "  )+>82Z;B82R8SN9H76.90Z7
M=65N9L.5.E1>:&V3/4(O:=*1LBZ3:BZ1)196:A6-Y0  @ "  ))F8$VD\X0N
M8EVB9W3[9"F?A&399=:<G%/89WJ:%T'!:-F84RXB:1B78!7E:4R.S@  @ "
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M;YE]%FX+<*E]5UZX<:5]>DY=<IY]FCR*<WU]NBC=<\9]PP^A=25]G@  @ "
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M=FN"WV+-=N&"K51?=T:"7$3E=ZR"$#/R> *!WR"?=^.!U0B#>A^!7   @ "
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M@)-Y_"OH@*EZ0AA(@/]Z$P)N@41[P   @ "  '"F?Y!_\F3O?W^ (UA2?U6
M)TJU?R& ##P'?OA_\"NS?NE_Y1@S?O-_Z *-?[U_^   @ "  &_V?CF("V1A
M?CJ'QE?/?@V'/4HK?<J&E#MR?9N&"RLI?7V%U!?W?2J&'0*6?G:!P   @ "
M &]I?2:0)&/7?2^/<E=%?0".9TFJ?+6-/#KU?'R,8"JD?%&,/!>0>[2+6P*?
M?6J!Q@  @ "  &[]?%.82V-J?&"70E;3?"R5OTD[>]:4(CJ7>XV3$BI;>TF2
M_Q=1>G6/CP*0?*"!O   @ "  &D#E']7"EW0DTA9]U&NDE5<Q411D95?8C5Y
MD25AL"1RD:)C50]/E(QC)P  B EIF@  @ !^U&@=DB->J%T?D11@_5$)D"%C
M.$/,CU%E3C47CLQG'R0^CQQH6P]ID6UG^@  AB)N9   @ "  &=1C[9F-UQ
MCLQG_5!0C>=IK4,<C1MK/32-C)%LE2/BC,)M;@]>CH)LZ0  A%YSIP  @ "
M &9^C7%MO%M>C)YN_T]BB\EP*D)EBP5Q/#/LBH!R("-OBIARG0\WB\]R#@
M@KQXF@  @ "  &6OBWUU3%J6BKQV%4Z;B?%VPD&>B2YW4#-FB)]WR",#B*)W
M_0\,B5-WE   @4Y\Y0  @ "  &3WB>)\\%GNB3!]2TX B&=]>T$)AY]]C3+>
MAP1]F2+9ALQ]HP\+AQ)]M0  @!N     @ "  &1:B(B$BUE2A^:$=TUHAR"$
M+T!VAE2#T#):A;"#BB* A5B#B0\SA2&#1P  @ "     @ "  &/>AX",15D-
MAN^+Y4TOAA^+)$ _A2R*.S(OA&>)L"(VA :* 0[E@Z"'\@  @ "     @ "
M &-\AK&4&5BMAB&3?$S+A4V24S_AA$^1!C'C@W.0;B("@NV0*@[;@EV*"P
M@ "     @ "  %S@GO%5WU)"G5E8GT; G A;13GYFOM=N"N)FGU?OAI)F\U@
MN :$G$IA!   @Z-M20  @ "  %P&G-U='5&LFUE?548WF?1A>3F5F,!C<BM1
MF!1E#!I0F1%EM ;?F-UEXP  @A!R,0  @ "  %M?FH5D0U#UF1ME_$6?E[UG
MHCD%EH1I)BKJE<5J5AHFEH=JM0<7E9QJY   @)=W%   @ "  %JVF$!K6E X
MEN=LGD31E9=MSCAJE&%NXRIJDY]OL1G=E#-OS@<NDK%P(P  @ ![90  @ "
M %H,EDQR@4^2E01S6T0PD[=T'#?&DGQTMRH"D:MU+1F4DAQU(0<QD"IUW@
M@ !_+@  @ "  %ESE+=YR$\&DWUZ0T.QDBYZE3=1D.EZPRF8D 1ZWQEQD"UZ
MS <[C?A[T0  @ "     @ "  %CPDVN!$TZ6DCZ!.T-,D.J!(S;MCY> ["DN
MCJ6 SAD@CJF ZP=0C!R X   @ "     @ "  %B(DER(8$XOD3J(.T+GC^:'
MQ#:0CH:'-BC<C7Z'!ABWC7.'1P<KBJ.$V0  @ "     @ "  %@WD8Z/Y4X)
MD'*/HT+#CQ6.SC9OC9"-VRCBC%>-PACYC B,H0=RB52%"0  @ "     @ "
M %"FJF%4349BJ)A6TCM-IPU9/2[LI>1;:2"&I=E<]PZ7J*-="   H A@?
M@ !Q+@  @ "  $_&J)1;*D7$ILQ=-SJ_I1Y?,BZ%H\%@]R!;HVUB*P['I;)B
M!P  G6QE%0  @ !U^   @ "  $\]IE-A[T4MI)9CCCI!HNME&"X1H7YF>2 3
MH0=G5@[1HN%G"@  FMYI[@  @ !Z/   @ "  $['I MHIT2CHEEIWCFDH+9K
M 2VAGTEL !_ GK]LD0[&H#]L*   F'=O*P  @ !]_P  @ "  $Y+H@MO<40K
MH&MP3CDSGL5Q$2TKG4QQI!^,G*5Q]@[ G=EQC@ UE@!U"0  @ "     @ "
M $W7H&IV8$/*GM-V\#CDG2AW52SKFYYWD1]8FM=WG [8FZEW7@!QD]IZ5
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M4P:-7W=#5D^,*V<_65J*\E9"7"N)U$0K7FZ(YC"I7Q2(4AC\8$V(20  @ "
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M6.V3)VT16Y61CEWL7@*/ZDV_8#:.>SQ;8<Z-<2EO86Z-21&"9JJ*8@  @ "
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M:0QO-V< :K9PH5B5;$!Q\DB];:YS(C=];LQT*R07;N%TRPM.<UYTLP  @ "
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M7ZB8(&+;8:662E2$8V24844I9.62UC1X9;Z2&R')9&*140IK;F2'"P  @ "
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M;K!U.ENB;]YV'4X%<.=VWC\\<=9WC"Z9<GMX$AM8<>YX(@2M>!EYLP  @ "
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M VN6?X1:3F"0?\%=(51F@ =?T$<0@%5B4SA#@+EDD"=T@6MF1!+7@OMF7P
M@0EJ8@  @ !_-FJ$?%-B(U]O?,MD7E-V?3)F?$8N?9!H;C>+??AJ)R;J?HIK
M9Q*4?XEK/P  @ !O>@  @ "  &EM>69I^%Y.>@1KH5)1>H5M+45+>O=NF#:_
M>VAOSB9,>]MPH1(Y?(]P2   @ !T_@  @ "  &AC=M5QTUU4=Y!R]5%=>"5S
M]411>*)TT38C>0MUC27(>6!V Q'U>?AUG@  @ !YX@  @ "  &=S=*!YQ5QP
M=7AZ8E"(=AYZU4.:=IU[)35_=O][9"5]=Q][DA'7=[E[8   @ !^"0  @ "
M &:N<LB!LUO+<[V!VT_V=&N!Q4,+=..!C#3I=3F!8R3W=2^!9!&I==J!B0
M@ "     @ "  &82<4F)FELT<DV)54]B<P&(O4*"<W2(!31G<[N'BR1R<XF'
MFQ%+=&J&P0  @ "     @ "  &68<!:1AEJ^<2B0ZD[K<>"/VT(3<DN.LS0+
M<GZ. B0O<B&.-A$1<S^*\   @ "     @ "  &"FC&]1F%8'B^U4W$IWBZE7
M_3V<BY5:Y"\:B]==91X(C2E>^@F CFI?*0  @ !I:0  @ !^<%^/B5)8_E4K
MB1%;NTFJB-Y>53SUB,1@O"ZAB.YBQAW)B?EC^ FDBJAC_0  @ !N*0  @ "
M %Z?AD%@8U0MAC%BF$C7AA=DKSPOA@1FEBX%AB1H*1UBAO5H_0FCAU%HZP
M@ !S9   @ "  %VP@VAGR5,R@W=I>D?5@W%K#3MG@VIL>BU5@XEMG!SCA"1N
M& F&A&=N#   @ !X6P  @ "  %S&@.AO/5).@1)P<4;T@1QQA3J+@15R;RS
M@2=S+1QG@8YS8PEA@>-SB@  @ !\K   @ "  %OT?L=VQ%&(?PIWA48]?Q]X
M'#G=?Q=XCBPC?Q1XXAPE?RAX\0E:?[1YF0  @ "     @ "  %L\?/!^/5#7
M?4]^DD69?6]^M#E'?61^MRN;?4]^NAO1?21^Q F-?=)_,P  @ "     @ "
M %JL>WF%RU!T>_F%SD5&?!N%>#D&>_&$_2MO>[:$PQN->UJ%&PE2?%R#WP
M@ "     @ "  %H[>DJ-;% %>M>-*T39>O^,;3BG>LV+DBLG>G6+2!MB>=F+
M,@E,>RJ&20  @ "     @ "  %2EEMQ0/4J,E?%353^)E4]62C,FE0)8^B3/
ME7=;%A+OF%);J &"E*5=C0  @ !M%   @ "  %.>D_U7/TF\DT19X#[%DJ=<
M73*(DD1>FR1GDHA@3Q+8E.=@F0'4D0IB:0  @ !Q^   @ "  %++D0Q>/TC<
MD'E@9SX*C^QB;3'8CX=D.2/DCZ]EAQ*;D:1EC@(&C<MG9P  @ !VY   @ "
M %( CD)E0$@&C<AF\3THC4MH@3$OC.EIX2-4C0%JT!)*CI-JG0(?BO!LI
M@ ![/   @ "  %$YB\AL54=$BVEMECQKBO=NM3!TBH]OGB+CBHIP/1'^B[YO
MY@(MB'AR6@  @ !_!@  @ "  %""B:MS@$:9B6=T7#O2B/UU#2_JB(QUCR)I
MB&AUUQ'BB1]UB )%AE5X2@  @ "     @ "  $_BA^)ZJ48,A[A[+3M8AU1[
M=2^ AM5[ER($AI-[IA&HAN5[BP)PA()]5P  @ "     @ "  $]@AF.!Q$6(
MAE*!\#K8A?:!UR\,A7"!IR&;A1&!IA$OA1B!PP)A@Q&!=0  @ "     @ "
M $[XA32),T5:A4:)0#JYA/.(O2\0A#B(%"'M@X.(&A'D@QV') +7@;2![
M@ "     @ "  $A8HG%.7S[?H3Q10C1IH&=3]BA9H"A63AG#H7-7OPBCHQM8
M90  D91?Y   @ !P>@  @ "  $='G^94_CWXGNQ7=S-XGAI9Q2>/G:];O!E%
MGJ%<V BGGW-=60  CMQD?@  @ !U40  @ "  $:;G0U;G3TTG"U=K#+"FV]?
MCB;;FOEA)!C#F[UAZ@B7F\YB4   C$-I40  @ !YJ0  @ "  $8'FCQB.CR$
MF6]CW#'VF+QE5B9 F$=FBQA'F.UG!@B F$QG7P  B=YN?   @ !]@   @ "
M $5DE[AHZ#O=EPQJ*3%>EEAK0"6HE=)L"A?[EDQL2PAUE0]LKP  A\9T+P
M@ "     @ "  $3%E9-OOCM*E0IPIS#DE%MQ7R5,D[YQTQ>XE !QT B2DBER
M9   AA!Y9P  @ "     @ "  $0[D\)VG#K/DUIW.3""DJYWEB3XD@%WO!=H
MDAYWF0B"C])XFP  A+)]R@  @ "     @ "  $/)DD%]D#IMD?9][3 RD4]]
M^"3#D(A]VA="D'-]R A2C?!^>   @T6     @ "     @ "  $. D02$QCHE
MD,Z$]"_QD#*$LR29CUF$91=*CP6$APB%C%F#6   @G&     @ "     @ "
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M2;A^36]Z3<1^<F!F479^C%!.5+]^J3[T5QU^U"OU5L!_"12'7F1_6   @ "
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M3CR$>&5;4<J$&5<85/B#L$? 5Z6#63<962:#*22F6)&#1 T\::&#$P  @ "
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M4Z.)N5LV5IZ(^$VS62J()S\'6Q:'AB[>6WR'01R=7.2'Q0;3='B$G0  @ "
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M9L1H$E3B:)QI]T?>:C9KO3E&:X1M32CP;!%N@A5=;6YNJ0#S?F5QE@  @ "
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M6@".,U#W7%Z--D0B7C*,(C8@7S^+:B9G7F&+B1.P9#B)\P$/?C6 N   @ "
M &3C>@Q-6EG<>KA0^$X'>XA4@D$#?&17W3)T?4Q:VR&4?H!=#0S,@*!=>
M@ !EG0  @ ![M&-%=<)4WUBH=L%8 DS]=[I;!4 J>*1=V#'(>8)@4R$<>F=B
M$0RT?*QB/0  @ !J2   @ !^]&'Q<:=<@U==<NY?%TON=!)AD#\O=0]CUS#Z
M=>9ET""!=GAG'@Q\>4%G&@  @ !O5@  @ "  &"P;=5D,E8;;U%F-$JP<)=H
M'3XW<:QIWS ><GYK61_5<K-L/PPP=EAL(   @ !TT0  @ "  %^$:EQKZ%4#
M; 1M7TFD;6ENO#TL;HMO\R]X;T]P^1]+;QUQB O^<]!Q;@  @ !YL@  @ "
M %YV9T9SLE0&:1ETI$B^:IQU=#QJ:\=V(B[/;'1VL!\#:]MV_0OT<9EW'P
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M&E=X?TY3?$V$?]56BD)Y@&!9<38L@/%<&R@3@;%>21;Q@S-?0P2-A A@;@
M@ !M\0  @ "  %9(>UI:LTQ4?!]=0$%[?,E?JC4^?5]AUR=3?@)CD19K?OMD
M+P2*@+9E5@  @ !S)   @ "  %4K=Z)A]4LQ>))C_4!6>55EY#18>?=GFB:(
M>G]HYA73>OAI+P1S?=QJ;P  @ !X(   @ "  %0:=#EI1THI=5)JSC]5=B]L
M-C-B=M!M;"7B=S=N6!5'=X1N7@1:>VEOXP  @ !\<@  @ "  %,F<2QPJTE#
M<F]QNSZ$<V1RIC*A= 9S9R4W=#USZQ4%=(=STP1B>4-UWP  @ "     @ "
M %)1;G=X"DAS;^=XJ3W$</9Y&C'U<99Y:R2A<9MYGQ2B<B9Y@ 20>$I[<P
M@ "     @ "  %&F;"=_=$?O;<Q_N#U8;O=_L3&H;XE_C21E;U)_B11"<#I_
ML 1<>** )P  @ "     @ "  %$E:C^&\D=O; &&Z3S<;4&&>#$Y;<Z%\R01
M;62%VQ00;J2%N 11>+6"ZP  @ "     @ "  $SOC:!*UT-@C6I.-CC5C8-1
M:2R]C?]41!Y5CU]65PR D=U6]@  B8I<-   @ !LK0  @ "  $N3B<M1E$(X
MB>94BS>UBA=74"O%BG]9OAV9BYA;; PYC15;U@  ADY@WP  @ !QC@  @ "
M $J%A?I89T$<ADM:Z3:\AI1=/"K7AO-?.QS<A]1@A ODB)Y@OP  @U1EN@
M@ !VB   @ "  $F-@E1?1T 7@LAA3S6K@R-C*RH!@X%DOQP@A#%EJPN(A+=E
MP@  @*IJW@  @ !ZZP  @ "  $B;?O%F/#\G?X]GSC3"?_YI-RD>@$]J5QN5
M@,%J^ L[@6!J_0  @ !P>0  @ !^O@  @ "  $>Z>^)M3#Y-?+!N<#/^?39O
M:"AQ?7UP(AK[?:9P; L3?H9PAP  @ !V50  @ "     @ "  $;X>3%T73V5
M>BUU'3-<>LMUIR?F>P5V QIR>N=V$PK4?#9V;   @ ![1P  @ "     @ "
M $9/=M![;#SK> -[T#*]>+Q[^"==>.U\ !GZ>(1[^PIM>F]\K0  @ !_>
M@ "     @ "  $73=-N"O#R'=D2"X#)O=R""GR<Z=SF"2QHD=G*"6PK.>+6"
M!@  @ "     @ "     @ "  $"9F45(JS>RF*U+Y2VCF)1.U"&JF5%1.Q)Y
MG#)24P-2F;Y48   A+)?B@  @ !P#0  @ "  #\WE;Q/!#94E8Y1V2PLE9E4
M8B!+ED!69A%NF*%7+P,)E159/P  @:YD0   @ !U 0  @ "  #Y!DA95>#4Z
MDAE7X2L>DCY: A\ZDM=;H!"@E,-<'P+2D,]>+@  @ !I(P  @ !Y=   @ "
M #UOCGU;_310CI]=]BH8CM5?J1YGCV1@Z __D-=A*@*JC09C.@  @ !N5@
M@ !]6   @ "  #R:BQ1BFC-TBVED)BE$BZUE=!V9C")F2P^GC1!F9P*9B<5H
MAP  @ !T!   @ "     @ "  #O+A_)I73*FB(=J@2B0B.5K:QT&B4)K\0\_
MB:1KU@*FAP-N,   @ !Y.P  @ "     @ "  #L5A2EP*3'TA?YP[R?XAG=Q
M>1R-AK]QM [GAJYQA@*6A,5T4P  @ !]F   @ "     @ "  #I\@KMW"C%=
M@\]W?"=VA&5WKAPNA)=WJ ZCA$EWD@)N@P)Z*P  @ "     @ "     @ "
M #H-@*I^)S#G@?9^3R<+@JQ^,1OC@LQ^ 0Z1@EQ^+@*)@8A^_P  @ "
M@ "     @ "     __\  /__  #__P  ;69T,@     $ PD   $
M           !                     0   0   @   B0$'07:!VD(V0HV
M"X4,QPW_#S$07A&+$K<3XA4+%C(75QAY&9@:M1O2'.\>)1]9((<ALB+:(_\E
M(R9$)V8HABFG*L<KZ"T(+B@O2#!I,8DRIC/"--XU^S<8.#4Y43IM.XD\I3W"
M/MX_^$$10BE#0D1<175&CT>I2,-)W4KW3!)-+$Y#3UE0;U&&4IQ3LE3)5=]6
M]E@-62-:.EM17&9=>%Z*7YM@K6&^8L]CX&3Q9@)G$F@C:3-J0FM2;%YM9VYQ
M;WIP@W&,<I1SG'2C=:IVL7>W>+UYPWK(>\U\SGW-?LQ_RX#)@<>"Q8/"A+^%
MNX:WA[.(KHFIBJ2+GHR8C9&.AH][D'"19))8DTR40)4SEB:7&9@,F/^9\IKD
MF]:<R)V[GJV?GZ".H7RB:J-7I$6E,Z8@IPZG_*CJJ=>JQ:NSK*&MCZY]KVNP
M6;%'LC:S)+02M0"U[;;:M\BXM;FCNI"[?KQKO5F^1[\UP"+!$,'^PNS#VL3'
MQ;7&H\>1R'[);,I9RT3,+LT8S@'.Z\_5T+[1I]*0TWG48=5)UC'7&-@ V.;9
MS=JRVYC<?=UBWD??+. 0X/3AV.*[XY[D>^57YC/G#N?HZ,'IFNIQZTCL'>SP
M[</NEN]V\%7Q,_(/\NKSP_2<]7/V2?<>]_/XQOF5^F'[*?OK_*?]7/X+_K3_
M6O__   !Z .G!2P&A >_".<*! L6#!P-'@X<#QD0%Q$4$A 3"Q0$%/P5\Q;F
M%]@8S!G6&MX;X1SA'=\>VQ_6(-$ARR+$([XDN"6S)JXGJBBF*:(JH"N>+)TM
MFBZ5+Y$PC3&),H8S@S2!-7\V?S=_.( Y@CI_.WX\?#U\/GP_?4!_08)"A4.)
M1(U%DD:81YI(FTF=2I]+HTRF3:I.KT^T4+I1P%+'4\Y4U5775ME7VUC>6>!:
MXUOG7.I=[5[Q7_5@^&'\8P!D V4!9?]F_&?Z:/AI]6KS:_!L[FWK;NAOY7#A
M<=YRVG/6=,UUPW:Y=Z]XI7F;>I![A7QZ?6]^9']8@$V!08(U@RF$'(40A?Z&
M[8?;B,J)N(JFBY6,@XUQCF"/3I ]D2R2&Y,*D_J4Z979ELF7NIBGF9.:@)MM
MG%J=2)XVGR6@%*$$H?6BYJ/8I,JEO::QIZ:HFZF1JH>K?ZQWK6^N9Z]@L%JQ
M5+)/LTRT2;5&MD6W1+A%N4:Z2+M*O$Z]4KY7OUW 8\%JPG+#>\2$Q8K&D,>6
MR)W)I<JMR[;,O\W(SM+/W-#FT?'2^]0&U1+6'M<JV#?91-I1VU[<:]UYWH;?
ME."<X:+BJ..MY++EMN:ZY[WHP.G#ZM3KY>SU[@3O$O @\2SR./-#]$[U6?9C
M]VKX;OEO^FS[9/Q6_43^+_\7__\   (% ]@%: ;&" 8),@I2"V4,<@UX#GH/
M>A!Z$7D2=1-P%&@57A92%T48-QDI&C0;/1Q '3\>.A\T("PA(R(9(P\D!"3Y
M)>XFXR?8*,PIP2JV*ZLLGRV3+H<O?#!P,60R63---$$U-C8K-R$X%CD+.@ Z
M]COM/.,]VS[3/\M Q$&]0K=#LD2L1:9&H4><2)=)E$J02XY,BTV*3HE/B%"(
M48E2B%.(5(A5B%:)5XI8BUF-6H];D5R3799>F%^;8)UAGV*@8Z%DHV6D9J9G
MIVBH::EJJFNJ;*MMJVZK;ZMPJ7&H<J5SHW2@=9UVF7>5>)%YC'J'>X)\?'UV
M?F]_:8!A@5J"48-(A#Z%-88KAR&(%XD,B@**]XOMC.*-V([-C\.0N9&ODJ63
MG)22E8F6@)=XF'"9:IICFUZ<69U5GE*?4*!/H4^B4*-2I%6E6:9?IV:H;JEX
MJH*KCJR<K:NNNZ_,L-^Q\[,)M""U.+91MVRXA[FDNL*[X;T!OB&_0\!EP8?"
MJL/.Q/'&%<<YR%[)@LJFR\K,[<X0SS+05-%TTI33LM3/U>O7!M@>V3;:3-MA
MW'3=A]Z8WZ?@L^&^XL?CS>31Y=+FT.?,Z,3INNJLZYOLA^UO[ECO7/!;\5;R
M3/,]]"KU$O7V]M;WL_B-^6+Z+_KT^['\9OT1_;/^3?[A_W'__P   =D#C04)
M!E0'?PB6":$*I N?#),-@@YP#U\03!$W$B$3"1/P%-85NQ:?%X,8@1E]&G0;
M9AQ5'4$>+!\7(  @ZB'3(KTCIB20)7HF9"=.*#DI)2H0*OTKZBS7+<0NL2^>
M,(PQ>3)G,U4T1#4R-B(W$3@!./$YXCK3.\0\M3VF/I@_BD!]06]"8D-51$E%
M/$8P1R-(%TD+2?]*\TOH3-Q-T$[%3[E0K5&A4I53B%1Z56U67U=16$-9-5HF
M6QA<"5SZ7>M>W%_,8+UAK&*;8XED>&5F9E1G0F@P:1YJ"VKX:^5LTFV^;JIO
MEG""<6QR5G- ="EU$G7[=N1WS7BV>9YZAGMN?%9]/GXE?PU_](#;@<*"J(.-
MA'*%5X8[AR"(!8CJB<^*LXN8C'V-8HY'CRV0$I#XD=Z2Q).JE)&5>)9@ET>8
M+YD8F@&:ZIO4G+^=JIZ6GX.@<:%?HD^C/Z0PI2*F%:<(I_VH\ZGJJN*KVZS5
MK="NRZ_'L,2QPK+!L\&TPK7%MLBWS;C3N=NZX[OMO/B^!+\1P"#!,,) PU+$
M9L5ZQH_'ILB^R=;*\<P,S2K.1\]CT(#1G]*_T^#5 ]8GUTS8<]F;VL3;[]T:
MWD;?<^"AX<_C N1-Y9GFY^@VZ8;JV.PK[8#NU_ Q\9#R[_1-]:KW!/A:^:OZ
M]OPZ_7O^N____P"  (  YD]_SG]8S9E_J'[-M-I_F7YYG!1_HWYE@TQ_QGZ%
M:H5__G[ 4;^ 8W\].0"!$H /_,5^?(LTY+5^8XELS$!^78?,LYI^;H9FFMA^
MF(5#@AA^V81/:5I_+X-G4*Y_KX*A.!2 =H'F^KQ]-I9QXOM],).2RLM]/I#/
MLCI]:8Y>F9-]K(PL@.]^!XHB:$Y^=8@33\%_#(8 -T%_Z(.L^.-\+J&WX4%\
M,YV_R3-\39GPL,)\A997F$5\WY,:?\M]3X_S9U9]T8RU3N]^?(E--H=_9X5<
M]S=[8ZT#WZ5[9J?KQZI[AZ,*KV![R9YIEOA\*YGX?K)\KY6W9FY]0Y%!3BY]
M_8Q[->5^](;O];QZRKA5WB]ZQ[(4QD-ZY*P4KAE[+*9AE=Q[F:#:?:1\))M9
M995\R)6H38)]D8^!-5M^D8A?]'=Z4L.JW.QZ1KPRQ0EZ7;4*K/EZIZX[E.E[
M'Z>;?-E[MJ#H9-A\8)G=3.U]-9)0-.A^/8FG\V-Y]\\!V]AYX\9 P_IY\KWD
MJ_=Z.K7LE )ZN*XD?"![6Z9 9$A\$)WE3&]\ZI3C-(E]]XK%\G5YM-I:VNMY
ME] RPP]YG\:4JQAYX[UJDSMZ9+1J>W=[#:M 8\)[S*&63 E\KY<S-#U]OHNV
M[E.(VWXVUX:'Q'W"P)^&PWUPJ8R%YGU5DE*%*GUU>P>$AGW&8\2#\7XU3(^#
M>'[I-9*#*(  [#V'?8C+UA2&<(= OVN%@X7CJ&.$NX3!D1Z$&X/?>=2#E(,M
M8IR#'8*-2Y*"PX(6--B"D('!ZGJ&1Y-EU'2%39#:O?R$;XYSIPN#Q(Q8C^V#
M.8IW>,J"RHB]8;:":8<#2LV")H5,-#."!X-OZ-N%3YW^TN"$7YITO'J#CI<4
MI:N"YY/HCK2"<I$+=[N"%8Y!8-:!QXMD2AB!EXAH,Z*!BX4$YUR$BZB@T6R#
MG:05NQ""U)^ZI%N"-YN4C8"!PI>5=KJ!>).[8 B!.8^R276!&HME,R2!'X9[
MY@"#\;-+T!N#!*VZN<V".JA8HS*!HZ,MC'N!-IX@=<B [ID47TJ OI/;2.2
MKXXZ,KF P8?/Y-6#<[WXSOJ"A[=6N+6!O+#BHB^!)JJHBY^ Q*2*=1& @YY5
M7J> 5)?12&F 4Y#9,F" <HC[X]:##LBES@6"),#BM\:!5[E3H4J O['ZBM"
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M') 4*\6%](B)L)VN*'HFGXJIS7H)CHZE?GH;?8"A2'IJ;$J=(7KX6P68\'O
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M8'6RR9&54R^KI([G1E"D38Q).B^<KXFK+Q^4N8<@)<&,A83%B.S&X:$O>W;
M"IT8;?VY&IE48(ZR&)7:4TNK ))_1FZCM8\G.E"<&8O(+TN4.8AY)?^,(H5J
MB,W&5*=0>W&_=Z)V;@VX@IWX8*JQ@)G*4VNJ<)7"1H^C.9&V.G*;JHVD+W23
MT8FA)C*+TH7SB+'%T*TR>W&^\:>';B6W^J(]8-*P^9U74YNI\)BC1L.BQ9/N
M.J2;2X\W+Z&3AXJ6)EJ+DX9A\L][8WFPV]U[O'G2Q*A\''H'K25\@WI>E7%\
M]WK=?:U]?'N"9?!^%7P^3D1^V7TT-LM_Z7Y]\+)YN83/VBUZ-(/*PRIZLX+H
MJ\][.X(RE#1[T(&J?(A\=H%"9.%]+H#C355^$("?-@%_.H!H[LQX69 "V&IX
MY8W:P9]Y>(O2JEYZ&8H0DNIZR8A]>V1[BX<%8^1\7X6&3'U]6X/^-4Q^FX(_
M[09W,YLQUJYWR)?OO_AX:)38J.!Y&9'RD9AYX8]4>D%ZNXS#8O)[IXH:2[A\
MN8='-*U^#(/]ZVEV1Z95U1MVWJ(#OG)WA9W>IW=X09GLD$UY%I8=>2AZ!I)R
M8@U[!HZ62P)\+(IO-"1]C86=Z@1UD[%OT[]V)ZP1O1YVS:;7IC=WCZ'/CR]X
M;ISF>!]Y:9?]83EZ?)+K2E][LHUM,Z]]'X<7Z-IU!;Q[TIUUE;8.N_]V-Z^Z
MI21V^ZF4CCUWY*.-=U%XZIUS8(%Z!I<,2=1[2Y S,TU\PHAHY^=TG,=QT;!U
M)[_NNQ!UPKA[I#=V@K$KC6!W<:GX=IMX@Z*N7_)YJIK\25YZ]I*[,OQ\=(F,
MYR=T5=)!T/9TV<F;NDQU:L#_HVYV)+B C*)W$[ 5=?1X*Z>(7VIY6YZ.2/EZ
ML93Z,KQ\-HJ!XIF$$7@;S8V#A7AXN!R##GCAHCB"JWEDC F"7'H,=;R"'WK9
M7X"!\'O#256!XGSL,WR"!'YUX.&"CH*IS%R"%X'FMQ*!LX$_H2B!98#!BNF!
M*X!K=*"!"8 Y7G. _H 92'6!%8 ?,N"!6H!)WU&!08U!RL& V8MNM9: @HFX
MG\6 38@^B;* +H;P<Y2 *86^78^ -82*1[J 9(-8,E: OX('W;^ *)?%R25_
MQY3TM %_?))"GEQ_4(^YB'1_2XUN<H=_7(LQ7+=_?XCC1Q-_Q89T,=V -(.L
MW$1_0J)!Q[-^XIY[LII^H)K2G0=^@)=*AT%^@I/=<8E^JI"36^]^X(T@1GM_
M.8EM,71_NH4PVOI^D*R^QG1^,:@$L6-][J-8F^-]TY[%ACU]WYI(<)Y^#)70
M6SE^5I$V1?1^PHP[,1M_48:.V>A^ K<RQ6Q]I+%^L%Q]7JO'FN1]0Z8AA5Y]
M6J"1;^9]DIKR6IY]X94718%^7([1,-!^^8?#V0U]E\&8Q)9].KKBKW]\[;06
MF@9\S:U-A)%\YZ:;;SE]+9_76AI]AYC#12%^")$K,)-^KXC.V&9]2LONP^Y\
M[L0GKL5\F+PUF41\;[0[@^!\B*Q8;J9\U:1@6:Q].YP41--]R),],&-^=(FM
MTN^,ZW;9OY*+?'=7J[V*+7?=EU^(_GA\@JF'YGE#;=&&WGHT61B%WGM&1'N$
M\7RA,%J$&GYKT76+E(#!OF2*-8 \JJ.(]'_1EEJ'U7^&@:^&TG]E;.B%XW]G
M6$"$_7][0\R$+'^Z+^Z#;H JT":*5(JYO1:)!8DUJ8.'R8?*E32&OX:3@)N%
MT(6#:_&$^8215VV$+(.B0RN#=X*_+XV"U('2SLZ)0I2EN[2'^)(WJ!"&SH_B
MD^F%RXVS?W:$]8NT:OJ$,XG"5JJ#?(?#0IV"VX6O+SF"2X-=S8&(:9Z$NFB'
M(ILTILF& )?ZDK*%!I39?F2$,9'.:A:#A8[:5?J"WHO$0A^"4(AY+O&!TX3&
MS%N'OJAIN4R&>J0VI;2%5Z )D:R$8IOM?7F#E9??:4>"Z9/.55V"5(^<0;*!
MV(L7+K.!;(8+RV:',[)$N%Z%\JTGI,>$SJ?_D,F#VJ+??+*#%YW*:*2"<YB@
M5-F!W9,]05>!<HU^+H"!%H<GRJ"&Q[P/MYR%BK8!I "$8Z_5D 2#:JFA>_R"
MJJ-W: N"%)TR5&F!AY:E00N!'H^G+E: SH@:R@J&=<7-MP.%/+[ HUF$$+=]
MCUF#$K E>V*"4:C49XV!P*%H5 :!/YFP0,6 X9&(+C2 E8CDP[N5^'7>L<J3
MLG9RGV^1D'<0C)2/D7?)>5R-J7BJ9?Z+RWFX4LN)ZWKJ/\2(#7QK+6F&)'Y@
MPGR4P7\TL-"2@W[8GH20;7Z3B[:.>GYR>(6,HGYY936*V7ZE4A2)#W[G/SN'
M1W];+2N%=( ,P5F3HHA_KZ*1;X= G7N/6H82BJ^-=X4;=Y:+L(1$9&6)_(.*
M46B(1H+7/L&&E((V+/2$UX&=P$62DY'8KGR0;(^ZG$N.98VJB:>,?8O'=IZ*
MS(H-8Y&)*8AB4,*'AX:O/E"%[X3R+,6$2X,0OR>1OILFK72/F)@QFSR-EY51
MB(N+P)*)=:B*#H_78L6(@(TU4"F&[8IV/>V%9(>0+)R#TH1BOB>1&Z1SK':.
M^*"KFD*,^)SHAZ&+)9DU=->)>)6+8A*'YY'<3Z:&8HX./9F$ZXG^+'F#:X6.
MO4Z0F*VNJZ6.>*D-F7.,=J1@AMJ*I)^V="B(_IL2886'<Y983SF%Z9%L/56$
M@HPU+%R#%8:2O)^0,;;9JOJ.$[%7F,.,$*NUABV*.:8'<XB(EJ!:8/^'%YJ4
M3MN%E)2./1N$+(XN+$6"SH=PO!F/W[_WJG*-QKF&F"Z+P++;A9:)Y:P7<P&(
M0:538).&QIYT3H:%3Y=5/.&#\X_?+#*"E8@GM0Z?/74RI&.<*'7.DV*9-W9Z
M@?&697=%<"R3HW@Z7D:0X7E>3)V.$7JH.S:++'Q$*JV('GY4M >>*7W\HZ.;
M%'VWDJZ8)WV.@4256WV*;WZ2I'VR7:./\GX!3 J-,GYJ.M2*8'\+*IV'97_N
MLQV=%X:\HJV:#86@D=&7((2@@&248H/1;K*1N8,I7/./&8*?2WZ,:8(?.GV)
MJ8&[*H^&P8%KLBF<*8]BH:J9)8U_D,*608N\?WN3?HH4;=V0Y(B<7$6.48<M
M2OV+L86\.C&)!(1**H.&,8+(L4R;2Y@?H,68495TC]>5=I+B?H^2NY!B;1>0
M%(W[6Z"-E(NE2H6+ XDX.>R(;(:R*GF%M(0#L'2:JZ#:H :7L)UECQV4TIGZ
M?<Z2&9:A;&*/@)-26PJ,_(__2AN*=XR1.;"'[XCR*G"%2H48K[N:+JEYGU&7
M-:4ZCFF45:#S?261G9RR:\Z/"9AU6I.,B90F2<6)_8^L.8*'A(KY*FF$\H8(
MKR&9SK'^GKV6U*SKC=23\J>^?).1-J*(:TB.I)U46B.,+I@'27J)I9*'.5N'
M*XS$*F.$JH;2KJJ9@;IVGD:6B+2!C523HZY9?!*0XZ@<:M>.4*'A6<N+W9N.
M23:)894*.3"&\HY)*EZ$<(=XIP&HNG3!EWZDW'5;A[BA'G8,=YN==7;B9SF9
MSG?F5L26&7D<1J&217IX-N".1'PJ*"^)_GY(IC*GQ'T*EO.CX'S/AS:@'7RW
M=QJ<<WS)9K68T7T+5DF5)WUX1C>17GX!-JB-;7[(*$N).'_1I7^FOX4]EC.B
MY(0ZAHV?'H-8=FJ;?(*L9A27XX(J5<&41X'*1=&0C(%Z-GB,JX%,*&2(BH$[
MI,:ESXU;E6:A_(N>A;&>/HH =:J:F8B.96>7#H=&53>3?88017&/T(3;-DR+
M_X.O*'J'\H*%I 2E$95JE*:A/Y+XA.Z=A9"E=.>9XXYQ9,B62HQ*5+F2R(H[
M11V/)8@8-BB+9(7J*(V'<(.KHV.D8YV/E >@F)I@A$^<WI=#=$Z9/)0Y9#R5
MII$W5$J2&8XX1-2.@XLG-@B*V8?U*)R' 82LHL^CY:66DXJ@%Z&D@]2<5IVT
M<\^8KYG.8\:5(I7R4^V1GY()1)>. HX ->^*9XG/**F&IH6)HDZCB*UZDQ&?
MMZC @UV;\J/U<UV81I\K8U^4NIIG4YB109601&"-IY"6-=N*"XMN*+2&6X9"
MH>BC/[5(DJZ?:J^X@O:;H:G_<OB7\J0^8PF499Z'4U>0[IB_1#.-7Y+7-<2)
MSXS**+R&'X;9F:RR;'1IBSRMQW3Z?)VI.G6M;;ZDLW:,7K"@&G>=3Z*;8'CB
M0/Z6=GI/,MR11'P4)?:+MWX\F1JQBWP\BN6LW'P!?$JH0GOT;6FCL7P87E:?
M%WQR3U&:8WS[0+^5@'VC,M&06WZ,)CR*XW^VF*&PB8/JBEVKXH+V>]*G0H(J
M;.BBM(&=7>&>(($^3O.9=X$&0(*4GX#B,L>/BH#G)GJ**8$0F"*OEHM[B<FJ
M](G;>RZF6HAB;%FAQX<;76*=/X8#3I*8H84!0$>3U(0&,K^.TH,?)J^)B()'
MEYBNSI,#B3RJ+Y"Z>IREEXZ7:\>A!HR67.V<=8JQ3CJ7Y(CA0!.3(8<',KB.
M+H4O)MR(_H-;EQ"N-9J&B+ZIDY>0>B.D]Y2T:U6@99'T7(>;U(]"3?"7-8R1
M/^J2?8G8,K.-GH<0)P*(BH1+EJNMI:'PB%JI!IY%><*D:IJH:OF?V)<=7#B;
M2I.93;B6KI +/\V1YHQJ,K"-'(BZ)R&(*H47ED>M1JDWB!JHH*3,>8:C]:!9
M:K6?49OQ6_6:PI>937Z6.I,X/ZN1@X[!,J^,NXHR)SN'W(7"E?2L_+!AA]"H
M3:LI>3VCG*74:G&>]:"&6[^:99M135J5WI84/YB1-)#',J^,>8ML)T^'G89,
MC1&\4G0<?Z*VXW2@<A:QA'519&2L%W8W5IRF?W=42.N@KGBK.[R:F'HJ+S"4
M(WP") &-27XPC+^[>'N"?WVV 7M"<?"PC7L[9#FK#7MO5FVE;'O?2,:?G7R%
M.ZN9BWU,+U*3(WY7)&Z,9'^>C(2Z;H*R?RZT_X''<:FOA($,8^FJ H":5B:D
M8X!=2)2>G(!-.YB8E8!4+W"2/X",),V+G8#IC$&Y;(F^?M6T 8@U<3^NBH;:
M8XZI H6Z5=>C;H302%^=LH0!.X67MX,_+XJ1=8*<)1^*\8(1B^^XE9"^?H*S
M*HZ8<.>MLHR@8S*H*XK2592BD(DH2#&<XX>8.W:6](8&+Z*0QH2#)62*7X,5
MBY>W\9>X?C2R?Y3P<*&M 9)+8O.G>(_)55NAWHU>2 Z<*8K_.VJ61XB<+[:0
M+88\)9^)Y(/VBT6W<)Z,??.Q]YL;<&FL;Y>^8K^FX)1_53"A3)%61_2;G(XK
M.V65KXKW+\B/J(?#)<Z)?X2TBQ"V]J4R?<6Q?*$/<#^K\9SV8INF7YCS51"@
MS94#1]J;*9$-.UR5/(T0+]F/-8D3)?6)+852BM2VIJN]?;&Q'J;3<#&K@:':
M8H6EVYSZ50*@/YA#1]F:H9.0.VJ4TX[>+_".ZXHO)A2(ZX71@0W&9'/V=(K
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MPPZ"I)A L4Z!]I6^GN"!99,VB]N \I"P>)6 GHXV94N <8O34CN 48E2/VV
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MJG@.@'";?7B-<3R88'DG8;.50GGF4A^2''K+0N^.W7O,-$&+AGT&)LN("'Z
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MGH+@)!:(_X'[@UFQ=9'L=O>LJX_F:E.GRHWE78:BU(OS4,N=RXH31%.8J8A
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M;H\T/O6<.XP_-*25R8E9*U:/0H:)(Y6(W8/Z>'NYM*$F;2>SZIV187RM_IG
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MEXB,.UJ8^(;I,=F3,(55*4:-:H/2(C"'SH)O<'ZR]94W9@VM\),A6T*HO)#
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M_)8 EV]O=9.&A7MP^I#Y<T=RH(YL80%T<8O=3Q!V:XD_/71XG89J+,E[#8-
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M/;J!SWD:,+:!Q'KE)0&!VGS<C.V![WAP@**!GGDN<\&!4'G89FJ!"'IY6)B
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M?MB&C)0G<\&%JY*0: *$I9"%6]2#EXXT3YR"LXOF0XN" 8F>.""!7H=>+5F
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M#FCC;]YOWFL_8P=QOFV75=ISOF_]2)MU[G*".]AX2G4J+Z]Z['@3).9]N'M
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MI(B#4\MK6(> 2H=M^X9303APMX4[.!=SI80[+ZEVI8-,)_%YR()?(8M\NH&
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M)BB EG_1(9J GH ;'@6 Q(!4  #__P  __\  /__  !M9G0Q      ,$(0
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M)CS<VA\[QNLC5[/L*F^CWS6"EM1*D(_-79J+R&NAB<1UIH;">ZJ#P'ZL@;^
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MR,MKFKK"<*FNNG>TH[1\O9JO@<.2K(7(BZF*S(2GDL^ IIS0@*.ESX"AILZ
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M+EZ5[CQMBN5)>8/?5H)^VF2)>M9LCG;3<9%STG64<=!YE6_/>Y=MSGZ8;,Z
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M]L U1.?/.477WSQ0R>=!9+OE1G:LW$Z%G]-:DI7,9YR.QG&DBL)YJH6_?JZ
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M9D_SAF9/\X9F3_.&9D_SAF9/\X9F3_.&9D_SAF9/\X9F3_.&9D_SAF:]RP8
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MP:B-@\&HC8/!J(V#P:B-@\&HC8/!J(V#P:C_BB<)_XLX%_^9/B#_H3XH_Z9
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MA(JBG8&*K9]_BKN??HK(GG^)R9V B,J<@(C+FX"(RYN B,N;@(C+FX"(RYN
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M=4ODX'5+Y.!U2^3@=4ODX'5+Y.!U2^3@=4ODX'7_G18!_[$2 =/#"0#'T0H
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M;>UIF7'J9J%UZ&.I>.9ALGKD8+M[XE_'?.!?VGW48N%]RF/@?L-DX'^]9M^
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ML2 $[,$: ]_3%P'0W"4$Q-DU$+C502&LT$LQH,Q2/Y7)64R+Q6!7@L-F8'K
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M(RC_D"0G_YDE)O^A)B7_IR8E_Z<F)?^G)B7_IR8E_Z<F)?^G)B7_IR:?P
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M;V&5[&]AE>QO897L;V&5[&__=Q(!_XD1 ?^9$0#SJ X U[4* ,_!"@#&Q1@
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M96..\V1DC/1C9(ST8V2,]&-DC/1C9(ST8V2,]&/_<1 !_X(/ /^1#0#>GPD
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M5DJS_E9*L_Y62K/^5DJS_E;ZAP( UI@  ,FE P"]KP, L[@! *G"! "AS0@
MFM 6 )+0* 2*SS8,@<Y!%7G,2AYRRU(F;,I:+6;)83)AR&@W7,=O/%C&=C]5
MQG]#4<6)14[%E$A+Q:!*2<6N2TC%OTM'QMA+1\7M2T;#^4U%PO].1<+_3D7"
M_TY%PO].1<+_3D7"_T[?D   S)\  +^J 0"SLP$ J;T" )_'!0"6T@D CMH2
M (C;) * VC((>-D^$''82!AJUU ?9-98)5_57RI;U&<O5]1N,U/3=C90TW\Y
M3-.(.TK3E#Y'TZ _1=2N0$34OT%#U=A 1-/L0$+2]D)!T?Y$0='^1$'1_D1!
MT?Y$0='^1$'1_D31F   PZ4  +6N  "IN   GL," )3-!@"*V0H A.,8 7WD
M)@-UY#((;N,\#V?C115AXTT;7.-5(%?C7214XV0G4.)K*DWB<RU*XWPP2..&
M,D7CD#1#XYPU0>2I-D#DN#<_Y<LW/^7D-S_C\S8]XOLX/>+[.#WB^S@]XOLX
M/>+[.#WB^SC&H0  MZL  *JT  ">O@  D\D" (C4!@!_[@X >>T; 7'M)P-J
M[C((9.X[#5[N0Q-8[DL74^Y2&E#O61Y,[V @2>]G(T?O;R5$\'<G0?" *3_P
MBBH]\94L._&A+3GRKBXX\KXO-_/0+S?SYR\V\?,O-O'S+S;Q\R\V\?,O-O'S
M+S;Q\R^YIP  J[   )^[  "2Q@  AM ! 'O=!0!T]Q$ ;?<< 6;X)@-?^"\&
M6ODX"E3Y0 Y0^D<13/I.%$C[519%^UL80OMB&D#\:!P]_' =.OUX'SC]@B V
M_8TB-/Z8(S+^I"0Q_[$E,/^_)B__SR8N_^,F+O_C)B[_XR8N_^,F+O_C)B[_
MXR:MK0  G[<  )+"  "&S0  >=H  '#R" !H_Q$ 8?\: 5K_(P-4_RL$3_\S
M!DK_.PA&_T(+0_])#4#_3PX]_U40.O];$3C_81,U_V@4,_]O%3#_>!8N_X(7
M+/^-&2K_F1HI_Z0:*/^O&R?_NAPF_\<<)O_''";_QQPF_\<<)O_''";_QQRA
MM   D[\  (;*  !XU@  ;.(  &/\!P!<_P\ 5?\6 4__'@))_R8#1/\N!$#_
M- 4\_SL&.?]!!S;_1@@S_TP(,?]1"2[_5PHL_UT**O]D"RC_; PE_W4-(_]_
M#B'_B@\@_Y40'O^@$![_J!$=_[$1'?^Q$1W_L1$=_[$1'?^Q$1W_L1&5O
MAL<  'G3  !KX   7NT  %;_ P!/_PP 2?\2 4/_&0$^_R ".?\G S7_+0,R
M_S,$+O\X!"O_/04H_T(%)O]'!23_3 8B_U$&(/]7!AW_7@<;_V4'&?]N"!?_
M> @5_X,($_^-"1/_E@D2_YX)$O^>"1+_G@D2_YX)$O^>"1+_G@G_0BT#_T(R
M!/](,@3_3#8&_TX\"/]01P[_4%(5_TY?&O]+:Q__2'<D_T6#)_]"CBK_09<L
M_S^@+O\_IR__/JXP_SVU,?\]O#+_/,4R_SS.,_\[WS/_.^HT_SOS-/\[^S3_
M//\S_CS_,_P]_S3V/_\U]3__-?4__S7U/_\U]3__-?4__S7_0RP#_T0P!/]*
M, 3_3C0&_U$Z"/]31@[_4E$5_U%=&O].:2#_2W0D_TB */]%BRO_0Y4M_T*=
M+_]!I3#_0*PQ_S^S,O\_NC/_/L(T_S[,-/\^W#7_/>@U_SWQ-?\^^C7]/O\U
M^S__-/@__S;R0?\W\$'_-_!!_S?P0?\W\$'_-_!!_S?_1"P#_T<N _]-+@3_
M43(%_U0Y"/]71 [_5D\5_U1:&_]19B#_3G(E_TM]*?](B"S_1I(N_T6;,/]$
MHC+_0ZDS_T*P-/]"MS7_0;\V_T')-O] US?_0.4W_4#P-_I ^#?W0?\V]D'_
M-_)!_SCL0_\YZD3_.>I$_SGJ1/\YZD3_.>I$_SG_12L#_TDL _]0+ 3_52\%
M_UDW"/]<0@[_6TT5_UA7&_]68R#_4F\E_T]Z*O],A2W_2H\P_TB8,O]'GS3_
M1J8U_T6M-O]%M#?_1+PX_D3&./Q$TCGY0^(Y]D3N.?-$]SGQ1/\Y[T3_.NM%
M_SOD1O\\XT;_/.-&_SSC1O\\XT;_/.-&_SS_1BL#_TTI _]4*03_62P%_UXU
M!_]A0 W_84H4_UY4&O]:7R#_5VLF_U1V*O]1@2[_3HLQ_DR4-/Q+G#7[2J,W
M^DFJ./A(L3GW2+DZ]D?"._5'S3OR1]\[[D?L.^M(]COI1_\]YT?_/N%(_S_:
M2O] V$K_0-A*_T#82O] V$K_0-A*_T#_1RH#_U G _]8)@/_7BH$_V,S!_]F
M/0W_9D<3_V11&O]@6R#_7&<F_5ER*_I6?2_X4X<S]E&0-?10F#?R3I\Y\4VF
M.^],K3SN3+4][$N^/>M+RC[I2]P^Y4SJ/>)+]3_?2_Y!W$K_0M1,_T/-3?]#
MRT[_0\M._T/+3O]#RT[_0\M._T/_2B@#_U0D _]<(P/_8R@$_V@P!O]L.PO_
M;$02_VI.&?YF6!_Y86(E]5YM*_);>##O6((T[%:+-^I4E#GH4YL[YE&C/>51
MJC[C4+(_X4^[0.!/QT#>3]A!V4_H0=1/]$/03OY%SD[_1LA0_T;"4?]'P%'_
M1\!1_T? 4?]'P%'_1\!1_T?_324"_U<A O]@( /_:"8#_VXN!?]R. K_<D$0
M_7!+%_=M5!WR:%XD[61I*NEA=##E7GXTXEN'..!9CSO=5Y<^VU6?0-A4ID+5
M4ZY#TE*W1-!2PD7.4M!&RU+E1LA2\DC%4OU)PE+_2KQ4_TJW5?]*ME7_2K95
M_TJV5?]*ME7_2K95_TK_4","_UL> O]D'@+_;20#_W,K!/]W-0C^>#X.]G='
M%/!T4!OJ;UHBY&ME*>!G;R_;8WDUUF"".M)=BC[/6Y)!S%F:0\I8H47(5ZE'
MQE:R2<16O$K"5<E+OU7?2[Q6[DRY5OI-MU;_3;)8_TVN6?]-K%G_3:Q9_TVL
M6?]-K%G_3:Q9_TW_4R "_UX< O]H' +_<2("_W@H _]\,0?X?CH+\'U#$>EZ
M3!CB=E<?W')A*-1M:R_/:70VRV5].\=BA4#$8(U#P5Z51K]=G$B\6Z1+NEJM
M3+A9MTZV6<-/M%G53[%:ZE"N6O=0K%K_4*A;_U"D7/]0I%W_3Z1=_T^D7?]/
MI%W_3Z1=_T__5AX"_V$9 O]L&@+_=2 "_WPE _V!+@7SA#<)ZH0_#N*!2!7;
M?5,=T7==)\MR9S#&;G WPFIX/+YG@$&Z98A%MV.02+1AF$NR7Y]-KUZH3ZU=
MLE&K7;Y2J5W.4Z9=Y5.D7O13HE[_4Y]?_U*<8/]2FV#_4IM@_U*;8/]2FV#_
M4IM@_U+_6!P"_V07 ?]P&0'_>1T!_X C OB&*@/MB3(&Y(H["MR(11+1@E <
MRGU:)L1X8R^^<VPWN6]T/;5L?$*R:H1&KF>,2JMEDTVH9)M/I6*D4J-AKE2A
M8;E5GV'(5IUAX5:;8O%5F6+]59=C_U259/]4E&3_4Y1D_U.49/]3E&3_4Y1D
M_U/_6AH"_V<5 ?]S%P'_?1L!_X0@ ?.*)@+HCBX$WY V!]2,01'+ATT;Q()7
M)KU]8"^W>&DVLG1Q/:YQ>$*J;H!'IFR(2J-JCTZ@:)A1G6>@4YIFJE689;57
ME67$6)1EVUB29N]7D6;\5X]G_E:.9_Y5C6C^58UH_E6-:/Y5C6C^58UH_E7_
M7!@!_VD3 ?]V%@'_@!D!_8@= >^.(@'DDRD"VI0Q!LZ0/P_&BTL:OH95);>!
M7BZQ?68VK'EN/*=V=4*C<WU'GW"$2YQNC$Z8;)12E6N=5))JIU>0:;)9C6G
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M6G%[^UER>OQ8<GK\6')Z_%AR>OQ8<GK\6')Z_%C_9Q$!_W4/ /^##@#TC@T
MVYD* -2A"P#,I!4 PJ0G [BB-@JPGD(5IYI,'Z"75"F9DUPQDY!C.(V-:C^(
MBG%$@XAX27Z&?TUZA(A1=H*157.!FUAO@*9:;7^T7&M_Q5QK@-]<:X#R6FN
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M55N0_E5;D/Y56Y#^55N0_E7_<PD ]80$ -B1 P#,G 4 PZ4% +NM! "SLPP
MJ[4< :.T+ 6;LCD.DK!$%XJM32"#JU0I?:E<,'>G8C9QI6D\;*1O06BB=T5D
MH7])7Y^(3%R>DD]8GIY25IVK4U2=O%13G=%44YWK4U.<^%-4FO]35)G_4U29
M_U-4F?]35)G_4U29_U/_> 8 X8D  -"6 @#&H0, O*D# +.P 0"KN @ I+H8
M )RZ*0.4N38+C+=!%(2U2AU\LU(E=K%:+'"O8#)KKF<X9JUN/&*K=4!>JGU$
M6JF&2%:HD4I3J)U-4:>J3D^HND].J,]/3J?I3TVF]T]-I?]/3J3_3TZD_T].
MI/]/3J3_3TZD_T_Z?P  V(X  ,F; 0"^I0( M*T! *NU  "AOP0 F\$4 )3!
M)0*,P#,(A+\^$7R]2!EUO% A;[I8)VJY7RUEN&4R8+=L-ERV=#I8M7P^5;2%
M05&TD$1.LYQ&3+.I2$JSN4A)M,Y(2;/I2$BQ]DE(L/]*2+#_2DBP_TI(L/]*
M2+#_2DBP_TKBA@  SI0  ,*A  "VJ0  J[$  *&Z 0"8PP4 D,D0 (K)( &#
MR2\%>\@[#73'111NQDX;:,56(6/$72=>PV0K6L)K+U;!<C-3P7LV3\"$.4S
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M/]ZF*C[?M2H]X,@J/=_C*CS=\2L[W/LM.MS]+CK<_2XZW/TN.MS]+CK<_2[
MGP  L:<  *2P  "8N@  C<,  ('- @!VUP< ;N@/ &GH&P%CZ"<"7NDR!5CI
M.PA4Z40,3^I,#TSJ4Q))ZEL51NIB%T3K:AE!ZW(;/^M['3SKAAXZ[)$@..R>
M(3?MK"(V[;LC->[/(S3NYB,TZ_4C-.OX(S3K^",TZ_@C-.OX(S3K^".SI0
MIJT  )FW  "-P0  @,L  '75 0!IX08 9/,1 %[S' %9]"8"5/0P!$_U. 9+
M]4 (1_9'"D3V3@Q!]U4./_=<#SSW8Q$Z^&H3-_AS%#7X?18S^8@7,?F4&"_Z
MH1DN^J\:+?N^&BS[SQLK^^<;*_OK&RO[ZQLK^^L;*_OK&RO[ZQNHJ@  FK0
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M3G]K_TQ_:_]+?VO_2W]K_TM_:_]+?VO_2W]K_TO_7A !_VL. /]V#@#[@ T
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M3&I[_TQJ>_],:GO_3&I[_TS_9@H _W4( .&! @#4BP4 RY,& ,2:!@"]G@X
MM9\? :R>+@6DFSL,G9A%%9:53AZ/DU8EB9!=+(2.9#)_BVLW>HIR/':(>4!R
MAH%$;X6*1VN#E4IH@J!-98&L3F.!O$]B@=%/8H'K3F.!^4UC@?],9(#_2V2
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M-$.[LC1"N\4U0[OB-$*Y\S5!N/TW0+?_-T"W_S= M_\W0+?_-T"W_S?.BP
MOY@  +*A  "GJ0  G+   )&X  "&P ( >\@' '3+$@!PS"(!:\LP V;+/ =A
MRT4,7,I.$5C*5A54RET94<ED'$[);!]+R70B2,A^)$7(B"=#R)4H0<BB*C_(
ML2L^R<0K/LGA*C['\BL]QOPM/,7_+CS%_RX\Q?\N/,7_+CS%_R[$DP  MI\
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M$"CVSA$G]^81)_7Q$2?U\1$G]?$1)_7Q$2?U\1&CJ   EK(  (B[  ![Q0
M;\X  &+7  !6W@  3O ' $KZ$ !&^QD 0OLB 3_\*@$[_3("./TY C7^/P,R
M_D8#,/],!"[_4P4K_UH%*?]B!B?_:P8D_W8'(_^"""'_D @@_YT)'_^K"1[_
MN@D=_\D)'/_="1S_W0D<_]T)'/_="1S_W0F8L   BKH  'S$  !OS0  8M@
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M/I%;_SZ07/\]D%S_/(]<_SR/7/\\CUS_/(]<_SS_51$ _U\- /]I#@#_<0X
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M,XYK@3:+:HDYB&B2/(5GFS^"9J9!@&:R0WYFP41]9ME$?&?O0WQG_$%\:/]
M?&C_0'QH_S]\:/\_?&C_/WQH_S__6PP _V<) /=Q!P#>>@4 U( ' ,Z%"0#'
MAQ$ OH@B ;:',02OA#X+J(%)$Z)]4AJ<>EH@EW=A)I-U:"N/<V\OBW%W,XAO
M?C:%;H8Z@FV//7]KF3]\:Z-">6JP0WAJOT1V:M1%=FOM0W9K^T)V:_]!=FS_
M0'9L_T!V;/] =FS_0'9L_T#_70H _VD' .QT P#:? 0 T(,& ,F(!P##B@\
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M/&YZDC]K>9U!:'BJ0V9XN$1E>,Q%97CG1&5X]T-F>/]"9GC_069X_T!F>/]
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M.U"4L#U/E,,]3Y3?/$^3\CQ/DOT\3Y+_/$^1_SQ/D?\\3Y'_/$^1_SSD=
MSX$  ,*,  "XE@  K9P  *.A  "8J   D*H- (NK&P"%JRH"?JHV!GBI00QR
MJ$D2;:=1&&FF6!QDI%\A8*-F)5VB;2E9H74L5J%^+U.@B#)/GY,U39^@-TN>
MKSA*GL$X29[=.$F=\#A)G/PX29O_.4F;_SE)F_\Y29O_.4F;_SG;>@  R(<
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M(3O"[B$YP/DB.+__)#B__R0XO_\D.+__)#B__R2]D0  L)L  *2B  "8J@
MC+$  ("Y  !UOP  :L8$ %[," !9SQ( 5] A %70+@%1T#D"3M!#!$O03 9)
MT%,(1M!;"T/08PU!T&L//M!U$3S1@!,ZT8P4.-&:%C;1J1<UT;L7--+2%S70
M[!8TS_<8,\[_&C/._QHSSO\:,\[_&C/._QJSF0  IJ$  )JI  ".L0  @;D
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M!!;_Y 06_^0$%O_D!!;_Y 23K@  A;<  'C   !JR0  7=(  %#9  !$WP
M.N0  #7W P R_PP +O\2 "O_&@ H_R$ )O\G "/_+0 @_S, 'O\Y 1S_/P$9
M_T4!%_]- 17_50$3_U\!$?]J A#_> (._X<"#O^6 @W_I (,_[ "#/^^ @S_
MP@(,_\("#/_" @S_P@*'M@  >;\  &O)  !>TP  4-L  $/@   XY0  +_
M "O_   G_P@ )/\. "'_$P >_QD &_\> !C_(P 5_R@ $_\M !'_,@ 0_S@
M#O\_  S_1@$*_T\!!_]9 03_90$!_W(! /^! 0#_CP$ _YL! /^G 0#_J0$
M_ZD! /^I 0#_J0'_+"\!_S L ?\R+ +_,S "_S$V _\P00/_+TT$_RU:!O\K
M9@?_*7,(_RA^"O\GB O_)Y$,_R>9#?\FGPW_)J4._R:K#O\FL0__)K@/_R;
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M*ZE*_RNH2_\KITO_*Z=+_RNG2_\KITO_*Z=+_RO_21( _U . /]9$ #_7Q(
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M,X1<_S.$7/\SA%S_,X1<_S/_4PH _UT& /5F! #?;0, U7(& -!U"0#)=A$
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M-UYYL3A=><(Y7'G=.5UY\3A=>/XW7GC_-EYX_S5>>/\U7GC_-5YX_S7U9
MW'   ,IZ  # @P  MHD  *Z-  "DCP  G9$0 )>2( "1D2X#BI Y!X2.0PQ_
MC4P2>HM3%W6)6AMQB&$@;H9H(VJ%;R=GA'<K8X-_+F""B3%=@90S6X"A-EE_
MKS=7?\ X5W_:-U=_\#=8?OTV6'[_-5A^_S58?O\U6'[_-5A^_S7I:   U'0
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M+4:8ZRU&E_DN1I;_+D:6_RY&EO\N1I;_+D:6_R[1=P  P80  +:.  "JE0
MH)L  )6?  "*I   ?:D  '>K$ !SJQX ;ZPL 6JK-P1EJT$'8:I)"UVI40]:
MJ5@35ZA?%E.G9AE0IVX<3:9V'TJE@2%(I8PD1:69)D.DJ"="I+@H0:3.)T&C
MZB= HO@H0*'_*4"@_RE H/\I0*#_*4"@_RG)?@  NHL  *^4  "CF@  F*
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M$2['_Q(NQ_\2+L?_$B['_Q*NEP  H9X  )6E  ")K0  ?+0  '"[  !DP0
M6<8  $[+ P!%T @ /M4. #W5&@ \UB8 .]<Q #G8.P XV44!-ME- 3795@(S
MVEX",=IH S#;<P0NVW\%+-N-!2K<G08IW*T&*-W!!BC=W@8GV^\')MGY"";8
M_@DFV/X))MC^"2;8_@FDG0  F*4  (NM  !^M   <;P  &7#  !9R0  3<T
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M 0/_QP&#M   =;T  &?&  !:SP  2]4  #_<   SX0  *>4  "'L   >_0
M&O\% !?_#  5_Q  $O\4 !#_&0 ._QX #?\C  O_*  (_RX !O\U  /_/0
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M%<@W_Q;&-_\7Q3?_&,0W_QC$-_\8Q#?_&,0W_QC_.Q< _T 3 /]%$P#_21@
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M))A+_R282_\DF$O_))A+_R3_2 P _T\( /]6" #U6PD Z5X* .1>#0#57Q4
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M+FMFL2]I9L$P:6;;,&EG\"]I9_TM:6?_+&IG_RMJ9_\K:F?_*VIG_RO^6
MX6,  ,]L  #$<P  NW@  +-Z  "K>@0 I'L2 )Y\(@"8?"\"DGH[!8QX10J'
M=TT.@W55$G]S7!9[<F(:>'!I'75O<"!R;G@C;VV!)FULBREJ;)8K:&NA+F9K
MKR]D:K\P8VO8,&-K[R]D:_PM9&O_+65K_RQE:_\L96O_+&5K_RST6P  W68
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M+51ZZBU4>ODL5'G_*U5Y_RI5>?\J57G_*E5Y_RKA90  S'$  +]Z  "T@@
MJX<  *&*  "5BP  C8T) (>.%@""CR0!?8\Q GB..P5SC40);XQ,#6N*5!%G
MB5H59(AA&&&':!M>AG >6X5X(5B$@B15A(TF4H.:*5""IRI/@K<K3H+,*TZ"
MZ"M.@?@J3X#_*D^ _RE/@/\I3X#_*4^ _RG;:@  QW4  +I_  "PAP  IHP
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M'SR;_Q\\F_\@/)O_(#R;_R#"?   M8@  *F0  ">E@  DYL  (>?  ![I
M;Z@  &.L! !?K1$ 7*T? %JN*P!7KC8!5*Y  U&M2 5.K4\'2ZU7"4FM7@M&
MK&8-1*QN#T&L>!$_JX03/*N1%3JKH!8YJ[ 7.*O#%SBJX1<WJ?,8-Z?^&3:F
M_QHVIO\:-J;_&C:F_QJZA   KH\  **6  "7FP  BZ$  '^F  !SJP  9Z\
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M!!_1_P2?FP  E*(  (>I  !YL0  ;;@  &"^  !4PP  2<<  #[+   UT $
M+=4& "7;"P DWA( (]X< "+?)0 AX"X (. W !_A0  >X4H '>)3 !SC7@ ;
MXVH &N1X !CDB $7Y9H!%N:L 17FP $4Y]T!$^7O 1/C^@$3X_H!$^/Z 1/C
M^@&6H@  B:D  'NQ  !NN0  8<   %3&  !(R@  /<\  #/3   JV0  (MX"
M ![K"@ <[!  &^T7 !GM'P 7[B8 %>XM !3O-0 3\#T $?!& !#Q4  /\EL
M#O)I  WS>  ,](H "_6<  KUK@ )]L( "?;9  CU[0 (]>T "/7M  CU[0"+
MJ0  ?;(  &^Z  !BP@  5<D  $?.   [T@  ,=@  "?=   ?X0  &>@  !;X
M!@ 4^@T $OL2 !#\%P ._!T #?TC  S]*0 *_C  "/\X  ;_00 #_TP  /]8
M  #_9@  _W<  /^)  #_FP  _ZL  /^[  #_S@  _\\  /_/  #_SP!_L@
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M!.@>_P7F'O\&Y1[_!N4>_P?E'O\'Y1[_!^4>_P?_*Q\ _RT< /\M&P#_+B
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M$[,V_Q.S-O\3LS;_$[,V_Q/_.1  _ST+ /]##0#_1Q  _T@4 /5'' #K1B8
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M(GE6L2-W5L$D=E;:)'57[R1U5_TC=5C_(G58_R%U6/\A=5C_(758_R'_30
MY5<  --?  #(9   OV<  +=H  "Q9P< J6@4 *-I) ">:#(!F6<]!)1E1P>0
M9$\*C&)7#8AA7A"%7V43@UYL%H!=<QA]77H:>UR#'7E;C!]V6Y<A=%JB(W):
MKR1Q6K\E<%K5)6];[25O6_PC;UO_(F];_R)O6_\A;UO_(6];_R'Z3P  X5H
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M)E]FZ"9@9ODD8&;_(V!F_R-A9O\B86;_(F%F_R+H6   TV,  ,1K  "Y<0
ML'4  *=W  ">=0  EG8- )!W&0"+>"< AG<S H%V/01\=48'>'-."W5R50YQ
M<5P1;G!C%&MO:A9I;G$99FYZ'&-M@QYA;(XA7VN:(UUKIR5;:[<F6FO*)EIK
MYR5;:_<D6VK_(UQJ_R)<:O\B7&K_(EQJ_R+C6P  SF8  ,!N  "V=   K'D
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M($M[_R!+>_\@2WO_($M[_R#09P  P'(  +1[  "J@@  H(8  )6(  "'B
M?(H  ':,#@!RC1H ;HXG &J.,@%FC3P#8XU$!6",3 A<BU,*6HM:#5>*81!4
MB6@248AQ%4^(>A=,AX4:2H:2'$B&H!U&AJ\>187"'D6%WQY%A/(>18/^'D6"
M_QY%@O\>18+_'D6"_Q[*;0  NG@  *^!  "EAP  FHL  (^-  "!C@  =)$
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M$3*A_Q&T@@  J(P  )V2  "2EP  AIP  'FA  !MI0  8:D  %6L  !+KP4
M1[ 0 $6P' !$L2< 0K$R $&R.P _LD,!/;)+ 3NR4P(YLEL#-[)D!#6R;@4S
MLGD&,;*'!R^QE@@NLJ8(+;*X"2RRT @LL.P)*Z_Y"BNN_PLJK?\+*JW_"RJM
M_PNMBP  H)(  )68  ")G0  ?:,  '&H  !DK0  6;$  $VT  !"N   .[H*
M #B[$P WO!X -;PI #2],@ SO3L ,KU$ #&^3  OOE4!+KY> 2R^: $JOG0"
M*;Z" B>_D0,FOZ(#)+^T R._RP,CON@#([SW!"*[_P4BN_\%(KO_!2*[_P6D
MD@  F)@  (R>  " I0  <ZL  &>P  !;M0  3[D  $2\   ZP   ,,0$ "K'
M"P HR!, )\D= ";))P ER3  ),HY "/*0@ BRTL (<M5 "#,7P ?S&P '<UZ
M !S-B@ ;S9P &<ZN 1C.Q0 8S>0 &,ST 1C*_ $8RO\"&,K_ AC*_P*;F0
MCY\  (*F  !UK0  :+,  %RY  !0O0  1,$  #G$   PR   *,P! "#0!@ 9
MU0L %M<0 !78&0 5V2( %-DK !/:-  3VCT $MM( !'<4P 1W5\ $-UM !#>
M?@ .WY$ #N"D  W@N  ,X-( "]_M  S>]P ,W?L #-W[  S=^P"2GP  A:<
M '>N  !JM0  7;P  %#!  !$Q0  .,D  "[-   ET0  'M4  !;: 0 1W@8
M$.<-  [G$@ -Z!D #.@A  OI*0 *ZC$ ">H[  ?K10 %ZU$ !.M>  /K;@ !
MZX   .J4  #JIP  Z[P  .O2  #KZ0  [.\  .SO  #L[P"'IP  >:\  &NW
M  !>O@  4<4  $/)   WS0  +=$  "/6   ;VP  $]\   [C   ,[@( "O8*
M  ?V#@ %]A(  _88  #U'@  ]24  /4N  #U-P  ]D(  /9.  #V70  ]FX
M /:!  #VE0  ]Z<  />W  #XQP  ^-   /C0  #XT ![KP  ;;@  &#   !2
MR   1,T  #?1   KUP  (=P  !C@   1Y   #.<   ?O   $^@   ?\#  #_
M"   _PT  /X0  #^%   _QH  /\A  #_*0  _S,  /\^  #_2P  _UL  /]L
M  #_@   _Y(  /^A  #_K0  _[,  /^S  #_LP#_'"8 _QPD /\:)0#_%2<
M_Q$N /\0.@#_#D<!_PU3 ?\+7P'_"FL!_PIU ?\*?P'_"H<!_PJ. ?\*E0'_
M"IL!_PF@ ?\)I0#_":L _PFQ /\)N #_"<$ _@G, /P)W@#Y">L ]0GV /,)
M_P#R"O\ \0K_ ?$+_P'Q"_\!\0O_ ?$+_P'_'R, _Q\A /\>(0#_&20 _Q<L
M /\5-P#_$T0 _Q%0 ?\07 '_#F<!_PYR ?\.>P'_#H0!_PZ+ ?\.D@'_#I@!
M_PZ= ?\.HP'^#J@!_ ZN ?L.M0#Z#KX ^ [) /4.VP#R#NH [@[U .P._P'K
M#_\!Z@__ >H0_P'I$/\!Z1#_ >D0_P'_(A\ _R(< /\A' #_'R  _Q\I /\<
M- #_&D  _Q=, ?\56 '_%&,!_Q-N ?\3=P'^$X !_!.( ?H2C@'Y$I4!^!*:
M ?82H 'U$J8!]!*L ?,2LP'Q$KP!\!+' >T2V 'I$^@!YA/U >04_P'B%/\"
MX17_ N$5_P+@%?\"X!7_ N 5_P+_)1L _R87 /\D%@#_)1P _R8E /\D, #_
M(3L _Q]( /\=5 ']&U\!^1II ?<:<P'T&7P!\AF$ ?$9BP'O&9$![AF7 >P9
MG0'K&:,!Z1FJ >@9L0'G&;H!Y1G% >,9U0'?&N@!W!OU M@;_P+5'/\#U!S_
M ],<_P32'/\$TAS_!-(<_P3_*1< _RH3 /\I$@#_+!@ _RPA /\L*P#_*3<
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M%(Q%M!6+1<06BD7<%HA&\!:&1OT6AD;_%H5'_Q6%1_\5A4?_%85'_Q7_/P
M[$@  -U/  #/4P  QE4  ,!3 P"[40P LU(9 *U3*0"H4S8!HU)" I]12P2<
M4%0&F4]<")9.8PJ436H,D4QQ#H]+> ^-2W\1BTJ'$HE*D!2'29H5A4FE%X-)
ML1B"2< 8@4K6&7]*[1A^2_P8?DO_%WU+_Q=]2_\6?4O_%GU+_Q;_0P  YDP
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M<5+-''!2Z!MP4_D:<%/_&G!3_QEP4_\8<%/_&'!3_QCO20  W5,  ,M:  #
M7P  MV(  *]A  "H7@( H5\0 )M@'@"68"P D6 X 8U>0@.)74L%A5Q2!X);
M60J 6F ,?5EG#GM8;A!X6'42=E=]%'17AQ9R5I$8;U:<&FY6J1ML5K@<:U;+
M'6I6YAQJ5_<;:E?_&FI7_QEK5_\9:U?_&6M7_QGK3   V%8  ,A>  "\8@
MLV4  *ME  "C8@  G&(. )9C' "19"D C&,U 8AB/P.$84@%@&!0!WU?5PEZ
M7ET+=UUD#75<:Q!S7'(2<%M[%&Y;A!=L6H\8:EJ:&FA:IQQF6K8=95K('65:
MY!UE6O8<95K_&V5:_QIE6O\995K_&65:_QGH3P  TUD  ,1A  "Y9@  L&@
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M&U=F_QI79O\:5V;_&E=F_QK;60  QV(  +IJ  "O<   IG,  )IS  "/<
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M%D%]_Q;":@  M74  *I]  "?@@  DH,  (6$  !YA0  :HD  &2* P!@C!
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M!C&@D@<PH*((+J"S""Z@R0@NG^<(+9WW"2V<_PHMF_\*+9O_"BV;_PJO@
MHXD  )>.  "-DP  ?Y4  '*8  !FG   6Z   $^D  !%IP  /JD, #RJ%  Z
MJA\ .:HI #BK,@ WJSL -:M# #2L2P RK%,!,:Q< 2^L9@(MK'$"*ZQ_ RJL
MC@,HK)X$)ZRP!":LQ00FJ^0#):GU!"6H_P4EI_\%):?_!26G_P6GB0  FX\
M )&4  "$F0  >)X  &NB  !?I@  4ZH  $BM   ]L   -+,# "^U#@ MM18
M++4@ "NV*0 JMC( *;<Z "BW0P GMTP )KA5 "2X7P CN&L (KAX 2"XB $?
MN)D!';FK 1RYP $<N-\!'+;R 1NU_ (;M/\"&[3_ ANT_P*?CP  E)4  (B;
M  ![H0  ;J8  &*K  !6L   2K,  #^V   UN0  ++P  "2_!@ ?P@T '<(4
M !S"'@ ;PR8 &L,O !G$.  8Q$$ %\1* !;%50 5Q6$ %,9O !/&?P 2QI$
M$<>D !#'N0 /Q]0 $,;N !#$^@ 0P_\ $,/_ !##_P"7E@  BYP  'ZB  !Q
MJ0  9*\  %BT  !+N   0+L  #6^   KP0  (\4  !O) 0 4S 8 $- +  [1
M$0 -T1D #=$A  S1*@ ,T30 "](^  K220 )TU4 "=-B  C3<@ &U(0 !=28
M  34JP #U<   =7<  '5[0 !U?8  =7V  '5]@".G0  @*0  '.K  !FL0
M6;@  $R]   _P   -,,  "K'   AR@  &<X  !+2   -U@$ "=L%  ;<#0 $
MW!$  ]T8  '>(   WB@  -\Q  #@/   X4<  .)4  #C8P  XW0  .2(  #D
MFP  Y:X  .7!  #EU0  YN<  .;G  #FYP"#I   =:P  &BS  !:NP  3<$
M $#$   SR   *,P  !_0   7U   $-D   O=   %X0   .0   #E!P  Y@T
M .<1  #H%@  Z1T  .HE  #K+@  [3D  .]%  #P4P  \60  /%V  #RB@
M\YP  /.M  #TNP  ],@  /3(  #TR !WK0  :K4  %R]  !/Q   0,D  #/-
M   GT0  '=8  !3<   .X   ".,   'F    Z@   .X   #N    [P0  / *
M  #Q#@  \Q(  /08  #V(   ^"H  /HU  #]0P  _E(  /]C  #_=@  _XD
M /^:  #_I@  _[   /^P  #_L #_%B, _Q4A /\1(0#_#20 _PDK /\&-P#_
M T0 _P!1 /\ 70#_ &@ _P!R /\ >P#_ (, _P"* /\ D0#_ )8 _P"< /\
MH0#] *8 ^P"L /D LP#W +L ]0#% /, T0#R .0 \0#Q .\ ^@#N /\ [@#_
M .T _P#M /\ [0#_ .T _P#_&2  _Q@= /\5'0#_$!\ _PXI /\,- #_"D$
M_P=- /\%60#_!&0 _P1N /\#=P#_ X  _P.' /\#C0#] I, ^P*9 /D"G@#W
M J0 ]0*J /,!L #Q ;@ [P'" .T!SP#K >, Z@'O .@"^P#G!/\ Y@7_ .8&
M_P#F!O\ Y@;_ .8&_P#_'!L _QL9 /\7& #_%1T _Q,E /\1, #_$#T _PY)
M /\,50#_"V  _PMJ /T+<P#["WP ^0J# /<*B@#U"I  ] J6 /,*FP#Q"J$
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M L ;_P+_)@X _R4+ /\H# #_*1  _R@6 /XF( #T)"L ["$X .8@1 #A'U
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M!:@ON@6F+\H&I##B!J$P\P>?,/\(GC'_")TQ_PB<,?\(G#'_")PQ_PC_,
M_S4  .\X  #B.@  VSD$ -8U"0#.-!, QC8B +\X,0"Z.#\ MCA* ;,X5 &P
M-UT"K3=D JLV; .I-G,$J#9Y!*8U@ 6D-8<%HS6/!J$UEP>?-: 'GC6J")PU
MM@B;-<4)F37="98V[PJ4-OT*DS?_"I(W_PJ2-_\*DC?_"I(W_PK_,P  ]CH
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M$7I%YA%Y1O<1>$;_$'A&_Q!X1O\/>$;_#WA&_P_P/P  WTD  ,U/  #!4P
MN%0  +%2  "K3@4 I$X1 )Y/( "94"T E5 Y 9)/0P&.3DP#BTU3!(E-6@6&
M3&$&A$MH"()+;@F 2G8+?DI^#'Q)APYZ29$/>$F<$'9)J!)T2;82<TG($W)*
MXQ-Q2O42<4K_$7%+_Q%Q2_\0<4O_$'%+_Q#L0P  V4P  ,A3  "]5P  M%@
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M%&!6_Q-A5O\285;_$F%6_Q+@30  RU8  +U=  "R80  J&,  )UA  "570
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M$DYE_Q+,6@  O&,  +!J  "E;P  F&X  (QM  " ;   =VT  '%N"P!M;Q0
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M"S][E T^>Z,./'NS#CQ[R X\>N8./'GW#CQX_PX\>/\./7?_#CUW_PZ\:
MKW(  *1Y  "6>@  B'H  'QZ  !P?   8W\  %R"  !7A L 4X44 %&&( !/
MABH 3H<T $R'/ %*AT0!2(=+ D:'4P)$AEH#0H9B!$"&; 8^A78'.X6#"#F%
MD0HXA* +-H2Q"S:$Q@LV@^0+-H+V"S:!_PPV@/\,-H#_##: _PRV;P  JG@
M )]_  "0?@  @W\  '>   !K@@  7H<  %6*  !.C 8 2HX0 $B/&@!'CR4
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M 1^ENP$>I=<!'J3O 1ZB^P(>H?\"'J'_ AZA_P*BA@  EXP  (N/  !]D0
M;Y0  &.8  !7G0  3:$  $.E   XJ   ,*L  "BN!P DKQ  (Z\7 "&O(0 @
ML"D '[ Q !ZP.@ =L4( '+%, !NQ5@ :L6$ &;)O !BR?@ 6LI  %;*B !2R
MM@ 3LLX $['K !.O^0 3KO\!$Z[_ 1.N_P&:C0  D)(  (27  !UF@  :)\
M %NC  !0J   1:P  #NP   QL@  )[4  ""X   8N@< %+P. !.\%0 2O!X
M$;TF !&]+@ 0O3< $+Y!  Z^3  .OE< #;YE  R_=  +OX8 "KZ9  B^K  '
MOL( ![[?  B^\  (O?H "+W\  B]_ "3E   AYD  'J?  !LI0  8*H  %.O
M  !'LP  /+8  #&X   GNP  '[X  !?!   1Q $ #,@(  C)#@ 'R10 !LD<
M  7))  $RBP  \HV  +*0   RTP  ,M9  #+:   RWD  ,R,  #+GP  R[,
M ,O(  #,X@  S.\  ,SQ  #,\0"*F@  ?*$  &^G  !BK0  5;,  $BX   [
MNP  ,+X  ";!   =Q   %<@   _+   *S@  !-("  #3"@  TP\  -04  #5
M&@  UB(  -<J  #9-   VC\  -Q+  #<6@  W6H  -U]  #=D0  W:0  -ZV
M  #>R   WMX  -[B  #>X@!_H@  <:D  &2P  !6MP  2;P  #S    OQ
M),<  !O+   3SP  #=(   ?6    VP   -X   #? P  X D  .$.  #B$@
MXQ<  .4>  #F)P  Z#$  .H]  #L2P  [%H  .UL  #N@   [I0  .ZE  #N
MM   [L(  .[&  #NQ@!TJ@  9K(  %BY  !+P   /<4  "_)   DS0  &=$
M !'6   +VP   ]X   #A    Y0   .@   #I    Z@   .L&  #M"P  [P\
M / 3  #R&@  ]",  /<N  #Y.P  ^TH  /Q;  #];0  _8   /Z3  #^H@
M_JT  /ZO  #^KP#_$!\ _PX= /\*'0#_ 2  _P H /\ -0#_ $$ _P!. /\
M6@#_ &4 _P!N /\ =P#_ '\ _@"& /P C #[ )( ^0"7 /@ G #W *( ]@"G
M /4 K0#S +4 \@"] /$ R0#O -P [@#K .T ]P#L /\ ZP#_ .H _P#J /\
MZ@#_ .H _P#_$QP _Q$9 /\-&0#_!AP _P,E /\ ,0#_ #X _P!* /\ 5@#_
M &$ _P!K /T <P#Z 'L ]P"# /4 B0#T (\ \@"4 /$ F0#P )\ [@"D .T
MJP#L +( Z@"Z .@ Q@#G -8 Y0#H .0 ]0#C /X X@#_ .$ _P#A /\ X0#_
M .$ _P#_%1@ _Q,4 /\/% #_#1D _PLB /\(+0#_!#D _P%& /\ 40#^ %P
M^@!F /8 ;P#R '< [P!^ .T A0#K (L Z@"1 .@ E@#G )P Y@"A .0 J #C
M *\ X0"X -\ PP#= -$ VP#F -D \P#7 /T U0+_ -0"_P#4 _\ U /_ -0#
M_P#_&!, _Q40 /\2#P#_$A4 _Q$= /\.* #_##0 _PI! /D(3 #U!E< \09A
M .T&:@#I!7( Y@5Z .0%@0#B!8< X :- -\&D@#=!I@ VP:> -D&I0#7!JT
MU :U -(&P #0!\\ S@CE ,P)] #*"_\ R S_ ,<,_P#'#/\ Q@S_ ,8,_P#_
M&PX _QD, /\8#0#_&!$ _Q<8 /\4(@#[$2X \Q Z .T.1@#H#5( Y0U< .$-
M90#>#6T VPUU -@-? #5#8( TPV) -$-CP#0#94 S@V< ,T.HP#+#JL R0ZT
M ,@.P #&#L\ PQ#F , 1]0"]$O\ O!+_ +L2_P"Z$O\!NA+_ ;H2_P'_'PH
M_QP$ /\?" #_'PT _QT2 /@:&P#N%B8 YA0S . 3/P#:$TL U!-6 - 37P#.
M%&@ RQ1O ,D4=P#'%7T QA6$ ,05B@##%9$ P1:8 , 6GP"^%J< O!>P +L7
MO "Y%\L MQCB +,9\@&Q&O\!KQO_ :X;_P&N&_\!K1O_ :T;_P'_(@0 _R(
M /\E @#\) < ]R$, .P=$@#A&AP V!HJ - ;. #+'44 QQU0 ,,>6@# 'F(
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M!)$PZ 6/,/@%C3'_!8TQ_P6,,?\%C#'_!8PQ_P7_+0  ZC4  -PZ  #./0
MQCP  , W @"[,PT LS09 *XV)P"I-S0 I3=  *(W2@"?-U,!G39: 9LV80&9
M-F@"ES5O I4U=0.4-7P#DC6$!) UC02/-98%C36@!8LUJP:*-;D&B#7*!X<V
MY0>%-O8'A#?_!X,W_P>#-_\'@C?_!X(W_P?T,@  XSL  -)!  #&1   O4,
M +<_  "Q.PD JCL4 *4\(@"@/3  G3T[ )D]10"6/4X!E#Q6 9(\70*0/&,"
MCCMJ XP[<02*.W@$B#J !8<ZB :%.I(&@SJ<!X$ZJ B .K4)?CO&"7T[X0E[
M//,)>SS_"7H\_PAZ//\(>CS_"'H\_PCN-P  W4$  ,M&  "_20  MDD  *Y&
M  "I000 HT$1 )U"'@"80RL E4,W )%#00".0DH!C$)2 8E!60*'05\#A4%F
M X- ;02!0'0%@$![!GX_A =\/XX(>C^9"7@_I0IW0+(*=4##"W1 W0MS0?$+
M<D'_"G)!_PIR0?\)<D'_"7)!_PGI/   U44  ,5+  "Z3@  L$X  *=+  "B
M1@  FT8. )9'&@"12"< CD@S (I(/0"'1T8!A$=. 8)&50* 1EP#?D5B!'Q%
M:01Z17 %>$1X!G9$@0AT1(L)<D26"G!$H@MO1*\,;D3 #&U%V0UL1>\,:T7]
M"VM&_PMK1O\*:T;_"FM&_PKE0   STD  ,%/  "U4@  JU(  *%/  ";2@
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M#%=4_PS130  P%8  +-<  "G7@  FET  (]<  "&6   ?UD  'E:#0!T6Q<
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M"DMBE M)8J(,2&*R#4=BQPU'8N0-2&'V#$AA_PQ(8/\+26#_"TE@_PO$6
MM6   *IF  ";9@  C68  ()E  !V9   ;F4  &AF!0!C9Q  8&@: %UI)0!;
M:B\ 66HX %=J0 %5:D<!4VI. E%J50-/:5T$36ED!4MI;09):'@'1VB$"49H
MD@I$9Z$+0V>Q#$)GQ0Q"9^(,0F;U#$-F_PM#9?\+0V7_"T-E_PN_7   L60
M *9J  "6:0  B6D  'UI  !Q:0  9VH  &)L 0!=;0T 66X6 %=O(0!5<"L
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M<0  ?G$  '-R  !H<P  7'8  %1Y  !.>P4 2GT/ $A^& !&?R, 17\L $.
M-0!"@#T 08!% #^ 3 $]@%0!/(!< CI_90(X?V\#-G]\!#1_B@0R?YH%,7ZJ
M!C!^O08P?MH&,'WP!C![_08P>_\&,'K_!C!Z_P:P;   I'4  )1U  "&=0
M>78  &YW  !C>0  5WT  $^!  !'A   0H8, #^'$P ]B!T /(@G #N),  Z
MB3@ .(E  #>)2  VB4\ -(E8 3.)80$QB6P!+XEX BV)AP(LB9<#*HBG RF(
MN@,IB-0#*8;N RF%_ 0IA/\$*83_!"F$_P2J=   GGL  (YZ  " >@  ='L
M &A^  !=@0  4H4  $F)  !!C   .9 % #61#P SDA< ,I(A #&2*0 PDS(
M+I,Z "V300 LDTH *Y12 "J47  HE&< )Y1S 264@@$DE),!(I.D 2&3MP$@
MD\\!(9+L 2"0^@(@C_\"((__ B"/_P*D?   EX   (=_  ![@   ;H(  &*%
M  !7B0  38X  $*2   ZE@  ,ID  "J<"0 HG1$ )IT9 "6=(@ DGBH (YXR
M "*>.@ AGD( ()Y+ !^?50 >GV  ')]M !N??  :GXT &)^? !>?L@ 6G\D
M%I[H !:<]P 6F_\!%YO_ 1>;_P&=@P  CX8  (*&  !TAP  9XL  %N/  !0
MDP  1I@  #R<   SH   *Z,  ".F   <J L &JD1 !BI&  7J2$ %JHI !6J
M,0 4JCD $ZI# !.K30 2JU@ $:ME !"K=  .JX8 #JN9  VKK  ,J\$ #*K?
M  RI\@ -J/P #:C_  VH_P"6B@  B8P  'J-  !LD0  8)4  %2:  !)GP
M/Z,  #6G   KJ@  (ZX  !NP   4LP$ #[4*  VV$  ,MA8 "[8?  JV)P )
MMB\ "+8Y  >W0P &MT\ !+=;  .W:@ "MWL  +>.  "WH0  MK0  +;+  "V
MY0  M?$  +7W  "U]P"/D0  @90  '*7  !EG   6*$  $RF  !!JP  -Z\
M "RR   CM0  &K@  !.[   .O0  "< %  /!#0  P1$  ,$7  #"'@  PB8
M ,(O  ##.0  Q$0  ,10  #$7@  Q6\  ,6!  #%E0  Q:@  ,6\  #$T0
MQ.8  ,3N  #$[@"&F   >9X  &NC  !=J0  4*X  $2S   WM@  ++D  "*\
M   9OP  $<(   S%   &R    ,L   #,!P  S T  ,T1  #-%@  SAT  ,\D
M  #0+0  TC@  -1$  #44@  U6$  -5S  #6AP  UIL  -:M  #7OP  V,X
M -C=  #8W0![H   ;J8  &"M  !3LP  1;@  #B\   KOP  (<(  !?&   0
MR0  "LP   +0    U    -<   #8    V@4  -L+  #<#@  WA,  -\9  #A
M(0  XRH  .4V  #G0P  YU,  .AD  #I=P  Z8P  .J?  #JK@  ZKH  .K#
M  #JPP!PJ   8J\  %6V  !'O   .<   "S$   @R   %LP   [0   'U
M -D   #=    X0   .,   #D    Y@   .<!  #I!P  ZPP  .P0  #N%0
M\!T  /,G  #V,P  ]T,  /A4  #Y9@  ^7H  /J.  #ZG@  ^ZD  /NP  #[
ML #_"QL _P<9 /\ &0#_ !P _P E /\ ,@#_ #\ _P!+ /\ 5P#_ &( _P!K
M /\ <P#] 'L ^P"" /H B #X (T ]P"2 /8 F #U )T ] "B /, J0#Q +
M[P"X .X PP#L -$ ZP#F .D \P#H /X Z #_ .@ _P#H /\ Z #_ .@ _P#_
M#A@ _PH5 /\!% #_ !@ _P B /\ +@#_ #L _P!' /\ 4P#] %X ^@!G /<
M;P#U '< \P!^ /( A #P (D [P"/ .X E #L )H ZP"? .D I0#H *P Y@"T
M .0 OP#C ,P X0#B -\ \ #> /L W@#_ -T _P#= /\ W #_ -P _P#_$!,
M_PT1 /\&$ #_ A4 _P > /\ *0#_ #8 _P!" /H 3@#T %D \0!B .X :P#L
M '( Z@!Y .@ ?P#G (4 Y0"+ .0 D #B )8 X0"< -\ H@#= *D V@"Q -@
MNP#5 ,@ T@#= -$ [0#0 /D SP#_ ,X _P#- /\ S0#_ ,T _P#_$0\ _PX-
M /\,#0#_"Q( _P<9 /\") #_ #  ]@ \ .\ 20#J %, YP!= .0 9@#A &T
MWP!T -T >P#; ($ V0"& -8 C #4 )( T@"8 -  G@#. *8 S "N ,H N #(
M ,0 Q@#7 ,4 Z@## /< P@#_ ,$!_P#  O\ P +_ , "_P#_% L _Q & /\0
M"0#_$ X _PX4 /\*'@#U!BD ZP0V .,#0@#? TX VP17 -8$8 #3!&@ T 1O
M ,X%=@#,!7P R@6" ,D%B #'!8X Q@64 ,0%FP#"!:, P :K +X&M0"]!L(
MNPC4 +H)Z0"W"_@ M0S_ +0,_P"T#/\ M S_ +0,_P#_%P0 _Q0  /\6 P#_
M% D _Q$. /(.%0#H#"$ W@HN -8+.P#0#$< S Q1 ,D,6@#&#6( Q UJ ,(-
M<0# #7< OPU] +T.@P"\#HH N@Z1 +D.F "W#J  M@ZI +0/M "R#\$ L1#4
M *X1ZP"K$OH J1+_ *@3_P"G$_\ IQ/_ *<3_P#_&@  _QL  /D;  #K&0
MY10& .40#@#9#A< SQ$F ,@2- #$$T  OQ1+ +P45 "Y%5T MQ5D +45:P"T
M%7$ LA5X +$6?@"O%H4 KA:, *P6E "K%YP J1>F *<8L "F&+T I!C/ *(:
MYP"?&O< G1O_ 9P;_P&<&_\!FQO_ 9L;_P'_'0  ]R$  .@D  #=)0  U"$!
M ,\;" #*%Q$ PAH@ +P<+0"W'3H LQY% + >3P"M'E< JQY? *D?9@"H'VP
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M WTQ_P-\,?\#?#'_ WPQ_P/M+P  VS<  ,D]  "^/@  LSP  *PX  "G,P0
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M!F!$_P;600  PTD  +9.  "G3P  FTT  ))+  ",1P  A4<$ (!'$ !\2!H
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M!E10DP=24*$(45"Q"5!0Q E04.$)4%#T"%%0_P=13_\'44__!E%/_P;)2P
MN5,  *M7  "<5@  CU4  (54  !\4   =5$  '!2"0!K4Q( :%0= &54)P!B
M5#$ 8%0Y %Y400!<5$@!6E1/ 5E45@%75%T"5E1E U14;@125'@%452$!D]4
MD0=.5* (3%2O"$Q4P@E+5-\)3%3S"$Q3_P=,4_\'35/_!DU3_P;%3@  ME8
M *=:  "860  BU@  (%7  !W5   <%4  &I6!@!F5Q  8E<: &!8) !=6"X
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M!CUBO <\8M8'/6'O!CUA_08^8/\&/F#_!CY@_P:Y60  JV$  )IA  "+80
M?V$  '1A  !I80  7V(  %ED  !49@D 46<1 $YG&@!,:"0 2VDM $EI-@!(
M:3X 1FI% $5J3 !#:E0!0FI< 4!I90(^:6\"/&E[ SMIB00Y:9@%.&BH!3=H
MN@4W:=,%-VCN!3=G_ 4X9O\%.&;_!3AF_P6T7@  IV4  )5E  "&9   >F4
M &]E  !D9@  66@  %)J  !-; 0 26X. $=N%@!%;R  1' I $)P,@!!<#H
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M 2)_]P$B?O\"(GW_ B)]_P*E<0  DW$  (-Q  !V<0  ;'(  &!U  !6>
M3'P  $.    [@P  ,X8  "V)"@ JBA$ *8L9 ">+(@ FBRH )8PQ "2,.0 C
MC$( (HU* "&-5  @C5X 'XUK !V->0 <C8H &XV< !F-K@ 8C,0 &(SC !F*
M]0 9B?\!&8C_ 1F(_P&==P  C'8  'UV  !R=P  97D  %I\  !0@   1H0
M #R)   TC   +9   "63 @ ?E0P '982 !R6&@ ;ER( &I<J !F7,@ 8F#H
M%YA# !:830 5F%@ %)AD !.8<P 1F(0 $)B6 !"8J0 .F+\ #I?=  ^6\@ 0
ME?P $)3_ !"4_P"5?0  A7P  'A\  !K?@  7X$  %2&  !*B@  0(\  #:3
M   MEP  )IH  !Z=   7H , $J(, !"C$@ 0HQD #Z,A  ZD*0 .I#$ #:0Z
M  RD10 +I%  "J1<  FD:@ 'I'L !J..  2CH0 "H[0  Z++  .BY@ #H?,
M Z'[  .A^P"-@P  ?X(  '&$  !DAP  6(P  $V1  !"E@  .)H  "^>   F
MH@  'J4  !>H   1JP  #*X'  >O#0 #KQ(  J\9  &O(0  KRD  + R  "P
M/   L$<  +!3  "P80  L'$  +"#  "OEP  KZH  *^_  "NV0  KNL  *[T
M  "N] "'B0  >(H  &J.  !=DP  49@  $6=   [H@  ,*8  ">J   >K@
M%K$  !"T   +M@  !;D#  "Z"@  N@X  +H3  "[&0  NR$  +PH  "\,0
MO3P  +Y(  "^5@  OF4  +YW  "^C   OI\  +VS  "^QP  OMX  +WK  "]
MZP!_D@  <)4  &*:  !5GP  2:4  #VK   RKP  *+0  !ZV   5N0  #KP
M  F_   "P@   ,0   #%!   Q@H  ,8.  #'$@  R!@  ,D?  #*)P  S#
M ,X\  #.20  SUD  ,]J  #/?@  SY,  ,^F  #/N   S\@  ,_;  #/VP!W
MG   :*$  %NG  !.K@  0;0  #2W   HN@  ';T  !/    -Q   !L<   #*
M    S@   -    #1    T@(  -,(  #5#   UA   -D5  #;'   W20  . O
M  #B/   XTL  .1<  #D;P  Y8,  .68  #EJ0  Y;8  .7#  #EPP!LI0
M7ZP  %&R  !$N0  -;P  "C    <Q   $L@   S+   #SP   -,   #8
MW    -\   #?    X0   .,   #D P  Y@@  .@-  #I$0  [!@  .XB  #Q
M+@  \SP  /1-  #U7P  ]G,  />'  #WF0  ^*4  /BP  #XL #_ Q< _P 5
M /\ %0#_ !@ _P C /\ +P#_ #P _P!( /\ 5 #_ %X _P!G /T ;P#[ '8
M^0!] /@ @P#V (@ ]0". /0 DP#R )@ \0"> /  I #N *L [0"S .L O0#J
M ,L Z #A .< \0#F /T Y0#_ .0 _P#D /\ Y #_ .0 _P#_!Q, _P 1 /\
M$0#_ !4 _P ? /\ *P#_ #< _P!$ /X 3P#Z %H ]P!C /0 :P#R '( \ !Y
M .\ ?P#M (0 ZP"* .H CP#H )0 YP": .4 H #D *< X@"O .  N0#> ,8
MW #: -H [ #8 /D U@#_ -8 _P#7 /\ V #_ -@ _P#_"A  _P,. /\ #0#_
M !( _P : /\ )@#\ #( ]P _ /0 2@#Q %4 [0!> .H 9@#H &X Y0!T .,
M>@#B (  X "% -X BP#< )  VP"6 -@ G #5 *, TP"K -$ M0#. ,$ S #1
M ,L YP#) /4 R #_ ,@ _P#( /\ R #_ ,@ _P#_# P _P8( /\""@#_  \
M_P 5 /P ( #Q "P [  Y .D 10#E $\ X0!9 -X 80#; &@ UP!O -0 =0#2
M 'L T "  ,X A@#, (P RP"2 ,D F #' *  Q0"H ,, L0#! +P OP#+ +T
MXP"\ /( NP#] +L _P"Z /\ N@#_ +H _P#_#@4 _PD  /\)!0#_!@L _P$0
M /  &0#F "4 X0 R -P /P#6 $D T0!3 ,X 6P#+ &, R !J ,8 < #% '8
MPP![ ,$ @0#  (< O@". +P E "[ )P N0"D +< K@"U +D LP#( +$ WP"P
M >\ KP'[ *X"_P"M _\ K0/_ *T#_P#_$   _PX  /\-  #V"P, \@<* .(!
M$0#; AT T@,K ,P#-P#(!$, Q 1- ,$$5@"^!5T O 5D +H%:P"X!7$ MP5V
M +4%? "S!H, L@:) + &D0"O!YD K0>A *L'JP"I"+< J G& *8*W0"E"_
MHPS] *(-_P"A#?\ H0W_ * -_P#_$0  _!(  .P3  #B$P  VP\# -8)"P#.
M"!0 Q@HB , ,, "\#3P N U& +4-3P"R#E< L Y? *X.90"M#FL JPYQ *H.
M> "H#GX IP^% *4/C0"D#Y8 HA"? * 0J0"?$+4 G1'% )L1W@"9$O$ EQ/_
M )84_P"5%/\ E13_ )04_P#_%0  [1L  . ?  #2'P  R1L  ,04!0#!$ X
MNA(; +03*0"P%#4 K!5  *D520"F%5( I!99 *(68 "A%F8 GQ9L )X6<@"<
M%GD FQ>  )D7B "8%Y$ EAB; )08I@"3&;( D1G! ) :V "-&^X BQS] (H<
M_P"*'/\ B1S_ (D<_P#T'0  Y"4  -,I  #'*@  O"8  +8@  "T&0L KAH5
M *@<(P"D'2\ H1XZ )X>1 ";'DP F1Y4 )<?6P"5'V$ E!]G )(?;0"1'W0
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M FTQ_P+?,@  R3D  +L^  "L/0  H3H  )HW  "5,P  D#$* (PQ% "',B
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M EX^DP-</J #6S^O!%H_P01:/]T$63_R!%D__P-9/_\#63__ UD__P/,/P
MO$8  *M(  "<1P  D48  (A$  ""0   ?#\  '= # !S0!4 ;T$@ &Q!*@!J
M03, :$$[ &9"0P!D0DH 8T%0 &%!5P!@0EX!7D)E 5U";@);0G@"6D*$ UA"
MD -70IX$5D.M!%5#OP140]H$5$/Q!%1#_@-40_\#5$/_ U1#_P/(0@  N$D
M *=+  "82@  C4D  (-'  !]0P  =D,  '%$"@!M1!( :D4= &=%)P!D13
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M!$9/N@1&3]$$1D_M!$9._ 1&3O\#1T[_ T=._P.]3   KE(  )Q1  "-40
M@5$  '=0  !N3   9TX  &)/  !=4 T 6E 4 %=1'@!542< 4U$P %%2. !0
M4C\ 3E)& $U230!,4U4 2E-= 4E390%(4V\"1E-[ D53B0-#4Y<#0E.G!$%3
MN 1!4\\$05/L!$%2^P-"4O\#0E+_ T)1_P.Z3P  JE0  )A4  ")5   ?5,
M '-3  !I40  8E(  %Q3  !85 H 5%42 %)5&P!/5B0 3E8M $Q7-0!+5SP
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M C%A^ (Q8?\",F#_ C)@_P*N7   FUT  (I=  !\70  <%T  &9=  !<7@
M4F   $QB  !%90  068* #YG$0 \:!H .V@B #EI*P X:3( -VHZ #9J00 U
M:DD -&I2 #-J6P Q:F4 ,&IP 2YJ?@$M:HX!+&J? 2MJL $J:L8!*FGE 2IH
M]@(K9_\"*V?_ BMG_P*I80  E6   (1@  !W8   ;&$  &)A  !88P  3F8
M $=H  ! :P  .FX% #9O#@ T<!4 ,W > #)Q)@ P<2X +W$U "YR/0 M<D4
M+')- "MR5P J<F$ *7)M "=R>P F<HL )'*< 2-RK@$C<L,!(W'B 2-P] $C
M;_\!(V[_ 2-N_P&A90  CF0  ']D  !R9   :&4  %YF  !4:0  26P  $)O
M   [<@  -'4  "YX"@ K>1$ *GD8 "EZ(0 G>B@ )GHP "5[.  D>T  (WM(
M ")[4@ A>UP ('MH !]\=@ =?(8 ''N8 !M[J@ :>[\ &GO> !IY\@ ;>/X
M&W?_ 1MW_P&9:0  B&D  'EI  !M:0  8VH  %EL  !/;P  17,  #UW   U
M>@  +GT  ">! P B@PT ((02 !^$&@ =A"( '(4J !N%,0 :A3D &85" !B&
M3  7AE8 %H9C !6&<0 4AH$ $H:3 !&&I@ 1A;L $(76 !&#[P 1@OL $H+_
M !*!_P"1;@  @6T  '1N  !I;@  77   %-S  !)=P  0'P  #>    O@P
M)X<  "&*   :C08 %8\- !.0$P 2D!H $I B !&0*@ 0D3( $)$[  ^11  .
MD4\ #9%<  R1:@ +D7H "I&-  B0GP 'D+, !X_)  >/Y@ 'CO0 "(W\  B-
M_P")<P  >W,  &]S  !C=0  5W@  $U]  !#@0  .88  #"*   HC@  (9$
M !J5   3EP  #IH(  N<#@ )G!, ")P:  ><(@ &G"H !)PS  .</0 "G4@
M )U4  "=8@  G'(  )R$  "<EP  FZH  )N_  ":VP  FNP  )KU  "9^ ""
M>0  =GD  &AZ  !<?@  48(  $:'   \C   ,I$  "F5   AF0  &9T  !*@
M   .HP  ":8%  .G#   IQ   *<5  "H'   J",  *@K  "I-   J3\  *E+
M  "I60  J6@  *EZ  "IC@  J:$  *BU  "HRP  I^0  *?O  "G\P!]@
M;X$  &&$  !5B0  28X  #Z4   TF0  *IX  "&B   9I@  $JD   VL   '
MKP   +(   "S!P  LPP  +,0  "T%0  M!L  +4B  "V*P  MS4  +=   "X
M3@  N%T  +AN  "X@@  N)<  +BJ  "WO@  M](  +?F  "WZ@!VB   9XL
M %J0  !.E@  0IP  #>B   LIP  (JL  !FO   1LP  "[8   2Y    O
M +X   "^    OP8  , +  #!#P  PA,  ,,9  #$(   Q2D  ,<T  #(0@
MR5$  ,EB  #)=0  R8H  ,F?  #*L0  RL$  ,G1  #)V0!NDP  8)@  %.>
M  !&I   .JL  "^P   DM0  &;@  !"\   *OP   <$   #$    R    ,H
M  #*    S    ,T#  #."   T T  -$0  #3%@  UAX  -HH  #=-   WD,
M -]4  #?9P  X'P  ."1  #@I   X+(  ."^  #@PP!FGP  6:8  $RM   _
MM   ,K@  "2\   8OP  $,,   C'    R@   ,T   #1    U0   -@   #9
M    VP   -T   #?    X00  .,*  #E#@  YQ,  .H<  #M)P  \#4  /%&
M  #R6   \VL  /.   #TE   ]*,  /2N  #TL@#_ !, _P 1 /\ $0#_ !4
M_P ? /\ + #_ #D _P!% /\ 4 #_ %H _@!C /L :P#Y '( ]P!X /4 ?@#T
M (0 \@") /$ C@#P ), [@"9 .T GP#L *8 Z@"N .@ N #F ,4 Y0#; .,
M[0#B /L X@#_ .$ _P#A /\ X0#_ .$ _P#_ !  _P . /\ #0#_ !( _P ;
M /\ * #_ #0 _@!! /L 3 #W %8 ] !? /$ 9@#O &T [ !T .H >@#I '\
MYP"% .8 B@#E (\ XP"5 .$ FP#@ *( W@"J -L M #9 ,  U@#0 -, Z #2
M /< T0#_ -$ _P#0 /\ T #_ -  _P#_  T _P ) /\ "@#_  \ _P 6 /L
M(@#W "\ ]  [ /  1P#M %$ Z0!: .4 8@#B &D X !O -X =0#< 'H V@"
M -@ A0#5 (L TP"1 -$ EP#/ )X S0"F ,L KP#) +H QP#) ,4 X@#$ /(
MPP#^ ,( _P#! /\ P@#_ ,( _P#_ P8 _P ! /\ !@#_  P ^0 1 /$ '0#K
M "D YP V ., 00#? $L VP!4 -4 7 #2 &, SP!J ,T < #+ '4 R0![ ,@
M@ #& (8 Q0", ,, DP#! )H OP"B +T JP"[ +8 N0#$ +< V@"V .T M #Z
M +0 _P"T /\ M #_ +0 _P#_!   _P   /\   #_  8 [  - .4 %@#> "(
MUP O -$ .P#- $4 R@!. ,8 5P#$ %X P0!D +\ :@"] '  O !U +H >P"Y
M ($ MP"' +4 C@"S )4 L@"> +  IP"N +( K "_ *H T0"H .@ J #W *<
M_P"G /\ I@#_ *8 _P#_!@  _P4  /$#  #H    X0 ' -4 $ #- !L QP G
M ,, ,P"_ #X O !( +D 40"V %@ M !? +( 90"P &H KP!P *T =@"L 'P
MJ@"" *D B0"G )$ I0": *, I "A *X H "[ )X!S0"= N8 G 3T )L$_P":
M!?\ F@7_ )D%_P#_"@  \0X  .00  #9#P  S@L  ,@#"P#" !, O (? +<#
M+ "S!#< L 5" *T&2@"J!E( J =9 *8'7P"E!V4 HP=K *((<0"@"'< GPA^
M )T(A0";"8X F@F7 )@*H0"6"JP E0NZ ),+S "2#.4 D WV (\._P".#O\
MC@[_ (T._P#V$0  YA<  -8;  #'&0  OA4  +D0  "W"@T L0L7 *P-) "H
M#C  I0X[ *(.1 "?#TP G0]3 )L/6@":#V  F!!F )<0; "5$'( DQ!Y )(0
M@0"0$(H CQ&4 (T1GP"+$:H BA*X (@2RP"&$^8 A13W (,5_P"#%?\ @A7_
M ((5_P#M&@  W"$  ,HE  "[(@  L1\  *L:  "I% 8 I1(1 * 4'@"<%2H
MF14U )86/@"4%D< DA9. ) 650".%UL C!=A (L79P")%VT B!=T (88? "%
M&(8 @QF0 ($9FP" &J< ?AJU 'T;QP!\'.( >AWU 'D=_P!X'?\ >!W_ '@=
M_P#E(@  T"D  +\L  "P*@  IR<  * C  "='P  FAH. )4<& "1'20 CAXO
M (P>.0")'D$ AQ]) (4?4 "#'U8 @A]< ( ?8@!_'VD ?2!P 'P@> !Z(($
M>2&, '<AEP!U(J0 ="*R ',CPP!R(]\ <"3S &\D_P!O)/\ ;B3_ &XD_P#=
M*0  R#   +<R  "H,   GBX  )<J  "3)P  D",* (PC$P"()!\ A"4J ((E
M- " )CT ?29$ 'PF2P!Z)E( >"98 '<F7@!U)F4 ="=L '(G= !Q)WT ;RB(
M &XHE !L**$ :RFO 6HIP %I*ML!9RKQ 6<K_P%F*_\!9BK_ 68J_P'4+P
MPC8  *\V  "A-0  EC0  ) P  "*+0  ARH& (,I$ !_*AH ?"LE 'DK+P!W
M+#@ =2Q  ',L1P!Q+$T <"Q4 &XL6@!M+&$ :RUH &HM< !H+7H 9RZ% &4N
MD0%D+IX!8B^L 6$OO0%A,-4!8##O 5\P_0%?,/\!7S#_ 5\P_P'--   O#L
M *DZ  ";.@  D#@  (DU  "#,@  ?S ! 'LO#@!W,!8 =# A '$Q*P!O,30
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M DX^MP)./LT"3C[I DT^^@)./O\!3CW_ 4X]_P' /P  KD,  )Q#  ".0P
M@D(  'I   !S/0  ;3P  &@]!0!D/0X 83X7 %X^(0!</BD 6CXQ %@^.0!7
M/D  53]& %0_30!3/U4 4D!< %! 90!/0&\!3D%Z 4U!AP%+098!2D&E DE"
MM0))0LL"24+H DE"^0))0?\"24'_ 4E!_P&]0P  JD4  )A%  "*10  ?T4
M '9#  !O0   :$   &-! 0!?00T 7$$4 %E"'0!70B8 54(N %-"-@!10CT
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M CM-]@([3?\!.TS_ 3Q,_P&S30  GDP  (U,  !_3   =$P  &I,  !@2@
M64L  %1,  !0304 3$X. $E/%0!'3QX 14\F $10+@!"4#4 05 ] $!11  _
M44L /E%3 #U27  \4F8 .E)R #E2?P$X4HX!-U*> 392KP$U4L0!-5+B 392
M]0$V4?\!-E#_ 3=0_P&N3P  F4\  (E/  ![3P  <$\  &9/  !<3@  5$\
M $]1  !*4@$ 1E,, $-4$@!!5!L 0%4C #Y5*P ]5C( /%8Z #M600 Z5DD
M.5=1 #A76@ V5V, -5=O #17? $S5XP!,5>< 3!7K0$P5\(!,%?@ 3!6] $Q
M5O\!,57_ 3%5_P&H4@  E5(  (12  !W4@  ;%(  &)2  !84P  3U0  $E6
M  !$5P  0%D( #U:$  [6A< .5L@ #A;)P W7"\ -EPV #5</@ T7$8 ,UU.
M #%=5P P76$ +UUL "Y=>@ L78D *UV: 2I=JP$J7;\!*5W> 2I<\@$J6_X!
M*UO_ 2M:_P&C50  CU4  ']5  !R50  9U8  %Y6  !45P  3%D  $5;   _
M70  .E\$ #9@#0 T81, ,F(< #%B(P P8BL +V,R "YC.@ M8T( +&-* "ID
M4P I9%T *&1I "=D=@ F9(8 )627 "1DJ0 C9+T (F3: "-C\0 C8OT!)&'_
M 21A_P&<6   B5@  'I9  !N60  8UD  %I:  !07   2%X  $%@   Z8P
M-&8  "]H"@ L:1  *FD7 "EJ'P H:B8 )VHN "9K-0 E:ST )&M& "-K3P B
M;%D (&QE !]L<@ >;(( '6R4 !QLI@ ;:[H &FO4 !MJ[@ <:?P '&C_ !QH
M_P"57   @UP  '5<  !I70  7UT  %9>  !,80  0V0  #QG   U:@  +VT
M "AP!  C<@T (7(2 "!S&@ ?<R$ 'G,H !UT,  <=#@ &W1  !IT2@ 9=%0
M%W5@ !9U;@ 5=7X %'60 !-TH@ 2=+8 $73/ !)S[  2<OH $W'_ !-Q_P".
M8   ?6   &]A  !E80  6V(  %%D  !(9P  /FL  #=N   P<0  *74  ")X
M   <>P< %WT. !9]$P 5?1L %'XB !-^*@ 2?C$ $7XZ !%^1  0?TX #W]:
M  Y_:  -?W@ #'^*  M^G0 *?K  "7W&  I]Y  *?/0 "WO]  MZ_P"&90
M=V4  &IE  !A9@  5F@  $QK  !";P  .7,  #%W   J>@  (WX  !R!   5
MA   $(<(  V)#@ ,B10 #(D;  N)(P *B2L "8DS  B)/0 &B4@ !8E4  2)
M80 "B7$  8F#  ")E@  B*D  (>^  "'V@  ANP  (;U  "&^@!^:@  <6H
M &=K  !;;   4'   $9T   \>   ,WT  "J!   CA0  '(@  !6,   0CP
M#)(&  :3#  "DQ$  )06  "4'0  E"0  )4L  "5-0  E4   )5,  "660
MEFD  )5Z  "5C@  E*$  )2U  "3S   DN8  )+R  "2]P!X<   ;7   &!R
M  !4=0  27D  #]^   U@P  +(@  ".-   ;D0  %)0   ^7   *F@  !)T#
M  ">"0  GPX  )\2  "@%P  H!T  *$E  "B+0  HC<  *-#  "C4   HU\
M *-Q  "CA   HID  **M  "AP@  H=P  *'K  "@\@!S=@  9G<  %E[  !-
M@   0H4  #B+   ND   ))4  !N:   4G@  #J$   FD   "IP   *H   "K
M!   JPH  *P-  "M$0  K18  *X<  "O)   L"T  +$Y  "Q1@  LE4  +)F
M  "R>0  LHX  +&C  "RMP  L<H  +'@  "QZ0!L?@  7X(  %*'  !&C0
M.Y,  #"9   FG@  '*,  !.G   -JP  !ZX   "R    M0   +<   "X
MN0(  +D(  "Z#   NQ   +P4  "]&P  OR,  ,$M  #".@  PDD  ,-:  ##
M;   Q((  ,27  #$JP  Q+P  ,3+  #$V@!EB0  6(X  $N5   _FP  ,Z(
M "BH   =K0  %+$   VV   &N0   +P   "_    PP   ,0   #%    Q@
M ,<   #)!   R@D  ,L-  #-$0  SQ@  -(A  #5+0  UCP  -A-  #97P
MVG,  -J*  #;G@  VZX  -NZ  #<PP!>E@  49P  $2C   XJ@  ++$  ""W
M   5NP  #;X   3"    Q0   ,D   #-    T    -(   #2    U0   -8
M  #9    VP   -X%  #@"@  X@\  .46  #H(   ["T  .T^  #M40  [F4
M .]Z  #OCP  \)\  /"K  #PLP#_ !  _P . /\ #@#_ !( _P = /\ *0#_
M #4 _P!! /\ 30#^ %8 ^P!? /@ 9@#V &T ] !T /( >0#Q '\ \ "$ .X
MB0#M (\ ZP"5 .H FP#H *( Y@"J .4 LP#C ,  X0#2 .  Z@#? /D W0#_
M -T _P#= /\ W@#_ -X _P#_  T _P * /\ "0#_  \ _P 8 /\ ) #^ #$
M^P ] /@ 2 #T %( \ !: .T 8@#K &D Z0!O .< =0#E 'H XP!_ .( A0#@
M (H W@"0 -P E@#: )T V "E -4 KP#2 +H T #* ,X XP#- /0 RP#_ ,L
M_P#+ /\ RP#_ ,L _P#_  @ _P # /\ !0#_  P _  4 /< 'P#R "L [P W
M .L 0@#G $P Y !5 .  70#= &0 V@!J -@ < #5 '4 T@!Z -  @ #/ (4
MS0"+ ,L D@#) )D QP"A ,4 J@## +4 P0## +\ V@"^ .X O0#\ +P _P"\
M /\ O #_ +P _P#_    _P   /\   #Y  < \0 0 .H &@#D "4 WP Q -L
M/ #7 $< T@!0 ,X 5P#+ %X R0!E ,8 :@#% '  PP!U ,$ >@#  (  O@"&
M +P C0"Z )0 N0"< +< I0"U +  LP"] +$ SP"O .@ K@#X *X _P"M /\
MK0#_ *T _P#_    _P   /T   #N  $ XP , -H % #1 !\ S  K ,@ -@#%
M $  P@!* +\ 4@"\ %D N@!? +@ 90"V &H M !O +, =0"Q 'H L "! *X
MB "M (\ JP"8 *D H0"G *L I0"X *, R "B .( H0#S *  _@"@ /\ H #_
M *  _P#_    ]@   .H   #@    TP & ,D #P#" !@ O0 D +D +P"V #H
MM !# +$ 3 "N %, K !9 *H 7P"I &0 IP!J *8 ;P"D '4 HP![ *$ @@"@
M (H G@"3 )P G0": *< F "T )8 PP"5 -P E #O ), ^P"3 /\ DP#_ )(
M_P#Y!0  Z@L  -P-  #+"@  P@4  +P "@"V !$ L0 < *X * "J #, IP ]
M *0 10"B $T H !3 )X 60"< %\ FP!D )H :@"8 '  EP!V )4 ?@"3 (8
MD@&/ ) !F0". J0 C *Q (L#P ")!=8 B ;M (@'^@"'"/\ A@C_ (8(_P#O
M#P  WA0  ,H5  "\$@  LQ   *X,  "K!@T IP,5 *(%( "?!RP G @V )D(
M/P"7"4< E0E. ),)5 "1"EH D I? (X*90"-"FL BPIR (H+>0"("X( APN,
M (4,EP"##*( @0VP ( -P !_#=@ ?0[O 'P/_0![#_\ >Q#_ 'L0_P#F%P
MT1X  +T=  "O'   IAD  *$5  ">$ 0 G0T/ )@.&0"4#B4 D0\O (\0.0",
M$$$ BA!( (@03P"'$%4 A1!; (0180""$6< @!%N '\1=0!]$7X ?!*( 'H2
ME !X$J  =Q.N '43O@!T%-4 <Q7N '$6_0!Q%O\ <1;_ ' 6_P#<'P  QB4
M +,E  "E(P  G"$  )8>  "2&0  D10+ (T4% ")%1\ AA8I (,6,P"!%SP
M@!=# 'X72@!\%U  >A=6 'D87 !W&&( =AAI '08<0!S&7H <1F$ &\:D !N
M&IT ;!NK &L<NP!J'-  :1WL &@>^P!H'O\ 9Q[_ &<>_P#1)@  O2H  *LJ
M  "=*@  DR@  (TE  "((@  AAT& (,;$ !_'!H ?!TD 'H=+@!W'C8 =AX^
M '0>10!R'TL <1]1 &\?6 !N'UX ;!]E &L@;0!I('8 :"&! &8AC0!E(IH
M8R*H &(CN !A(\T 8"3I & D^@!?)/\ 7R3_ %\D_P#*+   MB\  *0O  "6
M+P  C"T  (4J  " *   ?20  'HB#0!V(Q4 <R,@ '$D*0!O)#( ;20Z &LE
M00!J)4< :"5- &8E5 !E)5H 9"9A &(F:0!A)G( 7R=] %XGB@!=*)< 6RFE
M %HIM0!:*LH 62KG %@J^ !8*O\ 6"K_ %@J_P#%,0  KS,  )XS  "0,P
MAC(  '\O  !Y+0  =2H  '(H"@!O*!( :RD; &DI)0!G*BT 92HU &,J/0!B
M*D, 8"I* %\K4 !>*U< 7"M> %LL9@!9+&\ 6"UZ %<MAP!6+I4 5"ZC %,O
MLP!3+\< 4B_E %(O]P!2+_\ 4B__ %(O_P#!-@  JC8  )DV  "+-@  @34
M 'DS  !S,0  ;R\  &LN!@!H+1  9"X8 &(N(0!@+RH 7B\Q %PO.0!;+T
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M 4(\\P%"//\!0CS_ 4([_P&S/0  GCX  (T^  !_/@  =3X  &P]  !F.@
M8#D  %LZ  !7.@@ 4SL0 %$[& !..R  3#LH $L[+P!)/#8 1SP] $<\1 !&
M/4L 13U3 $0^7 !#/F8 0C]Q $$_?@! /XT /T"< #Y K0$]0, !/4#= 3U
M\@$]0/\!/C__ 3X__P&N0   FD   (E!  !\00  <4$  &A   !A/   6ST
M %8^  !2/@4 3C\. $P_%0!)/QT 1T E $9 + !$0#, 0T Z $)!0@!!04D
M0$%1 #]"6@ ^0F, /4-O #Q#?  [0XL .D2; #E$JP$Y1+X!.$3; 3E$\0$Y
M0_X!.4/_ 3E#_P&J0@  ED,  (9#  !X0P  ;D,  &5#  !=0   5D   %%"
M  !-0@( 24,, $9#$@!$1!H 0D0B $%$*@ _13$ /D4X #U%/P \1D< .T9/
M #I&5P Y1V$ .$=L #='>@ V2(D -4B9 #1(J@ T2+T ,TC9 #1(\  T1_T
M-$?_ #5&_P"F1   DD4  ()&  !U1@  :D8  &%%  !91   440  $Q&  !(
M1P  1$<* $%($  _21@ /4D@ #Q))P Z2BX .4HV #A*/0 W2T0 -DM, #5+
M50 T3%\ ,TQJ #),=P Q3(8 ,$R7 "]-J  N3;L +DW5 "Y,[P O3/T +TO_
M #!+_P"A1P  CD@  'Y(  !Q2   9DD  %U(  !52   3$D  $=*  !"2P
M/TP& #M-#@ Y3A4 -TX= #9/)  U3RL ,T\S #)0.@ Q4$( ,%!* "]14@ N
M45P +5%G "Q1=0 K480 *E*5 "E2I@ I4KD *%+2 "E1[@ I4/P *E#_ "I/
M_P"<2@  B4H  'I+  !M2P  8TP  %I,  !13   2$T  $-/   ]4   .5("
M #53#  S5!( ,509 #!5(0 N52@ +54O "Q6-P K5CX *E9& "E63P H5UD
M)U=D "97<@ E5X$ )%>2 "-7I  B5[< (E?/ ")7[  C5OH (U7_ "15_P"6
M30  A$X  '5.  !I3@  7T\  %9/  !-4   15(  #]3   Y5@  ,U@  "]:
M"  K6P\ *EL5 "A<'0 G7"0 )EPK "5<,P D73H (UU# ")=3  A758 (%YA
M !]>;@ >7GX '5Z/ !Q>H0 ;7K0 &EW, !M=Z0 ;7/D '%O_ !Q;_P"040
M?E$  '!1  !D4@  6U(  %)3  !*5   05<  #M9   U6P  +EX  "A@ P D
M8@P (F,1 "%C&  ?9"  'F0G !UD+@ <9#8 &V4^ !IE1P 995$ &&5= !=E
M:@ 697H %66+ !1EG@ 39;$ $F7( !)DYP 38_< %&+_ !1B_P")5   >%4
M &M5  !@5@  5U8  $]7  !&60  /5P  #9?   P8@  *60  "-G   =:@<
M&6P. !AL$P 6;1H %6TA !1M*0 4;3  $VTY !)N0@ 1;DP $&Y8  ]N90 .
M;G4 #6Z'  UNF@ ,;:T "VW"  MLX  ,:_, #6O]  UJ_P""60  <ED  &99
M  !<6@  5%H  $I<  !!7P  .6,  #%F   J:0  )&P  !UO   7<@  $G4)
M  ]W#P .=Q0 #G<;  UW(P ,=RH "W<S  IW/  )=T< "'=2  =W7P %=V\
M!'>   -WE  !=J<  ':[  %UU0 !=.L  G3V  )T_ ![70  ;5T  &)>  !9
M7@  3F   $5C   \9P  ,VL  "MN   D<@  'G4  !=Y   2?   #7\&  F!
M#  %@1$  X$6  *!'0 !@20  ($M  ""-@  @D   (),  ""60  @F@  ()Y
M  ""C0  @:   ("T  " RP  ?^<  '[R  !^^0!T8@  :&(  %YB  !39
M26<  #]K   V<   +70  "5X   >?   %X   !&#   -A@  "(D$  *+"@
MBPX  (L3  ",&   C!\  (TF  "-+P  CCD  (Y$  ".40  CF   (YQ  ".
MA0  CID  (VM  ",PP  C-\  (ON  "+]@!N:   9&<  %AI  !-;   0G$
M #AV   O>P  )G\  !Z$   6B   $(P   R/   &D@   )4   "6!P  EPP
M )</  "8$P  F1@  )H?  ";)@  FS   )P[  "<2   G%<  )QH  "<>P
MG)   )NE  ";N@  FM   )KG  ":\0!J;0  7F\  %%R  !&=P  .WP  #&"
M   GAP  'HP  !:1   0E0  "ID   2<    H    *(   "C 0  HP8  *0+
M  "E#@  IA(  *<7  "H'@  JB8  *LQ  "K/@  K$T  *Q=  "L<   K(4
M *R;  "KKP  J\,  *O9  "JZ !D=0  5WD  $M^   _A   -(H  "F0   ?
ME@  %IL  !"?   )HP   :<   "J    K@   +    "P    L0   +(#  "T
M"   M0T  +80  "W%0  N1T  +LF  "\,P  O4$  +U2  "]9   OGD  +Z0
M  "]I   O;<  +W&  "]UP!<?P  4(4  $2+   XD@  +)D  "&?   7I
M$*D   FN    L@   +8   "Y    O0   +\   "_    P    ,$   ##
MQ 4  ,8*  #'#@  R1,  ,L<  #.)@  T#4  -%%  #25P  TFL  -."  #3
MEP  TZD  -*X  #2Q !5C   29,  #V:   PH@  ):@  !JN   1M   ";D
M  "]    P0   ,0   #(    RP   ,T   #-    SP   -    #2    U
M -@   #:!@  W0P  . 1  #C&@  YB<  .<X  #H2@  Z5T  .IR  #KB
MZYL  .RH  #LL@#_  T _P + /\ "P#_ !  _P : /\ )@#_ #( _P ] /\
M2 #[ %( ^ !: /8 8@#S &D \0!O /  =0#N 'H [ !_ .L A #I (H Z "0
M .8 E@#D )T X@"E .$ KP#? +L W0#+ -L Y@#9 /< V #_ -@ _P#7 /\
MUP#_ -0 _P#_  @ _P $ /\ ! #_  T _P 5 /X (0#Z "P ]P X /0 0P#P
M $T [0!5 .H 70#G &0 Y !J .( < #@ '4 W@!Z -T ?P#; (4 V0"+ -4
MD0#3 )D T0"@ ,\ J@#- +4 RP#$ ,D W0#( /$ QP#_ ,8 _P#& /\ Q@#_
M ,< _P#_    _P   /\   #_  H ^  1 /$ ' #L "< Z0 R .8 /0#B $<
MW0!0 -D 6 #5 %\ T@!E -  :@#. '  S !U ,H >@#) '\ QP"% ,4 C ##
M )0 P0"< +\ I0"] +  NP"] +H T "X .L MP#[ +8 _P"V /\ M@#_ +8
M_P#_    _P   /T   #S  4 Z0 . .$ %@#; "$ U0 M -$ -P#. $$ R@!*
M ,< 4@#$ %D P@!? ,  90"^ &H O !O +L = "Y 'H MP"  +8 AP"T (X
ML@"7 +  H "N *H K0"W *L R "I ., J #U *< _P"G /\ IP#_ *8 _P#_
M    _@   /$   #E    UP * ,T $0#' !P P@ F +\ ,0"\ #L N@!$ +<
M3 "T %, L@!9 +$ 7P"O &0 K0!I *P ;P"J '0 J0!Z *< @0"F (D I "1
M *( FP"@ *4 G@"R )T P0"; -H F@#O )D _0"8 /\ F #_ )@ _P#]
M\    .$   #1    Q@ $ +T #0"W !4 LP @ +  *P"M #4 JP ^ *@ 1@"F
M $T I !4 *, 60"A %\ H !D )X :0"= &X FP!U )H >P"8 (, E@", )4
ME@"3 *$ D0"M (\ NP"- ,\ C #I (L ^ ", /\ C #_ (P _P#S @  X@<
M ,P'  "_!   MP   +$ " "K !  IP 9 *0 ) "@ "X G@ W )P 0 ": $<
MF !. )8 5 "5 %D DP!> )( 9 "0 &D CP!O (T =@"+ 'X B@"( (@ D@"&
M )T A0"I (, N "! ,H @ #E (  ]0!_ /\ ?P#_ '\ _P#H#0  T!   +X0
M  "Q#@  J T  *,(  "@ @P G  3 )@ '0"5 "< D@ Q )  .0". 4$ C %(
M (H"3@") E0 AP)9 (8"7P"$ V0 @P-K ($#<@" !'H ?@2$ 'T%C@![!9H
M>0:G '@&M0!V!\@ =0CC '4)] !T"O\ <PK_ ',*_P#=%0  Q!<  +$7  "E
M%@  G!,  )81  "4#00 DP@- (X'%0"+"2  B DJ (4*,P"#"SL @0M" ( +
M20!^"T\ ?0Q4 'L,6@!Z#&  > QG '<,;@!U#78 = V  '(-C !P#9D ;PZF
M &T.M0!L#LD :P_F &H0]P!I$/\ :1#_ &D0_P#0'0  N1X  *@>  ";'0
MDAL  (L9  "(%0  AQ$' (4.$ "!#QH ?A D 'L0+0!Y$#8 =Q$] '811 !T
M$4H <Q%0 '$15@!P$5P ;A)B &T2:@!K$G, :1-] &@3B0!F$Y8 912C &,5
MLP!B%<8 8A;C &$6]@!@%_\ 8!?_ & 7_P#'(@  L",  )\D  "2(P  B2(
M ((@  !^'0  ?!D  'H5#0!W%14 =!8? '$6* !O%S  ;A<X &P7/P!K%T4
M:1A+ &@840!F&%@ 91A> &,99@!B&6\ 8!EY %\:A0!=&Y( 7!NA %L<L !:
M',, 61W@ %@>] !8'O\ 6![_ %@>_P"_)P  J2@  )DH  "+*   @B<  'LE
M  !V(P  <R   '$<"0!N'!$ :QP: &D=(P!G'2P 91TS &,>.@!B'D$ 8!Y'
M %\>30!>'E0 7!]; %L?8@!9(&L 6"!V %8A@@!5(9  5"*> %,BK@!2(\
M42/= %$D\@!1)/\ 423_ %$C_P"Y*P  HRP  ),L  "&+0  ?"P  '0J  !O
M*   :R4  &DB!0!F(0X 8R(6 &$B'P!?(R< 72,O %PC-@!:(ST 621# %<D
M2@!6)%  5217 %,E7P!2)6@ 429S $\F?P!.)XT 32B< $PHK !+*;X 2RG:
M $HI\0!**?\ 2RG_ $LI_P"S+@  GB\  (XP  "!,   =R\  &\N  !J*P
M92H  &,G 0!?)PP 7"<3 %HG&P!8*"0 5B@K %4H,@!3*#D 4BE  % I1@!/
M*4T 3BE4 $TJ7 !,*F4 2BMP $DK? !(+(L 1RV: $8MJ@!%+KP 12[6 $4N
M[P!%+OX 12[_ $4M_P"N,0  FC(  (DS  !\,P  <C,  &LQ  !E+P  8"T
M %TL  !9+ D 5BP0 %0L& !2+"  4"PH $XM+P!-+38 3"T\ $HM0P!)+4H
M2"Y1 $<N60!&+V, 13!M $,P>@!",8D 03&8 $$RJ ! ,KL /S+3 #\R[@!
M,OT 0#+_ $ R_P"J,P  EC4  (8U  !Y-@  ;C4  &8U  !A,@  7#   %<P
M  !4, 8 43 . $XP%0!,,1T 2C$E $@Q+ !',3( 1C$Y $0Q0 !#,D< 0C)/
M $$S5P! ,V  /S1K #XU>  ]-8< /#:6 #LVIP [-KD .C;1 #HV[0 [-OP
M.S;_ #LV_P"F-@  DC<  ((X  !U.   :S@  &,W  !=-@  5S,  %,T  !/
M- , 2S0, $DT$@!&-1H 134B $,U*0!!-2\ 0#4V #\V/0 ^-D0 /3=, #PW
M50 [.%X .CAI #DY=@ X.84 -SJ5 #<ZI0 V.K@ -3K/ #8Z[  V.OL -CG_
M #<Y_P"B.   CCD  'XZ  !R.P  :#L  %\Z  !9.0  4S8  $XW  !*.
M1C@* $0Y$ !!.1< /SD? #XY)@ \.2T .SHT #HZ.P Y.T( .#M* #<[4P V
M/%P -3QG #0]=  S/8, ,SZ3 #(^I  Q/K8 ,3[- #$^Z@ Q/OH ,CW_ #(]
M_P">.P  BSP  'L\  !N/0  9#T  %P]  !5/   3CH  $D[  !%/   03T'
M #X]#@ \/14 .CX< #D^(P W/BH -C\Q #4_.  T/T  ,T!( #) 4  Q0%H
M,$%E "]!<@ N0H$ +4*1 "U"H@ L0K4 *T++ "Q"Z0 L0OD +4'_ "U!_P"9
M/0  ASX  '<_  !K/P  84   %D_  !2/P  23X  $0_  ! 0   /$$$ #E"
M#0 W0A( -4,9 #-#(0 R0R@ ,40O #!$-@ O1#T +D5% "U%3@ L15@ *T9C
M "I&;P I1GX *$:/ "='H0 F1[, )D?) "9&YP G1O@ *$7_ "A%_P"50
M@D$  '-"  !G0@  7D(  %5"  !.0@  14(  #]$   [10  -T8  #1'"@ Q
M2!  +T@6 "Y)'@ L224 *TDL "I),P I2CH *$I" "=*2P F2U4 )4M@ "1+
M;0 C2WP (DN- "%,GP A3+$ ($S' "!+Y@ A2_< (DK_ ")*_P"00P  ?D0
M &]$  !D10  6D4  %)%  !*1@  04<  #Q(   W20  ,DL  "Y-!P K3@X
M*4X3 "=/&@ F3R$ )4\H "1/,  C4#< (E _ "%02  @4%( 'U%= !Y1:@ =
M47D '%&* !M1G  :4:\ &5'% !E1Y  :4/8 &T__ !Q/_P"*1@  >4<  &M'
M  !@2   5D@  $Y(  !'20  /DL  #E,   S3@  +E   "A3 @ D5 L (E40
M "!5%@ ?5AX 'E8D !U6+  <5C, &U<[ !I71  95TX &%=9 !=89@ 56'4
M%%B' !18F@ 35ZP $E?" !)7X0 35O0 %%7_ !15_P"$20  =$H  &9+  !<
M2P  4TL  $M,  !$30  /$\  #51   O5   *58  "19   >6P< &ET- !A=
M$@ 771D %EX@ !5>)P 47BX $UXW !)>0  17TH $5]5 !!?8@ /7W$ #E^#
M  U?E@ -7ZD #%Z^  Q>V@ -7?  #5S\  Y<_P!^30  ;DX  &).  !83P
M3T\  $A0  ! 4@  .%0  #!7   J6@  )%T  !]?   98@$ $V4) !%F#P 0
M9A0 #V8;  YG(@ -9RD #6<R  QG.P +9T4 "F=0  EG70 '9VP !F=]  5G
MD  $9J,  F:W  -ESP $9>D !&3U  1D_ !W40  :5(  %U2  !44@  3%,
M $-5   [6   ,UL  "M>   E80  'V0  !EG   3:@  #VT&  MP#  (</_B
M_^))0T-?4%)/1DE,10 $"1$ !W 6  5P'0 $<"0  W L  )P-0  <#\  '!*
M  !P5P  <&4  '!V  !PB@  ;YX  &^R  !NR   ;>4  &WR  !M^0!P5@
M8U8  %E6  !15P  1U@  #Y;   V7P  +F(  "9F   ?:@  &6T  !-P   .
M<P  "W8$  5X"P !> \  'D3  !Y&0  >1\  'HF  !Z+P  >CD  'I$  !Z
M4   >E\  'IP  !Z@P  >I@  'JL  !YP@  >-\  'CO  !W]P!J6P  7UL
M %9;  !,7   0F   #EC   P:   *&P  "!P   9=   $W<   Y[   )?@
M!($"  """   @PT  (,0  "$%   A1D  (8@  "&*   AS$  (<\  "'20
MAU<  (=H  "'>P  AY   (:E  "%N@  A=,  (3J  "$] !E8   7&   %%A
M  !&9   /&D  #)M   I<@  (7<  !E[   2@   #8,   B'   "B@   (T
M  ".!   C@D  (\-  "0$   D10  )(9  "3(   E"D  )4S  "50   EDX
M )9?  "5<@  E8@  )6=  "4L@  E,@  )/B  "3[@!A90  5F8  $IJ   _
M;@  -70  "MY   A?P  &80  !&)   ,C0  !I$   "4    F    )H   ";
M    G (  )T'  ">"P  GPX  *$2  "B&   HR   *4I  "F-@  ID0  *95
M  "F:   IGT  *:4  "EJ0  I+T  *31  "DY !;;   3W   $-U   X>P
M+8$  ".'   9C0  $9(   N7   $G    *    "C    I@   *@   "I
MJ@   *P   "M!   K@D  + -  "Q$0  LQ<  +4@  "V*P  MSH  +=+  "X
M7   N'$  +B(  "XG0  N+$  +?"  "WT !4=@  2'P  #R"   QB0  )I
M !N7   2G0  #*(   .G    JP   *X   "R    M@   +@   "X    N@
M +L   "]    O@   , %  #!"P  PQ   ,86  #)(   RBX  ,L^  #,4
MS&0  ,UZ  #-D0  S:0  ,VT  #-P !-@P  08H  #61   IF0  'J   !.F
M   ,K    [$   "V    N@   +X   #"    Q@   ,@   #(    R@   ,L
M  #-    S@   -    #2 0  U0@  -D.  #=%0  X2$  .(Q  #D0P  Y58
M .9K  #F@@  YY8  .>E  #FL #_  D _P % /\ !@#_  X _P 6 /\ (0#_
M "T _P X /T 0P#Y $T ]0!5 /( 70#P &, [@!I .P ;P#J '0 Z0!Z .<
M?P#F (4 Y "+ ., D0#A )D WP"A -P J@#: +8 UP#& -4 X0#3 /0 T@#_
M -$ _P#1 /\ SP#_ ,H _P#_  $ _P   /\  0#_  P _P 2 /H '0#V "@
M\P S /  /@#L $@ Z !0 .4 6 #B %X WP!D -T :@#; &\ V0!T -8 >@#4
M '\ T@"% -  C #. ), S "< ,D I0#' +  Q@"^ ,0 U #" .X P0#^ ,
M_P#  /\ OP#_ +X _P#_    _P   /\   #Z  < \0 / .L & #F ", X@ N
M .  . #; $( U0!+ -$ 4@#. %D RP!? ,D 90#' &H Q@!O ,0 = #" 'H
MP0"  +\ A@"] (X NP"6 +D H "W *H M@"W +0 R@"R .8 L0#X +  _P"O
M /\ KP#_ +  _P#_    _P   /<   #J  ( X0 , -< $P#0 !T S  H ,D
M,@#& #P P@!% +\ 30"\ %, N@!9 +@ 7P"W &0 M0!I +0 ;@"R '0 L0!Z
M *\ @ "M (@ K "1 *H F@"H *4 I@"Q *0 P0"C -P H0#R *$ _P"@ /\
MH #_ *$ _P#_    ]P   .@   #9    RP ( ,, $ "] !@ N0 B +8 + "T
M #8 L@ _ *\ 1P"L $T JP!4 *D 60"G %X I@!C *4 : "C &X H@!T *
M>@"> (( G "+ )L E0"9 )\ F "L )8 N@"4 ,\ DP#K )( ^P"2 /\ D@#_
M )$ _P#W    YP   -,   #&    NP " +, # "M !( J@ < *< )@"D #
MHP X *  0 "> $< G !. )H 4P"9 %@ EP!= )8 8P"5 &@ DP!N )( = "0
M 'P CP"% (T CP"+ )H B@"G (@ M0"& ,< A0#D (0 ]0"$ /\ @P#_ (,
M_P#L    TP   ,$!  "T    K    *8 !P"@  X G0 6 )H ( "7 "D E0 R
M ), .@"1 $$ CP!( (T 30", %, BP!8 (D 70"( &, AP!I (4 ;P"# '<
M@@"  (  B@!^ )8 ?0"C 'L L !Z ,( >0#= '@ \0!W /T > #_ '@ _P#>
M"@  Q L  +(,  "F"P  G0@  )D$  "5  H D0 1 (X &0"+ ", B0 L (<
M- "% #L @P!" (( 2 "  $X ?P!3 'T 6 !\ %X >P!D 'D :@!X '( =@![
M '0 A@!S )( <0"? '  K0!N +X ;0'6 &T"[0!L _H ; /_ &P#_P#.$
MMQ$  *82  ":$0  D1   (L.  ")"P, AP4, (0!$P"! 1P ?@(E 'P#+@!Z
M S8 > 0\ '<$0P!U!4@ = 5. ',%5 !Q!5D < 9? &X&9@!M!FX :P=X &H'
M@P!H")  9PF= &4)K !D";P 8PK4 &,+[ !B#/H 8@S_ &(,_P##%@  K1<
M )T8  "0&   AQ8  ($4  !]$0  ? X& 'P*#@!X"A8 =0L? '(+* !P##
M;PPW &T,/@!L#$0 :PU* &D-3P!H#54 9PU< &4-8P!C#FL 8@YU & .@0!?
M#HX 70^< %P0JP!;$+T 6A#6 %D1\ !9$?T 61'_ %D1_P"Y&P  I1T  )0>
M  "('@  ?AT  '@;  !T&   <14  '$1"0!O$!$ ;! 9 &D0(@!G$2H 9A$R
M &01.0!C$3\ 8A%% & 22P!?$E$ 71)8 %P27P!:$V@ 61-R %<4?0!6%(L
M5!69 %,5J0!2%KH 41;2 %$7[0!1%_T 41?_ %$7_P"R(   GB(  (XB  "!
M(P  =R(  ' A  !L'@  :1L  &<8! !F%0X 8Q85 &$6'@!?%B8 718M %P7
M- !:%SL 61=! %@81P!6&$T 51A4 %,87 !2&60 41EN $\:>@!.&X@ 31N7
M $L<I@!*'+@ 2AW/ $D=ZP!)'?L 21W_ $H=_P"L)   F"4  (@F  ![)P
M<28  &HE  !F(P  8B$  & >  !>' L 6QL2 %D<&@!7'"( 51PI %0<, !3
M'3< 41T] % =0P!/'4H 31Y1 $P>6 !+'V$ 21]K $@@=P!'((4 1B&4 $0B
MI !$(K8 0R+, $,CZ0!#(_H 0R/_ $,B_P"F)P  DRD  (,J  !V*@  ;2H
M &4I  !@)P  7"4  %DC  !7(0< 52$/ %(A%@!0(1X 3B$E $TB+ !,(C,
M2B(Y $DB0 !((D8 1R-- $4C50!$)%X 0R1I $(E=0! )H, /R:2 #XGHP ^
M)[0 /2?* #THZ  ]*/D /2?_ #XG_P"B*@  CBL  '\M  !R+0  :"T  &$L
M  !<*P  6"@  %0F  !1)@0 3B4- $PE$P!*)AH 2"8B $<F*0!%)B\ 1"8V
M $,G/ !!)T, 0"=+ #\H4P ^*5P /2EF #PJ<@ [*H$ .BN0 #DKH0 X++(
M-RS( #<LY@ X+/@ ."S_ #@L_P"=+   BBX  'LO  !O,   93   %TO  !8
M+@  4RL  % J  !,*@  22H+ $8J$0!$*A< 0BH? $$J)0 _*BP /BLS #TK
M.0 \*T  .RQ( #HL4  Y+5D ."YD #<N<  V+W\ -2^/ #0PGP S,+$ ,C#'
M #(PY0 S,/< ,S#_ #0O_P"9+P  AS$  '<R  !K,@  8C(  %HR  !4,0
M3R\  $LM  !'+@  1"X( $$N#@ _+A0 /2X< #LN(@ Y+RD ."\O #<O-@ V
M,#X -3!& #4Q3@ T,5< ,S)B #(R;@ Q,WT ,#.- "\TG@ N-+  +33% "TT
MXP N-/8 +S/_ "\S_P"5,0  @S,  '0T  !H-0  7C4  %<T  !1-   2S(
M $8Q  !",@  /S(% #PR#0 Y,Q( .#,9 #8S(  T,R8 ,S,M #(T-  Q-#L
M,#5# # U3  O-E4 +C9@ "TW;  L-WL *S>+ "HXG  I.*X *#C# "@XX@ I
M./4 *C?_ "HW_P"2-   ?S4  '$V  !E-P  6S<  %0W  !--@  1S8  $(U
M   ]-@  .C8" #<W"P T-Q  ,C<6 #$X'0 O."0 +C@K "TY,@ L.3D *SE!
M "HZ20 J.E, *3M> "@[:@ G.WD )CR) "4\FP D/*T (SS" ",\X  D//0
M)3O_ "4[_P"--@  ?#@  &TY  !B.0  6#H  %$Y  !*.0  1#D  #TY   Y
M.@  -3L  #(["  O/ X +3T4 "P]&@ J/2$ *3TH "@^+P G/C8 )CX^ "4_
M1P D/U  (T!; ") :  A0'8 ($"' !]!F0 ?0:L 'D'  !Y!W@ ?0/, 'T#^
M " __P").0  >#H  &D[  !>/   53P  $T\  !'/   0#P  #@]   T/@
M,$   "U!!0 J0@P )T(1 "9#&  D0QX (T,E ")#+  A1#, ($0[ !]$1  >
M14X '459 !Q%90 ;170 &D6% !E&EP 91JD &$:^ !=%W  81?$ &43] !I$
M_P"$/   <ST  &8^  !;/P  4C\  $H_  !$/P  /4   #9!   Q0P  +$0
M "=& 0 D1PH (4@/ "!)%  >21L '4DB !Q)*0 ;2C  &DHX !E*00 82DL
M%TM5 !9+8@ 52W$ %$N" !-+E  22Z< $DN\ !%+V0 22O  $TK\ !1)_P!_
M/P  ;T   &%!  !70@  3D(  $="  !!0@  .D,  #)%   M1P  *$D  "-+
M   >308 &T\- !A0$0 74!< %E > !50)0 44"P $U$T !)1/0 144< $5%2
M !!17P /4FT #E)^  U1D0 -4:0 #%&X  Q1T0 -4.P #5#Z  Y/_P!Y0P
M:D0  %U$  !310  2T4  $1%   ^1@  -D@  "]*   I3   )$\  !]1   :
M4P  %%8) !%7#@ 06!, $%@9  ]8(  .6"@ #5@P  U8.0 ,6$, "UA.  I8
M6@ (6&@ !UAY  98C  %6)\ !%BS  17R@ %5^8 !5?S  96_ !S1@  9$<
M %E(  !02   2$@  $%)   Z2@  ,DT  "M0   E4@  (%4  !I8   56@
M$%T&  Q@#  *8!  "6 5  A@'  '8", !6 K  1@-  #8#T  6!)  !@50
M8&,  &!S  !@A@  7YH  %^N  !?Q   7N(  %[P  !>^ !L2@  7TL  %5+
M  !,3   14P  #U.   U4   +E,  "=6   @60  &EP  !5?   08@  #64$
M  AG"P #9PX  &@3  !H&   :!\  &DF  !I+@  :3@  &E#  !I3P  :5T
M &EM  !I@   :90  &BI  !HOP  9]P  &;N  !F]P!F3P  6D\  %%/  !*
M3P  05$  #A4   P5P  *%L  "%>   :8@  %&4  !!H   ,:P  !VX#  %P
M"0  < T  '$0  !Q%   <AH  ',A  !S*   <S$  ',\  !T2   <U8  '-F
M  !S>0  <XX  '.C  !RN0  <=(  ''K  !P] !A4P  5E,  $]3  !%50
M.U@  #)<   J8   (F0  !MH   4;   #V\   MR   &=@   'D   !Z!@
M>@H  'L.  !\$0  ?14  'X;  !_(@  @"H  ( U  " 00  @$\  (!?  "
M<0  @(8  ("=  !_L@  ?LH  '[E  !]\0!<6   5%@  $E:   _70  -6$
M "QE   C:@  &V\  !1S   .=P  "7L   -_    @@   (0   "& 0  A@8
M (@*  ")#0  BA   (L5  ",&P  CB(  (\L  "/.   CT8  (]6  "/:
MCWX  (^5  ".JP  C<$  (W<  ",ZP!970  3E\  $-B   X9@  +FP  "1Q
M   <=P  %'P   Z!   (A0   (D   "-    D    )(   "3    E    )8#
M  "7"   F P  )H/  ";$P  G1H  )\C  "@+@  H#P  *!,  "@7@  H'0
M )^,  "?H@  G[<  )[+  ">X !39   1V@  #QM   Q<P  )WD  !U_   4
MA0  #8L   :0    E    )@   "<    GP   *$   "B    I    *4   "G
M    J 0  *H)  "L#0  K1(  + 9  "R(P  LC$  +)"  "R5   LFD  +*
M  "RF   L:P  +*_  "QS@!,;@  0',  #5Z   J@0  'X@  !6.   .E0
M!IH   "?    I    *@   "L    KP   +$   "Q    LP   +4   "V
MN    +H   "\!@  O@P  , 1  ##&0  Q28  ,4W  #&20  QET  ,=R  #'
MB@  R)\  ,BO  #(O !&>@  .8$  "Z)   BD   %Y@   ^?   'I0   *H
M  "O    LP   +<   "\    OP   ,$   #"    Q    ,4   #'    R0
M ,L   #-    SP,  -(*  #6$   W!H  -TJ  #>/   WU   .!E  #A>P
MX9$  .*B  #BK0#_  ( _P   /\  P#_  P _P 3 /\ '0#_ "@ _@ S /L
M/@#W $@ \P!0 /  5P#M %X ZP!D .@ :0#G &\ Y0!T ., >0#B '\ X "%
M -X C #< ), V0"< -8 I@#3 +$ T0#  ,\ V@#. /$ S #_ ,L _P#+ /\
MQ@#_ ,$ _P#_    _P   /\   #_  @ ^P 0 /8 &0#R "0 [P N .T .0#H
M $( XP!+ .  4@#= %D V0!? -8 9 #3 &D T0!N ,\ = #. 'D S !_ ,H
MA@#( (X Q@"6 ,0 H #" *L P "Y +X S0"\ .H NP#\ +H _P"Z /\ N@#_
M +8 _P#_    _P   /X   #T  0 ZP - .0 % #? !\ VP I -@ ,P#3 #T
MS@!% ,H 30#' %, Q0!9 ,, 7P#! &0 OP!I +T ;@"[ ', N@!Y +@ @ "V
M (@ M "0 +( F@"Q *4 KP"R *T Q "L .$ JP#V *H _P"J /\ J@#_ *H
M_P#_    _0   .X   #B    U0 * ,T $0#' !D Q  C ,$ +0"_ #< NP _
M +< 1P"U $X L@!3 +  60"O %X K0!C *P : "K &T J0!S *@ >@"F ($
MI "* *, E "A )\ GP"L )X NP"< -( FP#N )H _P": /\ F0#_ )D _P#^
M    [@   -X   #+    P0 % +D #0"T !0 L0 > *X )P"K #  J@ Y *<
M00"D $@ H@!- *$ 4P"? %@ G@!= )T 8@"; &< F@!M )@ <P"7 'L E0"$
M )0 C@"2 )D D "F (X M "- ,@ C #F (L ^0"* /\ B@#_ (L _P#P
MVP   ,<   "Z    L    *@ "@"D !  H  8 )T (0"; "H F@ S )@ .P"6
M $$ E !( )( 30"1 %( CP!7 (X 7 ", &$ BP!G (H ;@"( '4 AP!^ (4
MB "# )0 @@"@ (  KP!_ ,  ?@#= 'T \@!] /\ ?0#_ 'T _P#@    Q@
M +4   "J    H@   )L !0"5  T D@ 3 )  ' "- "0 BP M (H - "( #L
MA@!" (4 1P"# $T @@!2 ($ 5P!_ %P ?@!B 'T : ![ '  >@!Y '@ @P!V
M (\ =0"< '0 J@!R +H <0#1 '  [ !P /L < #_ '  _P#-!   MP8  *<'
M  ";!@  DP0  (X   "*  @ A@ / (0 %@"! !X ?P G 'T +@!\ #8 >@ \
M 'D 0@!W $< =@!, '4 4@!S %< <@!= '$ 8P!O &L ;@!T &P ?@!K (H
M:0"8 &@ I@!G +8 9@#+ &4 YP!E /< 90#_ &4 _P# #   JPT  )L.  "/
M#@  A@T  ($+  !^!P$ ? $+ 'D $0!W !@ =0 A ', *0!Q #  ;P V &X
M/ !L $( :P!' &H 30!I %( : !8 &8 7P!E &< 8P!P &(!>@!@ 8< 7P*5
M %X"HP!< [, 7 /' %L$Y !;!?0 6P;^ %L&_P"U$   H1(  )$3  "%$P
M?!(  '81  !S#@  <@P$ '$'#0!N!!( ; 0; &D%(P!G!2H 9@8Q &0&-P!C
M!CT 8@=# &$'20!?!TX 7@A5 %T(7 !;"6, 6@EM %@*> !7"H4 5@N3 %0+
MH@!3"[, 4@S' %(,Y !1#?4 40W_ %$-_P"M%0  F1<  (D8  !]&0  =!@
M &T7  !J%   9Q$  &<.!P!F# X 8PP5 &$,'0!?#"4 70TL %P-,P!;#3D
M6@T_ %@-10!7#4L 5@Y1 %4.60!3#F$ 4@YK % /=@!.$(, 31"2 $P0H@!+
M$+( 2A'( $D1Y0!)$?< 21+_ $D1_P"E&0  DAP  (,=  !V'@  ;1T  &8<
M  !B&@  7Q<  %X4 0!>$0H 6Q 1 %D1& !7$2  51$G %01+@!3$30 41$[
M % 200!/$D< 3A). $P250!+$UX 21-G $@4<P!&%(  116/ $05GP!#%K
M0A;% $(7XP!"%_8 0A?_ $(7_P"?'0  C"   'TA  !Q(@  :"(  &$A  !<
M'P  61P  %<9  !5%@8 5!4. %$5% !/%AP 3A8C $P6*@!+%C  2A8W $D7
M/0!'%T, 1A=* $484@!#&%H 0AED $$9<  _&GT /AN- #T;G0 \'*X .QS#
M #L<X0 ['?4 .QS_ #P<_P":(0  AR,  '@D  !L)0  8R4  %PD  !7(P
M4R   %$>  !/' ( 31L, $L:$0!(&Q@ 1QL@ $4;)@!$&RT 0QPS $(<.0!
M'$  /QU' #X=3P ]'E@ /!YB #H?;0 Y'WL .""+ #<AFP V(:T -2'! #4A
MWP U(?, -B'_ #8A_P"6(P  @R8  '0G  !H*   7R@  %@G  !3)@  3R0
M $PB  !)(   1R ) $0?#P!"'Q4 0" < #\@(P ^("D /" O #LA-@ Z(3T
M.2%$ #@B3  W(E4 -B-? #0C:P S)'D ,B6) #$EF@ P):L ,":_ "\FW  P
M)O( ,";_ #$E_P"1)@  ?R@  '$J  !E*@  7"H  %4J  !/*0  2R@  $@E
M  !$)   020% #\D#0 ])!( .R09 #DD'P W)"8 -B0L #4E,P T)3H ,R9!
M #(F2@ Q)U, ,"== "\H:0 N*7< +2F' "PIF  K*JH *BJ] "HJV@ K*O$
M*RK^ "PI_P"-*   ?"H  &TL  !B+0  62T  %$M  !,+   1RL  $,H   _
M*   /"@" #DH"P W*!  -2@6 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK
M1P L*U$ *RQ; "HL9P I+74 *"V% "<MEP F+J@ )2Z\ "4NV  F+O  )B[]
M "<M_P"**P  >"T  &HN  !?+P  5B\  $XO  !(+@  0RT  #\L   [+
M-RP  #0L"0 R+ X ,"T3 "XM&@ M+2  *RTG "HN+0 J+C4 *2\] "@O10 G
M,$X )C!9 "4Q90 D,7, (S&# "(RE0 A,J< (3*[ " RU  A,N\ (C'\ "(Q
M_P"&+0  =2\  &<P  !<,0  4S$  $LQ  !%,0  0#   #LP   V,   ,S
M # Q!@ M,0T *S$1 "DR%P H,AX )S(D "4S*P E,S( )#,Z ",T0P B-$P
M(357 " U8P ?-7$ 'C:! !TVDP <-J4 &S:Y !LVT@ <-NT '3;[ !TU_P""
M,   <3(  &,S  !9-   4#0  $DT  !",P  /3,  #<S   Q-   +C4  "LU
M @ H-@L )3<0 "0W%0 B-QL (3@B " X*  ?.#  'C@W !TY0  <.4D &SI4
M !HZ8  9.FX &#I_ !<[D0 7.Z0 %CNW !4[T  6.NP %SKZ !@Y_P!],@
M;30  & U  !5-@  338  $8V  ! -@  .C8  #0V   N.   *CD  "8Z   C
M.P@ (#P. !X]$@ =/1@ '#T? !L^)0 :/BT &3XT !<^/0 6/T< %3]1 !0_
M7@ 4/VP $T!\ !) CP 10*( $4"V !! S@ 1/^L $C_Y !(^_P!Y-0  :3<
M %PX  !2.0  2CD  $,Y   ].0  -SD  #$Z   K/   )ST  "(_   >000
M&D(+ !A#$  70Q4 %40; !1$(@ 31"D $T0Q !)$.@ 114, $$5. !!%6P .
M16D #D5Y  U%C  -19\ #$6R  M%R0 ,1>4 #43V  U$_P!T.0  93H  %@[
M  !/.P  1SP  $ \   Z/   -#P  "X^   H0   (T(  !]$   :1@  %4@(
M !)*#0 12A( $$H8  ]+'@ .2R4 #4LM  U+-@ ,2T  "TM*  I+5@ )2V0
M"$MT  =+AP %2YH !$NN  1*Q  %2N  !4KP  9)^@!N/   8#T  %0^  !+
M/@  1#X  #T^   W/P  ,4   "I"   D10  'T<  !I)   53   $4X%  Y1
M"P +41  "E$4  E1&P (42( !U$I  51,@ $4CL  U)&  %24@  4E\  %)O
M  !2@0  498  %&I  !1OP  4-P  %#N  !0]P!H0   6T$  %!!  !(00
M04$  #M"   T0P  +44  "9(   @2P  &TT  !90   14P  #E4$  I8"@ &
M6 X  E@2  !9%P  61T  %DE  !9+0  638  %E!  !930  6EH  %II  !9
M?   69   %FE  !8N@  6-4  %?L  !7]@!C1   5D4  $U%  !%10  /T4
M #='   O20  *$P  ")/   ;4@  %E4  !%8   -6@  "5T#  1?"0  8 T
M & 0  !A%   81D  &(@  !B)P  8C$  &([  !B1P  8E4  &-D  !B=@
M8HL  &*@  !AM@  8<\  &#J  !@]0!=2   4DD  $I(  !#2   .DH  #)-
M   J4   (U,  !Q7   66@  $5T   U@   (8P   V8!  !G!@  : L  &D.
M  !J$0  :Q4  &P;  !M(@  ;2H  &TT  !M0   ;4X  &U=  !M;P  ;80
M &R:  !LL   :\@  &OF  !J\P!830  3DT  $A,   ^3@  -5$  "Q4   D
M6   '5P  !9@   09   #&<   =K   !;@   '    !R P  <@<  ',+  !U
M#@  =A$  '<6  !X'   >2,  'HM  !Z.0  >D<  'I6  !Y:   >GP  'F4
M  !XJ@  >,$  '??  !W[P!440  3%$  $)2   X50  +UD  "9>   >8@
M%F<  !!K   +;P  !7,   !W    >@   'P   !^    ?P(  ( &  "!"@
M@PT  (01  "&%0  B!P  (DE  "*,   BCX  (E-  ")7P  B7,  (B+  "(
MH@  A[D  (?1  "&Z !25@  1U<  #Q:   R7P  *&0  !]I   6;P  $'0
M  IY   "?0   ($   "%    B    (H   ",    C0   (\   "0!   D@@
M ),,  "5$   EQ4  )D=  ";)P  FS0  )M$  ":5@  FFH  )F"  ":F@
MF+   )C'  "7W@!+7   0&   #5E   K:@  (7$  !=W   0?0  "8,   &(
M    C    )$   "5    F    )H   ";    G0   )\   "@    H@   *0%
M  "F"@  J X  *H4  "M'0  K2H  *TY  "M2P  K5\  *UW  "LD   JZ<
M *NZ  "KRP!%9@  .6L  "YQ   C>   &7\  !"&   )C0   ),   "8
MG0   *$   "E    J    *L   "K    K@   *\   "Q    LP   +4   "W
M 0  N0<  +P-  "_$P  PA\  ,(N  #"0   PE0  ,%K  #!@P  P)L  ,&M
M  #!O  ^<@  ,G@  ">    <B   $I    J7    G0   *,   "H    K0
M +(   "V    N0   +L   "\    O@   ,    #"    Q    ,8   #(
MRP   ,X%  #1#0  UA0  -<C  #8-0  V4D  -I>  #;=0  VXP  -R?  #<
MJP#_    _P   /\   #_  D _P 0 /\ &0#^ "0 _  O /D .0#T $, \ !+
M .T 4@#J %D YP!? .0 9 #B &D X !N -X <P#< 'D V@!_ -< A@#4 (X
MT0"6 ,\ H0#, *P R@"[ ,@ T@#& .X Q@#_ ,4 _P#% /\ OP#_ +H _P#_
M    _P   /\   #^  4 ]P . /( %0#N !\ ZP J .D - #C #T W@!% -D
M30#4 %, T0!9 ,X 7@#, &, R@!H ,D ;0#' ', Q0!Y ,, @ #! (@ OP"0
M +T FP"[ *8 N0"T +< R "V .8 M0#[ +0 _P"T /\ LP#_ *X _P#_
M_P   /@   #M    Y0 + -T $0#7 !H T@ D ,\ +@#+ #< QP!  ,, 1P#
M $X O@!3 +P 60"Z %X N !C +8 : "U &T LP!S +$ >0"O ($ K0"* *L
ME "I *  J "M *8 O@"E -L I #T *0 _P"C /\ HP#_ *( _P#_    ]@
M .8   #7    RP & ,0 #@"^ !4 NP ? +D * "W #$ M  Z +  00"M $@
MJP!. *D 4P"G %@ I@!< *0 80"C &< H0!L *  <P"> 'H G0"# )L C@"9
M )D EP"F )8 M@"5 ,P E #K ), _0"3 /\ DP#_ ), _P#W    Y    -
M  #!    MP " *\ "P"K !$ IP 9 *4 (@"C "L H@ S )\ .P"< $( FP!(
M )D 30"7 %( E@!7 )4 6P"3 &$ D@!F )  ;0"/ '0 C0!] (P AP"* ),
MB "@ (< KP"% ,( A0#B (0 ]P"$ /\ A #_ (0 _P#E    S0   +P   "O
M    I@   )X !P":  X E@ 4 )0 '0"2 "4 D0 M )  -0"- #P C !" (H
M1P"( $P AP!1 (8 5@"$ %L @P!@ ($ 9P"  &X ?@!W 'T @0![ (T >@":
M '@ J0!W +H =@#3 '8 [P!V /X =0#_ '4 _P#0    NP   *L   "?
MEP   )   @"+  L B  0 (8 %P"$ "  @@ G ($ +P!_ #4 ?0 \ 'P 00![
M $8 >0!+ '@ 4 !W %4 =@!; '0 80!S &D <0!Q '  >P!N (< ;0"5 &L
MHP!J +0 :@#) &D Z !I /D :0#_ &D _P#     K    )P"  "0 @  B
M (,   !_  8 >P - 'D $@!W !H =@ B '0 *0!S #  <0 V '  / !O $$
M;0!& &P 2P!K %  :@!6 &@ 7 !G &0 90!L &0 =@!C (( 80"0 &  GP!?
M *\ 7@## %X X0!> /0 70#_ %T _P"T!P  H D  ) +  "$"P  ? H  '<'
M  !T!   <0 ) &\ #P!M !4 :P < &D (P!H "H 9P Q &4 -@!D #P 8P!!
M &( 1@!@ $P 7P!2 %X 6 != %\ 6P!H %H <@!8 'X 5P", %8 FP!5 *L
M5 "^ %0 V@!3 .\ 5 #[ %0 _P"I#0  E@X  (<0  !Z$   <A   &P.  !I
M#   9PD# &8$"P!D !  8@ 7 &  '@!> "4 70 K %P ,0!: #< 60 \ %@
M0@!7 4< 5@%. %4"5 !3 EP 4@-E %$#;P!/!'L 3@2* $T%F0!,!:D 2P6\
M $H&U !*!^T 2@?Y $H'_P"A$   CA(  'X4  !S%   :A0  &03  !@$0
M7@\  %T-!0!="0T 6@82 %@'&0!6!R  50<G %,'+0!2"#, 40@X % (/@!/
M"40 3@E* $P)40!+"ED 2@IB $@+;0!'"WH 1@R( $0,F !##*D 0@V\ $(-
MU0!"#>X 0@W[ $(-_P":%   AQ8  '@8  !L&0  8QD  %T8  !9%@  5A,
M %01  !4#@@ 4PT. %$-% !/#1L 30TB $P-* !+#2X 2@TT $D-.@!'#D$
M1@Y' $4.3P!$#E< 0@]A $$0;  _$'D /A"( #T1F  [$:D .Q&\ #H1U@ Z
M$?  .A+] #L1_P"3&   @1H  ',<  !G'0  7AT  %@<  !3&P  4!@  $X6
M  !,$P, 3!$+ $H0$ !($1< 1A$> $41) !$$2H 0A$P $$1-P! $CT /Q)$
M #T23  \$U0 .Q-> #D4:0 X%'8 -Q6% #85E@ T%J< -!:Z #,6TP S%NX
M-!;\ #06_P".&P  ?!T  &X?  !C(   6B   %,@  !.'@  2AT  $@:  !&
M&   118' $,5#@!!%1, /Q4: #X5(  ]%2< .Q4M #H6,P Y%CH .!9! #<7
M20 U%U$ -!A; #,99@ R&7, ,!J# "\:E  N&Z4 +1NX "T;T  M&^P +AO[
M "X;_P"*'@  >"   &HB  !?(P  5B,  $\B  !*(0  1B   $,>  !!&P
M/QH# #T:#  [&1$ .1D6 #<:'0 V&B, -1HI #0:,  S&S8 ,1L^ # <1@ O
M'$\ +AU9 "T=9  L'G$ *Q^! "H?D@ I'Z0 *""W "<@S@ G(.L *"#Z "D?
M_P"&(   =",  &<D  !<)0  4R4  $PE  !')   0B,  #\A   ]'P  .AX
M #<>"0 U'@X ,QX3 #$>&@ P'B  +QXF "X?+0 M'S, +" [ "L@0P J(4P
M*2%6 "@B8@ F(F\ )2-_ "0CD  C(Z( (B2U "(DS  B).D (R3Y "0C_P""
M(P  <24  &,F  !9)P  4"@  $DG  !#)P  /R8  #LD   X(@  -2(  #(B
M!@ P(@T +B(1 "PB%P J(AT *2(C "@C*@ G(S$ )B0X "4E00 D)4H (R94
M "(F8  A)VT ("=] !\GCP >**$ 'BBT !THR@ =*.@ 'BCX !\G_P!^)0
M;B<  & I  !6*0  32H  $8J  !!*0  /"@  #<G   T)@  ,"8  "TF P K
M)PL *"<0 "<G%  E)QH )"<A ",H)P B*"X (2DV " I/@ ?*D@ 'BI2 !TK
M7@ <*VL &RM[ !HLC0 9+)\ &"RR !@LR0 8+.< &2OW !HK_P!Z)P  :BH
M %TK  !3+   2BP  $,L   ^*P  .2L  #0J   P*@  *RH  "DK   F*P@
M(RP. "(L$@ @+!@ 'RP> !XM)0 =+2P '"TS !LN/  :+D4 &2]0 !@O7  7
M+VD %C!Y !4PBP 4,)X %#"Q !,PQP 3,.4 %##V !4O_P!V*@  9RP  %HM
M  !0+@  2"X  $$N   [+@  -BT  #$M   L+0  )R\  "0O   A, 4 'S$,
M !PQ$  ;,A4 &C(< !DR(@ 8,BD %S,Q !8S.0 5,T, %#1- !,T60 2-&<
M$35W !$UB0 0-9P $#6P  XUQ@ /-.0 $#3U ! T_P!R+   8RX  %<P  !-
M,   13   #XP   X,   ,S   "\P   I,0  )#(  "$S   =-0( &C8) !<W
M#@ 5-Q, %#@9 !,X'P 2."8 $C@N !$Y-@ 0.4  $#E+  XY5P ..F0 #3IT
M  PZA@ ,.ID "SFL  HYP0 *.=X "SGQ  PX_ !N+P  7S$  %,R  !*,P
M0C,  #LS   V,P  ,3(  "PS   G-   (38  !TX   9.0  %3L& !(]#  0
M/A  $#X5  X^'  ./B, #3XJ  P^,P ,/CP "S]'  H_4@ (/V  !S]O  8_
M@0 %/Y0 !#^H  ,^O  $/M< !3[L  4^]P!I,P  6S0  % U  !'-0  /S4
M #DU   T-0  +C4  "DW   C.   'CL  !H\   6/P  $D$$  Y#"@ ,1 X
M"D03  E$&0 (1"  !T0G  9$+P %1#@  T5"  )%3@  15L  $5J  !%?
M19   $2D  !$N0  1-$  $3J  !#]0!D-@  5S<  $PX  !#.   /#@  #<X
M   Q.   *SD  "4[   @/0  &D   !9"   21   #D<$  M)"0 '2@T !$L1
M  %+%@  2QP  $LC  !+*P  2S0  $L^  !,20  3%<  $QF  !,=P  2XP
M $NA  !+M0  2LX  $KI  !*]0!?.@  4CL  $@[  ! .P  .CL  #0[   N
M/   )SX  ")!   <0P  %D8  !))   .2P  "TX#  =0"  "40P  %$0  !2
M$P  4Q@  %,?  !3)@  4R\  %,Y  !310  4U(  %-A  !3<@  4X<  %*<
M  !2L0  4<H  %'G  !1] !9/@  3CX  $4^   ^/@  .#X  #!    I0@
M(T0  !U'   72@  $DT   Y0   +4P  !E4"  !7!P  6 L  %D.  !:$0
M6A4  %L:  !<(0  7"H  %PT  !</P  7$T  %Q;  !<;   7($  %N7  !;
MK0  6L4  %KD  !9\P!40@  2D(  $)"   \0@  -$,  "Q&   E20  'DP
M !=/   24P  #E8   I9   %6P   %X   !@!   80@  &(,  !C#@  9!$
M &46  !F'   9R,  &<M  !G.0  9T8  &=5  !G9@  9WH  &:1  !EJ
M9<   &3>  !D\ !/1@  1T8  $!%   W1P  +TH  "9-   ?40  &%4  !)9
M   -7   "&    )C    9@   &@   !J    :P0  &P(  !M#   ;PX  ' 2
M  !R%P  <QT  '0F  !T,@  =#\  '1.  !S7P  ='(  '.*  !RH0  <;@
M ''4  !P[ !,2@  14H  #M+   R3@  *5(  "!6   86P  $E\   UD   '
M:    &L   !O    <@   '4   !V    =P   'D"  !Z!@  ? H  'X.  "
M$0  @A8  (0>  "$*0  A#8  (1%  "$5@  @VH  (.!  ""F0  @;$  (#)
M  " Y0!*3@  /U   #53   K5P  (EP  !EB   29P  #&P   5Q    =0
M 'D   !]    @0   (,   "%    A@   (@   ")    BP0  (T(  "/#0
MDA   )06  "6(   EBP  )8[  "63   E6   )5V  "4D   DZ<  )*]  "2
MU0!$50  .5D  "]=   D8P  &FD  !)O   ,=0  !'L   "     A0   (D
M  "-    D0   ),   "4    E@   )@   ":    G    )X   "@!@  H@L
M *40  "H%P  J2,  *DQ  "I0P  J58  *AM  "FAP  IYX  *:S  "EQP ^
M7@  ,F,  "=J   =<   $W@   Q_   #A0   (L   "1    E@   )L   "?
M    H@   *0   "E    IP   *D   "K    K0   +    "R    M0(  +<)
M  "[$   OA@  +XF  "^.   ODL  +UA  "\>@  NY0  +JI  "ZN0 W:@
M*W   "!X   6@   #8@   6/    E@   )P   "B    IP   *P   "P
MLP   +8   "W    N0   +L   "]    OP   ,(   #%    R    ,H   #.
M"   TA   -4;  #5+   U$   -17  #3;@  U(8  -2;  #3JP#_    _P
M /\   #_  4 _P . /\ %0#\ "  ^0 J /8 - #Q #T [0!& .D 30#F %,
MY !9 .$ 7@#> &, W !H -D ;@#5 ', TP!Y -  @ #. (@ RP"1 ,D G #&
M *< Q "W ,( S #  .P OP#_ +X _P"] /\ MP#_ +( _P#_    _P   /\
M  #Z  $ \P + .T $@#H !L Y0 E .0 +@#? #@ V !  -( 1P#. $X RP!4
M ,@ 60#& %X Q !C ,( 9P#  &T OP!S +T >@"[ ($ N0"+ +8 E0"T *$
ML@"O +  P@"N ., K@#Z *P _P"M /\ J0#_ *8 _P#_    _P   /(   #F
M    W0 ' -( #@#- !8 R@ @ ,@ *0#% #( P  Z +P 0@"Y $@ MP!. +4
M4P"S %@ L0!= +  8@"N &< K !L *H <P"I 'L IP"$ *4 C@"C )H H0"H
M )\ N0"> -( G0#R )P _P"= /\ G #_ )D _P#\    [@   -T   #,
MP0 " +H # "V !( L@ : +  (P"O "P K0 T *D / "F $( I !( *( 30"@
M %( G@!7 )T 6P"< &  F@!F )D ; "7 '0 E0!] ), AP"1 ), D "A (X
ML0"- ,8 C #H (L _0", /\ C #_ (P _P#M    V    ,4   "W    K
M *8 " "A  X GP 5 )T '@"; "8 F@ N )< -0"5 #P DP!" )$ 1P"0 $P
MC@!1 (T 50"+ %H B@!@ (D 9@"' &T A0!V (0 @ "" (P @ ": '\ J0!]
M +P ? #< 'P ]0!\ /\ ? #_ 'P _P#9    P0   +$   "D    G    )0
M P"0  P C0 1 (L & ") "  B0 H (< +P"% #8 @P \ (( 00"  $8 ?P!+
M 'T 3P!\ %0 >P!: 'D 8 !X &< =@!P '4 >@!S (8 <0"3 '  H@!O +0
M;@#, &X [0!N /X ;@#_ &X _P#$    KP   *    "4    C    (8   "!
M  @ ?@ . 'P % ![ !L >0 B '@ *0!W #  =0 V '0 .P!R $  <0!% '
M2@!O $\ ;0!4 &P 6P!K &( :0!J &@ = !F (  90". &, G0!B *T 80#"
M &$ Y !A /@ 80#_ &$ _P"T    H    )$   "&    ?@   'D   !U  ,
M<0 + &\ $ !M !8 ;  = &L ) !K "H :0 P &@ -@!F #L 90!  &0 10!C
M $H 80!/ &  5@!? %T 70!E %P ;P!: 'H 60"( %@ F !7 *@ 5@"[ %8
MV !6 /$ 5@#_ %8 _P"H 0  E 4  (4'  !Z!P  <@8  &P$  !I 0  9P '
M &0 #0!C !$ 80 8 &  'P!? "4 7@ K %T , !; #8 6@ [ %D 0 !8 $4
M5P!+ %8 40!5 %@ 4P!A %( :@!0 '8 3P"$ $X DP!- *0 3 "V $P S0!,
M .L 3 #Z $P _P"="0  BPL  'P-  !P#0  : T  &(,  !?"@  708! %P!
M"0!:  X 6  3 %< &0!6 "  50 F %, *P!2 #$ 40 V %  .P!/ $$ 3@!'
M $T 30!+ %4 2@!= $D 9P!' ', 1@"  $4 D !$ *$ 0P"R $, R !# .8
M0P#U $, _P"5#0  @P\  '00  !I$0  8!$  %H0  !6#@  5 T  %,*! !3
M!@L 40,0 $\!%0!. 1L 3 $A $L!)P!* BP 20(R $@"-P!' ST 10-# $0#
M2@!#!%$ 0@1: $ %9  _!7  /@9^ #T&C@ \!Y\ .P>Q #H'Q@ Z!^, .@?S
M #H(_ ".$   ?!(  &X4  !B%0  6A4  %04  !0$P  31$  $L.  !+#08
M2@H, $D($0!'"!8 10@= $0((P!"""@ 00DN $ ),P _"3D /@I  #T*1P \
M"D\ .@M8 #D+8P X#&\ -@Q^ #4,C@ T#9\ ,PVQ #(-QP R#>, ,@WT #(-
M_@"($P  =Q4  &D7  !>&   51@  $\8  !*%@  1Q4  $43  !#$ ( 0PX(
M $(-#@! #1( /PT8 #T-'P \#20 .PTJ #D-,  X#C< -PX] #8.10 U#DT
M,P]7 #(/8@ Q$&X +Q!] "X0C@ M$:  +!&R "L1R  K$>8 *Q'V "P1_P"#
M%@  <AD  &0:  !9&P  41L  $L;  !&&@  0A@  #\7   ^%   /!($ #L1
M"@ Z$!  .! 5 #<0&P U$2$ -!$G #,1+0 R$3, ,!$Z "\20@ N$DL +1-4
M "L37P J%&P *11[ "@4C  G%9X )A6P "45Q@ E%>0 )17V "85_P!^&0
M;AL  & =  !6'@  31X  $<>  !"'0  /AP  #H:   X&   -Q8  #45!P T
M% T ,A02 # 4%P O%!T +10C "P5*@ K%3  *A4W "D6/P H%D@ )Q=2 "88
M70 D&&H (QEY "(9B@ A&9P (!FO !\9Q  ?&>( (!GT " 9_P!Z&P  :AX
M %T?  !3(   2B   $0@   ^'P  .AX  #<=   T'   ,AD  # 9!  N& L
M+!@0 "H8%  I&!H )Q@@ "89)@ E&2T )!HU ",:/0 B&T8 (1M0 " <6P ?
M'6@ 'AUW !T=B  <'IL &QZM !H>PP :'N  &AWS !L=_P!W'0  9R   %HA
M  !0(@  2"(  $$B   [(@  -R$  #,@   P'P  +1T  "L=   H'0@ )AT.
M "4=$@ C'1< (1T= "$=)  @'BH 'QXR !X?.@ ='T, '"!- !LA60 :(68
M&2%U !@BAP 7(ID %B*L !4BP0 5(M\ %2'R !8A_@!S(   9"(  %<C  !-
M)   124  #XD   Y)   -",  # B   L(@  *2$  "8A   D(08 (B$, " A
M$  >(14 '2(; !LB(0 ;(B@ &B,O !DC.  8)$$ %R1+ !8E5P 5)60 %"9S
M !,FA0 2)I@ $2:K !$FP  0)MT $27Q !(E_0!P(@  820  %0F  !*)@
M0B<  #PF   V)@  ,24  "TE   I)   )B0  "(E   ?)0, '28* !LF#@ 9
M)Q( &"<8 !<G'P 6)R4 %2@M !0H-0 3*3X $BE) !$I50 1*F( $"IQ  \J
M@P .*I8 #BJI  TJO0 -*M< #2KN  XI^P!L)   728  %$H  !(*   0"D
M #DH   T*   +R@  "LG   G)P  (B@  !XI   ;*@  &"L' !8K#0 4+!$
M$RP6 !(L'  1+2, $"TJ ! M,@ /+CP #BY&  TN4@ -+E\ #"]N  LO?P *
M+Y( "2^E  DNN0 (+M  "2[I  HN]P!H)P  6BD  $XJ  !%*P  /2L  #<K
M   Q*@  +2H  "DJ   D*@  ("L  !LM   8+@  %2\$ !(Q"@ 0,@X #S(3
M  XR&0 -,B  #3(G  PR+P +,S@ "C-"  DS3@ (,UL !C1J  4T>P $,XX
M S.B  (SM@ ",\T  S/G  0R\P!D*@  5BP  $LM  !"+0  .BT  #0M   O
M+   *RP  "8L   B+0  '2\  !DQ   5,@  $C0#  \V"0 ,. T "C@1  DX
M%@ (.!T !S@D  8X+  $.#0  S@^  (Y2@  .5<  #EE   Y=P  .8L  #B?
M   XLP  .,H  #CF   W\@!?+0  4BX  $@O   _,   ."\  #(O   M+P
M*2\  "0P   ?,0  &C,  !4U   2-P  #SD#  P["  (/0T !3X0  ,^%
M/AH  #XA   ^*   /C$  #\[   _1@  /U,  #]A   _<P  /X<  #Z<   ^
ML   /<<  #WD   ]\@!:,   3C(  $0R   \,@  -3(  # Q   K,0  )C(
M " T   ;-@  %C@  !([   //0  ##\#  A!"  $0PP  $,.  !$$@  118
M $4=  !%)   12T  $8V  !&0@  1DX  $9=  !&;@  18(  $68  !$K0
M1,0  $/C  !#\@!5-   2C4  $$U   Y-0  ,S0  "XT   H-0  (C<  !TZ
M   7/   $C\   ]!   ,1   "$8!  -(!@  20H  $H-  !+$   3!0  $T9
M  !.(   3B@  $XR  !-/0  3DH  $Y8  !-:0  37T  $R4  !,J@  2\$
M $OA  !*\@!0.   1C@  #TX   W.   ,3<  "HY   D.P  'CT  !A    3
M0P  #T8   M)   '2P   DX   !0!   40@  %(+  !3#@  5!$  %45  !6
M&P  5R,  %<L  !7.   5T0  %=2  !68P  5G<  %:.  !5I0  5+T  %/=
M  !3\ !+/   0CP  #L[   U.P  +3P  "8_   ?0@  &44  !-(   .2P
M"T\   51    5    %<   !8 0  6@4  %L(  !<#   70X  %\1  !@%@
M8AT  &(F  !B,0  8CX  &%,  !A70  87   &"(  !@H   7[<  %[4  !=
M[@!'0   /S\  #H_   Q0   *4,  "%&   :2@  $TX   Y1   *50  !%@
M  !;    7@   &$   !C    9 $  &4$  !G"   : L  &H.  !L$@  ;A<
M &\@  !O*@  ;S8  &Y%  !N50  ;F@  &U_  !MF   ;+   &O*  !JZ !$
M1   /D,  #5$   K1P  (TL  !M/   35   #E@   A<   "8    &0   !G
M    :P   &T   !O    <    '(   !T @  =08  '<*  !Y#@  ?!(  'X8
M  !_(@  ?RX  '\]  !^30  ?6$  'UW  !\D   >Z@  'K   !YWP!#1P
M.4D  "],   E4   '%4  !1;   .8   !V4   !J    ;@   '(   !V
M>0   'P   !^    ?P   ($   "#    A0   (<#  "*"   C T  (\1  "2
M&0  DB4  )(S  "21   D5<  )!M  "/A@  CI\  (VU  ",S0 ]3@  ,E$
M "A6   >7   %6(   YH   ';@   '0   !Y    ?@   ((   "&    B0
M (P   ".    D    )(   "4    E@   )@   ";    G@8  *$,  "D$0
MIAL  *8I  "F.@  I4T  *5B  "D>P  HY0  *&K  "AOP V5P  +%P  "%B
M   7:0  #W    =W    ?@   (0   "*    CP   )0   "8    FP   )X
M  "?    H@   *0   "F    J    *L   "M    L    +,$  "W#   NQ(
M +L?  "[,   NT,  +I8  "Y<   MXL  +>A  "WLP P8@  )6D  !IP   0
M>   "8    "(    CP   )8   ";    H0   *8   "J    K@   +    "Q
M    M    +8   "X    NP   +T   #     PP   ,<   #+ P  SPP  -,5
M  #2)0  TC@  -%.  #090  SWX  ,V6  #,J0#_    _P   /\   #_  ,
M_P + /P $0#Y !L ]P E /, +P#N #@ Z0!  .8 2 #B $X WP!4 -P 60#9
M %X U0!C -, : #0 &T S@!S ,L >@#( (( Q@", ,, EP#  *, O@"R +P
MR "Z .H N0#_ +@ _P"Q /\ J@#_ *< _P#_    _P   /L   #V    [0 '
M .< #P#B !8 WP @ -X *0#9 #, T0 [ ,P 0@#( $@ Q0!. ,( 4P#  %@
MO@!= +P 8@"Z &< N0!M +< = "U 'L L@"% +  D "N )P K "J *D O0"G
M -X I@#Y *4 _P"C /\ G0#_ )L _P#]    ]@   .L   #?    T0 # ,H
M# #% !( PP ; ,  ) "^ "P N0 U +8 / "S $, L !( *X 3@"L %( JP!7
M *D 7 "G &$ I@!G *0 ;0"B '0 H !] )X B "< )4 F@"C )@ M "6 ,T
ME0#Q )0 _P"5 /\ D #_ (X _P#S    Y@   -$   #"    N    +$ " "M
M  \ J@ 6 *@ '@"H "< I@ O *( -@"? #P G0!" )L 1P"9 $P EP!1 )8
M50"4 %H DP!@ )$ 9@"0 &X C@!V (P @0"* (T B "; (8 K "% ,$ A #F
M (, _0"$ /\ @P#_ ($ _P#D    RP   +H   "L    H@   )P ! "8  P
ME@ 1 )0 &0"3 "$ D@ H (\ , "- #8 BP \ (D 00"( $8 A@!+ (4 3P"$
M %0 @@!: ($ 8 !_ &< ?@!O 'P >@!Z (8 > "4 '< I !U +< = #4 ',
M] !T /\ = #_ '0 _P#+    M@   *8   ":    D@   (H   "&  @ @P .
M ($ % "! !L @  C '\ *@!] #  >P V 'H .P!X $  =P!% '4 20!T $X
M<P!4 '$ 6@!P &$ ;@!I &T <P!K '\ :0"- &@ G0!G *X 9@#' &4 Z@!F
M /\ 9@#_ &< _P"X    I    )4   "*    @0   'P   !V  0 =  , '(
M$ !Q !8 <  = '  ) !N "H ;0 P &L -0!J #H :0 _ &@ 1 !G $D 90!.
M &0 5 !C %L 80!C &  ;0!> 'D 70"' %L E@!: *@ 60"] %D WP!9 /@
M6@#_ %H _P"H    E0   (<   ![    <P   &X   !J  $ 9P ( &4 #@!D
M !( 8P 8 &, 'P!B "4 80 J %\ , !> #4 70 Z %P /@!; $0 60!) %@
M3P!7 %8 5@!> %0 : !3 ', 40"! %  D0!/ *( 3@"U $X T !. /  3@#_
M $\ _P"<    B0   'L#  !P P  : ,  &(!  !?    70 $ %L "P!9  \
M6  4 %< &0!7 "  5@ E %4 *@!3 #  4@ T %$ .0!0 #\ 3P!$ $X 2P!-
M %( 2P!: $H 8P!) &\ 1P!\ $8 C !% )T 10"P $0 QP!$ .@ 1 #Z $4
M_P"2!   @ <  '$*  !F"@  7@H  %D)  !5!P  5 0  %( !P!0  P 3P 0
M $X %0!- !L 3  @ $L )@!* "L 20 P $@ -0!' #H 1@!  $4 1@!# $X
M0@!6 $$ 7P!  &L /@!X #T B  \ )D / "K #P P0 [ .  .P#T #L _P")
M"@  > P  &H.  !?#@  5PX  %$.  !-#   2PL  $H( @!)! D 2  - $8
M$0!% !8 1  < $, (0!" "8 00 K #\ ,0 ^ #8 /0 \ #P 0P [ $H .@!2
M #D 7  X &@ -@!U #4 A0 T )8 - "H #, O  S -@ ,P#O #, ^P""#0
M<0\  &00  !9$0  41$  $L1  !'$   1 X  $(-  !!"P4 00<+ #\%#@ ^
M Q( / (8 #L"'0 Z R( .0,H #@#+0 W S( -@0Y #4$/P T!4< ,P50 #$&
M6@ P!F8 +P=S "X'@P M!Y4 + >G "L'N@ K!]( *P?K "L']P!]$   ;!$
M %\3  !4%   3!0  $84  !"$P  /A(  #P0   Z#@$ .@T& #H*#  X"1
M-@@4 #4(&0 T"1\ ,@DD #$)*0 P"2\ +PHV "X*/0 M"D4 + M. "L+60 I
M#&4 * QS "<,@P F#94 )0VG "0-NP C#=( (PWK ",-]P!X$@  :!0  %L6
M  !1%P  2!<  $(6   ]%@  .14  #<3   U$0  ,Q # #,."  R#0T , T1
M "\-%@ M#1L + TA "L-)P J#2T *0XT "@..P G#D0 )0Y. "0/60 C$&4
M(1!S " 0A  ?$)8 'A"I !T0O0 <$-@ '1#N !T0^0!S%   9!8  %<8  !-
M&0  11D  #\9   Z&   -1<  #(6   P%0  +A,  "T1!  L$ H *Q . "D0
M$@ H$!@ )A > "40)  D$"H (Q$Q "(1.0 A$4( (!)+ !X25@ =$V, '!-Q
M !H3@@ 9%)4 &!2G !<4NP 7$]0 %Q/N !@3^@!P%@  8!D  %0:  !*&P
M0AP  #P;   V&P  ,AH  "\9   L&   *A8  "@4 0 F$P< )1,, ",3$  B
M$Q4 (!,: !\3(0 >%"< '10N !P5-@ ;%3\ &A9) !D65  8%V$ %A=P !48
M@0 4&), $QBF !(8N@ 2%]( $A?L !,7^@!L&0  71L  %$=  !''0  /QX
M #D=   T'0  +QP  "L;   H&@  )AD  "08   B%P0 (!<* !X7#@ <%Q(
M&A<7 !D8'@ 9&"0 &!DL !<9-  6&CT %1I' !0;4@ 3&U\ $AQN !$<?P 0
M')( $!RE  \<N0 .'-  #AOJ  \;^ !I&P  6AT  $X?  !%'P  /2   #8?
M   Q'P  +1X  "D=   E'0  (QP  " ;   =&P$ &QL' !D<#0 7'!  %AP5
M !4<&P 4'2( $QTI !(>,0 1'CH $1]% ! ?4  /(%T #B!L  T@?  -((\
M#""B  L@M0 +(,H "R#E  P?] !E'0  5Q\  $PA  !"(0  .B$  #0A   O
M(0  *B   "8?   C'P  (!X  !T>   9(   %B $ !0@"P 2(0X $2$3 !$B
M&0 0(A\ #R(F  XC+P .(S< #2-!  PD30 +)%D "B1G  DD>  ()(L !R2>
M  <DL0 &),< !B/C  <C\0!B'P  5"$  $DC  ! (P  .",  #(C   L(P
M*"(  "0A   A(0  'B$  !HA   6(P  $R0# !$E"  /)@T #B<1  TG%@ ,
M)QT "R<C  HG*P )*#0 ""@^  <H20 &*%4 !2ED  0I=  #*8<  BF;  $H
MKP  *,4  2CA  $G\ !>(@  420  $8E   ])0  -24  "\E   J)   )B0
M "(C   ?(P  &R0  !@E   4)@  $2@#  \I"  ,+ P "BP0  @L%  '+!H
M!BPA  4L*  #+3   BTZ  $M10  +5(  "Y@   N<0  +80  "V9   MK0
M+,(  "S@   L\ !:)   328  $,G   Z)P  ,R<  "TG   H)@  )"8  "$F
M   =)@  &2<  !4I   1*P  #RP#  TN!P ), P !C$.  ,Q$@ !,A<  #(>
M   R)0  ,BT  #(V   S0@  ,TX  #-=   S;0  ,X$  #*6   RJP  ,<$
M #'?   Q\ !6)P  2BD  #\J   W*@  ,"H  "LI   G*   (R@  !XI   :
M*@  %BP  !(N   /,   #3$"  HT!P %-0L  C8.   W$   .!0  #@:   X
M(@  ."H  #DS   Y/@  .4H  #E9   Y:0  .7T  #B3   XJ   -[\  #?>
M   V\ !1*P  1BP  #PL   T+   +BP  "HK   E*P  ("P  !LM   7+P
M$S$  ! S   --0  "3<"  4Z!@ !.PH  #P-   ]#P  /A(  #\7  ! '@
M0"4  $ O  ! .@  0$8  $!4  ! 90  /W@  #^/   ^I@  /KT  #W<   ]
M\ !-+@  0B\  #DO   R+P  +2X  "@N   B+P  '3   !@R   3-0  $#<
M  PZ   )/   !3X   !!!   0@@  $,+  !$#0  1A   $<4  !(&0  2"$
M $@J  !(-0  2$$  $A/  !(8   1W,  $>*  !&H@  1;D  $79  !$\ !(
M,@  /C(  #8R   P,0  *S$  "4R   ?-   &38  !,Y   0/   ##\   A"
M   #1    $8   !( @  2@4  $L(  !,"P  3@X  $\1  !1%0  4AP  %(E
M  !2,   4CP  %%*  !16@  46T  %"$  !/G0  3K4  $W2  !-[@!#-@
M.S8  #0U   O-   )S4  "$X   :.P  %#X  !!!   ,1   !T<   )*
M30   $\   !1    4P(  %0%  !5"   5PL  %D.  !;$0  71<  %T?  !=
M*@  738  %Q$  !<5   6V<  %M^  !:EP  6:\  %C+  !7Z@ _.0  .#D
M #,X   K.0  (SP  !P_   50P  $$<   M*   %3@   %$   !4    5P
M %H   !<    70   %\   !@!   8@<  &0+  !F#@  :!(  &L9  !K(P
M:BX  &H\  !J30  :5\  &AU  !GCP  9J@  &7"  !DXP ]/0  -SP  "X]
M   E0   '40  !9)   030  "E$   15    6@   %T   !@    8P   &8
M  !H    :@   &L   !M    ;P(  '$&  !T"@  =@X  'D3  ![&P  >R<
M 'HU  !Y10  >%D  'AM  !WA@  =I\  '6W  !TT@ \00  ,D(  "A%   @
M2@  %TX  !!4   *60   EX   !C    9P   &L   !O    <@   '4   !W
M    >0   'L   !]    ?P   ((   "$ P  APD  (H.  ".$P  CQX  (XK
M  "..P  C4X  (MC  "*?   BI4  (BM  "'Q0 V1P  +$L  ")/   950
M$%L   IA   !9P   &T   !R    =P   'L   !_    @P   (8   "(
MB@   (T   "/    D0   )0   "7    F@$  )T'  "A#0  I10  *0A  "D
M,0  HT0  *)9  "@<   GXL  )VB  "=MP P4   )54  !M;   28@  "VD
M  %P    =P   'T   "#    B    (T   "1    E0   )@   ":    G
M )\   "A    HP   *8   "I    K    +    "T!P  N X  +H8  "Z)P
MN3D  +A.  "W90  MGX  +66  "SJP I6P  'F(  !1I   ,<0   GD   "!
M    B0   (\   "6    FP   *    "D    J    *L   "L    KP   +(
M  "T    M@   +D   "\    P    ,0   #(    S0<  -(0  #2'0  T2\
M -!$  #/6P  S7,  ,N-  #*H0#_    _P   /L   #Z    _  ( /@ #P#U
M !< ]  @ /$ *@#K #, Y@ [ .( 0P#> $D V@!/ -8 5 #3 %D T !> ,X
M8P#+ &@ R0!N ,8 =0## 'T P0"& +X D@"[ )X N0"N +8 PP"T .@ LP#_
M *\ _P"E /\ G@#_ )L _P#]    ]P   /(   #P    YP # .$ # #< !(
MV  ; -8 ) #2 "T S  V ,8 /0#" $, OP!) +P 3@"Z %, N !8 +8 70"U
M &( LP!G +$ ;@"O '8 K !_ *H B@"H )< I0"F *, N0"A -D H #Y )X
M_P"8 /\ D@#_ (\ _P#S    [    .,   #3    R    ,$ "0"]  \ NP 6
M +D 'P"W "< LP O *\ -P"L #T J@!# *@ 2 "F $T I !2 *, 5@"A %L
MGP!A )X 9P"< &\ F@!X )< @P"5 )  DP"> )$ L "0 ,@ C@#P (T _P"*
M /\ A0#_ (( _P#G    W0   ,8   "X    K@   *@ ! "E  P H0 2 *$
M&0"@ "( GP I )L , "8 #< E@ ] ), 0@"2 $< D !+ (\ 4 "- %4 C !:
M (H 80"( &@ AP!P (4 >P"# (@ @0"6 '\ IP!] +P ? #C 'P _0!\ /\
M> #_ '8 _P#6    P    *\   "C    F0   ),   "/  D C0 . (L % "*
M !P B@ C (@ *@"% #  @P V (( .P"  $  ?P!% 'X 2@!\ $\ >P!4 'H
M6@!X &$ =@!I '4 <P!S (  <0". &\ GP!N +( ;0#/ &P ] !L /\ :P#_
M &D _P#     JP   )L   "/    AP   (    !\  0 >@ , '@ $0!X !<
M>  > '< ) !U "H <P P '$ -0!P #H ;@ _ &T 1 !L $D :P!. &H 5 !H
M %L 9P!C &4 ;0!D '@ 8@"' &  EP!? *H 7@#" %X Z0!> /\ 7@#_ %T
M_P"L    F0   (H   !_    =P   '$   !M    :@ ( &D #@!H !( 9P 8
M &< 'P!G "4 90 J &, +P!B #0 80 Y &  /@!? $, 7@!( %T 3@!; %4
M6@!= %@ 9P!7 '( 50"! %0 D0!3 *, 4@"X %$ W !1 /D 4@#_ %( _P"=
M    BP   'P   !Q    :0   &0   !@    7@ % %P "P!;  \ 6P 4 %H
M&0!: !\ 60 E %< *@!6 "\ 50 T %0 . !3 #T 4@!# %  20!/ %  3@!8
M $T 8@!+ &T 2@!Z $D BP!( )T 1P"Q $< S !& /  1P#_ $< _P"0
M?@   '    !F    7@   %D   !6    4P ! %( " !0  T 3P 0 $\ %0!.
M !H 3@ @ $T )0!, "H 2@ N $D ,P!( #@ 1P ^ $8 1 !% $L 1 !3 $,
M70!! &@ 0 !U #\ A0 ^ )< /0"K #T PP ] .8 /0#[ #X _P"'    =0,
M &@&  !=!P  508  % &  !,!   2@$  $D ! !'  H 1@ . $4 $0!% !8
M1  ; $, ( !" "4 00 J $  +P _ #0 /@ Z #T 0  [ $< .@!/ #D 60 X
M &0 -P!Q #8 @0 U ), - "F #0 NP T -T - #U #4 _P!^!@  ;0D  & +
M  !6#   3@P  $@+  !$"@  0@@  $ % 0 _ 0< /@ + #T #@ \ !( .P 7
M #L '  Z "$ .0 E #< *@ V #  -0 U #0 /  S $, ,@!, #$ 50 P &
M+P!M "X ?0 M (\ + "B "P M@ L -  + #N "P _ !W"@  9PP  %H.  !0
M#@  20X  $,.   ^#0  .PP  #D+   X"0, -P4( #8"#0 U 1  -  3 #,
M&  R !T ,0 B #  )P O "P +@ R "T .  L $  *P!) "H 4@ I %T * !K
M "<!>@ F 8P )0"? "4 L@ E ,H )0#H "4 ]P!R#0  8@X  %80  !,$0
M1!$  #X1   Y$   -@\  #,.   Q#0$ , L% # ("@ O!@T +@41 "P$%  K
M QD *@,> "D#(P H!"D )P0O "8%-0 E!3T ) 5& ",&4  B!EP (0=I " '
M>0 ?!XL '@>= !X'L  =!L8 '0;C !T%\P!M#@  7A$  %(2  !($P  0!,
M #H3   U$@  ,1$  "X0   L#P  *@X# "H-!P I"PL * D. "<)$0 E"!8
M) @; ",)(  B"28 (0DL " *,P ?"CL '@M$ !T+3P <#%L &PQI !H,>0 8
M#(L & R> !<,L  6#,4 %@SA !8+\ !I$   6A(  $X4  !%%0  /14  #<5
M   Q%   +1,  "H2   H$0  )A ! "00!  C#@@ (PT, "(,#P @#!, 'PP8
M !X-'0 =#2, ' TJ !L-,@ :#CH & Y$ !<.4  6#UP %0]J !,0>P 2$(T
M$1"@ !$0LP 0#\D $ _D !$/\@!E$@  5Q0  $L6  !"%P  .A<  #07   O
M%@  *A4  "<4   D$P  (A,  " 2 P >$08 '1 ) !P0#0 ;#Q  &1 5 !@0
M&P 7$"$ %A H !41,  4$3D $Q%# !(23@ 1$EH $!)I ! 3>0 .$XP #A.>
M  T3L0 -$L4 #!+A  T2\0!B%   5!8  $D8   _&0  -QD  #$9   L&
M*!<  "06   A%@  'Q4  !P4 @ :$P0 &1(& !<2"P 5$@X %!(2 !,3&  2
M$Q\ $1,F !$4+0 0%#8 #Q5!  X53  .%E< #19E  P7=0 +%X< "A>:  D6
MK0 (%L$ "!;=  D5[@!?%@  41@  $8:   ]&@  -1L  "\:   J&@  )1D
M "(8   ?&   '!<  !D6 0 7%@, %18$ !,6"0 1%@T $!<1  \7%@ .%QP
M#A@C  T8*@ ,&3, #!D\  L:1P *&E, "1IA  <;<0 &&X, !1N7  0:J@ #
M&K\  QG:  09[ !<&   3AH  $,<   Z'   ,QP  "P<   G'   (QL  " :
M   =&0  &AD  !<8 0 5& ( $AD$ ! ;!P .&PP #1P0  P<$P +'!D "AP?
M  D=)P ('2\ !QXY  8>0P $'E   Q]>  (?;@ !'X   !^5   >J0  'KT
M !W8   =[ !8&@  2QP  $$>   X'@  ,!X  "H>   E'0  (1P  !X<   ;
M&P  &!L  !8; 0 3&P( $1P$  X>!P ,'PL "B .  @@$@ &(1< !2$=  0A
M)  "(BP  2(U   B0   (TT  "-:   C:P  (WX  ".3   BIP  (KP  "'7
M   A[0!5'0  2!\  #X@   U(   +B   "@@   C'P  (!X  !T=   :'0
M%AT  !,>   1'P( #B $  TB!P *) L !B4-  0E$  ")A0  "8:   F(0
M)RD  "<R   G/0  )TD  "A7   H9P  )WL  ">0   GI0  )KL  ";6   E
M[0!1(   12$  #LB   R(@  +"(  "8A   B(0  'B   !L?   8(   %"
M !$B   /(P  #24#  HF!@ &* H  RD-   K#P  +!(  "P7   L'@  +"8
M "TO   M.0  +48  "U4   M9   +7<  "R-   LI   *[H  "O6   J[@!-
M(@  020  #@D   P)   *20  "0C   A(@  '2(  !DB   5(P  $B0   \F
M   -*   "BH"  8L!0 "+@D  "\+   P#@  ,A   #,5   S&P  ,R(  #,K
M   S-@  ,T(  #-0   S8   ,W,  #**   RH0  ,;@  ##6   P[P!))0
M/B8  #0G   M)P  *"8  ",E   ?)   &R4  !8F   2*   $"H   TL   *
M+@  !C !  (R!   - <  #4*   W#   . X  #H2   Z%P  .A\  #HG   Z
M,@  .CX  #I,   Z7   .F\  #F&   XG@  .+8  #?4   V[P!$*0  .BD
M #$I   K*0  )B@  "(G   =*   &"D  !,K   0+@  #3    DR   %-0
M 3<    Y @  .P4  #P(   ^"P  /PT  $$0  !#%   0QL  $,C  !#+@
M0SD  $-'  !"5P  0FH  $&!  ! F@  /[(  #[/   ^[P _+   -BP  "\L
M   J*P  )2H  !\K   9+0  %"\  ! R   --0  "#@   0Z    /    #\
M  !!    0P(  $4%  !&"   2 L  $H.  !,$0  318  $T>  !-*   330
M $Q"  !,40  2V0  $M[  !*E   2:T  $C*  !'[  [,   ,R\  "TO   H
M+0  (B\  !LQ   5-   $#<   TZ   (/0   D    !#    1@   $@   !*
M    3    $X!  !/!   40<  %,+  !5#@  6!(  %D9  !8(@  6"X  %<\
M  !72P  5EX  %9S  !5C0  5*<  %+"  !2Y@ X,P  ,3(  "PQ   E,@
M'34  !8X   1/   #$    =$    1P   $H   !-    4    %,   !5
M5P   %D   !:    7 ,  %X'  !A"P  9 X  &83  !G'   9B<  &8T  !E
M1   9%<  &1K  !BA0  89\  &"Y  !>W  U-P  ,#4  "@W   @.@  &#T
M !%"   ,1@  !DH   !/    4P   %8   !9    7    %\   !A    9
M &4   !G    :0   &P!  !N!@  <0L  '0/  !W%0  =R   '8M  !V/0
M=4\  '1C  !S>P  <I4  '"O  !OR0 U.@  *SL  "(_   :0P  $D@   Q-
M   %4@   %<   !<    8    &0   !H    :P   &X   !Q    <P   '4
M  !W    >@   'P   !_    @@0  (8*  "*#P  C!<  (LD  "*,P  B44
M (=;  "&<@  A8L  (.E  ""O  O0   )40  !Q)   33@  #50   1:
M80   &8   !K    ;P   '0   !Y    ?0   (    "#    A0   (<   "*
M    C    (\   "2    E@   )D"  ">"0  HA   *(:  "A*0  H#L  )]0
M  "=9P  FH$  )J9  "9KP I20  'TX  !54   .6P  !6(   !I    <
M '<   !]    @@   (8   "+    CP   ),   "5    EP   )H   "=
MH    *,   "F    J@   *X   "R    MPH  +L1  "Z'P  N3   +=%  "U
M7   M'0  +&.  "OI  B5   &%L  !!B   ':@   ',   ![    @@   (D
M  "0    E0   )H   "?    HP   *8   "H    JP   *X   "P    LP
M +8   "Z    O0   ,(   #'    S $  -,+  #4%0  TR8  -$Z  #040
MS6@  ,N!  #*E@#\    ]@   /(   #Q    \P % /0 # #R !, \  < .T
M)0#H "X X@ V -X /@#9 $0 U !* -$ 3P#. %0 RP!9 ,D 7@#& &, Q !I
M ,$ < "^ '@ O "! +D C0"V )H LP"K +$ P "O .8 K@#_ *4 _P": /\
ME #_ (\ _P#T    [    .@   #G    WP   -D "0#2 !  SP 7 ,\ ( #,
M "@ Q@ P ,  -P"\ #X N0!$ +< 20"U $X LP!3 +$ 5P"O %T K0!B *L
M:0"I '$ IP!Z *4 A0"B ), H "B )T M@"; -0 F0#Y )8 _P"- /\ B #_
M (0 _P#H    WP   -D   #)    OP   +@ ! "U  T LP 2 +$ &@"P "(
MK0 J *D ,0"F #@ I  ] *( 0P"@ $@ G@!, )P 40"; %8 F0!< )< 8@"5
M &D DP!R )$ ?0"/ (L C0": (L K ") ,4 B #N (8 _P!_ /\ >@#_ '@
M_P#9    S0   +L   "N    I0   )\   "<  D F0 / )D %0"9 !T F  D
M )0 *P"1 #$ C@ W (P / "+ $$ B0!& (@ 2P"& %  A0!5 (, 6P"" &(
M@ !K 'X =0!\ (( >@"2 '@ HP!W +D =@#@ '4 _P!R /\ ;@#_ &P _P#'
M    M0   *4   "9    CP   (D   "%  0 A  , (( $0"" !< @@ > (
M)0!^ "L ?  Q 'H -@!Y #L =P!  '8 1 !U $D <P!/ '( 50!P %P ;P!D
M &T ;@!L 'H :@"* &@ FP!G *\ 9@#, &4 ]0!D /\ 80#_ &  _P"T
MH    )    "%    ?0   '<   !S    <  ( &\ #@!O !( ;P 8 &\ 'P!M
M "4 :P J &D , !H #0 9P Y &8 /@!E $, 8P!( &( 3@!A %4 7P!> %X
M9P!< ', 6P"" %D DP!8 *8 5P"_ %< Z@!7 /\ 5@#_ %0 _P"A    C@
M '\   !U    ;    &@   !D    80 $ &  "P!?  \ 7P 3 %\ &0!? !\
M70 E %P *@!; "\ 60 S %@ . !7 #T 5@!# %4 20!3 %  4@!8 %$ 80!0
M &T 3@![ $T C !, )\ 2P"U $H W !* /H 2@#_ $H _P"2    @    '(
M  !G    7P   %H   !7    50 ! %, !P!2  P 4@ 0 %( % !2 !H 40 ?
M $\ ) !. "D 30 N $P ,P!+ #@ 2@ ] $D 0P!( $H 1@!2 $4 7 !$ &<
M0P!U $( A@!! )@ 0 "N $  RP _ /( 0 #_ $  _P"%    =    &<   !=
M    50   $\   !,    2@   $@ ! !'  H 1P - $8 $0!& !4 1@ : $4
M'P!$ "0 0P I $( +0!! #, /P X #X /@ ] $4 / !. #L 5P Z &( .0!O
M #@ @  W ), -@"G #8 P  V .@ -@#^ #8 _P!\    :P   %X"  !4 P
M30,  $<#  !# 0  00   #\  0 ^  < /0 + #T #@ \ !$ /  6 #P &@ Z
M !\ .0 D #@ *0 W "X -@ S #4 .@ T $$ ,P!) #( 4P Q %X , !K "\
M>P N (X +0"B "T N  M -T +0#X "X _P!S 0  9 4  %<'  !-"   1@@
M $ (   [!P  . 4  #<#   V  0 -0 ( #0 #  T  \ -  2 #, %@ R !L
M,0 @ #  )  O "D +@ O "T -@ L #T *P!% "H 3P I %H * !G "< =P F
M (D )@"= "4 LP E ,\ )0#P "8 _P!M!@  7@D  %(+  !(#   0 P  #H+
M   V"P  ,@H  # (   N!@( +@,& "T "@ L  T +  0 "L $P J !< *0 <
M "@ (  G "4 )@ K "4 ,@ D #D (P!" "( 2P B %< (0!D "  <P ? (4
M'P"9 !X K@ > ,< '@#I !\ ^@!H"0  60P  $T-  !##@  / X  #8.   Q
M#0  +0T  "H,   H"P  )PD$ "8&"  F! L )0,. "0!$  D 10 (@$8 "$!
M'0 A "( (  H !\ +@ > 38 '0$_ !P!20 ; 50 &@%A !H!<  9 8( & "6
M !@ J@ 8 ,$ & #A !@ ] !C#   50X  $D/  ! $   .!   #(0   M#P
M*0X  "8.   C#0  (@P# " +!@ @"0D 'P<, !X&#@ >!1$ ' 45 !L%&@ :
M!1\ &@4E !D%*P 8!3, %P8\ !8&1@ 6!E( %0=? !0';@ 3!X  $@>4 !(&
MIP 2!;P $@39 !(#[P!?#@  40\  $80   \$0  -1$  "\1   J$0  )A
M "(0   @#P  '0X" !P-!0 :#0< &@L* !D*#0 8"1  %PD2 !8)%P 5"1P
M% DB !0**0 3"C$ $@HZ !(+10 1"U$ $ Q?  \,;@ .#(  #@R4  T+IP -
M"[H #0K2  T*Z@!<#P  3A$  $,2   Z$P  ,A,  "P3   G$@  (Q$  !\1
M   <$   &A " !@/!  6#@< %0X) !0-"P 3# T $@P0 !(,%  1#!H $0T@
M ! -*  /#3  #@X[  T.1@ -#E$ # ]>  L/;0 *#W\ "0^3  D/I@ (#KD
M" [0  <.Z !8$0  2Q(  $ 3   W%   ,!0  "D4   E%   (1,  !T2   :
M$@  %Q$" !41!0 3$ < $A ) !$/"@ 0#@P #@X.  X/$@ -$!@ #1 >  P0
M)0 ,$"T "Q$V  H100 )$4T "!):  <2:@ &$GP !1*0  02I  #$;@  Q'/
M  (1Z !5$@  210  #X5   U%@  +18  "<6   B%0  'A0  !L4   8$P
M%1(# !,2!0 2$0< $!$)  \1"@ -$0L #!(.  L2$0 *$A4 "1,;  D3(@ (
M$RH !Q0S  44/@ $%4H  Q58  (59P !%7H  !6.   5HP  %+<  !3/   3
MZ0!2%   1A8  #L7   R%P  *Q<  "47   A%@  '!8  !D5   6% $ %!,$
M !(3!@ 1$@@ #Q((  X3"0 ,% H "A4-  @6$  &%A, !189  07'P #%R<
M A@P  $8.P  &4<  !E5   99   &7<  !F,   8H@  &+<  !?/   7Z@!/
M%@  0Q@  #D9   P&0  *1D  ",9   ?&   &Q<  !@6   5%0( $Q4% !$4
M!@ 0% 8 #A4'  P6"  *%PH !QD,  0:#@ "&Q(  1L6   ;'0  '"0  !PM
M   <.   '40  !U2   =8@  '74  !V*   <H   '+8  !O0   :ZP!,&
M0!H  #8;   M&P  )AL  "$:   =&0  &1D  !<8   4%P, $A8$ ! 7!  .
M%P0 #!D%  H:!P '' D  QT+   ?#0  (!   " 4   A&@  (2(  "$J   A
M-0  (D$  ")/   B7P  (G(  "&(   AGP  (+8  !_1   ?[0!(&@  /1P
M #,=   K'0  )!T  " <   <&P  &!H  !89 0 3&0$ $1D!  X: 0 ,' (
M"AT#  <?!0 #(0@  "(*   D#   )@X  "82   F&   )Q\  "<G   G,@
M)SX  "=+   G7   )VX  ":%   FG0  );0  "31   C[@!$'0  .1\  # ?
M   H'P  (QX  !X=   ;'   &!L  !0<   1'   #AT   T?   *(0  !B(!
M  ,D!   )@8  "@(   J"P  *PT  "T0   M%0  +1P  "TD   N+@  +CH
M "Y(   M6   +6H  "V!   LF@  *[(  "K0   I[P! (   -B$  "TA   F
M(0  (2   !T?   :'@  %AX  !(?   /(0  #2(   HD   &)@   B@    K
M @  +00  "\&   P"0  ,@P  #0.   U$@  -1@  #4@   U*@  -38  #5#
M   U4P  -&8  #1\   SE@  ,J\  #'-   P[P \(P  ,B0  "HD   D(P
M("(  !PA   7(0  $R,  ! E   -)P  "2D   4K   !+@   #     R
M- $  #8$   X!@  .@D  #P-   ^$   /A0  #X<   ^)@  /C$  #X_   ]
M3@  /6$  #QW   [D0  .JL  #G)   X[0 W)P  +R<  "@F   C)0  'R0
M !DE   4)@  $"@   TK   )+@  !3     S    -0   #@    Z    /
M #X!  !  P  0@<  $0*  !&#0  21$  $D7  !((0  2"P  $<Z  !'20
M1EL  $5Q  !$BP  0Z4  $+#  !!Z  T*@  +"H  "<H   B)P  '"@  !8J
M   1+0  #3    DS   #-@   #D    \    /@   $$   !#    1@   $@
M  !*    3 ,  $X&  !0"@  4PX  %03  !4'   4R<  %,T  !30P  4E4
M %%J  !0@P  3YX  $VY  !,X  P+0  *RP  "8K   ?+   &"X  !(R   -
M-0  "#D   (]    0    $,   !&    20   $P   !.    40   %,   !5
M    5P   %D!  !<!@  7PH  &(.  !C%0  8Q\  &(L  !A/   8$X  %]B
M  !>>P  7)8  %NP  !9SP O,   *B\  "(P   :,P  $S<   X[   (/P
M 40   !(    3    $\   !2    50   %@   !;    70   &    !B
M9    &8   !I    ;04  ' +  !T$   =!@  ',E  !R-   <D4  '!9  !O
M<0  ;8L  &NF  !JP  N,P  )34  !TX   4/   #D$   ='    3    %$
M  !5    60   %T   !A    90   &@   !K    ;0   &\   !R    =
M '<   !Z    ?@   (($  "&"P  BA$  (D<  "(*P  ACT  (12  "#9P
M@8$  '^;  !^L@ I.@  (#T  !9"   /2   "$X   !4    6@   &    !D
M    :0   &X   !R    =@   'H   !]    @    ((   "%    B    (L
M  ".    D@   )8   "; P  H P  *(3  "@(0  GS,  )U'  ":7@  F'<
M )>/  "5IP C0P  &4@  !%.   )50   %P   !C    :@   '$   !V
M>P   (    "&    B@   (X   "1    DP   )8   "9    G    *    "C
M    IP   *L   "P    M@0  +P-  "Z%P  N2@  +<\  "T4@  LFH  *^%
M  "MG  <3@  $U0   M<   !9    &P   !T    ?    (,   ")    CP
M )0   ":    GP   *(   "D    IP   *H   "N    L0   +0   "X
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M____________________________________________
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M1TE*2TU.3U!24U155UA96UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z
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ML'ZDT;!^I-&P?J31_[@4#O^X'B?_M"I&]Z\V:=ZG0H_'FV*QQ)MRML*;?[G
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MF:F#S92H@\Z0IX3/C*:%T(FFAM&&I8?2A*6*TH&EC=* I8_2@*6/TH"EC]*
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M"?^Q(Q[_KC$Z_ZD^6>VB2WG9FER7R)5RL,65?;7#EX6XP9>+N[^3C+V^CX[
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M!/^O(1;_K2XO_ZD\2_>C26GHIDA_VJ=(E<RE4ZK'J%RRQ*QDML&N;KN]KWC
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MK\*(D*_"B)"OPHB0K\*(D*_"B)"OPHB0K\*(D*_"_Z@8 O^I(P__IS(E_Z-
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MHJ;-=*:HS7*IJ<QQK:K,<+*KRW"VJ\MOO*O(<,"KQ'' JL1QP*K$<<"JQ''
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M"(?_&1)^_RD;=?\U(VS_/"ID_T,O7O]*-%C_4#=4_U8Z4?];/$[_8#Y+_V1
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MCK1ZJ("NA;)VJY2X;ZNING*EM;IWG;6Y>IFVMWV6M[9^D[FT?Y&ZLH"0N[&
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MT9-@JM&3_XP. ?^/%@+_I1X#_[45 ]K*"P+0X0X"Q.L>#;CO+!VM[C<NHNQ
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M2C?_ODLW_\)+-__"2S?_PDLW_\)+-__"2S?_PDLW_\)+O[,  *Z^  "@S0
MDMX  (G_#0&!_QH%=_\C#&W_*A-D_S$97/\X'E7_0")0_T@F3/]/*4C_52M$
M_ULM0O]A+S__9S$]_VTR._]S,SG_>C4W_X(V-?^+-S/_E#@R_YPY,?^D.C#_
MKSLP_[([,/^R.S#_LCLP_[([,/^R.S#_LCLP_[([L+@  *#'  "1V   A.\
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MAY61BX2BEH:#LIF#A,N8A(/.EH2#T)2$@M*2A('3D(2!U(Z$@-:,A(#6C(2
MUHR$@-:,A(#6C(2 UHR$@-:,_W<2 ?]T&P/_@AX$_Y0G"/^@,@W_IS03^JXX
M&.^U/1SFO$8AW+],+,ZY5#_#L5U0MZIE7ZVD;&RCG71WF9A\@9&3AHJ)CY*1
M@HR?EGV*KYAZB\>8?(G.EGV(T)1^AM*2?X73D'^$U(Z @]:,@(/6C("#UHR
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M7TC;\6%)TO)C2=+R8TG2\F-)TO)C2=+R8TG2\F-)TO)C_I4  -2I  #"M0,
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MLT$4UK%'(\JK4C3 I%Q#MIYD4:V8;%REDG1FG8U];Y:(AG:/A9%]BH*<@H6
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MH.-[89OC>F.7Y'EFE.5W9I+F=V:2YG=FDN9W9I+F=V:2YG=FDN9W_W 2 ?^
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M<%6KZG!8INMP6:/K<%FCZW!9H^MP6:/K<%FCZW!9H^MP_W</ ?^-" #>H (
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M1C[F_T8^YO]&/N;_1C[F_T8^YO]&T)\  +VL  "NM0  HL(  )7/  "*W0,
MA/\2 7O_'@-T_RH);/\S#V3_.Q9=_T,;5_]*(%'_421,_U@G2/]@*D3_:"Q
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M2HPU_TB7./]&H#O_1:@\_T2P/O]#N#__0\%!_T+,0?]!WD+_0>M#_T#U0_]
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M;6:.[FMGB^]J:8GP:&F)\&AIB?!H:8GP:&F)\&AIB?!H_V<2 ?]Y# #_B@H
MWYH$ -.F!P#,L0@ Q[L( ,'"$P"XPB@$KK\X$*6\1!Z;N$XLD;57.(BQ7D*
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M6DZM^EI.K?I:3JWZ6DZM^EI.K?I:_W\  -R3  #*H@  O*P! +&U  "HP ,
MG\L& );9"P"1X!L!BM\L!H+?.0YYWD,7<=U-(&K<5BACVU\O7=IG-5C9<3I3
MV7L^3]F(0DO9ED5(V:9'1MJZ2$7;VT=$V/1)0M/_343)_T]%PO]01[O_4D>[
M_U)'N_]21[O_4D>[_U)'N_]2YHH  ,^;  "_IP  LK   *>[  "<Q@, D]$&
M (OJ#@"%Z!\"?N@M!G;H. YNZ$$69N=*'5_G4B-9YULI5>=D+5#G;3%,YW@U
M2>>$.$;HD3I#Z* \0.FR/C_JRSX^Z.\^/>;_/SW@_T(_U_]$0,[_1D#._T9
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MKHM@-Z>&:$"A@G!(G'YY3I9[@E22>(M9C7:578ETH&&%<ZYC@G*_9(!SWF2
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M8'-[]UYT>OE<='GZ6W5Y^UIU>?M:=7G[6G5Y^UIU>?M:_UT3 ?]L#0#_>PL
M]H@) -R3!@#5G0D T:4* ,JJ%0#!J2H$MZ8Z#ZZB1ANFGE HGII9,Y:683R/
MDVE$B8]Q3(.->5)]BH-7>(B-7'.&F6!OA*9C;(2W9&J$SV1JA/!B;(+V8&V
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M6%^-_%=?C?Q77XW\5U^-_%=?C?Q7_VH* /]\  #<C   S9@  ,.C P"ZJ@(
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M1$*Y_T1"N?]$W8@  ,>8  "XHP  JZL  *"T  "5O@  B\@# (#1!P!XX0T
M=.$= 6[A*P-HX#<(8>!"#ES@3117X%894^!?'4_@:2)+X',E1^!^*$3@BRM"
MX)HM/^&K+S[BP2\^XN4O/-_Z,3G>_S0YV?\V.M#_.#O,_SD[S/\Y.\S_.3O,
M_SD[S/\YS9(  +R@  "MJ   H;$  )6[  ")Q0  ?L\" '3:!@!NZQ$ :.L>
M 6+K*@-=[#4&5^P_"U+L2 ]-[%$32NU:%D;M8QE#[6T<0.UX'CWNA2$Z[I,C
M..^C)#;PMB8U\=(F-._S)C3L_R8RZ_\H,N?_*S/D_RPSY/\L,^3_+#/D_RPS
MY/\LP9P  +"F  "CK@  EK@  (G#  !]S0  <=@  &?F!@!B]A$ 7/<= 5?W
M)P)2]S$$3?@Z!DCY0@E$^4L+0?I4#C[Z7! [^V42./MO%#7[>Q8R_(D8,/V8
M&2[]JALL_K\<*__C'2K\^ATJ^O\=*O?_'"KW_QTJ]_\=*O?_'2KW_QTJ]_\=
MLZ,  *2K  "7M@  B<$  'O+  !OU@  8]\  %OU!@!5_Q  4/\9 4O_(P)&
M_RP#0O\T!#[_/ 4Z_T,&-_]+!S3_4P@Q_UL)+O]D"BO_;PPH_WP-)O^+#B3_
MG! B_ZX1(?_%$B#_Z1,?__P3'O__$Q[__Q,>__\3'O__$Q[__Q,>__\3IJD
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M48)L_T^!:_]-@&O_3(!K_TJ :_]*@&O_2H!K_TJ :_]*_U02 ?]A# #_;@H
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M36QY_TQL>?],;'G_3&QY_TQL>?],_UX, /]L 0#F>@  UH8  ,N/ @#$EP0
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M1U22_T=4DO]'_VX  -Y_  #*C0  OI@  +.@  "JIP  H:X  )>V  "1NA
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MMR(ZVM4B.M;R(S?4_R<VTO\I--'_*S;*_RTVRO\M-LK_+3;*_RTVRO\MQ9
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M"!O_X@D:__D)&O__"1G__PD9__\)&?__"1G__PD9__\)HJ<  ).Q  "%NP
M=L8  &G0  !;V@  3N   $/E   ^^P$ .O\, #;_$P R_QL +_\C "O_*@$H
M_S$!)/\W 2'_/P(?_T8"'/]. AG_6 ,6_V,#$_]P Q+_@001_Y,$$/^G! __
MO04._^ %#O_V!0[__P4.__\%#O__!0[__P4.__\%E:\  (:Z  !WQ0  :-
M %K;  !,X0  0.<  #?S   R_P  +O\' "K_#@ F_Q, (_\: !__(  ;_R8
M&/\K 17_,@$2_S@!$/]  0[_2 $,_U(!"?]= @;_:P($_WT" O^0 @'_HP(
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MY$'?(^!![R3<0/PGV$#_*=0__RK/0/\JQT+_*L)#_RK 0_\JP$/_*L!#_RK
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M/Y=:_SZ46_\\D5O_.X];_SJ/6_\ZCUO_.H];_SJ/6_\Z_TP2 /]6#0#_8 D
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M0'=J_S]W:O\^=VK_/G=J_SYW:O\^_U0, /]?  #R;   W78  -!] @#)@P0
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M/V-Z_S]C>O\__UX  .EM  #6>0  R(0  +Z,  "VDP  KI<  *:;! "@G1<
MFITI I.<-PB,FD,0AIA-&("651]ZE%TF=9)E+'"0;#%LCG4V9XU^.F.+B3Y?
MBI5!7(FC1%J)M$58B<M%6(CM1%B(_T-9AO]!6X/_0%V!_SY=@/\^78#_/EV
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MKS9'I\8V1J;I-D6D_C=%H_\W1J#_-TB<_S=)FO\W29K_-TF:_S=)FO\WXG0
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M&#3-^QLRR_\=,<K_'S#)_R$OR/\A+\C_(2_(_R$OR/\AOH\  *^:  "BH0
MEJD  (JP  !]N   <;\  &;&  !;S ( 4-(' $?:# !&W!@ 1=PG $3=-0%!
MW4 "/]Y+ SW>500ZWU\&.-]I!S7?=@DSX(0+,>"4#"_AI@TNX;P.+>+@#BW>
M^ \KW?\2*MS_%"G:_Q8HVO\6*-K_%BC:_Q8HVO\6LY@  *6@  "9IP  B[
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M @?__P('__\"!___ @?__P('__\"D:T  (*X  !SP@  9,P  %;5  !(W0
M.^(  ##G   G[@  (_\  "#_!  <_PP &?\1 !;_%@ 3_QL $?\A  [_)P -
M_RX "O\V  ?_/@ $_T@  /]4  #_8@$ _W,! /^' 0#_G0$ _[(! /_* 0#_
MZ@$ __,! /_S 0#_\P$ __,!A+<  '3!  !ES   5M@  $??   YY0  +>H
M "/N   <_0  &/\  !7_   1_P0 #_\+  W_#@ )_Q$ !O\5  /_&@  _R
M /\F  #_+@  _S<  /]!  #_30  _UP  /]M  #_@@  _Y8  /^H  #_N@
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M.O8:T#K_',TZ_Q[+.O\>RCK_'\0[_Q_ //\>P#S_'L \_Q[ //\>_SD; ?]
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M)[)&_R>P1O\GKD;_)ZI'_R:G2/\FITC_)J=(_R:G2/\F_T 4 /](#@#_3@L
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M,89;_S"%6_\OA5O_+X5;_R^%6_\O_TL, /]4  #[7@  XF4  -AK 0#/;@4
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M,FYJ_S)N:O\R_U,  /1?  #>:@  S7,  ,-Z  "[?@  M8$  *Z#"0"HA1H
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MK#A5@[\Y58/A.%6"^3=6@O\U5H'_-%A__S-9??\R67W_,EE]_S)9??\R[V
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M*D.?]2M"G?\K0IS_+$*;_RQ$E_\K1)?_*T27_RM$E_\KUW(  ,.   "VC
MJI0  )^9  "4G@  B:,  'ZH  !PK@  :K . &BQ'0!EL2P!8;$X UVP0P99
ML$P*5:]4#E*O71%.KF452ZYO&$BM>1M%K88>0JR5(#^LI2(^K;DC/:W8(CVK
M]2,\J?\E.Z?_)CNF_R8[I/\F.Z3_)CND_R8[I/\FS'H  +N(  "ND@  HID
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M"R31_PPCT/\-(]#_#2/0_PTCT/\-KI8  *"=  "4I   AJP  'FT  !LNP
M8,(  %3&  !(RP  /M   #75!  MW0H +.$3 "OB'P IXRH *.0U "?D/P F
MY4H ).95 "/F80$AYVX!(.=^ A[HD (=Z:0"&^F\ AKJX@(:YOP"&>7_ QGD
M_P08X_\%&./_!1CC_P48X_\%HYT  ):D  "(K   >K4  &R]  !?Q   4\H
M $?.   \TP  ,MH  "K?   E[@D (_ 1 "'Q&0 ?\2( '?(K !OS-  9]#X
M%_1( !7U4@ 3]E\ $O9N 1'W@ $0^)0!#_FJ 0[YQ@$.^>T!#?;_ 0WT_P$-
M\_\!#?/_ 0WS_P$-\_\!F:,  (NL  !\M0  ;;X  %_&  !2S0  1=(  #G8
M   OW@  )N(  !_J   <^P8 &?\. !?_$P 4_QH $O\A !#_*  ._S  #?\Y
M  O_0P )_TX !O]<  3_;  "_X   ?^6  #_K0  _\H  /_P  #__P  __\
M /__  #__P  __\ C:L  'VU  !NOP  8,@  %+0  !#UP  -]T  "OB   B
MY@  &>H  !7Y   2_P  $/\(  [_#@ ,_Q$ "?\6  ;_'  #_R(  /\J  #_
M,P  _ST  /])  #_5P  _VD  /]^  #_E0  _ZP  /_'  #_Z   __H  /_Z
M  #_^@  __H @+4  '"_  !AR0  4M,  $/;   UX0  *>8  ![J   5[@
M$/@   [_   +_P  "/\   3_!@  _PH  /\.  #_$0  _Q4  /\;  #_(P
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M#-8M_P[4+/\/TBS_$-$L_Q#/+/\0SBW_$,XM_Q#.+?\0_S(9 /\W% #_.A$
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M()Y'_Q^;1_\>FD?_'II'_QZ:1_\>_T - /]&! #_3   ^%(" .A5! #A50@
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M)7I:_R5Z6O\E_TD  /M2  #C7   TF,  ,=H  # :P  NFL" +5K#0"N;1T
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MJC!D;+PQ8VS9,&-L]"]C;/\M9&S_*V1K_REE:O\H96K_*&5J_RAE:O\H_5,
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M+5%][RQ2??\K4GS_*5-[_RA4>O\G5'K_)U1Z_R=4>O\GZ%X  -!K  # =@
MM'X  *N%  "AB0  EXL  (F-  "#CP@ ?I 7 'N1)P%VD30#<I _!FV/20MI
MCE$/98U9$V*,8!=>BV@;6XIQ'E>)>R%4B(8D48>4)T^&HBE-AK0J2X;,*DN%
M[BE,A/\I3(/_*$R#_R=-@?\F3H'_)DZ!_R9.@?\FX6,  ,EP  "[>P  L(0
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M&S>@_QPWG_\<-Y__'#>?_QPWG_\<Q'@  +6%  "ICP  G94  )*:  "&GP
M>J,  &ZH  !BK   5;   %"R#@!.LAL 3;,H $NS-0!)LS\!1K-) D2S4@1!
MLUL&/[-D"#RS;PHZLWL,-[.*#C6RF@\SLZT0,K/%$#*RZ1 QL/X2,*[_%"^M
M_Q4OK/\6+ZS_%B^L_Q8OK/\6NX$  *Z.  "AE0  EIH  (F@  !]I@  <:L
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M A';_P(1V_\"GIH  )*A  "$J0  =K$  &BX  !;OP  3L0  $+(   WS
M+=   "35   <VP  %=\% !3I#@ 2ZA0 $>L= !#K)@ .[#  #NTZ  WN1@ +
M[E, "N]B  GP=  (\8D !_*@  7RN@ $\>0  O']  +O_P #[?\  ^W_  /M
M_P #[?\ E:$  (:I  !XL@  :;H  %O"  !-R   0,P  #31   JU@  (=L
M !G@   2Y   #_ !  WY"@ +^@\ "?L5  ?['  $_"0  ?PL  #\-P  _$(
M /Q0  #\80  _74  /R,  #\I   _,$  /SK  #\_P  _?\  /W_  #]_P
M_?\ B:D  'FR  !JNP  7,0  $[,   _T0  ,M<  "?=   =X0  %>4   [H
M   *\0  "/T   7_ P !_PD  /\.  #_$@  _Q<  /\?  #_)P  _S$  /\^
M  #_30  _U\  /]U  #_C0  _Z8  /_"  #_YP  __P  /__  #__P  __\
M?+,  &R\  !=Q@  3L\  #_6   QW0  )>(  !KF   1Z@  #.X   7R
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M ?\"D0'_ I@!_P*? ?\!I0#_ :P _P&R /\!N@#_ <0 _P'1 /\ Y #_ /$
M_P#\ /P!_P#\ O\ _ /_ /P$_P'\!?\!_ 7_ ?P%_P'\!?\!_Q\F /\A(@#_
M("$ _QXC /\8)P#_$S  _Q$\ ?\.2@'_#5<!_PMC ?\*;P'_"GH!_PJ$ ?\*
MC0'_"I0!_PJ; ?\*H@'_"J@!_PJO ?\*MP'_"L  _PK, /\*X #["N\ ]PKZ
M /4+_P'U#/\!] W_ ?0-_P+T#?\"] W_ O0-_P+T#?\"_R(B /\D'0#_)!P
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M#+PM_PR\+/\,NRS_#+LL_PR[+/\,_S$1 /\U# #_-@< _SH+ /\\$ #_.Q4
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M%XU'_Q>-1_\7_SX" /]#  #K2P  W5$  -%4  #*5 $ QE(% ,%1$0"Y4R(
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MJB1R6;HE<5G2)7!:\"-O6O\B;UK_('!:_QYP6O\=<%K_''!:_QQP6O\<_T@
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M)EYGZB5>9_XC7V?_(5]F_Q]@9O\>8&;_'F!F_QY@9O\>[T\  -I<  #&90
MNFT  +!R  "G=0  G70  )1S  "-= T B78< (5W*P&!=S@#?'9#!GAU3 ET
M=%0-<7-;$6YR8Q1K<6L7:'!S&F5O?!UB;H<@7VV4(EULHB1:;+(E66S')5AL
MZ"59;/TC66O_(5IK_Q];:_\>6VK_'EMJ_QY;:O\>ZU,  --@  #":0  MG$
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M'DA]_QU)?/\<27S_'$E\_QQ)?/\<UF$  ,)N  "T>   JH   )^%  "4AP
MB(<  'N)  !PC   :XX- &B/&@!FCRD 8I U 5^//P-<CT@%68Y0"%:.6 M3
MC6 .4(QH$$V,<A-*BWT62(J*&$6*F1I#BJH;0HJ_&T&*X1M!B/D;08;_&T&%
M_QM"A?\:0H3_&D*$_QI"A/\:S6<  +QT  "O?@  I88  )J*  ".C   @HT
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M#2JE_PTJI?\-M8   *B+  "<D0  D98  (6<  !XH   :Z4  %^H  !3K
M2*\  #VR   VM0L -+45 #.V(0 RMBP ,;<W #"W00 ON$L +KA5 "RX8 $J
MN&T!*;E[ B>YC0(EN9\#)+FT R.YT@,CM_0$(K7_!2&T_P8AL_\'(;+_!R&R
M_P<ALO\'K8H  *"1  "5EP  B)T  'NC  !NJ   8:T  %6Q  !*M   /[<
M #2[   KO@, ),(, "+"%  BPQ\ (<,J "#$-  ?Q#\ 'L5* !W&5@ <QF,
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M9P  Y7L  .:2  #FJ@  Y\@  .?P  #H_P  Z/\  .C_  #H_P  Z/\ D9\
M (*G  !TKP  9;<  %>^  !)PP  /,<  ##+   ESP  '-0  !39   .W0
M">$   +E    Z08  .D-  #I$0  ZA@  .LA  #M*P  [S<  /%%  #R5@
M\V@  /-^  #TEP  ];   /;0  #W\P  ]_\  /?_  #W_P  ]_\ A:<  ':P
M  !FN   6,$  $K(   [S   +M$  "/6   9W   $>    SC   $YP   .H
M  #U    ]    /4%  #U"P  ]@\  /84  #X'0  ^B<  /PT  #_0P  _U4
M /]I  #_@0  _YH  /^R  #_SP  _^T  /_Y  #_^0  __D >+   &BZ  !9
MPP  2\L  #O1   MV   (=T  !;B   .Y@  ".H   #M    \    /@   #_
M    _P   /\   #_    _P8  /\,  #_$   _Q@  /\B  #_,   _T   /]3
M  #_:0  _X$  /^9  #_KP  _\,  /_5  #_U0  _]4 _Q,H /\3)0#_$24
M_PTG /\&+0#_ #4 _P!! /\ 3P#_ %P _P!I /\ = #_ 'X _P"( /\ D #_
M )< _P"= /\ I #_ *H _P"P /\ MP#_ ,  _P#, /\ WP#_ .P _P#X /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _Q8E /\6(@#_%"$ _Q C
M /\** #_ #  _P ] /\ 2P#_ %@ _P!D /\ < #_ 'H _P"$ /\ C #_ ),
M_P": /\ H #_ *8 _P"M /\ M #_ +P _@#( /T V0#[ .D ^@#V /D _P#X
M /\ ^ #_ /@ _P#X /\ ^0#_ /D _P#Y /\ _QHB /\:'@#_&!T _Q,> /\.
M(@#_"BP _P<Y /\#1@#_ %, _P!@ /\ :P#_ '8 _P!_ /\ B #_ (\ _P"6
M /\ G0#_ *, _@"I /P L #Z +D ]P#$ /4 T@#S .8 \@#T /$ _P#P /\
M[P#_ .\ _P#O /\ \ #_ /  _P#P /\ _QX= /\>&0#_'!< _Q<8 /\3'@#_
M$2@ _PXT /\,00#_"DX _PA; /\'9@#_!G$ _P9Z /\&@P#^!HL _ :2 /H&
MF0#X!I\ ]@:F /0&K0#R!K4 \ 7  .T%S@#K!>0 Z0;S .8(_P#E"O\ Y O_
M .0+_P'D"_\!Y O_ >0+_P'D"_\!_R$8 /\A$P#_(!$ _QL2 /\<&@#_&B0
M_Q8O /\3/ #_$4D _Q!5 /P.80#Y#FL ]@YU /0.?@#R#H8 \ Z. .X.E0#M
M#IL ZPZB .H.J@#H#K, Y@^] .4/S #A#^, W1#S -D1_P'6$O\!U!/_ =,3
M_P+2$_\"TA/_ M(3_P+2$_\"_R43 /\E$ #_) T _R,. /\C% #_(AX _Q\I
M /\<-0#Y&4, ]!A/ .\76P#L%V8 Z1=P .87>0#D%X$ XA>) . 7D0#?%Y@
MW1>? -L7IP#9&+$ UAB[ -09R@#0&N$!S!OS <D<_P+&'/\"Q!S_ \,<_P/#
M'/\#PQS_ \,<_P/#'/\#_R@0 /\I"P#_* 8 _RL+ /\K$ #_*1< _28B /0C
M+@#L(3L YB!) .(@50#>(&  VB%J -8A= #3(7P!T"&$ <\BC '-(I,!RR*;
M <DBHP'((ZP"QB.V L0CQ +")-L"OB7N [LE_@2X)?\%MB7_!;4E_P:U)?\&
MM27_!;4E_P6U)?\%_RP- /\M!0#_+@$ _S$% /\Q"P#]+Q  \2L8 .<I)0#?
M*#, V"A" -$J3P#-*UH R2ME <<K;@'$+'8"PBQ^ L LA@.^+(X#O2R6 [LL
MG@2Y+*<$N"RQ!;8LOP6U+=$%L2WJ!JXN^P>K+O\(J2[_"*@N_PBH+?\(J"W_
M"*@M_PBH+?\(_R\( /\Q  #_-0  ]C<  .HV @#G,P@ Y"\/ -DN&P#/,2P
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MK!6%1KL6A$;1%H)'[A: 1_\5?T?_%']'_Q)_1_\1?T?_$7]'_Q%_1_\1_SL
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M&VI5YAMJ5?L9:E7_%VI5_Q9J5?\5:U7_%&M5_Q1K5?\4\D,  -]/  #+6
MO5T  +-A  "K8@  HF   )M<  "57A  D& ? (QA+@"(83H"A&!%!(%@3@9^
M7U8)>UY="WA=90YV7&P0<UQT$W!;?15N6H@7:UJ4&6E9H1MG6; <95G#'&19
MXQQD6?H:9%G_&&19_Q=E6?\595G_%&59_Q1E6?\4[T8  -I2  #&6P  NF$
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M&%5F_Q=59?\65F7_%59E_Q569?\5XE$  ,I=  "[9@  KVP  *9Q  "9<
MCF\  (-N  !]< 4 >'(2 '5S(0!R<R\!;W,Z FQS1 1I<DP&9G)4"&-Q6PM@
M<&,-77!K$%MO=!-8;G\556Z+%U-MF1E1;:@:3VV[&TYMV1I.;/093VO_&$]K
M_Q=0:O\64&K_%5!J_Q50:O\5W54  ,5A  "W:@  K'$  *)U  "4=   B70
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M$3U^_Q$]?O\1Q68  +5Q  "J>P  GX(  )*"  "%@@  >8,  &V&  !?B@
M6(T! %2.#P!2CQL 4(\G $^0,P!-D#T!2Y!% DF03@-&D%8$1(]?!4*/: <_
MCW,)/8Z "SJ.CPPXCJ --XZS#C:.S XVC>\.-8O_#C6)_P\UB/\/-H?_#S:'
M_P\VA_\/OFT  +!Y  "E@@  F8<  (R(  !_B   <HH  &:-  !:D0  4)4
M $F7"0!'F!, 19@@ $29*P!#F38 09I  $":2 $^FE$"/)I: CJ:9 ,WFF\%
M-9E]!C.9C <QF9T(+YFP""Z9R@@NF.T(+I;_"BV4_PHMD_\++9+_"RV2_PLM
MDO\+MG4  *J!  ">B   DXT  (:.  !XCP  :Y(  %^5  !4F0  29T  $"@
M   ZH@T .*,7 #>C(@ VI"T -:0W #2D00 SI4L ,:54 3"E7@$NI6H!+*5X
M BJEB ,HI9H#)Z6M!":EQ@,FI.L$):+_!26@_P8DG_\&))[_!R2>_P<DGO\'
MKWX  *.(  "7C@  C9,  'Z5  !PF   8YL  %>?  !,H@  0J8  #BI   O
MK , *JX. "FN&  HKR, )Z\M ":P-P EL$$ )+!+ ".Q5@ BL6, (;%Q !^Q
M@@ >LI0!'+*I 1NRP0$;L><!&Z_^ AJM_P(:K/\#&JO_ QJK_P,:J_\#J(@
M )N/  "1E   A)H  ':?  !HH@  6Z4  $^I  !$K0  .;   "^S   FM@
M'KD% !B[#@ 7NQ8 %[P@ !:\*@ 5O34 %+U  !.^2P 2OE@ $KYG !&_>  0
MOXP $,"B  [ N@ .P.$ #[W[  ^\_P 0NO\!$+K_ 1"Z_P$0NO\!GX\  )25
M  "'FP  >:$  &NG  !>K   4K$  $6T   ZM@  +[D  "6\   =OP  %<,
M  _&!0 +R@T "<H4  C*'0 'RB< !\HR  ;+/@ %RTL !,Q:  /,:@ "S'X
M <R4  #,JP  S<@  ,SM  #,_P  R_\  <K_  '*_P !RO\ EY8  (J<  !\
MHP  ;JH  &"P  !2M@  1;D  #F\   NOP  (\,  !O&   3R@  #<T   C1
M   !U D  -0.  #5%0  UAX  -@G  #9,0  VSX  -Q+  #=6P  WFX  -Z$
M  #?FP  W[0  -[9  #?]P  W_\  -__  #?_P  W_\ C9T  '^E  !PK
M8;,  %.Z  !%OP  .,(  "S&   AR0  &,T  !#1   +U0  !-H   #>
MX $  .$)  #B#@  Y!,  .4;  #G)   Z2\  .L\  #M2P  [ET  .YQ  #O
MB0  \*(  /"\  #PXP  [_D  /#_  #P_P  \/\ @:4  '*M  !CM0  5+T
M $;$   WR   *LP  !_0   5U0  #MH   ?>    X@   .8   #I    Z@
M .P   #N!0  [PP  /$0  #S%P  ]2   /@K  #[.0  _4H  /Y>  #_=
M_XT  /^F  #_P   _^$  /_U  #_]0  __4 =*X  &6W  !6P   1\@  #C-
M   JT@  '=@  !/=   ,X@   ^8   #I    [    /    #S    ]    /8
M  #X    ^@   /T'  #_#0  _Q(  /\;  #_*   _S<  /]*  #_7@  _W8
M /^/  #_I@  _[H  /_1  #_T0  _]$ _P\D /\.(@#_"R$ _P,D /\ *0#_
M #( _P ^ /\ 3 #_ %D _P!E /\ < #_ 'H _P"$ /\ C #_ )( _P"9 /\
MGP#_ *4 _P"K /\ L@#_ +H _P#% /\ TP#_ .< _P#T /\ _P#^ /\ _P#_
M /X _P#^ /\ _@#_ /X _P#^ /\ _Q$A /\0'@#_#1T _P<? /\ (P#_ "T
M_P Z /\ 2 #_ %4 _P!A /\ ; #_ '8 _P!_ /\ AP#_ (X _P"5 /\ FP#_
M *$ _P"G /X K@#] +8 _ #  /L S0#Y .( ^ #P /< _ #V /\ ]0#_ /4
M_P#U /\ ]0#_ /4 _P#U /\ _Q4= /\3&@#_$!D _PL9 /\ '0#_ "D _P V
M /\ 0P#_ %  _P!< /\ 9P#_ '$ _P!Z /X @P#\ (H ^@"1 /D EP#X )T
M]P"C /4 J@#T +( \@"[ /$ R #O -P [@#L .T ^@#K /\ Z@#_ .H _P#J
M /\ Z@#_ .H _P#J /\ _Q@9 /\6%0#_$Q, _PX3 /\+&@#_!R0 _P(P /\
M/@#_ $L _P!7 /\ 8@#\ &P ^ !U /4 ?@#R (4 \0", .\ DP#N )D [ "@
M .L I@#I *X YP"W .8 PP#D -0 X@#I .$ ]P#? /\ W0#_ -T _P#= /\
MW0#_ -T _P#= /\ _QL3 /\:$ #_%@X _Q(. /\2%0#_#Q\ _PPK /\). #_
M!D4 ^P-1 /<"7 #R F8 [@)P .H"> #G H  Y@.' .0#C@#B Y4 X0.< -\$
MHP#=!*L VP2T -@%P #6!=  TP;G - (^ #."O\ S O_ ,L,_P#+#/\ RPO_
M ,L+_P#+"_\ _Q\0 /\>"P#_&@< _QD+ /\8$0#_%AD _Q(D /H0, #S#CX
M[@U* .D,5@#E#&$ X@QJ -X-<P#;#7L V0V# -8-B@#4#9$ T@V9 - .H #/
M#JD S0ZS ,L.OP#*#]  QA'I ,(2^0"_$_\ O1/_ ;P3_P&\$_\!O!/_ ;L3
M_P&[$_\!_R(, /\A! #_(   _R$% /\?# #_'!$ ]A@< .P5* #E$S8 WQ)#
M -D33P#3%%H T!5D ,T6;0#+%G4 R1=] ,<7A0#%&(P Q!B4 ,(9G # &:4
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ML02@+< $GRW8!)PN[P69+O\&ER__!I8O_P:5+O\%E2[_!94N_P65+O\%_RP
M /\N  #J-0  W3D  -$Y  #*-@  QR\& ,$M$0"Z,"$ M#(Q + T/@"L-4H
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M#GQ!Y YZ0OD->4+_#'A"_PMX0O\+>$+_"GA!_PIX0?\*]C8  .9   #12
MPTT  +E.  "Q30  J4D  *1%!@"?1A, FD@C )9),@"22CX!CTI( HQ*40.*
M25D$ATE@!85): >#2&\(@4AW"G]'@ M]1XH->D>5#GA&H@]V1K 0=4;"$'-&
MX!!R1_</<4?_#G%'_PUQ1_\,<4?_"W%&_PMQ1O\+\SD  .!$  #,3   OE$
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M$5]4_P]?5/\.7U/_#5]3_PU?4_\-YT0  ,]0  "_6   LUT  *A?  "<70
MDEL  (M8  "%6@H @5L6 'U<) !Z73$ =UT\ 71=1@)Q74X$;UQ5!6Q<70=J
M7&0):%ML"V5:=0UC6G\/85F+$5Y9F!)<6*<46UBX%%E9T!196/ 365C_$5I8
M_Q!:6/\.6E?_#5I7_PU:5_\-XT@  ,M3  "[6P  L&$  *1B  "780  CE\
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M#4MD_PU+9/\-T50  +Y>  "Q9P  IFT  )=L  "*:P  ?VL  '-K  !M;0
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MAP8SB)@',H>J!S"(P <PA^0',(7["#"#_P@P@O\(,('_"#"!_P@P@?\(MVL
M *IV  "@?P  D'X  ()^  !V?P  :H   %Z#  !3AP  2HL  $&. @ ]D X
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M !.KM  2J], $JCU !.G_P$3I?\!$Z7_ 1.D_P$3I/\!HX8  )>,  "-D0
M?9(  &V5  !@F   5)P  $B@   ^I   -*<  "JK   AK@  &;$  !*S!P /
MM1  #K47  ZU(0 -M2L #;4V  RV00 +MDX "K9<  FV;  (MG\ ![:4  :V
MJ@ %ML4 !K;J  >U_P (M/\ "+/_  FR_P )LO\ FHT  )"3  "$F   =)P
M &6@  !7I   2Z@  $"L   UL   *K,  "&U   8N   $;L   R^ @ &P L
M L 1  '!&0  P2(  ,(K  #"-@  PT(  ,-0  #$7P  Q'$  ,2'  #$G0
MQ+4  ,3:  #$]@  P_\  ,/_  ##_P  P_\ DY0  (>:  !XH   :J8  %RL
M  !/L0  0;4  #6W   IN@  '[T  !;    0PP  "L8   /*    S 4  ,P,
M  #-$0  SA@  ,XA  #0*@  T34  --#  #44@  U&,  -5X  #5CP  U:<
M -;"  #6Z0  UOT  -;_  #6_P  UO\ BIL  'NB  !LJ0  7K   %"V  !"
MN@  -+T  "C!   =Q   %,<   W+   &S@   -(   #7    V0   -H%  #<
M"P  W1   -\5  #A'0  XR<  .4S  #G0@  Z%0  .AG  #I?@  Z9<  .JO
M  #JS@  Z^\  .O^  #K_P  Z_\ ?:,  &ZK  !?L@  4;H  $+    TPP
M)\<  !O+   2SP  "],   +8    W0   .$   #D    Y0   .<   #I
MZP<  .T-  #O$0  \1D  /0D  #W,0  ^4$  /I5  #Z:@  ^X0  /N=  #\
MM@  _-(  /WM  #]]   _?0 <:P  &&U  !2O0  1,0  #3)   FS0  &M(
M !#8   (W0   .$   #E    Z    .P   #O    \0   /,   #U    ]P
M /D!  #["   _@X  /\5  #_(0  _R\  /]!  #_5@  _VT  /^'  #_H
M_[8  /_*  #_U   _]0 _PL@ /\''@#_ !T _P @ /\ )0#_ "X _P [ /\
M20#_ %8 _P!B /\ ;0#_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F
M /\ K0#_ +4 _P"^ /\ RP#_ .$ _P#P /X _0#] /\ _0#_ /T _P#] /\
M_ #_ /D _P#Y /\ _PT= /\+&@#_!!D _P : /\ 'P#_ "H _P W /\ 10#_
M %$ _P!> /\ : #_ '( _P!Z /\ @@#_ (D _P"0 /\ E@#_ )P _@"B /P
MJ0#[ +  ^0"Y /@ Q@#V -D ]0#K /0 ^0#S /\ \@#_ /, _P#S /\ \P#_
M /, _P#S /\ _Q 9 /\.%0#_"!0 _P 4 /\ &0#_ "4 _P R /\ 0 #_ $P
M_P!9 /\ 8P#^ &T _ !U /H ?0#Y (0 ]P"+ /8 D0#T )< \P"> /( I #P
M *P [@"T .T P #K ,\ Z0#F .@ ]0#F /\ YP#_ .8 _P#E /\ Y0#_ .4
M_P#E /\ _Q(4 /\0$ #_# \ _P,0 /\ %0#_ "  _P L /\ .@#_ $< ^@!3
M /< 7@#T &< \0!P .\ > #M '\ ZP"& .H C #H ), YP"9 .4 H #C *<
MX0"P -\ N@#= ,D VP#@ -@ \ #7 /X U0#_ -0 _P#3 /\ TP#_ -, _P#3
M /\ _Q40 /\2# #_#@D _PL, /\)$@#_ QH _P F /T ,P#T $  [P!- .L
M6 #H &$ Y0!J .( <@#@ 'H W@"  -P AP#: (X V "5 -0 G #2 *, T "L
M ,X M@#, ,0 R@#9 ,@ [0#' /L Q0#_ ,0!_P## ?\ Q '_ ,0!_P#$ ?\
M_Q@+ /\5!0#_$   _Q & /\/#0#_#!0 _ <? /$#*P#G #D X@!& -X!40#:
M EL U0)D -(#; #/ W0 S01[ ,L$@@#*!(D R 60 ,8%F #$!:  P@:I ,$&
MM "_!L$ O0C5 +L)[ "X"_T M@S_ +4-_P"T#?\ M W_ +0-_P"T#?\ _QL%
M /\8  #_%P  _Q8  /L3!@#Z$ X [@P6 .,)(@#:"3  TPH^ ,X+2@#*#%4
MQPU> ,4-9P#"#F\ P0YV +\.?@"]#X4 O ^- +H0E0"X$)T MQ"G +41L@"S
M$<  LA'5 *X3[@"K%/X J17_ *<5_P"G%?\ IA3_ :84_P&F%/\!_Q\  /\<
M  #Z'@  ZQX  .,<  #?%04 W@X- -,.& #+$2@ Q1,W , 41 "\%D\ N1=9
M +<780"T&&D LQEQ +$9> "O&H  KAJ( *P;D "K&YD J1NC *<<K@"F'+P
MI!W/ *$>Z@&>'OP!G!__ 9L?_P&:'_\!FA[_ 9D>_P&9'O\!_R(  /\A  #L
M)P  X"H  -0I  #-)   RAP( ,09$@"]'"( MQXQ +,@/@"O(4D K2)3 *HC
M7 "H)&0 IB1L *0D<P"C)'H H26" : EBP&>)90!G26> 9LFJ@&9)K<!F";)
M I4GY@*2)_D"D"C_ H\H_P*.)_\"CB?_ HXG_P*.)_\"_R8  /(I  #C,0
MTC0  ,@T  # ,   NRD" +@C#@"Q)AP K"@K *@J. "D*T0 H2Q. )\M5P"=
M+5\ FRUG 9DM;@&8+G4!EBY] I0NA@*3+I "D2Z: X\NI@.-+K,#C"[% XHO
MX02'+_8$A2__!(0O_P.$+_\#@R__ X,O_P.#+_\#^RD  .LQ  #9.   R3P
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M"&I"_P=J0?\&:D'_!FI!_P5J0?\%[3<  -9"  #$20  MTT  *M-  "@2@
MF$<  )-"  ".0PT B44: (9&* "#1S0 @$@_ 'Y(2 %[2% ">4A7 G=(7P-U
M2&8$<T=N!7%'=@9O1X ';4:,"6M&F II1J8+9T:V"V9&S ME1NP+9$?_"61&
M_PAD1O\'9$;_!F1%_P9D1?\&Z#L  -!&  "_30  LU$  *51  ":3@  DDL
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M"%12_P=44O\'VD8  ,-0  "U6   J%L  )E:  "-6   A%<  'M4  !V5@$
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MB A":)@)0&BI"C]HO0H^:-X)/F?W"3YF_P@_9?\'/V7_!S]D_P<_9/\'PU<
M +-A  "G:0  EF@  (=G  ![9P  <6<  &5H  !<:@  6&P! %1N#@!2;Q@
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M RJ!M@,I@=(#*7_S RE]_P,I?/\#*7O_ RE[_P,I>_\#L6H  *5T  "5=@
MA74  'AU  !M=0  87<  %=Z  !,?@  0X$  #N%   UB D ,HD1 #&)&P P
MB24 +XHO "Z*.  MBT$ +(M* "J+5  IBU\ *(MK ":+>@$DBXL!(XN> 2*+
MLP$AC,X!(8KQ 2"(_P(@AO\"((7_ B&%_P(AA?\"JW(  *%\  "/>P  @'H
M '-Z  !F?   6W\  %""  !&A@  /(H  #2-   LD0  )I,, "24$P CE!P
M(I4F "&5+P @E3@ 'Y9" !Z63  =EE@ ')9D !J7=  9EX8 &)>9 !>7K@ 5
ME\D %I7N !:3_P$6DO\!%I'_ 1:0_P$6D/\!I7L  )F#  ")@0  >X   &R"
M  !?A   5(@  $F+   _D   -90  "V7   EF@  '9X! !:@#  4H1( %*$;
M !.A)0 2H2X $:(X !&B0P 0HD\ #Z)<  ZC:P -HWT #:.2  RCIP *HL
M"Z+F  R@_@ -G_\ #9[_  V=_P -G?\ GH0  )*)  "#B   <X@  &6+  !8
MC@  3)(  $&7   WFP  +IX  "2B   <I0  %:@   ^K!  *K@P !ZT2  :M
M&P %K20 !*XN  *N.0 !KD4  *Y2  "N80  KG,  *Z'  "NG0  KK0  *[5
M  "M]   K?\  *S_  "K_P  J_\ EHL  (R0  ![D   :Y(  %V6  !0F@
M1)\  #FC   OIP  ):L  !RN   4L0  #K0   FW   !N D  +@.  "Y%
MN1P  +HE  "Z+P  NSH  +Q'  "\5@  O&<  +Q[  "\D0  O*D  +S$  "\
MZP  N_X  +O_  "[_P  N_\ D)(  (.8  !SFP  8Y\  %6C  !'J   .ZT
M #"Q   EM   &[<  !*Z   ,O0  !;\   ##    Q (  ,4*  #%#@  QA0
M ,<;  #()   RBX  ,PZ  #-20  S5D  ,UL  #.@P  SIL  ,VU  #.V@
MSO8  ,W_  #-_P  S?\ AID  '>@  !II@  6JP  $RR   ^M@  ,+D  "2\
M   9OP  $<(   K%   "R0   ,P   #0    T0   -(!  #3"   U0T  -<1
M  #:&   W"$  -\L  #A.@  XDH  .-=  #D<@  Y(L  .6E  #EP   Y>8
M .7X  #E_P  Y?\ >J$  &NI  !<KP  3;8  #^\   POP  (\,  !?'   /
MR@  !\X   #1    U@   -P   #?    X    .(   #D    Y@,  .@)  #I
M#@  [!4  .X>  #Q*P  ]#H  /5-  #V80  ]WD  /B3  #XK0  ^<8  /GD
M  #Y\P  ^?, ;:H  %ZR  !/N@  0,$  #'%   BR0  %LX   W2   $V
M -T   #A    Y    .@   #K    [0   .\   #Q    \P   /8   #X P
M^@L  /T1  #_&P  _RD  /\[  #_3P  _V8  /]_  #_F0  _Z\  /_#  #_
MU@  _]8 _P0< /\ &0#_ !D _P < /\ (@#_ "L _P X /\ 1@#_ %, _P!>
M /\ :0#_ '( _P!Z /\ @@#_ (D _P"/ /\ E0#_ )L _P"A /\ J #_ *\
M_P"Y /\ Q0#_ -D _@#L /T ^P#[ /\ ^P#_ /L _P#Z /\ ] #_ /  _P#P
M /\ _P<8 /\!%0#_ !0 _P 6 /\ &P#_ "8 _P T /\ 0@#_ $X _P!: /\
M9 #_ &T _P!U /\ ?0#_ (0 _P"* /T D #\ )8 ^@"= /D HP#X *L ]P"T
M /4 OP#T ,X \P#F /$ ]@#P /\ [P#_ .\ _P#N /\ [@#_ .H _P#J /\
M_PL4 /\&$0#_ !  _P 0 /\ %@#_ "( _P N /\ / #_ $D _P!4 /X 7P#[
M &@ ^0!P /< > #U '\ \P"% /( BP#P )( [P"8 .T GP#L *8 Z@"N .@
MN0#G ,< Y0#> ., \ #B /X X #_ .  _P#A /\ X0#_ .$ _P#A /\ _PT0
M /\)#0#_ 0P _P , /\ $@#_ !P _P H /P -@#Y $, ]@!. /( 60#O &(
M[ !K .H <@#H 'D Y@"  .0 A@#B (P X0"3 -\ F@#= *$ VP"J -@ M #5
M ,  T@#3 -  Z@#. /H S0#_ ,T _P#- /\ S #_ ,P _P#, /\ _Q , /\,
M!P#_ P( _P ( /\ #@#_ !8 ]@ B /  +P#L #P Z0!( .4 4P#A %P W@!E
M -L ; #7 ', U !Z -( @ #0 (< S@". ,P E0#* )T R "E ,8 KP#$ +L
MP@#+ ,  Y0"^ /4 O0#_ +P _P"\ /\ O #_ +P _P"\ /\ _Q$% /\.  #_
M"@  _P@! /\$"@#X !  Z0 : ., * #> #4 V0!! -, 3 #/ %8 RP!? ,D
M9@#& &X Q !T ,( >P#! (( OP") +T D "\ )@ N@"A +@ JP"V +< M #'
M +( X "Q ?( KP+_ *X#_P"M!/\ K03_ *T$_P"M!/\ _Q0  /\0  #_#P
M\@T  .H*  #I PD W0 2 -0 'P#- 2T R (Z ,0#10#  U  O019 +L%80"Y
M!6@ MP9O +4&=@"T!WT L@>$ +$(C "O")4 K0F> *L)J "J"K4 J K% *8+
MWP"D#?0 H@[_ * ._P"?#O\ GP[_ )\._P"?#O\ _Q<  /\3  #O&   Y!D
M -L6  #2$ ( SPD+ ,@(%@#!"B0 O PR +<-/@"T#DD L0Y3 *\06P"M$&,
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M 7TI_P%\*/\!?"C_ 7PH_P%\*/\!]20  .,N  #/-0  P3@  +0V  "K,0
MI2P  *(F!@">)A, F2@A )4J+@"2*SD CRQ$ (TM3 "++50 B2Y< (<N8P"&
M+FH!A"YR 8(N>@&!+X0!?R^/ GTOF@)[+Z<">B^W G@OS )V,.H"=3#^ G,P
M_P)S,/\"<R__ G,O_P)S+_\"\"H  -PU  #'.P  NC\  *P\  "B.   G#,
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M UU _P-=0/\#WSD  ,A#  "Y2@  J4L  )M)  "01P  B$0  (-!  !^008
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MB 5,4Y<&2U.G!TE3N@=(4]4'2%+S!DA2_P5(4?\$25'_!$E0_P-)4/\#RD@
M +E2  "J5P  F%8  (I5  !_5   =E,  &Q1  !G4P  8E0( %]6$@!=5QX
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M!#EBM 4X8\T%.&+O!#AA_P0X8/\#.%__ SE>_P,Y7O\#O%4  *U?  "<8
MBU\  'U?  !R7P  :%\  %U@  !58@  3V0  $MF"@!)9Q( 1V@= $5H)P!$
M:3$ 0VDY $)J0@! :DH /VI2 #UJ6P$\:F4!.FIP CAJ?@(V:8T#-&F? S-I
ML@,Q:<L#,6CM S%G_P,Q9O\#,F7_ S)D_P,R9/\#MUL  *ED  "69   AF,
M 'AC  !M8P  9&0  %EE  !0:   26L  $-M! ! ;@X /F\8 #UO(@ \<"L
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M !B!_0 9@/\!&7__ 1E^_P$9?O\!IG   )5S  "$<@  =G$  &MQ  !><P
M5'8  $EY   _?0  -X$  "^$   GB   ((L% !N-#@ :C14 &8T> !B.)P 7
MCC  %HXY !6.0P 4CT\ $X]; !*/:@ 1CWL $(^/  ^/I  .C[L #8_@  Z-
M^@ /B_\ $(K_ !")_P 0B?\ H7H  (YY  !^=P  <G<  &1X  !8>P  37X
M $*"   YA@  +XH  ">.   @D0  &)4  !*8!0 .F@X #9H4  R:'0 +FB8
M"YHP  J:.P )FD8 ")I3  :;80 %FG( !)J&  *:FP  FK$  9G/  *9\  "
MF/\ !)?_  66_P %EO\ F8$  (=_  !Z?@  :WX  %V!  !0A0  18D  #N-
M   QD@  *)8  !^9   8G0  $:    RC @ &I0H  :40  "E%@  IA\  *8H
M  "F,@  IST  *=*  "G6   IV@  *=\  "GD0  IJ@  *;#  "EZ0  I?P
M *7_  "D_P  I/\ D8<  (*&  !RA@  8X@  %6,  !)D0  /98  #*:   H
MG@  'Z(  !>F   0J0  "ZP   2O    L08  +$,  "R$0  LA<  +,?  "S
M*   M#(  +4_  "U30  M5T  +5P  "UA@  M9T  +6V  "UW   M/<  +3_
M  "T_P  M/\ BX\  'J.  !JD0  6Y4  $V:  ! GP  -:0  "JH   @K
M%K    ^T   )MP   ;D   "]    O@   +X&  "_#   P!   ,$6  #"'0
MPR<  ,4R  #&0   QE$  ,=C  #'>   QY$  ,>I  #'QP  Q^P  ,?^  #'
M_P  Q_\ @Y<  '&:  !AG@  4J,  $6I   XK@  ++,  ""W   6N@  #KT
M  ;     PP   ,<   #)    R@   ,P   #- P  S@D  - .  #2$P  U!L
M -@E  #;,@  W4(  -U4  #>:0  WH$  -Z<  #?M0  W]D  -_S  #?_P
MW_\ =Y\  &BF  !9K0  2K,  #NX   MNP  '[\  !3"   ,Q@   \D   #,
M    T    -4   #9    V@   -P   #>    X    .(%  #D"P  YQ   .H8
M  #M)   \#(  /%$  #R6   \V\  /2*  #TI   ]+\  /3?  #T\P  ]/0
M:J@  %NO  !,MP  /;T  "W!   ?Q@  $\H   O.    T@   -<   #<
MX    .4   #G    Z0   .L   #M    [P   /$   #S    ]@<  /D.  #\
M%@  _R(  /\S  #_1P  _UT  /]V  #_D0  _ZD  /^^  #_V   _]L _P 8
M /\ %@#_ !4 _P 8 /\ '@#_ "< _P V /\ 0P#_ $\ _P!: /\ 9 #_ &T
M_P!U /\ ?0#_ (0 _P"* /\ D #_ )8 _P"< /\ HP#_ *L _P"T /X OP#]
M ,\ ^P#G /H ^ #Y /\ ^0#_ /D _P#U /\ [@#_ .D _P#G /\ _P 4 /\
M$0#_ !$ _P 2 /\ %P#_ ", _P Q /\ /@#_ $H _P!6 /\ 8 #_ &@ _P!P
M /\ > #] 'X _ "% /H BP#Y )$ ^ "8 /< G@#U *8 ] "N /( N0#Q ,<
M[P#@ .X \@#L /\ [ #_ .P _P#K /\ Y0#_ .  _P#> /\ _P,0 /\ #@#_
M  T _P - /\ $P#_ !X _P K /\ . #_ $4 _@!0 /L 6@#X &, ]0!K /,
M<@#Q 'D [P!_ .X A@#L (P Z@"2 .D F0#G *  Y@"I .0 LP#A ,  X #3
M -X ZP#< /L VP#_ -H _P#: /\ V0#_ -0 _P#2 /\ _P<- /\ "0#_  8
M_P ) /\ #P#_ !@ ^P E /@ ,@#U #\ \@!* .T 5 #J %T YP!E .0 ; #B
M ', X !Z -X @ #< (8 V@"- -< E #4 )L T@"D ,\ K0#- +D RP#) ,D
MY #( /8 Q@#_ ,4 _P#& /\ QP#_ ,< _P#' /\ _PH& /\!  #_    _P $
M /\ "P#T !( [P ? .H + #E #@ X@!# -T 3@#9 %< U !? -$ 9P#. &T
MS !T ,H >@#( (  Q@"' ,4 C@## )8 P0"> +\ J "] +, N@#" +D VP"W
M /  M0#_ +8 _P"U /\ M0#_ +4 _P"U /\ _PP  /\$  #_    _@   /8
M P#H  T X  7 -D ) #1 #$ S0 \ ,H 1P#& %$ PP!9 ,  8 "^ &< O !N
M +H = "Y 'L MP"" +4 B0"S )$ L@": +  I "N *\ K "] *H T "H .L
MIP#[ *8 _P"F /\ I0#_ *4 _P"E /\ _PT  /\'  #T"0  Z@D  .($  #:
M  < SP 1 ,@ ' #" "D O@ U +L 0 "W $H M !3 +( 6P"P &( K@!H *P
M;P"K '4 J0!] *@ A "F (T I "6 *, H "A *L GP&Y )T#S "<!.@ F@;Y
M )D'_P"8"/\ EPC_ )<(_P"7"/\ _Q   /<0  #H%   W!4  ,X1  #&#0
MP@0+ +P % "W 2$ L@,N *X%.@"K!D0 J A- *8(50"D"5P H@IC * *:@"?
M"W$ G0MX )P+@ ":#(D F0R3 )<,G@"5#:H E VX )(-S "0#NH CA#\ (P0
M_P"+$/\ BQ#_ (L0_P"*$/\ ^Q,  .T:  #=(   S"$  +\=  "W%P  LQ$
M +(+#0"K#1D IPXF *,/,P"?$#X G1%' )H14 "8$E< EA)> )4390"3$VP
MDA-S ) 4? "/%(4 C16/ (L5F@"*%:< B!:U (86R0"$%^< @AC[ ( 9_P!_
M&?\ ?QG_ '\8_P!_&/\ ]1H  .0C  #/*0  P"H  +,F  "J(@  I1P  *05
M" "@%!, FQ8A )<8+0"4&3@ D1I" (\;2P"-'%( BQQ9 (D=8 "('6< AAYO
M (4>=P"#'X  @A^+ ( ?EP!^(*, ?2"R 'L@Q0!Y(>0 =R+Y '8B_P!U(O\
M="'_ '0A_P!T(?\ [R$  -LK  #',0  MC$  *DN  "@*@  FR8  )@A 0"5
M'A  D" ; (TA* ")(S, AR0] (4D1@"#)4X @295 '\F7 !^)F, ?"=K 'LG
M<P!Y)WP >"B' '8HDP!T** !<BBO 7$IP0%O*> !;2GW 6PI_P%K*?\!:RG_
M 6LH_P%K*/\!Z"@  - R  # .   KC<  *$U  "8,@  DBT  (XI  "+)PP
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M_P)6._\"5CK_ 58Z_P%6.?\!U#<  ,!!  "O1   G4,  )!"  "%0   ?CX
M 'D[  !T.@  <3H. &T\& !K/20 :3XO &<_. !E/T  9$!( &) 3P!A0%<
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M D=&_P)'1O\"QD,  +9,  "B3   D4P  (1+  !Y2@  <$D  &E&  !D1P
M7TD& %Q*$ !:2QL 6$PE %9,+P!533@ 4TU  %)-2 !13D\ 3TY7 $Y.7P%,
M3FD!2DYS DA-@ )&38\#14V? T--L0-"3<@#04WJ T%,_P)!3/\"0DO_ D)*
M_P)"2O\"PD<  +-/  ">3P  C4X  (!.  !U30  ;$P  &-*  !>3   6DT"
M %9.#@!43Q@ 4E B %%1+ !/434 3E(] $U210!,4DT 2E)4 $E270%'4F8!
M15)Q 4-2?@)!4HT"/U*= SY2KP,]4L8#/%+I CQ1_@(\4/\"/4__ CU/_P(]
M3O\"ODL  *Y3  ":4@  B5$  'Q1  !Q4   :%   %Y.  !840  5%(  %%3
M# !.5!0 3%4? $M6*0!)5C( 2%8Z $=70@!&5TH 1%=2 $-76@!!5V0!0%=N
M 3Y7>P(\5XL".E>; CA7K0(W5\0"-U?G C=6_0(W5?\"-U3_ C=3_P(X4_\"
MND\  *E6  "550  A50  'A4  !M5   9%0  %A4  !25@  3E<  $I9"0!'
M6A$ 1EH; $1;)0!#6RX 0EPV $%</@ _7$8 /EU/ #U=5P [76$ .EUL 3A=
M>0$V78@!-%V9 C-=JP(Q7<(",5SE C%;_ (Q6O\",5G_ C)9_P$R6/\!ME0
M *19  "06   @%@  '-7  !I5P  8%@  %19  !.6P  2%T  $-?! ! 8 X
M/F$7 #UA(  [8BD .F(R #EB.@ X8T( -V-+ #9C5  T8UT ,V-H #%C=@$O
M8X4!+F.6 2QCJ0$K8[\!*F/C 2IB^P$J8/\!*U__ 2M?_P$K7O\!L5D  )Y<
M  "+7   >UL  &];  !E6P  7%P  %%>  !)8   0V(  #QE   X9PH -6@2
M #1H&P S:20 ,FDM #%I-0 O:CT +FI& "UJ3P L:ED *VME "EK<@ H:X(
M)FN3 "1KIP C:[T (FK@ "-I^0$C9_\!(V;_ 2-F_P$D9?\!K&   )A@  "%
M8   =E\  &I?  !A8   5V   $UC  !$9@  /6@  #9K   P;@0 +' . "IQ
M%0 I<1X *'$F "=R+P F<C< )7)  "1R2@ B<E0 (7-@ "!S;0 ><WT '7.0
M !MSHP :<[D &7/< !IQ]P :</\ &V__ !MN_P$;;?\!IF8  )%E  !_9
M<60  &9D  !=9   4F8  $AI   _;   -V\  #!S   I=@  (GD( !][$  >
M>Q< ''L? !M[*  :>S  &7PY !A\0P 7?$X %GQ: !5\9P 4?7@ $GV+ !%]
MGP 0?;4 #WW5 !![]0 1>?\ $7C_ !)W_P 2=_\ GFL  (IJ  !Z:0  ;6D
M &)I  !7:@  3&T  $-P   Y=   ,7@  "E[   B?P  &X(  !2%"0 1AA
M$887 !"''P 0AR@ #H<Q  Z'.P -AT8 #(=3  N'80 *AW$ "8>$  >'F  &
MAJX !8;)  :%[  'A/\ "(/_  F"_P )@O\ E7$  (-O  !T;@  :6X  %QO
M  !0<@  1G4  #QY   R?0  *H$  "*%   ;B0  %(P   ^/ P *D@L !I(1
M  22&  "DB   9(I  "2,P  DSX  )-+  "360  DVD  )-[  "2D   DJ8
M )&_  "1Y0  D/H  (__  "/_P  C_\ C7<  'UU  !P=   8G4  %5X  !)
M?   /X   #2$   KB0  (HT  !J1   3E   #I<   F;   !G0@  )T.  "=
M$P  GAH  )XB  "?*P  GS4  *!"  "@4   H%\  *!Q  "@AP  GYT  )^U
M  ">V@  G?8  )W_  "<_P  G/\ AGT  'A\  !I?   6W\  $Z#  !!B
M-HP  "R1   CE@  &IH  !*>   -H0  !J0   "G    J0,  *D*  "J#@
MJQ,  *P9  "M(@  KBL  *\W  "O10  KU0  *]F  "O>P  KI0  *ZK  "N
MR0  KN\  *W_  "M_P  K?\ @80  '&$  !AAP  4XL  $:0   YE@  +IL
M ".@   :I   $J@   RL   $KP   +(   "V    MP   +<"  "X"   N0T
M +H2  "[&   O2$  +XK  # .   P$@  ,!:  #!;@  P88  ,&@  #!N@
MP>,  ,#Y  # _P  P/\ >8T  &B0  !9E   2YH  #V@   QI0  ):L  !JO
M   1LP  "[@   *[    O@   ,$   #$    Q0   ,8   #'    R 4  ,H+
M  #,#P  SA4  - ?  #3*P  U3H  -5,  #68   V'<  -B2  #8K   V<D
M -GL  #9^P  V/\ <)D  &">  !1I   0ZH  #6P   HM@  '+H  !&^   )
MP0   ,4   #(    RP   ,\   #2    TP   -8   #8    VP   -T   #?
M!P  X@T  .43  #H'0  ["H  .T\  #M40  [F<  .^!  #OG   \+<  /#3
M  #P[   \/0 9Z8  %BM  !)M   .KH  "J^   <P@  $,8   ?*    S@
M -(   #6    W    .    #C    Y    .8   #H    ZP   .T   #O
M\@(  /4*  #X$0  _!P  /\L  #_/P  _U4  /]N  #_B@  _Z0  /^Z  #_
MT0  _^$ _P 4 /\ $@#_ !( _P 4 /\ &0#_ "4 _P R /\ /P#_ $L _P!6
M /\ 8 #_ &@ _P!P /\ > #_ '\ _P"% /\ BP#_ )$ _P"8 /\ G@#^ *8
M_0"N /P N0#Z ,@ ^0#B /@ ] #W /\ ]@#_ /8 _P#O /\ YP#_ .( _P#>
M /\ _P 1 /\ #@#_  X _P / /\ % #_ "  _P M /\ .@#_ $8 _P!1 /\
M6P#_ &, _@!K /P <P#Z 'D ^0"  /< A@#V (P ]0"2 /, F0#R *  \ "I
M .X LP#M ,$ ZP#6 .H [@#I /X YP#_ .< _P#E /\ W0#_ -4 _P#1 /\
M_P - /\ "@#_  @ _P ) /\ $ #_ !L _P H /\ -0#_ $  ^@!+ /8 50#S
M %X \0!F .X ;0#L '0 ZP!Z .D @ #G (8 Y@"- .0 DP#B )L X "C -X
MK0#< +D V@#* -< Y@#4 /@ T@#_ -( _P#2 /\ S@#_ ,D _P#& /\ _P (
M /\  P#_    _P # /\ #0#\ !8 ]P B /, +@#O #H [ !% .@ 3P#D %@
MX0!@ -X 9P#; &T V0!T -4 >@#3 (  T0"' ,\ C@#- )4 RP"> ,D IP#'
M +, Q0#" ,, W #! /$ OP#_ +\ _P"^ /\ O@#_ +T _P"[ /\ _P   /\
M  #_    _P   /8 " #N !$ YP ; .$ )P#= #, V0 ^ -, 20#/ %( RP!9
M ,@ 80#& &< Q !M ,( <P#  'H OP"  +T B "[ )  N0"8 +@ H@"U *T
MLP"[ +$ S@"P .H KP#\ *T _P"M /\ K@#_ *X _P"N /\ _P(  /\   #]
M    \@   .@   #>  P TP 5 ,P (0#( "P Q  X ,$ 0@"] $L N@!3 +@
M6@"V &$ M !G +( ;0"P '0 KP!Z *T @@"L (H J@"3 *@ G0"F *@ I "U
M *( Q@"A ., GP#V )X _P"> /\ G@#_ )X _P"> /\ _P8  /L   #N!0
MX@0  -4   #+  8 PP / +T &0"X "4 M  Q +$ .P"N $4 K !- *D 50"G
M %L I0!B *0 : "B &X H0!U )\ ? "> (4 G ". )H F "8 *0 E@"P )4
MP0"3 -P D@#R )$ _P"0 /\ D #_ (\ _P"/ /\ _0H  / .  #A$0  SA
M ,(-  "[!P  MP * +$ $@"L !X J  I *4 - "B #X GP!' )T 3P"; %8
MF0%< )<!8P"6 FD E )P ),#> "1 X  D 2* (X$E0",!:$ B@6N (D&O@"'
M"-@ A@GP (0*_P"#"_\ @PO_ (,+_P"#"_\ ]A   .87  #2'   P!H  +,6
M  "L$@  J T  *8'#0"B!18 G0<B )D)+@"6"C@ E M! )(,2@"0#%$ C@U8
M (P-7@"+#64 B0UL (@.= "&#GT A0Z' (,.DP"!#Y\ @!"M 'X0O@!]$-L
M>A'T '@2_P!W$O\ =Q+_ '<2_P!W$O\ [Q<  -LA  #&)   M",  *@@  "@
M'   FQ<  )D1! "8#A  DQ ; (\1)P",$C( B1,\ (<31 "%%$P @Q13 ($5
M6@" %6  ?A9H 'T6;P![%G@ >1># '@7CP!V&)P =!BJ ',9NP!R&=0 ;QKQ
M &X;_P!M&_\ ;1K_ &T:_P!M&O\ YR   - I  "\*P  JRH  )XH  "6)
MD"   (T<  ",%PP B!@6 (0:(@"!&RT ?APW 'P=0 !Z'4@ >1Y/ '<>50!V
M'UP =!]C ',?:P!Q('0 <"!_ &XABP!L(9@ :R&G &DBN !H(L\ 9B+N &4C
M_P!D(_\ 9"+_ &0B_P!D(?\ X"8  ,@O  "T,0  HS   )8N  "-*P  AR@
M (0D  ""( @ ?B 2 'LB'@!X(RD =20S ',E/ !Q)4, <"9+ &XF4@!M)UD
M:R=@ &HG: !I*'$ 9RA[ &4HB !D*94 8BFD & IM0!?*<L 7BKL %PJ_P!<
M*?\ 7"G_ %PI_P!<*/\ V"P  ,,U  "M-0  G30  ) S  "&,0  @"T  'PK
M  !Y* , =B<0 '(I&@!P*B4 ;2LO &LL. !J+$  :"U' &<M3@!E+E4 9"Y=
M &,N90!A+VX 7R]X %XOA !<+Y( 6B^A 5DOL@%8,,@!5C#I 54P_@%5+_\
M52__ %4N_P!5+O\ T#$  +TZ  "H.0  ES@  (HW  " -@  >C(  '4P  !R
M+@  ;BX- &LO%@!I,"$ 9C$K &0R- !C,CT 83-$ & S2P!?-%( 731: %PT
M8@!:-&L 635U %<U@@!5-9 !5#6? 5(UL %1-<8!4#7G 4\U_0%/-?\!3S3_
M 4\T_P%/,_\!RS8  +@]  "C/   DCP  (4[  ![.@  =#<  &\U  !L,P
M:#0* &4U$P!B-AX 8#<H %XW,0!=.#H 6SA! %HY2 !9.5  5SE7 %8Z7P!4
M.F@ 4SIS %$Z?P%/.HT!3CJ= 4PZK@%+.L,!2CKE 4DZ_ %).?\!23G_ 4DX
M_P%*./\!QSH  +-   ">/P  CC\  ($^  !W/0  <#L  &HX  !F.   8CD'
M %\Z$0!<.QL 6CLE %D\+@!7/3< 5CT^ %0^1@!3/DT 4CY5 %$^70!//V8
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M> % 2(<!/DB7 3Q(J0$[2+X!.DC? 3I'^ $Z1O\!.D7_ 3M%_P$[1/\!NT4
M *9(  "21P  @D<  '9'  !K1P  8T8  %M#  !610  4D<  $Y("@!,21(
M2DD< $A*)0!'2BX 1DLV $5+/@!#2T8 0DQ- $%,5@! 3%\ /DQJ #Q,=@ [
M3(4!.4R5 3=,IP$V3+P!-4S= 35+]P$U2_\!-4K_ 39)_P$V2?\!N$D  *)+
M  ".2@  ?DH  ')*  !H2@  7TD  %5(  !02@  3$L  $E,!P!&31  1$X9
M $)/(@!!3RL 0% S #]0.P ^4$, /%%* #M14P Z45P .%%G #=1<P U48(
M,U&3 3)1I0$P4;H!+U': 2]0]@$O3_\!,$[_ 3!._P$P3?\!M$T  )U-  "*
M30  >DT  &Y-  !D30  6TT  %%-  !+3P  1E   $)2 P _4PT /505 #Q4
M'@ Z52< .54O #A5-P W5C\ -E9' #564  S5ED ,E=D #!7<0 O5X  +5>1
M "M7HP J5[@ *5?6 "E6]0 I5?\ *E3_ 2I3_P$J4O\!KU$  )A1  "%40
M=E   &I0  !@4   6%$  $Y2  !'4P  054  #M8   X60H -5H1 #1:&@ S
M6R( ,ELK #%;,P O7#L +EQ# "U<3  L7%8 *UU@ "E=;0 H77P )EV. "1=
MH0 C7;4 (EW2 ")<\P B6_\ (UK_ "-9_P D6/\ J%4  ))4  " 5   <50
M &94  !<5   5%4  $I6  !#6   /%L  #9=   P8 4 +6$. "MA%0 J8AT
M*6(E "AB+@ G8S8 )F,^ "5C1P C8U$ (F1< "%D:0 ?9'D 'F2* !QDG@ ;
M9+, &63. !IC\0 ;8?\ &V#_ !Q@_P <7_\ H5D  (Q8  ![6   ;5@  &)8
M  !96   4%D  $=;   ^7@  -V   #%C   J9@  )&D) "%J$  @:A< 'VH@
M !YK*  =:S  '&LY !MK0@ :;$P &6Q8 !=L90 6;'0 %&R& !-LF@ 2;*\
M$6S* !%K[P 2:?\ $VC_ !-H_P 39_\ F5T  (5=  !U7   :%P  %Y<  !5
M7   2UX  $)A   Y9   ,F<  "MJ   D;0  'G ! !=S"P 5=!$ %'08 !-T
M(0 2=2D $74R !%U.P 0=48 #W52  YU7P -=6X #'6!  MUE0 *=:H "'3#
M  ETYP *<_T "W'_  QQ_P ,</\ D6(  ']A  !P80  9&$  %IA  !/8@
M164  #QH   S;   *V\  "1R   ==@  %WD  !%\!  -?PP "W\2  I_&0 )
M?R( "'\J  9_-  %?S\ !']+  )_6  !?V<  ']Y  !_C@  ?Z,  'Z[  !]
MX   ??<  'S_  ![_P  >_\ B6<  'AG  !K9@  868  %1G  !):0  /VT
M #5Q   L=0  )'D  !U\   6@   $(,   R& @ &B0H  8D/  ")%   BAL
M (HC  "++   BS<  (M#  "+4   BU\  (MQ  "+A@  BYP  (JS  ")TP
MB/,  (C_  "'_P  A_\ @FT  '-L  !H;   6FT  $YO  !"<P  .'<  "Y[
M   E@   '80  !6(   0C   "X\   22    E 8  )4,  "5$   EA4  )<<
M  "8)   F"X  )DY  "91P  F58  )EH  "9?0  F90  )BK  "7R   ENX
M );_  "5_P  E?\ >W0  &]S  !A<P  4W8  $9Z   [?P  ,(0  ":(   =
MC0  %)(   Z6   )F0   9P   "@    H0   *(&  "B#   I!   *44  "E
M'   IR0  *@O  "H/0  J4P  *E>  "I<@  J(D  *BB  "HO   I^4  *;[
M  "F_P  I?\ =WL  &A[  !9?@  2X(  #Z'   RC0  )Y(  !V7   4G
M#J    >D    J    *L   "N    KP   +    "Q!   LPH  +0.  "U$P
MMAL  +@D  "Z,0  ND   +I2  "[90  NWT  +J7  "ZL0  NM(  +KS  "Y
M_P  N?\ ;X,  %^&  !1BP  0Y   #:7   JG0  'Z(  !6G   -K   !;
M  "T    MP   +L   "^    OP   ,    #!    PP$  ,0'  #%#0  QQ$
M ,H9  #-)   SC,  ,]$  #06   T&X  -&(  #0I   T,$  -'F  #1^
MT?\ 9X\  %>4  !)F@  .Z$  "ZG   AK0  %K,   ZX   &O    ,    ##
M    Q@   ,L   #-    S@   -    #1    U    -8   #: @  W D  -\/
M  #C%P  YB0  .<V  #H20  Z5\  .IX  #KE   ZZ\  .O,  #LZ   [/8
M7YX  %"D  !"JP  -+(  ":Y   9O@  #L(   3%    R@   ,T   #1
MV    -L   #?    X    .(   #D    Y@   .D   #K    [@   /$%  #U
M#0  ^18  /PE  #].0  _D\  /]G  #_@@  _YT  /^U  #_RP  _^0 _P 1
M /\ #P#_  \ _P 1 /\ %@#_ "( _P O /\ .P#_ $< _P!2 /\ 6P#_ &0
M_P!L /\ <P#_ 'H _P"  /\ A@#_ (P _@"3 /T F0#[ *$ ^@"I /@ M #W
M ,( ]@#: /4 \0#T /\ \P#_ /, _P#I /\ X #_ -@ _P#3 /\ _P . /\
M"P#_  H _P + /\ $0#_ !T _P J /\ -@#_ $$ _P!, /\ 5@#^ %\ ^P!F
M /D ;0#W '0 ]0!Z /0 @ #R (8 \ "- .\ E #M )L [ "D .H K@#I +H
MYP#- .4 Z0#D /L XP#_ .( _P#> /\ T0#_ ,P _P#( /\ _P ) /\ ! #_
M  $ _P $ /\ #@#_ !@ _P D /T , #[ #L ]P!& /, 4 #O %D [ !@ .H
M9P#G &X Y@!T .0 >@#B (  X "' -X C@#< )4 V@"> -8 J #4 +, T0##
M ,\ WP#. /0 S #_ ,L _P#+ /\ Q0#_ +\ _P"\ /\ _P " /\   #_
M_P   /T "P#W !, \0 > .T *@#J #4 YP!  .( 2@#= %( V0!: -4 80#2
M &< T !M ,X <P#, 'H R@"  ,@ AP#& (\ Q "8 ,( H0#  *T O@"[ +P
MT "Z .T N0#^ +@ _P"X /\ MP#_ +, _P"P /\ _P   /\   #_    ^0
M .X !0#E  X W@ 8 -@ (P#2 "X SP Y ,L 0P#' $P Q !4 ,$ 6P"_ &$
MO !G +L ;0"Y ', MP!Z +4 @0"T (D L@"2 +  FP"O *< K "T *L Q@"I
M .0 IP#X *8 _P"F /\ I0#_ *4 _P"D /\ _P   /\   #U    Z@   -X
M  #0  H R  2 ,( '0"^ "@ NP S +D /0"U $8 L@!- +  50"M %L K !A
M *H 9P"H &T IP!S *4 >@"D (( H@", *  E@"? *$ G0"N )L O@"9 -@
MEP#Q )8 _P"6 /\ EP#_ )< _P"7 /\ _P   /4   #G 0  U    ,D   #
M  0 N  . +, %@"O "$ JP L *@ -@"F #\ HP!' *$ 3P"? %4 G0!; )L
M80": &< F !N )< =0"5 'T E "& )( D0"0 )P C@"I (P N "+ ,T B0#K
M (@ _0"( /\ B #_ (@ _P"( /\ ^08  .D,  #4#@  PPP  +<)  "P @
MJP ) *8 $ "B !H G@ E )L , "8 #D E@!! )0 20"2 %  D !6 (X 7 "-
M &( BP!I (H < "( '@ AP"! (4 C "$ )@ @@"E (  M !^ ,@ ?0'G 'P"
M^0![ _\ >P3_ 'L$_P![!/\ \0X  -X5  #%%0  M!0  *D1  "A#@  G@H
M )L## "7 !, DP > ) !*0"- C, B@,\ (@$0P"&!4L A091 (,&5P""!UX
M@ =D '\(; !]"'0 ? A^ 'H)B0!X"98 =PJC '4*LP!S"\< <@SF ' -^P!P
M#?\ ;PW_ &\-_P!O#?\ Z!8  - >  "Y'0  J1P  )T:  "5%@  D!,  (\.
M P"."@X B0L7 (8,(P"##2T @ TV 'X./@!\#D8 >PY- 'D/4P!X$%H =A!A
M '40: !S$'$ <1%[ ' 1AP!N$90 ;!&B &L2L@!I$L< :!/G &83_0!E%/\
M913_ &43_P!E$_\ WQX  ,8D  "P)   H",  )0A  "+'P  AAL  (,7  ""
M$@@ ?Q$2 'P2'0!Y%"@ =A0Q '05.@!R%D$ <19( &\73P!N%U8 ;!== &L8
M9 !I&&T :!EW &89@P!D&9  8QJ? &$:KP!@&L0 7AOD %T<^P!<'/\ 7!O_
M %P;_P!<&_\ U24  +TJ  "H*0  F"D  (PH  "#)0  ?2(  'D?  !X&P,
M=AD/ '(:& !O'", ;1TM &L=-0!I'CT :!Y$ &8?2P!E'U( 8R!9 &(@80!A
M(&D 7R%S %TA?P!<(8T 6B*< %DBK !7(L  5B/A %4C^0!4(_\ 5"+_ %0B
M_P!4(O\ S2L  +8N  "B+@  DBX  (4M  !\*P  =B@  '(F  !O(P  ;2$,
M &HB%0!G(Q\ 920I &,D,0!B)3D 8"9! %\F2 !=)D\ 7"=6 %LG70!9)V8
M6"AP %8H? !4*(H 4RF9 %$IJ@!0*;X 3RG> $XI]P!-*?\ 32G_ $TH_P!.
M*/\ R#   + R  "<,@  C#(  ( Q  !V,   <"T  &LK  !H*0  9B@) &,H
M$0!@*1P 7BHE %PK+@!;*S8 62P] %@L1 !7+4P 52U3 %0M6P!3+6, 42YN
M % N>@!.+H@ 3"^7 $LOJ !)+[L 2"_; $@O]@!'+_\ 1R[_ $<M_P!(+?\
MQ#0  *LU  "7-0  AS4  'LU  !R-   :S(  &8O  !B+@  7RT% %PN$ !:
M+Q@ 6# B %8P*P!5,3, 4S$Z %(R0@!1,DD 4#)0 $XS6 !-,V$ 2S-K $HS
M=P!(-(4 1S25 $4TI@!#-+D 0C36 $(T] !"-/\ 0C/_ $(R_P!",O\ P#@
M *<X  "3.   @S@  '<X  !M-P  9C8  &$S  !=,@  63(" %<S#0!4-!4
M4C4? %$U* !/-C  3C8X $PW/P!+-T8 2C=. $DX5@!'.%\ 1CAI $0X=0!#
M.(, 03F3 $ YI  ^.;@ /3G3 #PY\P \./\ /3?_ #TW_P ]-O\ NSL  *([
M  "/.P  ?SL  ',[  !J.@  8CD  %TW  !8-@  5#<  %$X"P!/.1, 33D<
M $LZ)0!*.BT 2#LU $<[/ !&/$0 13Q+ $0\4P!"/%P 03UG #\]<P ^/8$
M/#V1 #H]HP Y/;8 .#W1 #<]\@ W//\ .#O_ #@[_P X.O\ MCT  )X^  "+
M/@  ?#X  &\^  !F/0  7CT  %@[  !3.@  3SL  $P\" !)/1$ 1SX9 $8_
M(@!$/RH 0S\R $) .@!!0$$ 0$!) #Y!40 ]05H /$%D #I!<  X07\ -T&/
M #5"H0 T0K0 ,D+. #)!\  R0/\ ,T#_ #,__P T/O\ L4   )I   "'0
M>$$  &Q!  !B0   6T   %0_  !./P  2D   $9!!0!$0@X 0D,6 $!#'P _
M1"< /D0O #Q$-P [13X .D5& #E%3@ X1E@ -D9B #5&;@ S1GP ,4:- #!&
MGP N1K, +4;, "U&[P M1?\ +D3_ "Y#_P N0_\ K$,  )9#  "#0P  =$,
M &A#  !?0P  5T,  %!#  !(0P  1$4  $%& 0 ^1PP /$@3 #I('  Y220
M.$DL #9)-  U2CL -$I# #-*3  R2E4 ,$M? "]+:P M2WH +$N+ "I+G0 H
M2[$ )TO* "=+[0 G2O\ *$G_ "A(_P I1_\ IT8  )%&  !_1@  <$8  &5&
M  !;1@  5$8  $Q'  !$2   /TH  #M+   W3 D -4T0 #-.&  R3B  ,4\H
M #!/,  O3S@ +D]  "Q02  K4%( *E!< "A0:  G4'< )5"( "10FP B4*\
M(5#( "!0ZP A3_\ (D[_ ")-_P C3?\ H4D  (Q)  !Z20  ;$H  &%*  !8
M2@  4$H  $E+  ! 3   .TX  #50   Q4@0 +5,- "Q4%  J5!P *54D "A5
M+  G53, )E4\ "5610 D5DX (E99 "%690 ?5G0 'E:% !Q6F  ;5JP &5;%
M !E6Z0 :5?\ &U3_ !M3_P <4O\ FTT  (9-  !U30  :$T  %U-  !430
M34X  $5/   \40  -E,  #%5   K6   )EH) "-;$  B6Q< (5P? "!<)P ?
M7"X '5PW !Q=0  ;74H &EU5 !A=80 777  %5V! !1=E0 37:H $5W" !%=
MYP 26_X $UK_ !-:_P 46?\ E%$  (!1  !P40  9%$  %E1  !140  25(
M $%3   X5@  ,ED  "M;   E7@  'V$# !IC#  89!$ %V09 !9D(0 59"D
M%&4Q !-E.@ 2940 $650 !!E70 /96L #F5]  UED0 ,9:4 "F2\  IDX  +
M8_D #&+_  UA_P -8?\ C54  'I5  !K50  7U4  %95  !.50  1%<  #Q9
M   T7   +%\  "9B   ?90  &6@  !-K!0 0;0T #FX2  UN&@ ,;B( #&XK
M  MN-  *;CX "&Y*  =N5P &;F4 !&YV  )NB@  ;9\  &VV  !LU@  ;/,
M 6O_  )J_P #:O\ A5H  '1:  !F6@  7%D  %-9  !(6@  /UT  #9@   N
M8P  )F<  !]J   9;0  $W$   YT P *=PH !7<0  %W%0  =QP  '<D  !X
M+0  >#<  'A#  !X4   >%X  'AO  !XA   >)D  '>P  !VS0  =?   '7_
M  !T_P  =/\ ?E\  &Y?  !B7@  65X  $U?  !"8@  .64  #!H   G;
M'W   !AT   2=P  #7L   A^   "@ @  ($-  "!$0  @A<  (,>  "#)@
MA#   (0[  "$2   A%<  (1H  "$?   A),  (.J  ""Q0  @>L  ('^  "
M_P  @/\ =V4  &ED  !?8P  4F0  $=G   \:P  ,6\  "AS   @=P  &'P
M !%_   ,@P  !H<   "*    C ,  (P)  "-#@  CA$  (\7  "0'@  D2<
M )(R  "2/P  DDX  ))?  "2<P  DHL  )&B  "1O   D.4  (_\  "._P
MCO\ <6L  &9J  !8:P  2VT  #]Q   T=@  *GL  ""    7A0  $(D   N-
M   $D0   )4   "8    F0   )H#  ";"   G T  )X1  "?%@  H!X  *(H
M  "B-0  HT0  *-5  "C:0  HH   **:  "ALP  H-@  *#V  "?_P  G_\
M;G$  %]R  !1=0  1'D  #=^   LA   (8H  !>/   0E   "ID   &=
MH    *0   "G    J    *D   "J    K 8  *T+  "O$   L!4  +(>  "T
M*0  M#D  +1*  "U70  M7,  +6.  "UJ   M,8  +/M  "R_P  LO\ 9GH
M %=]  !)@@  /(<  "^.   CE   &)H  !"?   )I    *D   "M    L
M +0   "W    N    +D   "[    O    +X"  # "   P@X  ,04  #''@
MR"P  ,D]  #*4   RF8  ,I_  #*FP  RK@  ,K=  #*]0  RO\ 7H8  $^+
M  !!D0  ,Y@  ">?   ;I0  $:L   FP    M0   +D   "]    P0   ,8
M  #(    R0   ,L   #,    S@   -    #2    U 4  -D,  #=$@  X1X
M .(N  #C0@  Y%<  .5O  #FC   YJ@  .7%  #EYP  YO8 5I0  $B;   Z
MH@  +*D  !^P   3M@  "[P   #!    Q0   ,D   #-    T@   -8   #:
M    VP   -X   #@    X@   .0   #G    Z0   .T   #P"@  ]!$  /@?
M  #Y,@  ^D@  /M?  #\>@  _9<  /VO  #]QP  _>0 _P . /\ #0#_  P
M_P . /\ $P#_ !X _P J /\ -@#_ $( _P!- /\ 5P#_ %\ _P!G /\ ;@#_
M '0 _P!Z /\ @0#] (< _ "- /H E #Y )P ]P"E /4 KP#T +P \P#/ /$
M[ #P /X [P#_ .\ _P#C /\ UP#_ ,X _P#* /\ _P * /\ !@#_  0 _P (
M /\ $ #_ !D _P E /\ ,0#_ #T _P!' /X 40#[ %D ^0!A /8 : #T &X
M\P!T /$ >@#O ($ [@"' .P C@#J )8 Z "? .8 J0#C +4 X@#& .  XP#?
M /@ W0#_ -T _P#4 /\ R0#_ ,( _P"^ /\ _P # /\   #_    _P ! /\
M#0#_ !0 _0 @ /H *P#W #8 \P!! .\ 2P#L %0 Z !; .8 8@#C &@ X0!N
M -\ = #< 'H V@"! -@ B #4 )  T@"8 ,\ H@#- *X RP"\ ,D TP#' /
MQ@#_ ,0 _P#$ /\ NP#_ +8 _P"S /\ _P   /\   #_    _P   /< " #P
M !  ZP : .< )0#D #  X0 [ -P 10#5 $T T0!5 ,X 6P#+ &( R0!G ,<
M;0#% ', PP!Z ,$ @0"_ (D O0"2 +L G "Y *< MP"U +4 R "S .8 L@#[
M +$ _P"P /\ K@#_ *H _P"G /\ _P   /\   #^    \0   .4  @#<  T
MTP 4 ,T 'P#* "H QP T ,0 /@#  $< O !. +H 50"W %L M0!A +, 9P"R
M &T L !S *X >@"L (( J@"+ *@ E0"G *  I0"M *, O@"A -L H #T )\
M_P"> /\ GP#_ )T _P"; /\ _P   /P   #N    X    -    #%  @ O@ 0
M +D &0"U ", LP N +  -P"M $  J@!( *@ 3P"E %4 HP!; *( 8 "@ &8
MGP!L )T <P"; 'L F@"$ )@ C@"6 )H E0"G ), MP"1 ,P D #L (\ _P".
M /\ C@#_ (X _P"/ /\ _    .\   #;    R0   +T   "U  ( K@ , *D
M$P"E !T H@ G *  ,0"= #H F@!" )@ 20"6 $\ E !5 ), 6P"1 &  D !G
M (X ;0"- '4 BP!^ (D B0"( )4 A@"B (4 L0"# ,0 @0#D (  ^0!_ /\
M@ #_ (  _P"  /\ ] (  . )  #'"   MP<  *P#  "F    H  ' )L #P"8
M !< E0 A )( *@"/ #, C0 \ (L 0P") $D AP!0 (8 50"$ %L @P!A ($
M: "  '  ?@!Y 'P A ![ )  >0"= '@ K !V +X =0#= ', ] !S /\ <P#_
M ', _P!S /\ Z0T  ,\0  "Y$   J1   )X.  "7"P  DP8  )  "P", !$
MB0 : (8 ) "# "X @0 V '\ /@!] $0 ? !+ 'H 40!Y %< =P!= '8 9 !T
M &P <P%U '$!@ !O HT ;@*: &P#J@!K [L :036 &@&\0!H!_\ 9P?_ &<'
M_P!G!_\ WQ0  ,,7  "N%P  GA8  ),5  "+$@  AA   (0, @"#!@T @ ,4
M 'P%'@!Y!R@ =P@P '4(. !S"4  <@E& ' *3 !O"E, ;0M9 &P+80!J"VD
M:0QR &<,?@!F#(L 9 V9 &(-J0!A#;L 8 W8 %X.\P!=#O\ 70[_ %T._P!=
M#O\ U!P  +D=  "D'@  E1T  (D<  "!&@  >Q<  '@3  !X$ 8 =PT/ ',.
M& !P#B( ;@\K &P0,P!J$#L :1!" &<120!F$4\ 9!%6 &,270!A$F8 8!)O
M %X2>P!<$X@ 6Q.7 %D3IP!7%+H 5A35 %45\P!4%?\ 5!7_ %05_P!4%/\
MRB(  + B  "=(P  C2,  ($B  !Y(0  <QX  &\;  !N%P  ;1,, &H4% !G
M%1X 918G &,6+P!A%S< 8!<^ %X810!=&$L 7!E2 %H96@!9&6( 5QIL %8:
M=P!4&H4 4AN4 %$;I !/&[< 3AO0 $T<\0!,'/\ 3!S_ $T<_P!-&_\ PR8
M *HG  "6)P  AR@  'LG  !R)@  ;"0  &@A  !F'@  9!L( &(;$0!?'!H
M71TC %L>*P!:'C, 6!\Z %<?00!6($@ 5"!/ %,@5P!1(5\ 4"%I $XA= !-
M(8( 2R*1 $DBH@!((K0 1R+- $8C[P!%(_\ 12+_ $8B_P!&(?\ O"H  *0K
M  "1*P  @BP  '8K  !M*@  9BD  &(F  !?)   72($ %LA#@!8(A8 5B,?
M %0D* !3)#  4B4W % E/@!/)D4 3B9, $PF5 !+)UP 22=F $@G<0!&)W\
M12B/ $,HH !!*+( 0"C+ #\H[0 _*/\ /RC_ $ G_P! )_\ MRT  )\N  ",
M+P  ?2\  '$O  !H+@  82T  %TK  !:*   5R<  %0G# !2*!, 4"D< $XI
M)0!-*BP 2RHT $HK.P!)*T( 2"Q) $8L40!%+%H 1"QD $(M;P! +7T /RV-
M #TMG@ \+;  .BW( #HMZP Z+?\ .BW_ #HL_P Z+/\ LC   )LQ  "(,@
M>3(  &TR  !D,@  73$  %@O  !5+   42P  $\M"0!,+1$ 2BX9 $DO(@!'
M+RH 1C Q $4P. !#,#\ 0C%' $$Q3P! ,5< /C%A #TR;0 [,GL .3*+ #@R
MG  V,J\ -3+' #0RZ0 T,O\ -3'_ #4Q_P U,/\ K3,  )8T  "$-0  =34
M &DU  !@-0  630  %0S  !0,   3#$  $DQ!@!',@\ 13,6 $,S'P!"-"<
M0#0N #\U-@ ^-3T /35$ #PV3  Z-E4 .39? #<V:P V-G@ -#>) #(WF@ Q
M-ZT +S?% "\WZ  O-OX ,#7_ # U_P P-/\ J38  )(V  " -P  <C@  &8X
M  !=-P  5C<  % V  !+-   1S4  $0V P!!-PT /S@4 #XX'  \.20 .SDL
M #HY,P Y.CH .#I" #8Z2@ U.E, -#M= #([:  P.W8 +SN' "T[F0 L.ZP
M*CO# "D[Y@ J.OT *CK_ "LY_P L./\ I#@  (XY  !\.@  ;CH  &,Z  !:
M.@  4SH  $TZ  !&.   0CH  #\[   \/ L .CP1 #@]&0 W/2$ -CXI #0^
M,  S/C< ,C\_ #$_1P P/U  +C]: "U 9@ K0'0 *4"$ "A EP F0*H )4#!
M "1 Y0 D/_P )3[_ "8]_P F/?\ GSL  (H\  !X/0  :CT  %\]  !6/0
M3ST  $D]  !"/0  /#X  #D_   V00@ -$$/ #)"%@ Q0AX +T,E "Y#+0 M
M0S0 +$0\ "M$1  J1$T *$18 "=%8P E17$ (T6" ")%E0 @1:@ 'T6_ !Y$
MXP ?1/L 'T/_ "!"_P A0?\ FCX  (4_  !T0   9T   %Q   !30   3$
M $9    ^00  .$,  #1%   P1@, +4<- "M($@ J2!H *4@B "A)*0 G23$
M)4DY "1)00 C2DH (DI5 "!*80 ?2F\ '4I_ !M*D@ :2J8 &$J] !=*X  8
M2?H &4C_ !I'_P :1_\ E4(  (!"  !P0P  8T,  %A#  !00P  24,  $)$
M   [10  -4<  #!)   K2P  )DT) "1.$  B3A8 (4\= "!/)0 ?3RP 'D\U
M !U//0 <4$< &E!1 !E070 74&L %E!\ !10CP 34*0 $5"Z !%0W@ 13_@
M$D[_ !--_P 43?\ CT4  'M&  !K1@  7T<  %5'  !-1P  1D<  #]'   W
M2@  ,4P  "M.   F4   (%,# !Q5#  :5A$ &588 !=6(  65B< %58P !16
M.0 35T( $E=- !%760 05V@ #U=Y  Y7C  -5Z  "U>V  M6U  +5O0 #%7_
M  U4_P .4_\ B$D  '9*  !G2@  6TH  %%*  !*2@  0TH  #M,   S3@
M+%$  "94   A5@  &UD  !5<!P 17@T $%X3 !!>&@ .7B( #EXJ  U>,P ,
M7CT "UY(  I>5  (7F( !UYS  5>A@ #7IL  EZQ  )=S  "7>X  US_  1;
M_P %6_\ @4X  '!.  !B3@  5TX  $Y.  !'3@  /D\  #91   N5   )U<
M "%:   ;70  %6   !!C P ,9@L "&<0  9G%0 %9QP !&<D  )G+0 !9S<
M &="  !G3@  9UP  &=M  !G@   9I4  &:L  !EQP  9>L  &3\  !D_P
M8_\ >E(  &I3  !=4@  5%(  $M2  !"4P  .54  #!8   H6P  (5\  !IB
M   490  $&@   QK 0 &;@D  &\.  !O$@  ;Q@  ' ?  !P)P  <3   '$[
M  !Q2   <58  '%F  !Q>0  <8\  '"G  !OP0  ;^<  &[\  !M_P  ;?\
M<U@  &57  !:5P  458  $97   \6@  ,ET  "IA   B9   &F@  !1L   .
M;P  "G(   1V    > 4  '@+  !Y#@  >A,  'L9  !\(   ?2D  'TS  !]
M0   ?4X  'U>  !]<@  ?8@  'RA  !\N@  >^(  'KZ  !Y_P  >/\ ;5T
M &!<  !77   2UT  $!?   U8P  *V<  "-K   :;P  $W,   YW   (>P
M GX   ""    @P$  (0&  "%"P  A@\  (@3  ")&0  BB$  (LK  "+-P
MC$8  (M6  "+:0  BX   (N9  "*LP  B=@  (CW  "(_P  A_\ :&,  %YB
M  !18@  1&4  #AI   N;@  )',  !IX   3?0  #8$   :%    B0   (T
M  "0    D@   )(   "4!0  E0H  )<.  "8$@  FA@  )LA  "<+0  G3P
M )U,  "<7P  G'8  )N1  ";JP  FLD  )KP  "9_P  F/\ 96D  %=I  !)
M;   /7$  #!V   E?   &X$  !*'   ,C   !)$   "5    F0   )T   "@
M    H0   *(   "D    I0$  *<'  "I#   JA$  *T8  "O(@  KS   *]!
M  "O5   KVL  *Z%  "NH0  KKX  *WF  "L_   K/\ 7G$  $]T  !">0
M-7\  "B%   =C   $Y(   R8   #G0   *(   "F    J@   *X   "P
ML0   +,   "T    M@   +@   "Z!   O H  +X0  #!%P  PR0  ,,U  #$
M20  Q%X  ,5W  #%DP  Q:\  ,71  ##\@  P_\ 5GP  $>"   ZB   +(\
M ""6   4G0  #:,   .I    K@   +(   "W    NP   +\   #"    P@
M ,4   #&    R    ,H   #-    SP   -((  #5#@  VQ@  -TG  #>.@
MWU   .!H  #@A   X:$  .&]  #AX@  X/0 3HL  $"2   RF0  ):$  !BH
M   .KP  !;4   "Z    OP   ,0   #(    S@   -$   #4    U0   -@
M  #:    W0   -\   #B    Y    .<   #K!0  [PX  /09  #U*P  ]D$
M /=8  #X<@  ^9   /FK  #XQ   ^.$ _P + /\ " #_  D _P , /\ $@#_
M !H _P F /\ ,@#_ #X _P!( /\ 4@#_ %H _P!B /\ :0#_ &\ _P!U /X
M>P#\ ($ ^P"( /D CP#W )< ]0"@ /, J@#R +< [P#) .T Y@#L /L ZP#_
M .L _P#= /\ S@#_ ,8 _P#" /\ _P $ /\   #_    _P % /\ #0#_ !4
M_P A /\ + #_ #@ _P!# /T 3 #Y %0 ]P!< /0 8P#R &D \ !O .X =0#L
M 'L Z@"" .@ B0#G )$ Y ": .( I #@ +  W0#  -H W #8 /0 U0#_ -,
M_P#+ /\ P0#_ +L _P"W /\ _P   /\   #_    _P   /\ "@#] !$ ^0 ;
M /8 )P#T #( \  \ .P 1@#H $X Y !6 .$ 7 #> &, W !H -D ;@#5 '0
MT@![ -  @@#- (H RP"3 ,@ G0#& *@ Q "W ,$ S #  .L O@#_ +T _P"]
M /\ M #_ *X _P"K /\ _P   /\   #_    ^@   /( !0#J  X Y0 6 .
M(0#= "L VP V -, /P#. $@ R@!/ ,< 5@#$ %P P@!A ,  9P"^ &T O !S
M +H >@"X (( M@"+ +0 E@"R *$ L "O *X P0"M .  JP#W *H _P"I /\
MI@#_ *$ _P"? /\ _P   /\   #W    Z    -P   #0  H R@ 1 ,4 &P#"
M "4 OP O +P . "X $$ M0!( +( 3P"P %4 K@!; *P 80"J &8 J !L *<
M<P"E 'L HP"$ *$ C@"? )H G0"G )L N ": -  F0#O )@ _P"7 /\ E@#_
M )0 _P"2 /\ _P   /8   #D    T@   ,4   "[  4 M0 . +  %0"L !\
MJ@ I *@ ,@"E #H H@!" *  20"> $\ G !5 )H 6@"8 &  E@!F )4 ; "3
M '0 D@!] )  AP". ), C "A (L L "* ,4 B #F (< ^P"& /\ AP#_ (<
M_P"& /\ ^    .4   #-    O0   +,   "J    HP * )\ $0"; !D F0 C
M )< + "5 #0 D@ \ )  0P". $D C !/ (H 5 ") %H AP!@ (8 9@"$ &X
M@P!W ($ @0!_ (T ?@"; 'P J@![ +P >@#; '@ ]0!X /\ > #_ '@ _P!X
M /\ [0   -$"  "[ @  K $  *(   ";    E@ % )$ #0"- !0 BP = (@
M)@"& "X A  V (( /0"  $, ?@!) 'T 3P!\ %4 >@!; 'D 80!W &D =0!Q
M '0 ? !R (@ <0"6 &\ I0!N +8 ;0#. &P [@!K /\ :P#_ &L _P!K /\
MWPL  ,(,  "N#   G@P  ),+  ",!P  B (  (4 "0"! !  ?P 7 'P ( !Z
M "@ >  P '8 . !T #X <P!$ '$ 2@!P %  ;@!6 &T 70!L &0 :@!M &@
M=P!G (0 90"2 &0 H0!C +( 80#) &  Z0!@ /P 8 #_ &  _P!@ /\ T!
M +81  "B$@  DQ(  (@1  " #P  ? T  'D) 0!X PL =0 1 ', &@!P ",
M;@$K &P!,P!J CD :0-  &<#1@!F!$P 9012 &,%60!B!6$ 8 5J %\&= !=
M!H$ 7 >/ %H'GP!9![  5P?& %8)YP!6"OL 50K_ %4*_P!6"O\ QA4  *T7
M  "9&   BA@  '\7  !V%@  <1,  &X0  !M#04 ;0D- &H)% !G"AT 90HF
M &,++@!B##4 8 P\ %\,0@!>#4@ 7 U/ %L-5@!9#5X 6 YH %8.<P!5#H
M4PZ/ %$.GP!0#K$ 3@[( $T0Z@!-$/T 31#_ $T0_P!-$/\ O!L  *4<  "2
M'0  @QX  '<=  !O'   :1H  &87  !D%   9! ( &(/$ !?$!@ 71 A %L1
M*0!:$3$ 6!(X %<2/@!6$D4 5!), %,34P!1$UL 4!-E $X4< !,%'T 2Q2,
M $D4G !'%:X 1A7% $45Z !%%OX 11;_ $45_P!%%?\ M1\  )XA  "+(@
M?"(  '$B  !H(0  8A\  %\=  !<&@  6Q<" %H5#0!7%A0 518= %07)0!2
M&"T 41@T $\8.P!.&4( 31E( $L:4 !*&E@ 2!IB $<:;0!%&WH 0QN) $(;
MF@! &ZP /QO" #X<Y0 ]'/P /AS_ #X;_P ^&_\ KR,  )@D  "&)0  =R8
M &PF  !C)0  720  %DB  !6'P  5!T  %,<"P!1'!( 3AT: $T=(@!+'BD
M2AXQ $D?-P!''SX 1B!% $4@30!#(%4 0B!? $ A:@ _(7< /2&' #LAF  Y
M(:H ."+  #<BXP W(OL -R+_ #@A_P X(?\ JB8  )0G  "!*0  <RD  &<I
M  !?*0  6"@  %0F  !1(P  3R(  $PB!P!*(A  2"(7 $<C'P!%)"8 1"0N
M $(D- !!)3L 0"5# #\E2@ ])E, /"9< #HF9P Y)G4 -R>$ #4GE@ T)Z@
M,B>^ #$GX0 Q)_D ,B;_ #(F_P S)?\ I2D  (\J  !]+   ;RP  &0M  !;
M+   52L  % J  !,*   2B8  $<G! !$)PT 0B@4 $$H'  _*2, /BDK #TI
M,@ \*CD .RI  #DJ2  X*U  -BM: #4K90 S*W( ,2N" # LE  N+*< +"R\
M "LLW@ L+/@ +"O_ "TJ_P M*O\ H2P  (LM  !Y+@  :R\  & O  !8+P
M42X  $PN  !(+   12L  $$K   _+ L /2P1 #LM&0 Z+B$ .2XH #<N+P V
M+S8 -2\^ #0O10 S+TX ,3!8 # P8P N,'  +#"  "HPD@ I,*4 )S"Z "8P
MW  F,/< )R__ "@O_P H+O\ G"X  (<P  !V,0  :#(  %TR  !5,@  3C$
M $@Q  !$,   0"\  #PP   Z,0D -S$0 #8R%@ U,AX ,S,E #(S+  Q,S,
M,#0[ "\T0P M-$P +#16 "HU80 I-6X )S5^ "4UD  C-:, (C6Y "$UV0 A
M-/8 (C3_ ",S_P C,O\ F#$  (,S  !R-   930  %HU  !1-0  2S0  $4T
M  ! -   .C,  #<T   T-08 ,C8. # W$P O-QL +C<B "TX*0 K.#$ *C@X
M "DY0  H.4D )CE3 "4Y7P C.6P (3I\ " ZC@ >.J( '#JW !LYU0 <.?4
M'3C_ !TX_P >-_\ DS0  '\V  !N-P  83<  %<W  !.-P  2#<  $(W   \
M-P  -3@  #(Y   O.@( +#L+ "H\$0 I/!@ *#T? "8])@ E/2X )#TU ",^
M/0 B/D8 (#Y0 !\^7  =/VD &S]Y !H_C  8/Z  %C^U !4^T@ 6/O, %SW_
M !@\_P 8//\ CC<  'HX  !J.0  7CH  %,Z  !+.@  13H  #\Z   Y.@
M,CP  "X^   I0   )D$( "1"#@ B0A0 (4(; "!#(P ?0RH 'D,R !Q#.@ ;
M1$, &D1- !A$60 71&< %41W !-$B@ 21)X $42S !!$T  00_( $4+_ !)"
M_P 30?\ B3L  '8\  !F/0  6CT  % ]  !(/0  0CT  #P]   V/@  +T
M "I"   E1   (48# !U(#  ;21$ &4D7 !A)'@ 7228 %DDN !5*-@ 42D
M$TI* !%*5@ 02F0 #TIT  Y*AP -2IL #$JP  I*R@ +2>P #$C_  U'_P -
M1_\ @SX  '$_  !B0   5D   $U   !%0   /T   #E!   R0@  *T4  "9'
M   A20  '$L  !9.!P 34 X $E 3 !%0&0 04"$ #U I  Y0,0 -4#L #5%&
M  M140 *45\ "5%O  =0@0 %4)8  U"K  )0Q0 #3^@  T_[  5._P &3?\
M?4(  &M#  !=1   4D0  $I$  !#0P  /$0  #5%   N1P  )TH  "%,   <
M3P  %U$  !)4 P .5PH "U@0  I8%0 (6!P !U@D  98+  %6#8  UA   %8
M3   6%H  %AI  !8?   6)$  %>G  !7P   5N4  %;Y  !5_P  5?\ =D<
M &9'  !92   3T<  $='  ! 1P  .$@  #!*   I30  (E   !Q3   650
M$5@   U; @ )7@D !%\.  !?$@  7Q@  & ?  !@)P  8#   & [  !@1P
M8%0  &!C  !@=@  8(L  %^B  !?NP  7^(  %[Y  !=_P  7?\ ;TL  &%,
M  !53   3$L  $1+   [3   ,DX  "M1   C5   '%<  !9;   17@  #6
M  AC   "9@<  &<,  !G#P  :!,  &D9  !J(0  :BD  &HT  !J0   :DT
M &I=  !J;P  :H4  &J=  !IM@  :-T  &CW  !G_P  9O\ :5$  %Q0  !2
M4   2D\  #]0   U4P  +58  "19   =70  %F   !!D   ,9P  !FH   !N
M    ;P,  ' (  !Q#0  <A   '04  !U&P  =B,  '<L  !W.   =D8  '96
M  !V:   =GX  ':7  !UL0  =-,  '/U  !S_P  <O\ 8U8  %A5  !05
M1%4  #E8   O6P  )E\  !UC   59P  $&P   IP   $<P   '8   !Z
M?    'P#  !^"   ?PP  ($0  ""%   A!L  (4D  "&+P  ACT  (9-  "%
M7P  A74  (6/  "$J0  @\D  (+Q  "!_P  @/\ 7UL  %9:  !)6P  /5X
M #)A   G9@  'FL  !5P   .=0  "7D   %^    @0   (4   "(    B@
M (L   "- 0  C@8  ) +  "1#P  DQ0  )4;  "7)@  ES0  )=$  "75@
MEFP  )6&  "5H@  E,$  )/J  "2_P  DO\ 76$  $]A  !"9   -FD  "IN
M   ?=   %7D   Y_   'A    (D   ".    D@   )8   "8    F@   )L
M  "=    GP   *$#  "C"   I0T  *<3  "I'   JB@  *HY  "J2P  JF$
M *EZ  "HF0  J+4  *?=  "G^   IO\ 5F@  $AL   Z<   +G8  ")]   7
MA   #HH   >0    E@   )H   "?    HP   *<   "J    JP   *T   "O
M    L0   +,   "U    N 4  +H,  "]$@  P!P  , M  # 0   OU4  +]N
M  "^BP  OJ@  +[)  "][P  O/X 3G0  $!Y   R?P  )8<  !F.   0E0
M!YP   "B    IP   *P   "P    M0   +D   "\    O0   +\   #!
MPP   ,8   #(    R@   ,T"  #0"P  U1(  -8A  #7-   V$D  -E@  #:
M?   VIH  -NU  #;V0  V_( 1H(  #B)   KD   '9@  !*@   *IP   *X
M  "T    N0   +X   #"    R    ,L   #.    SP   -(   #4    U@
M -H   #=    WP   .(   #F    Z@H  .\3  #P)0  \CH  /-1  #T:P
M](D  /6E  #UOP  ]=T _P & /\  P#_  4 _P + /\ $ #_ !< _P B /\
M+0#_ #D _P!$ /\ 30#_ %4 _P!= /\ 9 #_ &H _P!P /T =@#[ 'P ^0"#
M /< B@#U )( \P"; /  I@#N +, ZP#$ .D Y #G /D Y@#_ .4 _P#3 /\
MQP#_ +\ _P"[ /\ _P   /\   #_    _P " /\ "P#_ !( _P = /\ * #_
M #, _P ^ /P 1P#X $\ ] !7 /$ 70#N &, [ !I .H ;P#H '4 Y@!\ .0
M@P#B (L WP"5 -P GP#9 *L U0"[ -( U #/ /( S0#_ ,P _P#% /\ N@#_
M +0 _P"P /\ _P   /\   #_    _P   /\ !@#Y  \ ]0 7 /, (@#Q "T
M[0 W .< 0 #B $D WP!0 -L 5P#7 %T U !C -$ : #/ &X S !U ,H ? #(
M (0 Q0"- ,( F #  *0 O0"R +L Q@"Y .@ N #] +< _P"V /\ K0#_ *<
M_P"C /\ _P   /\   #_    ]0   .L  0#D  P W@ 3 -D ' #3 "8 T0 P
M ,P .@#( $( Q !* ,  4 "] %8 NP!< +D 80"W &< M0!M +, = "Q 'P
MKP"% *T D "J )P J "J *8 NP"E -H HP#U *, _P"B /\ G@#_ )H _P"7
M /\ _P   /X   #O    WP   -    #'  < P0 / +P %P"Y "  MP J +4
M,P"P #L K0!# *L 20"H $\ I@!5 *0 6@"C &  H0!F )\ ;0"= '0 G !]
M )H B "8 )0 E@"B )0 L@"2 ,D D0#K )$ _P"0 /\ D #_ (P _P"* /\
M_    .P   #9    QP   +H   "Q  ( JP , *< $@"D !L H0 D *  + ">
M #4 FP \ )@ 0P"6 $D E !/ )( 5 "0 %H CP!? (T 9@"+ &T B0!V (@
M@ "& (P A ": (( J@"! +X @ #@ (  ^0!_ /\ ?P#_ '\ _P!^ /\ \0
M -@   #"    LP   *@   "@    F0 ' )4 #@"2 !4 D  > (X )@"- "X
MB@ V (< /0"% $, A !) (( 3@"! %0 ?P!9 'X 8 !\ &< >@!O 'D >@!W
M (8 =0"4 '0 HP!R +4 <@#/ '$ \0!P /\ < #_ '  _P!Q /\ X0   ,0
M  "P    H@   )<   "1    BP " (8 "P"# !$ @0 8 '\ (0!] "D ?  P
M 'D -P!X #T =@!# '0 20!S $X <@!4 '  6@!O &( ;0!J &L = !J (
M: ". &< G0!E *\ 90#& &0 Z !D /T 8P#_ &, _P!D /\ SP4  +8'  "C
M"   E @  (D'  "" P  ?@   'L !@!W  X =0 3 '( &P!Q ", ;P K &T
M,@!L #@ :@ ^ &D 1 !G $D 9@!/ &4 5@!C %T 8@!E &  ;P!? 'L 70")
M %P F0!; *H 60"_ %D X0!8 /@ 6 #_ %@ _P!9 /\ P@P  *H-  "7#@
MB0X  'T.  !V#0  <0H  &\&  !M  H :P 0 &D %@!G !X 90 F &, +0!A
M #, 8  Y %\ /P!= $4 7 !+ %L 4@!: %D 6 !B %< ; !5 '@ 4P"& %(
ME@!1 *< 4 "[ $\!VP!. O0 3@/_ $X$_P!. _\ N!   *$2  ".$P  ?Q,
M '03  !L$@  9Q   &4.  !C"P, 8P8, &$$$0!> QD 7 0A %L%* !9!B\
M6 8U %8'.P!5!T( 5 =( %,(3P!1"%8 4 E? $X):0!-"78 2PJ$ $D*E !(
M"J8 1PJZ $8*V !%"_, 10S_ $4,_P!%#/\ L!0  )D6  "'&   >!D  &T8
M  !E%P  7Q8  %P3  !:$0  6@X& %H,#0!7#!0 50P< %,-) !2#2L 4 TQ
M $\.. !.#CX 30Y% $L.30!*#E4 2 ]> $</: !%#W4 0Q"$ $$0E0! $*8
M/A"[ #T0W  ]$?8 /1'_ #T0_P ^$/\ J1D  )(;  "!'   <AT  &<=  !?
M'   61L  %49  !3%@  4A,  %(1"@!0$!  3A$8 $P1( !*$B< 21(N $@3
M- !'$SL 11-" $0320!#%%( 011; #\490 ^%7( /!6! #H5D@ X%:0 -Q6Y
M #45V  U%O4 -A;_ #86_P W%?\ HQP  (T>  ![(   ;2$  &(A  !:(0
M5!\  % >  !-&P  3!D  $L6!@!)%@X 1Q<5 $47' !$&"0 0A@J $$8,0!
M&3@ /QD_ #T91@ \&D\ .AI8 #D:8P W&V\ -1M^ #,;D  R&Z( ,!NW "\;
MTP O'/, +QO_ # ;_P P&_\ G1\  (@B  !W(P  :20  %XD  !6)   4",
M $LB  !((   1AT  $4< @!#' P 01P2 #\=&0 ^'2$ /!XG #L>+@ Z'S4
M.1\\ #<?1  V'TP -"!6 #,@8  Q(&T +R!\ "TAC@ L(:  *B&U "DAT  I
M(?( *2'_ "H@_P K(/\ F2(  (0E  !S)@  92<  %LG  !3)P  3"8  $<E
M  !$)   0B$  #\A   ](0D .R$0 #DB%@ X(AX -B,E #4C*P T)#( ,R0Y
M #(D00 P)$H +R53 "TE7@ K)6L *B5Z "@EC  F)9\ )"6S ",ES@ C)?
M)"7_ "4D_P E)/\ E"4  ( G  !O*0  8BH  %<J  !/*@  22D  $0H  !
M)P  /28  #HE   W)@8 -28. #0G%  R)QL ,2@B # H*0 O*#  +2DW "PI
M/P K*4< *2E1 "@J7  F*FD )"IX ",JB@ A*IT 'RJR !XJS  >*N\ 'RG_
M " I_P A*/\ D"@  'PJ  !L*P  7RP  %0L  !,+   1BP  $$K   \*P
M."H  #4J   R*P, ,"L, "XL$0 M+!@ +"P? "HM)@ I+2T *"TT "<N/  F
M+D4 )"Y/ ",N6@ A+V< 'R]V !TOB  <+YL &B^P !@OR@ 8+NT &2[_ !LM
M_P ;+?\ C"L  '@M  !H+@  6R\  %$O  !)+P  0R\  #XN   Y+@  -"X
M # N   M+P  *S * "DQ$  G,14 )C$< "4R(P D,BH (S(Q "$S.0 @,T(
M'S-, !TS5P ;,V0 &C1T !@TA@ 6-)H %#.N !,SR  3,^P %#/_ !4R_P 6
M,?\ ARX  '0O  !E,0  6#$  $XR  !&,@  0#$  #LQ   V,0  ,3$  "LS
M   H-   )34& ",V#0 A-A( (#<9 !\W(  >-R< '3@N !LX-@ :.#\ &3A)
M !<Y50 5.6( %#EQ !(YA  1.9@ $#FM  XXQP ...L $#C_ ! W_P 1-O\
M@S$  ' R  !A-   530  $LT  !$-   /30  #@T   S-   +34  "@W   D
M.0  (#H" !T["P ;/!  &3T5 !@]'  7/2, %CTK !4^,P 4/CP $CY& !$^
M4@ 0/E\ #SYO  X^@0 ,/I4 "SZI  H^P0 */>0 "SW[  P\_P -._\ ?30
M &LV  !=-P  43<  $@W  !!-P  .S<  #4W   P-P  *CD  "4[   @/0
M'#\  !=!!@ 40PT $D,2 !%#&  10Q\ $$0G  ]$+P .1#D #41#  Q$3@ +
M1%L "41J  =$?  &1)  !$.E  )#O0 #0^   T/V  1"_P &0?\ >#@  &<Y
M  !9.@  3CH  $4Z   ^.@  .#H  #,Z   M.P  )ST  "%    <0@  %T0
M !-& P /20H #4H/  Q*%  +2AL "4HC  A**P '2C0 !4H^  1*20 "2E8
M $IE  !*=P  2HL  $JA  !)N0  2=T  $GU  !(_P  2/\ <CP  &(]  !5
M/@  2CX  $(]   \/0  -CT  "\^   I0   (T(  !U%   71P  $TH   ],
M @ +3PD !U -  -1$0  41<  %$>  !1)@  42\  %$Y  !11   4E$  %)@
M  !1<@  48<  %&=  !1M0  4-@  %#U  !/_P  3_\ ;$   %U!  !100
M1T$  $!    Y0   ,D$  "I#   D1@  'D@  !=+   23@  #E$   M3 0 &
M5@<  %<,  !8$   6!,  %D9  !:(0  6BD  %HS  !:/P  6DP  %I:  !:
M;   6H$  %F9  !9L0  6-$  %CT  !7_P  5_\ 944  %A%  !-10  140
M #Y$   U10  +4<  "5*   >30  &%   !)3   .5@  "ED   1<    7@0
M %\)  !@#0  81   &(5  !C&P  9",  &0M  !D.   9$4  &14  !D9@
M9'L  &.3  !CK0  8LP  &'R  !A_P  8/\ 7TH  %-*  !*20  0T@  #E)
M   O3   )T\  !]2   850  $ED   U=   (8    F,   !F    : $  &D%
M  !J"@  :PT  &T1  !N%@  <!T  '$F  !Q,0  <#X  '!.  !P7P  <',
M &^-  !OIP  ;L8  &WO  !L_P  ;/\ 6D\  %!.  !(30  /4X  #-1   I
M5   (%@  !A<   18   #&0   9H    :P   &\   !R    =    '4   !W
M!   > D  'H-  !\$   ?18  '\>  " *   @#4  (!%  !_5@  ?VL  '^$
M  !^H   ?;X  'SI  ![_P  >O\ 5E0  $Y3  !"5   -U8  "Q:   B7P
M&&,  !%H   +;0   W(   !V    >@   'T   "     @P   (0   "&
MAP(  (D'  "+#   C1   ) 6  "2'P  DBP  )([  "230  D6(  )%Z  "/
MEP  C[0  ([A  ",^P  C/\ 55D  $A:   [70  +V$  "1F   9;   $7(
M  IW   "?0   ((   "&    BP   (X   "1    DP   )4   "7    F0
M )L   "=!   GPH  *(/  "D%@  IB$  *8Q  "F0P  I5<  *1P  "CC@
MHZL  *'0  "@]0  G_\ 3F$  $!D   S:0  )VX  !MU   1?   "X,   ")
M    C@   ),   "8    G0   *$   "D    I0   *<   "I    JP   *T
M  "P    L@   +4(  "X#@  O!8  +PE  "\-P  NTP  +ID  "Y@0  MZ(
M +?   "WZ@  M_P 1FL  #EP   K=P  'W\  !.&   +C@   94   ";
MH0   *8   "K    L    +,   "W    MP   +H   "\    OP   ,$   #$
M    QP   ,H   #-!0  T0X  -09  #4*P  U$   --8  #3=   TY(  -*P
M  #2TP  TO( /GD  #&    CB   %Y$   V9   #H    *<   "N    LP
M +@   "]    P@   ,8   #*    R@   ,T   #/    T@   -4   #9
MW0   -\   #C    YP4  .L/  #L'P  [3,  .Y+  #O9   [X(  /"?  #Q
MN0  \=@ _P   /\   #_  0 _P ) /\ #@#_ !4 _P > /\ *0#_ #0 _P _
M /\ 2 #_ %  _P!8 /\ 7@#_ &4 _0!K /L <0#Y '< ^ !^ /8 A0#S (T
M\0"7 .X H@#K *\ Z #  .8 X #C /@ X@#_ -L _P#+ /\ P0#_ +D _P"T
M /\ _P   /\   #_    _P   /\ "0#_ !  _P 9 /\ (P#_ "X _0 Y /D
M0@#U $H \@!2 .X 6 #K %X Z0!D .8 :@#D '  X@!V -\ ?0#= (8 V0"/
M -4 F@#1 *< S@"V ,L S@#) /  QP#_ ,4 _P"[ /\ M #_ *T _P"I /\
M_P   /\   #_    _P   /L  @#V  T \0 3 .T '@#L "@ Z0 R ., .P#=
M $0 V !+ -, 40#0 %@ S0!= ,L 8P#) &@ Q@!O ,0 =@#" 'X OP"' +P
MD@"Z )\ MP"M +4 P0"R .0 L0#] *\ _P"L /\ I0#_ *  _P"< /\ _P
M /\   #[    [@   .0   #<  @ TP 0 ,\ & #+ "( R0 K ,8 - #! #T
MO0!$ +H 2P"W %$ M0!6 +( 7 "P &$ K@!G *P ;@"J '8 J !_ *8 B@"C
M )8 H0"E )\ M@"= -$ G #S )L _P"< /\ E@#_ ), _P"0 /\ _P   /8
M  #G    TP   ,8   "]  , N  - +, $P"Q !P KP E *X +@"I #8 I@ ]
M *, 1 "A $H GP!/ )T 50"; %H F@!@ )@ 9@"6 &X E !W )( @0"0 (X
MC@"< (P K0"* ,, B0#H (@ _P") /\ AP#_ (4 _P"" /\ \P   .,   #,
M    O    +    "G    H0 ( )X #P"; !8 F0 ? )@ )P"6 "\ DP W )$
M/0". $, C !) (L 3@") %0 AP!9 (4 8 "$ &< @@!O (  >@!^ (8 ? "4
M 'H I !Y +@ > #8 '< ]P!X /\ > #_ '< _P!U /\ Y@   ,L   "W
MJ    )X   "6    CP $ (L # "( !( AP 9 (4 (0"$ "D @@ P '\ -P!]
M #T ? !# 'H 2 !Y $T =P!3 '8 60!T &$ <@!I '$ <P!O '\ ;0"- &P
MG0!J *\ :0#( &@ [0!I /\ :0#_ &D _P!I /\ T@   +@   "E    EP
M (T   "&    @0   'P " !Y  X =P 4 '8 ' !T ", <P K '$ ,0!O #<
M;@ ] &P 0P!K $@ :@!. &@ 5 !G %L 90!C &, ;0!B '@ 8 "' %\ E@!=
M *@ 70"^ %P Y !< /L 7 #_ %P _P!< /\ P@   *H!  "8 P  B00  '\"
M  !X    =    '  ! !M  P :P 1 &D %P!H !X 9@ E &4 + !C #( 8@ X
M &  /0!? $, 7@!) %P 3P!; %8 6@!> %@ : !7 ', 50"! %0 D0!2 *,
M40"W %$ U@!1 /4 40#_ %$ _P!2 /\ M@<  )\)  "-"P  ?@P  ',+  !L
M"@  : <  &4#  !C  < 80 - %\ $P!= !H 7  A %L )P!9 "T 6  S %8
M.0!5 #\ 5 !% %, 2P!1 %( 4 !: $\ 9 !- &\ 3 !] $H C0!) )\ 2 "R
M $< S !' .\ 1@#_ $< _P!' /\ K P  )4.  "#$   =1   &L0  !C#P
M7@X  %L,  !:"0( 600* %< #P!5 !4 4P < %( (P!1 "D 3P O $X -0!-
M 3L 3 %! $H"2 !) D\ 2 )7 $8#80!% VT 0P-Z $(#BP!  YP /P.O #X#
MR  ]!.H /07\ #T&_P ^!O\ I!   (X2  !\$P  ;A0  &04  !<$P  5A(
M %,1  !1#@  4 P% % )# !/!Q$ 30<7 $L('P!)""4 2 DK $<),0!&"3@
M1 H^ $,*10!""DT 0 M5 #\+7P ]"VL / MY #H,B@ X#)P -PRO #4,QP U
M#.D -0W] #4-_P V#/\ G1,  (<5  !V%P  :1@  %X8  !6&   4!<  $T5
M  !*$P  21$  $D.!P!(#0X 1@T3 $0-&@!##B$ 0@XH $ .+@ _#C4 /@\\
M #T/0P [$$L .A!4 #@07@ V$&L -!!Y #(0B@ Q$)P +Q"P "T0R0 M$>P
M+1'_ "X1_P O$/\ EQ8  ((9  !Q&P  9!P  %D<  !1'   3!L  $<:  !$
M&   0Q4  $(3 @!!$@L 0!$0 #X2%P \$AX .Q,E #H3*P X$S( -Q,Y #84
M0  T%$@ ,Q11 #$47  P%6@ +A5W "P5B  J%9H *!6N "<5QP F%>H )Q7_
M "@5_P I%?\ D1H  'T<  !M'@  8!\  %8?  !.'P  2!X  $,=  ! '
M/AH  #T8   [%P< .18. #@7%  V%QL -1@B #,8*  R&"\ ,1DV # 9/0 N
M&48 +1I/ "L:60 J&F8 *!IT "8:A@ D&ID (AJM "$:Q0 @&N@ (1K^ "(:
M_P C&O\ C1T  'D?  !I(0  7"(  %(B  !*(@  1"$  #\A   \(   .1X
M #@;   U' 0 -!P- #(<$@ P'1@ +QT? "X=)0 M'BP *QXS "H>.P I'T,
M)Q]- "8?5P D'V0 (A]R " ?A  ?'Y< '1^K !L?PP ;'^< &Q_] !T?_P >
M'O\ B2   '4B  !E(P  620  $\E  !')0  020  #PC   X(P  -2(  #,@
M   P( $ +B$* "PA$  K(14 *B(< "@B(P G(BD )B,P "4C.  C(T$ (B1*
M "$D50 ?)&$ '21P !LD@@ 9))4 %R2J !8DP0 5).4 %B3\ !<C_P 9(_\
MA2(  '$D  !B)@  5B<  $PG  !$)P  /B<  #DF   U)@  ,24  "XD   K
M)0  *24' "<F#@ E)A, )"<9 ",G(  B)R< (2@N " H-@ >*#X '2A( !LI
M4P 9*5\ &"EN !8I@  4*90 $BFH !$IP  1*.0 $2C[ !,H_P 4)_\ @"4
M &XG  !?*   4RD  $DJ  !"*0  .RD  #8I   R*   +B@  "HH   F*0
M)"H$ "(K#  @*Q$ 'RP6 !TL'0 <+"0 &RTK !HM,P 8+3P %RU% !8N4  4
M+ET $BYL !$N?@ 0+I( #BZG  TMO0 -+=\ #2WY  XL_P 0+/\ ?"@  &HJ
M  !;*P  4"P  $8L   _+   .2P  #0K   O*P  *RL  "8L   B+@  'R\
M !PP"0 :,0X &3$3 !<Q&@ 6,B$ %3(H !0R,  3,CD $C-# !$S3@ 0,UL
M#C-I  TS>@ ,,XX "C.B  @RN0 (,MD "#+T  HQ_P +,?\ =RL  &8M  !8
M+@  32\  $,O   \+@  -BX  #$N   M+@  *2X  ",P   ?,@  &S,  !<U
M!0 4-@P $C<1 !$W%@ 1-QT $#@D  \X+  ..#4 #3@_  PX2@ +.%< "3AE
M  <X=@ %.(H  SB?  $WM0 !-],  C?Q  ,V_P %-O\ <RX  &(P  !4,0
M23$  $$Q   Y,0  -#$  "\P   K,   )3(  " S   ;-@  %S@  !,Z @ 0
M/ D #3T.  P]$P +/1D "CTA  D]*0 (/3$ !CX[  4^1@ #/E(  3YA   ^
M<@  /H8  #V<   ]L@  /=   #SP   \_P  //\ ;3(  %TS  !0-   1C0
M #XT   W-   ,C,  "TS   G-   (C8  !TX   8.@  %#T  ! _ @ -00@
M"4,-  9$$0 #1!8  D0=  !$)   1"T  $0V  !$00  1$X  $1<  !$;0
M1($  $28  !#KP  0\T  $+P  !"_P  0O\ :#8  %@W  !,.   0S@  #LW
M   U-@  ,#8  "DW   C.0  'CL  !@]   30   $$(   U% 0 (1P<  TD,
M  !)#P  2A,  $L9  !+(   2R@  $LR  !+/0  3$D  $Q7  !+:   2WT
M $N4  !*K   2LH  $GO  !)_P  2?\ 8CH  %0[  !).P  0#L  #DZ   S
M.0  +#H  "4\   ?/P  &4$  !-$   01P  #$D   A,   "3P4  % *  !0
M#0  41   %(5  !4&P  5",  %0L  !4-P  5$0  %12  !48P  5'<  %2/
M  !3J   4L8  %+M  !1_P  4?\ 7#\  $\_  !%/P  /CX  #<]   O/@
M)T   "!#   91@  $TD   ],   +3P  !E(   !4    5P(  %@'  !9"P
M6@X  %L1  !=%@  7AT  %\F  !?,0  7CT  %Y,  !>70  7G$  %V)  !=
MHP  7,$  %OK  !:_P  6O\ 5D0  $M#  !#0@  /$$  #)"   I10  (4@
M !I+   33@  #E(   I5   #60   %L   !>    8    &("  !C!@  90H
M &8.  !H$0  :A<  &L?  !K*0  :S8  &M%  !K5@  :FH  &J"  !IG0
M:+L  &?G  !F_P  9?\ 44@  $A(  !!1@  -T<  "Q*   C30  &U$  !-5
M   .60  "%T   %A    9    &<   !J    ;    &X   !P    <@4  ',)
M  !U#0  =Q$  'H8  ![(0  >RX  'H]  !Z3@  >6(  'EY  !XE@  =[,
M '7@  !T_   <_\ 3DT  $=,   [30  ,$\  "93   <6   $UP   UA   &
M9@   &H   !O    <@   '8   !Y    ?    'T   !_    @0   (,"  "&
M!P  B P  (L1  ".&   CB0  (XS  "-1   C%@  (MO  "*C   B:H  (C/
M  "&]P  A?\ 35$  $%3   T50  *5H  !Y?   490  #6H   5P    =@
M 'L   !_    @P   (<   "*    C0   (X   "1    DP   )4   "8
MF@4  )T,  "@$0  HQH  *,H  "B.@  H4X  *!E  "@@0  GJ   )W!  ";
M[@  FO\ 1ED  #E<   M80  (6<  !9N   .=0  !7L   "!    AP   (T
M  "2    E@   )H   "=    GP   *$   "D    I@   *@   "K    K@
M +$#  "T"P  N!$  +D>  "Y+P  N$,  +=:  "U=@  M)<  +2U  "QX@
ML/P /V0  #%I   E;P  &'<   ]_   &AP   (X   "4    F@   *    "E
M    J@   *X   "Q    L@   +4   "W    N@   +P   "_    PP   ,8
M  #)    S@H  -(3  #2(P  T3<  -!/  #.:@  S8H  ,JK  #+RP  R^\
M-W$  "EX   =@   $8D   B1    F@   *$   "G    K0   +,   "Y
MO@   ,(   #%    Q@   ,D   #,    S@   -(   #5    V@   -X   #A
M    Y0   .H+  #K%P  ZBL  .I#  #J7@  ZGH  .N9  #KM0  Z]4 _P
M /\   #_  $ _P ' /\ #0#_ !( _P ; /\ )0#_ "\ _P Z /\ 0P#_ $L
M_P!3 /\ 6@#] &  ^P!F /H :P#X '( ]@!X /0 @ #Q (D [P"2 .P G0#I
M *H Y@"\ ., W #? /< W0#_ ,P _P"^ /\ M0#_ +  _P"M /\ _P   /\
M  #_    _P   /\ !@#_  T _P 4 /\ 'P#_ "D ^P S /< /0#S $4 [P!-
M .P 4P#H %D Y0!? ., 90#@ &H W0!Q -H > #6 (  T@"* ,\ E0#, *(
MR "R ,4 R0#" .T P #_ +L _P"P /\ J #_ *0 _P"A /\ _P   /\   #]
M    ^@   /@   #P  D [  1 .@ &0#G ", Y0 M -X -@#6 #X T0!& ,T
M3 #* %( R !8 ,4 70## &, P !I +X < "\ '@ N0"! +< C0"T )H L0"I
M *X O "L .$ J@#\ *@ _P"@ /\ F0#_ )8 _P"4 /\ _P   /D   #R
MYP   -L   #1  0 R@ - ,< % #$ !T P@ F +\ +P"[ #< MP _ +0 10"Q
M $L K@!1 *P 5@"J %P J !A *8 : "C '  H0!Y )\ A "= )$ F@"@ )@
ML0"6 ,P E0#Q )0 _P"1 /\ BP#_ (@ _P"& /\ ]P   .P   #>    R0
M +P   "T    KP * *L $ "I !< J  @ *< * "B #  GP X )P /@": $0
MF !* )8 3P"4 %4 DP!: )$ 80"/ &@ C0!Q (L >P") (@ AP"7 (4 J "#
M +X @0#D (  _P"  /\ ? #_ 'L _P!Y /\ Z0   -<   #!    L0   *8
M  "=    EP % )0 #0"2 !( D  : (\ (@". "H BP Q (D . "' #X A0!#
M (, 2 "! $X ?P!4 'X 6@!\ &$ >@!I '@ <P!V '\ =0". ', GP!Q +,
M< #0 &\ ]@!O /\ ;P#_ &T _P!L /\ V@   +\   "L    G@   ),   ",
M    A0   (( "0!_  \ ?@ 5 'T ' !\ "0 >@ K '< ,0!U #< =  ] '(
M0@!Q $@ ;P!- &X 4P!L %H :P!B &D ; !G '@ 9@"& &0 EP!B *H 80#"
M &  ZP!A /\ 80#_ &$ _P!@ /\ Q0   *T   ";    C0   (,   !\
M=P   '( !0!P  P ;@ 1 &P %P!L !X :P E &D + !G #$ 9@ W &0 /0!C
M $( 8@!( &  3@!? %4 70!= %P 9@!: '( 60"  %< D !6 *, 50"Y %0
MW@!4 /L 5 #_ %4 _P!5 /\ M@   )\   "-    ?P   '4   !N    :0
M &8  0!C  D 80 . &  $P!? !D 7@ @ %T )@!; "P 6@ R %@ -P!7 #T
M5@!# %4 20!3 %  4@!8 %$ 80!/ &P 3@!Z $P B@!+ )P 2@"Q $D S@!)
M /, 20#_ $D _P!* /\ J@$  )0%  ""!P  = @  &H(  !C!@  7@0  %L
M  !9  4 5P , %8 $ !4 !4 4P ; %( (@!1 "@ 4  M $X ,P!- #@ 3  ^
M $L 10!* $P 2 !4 $< 70!& &@ 1 !U $, A0!! )@ 0 "K $  Q0 _ .H
M/P#_ $  _P!  /\ H @  (H+  !Y#0  ; T  &$-  !:#0  50L  %()  !0
M!@  3P(( $X #0!, !( 2P 7 $H '@!) ", 1P I $8 +P!% #0 1  Z $(
M00!! $@ 0 !0 #X 6@ ] &0 / !R #H @@ Y )0 . "G #< O@ V ., -@#Y
M #8 _P W /\ F T  (,.  !R$   91$  %L1  !3$   3A   $H.  !(#0
M1PH# $<'"@!%! X 1 (3 $("&@!! B  0 ,E #X#*P ]!#$ / 0W #L$/@ Z
M!44 .05. #<%5P V!6( - 9P #(&@  Q!I( , :E "\%NP N!=T +@;U "T'
M_P N!_\ D1   'T1  !L$P  7Q0  %44  !.%   2!,  $02  !!$   0 X
M $ -!@! "@P /@D0 #P)%@ ["AP .0HB #@**  W"RX -@LU #4+.P S"T,
M,@Q, # ,5@ O#&$ +0QO "L,?P J#)( * RE "<,NP E#-T )0WU "8-_P G
M#?\ BQ(  '<4  !G%@  6Q<  %$8  !)%P  0Q<  #\5   \%   .A(  #D1
M 0 Y#P@ . X- #<.$@ U#A@ - X? #(.)0 Q#RP , \R "\0.@ M$$( +!!+
M "H050 H$&$ )A!O "00@  C$), (1"G !\0O0 >$.  'A'W !\0_P @$/\
MAA0  ',7  !C&0  5QH  $T;  !%&@  0!H  #L9   X&   -18  #04   S
M$@0 ,A(+ #$2$  O$A4 +1(< "P3(@ K$RD *A,P "@3-P G%#\ )A1( "04
M4P B%%\ (!5M !\5?@ =%9$ &Q6E !D5NP 8%=X &!7X !D4_P :%/\ @A<
M &\:  !?'   4QT  $H=  !"'0  /!T  #<<   T&P  ,1H  "\9   N%@
M+!<( "L6#@ I%Q, *!<9 "<8(  E&"8 )!@M ",8-  B&3T (!E& !X940 =
M&5T &QIK !D:?  7&H\ %1JC !09N@ 2&=L $QGV !09_P 5&/\ ?1H  &L=
M  !<'P  4"   $<@   _(   .1\  #0?   Q'@  +1T  "L<   I&P  )QL%
M "4;#  D'!$ (AP6 "$<'0 @'2, 'QTJ !X=,@ <'CH &QY$ !D>3@ 7'EL
M%AYI !0?>@ 2'HT $1ZB ! >N  .'M@ #Q[U ! =_P 1'?\ >AT  &<?  !9
M(0  32(  $0B   \(@  -B(  #(A   N(0  *B   "<@   D'P  (B " " @
M"@ >(0\ '2$4 !PA&@ ;(B$ &2(G !@B+P 7(C@ %2-! !0C3  2(U@ $2-G
M ! C>  .(XL #2.?  PCM  +(]  "R+P  PB_P -(?\ =A\  &0B  !6(P
M2R0  $$D   Z)   -"0  "\C   K(P  *",  "0C   @(P  '20  !LE!P 9
M)@T %R81 !8F%P 5)QX %"<E !,G+  2)S4 $2@_ ! H2@ .*%8 #2AD  PH
M=  **(< "2B;  <GL0 %)\P !B?L  <F_@ ()O\ <2(  & D  !3)@  2"<
M #\G   W)@  ,28  "TF   I)0  )24  "(E   =)P  &2@  !8J!  4*PL
M$BP0 !$L%  0+!L $"PB  XL*0 .+3( #2T[  LM1@ *+5( ""U@  8M<  $
M+8,  BV8   LK@  +,D  "SK  $K_  "*_\ ;24  %TG  !/*   12D  #PI
M   U*0  +R@  "LH   G)P  (R<  !\H   ;*@  %RP  !,N @ 0, @ #C$-
M  TQ$@ ,,1< "S$>  HQ)@ (,BX !S(W  4R0@ #,DX  3)<   R;   ,G\
M #*5   QK   ,<<  ##J   P_   ,/\ :"D  %@J  !,*P  02P  #DL   R
M*P  +2L  "DJ   E*@  ("L  !PL   7+@  $S   ! R @ .- < "C<,  <W
M$  %-Q0  S<;  (W(@  -RH  #@S   X/@  .$H  #A8   X:   .'P  #>2
M   WJ0  -L4  #;J   V_0  -?\ 8RP  %0N  !(+P  /B\  #8N   P+@
M*RT  "<M   B+0  '2\  !@Q   4,P  $#4   XW 0 *.@< !CL+  (\#@
M/1(  #X7   ^'@  /B8  #XO   ^.@  /D8  #Y4   ^9   /G<  #Z/   ]
MIP  /<,  #SI   \_0  ._\ 7C   % Q  !$,@  .S(  #0Q   N,   *2\
M "0P   >,@  &30  !0V   0.0  #3L   H]   %0 4  $$*  !"#0  0Q
M $04  !%&@  1B(  $8K  !&-0  1D$  $9/  !&7P  1G,  $6*  !%I
M1,   $/H  !#_@  0O\ 6#0  $LU  !!-0  .34  #(T   M,P  )C0  " U
M   :.   %#H  ! ]   -0   "4(   1%    1P,  $@'  !*"P  2PX  $P1
M  !.%0  3QP  $\E  !/+P  3SP  $]*  !/6@  3FT  $Z%  !-H   3+P
M $OG  !+_@  2O\ 4SD  $<Y   ^.0  -S@  #$W   I-P  (3D  !L\   5
M/P  $$(   Q%   '2    DH   !-    3P   %$$  !2!P  5 L  %4.  !7
M$0  61<  %H?  !9*0  638  %E$  !95   6&<  %A_  !7F@  5K<  %7C
M  !4_0  5/\ 3CT  $,]   \/   -3L  "P\   D/@  '$$  !5$   02
M"TL   5.    40   %0   !7    60   %L   != @  7@8  & +  !B#@
M9!(  &<8  !G(@  9BX  &8\  !F30  96   &5W  !DDP  8[$  &'=  !@
M_   7_\ 24(  $%!   Z/P  ,$   "9#   >1@  %4H  !!.   *4@   U8
M  !:    70   &    !C    90   &<   !I    :P$  &T%  !O"@  <@X
M '42  !W&P  =B8  '8U  !U1@  =%D  '1O  !SBP  <JD  '#-  !O]P
M;O\ 1D8  $!%   U1@  *D@  "!,   740  $%8   E:   !7P   &,   !H
M    :P   &\   !R    =0   '<   !Y    >P   'T   "  P  @P@  (8-
M  ")$P  BAT  (HK  ")/   B$\  (9F  "%@0  A*   (+"  "!\   ?_\
M1DL  #I,   N3P  (U,  !A8   07@  "60   !I    ;P   '0   !X
M?    ($   "$    AP   (@   "+    C@   )    "3    E@   )D'  "=
M#0  H10  * A  "@,0  GD0  )U;  "<=@  F98  )FU  "6Y0  E?X /U(
M #)5   F6@  &V   !%G   );0   '0   ![    @0   (8   "+    D
M )0   "7    F0   )P   "?    H0   *0   "G    J@   *T   "Q!@
MM0T  +@6  "W)@  MCD  +50  "T:@  LHD  +"J  "NSP  K?4 -UP  "MA
M   >:   $W    MX    @    (<   ".    E0   )H   "?    I    *@
M  "L    K0   +    "S    M0   +@   "[    OP   ,,   #'    RP4
M -$.  #1&P  T"X  ,]%  #-7P  RWX  ,F>  #(O@  Q>D +VD  "-P   6
M>0  #8$   &+    DP   )L   "B    J    *X   "T    N    +T   #
M    P@   ,4   #(    RP   ,X   #1    U@   -L   #?    Y    .@&
M  #K$0  ZB,  .HZ  #I5   YW(  .63  #CLP  X]0 _P   /\   #_
M_P $ /\ "P#_ !  _P 7 /\ (0#_ "L _P U /\ /@#_ $< _P!. /\ 50#\
M %L ^@!A /@ 9@#V &T ] !S /( >P#O (0 [0". .H F0#F *< XP"Y -\
MU0#; /< U@#_ ,  _P"R /\ J@#_ *4 _P"B /\ _P   /\   #^    _
M /P  P#^  L _P 1 /\ &@#] "0 ^0 N /0 . #P $  [ !( .D 3@#F %0
MX@!: -\ 7P#< &4 V !K -0 <@#0 'L S0"% ,H D0#' )X PP"N ,  Q0"]
M .L NP#_ +  _P"D /\ G #_ )@ _P"5 /\ _P   /H   #T    \0   /(
M  #J  4 YP . .( %0#A !X X0 H -@ ,0#0 #D RP!  ,@ 1P#% $T P@!3
M +\ 6 "] %X NP!D +D :P"V ', M !\ +$ B "N )4 JP"D *@ N "F -P
MHP#[ )\ _P"5 /\ CP#_ (L _P") /\ ^0   .\   #G    WP   ,\   #(
M    P0 * +\ $0"\ !@ NP A +D *@"T #( L0 Z *X 0 "K $8 J !, *8
M40"C %8 H0!< )\ 8P"= &H FP!S )D ?@"6 (P E "; )( K0"0 ,< C@#P
M (T _P"& /\ @ #_ 'T _P!\ /\ [0   .    #1    OP   +,   "J
MI@ % *( #0"A !, H  ; )\ (P"; "L F  R )4 .0"3 #\ D0!$ (\ 2@".
M $\ C !5 (H 6P"( &, A@!K (0 =@"" (( @ "2 'X HP!\ +H >@#A 'D
M_P!W /\ <@#_ '  _P!O /\ W0   ,L   "V    IP   )T   "4    C@ !
M (L "@") !  B  5 (< '0"' "4 A  L (( ,@!_ #@ ?0 ] 'L 0P!Y $@
M> !. '8 5 !U %L <P!C '$ ;@!O 'H ;0") &P F@!J *X :0#, &@ ]@!G
M /\ 90#_ &0 _P!C /\ R@   +0   "A    DP   (D   ""    >P   '@
M!0!V  P =0 1 '0 & !S !\ <@ E '  + !N #( ;  W &H / !I $( : !(
M &8 3@!E %4 8P!= &( 9@!@ '( 7@"  %T D@!; *4 6@"^ %D Z0!9 /\
M60#_ %@ _P!8 /\ N0   *(   "0    @P   'D   !Q    ;0   &D  0!F
M  D 90 . &0 $P!C !D 8P @ &$ )@!@ "P 7@ Q %P -P!; #P 6@!" %@
M2 !7 $\ 5@!7 %0 8 !3 &P 40!Y %  B@!/ )X 3@"T $T V@!- /L 30#_
M $T _P!- /\ J@   )0   ""    =0   &L   !D    8    %T   !:  4
M6  , %< $ !6 !4 5@ ; %4 (0!3 "< 4@ L %$ ,0!/ #< 3@ ] $T 0P!,
M $H 2@!2 $D 6P!( &8 1@!S $4 A !$ )< 0P"L $( R0!" /$ 0@#_ $,
M_P!# /\ G@   (D   !X P  :@0  &$$  !: P  50$  %(   !0  ( 3@ )
M $T #0!, !$ 2P 7 $H ' !) "( 2  G $< +0!% #( 1  X $, /@!" $4
M00!- #\ 5@ ^ &$ /0!N #L ?@ Z )$ .0"F #@ OP X .@ . #_ #D _P Y
M /\ E0,  ( '  !O"0  8@H  %@+  !1"@  3 @  $D&  !' P  1@ & $0
M"P!#  \ 0@ 3 $$ & !! !X /P C #X *0 ] "X .P T #H .@ Y $$ . !)
M #< 4@ V %T - !J #, >@ R (P ,0"A #  N  O -X +P#Y "\ _P P /\
MC D  '@,  !H#0  7 X  %(.  !+#@  10T  $$,   _"@  /@@" #T$"  \
M 0T .P 0 #H %0 Y !H .  @ #8 )0 U "L -  P #, -P R #X ,0!& "\
M4  N %H +0!G "L =P J (D *0"= "@ LP G -$ )P#R "< _P G /\ A@P
M '(.  !C$   5A$  $T1  !%$0  0!   #P/   Y#@  -PT  #8+!  V" H
M-08. #0%$@ R!!< ,04< # %(@ O!2@ +@8N "T&-  K!CP *@9$ "D'3@ G
M!UD )@=E "0'=0 C!X< (@>; " &L  @!LL 'P7M !\&_@ ?!_\ @ X  &T1
M  !>$@  4A,  $@3  !!$P  .Q,  #<2   T$0  ,A   # / 0 P#08 , L+
M "\*$  M"A0 + L9 "H+'P I"R4 * PK "<,,@ F##H ) Q# ",,30 A#5@
M( UE !X-=0 <#8@ &@V< !D-L0 8#,H %PSK !<-_  8#/\ >Q$  &D3  !:
M%0  3A8  $46   ]%@  .!4  #,5   P%   +1,  "L2   J$ , *@\( "D.
M#0 H#A$ )@X6 "4/'0 D#R, (P\I "$0,0 @$#D 'A!" !T03  ;$%@ &1!F
M !<0=@ 5$(D %!"> !(0LP 1$,X $1#N !(0_@ 2$/\ =Q,  &45  !7%P
M2Q@  $(9   Z&0  -!@  # 7   L%P  *18  "<5   F% $ )1($ ",2"P B
M$@\ (1(4 " 2&@ >$R  '1,G !P3+@ :$S8 &11  !<42@ 6%%8 %!1D !(4
M=  1%(< $!2<  X4L0 -%,H #13K  X3_@ .$_\ <Q4  &$8  !3&@  2!L
M #\;   W&P  ,AH  "T:   I&0  )A@  "08   B%P  (!8! !X6"  =%@T
M&Q<2 !H7%P 9%QT &!@D !88*P 5&#0 %!@] !(92  1&50 $!EB  X9<@ -
M&80 #!F8  H9K0 )&,8 "1CG  D8^@ *%_\ ;Q@  %X:  !0'   11T  #P=
M   U'0  +QT  "H<   F&P  (QL  "$:   >&@  '!H  !H;!0 8&PP %AP0
M !4<%0 4'!L $QPB !(=*0 1'3$ $!T[  X=10 -'E$ #!Y>  H>;0 )'H
M!QZ4  4=J@ #'<(  QWF  0<^  %'/\ :QH  %L=  !-'@  0A\  #H?   R
M'P  +1\  "@>   D'@  (1T  !X=   <'0  &!X  !4? @ 3( D $B$. ! A
M$@ 0(1@ #B$?  XB)@ -(BX #"(W  HB00 )(DT !R):  4B:0 #(GP  2*1
M   BJ   (<   "'E   @^   (/\ 9QT  %<?  !*(0  0"$  #<B   P(0
M*B$  "8@   B(   'Q\  !P?   9(   %B$  !(C @ 0) < #B8,  PF$  +
M)A4 "B8<  DF(@ ()BH !B<S  0G/0 #)TD  2=6   G9@  )WD  ">/   F
MI@  )K\  "7D   E^0  )/\ 8R   %0B  !'(P  /20  #0D   N(P  *",
M "0B   A(@  'B$  !HB   7(P  $R0  ! F @ .* < "RH+  @K#@ &*Q,
M!"L8  (K'P !+"<  "PP   L.@  +$4  "Q3   L8P  +'8  "R,   KI
M*[X  "KD   J^@  *?\ 7R,  % E  !$)@  .B8  #(F   K)@  )B4  ",D
M   ?)   &R0  !<E   4)P  $2D   XK @ ++08 !R\+  0P#@  ,!$  #$5
M   Q'   ,2,  #(L   R-@  ,D(  #)/   R7P  ,G(  #&)   QH@  ,+P
M ##D   O^P  +_\ 6B<  $PH  ! *0  -RD  "\I   I*   )2<  "$F   <
M)P  &"@  !0J   1+   #BX   LP 0 ',@4  S0)   U#   -@\  #<2   X
M&   ."   #@H   X,@  .3T  #E+   Y6P  .&X  #B%   WGP  -[H  #;D
M   U_   -?\ 52H  $@L   ]+   -"P  "TK   H*@  )"D  !XJ   9*P
M%"T  !$O   -,0  "C0   <V   ". 0  #H'   ["@  /0T  #X0  ! %
M0!L  $ D  ! +@  0#D  $!'  ! 5@  0&D  $"    _FP  /K<  #WC   \
M_   //\ 4"\  $,O   Y+P  ,B\  "PM   G+   ("T  !HO   5,0  $3,
M  TV   ).   !3L    ]    0 $  $$$  !#!P  10L  $8.  !($0  2A8
M $H>  !**   2C0  $E"  !)40  260  $A[  !(EP  1[0  $;@  !%_
M1/\ 2C,  #\S   V,P  ,#$  "HP   C,0  '#,  !8U   1.   #3L   @^
M   #00   $,   !&    2    $H   !,!   3@<  $\+  !1#@  5!(  %49
M  !5(@  5"X  %0\  !42P  4UX  %-T  !2D   4:X  %#7  !/^P  3O\
M13<  #PW   U-@  +S0  "8U   >-P  %SH  !$]   ,00  !T0   !(
M2@   $T   !0    4P   %4   !7    6 (  %L&  !="P  7PX  &(3  !B
M&P  8B<  &(T  !A10  8%<  &!M  !?B0  7:<  %S,  !:^   6?\ 03P
M #H[   T.0  *CH  "$\   80   $4,   Q'   &2P   $\   !3    5@
M %D   !<    7P   &$   !C    90   &<!  !J!0  ;0H  ' .  !S%0
M<B   '(M  !Q/0  <$\  &]E  !N@   ;9\  &O!  !I\0  :/\ /T   #D^
M   N/P  )$(  !I&   22@  #$\   14    6    %T   !A    90   &@
M  !K    ;@   '$   !S    =0   '@   ![    ?@,  ($*  "%#P  AQ<
M (8D  "%-   A$8  ()=  "!=@  ?Y8  'ZV  !\YP  >O\ /T0  #-%   H
M2   '4P  !-2   ,5P   UT   !C    :    &T   !Q    =@   'H   !^
M    @0   (,   "&    B0   (L   ".    D@   )4!  "9"0  GA   )X:
M  "=*0  G#P  )I2  "8;   EHL  )2J  "2U   D/H .$L  "Q.   @4P
M%5D   U@   #9P   &X   !T    >@   (    "$    B@   (X   "2
ME0   )<   ":    G0   *    "C    IP   *L   "O    M D  +@0  "W
M'@  M3   +-&  "Q8   KWX  *R@  "KP0  J>X ,54  "1;   880  #FD
M  5Q    >0   ($   "(    CP   )0   ":    GP   *0   "H    J0
M *P   "O    LP   +4   "Y    O0   ,$   #&    RP   -$*  #3%
MT24  - [  #-5   RG$  ,B2  #%LP  P]X *6(  !QI   1<0  !WL   "$
M    C0   )4   "=    HP   *D   "O    M    +D   "\    O@   ,(
M  #%    R    ,P   #0    U    -H   #?    Y    .H   #N#   [1H
M .PO  #J20  Z&4  .:&  #DI0  XL8 _P   /\   #_    _  ! /P " #^
M  X _P 4 /\ '0#_ "8 _P P /\ .@#_ $( _P!) /X 4 #[ %8 ^0!< /8
M8@#T &@ \@!O /  =@#M '\ Z@") .< E0#D *, X "U -L T #5 /8 R@#_
M +8 _P"H /\ GP#_ )H _P"6 /\ _P   /L   #V    \P   /,   #V  D
M^@ . /T %@#[ "  ]P J /( ,P#M #L Z0!# .8 20#B $\ W@!5 -L 6P#6
M &  T@!G ,\ ;@#, '8 R0"  ,8 C #" )H OP"J +L P0"X .D M@#_ *<
M_P": /\ D@#_ (T _P"* /\ ^@   /$   #J    YP   .<   #D  $ X  +
M -L $0#: !H VP C -$ + #* #0 Q@ [ ,( 0@"_ $@ O !. +H 4P"X %D
MM@!? +, 9@"Q &X K@!W *P @P"I )$ I@"A *, M0"@ -@ G@#[ )4 _P"+
M /\ A0#_ (  _P!^ /\ [P   .,   #:    TP   ,8   "_    N0 & +<
M#@"T !0 M  = +, )0"N "T JP T *< .P"D $$ H0!& )\ 3 "= %$ FP!7
M )D 7@"7 &4 E0!N ), >0"0 (< C@"7 (P J0") ,0 B #O (4 _P!\ /\
M=@#_ ', _P!R /\ X    -    #&    M@   *D   "A    G0 ! )D "@"8
M !  F  6 )< '@"4 "8 D0 M (\ - ", #H B@ _ (@ 10"' $H A0!0 (,
M5@"! %X @ !F 'X <0!\ 'T >0"- '< H !U +8 <P#? '( _P!N /\ :0#_
M &< _P!E /\ S    +X   "K    G0   ),   "*    A0   (( !0"   T
M?P 1 '\ & "  "  ?0 F 'H +0!W #, =0 X '0 /@!R $, < !) &\ 3P!M
M %8 ; !> &H : !H '4 9P"$ &4 E@!D *L 8@#) &$ ]@!@ /\ 7 #_ %L
M_P!: /\ O0   *D   "7    B0   'X   !X    <P   &\  0!M  D ;  .
M &L $P!K !D :@ @ &@ )@!F "P 90 R &, -P!B #P 8 !" %\ 2 != $\
M7 !7 %H 80!9 &T 5P![ %8 C@!5 *( 4P"[ %( Z0!2 /\ 4 #_ $\ _P!/
M /\ K0   )@   "&    >    &X   !G    8P   &    !=  4 7  + %L
M$ !; !4 6P ; %H (0!8 "8 5@ L %0 ,0!3 #8 4@ \ %$ 0@!/ $D 3@!1
M $T 6P!+ &8 2@!T $D A0!( )D 1P"Q $8 V !& /P 10#_ $4 _P!% /\
MGP   (D   !X    ;    &(   !;    5@   %,   !1  ( 3P ( $\ #0!.
M !$ 3@ 6 $T ' !, "$ 2@ F $D + !( #$ 1P W $4 /0!$ $0 0P!, $(
M50!  &  /P!N #X ?@ ] )( / "I #L QP [ /, .P#_ #L _P \ /\ DP
M 'X   !N    80   %@   !1    3    $D   !'    10 % $0 "P!#  X
M0P 2 $, %P!" !T 0  B #\ )P ^ "P /0 R #L .  Z #\ .0!' #@ 4  W
M %L -0!H #0 >  S (P ,@"B #$ O  Q .< ,0#_ #( _P S /\ B0   '8#
M  !F!0  60<  % '  !)!@  0P4  $ #   ^ 0  /  # #L "  Z  T .@ 0
M #D %  Y !D -P > #8 (P U "@ -  N #, -  R #L , !# "\ 3  N %<
M+0!D "P <P K (< *@"< "D M0 I -P *0#[ "D _P J /\ @00  &X(  !?
M"@  4PL  $H+  !""P  /0H  #D)   V"   -04  #0"!@ S  H ,@ . #$
M$0 Q !4 ,  : "\ 'P N "0 +  J "L ,  J #< *0 _ "@ 20 G %0 )@!@
M "0 ;P C (( (@"7 "$ K@ A ,P (0#S "$ _P B /\ >PD  &@,  !:#0
M3@X  $4.   ]#@  . T  #,-   P#   +@L  "T) P M!@@ + 0, "L"#P J
M 1( *0$7 "@!'  G "$ )@ G "4 +0 D #0 (P$] "(!1@ A 5$ 'P%= !X!
M;  < 7\ &P"4 !H J@ : ,4 &@#K !D _P : /\ =0P  &0.  !5#P  2A
M $ 0   Y$   ,Q   "\/   L#@  *0X  "<- 0 G# 4 )PH* "8(#0 E!Q
M) 84 "(&&0 A!A\ ( <D !\'*P >!S( '0<Z !P(1  :"$\ &0A< !<(:P 6
M"'T %0>1 !0'IP 3!K\ $@7D !(%^@ 2!?\ <0X  %\0  !1$0  1A(  #T2
M   V$@  ,!(  "L1   H$0  )1   ",0   B#@0 (0T' "$,"P @"PX 'PL2
M !T+%P <#!P &PPB !H,*0 9##$ & PY !8-0P 5#4\ $PU< !(-:P 0#7X
M#PV2  X-IP -#+X #0S@  T,]0 -#/\ ;1   %P1  !.$P  0Q0  #H4   R
M%   +10  "@3   E$P  (A(  " 1   >$0, '! % !P/"  ;#PP &@X0 !D/
M%  7#QH %@\A !40*  4$#  $A Y !$01  0$%  #A!=  T0:P ,$'P "Q"0
M  D0I0 ($+P !Q#?  <0]  '#_\ :1$  %@4  !+%0  0!8  #<6   P%@
M*A8  "85   B%0  'Q0  !T3   :$P( &1($ !<2!@ 6$@H %1(. !02$@ 2
M$A@ $1,> !$3)0 0$RX #A,W  T40  ,%$L "Q18  D49P '%'@ !A2-  04
MHP #$[L  A/=  $2]  "$O\ 91,  %46  !(%P  /1@  #08   M&   *!@
M ",7   @%P  '18  !H5   8%0( %A4$ !05!0 2%@@ $18- ! 7$  .%Q4
M#A<;  T7(@ ,%RD "Q@R  D8/  '&$< !1A4  088P "&'4  1B+   7H0
M%[D  !?=   6]0  %O\ 818  %(8  !%&@  .QH  #(:   K&@  )1H  "$9
M   >&   &Q@  !@7   6%P( %!<# !(8!0 0&0< #AL+  P;#P +&Q, "AL8
M  @<'P ''"8 !1PO  0<.  "'$0  !U1   =8   '7(  !R(   <H   &[D
M !O>   :]@  &O\ 7A@  $\:  !"'   .!P  "\=   I'   (QP  !\;   <
M&@  &1D  !<9 0 4&0( $AH# ! ;!  .'0< #!X+  D?#@ &(!$ !2 6  ,@
M'  !(2,  "$K   A-0  (4   "%.   A70  (6\  "&&   @G@  (+@  !_>
M   >^   'O\ 6AL  $L=   _'@  -1\  "T?   G'@  (AT  !X=   ;'
M&!L  !4;   2'   $!T"  X?!  ,(08 "2(*  4C#0 ")!   "43   E&0
M)B   "8H   F,@  )CT  "9*   F6@  )FP  ":#   EG   );<  "3?   C
M^0  (_\ 51X  $<@   \(0  ,B$  "LA   E(   (!\  !T>   :'0  %AX
M !,>   0(   #B$   PC @ ()04 !2<)   H"P  *@X  "L1   L%@  +!T
M "PE   L+@  +#H  "Q'   L5@  +&D  "R    KF@  *K4  "G?   I^P
M*/\ 42(  $0C   X)   +R0  "@C   C(@  'R$  !P@   7(   $R$  ! C
M   .)   "R8   @H   $*@0  "P'   N"0  , P  #$/   S$P  ,QD  #,A
M   S*@  ,S4  #-#   S4@  ,V4  #)[   REP  ,;,  ##>   O^P  +O\
M3"4  #\F   U)P  +28  "<E   B)   'B,  !DC   4)   $28   XH   +
M*@  !RP   ,O    ,0(  #,$   U!P  -PH  #D-   Z$   .Q4  #L=   [
M)@  .S$  #L^   [3@  .V   #IW   YD@  .+   #?;   V_   -?\ 1RD
M #LJ   R*@  *RD  "4G   A)@  &R<  !4H   1*@  #BP   HO   &,0
M 30    V    .    #L!   ]!   /P<  $$*  !##@  11$  $48  !%(0
M12P  $0Y  !$2   1%L  $-Q  !"C0  0:L  $#2   _^@  /O\ 0BT  #@N
M   O+0  *2L  "0J   =*@  %RP  !$N   -,0  "30   0W    .@   #P
M   _    00   $0   !&    2 ,  $H'  !,"P  3@X  % 3  !0'   4"<
M $\T  !/0P  3U4  $YJ  !-A@  3*0  $K*  !)^   2/\ /C(  #4Q   N
M+P  *2X  " N   9,0  $C,   XW   ).@   CT   !     1    $<   !)
M    3    $\   !1    4P   %4!  !8!@  6@L  %T.  !?%0  7B   %XL
M  !=/   7$X  %MC  !:?@  6)T  %?   !5\@  5/\ .C8  #,T   M,@
M)#,  !LV   3.0  #CT   A!    10   $D   !,    4    %,   !6
M60   %L   !=    8    &(   !E    : 4  &L+  !O$   ;Q@  &XE  !M
M-   ;48  &M;  !J=0  :)0  &:V  !DZ0  8O\ .#D  #(W   H.0  'CL
M !4_   .1   !TD   !-    4@   %8   !:    7@   &(   !E    :
M &L   !M    <    ',   !V    >0   'T$  "!"P  A1$  (0=  ""+
M@#X  'Y4  !^:P  >XH  'JJ  !WU@  =?T .#T  "P^   B00  %T8   ]+
M   '40   %<   !<    8@   &8   !K    ;P   '0   !X    >P   'X
M  "     @P   (8   "*    C0   )$   "6 P  FPP  )T3  ";(0  FC,
M )=)  "48@  DW\  )"@  ".Q0  C/, ,40  "5(   :30  $%,   A:
M80   &@   !N    =    'D   !_    A    (D   "-    D0   ),   "6
M    F0   )T   "@    I    *@   "L    L@,  +<-  "W%P  M2@  +(^
M  "P5@  K',  *J4  "IM   I>4 *D\  !Y4   26P  "F(   !J    <P
M 'L   ""    B0   (X   "4    F@   )\   "D    I@   *D   "M
ML    +,   "W    NP   ,    #%    RP   -$$  #5#@  TQT  - R  #-
M2P  RF8  ,:'  #"J0  P<L (EL  !9B   ,:P   70   !]    AP   )
M  "7    G@   *0   "K    L0   +8   "Z    O    ,    #$    R
M ,L   #/    U    -H   #@    Y@   .L   #Q!@  \!,  .XG  #L/P
MZEL  .=Z  #DFP  X+L _P   /L   #V    \P   /0 !0#V  P ^@ 1 /\
M&0#_ "( _P L /\ -0#_ #T _P!% /P 3 #Z %( ]P!8 /4 7@#S &0 \0!J
M .X <@#L 'H Z0"% .4 D0#A *  W0"R -@ S@#2 /8 P0#_ *T _P"> /\
ME@#_ )  _P", /\ ^@   /(   #L    Z0   .D   #L  4 \@ , /@ $@#W
M !L ]0 E /  +@#K #< Y@ ^ .( 10#= $L V !0 -, 5@#0 %P S0!B ,H
M:@#( '( Q0!\ ,( B "^ )8 N@"H +< OP"T .@ K@#_ )T _P"0 /\ B #_
M (, _P"  /\ \    .4   #>    V@   -L   #<    V  ' -$ #@#1 !4
MT@ > ,L )P#% "\ P  W +T /0"Z $0 MP!) +4 3P"R %4 L !; *X 80"L
M &D J0!S *< ?P"D (T H0"> )X L@"; -4 F0#\ (P _P"" /\ >P#_ '8
M_P!T /\ X@   -,   #*    QP   +P   "V    L  ! *\ "P"L !$ K0 8
M *T ( "H "@ I  O *  -@"= #P FP!" )D 1P"7 $T E0!3 ), 60"1 &$
MCP!J (P =0"* (, B "4 (8 IP"# ,( @@#P 'P _P!S /\ ;0#_ &H _P!H
M /\ SP   ,$   "Y    K0   *    "8    E    )$ !@"0  T D  2 (\
M&0". "$ BP H (@ +P"& #4 A  Z (( 0 "  $4 ?@!+ 'P 4@!Z %D > !B
M '8 ; !T 'D <@") '$ G0!O +0 ;0#? &P _P!E /\ 8 #_ %X _P!< /\
MO@   +$   "@    D@   (D   ""    ?    'H  0!X  D =P . '@ % !W
M !H =  A '( )P!P "T ;@ S &P . !K #X :0!$ &@ 2@!F %$ 9 !: &,
M9 !A '  7P!_ %X DP!= *D 7 #( %L ]P!7 /\ 5 #_ %( _P!1 /\ L
M )\   "-    ?P   '0   !N    :@   &8   !E  0 8P + &, $ !C !4
M8P ; &$ (0!? "< 70 L %P ,@!: #< 60 ] %< 0P!6 $L 50!3 %, 7 !2
M &@ 4 !W $\ B0!. )\ 30"Z $P Z0!+ /\ 20#_ $< _P!' /\ H@   (T
M  !\    ;@   &4   !>    60   %<   !5  $ 5  ' %, #0!3 !$ 5  6
M %( &P!1 "$ 3P F $X *P!, #$ 2P W $H /0!) $0 1P!, $8 5@!$ &$
M0P!P $( @0!! )< 0 "O #\ UP _ /\ /@#_ #T _P ^ /\ E    '\   !O
M    8P   %D   !1    30   $H   !(    1P $ $< "@!&  X 1@ 1 $<
M%@!% !P 1  A $( )@!! "L 0  Q #X -P ] #X / !' #H 4  Y %L . !I
M #< >@ V (\ -0"G #4 Q@ T /4 - #_ #0 _P U /\ B    '0   !E
M6    $\   !(    0P   #\    ]    /  " #P !P [  P .P / #L $@ Z
M !< .0 < #< (0 V "8 -0 L #0 ,@ S #D ,0!! #  2P O %8 +@!C "T
M<P L (@ + "@ "L NP K .H *P#_ "L _P L /\ ?P   &P   != 0  40(
M $@#  !  P  .P(  #<    T    ,P   #( !0 R  D ,@ - #$ $  Q !,
M,  8 "\ '0 M "( +  H "L +@ J #4 *0 ] "@ 1@ G %$ )@!> "4 ;@ D
M (( (P"9 ", LP B -X (@#_ ", _P D /\ =P   &4$  !6!@  2P<  $((
M   Z"   -0<  # &   M!0  + ,  "L  P J  < *0 + "D #@ I !$ *  5
M "< &0 F !X )0 D "0 *@ C #$ (@ Y "$ 0P @ $X 'P!: !X :0 = 'P
M' "3 !L K  ; ,T &P#V !L _P < /\ < 4  %\(  !1"@  1@L  #T+   U
M"P  , L  "L*   H"0  )0@  "0' @ C! 8 (P() "(!#  B  \ (0 2 "
M%@ ? !L '@ @ !T )@ < "X &P V !H /P 9 $H & !7 !< 9@ 6 '@ %0"/
M !4 I@ 4 ,, % #N !0 _P 5 /\ :P@  %L+  !-#   0@T  #D-   Q#0
M+ T  "<-   C#   (0P  !\+ 0 >"@4 '0@( !T&"P <!0T ' 00 !L$%  9
M!!@ &00> !@$(P 7!"L %@0S !4$/  4!$< $P-4 !(#8P 1 W4 $ ** ! !
MH@ / +P #P#E  \ _@ 0 /\ 9PL  %<-  !)#@  /@\  #4/   N#P  * \
M "0.   @#@  '0X  !L- 0 9#00 & P' !@+"0 7"0P %PD. !8)$@ 5"18
M% D; !,)(0 2"2@ $@DP !$).@ 0"44 #PE2  X)80 -"7, # B(  L(GP *
M![< "@;;  H%]@ *!/\ 8PT  %,.  !&$   .Q$  #(1   K$0  )1   "$0
M   =$   &@\  !@/ 0 6#@0 %0X' !0-"0 3#0L $PP- !(,$  1#!0 $ P9
M ! ,'P /#"< #@TO  T-.0 ,#44 "PU1  D-8  (#7$ !@V&  4-G0 $#+0
M PS2  (,\0 ""_\ 7PX  % 0  !#$0  .!(  "\2   H$@  (Q(  !X1   ;
M$0  &!$  !40 @ 4$ 4 $A ' !$/"0 0#PH $ X,  X.#@ .#Q( #0\7  P0
M'0 ,$"0 "A L  D0-@ ($$$ !A!.  4070 #$&\  1"$   0G   #[0   [4
M   .\P  #O\ 7!   $T2  ! $P  -A0  "T4   F%   (1,  !P3   9$@
M%A(  !01 P 2$08 $1$( ! 0"@ .$ L #1$+  P1#0 +$A$ "A(5  D2&@ (
M$B$ !A,I  43,P #$SX  A-+   36@  $VP  !."   2FP  $K0  !'7   1
M]0  $?\ 6!(  $D4   ]%0  ,Q8  "L6   D%0  'Q4  !H4   7%   %!,!
M !,2!  1$@< $!()  X2"0 -$@D "Q,*  D4#0 '%0\ !A83  06&  #%A\
M A8G   7,   %SL  !=(   76   %VH  !:    6F0  %;0  !79   4]P
M$_\ 510  $86   Z%P  ,!@  "@8   B%P  '18  !D6   6%0  $Q0# !(3
M!@ 0$P< #Q,'  T4!P +%0@ "18)  88#  #&@X  1H1   :%@  &QP  !LD
M   ;+0  &S@  !M&   <50  &V<  !M]   ;EP  &K,  !G;   8^0  %_\
M418  $,8   W&0  +AH  "8:   @&0  &Q@  !@7   5%@$ $Q4% !$5!  /
M%00 #18$  L7!0 )&08 !AH(  (<"@  '@T  " 0   @$P  (!D  " A   A
M*@  (34  "%"   A4@  (&0  "!Z   ?E0  '[$  ![;   =^@  '/\ 31D
M #\;   T'   *QP  "0<   >&P  &AH  !<8   4%P( $A<" ! 8 0 -&0$
M"QH"  @< P %'00  A\&   A"   (PL  "4.   F$0  )A8  "8>   G)P
M)S(  "<_   F3@  )F   "9W   ED@  )*\  "/:   B^P  (?\ 2!T  #P>
M   Q'P  *!X  "(>   ='   &1L  !8:   2&@  $!L   T<   +'0  "!\
M  0A   !(P(  "4$   G!@  *0D  "P,   N#P  +A,  "X:   N(P  +BX
M "X[   N2@  +5P  "UR   LC@  *ZP  "K4   I^P  */\ 1"   #@A   N
M(0  )B$  " @   <'@  &!T  !0=   0'@  #A\   LA   '(P   R4    G
M    *0   "P!   N P  , 8  #,*   U#0  -A$  #87   V'P  -BD  #8V
M   V10  -5<  #5M   TB0  ,J@  #'/   P^@  +_\ /R0  #0D   K)
M)",  !\A   ;(   %B   !$A   .(P  "B4   8H   "*@   "T    O
M,@   #0    W    .0,  #L&   ^"@  0 X  $$2  !!&@  0"4  $ Q  !
M0   /U(  #YG   ]@@  /*(  #K'   Y^   ./\ .B@  # H   I)P  (R4
M !\C   8)   $B4   XH   **@  !2T    P    ,P   #8    X    .P
M #X   !     0@   $4"  !'!@  2@H  $T.  !-%0  3!\  $PK  !+.@
M2DP  $EA  !(?   1YL  $6_  !#\P  0O\ -BP  "TK   G*0  (R<  !LH
M   4*@  #BT   HP   $,P   #<    Z    /0   $    !#    1@   $@
M  !+    30   %    !3 0  5@8  %D+  !;$   6QD  %HE  !9-   6$8
M %=:  !5=   5),  %*U  !0Z@  3_\ ,S   "PN   G+   'BT  !8O   0
M,@  "C8   ,Z    /P   $(   !&    20   $P   !/    4@   %4   !8
M    6@   %T   !@    8P   &<&  !K#   ;!(  &L>  !K+   :3T  &=2
M  !F:@  9(D  &&K  !?W   7?\ ,3,  "PQ   B,@  &34  !$Y   */0
M D(   !'    3    %    !4    6    %L   !?    8@   &4   !H
M:P   &X   !Q    =0   'D   !]!@  @@T  ((6  " )   ?C4  'Q)  ![
M80  >'\  ':?  !SQ@  </< ,38  "8X   <.P  $D    M%   "2P   %$
M  !6    6P   &    !E    :0   &X   !R    =@   'D   !\    ?@
M ((   "%    B0   (X   "3    F 8  )P.  ";&@  F"L  )9   "260
MD7,  (V5  "+M0  B.@ *SX  "!!   51P  #4T   )4    6P   &$   !H
M    ;@   ',   !Y    ?@   (,   "(    C    (\   "2    E0   )D
M  "=    H0   *4   "J    L    +<'  "X$0  M2$  +(U  "O30  JFD
M *B(  "FJ   HM$ (T@  !A.   .5   !%P   !D    ;0   '4   !\
M@P   (D   "/    E0   )L   "@    HP   *8   "I    K0   +$   "U
M    N0   +X   #$    R@   -(   #:"@  UA8  -(I  #.00  REP  ,5\
M  #"G0  P;T '%4  !%<   '90   &X   !W    ?P   (@   "0    F
M )\   "E    K0   +,   "X    N@   +X   #"    Q@   ,H   #.
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M_________________________________________________P
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MV-G:V]S=WM_@X>+CY.7FY^CIZNOL[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$
M     P0A   !                     0                    $    !
M @,$!08'" D*"PP-#@\0$1(3%!46%Q@9&AL<'1X?("$B(R0E)B<H*2HK+"TN
M+S Q,C,T-38W.#DZ.SP]/C] 04)#1$5&1TA)2DM,34Y/4%%24U155E=865I;
M7%U>7V!A8F-D969G:&EJ:VQM;F]P<7)S='5V=WAY>GM\?7Y_@(&"@X2%AH>(
MB8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@H:*CI*6FIZBIJJNLK:ZOL+&RL[2U
MMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-SL_0T=+3U-76U]C9VMO<W=[?X.'B
MX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O\  0$" @,#! 0%!@8'!P@(
M"0D*"PL,# T-#@\/$! 1$1(3$Q04%186%Q<8&1D:&AL<'!T>'A\@("$B(B,D
M)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C] 0D-$149(24I,34]0
M4E-55UA:7%Y@8F1F:&IM;W%T=GE\?H&#AHF+CI"2E9>9FYV?H:.EIZBJK*VO
ML+*SM;:WN;J[O+V_P,'"P\3%QL?(R<K+S,W-SL_0T=+2T]35UM;7V-G9VMO;
MW-W=WM_?X.'AXN/CY.7EYN;GZ.CIZ>KKZ^SL[>[N[^_P\/'R\O/S]/3U]O;W
M]_CX^?GZ^_O\_/W]_O[_  $! @(# P0$!08&!P<(" D)"@L+# P-#0X/#Q 0
M$1$2$Q,4%!46%A<7&!D9&AH;'!P='AX?(" A(B(C)"0E)B8G*"DI*BLL+2TN
M+S Q,C(S-#4V-S@Y.CL\/3X_0$)#1$5&2$E*3$U/4%)355=86EQ>8&)D9FAJ
M;6]Q='9Y?'Z!@X:)BXZ0DI67F9N=GZ&CI:>HJJRMK["RL[6VM[FZN[R]O\#!
MPL/$Q<;'R,G*R\S-S<[/T-'2TM/4U=;6U]C9V=K;V]S=W=[?W^#AX>+CX^3E
MY>;FY^CHZ>GJZ^OL[.WN[N_O\/#Q\O+S\_3T]?;V]_?X^/GY^OO[_/S]_?[^
M__^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2J
MPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E
M)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMV
MM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_
MI# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF
M><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# .
M_Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*W
MH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z
M&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+
ML9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q
M0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"
MTZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_
MNTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:
MB=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR
M_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=RE
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%5
M1?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#
M7EKRQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKR
MQ&5PY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5P
MY,)LAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)L
MAM>Z<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z
M<)G,LG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,
MLG2JPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYO^E)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2J
MPZMVM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^E
M)0;_I# ._Z8Z&/^Q0R/_NTLR_\%51?[#7EKRQ&5PY,)LAM>Z<)G,LG2JPZMV
MM[VF><*WH7W+L9V"TZN:B=REEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YO^F)0;_
MI# ._Z<Z&/^R0R+_O$LR_\-41?S&75KQR&1QX\9JA]; ;YO+N'*LPK%TNKNM
M=\2TJ7O-JZ-_U**>A=N9FH[AF9J.X9F:CN&9FH[AF9J.X9F:CN&9FH[AF9J.
MX9F:CN&9FH[AF9J.X9F:CN&9FH[AF9J.X9F:CN&9FH[AF9J.X?^F)0;_I3 .
M_Z@Z%_^S0R+_ODLQ_\541?G)7%OOS6-QX\QIB-7&;9S)OW"NO;9RNK2P=<.K
MJGC*HJ5\T9FA@=B0G8G=D)V)W9"=B=V0G8G=D)V)W9"=B=V0G8G=D)V)W9"=
MB=V0G8G=D)V)W9"=B=V0G8G=D)V)W9"=B=V0G8G=D)V)W?^F)0;_I3 ._ZHZ
M%_^U0R+_P$LQ_<A31?;-6UOMT6%RX=!GB='+:YW"P&ZMMK=QN*RQ<\&CK';(
MFJAYSI*D?M2)H(78B:"%V(F@A=B)H(78B:"%V(F@A=B)H(78B:"%V(F@A=B)
MH(78B:"%V(F@A=B)H(78B:"%V(F@A=B)H(78B:"%V/^G)0;_I3 ._ZLZ%_^V
M0R'_P4LQ^LM21//16EKJV6!RWM9EB<O,:IR[P6VKK[EPMJ6T<KZ<KW3$E*MW
MRHNG>\^$I('4A*2!U(2D@=2$I('4A*2!U(2D@=2$I('4A*2!U(2D@=2$I('4
MA*2!U(2D@=2$I('4A*2!U(2D@=2$I('4A*2!U/^G)0;_IC ._ZTZ%O^X0B'^
MQ$HP]\Y21/#66%KGX%YRUMIDB,3-:9JTPVRHJ+MOLIZV<+J6LG+ CJYVQH:J
M>LI_IW_.?Z=_SG^G?\Y_IW_.?Z=_SG^G?\Y_IW_.?Z=_SG^G?\Y_IW_.?Z=_
MSG^G?\Y_IW_.?Z=_SG^G?\Y_IW_.?Z=_SO^H)0;_IS ._ZXY%O^Z0B#[QDHO
M]--10^O=5UKCYEQQSMMDA[W/:9BNQ6NEHKYNKYBY;[:0M7&\B+%TP8&N>,5[
MK'W)>ZQ]R7NL?<E[K'W)>ZQ]R7NL?<E[K'W)>ZQ]R7NL?<E[K'W)>ZQ]R7NL
M?<E[K'W)>ZQ]R7NL?<E[K'W)>ZQ]R?^H) ;_IS -_[ Y%?^]0A_WR4HO[]A0
M0N;C55G<Z%MPQMUCA;;1:)6GR&NAG,%MJI.\;[&*N7&VA+5TNWVR=[]WL'S"
M=[!\PG>P?,)WL'S"=[!\PG>P?,)WL'S"=[!\PG>P?,)WL'S"=[!\PG>P?,)W
ML'S"=[!\PG>P?,)WL'S"=[!\PO^I) 7_J# -_[,Y%/[ 0A[SS4HMZ=U/0.'I
M4UG3ZEMOO]]C@J_39Y&ARVJ=EL5MI8W ;ZN&O7&P?[ISM7JW=[ATM7N[=+5[
MNW2U>[MTM7N[=+5[NW2U>[MTM7N[=+5[NW2U>[MTM7N[=+5[NW2U>[MTM7N[
M=+5[NW2U>[MTM7N[=+5[N_^J) 7_J2\-_[8X$_G$01WMTDDKXN--0-OO4EC*
M[5IMM^%B?ZC69XV;SVJ7D<EMGXC%;Z6"PG&I>[]TK7:]=[!QNWNS<;M[LW&[
M>[-QNWNS<;M[LW&[>[-QNWNS<;M[LW&[>[-QNWNS<;M[LW&[>[-QNWNS<;M[
MLW&[>[-QNWNS<;M[L_^K) 7_JR\-_[HX$O/)01ODVDDHV.A,0,[S45? [UEK
MKN1A>J#<9X:4U&N0B\]NEX3,<)Q]R7.@>,9UHW/$>*9NPGRI;L)\J6["?*EN
MPGRI;L)\J6["?*ENPGRI;L)\J6["?*ENPGRI;L)\J6["?*ENPGRI;L)\J6["
M?*ENPGRI;L)\J?^M) 7_L"\+^\ X#^K001?:XD8HS.Y,0</Y4%6U\UAFI>EA
M=)?A9WZ-VVN&A==OC'_4<I%ZT764=<]XEW'->YILS'Z<;,Q^G&S,?IQLS'Z<
M;,Q^G&S,?IQLS'Z<;,Q^G&S,?IQLS'Z<;,Q^G&S,?IQLS'Z<;,Q^G&S,?IQL
MS'Z<;,Q^G/^O(P3_MBT)\<@V#-W</1/-ZD8JP?9+0+;_3U&J]UA@F^]A:X_H
M:'2%Y&U[?^!Q@'G>=(-UW'B&<MI[B6[8?HMKUH*-:]:"C6O6@HUKUH*-:]:"
MC6O6@HUKUH*-:]:"C6O6@HUKUH*-:]:"C6O6@HUKUH*-:]:"C6O6@HUKUH*-
M:]:"C?^Q(P3ZORP&X]0O!\[F.Q;!\T4KM/])/:C_3DR>_5=8D?9A88;Q:6E_
M[6]N>>IT<G7H=W5QYWIW;N5]>6OD@'MIXX1\:>.$?&GCA'QIXX1\:>.$?&GC
MA'QIXX1\:>.$?&GCA'QIXX1\:>.$?&GCA'QIXX1\:>.$?&GCA'QIXX1\:>.$
M?/^U(@/KRR("T.,G!\+Q.AFT_D(JIO]&.9O_3462_U9/AOYB5G[Z:EQW]W!@
M<_5U8V_S>&5M\GQG:O%_:&CP@FIF[X5K9N^%:V;OA6MF[X5K9N^%:V;OA6MF
M[X5K9N^%:V;OA6MF[X5K9N^%:V;OA6MF[X5K9N^%:V;OA6MF[X5K9N^%:_;"
M&P'4WQ$!PN\F"[7\.AJG_SXGF?]$,XW_2SV%_U5%?/]A2W7_:D]P_W!2;/]U
M5&K^>59H_7Q79OQ_6&3\@EIC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;
M8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6]3/"@#$
M[1("M?LF#:C_-AF9_SLCC/]!+(#_2C1X_U,Z<?]?/VS_:4-H_V]%9?]T1V/_
M=TAB_WM)8?]^2E__@4I>_X1+7O^$2U[_A$M>_X1+7O^$2U[_A$M>_X1+7O^$
M2U[_A$M>_X1+7O^$2U[_A$M>_X1+7O^$2U[_A$M>_X1+7O^$2_^?(@7_G2T,
M_YXX%?^H01[_L4DK_[93//^X74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"
MC8BYOHB,O[J#D<6W?Y?+M'V@SZYYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX
M%?^H01[_L4DK_[93//^X74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BY
MOHB,O[J#D<6W?Y?+M'V@SZYYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H
M01[_L4DK_[93//^X74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,
MO[J#D<6W?Y?+M'V@SZYYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_
ML4DK_[93//^X74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#
MD<6W?Y?+M'V@SZYYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK
M_[93//^X74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W
M?Y?+M'V@SZYYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93
M//^X74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+
MM'V@SZYYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X
M74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@
MSZYYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X74_[
MMF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X74_[MF9C
M[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X74_[MF9C[K1O
M=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X74_[MF9C[K1O=^*L
M=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYYI-&N>:31KGFD
MT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X74_[MF9C[K1O=^*L=8G8
MI'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X74_[MF9C[K1O=^*L=8G8I'N9
MSIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT?^?
M(@7_G2T,_Y\X%?^J0![_LTDK_[E2//^[7$_ZNF5D[;AM>.&P<XO5J'F<S)]]
MJL67@;6_D86^NHR)Q;:'C\RR@Y;2KX&@UJ=^HM.G?J+3IWZBTZ=^HM.G?J+3
MIWZBTZ=^HM.G?J+3IWZBTZ=^HM.G?J+3IWZBTZ=^HM.G?J+3IWZBT_^?(@7_
MGBT,_Z W%/^K0![_M$DK_[M2//^]6U#ZOF1D[+QL>>"U<HW3K7>>RJ1ZK<*<
M?KF\EH+#MY"'RK*+C-*NAY78IH.=VJ&"H=6A@J'5H8*AU:&"H=6A@J'5H8*A
MU:&"H=6A@J'5H8*AU:&"H=6A@J'5H8*AU:&"H=6A@J'5H8*AU?^@(@7_GBT,
M_Z$W%/^L0!W_MD@K_[U1//_ 6E#ZP6-E[,%J>MZY<(_2L76AR*AXL,"A>[RY
MFW_'M):$S["4C=6KD9?:H(F<W)J(H->:B*#7FHB@UYJ(H->:B*#7FHB@UYJ(
MH->:B*#7FHB@UYJ(H->:B*#7FHB@UYJ(H->:B*#7FHB@U_^@(@7_GBT,_Z(W
M%/^M0!W_MT@J_[]1//_"6E#YQ&)EZ\5I>]Z^;I#1MG.CQJYVL[ZG><"XHW_)
MM*&&SZR<C=6CEI3:FI&<W)6.G]B5CI_8E8Z?V)6.G]B5CI_8E8Z?V)6.G]B5
MCI_8E8Z?V)6.G]B5CI_8E8Z?V)6.G]B5CI_8E8Z?V/^@(@7_GRT,_Z,W%/^N
M0!W_N$@J_\%0//[%65#WR&!FZ\IG?-W#;9'/O'&EQ;1TM;VP><"VK'_(KJ>%
MSZ6ABM6<G)':E9F<W(^4G]B/E)_8CY2?V(^4G]B/E)_8CY2?V(^4G]B/E)_8
MCY2?V(^4G]B/E)_8CY2?V(^4G]B/E)_8CY2?V/^A(@7_GRT,_Z0W%/^P/QS_
MND@J_\-0._O(6%#URU]FZ<]F?-S):Y+.PV^FP;IRM;:R=L"LK'O(I*A_SIRD
MA=24H(W8C9^9VXJ<G]B*G)_8BIR?V(J<G]B*G)_8BIR?V(J<G]B*G)_8BIR?
MV(J<G]B*G)_8BIR?V(J<G]B*G)_8BIR?V/^A(@7_H"T,_Z8V$_^Q/QS_NT@I
M_L9/._C+5U#RT%YFY]1D?=K/:9/(Q6VFNKMPM*VS<[^CK7;'FJAZS9*E?]**
MHH;7A*"1V82BG->$HIS7A**<UX2BG->$HIS7A**<UX2BG->$HIS7A**<UX2B
MG->$HIS7A**<UX2BG->$HIS7A**<U_^A(@7_H"T,_Z<V$_^S/QS_O4<I_,A.
M._7.5D_NU5UFY-IB?=/2:)+!QFRDL[QOL::U<KR<KW3$DZMWRHNG>\^#I('4
M?:*+UGNCE=5[HY75>Z.5U7NCE=5[HY75>Z.5U7NCE=5[HY75>Z.5U7NCE=5[
MHY75>Z.5U7NCE=5[HY75>Z.5U?^B(07_H"T,_Z@V$O^T/QO_OT<H^<M..O+3
M54_JW%MFX.!A?<S39Y&[R&NBK+YNKZ"W<+B5LG/ C:YVQ86J>LI^J'_.>*:'
MT76EC])UI8_2=:6/TG6EC])UI8_2=:6/TG6EC])UI8_2=:6/TG6EC])UI8_2
M=:6/TG6EC])UI8_2=:6/TO^B(07_H2P+_ZHV$O^V/AO]PD<H]<U..>[95$[F
MXUEEV.)@>\759H^TRFJ?I<%MJYFZ;[20M7*[B+%UP(&N>,5ZK'W)=*J$RW&I
MB\QQJ8O,<:F+S'&IB\QQJ8O,<:F+S'&IB\QQJ8O,<:F+S'&IB\QQJ8O,<:F+
MS'&IB\QQJ8O,<:F+S/^C(07_HBP+_ZPU$?^Y/AKYQ4<G\-%-..G@4DSBZ5=D
MSN1?>KW79HRMS&J;G\1LIY.^;Z^*N7&U@[9TNGRS=[YVL7S"<:^"Q&ZNA\9N
MKH?&;JZ'QFZNA\9NKH?&;JZ'QFZNA\9NKH?&;JZ'QFZNA\9NKH?&;JZ'QFZN
MA\9NKH?&;JZ'QO^D(07_HRP+_Z\U$/^\/ACTR48EZMA--N+G3TS<[U5CQN9?
M>+3:98FET&F6F,ALH8W#;ZB%OW&N?KMTLGBY=[9SMWNY;K6 O&NTA;YKM(6^
M:[2%OFNTA;YKM(6^:[2%OFNTA;YKM(6^:[2%OFNTA;YKM(6^:[2%OFNTA;YK
MM(6^:[2%OO^E(03_I"P+_[,U#_O!/A?MST8BX=]+--CK3TS/\U1BO.A>=*O>
M9(2=U&F0D<YMF8?);Z" Q7*E>L)TJ73 >*QPOGNO:[R LFB[A+-HNX2S:+N$
MLVB[A+-HNX2S:+N$LVB[A+-HNX2S:+N$LVB[A+-HNX2S:+N$LVB[A+-HNX2S
M:+N$L_^F(03_J"L*_[@T#?/'/13DV$4>UN9)-<OQ3DS$]U-?L>Q=<*'B9'V5
MVVF'BM5NCX+0<95[S72:=LMWG7')>:!MQWVB:<6!I6;$A:9FQ(6F9L2%IF;$
MA:9FQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$A:9FQ(6F9L2%
MIO^H( 3_KBH(_+\S"^G//!#7X4(>RNU)-;_X34JW^U);IO%=:9CI972,XFI]
M@]UOA'S:<XEWUW>,<]5ZCV_3?9%LT8"4:-"$EF7/AY=ESX>79<^'EV7/AY=E
MSX>79<^'EV7/AY=ESX>79<^'EV7/AY=ESX>79<^'EV7/AY=ESX>79<^'E_^J
M( /_M2D&\,@Q!]K=,PS+ZD(AOO9(-;+_3$:I_U%5F_==8([P96J%ZVQQ?>=Q
M=G?D=GISXGE];^%\?VS?@(%IWH.#9]V'A67<B89EW(F&9=R)AF7<B89EW(F&
M9=R)AF7<B89EW(F&9=R)AF7<B89EW(F&9=R)AF7<B89EW(F&9=R)AO^M'P/Y
MOR4#W]8B LOH,@^^]$$BL/]%,Z3_2D&<_U%-C_Y=5H7Y9EY]]&YD=O)S:'+O
M>&MN[GQM;.U_;VKL@G!GZH5R9>J)<V/IC'1CZ8QT8^F,=&/IC'1CZ8QT8^F,
M=&/IC'1CZ8QT8^F,=&/IC'1CZ8QT8^F,=&/IC'1CZ8QT8^F,=/^V' +HS10!
MS.8=!+[S,1*Q_SXBH_]"+Y;_2#J-_U!$A/]<2WO_9U%T_FY6;_QS66S[>%MI
M^7Q=9_A_7F;X@U]D]X9@8O:)86'VC&)A]HQB8?:,8F'VC&)A]HQB8?:,8F'V
MC&)A]HQB8?:,8F'VC&)A]HQB8?:,8F'VC&)A]HQB8?:,8O/$#P#.V@L O?,=
M!['_,A2C_SH?E?\_*HG_1C. _T\Z>/];0''_9D5L_VU(:/]S2F;_=TQD_WM-
M8O]_3F'_@D]@_X507O^)45[_BU%>_XM17O^+45[_BU%>_XM17O^+45[_BU%>
M_XM17O^+45[_BU%>_XM17O^+45[_BU%>_XM17O^+4<S+"0"^Y@P!K_\>":3_
M,!.5_S4<A_\\)'S_1"MS_TTQ;/]8-6?_8SEC_VL[8?]Q/5__=3Y=_WD_7/]\
M0%O_?T%:_X)!6?^&0EC_B$)8_XA"6/^(0EC_B$)8_XA"6/^(0EC_B$)8_XA"
M6/^(0EC_B$)8_XA"6/^(0EC_B$)8_XA"6/^(0O^9'P7_EBL+_Y4V$O^@/AK_
MJ$<F_ZY1-/^O6T7_K657^*EO:.VC>'GCFW^'VY*%E-2+C)[/A9&FRX"5K,=\
MF;'%>9ZUPG:CN<!TJKR]<;*^N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO_^9'P7_EBL+_Y4V$O^@/AK_J$<F
M_ZY1-/^O6T7_K657^*EO:.VC>'GCFW^'VY*%E-2+C)[/A9&FRX"5K,=\F;'%
M>9ZUPG:CN<!TJKR]<;*^N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EO
ML;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO_^9'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1
M-/^O6T7_K657^*EO:.VC>'GCFW^'VY*%E-2+C)[/A9&FRX"5K,=\F;'%>9ZU
MPG:CN<!TJKR]<;*^N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y
M;[&_N6^QO[EOL;^Y;[&_N6^QO_^9'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1-/^O
M6T7_K657^*EO:.VC>'GCFW^'VY*%E-2+C)[/A9&FRX"5K,=\F;'%>9ZUPG:C
MN<!TJKR]<;*^N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_
MN6^QO[EOL;^Y;[&_N6^QO_^9'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1-/^O6T7_
MK657^*EO:.VC>'GCFW^'VY*%E-2+C)[/A9&FRX"5K,=\F;'%>9ZUPG:CN<!T
MJKR]<;*^N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO_^9'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1-/^O6T7_K657
M^*EO:.VC>'GCFW^'VY*%E-2+C)[/A9&FRX"5K,=\F;'%>9ZUPG:CN<!TJKR]
M<;*^N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EO
ML;^Y;[&_N6^QO_^9'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1-/^O6T7_K657^*EO
M:.VC>'GCFW^'VY*%E-2+C)[/A9&FRX"5K,=\F;'%>9ZUPG:CN<!TJKR]<;*^
MN6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y
M;[&_N6^QO_^9'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1-/^O6T7_K657^*EO:.VC
M>'GCFW^'VY*%E-2+C)[/A9&FRX"5K,=\F;'%>9ZUPG:CN<!TJKR]<;*^N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_
MN6^QO_^9'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1-/^O6T7_K657^*EO:.VC>'GC
MFW^'VY*%E-2+C)[/A9&FRX"5K,=\F;'%>9ZUPG:CN<!TJKR]<;*^N6^QO[EO
ML;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO_^9'P7_EBL+_Y4V$O^@/AK_J$<F_ZY1-/^O6T7_K657^*EO:.VC>'GCFW^'
MVY*%E-2+C)[/A9&FRX"5K,=\F;'%>9ZUPG:CN<!TJKR]<;*^N6^QO[EOL;^Y
M;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO_^9
M'P7_ERL+_Y<V$O^A/AK_JD8E_[!0-/^Q6D7_L&17]ZQM:>RG=WOAGGV*V9:#
ME]&.B:++B(ZKQX*3L<1^E[?!>IR[OG>BO[QUJL*U<:[#LW*OP;-RK\&S<J_!
MLW*OP;-RK\&S<J_!LW*OP;-RK\&S<J_!LW*OP;-RK\&S<J_!LW*OP?^9'P7_
MERH*_Y@U$O^C/1K_K$8E_[-/-/^T64;_M&-8]K%L:^JM=7W?HWN-U9N!G,V2
MAJC'BXJQPH6/N;^ E+Z[?)K#N7FAQ[5VJ<JM=:S&JW:MQ*MVK<2K=JW$JW:M
MQ*MVK<2K=JW$JW:MQ*MVK<2K=JW$JW:MQ*MVK<2K=JW$JW:MQ/^:'P3_F"H*
M_YHT$O^E/1G_KD8E_[5.-/^W6$;_MV%9];5J;.FR<W_=J'B0TY]^H,J6@JS$
MCH>WOHB,O[J#D<6W?YC+M'RASZMXI<^E>:K(I'FLQJ1YK,:D>:S&I'FLQJ1Y
MK,:D>:S&I'FLQJ1YK,:D>:S&I'FLQJ1YK,:D>:S&I'FLQO^:'P3_F"H*_YLT
M$?^F/1G_KT4E_[=.-/^Z5T;_NV!9]+EI;>>V<8'<K':3T*1[H\B:?[' DX2\
MNXR)Q;>(D,NTAIG.LH:DT:1\I-&??:G*GGVJR)Y]JLB>?:K(GGVJR)Y]JLB>
M?:K(GGVJR)Y]JLB>?:K(GGVJR)Y]JLB>?:K(GGVJR/^;'P3_F2H*_YPT$?^G
M/!G_L44D_[E--/^\5T;^OE]9]+UG;N>Z;X+:L725SZAYIL6??;2^EX' N92*
MQK61DLNOC9C/JHJATIZ"H].9@:C,F(*IRIB"J<J8@JG*F(*IRIB"J<J8@JG*
MF(*IRIB"J<J8@JG*F(*IRIB"J<J8@JG*F(*IRO^;'P3_F2H*_YTT$?^I/!C_
MLD4D_[M-,_^_5D;]P5Y:\\%F;^:_;8/9MG.7S:UWJ,2E>[>^H8/ MIN)QJZ5
MC\RHD97/HHZ>TIF'HM.4AJ?-DX:HRY.&J,N3AJC+DX:HRY.&J,N3AJC+DX:H
MRY.&J,N3AJC+DX:HRY.&J,N3AJC+DX:HR_^;'P3_F2H*_YXS$?^J/!C_LT4D
M_[Q,,__!54;[Q%U:\\5E;^7#;(38NW&8S+)UJ\.M?+:YI8&_L)Z&QJB9C,NA
ME9+0FY*;TY2.HM2/BJ;.CXJHRX^*J,N/BJC+CXJHRX^*J,N/BJC+CXJHRX^*
MJ,N/BJC+CXJHRX^*J,N/BJC+CXJHR_^;'P3_FBH*_Y\S$/^K/!C_M40C_[Y,
M,_[#547YQUQ:\<ED;^7(:H76P6^:RKETJKZP>K:SJ7^_JJ*$QJ*=BLN;FI#/
ME9>9TH^4HM2*D*;.BH^HS(J/J,R*CZC,BH^HS(J/J,R*CZC,BH^HS(J/J,R*
MCZC,BH^HS(J/J,R*CZC,BH^HS/^<'P3_FBH*_Z S$/^L/!C_MD0C_[],,OS&
M5$7VREQ:[\UB<.3-:(;3Q6V:Q;QSJKFT>+6NK7V^I:>"Q9VBB,N5GX[/CYR6
MTHN<HM.&E:;.AI2GS(:4I\R&E*?,AI2GS(:4I\R&E*?,AI2GS(:4I\R&E*?,
MAI2GS(:4I\R&E*?,AI2GS/^<'P3_FBD*_Z(S$/^M.Q?_MT0C_\%,,OG)4T7S
MS5I:[-)@<.#09H;.R&R:P+]QJ;2X=[6IL7R^GZR!Q9>HALJ0I(S.BJ*5T86B
MH=*!G*;.@9JGS(&:I\R!FJ?,@9JGS(&:I\R!FJ?,@9JGS(&:I\R!FJ?,@9JG
MS(&:I\R!FJ?,@9JGS/^<'@3_FRD*_Z,S$/^O.Q?_N40B_<-+,?;,4D3PTEE9
MZ-I?<-O59(;)S&J9NL-OJ*V[=+2BM'F]F*]]PY"L@\B)J8G,@Z>1SWZFG-!]
MI*;-?**HRWRBJ,M\HJC+?**HRWRBJ,M\HJC+?**HRWRBJ,M\HJC+?**HRWRB
MJ,M\HJC+?**HR_^='@3_FRD*_Z4R#_^Q.Q;_O$0A^L9+,?/144/KVE=9X]]=
M;]/;8X7"SVF7L<1MIZ2\<+*8M72[CK%XPH:M?<: JX+*>JF*S7:HE,YVJ:/,
M=ZNHRG>KJ,IWJZC*=ZNHRG>KJ,IWJZC*=ZNHRG>KJ,IWJZC*=ZNHRG>KJ,IW
MJZC*=ZNHRO^='@3_G"D*_Z<R#_^S.Q;_OD,@]<I++^[64$+FX597W.1;;LO>
M8X.ZT6B4J<=LHYN^;JZ0N'&WAK1TO7ZP>,)WKGS&<JR#R6VKC,IMJYG);JR?
MQVZLG\=NK)_';JR?QVZLG\=NK)_';JR?QVZLG\=NK)_';JR?QVZLG\=NK)_'
M;JR?Q_^>'@3_G2D)_ZDR#O^V.A3ZPD,?\,Y*+N?=3T#BZ5)7TNA:;<'@8H"Q
MU&>1H<IKGI3#;JB)O7&P@+ETMGFV=[ITM'N];K*!P&JPB,)GL)+#9K"6PV:P
MEL-FL);#9K"6PV:PEL-FL);#9K"6PV:PEL-FL);#9K"6PV:PEL-FL);#9K"6
MP_^?'@3_GBD)_ZTQ#?^Z.A/TQT(=Z-5**]_D3#_7[%%6R>Y9:[?C87RHV&>+
MFL]KEXW);J"#Q'&G>\!TK'6]>+!PNWNS;+F MFBXAKADMX^Y8[:1NF.VD;IC
MMI&Z8[:1NF.VD;ICMI&Z8[:1NF.VD;ICMI&Z8[:1NF.VD;ICMI&Z8[:1NO^@
M'@3_H2@(_[$P"_O .1'LSD(9W]]'*-/I3$#*\5%5OO)8:*WF87>>W6>$DM5L
MCX?/;Y9^RW.<>,AVH7+&>:1NQ'RG:<*!J6; AJQBOXVM8;^/KF&_CZYAOX^N
M8;^/KF&_CZYAOX^N8;^/KF&_CZYAOX^N8;^/KF&_CZYAOX^N8;^/KO^B'0/_
MIB<'_[<O"?+'. WAV$$4TN9&*L?P3$"^^%!3LO578Z+K87"5XV=[BMUMA('8
M<8MZU'60=-)YDW#0?)9LSG^9:,R#FV3+B)UARHV?8,F/GV#)CY]@R8^?8,F/
MGV#)CY]@R8^?8,F/GV#)CY]@R8^?8,F/GV#)CY]@R8^?8,F/G_^D'0/_K28%
M^[XM!N;0- C3XCP6Q^Y&*[OY2CZP_D]/IOI77)CQ86B,ZVAQ@^9N>'OB<WUU
MWWB!<=U[A&W;?X=JVH.)9]F&BF37BXQAUI".8-61CF#5D8Y@U9&.8-61CF#5
MD8Y@U9&.8-61CF#5D8Y@U9&.8-61CF#5D8Y@U9&.8-61CO^G' /_M2,#[LDF
M ]7?*0?'[#P9NOA$*ZW_2#NC_TU)FO]75(WY85V$]&IE?/!P:G;M=FYQZWIQ
M;>E^=&OH@G9HYH5W9N6(>6/DC'IAXY%\8..2?&#CDGQ@XY)\8..2?&#CDGQ@
MXY)\8..2?&#CDGQ@XY)\8..2?&#CDGQ@XY)\8..2?/^K&P+WP!T!V=P2 <?K
M* JZ]SL:K/]!*:#_1C:5_TQ!C?]62X/_85)[_6M7=/IQ7&_X=E]L]GMA:?5_
M8V?T@V1E\X9F8_**9V'QCFA?\))I7_"3:E_PDVI?\)-J7_"3:E_PDVI?\)-J
M7_"3:E_PDVI?\)-J7_"3:E_PDVI?\)-J7_"3:O^W%0'6SPL Q^H3 KGW*0VL
M_SD:GO\^)I+_1#"'_TLY@/]40'C_849R_VI*;/]P36G_=E!F_WM19/]_4V/_
M@U1A_X958/Z)5E[^C5==_9)87/V36%S]DUA<_9-87/V36%S]DUA<_9-87/V3
M6%S]DUA<_9-87/V36%S]DUA<_9-87/V36-;$" #&U D N/<4!*O_*0Z>_S08
MD/\Z(83_02EZ_TDP<O]2-FS_7CIH_V@]9/]O0&'_=$%?_WE#7O]]1%W_@$5<
M_X1%6_^'1EK_BD=8_X]'6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_
MD$A8_Y!(6/^02%C_D$A8_Y!(6/^02,3'!P"WVP<!J?\6!I__*@V0_S 5@_\V
M''?_/B)N_T<H9O]0+&'_6B]=_V0Q6_]L,UG_<358_W4V5O]Y-E;_?#=5_W\W
M5/^".%/_A3E2_XDY4O^*.5+_BCE2_XHY4O^*.5+_BCE2_XHY4O^*.5+_BCE2
M_XHY4O^*.5+_BCE2_XHY4O^*.?^2'03_D"D)_XTU$/^8.Q?_H$0A_Z9.+?^G
M63S_I61,_Z%N6_>;>&KNE8%WYXZ)@N&&CXO<@)63V'R;F=1XH)[1=:2BSW.I
MI<UQKJC,;[6JRFV^K<-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN
MPVF]KL-IO:[#:;VNPVF]KO^2'03_D"D)_XTU$/^8.Q?_H$0A_Z9.+?^G63S_
MI61,_Z%N6_>;>&KNE8%WYXZ)@N&&CXO<@)63V'R;F=1XH)[1=:2BSW.II<UQ
MKJC,;[6JRFV^K<-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]
MKL-IO:[#:;VNPVF]KO^2'03_D"D)_XTU$/^8.Q?_H$0A_Z9.+?^G63S_I61,
M_Z%N6_>;>&KNE8%WYXZ)@N&&CXO<@)63V'R;F=1XH)[1=:2BSW.II<UQKJC,
M;[6JRFV^K<-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-I
MO:[#:;VNPVF]KO^2'03_D"D)_XTU$/^8.Q?_H$0A_Z9.+?^G63S_I61,_Z%N
M6_>;>&KNE8%WYXZ)@N&&CXO<@)63V'R;F=1XH)[1=:2BSW.II<UQKJC,;[6J
MRFV^K<-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#
M:;VNPVF]KO^2'03_D"D)_XTU$/^8.Q?_H$0A_Z9.+?^G63S_I61,_Z%N6_>;
M>&KNE8%WYXZ)@N&&CXO<@)63V'R;F=1XH)[1=:2BSW.II<UQKJC,;[6JRFV^
MK<-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN
MPVF]KO^2'03_D"D)_XTU$/^8.Q?_H$0A_Z9.+?^G63S_I61,_Z%N6_>;>&KN
ME8%WYXZ)@N&&CXO<@)63V'R;F=1XH)[1=:2BSW.II<UQKJC,;[6JRFV^K<-I
MO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]
MKO^2'03_D"D)_XTU$/^8.Q?_H$0A_Z9.+?^G63S_I61,_Z%N6_>;>&KNE8%W
MYXZ)@N&&CXO<@)63V'R;F=1XH)[1=:2BSW.II<UQKJC,;[6JRFV^K<-IO:[#
M:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KO^2
M'03_D"D)_XTU$/^8.Q?_H$0A_Z9.+?^G63S_I61,_Z%N6_>;>&KNE8%WYXZ)
M@N&&CXO<@)63V'R;F=1XH)[1=:2BSW.II<UQKJC,;[6JRFV^K<-IO:[#:;VN
MPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KO^3'03_
MD"D)_X\T$/^:.Q?_HD0@_ZE-+?^J6#S_J&),_Z1L7/6?=FSLF7]ZY)&'AMZ)
MC9#8@Y.8TWZ9G]!ZG:3-=J*IRW2GK,EQK:_';[2RP6RYM+QLN[&\;+NQO&R[
ML;QLN[&\;+NQO&R[L;QLN[&\;+NQO&R[L;QLN[&\;+NQO&R[L?^4'03_D2@)
M_Y$S$/^<.A;_I$,@_ZQ,+?^M5CW_K6!-_JEJ7O2E=&[JGWU]X9:#B]F.BI;3
MAY"@SH&5I\I\FJW'>)^RQ'6EML)RJ[G <+2[MVZUN;-ON+6S;[BULV^XM;-O
MN+6S;[BULV^XM;-ON+6S;[BULV^XM;-ON+6S;[BULV^XM?^4'03_DB@)_Y,R
M#_^>.A;_IT,@_ZY++?^Q53W_L%]._:YH7_*J<G#GI'J!WIJ C]62AYS.BXRF
MR821K\1^E[7!>9R[OG:CO[QTJ\*T;Z[#KG*SO*MSMKBK<[:XJW.VN*MSMKBK
M<[:XJW.VN*MSMKBK<[:XJW.VN*MSMKBK<[:XJW.VN/^5' 3_DB@)_Y4R#_^@
M.A;_J4(?_[!*+?^T5#W_M%Y._;-G8/&O<'+FJ7B#VY]^D]*7@Z'+CHFLQ(:.
MM<" E+V\>YK#NGJCQ;=YJ\>L<ZS&IW6QOZ5WM;JE=[6ZI7>UNJ5WM;JE=[6Z
MI7>UNJ5WM;JE=[6ZI7>UNJ5WM;JE=[6ZI7>UNO^5' 3_DR@)_Y8Q#_^A.17_
MJD(?_[)*+/^V4SS_MUU.^[9E8?"T;G3DK76&V:1[EL^;@*7'DH6QP8J+N[V'
ME,"[A9W$MH*DQ[!^JLBE=ZK(H7FPP9]ZL[R?>K.\GWJSO)]ZL[R?>K.\GWJS
MO)]ZL[R?>K.\GWJSO)]ZL[R?>K.\GWJSO/^5' 3_DR@)_Y<Q#_^C.17_K$(?
M_[1*+/^Y4SS_NEQ.^+ID8N^X;'7CLG.(V*EYF<V??JG%F(2TOY.,O+B-D\&S
MB9G%KH:AR*J$J<F??*G*FWVNPIE^LKV9?K*]F7ZRO9E^LKV9?K*]F7ZRO9E^
MLKV9?K*]F7ZRO9E^LKV9?K*]F7ZRO?^6' 3_DR@)_Y@P#O^D.17_K4$>_[5)
M+/^[4CS]O5M.]KUC8NZ]:W;BMG&)U:YWF\NE?*K"G8.TN9:)O+*1D,&LC);&
MIXF=R*.'ILJ9@*C+EH&NQ)6!L;Z5@;&^E8&QOI6!L;Z5@;&^E8&QOI6!L;Z5
M@;&^E8&QOI6!L;Z5@;&^E8&QOO^6' 3_E"<)_YDP#O^E.13_KD$>_[=)*_^]
M43S\OUI.],%B8NS!:7?ANW"+TK%TG<>H>ZJ\H(&TM)J'O*R4C<*FD)3&H(V;
MR9R+I,N5AJC+D86MQ9"%L;^0A;&_D(6QOY"%L;^0A;&_D(6QOY"%L;^0A;&_
MD(6QOY"%L;^0A;&_D(6QO_^6' 3_E"<(_YHP#O^F.!3_L$$=_[A)*_^_43SZ
MPEE.\L1A8^G%:'?=OFV,S;1SG<*K>:JWI'ZTKIV$O*:8BL&@E)'&FI&8R9:/
MH<N0BZC,C(FLQ8R)L,",B;# C(FPP(R)L,",B;# C(FPP(R)L,",B;# C(FP
MP(R)L,",B;# C(FPP/^7' 3_E2<(_YLP#O^G.!3_L4$=_[I)*__"4#OXQEA.
M\,A?8^;(9GC8P6N-R;=QG;VO=ZFRIWRSJ:&"NZ&<B,&:F(_&E):6R9"4G\N+
MD:C,AXZLQH>-L,&'C;#!AXVPP8>-L,&'C;#!AXVPP8>-L,&'C;#!AXVPP8>-
ML,&'C;#!AXVPP?^7&P/_E2<(_YTO#?^I.!/_LT =_[Q(*OS%3SOVR5=.[<U>
M8^++9'C2Q&J,Q+MOG+BR=:FMJWNSHZ: NYNAAL&4G8W%CIN4R(J9G<J&F:C+
M@I.LQH*2K\&"DJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\&"
MDJ_!@I*OP?^7&P/_E2<(_YXO#?^J.!/_M4 <_[Y(*?G(3CKSS59-ZM-<8M[/
M8GC-QVB+O[YNF[*W<ZBGL'FRGJM^NI6GA,".HXO$B*&2QX.?FLF H*?*?9JL
MQGV8K\%]F*_!?9BOP7V8K\%]F*_!?9BOP7V8K\%]F*_!?9BOP7V8K\%]F*_!
M?9BOP?^8&P/_EB<(_Z O#?^L-Q+_MT ;_<%(*/;+3CGOTU1,YME:8MC487?'
MRV>*N<-LFJV\<J>AMG>QF+%]N(^M@KZ(JHG#@JB0QGVGF<AZIZ7)=Z*LQ7B?
ML,%XG[#!>)^PP7B?L,%XG[#!>)^PP7B?L,%XG[#!>)^PP7B?L,%XG[#!>)^P
MP?^8&P/_ER8(_Z(O#/^N-Q+_N3\:^<1')_'.33CJVU-+X-]98-#:7W;!T&6)
ML\EKF:;"<*6;O76OD;A[MHBU@+R!LH; >["-PW:NEL5SKJ'&<JVMQ'*IL,!R
MJ;# <JFPP'*IL,!RJ;# <JFPP'*IL,!RJ;# <JFPP'*IL,!RJ;# <JFPP/^9
M&P/_F"8(_Z0N"_^Q-A'^O3\9],A')>O433;EXU!)V>-77\G?7G2ZUV2&K,]I
MEIW';:.1P'&LAKMULWZW>KEWM'^]<K*%OVVQC<%JL)?":;&EP6RTLKULM+*]
M;+2RO6RTLKULM+*];+2RO6RTLKULM+*];+2RO6RTLKULM+*];+2RO?^:&P/_
MF28(_Z<M"O^U-@_YP3\7[LY&(^3<3#+=YT])S^A67L#D77*RWF2"H]1ID97+
M;9R)Q7"E?\!SK'>\=[%PN7RU:[>!N&>VA[ICM9"[8;6;O&.WIKECMZ:Y8[>F
MN6.WIKECMZ:Y8[>FN6.WIKECMZ:Y8[>FN6.WIKECMZ:Y8[>FN?^;&P/_FR4'
M_ZLM"?^Y-0WRQSX5Y=5&']KC23//ZTY)QNU47;?J7&ZHXF-]FMEIBH[2;92$
MS'&;>\AUH7/$>*9NPGRI:<"!K&6^AZYBO8ZP7[V7L5Z\GK%>O)ZQ7KR>L5Z\
MGK%>O)ZQ7KR>L5Z\GK%>O)ZQ7KR>L5Z\GK%>O)ZQ7KR>L?^<&@/_H"0&_[ L
M"/G - OISST0VM]"'<[I23/$\4Y(N_)26JWP6VF>YV-VDN!I@8?:;XE^U'.0
M=]%WE7'.>YELS'^<:,J#GF3)B*!AQXZB7L:5I%S&FZ1<QIND7,:;I%S&FZ1<
MQIND7,:;I%S&FZ1<QIND7,:;I%S&FZ1<QIND7,:;I/^>&@/_I2,%_[<J!?#(
M,@?<VS4,SN="'\+Q2#2X^4Q&K_=15:+U6V*5[61MBN=K=H#B<'UYWG6"<]MZ
MAV[9?HIKUX*,9]6&CF34BY!ATY"27M&6E%S1FY5<T9N57-&;E5S1FY5<T9N5
M7-&;E5S1FY5<T9N57-&;E5S1FY5<T9N57-&;E?^A&0+_K2$#^+\F ^+4)0/.
MY3,/PO!"(;;Z1S.K_DM"HOY03Y?[6UJ+]65C@O!L:GKL<G!TZ7AT;^=\=VSE
M@7IHXX1\9N*(?6/AC']@X)&!7M^6@ES>FH-<WIJ#7-Z:@US>FH-<WIJ#7-Z:
M@US>FH-<WIJ#7-Z:@US>FH-<WIJ#7-Z:@_^C&0+_MAT!Z<P7 <_C'@/"\#,2
MM?I (JG_1#"=_TD]E?]02(O_6U""_657>OEM773V<V%O]'ED:_)^9VCQ@FEF
M\(9J9.^*;&+NCFU@[9)N7>R7<%SKFW%<ZYMQ7.N;<5SKFW%<ZYMQ7.N;<5SK
MFW%<ZYMQ7.N;<5SKFW%<ZYMQ7.N;<?^L%0'SPQ  T=H+ ,'O'P:T^S,3J/\\
M()O_0BR0_T@VA_]//W__6D9X_V5+<?]M3VS_<U)I_WE59OY^5V3]@EAB_(99
M8?N*6E_ZCEM>^I)<7/F775OXFUY;^)M>6_B;7EOXFUY;^)M>6_B;7EOXFUY;
M^)M>6_B;7EOXFUY;^)M>6_B;7OJY#@#-RPD P.8- ;+\( BG_S,3FO\Y'8W_
M/R:"_T8N>O].-7/_6#IM_V,_:?]L0F7_<D1B_W=&8/]\1U__@4A=_X5)7/^(
M2EO_C$M:_Y!,6/^535?_F4U7_YE-5_^935?_F4U7_YE-5_^935?_F4U7_YE-
M5_^935?_F4U7_YE-5_^93<W!!@"^T < L?8. J7_(0F9_RX2C/\T&8#_.R!V
M_T,G;?],+&;_5#!B_V S7O]I-5S_;S=:_W0X6?]Y.5C_?3I7_X [5O^$.U7_
MASQ4_XL]4_^0/5+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3
M/E+_DSY2_Y,^4O^3/KW%!0"PUP4 H_\0 YG_(@F+_RD/?O\P%7/_.!II_T ?
M8O])(UO_4297_UHH5?]B*E+_:2M1_V\L4/]S+4__=RY._WHN3O]]+TW_@"],
M_X0P2_^(,$O_BS!+_XLP2_^+,$O_BS!+_XLP2_^+,$O_BS!+_XLP2_^+,$O_
MBS!+_XLP2_^+,/^+' 3_B"@(_X0T#O^/.A3_ET(<_YY+)_^>5S3_G6)"_YEM
M3_^3>%SXC8)G\HB+<>R"DWGH?)F Y'B>AN%THXK?<:B.W6^ND=MMLY3:;+F6
MV&O"F-5IS)K,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,
M9<N;S&7+F__B_^))0T-?4%)/1DE,10 '"?^+' 3_B"@(_X0T#O^/.A3_ET(<
M_YY+)_^>5S3_G6)"_YEM3_^3>%SXC8)G\HB+<>R"DWGH?)F Y'B>AN%THXK?
M<:B.W6^ND=MMLY3:;+F6V&O"F-5IS)K,9<N;S&7+F\QERYO,9<N;S&7+F\QE
MRYO,9<N;S&7+F\QERYO,9<N;S&7+F_^+' 3_B"@(_X0T#O^/.A3_ET(<_YY+
M)_^>5S3_G6)"_YEM3_^3>%SXC8)G\HB+<>R"DWGH?)F Y'B>AN%THXK?<:B.
MW6^ND=MMLY3:;+F6V&O"F-5IS)K,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,
M9<N;S&7+F\QERYO,9<N;S&7+F_^+' 3_B"@(_X0T#O^/.A3_ET(<_YY+)_^>
M5S3_G6)"_YEM3_^3>%SXC8)G\HB+<>R"DWGH?)F Y'B>AN%THXK?<:B.W6^N
MD=MMLY3:;+F6V&O"F-5IS)K,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;
MS&7+F\QERYO,9<N;S&7+F_^+' 3_B"@(_X0T#O^/.A3_ET(<_YY+)_^>5S3_
MG6)"_YEM3_^3>%SXC8)G\HB+<>R"DWGH?)F Y'B>AN%THXK?<:B.W6^ND=MM
MLY3:;+F6V&O"F-5IS)K,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+
MF\QERYO,9<N;S&7+F_^+' 3_B"@(_X0T#O^/.A3_ET(<_YY+)_^>5S3_G6)"
M_YEM3_^3>%SXC8)G\HB+<>R"DWGH?)F Y'B>AN%THXK?<:B.W6^ND=MMLY3:
M;+F6V&O"F-5IS)K,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QE
MRYO,9<N;S&7+F_^+' 3_B2@(_X4S#O^0.13_F$(<_YY+)_^?5C3_GF%"_YIM
M4/^5=UWWCX%H\8F+<NN#DGOG?9B"XWB=B.!THXS=<JB0VV^MD]INLY;8;+J8
MUFO"F]%IRIS*9LJ<RF;*G,IFRIS*9LJ<RF;*G,IFRIS*9LJ<RF;*G,IFRIS*
M9LJ<RF;*G/^,' /_B2<(_X@R#O^3.!3_FT$<_Z)*)_^D5#3_HE]#_Y]J4?V:
M=%_UE'YL[8Z(>.>'CX'B@)6*W7N:D-IWH);6=*::U'&LGM)OLJ'0;;FCSVS#
MIL5GPZ; :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>A
MP&G'H?^-' /_BB<(_XHQ#?^6-Q/_GD ;_Z5))_^G4S3_IUU#_Z1H4_R@<F+R
MFGQPZI2%?>.+BXC=A)*1V'Z8F--ZGI_0=:2DS7*JJ,MOL*O);;BNPFF\L+QK
MP*JW;<2EMVW$I;=MQ*6W;<2EMVW$I;=MQ*6W;<2EMVW$I;=MQ*6W;<2EMVW$
MI?^-&P/_BR<(_XPP#?^8-Q/_H$ ;_Z=()O^K4C3_JUQ$_ZEF5/JE<&3PGWES
MYYB"@=^/B(W9B(^7TH&5H,Y[FZ?*=J&MQW.HL<5PK[7!;;>WN6NXM;-NO:ZP
M<,&HL'#!J+!PP:BP<,&HL'#!J+!PP:BP<,&HL'#!J+!PP:BP<,&HL'#!J/^.
M&P/_BR8(_XXP#?^:-A+_HC\:_ZE()O^N433_KEM$_ZQD5?FJ;F7OI7=VY9U_
MA=R4A9+4C(R=SH22I\E]F*_$>)ZUPG6GN<%TL;NX<+.[L6^VN*QQN[&I<[^K
MJ7._JZESOZNI<[^KJ7._JZESOZNI<[^KJ7._JZESOZNI<[^KJ7._J_^.&P/_
MC"8(_Y O#?^;-A+_I#\:_ZM')O^Q4#3_L5E$_+!C5?:N;&?MJG5XXZ%\B-F8
M@Y;1D(FCRH>/K<6"E[3"?Z"XOGRHN[MZL+VQ=+*]J7*TNZ9TN;.C=KZMHW:^
MK:-VOJVC=KZMHW:^K:-VOJVC=KZMHW:^K:-VOJVC=KZMHW:^K?^/&P/_C"8'
M_Y$N#/^=-A+_ICX:_ZU')?^S3S3_M%A$^K1A5O.R:FCLKW-ZX:9ZB]:=@)K-
ME(:GQHV-K[^'E+6Z@IRYM7^DO+)]K+ZK>;&_HW:RO:!XN+6>>;VOGGF]KYYY
MO:^>>;VOGGF]KYYYO:^>>;VOGGF]KYYYO:^>>;VOGGF]K_^/&P/_C28'_Y,N
M#/^>-1'_J#X9_Z]&)?^V3C/^MU=$][=@5O"V:&GHLW![WJIWC="??)W'EX.G
MOY"*K[B+D;:RAIBZK8.@O:F!J;^E?K# G'FQOYI[M[>8?;NPF'V[L)A]N["8
M?;NPF'V[L)A]N["8?;NPF'V[L)A]N["8?;NPF'V[L/^0&@/_C28'_Y0M#/^@
M-1'_J3X9_[%&)/^X33/\NU9$];M?5NV[9VGCM6Y]UJQSC\JC>IW!FX"GN)2'
ML+&/CK:KBI6[IH>=OJ*%I<"?A*_!EGZPP91_MKB3@+NRDX"[LI. N[*3@+NR
MDX"[LI. N[*3@+NRDX"[LI. N[*3@+NRDX"[LO^0&@/_CB8'_Y4M#/^A-1'_
MJST8_[-&)/^Z33/ZOE5$\[]=5NJ_96K?N&M^T*]QC\6F>)R[GWZGLIB%KZN3
MB[:ECI.[GXN:OIN)HL&8B*S"D(*OPH^#M;F/A+JSCX2ZLX^$NK./A+JSCX2Z
MLX^$NK./A+JSCX2ZLX^$NK./A+JSCX2ZL_^0&@/_CB4'_Y8L"_^B-1#_K#T8
M_[5%(_^\3#+XP51#\,-<5N?#8VK:NVE^S+)PC\"J=IRVHGRGK9R"KZ67B;:>
MDY"[F8^8OI2-H,&1C*G"BXBNPHJ(M+J*B+FTBHBYM(J(N;2*B+FTBHBYM(J(
MN;2*B+FTBHBYM(J(N;2*B+FTBHBYM/^1&@/_CR4'_Y@L"_^D-!#_KCT8_[=%
M(_^_3#+VQ5-#[LA;5N/&86K4OVA^Q[9NCKNM=)RQIGJFIZ" KY^;AK68EXZ[
MDY65OHZ2G<&*DJ?"AHZNPH2-M+N%C+FTA8RYM(6,N;2%C+FTA8RYM(6,N;2%
MC+FTA8RYM(6,N;2%C+FTA8RYM/^1&@/_CR4'_YDL"_^F- __L#P7_[E$(OS!
M2S'TR5)"Z\U95=_)8&K/PF9]PKELC;:Q<INKJWBFHJ5^KIF@A+62G8NZC)J3
MOH>8F\"$EZ7"@):OPG^2L[R D;BU@)&XM8"1N+6 D;BU@)&XM8"1N+6 D;BU
M@)&XM8"1N+6 D;BU@)&XM?^2&@/_D"4'_YLL"O^G- __LCP6_[M$(?G%2S#Q
MSE%!Y])85-K.7FG*QF5\O;UKC+"V<)JEL':EG*I\K9.F@K2,HXFYAJ"0O8&>
MF;]]GJ+!>YZOP7F9L[QZE[BU>I>XM7J7N+5ZE[BU>I>XM7J7N+5ZE[BU>I>X
MM7J7N+5ZE[BU>I>XM?^2&0/_D"4'_YTK"O^J,P[_M3P5_+]$(/3(2B[MTU _
MX]A64]/276C%RF-[M\)IBZJ[;YB?MG2CE;%ZK(VM@+*%JH>W?Z>.NWJFE[YW
MIJ"_=*:MOW.AM+MTGKBU=)ZXM72>N+5TGKBU=)ZXM72>N+5TGKBU=)ZXM72>
MN+5TGKBU=)ZXM?^3&0/_D20'_Y\K"?^L,PW_N#L4^,-#'N_-2BSGVD\]W=Y5
M4<W86V>^SV)ZL,AGB:3";9>9O'*AC[AXJ8:U?K!_LH6U>;",N'2OE;MPKY^\
M;J^LO&VKM;ENI[FT;J>YM&ZGN;1NI[FT;J>YM&ZGN;1NI[FT;J>YM&ZGN;1N
MI[FT;J>YM/^4&0/_DB0'_Z(J"/^P,@S^O#H2\L="'.C322GAX4P[U.-34<;=
M6F6WU6!XJ<]FAYW):Y21Q7">A\%VIG^^?*QXO(2Q<KJ+M&VYD[9JN)RX9[>G
MN&>WM[9HLKNQ:+*[L6BRN[%HLKNQ:+*[L6BRN[%HLKNQ:+*[L6BRN[%HLKNQ
M:+*[L?^5& /_E2,&_Z4I!_^T,0KXP3H0Z\Y"&.#=1R75Y4L[R^=14+WC66.O
MWE]THMAE@Y;3:H^*SF^9?\ASH77$>*=NP7VK:;Z$KF6]B[%AO).R7[R=LE^\
MK+%BO[ZM8K^^K6*_OJUBO[ZM8K^^K6*_OJUBO[ZM8K^^K6*_OJUBO[ZM8K^^
MK?^6& /_F2$%_ZHH!O^Y, CPR#@-X=A $]3C12;*ZTL[P>Q/3[/H5V"FY5]O
MFN)F?([<;(:$U7&/>M!UE7/->IMLRG^?9\>$HF/&BJ1?Q)&F7,29IUK#I*=:
MQ+"G6L2PIUK$L*=:Q+"G6L2PIUK$L*=:Q+"G6L2PIUK$L*=:Q+"G6L2PI_^8
M%P+_GB $_Z\F!?C +@;FT#,(U>$\%,GJ12B_\DH[M?%.3*GO5EN=[5]HDNIG
M<X?C;7Q^WG*"=MIXB'#7?8QKU(*09M*'DF/1C)5?SY*67,Z9F%G.HIE8S:N:
M6,VKFEC-JYI8S:N:6,VKFEC-JYI8S:N:6,VKFEC-JYI8S:N:6,VKFO^:%P+_
MI1X#_[<C ^W))@/6WBD&R>D[%[[S1"FS^$DZJ/=-2)_V5564]5]@B?%H:(#L
M;W!XZ'5U<N5Z>6WB?WUIX(2 9=^)@F+=CH1?W).&7=N9AUK:H8E8V:B)6-FH
MB5C9J(E8V:B)6-FHB5C9J(E8V:B)6-FHB5C9J(E8V:B)6-FHB?^<%@+_K1L"
M]L$= =O:$P')Z"D)O?,[&;+]0RBF_D<VG/U,0Y/]54V*_5]6@?EI77GU<&)S
M\G9G;O!\:FKN@6UG[(9O9.N+<6'JCW)?Z91T7>B9=5KGH'=8YJ9X6.:F>%CF
MIGA8YJ9X6.:F>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X6.:F>/^B%0'_MQ4 V,\+
M ,KG$P*\\RD+L?T[&:3_0":9_T4RC_]+/(?_5$1__U]+>/]I4''_<%1L_798
M:?M\6F;Z@5QC^(9>8?>+7U_VD&%>]I5B7/6:8UKTH&18\Z5E6/.E95CSI658
M\Z5E6/.E95CSI658\Z5E6/.E95CSI658\Z5E6/.E9?^M$ #6PP@ R-,* +OT
M%0.O_RH-H_\W&)?_/2*+_T,L@?]*-'K_4CIS_UX_;O]H0VG_;T=F_W5)8_][
M2V'_@4Q?_X5.7?^*3US_CU!:_Y-16?^84E?_GE-6_Z-45O^C5%;_HU16_Z-4
M5O^C5%;_HU16_Z-45O^C5%;_HU16_Z-45O^C5-FZ!0#%QP< N=D( *S_%P6B
M_RL-E?\S%HG_.1Y^_T E=?](*VW_4#!G_UHT8_]E-V#_;3E>_W,[7/]X/5K_
M?3Y8_X(_5_^&0%;_BT!5_X]!5/^40E/_FD-1_Y]#4?^?0U'_GT-1_Y]#4?^?
M0U'_GT-1_Y]#4?^?0U'_GT-1_Y]#4?^?0\:^!0"WS04 JN0( 9__&0:4_R@,
MA_\N$WO_-1EQ_ST>:?]%(V+_329;_U8I6/]?+%;_:"U4_VXO4_]S,%+_>#%1
M_WPQ4/^ ,D__A#-._X@S3?^,-$S_DC1+_Y8U2_^6-4O_EC5+_Y8U2_^6-4O_
MEC5+_Y8U2_^6-4O_EC5+_Y8U2_^6-;?$ P"IU ( G/D+ I/_&P6%_R,*>?\I
M#V[_,11E_SD87?]!&U?_2AY3_U(@4/]9(DW_8"-+_V8D2O]K)4G_;R5(_W,F
M1_]W)D;_>R=%_WXG1?^"*$3_ARA#_XLI0_^+*4/_BRE#_XLI0_^+*4/_BRE#
M_XLI0_^+*4/_BRE#_XLI0_^+*?^#' /_@"<'_WLS#?^&.!'_CD 9_Y-)(O^5
M52W_DV$Y_Y!M1?^+>$__AH19_(*.8?=]EFCT>)UN\72C<^YQJ7?L;JYZZFRS
M?>EJN7_G:,"!YF?'@^-ESX7=8]B&TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'
MTV#:A]-@VH?38-J'TV#:A_^#' /_@"<'_WLS#?^&.!'_CD 9_Y-)(O^552W_
MDV$Y_Y!M1?^+>$__AH19_(*.8?=]EFCT>)UN\72C<^YQJ7?L;JYZZFRS?>EJ
MN7_G:,"!YF?'@^-ESX7=8]B&TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'TV#:
MA]-@VH?38-J'TV#:A_^#' /_@"<'_WLS#?^&.!'_CD 9_Y-)(O^552W_DV$Y
M_Y!M1?^+>$__AH19_(*.8?=]EFCT>)UN\72C<^YQJ7?L;JYZZFRS?>EJN7_G
M:,"!YF?'@^-ESX7=8]B&TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@
MVH?38-J'TV#:A_^#' /_@"<'_WLS#?^&.!'_CD 9_Y-)(O^552W_DV$Y_Y!M
M1?^+>$__AH19_(*.8?=]EFCT>)UN\72C<^YQJ7?L;JYZZFRS?>EJN7_G:,"!
MYF?'@^-ESX7=8]B&TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?3
M8-J'TV#:A_^#' /_@"<'_WLS#?^&.!'_CD 9_Y-)(O^552W_DV$Y_Y!M1?^+
M>$__AH19_(*.8?=]EFCT>)UN\72C<^YQJ7?L;JYZZFRS?>EJN7_G:,"!YF?'
M@^-ESX7=8]B&TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'
MTV#:A_^#' /_@"<'_WTR#/^(-Q'_D#\8_Y5)(O^75"W_EE\Y_Y-K1?^.=U'_
MB();^H2,9/5_E&OQ>IMR[G:B=^MRIWOI;ZU_YVRR@N5JN(3D:;^'XFC'B>!F
MSXK68]:,SV+8BL]BV(K/8MB*SV+8BL]BV(K/8MB*SV+8BL]BV(K/8MB*SV+8
MBO^$&P/_@2<'_X Q#/^+-A'_DSX8_YE'(O^<4BW_FETZ_YAI1_^3=%/^CGY?
M]XB):?&"D7+M?9AYZ7B??^5TI(3C<*J(X&VPC-YKMX_=:K^1VVG(D]5FSY7+
M9-&3QF74CL9EU([&9=2.QF74CL9EU([&9=2.QF74CL9EU([&9=2.QF74CO^%
M&P/_@B8'_X(P#/^.-1#_ECT8_YQ&(?^@4"W_GUL[_YQF2/^8<5;[DWQB](V&
M;>Z'CG?H@)6 Y'J<A^!UHHS=<JB1VF^OE=AMMYG5:\"<TFG)GLEER9["9\V8
MOFG1D[YIT9.^:=&3OFG1D[YIT9.^:=&3OFG1D[YIT9.^:=&3OFG1D_^&&P/_
M@R8'_X4O"_^0-!#_F3T7_Y]&(?^C3RW_HUH[_Z!D2?^=;UCZF'EE\9*#<>J+
MC'SD@Y*&WWV9CMIXH)76=*>:TW"NG]%MMJ//:\"EQV;"I\!HQJ*[:LN;MVS.
MEK=LSI:W;,Z6MVS.EK=LSI:W;,Z6MVS.EK=LSI:W;,Z6MVS.EO^&&P/_@R8'
M_X<N"_^3-!#_FSP7_Z%%(/^G32W_IE@[_Z1B2ORA;%GWG'9H[Y: =>>/B8'@
MAY",VH"6E=5ZGIW1=:6CS7"LJ,MMM:S':[ZMO6B_K+AKPZ:S;<B?L&_,F;!O
MS)FP;\R9L&_,F;!OS)FP;\R9L&_,F;!OS)FP;\R9L&_,F?^'&@/_A"4'_XDM
M"_^5,P__G3P6_Z1$(/^J3"W_JE<[_JA@2_BE:EKSH71J[9Q^>>23AH;<BXV2
MU8.4G,]\FZ7+=Z.JQW2KK<1SM:^_<+RPM6N\L+!NP:FL<,:BJ7+*G*ERRIRI
M<LJ<J7+*G*ERRIRI<LJ<J7+*G*ERRIRI<LJ<J7+*G/^'&@/_A"4'_XLL"O^7
M,P__GSL6_Z9$'_^L2RS_KE4[^ZQ?2_6J:%SNIG%LYZ!Z?-^7@HK5CHB8S86/
MH<> EZ?">YZLO7BGK[IVL+&W=;JRK7"ZLJEQOZRE=,2DHW7)GJ-UR9ZC=<F>
MHW7)GJ-UR9ZC=<F>HW7)GJ-UR9ZC=<F>HW7)GO^(&@/_A24'_XPK"O^8,@[_
MH3L5_ZE#'_^O2RS_L50[^+%=2_&O9ESJJV]NX:-V?]69?8_,D829Q8J,HKZ$
MDZBY?YJMM'RCL+!ZJ[.M>;:TIG2YM*)UO:^?=\.FG7G'H)UYQZ"=><>@G7G'
MH)UYQZ"=><>@G7G'H)UYQZ"=><>@G7G'H/^(&@/_A24'_XXJ"O^:,@[_HSH5
M_ZM"'O^Q2BO]M5,[]K5<2^ZS9%WEKFQOVZ5S@<Z=>H_%E8&9OHZ(HK>(D*FQ
MA)>NK("?L:A^J+2E?;*UGWJXMIMYN[&9>\&HF'S&HIA\QJ*8?,:BF'S&HIA\
MQJ*8?,:BF'S&HIA\QJ*8?,:BF'S&HO^)&@/_AB4&_Y J"O^<,0W_I3H4_ZU"
M'O^T2BO[N%(Z\[E:2^JX8E[AL6IPTZEP@<B@=X^_F7Z9MY*%HK",C*FJB)2N
MI82<LJ""I+6=@:ZVF7^WMY1]NK.3?\"JDG_%HY)_Q:.2?\6CDG_%HY)_Q:.2
M?\6CDG_%HY)_Q:.2?\6CDG_%H_^)&0/_AB0&_Y$I"?^=,0W_ISD4_Z]"'?^V
M22KXO% Z\+U92^>\85[<M6=QSJQO@<.D=8ZYG'R9L9:"HJJ1BJFCC)&NGHF9
MLIF&H;66A:NWDX6VMXZ!N;2.@[^KC8/$I8V#Q*6-@\2EC8/$I8V#Q*6-@\2E
MC8/$I8V#Q*6-@\2EC8/$I?^)&0/_AR0&_Y,I"?^?,0W_J3D3_[%!'/^Y22GV
MP$\Y[<)72N2_7UW6N69PR;!M@+ZH<XZTH'J9JYJ HJ25AZF=D8ZNEXZ6LI*+
MG[6/BJFWC(JTN(B&N+6(A[ZLB(?#IHB'PZ:(A\.FB(?#IHB'PZ:(A\.FB(?#
MIHB'PZ:(A\.FB(?#IO^*&0/_AR0&_Y0I"?^A, S_JSD2_[1!'/R[2"CTPTXX
MZ\=62N##7EW1O&5OQ+-K@+FK<8VOI'>8IIY^H9Z:A*B7EHRND9.4LHR1G+6(
MCZ:WA8^QN(*,M[:"C+ZM@XS#IH.,PZ:#C,.F@XS#IH.,PZ:#C,.F@XS#IH.,
MPZ:#C,.F@XS#IO^*&0/_B"0&_Y8H"/^C, S_K3@2_[9 &_J^2"?QQTXWY\Q5
M2-S'7%S,OV-OO[=I?[2P<(RIJ767H*-[H)B?@JB1FXFMBIF2LH66FK6!E:2W
M?I6OMWN2M[9]D;VN?9#"IWV0PJ=]D,*G?9#"IWV0PJ=]D,*G?9#"IWV0PJ=]
MD,*G?9#"I_^+&0/_B20&_Y@H"/^E+PO_L#@1_[E &?C"1R;NRTTUY-!41M7+
M6UO'PV)NNKMH?JZT;HNCKG.6FJEZGY*E@*:*H8>LA)^/L7Z=F+1ZG*&V>)NL
MMG6:M[9WF+VN>);"IWB6PJ=XEL*G>);"IWB6PJ=XEL*G>);"IWB6PJ=XEL*G
M>);"I_^,& /_BB,&_YHG!_^G+PK_LS</_+T_&//&1B/JT$PRX-521<_/65K!
MR&!LM,!F?*BZ;(J=M'*5E+!XGHNL?J6#J(6J?::,KWBDE;)THY^T<:.JM6^D
MN;1PH+ZM<IW"IW*=PJ=RG<*G<IW"IW*=PJ=RG<*G<IW"IW*=PJ=RG<*G<IW"
MI_^,& /_C"(&_YTG!_^J+@G_MC8.]\$^%NW,1B#DV$LNV=Q01,G46%B[S5YK
MKL9E>J+ :HB7NW"2C;=UFX2S?*)]L8.H=J^*K'&MDZ]MK9VQ:JVILFFMM[%J
MJ;^L:Z;#IFNFPZ9KIL.F:Z;#IFNFPZ9KIL.F:Z;#IFNFPZ9KIL.F:Z;#IO^-
M& +_CR %_Z F!O^N+0C]NS4,\<<]$^731!S=X$@MT.%/0L+;5E:TTUUHI\UC
M>)K(:(6/PVZ/A<!TF'V]>IYVNH&D<+F)J&NXDJIGMYRL9;BHK6.XMJUDM<&I
M9;#%I&6PQ:1EL,6D9;#%I&6PQ:1EL,6D9;#%I&6PQ:1EL,6D9;#%I/^.%P+_
MDQ\$_Z0E!?^S+ ;WP3,)Z,X\#]S>0!G0Y4@NQ^5-0KG@552LVUMEG]5A=)+0
M9H&'S6R+?LIRDW;(>9EOQH&>:L6)HF7%DJ1BQ)VF7\2GIUW$M*=>P\2D7[W(
MH%^]R*!?O<B@7[W(H%^]R*!?O<B@7[W(H%^]R*!?O<B@7[W(H/^0%P+_F!T$
M_ZDC!/^Y*03NR#$&W=HT"M#D01O&ZT<NO.I,0;#F4U*CXUIAE^!A;HS=:'F"
MVVZ">MEUB7+5?(]KTH*39<^(EV#-CYI<S)><6LN@G5C+JYU7R[J=6<S,F5G,
MS)E9S,R96<S,F5G,S)E9S,R96<S,F5G,S)E9S,R96<S,F?^2%@+_G1P#_Z\@
M O; )0+BTR0#T.,R#,7L0!VZ\4<OL.]+/Z7M44Z:ZUI:C^IB987H:FY]YW)U
M=>-X>V_@?H!IW82$9-N*AV#9D8E=V)B+6M:@C5C6J(Y6U;2.5-7!CE35P8Y4
MU<&.5-7!CE35P8Y4U<&.5-7!CE35P8Y4U<&.5-7!CO^4%0+_I!D"_[<< >G+
M%@'1X1T"Q>PQ#KKU0!ZN]T4NH_5*/)KT4$B0\UI3AO-C6W[R;&)W\7-H<>YZ
M;6SK@'!GZ89S8^>,=F#FDGA=Y)AZ6N.>>UCCI7U6XJ]^5.&X?E3AN'Y4X;A^
M5.&X?E3AN'Y4X;A^5.&X?E3AN'Y4X;A^5.&X?O^8$P'_K10!\\,/ -+8"P#$
M[!X$N/8Q$:W]/AZB_4,KE_Q(-X[\3T&%_%E)??QC4'?\;59P^W1::_EZ7FCW
M@6%D]8=C8?.-95_RDV==\9EH6O">:5COI6M6[ZUL5.ZT;53NM&U4[K1M5.ZT
M;53NM&U4[K1M5.ZT;53NM&U4[K1M5.ZT;?^C$ #QN0P SLD) ,3?"P"V]Q\&
MK/\R$J#_.QV4_T$GBO]',8'_3CEZ_U@_<_]B16[_;$EI_W-,9O]Z3V/_@%%@
M_X937O^,5%S_DE5:_IA76?V=6%?\I%E5^ZM:5/NQ6U3[L5M4^[%;5/NQ6U3[
ML5M4^[%;5/NQ6U3[L5M4^[%;5/NQ6_"O" #-OP< P,T( +3N#@*I_R$(G_\Q
M$9+_-QJ'_SXB??]%*77_33!N_U4U:?]@.67_:CQA_W$^7_]W0%S_?D):_X1#
M6?^)1%?_CT56_Y1&5?^:1U/_H$A2_Z=)4?^M2E'_K4I1_ZU*4?^M2E'_K4I1
M_ZU*4?^M2E'_K4I1_ZU*4?^M2L^X! "^PP4 LM0& *;^$ .<_R,(D/\M#X3_
M,Q9Y_SL<</]#(FG_2B=B_U(J7?]<+5K_93!8_VTQ5O]S,U3_>313_WXU4O^$
M-E#_B3=/_XXX3O^3.$W_F3E,_Z Z2_^F.DO_ICI+_Z8Z2_^F.DO_ICI+_Z8Z
M2_^F.DO_ICI+_Z8Z2_^F.K^\ P"PR@, H]P# 9G_$@./_R((@O\H#7;_+Q)M
M_S<79?\_&U[_1QY8_TXA5/]7(U'_7R5._V4F3?]L)TO_<2A*_W8I2?][*DC_
M@"I'_X4K1O^)*T7_CBQ$_Y0L0_^:+4/_FBU#_YHM0_^:+4/_FBU#_YHM0_^:
M+4/_FBU#_YHM0_^:+;'" 0"CT@  E>L# 8S_$P. _QP&=/\C"FG_*@Y@_S(2
M6?\Z%5/_0A=._TD92_]1&DC_6!Q&_UT=1/]C'4/_9QY!_VP?0/]P'S__=" ^
M_W@@/?]\(#S_@2$[_X<A._^,(CO_C"([_XPB._^,(CO_C"([_XPB._^,(CO_
MC"([_XPB._^,(O]Z'0/_=B@&_W(S"_]\-P__A#\5_XA('?^+4R?_B6 Q_X9M
M._^">43_?H9,_WN14_]WFEC_=*)=_'&H8?INKF3X:[1G]VFZ:?5HP6OS9LAM
M[V/-;^QATW#G7]UQXEWE<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF<]U;YG/=
M6^9SW5OF<_]Z'0/_=B@&_W(S"_]\-P__A#\5_XA('?^+4R?_B6 Q_X9M._^"
M>43_?H9,_WN14_]WFEC_=*)=_'&H8?INKF3X:[1G]VFZ:?5HP6OS9LAM[V/-
M;^QATW#G7]UQXEWE<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF<]U;YG/=6^9S
MW5OF<_]Z'0/_=B@&_W(S"_]\-P__A#\5_XA('?^+4R?_B6 Q_X9M._^">43_
M?H9,_WN14_]WFEC_=*)=_'&H8?INKF3X:[1G]VFZ:?5HP6OS9LAM[V/-;^QA
MTW#G7]UQXEWE<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF
M<_]Z'0/_=B@&_W(S"_]\-P__A#\5_XA('?^+4R?_B6 Q_X9M._^">43_?H9,
M_WN14_]WFEC_=*)=_'&H8?INKF3X:[1G]VFZ:?5HP6OS9LAM[V/-;^QATW#G
M7]UQXEWE<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF<_]Z
M' /_=R<&_W0R"_]_-@__ACT5_XM''?^.42?_C%XQ_XEK//^%=T;_@8-._WV/
M5O]YF%S\=:!A^7*F9?=OK6GU;+-L\VJY;_)HP''P9LAS[&3-=>AAU';C7]YW
MVUWC>=5=Y7;57>5VU5WE=M5=Y7;57>5VU5WE=M5=Y7;57>5VU5WE=O][' /_
M=R<&_W<P"O^"-0[_BCP5_X]&'?^23R?_D5PR_XYH/?^*=$C_AH!2_X&+6OQ]
ME6'X>)UG]72D;?)QJG'P;K!T[FNV=^QIOGKJ9\=]YV7.?^)BUH#97]V!T%_@
M?LQ@XWO,8.-[S&#C>\Q@XWO,8.-[S&#C>\Q@XWO,8.-[S&#C>_]\' /_>"8&
M_WHO"O^%,P[_C3L4_Y)$'/^63B?_E5HR_Y)E/O^.<4K_BGU5_H6(7OF DF?T
M>YIN\':A<^URIWCJ;ZY]Z&RT@.9IO(/D9\:&X67/B-EBUXK/8=F(R&+=@L1C
MX'_$8^!_Q&/@?\1CX'_$8^!_Q&/@?\1CX'_$8^!_Q&/@?_]]&P/_>28&_WPN
M"O^(,@[_D#H4_Y5#'/^:3"?_F5@S_Y9C/_^2;DS_CGI7_(F%8O6$CVOP?I=S
M['F>>NATI8#E<*N%XFRSB>!JNXS>:,:/VF;1DLYBT9+'9-6,P67;AKUFW8*]
M9MV"O6;=@KUFW8*]9MV"O6;=@KUFW8*]9MV"O6;=@O]]&P/_>B8&_W\L"O^+
M,0W_DSH3_YA"'/^=2R;_G58S_YMA0/^7;$W[DG9:]XV!9O*(C'#L@I1YYWN;
M@>-UHHC?<:F.W&VQDMEKNY;7:<B9S&3+F\5ESI? 9]*1NFC8BK9IVX:V:=N&
MMFG;AK9IVX:V:=N&MFG;AK9IVX:V:=N&MFG;AO]^&P/_>R8&_X$K"?^-,0W_
ME3D3_YM"&_^@2B;_H50S_Y]?0?N<:4_VEW-=\9)^:NR,B'7GA9& XGZ8B=UX
MH)'8<J>7TFVOG<]LN9_,:\6@PV?'H+QHRYNW:M"4LFS5C:]LV8FO;-F)KVS9
MB:]LV8FO;-F)KVS9B:]LV8FO;-F)KVS9B?]^&@/_>R4&_X,J"?^/, S_F#@2
M_YY!&_^C22;_IE(S_:1=0?>A9U#QG'%?ZY=[;>6/@WK>AXN&U7Z2D<]XF9?*
M=*&<QW&JG\-OLZ'!;K^CNFO%H[-KR)^O;<V8JV_2D:EPUHRI<-:,J7#6C*EP
MUHRI<-:,J7#6C*EPUHRI<-:,J7#6C/]_&@/_?"4&_X8I"/^2+PS_FS@2_Z%
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M!/^L)P7]NB\&[\<V"N/4/A#8WT,?R]Y*-+[64DBPT%I:I,I@:9C&9G:-P6R
MA+YRB7N[>)!TN7^5;K>'FFFVD)UEM9N@8K2FH6"ULZ%?ML6@8;',FF*NSY5B
MKL^58J[/E6*NSY5BKL^58J[/E6*NSY5BKL^58J[/E?^'%P+_D1H#_Z(@ _^R
M)0/UP"L$YL\Q!MC>. _,Y4,@P^)),[;>44:IV%A7G-)>99#.9'*&RVI\?,AP
MA'3&=XINQ'Z/:,.'E&/"D)=?P9N97,&FFEO"LYM:P\6:6[[/E5RZTI%<NM*1
M7+K2D5RZTI%<NM*17+K2D5RZTI%<NM*17+K2D?^)%@+_EAD"_Z@= OZX(0+L
MR2("V=TE!,SE-Q'"ZD,BM^=(,ZSD3T2@X%93E-U=8(C:8VM^UFIU==1P?6[2
M=X-GT7^(8M"'BU[0D8Y:T)R06-"GD5;0M9)5TL>15LW4CE;(UHM6R-:+5LC6
MBU;(UHM6R-:+5LC6BU;(UHM6R-:+5LC6B_^+%0+_G1<!_Z\9 ?3!& '=V!$
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M&_]P'@/_;"D&_VDS"?]R-PW_>3X2_WU'&?^ 42'_?E\I_WQM,O]Y>SG_=HA
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M"/]I-@O_;CT/_W%&%?]S41S_<UXC_W!M*?]N?##_:XDU_VF6.?]GH3W_9JI
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M+C__O"\^_\TP/O_-,#[_S3 ^_\TP/O_-,#[_S3 ^_\TP/O_-,+NQ  "LO
MG\D  )/9  ")_ L!@/\7 G;_( 5L_R@)9/\P#5W_.!!7_T 34?]'%DW_3AA*
M_U891_]<&D3_8QQ"_VD=0/]P'C__>!X]_X ?._^((#K_D2$X_YLB-_^D(C;_
MK2,U_[@C-?^Y(S7_N2,U_[DC-?^Y(S7_N2,U_[DC-?^Y(ZVV  "?Q   DM(
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M_WL= _^'(P3_D"H&_Y<R"OV<.Q#TGT,9[*%+)>.<5C/:EF!!SXYI3L>(<EC
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MB(9SD(6.>(R"EGR(@*" A'^K@H%_N(-_?\J$@8'A?8&!YG:!@.MO@(#O:H"
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M4DCFZ%)(Y/A12.'\3TCA_$](X?Q/2.'\3TCA_$](X?Q/2.'\3^&9  #-J0
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M'"[_OQPN_[\<+O^_'"[_OQPN_[\<+O^_'*FU  ":P@  C,\  '_>  !V_P4
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MKS('TJP^%<>F2R2]H%4SM)I>/ZR594JED&U2GHQT69B(>V"3A8-ECH*+:HJ
MDVZ&?IUQ@GVG=']\M'9]?,5V?7[@<W]_[FM_?_-E?W[W7G]^^%U_?OA=?W[X
M77]^^%U_?OA=?W[X7?]E& +_=1,!_X04 ?^1%P'_G!L!\J4@ >:N)@+;M"X&
MSJ\]%,.J22.YI%,QKYY</J>99$F@E&M1F9!R69.->5^.BH!DB8>(:82%D6Z
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M9E*SZ6-4LO=?5:[Z6U:M^UI6K?M:5JW[6E:M^UI6K?M:5JW[6O]^"0#RD0(
MUJ$" ,JM!0# MP4 N,(% ++/"0"KU!< H],K!IG0.A*/SD4?A<M.*GW)5C1U
MQUT];L5E1&C$;$ECPG-.7L%[4UG!A%95P(]94K^;7$^_J%U-O[A>3,#-7DS
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M.$#L_SA [/\X0.S_.$#L_SA [/\X0.S_.,N@  "ZJP  K;0  *'   "6S $
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M9F*2YV)EE/A<9Y+]5V>1_U)GD?]29Y'_4F>1_U)GD?]29Y'_4O]N#@#_?PD
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M2TZY_TE.N?])3KG_24ZY_TE.N?])3KG_2>^%  #4E0  QZ,  +JL 0"PM
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M//@;_SW_&_\]_QO_/?\;_SW_&O\]_QG_/?\9_SW_&?\]_QG_/?\9_SW_&?]
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M7')\Z%AU?OE1=X#_3'> _T=W@/]&=X#_1G> _T9W@/]&=X#_1O]D#P#_<@D
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M3%^7_T=@EO]&8);_1F"6_T9@EO]&8);_1O]P P#K@0  UH\  ,J: 0#!HP,
MN:H" +&R 0"JMQ$ H[<D INU- J3LD 4BJ]*'H.M4R=\JUHN=JAA-7"G:#MK
MI6] 9Z-W1&*B?TA>H8E,6J"43U>?H%%4GZY34Y_ 4U*?W5)5G_-.5Z#_2EF@
M_T99G_]%69__15F?_T59G_]%69__1?]U  #@A@  SY,  ,2? 0"ZIP$ L:X
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M-T7!_S=%P?\W1<'_-]6+  #%F@  MZ0  *NL  "@M   EKX  (O'! "!T @
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M3X%JZ$R#;?E%A&__/X5P_SN&<?\XAG'_.(9Q_SB&<?\XAG'_./];#P#_9P@
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M0VZ!_S]O@?\\;X'_/&^!_SQO@?\\;X'_//]D" #_<@  X7\  -.) 0#*D@,
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M.E:;_SI6F_\Z5IO_.O%T  #9@P  R)   +Z:  "SH0  JJ<  *&N  "7M08
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M)<.3  "UG@  J*8  )VN  "1M@  A;\  'G'  !OS@0 9-8) %[>$0!;WB
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M"B/^L HB_L0+(?_@"R']\@H@_/P*(/S\"B#\_ H@_/P*(/S\"J*G  "5L0
MA[L  'G&  !LSP  7]D  %+?  !(Z   0_\( #__$  [_QD -_\A #3_*0$P
M_S !+?\W BK_/@(G_T0")?]+ R+_4P,@_UP#'?]F!!O_<@09_X %%_^/!1;_
MGP85_Z\&%/_ !A3_U@83_^D&$__I!A/_Z083_^D&$__I!I>O  "(N@  >L4
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M/I5:[#N57?LUEE[_,99?_RV68/\JEF#_*I9@_RJ68/\JEF#_*O]2#P#_7 H
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M.'IO_S1[</\P?'#_,'QP_S!\</\P?'#_,/];" #_9@  YW(  -I[  #/@@,
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M,F:!_S)F@?\R9H'_,O]D  #E<@  TWX  ,>'  "^CP  MI4  *Z9  "FFPP
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MK:,N1*VS+T.MR"]"K.<O0ZOY+42K_RM$JO\I1*K_*42J_RE$JO\I1*K_*=&
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M'#C)R1PXR.@<-\?Y'#?%_QPVQ/\<-L3_'#;$_QPVQ/\<-L3_'+Z1  "PFP
MI*,  )BJ  ",L@  @+D  '3   !HQP  7<T% %/3"@!/UQ( 3=@B $O8, !)
MV#P"1MA& T393P1!V5@&/]EA"#S9:PHZV78,-]F"#C7:D \TVJ 0,MJQ$3';
MQQ$QVN<1,-CV$C#6_Q,OU/\3+]3_$R_4_Q,OU/\3+]3_$[.:  "FH0  FJD
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M P[_U0,._^T##O_P P[_\ ,.__ ##O_P Y.N  "$N   =L(  &?,  !:U0
M3-P  #_A   UY@  +?0  "K_ @ F_PL (_\1 "#_%P =_QT &?\C !;_*0 4
M_R\ $O\U !#_/0 ._T4!#/]. 0K_6 $'_V4!!?]T 0/_A0$"_Y8! ?^F 0#_
MM0$ _\8! /_* 0#_R@$ _\H! /_* 8:W  !WP0  :,P  %K7  !+W@  /N0
M #+I   G[0  (_\  !__   ;_P4 %_\, !3_$  1_Q0 #_\8  W_'0 +_R(
M"/\H  7_+@ "_S4  /\]  #_1P  _U(  /]>  #_;0  _WX! /^. 0#_FP$
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M)[))\R6P2O\BKDO_'ZY,_QVM3/\;K4W_&JU-_QJM3?\:K4W_&O]'$0#_3PT
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M*XE>_RB)7_\EB5__(XE?_R.)7_\CB5__(_]1"0#_6@  ]60  .!L  #7<0,
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M*'%O_RAQ;_\H<6__*/]9  #K90  VW   ,UX  #$?@  O((! +:$ 0"NA0X
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M+$6<P2Q%G-\K19OT*4::_R='FO\E1YK_)$>:_R1'FO\D1YK_)-1W  #"A
MMH\  *N6  "AG   EJ   (NE  !_J@  =*X% &^O% !LKR0 :*\R F2N/05?
MK48)6ZQ/#5BL5A%4JUX44:IF%TZJ;AI+J7@=2*F#($6HCR)#J)TD0:BM)4"H
MP"4_J-\E/Z;T(T"E_R) I?\A0*3_($"D_R! I/\@0*3_(,I^  "[BP  KY4
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M"BK/_@LISO\,*<W_#2G-_PTIS?\-*<W_#:Z8  "BGP  EJ8  (FN  !\M@
M;[T  &/#  !7R   3,T  $+2 P YV0D -=\0 #3?&P RX"< ,>$R ##A/0 N
MXD< +>)0 2OB6@$JXV4"*.-Q B;D?P,EY(\#(^6A!"+EM 0AY<T$(.3L!"#B
M^P0?X?\%'^#_!1_@_P4?X/\%'^#_!:2>  "8I0  BZX  'VV  !PO@  8\8
M %;+  !+T   0-4  #;<   OY0< +>T0 "ON&  I[B( )^\K "7O-  C\#P
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M  #_U@  _]8  /_6 (*U  !SOP  9,D  %;3  !'VP  .N   "[E   CZ0
M&NT  !7]   2_P  $/\"  [_"0 +_PT "/\0  3_$P !_Q@  /\>  #_)
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M#=4S^ W2,_\-T#/_#,XS_PS--/\+S#3_"\PT_PO,-/\+S#3_"_\Y%@#_/A(
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M&YY+_QF=3/\7G4S_%IU,_Q:=3/\6G4S_%O]'"P#_30( _U0" /=:! #K70<
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M'7U>_QU]7O\=?5[_'?]0  #U60  X6,  -)J  #);@  PG ! +UP P"V<!
MKG$B *AP,@*A;C\&G&Q*"Y=J4Q"2:%L4CF9B&(ME:1N(8W >A6)X(8)A@"2
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M+%-\OBU2?-HM4WSR*55\_R56?/\B5WS_(%=\_R!7?/\@5WS_(.5D  #/<
MP7H  +:#  "MB0  HXP  )F.  "-CP  AI . (&1'0!]D"P!>(\X!'..0@AN
MC4L,:HQ3$&>*6A1CB6$78(AH&UV'<!Y:AGDA5H6#)%2%CR91A)PH3X2J*DV$
MO"I-A-<J38/Q)T^#_R10@_\B4(/_'U"#_Q]0@_\?4(/_']YI  #)=0  O(
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M&SN@_AH[G_\9/)__&#R?_Q@\G_\8/)__&,1\  "VB0  JI(  )^7  "5G
MB:$  'VF  !QJ@  9*X  %JQ" !7L10 5;(C %.R, %0LCL"3;)$ TNQ305(
ML54'1;%="4.Q90M L&\-/K!Z#SNPAQ$YKY83-Z^F%#:ON!0UL-$4-:[O%#2M
M_A0TK/\4-*O_%#2K_Q0TJ_\4-*O_%+N%  "OD   HY<  )B=  ",HP  @*@
M '2M  !HL@  7+8  %"Z 0!)O T 2+P9 $:])P!%O3, 0[T] 4&]1P$_O5 "
M/;U8 SJ]804XO6L&-KUW"#2]A DRO9,*,+VD"R^]MPPNOM ++KSN#"VZ_@TL
MN?\-++C_#BRX_PXLN/\.++C_#K./  "FEP  FYT  (^C  "#J@  =K   &JU
M  !>N@  4KX  $?" 0 ]QP8 .,D0 #?)&P VRB< -<HS #3+/0 SRT< ,<M1
M 3#+6P$NS&4"+,QQ BK,?P,IS) $)\RA!";-M 0ES<X$)<ON!"3)_ 8CR/\'
M(\?_!R/'_P<CQ_\'(\?_!ZF6  ">G0  DJ,  (6K  !XL@  :[@  %^^  !2
MP@  1\8  #W*   TSP0 *]0) ";9#P EV1D )=HE "3:,  CVSL (]M% "+<
M4  AW5L (-UH ![>=@ =WH<!'-^9 1K?K $9W\0!&-[G 1C<^ $8V_\"%]K_
M A?:_P(7VO\"%]K_ J"<  "4HP  AZL  'FS  !LN@  7\$  %+&  !&R@
M.\X  #'3   IV0  (=X% ![H#@ =Z!4 &^D> !GI)P 8ZC  %NHY !7K0P 4
M[$X $NQ: !'M9P 0[G< $.Z*  [OG@ .\+, #?#-  SO[  ,[?P #.O_  SK
M_P ,Z_\ #.O_ )>C  ")JP  >[0  &V\  !?Q   4LH  $7.   YTP  +]@
M "7=   =X0  &.P" !;W"P 4]Q$ $?@7 !#X'@ .^24 #?DM  OZ-0 )^S\
M!_M*  3\5P #_68  OYW  #]BP  _9\  /RU  #\T0  _.T  /S\  #\_0
M_/T  /S] (NK  !]M   ;KT  &#&  !2S0  1-(  #?8   LW0  (N$  !GE
M   3Z@  $/H   [_!@ -_PP "O\0  ?_%  $_QH  ?\@  #_)P  _S   /\Z
M  #_10  _U,  /]B  #_=0  _XH  /^?  #_LP  _\<  /_E  #_Y0  _^4
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M)@'_)20 _R4D /\C)P'_'2P!_Q@U ?\50@'_$E !_Q!= O\.:@+_#G8"_PZ
M O\.B@+_#I("_PZ: O\.H +_#J8!_PVM ?\-LP'_#;L!_PW% ?\-T0'_#>,!
M_PWO ?X-^@'Z#?\!^0[_ ?D._P'Y#O\!^ [_ ?@._P'X#O\!^ [_ ?\F(P#_
M*"  _R@@ /\F(@#_(B@!_R R ?\</P'_&4P!_Q=9 O\590+_$W$"_Q-\ O\3
MA@+_$XX"_Q*6 O\2G0+_$J,"_Q*I O\2L +_$K<"_Q+! O\2S ']$M\!^1/M
M ?43^ 'S$_\!\A/_ ?$3_P+P%/\"\!3_ O 4_P+P%/\"\!3_ O\J'P#_+!P
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M"KLS_PJZ,_\)NC/_";HS_PFZ,_\)NC/_"?\Y$ #_/0L _T ) /]$#0#_1A$
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M$HY,_Q*.3/\2CDS_$O]%  #_2P  Z5,  -Y8  #36P  S5L$ ,I8!P#"6!4
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M  #B7   SV4  ,-K  "Y;P  L7$  *IQ  "B;P@ FV\7 )9P)P"0;S4"BVY
M!89L20B":E(,?FE9#WMH8!)W9F84=69N%W)E=AIP9'X=;6.('VMCDR)I8J D
M9F*N)65BOR9D8MHF9&/R(F5D_QYF9/\;9V3_&6=E_QAG9?\89V7_&/!3  #=
M7P  RV@  +]O  "V<P  KG4  *9U  "=<P4 EG,4 )%T) "+<S("AG(^!(%P
M1PA];T\+>6U7#G9L7A%S:V04<&IL%VUJ<QIK:7P<:&B&'V9GD2)C9YXD86:L
M)6!FO29?9]8F7V?Q(F!H_QYA:/\<8FC_&F)H_QEB:/\98FC_&>Q7  #98@
MQVL  +QR  "S=P  JGD  *%Y  "7=P$ D'@1 (MX(0"&>"\!@7<[!'QU10=X
M=$T*=')5#G%Q7!%N<&,4:V]J%FAN<1EF;GH<8VV$'F!LCR%>;)PC7&NJ)5IK
MNR99;-,F6FSO(UML_Q]<;?\<76W_&EUM_QE=;?\976W_&>A:  #29@  PV\
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M'TI^_!Q+?O\:2W[_&4Q^_QA,?O\83'[_&-5G  ##<P  MGP  *R$  "BB0
MF(L  (V-  !\C0  =8X$ &^/$@!MD"$ :9 N 66/.0)BCD($7HY+!UN-4@I8
MC%D,5HMA#U.+:!)0BG$438E[%TJ)AQE(B)4;1HBC'42(M!U#B,H=0X?J'$2&
M^QI$AO\818;_%T6%_Q=%A?\7187_%\UM  "]>   L8(  *>*  "<C@  DI
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M#2^E_PTOI?\-+Z7_#;:$  "JC@  GI0  )29  "'G@  >Z,  &^H  !CK
M5Z\  $NR  !!M08 /K81 #VV'@ [MBD .K<T #FW/@ WMT< -K=0 32W6@$R
MMV0",+=O RZW? 0LMXL%*K><!2FWK@8HN,4%*+?F!2>U^0<FL_\')K+_"":R
M_P@FLO\()K+_"*^-  "BE   EYH  (N@  !^I@  <:L  &6P  !9M   3;<
M $*[   XO@$ +\() "W#$@ LPQX *\,I "K$,P IQ#T *,5' "?%40 FQ5P
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M ).A  "%J0  =[$  &FY  !;P   3L8  $'*   US@  *M(  "'6   9VP
M$M\   WC   +\0@ "?,.  ?S$P $\AH  O(B  #R*@  \C0  /(_  #R3
M\EP  /)M  #R@@  \I@  /.M  #SQ@  ].4  /3V  #T^P  ]/L  /3[ (>I
M  !YL@  :KH  %S"  !.R0  0,X  #/3   HV   'MT  !7A   /Y   "N@
M  7S   #_0$  /P(  #[#0  ^Q$  /L6  #\'@  _"8  /PP  #]/   _DD
M /Y:  #^;0  _X(  /^8  #_K   _\   /_8  #_Y   _^0  /_D 'NR  !L
MNP  7<0  $_-  ! T@  ,MD  ";>   ;X@  $N8   SJ   %[0   /0   #_
M    _P   /\   #_!   _PD  /\.  #_$@  _Q@  /\A  #_*P  _S<  /]&
M  #_6   _VL  /^   #_E0  _Z8  /^S  #_NP  _[L  /^[ /\;)@#_'"0
M_QHD /\5)P#_$"T _PHV /\%0P#_ 5 !_P!> ?\ :P'_ '8!_P"! /\ B@#_
M )( _P": /\ H #_ *8 _P"L /\ L@#_ +D _P#" /\ S0#_ -\ _P#L /\
M^ #_ /\ _0#_ /T _P#] /\ _0#_ /T _P#] /\ _0#_ /\?(P#_'R$ _QXA
M /\9(P#_$RD _PXR /\,0 #_"4T!_P=: ?\$9P'_ W,!_P-] ?\#AP'_ X\
M_P*6 /\"G #_ J( _P*H /\"KP#_ ;8 _P&^ /\!R0#_ =L _P#J /P ]@#X
M /\ ]P+_ /<#_P#V!/\ ]@3_ /8%_P#V!?\ ]@7_ /\B'P#_(AP _R$< /\>
M'P#_&"0 _Q4O /\2/ #_$$D _PY6 ?\,8@'_"VX!_PMY ?\+@@'_"XL!_PN2
M ?\*F0'_"I\ _PJE /\*JP#_"K( _PJ[ /T*Q@#["M0 ]PKG /,*] #P"O\
M[PO_ .X,_P#M#/\![0S_ >T,_P'M#/\![0S_ ?\E&P#_)A@ _R47 /\A& #_
M("$ _QXK /\:-P#_%T4 _Q11 ?\27@'_$6D!_Q%T ?\1?0'_$(8!_1". ?P0
ME0'Z$)L!^1"A ?<0J 'V$*\!]!"W /,0P@#Q$-  [1#E .@1\@#F$?X!Y!+_
M >,2_P'B$O\!XA+_ >$2_P'A$O\!X1+_ ?\I%@#_*A, _RD2 /\G$P#_*!P
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M!Z<S_P>G,_\'IS/_!_\W!P#_.@  _SX  /I! 0#Q008 \3\- .8\$@#;.A\
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M&VQ5O1QK5M4=:U;P&FM7_Q=K6/\4;%C_$FQ8_Q%L6/\1;%C_$?%+  #?5@
MS%X  ,!D  "W9P  KF@  *=F  "?8@8 F&,4 ))D) "-8S(!B6(] H1A1P2!
M8$\'?5]6"7I>70MW760-=5QK$'-<<Q)P6WL4;EN%%VQ:D!EJ6IP;:%FJ'&9:
MNAUE6M$=95KN&V5;_A=F6_\59ES_$V=<_Q)G7/\29US_$NU.  #:60  R&$
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M&U9G^QA79_\65VC_%%AG_Q-89_\36&?_$^%8  #+8P  O6L  +)R  "I=@
MH'@  )9W  "(<P  @7,+ 'QT%P!X="8 ='0R 7!S/0)M<T8$:G).!V=Q50ED
M<%P+87!C#E]O:A!<;G,26FY\%5=MB!=5;)094VRC&U%LLQQ0;,@<3VSG&U%L
M^AA1;/\54FS_%%)L_Q-2;/\34FS_$]Q<  #'9P  N6\  *]V  "E>P  G'P
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M$4" _Q! @/\00(#_$,9K  "W=@  K'\  **%  "7B0  C(L  (&-  !SC@
M98\  %V/"0!:D!0 6) A %:1+0!3D#@!49!! DZ020-,D% $2H]8!4>/8 =%
MCFD)0HYS"T"-?PT^C8T//(V<$#J-K!$YC<$1.(WA$#B+]A XBO\/.8G_#SF)
M_PXYB?\..8G_#K]R  "R?0  IX8  )R*  "1C@  AI$  'J3  !ME0  7Y<
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M!*J+  "=D0  DY<  (><  !ZH@  ;:<  &"K  !5KP  2;$  #ZT   SMP
M*KH# "2\#0 BO14 (;T@ "&]*@ @O3, '[X] !Z^1P =OE( '+]> !J_;  9
MOWP &+^. !? H0 6P+8 %,#3 !6^\0 5O/\!%;O_ 12Z_P(4NO\"%+K_ J&2
M  "6F   BIX  'VD  !OJ@  8J\  %:T  !*MP  /KH  #.]   JP   (<0
M !G'!0 3RPL $<P2 !',&P 0S"4 #\TO  [-.@ .S48 #<U2  W.8  ,SG
M"\Z#  K.EP )SJP ",[&  C.Z  (S?L "<O_  G+_P )R_\ "<O_ )B8  "-
MG@  ?Z4  '&L  !DLP  5[D  $J]   ^P   ,L,  "C&   ?R@  %\T  !'1
M   ,U@4 "-D,  ;9$@ %VAL !-HD  /;+@ !VSD  -Q%  #=4@  WF(  -YS
M  #>B   WYT  -^S  #?S@  X.X  -_Z  #?_P  W_\  -__ (^?  "!I@
M<ZX  &6U  !8O0  2L(  #W%   QR0  )LP  !W0   4U   #MD   G=   #
MX0   .,'  #C#0  Y!(  .49  #F(@  YRL  .DV  #K0P  [%(  .QB  #M
M=@  [HP  .ZA  #OMP  []$  ._K  #P]@  \/8  /#V (2G  !UKP  9[<
M %F_  !+Q@  /,H  "_.   DT@  &M@  !+<   ,X   !>,   #G    ZP
M .L   #M!0  [@L  / 0  #Q%0  \QX  /0G  #W,P  ^4   /I1  #[8P
M_'<  /V-  #]HP  _K8  /[)  #_WP  _]\  /_? '>P  !HN0  6L$  $S*
M   \SP  +M0  "+:   7W@  $.(   GF    Z0   .P   #P    ]@   /8
M  #W    ^    /H'  #[#0  _1$  /\9  #_(P  _R\  /\^  #_3P  _V(
M /]W  #_C0  _Y\  /^N  #_N@  _[H  /^Z /\6(P#_%2$ _Q(A /\.) #_
M!BH _P S /\ 00#_ $X _P!< /\ : #_ '0 _P!^ /\ AP#_ (\ _P"6 /\
MG #_ *( _P"H /\ K@#_ +4 _P"] /\ QP#_ -8 _P#G /X \P#^ /X _0#_
M /P _P#[ /\ ^P#_ /L _P#[ /\ ^P#_ /\:( #_&1X _Q8> /\0( #_"B4
M_P0P /\ /0#_ $L _P!8 /\ 9 #_ '  _P!Z /\ @P#_ (L _P"2 /\ F #_
M )X _P"D /\ J@#_ +$ _0"Y /L PP#Z -  ^ #C /< \0#V /P ] #_ /0
M_P#S /\ \P#_ /, _P#S /\ \P#_ /\=' #_'!D _QD9 /\4&P#_#O_B_^))
M0T-?4%)/1DE,10 ("2$ _PPL /\).0#_!48 _P)3 /\ 7P#_ &L _P!U /\
M?@#_ (8 _P". /\ E #^ )L _ "A /H IP#X *X ]0"U /, OP#Q ,L \ #?
M .X [@#L /D ZP#_ .H _P#J ?\ Z0'_ .D!_P#I ?\ Z0'_ /\@%P#_'Q0
M_QP3 /\7%0#_%AT _Q,H /\0- #_#4$ _PQ. /\)6@#_"&8 _PAP /X'>0#\
M!X$ ^@>) /@'D #V!I8 \P:= /$&HP#O!JH [0:R .H&NP#H!L@ Y@;< .0&
M[ #B"/H X K_ -X+_P#="_\ W0S_ -P,_P#<#/\ W S_ /\C$@#_(Q  _R$.
M /\>$ #_'A@ _QPC /\8+P#_%#L _Q)) /P050#X#V  ] ]J /$/= #O#GP
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M [$D_P.O)/\#KR3_ ZXD_P.N)/\#KB3_ _\O!@#_+P  _S(  /\S @#Y,@@
M]R\. .LK%@#A)R( V"<R - I00#+*DX QBI9 ,,J8@' *FL!O2IS ;LJ>@*Y
M*H("N"J) K8JD *T*I@#LRJA [$JJ@.O*[4$KBO$!*PKVP2H+.\$IBS^!:0L
M_P2C+?\$HBW_!*(L_P2B+/\$HBS_!/\R  #_,P  ^3@  .DY  #B.0  WC4'
M -XN#0#1+QL R3$L ,,S.P"],T@ N313 ;8S7 &S,V4"L#-M JXS= .L,GL#
MJS*#!*DRB@2G,I,%I3*;!J0RI0:B,K 'H#*^!Y\RT0><,^H'FC/[!Y@T_P>7
M-/\&EC3_!I8T_P66-/\%EC3_!?\U  #_.   ZCX  -]"  #50@  SS\# ,TX
M" #%.!4 O3HF +<[-@"R/$, KCQ. :H[5P*G.V #I3IG Z,Z;P2A.G8%GSE]
M!ITYA0>;.8T'F3B6")@XH F6.*L*E#BX"I,YR@N1.>4+CSKW"HTZ_PF,._\(
MC#O_!XP[_P>,._\'C#O_!_\X  #Q/@  XT4  -1)  #+2@  Q4<  ,%!! "Z
M/Q$ LT$A *U",0"H0SX I$-) :!"4P*=05L#FT%B!)A :@660'$&E#]X!Y(_
M?PB0/X@*CSZ1"XT^FPR+/J8-B3ZS#8@^Q Z&/^ .A#_T#8- _PN#0/\*@D#_
M"8)!_PB"0?\(@D'_"/\\  #K0P  W$H  ,Q/  ##4   O$X  +=) 0"Q1@X
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M#.I)  #54P  Q5H  +I?  "P8@  J&(  )]?  "66@  CUH0 (I;'@"%6RP
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M%%==L!567L0655[C%59>]Q)67O\05U[_#E=>_PU77O\-5U[_#=Y3  #(70
MNV0  +!J  "F;0  G6X  )-M  "%9P  ?F<) 'AG%0!T9R, <6@O &YG.0%K
M9T(":&9* V5F4@5C95@&8&5?"%YD9PI<9&\,6F-Y#EACA!!58I$24V*?$U)B
MKA518L(54&+A%5%B]A)18O\04F+_#E)B_PU28O\-4F+_#=E6  #$8   MV@
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M$$!T\P] =/\.07/_#4%S_PQ!<_\,07/_#,9D  "W;@  JW8  *)\  "7?P
MC($  (&!  !R@   97\  %U_" !9?Q, 5X @ %6 *P!3@38 48 ^ 4^ 1@)-
M@$X"2W]5 TE_705&?V8&1'YP"$)^>PD_?H@+/7V7##Q]IPTZ?;H..G[6#3I\
M\0TZ>_\,.GO_"SIZ_PLZ>O\+.GK_"\!I  "R=   IWP  )V!  "2A   AX8
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M!"*9_P0BF?\$(IG_!*R!  "@B   E8X  (N2  !_E@  <IH  &6=  !9H
M3J,  $*D   WI@  +J@% "FI#P HJ1@ )ZHB ":J+  EJC4 )*H_ ".J2  B
MJU, (:M> ""K:@ >JWD ':N+ !NKG0 :J[$ &:O* !FJ[ $9J/T!&*?_ ABF
M_P(8IO\"&*;_ J6)  "9CP  CY0  (.9  !UG@  :*(  %RF  !0J0  1*P
M #FN   OL   )K,  !ZU!@ 9MP\ &+<7 !>W(0 6MRH %;<T !2X/@ 3N$D
M$KA4 !*Y8@ 1N7$ $+F#  ^YEP .N:P #;G$  VXYP .MOL #K7_  ZT_P .
MM/\ #K3_ )R0  "2E0  AIL  'F@  !KI@  7JL  %*O  !&L@  .K4  "^W
M   EN@  ';T  !7    0PP8 "\8.  K%%0 )Q1X ",4H  ?%,@ &QCT !<9)
M  7&5P #QF8  L9W  '&BP  QJ   ,6V  #&T@  Q>\  ,7\  #%_P  Q?\
M ,7_ )66  ")G   >Z,  &VI  !@KP  4[0  $:X   ZNP  +KX  "3!   ;
MQ   $\<   [*   (S@$  = *  #0$   T!8  -$>  #2)P  TS$  -0\  #5
M20  UE@  -9I  #6?   UI(  -:G  #6OP  UN   -;S  #6_@  UO\  -;_
M (R=  !^I   ;ZL  &&R  !4N0  1KT  #G!   MQ   (L<  !G+   1S@
M#-(   75    VP   -P#  #="@  W@\  -\4  #A'   XB0  .0N  #F.@
MYTD  .A9  #H:P  Z8$  .F8  #IK0  Z<4  .GB  #I\@  Z?4  .GU ("E
M  !QK0  8[4  %6\  !'P@  .<8  "S*   @S@  %M(   _6   (VP   -\
M  #C    Y0   .<   #H 0  Z@<  .L-  #M$0  [Q@  /$A  #S*P  ]C@
M /=(  #X6@  ^6T  /J$  #ZFP  ^J\  /K"  #ZV@  ^M\  /K? '2N  !E
MM@  5KX  $C&   YRP  *]   !_4   4V@  #=\   7C    Y@   .D   #M
M    [P   /$   #S    ]0   /8"  #X"0  ^@X  /T3  #_'   _R@  /\V
M  #_1P  _UH  /]N  #_A0  _YH  /^K  #_N0  _[P  /^\ /\1( #_$!X
M_PP> /\$(0#_ "< _P P /\ /@#_ $P _P!9 /\ 90#_ '  _P!Z /\ @P#_
M (L _P"2 /\ F #_ )X _P"D /\ J@#_ +  _P"X /\ P@#_ ,X _P#B /X
M\ #] /L ^P#_ /L _P#[ /\ ^@#_ /H _P#Z /\ ^@#_ /\4' #_$AH _PX:
M /\(' #_ "$ _P M /\ .@#_ $@ _P!5 /\ 80#_ &P _P!V /\ ?P#_ (<
M_P". /\ E #_ )H _@"@ /T I@#\ *P ^P"T /D O0#X ,D ]P#< /4 [ #S
M /@ \P#_ /( _P#Q /\ \ #_ /  _P#P /\ \ #_ /\7& #_%18 _Q$5 /\,
M%P#_!1T _P H /\ -@#_ $, _P!0 /\ 7 #_ &< _P!Q /\ >@#\ (( ^@")
M /@ D #W )8 ]0"< /0 H@#S *@ \0"P /  N #N ,, [ #3 .H YP#I /4
MYP#_ .8 _P#E /\ Y0#_ .4 _P#E /\ Y0#_ /\:$P#_&!$ _Q00 /\/$0#_
M#1D _PHD /\%, #_ 3X _P!+ /\ 5P#^ &( ^@!L /4 =0#R 'T \ "$ .X
MBP#L )$ ZP"7 .D G@#G *0 Y@"L .0 M #B +\ X #- -X XP#< /( V@#]
M -@ _P#6 /\ U0'_ -4!_P#5 O\ U0+_ /\>$ #_' T _Q<+ /\5#@#_%!4
M_Q$? /\.*@#_"S@ _0A% /@&40#T!%P [@1F .H$;P#F W< Y 1_ .($A@#@
M!(P W@23 -T%F@#;!:  V 6H -4%L0#2!;L T ;) ,X'X #,"/$ R0K_ ,<+
M_P#&#/\ Q0S_ ,4,_P#%#/\ Q0S_ /\A# #_( 8 _QP# /\="@#_&Q  _Q@8
M /\4(P#V$3  [PX^ .H.2@#E#58 X0U@ -T-:0#9#7$ U0UY -,-@0#1#8@
MSPV/ ,T.E@#+#IT R@ZE ,@.K@#&#[D Q!#( ,(0WP"^$?( NQ+_ +D3_P"W
M$_\!MA/_ ;83_P&V$_\!MA/_ ?\E!@#_(P  _R,  /\D P#_(0H _1T1 /$:
M&P#H%B< X10U -H30P#3%$\ SA59 ,L58P#(%FL Q19S ,,7>P#!%X( P!B)
M +X8D "\&)@ NQF@ +D9J0"W&;0 M1K" +0:U@"P&^T!K1S\ :L=_P&I'?\!
MJ1W_ :@=_P&H'?\!J!W_ ?\H  #_)P  _BH  .\J  #G)P$ YR() .0=$ #9
M&QT SQTM ,D>/ #$($D OR!3 +PA70"Y(64 MR)M +4B= "S(GP L2*# ; B
MB@&N(I(!K".; :LCI &I(Z\!IR.\ :8DS@&C).@"H"7Y IXE_P*=)?\"G"7_
M ILE_P*;)?\"FR7_ O\L  #_+0  [3(  .(T  #:,P  TRX# -(E"@#))1<
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M!O$[  #?10  S$P  +]/  "V4   KD\  *=*  "@1 < FD44 )5&(@"01C
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M#6),KPYA3<(.8$WA#F!-]@Q@3O\*8$[_"6!._PA@3O\(8$[_".-'  #-4
MOE<  +-;  "J70  H5T  )A:  "-4P  AE(, (!3& !\4R4 >50Q '54/ !S
M4T0!<%-, FU24P)K4ED#:5)@!&=1: 9E47 '8U%Y"&%1A I@4)$,7E">#5Q0
MK0Y;4< .6E'>#UI1]0Q:4O\*6U+_"5M1_PA;4?\(6U'_"-]*  #)4P  NUH
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M#DM>\0Q,7O\+3%W_"DQ=_PE,7?\(3%W_",]4  "^7@  L64  *=J  "=;0
ME&T  (EL  !X90  ;V0  &ED#@!E9!D 8F0E &!E, !>93H 7&5" 5IE2@)8
M9%$"5F18 U1D7P129&<%4&-Q!TYC>PE,8X@*2F.7"TACI@Q'8[@-1F/1#49C
M[PQ&8O\*1V+_"4=B_PE'8O\(1V+_",I8  "Z8@  KFD  *-N  ":<0  D'(
M (1Q  !T:P  :6D  &-I"P!?:14 7&HA %IJ+0!8:S8 5FL_ 55K1P%3:DX"
M46I5 T]J701-:F4%2FEN!DAI>0=&:88)1&F5"D-HI0M!:;<,0&G/#$!H[@M!
M:/\*06?_"4%G_PA"9_\(0F?_",5=  "V9@  JFT  *!S  "6=@  BW<  (!V
M  !P<@  97$  %QP!P!8<!$ 5G = %1Q* !2<3, 4'$\ $]R1 %-<4L!2W%3
M DEQ6@-'<6($17!L!4-P=P9!<(0'/W"3"#UOHPD[<+4*.W#-"CIO[ D[;OX(
M.V[_"#MM_P<[;?\'.VW_![]B  "Q:P  IG,  )UY  "2>P  AWP  'M\  !M
M>@  8'@  %9W 0!0=PX 3G@8 $QX) !+>2X 27DW $AY0 !&>4@!1'E/ 4)Y
M5P)!>6 "/WAI SQX= 0Z>((%.'B1!C=XH0<U>+,'-'C+!S1WZP<T=OT'-'7_
M!S5U_P8U=/\&-73_!KEH  "M<0  HGD  )A^  "-@   @H$  ':"  !I@0
M6X$  %&!  !(@ H 18$3 $.!'@!"@BD 08(R $"".P ^@D, /8)+ #N"4P$Y
M@EP!-X)F C6"<0,S@G\#,8&.!#"!GP0N@;$%+8'(!2V!Z00M?_P%+7[_!2U]
M_P4M??\%+7W_!;-N  "H>   G7\  )*#  "(A@  ?8<  '"(  !CB0  58H
M $N*  !!B@( .XL. #F+%P XC"( -XPL #:,-0 TC#T ,XQ& #*-3P QC5@
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M :"&  "5C   C)$  '^5  !QF@  9)X  %BA  !,I   0*8  #6G   JJ0
M(JP  !FN   2L D $+$0 !"Q&  .L2( #K$K  VQ-0 -L4  #+%+  NQ6  *
ML6< "+%X  >QBP %L:  !+"U  2PT  $L.\ !:_^  :N_P &KO\ !J[_ )B.
M  "/DP  @I@  '6=  !GH@  6J<  $ZK  !!K0  -:\  "NQ   AM   &+8
M !&Y   -O , ![X,  .]$@ !O1D  +XB  "^*P  OC8  +Y!  "_3@  OUP
M +]M  "_@   OI4  +ZJ  "^P@  O>0  +WV  "]_P  O?\  +W_ )*4  "%
MF@  >*   &JF  !<JP  3[   $*S   UM@  *K@  ""[   7O@  $,$   O$
M   $QP   ,D'  #)#0  R1(  ,H9  #+(@  RRL  ,TU  #.00  SE   ,]@
M  #/<@  SX<  ,^=  #/LP  S\X  ,_K  #.^   SOX  ,[^ (B;  !ZH@
M;*@  %ZO  !0M0  0KD  #6\   IOP  'L(  !7&   .R0  ",P   #0
MTP   -4   #6!@  V P  -D1  #;%@  W!\  -XH  #@-   XD$  .)1  #C
M8P  XW<  .2.  #DI   Y+H  .74  #EZ@  Y?,  .7S 'RC  !NJ@  8+(
M %&Y  !#O@  -<(  "C&   <R0  $\T   S1   $U0   -H   #>    X0
M .(   #D    Y0,  .<)  #I#@  ZQ(  .T:  #O)   \C$  /1!  #T4P
M]68  /5\  #VDP  ]JD  />\  #WS@  ]]\  /?? '"L  !AM   4[L  $7#
M   VQP  )\P  !O0   1U0  "ML   #?    X@   .4   #I    [    .T
M  #P    \0   /,   #U!   ]PH  /H0  #\%@  _R$  /\N  #_0   _U,
M /]H  #_@   _Y8  /^H  #_M@  _[\  /^_ /\-' #_"AL _P(; /\ '@#_
M "0 _P N /\ / #_ $H _P!6 /\ 8P#_ &T _P!W /\ ?P#_ (< _P". /\
ME #_ )H _P"@ /\ I@#_ *P _P"T /\ O0#_ ,D _@#= /T [0#\ /H ^P#_
M /H _P#Y /\ ^@#_ /H _P#Z /\ ^@#_ /\0&0#_#1< _P86 /\ & #_ !X
M_P J /\ -P#_ $4 _P!2 /\ 7@#_ &D _P!R /\ >P#_ (( _P") /\ D #^
M )8 _0"< /P H0#[ *@ ^0"O /@ N #V ,, ] #2 /, YP#R /8 \ #_ .\
M_P#P /\ [P#_ .\ _P#N /\ [@#_ /\2% #_#Q( _PL2 /\ $@#_ !H _P E
M /\ ,P#_ $  _P!- /\ 60#_ &0 _0!M /L =@#Y 'T ]P"$ /4 BP#T )$
M\P"7 /$ G0#P *, [@"J .P LP#J +T Z #+ .< X0#E /$ XP#] ., _P#B
M /\ X0#_ .$ _P#@ /\ X #_ /\4$ #_$0X _PT- /\'#P#_ A4 _P @ /\
M+0#_ #H _P!' /D 4P#U %X \@!H /  < #M '@ ZP!_ .D A0#H (P Y@"2
M .4 F #C )\ X0"F -\ K@#< +@ V@#% -8 V0#4 .P T@#Y -$ _P#/ /\
MS@#_ ,X _P#. /\ S@#_ /\7# #_% @ _P\% /\."P#_#!$ _P<: /\!)@#\
M #0 ] !! .T 30#I %@ Y@!B ., :@#@ '( W@!Y -L @ #9 (8 U@"- -,
MDP#1 )H SP"A ,T J@#+ +, R0"_ ,8 T #% .@ PP#V ,$ _P#  O\ OP/_
M +\#_P"_ _\ OP/_ /\;!@#_%P  _Q0  /\3!0#_$0T _PX4 /D*'P#P!BP
MY@,Y . #1@#< U$ U@1; -($9 #/!6P S 5S ,H%>@#(!8$ Q@6' ,4&C@##
M!I8 P0:= +\&I@"]!K  NP>\ +D(S0"X"N4 M0OW +,-_P"Q#?\ L W_ + .
M_P"O#O\ KP[_ /\>  #_&P  _QL  /H:  #U%@4 ]A$- .L.%0#B"R( V LQ
M - ,/@#+#4H QPU5 ,0.7@#!#F8 OPYM +T.= "[#WL N0^" +<0B@"V$)$
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M ?HI  #L,   W38  ,TX  #$-P  OC(  +HK @"U)0X KB<= *@I*P"D*C@
MH"I# )TK3 ":*U4 F"M< )8K8P"4*VH!DBMQ 9 L> &/+($!C2R* 8LLE **
M+)\"B"RK H8LN@*%+<X#@R[J X$N_ . +O\"?R[_ G\N_P)^+O\"?B[_ O0N
M  #D-P  TCT  ,4_  "[/P  M#P  *\U  "I+PL HR\7 )XQ)@"9,C, EC(^
M )(S2 "0,U  C3-8 (LS7@&),V4!AS-L 88S<P&$,WP"@C.% H SCP-_,YH#
M?3.G WPSM01Z,\D$>33F!'<U^01V-?\#=37_ W4U_P-U-?\#=37_ _ S  #=
M/0  RD,  +Y%  "U1@  K4,  *8]  "@-@8 F383 )0X(0"0.2X C#DY (DY
M0P"'.4P A#E3 8(Y6@& .6$!?CEH GPY;P)Z.7<">3F  W<YBP1U.98$=#FC
M!7(YL05Q.<0&;SKB!FXZ]P5N._\$;3O_!&T[_P-M.O\#;3K_ ^HY  #50@
MQ$@  +E+  "O2P  ITD  )]$  "8/@$ D3P0 (P]'0"(/BH A#\U ($_/P!^
M/T@ ?#]/ 7H_5@%X/UT!=CYD G0^:P)R/G,#<#Y\ V\^AP1M/I,%:SZ@!FH^
MK@9I/\ '9S_>!V<_]09F0/\%9D#_!&9 _P1F/_\$9C__!.4]  #/1@  OTP
M +1/  "J4   HD\  )E*  "11   BD$- (1"&0" 0R8 ?40R 'I$/ !W1$0
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M"51,[PA43?\&54S_!E5,_P553/\%54S_!=5(  #"40  M5<  *I;  "@7
MEUP  (U9  "!4P  =T\$ '%/$ !N4!P :E H &A0,@!E4#L 8U!# &%02@%?
M4%$!75!8 EQ07P):4&<#6%!Q!%=0>P554(@&4U"6!U)0I0A04+<)4%#."4]0
M[0A04/\'4%#_!E!0_P504/\%4%#_!=!+  "_5   LEH  *=>  "=8   E&
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M!4%=_P5!7/\%05S_!<-6  "T7P  J&8  )YJ  "5;0  BFT  ']L  !O9P
M9&0  %MB!0!68A  5&(; %)C)0!08R\ 3F0X $UD0 !+9$@ 2F1/ 4AD5P%&
M9%\"161H D-D<P-!8W\$/V..!3UCG@8\8[ &.V3&!CMDY@8[8_H%.V+_!3MB
M_P4\8?\$/&'_!+Y;  "P8P  I6H  )MO  "1<@  AG(  'MQ  !L;0  8&L
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M JYL  "C=@  F7P  (Y_  "$@@  >(,  &R$  !?A   480  $>$   \A
M,X0) #"$$0 OA!H +80D "R%+0 KA34 *H4^ "F%1P HAE  )X9: ":&9@ D
MAG, (X:# "&&E0 @AJ<!'H:\ 1Z&W@ >A/4!'H+_ 1Z"_P$>@?\!'H'_ :AT
M  ">?0  DX(  (F%  !^B   <8H  &6+  !8C   3(T  $".   VC@  +(\
M "60#  CD!, (I < "&0)0 @D2X 'Y$V !Z10  =D4D ')%4 !J18  9D6X
M&)%^ !:2D  5DJ0 %)&Y !.1V  3C_0 %([_ !2-_P 4C/\!%(S_ :-]  "8
M@P  CH@  (2,  !WCP  :9$  %V3  !0E0  19<  #F8   NF0  )9H  !V;
M @ 6G0P %9T3 !2=&P 3G20 $ITM !&>-P 1GD$ $)Y,  ^>6  .GF< #9YW
M  R>B@ +G9X "IVR  F=S  )G.P "IO^  N:_P +F?\ "YG_ )R$  "1B@
MB(X  'N2  !ME@  8)D  %2<  !(GP  /*   #"A   FHP  ':4  !6G   0
MJ04 "ZL-  BJ$P 'JAL !JHD  6J+@ $JC@  JI$  &J4   JEX  *IN  "J
M@0  JI4  *FJ  "IP0  J.0  *CV  "G_P  I_\  *?_ )6+  ",D   ?Y4
M '&:  !CG@  5J(  $JF   ]J   ,:H  ":K   =K0  %+    ZR   )M0$
M K8*  "V#P  MA4  +<=  "W)0  MR\  +@Y  "X1@  N%0  +AD  "X=@
MN(L  +>@  "WM@  M],  +;O  "V_   MO\  +;_ (^2  ""EP  =)T  &:B
M  !8IP  2ZP  #ZO   QL0  )K,  !RV   3N   #;L   :^    P0   ,($
M  #""P  PQ   ,05  #$'   Q20  ,8N  #(.@  R4<  ,E7  #):0  R7T
M ,F4  #(J@  R,,  ,CD  #(]   R/T  ,C] (69  !WGP  :*8  %JK  !-
ML0  /[4  #&X   EN@  &KT  !'    +PP   \<   #*    S0   ,X   #/
M P  T D  -$.  #3$@  U1D  -<B  #:+0  W3D  -Y)  #>6@  WVX  -^%
M  #?G   W[(  -[+  #>Y@  W_0  -_T 'FA  !KJ   7*\  $ZU  ! NP
M,;X  "3!   9Q0  $,@   G,    SP   -,   #9    W    -T   #?
MX0   .(%  #D"P  YA   .@6  #J(   [2L  / Z  #Q2P  \5X  /)S  #S
MBP  \Z(  /.V  #SR0  \^$  //A &VJ  !>L0  4+D  $&_   RQ   ),@
M !?,   .T   !M4   #:    W@   .(   #F    Z0   .H   #L    [@
M /    #R    ] 8  /8,  #Y$@  _!P  /\I  #_.@  _TT  /]B  #_>
M_Y   /^C  #_LP  _\$  /_! /\'&0#_ 1< _P 7 /\ &@#_ "$ _P K /\
M.0#_ $< _P!4 /\ 7P#_ &H _P!S /\ >P#_ (, _P"* /\ D #_ )8 _P";
M /\ H0#_ *@ _P"O /\ N #_ ,0 _@#5 /P Z@#[ /@ ^@#_ /D _P#X /\
M^ #_ /8 _P#S /\ \0#_ /\+%0#_!1, _P 3 /\ % #_ !H _P G /\ - #_
M $( _P!/ /\ 6P#_ &4 _P!N /\ =@#_ 'X _P"% /X BP#] )$ ^P"7 /H
MG0#X *, ]P"K /8 LP#T +X \P#, /$ XP#O /, [@#_ .T _P#L /\ ZP#_
M .P _P#L /\ ZP#_ /\-$0#_"1  _P / /\ $ #_ !8 _P B /\ +P#_ #T
M_P!* /\ 50#] &  ^@!I /@ <0#V 'D ] !_ /, A@#Q (P [P"2 .X F #L
M )\ ZP"F .D K@#G +@ Y0#% ., V@#A .T WP#[ -X _P#= /\ W0#_ -T
M_P#= /\ W0#_ /\/#0#_# L _P,) /\ # #_ !( _P = /\ *0#[ #< ^ !$
M /4 4 #R %H [@!C .P :P#I ', YP!Z .4 @ #C (8 X0", -\ DP#= )D
MVP"A -D J0#5 +( T@"^ -  S@#. .8 S #V ,H _P#* /\ R0#_ ,@ _P#(
M /\ R #_ /\1" #_#0( _P<  /\%" #_  X _P 6 /< (@#O #  ZP ] .@
M20#D %0 X != -T 90#9 &T U0!S -( >@#0 (  S@"' ,P C0#* )0 R ";
M ,8 I #$ *T P@"X ,  QP"] -\ O #Q +L _@"Y /\ N #_ +@ _P"X /\
MN #_ /\4  #_#P  _PT  /\,  #_!PD ^ $0 .@ &@#C "@ W0 V -@ 0@#2
M $T S@!7 ,H 7P#' &8 Q0!M ,, = #! 'H OP"! +T B "[ (\ N0"7 +<
MGP"U *@ LP"S +$ P@"O -@ K@+M *P#^P"K!?\ J@;_ *D&_P"I!O\ J0;_
M /\6  #_$@  ]Q(  .P1  #F#@  Y08( -T#$@#4 R  S00M ,@$.@##!48
MOP50 +P&6 "Y!F  MP=G +4';@"S!W4 L0A[ *\(@@"N"8H K F2 *H)FP"H
M"J4 I@JP *4+OP"C#-0 H0WM )\._@"=#O\ G __ )L/_P";#_\ FP__ /\:
M  #W&0  ZAX  -\>  #5&@  T!," ,X,"P#'"Q8 P TE +H.,@"V#C\ L@])
M *\04@"L$%H JA!A *@1: "F$6\ I!%V *(1?0"A$84 GQ*. )T2EP"<$J(
MFA.M )@3O "7%-  E!7L )(6_0"0%_\ CQ?_ (X7_P".%_\ CA?_ /H=  #N
M(P  WR@  - J  #')P  P2$  +T9!0"Y$A  LA4> *T6+ "H%S@ I!A# *$9
M3 "?&50 G!I< )H:8@"9&FD EQMP )4;=P"4&W\ DAR( ) <D@"/')T C1VI
M (L=MP"*'LH B!_G (8@^@"$(/\!@R#_ 8,@_P&"(/\!@B#_ ?4D  #E+
MTS$  ,8S  "\,0  MBT  + E  "L'0P IAX8 *$@)@"<(3( F2(] )4B1P"3
M(T\ D2-6 (\C70"-)&0 BR1K (DD<@"()'H AB2# (0EC0"#)9@!@26D 8 F
ML@%^)L4!?2?B 7LG]P%Y*/\!>"C_ 7@H_P%X*/\!>"C_ >\K  #=,P  RCD
M +X[  "T.@  K38  *8O  "A* < FR<3 )8H( "1*2T CBHX (LK0@"(*TH
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M V Z[@-@.O\#7SK_ E\Z_P)?.O\"7SK_ MT[  #'0P  N4D  *Y+  "D3
MFTH  ))%  ")/P  @3H) 'LZ% !W.R  =#PK '(\-0!O/3X ;3U& &L]30!I
M/5, :#U: &8]80%D/6D!8SUR 6$]?0)@/8D"7CV6 UT^I0-;/K8$6C[,!%H_
M[ 19/_X#63__ UD__P)9/_\"63[_ M8_  ##1P  M4P  *I0  "@4   ET\
M (Y+  "$10  >D & '4_$0!Q0!P ;4 H &M!,@!I03L 9T%" &5!20!C05
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M TI+_P-*2_\#2DO_ \A)  "X40  K%<  *%;  "87   CEP  (-9  !V4P
M:TX  &1-"@!?3!, 7$T> %I-* !833$ 5DTZ %1-00!33D@ 4DY/ %!.5P%/
M3E\!34YH 4Q.<P)*3W\"24^- T=/G01&3ZX$14_#!$10Y 1$3_D$14__ T5/
M_P-%3O\#14[_ \1,  "U50  J5L  )]>  "58   BV   (!>  !R5P  9U,
M %Y1!P!941$ 5U$; %11)0!24B\ 45(W $]2/P!.4D8 35-- $Q350!*4UT!
M25-F 4=3< )%4WT"1%.+ T)3FP-!5*P$0%3!!#]4X@0_5/@#0%/_ T!3_P-
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M KA9  "J80  H&<  )9L  ",;@  @6X  '9L  !G:0  7&8  %%D  !(8@D
M1&(1 $)B&P!!8R0 /V,M #YC-0 ]9#T /&1% #MD30 Y9%4 .&1? #9D:0$U
M9'8!,V2% 3%EE0(P9:<"+V6[ BYEV@(N9/0"+F/_ B]C_P(O8O\"+V+_ K->
M  "G9@  G&T  )-Q  "(<P  ?7,  ')R  !D<   6&X  $UL  !":@, /&D.
M #IJ%@ Y:B  .&HH #9K,0 U:SD -&M! #-L20 R;%( ,6Q< "]L9@ N;',
M+&R" 2ILDP$I;*4!*&RY 2=MU@$G:_(!)VK_ 2=J_P$H:?\"*&G_ JYD  "C
M;   F7,  (YV  "$>   >7D  &UX  !@=P  4W8  $AU   ^<P  -'(* #%S
M$0 P<QH +W,C "YS*P M=#0 +'0\ "MT1  I=$T *'57 "=U8P E=6\ )'5_
M ")UD  A=:( ('6W !]UT@ ?=/$ 'W/_ 1]R_P$@<?\!(''_ :EK  "><P
ME'D  (I\  " ?@  ='\  &=_  !:?P  37X  $-^   X?0  +WT" "A]#0 F
M?10 )'T< "-^)0 B?BT (7XV "%^/P ??T@ 'G]2 !U_7@ <?VL &G]Z !E_
MC  7?Y\ %G^S !5_S@ 5?N\ %GS_ !9[_P 6>_\ %WO_ *1R  ":>@  CW\
M (6"  ![A   ;88  &"'  !4AP  2(@  #R(   RB   *(@  ""(!0 :B0X
M&8D5 !B)'0 7BB8 %HHN !6*-P 4BD$ $XI, !*+6  1BV4 $(MU  ^+AP .
MBIL #8JO  R*R  ,B>H #8?\  Z'_P .AO\ #H;_ )][  "4@0  BH4  ("(
M  !SBP  98T  %F/  !,D   09(  #22   JD@  (9,  !F4   2E@8 #I<.
M  V7%0 ,EQT #)<F  N7+P *ESD "9=$  B74  &EUX !9=N  .6@  !EI0
M )6H  "5O@  E.   )3T  "3_P !DO\  9+_ )B"  ".B   A8P  '>/  !J
MD@  794  %"8  !$F@  .)L  "R<   BG0  &9X  !*@   -H@( !Z,+  &C
M$   HQ<  *,?  "C)P  HS$  *0\  "D2   I%8  *1E  "C=P  HXL  *.@
M  "BM@  H=(  *'P  "@^P  H/\  *#_ )&*  ")C@  >Y(  &V7  !@FP
M4YX  $:A   YHP  +:0  ".F   9J   $:H   RL   %K@   *\'  "O#0
MKQ$  + 8  "P(   L2@  +$R  "R/@  LDP  +);  "R;   LH$  +&7  "Q
MK   L,8  +#H  "O]P  K_\  *__ (R0  !_E0  <9H  &.?  !5I   1Z@
M #JJ   MK   (JX  !BP   0LP  "K4   *X    NP   +L   "\!P  O T
M +T1  "^%@  OQX  , G  #!,@  PD   ,-/  ##8   PW0  ,.+  ##H0
MP[@  ,+7  #"[P  POH  ,'^ (&7  !SG0  9:,  %>H  !)K0  .[$  "VS
M   AM@  %KD   Z[   'O@   ,$   #%    QP   ,@   #)    R@4  ,L+
M  #-#P  SA0  - <  #3)@  UC(  -A!  #84P  V68  -E\  #9E   V:L
M -G#  #9X0  V?   -GT ':?  !GI@  6:P  $NR   \MP  +KH  "&]   5
MP   #<0   7'    R@   ,X   #2    U0   -8   #9    VP   -T   #?
M!P  X0P  .,1  #F&0  Z20  .PR  #M0P  [E8  .]K  #OA   [YP  .^R
M  #OQ@  []T  ._D &JH  !;KP  3+8  #Z\   OP   (,0  !3(   ,S
M M    #4    V0   -X   #B    Y0   .8   #H    Z0   .P   #N
M\ (  /()  #U#P  ^!<  /PC  #_,P  _T8  /]:  #_<0  _XD  /^?  #_
ML0  _\   /_& /\ %0#_ !0 _P 4 /\ %P#_ !T _P H /\ -P#_ $0 _P!1
M /\ 7 #_ &8 _P!O /\ =P#_ 'X _P"% /\ BP#_ )$ _P"7 /\ G0#_ *0
M_P"K /\ M #^ +\ _0#. /L Y@#Y /8 ^ #_ /< _P#W /\ ]P#_ /  _P#L
M /\ Z0#_ /\#$@#_ !  _P 0 /\ $0#_ !< _P D /\ ,@#_ #\ _P!, /\
M5P#_ &$ _P!J /\ <@#_ 'D _0"  /P A@#Z (P ^0"2 /@ F #V )\ ]0"F
M /0 K@#R +D \ #& .X W@#M /  ZP#^ .H _P#I /\ Z0#_ .< _P#C /\
MX #_ /\'#@#_  T _P + /\ # #_ !, _P ? /\ + #_ #H _P!& /X 4@#[
M %P ^ !E /4 ; #S '0 \0!Z .\ @0#N (< [ "- .H DP#I )H YP"A .8
MJ0#C +, X0"_ -\ T #= .D V@#Y -D _P#7 /\ U0#_ -4 _P#5 /\ U #_
M /\)"@#_ 04 _P # /\ "0#_ !  _P 9 /L )@#W #0 ] !  /( 3 #N %8
MZ@!? .< 9P#D &X X@!T .  >P#> ($ W "' -H C0#6 )0 U "; -$ HP#/
M *T S "X ,H QP#( .  Q@#S ,4 _P## /\ PP#_ ,, _P## /\ PP#_ /\+
M 0#_ P  _P   /\  P#_  L \P 2 .X 'P#J "T Y@ Z .( 10#> $\ V0!8
M -0 8 #1 &@ S@!N ,P = #* 'L R "! ,8 AP#$ (X P@"6 ,  G@"^ *<
MNP"R +D P "W -0 M0#L +, ^P"S /\ L@#_ +( _P"Q /\ L0#_ /\-  #_
M!@  _P,  /<   #T  , YP - .  & #: "4 TP R ,X /@#* $D Q@!2 ,,
M6@#  &$ O@!H +P ;@"Z '0 N ![ +8 @0"T (@ L@"0 +  F0"N *( K "M
M *H N@"H ,L I@#F *4 ]P"D /\ HP#_ *( _P"B /\ H@#_ /\0  #[#
M[PX  .8-  #?"0  V@ & -  $0#) !T Q  J +\ -P"[ $( MP!+ +0 5 "R
M %L KP!B *T : "K &X J0!U *@ >P"F (, I "+ *( E "@ )X G@&H )P"
MM0"; \8 F07B )@&] "6"/\ E0G_ )0)_P"4"?\ E G_ /P1  #Q%0  XQD
M -89  #,%0  QQ   ,0'"@"] Q0 MP0A +(&+@"N"#H J@E$ *<)30"D"E4
MH@I< * *8@">"VD G MO )L+=@"9#'X EPR& )8,D "4#)H D@VF )$-LP"/
M#<4 C0[B (L0]@")$/\ B!'_ (<1_P"'$?\ AQ'_ /89  #G(   UB0  ,@E
M  "_(@  N1P  +04 0"Q#0X J@X9 *4/)P"A$#, G1$^ )H11P"8$D\ E1)6
M ),27 "1$F, D!-I (X3< ",$W@ BQ.! (D4BP"'%)8 AA6B (05L "#%L$
M@1?= '\8] !]&?\ ?!G_ 'P9_P![&?\ >QG_ .\A  #=*0  RBT  +XO  "U
M+   KB<  *@@  "C%P@ GA83 )D7(0"4&2T D1HX (X:00"+&TD B1M0 (<;
M5P"%'%X A!QD ((<:P" '', ?QU\ 'T=A@!\'I$ >AZ> '@?JP!W'[P =B#4
M '0A\ !R(?\ <2+_ '$A_P!Q(?\ <2'_ .@H  #2,   PC4  +<W  "M-0
MI3$  )XK  "8(P( DAX0 (T@&P")(2< AB(R (,C/ "!(T0 ?B-+ 'PD4@![
M)%D >21? '<D9@!V)6X ="5W ',E@0!Q)HT ;R:9 &XFIP!M)[@ ;"?. 6HH
M[0%I*?\!:"G_ 6@I_P%H*/\!:"C_ >$N  #+-@  O#L  +$]  "G/0  GSD
M )<S  "/+0  B"<, (,G%@!_*"( ?"DM 'DJ-P!W*C\ =2I' ',K3@!Q*U0
M<"M; &XK8@!L*VH :RQR &DL?0!H+(D 9BV6 64MI %D+K0!8R[* 6$OZ0%@
M+_T!8"__ 6 O_P%@+_\!8"[_ =HT  #%/   MT$  *Q#  "B0P  F4   ) Z
M  "(-   @"X( 'HM$@!W+AX <R\I '$P,P!O,#L ;3!# &LQ2@!I,5$ 9S%7
M &8Q7@!D,68 8S)O &$R>0!@,H4!7S*2 5TSH0%<,[$!6S3& 5HTY@%9-?L!
M637_ 5DT_P%9-/\!633_ =(X  # 0   LT4  *A(  ">2   E48  (M   ""
M.P  >34$ ',S$ !O-!H ;#0E &DU+P!G-3< 938_ &,V1@!B-DT 8#94 %\V
M6P!=-V, 7#=K %LW=@%9-X(!6#B/ 58XG@%5.*\"5#G# E,YY )3.OD!4SG_
M 5(Y_P%3.?\!4SG_ <T\  "\1   KTD  *1,  ":3   D4L  (=&  !]0
M<SL  &PX#0!H.1< 93DB &,Z*P!@.C0 7CH\ %TZ0P!;.DH 6CM0 %@[6 !7
M.V  5CMH %4\<P%3/'\!4CR- 5 ]G %//:P"3C[! DT^X0)-/O@"33[_ 4T^
M_P%-/?\!33W_ <E   "X2   K$T  *%0  "740  CD\  (1+  !Y10  ;D
M &8]"P!B/10 7ST> %P^* !:/C$ 6#XX %<^0 !5/T8 5#]- %,_50!20%T
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M ;U*  "O4@  HU@  )E;  "070  AEP  'M9  !M4P  8D\  %=, 0!12@T
M3DH5 $Q+'P!*2R@ 24LP $=+. !&3#\ 14Q& $1,3@!#358 0DU? $!-:@ _
M378!/4Z$ 3Q.E $[3J4!.4^Y CE/U (Y3_(!.4[_ 3E._P$Y3?\!.DW_ ;I.
M  "L5@  H5L  )=?  "-80  @V$  'A>  !I6   7U8  %12  !,3PL 24\2
M $=0' !%4"4 0U M $)0-0!!43P 0%%$ #]13  ^4E0 /%)= #M29P Z4G,
M.%." 3=3D@$U4Z0!-%.W 3-4T0$S4_$!-%/_ 312_P$T4O\!-%+_ ;92  "I
M6@  GF   )1D  "+9@  @&4  '1C  !F7@  7%P  %%8  !'50< 0E40 $!5
M&  _5B$ /58J #Q6,@ [5CD .E=! #E720 X5U$ -UA: #5890 T6'$ ,EB
M 3%8D $O6:(!+EFU 2U9SP$M6>\!+EC_ 2Y7_P$N5_\!+E;_ ;)7  "E7P
MFV4  )%I  "':@  ?&H  '%H  !C90  6&(  $U?  !#70( /%L- #I<%  X
M7!T -UPF #5=+@ T738 ,UT^ #)=1@ Q7DX ,%Y7 "]>8@ M7FX +%]] "I?
MC@ I7Z  *%^S 2=?S  G7^T!)U[_ 2==_P$H7?\!*%S_ :U<  "B9   F&H
M (YN  "#;P  >6\  &YN  !@:P  5&D  $EG   _90  -6,) #)C$0 P8QD
M+V0A "YD*0 M9#$ +&0Y "ME0@ J94H *&54 "=E7P F9FL )&9Z "-FBP B
M9IT (&:Q !]FR0 ?9NL (&7^ "!D_P @8_\!(6/_ :EB  ">:@  E7   (IS
M  " =0  =74  &ET  !<<@  3W$  $1O   Z;@  ,&T# "EL#0 G;!0 )FP<
M "5M)  D;2P (VTT ")M/0 A;D8 (&Y0 !YN6P =;F< '&YV !INAP 9;YH
M&&^N !9OQ@ 6;ND %VW\ !AL_P 8:_\ &&O_ *1I  ":<0  D'8  (9Y  !\
M>P  <7L  &1[  !7>@  2GD  #]X   U>   *W<  ")V!P ==@\ ''<6 !MW
M'@ :=R8 &7<N !AW-P 7>$  %7A* !1X5@ 3>&, $GAR !%X@P 0>)< #WBK
M  YXPP .=^8 #G;Z  ]U_P 0=?\ $'3_ )]Q  "5>   BWP  ()_  !W@0
M:H(  %V"  !0@@  1((  #B"   N@@  )((  !R"   4@@D $8,0 !"#%@ 0
M@QX #H,G  Z#,  -@SD #8-$  R#4  +@UT "8-L  B#?@ &@Y$ !8*E  ."
MNP $@=L !('R  6 _P &?_\ !G__ )IY  "0?@  AH,  'V%  !OAP  8HD
M %6*  !)BP  /8P  #&,   FC   '8T  !6.   /CP, "I ,  :0$0 $CQ@
M X\@  &/*0  CS(  ) ]  "020  CU8  (]E  "/=@  CXH  (Z?  ".M
MC<\  (SN  ",^P  B_\  (O_ )2   "+A0  @HD  '2,  !FCP  69$  $R3
M  ! E0  -)8  "B6   >EP  %9@   ^:   *FP   IP)  "<#@  G!,  )P:
M  "<(@  G2L  )TU  "=0   G4X  )U<  "=;@  G($  )R7  "<K   F\8
M )KH  "9^0  F?\  )C_ (Z(  "&C   >)   &J4  !<EP  3YH  $*=   V
MG@  *9\  !^A   5H@  #J0   BF    J    *D$  "I"@  J0X  *D3  "J
M&@  JB(  *LK  "L-@  K$0  *Q3  "L8P  K'<  *N.  "KI   J[P  *K>
M  "I]   J?T  *G_ (F.  ![DP  ;9<  %^<  !1H   1*0  #:F   JJ
M'JD  !2K   -K@  !K    "R    M0   +4   "U P  M@D  +<.  "X$@
MN!D  +HA  "[*P  O#@  +U'  "]6   O6L  +V!  "]F0  O;   +W,  "\
MZ@  O/<  +O^ 'Z5  !PFP  8J   %.E  !&J@  .*T  "JO   >L0  $[0
M  RW   #N0   +P   "_    P@   ,(   ##    Q    ,8&  #'#   R!
M ,H6  #,(   SRL  - Z  #12P  T5X  -)S  #2BP  TJ0  -.[  #3V
MT^T  -/V '.=  !DHP  5JD  $>O   YLP  *K8  !VY   2O   "K\   ##
M    Q@   ,D   #-    SP   -    #2    U    -8   #9 @  VP@  -X.
M  #A$P  Y!T  .@J  #H/   Z4\  .ED  #J?   ZY4  .NL  #KP@  [-4
M .SE &:F  !8K   2;,  #NY   KO   '<   !'$   )R    ,P   #/
MTP   -D   #=    X    .$   #C    Y0   .<   #J    [    .X$  #Q
M"P  ]1(  /@<  #[*P  _3X  /Y3  #^:@  _X,  /^;  #_K@  _[X  /_*
M /\ $@#_ !  _P 1 /\ $P#_ !D _P F /\ - #_ $$ _P!- /\ 6 #_ &(
M_P!K /\ <P#_ 'H _P"! /\ AP#_ (T _P"3 /\ F0#_ *  _P"G /X KP#\
M +H ^@#) /D X0#X /, ]P#_ /8 _P#U /\ \0#_ .D _P#D /\ X0#_ /\
M#P#_  T _P - /\ #@#_ !0 _P A /\ +@#_ #P _P!( /\ 4P#_ %T _P!F
M /X ;0#\ '4 ^P![ /D @@#X (@ ]P". /8 E #T )L \P"B /$ J@#O +0
M[0#! .L U0#J .P Z #\ .< _P#E /\ Y@#_ .  _P#9 /\ U #_ /\ "P#_
M  @ _P & /\ "0#_ !  _P < /\ *0#_ #8 _P!" /L 3@#W %< ] !@ /(
M: #O &\ [0!V .P ? #J (( Z "( .< C@#E )4 XP"< .$ I #? *X W0"Y
M -H R@#7 .0 U #V -$ _P#0 /\ T #_ ,\ _P#+ /\ QP#_ /\  P#_
M_P   /\ ! #_  T ^@ 6 /8 (P#S #  \  \ .T 1P#I %$ Y0!: .( 8@#?
M &D W0!O -H =@#8 'P U "" -( B #0 (\ S0"6 ,L G@#) *@ QP"S ,4
MP0#" -@ P #O +\ _@"^ /\ O0#_ +P _P"\ /\ O #_ /\"  #_    _P
M /\   #T  < [0 1 .@ ' #C "D WP U -L 00#6 $L T0!4 ,T 7 #* &,
MR !I ,8 ;P## '4 P0![ +\ @@"^ (@ O "0 +H F "X *( M0"L +, N0"Q
M ,L KP#G *X ^ "L /\ JP#_ *P _P"L /\ JP#_ /\$  #_    ]@   .X
M  #G    WP , -8 %0#/ "( R@ N ,< .@## $0 P !- +P 50"Y %P MP!C
M +4 :0"S &\ L0!U *\ >P"M (( JP"* *D D@"G )P I0"F *, LP"A ,,
MGP#> )X \@"= /\ G #_ )P _P"; /\ FP#_ /\'  #V"0  Z0L  -\*  #5
M!   S@ % ,8 $ #  !H NP G +< ,@"S #T L !& *T 3P"J %8 J !< *8
M8P"D &@ H@!O *$ =0"? 'P G0"$ )L C0"9 )< EP"B )4 K@"3 +T D0#3
M )  [0"/ /P C@#_ (T!_P"- ?\ C0'_ /D.  #J$@  W!4  ,T5  #$$0
MO@P  +H""@"T !( K@ > *H *@"F #4 H@ _ *  2 "= 5  FP)6 )D"7 "7
M V, E0-I ),#;P"1!'8 D 1_ (X%B ",!9( B@:> (@&J@"&![H A0C/ (0*
MZP"""_P @0S_ ( ,_P" #/\ @ S_ /$5  #@'0  S2   ,$A  "X'0  L1<
M *P0  "H"0T H@<6 )T)(P"9"BX E0LX ),,00"0#$D C@U0 (P-5P"*#5T
MB UC (<-:@"%#G$ @PYZ ((.A " #H\ ?@^; 'P/J ![$+@ >A#. '@1[ !V
M$O\ =1+_ '03_P!T$_\ =!/_ .@>  #3)@  PRH  +@J  "N*   IR,  * <
M  ";$P, E@\0 ) 0&P",$2< B1(R (83.P"$$T, @A1+ ( 440!^%%< ?!1>
M 'L590!Y%6P =Q5T '86?@!T%HH <A>6 '$7I !O&+0 ;AC) &T9Z !K&OP
M:AO_ &H;_P!J&_\ :AO_ . F  #*+0  O#$  + S  "G,0  GRP  )<F  "0
M'P  BA<, (48%@"!&2( ?AHL 'L;-@!Y&SX =QQ% '4<3 !S'%, <1U9 ' =
M8 !N'6< ;1YP &L>>@!J'H4 :!^2 &<?H !E(+  9"'% &,AY !B(OH 82+_
M &$B_P!A(O\ 82+_ -<L  ##-   MC@  *HY  "A.   F#4  ) O  "(*
M@"$( 'L@$@!W(1T ="(G '$B,0!O(SD ;2-! &LC2 !I(TX :"15 &8D6P!E
M)&, 8R5K &(E=0!A)8$ 7R:. %XFG0!=)ZT 6RC! %LHX !:*?< 62G_ %DI
M_P!9*?\ 62C_ ,\R  "^.0  L3T  *8_  "</P  DSP  (HV  "!,   >2H#
M '(F#P!N)QD :R@C &DH+ !F*34 92D\ &,I0P!A*DH 8"I1 %XJ5P!=*E\
M7"MH %HK<@!9+'T 6"R+ %8MF@!5+:H 5"Z] %,NW !2+_4 4B__ %(N_P!2
M+O\ 4B[_ ,HV  "Z/0  K4(  *)$  "81   CT$  (4\  ![-P  <C$  &LL
M# !G+14 9"T? &$N* !?+C$ 72XY %PO0 !:+T8 6"]- %<O5 !6,%P 53!D
M %,Q;@!2,7H 43&( % REP!.,J@ 33.[ $TTV !,-/, 3#3_ $PT_P!,,_\
M3#/_ ,8Z  "V0@  J48  )Y)  "520  BT<  (%"  !W/0  ;3<  &0R"0!@
M,A( 73(< %HR)0!8,RT 5C,U %4S/ !3-$, 4C1* %$T40!0-%D 3S5A $TU
M; !,-G< 2S:% $HWE0!(-Z8 1SBX 4<XTP%&./$!1CC_ 48X_P!&./\ 1C?_
M ,$^  "R10  IDH  )Q-  "230  B$L  'Y'  !S0@  :3T  %\W!@!:-A
M5S<8 %0W(@!2-RH 4#<R $\X.0!-.$  3#A' $LX3@!*.58 23E? $@Z:0!'
M.G4 13N# $0[DP!#/*0!0CRV 4$]T %!/? !03W_ 4$\_P%!//\!03S_ +Y"
M  "O20  HTX  )E0  "/40  A5   'M,  !O1@  94(  %H] @!4.PX 43L5
M $\['P!-.R< 2SLO $D\-@!'/#T 1SQ$ $8]2P!%/50 1#Y< $,^9P!"/W,
M0#^! #\_D0 ^0*( /4"U 3Q!S@$\0>X!/$'_ 3Q _P$\0/\!/3__ ;I%  "L
M3   H5$  )=4  "-50  @U0  'A1  !L2P  84<  %9"  !/0 P 3#\3 $E
M' !'0"0 1D L $1 ,P!#0#H 0D%" $%!20! 0E$ /T): #Y#90 ]0W$ .T-_
M #I$CP Y1*  .$6S 3=%RP$W1>P!-T7_ 3=$_P$X1/\!.$/_ +=)  "I4
MGE4  )18  "+60  @%@  '96  !H4   74P  %-(  !*10D 1D01 $1$&0!"
M1"( 044I #]%,0 ^13@ /44_ #Q&1P [1D\ .D=8 #E'8@ X2&X -DA\ #5(
MC0 T29X ,TFQ #))R0 Q2>L ,DG^ #)(_P R2/\ ,TC_ +1,  "G5   G%D
M ))<  "(70  ?ET  '-:  !E50  6U(  %!.  !&2@4 0$D. #Y)%@ ]21X
M.THF #I*+@ Y2C4 .$L] #=+1  V2TT -$Q6 #-,8  R3&P ,4UZ #!-BP N
M39P +4ZO "Q.QP L3ND +$W] "U-_P M3/\ +4S_ +!0  "D6   F5T  (]A
M  "&8@  >V$  '!?  !B6P  6%@  $Y5  !#40$ .T\, #A/$P V3QL -4\C
M #10*P S4#( ,E Z #%00@ P44H +E%3 "U270 L4FD *U)X "E2B  H4YH
M)U.M "93Q0 F4^< )E/\ "=2_P G4?\ )U'_ *Q5  "@7   EF(  (UF  "#
M9P  >&8  &UE  !@80  55X  $I;   _6   -58( #%5$  P5A< +E8? "U6
M)P L5B\ *U<V "I7/@ I5T< *%=0 "986@ E6&< )%AU "-9A@ A69@ (%FK
M !]9P@ ?6>4 'UCZ "!8_P @5_\ (5?_ *A:  "=8@  DV<  (IK  !_;
M=6P  &IK  !=:   464  $9C   [8   ,5X# "I=#0 H71, )ET; "5>(P D
M7BH (UXR ")>.@ A7D, (%], !]?5P >7V, '&!Q !M@@@ 98)4 &&"I !=@
MP  68.( %U_Y !A>_P 97O\ &5W_ *1@  "9:   D&X  (9P  !\<@  <G(
M &9Q  !8;@  3&P  $%K   V:0  +6<  "-F"  ?9@\ '685 !QF'0 ;9B4
M&F8M !EG-0 89SX %V=( !9G4P 5:%\ $VAN !)H?P 1:)( $&BF  ]HO0 .
M:.  $&?W !!F_P 19?\ $67_ )]G  "6;P  C',  ()V  !X>   ;7@  &!W
M  !3=@  1G0  #MS   Q<@  )W$  !YQ   6< H $W 0 !-P%P 2<!\ $7$G
M !!Q+P 0<3@ #G%"  YQ3@ -<5L #'%I  MQ>@ *<8T "'&A  9QM@ &<-(
M!W#O  AO_P );O\ "6[_ )MO  "1=0  AWD  'Y\  !T?@  9GX  %E^  !-
M?@  0'T  #5]   J?   (7P  !A\   1? 0 #'P,  I\$0 )?!D "'PA  =\
M*0 &?#( !'P]  -\2  !?%4  'QC  !\=   ?(<  'N<  ![L0  >LL  'GK
M  !Y^@  >?\  'C_ )9W  ",?   @X   'F#  !LA   7H4  %&&  !%AP
M.8<  "V'   CAP  &H<  !*'   -B $ !HD*  &)#P  B10  (@;  "((P
MB2P  (DV  ")0@  B$X  (A=  "(;0  B($  (>5  "'JP  AL0  (7F  "$
M^   A/\  (3_ )!^  "'@P  ?H<  '&)  !CBP  5HT  $F/   \D0  ,)$
M "21   :D@  $I,   V4   &E0   )8&  "6#   E1   )85  "6'0  EB0
M )8N  "6.0  ED8  )95  "690  EG@  )6.  "5I   E+P  )/?  "3]0
MDO\  )+_ (N&  "#B@  =8T  &>0  !9E   3)<  #^9   RF@  )IL  !N<
M   2G0  #)\   2@    H@   *,!  "C!P  HPP  *,0  "D%0  I!P  *4E
M  "F+P  ICP  *9+  "F6P  IFX  *6$  "EFP  I+,  */0  "C[P  HOP
M *+_ (:-  !XD0  :I4  %R9  !.G0  0:   #.B   FHP  &Z4  !&G   *
MJ0   :L   "M    KP   +    "P    L 4  +$+  "R#P  LQ0  +0;  "U
M)   MS   +<_  "W4   MV(  +=X  "WD   MJD  +;"  "VY   MO4  +7^
M 'N3  !MF   7YT  %"B  !"I@  -*D  ":K   :K0  $*\   FR    M
M +<   "Z    O    +T   "^    O@   , "  #!"   P@T  ,02  #&&0
MR20  ,HR  #+0P  RU4  ,QJ  #,@P  S)P  ,NU  #,S@  S.D  ,SV '";
M  !AH0  4J8  $2K   VL   )[(  !JU   0N   ![L   "^    P0   ,0
M  #(    RP   ,L   #-    S@   -    #2    U0,  -@*  #;$   WA@
M .(D  #C-0  Y$@  .5<  #F<P  YHT  .:E  #FO   YM,  .?G &.D  !5
MJ@  1K   #BU   HN0  &KP   _    %Q    ,<   #+    SP   -0   #8
M    W    -T   #?    X0   .,   #E    Z    .H   #M!@  \0X  /46
M  #X)0  ^3@  /E-  #Z8P  ^WP  /R5  #\J@  _+L  /W+ /\ #P#_  X
M_P . /\ $ #_ !8 _P C /\ , #_ #T _P!) /\ 5 #_ %X _P!F /\ ;@#_
M '8 _P!\ /\ @@#_ (D _P"/ /\ E0#^ )L _0"C /L JP#Z +4 ^0## /<
MVP#V /  ] #_ /, _P#R /\ [ #_ .( _P#< /\ U@#_ /\ # #_  D _P (
M /\ "@#_ !( _P > /\ *P#_ #@ _P!$ /\ 3P#_ %D _@!A /P :0#Z '
M^ !W /< ?0#V (, ] ") /( CP#Q )8 [P"= .T I0#L *\ Z@"\ .@ S0#F
M .@ Y #Z ., _P#B /\ X #_ -4 _P#. /\ RP#_ /\ !@#_  $ _P   /\
M! #_  X _P 9 /\ )0#] #( ^P ^ /< 20#S %, \ !< .X 8P#L &H Z@!Q
M .@ =P#F 'T Y "# .( B0#@ )  W@"7 -P GP#9 *D U@"T -, Q #0 -X
MS@#S ,P _P#+ /\ R@#_ ,@ _P#" /\ O@#_ /\   #_    _P   /\   #[
M  L ]@ 3 /$ ( #M "P Z@ X .< 0P#C $T X !6 -P 70#9 &0 U0!K -(
M<0#0 '8 S@!\ ,P @P#* (D R "1 ,8 F0#$ *, P0"M +\ NP"] ,\ NP#K
M +D _ "W /\ MP#_ +8 _P"T /\ L0#_ /\   #_    _P   /8   #N  4
MYP / .$ &0#; "4 U0 Q -( / #. $8 R@!/ ,< 5P#$ %X P0!D +\ :@"]
M '  NP!V +D ? "X (, M@"* +, DP"Q )P KP"G *T LP"K ,4 J0#A *<
M]0"F /\ I0#_ *0 _P"D /\ I #_ /\   #\    \0   .@   #@    U  +
M ,P $P#' !\ P@ J +\ -0"\ #\ N !( +4 4 "S %< L !> *X 9 "L &D
MJP!O *D =0"G 'P I0"$ *, C "A )8 GP"A )T K0": +P F #2 )< [@"5
M /X E #_ )4 _P"5 /\ E0#_ /P!  #P!0  XP<  -4%  #,    Q0 $ +X
M#@"X !< LP C *\ +@"K #@ J0!! *8 2@"C %$ H0!7 )\ 70"= &, FP!I
M )H ;P"8 '8 E@!] )0 A@"2 )  D "; (X IP", +8 B@#) (@ YP"' /D
MAP#_ (8 _P"& /\ A@#_ /0,  #D$   T1(  ,41  "]#@  M@@  +$ " "K
M !$ I@ ; *$ )@"> #$ F@ Z )@ 0P"5 $H DP!1 )$ 5P"/ %T C@!C (P
M:0"* '  B !W (8 @ "$ (L @@"6 (  HP!^ +$ ?0#$ 'L"X0!Z _4 >@7_
M 'D%_P!X!O\ > ;_ .H3  #6&@  QAT  +H<  "Q&0  JA,  *0-  "?!0P
MF0 4 )4 'P"1 BD C0,S (L$/ "(!40 A@9+ (0&40""!U< @0== '\'8P!]
M"&H >PAR 'H(? !X"88 =@F2 '0*H !S"J\ <0O! ' ,WP!O#?8 ;@[_ &T.
M_P!M#O\ ;0[_ .$<  #+(P  O"8  +$F  "H)   H!X  )D8  "3$ ( C@L.
M (@+%P"$#"( @0TL 'X--0!\#CT >@Y% '@.2P!W#E$ =0]8 ',/7@!Q$&4
M<!!N &X0=P!L$(( :Q"/ &D1G0!H$:T 9A+  &42WP!D$_8 8Q3_ &,4_P!B
M%/\ 8A3_ -8D  ##*@  M2X  *HO  "@+0  F"@  ) B  ")&P  @A,( 'T1
M$@!Y$AP =A,G ',4, !Q%#@ ;Q4_ &T51@!L%4P :A93 &@660!G%F$ 919I
M &07<@!B%WX 81B+ %\8F0!>&:D 7!F\ %P:V !:&_, 6AS_ %D<_P!9'/\
M61S_ ,TJ  "],0  KS4  *0V  ";-   DC$  (DK  "!)0  >1T# ',8#@!O
M&1@ ;!HB &D;*P!G&S, 91P[ &0<00!B'4@ 8!U. %\=50!='5P 7!YD %L>
M;@!9'WD 6!^' %8@E@!5(*8 5"&X %,AT@!2(O$ 4B/_ %(C_P!2(O\ 4B+_
M ,@O  "X-@  JSH  * \  "6.P  C3@  (,R  !Z+0  <B8  &H@# !F(!,
M8R$= &$A)@!?(B\ 72(V %LB/0!:(T0 6"-* %<C40!5(U@ 5"1A %,D:@!1
M)78 4"6# $\FDP!.)Z, 3">U $PHS@!+*.X 2RG_ $LH_P!+*/\ 2RC_ ,,T
M  "S.P  IS\  )Q!  "20   B3X  '\Y  !U,P  ;"T  &,G" !>)A$ 7"89
M %DG(@!7)RL 52@R %0H.0!2*$  42A& % I30!.*54 32E= $PJ9P!+*G,
M22N  $@KD !'+*$ 1BVS $4MRP!%+NP 1"[_ $0N_P!%+?\ 12W_ +XX  "P
M/P  I$,  )E%  "/10  A4,  'L^  !Q.0  9S0  %XN! !8*PX 52L6 %(L
M'P!0+"< 3RPO $TM-@!,+3P 2BU# $DM2@!(+E( 1RY: $8O9 !%+W  0S!^
M $(PC0!!,9X 0#*Q #\RR  _,^H /S/^ #\R_P _,O\ /S+_ +L\  "M0P
MH4<  )9)  ",20  @T@  'A$  !M/@  8SD  %HT  !2, P 3S 3 $PP' !*
M,"0 23$K $<Q,@!&,3D 1#%  $,R1P!",D\ 03-8 $ S8@ _-&T /C1[ #TU
MBP \-IP .S:O #HWQ@ Y-^@ .3?\ #HW_P Z-O\ .C;_ +=   "J1@  GDL
M )1-  "*3@  @$P  '5(  !J0P  8#X  %8Y  !--0D 2301 $<U&0!%-2$
M0S4H $$U+P! -38 /S8] #XV10 ]-TT /#=5 #LX8  Z.&L .3EY #@YB0 W
M.IL -3JM #4[Q  T.^8 -#O[ #4[_P U.O\ -3K_ +1#  "G2@  G$X  ))1
M  "(4@  ?E   '--  !G2   7$0  %(_  !(.@8 1#D/ $$Y%@ _.1X /CDF
M #PY+0 [.C0 .CH[ #D[0@ X.TH -SQ3 #8\70 U/6D -#UW #,^AP Q/ID
M,#^K "\_P@ O/^0 +S_Z # __P P/O\ ,#[_ +%'  "D30  F5(  (]5  "&
M5@  ?%4  '%2  !D3   64D  $]%  !%0 , /SX- #P^$P Z/AL .3XC #<^
M*@ V/S$ -3\X #0_0  S0$@ ,D!1 #%!6P P06< +D)U "U"A0 L0Y< *T.J
M "I#P  I1.( *D/Y "I#_P K0O\ *T+_ *Y*  "A40  EU8  (U9  "#6@
M>5H  &Y7  !A4@  5TX  $U+  !#1P  .D,* #9#$0 T0Q@ ,T,@ #)$)P Q
M1"\ ,$0V "]%/0 M148 +$5/ "M&60 J1F0 *4=R "A'@P F1Y4 )4BH "1(
MO@ C2.  )$CW "5'_P E1_\ )D?_ *I/  "?50  E%H  (M>  "!7P  =UX
M &M<  !?6   554  $M1  ! 30  -4H' #!)#@ N214 +4D= "Q))  K2BL
M*DHS "A*.P G2T, )DM, "5+5@ D3&( (TQP "%,@  @39, 'TVF !Y-NP =
M3MT 'DWV !Y,_P ?3/\ ($O_ *=3  "<6@  DE\  (AC  !^9   =&,  &EA
M  !<7@  4EL  $=8   \50  ,E(" "I0#  G3Q( )E 9 "50(  D4"@ (U O
M ")1-P A44  (%%) !Y24P =4E\ '%)M !I3?0 94Y  &%.D !93N0 54]D
M%E/T !=2_P 84?\ &5'_ *-9  "88   CV4  (5H  ![:0  <6D  &9G  !9
M9   36$  $)?   X7   +EH  "58"  @5PX 'E<4 !U7'  <6", &U@K !I8
M,P 96#P &%A% !994  565L %%EI !-:>@ 26HT $5JA !!:MP .6M4 $%GS
M !!9_P 16/\ $5C_ )]?  "59@  C&L  ()M  !X;@  ;F\  &)M  !5:@
M2&@  #YF   S90  *6,  "!A 0 88 L %6 0 !1@%P 38!X $F F !)@+@ 1
M83< $&%   ]A2P .85@ #6%F  QB=@ +8HD "F&=  EAL@ (8<L "&'K  E@
M_0 *7_\ "U__ )MF  "2;0  B'$  'YS  !U=0  :G0  %QS  !/<@  0W
M #AO   M;@  )&P  !MK   3:P0 #FH,  UJ$@ ,:AD "VHA  IJ*0 ):C(
M"&H\  =K1P %:U, !&MA  )K<0  :H0  &J8  !JK0  :<8  &GG  !I^
M:/\  &C_ )=M  "-<P  A'<  'MZ  !P>P  8WL  %9Z  !)>@  /7D  #%X
M   G=P  '78  !5V   /=@( "78*  1V#P  =A4  '8<  !V)   =2P  '4V
M  !U00  =4X  '5<  !U;   =7X  '23  !TJ   <\   '/C  !R]P  <O\
M ''_ ))U  ")>@  @'X  ':   !I@0  6X(  $Z"  !!@@  -8,  "F"   ?
M@0  %H$  !""   *@@   H,'  ""#0  @A$  ((7  ""'@  @B8  ((O  ""
M.P  @D<  ()5  "!90  @7@  (&-  " H@  ?[H  '_=  !^]   ??\  'W_
M (U\  "$@0  >X0  &Z&  !@B   4HH  $6+   YC   +(P  "&,   7C
M$(T   F.   "CP   ) #  "/"0  CPX  (\2  "0&   D!\  ) H  "0,@
MD#\  )!-  "070  CW   (^%  ".G   CK,  (W0  ",\   B_X  (O_ (B$
M  " B   <HL  &2-  !6D   2),  #N5   NE@  (I8  !>7   /F   ")D
M  ";    G0   )T   "= P  G0D  )T-  ">$0  GA<  )\?  "?*0  H#4
M *!#  "@5   H&8  )][  ">DP  GJL  )W&  "=Z0  G/D  )S_ (.+  !U
MC@  9Y(  %F6  !+F0  /9P  #">   CGP  %Z    ZB   'I    *8   "H
M    J@   *H   "J    JP$  *L'  "L#   K1   *X6  "O'@  L2D  +$X
M  "Q2   L5H  +%O  "QB   L:   +"Z  "OW0  K_(  *_] 'B1  !JE@
M7)H  $V?   _HP  ,:8  ".G   7J0  #JL   6N    L    +(   "U
MMP   +<   "X    N0   +H   "\ P  O0D  +X.  # %   PQX  ,4K  #%
M/   QDX  ,9B  #&>@  QI0  ,:M  #&R   Q>4  ,7S &R9  !>G@  3Z0
M $&H   RK   )*\  !:Q   -M    [<   "Z    O0   ,    #$    Q@
M ,8   #(    R0   ,L   #,    S@   - &  #3#0  V!,  -P>  #>+0
MWT   .!4  #A:P  X84  .&?  #AMP  X<\  .'F &"A  !2IP  0ZT  #2R
M   EM0  %[D   V\   !OP   ,,   #'    R@   ,\   #3    U@   -<
M  #:    W    -\   #A    XP   .8   #I 0  [ L  / 2  #S'P  ]#$
M /9&  #W7   ^'0  /B/  #YI@  ^;@  /C) /\ #0#_  L _P + /\ #@#_
M !, _P ? /\ + #_ #D _P!% /\ 4 #_ %D _P!B /\ :@#_ '$ _P!W /\
M?@#_ (0 _@"* /T D #\ )< ^@"> /D IP#W +$ ]@"^ /4 T@#S .P \0#^
M /  _P#P /\ Y@#_ -P _P#2 /\ S0#_ /\ !P#_  0 _P " /\ !@#_ !
M_P ; /\ )P#_ #, _P _ /\ 2@#^ %0 ^P!= /D 9 #W &L ]0!R /, > #R
M 'X \ "$ .\ B@#M )$ [ "9 .H H0#H *L Y@"V .0 QP#B ., X #W -X
M_P#= /\ V0#_ ,P _P#% /\ P0#_ /\   #_    _P   /\  0#_  T _P 6
M /P (@#Y "X ]@ Y /, 10#O $X [ !7 .D 7@#F &4 Y !L .( <@#@ '<
MWP!^ -T A #; (L V "2 -4 FP#2 *0 SP"O ,T O@#+ -4 R0#O ,< _P#%
M /\ Q #_ +X _P"X /\ M0#_ /\   #_    _P   /X   #W  D \0 1 .L
M' #G "@ Y  S .$ /@#= $@ V !1 -, 6 #0 %\ S@!E ,P :P#* '$ R !W
M ,8 ?0#$ (0 P@", ,  E "^ )X NP"H +D M@"W ,@ M0#F +, ^@"Q /\
ML #_ +  _P"L /\ J0#_ /\   #_    ^@   /$   #H  , X  - -@ %@#1
M "( S0 M ,H -P#& $$ P@!* +\ 4@"] %D N@!? +@ 90"W &H M0!P +,
M=@"Q 'T KP"% *T C0"K )< J0"A *< K@"E +X H@#8 *  \@"? /\ G@#_
M )X _P"> /\ G #_ /\   #W    ZP   .$   #6    RP ) ,4 $0"_ !L
MNP F +< ,0"T #H L0!# *X 2P"K %( J0!8 *< 7@"F &0 I !I *( < "@
M '8 G@!^ )P A@": )  F "; )8 IP"4 +8 D@#* )  Z0"/ /P C@#_ (T
M_P", /\ C0#_ /@   #I @  VP,  ,P!  #$    O0 " +8 #0"P !4 JP @
M *< *@"D #0 H0 \ )X 1 "< $L F@!2 )@ 6 "6 %T E0!C ), :0"1 '
MCP!W (T @ "+ (H B0"5 (< H0"% *\ @P#! ($ X "  /4 ?P#_ '\ _P!_
M /\ ?P#_ .X*  #<#@  RA   +X.  "U"P  KP,  *D !P"C !  G@ 8 )D
M(P"6 "P DP U )  /@". $4 C !+ (H 40"( %< A@!= (4 8P"# &H @0!Q
M '\ >@!] (0 >P"/ 'D G !W *H =0"[ '0 U !R /  <@#_ '( _P!Q /\
M<0#_ .,1  #-%P  OQD  +,9  "J%0  HQ   )T*  "7 0H D0 2 (T &P")
M "4 A0 O (, -P"  #X ?@!% 'T 2P![ %$ >0!7 '@ 70!V &0 = %K '(!
M= !P G\ ;@*+ &P#F !K Z8 :02W &@%S@!G!^P 9@C] &8)_P!E"?\ 90G_
M -8:  #$(   MB,  *LC  "A(   F1L  )(4  ",#@$ A@<- ( $% !\!AX
M>0<H '8(, !T"#@ <@D_ ' )10!O"DP ;0I2 &P*6 !J"U\ : MG &<+< !E
M#'H 8PR' &(,E0!@#:0 7PVV %X-S@!<#NT 7 __ %L0_P!;$/\ 6Q#_ ,TA
M  "\*   KRL  *0K  ":*0  DB0  (D?  ""&   >Q$% '4-#P!Q#1< ;@XA
M &L.*@!I#S( 9Q Y &400 !D$$8 8Q!- &$04P!?$5H 7A%B %P1:P!;$78
M61*# %@2D@!6$Z( 51.T %03RP!3%.P 4A7_ %(6_P!2%?\ 4A7_ ,8H  "V
M+@  J3(  )\R  "5,0  C"T  (,G  !Z(0  <AH  &L3"P!G$Q, 9!0< &$4
M)0!?%2T 714T %P5.P!;%D( 619( %@63P!6%U8 51=> %,79P!2&'( 4!A_
M $\9C@!.&I\ 3!JP $L;QP!+&^D 2AS] $H<_P!*'/\ 2AS_ ,$M  "Q-
MI3<  )HX  "0-P  AS0  'TO  !T*0  ;",  &0<!P!>&1  6QH8 %D;(0!7
M&RD 51LP %0<-P!2'#T 41Q$ $\=2P!.'5( 31U: $L>8P!*'FX 21]\ $<?
MBP!&()P 12&N $0AQ !#(N8 0R+\ $,B_P!#(O\ 0R+_ +PR  "M.   H3P
M )<^  "-/0  @SH  'DU  !O,   9BH  %XD @!7( T 5" 4 %$@'0!/(24
M3B$L $PA,P!+(CH 22)  $@B1P!'(DX 1B-7 $0C8 !#)&L 0B1Y $$EB  _
M)ID /B:K #TGP0 ])^, /2CZ #TH_P ])_\ /2?_ +@V  "J/0  GD   )1"
M  "*0@  @#\  '8[  !L-@  8C   %DJ  !1)0L 3241 $LE&0!))2$ 1R8H
M $4F+P!$)C8 0R8] $(G1 !!)TL /RA4 #XH70 ]*6D /"EV #LJA@ Y*Y<
M."NI #<LOP W+.  -RSX #<L_P W+/\ ."S_ +4Z  "G0   G$0  )%&  "'
M1@  ?40  '-   !H.P  7S8  %4Q  !,*P< 1RD/ $4J%@!#*AX 02HE #\J
M+  ^*S, /2LY #PK00 [+$@ .BQ1 #DM6P X+F8 -BYS #4O@P T+Y4 ,S"G
M #(PO0 Q,=X ,3'W #(Q_P R,/\ ,S#_ +$^  "D1   F4@  (]*  "%2@
M>TD  '!%  !E0   6SL  %(V  !(,00 0BX- #\N$P ]+AL .RXB #DO*0 X
M+R\ -R\V #8P/@ U,$8 -#%/ #,Q60 R,F0 ,3)Q # S@0 O-), +C2F "PU
MNP L-=L +#7U "TU_P M-/\ +C3_ *Y!  "B2   ETP  (U.  "#3@  >4T
M &Y*  !B10  6$   $X\  !%-P  /3,+ #DS$0 W,Q@ -C,? #0S)@ S,RT
M,C0T #$T/  P-40 +S5, "XV5@ M-F( +#=O "LW?P J.)$ *#BD "<YN0 F
M.=@ )SGT "@Y_P H./\ *3C_ *M%  "?2P  E$\  (M2  "!4P  =U(  &Q/
M  !?20  5D8  $Q"  !"/0  .#@( #0X#P R.!4 ,3@= "\X)  N."L +3DR
M "PY.0 K.D$ *CI* "D[5  H.U\ )SQM "4\?0 D/8\ (SVB "(]MP A/M0
M(3[S "(]_P C/?\ (SS_ *A)  "=3P  DE,  (E6  !_5P  =58  &I3  !=
M3P  4TP  $I(  ! 1   -D % "\]#0 M/1, *ST: "H^(0 I/B@ *#XO "<^
M-P F/S\ )#]( "- 4@ B0%T (4%J "!!>@ >08T '4*@ !Q"M0 ;0M$ &T+Q
M !Q"_P =0?\ 'D'_ *5-  ":4P  D%@  (9;  !]7   <EL  &=8  !;5
M45(  $A.   ]2@  ,T<  "I#"P F0Q  )4,6 "1#'@ C1"4 (D0L "%$-  @
M13P 'D5% !U%3P <1EH &T9H !E&>  81XH %T>> !9'LP 42,X %4?O !9'
M_P 71O\ %T;_ *)2  "76   C5T  (1@  !Z80  <&   &5>  !96@  3U@
M $14   Y40  +TX  "9+!@ @2@X 'DH3 !U*&@ <2B$ &TLH !I+,  92S@
M%TM" !9,3  53%< %$QE !--=0 238@ $4V< !!-L0 .3LP #TWN !!-_P 1
M3/\ $4S_ )Y7  "470  BV(  (%E  !W9@  ;68  &-D  !680  2EX  #];
M   U6   *U8  ")4 0 :4@H %E(0 !52%@ 44AT $U(D !)2+  14C0 $5(^
M !!32  /4U0 #E-B  U4<@ ,5(0 "U28  E4K0 (5,4 "53G  I3^P +4O\
M"U+_ )M=  "19   B&@  'YK  !T;   :VP  %]J  !29P  160  #IB   P
M8   )EX  !U=   56P4 $%H,  Y:$0 .6A@ #5L@  Q;)P +6S  "ELZ  E;
M10 '6U$ !EM>  1;;0 #6X   5N4  !;J   6\   %KB  !:]@ !6O\  EG_
M )=D  ".:P  A&X  'MP  !R<@  9W$  %EP  !,;@  0&P  #5K   J:0
M(6<  !AF   19@$ #&4*  =E#P $910  V0;  )D(P  9"P  &0U  !D0
M9$P  &1:  !D:0  9'L  &2/  !CI   8[L  &+=  !B]   8O\  &'_ )-L
M  ")<0  @'4  'AW  !M>   8'<  %)V  !&=0  .70  "YT   C<@  &G$
M !)Q   -<0  !G$(  !P#0  <!(  ' 7  !O'P  ;R8  &\P  !O.P  ;T<
M &]4  !O9   ;W4  &Z*  !MH   ;;8  &S6  !K\@  :_\  &O_ (YS  "%
M>   ?7L  '-]  !E?@  6'X  $M^   ^?@  ,GX  "9]   <?   $WP   U\
M   &?0   'T%  !\"P  ? \  'P3  !\&0  ?"$  'PI  !\-   >T   'M.
M  ![7@  >V\  'J$  !ZF@  >;$  'C.  !W[P  =OX  ';_ (EZ  "!?P
M>((  &N#  !=A0  3X8  $*'   UB   *8<  !V'   4AP  #8@   :)
MB@   (H   ")!@  B0P  (D/  ")$P  B1H  (HB  "*+   BC@  (I&  ")
M5@  B6@  (E\  "(E   AZL  (;&  "%Z@  A?L  (3_ (6"  !]A@  ;X@
M &&+  !3C0  18\  #B1   KD0  'Y(  !22   -DP  !)0   "6    EP
M )@   "7    EP4  )<+  "8#@  F!,  )D:  "9(@  FBX  )H]  "930
MF5X  )ES  "8BP  F*,  )>\  "6X@  EO<  )7_ (")  !RC   9(\  %:3
M  !(E@  .ID  "R:   ?FP  %)P   R>   #GP   *$   "C    I0   *4
M  "E    I0   *8"  "G"   IPT  *@1  "I&0  JR,  *LQ  "K00  K%,
M *QG  "K@   JIH  *JS  "JT   J>\  *G[ '6/  !GE   69@  $J<   \
MGP  +:(  ""C   3I0  "Z<   &I    JP   *X   "Q    L@   +(   "S
M    M    +4   "V    N 0  +D+  "[$   O1@  +\D  "_-0  P$<  ,!;
M  # <@  P(T  ,&F  # P0  O^,  +[S &J7  !;G   3:$  #ZE   OJ0
M(:L  !.M   +L    +,   "U    N    +P   "_    P0   ,$   ##
MQ    ,8   #'    R0   ,L   #."   T0\  -48  #8)P  V3D  -I-  #;
M9   VWX  -R9  #<L   W,D  -SC %V?  !/I0  0*H  #*O   BL@  %+4
M  JX    NP   +\   ##    Q@   ,L   #.    T0   -$   #4    U@
M -D   #;    W@   .    #D    YP8  .L.  #O&0  \"H  /(_  #S50
M]&T  /2(  #TH0  ]+8  /3' /\ "0#_  8 _P ' /\ # #_ !$ _P < /\
M* #_ #0 _P!! /\ 3 #_ %4 _P!= /\ 90#_ &P _P!R /X > #\ 'X ^P"$
M /H BP#Y )( ]P"9 /8 H@#T *P \P"Y /$ RP#P .@ [@#[ .T _P#L /\
MX0#_ -( _P#) /\ Q #_ /\  0#_    _P   /\ ! #_  X _P 7 /\ (P#_
M "\ _P [ /T 1@#Z %  ]P!8 /0 7P#R &8 \ !L .\ <@#M '@ [ !^ .H
MA0#I (P YP"3 .4 G #C *8 X0"Q -\ P0#= -T VP#T -D _P#6 /\ SP#_
M ,0 _P"] /\ N0#_ /\   #_    _P   /\   #_  L _  3 /< '@#T "H
M\@ U .X 0 #I $H Y@!2 ., 60#@ &  W@!F -P ; #: '( UP!X -0 ?@#2
M (4 T "- ,X E0#, )\ R0"J ,< N #% ,T PP#K ,  _@"_ /\ O@#_ +8
M_P"P /\ K0#_ /\   #_    _P   /D   #R  8 ZP / .8 &0#A "0 W@ O
M -H .0#3 $, SP!, ,P 4P#) %H QP!@ ,4 9@## &L P0!Q +\ =P"] 'X
MNP"& +D C@"W )@ M0"C +, L "Q ,( K@#@ *P ]P"K /\ J@#_ *@ _P"C
M /\ H #_ /\   #_    ]0   .L   #A    U@ , ,\ $P#* !X Q@ I ,(
M,P"_ #T NP!% +@ 30"V %0 LP!: +$ 7P"P &4 K@!J *P < "K '< J0!_
M *< AP"E )$ HP"< *  J0"> +@ G #. )H [@"9 /\ EP#_ )8 _P"6 /\
MDP#_ /T   #Q    Y0   -D   #-    Q  & +T #P"W !@ LP B +  + "M
M #8 J0 ^ *< 1@"D $T H@!3 *  60"? %X G0!D )L :@": '  F !W )8
M@ "4 (H D0"5 (\ H@"- +  BP## (D XP"( /D A@#_ (8 _P"& /\ A@#_
M /,   #C    T0   ,4   "]    M@   *X "P"H !( I  < *  )@"< "\
MF@ W )< /P"5 $8 D@!, )$ 4@"/ %@ C0!= (L 8P"* &H B !Q (8 >0"$
M (, @@"/ '\ FP!^ *D ? "[ 'H U0!X /( > #_ '< _P!W /\ =P#_ .<'
M  #1#   PPT  +@,  "N"   J    *( !0";  X E@ 5 )( 'P". "@ BP Q
M (@ .0"& $  A !& (( 3 "  %( ?P!7 'T 70![ &, >@!K '@ <P!V 'T
M= "( '$ E0!P *0 ;@"T &P R@!K .H :@#\ &H _P!J /\ :@#_ -H0  #&
M%   N!8  *T5  "D$@  G X  )8'  "0  D B@ 0 (4 & "! "$ ?@ J 'L
M,@!Y #D =P!  '4 1@!S $P <@!1 '  5P!N %X ;0!E &L ;@!I '< 9P"#
M &4 D0!C )\ 8@"O &  Q !? .0 7P'X %X"_P!> O\ 7@+_ ,X8  "]'0
ML"   *4?  ";'   DQ<  (L1  "$#   ?@0+ 'D $@!U !L <@ C &\ *P!M
M 3, :P$Z &D"0 !G T8 9@-, &0$4@!C!%D 801@ %\%:0!>!7, 7 9_ %H&
MC0!9!YP 5PBM %8(P0!5">$ 5 OV %0+_P!4"_\ 5 O_ ,8?  "V)0  J2@
M )XH  "4)0  BR$  (,;  ![%   = X# &X)#0!I"!0 9@D= &0*)0!B"BT
M8 LT %X+.@!="T  6PQ' %H,30!8#%0 5PU< %4-9 !4#6\ 4@U[ % .B@!/
M#IH 3@ZL $P/P@!,$., 2Q#Y $L0_P!+$?\ 2Q#_ +\F  "P*P  I"\  )DO
M  "/+0  ABD  'TD  !T'@  ;!<  &41!P!?#A  7 \7 %H0'P!8$"< 5A N
M %00-0!3$#L 4A%" % 12 !/$5  3A%7 $P28 !+$FL 21)X $@3AP!&$Y<
M112I $04O@!#%=\ 0Q;X $,6_P!#%O\ 0Q;_ +HK  "K,0  H#0  )4U  "+
M-   @3$  '@K  !O)@  9B   %X9 0!7% T 5!03 %$4&P!/%2, 3A4J $P5
M,0!+%C< 218^ $@61 !'%TP 11=4 $0770!#&&< 01AT $ 9@P _&I0 /1JF
M #P;NP [&]L .QSV #P<_P \'/\ /!S_ +4P  "H-@  G#D  )$[  "'.@
M?C<  ',R  !J+0  82<  %DA  !1&PD 3!D0 $H:%P!(&A\ 1AHF $4;+0!#
M&S, 0ALZ $$<00! '$@ /AQ0 #T=60 \'F0 .QYQ #D?@  X'Y( -R"D #8@
MN  U(=8 -2'T #4B_P U(?\ -B'_ +(T  "D.@  F3X  (\_  "%/P  >SP
M ' X  !G,@  72T  %0H  !,(@4 1A\. $,?% !!'QL /Q\B #X@*0 ](#
M.R V #HA/0 Y(44 .")- #<B5P V(V( -"-N #,D?@ R)(\ ,26B "\EM@ O
M)M( +R;R "\F_P P)O\ ,";_ *\X  "B/@  ED(  (Q#  ""0P  >$$  &X]
M  !C.   6C,  %$N  !(* $ 0"0, #TC$0 [)!@ .20? #@D)@ V)"P -24S
M #0E.@ S)D( ,B9* #$G5  P)U\ +RAL "XH>P L*8T *RJ@ "HJM  I*L\
M*2OP "HK_P J*O\ *RK_ *P\  "?0@  E$8  (I'  " 1P  =D4  &Q"  !A
M/0  5S@  $XS  !$+@  /"D) #<H$  U*!4 ,R@< #(H(P P*"D +RDP "\J
M-P N*C\ +2M( "PK4@ K+%T *BQJ "@M>0 G+8L )BZ> "4NLP D+\T )"_N
M "4O_P E+_\ )B[_ *D_  "=10  DDD  (A+  !^3   =$H  &I'  !>0@
M5#T  $LY  !!-   ."\& #(M#0 P+1, +BT9 "TM(  K+2< *BXN "DN-0 I
M+ST *"]& "<P3P E,%L )#%H ",Q=P B,HD (3*= !\SL0 >,\L 'C/M !\S
M_P @,_\ (3+_ *9#  ":20  D$T  (9/  !\4   <T\  &A,  !<1@  4D,
M $D_   _.P  -C8" "XR#  K,A$ *3(7 "@R'@ F,B0 )3,K "0S,@ C-#H
M(C1# "$U30 @-5@ 'S9E !XV=0 <-X< &S>; !HWKP 9.,@ &3CK !HX_P ;
M-_\ &S?_ *-'  "830  CE$  (13  ![5   <5,  &90  !:3   4$D  $=%
M   ]00  ,ST  "HY"0 E-PX (S<4 "(X&P A."( (#@H !\X,  >.3@ '3E!
M !PZ2P :.E8 &3MC !@[<@ 6.X4 %3R9 !0\K0 3/<8 $SWI !0\_0 5//\
M%CO_ *!+  "540  BU4  ()8  !Y60  ;E@  &16  !840  3D\  $5+   Z
M1P  ,$,  "= !0 @/@T '3X1 !P^%P ;/AX &CXE !D^+0 8/S4 %C\^ !4_
M2  40%, $T!@ !)!<  108( $$&7  ]!K  .0L0 #D+G  ]!_  00?\ $$#_
M )U0  "35@  B5H  (!=  !V7@  ;%T  &);  !65P  3%4  $%1   V3@
M+$L  "-(   ;10D %T0/ !5$%  411L $T4B !)%*0 113$ $44[ !!&10 /
M1E  #D=>  U';0 ,1W\ "T>3  E'IP (1[X "$?@  E']@ *1O\ "T;_ )I5
M  "06P  AV   'UB  !S8P  :F(  &!A  !37@  1UH  #Q7   R50  *%(
M !]0   73@0 $4P,  ],$0 .3!< #DP>  U-)0 ,32X "TTW  I-0@ )34T
M!TY:  9.:0 $3GL  DZ/  %.I   3;H  $W;  %-\@ !3?\  DS_ )9;  "-
M8@  A&8  'IH  !Q:0  :&D  %QG  !/9   0F$  #=?   M7   (UH  !I8
M   25P$ #58)  E5#@ '51, !E4:  15(@ #52H  E4T  !5/@  54H  %97
M  !690  57<  %6+  !5H   5;8  %34  !4\0  4_T  %/_ )-B  "*:
M@&P  '=N  !O;P  8VX  %9L  !):@  /6@  #)F   G90  '6,  !5B   .
M80  "6 (  -@#0  7Q$  %\7  !?'@  7R8  %\O  !?.@  7T4  %]3  !?
M80  7G(  %Z'  !=G   7;(  %S/  !<[P  6_T  %O_ )!J  "&;P  ?7(
M '5T  !J=0  770  $]S  !"<@  -G   "MO   @;@  %VT  !!L   *;
M FL&  !K"P  :@\  &H4  !J&@  :B$  &DJ  !I-   :4   &E.  !I7
M:6T  &B"  !HF   9ZX  &;*  !E[0  9?P  &3_ (MQ  ""=@  >GD  '![
M  !B>P  57L  $AZ   [>@  +WH  "-Y   9>   $7<   IW   #=P   '<"
M  !W"   =@T  '80  !V%0  =AL  '8C  !V+@  =3H  '5'  !U5@  =6@
M '1\  !TD@  <ZH  '+$  !QZ0  </L  '#_ (9Y  !_?0  =G\  &B!  !:
M@@  3((  #^#   RA   )8,  !J#   1@P  "H,   *#    A    (4   "$
M P  @P@  (,-  "#$   @Q4  (0<  "$)@  A#(  (0_  "#3P  @V   ()U
M  ""C   @:0  ("]  !_XP  ?OD  '[_ (*   !ZA   ;(8  %Z(  !0B@
M0HL  #6-   GC0  &XT  !&.   *C@   (\   "1    D@   )(   "2
MD@$  )('  "2#   DA   ),5  "3'0  E"@  )0V  "410  DU<  )-K  "3
M@@  DIP  )&V  "0V   C_,  (__ 'Z'  !PB@  88T  %.0  !%DP  -Y4
M "F6   <EP  $9@   F9    FP   )P   ">    H    *    "@    H
M *$   "A!   H@D  *,.  "D%   I1T  *8J  "F.@  IDP  *5@  "E>
MI9(  *2L  "DR0  H^L  *+Z '..  !DD0  5I4  $>9   YG   *IX  !V@
M   1H0  "*,   "E    IP   *D   "L    K@   *X   "N    KP   +
M  "Q    L@   +,&  "U#0  MQ,  +D>  "Y+@  ND   +I4  "[:@  NH4
M +FA  "YNP  NMX  +GR &>5  !8F0  2IX  #NB   LI@  ':@  !&J   '
MK    *\   "Q    M    +@   "[    O    +P   "^    OP   ,    #"
M    Q    ,8   #( P  RPL  ,\2  #1(   T3(  -)&  #370  U'8  -22
M  #5JP  U<0  -3B %N=  !,H@  /:<  "^L   ?KP  $;$   >U    N
M +L   "^    P@   ,<   #*    S    ,P   #.    T    -(   #5
MV    -L   #?    X@   .8+  #K$P  ["0  .TX  #N3@  [V<  /""  #P
MG   \+(  /'% /\  P#_  $ _P $ /\ "0#_  \ _P 8 /\ ) #_ #  _P \
M /\ 1P#_ %$ _P!9 /\ 8 #] &< _ !M /H <P#Y 'D ^ !_ /8 A0#U (P
M\P"4 /( G0#P *< [@"S .P Q #K .$ Z@#X .D _P#G /\ V0#_ ,L _P#"
M /\ O0#_ /\   #_    _P   /\   #_  P _P 4 /\ ( #_ "L _@ W /H
M0@#V $L \@!3 /  6P#N &$ [ !G .H ;0#H ', YP!Y .4 ?P#C (8 X0".
M -\ E@#= *  VP"L -@ NP#4 -$ TP#P -  _P#. /\ R #_ +T _P"V /\
ML@#_ /\   #_    _P   /\   #]  @ ]P 0 /, &@#O "8 [0 Q .@ .P#C
M $4 X !- -P 50#9 %L U@!A -, 9P#1 &P SP!R ,T > #+ '\ R0"' ,<
MD #% )H PP"E ,  L@"^ ,4 O #E +H ^P"X /\ MP#_ +  _P"I /\ I0#_
M /\   #_    _@   /4   #L  , Y0 - -\ %0#: "  U  J -  -0#+ #X
MR !' ,4 3@#" %4 P !; +X 80"\ &8 N@!L +@ <@"V '@ M0"  +, B "Q
M )( K@"> *P J@"I +L J #5 *8 \P"D /\ HP#_ *$ _P"; /\ F #_ /\
M  #[    \    .4   #8    S@ ) ,< $0#" !H O@ D +L +@"W #@ M !
M +$ 2 "N $X K !4 *H 6@"I %\ IP!E *4 :P"D '$ H@!X *  @0"> (L
MG "6 )D HP"7 +( E@#' ), Z "2 /X D0#_ )  _P"- /\ BP#_ /D   #K
M    W0   ,\   #&    O  $ +4 #0"P !4 K  > *@ * "E #$ H@ Y )\
M00"= $@ FP!. )D 4P"7 %D E@!> )0 9 "2 &H D !Q (X >@", (, B@"/
M (@ G "& *H A "\ (( W "! /8 @ #_ '\ _P!_ /\ ?@#_ .P   #:
MR0   +X   "V    K@   *< "0"A !  G  8 )@ (@"5 "H D@ R )  .@"-
M $$ BP!' (D 30"' %( A@!8 (0 70"" &0 @0!K '\ <P!] 'T >P"( '@
ME0!V *, =0"T ', S !Q .T < #_ '  _P!P /\ < #_ -\%  #*"@  O L
M +$)  "H!   H0   )L  P"4  P CP 3 (H &P"' "0 A  L ($ ,P!_ #H
M?0!! 'L 1P!Y $P =P!2 '8 5P!T %T <@!D '  ;0!O '8 ; "" &H CP!I
M )T 9P"N &4 PP!D .0 8P#Z &, _P!B /\ 8P#_ - .  "_$@  LA,  *<2
M  "=$   E0L  (\#  ")  < @@ . 'X %0!Z !X =@ E '0 +0!Q #0 ;P Z
M &X 0 !L $8 :@!, &D 4@!G %@ 9@!? &0 9P!B '$ 8 !\ %X B0!< )@
M6P"I %D O !8 -P 6 #T %@ _P!7 /\ 5P#_ ,86  "V&@  JAT  )\<  "5
M&0  C10  (4/  !^"0  =P$* '( $ !N !< :@ ? &@ )P!E "X 9  T &(
M.P!@ $  7P!& %T 3 !< %, 6@!: %@ 8@!7 &P 50!W %, A0!2 )0 4 &E
M $\!N !. M( 303P $T%_P!-!?\ 307_ +\=  "P(@  HR4  )DE  "/(@
MA1T  'T8  !U$@  ;@T" &<&# !C Q$ 7P(9 %T#(0!;!"@ 600O %<%-0!6
M!3L 5 9! %,&1P!1!DX 4 =5 $X'7@!-"&< 2PAS $D)@0!("9( 1PJC $4*
MM@!$"]  1 SO $,-_P!##?\ 1 W_ +DD  "J*0  GBP  )0L  "**@  @"8
M '<A  !N&P  9A0  %\/!0!9"PT 50H3 %,+&P!1"R( 3PPI $T,+P!,##8
M2PT\ $D-0@!(#4D 1@U1 $4.6@!$#F0 0@YP $ .?P _#Y  /A"B #P0M@ [
M$-$ .Q'Q #L1_P [$?\ /!'_ +0I  "F+P  FC(  ) R  "&,0  ?"T  '(H
M  !I(P  81T  %D6  !1$0@ 3 \0 $H0%@!($!T 1A D $40*P!#$3$ 0A$W
M $$1/@! $44 /A)- #T25@ \$F$ .A-M #D3?  W%(T -A2? #45LP T%<T
M,Q;N #06_P T%O\ -!;_ *\N  "B-   ES<  (PX  ""-@  >#0  &XN  !E
M*@  7"0  %0>  !,& 0 1A0- $(4$@! %!D /Q0@ #T5)P \%2T .Q4T #D6
M.@ X%D( -Q9* #874P U%UX ,QAJ #(9>0 P&8H +QJ= "X:L0 M&\H +1OL
M "T<_P N&_\ +AO_ *PR  "?.   E#L  (H\  " /   =CD  &LT  !B+P
M62H  % E  !''P  0!H* #P9$  Z&18 .!D= #8:(P U&BD -!HP #,:-P R
M&SX ,1M' "\<4  N'5L +1UG "P>=@ J'H@ *1^; "@?K@ G(,< )B#J "<@
M_@ H(/\ *"#_ *DV  "=/   DC\  (=!  !]0   =#X  &DZ  !?-0  5C
M $TK  !$)0  .R ' #8>#@ S'A, ,AX9 # >(  O'B8 +A\M "T?-  L(#L
M*R!$ "HA3@ I(5@ )R)E "8B=  E(X4 (R.9 "(DK0 A),4 (27H "(E_0 B
M)/\ (R3_ *8Z  ":/P  CT,  (5%  ![1   <D,  &<_  !=.@  4S8  $HQ
M  !!+   ."8# #$C#  N(A$ +"(6 "HB'0 I(B, *",J "<C,0 F)#D )25!
M "0E2P C)E8 (B9C "$G<@ ?)X, 'BB7 !THJP ;*<, &RGF !PI^P =*?\
M'BC_ *,^  "80P  C4<  (-)  !Z20  <$<  &9$  !:/P  43L  $<W   ^
M,@  -2T  "PH"0 H)P\ )R<4 "4G&@ D)R$ (R@G "(H+@ A*38 ("D_ !\J
M20 >*E0 '2M@ !LK;P :+($ &2R5 !<MJ0 6+<$ %BWD !<M^@ 8+?\ &2W_
M *%!  "51P  BTL  ()-  !X30  ;DP  &1)  !81   3T   $8]   ].
M,S0  "HO!@ D+ T (2P2 " L&  ?+1X 'BTE !TM+  <+C0 &RX\ !HO1@ 8
M+U$ %S!> !8P;0 5,7\ $S&3 !(QJ  1,K\ $3+B !(R^0 3,?\ $S'_ )Y%
M  "32P  B4\  (!1  !V4@  ;5   &).  !620  348  $1#   [/P  ,3H
M "<V P ?,@L '#(0 !LR%0 9,AL &#(B !<S*0 6,S$ %30Z !0T1  3-$\
M$C5< !$U:P 0-GT #S:1  XVI@ --[P #3?=  TV]@ .-O\ #S;_ )M)  "1
M3P  AU,  'Y6  !U5@  :E4  &!3  !53P  3$P  $))   X10  +D$  "0]
M   <.@@ %C@. !4X$@ 4.!@ $SD? !(Y)@ 1.2X $#DW  \Z00 ..DP #3M9
M  T[:  +.WH "CN-  D\H@ '/+@ !SS5  @\\  )._\ "CO_ )A.  ".5
MA5@  'Q;  !R6P  :%H  %Y8  !350  25(  #Y.   T2P  *D<  "%$   8
M0@, $D + ! _$  ./Q4 #C\<  U (P ,0"L "T T  I /@ )04H !T%6  9!
M90 $078  T&*  %!GP  0;0  $'0  %![@ !0?P  D#_ )54  ",60  @UX
M 'E@  !P8   9F   %U>  !16P  15<  #I4   O40  )4\  !Q,   42@
M#D@(  M'#@ (1Q( !T<9  9'(  %2"@  T@Q  )(.P  2$<  $A3  !(8@
M2',  $B&  !(FP  2+$  $?,  !'[0  1_L  $?_ )):  ")8   @&,  '=E
M  !N9@  968  %ED  !,8   0%T  #5;   J60  (%<  !=5   04P  "U('
M  51#0 !4!$  % 6  !0'0  4"4  % N  !0.   4$,  %!0  !07@  4&\
M %"#  !/F   3ZX  $[)  !.ZP  3?L  $W_ (]A  "&9@  ?6D  '1L  !L
M;0  86L  %-I  !&9P  .F0  "]C   D80  &E\  !)>   ,7   !EP&  !;
M"P  6@\  %H3  !:&0  62$  %DI  !9,P  63\  %E,  !96@  66L  %A^
M  !8E   5ZL  %?%  !6Z0  5?L  %7_ (QH  "";0  >G   ')R  !G<@
M6G$  $QP   _;@  ,VT  "AK   =:@  %&@   UG   '9P   &8#  !F"0
M90T  &41  !D%0  9!P  &0D  !D+@  9#H  &-'  !C50  8V8  &-Z  !B
MD   8:<  &#!  !?Y@  7_H  %[_ (=O  !_=   >'<  &YX  !@>   4G<
M $5W   X=@  *W8  "!T   6<P  #G,   =R    <@   '(   !Q!0  <0H
M '$.  !P$0  <!<  ' >  !P)P  <#,  &]   !O4   ;V   &YT  !NBP
M;:(  &R\  !KX@  :O@  &G_ (-W  !\>P  <WT  &5^  !7?P  27\  #Q_
M   O@   (G\  !=^   /?@  !WX   !_    ?P   '\   !^    ?@4  'X*
M  !^#0  ?A$  'X7  !^(   ?BL  'TY  !]2   ?5D  'QM  !\A   >YP
M 'JV  !YV@  >/4  '?_ (!_  !W@@  :8,  %N%  !-A@  /X@  #*)   D
MB0  &(D   ^)   'B@   (L   ",    C0   (T   ",    C    (P#  ",
M"   C0T  (T1  "-%P  CB(  (XO  "./P  C5   (UD  ",>P  C)4  (NN
M  "*S0  B>\  (G_ 'N%  !MB   7HH  %"-  !"CP  -)$  ":2   9DP
M#I0   :5    E@   )@   ":    FP   )L   ";    FP   )L   "<
MG04  )T+  ">$   GQ<  * D  "@-   H$8  *!9  "?<   GXH  )ZE  ">
MP@  G>@  )SY '",  !ACP  4Y(  $26   VF0  )YL  !F<   /G0  !9\
M  "A    HP   *4   "H    J0   *D   "I    J@   *L   "L    K0
M *X!  "P"0  L@\  +,8  "T)P  M#D  +5-  "T9   M'X  +.:  "SM
ML]4  +/P &23  !5EP  1YL  #B?   IH@  &J0   ZF   $J    *L   "M
M    L    +0   "V    N    +@   "Y    N@   +P   "]    OP   ,
M  ##    Q0<  ,D/  #*&@  RRP  ,Q   #-5@  SF\  ,V+  #,J   S,(
M ,SB %B;  !)H   .J4  "RI   <JP  #ZX   2Q    M    +<   "Z
MO@   ,,   #&    R    ,@   #*    RP   ,T   #/    T@   -4   #9
M    W0   .$%  #F#P  YQX  .@R  #I2   ZF   .M[  #KEP  [*X  .S"
M /\   #_    _P   /\ !@#_  T _P 5 /\ (0#_ "P _P X /\ 0P#_ $P
M_@!4 /L 6P#Z &( ^ !H /8 ;@#U '0 ] !Z /( @ #Q (< [P"/ .T EP#K
M *$ Z0"M .< O0#E -@ Y #S .( _P#@ /\ T #_ ,0 _P"\ /\ M@#_ /\
M  #_    _P   /\   #_  D _P 1 /\ ' #] "< ^0 R /4 /0#Q $8 [0!/
M .L 5@#H %P Y@!B .0 : #C &X X0!S -\ >0#= (  V@"( -@ D0#4 )L
MT@"F ,\ M #, ,D R0#I ,@ _P#' /\ P0#_ +< _P"O /\ JP#_ /\   #_
M    _P   /\   #X  4 \@ . .X %P#J "( Y@ L .$ -P#= $  V !) -,
M4 #0 %8 S@!< ,P 8@#* &< R !M ,8 <P#$ 'D P@"! ,  B@"^ )0 O "?
M +D K "V +X M #= +, ]P"Q /\ L #_ *@ _P"B /\ G@#_ /\   #_
M^0   .\   #F    WP + -8 $@#0 !P S  F ,@ , #$ #H P !" +T 2@"[
M %  N !6 +8 6P"U &$ LP!F +$ ; "P '( K@!Z *P @@"I (P IP"8 *4
MI0"C +0 H #+ )\ [@"= /\ G #_ )D _P"4 /\ D0#_ /\   #V    Z@
M -T   #/    QP & ,  #P"[ !< MP @ +, *@"P #, K0 [ *H 0P"G $D
MI0!/ *, 50"B %H H !? )X 90"= &L FP!R )D >P"7 (4 E "0 )( G0"0
M *P C@"_ (P X@"+ /H B0#_ (D _P"& /\ @P#_ /0   #D    U    ,@
M  "_    M0 ! *X "P"I !( I0 ; *$ (P"> "P FP T )@ / "6 $, E !)
M )( 3@"0 %, C@!9 (T 7@"+ &0 B0!K (< <P"% 'T @P"( ($ E0!_ *0
M?0"U 'L SP!Y /$ > #_ '< _P!W /\ =0#_ .4   #1    PP   +@   "O
M    J    *  !@":  X E0 5 )$ '@". "8 BP M (@ -0"& #P A !" ((
M1P"  $T ?P!2 'T 6 ![ %X >0!E '@ ;0!V '8 <P"! '$ C@!O )T ;0"N
M &P Q !J .< :0#] &@ _P!H /\ :0#_ -4#  ##!P  M@@  *L&  "B
MFP   )0   "-  H B  0 (, & !_ "  ?  G 'H +@!W #4 =0 [ '0 00!R
M $< < !, &\ 4@!M %@ :P!? &D 9@!G '  90![ &, B !B )< 8 "G %X
MNP!= -P 7 #V %P _P!; /\ 6P#_ ,D-  "Y$   K!$  *$0  "7#0  CP@
M (@   ""  4 >P - '< $@!S !H ;P A &P * !J "\ :  U &< .P!E $$
M8P!& &( 3 !@ %( 7P!9 %T 80!; &H 60!U %< @@!5 )$ 5 "B %, M0!1
M ,\ 4 #O %  _P!0 /\ 4 #_ +\4  "P&   I!H  )D9  "/%@  AQ$  '\-
M  !W!@  <0 ( &L #@!G !0 9  ; &$ (@!> "D 70 O %L -0!9 #L 6 !!
M %8 1@!5 $T 4P!4 %( 7 !0 &4 3@!P $P ?0!+ (T 20"> $@ L !' ,<
M1@#I $8 ^P!& /\ 10#_ +@;  "J(   GB(  ),B  ")'P  @!H  '<5  !O
M$   : L  &$$"@!= !  60 6 %8 '0!4 ", 4@ J %  , !/ #4 3@ [ $P
M00!+ $@ 20!/ $<!5P!& 6$ 1 )L $,">0!! XD 0 .: #X$K0 ]!,0 / 7E
M #P'^  \!_\ / ?_ +(B  "E)P  F2D  (XI  "$)P  >R,  '$>  !I&
M81(  %H- P!3" P 3P41 $P%%P!*!AX 2 8D $<&*@!%!S  1 <V $,(/0!!
M"$, 0 A+ #X)4P ]"5T .PIH #H*=@ X"X< -PN9 #4+K  T#,( ,PSD #,-
M^0 S#?\ - W_ *TG  "@+   E2\  (LO  " +@  =RH  &TE  !D(   7!H
M %04  !,#P8 1@P- $,,$@!!#!@ /PP? #X,)0 \#2L .PTR #H-.  X#3\
M-PY' #8.4  T#EH ,PYF #$/=  P#X4 +A"8 "T0JP L$,, *Q'E "P1^@ L
M$?\ +1'_ *HL  "=,0  DC0  (<U  !]-   =#$  &HK  !@)P  6"$  $\;
M  !'%@  0!$) #L0#P Y$!0 -Q ; #80(0 T$"< ,Q$M #(1-  Q$3L ,!%#
M "X230 M$E< +!)C "H3<0 I$X( )Q25 "84J0 E%<  )!7C "46^@ F%O\
M)A7_ *8Q  ":-@  CSD  (4Z  ![.0  <38  &<Q  !=+0  5"@  $PB  !#
M'0  .Q<% #44#0 R$Q$ ,107 "\4'0 N%"0 +!0J "L5,0 J%3@ *19  "@6
M2@ G%U0 )A=@ "08;P C&(  (1F3 " 9IP ?&;X 'AK@ !\:^  @&O\ (!K_
M *,T  "8.@  C3T  (,^  !Y/0  ;SL  &4W  !;,@  4BT  $DH  ! (P
M.!X! # 9"@ L& \ *A@4 "D8&@ G&"  )ADG "49+0 D&C4 (QH^ "(;1P A
M&U( (!Q> !\=;  ='7X '!V1 !H>I0 9'KP &!_= !D?]@ :'_\ &Q[_ *$X
M  "5/0  BT$  (%"  !W0@  ;4   &,\  !9-P  3S,  $8N   ]*0  -20
M "T@!P G'0T )1T2 ",=%P A'1T (1TD " >*P ?'C( 'A\[ !T?10 <($\
M&B%< !DA:@ 8(GL %B*/ !4BHP 4([H $R/: !0C]0 5(_\ %B/_ )X\  "3
M00  B40  ']&  !U1@  ;$0  &)!  !7/   33@  $0T   \,   ,RL  "HF
M P C(@L ("$0 !XA%0 <(AL &R(A !HB*  :(S  &2,X !@D0@ 6)4T %259
M !0F:  3)GD $B:- !$GH@ 0)[@ #B?6 ! H]  1)_\ $2?_ )Q   "110
MAT@  'U*  !T2@  :DD  &!&  !500  3#X  $,Z   Z-@  ,3(  "@M   @
M*0D &R<. !DG$@ 8)Q@ %B<? !4H)0 4*"T $R@V !(I0  2*4L $2I7 ! J
M9@ .*W< #BN+  TLGP ,++4 "RS/  PL[P -+/\ #2O_ )E$  "/20  A4P
M 'Q.  !S3P  :4X  %Y+  !31P  2D0  $)    Y/0  +S@  "4T   =, 4
M%BT, !0L$  3+14 $BT< !$M(P 0+2H #RXS  XN/0 -+T@ #2]5  PP8P *
M,'0 "3"(  @QG  &,;$ !C'+  8QZP ',/P "##_ )=(  "-30  @U$  'I3
M  !Q5   9U(  %U0  !23   24H  $!&   U0@  *SX  "(Z   :-P$ $C0)
M  \S#@ .,Q, #3,9  TS(  ,-"@ "S0Q  HU.P (-48 !S52  4V8  $-G$
M C:$   VF0  -J\  #;(   VZ   -OD  37_ )1-  "*4@  @58  'A8  !O
M60  95@  %M5  !14@  1T\  #Q,   Q2   )T0  !Y!   6/P  $#P'  LZ
M#0 ).A$ "#L7  8['@ %.R8 !#LN  ([.  !/$,  #Q/   \7@  /&X  #R!
M   \EP  /*P  #O%   [YP  ._@  #O_ )%2  "(6   ?UP  '9=  !M7@
M8UT  %I<  !.6   0E0  #=1   M3@  (TL  !I)   21@  #40&  =##  #
M0Q   $,5  !#&P  0R,  $,K  !#-0  0T   $--  !#6P  0VL  $-^  !#
ME   0JH  $+#  !!Y@  0?D  $'_ (Y8  "&7@  ?6$  '-C  !K9   8F,
M %=A  !)70  /5H  #)8   G50  'E,  !51   .3P  "4T%  )-"P  3 X
M $P3  !+&   2Q\  $LH  !+,@  2ST  $M)  !+5P  2V<  $I[  !*D
M2:<  $G   !(Y   2/@  $?_ (M?  "#9   >F<  '%I  !I:@  7FD  %!F
M  !#9   -V$  "Q?   A70  &%L  !!9   *6    U<#  !7"0  5@T  %40
M  !5%0  5!L  %0C  !4+0  5#D  %1%  !44P  5&0  %-W  !3C0  4J0
M %&]  !0X@  4/@  $__ (AG  !_:P  =VX  &]P  !E<   5VX  $IL   ]
M:P  ,&D  "5H   :9@  $60   MC   $8@   &(!  !A!@  8 L  & .  !?
M$@  7Q<  %\>  !>*   7C,  %Y   !>3P  7E\  %UR  !=B   7*   %NY
M  !:WP  6?<  %C_ (1N  !\<@  =74  &MV  !==0  3W0  $)S   U<P
M*'(  !UP   3;P  #&X   1N    ;@   &X   !L @  ; <  &L+  !K#@
M:Q(  &H9  !J(@  :BT  &HZ  !I20  :5H  &EL  !H@P  9YL  &:U  !E
MV   9/4  &3_ (!U  !Z>0  <'L  &)[  !4?   1GP  #E\   L?   'WL
M !1Z   ->@  !'H   !Z    >@   'H   !Y    >0$  '@&  !X"P  > X
M '@3  !X&@  >"4  '@R  !W00  =U(  '=E  !V?   =94  '2O  !SS@
M<O$  ''_ 'Y]  !U@   9X$  %B"  !*@P  /(0  "Z%   AA0  %84   V%
M   #A0   (8   "'    B    (@   "'    AP   (<   "'!   APD  (<.
M  "($P  B!P  (@I  "(.   ATH  (==  "&<P  AHT  (6G  "$Q0  @^P
M (+^ 'B$  !JA@  7(@  $V*   _C   ,8X  "./   6CP  #9    *1
MD@   ),   "5    E@   )8   "6    E@   )8   "7    EP   )<'  "8
M#0  F1,  )H?  ":+0  FC\  )I2  "::   F8,  )F?  "8N@  E^(  );X
M &V*  !?C0  4)   $&3   SE@  ))<  !:8   -F0   9L   "=    GP
M *$   "D    I0   *0   "E    I0   *8   "G    J    *D   "J!
MK P  *X3  "N(0  KC,  *Y'  "N70  KG8  *Z3  "NK@  K<T  *SO &&1
M  !3E0  1)@  #6<   FGP  %Z$   VC    I0   *<   "J    K    +
M  "R    M    +,   "T    M0   +<   "X    N0   +L   "]    OP$
M ,,+  #%%0  Q24  ,8Y  #'3P  QV@  ,:%  #&H@  QKP  ,;> %69  !'
MG0  .*(  "FF   9J   #:L   "M    L0   +0   "W    N@   +\   #!
M    Q    ,,   #%    Q@   ,@   #*    S0   ,\   #2    U@   -L
M  #@#   X1@  .,K  #D00  Y5H  .9T  #FD0  Y:P  .7$ /\   #_
M_P   /\  0#_  H _P 2 /\ '0#_ "@ _P T /\ /@#] $@ ^@!0 /< 5P#U
M %T ] !C /( :0#P &\ [P!T .T >P#K ($ Z0") .@ D@#F )P Y "H .(
MMP#? ,T W #N -D _P#9 /\ R@#_ +X _P"U /\ L #_ /\   #_    _P
M /\   #_  8 _P / /P & #X ", ]  N /  . #K $( Z !* .4 40#B %@
MX != -X 8P#< &@ V0!N -8 = #4 'L T0"" ,\ BP#- )4 R@"A ,@ KP#%
M ,$ P@#C ,  ^P#  /\ NP#_ +  _P"H /\ I #_ /\   #_    _P   /L
M  #S  $ [0 , .@ $P#C !X X  H -H ,@#3 #P SP!$ ,P 2P#) %$ Q@!7
M ,0 70#" &( P0!G +\ ;0"] '0 NP![ +D A "W (X M "9 +( IP"O +<
MK0#0 *L \@"J /\ J0#_ *$ _P"; /\ EP#_ /\   #_    ]    .D   #@
M    U0 ( ,X $ #) !@ Q0 B ,$ *P"\ #4 N0 ] +8 10"S $L L0!1 *\
M5@"N %L K !A *H 9@"I &T I@!T *0 ? "B (8 H "2 )X GP"< *X F0##
M )< YP"6 /\ E0#_ )( _P"- /\ B@#_ /P   #P    XP   -0   #(
MOP # +D #0"S !, KP < *P )0"I "X I0 V *, /@"@ $0 G@!* )T 4 ";
M %4 F0!: )< 7P"6 &8 E !L )( =0"0 'X C@"* (L EP") *8 AP"X (4
MU@"$ /8 @@#_ ($ _P!^ /\ ? #_ .T   #=    S    ,$   "X    K@
M *< "0"B !  G@ 7 )H 'P"7 "< E  O )$ -P"/ #T C0!# (L 20") $X
MB !3 (8 60"$ %\ @@!E (  ;0!^ '< ? "" 'H CP!X )X =0"O ', QP!R
M .P <0#_ '  _P!P /\ ;@#_ -T   #)    O    +$   "I    H0   )D
M P"3  P C@ 2 (H &0"' "$ A  I ($ , !_ #< ?0 ] 'L 0@!Y $@ > !-
M '8 4@!T %@ <@!? '$ 9P!O '  ; ![ &H B !H )< 9@"H &4 O !C .$
M8@#Z &$ _P!A /\ 80#_ ,T!  "\!0  KP4  *4"  "<    E    (T   "&
M  @ @0 . 'P % !X !L =0 C '( *0!P #  ;@ V &T / !K $$ :0!' &@
M3 !F %( 9 !9 &, 8 !A &D 7P!T %T @0!; )  60"A %< M !6 -  50#R
M %4 _P!4 /\ 50#_ ,$,  "R#@  I@\  )L.  "2"P  B04  ((   ![  (
M=0 + '  $ !L !8 :  = &8 (P!C "H 80 P &  -@!> #L 70!! %L 1@!:
M $P 6 !3 %8 6P!4 &0 4@!N %$ >P!/ (H 30"; $P K@!+ ,8 2@#J $D
M_@!) /\ 20#_ +D2  "J%@  GA<  )06  "*$P  @1   'D+  !Q P  :P &
M &4 #0!A !$ 70 8 %H '@!8 "0 5@ J %0 , !3 #8 40 [ %  00!. $<
M30!. $L 5@!) %\ 1P!I $8 =@!$ (4 0P"7 $$ J0!  +\ /P#B #\ ^  ^
M /\ /P#_ +(9  "D'@  F!\  (X?  "$'   >A@  '(2  !J#@  8@@  %P!
M" !7  X 4P 3 %  &0!. !\ 3  E $H *P!( #  1P V $8 / !$ $( 0P!)
M $$ 40 _ %H /@!E #P <@ Z ($ .0"3 #@ I0 V +H -@#; #4 ]  U /\
M-0#_ *P@  "?)   E"8  (DF  !_)   =2   &P;  !D%0  7!   %0, 0!.
M!@H 2@(/ $< % !$ !H 0@ @ $  )0 _ "L /@$Q #P!-P [ CX .0)% #@#
M30 V U8 -01A #,$;@ Q!7X , 60 "\%HP M!K@ + ;4 "P'\  L"/\ + C_
M *@E  ";*@  D"P  (8M  ![*P  <B<  &@B  !?'0  5Q<  $\2  !(#@0
M00H+ #X'$  [!A4 .0<; #@'(0 V""8 -0@L #,(,@ R"3D ,0E! "\)20 N
M"E, + I> "L+;  I"WP * R/ "8,H@ E#+< ) S3 ",-\  D#?\ )0W_ *0J
M  "8+P  C3(  (,R  !Y,0  ;RX  &4I  !<)   4Q\  $L9  !#$P  /! &
M #4-#  S#!$ ,0P6 "\,'  N#2( +0TH "L-+@ J#34 *0T] "<.1@ F#E
M) Y< ",/:@ B#WL (!". !\0H@ =$+< '!#4 !T1\@ =$?\ 'A'_ *$O  "5
M,P  BC8  ( W  !V-@  ;3,  &,O  !9*@  4"4  $@@   _&@  .!4  # 1
M"  L$ X *A 2 "@0&  G$!X )1 D "00*@ C$3( (A$Z "$10P @$DX 'A):
M !T3:  ;$W@ &A.+ !@4H  7%+4 %A31 !85\0 7%?\ &!3_ )XS  "3-P
MB#H  'X[  !T.P  :S@  &$T  !7+P  3BL  $4F   ](0  -!P  "T7!0 F
M$PP (Q,0 "(3%0 @$QH 'Q,A !X4)P =%"\ '!4W !L500 :%DL &197 !<7
M90 6%W8 %!B) !,8G@ 2&+, $1G. !$9[P 2&?\ $QG_ )PV  "1.P  ACX
M 'P_  !S/P  :3T  %\Y  !5-0  3#   $,L   Z)P  ,B(  "H> 0 B&0D
M'A<. !P7$@ :%Q< &1@> !D8)  8&2P %QDT !8:/@ 5&DD $QM5 !(;8P 1
M''0 $!R'  \=G  .';$ #1W+  T=[  .'?\ #QW_ )DZ  "//P  A$(  'M$
M  !Q0P  :$(  %X^  !3.@  2C8  $$R   Y+0  ,2D  "@E   @( 8 &AT,
M !<<$  5'!4 %!T; !0=(@ 3'2D $AXR !$?/  0'T8 $"!3  X@80 -(7$
M#"&%  LBF0 *(JX "2+'  DBYP *(OL "R'_ )<^  ",0P  @T8  'E(  !P
M2   9T8  %Q$  !2/P  23L  $ X   X-   +S   "<L   >)P, %B,* !(A
M#@ 1(1, $"(9 ! B(  /(B< #B,O  TD.0 ,)$0 "R50  HE7@ ))F\ !R:"
M  8FE@ $)JP  R;$  0FY0 $)O< !B;_ )5"  "*1P  @4H  'A,  !O3
M94L  %M(  !01   1T$  #\^   W.P  +38  "0Q   ;+0  $RH'  \H#0 -
M)Q$ #2@6  PH'0 +*"4 "BDM  DI-P '*D( !BI.  0K7  #*VP  2M_   K
ME   *ZD  "O!   KXP  *_8  "K_ ))&  "(2P  ?T\  '91  !M40  8U
M %I-  !/2@  1T<  #Y$   S0   *3P  " X   7-   $3$%  PO#  )+A
M!RX5  8O&P %+R,  R\K  (P-0  ,#\  #!,   Q60  ,6D  #%\   QD0
M,:<  #"_   PX0  ,/4  "__ )!+  "&4   ?50  '56  !K5@  8E4  %A3
M  !.4   14T  #I)   O10  )4(  !P^   4.P  #CD%  DW"P $-@\  383
M   V&0  -B   #8I   V,@  -ST  #=)   W5P  -V<  #=Y   WCP  -J4
M #:]   VX   -?4  #7_ (U0  "$5@  ?%H  ');  !I6P  8%L  %=9  !,
M5@  0%(  #5.   J2P  ($@  !=&   00P  "T$$  1 "@  /PX  #X1   ^
M%@  /AT  #XF   ^+P  /CH  #Y&   ^5   /F0  #YV   ]C   /:,  #R[
M   \W@  ._4  #O_ (I7  ""7   >5\  '!A  !H80  7V$  %1>  !'6P
M.E<  "]5   E4@  &U   !)-   ,2P  !DH#  !)"0  2 T  $<0  !'%
M1AH  $8B  !&+   1C<  $9#  !&40  1F   $5S  !%B0  1*   $2X  !#
MW   0O4  $+_ (A=  !_8@  =V4  &YG  !G:   6V8  $YC  !!80  -%X
M "E<   ?6@  %5<   Y6   '5    %,!  !2!@  40L  %$.  !0$0  3Q8
M $\>  !/)P  3S(  $\_  !/30  3ET  $YO  !.A0  39T  $RU  !+V
M2O4  $K_ (5E  !\:0  =&P  &UN  !B;0  5&L  $=I   Z9P  +64  ")D
M   88@  $&    E?    7@   %X   != P  7 @  %L,  !:#P  6A,  %D9
M  !9(@  62T  %DZ  !92   6%@  %AK  !7@0  5YD  %:R  !5T@  5/0
M %/_ (%L  !Y<   <W,  &AS  !:<@  3'$  #]P   R;P  )6X  !IL   1
M:P  "6H   !J    :0   &D   !H    9P,  &8(  !F#   9@\  &44  !E
M'   92<  &0T  !D0P  9%,  &1E  !C>P  8I0  &&M  !@S0  7_$  %[_
M 'UT  !W=P  ;GD  %]Y  !1>0  0WD  #9X   I>   ''<  !%V   *=0
M '4   !U    =@   '4   !T    =    ',"  !S!P  <PP  '(0  !R%0
M<B   '(L  !R.P  <4P  '%?  !Q=   <(X  &^H  !NQ@  ;.T  &O_ 'M[
M  !R?@  9'X  %5_  !'@   .8$  "N"   >@0  $H$   J!    @0   ((
M  "#    @P   (,   ""    @@   ((   ""    @@4  ((*  ""#P  @A<
M ((C  "",@  @D,  (%6  "!;   @(8  '^A  !^O0  ?>8  'S\ ':"  !H
M@P  684  $N'   \B0  +HH  ""+   3BP  "HL   ",    C0   (\   "1
M    D@   )$   "1    D0   )$   "1    D@   )("  "3"0  E \  )09
M  "4)P  E#@  )1,  "38@  DWP  ).8  "2LP  D=@  )#V &J(  !<B@
M38T  #^0   PD@  (90  !25   *E@   )<   "9    FP   )T   "?
MH    *    "@    H    *$   "B    HP   *0   "E    I@<  *@0  "H
M'   J"T  *E   "I5@  J6\  *F+  "HJ   I\<  *;L %^/  !0D@  098
M #.9   CG   %)T   J?    H0   *,   "F    J    *P   "N    KP
M *\   "P    L    +(   "S    M    +8   "W    N@   +T'  "_$
MOQ\  , S  # 20  P&(  ,!^  # FP  P+<  +_8 %.7  !$FP  -9\  ":C
M   6I0  "Z<   "J    K0   +    "S    M@   +L   "]    P    +\
M  #!    P@   ,0   #&    R    ,H   #,    SP   -,   #:!P  VQ,
M -TE  #>.P  WU,  .!N  #?C   W:D  -W" /\   #_    _P   /\   #_
M  < _P 0 /\ &0#_ "0 _P O /P .@#Y $, ]0!+ /, 4@#Q %D [P!> .T
M9 #K &D Z0!O .< =0#F 'P Y "$ .( C0#@ )< W0"B -H L0#5 ,4 T@#H
M -  _P#/ /\ Q #_ +@ _P"O /\ J0#_ /\   #_    _P   /\   #_  (
M^P - /< %0#S !\ [P I .H - #F #T X@!% -X 3 #; %, V !8 -0 7@#2
M &, T !I ,X ;@#, '4 R@!] ,@ A0#& )  P@"; ,  J0"^ +H NP#9 +D
M]P"X /\ M #_ *D _P"B /\ G0#_ /\   #_    _P   /8   #N    YP *
M .$ $0#< !H UP C -  +@#+ #< QP _ ,0 1@#! $T OP!2 +T 6 "[ %T
MN0!B +@ : "V &X M !U +$ ?@"O (@ K0"3 *H H0"H +$ I@#( *0 [0"B
M /\ H@#_ )L _P"5 /\ D0#_ /\   #\    [@   .,   #8    S0 % ,8
M#@#! !4 O0 > +D )P"U #  L@ X *\ 0 "L $8 J@!, *@ 40"G %8 I0!;
M *, 80"A &< GP!N )X =@"; (  F0", )< F0"4 *@ D@"\ )  WP". /L
MC@#_ (L _P"& /\ @P#_ /@   #I    W    ,P   #!    N    +( "@"L
M !$ J  8 *4 (0"B "D G@ R )P .0"9 #\ EP!% )4 2@"4 %  D@!5 )
M6@"/ &  C0!G (L ;P") '@ A@"$ (0 D0"" *  @ "R 'T S !\ /$ >P#_
M 'H _P!W /\ =0#_ .8   #3    Q@   +L   "Q    IP   *$ !0";  T
MEP 3 ), &P"0 ", C  K (H ,@"( #@ A@ ^ (0 1 "" $D @0!. '\ 4P!]
M %D >P!@ 'D : !W '$ =0!\ ', B0!P )@ ;P"I &T OP!K .8 :@#_ &D
M_P!I /\ 9P#_ -,   ##    M0   *L   "C    FP   )(   ",  H AP 0
M (, %@!_ !T ?0 D 'H *P!X #( =@ X '0 /0!R $( <0!( &\ 30!M %,
M; !9 &H 80!H &H 9@!T &0 @0!A )$ 7P"B %X M@!< -4 6P#W %L _P!:
M /\ 6@#_ ,4   "V @  J0(  )\   "6    C@   (<   "   4 >@ , '4
M$0!Q !@ ;@ > &L )0!I "L 9P Q &8 -P!D #P 8P!! &$ 1P!? $T 7@!3
M %P 6P!: &0 6 !N %8 >P!4 (H 4@"; %$ K@!0 ,@ 3P#N $X _P!. /\
M30#_ +L*  "L#0  H T  )4,  ","   @P(  'P   !U    ;@ ( &D #@!E
M !, 8@ 9 %\ 'P!= "4 6P K %D ,0!8 #8 5@ [ %4 00!3 $< 40!. %
M50!. %X 3 !H $H =0!( (0 1P"5 $4 J !$ +\ 0P#D $( _ !" /\ 0@#_
M +(1  "E%   F14  (X3  "$$0  >PT  ',(  !L    90 # %\ "P!;  \
M5P 4 %0 &@!1 !\ 3P E $X *P!, #  2P V $D / !( $( 1@!( $4 4 !#
M %D 00!C #\ ;P ^ 'X / "0 #L HP Z +@ .0#9 #@ ]0 X /\ . #_ *P7
M  "?&P  DQT  (D<  !_&0  =14  &P0  !D#   708  %8 !@!1  P 30 0
M $H %0!' !H 10 @ $0 )@!" "L 00 Q #\ -@ ^ #T / !$ #L 2P Y %0
M-P!? #8 :P T 'H ,@", #$ G@ P +, +P#. "\ [P N /\ +@#_ *<>  ":
M(@  CR0  (0D  !Z(0  <1T  &<8  !?$P  5PX  % *  !) P@ 10 - $$
M$0 ^ !8 /  ; #H (0 Y "8 -P L #8 ,@ T #@ ,P _ #$ 1P P %  +@!;
M "T 9P K '8 *@"( "@ G  G +  )@#) "4 Z@ E ?L )0'_ *(C  "6*
MBRH  ($J  !W*   ;24  &0@  !;&P  4A4  $L0  !## ( /0<) #D##@ V
M 1( ,P$7 #$!'  P 2( +P(G "T"+0 L S0 *@,[ "D$0P H!$T )@58 "4%
M90 C!G0 (@:& " &F@ ?!ZX '@?& !T'YP ="/@ '0G_ )\H  "3+0  B"\
M 'XO  !T+@  :BL  &$F  !8(0  3QP  $<7   _$@  . X$ #$+"@ N" X
M*P<2 "D'%P H"!T )P@C "4(*0 D"3  (PDW "$*0  @"DH 'PM5 !T+8@ ;
M#'( &@R% !@,F0 7#*T %@S& !4-Y@ 5#?D %@W_ )PM  "0,0  AC0  'PT
M  !R,P  :#$  %\L  !5)P  3",  $0=   \&   -!,  "T0!@ F#0L ) P/
M "(,$P A#!D 'PP? !X-)0 =#2P &PTT !H./0 9#D< %PY3 !8.80 4#W$
M$Q"$ !(0F  1$*X $!#& ! 0Z  0$/L $1#_ )DQ  ".-0  A#@  'HY  !P
M.   9S8  %TR  !3+0  2B@  $(D   Y'P  ,1H  "H5 0 C$0< '1 - !L/
M$  9#Q4 &! ; !<0(0 6$"D %1 Q !01.@ 3$44 $A)1 !$27P 0$F\ #A."
M  X3E@ -$ZL "Q/"  L4XP ,%/H #1/_ )<U  ",.0  @CP  '@]  !O/0
M93H  %LW  !2,@  22X  $ J   W)0  +R$  "@<   @& , &10* !42#@ 4
M$A( $Q,8 !(3'P 1%"8 $10N ! 4.  /%4( #A9/  T67  ,%VP "Q=_  D8
MDP (&*@ !AB_  <8X  '&/4 "1C_ )4X  "*/0  @$   '=!  !M00  9#\
M %H\  !0.   1S,  #XP   V*P  +B<  "<C   ?'P  %QH( !(7#0 0%Q$
M#Q<6  X8'  .&", #1DL  P:-0 +&D  "AM,  D;6@ ''&D !1Q\  0=D0 "
M':8  1V\  (<W0 "'/(  QS_ ),\  "(00  ?T0  '5%  !L10  8T0  %E!
M  !//0  1CD  #XV   U,@  +BX  "4J   =)0  %"$$  \="P -'1  #!T4
M  L=&@ *'B( "!XJ  <?,P &(#X !"!*  ,A5P !(6<  "%Y   AC@  (:0
M "&Z   AVP  (?(  "#^ )!   "&10  ?4@  '1*  !K2@  8DD  %A&  !.
M0@  13\  #T\   U.0  *S0  "(O   9*P  $B@$  TD"@ )(PX !B,2  4C
M&0 $)"   B0H  $E,0  )3P  "5(   F50  )F4  "9W   FC   )J(  ":Y
M   FV0  )?(  "7^ (Y%  "$20  >TT  '-/  !J3P  8$X  %=+  !-2
M1$4  #Q"   Q/0  )SD  !XU   5,@  #RX#  HL"@ %*PX  2H1   J%@
M*AX  "HF   K+P  *SD  "M%   L4P  +&(  "QU   LB@  *Z   "NW   K
MU@  *O(  "K_ (Q)  ""3@  >E(  '%4  !H5   7U,  %91  !,3@  0TL
M #='   M0P  (S\  !H\   2.   ##8#  8S"0  ,@T  #(0   Q%   ,1L
M #$C   Q+   ,C<  #)#   R4   ,F   #)R   RAP  ,9X  #&U   PU
M,/(  "__ (E/  " 5   >%<  &]9  !F60  7ED  %57  !)4P  /D\  #),
M   H2   'D4  !5"   .0   "#T"  $\"   .PP  #H/   Y$@  .1@  #D@
M   Y*0  .30  #E    Y3@  .5T  #EO   XA0  .)P  #>S   WT@  -O(
M #7_ (=5  !_6@  =ET  &U?  !E7P  75\  %)<  !$6   .%4  "U2   B
M3P  &$P  !!*   *2    T8!  !%!@  1 H  $,-  !"$   014  $$=  !!
M)@  03$  $$]  !!2@  05H  $%L  ! @0  /YD  #^Q   ^T   /?(  #S_
M (1<  !\8   <V,  &QE  !D9@  660  $MA   ^7@  ,EL  "99   <5@
M$E0   Q2   $40   $\   !. P  30@  $P,  !+#@  2Q(  $H9  !*(@
M2BP  $HY  !*1P  2E8  $EH  !)?@  2)8  $>O  !&S0  1?$  $3_ (%C
M  !Y9P  <FH  &ML  !@:P  4FD  $1F   W9   *F(  !]@   57@  #5T
M  9;    6@   %D   !8    5P0  %8(  !6#   51   %04  !4'0  5"<
M %0T  !40@  4U(  %-D  !2>0  4I(  %&K  !0R@  3^\  $[_ 'YJ  !W
M;@  <'$  &9Q  !8<   2F\  #QM   O;   (FH  !=I   .9P  !F8   !E
M    90   &4   !C    8@   &($  !A"   80T  & 0  !@%P  8"$  %\N
M  !?/   7TT  %Y>  !>=   78T  %RG  !;Q0  6NT  %G_ 'MR  !U=@
M:W<  %UV  !/=@  074  #-U   F=   &7,  !!R   '<0   '$   !Q
M<0   '$   !O    ;P   &X   !N @  ;@@  &T,  !M$0  ;1H  &TF  !L
M-0  ;$8  &M8  !K;0  :H8  &FA  !HO@  9^@  &;^ 'EZ  !P?   87P
M %-]  !$?0  -GX  "A^   ;?0  $'T   =]    ?0   'T   !^    ?P
M 'X   !]    ?0   'P   !\    ?    'P&  !\#   ?!(  'P=  !\+
M?#P  'Q/  ![90  >WX  'J:  !YM@  >-\  '?Z '.   !E@0  5H,  $B$
M   YA@  *X<  !V'   1AP  !X@   "(    B0   (H   ",    C0   (T
M  ",    C    (P   ",    C    (T   "-!   C@P  (X3  "/(0  CC(
M (Y&  ".6P  C70  (V0  ",K0  B\X  (KS &B&  !:B   2XL  #R-   M
MCP  'I   !&1   'D@   ),   "5    EP   )D   ";    G    )L   ";
M    G    )P   "=    G@   )X   "?    H0,  *(,  "B%@  HR8  *,Z
M  "C3P  HV@  **&  "BH@  HL   *'H %R-  !-D   /Y,  #"6   AF0
M$IH   >;    G0   *    "B    I    *@   "J    JP   *H   "K
MK    *T   "N    KP   +$   "R    M    +<!  "Y#0  N1H  +HM  "Z
M0P  NEL  +IW  "[E   N[$  +G2 %"5  !!F   ,IP  ".@   3H@  "*0
M  "G    J@   *P   "O    L@   +<   "Y    NP   +H   "\    O0
M +\   #     P@   ,0   #&    R0   ,T   #2 0  U \  -4?  #7-0
MV$T  -AI  #7A@  UZ,  -:] /\   #_    _P   /\   #_  , _P - /\
M%0#_ "  _  K /@ -0#T #\ \ !' .X 3@#K %0 Z0!: .< 7P#E &0 XP!J
M .$ < #? '8 W0!^ -L AP#8 )$ TP"= ,\ JP#- +T RP#@ ,D ^P#' /\
MO0#_ +$ _P"I /\ HP#_ /\   #_    _P   /\   #\    ]@ + /$ $0#M
M !L Z0 E .0 , #? #D V@!! -4 2 #1 $X SP!4 ,T 60#+ %X R0!C ,<
M:0#% &\ PP!W ,  ?P"^ (H NP"5 +@ HP"V +0 M #- +( \@"P /\ K #_
M *, _P"< /\ EP#_ /\   #_    ^@   /$   #H    X  & -D #@#2 !8
MS@ ? ,@ *0#$ #( P  Z +T 00"Z $@ N !- +8 4P"T %@ L@!= +  8@"N
M &D K !O *H > "H (( I@". *0 FP"A *L GP#  )T Y@"; /\ F@#_ )0
M_P". /\ B@#_ /\   #V    Z    -P   #.    Q@ ! +\ "P"Z !$ M@ :
M +( (@"N "L J@ T *@ .P"E $$ HP!' *$ 3 "? %$ G@!6 )P 7 ": &(
MF0!H )< < "5 'H D@"& )  DP"- *( BP"U (D TP"' /< A@#_ (0 _P!_
M /\ ? #_ /(   #C    T@   ,4   "Z    L0   *L !P"E  X H0 4 )X
M' ": "4 EP M )0 - "2 #H D !  (X 10"- $H BP!0 (D 50"( %L A@!A
M (0 :0"" '( ?P!] 'T BP![ )H > "K '8 Q !T .L <P#_ ', _P!P /\
M;@#_ -\   #,    OP   +0   "K    H0   )H  @"4  L D  0 (P %P"(
M !X A0 F (, +0"! #, ?P Y 'T /P![ $0 >0!) '@ 3@!V %0 = !: ',
M8@!P &L ;@!U &P @P!J )( : "C &8 N !D -X 8P#[ &( _P!B /\ 8 #_
M ,P   "\    KP   *4   "=    E    (P   "&  < @0 - 'P $@!X !D
M=0 ? ', )@!Q "T ;P R &T . !K #T :@!" &@ 2 !G $X 90!4 &, 6P!A
M &0 7P!N %T >P!; (H 60"; %< KP!6 ,L 50#R %0 _P!4 /\ 5 #_ +X
M  "P    I    )D   "0    B    ($   !Y  ( <P * &\ #P!K !0 9P :
M &4 ( !C "8 80 L %\ ,@!> #< 7  \ %L 0@!9 $< 5P!. %8 50!4 %X
M4@!H %  = !. (, 3 "5 $H J !) ,  2 #H $< _P!' /\ 1P#_ +0)  "F
M"P  FPP  ) *  "&!0  ?@   '8   !O    :  % &, # !? !  6P 5 %@
M&@!6 "$ 5  F %, + !1 #$ 4  V $X / !- $( 2P!( $D 4 !( %@ 1@!B
M $0 ;@!" 'T 0 ". #\ H@ ] +@ /0#= #P ^  \ /\ / #_ *P0  "?$@
ME!(  (D1  !_#P  =@P  &X%  !F    8  ! %D " !5  T 40 1 $X %@!+
M !L 20 A $@ )@!& "L 10 Q $, -@!" #P 0 !# #X 2P ] %, .P!= #D
M:0 W '@ -@") #0 G  S +$ ,@#. #( \0 Q /\ ,0#_ *86  ":&0  CAH
M (0:  !Z%@  <!(  &@.  !?"@  6 ,  %$ ! !,  H 2  . $0 $@!! !8
M/P ; #T (0 \ "8 .@ L #D ,0 W #< -@ ^ #0 1@ S $\ ,0!9 "\ 90 N
M ', + "% "L F  J *T *0#& "@ Z@ H /X * #_ *$<  "5(   BB$  '\A
M  !U'P  ;!H  &,6  !:$0  4@T  $L'  !$  8 0  + #P #P X !( -@ 7
M #0 '  S "$ ,0 G #  +  N #, +0 Z "L 0@ J $L * !5 "8 80 E '
M) "! "( E0 A *D ( #! "  Y  ? /D 'P#_ )TB  "1)@  AB@  'PG  !R
M)0  :2(  %\=  !7&   3A,  $8.   _"P  . 4' #0 #  Q !  +@ 3 "P
M&  J !T *0 B "< *  F "X )  V ", /@ B $< ( !2 !\ 7@ = &T ' !^
M !H D@ 9 *< & "] !< WP 7 ?4 %P+_ )HG  ".*P  A"T  'DM  !P*P
M9B@  %TD  !4'P  2QH  $,4   [$   - T" "T)"0 I!0T )@,0 "0!$P B
M AD (0(> " ")  > RH '0,R !L$.@ :!40 &05/ !<&7  6!FH % =\ !,'
MD  2!Z4 $0>[ ! 'VP 0"/( $ G_ )<K  ",+P  @3$  '<R  !N,0  9"X
M %LJ  !1)0  22   $ ;   X%@  ,1(  "D.!  C# D 'PD- !T'$  ;!Q4
M&0@: !@((  7"2< %@DN !4*-P 3"D$ $@M- !$+6@ 0"VD #@Q[  X,D  -
M#*4 # V[  L-V0 +#?$ # W_ )4O  "*,P  ?S8  '8V  !L-0  8S,  %DO
M  !0*P  1R8  #XA   V'0  +A@  "<3   @$ 4 &0X* !4,#@ 4#!$ $PP6
M !(,'  1#2, $ TK  \--  .#C\ #0Y*  P/6  +#V< "A!Y  @0C0 '$*(
M!A"X  40U  %$.\ !A#_ )(S  "(-P  ?CH  '0[  !K.@  83@  %@U  !.
M,   12P  #TG   U(P  +1\  "8:   >%@$ %Q,& !$0"P .#@X #@\3  T0
M&0 -$"  #! H  L1,@ *$3P "!)(  <250 &$V4 !!-V  ,3BP !%*   !.V
M   3T0  $^X  !/[ ) V  "&.P  ?#X  ',_  !J/P  8#T  %<Y  !--@
M1#$  #PN   T*@  +"8  "4B   >'@  %AH" ! 5"0 ,$PX "A,2  D4%P (
M%!\ !Q4F  85+P $%CH  Q9&  $74P  %V(  !AT   8B0  &)\  !BU   7
MT   %^T  !?[ (XZ  "$/P  >T(  ')#  !H0P  7T(  %8_  !,.P  0S<
M #LT   S,   +"P  "0I   ;)   $Q\"  T;"0 )&0T !AD1  09%@ "&1T
M 1HD   :+0  &S@  !M$   <40  '&   !UR   =AP  ')T  !RS   <S@
M&^T  !O\ (P^  ""0P  >48  '!(  !H2   7D8  %5$  !+0   0ST  #LZ
M   S-P  *C(  " M   7*0  $"4"  LB"0 %( T  1\0   ?%   'QL  " B
M   @*P  (38  "%!   A3P  (5X  ")P   BA0  (9L  "&R   AS0  (.T
M !_\ (I#  " 2   >$L  &],  !F30  74L  %1)  !*1@  0D,  #I    O
M.P  )3<  !PS   3+P  #2P"  <I"  !)PP  "8.   E$@  )AD  "8A   F
M*0  )C,  "<_   G30  )UP  "=M   G@@  )YD  ":P   ES   )>X  "3]
M (A(  !_3   =E   &Y1  !E4@  7%$  %-/  !*3   04D  #5$   K0
M(3P  !<Y   0-@  "C(!  ,P!P  +PL  "X.   M$0  +18  "T>   M)P
M+3$  "T]   M2@  +5D  "UK   M@   +)<  "RO   KRP  *NX  "K^ (5-
M  !]4@  =54  &Q7  !C5P  6U8  %-5  !'40  .TT  #!)   E1@  '$,
M !,_   -/0  !CH    X!0  -PD  #8-   U#P  -!0  #0;   T)   -"X
M #0Z   T1P  -%<  #1H   T?0  ,Y4  #*M   QR@  ,>X  ##_ (-3  ![
M6   <UL  &I=  !B70  6UT  $]:  !"5@  -E(  "I/   @3   %DD   Y'
M   (1    $(   !! P  /P<  #X+   ]#@  /1$  #P8   \(0  /"L  #PW
M   \1   /%,  #QE   [>@  .I(  #JK   YR   ..T  #?_ (%:  !Y7@
M<6$  &EC  !B9   5V(  $E>   \6P  +U@  "15   94P  $%$   I/   !
M30   $P   !*    200  $@(  !'#   1@\  $84  !%'   12<  $4S  !%
M0   15   $1A  !$=@  0X\  $*H  !!Q@  0.P  #__ 'YA  !V90  ;V@
M &AJ  !=:0  3V8  $)D   T80  *%\  !U=   26P  "UD   )8    5@
M %8   !4    4P   %($  !1"0  4 T  % 0  !/&   3R(  $\N  !//
M3TL  $Y=  !.<@  38L  $RE  !+P@  2>H  $C_ 'MI  !T;   ;F\  &1O
M  !5;0  1VP  #EJ   L:0  (&<  !1E   -9    V(   !B    80   &
M  !?    7@   %T   !<!   7 D  %L-  !;$@  6QP  %HH  !:-@  6D8
M %E8  !9;0  6(4  %>@  !6O0  5>@  %/^ 'EP  !S=   :74  %MT  !,
M<P  /G,  #!R   C<0  %F\   UN   $;0   &T   !M    ;0   &P   !K
M    :@   &D   !I    :0,  &@)  !H#@  :!4  &<A  !G+P  9S\  &92
M  !F9@  97\  &2:  !CMP  8N$  &'\ '=X  !M>@  7WH  %!Z  !">@
M,WL  "5[   8>@  #GD   1Y    >0   'D   !Z    >@   'H   !X
M>    '<   !W    =P   '<!  !W"   =PX  '<8  !W)@  =C8  '9)  !U
M7P  =7<  '23  !SKP  <M,  ''W '%^  !C?P  5(   $6"   V@P  *(0
M !J$   .@P  !(0   "$    A0   (8   "(    B0   (@   "'    AP
M (<   "'    AP   (@   "(    B <  (D0  ")'   B2P  (@_  "(50
MB&T  (>)  "&IP  A<<  (3O &:$  !7A@  2(@  #F*   JC   &XT   ^-
M   $C@   )    "1    DP   )4   "7    F    )8   "7    EP   )<
M  "8    F    )D   ":    FP   )T'  "=$0  G2$  )TS  "=20  G&(
M )Q_  "<G   G+D  )OB %J+  !+C@  /)$  "V3   >E0  $)8   28
MF@   )P   ">    H0   *0   "F    IP   *8   "G    IP   *@   "I
M    J@   *P   "M    KP   +$   "S"0  LQ4  +0G  "T/0  M54  +5P
M  "TC@  M*P  +3, $V2   _E@  +YH  ""=   1GP  !:$   "C    I@
M *D   "L    KP   +,   "U    MP   +8   "W    N    +H   "[
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M______________________________________________________\
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M______________;$FG-%)C1]S/_______________________________[6
M53 * !E@LO______________________________SW0U"P    I2I_______
M________________________EC0       !/I_______________________
M_______V:1T   D,!@E2L?_____________________________+.PX3-4Q;
M34Q>P_____________________________^I8#9@AI^VK*FXV?__________
M___________________@EXV^Y?__________________________________
M____[?G_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^O9RKS'___________________________________/
MFH%M6D:(ZO_______________________________\1\/B80  !4L/______
M________________________X(,\       NA^W_____________________
M________K%,0       7;=;____________________________[@#$
M   )8<S____________________________26@(         7<S_________
M__________________^H-0          7-/_________________________
M__]]#0          5-;__________________________^Y]10
M1-3___________________________RJ9"\"   $(C=)6,[_____________
M_______________II&M!*#]C?Y6GNMK_____________________________
M_]6RK++,Y/K_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^6[EW=BR/______
M___________________________;GF<V"@ "C/______________________
M_________\A_/P4     7L______________________________V8$Y
M    /*K_____________________________GDP         (Y#_________
M___________________<;QH         $'WY________________________
M__^O2            &_N__________________________^$$P
M &3F_________________________^Q1             %?>____________
M_____________[@5             $C6_________________________W04
M             #C/________________________^:):$P           "/%
M_________________________]^;7"P           VZ________________
M___________OL7U5.2(1!P$"$2*R_______________________________?
MOZ69F)J@K+W:________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________COIV ?/O________________________________RMX17
M, X ':S______________________________]**3!4      '+S________
M____________________UG\V         $O)________________________
M___ZD3X          "^K___________________________ 6@
M !J5__________________________^-)             B$____________
M_____________^=>              !W_________________________[0E
M              !J_________________________WT               !;
M]/_______________________2L               !,Z_______________
M________I0                 \X?______________________, P
M           MV?____________________^9BF$G               GU___
M____________________[;Z)52<            EW/__________________
M_______^RIUV74H\,BTL,#E'WO_______________________________>;=
MUM+0T]GD____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^_4N];_________
M________________________Y[B/:DLO%6__________________________
M_____^2A9S0'     #S)____________________________UH([
M !*7___________________________MA3$           !O____________
M______________^F0@            !0X?_______________________^QI
M               WR?_______________________[,O               B
MMO_______________________WD                0I_______________
M________\C0                 F?______________________J0
M            C/______________________1@                  ?___
M___________________?                    =/__________________
M__^7                    :O_____________________.
M        8_______________________*2(!                8?______
M________________N:. 5S<7            :/______________________
M____^M.NE(9\=7%P<G>!E/______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________;NIV"
M:6G3_______________________________(DV4]&0   !V>____________
M________________VXY,$P        !N___________________________;
M?"P           !%U_________________________^+*@             B
MM/_______________________\)$               #E_______________
M_________WT!                ?_______________________YS8
M            :O______________________G0                  6/__
M____________________1@                  1_C_________________
M___I                    ->G___________________^6
M        )=O___________________^\                    &,[_____
M_______________K                    #\+_____________________
M                    "KG_____________________)P
M    "K7_____________________<                   #;G_________
M____________X)R,<%5",R8;% \-#A(:)K__________________________
M___YY-C2SLS+S,_6X/S_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________KT[SC____________________________
M____TJF%94@L$@&%____________________________\:MQ/ \       !/
MX/_________________________5?S4            ?LO______________
M_________^-U'0              B?_______________________Y C
M            9_______________________U4,                 2/;_
M____________________B@                  +MW_________________
M____.                   %\C___________________^^
M        !+;___________________^<                     *7_____
M______________^Z                     )/____________________<
M                     (+_____________________
M     '3_____________________$P                   &C_________
M____________0@                   &#_____________________>@
M                 %W_____________________T0
M &'______________________R0                  &;_____________
M_________\FLF8E]=G%L:6=F9VMP>HS_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________BQ:J1>6%W________________
M_____________]VF=U L#      QQ/_________________________@DDX3
M            C________________________])P'0              8/__
M____________________[F\/                -^+_________________
M____EAP                 %,#_____________________0
M         */___________________^N                     (G_____
M______________^>                     '+___________________^\
M                     %_____________________:
M     $W____________________Z                     #O_________
M____________#@                   "KY____________________,P
M                 !OI____________________7@
M  _;____________________CP                    ;0____________
M________T                     #*_____________________RL
M              #(_____________________X                    #+
M______________________<6 04% P$       $&#1C+________________
M_______\Z^'8S\S-S]#2U-?<XNK_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________\=K&_______________________________QQJ.$:$TR&  5J___
M________________________N7Q&&           <?__________________
M_____]=\+P              .^/_____________________WV0)
M        #+7_____________________= ,                  (W_____
M_______________%%0                   &K___________________^9
M                     $O___________________^V
M     ##]___________________7                     !GG________
M___________V                      73____________________#@
M                  #!____________________+P
M  "O____________________4@                    ">____________
M________>0                    ".____________________I0
M              " ____________________V                     !T
M_____________________S8                   !M________________
M_____WP                   !I_____________________]<-
M          !H______________________]P                  !A____
M____________________4#Q&3E1976%D:&QP=GZ)____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________OU;NCBW-:E?__________________________^+^.9$$A
M!0      4OS_______________________>=5A@             %\'_____
M________________Y6P6                 (W_____________________
M8P                   %[___________________^=
M     #7\__________________^A                     !'9________
M___________*                      "[___________________N
M                  "A____________________#
M  "*____________________+0                    !V____________
M________30                    !D____________________;P
M              !2____________________E                     !
M____________________O                      P________________
M____Z@X                    B_____________________T0
M           5_____________________X$                    +]?__
M_________________\@+                   "[/__________________
M__]>                    Y?_____________________)'
M        VO______________________G0$             !PX7Q?______
M_________________]6YO,''SM7;X>;M]/O_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________C?S_______
M_______________________LQJ6(;50[(0< ,M[_____________________
M___7DEDI             *#______________________XDV
M     &?_____________________9@                   #+V________
M__________^5                      /(__________________^G
M                  "@___________________7
M  !\____________________                      !>____________
M________)0                    !#____________________2
M               L____________________:@                     8
M____________________BP                     %\_______________
M____KP                      X?__________________U0
M            S____________________R0                     OO__
M_________________U0                     KO__________________
M_XL                     G____________________\L.
M        DO____________________]7                    AO______
M______________^J"@                  >?______________________
M;0                  9O______________________]U4
M    1?________________________]J(RLU/TI58&IU?H>1G/__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________Z,^V
MG8-I3KG_________________________[+*#7#H= @       'O_________
M_____________\5M*0               $#_____________________@QL
M                  ?+__________________^2
M  "8__________________^D                      !J____________
M_______=                      !!____________________#@
M               =____________________.0
MZ/__________________8                       SO______________
M____A0                      M___________________J
M            H___________________RP                      D/__
M________________[Q8                     ??__________________
M_SX                     ;/___________________VD
M        6O___________________YD                     2?______
M_____________](6                    .?____________________]8
M                    *?____________________^B
M    &?_____________________U5@                  !/__________
M____________NR\                  /C______________________ZLI
M                 ,_________________________)1P     '$R N/E)H
MA.W_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________TU<G_________________________
M___ZTK"2=UU"* P  $K________________________%?447
M !'8____________________Q%                    "?____________
M______^B#                     !H__________________^4
M               V___________________:                       '
M[/__________________%0                      Q/______________
M____2                       HO__________________=0
M            @___________________G0                      :?__
M________________PP                      4O__________________
MYP\                     /O___________________S,
M        *____________________U@                     &/______
M_____________X$                     !?___________________ZP
M                     /___________________]XB
M     /+___________________]<                     -__________
M__________^?                     ,S____________________H2@
M                 +?_____________________H!8
M )S______________________WH"                 '?_____________
M__________]Z"P              !4S_________________________HE=H
M=("-G*N\T.?_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________[>/_____________
M_____________]*C>E@Z*2,<%@X&  "?_____________________ZQ2#@
M              !I___________________D0P                     T
M__________________]Y                        X_______________
M___-                        LO__________________$P
M            A?__________________3P                      7?__
M________________@P                      .O__________________
ML@                      '/__________________VP,
M         O___________________RH                      /O_____
M_____________T\                      .?__________________W0
M                     -3__________________YL
M     ,#__________________\0'                     *W_________
M__________ S                     )K___________________]G
M                 (;___________________^C
M '+____________________C1                    %S_____________
M________D08                  $'_____________________ZU\
M             !W______________________\I+                  #_
M_______________________+5P  #!@D,3].8'2+I\?_________________
M_________]?G\O______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________^O4S<?"OKJWL["MJ:BE________________
M____W7Y3/S C&1$) @          V_________________]V
M            I_________________^Z                        =?__
M________________!P                      1O__________________
M3@                      &O__________________C
M         /W_________________P0                       -O_____
M____________\1D                      +[__________________T0
M                     *3__________________VL
M     (W__________________Y$                      'G_________
M_________[<                      &;__________________]XA
M                 %/___________________]*
M #____________________]W                     "O_____________
M______^L"@                   !;____________________G10
M              #_____________________B@                    #_
M____________________UDT                   #]________________
M_____Z<N                  #5______________________^8*@
M    !A@M16#@________________________J&-T@8^<J[O-XOK_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^?+MZF=E8Z)A(!\>'1P;&AED/________________^\
M:D@M&0H                 ,?__________________
M         ___________________0@                       -S_____
M____________C@                       ++_________________S@
M                     (W__________________RD
M     &O__________________UH                      $[_________
M_________X8                      #3__________________ZX
M                 ![__________________]07
M  K___________________H]                      #_____________
M______]E                      #___________________^.
M              #___________________^\&0                    #O
M___________________Q3@                    #8________________
M____BP                    "_____________________S$,
M          "A_____________________Y$9                  !Z____
M__________________)T"@               !%?____________________
M___H=!,?+#A%4V)RA9NTTO7__________________________]?H]/______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________^_?S\>[LZ^OL\?______
M____________V;*9AWEM9%U644M&03PX,BTH(\3_________________2R4+
M                     )+_________________B
M     &;_________________UP                       #W_________
M_________S,                      !C__________________VP
M                  #__________________YT
M  #__________________\D,                      #V____________
M______$U                      #?__________________];
M              #+__________________^"                      "W
M__________________^I!@                    "C________________
M___3+P                    "-____________________7@
M          !W____________________DP<                   !>____
M________________S4,                   ! ____________________
M_X<0                   <_____________________]A>
M        ______________________^_3@      #APL/E)JAJ7(________
M________________PGR,FJ>VQ=;H_?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________[N'7S\G#OKJVL:VIIZ:FIZ[_________
M________OH9M6TQ -R\H(AP6$ L$     !3_________________UP4
M                  #__________________S0
M  #V_________________W8                       #2____________
M_____[                        "R_________________^$D
M              "6__________________]1                      !\
M__________________]Y                      !F________________
M__^@                      !1___________________'(P
M           \___________________N2P                     G____
M________________=                      0____________________
MHQ8                     ____________________V$P
M        _____________________X@/                    ________
M_____________\M3                    ______________________^E
M.           "1TT3FN,________________________F3E#45]N?8Z@M<OE
M_____________________________^OY____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________^O,N:RAF9&+AH%\>'1P:VAF9FCQ____________
M_____V%%,B,8#@8               ">_________________WX
M              !U_________________\,                       !2
M__________________LW                       R________________
M__]J                       6__________________^6
M            __________________^_&P                      ____
M_______________F0@                      ____________________
M:0                      ____________________D (
M        ____________________N2P                     ]/______
M____________Z%P                     V?___________________Y$8
M                    O/___________________\I3
M    G?____________________^8+@             0*49FQ/__________
M___________N?QT,&B@W1E=I?I6OS.[_________________________YZ"J
MN<C8Z?S_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________]]?#KYN+?V]C4TM'0TM?@
M_________________\Z>BGQQ:6%;5E%,2$,^.C8R+RXQ________________
M_](E$0,                     __________________]"
M            __________________]]                        ____
M______________^P"P                      ]O_________________=
M.0                      W/__________________8@
M        Q?__________________B0                      K_______
M____________KR(                     F?__________________UD@
M                    @O___________________W(
M    :?___________________Z$H                    3O__________
M_________]-<                    ,_____________________^6+@
M            %3)2=______________________@<A,   $/'R]"6'"+J,CL
M________________________RF]N?HZ>L,/8[_______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________YX-+(P+JUL*RHI:*?G9N;G*"G____
M______________^"9%9+0SPV,"LG(AT8$PX)!   U/________________^2
M                        K?_________________,'@
M        B__________________[4@                      ;?______
M____________@                       4?__________________J1L
M                    .O__________________T$(
M    (___________________]6@                     #/__________
M_________X\4                     /___________________[@^
M                 /___________________^5M P
M /____________________^?-P              $"]0=/______________
M_______=<A0     !A<J05IUE+;:________________________O%A$5&1U
MAIJOR./______________________________]+-X?'_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________S[
M^OO]_______________________NN:B=EH^*AH)_>WAV=')S=7A_D/______
M___________K3SHP*"$;%1 +!P(         (___________________:0
M                     /__________________FPH
M     /__________________R#D                      /__________
M________\&,                      /___________________XH.
M                 /___________________[ T
M /___________________]5;                     /______________
M______^%&@                   ^S___________________^Q20
M        &#E=@?_____________________E>QX       PA.%)OC[/9____
M____________________NU@I.4E:;("7L,WM________________________
M_____[.>M,77Z_______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________KOY^'<V=;4TM#0T-'3
MV>#K]___________________N(I^=W%L:&1A7EM96%=765YE<?__________
M________OS$?%A *!0               /__________________[58
M                 .C__________________X($
M ,S__________________ZLO                     +/_____________
M_____])7                     )O___________________=\$
M             (7___________________^B-P                 %*Y3_
M___________________+80(            ,+%!VGM'_________________
M___UC3        TC.U=VF;[E________________________PV,8*CM,7W2-
MI\;G_____________________________ZA_EJB[T.?_________________
M___________________]________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________]W.Q;^\N;:TL[&RLK6YP,G5
MX____________________Y=L9%Y955%/3$I(1T9(2U!99J'_____________
M_____Z<F#@<"                 %;__________________\Y0
M             #K___________________1Y"P                   "'_
M__________________^?,@                    [_________________
M___$6                 @Q6H3____________________I?Q\
M  8G2W&:PNG_____________________ITD      A<O2FB*KM7\________
M________________TW4>)CA*7G6/J\OO____________________________
M_ZYRA9BLPMOV___________________________________?[___________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________^_LJJFHZ&@GY^AHZ:LM,#-W>S_
M__________________^*6E-/2TA&1$-"04)#1TY9:7W_________________
M__^>+@8                   #____________________#5@
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M______\
M
M                                                         /__
M____________________________________________________________
M____________________________________________________________
M________________________________________________    _]L 0P "
M 0$" 0$" @(" @(" @,% P,# P,&! 0#!0<&!P<'!@<'" D+"0@("@@'!PH-
M"@H+# P,# <)#@\-# X+# P,_]L 0P$" @(# P,& P,&# @'" P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S?%OB&
M/PEX4U+5I@K1Z;:RW3;G\M2L:%CENPXZ]NM:5<5^T:^S]GSQXW]WP[J!/_@-
M)6=27+%R-L/3=2I&FNK2^]V$^!?QKT_XY^ [37+)K*,73R((8+Q;G&QRI^8
M9Z>G%=M7P3_P24^+BWVG:/X9C:7RPE[-M,2[?OEOO=:^]JY\#BHUZ7M(GJ\0
M9+6RO%O"UE9[_BU^@4445V'B!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(^AY%:E?J\975T?PQ4IRA)PENM&%%%%,@**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLIJ*,G#N?G_'F#E.E#$K:.C^=K?D?5]%%%?0'Y:%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !117'?&KXLV/P9\(1ZOJ"RM#)<); (RJ=S!B/O$#^$U,
MI**NS2E3E4FH0W9^)'_!?C]IBW^-/QG\)KIMU8W%K;:--:RFV+[0PN&."">O
M2OSSKJ/BUX_U'X@>+;FXU"\N+QH9I5C,IR44N3@5R]?&U*CG)R?4_H3+\)'#
M8>-"&T4%%%%9G8%%%% !1110 4444"N%?IU_P;O_ +2?_"-?%+1?AJ\UBO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-W_ (.#OVFK
M'PM^S@GAG3KFUFU[3_$UB\]K-;3?)&UI.^=_"'[Z=&[].#C]$O$^N1^&/#FH
M:G-M\G3[:2Y?<X0;44L<D\#IU[5_/!_P6K_:)N_BQ^V_X\L;>\N6T,3:;-!;
MB[\ZW1ETRV!*@<9W%N1W)KS,SK<M+E74^NX-R_V^.]I+:"O\[K3\3X\ED,LC
M,>K$DXIM%%?-'[,%%%% !1110 4-THHSGH-WTH$^P+R*:)23M7DFK-EI4ETW
MWF48S@K6W9Z!%"-S"-F!SRM1*JEN;T,'4J/W=#'M=#FO.2AP1GAA6Q8:''8-
MG=)USR0>U7%184 557MQ1OW#^M<TJSEL>S1R^E3UE\1^\?\ P1'_ &D[?XK?
ML_Z9X/AFLY)/!6@6,+K';RI(N=Z_.S?*WW?X:^XZ_!G_ ((K?M1R_ 3XF>)+
M>XFFEAUQ;"SC0WH@5,2N.A!W?>Z"OWF#;NG-?79/B/:4+/=?TC\ XZROZGF4
MI15HSU7K97_%A1117K'Q84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\_?\%(/
MCIIOPB_91^(EO<7+6^IZEX.UDV*^09%>1;.0+D@8'S,O6OYHO''C"[\>>*;K
M5KYD>ZN]F\HFU3M14''T45^H?_!Q%^U/'JOC;PEH.C7D<T*Z=JEA>K9:J&56
M,D:$2H@Z]?E;W%?E-7R^8UN>K;HC]HX/RWZM@E4EO/5_D%%%%<&Y]8%%!XH<
ME@ B[OI1H3S,"-HIIDW':O)SBK%II,UV_*R(.>2AK;L="CMHU+,CM@'E*B51
M1.BCA:E;961C6>BS7)&5XY[UL66A1VIW,&SP>M75547A0OT%+G ]:Y95G(]?
M#Y?"GOJ"*(T^7I2E<BD X_I3JP9WI):(;C%&SFG44@L;GPTUUO#GC[1;Q6"+
M;W]O*Q*[L!9%/2OZ5/V0?CI'^T1\'8_$45P+I6O)K8N(##RF.-I^M?S'HYC<
M,K%64Y!!QBOV$_X($?M26\GPYTCX<W5Q#/J=]J6H78,NIAIPHC#X$!&XCY#S
MGIDU[62XCDK<CVE_2/SWQ%RMXG +$15Y4]?E:[_)'Z@4445]D?@(4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%1SW"6D#R2,J1QJ69B<  =30!Y
MW^T_^T'I?[-7PYB\1:Q)=16LM['9@P0"9BS*[#Y<],(>:_F#_:7^+FJ?&#XD
M:O?:E<K<B*[N5MR(5CVHTK,,A0/7O7Z8?\'#O[:<&OW.H?"O3;BU$NCZKIVI
M&>WOCYS V;L08P.!^^'.>PK\D[YV>*1FR2P)))Y-?-X^O[2IRK9'ZQPME?U?
M!^VFO>G9_+I^9G)]VEI$^[2UQGO!1110(**** "BBB@ HHHH **** "@G%%!
MYH&%&.:**  =::R;S3J*%8-.HU2T!S'U]ZV-&\<W%HP6:3Y2Q) 0>E9&,TI
M(Z"IE&,M)&E&O5I2YJ<FCOM,\1VNHQ#ERY )RN.35UH<G<.E>9)OA;<LC=<X
M!K9TGQI)9,JR1[@N3EG-<E3"]8GT6%SY27+B%\SLR,(PK+NABZ-6+'Q+;:C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-;JYU*30Y4U#4'M8;.W9#(8P0WF'$G\(XSBOVMTR_35-.M[I RQW$:RJ&^\
MP!&??FOY/O"?BJZ\&ZRM]9G$RJ4'S%>#UZ$&OZ)/^"5W[6UC^TM\!-/L;>\T
MRXN?".D:58W*VN_?&YM]I$F[/S9B/3T->_E&*?\ !E\C\KX^R3E:S"DM-I:>
M>_SN?4U%%%?0GY>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[_U+?[M<1]+4^%E!/NTM(GW:6M#@"BBB@04444 %%%% !1110 4444 %%%%
M!136;%/2WDDZ+P?>@:38TG%+% TQJ]::4JIN;<&QZBK2J(1\OZU/,=%/#R>L
MBK;Z5\HW;3Q5I$6 <+CZ4I;-(3FHN=4:<8[ 3NHS114&@ <U8B^457'6IT^[
M0]BZ>X\#CFFG!'2G'[E-J34<)&3[K;:GMM0V##9/%5J#'N6C0<92CJC3BE67
MVJ01XK)3]TW'ZU,FJ,H"MM].AK-Q?0Z88A?:+[1\U]@?\$B_VR+_ /9X^.>B
M^'%O=6ALO&GB;1[2X6WD187C^T>61)N(^7$IZ=LU\=Q3+,/E;/X5>T/5YO#^
MMV=_"L;36,Z7$:N"5+*P89P0<<>HJJ<Y4Y*2Z$XO#TL31E1GJI(_K \.Z_;^
M)]'AOK5UDAGW;2K!@<$J>1QU%:%?G_\ \$1?VX=)^*WP)\(_#VXOM/7Q-86>
MHWEQ9065RA11?RL#YC9C/RR*<!L\^H(K] *^TPM95::FC^=<VRZ>!Q4L/-;-
MV\U?1_,****Z#S0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ#4*,XHHH !\QI61<=*2B@ 61H_NLP]JM0:CR RD]N357/%'>BPXRE'8]_\
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MZ$5(*<7&2T9_4+^P;^TKIW[3W[-GA?Q)#<6<>H:G;S336*:DM[-;A+B2++,
M&(.T')4?> ]Z]KK\-_\ @A5^WQ)\)/&FI>&_$MQ>S^&]+\/2I96]I91-)'*U
MW&^2Q*L1AGZD]:_<BOJ\OQ'M:=WNMS\.XDRMX+&2BOADVU_E\KA1117<?/A1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB:5OEQ^- >0TMBE2&28X56^HJY;Z7G[P5NAZFKB1I;]%J>8Z(X>3WV*EMIH
M&XL#QU%65C6/Y0J\=\4XMO-&<U,I,ZH4XQV#&****S- HHHH **** "BBB@
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M$91<79A1113)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV#38<'V"IHMMW RR'VXJJRX/]ZI[ 81OK4N^X+=)]3,U7PG'='=$)&8L"?F
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M)[9'(E(.=V=P)8 DAO>O4*^QIS4E='X+6HRI3=.6Z=@HHHJC(**** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;'Y?4RZ5.,8R32=EHVFDUYJ^Y_3WI]ZNI6$%Q'N6.XC61<CG!&1_.K%?-O\
MP3D_:UT_]I/X7-:VLVGO+X7L["SD^SN[-N:$CY]PZ_N^WO7TE7ZIA<1&M252
M.S/X;S?+:V7XN>$KJTHO_@K\&@HHHKH/-"BBB@ HHHH **** "BBB@ HHHH
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M_>O(****[#Q HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD?9T:-.C'DH145_7<')*T+\H_O4.^T>]"\C\*C8VT<M-QM%'.:*1F]PHHHH
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M?],N7>LR7E];_>5?,[-U!(KT+PE/Y>@Q8'.6Z?4UYDB_Z9;K_MC^8KTGPO\
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M 'V_F:X,P_AH^MX1_BS]/\BZG6G4U.M.KRX['VX4444P"BBB@ HHHH ****
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MG_ #S7]#]?3Y76YZ7*]T?C7%V7_5L:YQ6D[OY[O\PHHHKTCY4**** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:7I?0****W.$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"KJNH1Z/IES=S-Y<-K
M$TLC8+;54$DX'/0=J_#_ /X+(_M.Q_%?]H[5M+T>2QO-#N+"R87"V\T<Q95!
M(^<CC(_NU^JW[>?[1%K\!/@MJ:S;1<:YI>H06SF[6W:-U@X9<C+$%QP,=*_F
M_P#$WQ+U;Q;K;7^I7U[?7+*$,D\Q=R ..37R_$%9RBJ$?5G[)X4X.%'$2S&N
MKJUE]^K^31K&/!I./>J&G>(EN=JLN"V!DO6@2I3*LK>PKXN4)1=F?T91Q%*M
M'FIL56S3X>6J-1CVJ6(<_>[5F_(Z*:U/,M:.;V+_ '?ZFJ[=*FUD;+Z/_=J#
MJ:^DI_"C\AKZU)+S%9230>%IK,Q;"JS?2KUCH<EV5)8J#@\K1*5MR80E.5J:
M*.&E/R#<:O6/AJ:[*LZ,JY'(8=#6W9^'XK/EA'(?]VK@"QK\BA0.PKGEBG]D
M]C#Y.G[U9_(J:?H45D%RTF<$8)!_I5POA<"FELF@5RRDV[L]JG3A!<M-6#-%
M.'S-1LJ2M=A,XIWS>U"KBCYO:F ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U
M !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U,/!I_P WM3#UH ,U7U1L
M0-[K5BJ^K?ZD_P"Y5P^(Y\5_"9CT445V'SX4444 %%%% !1110 4444 %%%%
M !0!NHHH  ,4*VT444 #0+./F)'TJK/IY'W<G\15K.*,T)M$RA&6YERQ/']Y
M:48V^]:30K(.=M5)K#'W3^0K12[G+*@XZHKT'I2LA0]Z3-,R8Z/_ (^[?_?'
M\Q7I'AG_ ) ,7^\W\S7FL9S>V_\ UT'\Q7I7AH;/#\?^\W\S7!F.D$?6\(ZU
MJENW^1<6E;GZ4U>13UC'\3*OUKRS[J/<;NXIR HNX_=-4=2U^'3EZ+)QGAA7
M.ZIXOFN7*Q>;&,GH_:MJ>&G,\O%YQ0P[U=WV.AU'Q-:Z>C;9OF ! 9&_PKG-
M5\637^0JPE<G!VD<'\:S&:25OWDC2>N:0#::]"GAH06I\MC,XKXCW=EV7_#L
M:P,K;FZU(.E(/O4@;)KH/(';<'/K49&*<QQ]*;05IT"BBB@ HHHH **** "B
MBB@ HHHH *!UHH'6@!E]_J36<.M:-]_J36<.M:PV/-Q/QCC]RFTX_<IM4C#J
M%%%%,9^IG_!NC^T?#H?Q-\5Z+K$UG9V-GH$4=M(EO*TCO]I7ABN1W/85^U%?
MRS_L>?'V^^ ?Q$>ZL9+R-M2\FV<V]SY!*^:#R<<CVK^I#3]2AU2$R6\L<R [
M=R.&7/U%?0915O!P?0_*..<%[/$QQ"^VORM_F6****]@^&"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHKSW]IWXR6O[/\ \#M:\77OV?[/I/D!A-=BT0^9<1Q#,A!"
M\R#MST[U%2:@N9FU"C*M4C2AO)I+U>A^4O\ P<!_M2IXY\4>'O"]A=K++X6U
M35;2YC:U*^7GR$QN(^;[AY'I7YD UZ?^V5\4I/B_^T[X]UQ;AYK/4]?O+RW0
M77VF*-9)68!&Z$8QR  :\O!KX7$UG4JN;/Z6R3 QP>"IT(]%^+U?XL<RA1N'
M6K&GZW-8'[RJN".F:K-Q2?>%<S2:LSUZ=64)\U-V9TUEXEAO?E:3YC@<+6G:
M*)%W+]W'!KAE#!ODW?A6EI5[<6Y^;SF^4CDGUKDJ85+5'OX'.IWM65_,YG6=
MTE[$J]2M266AS7G501C^]6U'';/<J6:#/;.*T$\O;^[\O_@.*[95G%)(^=I9
M;&I4E.4M+_Y%&P\.PVOS,K;@?[U70-@VK]T#BE8TWO7,YR>Y[-.C3IJT$+C)
MIPXI"PHS\E0:,7YO:D*EJ7YO:CYO:F(0 @=J7YO:CYO:CYO:@ ^;VH^;VH^;
MVH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /
MF]J/F]J/F]J/F]J #YO:F4_YO:F4P%7K5;5O]5_P"K*]:K:M_JO^ 5=/XS'&
M?P3'HHHKK/G0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@C:**
M</N4#1&\2R#FJ\FG=U'ZU;SQTI,G^Z6JE)D2IQ;,Q-T6HVX/_/0?S%>E^&H2
M^@QM_#N;^9KBX],\UUD/R^60V-O6K<OB62VMOLT8=0IW960C]*Y\33=6*BCU
M<CQ4<!.<ZRT>WX>IT^H^)K;3XV7>P;!Q\IZUSVK>+)KSY8F5E# C*>U9#F25
MMS.[?4YH&%-33PT(F^,SK$8C1^ZO(3#2G]Y^E.R%HZBD(YKH/)Y=.XVBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *!UHH'6@!E]_J36<.M:-]_J
M36<.M:PV/-Q/QCC]RFTX_<IM4C#J%%%%,98TNX^R:G;S?\\Y5?IZ$&OZ1?\
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M[P?ABO)S?$>SH\O5GVW N6?6<P562]V%G\]U^1\E3S-<3-(YW/(=Q/O48YH
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M 9??ZDUG#K6C??ZDUG#K6L-CS<3\8X_<IM./W*;5(PZA1113&%%%% '[S_\
M!!GX]S?$[X=R>'Y)KZ1?"_AG1[=%EC18T"QF/Y"IR1\G?M7Z&U^$_P#P;J_&
M*#X7_&?QM!</;I_;D.FV:>:K$DF>0<;>A^;OQ7[L5]/E=3FHV['XOQ=A?8YA
M)I:.UON5PHHHKT3Y<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]A/XGCXM? 2'5_,CFS?3PYCC:-?EV]FY[U[.45+2E _.>/,+>-.NNEU]]O\
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MF"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !3DZ4VG)TH'$YZX_UZ_2DI;C_7K]*2NX^;E\3"BBBF2%%%% !1110
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M"JM)LKE;(?)9\5*L:Q@4%L&ACDU-RHQ[B[N*16Q244C0*5>M)10 XMFFT44
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M< =Z?6L8I;'GU*LYN[8W;Q2E<TM%,FXA.*4=***"0HHHH *#THH/2@"QI/\
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M1O-1<N,>XH;%-H)HI&@H&:0C!IP>D)YH 2BBB@ HHHH **** "G#I3:</NT
M--4?$7_'NW^X:O#K5'Q%_P >[?[AK6C\9S8O^"SG$^[2TB?=I:[&?.!1112
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MM_V[_P"DQ"BBBN\^9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM%%(\^=:<W[S&A #GO2@Y-+U-%48A1110 4444 %%%% !1110 4444 %%%%
M!0>E%!Z4 6-)_P!>OXUJ5EZ3_KU_&M2L9[GI87X [T4=Z*DZ(A11104%%%%
M!1110!^T?_!LQ:&V\!?%1C_RTET@C_OW=5^HM?G#_P &[&AG2/A9XYD.[_2D
MT=QD@_\ +&X/&/K7Z/5]=ENF'C\_S9^#\72OFU9_X?\ TE!1117<?-A1110
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M&@ ?,Y9>#P16DD"PCY57\J?G?Q25A*39Z5.A&FM$-W&E^]2XR* ,5)I:[NP
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M !0>E%!Z4 6-)_UZ_C6I67I/^O7\:U*QGN>EA?@#O11WHJ3HB%%%%!04444
M%?IA_P &\'PVED_:'T;Q-MF\J.WU*#.5\O/E8^O>OS/ZU^VW_!NE\+XW_9IM
M?%16$31ZMJ%J#M/F8Q'WZ=Z[,!'FKQ]3YWBK$*EEE2_VDU]Z9^F5%%%?8'X*
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!^9?\ P7U^%YTOX;V_BKRYE&I>)[*VWF12AQI]P.%^\/\
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MBOJ#\>"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*39ZE/#P@M-Q"S'TI<T45)MNAJKBG444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M<[\2_!]GXT\&7UG>6L%T/L\IB$J;MC%& ('XU_._^TE\#K[X!^.+71[XJTMQ
M8)>#$+1?*TDB=&YZH>:_I!9=ZD>M?F%_P7=_9DN-8OI/B1##.UIX?\/V5B\O
MVA JLVH2K@I]X_\ 'P.1QS[&OEN)L#[2C[:.\?R/VSP7XE^I9D\NJ.T*UNOV
ME=)+U;_X<_+FBBBOSP_K0**** &<>]3V_P!VH./>I[?[M)FD#QGQ!_R$8/\
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M<84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[>G0****Z3S HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;V%O':PNYD9$Z%L $_H/RK0HHKZ-*VQ^4RDV[L****9(4444 %%%% !1110
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M:**_0(Q459'\JU*DIRYI;A1115&84444 %%%% !1110 4444 %%%% !1110
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M"?\ @FY_P2BO/&LVF>*?&5KK&D">.ZADTS5O#K>7&0Q56/FD<G&1\O>O5_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M34+N"V%P;&5XH_-8*') ^Z,Y^E5&#D[(QK8BG1@YU6DEW.&KW+]FW]@OQ_\
MM ^)+86?AG5+K15N%BO;FVG@1H0RDC&YOZ&OM[]C3_@BB^D&SU[QA=>%]>L+
MBUGB^PW-A(763S<*Y##' 4_@U?H;\.?@OX5^$]FT/AW0-*T=9"K2"TMQ%YC*
M, G'XU]1EO#=2K:=?W5^)^*<8>,F#P2EA\JM4GJN;7E3V[IWW/F;]AG_ ()9
M>&?V=M$AUJ:Z\70>(-1LGM+VUNKNV>&$>=N&T)"#G"KU8]3^'V)117W.%PM/
M#PY*2LC^:,ZSW&9KB'B<;-RD[_+R7D@HHHKI/'"BBB@ HHHH **** "BBB@
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M+@M=:?+#PGWOO*.G?TKQJE*<':2/T3!YAA\3!5*$TT_ZV>IS]5=8_P"/=O\
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M?A3%_P &Q7QZ#_-XL^$++[:KJ/\ \@UH67_!LG\:%_X^/$OPG?IC&JZC^/\
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MHHK=*QYSDWJPHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
***** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>collabprofitsharingchart.jpg
<TEXT>
begin 644 collabprofitsharingchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MB#7[>1_ZN/\ W%_]!%?B'_P4G_Y22?\ !"G_ +.M_:@_]8Y^(-?MY'_JX_\
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M9?\ QN@#H**Y_P#M'6_^@#_Y5K+_ .-T?VCK?_0!_P#*M9?_ !N@#H**Y_\
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M^(?_  4G_P"4DG_!"G_LZW]J#_UCGX@U^WD?^KC_ -Q?_010 ^BBB@ HHHH
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M#V'_ (#I_A1_PC'A[_H#V'_@.G^%;M% &%_PC'A[_H#V'_@.G^%'_",>'O\
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MY;P.5!Z%@J@GO@5]*V6EZ=IOF&PL[>T\[9YOD1B/S-F[9NQUV[FQGIDU\[_
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MDU6U6V26YBO+7W__ (<?Z5_TE1_X+,?^)IZ#_P#.:H_XA+FW_0TRW_P'%?\
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MN-;UB;37U*Z]THHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
1BB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>costofsaleschart.jpg
<TEXT>
begin 644 costofsaleschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
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M"\'?LH_$[XB_M?\ Q!35;SP'/\2/&OAOQIX.\!_!/1_$&@ZO\/\ PHUCJGB
M:;IFN6MC:M=3:M-I3/HT6L??7Q>^'=G\7?A3\3/A5J&I7FC6'Q+^'WC7X?WN
MKZ?%;SW^EVGC3PSJOAFYU&RANPUK-=V,&J275M%<JUO)/#&DP,;,*^8-7_8K
MM+3PS^S6GPQ^*7B'X7_$O]F+P#=_#+P9\2]+\)>"=?DUOP?XA\%>#_!?C2P\
M3^#]?TV;PY?7&O#P%X/\46-_;BVN=#\4^&M)=&U'PZ^M>'-9 /8/A9^U1\"O
MC;XMU[P9\)O'"^/M6\,>'O"'BG7KWPWH'B:_\+:=H7Q!\$>#?B/X#O9?&BZ.
MOA%V\:>"/'GA[Q)X5LX=:DU#7=-;5IM/M)O^$>UT:?\ "7AG_@KQ\(O$.M_#
M>2_^%GQD\%^!?&FK?MX:'K.O>,/AK\2X?&.A7?[#?Q+\&> /$.H:/\,= \!:
M[XG\8>'O$]GXEU?Q+JVKZ6L2_#6/PGK?AOQ?#'XITK7M+T;ZK_9+_8O\ ?L>
M+\1]-^''B#Q-J?AKQR?@U!IVC>)#IMS-X9T[X+_ +X<? /1K>+5;*ULY]9N]
M<TKX=6OB?7M1OX(I9=?U?44M(;;3DM+:+QO0_P#@G#X=T+QXWB:W^+?BZ3PQ
MI,7[=$/@KP>?#GAB)O#D7[?OC3P[\3OB[%>^)(434?$J^'_B)I.IZOX$>_MK
M:XTW1M83P[JT^L1:18Z@P!])>&?VO_V>O&7C?2/ 7A;Q\->U'7[W2-'T3Q#I
M?AGQ?=_#C5O$VO?#^S^*^C>"]/\ BO'H!^&EWX[U/X:7]EX[L_ \/BI_%,WA
MBZ@U1=*\N15/F_QF_;'D^"WQ=N?@MKOPYDOO%_C_ ,*>'-7_ &7!;>)EMK/X
M^>+KG7O^$9^(7@%IKC1/^*-U3X/M?>&OB)X^OU_X22"T^"FMZK\2+2UFM_ W
MB_3M.\)_9Q_X)0?!;]FWQ_\ #[QOX:U#1/$-QX&L?!FI2:CXE^#'P=U#XAZK
M\0/"?P?\/?!RX\16OQ;NO#%YXZ\+>'->T[P[!XQO/!?AJ^L#I_C2^U,Z/XEL
MO!]_<^#Y?L/XR_LT^%_C7\3_ -GOXC^)-8U*W7X Z]\5-:M/#=K;63Z9XOA^
M*WP8\8_!;6-,UF\D"ZEI]O9Z)XSOM1M9]'FM[J2\@CMYI!:RRJ0#D-'_ &[?
MV;O$&CW.L:!XG\8^(46PT'6-$L/#_P &OC1K&M>/O#GB<ZM'H'C3X6:!9_#^
M76OB?\/=7N-"U2.R^(?@>QUSP2(H(;VZUZVL+_3;N]P[S_@HU^QK8V3ZG<?&
M:S73;;X;O\6M5OH_"'Q GM_#O@*+QEX^^&T^K^*C!X4DE\*WEO\ $SX:>+?A
ME<>'?$$6G>)H?B59V'@$Z.?%>N:+I-]\G>&?^".7PC\#>$M'\)^"O%VB:#8^
M#+OP98>$;6+]GOX"#2/$W@?P1I/B#0]+\)?M$:98>$M,G_:022UUVSUJ:[\=
M:I9Z='X\\%> ?B):^'8?%^@WFIZQZ)\&O^"6GP]^!VB?$WP_X+^*7BN#3?B+
M\'_$'P?2VNO /P;O=)T#1]?_ &H_VD?VHYY;?P7J7@34?AKJFF#7/VDO$/@6
M7P7J/@<^#7\#:)IVG6NCV$]U<2P@'WIX*^-?P^\<^"=;^(-C?:YX:\->%Y-7
MA\5R?$SP9XS^$FJ^%'T#38-8UE_$WA_XG:!X3UW1+33])N8=4DU*_P!/BTN?
M2Y$U.TO;FP87!\+3]O[]EG^Q-&UVY\=>(].A\2>*OA_X-\-:5JWPF^+^D>*O
M$^L?%O3O%>J?":?PSX-U3P):>+/$.@?%&V\$>*(?A]XHT?1;WP[XKU/1;_1=
M*U*?6;6>PBI_"+]B?P;\/_@5\:O@+XK\3:KXW\%_'P>,;3QGX;TW3;+X>^ /
M"_A[QQ\/M,^&NO\ @WX/_#_PW/<Z5\*_"-_HVG7&O7>C:%>W$<WCKQ%XI\6)
M)!<:RUK;^"_#K_@EA\-/AY!\.1I/BS3M*O?AQ\=/@C\8;:^\"?!'X*?"R7Q9
M:? /0_B1H?@_P_X[?X?^%=&N_%.J:NOQ/U_4O%/BO4+UO,U,"7PIX=\(V^H:
MU:ZD =%\??\ @J/^S[\*O@7XS^+GP\FU?XQZ[X9^'0^(=OX(TGPM\2=%%G:R
M_$/6/A59:1\3?$7_  K[5[7X)ZUJ/Q"\+>,_!6GZ/\3K+0-:NO%O@WQ1H$>F
M?;-"U7['[W<?MQ_LQV2>.;G4_B/)I.E> -/\<ZIJ?B+5?!GQ T[PKX@L_AGX
MOL/A_P"/Q\-O$]WX5AT/XM7GA#QYJVD>"=<TWX7WWB[4;7Q?J^E>'8K6XU/4
MK&"?X]U+_@DQX8/@KXR^ _"_Q^^)/A+1/VC)/'K?' V?AGP%J=WXO76_VA?C
M+^T+X#.EW&JZ9</X7G\#:I\:_$G@349M/,__  F_@33M#M]1CTGQ#:R^()M/
M0O\ @D5\ O#H^(]CHMY8^']/\33:YJ?@/6O#'PF^#VA_%/X?^(]7^,7AWX\Z
M3KU]\81X0O?&_P 17\!?$CPGH$_@K2/%MR="G\-V$6@_$'3OB#+%::K: 'OG
MPW_;;T?XFV_[:.I:+X!U^PTO]D;7K#1%3Q+;^(_!_B3QI-<_LT_#S]H2\BUC
MP=XQ\)^'_$?P\U'3YO'3^#Y-,U>QU&65=,B\1))]FU**QA\A^%G_  44U&W\
M'_ OQY^U7\// _P,\&?M&_ 6X^//PW\8^"?B?X@^*NA65O8>#/"?Q"U'X;>,
M['5/A5\.O$UC\0I?"/BZUU#PM;>$]&\::9XRO='U_0-/N++Q!'X?TWQ+[M\.
M/V0CX1TS]JEO%OQ6\3?$#Q7^US?V.L?$;Q+=^'?"_AN+1]4L_@)X._9_5/!^
M@Z%;K8:=I$7AGP3I.HV>GZC-JMU%J;W;7NJZD9WG;Y?M_P#@E+H/C7X-^"?@
MQ^T7\<O%'QK\._!_X,Z/\%_@G#%\._AWX%TGP%9:&?AVUAX^U+P[!9^*-/\
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M[S5_$%SJNM:AH_&;]D;4OC=XOC?Q9\</'+_".X\=_#?XEZA\+$\.>!7O=/\
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M>ZSX(@^'GA/XC>.=:U7Q;\-/BCX=T+5?"?PANXK/XHZYX(UW5_!MGI/Q$LO
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M_@A3_P!G6_M0?^L<_$&OLS_@H%_R1WPG_P!E!TK_ -1WQ)7QG_P4G_Y22?\
M!"G_ +.M_:@_]8Y^(-?9G_!0+_DCOA/_ +*#I7_J.^)*^JX(_P"2LR+_ +#H
M?^D3/A?$S_D@N)_^Q;+_ -/4C\@J/Z=***_JX_@D**** "BBB@ K]G/V"_\
MDA3?]CQXJ_GIM?C'7[.?L%_\D*;_ +'CQ5_/3:_./%/_ ))7_NIX+_TWB3]D
M\"_^2Y?_ &)<P_\ 3^!/M2OPA_:\_P"3BOB1_P!?6@?^HGH-?N]7X0_M>?\
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MO_L2YA_Z?P1];_V_%_T#->_\$U[_ /&Z_#G]K2<7/[0?Q$G6*XA$ESH!$=U
M]O.N/"FA+\\,@#IG&Y-P&Y"KCAA7[QX'H/R%?A%^UY_R<3\2/^OK0/\ U$]!
MKX'PD_Y*''_]B:O_ .IV /U?Z0'_ "2.5?\ 91X;_P!5F:GS;1117]"G\B!1
M110 4444 ;?AD[?$OAML,=OB/0&PH+,<:Q9'"J.68XPJCDD@#K7]&XU^$?\
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M_GIM?C'7[.?L%_\ )"F_['CQ5_/3O\#7YQXI_P#)*_\ =3P7_IO$G[)X%_\
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M-BG3]J[G4G:,G [9XK\=:_9S]@O_ )(4W_8\>*OYZ;7YQXI_\DK_ -U/!?\
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MI.GP31>#=5>.6*TA22-PB89'5 589R"#D&OP:;J?J?YU^_?[3/\ R0+XL?\
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M<L[QT+_M/,K6_M#'62HI)XO$-6P]1U<.K.I:U"JW5HK_ )=5&YPY9-M^+O\
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M/#(KV]W#<6LZLCL&AN8)H)5)2:*2-F1@#\AM:USXI^(/VJO$U[KFK?M:^(/
MW_"UO J_"S4_@G^T=^QIX'^ \/@ :;X32XTSQ'\-]6^-VF?%WQ)':>*$\2W/
MC*\O_#>H^*?%EA?R6'AO28[.#1M%B_8(?U/7ZGT_3T'7FOS?TW]@_0_#>NZ9
M<>%OA'^P-IW]C7=KJ6B>/_\ ABSPO8_$?1=0TZZCN]+U.TCT#Q5H_AS_ (2+
M3IX(+FSUW3O["M+?48H+Z#P_"L(M'_1+2[6ZL=-L+.^U&?5[RUL[:"[U6YM[
M.TN-2N8H42>^GMM.@M;"WENY5>>2&SMH+:)I"D$21JJ@ _$__@I/_P I)/\
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MYYO@/\$_%>E^)?VR? MG\"?BYIOPMM_$?@%-0\>:K^SQ\,9_VG?!NK>"K/\
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M 'PH\*:UIGP_^/?@_P#:0C^ ?AKPW\-O!&C?L^^ /'/PE\=>.?!'Q<^.NO\
MA0_$_7O$?AGQEJ?P1T_QM!X[MO'7Q+^$_B'Q7\']#^"OA_QO#8_#_P 7:YJ_
M@>&QT#]NL#.<#.2V>^X]6SZG)R>O-)M7IM&, =!T!R!] >0.QY'-=BSZ:I0H
M+"8?V4)0?(XTVIJG*I42J)TG&7M:E24L0E&-.5Y/#4\)4JUJE0;OZ?\  2TZ
M+;>U^[9\J_'WQ-XB\;?"#XN:%\-_ OBYOB%IWQ \._ [1=3\0_#6[>+1=6\=
M^)?A]X6\2_&CX<3>)M-N(O%O@7X=^#O'^M>+]-^)FDP'1WU3P7JT4\@?P_JL
M4?T=X7\)^%_ 7AO0/ _@C1K/P]X-\'Z/I_AGPIH5A"D%II7A[1;9+#2;.*.-
M54O'9PQ-<W# S7EX]Q>W3RW5Q-*^[17CSK<U&-",>2$:LZS]YMSE.G2@E+9-
M4_9SE2TO#V]5)^\VQOMHO7T_R+VF?\A+3O\ L(6'_I9!7Z%5^>NF?\A+3O\
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M#4!NPCL=N<#=]W) SR,_+\:_\DKG?_8&_P#TY3''=>J_,^6Z***_E<04444
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MC:S:JSV]K;P.5-A?L4W11HVPD E,[<@'&0,?EQ_P4G_Y22?\$*?^SK?VH/\
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MP"_X_O$W_7IIG_HZ]KZ7K^F/#G_DD<M_Z^8__P!3\2 4445]P 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>eloctate.jpg
<TEXT>
begin 644 eloctate.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !D 9(# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:D)"@DG
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M_ UI.TX\T>AG"\)6?4Z3QS;>(KB.R_X1QIE92_G>7*J<<8SDCWKD/[,^(_\
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M19@@%&]5]O;\O0.3UYGL:8=0@O91^+KY_P!=CSVO<?AMJ<^I^$8C<L7>WD:
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M^QHC.,6UNF$HN23V8W3O$VD:K"LEIJ%NV1G8SA6'U4\TM_XBTG3(6DN]0MT
M'W0X+'Z <FN%N_@\/,)L=5(3LLL62/Q!_I26OP>/F WFJY0=5BBY/XD\?E1R
MT_Y@YJG8Y_7-0N?B%XNAAL(F$0Q'$&_A3.2[>GK^0KV>VLX[6PBLT&8HHA$
M>X Q5'0O#>F^';<Q:?!M9OORL<N_U/\ 3I6K2J34K);(<(-:O<\0C:[^'/C8
MM)$SP D?]=8CW!]>GXBO6-,\5:-J\*R6NH09(YC=PKCZ@U/K.A6&OVGV?48!
M*@Y5NC(?4'M7"7GP>0R%K'5&5.RS1Y(_$'^E4Y0J?%HR5&4/AU1W5YK^E:?$
M9+O4+:-1ZR D_0#DURUC\3[;4/$2V%OI]Q+;R,$BE3ER?4KZ?CTK*M_@ZQ<&
MZU8;.XCAY/XDUVOA_P )Z7X;C/V&$F9AAIY#EV]L]A]*35.*[C3FWV-JHKG_
M (]I?]P_RJ6FR)YD;)G&X$9K$U/(OA)_R--W_P!>K?\ H:UZ_7)^%? <7A?4
MY;R.^><R1&/8T87&2#GK[5UE:U9*4KHSIQ<8V9A>,-?7P[X>GN@1]H?]W /5
MSW_#K^%>0Z#H'B2^(U71X92P=@)Q(JG/?&3GOUKU+Q9X*/BNYA>;4I((H5PD
M2Q@C)ZG.>IX_*M[2].ATG3+>QMAB*! H]_4GW)Y_&JC44(Z;BE!SEKL>7?V9
M\1O^>MY_X%+_ /%5SVHZ9K_AG48-5U"%XIWF\Q92X;<X.3G![^_6O?:R_$6A
M6_B/2)+"Y8H&(9) ,E&'<?J/QIQKZZK04J6FC)=$U6'6]'MK^#[LR9*_W6[C
M\#FK]<_X3\+MX6MI[=;][F"1@ZHT878W<CGOQ^5=!6,K7T-8WMJ>-_#_ /Y*
M*_\ VV_K7LE<AH/P_BT/Q =42_DE8[_W9C 'S>^:Z^KJR4I71%.+BK,*\3TZ
M:V@^*TTEZ\20+>S[VE("C[W7/%>V5Y_J/PH@U#4KJ\;5)4-Q*TI40@XW$G'7
MWHI2BKW"I%NUCI/[8\,?\_VD_P#?R.GQZ[X<A;=%J.EHW3*S1@_SKD/^%.V_
M_07F_P"_(_QH_P"%.V__ $%YO^_(_P :=J?\PKS['>6>KZ?J,C1V5];7#J-Q
M6*56('KP:N5RGA/P+%X5OYKF.^>X,L?E[6C"XY!SU]JZNLY))^Z:1;:U"BBB
MI&%%%% !1110 4444 %9'B:_:PTAS&<22G8I';U/^?6M>N8\;JQLK9A]T.0?
MR_\ K5K12=1)G-C)N%"3B9?AC15U*X:XN!F&(]/[S>E=T %    '  KG_!DB
M-I,B+C<LI)'U _PKH:K$2;FT^AG@*<844UNS/U?28=6M3'( )%_U;]U/^%<7
MHMU+I&MJCDJN_P N5?QQ^E>B5YQJY%QX@G\GG,I QW.:UPS<DX/8YLQBJ<H5
M8_%<]'HI*6N,]8:[B-&=NB@DXK(\/^)[7Q(DCV=O=QQH!B2:+:K]1\IR<XQ6
MI<_\>LO^X?Y5S7PU_P"1'L_]Z3_T,U22Y6R6WS)'3-/$DHC:5!(W12PR?PJ2
MO'];DN-2U+5/%-N[%-,O(HX,'Y2JG!/Y[3_P*O0=?\4QZ+X<AU>*#[3%,4VK
MOV\,,@YP:J5-JUA*:=[F_17&)\0)%U:RAN]'N+:ROV"V]Q(W+9Q@[<=.1WZ&
MLC7_ !!K<7Q#LH8K*X\N,-Y5H+C"W(&\!_0<>OI0J4FP=1'H#ZE9QZ@EB]S$
MMW(-RPEOF8>H'X&F6.KV.I3W,-G<++);-LF4 _(>1C]#7.R:C9OX^TRWN=)"
MZC+:^8+@S',/RL2N.AZ$9]ZYC0-<NM&USQ,;'3)K^5KDNP0[5159\DGGGG@?
M6FJ=T)SLSU:BN;L_&UC<>$GUV5'BCC)1XLY;?_='KG(JM9>-;G^T;&WUC1Y-
M/BU#BUE,H<,>P88XZC\ZGDD5SHZVBN/NO'<Z:Y?Z59Z-/=W-M]P1R<,.Y/'
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M7?Z?XF2S\%66K:XYC=XQNPOS2-VP/4@9KS>V\-Q/\/QKUMO^VVTY9@?F5E#
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MGTT%_HW@_3O$=KK=[]ID<!X99-R-DG@#\.AS7?\ CC_D3-3_ .N7]17,^$O
MFF:EH>FZA?2W=P2N\0/)^Z!R>@QG''K3IM1C=]Q33<K(WKOQWINF/!%J"S1S
M2VJW/RJ".1]T<YSFGWGC?3;*PLIY$N6EO5W0VR1YE(Z=,\?G6'JD,<GQCTI7
M165;4D C@$!R/RI-5D2S^+^GSWS!('M]L3N<*#M88S]?YT<D=/2X^:7XF]9>
M-M.OK2\EBBNQ/9C,MHT6)@,XX7///O6)X'\:76L:C<6VH)<RO+*1"RP@1Q*
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4CO115TVW)(F:M%GBU%%%>@<1_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>eloctatechart.jpg
<TEXT>
begin 644 eloctatechart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-/C/\ $/\ X5'\
M(?BG\5/['D\0_P#"M?AQXZ^(']@Q7?V"76_^$+\*ZOXF_LB.^^S7GV.34_[+
M^PI=?9+G[,TXF^SS^7Y3_!?[/?\ P4>\*?$'X5>%?BO\5=;^ L5E\2+'PU/X
M"\'?LH_$[XB_M?\ Q!35;SP'/\2/&OAOQIX.\!_!/1_$&@ZO\/\ PHUCJGB
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MQ^T7\<O%'QK\._!_X,Z/\%_@G#%\._AWX%TGP%9:&?AVUAX^U+P[!9^*-/\
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M[S5_$%SJNM:AH_&;]D;4OC=XOC?Q9\</'+_".X\=_#?XEZA\+$\.>!7O=/\
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M>ZSX(@^'GA/XC>.=:U7Q;\-/BCX=T+5?"?PANXK/XHZYX(UW5_!MGI/Q$LO
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M/^$HT7_G[;_P$O\ _P"1*/\ A*-%_P"?MO\ P$O_ /Y$K?P/?\S_ (T8'O\
MF?\ &@# _P"$HT7_ )^V_P# 2_\ _D2C_A*-%_Y^V_\  2__ /D2M_ ]_P S
M_C1@>_YG_&@# _X2C1?^?MO_  $O_P#Y$H_X2C1?^?MO_ 2__P#D2M_ ]_S/
M^-&![_F?\: ,#_A*-%_Y^V_\!+__ .1*/^$HT7_G[;_P$O\ _P"1*W\#W_,_
MXT8'O^9_QH P/^$HT7_G[;_P$O\ _P"1*/\ A*-%_P"?MO\ P$O_ /Y$K?P/
M?\S_ (T8'O\ F?\ &@# _P"$HT7_ )^V_P# 2_\ _D2M"QU2RU+S?L<QE\G9
MYF8;B+;OW;?]?#%NSL;[N[&.<9&;^![_ )G_ !I<8_\ UD_SH **** "BBB@
M HHHH **** "BBB@#\0/^"D__*23_@A3_P!G6_M0?^L<_$&OD[_@ZB_Y,(^"
MO_9V'@S_ -5+\8:^L?\ @I/_ ,I)/^"%/_9UO[4'_K'/Q!KY._X.HO\ DPCX
M*_\ 9V'@S_U4OQAKYWBW_DG,W_[!7_Z<@?J7@G_R=;@?_L=4_P#TQ7/X%Z**
M*_G$_P!5@HHHH **** "O]#+_@V&_P"4:,O_ &<A\;/_ $+PC7^>;7^AE_P;
M#?\ *-&7_LY#XV?^A>$:^[\._P#DH7_V 8G_ -+H'\Y_2D_Y-<O^RFR?_P!1
M\R/Z)J***_=3_.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#\._P#@I=$9O^"CW_!"R)9IK<O^U9^T
M^!-;LB3)C]COX@'Y&DCE4!L;6!C.4+ %20P^0O\ @Z6T^2T_8,^#$CZGJ=Z'
M_:N\&J([V>VEC7/PG^,#;PL-G;MY@QM#%\ -)\I+ K]A?\%)_P#E))_P0I_[
M.M_:@_\ 6.?B#7R=_P '47_)A'P5_P"SL/!G_JI?C#7SO%O_ "3F;_\ 8*__
M $Y _4O!/_DZW __ &.J?_IBN?P+T445_.)_JL%%%% !1110 5_H/_\ !LGI
MTMW_ ,$U)'35-4LP/VCOC4OE6<]M'$=K>$_F*RV<[%CG)/F 9S\O/'^?!7^A
ME_P;#?\ *-&7_LY#XV?^A>$:^[\._P#DH7_V 8G_ -+H'\Y_2D_Y-<O^RFR?
M_P!1\R/Z!O[#G_Z#^O?^!-C_ /*VC^PY_P#H/Z]_X$V/_P K:Z"BOW4_SC.?
M_L.?_H/Z]_X$V/\ \K:/[#G_ .@_KW_@38__ "MKH** .?\ [#G_ .@_KW_@
M38__ "MH_L.?_H/Z]_X$V/\ \K:Z"B@#G_[#G_Z#^O?^!-C_ /*VC^PY_P#H
M/Z]_X$V/_P K:Z"B@#G_ .PY_P#H/Z]_X$V/_P K:/[#G_Z#^O?^!-C_ /*V
MN@HH Y_^PY_^@_KW_@38_P#RMH_L.?\ Z#^O?^!-C_\ *VN@HH Y_P#L.?\
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M_0MZK_X%:#_\N* -NBL3^U-1_P"A;U7_ ,"M!_\ EQ1_:FH_]"WJO_@5H/\
M\N* -NBL3^U-1_Z%O5?_  *T'_Y<4?VIJ/\ T+>J_P#@5H/_ ,N* -NBL3^U
M-1_Z%O5?_ K0?_EQ1_:FH_\ 0MZK_P"!6@__ "XH VZ*Q/[4U'_H6]5_\"M!
M_P#EQ1_:FH_]"WJO_@5H/_RXH VZ*Q/[4U'_ *%O5?\ P*T'_P"7%']J:C_T
M+>J_^!6@_P#RXH VZ*Q/[4U'_H6]5_\  K0?_EQ1_:FH_P#0MZK_ .!6@_\
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M .4DG_!"G_LZW]J#_P!8Y^(-?)W_  =1?\F$?!7_ +.P\&?^JE^,-?.\6_\
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M ;E%8?\ PC/AW_H":7_X!6__ ,;H_P"$9\._] 32_P#P"M__ (W0!N45A_\
M",^'?^@)I?\ X!6__P ;H_X1GP[_ - 32_\ P"M__C= &Y16'_PC/AW_ * F
ME_\ @%;_ /QNC_A&?#O_ $!-+_\  *W_ /C= &Y16'_PC/AW_H":7_X!6_\
M\;H_X1GP[_T!-+_\ K?_ .-T ;E%8?\ PC/AW_H":7_X!6__ ,;H_P"$9\._
M] 32_P#P"M__ (W0!N45A_\ ",^'?^@)I?\ X!6__P ;H_X1GP[_ - 32_\
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M+PC7^>;7^AE_P;#?\HT9?^SD/C9_Z%X1K[OP[_Y*%_\ 8!B?_2Z!_.?TI/\
MDUR_[*;)_P#U'S(_HFHHHK]U/\XPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /PZ_X*7BX/_!1[_@A8
M+4P+/_PU9^T_Y9N%E:$'_ACOX@;MZPNDA.S=LVL!OV[LKN!^0_\ @Z675Q^P
M9\%SJ$FF/#_PU=X-V"RBO4D$G_"I_B_MR;FXE3R]N[(V[\^7A@-X/V%_P4G_
M .4DG_!"G_LZW]J#_P!8Y^(-?)W_  =1?\F$?!7_ +.P\&?^JE^,-?.\6_\
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M_9V'@S_U4OQAKZL_X*73P6O_  4?_P""%D]S-'!"G[5O[3V^65PD:[OV._B
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M^!MO_P#'*/\ A)O#O_0;TO\ \#;?_P".4 ;E%8?_  DWAW_H-Z7_ .!MO_\
M'*O66IZ=J/F?8+ZUO/)V^;]FGCF\O?NV;_+9MN[8VW.,[3CI0!>HHHH ****
M "BBB@ HHHH **** /Q _P""D_\ RDD_X(4_]G6_M0?K^QS\0<U\G_\ !U$2
M?V"/@KDD_P#&6'@P]>__  J7XP\_J?S/K7UA_P %)_\ E))_P0I_[.M_:@_]
M8Y^(-?)W_!U%_P F$?!7_L[#P9_ZJ7XPU\[Q;_R3F;_]@K_].0/U+P3_ .3K
M<#_]CJG_ .F*Y_ O1117\XG^JP4444 %%%% !7^AE_P;#$_\.T)1GC_AI#XV
M<?\  O"7^)_,U_GFU_H9?\&PW_*-&7_LY#XV?^A>$:^[\._^2A?_ & 8G_TN
M@?SG]*3_ )-<O^RFR?\ ]1\R/Z)&X5L?W3_(U_F3?\%Z?^4LW[7O_8;^%?Z?
M KX8XK_39?[C?[K?R-?YDW_!>G_E+-^U[_V&_A7_ .J*^&-?9>)7_(DPG_8S
MI?\ J+BS\&^B9_R<'/O^R,QW_J\X?/R"I0I() )"@,Q )"J72,,Q (53)+%&
M&; ,DL48.^1%9*_=3_@EKX+D\<?L^?M(^&;3P5X7T-_$T1TC6_COXG^'_P '
M?C5\.M,T>?QW^SS;IX/_ &B/!GC*^T[Q]\._A;X8A;7/'5MXX\.ZOHNCW>@:
MK\2?%UI:^(_'/PE\+0V?X_E^"EC\2L/&;A)TZLTU#G;=.#DHV<H1CS-).<YP
MC%7=W+EC+^Y^),]I\.Y8\SJT8UJ<<5@\/.,\0L/&$,3B*=&=5R5+$5JCI0E*
M<:&&PV(KUIJ,(TXP<ZU+\)1<VK3?9UNK5K@$@VRW,#7((&2#;B0S J.6!3('
M)P.:='-#-O$,\$QC;9*(9HI3$_/R2B-F,;\'Y'VMP>.#7[FR> =8^*WP-\"^
M"KW2_B3\$OAUX4^"O[(5WHWCKXPZI\'++]B;XR>+)_&GPI\"7OAE?%_@_P "
MQ^-H[?X@7VN:Y\0;[Q18_%_7OB%ID/AOQM9_$7X;>#XM+U"70MK_ (*%_#&X
M^*'@."^^%'PC^,=IK]I^U5\5]"\+_#KXG? +P/\ "?QYIOPW\/?"/Q+XYO\
M1/V7-(^'.BZ7/\1?V6O NB^$=:USQ-XA\8L=9\(G3_AO=BVM)O$/BS4-5[ZF
M23C0JUH593]G2I3A3=%QG5E.<X3C&//*5HN%H/E;J.2M%13DO H\=X:IF&#P
M-7!TZ*Q&)QE#$8B.8PK4<###X?#8BC4KU8X6&'<Z]/$.5:FJ\88.%.3J5ZE1
MJB?@T60,J%T#N&9(RZB1U3&]D0G>ZIE=[*I5-R[B-PRZOV%D^&GP@TO_ ()K
M?'.P\ ?$?]G7QSK.B3_L@?%#QQXRTS73>?$F?XE^,O$'Q%N-=^'&D#5/"5GK
M7A_0_"/AF/2/A[X>\-VE_;V?CSQ?IGQ!\9ZE<-8ZEX=BLOQZ(P2.#@XR.A^G
MM7!C,%/!K#<\XS>(H*O[CC*,&ZE2FX*<92C-Q<-91M%MM1YDE)_1Y-G5+.7F
MGLJ%:@LMS.>7-8B,Z=2LHX+!8R&(=&I3IU*$:L,;'DI5$ZBA%2JJG4G*C3])
M^#/_ "6/X/\ _97?A3_ZL7PQ7^P8G0_[\GZ2,!^E?X^?P9_Y+'\'_P#LKOPI
M_P#5B^&*_P!@R/[I_P!^3_T8U?J'AC_ SC_K[@O_ $C$G\=_2]_WS@3_ +!^
M(O\ TYD@^BBBOU,_C4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH _$#_@I/_RDC_X(4_\ 9UO[4'09_P";.?B#Z5\G?\'4.?\ A@CX*\$8
M_:P\&9RI&/\ BTOQA'.1Z@_D?2OU]_;=_P"">OPD_;LE^"VJ?$#XB?M _";Q
MA^S]XN\2>-_A9\1/V;_BYJ?P:^(7AK7?%OAE_!^NS6GBO2--U#4(8[[P]+<Z
M9)]D-I/]EO+VW^T&WO+F&7\^_BM_P;S_ +.WQWT"Q\*?'#]MC_@JK\8O"VEZ
MM#K^F^&_B?\ MV>-?'&A:?KMM:7FGVVM6>E>(O#.H65MJMO8:CJ%E#?Q0K<Q
M6E]>0)(([B56\S.<!/-,KQN7TZD:4\51]E&I-.48/FC*\E'5K3IJ?7<!\24>
M$.,,@XFQ&%JXRAD^/CBZF%H3A3JUHQIU(<E.=3W(RO-.\M+)G^<_@^A_(T8/
MH?R-?WP_\0F__!-'_HH_[<'_ (DRW_S!4?\ $)O_ ,$T?^BC_MP?^),M_P#,
M%7YA_P 0RQW_ $-<)_X(K>7GYO[O,_L#_B;KAW_HCL\_\+\O_P#D?7^EK_ ]
M@^A_(T8/H?R-?WP_\0F__!-'_HH_[<'_ (DRW_S!5\UZ=_P;)?\ !/.Z_:\\
M6_ Z3XC?MF?\(CHO[.'P^^*MGM_:18:T/$?B;XJ?%#P;J1GN_P#A"#OTPZ7X
M1TK[+;"V00W2WDAFE:;;$?\ $,L=_P!#3"?^":WEY^OW>8?\3=<._P#1'9Y_
MX7Y?Y?W?7\#^++!]#^1HP?0_D:_OA_XA-_\ @FC_ -%'_;@_\29;_P"8*C_B
M$W_X)H_]%'_;@_\ $F6_^8*C_B&6._Z&N$_\$5O+S\W]WF'_ !-UP[_T1V>?
M^%^7_P#R/K_2U_@>P?0_D:_T,?\ @V&X_P"":,N0?^3D/C9V/][PEZ#V/Y&O
M+_\ B$W_ .":/_11_P!N#_Q)EO\ Y@J^B/A=_P &^GP"^!WAEO!7P5_;C_X*
MN_"/P:VIWVM'PG\-?V\O'/@OPV=8U,0#4M5_L7P_X;L-/_M'4/LUN;V\\CS[
MDPQ&9W**1]#PSP9B<AS+Z]5QM#$0>'JT/9TZ=2$DZCIR4KRTLN1IK?J?F'BY
MX^91XD<(_P"K>"X>S++*ZS7 YC]9Q>*PM:ER82GBH2I<E%*?--XA.+V2BT]T
MS]ZV.5; /W3_  MZ'VK_ #)_^"] )_X*S?M><'_D-_"L]#G'_"BOACSCK7]F
MA_X(K>'2"#_P4S_X+.X/!_XV/_%3_P"4]?,'C[_@UZ_8/^*WB[6/B!\4?C]_
MP4,^(_CSQ%):2^(/&GCG]KC5?%/BK7);"PM=+L9-6U[6?!=YJ6H/9Z98V6G6
MK75S(8+&TMK6(K#!&B^YQ3D57B# 4<'1Q%/#2I8N&(<ZL9SBXQI5J;BE#6]Z
MJ>NED^MC\[\&_$?!>&'$F89YCLLQ>:TL;D=?*8X?!UJ-"I"I6S#+<8JTIUTX
MN$8X&4'%+F<JD7LF?Y]V#Z'\C5ZTU'4K"WU>TL;V\L[7Q!IL6C:];6L\T%OK
M>D0:KI^NP:5J\,3+'J6FPZWI&E:Q%8WBS6L>JZ9I^H)$MW96TT?]Z?\ Q";_
M /!-'_HH_P"W!_XDRW_S!4?\0F__  31_P"BC_MP?^),M_\ ,%7P2\,L<O\
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MK^'O^DF?_!9W_P 6/_%3_P"4] '[39'O^1_PHR/?\C_A7XL_\.5_#W_23/\
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M-\.MJS>'/ /A&'4-1@\'^!M(\.^%H-1OX='2\G]RHHH **** "BBB@ HHHH
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IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>environsustainability.jpg
<TEXT>
begin 644 environsustainability.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_X0"217AI9@  34T *@    @ !0$^  4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW716=EOMV8?%*LKI-+S-JBBBOLCJ"BBB@ HHHH **** "BBB@ HHHH ****
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MID7X/?\ !0[P3\1/$\^@V7@N;P]<Z?#JNM@?8]-OXQ*T48<Y\J1W="&'+*)
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M>J3Y\5A55E+ZNU[UKIWZ=G_P#P/X5?\ !3OX!_L^_ NS\%:+HOQ TW2[:V>
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MMW9V^=E?4^T\0G[*=#&QT]K%7?71*]ODT?6GQ=O_ -JK]F_X>W/CB;Q=\/\
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M5MC:@8U)2,N/F"Y))"D%N!D#.9/@[XVT.Y^&"W%CIUOX;T;2 T*VZ[5AMT4
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M_L/^"[[7+K4/[:\ ^*;KP]JLMP^VX:ZAC'V26X7O( 2C$YR^2<[N;'PZ\8_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOV*[>>U1H+OS$#0W?ED;5=T!# <!E?& 0!^5O_!:3]LR']K+]L:ZTG0KA9/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M /B*9)^SG\/91\W@/P:WUT6V/_LE=E12]G'L@]K/NSSN^_9!^$NJ?\?7PO\
MAW<?]=?#=F_\XZYWQ%_P3I^ /BV'R]1^"?PINDZ$-X4L1G\HQ7LU%2Z%-[Q7
MW(J.)JK:3^]GS)K?_!&+]E/7BK2? /X:VLBG*RV&D)8R*?4/#L8'W!KI_ 7_
M  3M^''PBLC;^"Y/'?A",OOV:=XUU<Q9]/*EN'BQ[;,5[I12^KTK\W*K^AH\
M;B&N5S=O5F;X2\.MX4T*&Q;4M2U;R>!<7\BR3N/]IE5<_4C-:5%%;+161RMW
M=PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
=HH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>equitinlossofinvesteechart.jpg
<TEXT>
begin 644 equitinlossofinvesteechart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-?C-\0_P#A4?PA
M^*?Q4_L>3Q#_ ,*U^''CKQ__ &##=BPEUO\ X0OPKJWB;^R(KXVUX+.34_[+
M^PI=&UN1;M.)OL\^SRG^#/V?/^"COA/X@?"KPK\6/BMK7P$MK#XCV/AJ?P%X
M0_94^*/Q%_; ^("ZK>> [CXD>-?#?C3P;X"^".C>(= U?X?^$VL=4\0?V9IF
MO6MC:-=W&K3:0&T>/6/OCXO_  [M/B[\*/B;\*K_ %.[T6Q^)?P]\;?#^\UC
M3X;>XOM*M/&GAC5?#-SJ5E!=@VLUW80ZH]W;17(,$DT*),#&S5\O:M^Q5:V7
MAG]FM?A?\4==^%_Q+_9B\ W?PR\'?$K3/!_@K7VUWPAXB\%>#_!?C2Q\4>#=
M<L'\/7MUKO\ P@7@_P 4V&H6[6]UH7BCPUI3*VI>')=:\-ZR >Q_"[]J;X%?
M&SQ;KW@OX3^.8_'VK^&/#WA'Q3KUWX;T+Q-?^&-.T+X@>"?!OQ&\!WTOC1=&
M7PBY\:>"/'GAWQ)X5M(=:DO]>TQ]5FTZUG_X1[7AIWPGX9_X*\?!_P 0ZW\.
M'OOAA\8O!?@7QIJW[=^AZSK_ (P^&OQ,M_&&@WG[#?Q*\&> ?$5_I'PQT+P#
MKGBCQCX=\3V?B75_$VJ:QI21+\-8?"FN>'/&,$/BG2M?TK1/JC]DK]B[P!^Q
MVOQ(TWX<>(?$NJ>&?'+?!F#3=&\2?V;<3^&=-^"WP"^''P#T>W35;&VLYM9N
M]=TOX=6OB?7=1OK:"237M7U&.T@MM.CM+>+QK0O^"<.@:%X\;Q+;_%SQ7)X8
MTB+]NJ'P5X0/AKPU%)X=A_;^\:^'?B=\6XK_ ,2PE=0\2KX=^(FDZGJW@22^
MM+6XT_1=8C\.ZO/K":19:BX!]+>&OVO?V>_&/C?2/ 7A;Q^NO:EK]YI.D:)K
M^E^&O&%W\.=5\2Z]\/[/XK:-X,T_XKQZ ?AG=^.]4^&E_9>.[+P-#XK?Q5/X
M6NH-672?)E0'S;XR_MCO\%_B[<_!;7OAQ->^,/'WA/PYJ_[+JVWB9+>S^/OB
MV[U\>&/B!X $UQHG_%&ZK\'WO_#/Q"\?WX_X22"R^"NN:G\2K6WFM? _C#3M
M-\%_9P_X)/?!C]FWX@?#WQOX<U+0_$4_@:R\&:G)J7B7X,?"'4/B)JOQ \)_
M![P]\'+CQ%:?%J[\.WOC;PKX;U[3_#L'C&[\&>&[FRDTWQE?:FNC>*++P=?W
M/@^3[%^,W[-'ACXV?$_]GKXC^(]9U&V3X Z_\5=:M?#5K:V<FG>+X?BO\%_&
M/P5UC3-8O9-FHZ;!9:+XSOM2M;C1Y8+J6[@CMII!:RR@@')Z/^W9^S;K^CW.
ML:#XI\8>($6QT'5]$L/#_P &_C1K&M>/O#WB<ZM'H'C/X5Z!9?#Z76_BE\/M
M7GT+54LOB%X$L->\$^5;1WMQKT%A>Z==WF'>?\%&/V-;&R?4KCXT6*Z=;?#A
M_BUJE\GA+Q_-;^'O ,7C'Q[\.)]8\5&'PI)+X5N[?XE_#7Q;\,KGP[XABTWQ
M-!\2K.P^'[Z/_P );KFB:1?_ "5X8_X(Y?"?P+X2T;PGX*\8:%H-EX+NO!>G
M^$K6/]GOX%'2/%/@7P1I/B#0],\(?M%Z98^&=,N/VCTEM==LM;GNO&FK:;I2
M>/?!'@'XB6WAJ+Q;H-YJ.L>B?!G_ ()9_#_X&Z)\3O#_ (,^*7BF+3?B+\'O
M$'P>CM;OX??!N^TCP_H^O_M1_M)?M1SRP>"M3\#:E\-M5TL:Y^TEX@\"R>"]
M0\$?\(>_@;0].L+32=/N+N>6  ^]_!7QJ^'WCKP5K?Q T_4-:\.>&O"\NKP>
M*Y?B5X-\9_"75?"DF@:;!K&M-XG\/?$_0/"6O:%:Z?I5S#JDFHZCIT.F3:7(
MFIVE[<6#K<GPM/V_/V6/[$T?7KGQ[X@TZ#Q'XJ^'_@[PUI>K?"CXOZ/XI\3Z
MQ\6M.\5:I\)YO#/@W5/ EGXL\1:#\4+;P3XHB^'WBG1M%OO#GBW4]%O]%T?4
M[C6;6?3XZ/PB_8G\'^ /@3\:O@+XM\4:KXX\%_'L>,;/QEX;TS3K7X>^ /"O
MAWQS\/=,^&NO^#/@]X T"[OM.^%?A&_T;3KG7[K1M$U&ZCE\=^(O%/BN-[>;
M639V_@GPZ_X)8?#;X>0?#@:5XNTS2K[X<?'3X'_&&WOO GP1^#/PMF\6V?P"
MT/XDZ)X0\/\ CN3P'X;TJ\\4:KJZ_$_7]2\4>*[Z^*-J?[WPGX:\(6^HZW:Z
MD =+\?O^"HW[/GPH^!?C+XN?#ZXU7XQZYX:^'(^(EMX'T?PQ\2-%^RV<OQ#U
MCX566D_$OQ&?A]J]K\$]9U'XA>%_&7@K3](^)UEX?UJ[\7>#?%'A^+2S?:#J
MRV?O=Q^W%^S'8IXZNM3^)#:3I7P_T_QSJFJ^(M5\&^/]-\*Z_9_#/Q=8> /'
M_P#PK?Q1>>%8=!^+5WX0\=ZMI'@G7M-^%]_XNU&S\7ZOI7AQ;6;5-3L;>X^.
MM2_X)+^&_P#A"OC/X#\+?'_XC>$M$_:-D\>M\<#:>%O FJ7?BU=;_:&^,O[0
MO@+^RKC5;"=O"T_@?4OC7XC\!ZG-8_:1XW\"Z;HD-]'HWB*VFU^;2T+_ ()%
M? 3PZ/B/8Z+>Z?X?T_Q++KNI^ M<\,?";X1:)\5?A_XCU?XQ^'/CUI.NW_Q?
M/A6^\9_$1O ?Q'\)>'Y?!NC^*9H]#N?#=A%H7Q#L/B#/%9ZO9@'O_P -_P!M
MO1?B;;_MHZEHG@+7['2OV1M>L-#"^)(/$?@_Q)XTFN/V:OA[^T'>1:QX.\8^
M$_#_ (D^'FI:?-XY;P?)I>LV&H32#3(_$2N+?4HK"'R/X6_\%$[^'PA\"_'?
M[5/P[\$? OP9^T;\!;CX]?#;QAX+^*.O_%;0;.VT_P &>%/B%J7PV\:6FI_"
MKX<^)=/^(<GA#Q=:ZCX7M?"FB^--+\8WFC^(-!TZZM/$$6@:9XD]S^''[(3^
M$M,_:J;Q=\5O$GQ \5_M=:A8ZS\1?$ESX;\,>&8=&U2S^ ?@W]G]4\'Z#HD1
ML=/TB+PUX)TK4K/3]2N-5NXM2DNS>ZKJ7GO.WR]!_P $I=$\;_!KP1\%_P!H
MSXY^)?C5X=^#WP9T;X+_  2AMOAS\/O >D^ [/0C\.S8^/\ 5?#L4'BRP\?_
M !%\OX6>$=*FN_%,LO@UO#4GBKP['X*AL?&7B!KD ^MM5_;H_9JT31;/6-5\
M8>)[&ZN-3\5:5>>#YOA+\7S\3/#D_@/1/#_B?QW>^,_A7%X$D^(O@G0?!?AC
MQ9X4\3>)?$_BOPSI/AS3/#_BOPGJ\FJ/9>*_#LNIR:S^W1^RYX?E^(1U?XFB
MRTKX8^'?B3XF\3^*Y/"'CL^ Y[+X.>'[OQ5\5]/\(_$!?#!\$_$#Q+\.O#UA
M?ZIXQ\)^!=?\0^)=#@TW5X[O2UN-#UR'3?!/"'_!./3/AK%X:\1_"3XK1_!7
MXJZ9'\4M$UWQI\'?@9\$/ 7AW5/!/QCB^%<?C#P_I?PVL/"TWA[2M7T^Y^"?
MPTUSP=XWU>\\6>)M%US0[B+5[GQ-X3U!O"-MP>L?\$B/@G?+^T98:5K>G:#I
MOQ[\%?M/:"FM6_P;^#FH?%?PIXF_:T\.^-=%^*/B=_C3J/A:7XA>)[2VOOB%
MXOUKPOX=O=2TR.R;7+G0-:U?Q!X5M]+T73@#W_Q1_P %&/V9-(LO%-KH?B_4
M=;\:Z!=:UX=M/".H^!_B7X56Y\>Q?#B_^*/@?PAK?B#7?!$&C^#W^+GA*R75
MOA)K7B*:TTCXG6$K3?#^X\3W$36C9WPB_P""D'[._P 2?A!X$^)&M:QK/@[Q
M/XO^%_P$^(Y^&#^"OB7K/B[4_P#AH31OM7@C3_A3I4?@2QU_XY:9J.OV7B+P
MQIGB?X8^']<TN_O?#.LW-P--M;2=XN#^(G_!,CP5\1-6^)6J7_Q5\:V/_"R_
MBQ^S%\5=0MK;1_#DL6GW?[,WPKM?A9I.B6KSQF2:P\76%L-6UJYN";RQOW\O
M3&2!%KA-<_X)%_#/Q?X:\!:1\0/B7KGQ-U7X%>!?A'\,?V=M0^(GP^^&WB?0
MO '@3X/VFI6=AI/C/P1<:/#X<^+EYXYL]4DTWXB:GXBBTIK_ $_2_#TWA*V\
M&>(-,N/$&I 'W!X1_:^_9]\>^.O"?PT\'>-[SQ#XY\9^$;GQWI'ANP\%>/3J
M-EX4T_Q5XO\  FM:MXLCG\,0+X#'AOQSX&\2>!_%5EXX;P[J/A?QI:6WA+7;
M.Q\0:IIFG7?E_P :_P!KOQ+\%_C3X!^'&I?#GP/J&@?$/Q_\-/A[X4MG^.GA
MRR^//CV3Q_K^@:!K_CGX6_ *#PUJE]XL^'GP>DUN36/BMJNL^,_"6LZ-X4\.
M^-/%>GZ'>Z/X=L9O$<G[/W[#?@K]GKXG:3\2_"_B-B^G?L_6GP*;PEHW@3X?
M_#_P:H/QK\?_ !TUCQ7I7ASP!H?A_1]"NM3\4_$36+,:186'V9+""WO=0OM8
M\0W.JZUJ&C\9_P!D75/C?XPB?Q9\</&S?"2?QW\-_B7?_"]?#/@9]2TSQ-\+
M/$7A#Q9X<T[P%\4TT>V\<^!?!^J>)/!&CZSXITBUEU77;VZOO$46@>+/#%EK
M'V.T +_P#_:LO_C;\>?VF_@K?_"+Q/\ #-/V>S\(9M,UCQ?K.D2ZWX_TGXK:
M/XTU&VU^3PCI/VQ_!-A#<>"[R/2-/UO6KGQ%JNDW=CK6JZ/X:>ZBTL>R_%KQ
M?\5/#4/A?3_A%\++#XE>(_$NMW.G7=UXF\<1?#WP%X)TBST;4-3G\1>,?$5K
MX>\:^)F@N[RVL?#^B:3X3\#^)M4U'6]6M6O5T;0K75-;L?D#P9^QU^T!X$^-
M?[2GQVTW]JVTO_$W[0G@?3/#3Z,WP"\%:5I_A+6/A]X5\:^'_@YKND:D?$NM
M2W4GA"Z\8R:EK]MK>F:M9>+GT^WMY[72[.2XMY?6_P!IG]G3XK?'_P"%'@_X
M9:/^T3J?PWCMKK36^+5Y8?#O0]=L/C=H5KH;V.J^"/%>G1Z[X8U+0/!7BG66
M35_%.D^#?$6B7.NZ;$_@S4+^7PCJ6N:3JH!\QZ?_ ,%,]3\5?#W5_B5X#^ D
MFN:!\)/@3/\ M$?M'0ZG\5M!TR\\(> +7XA?&?X=A/@]/IOAO7M,^-.H:Z?V
M>OB]X]\$:I=WOPX\(>,/A[H_@_5K/Q#9WWQ!TRQTSZ-T?]K\:[^UKIO[-]C\
M*_$<7@[6OV;_ ![^T'X:^-M_K>BPZ+XWM_ GBOX):!>:-X'\(6AOM?U30YK+
MXVZ/>#QMK<WARRN-5TR^T/0]*UQ(-0U6P\Y\0_L%:EXK\.G1K_XX:EX7E\=_
M _3/V9_V@H?AG\+?A_X*\+_%7X&^'-3\=R>$/"WAOPG.GB*W^#VL>%/#'Q(\
M:>!=&\2>#]1O&M_#/B;5!'I46KV/A'5/"FQK/['WQ1N_VLO!7[2&@_M$VWA?
MPOX!^&WB7X)>'/A%IGP3\+-:6?PB\<>(_A-XI\7>'T\<OXJCUQ/$$NJ_"#PZ
MOAOQ.FF+#X;L+K4+8:!JDK0W48 ?L5_MEZK^U1]MFUJ+X Z#)/X$\'_$#1?"
MGPV^,OC3XB>.K?1?%L27"7'B'3/%'P7^&&B3:5IAN;;1+SQ/X"U_QUX:/BN+
M4-!.IQ36T<EQ[U\=/B=\6_A^E@/A?\)/#?CNWB\.^+?%WB[Q=\1?BS8?!WX<
M^#]&\(PZ;<'3+_Q+_P (IX]U>7Q/XFBO+V;1$?PM:^#]*TO0=?UGQAXPT"*U
MTJQUSQZ/]EGXOV<^N^,W_:A\6^*?C!H/P?\ '/P9^ _CWQ)\._A?9Q?#'1_'
MNK^!]<USQ1XC\/:%X<M=#^)/C34=4^&W@2;5;_4]/T;PU):^'?LNB>#= DUC
M6KJ]T?VOOV7?B)^TXG@+1=#^.J?#SX>>'+S5=3\=?"G6?A1X<^)W@#XRW[MI
MK^%H/B1IVI^(?#&I:QX7\)36M_J">!'U63P7XLU2]M+CQOHGB&TT33;! #P?
M_AYC8:QX-U'XQ>$/A%>W7P2^&OPB_9Q^,G[06O\ BSQI:^%?B%\,O#_[1OA;
M2OB#8Z5HOP^MO#OB"P\6Z_\ "WX;:YH_CWXH6>K>,O!<*:/J5MIO@6X\8>(%
MN=-@^B/!7[6%YXM_:X^*?[+U_P#"/Q1X+L?AQ\&O#7Q=T_XC^*]9T>T3QU9Z
MW\3O'OPTO3H7@^R-]J.E^%+"]\"W-]I/BWQ'J6EW7BF"ZFNK#PU:Z%:V&O:U
MP'C?]A"+XBZAKT_B?XO:_#H_QF\*?"SPW^UCX5\.^#O"NC^'_CY-\)X5M]-U
M&S2Y.K:I\+AXOTD+X)\?V7AW4]736_AW::5X>TJX\/ZOIR^*9<?Q#^POXT\;
M_M.?$[XX>/?CY#XE^'?Q=^#=[^SCXV^",7PBTKP]::A\"9M=^(7B&V\)V_Q*
MT'QO9^-M-\1B^^(^LP:CXUTW[)>WMC!:+:Z;I5^AU*@#T+]F/]L>W_:5^+W[
M1WP_TKP#/X=\(_!L?!G5_A]X]N?$*ZA+\7_ OQD\'Z[XET3QS%X:&BV,G@[2
M[R?P[J$GAFSN]5UF^\0^$;SP_P"+;E=$;6ET6TU_&'[>G[+WP\N/'47C[Q]K
M'@FW^'OA3XC>.-;U;Q9\-/BEX=T'4_"?PAO(K+XHZWX(U_5_!EGH_P 1;/P%
M)<0W'B1_ E[X@-GISOJL0N-+M[F]AYS]FS]@?X3?LM_&WXY_&?X<^(/B5<S?
M&OP]\*?#,WA3QA\3/B3X]T7PIIGPMT;4M)M(M)N/'WC;Q7?Z@^I_;HGCGU9Y
M[KPY8VIT+PY<6&B7U_93_('Q&_X(P_#?XES>,[O7OC1XR;6?$GAK]J7P=:^-
MW\!?#6[^*%WX=_:IT37=-\1P?$;XG7.DGQE\5KSP!<ZX(_AI+XDU*UTWP_X;
MTO3/#D^CWAMDU< 'W5<_MS_LV0/-8+XQ\13^)H?&VM?#^;P+!\*_BY<?$2TU
M_P />#]!^(>KWNI?#RU\"7'CC2_!UAX \5^%?&]Q\0+[P_!X(7PKXH\.:M'K
MTD>NZ5%=YGPJ_:>^('QQ_9"_9R_:0^%OP2&O^+OVC/A[\(O'6F_#Z[^(.GZ3
MX6\!6GQ/\,V7BO4-3\9_$2?09M0E\*>#=-GG2YU'PSX"U[Q-XAOSI6GZ+X1:
M;56ET_@M<_8'MV_:5^(W[5?@3XT>,? 'Q6^(OB.RFN[ZR\+^#?$.FZ9X!O/A
M)\)/A5XS\ 6NG^(;.[@N(?$#_!7P)X[TKQ)<+_:WACQAI86.+6/#-YJOA[4M
M>]_8S\7>'OV*OA#^QQ\%/VC/''PBMOA1X'^&/PQ/Q5L/#.A:WXV\4_#[X>:%
M;^'[[P_?%+_0&\.W?C?3K&TL_$'B?P;JN@^*=-M9-1/A35] U*[@U6Q /.?#
MW[?WCOX@78\ _#'X Z1XI^-WAQ?VE+[XB>#+_P",MKHG@JST;]F/XF:5\)O$
M-W\.?B(O@#4YO'MS\1/&^JG0/ARNL>$/ NEVNI^'O'&G?$;5O!.J^$;C3;_M
M-$_;\T/QG\8OV.? 7@;X4^,-2^&W[87PT\3?$[PI\:M?U+1?#NA6.GZ;\(-&
M^,6@Z)H_AF.76/$'BS5;S0-82V\57JIH?AWPAJ"P:9#K'B35Y[O3]+S=+_82
M\2:)X?\ AY)X7^.<'PP^(W@#P%XW^"=GXP^#GP1^'7@;PZ_P'\<ZIX>UN;P)
MIWPWU.Y\7Z#H>N^$=<\,V.O> _&UK?W$^C:Q=ZS+JVA>(M.UO5-+NLWQ5^P3
MXP'Q1_94\6_"7X^P_"WX>?L=>$F\#?![X62?!OPYXW@A\,ZG\/-)^%WB*P\0
M^,=8\6:=KNJM>^$]'MXM+N8;:QGTF_9[RX?6%Q;T =]X&_;!\2Z[^U#!^S7X
MJ^&GA#2M8U+0/B/XF:S\#?&SPY\4/B-\+-%\$:AX;7PUJ7[1?P]T+0+*R^$]
MA\7-#\3Z;K'PXNM.\9^-4O;F6+0M0\B]E>XMONROBOPM^R+JUK\:_ 7Q@^(O
MQP\9?%*;X/+XZ3X56.K^%? ?AK7;)?B#H<GA?5E^(GC?PCH^E:U\3X=)\-2?
MV/X?L-0M=#TDRP:;XE\4:=XJ\9:'H/B/3/M2@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK\?O^"@7Q5^)?
M@S]O'_@CK\._"'C_ ,7^%O WQE_:1_:&\-?%;PKX>\0:CH^B_$+0?#G[+7C7
MQ9H.D>+;/3YX!K.G:1XDL+/6["TNF:"#4K>*Z"&6-&7]84\.:840E;[)53_R
M&-:[@'OJ)/YDGWH Z"BL'_A&]+]+[_P<:U_\L:/^$;TOTOO_  <:U_\ +&@#
M>HK!_P"$;TOTOO\ P<:U_P#+&C_A&]+]+[_P<:U_\L: -ZBL'_A&]+]+[_P<
M:U_\L:/^$;TOTOO_  <:U_\ +&@#>HK!_P"$;TOTOO\ P<:U_P#+&C_A&]+]
M+[_P<:U_\L: -ZBL'_A&]+]+[_P<:U_\L:/^$;TOTOO_  <:U_\ +&@#>HK!
M_P"$;TOTOO\ P<:U_P#+&C_A&]+]+[_P<:U_\L: -ZBL'_A&]+]+[_P<:U_\
ML:/^$;TOTOO_  <:U_\ +&@#>HK!_P"$;TOTOO\ P<:U_P#+&C_A&]+]+[_P
M<:U_\L: -ZBL'_A&]+]+[_P<:U_\L:/^$;TOTOO_  <:U_\ +&@#>HK!_P"$
M;TOTOO\ P<:U_P#+&C_A&]+]+[_P<:U_\L: -ZBL'_A&]+]+[_P<:U_\L:/^
M$;TOTOO_  <:U_\ +&@#>HK!_P"$;TOTOO\ P<:U_P#+&C_A&]+]+[_P<:U_
M\L: -ZBL'_A&]+]+[_P<:U_\L:/^$;TOTOO_  <:U_\ +&@#>HK!_P"$;TOT
MOO\ P<:U_P#+&K]CIMKI_FFV$X\W9O\ .O+V[^YNV[?MES<>7]XY\O9NXW;L
M+@ OT444 %%%% !1110 4444 %%%% 'X@?\ !2?_ )22?\$*?^SK?VH/_6.?
MB#7[>1_ZN/\ W%_]!%?B'_P4G_Y22?\ !"G_ +.M_:@_]8Y^(-?MY'_JX_\
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M_P""ZWQF01,_P ^&:K-$9X6;QAXQ59H%FFMC/"S:8!- +FVN;8S1EHA<6US
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M-4J*A.G2I3AS8CDJ1I72<X/$.$I23:<G&]/XZ'LJGOGTC?\ B/X97/[.&E^
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M_'FK7.DMK^N:9>-8^$=*M[>RTW2X?UF'X]3UQZGT[>G?&,\T ?B#_P %)_\
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M7H?]Y_\ T-J_,_$#^+EG^'&?^ZI^O^%O\/.?\>!_])Q1\:?\%#O^3)/VF_\
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M$<'^_,:-<G)_M_7/O-_RUTSCYCP/^)3T]!V&!D]:_,_$#^+EG^'&?^ZI^O\
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M[S_^AM7^?A\/?^2@_#[_ +'_ ,"_^I=HM?Z!Z]#_ +S_ /H;5^9^('\7+/\
M#C/_ '5/U_PM_AYS_CP/_I.*/C3_ (*'?\F2?M-_]DD\3?\ HN"OXCG^^W^\
MW\S7]N/_  4._P"3)/VF_P#LDGB;_P!%P5_$<_WV_P!YOYFO0X!_Y%^,_P"P
MQ_\ IB@>7XG?\C; ?]@#_P#3]4;1117WA^:!1110 4444 ?OA_P0>_Y'S]I/
M_L4?A;_Z??&]?TH5_-?_ ,$'O^1\_:3_ .Q1^%O_ *??&]?TH5^*\8?\E!CO
M\.%_]1*!_0_ 7_)+9=_CQO\ ZG8@****^9/L0HHHH **** "BBB@ HHHH _$
M#_@I00/^"D?_  0I)( _X:M_:@Y/ _Y,Y^(-;'_!<-E/[+'PWPRG_B^OAWN/
M^A!^('O7U;^W#_P3S^&O[=5W\#M=\7?%_P#:.^!GCC]G7QAXI\<?"OXD_LR_
M$G2_AAX_T#7/&?A*7P/X@9-?U+PCXMVV][X:N;S3&6TMK.?[/?7L+7#P74L+
M?"_Q!_X(+>!?BSHUMX<^)_\ P4S_ ."P?C_0+/4X-:M-&\5?MC>&M5TZVU>V
MMKNSM]2BMIO@OY:WD-I?WUM%/C<D-W<(,"5L^AE6,A@,QPF,J0E4AAZJJ2A"
MRE))-63DTKZ]6>7G6 J9GE>-P%*<*53%4?9QJ5.9PB^:,KR44Y6LNB;/YH,C
MU'YBC(]1^8K]_/\ B&/_ &3?^CT_^"H?_B4OA'_YR]'_ !#'_LF_]'I_\%0_
M_$I?"/\ \Y>OT/\ U_P/_0!C/_ Z'_R?]6?E?\H_XA?F?_0RR_\ \!Q/_P J
M_JS\K_@'D>H_,49'J/S%?OY_Q#'_ +)O_1Z?_!4/_P 2E\(__.7KYOT[_@WL
M_9QNOVM_%?P)D_;-_P""E(\(:)^SIX!^+%I.G[3GA<>(F\2^*/BE\3?!>H1W
M%Z?A$;=]&32O!VEO:6JV$<L5Z]]*]W,LR10'^O\ @?\ H QG_@=#_P"3_JS\
MKG_$,,T_Z&6 _P# <3_\J/R3R/4?F*,CU'YBOW\_XAC_ -DW_H]/_@J'_P")
M2^$?_G+T?\0Q_P"R;_T>G_P5#_\ $I?"/_SEZ/\ 7_ _] &,_P# Z'_R?]6?
ME<_XA?F?_0RR_P#\!Q/_ ,J_JS\K_@'D>H_,5_6;_P $5F7_ (8TD^9?^2Q?
M$KN/[V@>]?%W_$,?^R;_ -'I_P#!4/\ \2E\(_\ SEZ]I\!?\$'O!GPLT'_A
M%OAK_P %./\ @L-X$\-?;KK4_P"PO#'[8_AO2]+_ +1OBAO;W[+#\%]@N;HQ
MQF>0<N44GI7A\0<58;.,!]3I87$49^WIU>>K*DXV@IIKW)-W?/II;1^1])PM
MP5C<@S3Z_B,9A:]/ZK6P_LZ*K*?-5E2DI7G",;+V;3UO=Z:'[LLZ8/S+T/\
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M+VV(JUDESJ,O=511=UNG:ZLS[5HHHKR3W HHHH **** "BBB@ HHHH ****
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MYWU33O#>A)J%E9:9X^LM)\&V,-K:3: A\97&K7?B&7Q/8?V!^BM%% !1110
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MKG7-<N?#/@70?#GA^XUO6)M-?4KKW2BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>fampyra.jpg
<TEXT>
begin 644 fampyra.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  C 'X# 2(  A$! Q$!_\0
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MM@''\S110T@N%I:01VT>V-1\H_EBG?8;<.7\I=Q&,_Y^@HHH458&W<<;2!@
M8EP.F.,=_P"M2A0%VXXQC%%%.PC#U#PIHMR&EDTZ'>3DE<K_ "(K.M_!VAM,
M U@I&>AD?_&BBLY15]C*45?8WK70=,LHFCM[&!$?AAMSG\34,GAS26<$V,0/
MMD#\J**)PBUJC>$G'X78M6>E65B=UM:Q1M_> Y_.KE%%:122T$VV[L****8@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>financialhighlightschart.jpg
<TEXT>
begin 644 financialhighlightschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &J 3T# 2(  A$! Q$!_\0
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MA[X=:5X1;PQX/UK0=8^'GAFY\"^-IO\ A*O$^E;-0C\57?CB&>PATOS?4?\
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MBO\ B?$W[ L_C73=1T[Q#\:]9L+;XJ_";P7\$OVH=+\#?#OP+X.\.?'#X>>
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MB&PDU2\N+TV_GRL] '[945@?\(SI/_/.[_\ !KJ__P GT?\ ",Z3_P \[O\
M\&NK_P#R?0!OT5@?\(SI/_/.[_\ !KJ__P GT?\ ",Z3_P \[O\ \&NK_P#R
M?0!OT5@?\(SI/_/.[_\ !KJ__P GT?\ ",Z3_P \[O\ \&NK_P#R?0!OT5@?
M\(SI/_/.[_\ !KJ__P GT?\ ",Z3_P \[O\ \&NK_P#R?0!OT5@?\(SI/_/.
M[_\ !KJ__P GT?\ ",Z3_P \[O\ \&NK_P#R?0!OT5@?\(SI/_/.[_\ !KJ_
M_P GT?\ ",Z3_P \[O\ \&NK_P#R?0!OT5@?\(SI/_/.[_\ !KJ__P GT?\
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M 3]Z;L/^NE&X&^6 _O?]\L?Y"C(]_P#OEO\ "OX>?^"IW[2_QH\6_MC?&3P
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MW/E]2+OJFCYG'QJ_:)\32QKX$_9(\2:197" PZS\</BK\._AU9IN##S9M&\
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M&[UCPYXJTBSN9Q<W.G6?B;PU?Z3K/]E7$X,\^DW%W/IKW#-<_9!<GSJ^A?\
MA%M _P"@9!_WU+_\<H_X1;0/^@9!_P!]2_\ QRN+ 9GF.5XRGF&68_&9?CZ+
ME*EC<%B:V%Q=-S3C-PQ%"<*L>>,I1G::YXR<973:?7CLMR_,\)4P&8X'!X_
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M>6MG;VUWJEQ!:VUQJ5S!$D4U_/;V,%M8P37<B-<2Q65M;6D<DC+;6\$ CB0
MO5^>7[67[?&D?LN_$K1OAQJ7A?P>;G4_A;JOQ3T_4_B;\6]/^$$7Q,;2_$Z>
M%Y/A#^SK;7OA'Q:_QJ_:"ENY=-E3X7PS>$PH\6^ +<Z\]QXQM19?H;7P%^TY
M^PKI_P"T1XC\?ZY#\19/"]O\8?A)I?P-^)^G:]\/_"GQ25/A_I%YXOO;>Z^%
M,_C*4)\*/&LL_C;5;B]URTM?$OA_4-3TWPOKM_X-N-=\.6>I. >Q?&C]H+5/
MA]JWP5\ ^!?!%EXT^+_Q]U_7-*\"^#?%WBV7X<Z'INF>#_!E_P"._''B7QOX
MFM/"_CS5-&TOPUI-I9:3):Z#X/\ %6KWGBKQ#H&EI80:;-J>N:5\JR_\%)O[
M;\)ZUXM^'7P0U3Q3!\(O@GKOQU_:=T;6?B%H'AG7OA'X?\)_$?XI?"KQ3X+\
M*V]KH_B73OB;\3=-\6_ ;XX"TTB?4_ ?A'4]*^'PNT\;6UYXGT'3Y?:/&'[*
MWCCQ-X@T'Q9I7QGO/#?BKX+^--,U?]FGQ!?^#M)\:7'@GPA>?!+1?A3\1O!7
MQ$35=2T[4_BGI?Q#U$:]XLU+4;_Q!H7BG3]<3PW=:?XAC@T4V5[Y3>?\$VM"
MT[PK=^$? 'QH\=>#K+XC?"'7O@;^T=JL_A_PAXBU_P"-G@OQ?X_^)'Q0\6^(
M%O+FRT[3OA_\3=4\9_&CXS7-KXLT'2=0T+2=,^)VO6-KX)DNM)\':EX: .RA
M_;MT_4/'$ESHO@*TUC]GBU_:#\!_LM77QNM?'=M_:S_&'XCZ5X7?PS<:=\-_
M^$9:.^^&;^,_'7@WX7WWBN7QU9>*(?'.LO):_#^]\(:?=>*3^@ .0#@C(!P>
M",]B.Q'>O@T_L*^'K;XAF\T?Q[J^B_ JX^-O@7]I74/@)9>'-"&ER?&WX;Z7
MX7L_"FJ6'C8N-?TWP+%K_@CPA\1=2\#K8W%U>?$/P_;:E:^*].\,WVL^$-2^
M\@, #). !DG)..Y/<^IH BG8+%)D-S&_16;^$_W0<?C7XE?\$OS_ ,9R_P#!
M</K_ ,GW?#+L?^C3OA+[>W]>A%?K)\2/@E\*_BO+I][\0_!.B^*[K1+2^MM*
MGU5+EWLH+UX9KJ*$V]U;@+/+;0.^X,<Q+@@9!_''_@E-X&\)>'OVR?\ @MGX
M9T70;#3= TK]NSX:)IVEVR.EK9HW[*OPPNBD*F1F5?/O[N7;N(W3O@ ;0H!^
M\F1[_D?\*,CW_(_X5@_\(MX?_P"@5;?E)_\ %T?\(MX?_P"@5;?E)_\ %T ;
MV1[_ )'_  HR/?\ (_X5@_\ "+>'_P#H%6WY2?\ Q='_  BWA_\ Z!5M^4G_
M ,70!O9'O^1_PHR/?\C_ (5@_P#"+>'_ /H%6WY2?_%T?\(MX?\ ^@5;?E)_
M\70!O9'O^1_PHR/?\C_A6#_PBWA__H%6WY2?_%T?\(MX?_Z!5M^4G_Q= &]D
M>_Y'_"C(]_R/^%8/_"+>'_\ H%6WY2?_ !='_"+>'_\ H%6WY2?_ != &]D>
M_P"1_P *,CW_ "/^%8/_  BWA_\ Z!5M^4G_ ,71_P (MX?_ .@5;?E)_P#%
MT ;V1[_D?\*,CW_(_P"%8/\ PBWA_P#Z!5M^4G_Q='_"+>'_ /H%6WY2?_%T
M ;V1[_D?\*,CW_(_X5@_\(MX?_Z!5M^4G_Q='_"+>'_^@5;?E)_\70!O9'O^
M1_PHR/?\C_A6#_PBWA__ *!5M^4G_P 71_PBWA__ *!5M^4G_P 70!O9'O\
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M\Z@ X"VTGB^Q1MS8!8W*;!E@KGY: />:*\/_ .$*^)G_ $%?@O\ ^&C\0?\
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MU;\.?CAXHO/"7A+2_&%EJ5EHESKTTNO:7IMG9&SM;RPLI(TEL]:U&5K@RZA
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M-T?5=5T?3D^I2WN]2NE'LUJK?[-:S:#HC?>T?2V_WM.LC_."F_\ "/:#_P!
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MPVQ_^,4G_"/Z#_T!M)/TTVQ/\K>NL#3^T6__ #WA_P"_J?\ Q5'VFW&29X<
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MC^UM,_Z"%C_X&6W_ ,=H_LG3/^@?8_\ @';?_&J/[)TS_H'V/_@';?\ QJ@
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M ."/7_1W\7_AA?VH/_G)4?\ $0__ ,$>O^COXO\ PPO[4'_SDJ_:C ]_S/\
MC1@>_P"9_P : /Q7_P"(A_\ X(]?]'?Q?^&%_:@_^<E37_X.(O\ @CM$CRR_
MMAVT,4:-)+--\"?VG8H8HT4M)+++)\%%CBBC0%Y)9&6.-%9W95!(_:K ]_S/
M^->#?M3^ _$?Q1_9E_:)^&G@ZUAOO%OQ#^!7Q>\#>%[*YO8-/M[OQ%XN^'GB
M/P]H=K/?W<D=K90W&J:C:PRW=S)';VR.T\SI'&S  _- ?\'$'_!'D@$?M@0D
M$ @CX#?M0$$$9!!'P2(((((()!!!!Q1_Q$/_ /!'K_H[^+_PPO[4'_SDJ_8G
MPII]SI7AGP]IEZ@CN]/T+1[&ZC602*EQ9Z;:VTZ*Z,4<++$ZAU)5P P)!!K?
MP/?\S_C0!^*__$0__P $>O\ H[^+_P ,+^U!_P#.2H_XB'_^"/7_ $=_%_X8
M7]J#_P"<E7[48'O^9_QHP/?\S_C0!^*__$0__P $>O\ H[^+_P ,+^U!_P#.
M2K[2_9 _X*)_L=?MZ/X_C_90^,*?%9_A</#)\=!? /Q1\$?V&/&/]N?\(X2?
MB1X(\'#4O[1_X1S6<?V.=0^R?8S]N^R_:+7S_M; ]_S/^-+C'K^))_G0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)D @$@$YP
M,\G'7 [X[XI:_-+]KG5/C?HWQ*\/67P5^.WB^?XS^)]1^',7P8_9Z\+>$/#5
MS\.],\,6/B_3H/C%\3_VD[R]T;Q!KMQ\+I- N=5M;_Q9+K_P_CT)].T/PA\*
M+;6?B_KUI_;8!^EF1G&1G&<9YQZXZXI<@YP0<'!]CZ'T/(K\<?"?QU^.5S\0
MOAG\38?B=XBURY^,'[>_[3W[(.J?L]W]AX,/@CP)\//A2W[2>D>!/$MII>FV
MD/C.T\7^'+3X(^$?BYXXUJ3QG>S^(_"_CSQ1I<VGV6DMX%G\+P?"7]K[XJ?"
M+X'?MP^-/CKX^3XN>,OA-^W-X\^ GPZU>7P3<>%O"%I/KF@?!E/ FC7NA^"K
M3Q#J?A#X3^$O$'CC4M0UK6M6U+Q5K^C^"+#4;W6_%/B7Q"%N[\ _90$'D$$9
M(R#GD'!''<'@^AI:_,O_ ()3?M ZK^T'^SOX_P!6\0_&2_\ CMX@^'_[5?[6
M7PNN/B%J>AP>'+W5?#O@[X^^.[+X>9T>ST70[+3[$?#P^&GT>P@M9Y]-T9[#
M3M4OKS5[6^N)/TTH **** "BBB@ HHHH 0D#&2!DX&3C)]!ZFC(SC(SC.,\X
M]<=<5^<W[=VJ_%;P]9I??"7XX_$?0OBSKG@S4]!_9F_9_P#A3X7\$ZGJGQ%^
M/4<VH3VOBSXG7/BK0_$K:G\$_#Z7?A2S^(,FH#P/X$^'WA23Q3XC\3>+;OQ'
MKG@9?#_@VM_'CX[VOC_XA_%*\^)6NZ7J7PO_ &_?V=?V.+;]G.TM/!R_#[Q=
M\._B?!^SWH7C#Q"+"_L#XVF\8:L/C)XH^./A#Q._B^UNM*\&>#O#FBMHTV@1
M^+SX@ /V2) SD@;1ELD<#&<GT&.>>U(K*PRK*P'!*D$9].":_&G0OB9^U7J"
M?\%8/A]KGQGL_$'C[X7^(?A#HGP9U?0;/P3\(= ^'C_%']F[X;>+)?#W@'4O
M&]]J.EZ1/'XA\37TVA>(_B?XG\2W5QXKOH[R^NH=.ET_PYI_U=^QGXA\2:3K
M'QP^!GQ$U+XDZK\3/A5XE\':]KEYX\^,&G?'&Q?PS\3_  O)J7@Q/#7C>U\
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M,O@S\,?%-WXC\::3\1M?N?$'@GP]J\^L^/=!\&67PZT?QAJ<E_83M>^(].\
M:;8^";;5IR]XGA.UA\/&1M*3[*0#\T/@;_P5"^(/QE\6^#;:T_9Q\2IX/U"'
MX5^%_%^KZ;HOQ-?3]'\<?$7]ESP)^TE?^(H?B9J_@73/@MIWP[\,7'Q \/\
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M #^?6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***R#K^B+K:>&CJVG#Q ^FMK*:*;N :HVDI<BT;4EL2_V@V2W3"W-R(_*$I"
M;LYQ483GS<D92Y8N<N6+ERPC\4I63M&/63T75D3J4Z?+[2<(<\XTX<\E'FJ2
MTC"-VKSD](Q6LGHDV:]%%%26%%%)N7GYA\OWN1\O&>?3CGGMS0 M%%(2!C)
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MBF1R"6..0*Z"1$<+(ACD4.H8*Z, R. <,IY5@5/(-?@Y^U+^TG^T!\#/$O\
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MP.^#'AOQ_J?Q5\/_  G^'&B?$W6M.ATC5_B%I/@GPWI_C74]+M[2RT^*PO\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>fumaderm.jpg
<TEXT>
begin 644 fumaderm.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M_P 8H^N4?YG_ . 3_P#D0^L4OYOPE_D'_"56'_3Q_P" EW_\8H^N4?YG_P"
M3_\ D0^L4OYOPE_D'_"56'_3Q_X"7?\ \8H^N4?YG_X!/_Y$/K%+^;\)?Y!_
MPE5A_P!/'_@)=_\ QBCZY1_F?_@$_P#Y$/K%+^;\)?Y!_P )58?]/'_@)=__
M !BCZY1_F?\ X!/_ .1#ZQ2_F_"7^0?\)58?]/'_ ("7?_QBCZY1_F?_ (!/
M_P"1#ZQ2_F_"7^0?\)58?]/'_@)=_P#QBCZY1_F?_@$__D0^L4OYOPE_D'_"
M56'_ $\?^ EW_P#&*/KE'^9_^ 3_ /D0^L4OYOPE_D'_  E5A_T\?^ EW_\
M&*/KE'^9_P#@$_\ Y$/K%+^;\)?Y&U:W45Y$EQ VZ.55=#@C*L RG! (R"#@
M@$=QFNV,E-*<=4TFO1ZHZ4U)*2V:NOF<9XID*W5H.PF8_P#DO<#^M>9COX</
M\:_])F<&+^!?XE^3*GFBO!/&#S10 >:* #S10 >:* #S10 >:* #S10 >:*
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MMNG%::;6;T_$SHT8U%!MN\IRCI;HFUT\B6*RLY?)*R3 7081@A,AESDMVQZ
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MT4 'V2+^Z* #[)%_=% !]DB_NB@ ^R1?W10 ?9(O[HH /LD7]T4 'V2+^Z*
C#[)%_=% !]DB_NB@ ^R1?W10 HM(O[HH O1(J#"C H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>gainlossfairvaluechart.jpg
<TEXT>
begin 644 gainlossfairvaluechart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-?C-\0_P#A4?PA
M^*?Q4_L>3Q#_ ,*U^''CKQ__ &##=BPEUO\ X0OPKJWB;^R(KXVUX+.34_[+
M^PI=&UN1;M.)OL\^SRG^#/V?/^"COA/X@?"KPK\6/BMK7P$MK#XCV/AJ?P%X
M0_94^*/Q%_; ^("ZK>> [CXD>-?#?C3P;X"^".C>(= U?X?^$VL=4\0?V9IF
MO6MC:-=W&K3:0&T>/6/OCXO_  [M/B[\*/B;\*K_ %.[T6Q^)?P]\;?#^\UC
M3X;>XOM*M/&GAC5?#-SJ5E!=@VLUW80ZH]W;17(,$DT*),#&S5\O:M^Q5:V7
MAG]FM?A?\4==^%_Q+_9B\ W?PR\'?$K3/!_@K7VUWPAXB\%>#_!?C2Q\4>#=
M<L'\/7MUKO\ P@7@_P 4V&H6[6]UH7BCPUI3*VI>')=:\-ZR >Q_"[]J;X%?
M&SQ;KW@OX3^.8_'VK^&/#WA'Q3KUWX;T+Q-?^&-.T+X@>"?!OQ&\!WTOC1=&
M7PBY\:>"/'GAWQ)X5M(=:DO]>TQ]5FTZUG_X1[7AIWPGX9_X*\?!_P 0ZW\.
M'OOAA\8O!?@7QIJW[=^AZSK_ (P^&OQ,M_&&@WG[#?Q*\&> ?$5_I'PQT+P#
MKGBCQCX=\3V?B75_$VJ:QI21+\-8?"FN>'/&,$/BG2M?TK1/JC]DK]B[P!^Q
MVOQ(TWX<>(?$NJ>&?'+?!F#3=&\2?V;<3^&=-^"WP"^''P#T>W35;&VLYM9N
M]=TOX=6OB?7=1OK:"237M7U&.T@MM.CM+>+QK0O^"<.@:%X\;Q+;_%SQ7)X8
MTB+]NJ'P5X0/AKPU%)X=A_;^\:^'?B=\6XK_ ,2PE=0\2KX=^(FDZGJW@22^
MM+6XT_1=8C\.ZO/K":19:BX!]+>&OVO?V>_&/C?2/ 7A;Q^NO:EK]YI.D:)K
M^E^&O&%W\.=5\2Z]\/[/XK:-X,T_XKQZ ?AG=^.]4^&E_9>.[+P-#XK?Q5/X
M6NH-672?)E0'S;XR_MCO\%_B[<_!;7OAQ->^,/'WA/PYJ_[+JVWB9+>S^/OB
MV[U\>&/B!X $UQHG_%&ZK\'WO_#/Q"\?WX_X22"R^"NN:G\2K6WFM? _C#3M
M-\%_9P_X)/?!C]FWX@?#WQOX<U+0_$4_@:R\&:G)J7B7X,?"'4/B)JOQ \)_
M![P]\'+CQ%:?%J[\.WOC;PKX;U[3_#L'C&[\&>&[FRDTWQE?:FNC>*++P=?W
M/@^3[%^,W[-'ACXV?$_]GKXC^(]9U&V3X Z_\5=:M?#5K:V<FG>+X?BO\%_&
M/P5UC3-8O9-FHZ;!9:+XSOM2M;C1Y8+J6[@CMII!:RR@@')Z/^W9^S;K^CW.
ML:#XI\8>($6QT'5]$L/#_P &_C1K&M>/O#WB<ZM'H'C/X5Z!9?#Z76_BE\/M
M7GT+54LOB%X$L->\$^5;1WMQKT%A>Z==WF'>?\%&/V-;&R?4KCXT6*Z=;?#A
M_BUJE\GA+Q_-;^'O ,7C'Q[\.)]8\5&'PI)+X5N[?XE_#7Q;\,KGP[XABTWQ
M-!\2K.P^'[Z/_P );KFB:1?_ "5X8_X(Y?"?P+X2T;PGX*\8:%H-EX+NO!>G
M^$K6/]GOX%'2/%/@7P1I/B#0],\(?M%Z98^&=,N/VCTEM==LM;GNO&FK:;I2
M>/?!'@'XB6WAJ+Q;H-YJ.L>B?!G_ ()9_#_X&Z)\3O#_ (,^*7BF+3?B+\'O
M$'P>CM;OX??!N^TCP_H^O_M1_M)?M1SRP>"M3\#:E\-M5TL:Y^TEX@\"R>"]
M0\$?\(>_@;0].L+32=/N+N>6  ^]_!7QJ^'WCKP5K?Q T_4-:\.>&O"\NKP>
M*Y?B5X-\9_"75?"DF@:;!K&M-XG\/?$_0/"6O:%:Z?I5S#JDFHZCIT.F3:7(
MFIVE[<6#K<GPM/V_/V6/[$T?7KGQ[X@TZ#Q'XJ^'_@[PUI>K?"CXOZ/XI\3Z
MQ\6M.\5:I\)YO#/@W5/ EGXL\1:#\4+;P3XHB^'WBG1M%OO#GBW4]%O]%T?4
M[C6;6?3XZ/PB_8G\'^ /@3\:O@+XM\4:KXX\%_'L>,;/QEX;TS3K7X>^ /"O
MAWQS\/=,^&NO^#/@]X T"[OM.^%?A&_T;3KG7[K1M$U&ZCE\=^(O%/BN-[>;
M639V_@GPZ_X)8?#;X>0?#@:5XNTS2K[X<?'3X'_&&WOO GP1^#/PMF\6V?P"
MT/XDZ)X0\/\ CN3P'X;TJ\\4:KJZ_$_7]2\4>*[Z^*-J?[WPGX:\(6^HZW:Z
MD =+\?O^"HW[/GPH^!?C+XN?#ZXU7XQZYX:^'(^(EMX'T?PQ\2-%^RV<OQ#U
MCX566D_$OQ&?A]J]K\$]9U'XA>%_&7@K3](^)UEX?UJ[\7>#?%'A^+2S?:#J
MRV?O=Q^W%^S'8IXZNM3^)#:3I7P_T_QSJFJ^(M5\&^/]-\*Z_9_#/Q=8> /'
M_P#PK?Q1>>%8=!^+5WX0\=ZMI'@G7M-^%]_XNU&S\7ZOI7AQ;6;5-3L;>X^.
MM2_X)+^&_P#A"OC/X#\+?'_XC>$M$_:-D\>M\<#:>%O FJ7?BU=;_:&^,O[0
MO@+^RKC5;"=O"T_@?4OC7XC\!ZG-8_:1XW\"Z;HD-]'HWB*VFU^;2T+_ ()%
M? 3PZ/B/8Z+>Z?X?T_Q++KNI^ M<\,?";X1:)\5?A_XCU?XQ^'/CUI.NW_Q?
M/A6^\9_$1O ?Q'\)>'Y?!NC^*9H]#N?#=A%H7Q#L/B#/%9ZO9@'O_P -_P!M
MO1?B;;_MHZEHG@+7['2OV1M>L-#"^)(/$?@_Q)XTFN/V:OA[^T'>1:QX.\8^
M$_#_ (D^'FI:?-XY;P?)I>LV&H32#3(_$2N+?4HK"'R/X6_\%$[^'PA\"_'?
M[5/P[\$? OP9^T;\!;CX]?#;QAX+^*.O_%;0;.VT_P &>%/B%J7PV\:6FI_"
MKX<^)=/^(<GA#Q=:ZCX7M?"FB^--+\8WFC^(-!TZZM/$$6@:9XD]S^''[(3^
M$M,_:J;Q=\5O$GQ \5_M=:A8ZS\1?$ESX;\,>&8=&U2S^ ?@W]G]4\'Z#HD1
ML=/TB+PUX)TK4K/3]2N-5NXM2DNS>ZKJ7GO.WR]!_P $I=$\;_!KP1\%_P!H
MSXY^)?C5X=^#WP9T;X+_  2AMOAS\/O >D^ [/0C\.S8^/\ 5?#L4'BRP\?_
M !%\OX6>$=*FN_%,LO@UO#4GBKP['X*AL?&7B!KD ^MM5_;H_9JT31;/6-5\
M8>)[&ZN-3\5:5>>#YOA+\7S\3/#D_@/1/#_B?QW>^,_A7%X$D^(O@G0?!?AC
MQ9X4\3>)?$_BOPSI/AS3/#_BOPGJ\FJ/9>*_#LNIR:S^W1^RYX?E^(1U?XFB
MRTKX8^'?B3XF\3^*Y/"'CL^ Y[+X.>'[OQ5\5]/\(_$!?#!\$_$#Q+\.O#UA
M?ZIXQ\)^!=?\0^)=#@TW5X[O2UN-#UR'3?!/"'_!./3/AK%X:\1_"3XK1_!7
MXJZ9'\4M$UWQI\'?@9\$/ 7AW5/!/QCB^%<?C#P_I?PVL/"TWA[2M7T^Y^"?
MPTUSP=XWU>\\6>)M%US0[B+5[GQ-X3U!O"-MP>L?\$B/@G?+^T98:5K>G:#I
MOQ[\%?M/:"FM6_P;^#FH?%?PIXF_:T\.^-=%^*/B=_C3J/A:7XA>)[2VOOB%
MXOUKPOX=O=2TR.R;7+G0-:U?Q!X5M]+T73@#W_Q1_P %&/V9-(LO%-KH?B_4
M=;\:Z!=:UX=M/".H^!_B7X56Y\>Q?#B_^*/@?PAK?B#7?!$&C^#W^+GA*R75
MOA)K7B*:TTCXG6$K3?#^X\3W$36C9WPB_P""D'[._P 2?A!X$^)&M:QK/@[Q
M/XO^%_P$^(Y^&#^"OB7K/B[4_P#AH31OM7@C3_A3I4?@2QU_XY:9J.OV7B+P
MQIGB?X8^']<TN_O?#.LW-P--M;2=XN#^(G_!,CP5\1-6^)6J7_Q5\:V/_"R_
MBQ^S%\5=0MK;1_#DL6GW?[,WPKM?A9I.B6KSQF2:P\76%L-6UJYN";RQOW\O
M3&2!%KA-<_X)%_#/Q?X:\!:1\0/B7KGQ-U7X%>!?A'\,?V=M0^(GP^^&WB?0
MO '@3X/VFI6=AI/C/P1<:/#X<^+EYXYL]4DTWXB:GXBBTIK_ $_2_#TWA*V\
M&>(-,N/$&I 'W!X1_:^_9]\>^.O"?PT\'>-[SQ#XY\9^$;GQWI'ANP\%>/3J
M-EX4T_Q5XO\  FM:MXLCG\,0+X#'AOQSX&\2>!_%5EXX;P[J/A?QI:6WA+7;
M.Q\0:IIFG7?E_P :_P!KOQ+\%_C3X!^'&I?#GP/J&@?$/Q_\-/A[X4MG^.GA
MRR^//CV3Q_K^@:!K_CGX6_ *#PUJE]XL^'GP>DUN36/BMJNL^,_"6LZ-X4\.
M^-/%>GZ'>Z/X=L9O$<G[/W[#?@K]GKXG:3\2_"_B-B^G?L_6GP*;PEHW@3X?
M_#_P:H/QK\?_ !TUCQ7I7ASP!H?A_1]"NM3\4_$36+,:186'V9+""WO=0OM8
M\0W.JZUJ&C\9_P!D75/C?XPB?Q9\</&S?"2?QW\-_B7?_"]?#/@9]2TSQ-\+
M/$7A#Q9X<T[P%\4TT>V\<^!?!^J>)/!&CZSXITBUEU77;VZOO$46@>+/#%EK
M'V.T +_P#_:LO_C;\>?VF_@K?_"+Q/\ #-/V>S\(9M,UCQ?K.D2ZWX_TGXK:
M/XTU&VU^3PCI/VQ_!-A#<>"[R/2-/UO6KGQ%JNDW=CK6JZ/X:>ZBTL>R_%KQ
M?\5/#4/A?3_A%\++#XE>(_$NMW.G7=UXF\<1?#WP%X)TBST;4-3G\1>,?$5K
MX>\:^)F@N[RVL?#^B:3X3\#^)M4U'6]6M6O5T;0K75-;L?D#P9^QU^T!X$^-
M?[2GQVTW]JVTO_$W[0G@?3/#3Z,WP"\%:5I_A+6/A]X5\:^'_@YKND:D?$NM
M2W4GA"Z\8R:EK]MK>F:M9>+GT^WMY[72[.2XMY?6_P!IG]G3XK?'_P"%'@_X
M9:/^T3J?PWCMKK36^+5Y8?#O0]=L/C=H5KH;V.J^"/%>G1Z[X8U+0/!7BG66
M35_%.D^#?$6B7.NZ;$_@S4+^7PCJ6N:3JH!\QZ?_ ,%,]3\5?#W5_B5X#^ D
MFN:!\)/@3/\ M$?M'0ZG\5M!TR\\(> +7XA?&?X=A/@]/IOAO7M,^-.H:Z?V
M>OB]X]\$:I=WOPX\(>,/A[H_@_5K/Q#9WWQ!TRQTSZ-T?]K\:[^UKIO[-]C\
M*_$<7@[6OV;_ ![^T'X:^-M_K>BPZ+XWM_ GBOX):!>:-X'\(6AOM?U30YK+
MXVZ/>#QMK<WARRN-5TR^T/0]*UQ(-0U6P\Y\0_L%:EXK\.G1K_XX:EX7E\=_
M _3/V9_V@H?AG\+?A_X*\+_%7X&^'-3\=R>$/"WAOPG.GB*W^#VL>%/#'Q(\
M:>!=&\2>#]1O&M_#/B;5!'I46KV/A'5/"FQK/['WQ1N_VLO!7[2&@_M$VWA?
MPOX!^&WB7X)>'/A%IGP3\+-:6?PB\<>(_A-XI\7>'T\<OXJCUQ/$$NJ_"#PZ
MOAOQ.FF+#X;L+K4+8:!JDK0W48 ?L5_MEZK^U1]MFUJ+X Z#)/X$\'_$#1?"
MGPV^,OC3XB>.K?1?%L27"7'B'3/%'P7^&&B3:5IAN;;1+SQ/X"U_QUX:/BN+
M4-!.IQ36T<EQ[U\=/B=\6_A^E@/A?\)/#?CNWB\.^+?%WB[Q=\1?BS8?!WX<
M^#]&\(PZ;<'3+_Q+_P (IX]U>7Q/XFBO+V;1$?PM:^#]*TO0=?UGQAXPT"*U
MTJQUSQZ/]EGXOV<^N^,W_:A\6^*?C!H/P?\ '/P9^ _CWQ)\._A?9Q?#'1_'
MNK^!]<USQ1XC\/:%X<M=#^)/C34=4^&W@2;5;_4]/T;PU):^'?LNB>#= DUC
M6KJ]T?VOOV7?B)^TXG@+1=#^.J?#SX>>'+S5=3\=?"G6?A1X<^)W@#XRW[MI
MK^%H/B1IVI^(?#&I:QX7\)36M_J">!'U63P7XLU2]M+CQOHGB&TT33;! #P?
M_AYC8:QX-U'XQ>$/A%>W7P2^&OPB_9Q^,G[06O\ BSQI:^%?B%\,O#_[1OA;
M2OB#8Z5HOP^MO#OB"P\6Z_\ "WX;:YH_CWXH6>K>,O!<*:/J5MIO@6X\8>(%
MN=-@^B/!7[6%YXM_:X^*?[+U_P#"/Q1X+L?AQ\&O#7Q=T_XC^*]9T>T3QU9Z
MW\3O'OPTO3H7@^R-]J.E^%+"]\"W-]I/BWQ'J6EW7BF"ZFNK#PU:Z%:V&O:U
MP'C?]A"+XBZAKT_B?XO:_#H_QF\*?"SPW^UCX5\.^#O"NC^'_CY-\)X5M]-U
M&S2Y.K:I\+AXOTD+X)\?V7AW4]736_AW::5X>TJX\/ZOIR^*9<?Q#^POXT\;
M_M.?$[XX>/?CY#XE^'?Q=^#=[^SCXV^",7PBTKP]::A\"9M=^(7B&V\)V_Q*
MT'QO9^-M-\1B^^(^LP:CXUTW[)>WMC!:+:Z;I5^AU*@#T+]F/]L>W_:5^+W[
M1WP_TKP#/X=\(_!L?!G5_A]X]N?$*ZA+\7_ OQD\'Z[XET3QS%X:&BV,G@[2
M[R?P[J$GAFSN]5UF^\0^$;SP_P"+;E=$;6ET6TU_&'[>G[+WP\N/'47C[Q]K
M'@FW^'OA3XC>.-;U;Q9\-/BEX=T'4_"?PAO(K+XHZWX(U_5_!EGH_P 1;/P%
M)<0W'B1_ E[X@-GISOJL0N-+M[F]AYS]FS]@?X3?LM_&WXY_&?X<^(/B5<S?
M&OP]\*?#,WA3QA\3/B3X]T7PIIGPMT;4M)M(M)N/'WC;Q7?Z@^I_;HGCGU9Y
M[KPY8VIT+PY<6&B7U_93_('Q&_X(P_#?XES>,[O7OC1XR;6?$GAK]J7P=:^-
MW\!?#6[^*%WX=_:IT37=-\1P?$;XG7.DGQE\5KSP!<ZX(_AI+XDU*UTWP_X;
MTO3/#D^CWAMDU< 'W5<_MS_LV0/-8+XQ\13^)H?&VM?#^;P+!\*_BY<?$2TU
M_P />#]!^(>KWNI?#RU\"7'CC2_!UAX \5^%?&]Q\0+[P_!X(7PKXH\.:M'K
MTD>NZ5%=YGPJ_:>^('QQ_9"_9R_:0^%OP2&O^+OVC/A[\(O'6F_#Z[^(.GZ3
MX6\!6GQ/\,V7BO4-3\9_$2?09M0E\*>#=-GG2YU'PSX"U[Q-XAOSI6GZ+X1:
M;56ET_@M<_8'MV_:5^(W[5?@3XT>,? 'Q6^(OB.RFN[ZR\+^#?$.FZ9X!O/A
M)\)/A5XS\ 6NG^(;.[@N(?$#_!7P)X[TKQ)<+_:WACQAI86.+6/#-YJOA[4M
M>]_8S\7>'OV*OA#^QQ\%/VC/''PBMOA1X'^&/PQ/Q5L/#.A:WXV\4_#[X>:%
M;^'[[P_?%+_0&\.W?C?3K&TL_$'B?P;JN@^*=-M9-1/A35] U*[@U6Q /.?#
MW[?WCOX@78\ _#'X Z1XI^-WAQ?VE+[XB>#+_P",MKHG@JST;]F/XF:5\)O$
M-W\.?B(O@#4YO'MS\1/&^JG0/ARNL>$/ NEVNI^'O'&G?$;5O!.J^$;C3;_M
M-$_;\T/QG\8OV.? 7@;X4^,-2^&W[87PT\3?$[PI\:M?U+1?#NA6.GZ;\(-&
M^,6@Z)H_AF.76/$'BS5;S0-82V\57JIH?AWPAJ"P:9#K'B35Y[O3]+S=+_82
M\2:)X?\ AY)X7^.<'PP^(W@#P%XW^"=GXP^#GP1^'7@;PZ_P'\<ZIX>UN;P)
MIWPWU.Y\7Z#H>N^$=<\,V.O> _&UK?W$^C:Q=ZS+JVA>(M.UO5-+NLWQ5^P3
MXP'Q1_94\6_"7X^P_"WX>?L=>$F\#?![X62?!OPYXW@A\,ZG\/-)^%WB*P\0
M^,=8\6:=KNJM>^$]'MXM+N8;:QGTF_9[RX?6%Q;T =]X&_;!\2Z[^U#!^S7X
MJ^&GA#2M8U+0/B/XF:S\#?&SPY\4/B-\+-%\$:AX;7PUJ7[1?P]T+0+*R^$]
MA\7-#\3Z;K'PXNM.\9^-4O;F6+0M0\B]E>XMONROBOPM^R+JUK\:_ 7Q@^(O
MQP\9?%*;X/+XZ3X56.K^%? ?AK7;)?B#H<GA?5E^(GC?PCH^E:U\3X=)\-2?
MV/X?L-0M=#TDRP:;XE\4:=XJ\9:'H/B/3/M2@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK\?O^"@7Q5^)?
M@S]O'_@CK\._"'C_ ,7^%O WQE_:1_:&\-?%;PKX>\0:CH^B_$+0?#G[+7C7
MQ9H.D>+;/3YX!K.G:1XDL+/6["TNF:"#4K>*Z"&6-&7]84\.:840E;[)53_R
M&-:[@'OJ)/YDGWH Z"BL'_A&]+]+[_P<:U_\L:/^$;TOTOO_  <:U_\ +&@#
M>HK!_P"$;TOTOO\ P<:U_P#+&C_A&]+]+[_P<:U_\L: -ZBL'_A&]+]+[_P<
M:U_\L:/^$;TOTOO_  <:U_\ +&@#>HK!_P"$;TOTOO\ P<:U_P#+&C_A&]+]
M+[_P<:U_\L: -ZBL'_A&]+]+[_P<:U_\L:/^$;TOTOO_  <:U_\ +&@#>HK!
M_P"$;TOTOO\ P<:U_P#+&C_A&]+]+[_P<:U_\L: -ZBL'_A&]+]+[_P<:U_\
ML:/^$;TOTOO_  <:U_\ +&@#>HK!_P"$;TOTOO\ P<:U_P#+&C_A&]+]+[_P
M<:U_\L: -ZBL'_A&]+]+[_P<:U_\L:/^$;TOTOO_  <:U_\ +&@#>HK!_P"$
M;TOTOO\ P<:U_P#+&C_A&]+]+[_P<:U_\L: -ZBL'_A&]+]+[_P<:U_\L:/^
M$;TOTOO_  <:U_\ +&@#>HK!_P"$;TOTOO\ P<:U_P#+&C_A&]+]+[_P<:U_
M\L: -ZBL'_A&]+]+[_P<:U_\L:/^$;TOTOO_  <:U_\ +&@#>HK!_P"$;TOT
MOO\ P<:U_P#+&K]CIMKI_FFV$X\W9O\ .O+V[^YNV[?MES<>7]XY\O9NXW;L
M+@ OT444 %%%% !1110 4444 %%%% 'X@?\ !2?_ )22?\$*?^SK?VH/_6.?
MB#7[>1_ZN/\ W%_]!%?B'_P4G_Y22?\ !"G_ +.M_:@_]8Y^(-?JW\9KV]L?
M"FF2V-Y=64K:Q:QM+:7,UM(T9L+]C&SP.C,A958H25+*K8RH(\W.,RCE&68S
M,ITI5XX.E[65*,E"4US1C92:DHOWKW:>P;GLE%? '_"1^(?^@_K?_@VO_P#Y
M(KFO&/Q37P!X9U;QAXN\8:YI7AW1([.34;V.XU_5+D/J.IV.B:796&DZ0M]J
M^L:MK&MZIIFB:)HVDV5YJFLZSJ5AI>G6MQ>7<,3?F<?%K#3E&$<DQ4ISE&,8
MQQ5-RE*32C&,51;<I-VBDFVVDDWN'Z245^)OP]_;HT'XG_##P7\2O!_A?]J3
M5[KQU?7^F:1\,+'X1^/Y_BG;7FEZ0/$.I3:CHMS-8>&[?0K;09;748?%@\7-
MX8U:>^M?#VAZKJGBTS^'H&R?\% /@X^@>&?%VD^//B1XG\%^(/AQX;^,&L>-
M/"_A;QIJWACX8?"SQ?XBU3PCX=\=_&.]?['=_#K1;[Q/H'B;1[BWU#3[S7=&
M/A'QCK&NZ-I?AKPKK>N6G6_$JHI.+X:S'F4W3:5:+]]-I1NJ#3<Y1G&G:ZJR
MC*-/GE&2'9[VT_K\KJ_:ZN?MI17Y1_%G]H2_^$DWA'3[K1OC9\0M?\;ZGXCT
MW0O#'PETA?&&OE/".B?V_P")-6U&/5?%_A32--T+2K&2UBEU*XUG-Q?ZAI]C
M96]U-=+M]+T;QGXGU?2-+U6>;QQX=GU+3K._F\/^*+BYTOQ+H<MW DTFD^(-
M-MM5U*WT_6M/9S:ZG90:A?0VMY%-!'=W"H)6YGXKX>,(5)9)B5"I=PD\91]]
M1DXR<5[*[BI1G'FMR\R<;WBT%GO_ %W_ "/T1HKX _X2/Q#_ -!_6_\ P;7_
M /\ )%?5/P<N[N]\'M->W=S>3?VQJ*>==W$US+L7R-J>9.[OL7)VKNVKDX S
M7N<-<?4.(\R_LZGEU;"R^KU<1[6=>%2-J4J4>7EC3B[R=2][Z)=1=+^GXW_R
M/5J***_0 "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HKR>]^//P/TWQ(W@W4?C'\*K#Q>EW]@;PK>_$3P?:
M^(UO?,6'[(VB3ZS'J2W1E=8A;-;+.9"$$98@5ZQ0!^('_!2?_E)'_P $*?\
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MI_@]I45[X1:9[O5(6_M?4$V6FIWMI#A?)P1#;S1Q[SGYGV[F/4G Q]UX7_\
M)3O_ +%N+_\ 3N%#H_5?E(]PR/4?F*,CU'YBL/\ L"W_ .@AKO\ X/=4_P#D
MFC^P+?\ Z"&N_P#@]U3_ .2:_HP1N9'J/S%&1ZC\Q6'_ &!;_P#00UW_ ,'N
MJ?\ R31_8%O_ -!#7?\ P>ZI_P#)- &YD>H_,49'J/S%8?\ 8%O_ -!#7?\
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MU%%%?T8(**** "BBB@ HHHH **** "BBB@ HHI RDD C(_S^(SQD<9!'4$
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M]M>U;RMN[/E_9K2UQOW#?OW_ '5V[><@%^BBB@ HHHH **** "BBB@ HHHH
M_$#_ (*3_P#*23_@A3_V=;^U!_ZQS\0:_;R/_5Q_[B_^@BOQ#_X*3_\ *23_
M ((4_P#9UO[4'_K'/Q!K]O(_]7'_ +B_^@B@!]%%% !1110 4444 %%%% !7
MQ1\5/^1^\0_]=;'_ --=C7VO7Q1\5/\ D?O$/_76Q_\ 378U^7^+'_(@P/\
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M]X_^'NJ_#/7H_%NEW^C:F=;TX>&]8O&L+>UNM*GM=2\JZ-U-$KVTGT$-*U,
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MOB%$\"Z]JUYI'A'2M0GCM&TRVB,VH:BEM']JCG\S^AQ_GT[T %%%% !1110
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,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>gazyva.jpg
<TEXT>
begin 644 gazyva.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( 2$!@@,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /LN@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@!"
M0HR> * \D<MJ7C;1])RL]S'O7^!2"WY9 _6I;2/6HY=BL19TZ4K=VK(XNX^-
M6A6QVA+N3'=$A(_6=:GG1[4.'<9/7FI1]937Y4V0Q_'#0I#CR;U?=HX /TN#
M2YUYEOAO&1^W1?I*?_RLZ;3OB7H6H<"<0$]!+M7_ -!9JI21YE7)\91_Y=\W
M^"[_ #2.VMKN&\020.LB'H5.15^AX<Z<J3Y:D7%KHU8L4&84 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % '$^+?'5AX3C/G-YEP1\L2\DG_:Q]T5#DHGN8#+
M*V82_=KEAUD]OEW/F/Q-\2=5\0LR>8;> GY8XSC'U88)K!R;/U'!Y/AL$D^7
MGJ=92V^X\^>1G.YB23U)))_,U!] O=TBK+LM!E PZ4"%R:!W-[2/$VHZ'();
M.9T*]B25_P"^2<4TVMC@KX.ABH\E:FGYI6?WGT/X-^+T&IE;35@()C@"4?<8
M^_9:WC/HS\ZS#()X=.MA/?ANX]5Z=SVY'5P&4@J1D$<@CVK4^&:<79Z-=!U
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MH0!V/>L)QMJC]1R+,_:Q^IXF7O17N2;W7:YXC_9]S_SRD_[X;_"LC[?VE/\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_P!V/)_I5G@2WT.OH)"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?$;7=/4)#<O@>H#?SJ^9H\:IE."JN\Z6OD[%UOBKXA88-R1]%4?THYF8K),
MO^77_DS.<U#Q9JFI_P#'Q<2,/0,5'Z8I79Z-+ X;#_PJ<5ZI,YYG+G+$DGKF
MI/0VT6B[(85S03*-]#IO"7@B[\6W2PPJ5A!_>2D?*H[\^OM6D5?8^7S'$4\#
M!RFUSOX8]3[7\/Z#;>'+-+&S4*D8Y/0L>['W-="5M#\DK595YNI/=_@;5,YP
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M2^=CIHWO>]/0X]2[&;GO2T*U+J&3O2 G%(84 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 &* # H ,"@ QB@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M^A4]?TS7H+5'F[.W8^SO VO#Q!I4-P3F55"2?[X'-<$X\KL>C!W5SKZS- H
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MES+S.2<>1V6QZ9\%O$7^LTB4_P#32/)Z8X*C\>:QJQ^T;4I?9/H6N4ZPH *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M/S'^\.2,>E>EBY^QKQFDG9;'S&3T'C,!4P[DX\TOBZHD_P"%=X_Y>3_WS_\
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MA^-?+SBX2<'T=C]6HU57IQK1VDDRU4'0% !0 4 % !0 4 % !0 4 % !0 4
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M_(T_'O\ R"G_ -]/YUA@?XR]&>AGW^XS_P 4?U(/ G_()/\ UTE_G5X[^/\
M)&&0_P"X?]O3.1\,?\AQ_J_\S7H8G_=H^B/G,K_Y&53U9Z?XA_Y!UQ_US/\
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MTB5[BY5WD(PN%)QZG/J:Z<51J5DH4](K<\S*L;A\#.5?$:S>WEYG>CX@6?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
8 * "@ H * "@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>geographicsaleschart.jpg
<TEXT>
begin 644 geographicsaleschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &8 3T# 2(  A$! Q$!_\0
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MP9I4]AK%TCQ>BW?[0?P'L/BM8_ B^^-7PFL_C?J=I]OT[X.W7Q&\'6_Q2O[
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M:,8QZGC@@G.2".03DY(.3D\\F@ #IWZ]R>,9)/). !D]@*6B@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKY>^-_P"UK\-/@+\7_P!F
M#X(>+].\7ZCXX_:W\=^-OAY\*AX>TK3KO18->\ ?#W5?B9KTGBW5+_6=,.B:
M<?#>CWBV%Q:VNJSW6I>5:FUAB9[F/V7Q!XZ3PO91:AK&A:I#:SW"6L;07&D7
M+F:2*6904CU+(3RX9"7!*@A1_$*PQ.)P^#H5<5BJT*&'HQYZM:K)1ITXW2YI
M2>B5VE?S [RBO$O^%[>%O^@7K_\ WXT[_P"65'_"]_"W_0+U_P#[\:=_\LJ\
M+_6_A?\ Z'N6_P#A1#^NJ^\=GV?]?\.OO/;:*\1_X7OX6_Z!>O?]^=._^65+
M_P +V\+?] O7_P#OQIW_ ,LJ/];^%_\ H>Y;_P"%$/ZZK[PL^S^X]MHKQ+_A
M>_A;_H%Z_P#]^-._^65'_"]O"W_0+U__ +\:=_\ +*C_ %OX7_Z'N6_^%$/Z
MZK[PL^S^X]MHKQ+_ (7MX6_Z!>O_ /?C3O\ Y95VF@>-O^$FL#J6D:!JDMH)
MY;;?/<:1;OYL&WS!Y;ZB6VC<N&Z'/'2NS \09)F5?ZM@,SP>+K\DJGLJ%:,Y
M\D.7FGRK7ECS1N_-=Q6?8[FBL'^U=4_Z%R^_\#]%_P#EA7!ZQ\7]%T'4KG2=
M3T?6X[VT,8G2$:9/&IEACG3;*FI;7S%*A;'W6)0\J:ZL?F6 RNE"OF.+H8.C
M.HJ,*E>:A"564934$WHY.,)R2[1?8#UJBO$O^%[>%O\ H%Z__P!^-._^65'_
M  O?PM_T"]?_ ._&G?\ RRKR?];^%_\ H>Y;_P"%$/ZZK[QV?9_U_P .OO/;
M:*\2_P"%[^%O^@7K_P#WXT[_ .65'_"]_"W_ $"]?_[\:=_\LJ/];^%_^A[E
MO_A1#^NJ^\+/L_Z_X=?>>VT5XE_PO?PM_P! O7_^_&G?_+*C_A>WA;_H%Z__
M -^-._\ EE1_K?PO_P!#W+?_  HA_75?>%GV?W'MM%>+1?''PU/+%!%I6O-)
M-+%#&#%IJ@R32+&@+'4@ "[J"3P!D]J]+_M75/\ H7+[_P #]%_^6->GE^;Y
M9FJJRRW'8?&J@X*J\/4514W44G#FMMSJ$N7OROL*S[&]17):IXGN='T^[U2^
M\/:BEG8P/<7+QWFC2R+%&,L5C&HAG;T4')/2O/\ _A>WA<?\PO7_ /OQIW_R
MRK/'YYE&5U(4<QS'"X.K4A[2$*]54Y2IN4H*<4]X\T91OW30[/LSVVBO$O\
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M44 %?77P2_Y$MO\ L-:E_P"T*^1:^NO@E_R);?\ 8:U+_P!H5^B>&'_)3O\
M[%N+_P#3V%'T?JORD>O5\4?%3_D?O$/_ %UL?_378U]KU\4?%3_D?O$/_76Q
M_P#378U]YXL?\B# _P#8XH_^H6/$>?4445_/X!1110 4444 7M,_Y"6G?]A"
MP_\ 2R"OT*K\]=,_Y"6G?]A"P_\ 2R"OT*K]L\(OX6??]?,M_P#2<:/HO5_E
M$XOXB_\ (C>)_P#L$W'\EKX<;J?J?YU]Q_$7_D1O$_\ V";C^2U\.-U/U/\
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ME7#_ "/Y.T[HH9$YVGC=D=P*_1/##_DIW_V+<7_Z=PH^C]5^4CW*OBCXJ?\
M(_>(?^NMC_Z:[&OKC_A)]%_Y_1_X#WG_ ,C5\@?$NY@O/&^NW-M()899+(HX
M5TW :99*?ED1'&&5E.5&2,C*D$_>>+'_ "(,#_V.*/\ ZA8\1PM%%%?S^ 44
M44 %%%% %[3/^0EIW_80L/\ TL@K]"J_/336"ZA8,QPJWUDS'DX5;N$DX ).
M "< $GL":^[/^$GT0_\ +Z/_  'O/_D:OVSPB_A9]_U\RW_TG&CZ+U?Y1,KX
MB_\ (C>)_P#L$W'\EKX<;J?J?YU]E>/?$&DW7@WQ';PW8>6;2[A(U\BZ7<Y
MPNY[=5&<8RS #N17QJW4_4_SKR/%G_D<Y;_V+/\ W:Q =%ZO\HB4445^5""B
MBB@ HHHH ^@?@%_Q_>)O^O33/_1U[7TO7RU\$-2LM-O/$+7DPA$UMIRQYCFD
MW%);PM_J8Y,;0R_>VYSQG!Q]*V.J66I>;]CG$WD[/,_=S1[?,W;?]=%'G.T_
M=SC'..,_TQX<_P#)(Y;_ -?,?_ZGXD#0HHHK[@ HHHH **** "BBB@ HHHH
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M9D'_ (=,)_\ +3VJBO%?^&@/AM_S^:YST_XD%QS_ .1Z/^&@/AO_ ,_FN?\
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MPV67)^=.I_C3U^M?4G[3.1\ _BP02#_PA>K8()!'RQ]".17X#,[Y/[R3J?\
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M/Q!K[,_X*!?\D=\)_P#90=*_]1WQ)7U7!'_)69%_V'0_](F?"^)G_)!<3_\
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M(([&OP8;J?J?YU^_?[3/_) OBQ_V)>K?^@1U^ C=3]3_ #KV?"/_ )$>9?\
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MOV<_8+_Y(4W_ &/'BK^>FU^<>*?_ "2O_=3P7_IO$G[)X%_\ER_^Q+F'_I_
MGVI7X0_M>?\ )Q7Q(_Z^M _]1/0:_=ZOPA_:\_Y.*^)'_7UH'_J)Z#7P/A)_
MR4./_P"Q-7_]3L ?J_T@/^21RK_LH\-_ZK,U/FVBBBOZ%/Y$"BBB@ HHHH W
M/#'_ ",_AG_L9/#_ /Z>;&OZ4QT_%OYFOYK/#'_(S^&?^QD\/_\ IYL:_I3'
M3\6_F:_#_&'^+D'_ %[S+_TK G]._1W_ ('%?_7W)_\ TC,CPS]IG_D@7Q8_
M[$O5O_0(Z_ 1NI^I_G7[]_M,_P#) OBQ_P!B7JW_ *!'7X"-U/U/\Z]GPC_Y
M$>9?]C67_J)A3YWZ0/\ R4N3?]B1?^IV*$HHHK]7/P0**** "BBB@#]'O^"=
M?_(P_%3_ + OA'_TX^(*_5*ORM_X)U_\C#\5/^P+X1_]./B"OU2K^8_$K_DK
M\R_Z]X#_ -5V$/[=\&/^3=Y+_P!?\W_]6^-"BBBO@S]3"BBB@ HHHH *:V=K
M8QG!ZXQ[]>.GKQZ\4ZFM]UN-W!X]?8^WKC)QT!/% '\XOB73/B)XV_:7\1>%
M/CK#^RQX-UVP_:^\%7X^)WPTT3]L_P 3Z#H5GK.H? #6/"?P[^)^NV'@G2?V
M6[WXE_$2Q^&_PWBA^'/QF\:PZ4/&B?"SQSJ/A'5/%=EX13Q!_1TO0<YZG\R3
MWYR.A)Y)Y/.:_#,^#OVA/B_\6_B#>+^QI^U%\+_"FJ_M1^$=8U_P7XQ_:#_9
MUTK]EKXB?\(+K?PXG@^/GC7P_H?B37OCG*7TK0[?Q W@7X37=S\/OB#XJ\%:
M#;>+[#5)M<\;2Q?N:HP/Q/ZDGGW]>V<XXH _$'_@I/\ \I)/^"%/_9UO[4'_
M *QS\0:^S/\ @H%_R1WPG_V4'2O_ %'?$E?&?_!2?_E))_P0I_[.M_:@_P#6
M.?B#7V9_P4"_Y([X3_[*#I7_ *COB2OJN"/^2LR+_L.A_P"D3/A?$S_D@N)_
M^Q;+_P!/4C\@J***_JX_@D**** "BBB@ K]G/V"_^2%-_P!CQXJ_GIM?C'7[
M.?L%_P#)"F_['CQ5_/3:_./%/_DE?^ZG@O\ TWB3]D\"_P#DN7_V)<P_]/X$
M^U*_"']KS_DXKXD?]?6@?^HGH-?N]7X0_M>?\G%?$C_KZT#_ -1/0:^!\)/^
M2AQ__8FK_P#J=@#]7^D!_P DCE7_ &4>&_\ 59FI\VT445_0I_(@4444 %%%
M% &YX8_Y&?PS_P!C)X?_ /3S8U_2F.GXM_,U_-9X8_Y&?PS_ -C)X?\ _3S8
MU_2F.GXM_,U^'^,/\7(/^O>9?^E8$_IWZ._\#BO_ *^Y/_Z1F1X9^TS_ ,D"
M^+'_ &)>K?\ H$=?@(W4_4_SK]^_VF?^2!?%C_L2]6_] CK\!&ZGZG^=>SX1
M_P#(CS+_ +&LO_43"GSOT@?^2ER;_L2+_P!3L4)1117ZN?@@4444 %%%% 'Z
M/?\ !.O_ )&'XJ?]@7PC_P"G'Q!7ZI5^5O\ P3K_ .1A^*G_ &!?"/\ Z<?$
M%?JE7\Q^)7_)7YE_U[P'_JNPA_;O@Q_R;O)?^O\ F_\ ZM\:%%%%?!GZF%%%
M% !1110 5FZS9W>H:3JEC8:I<Z)?7NG7MI9ZS9PV=Q=Z3=7-K+!;ZG:P:A!<
MV$US832)=P17MO/:2RPHES#+ TD;:51S2PP0RSW$D<,$,;RS2S.D<444:EY)
M)9'*HD:(K,[NP55!9B ": /Q4^'O[2O[:GP]^+&L_"?XV_&']G3QSHOAKXW>
M$?AQJOQ.\._LR_M.KX3TG3?$=E\.;#PYX4\<?%?PYJ$?P=\ _&#QC+XA34IM
M$U?4?$&A^&O$OC3P[HVLZ_:PZKH&AG]K@<C/U_GT.><CH??/ K\]/B;\'_V6
M(_C)HOB3Q=\3/'VD6WQ+\5>"OBKK?P@T3Q_XJ_X45XZ\:Z#J'AO3_ 7Q/^(7
MAK0].O\ 1=(M[[7_  _X.M;.ZU7Q'X5^'OQ#\4:%I*:WI?BS71="Y_0L8P,=
M/Z]\^^<Y[YSGF@#\._\ @I=$TW_!1[_@A9$LTUNS?M6_M/XFMVC69,?L=_$!
MOD,L4T?S ;6W1ME&8#:2&'V#^WM836OPB\+22:IJ=ZK^/]+417LEF\:D^'O$
M9W@6]A:N9 !M#%]NUGRA)!7Y$_X*3_\ *23_ ((4_P#9UO[4'_K'/Q!K[,_X
M*!?\D=\)_P#90=*_]1WQ)7U7!'_)69%_V'0_](F?"^)G_)!<3_\ 8ME_Z>I'
MY!4445_5Q_!(4444 %%%% !7[$_L+Z?-=? ]I(]5U.R7_A-?%"^3:262PY4Z
M?E\7%A<R;VW<GS-O'"CFOQVK]G/V"_\ DA3?]CQXJ_GIM?G'BG_R2O\ W4\%
M_P"F\2?LG@5_R7+_ .Q+F'_I_!'UM_8US_T,&N?]_=,_^5-?AS^UI$T'[0?Q
M$B>>>Z9+G0 9[EHFGDSX4T(Y<PPP1_*#M4+$N$50=S LW[R5^$/[7G_)Q7Q(
M_P"OK0/_ %$]!KX'PD_Y*''_ /8FK_\ J=@#]7^D!_R2.5?]E'AO_59FI\VT
M445_0I_(@4444 %%%% &WX9&?$OAL!F4GQ'H #*0&4G6+$;E)# ,O5<J1D#(
M(XK^C8:-<_\ 0P:YU/\ RUTSU/\ U":_G*\,?\C/X9_[&3P__P"GFQK^E,=/
MQ;^9K\/\8?XN0?\ 7O,O_2L"?T[]'?\ @<5_]?<G_P#2,R/G3]I'2[B'X$?%
M25]:UBX5/!NK,89I=/,,@")\D@BTV*0J<\[)4;&0&&<U^#C=3]3_ #K]^_VF
M?^2!?%C_ +$O5O\ T".OP$;J?J?YU[/A'_R(\R_[&LO_ %$PI\[](+_DI<F_
M[$B_]3L6Q****_5S\$"BBB@ HHHH _1'_@GQ:27>O_%!8[^^L2FC>$R6LGMD
M,@;4-?&)/M-K= A<978$/S-N+9&W]4+&REM/-\S4+Z^\S9M^VO:MY6W=GR_L
MUI:XW[AOW[_NKMV\Y_+S_@G7_P C#\5/^P+X1_\ 3CX@K]4J_F/Q*_Y*_,O^
MO>7_ /JNPG^9_;O@Q_R;O)?^O^;_ /JWQH4445\&?J84444 %%%% !5#58[^
M73-0CTLV*ZE)97::>VIPRW&FB]:WD6T.H6\$D,\]D+@QF[A@EBFEMQ(D4D<C
M*ZWZ* /R\^$7[&OQ#MM:M?'GCJ3P=I_B#P_XMT>_TOP9KNF^'/&_@&ZM$EMM
M0\97>CZ#X(T+X8:5X'2[\2VX\0_#7^RK6ZGT:]4:S\1='\8Z]+#)IGZA 8&.
M/PI:* /Q _X*3_\ *23_ ((4_P#9UO[4'_K'/Q!K[,_X*!?\D=\)_P#90=*_
M]1WQ)7QG_P %)_\ E))_P0I_[.M_:@_]8Y^(-?9G_!0+_DCOA/\ [*#I7_J.
M^)*^JX(_Y*S(O^PZ'_I$SX7Q,_Y(+B?_ +%LO_3U(_(*BBBOZN/X)"BBB@ H
MHHH *_9S]@O_ )(4W_8\>*OYZ;7XQU^SG[!?_)"F_P"QX\5?STVOSCQ3_P"2
M5_[J>"_]-XD_9/ O_DN7_P!B7,/_ $_@3[4K\(?VO/\ DXKXD?\ 7UH'_J)Z
M#7[O5^$/[7G_ "<5\2/^OK0/_43T&O@?"3_DH<?_ -B:O_ZG8 _5_I ?\DCE
M7_91X;_U69J?-M%%%?T*?R(%%%% !1110!N>&/\ D9_#/_8R>'__ $\V-?TI
MCI^+?S-?S6>&/^1G\,_]C)X?_P#3S8U_2F.GXM_,U^'^,/\ %R#_ *]YE_Z5
M@3^G?H[_ ,#BO_K[D_\ Z1F1X9^TS_R0+XL?]B7JW_H$=?@(W4_4_P Z_?O]
MIG_D@7Q8_P"Q+U;_ - CK\!&ZGZG^=>SX1_\B/,O^QK+_P!1,*?._2!_Y*7)
MO^Q(O_4[%"4445^KGX(%%%% !1110!^CW_!.O_D8?BI_V!?"/_IQ\05^J5?E
M;_P3K_Y&'XJ?]@7PC_Z<?$%?JE7\Q^)7_)7YE_U[P'_JNPA_;O@Q_P F[R7_
M *_YO_ZM\:%%%%?!GZF%%%% !1110 4444 %%%% 'X@?\%)_^4DG_!"G_LZW
M]J#_ -8Y^(-?9G_!0+_DCOA/_LH.E?\ J.^)*^,_^"D__*23_@A3_P!G6_M0
M?^L<_$&OLS_@H%_R1WPG_P!E!TK_ -1WQ)7U7!'_ "5F1?\ 8=#_ -(F?"^)
MG_)!<3_]BV7_ *>I'Y!4445_5Q_!(4444 %%%% !7[.?L%_\D*;_ +'CQ5_/
M3:_&.OV<_8+_ .2%-_V/'BK^>FU^<>*?_)*_]U/!?^F\2?LG@7_R7+_[$N8?
M^G\"?:E?A#^UY_R<5\2/^OK0/_43T&OW>K\(?VO/^3BOB1_U]:!_ZB>@U\#X
M2?\ )0X__L35_P#U.P!^K_2 _P"21RK_ +*/#?\ JLS4^;:***_H4_D0****
M "BBB@#<\,?\C/X9_P"QD\/_ /IYL:_I3'3\6_F:_FL\,?\ (S^&?^QD\/\
M_IYL:_I3'3\6_F:_#_&'^+D'_7O,O_2L"?T[]'?^!Q7_ -?<G_\ 2,R/#/VF
M?^2!?%C_ +$O5O\ T".OP$;J?J?YU^_?[3/_ "0+XL?]B7JW_H$=?@(W4_4_
MSKV?"/\ Y$>9?]C67_J)A3YWZ0/_ "4N3?\ 8D7_ *G8H2BBBOU<_! HHHH
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M^QD\/_\ IYL:_I3'3\6_F:_#_&'^+D'_ %[S+_TK G]._1W_ ('%?_7W)_\
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M-9X8_P"1G\,_]C)X?_\ 3S8U_2F.GXM_,U^'^,/\7(/^O>9?^E8$_IWZ._\
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M&]E9IX3^'?B29;WRIX_M\=A8.L;ZA#(O<_\ "EO^"RW_ $CJ_9V_\6%Z+_\
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MEXL'@B^^-VO_  Z\1>$?"W@:ST2XT1-$U#2=7N/AMX6T#5EMO!D=U=226%V
M?M'9^(M U#6-8\/6&MZ1>Z]X>ATNYU[1+34[&YU?1;?7([J71I]6TR"XDOM,
MAU:*QO9-,EOK>WCU".TNGLVF2WF*;-?BM_P3U^'G[3/@?]MK]KKQ%\=?@$O@
M>Z^*'[.O[(VK>.?C+;?$&Q\:Z-\4?C+X;\9?M1R>(Y-$O[+P/X:M[J&RTGQA
M8:-9^%+:]F_X5'X"\-?#;P]/%=6GB32;B#]J: "BBB@ HHHH *YR#QAX4N?$
M][X*M_$WA^?QAIVF0ZUJ'A6'6M,E\26.CW,JPV^JWF@I=MJUKID\SI%!?SV<
M=I-(Z)',S,H/1'&#D9&"".N?;\:_#SQ':>!_BI^UQ'X.^$'PE\<?L\>)/@W\
M6/CGXXTWXV^(OV:/C_:^)OCW^TGXQ^&/Q)\"RW4'Q9E^'1\(67[-^BS^/+K6
M;_Q7XO\ B-+IOQ,U/P5X&\%_#OP[I7PU\,Z3JGB$ _:31?%GA?Q)<ZY9^'O$
M6A:[=>&=6GT'Q';:-K&G:K<:#K=LJO<:/K4&GW-S+I6JP(Z/+INH);7L:LK/
M  0:SM1^(?@+2/"J^.=5\:^$=-\%ND$B>+K_ ,3:'9>&&CNK@6ELZ^(+F_BT
M=DN+HBW@87I$TY\F,M+\E?B+\!?AGX8T#3_A--XL^!_QD^$WPY^$G[!4/P2_
M;2@TOX0_&#PMX@^)7QLE^('P)N?!OA[3A\,-._X3OX]W/A_4/#/QYUSQ5X\^
M'MMX^\,ZQX5^+M\]_P"+M5TGXA^(XQS_ .RE'X:'_!,[]D/X9^*_@U\5_!?Q
M"^$7A.+P3:^(_&G["?Q/^*-I^SKX]LM-N))VO?@7XC\*:!XFU>T\3>"-5U3P
M-H?B[P1X7\0^$M"FU*]TC4?$.AS7,%EJ(!_0-!/#=0PW-M+'/;SQ1S03PR)+
M#-#*@>*6*6,M')%(C*\<B,R.C*Z,RD$RU\:?\$^/!GB3X=_L;_ 7P/XK\#:M
M\.=9\*^#Y]#/A77;R\GU6WTNP\1:Y#X>U>]TR_EFNO!LGBKP\-+\6+\-))&7
MX4Q:Y'\,XML/A*-%^RZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH 3 Y!Y!X())!_ Y%&!_DD$]N3U/'K2T4 )M!Z@'IG/.<9(!SU )) /0]*6
MBB@ HHHH **** "@C/K^9'\J** $P#U&>G7VZ9]<=1GOSUHQWY_,_P LXI:*
M "BBB@ HHHH **** "DQWY_,_P LXI:* $P/3' ''' Z 8Z#V'%&!^7())R.
MW!ZCCCCMGUI:*    8   Z < ?A1110 4444 %%%% !1110 4444 %%%% !1
M110 45\C>+/VU/@_X-\3^(/">KVOC5M4\-ZO>Z+J#6?AZWN+1KRPE,,YMIVU
M:%IH"X/ER-%&67DH*=X0_;1^$/C7Q3X?\(Z/:^-5U7Q)JMKH^GM>^'K>WLUN
M[LLL1N9UU:9H805.^012%>R'M]!_JIQ(L/\ 6O[&Q_U;V/UCVWL)>S]AR>T]
MKS;<GL_?OVU/DO\ 7O@[ZW]1_P!8\J^N/$K!_5OK,?:_6G55!4.7?VGMFJ?+
MOS.Q];T4#D ^M%?/GUH45C:YXC\/^&+6VOO$FNZ-X?LKW5]$\/V=YKFJ6.DV
MMWKWB;5[/0/#FBVUQ?SV\,^KZ_KNHV&BZ)IL3O>ZKJU]9Z;807%Y<P02266N
MZ)J6H:SI.G:QI5_JOAVXL[3Q!IMEJ-G=:AH=UJ%A;ZK86VL64$TESIEQ>Z7=
MVNI6D-]%!)<V%S;WD"O;S1R, :M%<)X3^*/PT\>:KXFT+P/\0O _C'6_!=\-
M+\8Z/X5\7>'O$6J>%-3,MQ -.\2Z?H^HWMYH-\9K2ZB%IJL-I<&2VGC\O?#*
MJ=W0 4444 %%%% !1110 445QOBOQSHG@UK%-76^8Z@MPUO]CMTG %L81+YF
MZ:+:<SIMQNS\W3'/+C,;A<OP\\7C:]/#8:FX*I6K24*</:5(TH<TGHN:I.,5
MYR2Z@=E17C__  N[P7_SSUK_ ,%\7_R77I^D:I;:UIECJUF)1:ZA;1W4 G01
MS"*5=RB1 SA7QU 9@/4UQY?GN49K4G2R[,<+C*M.'M)PH55.4:=XQYY);1YI
M1C?NP-&BB@D#J<=!SZDX _$\#WKU@"BO'? _[0_P!^)OB;5O!?PW^.'P@^(/
MC'0/M_\ ;WA3P1\3/!/BSQ+HG]E7G]G:G_:^@Z#KFH:KIO\ 9VH V-]]LM(?
ML=X/LMSY4_R5[!O3&=RXZ9W#&<9QG..G/TYH =14"7-O)--;1SPO<6ZQ-/ D
ML;30K.':!I8E8R1K,L;F(NJB0(Y0L%.$N;NULX+BZN[F"UMK6&6XN;BXFB@@
MM[>"-I9IYYI62.&&&)6DEED98XT4N[*H) !8HKA] ^)OPW\5Z?X1U;PO\0/!
M/B32_B E_)X#U+0/%>@:Q8>-8]+M[B[U.3PE>:=J%S;>)$TZUM+JYOWT66]6
MTM[:XFN#'%#*Z:6D^-/!^OIHLFA>*_#6LQ^(]-U'6?#SZ3KNE:BFNZ1H]U86
M6KZIHS65W.NJ:=I=YJFF6FHWUB9[6QN=1L;>ZEBEN[=) #IJ*Q/$7B;PYX0T
M+5/$_BS7]$\,>&M#LI]2UKQ#XAU6PT30](TZU7=<W^J:MJ=Q:Z?I]E;K\T]U
M=W$,$*\R2**-1\3>'-(U30-$U77]$TS6?%=[>Z;X7TG4-5L++4_$>HZ;I-[K
M^HV&@V%S<17>L7MAH6F:CK5[:Z=#<SVNDZ?>ZC/''9VD\T8!MT444 %%%% !
M1110 4444 %%%% !1110!_/9\?O^2X?%O_LH/B;_ -.#U+^SU_R73X2?]CYH
M?_HR6OU5\6?L5_!_QEXG\0>+-7NO&JZIXDU>]UK4%L_$-O;VBWE_*9IQ;0-I
M,S0P!R?+C:60JO!<T[PA^Q=\(?!7BGP_XNT>Z\:MJOAO5;76-/6]\0V]Q9M=
MVA9HA<P+I,+30DL=\8EC+=G'?]\_XB-PW_87]G7Q_P!9_L?ZC_ND?9^W^H_5
M_C]M?D]I]KEVUL?RC'P<XQ7%4<XME7U-<1+,_P#?I>U^J_VFL6_W?U>WM/8W
M]SFMS+EYM;KZV7H/H/Y4M X 'I17X&?U:M$EV2/B3]O_ .'_ (M\?? ;0)/!
MGAG6?&>J?#?]I']D#XYZCX6\-6-MJGBC6O"/P'_:F^$?Q;\=V_A;2KJ\L(]8
M\2V_@OPEKVH:'HD5W%?:WJ%E!I.EB;5+VR@EX#X+^)-9TGXK_'CXIW/PB^-:
M>'?VK?CGX*T#X=VVH?##Q%X:UG2M.^'O[+>BZ7?^-?BEIFK+8Z]\*/ FK^(?
M .M>#M$\1^-]-T>[F\27?AVT&EPVWB/0K^[_ $9(!!! (/!!&01Z$'K0%4=%
M YSP .?7Z^] S\(?V8+7Q[^RYXFT(^&O@+\?/&GP)^#?[-GCCP]J.B?$+]E7
MP[8?M0_ ]?#>J?#Z;P9\"?A+\5_AC;:-IG[7=CXPDMM5&KC1;#QI=ZC=^!-)
M\>ZY\8]9UV_DA\3_ +O@Y]1]?\_Y--"(,X51GKA0,\YYXYYY^O-.H **** "
MBBB@ HHHH *^;OC]_K_"W_7+6/\ T/3:^D:XWQ7X&T3QDUB^KM?*=/6X6W^Q
MW"0 BY,)E\S=#+N.8$VXVX^;KGCYKB[*L5G608W+L%[/ZSB'A?9^VFZ=/]UC
M,/7GS249-6ITI6]UW=EI>Z#X:7J/J/YU]S?#W_D2/"__ &!K+_T6*Y#_ (4C
MX+_YZ:U_X,(O_D2O3](TNVT73+'2;,RFUT^VCM8#.XDF,42[5,CA4#/CJ0J@
M^@KY'@/A#-^'<PQF*S%854J^"]A#V%=U9>T]M1J>\G3A:/+&2O=ZJUA]$O-_
MC;_(T:9("5  S\\1_ 2H2?P )/L*?17ZF(_EI^'_ .RY^WY\/_V?O@7JOA'1
M-13QQX0L?^"@OBGX">"X/@MX<\&^-/@/^T;XDG^-]E\(=7^*7C*YUF]O_&7P
M\\>?"CQK\68O#4>O6?A7PO+\9M6^ ]SXP&KZ9?6RZ?\ 3G]B_MA2_!ZTGU'X
MD_M-1^%(?CR+O3='T3X2?M:VGB"^\)CX*3V-]X>\:>);GXE:I^W%IO@^7XFW
M,'BKP]XMT#P_K>@V/Q L+WPGKGA+6?@I>Z9J%G^_.!Z#OV'?K^>3GUI-B8QM
M7&<XVC&<8SC'7'&?3B@#\;?V#/AG\5O"_P"UU\>?C!\9?A[\?O _BK]H_P#9
MB_8X\50VOCGQIXH^)/@O2?$G@;P#J_A?XN>#?$GB70H;'X1Z=\5/#'BN71Y(
M[.W\.>#K_5--UK7-6\%Z!::->^+K"P^5/VL/AY^VS\7/A)^UU\.XM,_:MUKQ
M_P"*OAE_P4AT7XH^'M,U'Q-I/P2\2_#>3P;\2)?V&O#G[-<NB7FGZ??^._$-
MY%\$M&U+1_ MS_PD'B32+[XX>&_V@8;R75-(L9_Z/@ .@ X X ' Z#Z#L.@H
MVKDG:,G@G R0>H)[YP/RH _,;]K7X8?$SX=?LP_ GQ3^SEX*\9?$'XM_LP>,
M?AYJWP\\(?;+WQ=X[U:T\9>$=?\ V>/&:WFN^)KZ;4]1/AOP?\8M;\<Z_=ZM
MJ4DTUIX*DGF::>VMTKX@\*?LW_M"?L]V'Q-^%GPR\!?%C0_A'^RUXU^#OP9^
M%OC+X?QSKX^\<_L@?&SXOZ+^T-^U!>?!'[!--K]WXM\'V%SX>^%NH-H$<'B^
M/3? WB&/X>I<>-(/"TP_H9(!ZC/UI" <Y .>N0#GZ^OXT ?S"_&SX5_MS_&'
MX2_MM^!_$>D?M5>+_A-<_L;?%9/V:? /B)=>F\0^.[W7?CW\;]"^'FA_$;3K
MG9K'BSXNV_P?NM$FM_"_C&:3Q&W@VX^&.K_%&PO?B/I4EQIGU1H'P[_:%\4_
MMM_LL^+OB3X:_:.UWQ3\,/VQ?VT?$?Q.UW7(-1G_ &:/!WP;\2_!#]IKP1^S
M!J7PKDGQX7L[?4/A[X@^&_AR^G\'!O$"^,-8\3V?QA<>*[_1?,_=+:H& HQC
M&,#&.N/IGM1M4'( R>IP,G\>M "T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>incometaxchart.jpg
<TEXT>
begin 644 incometaxchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %2 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-/C/\ $/\ X5'\
M(?BG\5!H[^(#\-?AQXZ\?C08[O[!)K7_  A?A75O$W]DQWPMKPV;ZE_9?V);
MH6EU]G:<3?9Y]GE/\"?L[?\ !2/PO\1/A)X6^+GQ5UKX"&S^(VG>%9_ 7@[]
MDGXF?$;]L+Q\NL:A\.Q\3_&OAKQCX0\"?!;1_$&AZIX \)7FF:KK<NGZ9K%K
M:V,LEUJ\FC&ZT2#5OT#^+GP\LOBW\*_B5\*]2U"[TG3OB5X \:> +_5+".&:
M]TVR\:>&=4\-75_9Q7(-O+=65OJDES;QS@PO-$B2CRRU?,>O?L86\?AK]FQ/
MAI\5/$GPQ^)/[,/@2Y^&G@CXDZ;X8\'^))M3\&Z]X \(_#WQAIOB#PEXCL;G
MP_=3ZS9^ _!WB'3;Z#R)M"\3>%]%<C5?#9UGPSK0!ZW\+/VIO@;\;?%VO>"_
MA1XU_P"$[U7PQX>\'^*M>O\ P_X?\37?A73M"^(7@CP9\2/ -Y+XT.CIX2D?
MQKX'\>^'O$GA6RAUF34-<TUM7FL+28>'M=&G_!_A7_@KS\)/$NL_#B:\^%WQ
M>\(>!?&>J_MYZ)K.N>*?AQ\3E\9:'??L,?$+P5X'\07NC?#+0_A[K/BCQ?H'
MBJW\3:OKNHZQI<<<?PZ_X1;5_#WBM%\0Z;KUEHOUE^R=^QE\/?V/U^(FG?#;
M6O$-_P"'O' ^#5M9:1X@.GSR^'=.^"_P&^'?P&T2WCU&RMK.35;G6-(^'EIX
MDUN^NK:W:77M6U$6L%O8BW@C\9T#_@G!X7T#QW<^)8OBIXJN?#.GR_MR-X(\
M(2^'_#T;>%+?]OKQ7X8^(OQ@LKCQ%"RWWB.WT3XAZ+JNM^!Y-0L[>]TW2==;
MP[JUWK$6EV6H, ?2'AK]L#]GOQAXYT?P!X7\=OKNI>(+O2=)T/Q%IOA;QC<_
M#;5O$VN^ +3XJZ-X*T_XL)X?_P"%:77CW4OAK?V?CJS\#P^*F\4S>&+F'4QI
M>R0)7FOQH_;&N/@M\7KCX*ZS\.)-2\8_$3PGX8U3]EA+3Q+]GM?CSXRN_$1\
M+_$/P!++=:(H\(:I\(!?^&_B/X[OH#XF@M?@KJ^K?$2"!X/!/BO3M/\ $?V=
MO^"4GP3_ &<?B%X \<^&+GP_K<G@>U\&:NUYXA^#'P>U'XA:I\1/"?P9\._!
M6?Q/!\8+[PQ?_$3PWH&O:1X;MO%EYX,\.ZK8KI_C&\U!=&\1V'@N]N?!DWV%
M\8?V;?"OQG^)GP ^(WB35-1A'P%UWXI:Q9>';:"W;3?%<'Q5^#GB[X-:UIFL
M71:._LK:UT3Q?>ZA;3:7+#<O>00PO(L#R&@#C=#_ &ZOV<_$^E76J^&?$'CK
MQ,%M- U30M.\/_!;XSZMKOC_ ,-^*;C4[/P[XX^%^@6?@*;5_B5\.M9N]'U"
M*T^(O@JTUKP.D<5O=7GB"ULM1TNZOL.?_@HO^QY;VGV]_B[&UE#\-F^+>IW,
M'@SX@W4?A[P''XQ\>_#B?5?%*VWA26?PQ?6WQ*^&GBWX9W'AS78;#Q+'\1[.
MP\"?V.WBC6]&TN^^4?#7_!'?X2>"/".C^%/!?BKP]X>MO!L_@72_"D5I^SM^
MS_#I7BCP%X T[Q#I.C^#OVB-+TWP=I<G[2$;6^O6FKR7WCO4K.S@\<>"? 'Q
M%L]!M_&VA:CK6N^A_!W_ ();?#CX(:!\2O#?@GXE^*[/3OB%\&]?^#212^"/
MA)>:?H&AZ_\ M-_M&?M.7,EMX/U/P3J7PWU+3CKO[1OB+P7-X0O_  /_ ,(A
M+X*T?3].M](L7N)3  ?=_@GXV?#_ ,=^"-<^(5E>:[X8\->%I];M_%<GQ-\&
M^,/A-JGA63PW81:IK<GB30?B7H7A76M&LK#2YHM4?5+RQ32;C2Y$U*SOKFQ8
M7%>$)_P4!_9;.BZ5K<_C7Q/81^(/%OP]\%^&M(U;X2?%[1_%GBC6/BYIWBO4
M_A-<>&?!FJ^!;/Q7K_A_XH6_@CQ3#X \4:3HUWX>\5:EHE_HVEZC-K%O+8I%
M\(?V*O!GP]^!GQH^!'B?Q!?>,O!GQZ?QG!XR\-:1I.G?#CX?^%_#_CKP!IGP
MXU_P9\(/AYX8EFT?X6>$+W1M.N-<NM'T2[NOM'CCQ#XH\6-.EUK+6UOX-\-_
M^"6?PQ^'5O\ #M=,\3:3IMW\.?C?\#OB]9W?@/X(?!3X3MXFM_V?]!^(F@^"
M]$\<'X<^%-"NO%>K:G'\2M=U+Q1XKU2]F$NJ_O\ PKX<\(6M_JUG?@&]\??^
M"HOP"^%?P)\8_%WX>G6OB]KOAOX:K\2+7P/IWA/XFZ$MI:3?$?4OA/9Z-\3/
M$9^'>L6GP4UN_P#B!X;\:>$+'1_B;9^']:NO%'@?Q9H4&EO>Z%J2VWO,_P"W
M)^S)9#QW/J7Q#N-*TOX?:=XXU34O$6J^"/B#IWA;Q'9_#3Q=I_P_\??\*S\3
MW?A6+0_BY>>$O'FKZ-X(UK3?A??>+=1M_%^LZ1X=AM;C4]3LH)_D34_^"37A
M%O!OQB\">&/CG\0O"?A_]HEO&Y^.$%EX:\#:E<>,QJ_[0_Q@_:)\"O87>JZ=
M<7/AB?P/K'QH\2^"+V339I8_&/@>STBWOH-(\0VA\0/HZ)_P2.^ .@)\3M.T
M>;2O#^E^+&\2WW@/5O"_PA^#6A?%#X=Z_P"(?C+X=^/MEKMU\85\&WOCSXBS
M^"/B5X3T&Y\':;XQOI=&G\.V2Z%\0;#X@3I::O9@'N_PU_;<T?XGVW[:.J:+
MX!U_3]*_9'UW3M$2/Q1:^)O!GB;QE+=?LS?#O]H:\BUOP9XS\(^'_$GP[U*P
MF\=OX/DTO5K#49I$TR+Q$C_9]2BL(?(_A3_P41U2#P;\"/'G[5WP^\!? [PA
M^T=\ KCX]_#GQ;X&^*'B+XJ:'90Z=X+\'_$+4_AGXNL=6^%7P[\36WQ D\)>
M,K:^\)P>$M'\8Z?XUOM%U[P_8OIWB+_A'-*\3>\_#;]D0>$-+_:D;Q?\4O$?
MQ!\6_M;ZC9ZW\2_$]WX>\.>&HM/U:U^!'@_X!@>$]!T2,V6F:1#X8\%:3>6.
MGWUQJEW!>F?[;JVIO+)<O\O6_P#P2GT#QK\&_!?P7_:+^-_B;XV>&_A%\%-'
M^"7P5ME^'GP]\%Z-X"T_1$^'26GCS4O#GV3Q=8>/_B')%\*_"&F75UXPFO?!
MLGAS_A)?#L7@F&Q\8^)&O@#ZMU/]NS]FW1M"L=:U3Q1XOL[JZUCQ9HM[X.?X
M0_%^3XF^&;CP#HGAWQ-X\OO&OPMM_ LWQ"\%Z!X+\,>,/"'B7Q+XE\3^&]+T
M#3- \7^$=5?4GM/%7A]]2FUG]NO]E[P_/\0QJ_Q):RTKX8^'OB9XE\2>+9/!
M_CEO =Y:?!GP]>>*_BQIO@[Q^OAH^"_B#XF^'?A[3]0U3Q;X3\#:[X@\1Z1#
MIFL1S::;C0M<ATWPCPK_ ,$X=(^'D7AGQ%\)_BDGP5^*NE#XJZ1K/C7X,_ [
MX&?#KP]J/@WXSP_#*'QIX>TKX:Z+X1'AS2-2L+CX.?#O7?!GC/5;KQ5XHT3Q
M!H3-K5YXJ\,7C^%(>*U?_@D=\#KYOVA;/2]2TG0=-^._@S]IS0/[8M?@U\&K
MOXK^&-?_ &L_#OBW1/BCK\GQOO?"<GQ,\3V%K=^.?%6L^%?#NH:UIZV$NNWV
MB:WK'B+PO;Z+HND 'NGB7_@HQ^S5IEGXHM="\3ZOJ_C/0;S7O#EMX6U?P'\2
M_"$,WCJV^&^I?%'P-X6U[Q#X@\$V^D^$$^+WA73_ .TOA#KNO2VVD_%&SE+_
M  ^G\3W4?V)\WX0_\%(OV>OB/\(/ WQ%U[4O$'@SQ5XM^%_P#^(I^&$G@/XH
M:MXMU<_M":!'J/@FQ^$FE_\ "!:?KOQUTF_UVW\0>&=/\4_##0==TFZO/#6K
MW5ZVEVEK,\7(?$'_ ()F> /B%JOQ'U34/B1XQLC\2/BK^S/\4]1M[;3-#>.Q
MO?V:?A;;_"S1-'M7E&^2P\3Z9!_:6LSS'[5:7KM'IY$ 6O/]8_X)&_##Q7X:
M\#:3\0/B+J_Q/U7X'>"/@[\,_P!G:]^(_P .?AAXK\/?#SP%\&+?4;?2M"\7
M>!+S0H_#/Q:D\9PZK/8_$#4?$T.G3WVGZ;X?D\)Q^#/$.E3>(]1 /MGP9^V!
M\ /B%XZ\(_#3P7XPU+Q%XX\:>#[KQ[I?AVP\$>/#?:;X3TWQ7XO\!:WJOC 7
M'AJ"/P'_ ,(UX]\#>(_ GBFR\:OH&H>&_&MM9^$]9M+/7]6TJPN_,?C;^UWX
ME^"_QM^'GPUU+P!\/[W0OB/\0/AI\/?"5C<?'/0-/^/7Q!;Q[KVA:!XB\=?"
MOX#P>&=4O/%/P^^#DVN?VM\4]4UOQCX4U72O"WA_QIXHL](FTGP_IDGBBS^S
M]^P[X&_9Z^)&D?$?PMK[F?3/@#;? H^&='\#_#[X?^#U@;XT>/?CCJWB;2O#
M'P[T#PUX?T"YU+Q3\0=7M1I.EZ3':QV$%O=7UWJVNSZGJ]_J?&']DS5?C1XR
M2;Q3\;?&S_"*Y\?_  S^)FH_";_A'_!<TMEXD^%&O^#O%?AW3?!7Q,.DP^.O
M _A'5O$_@?1]?\4:3875_KEQJ%UK@\,>*O"5GK$]I& 3? +]JS4OC;\>_P!I
M[X*ZA\(_$?PUC_9[;X/3:1K7BO6](N-:^(.C?%C0O&.JVOB%_"ND"]'@S3X[
MCP==KHVGZOKEWXCU+2;NSU76]&\*W<W]BQ^R_%OQ=\5O#</A;3?A!\+]+^(W
MB3Q-KESIUW>>+/' ^'O@'P5I-EHNI:M/K_B_Q#8^&_&_B=TO;JSLO#N@Z3X6
M\$>(;_4->U>S;46T30;75-;L_D3P?^QU\?? WQJ_:3^.^F?M7+?^*_VA?!6G
M^';G2V^!?@O3;'POK'P^\)^-/#GP6US1[Z7Q#KOFR^"IO&,VHZ]:ZOI&JV/C
M*XL;9+JTTRR:XLI_6?VEOV<_BI^T!\*O!?PSTO\ :'U7X<Q6=[ILGQ;N;#X>
M>'?$&G?'+0K70)M/U7P+XPTTZMX<O=%\#>*=;DCUKQ5HW@[7-"F\0Z= W@O4
MKR;P;JFO:+JP!\OZ=_P4SU;Q=\/=4^)?@#X##6O#_P )_@)+^T?^T9%JWQ4T
M?2[OPE\/8/B!\9/ $<?P?GT_PQK>G?&'4=>C_9]^+?C[P3J>JW7PT\+>+/A_
MI7A'4[?6;&_\=6MEHWTCI'[7K:Y^UQIG[-ME\+=?B\&:W^S9X[_:%\,_&R]U
MO2(](\<6_@?Q9\$_#]UH_@CPC:?;=:U'1)+'XU:3=/XPUVY\.0S:QIEYHNB:
M-K5M%=ZU:^<^(OV"+_Q9X=71M4^..L^'[GQO\#]-_9I_: _X5O\ #3X?^!_#
MGQ8^"'A[6/&MWX3\+Z#X3\C7+'X1ZOX7\.?$'QEX#TCQ'X0N[MK?PCXIUJ"/
M2X]7MO"6K^$]S6/V/_B;>?M9^#/VD]%_:)7PWX;\!_#CQ%\$_#OPCT_X.>&&
MTZS^#GC3Q#\+?%?B[PNGC/\ X2>'6XM=N=<^$WAQ] \5P:=&_AVPDO+--&U%
MVCNE *O[%'[96O\ [4SWTGB.V^ 7AU[CP#X/^(?A_P *_#?XN>/?'WC=="\6
M_OEN]:L?%_P6^%^@W^BZ5Y]IH-]XK^'>O^//#"^,HM5\.2:I#<643W7OOQW^
M)_Q;^'L5B_PQ^%7A7QK9V_AKQEXR\9>+_B/\5K;X1?#SP?HO@VWTRY_LN]\0
MP^$?'VL3^)O$\=]>SZ,&\,6WA+2-(\/>(=9\6>*]&^S:1INO>00_LK?%JPE\
M0>,A^T_XS\4?&/1?@YXU^"_P,^('B7P%\+X!\,]%\<:OX,U[6/$_B#P_H_AB
M#0?B1XVU#5OA[X)FU;5-8TW3/#\]IX=CM-)\(:)-J^NWFI:W[7?[+WQ _:;3
MP%H^B_'/_A7GP_\ #5UK&H^-_A9JOPJ\+_$WP!\8]0F.FMX53XDZ;K6LZ!J&
ML^'/!EQ:WVIVG@=M3;P7XGUB]M+SQSH7B6WT+2+&W / G_X*7VFK>#]0^,/A
M'X2RW'P2^&7PB_9P^,?[0VN^+O&\/ACXB?#70OVD?"VE^/[#2= \!67AGQ#I
M7BS7?A9\.=;TCQY\4+76O&O@B!='U*WT[P1<>+-=2YL8/H7P7^UC?^*_VO/B
MK^R_J7PE\1>"M*^&_P %?"_Q@TSXD^*=<T6W7QS:ZU\4/B'\,]4;1?"%@;^^
MTGPEIMYX"EOM*\5>)=4TJ_\ $L-U<7=IX6LM M],U[7.'\;_ +"</Q%U'6;C
MQ/\ %_Q+'H_Q@\*?"CPW^U?X5T#PKX5TGP_^T%/\) $TO4U6X35-5^&#>+--
MV^#/'MGX5U2]AUSX?6NF^'M.DT+5K!/%$F-XA_86\7>-_P!ICXE_&_Q[\>CX
MF^'WQ;^#VH?LX^./@FOPKTO0=/U/X!W6N_$#Q+!X+A^(.A^-+/Q?I^O+JGQ%
MUJ&_\:Z>EK?WVE);VD&G:=> ZF #N_V7OVRH?VF?B[^TCX!TOP#-X<\(?!MO
M@QJ_P\\<W6O/>W/Q<\!_&3P=KGB30O')\,/HFGR^#=-OYO#FH3^&+.YU36;W
M7O"-]X?\47:Z)+JQT6TWO&?[>'[,?PYF\?)\0/&^O>"+3X=>$_B1XYUC6?%O
MPS^*'AWP_K7A7X/W5M9_%+6? .OZOX.L](^)5KX">\M;GQ&? 5YXA:UTR1]:
M@%UHUM=W]OA?LX?L'_"C]E_XT_''XR?#OQ#\3;JY^-OAKX/>%+SPSXR^)_Q*
M\?:-X:TCX.Z#J>@Z-#I<OC[QKXJN[U[FWU!$MY]2,MUX>TZV&@^'KBQT2ZN[
M&7Y ^(/_  1E^%WQ(NO&=]XA^+GBVXU?Q)X<_:D\'VGC)_ GPVF^)MQX<_:J
MT35=-\56_P 0_B>VCIXU^*M]X+GU*&'X?77BC58K/1?#FCZ+X?NM*OYK$:TP
M!]NW'[=?[.$)FL8_$_BRX\40^-]>^'TW@&'X2?%^7XD6NO>&_"6A^/M7O]0^
M'</@27QMIO@JS\"^*?"OC*3XB7N@P>!6\,^*?#>JP^()8]<TR.ZSOA7^T]\0
MOC?^R!^SC^TC\+O@G'KWC#]HSX>_"#QSIWP_N_B!9Z5X3\!6WQ1\,V/BB_U/
MQE\0Y?#T^J2^$_!UA<3)<ZCX9\ :[XEU^^;2['2?"BMJ<MSIO#^(OV!["X_:
M-^(G[4O@;XP>+_A]\6/B'XDM;B^U.P\-^$=?L;#P)?\ P@^%GPB\:> ;;3_$
M-G>6\L'B&'X/>"/&NE^(94&J>&O&&CPLL&L^&[G5O#NJ[-_^QKXHT#]B[X1?
ML=?!3]H?QS\'K'X4^"_AA\-!\3M+\.:%K?C/Q1\//AUHMMH-]X9OG>\T:3P]
M+XXTRQM;#Q!XF\&ZKH'BS3;.2_/A/6M U&ZAU.R /,]!_;\^('C^XA\"?##X
M#:!XJ^-?AZ/]I;4_B+X1OOC%_8O@:#0/V8/B?IGPA\1W_P ,_B&GPZU.[\>R
M_$;QWJ<N@?#C^V?!G@?3K74O#7CC3OB'J/@[5/"S6.I=KHO[?6C^,OC)^QKX
M$\#_  J\6ZG\,OVQ/AEXJ^)WA;XU:]JNAZ!HEA9Z3\(M"^,.A:%HWABVGUO7
M_%.JWF@:TMOXJOV&@^&_"M^L&FV.L^*-7;4M/T?-TO\ 82\2Z-X;^'X\-_'?
M_A6WQ#\!> O'GP2LO&'P?^"GPV\!>'O^%">/=5\/:R_P^TOX;W3>*/#V@:OX
M,U7PSIVL^ ?&UA>27FBZU)J4^KZ/XCTS6-6T>]I^*?V"O%G_  M/]ECQC\*?
MCV/AAX _8\\+?\(5\&_A:_PCT#QI9VOAK5/A[HWPM\4Z=X@\5ZMXLT[6M7&J
M>#-$M;72KA+:SN-#U%I=1EDUC<+8 '<>!?VO_$NN_M2C]FGQ3\.O!.F:Q?\
MA_XB>*/[.\"_&S0?B?\ $[X6Z%X+U#P_'X:U7]HWX>:+X=L=/^$^G?%O1?$F
MFZM\.KO3/&OC9+N\E30+T+=FXN[/[MKXO\*?LD:I9?&;P'\6OB%\;_&_Q3/P
M>_X6#_PJ72]>\.^"-#UC23\2M)_X1[76\=^-?#&CZ;KGQ*&F>' FA>'K;4HM
M&T](H+#6_$]CXL\7:/HOB/3?M"@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"$9TC_ )XW/_@SU7_Y.KU -^BL#_A&=(_YXW/_ (,]5_\ DZC_ (1G2/\
MGC<_^#/5?_DZ@#?HK _X1G2/^>-S_P"#/5?_ ).H_P"$9TC_ )XW/_@SU7_Y
M.H WZ*P/^$9TC_GC<_\ @SU7_P"3J/\ A&=(_P">-S_X,]5_^3J -^BL#_A&
M=(_YXW/_ (,]5_\ DZC_ (1G2/\ GC<_^#/5?_DZ@#?HK _X1G2/^>-S_P"#
M/5?_ ).H_P"$9TC_ )XW/_@SU7_Y.H WZ*P/^$9TC_GC<_\ @SU7_P"3J/\
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M0_MJZ_#K7A;P%\.?#'B+XW>!?"OAQXW_ &E9/C7XS^*6GZ[^R[877B_X(?\
M")_M+?#GX,^'OC!KW@OQMX<^*NB:KI'PG\2ZMJ_A7]GNXU?Q_%XRT_X?>((_
M"_\ 11\./ /ACX5^ O!WPV\%V4FG>%/ OAO2/"OA^TGNKB_NH]*T2RAL+1[[
M4;MY;W5-0N(X?M.HZK?337VIW\USJ%[-+=7,LC 'XZ_\%)_^4DG_  0I_P"S
MK?VH/_6.?B#7ZM?&S_D2;7_L,Z=_Z37E?E+_ ,%)_P#E))_P0I_[.M_:@_\
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MK2IQE&$6HRP^(:3C3M"*72,4HI622M8-/>MM;]4?4E%%%?T^2%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(W0^PS
MTSTYQCOGH1D9'<=:6D/0X )P< ]#['V/>@#^?_1?AA\7A^TE\6/AP?C#\<?B
MW\+=)_:L\->(_&OA_P",W[77P8^$#WD^J'X6_$2WTO0OA;X:_9LU_P"(?B#X
M8Z+)!I0\+6MC\4?AB/B+<:/KWA[^Q+#0+W4=7\4?T #@?B>^>YY_'J1VZ=J_
M!+XQ>%/B1+_P4+U!HOV4?"7BF\US7_!&J^"?&%S^R%\-?%'@6YB\/_$W]F.Y
MT_Q_XH_:AN/ASJ?B70/'3?#&7]I]]5M/$?CWP_JWA6[^&_@?_A7OA+6]2_LF
M[\:_O:O3\_;/)Y(P,$]3P.2: /P]_P""EL;2_P#!2#_@A4B320,?VKOVG2)8
M1$9%V_L>>/V( FCFC(< H^Z-CL9MI5MK#]3?C#8SVW@VVDEU;4;U3J^GKY%V
MNFB($V]WAP;33K67<N" #*4P3N1C@C\MO^"D_P#RDD_X(4_]G6_M0?\ K'/Q
M!K]6OC9_R)%K_P!AG3O_ $FO*^:XQ_Y)?///+ZR^3LF!\F4445_*@!1110 4
M444 %>T_!*VEN==UE(KZ[L2-'C8R6@M"[C[<@V-]LM+M H(W91$?/5RI*UXM
M7NGP'_Y&#6_^P+%_Z7I7U7!'_)69)_V%5/\ U%KC6TO3]4?1/]DW?_0Q:W_W
MQH?_ ,I:\V^(GB;4_ \>D/!?ZIJ7]I27J.)[C2;7R?LJVS*5,.@2[]_GD$,%
MV[003DBO9*^>/C]_J/"W_7?5_P#T5I]?O_&>/Q>6<-9ECL#6>'Q5!81TJRA3
MFX>TQV%I3M&K"<'S4ZDX^]%VO=6:30M_DW]R;.4_X7-K7_/*\_\ !E8?_,U2
M'XS:T"H\N\R[K&H_M/3P7D9)9%C0'PV"\C1P32K&FZ1HH9I I2&5D\:K\5/^
M"K&JV^@?$G]E#Q'=:AK/B:70?B)8:AH7P8.I_'?X>3>,M<LO!OQTU)-3^"GQ
M8^#J7]G8_':_DMM+\&6?AW5/#7B3Q)!/??#:_P!'E\-^$]9\=7>J_B>6\7<7
MYCBX86.>UZ;G"I)..!P%63=.FYQBH_5Z<5S.$8N=2I3IP5YSFDK,5GV6GGY?
M\'^K6_H6/Q?\0B$7)L]3%LS;5N3>6@MV;)&Q9SX8\HME6&T.6RI&,@X<WQ<\
M2H8@]AJZ&X(%N'N;=3<%MI46X;PL//+!T*B+>2'4C(89_G%U?7/&_AW]IS1Y
MO"%DOC;X\V7[7_BCXB_$'5_#/Q \6:K^T'??LCZA\,_&GBWQ!^SGXI^!$^F6
M?A?PCIOPS\,S^%/ W@GQ%>Z_J7P3\6_$_2O &N?"_5]8^(GC3Q"ND?/OPT7Q
M=:^!-?\ #<?Q%^%EVDG[./@7Q[\6O%?PY\?_ !ULKS7[?PS^T1\'-;\>_#;_
M (*'>-+JQ\2:Q\/?V@OB]\.[[4OAM'\3?AYI&F)H#WO[0E[XG\+:%\,;.P;0
M_7AG'&$H1G_K-.*E'#2BO[.R^3:KU)P<[1@VJ25)2HRJ*%2NVZ<J-"<9(=EY
M;VZ^77[[VVON]+_U<2?&+7X7:.>VU""10"T<U_9PR*" REHY/#*NH92&!91E
M2&&00:=+\7O$4 C,]GJ< E4M$9[RUA$J@*2\1D\,*)% =3N3<N&4Y^89_%;]
MCKQ];6%I\=-"C\0^$OA1\-/C!^T)>>!?V'= \.>)-5^)GAK3M:A_9IT'Q+\3
M- ^$/B*]L(?#_CWP_P"%?B-X=\>>-[&+PDEK\)KC7='\>Z%X!OM0T6T2YO\
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M@#$_LF[_ .ABUO\ [XT/_P"4M']DW?\ T,6M_P#?&A__ "EK;HH Q/[)N_\
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M#JT?@ZV:]U"RNH?[7T\".WTR6SD#_9[O:QF?4[M2H&04\D%B00ZX(/S7&/\
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M?ZCPM_UWU?\ ]%:?7[GXA?\ )'YQZ8'_ -6>"!;_ "E^3/FZBBBOYB$%%%%
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M#_UCGX@U^K7QL_Y$BU_[#.G?^DUY7S7&/_)+YY_V 5OT ^3****_E0 HHHH
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MQM5TS0[2"W2[FLRE]K4D4_FP)$[,%M]'NH_+(E7:?-W$ALHHP3\35];? _\
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MT@I@%O-$8.Y=A8[@O[GXA?\ )'YQZ8'_ -6>"!;_ "E^3/GNBBBOYB$%%%%
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MEVS32E^_HJE4J)W52:=XNZE).\%RP=T[WC%M1_E3LK(#CO#?PZ^'G@W^S/\
MA#OA]X!\(?V+::QI^B_\(EX(\*>%_P"QK#Q#?VFJ^(;#2/[ T?3O[*L?$&JZ
M?I^J:]9Z?]FM=;U*PL=0U6*\O;*UGAV=!\.^'?"NG+H_A;P]X>\+:.ES>7J:
M/X7T'1_#>D)>ZA.;G4+U=*T*RT_3UO-0N6-Q?W8MA<WLY,UU+-+\U;%%*4YR
MOS3E+F:<N:3=VKM-W>K3E)IO7WGW87??^OZ2^X*^MO@?_P B9-_V'+__ -$6
M5?)-?4OP9O;FW\(S1Q:1J-\AUJ^;SK632EB!,%F#&1>ZG:3;UP"2(BA##:['
M<!^@>&/_ "5$?^Q?B_\ TO#@>YT56M9Y;B(R2V=S8L'9?)NVM&E( !$@-E=7
MD.QLD &4/E3N11@FS7]' %%%% !1110 4AS@XZX./K^/%+6;K-^-+TG4]2,<
M<PT_3KZ^,4UY:Z?%+]DM9KGRY;^^DBL[*-_*VO=W<L=M;*3/<2)#&[  _$OQ
M_P".(-._;U\2>!_'27OCC7-3^,_PM;X?72_\%%OC7\(K#P1H^L>'/ O]B>!]
M0_9_^'VFZ/\ !6SUN:ZMM7\3^&_ 'C37;GQY\<K#79?[3LM3L=6TZ*Y_<4?U
M/?/<_P"<=NG:OYT=8_:"^$GQ%^/Z>&O"_P 6O"MQ\)/C1\;O@C\2/&OPL\(?
MMP?\$Z=4\*^,OB?%-\);K[78M=:UJ7Q_CM(/%7A#P[;^(? _@;7#<>/=:\*D
M>"+G2M+\4W>G:W_1<O3\3W!R<G)XXY/..W3 QB@#\0?^"D__ "DD_P""%/\
MV=;^U!_ZQS\0:_5KXV?\B1:_]AG3O_2:\K\I?^"D_P#RDD_X(4_]G6_M0?\
MK'/Q!K]6OC9_R)%K_P!AG3O_ $FO*^:XQ_Y)?//^P"K_ .V@?)E%%%?RH!GZ
MOJ<&BZ5J>L722R6NE6-UJ%PD"JT[PVD332+"KO&C2LJD('D12Q&YE&2/#_\
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MUX3\;O!VO6D/AK[7\3_'.II)/J>%N+;P-:M$$CL2WE2Z7X-L)%,N0'+F3"J
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MINHV(LE\O5;M08;>\TN]$!;!:0Q./,D9G?\ A"^H?\(U=_\ 0Z>-?_ _0_\
MYGJ_FSC7A[(,JXQXJRO YKAL!@LMXCSK 83 U,/F]>>#PV$S'$8>CAI5Y4,3
M*M["G35-5IUZLZJBISDYMW_:>&<WS7'\.9!CL7@*^*Q.-R;+,7B,5"KE]*.(
MK8C!4*U2NJ2K4%2]K.;FZ<:5.$'+EA%12.IKZ2^ /_'MXI_Z^-)_]%7U?(G_
M  CFI*?W7C?Q:H(Y$Q\.79)!."IG\.G9P<$+@-@$]!7OWP2\'^(+V'Q(UO\
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M1:4DGH?J1I>HVVL:9IVK6?F_9-3LK:_M1,@CF%O=Q+-$)8PSA)-CC>@=PK9
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M8_WDPA5_)C_>2[$^:C_5_/O^A'G'_ALQOE_TX\T%O3[U_77\^S/UBHK\H?\
MA^'_ ,$MO^CHY/\ PP?[47_SD*/^'X?_  2V_P"CHY/_  P?[47_ ,Y"C_5_
M/O\ H1YQ_P"&S&^7_3CS06]/O7]=?S[,_5ZO=/@/_P C!K?_ &!8O_2]*_"W
M_A^'_P $MO\ HZ.3_P ,'^U%_P#.0KU7X3?\%Z?^"3WAC6-4NM9_:LDM8+G3
M([>%_P#A0'[4C[YENUE*X7X($C" G)^E?2\'9+G&'XGR>OB,IS.A0IXF<JE:
MO@,72I4XO#5DG.I4HQA!-RBKR:5VENP6S\UW\T_Z_P" ?T0U\\?'[_4>%O\
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M=')_X8/]J+_YR%1_\/R/^"6/F^1_PU0//\KS_L__  HC]I[[1Y'F>5Y_D?\
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M317Y0_\ #\/_ ();?]'1R?\ A@_VHO\ YR%'_#\/_@EM_P!'1R?^&#_:B_\
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M&D&B^'M:\1Z;XA\)R>,]#3XNZ#I'A_4]6T#Q3H_BOPCHEEJ>IV=@+GR'1_\
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MWP\\*2O\1UDO3J<H\:E]*;_A(Q-JC-JTW]J?:#-J[-J\I?4V-V?<:* /"/\
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MC&P\":E%KEQ92:DE]X-L?B'X\M/#%TMP)]#MO&?BB#37MX]=U);CG[3]FO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>noncontrollinginterestchart.jpg
<TEXT>
begin 644 noncontrollinginterestchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MZ5X3L/VZOB#KWB/X5?LV?%C3Y?VA?A+:/\;_ (J?"_\ :6\:ZQ\%?$FI:/\
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MW0!T%%<__:.M_P#0!_\ *M9?_&Z/[1UO_H _^5:R_P#C= '045S_ /:.M_\
M0!_\JUE_\;H_M'6_^@#_ .5:R_\ C= '045S_P#:.M_] '_RK67_ ,;K0L+B
M^N/-^V6'V'9L\O\ TN"Z\W=NW?ZE5\O9A?O9W;N.AH T**** "BBB@ HHHH
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M?^"D_P#RDD_X(4_]G6_M0?\ K'/Q!K]4OCA_R*&E_P#8;M/_ $WZA7R_&O\
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MOKKX)?\ (EM_V&M2_P#:%?(M?77P3./!;=?^0UJ78G_GAZ"OT3PP_P"2G?\
MV+<7_P"G<*/H_5?E(]>HI,CW_(_X49'O^1_PK^C!"T4F1[_D?\*,CW_(_P"%
M "T4F1[_ )'_  HR/?\ (_X4 +129'O^1_PHR/?\C_A0 M%)D>_Y'_"C(]_R
M/^% "T4F1[_D?\*,CW_(_P"% "T4F1[_ )'_  HR/?\ (_X4 +129'O^1_PH
MR/?\C_A0 M%)D>_Y'_"C(]_R/^% "T4F1[_D?\*7.?7\01_.@ HHHH ****
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MIWAG1+C5Y=?\5:M<2)I6FMH^C^)];T  ]M_S^72LO1-#T7PSI&GZ!X<TC2]
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M/AIKKX?/::G<ZS?Z;X4\7_!GQMX2UG5]5TS2].U'6M,G;PU-K&EQ?VE)]64
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ML#]%:** "BBB@ HHHH #G'!P?7&?TXK\U;K]E?\ :)\>_M*^)?B7\=?%_P
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D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>otherincomeexpensechart.jpg
<TEXT>
begin 644 otherincomeexpensechart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M5/\ Y"J,7FV5Y?.-/'9E@<%4G'GA3Q6+H8><X.3CSQC5J0<H\R<>9)JZ:O=
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M[["RVVFF0_9(+KS5,MX%'[YE\O8<G*YW;N?NBOI6PM[ZW\W[9?\ V[?L\O\
MT2"U\K;NW?ZEF\S?E?O8V[>.IKYX^ 7_ !_>)O\ KTTS_P!'7M?2]?TQX<_\
MDCEO_7S'_P#J?B0"BBBON "BBB@ HHHH **** "BO)[WX\_ _3?$C>#=1^,?
MPJL/%Z7?V!O"M[\1/!]KXC6]\Q8?LC:)/K,>I+=&5UB%LULLYD(01EB!7K%
M'X@?\%)_^4DG_!"G_LZW]J#_ -8Y^(-?JE\</^10TO\ [#=I_P"F_4*_*?\
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M1XQUW7?%,^@>*-'\+>&?Z4_[,U7_ *&2_P#_  !T;_Y7T?V9JO\ T,E__P"
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MXP,QDV]BDX#>L3JXZJ17QX;.\)/^AW?4_P#+M/\ _&Z_,O%B,I9SEO+&4O\
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M$[X;>-=;_9_\(>&O#\/CNX \"2P:Q8>+?VE?BCX_\:>$M/D'P:L_A)X-\/\
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M "BBB@ KZF^#UC>W'A%I+?5[FQC_ +7U!?(AM=.F3<OD[GWW5I/*2^>1OVC
M"J.<_+-?77P2_P"1+;_L-:E_[0K]$\+_ /DIW_V+<7_Z=PH^C]5^IZ!_96J?
M]#'??^ &B_\ ROH_LK5/^ACOO_ #1?\ Y7UO45_1@C!_LK5/^ACOO_ #1?\
MY7T?V5JG_0QWW_@!HO\ \KZWJ* ,'^RM4_Z&.^_\ -%_^5]']E:I_P!#'??^
M &B__*^MZB@#!_LK5/\ H8[[_P  -%_^5]']E:I_T,=]_P" &B__ "OK>HH
MP?[*U3_H8[[_ , -%_\ E?1_96J?]#'??^ &B_\ ROK>HH P?[*U3_H8[[_P
M T7_ .5]']E:I_T,=]_X :+_ /*^MZB@#!_LK5/^ACOO_ #1?_E?1_96J?\
M0QWW_@!HO_ROK>HH P?[*U3_ *&.^_\  #1?_E?1_96J?]#'??\ @!HO_P K
MZWJ* ,'^RM4_Z&.^_P# #1?_ )7T?V5JG_0QWW_@!HO_ ,KZWJ* ,'^RM4_Z
M&.^_\ -%_P#E?5^QM+JV\W[3J4^H;]FSSK>R@\K;NW;?L=O;[M^1GS-^-HV[
M<MF_10 4444 %%%% !1110 4AZ''7!Q_D\?G2TUV"JS%@H568LQ 50 26))
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MPBMM+OM:FTKPUX-T_P /?K-_96J?]#'??^ &B_\ ROH_LK5/^ACOO_ #1?\
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MKN].+3;TU$;U%8/]E:I_T,=]_P" &B__ "OH_LK5/^ACOO\ P T7_P"5]?6
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MOQ#>_#2T^'EUX&\8Z-XLB\>ZQXPTC2FMOM_AF."3XAV,G@Q@#]&**^*OC/\
MM@'X6?'3PM\"]+^'-OXIU?Q!I'@35;C6M7^,OP9^%]K')\0O%?C'PSH6B>'-
M$^(WBO1O$WCWQ"B>!=>U:\TCPCI6H3QVC:9;1&;4-12VC^U1S^9_0X_SZ=Z
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M(O 5Q??#CX@ZY\-8[+QEIGC+1M"TVT\*^(M(T^*]\.WVD>)M>Z_90_:/U/\
M;&\:_'6Y^(_P>T/X3>,?@)'^R^GAGP9X=^*/A[XM^&_A?I?BSQQXOT+Q+X:^
M(*>.)M"TGXD6=]XQ2VBU"W\,#2]-.E6^I:9%'=E8D_3"B@#\ZOV5?V!#^RS^
MT!\3OBQI/QZ^+OQ \%^+_@%\ /@5X3^'7Q#UG2-:B\(Z5\#]7^*EYI\[ZIIW
MAO0DU"RLM,\?66D^#;&&UM)M 0^,KC5KOQ#+XGL/[ _16BB@ HHHH ****
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4% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>otherrevenueschart.jpg
<TEXT>
begin 644 otherrevenueschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-/C/\ $/\ X5'\
M(?BG\5/['D\0_P#"M?AQXZ^(']@Q7?V"76_^$+\*ZOXF_LB.^^S7GV.34_[+
M^PI=?9+G[,TXF^SS^7Y3_!?[/?\ P4>\*?$'X5>%?BO\5=;^ L5E\2+'PU/X
M"\'?LH_$[XB_M?\ Q!35;SP'/\2/&OAOQIX.\!_!/1_$&@ZO\/\ PHUCJGB
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MQ^T7\<O%'QK\._!_X,Z/\%_@G#%\._AWX%TGP%9:&?AVUAX^U+P[!9^*-/\
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M[S5_$%SJNM:AH_&;]D;4OC=XOC?Q9\</'+_".X\=_#?XEZA\+$\.>!7O=/\
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M>ZSX(@^'GA/XC>.=:U7Q;\-/BCX=T+5?"?PANXK/XHZYX(UW5_!MGI/Q$LO
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MROO 'B?X9:QXO\,_#_5+K_@H#H7[9OQPN/AK\1KOXF>"+R;1#J)TZVDTC6?
M4&H?$'PY\'/ G@RVO_ ZZM-?Z9^N2_'>X>00IX0E>8YQ"FIRM,<+N.(ETLR<
M+\Q^7A?F/'-21?'*]G0RV_@J[N(E)5I8+ZXFC5EP65I(M)=%90064L" 02 "
M*/\ B(O!_P#T-G_X09EU_P"Y3U^Y^5RW]77E_FOZ3/ _COX ^)7QAL+&3QY^
MRQX-^*%E\,?BWXEL?#F@G]HC6O!-_P"// FJ?#G3](MOB;;6>DZ18>%X'U37
M]?\ $F@:U\&?B/JVJ66FZ5HMEXVTWQ-J7B"#1M&/T'^R]\/_ (@_"WX%> ?
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M9H_MY_\ H":]_P""]/\ Y*H Z"BN?_MY_P#H":]_X+T_^2J/[>?_ * FO?\
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ME2FJJT;5.3]E*27M:=3W94VG:VFSO^6GX?B?BM\!_P!H#]F^^_X)W?L8:_\
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M]9$*, L1=PD*"Q"@L1@%F502-S 9(^\/[4U#_H6]7_\  GP__P#+NOA#3/\
MD):=_P!A"P_]+(*_0JOVSPB_A9]_U\RW_P!)QH^B]7^AYKX^U&]E\&>(XY-!
MU.V1]+G5IYKC16BB!QEW6WU:>8J.XBBD?T4U\9-U/U/\Z^X_B+_R(WB?_L$W
M'\EKX<;J?J?YUY'BS_R.<M_[%B_]2\0&J2U>[_"PJKN95Y^9E7Y0&8Y(&%5F
M16<YPJM)&K-@-(@)8?G#^S'^V%\7?VI-2_:,T#PGX&^!OA3Q-\,/%NA:)X.\
M/>,/B?XJF\4^&#JOA7X9Z[/X:_:%^&]CX2T;Q_X8UV&?Q5XKTY/%7A*UO/!2
M^*_"^J>"//NET6+Q;XG_ $:=%D1XV!*2(\;@,Z%D=2CJ'B9)4)5B \4D<J$A
MXI(Y%5U^(?AO^P[X;\!^/?C?\2M5^+?Q:^('C3XKZ!XW\$>%?%7C+5M$O?%/
MPL\!_$#X;_"/P!XATZPU^ST2POO'?BQY?@QX)UBT\<>/'UC48(M T:R%I_:;
M^+/$7B_\[P4L!&CC5BX1=9TZ/U.;C5GR5(UHRJ+V=.4(24X)*;JSCR0C+D52
M3]G(3V_5NW3MKIY>78\MUS]N+X@> _@S\,/BM\2M$_9\\)^'OC%\9O&'@+PG
M\8=1\9_%+1OV?M ^'6A>&->UCP;\3_&TU_X6U'XE6H^,.K^$]=TSX:Z58Z;!
MI5SHUSX<\4^(?$&B0ZO;:5=?5OA/XO>._B'^SSX$^+_@'X8V&K^-/B+H/A75
M_#_@G4O&T.E>%X+7Q3KD.FP^,+_QH^C-J<WP[@\.2CXDVDVG^$IO'6N>$+C3
M-*L?!]OXOU!]+L:FI?LV:%':? >Y\!^-?%7PQ\:?LW> [KX:_"OQQH.E^#/$
MLVG>$-6\)^"_!WB'3=6\'>.O#WB'P9J<VN:5\/\ PQ)_:T.EZ=KNCW-I=P:3
MJT&B:QKVBZMP=O\ L?77AGX.ZA\#OA7^TC\<_A)X,N? UCX1TNX\*6WPNN?$
M7AO6;WXG^+OB?\2OB'H.N7G@2"\TOQ;\7;CQGJ?A/Q'::0VD>%O!?A.&RA^$
M>@^ -7MX]53KJSR>K3H^RITL/66,YJCJ+&3IO"NM77).%*[M&C]5DW1J1J5'
M&M&,,/*"EBVGM_G;^7NWIIV_!67J/P$^+NO?%6V^*NF^*?#WA_1O$_P<^,?B
M3X+^(=4\#ZYJ7B7X<>+=9\->'?"/B*^UKP+K.MZ7HVN"WTN3Q<O@[QAX?UJQ
M;5/!GQ$\->+/"EUJ.J-I?VQO>Z\?^!GPHN/@G\/].^'(\9?\)AHF@2&W\*I%
M\.?AS\,+#POH AB\KPWIGASX9:-HFAS6J7_V_5Y]7U"WNM?U+4=5OKC5=0O)
MF\Y_8*\K%>P>(JO#J*H\UJ?*JBBXI)<R55*<.=KF<)7]FWR*4HQ4FK]F_P N
MWGY+[D>Z_ ZYGMKWQ$8-/NM0+VNFAEM9+"-H@);PAG^W7EFI#9('EF0@@[@H
M*D_2UG=7%SYGGZ;>:?LV[?M4NGR>;NW9V?8;V\QLP-WF^7G<-F[#;?G7X!?\
M?WB;_KTTS_T=>U]+U_2/AS_R2.6_]?,?_P"I^)$%%%%?< %%%% !1110 445
M%/#'<0S031I-%-%)%)%( R2QR(4>-P>"KJQ5@>""0: /)+W]H3X#:;XC?P?J
M/QI^%%AXLCNC8R>&KSXB>#[778[X3+;FRDTN;64NX[WSF6/[')$MT7(40[B
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MXH^*G_(_>(?^NMC_ .FNQKZW^W:__P! "/\ \'-M_P#(E?(/Q+>>3QOKKW,
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MCA_R*&E_]ANT_P#3?J%?+\:_\DKG?_8&_P#TY3''=>J_,^5****_E<04444
M%%%% !7UU\$O^1+;_L-:E_[0KY%KZZ^"7_(EM_V&M2_]H5^B>&'_ "4[_P"Q
M;B__ $]A1]'ZK\I'KU?$WQ5DC'C_ ,0AI8E(EL<AI8U8?\2NQZJS C\1TYK[
M9K\(OVNR1^T5\2,$C_2M [G_ *%/0:_H^'AK'Q1;R*6<O(_J2_M;ZTLO69>T
M]BU@_J_L'C<!R<WUWVGM?:RY?9<GLWS\T/@_$'C5\"Y1A,U66K-/K.94LO\
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MJI*.&PBISQ&)J82M6J2H>P]@W*O@<)72=/EA6P].K3C&HG)^-^,?AGXB\?\
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M\M9+..,OTVAW52<9(&:_!QNI^I_G7[]_M,_\D"^+'_8EZM_Z!'7X"-U/U/\
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M/^2AQ_\ V)J__J=@#\)^D!_R2.5?]E'AO_59FI\YT445_0I_(@4444 %%%%
M&YX8_P"1G\,_]C)X?_\ 3S8U_2F.GXM_,U_-7X9W?\)+X;VE0W_"1Z!M+ E0
MW]L6.TL 5)4'!8!E)&0&4\C^C@0^)/\ H(:'U/\ S"+_ -3_ -1S\_TXK\/\
M8?XN0?\ 7O,O_2L"?T[]'?\ @<5_]?<G_P#2,R/*/VF?^2!?%C_L2]6_] CK
M\!&ZGZG^=?O+^TE%KP^!'Q5-S>Z1) /!NJ^:D&F7L,S)L3(CE?5YT1CV9HI
M#C*D9K\&FZGZG^=>SX1_\B/,O^QK+_U$PI\[]('_ )*7)O\ L2+_ -3L4)11
M17ZN?@@4444 %%%% 'Z/?\$Z_P#D8?BI_P!@7PC_ .G'Q!7ZI5^4/_!/=-1?
M7_BA_9\]E PT;PGYIO;2XN@R_P!H:_L$8@O;,H0=VXLT@;*@!<$G]4+)-33S
M/[1N+&?.WR?L5G<6FS&[?YAGOKWS-WR[=HCVX;._<-O\Q^)7_)7YE_U[R_\
M]5V$/[=\&/\ DW>2_P#7_-__ %;XTO4445\&?J84444 %%%% !1110 4444
M?B!_P4G_ .4DG_!"G_LZW]J#_P!8Y^(-?JE\</\ D4-+_P"PW:?^F_4*_*W_
M (*3_P#*23_@A3_V=;^U!_ZQS\0:_5+XX?\ (H:7_P!ANT_]-^H5\OQK_P D
MKG?_ &!O_P!.4QQW7JOS/E2BBBOY7$%%%% !1110 5]=?!+_ )$MO^PUJ7_M
M"OD6OKKX)?\ (EM_V&M2_P#:%?HGAA_R4[_[%N+_ /3V%'T?JORD>O5^$/[7
MG_)Q7Q(_Z^M _P#43T&OW>K\(?VO/^3BOB1_U]:!_P"HGH-?V_X2?\E#C_\
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M_P"P+X1_]./B"OU2K\K?^"=?_(P_%3_L"^$?_3CX@K]4J_F/Q*_Y*_,O^O>
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MPUKWBWPP_@[79K7Q5IVDZI?0QWWAV:YTQ_L?V2<6MY>VYN&M[RXAD^*_$?\
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MV,DUNVTUH?N%D>_Y'_"OPC_:[!/[1/Q(X/\ Q]:!V(_YE/0?45VW_#EK1_\
MI)]_P6A_\6,?$;_YG*\^UK_@@!\%?$>IW6M>(/V^O^"MVMZQ?&-KS5-4_;V\
M9WM_=M##';PFXNI_"CS2F*WAB@C+L2D44<8PJ*!\WP7Q)A^%\SQ&.Q.&K8J%
M; SPBA0E",XRGB,-6YVZC2Y5&A)-+6[72Y]CXD\&8OCC)<'E>#QN&P-3#9I2
MQ\JN)A5G"4*>%QF&=.*I)R4V\3&:;TM"2W:/GC!]#^1HP?0_D:]S_P"(>7]G
MS_H^7_@J]_XG9XM_^9*C_B'E_9\_Z/E_X*O?^)V>+?\ YDJ_3/\ B+V5_P#0
MHS#_ ,&X;R_O^;^[S/Q7_B7O//\ HH,I_P#!&,\O[GF_N\SPS!]#^1HP?0_D
M:]R/_!O-^SXN#_PW)_P5>/S*,?\ #=GBW^)@O_0I>_;!]"#R/G/]D3_@A]\'
M_CK^S'\#/C!XN_;C_P""I*^*/B+\-O#7BS7AH?[<?BRRT@ZIJUF)KLZ=:+X7
MG6VLS*"8(!/-Y:$*9)&!=C_B+V5_]"C,/_!N&\O[_F_N\P_XE[SS_HH,I_\
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M#X7P&*P>)P.)Q4L1C'B8SH3I1C&+HT:7+)5))MWIN6BM;3<\SQ)\,,QXXS7
MYA@\SP6!AA, L'*GB:=><YR^L5:W/%THN*CRU4K/6\7W1X9@^A_(T8/H?R->
MY_\ $/+^SY_T?+_P5>_\3L\6_P#S)4?\0\O[/G_1\O\ P5>_\3L\6_\ S)5]
ME_Q%[*_^A1F'_@W#>7]_S?W>9^<_\2]YY_T4&4_^",9Y?W/-_=YGAF#Z'\C1
M@^A_(U2^+W_!#;X-^!?B=^RMX-T?]N/_ (*F'3?C3\:?%O@#Q4U]^W)XLGNA
MH6@_LV_'CXLVHT:0^%HS9ZD?$WPW\/>;<J)]VD#5;-H,78N+;Z _XAY?V?/^
MCY?^"KW_ (G9XM_^9*C_ (B]E?\ T*,P_P#!N&\O[_F_N\P_XE[SS_HH,I_\
M$8SR_N>;^[S/#,'T/Y&C!]#^1KW/_B'E_9\_Z/E_X*O?^)V>+?\ YDJ/^(>7
M]GS_ */E_P""KW_B=GBW_P"9*C_B+V5_]"C,/_!N&\O[_F_N\P_XE[SS_HH,
MI_\ !&,\O[GF_N\SZJ_X)V CQ#\4\@_\@7PCV/\ T$?$'M7ZI9SZ_B"/YU^%
M7AG_ ((-_"WP7)>3>$/^"AW_  5]\+S:A'#%?2Z#_P % /'&ER7D=LTKV\=R
M]IX6B:9('FF:)9"P0R.5QN.?T _9"_8KL_V0V\?-:?M0?MI?M'?\)\OAI9%_
M:[_:-\1_'U?"/_"-'7"I\!#7]-T__A%FUS^W&'B4VOF_VR-*T,3;/[,BW?DW
M%6=4N(,[Q6:T*-3#TL1##1C2JN,JD70PM&A+F<&XOFE2<E9[-7U/W[@3AO$<
M)<,8#(L3B:.+K82IC9SKT(SC2G]:QN(Q45&-1*:Y(UE"5UK*+:T:/M6BBBOG
M3Z\**** "BBB@ HHHH **** "BBB@ HHK.UC4H]&TK4]7FMM1O8=+T^]U&6T
MTC3KS5]5NHK&VENI+?3=*T^*>_U/4)TB:*RT^R@FN[VZ>*UMHI)Y8T8 T:SE
MTC24U:77ETS3UUN?3X-)FUA;*U759M*M;JYO;;39=1$0O)-/M[R\N[N"R>9K
M:&YNKF>.)99Y7?\ /R[_ ."A&G>$9O$FB_%GX!_%[X:>.(O /@;XE?#SX?7=
MSX"\3>)_B+HWQ.^*_AOX&^!/"8;P[XJN-#\#_$_4/BQXS\'>#=6\)^,]7T[1
M]+NO$L%_:^+]8TS0O%]UX<SOBC_P4>\-?!?X'_&?XF?$+X(_%N/Q_P# #Q+:
M>%/BE\&O"$7ASQIJ_A^XU+PKX6\>:7XLG\>Z7JD7P]L?AM?^!_&.C^(K?QEK
M^L:%)/<QZGX+L]"N_B'8'PG* ?I+17PW\;OVR)/A1\>?#/P,TSP;X)U;4-;T
M+P#K5UK7CC]H+X8?!YI)/B)XQ\8^$]%T/P;X:\9&;Q#\0-?B'@?5]2NM.T&W
MCR+G2--MI9]0OVBM_N,'/YD=<]"1^O7';I0 M%%% !1110 445X?\8_BCXX\
M 2^&-(^'GP2\<?&?Q)XG;69Q;>'=3\+^%/#'AW2O#\>FR7]YXJ\<>,]2T[0M
M)OM4EU6STSPCX?B%]K7B?4WNY(+6ST#0_$OB#1 #W#_/Y=*SM)TC2M!TVRT;
M0]-T_1](TVWCL].TO2K*VT[3K"TA&V*VLK&SB@M;6WB7B."WACB0<*@%?G5+
M_P %+?AQJO@_2OBCX#^&/Q-\9_"G2/@1\._VEOC3XOB'A+0[SX)?"+XGOXN'
MA_5=>\+:KXB76/%^NZ1IW@'QQXL\7Z!X'_M?^R/!/AF;Q!I6H^(9M?\ !NE>
M)?=?!?[6WA7QS^U/\0OV6]+\$_$'3]7^'WPHT/XJ3>/?$.ACP_X.\56>K^/O
M$/P]N=-\%0:K);>)/$$&CZSX<NOM'BR/1X/!NL":-/"FM>(%M[ZXM@#ZQHKY
M(^!O[77A'X]?'7]H7X+^$_#/B"VL_@/H?PFU^U^(M]<Z/)X4^*&F_$_6/B_X
M8EU+P)!9W<VKR:+X8\7_  5\9^&+K6]4M;.P\07MDU_X9?4=#-OJEY];T %%
M%% !1110 44$X!."<#.!U/L,X&?QKXPUS]L$>#/BCX<\*?$3X,?$GX?_  T\
M<?$CQ=\(/ WQC\37'A.VTC7?'7@KP;X_\?:I>W?@B+6Y/'V@_#C5?#/PN\=7
M7A;XBZEI T[6TT2/5I=-TWPEK7A_Q1J@!]@7>E:9?W.EWM]IUC>7FB7DVHZ-
M=W5G;7%SI-_<:=?:1/>Z9/-$\MA=S:5J>HZ9+<VCPSR:??WMD\C6MW<127Z^
M"?AO^WEH'C.WLKWQ'\&OB_X)@\=?""']H'X&V2Z-IWC[Q)\9?A'=ZYX.\.PZ
MAHGA?X>7WB#6/#GC2SU'XD?#6X\0>!_$T-I-X<TCXA>'-4U;6H8K#QI'X1G\
M&_ML7/Q-_99^"7[37PY^!WC76;/XV^'[7Q);>%]?\9?#+P7:_#C3)XKV62?X
MH>/==\3)X0T9!<V<6@60\.3^*Y=6\2ZEIUE80R:3]OUZP /N^BO(?@+\9- _
M:#^#WP^^,WAC1?$_AW0OB'X<M?$6GZ'XRTN/2/$FEQW$DUO+9ZG:V]U?V$SP
MW-M.MMJ>CZCJF@:W9?9=:\/ZMJNB:AI^H7/KU !1110 4444 %%%% !1110
M4444 %%%% !1110 5F:W'K$VCZK%X>N].L->DTV^CT6^U>PN=5TJSU9[29=-
MNM3TRSU#2;O4=/M[XP37UC:ZIIMS>6J36\&H64TJ746G10!^4G@O]@OXW:GX
M/^*6D?'GXV_"OQS\3/B)JOPI^(7_  T!X1^#OC'1_B0OQ?\ @3\3="^*_P &
MM4OM&\;_ !A\=>";/X0?#SQ5H4;^'?@9X,TGPCX>LK"_UPC67\3>)_%7B[7:
M_P =?V ?C3\7O@=^TSX#M/C7\(M)^*7[9.MZ3<?'3XB7_P $?%]YX;TOPSX4
M\$>%? _@?PQ\+_!6G?&G3=4TM?#EAX4AOKG5/&?C/Q?/K6L:YXBOOL^F65SI
MFDZ5^L=% 'Y^?%S]E;XX?'/PKXC\+>.?BM\$+&T^+_PA7X.?&^ZT3]G![S71
MX?.K>,;N[O/@YXJU[XGW6N>%KN[T[Q4([#3_ (ER?%C0O"?BFS3QMX8TRSO+
MG5-)U/[]MX5MH(H$9V2&-(E:1VED*QJ$4R2.2\CD %Y')>1LNQ+,34U% !11
M10 4444 %?&W[8_P.^/7Q^\+^%_ WPE^,'@KX9^!KJ^U<?&CPWXI\$>.==O/
MBOX8GLK>#2O ]MXR^'GQ3^&'BOP)X7N+MKZ;QTGA^^_MSQGI/V7PQ#KOA[1;
MC7X=<^R:* /S+\8_L$>*O%^D^-=%T[XC_#7X;:#^T+\ /A[^S?\ M1^$_ /P
M5EMO#>M_#WX?67C;P]8K\![;4?B#)_PJ2^O?A[X^\1?#-H?$]O\ $[1])\/?
M\(WJFAZ9I^K^&"NMZ=Y^R+\>=5_:]\:_'J_^+OPHT[X7^-/@.G[,,W@'PC\-
M?B9X6^).B?"6P\4^-O%NC:KX=^*]C\:VL]&^)5G?>,3:CQ'8>"H--LHM,M;W
M1M)T[4-DT/Z0T4 ?GI^RW_P3_P!&_98^/OQ,^+_AKXT_&/QGX7\:? KX$_ W
MPU\-OB'XQU#Q7I_@S1O@GJ_Q/O\ 3YXM2NS$NI6D=AX]L]*\):;_ &=9-X0A
MMO%<BWNK?\)E)'I7Z%T44 %%%% !1110 'VXK\XW_9,^/'B[]I+Q5\5OC7\3
M/@=\7/AIJL?C[P5X)\#ZI\(OB-I/B#X2?!;QSH]SH>I^$/ -]#\;+WP+;?$#
MQ-ISQVOQ(^,6I>!;[Q5XNTVXO?#&F0^%?!BV7AFV_1RB@#\Y_AI^QU\8?A8O
MA#7+#XT?#_QAXT^ O[/\G[,_[,=YXI^#NJV&@>&/AUJVO?#34?%>M_%JQ\._
M$VTUCX@>/_$.B_"/X?:!+J/@_6/AGX7LY?#EQK-IX6C_ .$EU'2[3AO@G^P_
M^T#\+/V3/A?^RYX@^+_[./Q*\/\ PLL%\)MHGC?]ES5/%'PN^*'@>&*WO=,B
M^(W@CQ)\9-3UJ+Q;X=\4Q'Q#H>L>%O&&E^'R!]AU;PIJ4PL=5TK]4:* /#?V
M;?@L/V>?@EX!^#@\7ZQXY'@G3;ZS_P"$BUF$633'4M<U77CI>B:0MWJ">'/!
MGALZL?#7@'PE'J.I1>$/ VC^'?"\6I:C'I"WL_N5%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ?'?[7WQI\<_!G1/!-_X(FTF&XUW6M5L=0.JZ6-31K>
MTTQ+J$0J;FV\EQ,Q+OE]RX7 QD_"P_;F^/I('V[P?R<?\BHO_P LZ^DO^"B8
M)\,?#$*K,?\ A)M>/RJ6_P"8)%Z U^5H1\C]W)U'_+-_7_=K^AN N'LCQ_"^
M Q6-RG 8K$5*F,4ZU?#4ZE22ABZL8J4Y1;?+&,8J[T226A_(OBMQ;Q1E7'&:
MX++,]S7!8.C2RYTL-A<97HT:;J9;@ZM1QIPFHQ<ZDISDTE>3;>NI_0-^SWXW
MU[XC_![P9XT\3O9R:YK=OJTE^]A:_8K1FL]?U73X?)M?-G\H"VM(0P\UMSAG
MXW8'L]?-?[( (_9S^&H((/V37^""#_R-FO=0<&OI2OQ#/Z-+#Y[G5"A3A2HT
M<US"E2I4XJ,*=.GBZT(4X16D80BE&,5HDDEHC^F^%,17Q7"W#6*Q-6=?$XG(
M,GQ&(K59.=2M7K9=AJE6K4G)N4IU*DI3G)MN4FVW=A7YF^$/^"BIUKQXFG^)
M/@?KGACX5:Q^UK\3OV-?"?Q*@^)'@/Q+K&J?%+X:?$+XA_#:XU36/A;IS6WB
MW0?!>LZY\--?NH-7@N-<U'0] FL_%'B;1M*\+VVNZWHOZ95^2UK_ ,$F_A1:
M:IJ?C&"_\*V'Q0\6?M$?MC?$GXA_%#0OAOIV@^.O'7P4_;/U/XMCQS\#=8\4
MZ=JZ>(FN/"FA?$CP^?!?CV;5+J;2/$OPV\/:C:^'K;0M2UGPW<^0>^?;_P /
M?VMOV:_BOJ-CI/PZ^-'@'Q=J6J:T= TJST;6DGGU6^?PKX@\<6,VEJ\40U+2
M-:\'^$_%7B7PYXALC/X?\3:+X8\17_A[5-4@T34VM?-?'?[?G[-'A3P9\2?$
MN@?$7P_X_P!7^'WPE\??%B#PIX9U#9>>+[3X?_#?5_BIJ?A7PSKFHVUOX8O?
M&3^$-(GUB;PRNK2:]I&CE]<UC2K/1[6ZNXOC?Q__ ,$_OB[%X2T&&'XD77C;
MXPGPS^RW^SC\/?B=\./ GA_X8:/\&/@[\#?%OC+4_$OQ'\9Z+XE^)VOR^(O%
MWC'X<^/_ (E^"M>E\%Q&U67Q3I>@>#/ 7AO3M1U_Q!!#\7?^"2VK?%KQ/J.J
MZE\?;:'3=,\5_'C6OAO-?> /%.K>*O!O@_XW?LU_'?\ 9PL?A#]HF^,"?#ZW
M^&WPH\/_ !DT^;P-IW@GX:^"-3U#3/ ^EV'B[4];U[5/$'BO5P#Z[_9W_P""
MAO[.?[2'C7Q5\,O"VM:WX=^(_@O6/!OAG6O#'C'0M1T:/4/$OC#X&>'OV@DT
MGPEK\EN="\4R:-X%UN^;5?L5Y#<_:/"?BC4+*RN_#5II^O:G]F>&O$FA>,?#
MNA^+/#&IVNM>&_$NDZ?KV@ZQ8N9+'5='U:TBOM-U*RE94,MI?6<\-S;3;0LL
M$L<B_*P)_'WQW_P3X^*'A+0O$WAGX8>/K_6Y_B_\1OV6/$$?BO2_"^E:+XA^
M"'C'X0?!7X4?LS_$OXE+K6N?$BWTZ[^'OC;]F[X8^)O"I\&:1X+\0^/(O&GQ
M%E@MM:N/#\XO/#G[%:+H^F^'](TO0M&LH--TC1=/LM)TK3[5!';6&F:;;166
MGV5O&"0D-I9P06\2@D".)1F@#3HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!CQ1R8$D:2 '(#H
MKX)X)&X'!QQQ4?V6V_Y]X/\ OS'_ /$U/134I+9M>C:$XQ;NTK][>G^2^X:J
MJBA4544=%4!5'.>   .>>!UIU%%(:5E9;+1!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% 'E'Q5\7ZUX1L]&GT9[5)+V\N8;@W-M]I!CBMQ*@0>9'M;<>3D
MY'&.]>+?\+H\<?\ /QI?_@L'_P DUZ'\>@3IOAS )_XF%]T!/_+F/2OF;8_]
MUO\ OD_X5_/_ !WG^>8#B?'X;!9KC\+AX0P;IT:&)JTZ47/!T)SY81DDG*<G
M*5EK)MO5E):*ROJ^_EV^?XGW1X#UF^\0>$](UC4FB>]O([IIVAB\F(F&^NK=
M-D6Y]G[N) 1N.6R>,X'75Y[\*01X \.@@@^5?\'@_P#(5OJ]"K]KR*K5KY'D
MU>O.=6M6RK+JM:I4;E.I5J82C.I.<GK*<YMRDWJVVV3^ A. 3Z=AU/L/<]J^
M-?"7[6]]XW\>W-GX:^!WQ)U?X*V_Q4\=_!%_COI]QX<O-#@^(/PTU7Q#X:\:
M:K?^#+?4)/%VG?";1?&_A/Q'\.;CXGW4"VB>--,9YM"@\$W-KXUF^RB,C'Z\
M<'L1D$9!Y&0>:^!+;]C+QA:6_CKX467QPFTG]ECX@>/?C9\0=<^%VA^ [72O
MB1,W[0)\<:[\1_AV/BY%XEDL(/AE=?$GXB>*/B+IEO8_#JS\?6-Y-IGA<^.I
M/#.FM;7OJ@>EV?[=/[(FH:'<^)++]H'X;7.C6WB31/"8O8M;9EO=;\5:+XC\
M0>#8-)A^RBZUNS\=:3X1\377@+5]&@O]&\='0M4M_"&HZU=VDEN-SPQ^V+^R
M]XQU/7=)T#XZ?#BZO?#/AOQOXOU];CQ%!I=OI/AOX8Z[=^&OB9JU[?:PFGV$
M5K\-M<LY-.^(0^TM-X'GFL6\40Z5#J6G2W?Q;IO_  33\47WC+X!>/O'_P >
M-&\2>(_V?=9_9;TOPZ=!^$3^$M*UOX7_ ++-G\:O^$=T;6]+?XB^(81\0O%^
MM?&*;6M?\:Z<]EX;T-?#EEI?@[P#HD&HZM<W7DWPW_X)B?$3XC_![6?A_P#M
M'^/[?PKHUGXD_P""D:?#KPEX'T#3IO$WAG_AL?\ :)^+WB+1O&_B7QY#XMU7
M0O&MC9?#CQ+I'B'1? S^%-!V:MXGOM)^(5[KT^@6MO$ ?HM9?MO?LH:AI6B:
MO;?'3P&;7Q%XDU7P=I$$U_>6NJ7?BK1-&TGQ+J7ATZ'=V$&N6VL6_A77=&\7
MBPN].M[BX\'ZG9^+;1)_#DZ:H?-/B7_P4M_9!^&'@JR\>:E\2+GQ+HE]\4_@
MU\)HX?!'A7Q1XEU9-6^._B[_ (0_X>^*SI$&D0W]Y\-]4N[?6=1M_'^DP:EX
M<UNP\.:W:>$;SQ+XB@M-!O?*+W_@GAXY\5?'#1?VC_&O[0\-E\7XO$7CK6]:
MUSX7_"\^#=,LEUG]EKQ)^S/X%G^'ND^*?'GQ$/ACQ%X*'BS7?B)=^(/$=YXT
M?Q'K5Y!X;DL=.\+:3IMG%X_HO_!)3Q)I6JZKXXE_:#T:Z^)T_A3]E&Q@U_\
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MA\7RZ5XCUI];ETG1;W3[75-#T%"]U#=_07@W]@'5?"'QU\'?$R/XMV6H>"?
M'[8GQ^_; \,^$)_ ETGB?^WOVD_@U\9/AK\0?!6J^,3XUFTRYT?2_$7Q5'BS
MP?JVG^$-*OK+2-,N?"FLV^L7-]'XEM0#ZHT_]JK]G75O$W@7PAI'QB\!ZOKG
MQ*\/^&?%'@F'2=<AU2RU_0O&]E/J7@:_M]9L%N-$ME\=6-K=W7@>WU#4K*\\
M90V=XWAFVU7[+<"/KOA+\;/A5\=_#DGC#X0>.="^(7A6.ZALO^$B\-3S7VBS
M7<VG66J&WM=1,$5K>2P6NH6RWBVDDYL+PS:;??9M2M+NT@_*?]GW_@CSH7P)
MU_X6ZD_Q1T?Q]9>$;KX&>)O&2>*?!_Q(^W:[X]_9^?0(?!7B#P=INF_'NP^&
MOAJT>T\(>#[I;7QI\-/B=JGAKQ!HM[KGA36M.N-7LD\.?HM^Q]^SU_PRG^S5
M\(?V>O\ A*4\:GX6>%$\-OXJCT-?#2:[+_:>HZE-J7]A+J6KKISSR:@PEA&I
M7C/(C3O.[RM@ ^E:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH 0JK?>4-CID X_.F^7'_SS3_OE?\*?12LNR^X!  !@
M  #H , ?@*6BBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>plegridy.jpg
<TEXT>
begin 644 plegridy.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" "6 /H# 2(  A$! Q$!_\0
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MMO#:P+%;":2<'!9L!<>W?K66FL^,[E4ECTRW2*3!''8_C5/XH_\ 'QIOT?\
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M[:>ZB/\ L28_I4I-$Q4HZ&U6?J6LV^GH06#S=HP>?Q]*GFL_.B"-<3@ 8RK
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M@>QR*W:* .-3X9:4'!>XNV4?P[@/Z5T^FZ7::3:BWL85BCZG'4GU)[U;I"<
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M]MCTSXA7;78D1;N"-(6"$ACQZ?2@#-@N],URYO[G6=3>&19FCMXA,4\I1T8
M=:CGU>\N_ -O*+E_M$=ZL/G \L!T)]>"*M:5>:=X<;4+'680LJSM+"SP[O-4
M] IQST_6EUK[9<>#+62ZM4@FDNT?RHDQM7G&1ZT 6]=T5=+\):O(;F>XGN(U
M,KR-D%LCH.U5=1D&B>&M-MX+R: 7[1B29WSY:[06P>U;WC!6?PGJ"JI9C&,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>plegridychart.jpg
<TEXT>
begin 644 plegridychart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-/C/\ $/\ X5'\
M(?BG\5/['D\0_P#"M?AQXZ^(']@Q7?V"76_^$+\*ZOXF_LB.^^S7GV.34_[+
M^PI=?9+G[,TXF^SS^7Y3_!?[/?\ P4>\*?$'X5>%?BO\5=;^ L5E\2+'PU/X
M"\'?LH_$[XB_M?\ Q!35;SP'/\2/&OAOQIX.\!_!/1_$&@ZO\/\ PHUCJGB
M:;IFN6MC:M=3:M-I3/HT6L??7Q>^'=G\7?A3\3/A5J&I7FC6'Q+^'WC7X?WN
MKZ?%;SW^EVGC3PSJOAFYU&RANPUK-=V,&J275M%<JUO)/#&DP,;,*^8-7_8K
MM+3PS^S6GPQ^*7B'X7_$O]F+P#=_#+P9\2]+\)>"=?DUOP?XA\%>#_!?C2P\
M3^#]?TV;PY?7&O#P%X/\46-_;BVN=#\4^&M)=&U'PZ^M>'-9 /8/A9^U1\"O
MC;XMU[P9\)O'"^/M6\,>'O"'BG7KWPWH'B:_\+:=H7Q!\$>#?B/X#O9?&BZ.
MOA%V\:>"/'GA[Q)X5LX=:DU#7=-;5IM/M)O^$>UT:?\ "7AG_@KQ\(O$.M_#
M>2_^%GQD\%^!?&FK?MX:'K.O>,/AK\2X?&.A7?[#?Q+\&> /$.H:/\,= \!:
M[XG\8>'O$]GXEU?Q+JVKZ6L2_#6/PGK?AOQ?#'XITK7M+T;ZK_9+_8O\ ?L>
M+\1]-^''B#Q-J?AKQR?@U!IVC>)#IMS-X9T[X+_ +X<? /1K>+5;*ULY]9N]
M<TKX=6OB?7M1OX(I9=?U?44M(;;3DM+:+QO0_P#@G#X=T+QXWB:W^+?BZ3PQ
MI,7[=$/@KP>?#GAB)O#D7[?OC3P[\3OB[%>^)(434?$J^'_B)I.IZOX$>_MK
M:XTW1M83P[JT^L1:18Z@P!])>&?VO_V>O&7C?2/ 7A;Q\->U'7[W2-'T3Q#I
M?AGQ?=_#C5O$VO?#^S^*^C>"]/\ BO'H!^&EWX[U/X:7]EX[L_ \/BI_%,WA
MBZ@U1=*\N15/F_QF_;'D^"WQ=N?@MKOPYDOO%_C_ ,*>'-7_ &7!;>)EMK/X
M^>+KG7O^$9^(7@%IKC1/^*-U3X/M?>&OB)X^OU_X22"T^"FMZK\2+2UFM_ W
MB_3M.\)_9Q_X)0?!;]FWQ_\ #[QOX:U#1/$-QX&L?!FI2:CXE^#'P=U#XAZK
M\0/"?P?\/?!RX\16OQ;NO#%YXZ\+>'->T[P[!XQO/!?AJ^L#I_C2^U,Z/XEL
MO!]_<^#Y?L/XR_LT^%_C7\3_ -GOXC^)-8U*W7X Z]\5-:M/#=K;63Z9XOA^
M*WP8\8_!;6-,UF\D"ZEI]O9Z)XSOM1M9]'FM[J2\@CMYI!:RRJ0#D-'_ &[?
MV;O$&CW.L:!XG\8^(46PT'6-$L/#_P &OC1K&M>/O#GB<ZM'H'C3X6:!9_#^
M76OB?\/=7N-"U2.R^(?@>QUSP2(H(;VZUZVL+_3;N]P[S_@HU^QK8V3ZG<?&
M:S73;;X;O\6M5OH_"'Q GM_#O@*+QEX^^&T^K^*C!X4DE\*WEO\ $SX:>+?A
ME<>'?$$6G>)H?B59V'@$Z.?%>N:+I-]\G>&?^".7PC\#>$M'\)^"O%VB:#8^
M#+OP98>$;6+]GOX"#2/$W@?P1I/B#0]+\)?M$:98>$M,G_:022UUVSUJ:[\=
M:I9Z='X\\%> ?B):^'8?%^@WFIZQZ)\&O^"6GP]^!VB?$WP_X+^*7BN#3?B+
M\'_$'P?2VNO /P;O=)T#1]?_ &H_VD?VHYY;?P7J7@34?AKJFF#7/VDO$/@6
M7P7J/@<^#7\#:)IVG6NCV$]U<2P@'WIX*^-?P^\<^"=;^(-C?:YX:\->%Y-7
MA\5R?$SP9XS^$FJ^%'T#38-8UE_$WA_XG:!X3UW1+33])N8=4DU*_P!/BTN?
M2Y$U.TO;FP87!\+3]O[]EG^Q-&UVY\=>(].A\2>*OA_X-\-:5JWPF^+^D>*O
M$^L?%O3O%>J?":?PSX-U3P):>+/$.@?%&V\$>*(?A]XHT?1;WP[XKU/1;_1=
M*U*?6;6>PBI_"+]B?P;\/_@5\:O@+XK\3:KXW\%_'P>,;3QGX;TW3;+X>^ /
M"_A[QQ\/M,^&NO\ @WX/_#_PW/<Z5\*_"-_HVG7&O7>C:%>W$<WCKQ%XI\6)
M)!<:RUK;^"_#K_@EA\-/AY!\.1I/BS3M*O?AQ\=/@C\8;:^\"?!'X*?"R7Q9
M:? /0_B1H?@_P_X[?X?^%=&N_%.J:NOQ/U_4O%/BO4+UO,U,"7PIX=\(V^H:
MU:ZD =%\??\ @J/^S[\*O@7XS^+GP\FU?XQZ[X9^'0^(=OX(TGPM\2=%%G:R
M_$/6/A59:1\3?$7_  K[5[7X)ZUJ/Q"\+>,_!6GZ/\3K+0-:NO%O@WQ1H$>F
M?;-"U7['[W<?MQ_LQV2>.;G4_B/)I.E> -/\<ZIJ?B+5?!GQ T[PKX@L_AGX
MOL/A_P"/Q\-O$]WX5AT/XM7GA#QYJVD>"=<TWX7WWB[4;7Q?J^E>'8K6XU/4
MK&"?X]U+_@DQX8/@KXR^ _"_Q^^)/A+1/VC)/'K?' V?AGP%J=WXO76_VA?C
M+^T+X#.EW&JZ9</X7G\#:I\:_$G@349M/,__  F_@33M#M]1CTGQ#:R^()M/
M0O\ @D5\ O#H^(]CHMY8^']/\33:YJ?@/6O#'PF^#VA_%/X?^(]7^,7AWX\Z
M3KU]\81X0O?&_P 17\!?$CPGH$_@K2/%MR="G\-V$6@_$'3OB#+%::K: 'OG
MPW_;;T?XFV_[:.I:+X!U^PTO]D;7K#1%3Q+;^(_!_B3QI-<_LT_#S]H2\BUC
MP=XQ\)^'_$?P\U'3YO'3^#Y-,U>QU&65=,B\1))]FU**QA\A^%G_  44U&W\
M'_ OQY^U7\// _P,\&?M&_ 6X^//PW\8^"?B?X@^*NA65O8>#/"?Q"U'X;>,
M['5/A5\.O$UC\0I?"/BZUU#PM;>$]&\::9XRO='U_0-/N++Q!'X?TWQ+[M\.
M/V0CX1TS]JEO%OQ6\3?$#Q7^US?V.L?$;Q+=^'?"_AN+1]4L_@)X._9_5/!^
M@Z%;K8:=I$7AGP3I.HV>GZC-JMU%J;W;7NJZD9WG;Y?M_P#@E+H/C7X-^"?@
MQ^T7\<O%'QK\._!_X,Z/\%_@G#%\._AWX%TGP%9:&?AVUAX^U+P[!9^*-/\
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M[S5_$%SJNM:AH_&;]D;4OC=XOC?Q9\</'+_".X\=_#?XEZA\+$\.>!7O=/\
M$_PK\0^#_%GAO3_ OQ0718/'7@7PAJ7B7P/HVM>*-(LKC4M;O;N\\01Z!XJ\
M,6>LM:6P!>^ G[5FH?&WX]?M.?!6_P#A#XF^&:?L]_\ "H)M+UCQ?K6CS:YX
M_P!)^*VC>--1M]>E\):0+QO!-C#<^"[Q-'T[6M;NO$6JZ1=V.LZMI'AF2ZBT
MH>R_%KQ=\5O#</A?3OA#\+-/^)/B/Q+K5SI]Y=^)_'$?P]\!>"=(L]&U#4Y_
M$/C#Q!:^'O&GB>2*[O+:Q\/Z)I'A/P1XDU/4-:U:V>_&BZ%::IK=E\A>#/V.
M?C[X%^-7[2?QVTS]JZ*_\3_M">"--\-2:._P%\"Z7IWA+5_ 'A7QKX?^#NNZ
M1J/]O:S-<R^#[KQC)J6NVNMZ;J]CXNDT^WM[BTTVSDN+:;UG]IG]G+XJ?M _
M"GP?\,=*_:(U;X<16MUIK?%F\T_X>^']=T_XWZ':Z&]AJO@GQ=IHUCPYJ&A^
M"?%&LNFL>*='\':_H<VO:=$W@W4;V;P?J6N:/JH!\Q:=_P %,]5\5_#W5_B5
MX#^ ;:WH'PD^!%Q^T3^T=#JGQ7T/3;SPEX MOB#\:/AXJ?!R?3?#.NZ9\:+[
M7_\ AGKXN>/O ^K7MW\-_"'C#X>Z3X.U:T\06=[\0=-LM*^C='_:_.N_M:Z;
M^S?8_"OQ%#X-UO\ 9N\>_M!^&OC;?ZYHL.C^.(/ GBOX(Z!=Z/X(\'6C7VO:
MEH4]E\;='O!XUUR;PY:W&K:7?:)H>D:U';W^K6/G?B']@K4/%?AXZ/J'QPU;
MPS/XZ^"&F?LT_M!1_#3X8_#SP5X8^+'P-\.ZGX[E\(^%- \)S6_B&V^$.K>%
M/#/Q(\9^!=&\2>"]0GEMO#'B;51'IL>L67A+5/"FQK/['OQ/N_VL?!?[2&A?
MM%1>%_#'@+X;^)?@GX<^$6F?!7PD;&R^$7CCQ%\)_%/BWP\GC=O$D>O)KTNK
M?"#PZOASQ-'8+'X;L+G4+9="U.5X+J( 9^Q5^V7JW[5!O9=<C^ 6@2S^ _"'
MQ!T3PG\-_C!XW^('CF#1/%L<=PMSK^G>*_@S\,=$N=)TLW-OHEYXH\ Z[XY\
M,_\ "5QWVA'5(IK>)[CWSXZ?$[XM_#^.Q/PO^$OACQS:P^'?%OB[Q?XO^(_Q
M:L?@[\.?!^C>$8M-N3IE_P")%\)^/M8E\3>)H;R^FT7?X6M?!VD:7H.OZUXP
M\8:#':Z58:[X_'^RQ\7;2?7O&;?M1>,O%'Q@T/X0>.?@U\"/'WB;X?\ PMMH
M_AAHWC[5O ^N:YXH\0>']#\,6FA?$GQIJ.J?#;P)/JVHZOIVE>');;PX+71?
M!^@R:QK5U?:/[7O[+GQ"_:=3P%HVB_'4_#SX>^&[S5=3\<_"K5OA5X8^)OP_
M^,>H.VFOX6A^)&FZOK?AS4M8\->$9[6^U&+P,^JOX+\4ZM>6EUXWT+Q%;:)I
M=C$ >"_\/,;+6/!FH_&/PC\(KNY^"7PS^$/[./QD_:$UWQ;XUMO"OQ#^&>@?
MM&^%M*^(-GI.B?#^U\.>(-/\6:_\+/AKKFC^/?B?9ZMXR\%PC2=1M]+\"W'B
M_P 0+<Z?#]$>"_VL+WQ9^US\4_V7M0^$?B;P78?#CX,^&OB[IWQ'\5ZUHUJO
MCJSUOXG>/?AI>MH?@^Q-]J&E>%+"]\"7-]I/BSQ'J>F7?BB"ZFNK+PS9Z%:Z
M?KNM\%XV_80M_B)J&N3^*/B[XCCTCXR^%?A9X;_:P\*^'O"/A/1_#WQ^E^$T
M2P:9J,$=PFK:I\,!XNTH+X*^(%EX:U34H]=^'=II?AS3)] U;3D\428_B']A
M;QCXW_:;^)OQQ\>_'Q?$WP\^+OP<O?V<?&_P03X2:)H-AJ/P)FUSXA>(;;PE
M!\1]"\86?C;3O$(OOB/K4&H>--.>TOKZPAM$MM/TR_0ZE0!Z#^S'^V/#^TK\
M7OVC_ &E^ 9_#G@_X-CX,:Q\/?'MQXA&H3?%_P "?&3P?KOB71/'*>&O[%L9
M/!NF7D_AV_E\,V-UJNLWWB#PC>>'_%ETNB2:T-$L]7QC^WM^R[\.[GQW#X_\
M>ZSX(@^'GA/XC>.=:U7Q;\-/BCX=T+5?"?PANXK/XHZYX(UW5_!MGI/Q$LO
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M_#+[@LNR^Y#/+B_YY1?]^H__ (FOWC_X)PA5_9V8*JJ/^%@^,>%4*.NE\X4
M9]^IK\'Z_>'_ ()Q?\F[-_V4'QC_ .A:77X]XWM_ZDK7_F<8#_TWBC]3\'4E
MQCHDO^$C'=/^G^"/O>BBBOX_/ZN"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _#O_@I=')+_P %'_\
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MQ1_STT'_ +]:E_\ )%&SQ1_STT'_ +]:E_\ )%?Q^?U:=!17/[/%'_/30?\
MOUJ7_P D4;/%'_/30?\ OUJ7_P D4 =!17/[/%'_ #TT'_OUJ7_R11L\4?\
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M^PG.M'#J*]FI*JU6:I5/8^T5*;2J<O7]A/[9T;_H,:/_ .#;3?\ Y*K][?\
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M+[4?#^C^'[_28/B1' _]O6$7]"0_J?7U/K_^KTXQ7Y3Z_P#L_?'-?VJ?&OQ
M?X=>*O&G@_Q-\6/!/B?1?%VF?\%!?C%\#M+\/>%-'T/P;H\NFW7[-GPO\%:7
M\//%T>AW.BZMJ4R>,-5U[7/B+%?2:+XMUS^R(M,M++]6!_4]\]S_ )QVZ=J
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MF_W=4_\ !#KO_P K:/\ A(M-_NZI_P""'7?_ )6T ;E%8?\ PD6F_P!W5/\
MP0Z[_P#*VC_A(M-_NZI_X(==_P#E;0!N45A_\)%IO]W5/_!#KO\ \K:/^$BT
MW^[JG_@AUW_Y6T ;E%8?_"1:;_=U3_P0Z[_\K:/^$BTW^[JG_@AUW_Y6T ;E
M%8?_  D6F_W=4_\ !#KO_P K:/\ A(M-_NZI_P""'7?_ )6T ;E%8?\ PD6F
M_P!W5/\ P0Z[_P#*VC_A(M-_NZI_X(==_P#E;0!N45A_\)%IO]W5/_!#KO\
M\K:O66HVU_YGV<70\K;O^TZ??V/W]VW9]MMK?S?NG=Y6_9QOV[ER 7J*** "
MBBB@ HHHH *9(ZQQO([JBHC.SN55455+,S,Q50J@%F+,J@ DD $T^JM]9Q:A
M97=C.$:&\MKBUF62&WN4:*YB>&17M[N&XM9U9'8-#<P302J2DT4D;,C 'Y#:
MUKGQ3\0?M5>)KW7-6_:U\0>!O^%K>!5^%FI_!/\ :._8T\#_  'A\ #3?":7
M&F>(_AOJWQNTSXN^)([3Q0GB6Y\97E_X;U'Q3XLL+^2P\-Z3'9P:-HL7[!#^
MIZ_4^GZ>@Z\U^;^F_L'Z'X;UW3+CPM\(_P!@;3O[&N[74M$\?_\ #%GA>Q^(
M^BZAIUU'=Z7J=I'H'BK1_#G_  D6G3P07-GKNG?V%:6^HQ07T'A^%81:/^B6
MEVMU8Z;86=]J,^KWEK9VT%WJMS;V=I<:E<Q0HD]]/;:=!:V%O+=RJ\\D-G;0
M6T32%((DC55 !^)__!2?_E))_P $*?\ LZW]J#_UCGX@USO_  <"D_\ #(/P
MLY_YN'\+_P#JNOB3_B:Z+_@I/_RDD_X(4_\ 9UO[4'_K'/Q!KG?^#@7_ )-!
M^%G_ &</X7_]5S\2:_2O![_DYW!G_8XI_P#IFL?G?BS_ ,FXXM_[%;_]2*!_
M(11117^GQ_FV%%%% !1110 5_9G_ ,$&O^3%Y/\ LM_Q3_\ 0O#M?QF5_9G_
M ,$&O^3%Y/\ LM_Q3_\ 0O#M?S[])?\ Y-JO^RBRG_TSCS]W^CK_ ,G#E_V(
M,R_]2,O/VEHHHK_/D_O$**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#\//\ @I9+%!_P4@_X(5RS21PQ
M)^U;^T^6DED2*-<_L=?$ #<\C*@RQ"C)&YB%&6(!Y7_@O[J%A=_LB?"Z.UOK
M.YD3]H;PPS);W=M.X4?#OXD*6*0RNVT,0"V-H+*"<LN>L_X*5(DG_!2+_@A4
MDB*Z-^U;^U "KJKJ?^,.OB"1E6!!P<$9'! (Y -<S_P< VUO#^R%\+6AMX(6
M/[0WA@%HH8XV(/PZ^))(RBJ=I(!(SC(7CY1C]*\'O^3G<&?]CBG_ .F:Q^=^
M+/\ R;CBW_L5O_U(H'\AU%%%?Z?'^;84444 %%%% !7]DW_!"+4M/M/V&I([
MJ^LK:3_A=WQ2;R[B[MX7VLWA[!V2RH^#@X.,>_-?QLU_99_P0>M;:;]AF1IK
M:WE;_A=WQ2&Z2&-VP&\.X&YE+8&>F<?D*_GWZ2__ ";5?]E%E/\ Z9QY^[_1
MU_Y.'+_L09G_ .I&7G[+_P!NZ+_T%M,_\&%G_P#'Z/[=T7_H+:9_X,+/_P"/
MU:^P6/\ SY6G_@-#_P#$4?8+'_GRM/\ P&A_^(K_ #Y/[Q*O]NZ+_P!!;3/_
M  86?_Q^C^W=%_Z"VF?^#"S_ /C]6OL%C_SY6G_@-#_\11]@L?\ GRM/_ :'
M_P"(H J_V[HO_06TS_P86?\ \?H_MW1?^@MIG_@PL_\ X_5K[!8_\^5I_P"
MT/\ \11]@L?^?*T_\!H?_B* *O\ ;NB_]!;3/_!A9_\ Q^C^W=%_Z"VF?^#"
MS_\ C]6OL%C_ ,^5I_X#0_\ Q%'V"Q_Y\K3_ ,!H?_B* *O]NZ+_ -!;3/\
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M5-%;P0;O)@AAW8W>5&D>[&<;MBC.,G&>F3CK0!+1110 4444 %%%% !1110
M4444 ?B!_P %)_\ E))_P0I_[.M_:@_]8Y^(-<[_ ,' O_)H/PL_[.'\+_\
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M]=U/3;W7C#JK:!;:FFA:VU@[P5\?_A#\1?BC\7_@QX*\:6GB#XE? 6#P)/\
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M%^%\UK"T<C_M">&(R6N;R8;#\._B0Q4+<7,R#E5^;;O^4 , 6W=I_P %)_\
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M_4A_Q"\?L'?]%_\ ^"AW_B7>L?\ S&5\UZ=_P;I?L8W7[7GBWX&R?'W]OO\
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MM_:>#Q_UC%8C"U:7)AJ>(A*GRT??YI>W33V7*[[IGZ'X9>"V9\!\3//L7G>
MS"D\NQ6!^KX;#XFE4YL14PU15.:JW#EC[!Q:W;DFM%K^[A/!Z]#_  G_  K^
M$K_@KK_RD4_:1X(_XF?P^Z@C_FDO@,]_8@_0YK^A#_ARMX=_Z29_\%G?_%C_
M ,5/_E/7@?C#_@VK_8^^(?B34_&/C_\ :I_X*8>-_%VM/;R:QXH\5_MI^)M>
M\0:K):6EOI]H^HZMJ7A.XO;QK:PM+6RMVGF<Q6EM!;IB*)%'P/A%X@X+PWXB
MQ^=8[+L5F5+&9+7RN-#"5:5*I"I6QV7XM592K>ZX1C@Y0<5[S<XM:)GW7BKP
M'B_$+(,#D^#S##9=4PF<4<RE6Q5*K5A.%+!8["NE&-*TE-RQ<9J3TY826[1_
M*57ZG?L*?#73OB!\(OC#HL?PMT#4?%'BHOX<TKXB_$;X8W_Q%^%E_"?%WP6@
MMO!/B#Q)X;URS\6?!F3P_=:A?^)=2\6:;I\*/HNNMXZO-=M='^%FHVDWZA?\
M0O'[!W_1?_\ @H=_XEWK'_S&5T.B_P#!M)^QMX<TWQ3H^@?M/?\ !231M*\;
MZ-%X=\8Z=IW[9&O6UGXGT*'4K+6(=)UJ"/P<$O;&/5-.L;U89 ?WEN(R3!-<
MPS?M?$7TELGSG+7@L)D&<X"O]:P>(AB'B<'54?JV)IUFG3C5IQJ74;J-7G@Y
M15E3J>SQ%'\=X?\ HZYKE&8K&8K/LIQM'ZMBZ$L/]5Q5-R^L4)T4U4E"I*G;
MG:<J7)-)M-U*3G0K?B%KM@?#7[.NJ:E\2_@UX%\"IKW@WX<1?LY:7I/P]\[X
MCWVN:)XFT*7Q=^T/XT^(5QIK:U=_#3QOI&F^*M.6T\?:K=>'/B-J_B?1[3X:
M>%X/"?A/^W8^+^/EQXDU/0?@M\-SX)\.ZE\0KKX<VGQT\:WG@#X/>#?#7B5X
MOB/X=E\7^%O",-C\-O"&BWE[X=\$_"6TTSQ?K'VFVO!)KGB;7M4NYH=-T+3S
M;?T&ZC_P;G?LN:IX>?PGJG[8?_!4K4_"TMM8:?+X:U#]NWQ[>:!)8V!M8["S
MDT6YT"73'M+);6U6TMC:^3;+;6XMTB\F(I\H?L=_\&^W[*GQJ_9U^ WQZ\3?
MM/?\%%[?X@>/OA+X:U75]7\/_ME>*-/2(:KX<;1;O3M)FB\-RW=GHIT9Y-&@
MTR.]DM8]%<Z40]GNC?@P7TC<GH55B:_"V.EB*.-Q^.P\88S#U*<:M?!T,%A8
M*I6YL13I>SA4Q&80E4Q$\9F,WCW5A+DH4^S%_1]S6M3>'H\3X*-"K@\!@J\I
M8.O"I*E0Q=7&8B3A1Y*%2HISIT,#*,*$<)@(+ JG./-5G\>?$?X4^ K+]G3Q
M?H^F^&=#L_''PW_9@^"/Q U[2(?@];6GAJR\0:_KO@>[\1_%CPG^US'8#4_B
MCXI\5:)XJTR.;X3W$EOX1:Y\3>)/#7A77-=;X<6D$_Y2D8)'3!(_(U_5C+_P
M;3?L<3^&;+P7/^U)_P %+YO"&G7 N]/\*R_MK>+9?#=C=*TCK<V>@OX8;2;6
MX#S2N)H+..0-)(P8%V)YW_B%X_8._P"B_P#_  4._P#$N]8_^8RNWA_Z2N49
M10QE+%9#G>.EB<=/%0G+%8"/LXRH8>E**^TU4JT:F(_>RKXB+JRC7QF-JWQ$
M^7/?H[9GFM;!U<+GF3X*.'P4,+.$<+C9*;A7KU(3>MDX4ZL*'[J-&@XT8NAA
M,'3<</'^:7X9_P#)2_AK_P!E(^'W_J9Z'7^D^IX/7[S_ ,)_O'VK^<&V_P"#
M8']A>RN;:]LOVA_^"BMG>65S;WEG=VW[8&MP7-I>6D\=S:7=M/'X.62"YM;F
M**XMYXV62&>..6-E=%8?37_#E;PZ.G_!3/\ X+.]S_RD?^*G<Y/_ #!_6ORK
MQB\4L!XF5L@JX'*L9EBR>GF4*L<96H5G6>.E@91=-T=(JG]4DI<V[DK:)GZ9
MX2^&>.\.:6>4\;FF$S)YM4R^=-X6C6H^Q^IQQ<9JI[:_,Y_68\O+MRROT/VF
MR/?\C_A1D>_Y'_"OQ9_X<K^'O^DF?_!9W_Q8_P#%3_Y3T?\ #E?P]_TDS_X+
M._\ BQ_XJ?\ RGK\6/V$_:;(]_R/^%&1[_D?\*_%G_AROX>_Z29_\%G?_%C_
M ,5/_E/1_P .5_#W_23/_@L[_P"+'_BI_P#*>@#]ILCW_(_X49'O^1_PK^=C
MXO\ _!*9? OQ/_95\':/_P %,O\ @L9_9OQH^-7B[P!XJ:^_X*+_ !2GNAH6
MA?LV?'CXLVJZ/(=*C:SU%O$WPX\/&6Z3SBVDKJEFT!6\\^V^@?\ AROX>_Z2
M9_\ !9W_ ,6/_%3_ .4] '[39'O^1_PHR/?\C_A7XL_\.5_#W_23/_@L[_XL
M?^*G_P IZ/\ AROX>_Z29_\ !9W_ ,6/_%3_ .4] '[39'O^1_PI<Y]?Q!'\
MZ_%C_AROX>_Z29_\%G?_ !8_\5/_ )3U]I?LA?L4Z=^R"WCYK#]IO]M']HK_
M (3Y?#2RK^US^TCXJ_:!7PE_PC1UPH? :^);.T'A5M;_ +<8>)#9^8=9&EZ(
M+C;_ &9#N /M6BBB@ HHHH **** "BBB@ HHHH **** "BBL[6-3CT;2=3U>
M:UU&]BTO3[W49;/2-/N]6U6ZCL;66ZDMM-TJPBFOM2U"=(3%9:?9PRW=[=/%
M:V\;S2HI -&LY=(TI-5EUU=-T]=:GT^#29M76RMEU272[6YN;VVTZ74!$+R2
MPM[R\N[J"S>9K:&YN;B>.)99Y7?\^KS_ (*#V/A";Q)HGQ:^ /Q;^&OCJ/P!
MX%^)/P[^'UQ>^ O$_B;XAZ1\4/BQX;^!G@/PB\GA_P 3S:'X%^)^H?%GQGX/
M\':KX5\8ZO9:'IEQXCBU"S\9:UIF@>,+GPYG?%'_ (*/>'?@O\#_ (S_ !+^
M(/P/^+*_$+]G_P 2VGA3XI?!OP>OASQGJ>@3ZGX5\+>/=*\73?$#3M2M_A_8
M_#74/ _C#2/$%OXP\0:IH5Q<7D6J>"K+P_>?$&P/A28 _2>BOAGXW_MD2_"C
MX]>&?@9IOA#P%J=]K6@^ -<N]:\>_M"_#3X.22R?$3QEXQ\):+H?@OPQXOAN
M_$'Q!U^(>!]6U&ZT_0X8 ?M6CZ9:S7&H7[QVWW*#G\R.N>A(_IT[=#0 M%%%
M !1110 445X?\8_BAXZ\ R^&-(^'7P2\:_&?Q)XG;6K@V^@ZMX8\)>%_#FE>
M'H]-DOKOQ3XX\8:A9:+I=_JLVJV6F>$?#\$=_K/B;4FO)8K>QT#0_$FOZ, >
MX?Y_+I6?I6DZ7H6FV6CZ)IMAI&DZ;;QVFGZ9I=G;:?I]C:Q#;%;6=C9Q0VMK
M;QCB.&"*.)!PJ@5^<TG_  4N^'>K>#M+^*7@+X7_ !+\9?"G1_@-\._VE_C7
MXN5O".A7WP3^$/Q0?Q<?#VJ:UX6U/Q"=6\9:_I&F> /''BWQ=H'@A]472O!'
MAJ3Q!I&I^(Y_$'@[2?$GN_@S]K;POXX_:H^(/[+>F>!_B#IVJ_#[X3Z%\5)/
M'_B+11X?\'^++/6/'WB'X>W.F^";;5)+?Q)K]MI&L^';GSO%RZ1;^#M:$R)X
M3UCQ!';WMS;@'UE17R/\#/VN_"?Q[^.O[0WP8\*>&-?MK'X$:%\)?$%G\1KV
M[T>7PK\4M,^*&L?&#PQ+J?@6VL[J;5WT3PSXO^"GC+PS/KFJ6]K8>(KNS.H^
M&6U#0C;:I>_7% !1110 4444 %%!. 3@G S@=3[#.!G\:^+]<_; ;P7\4?#G
MA7XC?!;XC_#[X9>.?B1XO^#_ (%^,?B6[\)V^EZYXZ\$^#/B!X_U2_O? L.L
MR^.] ^&VJ^&/A;X[NO"WQ#U'3#9ZTFBPZO/I.E^$=:T'Q1J0!]A76EZ;?7.F
M7E[I]C>7>BWDNH:/=75I;W%SI5_/I][I,][IL\T;RV%W-I>I:AILMS:/#/)8
M7UY9/(UM=3Q27J^"/AO^WEH?C.WL;WQ'\&/B]X+A\=_!^']H+X%V$6D:;\0/
M$OQD^$=UKG@WP[%?:/X6^'U[KNK^&O&MC?\ Q(^&ESXA\$>)8[9O#FC_ !"\
M/:KJFO10Z=XV3PA-X-_;9N_B9^RO\$OVF_AY\#O&&JV?QK\/6OB6'PSXC\;_
M  R\$V/PUTN>.]DDG^*'Q USQ&/">D)]JM(M L1X:;Q9+JWB74M/L[*%M(_M
M#7[  ^\:*\A^ GQDT+]H/X._#WXS^&M$\4>&]$^(?ART\16&A>,M,CTGQ)I<
M=Q)-!+9ZE;6US?:?.T5Q;3"UU31]1U/0=<L#::WX?U75-$U'3]0N?7J "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K,UJ+6)M'U6+P]>:=I^O2Z;?1Z
M+?ZOI]QJVE66K/:S+IMWJ>EVFHZ1=ZCI]M>F":]L+75=-N+RU26V@U"REE2Z
MATZ* /RF\%_L$_&O4/!WQ3T;X[_'#X6^._B5\1=5^%7Q#/[0'A'X->+M#^)B
M_&'X%?$O0OBK\&]7U#2O&WQE\?\ @FU^$?P[\5:%$_ASX&>#=&\'^&[#3[_7
M FK-XB\3^*O%6N0?'3_@G_\ &;XO? []IGP#:_&_X3:1\4/VR-;TJY^.OQ&O
M_@=XLO?#NF^&O"O@GPKX(\#^%_A=X)T[XV:9J>CIX;L/"<%[<:GXT\:>,[C6
M=8UOQ'?&#3;2ZTS2M)_6"B@#\_OBY^RO\</CCX5\2>%/'/Q<^"MC9?%_X1+\
M'/CA/H7[.'VG6G\/-JWC"[O;SX.^*->^)][KGA*[O=,\4B&RT_XES?%S0?"O
MB>S3QKX7TNQO;C4]+U+[[MX%MH(;=&=DAC2)&D=I)"L:A%+R.2\CD %Y')>1
MLNQ+,34U% !1110 4444 %?''[8WP,^/'[0'ACPOX&^%'QC\%_#'P-<WVK_\
M+G\,^*? OC;Q#<_%GPQ/96\&E>!HO&'P^^*WPM\5^!O"T]VU]-XYB\/ZA_;7
MC72C:^&$US0-#G\06^N_8]% 'YG>,OV"?%'C#2_&NC6'Q)^''PXT']H3X _#
M[]F_]J3PGX ^"KVGAO7_ (>?#ZT\:Z!9)\"+;4?B#.?A!?WOP^\?>(_AF\7B
M2'XH:/I?AQO#NI:'IFG:QX9#:SI7G[(GQVU;]KOQI\>]0^+_ ,*;#X8>-/@.
MO[,4_P /O"7PQ^)7A7XCZ+\)+#Q5XU\6Z-J7AWXLZ?\ '$VVB_$JSOO&+6H\
M3:?X)M].LH-,M;S1M&TS4-D\/Z/T4 ?GM^RY_P $_M"_98^/GQ,^+_A?XS?&
M/QCX8\:_ KX%? WPW\-OB'XTU;Q9IW@S1?@IJ_Q.O]/N(=2OYPNI6BV/CVST
MKPGIITVR/@V"U\5/#>:I_P )G/'I?Z$T44 %%%% !1110 'VXK\Y3^R3\=O%
MG[2/BOXK_&GXH?!#XN_#;5H_'W@KP5X&U;X._$+2O$'PD^"WCG29]%U/P;\/
M]1@^.-YX&L_'GB;3S%;?$GXPZCX OO%?C+3YKSPU81>%_!BV'AFT_1JB@#\Z
MOAI^QS\7OA8OA#6].^-?@+QAXT^ WP D_9H_9CO?%?P;U*ST#PK\.=6U_P"&
MNI>*]9^+-AX<^)UCK'Q#\?\ B'1?A)\/?#\VJ>$=;^&/A>T?PW/K%IX3B;Q)
MJFF0<-\$_P!A[]H#X5?LG?"[]EW7OC)^SK\2?#_PKL!X3.C>-OV6M1\3_"_X
MG^!XH8+S38/B1X'\1_&?5-;7Q9X=\41?\)#H6M>%/&FC:!@?8=8\)ZI,MCJ>
ME_J=10!X;^S;\%E_9X^"7@+X.)XNUCQPO@K3K^T_X2+685LVF;4]<U77WTS1
M=(2ZOX_#?@WPZVK-X<\ ^$8=0U&#P?X&TCP[X6@U&_AT=+R?W*BB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *0\?F/U(%+2'I^*_S% '\7.M_\%OOV];#6]<L+?Q!\(Q;V&N:W86P
M?X4P,XMK'5KRSMP[?\))\[B&! [X&]LM@9P/MW_@FO\ \%2/VM/VGOVNO _P
M=^*^L?#R[\$Z[X8^(6JZA;^'O $6@ZHUWX<\,S:IIC0ZFNM7K0QI=HK3QBW<
M3QYC+)G=7\VGB>VN?^$G\4?Z-<_\C1XF_P"76X_Z#^I'_GE7Z??\$58)H_\
M@H5\+F>&=%_X0?XO#<\$R*,^"+G&6>-5&>@R>3P*_P!&..?#S@/!<!<58[!\
M)Y!AL=A>&,VQ.&Q-'+,+3KT,31RVK4IUJ52-)2A4IU(QG"<6I*233N?Y_<%<
M?<;XWCCAC XSBC/<1@\3Q)E6&Q&&K9CBJE"MAZN8X>E5HU*<JCC.G.FW&49)
MIQ;3T/[=Z***_P YS_0$\)^*OQUTKX5_$?\ 9L^'.H:!JFK7O[2/Q6\4?"G1
M=3L+FPAL_#.H>&/@9\6?CE/J^LQ7;I<W=A=:5\)]0T&"#35DNDU35["YE46,
M%VZ^/6/[?7[.=A)XJM/B5X[\/_"35/#7CWXP>$H]+\;ZU:0W.J>'O@S\4?\
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MAM\3;_XA>&I7^(?BCXC? #P_J7A/0_BA#XMTWQ1%H]M;>,=!U[5)/&'A>_\
M"6JZC+KUKIVKVGC$B;5K:^^=OBA_P2[U/XF^ OB/\(KSX[Q:=\,+_1_VZ[GX
M-Z=#\-9)O%W@'QW^WEX<^+F@>.=:\=^+9?'YA^)OAGP$WQP^)-UX-\,V&@>
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MBV_4]3_JN]2165I"XDBMK>.0 @/'!"C@$8.&1%89'!YY'!JS15<TGO*7WO\
MS%RQWLK][+^NB"BBBI&%%%% !1110 4444 %%%% !1110 5&\44F/,CCDQG&
M]%?&<9QN!QG SCK@5)10FUJG9]T)I/1ZK_+4@^RVW_/O!_WYC_\ B:F554!5
M4*JC 50  !T  P !Z"EHIMM[MOU;8**6R2_JWZ!1112&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>principalproductschart.jpg
<TEXT>
begin 644 principalproductschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (! 3T# 2(  A$! Q$!_\0
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M->'O$&B+J6I^#K/Q#>6-E%;>$_&'BVS\!:C<W&N0QO>^V:S\??@9X=^%EO\
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MOQ*EMX8DU?X$^!;&7XF_#^W\9WUEXCF.L?"[XCVVE@'ZZ45@_9/$'_0:L_\
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M3OOBEK7PL\.GQA_9EMJ>K>';C]_U&!CKR>??)SGWSU]\T ?B#_P4G_Y22?\
M!"G_ +.M_:@_]8Y^(-?4O_!2W_DAO@W_ +*9H_\ ZB_BJOEK_@I/_P I)/\
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M4G#ZWAGAIQ>*A5YHJE*%.5>K5P<J]65.I.<VZ=6A*5..'H*5.%"4JW1>$O\
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M9?'QO ?CZ%OBFWQ2^''Q*\&PZEX(MH[_ ."OQ'^!NF?!_4/%6E^(K+3;4/\
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M%SX4USX=W_C",1>%_'\_B#PW:P:?%Q>K?M.G5?#>MROX#4?%GQC\*/ ?P/\
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M#/\ ]5N7GF_2(_Y*C)?^Q%'_ -3\8-HHHK^DS^?@HHHH **** /V=_X(W_\
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MTHC<^"==N02-[<D#0B ?;)QTR>M?YO/PS_Y*7\-?^RD?#[_U,]#K_2@7H?\
M>?\ ]#:OXR^E?_O?!'_7CB#_ -+R4_KOZ+W^[<9?]?\ (_\ TWFA\A?MLSZT
MW[)_Q]6XTS3H83\-=?$DL6L3SR(NR'+)"^CP+(PZA3-&#TW#((_DX?[[?[S?
MS-?UN?MP?\FE?M ?]DS\0?\ H$-?R1O]]O\ >;^9KVOHR_\ )*9]_P!E#/\
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M)O4\N[L;EK3]E>VN1#/'\DGDSQ.5)4. 2#\<G_@U]^!1))_X*!?\%$LGD_\
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M^+?V7I#JMMHLM_/I<5RNI_LQWZ8LI=4U!X6B6-Q]KF#,RL /U"_90_98\?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-2U$ ^C:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#\W_P#@KHZ1_P#!.C]IUY'2-!X7\*9=V5$7/Q*\
M$@;F8A1DD#DCD@5_""UU:9/^EVG4_P#+U;^O_72O]-*_T^QU6TFT_4[*TU"Q
MN55;BSOK:"\M)U1UD59K:YCE@E59$1U$D; .JL,,H(Y?_A7'P_\ ^A'\'_\
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M*-4UJPU.VCBT3PQ9>)4T./1KV"RFDN_V.1=B(N<[55<^NT 9_'%.HH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\5+%:6?Q.UO6?!$_A_Q7HEKX&MO-\,0:9K.GZMKEYJ'Z:T4 ?&_P&_96U?\
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$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>rdpiechart2013.jpg
<TEXT>
begin 644 rdpiechart2013.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $9 3T# 2(  A$! Q$!_\0
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M\_9^2T\3>%]0U71+.YMM9\)?$'6+^X;3]7M)[/5H+*6VE>".2.0 CT/_ (*
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MXHUG7-=U( ^@J*** "B@D#J<=!SZDX _$\#WHH **** "BBB@ HHHH ****
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M/\??'7AB[\3>&M*L/#^N>%_!/C_XMZ'XQT9]3U2/Q4WBC4HO#WAG6^Y^%_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[-K[BSTVRGTN'6O VJ?"VPUO2M4NM4U.[^)GA_XD>,&O&L_%MI+= 'U==?\
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M>.1&9)$(PR,RG@F@#\>:\;_:'_Y(5\6?^Q'U?^<%?8?QF^&TGP]\3N+*)_\
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M&?PXMK2ZO+$^,[O[.TC]OSXSZ58Z;:?$/X4Z1X>UCQ3KOQ<^!_PXNM:TR_\
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MX8K>1% /4<#W_,_XU'/!'<P36\JAHIXI(95./FCE1HW4Y!!!5F&"".>14M%
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MUE&7/B-'[OL(\WQ1OW]_/3\4SJZ0@'@^H/X@@C\B :6BOZ-$>+_"']GKX._
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M'PE^+R7.B1P^$99'^ZD8.B."K!U#!E.58,,AE()RK Y4YZ$4 .HHHH ****
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M88XXE2->ZHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH Y+6U*>(_!TXSA[S6K GH,7.A7=X 3U)+:8NU3\IP6/S(
ME=8?ZC^8S61J^E-J?]GR17<EE<Z7J"ZC:S1Q13#S?L=Y8212Q3##Q2VU].C!
M7C<-L97&TAIK&WO[=I6O=0%ZK*NQ190VIC()+-F%W,FX$#:0,8XR2: /Y9]
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K %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>rdpiechart2014.jpg
<TEXT>
begin 644 rdpiechart2014.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $9 3T# 2(  A$! Q$!_\0
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M\_9^2T\3>%]0U71+.YMM9\)?$'6+^X;3]7M)[/5H+*6VE>".2.0 CT/_ (*
M?"_1E\:^&/CAIVJ?#+XN?"[QQXS\%_$CX?\ A+3/&'QK@T33O!7A7X?_ !"U
M#XKV6K?#_P %3:S%\$)/AY\5_AOXIN?B1XT\(^!K'P[)XI@\.>*+/2O$-G-9
M/ZCJ?[:7[-6C>)/&/AS4_B3;VB> =)UW5O%?B^3P[XN;X8:7_P (OX%M?B?X
MDT8?%B+0)/AM?^*]!^'5]9^-M5\(:;XIO/$UIX;G&I/I9CBN%A^0?'O_  29
M^%'Q(U*T\>>-?%EMX]^-.M7'Q)7XH_$[XK?!SX-_%B+QSIWQ4C^'EIJT&E?#
M_P <>%M3\$^ ;WP+HWPJ\"^'/A)?Z#87,?A7P]H]QIWBNP^(9UK6Y[_TKQ!_
MP3E\#>(]!^.GPHN_B3XTL/V;?C[;?$'4/%_P*T;1/ =AI,/C/XF^$M*\*>)=
M=L?$[>&[G5$T&UNM(M_'7AWP*+&/0-)\=3W,L[:EX(CTOP)I@!ZW/^W5^SC:
MZ?IMS=Z_X\M-9UCQ9K/@73? -W\$_C5;?%B[\7Z+\,-9^-$GAZ/X1S^ (OB4
M=3U3X6>']8\;>&H#X6SXHT73[E] .H7$$]O%X?X^_P""I'[/.BWGP9A^&U_=
M_%6R^*OQ7^!G@R:_TC0OB#IX3X=_M >%OBKKG@#XN_#FV_X0+4+CXU>'M8UO
MX6:KX,T^W^'2:K%<>*FOM!N=2L-;TPZ9=:_PG_X)U^ _AAXG^#OC2SUKPS8>
M(OA3\;O%/QMN(OAK\$/A+\%?#/BW5O$'[.?Q$_9NM-*U;PY\-]$TN(IIWAOX
MBZIXGDUC4+[7-7N/$OGVNGS:)X4N+7PYIOD>B_\ !);P3X9'[-E_X?\ C7\0
M-,\1_LM?!?\ 9\^%?PZUM/#WA*Z%UJ?[.-[\6-0\'^+?$.F75O/:Z@NLS_%G
M5;?Q1X<MS9VUYIME%;Z9J>E7D_\ :-L ?5UM^WO^RW=6_AJYA^(6HM#X@M[F
MZU*3_A7GQ,5/AQ;67CS6?A9?W'QM+^#E_P"%%0V'Q+\.>(_ =])\8/\ A"A9
M^*/#GB33;CR_^$=UN;3_ %[X;?'WX;_&(?$;_A5]_J_C)OA9XM\7?#_Q6UKX
M;UW1M/3Q_P"!/$WB?P;XM\%:5X@\46&A>&M9\0^'_$_A+5-)UJVTW6;BWT9Y
M]'N]7NK&PUO2[JY_/5_^"0GP2N/&%M\0M8UG2/&7COQ9=W6J?''Q9\2?@C\#
MOB3JGQ%UR^^+'C3XRWOB'P?%XS\&:MIGP9UB7Q+\0/$_AQ7\(Z?J&G_\(#+H
M^DW&FW/BCP]H_C6V^Z_@W^SUI?P;^'GQ'^'VB^+O$L\7Q&^+O[2'Q>N/$-N;
M'2=>T#5_VCOBWX[^+>L6NA7$$-S! ?">J^.[JP\.:C<V]Q<M'IMC>ZA%/<F=
M' /G;X4_MP>*_&WCCXN?#C6?@QI?B'QK\*O!GA'Q1K&@_LY?&#PO\>I?#/BK
MQ7XOU#P8?@3\5=5N=)^&WAOX;?'+0[^PDU;5=#N];U7PA'X7M==\2R>+K72=
M!>YU#WG]CK]H6;]JW]F3X,?M#W/@X?#ZY^+/@FQ\6W7@H>((_%0\,W-S=7MI
M<:./$<.EZ)#K7V2:R=/[1ATJQAN<^9% L94MY)H'[(7Q&T'Q3XG^+$G[1^KZ
M_P#'*7X6VWP<\!_$/7/A/\/X=.\.^#E\;Z-XZU/4?&'@KPH_A>Q^)GC?7M4T
M6 7OB'4]4T/3-'\_4)O!GACPJ^M^(UUN/]DW]D_XL_LI_"WX&_!.R_:'E\>?
M#OX0ZYK%O<17WPK\*^&M7\3_  XG\#>)M.T3P5JUW8WVNM'?Z7\1];TWQY_P
ME>B2^'[ZZM=%3PO>6=SIEY=O. =%\<?VG?B5\%/%<-[J'P-M[WX+0_%#X&_"
M*;QM=_$JQT_X@^,/%7QU\8^#_ NDWWPF^%MEX7UN#Q=H7A'Q%XWTBR\2IXE\
M;^!?$VI?V9XQF\)>'=:M_#=E/XEX+PA^W?=^(?$GA+5KSX4Y^"'Q?\>_'SX6
M? ;Q]X3\:P^+/''C_P =_L_6?Q*U35+'4_AF?#FC6VBZ?\3='^#?Q0U7X43:
M+XX\5ZIJ<'A[2;3Q5I/A?4_%-I9:=N?$/]DSXN>-_P!I[2/V@8?VD;?_ (1S
MPG<^&6^''PE\7? _PCXVT#X5I9Z?'IOCW5_ &M2>)]"N+#Q]\2;*?6=+U7XC
MZWI&O^*_#7A[4Y/"W@^[T?PY/KFFZ^>'/V'8/"'BG3-2\/?%SQ-%X+^&OB?X
MU?$K]GGX;ZAX6\)7GA[X._%?XZ6'CJS\2^*Y;^UM]-UWQ[H_AC_A9GQ!B^'W
MA'7;ZRM?#FE^-=>TF^U378;7PE-X5 -'X%_MK6'Q.^"'Q<^-/Q!^&FO_  F'
MPG^._P 9O@;?> I-9TGQWXQU+7?AA\3I_AAX=TVU7PP#HM[XX^(6NR:/I>D^
M#_#^J^(+.'Q1K5IX;T[Q/KZ[-6G]#_8V_:#UO]J+]G[PU\9/$W@"#X7>)-4\
M7_&/P5X@\!6WBI/&\'A[6_@]\:?B'\&]6@C\4Q:+X>AU=;N_\ 7&I&:WTF"V
MA-X;2VFOX+>/4+KYL^$'_!.B#P[X;\=^"OCO\8=;^./A?Q9^T+K_ .U9HD.@
M:+XA_9[\1>"?CKXM\7Z_XR\0>*M!\:_"#XF:?XG_ +/BU37YQX:T1]2B&@I%
M'-/>ZQ=);3VOT=^QW^RAX)_8Q^#/_"EO .O^,?$NAM\1/BS\17U3QOXH\2>*
M-6_M#XJ_$GQ/\0KK3H+CQ)KNO36>GZ-_PD4>D016=S"FJS6-QXHUB*Y\5>(/
M$&J:@ ?4U%%% !102!U..@Y]2< ?B>![T4 %%%% !1110 4444 %%%% 'QA^
MW#\?]4_9^^&?@[4M!\2Z;X1U_P"(?Q1T#X:Z/KFLZ#X6U/2K6XU/P_XL\2W:
MW6M_$'XE?"CX;>"I9-,\*7HT_P 3>/?%4VCMJ(MO#VE>&?%GBO7O#^@W?Y9^
M"?\ @J7\<=:T/X,>.?'VL?"/P)X=DN-=\/\ Q"\+>&]%\*^/?B/XBUSP7^V#
M\6/V;?$6O)\/]2^.W@?Q??>"/%?A3P%H.N?#_4OV;++]H'7;;QSJOB3^W/#&
MI^%--\*:9XM_H.U'3=.UBSFT[5;&SU*PN/+\^RU"U@O;.?RI4FB\ZUNHY8)1
M'-''+&)(V"2QI(N'16%27P_H4]Q874VC:5+=:7=W>H:;<R:=9O<:=?:@9#?7
MMC,T)EL[N],TOVNZMFBN+KS'\^23>V0#\LO^"DG[;/Q _9A:UT?X4:QX=B\;
M:;\$?C!\<X_"WBOPUX4BT_QS%\,/[,73?#%EXQ\>?%OX;V]U+JM]/<:=J7@O
MX8>'?B%\4KR*]T_5K./PM91V)\2\'^W%XO\ %7QO\,_\$L;[PYX#U#QA:_'?
M]H>P\0^)/@Y!\8_$WP<TSQ7H^J?L*?M)?%"'P_X@\>^&8Q?3:=X5UO3])\3V
MVGW6G7%GK&L>&-,6:V@F,4]O^R-[I.EZE)9RZAIUA?2Z?-)<6$EY9VUT]E/-
M;RV<L]H\\4C6TTEI//:R2P&.1[>:6!F,4CHTG]GV.+$?8[3&F,'TX?9H/] <
M6LMD&LAY>+1A9SS6H:W\HBVED@!\F1T8 _!'X6?M-_M>_ ;XZ^ OV0?'J>&=
M5/@[QQ\%?#<EUXS\?>!M9O?'_@7]H?X@:SXAU27PU\0/BO\ &CP-\>OB#;?L
MY>!/$&G?"/P)XA\+? GQ[J7Q2\6?![Q5=?$2]T:[\0^7X43X%?\ !0G]H[XD
MZ9\&=:^(_P 4/V?O@S8?$;X9Q?%[0;WQ9\.?$,FB_%;48OC_ *[\";GX&^!)
MK?Q];ZQ<^*M+TGP_IOCGQ1?Z#INO^(;?6?BW\/\ 3M&\-R>'= U?_A*?WLFT
MK3+B_L]5GT^RFU/3H[F'3]0EM8)+ZQBO1&+R*SNWC:XM8[M8HENH[>2-+E8X
MUG$@10(/[!T39IL?]D:9Y>C7#7FD)_9]F$TN[9)HVNM.00A;&Y,=S<1F>U$,
MICGG0N5ED# '\]7B#_@J/^U79_#W]K'X@0>"/AWX;U7X4_#7]H[Q?IGPZ\7Z
MC\*[C7_A;K_P9^-WASX9^ -!\2^&O!?Q\\6?%[Q#!XQT+5;F[^(>H>/?A?\
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M#X](^(?Q4T?P_87>NZSX<M/A_P""[G4=>TZQAEU>[MIH]:UB;0M*NN!^$/\
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M7A%I/''PXU$:9KL^AG5;>*/5=%FN0_V.YB=+Z*- -6T_2YYH(9?IN@ HHHH
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MX ECEMVO?%/Q-NE^)]GX,7Q'X,74/AW=VNL->CS/X_?\%)_B/\&-:_:3T)-
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MSX>?"76OC#X?T";5? MEX@\!^!+2XM_^%7Z=X4UF#PYX132/!ZV'AJ*YTB8
M])T3_@F+!X<?Q'K^B?&9AXX/BS]BCX@?#S6[_P"'_P!JT+PSXR_8Q^$^E?"C
M2/\ A*_#L'C:QN?''A3XA:7;ZW-KNA6OB#PEJ>@1:_)_8/B)-;TNPUY>5\0_
M\$H8?$_A_P#:6M=2^.\J>)?VHOV9?CU\#O&_B&U^&Z0V6E>-OV@OC7X^^-/B
MSXD^'=$?QY<&TT#1K[QI;>&O#GP[?5I+B+1_#EC?:SXWU?7K_5-3N?8/V*/B
MSKWCK]EYO"WB/XT6VG_&@>)_VI/"^A:MXXUK2?B/K/AJP^%GQC\2>$R=)\1W
M^I:,?VBO"GP/L=7\'>#[WXRNEE'X[EL],U7Q[;Z%XFUG5-&C^2?A/XQ^-OC'
M]@B#QG8_M->)?$OBGX6_M%?MS^$M?\5:]XRN9/B'XRGTS]J3]HKX._L[3"_\
M":8J:_KN@>(8/A[_ ,(3\'5T70_AY\2Y8-$\ W4.C>%EM8(@#]/_ -GC]GN]
M^ /B']H%[+QC9>(O!7QE^-WB[X\:'HDWAF?3?$O@_P 5?$N6+4?B)I>J>*%\
M2W^F>*]"NM=M+:^\)1VOA3PKJ'AZQEO-,U:[\3NUKJ%M[[-XGT6W,HFO#$(#
M()GDM;Y8XA#N\UWE-KY:QQA69Y"_EJBER^P%J^2_V,OCC_PMOP[XOT_7I_$L
MWQ$T?6IO$_C)=8$1T*U'C+Q'XSTO3]'\$I!JVJMIOA3PGJ/@+Q'X(TG1]672
M?$LEGX8M_%FO:1#-XP@O;_[1=%D1D=5='4JZ.H9'5@5965@059258$$$$@CF
M@ 5E=5=&5T=0R.I#*RL 596!(96!!!!((((.*=7*>%G-G#>^'9G)F\.W"V=N
M7)+S:-.GVC0Y\D!GV61.FRR')DO-,NV  Q5#QE\3?A]\/;<W/C;QEX=\,QX4
MK'JVJVMM=3;@2HM[$R-?7+$ D+!;2$@$XQ0!W5%?&NN?MX_L]:/(\=GK7B/Q
M*R2B/.@>%M2,;@@DRQW&L_V-;R1(1@LLA9B08T=3FO(/&O\ P5!^"'@;PEXC
M\8ZGX,^*EUIOAG2KG5[VWL-+\*/>SVUJ4#I:I<>*[>!IFWC:LL\*=<R#C.^&
MPU?&8G#X/"TI5L3BZ]'"X:C"W/5Q&(J1I4:4;M+FJ5)QA&[2NU=I:F.)Q%'"
M8>OB\34C1P^%HU<1B*LK\M*A0IRJU:DK)OEA3C*4K)NR=DS]*:*_"[3/^#@'
M]CNZN3#J?P__ &A='@VC;=OX0\%:FGF&1$(>WTSXA3W01$9Y6=8G)6,HB/*R
M(WU1\.O^"NG_  3_ /B/<Q6%K\?=)\'ZC//'!#:?$OP_XH^'L4C28"LNK^)-
M(M= ";SL9GU9-I!9@(RKG[3'^&'B'EM-UL7P9Q#&E%<TJM#+<1C*<(V3<ISP
M<:\8))J[FXI:WV=OCL%XD\ YA45+"\79"ZLFE&G6S"AA)S;V4(8N5"4V^T$_
MQ5_TIHK$T#Q+X>\5:7;ZWX8UW1O$>BW:[K75]!U2QUC2[E< [K?4=-GN;.88
M92#',W# ]"*VZ^&G"=.4H5(RA.#<90G%QE&2T<91DDTT]&FDT?:PG&I&,X2C
M.$TI1E%J491:NG%JZ::U33LPHHHJ2A"0"!SDYQP<<>IQ@>P)&><9P: 0<XSP
M<'@C\B1@_49&>.H-?D!_P4+\?>*OA'^TM^S!\=M+\2>+[#P9^S9\%OVF?CI\
M7O"N@7VO3Z+XJ^">F_$C]D_X>?&J]UWP=I%RMOXNU+X=_"SXB>*?BEX0CN+"
M_P!2T_6_!(M]"\BXUBZ2Y^&OAY^U#\:OA9\4?VJ[35?B=J/AOXB_'S]I?X*>
M)-(TSQ\WAK4O"/P[A\;?L3^"OB]/\+M \0_&7XF?#OX:?#&+P]:ZAX1T&/2V
M?Q%KOCC4-,\63^%O!%[JTGB+QCX= /Z92<<\_@">IQT&3]?3J>**_E]U_P#X
M*#_M-?M)?LY:E\29K&U\(6GA"]_X(R_$.7X8_#:VN-"\=^*_'/[2G[3OPF3Q
M_P"!;;QSK?BS3;/0_##7_A;6=!M-+U=9(M1T?QC=:-XNUAM&TFZ;6??_ !+_
M ,%(OVI--\=>$?"</A;P%I>OVGAS1M:\4^%O$6M_"'PAI6O?&35_VA/B-\+O
MB3^S5I_B+XA_&7P7XNOX/@/HGA/P_HA\=_"3P%\4?%GCWQ'X[\ _$F;P9HG@
M7QCX8\)^( #^@/(/0Y[?CZ4$X]>3C@$_RZ#W/%?S&:?^W5^UI\#]7^,'P[UO
MXKZ+\0-<'[6W_!0*ZD\2_$:3X(>%V^%?A?X2^-_!C?L[?!*]M?BW\=_@YI&E
M^'OBOX1\7ZG\0]$F35KKQ>_PG\&ZO)\*O#6M06^K>(] ]?\ C'^UA\;?B3\6
MO@7X?\1^._!WPFU+0?\ @H[^QI\.[G]F_P ,3WTWQ'U;X>ZO\.M \?>(?BC?
M^--/\86MWXI^%GC?Q5XTU+P_I<TW@.V\"7WAWPQ8Z5=W+^-IM4AMP#^A2BOQ
MP_:W_;@^+WP:_:4^(_PI\$^*OAC9GX=_ 7]E#XR> OA9XD\-3:KX_P#VC_&/
MQB^.?QU^%GB?X+^!]03Q3HTUMKNM:3X \.#PK<:+I&OZQI'BC4;/4[W2M1\.
M1ZMIM_YQ9?MR_M":AX,\!>)?%_QA^"'P-\-?$[X@_M[:3I_Q;\<?#P7G@'PB
MG[&_QM\6_"OX=_#&\-[\1?#UGK?CSXXZ9HVI_$'4;LZQIK0^%_AOXQ\.^!M'
MEUJ['B[3 #]UB<>O)QP"?Y=![GBBOYKO&_[:W[17QNO?V;]3\3ZSX?\ @9XX
M3]M_]D#0'_9#M[+6=.^+C^&]>^!ME\4+KQKXLUB#QS:ZSJOP\\>>//&;>&X=
M)U'P?:>%(]$T"R\*:IJ0^(B:U]G[[P)_P4X^,_Q M/A'I'_"<?"'P?I/C3]G
M?_@G7JOQB^-UQX=MM2\%?LZ_%_\ :"T']KB^^/K^+H;GQ;8:):7.G^-?@;\.
M?@UX>\+>(]9M;3X;_$/X@V<7C9]4N9K7P]>@']"?^?\ /Y&BOYX?%O[67[2?
M@KX[?%+QE%^U?\&K[POXM_8O_8G\7?"KPIXITC3_ (>?"3Q-J?B[]H/XV^ _
MCA\4/@N/B1XRT21O%,/@O0-$UK28_'7B"P^'TFN>/?A9I'Q*\>Z9\/\ 3O#/
MB/7OT/\ V1?VEKWX[W'PQN=3^/'@6\U>Y\&_M$:9KGP@N_AQX9\)_$#XD:I\
M*?C%X-\%_P#"XO!NK>%_C?\ %+PKJ'P^^'5CJEEX+\::M\,M5^(_PV\:>,_B
M!HVM:/XU\&G3H_ K 'Z'T444 %%%% !1110!QOBOX=> /'=SX=O/&W@CPAXP
MN_"&K)K_ (4NO%/AC0_$5QX8UV,*L>M>'I]9L+V71-6C5%5-2TQK6]554"<!
M5QYQ\8/V:?@S\<?!S^!O'G@O2Y]%?Q1H?C 2:1:VFB:K%K6B_%'P=\8IY8-5
ML;5;R&W\2^._ GAS5?&EM&XB\7K:20:\+T3,X]YHH \LG^!WP7NM!\+>%;GX
M2?#*X\,>!]7.O^"O#D_@'PE/H/A#7#<W%[_;'A?1Y='?3O#VJK=W=U<KJ.D6
MUG>BXN)YO/,LTCMT7_"O/ /VDWO_  A'A#[8?%LWCXW?_",Z)]I/CJXT*3PQ
M/XS,_P!@\T^+)O#<TWA^7Q&7_MF31)9-)>];3W:V/8T4 >0VW[/_ ,";/P9K
M/PYM/@Q\)[7X?^(]1_MCQ!X&MOAOX+@\':[JQF@N#J>L^%XM#30M4U%I[6VG
M-[?V%Q=>=;P2B4/%&R[=_P#"+X5:IKG@[Q-J?PU^'^H^(_AY:PV7@'Q!?>"_
M#-WK?@BSMT$<-KX0U:XTN34/#-M%&JI%!HEQ811HH6-%  KT.B@#AH_AC\-X
M?!>J_#>+X?\ @B+X>:XOB1-:\"1^$_#Z>#=73QEJ>HZUXN35/"RZ<-"U!/%.
ML:QJVJ^(UO+"8:YJ6J:C?ZH+N[OKJ:7@O#_[+G[-/A/P[XI\(^%OV>_@=X:\
M*>.#IA\:>&= ^$GP]T;P]XO_ +%DN)='_P"$HT33?#EMIGB#^RI+NZ?3?[7M
M;PV#W-P]H87FE9_=J* /,[[X+?![5-/L-)U/X5?#;4=+TOP5X@^&^FZ;?^!/
M"MY8:?\ #SQ9_9/_  E/@2QLKC29+:S\&>)/[ T/^W_"UM%%H.L_V-I7]I:?
M<_V=9^1D>!/V=_@%\+8-1M?AG\$/A#\/+;5]3T+6M5@\"_#/P3X0AU+6/"]Q
M<77AK5M0B\.Z%IL=[J7AZYNKJXT._N5EN](GN9YM/FMI)I';V.B@#&TCPYX?
MT"35YM#T/1]%EU_5KC7M=ETK3+'37UG7+N.**[UG5GLH(&U'5;F*W@BN-1O3
M/>3QP0I+.ZQ(%\5^,_[3'PQ^"=O+;^(-4.J^*FMQ-8^#-$:.ZURY#G;%)>;F
M6ST6S8_-]KU6>V\R-7-I#=R@1-\G_M0?ML?V)/J/P^^#%_#-K%O++9>(/'D2
MPW5KI<T1>*YTWPPDL<MM?:E&X,=SK;K/86#I)!8QWEWNN++\HKN[NK^[NK^^
MN;B]OKV>2ZO;V\GENKR\NIF+S7-W=3O)/<W$KDM)--(\CDY9C0!]7?%+]LOX
MN_$'5+R?0KX?#C2+BQ?2A8^%YW_M:XT[[0]Q&FI^))XUOY+B-I)1'+I,6C+"
ML]Q'&K":1W^3[FXN+RYEO;R>>\O9V+3WEW-+=7D['JTUU</)<3,>YDD8\#G
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M90IQLH4\;&%3FBHQC#$T<1"$52C3;NT445^0GZN%%%% !1110 4444 %%%%
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M%% !3)(XYHY(9HXYH9HWBFAE19(I8I%*212QN&22.1&9)(W5D=&*L"I(I]%
M'PG\9_@7)X9-QXI\&VTL_AS#SZII*%II_#_.7N+8$F6?1>>1^\GTP#$IDL]L
MT/Y__M#_ /)"OBS_ -B/J_\ ."OWK(# J0"&!4@@$%6!#*P((96!*LI!#*2"
M""17YQ_MG?LU:IKGPG^)UW\+-.MII]:\*:C:7'A<W=KIT%M=W#P W^G75[+#
M96NF ;IK^VN)XH]/59+FV+6VZ"'W>%\10PG$W#F*Q5:EAL-AL^R?$8G$5ZD*
M5##X>AF.&JUJ]:K4<84J-&G"52K4G*,(0C*4FHIL\+BB$ZG#/$=.G&4ZE3(,
MYA"$$Y3G.>78F,(1BDW*4I-1C%)MMI)79_*JW4_4_P Z:Q"J7=E1%^\[L%1?
M]YF(5?Q(K]:_@_\ \$P;+6I;6^^-O[0?@?P7:,4FN/#/@*&[\4:^T08&2WF\
M3:S8Z7X7L)F!V%[*S\0",DLGFA3G]4?A%^RE^P9\&6M+W0- \$^*/$-IL9/%
M7Q)U(^.];6=""+BU@UBV/A[37W#<ITO0;-HS]QQ@&O[8X\^DYPAP<ZN$RCAK
MCOCC-::<5A^'^%,XHY;"JME7SK,\'A,+4H3Z8C*J>;Q2UY'L_P"!^&O"?-\^
M5.OC<\X6X=P<VFZF9Y]EM3%R@[7=/+\'B:]6-2-]:6-J8%]Y+<_G#^$O[+'[
M0WQR:)_AA\)O%WB#3)6"GQ+<V \/^$80Q_UDOBKQ"^F:(\8ZG['=W<N,E87/
M!_4KX1_\$8];NA:ZC\=/BW8Z/&P22X\*?"ZP_MG4 " 6MKKQCXC@MM*A<'*/
M)IOA[4E!!,5RXPS?N'%\1OA_+%$(_&GAKR8E\N&,ZI;Q)"B<!(87,8AC7HJ1
MQI&!]T8Q4H^(/@-B%7QGX9)8@ ?VQ9C))P!DR@#)[D@>IK^*N//I<?2"XC=?
M"\,<(XOP_P  W**E@N'LPSC/%!Z2IU\SS;+GA(M+:K@LFP&(IMWC635S^@^&
M_!7PKRI4JV;\087B?$KE=L1F^#P&7.6CC*G@L#BU7DFW\&(Q^*I332E3:=CP
M#X/?L0_LO? _[)=>#/A/H-_X@M I7QAXX0>.?%;2J<^='J/B".YL]-?/*#1=
M-TM(N @& :^KR2VW<2VQ0B;B6V(.%1,D[$4<*BX51P !7,_\)GX/_P"AK\-?
M^#W2_P#Y*J:'Q7X5N"P@\3^'92H!8)K>F-@'.,XNN,X-?Q_Q#7X]XGQL\VXI
MGQ9GN/E=2Q^=_P!K9AB(QE+X(U\:JLJ=)-I0I0E&E#2,(Q5D?N>5KAC**$,!
MDSR++L,K<N%RZ6 PM-N*^)TL.X*<[:RG)2F]92DW=F_6IH=XVGZUH]^I939Z
MII]QE>6VQ7<3N #@$E PQWSCO7)_\)%X=_Z&'0?_  <Z9_\ )568]7TEPLD>
MJZ7(A^97CU.P=6 /5&6X(;D$#&<D8'-?/QP.9X6I2KO XRDZ=2%2G*>&KP7/
M"2G&S<%JFDU;56OT/7AC,'.24<5AIO1M1KTI.VG12>FJ^]=S])Z1BH5BY 4
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M^\(Q>"_@=\._!_BZ3XB+#J^I?'CQAX4T/X(:/J/B+PAX+N5\!^-;NYNO$-B
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MX66GCOQ;)XX^#5MX/LO'_P '-6T"T\(>#M?LKZ'2)?B7*EKK<0!]@:/^VI\
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M@M+.T@EN;NZNI8X+:VMK>-II[BXGF9(H8((D>6::5UCBC1I)&5%9A^<&G?\
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M(;CPG%HGQ1\-Z;\6_%?AKP#X@\3?#>_\5:#X<\0:]I-OKNH6$.HV<\\&J_\
M!0C]DG0]+DU76?B;?Z2MG8_$W5=<TO4OAI\6++Q-X.TOX+ZYX'T#XN:K\0/"
M,_@5/%7P]TWX:R_$KP-K7C?4/&NC:%9^'/!?B73O'^ISV_@AW\0)\0?&O_@E
M;XGU'X*:+\//AG\8-6UB;X1R_#KP1^S-HOB32_"GAVW^#OPHG_:^_9T^/OQ-
MBU#Q);:-K-Q\1_%FE^%_@9H7AKP%?Z_I5A9?V1X<TS2-<TK5_$&NZ_XQO?8O
M$'_!,;0/&%S\:/$GB[XR>(]4^(/[0/P-_;-^#GQ/\567A'0M*M+ZZ_:]\/\
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M.>[0S1D_)/;2[56:"3^"10,'*.J2*Z+E4 %%%% !1110!XO^T#I(U7X5^(G
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M2XC#KP1PZGJC?7H0PY4CJ/<&IJY:WGD@D5TY[%.<.IZJ<?F/1L$<U]N?LO\
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M3H]UK]SX;E\-)K=E^\E&/\_X>E> ?5G\YF@?L??MG:#\!O@KX?U3PI\7]?\
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MO/WOLKVI8?>)."/&=8^#WC#3=SV<5IK4 Y#6$PAN=OJ;.\,1S[13SGH1D'@
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M110 4444 %%%% !1110 4444 %1M#$W#11L,@X9%/(((/(Z@@$'J" 1S4E%
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MM6T0:]8:1J6GVOB;1[74X+;4)?#7B2+5O#-_>V=C<ZEI%Y+8VC0]R !TX_\
MKDDGZDDDGN>M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
=%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>rdpiechart2015.jpg
<TEXT>
begin 644 rdpiechart2015.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $9 3T# 2(  A$! Q$!_\0
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M\_9^2T\3>%]0U71+.YMM9\)?$'6+^X;3]7M)[/5H+*6VE>".2.0 CT/_ (*
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M*8/CIJ/Q7^(&O^ OC%XA\'Z;XY_:=N_'NF:/\.K[P_JFB> 8/@IX;_:2\/\
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M%:5O;P6D$-K:PQ6]M;0QV]O;P1I#!!!"BQPPPPQ*D<444:JD<<:JB(JHBA0
M ":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN?$_XCZ]\7/$>O6OC&[OI/$L&OQ?$7Q%?>+-&UO^T9-5TG6([*\@NVGM(Y"
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MUSQ?+,T6K76A6/AR*YUN+E/ /[;/@?XA?$:\^&&A^$/%W_"5-XRDT#1+*?\
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M=*$?_+*-XU^TV*QH,+$B/ \$:1A403;54+P/X \7OI;\'>)<LNX-X=X3S*6
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M\.K^+]?T[PMX:L))((+ATFUCQ#J^F:19[HPCWE[;QLZ;P: /0Z*^:+7]L/\
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M( JJJJ JJJ@*JJ %     %.H'0=N.GI10 4444 %?/\ ^TI\![;]HOX?>'_
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MIPRK/\NQ%:HXJ&%G6^J8V<I-)1A@L6L/BYRN[>Y1EKLS]&T7:B*3G:JKGUP
M,TZBBOZ,2LDNR2^X^I/RK\??MO\ QE^#WQ1_X*!6?Q(^'_@4^ ?V6_V/_ /[
M3/PG\.^%=6\0:QXS\7Q^(?%O[4OAIT\?^(S9)IFE#Q1_PH_PW?66A>&_#>I?
M\(+INL7K:CXC\67[26^E?07P+^+/QBM_CA\1/V;OCSJO@'Q?XT\-?"3X4_&_
M1/&WPP\&>)?!/AR?0_B3XK^)7@36_!VH:)K_ (J\:.E_X0\6?#:ZN-#UR/Q!
M'<>(_"VO60U+1--U;0=0O=6HQ_L%?"F;XV?$;XX^(/&WQM\9ZS\6_!VH?#3X
MD>"_&?Q/O_$/PM\7_"RY'Q&.F?#'5_ %UIB:3+X(\-3?%CQY<>'=)CDBFT^;
M79&EO;M+>U2+K?"7[&WPO\%:;?VV@^*/C9#K>J^)/A)K.J>.;GXW_$F]^(>H
M^'_@?XC_ .$B^'/PROO&MUKLFN7?PGTPSZMI.L^ )[E]&\9:3XG\8P^-!X@O
M?&'B34-38'Q1;?MK?M+ZIX=^'WQ2\+^'/ ?BKP?^TU\2OVB/@U\#OAA8^$/%
M=G\1? /B#X.I\8-:\)^*_%NOWGBN:Q\>+XM\$_ ?XAZWXD\'Q>'/ CZ/XFU'
MP=X1T'7]26+4M3UGZ;_9>_:CUGXN^,O$/@;QUJ?A+P_XA\*PZ_X<L_#C64VB
M^+O&^M>$_&?B6PUKQDNA7.LZD/"VFIX3MO"(OO!D\]YKNC^-)OB'HUU(++P1
M]HN/3/#/['_P9\(?$:]^)N@VGBRUU<:C\0O$'A70YO''B:_\#_#7Q=\6YKVY
M^*'C3X9^"-0O[KPYX+\5>.KO4M4N]:U72[']S/K7B8Z-!I,?B_Q;'KE_P-^R
M9\$OASXM\)^-/"GAJ[L-7\%^%-,\+:''+K6IWFGI)I7AR;P?#XJO;.ZGD74O
M'%QX4N[[P_J7BV]>;5=4L-1U!K^2XO+N:[8 ^E**** "BBB@ HHHH *JWM[9
MZ=:SWVH75O965K$\US=W<\5M;6\*#+S3W$SQPP1(.7EE=$4<EA5JOC?]L_X*
M^+OC-X7^$A\,>&O"GQ)TWX8_&SP_\3O&WP2\=ZM!HW@SXV>%-+\&>/O# \&Z
MY>WVA>(M(,_AWQ-XM\-_%3PU9^(=)NO#NH>+/A[H=EJCZ<);;6=, /9C\'/@
M-#HU[X$/PO\ A-%H'B^U8:AX0/@;P5'I'B:RL-7N_$CB]\/'2%L=;M;/7M:O
M=><3V-W#:ZMJMUJK>5>WTMQ-3^(7Q ^ ?P>\.VOQ*^(>O?#WP7X?^'][I/PS
ML/%FIKI%M#X/N_B%XA\)>$--\%6%];027&@?\)+XAD\&Z3+H=I]CAGE@T5[^
MW2UT^WGM?RZN/V"/C1-X^\-WL'@?X+Z+]KU;]C3Q+X2^)VC^-M>U#Q#^QSH'
M[-^MZ'JWQ'^!GP1M?$'@J;Q-XA\#?$.STSQ!I&C7UKXA\'6FKP?%7Q_:^-='
MTS0='T+2-=\%U'_@EU\:M>^"OQH^$2?"?]GS2_"5]8?L_:]X:\(^-M<\%_$7
M5_&/C_\ 9]_:.\-_&2RT:/XN:)\ /AYXFU7X=>(?A_8^,/A_;>*?VC=!^*OQ
MH?7O&=SJ'B7Q-<Z*_B>3Q4 ?NOH?@7X*>%[5],\.>#OAAX>L_"VO2_$1[#1O
M#GA#1[;P[XGU33]0AF\;O:V%C;0Z/KNHZ7>ZI&_B=H[;4+W3[N_4W\MK<7(?
MP3]H_P"&7[*VC^"-(O?B5\/$_LB_^/7PS^*>G>'_ (6> =7U7Q/\2?C=X1U\
M>,/!<UYX7^&?A^^USX@7]W>Z-/>Z['J]G>Z?>:#9ZE<>)[V#0K:^N8OA+P]^
MQC\9] ^)OQN\<1?LR? +Q+X(^)_@']J%_'/P=^*'CSX>^-=+^+R?'#33K^@_
M!2Q^(L'[/.F?$OP7X4\0>*X+/P[\6=+^*OB+X[?!_P &^$T_L'X.>#+SPSIO
MABP\/_IO\:]'^)5Y\);/0/ASX#T#6VO;>TT7QEX#M/BOXN^#6L1^#+CP[?V=
M]8?##XK>!K*WU+PQXMT76/[$_L342OA^UNM'M-1MX-:\,W]Q87]J ?-WB?\
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M(_A?PEIWBO\ 9G\8_#SXT7^C7=A>^%/%4NK?$/PMX=U#39_'_@71O%FL:+=
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M?$X\P;9+'3E>XL=)=599]1:ZO(W46%L\LW_!5+P;X\\4^$/V0]3\"V/CYO\
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M?"O]G[X7?!ZWC'A'P_&VL"$07'BC6&75/$MTNTHX.I31J+**13A[32H;"S;
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M H(!X(R/0T44 )@>_P"9QZ=,X_2JLEA8RC$MG:2#>LF)+>%QO1Q(CX9"-ZN
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>researchanddevelopment.jpg
<TEXT>
begin 644 researchanddevelopment.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #& 3T# 2(  A$! Q$!_\0
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MOX3+7'B#P=IVC72V^B>-=/M_%\(!ZY\8?^"H?[+OPI^'GQU\;6FI^-O'>I?
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M/OD 9&.^0-O?%+D9 SR1GCGCU.. /3/7M0 M%-# G /Z'!]<$C!QWP3CO3J
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M%MG_ ,*[^&O@CXJ:5\/1^TMXMU?PCJ][X6\#QZX?$G@K^W-"ATV:X\=G[?\
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MC6-;\5R06:ZOJ"Z7ID*66AP:SJUU/=WQ,7[BP:WME1Y+NX@!A68 _I2R/?\
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MH<>M &[D>_Y'_"C(]_R/^%87_"+^'_\ H$V?_?O_ .O1_P (OX?_ .@39_\
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M)OC=-\3F.5=ZE=T;KRDBYRC#E6 8<@5)2'.#CK@XZ=>W7C\^* /PH^+'Q?\
MA#H/[0&K?"GP]^S9\*O$WB/X?_&GP?X6^*'BKQAXR\3WW[1;^#_'NN_L]^"O
M VO>&];@L)O&6B^/_BAX[^-_B77/A'!K/CG^S_&/@7X"^/=7T^_M+ZYEC\(?
MN5IEE'ING6.G137MS%I]I;V45QJ-[=:EJ$\=I$D$<U]J-[+/>W]W*D8>XO;R
M>>[NY6>>YFEFD>1OQ"\?_$)K']OOQ'\.O'^K_$OQ+XFU;XP?"^Z^%>D^%_\
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MBP&**UT^="1_9@W;KJUFD#'!S\^WD *,<@'WFW0_0_RK\ _VR/\ DY+XF_\
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M_P $*?\ LZW]J#_UCGX@U]>_\%$_^2+^$?\ LHVD_P#J->)Z^/O^"EDJ0?\
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M*_I=/B;1U+*;F0%6=2/L6H\$,01Q9D=1V)'O0!Y%^U+_ ,F\_%[_ +$C5_\
MT&.OYY6ZGZG^=?T!?M.:]I=W^S_\7(()Y'E?P3JH53:7J EO)49>6VC102P&
M68 9YXR1_/ZW4_4_SH 2BBB@ HHHH **** /TP_X)M?\C)\6/^P'X/\ _3EX
MAK]:*_(K_@G/J-IIWB'XK/=R-&KZ'X0VE89YL[=3UX-D012E<%UQN SGC.&Q
M^LMCJEEJ7F_9)6D\G9YFZ"YAQYF[;C[1#%NSL;.S=C'S8R,@&A1110 4444
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M:_\ 12?AO_X</P3_ /+ZC_A9GPU_Z*3\-_\ PX?@G_Y?4 =M17$_\+,^&O\
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M_P#L9_#G_I\L*_IZ'3\6_F:_E-\,_$[X9Q^)O#,C_$KX;*D?B3P\[L?B'X)
M5$UJQ9F)_M[HJ@D^PK^E+_AH/X$*6!^-'PFR&8'_ (N5X('1B.AUX$?0@'U
M- &'^U+_ ,F\_%[_ +$C5_\ T&.OYY6ZGZG^=?N%^TS\>/@A?_ 'XM6EG\8O
MA3/<S^"M52&&/XD>"6>5V$2JB@:\>23QG [9R0#^ [?$SX:Y/_%R?AOU/_-0
M_!/K_P!AZ@#M:*XG_A9GPU_Z*3\-_P#PX?@G_P"7U'_"S/AK_P!%)^&__AP_
M!/\ \OJ .VHKB?\ A9GPU_Z*3\-__#A^"?\ Y?4?\+,^&O\ T4GX;_\ AP_!
M/_R^H [:BN)_X69\-?\ HI/PW_\ #A^"?_E]1_PLSX:_]%)^&_\ X</P3_\
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M?^";W[*/_"G!^S)\.X](,O[,GPU_X03_ (61_P +?^*DWB$V+MX6_LL^,?\
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ME!_TC?\ V)/_ !&GX4?_ #,T?\.</^"4'_2-_P#8D_\ $:?A1_\ ,S7Z3T4
M?FQ_PYP_X)0?](W_ -B3_P 1I^%'_P S-._X<Y?\$H?^D;_[$7_B,WPE_P#F
M8K]):* /S:/_  1R_P""4)X_X=O_ +$7X?LS_"8?J/#&:;_PYP_X)0?](W_V
M)/\ Q&GX4?\ S,U^D]% 'YL?\.</^"4'_2-_]B3_ ,1I^%'_ ,S-'_#G#_@E
M!_TC?_8D_P#$:?A1_P#,S7Z3T4 ?B;\9?^"./_!.3_A:W[(X\'?\$W_V3O\
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M6+PEXJU'7/#MK;:=#]@QQQQ(D42+''&JI'&BA41% 5415 5410%55 55 50
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>researchanddevelopmentchart.jpg
<TEXT>
begin 644 researchanddevelopmentchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +: 3T# 2(  A$! Q$!_\0
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MK>@?"3X$7'[1/[1T.J?%?0]-O/"7@"V^(/QH^'BI\')]-\-:[IGQHO\ 7_\
MAGKXN>/_  /JM[>?#?PAXP^'ND^#M5M/$%G>_$'3;/2OH[1_VOSKO[6NF_LW
MV/PK\10^#=;_ &;O'O[0?AKXVW^N:+#H_C>#P)XK^".@7>C^"/!UHU]KVI:%
M/9?&W1[P>-=<G\.6EQJNF7VB:'I&M1V]_JUCYUXA_8*U#Q7X>.CZA\<-6\,S
M>.O@AIG[-/[0,7PT^&'P\\%>&/BQ\#?#FJ>.Y?"/A70/"<T'B&V^$&K>%/#/
MQ'\9^!=&\2>"]0GDM_#'B;51'ID6KV7A+5/"FQK/['OQ/N_VL?!?[2&@_M%1
M>%_#'@+X;^)?@GX<^$6F?!7PD;&R^$7CCQ%\)_%/B[P\GC=_$D>O)KTVJ_"#
MPZOASQ/'8+'X;L+G4+9=!U.5X+F( 9^Q5^V7JW[5!O9=<C^ .@2S^ _"'Q!T
M3PG\-_C!XW^('CF#1/%L<=PMSK^G>*_@S\,=$N=)TLW-MHEYXH\ Z[XY\,_\
M)7'?:$=4BFMXGN/?/CI\3OBW\/TL3\,/A+X8\<VL/AWQ;XN\7^+_ (C_ !:L
M?@[\./!^C>$8M,N/[,O_ !(OA/Q]K$OB;Q-%>7TVB[_"UKX/TC2M U_6O&'C
M#08[72K#7/'X_P!ECXNVD^O>,V_:B\9>*?C!H?P@\<_!KX$>/O$WP^^%MM'\
M,-&\?:MX'US7/%'B#P]H?AFTT+XD^-=1U3X;>!9]6U'5].TKPY+;>'%M-%\'
MZ#)K&M75]H_M>_LN_$+]IQ/ 6C:)\=?^%>?#WPW>:KJ?CGX5:O\ "GPS\3OA
M_P#&2_=M-?PM#\2--U?7/#FI:QX9\(SVM]J,7@5]5?P7XIU6]L[KQMH?B*VT
M/2[&( \%_P"'F%EK'@W4?C'X1^$5W<_!+X9_"']G'XR?M":[XN\:VWA7XA_#
M/0/VC?"VE?$&STG1/A_;>'/$&G^+-?\ A7\-=<T?Q[\3[35_&7@N :3J-OI?
M@6X\7^($N=/A^B/!?[6%[XL_:Y^*?[+VH?"/Q-X+L/AQ\&?#7Q=T[XC^*]:T
M>U7QU9ZW\3O'OPTO6T/P?8F^U#2O"=A>^!+F^TGQ9XDU/2[OQ1!=375CX9M-
M"M=/UW6^"\;?L(6_Q$U#79_$_P 7?$4>D?&7PK\+/#?[5_A7P]X1\)Z/X>^/
MTOPGB6#3-1MX[A-6U3X7CQ?I0'@KX@67AK4]3CUSX=VFE>'=+GT#5M.3Q1+C
M^(?V%O&/C?\ :;^)OQP\>_'Q?$WP\^+OP<O?V<?&_P $$^$FBZ!8:C\")M<^
M(7B&V\(P?$?0O&-GXWT[Q"+[XCZU!J'C33GM+Z^L8;1+;3]+OT.HT >@?LQ_
MMCP_M*_%[]H_X?Z7X!F\.>$/@V/@QK'P]\>W'B$:A-\7_ GQD\'Z[XDT3QRG
MAK^Q;&3P;IE[/X<U"7PS8W6JZS?>(/"-YX?\672Z))K0T2SUO&/[>O[+OP[N
M?'</C_Q[K/@BW^'GA/XC>.=:U7Q;\-/BCX=T+5/"?PANXK/XHZYX(UW5_!EG
MI/Q$LO ;W$%QXC?P-=Z^;73G?5H!=:5;W-[!S_[-G[ WPD_9;^-OQR^,_P .
M->^),\_QL\/?"KPS/X5\7?$KXD>.]$\*Z7\+=(U+2K2+29_'GC3Q5?W[ZG]N
MB=)]6DGN?#UE:G0_#EQI^BWM_97'R!\1?^",/PS^)4WC.[UWXS>-&UGQ+X;_
M &I/!]MXU;P)\,[KXGW7AW]JG1-=TWQ+!\1?B=<Z*?&?Q6O? 5SK@C^&LWB?
M5(=/\/\ AW2]+\.3Z3>FU75J /NBY_;H_9L@DFTY?%_B2?Q1!XVUKP!-X#@^
M%7Q=N/B+::]X>\'Z!\0]7OM2^'EMX$G\;Z7X-L? 'BSPIXWN/B!?Z!!X)'A?
MQ1X<U2/79!KFEPW>9\*OVG?B#\<?V0OV<?VD/A;\$EU[Q?\ M&?#WX0^.].^
M']Y\0;#2?"O@*T^)_ABR\5:CJ?C+XB3Z!-J,WA3P;IL\Z7&H>&/ 6N^)O$5^
M=*T_1O"7FZJ\VG\)KG[ ]JW[2GQ&_:J\"_&?QG\/_BO\1?$=C-=W]CX9\&>(
M-/TSP%=_"7X2_"KQG\/[73_$=A>V]Q;^(6^"W@7QWIGB.Y3^U_#/C#2@(4U;
MPU>:KX>U+7O?V,O%?A_]BKX1?L;_  6_:+\=_"*T^%/@?X9?#'_A:>G^&]!U
MOQMXJ^'OP[T*W\/WOA[4&%YH;>'[GQQIUE:6?B+Q-X-U/P_XIT^T?4/^$4UC
M0-1O(=3L@#S?P[^W[X]^(-V/ 'PQ^ 6B^*?C=X=3]I2_^(?@Z_\ C+;:)X(M
M=&_9C^)NE?"7Q!=_#CXBI\/]4G\>7'Q$\;ZJWA_X=C6?"'@;2[/4_#OCG3OB
M+JW@S5?",VG:CVFB?M^:+XS^,7[''@/P/\*/%^H_#7]L+X:>)OB=X4^-7B#5
M-$\/:'8V&F?"#1OC%H6AZ-X7AFUCQ!XKU6\T'6$MO%=]MT+P]X0U%(-,@U;Q
M+JT]W8:7G:7^PEXCT7P_\/7\,?'1?AE\1? '@/QM\$[+QC\'/@G\-O GA]O@
M/XYU3P[K<W@'3?AOJ+^+?#VA:SX1UKPS8Z[X"\:V=Y-=:)K%UK$FJ:+XATW6
M]5TN[SO%7[!'BW_A:/[*WB[X3?'Y?A9\/OV._"3>!_@]\+&^#OACQM;0>&M2
M^'FD_"_Q%I_B#QCK7B:QU_56OO">CV\.F7,4-E/I-^SWD[ZNN+>@#O/ W[8'
MB77?VHH?V:_%7PU\&Z7K&I:!\1_$SV7@7XV>'OBA\1_A7HO@C4/#:^&=2_:,
M^'VB>'K"R^%-C\7-#\4:;K'PYN=-\9>-4O+F6+0M0$-Y+)=6WW;7Q7X6_9%U
M6T^-7@+XO_$7XX>-?BG-\'E\=+\*+#6O#'@+PYK>GCXA:')X7U<?$'QOX1T3
M2=<^)T6E>&I#HWA^QU.#1=*WPZ?XC\4:?XK\9Z)H/B32_M2@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ R/7
MKT]Z*_(3]OKXM_%#P%^WQ_P1Q\">"_'_ (M\*^"_C!^TE^T1X;^*?A70=;O-
M-T'XA:#X?_99\:^*M"TCQ?IMO(EOKNG:1XCL+36M/M+U9(;74X(KR-1/'&Z_
MKS&240GDE%)/J2!0 ZBO-_BY\4O#'P6^'GB;XF>,?M[>'_"]K:SW<6F0VTU]
M=3ZAJ=CHNF65NU_>:;I5HU]JVIV%DVI:WJFD:!I27#ZIK^L:1HMG?ZE:_'WP
MC_;C\:?&7X)_#'XG>%OV0?CK)XM^)KZE+9^ DU;X7OH>EZ+I&F:1JUQXJN?C
M%<>,K3X9S^'=636K+1/":IJD/B;Q)XJ&HZ1%X:LK'P]XFUO1@#]":*^48?VQ
M/A9J'[+?A?\ :RT33_&FL^!/'&C^!KKP=X6M-"MX/B%X@\3_ !*\4Z+X!\$?
M#RTT6^U.UTF+QAKWQ"\0Z3X)@-UK\/AF'5KK[?/XC7PY&VMUXE\3?^"C_@;X
M-?!+XO\ Q1^(WP>^,EAXU^!/B:W\(_$WX,>&M)\/>-/%?A[4+WPMX5\=6'B*
MY\6^']>N?AK9_#J[\#>,=&\4Q>.]:\5Z-8/$-0\*PV4OQ#L7\&N ?HW17R!^
MT+^UK'^SS)XIUO6_@K\6_$_PN^&'A"R\>_&+XM:!9^%K+PEX%\*7MSJT-Q=Z
M/;^)O$FAZY\3M5\,V&CW/B3QKX>^'>G:WJOAWPY+IS+'J7B36=&\,:AM_M'?
MM1:-^SY??"[PVW@W7_&WC/XQ>(?$7ASP3I%GK'A'P7X=%SX2\,7GC'7YO$GQ
M!^(.N>'?!_A\QZ#873:-I+W]YXC\2WJ31Z+HMSI^E>(M3T0 ^I**\W^$'Q/T
M/XS_  S\%?%+PU8ZWIFA^.-!L]?T[3_$=C%I^LV<%V'4VU]#;7-]82R0RQ2I
M'?:5J&IZ+J< AU/1-4U/2+RQO[GTB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0/\ @I/_
M ,I)/^"%/_9UO[4'_K'/Q!K]O(_]7'_N+_Z"*_#W_@I>\T?_  4>_P""%CP0
M_:)1^U9^T_LA\Y(-Y/['?Q !_>NKJNU27P5);;L7#,"/OW]K/XR_$;X0_#G0
M?$7A&WTS1]0OO%]AHL]SJ*V7B"%[.?1M;O'A2TQ;!)&FL8'%T'(18WCV'S@5
M /H[XF>%M;\:^!/$OA7P]XDMO">KZWI_V*UUN_\ "VB^-]*B5IX)+NPUSPCX
M@V:9XB\/ZW91W.A^(=)>YTZ[O-$U+4(M+UC1=4-EJUE^,_PD_P""9O[5'P4_
M9D\._ CX??M!?"+PK:^+O$$&L_M"^"_#W@CXI^'/AQK>C:7X*T?PG;>"/@WJ
M7@SXF>&O&WPKL?'-]87/BGXX^,-'N[3Q?\2-3N9+70+GX>17FJW5^G_#=_[1
M?_0<\*?^$=9?_)=<WKW_  4A^+GA:_\ #.E^)OB+\,O#NI>--9;P[X/T_7-(
MT'2KSQ1KZ6%YJK:-H%M>ZG#+JFHKIVGWEV;:T61Q'!L_UTUM%, ?H'XM_9I^
M+'Q(^&'AWX):WKGP7^''@CP7X"^"FN^!;CX6?#'58+/P%^T+\"OB[H'Q(^&N
ML>%_"^O^,Y]/?X/>%HO '@JRD^'-S'INJWELNHV%GXUL[:[C&E>!?'G]@?X]
M?%SX&?M.^"=/^+/P4TWXL_MFZUHTGQN\<ZC\*?'LOA'P]X6\'^!/"G@7P)X=
M^&GA/3/BE;ZYYV@VGA1-4U#5O&/BO6'UG6O$&OW<5II.G-I6C:=X<?\ @H)\
M=AJS: ?%_@,:\FDQZ^^AMX=T<:RF@RWTFF1:X^E'4!J":-+J4,VG1:J]NMA+
M?PS6<=PUS#+$G"^'/^"JGBKQC;:_>^$OCI\!_%%EX4LTU#Q3>^'[[P+K%EX9
MT^1I4CO_ !#>V'B*>UT2QD>"=4O-3FM;9VAE5928V  /N;XS?LY_MI?&7Q-\
M-+[Q1\3OV7]:^'O@S3O#7B#6?@SJWPQ^-$/@3Q-\9/#_ (LN?$%EX\\2OI7Q
M?M;_ ,;>'/#D-IX:N/ OPX\5B?POH7C'3[SQOKMMXKUJW\&/X,Z;X_?LA_$W
M]H74;#5OB3XD_9Y^)FD^#/%GQ27P1\%?BU\"O$'CK]G[5? OCJ/P1!X3UCXF
M^ +_ .*&/%GQY^&=OX?\5Z=X;^)T$MKX97P_\0_&.DV7PZT;4=4B\1V'Q+H'
M_!0_XV>+-+M-<\*^./AWXGT34-XL-9\.:'H6NZ5>F.4P2K::CI.IWEG<213*
M898HIFDBF!AE1) 5%3P__P %'OB[XM_M/_A%/B/\+/%/]B7S:9K/_",V/ACQ
M#_9&I+OSI^J?V/K-[_9UY^[EQ;7GDROY4VQ&\F78 ?L#^S/\%[C]GCX$_#/X
M+7/CC6_B-+\._#4/AX>+=>2>"ZOX8;N[N;:RL+&ZU/7+S2O#>@6MU#X<\(:+
M>Z[K]]H?A+2-#T>]U[6[JQFU6\]TK\+/^&[_ -HO_H.>%/\ PCK+_P"2Z_2#
M]E;XM_$+XK_"T^*O%=IIVKZK_P )/KNE_:]/^QZ%;_9; V?D1?80MQ^\C\YP
M\WF9DRORC H ^LZ*Y[^T-=_Z *?^#BT_^1Z/[0UW_H I_P"#BT_^1Z .AHKG
MO[0UW_H I_X.+3_Y'H_M#7?^@"G_ (.+3_Y'H Z&BN>_M#7?^@"G_@XM/_D>
MC^T-=_Z *?\ @XM/_D>@#H:*Y[^T-=_Z *?^#BT_^1Z/[0UW_H I_P"#BT_^
M1Z .AHKGO[0UW_H I_X.+3_Y'H_M#7?^@"G_ (.+3_Y'H Z&BN>_M#7?^@"G
M_@XM/_D>C^T-=_Z *?\ @XM/_D>@#H:*Y[^T-=_Z *?^#BT_^1Z/[0UW_H I
M_P"#BT_^1Z .AHKGO[0UW_H I_X.+3_Y'H_M#7?^@"G_ (.+3_Y'H Z&BN>_
MM#7?^@"G_@XM/_D>C^T-=_Z *?\ @XM/_D>@#H:*Y[^T-=_Z *?^#BT_^1ZT
M;"XOY_-^VV L=NSR\7D5WYN=V_\ U4<?E[,+][.[=QC:<@&A1110 4444 %%
M%% !1110 4444 ?B!_P4G_Y22?\ !"G_ +.M_:@_]8Y^(-?7O_!1/_DB_A'_
M +*-I/\ ZC7B>OD+_@I/_P I)/\ @A3_ -G6_M0?^L<_$&OKW_@HG_R1?PC_
M -E&TG_U&O$] 'XTU^:_[;G@?Q?JWQ+^!WB;P!\,M<\=^+5UN70K&VU?P=X,
M^(?P>\2BR^''Q[U+3/"7C^RUN_TW7OAO"VN:Q;QZEX[M-3TK09=$\0#6)!K_
M (N^'OA;1A^E%&2,X)&1@X)&X9#8;'4;E5L'(W*K8RH( /@33+*QT[]MKQ]K
MNE_"3XK6-EX\_9PD^'/B;QY!\,/'A\)^(?BLOQ8UOQ#<VK_$S7--CT:30X/"
M364/ASQ/=7=AX%LK?[)8Z>=,9[BS'GWB+P!\4-<^'UE\-?"F@?'2_P#AM9^&
M?@[9>*;SXI>!/!ND^//AIXR^'WQ&\%:II7BKX,^"M#TS0M+^)UWX"\/>&9]7
MU?P#YWB?X3^(=1LM ?1[[Q<MUX@\.Z_^G>U<YVC/K@9_.C:HR H /48'/U]:
M /C3X+7?B;PSH_Q!L/B-X)^*7BJQ^*7Q7^(-_IOC23X3R^%/$7BSPD/A%H6H
MW6O_ !.^&WAN;3[;X6+,FAZA\(/ \.E:3HMW\1=1T7PWJ,GAW1?$?BZ>]NHO
MV=);7Q?\0M9^(T_PJ\>?!6:Q^%&@?"KP/\-=>^#WBSX<Z;X:^&.@^*&UVQB\
M4>(]3T32_"_BGXA7.I36HLO#/A:XU/1/AIX5M;K1M'U?Q#=ZKXJURX^T-JCH
M!QG' []?S[T!5'0 ?0 ?RH 6OVW_ ."??_) V_['OQ9_/3:_$BOVW_X)]_\
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M\&>)S>0V,EQJ>H^.+VR\3^(=+BM;[1E\0_#JXTV'4M3TF&UO-2 /U?\ '?\
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MXF_]??A[_P!1#P_0!\R4$;AAOF'3#<@#.< '( SDX]23U-%% "!548"@ ]0
M /R%&!QP..!QT'H/2EHH 3 YX')R>.IXY/OP.?84M%% &YX8W?\ "3^&-H!;
M_A)?#NT,2JEO[;L-H9@&*J3@%@K$#)"L1@_TP";Q'_T#=$ZG_F-W_J?^I?\
MS_3BOYH/"W_(T^%_^QG\.?\ I\L*_IZ'3\6_F: ,7SO$?_0-T3_P=W__ ,S]
M'G>(_P#H&Z)_X.[_ /\ F?K;HH Q/.\1_P#0-T3_ ,'=_P#_ #/T>=XC_P"@
M;HG_ (.[_P#^9^MNB@#$\[Q'_P! W1/_  =W_P#\S]'G>(_^@;HG_@[O_P#Y
MGZVZ* ,3SO$?_0-T3_P=W_\ \S]'G>(_^@;HG_@[O_\ YGZVZ* ,3SO$?_0-
MT3_P=W__ ,S]7K-]2?S/[0MK&WQM\K['?3WF_.[?YGGZ?8^7M^7;M\W=EL[-
MHW7:* "BBB@ HHHH **** "BBB@ HHHH _$#_@I/_P I)/\ @A3_ -G6_M0?
M^L<_$&OU4^-W_(I:5_V&[7_TW:C7Y5_\%)_^4DG_  0I_P"SK?VH/_6.?B#7
MZJ?&[_D4M*_[#=K_ .F[4: /EJBBB@ HHHH **** "OK7X*_\B8W_89U+^<%
M?)5?6OP5_P"1,;_L,ZE_."@#UINA^A_E7X!_MD?\G)?$W_K[\/?^HAX?K]_&
MZ'Z'^5?@'^V1_P G)?$W_K[\/?\ J(>'Z /F2BBB@ HHHH **** -WPM_P C
M3X7_ .QG\.?^GRPK^GH=/Q;^9K^87PM_R-/A?_L9_#G_ *?+"OZ>AT_%OYF@
M!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q _X*
M3_\ *23_ ((4_P#9UO[4'_K'/Q!K]5/C=_R*6E?]ANU_]-VHU^4O_!2\7!_X
M*/?\$+!:F 3_ /#5G[3_ )9N!*T(/_#'?Q W;Q"R2$[-VS:P ?:6RNX']2/C
M"NL#POIO]H/I;0_VS;>6+*.]24/]@U#&3<SR(8MN[.5$F[9@@;P0#YLHHHH
M**** "BBB@ KZU^"O_(F-_V&=2_G!7R57U!\(EUH^$B=/DTM;?\ M;4.+R*\
M>;S,P[^8)XX]O3;\N?4F@#W \@CUK\N/V@/V?_"GC/XO>,O$NHZSXBM;S4Y]
M*>:"R?3!:QFWT'2K-!$+BPFEPT=NC-OD;YV;&%P!^D^SQ1_SVT'_ +\:E_\
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MO ?B)O@]XVB\/6'A#1O!-Y:^')]1M]=C\PU_1_B-!H6B?$_6? OB+3/VF'^
MO@K0_@_\*A^PCX$\4?#[XAZ[\-OB=\:9_AIX>U/5[CPGXRM?V?9_%OA/Q)X7
M\0?%OX;:3XD^!3?!6[\1IXLTWQ=J4'A\:'H !^@6J_LV?#+0K*?4]=\;:QH6
MF6C1)=ZGKNK^%]$TRT>>9;>!+O4M5M+.QM7GN72W@2XN(VGN'2"(/,ZH;_\
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M% 'OGP&_Y"'B7_KSTO\ ]'WU?2E?-?P&_P"0AXE_Z\]+_P#1]]7TI0 4444
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MO^"BW_)%?"'_ &4?2/\ U&?%%?D'CZVO!SC]IV?]ARU7_87AD>7G7_(JQO\
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M^>F5^Z_0_G.7B^U*4FO]4\[=FV_^8K*3V.%VWFFK;_V6OU_O4C[CKXN^*/\
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MWU_YFS;]L-F?*V[L^7]ELK3[^X;_ #/,^ZNW;SN^>O@-_P A#Q+_ ->>E_\
MH^^KZ4H **** "BBB@ HHHH *BFACN(98)06CFC>*10SH2DB%' 9&5URK$;D
M96&<J00#4M% 'SG/^SONO'CM/C=^T+IWA>2?S7\'6OQ.:2Q$9D61K6#Q;J&A
M7_Q5LK8[3&D=C\1+9X(28[:6!0H7WW2]-M-&TVPTG3TDCL=,L[:PM(YKFZO)
MDMK2%((5EN[Z:YO+J41HOF7%W<3W,[[I9YI97=VOT4 ?B!_P4G_Y22?\$*?^
MSK?VH/\ UCGX@U]=?\%%O^2*^$/^RCZ1_P"HSXHKY%_X*3_\I)/^"%/_ &=;
M^U!_ZQS\0:^RO^"@B(_P=\)AT5Q_PL+2B RA@#_PCGB3!P<\C/!KYOB_@/&>
M)_#6<< 9?C\+E>-XHPO]FX?,,;3JU<+A:DJM.LJM>G0O6G"U%QM3]Z\D]KGS
M7&&8PRGAG.<QJ4YU883".K*G!J,YI5(1M%RT3UZGXJ45U?D0?\\8O^_:?X5X
M?\3_ (^_#7X2^*/!/@_Q/;^*+_6O&VI06:1^$/!'B#QC%X6T^ZT?QIK%EXD\
M9-X>T^^FT;0;]/A_XJM+%XH+[5+M]'U?4(-+DT70=>U/3?Y@K?LS.-\/#VE?
MQ4X+HT^:$.>IEF=QCS3E&,5=Q6K<ODDV[)-K^;,-XFX?&5?8X7(LRQ%7DG4]
MG2G1J3Y*<7.<N6-W913Z:NT5=N*?HM%<;<?&?P%8^,;'P;JMCXMT,ZOXGU[P
M/H?C+7_ VLZ+\-?$'C?PQH&L^*?$'A'0_'6H0P:9?ZOIOA[PWXCU47(BB\.Z
MG;^'M=30]?U6ZTNZMDR/#W[1'P@\0:;J6LR:CJWA72;'PGH_Q!L=0\=^$M8\
M)0>*?AWXBU5=#\.^/O!45_:R7OBGPSK^M366D:2+"T7Q%<ZEJ_A^S?P[#/XF
M\.)JN7_%-/C&_*_%K@924IQ:> SA6=*,)U+W6BA"I&;;LN2497M*+?1_Q$-\
MJFN&LXE&4:,TXJ$KQQ%25&C91BVW.K"I3C%7E[2G.%N:$DO2:*S_ (<_$'P9
M\4_AMX/^+7A.>0^!_'/A6R\:Z%J.N:;)X?ND\.7]J][%>ZQIVHA)]%>&UCDG
MOK>_,<NGI')]L$+1R!,+X=_&+P#\3[MK'PW!XCLKJ?POI?CS0XO%O@_5/";>
M,/AYKEY+I^C?$/P:-6B1]>\&ZE>QI;Q7X2SU&T:\TJ35=(TZ#6]%EU"U^S.X
MU;H1_P"(K<$WQ,>?#K^S<Z?MH<L)<U/W??CRS33C=--6^)&+\2J26*D\@S1+
M!5/98M\U+_9JG/*FX5M/W<E.,XN,K-.$KK1G6U^WO_!/K_D@;_\ 8^^+?YZ9
M7XV^1!_SQB_[]I_A7[/_ +!*HGP*8(BH/^$Y\5'"@*,DZ;DX'?W]J_1O#;Z%
MG%/@-Q)_KYG'&O#V?8-Y=BLC^H99@<RP^)]MF-3#5H5_:8N*I>SIK!3C./QM
MSBXZ)GVOAKQWA.(>)/[/HX#$X:?]G8JO[2K4I2A:G4PT7&T-;MU%9[+E?='V
MM7QA\45<^//$!".1YMER$8@_\2RRZ$ @U]GU^ _[8]]>P_M)?$R.*]O8HUNO
M#NV.*]NHHUSX/\/DA8XYE1022QPHR22>37T7C-XKT_"#AK+^(JN13S^./SS#
MY*L)#,HY8Z3KX',,;]9=>6!S!34%@'3]BJ,7)U5/VBY.6?[=FN9+*\/"NZ+K
MJ=:-+E514[7A.?-S.$[V4&K66KO?2S^ZMC_\\Y/^_;__ !-&Q_\ GG)_W[?_
M .)K\>O[2U$9/]HZCP"?^0A>YX[#-P!D]LD#U('->Q>+/A9XH\*3^&M-F\:Z
M+=Z_KD-TVHZ$_B34-'N?#LMG>Z[;75Q?7>O?V9I]SH-FF@7OVSQ%974FGQ7<
M;6T(N89]+O-3_GS _3*KYE0QF)P/A5C,31P'U58J5/B^AS0GC:ZP^%I4Z<N'
M%4Q%:O6<HTZ&'A5K2C3J5>14J=2</$AQ4ZD92AELY*'+S6Q4='.2C%).A>4I
M.]HQ3;M>UDVOTCV/_P \Y/\ OV__ ,31L?\ YYR?]^W_ /B:_--_AIXK@\7^
M-/"UQXF"P> GMDU[Q!9/XLU>QD?4)K*UTF#1=*TNSN?$.LWVLW5]'%IFGVVF
M+<RQ07MY<"VM+.>59--^&VL:IJHT"S^)/AF?7-1US4O#_A;3;76_$MXWBF_T
MRVAN&,4\%@8_#=M>R3II^G2>*TTF6XU6.\LI;>V2PN[J/OC]+;-95%1_XA)B
MHU7C*V C2J<;Y?2J3Q=#%U,OJ4:<*N10G5YLPI5<OP]2FI4L7F%.6 PDZV,3
MHJUQ-4O;^S)7YW"WURFFY*7(TDZ*;]]2A%JZE-<D>:=XGZ4;'_YYR?\ ?M__
M (FC8_\ SSD_[]O_ /$U^5O@[P]K/BZ+Q#>CQ)-I&E>%M(MM:UF^N7\2:M<1
MVEYJ=II%JEEHF@0ZCJ^HS/?7L*SFWMUMK"W#W5]<P1>7YN5XHL-=\)^(-5\.
MW^KW%Q=Z3<K;RSV>IZFUM,);>"\@EC%RUM=0^9;7,+RVMY;6U[93F6SO;:WN
M[>>%/-J?3.J4LOH9K4\+<3# 8FHJ5#$/C'#/VDG/%4XM4EPZZT:<ZF!QU.E6
ME3C1K5,'BJ=*I.IAZ\:>;XK:A&H\MFH2=E+ZU'75K;V%[-PJ)-JS<&DVXR2_
M7334?^T=/_=R?\?]C_RS?_G\@_V:_0 =/Q;^9K^8KPMJ.HGQ/X9!U'4"#XE\
M. @ZA>D$'7-/!!!G(((."#P1P>*_IT7H?]Y__0C7[=X)>-M'QEH<15J7#=3A
M[_5^KE=.4:F;1S7ZT\RACIIIQRW+O8^Q^I6:M5]I[6]X<EI>OE.;K-57:H.A
M[!TTTZBJ<WM%/9JG"UN3L[W\M>.^(?\ R)7B;_L$77\DKXC;J?J?YU]N?$/_
M )$KQ-_V"+K^25\1MU/U/\Z_=3V!**** "BBB@ HHHH ]\^ W_(0\2_]>>E_
M^C[ZOI2OFOX#?\A#Q+_UYZ7_ .C[ZOI2@ HHHH **** "BBB@ HHHH ****
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M &&M2_\ :%?H?AA_R4[_ .Q;B_\ T]A1]'ZK\I'KU?A!^UX1_P -%?$CD?\
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MK7XIZAH?B#1?B%I?[.U_X2OO WQ/BTW1O!_AOQ-K6M:IXZU72=8U>\\#>'_
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MNO$$GA'P%I.L6'@+P?)KL[ZO)X6\,:/)?QVL[-96O%_\-H?LC?\ 1RGP:_\
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M?+6C2I%?V9_\$&O^3%Y/^RW_ !3_ /0O#M?QF5_9G_P0:_Y,7D_[+?\ %/\
M]"\.U^4_27_Y-JO^RBRG_P!,X\_3_HZ_\G#E_P!B#,O_ %(R\_:1NA^A_E7\
M)7_!74G_ (>)_M(C)Q_:?P^XR?\ HDW@.O[M6Z'Z'^5?PD_\%=?^4BG[2/\
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M0 4444 =M\,_^2E_#7_LI'P^_P#4ST.O]*!>A_WG_P#0VK_-?^&?'Q+^&I)
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M&.D_"GP!\2_!_AKQS\-+WQOXY\7Z5X7\&^/_ !E9^+]6\=_"+1-+T^71/C9
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MF<>?N_T=?^3AR_[$&9_^I&7G[''0=$P?^)1I?0_\PZR_^,5_"U_P5OAAM_\
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M_&97]F?_  0:_P"3%Y/^RW_%/_T+P[7\^_27_P"3:K_LHLI_],X\_=_HZ_\
M)PY?]B#,O_4C+S]I&Z'Z'^5?PD_\%=?^4BG[2/\ V$_A]_ZJ;P'7]VS=#]#_
M "K^$G_@KK_RD4_:1_["?P^_]5-X#K\/^BU_R7F=?]DCC?\ U<Y$?L_TF/\
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M %6,#W_,_P"-&![_ )G_ !H_XFEX\_Z$G"/_ (1YS_\ /SU_I:G_ !+1P/\
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MHY)7$92*-Y&5&_N''_!PY_P1_ _Y.TO.K'_DW/\ :O[L2/\ FA?O7[48'O\
MF?\ &C ]_P S_C7YAXA^)^>>)53*JN=X+*<'+*(8R&'65T<92518YX5U76^M
MXW&N3B\)3]GR.G92GS<]XN/Z/P%X;9)X=T\SIY-B\UQ:S6>$GB'F=;"5G!X.
M.(C35'ZK@L&HJ2Q,^?G51MQARN-I<W\T_P"W5_P76_X)9?%[]D#]H?X9_#O]
MIG4?$GCCQK\,/$.@>%]!@_9[_:BM)M6U>]CB%K9176H_!.TL('F*%1)=W5O
MIP9)47+#^0!OVH_@D68CQ#XKP6)'_%H?C-T)_P"R>U_JKX'O^9_QHP/?\S_C
M7H^'_C#Q'X<9;C<LR;+\DQ=#'8YX^K/,Z&/JUHU70HX?DIRPN8X."I\E"+2E
M3E+G<GSM6BN#COPEX=\0<QP>99QCLZPM?!8/ZC2AEM? TJ4J7MJM?FJ1Q67X
MR;J<]62O&<8\JBN2Z<G_ )4__#4?P3_Z&#Q7_P"&A^,W_P [VC_AJ/X)_P#0
MP>*__#0_&;_YWM?ZK&![_F?\:,#W_,_XU]]_Q-+QY_T).$?_  CSG_Y^>O\
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M?AWQ5)XC?5(X/U9MYDN((KB/?Y<\:3)YB-'($E42('C<*\;;6&8W570_(X#
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MAEV"I2E"3DKJ-2$H/3XHM']2'[&@"_LB?LMJH"JO[/'P9"JH"JH'P[\.@!5
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M'O\ ;S_:0D_9C_;-^,/P8\-_!3P3!\(OAO\ M<:3\,=9\<^.-1O/B1:_%/\
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M^ROLD&C_ !$N==U>[\::.(#I?B2\U"YN]5L[FYD,H[/P)\(/A7\,/!\WP_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%WB3PEXJT[QUX8UWQ'=#2Q/K&K>'_&^DZ;XQTB_OGFN+'Q796_B*&1=807M
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MX::7IVK:?\*_ASXJ^('P_P# VM^$]&USQ)%\3M1\ ^)_A;\'-+\*P^!]?O\
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M/[E/AIX/2?QIJVD^)+#QEINH^)YDTA9-:N[+QAI=AXMMYKYIF3Q1:Q^(CG6
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M9!) ()&,C(R,],CJ,]L]: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#\??\ @I%'&_Q"^&I>.-R/!FM8+QHY _MZ
M'@%E) ]0.*_.)X(-C?N(/NM_RQB]#_L5^UW[6O[,/C[X[^*?".M^$-5\*:?:
M:#X?U#2KR/Q!>ZI:SR7%WJ<=[&]NMAH^I(\(B0J[221N'X"%?FKY-;_@G9\;
M"K >)/AKD@@?\3?Q'W'_ &*U 'ZJ?!, ?!OX3@  #X;>"     !X:TT  #@
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K 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>reserveschart.jpg
<TEXT>
begin 644 reserveschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &I 3T# 2(  A$! Q$!_\0
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M> ==\4>,/#OB>S\2ZQXEU;6-*6)?AK'X4UOPWXPAC\4Z5K^E:+]5_LE_L7^
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MCGX_>!?C5^TG\==,_:OAO_$W[0G@C3?#4FCO\!/ VEZ?X2UCX?\ A7QKX?\
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M1_"5GX%\#Z%X=M+#1="2TFZSXM_ ;XA_$S0?C)X;T_\ :1\?>#]$^*VE>&M
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MJWQ,_90D_:(L-2^(7B%/$'C;7_"EJWQ)T[X7+XT^,>M:E>7?AN_T_7=5\"_
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M]JO;79I,3[[*Y:V=\WH7:[*K%E&<A>,'FO&Z]Q^!7_(?UK_L#1?^ERT >_\
M]@?]1?7O_!K+_P#&J/[ _P"HOKW_ (-9?_C5=!10!S_]@?\ 47U[_P &LO\
M\:H_L#_J+Z]_X-9?_C5=!10!S_\ 8'_47U[_ ,&LO_QJC^P/^HOKW_@UE_\
MC5=!10!S_P#8'_47U[_P:R__ !JC^P/^HOKW_@UE_P#C5=!10!S_ /8'_47U
M[_P:R_\ QJC^P/\ J+Z]_P"#67_XU7044 <__8'_ %%]>_\ !K+_ /&J/[ _
MZB^O?^#67_XU7044 <__ &!_U%]>_P#!K+_\:H_L#_J+Z]_X-9?_ (U7044
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MS:5].2;6]-AO#=:1)<33W,FBZFLBZIHCW,TMR^D7UBUQ)),9'8 _*G_@I/\
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M3XD_Y_M$_P#!7J/_ ,NJ/)\2?\_VB?\ @KU'_P"75 &[16%Y/B3_ )_M$_\
M!7J/_P NJ/)\2?\ /]HG_@KU'_Y=4 ;M%87D^)/^?[1/_!7J/_RZH\GQ)_S_
M &B?^"O4?_EU0!NT5A>3XD_Y_M$_\%>H_P#RZH\GQ)_S_:)_X*]1_P#EU0!N
MT5A>3XD_Y_M$_P#!7J/_ ,NJ/)\2?\_VB?\ @KU'_P"75 &[156S6]6(B_EM
M9I][$/:036\7E\;5,<]S=.7!W;F\T*00 BX)-J@ HHHH **** "D8X4G..#@
MGG!QP<=_IWI:1ONGOP?7^G/Y<^E '\YWQWURW\3_ +36K?%73?VE-"^)7AZV
M_:.\'?"6+PKHW[:OC;0_A]X!@;QS^S4=&TSQ5^S'X,\?Z)H_Q"\S3;WXQ?"K
MQ)X(TGPIXXU7QOXG\;^"->U:SN]&UK7=1\ ?T70HD<:1QJJ1QJ$1$4(B(GRJ
MBJN%544!0J@(H " * *_#*S^$.G^ OVR?'=]HWP>^./POL8?CWX8UOP7J_[.
MO[!_[,=W\(O$6EZ[H7@L:UXF\6?&?QA\)/&OQ:&NZGK9\0V?Q)\8^'?%7@NQ
MTO1A;1>$X+*ZTR\U>Y_= ?X_S]NWI[4 ?B#_ ,%)_P#E))_P0I_[.M_:@_\
M6.?B#7ZM_&O_ )$JT_[#6F_^D]Y7Y2?\%)_^4DG_  0I_P"SK?VH/_6.?B#7
MZM_&O_D2K3_L-:;_ .D]Y0!\IT444 %%%% !1110 5[C\"O^0_K7_8&B_P#2
MY:\.KW'X%?\ (?UK_L#1?^ERT ?3]%%?&_[77C;XR>#+7P$_PBGU2"74+KQ&
MFO\ ]FZ-I>L%XK:#2&TT3+J=E>"W DGO/+,/EF0EA)O"*%]#*\OEFN/P^ AB
M<)A)8AU$L1CJKH86G[.C4K/VM50FX<RIN$/=?-4E".E[KR<\S:&197BLUJ8/
M'YA#"^Q<L)EF'6*QU;VV(I8=>PH.I253V;JJK4O./)1A4GKR\K^GO&WAB7QE
MX6UGPU!XG\4^"[C5;98;;Q5X*U"TTOQ1H-U%<0W5MJ6CW6H:=J^F&ZMY[>-F
MM=6TG5='U" S:?J^F:AIMU=6<WY*Z?\ \$F;_2OV2OB]^S9IG[2NMZ7XD_:/
MTW5_"_Q_^*UI\(OAW(_BOP5>:/XL\.:;HGA+X?1#2?!_@O6M.T?Q-ONO',]M
MXE\6Z[JEL)=:U&]TRU\/:5X?J?\ "\?VT?\ G^\4_P#A$^%?_E+52_\ V@?V
MP-)L;W5-6U_6=(TK3;2XO]2U75O"_@K3-+TVPLXFGO+_ %+4K[2[>QT^PL[>
M.2XO+V\G@M;6WCDGN)HXD9Q]E_Q#S$_]%+PCT_YF\_+_ *A//^KH_.O^(N8+
M_HC>/O\ Q'Z?E_U'^;_I:_9WQ!_93\:_'7X>7WPA_:!^--SX^^'^N_#@:-XD
M@T#X>^"O!&HW?Q9T;XK:+\2?AS\8=%7['XGCT35OAL?#.AVNE^&;RZU[P;K^
MHVD.J^(-!NRLUK/A:1^QCXWT'4O'7Q'TG]IGQQ;_ !V^*'B3P_K'Q'\?2_#[
MX9W/@SQCH?@_PA#X(\'>"M3^$DVD-H<6A^%]-CFU[2]5LM=M?&+>,-0U"]O_
M !+>^&'L_!]C^7]K_P %/_$5]\.- ^+MC^T=X?O_ (;^*?$M]X-T#Q5I?A[0
MM;MM1\6Z;9ZGJ5_X:73-!\*:IX@MM;M-*T?4=9GT^^T>UG30[==<(_LFZLKR
MYZS5O^"@WQ.\/P^!9_$'QUT7P_%\3-)T_7_ ?_"0:/X2T*7Q'H.K7T&EZ7KL
M5MK'A^RNM(T34=6NK71[/6/$L&B:;<:U<0Z+'='5Y%LBEX>XEI-<3<(M-)I_
MVO/9\O\ U">?ST[H;\6\&FT^#./TT[-/AZ"::LFG_M^C3O\ =Y:_H&?V"I]*
M^#MA^S[X+_:+^+/A;X/ZUX'\:?#_ .*WA7^POA;K,GCK2?B1XF\<^+/'VL>'
M[^\\%0K\+/$GB6_^(OB;2 /!MF/!WAOPH- T#P=X*\/#PQHM];=/XR_8^\1>
M*=>T'QG!\=O$-EXQ^&?B;Q])\#)]1^'?PY\1>%/AE\,_B%X0^'GA75?AC<^#
M-0TR*R\;G2W\!R:MX=^)NO:A!\5=)_X2;Q'X;3Q7+X,UG6_#VK_"/C[]K7]I
M;X5^'YO%7Q)\>7G@?P[#?V>DMJWB/PKX6LX)=7U&22+3]&LK>/09]0U/6K^2
M&=;+1M*L[[5;K[/<O!9O':W+Q:OA?]IG]JOQOX<T/QAX,\87OB[PEXFTRUUK
MPYXG\,^'O ^N>']>TB^3S+/4]'U?3=,N+#4+&X3)CN+:>1-RO$Y66.2-'_Q#
MS%?]%+PET_YF\^MO^H3S?K;S0O\ B+F"_P"B-X^Z?\T_3\O^H_U]/EK^I_[.
MGP*\,_LV?!WPA\&?".I:QK&B>$_^$@N$U/71I,-]?:EXK\5:[XUU^XCT[0-,
MT7P[H.F2>(/$FJG0_"OAG1M'\+>$M$_L[PSX9TG3="TG3[*'VVOQ@_X7C^VC
M_P _WBG_ ,(GPK_\I:^V/V1?&WQD\9VGCU_B[<:I/-I]WX=30?[2T;2]'*17
M-OJS:B(5TRRLQ< R0VGF&;S#&0HC*AG!\W-N#J^4X"MCYYWP[C(T723P^ S&
M6(Q4_:U:=)>RI/#TU-0=13G[RY:<92ULD_8R'Q$PN?9KALJI\-<79?/%*NUB
M\TR>&$P-+V&'J8A^VKK%U7!U%2=*DN27-6G"&E^8^QZ***^//T,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "D;&TY.!@Y(X(&.N?;K2TAZ'Z'KT_'@_
MR/TH _ +XP_"2^U3]LOQY\=K#Q]X:M/A)X>^,GPZ^$WQ1^+5QX'\>3_%WP'X
MU\0?$C]D7X@^&?A_X=UNRDD\*ZYX \#ZW\)]$\':?XM,^B:+\,9_V@O&Z:[X
M;\82Z3XIN]3_ '\7[H__ %8.>0!V / '8"OPR\?+X7L?^"@GBA==T[]E#QGJ
MB?$7X3^-;23QG\4OVC?!_B/PV8M0^%7P\T:X\5>"?!'P3U']F;X@?%7PAXE\
M<?#X?#>^\>Z_??$SPNWC'X<6FJ^*-)TN7P?J5A^YR]!Z=NO3MUYSCK[T ?AY
M_P %+I6A_P""C_\ P0LD6":Y9?VK?VG\0VXB,SY_8[^("_)YTL,7R@[FW2KA
M%8C<V%/ZG?%^_GN?!]K%)I6I62C5]/837:V B)6"Z C_ -&U&ZD#L"2/W>SY
M3N<'&?RV_P""D_\ RDD_X(4_]G6_M0?^L<_$&OU;^-?_ ")5I_V&M-_])[R@
M#Y3HHHH **** "BBB@ KV7X+W4EKKFKO%8WE\SZ3$ICLQ:EXQ]M!WO\ :KJT
M3:2 HV.[9/*@9->-5[C\"O\ D/ZU_P!@:+_TN6@#Z"_MB[_Z%[6_^^=(_P#E
MS7A7QMO)KN#PV)=.OK#RYM4*F\%F!+NCLLB/[+>W9RF 6\P1C##:6.0/I*OG
MSX]?ZCPO_P!=]6_]%6% 'SE7FOQC\)Q^.OA=XX\'R^$F\>1>(M%73Y/!\7C*
M+X>7>OJNIZ=>?9=+\=7%O<VGA/7;9K1=3\.:W?Q+I=IXAL-+&K7%CI<EY?6W
MI5% K+LOZ_X9?<?B;^RG\(_V@M'^"7PSU#XV_"[]I2\TCPC\2O%&K^#M/^&?
MC;X9?"7]K?2M!\3^'?B!X;\82?%>?P1K_@";QKX4O];U6ULO!7]D?$;PS\6=
M&T.Z?6O$-UKG@%M-TP>A?$/3OVDM<^%^C? 'XE_L^?''QJGQF^$MYX:_:N_:
M&^'>C?"'XG?$CQ+\*YO'7CV'PA^S:=<N/B%X$M]>^*T'POUR+2/B7\8M7LM0
M\"^$M0\1>*_$7PPTCQ?X[\3'Q#X>_7 \]>?KS2%5/50?J ?YT#LNQ^?_ .T!
MX4^*/Q$^(WP'^(.@> ?C[X:\$_LY_%[XR^'?%GAGX9Z_\/= ^+/Q#\%?$'X%
MZ=X5\*?&#X$ZM=>.%DT^P\-:_J%]X*N?[0\0>"_BU#X?U+XARZ):0V[)>ZS]
M#?LOZ#\4O#'P%^'6A?&@6R_$BPLO$/\ ;L</_"+M?06%YXT\3ZCX0M?%%UX'
MLM.\%:G\0+7P/>>&K?XEZYX1L;;PWX@^(<?BC7-*$]OJ O+GWK YX'/7CK]?
M6EH%9=E_7_#+[@KW[X)7DUI!XD$6G7U_YDVEEC9BS(BVQWN!)]JO;0Y?)*^6
M)!A3N*G /@-?1OP%_P!1XH_Z[Z3_ .BK^@=EV_K^DCV;^V+O_H7M;_[YTC_Y
M<T?VQ=_]"]K?_?.D?_+FMVB@#"_MB[_Z%[6_^^=(_P#ES1_;%W_T+VM_]\Z1
M_P#+FMVB@#"_MB[_ .A>UO\ [YTC_P"7-']L7?\ T+VM_P#?.D?_ "YK=HH
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M58T554  'XD_\%)_^4DG_!"G_LZW]J#_ -8Y^(-?JW\:_P#D2K3_ +#6F_\
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M*YP6&>HH ^D:*Q/^$E\._P#0=TC_ ,&-I_\ ':/^$E\._P#0=TC_ ,&-I_\
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M]AK3?_2>\H ^4Z*** "BBB@ HHHH *]Q^!7_ "']:_[ T7_I<M>'5[C\"O\
MD/ZU_P!@:+_TN6@#Z?KY\^/7^H\+_P#7?5O_ $585]!U\^?'K_4>%_\ KOJW
M_HJPH ^<J**,CKGCUH ***,C&<C'KVH **** "OHWX"_ZCQ1_P!=])_]%7]?
M.5?1OP%_U'BC_KOI/_HJ_H ^@ZS[S5M+T^1(K_4;"RDD3S$CN[RVMG= 2I=$
MGEC9E# J64%<\9SQ6A7Q)^U!\-?!GC7Q9X;OO$NE/?W5GX=FL[>1;Z\M1';O
MJ<T[(4MYHT;,I+;F!8= <<5UX*."GB(QS"MB:&&Y9.53"8>GBJRDE[B5&KB<
M)!QE*RDW6BXJ[2DU9\&8SS*GA92RG#8+%8U3IJ%''XRM@<,X.:51RQ&'P685
M8RC"[BEAI*4DHN4$^9>]?%GP1\%?CI\/O$_PL^+6F>"_'7@+Q?I=WI.N^'=>
MN=+N[6X@NH)8!<VLC3_:-,U:Q,INM(UO39K35]&U".#4=*O;2]MX9T^>?%O[
M#W[#/C?P/\,/AMXD^%'P\O/ OP:MK&#X:^%[7Q#JNB:/X6N=-U'3]:L-:M;/
MP[XFT>&Z\3VNOZ99^(H/%>HI>>)8O$<;:_'JJ:O-->2?.?\ PH'X4_\ 0MR_
M^#?5/_DFO OVG!\$?V9O@SXK^+NL> +OQ'_8J)I^C:(OBZ/PS8:GXFU*RU*7
M0++7?%WB+4K/P_X/\/W5YI_V74?$FK3M';//::=IEEJ_B+5M#T74O8^K\)_]
M#7/O_#'@?+_J?^3^_P CY[ZWQ[_T(^%/_$FS9=O^J3]?O\C]+/$?[)_[)?B_
M0_&GAGQ1X6\/:[X>^(.E_#C0O%ND7OC+6DMM:T/X4>&;WPAX'TG49[+Q+::E
MJ%EIF@ZGJ5C=1ZA?W;:S#?3)K;ZB@B6.G8?L<?L3:?X#\&_#%/A+\+;SP)\/
MKW4+OP;X;UB\?7['P_;:O!IEKK&@6#Z[KFI7:^#M9M-%T:SUGP--<S>"]6L]
M'TJTU#0+FWTVRB@_(N[\8:/;_!_0/B\G[&_Q'?38_@CJWQ\^)$.H_%OP%X>T
M3PAX*T#1Y->O[7PAXTFU[5_#?Q1\3:WX?LM4\7^#M$L;KPQ:W/@ZTM-0\::]
MX%UC5K+0GV_'7Q"_9T\)>/OV7_ 6C_#7Q/XPN/VF/%/P\TA-5M=;NO#\'PK\
M._%KP/XX\:?#3Q/X]TW69#J0O?&@\ >(]+TCP3:QV_B)1HOB36;U[73O#\GV
M\^K\)_\ 0USY_P#=#P'E_P!3_P!?O\A?6^/?^A'PIT_YJ?-?*_\ S2GK][M>
MR/W6\6^&OA%X[N? ]WXOM/!_B&Y^&OC.P^(7@.74KVQF;PIXUTS1==\.V'B7
M1 MXBV6JVFA^)M?TJ&X12$LM6O8-A68X\0N_V2/V+;_PWX3\(WWPB^$%YX<\
M$S^+9/#>E7,-A-;V5KX]\5:AXW\;Z+</)J#7&K>&/%WBS5+W7_$OA/69]1\+
MZUJ<B7&H:/.;>V$/Y<?%^[^&GPX\4R>"?"'P)\2_%SQ3H?PB\1_'[QSI&@_$
M'2_"4WA;X1^&M:;PZ^I6$GB:X>+Q9XW\3ZU::[8^!? -F=*&OMX7\02ZEXI\
M.QPZ:=3]X\*_"GX%^-_"WA?QMX5TS^V/"WC3PUX?\8>&-7@U75TAU7PWXJT:
MR\0:!J<4<MPLL27^D:C9W8AF59H?.\F95E1U!]7X3_Z&N??^&/ ^7_4_\G]_
MD'UOCW_H1\*=/^:FS;R_ZI/3KOW?8_7&#7O"]K!#;6VL:#;V]O%'!!!#J.FQ
M0P0Q((XH88HYUCBBB152.-%5$10J*%  UK2]L[^(SV-U;7D(=HS+:SPW$0D4
M LADA=T#J&&Y=VX9&0,BOR6_X4#\*?\ H6Y?_!OJG_R37WC^S5X3T'P;\/+G
M2?#MDUAI[^)M6O6@:XGN2;F>#3TED\RX>20!EBC&T-M&W( ).>3&TLAA0YLN
MQV:XC$\\4J>+RS"X2BZ=GSR=6EFN,GSII<L?8VE=WG&ROZ&6U^*:F)4<WRS(
ML+@_9S;K9?G6/QV(]JN3DC[#$9#E]/DE>;E/ZQS1:24):\OT%1117CGT(444
M4 %%%% !2'H>G0]3@?B>P]Z6CKUH _&CXH_$59?VO-6\,:I^TIXCT;P;X;\;
M^%]9OO@G8:7\9],^$_B&X3Q9\%/ .I?\)5^T3HT%SKFA>*="\6?&/X83^(/@
MMX$GM?@!"/$WAU?C1I-_)XB\3:QHW[++T&/?UZYYSGD'/4=CQVKX$^,O[(O[
M+EA\6(?VJOB#!\38+VPU30EUOP?X8\3_ !3UKX:^*/%.M^,OA9)I'B'Q%\&/
M!4.MVNL:G<>,?AI\'M6UV]M-'@T;4+CX?^&]=\=VU]9:-?7]?>MK<0W5M!=6
M[;[>YABN(7VNF^*9%EC?;(J2#>C!L.JN"<, V10!^(__  4G_P"4DG_!"G_L
MZW]J#_UCGX@U^K?QK_Y$JT_[#6F_^D]Y7Y/_ /!2Z%+C_@H__P $+(9#($?]
MJW]I[<89IK>3Y?V._B PVS6\D4R<J,[)%W#*ME693^I_Q@TJTLO!]K- U\7.
MKZ>F+C5-4O8]K079.(;R\N(@WRC$@3S%&0K ,P(!\R4444 %%%% !1110 5[
MC\"O^0_K7_8&B_\ 2Y:\.KV;X+6,%]KFKI.;D+'I$3K]FO;VQ;<;U5^9[*XM
MW=<'A'9D!^8+N - 'U57SY\>O]1X7_Z[ZM_Z*L*]H_X1_3O[^J_^#_7O_EE7
MA/QNTZVL(/#9MVNSYLVJ!_M6H7]\/DCLBNP7MS<"(_,=QC"%^ Q8*N #X\^+
M>I^,='^&GC34?AW>>%+#Q[;Z-L\&7/CG4-*TKPH/$EY?V-AI<&K7^O36^@V[
MWUQ=C3]'&NS1Z%<>(KK1[36R=)N+U6_&'PS^TW^TS>?\$ROVEO'WA#XX^+(_
MV@_V>? _C?Q[XSUGXU_!OPEJ/Q5\$^')+7QOKW@2VT.[\'WA^%/CI?&3^']N
M@_$C7=)OK7PKH5EXFT";POJ^KZ)X8O(_W1U?1]'\0Z7J&A>(='TCQ#H.KVDV
MGZQH/B#2['6]"UG3KE=EUINKZ/J<%UIVJ:==1DQW5C?6T]M/&2DL;"OE^+]A
M;]D:/X-67[/<GP&\%W7P:L]3UC69/ <\GB"WTO6=5U_[9'J]]XKN-(UO2M2\
M9RWEG>R:6T?BZ]UNUCT:#3])BMTL-,T^&V /?_B=IOBRX\$>)K+POXRL/A9X
M@%A%)_PGVOZ#I^M6O@G2[>ZM+WQ+X@;1_$=S8Z U_8^%8=9ET>]\422^&-&U
M5[#7O$>GZOH>FWVE7WQ!X'UGX^>.O!WC:XT#XC?'SQ5\/7^*T=W^SMJ_A;PC
M\!_#O[5G[27P:L? 7A6U\67GA"]^+.A^ OAO%X+T7XM:UKNL^#_BK>_#_2-9
M\??"K1;&8BUT/7O#?BCQ1[YKG['O[-?B?PY-X+\2_";0/$7@>X^&US\)+GP;
MKVH>)]9T2\\ WOQ)T[XNWF@7\VI>(+K7M1MKCXA:/I/B%OM^MW)2:PAM(BFG
MO/:2VX/V2/V:X/#C>$_^%/\ AVZT$^(?^$LAM]4UCQQKFHZ?XE.E-H<FM:)X
MFUSQ;J7BWPW>W6BR2:1?_P#"-Z_I%OJ>F2/8ZG!>6SM&P!^7NE_MB?M%^-O
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MM9B"7R)S>7,TB06@@GQ!.;F2+R9R(9=DIV5.$=G$:QR-(Q"K&J,9&9@"JK&
M79G!!0*I+@@J"",@#:*K)>6<L,%Q%>V4UO=S_9;2YAO+66VN[OS)(?LEI<1S
M-!=7?GQ30"UMY);@SPS0B+S8I$6=71MP5E;8Q1]K*VQP%8H^TG8X5T8HV&"N
MC$;74D =7N/P*_Y#^M?]@:+_ -+EKPZO<?@5_P A_6O^P-%_Z7+0!]/U\^?'
MK_4>%_\ KOJW_HJPKZ#KY\^/7^H\+_\ 7?5O_15A0!\Y4444 %%%% !1110
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MHU/X5?M7_#>XN@-@ETXOI'Q=^)EK8(0LABUGR-3E4RKYFB.L($WKOP<\7_\
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M'_"'^#_^A/\ !_\ X27AK_Y54 ?BY_P5(_;9^'GB/]BOXMZO^Q!_P4Q_9_\
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M)T'_  D_QXM9[)H([?2WLO$R+X!\ FT>5E^'-UJD<DD)OV@ !^TVGV6I^#_
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MMX.\7>!1JOC*Z^'5QX?\;?9/#WB^.TUGQ/'8Z;97WB;1K[6+&[T][C>_9O\
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M !"OAO\ Z",V_P#"G#?_ #'Z_P!+4/YQ_P#AYY\*_P#HU7_@J)_XK*_:I_\
MF4K&_P"'K_P+_P"$@_X1/_AG/_@I7_PE/]C_ /"0_P#"-?\ #M[]IS_A(/[
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M3P1J?A+0=3N?M?VG4=%\-7NA3Z)I5_<?;[[S[RPL;>YF^V77F2M]HFW^PT4
M<+I?PO\ AKHG@JR^&^C?#[P1I/P]TUHGT_P+IGA+P]8>#;!X-9'B*%[/PM::
M;#H-JT6OJ-<B:#3XS'K &IH5O@)Z[K_/Y]:** "BBB@ HHHH *P?$_A;PUXU
MT#5?"OC'P]H?BOPQKEH]AK7AWQ+I&G:]H6KV,K*TEEJFCZM;7FG:A:2,B,]M
M>6TT+E%+(2H(WJ* /'_#/[/GP'\%Z'XK\,^#_@K\)?"OASQU%%#XVT'PW\-?
M!.A:+XPA@2YCAB\4Z3I6A6FG^(8HH[V\2*/6+:]2-+JY5%43RAX_&'[.WP!^
M(-IX;T_QY\$/A!XUL?!NEG0_"-GXM^&7@?Q+:>%]&*6\9TCP[;:WH-]!H>F&
M.SM(SI^EQVEH4M;=##M@B">R44 >?VOPH^%]CK?AGQ+9?#GP):>(O!>@P^%O
M!^O6O@[PY;ZUX5\,V]L;*#P[X;U6'3$U#0="@LR;6'2-)N+33HK8F".V6([*
M] HHH **** "BBB@ HHHH **** "BBB@ HHHH ***J7U_9:9;27NHW=O96D.
MP2W-U*D,$9D=8T#R2%57?(RHN3\S,%') J9SA3A*I4G&%.$7.<YR480A%-RE
M*4FHQC%)MR;223;=@+=%<I_PG7@S_H:-"_\ !G:__'*U],UO1]:69](U.QU)
M+=E2=K*YBN!"[@LBR&)FV%E!*AL$@$CI7+1S'+\14C2H8["5JLKN-.EB:-2I
M+E7-*T(3<G:*;=EHDV]$[!J4445V %%(6 ZY'&<X. /<XP/Q-+_G_/K^% !1
M110 444@((R""/4'(]/YT +1110 4444 %%%% !1110 4444 %%%% !1110
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MO)9;NUMK7RH;>ZEDN($CFD=R ?S9/_P40^-7QS\??!'X>:KXDTJWT:^^/O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 445EZWK>C>&](U+7_ !#JVF:%H6C65QJ6KZSK-_::7I.EZ?:1
MM-=7VHZE?S6]E8V=M"K2W%U=3PP0QJSRR(H) !J45\__ /#5_P"R_P#]'&?
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MBN]-U;2KV[L+VVD4I-;7$B$<Y'[2>7&>J)_WRO\ A1Y<?_/-/^^5_P * /\
M$(_:O_81^/?P'_;<U/\ 9&B_9]^+_@;QSX\\?Z59? +X/?$BU\&ZE\5_$7@_
MXG>)[C3O@Q8:A=>!=?\ $G@K6_$>KP36.@ZI>^&_$5]I!\266K6[W-I/:W=O
M:_Z2_P#P3?\ B+\>?^"=O[&7P._9/\!?\$7?V^[H?#?PG ?&_BBT\3?L16S^
M//BCKS'6?B1XYN2?VF;>Z=-?\57=^VC07_G7.D^%[70- $[V^D6^/U]^,/\
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MJ7EC;-%#)JNJ!5U&Z]?H  Z<?Y_S^'%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>restructuringchargeschart.jpg
<TEXT>
begin 644 restructuringchargeschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-?C-\0_P#A4?PA
M^*?Q4_L>3Q#_ ,*U^''CKQ__ &##=BPEUO\ X0OPKJWB;^R(KXVUX+.34_[+
M^PI=&UN1;M.)OL\^SRG^#/V?/^"COA/X@?"KPK\6/BMK7P$MK#XCV/AJ?P%X
M0_94^*/Q%_; ^("ZK>> [CXD>-?#?C3P;X"^".C>(= U?X?^$VL=4\0?V9IF
MO6MC:-=W&K3:0&T>/6/OCXO_  [M/B[\*/B;\*K_ %.[T6Q^)?P]\;?#^\UC
M3X;>XOM*M/&GAC5?#-SJ5E!=@VLUW80ZH]W;17(,$DT*),#&S5\O:M^Q5:V7
MAG]FM?A?\4==^%_Q+_9B\ W?PR\'?$K3/!_@K7VUWPAXB\%>#_!?C2Q\4>#=
M<L'\/7MUKO\ P@7@_P 4V&H6[6]UH7BCPUI3*VI>')=:\-ZR >Q_"[]J;X%?
M&SQ;KW@OX3^.8_'VK^&/#WA'Q3KUWX;T+Q-?^&-.T+X@>"?!OQ&\!WTOC1=&
M7PBY\:>"/'GAWQ)X5M(=:DO]>TQ]5FTZUG_X1[7AIWPGX9_X*\?!_P 0ZW\.
M'OOAA\8O!?@7QIJW[=^AZSK_ (P^&OQ,M_&&@WG[#?Q*\&> ?$5_I'PQT+P#
MKGBCQCX=\3V?B75_$VJ:QI21+\-8?"FN>'/&,$/BG2M?TK1/JC]DK]B[P!^Q
MVOQ(TWX<>(?$NJ>&?'+?!F#3=&\2?V;<3^&=-^"WP"^''P#T>W35;&VLYM9N
M]=TOX=6OB?7=1OK:"237M7U&.T@MM.CM+>+QK0O^"<.@:%X\;Q+;_%SQ7)X8
MTB+]NJ'P5X0/AKPU%)X=A_;^\:^'?B=\6XK_ ,2PE=0\2KX=^(FDZGJW@22^
MM+6XT_1=8C\.ZO/K":19:BX!]+>&OVO?V>_&/C?2/ 7A;Q^NO:EK]YI.D:)K
M^E^&O&%W\.=5\2Z]\/[/XK:-X,T_XKQZ ?AG=^.]4^&E_9>.[+P-#XK?Q5/X
M6NH-672?)E0'S;XR_MCO\%_B[<_!;7OAQ->^,/'WA/PYJ_[+JVWB9+>S^/OB
MV[U\>&/B!X $UQHG_%&ZK\'WO_#/Q"\?WX_X22"R^"NN:G\2K6WFM? _C#3M
M-\%_9P_X)/?!C]FWX@?#WQOX<U+0_$4_@:R\&:G)J7B7X,?"'4/B)JOQ \)_
M![P]\'+CQ%:?%J[\.WOC;PKX;U[3_#L'C&[\&>&[FRDTWQE?:FNC>*++P=?W
M/@^3[%^,W[-'ACXV?$_]GKXC^(]9U&V3X Z_\5=:M?#5K:V<FG>+X?BO\%_&
M/P5UC3-8O9-FHZ;!9:+XSOM2M;C1Y8+J6[@CMII!:RR@@')Z/^W9^S;K^CW.
ML:#XI\8>($6QT'5]$L/#_P &_C1K&M>/O#WB<ZM'H'C/X5Z!9?#Z76_BE\/M
M7GT+54LOB%X$L->\$^5;1WMQKT%A>Z==WF'>?\%&/V-;&R?4KCXT6*Z=;?#A
M_BUJE\GA+Q_-;^'O ,7C'Q[\.)]8\5&'PI)+X5N[?XE_#7Q;\,KGP[XABTWQ
M-!\2K.P^'[Z/_P );KFB:1?_ "5X8_X(Y?"?P+X2T;PGX*\8:%H-EX+NO!>G
M^$K6/]GOX%'2/%/@7P1I/B#0],\(?M%Z98^&=,N/VCTEM==LM;GNO&FK:;I2
M>/?!'@'XB6WAJ+Q;H-YJ.L>B?!G_ ()9_#_X&Z)\3O#_ (,^*7BF+3?B+\'O
M$'P>CM;OX??!N^TCP_H^O_M1_M)?M1SRP>"M3\#:E\-M5TL:Y^TEX@\"R>"]
M0\$?\(>_@;0].L+32=/N+N>6  ^]_!7QJ^'WCKP5K?Q T_4-:\.>&O"\NKP>
M*Y?B5X-\9_"75?"DF@:;!K&M-XG\/?$_0/"6O:%:Z?I5S#JDFHZCIT.F3:7(
MFIVE[<6#K<GPM/V_/V6/[$T?7KGQ[X@TZ#Q'XJ^'_@[PUI>K?"CXOZ/XI\3Z
MQ\6M.\5:I\)YO#/@W5/ EGXL\1:#\4+;P3XHB^'WBG1M%OO#GBW4]%O]%T?4
M[C6;6?3XZ/PB_8G\'^ /@3\:O@+XM\4:KXX\%_'L>,;/QEX;TS3K7X>^ /"O
MAWQS\/=,^&NO^#/@]X T"[OM.^%?A&_T;3KG7[K1M$U&ZCE\=^(O%/BN-[>;
M639V_@GPZ_X)8?#;X>0?#@:5XNTS2K[X<?'3X'_&&WOO GP1^#/PMF\6V?P"
MT/XDZ)X0\/\ CN3P'X;TJ\\4:KJZ_$_7]2\4>*[Z^*-J?[WPGX:\(6^HZW:Z
MD =+\?O^"HW[/GPH^!?C+XN?#ZXU7XQZYX:^'(^(EMX'T?PQ\2-%^RV<OQ#U
MCX566D_$OQ&?A]J]K\$]9U'XA>%_&7@K3](^)UEX?UJ[\7>#?%'A^+2S?:#J
MRV?O=Q^W%^S'8IXZNM3^)#:3I7P_T_QSJFJ^(M5\&^/]-\*Z_9_#/Q=8> /'
M_P#PK?Q1>>%8=!^+5WX0\=ZMI'@G7M-^%]_XNU&S\7ZOI7AQ;6;5-3L;>X^.
MM2_X)+^&_P#A"OC/X#\+?'_XC>$M$_:-D\>M\<#:>%O FJ7?BU=;_:&^,O[0
MO@+^RKC5;"=O"T_@?4OC7XC\!ZG-8_:1XW\"Z;HD-]'HWB*VFU^;2T+_ ()%
M? 3PZ/B/8Z+>Z?X?T_Q++KNI^ M<\,?";X1:)\5?A_XCU?XQ^'/CUI.NW_Q?
M/A6^\9_$1O ?Q'\)>'Y?!NC^*9H]#N?#=A%H7Q#L/B#/%9ZO9@'O_P -_P!M
MO1?B;;_MHZEHG@+7['2OV1M>L-#"^)(/$?@_Q)XTFN/V:OA[^T'>1:QX.\8^
M$_#_ (D^'FI:?-XY;P?)I>LV&H32#3(_$2N+?4HK"'R/X6_\%$[^'PA\"_'?
M[5/P[\$? OP9^T;\!;CX]?#;QAX+^*.O_%;0;.VT_P &>%/B%J7PV\:6FI_"
MKX<^)=/^(<GA#Q=:ZCX7M?"FB^--+\8WFC^(-!TZZM/$$6@:9XD]S^''[(3^
M$M,_:J;Q=\5O$GQ \5_M=:A8ZS\1?$ESX;\,>&8=&U2S^ ?@W]G]4\'Z#HD1
ML=/TB+PUX)TK4K/3]2N-5NXM2DNS>ZKJ7GO.WR]!_P $I=$\;_!KP1\%_P!H
MSXY^)?C5X=^#WP9T;X+_  2AMOAS\/O >D^ [/0C\.S8^/\ 5?#L4'BRP\?_
M !%\OX6>$=*FN_%,LO@UO#4GBKP['X*AL?&7B!KD ^MM5_;H_9JT31;/6-5\
M8>)[&ZN-3\5:5>>#YOA+\7S\3/#D_@/1/#_B?QW>^,_A7%X$D^(O@G0?!?AC
MQ9X4\3>)?$_BOPSI/AS3/#_BOPGJ\FJ/9>*_#LNIR:S^W1^RYX?E^(1U?XFB
MRTKX8^'?B3XF\3^*Y/"'CL^ Y[+X.>'[OQ5\5]/\(_$!?#!\$_$#Q+\.O#UA
M?ZIXQ\)^!=?\0^)=#@TW5X[O2UN-#UR'3?!/"'_!./3/AK%X:\1_"3XK1_!7
MXJZ9'\4M$UWQI\'?@9\$/ 7AW5/!/QCB^%<?C#P_I?PVL/"TWA[2M7T^Y^"?
MPTUSP=XWU>\\6>)M%US0[B+5[GQ-X3U!O"-MP>L?\$B/@G?+^T98:5K>G:#I
MOQ[\%?M/:"FM6_P;^#FH?%?PIXF_:T\.^-=%^*/B=_C3J/A:7XA>)[2VOOB%
MXOUKPOX=O=2TR.R;7+G0-:U?Q!X5M]+T73@#W_Q1_P %&/V9-(LO%-KH?B_4
M=;\:Z!=:UX=M/".H^!_B7X56Y\>Q?#B_^*/@?PAK?B#7?!$&C^#W^+GA*R75
MOA)K7B*:TTCXG6$K3?#^X\3W$36C9WPB_P""D'[._P 2?A!X$^)&M:QK/@[Q
M/XO^%_P$^(Y^&#^"OB7K/B[4_P#AH31OM7@C3_A3I4?@2QU_XY:9J.OV7B+P
MQIGB?X8^']<TN_O?#.LW-P--M;2=XN#^(G_!,CP5\1-6^)6J7_Q5\:V/_"R_
MBQ^S%\5=0MK;1_#DL6GW?[,WPKM?A9I.B6KSQF2:P\76%L-6UJYN";RQOW\O
M3&2!%KA-<_X)%_#/Q?X:\!:1\0/B7KGQ-U7X%>!?A'\,?V=M0^(GP^^&WB?0
MO '@3X/VFI6=AI/C/P1<:/#X<^+EYXYL]4DTWXB:GXBBTIK_ $_2_#TWA*V\
M&>(-,N/$&I 'W!X1_:^_9]\>^.O"?PT\'>-[SQ#XY\9^$;GQWI'ANP\%>/3J
M-EX4T_Q5XO\  FM:MXLCG\,0+X#'AOQSX&\2>!_%5EXX;P[J/A?QI:6WA+7;
M.Q\0:IIFG7?E_P :_P!KOQ+\%_C3X!^'&I?#GP/J&@?$/Q_\-/A[X4MG^.GA
MRR^//CV3Q_K^@:!K_CGX6_ *#PUJE]XL^'GP>DUN36/BMJNL^,_"6LZ-X4\.
M^-/%>GZ'>Z/X=L9O$<G[/W[#?@K]GKXG:3\2_"_B-B^G?L_6GP*;PEHW@3X?
M_#_P:H/QK\?_ !TUCQ7I7ASP!H?A_1]"NM3\4_$36+,:186'V9+""WO=0OM8
M\0W.JZUJ&C\9_P!D75/C?XPB?Q9\</&S?"2?QW\-_B7?_"]?#/@9]2TSQ-\+
M/$7A#Q9X<T[P%\4TT>V\<^!?!^J>)/!&CZSXITBUEU77;VZOO$46@>+/#%EK
M'V.T +_P#_:LO_C;\>?VF_@K?_"+Q/\ #-/V>S\(9M,UCQ?K.D2ZWX_TGXK:
M/XTU&VU^3PCI/VQ_!-A#<>"[R/2-/UO6KGQ%JNDW=CK6JZ/X:>ZBTL>R_%KQ
M?\5/#4/A?3_A%\++#XE>(_$NMW.G7=UXF\<1?#WP%X)TBST;4-3G\1>,?$5K
MX>\:^)F@N[RVL?#^B:3X3\#^)M4U'6]6M6O5T;0K75-;L?D#P9^QU^T!X$^-
M?[2GQVTW]JVTO_$W[0G@?3/#3Z,WP"\%:5I_A+6/A]X5\:^'_@YKND:D?$NM
M2W4GA"Z\8R:EK]MK>F:M9>+GT^WMY[72[.2XMY?6_P!IG]G3XK?'_P"%'@_X
M9:/^T3J?PWCMKK36^+5Y8?#O0]=L/C=H5KH;V.J^"/%>G1Z[X8U+0/!7BG66
M35_%.D^#?$6B7.NZ;$_@S4+^7PCJ6N:3JH!\QZ?_ ,%,]3\5?#W5_B5X#^ D
MFN:!\)/@3/\ M$?M'0ZG\5M!TR\\(> +7XA?&?X=A/@]/IOAO7M,^-.H:Z?V
M>OB]X]\$:I=WOPX\(>,/A[H_@_5K/Q#9WWQ!TRQTSZ-T?]K\:[^UKIO[-]C\
M*_$<7@[6OV;_ ![^T'X:^-M_K>BPZ+XWM_ GBOX):!>:-X'\(6AOM?U30YK+
MXVZ/>#QMK<WARRN-5TR^T/0]*UQ(-0U6P\Y\0_L%:EXK\.G1K_XX:EX7E\=_
M _3/V9_V@H?AG\+?A_X*\+_%7X&^'-3\=R>$/"WAOPG.GB*W^#VL>%/#'Q(\
M:>!=&\2>#]1O&M_#/B;5!'I46KV/A'5/"FQK/['WQ1N_VLO!7[2&@_M$VWA?
MPOX!^&WB7X)>'/A%IGP3\+-:6?PB\<>(_A-XI\7>'T\<OXJCUQ/$$NJ_"#PZ
MOAOQ.FF+#X;L+K4+8:!JDK0W48 ?L5_MEZK^U1]MFUJ+X Z#)/X$\'_$#1?"
MGPV^,OC3XB>.K?1?%L27"7'B'3/%'P7^&&B3:5IAN;;1+SQ/X"U_QUX:/BN+
M4-!.IQ36T<EQ[U\=/B=\6_A^E@/A?\)/#?CNWB\.^+?%WB[Q=\1?BS8?!WX<
M^#]&\(PZ;<'3+_Q+_P (IX]U>7Q/XFBO+V;1$?PM:^#]*TO0=?UGQAXPT"*U
MTJQUSQZ/]EGXOV<^N^,W_:A\6^*?C!H/P?\ '/P9^ _CWQ)\._A?9Q?#'1_'
MNK^!]<USQ1XC\/:%X<M=#^)/C34=4^&W@2;5;_4]/T;PU):^'?LNB>#= DUC
M6KJ]T?VOOV7?B)^TXG@+1=#^.J?#SX>>'+S5=3\=?"G6?A1X<^)W@#XRW[MI
MK^%H/B1IVI^(?#&I:QX7\)36M_J">!'U63P7XLU2]M+CQOHGB&TT33;! #P?
M_AYC8:QX-U'XQ>$/A%>W7P2^&OPB_9Q^,G[06O\ BSQI:^%?B%\,O#_[1OA;
M2OB#8Z5HOP^MO#OB"P\6Z_\ "WX;:YH_CWXH6>K>,O!<*:/J5MIO@6X\8>(%
MN=-@^B/!7[6%YXM_:X^*?[+U_P#"/Q1X+L?AQ\&O#7Q=T_XC^*]9T>T3QU9Z
MW\3O'OPTO3H7@^R-]J.E^%+"]\"W-]I/BWQ'J6EW7BF"ZFNK#PU:Z%:V&O:U
MP'C?]A"+XBZAKT_B?XO:_#H_QF\*?"SPW^UCX5\.^#O"NC^'_CY-\)X5M]-U
M&S2Y.K:I\+AXOTD+X)\?V7AW4]736_AW::5X>TJX\/ZOIR^*9<?Q#^POXT\;
M_M.?$[XX>/?CY#XE^'?Q=^#=[^SCXV^",7PBTKP]::A\"9M=^(7B&V\)V_Q*
MT'QO9^-M-\1B^^(^LP:CXUTW[)>WMC!:+:Z;I5^AU*@#T+]F/]L>W_:5^+W[
M1WP_TKP#/X=\(_!L?!G5_A]X]N?$*ZA+\7_ OQD\'Z[XET3QS%X:&BV,G@[2
M[R?P[J$GAFSN]5UF^\0^$;SP_P"+;E=$;6ET6TU_&'[>G[+WP\N/'47C[Q]K
M'@FW^'OA3XC>.-;U;Q9\-/BEX=T'4_"?PAO(K+XHZWX(U_5_!EGH_P 1;/P%
M)<0W'B1_ E[X@-GISOJL0N-+M[F]AYS]FS]@?X3?LM_&WXY_&?X<^(/B5<S?
M&OP]\*?#,WA3QA\3/B3X]T7PIIGPMT;4M)M(M)N/'WC;Q7?Z@^I_;HGCGU9Y
M[KPY8VIT+PY<6&B7U_93_('Q&_X(P_#?XES>,[O7OC1XR;6?$GAK]J7P=:^-
MW\!?#6[^*%WX=_:IT37=-\1P?$;XG7.DGQE\5KSP!<ZX(_AI+XDU*UTWP_X;
MTO3/#D^CWAMDU< 'W5<_MS_LV0/-8+XQ\13^)H?&VM?#^;P+!\*_BY<?$2TU
M_P />#]!^(>KWNI?#RU\"7'CC2_!UAX \5^%?&]Q\0+[P_!X(7PKXH\.:M'K
MTD>NZ5%=YGPJ_:>^('QQ_9"_9R_:0^%OP2&O^+OVC/A[\(O'6F_#Z[^(.GZ3
MX6\!6GQ/\,V7BO4-3\9_$2?09M0E\*>#=-GG2YU'PSX"U[Q-XAOSI6GZ+X1:
M;56ET_@M<_8'MV_:5^(W[5?@3XT>,? 'Q6^(OB.RFN[ZR\+^#?$.FZ9X!O/A
M)\)/A5XS\ 6NG^(;.[@N(?$#_!7P)X[TKQ)<+_:WACQAI86.+6/#-YJOA[4M
M>]_8S\7>'OV*OA#^QQ\%/VC/''PBMOA1X'^&/PQ/Q5L/#.A:WXV\4_#[X>:%
M;^'[[P_?%+_0&\.W?C?3K&TL_$'B?P;JN@^*=-M9-1/A35] U*[@U6Q /.?#
MW[?WCOX@78\ _#'X Z1XI^-WAQ?VE+[XB>#+_P",MKHG@JST;]F/XF:5\)O$
M-W\.?B(O@#4YO'MS\1/&^JG0/ARNL>$/ NEVNI^'O'&G?$;5O!.J^$;C3;_M
M-$_;\T/QG\8OV.? 7@;X4^,-2^&W[87PT\3?$[PI\:M?U+1?#NA6.GZ;\(-&
M^,6@Z)H_AF.76/$'BS5;S0-82V\57JIH?AWPAJ"P:9#K'B35Y[O3]+S=+_82
M\2:)X?\ AY)X7^.<'PP^(W@#P%XW^"=GXP^#GP1^'7@;PZ_P'\<ZIX>UN;P)
MIWPWU.Y\7Z#H>N^$=<\,V.O> _&UK?W$^C:Q=ZS+JVA>(M.UO5-+NLWQ5^P3
MXP'Q1_94\6_"7X^P_"WX>?L=>$F\#?![X62?!OPYXW@A\,ZG\/-)^%WB*P\0
M^,=8\6:=KNJM>^$]'MXM+N8;:QGTF_9[RX?6%Q;T =]X&_;!\2Z[^U#!^S7X
MJ^&GA#2M8U+0/B/XF:S\#?&SPY\4/B-\+-%\$:AX;7PUJ7[1?P]T+0+*R^$]
MA\7-#\3Z;K'PXNM.\9^-4O;F6+0M0\B]E>XMONROBOPM^R+JUK\:_ 7Q@^(O
MQP\9?%*;X/+XZ3X56.K^%? ?AK7;)?B#H<GA?5E^(GC?PCH^E:U\3X=)\-2?
MV/X?L-0M=#TDRP:;XE\4:=XJ\9:'H/B/3/M2@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK\?O^"@7Q5^)?
M@S]O'_@CK\._"'C_ ,7^%O WQE_:1_:&\-?%;PKX>\0:CH^B_$+0?#G[+7C7
MQ9H.D>+;/3YX!K.G:1XDL+/6["TNF:"#4K>*Z"&6-&7]84\.:840E;[)53_R
M&-:[@'OJ)/YDGWH Z"BL'_A&]+]+[_P<:U_\L:/^$;TOTOO_  <:U_\ +&E=
M=U_7_#K[P-ZBL'_A&]+]+[_P<:U_\L:/^$;TOTOO_!QK7_RQHNNZ_K_AU]X&
M]16#_P (WI?I??\ @XUK_P"6-'_"-Z7Z7W_@XUK_ .6-%UW7]?\ #K[P-ZBL
M'_A&]+]+[_P<:U_\L:/^$;TOTOO_  <:U_\ +&G==_Z_IH#>HK!_X1O2_2^_
M\'&M?_+&C_A&]+]+[_P<:U_\L: -ZBL'_A&]+]+[_P '&M?_ "QH_P"$;TOT
MOO\ P<:U_P#+&@#>HK!_X1O2_2^_\'&M?_+&C_A&]+]+[_P<:U_\L: -ZBL'
M_A&]+]+[_P '&M?_ "QH_P"$;TOTOO\ P<:U_P#+&@#>HK!_X1O2_2^_\'&M
M?_+&C_A&]+]+[_P<:U_\L: -ZBL'_A&]+]+[_P '&M?_ "QH_P"$;TOTOO\
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M+(OYX?M-^ /VCOV@?!FJ:-X(T?P)X$M?!/B'XN6U[X*^+MIJ'B#1_CUJ6F^
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M_P#!2?\ Y22?\$*?^SK?VH/_ %CGX@U^J7QP_P"10TO_ +#=I_Z;]0K\J/\
M@I<\L?\ P4?_ ."%CP0?:95_:L_:?V0^:D&_/['?Q !_>R HNU27P1E]NQ<,
MP-?J)\9+K49_"VG)=Z9]BB76;4K+_:%K=[G^PWX$>R%%;E26\S.P;<8RRX^7
MXU_Y)7._^P-_^G*8X[KU7YGS/1117\KB"BBB@ HHHH *^NO@E_R);?\ 8:U+
M_P!H5\BU]2_!^[U*#PBR6FE_;(O[7U!O.^WVUM\Y,.Y/*E1G^7 ^;.&SQTK]
M$\+_ /DIW_V+<7_Z=PH^C]5^4CW.BN?_ +1UO_H _P#E6LO_ (W1_:.M_P#0
M!_\ *M9?_&Z_HP1T%%<__:.M_P#0!_\ *M9?_&Z/[1UO_H _^5:R_P#C= '0
M45S_ /:.M_\ 0!_\JUE_\;H_M'6_^@#_ .5:R_\ C= '045S_P#:.M_] '_R
MK67_ ,;H_M'6_P#H _\ E6LO_C= '045S_\ :.M_] '_ ,JUE_\ &Z/[1UO_
M * /_E6LO_C= '045S_]HZW_ - '_P JUE_\;H_M'6_^@#_Y5K+_ .-T =!1
M7/\ ]HZW_P! '_RK67_QNC^T=;_Z /\ Y5K+_P"-T =!17/_ -HZW_T ?_*M
M9?\ QNC^T=;_ .@#_P"5:R_^-T =!17/_P!HZW_T ?\ RK67_P ;H_M'6_\
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MC_P'O/\ Y&H_X2?1?^?T?^ ]Y_\ (U;V![_F?\:,#W_,_P"- &#_ ,)/HO\
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M_4]!_P"$8\/?] >P_P# =/\ "C_A&/#W_0'L/_ =/\*W:*_HP1A?\(QX>_Z
M]A_X#I_A1_PC'A[_ * ]A_X#I_A6[10!A?\ ",>'O^@/8?\ @.G^%'_",>'O
M^@/8?^ Z?X5NT4 87_",>'O^@/8?^ Z?X4?\(QX>_P"@/8?^ Z?X5NT4 87_
M  C'A[_H#V'_ (#I_A1_PC'A[_H#V'_@.G^%;M% &%_PC'A[_H#V'_@.G^%'
M_",>'O\ H#V'_@.G^%;M% &%_P (QX>_Z ]A_P" Z?X4?\(QX>_Z ]A_X#I_
MA6[10!A?\(QX>_Z ]A_X#I_A1_PC'A[_ * ]A_X#I_A6[10!A?\ ",>'O^@/
M8?\ @.G^%'_",>'O^@/8?^ Z?X5NT4 87_",>'O^@/8?^ Z?X5>LM+T[3?,-
MA9V]IYVSS?(C$?F;-VS=CKMW-C/3)J_10 4444 %%%% !1110 4444 %%%%
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M$:ZGS59T9J7[RG&/*O9M/6]VK)H=]+>:?W7_ ,S]K]Z?WE_[Z'^-&]/[R_\
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M6/@KPA_8!\0?VV!XF,IO_P"TQH^A[!:_86\\ ^U:*** "BBB@ HHHH ****
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MH%>2188TC#RNTLKA%"!I9&RTDC ;I)&.Z1RSMRQJ:B@ HHHH **** "OC/\
M;*^$'[1OQN\+^%? WP2^)OP_\ >"[_4-7_X79I'BS1_B(GB#XB^%7L;>#2O!
M/ASQ_P##7QIX2\2_#O1=1NY=0?QUJ.A?\55KVC):^'_#_B/PE%=ZQ?7GV910
M!^7'BS]@?QOXFT+QKX<T+QI\(OA=X8_:,_9T^'/[,_[3G@_P3\*-6GT&'P#\
M.=)\=>%;'_AGM;SQG81> KB^^''Q!USX:QV7C+3/&6C:%IMIX5\1:1I\5[X=
MOM(\3:]U^RA^T?J?[8WC7XZW/Q'^#VA_";QC\!(_V7T\,^#/#OQ1\/?%OPW\
M+]+\6>./%^A>)?#7Q!3QQ-H6D_$BSOO&*6T6H6_A@:7IITJWU+3(H[LK$GZ8
M44 ?G5^RK^P(?V6?V@/B=\6-)^/7Q=^('@OQ?\ O@!\"O"?PZ^(>LZ1K47A'
M2O@?J_Q4O-/G?5-.\-Z$FH65EIGCZRTGP;8PVMI-H"'QE<:M=^(9?$]A_8'Z
M*T44 %%%% !1110 '..#@^N,_IQ7YJW7[*_[1/CW]I7Q+\2_CKXO^ 7Q2^$]
MV?B!X*^'OA(^#OBGH?B#X1_!OQOX>O\ POJ>E>$+,>/M0\#7/Q:\6:/<MI_Q
M"^,6KZ/<ZYJFAZCJGA#PE:>#?!MQ<Z!J/Z544 ?FU\-/V0?CG\+4\&>(;;XK
M?"OQIXW_ &>?V>I_V8OV9#KGPR\2^'_#UCX!UC7?A3?>*_%7Q@_L7QU?:OXD
M\=^(-"^#O@+1"G@:;P;X6TZ^T35-:MM(-OXLET/P_P !\$OV)?VD/AI^Q_\
M#+]ECQCXX_91^*&@_"_3$\'7?A;QU^SYXG\9?"GXL^";<6.H:3)XY\+^*?B%
M>ZMHWBWPWXJMWU_2;O1=3U'PY<QK]AO_  ^UZ=.UK1/UDHH \+_9I^#-S^SY
M\#_A_P#!Z[\::IX_F\$:7>Z>/$FJ6TM@C07FMZIK%KH>@Z3<:GK=QH'@KPC:
MZE!X0^'_ (:N=<URY\,^!=!\.>'[C6]8FTU]2NO=*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
F*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>rituxan.jpg
<TEXT>
begin 644 rituxan.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0!<17AI9@  34T *@    @ ! ,"  (
M   6    /E$0  $    ! 0   %$1  0    !   7$E$2  0    !   7$@
M  !0:&]T;W-H;W @24-#('!R;V9I;&4 _^(,6$E#0U]04D]&24Q%  $!   ,
M2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M245#('-21T(               $  /;6  $     TRU(4" @
M                                                   18W!R=
M 5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA9
M6@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P
M9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@
M   4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P
M!#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@
M2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#
M-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                         %A9
M6B        #S40 !     1;,6%E:(                     !865H@
M    ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@
M   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                        9&5S8P         N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M           N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A
M8V4@+2!S4D="                             &1E<V,         +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y
M-C8M,BXQ                                  !V:65W       3I/X
M%%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE
M87,          0                        */     G-I9R      0U)4
M(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!*
M $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +<
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MCPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N
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M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R_\  $0@
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M,"#P?4'U![BK_LZ,H7C*_P"1'UZ2E:4;'UA/J%E:S1PW%Y;PRR?<224*S=N
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MCF?;\O\ ,.5=_P RQ15?[/+_ ,_L_P#WRG_Q-'V>7_G]G_[Y3_XFCF?;\O\
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HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>sellinggeneraladminchart.jpg
<TEXT>
begin 644 sellinggeneraladminchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M7_SSUK_P7Q?_ "71_P +O\%_\\]:_P#!?%_\ET?ZX<+_ /0\R[I_S$0ZV_\
MDE^('L%%>1P_&KP=/-#!''K)>>:*!,V$8&^:18D+'[4<*&<;C@X&3@]*]<KT
M\OS?+,V5666XW#XQ4'!570J*:INHI.'-;;F4)V[\K[ %%%%>D 4444 %%%%
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MTM?_ "T\O)J]K-^VZ6<ZCIIX.;^P.1T.;R#I[5^A=?GIIHSJ%@H)7-]9*&7
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MOO,V;?MKVK>5MW9\O[-:6N-^X;]^_P"ZNW;SD OT444 %%%% !1110 4444
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MKNF7VK>)?@/I&BK%X*^#VJ^&=-U"'4? -\L,]/\ X)F1ZKHG[#_[._P[\1^
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M(4_]G6_M0?\ K'/Q!K]4OCA_R*&E_P#8;M/_ $WZA7R_&O\ R2N=_P#8&_\
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MI0-N4D-OH\$X4]S%-&_HXKXP;J?J?YU]Q_$7_D1O$_\ V";C^2U\.-U/U/\
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M_P!]#_&OE7_AQ_I7_25'_@LQ_P")IZ#_ /.:H_X<?Z5_TE1_X+,?^)IZ#_\
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MN-:M;N]T>#6&M)AI<VJV=A=Z??76FQ7QMWO[:ROK*[GM%FBMKNVG>.>/5HH
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' **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>stockperformancechart.jpg
<TEXT>
begin 644 stockperformancechart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '@ F4# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYK'5OM6F^*O!_BK1;NU\JPL=2U0 ^A:**3(]_P C_A0 M%%% !1110 4444
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MB@#!_P"$;TOTOO\ P<:U_P#+&C_A&]+]+[_P<:U_\L:WJ* , ^&]+]+[J/\
MF,:UZC_J(USGA#1[34/#FE7EY)J,]S/;L\LTFLZTSR,)YDW,?[1&3M4#H.E>
M@GI^*_S%<EX$_P"13T7_ *]7_P#2JXH T/\ A&]+]+[_ ,'&M?\ RQH_X1O2
M_2^_\'&M?_+&MZB@#!_X1O2_2^_\'&M?_+&C_A&]+]+[_P '&M?_ "QK>HH
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M;;>NPKC]9_Y&OPA_N^(__3;;T =A1110 4444 %%%% !1110 4444 <AHO\
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MAI'_ "-GBS_KAX;_ /2*_KKZY#2/^1L\6?\ 7#PW_P"D5_0!U]%%% !1110
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M.E2I4XN4ZE2I-J,(0BG*4I-1BDVVDCK]%_Y&?QA_UUT#_P!,XKKZ_GS^$/\
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MY+P)_P BGHO_ %ZO_P"E5Q76GI^*_P Q7)>!/^13T7_KU?\ ]*KB@#KJ***
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MN_\ @M/_ ,?H_MT_] ?7?_!:?_C];V!Z#\A1@>@_(4 8/]NG_H#Z[_X+3_\
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MANP3^R=;?#ZA\R:=E3G5+YN#YXR1G!XX(KJO[=/_ $!]=_\ !:?_ (_6=X%
M_P"$7T[@??U'M_U%K^NOP/0?D* ,'^W3_P! ?7?_  6G_P"/T?VZ?^@/KO\
MX+3_ /'ZWL#T'Y"C ]!^0H P?[=/_0'UW_P6G_X_1_;I_P"@/KO_ (+3_P#'
MZWL#T'Y"C ]!^0H P?[=/_0'UW_P6G_X_1_;I_Z ^N_^"T__ !^M[ ]!^0HP
M/0?D* ,'^W3_ - ?7?\ P6G_ ./T?VZ?^@/KO_@M/_Q^M[ ]!^0HP/0?D* /
M./&FLF7PUJ4?]DZVFY;0;GT["C%_:'D^><9Q@<<UU UT_P#0'UWJ?^8:?4_]
M-ZH>.@/^$6U3@?=M.W_41LZZT 8Z#JW8>IH PO[=/_0'UW_P6G_X_1_;I_Z
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M_>J5)7Y*5*"O.M6J-6IT:49U:DO=IPE)I'TR=>(&?['U[\-,)/Y"<FOYM?\
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M_'/X??'[X3? _P"('QO^*'QG^%.A_#"/XA_#&\^)=GX,MM2M]6\0>)-<\/\
MBE-2O_ ?AKPCH_C'6- BT'1;.T\2:UH<?B33M.UM[&2>2*_:\O\ X3_X)7^.
MOB1X"_X*#?LK7GPPO-2@UGQ3\7?"O@+Q)8Z=)((_$/P]\57GV+QWHVLP)F.]
MTBV\-+J/B%UNE>+3;O0[;6H6@N-/2=/T7!>&E'%\,RSJ.<*6)GA*V-H1IT6L
M&Z5)3E&G5G65.NIRC3:J5'&$:$Y2BZ=6-/GG^58_Q;KX+BZ'#T\B<,+#'8;+
ML5.K73QZKUY4H2JT8475P\J<)54Z5/GG+$4U&2JT95.2'^D[12#H._'!]1V/
MXCFEK\G/VP**** "BBB@ HHHH **** "BBB@ HHHH **** "OSN_X*[?\HJO
M^"D__9B'[67_ *HSQQ7Z(U^=W_!7;_E%5_P4G_[,0_:R_P#5&>.* /4_^"?/
M_)AG[$__ &:/^S7_ .J6\$5]?5\@_P#!/G_DPS]B?_LT?]FO_P!4MX(KZ^H
M**** "N0TC_D;/%G_7#PW_Z17]=?7(:1_P C9XL_ZX>&_P#TBOZ .OHHHH *
M*** "BBB@ HHHH *0]/Q7^8I:0]/Q7^8H Y'P)_R*^G?[^H_^G:_KKZY#P)_
MR*^G?[^H_P#IVOZZ^@ HHHH **** "BBB@ HHHH Y'QU_P BMJG^[:?^G&SK
MK1T_%OYFN2\=?\BMJG^[:?\ IQLZZT=/Q;^9H 6BBB@ HHHH **** "BBB@
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M]E:I_P!#'??^ &B__*^C^RM4_P"ACOO_   T7_Y7T ;U%8/]E:I_T,=]_P"
M&B__ "OH_LK5/^ACOO\ P T7_P"5] &]16#_ &5JG_0QWW_@!HO_ ,KZ/[*U
M3_H8[[_P T7_ .5] &]16#_96J?]#'??^ &B_P#ROH_LK5/^ACOO_ #1?_E?
M0!O4AZ?BO\Q6%_96J?\ 0QWW_@!HO_ROI#I6J?\ 0QWW4?\ +AHOJ/\ J'__
M *J ,_P)_P BOIW^_J/_ *=K^NOKS?P5INI2>&]/=-?O(E+ZAA%L-'*KC5+X
M'!>P9CN(+'+$ DXP.!U7]E:I_P!#'??^ &B__*^@#>HK!_LK5/\ H8[[_P
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M7_Y7T ;U%8/]E:I_T,=]_P" &B__ "OH_LK5/^ACOO\ P T7_P"5] &=HO\
MR,_C#_KKH'_IG%=?7F^D:=J3>(_%B#7[Q6270]SBPT?=)NTH,NX&Q*KL'RC8
MJ\=<GFNJ_LK5/^ACOO\ P T7_P"5] &]16#_ &5JG_0QWW_@!HO_ ,KZ/[*U
M3_H8[[_P T7_ .5] &]16#_96J?]#'??^ &B_P#ROH_LK5/^ACOO_ #1?_E?
M0!O45@_V5JG_ $,=]_X :+_\KZ/[*U3_ *&.^_\  #1?_E?0!O45@_V5JG_0
MQWW_ ( :+_\ *^C^RM4_Z&.^_P# #1?_ )7T ;IZ?BO\Q7)>!/\ D4]%_P"O
M5_\ TJN*OG2M4_Z&.^ZC_EPT7U'_ %#_ /\ 57+>"=-U*3POH[IK]Y$K6S8C
M6PT@JH^T3C 9[%W/3/S,3GZXH ](HK!_LK5/^ACOO_ #1?\ Y7T?V5JG_0QW
MW_@!HO\ \KZ -ZBL'^RM4_Z&.^_\ -%_^5]']E:I_P!#'??^ &B__*^@#>HJ
MA8VEU;>;]IU*?4-^S9YUO90>5MW;MOV.WM]V_(SYF_&T;=N6S?H **** "BB
MB@ HHHH **** "BBB@ K\[O^"NW_ "BJ_P""D_\ V8A^UE_ZHSQQ7Z(U^=W_
M  5V_P"457_!2?\ [,0_:R_]49XXH ]3_P""?/\ R89^Q/\ ]FC_ +-?_JEO
M!%?7U?(/_!/G_DPS]B?_ +-'_9K_ /5+>"*^OJ "BBB@ KD-(_Y&SQ9_UP\-
M_P#I%?UU]<AI'_(V>+/^N'AO_P!(K^@#KZ*** "BBB@ HHHH **** "D/3\5
M_F*6D/3\5_F* .1\"?\ (KZ=_OZC_P"G:_KKZY#P)_R*^G?[^H_^G:_KKZ "
MBBB@ HHHH **** "BBB@#D?'7_(K:I_NVG_IQLZZT=/Q;^9KDO'7_(K:I_NV
MG_IQLZZT=/Q;^9H 6BBB@ HHHH **** "OS#_:S^+WQ&^.?Q1/[ /[+GB.^\
M,^.=8T/3-?\ VJOCOH9+-^S%\$_$#.L&F:'>A'M4^/\ \8=/BO=+^&>CN_VS
MPOH1U+XB:A!!;6NC3S>I_MH?M/\ BGX3VO@[X'? #2-.\=_M@?'^34M$^"O@
MJ]W3:'X3TO3T1?%OQU^*3PASH_PG^%MM<1:AJLT^R?Q5K[Z3X,T2.YO]3N#9
M^E?LF_LO^%OV5OABW@_3-8U3QQX[\6:W?^/_ (S_ !=\4".7QK\8_BSXB$4O
MBOQ]XIN4'R27LZ)8Z!HL)^P>%_#-EI/AW35%M8>9+[F#IT\NP\,UQ4(SKU7+
M^R,+4BI1J3IR<99CB*<DU/"8:I%PH4YIT\7C(.$U4H8;%4I_/8ZK4S7$U,FP
MDYT\-1Y/[:QE*3A*G3J052&5X6K%WAC,73E&>)J0:J8+ SC.$J6(Q>$K0]3^
M#GP@^'GP#^&'@GX._"GPU8>$?A_\/]"M/#WAG0=/4^7:V5L&>6XNKA\W&HZM
MJ=Y+<ZIK>L7KS:CK6L7E]JNHSSWMY/*^YK/_ "-?A#_=\1_^FVWKL*X_6?\
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M/&">=IWB>Z@U#PGJ_A1[NT@UFTU>\U$ ^P*_.[_@KM_RBJ_X*3_]F(?M9?\
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M: -VBL+_ (2?P]_T&+#_ ,"$_P :/^$G\/?]!BP_\"$_QH W:*PO^$G\/?\
M08L/_ A/\:/^$G\/?]!BP_\  A/\: -VBL+_ (2?P]_T&+#_ ,"$_P :/^$G
M\/?]!BP_\"$_QH W#T_%?YBN2\"?\BGHO_7J_P#Z57%:!\3^'O\ H,6'4?\
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M (UR.B_\C/XP_P"NN@?^F<5U] "8'O\ F?\ &C ]_P S_C2T4 )@>_YG_&C
M]_S/^-+10 F![_F?\:,#W_,_XTM% "8'O^9_QHP/?\S_ (TM% #2/KU'\1]1
M[UR?@7GPIHI))_T5NY_Y^;@>OH!76GI^*_S%<EX$_P"13T7_ *]7_P#2JXH
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MG:R6-S^UG\2=!O,/%\2?B1IDTB?"C1KZVCD^''PYN;;4XU_X27Q)<WL/ZO@
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MB@ HHHH **** "BBB@!#T_%?YBN2\"?\BGHO_7J__I5<5UIZ?BO\Q7)>!/\
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M/&\,RI(K* #?K\[O^"NW_**K_@I/_P!F(?M9?^J,\<5^B-?G=_P5V_Y15?\
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M"B@#G_\ BIO^H'_Y4Z/^*F_Z@?\ Y4ZZ"B@#G_\ BIO^H'_Y4Z/^*F_Z@?\
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MXVNH_'_XU:/J.V=/]3)=^"_@OX.O8R&>RU9&V2U^+_\ P3:_X()>)O@O\;?
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M;@MD$,T_BBZUB5R#D@LY.6;^^^[X_BKCC%Y]Q!F6=<*+*,1DF9UJ>-RS-_\
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M39&.)2;D3"5 #][J*_&O_AJ__@L__P!(COV=?_%H^A?_ $)='_#5_P#P6?\
M^D1W[.O_ (M'T+_Z$N@#]E**_&O_ (:O_P""S_\ TB._9U_\6CZ%_P#0ET?\
M-7_\%G_^D1W[.O\ XM'T+_Z$N@#]E**_&O\ X:O_ ."S_P#TB._9U_\ %H^A
M?_0ET?\ #5__  6?_P"D1W[.O_BT?0O_ *$N@#]E**_&O_AJ_P#X+/\ _2([
M]G7_ ,6CZ%_]"71_PU?_ ,%G_P#I$=^SK_XM'T+_ .A+H _92D/3\5_F*_&S
M_AJ__@L__P!(COV=?_%H^A?_ $)=(?VL/^"SP'/_  2._9UZJ.?^"H^A#DL
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M_P"&K_\ @L__ -(COV=?_%H^A?\ T)='_#5__!9__I$=^SK_ .+1]"_^A+H
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M'6F^$M ^!MIXHUB]\:^$%\8_$W4_$?Q<^(.G^!O'>GV'A'1/ O@*+QOTFE^
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M._ ,<.B:[XN\4K=_O3@?3KT)'7KTI: &1 B.,$$$(HP>#P .1V/J.QXI]%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5Y\2[F[\2^.=1^('CKX5Z+\$[;7;;Q#>:=X6\/\ @V#1O&'B=?!9U35)IK,
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MU3Q)X=T2ZT&RUG7M%TB\\4ZP?#WAFTU/5+&PN?$6OC2=4U\Z'H5O=SPRZOK
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M=*G6I^SC.\HRJ^]S-IQH\[3LUSJ,9?$K_O717Q?\)OB=^T;\7_ NC>.O#+_
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MAV:36])-YIB1:]HLC7035;!KCEM0^-WP:TGP)IGQ2U7XM?#+3?AGK36RZ/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>tecfidera.jpg
<TEXT>
begin 644 tecfidera.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !2 7(# 2(  A$! Q$!_\0
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M.BJO:4XJ75HYW5]=U/Q7JBF>1W:1]L,(.%3/8"NMM/A',]INNM2BCG(SL7D
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$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>tecfiderachart.jpg
<TEXT>
begin 644 tecfiderachart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
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M"\'?LH_$[XB_M?\ Q!35;SP'/\2/&OAOQIX.\!_!/1_$&@ZO\/\ PHUCJGB
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MQ^T7\<O%'QK\._!_X,Z/\%_@G#%\._AWX%TGP%9:&?AVUAX^U+P[!9^*-/\
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M[S5_$%SJNM:AH_&;]D;4OC=XOC?Q9\</'+_".X\=_#?XEZA\+$\.>!7O=/\
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M>ZSX(@^'GA/XC>.=:U7Q;\-/BCX=T+5?"?PANXK/XHZYX(UW5_!MGI/Q$LO
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MID9XQGCKQD?F* .?_LW6_P#H8'_\%.G4?V;K?_0P/_X*=.KH:* .>_LW6_\
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M;M;V6?3M-^R_.O\ PEOA/_H:O"__ (4FB?\ R?1_PEOA/_H:O"__ (4FB?\
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M?=&]'$X?$<WU>O1K\EN?V-6%7EYKVYN24N6]G:]KV=MF;]%8']FZS_T,+_\
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M\J*/[+U+_H9-4_\  30O_E17\B']6FY16'_9>I?]#)JG_@)H7_RHH_LO4O\
MH9-4_P# 30O_ )44 ;E%8?\ 9>I?]#)JG_@)H7_RHH_LO4O^ADU3_P !-"_^
M5% &Y16'_9>I?]#)JG_@)H7_ ,J*/[+U+_H9-4_\!-"_^5% &Y16'_9>I?\
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M_P"IGH=?Z4"]#_O/_P"AM7^:_P##/_DI?PU_[*1\/O\ U,]#K_2@7H?]Y_\
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M:X>Q\-V?AKX>W_C/3;+5/ =CXM_M;7=(\+:_%9P6MY?7/R#8?%F?2&M+W2/
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M]#)JO_@)H7_RGI/[,U#_ *&/5O\ P#T/_P"4U?R(?U:?!W_!3?XW_M ?L_\
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MI^TC_P!A/X??^JF\!U^'_1:_Y+S.O^R1QO\ ZN<B/V?Z3'_)$9/_ -E5A/\
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M="B?5KV\N=!L8EN_#MSINJE[UOFBO?RB.<QEFCSAX9\^9RJ9<L-6]K3IY=+
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MOLZ+#<B]D\Z5I\1'_$U?#_\ T2F=?^%F!_K_ (9^5S_B6+/?^BIRC_PCQO\
MF_Z3\K_@'17]2'_$+Q^P=_T7_P#X*'?^)=ZQ_P#,91_Q"\?L'?\ 1?\ _@H=
M_P")=ZQ_\QE'_$U?#_\ T2F=?^%F!_K_ (9^5S_B6+/?^BIRC_PBQO\ G_5G
MY7_EOK^S/_@@WQ^PO)D'_DM_Q3['^]X>]O8_D:^7/^(7C]@[_HO_ /P4._\
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M_P 2Q9[_ -%3E'_A'C?+S]?N]#^?ZBOZD/\ B%X_8._Z+_\ \%#O_$N]8_\
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MG#PG3I36,Q^)QD5&%2\TX1KJ$KO646UHT?:M%%%?!GVX4444 %%%% !1110
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ME^,OA3H_P&^'?[2_QK\7*WA'0K[X)_"'XH/XN/A[5-:\+:GXA.K>,M?TC3/
M'CCQ;XNT#P0^J+I7@CPU)X@TC4_$<_B#P=I/B3W?P9^UMX7\<?M4?$']EO3/
M _Q!T[5?A]\)]"^*DGC_ ,1:*/#_ (/\66>L>/O$/P]N=-\$VVJ26_B37[;2
M-9\.W/G>+ETBW\':T)D3PGK'B".WO;FW /K*BOD?X&?M=^$_CW\=?VAO@QX4
M\,:_;6/P(T+X2^(+/XC7MWH\OA7XI:9\4-8^,'AB74_ MM9W4VKOHGAGQ?\
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M=?Z?<0ZE?SA=2M%L?'MGI7A/33IMD?!L%KXJ>&\U3_A,YX]+_0FBB@ HHHH
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MQQXJ74_&MU8Z)'IOB5=(L/#_ (4N+GR[_P .>'/#D)O+&[ /T/HHHH ****
M"BBB@ HHHH **** "BBB@"E_9UA_SY6G/)_T6WZGJ?\ 5=ZDBLK2%Q)%;6\<
M@! >."%' (P<,B*PR.#SR.#5FBJYI/>4OO?^8N6.]E?O9?UT04445(PHHHH
M**** "BBB@ HHHH **** "HWBBDQYD<<F,XWHKXSC.-P.,X&<=<"I**$VM4[
M/NA-)Z/5?Y:D'V6V_P"?>#_OS'_\34RJJ@*JA548"J   .@ &  /04M%-MO=
MM^K;!12V27]6_0****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
C **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>tysabri.jpg
<TEXT>
begin 644 tysabri.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !W -@# 2(  A$! Q$!_\0
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M)T!2444 +2444 +2444 +2444 +1110 E+110 E+110 4E%% !1110 M%%%
M!4%X\J6<S6Z!Y@AV*3C)[444UN)['/>!M->ST^>XG&)KB0YYS@+D?SS1116E
..>3E4DV8X:"IT8Q78_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>tysabrichart.jpg
<TEXT>
begin 644 tysabrichart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
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M"\'?LH_$[XB_M?\ Q!35;SP'/\2/&OAOQIX.\!_!/1_$&@ZO\/\ PHUCJGB
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MQ^T7\<O%'QK\._!_X,Z/\%_@G#%\._AWX%TGP%9:&?AVUAX^U+P[!9^*-/\
M'WQ%$?PL\(Z5+>>+)+GP<WAM_%/AV/P5#8>,O$1O #ZSU3]NG]FK1=$M-8U7
MQ=XILKNXU/Q5I5[X-E^$GQ?;XF^&YO 6B>'?$WCN]\9_"N'P++\1/!6@^"_#
M'B[PGXF\2>)O%/AK2O#NG>'_ !9X2U9M4DM/%?AR35'ZS^W5^RYX?E^(3:O\
M3/L>E?#'P[\2O$OB;Q8_@_QV? =S9_!OP_>>*OBQIWA#X@+X9/@KX@>)OAUX
M>T^_U3QAX3\#:]XA\2:+#INL1W.F"YT'78=,\(\(_P#!.+2?AM%X9\0_"7XJ
M_P#"E?BIID7Q1T/7/&OP<^!_P,^'_A_5/!/QCC^%D?C'P]IGPVTSPA)X:TG5
M+"Y^"GPUUSP=XUU2?Q3XHT37=#G35KOQ-X5U!_"4'!ZQ_P $B?@E?#]HNQTK
M6['0=-^/G@O]IW0?[9MO@Y\&+[XK>%?$O[6?AWQIHOQ1\3M\:]0\(S?$;Q/;
M6U]\0O%^M^%O#NH:MI\-B^N7>@ZSJFO^%;?2]$TT ]\\4?\ !1C]F;2++Q3:
M:)XMU/6O&F@W>M>'+7PGJ7@7XF>%$N/'J?#B_P#BCX$\(:YXAUSP1!H_@]OB
M]X2LEU;X1ZWXAFM-)^)UA*9O %QXEN8C9MG?"+_@I#^SO\1_A!X$^(VN:OK7
M@WQ1XP^%_P !/B-_PK!_!/Q,UCQ=JI_:$T47?@BP^%&E)X$L-?\ CEI>H:_9
M^(O#&G>)_AGH&MZ7>7GAG6+JZ&F6EI-)'PWQ#_X)D>"/B)JWQ*U34/BIXVL?
M^%E?%C]F/XJZC:VVD^')8K"\_9G^%EM\+-'T6U>>$R2Z?XML+8:MKEQ<$WEE
M?L8]+>.W50.$US_@D7\+_%WAGP'I'C_XDZ]\3=5^!?@;X1_#']G?4?B-X ^&
M?BK1/A]X#^#]GJ-EI^D>,/!%WH,?AKXMW?CFSU673?B+J?B:#3I-1T_2_#TO
MA2#P9X@TN;Q!J(!]N^$/VP/V??'WCOPG\,_!OC6^\0^.?&?A&Y\=Z3X<L/!'
MC[^T+'PGIWBOQ?X#UO5O%J7'AB!? 0\->._ OB3P/XKL?'#>'M2\,>-+2U\)
MZY9V/B#5-,T^[\P^-G[7?B;X+_&KP!\.-2^'7@34-!^(?Q ^&GP]\*6DGQT\
M/6/QZ\?2>/\ 7] T#Q!XY^%OP$@\,ZG>>*OA[\'7UN76?BMJFM>,_">LZ1X3
M\.^-/%5AHMWI/A[3Y/$LO[/_ .PWX(_9[^)VD_$OPMXCD,FG?L_6GP*;PGH_
M@;X>^ /!H0_&KQ_\<]7\5:5X;^'N@>'-&T*[U+Q3\1-8LQI&G:<+6/3X+>\O
M[S5_$%SJNM:AH_&;]D;4OC=XOC?Q9\</'+_".X\=_#?XEZA\+$\.>!7O=/\
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M>ZSX(@^'GA/XC>.=:U7Q;\-/BCX=T+5?"?PANXK/XHZYX(UW5_!MGI/Q$LO
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MH6D>+]-MI$M]=T[2/$=A::UI]I?+)#:ZG!%>1H)XHW7]>8R2B$\DHI)]20*
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M\:_'WCOQ!X@U;QQ<:D=5U3PVWAB_T6U\/>+=2LCHB6!L- T<:?%:)I<'N_\
MP\Q^")Q_Q2/Q/X_ZA7AG_P":O_)P>H%,_P"'EOP.R6_X0[XF;CGYO['\+YYZ
MG/\ PE6>>_K7T7_$-^.?^B:S'_P&E_\ +3P/^(@\&?\ 108#_P "J?\ RO\
MJS\K_%W[7_PE^+7[1F@?%_6?@7\/OCAX=O?^"A/[(7PS^&>N:9X^^$7@#5H_
MA_JVBR_$)O ]Y>_$2^^,<<O[.VO_  VC^)%UXQ^(T&K_  ]^*.CZHEGINJ?
M^63XN)JT=S[-?_!WXKZE\3_$7PN\&Z7^U[H?@WQU\0OVAX/V@?\ A,_%/PMT
M[X$:M\$?B]X>^+>I7FK?!/5O#$D-[I7Q$\1_$OQ/X4\2^ ;NSBC^)7@ZXO\
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M;4]1T[3(/"?Q,2?4M0L--@>72O#8B2;4+R"RA>4KXI9Q$DDZM*41W$88JCL
MI_0L<_K^AQ7A9SPYGG#\L/'.LMQ&72Q2JRPZQ"@G55%P55QY92^!U:=[V^)6
MN>UE.?Y-GJKRRC,*&.6&=-5W1<G[)U5-TU+FC'XO9SM:_P +\KE%%%>*>P%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?B!_P4G_Y22?\
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MA@?_ ,%.G4 =#17/?V;K?_0P/_X*=.H_LW6_^A@?_P %.G4 =#17/?V;K?\
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M;63>N/F_=;>?E8X-?AC7[P_\$XO^3=F_[*#XQ_\ 0M+K\_\ &_\ Y(E?]CC
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M90ZTMF=)DN+55*)?C3M:%[]F.?WGV8B;'*]"*_+(_P#!37XR D#P)\,>"?\
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M9>._C_JOC>P\4>$-"M(O#&FZ#>69\(1WBS22:K=ZK!.+[^WM<>/RE2PB-O\
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M*HS^QU\00,LQ &20!SR2 ,D@5]0_\%*;BWF^!_@Y8IX)67XEZ.2L4T<C ?\
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M'\Q!1110 4444 =!X2_Y&WPG_P!C5X9_]/NGU_5N.GXM_,U_*1X2X\6>%"2
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M:6MKYFWS/LUO#!OVYV[_ "D3=MW-MW9QDXQDY_(#_@E[_P C-\8?^P#X*_\
M3GXDK]BJ_C_QB_Y+_.?^O65?^JC ']5^%'_)#93_ -?LS_\ 5GBPHHHK\P/T
M8**** "BBB@ K,UJWN+S1]5M+3R1=7.FW]O;?:+B]M+?[1/:310^?=:;)#J-
MO#YKKYL]A+%>0INDM9$N%C<:=(<X..N#CZ_CQ0!_/;9>$+GPS^TQI7@SP?I?
MBWQC9_#OXE_"[PYXUU7PGXP_X+"_%CP_X6\8G3O WB/Q3H6M^-K+QWKOP*:Y
MTJ37%U*;3O%%]J/A_1_#]_I,'Q(C@?\ MZPB_H2']3Z^I]?_ -7IQBORGU_]
MG[XYK^U3XU^(#_#KQ5XT\'^)OBQX)\3Z+XNTS_@H+\8O@=I?A[PIH^A^#='E
MTVZ_9L^%_@K2_AYXNCT.YT75M2F3QAJNO:Y\18KZ31?%NN?V1%IEI9?JP/ZG
MOGN?\X[=.U 'X@_\%)_^4DG_  0I_P"SK?VH/_6.?B#7._\ !P+_ ,F@_"S_
M +.'\+_^JY^)-;O_  4NCDE_X*/_ /!"R.*>2V=OVK?VGML\20O(F/V._B 3
MM6XBFA.X H=\;85B5PX5AR7_  7ZL[NW_9%^%SW&KWE^C?M"^&%$5Q;Z9"BL
M?AW\2") UE8VTFX %0I<QX<Y0E4*_I7@]_R<[@S_ +'%/_TS6/SOQ9_Y-QQ;
M_P!BM_\ J10/Y&****_T^/\ -L**** "BBB@ K^S/_@@U_R8O)_V6_XI_P#H
M7AVOXS*_LB_X(2V5Y<?L-R/!K%[8)_PNWXI#R;>WTN5"0WA[+[[RPN9@QSR!
M)MZ848%?S[])?_DVJ_[*+*?_ $SCS]W^CK_R<.7_ &(,R_\ 4C+S]M6Z'Z'^
M5?PD_P#!77_E(I^TC_V$_A]_ZJ;P'7]S1TO4L'_BI=4Z'_EST(_^XBOX7_\
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M/)#9VT%M$TA2")(U50 ?B?\ \%)_^4DG_!"G_LZW]J#_ -8Y^(-<[_P<"_\
M)H/PL_[.'\+_ /JN?B371?\ !2?_ )22?\$*?^SK?VH/_6.?B#7._P#!P+_R
M:#\+/^SA_"__ *KGXDU^E>#W_)SN#/\ L<4__3-8_._%G_DW'%O_ &*W_P"I
M% _D(HHHK_3X_P VPHHHH **** "O[,_^"#7_)B\G_9;_BG_ .A>':_C,K^S
M/_@@U_R8O)_V6_XI_P#H7AVOY]^DO_R;5?\ 9193_P"F<>?N_P!'7_DX<O\
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MA,5PGQ!+$X:E6E'B*48RJ04FE_9N7RLF^E];=SP/I)8W&87BK(XX;$UJ,99
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M[(OPN2XTB\L$7]H7PPPEN+C3)D9A\._B0!&%LKZYDW$$L&*"/"'+@L@;LO\
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M/\^OI"_\G6XA_P"O&1_^J'+#^\/ 7_DU^0?]A&=_^KO,"W1117XH?L04444
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M%_\ ^"AW_B7>L?\ S&4?\0O'[!W_ $7_ /X*'?\ B7>L?_,97]9_\35\/_\
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M:OA__HE,Z_\ "S _U_PS\KG_ !+%GO\ T5.4?^$6-_S_ *L_*_\ +?7]F?\
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M]%__ ."AW_B7>L?_ #&4?\35\/\ _1*9U_X68'^O^&?E<_XEBSW_ **G*/\
MPBQO^?\ 5GY7_FE^&?\ R4OX:_\ 92/A]_ZF>AU_I/J>#U^\_P#"?[Q]J_G!
MMO\ @V!_87LKFVO;+]H?_@HK9WEE<V]Y9W=M^V!K<%S:7EI/'<VEW;3Q^#ED
M@N;6YBBN+>>-EDAGCCEC9716'TU_PY6\.CI_P4S_ ."SO<_\I'_BIW.3_P P
M?UK\+\8O%+ >)E;(*N!RK&98LGIYE"K'&5J%9UGCI8&473='2*I_5)*7-NY*
MVB9^T^$OAGCO#FEGE/&YIA,R>;5,OG3>%HUJ/L?J<<7&:J>VOS.?UF/+R[<L
MK]#Z]_X*9G/[ W[6'!_Y(QXK['_GG;^U?P)O]]O]YOYFO[$/%'_!"SX;>./#
M^K^$O&G_  42_P""P?BWPKK]E+INN^&_$?\ P4-^).LZ%K6G3[?/L-5TN_T*
M>SO[.;:HEMKF&2*0 !T(KY]/_!KQ^P<22?C_ /\ !0XD\DG]KO6,D^I_XHVO
M9\(?&7+/#;)<SRO'9-C\SJ8_-'CX5<)7P]*%.#PF&P_LY*M[SES4)2NM.5I;
MGD>*WA#F/B'G.79G@\XP.74\%EJP,J6*P^(JSG/ZU7K^TC*BU%1Y:JC9^]>+
MZ6O_ "WT5_4A_P 0O'[!W_1?_P#@H=_XEWK'_P QE'_$+Q^P=_T7_P#X*'?^
M)=ZQ_P#,97ZW_P 35\/_ /1*9U_X68'^O^&?E?\ +?\ B6+/?^BIRC_PBQO^
M?]6?E?\ EOHK^@[XO_\ !N-^Q;X&^)_[*?@[1_C]^W[_ &;\9_C5XN\ ^*C>
M_M::O-<_V'H7[-?QY^+%JNCN?"$9M-1/B;X<>'C+<J)\Z2FJ6A@Q=_:+;Z"_
MXA>/V#O^B_\ _!0[_P 2[UC_ .8RC_B:OA[_ *)/.O\ PLP/]?T_*Y_Q+%GO
M_14Y1_X1XWRWU]>^WF?RWT5_4A_Q"\?L'?\ 1?\ _@H=_P")=ZQ_\QE'_$+Q
M^P=_T7__ (*'?^)=ZQ_\QE'_ !-7P_\ ]$IG7_A9@?Z_X9^5S_B6+/?^BIRC
M_P (L;_G_5GY7\G_ .#=O_DH7[4W!/\ Q1?PCZ G_F8?'Y[ ]LG\#7]4&<^O
MX@C^=?@#\./^#=W]FWX.W.JWGPC_ &T?^"J'PON]>@L[;7+KP!^W3XT\)7&L
M6VGRW$UA;ZG+HGAFS>^ALIKNZEM([AI$MY+FX>(*TTA;]*?V0OV*=._9!;Q\
MUA^TW^VC^T5_PGR^&EE7]KG]I'Q5^T"OA+_A&CKA0^ U\2V=H/"K:W_;C#Q(
M;/S#K(TO1!<;?[,AW?R]XE\7X;CKC',^)L)@Z^ P^/IY?"&%Q,Z=2M3>#R["
M8*;G.E[C4YX=SCR[1DD];G])^'?"F(X*X2R[AS%8NCCJV"J8^I+$X>$Z=*:Q
MF/Q.,BHPJ7FG"-=0E=ZRBVM&C[5HHHKX,^W"BBB@ HHHH **** "BBB@ HHH
MH ***SM8U./1M)U/5YK74;V+2]/O=1EL](T^[U;5;J.QM9;J2VTW2K"*:^U+
M4)TA,5EI]G#+=WMT\5K;QO-*BD T:SETC2DU6775TW3UUJ?3X-)FU=;*V75)
M=+M;FYO;;3I=0$0O)+"WO+R[NH+-YFMH;FYN)XXEEGE=_P ^KS_@H/8^$)O$
MFB?%KX _%OX:^.H_ '@7XD_#OX?7%[X"\3^)OB'I'Q0^+'AOX&> _"+R>'_$
M\VA^!?B?J'Q9\9^#_!VJ^%?&.KV6AZ9<>(XM0L_&6M:9H'C"Y\.9WQ1_X*/>
M'?@O\#_C/\2_B#\#_BROQ"_9_P#$MIX4^*7P;\'KX<\9ZGH$^I^%?"WCW2O%
MTWQ T[4K?X?V/PUU#P/XPTCQ!;^,/$&J:%<7%Y%JG@JR\/WGQ!L#X4F /TGH
MKX9^-_[9$OPH^/7AGX&:;X0\!:G?:UH/@#7+O6O'O[0OPT^#DDLGQ$\9>,?"
M6BZ'X+\,>+X;OQ!\0=?B'@?5M1NM/T.& '[5H^F6LUQJ%^\=M]R@Y_,CKGH2
M/Z=.W0T +1110 4444 %%%>'_&/XH>.O ,OAC2/AU\$O&OQG\2>)VUJX-OH.
MK>&/"7A?PYI7AZ/39+Z[\4^./&&H66BZ7?ZK-JMEIGA'P_!'?ZSXFU)KR6*W
ML= T/Q)K^C 'N'^?RZ5GZ5I.EZ%IMEH^B:;8:1I.FV\=II^F:79VVGZ?8VL0
MVQ6UG8V<4-K:V\8XCA@BCB0<*H%?G-)_P4N^'>K>#M+^*7@+X7_$OQE\*='^
M WP[_:7^-?BY6\(Z%??!/X0_%!_%Q\/:IK7A;4_$)U;QEK^D:9X \<>+?%V@
M>"'U1=*\$>&I/$&D:GXCG\0>#M)\2>[^#/VMO"_CC]JCX@_LMZ9X'^(.G:K\
M/OA/H7Q4D\?^(M%'A_P?XLL]8\?>(?A[<Z;X)MM4DM_$FOVVD:SX=N?.\7+I
M%OX.UH3(GA/6/$$=O>W-N ?65%?(_P #/VN_"?Q[^.O[0WP8\*>&-?MK'X$:
M%\)?$%G\1KV[T>7PK\4M,^*&L?&#PQ+J?@6VL[J;5WT3PSXO^"GC+PS/KFJ6
M]K8>(KNS.H^&6U#0C;:I>_7% !1110 4444 %%!. 3@G S@=3[#.!G\:^+]<
M_; ;P7\4?#GA7XC?!;XC_#[X9>.?B1XO^#_@7XQ^);OPG;Z7KGCKP3X,^('C
M_5+^]\"PZS+X[T#X;:KX8^%OCNZ\+?$/4=,-GK2:+#J\^DZ7X1UK0?%&I 'V
M%=:7IM]<Z9>7NGV-Y=Z+>2ZAH]U=6EO<7.E7\^GWNDSWNFSS1O+87<VEZEJ&
MFRW-H\,\EA?7ED\C6UU/%)>KX(^&_P"WEH?C.WL;WQ'\&/B]X+A\=_!^']H+
MX%V$6D:;\0/$OQD^$=UKG@WP[%?:/X6^'U[KNK^&O&MC?_$CX:7/B'P1XECM
MF\.:/\0O#VJZIKT4.G>-D\(3>#?VV;OXF?LK_!+]IOX>? [QAJMG\:_#UKXE
MA\,^(_&_PR\$V/PUTN>.]DDG^*'Q USQ&/">D)]JM(M L1X:;Q9+JWB74M/L
M[*%M(_M#7[  ^\:*\A^ GQDT+]H/X._#WXS^&M$\4>&]$^(?ART\16&A>,M,
MCTGQ)I<=Q)-!+9ZE;6US?:?.T5Q;3"UU31]1U/0=<L#::WX?U75-$U'3]0N?
M7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K,UJ+6)M'U6+P]>:=I^
MO2Z;?1Z+?ZOI]QJVE66K/:S+IMWJ>EVFHZ1=ZCI]M>F":]L+75=-N+RU26V@
MU"REE2ZATZ* /RF\%_L$_&O4/!WQ3T;X[_'#X6^._B5\1=5^%7Q#/[0'A'X-
M>+M#^)B_&'X%?$O0OBK\&]7U#2O&WQE\?^";7X1_#OQ5H43^'/@9X-T;P?X;
ML-/O]<":LWB+Q/XJ\5:Y!\=/^"?_ ,9OB]\#OVF? -K\;_A-I'Q0_;(UO2KG
MXZ_$:_\ @=XLO?#NF^&O"O@GPKX(\#^%_A=X)T[XV:9J>CIX;L/"<%[<:GXT
M\:>,[C6=8UOQ'?&#3;2ZTS2M)_6"B@#\_OBY^RO\</CCX5\2>%/'/Q<^"MC9
M?%_X1+\'/CA/H7[.'VG6G\/-JWC"[O;SX.^*->^)][KGA*[O=,\4B&RT_P")
M<WQ<T'PKXGLT\:^%]+L;VXU/2]2^^[>!;:"&W1G9(8TB1I':20K&H12\CDO(
MY !>1R7D;+L2S$U-10 4444 %%%% !7QQ^V-\#/CQ^T!X8\+^!OA1\8_!?PQ
M\#7-]J__  N?PSXI\"^-O$-S\6?#$]E;P:5X&B\8?#[XK?"WQ7X&\+3W;7TW
MCF+P_J']M>-=*-KX837- T.?Q!;Z[]CT4 ?F=XR_8)\4>,-+\:Z-8?$GX<?#
MC0?VA/@#\/OV;_VI/"?@#X*O:>&]?^'GP^M/&N@62? BVU'X@SGX07][\/O'
MWB/X9O%XDA^*&CZ7X<;P[J6AZ9IVL>&0VLZ5Y^R)\=M6_:[\:?'O4/B_\*;#
MX8>-/@.O[,4_P^\)?#'XE>%?B/HOPDL/%7C7Q;HVI>'?BSI_QQ-MHOQ*L[[Q
MBUJ/$VG^";?3K*#3+6\T;1M,U#9/#^C]% 'Y[?LN?\$_M"_98^/GQ,^+_A?X
MS?&/QCX8\:_ KX%? WPW\-OB'XTU;Q9IW@S1?@IJ_P 3K_3[B'4K^<+J5HMC
MX]L]*\)Z:=-LCX-@M?%3PWFJ?\)G/'I?Z$T44 %%%% !1110 'VXK\Y3^R3\
M=O%G[2/BOXK_ !I^*'P0^+OPVU:/Q]X*\%>!M6^#OQ"TKQ!\)/@MXYTF?1=3
M\&_#_48/CC>>!K/QYXFT\Q6WQ)^,.H^ +[Q7XRT^:\\-6$7A?P8MAX9M/T:H
MH _.KX:?L<_%[X6+X0UO3OC7X"\8>-/@-\ )/V:/V8[WQ7\&]2L] \*_#G5M
M?^&NI>*]9^+-AX<^)UCK'Q#\?^(=%^$GP]\/S:IX1UOX8^%[1_#<^L6GA.)O
M$FJ:9!PWP3_8>_: ^%7[)WPN_9=U[XR?LZ_$GP_\*[ >$SHWC;]EK4?$_P +
M_B?X'BA@O--@^)'@?Q'\9]4UM?%GAWQ1%_PD.A:UX4\::-H&!]AUCPGJDRV.
MIZ7^IU% 'AO[-OP67]GCX)> O@XGB[6/'"^"M.O[3_A(M9A6S:9M3US5=??3
M-%TA+J_C\-^#?#K:LWASP#X1AU#48/!_@;2/#OA:#4;^'1TO)_<J** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ I#Q^8_4@4M(>GXK_,4 ?Q<ZW_P6^_;UL-;URPM_$'PC%O8:YK=A
M;!_A3 SBVL=6O+.W#M_PDGSN(8$#O@;VRV!G ^W?^":__!4C]K3]I[]KKP/\
M'?BOK'P\N_!.N^&/B%JNH6_A[P!%H.J-=^'/#,VJ:8T.IKK5ZT,:7:*T\8MW
M$\>8RR9W5_-IXGMKG_A)_%'^C7/_ "-'B;_EUN/^@_J1_P">5?I]_P $58)H
M_P#@H5\+F>&=%_X0?XO#<\$R*,^"+G&6>-5&>@R>3P*_T8XY\/. \%P%Q5CL
M'PGD&&QV%X8S;$X;$T<LPM.O0Q-'+:M2G6I5(TE*%2G4C&<)Q:DI)-.Y_G]P
M5Q]QOC>..&,#C.*,]Q&#Q/$F58;$8:MF.*J4*V'JYCAZ56C4IRJ.,Z<Z;<91
MDFG%M/0_MWHHHK_.<_T!/"?BK\==*^%?Q'_9L^'.H:!JFK7O[2/Q6\4?"G1=
M3L+FPAL_#.H>&/@9\6?CE/J^LQ7;I<W=A=:5\)]0T&"#35DNDU35["YE46,%
MVZ^/6/[?7[.=A)XJM/B5X[\/_"35/#7CWXP>$H]+\;ZU:0W.J>'O@S\4?^%3
M>*/B3&UC'<0Z=X$MO$TMB-5US57M++PM;:A:W'B:ZTVV9KD>@_M%_ ?6OC#=
M_!7QCX(\9:1X$^*'[/GQ5NOBS\.=<\2^#Y_'GA&ZU35OA;\2?@]XCT#Q;X6L
MO%'@O5;[1M;\$?%+Q'!#=Z+XJT35]&UR'1M8M[B[@LKO2=1^,O%G_!,>[\76
M'Q@;4/C7:0^(?C5^R!^VY^S;XJU>P^&GV.QMO&W[:_Q1M_BAXF^)^C:1_P )
MQ=S6>A>#KZWAT;1_A_<:Q>WNJZ7:6$VK>-Y-4BNKZ[ /8[#_ (*._L^0_'G1
M_P!G3Q3K,>B^/?$WB']I/2]"U#2+Q/%O@BQL/V8M5\(Z9X[E\?>,M*M8=(^'
M6O%?%T5[)X;\029\/VVCZK_PDNKZ6\VA+K?L4'[9W[+]SX)/Q"@^,_@U_"Q\
M6:-X'M[LW&H)?ZAXJ\1V;ZKX=T72?#[Z<OB36+KQ!H,-SXFT%M*T>\M]9\*6
M=]XKTV>Y\-V%[JMO\'Z__P $G?[=3QC;W'QRF>Q^)=_^W3X8\?VI\#74,MY\
M&OV]M(^%&E?$GPWX=OK3QQ;3Z-\1/"#?"'P_>^#?'E^FN:!(]]J]OK?@.]6:
MTFM.N^'_ /P38UWX;ZMX+^)?AOXH_#^P^.7P\^(FF>+_  [XLC^&7Q5UOP7K
M.A67PL^)OP>NO#?CGPW\0/VF/'?CK66F\,?%?Q3JOA^[T+XI>%].\#Z]+;P:
M#H<FAW?BBQ\3 'L>C?\ !0?X:ZG^Q'>?MR2^%O$</P]AU+Q/I=GH=MJOA2YO
MKU]&^.FK_ 72=7F\3W6L:9X)T3PEK'B"PL_$VH^-=?UW3/"W@SP/>W7BGQ9J
MNGZ5HNJ7,+;?_@H+\/?#.K_L]^#OC3X)\9?#'QO^TS\7-8^#WPHBTA](^+?@
M#Q3J>D?#C4/B:_C'1_B;\-KG5=!G^'\^G6(\+-K&I6FC:S8^-I9K34O#MKX5
MTW5?&-ET?P:_9)\4_!']D6S_ &:?"/QGD7Q1INL_$#7+;XIWGPV\,ZE8:C<^
M/?C/XN^+FIZ7XC^&6J7MWH6J>%M6A\6WW@KQ3HECK&C7E_X>N-0E\.:]X3U>
M73=2TKYY\.?\$UM9\)Z_I/Q)\'?$_P"'OPT^(VE?M&6'Q]LO#?PE^"<_@/\
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M&8#$UL)BZ,LN]EB,/4E2K4U4S/!TJG).#4H\U.<X2L]8R:>C/ A_P4,_:3)
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MT]/#%[X@_LW3/#,T&DP7-Q[A^S9^Q%XL^"/Q9^'_ ,3O%GQDT?Q]%\+?V1]
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M_P#B:F554!54*JC 50  !T  P !Z"EHIMM[MOU;8**6R2_JWZ!1112&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
144 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>unconsoljointbusinesschart.jpg
<TEXT>
begin 644 unconsoljointbusinesschart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (5 3T# 2(  A$! Q$!_\0
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MK9S:S=ZYI7PZM?$^NZC?6\,DNOZOJ26D-OIR6EM%XUH?_!.'P]H7CQO$MO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** #(]>O3WHK\A/V^OBY\4/ 7[>_\ P1Q\!^"O'_BWPKX+^,/[27[0_AOX
MJ>%=!UJ[TW0OB%H/A[]EGQMXJT+2/%^G6[K!KFGZ1XCL+36M/M+U9(;;4H(K
MR-1/'&Z?KS&240GDE%)/J2!0 ZBO*/CAX@^(WA;X6>,==^$WAVQ\5?$&PT^!
M_#>A7[6[QWMU-J5C:W1MK&[UOPS:ZWJMIIL]]?Z)X:N/$_A>#Q3K-I8>&IO$
MWAV/5FUJQ_#[1OV^OVK9_P#@E=\0?V@_"OQ/^&'CGX]?"#P_9Z_\2=;^)WP6
M\4_"_P ;>#-%U#2=#\0:+9:W\$X-07P_XI\3>,K+5UE\%^.]%UWPQ\+K[PE?
M67BJST_Q=J&B:EHVL@']#%%>?_$U/'<_@+Q+%\-=;T;PYXV>R(T77==\)ZAX
MYT_2@EY"=1O4\(Z9KWABY\1ZI!HZ7[:%I!U[3;:]US^S8[^<Z>;J&7\K_ /[
M1/[4'C[X1?&N5?&_BS3M8^!?QMB\+:A;Z7^RH=:_; U[X>Z]\.?AWXA\))XB
M_9QD\0VWA+P3K]YXT\6^(M0M_$T>GZMH_B[X*Z#HNMZ7H/AGQ'JVJZCI(!^R
M%%?SW>./^"C7[3NB_!&/XWZCJ/@[P]=> _V+_#/[1?A[POX&^#?C'XC^!/VK
M?B]X=_X6A=_M$_!RU\=&\W_"&;X567P_T#P]KWAZ75+7Q=\-/$_C'4_$WBO4
MO%?@WPNNGZA^KG[3/B_QOX?^'VE_$#2OC=X)_9N^&&@Z5J7B?XG?$+QEX('C
M3Q;:1R6^D1>"O"_A;PSJUU;: UYK>LZC<6NM1S6^N>*=6NK72?!?@30)_$7B
MB/6-# /K6BO$/V:_%_Q5\?\ P#^$/C7XX>"K;X=?%OQ3\/\ PUKGQ \%6L-[
M9Q>'?$VHZ=%<:CIYTO4KF]U+0I@SI/<^'-1U#4]0\-74\WA^^U/4KO3)K^X]
MOH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH _#O\ X*72M#_P4>_X(62K!-<,O[5O[3^(;<1F
M9\_L=_$!?D$TL,?R@[VW2+A%8C<V%/[1IK-T$3_BGM=(VJ!^[TK/0=0-8./Z
M5^,/_!2?_E))_P $*?\ LZW]J#_UCGX@U/\ \%V-1U#3?V4?AG/IU]?:?,WQ
M[\.1--87EU92O&WP^^(C&-Y;2:&1XRRJQC9BA948KN12/J."^&WQAQ5DG#*Q
MBR]YSC%A%C7A_K2P]Z=2I[1X=5L.ZOP6Y?;4][\VEG\-XE\:Q\.>!.)N-YY=
M+-X<.9=+,)9;'%K RQ:C6HT726+>'Q:H/][S<[PU;X;<NMU^MOCGP_X;^)7A
M36?!'CKP!>^)O"WB"V2UU71]3MM-DMKA8;F"^M)XWBUJ*YM+[3M0M;34]+U*
MQGMM1TK5+.SU/3;NTU"TMKF+XGM?^";O[)]O^SQ'^RZ_PX^,;_"6ZVGQ=9V/
MQI^)7AGQ/\3V33+;1XE^*_C/P=\2?#OB7XB6EIIEE86.F:3XEU&]T71K/3M/
MM='TVP@LK>-/XLO^$L\4?]#+XB_\'^L?_)U6;+7_ !KJ5Y:Z=IVL^+=0U"^N
M(;.QL+#5?$%[?7MW<R+#;6EG9VMU+<W=U<3.D5O;6\4D\\KI'%&[LJG^J7]#
M^O%.4O$"A&,5>4GPU)**23DVWGUDDN9MO1)'\&0_:*X2I*,(>$>+G.<HQC"'
M&E.4I2DXI1C%<*MRDVVHI)MNR2;>O]T]U^R[\+M6B;3_ !/H_P :?&FC?\(!
MH7P_CT_QM\8/B-XJNDM_#GQ$N?BAHWBL^(-:^)MWXB_X6+HWBYM.O= ^(\6I
MP^.M!@T;2K+3?$4-EI]A;6>5'^QS^S[!:H+7X=_%2Q\1?\)'>^++KXE:?\9/
MBKI_QFU;7=3\.:'X0U.YUWXTV?Q7@^*>NVFH>%_#/AWP_<Z-J_BR\T,:/H.B
M6,&F01:1IWV;^+J]^&W[1^G^/KOX677A'XOI\1K&"2\NO!<=MXON/$,=C$BR
M/J0L+:2:272U1T/]JQ%]-)8(+LR';6;8>#?C_JEMXKO--\+_ !BO[7P)<7EI
MXVGM--\<S)X1O-/BEGU"S\2;$+:/>:?;V]Q<W]G?+#=6-K;SW=W##;0R3+P+
MZ*>#E"%1>*&5NG.E0KQFLEI.$J.*E&&'JQDN(K.EB)-QH5$^6K*RIN3/5?T^
M,PC4G2EX%Y_&K3K8G#5*;XEKJI3Q&"@JF,H3@^$.:-;"T^:>(I-*=&"YJD8K
M4_M?U#]CS]G#4=)\'>')/@SXEL_!_@G0/#/A:P\ :/XS\7Z'\-]?\/>#_$-_
MXM\.Z5\1/AUI'Q#LO!7Q3MM.\4ZKJGB(-\2=#\53WFLZIJM]J4U])JNH_:LC
MX@_L5? 'XFZCI.L>*/"OQ\75] ^*_C+XW:#J.@?M&?''PQ<Z%\3/'FDZ;H>N
M^(=$&@?&33X=(AMM*TN.T\)Z%I\-MX?\!?;]>N/ VE^';KQ'KT^H_P 0NBZE
M\0/$>KZ7X?\ #VH^,M=UW7-0LM)T71M(U/Q!J6J:OJNI7$=II^FZ986=U-=7
MU]?74L5O:6MM%+-<32)'$C,P!BU+6_'&CZC?Z1JVK^+=,U72KV[TW4]-O]7U
MVUOM/U&PN)+2^L;RUFO$FMKNSNH9K:YMY466&>*2*15=& [%]$*HZGLO^(A8
M;VJ@JCI+AQ^T5-M153D_M_FY'+FBI6Y6U:]SS?\ BHC05%8A^#^.6'=5T57_
M -<H^Q=:,8SE253_ %4Y/:*$N=PYN91M*UG=_P"A#X0L8O!7AG1?"FEZ9\0=
M3T_0;"'3K34/%_B:_P#''B:[A@W;9M:\6^+O%6L^)=?OWW'SM2UK5+Z_GPOG
M7#[5QTG]LW1_YE[7/^_>E#^>KU_G6_\ "6>*/^AE\1?^#_6/_DZOZ\_^")%]
M>ZA^Q<]Q?WMY?W!^,/Q&3S[Z[N;V?8L7AO:GG74LTH1<G:F_:I)( +$G\\\4
M?H_5?#3AA<23XJIYPGF.$R_ZG')I8%WQ4*T_:^W>:8Q?NW1:Y/8^]S7YX\OO
M?L/@7]+G#>-G&TN#:7 =;AR4<GQV;/,*G$D,TC;!5,)3=#ZK'(\O=ZCQ-U4^
ML6BH6Y)<UU^K_P#;-W_T+VN?]\:3_P#+BC^V;O\ Z%[7/^^-)_\ EQ6]17\Z
M']D&#_;-W_T+VN?]\:3_ /+BC^V;O_H7M<_[XTG_ .7%;U% &#_;-W_T+VN?
M]\:3_P#+BC^V;O\ Z%[7/^^-)_\ EQ6]10!@_P!LW?\ T+VN?]\:3_\ +BC^
MV;O_ *%[7/\ OC2?_EQ6]10!@_VS=_\ 0O:Y_P!\:3_\N*/[9N_^A>US_OC2
M?_EQ6]10!@_VS=_]"]KG_?&D_P#RXH_MF[_Z%[7/^^-)_P#EQ6]10!@_VS=_
M]"]KG_?&D_\ RXH_MF[_ .A>US_OC2?_ )<5O44 8/\ ;-W_ -"]KG_?&D__
M "XH_MF[_P"A>US_ +XTG_Y<5O44 8/]LW?_ $+VN?\ ?&D__+BC^V;O_H7M
M<_[XTG_Y<5O44 8/]LW?_0O:Y_WQI/\ \N*OV5Y+=^9YNGWUAY>S;]M6T7S=
MV[/E_9;R[SLVC=OV8W+MW9.+]% !1110 4444 %%%% !1110 4444 ?B!_P4
MG_Y22?\ !"G_ +.M_:@_]8Y^(-1?\%Y?^33/AC_V7[PU_P"J\^(M2_\ !2?_
M )22?\$*?^SK?VH/_6.?B#7E7_!QYKNK^'_V+?A)>:-?2Z?<R_M+>$[:2:%8
M69X'^&7Q1D:(B:*5=K/$C$A0V5'.,@_H7A1F%'*O$7A+,<1"I.CA,TC5J0HJ
M,JLHJA6C:"G.G!N\E\4XKS/R/QYR/%<2^#_'V18*KAZ.*S/(YX:C5Q4JD</"
M;Q6&GS594:=:HHV@_@I3=[:=5_,%D>H_,5ZC\%O$O_"(_$_PGXC7Q+HGA-M,
MN=19=>\2:+K/B'P[:&[T+5=.,&OZ7X;=/$;:)JBWC:/JM_X>8Z]HMCJ$^MZ,
MDFHZ;;(?S;_X6=X[_P"ADOO^_=C_ /(='_"SO'?_ $,M]_W[L?\ Y#K_ $4Q
M?BAP_C,+B<)5P&<*GBL/5P]1JAETVH5Z;ISM&MBJM*3Y9R]VK3J4Y6M.$XMQ
M?^0F6_1WXURS,,#F5#.^%Y5L!C,-C:498K.X1E4PU:G6A&4Z&64J\$Y0LY4:
MM.K%:TZD)J,C^F[XM?%+X!S^*/CMX*\.>)OAMK?C3QKH'@5;7_A8'CGXB^(/
MV=+&?P=\4=?\1:EX&T3Q5<?8]:BTSQ!H&K:%X\U+PJ^HM\.O^$^T!DM-9U/5
M(K+3:R_"'QR^ -I\4]&\7W7C'1[SP%\"OVC/$WQ9\(7>J_$WXDV'C+6;+Q'X
M7\ OXR5/"VN^#->UOXT:%KVO^$+KPW\,1J/C7PMXTM-"6STOXM3OX0NS)'_-
M,/B?X\'3Q+?# P,1V(P/08LQ@?2C_A9_CSD?\)+?X/4;++GZ_P"B<U^=4\5P
MA#"RPLZ_&-6-3#2H3G*M@E)5*^ PF58JO3Y<8G"<LOPOU:A>4W"-?%?6I8V-
M>4#]EJ\/^)E3&T\93H^&=%TL9#$TZ<*&;.+I8;,\9G>"PM7FRAQJ4Z>;8V6,
MQ+C"G[66%P2P4<MEA:=1_LS\"?%'PD^$_BX>)?%?BC4K7Q)XLL?!.I>#/$GP
MPM=(\3V_PETSQ%XJN)?'VD>)8O$.I^"Y]&\=6GA>RB\+F_T"36H?#?A_Q!KU
M_IS7FKSZ5)8>-_M#ZOX2U_X\_&37_ NL7&O>$M>^)_CO7-"UBZL[;3VU&RUG
MQ/JFIBZMK:UO+Z,:9+)=R'1YFG2XN])^Q7=Y9Z==SSZ?:_F5_P +/\><?\5+
M?\<#]W9< = /]$XQ2?\ "SO'AZ^);[_OW8__ ")7U^$X[X=PN;ULY=+B&MB<
M1@U@JE*K3RQT%2C+#.FZ:6(5:G[-8?W:2K.@JE;%5O9>VQ%2I+\ZS'P7XWQ_
M#N'X96*X'PF!PN9_VI2K8>MGZQ;K2IXN%:-:4LO>&J^V>,?/6>&6)]EA<%AO
M;/#82C27VGD>H_,5_85_P0]_Y,H;_LL?Q'_]%>&Z_@B_X6=X[_Z&2^_[]V/_
M ,AU_<C_ ,&\FMZKK_\ P3]EO]9OI=0O!\?/BY;"XF6)7$$!\,I#'B&.)-J+
MD#Y=W/)-?E'TA^.LLXB\/E@,)A<?1K+/<MK<^)AAHT^6G2Q?,KTL35ES-RT]
MRUD[M:7_ '7Z(O@YQ!P)XL3SK,\RR7%X:7#&;X/V6 JX^=?VE;$9;*,N7$Y?
MAJ?(N27,_:<RTM%[G[IT445_"Q_J$%%?+_QR_;&_9_\ V=/&GPU\ _%7QC=:
M)XC^*.L_V5H\&G>&?$_B2ST"V?0/&>OVOB3Q]J7AW2=3LO 7A&_C\!>)=/L/
M$OBB;3]-NM0TS4/*E.G:+XCU+1>Q\._M(?!+Q=\;?&?[.GA?XA:+X@^,?P[\
M(:3XY\<^#='6]U"7PIX?US7M0\-Z6VMZS:VLGA^SUFXU;2[V*;PN^JGQ-IUL
MMKJ.IZ39:?J6F7-X >WT5XCX]_:.^"?PR^)WPD^#'C;X@Z+HWQ4^.>N7WA[X
M7>! +S4?$?B6^TWPSXJ\7WMRUAI=K>R:)HD.A>"O$LP\2>(3I7A^>_TW^P[;
M4I]<NK/3I^2TS]L3]GG5_B)=_#"S\=7(\0V^N^-_"5KJMYX-\=:?X U[QI\,
M]/UC5OB1X%\)_%&_\-6WPW\7^.? .F>'M>O?%WA#PUXIU37]%B\/>*$N;$3^
M$O%,6C 'TW17@'P*_:0\"_M#V%WJ_@'P[\8=,T6#2]!UNPUSXE_ [XL_"+1_
M$FD>)(;BYTC4/"5_\2_"/A>#Q3;3VD"W<SZ(UX;*UN]/FO5@2_M#+IZY^T3\
M'_#GQT\"?LVZMXOC@^,WQ(\&>,OB#X3\'0Z3K=Z]WX2\!S:3;^(M4U#6;/3I
M] T)DEUBW_LFPUS5-/U+Q%':ZQ-H-IJ,&A:Q)9 'ME%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!^('_  4G_P"4DG_!"G_L
MZW]J#_UCGX@UXI_P<J_\F2?"#_LYSPE_ZJ_XJU[-_P %+HY)?^"C_P#P0LCB
MGDMI&_:M_:?VSQ)#(Z8_8[^(!.U+B.6([@"A+QM@,67#!2/"/^#DFSN[?]BC
MX1O<:M=7Z-^TUX3413VNFP(K'X8_%0APUG9V\FX %0I<QD.<IE4(^KX&_P"2
MMR+_ +#5_P"FJA\7XB?\D3Q'_P!B^7_IVD?Q-4445_6I_$84444 %%%% !7]
MW'_!N9_RCRF_[."^,/\ Z'X9K^$>O[I?^#=BRO+G_@GM*]OJ]U8H/V@/C /)
M@M=-F0D/X9R^^[L[B4%NX#[?11@"OS7Q7_Y)3_NJ8+_TWBC]9\%_^2S_ .Z1
MCO\ T]@S]^Z*P3I6I@$_\)'J''_3CHG_ ,K*_"/]KO\ X*^>/OV8?VBOB1\"
M].^$NB>,;/P%=>'[:#Q)J/BYM(O=3&M^$M!\3.\^G6G@V\MK8VTFM/9HL5S*
M)([=)F*O(T:?BO!_!'$O'F8U\IX7P$<PQV&P4\PK49XS!X)0PE/$8;#3J^UQ
MV(P]*3C6Q="/)&;J-3YE%QC)K]X\1?$_@KPIR;"9_P =9M/)\JQV9TLHPV)A
ME^99DZF85L+B\;3H.CEF$QE>"EAL#BJGM9TXTDZ:A*:G.$9?0/\ P4+_ &8/
MVE?C%\:/V=?'G[->B^'_  KXQ\+>);F&W_:$T?XK>)? ?BSX436OP<_:5TG1
M]4^)/P__ +"\0^#OC?\ "S2/&'Q"\,7FF>$)[&;Q#<W6K^-OAZ?["\(?%7Q3
MXS\/]9X7\!?M&Z3_ ,%(M?\ C-+^SOI^F_ _5O@+IOP#E\=Z=\5/AU;7EQK&
MD_&#QY\5=5^*,WPWL83K":;XK;Q'9Q2V/VV?Q5_:\EU)JMO-%'_:$GY@?\/]
MOB7_ -&_^%__  X%U_\ ,)1_P_W^)G_1O_A?_P .!=?_ #"5^C?\2X>,'_1+
MT?\ P_</^7_4T\_P?8_&O^)S?HZ_]%U7_P#$6XN_^<?K_3T_2/\ :1T[]JSX
MH>)OV$?BAX1_8]LKC7OA=\2?"/[1/QBTP_'7X9Z)J>CW9^ 7[2OPI;X.6&LZ
M[H^FWWBW4O"'B'XVZ=XAM]8N[#1/#4^G/XA6R_L_6I&MI^7N/V(?BSK'QU\'
M6VGZ3?>"O@-\(_VE?BU^U;X4\/ZK\<M/\5^ +[QC\4OA_P#&K1]0T'PCX(\/
M?"3PK\2O#G_"<>._CEXH\7_$W3O'OQ(\;>"/ \,OB/1O@]8:@GBO3[[PA\"?
M\/\ ?XF?]&_^%_\ PX%U_P#,)1_P_P!OB9_T;_X7_P##@77_ ,PE'_$N'C!_
MT2]'_P /W#_E_P!33S_!]@_XG-^CK_T75?\ \1;B[_YQ^O\ 3T_3#X%_!'X_
M? G7M3\;?#O]G[PWX#T+3/AMX#^%FH? J#]JGQ;XXTKXJ>+E^)'@FPU;XU/X
MY\;^&]7715^%GPJ@\7MX>U#6M(7XF?&9+^'POXV@\+/H'A:_BYF#]B#]JC0O
MV]?@E^T0WQN^'7CSX9Z/XJ_:P\6_$7^T_A+<>&O']E9?%[1?AIX<^'_@>VU2
M'XKZOI_B.U\-^#O VB> ] \0V/AKPY'X8T7PB-1U+P]XBUCQCJ][#^>O_#_;
MXF?]&_\ A?\ \.!=?_,)1_P_V^)G_1O_ (7_ /#@77_S"4?\2X>,'_1+T?\
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M5?\ DR3X0?\ 9SGA+_U5_P 5:^KX&_Y*W(O^PU?^FJA\7XB?\D3Q'_V+Y?\
MIVD?Q$T445_6I_$84444 %%%% !7]W'_  ;F?\H\IO\ LX+XP_\ H?AFOX1Z
M_NX_X-S/^4>4W_9P7QA_]#\,U^:^*_\ R2G_ '5,%_Z;Q1^L^"__ "6?_=(Q
MW_I[!G[SMT/T/\J_B!_X*P?\I _VB/\ L)^ _P#U5?@6O[?FZ'Z'^5?PV_\
M!6?7-$M/^"A'[1=O=:SI-K<1ZIX"$D%QJ-G!-&6^%/@1U#Q2S)(A9&5AN495
M@PX(-=?T3ZM*CQ_G<JM6G2B^#\;%2J3C"+D\\X>:2<FE=I-I;V3?1GQWT_\
M#8G%>$?"]/"X>OB:B\1<MDX4*52M-1_U:XJ7,XTXR:C=I7:M=I7NT? 5?9_[
M.G[-GA'XP_"_XL^-M7UKQU>Z[X-L)OL'A?X8>']!\8>(_#L5OJG@=$\9^)?!
MUUXCTKQ5XC\,ZC:^(M;M[:U\*6$OV2#PMXFU._U>WU"QT/0M=^%O^$D\.?\
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M[QR;7"^66=O^%_#_ /JNS(_+3C^ZO_?*_P"%'']U?^^5_P ***_HJR[+^O\
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MT/P\ZZK>W-_)>SZV(+KQ7J]^MU+'JFO>(-6U59'6]!KP7_A//!?_ $-&B?\
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M#!_<Q=#_ ,LT_P#B:_SM/^"V "_\%/OVIU4!0-8^&V H  _XLO\ #CH!@?\
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M->SX/_\ (ES+_L:2_P#43"G@>.G_ "4.4_\ 8G7_ *F8DCHHHK]</Q$****
M"BBB@#^I/_@V%1'^)?[7X=$?'@+X+8W*K8SXG^).<9!Q^'H/05_86L:)G8B)
MG&=JA<XSC. ,XR<?4U_'M_P;!_\ )3/VO_\ L0O@K_ZD_P 2J_L+K^6_$O\
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M_*3_ /:H_P"PQ\-O_5+_  XK_1/;H?H?Y5_G8?\ !;'_ )2?_M4?]ACX;?\
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M<5_HGMT/T/\ *O\ .P_X+8_\I/\ ]JC_ +#'PV_]4O\ #BOS_P (?^2BQ_\
MV):__J=EY^G>.?\ R2V6?]C_  __ *KLS/ROHHHK^BC^6 HHHH **** /0?A
M+_R5?X5_]E1^&G_J>^':_P!5R/[I_P!^3_T8U?Y4?PE_Y*O\*_\ LJ/PT_\
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M/]?<3]5;>&_L_-/J[:DFZ'UK"^Q;4W*:;I\K:E*4D])-N[?[\MT/T/\ *O\
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M"NE:R\2Z?J&OZ?::EI]QJ&F6MQ+<V,5[;->) 9D!^_O@]8WG@#X=_MH?L_\
MB[]IKX&>'M"U?P;XF^'/A7PGJWQ4U#1_#'BOXO:9\7_@7K%SXVL[%?"!DO-"
MG\&^!/$%AH/C'Q%%$;.2QOM$L=/TJXU6]%[S7CK6_P#A)_V'O W@OQ+^T+\(
M_%OBSX>?&G6/&GAOX;#XE7%_XE\/_"23X*^%?!FB^%?#7AX>&[;2K35U\56F
MM2WWA:UO(KZ>XGN_$&J7=[=7TU[-I_:55UN2-*#I2QE*C"HHXAMX:MA(5H5K
M.E&+?MI.G-N4:=-+E<I2NS/^R:*H>TE6FJL<!6Q,Z3EAHI8JAC94*F&O[>4K
M?5TJL+1E5JM\RIQAH?+'Q ^ _P :?A3I6G:Y\2_A;XW\"Z+J^ISZ+I6K^)=%
MDL--U'6;:Q&IW.DVEZ));>;4H--*ZA-9!Q<1V3QW+((9(W;AIO"7BFW\*Z?X
MZG\.:[#X)U;Q!J?A32O%\VE7L?AG4_%&BV-IJ>L^'=.UMX5T^^UK2-.OK*]U
M33K6>:YT^WN[=[Q(3*BGZ)^)!\#>*;GX'_!SP+\0/ /ASP%\//@=I&KZIXLU
MF;5M(\)7OQK\8>#Y_BI\9[C59]+\/ZAJ<_BW4O%_]E?!?0Y6TF>V\SP9X/T,
M:A9:#"^J0^I>,]?;Q;^PM\._"7B7]H'X4^(_&'@+XP:GXY\._#&X^)%Q=^+O
M"OPFN_@EX-\(Z)X0T3PTGAV'2-/U^S\4VFMG5O"-E?K>F^:^UW4[[4+F]EO[
MBUC<1&&#]I3A*6(Q')4:HXBDX8>I[?ZO45-^VY9S5.FZL:E9*BY\LM7&^<LO
MPTYX[V564(87"\]-2KX:LJF)I+#?6J7ME[#VE.#JU50E2H-XA04HV2FE\B_"
M7_DJ_P *_P#LJ/PT_P#4]\.U_JN)T/\ OR?^C&K_ "H_A*,?%?X6#@X^*7PT
M&1T/_%>^'>GM7^JY']T_[\G_ *,:OQ_QD_C9!_@S/\\O/W/P&_@<3?\ 7W*O
M_2,>?GG_ ,%9?^4;W[9G_9!O&?\ Z*M:_P W*;_6R_\ 71__ $(U_I&_\%9?
M^4;W[9G_ &0;QG_Z*M:_S<I03-*!NR9' "H9&R6.-L89#(W]V)71I&Q&'0L&
M'L^#_P#R)<R_[&DO_43"G@>.?_)191_V)U_ZF8DCHK]/?VF/V<?V:/AYX!^
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M_P#)99I_U[R__P!5^%/ZY\)/^2#R?_K[F?\ ZM,8%%%%?!GZ2%%%% !1110
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M/^>5\7B\4Z+P[Q%=T&XMT75G[)N*A&-Z?-RNRI4DM-/9T_Y(V_J5_P"#8/\
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M7#IA-H;=,^YPS#:I"K_HJMT/T/\ *O\ .P_X+8_\I/\ ]JC_ +#'PV_]4O\
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M@;_DK<B_[#5_Z:J'Q?B)_P D3Q'_ -B^7_IVD?Q$T445_6I_$84444 %%%%
M!7]W'_!N9_RCRF_[."^,/_H?AFOX1Z_NX_X-S/\ E'E-_P!G!?&'_P!#\,U^
M:^*__)*?]U3!?^F\4?K/@O\ \EG_ -TC'?\ I[!G[SMT/T/\J_SL/^"V/_*3
M_P#:H_[#'PV_]4O\.*_T3VZ'Z'^5?YV'_!;'_E)_^U1_V&/AM_ZI?X<5^?\
MA#_R46/_ .Q+7_\ 4[+S].\<_P#DELL_['^'_P#5=F9^5]%%%?T4?RP%%%%
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MD_Q*K^PNOX]/^#8/_DIG[7__ &(7P5_]2?XE5_877\M^)?\ R66:?]>\O_\
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M27<O0XB*]<,17YKXK_\ )*?]U3!?^F\4?K/@O_R6?_=(QW_I[!G[\-T/T/\
M*O\ .P_X+8_\I/\ ]JC_ +#'PV_]4O\ #BO]#0ZM>X/_ !3FM]#_ ,M-!_\
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MG'^V3')H>K6J-\"/&2F>=](,48,=K\SBWU:>;:.IV1.V <*3@'_.'F_ULO\
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M_P"4DG_!"G_LZW]J#_UCGX@UXI_P<J_\F2?"#_LYSPE_ZJ_XJU[7_P %)_\
ME))_P0IZ_P#)UO[4'0$_\V<_$'T_6O%/^#E4'_AB3X0\-Q^TYX2SE2/^:7_%
M48Y'7.1CV-?5\#?\E;D7_8:O_350^+\1/^2)XC_[%\O_ $[2/XB:*7!]#^1H
MP?0_D:_K4_B,2BEP?0_D:,'T/Y&@!**7!]#^1HP?0_D: $K^[C_@W,_Y1Y3?
M]G!?&'_T/PS7\)&#Z'\C7]V__!N;Q_P3RFR#_P G!?&'L2.7\,XY [X-?FOB
MO_R2G_=4P7_IO%'ZSX+_ /)9_P#=(QW_ *>P9^\[=#]#_*O\[#_@MC_RD_\
MVJ/^PQ\-O_5+_#BO]$XG@]>A_A/^%?YV7_!; $_\%/OVI^#_ ,ACX:GH>A^"
M_P .,'IW[5^?^$/_ "46/_[$M?\ ]3LO/T[QS_Y);+/^Q_A__5=F9^5U%+@^
MA_(T8/H?R-?T4?RP)12X/H?R-&#Z'\C0 E%+@^A_(T8/H?R- 'H'PE_Y*O\
M"O\ [*C\-/\ U/?#M?ZKD?W3_OR?^C&K_*D^$H/_  M?X5\'_DJ/PT[?]3[X
M=K_5:0\'@_?D_A;O(Q';TK\*\9/XV0?X,S_/+S^C? ;^!Q-_U]RK_P!(QY^>
MG_!67_E&]^V9_P!D&\9_^BK6O\W*;_6R_P#71_\ T(U_I&_\%9.?^";W[9F
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M^BN_MY_^)5ZE_P#,77]+M%']IYE_T,,=_P"%=?\ ^6>2^X/[)RK_ *%>7?\
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MAWXJT*-_#?P,\&Z)X/\ #5AI]_KBIJS>(?$WBKQ3KL'QT_X)_P#QF^+WP/\
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MOX&^%/QC\&?#'P+<WVL?\+G\,^*/ GC;Q%<?%KPS/96\&E>!H_%_P_\ BO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ;X6\7_%K3/ &A7'[+?Q1M](L;#P5X;TWQ]%X8T[PMJ7PV_HQHH _'#X;_\
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M.PU+2+?]G/PIXU\.W&NWNI6^JW-C?3^-KWQG<ZP=+T[2-&TWPPELNCZ9'<6
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M\2/$WP@_9I^.'Q/\&2V,'BOP'\-/%/BCP_-J5DNI6$6JZ3I[W-F]W8/+"MW
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M9?V7C_:7]ES>T]I"W-R\FG,_Y*^D-]%S_B//$&0Y[_KM_JO_ &)D]3*?JO\
MJZ\Y^L^TQM7&>W]M_;F5>QM[7V?LO95;\O-[17Y5_,#_ ,$!8I8_BS^T-YD4
ML>?ASX(P9(I(P2/%>K9 +JH)Y!X)_0X_J*J"*VMX"3#!#$6 #&.*.,D#D E%
M4D9['-3U^?>)7&__ !$/B[,.*?[-_LGZ]1P-+ZC]<^O>S^I8*A@^;ZS]5P?/
M[3V'M+>PCR<W+>5N9_K_ (+>&7_$(/#W*. _[:_U@_LK$9G7_M3^S_[+]O\
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MEK<77V+SQ ;B<P^9Y9FE*^8W744 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6792565664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jan. 29, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218,672,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,898,425,323<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6793037376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 9,188.5<span></span>
</td>
<td class="nump">$ 8,203.4<span></span>
</td>
<td class="nump">$ 5,542.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnconsolidatedJointBusiness', window );">Unconsolidated joint business</a></td>
<td class="nump">1,339.2<span></span>
</td>
<td class="nump">1,195.4<span></span>
</td>
<td class="nump">1,126.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">236.1<span></span>
</td>
<td class="nump">304.5<span></span>
</td>
<td class="nump">263.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">10,763.8<span></span>
</td>
<td class="nump">9,703.3<span></span>
</td>
<td class="nump">6,932.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of sales, excluding amortization of acquired intangible assets</a></td>
<td class="nump">1,240.4<span></span>
</td>
<td class="nump">1,171.0<span></span>
</td>
<td class="nump">857.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">2,012.8<span></span>
</td>
<td class="nump">1,893.4<span></span>
</td>
<td class="nump">1,444.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,113.1<span></span>
</td>
<td class="nump">2,232.3<span></span>
</td>
<td class="nump">1,712.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">382.6<span></span>
</td>
<td class="nump">489.8<span></span>
</td>
<td class="nump">342.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">93.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationProfitSharing', window );">Collaboration profit sharing</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">85.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="nump">30.5<span></span>
</td>
<td class="num">(38.9)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">5,872.8<span></span>
</td>
<td class="nump">5,747.7<span></span>
</td>
<td class="nump">4,441.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GainOnSaleOfRights', window );">Gain on sale of rights</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">4,891.0<span></span>
</td>
<td class="nump">3,972.4<span></span>
</td>
<td class="nump">2,515.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(123.7)<span></span>
</td>
<td class="num">(25.8)<span></span>
</td>
<td class="num">(34.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">4,767.3<span></span>
</td>
<td class="nump">3,946.6<span></span>
</td>
<td class="nump">2,480.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">1,161.6<span></span>
</td>
<td class="nump">989.9<span></span>
</td>
<td class="nump">601.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of investee, net of tax</a></td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
<td class="nump">17.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">3,593.2<span></span>
</td>
<td class="nump">2,941.6<span></span>
</td>
<td class="nump">1,862.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">46.2<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 3,547.0<span></span>
</td>
<td class="nump">$ 2,934.8<span></span>
</td>
<td class="nump">$ 1,862.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 15.38<span></span>
</td>
<td class="nump">$ 12.42<span></span>
</td>
<td class="nump">$ 7.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 15.34<span></span>
</td>
<td class="nump">$ 12.37<span></span>
</td>
<td class="nump">$ 7.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">230.7<span></span>
</td>
<td class="nump">236.4<span></span>
</td>
<td class="nump">236.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">231.2<span></span>
</td>
<td class="nump">237.2<span></span>
</td>
<td class="nump">238.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GainOnSaleOfRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on sale of our royalty and other rights related to future sales of BENLYSTA recognized in our consolidated statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GainOnSaleOfRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnconsolidatedJointBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from unconsolidated joint business consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnconsolidatedJointBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35755396&amp;loc=d3e33749-111570<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 9<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 11<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 3, 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51677171&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6965399840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 3,547.0<span></span>
</td>
<td class="nump">$ 2,934.8<span></span>
</td>
<td class="nump">$ 1,862.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains (losses) recognized during the period, net of tax</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Less: reclassification adjustment for (gains) losses included in net income, net of tax</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="num">(6.4)<span></span>
</td>
<td class="num">(10.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax', window );">Unrealized gains (losses) recognized during the period, net of tax</a></td>
<td class="nump">110.8<span></span>
</td>
<td class="nump">101.7<span></span>
</td>
<td class="num">(26.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax', window );">Less: reclassification adjustment for (gains) losses included in net income, net of tax</a></td>
<td class="num">(172.3)<span></span>
</td>
<td class="num">(6.3)<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="num">(61.5)<span></span>
</td>
<td class="nump">95.4<span></span>
</td>
<td class="num">(13.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation</a></td>
<td class="num">(6.2)<span></span>
</td>
<td class="num">(12.0)<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(96.4)<span></span>
</td>
<td class="num">(109.2)<span></span>
</td>
<td class="nump">37.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(164.5)<span></span>
</td>
<td class="num">(31.8)<span></span>
</td>
<td class="nump">27.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">3,382.5<span></span>
</td>
<td class="nump">2,903.0<span></span>
</td>
<td class="nump">1,889.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">46.2<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 3,428.7<span></span>
</td>
<td class="nump">$ 2,909.8<span></span>
</td>
<td class="nump">$ 1,889.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4613674-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569643-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of (increase) decrease in accumulated other comprehensive (income) loss related to pension and other postretirement defined benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e689-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph c<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=d3e41638-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6792946016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,308.0<span></span>
</td>
<td class="nump">$ 1,204.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">2,120.5<span></span>
</td>
<td class="nump">640.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,227.0<span></span>
</td>
<td class="nump">1,292.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DueFromUnconsolidatedJointBusiness', window );">Due from unconsolidated joint business, net</a></td>
<td class="nump">314.5<span></span>
</td>
<td class="nump">283.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">893.4<span></span>
</td>
<td class="nump">804.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">836.9<span></span>
</td>
<td class="nump">309.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,700.3<span></span>
</td>
<td class="nump">4,535.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">2,760.4<span></span>
</td>
<td class="nump">1,470.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">2,187.6<span></span>
</td>
<td class="nump">1,765.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">4,085.1<span></span>
</td>
<td class="nump">4,028.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,663.8<span></span>
</td>
<td class="nump">1,760.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">1,107.6<span></span>
</td>
<td class="nump">754.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">19,504.8<span></span>
</td>
<td class="nump">14,314.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of notes payable and other financing arrangements</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">208.7<span></span>
</td>
<td class="nump">168.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">267.4<span></span>
</td>
<td class="nump">229.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">2,096.8<span></span>
</td>
<td class="nump">1,817.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,577.7<span></span>
</td>
<td class="nump">2,218.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable and other financing arrangements</a></td>
<td class="nump">6,521.5<span></span>
</td>
<td class="nump">580.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Long-term deferred tax liability</a></td>
<td class="nump">124.9<span></span>
</td>
<td class="nump">52.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">905.8<span></span>
</td>
<td class="nump">650.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 10,129.9<span></span>
</td>
<td class="nump">$ 3,500.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4,196.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(224.0)<span></span>
</td>
<td class="num">(59.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">12,208.4<span></span>
</td>
<td class="nump">9,283.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 22.6 million shares, respectively</a></td>
<td class="num">(2,611.7)<span></span>
</td>
<td class="num">(2,611.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">9,372.8<span></span>
</td>
<td class="nump">10,809.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">9,374.9<span></span>
</td>
<td class="nump">10,814.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 19,504.8<span></span>
</td>
<td class="nump">$ 14,314.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DueFromUnconsolidatedJointBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from unconsolidated joint business for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DueFromUnconsolidatedJointBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3-4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Subparagraph a(1)<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 4<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 12<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Available-for-Sale Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, netted by jurisdiction and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 25<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20, 22<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 27<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6687302864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock at cost, shares</a></td>
<td class="nump">22.6<span></span>
</td>
<td class="nump">22.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6792722208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 3,593.2<span></span>
</td>
<td class="nump">$ 2,941.6<span></span>
</td>
<td class="nump">$ 1,862.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">600.4<span></span>
</td>
<td class="nump">688.1<span></span>
</td>
<td class="nump">531.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">161.4<span></span>
</td>
<td class="nump">155.3<span></span>
</td>
<td class="nump">136.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(145.6)<span></span>
</td>
<td class="num">(308.2)<span></span>
</td>
<td class="num">(245.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">82.2<span></span>
</td>
<td class="num">(50.3)<span></span>
</td>
<td class="num">(27.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">29.0<span></span>
</td>
<td class="num">(512.4)<span></span>
</td>
<td class="num">(126.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(174.4)<span></span>
</td>
<td class="num">(185.9)<span></span>
</td>
<td class="num">(243.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(156.6)<span></span>
</td>
<td class="num">(94.5)<span></span>
</td>
<td class="num">(160.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">74.2<span></span>
</td>
<td class="nump">244.3<span></span>
</td>
<td class="nump">284.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Current taxes payable</a></td>
<td class="num">(410.2)<span></span>
</td>
<td class="nump">61.0<span></span>
</td>
<td class="nump">156.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other long-term liabilities and taxes payable</a></td>
<td class="nump">93.6<span></span>
</td>
<td class="nump">33.8<span></span>
</td>
<td class="nump">161.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Due from unconsolidated joint business</a></td>
<td class="num">(31.1)<span></span>
</td>
<td class="num">(30.7)<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows provided by operating activities</a></td>
<td class="nump">3,716.1<span></span>
</td>
<td class="nump">2,942.1<span></span>
</td>
<td class="nump">2,345.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">4,063.0<span></span>
</td>
<td class="nump">2,718.9<span></span>
</td>
<td class="nump">5,190.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(6,864.9)<span></span>
</td>
<td class="num">(3,583.1)<span></span>
</td>
<td class="num">(3,278.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of TYSABRI rights</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(3,262.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Contingent consideration related to Fumapharm AG acquisition</a></td>
<td class="num">(850.0)<span></span>
</td>
<td class="num">(375.0)<span></span>
</td>
<td class="num">(15.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of businesses</a></td>
<td class="num">(198.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(643.0)<span></span>
</td>
<td class="num">(287.8)<span></span>
</td>
<td class="num">(246.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(59.9)<span></span>
</td>
<td class="num">(16.0)<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(4,553.6)<span></span>
</td>
<td class="num">(1,543.0)<span></span>
</td>
<td class="num">(1,604.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury stock</a></td>
<td class="num">(5,000.0)<span></span>
</td>
<td class="num">(886.8)<span></span>
</td>
<td class="num">(400.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of stock for share-based compensation arrangements</a></td>
<td class="nump">54.2<span></span>
</td>
<td class="nump">54.9<span></span>
</td>
<td class="nump">66.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities', window );">Excess tax benefit from share-based compensation</a></td>
<td class="nump">78.2<span></span>
</td>
<td class="nump">96.4<span></span>
</td>
<td class="nump">73.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from borrowings</a></td>
<td class="nump">5,930.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of borrowings</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="num">(452.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(74.4)<span></span>
</td>
<td class="num">(17.7)<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by (used in) financing activities</a></td>
<td class="nump">986.4<span></span>
</td>
<td class="num">(755.9)<span></span>
</td>
<td class="num">(716.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">148.9<span></span>
</td>
<td class="nump">643.2<span></span>
</td>
<td class="nump">23.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(45.8)<span></span>
</td>
<td class="num">(40.9)<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of the year</a></td>
<td class="nump">1,204.9<span></span>
</td>
<td class="nump">602.6<span></span>
</td>
<td class="nump">570.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of the year</a></td>
<td class="nump">$ 1,308.0<span></span>
</td>
<td class="nump">$ 1,204.9<span></span>
</td>
<td class="nump">$ 602.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section I<br> -Subsection 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other assets used in operating activities less other operating liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets and liabilities, other noncurrent assets and liabilities, or a combination of other current and noncurrent assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current liabilities, other noncurrent liabilities, or a combination of other current and noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other income (expense) included in net income that results in no cash inflows or outflows in the period. Includes noncash adjustments to reconcile net income (loss) to cash provided by (used in) operating activities that are not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow or inflow from other investing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of or capital improvements on other tangible or intangible assets not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow from other financing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3095-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3098-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6800013936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total Biogen Inc. shareholders' equity</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Noncontrolling interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2012</a></td>
<td class="num">$ (6,963.8)<span></span>
</td>
<td class="num">$ (6,961.5)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (3,854.5)<span></span>
</td>
<td class="nump">$ 55.3<span></span>
</td>
<td class="num">$ (4,486.8)<span></span>
</td>
<td class="num">$ (1,324.6)<span></span>
</td>
<td class="num">$ (2.3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning Balance, shares at Dec. 31, 2012</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(254,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,862.3<span></span>
</td>
<td class="nump">1,862.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,862.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">27.6<span></span>
</td>
<td class="nump">27.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Deconsolidation of noncontrolling interests</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="num">(400.3)<span></span>
</td>
<td class="num">(400.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (400.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">66.7<span></span>
</td>
<td class="nump">66.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">66.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="num">(89.7)<span></span>
</td>
<td class="num">(89.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(89.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense related to share-based payments</a></td>
<td class="nump">146.2<span></span>
</td>
<td class="nump">146.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Tax benefit from share-based payments</a></td>
<td class="nump">45.9<span></span>
</td>
<td class="nump">45.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2013</a></td>
<td class="num">(8,620.8)<span></span>
</td>
<td class="num">(8,620.2)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">(4,023.6)<span></span>
</td>
<td class="num">(27.7)<span></span>
</td>
<td class="num">(6,349.1)<span></span>
</td>
<td class="num">$ (1,724.9)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, shares at Dec. 31, 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(256,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,941.6<span></span>
</td>
<td class="nump">2,934.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,934.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">31.8<span></span>
</td>
<td class="nump">31.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distribution to noncontrolling interests</a></td>
<td class="num">(9.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Acquisition of noncontrolling interests</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="num">$ (886.8)<span></span>
</td>
<td class="num">(886.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (886.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="num">(2,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">$ 54.9<span></span>
</td>
<td class="nump">54.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">54.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="num">(140.3)<span></span>
</td>
<td class="num">(140.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(140.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense related to share-based payments</a></td>
<td class="nump">165.0<span></span>
</td>
<td class="nump">165.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Tax benefit from share-based payments</a></td>
<td class="nump">93.0<span></span>
</td>
<td class="nump">93.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2014</a></td>
<td class="num">(10,814.0)<span></span>
</td>
<td class="num">(10,809.0)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">(4,196.2)<span></span>
</td>
<td class="num">(59.5)<span></span>
</td>
<td class="num">(9,283.9)<span></span>
</td>
<td class="num">$ (2,611.7)<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, shares at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(257,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">3,593.2<span></span>
</td>
<td class="nump">3,547.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,547.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="num">(164.5)<span></span>
</td>
<td class="num">(164.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(164.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distribution to noncontrolling interests</a></td>
<td class="num">(60.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Acquisition of noncontrolling interests</a></td>
<td class="nump">10.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="num">$ (5,000.0)<span></span>
</td>
<td class="num">(5,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="num">(16,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to the 2015 Share Repurchase Program, at cost</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">4,377.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">622.5<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to the 2015 Share Repurchase Program, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">54.2<span></span>
</td>
<td class="nump">54.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">54.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="num">$ (125.1)<span></span>
</td>
<td class="num">(125.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(125.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense related to share-based payments</a></td>
<td class="nump">$ 183.2<span></span>
</td>
<td class="nump">183.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Tax benefit from share-based payments</a></td>
<td class="nump">69.0<span></span>
</td>
<td class="nump">69.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2015</a></td>
<td class="num">$ (9,374.9)<span></span>
</td>
<td class="num">$ (9,372.8)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (224.0)<span></span>
</td>
<td class="num">$ (12,208.4)<span></span>
</td>
<td class="num">$ (2,611.7)<span></span>
</td>
<td class="num">$ (2.1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, shares at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(241,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6419406&amp;loc=d3e23524-113945<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in noncontrolling interest balance because of a business combination that occurred during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares (units) reissued during the period, excluding reissuance of shares (units) held in treasury used to satisfy equity-based compensation obligations exercised by the holders of such rights. Upon reissuance of shares (units) from treasury, either the common or preferred stock (unit) reissued is outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of treasury stock (units) reissued during the period, excluding reissuance of shares (units) held in treasury used to satisfy equity-based compensation obligations exercised by the holders of such rights. Upon reissuance of shares (units) from treasury, either the common or preferred stock (unit) reissued is outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6788134400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. We also have a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, which entitles us to certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL, and other potential anti-CD20 therapies.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our innovative drug development efforts, we aim to leverage our manufacturing capabilities and scientific expertise to extend our mission to improve the lives of patients living with serious diseases through the development, manufacture and marketing of biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. Product revenues are recorded net of applicable reserves for discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We establish reserves for trade term discounts, wholesaler incentives, Medicaid rebates, co-payment assistance (copay), Veterans Administration (VA) and Public Health Service (PHS) discounts, managed care rebates, product returns and other governmental rebates or applicable allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Reserves established for these discounts and allowances are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These reserves are based on estimates of the amounts earned or to be claimed on the related sales. Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves are categorized as follows: discounts, contractual adjustments and returns.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, patient copay assistance, VA and PHS discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid, and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consists of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Copay represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other governmental rebates or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the discounts, rebates and product returns described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify these payments in selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Unconsolidated Joint Business</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from unconsolidated joint business consists of (i)&#160;our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; (ii)&#160;reimbursement of our selling and development expenses in the U.S. for RITUXAN; and (iii)&#160;revenue on sales in the rest of world for RITUXAN, which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales outside the U.S. and Canada by the Roche Group and its sublicensees. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by Genentech in the U.S. and by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less the cost to manufacture, third-party royalty expenses, distribution, selling, and marketing expenses, and joint development expenses incurred by Genentech, the Roche Group and us. We record our share of the pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales outside the U.S. on a cash basis as we do not have the ability to estimate these profits or royalty revenue in the period incurred. Additionally, our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. includes estimates made by Genentech and those estimates are subject to change. Actual results may differ from our estimates. For additional information related to our collaboration with Genentech, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. If we are unable to reasonably estimate royalty revenue or do not have access to the information, then we record royalty revenues on a cash basis. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Multiple-Element Revenue Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may enter into transactions that involve the sale of products and related services under multiple element arrangements.&#160;In accounting for these transactions, we assess the elements of the contract and whether each element has standalone value and allocate revenue to the various elements based on their estimated selling price as a component of total revenues.&#160;The selling price of a revenue generating element can be based on current selling prices offered by us or another party for current products or management&#8217;s best estimate of a selling price. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;2</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, derivative contracts, marketable debt securities, and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We validate the prices provided by our third-party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources and analyzing pricing data in certain instances. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying amounts reflected in the consolidated balance sheets for current accounts receivable, due from unconsolidated joint business, other current assets, accounts payable, and accrued expenses and other, approximate fair value due to their short-term maturities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consider only those investments which are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, cash equivalents were comprised of money market funds and commercial paper, overnight reverse repurchase agreements, and other debt securities with maturities less than 90 days from the date of purchase.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our consolidated statement of income.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The credit and economic conditions in certain countries in the E.U. continue to remain uncertain and have, from time to time, led to a lengthening of time to collect our accounts receivable in some of these countries. In recent years, our collection efforts in Portugal and select regions of Spain have been subject to significant payment delays due to government funding and reimbursement practices. As a result, a portion of these receivables have been routinely collected beyond our contractual payment terms and over periods in excess of one year. Our accounts receivable collection efforts in Portugal and Spain have improved during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> with our receivables in Spain now expected to be collected within one year. Our net accounts receivable balance from product sales in Portugal and Spain totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were classified as non-current and included in investments and other assets in our consolidated balance sheets. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives, and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable arise from product sales in the U.S. and Europe and have standard payment terms which generally require payment within </font><font style="font-family:inherit;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 to 90 days</font></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, two wholesale distributors individually accounted for approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.4%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.1%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.4%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of accounts receivable, net, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Marketable Securities and Other Investments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Available-for-sale debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheet. When assessing whether a decline in the fair value of a marketable equity security is other-than-temporary, we consider the fair market value of the security, the duration of the security&#8217;s decline, and prospects for the underlying business, including favorable or adverse clinical trial results, new product initiatives and new collaborative agreements with the companies in which we have invested.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the cost method or the equity method of accounting, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any decline in their value has occurred that would be other-than-temporary, based on the implied value of recent company financings, public market prices of comparable companies, and general market conditions and are included in investments and other assets in our consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Evaluating Investments for Other-than-Temporary Impairments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For equity securities, when assessing whether a decline in value is other-than-temporary, we consider the fair market value of the security, the duration of the security&#8217;s decline, and the financial condition of the issuer. We then consider our intent and ability to hold the equity security for a period of time sufficient to recover our carrying value. Where we have determined that we lack the intent and ability to hold an equity security to its expected recovery, the security&#8217;s decline in fair value is deemed to be other-than-temporary and is reflected in earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Equity Method of Accounting</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In circumstances where we have the ability to exercise significant influence over the operating and financial  policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship.&#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceed the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when selected for use in a clinical manufacturing campaign.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Capitalization of Inventory Costs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Obsolescence and Unmarketable Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring which we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from </font><font style="font-family:inherit;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three to five years</font></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td width="50%" rowspan="1" colspan="1"></td><td width="50%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts on our consolidated balance sheet and include any resulting gain or loss in our consolidated statement of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded as amortization of acquired intangible assets in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd (Elan), an affiliate of Elan Corporation, plc. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TYSABRI and AVONEX using the economic consumption method based on revenue generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TYSABRI and AVONEX is performed annually during our long range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of TYSABRI or AVONEX.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives, however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired In-process Research and Development (IPR&amp;D)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value. The revenue and costs projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology, and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business, then the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Certain IPR&amp;D programs have a fair value that is not significantly in excess of carrying value, including our program for the treatment of TGN. Such programs could become impaired if assumptions used in determining the fair value change.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, then we would need to determine the implied fair value of our reporting unit&#8217;s goodwill. If the carrying value of our reporting unit&#8217;s goodwill exceeds its implied fair value, then we would record an impairment loss equal to the difference. As described in Note&#160;24, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements, we operate in one operating segment which we consider our only reporting unit.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used, including property, plant and equipment and definite-lived intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions that qualify as business combinations completed after January&#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue these contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step, and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Derivative Instruments and Hedging Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of derivatives are recorded each period in current earnings or accumulated other comprehensive income (loss), depending on whether a derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We also assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion to current earnings. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Translation of Foreign Currencies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net, in net income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Royalty Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Share-Based Compensation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share-based compensation programs grant awards that have included stock options, restricted stock units which vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units which settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units which can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of the Board of Directors and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date on which the employee is retirement eligible.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&#8217; vesting periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures, when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs and PUs and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs and PUs are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price of common stock under our ESPP is equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the lesser of (i)&#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes model. The fair value of the look-back provision plus the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> discount is recognized as compensation expense over the 90 day purchase period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable, and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets on our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of unconsolidated joint business revenues.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For collaborations with commercialized products, if we are the principal, we record revenue and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Advertising costs are expensed as incurred. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, advertising costs totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$108.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$92.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$72.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All tax effects associated with intercompany transfers of assets in our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through the consolidated statement of income when the asset transferred is sold to a third party or otherwise recovered through amortization of the asset's remaining economic life.&#160;If the asset transferred becomes impaired, for example through the discontinuation of a research program, we will expense any remaining deferred charge or prepaid tax.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Earnings per Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2014, the FASB issued ASU No. 2014-11, Transfers and Servicing (Topic 860): Repurchase-to-Maturity Transactions, Repurchase Financings, and Disclosure. The new standard expanded secured borrowing accounting to include repurchase-to-maturity transactions and repurchase financings and set forth new disclosure requirements for repurchase agreements, securities lending transactions, and repurchase-to-maturity transactions that are accounted for as secured borrowings. We adopted this standard on April 1, 2015 and expanded our disclosures presented in Note 8, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. The adoption of this standard did not have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015, the FASB issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The new standard requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU No. 2015-15, Interest - Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements, which clarified that debt issuance costs related to line-of-credit arrangements can be presented in the balance sheet as an asset and amortized over the term of the line-of-credit arrangement. We adopted these standards as of September 30, 2015 with retroactive application. The adoption of these standards did not have a significant impact on our financial position or results of operations. For additional information, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015, the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. Under this standard, if a cloud computing arrangement includes a software license, the software license element of the arrangement should be accounted for consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015, the FASB issued ASU No. 2015-07, Fair Value Measurement (Topic 820): Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent). The new standard removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The new standard will be effective for us on January 1, 2016. Early application is permitted. We maintain investments in certain venture capital funds which primarily invest in small, privately-owned, venture-backed biotechnology companies. The value of our investments in these venture capital funds is estimated using the net asset value of the fund and has been included in the fair value hierarchy disclosure as a Level 3 measurement. These venture capital investments are not material to our financial position or results of operations. We adopted this standard as of June 30, 2015 and our investments in venture capital funds are no longer included in our disclosures reflected in Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The new standard applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The new standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined and sets forth new disclosure requirements related to the adjustments. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. The new standard requires that deferred tax assets and liabilities be classified as noncurrent in a classified statement of financial position. We adopted this standard as of December 31, 2015 with retroactive application. As a result, we reclassified our deferred tax assets classified as current to noncurrent and our deferred tax liabilities classified as current to noncurrent in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> consolidated balance sheet, to conform our prior year presentation to our current year presentation. For additional information, please read Note 16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964257488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Acquisitions</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Convergence Pharmaceuticals</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 12, 2015, we completed our acquisition of all of the outstanding stock of Convergence Pharmaceuticals (Convergence), a clinical-stage biopharmaceutical company with a focus on developing product candidates for neuropathic pain. Convergence&#8217;s lead candidate is a Phase 2 clinical candidate Raxatrigine (CNV1014802), which has demonstrated clinical activity in proof-of-concept studies for trigeminal neuralgia (TGN). Additionally, Raxatrigine has potential applicability in several other neuropathic pain states. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price consisted of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> cash payment at closing, plus contingent consideration in the form of development and approval milestones up to a maximum of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$450.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$350.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is associated with the development and approval of Raxatrigine for the treatment of TGN. The acquisition was funded from our existing cash on hand and has been accounted for as the acquisition of a business. In addition to obtaining the rights to Raxatrigine and additional product candidates in preclinical development, we retained the services of key employees of Convergence.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence, we recorded a liability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> representing the fair value of the contingent consideration.&#160;This amount was estimated through a valuation model that incorporates industry-based probability adjusted assumptions relating to the achievement of these milestones and thus the likelihood of making the contingent payments. This fair value measurement is based upon significant inputs not observable in the market and therefore represents a Level 3 measurement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price, as adjusted, consisted of the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash portion of consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">200.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">274.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">474.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the second quarter of 2015, we adjusted our preliminary estimate of the fair value of the assets acquired and contingent consideration as of the date of acquisition as a result of finalizing the purchase price accounting. This resulted in an increase in the value of our estimated contingent consideration and goodwill by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$36.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our revised purchase price allocation is reflected in the chart below. Our purchase price allocation is substantially complete.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subsequent changes in the fair value of the contingent consideration obligation will be recognized as adjustments to contingent consideration and reflected in our consolidated statements of income. For additional information related to the fair value of this obligation, please read Note 7,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of February&#160;12, 2015, as adjusted:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">424.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">128.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(84.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">474.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of the IPR&amp;D programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was primarily driven by the value associated with the lead candidate, Raxatrigine, which is in development for the treatment of TGN and is expected to be completed no earlier than 2020, at a remaining cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$145.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value associated with Raxatrigine for the treatment of TGN was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have recorded additional IPR&amp;D assets related to the use of Raxatrigine in two additional neuropathic pain indications, with a total estimated value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$220.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The remaining cost of development for these two indications is approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$415.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with an expected completion date of no earlier than 2021. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have attributed the goodwill recognized to the Convergence workforce's expertise in chronic pain research and clinical development and to establishing a deferred tax liability for the acquired IPR&amp;D intangible assets which have no tax basis. The goodwill is not tax deductible.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pro forma results of operations would not be materially different as a result of the acquisition of Convergence and therefore are not presented. Subsequent to the acquisition date, our results of operations include the results of operations of Convergence.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TYSABRI</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On April 2, 2013, we acquired full ownership of all remaining rights to TYSABRI from Elan that we did not already own or control. Upon the closing of the transaction, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Elan, which was funded from our existing cash, and our collaboration agreement with Elan was terminated. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as the acquisition of an asset as we did not acquire any employees from Elan nor did we acquire any significant processes that we did not previously perform or manage under the collaboration agreement. Under the collaboration agreement, we manufactured TYSABRI and collaborated with Elan on the product's marketing, commercial, regulatory, distribution and ongoing development activities. The collaboration agreement was designed to effect an equal sharing of worldwide profits and losses generated by the activities of the collaboration. For additional information related to this collaboration, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment was capitalized in the second quarter of 2013 as an intangible asset in our consolidated balance sheet as TYSABRI had reached technological feasibility. We adjusted the value of this intangible asset by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$84.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to deferred revenue from two sales-based milestones previously paid by Elan as well as transaction costs. The net intangible asset capitalized was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.18 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Commencing in the second quarter of 2013, we began amortizing this intangible asset over the estimated useful life using an economic consumption method based on actual and expected revenue generated from the sales of our TYSABRI product. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the April 2, 2013 closing of the transaction, we began recording 100% of U.S. revenues, cost of sales and operating expenses related to TYSABRI in our consolidated statements of income. Under the terms of the acquisition agreement, we continued to share TYSABRI profits with Elan on an equal basis until April 30, 2013. We recorded the profit split for the month ended April 30, 2013, as cost of sales in our consolidated statements of income as we controlled TYSABRI effective April 2, 2013. Between May 1, 2013 and April 30, 2014, we made contingent payments to Elan of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on worldwide net sales of TYSABRI. Commencing May 1, 2014 and thereafter, we will make contingent payments to Elan of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net sales up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net sales that exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In 2014, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> threshold was pro-rated for the portion of 2014 remaining after the first 12 months expired. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013. Following that acquisition, we began making these royalty payments to Perrigo. Royalty payments to Perrigo and other third parties are recognized as cost of sales in our consolidated statements of income.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6788122928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Restructuring</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On October 21, 2015, we announced a corporate restructuring, which includes the termination of certain pipeline programs and an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in workforce. We anticipate making cash payments totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under this program, which includes approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to previously 2015 accrued incentive compensation, for a total net expected restructuring charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$105 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These amounts will be substantially incurred and paid by the end of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of these charges during the fourth quarter of 2015, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$86.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was related to our workforce reduction and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was related to the pipeline program terminations.&#160;Our restructuring reserve is included in accrued expenses and other in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the charges and spending related to our restructuring efforts during 2015:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Workforce</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reduction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Pipeline</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges incurred during the fourth quarter of 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">86.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">93.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Previously accrued incentive compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves established</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">102.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">109.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts paid through December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(68.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(72.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 3, 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964173744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Reserves<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReservesForDiscountsAndAllowancesAbstract', window );"><strong>Reserves for Discounts and Allowances [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Reserves for Discounts and Allowances</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of our acquisition of all remaining rights to TYSABRI from Elan, we began recognizing reserves for discounts and allowances for U.S. TYSABRI revenue in the second quarter of 2013. In addition, following our recently launched products, we began recognizing reserves for discounts and allowances related to these products' revenue. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">387.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">49.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">483.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">459.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,732.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,229.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(32.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(405.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,258.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,666.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(44.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(296.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(351.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">56.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">548.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">57.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">662.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2014</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">345.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">426.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">347.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,265.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,651.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(28.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(299.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(933.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,237.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(46.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(261.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(33.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(341.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">387.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">483.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2013</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">861.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,120.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(189.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(560.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(750.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(135.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(165.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">345.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">426.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total revenue-related reserves above, included in our consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">144.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">124.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">518.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">359.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">662.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">483.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReservesForDiscountsAndAllowancesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReservesForDiscountsAndAllowancesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any allowance and reserve accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period). Alternatively, disclosure of the required information may be within the footnotes to the financial statements or a supplemental schedule to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 09<br> -Article 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6788113776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">213.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">128.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">577.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">511.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">143.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">164.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">933.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">804.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">893.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">804.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">933.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">804.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory included in investments and other assets in our consolidated balance sheets primarily consisted of work in process.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our inventory included </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with our ZINBRYTA program, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with our BENEPALI program and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with our FLIXABI program, which have been capitalized in advance of regulatory approval. In January 2016, the European Commission (EC) approved the marketing authorization application (MAA) for BENEPALI for marketing in the E.U. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our inventory included </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with our ZINBRYTA program, which has been capitalized in advance of regulatory approval. For information on our pre-approval inventory policy, please read Note 1,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 6<br> -Subparagraph a, b, c<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964231408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td width="21%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(506.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(481.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,552.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">452.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,396.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">608.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">730.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">730.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">314.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">314.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks and tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,303.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(502.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,800.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,280.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(300.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,980.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,646.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3,561.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,085.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,207.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,178.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,028.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$382.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$489.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$342.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Amortization of acquired intangible assets during 2014 included total impairment charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to one of our out-licensed patents and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to one of our IPR&amp;D intangible assets. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Out-licensed Patents</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents to third-parties primarily relate to patents acquired in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. During 2014, we recorded a charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the impairment of one of our out-licensed patents to reflect a change in its estimated fair value, due to a change in the underlying competitive market for that product. The charge was included in amortization of acquired intangible assets. The fair value of the intangible asset was based on a discounted cash flow calculated using Level 3 fair value measurements and inputs including estimated revenues. There were no impairment charges related to our out-licensed patents during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$443.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquire that have not reached technological feasibility at the date of acquisition. Upon commercialization, we determine the estimated useful life. In connection with our acquisition of Convergence in February 2015, we acquired IPR&amp;D programs with an estimated fair value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$424.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This amount has and will be adjusted for foreign exchange rate fluctuations. For a more detailed description of this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of anticipated lifetime revenues and anticipated development costs is performed annually during our long- range planning cycle, which was updated in the third quarter of 2015.&#160;This analysis is based upon certain assumptions that we evaluate on a periodic basis, including anticipated future product sales, the expected impact of changes in the amount of development costs and the probabilities of our programs succeeding, the introduction of new products by our competitors and changes in our commercial and pipeline product candidates.&#160;&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2014, we updated the probabilities of success related to the early stage programs acquired through our recent acquisitions.&#160;The change in probability of success, combined with a delay in one of the projects, resulted in an impairment loss of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in one of our IPR&amp;D assets during 2014.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,742.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For a more detailed description of this transaction, please read Note&#160;2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"> </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long range planning cycle was completed in the third quarter of 2015. Based upon this analysis, the estimated future amortization of acquired intangible assets is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="81%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">346.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">318.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">291.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">275.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">269.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,500.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,760.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,232.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">908.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">527.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,663.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,760.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$900.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$128.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to our acquisition of Convergence. Other includes changes related to foreign exchange rate fluctuations. The increase in goodwill during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$600.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$72.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to future contingent payments to the former shareholders of Fumapharm AG, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. For additional information related to our acquisition of Convergence, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> accumulated impairment losses related to goodwill.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6588002160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">909.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">909.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,510.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,510.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,875.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,875.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">494.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">494.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">27.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">27.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,895.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,857.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">520.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">716.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">716.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,063.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,063.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">849.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">849.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,943.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,937.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">220.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third-party pricing services. For a description of our validation procedures related to prices provided by third-party pricing services, refer to Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">602.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">634.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,497.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,014.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,764.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,757.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,645.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">647.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our notes payable to Fumedica was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable, and corroborated sources. For additional information related to our debt instruments, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">274.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">30.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(38.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(26.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$301.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques or transfers between fair value measurement levels during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. During the third quarter 2014, we updated the probabilities of success related to the early stage programs acquired through our recent acquisitions. We adjusted the value of our contingent consideration liabilities to reflect these changes. The change in probability of success, combined with a delay in one of the projects, resulted in a net gain of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during 2014, which was&#160;recorded in (gain) loss on fair value remeasurement of contingent consideration and reduced the fair value of our contingent consideration obligations. The fair values of the intangible assets and contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. For additional information related to the valuation techniques and inputs utilized in valuation of our financial assets and liabilities, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence in February 2015, we recorded a liability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing the fair value of the contingent consideration. This valuation was based on probability weighted net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$450.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was the estimated cost of debt financing for market participants. This liability reflects the revised estimate from the date of acquisition for our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. For a more detailed description of this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$297.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$197.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is reflected as a component of accrued expenses and other in our consolidated balance sheets as we expect to make the payment within a year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Stromedix in March 2012, we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$122.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$131.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon probability weighted net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$419.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net increase in the fair value of this obligation was primarily due to changes in the discount rate, partially offset by changes in the expected timing related to the achievement of certain remaining developmental milestones.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon completion of our purchase of the noncontrolling interest in our joint venture investments in Biogen Domp&#233; SRL and Biogen Domp&#233; Switzerland GmbH in September 2011, we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$38.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net decrease in the fair value of this obligation was primarily due to payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of sales-based milestones. Our obligations under this agreement were completed as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Biogen Idec International Neuroscience GmbH (BIN), formerly Panima Pharmaceuticals AG (Panima), in December 2010, we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$81.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$77.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$69.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon probability weighted net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net increase in the fair value of this obligation was primarily due to changes in the probability and expected timing related to the achievement of certain remaining developmental milestones and in the discount rate.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence, we also allocated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$424.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the total purchase price to acquired IPR&amp;D, which was capitalized as an intangible asset. The amount allocated to acquired IPR&amp;D was based on significant inputs not observable in the market and thus represented a Level 3 fair value measurement. This estimate was also adjusted from our preliminary estimate as of the date of acquisition to reflect revised estimates to our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. These assets will be tested for impairment annually until commercialization, after which time the IPR&amp;D will be amortized over its estimated useful life. For a more detailed description of this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6787951984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of </font><font style="font-family:inherit;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less than 90&#160;days</font></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from the date of purchase included in cash and cash equivalents on the accompanying consolidated balance sheet:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">134.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">305.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">673.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">321.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">79.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">909.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">716.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short term maturities. Our overnight reverse repurchase agreements are collateralized with agency-guaranteed mortgage-backed securities and represent approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of total assets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">394.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">394.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,116.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,120.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,723.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,724.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,152.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,155.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">491.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">493.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,880.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,891.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">28.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">370.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">370.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">692.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">693.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">269.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">270.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">579.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,111.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,112.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,120.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,122.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">640.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">640.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,575.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,583.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,343.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,345.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">184.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">185.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">126.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">126.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,880.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,891.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,111.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,112.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;months and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,063.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,718.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,190.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of agency mortgage-backed securities and government securities. Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of agency mortgage-backed securities and corporate securities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$96.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964233952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Derivative Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These contracts have been designated as cash flow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and, beginning in the fourth quarter of 2015, in operating expenses when the expense in the currency being hedged is recorded. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">945.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,174.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss francs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">80.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">76.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Australian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,103.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,302.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$72.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$23.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect all contracts to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments on our consolidated statements of income related to our forecasted revenues:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27" rowspan="1"></td></tr><tr><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">173.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The effect of foreign currency forward contracts designated as hedging instruments on our consolidated statements of income related to our forecasted operating expenses was immaterial for 2015.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interest Rate Lock Contracts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into treasury rate locks, with an aggregated notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, that were designated as cash flow hedges to hedge against changes in the 10-year and 30-year U.S. treasury interest rates that could have impacted our anticipated debt offering. In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, as described in Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we settled the treasury rate locks and realized an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> gain. As the hedging relationship was effective, the gain was recorded in AOCI and will be recognized in other income (expense), net over the life of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interest Rate Swap Contracts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes,  as described in Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with one month durations, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$721.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$23.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to these contracts were recognized as a component of other income (expense), net, for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our consolidated balance sheets for our outstanding derivatives including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="54%" rowspan="1" colspan="1"></td><td width="27%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance&#160;Sheet&#160;Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Fair Value<br clear="none"/>As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="54%" rowspan="1" colspan="1"></td><td width="27%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value<br clear="none"/>As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=d3e41620-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624163-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5579240-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624177-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80784-113994<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=d3e41641-113959<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5579245-113959<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624258-113959<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80748-113994<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5708775-113959<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5708773-113959<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5580258-113959<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624181-113959<br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=d3e41638-113959<br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964231408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">74.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,035.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">947.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">166.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">155.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,079.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,011.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Computer software and hardware</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">647.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">547.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">72.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">441.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">168.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,517.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,952.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,330.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,186.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,187.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,765.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation expense totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$217.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$198.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$187.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we capitalized interest costs related to construction in progress totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research Triangle Park Facility Purchase</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 24, 2015, we purchased from Eisai, Inc. (Eisai) its drug product manufacturing facility and supporting infrastructure in Research Triangle Park (RTP), North Carolina for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$104.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The purchase price consisted of the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">58.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">104.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On August 24, 2015, we also amended our existing </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> year lease related to Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. As amended, the lease provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> year term and our agreement to purchase the facility upon expiration of the lease term and Eisai's completion of certain activities. Accordingly, we recorded the assets along with a corresponding financing obligation on our consolidated balance sheet for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net present value of the future minimum lease payments. The assets were recorded as a component of buildings and machinery and equipment. We expect to complete the purchase of the oral solid products manufacturing facility at the end of the lease term in the third quarter of 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 1, 2015, we purchased land in Solothurn, Switzerland for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">). We plan to build a biologics manufacturing facility on this land in the Commune of Luterbach over the next several years. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$99.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> capitalized in construction in progress related to the construction of this facility. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Weston Exit Costs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of our decision to relocate our corporate headquarters to Cambridge, Massachusetts, we vacated part of our Weston, Massachusetts facility in the fourth quarter of 2013. We incurred a charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in connection with this move. This charge represented our remaining lease obligation for the vacated portion of our Weston, Massachusetts facility, net of sublease income expected to be received. The term of our sublease for the vacated portion of our Weston, Massachusetts facility started in January 2014 and will continue through the remaining term of our lease agreement.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964317568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Indebtedness</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing arrangement for the purchase of the RTP facility</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Non-current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">2008 Senior Notes</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">565.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">571.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">2015 Senior Notes</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,485.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">992.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,733.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,721.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing arrangement for the purchase of the RTP facility</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">18.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,521.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary description of our principal indebtedness as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Senior Notes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On September 15, 2015, we issued senior unsecured notes for an aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2020, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.792%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">3.625%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2022, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.920%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2025, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.764%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15,&#160;2045, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.294%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These notes are senior unsecured obligations and may be redeemed at our option at any time at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the principal amount plus accrued interest and a specified make-whole amount. The notes also contain a change of control provision that may require us to purchase the notes at a price equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The costs associated with this offering of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> have been recorded as a reduction to the carrying amount of the debt on our consolidated balance sheet. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. Interest on the notes is payable March 15 and September 15 of each year. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this offering, we also entered into interest rate swaps. The carrying value of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes includes approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to changes in the fair value of the interest rate swaps. For additional information, please read Note 9, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2008 Senior Notes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March&#160;4, 2008, we issued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Senior Notes due March&#160;1, 2018 that were originally priced at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">99.184%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par. The discount is amortized as additional interest expense over the period from issuance through maturity. These notes are senior unsecured obligations. Interest on the notes is payable March&#160;1 and September&#160;1 of each year. The notes may be redeemed at our option at any time at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the principal amount plus accrued interest and a specified make-whole amount. The notes contain a change of control provision that may require us to purchase the notes under certain circumstances. There is also an interest rate adjustment feature that requires us to pay interest at an increased rate on the notes if the credit rating on the notes declines below investment grade. In accordance with ASU No. 2015-03, during 2015, we reclassified </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our debt issuance costs related to our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes from an asset to a reduction to the carrying amount of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes in our 2014 consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon the issuance of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Senior Notes due in 2018, we entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. These contracts were terminated in December 2008. Upon termination of these swaps, the carrying amount of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Senior Notes due in 2018 was increased by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and is being amortized using the effective interest rate method over the remaining life of the Senior Notes and is being recognized as a reduction of interest expense. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remains to be amortized. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Notes Payable to Fumedica</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our 2006 distribution agreement with Fumedica, we issued notes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs which were payable to Fumedica in varying amounts from June 2008 through June 2018. Our remaining note payable to Fumedica had a carrying value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015, we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> outstanding borrowings and were in compliance with all covenants under this facility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2013, we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$750.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">364</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-day senior unsecured revolving credit facility. In March 2014, the revolving credit facility expired and was not renewed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financing Arrangement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015 we recorded a financing obligation in relation to the amendment of our lease agreement of Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the financing obligation totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$19.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, Plant and Equipment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Maturity</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total gross payments, excluding our financing arrangement, due under our debt arrangements are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="80%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">553.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,500.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,500.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,559.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our debt is disclosed in Note&#160;7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6788063152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares of Preferred Stock authorized, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.75 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares are authorized as Series A, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares are authorized as Series X junior participating and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.25 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares are undesignated. Shares may be issued without a vote or action of stockholders from time to time in classes or series with the designations, powers, preferences, and the relative, participating, optional or other special rights of the shares of each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. No shares of Preferred Stock were issued and outstanding during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table describes the number of shares authorized, issued and outstanding of our common stock as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td width="24%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">241.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">257.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">234.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015, our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2015 Share Repurchase Program). As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the 2015 Share Repurchase Program was completed and we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011, our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2011 Share Repurchase Program), which has been used principally to offset common stock issuances under our share-based compensation plans. The 2011 Share Repurchase Program does not have an expiration date. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we purchased approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$886.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under our 2011 Share Repurchase Program. We did not repurchase any shares of common stock under our 2011 Share Repurchase Program during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares remaining available for repurchase under this authorization.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section C<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964332592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Comprehensive Income (Loss) Note</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="26%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(99.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(59.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">110.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(96.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(172.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(171.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(61.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(96.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(164.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(37.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(195.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(224.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="26%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(109.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(109.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(99.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="26%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(55.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(26.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="28%" rowspan="1" colspan="1"></td><td width="25%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">173.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">171.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e640-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e716-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e709-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Reclassification Adjustments<br> -URI http://asc.fasb.org/extlink&amp;oid=6522872<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6588002160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,547.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,862.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">230.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">231.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Earnings per share for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects, on a weighted average basis, the repurchase of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares, respectively, of our common stock under our share repurchase authorizations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964332592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Share-based Payments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="55%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">88.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">102.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">127.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">160.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reversal of previously accrued incentive compensation included in restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(8.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">207.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">252.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">255.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">196.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">246.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(55.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(72.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(73.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">140.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">172.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="55%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">38.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">119.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">115.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">103.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">109.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">207.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">252.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">255.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">196.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">246.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Windfall tax benefits from vesting of stock awards, exercises of stock options and ESPP participation were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$78.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$96.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$73.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These amounts have been calculated under the alternative transition method.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, unrecognized compensation cost related to unvested share-based compensation was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$184.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;years.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-Based Compensation Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share-based compensation plans pursuant to which awards are currently being made: (i)&#160;the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006&#160;Directors Plan); (ii)&#160;the Biogen Inc. 2008 Amended and Restated Omnibus Equity Plan (2008 Omnibus Plan); and (iii)&#160;the Biogen Inc. 2015 Employee Stock Purchase Plan (ESPP). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Directors Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2006, our stockholders approved the 2006&#160;Directors Plan for share-based awards to our directors. Awards granted from the 2006&#160;Directors Plan may include stock options, shares of restricted stock, restricted stock units, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. We have reserved a total of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock for issuance under the 2006&#160;Directors Plan. The 2006&#160;Directors Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a </font><font style="font-family:inherit;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5-to-1</font></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> ratio. In June 2015, our stockholders approved an amendment to extend the term of the 2006 Directors Plan until June 10, 2025.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Omnibus Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2008, our stockholders approved the 2008 Omnibus Plan for share-based awards to our employees. Awards granted from the 2008 Omnibus Plan may include stock options, shares of restricted stock, restricted stock units, performance shares, shares of phantom stock, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for issuance under the 2008 Omnibus Plan consist of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares reserved for this purpose, plus shares of common stock that remained available for issuance under our 2005 Omnibus Equity Plan on the date that our stockholders approved the 2008 Omnibus Plan, plus shares that were subject to awards under the 2005 Omnibus Equity Plan which remain unissued upon the cancellation, surrender, exchange or termination of such awards. The 2008 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a </font><font style="font-family:inherit;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5-to-1</font></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> ratio.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have not made any awards pursuant to the 2005 Omnibus Equity Plan since our stockholders approved the 2008 Omnibus Plan, and do not intend to make any awards pursuant to the 2005 Omnibus Equity Plan in the future, except that unused shares under the 2005 Omnibus Equity Plan have been carried over for use under the 2008 Omnibus Plan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We currently do not grant stock options to our employees or directors. Outstanding stock options previously granted to our employees and directors generally have a ten-year term and vest over a period of between one and four years, provided the individual continues to serve at Biogen through the vesting dates. Options granted under all plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the options&#8217; vesting periods. The fair value of the stock options granted in 2010 was estimated as of the date of grant using a Black-Scholes option valuation model. There were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> grants of stock options made in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, all outstanding options were exercisable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The expected life of options granted is derived using assumed exercise rates based on historical exercise patterns and represents the period of time that options granted are expected to be outstanding. Expected stock price volatility is based upon implied volatility for our exchange-traded options and other factors, including historical volatility. After assessing all available information on either historical volatility, implied volatility, or both, we have concluded that a combination of both historical and implied volatility provides the best estimate of expected volatility. The risk-free interest rate used is determined by the market yield curve based upon risk-free interest rates established by the Federal Reserve, or non-coupon bonds that have maturities equal to the expected term. The dividend yield of zero is based upon the fact that we have not historically granted cash dividends, and do not expect to issue dividends in the foreseeable future. Stock options granted prior to January&#160;1, 2006 were valued based on the grant date fair value of those awards, using the Black-Scholes option pricing model, as previously calculated for pro-forma disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our stock option activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">221,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">56.98</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(114,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">59.82</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">107,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.94</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total intrinsic values of options exercised in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$38.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$86.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The aggregate intrinsic values of options outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The weighted average remaining contractual term for options outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;years. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit realized for stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received from the exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Market Stock Units (MSUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees prior to 2014 vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">four</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on actual stock performance. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees in 2014 and 2015 vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on actual stock performance. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our MSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">403,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">219.29</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">185,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">493.43</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(277,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">165.63</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(42,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">294.85</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">269,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">339.89</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">MSUs granted in 2015 include approximately </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">8,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">19,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">24,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">34,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> MSUs issued in 2015 based upon the attainment of performance criteria set for 2014, 2013, 2012 and 2011, respectively, in relation to awards granted in those years. The remainder of MSUs granted during 2015 include awards granted in conjunction with our annual awards made in February 2015 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, including the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price on grant date for MSUs awarded prior to 2014, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price on the date of grant for MSUs awarded in 2014 and 2015, expected volatility of our stock price, risk-free rates of return and expected dividend yield. The assumptions used in our valuation are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="44%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of expected stock price volatility</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">31.0% - 33.2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.7% - 35.1%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.7% - 25.7%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of risk-free interest rates</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2% - 1.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1% - 0.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1% - 0.7%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 calendar day average stock price on grant date</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$277.35 - $426.27</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$280.88 - $335.65</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60 calendar day average stock price on grant date</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.33 - $240.14</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average per share grant date fair value</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$493.43</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$395.22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$193.45</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total fair values of MSUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$109.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$117.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Settled Performance Units (CSPUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CSPUs awarded to employees vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December&#160;31 of each year. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs awarded prior to 2014 are settled in cash based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. CSPUs awarded in 2014 and 2015 will be settled in cash based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our CSPU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="82%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">335,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">115,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(222,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(36,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">192,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">CSPUs granted in 2015 include approximately </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">48,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> CSPUs issued in 2015 based upon the attainment of performance criteria set for 2014 in relation to awards granted in 2014. The remainder of the CSPUs granted in 2015 include awards granted in conjunction with our annual awards made in February 2015 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total cash paid in settlement of CSPUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$79.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$92.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Performance-vested Restricted Stock Units (PUs)</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning in the first quarter of 2014, we revised our long term incentive program to include a new type of award granted to certain employees in the form of restricted stock units that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the cash settled performance units, and vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="82%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">57,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">89,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(33,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">103,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">PUs granted in 2015 include approximately </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">42,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> PUs issued in 2015 based upon the attainment of performance criteria set for 2014 in relation to awards granted in 2014. The remainder of the PUs granted in 2015 include awards granted in conjunction with our annual awards made in February 2015 and PUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> PUs were converted to share settlements, of which approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares were vested and issued. All other PUs that vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were settled in cash totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Time-Vested Restricted Stock Units (RSUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs awarded to employees generally vest no sooner than </font><font style="font-family:inherit;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one-third per year over three years</font></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes. The fair value of all RSUs is based on the market value of our stock on the date of grant. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our RSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,137,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">221.01</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">459,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">388.88</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(626,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">190.65</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(160,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">302.35</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">810,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">323.87</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">RSUs granted in 2015 primarily represent RSUs granted in conjunction with our annual awards made in February 2015 and awards made in conjunction with the hiring of new employees. RSUs granted in 2015 also include approximately </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">7,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> RSUs granted to our Board of Directors.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs granted in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> had weighted average grant date fair values of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$321.72</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$176.53</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total fair values of RSUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$239.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$281.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$209.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan (ESPP)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015, our stockholders approved the Biogen Inc. 2015 ESPP (2015 ESPP). The 2015 ESPP, which became effective on July 1, 2015, replaced the Biogen Idec Inc. 1995 ESPP (1995 ESPP), which expired on June&#160;30, 2015. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our ESPP activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 2015 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">78,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 1995 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">98,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">180,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">245,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 2015 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">19.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 1995 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">30.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964286848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Tax Expense</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax provision and the income tax expense consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income before income taxes (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,386.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,557.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,953.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,380.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,389.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">527.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,767.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,946.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,480.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income tax expense (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,214.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,159.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">700.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">38.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">54.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,307.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,298.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">846.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(129.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(280.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(200.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(35.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(145.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(308.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(245.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,161.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">989.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">601.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Tax Assets and Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Significant components of our deferred tax assets and liabilities are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">189.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory, other reserves, and accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">243.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">217.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangibles, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">328.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">251.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">63.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">871.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">693.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(440.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(432.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(102.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(107.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(542.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(539.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In accordance with ASU No. 2015-17, at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we reclassified </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$137.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our deferred tax assets classified as current to noncurrent and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our deferred tax liabilities classified as current to noncurrent in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> consolidated balance sheet, to conform our prior year presentation to our current year presentation.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to deferred tax assets and liabilities, we have recorded prepaid tax and deferred charges related to intercompany transactions. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total deferred charges and prepaid taxes were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$697.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$238.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2013, we recorded a deferred charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$203.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in connection with an intercompany transfer of the intellectual property for ZINBRYTA. The net book value of this deferred charge as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$166.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$179.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The deferred charge will be amortized to income tax expense over the economic life of the ZINBRYTA program. Our regulatory submissions in Europe and the U.S. have been accepted for review by the relevant authorities. If the ZINBRYTA applications are not approved, we may have to accelerate the amortization of this deferred charge and record an expense equal to its remaining net book value.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="55%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration and other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> benefited from lower anticipated taxes on foreign earnings and reflects a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> benefit from the 2015 remeasurement of one of our uncertain tax positions, described below under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">"Accounting for Uncertainty in Income Taxes"</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> increased primarily as a result of the absence of a benefit related to the 2013 change in our uncertain tax position related to our U.S. federal manufacturing deduction and our unconsolidated joint business described below under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">"Accounting for Uncertainty in Income Taxes"</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, lower current year expenses eligible for the orphan drug credit and a lower relative manufacturing deduction due to unqualified products, partially offset by a higher percentage of our 2014 income being earned outside the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had net operating losses and general business credit carry forwards for federal income tax purposes of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$127.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which begin to expire in 2020. Additionally, for state income tax purposes, we had net operating loss carry forwards of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$91.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which begin to expire in 2016. For state income tax purposes, we also had research and investment credit carry forwards of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$125.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which begin to expire in 2016. For foreign income tax purposes, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of net operating loss carryforwards, which begin to expire in 2021.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. Our estimates of future taxable income take into consideration, among other items, our estimates of future income tax deductions related to the exercise of stock options. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax assets are utilizable, we believe it is more likely than not that we will realize the benefits of the deferred tax assets of our wholly owned subsidiaries. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to establish a valuation allowance, which could materially impact our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, undistributed foreign earnings of non-U.S.&#160;subsidiaries included in consolidated retained earnings and other basis differences aggregated approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We intend to reinvest these earnings indefinitely in operations outside the U.S.&#160;The residual U.S. tax liability, if cumulative amounts were repatriated, would be between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="56%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at January&#160;1,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">131.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">110.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">125.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions based on tax positions related to the current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">19.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reductions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(49.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(92.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statute expirations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(42.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(60.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at December&#160;31,</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">67.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">110.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in the U.S.&#160;federal jurisdiction, various U.S. states, and foreign jurisdictions. With few exceptions, including the proposed disallowance we discuss below, we are no longer subject to U.S.&#160;federal tax examination for years before 2013 or state, local, or non-U.S.&#160;income tax examinations for years before 2004. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Included in the balance of unrecognized tax benefits as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> are </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$32.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize potential interest and penalties accrued related to unrecognized tax benefits in income tax expense. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net interest expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net interest expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net interest expense of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have accrued approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the payment of interest as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2015, we received a final assessment from the Danish Tax Authority (SKAT) for fiscal 2009, regarding withholding taxes and the treatment of certain intercompany transactions involving our Danish affiliate and another of our affiliates.&#160;The audits of our tax filings for 2010 through 2013 are not completed but have been prepared in a manner consistent with prior filings, with similar transactions. In December 2015, we received draft assessments for these periods.&#160;The total amount assessed for all periods is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including interest.&#160;For all periods potentially under dispute, we believe that positions taken in our tax filings are valid and we are contesting the assessment vigorously.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Federal Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2013, we received updated technical guidance from the IRS concerning our current and prior year filings and calculation of our U.S. federal manufacturing deduction and overall tax classification of our unconsolidated joint business.&#160;Based on this guidance we reevaluated the level of our unrecognized benefits related to uncertain tax positions, and recorded a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> income tax benefit.&#160;This benefit is for a previously unrecognized position and relates to years 2005 through 2012. We recorded an offsetting expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for non-income based state taxes, which is recorded in other income (expense) in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2011, in conjunction with our examination, the IRS proposed a disallowance of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in deductions for tax years 2007, 2008 and 2009 related to payments for services provided by our wholly owned Danish subsidiary located in Hiller&#248;d, Denmark. We believe that these items represent valid deductible business expenses and are vigorously defending our position. We have initiated a mutual agreement procedure between the IRS and SKAT for the years 2001 through 2009, in an attempt to reach agreement on the issue. In addition, we have applied for a bilateral advanced pricing agreement for the years 2010 through 2014 to resolve similar issues for the subsequent years.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net effect of adjustments to our uncertain tax positions was a net benefit of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. It is reasonably possible that we will adjust the value of our uncertain tax positions related to our unconsolidated joint business and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with the authorities. In addition, the IRS and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964332592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Supplemental Cash Flow Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="51%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid during the year for:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,674.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,163.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">643.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-cash Investing and Financing Activity</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2015, we accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total cumulative sales of Fumapharm Products. The amount, net of tax benefit, was accounted for as an increase to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm and is expected to be paid in the first quarter of 2016. For additional information related to this transaction, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitment and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the construction of our manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$59.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our consolidated balance sheet. For additional information related to this transaction, please read Note 10,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Property, Plant and Equipment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2015, upon completion of our acquisition of Convergence, we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as part of the purchase price. For additional information related to this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July and November 2013, the construction of two office buildings in Cambridge, Massachusetts was completed and we started leasing the facilities.&#160;Upon completion of the construction of the buildings, we determined that we were no longer considered the owner of the buildings because we did not have any unusual or significant continuing involvement.&#160;Consequently, we derecognized the buildings and their associated financing obligation of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$161.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from our consolidated balance sheet.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(95.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(29.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairments on investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(32.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(15.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(13.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(123.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(25.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(34.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Current Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets includes prepaid taxes totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$57.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">518.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">359.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">504.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">265.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">270.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">393.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">167.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">172.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">579.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">505.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,096.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,817.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Long-Term Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">301.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">369.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">249.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other long-term liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">905.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">650.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Pricing of TYSABRI in Italy - AIFA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011, Biogen Italia SRL (formerly Biogen Idec Italia SRL), our Italian subsidiary,&#160;received a notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 through mid-February 2011 exceeded by EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006. In December 2011, we filed an appeal against AIFA in administrative court in Rome, Italy seeking a ruling that the reimbursement limit in the Price Determination Resolution should apply as written to only &#8220;the first 24 months&#8221; of TYSABRI sales, which ended in mid-February 2009. That appeal is still pending. Since being notified in the fourth quarter of 2011 that AIFA believed a reimbursement limit was still in effect, we deferred revenue on sales of TYSABRI as if the reimbursement limit were in effect for each biannual period beginning in mid-February 2009. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2013, we negotiated an agreement in principle with AIFA's Price and Reimbursement Committee that would have resolved all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for the periods from February 2009 through January 2013 for an aggregate repayment of EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The agreement was sent to the Avvocatura Generale dello Stato (Attorney General) for its opinion. As a result of this agreement in principle, we recorded a liability and reduction to revenue of EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> at June 30, 2013, which approximated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the claim related to the period from mid-February 2009 through mid-February 2011. In October 2014, we proposed a revised settlement for the period from February 2009 through January 2013 of EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to be paid in one payment. AIFA and Biogen Italia SRL are still discussing a possible resolution for the period from February 2009 through January 2013.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2014, AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. As a result, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of TYSABRI revenues related to the periods beginning February 2013 that were previously deferred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have approximately EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recorded as accrued expenses and long-term deferred revenue in our consolidated balance sheets for this matter as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6788077296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2007, we entered into a collaboration agreement with Neurimmune SubOne AG (Neurimmune), a subsidiary of Neurimmune AG, for the development and commercialization of antibodies for the treatment of Alzheimer&#8217;s disease. Neurimmune conducts research to identify potential therapeutic antibodies and we are responsible for the development, manufacturing and commercialization of all products. Our anti-amyloid beta antibody, aducanumab (BIIB037), for the treatment of Alzheimer&#8217;s disease resulted from this collaboration. In September 2015, we announced that the first patient had been enrolled in a Phase 3 trial for aducanumab, which triggered a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment due to Neurimmune. As we consolidate the financial results of Neurimmune, we recognized this payment as a charge to noncontrolling interest in the third quarter of 2015. Based upon our current development plans for aducanumab, we may pay Neurimmune up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$275.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestone payments. We may also pay royalties in the low-to-mid-teens on sales of any resulting commercial products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and are required to fund </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the research and development costs incurred in support of the collaboration agreement. Accordingly, we consolidate the results of Neurimmune.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts that are incurred by Neurimmune for research and development expenses in support of the collaboration that we reimburse are reflected in research and development expense in our consolidated statements of income.  During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, these amounts were immaterial. Future milestone payments and royalties, if any, will be reflected in our consolidated statements of income as a charge to noncontrolling interest, net of tax, when such milestones are achieved. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Rodin Therapeutics, Inc. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2015, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for preferred stock in Rodin Therapeutics, Inc. (Rodin) and entered into an option and collaboration agreement which gives us the right to purchase all remaining outstanding shares of Rodin, at any time until 35 days after acceptance of an Investigational New Drug (IND) application by the FDA. Rodin is a discovery-stage biotechnology company developing novel therapeutics for neurological disorders. We committed to make additional investments in Rodin&#8217;s preferred shares of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, if certain development milestones are achieved. If we exercise our option to purchase the outstanding shares of Rodin, we could pay additional amounts upon achievement of clinical and commercial milestones. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Through our fixed price option to purchase Rodin, purchases of equity, our collaboration and presence on the program advisory committee and Rodin Board of Directors, we are deemed to be the primary beneficiary of Rodin, a variable interest entity. Therefore, we consolidate the results of Rodin. As part of the initial consolidation of Rodin, we recorded an IPR&amp;D intangible asset of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and assigned approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to minority interest in our stockholder's equity. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Rodin are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Rodin other than contractually required amounts. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total carrying value of our investments in biotechnology companies totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income, as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=52262685&amp;loc=SL6759159-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=52262685&amp;loc=d3e5728-111685<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=52262685&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6788149120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our business strategy, we have entered into various collaboration agreements which provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depending on the collaborative arrangement, we may record funding receivables or payable balances with our partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaboration arrangements are discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We collaborate with Genentech on the development and commercialization of RITUXAN. In addition, in the U.S., we share operating profits and losses relating to GAZYVA with Genentech. The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacturing and commercialization of GAZYVA in the U.S. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our collaboration agreement will continue in effect until we mutually agree to terminate the collaboration, except that if we undergo a change in control, as defined in the collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech&#8217;s offer or purchase Genentech&#8217;s rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to any other anti-CD20 products in development in exchange for a royalty and our rights to GAZYVA in exchange for the compensation described in the table below. Our collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">RITUXAN</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech is responsible for the worldwide manufacturing of RITUXAN. Development and commercialization rights and responsibilities under this collaboration are divided as follows:</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">U.S.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share with Genentech co-exclusive rights to develop, commercialize and market RITUXAN in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Canada</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Genentech have assigned our rights under our collaboration agreement with respect to Canada to the Roche Group.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Outside the U.S. and Canada</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have granted Genentech exclusive rights to develop, commercialize and market RITUXAN outside the U.S. and Canada. Under the terms of separate sublicense agreements between Genentech and the Roche Group, development and commercialization of RITUXAN outside the U.S. and Canada is the responsibility of the Roche Group and its sublicensees. We do not have any direct contractual arrangements with the Roche Group or it sublicensees.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the collaboration agreement, the Roche Group pays us royalties between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on sales of RITUXAN outside the U.S. and Canada, with the royalty period lasting </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11 years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from the first commercial sale of RITUXAN on a country-by-country basis. The royalty periods for the substantial portion of the royalty-bearing sales in the rest of world markets expired during 2012 and 2013. We expect future revenue on sales of RITUXAN in the rest of world will be limited to our share of pre-tax co-promotion profits in Canada.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to FDA approval of GAZYVA, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the development and commercialization expenses as research and development expense and selling, general and administrative expense, respectively, in our consolidated statements of income. After GAZYVA was approved by the FDA in the fourth quarter of 2013, we began to recognize our share of the development and commercialization expenses as a reduction of our share of pre-tax profits in revenues from unconsolidated joint business. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercialization of GAZYVA will impact our percentage of the co-promotion profits for RITUXAN, as summarized in the table below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Ocrelizumab</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech is solely responsible for development and commercialization of ocrelizumab, a humanized anti-CD20 monoclonal antibody currently in development for MS, and funding future costs. Genentech cannot develop ocrelizumab in CLL, NHL or RA. We will receive tiered royalties between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on U.S. net sales of ocrelizumab if approved for commercial sale by the FDA. There will be a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction to these royalties if a biosimilar to ocrelizumab is approved in the U.S. In addition, we will receive a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> royalty on worldwide net sales of ocrelizumab outside the U.S., with the royalty period lasting </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11 years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from the first commercial sale of ocrelizumab on a country-by-country basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercialization of ocrelizumab will not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Profit-sharing Formulas</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">RITUXAN Profit Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax co-promotion profit-sharing formula for RITUXAN provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share on the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of co-promotion operating profits earned each calendar year. Our share of annual co-promotion profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="82%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until GAZYVA First Non-CLL FDA Approval</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First Non-CLL GAZYVA FDA Approval</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the FDA&#8217;s first approval of GAZYVA in an indication other than CLL.</font></div><div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the earlier of (1)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12 month period were at least </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or (2)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12 month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">Second GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12 month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$500.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect our share of RITUXAN pre-tax profits in the U.S. to decrease to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if GAZYVA is approved by the FDA in RITUXAN-refractory indolent non-Hodgkin&#8217;s lymphoma. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, should the FDA approve an anti-CD20 product other than ocrelizumab or GAZYVA that is acquired or developed by Genentech and subject to the collaboration agreement, our share of the co-promotion operating profits would be between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> based on certain events.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">GAZYVA Profit Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax profit-sharing formula for GAZYVA provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share on the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of operating profits earned each calendar year. Our share of annual profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="82%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our share of operating losses on GAZYVA was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Unconsolidated Joint Business Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2013, we reduced our share of RITUXAN revenues from unconsolidated joint business by approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which revenue on sales in the rest of world for RITUXAN was reduced by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and pre-tax profits in the U.S. were reduced by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to reflect our share of the royalties and interest awarded to Hoechst in its arbitration with Genentech. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from unconsolidated joint business are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,269.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,117.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,087.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue on sales in the rest of world for RITUXAN</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total unconsolidated joint business revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,339.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,126.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1) GAZYVA sales began in the fourth quarter of 2013.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> profit-sharing threshold was met during the first quarter.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to regulatory approval, we record our share of the expenses incurred by the collaboration for the development of anti-CD20 products in research and development expense in our consolidated statements of income. We incurred </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in development expense for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. After an anti-CD20 product is approved, we record our share of the development expenses related to that product as a reduction of our share of pre-tax profits in revenues from unconsolidated joint business. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Elan</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On April 2, 2013, we acquired full ownership of all remaining rights to TYSABRI from Elan that we did not already own or control. Upon the closing of the transaction, our collaboration agreement with Elan was terminated. For additional information related to this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We previously collaborated with Elan on the development, manufacture and commercialization of TYSABRI. Under the terms of our collaboration agreement, we manufactured TYSABRI and collaborated with Elan on the product&#8217;s marketing, commercial distribution and ongoing development activities. The agreement was designed to effect an equal sharing of profits and losses generated by the activities of our collaboration. Under the agreement, however, once sales of TYSABRI exceeded specific thresholds, Elan was required to make milestone payments to us in order to continue sharing equally in the collaboration&#8217;s results. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., we previously sold TYSABRI to Elan who then sold the product to third-party distributors. Our sales price to Elan in the U.S. was set prior to the beginning of each quarterly period to effect an approximate equal sharing of the gross profit between Elan and us. We recognized revenue for sales in the U.S. of TYSABRI upon Elan&#8217;s shipment of the product to the third-party distributors, at which time all revenue recognition criteria had been met. We incurred manufacturing and distribution costs, research and development expenses, commercial expenses, and general and administrative expenses related to TYSABRI. We recorded these expenses to their respective line items in our consolidated statements of income when they were incurred. Research and development and sales and marketing expenses were shared equally with Elan and the reimbursement of these expenses was recorded as reductions of the respective expense categories. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as a reduction of research and development expense resulting from reimbursements from Elan. In addition, for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as a reduction of selling, general and administrative expense resulting from reimbursements from Elan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the rest of world, we previously were responsible for distributing TYSABRI to customers and were primarily responsible for all operating activities. Generally, we recognized revenue for sales of TYSABRI in the rest of world at the time of product delivery to our customers. We made payments to Elan which effected an equal sharing of rest of world collaboration operating profits. These payments also included the reimbursement we paid to Elan for half of the third-party royalties that Elan paid on behalf of the collaboration relating to rest of world sales. These amounts were reflected in the collaboration profit sharing line in our consolidated statements of income. For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$85.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was reflected in the collaboration profit sharing line for our collaboration with Elan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acorda</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2009, we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine in markets outside the U.S.&#160;We also have responsibility for regulatory activities and the future clinical development of related products in those markets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the collaboration and license agreement, we pay Acorda tiered royalties based on the level of ex-U.S. net sales. We may pay up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$375.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of additional milestone payments to Acorda, based on the successful achievement of certain regulatory and commercial milestones. The next expected milestone would be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, due if ex-U.S. net sales reach </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> over a period of four consecutive quarters. We will capitalize these additional milestones as intangible assets upon achievement of the milestone which will then be amortized utilizing an economic consumption model and recognized as amortization of acquired intangible assets. Royalty payments are recognized as a cost of goods sold.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the collaboration and license agreement, we have also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement is a sublicense arrangement of an existing agreement between Acorda and Alkermes, who acquired Elan Drug Technologies, the original party to the license with Acorda. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, total cost of sales related to royalties and commercial supply of FAMPRYA reflected in our consolidated statement of income were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Swedish Orphan Biovitrum AB (publ)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2007, we acquired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the stock of Syntonix. Syntonix had previously entered into a collaboration agreement with Swedish Orphan Biovitrum AB (publ) (Sobi) to jointly develop and commercialize Factor VIII and Factor IX hemophilia products, including ELOCTATE and ALPROLIX. In February 2010, we restructured the collaboration agreement and assumed full development responsibilities and costs, as well as manufacturing rights. In addition, the cross-royalty rates were reduced and commercial rights for certain territories were changed. As a result, we have commercial rights for North America (the Biogen North America Territory) and for rest of the world markets outside of, essentially, Europe, North Africa, Russia and certain countries in the Middle East (the Biogen Direct Territory).&#160;Subject to the exercise of an option right that Sobi controls, Sobi will have commercial rights in, essentially, Europe, North Africa, Russia and certain countries in the Middle East (the Sobi Territory). The collaboration agreement was amended and restated in April 2014. (References to the collaboration agreement refer to the amended and restated collaboration agreement).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2014, Sobi exercised its option to assume final development and commercialization activities in the Sobi Territory for ELOCTA (the trade name for ELOCTATE in the E.U.). In July 2015, Sobi exercised its option to assume final development and commercialization of ALPROLIX within the Sobi Territory. Upon each exercise of opt-in right under the terms of the collaboration agreement, Sobi made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment in escrow. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon EMA regulatory approval of each such product, Sobi will be liable to reimburse us </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the sum of all shared manufacturing and development expenses incurred by us from October 1, 2009 through the earlier of the date on which Sobi is registered as the marketing authorization holder for the applicable product or 90 days post-regulatory approval, as well as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of certain development expenses incurred exclusively for the benefit of the Sobi Territory (the Opt-In Consideration).&#160;This reimbursement will be recognized in proportion to collaboration revenues, over a ten year period, consistent with the initial patent terms of the products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTA was approved by the EC in November 2015. Through </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in expenditures for ELOCTA, net of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> escrow payment discussed above, are reimbursable by Sobi under the collaboration agreement due to its election to assume final development and commercialization of ELOCTA within the Sobi Territory. Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$175 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in expenditures for ALPROLIX may be reimbursable by Sobi under the collaboration agreement due to its election to assume final development and commercialization of ALPROLIX within the Sobi Territory. The escrow payment made with respect to ALPROLIX will be applied to the amount of the Opt-In Consideration to be reimbursed by Sobi upon EMA regulatory approval. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To effect Sobi&#8217;s reimbursement to us for the Opt-In Consideration exceeding the escrow payment for the applicable product, the cross-royalty cash payment structure for direct sales in each company&#8217;s respective territories will be adjusted until the Opt-In Consideration is paid in full (the Reimbursement Period). The mechanism for reimbursement is outlined in the table below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the collaboration agreement, cash payments are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="35%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rates post Sobi Opt-In</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Royalty and Net Revenue Share Rates:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Method</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rate prior to 1st</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">commercial sale in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">the&#160;Sobi&#160;Territory:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Base Rate following</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">1st&#160;commercial&#160;sale&#160;in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">the Sobi Territory:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rate during the</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reimbursement</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period:</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sobi rate to Biogen on net sales in the Sobi Territory</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10&#160;or&#160;12%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base&#160;Rate<br clear="none"/>plus 5%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net sales in the Biogen North America Territory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10&#160;or&#160;12%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br clear="none"/>less 5%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net sales in the Biogen Direct Territory</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15&#160;or&#160;17%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br clear="none"/>less 5%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net revenue</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">from the Biogen Distributor Territory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Net<br clear="none"/>Revenue<br clear="none"/>Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br clear="none"/>less 15%</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net revenue represents Biogen&#8217;s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If the reimbursement of the Opt-in Consideration has not been achieved within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the first commercial sale of such product, we maintain the right to require Sobi to pay any remaining balances due to us within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90 days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the six year anniversary date of the first commercial sale.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect to recognize the effect of the cash reimbursement as an adjustment to the Base Rate in the table above.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Should Sobi terminate the collaboration agreement with respect to ALPROLIX, we will obtain full worldwide development and commercialization rights and we will be obligated to pay royalties to Sobi subject to separate terms, as defined in the collaboration agreement.&#160;In addition, if EMA approval for ALPROLIX is not granted within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the filing date, Sobi shall have the right to require that the escrow payment be refunded and revoke its option right for such product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie Biotherapeutics, Inc. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie Biotherapeutics, Inc., a subsidiary of AbbVie, Inc. (AbbVie) aimed at advancing the development and commercialization of ZINBRYTA in MS. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the agreement, we and AbbVie will conduct ZINBRYTA co-promotion activities in the E.U., U.S. and Canada territories (Collaboration Territory), where development and commercialization costs and profits are shared equally. We are responsible for all manufacturing activities in the Collaboration Territory.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., AbbVie will recognize revenues on sales to third parties and we will recognize our 50% share of the co-promotion profits or losses as a component of total revenues in our consolidated statements of income.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and Canada, we will reflect revenues on sales to third parties in product revenues, net in our consolidated statements of income. We will record the related cost of revenues and sales and marketing expenses to their respective line items in our consolidated statements of income when these costs are incurred. The reimbursement with AbbVie for the 50% sharing of the co-promotion profits or losses in the E.U. and Canada will be recognized in our total costs and expenses. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outside of the Collaboration Territory, we are solely responsible for development and commercialization where we will pay a tiered royalty to AbbVie on net sales in the low to high teens.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are the responsible party for manufacturing and research and development activities in both the Collaboration Territory and outside the Collaboration Territory and will record these activities to their respective lines in our consolidated statements of income, net of any reimbursement of research and development expenditures from AbbVie.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we made milestone payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the development of ZINBRYTA as a result of filing for regulatory approval in the U.S. and E.U. during the year. These payments were recorded as research and development expense in our consolidated statements of income. We may incur up to an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$32.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of milestone payments related to the development of ZINBRYTA, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is due upon regulatory approval in the U.S. and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is due upon regulatory approval in the E.U. These future payments will be capitalized as an intangible asset in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of activity related to this collaboration is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="56%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">113.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">117.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">133.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of development expense reflected in our consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Long-Term Strategic Research Collaboration</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2013, we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> year research collaboration with Ionis Pharmaceuticals, Inc. (Ionis), formerly known as Isis Pharmaceuticals Inc. under which both companies collaborate to perform discovery level research and then develop and commercialize antisense or other therapeutics for the treatment of neurological disorders.&#160;Under the collaboration, Ionis will perform research on a set of neurological targets identified within the agreement. Once the research has reached a specific stage of development, we will make the determination whether antisense is the preferred approach to develop a therapeutic candidate or whether another modality is preferred. If antisense is selected, Ionis will continue development and identify a product candidate. If another modality is used, we will assume the responsibility for identifying a product candidate and developing it. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of this agreement, we paid Ionis an upfront amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;Of this payment, we recorded prepaid research and discovery services of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing the value of the Ionis full time equivalent employee resources which are required by the collaboration to provide research and discovery services to us over the next six years.&#160;The remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the upfront payment was recorded as research and development expense as it represented the purchase of intellectual property that had not reached technological feasibility.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ionis is also eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we triggered milestones of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to the advancement of IONIS-SOD1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the treatment of ALS and other neurological targets identified.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For non-ALS antisense product candidates, Ionis will be responsible for global development through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise. &#160;&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For product candidates using a different modality, we will be responsible for global development through all stages and will pay Ionis up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon the achievement of certain regulatory milestones and royalties on future sales if we successfully develop the product candidate. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Collaborations </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December, June and January 2012, we entered into three separate exclusive, worldwide option and collaboration agreements with Ionis under which both companies will develop and commercialize antisense therapeutics for up to three gene targets, Ionis&#8217; product candidates for the treatment of myotonic dystrophy type 1 (DM1), and the antisense investigational candidate nusinersen (ISIS-SMN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for the treatment of spinal muscular atrophy (SMA), respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Antisense Therapeutics</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the December 2012 agreement relating to the development and commercialization of up to three gene targets we provided Ionis with an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and will make potential additional payments, prior to licensing, of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> based on the development of the selected product candidate as well as a mark-up of the cost estimate of the Phase 1 and Phase 2 trials. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we triggered a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment. Ionis will be responsible for global development of any product candidate</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive up to another </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">if we successfully develop the product candidate after option exercise. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">IONIS-DMPK</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub>&#160;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the June 2012 agreement for the DM1 candidate, we provided Ionis with an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and agreed to make potential additional payments, prior to licensing, of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$59.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> based on the development of the selected product candidate. During 2015, we amended the agreement to adjust the amount of potential additional payments by an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> due to changes in the clinical trial design. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we triggered milestones of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to the selection and advancement of IONIS-DMPK</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"> </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to treat DM1. Ionis will be responsible for global development of any product candidate through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We also have an option to license the product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive up to another </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales if we successfully develop the product candidate after option exercise. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, were reflected in research and development expense in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Nusinersen</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the January 2012 agreement for the antisense investigational drug candidate, nusinersen, we paid Ionis </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as an upfront payment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2014, we amended the agreement to adjust the amount of potential additional payments and terms of the exercise of our opt-in right to license nusinersen. Consistent with the initial agreement, Ionis remains responsible for conducting the pivotal/Phase 3 trials.&#160;We are providing input on the clinical trial design and regulatory strategy for the development of nusinersen. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we triggered clinical trial payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$57.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the advancement of the program. We are recognizing these payments as research and development expenses as the trial costs are incurred. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015, we amended the agreement and may pay up to an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$92.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> due to changes in the clinical trial design. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may exercise our opt-in right upon&#160;completion of and data review of the first successful Phase 2/3 trial or completion of both Phase 2/3 trials.&#160;An amendment in December 2014 provided for additional opt-in scenarios, based on the filing or the acceptance of a new drug application or marketing authorization application with the FDA or EMA. Under the amended collaboration agreement, we may pay Ionis up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$325.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in a license fee and payments, including </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in payments associated with the clinical development of nusinersen prior to licensing, a license fee and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales of nusinersen if we successfully develop nusinersen after option exercise.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$13.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, were reflected in research and development expense in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and E2609 Collaboration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March 4, 2014, we entered into a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize two Eisai product candidates for the treatment of Alzheimer&#8217;s disease, BAN2401, a monoclonal antibody that targets amyloid-beta aggregates, and E2609, a BACE inhibitor, (Eisai Collaboration Agreement).&#160;Under the Eisai Collaboration Agreement, Eisai serves as the global operational and regulatory lead for both compounds and all costs, including research, development, sales and marketing expenses, will be shared equally by us and Eisai. Following marketing approval in major markets, such as the U.S., the E.U. and Japan, we will co-promote BAN2401 and E2609 with Eisai and share profits equally. In smaller markets, Eisai will distribute these products and pay us a royalty. The Eisai Collaboration Agreement also provides the parties with certain rights and obligations in the event of a change in control of either party.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Eisai Collaboration Agreement also provides Eisai an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for Alzheimer&#8217;s disease (Aducanumab Option) and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). Upon exercise of each of the Aducanumab Option and the Anti-Tau Option, we will execute a separate collaboration agreement with Eisai on terms and conditions that mirror the Eisai Collaboration Agreement.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Option</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai may exercise the Aducanumab Option after either (i) completion of both the current Phase 1b clinical trial for aducanumab and the current Phase 2 clinical trial for BAN2401 (Post-Phase 2 Aducanumab Option), or (ii) completion of the Phase 3 clinical trial for aducanumab (Post-Phase 3 Aducanumab Option) under certain conditions. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration we will receive if Eisai exercises the Post-Phase 2 Aducanumab Option depends on the development status of BAN2401. If BAN2401 is then determined to advance to Phase 3, we will be entitled to receive a single payment from Eisai upon regulatory approval of aducanumab and we will no longer be required to pay Eisai any milestone payments for products containing BAN2401 under the Eisai Collaboration Agreement. If the development of BAN2401 has instead been terminated, we will receive development and commercial milestone payments from Eisai (Post-Phase 2 Aducanumab Milestone Payments). If Eisai does not exercise its Post-Phase 2 Aducanumab Option, we may elect to terminate the Eisai Collaboration Agreement with respect to BAN2401 but, under certain conditions, will have the option to reinstate the Eisai Collaboration Agreement after completion of a BAN2401 Phase 3 clinical trial.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If Eisai exercises its Post-Phase 3 Aducanumab Option, Eisai will be required to pay us all Phase 3 development and commercialization costs plus a mark-up and an amount equal to any unpaid Post-Phase 2 Aducanumab Milestone Payments that would have been payable if Eisai had exercised its Post-Phase 2 Aducanumab Option. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Anti-Tau Option</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon the effective date of the Eisai Collaboration Agreement, we paid Eisai </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflecting the fair value of the options granted under the Eisai Collaboration Agreement, both of which were classified as research and development expense in our consolidated statements of income. During the second quarter of 2014, Eisai exercised its option under the Eisai Collaboration Agreement to expand the joint development and commercialization activities to include Japan. Upon such exercise, we paid Eisai an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as research and development expense in our consolidated statements of income, which represented the difference between the payment made upon exercise of the option and the fair value of that option recorded as research and development expense upon closing of the agreement in the first quarter of 2014. We could pay Eisai up to an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under the Eisai Collaboration Agreement based on the future achievement of certain development, regulatory and commercial milestones.&#160;  </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our arrangements with Eisai, Neurimmune is entitled to milestone and royalty payments related to the development and commercialization of aducanumab and certain anti-tau antibodies. For additional information regarding our agreement with Neurimmune, please see Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of activity related to this collaboration is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="56%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">84.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of development expense, excluding upfront and milestone payments, reflected in our consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sangamo BioSciences, Inc. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 22, 2014, we completed an exclusive worldwide research, development and commercialization collaboration and license agreement with Sangamo BioSciences, Inc. (Sangamo) under which both companies will develop and commercialize product candidates for the treatment of two inherited blood disorders, sickle cell disease and beta-thalassemia.&#160;The collaboration is currently in the research stage of development.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the agreement, we paid Sangamo an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, with additional payments of up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> based on the achievement of certain development, regulatory and commercial milestones, plus royalties based on sales.&#160;We recorded the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment as research and development expense. Under this arrangement, Sangamo will be responsible for identifying a product candidate for the treatment of beta-thalassemia and advancing that candidate through a completed Phase 1 human clinical trial, at which point we would assume responsibility for development.&#160;We will jointly develop a sickle cell disease candidate through the potential filing of an investigative new drug application, after which we would assume clinical responsibilities. We will lead the global development and commercialization efforts and Sangamo will have the option to assume co-promotion responsibilities in the U.S.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$13.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of expense was reflected in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Applied Genetic Technologies Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 2, 2015, we announced a collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases with Applied Genetic Technologies Corporation (AGTC). The collaboration will focus on the development of a portfolio of AGTC&#8217;s therapeutic programs, including both a clinical-stage candidate for X-linked Retinoschisis (XLRS) and a pre-clinical candidate for the treatment of X-Linked Retinitis Pigmentosa (XLRP). The agreement also includes options for early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition, as well as an equity investment in AGTC.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2015, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$124.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which included a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equity investment in AGTC, prepaid research and development expenditures of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and total licensing and other fees of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of prepaid research and development expenditures were recorded in investments and other assets in our consolidated balance sheets and will be expensed as the services are provided. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$54.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as research and development expense associated with AGTC in our consolidated statements of income, including the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> total licensing and other fees, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in research and development services, a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> premium on our equity investment and a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> clinical development milestone related to XLRS. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AGTC is eligible to receive development, regulatory and commercial milestone payments aggregating in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which includes up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$472.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> collectively for the two lead programs and up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$592.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> across the discovery programs. AGTC is also eligible to receive royalties in the mid-single digit to mid-teen percentages of annual net sales. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We were granted worldwide commercialization rights for the XLRS and XLRP programs. AGTC has an option to share development costs and profits after the initial clinical trial data are available, and an option to co-promote the second of these products to be approved in the U.S. AGTC will lead the clinical development programs of XLRS through product approval and of XLRP through the completion of first-in-human trials. We will support the clinical development costs, subject to certain conditions, following the first-in-human study for XLRS and IND-enabling studies for XLRP. Under the manufacturing license, we have received an exclusive license to use AGTC&#8217;s proprietary technology platform to make AAV vectors for up to six genes, three of which are in AGTC&#8217;s discretion, in exchange for payment of milestones and royalties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Mitsubishi Tanabe Pharma Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On September 9, 2015, we announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to exclusively license amiselimod (MT-1303), a late stage experimental medicine with potential in multiple autoimmune indications. Amiselimod is an oral compound that targets the sphingosine 1-phosphate receptor. Under the terms of the agreement, we will receive worldwide rights to amiselimod, excluding Asia. We will be responsible for global commercialization and development costs except for costs related to the Asian territories, which are the responsibility of MTPC. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2015, the agreement became effective and we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was recorded as research and development expense in our consolidated statements of income. In the future we may pay up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$484.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in milestone payments for multiple indications and territories, along with average royalties in the mid- to high-teen percentages of annual net sales. MTPC has the right to participate in our global clinical trials related to amiselimod and has an option to co-promote non-MS indications in the U.S. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into several research, discovery and other related arrangements that resulted in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$40.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, recorded as research and development expense in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These additional arrangements include the potential for future milestone payments based on clinical and commercial development over a period of several years. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012, we entered into a joint venture agreement with Samsung BioLogics Co. Ltd. (Samsung Biologics), establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&#160;Samsung Biologics contributed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> stake in Samsung Bioepis and we contributed approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for the remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> ownership interest.&#160;Under the joint venture agreement, we have no obligation to provide any additional funding and our ownership interest may be diluted due to financings in which we do not participate. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership interest is approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects our additional contribution of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.3 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) in the first quarter of 2015 and the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;The exercise of this option is within our control and is based on paying for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the total investment made by Samsung Biologics into Samsung Bioepis in excess of what we have already contributed under the agreement plus a rate that will represent their return on capital.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Samsung Biologics has the power to direct the activities of Samsung Bioepis which will most significantly and directly impact its economic performance.&#160;We account for this investment under the equity method of accounting as we maintain the ability to exercise significant influence over Samsung Bioepis through a presence on the entity&#8217;s Board of Directors and our contractual relationship.&#160;Under the equity method, we recorded our original investment at cost and subsequently adjust the carrying value of our investment for our share of equity in the entity&#8217;s income or losses according to our percentage of ownership. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our share of losses exceed the carrying value of our investment. We suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), which was classified as a component of investments and other assets in our consolidated balance sheets. We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our consolidated statements of income. During the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a loss on our investment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 17, 2013, pursuant to our rights under the joint venture agreement with Samsung Biologics, we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of one anti-TNF biosimilar, Japan.&#160;Under the terms of this agreement, we have paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$46.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which has been recorded as a research and development expense in our consolidated statements of income as the programs they relate to had not achieved regulatory approval. Samsung Bioepis is eligible to receive an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestones, including </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon the regulatory approval of each anti-TNF biosimilar product candidate in the E.U. In January 2016, the EC approved the MAA for BENEPALI for marketing in the E.U. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon commercialization, we will reflect revenues on sales to third parties in product revenues, net in our consolidated statements of income. We will record the related cost of revenues and sales and marketing expenses in our consolidated statements of income to their respective line items when these costs are incurred. A </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> profit share with Samsung Bioepis will be recognized in costs and expenses. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">License Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we entered into a license agreement with Samsung Bioepis. Under the terms of the agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture, and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we will receive single digit royalties on all biosimilar products developed and commercialized by Samsung Bioepis. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we entered into a technical development services agreement and a manufacturing agreement with Samsung Bioepis. Under the terms of the technical development services agreement, we provide Samsung Bioepis technical development and technology transfer services, which include, but are not limited to, cell culture development, purification process development, formulation development, and analytical development. Under the terms of our manufacturing agreement, we manufacture clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis pursuant to contractual terms.&#160;Under limited circumstances, we may also supply Samsung Bioepis with quantities of drug product of biosimilar products for use in clinical trials through arrangements with third-party contract manufacturers. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$43.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues in relation to these services, which is reflected as a component of other revenues in our consolidated statement of income.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6788077296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies regarding contingencies, see Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Patent Matters </font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Forward Pharma German Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On November 18, 2014 Forward Pharma A/S (Forward Pharma) filed suit against us in the Regional Court of Dusseldorf, Germany alleging that TECFIDERA infringes German Utility Model DE&#160;20 2005 022 112&#160;U1, which was issued in April 2014 and expired in October 2015. Forward Pharma subsequently&#160;extended its allegations&#160;to assert that TECFIDERA infringes Forward Pharma's European Patent No. 2,801,355, which was issued in May 2015 and expires in October 2025. Forward Pharma seeks declarations of infringement and damages for our sales of TECFIDERA in Germany. Under German law, disgorgement of profits on infringing sales is a measure of damages. A hearing has been scheduled for early 2016.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interference Proceeding with Forward Pharma</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015, the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of multiple sclerosis with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. A hearing has been scheduled for early 2017.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Inter Partes Review Proceeding</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On September 28, 2015, the Coalition for Affordable Drugs V LLC, an entity associated with a hedge fund, filed a petition with the USPTO for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of the '514 patent, which we opposed. The USPTO has not yet decided whether to institute review. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Several parties have filed oppositions in the European Patent Office requesting revocation of our European patent number 2 137 537 (the '537 patent), which includes claims covering the treatment of multiple sclerosis with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. The '537 patent expires in 2028.&#160;A hearing has been scheduled for early 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Patent Licensing Matter </font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are in discussions with Pfizer regarding its proposal that we take a license to its U.S. Patent No. 8,603,777&#160;(Expression of Factor VII and IX Activities in Mammalian Cells) and pay&#160;royalties on sales of ALPROLIX. </font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Patent Revocation Matter</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2015, Swiss Pharma International AG brought an action in the Patents Court of the United Kingdom to revoke the UK counterpart of our European Patent Number 1 485 127&#160;(&#8220;Administration of agents to treat inflammation&#8221;) (the '127 patent), which was issued in June 2011 and concerns administration of natalizumab (TYSABRI) to treat multiple sclerosis. The patent expires in February 2023.&#160;On January 11, 2016 the same entity brought an action in the District Court of The Hague seeking to revoke the Dutch counterpart of the '127 patent. A hearing has been scheduled in the Dutch action for early 2017. No hearing has yet been scheduled in the UK action.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On May&#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (manufacturer, marketer and seller of REBIF), Pfizer Inc. (co-marketer of REBIF), and Novartis Pharmaceuticals Corp. (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. The court has consolidated the two lawsuits, and we refer to the two actions as the &#8220;Consolidated '755 Patent Actions.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims in the Consolidated '755 Patent Actions seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees, and EMD Serono and Bayer have each filed a counterclaim seeking a declaratory judgment that the '755 Patent is unenforceable based on alleged inequitable conduct. Bayer has also amended its complaint to seek such a declaration. No trial date has been set.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Italian National Medicines Agency</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011, Biogen Italia SRL&#160;received notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in December 2006. On December&#160;23, 2011, we filed an appeal in the Regional Administrative Tribunal of Lazio (Il Tribunale Amministrativo Regionale per il Lazio) in Rome, Italy seeking a ruling that the reimbursement limit in the Price Resolution should apply as written to only &#8220;the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months&#8221; of TYSABRI sales, which ended in mid-February 2009. The appeal is still pending. In June 2014, AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. AIFA and Biogen Italia SRL are discussing a possible resolution for the period from February 2009 through January 2013.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government in this matter. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also received a subpoena from the federal government for documents relating to our relationship with certain pharmacy benefit managers, with which we cooperated. We do not anticipate any further involvement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 6, 2015, four qui tam actions filed against us by relators suing on behalf of the United States and certain states were unsealed by the U.S. District Court for the District of Massachusetts. The actions, which have been administratively consolidated, allege sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seek single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. The United States declined to intervene in two of the actions, both of which have since been voluntarily dismissed, and has not made an intervention decision in the other two actions, which we have moved to dismiss. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in In re Biogen Inc. Securities Litigation, filed by a shareholder on August 18, 2015 in the U.S. District Court for the District of Massachusetts. The amended complaint alleges violations of federal securities laws under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5. The lead plaintiff seeks a declaration of the action as a class action, certification as a representative of the class and its counsel as class counsel, and an award of damages, interest, and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6787951984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rent laboratory and office space and certain equipment under non-cancelable operating leases. These lease agreements contain various clauses for renewal at our option and, in certain cases, escalation clauses typically linked to rates of inflation. Rental expense under these leases, net of amounts recognized in relation to exiting our Weston, Massachusetts facility, which terminate at various dates through 2028, amounted to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Rent expense was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$56.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition to rent, the leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28" rowspan="1"></td></tr><tr><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">75.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">75.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">67.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">63.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">382.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">732.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(28.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(59.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">61.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">56.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">353.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">672.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">As a result of our decision to relocate our corporate headquarters to Cambridge, Massachusetts, we vacated part of our Weston, Massachusetts facility in the fourth quarter of 2013. We incurred a charge of </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">$27.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> in connection with this move. This charge represented our remaining lease obligation for the vacated portion of our Weston, Massachusetts facility, net of sublease income expected to be received. The term of our sublease to the vacated portion of our Weston, Massachusetts facility started in January 2014 and will continue through the remaining term of our lease agreement.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under certain of our lease agreements, we are contractually obligated to return leased space to its original condition upon termination of the lease agreement. At the inception of a lease with such conditions, we record an asset retirement obligation liability and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. In subsequent periods, for each such lease, we record interest expense to accrete the asset retirement obligation liability to full value and depreciate each capitalized asset retirement obligation asset, both over the term of the associated lease agreement. Our asset retirement obligations were not significant as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Financing Arrangement</font></div><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015 we amended our existing lease related to Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. For additional information, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, Plant and Equipment</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net present value of the future minimum lease payments were as follows:</font></div><div style="line-height:120%;padding-left:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="79%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">20.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net present value of the future minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">19.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of net liabilities associated with uncertain tax positions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several on-going clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on our consolidated balance sheet for expenditures incurred by CROs as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$559.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cancellable future commitments based on existing CRO contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones had not occurred as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing Commitments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 1, 2015, we purchased land in Solothurn, Switzerland where we plan to build a biologics manufacturing facility over the next several years. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$126.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the construction of this facility.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TYSABRI Contingent Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013, we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the terms of the acquisition agreement, we are obligated to make contingent payments to Elan of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net sales up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net sales that exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo in December 2013. Following that acquisition, we began making these royalty payments to Perrigo.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence, Stromedix, Inc. (Stromedix), Biogen International Neuroscience GmbH (formerly Biogen Idec International Neuroscience GmbH) (BIN), Biogen Hemophilia Inc. (formerly Biogen Idec Hemophilia Inc.) (BIH) and Fumapharm AG, we agreed to make additional payments based upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence, Stromedix and BIN, formerly Panima Pharmaceuticals AG, occurred after January&#160;1, 2009, we record contingent consideration liabilities at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestones related to these acquisitions. For additional information related to our acquisition of Convergence please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIH</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of BIH, formerly Syntonix, in 2007, we agreed to pay up to an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$80.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if certain milestone events associated with the development of BIH&#8217;s lead product, ALPROLIX are achieved. The first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$40.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contingent payment was achieved in 2010. We paid an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the second quarter of 2014 as ALPROLIX was approved for the treatment of hemophilia B. A second </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contingent payment will occur if, prior to the tenth anniversary of the closing date, a marketing authorization is granted by the EMA for ALPROLIX. This payment will be accounted for as an increase to intangible assets if achieved. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006, we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$220.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon closing of the transaction and agreed to pay an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if a Fumapharm Product was approved for MS in the U.S.&#160;or E.U. In the second quarter of 2013, we paid this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contingent payment as TECFIDERA was approved in the U.S. for MS by the FDA. We are also required to make additional contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior twelve month period, as defined in the acquisition agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$850.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent payments as we reached the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2014, second quarter of 2015 and third quarter of 2015, respectively, and accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total cumulative sales of Fumapharm Products in the fourth quarter of 2015.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will owe an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contingent payment for every additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, until such time as the cumulative sales level reaches </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments shall be due. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level has been reached.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964209760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Guarantees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteesAbstract', window );"><strong>Guarantees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteesTextBlock', window );">Guarantees</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Guarantees</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we did not have significant liabilities recorded for guarantees.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for each guarantee obligation, or each group of similar guarantee obligations, including (a) the nature of the guarantee, including its term, how it arose, and the events or circumstances that would require the guarantor to perform under the guarantee; (b) the maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee; (c) the current carrying amount of the liability, if any, for the guarantor's obligations under the guarantee; and (d) the nature of any recourse provisions under the guarantee, and any assets held either as collateral or by third parties, and any relevant related party disclosure. Excludes disclosures about product warranties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6800043456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation and Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Employee Benefit Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We sponsor various retirement and pension plans. Our estimates of liabilities and expenses for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">401(k) Savings Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a 401(k) Savings Plan which is available to substantially all regular employees in the U.S. over the age of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan&#8217;s matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense related to our 401(k) Savings Plan totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$51.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Compensation Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees, which are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$126.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$105.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pension Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries in which we maintain an operating presence.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by Swiss government and was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.75%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#8217;s contribution. Minimum employee contributions are based on the respective employee&#8217;s age, salary, and gender. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the the Swiss plan had an unfunded net pension obligation of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and plan assets which totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$63.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$43.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized expense totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to our Swiss plan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The obligations under the German plans are unfunded and totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net periodic pension cost related to the German plans totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49170332&amp;loc=SL14450702-114947<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e2410-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39675-114964<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6414199&amp;loc=d3e39622-114963<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964257776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, which is discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders, and, therefore, our chief operating decision-maker manages the operations of our company as a single operating segment. Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area and information relating to major customers are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue by product is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="36" rowspan="1"></td></tr><tr><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,908.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">730.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">3,638.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,426.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">482.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,909.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">864.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">11.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">876.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AVONEX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,790.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">840.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,630.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,956.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,056.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,013.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,902.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,103.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,005.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">PLEGRIDY</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">227.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">111.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">338.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">27.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">16.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">44.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,103.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">783.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,886.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,025.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">934.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,959.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">814.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">712.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,526.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">89.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">89.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">80.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">80.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">74.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">74.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">308.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">11.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">319.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">58.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">58.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">208.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">25.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">234.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">72.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">76.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">51.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">51.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">62.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">62.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">60.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">60.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">6,545.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,642.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">9,188.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">5,566.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,636.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">8,203.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,581.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,961.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">5,542.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Geographic Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables contain certain financial information by geographic area:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td width="29%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Germany</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,545.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,497.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">668.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">143.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">333.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,188.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,269.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">65.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,339.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">142.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">29.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">62.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">236.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,296.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">879.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,187.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2014 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Germany</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,566.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,383.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">811.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">112.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">328.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,203.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,117.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,055.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">701.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,765.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2013 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Germany</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,581.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,170.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">417.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,542.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,087.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,126.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">193.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">263.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">984.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">758.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,750.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Represents amounts related to Europe less those attributable to Germany.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenues from Unconsolidated Joint Business</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our total revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, are derived from our joint business arrangement with Genentech. For additional information related to our collaboration with Genentech, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Significant Customers</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recorded revenue from two wholesalers accounting for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$684.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$731.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our long-lived assets were related to our manufacturing facilities in Denmark.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8981-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e9038-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 33<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8971-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8595-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8380-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 35<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8984-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e9031-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8538-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8864-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8924-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6788081104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Quarterly Financial Data (Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="36%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(c) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,172.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,198.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,391.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,425.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,188.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">330.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">337.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">337.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">333.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,339.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">52.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">49.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">79.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">236.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,555.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,591.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,777.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,839.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,763.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,242.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,305.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,467.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,507.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,523.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">820.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">924.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,019.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">828.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,593.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">822.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">927.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">965.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">831.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,547.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.50</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.94</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.16</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.77</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.38</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.49</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.93</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.15</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.77</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.34</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">232.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">220.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">230.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">232.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">220.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">231.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="36%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2014</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(f) (g)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(f)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(f)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,742.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,056.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,117.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,287.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,203.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">296.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">303.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">290.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">103.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,129.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,421.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,511.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,640.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,703.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,850.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,129.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,208.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,343.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,532.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">479.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">723.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">856.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">882.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,941.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">480.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">714.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">856.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">883.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.02</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.63</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.75</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.02</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.01</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.62</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.74</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)  Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc., for the third quarter of 2015, include a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$48.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recorded upon entering into the collaboration agreement with AGTC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc., for the third quarter of 2015, reflects the attribution of a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> charge to noncontrolling interests, net of tax, related to a milestone payment due Neurimmune upon the enrollment of the first patient in a Phase 3 trial for aducanumab.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc., for the fourth quarter of 2015, include a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recorded upon entering into the collaboration agreement with MTPC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc., for the fourth quarter of 2015, include pre-tax restructuring charges totaling </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc., for the first quarter of 2014, include pre-tax charges to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$117.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recorded upon entering into the collaboration agreement with Eisai.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net and total revenues for the second, third and fourth quarters of 2014 include net revenues related to ALPROLIX as commercial sales of ALPROLIX commenced in the second quarter of 2014.  Product revenues, net and total revenues for the third and fourth quarters of 2014 include net revenues related to ELOCTATE and PLEGRIDY as commercial sales of ELOCTATE and PLEGRIDY commenced in the third quarter of 2014.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net and total revenues for the second quarter of 2014 include the recognition of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$53.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of revenue previously deferred in Italy relating to the pricing agreement with AIFA.</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=51655806&amp;loc=d3e765-108305<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=51825399&amp;loc=d3e1280-108306<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=51655806&amp;loc=d3e725-108305<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section G<br> -Subsection 1<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 302<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6793636608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Business Overview</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. We also have a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, which entitles us to certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL, and other potential anti-CD20 therapies.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our innovative drug development efforts, we aim to leverage our manufacturing capabilities and scientific expertise to extend our mission to improve the lives of patients living with serious diseases through the development, manufacture and marketing of biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. Product revenues are recorded net of applicable reserves for discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We establish reserves for trade term discounts, wholesaler incentives, Medicaid rebates, co-payment assistance (copay), Veterans Administration (VA) and Public Health Service (PHS) discounts, managed care rebates, product returns and other governmental rebates or applicable allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Reserves established for these discounts and allowances are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These reserves are based on estimates of the amounts earned or to be claimed on the related sales. Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves are categorized as follows: discounts, contractual adjustments and returns.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, patient copay assistance, VA and PHS discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid, and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consists of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Copay represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other governmental rebates or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the discounts, rebates and product returns described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify these payments in selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Unconsolidated Joint Business</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from unconsolidated joint business consists of (i)&#160;our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; (ii)&#160;reimbursement of our selling and development expenses in the U.S. for RITUXAN; and (iii)&#160;revenue on sales in the rest of world for RITUXAN, which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales outside the U.S. and Canada by the Roche Group and its sublicensees. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by Genentech in the U.S. and by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less the cost to manufacture, third-party royalty expenses, distribution, selling, and marketing expenses, and joint development expenses incurred by Genentech, the Roche Group and us. We record our share of the pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales outside the U.S. on a cash basis as we do not have the ability to estimate these profits or royalty revenue in the period incurred. Additionally, our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. includes estimates made by Genentech and those estimates are subject to change. Actual results may differ from our estimates. For additional information related to our collaboration with Genentech, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. If we are unable to reasonably estimate royalty revenue or do not have access to the information, then we record royalty revenues on a cash basis. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Multiple-Element Revenue Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may enter into transactions that involve the sale of products and related services under multiple element arrangements.&#160;In accounting for these transactions, we assess the elements of the contract and whether each element has standalone value and allocate revenue to the various elements based on their estimated selling price as a component of total revenues.&#160;The selling price of a revenue generating element can be based on current selling prices offered by us or another party for current products or management&#8217;s best estimate of a selling price. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;2</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, derivative contracts, marketable debt securities, and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We validate the prices provided by our third-party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources and analyzing pricing data in certain instances. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying amounts reflected in the consolidated balance sheets for current accounts receivable, due from unconsolidated joint business, other current assets, accounts payable, and accrued expenses and other, approximate fair value due to their short-term maturities.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consider only those investments which are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, cash equivalents were comprised of money market funds and commercial paper, overnight reverse repurchase agreements, and other debt securities with maturities less than 90 days from the date of purchase.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our consolidated statement of income.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The credit and economic conditions in certain countries in the E.U. continue to remain uncertain and have, from time to time, led to a lengthening of time to collect our accounts receivable in some of these countries. In recent years, our collection efforts in Portugal and select regions of Spain have been subject to significant payment delays due to government funding and reimbursement practices. As a result, a portion of these receivables have been routinely collected beyond our contractual payment terms and over periods in excess of one year. Our accounts receivable collection efforts in Portugal and Spain have improved during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> with our receivables in Spain now expected to be collected within one year. Our net accounts receivable balance from product sales in Portugal and Spain totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were classified as non-current and included in investments and other assets in our consolidated balance sheets. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives, and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable arise from product sales in the U.S. and Europe and have standard payment terms which generally require payment within </font><font style="font-family:inherit;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 to 90 days</font></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, two wholesale distributors individually accounted for approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.4%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.1%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.4%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of accounts receivable, net, respectively. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Marketable Securities and Other Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Available-for-sale debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheet. When assessing whether a decline in the fair value of a marketable equity security is other-than-temporary, we consider the fair market value of the security, the duration of the security&#8217;s decline, and prospects for the underlying business, including favorable or adverse clinical trial results, new product initiatives and new collaborative agreements with the companies in which we have invested.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the cost method or the equity method of accounting, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any decline in their value has occurred that would be other-than-temporary, based on the implied value of recent company financings, public market prices of comparable companies, and general market conditions and are included in investments and other assets in our consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Evaluating Investments for Other-than-Temporary Impairments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For equity securities, when assessing whether a decline in value is other-than-temporary, we consider the fair market value of the security, the duration of the security&#8217;s decline, and the financial condition of the issuer. We then consider our intent and ability to hold the equity security for a period of time sufficient to recover our carrying value. Where we have determined that we lack the intent and ability to hold an equity security to its expected recovery, the security&#8217;s decline in fair value is deemed to be other-than-temporary and is reflected in earnings as an impairment loss.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method of Accounting</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In circumstances where we have the ability to exercise significant influence over the operating and financial  policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship.&#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceed the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when selected for use in a clinical manufacturing campaign.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Capitalization of Inventory Costs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Obsolescence and Unmarketable Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring which we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from </font><font style="font-family:inherit;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three to five years</font></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td width="50%" rowspan="1" colspan="1"></td><td width="50%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts on our consolidated balance sheet and include any resulting gain or loss in our consolidated statement of income.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded as amortization of acquired intangible assets in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd (Elan), an affiliate of Elan Corporation, plc. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TYSABRI and AVONEX using the economic consumption method based on revenue generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TYSABRI and AVONEX is performed annually during our long range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of TYSABRI or AVONEX.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives, however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-process Research and Development (IPR&amp;D)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value. The revenue and costs projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology, and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business, then the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Certain IPR&amp;D programs have a fair value that is not significantly in excess of carrying value, including our program for the treatment of TGN. Such programs could become impaired if assumptions used in determining the fair value change.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, then we would need to determine the implied fair value of our reporting unit&#8217;s goodwill. If the carrying value of our reporting unit&#8217;s goodwill exceeds its implied fair value, then we would record an impairment loss equal to the difference. As described in Note&#160;24, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements, we operate in one operating segment which we consider our only reporting unit.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used, including property, plant and equipment and definite-lived intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Contingent Consideration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions that qualify as business combinations completed after January&#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue these contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step, and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments and Hedging Activities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of derivatives are recorded each period in current earnings or accumulated other comprehensive income (loss), depending on whether a derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We also assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion to current earnings. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Translation of Foreign Currencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net, in net income.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyCostofSalesPolicyTextBlock', window );">Royalty Cost of Sales</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Accounting for Share-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share-based compensation programs grant awards that have included stock options, restricted stock units which vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units which settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units which can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of the Board of Directors and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date on which the employee is retirement eligible.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&#8217; vesting periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures, when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs and PUs and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs and PUs are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price of common stock under our ESPP is equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the lesser of (i)&#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes model. The fair value of the look-back provision plus the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> discount is recognized as compensation expense over the 90 day purchase period. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable, and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets on our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of unconsolidated joint business revenues.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For collaborations with commercialized products, if we are the principal, we record revenue and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Advertising costs are expensed as incurred. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2013</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, advertising costs totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$108.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$92.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$72.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All tax effects associated with intercompany transfers of assets in our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through the consolidated statement of income when the asset transferred is sold to a third party or otherwise recovered through amortization of the asset's remaining economic life.&#160;If the asset transferred becomes impaired, for example through the discontinuation of a research program, we will expense any remaining deferred charge or prepaid tax.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2014, the FASB issued ASU No. 2014-11, Transfers and Servicing (Topic 860): Repurchase-to-Maturity Transactions, Repurchase Financings, and Disclosure. The new standard expanded secured borrowing accounting to include repurchase-to-maturity transactions and repurchase financings and set forth new disclosure requirements for repurchase agreements, securities lending transactions, and repurchase-to-maturity transactions that are accounted for as secured borrowings. We adopted this standard on April 1, 2015 and expanded our disclosures presented in Note 8, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. The adoption of this standard did not have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015, the FASB issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The new standard requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU No. 2015-15, Interest - Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements, which clarified that debt issuance costs related to line-of-credit arrangements can be presented in the balance sheet as an asset and amortized over the term of the line-of-credit arrangement. We adopted these standards as of September 30, 2015 with retroactive application. The adoption of these standards did not have a significant impact on our financial position or results of operations. For additional information, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015, the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. Under this standard, if a cloud computing arrangement includes a software license, the software license element of the arrangement should be accounted for consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015, the FASB issued ASU No. 2015-07, Fair Value Measurement (Topic 820): Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent). The new standard removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The new standard will be effective for us on January 1, 2016. Early application is permitted. We maintain investments in certain venture capital funds which primarily invest in small, privately-owned, venture-backed biotechnology companies. The value of our investments in these venture capital funds is estimated using the net asset value of the fund and has been included in the fair value hierarchy disclosure as a Level 3 measurement. These venture capital investments are not material to our financial position or results of operations. We adopted this standard as of June 30, 2015 and our investments in venture capital funds are no longer included in our disclosures reflected in Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The new standard applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The new standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined and sets forth new disclosure requirements related to the adjustments. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. The new standard requires that deferred tax assets and liabilities be classified as noncurrent in a classified statement of financial position. We adopted this standard as of December 31, 2015 with retroactive application. As a result, we reclassified our deferred tax assets classified as current to noncurrent and our deferred tax liabilities classified as current to noncurrent in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> consolidated balance sheet, to conform our prior year presentation to our current year presentation. For additional information, please read Note 16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltyCostofSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Cost of Sales [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltyCostofSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 203<br> -Paragraph 02-03<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph k<br> -Article 1<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02, 03<br> -Article 3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=d3e41620-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5579240-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5579245-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=d3e41675-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=d3e41638-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the equity method of accounting for investments in common stock or other interests including unconsolidated subsidiaries, corporate joint ventures, noncontrolling interests in real estate ventures, limited partnerships, and limited liability companies. The accounting policy may include information such as: (1) initially recording an investment in the stock of an investee at cost; (2) adjusting the carrying amount of the investment to recognize the investor's share of the earnings or losses of the investee after the date of acquisition; and (3) adjustments to reflect the investor's share of changes in the investee's capital (dividends). This disclosure may also include a detailed description of the policy for determining the amount of equity method losses recognized after an investment has been reduced to zero as a result of previous losses, reasons for not using the equity method when the investor company owns 20 percent or more of the voting stock of the investee's company (including identification of the significant investee), reasons for using the equity method when the ownership percentage is less than 20 percent, and discussion of recognition of equity method losses when an investor's total investment in an investee includes, in addition to an investment in common stock, other investments such as preferred stock and loans to the investee. An entity also may describe how such investments are assessed for impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51717228&amp;loc=d3e202-110218<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section CC<br> -Subsection 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 206<br> -Paragraph b<br> -Subparagraph i, ii<br> -Chapter 2<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 6<br> -Subparagraph a<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2,12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6872867&amp;loc=d3e40691-111596<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section M<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e4975-111524<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3-5<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6389767&amp;loc=d3e17916-109280<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section B<br> -Paragraph Question 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6788045088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock', window );">Property, plant and equipment estimated useful lives</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td width="50%" rowspan="1" colspan="1"></td><td width="50%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of property plant and equipment useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6958082880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Purchase price</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash portion of consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">200.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">274.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">474.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Estimated fair values of separately identifiable assets acquired and liabilities assumed</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">424.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">128.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(84.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">474.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1486-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6624946400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Charges and spending related to our restructuring efforts</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Workforce</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reduction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Pipeline</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges incurred during the fourth quarter of 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">86.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">93.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Previously accrued incentive compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves established</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">102.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">109.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts paid through December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(68.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(72.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6792665888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Reserves (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReservesForDiscountsAndAllowancesAbstract', window );"><strong>Reserves for Discounts and Allowances [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of the change in reserves</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">387.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">49.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">483.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">459.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,732.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,229.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(32.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(405.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,258.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,666.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(44.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(296.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(351.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">56.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">548.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">57.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">662.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2014</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">345.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">426.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">347.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,265.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,651.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(28.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(299.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(933.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,237.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(46.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(261.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(33.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(341.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">387.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">483.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2013</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">861.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,120.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(189.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(560.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(750.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(135.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(165.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">345.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">426.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves, included in consolidated balance sheets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">144.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">124.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">518.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">359.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">662.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">483.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReservesForDiscountsAndAllowancesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReservesForDiscountsAndAllowancesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6787964064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">213.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">128.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">577.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">511.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">143.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">164.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">933.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">804.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">893.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">804.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">933.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">804.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 2<br> -Paragraph 6<br> -Subparagraph a,b,c<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6699421440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td width="21%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(506.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(481.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,552.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">452.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,396.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">608.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">730.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">730.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">314.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">314.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks and tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,303.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(502.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,800.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,280.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(300.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,980.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,646.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3,561.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,085.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,207.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,178.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,028.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization of intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="81%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">346.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">318.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">291.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">275.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">269.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,500.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,760.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,232.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">908.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">527.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,663.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,760.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6698766208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">909.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">909.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,510.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,510.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,875.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,875.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">494.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">494.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">27.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">27.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,895.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,857.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">520.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">716.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">716.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,063.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,063.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">849.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">849.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,943.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,937.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">220.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">602.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">634.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,497.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,014.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,764.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,757.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,645.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">647.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">274.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">30.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(38.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(26.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13476-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13467-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6447952&amp;loc=d3e13220-108610<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6698765920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">134.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">305.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">673.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">321.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">79.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">909.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">716.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Marketable securities including strategic investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">394.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">394.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,116.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,120.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,723.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,724.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,152.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,155.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">491.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">493.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,880.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,891.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">28.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">370.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">370.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">692.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">693.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">269.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">270.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">579.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">198.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,111.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,112.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: Available-for-sale securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,120.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,122.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">640.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">640.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,575.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,583.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,343.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,345.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">184.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">185.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">126.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">126.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,880.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,891.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,111.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,112.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable securities, excluding strategic investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,063.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,718.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,190.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964659680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">945.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,174.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss francs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">80.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">76.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Australian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,103.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,302.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of derivatives designated as hedging instruments on our consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27" rowspan="1"></td></tr><tr><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">173.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of the fair value for our outstanding derivatives</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="54%" rowspan="1" colspan="1"></td><td width="27%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance&#160;Sheet&#160;Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Fair Value<br clear="none"/>As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="54%" rowspan="1" colspan="1"></td><td width="27%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value<br clear="none"/>As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964352496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Components of property, plant and equipment, net</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">74.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,035.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">947.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">166.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">155.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,079.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,011.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Computer software and hardware</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">647.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">547.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">72.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">441.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">168.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,517.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,952.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,330.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,186.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,187.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,765.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock', window );">Property plant and equipment purchase price allocation [Table Text Block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">58.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">104.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment purchase price allocation [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PropertyplantandequipmentpurchasepriceallocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6788036256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Indebtedness</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing arrangement for the purchase of the RTP facility</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Non-current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">2008 Senior Notes</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">565.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">571.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">2015 Senior Notes</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,485.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">992.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,733.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,721.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing arrangement for the purchase of the RTP facility</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">18.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,521.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Total debt maturities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="80%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">553.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,500.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,500.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,559.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6788063440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfCommonStockTableTextBlock', window );">Summary of common stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td width="24%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">241.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">218.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">257.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">234.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfCommonStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfCommonStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6787979904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="26%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(99.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(59.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">110.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(96.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(172.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(171.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(61.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(96.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(164.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(37.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(195.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(224.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="26%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(109.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(109.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(99.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="26%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(55.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(26.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="28%" rowspan="1" colspan="1"></td><td width="25%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">173.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">171.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6787930800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,547.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,862.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">230.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">231.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780871728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="55%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">88.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">102.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">127.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">160.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reversal of previously accrued incentive compensation included in restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(8.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">207.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">252.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">255.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">196.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">246.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(55.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(72.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(73.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">140.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">172.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="55%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">38.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">119.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">115.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">103.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">109.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">207.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">252.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">255.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">196.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">246.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock option activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">221,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">56.98</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(114,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">59.82</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">107,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.94</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock', window );">Tax benefit and cash received from stock option exercises</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit realized for stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received from the exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock', window );">Market stock units activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">403,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">219.29</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">185,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">493.43</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(277,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">165.63</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(42,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">294.85</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">269,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">339.89</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock', window );">Assumptions used in valuation of market based stock units</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="44%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of expected stock price volatility</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">31.0% - 33.2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.7% - 35.1%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.7% - 25.7%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of risk-free interest rates</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2% - 1.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1% - 0.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1% - 0.7%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 calendar day average stock price on grant date</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$277.35 - $426.27</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$280.88 - $335.65</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60 calendar day average stock price on grant date</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.33 - $240.14</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average per share grant date fair value</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$493.43</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$395.22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$193.45</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock', window );">Cash settled performance shares activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="82%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">335,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">115,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(222,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(36,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">192,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PerformanceunitsactivityTableTextBlock', window );">Performance units activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="82%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">57,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">89,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(33,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">103,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock', window );">Time-vested restricted stock units activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,137,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">221.01</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">459,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">388.88</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(626,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">190.65</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(160,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">302.35</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">810,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">323.87</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock', window );">Shares issued under employee stock purchase plan</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 2015 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">78,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 1995 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">98,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">180,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">245,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 2015 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">19.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 1995 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">30.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumptions used in valuation of market based stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PerformanceunitsactivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance units activity [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PerformanceunitsactivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Cash Settled Performance Shares Activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Market Stock Units Activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfMarketStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued under employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Time Vested Restricted Stock Units Activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of cash proceeds received from the exercise of stock options and similar instruments granted under share-based payment arrangements and the tax benefit realized from stock options exercised during the period.  Disclosure may also include the intrinsic value of stock options exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashProceedsReceivedFromShareBasedPaymentAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6698273104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Income before income tax provision and the income tax expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income before income taxes (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,386.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,557.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,953.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,380.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,389.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">527.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,767.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,946.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,480.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income tax expense (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,214.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,159.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">700.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">38.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">54.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,307.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,298.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">846.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(129.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(280.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(200.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(35.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(145.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(308.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(245.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,161.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">989.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">601.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of deferred tax assets and liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">189.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory, other reserves, and accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">243.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">217.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangibles, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">328.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">251.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">63.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(14.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">871.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">693.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(440.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(432.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(102.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(107.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(542.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(539.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="55%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration and other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of beginning and ending amount of unrecognized tax benefits</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="56%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at January&#160;1,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">131.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">110.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">125.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions based on tax positions related to the current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">19.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reductions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(49.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(92.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statute expirations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(42.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(60.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at December&#160;31,</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">67.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">110.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=51663037&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6965205632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplementary cash flow information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="51%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid during the year for:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,674.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,163.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">643.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(95.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(29.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairments on investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(32.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(15.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(13.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(123.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(25.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(34.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">518.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">359.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">504.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">265.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">270.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">393.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">167.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">172.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">579.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">505.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,096.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,817.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Other long-term liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="67%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">301.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">369.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">249.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other long-term liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">905.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">650.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6963695104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CoPromotionProfitSharingFormulaTableTextBlock', window );">Co-promotion profit sharing formula</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="82%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until GAZYVA First Non-CLL FDA Approval</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First Non-CLL GAZYVA FDA Approval</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the FDA&#8217;s first approval of GAZYVA in an indication other than CLL.</font></div><div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the earlier of (1)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12 month period were at least </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or (2)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12 month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">Second GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12 month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$500.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PretaxProfitSharingFormulaTableTextBlock', window );">Pretax profit sharing formula</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="82%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock', window );">Revenues from unconsolidated joint business</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,269.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,117.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,087.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue on sales in the rest of world for RITUXAN</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total unconsolidated joint business revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,339.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,126.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock', window );">Mechanism for reimbursement, under the amended agreement amounts payable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="35%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rates post Sobi Opt-In</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Royalty and Net Revenue Share Rates:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Method</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rate prior to 1st</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">commercial sale in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">the&#160;Sobi&#160;Territory:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Base Rate following</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">1st&#160;commercial&#160;sale&#160;in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">the Sobi Territory:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rate during the</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reimbursement</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period:</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sobi rate to Biogen on net sales in the Sobi Territory</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10&#160;or&#160;12%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base&#160;Rate<br clear="none"/>plus 5%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net sales in the Biogen North America Territory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10&#160;or&#160;12%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br clear="none"/>less 5%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net sales in the Biogen Direct Territory</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15&#160;or&#160;17%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br clear="none"/>less 5%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net revenue</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">from the Biogen Distributor Territory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Net<br clear="none"/>Revenue<br clear="none"/>Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br clear="none"/>less 15%</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net revenue represents Biogen&#8217;s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.</font></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock', window );">Summary of activity related to collaboration with AbbVie Inc.</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="56%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">113.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">117.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">133.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of development expense reflected in our consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock', window );">Summary of activity related to collaboration with Eisai</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="56%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">84.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of development expense, excluding upfront and milestone payments, reflected in our consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionProfitSharingFormulaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profit sharing formula.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionProfitSharingFormulaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PretaxProfitSharingFormulaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pretax Profit Sharing Formula [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PretaxProfitSharingFormulaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mechanism for reimbursement, under the amended agreement amounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from unconsolidated joint business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of activity related to collaboration with company seven.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6965192784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Minimum rental commitments under non-cancelable leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28" rowspan="1"></td></tr><tr><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">75.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">75.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">67.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">63.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">382.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">732.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(28.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(59.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">69.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">61.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">56.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">353.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">672.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">As a result of our decision to relocate our corporate headquarters to Cambridge, Massachusetts, we vacated part of our Weston, Massachusetts facility in the fourth quarter of 2013. We incurred a charge of </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">$27.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> in connection with this move. This charge represented our remaining lease obligation for the vacated portion of our Weston, Massachusetts facility, net of sublease income expected to be received. The term of our sublease to the vacated portion of our Weston, Massachusetts facility started in January 2014 and will continue through the remaining term of our lease agreement.</font></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="79%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">20.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net present value of the future minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">19.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6788045088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Revenue by product</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="36" rowspan="1"></td></tr><tr><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,908.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">730.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">3,638.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,426.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">482.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,909.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">864.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">11.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">876.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AVONEX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,790.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">840.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,630.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,956.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,056.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,013.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,902.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,103.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,005.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">PLEGRIDY</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">227.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">111.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">338.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">27.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">16.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">44.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,103.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">783.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,886.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,025.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">934.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,959.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">814.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">712.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,526.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">89.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">89.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">80.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">80.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">74.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">74.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">308.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">11.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">319.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">58.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">58.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">208.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">25.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">234.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">72.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">76.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">51.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">51.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">62.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">62.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">60.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">60.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">6,545.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,642.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">9,188.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">5,566.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,636.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">8,203.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,581.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,961.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">5,542.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Geographic information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td width="29%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Germany</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,545.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,497.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">668.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">143.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">333.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,188.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,269.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">65.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,339.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">142.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">29.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">62.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">236.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,296.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">879.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,187.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2014 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Germany</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,566.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,383.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">811.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">112.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">328.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,203.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,117.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,055.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">701.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,765.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2013 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Germany</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,581.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,170.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">417.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,542.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,087.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,126.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">193.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">263.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">984.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">758.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,750.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964404560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="36%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(c) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,172.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,198.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,391.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,425.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,188.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">330.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">337.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">337.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">333.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,339.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">52.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">49.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">79.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">236.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,555.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,591.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,777.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,839.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,763.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,242.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,305.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,467.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,507.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,523.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">820.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">924.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,019.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">828.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,593.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">822.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">927.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">965.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">831.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,547.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.50</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.94</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.16</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.77</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.38</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.49</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.93</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.15</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.77</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.34</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">232.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">220.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">230.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">235.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">232.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">220.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">231.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="36%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2014</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(f) (g)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(f)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(f)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,742.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,056.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,117.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,287.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,203.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unconsolidated joint business revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">296.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">303.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">290.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">103.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,129.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,421.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,511.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,640.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,703.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,850.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,129.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,208.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,343.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,532.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">479.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">723.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">856.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">882.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,941.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">480.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">714.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">856.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">883.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.02</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.63</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.75</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.02</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.01</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.62</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.74</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)  Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc., for the third quarter of 2015, include a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$48.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recorded upon entering into the collaboration agreement with AGTC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc., for the third quarter of 2015, reflects the attribution of a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> charge to noncontrolling interests, net of tax, related to a milestone payment due Neurimmune upon the enrollment of the first patient in a Phase 3 trial for aducanumab.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc., for the fourth quarter of 2015, include a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recorded upon entering into the collaboration agreement with MTPC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc., for the fourth quarter of 2015, include pre-tax restructuring charges totaling </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc., for the first quarter of 2014, include pre-tax charges to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$117.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recorded upon entering into the collaboration agreement with Eisai.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net and total revenues for the second, third and fourth quarters of 2014 include net revenues related to ALPROLIX as commercial sales of ALPROLIX commenced in the second quarter of 2014.  Product revenues, net and total revenues for the third and fourth quarters of 2014 include net revenues related to ELOCTATE and PLEGRIDY as commercial sales of ELOCTATE and PLEGRIDY commenced in the third quarter of 2014.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net and total revenues for the second quarter of 2014 include the recognition of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$53.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of revenue previously deferred in Italy relating to the pricing agreement with AIFA. </font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=51825399&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6966212208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Current balance included within accounts receivable, net</a></td>
<td class="nump">$ 1,227.0<span></span>
</td>
<td class="nump">$ 1,292.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessTextualAbstract', window );"><strong>Business (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentTermsOfAccountsReceivable', window );">Payment terms of accounts receivable arising from product sales</a></td>
<td class="text">30 to 90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedUsefulLivesOfLeaseholdImprovements', window );">Estimated useful lives of leasehold improvements</a></td>
<td class="text">Lesser of the useful life or the term of the respective lease<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PurchasePriceOfCommonStockUnderEspp', window );">Purchase price of common stock under ESPP</a></td>
<td class="text">85% of the lower of (i) the market value per share of the common stock on the participant's entry date into an offering period or (ii) the market value per share of the common stock on the purchase date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfMarketValuePerShareOfCommonStock', window );">Percentage of market value per share of common stock</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CompensationExpenseOverPurchasePeriod', window );">Compensation expense over purchase period</a></td>
<td class="text">The fair value of the look-back provision plus the 15% discount<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DiscountRateRecognizedInCompensationExpense', window );">Discount rate recognized in compensation expense</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="nump">$ 108.6<span></span>
</td>
<td class="nump">$ 92.9<span></span>
</td>
<td class="nump">$ 72.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MajorDistributorAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables', window );">Percentage receivables of wholesale distributor accounted in consolidated receivables</a></td>
<td class="nump">35.40%<span></span>
</td>
<td class="nump">34.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MajorDistributorAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables', window );">Percentage receivables of wholesale distributor accounted in consolidated receivables</a></td>
<td class="nump">23.10%<span></span>
</td>
<td class="nump">23.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=biib_SpainandPortugalMember', window );">Spain and Portugal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Current balance included within accounts receivable, net</a></td>
<td class="nump">$ 62.4<span></span>
</td>
<td class="nump">$ 90.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetNoncurrent', window );">Non-current balance included within investments and other assets</a></td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="nump">$ 12.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CompensationExpenseOverPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Compensation expense over purchase period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CompensationExpenseOverPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DiscountRateRecognizedInCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate recognized in compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DiscountRateRecognizedInCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedUsefulLivesOfLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated useful lives of leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedUsefulLivesOfLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentTermsOfAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment  terms of accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentTermsOfAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfMarketValuePerShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of market value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfMarketValuePerShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage receivables of wholesale distributor accounted in consolidated receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PurchasePriceOfCommonStockUnderEspp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Price Of Common Stock Under ESPP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PurchasePriceOfCommonStockUnderEspp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3-4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Subparagraph a(1)<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 4<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, more than one year from the balance sheet date, for goods or services that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MajorDistributorAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MajorDistributorAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MajorDistributorAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MajorDistributorAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=biib_SpainandPortugalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=biib_SpainandPortugalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780797472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions Acquisitions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash portion of consideration</a></td>
<td class="nump">$ 200.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration obligation</a></td>
<td class="nump">274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
<td class="nump">$ 474.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6961799280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions Acquisitions (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Feb. 12, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 2,663.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,760.2<span></span>
</td>
<td class="nump">$ 1,232.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 424.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 474.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=35744172&amp;loc=d3e2207-128464<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=35744172&amp;loc=d3e2207-128464<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6800241744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Feb. 12, 2015</div></th>
<th class="th"><div>Apr. 02, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of TYSABRI rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 3,262.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.7<span></span>
</td>
<td class="nump">$ 120.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash portion of consideration</a></td>
<td class="nump">$ 200.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration obligation</a></td>
<td class="nump">274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Increase in contingent consideration liability</a></td>
<td class="nump">36.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Increase in goodwill</a></td>
<td class="nump">$ 36.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember', window );">TYSABRI product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of TYSABRI rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,180.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentForFirst12Months', window );">Future contingent payment for the first 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion', window );">Future contingent payment for annual worldwide net sales up to $2.0 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentThreshold', window );">Future contingent payment threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion', window );">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_RaxatrigineMember', window );">Raxatrigine | Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_NeuropathicpainindicationsMember', window );">Neuropathic pain indications | Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment for annual worldwide net sales that exceed $2.0 billion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment for annual worldwide net sales up to $2.0 billion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentForFirst12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment for the first 12 months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentForFirst12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=35744172&amp;loc=d3e2207-128464<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_RaxatrigineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_RaxatrigineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_NeuropathicpainindicationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_NeuropathicpainindicationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6965333136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Oct. 21, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 93.4<span></span>
</td>
<td class="nump">$ 93.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment', window );">Previously accrued incentive compensation</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Restructuring amounts paid</a></td>
<td class="num">(72.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">37.3<span></span>
</td>
<td class="nump">37.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Workforce reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">86.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment', window );">Previously accrued incentive compensation</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Restructuring amounts paid</a></td>
<td class="num">(68.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">33.7<span></span>
</td>
<td class="nump">33.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember', window );">Pipeline programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment', window );">Previously accrued incentive compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Restructuring amounts paid</a></td>
<td class="num">(3.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 3, 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 3, 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (expense) reversal of expense related to a previously accrued restructuring cost liability. Excludes adjustments for costs incurred, costs settled, and foreign currency translation adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394291&amp;loc=d3e17658-110867<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 3, 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6781406160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated', window );">Restructuring and related cost, expected percentage of positions eliminated</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RestructuringandRelatedCostExpectedCashPayments', window );">Previously accrued incentive compensation</a></td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment', window );">Previously accrued incentive compensation</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Total restructuring charges expected</a></td>
<td class="nump">105.0<span></span>
</td>
<td class="nump">105.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">93.4<span></span>
</td>
<td class="nump">$ 93.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Workforce reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment', window );">Previously accrued incentive compensation</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">86.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember', window );">Pipeline programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment', window );">Previously accrued incentive compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RestructuringandRelatedCostExpectedCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Expected Cash Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RestructuringandRelatedCostExpectedCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and related cost, expected percentage of positions eliminated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 3, 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 3, 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (expense) reversal of expense related to a previously accrued restructuring cost liability. Excludes adjustments for costs incurred, costs settled, and foreign currency translation adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394291&amp;loc=d3e17658-110867<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 3, 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6966137984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Reserves (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">$ 483.8<span></span>
</td>
<td class="nump">$ 426.2<span></span>
</td>
<td class="nump">$ 237.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">2,229.4<span></span>
</td>
<td class="nump">1,651.8<span></span>
</td>
<td class="nump">1,120.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(32.3)<span></span>
</td>
<td class="num">(16.0)<span></span>
</td>
<td class="num">(16.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns relating to sales in current year</a></td>
<td class="num">(1,666.6)<span></span>
</td>
<td class="num">(1,237.2)<span></span>
</td>
<td class="num">(750.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns relating to sales in prior years</a></td>
<td class="num">(351.6)<span></span>
</td>
<td class="num">(341.0)<span></span>
</td>
<td class="num">(165.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">662.7<span></span>
</td>
<td class="nump">483.8<span></span>
</td>
<td class="nump">426.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">47.6<span></span>
</td>
<td class="nump">47.0<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">459.7<span></span>
</td>
<td class="nump">347.3<span></span>
</td>
<td class="nump">236.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns relating to sales in current year</a></td>
<td class="num">(405.9)<span></span>
</td>
<td class="num">(299.7)<span></span>
</td>
<td class="num">(189.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns relating to sales in prior years</a></td>
<td class="num">(44.0)<span></span>
</td>
<td class="num">(46.0)<span></span>
</td>
<td class="num">(13.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">56.1<span></span>
</td>
<td class="nump">47.6<span></span>
</td>
<td class="nump">47.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">387.1<span></span>
</td>
<td class="nump">345.5<span></span>
</td>
<td class="nump">196.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">1,732.1<span></span>
</td>
<td class="nump">1,265.4<span></span>
</td>
<td class="nump">861.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(16.3)<span></span>
</td>
<td class="num">(28.5)<span></span>
</td>
<td class="num">(16.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns relating to sales in current year</a></td>
<td class="num">(1,258.1)<span></span>
</td>
<td class="num">(933.4)<span></span>
</td>
<td class="num">(560.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns relating to sales in prior years</a></td>
<td class="num">(296.1)<span></span>
</td>
<td class="num">(261.9)<span></span>
</td>
<td class="num">(135.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">548.7<span></span>
</td>
<td class="nump">387.1<span></span>
</td>
<td class="nump">345.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">49.1<span></span>
</td>
<td class="nump">33.7<span></span>
</td>
<td class="nump">26.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">37.6<span></span>
</td>
<td class="nump">39.1<span></span>
</td>
<td class="nump">22.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(14.7)<span></span>
</td>
<td class="nump">13.5<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns relating to sales in current year</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns relating to sales in prior years</a></td>
<td class="num">(11.5)<span></span>
</td>
<td class="num">(33.1)<span></span>
</td>
<td class="num">(17.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">$ 57.9<span></span>
</td>
<td class="nump">$ 49.1<span></span>
</td>
<td class="nump">$ 33.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of the amount of, and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 09<br> -Article 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6963668224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Reserves (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">$ 662.7<span></span>
</td>
<td class="nump">$ 483.8<span></span>
</td>
<td class="nump">$ 426.2<span></span>
</td>
<td class="nump">$ 237.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">144.6<span></span>
</td>
<td class="nump">124.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">$ 518.1<span></span>
</td>
<td class="nump">$ 359.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 09<br> -Article 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6966029232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 213.0<span></span>
</td>
<td class="nump">$ 128.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">577.6<span></span>
</td>
<td class="nump">511.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">143.0<span></span>
</td>
<td class="nump">164.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">933.6<span></span>
</td>
<td class="nump">804.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, current</a></td>
<td class="nump">893.4<span></span>
</td>
<td class="nump">804.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, noncurrent</a></td>
<td class="nump">$ 40.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section BB<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section BB<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section BB<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6966258336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-downs on excess, obsolete, unmarketable or other inventory</a></td>
<td class="nump">$ 41.9<span></span>
</td>
<td class="nump">$ 50.6<span></span>
</td>
<td class="nump">$ 47.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Preapprovalinventory', window );">Pre-approval inventory</a></td>
<td class="nump">24.7<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Preapprovalinventory', window );">Pre-approval inventory</a></td>
<td class="nump">18.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Preapprovalinventory', window );">Pre-approval inventory</a></td>
<td class="nump">$ 24.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Preapprovalinventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre-approval inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Preapprovalinventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4542-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6793388608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Feb. 12, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 2,663.8<span></span>
</td>
<td class="nump">$ 1,760.2<span></span>
</td>
<td class="nump">$ 1,232.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">7,646.3<span></span>
</td>
<td class="nump">7,207.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(3,561.2)<span></span>
</td>
<td class="num">(3,178.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">4,085.1<span></span>
</td>
<td class="nump">4,028.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2016</a></td>
<td class="nump">346.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2017</a></td>
<td class="nump">318.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2018</a></td>
<td class="nump">291.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2019</a></td>
<td class="nump">275.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">269.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Finitelivedintangibleassetsfutureamortization', window );">FiniteLivedIntangibleAssetsFutureAmortization</a></td>
<td class="nump">1,500.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">382.6<span></span>
</td>
<td class="nump">489.8<span></span>
</td>
<td class="nump">$ 342.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">543.3<span></span>
</td>
<td class="nump">543.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(506.0)<span></span>
</td>
<td class="num">(481.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 37.3<span></span>
</td>
<td class="nump">61.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of out-licensed patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 3,005.3<span></span>
</td>
<td class="nump">3,005.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,552.9)<span></span>
</td>
<td class="num">(2,396.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 452.4<span></span>
</td>
<td class="nump">608.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 3,303.2<span></span>
</td>
<td class="nump">3,280.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(502.3)<span></span>
</td>
<td class="num">(300.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 2,800.9<span></span>
</td>
<td class="nump">2,980.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">$ 730.5<span></span>
</td>
<td class="nump">314.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of in-process research and development asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">$ 64.0<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">443.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI product | Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 2,742.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 424.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Finitelivedintangibleassetsfutureamortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>FiniteLivedIntangibleAssetsFutureAmortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Finitelivedintangibleassetsfutureamortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IndefiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets and goodwill additional.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6781155328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 1,161.6<span></span>
</td>
<td class="nump">$ 989.9<span></span>
</td>
<td class="nump">$ 601.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">1,760.2<span></span>
</td>
<td class="nump">1,232.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">908.1<span></span>
</td>
<td class="nump">527.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherChanges', window );">Other goodwill adjustments</a></td>
<td class="num">(4.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">2,663.8<span></span>
</td>
<td class="nump">1,760.2<span></span>
</td>
<td class="nump">$ 1,232.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember', window );">Fumapharm AG | TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">120.2<span></span>
</td>
<td class="nump">72.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="nump">$ 600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a,h)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other (increase) decrease of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6793438480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 4,880.9<span></span>
</td>
<td class="nump">$ 2,111.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">909.5<span></span>
</td>
<td class="nump">716.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">37.5<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">27.2<span></span>
</td>
<td class="nump">72.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">40.1<span></span>
</td>
<td class="nump">36.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,895.2<span></span>
</td>
<td class="nump">2,943.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">14.7<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">506.0<span></span>
</td>
<td class="nump">215.5<span></span>
</td>
<td class="nump">$ 280.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">520.7<span></span>
</td>
<td class="nump">220.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,510.9<span></span>
</td>
<td class="nump">1,063.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">2,875.9<span></span>
</td>
<td class="nump">849.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">494.1<span></span>
</td>
<td class="nump">198.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">37.5<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">37.5<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">909.5<span></span>
</td>
<td class="nump">716.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">27.2<span></span>
</td>
<td class="nump">72.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">40.1<span></span>
</td>
<td class="nump">36.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,857.7<span></span>
</td>
<td class="nump">2,937.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">14.7<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">14.7<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,510.9<span></span>
</td>
<td class="nump">1,063.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">2,875.9<span></span>
</td>
<td class="nump">849.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">494.1<span></span>
</td>
<td class="nump">198.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">506.0<span></span>
</td>
<td class="nump">215.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">506.0<span></span>
</td>
<td class="nump">215.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Trading Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27723805&amp;loc=d3e24584-111560<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Available-for-Sale Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 1<br> -Subparagraph a, f, g<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6965860192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract', window );"><strong>Summary of fair and carrying value of debt instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value</a></td>
<td class="nump">$ 6,645.9<span></span>
</td>
<td class="nump">$ 647.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember', window );">Notes Payable to Fumedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract', window );"><strong>Summary of fair and carrying value of debt instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">9.4<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract', window );"><strong>Summary of fair and carrying value of debt instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">602.6<span></span>
</td>
<td class="nump">634.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract', window );"><strong>Summary of fair and carrying value of debt instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,497.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract', window );"><strong>Summary of fair and carrying value of debt instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,014.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract', window );"><strong>Summary of fair and carrying value of debt instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,764.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract', window );"><strong>Summary of fair and carrying value of debt instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,757.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of fair and carrying value of debt instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfFairAndCarryingValueOfDebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13476-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6966102672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="num">$ (49.4)<span></span>
</td>
<td class="nump">30.5<span></span>
</td>
<td class="num">(38.9)<span></span>
</td>
<td class="num">$ (0.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.5)<span></span>
</td>
<td class="num">(26.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215.5<span></span>
</td>
<td class="nump">280.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 506.0<span></span>
</td>
<td class="nump">$ 215.5<span></span>
</td>
<td class="nump">$ 280.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6799473920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2012</div></th>
<th class="th"><div>Sep. 30, 2011</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Feb. 12, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 301.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 301.3<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsChangesInValuationTechniques', window );">Fair value measurements, changes in valuation techniques</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0<span></span>
</td>
<td class="text">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (30.5)<span></span>
</td>
<td class="nump">$ 38.9<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">$ 274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate used for net cash outflow projections for fair value measurement</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 424.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_StromedixMember', window );">Stromedix, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131.5<span></span>
</td>
<td class="nump">130.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 419.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate used for net cash outflow projections for fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_CorporateJointVentureInvestmentsMember', window );">Biogen Dompe SRL and Biogen Dompe Switzerland GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MilestonePaymentsMadeDuringPeriod', window );">Milestone payments made during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecInternationalNeuroscienceMember', window );">Biogen Idec International Neuroscience GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.0<span></span>
</td>
<td class="nump">69.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 365.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 365.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate used for net cash outflow projections for fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 301.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 301.3<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MilestonePaymentsMadeDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Made During Period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MilestonePaymentsMadeDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementsChangesInValuationTechniques">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the changes in valuation technique(s) and related inputs used to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementsChangesInValuationTechniques</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_StromedixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_StromedixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_CorporateJointVentureInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_CorporateJointVentureInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecInternationalNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecInternationalNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6792711040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 909.5<span></span>
</td>
<td class="nump">$ 716.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">21.9<span></span>
</td>
<td class="nump">54.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight Reverse Repurchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">134.7<span></span>
</td>
<td class="nump">305.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">673.8<span></span>
</td>
<td class="nump">321.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 79.1<span></span>
</td>
<td class="nump">$ 35.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6781834560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">$ 4,880.9<span></span>
</td>
<td class="nump">$ 2,111.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(10.6)<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">4,891.2<span></span>
</td>
<td class="nump">2,112.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">394.3<span></span>
</td>
<td class="nump">370.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">394.8<span></span>
</td>
<td class="nump">370.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,116.6<span></span>
</td>
<td class="nump">692.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4.1)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,120.6<span></span>
</td>
<td class="nump">693.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,723.4<span></span>
</td>
<td class="nump">269.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,724.4<span></span>
</td>
<td class="nump">270.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,152.5<span></span>
</td>
<td class="nump">579.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3.1)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,155.6<span></span>
</td>
<td class="nump">580.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">491.3<span></span>
</td>
<td class="nump">198.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">493.0<span></span>
</td>
<td class="nump">198.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MarketableEquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">37.5<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">9.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 28.3<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MarketableEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MarketableEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780746960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, Estimated Fair Value</a></td>
<td class="nump">$ 2,120.5<span></span>
</td>
<td class="nump">$ 640.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, Amortized Cost</a></td>
<td class="nump">2,122.0<span></span>
</td>
<td class="nump">640.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, Estimated Fair Value</a></td>
<td class="nump">2,575.9<span></span>
</td>
<td class="nump">1,343.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, Amortized Cost</a></td>
<td class="nump">2,583.9<span></span>
</td>
<td class="nump">1,345.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, Estimated Fair Value</a></td>
<td class="nump">184.5<span></span>
</td>
<td class="nump">126.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, Amortized Cost</a></td>
<td class="nump">185.3<span></span>
</td>
<td class="nump">126.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Total available-for-sale securities, Fair Value</a></td>
<td class="nump">4,880.9<span></span>
</td>
<td class="nump">2,111.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total available-for-sale securities, Amortized Cost</a></td>
<td class="nump">$ 4,891.2<span></span>
</td>
<td class="nump">$ 2,112.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the next fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6956720688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ProceedsFromMarketableDebtSecuritiesAbstract', window );"><strong>Proceeds from Marketable Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 4,063.0<span></span>
</td>
<td class="nump">$ 2,718.9<span></span>
</td>
<td class="nump">$ 5,190.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains', window );">Realized gains</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses', window );">Realized losses</a></td>
<td class="num">$ (3.5)<span></span>
</td>
<td class="num">$ (0.5)<span></span>
</td>
<td class="num">$ (2.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ProceedsFromMarketableDebtSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from marketable debt securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ProceedsFromMarketableDebtSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross profit realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780845712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual 1)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FinancialInstrumentsTextualAbstract', window );"><strong>Financial Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Original maturities of commercial paper and short-term debt securities</a></td>
<td class="text">less than 90&#160;days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Overnightreverserepurchaseagreementspercentoftotalassets', window );">Overnight reverse repurchase agreements, percent of total assets</a></td>
<td class="nump">0.71%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">16 months<span></span>
</td>
<td class="text">15 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FinancialInstrumentsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FinancialInstrumentsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Overnightreverserepurchaseagreementspercentoftotalassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Overnight reverse repurchase agreements, percent of total assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Overnightreverserepurchaseagreementspercentoftotalassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6959650240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details Textual 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 96.0<span></span>
</td>
<td class="nump">$ 47.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6792723424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 1,103.0<span></span>
</td>
<td class="nump">$ 1,302.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">721.0<span></span>
</td>
<td class="nump">365.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Other current assets | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of derivatives designated as hedging instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivatives</a></td>
<td class="nump">16.6<span></span>
</td>
<td class="nump">69.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Other current assets | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of derivatives designated as hedging instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivatives</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Investments and other assets | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of derivatives designated as hedging instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivatives</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Accrued expenses and other | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of derivatives designated as hedging instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="nump">10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Accrued expenses and other | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of derivatives designated as hedging instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Other long-term liabilities | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of derivatives designated as hedging instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_EUR', window );">Euro | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">945.5<span></span>
</td>
<td class="nump">1,174.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_CHF', window );">Swiss francs | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">80.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_CAD', window );">Canadian dollar | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">76.7<span></span>
</td>
<td class="nump">56.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_GBP', window );">British pound sterling | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">34.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_AUD', window );">Australian dollar | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">19.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_JPY', window );">Japanese yen | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 16.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226000-175313<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51814546&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51814546&amp;loc=SL51823488-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624163-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964687072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details 1) - Revenue - Foreign Exchange Contract - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeByNatureAxis=us-gaap_SalesMember', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Amount Reclassified from Accumulated Other Comprehensive Income into Income Gain/(Loss) (Effective Portion)</a></td>
<td class="nump">$ 173.2<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="num">$ (13.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeByNatureAxis=us-gaap_SalesMember', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in earnings of foreign currency forward contracts due to hedge ineffectiveness</a></td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="num">$ (1.5)<span></span>
</td>
<td class="num">$ (0.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624177-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeByNatureAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeByNatureAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6965962560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Gain on treasury rate lock settlement</a></td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="num">$ (19.1)<span></span>
</td>
<td class="nump">$ 24.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLowerRemainingMaturityRange1', window );">Lower range of durations of foreign currency forward contracts</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeHigherRemainingMaturityRange1', window );">Higher range of durations of foreign currency forward contracts</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="num">$ (1.8)<span></span>
</td>
<td class="nump">$ 72.1<span></span>
</td>
<td class="num">(23.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1', window );">Expected settlement time for contracts, in months</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains (losses) of other income (expense) related to foreign currency forward contracts</a></td>
<td class="nump">$ 23.8<span></span>
</td>
<td class="nump">15.5<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">1,103.0<span></span>
</td>
<td class="nump">1,302.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">721.0<span></span>
</td>
<td class="nump">$ 365.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate lock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Gain on treasury rate lock settlement</a></td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate lock | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">1,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeHigherRemainingMaturityRange1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>High end period remaining until maturity for the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeHigherRemainingMaturityRange1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLowerRemainingMaturityRange1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Low end period remaining until maturity of derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLowerRemainingMaturityRange1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6961852448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">$ 74.7<span></span>
</td>
<td class="nump">$ 56.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings</a></td>
<td class="nump">1,035.6<span></span>
</td>
<td class="nump">947.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">166.6<span></span>
</td>
<td class="nump">155.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Machinery and equipment</a></td>
<td class="nump">1,079.6<span></span>
</td>
<td class="nump">1,011.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ComputerSoftwareAndHardware', window );">Computer software and hardware</a></td>
<td class="nump">647.1<span></span>
</td>
<td class="nump">547.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and fixtures</a></td>
<td class="nump">72.9<span></span>
</td>
<td class="nump">64.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">441.2<span></span>
</td>
<td class="nump">168.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total cost</a></td>
<td class="nump">3,517.7<span></span>
</td>
<td class="nump">2,952.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,330.1)<span></span>
</td>
<td class="num">(1,186.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">$ 2,187.6<span></span>
</td>
<td class="nump">$ 1,765.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ComputerSoftwareAndHardware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Computer software and hardware</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ComputerSoftwareAndHardware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964393664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment (Details 1) - Eisai<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Research Triangle Park facility purchase</a></td>
<td class="nump">$ 104.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_EisaiMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Research Triangle Park facility purchase</a></td>
<td class="nump">58.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_EisaiMember', window );">Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Research Triangle Park facility purchase</a></td>
<td class="nump">25.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_EisaiMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Research Triangle Park facility purchase</a></td>
<td class="nump">$ 20.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6800095552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details Textual)<br> SFr in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217.9<span></span>
</td>
<td class="nump">$ 198.4<span></span>
</td>
<td class="nump">$ 187.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest cost capitalization related to construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">$ 441.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441.2<span></span>
</td>
<td class="nump">$ 168.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">99.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_CambridgeLeasesMember', window );">Cambridge Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Chargesrecognizedtovacatebuilding', window );">Charges recognized to vacate building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Solothurn, Switzerland land purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Term of original lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TermOfLease', window );">Term of amended lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Capital lease obligation</a></td>
<td class="nump">19.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.3<span></span>
</td>
<td class="nump">$ 19.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land | Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Solothurn, Switzerland land purchase</a></td>
<td class="nump">$ 62.5<span></span>
</td>
<td class="nump">SFr 64.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Solothurn, Switzerland land purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Chargesrecognizedtovacatebuilding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charges recognized to vacate building</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Chargesrecognizedtovacatebuilding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TermOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Of Lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TermOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 16<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Allowance for Funds Used during Construction<br> -URI http://asc.fasb.org/extlink&amp;oid=6504829<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_CambridgeLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_CambridgeLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6782859536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Indebtedness (Details)<br> SFr in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2006 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrentAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Financing arrangement for the purchase of the RTP facility</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of notes payable and other financing arrangements</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">6,559.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Financing arrangement for the purchase of the RTP facility</a></td>
<td class="nump">18.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Non-current portion of notes payable and other financing arrangements</a></td>
<td class="nump">6,521.5<span></span>
</td>
<td class="nump">580.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Note payable to Fumedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrentAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable to Fumedica</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
<td class="nump">SFr 61.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">565.3<span></span>
</td>
<td class="nump">571.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">1,485.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">992.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">1,733.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">$ 1,721.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20, 22<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section H<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and capital leases due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6777566432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Indebtedness (Details 1)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Total debt maturities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2016</a></td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2017</a></td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2018</a></td>
<td class="nump">553.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2019</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2020</a></td>
<td class="nump">1,500.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">2021 and thereafter</a></td>
<td class="nump">4,500.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Total</a></td>
<td class="nump">$ 6,559.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6793329760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Details Textual)<br> SFr in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2008 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Mar. 04, 2008 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2006 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemptions percentage of 2015 notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage', window );">Redemption percentage for change in control provision on the 2015 Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,559,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Senior unsecured revolving credit facility maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Amount outstanding under the credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.184%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRedemptionOfNotes', window );">Percentage of redemption of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncreasedCarryingAmountOfSeniorNotes', window );">Increased carrying amount of interest rate swap</a></td>
<td class="nump">$ 62,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DebtInstrumentUnamortizedInterestOnDebt', window );">Interest to be amortized on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Note payable to Fumedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 61.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ParValueOfNotesPayable', window );">Par value of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,700,000<span></span>
</td>
<td class="nump">SFr 11.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.792%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.792%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,485,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 992,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.764%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.764%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,733,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.294%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.294%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,721,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable and other financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 571,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | 2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value of the interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Capital lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Make Whole Provision Redemption Price, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentUnamortizedInterestOnDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument unamortized interest on debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentUnamortizedInterestOnDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncreasedCarryingAmountOfSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increased carrying amount of senior notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncreasedCarryingAmountOfSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ParValueOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Par value of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ParValueOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfRedemptionOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of redemption of notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfRedemptionOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageParValueOfSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Par Value Of Senior Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageParValueOfSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 16<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226000-175313<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51814546&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the amount outstanding under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13476-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6781765360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000.0<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">241.2<span></span>
</td>
<td class="nump">257.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">218.6<span></span>
</td>
<td class="nump">234.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6799183664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details Textual) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityTextualAbstract', window );"><strong>Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of share repurchases under the 2015 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, shares</a></td>
<td class="nump">16,800<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock, value</a></td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="nump">$ 886.8<span></span>
</td>
<td class="nump">$ 400.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Common stock shares authorized for repurchase</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=biib_SeriesXPreferredStockMember', window );">Series X junior participating</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=biib_UndesignatedPreferredStockMember', window );">Undesignated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=biib_SeriesXPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=biib_SeriesXPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=biib_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=biib_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6965960496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">$ (59.5)<span></span>
</td>
<td class="num">$ (27.7)<span></span>
</td>
<td class="num">$ (55.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="num">(19.1)<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="num">(171.0)<span></span>
</td>
<td class="num">(12.7)<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(164.5)<span></span>
</td>
<td class="nump">31.8<span></span>
</td>
<td class="nump">27.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(224.0)<span></span>
</td>
<td class="num">(59.5)<span></span>
</td>
<td class="num">(27.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Unrealized Investment Gain (Loss) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="num">(6.4)<span></span>
</td>
<td class="num">(10.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="nump">71.7<span></span>
</td>
<td class="num">(23.7)<span></span>
</td>
<td class="num">(10.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="nump">110.8<span></span>
</td>
<td class="nump">101.7<span></span>
</td>
<td class="num">(26.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="num">(172.3)<span></span>
</td>
<td class="num">(6.3)<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">61.5<span></span>
</td>
<td class="num">(95.4)<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">10.2<span></span>
</td>
<td class="nump">71.7<span></span>
</td>
<td class="num">(23.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Accumulated Defined Benefit Plans Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(31.6)<span></span>
</td>
<td class="num">(19.6)<span></span>
</td>
<td class="num">(21.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="num">(6.2)<span></span>
</td>
<td class="num">(12.0)<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="num">(2.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(37.8)<span></span>
</td>
<td class="num">(31.6)<span></span>
</td>
<td class="num">(19.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Accumulated Translation Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(99.2)<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="num">(27.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="num">(96.4)<span></span>
</td>
<td class="num">(109.2)<span></span>
</td>
<td class="nump">37.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">96.4<span></span>
</td>
<td class="nump">109.2<span></span>
</td>
<td class="num">(37.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">$ (195.6)<span></span>
</td>
<td class="num">$ (99.2)<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6783474688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (123.7)<span></span>
</td>
<td class="num">$ (25.8)<span></span>
</td>
<td class="num">$ (34.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,161.6<span></span>
</td>
<td class="nump">989.9<span></span>
</td>
<td class="nump">601.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="num">$ (2,425.9)<span></span>
</td>
<td class="num">$ (2,391.7)<span></span>
</td>
<td class="num">$ (2,198.6)<span></span>
</td>
<td class="num">$ (2,172.3)<span></span>
</td>
<td class="num">$ (2,287.0)<span></span>
</td>
<td class="num">$ (2,117.3)<span></span>
</td>
<td class="num">$ (2,056.3)<span></span>
</td>
<td class="num">$ (1,742.8)<span></span>
</td>
<td class="num">(9,188.5)<span></span>
</td>
<td class="num">(8,203.4)<span></span>
</td>
<td class="num">(5,542.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 831.6<span></span>
</td>
<td class="nump">$ 965.6<span></span>
</td>
<td class="nump">$ 927.3<span></span>
</td>
<td class="nump">$ 822.5<span></span>
</td>
<td class="nump">$ 883.5<span></span>
</td>
<td class="nump">$ 856.9<span></span>
</td>
<td class="nump">$ 714.5<span></span>
</td>
<td class="nump">$ 480.0<span></span>
</td>
<td class="nump">3,547.0<span></span>
</td>
<td class="nump">2,934.8<span></span>
</td>
<td class="nump">1,862.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171.0<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Unrealized Investment Gain (Loss) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(5.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (173.2)<span></span>
</td>
<td class="num">$ (6.8)<span></span>
</td>
<td class="num">$ (13.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6963655888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Idec Inc</a></td>
<td class="nump">$ 831.6<span></span>
</td>
<td class="nump">$ 965.6<span></span>
</td>
<td class="nump">$ 927.3<span></span>
</td>
<td class="nump">$ 822.5<span></span>
</td>
<td class="nump">$ 883.5<span></span>
</td>
<td class="nump">$ 856.9<span></span>
</td>
<td class="nump">$ 714.5<span></span>
</td>
<td class="nump">$ 480.0<span></span>
</td>
<td class="nump">$ 3,547.0<span></span>
</td>
<td class="nump">$ 2,934.8<span></span>
</td>
<td class="nump">$ 1,862.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">220.4<span></span>
</td>
<td class="nump">232.2<span></span>
</td>
<td class="nump">235.3<span></span>
</td>
<td class="nump">235.0<span></span>
</td>
<td class="nump">235.5<span></span>
</td>
<td class="nump">236.2<span></span>
</td>
<td class="nump">236.7<span></span>
</td>
<td class="nump">236.8<span></span>
</td>
<td class="nump">230.7<span></span>
</td>
<td class="nump">236.4<span></span>
</td>
<td class="nump">236.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">220.8<span></span>
</td>
<td class="nump">232.6<span></span>
</td>
<td class="nump">235.7<span></span>
</td>
<td class="nump">235.6<span></span>
</td>
<td class="nump">236.3<span></span>
</td>
<td class="nump">237.0<span></span>
</td>
<td class="nump">237.4<span></span>
</td>
<td class="nump">237.8<span></span>
</td>
<td class="nump">231.2<span></span>
</td>
<td class="nump">237.2<span></span>
</td>
<td class="nump">238.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EarningsPerShareTextualAbstract', window );"><strong>Earnings per share (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EarningsPerShareTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EarningsPerShareTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1500-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6783858144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (183.2)<span></span>
</td>
<td class="num">$ (165.0)<span></span>
</td>
<td class="num">$ (146.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">207.3<span></span>
</td>
<td class="nump">252.4<span></span>
</td>
<td class="nump">255.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(11.0)<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
<td class="num">(9.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">196.3<span></span>
</td>
<td class="nump">242.4<span></span>
</td>
<td class="nump">246.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(55.8)<span></span>
</td>
<td class="num">(72.2)<span></span>
</td>
<td class="num">(73.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(88.6)<span></span>
</td>
<td class="num">(102.1)<span></span>
</td>
<td class="num">(95.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(127.3)<span></span>
</td>
<td class="num">(150.3)<span></span>
</td>
<td class="num">(160.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(8.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (140.5)<span></span>
</td>
<td class="num">$ (170.2)<span></span>
</td>
<td class="num">$ (172.8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780863408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 183.2<span></span>
</td>
<td class="nump">$ 165.0<span></span>
</td>
<td class="nump">$ 146.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">207.3<span></span>
</td>
<td class="nump">252.4<span></span>
</td>
<td class="nump">255.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(11.0)<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
<td class="num">(9.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">196.3<span></span>
</td>
<td class="nump">242.4<span></span>
</td>
<td class="nump">246.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">38.1<span></span>
</td>
<td class="nump">37.4<span></span>
</td>
<td class="nump">32.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">119.0<span></span>
</td>
<td class="nump">115.4<span></span>
</td>
<td class="nump">103.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">22.4<span></span>
</td>
<td class="nump">65.5<span></span>
</td>
<td class="nump">109.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 13.9<span></span>
</td>
<td class="nump">$ 12.2<span></span>
</td>
<td class="nump">$ 9.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964648816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 2)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StockOptionActivityAbstract', window );"><strong>Stock Option Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance, Outstanding shares | shares</a></td>
<td class="nump">221,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 56.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised | shares</a></td>
<td class="num">(114,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">$ 59.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Cancelled | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance, Outstanding shares | shares</a></td>
<td class="nump">107,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 53.94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StockOptionActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock option activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StockOptionActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964346256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract', window );"><strong>Tax benefit and cash received from stock option</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions', window );">Tax benefit realized for stock options</a></td>
<td class="nump">$ 11.9<span></span>
</td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="nump">$ 29.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions', window );">Cash received from the exercise of stock options</a></td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="nump">$ 28.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax benefit and cash received from stock option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TaxBenefitAndCashReceivedFromStockOptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate proceeds received by the entity during the annual period from exercises of stock or unit options and conversion of similar instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the aggregate tax benefit realized from the exercise of stock options and the conversion of similar instruments during the annual period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6961908944">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 4) - Market stock units - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MarketStockUnitsActivityAbstract', window );"><strong>Market stock units activity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">403,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 219.29<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">185,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 493.43<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 395.22<span></span>
</td>
<td class="nump">$ 193.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(277,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 165.63<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(42,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 294.85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">269,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">403,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 339.89<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 219.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">MSUs granted in 2015 include approximately 8,000, 19,000, 24,000 and 34,000 MSUs issued in 2015 based upon the attainment of performance criteria set for 2014, 2013, 2012 and 2011, respectively, in relation to awards granted in those years. The remainder of MSUs granted during 2015 include awards granted in conjunction with our annual awards made in February 2015 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MarketStockUnitsActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Market stock units activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MarketStockUnitsActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6963649120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 5) - Market stock units - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ValuationOfGrantedStockUnitsAbstract', window );"><strong>Assumptions used in valuation of market based stock units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Minimum range of risk-free interest rates</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Maximum range of risk-free interest rates</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageStockPriceOnGrantDateInDollarsMinimum', window );">Average stock price on grant date minimum</a></td>
<td class="nump">$ 227.35<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 280.88<span></span>
</td>
<td class="nump">$ 150.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageStockPriceOnGrantDateInDollarsMaximum', window );">Average stock price on grant date maximum</a></td>
<td class="nump">$ 426.27<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 335.65<span></span>
</td>
<td class="nump">$ 240.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 493.43<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 395.22<span></span>
</td>
<td class="nump">$ 193.45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ValuationOfGrantedStockUnitsAbstract', window );"><strong>Assumptions used in valuation of market based stock units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Range of expected stock price volatility</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">31.70%<span></span>
</td>
<td class="nump">21.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ValuationOfGrantedStockUnitsAbstract', window );"><strong>Assumptions used in valuation of market based stock units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Range of expected stock price volatility</a></td>
<td class="nump">33.20%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">35.10%<span></span>
</td>
<td class="nump">25.70%<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">MSUs granted in 2015 include approximately 8,000, 19,000, 24,000 and 34,000 MSUs issued in 2015 based upon the attainment of performance criteria set for 2014, 2013, 2012 and 2011, respectively, in relation to awards granted in those years. The remainder of MSUs granted during 2015 include awards granted in conjunction with our annual awards made in February 2015 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageStockPriceOnGrantDateInDollarsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average stock price on grant date in dollars maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageStockPriceOnGrantDateInDollarsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageStockPriceOnGrantDateInDollarsMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average stock price on grant date in dollars minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageStockPriceOnGrantDateInDollarsMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ValuationOfGrantedStockUnitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation of granted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ValuationOfGrantedStockUnitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964154336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 6) - Cash settled performance units<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2015 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CashSettledPerformanceSharesAbstract', window );"><strong>Cash settled performance shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="nump">335,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="nump">115,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="num">(222,000,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="num">(36,000,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="nump">192,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">CSPUs granted in 2015 include approximately 48,000 CSPUs issued in 2015 based upon the attainment of performance criteria set for 2014 in relation to awards granted in 2014. The remainder of the CSPUs granted in 2015 include awards granted in conjunction with our annual awards made in February 2015 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CashSettledPerformanceSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash settled performance shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CashSettledPerformanceSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964332016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments Share-Based Payments (Details 7) - Performance units<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2015 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="nump">57,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="nump">89,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="num">(33,000,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="num">(10,000,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="nump">103,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">CSPUs granted in 2015 include approximately 48,000 CSPUs issued in 2015 based upon the attainment of performance criteria set for 2014 in relation to awards granted in 2014. The remainder of the CSPUs granted in 2015 include awards granted in conjunction with our annual awards made in February 2015 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6781064240">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 8) - Time-vested restricted stock units - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RestrictedStockUnitsActivityAbstract', window );"><strong>Time-vested restricted stock units</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,137,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 221.01<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">459,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 388.88<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 321.72<span></span>
</td>
<td class="nump">$ 176.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(626,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 190.65<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(160,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 302.35<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">810,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,137,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 323.87<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 221.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">RSUs granted in 2015 primarily represent RSUs granted in conjunction with our annual awards made in February 2015 and awards made in conjunction with the hiring of new employees. RSUs granted in 2015 also include approximately 7,000 RSUs granted to our Board of Directors.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RestrictedStockUnitsActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted stock units activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RestrictedStockUnitsActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6793632624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 9) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_A2015ESPPMember', window );">2015 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="nump">78,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Cash received under ESPP</a></td>
<td class="nump">$ 19.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_A1995ESPPMember', window );">1995 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="nump">98,000<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="nump">245,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Cash received under ESPP</a></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="nump">$ 46.4<span></span>
</td>
<td class="nump">$ 38.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_A2015ESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_A2015ESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_A1995ESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_A1995ESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6781720864">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details Textual)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>Plan </div>
<div>Increment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($) </div>
<div>Increment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,200,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedPaymentsTextualAbstract', window );"><strong>Share-Based Payments (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation', window );">Windfall tax benefits from vesting of stock awards, exercises of stock options and ESPP participation | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 78.2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 96.4<span></span>
</td>
<td class="nump">$ 73.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to unvested share-based compensation | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 184.3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards', window );">Weighted-average period to recognize the cost of unvested awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year 9 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade', window );">Number of share-based compensation plans pursuant to which awards are currently being made | Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares granted under stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 38.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 42.7<span></span>
</td>
<td class="nump">$ 86.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic values of options outstanding | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 27.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term for options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">3 years 2 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfEqualAnnualIncrements', window );">Number of equal annual increments | Increment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">185,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of vested awards | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 109.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 117.4<span></span>
</td>
<td class="nump">$ 50.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 493.43<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 395.22<span></span>
</td>
<td class="nump">$ 193.45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfEqualAnnualIncrements', window );">Number of equal annual increments | Increment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">115,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash in settlement of CSPS awards upon vesting | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 79.8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 92.8<span></span>
</td>
<td class="nump">$ 48.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfEqualAnnualIncrements', window );">Number of equal annual increments | Increment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">89,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards', window );">PUs converted to share settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash in settlement of CSPS awards upon vesting | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12.4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">459,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of vested awards | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 239.7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 281.1<span></span>
</td>
<td class="nump">$ 209.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 388.88<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 321.72<span></span>
</td>
<td class="nump">$ 176.53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationPlanAxis=biib_DirectorsPlanMember', window );">Directors Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSharesOfCommonStockForIssuance', window );">Total number of shares of common stock for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RatioOfNumberOfSharesReservedUnderPlan', window );">Ratio of total number of shares reserved under the plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1.5-to-1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationPlanAxis=biib_OmnibusPlansMember', window );">Omnibus Plans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSharesOfCommonStockForIssuance', window );">Total number of shares of common stock for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RatioOfNumberOfSharesReservedUnderPlan', window );">Ratio of total number of shares reserved under the plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1.5-to-1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2014Member', window );">Attainment Of Performance Criteria in 2014 | Market stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2014Member', window );">Attainment Of Performance Criteria in 2014 | Cash settled performance units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">48,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2014Member', window );">Attainment Of Performance Criteria in 2014 | Performance units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">42,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2013Member', window );">Attainment Of Performance Criteria in 2013 | Market stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">19,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2012Member', window );">Attainment Of Performance Criteria in 2012 | Market stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">24,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2011Member', window );">Attainment Of Performance Criteria in 2011 | Market stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">34,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Director [Member] | Time-vested restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">7,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Settlement of PUs | Performance units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards', window );">PUs converted to share settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">MSUs granted in 2015 include approximately 8,000, 19,000, 24,000 and 34,000 MSUs issued in 2015 based upon the attainment of performance criteria set for 2014, 2013, 2012 and 2011, respectively, in relation to awards granted in those years. The remainder of MSUs granted during 2015 include awards granted in conjunction with our annual awards made in February 2015 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">CSPUs granted in 2015 include approximately 48,000 CSPUs issued in 2015 based upon the attainment of performance criteria set for 2014 in relation to awards granted in 2014. The remainder of the CSPUs granted in 2015 include awards granted in conjunction with our annual awards made in February 2015 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">RSUs granted in 2015 primarily represent RSUs granted in conjunction with our annual awards made in February 2015 and awards made in conjunction with the hiring of new employees. RSUs granted in 2015 also include approximately 7,000 RSUs granted to our Board of Directors.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share-based Compensation, Shares Used to Settle Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EmployeeServiceSharebasedCompensationSharesUsedtoSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum target number of market stock units granted based on stock performance in percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum target number of market stock units granted based on stock performance in percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days for calculation of average closing stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfDaysForCalculationOfAverageClosingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfEqualAnnualIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equal annual increments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfEqualAnnualIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share-based compensation plans pursuant to which awards are currently being made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfSharesOfCommonStockForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of common stock for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfSharesOfCommonStockForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RatioOfNumberOfSharesReservedUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of total number of shares reserved under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RatioOfNumberOfSharesReservedUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedPaymentsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedPaymentsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period to recognize the cost of nonvested awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Windfall tax benefits from vesting of stock awards, exercises of stock options and ESPP participation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_WindfallTaxBenefitsFromVestingOfStockAwardsExercisesOfStockOptionsAndEsppParticipation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationPlanAxis=biib_DirectorsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationPlanAxis=biib_DirectorsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationPlanAxis=biib_OmnibusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationPlanAxis=biib_OmnibusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationPlanAxis=biib_AttainmentOfPerformanceCriteriain2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964403616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Income before income taxes (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 3,386.7<span></span>
</td>
<td class="nump">$ 2,557.4<span></span>
</td>
<td class="nump">$ 1,953.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">1,380.6<span></span>
</td>
<td class="nump">1,389.2<span></span>
</td>
<td class="nump">527.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">4,767.3<span></span>
</td>
<td class="nump">3,946.6<span></span>
</td>
<td class="nump">2,480.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">1,214.1<span></span>
</td>
<td class="nump">1,159.5<span></span>
</td>
<td class="nump">700.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">38.6<span></span>
</td>
<td class="nump">65.2<span></span>
</td>
<td class="nump">98.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">54.5<span></span>
</td>
<td class="nump">73.4<span></span>
</td>
<td class="nump">46.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">1,307.2<span></span>
</td>
<td class="nump">1,298.1<span></span>
</td>
<td class="nump">846.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(129.6)<span></span>
</td>
<td class="num">(280.9)<span></span>
</td>
<td class="num">(200.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">(21.0)<span></span>
</td>
<td class="num">(35.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(14.1)<span></span>
</td>
<td class="num">(6.3)<span></span>
</td>
<td class="num">(8.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="num">(145.6)<span></span>
</td>
<td class="num">(308.2)<span></span>
</td>
<td class="num">(245.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 1,161.6<span></span>
</td>
<td class="nump">$ 989.9<span></span>
</td>
<td class="nump">$ 601.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section I<br> -Paragraph Question 1-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section I<br> -Subsection 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section I<br> -Subsection 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section I<br> -Subsection 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section I<br> -Subsection 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section I<br> -Subsection 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section I<br> -Subsection 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964155440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Components of deferred tax assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">$ 189.3<span></span>
</td>
<td class="nump">$ 69.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory, other reserves, and accruals</a></td>
<td class="nump">243.9<span></span>
</td>
<td class="nump">217.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles, net</a></td>
<td class="nump">328.3<span></span>
</td>
<td class="nump">251.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">24.7<span></span>
</td>
<td class="nump">20.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">63.8<span></span>
</td>
<td class="nump">86.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">35.8<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(14.1)<span></span>
</td>
<td class="num">(11.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">871.7<span></span>
</td>
<td class="nump">693.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Purchased intangible assets</a></td>
<td class="num">(440.1)<span></span>
</td>
<td class="num">(432.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther', window );">Depreciation, amortization and other</a></td>
<td class="num">(102.7)<span></span>
</td>
<td class="num">(107.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">$ 542.8<span></span>
</td>
<td class="nump">$ 539.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation amortization other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilitiesDepreciationAmortizationOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Carryforwards<br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, before jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6687282080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="num">(9.50%)<span></span>
</td>
<td class="num">(6.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(2.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction', window );">Manufacturing deduction</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(6.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Permanent items</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration', window );">Contingent consideration</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">24.40%<span></span>
</td>
<td class="nump">25.10%<span></span>
</td>
<td class="nump">24.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation manufacturing deduction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964656752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract', window );"><strong>Reconciliation of the beginning and ending of unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at January 1</a></td>
<td class="nump">$ 131.5<span></span>
</td>
<td class="nump">$ 110.1<span></span>
</td>
<td class="nump">$ 125.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current period</a></td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">20.8<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior periods</a></td>
<td class="nump">19.5<span></span>
</td>
<td class="nump">86.1<span></span>
</td>
<td class="nump">71.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior periods</a></td>
<td class="num">(49.9)<span></span>
</td>
<td class="num">(23.4)<span></span>
</td>
<td class="num">(92.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Statute expirations</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(42.5)<span></span>
</td>
<td class="num">(60.5)<span></span>
</td>
<td class="num">(5.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at December 31</a></td>
<td class="nump">$ 67.9<span></span>
</td>
<td class="nump">$ 131.5<span></span>
</td>
<td class="nump">$ 110.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Unrecognized Tax Benefit<br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6782912704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2011</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Deferredtaxassetreclassification', window );">Deferred tax asset, reclassification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Deferredtaxliabilityreclassification', window );">Deferred tax liability, reclassification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Totaldeferredchargesandprepaidtaxes', window );">Total deferred charges and prepaid taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">697.9<span></span>
</td>
<td class="nump">$ 238.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net book value of deferred charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542.8<span></span>
</td>
<td class="nump">539.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetBenefitForPreviouslyUnrecognizedPosition', window );">Net benefit for a previously unrecognized position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseForNonIncomeBasedStateTaxes', window );">Expense for non-income based state taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices', window );">Proposed Disallowance By Tax Authorities For Payment For Services</a></td>
<td class="nump">$ 130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Net effect of adjustments to our uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries', window );">Undistributed Foreign Earnings Of Non Us Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
<td class="nump">53.6<span></span>
</td>
<td class="nump">32.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Net interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="nump">17.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Notice of assessment of corporate withholding tax including penalties and interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries', window );">Estimated Tax Liability On Undistributed Earnings Of Foreign Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries', window );">Estimated Tax Liability On Undistributed Earnings Of Foreign Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business | Domestic Country</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business | Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilityRecognized', window );">Deferred tax liability recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net book value of deferred charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166.3<span></span>
</td>
<td class="nump">$ 179.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilityRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liability recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilityRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Deferredtaxassetreclassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset, reclassification</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Deferredtaxassetreclassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Deferredtaxliabilityreclassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liability, reclassification</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Deferredtaxliabilityreclassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated tax liability on undistributed earnings of foreign subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedTaxLiabilityOnUndistributedEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseForNonIncomeBasedStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense for non-income based state taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseForNonIncomeBasedStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncomeTaxesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncomeTaxesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetBenefitForPreviouslyUnrecognizedPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net benefit for a previously unrecognized position</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetBenefitForPreviouslyUnrecognizedPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proposed disallowance by tax authorities for payment for services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Totaldeferredchargesandprepaidtaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total deferred charges and prepaid taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Totaldeferredchargesandprepaidtaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, before jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Carryforwards<br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6487024&amp;loc=d3e29054-158556<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6479915&amp;loc=d3e66715-112838<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 995<br> -SubTopic 740<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6503627&amp;loc=d3e59836-110443<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28200-109314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6966039968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related rebates</a></td>
<td class="nump">$ 662.7<span></span>
</td>
<td class="nump">$ 483.8<span></span>
</td>
<td class="nump">$ 426.2<span></span>
</td>
<td class="nump">$ 237.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash Paid During the Year</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">39.1<span></span>
</td>
<td class="nump">41.2<span></span>
</td>
<td class="nump">53.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">1,674.8<span></span>
</td>
<td class="nump">1,163.2<span></span>
</td>
<td class="nump">643.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">22.1<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">95.5<span></span>
</td>
<td class="nump">29.5<span></span>
</td>
<td class="nump">31.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Impairment on investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain (loss) on investments, net</a></td>
<td class="num">(3.8)<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="nump">21.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="num">(32.7)<span></span>
</td>
<td class="num">(11.6)<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherIncomeExpenseNet', window );">Other, net</a></td>
<td class="num">(13.8)<span></span>
</td>
<td class="num">(8.7)<span></span>
</td>
<td class="num">(14.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(123.7)<span></span>
</td>
<td class="num">(25.8)<span></span>
</td>
<td class="num">$ (34.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="nump">504.7<span></span>
</td>
<td class="nump">265.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">270.8<span></span>
</td>
<td class="nump">393.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">167.9<span></span>
</td>
<td class="nump">172.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">55.7<span></span>
</td>
<td class="nump">120.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">579.6<span></span>
</td>
<td class="nump">505.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">2,096.8<span></span>
</td>
<td class="nump">1,817.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract', window );"><strong>Other Long-Term Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">301.3<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Employeerelatedliabilitiesnoncurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">235.4<span></span>
</td>
<td class="nump">200.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">369.1<span></span>
</td>
<td class="nump">249.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other long-term liabilities</a></td>
<td class="nump">905.8<span></span>
</td>
<td class="nump">650.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related rebates</a></td>
<td class="nump">$ 518.1<span></span>
</td>
<td class="nump">$ 359.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Employeerelatedliabilitiesnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee related liabilities noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Employeerelatedliabilitiesnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other nonoperating income and expense, which does not qualify for separate disclosure on the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 35<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=27723805&amp;loc=d3e25351-111560<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period net of cash paid for interest that is capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion (due beyond one year or one operating cycle) of other accrued expenses (expenses incurred at the end of the reporting period but not yet paid) not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 09<br> -Article 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6782057360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details Textual)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2013 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2011 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 908.1<span></span>
</td>
<td class="nump">$ 527.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,096.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,817.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,096.8<span></span>
</td>
<td class="nump">1,817.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550.6<span></span>
</td>
<td class="nump">57.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,425.9<span></span>
</td>
<td class="nump">$ 2,391.7<span></span>
</td>
<td class="nump">$ 2,198.6<span></span>
</td>
<td class="nump">$ 2,172.3<span></span>
</td>
<td class="nump">2,287.0<span></span>
</td>
<td class="nump">$ 2,117.3<span></span>
</td>
<td class="nump">$ 2,056.3<span></span>
</td>
<td class="nump">$ 1,742.8<span></span>
</td>
<td class="nump">9,188.5<span></span>
</td>
<td class="nump">8,203.4<span></span>
</td>
<td class="nump">$ 5,542.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Accrued expenses and other long-term deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">905.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">905.8<span></span>
</td>
<td class="nump">650.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_CambridgeLeasesMember', window );">Cambridge Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerecognitionOfConstructionInProgressAssets', window );">Derecognition of construction in progress assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration obligation</a></td>
<td class="nump">$ 274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,638.4<span></span>
</td>
<td class="nump">2,909.2<span></span>
</td>
<td class="nump">$ 876.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900.0<span></span>
</td>
<td class="nump">$ 600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Seven billion | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_IT', window );">ITALY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Proposed settlement | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 35.6<span></span>
</td>
<td class="nump">&#8364; 33.3<span></span>
</td>
<td class="nump">&#8364; 30.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent', window );">Loss contingency, adjustment related to claim amount, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Accrued expenses and other long-term deferred revenue | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative sales level</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerecognitionOfConstructionInProgressAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derecognition of construction in progress assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerecognitionOfConstructionInProgressAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LossContingencyAdjustmentRelatedToClaimAmountPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Adjustment Related To Claim Amount, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LossContingencyAdjustmentRelatedToClaimAmountPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51662447&amp;loc=d3e5865-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51662447&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_CambridgeLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_CambridgeLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_SevenbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_SevenbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964699600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.2<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract', window );"><strong>Investment in Variable Interest Entities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Additional investments committed to if certain development milestones are achieved</a></td>
<td class="nump">$ 559.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="nump">29.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.2<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract', window );"><strong>Investment in Variable Interest Entities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement', window );">Remaining potential development milestone payments and royalties on commercial sales under the terms of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement', window );">Percentage of funding for R&amp;D cost required in support of the collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_RodinTherapeuticsMember', window );">Rodin Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract', window );"><strong>Investment in Variable Interest Entities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Payments to acquire interest in peferred stock of an affiliates</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Additional investments committed to if certain development milestones are achieved</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestInVariableInterestEntity', window );">Minority interest in our stockholder's equity</a></td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInVariableInterestEntitiesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected total payments including upfront and milestone payments as well as the greater of an annual maintenance fee or usage-based royalty payments under the terms of collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development cost in support of the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestInVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestInVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_RodinTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_RodinTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6799324960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract', window );"><strong>Revenues from unconsolidated joint business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="nump">$ 2,425.9<span></span>
</td>
<td class="nump">$ 2,391.7<span></span>
</td>
<td class="nump">$ 2,198.6<span></span>
</td>
<td class="nump">$ 2,172.3<span></span>
</td>
<td class="nump">$ 2,287.0<span></span>
</td>
<td class="nump">$ 2,117.3<span></span>
</td>
<td class="nump">$ 2,056.3<span></span>
</td>
<td class="nump">$ 1,742.8<span></span>
</td>
<td class="nump">$ 9,188.5<span></span>
</td>
<td class="nump">$ 8,203.4<span></span>
</td>
<td class="nump">$ 5,542.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnconsolidatedJointBusiness', window );">Total unconsolidated joint business revenues</a></td>
<td class="nump">$ 333.9<span></span>
</td>
<td class="nump">$ 337.2<span></span>
</td>
<td class="nump">$ 337.5<span></span>
</td>
<td class="nump">$ 330.6<span></span>
</td>
<td class="nump">$ 304.5<span></span>
</td>
<td class="nump">$ 290.7<span></span>
</td>
<td class="nump">$ 303.3<span></span>
</td>
<td class="nump">$ 296.9<span></span>
</td>
<td class="nump">1,339.2<span></span>
</td>
<td class="nump">1,195.4<span></span>
</td>
<td class="nump">1,126.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract', window );"><strong>Revenues from unconsolidated joint business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,545.8<span></span>
</td>
<td class="nump">5,566.7<span></span>
</td>
<td class="nump">3,581.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember', window );">Roche Group - Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract', window );"><strong>Revenues from unconsolidated joint business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnconsolidatedJointBusiness', window );">Total unconsolidated joint business revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,339.2<span></span>
</td>
<td class="nump">1,195.4<span></span>
</td>
<td class="nump">1,126.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember', window );">Roche Group - Genentech | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract', window );"><strong>Revenues from unconsolidated joint business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,269.8<span></span>
</td>
<td class="nump">1,117.1<span></span>
</td>
<td class="nump">1,087.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_GAZYVAMember', window );">GAZYVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract', window );"><strong>After First GA101 Threshold Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Until First GAZYVA Threshold Date</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First Threshold Date and until Second Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CoPromotionProfitSharingFormulaAbstract', window );"><strong>Co-promotion profit sharing formula</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne', window );">Until GAZYVA First Non-CLL FDA Approval</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract', window );"><strong>After First GA101 Threshold Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Until First GAZYVA Threshold Date</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First Threshold Date and until Second Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN | Roche Group - Genentech | Outside the U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract', window );"><strong>Revenues from unconsolidated joint business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69.4<span></span>
</td>
<td class="nump">$ 78.3<span></span>
</td>
<td class="nump">$ 38.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionProfitSharingFormulaAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profit sharing formula.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionProfitSharingFormulaAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from unconsolidated joint business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesFromUnconsolidatedJointBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnconsolidatedJointBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from unconsolidated joint business consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnconsolidatedJointBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_GAZYVAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_GAZYVAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_RituxanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_RituxanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6961890656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Details 1)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2"><div>Dec. 31, 2015</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember', window );">Sobi rate to Biogen on net sales in the Sobi Territory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementMethod', window );">Reimbursement, under the amended agreement, Method</a></td>
<td class="text">Royalty<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RateDuringReimbursementPeriod', window );">Rate during the reimbursement period</a></td>
<td class="text">Base&#160;Rate
plus 5%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember', window );">Sobi rate to Biogen on net sales in the Sobi Territory [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BaseRateAfterFirstCommercialSale', window );">Base rate following first commercial sale in the territory</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember', window );">Sobi rate to Biogen on net sales in the Sobi Territory [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BaseRateAfterFirstCommercialSale', window );">Base rate following first commercial sale in the territory</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember', window );">Biogen rate to sobi on net sales in the Biogen North America Territory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementMethod', window );">Reimbursement, under the amended agreement, Method</a></td>
<td class="text">Royalty<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RateDuringReimbursementPeriod', window );">Rate during the reimbursement period</a></td>
<td class="text">Base Rate
less 5%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember', window );">Biogen rate to sobi on net sales in the Biogen North America Territory [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BaseRateAfterFirstCommercialSale', window );">Base rate following first commercial sale in the territory</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember', window );">Biogen rate to sobi on net sales in the Biogen North America Territory [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BaseRateAfterFirstCommercialSale', window );">Base rate following first commercial sale in the territory</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember', window );">Biogen rate to sobi on net sales in the Biogen North America Territory [Member] | Sobi Territory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RatePriorToFirstCommercialSale', window );">Rate prior to first commercial sale in the territory</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember', window );">Biogen rate to sobi on net sales in the Biogen direct Territory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementMethod', window );">Reimbursement, under the amended agreement, Method</a></td>
<td class="text">Royalty<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RateDuringReimbursementPeriod', window );">Rate during the reimbursement period</a></td>
<td class="text">Base Rate
less 5%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember', window );">Biogen rate to sobi on net sales in the Biogen direct Territory [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BaseRateAfterFirstCommercialSale', window );">Base rate following first commercial sale in the territory</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember', window );">Biogen rate to sobi on net sales in the Biogen direct Territory [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BaseRateAfterFirstCommercialSale', window );">Base rate following first commercial sale in the territory</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember', window );">Biogen rate to sobi on net sales in the Biogen direct Territory [Member] | Sobi Territory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RatePriorToFirstCommercialSale', window );">Rate prior to first commercial sale in the territory</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember', window );">Biogen rate to Sobi on net revenue from the Biogen distributor Territory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementMethod', window );">Reimbursement, under the amended agreement, Method</a></td>
<td class="text">Net
Revenue
Share<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RateDuringReimbursementPeriod', window );">Rate during the reimbursement period</a></td>
<td class="text">Base Rate
less 15%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2],[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember', window );">Biogen rate to Sobi on net revenue from the Biogen distributor Territory [Member] | Sobi Territory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract', window );"><strong>Mechanism for reimbursement, under the amended agreement amounts payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RatePriorToFirstCommercialSale', window );">Rate prior to first commercial sale in the territory</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BaseRateAfterFirstCommercialSale', window );">Base rate following first commercial sale in the territory</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2],[3]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Net revenue represents Biogen&#8217;s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BaseRateAfterFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Base rate after first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BaseRateAfterFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RateDuringReimbursementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate during the reimbursement period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RateDuringReimbursementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RatePriorToFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate prior to first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RatePriorToFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mechanism for reimbursement, under the amended agreement amounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementUnderAmendedAgreementAmountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementUnderAmendedAgreementMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement, under the amended agreement, method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementUnderAmendedAgreementMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=biib_SobiTerritoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=biib_SobiTerritoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6965590576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Details 2) - AbbVie - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Total expense incurred by collaboration</a></td>
<td class="nump">$ 113.8<span></span>
</td>
<td class="nump">$ 117.8<span></span>
</td>
<td class="nump">$ 133.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="nump">$ 60.8<span></span>
</td>
<td class="nump">$ 67.4<span></span>
</td>
<td class="nump">$ 71.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseReflectedWithinStatementsOfIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen Idec's share of expense reflected within our consolidated statements of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseReflectedWithinStatementsOfIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AbbvieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AbbvieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6965202336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Collaborative and Other Relationships (Details 3) - Eisai - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Total expense incurred by collaboration</a></td>
<td class="nump">$ 84.1<span></span>
</td>
<td class="nump">$ 57.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="nump">$ 40.4<span></span>
</td>
<td class="nump">$ 29.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseReflectedWithinStatementsOfIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen Idec's share of expense reflected within our consolidated statements of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseReflectedWithinStatementsOfIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6888149104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Details Textual)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="13">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2010 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th"><div>Jan. 31, 2007</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,425.9<span></span>
</td>
<td class="nump">$ 2,391.7<span></span>
</td>
<td class="nump">$ 2,198.6<span></span>
</td>
<td class="nump">$ 2,172.3<span></span>
</td>
<td class="nump">$ 2,287.0<span></span>
</td>
<td class="nump">$ 2,117.3<span></span>
</td>
<td class="nump">$ 2,056.3<span></span>
</td>
<td class="nump">$ 1,742.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,188.5<span></span>
</td>
<td class="nump">$ 8,203.4<span></span>
</td>
<td class="nump">$ 5,542.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,012.8<span></span>
</td>
<td class="nump">1,893.4<span></span>
</td>
<td class="nump">1,444.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (Loss) from Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.5)<span></span>
</td>
<td class="num">(15.1)<span></span>
</td>
<td class="num">(17.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.5<span></span>
</td>
<td class="nump">49.0<span></span>
</td>
<td class="nump">$ 55.6<span></span>
</td>
<td class="nump">$ 52.0<span></span>
</td>
<td class="nump">$ 49.2<span></span>
</td>
<td class="nump">$ 103.4<span></span>
</td>
<td class="nump">61.9<span></span>
</td>
<td class="nump">90.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236.1<span></span>
</td>
<td class="nump">304.5<span></span>
</td>
<td class="nump">263.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecHemophiliaMember', window );">Biogen Hemophilia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Stock acquired in acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MilestonePaymentsMadeDuringPeriod', window );">Milestone Payments Made During Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_GenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_ElanMember', window );">Elan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner', window );">Reimbursements of research and developments expense from Elan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner', window );">Reimbursements of selling general and administrative expenses from Elan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration', window );">Amount reflected in collaboration profit sharing line for collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AcordaMember', window );">Acorda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones', window );">Expected additional milestone payments for successful achievement of regulatory and commercial sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold', window );">Expected additional milestone payments when certain sales threshold is met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ForeignSalesRequiredToTriggerMilestone', window );">Foreign sales required to trigger milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.6<span></span>
</td>
<td class="nump">29.2<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SwedishOrphanBiovitrumMember', window );">Swedish Orphan Biovitrum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ConsiderationPerProductDeveloped', window );">Consideration per product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfReimbursementExpenses', window );">Percentage of reimbursement expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfDevelopmentReimbursementExpenses', window );">Percentage of development reimbursement expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementCostAchievingPeriod', window );">Reimbursement cost achieving period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TimePeriodForPayingRemainingBalanceDue', window );">Time period for paying remaining balance due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PeriodForGrantingOfApprovalByApprovingAuthority', window );">Term for revocation option right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AbbvieMember', window );">AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.8<span></span>
</td>
<td class="nump">67.4<span></span>
</td>
<td class="nump">71.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IsisPharmaceuticalsMember', window );">Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Termofcollaborationagreement', window );">Term of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Total upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and discovery services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LicenseFee', window );">License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments', window );">Expected License Fee And Regulatory Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality', window );">Additional milestone payments for product candidate using a different modality</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">117.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.4<span></span>
</td>
<td class="nump">29.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Total upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MilestonePaymentsMadeDuringPeriod', window );">Milestone Payments Made During Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SangamoBioSciencesMember', window );">Sangamo BioSciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="nump">28.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Total upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AGTCMember', window );">AGTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Total upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and discovery services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Purchaseofcommonstock', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">Total licensing and other fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Researchanddevelopmentservices', window );">Research and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Premiumonequityinvestment', window );">Premium on equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 484.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember', window );">Other research and discovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Biosimilar Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentsExpectedProfitShare', window );">Equity Method Investments, Expected Profit Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltiesTermsOfCollaborationAgreement', window );">Royalties Terms Of Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10% and 12% on sales of RITUXAN outside the U.S. and Canada, with the royalty period lasting 11 years <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PeriodOfCollaborationAgreement', window );">Period of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion', window );">Percentage of Co promotion Operating Profits first fifty million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion', window );">Percentage of share of Co promotion profits exceeding $50 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld', window );">Royalty Period For Substantially All Remaining Royalty Bearing Sales Rest Of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">expire through 2012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne', window );">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage of royalties as per collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage of royalties as per collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_GAZYVAMember', window );">GAZYVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated', window );">Percentage of future development and commercialization expenses payable related to GAZYVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion', window );">Percentage of Co promotion Operating Profits first fifty million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment', window );">Co-promotion operating profit threshold for Rituxan in U S and Canada to determine share of co promotion operating profit prior to amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SalesTriggerGrossSalesThreshold', window );">Sales Trigger Gross Sales Threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingLosses', window );">Percentage Of Co Promotion Operating Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_NewAntiCd20Member', window );">New Anti-CD20 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Futurepercentageofcopromotionoperatingprofits', window );">Future percentage of co-promotion operating profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_NewAntiCd20Member', window );">New Anti-CD20 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Futurepercentageofcopromotionoperatingprofits', window );">Future percentage of co-promotion operating profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember', window );">ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 319.7<span></span>
</td>
<td class="nump">$ 58.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember', window );">ELOCTATE | Swedish Orphan Biovitrum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXMember', window );">ALPROLIX | Swedish Orphan Biovitrum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_OcrelizumabMember', window );">Ocrelizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyrate', window );">Reduction in royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_OcrelizumabMember', window );">Ocrelizumab | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Future royalties percentage to be received on sale of ocrelizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_OcrelizumabMember', window );">Ocrelizumab | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Future royalties percentage to be received on sale of ocrelizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SOD1Member', window );">SOD1 | Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_DMPKMember', window );">DMPK | Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LicenseFee', window );">License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments', window );">Expected License Fee And Regulatory Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SMNRxMember', window );">SMNRx | Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.0<span></span>
</td>
<td class="nump">42.8<span></span>
</td>
<td class="nump">57.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseReflectedWithinStatementsOfIncome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.9<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments', window );">Expected License Fee And Regulatory Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.0<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_LeadprogramsMember', window );">Lead programs | AGTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_DiscoveryprogramsMember', window );">Discovery programs | AGTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Biosimilar Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement', window );">Investments By Third Party In Joint Venture As Per Agreement.</a></td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 280.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_JointVentureOwnerShipPercentageByThirdParty', window );">Joint Venture Owner Ship Percentage By Third Party.</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 6.3<span></span>
</td>
<td class="nump">&#8361; 9.1<span></span>
</td>
<td class="nump">&#8361; 49.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of equity interest to the portion of total capital stock</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageMaximum', window );">Equity Method Investment Ownership Percentage Maximum</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.9<span></span>
</td>
<td class="nump">58.5<span></span>
</td>
<td class="nump">43.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Biosimilar Agreement | Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalProductsAxis=biib_NewAntiCd20Member', window );">New Anti-CD20 | Third Party Anti CD-20 | Roche Group - Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=biib_HoechstMember', window );">Hoechst</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages', window );">Decrease In Share Of Co Promotion Profits Due To Estimated Compensation Damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement', window );">Amount recorded to reflect fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_ForeignCountryMember', window );">Outside the U.S | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_ForeignCountryMember', window );">Outside the U.S | RITUXAN | Roche Group - Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69.4<span></span>
</td>
<td class="nump">78.3<span></span>
</td>
<td class="nump">38.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_ForeignCountryMember', window );">Outside the U.S | Ocrelizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Future royalties percentage to be received on sale of ocrelizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Revenue on sales in the rest of world for RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,545.8<span></span>
</td>
<td class="nump">5,566.7<span></span>
</td>
<td class="nump">3,581.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142.0<span></span>
</td>
<td class="nump">212.6<span></span>
</td>
<td class="nump">193.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S | Roche Group - Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,269.8<span></span>
</td>
<td class="nump">$ 1,117.1<span></span>
</td>
<td class="nump">$ 1,087.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payments for product candidate using a different modality</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount reflected in collaboration profit sharing line for collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ConsiderationPerProductDeveloped">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration per product developed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ConsiderationPerProductDeveloped</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in share of co-promotion profits due to estimated compensation damages.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment ownership percentage maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentsExpectedProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Expected Profit Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentsExpectedProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected additional milestone payments on successful achievement of regulatory and commercial sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected additional milestone payments when meeting certain sales threshold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected license fee and regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseReflectedWithinStatementsOfIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen Idec's share of expense reflected within our consolidated statements of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseReflectedWithinStatementsOfIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ForeignSalesRequiredToTriggerMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign sales required to trigger milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ForeignSalesRequiredToTriggerMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future royalties percentage to be received on sale of product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Futurepercentageofcopromotionoperatingprofits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future percentage of co-promotion operating profits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Futurepercentageofcopromotionoperatingprofits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments by third party in joint venture as per agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_JointVentureOwnerShipPercentageByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint venture owner ship percentage by third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_JointVentureOwnerShipPercentageByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability For Fair Value Of Options Granted Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LiabilityForFairValueOfOptionsGrantedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MilestonePaymentsMadeDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Made During Period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MilestonePaymentsMadeDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Co Promotion Operating Losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits first fifty million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development and commercialization expenses payable related.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfDevelopmentReimbursementExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development reimbursement expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfDevelopmentReimbursementExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfReimbursementExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of reimbursement expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfReimbursementExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfRoyaltiesAsPerCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties as per collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfRoyaltiesAsPerCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PeriodForGrantingOfApprovalByApprovingAuthority">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for granting of approval by approving authority.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PeriodForGrantingOfApprovalByApprovingAuthority</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PeriodOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PeriodOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Premiumonequityinvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium on equity investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Premiumonequityinvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Purchaseofcommonstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Purchaseofcommonstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyrate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyrate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementCostAchievingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement cost achieving period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementCostAchievingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursements of research and developments expense from collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursements of selling general and administrative expenses from collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Researchanddevelopmentservices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Researchanddevelopmentservices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltiesTermsOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties terms of collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltiesTermsOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty period for substantially all of the remaining royalty-bearing sales of RITUXAN in the rest of world.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SalesTriggerGrossSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales trigger gross sales threshold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SalesTriggerGrossSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Termofcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Termofcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales to be achieved in any twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TimePeriodForPayingRemainingBalanceDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Time period for paying remaining balance due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TimePeriodForPayingRemainingBalanceDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35755396&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35755396&amp;loc=d3e33749-111570<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 9<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 11<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecHemophiliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecHemophiliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_GenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_GenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_ElanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_ElanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AcordaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AcordaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SwedishOrphanBiovitrumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SwedishOrphanBiovitrumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AbbvieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AbbvieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IsisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IsisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SangamoBioSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SangamoBioSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AGTCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AGTCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_MitsubishiTanabePharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_MitsubishiTanabePharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_RituxanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_RituxanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_GAZYVAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_GAZYVAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_NewAntiCd20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_NewAntiCd20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ALPROLIXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_OcrelizumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_OcrelizumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_SOD1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_SOD1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_DMPKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_DMPKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_SMNRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_SMNRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_LeadprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_LeadprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_DiscoveryprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_DiscoveryprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalProductsAxis=biib_NewAntiCd20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalProductsAxis=biib_NewAntiCd20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ThirdPartyAntiCdTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ThirdPartyAntiCdTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=biib_HoechstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=biib_HoechstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6787980192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2011</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_IT', window );">ITALY</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementLimitStatedInResolution', window );">Reimbursement Limit Stated In Resolution</a></td>
<td class="text">24 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementLimitStatedInResolution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement limit stated in the resolution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementLimitStatedInResolution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6792443536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract', window );"><strong>Minimum rental commitments under non-cancelable leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Minimum lease payments, 2016</a></td>
<td class="nump">$ 75.9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Minimum lease payments, 2017</a></td>
<td class="nump">75.7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Minimum lease payments, 2018</a></td>
<td class="nump">67.9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">Minimum lease payments, 2019</a></td>
<td class="nump">66.7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">Minimum lease payments, 2020</a></td>
<td class="nump">63.2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Minimum lease payments, Thereafter</a></td>
<td class="nump">382.7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Minimum lease payments, Total</a></td>
<td class="nump">732.1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear', window );">Less: income from subleases, 2016</a></td>
<td class="num">(6.0)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears', window );">Less: income from subleases, 2017</a></td>
<td class="num">(6.0)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears', window );">Less: income from subleases, 2018</a></td>
<td class="num">(6.3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears', window );">Less: income from subleases, 2019</a></td>
<td class="num">(6.3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears', window );">Less: income from subleases, 2020</a></td>
<td class="num">(6.3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter', window );">Less: income from subleases, Thereafter</a></td>
<td class="num">(28.9)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions', window );">Less: income from subleases, Total</a></td>
<td class="num">(59.8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInOneYear', window );">Net minimum lease payments, 2016</a></td>
<td class="nump">69.9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInTwoYear', window );">Net minimum lease payments, 2017</a></td>
<td class="nump">69.7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInThreeYear', window );">Net minimum lease payments, 2018</a></td>
<td class="nump">61.6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInFourYear', window );">Net minimum lease payments, 2019</a></td>
<td class="nump">60.4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInFiveYear', window );">Net minimum lease payments, 2020</a></td>
<td class="nump">56.9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsThereafter', window );">Net minimum lease payments, Thereafter</a></td>
<td class="nump">353.8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePayments', window );">Net minimum lease payments, Total</a></td>
<td class="nump">$ 672.3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As a result of our decision to relocate our corporate headquarters to Cambridge, Massachusetts, we vacated part of our Weston, Massachusetts facility in the fourth quarter of 2013. We incurred a charge of $27.2 million in connection with this move. This charge represented our remaining lease obligation for the vacated portion of our Weston, Massachusetts facility, net of sublease income expected to be received. The term of our sublease to the vacated portion of our Weston, Massachusetts facility started in January 2014 and will continue through the remaining term of our lease agreement.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum rental commitments under noncancellable leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInFiveYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in five year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInFiveYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInFourYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in four year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInFourYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInThreeYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in three year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInThreeYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInTwoYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in two year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInTwoYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals to be received by the seller-lessee for sale-leaseback transactions accounted for using the deposit method or as a financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6456377&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6456377&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6456377&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6456377&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6456377&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6456377&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6456377&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6959716784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies Commitments and Contingencies (Details 1)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent', window );">Capital leases, future minimum payments due in 2016</a></td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">Capital leases, future minimum payments due in 2017</a></td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears', window );">Capital leases, future minimum payments due in 2018</a></td>
<td class="nump">16.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears', window );">Capital leases, future minimum payments due in 2019</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears', window );">Capital leases, future minimum payments due in 2020</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter', window );">Capital leases, future minimum payments due thereafter</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Capital leases, future minimum payments due total</a></td>
<td class="nump">20.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Less: interest on capital lease</a></td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Net present value of the future minimum lease payments</a></td>
<td class="nump">$ 19.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount necessary to reduce net minimum lease payments to present value for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6965507792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Dec. 31, 2006</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
<th class="th"><div>Apr. 02, 2013</div></th>
<th class="th"><div>Jan. 31, 2007</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Cancellable future commitments</a></td>
<td class="nump">$ 559.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 559.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908.1<span></span>
</td>
<td class="nump">$ 527.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments And Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Lease rent expense which terminates at various dates through 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.6<span></span>
</td>
<td class="nump">62.4<span></span>
</td>
<td class="nump">$ 56.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Liabilities associated with uncertain tax positions</a></td>
<td class="nump">45.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch', window );">Accrued expenses</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="nump">2,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember', window );">TYSABRI product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments And Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion', window );">Future contingent payment for annual worldwide net sales up to $2.0 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentThreshold', window );">Future contingent payment threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion', window );">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecHemophiliaMember', window );">Biogen Hemophilia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MilestonePaymentsMadeDuringPeriod', window );">Milestone payments made during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember', window );">Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Amount paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_CambridgeLeasesMember', window );">Cambridge Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Chargesrecognizedtovacatebuilding', window );">Charges recognized to vacate building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Cancellable future commitments</a></td>
<td class="nump">126.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900.0<span></span>
</td>
<td class="nump">$ 600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_SixbillionMember', window );">Six billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Amount paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">6,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_FourbillionMember', window );">Four billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">4,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_FivebillionMember', window );">Five billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_SevenbillionMember', window );">Seven billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">7,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_OneBillionMember', window );">One billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember', window );">Each additional one billion up to twenty billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_ThreeBillionMember', window );">Three billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses on funding commitment related to clinical research.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Chargesrecognizedtovacatebuilding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charges recognized to vacate building</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Chargesrecognizedtovacatebuilding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CommitmentsAndContingenciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CommitmentsAndContingenciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative sales level</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment for annual worldwide net sales that exceed $2.0 billion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment for annual worldwide net sales up to $2.0 billion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MilestonePaymentsMadeDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Made During Period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MilestonePaymentsMadeDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current portion of the amount recognized for uncertain tax positions as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecHemophiliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecHemophiliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_CambridgeLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_CambridgeLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_SixbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_SixbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_FourbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_FourbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_FivebillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_FivebillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_SevenbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_SevenbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_OneBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_OneBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_ThreeBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_ThreeBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964619776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis=biib_SavingsPlanMember', window );">Savings plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumQualifyingAgeForEmployeeBenefitPlan', window );">Minimum Qualifying Age For Employee Benefit Plan</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeBenefitPlansTextualAbstract', window );"><strong>Employee Benefit Plans (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expenses related to savings plan</a></td>
<td class="nump">$ 51.8<span></span>
</td>
<td class="nump">$ 49.3<span></span>
</td>
<td class="nump">$ 39.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis=biib_DeferredCompensationPlanMember', window );">Deferred compensation plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeBenefitPlansTextualAbstract', window );"><strong>Employee Benefit Plans (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred compensation related to Employee Benefit Plan</a></td>
<td class="nump">$ 126.9<span></span>
</td>
<td class="nump">$ 105.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis=biib_SwissplanMember', window );">Swiss plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeBenefitPlansTextualAbstract', window );"><strong>Employee Benefit Plans (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfMinimumInvestmentReturn', window );">Percentage of minimum investment return</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Unfunded net pension</a></td>
<td class="nump">$ 42.4<span></span>
</td>
<td class="nump">$ 31.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Employee Benefit Plan obligations</a></td>
<td class="nump">63.9<span></span>
</td>
<td class="nump">43.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionExpense', window );">Pension Expense</a></td>
<td class="nump">12.9<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis=biib_GermanPlanMember', window );">German plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeBenefitPlansTextualAbstract', window );"><strong>Employee Benefit Plans (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Employee Benefit Plan obligations</a></td>
<td class="nump">27.6<span></span>
</td>
<td class="nump">24.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Periodic pension cost</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EmployeeBenefitPlansTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EmployeeBenefitPlansTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MinimumQualifyingAgeForEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum qualifying age for employee benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MinimumQualifyingAgeForEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfMinimumInvestmentReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of minimum investment return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfMinimumInvestmentReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>1) For defined benefit pension plans, the benefit obligation is the projected benefit obligation, which is the actuarial present value as of a date of all benefits attributed by the pension benefit formula to employee service rendered prior to that date.  2) For other postretirement defined benefit plans, the benefit obligation is the accumulated postretirement benefit obligation, which is the actuarial present value of benefits attributed to employee service rendered to a particular date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Projected Benefit Obligation<br> -URI http://asc.fasb.org/extlink&amp;oid=6522206<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Accumulated Postretirement Benefit Obligation<br> -URI http://asc.fasb.org/extlink&amp;oid=6503904<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The funded status is measured as the difference between the fair value of plan assets and the benefit obligation. Will normally be the same as the net Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21915240&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of net periodic benefit cost for defined benefit plans for the period. Periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the cost recognized during the period for defined contribution plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of pension benefit costs recognized during the period for (1) defined benefit plans and (2) defined contribution plans. For defined benefit plans, pension expense includes the following components: service cost, interest cost, expected return on plan assets, gain (loss) on plan assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments. For defined contribution plans, the pension expense generally equals the firm's contribution to employees' accounts (if the firm contributes) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis=biib_SavingsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis=biib_SavingsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis=biib_DeferredCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis=biib_DeferredCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis=biib_SwissplanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis=biib_SwissplanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis=biib_GermanPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansDisclosuresDefinedBenefitPlansAxis=biib_GermanPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6782230336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 2,425.9<span></span>
</td>
<td class="nump">$ 2,391.7<span></span>
</td>
<td class="nump">$ 2,198.6<span></span>
</td>
<td class="nump">$ 2,172.3<span></span>
</td>
<td class="nump">$ 2,287.0<span></span>
</td>
<td class="nump">$ 2,117.3<span></span>
</td>
<td class="nump">$ 2,056.3<span></span>
</td>
<td class="nump">$ 1,742.8<span></span>
</td>
<td class="nump">$ 9,188.5<span></span>
</td>
<td class="nump">$ 8,203.4<span></span>
</td>
<td class="nump">$ 5,542.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=country_US', window );">U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,545.8<span></span>
</td>
<td class="nump">5,566.7<span></span>
</td>
<td class="nump">3,581.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=biib_RestOfWorldMember', window );">Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,642.7<span></span>
</td>
<td class="nump">2,636.7<span></span>
</td>
<td class="nump">1,961.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,638.4<span></span>
</td>
<td class="nump">2,909.2<span></span>
</td>
<td class="nump">876.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,908.2<span></span>
</td>
<td class="nump">2,426.6<span></span>
</td>
<td class="nump">864.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">730.2<span></span>
</td>
<td class="nump">482.6<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,630.2<span></span>
</td>
<td class="nump">3,013.1<span></span>
</td>
<td class="nump">3,005.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,790.2<span></span>
</td>
<td class="nump">1,956.7<span></span>
</td>
<td class="nump">1,902.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">840.0<span></span>
</td>
<td class="nump">1,056.4<span></span>
</td>
<td class="nump">1,103.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338.5<span></span>
</td>
<td class="nump">44.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227.1<span></span>
</td>
<td class="nump">27.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111.4<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TysabriMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,886.1<span></span>
</td>
<td class="nump">1,959.5<span></span>
</td>
<td class="nump">1,526.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TysabriMember', window );">TYSABRI | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,103.1<span></span>
</td>
<td class="nump">1,025.1<span></span>
</td>
<td class="nump">814.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TysabriMember', window );">TYSABRI | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">783.0<span></span>
</td>
<td class="nump">934.4<span></span>
</td>
<td class="nump">712.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.7<span></span>
</td>
<td class="nump">80.2<span></span>
</td>
<td class="nump">74.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.7<span></span>
</td>
<td class="nump">80.2<span></span>
</td>
<td class="nump">74.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember', window );">ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319.7<span></span>
</td>
<td class="nump">58.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember', window );">ELOCTATE | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308.3<span></span>
</td>
<td class="nump">58.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember', window );">ELOCTATE | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXProductMember', window );">ALPROLIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234.5<span></span>
</td>
<td class="nump">76.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXProductMember', window );">ALPROLIX | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208.9<span></span>
</td>
<td class="nump">72.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXProductMember', window );">ALPROLIX | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.4<span></span>
</td>
<td class="nump">62.5<span></span>
</td>
<td class="nump">60.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNetAbstract', window );"><strong>Revenue by product</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.4<span></span>
</td>
<td class="nump">$ 62.5<span></span>
</td>
<td class="nump">$ 60.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=biib_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=biib_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_PLEGRIDYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_PLEGRIDYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TysabriMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TysabriMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ALPROLIXProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_FUMADERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_FUMADERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6784156976">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,425.9<span></span>
</td>
<td class="nump">$ 2,391.7<span></span>
</td>
<td class="nump">$ 2,198.6<span></span>
</td>
<td class="nump">$ 2,172.3<span></span>
</td>
<td class="nump">$ 2,287.0<span></span>
</td>
<td class="nump">$ 2,117.3<span></span>
</td>
<td class="nump">$ 2,056.3<span></span>
</td>
<td class="nump">$ 1,742.8<span></span>
</td>
<td class="nump">$ 9,188.5<span></span>
</td>
<td class="nump">$ 8,203.4<span></span>
</td>
<td class="nump">$ 5,542.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusiness', window );">Revenues from unconsolidated joint business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,339.2<span></span>
</td>
<td class="nump">1,195.4<span></span>
</td>
<td class="nump">1,126.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">79.5<span></span>
</td>
<td class="nump">$ 49.0<span></span>
</td>
<td class="nump">$ 55.6<span></span>
</td>
<td class="nump">$ 52.0<span></span>
</td>
<td class="nump">49.2<span></span>
</td>
<td class="nump">$ 103.4<span></span>
</td>
<td class="nump">$ 61.9<span></span>
</td>
<td class="nump">$ 90.1<span></span>
</td>
<td class="nump">236.1<span></span>
</td>
<td class="nump">304.5<span></span>
</td>
<td class="nump">263.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,187.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,765.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,187.6<span></span>
</td>
<td class="nump">1,765.7<span></span>
</td>
<td class="nump">1,750.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,545.8<span></span>
</td>
<td class="nump">5,566.7<span></span>
</td>
<td class="nump">3,581.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusiness', window );">Revenues from unconsolidated joint business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,269.8<span></span>
</td>
<td class="nump">1,117.1<span></span>
</td>
<td class="nump">1,087.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142.0<span></span>
</td>
<td class="nump">212.6<span></span>
</td>
<td class="nump">193.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,296.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,055.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,296.5<span></span>
</td>
<td class="nump">1,055.5<span></span>
</td>
<td class="nump">984.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember', window );">Europe</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,497.6<span></span>
</td>
<td class="nump">1,383.9<span></span>
</td>
<td class="nump">1,170.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusiness', window );">Revenues from unconsolidated joint business</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.6<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
<td class="nump">26.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">879.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">701.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">879.4<span></span>
</td>
<td class="nump">701.9<span></span>
</td>
<td class="nump">758.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">668.1<span></span>
</td>
<td class="nump">811.8<span></span>
</td>
<td class="nump">417.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusiness', window );">Revenues from unconsolidated joint business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_AsiaMember', window );">Asia</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143.7<span></span>
</td>
<td class="nump">112.8<span></span>
</td>
<td class="nump">93.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusiness', window );">Revenues from unconsolidated joint business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.9<span></span>
</td>
<td class="nump">58.5<span></span>
</td>
<td class="nump">43.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333.3<span></span>
</td>
<td class="nump">328.2<span></span>
</td>
<td class="nump">280.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusiness', window );">Revenues from unconsolidated joint business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.9<span></span>
</td>
<td class="nump">70.6<span></span>
</td>
<td class="nump">33.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other revenues from external customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
</tr>
<tr><td colspan="13"></td></tr>
<tr><td colspan="13"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents amounts related to Europe less those attributable to Germany.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesFromUnconsolidatedJointBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from unconsolidated joint business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesFromUnconsolidatedJointBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentsGeographicalAreasAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentsGeographicalAreasAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_AsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_AsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6965142304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesInPercentageFromUnconsolidatedJointBusiness', window );">Revenues from unconsolidated joint business in percentage</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets related to operations in Denmark</a></td>
<td class="nump">$ 2,187.6<span></span>
</td>
<td class="nump">$ 1,765.7<span></span>
</td>
<td class="nump">$ 1,750.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SegmentInformationTextualAbstract', window );"><strong>Segment Information (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MajorDistributorAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Entity wide percentage of revenue from major distributors</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MajorDistributorAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Entity wide percentage of revenue from major distributors</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_DK', window );">DENMARK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets related to operations in Denmark</a></td>
<td class="nump">$ 684.9<span></span>
</td>
<td class="nump">$ 676.0<span></span>
</td>
<td class="nump">$ 731.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesInPercentageFromUnconsolidatedJointBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues in percentage from unconsolidated joint business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesInPercentageFromUnconsolidatedJointBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SegmentInformationTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Segment Information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SegmentInformationTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MajorDistributorAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MajorDistributorAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MajorDistributorAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MajorDistributorAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_DK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_DK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6965538320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 2,425.9<span></span>
</td>
<td class="nump">$ 2,391.7<span></span>
</td>
<td class="nump">$ 2,198.6<span></span>
</td>
<td class="nump">$ 2,172.3<span></span>
</td>
<td class="nump">$ 2,287.0<span></span>
</td>
<td class="nump">$ 2,117.3<span></span>
</td>
<td class="nump">$ 2,056.3<span></span>
</td>
<td class="nump">$ 1,742.8<span></span>
</td>
<td class="nump">$ 9,188.5<span></span>
</td>
<td class="nump">$ 8,203.4<span></span>
</td>
<td class="nump">$ 5,542.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnconsolidatedJointBusiness', window );">Unconsolidated joint business revenues</a></td>
<td class="nump">333.9<span></span>
</td>
<td class="nump">337.2<span></span>
</td>
<td class="nump">337.5<span></span>
</td>
<td class="nump">330.6<span></span>
</td>
<td class="nump">304.5<span></span>
</td>
<td class="nump">290.7<span></span>
</td>
<td class="nump">303.3<span></span>
</td>
<td class="nump">296.9<span></span>
</td>
<td class="nump">1,339.2<span></span>
</td>
<td class="nump">1,195.4<span></span>
</td>
<td class="nump">1,126.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">79.5<span></span>
</td>
<td class="nump">49.0<span></span>
</td>
<td class="nump">55.6<span></span>
</td>
<td class="nump">52.0<span></span>
</td>
<td class="nump">49.2<span></span>
</td>
<td class="nump">103.4<span></span>
</td>
<td class="nump">61.9<span></span>
</td>
<td class="nump">90.1<span></span>
</td>
<td class="nump">236.1<span></span>
</td>
<td class="nump">304.5<span></span>
</td>
<td class="nump">263.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">2,839.3<span></span>
</td>
<td class="nump">2,777.9<span></span>
</td>
<td class="nump">2,591.6<span></span>
</td>
<td class="nump">2,555.0<span></span>
</td>
<td class="nump">2,640.7<span></span>
</td>
<td class="nump">2,511.4<span></span>
</td>
<td class="nump">2,421.5<span></span>
</td>
<td class="nump">2,129.8<span></span>
</td>
<td class="nump">10,763.8<span></span>
</td>
<td class="nump">9,703.3<span></span>
</td>
<td class="nump">6,932.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">2,507.5<span></span>
</td>
<td class="nump">2,467.9<span></span>
</td>
<td class="nump">2,305.5<span></span>
</td>
<td class="nump">2,242.6<span></span>
</td>
<td class="nump">2,343.4<span></span>
</td>
<td class="nump">2,208.8<span></span>
</td>
<td class="nump">2,129.6<span></span>
</td>
<td class="nump">1,850.5<span></span>
</td>
<td class="nump">9,523.4<span></span>
</td>
<td class="nump">8,532.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">828.7<span></span>
</td>
<td class="nump">1,019.5<span></span>
</td>
<td class="nump">924.8<span></span>
</td>
<td class="nump">820.2<span></span>
</td>
<td class="nump">882.6<span></span>
</td>
<td class="nump">856.1<span></span>
</td>
<td class="nump">723.1<span></span>
</td>
<td class="nump">479.7<span></span>
</td>
<td class="nump">3,593.2<span></span>
</td>
<td class="nump">2,941.6<span></span>
</td>
<td class="nump">1,862.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Idec Inc</a></td>
<td class="nump">$ 831.6<span></span>
</td>
<td class="nump">$ 965.6<span></span>
</td>
<td class="nump">$ 927.3<span></span>
</td>
<td class="nump">$ 822.5<span></span>
</td>
<td class="nump">$ 883.5<span></span>
</td>
<td class="nump">$ 856.9<span></span>
</td>
<td class="nump">$ 714.5<span></span>
</td>
<td class="nump">$ 480.0<span></span>
</td>
<td class="nump">$ 3,547.0<span></span>
</td>
<td class="nump">$ 2,934.8<span></span>
</td>
<td class="nump">$ 1,862.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 3.77<span></span>
</td>
<td class="nump">$ 4.16<span></span>
</td>
<td class="nump">$ 3.94<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="nump">$ 3.63<span></span>
</td>
<td class="nump">$ 3.02<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="nump">$ 15.38<span></span>
</td>
<td class="nump">$ 12.42<span></span>
</td>
<td class="nump">$ 7.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 3.77<span></span>
</td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="nump">$ 3.93<span></span>
</td>
<td class="nump">$ 3.49<span></span>
</td>
<td class="nump">$ 3.74<span></span>
</td>
<td class="nump">$ 3.62<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="nump">$ 15.34<span></span>
</td>
<td class="nump">$ 12.37<span></span>
</td>
<td class="nump">$ 7.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">220.4<span></span>
</td>
<td class="nump">232.2<span></span>
</td>
<td class="nump">235.3<span></span>
</td>
<td class="nump">235.0<span></span>
</td>
<td class="nump">235.5<span></span>
</td>
<td class="nump">236.2<span></span>
</td>
<td class="nump">236.7<span></span>
</td>
<td class="nump">236.8<span></span>
</td>
<td class="nump">230.7<span></span>
</td>
<td class="nump">236.4<span></span>
</td>
<td class="nump">236.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">220.8<span></span>
</td>
<td class="nump">232.6<span></span>
</td>
<td class="nump">235.7<span></span>
</td>
<td class="nump">235.6<span></span>
</td>
<td class="nump">236.3<span></span>
</td>
<td class="nump">237.0<span></span>
</td>
<td class="nump">237.4<span></span>
</td>
<td class="nump">237.8<span></span>
</td>
<td class="nump">231.2<span></span>
</td>
<td class="nump">237.2<span></span>
</td>
<td class="nump">238.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnconsolidatedJointBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from unconsolidated joint business consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnconsolidatedJointBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelectedQuarterlyFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6964898672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,012.8<span></span>
</td>
<td class="nump">$ 1,893.4<span></span>
</td>
<td class="nump">$ 1,444.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.2<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 93.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">2,425.9<span></span>
</td>
<td class="nump">$ 2,391.7<span></span>
</td>
<td class="nump">$ 2,198.6<span></span>
</td>
<td class="nump">$ 2,172.3<span></span>
</td>
<td class="nump">$ 2,287.0<span></span>
</td>
<td class="nump">$ 2,117.3<span></span>
</td>
<td class="nump">$ 2,056.3<span></span>
</td>
<td class="nump">$ 1,742.8<span></span>
</td>
<td class="nump">9,188.5<span></span>
</td>
<td class="nump">$ 8,203.4<span></span>
</td>
<td class="nump">$ 5,542.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AGTCMember', window );">AGTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">$ 117.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_IT', window );">ITALY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Development Milestone And Collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 3, 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AGTCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AGTCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_MitsubishiTanabePharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_MitsubishiTanabePharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>183
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M;W!S+V%P<"YX;6R]65%SVC@0_BL:GG(SUX)I2'*9E)F$Y'J=::=<H;EGQ5Y
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M,<I*,XG18!B&XX APF$<\8K-F"I!*BJNIG 0;FS  :Y%AJ?P_N3UETJHJU?
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M9\+VJEMZWKP#4 *@Y$6@=]UZ Z 40.EW0&]UH]NY4=L)[@&2 21[$40=G&L
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M]/7@;\CRZ]5+73U>OQSKIWZ\3(?K=CJNFK[TS>MR^G8] MS]#U!+ P04
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M)>APLJM0BP&4TWV "A6.U0H"Q0(MIX3/X%\N]HL3?V)0":S"CO"JRDH!B5*
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M'YMTI5+B]'!](,LKK3X 4$L#!!0    ( '"#0TCG-.7(HP$  +$#   9
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MG;3S)QN/H=':@3>1W>PPZOS[F1,!C0OAG8]-NE(I<;J_/)#YE99?4$L#!!0
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M2&A=V'[Q>Y-&*@4.A^L#65YI]0]02P,$%     @ <(-#2*3$B3:C 0  L0,
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M][,D EH7PCL?FW2E4N+T<'T@RRNM/@%02P,$%     @ <(-#2 AIR8JD 0
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MXWIO-L.H@9:-PKWJZ2?,(^R#8*V%C5]4C]9I>:-@)-E[6KF*ZY3^' XS;9M
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M%SPSG'/FC"_EA.;%]@".O"FI[2GKG1N.E-JZ!\7M'0Z@_9\6C>+.IZ:C=C#
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M@LZ?;#R&%M&!-Y'?'3+2^_>S)!):%\(''YMTI5+B<+@]D.655G\!4$L#!!0
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M0NM"^-G')EVIE#@<;@]D>:75/U!+ P04    " !P@T-(L5-TK@T#   Q#@
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M+8%=$MC=E?CMOL2$.=]A\NR_)&1UIQ),%T?'HEJ/*@[J*KI,YR.-/?F$5^7
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M*F6FJ9X+UX%NH7A_>4_F1RW_ E!+ P04    " !P@T-(?D$TCK\!  ![!
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M29<%A];ZZ:V;Z_ANX\*JX=*%RZ^@^@102P,$%     @ <(-#2)GMCX&T 0
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MJ*V?'MU<QW<;%Q;[>Q?.OX+B+U!+ P04    " !P@T-(*&Z+<J8!  "Q P
M&0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6QU4]MNG# 0_17+'Q"#ETW;
M%8N4354E#Y6B/+3/7AC BB_4-DOR]_&%)22B+]@>SCESQC,N)VU>; _@T*L4
MRAYQ[]QP(,36/4AF;_0 RO]IM9',^:/IB!T,L":2I" TRVZ)9%SAJHRQ)U.5
M>G2"*W@RR(Y2,O-V J&G(\[Q-?#,N]Z% *E*LO :+D%9KA4RT![Q77XX%0$1
M 7\X3':U1\'[6>N7<'ALCC@+%D! [8("\\L%[D&((.03_YLU/U(&XGI_5?\5
MJ_7NS\S"O19_>>-Z;S;#J(&6C<(]Z^D!YA+V0;#6PL8OJD?KM+Q2,)+L-:U<
MQ75*?V@QT[8)=";0A? ]B\93HFCS)W.L*HV>D$E7.[#0P?Q _474R,:@2=5[
MH]9'+]5N_Z,DER T8VC$G-:8?$$0K[ZDH%LI9CI=T>DV?;=%WR6'NS4]_T_^
M8DN@2 +%NL3;['.)"7/ZC/F:A*SN5(+IXNA85.M1Q4%=19?IO*.Q)Q_PJAQ8
M![^9Z;BRZ*R=[VQL0ZNU V\BN]ECU/OWLQP$M"YLO_F]22.5#DX/UP>RO-+J
M'5!+ P04    " !P@T-(!SR)F[(!   6!   &0   'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q]5-MNFS 8?A6+!ZC!)-D4$:2FT[1>5*IZL5T[\ -6?6"V
M"=W;SP="H:*]P?;/=_JQ33$J_6HZ (O>!)?FE'36]D>,3=6!H.9.]2#=FT9I
M0:U;ZA:;7@.M TEP3-+T@ 5E,BF+4'O69:$&RYF$9XW,( 35_\[ U7A*LN16
M>&%M9WT!EP6>>343( U3$FEH3LE]=CSO/2( ?C,8S6*.?/:+4J]^\5B?DM1'
M  Z5]0K4#5=X ,Z]D#/^.VF^6WKB<GY3_QFZ=>DOU,"#XG]8;3L7-DU0#0T=
MN'U1XR^86@@)*\5->*)J,%:)&R5!@K[%D<DPCO'-(9]HVP0R$<A,^)Z&X-$H
MQ/Q!+2T+K4:DXZ?MJ=_![$C<AZB0"44=NW=!C:M>R_Q "GSU0A.&!,QYB<EF
M!';JLP79LICH9$$GV_1\BY['A/F2GGWBO]L2V$6!W:K%?-UBQ)S7F-VVR?X+
MD_U*8+]ILL8</IC@Q<8)T&TXGP95:I#A-BRJ\Q6X)V'CW^%ET=,6GJANF33H
MHJP[/F&O&Z4LN!#IG4O1N4LZ+S@TUD^_N;F.YS8NK.IOMW#^%93_ 5!+ P04
M    " !P@T-(MAM2QJ<!  "Q P  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6QM4]MNG# 0_17+'Q"#V633%8N4316U#Y6B/+3/7AC BB_$-DOZ]_6%
M)6S%"[:'<\Z<\8S+29MWVP,X]"F%LD?<.S<<"+%U#Y+9.SV \G]:;21S_F@Z
M8@<#K(DD*0C-L@<B&5>X*F/LU52E'IW@"EX-LJ.4S/P]@=#3$>?X&GCC7>]"
M@%0E67@-EZ LUPH9:(_X*3^<=@$1 ;\Y3':U1\'[6>OW</C9''$6+(" V@4%
MYI<+/(,00<@G_I@UOU(&XGI_57^)U7KW9V;A68L_O'&]-YMAU$#+1N'>]/0#
MYA+N@V"MA8U?5(_6:7FE8"399UJYBNN4_A3[F;9-H#.!+H3'+!I/B:+-[\RQ
MJC1Z0B9=[<!"!_,#]1=1(QN#)E7OC5H?O53%P[XDER T8VC$G-:8?$$0K[ZD
MH%LI9CI=T>DVO=BB%\EAL:;G^VV!W9; +@GL;DI\O"TQ84ZWF&__)2&K.Y5@
MNC@Z%M5Z5'%05]%E.I]H[,D7O"H'UL$O9CJN+#IKYSL;V]!J[<";R.[N,>K]
M^UD. EH7MGN_-VFDTL'IX?I EE=:_0-02P,$%     @ <(-#2&.LP<(D @
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MFIJY]!WH%UKTU_=D?M3R_U!+ P04    " !P@T-((/+_QM !  #=!   &0
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M>S[AKAM$"\Y$>N=<=*Y)EX6 QOKIO9OK^&[CPN)P[<+E5U#^ U!+ P04
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M &GJ$#?)BD/%:.H#1Q4S=@FG5EUBFCXXL^D2"$KQ+@&@6%,!N''/!V05:RH
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MJ42V[XV*W*=!$/E%=BXGBWD_]KU:S.6UR<^E^%YY];4HLNK?4N3R]C(AD_O
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M2AU$J8=&7N[G:H_#O<5_4$L#!!0    ( '"#0TC<F(]!^@(  "L,   9
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M&CYLXBR^3[S5ETJ9"5 68-*=ZI9ULN9=)-AY$W_)GO>Y(2SPLV:#]/J1J?W
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MR]P++HQ)JGSB2%UUH[K^NNCH1>IIKN;<-$*SD&Q\M/7UOZ7Z!U!+ P04
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MBKB428D;"B;C;,B ,AIDBF VSI>6Y:2KH!)-.#!%<+U/8AE7PHC_?>+8J2Y
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M+1C.\".E@DBB))(_N+.\KCTF+3D*-2SDF.D+C)X(>AGO8X]+X>8_4$L#!!0
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M6Q)CU  P<>::(T$:@^"4326&L;UC$;%"]>L$03:D>PCA85,"[GP<12O(38T
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MY3)HR%6H;B[[3+\=>B!H/S^%RWM<_@-02P,$%     @ <(-#2'LZNZ<? @
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M[>&<,V=\F6QB_%VT !)]4-*+D]=*.1Q]7Y0M4"R>V "]^E,S3K%42][X8N"
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M@CWC<X[/S.!J5/K-]  6?0@NS0'WU@Y[0DS3@Z!FHP:0[J136E#K0GTF9M!
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M(-(6""6EU I8+3=R()1J(97XSZCY2*F)[OZN_LU4J]R?L" '1G\WE:R5V2@
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M9OOO:X-A[<BVR"& >3-^;^P9/*L[[=[["R',^VSJME_[%\:N3V'8'RZD*?N
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M,%:0*2C9HJ"XTACEKN]((8.2*WKSP$;5E<E(3V5+P0%C<DFU$"U1"\;DDBP
M+=@"$C1G1F29R)6"H*4@SBPN7"<$6'1$ -<9 6*7W$S*U4X)F65QP959H&96
M"C:UQFR8U*:+U+J^IZ!F0QJGQD^2#DIL:^M*&<@UM;G%A3$;)K7%$K78]:G!
MT0*U.BBQG5-=*8.1IM:R/; Q&::S+BQ2Z_J"8+Q$K0YZ7)A0Z40:TIV'EJ[W
M#O36,G&N5T;GMO$91"?S,+[E[>38_'VYV:RNY9G\*KMSU?;>&V6\3QJ:FA.E
MC'!V4<"3Y,(;WOFA)B<F;C-^WXTMX/C Z'7J:.>V>O,?4$L#!!0    ( '"#
M0TB.[YCSC0(  ,D(   9    >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;'V6
M38_;(!"&_XKE>VWSY8\HL=2XJMI#I=4>VC-)2&*M;5(@F^V_+Q@GA10[AQCP
M.S// !Y8W[AXDV?&5/31=X/<Q&>E+JLTE?LSZZE,^(4-^LV1BYXJW16G5%X$
MHX?1J.]2F&5YVM-VB.OU./8BZC6_JJX=V(N(Y+7OJ?BS91V_;6(0WP=>V]-9
MF8&T7J</NT/;LT&V?(@$.V[BSV#5 &@DH^)GRV[2:4<&?L?YF^E\/VSBS#"P
MCNV5<4'UXYTUK.N,)QWY]^3T7TQCZ+;OWK^.Z6K\'96LX=VO]J#.FC:+HP,[
MTFNG7OGM&YMR(,;AGG=R_(_V5ZEX?S>)HYY^V&<[C,^;?9/CR2QL "<#^#
MRP9H,D!/!JDE&_/Z0A6MUX+?(F$7XT+-FH,5TC.WC^0X*.QTZ<RD'GVO"U2N
MTW?C:-+ 4;-U-3"D:%P%RAZ25 ,\*&"( ED*Z$;(2-@!"CG U@'RTJA\R-*F
M836#U>"D"(D:5T3RI JCX 44[*+@S(]2613L1 $9(DD>DC6NK,*%@^S1D 4:
MXM& ( UQ:?)\!L93$9+,K%*^ )-[,# (DWM34U0S-+X,@ 2%<8H%G,+#04&<
MPHF3ZR4(SF#CJHA6E6&8<@&F]&!P$*9T=S!,JLSYA<%*#W]NDJH%KLKC(D&N
MRHF",4B"*]M4WC8KG87U8$SMG:4Q+QV<X-[83B(;"1%0/'_K$Y"G@Q6!SNKZ
M2,$*>D?R2B@.AMI.(AOJ$T HF]E)3T)0Y@F>@0H6U#L4]*#*8$&<1%/^H"R>
MO[6I)GHZ4.3DOT*4.H?.A9[8#RI.[2"C'5?Z_!H/FR/GBFEO6:(+R5G?*QZ=
MCAV5:1:Z+>Q):SN*7^X7A\?MI?X+4$L#!!0    ( '"#0TA9]&E*%@(  'H&
M   9    >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;(U56V^;,!3^*Q8_@(N!
MA$0$J6DU;0^3JCYLSPXX@&IC:CNA^_?S!2B9')87;!^?\UT '^<#X^^BP5B"
M3THZ<? :*?M]$(BRP10)G_6X4SMGQBF2:LGK0/0<H\H441+ ,-P$%+6=5^0F
M]LJ+G%TD:3O\RH&X4(KXGR,F;#AXD3<%WMJZD3H0%'DPUU4MQ9UH60<X/A^\
MIVA_C&*=8C)^M7@0BSG0XD^,O>O%C^K@A5H#)KB4&@*IX8J?,2$:23%_C*!?
MG+IP.9_0OQF[2OX)"?S,R.^VDHU2&WJ@PF=T(?*-#=_QZ"'5@"4CPCQ!>1&2
MT:G$ Q1]VK'MS#C8G2P<R]P%<"R <P&TPBV1D?F")"IRS@; [;OMD?Z$T1ZJ
M%U$"88+<NE="A8I>BVVRRX.K!AISH,DY+G.2+)MS H4_DT 7R0@ ER1IZ :(
M70"Q51DO &"8N $2%T!B 9(;!=&MS<RJM#F=R8G"Q+]C-%VA26]HH!M@LV)T
M\XC1[8J"[9K1G36Z71A-,W_C9LE66+(;EM@-L%OQN7O$ISY4=R7HS?\Z'9.L
M59CZNSM$SA,R$=T<D?@>A//_']U&\"&[SA,PJ8@?^(/'I-%NZ/_[88)%;Z"8
MUZ8%"E"R2V<Z[B(ZM]DG:'K+5WJ1]ZC&/Q&OVTZ $Y.J0YEV<F9,8B4C]-4Q
M:-1%,"\(/DL]W:HYMZW1+B3KITX_7S?%7U!+ P04    " !P@T-(08;&K$8#
M  #?#0  &0   'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6R-5]MRHS ,_16&
M#P!LS"V39*9I+KL/.]/IP^XS39R$*> L.$WW[]?&)K4S@I*' .9(.I(E(<]O
MK'EOSY1RY[,JZW;AGCF_S'R_W9]IE;<>N]!:O#FRILJY>&Q.?GMI:'[HA*K2
MQT$0^U5>U.YRWJV]-,LYN_*RJ.E+X[37JLJ;?RM:LMO"16Z_\%J<SEPN^,NY
M?Y<[%!6MVX+53D./"_<)S7:82$B'^%W06VO<.Y+\&V/O\N'G8>$&D@,MZ9Y+
M%;FX?-!G6I92D[#\5RO]LBD%S?M>^[9S5]!_RUOZS,H_Q8&?!=O =0[TF%]+
M_LIN/ZCV(9(*]ZQLNW]G?VTYJWH1UZGR3W4MZNYZ4V^23(O! E@+X+L 1J,"
MH18(OP3"40&B!<A4"Y$6B*8*Q%H@GBJ0:('D0<!7T>WV9IWS?#EOV,UI5$)=
M<IFW:):(W=\[;;?8J"T7N].*U8]E$I&Y_R$5:0SN,"L30](4PFQ,#+HC?,'@
M3@-#-+0);-&((!//-B:&,&L;$X!4)]C:VI@$PNQL3 H['4).ARKVH:$ !P16
M0" %1"D@%H/,9IDJ;Q6F5D90XH&HK8E"6>H1"+6S4&GB#?@<C5".3,KQPP9E
MBG)DF@D>N2C0U@3%,&9G8@;9QB-L8Y,MB:"@K&+#""'(PZ!/WZ#T-I@H%*=>
M#%-.1B@G5H '2C$=R<IT2E9F(PRRL:#%*FB9X6B609#- ,2B(;\U@SSD2R,4
M>$ %V!UU+!":$@P$=K:>A=4FXA L+ W259IX0US!;M(;"BU#0US!?M*[2R:Y
M.U;?R"YPL&36R*YP,E2::*PVD56<\</W@&A+-B@9L#-64,BNJ!2V8X)(-%"W
M"*R[WDYJV<F@-K+2H+Y1>RD<7Q.% P],NLVP+IOT6*TCJ]B3 %:!P3+528>#
M*4F'P3+5+##Z/NE6&J2_&-A[0*%03QD6C'@D,'Y#D\U8 \!6 TB&5(P-"GC2
MI(#'1@5,)M0E)D-YHPSYQFQ9T>;4G1M:9\^N-9=DC=7[V>0)R]GT87V%9FL$
MK&_$64;-LE_JE_-+?J*_\N94U*WSQKB8B+OQ]<@8IX)VX(EV<A:GK?M#28]<
MWB;BOE'G#_7 V:4_3MW/=,O_4$L#!!0    ( '"#0TAJZ)C1)@,  +L-   9
M    >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;(U7T9*;(!3]%<</4$$1W$DR
MT\U.IWWHS,X^M,]N0A)G55(AF^W?%P132)'U)2HY]W+N@7O$U94-;_Q$J8@^
MNK;GZ_@DQ/DA3?GN1+N:)^Q,>_G/@0U=+>3C<$SY>:#U?@SJVA1F69EV==/'
MF]4X]CQL5NPBVJ:GST/$+UU7#W\>:<NNZQC$T\!+<SP)-9!N5NDM;M]TM.<-
MZZ.!'M;Q%_#P!(F"C(B?#;URZSY2Y%\9>U,/W_?K.%,<:$MW0J6HY>6=;FG;
MJDQRYM\FZ;\Y5:!]/V7_.I8KZ;_6G&Y9^ZO9BY-DF\71GA[J2RM>V/4;-34@
ME7#'6C[^1KL+%ZR;0N*HJS_TM>G'ZU7_@S,3Y@^ )@#> B (!N0F(%\:4)B
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MHTJ0S*U!R$^ ;2@EG$L1L@*PR M R S $C< MAV@$EG[WM'.@6';AUU"(=<
MV)$%S:3P-OPD"UDD2ZA+0;5$ELIVKX*@>]<P_N7@9@P,>CO>L(&9H\E,0=#;
M\=-;&"S1!'K[=&(!%VAB0+K6JH()]$KBP.8D"74\S!U)9G8:]#;@)$FQ2!)O
M TXLT!))D+U-<)Y;=N%H@A9H$NIE6#J:D)D4WNZ;-,&+- F];B$):6+.:Y X
MFL@7[MWKQ9S9'-R])JEU:C[71_JC'HY-SZ-7)N0!?#PM'Q@35";*$BGN27Y)
MW1Y:>A#J%LO[07];Z ?!SM.GTNU[;?,74$L#!!0    ( '"#0T@5&5^;[@$
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MO$T]OFDKN\NS[>7FD+\UW:5NKZOA>'*X:<K3>-IZ.?)=_@M02P,$%     @
M<(-#2%#&%2_0 0  RP0  !D   !X;"]W;W)K<VAE971S+W-H965T.#8N>&UL
M?93+;J,P&(5?Q>(!8IM+VD8$:<*HFEF,5'4QLW; !%0;4]L)G;<?7X Q%<TF
MOG#.^;\?'.>CD&^JI52##\YZ=8Q:K8<#A*IJ*2=J)P;:FR>-D)QHLY07J 9)
M2>U,G,$8H3WDI.NC(G=[+[+(Q56SKJ<O$J@KYT3^/5$FQF.$HWGCM;NTVF[
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MU8&4LD645=!31'%&**9.#9,V]0466*@ "TPAC"1I%40D1H 7C")LZ@HL-(G
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M/7X9O/'6=?7P=X=;<M_XT)\7?C;G"^4+X;8,E[ACT^%^;$CO#?BT\9_A4X4
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M\_IA>URPW(5@A<2WW'M,3?;#!Q2U9F+VO2I@48;O,I#&0(79F!@P(D(1?92
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M.3>W)CM0I&Y#O8I>HSB7]<OPPDNS>*S>+VU_?S\Z>GVIYHOL7\.X.;X3ZX/
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MS.PY6A%=N6,@^\7.EDMG)O7J^Y:6=!V_&T>#!O>:'=1@GV(/%21Y2F(-\*3
M/@IB*3"TIZG? ?$Y2*T# M.@B0M9VC2LINTUJ*01<56%306J<NHG21=(4H<$
MN3&H)4E!#)R2B/I4>T>%"L#KP&0+,)D#@[TP&0A#<#DMRP #53A#4>&'R1=@
M<@?&&V:7.Y4!42"+(TJBW(]2+* 4  6ATHM2P(- HHDHMRA05,Z E L@)3SX
MF9>CA/N3S7! 43[S!Z0+'-39F]0+0D&,3RB-O&=[[ZI0E/EA3(>=I3$O 8Z_
M+H-HJ'V!9@Z+(\LI =@ND+=+CD!.FZ2Y'PC!U-,TF:G01$<PV%,7R=LR1R3L
M('F3WPVB<3<2/"W2<'RFNIE_-UIJP<CMP:6W!R/87K,43X]S.? X,D+_JU ,
M;KD;N_ ?K+M4K0P.0ND+L[_=SD(HKITED>Y=5_TA\YS4_*S,L-#CSE[M=J+$
M;?Q2>7XN;?\"4$L#!!0    ( '"#0TC)\TAKD0(  %(*   :    >&PO=V]R
M:W-H965T<R]S:&5E=#$P-"YX;6R-EM^.HC 4QE^%\ ##7U$,D@R0S>[%)I.Y
MV+VN6(4,4*:M,OOVVQ9D:',DW@B4W_?U:SW:DPR$?K *8VY]M4W'#G;%>;]W
M'%96N$7LA?2X$V_.A+:(BT=Z<5A/,3HI4=LXONM&3HOJSDX3-?9&TX1<>5-W
M^(U:[-JVB/[+<$.&@^W9]X'W^E)Q.>"DB3/K3G6+.U:3SJ+X?+!?O7WA^1)1
MQ)\:#VQQ;\GP1T(^Y,.OT\%V90;<X))+"R0N-YSCII%.8N;/R?1[3BE<WM_=
M?ZCEBOA'Q'!.FK_UB5<BK6M;)WQ&UX:_D^$GGM:PD88E:9CZM,HKXZ2]2VRK
M15_CM>[4=1C?[-Q)!@O\2>#/ B]:%023(/@6A*N"<!*$AL 9EZ(VHD <I0DE
M@T7';Z]'LDB\?2BVNK28&J3C_HJM8&+TEL9QG#@W:30QOF*R)>/-A"/<YRE\
M:(I)[B_D/C1!OB0"%T(*#7D0(H!"!.,Z@Z4^CF"#$#((1X-PN0FN:Z0<H<R
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MA$JV!S-5;-/4!3S0Z"*OAC@Y?\],8*(:!1I=Q=60R(??Z0CLX'IN-*H&=J7
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M971S+W-H965T,3$W+GAM;(65RXZ;,!2&7P6Q+Y@[1 2IF:IJ%Y5&LVC7#IB
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M"Y(]:.V"=))@F UP=$$$+8<+$8D2L7-(QUYB,]RXB$2E*(N_>KEU$2K$('<
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MO*4=+MI<[/)L>_ERR%^;[C)NKZOA7=+PI2E/XZNQR_NYU7]02P,$%     @
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MCN@6VSZ^*A1"K7[FB!":^9^::0#A#K2U0!/"5_33'AC:8S#'ACF&-MB9"!)
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MN"VM#Z)7^%CMFN'?Q>-[TU;[262YV!=_QL_M8?C\&.\(:<5P 6H%Z%% L:
MLP+L*' T#!?@5H!_"O"@@+ "(E9 6@$9*Z"L@(H5T%9 QPH8*V!B!?HQ'T<N
MC18Y#O;G:)/P:)-IN F-?LHTX(3-1%;C7!QF\F71%IMU77TLZC']WHH^R\E9
M)]4I7S3#U7K,D&XR-]W5WQO"E%BO?O>J+$0'Z,*%N-88\P 4'8E59\/1$(H:
M8I]!'7F*/>'2)313&'/E,APCKJ$6U)<;EV$IAMRZB,29._@H@S'W@.&HGH>3
MH<E.&YP#Q#- #!T@-LX4YH:6*EP#1S7P40-W36#02CW.@A$YC*YR*A*#89<
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M9>=JEUC+Q6M9/!U_[,KGMO^JNN_U^,)\_-%6;]/[_^-_0MC\#U!+ P04
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M),L_[\J*7@A.671,3V,F0V(,F3,O]L;1SK['=$\<^4>Z@"E7&8R<W"79BD@
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MC>4EGJ+WHFQ\!8K2X5)75:LR,.N0_R#IM'/G<Z<'E:A4H,(*BP=\S&N0I&S
M7XLO&?]%"B<%=H.5+K3@C8W>V$=<I-.K!"T&/&-PP%JO>Z&;YLW,EK6]19Y+
M=&-F2F*,)F*HEF1G<VF:BD4[,VZ7C=V2YA"AHE*SVB?L]L@">MK>FP_3A]J,
M4D,(VR*_R]#FN'IHI8?':)3-]$=H"+2C19HNY19R1='KK9-*+10X,.M#E,7W
MNV)QFY1/N.,<?4C"1^">CW_Z</[\\G6'5^6BPY4#),3R X[2J]TZV0*AKZ/S
M']E#Q:/O>3#-5G?DD9?:[E,E']E--=7;=N6QG33:SIZ=E)F2>1)PROU[GI7E
MCN0%NB*)L9(AVL$N]NI;+S\O8!%)QU+3D<GJ0-X33NPJ+XK\ODW 7Z9P[APW
M[[YNSX$ZEOTX:5W<#G<1KFK*_I8#K:R7U]>@6^ LT\\+8IH1!EZBA3#0_ EC
M=9IV,:SV3;9!78@V_S:-'D W>L+]*;+//7=VBU+Q#AXH1DFG>9J2=:!>NT^E
M>*K2&?@B]BLA#17=;81J8:"EV.#%\-$[5)]Y],YN+]H^-\6+U$LD9S(>IJW"
ML3,\9A$H;:*,?<$M7?K;:\.7[(T@4Y=H>-#G?.N4'_["/0XY]-]DS*[Y4E"0
MPWK+Z 5[)-^+-_*/J,[&'#>,WFU9[KS\G!:+K&P&PJVJ=F%Y[[GGO<C#['7O
MF2%&Y_=) 0^49\3N(:2K\73:'%?N$1I1,$+5<F_ENRU^@VZ6WW732XJ9=IV4
M1I@OO+SKF#1N>X$A+73NX>OM\>T]HIP<>MO^EVH$-@][J<9M8 -G-LIE2!FH
M%8F\PG=%AHZ1=B:5R)Q&$+4W1;+><W"_\0.ZCLW^]6KD"!RV7HW;/NS6:XR=
MP[M\R&XVY/;'T\)F"!U58(DMKID?6B[98_,>_ISHN>B<T;N[M+C+TGL5@1F\
M3G2SRJ] *EYE.>FSR2+=D?U._#[9/("2MB 5!K9EF96+' :AB*Y$?>GS.MGL
MKA.-O'),>)7QE;AU1;+%F< ^;N'TDTA'W0\W%37(2K=_D^Z*?)ERL!@])?A(
MU(6 P6!F496O\IML@7KY4I1J,D=W59ZMU[L-79\7*,Y[T;M=(=8!L@:.T+L
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M2FK8=H6^JECSBQ0,$''L+4$31>U14@21+,&J*M!HIQK9=K'26*?&VB2D8;T
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MU^(_[/UU'I?"S2QV,-I)K5H>;L3&'*1U:R$4_A7VU#<:$+Q0V\L &KMX5I1
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M1?$VG)>=4\O-PJ+AQ6^F26MK;EXR46XMD>L*R<'9,T@./+=;D6K-TM3GCMQ
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MGEL&N#SRVH2CVR=QA9 .4)Q%,?OUPD;GKU_43!,6$4,.VC4K7GJ1R7SUGS_
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M*4JN\A3XXE-Y#425>H_MGA0P;Z&U)'YGL8E?,HV"W' XWX)=R5<6AK$S'L5
MEHY)2ZH.]4R5R>PB#*)QG;*>+(70GYZTG>'HY4]CIGEB!7,4YE=D3$"CS'U=
M](1;N6MBXX)%3I.2C*Q'!H<(O6&:IQ K4F7S!7.W.*6I>U]L2^79&0Q1?I;^
M/>%_Q^.#(^L8\-=V-TSUQ44(=@;'AUP6\P2I5"=#M[+GU<K-QZ=;5)"$#IDO
M5!,-=44OF<^TG 7H<"RQSI.",>,NA)TWP'IH<W&Y;>O0+C[D8C=<?9-830&L
M/6_:3_%#[-WFLP"Y'(B(+2,EV3%< R00W L.+1(!0#?U@R$HRZG!"GE.NW5*
M?,^135.FIX\)O\?3F<DD\54HG?:=)"UZ(-SD4<-K*C]!L6\N=50&(RG2VMV=
M3B=,;D5N\S87(!J=UI"]T2A+292"HY<T4C=81MD:F9I 'V9*^- "?3_D2<Z%
MF?Q4VWFD'/TY$W-7M6F1)WQ9S7- (DM3$P">CNB=3<$G*)I.GT62JB2^0)3'
MLH1.2-OMMV\:26UCND@.ET3Z1L!NZ@NDME[Z#GO_H&C(N@>.:0%CH>8%#]&)
MV<V=NZQI3#XZDF +W?I+,R*T8TB[EJJ.[T5_8JB(<SF3TD%)!"]&/'I?H=['
MGGN;?N'^PEL!E#?9XO<Y" L*+2%,50$W-1ARN7ZCI<[NE+K@%V52Y:?ZSYXD
MA$C7"NCTWBU5S=4'M9,B4.D1G6GU%[2S'IYB. /QOI\G 3YY!E-(=C>UM(LE
MK=\) U*$R6%!^##RA^BQ]:S/D 771:Z;[T#FNA2H>K$H^19F;Q<8AMIZ2.:A
M?ZA[#=TXQ5^J<=S:RXTA>PC!__2B-JQ-7N+(KIV#<YGFRM,/^&.7Y!J9 P0G
MAT(17@)3-!3X#X4I569@LW2.(D6+D8*'R9:W#'2))B?=TSOA_..'\\O]RX^O
MAX.+GWNJN[V[9$,"<N<)6<^8>R+[X,=4$+87)Y*'5VU_Q\VBNDITGKA.ESN?
MA0?L2O6WD51_LYX*/8I44"24&?'P='Z <QK%^/(:IQ*L\ZB>'E%/P;[V4+*7
MOM^[ZU8&9N3QN1W;D".I\2S1N*-YVE)Y)HNL8%XJ,2:<'+(;SIQ0 XOL''0O
MLMV[@1/DI$H-+FOCN=JV N^?8G8WG8A/EN#\A^/X.-TMG(3NJ*:3'"QU[\0+
MVZ@GD@6"S&.?PA7D6P>)O)!CA_P! Y?M$45(BI?]HFO,>[E#6&ZDWJZ&H]9>
MV&76)_^"<PH<%REO3? PI+MIY\S.]J];NR\[;:"TPY\BXZ.QI;XR+B-,+S8%
MAD=M<X0RCXL0F?! K<Q$1YZNY]58HV6+I8$9?H[5T#(6>#&XMY0EJ*)=I+2S
M%+NV3.=]L7RL"#L^&\P?G?RJ[FZ=JO!X5PR&@]W7[X=[F4\4,FIR4BTL;.$5
M*!%J]S5GEEW25?7^ ]U4>]WO;NX $EINFMF&F"%SZ<#NY?OI7HJAG_KW?[;3
MT9-]9*N\C2(<;$AZ>W98HV^ZI4HW\WSK_;B^M1JUJ:.^,TY5@6 1A0*S1G0%
MM<J'@UEZ(SO4B$#;;I2]E#B"H#6)@=,E@ *@,8>#>W]S%YS'1*;O5GUI8J-\
M.PTQENBF:CH<?E$QU^'68JX'+U<VQ%79'M1_HA:R50OHO@/^9]8#U+G)FFER
M<9<=V^#7*@=F'__MKV=6R5^___1O).AZI)%6L;>22"6BD[+A+=D+14KDB,4R
M4ON!).,WR97)V1>1*Y$L8*U;\@\B%Q,V!S 1_'?OBM@Z!K"9Q?[R(Y.:)? /
M3J#Q89_.<YR*K#0);:N1=W!JL\.&1ZG--WR!S==X-"TG_G=8@+K=Z FZ4&D3
M_<\C-$,V\_\O.?\GEIR_)2-TYRPZ3W'A3#YQEGDP/7%M+H,O&-'[$)3@ONO
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MZC4ZM,XW'><>^'ARI^]_=I_+ZY2PP&CIR L5A:?5/Q\72!H*V]4U-:.=E(>
MRC,D9K72(JL8W6JN1,$DJI9E75?/$"8''?WE!R(%L&=@N!IE3^TZD=VAR$%_
MD-(.X@6_2M5.UME\ZSI?\6.CKJ?T=.]^(O(!_6)[BV0H&%.VNAC\'N,G.F7?
M,.YX@X2O L^)KH<2F-@DL+1(%V7F8-)UPED ;!^4P#B:+E<C7>T;7.LR0_#G
MZ&PQ8FSED65L_8CE0S_*,*/X*%FPZX7P2/GB8J3I+;SR)CR:&$HORI6D4[S8
M^I:54Q\K)[1J]LH%&F.2IRI\'KMTQNL0^HV( 77$F^==K3Z?+U%TM9E;T+LY
M,UL9<P/S=[OR6G_ K',$8>9Z-_-[_]@G>6P//>;'YE7!.5S^U-*%MGT/>3L#
MGE38P%'"W/;;(4V;TVERUV+6.@___/OUO_SS[YOR7_Z9_EO_R[M2W36M3XA=
M^160A#?%:O9(\-7 HNXZLED/PM-.^UP35=_@?YM>-:C?^K_WOTI->%N1\+Y:
M2.$A*MM2N6,S6^2ER%6NJ.RVEM --&FEB*6\/12$ECQ[0B-8]O>\45Y59V:2
M9PBLITX9GY4@::,J25(22P8.\KC&F4[@@W>JZ64 :U^:(O/3T-XG;>_ ;1%X
M@W1V7'>HQ(> ? ??NF5V5Z9\R4S01\,R,CP5VR5Y>/K[R\%N_+<],J7)IMB4
M:Y](O/%ZR45QPSKI*RHM00-X3>PABWE57V?2F4?20HFJ^X:OL,]O7KT]?_WF
M@G+DKLG8<L.2;G^_9N#G>_ >OG[C>DE<.)/!X6@T& Y'@^^'F7(JTI'E/.>(
M$TH3<80.T;/J,+-*,F#*!G3BB'=,\?.:;7<DNE&710=C2@^WX?O['[?[NT:(
ML\)*?*@.!J/LU!DBX\FD>PSO\\?@#.,1-/$(1ATC*(J?:).ZK:VP#]A\W#$O
MH^;Y$K 6)80-?,)F,+I>:K'(HBSRAXS4M)NJ#IR*/GMJI2\S=7T1/7=:W4:
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MG]J*OX2$/AZ9^J:(U<1Y(''N^X4%/9,C?6=R?#!,GA\/(F9D=D"OI#@$3PU
M,4IAO&D\=W:;+@/73/XSRT6W96FS9$S'7:P J H2)FR?X&V:8MFZ8..DDBTW
M2_0-)R_L]\[-F2RJ\-9!$:>BA_(I.\(#7A'43-=T/3".':H6:/E@>;%5!474
MTOZU6/V.X5>G_YW2_\YH<0]!0"!-,-7?>QD3'QB/?B*N_YW!R>3@C/\Y89X]
M^NWXF'\;'XS</^/3$7X]&8_<LKYSXNGK[H$.=HD:<\_\,V[_,SIUKW#_3LX.
M3@=<;6#9W4'7@3/NSAEW9^CV*2@!B0O0[3'Z;#P9"T/@R+5/8S)EZ-2_[#4]
M[+H%1;\*P>;7=TRF=^NT :U 2E][E2^OZG)^4R1G#E?#?3Z#.6=#5MM/:/#)
M=?B1QG$%>."(:[ZJ*4UA9(]2N^PG&8?@8$>M)7G44G"Q@:?$7SS) <?L=38_
M*"G#]*QQ^9VOFT!WAJ\DJP5KV%QEU8ODE+;O'Q1'[J_J!ADUM>1E&*< (XYB
MECR;/1QFQ?8HN5@4<J.71/>W F,3H-\Y",ZHO*>EG:^+]:9>\:-SN0DEV.R+
ME?K+7I)RC/=-I$>K?].UY!Y2*I7J)/(U;!*X10,\UM#C0=D$=ZGKFY.[# H(
MFV,1*8#D!:XY@Y%Q<TR)&MA/>ZI2J&KJ#):\K&/:O/ R3@#PL"\M-V'$)\:Q
MX/A,&(*JQOX.(O?E;.8&Q%K;\\;G'@)W'W>.<WK<&0)R18H0102P_6WB,S5:
ME8U/-YAT2!$QK;7\2&#%_L;%/T&*:6/@B'G/A59)JIZF&+UEG=(MW=34X;79
MGB;UD7:YUV:YHR9Q$PW^CC8N&6CDMW :LTW*B*FHK2"\^/Q)RU:^RFOWZ"H/
M;-DF3BFI O,GW\7(3Z,H&! HD6Y)W_.YP#H/,[)?0#WH?EKD8DV_\8HH[]NF
MB"-102,/:5S;E F^ZBD$"%$<[WM)DNNY^YZX_/O>":5@9T!)J*P:\ ^G@R'=
MZ- 1_OJ7_X/U!/K!Z KX%?K"Z-!]5Z]Y.5J[A[BU/_RZT>P,AG3;?\Y_=LHB
M[Z"/9DO_*&16\\*?1S(G[EC@BIMRL_(5:%TS 5T%%80O$H_4-2(X.CM(6%3;
M;\F@'XJ9095KV<^^5#FJI-"%LS 8;+X_0BFR_&>3G,HF:?_.\#6XX]32HXG1
MNPE>4JRC&4FA=#US<B"6^ML-BVEKM3W=IT90;4[1O:D@Y35)HUEOYNIR]#96
ME,#!#&TLQ984_;9"*OEN1,<.5OO*+YSA!JYO\I4D^U+AC(N/C:]/R]\5I!=]
M@F:" X'U="CJXJWFF%P6FX&!"REPG;KK@[! /G^\VLX-6SU%_,UWF!VQ)=OF
MOO>LC*%JBGLPB2AP8+[Z\>J!M :,C[=ZH>[>:Z:QOP/>S'=WA4U+O(@91%Z%
M;(MVV@0*",UUIFRBQIV;I_ZW9QQ<V*#0<T0:Y&5.*[&C58W#TP:EB^BDTE6@
MH;#ZO-_A$7%?!._P.,0T UC8"YJ#,'KK"3 ^B[!9KPKHS?.-3R''.D()[,G*
M[F-SX?3^5N(+H4Z*&?DSNE*]N6LFNUOI>*N9VB6]*Z3ZI?$%8</ZHEO^8 E0
MM.<F;;-ASL+.ZUCG7%0AS?2"2[E7]+L1/GH-71J5/"[#E?#"N?8I5GWI1FY<
M[R--R$IC&P\?:JSK(3 F.P41/N/5X+):.'W260_ 9JY_*6I\XM4F.D2PM38E
M!9_=KF9FW5X]+.&)%J$O7-%/W!+Q-%L94X'VZ]A<8VI>TAJAT*>W9,I@OQWX
MP+<1-?[LG*\"07\^DQ0U3MZB44-MKQZ(.X#"EQ47?0ZVG:3ONLG1ERCN=U[R
M%L\7I!P^4B-\>)"\V\-6+GW@NS8M'54GA<8@LLQ^LR(*G7=-#D^_ @IFM:+9
M#%R>H2",4)Z1-G=E_'2CR5,/8J", (D?/_ %)UL]"JZSI&*3H6%A:: TM;YJ
MS7/I#N@UJ+@\"]3GGZB"S$V5THR,;=HZAF-F'W-^53@-@28Z<,.T>+TIOY+;
MCRZSN$R@$3O?J!_>'=8K,;^Q#U/W"^>6^0YAF*Y5=YA($%*]-K>3EL6\_%EQ
MF/X/>P$]%.&K/Q K=N.$*"D/WRZOONL!LS[QU-Y@]YOS#^$EWQ7+ZNZV)"3&
M%H1L\BTT\AV'TMYNECG0 (/IM[S98S:_3OX[R+"GV$6"9$<N/<N?Y*!MF5G&
MFIQ_,$4V/CF=<9FW4*G4\7"=P>SQ,&NN[&[]"N;8QJG$D4H.WTM91YZ-54M,
M^'H(=<'?X8UJ;RCX&.I"*YNR^>%Y@0SC4%)/^V#L3S4"""KVS%4>\RTU\<1N
M,Y[MD\E63]:C;66/LL'4KE_V(JO:;;MGG#= HL^_,RM_^;@BQN"?,XX[')XD
M6[67N>DT8LGIWYR=;#UI[O+Y=\A%XQ"S5@SU=1\1+)4RI&S+,!ALY\CVH7UK
MB,R4^J4<5SG$#@&W6C*@B,G?%)%J"O($)B[H(Y+GH3PYO4>!8IV,+K=!3GR#
MFD;<:/S2KA&@L"<=03?'AN*3[]@5N$1#J5,?/*^@9C.M7-[+!>44"@-!1,[5
M^VE4<E.<Y%%O. 8L\3 P$$AQIUFM?NFTT!-H!L,*6LG(RLKA<:RLV&] NH4D
MB[*)-G3TU/?OIZ_?7+SG)$F?6[6[=O*:+NC,M"L1>S*.=3_LC$8M/G2=2IE9
MI\.MFMSP>4;G)-E0PTE\0O+VZ]L[Y_UEA!<A5BXBD!%8;>=>' >Z0$Q/_.*.
M3>7>&68GZH%]M?1&=L;;U].#"+A@N0_2^ZQ'@1/TC8'+X):*MH-[J?F(KPI1
M2"-6M'Q-TB:]&6>;);(7[A4(AO).R5L^61H<#A!0#:A*"V$&=;#[,9DD.8L/
MQ0)0)SJ+? =U5;_M5($[>+5Y(YZF%&1=$\K..5_\Q;UDY\AHK-E@9Y+HOSO'
MY@]]4Y5P#?:/OS,T=Y1U[]&)3#8IR,DG*7,8SI7XDW;&AZTCB1%S21XS'.H4
ME[!,Q[5U$3L',0FU1"O4MXTK^!T^(;/AND*IH4@:Q)WMGOZ>SNHBE]=FYPU'
M6O?8C[-GP=2@&4?;@SEVX8I _27) NGI&'>AD1LKM$*&(6,IJ(U5Y2&K75N6
MZS!?P6O3KLOXS,OEIJKF4FS+.P6AO="#]1P^1*]H&!X+IRVMY@03$PI$*8#D
M(40S:[J@;&OGC438L4<;;>6,'[D@.9>X@7]Y7H"IE-YCZZYJ<2ARI<_%OC?#
M,CXPH!,WA=9P.Y9BY]?&OJ/LQKGV0G=QN=(U8;"[CK9G:7V*AVRS%FKJ6]<N
MJ0EMB%3X9 L(RGRIST\2<Z:JFT& J\$C;@T)/Y6@P_:OX&+N*YX&J"+S8KD*
MF$.D87/",[L8H2$GQ3XJV<%:VT,!KY0237H695YQ(IWNGLP@GM"$WU:DN:R
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MX1^)G+/VTBM,2,7U+C7%MZ6C?L]R[(UF$Z:??\8$%'>F?DI+$/3(6[B'5(4
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MAXY+B)5$.%*)26"6/NO0/&+>N93(,]S(#VJ&%Z0.@_ R E^37J"R+40(X^4
MD@9<A,!701QR7U7;2V6PR?O89J&G7*N%FL9WV30+6\)50W/%$CE6]*W+/UV&
M*"* &_%(9@$M*-%!FW(:@19GEE9E;K,QJ(F4QB%9S26%$<V*UB&ECE@&U;MF
MQ!DIST;CH:"/+'H'('8'UQ,$@9>62C99ZCY$"08BT>86$4=/+*SX*X/>AH_\
M_6__5MZWRDD"@RC-2D:O[G0HS$/#).K(H@]*K5-G*EO/H0(0&<H%HP1!7#(4
ML?,Y9PD(#)"54\"N5]KE2E[JY1-;H71ELN=$)&L1E^N[G'P2;2<J1^X F;K4
M1G5LL'RQ\D$O^9!!:\VG)1@E@7LSU*AW&4U$:Q>Z%"7;PJJ5*9%O""?(-DP<
M W%(ZK-R#Z]D#YVC4L:5M$AZX=/LH<LG992P5MB\J\6[N4J[M^@;TD?5[N*5
MA2Q%?H8=;MJ;05-D2_>T28%>[4'5)$*W%P5F!=>S+(N71JGW4/O6^3)Q M6,
M-L#D$:10<DH;Q,2RL\&!"+$%"EWS7,"='G.# V5-8 /W&+MJ 9N$Q$:)+[1L
M5](.>]UV'%BU<L8!9RMJOI%8<G.LLU/RIY67S_2H1CPQ]=,<<44L7!:XM\%5
MP%,CV(@ED&<4#TB 8<;B1AJ26\F(+T9X /$ O2 2B37L?:<I5&<HMV9O#14[
MYQL L#3"(IG?K'YLM$$3S#!E2"*TJE*X,],US*,U^[K.]-1)M[\)'CXK4$B>
M+T@8\9?&TC--4*5[PUH7:N"@+Y>_*$:"Y+#\/,.R/*OYEI276"VW]EEZU0?K
M+R8JAV/M-;,\SPY0E=5SPI5^:U\(1$([F<S;E1** !4BEV)5)N("ZT-R34$"
M#A5A5K?D $Z8*.J:W&6#J.)69I^4Y6W!/6E#TH"V&BU(;GG(,S.*=KEFA%,#
M&6=FIL+F93W"Y?H^6[#C7\FI1U<7H(;H!AECCM V'* /W;E;OW3FHE0^N>7(
M'!28A4G@8R%8_,WS;+O0JV>#P1L#OH92-"6@R=BD.!3(%WJ A]%N@JA&RKG4
M;FFV-!'B;D6#NO:V3@1$;JJKE>=$' L2?]RT\X(02V8Z\FTG3H IGF"/W>D1
MOI1"X9;W!FME,P\JV)[,?BB7E(*Q(Z2L&_T<ZTF*.3E']YGE1"$?LM8KUBS#
M54)FVAGW9*F>$->9,8^#597.2GW);0TC/(Q._?*AH#=!D@K9R9V3:2Q_-CXS
M,6Q-*"S.N[56P/RV8(!P-M1HHQ_#K$]-+>?@N]KN.BO=$3X"*QJJ,*_-Q)C6
MTW<;(YY7:!2#Q=H6A167'(_:2NAR:L<LI(C5E06)7.P1J7P8O>/D5DR]F6VH
M?)W&PH32&$@U&O\'IH]NTJNSFT]_'G_$0;P?_]///X[; 79[^QR]S\&WD",+
M)36.*;B4<N8WJ.-<[<.W>Q$QGR#;$.HTI!6Z ,U8/6U30@UPG2"UY>YUXC)9
M%QVTZD*0D$VD%D4[<9KF[$[@'ND <!E&.Y;23JZD@[_FDG#HQ38XQH)73,1H
M0[<@ZCMZ%II'[IWID5&MK8K1E?L/$3F.W[-27N?S.;INWW.)&4QTGR)HX88)
MNDI2T._>6^]F[KO.'6%0#=#[->.(Y,J[VX\(T[7?233$WND$*0I[V#Y2B*($
M(<WS>UBGF9TN4$+JH* ,=\Q0/A$ %.9M?1M:W6&AJ<V,S!7@E8).7)F!2\A7
MKPJC1HVMIBS(K.!->KHTANDB(ONS7PBP364 H4OU2QJYPY78;JZR&W>&5NW;
M=O1FE!R.W.JX@^1P8#WAU/0+^<.-D$L6.U1V-MD78CX<Y9U#7)):7"3Y-KL=
M.5H*?6KX@O;,T>L(G^(F.6F(>:--"W[Y<:YT"\S7SK[4N1 MB5M<)99Z2%<L
M- %'%<.WN%23*<I@$E<*)]TKP-?+\?[:0. R"N@/]/&B^32T_8"K=BVRB504
M)+>DK:R3101NH^P+Q\I1AISQG)@['&6)X&2%5!UP;LQM(!E&JZ0V:C09DDGN
MU)8OX(73BIGJ2KN*H1D;)M6GQ?I/8(C959XPHXI CL$XU"&:# S&#0.-CZ$D
MD*G-Z#$E1(N3XA3H,+X#B<0DP(;8/>;!<&B375Y:AM7VQ-M,"[@PF*6U9&S;
M=PS9QDS$83&U&%<FI)0R8606:[(Y%EB.!5S"QA'\[$+UFJV7?LN0/[KUWQ46
MQ(Z67P& Q&#V>J.@+,Y"IW&V&5P8?8C.7(T\:]"&C'C"TJUQ#6H;V>+9&E9Y
M;9=K>_5)%2!FQ*Q(3%JP-Y(S5&BC]M__]M^ .@^(.JFNBZ*SO__MO\/0\P+#
MYJ08B2XQ03'HR_EG2CD+=N$>KZIQ5(:4Z20WJ#T, /H:7T$'\)+D!J<"ZSKC
M87=CSU57\^R)HA*MF%W<=&<8&Z4!+@3:T>(;]#DWM<X5UUUP^I.)9#-&3DK;
MV&RP<J^!<\G4:#?N9;^\Y3K8[&"?&3A(?-J&A2V%Q<,Z4 J<D_=F0X4YD_.T
M0X2&U5C=&M04,:D4?YZ7L6@AL,V<7;@"1 A"0$JY"85>JS.S0J%J/S'8!#$:
MS+K^C&E($9:/HJV?S+/98V')-+A6^92"!<^7F(EDDIGT55^RD;([WRHW &]2
MKA0X\Z$7BD);L[:[7<A?".9;[GQ7\0@.6:B!.B/FKPN_XX#X<6,?D< 3W+_,
MR5HHU;NXA8VT<P_UD*@@&F1%S*G>.97Z++01P;ZOK)'JPL\<@HDC% .VUMJH
MJ-W.UZTU0=YG&K.JW^CMTMMX&%T$N 1K&8B'1*;M;+,MM'/"#L2G,TGB+L6W
M O5:>/5:(I)R\-5Q^1I*%X#$EXR*X@7=.?DJ3 WN0QEA@^OJGZ82O;N"M)OH
MEQ75FQ1."UW%#;.%E'IB0FU#,K8[3+7*1NE;*O1J^)(NCFA;:S#OV<&!-R_(
M[:=?Y&VQJAA8YTU+PS;4-8>BVX><"M&+K \A3APPAX$%@AVC885='X<#8Q\>
MP"S?G<#@"4;A E"H'5AUP9CI-@J>>:?H>&("^8T?858(N"]:1+!8)UVUNFQZ
M/G4B.]EM2,@,2P;2(QR]6PIZ>,K!0YE/#R1.T+C-Q%_!@25*LP1 %I0V3/Q7
ME1G_HSI_5D31Y5J)34">P0KI <L=(!U9_LJ5\S[%'5)H"<_C5"^VU>NU(,AP
ME$KK='S][JVI!28(,Y%$RU-=B4@7U)@NR8PF(0:40@6.-7W/D^/F$U7,,O*E
M-KRUK7*,4,8F_VRQ/:$K*;\+-QU-2X/?1#H5 %IX5IMK^C8US"MIU2?":%E5
MM8S*>TPI/@*SL#ZH,P8*.@DWL'HRON J?T)HP*@UOO[T-OJX/,1W#R#)]\K&
M#SMBKP2;N8ZVQ491JY*.6C?+E2+]?J?_5OPEQ1:L&SGHX1G>"+/" 21C(80S
MG9$)"XRJSNC"X'9)ZSK0>7#WVQG6Y"57&!"<I@=N22QZJ"C9_G;I7:XWHT4!
MZD1!ZB3;Y#&506:(3A"Y[7!GV25;:+W'9$$9K (> XFAA5W/DZP  &_L]8P[
M.-[>J\[1V!+8Q.M/LDV] ]CEO;?I>U;YL[F<D1--G<=H+:%MQ-(N?)6[9\<@
MDECKC_T[F>+Q &;M?C2DG<,9D2@+1GT2=D'A!ML_UQI6>_"PA%6"[_!4LW!
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M],(W5T DA$CS!0K-XG'\.I(YR=94#6NNR\6BH0=3:\@%B879LE(A:<CWX8U
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MSRHX"WR(+<)6S4Y3%5N@D/V"GK^%=%4U0)@32UV 7 ^E!C>S"1J:TF$?[6V
M,3&@!,'VJ =2E\3?QNJ9#KITTR&H#STT&8O;N]L>] GG(FV/NGVT$"3M+KYQ
MYBV"/0P.'/D^.J5ZX=AU@@ 3& _;XVPE1'A 2R_L7!^4(J7' $R;C+ ';KD!
M!$QT36PZQ-$B_%L[P22'(:K7 N9G]]J*DY'VRV&\.OW:H>07ZKK%^$X):STI
M087)$%HQHTDQ&AD9(F@DZCOR^[72SI!4>$7K^+C@4WCKA"N ,"%OU%S)(MSO
MQ#XRBQM4UP!']M5#CP(US+]'.9\JL: P/QPAB?1'#%"#H#-M]ED8-"0T'DFM
MS:1+"BY0EU5>A,S&*682)3WP[(!9E8%^E<J$U5"3+H;[@(&J2A]%Q(<AN-[(
M[IV"E:4/C.+'0!ERO;\,W281*?YR*W6#O7"0&A1'0?A(-*L*A.<T"%#2ZG8[
MXJSJHIGAK6K+!.NU78@1$V33 @,=(6QU!A8@926$+GC#NHDXJ7LI*O(!;\YR
M >$_4K!T\Y1S2?%/A]>'T1T?)ZP?2]CN7)R>5'L=GRT??QN%X%IWCUTCA-=W
MI1]TH(DM@K$+#+ZP4\3\H204'VIM'K9L'!P7 .M[Q/0M8/$E&MR"3O$O$EC)
M((4VJ&#=_@.7P8A.##1=;*%<-=DZ3>4JSNZ3'P1/2,0,I3$R1.M28LMC@:XB
ML8U7YL0;$K+RT%H=PCSS]B_"#,?O0!V*X0=X7;_;034 >*^SEI$LV,RA*VY5
M5LFN]P>6J$"BM95$9D&/@S6!@LP@-@5O&0S_-&G24MJW5-:\A(-><KS&L+ )
M>AUBIS4,I7/+M-\QU!R]"O9?]>X0+B;D&1J5K='+K>Z([R0&-!PE2%YT!L P
MLII)J=)6S-$0#&>)+U[KDNO06,*TW1&/8M>$'7BRK>)N S;06$M:WB1QLUI^
M#9,,;IRWQU0WHCI&;K6B86+M!.W1M)"T?POABE"4 3[6@K?%9+L[<,7I8FUO
M".M2B4:4\-9+'5&(S)OM_D#<>G&?LTW4?5?&'/A&4B*/E.4.T(_X..! 0$;1
MSVC!;=1C+ #F@2G1T-FC6I*U3BZR:[+HX!BZ6\ Y+:$([I.,GISB8QA6@1$;
M(ELI[81 ;^\=][:\)9>=D';/.+,%EIE:;@WY20)NIEMQ&71Z2SR[$@UUV$/2
MDRLRQ0:^ 29C!5 B(JIH,% 4DD0PP0!W#,=]PZ"+@7CL)E 54:^#,A.Z'+0S
MP9&8H&-AQYC"/%24#DM[M7S.YCKUD<#<L+X&E&N+D5& &\D2%:4><*\'":B(
ML4*\HH>I$[V.P2VHP9H$3:,SZHM['#(=O@&FP\ZU0P4S)G<%!KTV6;ZTAP!N
M<#&S_(DP;4D7+-TV:5;E1HTZ/9QXOQ=@O$>0GWB[9 >LJ<)WE5-(5?$P6U7K
MN4=+@!%\Q!1-T&W!6 ^V :Z9 D$TY5<^(93@^_$__?SC6/'XM>(<$!M^='X>
MG1Z/H_$*5&0UIVX'1; QAE#O?IP0"ND!?OKF0>TC9N:@/2@=60W6/4A-78-
M,JUJ"P +I*WZ)TF2=$<NT[$G\)AG"RH.I#[^^]_^K:"*1E ]@QY0=,CO4:GK
MV6*JXZ5,T275_&'M[$P_ZDJ8SR@$I!6_Q8_LLM&50]8CFMV11'^/\ J4R&Q&
MJ?,#P.2"PAL<BWRR95=_]*@.S(/(1I@YK&0'*+6P(>-R1XX9I+BW$AHA+0H8
MJ@5P4(S7 AQ/0?>-9Z,W !.8:^;#(#%0+;QN(EA_9@V^:\6*2O,XK*<5LS5-
M9_G:PZ5$!3-<*$93.V0NT HY4_EG9-?WV7J*> 1J*$\/.5(FOZNKSA$%Y5R<
M<\&;8@C:*U!R"07#ONS%8?Z]LH(*?'\&!]@NG-B>ORZ5PJ=+?_T6(A_%>/RN
M8!,OA=T<F,77)<I(EU=]79W=?/KS^"/A_.+$!:Q:1%\EG#W>0ATSJ3,D1<_*
MD4/ZY@9^A$:^_DADWWC YK[.<'!H<K AHDO N;EJ"W;QM%S/I\[X^G!?#L 8
M!&9=OCEKUUN$#Y+#P<U)J*+QJ,?V3X"X\ QM'W*00F?%(Y<]MR;?MLS.F?H
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M89C;R0.-M:ZNF;B7;1/=Q.@^JAV,.1S?WOXXPPC_<F/?)LB)[>W>%>@<!3H
M]EC!BL8XU/& ?F(:L'42]?T=:MVI8-L(Y@6]2J1&DO-O$' Q[;_>)[,BF_W[
M7NDA^1E[ XU0W7"5;>RI[4HQ0H8Q4&-40@H <*TX*KS]L@WI$A1=0D9$-;*
MR^]Q9L&$:!-%;2F_#[/%[''[&(%QB./FI1&27A"C#>,1\0QB=;S=9O<^I5$3
M_CPBST/B](W)DZ8MDMZIYM[*((QBUAJ!K@YZY#:38D?T%QE'TR&EA5"Q*(*Q
MX!6CB,;M+0U8LNG,C]3_D1#0*:3$#3EK[S$\0/19CN@'#H=<LGW:HQXAV:6]
ME,]0@CFI;^UZF!+K/,TG%"*@CHPZ/9"OE#--"#[A0YY-61/$PH]'V>/M>C:]
M5S3W(2L*I8YM(6"JP!*;G[,)4A'<0]+'3TB!I:=-VKY4 P^59$NQ)J@^-1G'
MU,.W;Q"S7-1'2E18Y!-SW+&"*)2C!]52_<JOZILVGW)-.JC1COXQ7&3+@B96
M!3TI8[S</2^=2"1$()1A%Y"]S760""G 4A02X]#E1;[B7C0,.,]K/NOB=4).
M!6<4I0&RPVYSC<Y'JHVLBCTB&HY6(OP[T$I[/Z6*$W+$$+K&I*; TG)8-WU5
M[(VFL@-+(:&B$P/Y90BH48,2E +B+!NN8&"7$2I>#C0['5H4A 'GDDFH7/$>
M9UQY9N-1(&<AO^?Z)]IK5,DK1:6ZA3+<2Q!1OXVWNIR+BS%FZ!<KL.0@S/<G
M5'EIK5[CB0^*)\U6:ONO)_-\O832@JT/UV^_CVY.CD[/CD^NQI1VAJ$J;[ "
M##+@=C\=TL74AL!3V/CN,.%XGU&'M.AAOTLZ-$5 # ?@VAS_>/'QY,^ 3C*"
MMH9H TY4>QT,SQDA^%[<[O3Z5-LF3K%4W*@#+@,"QHNYYDTONCP_>7]U=OQS
ME& N+V!)0F GA'@G(#,AZ74%[5K^O_GY>OSNZDRW-AAB(:;V$'VOJF_T8D.J
M71='A&Y91",?Q E6L>LA!O;I^,/ESVJ%$) ?;@3\!__"J0GXZ@"R^_&?/^:/
MR]4#>,"_CT[.+XYNQC<G$<0!I1$-/886>D-!>Y%?Y/_Q^>75Q?G9GQ7!P*65
M0"11@G"$ \SA59\-[$(,F$% ,0!$N=K<\7UT^NG#6&WP!^H)>L=_L"P/>'_[
M@D^,E5;P'XW]Y#05(=Q)EQP0:B>[=#F/VO%PR+4H>GV)*^NG]-NPG72H4%7:
M[@TYV;,]ZI/G1+W1#< >OL\A$4@MX*3&W?N'78C3:-4"E,@5:;SO,3SB63&V
M6<:K11.]+$\4A0O%)_,U@%5.MNH">,S7[@(0WCV*!7WRQ,5=KO^94NDG69A/
MS>U28B-+K7HJ]&^?I"4Q75UP#-7. <?=1'(I,(V/1IQ8Y0T@&50)5^!PFJ/6
M:Z#CVE"[$LNV#JB,0((3HWHC,>\T87_MPIWY%IMAZ VB%*F2Q! ]R<"+$EK)
MA#B:T.$>FR%F2E->1=<#Z3#:&5D/&V]&$A/K3&/>#$2K&EJ;G7;@D(<WH]/K
M<6PD9<DD# @KR$8:?BV0T/_M-\,^WI)&V(UI[48TO&1('_.IWV<OR% L],MK
M15=4R@<#[;=['(P1';*$BJY2U$8W%?4+OX&F0WLQ&M*%-^@-R0$LT+PXJI1V
MHM?Q X[_1-+W_-F*B#G.-EG4^K3(E':IEJ$2]"@L?01#NDVRA@[K)L\(]R^^
M#?GS!FQ;^J]3TA3TET@)/V,%4&2RF1KBK?I_HOY7PRW3B(4*."!^H7X;#5EF
M2$?"-[H)L;2]V22 %2+-,]1\F@Z8$M(Z'@D%BI ^>X1MT1WA7P,*."8NZ-2N
M)!CN7J_'.?F]4<R3& P&7+!FF%*,:]Q11P_T08*G9^<6*;I)&_(9>?H=+M71
M[O:EC5Z'(?.5N $LR@(,4'PKH3,S2B1RJ!/3B(<)E0E6!P_/5V.<@6%"]#I*
MZ$R-^K0@0V9+@D-@-:@)"GT$ZEH.Y-#O #<X[&$ZQ.$(#D[WD/'8!LB]>X?I
MD-+\P^GYNYKNCJCIE)KNN4T'LIF*2I2 %TXP08<@_)M&4*@NP1I"749=>.'4
MDI3DOAX"-P ))1AQ2&@%O_7)5S<Z8'W<J?_O^>==]>E7#+";L*0(,C[S@7C
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M@77]@9FA--N#&/6_5]D$="X>UH@<F(/I,CV978$R3YO/)H*L.SM1R(SUA*V
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M:!/^'<\P9B^PZCF8;3-N*%#2[BI[@H)W.;A<O"^!1='VHU3J77\ P0_IWR"
M>-\*\!S/H7)R;:'/FB? -[7CH9?S.]-$W;7QTWJVR0^FRZ<%HM# Y5T4;:6S
M*)TTW^20H&L5DH>"RRR:5\S_G\X^OKOZ^68<N)X.#%!"U=OO3CZ>7([/S[PM
M.3_[\_B=][$!MZ-:OD1T[UENW)^\8.?5:IQCI)K?>-TZ"EF4-)8VH1'XBH>I
MJ#.V',?[3E @LU375>9I#?3,2H3CI]:969"0\.(WO1"]QF]ZN0:-W_3PM9N^
MF7A9>K3KN.EFO6FY21*NVZ&+[>: <'LPHV@3XO8@Q_G2J7_F-2 4Y;)X#3?I
M&^QB9.7S%DA;^,%42>F!F&[ANR,J;']5_9'2Z9N3PJT<D\X)6GL^>5@LY\M[
MCP^$GJF>6=73X7&-)3 #CM)L86:TAB 7.F$5&[G'J]6C[8>79<^VPW.+A^'&
MH8+R'9)Y1&&X/FYBC1G;O!VB;'&6UY/S;+<1B$;B,=9U-LWA"J(EV,"?T2)[
M].]\SI;Y-6I"827M7[WU%731\![:0XK3[];=.?8M,C.K32AOMK>ZRI(BO;0M
M<$E0>8+N'FV:J6F0[';R;9152\"F:Z@]4-GIZ?8Q6X%V'HW?JSW2F5;><P;<
M_(,:Y'8MX(Q[*U4$P^L;UK0,A,6439&OZI&TG:&TH;">$O8"'A.T[8)'Z3.@
M&H7(2QO/?=:W5F^QCD^JAZ]-02$;/N4(B"<6O#JKP+F%M_L"2_=+E@6-,I+1
M^_6KK)I[#V[,!1Z*KVWJ@Q(![L$D4/)>1.#JA)3TRO;_M%W",<2R.*AUCLGS
M320%Q3^!70%O^#5Z ?&\<O/[;,+K=]UHPUZ_VY=OKAVW0LSOXA:4:^049XO5
MUHPG>>$&?X,N]MGD;]-]HXW^-EV_SF9_6BRKQI*^PD:_0O,OW>37Z7KO#7Z=
M;E^^N;LDB#V$-[(%F- 83_=;0HKY)4/V*'%*23DY^";"#S*V3[NFQ?[A<-#[
M+KK.%V#0I-<@9CFD8B>'HT[P45\SAER <+.)9UKL'G8J'O6\'+W#)#P"O];1
MSEU)&N_*=;[2CEBO]%O(V]^V(6Q=5*E:J5Q@S*MLTL$Y?B;*;B"'VX_7R\Z[
MUFY?BZ*Z8*M-R_;R>JBZME':M[^8&+)'YV"3!Z-P*Z6A2C?[YVW ,^T$D&%N
M"HB[X)Y$Z//E=H/HYTKE^VMN@<7?!?OWYK=9+^&4?FF'T+#^(,AI(%)'UU?G
MR(#<#Y]FFW_)UW-4#1]O_^BMKN?=CQY!UV4PP/ >2R3Z-)\0\O@B8WL@NC^+
MR0P=G*'^SNRB:U1]&P_D @YDF,$$64F8:0390Y 1!+3:*MCJO;RV)COX; &.
MN1<JA%:0\IUND;4IC&U>HLL:8B:RC50OQ[!9"?_EB%LO)@J)4M>9K-'_CDQ,
M^66V\ATJ%W#5@I&"RP.# TD'_XPE$ML_SHK6GJ5(Z^EVX?LZKA_4=4H0VL<@
M0%Q7WYZUB[W'W6DIVMBEA/9MGNMZUYS.,S-@@M>GA:Z8B87>=SYUCB84CS+)
M#IQ/HY!%MU+8$F#YYB]8$76^W20@5U7U$'ZXIO7FXE-5EWNT4#<.0P4Y;7Z-
MX%9/>GL(".:DVV[<#_I8?Q^-/ZLV85@'ZN(XN(:XSFJJ/-YB&!-P="QVL5PC
M4VA'QA)?3;B5+]<3(;Q&.%'Z38',N@,=&:W#S4?0H*FFXWEY]\U[X[H'SB9A
M\*VAGG9-EXU>KQ_!#F),&Q/C)1C+\RFC;Y2Y8C71N>]95Q*<QV!:R)4PO?L0
M:]3?SH,L<<=\6<)4_+_ABU5>S(OP)6ME6ZW@9J19FEMKA]IKW]'_ZW^$TF+,
MU;KFJW5MKE:=Y*3(@H.&,!:'R"@8L=HY',0!,2H0C2T5/'G"SR;M \G )LF*
M^,-^U1>]BB\:;N8>''4#U]O];!+5F+#-0R9('".=[Y:JT1J#]U>)=<=Y,;M?
M2*;W'_/I/0C9ILGJ?AT64J\)WM\#_K^ZX!=+ELHI1BN@YT?[#DAJ_)Q(C1^Y
MLY243,8RB8]B8?77O;NP+L2IF;[ZW6[F@9N9F=T(^E3L)EYA+J^]9&<U"0HO
M6+JZKFH5G'T[$C_-\TO7MW8TWX8PPX5Y]I\[H&^]A*R?9@7<CXK7O:37HVR1
M36?JSIA"KO5+]NP=,&Y,Y]C"=05@5F2]W+>A\59]H^[GKQG,#]DJ6^0%2%B+
M%[R^@Q^3YB=QC0=1-7$TCN(-9AU8K IQ&;#HXMZ,2S(Q=X)-!S1#,#Q=Y9.Y
M8AFSNQG8GD  LUWT4M/O<;7.'Z#0%ZX9 @Q@0BG_#AKJ[UOG6.VM9:I'7E+N
MCR\9!<NP>3>,8L!N$3A89(VG L8-WAGBM)-G^. I6T^-7QF-M&J<L' P9%V9
M-%"+92==[&M[Q!IXL#UK--%QE5* X(T*78S18XZ8 [Q&0@-:V$I1QT;S]>0F
M$IO*'_]1B8>OV<NP0CI#N@"RP$*K3M[M_KWH:#FS>)'2R7(J8B!O 7I%Q6@"
M! 5!:T%BM$-1]A^J:Z><!_*:_2=>P,C<1HJG;/6"1DRJ\*5.%=9)I?L+J>?J
M?=]306FW@0S\)GGZ;M)L7I7PJE-BB^7=YBGC5-T'M5'PAW?E.PF]=Q4)O>!"
MP00)3D3#[(\ ZR U?!+0K@GL.K-XZM2JZQQN9U6?O1T(7*O?Q&9;3/<> JXT
M]TKUF"C\.X\#YF[6ZJJ_GP-&^?H7 Y\N"FD5J=330&72<\.9:DY^?;JV9]IN
MGJ=0-7'GF:,_GD8MU4?M4]T&+:65SQA:J@(9T%P"<< FA XO4<9.:8]FM'Z]
MG"N>J8Z/+V5R!0.&GO>^Y_0BN^CSDN'WH]N*C0]5%S%#:#LN*ORGBK)N!'!?
MS#)!&(^X(O->WI:*7\&7!7F_7/$@Q",5IZY<2/X^.'4(;+U5.T8 +YH[OYB0
M._U*(BT5E_5BZMCV IEI:Q0EG%13;7)B^?;JYE(??]^88-+QJWJSGUG8008-
M&H,Q..]8&N-=:!:^[+#$.DO[A3_4/1C<QRC><;LFG22FF&)=7:%9PU4<KXXR
MA@T84[>2>M#SWNGN:.EV4RN:*+%LMM(V**H[6.WQO<JG^>.*!%DW(Q(1C'>\
M8[^"(J4D(T8,QF>AP[#2A<W:02$^.PGF^>*\H588 D\$,5ZXU2V6_>3<]>7\
M,Z9I4LTQ?9<^<@;][7*]IN)]BLFK+_US)ERLU$+YL;3?#0(NL<JXW&Z4@DG)
MAJ86XHXVP^N\RBR5H&YK1Z/#>-CUX::<75Z;/N3 ^Z>#(L+!@[U>/YOT85*4
MR_)TY5U*168R[5A17<*Q\\9GSZ^6:ZD)#D:)-T'U<?C30=]?#?5Q,O(_#JH)
M>X14G3J*&^RUOU"^MD8^4%M_8 16_E&?,JD!H=KR?+;=/*B[^U_\M.3@XU2)
MK]&C%CWOF$7(!&"F<_.PW!:JG5VWKQV3Y!?S!FL,PLLASM:.]'F.BF^Z4C*=
M*I?56+]I<US$Z3(^I,(Z],0 J1:I<3)=4HZ\SP)LF6 2V(I]W@@&%=K[ZR\'
M%W.MDA"O<ZR)Z"5J\.=_COZZQ=.B,=8V 8KYM# F.V]YFUG6Q)"V=Q[(7LTW
MS=(A*6GBM"36$C"CO+51::U@P(HT](O=S=WF8'$!-8$MDY-P?L;X46=[ETR8
MV3[C#YF)M/S(('G[MO'R!<QKD_CM=F&<5OR/\0:A.59O\P<L"5*[Q="2_0ZN
MH65'4C3_)\4N9G=X7V+JSRE$)8)Q"2J,->CB&++QU,]W^2('X&I0SPL+;J!1
M(S=*/B_FI+CN^6KSX[9'X)=C"*GC\MZ7-L*2%]AKO^E]>54Z%?9"J(L,T6B;
MS;N. 7B][-ET0Z)K3KY*8OF-QO0*!^';#?;$1I.G>S=T3?@BU@Z1Y*/2OY0L
MMUS[:O=N2&D*Y)WX2LYBB> S@58%G3\2=/[%%@L76;?\;MG,.,P :Q]6ST28
M>#T>RS,K#5'F].2=[<IR =1='H+VK]TNDJ,J9:]J6<<;&B&PLJ*+QN''U7SY
MG.<L^!@4/<5E/1UP]I@?P%E#G1(P%\FIPC"ULY#]'<-M:Y[ Q3IXAWJ5KD6Y
M?]@RMG*+K3@(KR>FS"]%(Y<A*)OX.^W6FV"S7F]O,2JJPLB'3*NH:C.LTN\8
M@3._C?8H\!9SK$- H86SB:(#'HBP2Z%RI!IFPL@@>^WN/M>E<7C36:A9"L4[
MEV#7YM!S7?E\4PG Y9P*?],4JR:_(8)E87%!L+T$R?ERUP,G>YRW^M5+ZAT(
M;Z+?,W^JX%+8_P79/,9<K]OSJ6B9_!U)E>WHPC+A,*?]M8(1!M[6W%L"_DZ^
M0$0C:GX ?OUK9,8=YJOMZ+V2Y:")JFYW]&$WL+LS>?<KNK.;V-WA$9;6GG]-
MAW83U1TRYM=+-K;\ZE?O:B61-P\AOD$5DE0$G68BI9RY^+=USNM>UY(E*/W%
M3N;@=H(!.3)]X%=U[]=/O@N3]Z]0]6'U<@;.W*<%W=EM$OM>=$SQR$#AP;PF
MHKQT0,M?_R7V\;@:]5/9HG3X(\[OI8V'WY:V3Y?KNWSV%<U7-E ^1;OV:>>I
M:[1)'ZX_%=$]<T!UGM .IVOG &;9%\Q6F#]'PW:GHQ3->$0_DR[\Q,.5TJ_8
M%IE+=5-T,^N:04KR5UJ1X.+8]^<$L-C6LPPN5SQI5$$&7-:4<XD]@:&S;950
MF#]CF X!'$(?RRB#B!IG3IN'9<%)%%3$G8JG3TE-<%: \PW=5? :5"+C7[<+
MJY0]U%YG:%A^&K,7U:.G^>U::KKW< KE%?<:@W5ZF*TY#U8D<AJZF@>^6DA!
M*"HO >[PC:7Z,,/.YS,"YB$G Z@9H"GQ2Q#QI)[%]OQ*\;6LJ%?)BBK\<SKD
M:JH$BRED[C[/<A]\-U@)1(#[=9#9>E;\<G"WSDON@T"^02##LA/*-Q#HZ+V[
M"#KE.H>#ZI0&%O2HML>"5I\*:SR&(;,:O!C&P_)48^N5ZFSZ"N"N*UD9C11K
MC^?S$LY?T ,87"'U:6")DN"G%6A?:1K:W;07!/?OA1JN)_$^D/A^TKXC<(?O
MX\H&*QZ_OFS,GKO(GR-ZY56Y\&X.2\6:/-8*?>V8PNOR5J^S?\_,]=:EO'IR
M'  Y[E0G*PT?8RNNYO8Y"@P@&L/B[G=&AC"HW6:@6@GU*B2 **ZB%/P9UMC"
M4M407[[KWMR'4$H/[""31?YDDTIPR-F\6%:<S $>3.<M13,PW'=+B/Y5/1S/
ME-JP62H!9;\=&#56B+2E@37]IT6^+AYF*W2@1*V3ZXO+MQ&@2,R7@ )1#_AZ
M;;O&:TI2X<J$OG UI>H&XM$HW$#]LFCONJ$[6)M/0(TO",V$)<)X#^AFER4E
M%)&YSSL2H=FXP_!25%F'?U+<^2Z;S]G)BBHN)\S"(6:*I]-+IZ2M%=C"TV I
M+E;MC^W+7D(NS1O?GVV%:WHV3CM^=,N:3[6M,="\5Z:7/:Y8:I+[Y?P6*F*K
M>Z%9>I1'6=^CJA0 ]SH(#7*%GLG5=@W161CH\_0P ^1/XCU@MV3OL.(1MSFL
M//*C7_%([NC0L!(Z/+5V!8W/K!@:U"?6(3BRB[EMD_($4)W)66JAL)NP8[EJ
MMD<+HR0H4&4R@S> B7$@=P2:]60]4NFBJAHD9L7R?\9+@>Z&F9RK C,?)V'$
M&S<>S,X5"LH$=,_)EA Q0 U2FA6+RM;MW6(QVSN>W[Q?DJ:]?I-P%<:X%_RX
MBABKGT,0& R&%/\7(^TS.<"U@Z9&HU5X^QTNWM@/?US&(8/.G /?B$J#*E.M
M ?,OB5\<"RX[*)!ITHT 9N/Z\EJ&@I*YL-_ N$"JG2#Z#[-(<GN8!OUAI-XP
MM(P1Y"^T7IZ46RX_"5LH\::^CJAVU8  >&UQZ86I%?85\G/$A[V#S?+ "VB[
M>%S,;K<T>C^$QZ@T%W>.H'PD*@WK*0@@O<L/N5=S^VF)>S6]4^)OW%KZNO-.
M7K>YN%%S0L%V?,3^7NAKYQC"T6JPSNP=O<F^O*1:#;_-\6@S[6F%ME@&>^L'
M&JB'%$?PPB$XC=CC,F$TH=,<@/L\Y_/U)E _3,J;5<D/QD%<E2 46*1]L".A
M1#A&?P=64!<.H3 XJ>-"]7ZP $L !\V DQ?!=#<(2H%$+XK'F >J5?RHP?>4
MT+Q\"O$]6IZI78\O#( BI7T#$/3^5IA\K+9;SZ&RMDQ@'!;&0+/-\MW(0"E;
M+*42*CF7!JN9(741@?O&T5Y S C:\D*F/!HN) %S+JV(2.4'6S%*+MYT6B,8
M@/]Q'TR$?N824:/ _)=H)=J"T3-<&Z,50T%1OY\89N5_G!SV Q_'H<7ZD"VV
M=YF4VII6%1I3/0W#$PWUI!B@XG[ $V>@\?N[-@P53PY#H?LO!TJKMCI0N]4?
M7B>X; 8* *@Z6/LP6 LV"=N#NR%Z"Q^(YB[G*R@[#SDK6K@%"<?$,6/P#2E(
M*+G;V8N6+EYNEAU\8%G\0>T\F+$\T4C#KAH5 )HTY=LL[1IU8"<JN;HU3,%S
M&@)[,18.HU=#65#;R4M?)E8##O/5;!T.U;ZN%GFMA3K.)R@@1*FW5.%=WA>1
MP3;8>%W -4:,0XF&Z_6S9/G76=2.O=NC[<6MU[ZCJXKN?J]T3TBQ/LQY7>=0
M_##,NN&RO%TN?S$*5:F-X L<18'5,Z%]*=3H' "A$>_<<Q078MDN%P<L@Q"5
M%]6W#*1O+^&9XUFA[^WHW3/L>\3)*0B\HX0I;0&'WZ^54 '0^J&I&& 5J[:'
MF'*WJH,U2+LNS=>37Y61[M-"5\Q6<]"X,6(-4++T1W7$E>1ZO;U5?'>6A<K
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MD"TTE/'@A9M992ITH>.01S*V)JE7=<7#+C@0DJPB]++J!NK@SJ/)MMBHEGT
M<F9;?\P?EZL',#%Y1$&Y/Q-C&,M,76C?&"56/6WE^@!)+.S2O PJ=I7VF)-
M.+BCDA:$SLMNXI*11-\?O(Z-&A.#RST[KS&:= JYV.#HPTW5MU)ELXQG;-@4
MYA3:YD,R$2%GP^A!,#]3N9$:ACB>+-=3;W]T+GUFS,P!XRJBE6PG$W6OWFWG
M8DD6,6>=WX/38LEU$#S#J[%#O[![=14NM!!#;6ZTQ6:F.JAV[]+3VC(+,L]Z
M=G^O:%WWX]'LDQ+XBH?H8KV"BH:*QM4%O_:E>U>D S UM3$@3]2;CUTIL<H6
MY[YC6^^:O>\0)YFG:=>J2V!#]+MDNMTAHBP""IKD*H;_!$CF\KNCBL092<$"
MG'#!'"1<J#5DQWA$BC*'1R4Z!L<B$TT<F.]2HDA[O4HD:8C1DY+.ENJ@[JJ&
MK='*FUGTV1:]4L>=QQ*@;TS5PV(7-O\'L6[A1V:+]]3E7%"R_3-4(BDJ@L[.
MT9F?1Z>YO[YR"JUGHK%J]<H<;)\WUSBJ*C@('X]H CEXF >U+4B.-4!JC\MI
M%L)^L%KWAN(=8"58*MT*3NXUU6WW!_O^YLA;V(9(A[2E)CC"JMH0").XJKA@
M*C=*[>_C;/L(2A.7;#9^/__&W!3;6\6LE)*6+;);J>4>24GLP$4@-WV(>OR5
M?"RV  PT6Q8SM:O9VI1!]ZBH2M1H1YK +NGF"AH.3.S)#;KG+NYLZ1EP!RIZ
MCKX\SK\O5NK(_C__8<6I'/_A#W'G.YQ;G'QGU&2ULV)H7[K&]$/"?("2A%G;
MY.V31_%9V.(\H[2Z..9\T0#;1FCFQOQ!6JKG_T=+.#R/6/S4BJN[9%\1J?!W
MLSNHNT BO.<$"5IXW5ZTJN1T)PZI_ O40X9NW_0Z5=VPQ9YE-8J"W=Y"UBWX
M<.?/T7@^CXQW5QY_EY,H<XV[= 6./K7]/X&CK]P#QG/GNH(V"-LULT(B@G6J
M7+OWZSP#3] -W/7DQ3G%A63E2' ,;YZ6,!7Y\\*7&[Y)MX%^C*NHPMQ9DC=,
M3!=!OM:*B5;C89MFV1>.U<JJ[UNQIFBY5VQ"5NA(V.]XM#PP1&@B#UGX-?(?
M.D=GF^V7#.TZGZ)KZRA#\SI@P1#XQ"9PKVUM'D-'5;A8[.-L0Y@L$!Z#%C/U
M%_L"N0P'AUM0N%$^H;,32X8Y^\-8&@J(H?OVD2V>]VB=3MH-R\+OL0O^3%;V
M1?1]'JQN_C%_4@+%9G9P=)QTJ@GWE*C)K9(SJ:,#KZ=T&,PQ+_<?INV3\XNC
MF_'-2=7G8#9NJ!R,SR^O+L[/_KS'*Q<3=29F_[)]S&Y](6)J8M?D3@IE+EEM
M[%QFPQBL!2>ZTF@J?',B.$/U\))N:-%+8ZGP/*8AY_SUQ3%D\382R(\_7/YC
MTV>O/WR\^M+TX?,\FVI@7RCP') 9C[7<O>-!.S -4D? < O5!]4^GBVB'S X
MY4?U+6S,N(#[T\@[GJ+B/H[P.TJF OP=LY%N)UX3C0U#)1 )D4A-Q2%,O3>!
MR@P1S47G@@)T,-ZC:D VNI 92@5E=T=00&@?*59ME_EX)]^RMPT^CXZ.#_"+
MAC%"?URJ#_W@^^.<ZC\!*1!^?IG!BMAPO,VCFV5D-&('F>LX>U2+TUP%J:CF
MIRU08#+*&?:&0,Q<# P!5JE ["C%J\#)".KW_G,[HV%V-U'#3;F/9BW7#?Q<
MJ:04>V^BW+QG,/=%Q\_.=J!AN78;D@$PX!W.!$C&2Z@8X,MM2;<"N>8( T6-
M)\8=B@G.JR\.Q;"95$-2E'HT=??W>-8S>-<\.]SCV5'S9_U"8E7/WE06,ZQ\
M(X3,3Z5V.5N$L**WM_AFQ?KM>L%;Q%TO>"NYZP5O.7>\X*]I[0O5"UO_6FAU
MP7?\N =Q[GC>6]L=SWM+N^-Y;V7KG_<7MN[YZG6M?2NTK$H"R<!$M)VC!@(>
MTFD^H2J3>!O,EU@?EURGDFOYH 2F?]ZJRU'=U_"8+KW;5O=U42AE90NY":K3
MIYPK[$[1RBE]_(1VO=+3IJ0D>^WOU*.;AXA[XD*:Z:%ZV[B',\XBAF_?)(/#
M1 P6C-"XR!V 1O A*#$.D#O5K_RJ=L^#'+Q=6X;P<BE=75Y63\K(0[OGI:M<
M"+'+"=#PN*Y03N"H&ZD<#,':\B*+8R\:!GB]U^QO$G  1 Z"6P.C7R@+9&N,
M+YL'&WO-'A$-)ZN48.MOI69WULZZM$[E8T5U;*R0DZ!MTU!BDJ"#/'ZQ?Q.^
M4W?O)CRNLG\3'J/9NPF?]^S31'4EX+U:J;M03:;XQ&XRQ/L$]M4I%UKJV.6+
M+Y.BO@;ZH1.@/:RU@=8R'NS$#*-NA&-_A%4Q U@4/5I;KD1&EB2;&>2,  @&
M)/4LMP6BUQ66\37QA0N3U>G5RVF(:U#.!_-44IT3I/?0\S>9E6J["+J^,:0Z
M&X\5(72W8;FMPE,/KF=?K-2^INF!I\ C7_ :N 7W?ZV<@-CTO8O%2WH[R4#3
M-.ZZI=6*4K7@BGI2V_+\@J;!-/FB(4DBM%OH<?]:8-EG*IP&,,=5$:.AHI(6
M&'*M]B>:A57/;ZPD$7"C!.?@:8$5WJ2J!=#\JCH7_40,]Y;!OK#6(3!]AG$I
MX]?6K5C@%:N_1G._?IH5.[;&M64)YS?N5=6GXB<!$,F!'Z[\:0%Y@#E!><&H
M0X@SH7'79>Q?4CM26Z[\]7L$UMHYQ]ER.IO(F##VP^<(]SC?LP4B%;H6C.9Y
M>E8^GG=4K:,9R%6ROZYM9_SCQ<>3/X<_#3>MOZMM]_+\Y/W5V;&?1<V?A]NV
MOJV?_<_7XW=79Q4?5RR)_K*VZ=/QA\N?_<1T_CC<M/FRMFG+S1%HQ/JV?L?8
M\U'C$0GMFOFV?OJ?/HP5W7RH^KQB <RWM:W7G8L]L"<1%&..#I0POL#)=KU<
M51QO/_2E\.,JKTSH>*8+3AM^B<U3&#P5+"I72>6N_ H!=0L0#AZND6DU"D9!
MS?JSL)(W3B3:](BC37?82>U(U?I<7\I\8,[O,?=^R!OA[:"]O.R$!,NW:OHX
M7SQF:[\>:F@E&]RW!N9ZG8/^CCO&ZP=5\\(K>4)0!$]@ U^5P@VM-7[,_JI$
M"3M9HMQ0&G3EI6GPTR3T:1)<T"28@G5\\O'#^.H?RQ__B4P[\V<+]>4XVV11
MZ],BVTZAXEE5)?I B8:]ZPY?YQQY&QJ'O9_5N_CI1<GGY(8G7\]7K<G>BNCU
MY"&?;N?H>#JV/$0FUHYT2CNF*7P\?U\4FS_\?U!+ 0(4 Q0    ( '"#0TAT
M31(4S (  ,Y&   3              "  0    !;0V]N=&5N=%]4>7!E<UTN
M>&UL4$L! A0#%     @ <(-#2$AU!>[%    *P(   L              ( !
M_0(  %]R96QS+RYR96QS4$L! A0#%     @ <(-#2+H3/<AV P  9DD  !H
M             ( !ZP,  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ <(-#2/G;>&^T!   Z1H  !               ( !F0<  &1O
M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !P@T-(\!N\%#X!  !I P  $0
M            @ %[#   9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !P
M@T-(F5R<(Q &  "<)P  $P              @ 'H#0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( '"#0TA)%98>I (  '\0   -
M  "  2D4  !X;"]S='EL97,N>&UL4$L! A0#%     @ <(-#2'.W*U*,!P
M124   \              ( !^!8  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( '"#0TA@N /8F (  (,)   8              "  ;$>  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !P@T-( Q1D8-P$  "S%@
M&               @ %_(0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ <(-#2+BK=_Q@ P  ?PT  !@              ( !D28  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( '"#0TC[+\W_F@0
M #$6   8              "  2<J  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " !P@T-(T!X\I<L!  #1!   &               @ 'W
M+@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ <(-#2(5R
MPC>B!0  #AP  !@              ( !^#   'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( '"#0TBX<Q.4"0<  /LH   8
M  "  = V  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !P
M@T-(YK\\8J,!  "Q P  &               @ $//@  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ <(-#2$8>X1*E 0  L0,  !@
M         ( !Z#\  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( '"#0TCL-D,4I $  +$#   9              "  <-!  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ <(-#2('_VI2E 0  L0,
M !D              ( !GD,  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " !P@T-(2:QSKZ0!  "O P  &0              @ %Z10
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( '"#0T@3\U!U
MHP$  +$#   9              "  55'  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ <(-#2.<TY<BC 0  L0,  !D
M ( !+TD  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !P
M@T-(%SC7E*4!  "Q P  &0              @ $)2P  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( '"#0TBDQ(DVHP$  +$#   9
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M970R,"YX;6Q02P$"% ,4    " !P@T-()Z#*Q:,!  "Q P  &0
M    @ $H5@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M '"#0T@[(6ZVHP$  +$#   9              "  0)8  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ <(-#2-FQ5D"B 0  L0,  !D
M             ( !W%D  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " !P@T-(HT[9H:$!  "Q P  &0              @ &U6P  >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( '"#0TA[N1<:I $
M +$#   9              "  8U=  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ <(-#2+& 1XF? 0  L0,  !D              ( !
M:%\  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !P@T-(
M%3JJ,J,!  "Q P  &0              @ $^80  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( '"#0TBJ#>#LHP$  +$#   9
M      "  1AC  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ <(-#2,;AEBFC 0  L0,  !D              ( !\F0  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !P@T-(9K"MIZ(!  "Q P
M&0              @ ',9@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( '"#0TC<WJSII $  +$#   9              "  :5H  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ <(-#2+:L2G2D
M 0  L0,  !D              ( !@&H  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " !P@T-(L5-TK@T#   Q#@  &0
M@ %;;   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( '"#
M0TB$\4@EI0$  +$#   9              "  9]O  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ <(-#2 YA!1*P 0  %@0  !D
M         ( !>W$  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    " !P@T-(0]99\J@!  "Q P  &0              @ %B<P  >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( '"#0TA@,RR6L0$  !8$
M   9              "  4%U  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L! A0#%     @ <(-#2&]MZQ"F 0  L0,  !D              ( !*7<
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !P@T-(2USF
M:\$!  ![!   &0              @ $&>0  >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+ 0(4 Q0    ( '"#0TBMQ.C)PP$  'L$   9
M  "  ?YZ  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
M<(-#2&/+4N#. 0  X 0  !D              ( !^'P  'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    " !P@T-(?D$TCK\!  ![!   &0
M            @ ']?@  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( '"#0TB 2Y*%M0$  !8$   9              "  ?.   !X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ <(-#2)GMCX&T 0
M%@0  !D              ( !WX(  'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    " !P@T-(*&Z+<J8!  "Q P  &0              @ '*
MA   >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( '"#0T@'
M/(F;L@$  !8$   9              "  :>&  !X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ <(-#2+8;4L:G 0  L0,  !D
M     ( !D(@  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '"#0T@L8R)KLP$  !8$   9              "
M ?&2  !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ <(-#
M2+H=0VFR 0  %@0  !D              ( !VY0  'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6Q02P$"% ,4    " !P@T-(&4+A1Z<!  "Q P  &0
M        @ '$E@  >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0
M   ( '"#0TCRC1(CTP,  *,3   9              "  :*8  !X;"]W;W)K
M<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ <(-#2' \MA0C @  <08
M !D              ( !K)P  'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q0
M2P$"% ,4    " !P@T-(1X8S6S\"  !^!P  &0              @ $&GP
M>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( '"#0TC+ =&$
M'P0  .@3   9              "  7RA  !X;"]W;W)K<VAE971S+W-H965T
M-3@N>&UL4$L! A0#%     @ <(-#2-R8CT'Z @  *PP  !D
M ( !TJ4  'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " !P
M@T-(1:3R7J4"  #Q"0  &0              @ $#J0  >&PO=V]R:W-H965T
M<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( '"#0TA'%$H9E 0  *D6   9
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M970V-2YX;6Q02P$"% ,4    " !P@T-(EO[_Q[@"  "F"0  &0
M    @ &PO0  >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    (
M '"#0TCW+%6LH@4  +DE   9              "  9_   !X;"]W;W)K<VAE
M971S+W-H965T-C<N>&UL4$L! A0#%     @ <(-#2$@Q)]"0 @  ( H  !D
M             ( !>,8  'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"
M% ,4    " !P@T-(,W9K/'0"   W"   &0              @ $_R0  >&PO
M=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( '"#0TC.#1WI&P4
M &L<   9              "  >K+  !X;"]W;W)K<VAE971S+W-H965T-S N
M>&UL4$L! A0#%     @ <(-#2"(985A- @  !P@  !D              ( !
M/-$  'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " !P@T-(
MX4FPS'8$  "9&   &0              @ ' TP  >&PO=V]R:W-H965T<R]S
M:&5E=#<R+GAM;%!+ 0(4 Q0    ( '"#0TCJ#'\K3 (  )L'   9
M      "  6W8  !X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%
M  @ <(-#2'LZNZ<? @  '08  !D              ( !\-H  'AL+W=O<FMS
M:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " !P@T-(/QM4#>4!   O!0
M&0              @ %&W0  >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+
M 0(4 Q0    ( '"#0TC/)$X*J@$  / #   9              "  6+?  !X
M;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ <(-#2)5)"-^.
M P  G1$  !D              ( !0^$  'AL+W=O<FMS:&5E=',O<VAE970W
M-RYX;6Q02P$"% ,4    " !P@T-(C$ZM,!8"   O!@  &0
M@ $(Y0  >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( '"#
M0TB#U8XV;0,  &(/   9              "  57G  !X;"]W;W)K<VAE971S
M+W-H965T-SDN>&UL4$L! A0#%     @ <(-#2([OF/.- @  R0@  !D
M         ( !^>H  'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"% ,4
M    " !P@T-(6?1I2A8"  !Z!@  &0              @ &][0  >&PO=V]R
M:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( '"#0TA!AL:L1@,  -\-
M   9              "  0KP  !X;"]W;W)K<VAE971S+W-H965T.#(N>&UL
M4$L! A0#%     @ <(-#2&KHF-$F P  NPT  !D              ( !A_,
M 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q02P$"% ,4    " !P@T-(%1E?
MF^X!  "A!0  &0              @ 'D]@  >&PO=V]R:W-H965T<R]S:&5E
M=#@T+GAM;%!+ 0(4 Q0    ( '"#0TBFOZV5/@4  /X=   9
M  "  0GY  !X;"]W;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @
M<(-#2%#&%2_0 0  RP0  !D              ( !?OX  'AL+W=O<FMS:&5E
M=',O<VAE970X-BYX;6Q02P$"% ,4    " !P@T-(7=*2XKD"  !9"@  &0
M            @ &%  $ >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4
M Q0    ( '"#0TB+PDQ(G 0  -D7   9              "  74# 0!X;"]W
M;W)K<VAE971S+W-H965T.#@N>&UL4$L! A0#%     @ <(-#2 MI%XT.!
M 1(  !D              ( !2 @! 'AL+W=O<FMS:&5E=',O<VAE970X.2YX
M;6Q02P$"% ,4    " !P@T-(\[84@.<#  !T$@  &0              @ &-
M# $ >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;%!+ 0(4 Q0    ( '"#0TCJ
MY#:Z(0,  *$,   9              "  :L0 0!X;"]W;W)K<VAE971S+W-H
M965T.3$N>&UL4$L! A0#%     @ <(-#2%AG%J=2 P  0PX  !D
M     ( ! Q0! 'AL+W=O<FMS:&5E=',O<VAE970Y,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '"#0TA'C1PZ, (  +8&   9              "
M 8$B 0!X;"]W;W)K<VAE971S+W-H965T.3<N>&UL4$L! A0#%     @ <(-#
M2#'3<G@N @  LP8  !D              ( !Z"0! 'AL+W=O<FMS:&5E=',O
M<VAE970Y."YX;6Q02P$"% ,4    " !P@T-((EB .]\"  !C"@  &0
M        @ %-)P$ >&PO=V]R:W-H965T<R]S:&5E=#DY+GAM;%!+ 0(4 Q0
M   ( '"#0TB*2EA$5@(  +8'   :              "  6,J 0!X;"]W;W)K
M<VAE971S+W-H965T,3 P+GAM;%!+ 0(4 Q0    ( '"#0TA,&D\53 8    E
M   :              "  ?$L 0!X;"]W;W)K<VAE971S+W-H965T,3 Q+GAM
M;%!+ 0(4 Q0    ( '"#0TC?NJ[[3P,  #4-   :              "  74S
M 0!X;"]W;W)K<VAE971S+W-H965T,3 R+GAM;%!+ 0(4 Q0    ( '"#0TCY
M'TE-F@(  #H)   :              "  ?PV 0!X;"]W;W)K<VAE971S+W-H
M965T,3 S+GAM;%!+ 0(4 Q0    ( '"#0TC)\TAKD0(  %(*   :
M      "  <XY 0!X;"]W;W)K<VAE971S+W-H965T,3 T+GAM;%!+ 0(4 Q0
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M965T,3 X+GAM;%!+ 0(4 Q0    ( '"#0T@ <3Q)]@(  )D+   :
M      "  1)- 0!X;"]W;W)K<VAE971S+W-H965T,3 Y+GAM;%!+ 0(4 Q0
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M965T,3$S+GAM;%!+ 0(4 Q0    ( '"#0TA-1K!88 X  +9@   :
M      "  39= 0!X;"]W;W)K<VAE971S+W-H965T,3$T+GAM;%!+ 0(4 Q0
M   ( '"#0TBF<[$ELP$  /P#   :              "  <YK 0!X;"]W;W)K
M<VAE971S+W-H965T,3$U+GAM;%!+ 0(4 Q0    ( '"#0T@Z:+AX. ,  -,-
M   :              "  ;EM 0!X;"]W;W)K<VAE971S+W-H965T,3$V+GAM
M;%!+ 0(4 Q0    ( '"#0TA\#@5[!P(  &P&   :              "  2EQ
M 0!X;"]W;W)K<VAE971S+W-H965T,3$W+GAM;%!+ 0(4 Q0    ( '"#0TB[
M8&%)"04  *L;   :              "  6AS 0!X;"]W;W)K<VAE971S+W-H
M965T,3$X+GAM;%!+ 0(4 Q0    ( '"#0TC$)GKZ\0(  *L+   :
M      "  :EX 0!X;"]W;W)K<VAE971S+W-H965T,3$Y+GAM;%!+ 0(4 Q0
M   ( '"#0TBZ-'D>V@8  "\I   :              "  =)[ 0!X;"]W;W)K
M<VAE971S+W-H965T,3(P+GAM;%!+ 0(4 Q0    ( '"#0TB4;P86%08  ) @
M   :              "  >2" 0!X;"]W;W)K<VAE971S+W-H965T,3(Q+GAM
M;%!+ 0(4 Q0    ( '"#0T@ZVC4VI0(  -4)   :              "  3&)
M 0!X;"]W;W)K<VAE971S+W-H965T,3(R+GAM;%!+ 0(4 Q0    ( '"#0T@M
M[%".M 4  ! <   :              "  0Z, 0!X;"]W;W)K<VAE971S+W-H
M965T,3(S+GAM;%!+ 0(4 Q0    ( '"#0TB!2Z1-MP,  #$0   :
M      "  ?J1 0!X;"]W;W)K<VAE971S+W-H965T,3(T+GAM;%!+ 0(4 Q0
M   ( '"#0TB-M%#-'ED! %Y9!0 4              "  >F5 0!X;"]S:&%R
C9613=')I;F=S+GAM;%!+!08     A0"% *XD   Y[P(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.1.900</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>680</ContextCount>
  <ElementCount>629</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>198</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Restructuring Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuring</Role>
      <ShortName>Restructuring Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Revenue Reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenueReserves</Role>
      <ShortName>Revenue Reserves</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Indebtedness</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Indebtedness</Role>
      <ShortName>Indebtedness</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Accumulated Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2121100 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2123100 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2124100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Guarantees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Guarantees</Role>
      <ShortName>Guarantees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2126100 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2127100 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited</Role>
      <ShortName>Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2301302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2302301 - Disclosure - Acquisitions Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables</Role>
      <ShortName>Acquisitions Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Restructuring Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuringTables</Role>
      <ShortName>Restructuring Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringRestructuring</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Revenue Reserves (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenueReservesTables</Role>
      <ShortName>Revenue Reserves (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenueReserves</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Indebtedness (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessTables</Role>
      <ShortName>Indebtedness (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Indebtedness</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Equity</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2317301 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShare</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2320301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2324301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2327301 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformation</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2328301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2401403 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Acquisitions Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails</Role>
      <ShortName>Acquisitions Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Acquisitions Acquisitions (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsAcquisitionsDetails1</Role>
      <ShortName>Acquisitions Acquisitions (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Acquisitions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsDetailsTextual</Role>
      <ShortName>Acquisitions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AcquisitionsAcquisitionsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Restructuring Restructuring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuringDetails</Role>
      <ShortName>Restructuring Restructuring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringRestructuringTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Restructuring Restructuring (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual</Role>
      <ShortName>Restructuring Restructuring (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringRestructuringTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Revenue Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenueReservesDetails</Role>
      <ShortName>Revenue Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenueReservesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Revenue Reserves (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenueReservesDetails1</Role>
      <ShortName>Revenue Reserves (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenueReservesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Inventory (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetailsTextual</Role>
      <ShortName>Inventory (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Financial Instruments (Details Textual 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1</Role>
      <ShortName>Financial Instruments (Details Textual 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Derivative Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails1</Role>
      <ShortName>Derivative Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Derivative Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual</Role>
      <ShortName>Derivative Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2413403 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails1</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2413404 - Disclosure - Property, Plant and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual</Role>
      <ShortName>Property, Plant and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Indebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails</Role>
      <ShortName>Indebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IndebtednessTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Indebtedness (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails1</Role>
      <ShortName>Indebtedness (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IndebtednessTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2414404 - Disclosure - Indebtedness (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetailsTextual</Role>
      <ShortName>Indebtedness (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IndebtednessTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2415403 - Disclosure - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityDetailsTextual</Role>
      <ShortName>Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2416403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2417402 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShareTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2418403 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2418404 - Disclosure - Share-Based Payments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails2</Role>
      <ShortName>Share-Based Payments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2418405 - Disclosure - Share-Based Payments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails3</Role>
      <ShortName>Share-Based Payments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2418406 - Disclosure - Share-Based Payments (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails4</Role>
      <ShortName>Share-Based Payments (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Share-Based Payments (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails5</Role>
      <ShortName>Share-Based Payments (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Share-Based Payments (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails6</Role>
      <ShortName>Share-Based Payments (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Share-based Payments Share-Based Payments (Details 7)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetails7</Role>
      <ShortName>Share-based Payments Share-Based Payments (Details 7)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Share-Based Payments (Details 8)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails8</Role>
      <ShortName>Share-Based Payments (Details 8)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>2418411 - Disclosure - Share-Based Payments (Details 9)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails9</Role>
      <ShortName>Share-Based Payments (Details 9)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>2418412 - Disclosure - Share-Based Payments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual</Role>
      <ShortName>Share-Based Payments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>2419404 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>104</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>2419405 - Disclosure - Income Taxes (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails3</Role>
      <ShortName>Income Taxes (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>105</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>2419406 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>106</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>2420402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>107</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>2420403 - Disclosure - Other Consolidated Financial Statement Detail (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>108</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>2421401 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</ParentRole>
      <Position>109</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Collaborative and Other Relationships (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails</Role>
      <ShortName>Collaborative and Other Relationships (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</ParentRole>
      <Position>110</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>2422403 - Disclosure - Collaborative and Other Relationships (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails1</Role>
      <ShortName>Collaborative and Other Relationships (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</ParentRole>
      <Position>111</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>2422404 - Disclosure - Collaborative and Other Relationships (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetails2</Role>
      <ShortName>Collaborative and Other Relationships (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</ParentRole>
      <Position>112</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>2422405 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsDetails3</Role>
      <ShortName>Collaborative and Other Relationships Collaborative and Other Relationships (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>2422406 - Disclosure - Collaborative and Other Relationships (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual</Role>
      <ShortName>Collaborative and Other Relationships (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</ParentRole>
      <Position>114</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>2423401 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>115</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>2424402 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>116</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>2424403 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>2424404 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>118</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>2426401 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>119</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>2427402 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformationTables</ParentRole>
      <Position>120</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>2427403 - Disclosure - Segment Information (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationDetails1</Role>
      <ShortName>Segment Information (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformationTables</ParentRole>
      <Position>121</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>2427404 - Disclosure - Segment Information (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationDetailsTextual</Role>
      <ShortName>Segment Information (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformationTables</ParentRole>
      <Position>122</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>2428402 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>123</Position>
    </Report>
    <Report instance="biib-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>2428403 - Disclosure - Quarterly Financial Data (Unaudited) (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>124</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>biib-20151231.xml</File>
    <File>biib-20151231.xsd</File>
    <File>biib-20151231_cal.xml</File>
    <File>biib-20151231_def.xml</File>
    <File>biib-20151231_lab.xml</File>
    <File>biib-20151231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>189
<FILENAME>0000875045-16-000042-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-16-000042-xbrl.zip
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M^\'@/L;).(@&(C.\K=8!BU?+B>K1UAMJZR^Q]:UP!&4YUYV83$9BV"D(9![
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MOYPW+[5KF$KPO3W#5)J0OZH!X[(!+*OL[I$OV8BCLKZBOPGG8DH6FI*U:_E
MK9:FZ-0PKL;; B4%%[0%2A8:8@N41W016Z!\H0O'P;W0_LV)@WNJ[]%G\KE6
M9?W5?=/!6*,X_NK^3%N-WB.MQE:C4PU.RI04FXZGHV 2?A69I'V0D\]7QO\%
M@V<Z'&83,(/1=23<<#2"/W]YN8_OOP'AK_,7-E38SOF@?#J&#0B2,7W:^-CV
M3/&]&#P"()*6#)[,]-DVUN:S".OQ]DCJ;O=HT\+6'.E7=^3,-W;V+%GSD]Q<
MJ:_<]])W_"NTK9W1'/FVEQH*G,/K#TI%'ZBB"]Q32KC!2GA6%K0V&U?-*3_S
MG/+-LJ$Z@VC)L0?1UM"32_=+J<G::G*3>4I+-E=+2B6IK9?2*25Y226IU4O\
M:!?,!MR%WY4O>:B2W&2>4I+-59)Y]O]SGOU763*5)>N'5&T<2M3*5)_\$$Z9
M)V6>6BI(E[\NN**3=_^<"!4+'RQ'1?8I26JNHP<&1C-K1,,%-C<=LB= S_'4
MHF;64HOP^.74(H^GB?(N#CY(V>2>4HK-58IE_=6>> 1&#UT1P1\F-Z,@2KTP
M'8SB=)J(M.3=%;?\6YBF+Z.VM?D=1''N3*^3?+[CEHMV:6]>R/8&S/PJDG$0
MW?0*-)LTMU=WZ$?3'0H'O6GY/Z[14<#IC=DI&0^O@-,&X#0A*4:.XZ_ FR))
MQ)#%XQ?8F4 &(OW"T&X.G,67.<D@DR,YM H@#0#(2<J^CP00%26W%P)',B(*
M NTT$\=U0.^"KV'TE/;+.!2([HD+>MQLB5(@*E>B-$ZS-4ZWLB5*XRA#I31.
MLS7.I8W5$2,DE9SM4(RTO0#FYH/_Z^V5]\=&Q<QBAD=>]7$W(S-=FTGRY:XM
MJ-A11K+.@2.5K>SD7]5+0KMMTW849;VFP4,2MDOO["I46J6G)Y:H)&SJ3!5>
MDVK3&A?P5-YT_N4C]?S;C[4LSVP^G$@GUX^_Q\#1S@!FG1OGL4*SZ7&;S%18
MW><E=0!NU9V>CFUY9<>8_G;]R?]G?]WB5?J54WRNN[5VX/'#S>WUAZM_SI_H
MC"8JI:M'"NE0)[F/.JF&5]UBM=0J5"HSV7DSV00\;KAM70-8T[:\59[108F$
M]F&D8<F#7JJARBEL_\,UNZ?W?F?<]'6"5!+[*)Y09[.9Y_>*5"[SH-.U/EK+
MRL=QREB>)]7*Z<>;/VYI9[3?&CT]\MBK;_B:O]J%':_L@'=LRRL[Q*5IWCY:
MG]KY[A9;H2;X[Y41JJQ0-S;\Q <JG8W9+G*XTONP[;2%NIT%ZR6*=B^*U58Y
M>PJKO<9J$[R RGIU/;'==ZQ63_-W!*M-T*O53SI77?H^!L^58YH6!\VM\DI5
MJTXG55#75(J2\:,U/_3=0^J=-]\JK!YRN-U9J%[@H+OW2*WN.:GL<[^SSTUP
M^TZ,UO8YBDU#:"\KOZL7%:B2R[Z67+8XQ]P!L%VD&KP)JJER(**VO'<>_4$G
M29URD2YQ>J0\)'6ZV61\]MY+.JB!J@-@J^J0=\Q<'C;EK^^:J6^IVB8HI@-+
M+SN MHM,_VJ5WZ0J;7I0:=,$)726!JK.FLT+-E/UWGP>F KKHS+M15ZD5<&'
MPF0O,-D$/5D](%9G[/TX8V\"*D]KO3OK</8N@]P$JW[0S.X.@.T"&>0F)&D.
MFQO4=\UT@82-*I]49QWJK*,52#TT".D"W"YR%5.K?'PUG.OR^>1>YNM.VX/8
M*6CVXIK*)F#RP"DWO8)87PVE&ES:%2FO-?"@W:%8DV.C)D"AUMTR"@I=#I,/
MG&#="^PT[/Z9WF/UQ.?*G05K_R8--,'%/FE;0*<"_3Y<3]($1!XZ^Z(+$+M(
M2KP)1O.D)W9*#;5,#34!D0<-.^D OBY0W-(JJZ/N>U?RKF[6[O;-VDU02-5;
M(M791T>V_&TVJ)>ZJ$=U(:TRDJH$N,<EP$W0I8?=W=$GL'7LM/BTEV!URFKV
MHF2M"4KH;4,D.H"T2R85F@" P^Y'Z,#&7^*^GE99H8,*53IEA2Y1G-)+*W10
MFV[?8[:>C6UO8'*A:ZI0J:8+93R[JZ-Z.F6M"<KJI'?#=A:Q?<N$-C DZ3+R
MF@R%)IC;TT:G[<9.PR+5WF/U+$,2.@O9OKJ&33"X)YV3U;ZXMUGN8"_+-D[;
M/MDM2/8A*]T$3&X+2WX5\5,2O#R'@V"T!.:<8:MO_IK$TY?T^I%EW M%FKUP
M/7D62;O,^%;2YY \A/:>.(I7,^56 47Y$_XTB5]$9P"2/[)*UNGV/HQ@A^%3
M19V0O_.VK21J*R^PE>386[EKCHO:S<['0%<SZZ[V_NR2K)]"DBL[:GD<X/D=
MV,/<)_?\GKA2!REMFH8MZ[ZO(+9+HGJBL&M)N=+9793\;;/65#3>HFC\TFF=
MZB%<^U*&%5R%4Z;O3AFN54^B*.%OE/"?.AU3+XA3OF#; SBUDUURZZI+L K<
M&R:QE;UQ%8QUT8>NYHPI'[I![E(MJ54[UR\)57:U(1):.;^M MU&!;J-RY;7
M=M!42-4%U7^0E5?:OZU;7=E<*(>NS0J]?A&ATN9M=_"4<FZSQ!Y4EJ24\R%;
MW80L=KTS9272]97Q2<Z4JVV;"K4;%6J?&A3U3J24SJZ_;4<_D:K?F:'\XU9+
MGU+)357)IZP/R7;]8_"?./'"%$A\F$[B9(F'E1>OHY8<-6>;64;2?)_+:.J)
M7[V2RE0;WZ<<]@%E0?]H^G;7":C^T5Y%75M>[[_%G9/7!4T]DM>:Y09*7FO+
MZP7;V=6V-2A(6CE$4&JV;U4=M3=>^</=V/C:$;"2^&Y$P.0S_GSOG6T3WR C
MI):,:.9[73LVJU!+6%5/G6CZ*>Q(.UB%M$MKWAFJ%E[R_>N+N'ZD21)$3YF'
MN=2^?I@&+;L?J92:N>)=(:>IAO8$DF&T0]\:]?2M<0I]:WS66\(JJQZKG!.P
MJA6FJ78FZ>T".(W"&9^BZ:;B'(L@G2;BE_E7P1_S;\G?67ZO_)J2+TV?@T2D
MV[]T]G[MKYVFPQN1W,D/KW[W,/P*^[#*+/F)3].Q2 )P7U>4\_*WPC0F&%D_
M?[GSBLOX7VL+6?^BE5_P1!2/PVCK;^RF=?U'-KXK?VM!VG[.E'%[)Y5[OO)F
M%$1EWSF[*!3>K/V-5]$@R:S=UJ]=/%'[NP?/C[L8P/[.:W^E_^5VUU?"V_7E
M8F:LM](_?[_V]_[C]O==2X6W]W_E;#K\8)!,Q=#__@(NBTBO(SZ-AF'TQ.+Q
M.)S(M=V*$2B;X7W,1F$DTWNW(A5!,GA^-]<QM^)QF9S^X=U0#,)Q,$K_ZX?W
MQ@\SS1P,)N]=&SF:;9N<VC[B"+2U172;8@?IFLD]]L,[N:[LNS)L8T/+_OG;
M3V]=YY+6X3"<@%L6C#Z&(Y%.XDC<!*_RLT52\&=<84BV]_'F'S,7K8K?>I6&
MZ0THAW$P$-.)7&(Z]V*W,<W7-4)L9AJ<^P[V"'8T-F<:8;Z&-IEF..M,VTKP
M03Q936)OY\G=QT^WWT_)%*1S@Q/7P)JA<PO;V*8H9XIN<7.3*4C33LD5HQ)7
MW#!.PW$X"I)T@S=WX(,,IR/@C__7%+R(CV+R' ^OHJ_PN_(7BZ\*\2D8KW(\
M&*?3Z&GY$_0I$1F;]W#2(=2T#4WG&K%-Y#"-$6W&2>2YON_LD\E+,/+D(N=3
MCG3/-#%WF&T2"V/?T5V=8NY;IF5L\H3@R[,D3 ?Q5Y&\OB3R$&:\B; =_*&_
MWK,]#+&P8^N:06W#U@SDVIK.<L6M,XQY40?-87))EGP0P? DW+"!/ ]4K\DT
MW0"]XUF,SD7&9P;1"O"P&L"-DZMDC5#&$-=<QP CA2W;-C (#3%\!";)+"@2
M!Y]+D5Q2NVH.LC1.D&=QS'7+,2C/[12Q77>3*=;9M&M]$;!7[:]F^:Y' .^N
M:W%N:M2S9W1AC7FLH!#0&0UPQ:SA-M)TB[K,LAR;VICIQ -$>W/I=JB'"T[J
M@K++DE9?8%V; 3J1X1,"Y!K8](@S)Y2YAE/<PR:0^3&<I-.','T.[X,H>! S
MDEF<O,00KL-O[2&:&](_Y-3A!N(^@)4:=DXTX:9>T-TV:0#5=_!2,(Y!_]P-
M0A$-Q+Z]=:AM8P,;!/[K$-<Q=7WAU?E,IYMDZF_!\#A_Y&7V2/H(VS$S1(,
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M,89P#B*=@]@52@]KK7(L&^*R)^:]<=<0U-U,D\$SZ(";K"VX0KZ0:;;/B6Z
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M.#+M(RYNSZ19)!M5P<1I##BE&]0BBRL]D&>PPO%EA55!;)B-QANR($E>Y;B
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MTZFP]O4555Q_/$WJK]]D).L@(-BCK@72ZKJY;K(M%Q6QLMY!4FE%U=9_'1W
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MY1 ;:FD,NP0SB#P\FA^\.QB1@D;4"6JCZ)X[HI9'IL0Q/1>91-<,;A%MD:W
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M\=<TNU2O]/M6GI3#8*:)O&9F7^N(C[@AAS&:<JZFSHGOS=T'Y,B1^EO',1S
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MR@9F9-:1RF@:@FN[1^]"*IID/31Q4FEL**T1:0@08:UG.6D@#"70A8=]2Y^
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M/N;R#;/:9;1$Z4+ T-4&HT,I=R@1E^!D%B3&%7M6$MO#$5T6$VHL+1U-@KI
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M<PBG7LEWGYY=0[7%#>$V2BL9>%%7 &3G&>M"!RB&;M@D4"4;J-F9Z '5M<&
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MJ^60#Q6B1%^LC4QQC )DS1,:/ L&!10 5/?TC0W2M#<+&\.95%A=&V%*\D5
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MVB9=2%%'8,+$4%BTS#JM6V.MC"#IMLOU1&@,:6V)T6H1^^SZ#L.ZOA!]7%3
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M9 29Y3LE)[]^>#[P"!),]:,!+68PMC#3W&E5.M)8Y*PD31PGX*1]A;^>38:
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ME9R+WL>4#4\R)40(3<V;SN^KV//>4\Y_]MI'6V1(N&.2%Y,A!7DBA28WP/O
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MF@IIX$%G6IRY.:?0L"1SJ5F*Q)HMI)(9M'5SJI75?.1##[4+8UNR>5 J\!A
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M"[4XFXB\8%&7%3LN"-'N"&?:U+T(CY3"*\ZNA[%4IKE(6A0EH#[R;+1M]DJ
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M(_!L.$5#48<DG28'(=K,)XLZP^6'==^;LR)HE"N9CE)D4)ER" WD"H6*6&=
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MGR$D"(;2=93,6:5\:EV^SU[<$RMORVPMX,5A\'\3R>%-_BO,LK ^E(6O7/#
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M&7X83B97_>++I@@+CAHW2:? @XR,M=MD!$4NI@M!:@\DO9L,!].+R;>5*(H
MP:&4P1LOHQ8<FTJK$EQV4<1U9Q5G;<+$%F502PQ,1B&S*"NVA/$M_AU2'M.U
M7 NP>\'Y#NA:2P93)@LD#%,V.Z)%:>V:HAM:[;M6M^R!I'5DT(O$LHC&>4F1
M5I0NN,:THM8Z=8(5;D8&Y19E$(7S+JG(295 ,VMYO+*#H,L,4:<,ZLY9R1W0
MM98,YLR)+(K:(E/*\DSJ=O4*#KZD=]N0P?5)6D<&$]>9_)8UVF*Q@$1-4X,M
MB]^QL]*A-G)7N$49-$240F>2M&5I9$HB-3+H0[2==E#RS?CB]>E:2P:-3R)G
M\KM*@X^4Z[89&ABO;)?5V -)Z\B@#3Q[RN*C=1JC)6'$J\$;<$B_?9P,E@-<
M_G6\F%#P>!F47WYY^OSE[/S;<#C_HC<7DY-/%)26?8K3I1TUY:M^&7R^T5#@
MN+68?GWS9BE(K2=K'TUV3EE6OBFTKW"9S$H7$B3(.UOA'D;55A@C-\88@4[Z
MG&(*.LR[!31K(FA*ESL%@1MVL(Q9]OQEE;,2  L<*Z!(V?D&FB,)UU5$K9]C
M#X[<3<@!\$SING:8B%C,T9FV"SS)V"D'UAPQ7\H7K<(7HR0*IEE23G.)E&NF
MIKR1G,A=&:;>+5_F_WBGA-?QBG?'EF[:^T>C GI%&0.% !*BRKQ)[C0&UY4J
M\"H'6IO,33-);I=)CC)Y%Q$#,48#RYS[!J3119ZZS(\Y.!XM>PYF%A"L"JPD
M)0@R)=^\=PHG.FLRG,N#)')[VI(I+2MX'$)@U-R9\J1W%8X [TQJJN!K>SRZ
M%4B^'8XZ(M0=6!3C6(J!TG+4BCO'64[-Y(N&$+OD:"UEZ:1RTSS:LD%1-I/5
MC<EYDX620HJV]8+^JG/9L3@X'FU9UP0B4RHZBG,-$SYJT+G5-6N[&@MVPJ-Y
M!\:]_G^SR=!MH<DY$RL2_6_TFC,E>8O;1,%.A:HE3%4 >PA%6V#)8]*@V_:8
MC#%H2H8=I<40P"7=PB-Y8E357:@J3+@#8<EC,H*[+.&D+;:4;E0V2/:EF7Z@
MK E=)25LQ7#N %ER?S)PIY67LD;-YF-I@46P%.&T@&?TQPKPS*YH2#;#DK42
M@07UUB"X-PZML4$"_5^+@:.,#I4JF+H\ONX9MT+@FO[$G9Z.R@</SMX,1J>O
MQF'P930;G"TK3E,2:)FP.EA3-J1GR@F;YP07:X#")\*L=1YHN>4L"%&VKPAE
M PM-,F"""N8N@XZ=,V\H(AC/RC\.QM^6\(9KCB$S1VQ)"-&XX!H+BYRY=/C"
MLZ1G7[M(%A-4J9=;9>C7T$3PWDK/*WLIV3H&<W<4[L:6F(R@$8* 9, D&]K'
M5L]15>+P5+BUQDM[4-)9@8SROZR52\XTH(@\&5=9VV/GS#K&1 3&B"=)1>^5
MSE;)U!A:GR#4L,:')SU+:O?):R4*>IGS!7-6(+2PVA:8BA6%@-4#]T%0N!-K
MXAE*IRU'#\IG]$[9IIYOC-;5U,%3X=8:=0'-@;CBN4?G8I#2ZX9#VM@:IOW8
M.;..-:&PWQ5/I#(WTJ/(0EXUGTG0/E9PP;N4GK6JD_>7XJ/)U@8.B:-3V9>M
M%LWMQV"J>4*EU@F^'E43VF;Y]8&A28AHZ'^RT$A&-Z -#1)%#LE7M8 GPJS5
M;4ER.=GRZF52FN/ZIK:M3(&)E;4]=LZL8TM\J4@GCXE++A$DMZ:IFB %1A5O
M#D]XEJ0YP8((D!30U3OK(K-!MVF.456:@[):S7(0!.[$E+! _Z=M--Y2WJN8
M4&U9T7EF*J_[1)BUNBF!5%XE5,Q1EU;I:+!!O1(>/5:.Z=@YLXXIT673NW4,
M(<K,+ !YI?;]W+JJFG1XPK,DQW$%Z)]#5AZ8I?!$4F1R%7=1L!H[3,F*W4D[
M)G GIB3)F TW@@D,#!@X2GN;KDRF0KT2ZVDP:XVH1'M%$N1<-II)J8OW;3)F
MW;&@Y=@YLU940F&92=XHBF U*$G.NUTMA&XWPO-V^*5YYIF<?YP,/KN+V:?S
MR>C_#$_=Y_.+\8QWM07#+9K,3=?AK.#1RJ IZ*3<%J1K1H92I$2GWA'7_'>'
MJN4'6T[+'=R>]@/>G?OA]1=W-#[S_^0+9FV2-DERSG4!!E/6MD/PY#9%Y[S7
MBB2N>-XM$KX(1,(FRBF &0 154X830OGE5":KN9ZWEG?VP+=IVY\^G8X&TVZ
MNB-V;O04.B&L%SP+G[A+UMMF',OPI+M65W+5V3BT(H5[YLQ:TT^6A^0D2RE8
M1^SQ/+&V* B\"^MLP[SY='YV.IQ,+RE:BN5P6_>59#%B]J3^+G@GDF_@8)'^
MJX"T.#,="\>J0ZQ[Q$5:RC50B&Y9-G1 D4S,+98<MT)693,K-'2R=XT3OAJ?
MG%V4R=TWYY/YU.]L-AF]OY@5D+1WY[^<CPL%D_.SLTOTESET8>?DYX)BH"7_
M8;20*H!R+@ILC*X2,E7/+JK@VRREZB'GWA$GUHU>3TXN/E^<T9>>SM<IE2^;
M##\-Q]/1UR$=ZOSS<&FY-=C$-0F)TUX'RYEHZFO*Y+J"\#UBIW%_J@Q^4'J
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MUFC=N[(OL5F8+W->X#$$9DO$&&]S4R<#9Q'JICL%^_)YN%5G49HX0QE<9 [
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M.230]"M%C3XC&76=-#A*=KIM7M7/L3_B%L8<TH,6%.%+.F^TS-C$BDO6%&\
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MW ?%.X1)PD*;EN(G]3(>^*XU'@>.NE[E2,KJ1N;>=HG4:0-'6://@0=D1=D
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M8/$*^]#[OS]^Z\'BFR"9R \K7PL/J"0>,'%]G"K, ;P Z_(:\' NBJ<N'??
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M1FV1CJ-&]LN[CO[CFV*W" #1C5I[WQMWNF^W;"(R*988Y!CYLF_0<C.<&R#
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M'/\JD,".4N[<HU3K]3HW]=O:S:W>ZMPTVXUZLQ/U*+UJZE=WU*/TB#U*-?W
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M-DQ7!Z8SW0"S'@\1U4(8947:@GB+R(?L4139I5^Y#5&O=ZOZ\4E;%C@ENZ6
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M=:@N=+>Z4*U6*U(E:"OO.D+]5 H>:8)'G2!5@E(E:-Z5H"K\I^H^65CNN8G
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MX@OM!2B,5"V60VE-%@U9-&31D$53!'"LU_1JG2R:G"R:TAHTFS)"TN.N@^O
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M*#SV%3TM4W@A"[I]F"R/GY"M6.KM1K69CUR"(3 ![:I,!D#$2> !A@$S33S
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M;')S4)VA6L8C+0,I0WL':"TM=("]N>6R'Y&K9=2J0-R0,T/*HCS'EL^,7'P
MMMLX:36BE2+!L%JMV9"<ZC!1Y48D1:*^ +HS5!TZ,+*, >2'9KW:S(=_$Z9
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M9:@T0Z!@Z F!#K$ 1%X2 O(*(9)"";HE9)0(LZ.-K@6> 5 8SD88"P=(LZE
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M0G3CWO?I>;^0)D@3+.($=]O(V;).H$A[/9UT%3D^3GUZ"5&][]IF^/R>9.Z
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MB^6/E)3W PG#ES*69H0,P48<R*(JZ!1>@*7W#*:?&Z!2F%$.'L.'GA"A7(5
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MJ+#^"ID)^/7A_NGKOWJ?JN"+,IPI?E]A$6=^K3Y6E<@@,P-[3P1R(3 U0,W
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M-QZN, M@)6-X?+:CC.=-&'9@QE%53UCC?N#)V<GQT4D6ZTZ[D*K:]HA8LM;
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M9$K'J_H":G?Z.*PXSN-!R%>)W:8]3!^M_&)Q-V+=*K$>O$ZQ_O9$9F)=UO,
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M[9JUM<(G[4RII#1H8WR6FXQGD(4HSQV&>-*A@=P3Y3O6)P[V8K% +#$WRCF
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M8!)/\SE?_77I<$>=L]-!@&YL<[_Z[>/%U8>O'RD(^/;A\OH&/EU81S'$E)@
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M K(-JH*DC$5@H"?PDMD89-0E%@T]12FA!<G+'2XF/LM#0"IG #>=4="@<+.
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M':OIM97 >95\6MHJB857FD++INZ^BN3Q6%JV98G#B%0'J+B9$LEIEDNXUR(
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MV8V1[#*+DHQH&]$VHMT4T1[VJYJ>9B2[WEJJMF;8-B*W5100EC2$I^EDK6^
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M2_9 0@1<M(@DV6;<YR&1+$1-!;125R'-X=9K?/;<>*A,;AGV<._.>Y;#'@I
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M$M&!##X((-PUA%T3B02Q#>0F!JL,HK$%/%7>F&-DK,(A<$!1GIE(.^CKPBU
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MN$X6W %:[%,R&S%%I$DMHR_H"&URN7\!S88U(&B;+J978Q1+IT^#-5"Y.N?
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M1_*74[#I8.;_E3 @4HBW%E@0B+FY[NJDZU" SML\'YTPX)S<?H.-SW:<+K>
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M3GZK)Z/[]%UWFTG.'1B&_8G1'Q8 @U+W:ZO5+KG_Z&H_BB?BXX[F1;[RF1>
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MN*V;:6"8NP@"&01X*<P;GNWCNYZ?)0T'V"VPK7BVK@@C,JLL;2G@CA"LMD2
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M@]#+Z/$A,C84^*0& U.S@(E/:C \,3PQ/#44GDI,!&!88EAB6&)8:G@PJL7
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MRWQ!1Q.KE>_]22>*G:=J9_--OZ=W^\DIA3-?FF^,7J_;JV4R'<V7P4J:H?T
M:]39/KB9G-L,L6S0GJ<W10!/G3OP5&EI @^'FMYR!5 'M^'CX V^YG@(6M)?
M:HXM9K9CA[;:W(Q/B6;GC6?"$:XIM6 A90B/M\,%#=*72V%3PG1RQ7-O%:;I
M1_"+_',EW0"/K*([BD/I;J_FV1_]]Z4Z+%\I\[A>M8)F9CO>R(N*TT)I+ES[
M#SI2#&P)SPWFT@^TF0P?I<SOC>?/"VL.GB'&@I(^G5X&]L$X1(!!"5FQ.+,*
M.?8%7>TN6R^XR[>T/R+A VH@^08=X'$M6BF4P$M W<PR+ &A#R+3E$&0K^N
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MBTSHR'R8?!6!!8E+&$NGZ[FHD[&Z,U(GK?(>6^N_>38".XP<)=IV'^ WM3D
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M0R<W-6O#B0(HO??%,E /%FZAE5:]=3LP!C4%(A'%$:^7:+#!&BN[ZQ'>K,V
M2M9O44"3!PL3_H$P $G^C&U3']=W[H#JB6@1P1;[ -<)#2Q,6DUA8\S6DH'I
MVZMD:4@_A##40)AJZ5<.\ YZ$<+2?O+@F49UT:D= '&=L<^V"UFJ.Z'<")@N
M<#%MBRCFLEWAHCS >^ +LH#+MN9.C537X!NXPGD*;#(+A NVA;VBZ:-H@YS)
MU*HG+LQ?D4<ITPO0*0!'6/K E$NJH.A&P@$+*;;C$1(<#T@ 3(JLNG+@"O*>
MGDQ'YBVE:*56(':TR-/6_@"P")5]A(C1S:P+)2W)-.S$[XD(U:0/+.\BBD9+
MXO<,2B4B!^$A>D@P<-NS@&YPMQUT<@Y.?L[S* 1O*#'OM$ X$JXE;/P3XX8X
M:O!V3/)$E4P&R3QB@88?MBE'38\6]."9(,BV5900J98B8!"9II0XJ$[B]:F!
MQ'+LRL=D:$"%)[HY\4T]7[TE-ZCXYQCV56U+>R61=],9FO M"420HWCV5]E6
MRJD%(@ZC[&([%5M)^+-PP6B-@F S1@'*'40!D.1>9NN9:KQPX7O1O5*;X">0
MWL_!WQJSRUP<(GO[4^[='5S5F8V6A=*9P'".>*(E=].0 =S[&W!L0#'OR(D%
M#O1KSEUWO*"&6'5]0=N, MO!VNTX?I[CVVV,KY6]_9@K>_LY*WM;233WY/O=
M^]?[+8SQ%MBYH//@@B5H'>2C^#EPZ==_?[F^^?Q1F_O>4GL/RN^BO?4:G'6C
M,ZYMD[HD,SM;!+:WJ["WFX:[[U-7]H,R+#<WG#]F<?WKXI(EY0YW-)X*<[9K
MN.58>XT!_Y\1O/,$1QL>T#_S(3QEN4M@5&\)3T6&C?T(7)V"[1E\YA),>@U#
M._;<!OLY+,@6$+[<W .)(\>H<1)5D=CR7>TZ=J8Z6][4#F=*)IX86G3[^WAP
MP?8XDH!$SL423N"E=O#C0KKP %_#I\#D  ES7H9I^V:T!)EVP3;5'KW(L?+$
M 74JYG/<C2,?Z:7123!HI9_NJK4L_2[EGM@)P!4N=)=)?:)KY\@7/67M)O.'
MP_Q"=C:">K%SN_]N)')"ZO<"&V-X*M#FGN-XC\&[H]<FMQ08Z[+G3SN)GWO,
M6BYV;P/Q\7/^/2Y(AG#6N0"O21],R:.:*1TGON;[-[TW]#D ]S[Y7+#L7X%C
M ^TG\,0_>TNQE>'^:%OA OZ$:<8)N8"\CE@%\EWRQQ8K9H/*%_5*DW0'A27:
M]B@+1F/Y_LU$__;%]-_U1.3XQJ/O&]?RPL.JH558P[*J>FF3<F%HDMB&CTI&
M9IYCQ<=V/KJ)%1T<<O@DG5B_2>TI7EB.YY< 85GZU2["^B'UXB6Y)FV8.&_:
M3I^ME$J!I1X7:LPYA"/S14H[O,8E,*HN@<$5+NCI_<&HQ,+@C>? YE18;4*'
MKSJA<7R,;<#=,C:D52_S@'3;"R^R0#XGD!,6R!+:UTQU[NW. EF*0![2!(D%
M<I= CLNLU\8"><$":1P"[-QM]5B!'4WK:Y?# OVR0/?:*M'4Z*,:3N,BMES$
MMK$(JW>&O5X32H\WAHNYRM#+:5"CVM*@\GM9:WE%Q;M;__ \"P^\E#+OC7RC
M)*7@) D>='J;\B,HS9R2#%:^]V!;>, "Q,-Q\%#/H_"M)$][(V'_/B:--A,.
MIM0<GV:Q:[YGFE,QG78GO6%O-#&,$<QO,BPOPV+RR@R+43T)#[G[!G6_L)T3
M/'O?N8+L!/6X5_6I'#>[D6P=.1[%>F\[JZ-2IY"3G2XPV6E_"_WT4K)/)M0A
M:4]GEN'4N&K)I?'XY;'R3N;=.S/GM=U]VQKS2YS%CC:3][9*D@<MBN5"3XD+
MS0^1-"G0QW&\.(XW'I49QVL\#W)#EY,J]/)1KRF,==+N!FU&K1BGC+[1/22;
M91]S\?1<TYQ]VRW[36^M ??1-7TZ!Q]Z:7C[&*>$\Z36C8EI;\)Y4FPM5.#^
MOR1I;1 H>M[0&'>W6PX<R4%MD1169+N.[V-M@DHT%R<4KFFVMX.J&F<=0=NV
M]!8LH#-W&CR!\CSQ[F=]RE61<6+H1FE&VDNT8Q5\*7L!TK7*W@7@?."3;Q-P
M/O">)RXZHU&_>\CQ3\X'YM#!J38:N,]R93L1W&>Y["U5[K.\;G^>\PF(6O/^
M[62; VY-L_A;T>0L[F^5EC.M]&7?3'N];J^V>O$F? \KA-4XX3DR"($EL7+_
MPI8/,-NW\D_3B0+L_%=]G7RC5V.A_%#\J<VD*^=V&'P7%T)_HA,<<4L#ZO/A
M:\%"^'+A.0!ZE+W\(5J*%?8JTZ[_@:5@<S_!7;:?+ZU>-;TFW7[]W6"?;7W4
MU2A(G+1_#-+C/;DG[-/5Y]2 4G$KZ5H!972I@#(VZNK86CV>5%0JOC8+@?H'
MP$!0OK%GN(OD4#68\]"@2C3G> B(N,QZ$N]%Q:+V7GKM_09NO>72#K/&LK?)
MG$Q;-J<!@;;?NCP/^MQ/[<3]U.H2XNO6]FNAE@(+4;')YGK5<J8PS6@9M[S>
M:'.U;H(EYM3S#)K\_;>_1,'5O1"K=\G^P[5K9:T[5.>..SLPX44 WU^!-6\<
MS_S][__]7W_;X\[DIT\@2^83@3\\X;.<?__FPQVN_#\'__YZ]T:S+?A"F.'5
M];3?NQOU[CX8D]YD>M-_?]O_T)]<&U.]_[YW<WOSYN\;XI4G[ N'K8LB%>?1
M[B,AXV9'5LN>SZ5/?4EG,GR44C536$4^F-\!GL^W39EVZ"OHO8[3L.>VLF72
M#@GN6L,$5Z:M7+%=!G)BW(\=^WBJ]NMK;UW*<.%9JO\"70I7=+5T#G9 C5_C
M7@W2ZFBS"-M&/-CR,7YHQN#K]Z47B;2IB.HS];,9>EO(0KU'#VCP :MJF]0=
M:Q'WG#6%[S_A_-:HECHL2V0;FLQ,4I-L>!&2LFVZX5=)#3N$+POX2#7^6^%B
M J$BUPX1A<!2WJ!>5_LX?X:H.2[+-Q?&GS:>#EZ&E-962^+"H5"?$!<5@.K>
MXDKUV/7FP,!NCKW5E'?[:>FN__BO08:SN^>UYQ/2&2'1ML>R.0?5C;VHW:'\
M X0BH5J&#5T-E+MJZ#53'5<V&G8-:K?HOLA[&O;'S"9MBF%'YH*WDA2Y2+HN
MTD=<Q" >>-SR53T/8-2GQ?9<:K&77_$2U?"Z,MU3 V]^WEL3WTVFUZ/K_F@\
MZ8V&QNC]7>]N$FOB.V-\/;A,38QMCK:;"1$3!.%:RZ&7VS)VDFZZ^?;GH-*\
M*,QN2Z^%9ZU\+V[0NJOC>OKR.;91^E_A8I_R3-+)W.Y-.]C*SY)+X?\>]^_%
MCYHK8-%4'[!=;;\0>?#QX5HS>*4LJ>%5&MK(NY34?AGN)R&SLOZ].4F,2P*!
M\R_Q;:@-E/V0&KUKO9V(N"GZ(77@XA4@I]E&_?MQ:S5R]OZK&8ZN*.(Y6K/4
M3-/0NHD7-VN\%05R'CF:8S^ O&>V8&';N=@NM-<[N<5QH;13F@F*C<PI$7@N
MK.93]C85.PZ 6W%J5]3M.7DHOCUNZ+;VK-0Z*WK<6L]"LB\3!@\.ZB56P-"9
M0E'M]L" :AU?GK(%K?8)0X("VTQ*WQ4JQM71?@@M[2W^_EV'V@?.Y[9C4Z?T
MN;KMUO-!/8NDB:G9U>Z*9&)SN,%&K\.XBU^^]WO*/"I2[DK5W)SZ6*-,+#&D
M1KWM;FSO7L+K/[KP>NI;?/?^-IZ0*2/:N@_R(\5' G#WN]JOF40F?=1W0T-"
M-'Q%/.[]1#1M(1E+D@;#)8/(4@L0-^%6W=HCX#K?>4J>F[R_H,/D]7H_Q[VZ
M)A;, >Z..T3F/,'-[I*%O0>3Y8(GJ!GAC4DOR%V="*6 .S 9\W"/\K4M(Y/)
M>PG?M0U!GM5LF9'2R5LH"=J\: V!# /AX$& O2!\:.>G]@-HG+4@!.@(4T0!
M"=63MA /*%J6! ?!!O @]=;1%MXCKGQ'7406333[C5;3BV,36^&+7V7RBU=H
M5Q$\;+YJXRFG"W<@A%([[Z5X.CC0<9!S4^RGK#DY()(@,5(&:11R#S?F_8?W
MH\G@9M S^H/>9/KA3A\,$C=F.!R.:W5C-KLW&R7+E9&EU ['$WTZ4C]N%RE-
M25D*GC3&.VOO)D;U.2>59T908,6R+<(10MA\HVFPTF9@JH6VS%E2"(/W*:^V
M3?F!:J#J7:@5/-(!2T4.4E%46S? +4]E82EK^=Z7L5=!BL.CC!P*SKJV GD$
M<J">[8+G#[]$?D!(/D/+#]0E**^G%1J88(K0(Y(?P%+W0[")X I$51_ TZ,/
M,"N\'E8KC)6O&04AN#,^F'2_T-!4:"T;,2UU9F$E4U.N)F[M:VCK.OA69<3&
M4R??TP^?:.'CK:T@HCBFA;H,W*C(Q[]G3SMN%%2+6 :1$R816)B(_4",1?YC
M()\C=3;H(/(?,)5%!8I3-Q!?F[-XTP51ONE2_&DOHZ6V\M#KP< B6!B12V.)
M'=TTZX&"AV@?DDZ-/2E@A*7X/7Y%3-=GAHMNK^O82YO<V?^;VB>>AC:MVOA\
M4*9.2COT?7T<FND%RKD"XP//'#GB,8AL936 "@ZQXK$C[.6Z4?;"D"C8G"S!
M5IONS1TH>%2.I6$V0&JXUH&GF"9Q\3U:/=D\=N/$UM,$*X/F*H.#+<=MXR]O
M&WY,;>6?_3L[6'F!<'Z>_P!^X \@PU;>I#S$>)SV#7TP&8]OC.L/ACZ<3L<W
MM['Q.)P.)A\N,P:.9+U"/\5*G!C !0"QA714* @C<9TX3Q1!$M !'/;PJ4/N
M>$C7(.#%06MRVY3[$S]VRTWJQ/'GPCWBLKR>#*K).5=3PQPJ\H#PC-CJ*#_H
M_"R3.[FA]=*Y(O0^(5"G(2)P$1. QRM!<=E!FB 0Y_R)8*'AF:X@U@M([320
M% 5RC>;*OP?2TVKBCJ9%$DTQPJ[V49DX]*-:Q" "YS_WCL2YEW^NP#=7:FLF
MR9"P39MN\Y(9O<P!G3PWX*,??3L$[7YE>8]NK!%!JV6J#53@+@E1$Y$J-\)7
M+[:W]E/(+DJ5<R /S^4Y!@[7X-3]I((KG^/8"CCL=UED9>\]Q,%T>G=S,Q[I
MU^^-X>WMS<W@>J3P<V",]>'U9>)G&C;_^.DS60[X[VXSMR>_P99+B-B]]Q<S
M&DI$:O3Y&+S,1[;)DI]+$=A*E)79NOT:43Q&.\A2)\@*CT4_"?[F3$H:F9*=
MY%FY^#JY/%E<#NSM!SMI*4)AY<[FHS/D2(+2^5 T1N$"%0-+\">Y$?<2<^@
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MY'4U;/9RI8\[F@BUK5F6&\,JZ+>D%?::^7_LO>ERXEBZ+OS[^ZY"D=$5[8S
M-."YZM2)(#UTNW?E<'+HZC[_A%A@50J)UF"2NOKS3FN0$)X2,(FU8^]=:4#2
MTEKO/#VK?*PW4UZJ@LC/LG 4@IV]UJ?]I7MPTNYJ0*/UOM@=2(?.Z_KP5P'?
MPX/SQ .*UG]AX'#->]$^?KZ=<($>'[(=\$B\Q_.PP"+6S4KW)TABBDCX.>S
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MP4QY'^2)6"E=U+JX"W\ WQ+MD86#6^.D[5I&VIGDHU]./V[8?^\>=#;%W58
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MH?SY]D% N 6B)C'44N C#-DXWE 0ZTFM24]+W1T=G/8.CI89X>?:US#0:O8
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M8%_W&S0-(N9@/V:.M3<%,B\PH@>O-!(L:2W<*9GAYRX3DKO!@I<4RZA(B=-
M!=*83VO_Z"=DC#<-B@:!D.&0\>(29]O]R4@LD>7RWP(1@=M>WUR!,JYDCC$:
MHT%39?6,F+$D9TF>)RSY022$>%9DVZ!>G-'!8L!<PPRC:\:BUU6(.J^-N2 2
M?Z0)6+,);.W SX,;12=?Q"$C1FKA&2?DO,'^3+"E72\-!:WI;,\L;#%#1+.0
M0X#B:J@4/W"("6V9[R0= A,'<9QA'-9J5Y.+R0BU/;S# 7[(8_KER#*OGN7U
MLA>X*V+\Y%C*/4"R[/0^/I#2ZQUW#KO]WO'5Z5FO<W!RU3_H2"#EY.KBS='F
M461_"(WRUI[[A1KDWB<5 -/E=;F>'UJ)]-'&PM?<!WFSCQ0,XA#>-S/O6\&'
MS\%:"4UHB24X2C'$6Q:C:0R2ASV$*$'CC.[@UON J5A,"C%N24(CIFVJP$?-
M$)M:X)GW\/+7Y/Z!P,U!PB('4YI1[#'$;R9$ZPSS/)&V V7Q<TI9HH4'0@+T
M'0DOD-N@1_#.)-HH_UY5*?IS=ES(%D<1KD :E6X/$F;9+5A7(5BY,3Q1O2'L
MMWX$255^3MW-!VJ$5Y,(T^X#'L.M2N=M[^.=FYVJ:9+FO-GB"<J6BKW[FO:R
MQ4#F6N*#T$"#5,M^AC5_:::DP_B71'4[R_KO"\W&]+;,8R[C Q5A+"#.2U%7
M+*@K!K!?2-.ICRR]>"DY9A6N_[[0+7AK&#1E;\^- Z'/%)!/+?XIR2<63.@Q
M+7]',B%H%?O(G/NYF@#;@$.UZ*XNRCQQ^O6MN/YF6*0F3NE^6PJRR7(YC01F
M#7FVF4G_%4 &:33'5QP4\*:5&-'(OX4UXLM@!&$(T@##XSIHG"-PGJ3$,^3Q
MF6,XE:,W^!VA70^2E#[V_'&JI(Z G.Y<P,;]..0HG#%/26KQ>8(9_,(DQ+LD
MWG\Y4D('C_BTK3)VN9VC1D(GLYLD4U7[ ?5>56K8**K#L<"1^%LL^\%Z7E^;
M)VWO,R6"2D+$-4P*$@I._H:L<DYD><):LG+]X0@-$2GE:0%;@F;DD"++(O #
M@+ENPBEZ8P@KZH^5([@D:,/J/"O&8]P>S1MN\":,1_!F(,@HX"3>GN2UW-<!
M*\#$9(UP R^J+-[,3J%MDX AE:;&;-$A[GJ95DK^A9-IA)Z3$6:PD9R?PG.<
MZ^JB>(RN%QV<%G]3<&2=,V=99(Z?I=I8P=91#HLN 5'*?O):%,,+$S^7-A7B
M3C! ]?'>GOMG?>[>-28.4_K1SDDF)"S4;3H.)C$PXB4Q9N=$4H:QE(^)![-O
MS#@WG =R7!CV#]A5 ?E"U&9TXD3YE%H %JCC-.0MV7'.9"-9.Z6U&#&0\(Q#
M^6VOO[ ",/Q#DRXFF8;<'N=5$R>F],IM.,08FVO<V+@:+0+<D=R$M<6\][Z4
MGXFL'5NY:]U"1Z)S(BLM>SV4U'/$#=D82>X&STO.ERN]C6<''EWKX1[BKG5T
M8*5LS<Y7'7(BQ*)Z;"TGJ:OCAYS>C/UH#D=-&4!.EFCU,A/_=FA<4'1I[9>L
M46J]6"<.>J?_6DI_:?]5V\?U%/D[&06+:_,=:YNJ6^;550SAETGK7M,;*:QL
M<PS1\-5$7,O4-L&-*Z&8H7Z+*M>&Z#J-I+@##28_17F12;K9$0_X\UTCXH]J
M[*=#DCPH("D;40JAN,?HA+J=Z+NAV(1#P/?2?LEVTG&02K$$R4\20#,@NAMR
MK*I^6ML[MR)*!ZXD***TM0IK!CI#'K"53F@]H5P*_.S&P_;C#$Q"S-R'\N9"
M^4NIGEU5LXX=HPD4; MN Q>EW.?1&Q9]9D>=*^9TR;VQ:/4-*"^?DH6?XUN5
MZAB$ <CVE40[D,1-$@U=M\1(3JH-$)N&[A].U!)R(M/83U,*%TA"PXC/9;'-
MR ^^NK'-NG7Y53_/IFVJPGQ]\G:5@K0^\U*;5:E/O61ZYK,:OIF?2ST&&%QO
M_9Q>_ )$S6=4W(_)SIQ<75YTKCH'E[W+_N5)I_/FZ$*7N1Y==$]/UYZ=>< U
MI1$$'2U21(3@W^Y-N:*S+(;P-^;&'#0)0!'(;WY]U7E%?V=3/]!_/_YM9^$P
MO_GY[*Q]VCGJ')_V>L?P?J='/^F^= IU33/UL_['@F2T2W0'"ME>]>/:&5$/
MF$E$2_OUU6'WIWO;X,L-^7+ADZ_K;?J!S0LV+[B-+_B#@+@LGWQQNEK+S-[N
MNP;QG=PW\;(T,V1Q*LAS3<3$2*=*U[N]Y<%4]-V,5>0 ["MW@H-NP_*6=E\U
MPY>>G51W@"(?0X,/GLG^),FZCLW^@21O_4'L7<>ZSS1[_102OQ=09O.[OJU$
M?ZEK A\:9]F*55^!MVNEH/<O=*8;7;%Z7=$PTL.UAPYE_E",A(V##>,TC--H
MH$8#-8ST8S/2[FN@!K]ER?B:@A)+2<PC<[ D +/.SRF/MG\8^#8-M&_FU?.P
MGU:WUVFO+.JW_33XG /I-XFJ^Z.9'YL3AXW$VW5@3Q1JO15.G]\&2FJ -'9+
M/&VQ%%JMW/G!Q0O=[_APA392(S4:J=%(C1<B-4X;J=$$E!X:4/)'.995ZYB2
MS-_Q1EC<3X.9GQ+.;9"!J\[!T<E1^ZQQ#IJ@QN9R*@T3+C#AZ4'#A(VM_0R\
MM@LL1??KM@X.#]HGC879\$K#*P_@E:-VK^&5QAM[G#>V9N=K2YM4GLLN[)X>
MKC 9_=3-W17N;ERW3;AN#0M76/BHO8@?U;!P8\QN.Z?N D,R"_:.5QA;N6?7
M&DYK..U%<]K*4GPOA=.^T^GL[JS7^1FA?N\>?[@>6CL 6ALF!0['^1X6W0IK
M;)M*+N_;Y!=4DWG8.CWMK,LJ><S6[HH4;9S[-=5E-:*Q$8V;%HUGW=7E)AK1
MV+AR6R@!MUC0;5BT_> 23 IXNMUNN[NQ/6M$4R.:&M'4B*8'BJ;>NJ)R.RR:
MG+#<WVA0<NWO:_Y=-]7Z\0.KW<'7OZDQ_317:=:/AW@]4*&*@U!ECYEP?7YR
M?-@YO^I>'?0O>V_@?XX/CF7"]>%Q]W3#^*,5$)_>BAF@9[V+HY/3[MDQ?[DP
M_N.W, _'-(#^3LIXZ&O50?*4A/#1M#RU^Z SW1QZ6&IP:Z(Y(MXDT2V/<[_U
M4X1<!W;QPXE@6"+5,;"QPN67H.\8 9DHTANJ+$C# 8)!*="<;0\A!L(8D21X
ML+]/H! X']^"?'E3'/3.T(8(4H$?!2YAM[Q,*>]=DBNOV_(6SF9%.\-_XFU*
MP$Z?BLG$9VR43Z&%#^O;Y7^0Y:]K8;2,]N)[?Q_XA ;0.EX_S=4,W2WM<STW
M?O )!D&$W6I>__CYWOYN^##@DQF0OO?AQ@=6\?ZNX/_'GFS!BY%+[V/@\EL>
M>=L]Y9&W7F5K^G_[Y.V5/WOMC<((9$Y6A+GG$_1N[A691A[]J,8,8',.<H?@
M@2Z*+%/1,$E'+=GJ.2+:P.](GOFY]_GR_.KZXO)C'Z47PKJ#=))#^9(S)L?;
M9*@B[^+2FO*]#JRX<^1U>CT/+"W[Q9=N2Z-T^AF#DI"H[4_3,.*W)#BT;U."
M3()OW@=Y@KN NKM=W8*L&&3JOP6);OL0.# 5$W8?@HKAVS!6O/V%($VE^?)W
M+#_IKYEW6:3)5%E:?)>TO5[KM--M'1P=U;_56W].ZW;>*2N_4Z_FG93ZRL@D
M/F/ T !DO3"#VC;T)SZN$\%84(LPQCW\TGT9?::(HH9@+W)PD3]K><,P&R>I
MW!&N Z4VP@U+8OTPI &^;9@A3JWRLR(EP!IY>-OK>S=@2N(/$:-NH%3L9<&-
M&A9(A;@T^#:B33AN>S^^X+Y;=%WCM+:12A%+T_M@; 2&=RJ?\HZ+KVN'HX\8
M?^=+^U-;LP[2[V<$644@).\] @<I;^_+IP^?W[\6RB?\50( ,CLZ4/D,":RR
MDRZ>CT9(=1_6=Z -D6>[W;\=G1RW3D^Z#.8)O./^'']RVCHX.VL=@3#:PZ7_
M%?\UI:]?$\ZK^XE&"C5F(H$.:7,P3Y6?:PZ;%%$>3C%7#PY8FB"J%I'&X6G'
MFQ!<XS!$[-=YY(V*"7*_0C,1&/,V' H_"=RH9?+(!P/S,8QX\D(8$0XTS>%8
M/A+DIL./.\Y[8#I\4M.<;8<>VP["@^<)K)88 2FB/QHA="C&*2[28IQY__)^
M^^V\1=!:8,^#8J]"U/E 9,,Q8@S&PY:8&@@$EO--#8P=<3(]8\,N"LD+8$P\
M^+4Z(0+DJM'5''G0LBCDR72:9&K((H/W!)D3D?GF*D=!1VRM8>40OPSLM3 O
M<B7WWP%?YQZPX(I1);K@/>X<(S+O.+=^4K>$1(TTBXX_8>(Q9R5V$[0!OV2[
M$&)49>2" ]TD@8$.1%5AKA%]%1<L&;SNP8EW!/\G.@[^)3I.D_!V:+;/Y=6Y
M=C38SZ=M:]4_QAC=<;XR_G* @,2P(QP\6''L8.NX2<)Y<!%X-P'XML0\1(H?
M1O#3U FLH:\#! @\YD<&>C+WO\(MO(CV36E(R47[\+AST#HY.;&TMW?Y;9HJ
M>B"2.X:6@>#^=7U-1N;UO[U^D(>WC!%+GN%D KL'7'F.R(*OZ5=3WW%BTV3N
M1_1SN*-Q[OJ_??CX_K?K?]<HAJ?D ]:FG^GN?3 D9(R\5I2PVUF(%@<!$<,.
MP6W']"U]$/BQ8#=/P#OP?/3/$1@ZW!B6=C4"_]P<_-'*<V;A'>=@\!P-UA,;
MKI]F(5"&!$?(LH]]P6'N_]T;T/RCG'#$ ]HF496\?YD-=9%A&H=HS/X/O.<P
MF3!0[6WRE5' O_R/1Y%LE:(R7E"?FO]9?79!MQUYW9XK K0KV@-5-)R$<9CE
M%L77']-RX)&D.3'&$J$0H&"FOK#[RVM1QW#GJCHNQY;^6<0*=XB]V" !#SD%
M6><O/!AV"T[Y3U"[ V_O\W\^]=]\O'YMU[&HNEGE+FK;*S5("TP @-H]<-0N
M.!S_]&/ZILOH7,>,N.M/E/8DEA[3!:XU#')[3OCP?_CC0E$DC,R-TC%=%#EL
M1N6D*GMVCS^LGTUWDO54?>1W2>D.:+#7WP7(AF^QZS;%7T^.CEYB(/ZMJY;%
MH>ZTO#=A BSMO>V#4 K:WAZF]A32CWQQ#?Z=_O:U<9:#9#(%:YKB1B8N9F]?
M80<DRA*7 *ECMOF?*LV4$ZDO18<'L 1_#C+J'PHLB)L +2(6GX$JJ'HADR73
MST#B3(!]1YA\3U7:$G1RQ#D'P9*!>8(#YT;>F\O/_4^7']^_H\_=2_#;RW]_
M[O_KN@_"ZO+MA?<))$F<M.0Q#[K]Q\LWUU=PN=AI?&60[)N?.[_!*]\EM^@R
M90NO=IZD4WIH[6/T.K5XKYIV)ZVCT],64OJ>0^]&!HLGA&=29(H#\QRB!!$R
M4+G/KLQD4L3)) $Y(6(X96F+9^5[MV'J0K2WY ,P696?J19:00$F^O"J8I*D
M(I$MZ7"*8)+$\$"0NA*-=U/18$WE)J*/.V#,R;80QXT/!B=&&9(B Z)=I,_%
M]!$)]  )L^4EDMTXT>R@A;5O4A<)+.V/8C@FHB0#.\R]8:(X J))ED6W(UH8
MS)Y,/Z.%0ES#+0B'84O.DQ]FMB!54:A&>J'(BJ1S<UA$K.;97[V1P@T*8%LR
MG8U!"]]L+7(;RGDX%>JHHZ 7^;FS!/,EF%'+^.$S=+A''+#1OV -0,#O^)%C
M"9R[-W3?L\^7M!WEOSX3=SN$*5&>9O&696'<52LV. 8"LDV(4E2]L)X<\7W;
M:DBDCAK)E3+A>Z(K"G?",N(DWG>EZ:/HS9+7 N557A'_U'P(+ZO\X,9A0?N^
M#V*K*@?!CH)QB+4F@:+P[@#$RA!9EA0&F2[JOT#0#'4/<J@(<BL7,&>:P1(G
M-HEJI0+0/"[)RPHTG=PT)9E,H*50DJ''9^TNE?_XIM$C2S:N<_;NWVE7Y:T:
MA@&\7.;UL99GON-FT[5F#)"K-]Y_"XS(D_Y%C\783KQ+WJ>/OSEQ#_#^0BS
M B6!L<U1BHX:W.O>+?7V\+]_P@WEITB>D7=%YD&"VK1_?06:GWC&ILO9(Y)1
M3I-PN._X.9TS4!28-B+&3%4X&11@>1'K1>$$])G*D(O"#)P";PK?%3XSB>]]
M2''Y%VB#@$O&=L!'!4*KH'_N\??VD]?>&#8:Q1D8<+A2E"Z.+]PY;GOO[2>.
M27K0DFV=Z= QNEE3\%JCA<H/US$%P?,Y#0<%?@X[\9O_9YAX>]>1^51Y_8GS
M\\3<!A0SK"F,^)K7^)2/R01,%]SYN2.TTB(RE22XCKHMU Y[93^\["8IHB&^
M2(2I*&^6ACG(-RJ;B^$C1\D2K84I6"MK#6CU%F&G5YI4 O62WV2.0> 2*%&L
MMD-%-,>+!,L&C3Y]T(-Y")I4$N-ML*M-Y."PQ60&OTV36Z%PL_O^"#9TXAX>
M!E;1=JL]1&)3TGS$1\Z2N@=M>0[JO"KC4[Q6!VN)9$R(T%F,]H. ZL)DR \K
MLZD>A*TC$?3<EZ9U_HX)FGCB% ONN)KY7;']A/7LL1*_ 20RII> VD8@N-&S
M&IM]P=D)17Z3\*0$219@03I%,X#^;"D51>2!T!)1-U,L3P<1Q=_08XVN G.0
M#-&L&$P3%?O@5NC*XB0!HN5[F_RX70\+/V KKAM>>;YW&T^,K$NS=;[9-*OJ
M%\^-), P"0HVWVF_)32()\9_@]E_$TYYF\&!SL%@]:8<'9B#*1HK\(8Q< '.
M<HJ2%']GDO7ZH#!?#XL<)N2E@D(&&V/*! 5>,IHSJ/FX2AP7\^*$S/\I0N^S
M/WE1(<!_%F!O'.M2&K1JP:8-O1RV07O^8GC9H,E@SF29I!G6XZ)LP1#1C1^-
M*NF(3RBP6*QHLLWXHQDJW2+.0)>S76@JZ1X0*'SK9QGXE07X7[G$.62QVHH@
M(48^FE\R"^%EW3A(2_S&)8+1+V4V;\,D,KD'EYFO@._!;V<O'KQT=JQ)5D?^
MS WH9];I]M HB%B:YZE"L\!$NP)X*EDV'-AJ<2@.9'G+NM].=2 YXI(LR?2&
ME$\ O=F0]$C"-[L%H4$B>I;HUS%;.  *P@^=K83%!K*A(!_@??P4B [-FTF8
M94J"5[H&B%.<L7D2;1H6!65.?B3ATB ;8G+JB^B9$S+=8,'R%#"VMCGMNO7B
M[9.9H_1R)-SOJB1\I!N*32C*:@"E8*%1RA;34(W G?!1$<.OP:. S[1ACV'[
MVBW4]8(@Q$#E@U96-[#GA&7C]8MQ 4)3&AV.W-3(4P6=!*^<<#:)L,S*)_+^
MM7"RT[,HV LR%Y<&2\$UG+<][6V?_')R^L?>@.LUW _S/9\_[)YXY^VK]D?W
MFMYAI]WM#/:/>'%@K8($I66%HY%$\TNQM+*P0>?7Q]0#L"I_TJ*SH@XL^X-4
M804*&KGDVLLMY+)8!_)0FT1X 7\A'[!DPK !E5;;$O^25%T,;#;2YCM;N]($
M@Z_ )_Z FVEPD]^3T*<.5Z=N^04X<RA=R#UPVS"GLD>1V2.G(9/UXT);I@?"
M"!F;.CJQS)9</_$68FS"C+Q!D6'T,',,&##];T!*L>8M<I >1+9H^C-M@P7C
M/L62LA^   $>@ <"%PY!,J&ZGQE'8H )@UN^,U9<$+\X$8[J4]2WD LZ=4/I
MC()AG!K!#Q5%VOWA+::"/34:*12&7$-IWBS!X?2Q#SO@)ASOYK+%ENT'M5J[
MO=EO58HN5C\ (UDJ6.$Z$-FFH!7^'8 P*-+'-6OW.R>G_>/C-\>71T?]WO%9
M]^+JD)NU>Q=G9]W#S39K][:C6=N9H''GO]SC>&ER%FCV%HF2.K/*!0-KDZHE
M(=K;G+-J J/=GO989U(]H-#9X9YS0PLD>J)(*V\0>^"4<1M5EB-;PA=W;)^W
MYWR)M1D>^E T(P/N VI_$";3TB6T%!1VTE,R2H*"JER'(""C9$J-\"+S US)
MD)PSM/QBA=5X/NW&%.RGMKNR4B<8V5CF:FY@A)6#J.R9!3K??_2_^6!/CN&,
MX87>_:O;Z1Z>=GJOK:>,WN$$.">G&)&]ARB/N6BJ9+0/_TOE>%,\U&(8RMKQ
M]@HS01&]AA^-0]_;^_SW=Z_!B!JR9$:%U2HM!A\\33"M2^*>>]E$#6*<0-H'
M6 U6MT?"".N,*CX+D5-]8I$&=)Y3RAMAO (TIB+;U5]O&N@OO0[8\QY<']7Y
MABM-"05^=H.%X=SW"PP!6A,.I 7^0Y'9X1 Y;\!0B?]0*4P0SC+-PYSR ;J!
MA8'UGF 2M9ARWG+B?PLG!5VVWET\/.JT.QO9Q9:-TZSWE0XV]DHDT2KM>7CB
M2T\:R^<<N:+]Z%(;#P@C'2>TZ@'+CK'A3TG>#=6'L4Z)/.%'-^P^#FW5ATPU
MD<X;J8NJJAUCJ5)BTA<I2';Z $,1NMF()D-1\;3[#O1,(SGK= ;)9&5DM;,Y
M+2[CPH=(H1?L]2VE=V!A7]7<4Z OD[GB#QPULZ%&A(T)4]AXD!VQ"FP/9XV%
MX&R ;%V 0Z^&U"RC%=+:14;OY+!]M!G^,M$438,C/TP]X*3"AE:62%^GGO<S
M1C;\"7(",9(.E0Q-PMJG>[+4GM @#2Z5C&%_ITDJ9#PLP/"8[W,A%Q#ZP(0+
MAG\4I/9 &!23*0>VW/08L]T-.I^:S=G#=$0_EUP6S*-1^!5\U9LD(54Z\;_J
M#7!>5Q02!=O@!9VMD2$1$ZE#XP474RSG<&8&A?$4S$QRC),!,AY5HHG2XLI=
M691*%<@/98\##;G?D(^] _=A&[-Q-A4-6;1Q6A3FD_-NE2T>5O91E,S@37Y^
M\E8X;XZ/"4?SAWC)I?!1I^(3XM_N<SCX4MYT_(VYL50EJBB2W_SZJO.*_LZF
M?J#_?KQ_/PN'^0W\$UY3YO6!*QGYTTS]K/^Q</)V42X(A9G?=U@+./( & M:
MRZ^O3D]^NG<R8'D,H5S8?>IU3[[P4=<]#KUCC8 PZ\+W.%TMUY_JB08+<8N]
MZUBKN^SUW6&[>AB>@V> X;EGUVMV>KL&S#:(I_4JZ9Q\T235-F')Z'D$<:Y\
MNO'2:?5"W:1DGA4KZ<E!3C\8K'K [W>@)JQC/S<,J6 VE((X:]_4K:' +4;K
MVEV!N<1!?(HB;S!F'\G>)PU,]-9P^*[C\94=]?50W;I1IK9&4VV3K;1."*I=
M,J8.0=H>/_^N;PT-/SL(P\86]N-%5B\*,\0N4U@45>E/Y7H)$UC'9,@4^[TQ
M=Y_.%ZH=%_,".%H:X]280>%!ML/EF5H_TY<-Y:9NYD4*.[,BHL@]%G-%X9]Z
M^94<N 42D+@\7\A5=%1H'J0X84('VLVB*:5G,A/+EPKO,4Z2X0P["@?S=>=2
MCS>6'89]FF+^"SL?VMY[:BBZ#3-NZ2WM<!3I:5RTO:-(!;D=!00_37,-^("W
MN?-R'%Z>^U3800T77)^S:^G%3V9$.VX/C5;7Q0D/3JAYR2"2,G*/B8\3D.,8
MGC6T:9&)'K%U)PF7C@U)OS3S@TIFS) (3,--%*-W.*EF%\A#]_Y)KJWZ5G#0
M=O58MD$<F&)Y$N%XG+3N"%"NZ"#XSX6!3E>XU'_14M_:3-IZ!^>69O!S(K*T
M_;9<U1[$IEABDZD]DZSS.-^5$;@*_(Z3L%8:6WHRBB)34U]JC:FR.1R%=(\Z
MO:.3\]3MBBEBYA<<42EE@O9$;+V@DVALDHE-,K%))C;)Q":96%9?36S\>\O.
M]JF3)B,W!3Q.G">%N#:V1F]5\80F3-:D%#<3!>NM,@JV]12XQ0F'G16;[V7^
M2 ZN=&B-_J=H\WLSBB\L8WBR =YMV'.WV?/O$AYM^/'[^;';.VT?-!S9<.3W
M97MP5#-&PW+_FVU5:?CS^_ES[_2P?;8Q%\)2W&-W;[N(LF8C'QR+:7C\#J.X
MY<7J,2&#AJ^7\76WW6G8^L=AZZ:XKBFN^R&CADUQ75-<M\5N5%-<]Q13S"DE
M6UXA=_WA(V72\/\NL)]]G/H3IW)A1N-V&#FAU"M?V_J.X^-EU@3-H\#DG^?'
M?C1'(-HB#Z5DSC>_]%)9WL+NKW(ONMV?UGI_J?*S\P-FA*D;3F3L;!K>JEA/
M#>;]KQL94AZ55!H_9)" J6C+G2VR;'X(3YK,"%\ID+*H@3M]*DX(9B_$J;8W
M/F'X=G!@+]4Y3F3F!T[HI5)(G%[RC8@I6G>]8??P:$,%ASQCQ>&*ZJD\9% +
M'?9Z=P0[Y#:U(WJ2OYTK8JOMRM)"JIPJ97>"QN;NG,QM=FZT,!\+I*.,4-7S
MX'VX(1J=M@#+"*XU;W9O<YO]F9!8JLQ6P]X9HYLYVT1SAS;(E8?=37&E)H#8
MRBZ16C276Q1&C?CJTH9F:LD8%)GB;C"XGC8'I<CL"!0S_V3) W>M7E++!C_/
M$9A((_.94G2G%%BD@3NO<):D7PD*[:^LE1!QCO8X *LBUI*@5(-2-S"*SR&Q
M@$]B4=2&EXW4-A9-688MY&_=*?) 8G@S(!B-Q6O>-&1:P:]!1A9!CK?8M>/^
MD"8TN$XW/E"UJJ"H$)P[3<(U(Z1Y$BZ-V1_!6=!1E;LF:B:/N012'C2$(XCQ
MWL)K" ?BE+";@4KV;FPT,0I)W7(9E%,)_%7=+]8[7VSK9[,*P-5*7ONX\M:;
MG+O:!],[\KB&^H![B#3WCPH<L#J+54H(-3)QU:I@.]].HWW1J+W+R(]Y'!@.
MD@Z9Z/T(FP?F>#N<[XRM#FD2M;TO.&2+)[[3B$A-^3F\3:;'QL^4@9THIO ,
M.\MK_1;.0;MWY TV,;L-]A&WS@5.OW."(8^VYU:0*/('B>X6&:>*1YF1:4#'
M@3?3D'XH'#8D?#=%Q[^KRN1&GLUO:6C9*,>8-1D!]3G$RAQ L\WM0$5+W#'"
M.H5#AUGHIZZ-)%6BU!A1Y@0'OAB$*<\Z307@21 <N*NH]DR!8^[[B?"+0:\>
M6K1(:NG3%VF_C5Y)N%"F4?XU$SLNQ*&M8%!.5(KM+=AT-BX('FC>PK@$FS:Z
M1RF)QTE(Z+6. >*,J?^\?-$2/,$M9(-(9L.C8?O? AMK;AC6'F>B)FD$EL50
ME;"B$:5!Z1'ZN04><H!^3,.6LX2'=TF%6?G*Q;8HIRGEK+4VN;2HH8@'SNW:
M;I4#R/#101E;;Y>4]WS-4<\QRWE7]$Y5I2(G!OZ4:.M/VR9:VW5\0%9KO. :
MU#8I#OP(,>*!E16+7"V7$-4]131I9#45W,1@D8W)E1D!@X7LG3 XH8Z>ECJ!
MB3<7EK#V7M_3P_;AIL:Z&CED7#=0(RHN--3P+&&<,QFVZHQ)=?6-'Y)8)(E/
M*B\B4!U743HP8S&=8V577<I8?S#OH-T]W0@7X$Q^T'(Q=M?=3?&D7@=JC%LX
MP;%RTMA>1X+8U%/IC"PR!78U.-TC#/^1.PXJ#AZ43&"IR"\R$->;J/PF&3HP
MZ*#-<9H^+,G$>C016*UGX"@-5C3RH>8TT>\K-P W+7^O;",JO&K)A[G/D^"C
MXX@M_@S;(?&WA-LE^XDX?1)?M.B!%A(5MS]&8\/A2[W##^_.MH8<6N99G<]?
MMNFX/[S@YQ$8F7NN9 B5##IC.U%0QL,A"Y'LU4&G)2#'OSO1:[$ $7 TFT:A
MS9<0Q+/ -Y=O0%VWY;UZZ Z(T2VN8.38J6S[H1E3.MFV]T;E,QS3_M:?>UTY
M;CR:TIH.K<-8,_Q9NUGKSZ/UUIM'PQ.VEC#*ZBHZ?$FFV2T[M+$C@KVF[:)
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M#R'#;@#+]?:ZKZ57 K-).-J$"TY=\J 1B6Y)X.(T)UX3G>M>C^]HH>NI%'8
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M8<YRL5#W_M7GL/R' M84>/]0?H1Q4VDSV?OPCT^OW?7P?&=$+")ZEX=/#3>
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MT\R\6+8%2C'E?_5;Q#_EXRI;!*5VWIF2GE6J]*45+]>$"Y2W<!.M4C,<F_\
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M<1A$AC_0V^QQ!^3"Y7LE*&+.+&)4%D\13H7KXX>*X-A1,9A:J9:H!)*U0S7
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M,Q9UD3MI-1E+BX3GNC#L']1DY0CT1?FZ:K".TRB0S#MNINT+HI3&3+&=M^8
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M,Y*A";DGM@V? Q3.))HIC?8@;4_3 Y8LG7*_R/VT7YK-M25P&VJ_B].!Y1N
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M[%166\Z95/1!%K'$G#;\BDR>C]7%:1;JGVI4)&+FXS/QS*:>A0DME)E[3[3
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M\/VF)(6=1BPI+"G+2 K?Y+*DL*0\+RD=KGK)DL*2LI1.X8M^=A/L2$[$6Q3
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MIP3QJ&%!6 AJU,*@+FG>*%13 ;UC4^X/F&X*PR: $0F^*&MX'!RV1 5)1DN
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M3TT$_FFH'^=G8C%4,<,^V2* C_"Y7P OP.!%+V-8G%+)7,P*GYF 1;[B"GW
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M#>R;=NC+-(PH^\%]]N>H^B]9U,+V"/+0Y+9'0$=5^ )U8;4+D'P"(9H] FO
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M+^>TFEI66S9=-8<F+X& ,\ 9X(R.<X9NJ6 ,, 88 XQ1V,NP99M?F 6< <X
M9W2<,RQ3YQ?D &. ,< 8'6<,11F.0!@@#! &"*.8BS$RAPH88_,^D5>W55?&
M__/EM_/_+:$L3S>@UEE55Z(HOIG32V4PLI%QP<^ (^,"$"P)04N7AS( "  "
M@$WE29O(.L0FMA&DM1]0*S?2-DR$>X 4(.5=I,@,*3A) 5* E+>1H@UD14-
M$$@!4M[WOF05-@5( 5+>18HBPZ8 *4!* >]+-H;<1BEW!2DXCMVJ+5\_G_]R
M>3'YLPI ]2P8K8[XV:?>AZ)Q&@0 ELV(4!14<P.  &!C#14TBY_?V7L  F>]
MV[HQ#]+"O@TP 4S>C@4B80$P 4S>;2^A(PH(F  F[\!D*21+551N6@2T "U
M"] "M  M0 O.8\N,G?CS:GQZ>5$%IOH5C.:<,-3[<#3.@P#!LB,!+ WUL0 @
M -B<#;0LCIU9>@]!(*UW.SAE(*L&\LZ!%"#E':38&OJ, B? 29&."S9.9H$4
M(.6]MI**CE[WP EP\@Y.1HHZU( 3X 0X><?S,E03GM?+^\1)[%9MF8Y__?KG
MY;@*//4K"EU!$D3O(]$X# (,RW8KMOE530!_P!_P!_QA]]8"F+4?3<BE!5J
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M4>BF3B)%])X&*8W1%; &;A)&6*TE=6@<- X:)[+@X)]R4BSH#_0'^@/]@?Y
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M,C 4>6AC0P:[4)]=  @1&0$0 43A@ AK"! "A+"&K0,B-H\[-H^_9+@/YC3
MQI$O2M6!-3)@*F$J82IA*@%$ +'70(0U! @!0EC#U@$1&\=="69AE-R26RJ1
MP)7"K.N61+(V&E*F$M3%;I(K='5;'RH +:PGK">L)X ((/88B+"%@" @"%O8
M,B"B5.G]4J6L64_R@+TC5[!J(Q1#PUS"7 *!0" 0V$\$PF$%$ %$ +&50,3.
M<<?.<<+^Y9YD \KRJ<@1<4HU>05(=V7KC(8JT DS"3,),PD@ H@]!B),(1 (
M!,(4M@N(V#'NV#%^]4FPS%.-I5D822Z=T2BB&?SF"QK$;#,9OCV@>U_4OC/U
MLF^HUF6..3S[RK8K<(?=K</N L&5VV4 &4 &D&&*@6 @& B&*6[O%EK7N[J%
MO@X3XE>C9AI3,S=,LTS@1SW;![%"Z*9(,U3>$W*/AJP8 \LV.(;T]Q9M5W@2
M#L_^#@^H$=0H#C5RS5('+X(7N\"+JU_+OOIZ$P32Y$^:50B\06?3& U'S<M=
M&"T&XX)QX8G"$VTXGME'A_303G8=C&<N7V;+G'@)^UEG^0N?/7+C^1B6*H;Q
M@=6&QD'C!!$<- X:!XT37W!( *^F9/A-#<0VN 8J[,XN5]$YA@9%4",$]P2T
M!" MD);@H3D1M G<!>X"=W6;N^!P@;1 6B"M5I$6'"ZT/^ 6_3IC[[$KSJ8]
M.V$0>RZ-\HX'4GC#+B3_LYH&>BC8VDP,D\VAS W.?2_5@JO"X7@%$&[>+@/(
M #* #" #R  R@ RGNL5[:/0_V$/-4%J!THJJ25*512A(ZPI+PM&I*B46Q AB
M[-0V$/0(>@0]@A[;28]<<V? B^!%\")XL0.\6&'0L8_$N!9U_#$A[-:W?G[M
M[[7[8L^1?KRC.<LIJOQAYP6N?6>##F2F?KEPO( QW?+U^J)!&,V)OZ'$2O:9
MIX7S*Y8<ZONKSWPZDH_RU^QQ.(^OMXCTVIO36/J-?I,NPSEY1;+?/#>Y.['M
MH24S?;-4U63W9QD?'A6&/6^?+&)Z\OC'/U\^X^=+7(_E/NN)N36^7R <G%_:
MIR/=^/"N"FX"8?5%9=_O[?W%MGRO-1>*&VST!LL=U!0\WJK?S]QME2R^EMQZ
M;/SR;<GJ-Z'O+M<_O@@DMIB?94'^4,*F%R]1KU_J;TO:86:.1DW(>AQ+X4S:
MY2Y,J$/G-S22-&6P\T.JK.B\/"_LJZ#%>VCQ[VF84/=-(8MVR5\CSZ%O)WF+
M=LE>\*S08R?KW="JR_^51'_1=[I,B';-QY_I/?4EI8P9!,&"8'GKX17[>6_&
M1,0$W";\?$F8\K3KBF_89^_SD$N;+OLB6*3MY%85W IN!;>6O^X_@A!<52]7
M:86Y"EV&BW89'N=3R"MI,%P/B0EG!& DH3_0'^@/]$=,^4!_JG.<.MRSA,1W
M$OU/ZMT3G_G!C7;K%5U6W%*\6IZHE:\W4LRAQDL@74FP@ID":X UWA!&!75
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M61A)+IW1**(9?.8+&L1L!Q0&5:"NBE%)0J)2XQC5?D]H78$KS!N )H+Y ]Z
M-^ -A@U  ]!@V%J(MP/W?;K>U7W?=9@0OQIMTI@VN6&:I0ER@Z* $N369;RP
M]-K<AEP=V+I6E;^P169=(3 X#* F4%-;LDY!2Z ET!)HB9/'I(WXM:T$-8&:
M0$V@IE8$I#I,3X<VU^E@0&KY,EOFQ$O8SSK+7_CLD1O/Q]@IC'VI53[0'^@/
M] ?Z _T14#[(XZRF7*W:!&D!Y849P6OK&4.=ESBZLDV#H0)G@#-0; +N '>
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M9>:=%<\EX6G814LB:0BI &/WP6@!C(>#43'Y#7$$&GN,QC)I-D#C#C16D18
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M@@J.-/8)YOR81R>V?G[M[[7[8H^)?KS+L^5/%%7^L/,"U[ZSH70RTZA<.%[
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M(9N"@WZ$"02IB>@C $<(%,!4P5050@I,%9 "I!1!"L:2 2E 2I'M#[K/ "E
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M^O7Z*QPNL-,F.[E@IRK8Z9&;,L<D2ITDS7&Z9*I5&"=[HP(RLK6A7@L9@4I
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M#^ON=@F[SL](%VGDY%4JV:$?Y::9&[%J;?%=<L,TVU ?$JP6/V8C4M3PO2>
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MQY6]453YP]JZBR1?XUA9LA-;ITQ,$3#J$XQJ8_)?:#0GP0.T$%K8H!:.8X]
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MP!@P;CN,]1K"N( Q8 P85PEC384UKA7&V$7OV$5_)0_Y%OK':%E%CN/86@A
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MH,("M+)Y.< G\ E\'GZP:/"K 0! *]S3=G9+BR&CXM7A]F,VS:BJO4.'1]/
MS0 O@9<JE9:F&_Q*:$!,("80$XB)"S%I_#+:P$O@)? 2>(G+1DXUJSJF[3 Q
M%1HR6MN%K0GMU033=1W-4SM>BG5]-JF6#1ZM0^NN[ZB49,-5I(C>TR"E'_-<
M#.JRU^Q;]S26R WCVH'D!8Z?NNP?V ^$*9-,&.2!T?S#J[B7%-]1FL0#B43L
M[W0^)Q'[.5<BL30+?<;6\<G>\MLEC;7O;)!H?\>]6@=.>S5'=8_2U-LR\U/L
M&]QK5JA(\?D*YDEQ.&@;B7W0UN"4PE@*9]*$.G1^0R-)4P9[F&U,M6WW5-L;
MXOQU&X5IX&:6*XQ._N'F_U7Q.)H'PNH656.DW9 =CT25%6Z13VRL,2]Q#U9@
M*EBXJ@Q'^MNW1I?439V$\6IFY(BSG&?-MD4.]>[SG6:#$-])NFV=0;G)JYS#
M1^]9J+<$78$\:XDI;1&HHNM#LW*A"J.!B(>+&P_?B_-$42S1APNTEK.6+*7R
M9"E1=$;@QIR==>#.POF""9,MN'3@HI2Z$OV^H$&<A;4#5V)KT4HZP-2Z:18M
M*7N+ZV$H5GTE%#N%VQ7 P_NH#ZE= .0R[\6PZRL#[@K24,*_Z]SXS3/C:M2,
M4]J,$.9!I/#(>T(^)'XB\G9CBU!-4ZTQ.U (382C(FZ8!&F#M4BOI?RU3!NT
M-'[C79$VN/'Y+7__]&,:?[PE9'%RY=Q1-_7IE]G_$#\EV4'1.'!_3]D=SQZ8
M%HU7)T83+W;\,$XC>LT$<NJ'SE\___UO/[U<)IQ-O>#_;^];G]LVDGT_G_-7
MH+S)O4X53>/]\&Y2!1)@KDXYB8]LGVP^G0+)D80$!+AX2-;^];=[ / E2"1$
M@"3(3M6N11(SZ.GI_DU/3T^WG[*/_CV;7H6I%][Z0)>=)"Q-1ED*[>U9!)/V
M;_XJ-W=C?$':%_UB3!YR_9K=_/AFY. Y]'^K?WQQW@C^%+[P)ND[V] =2=+L
MD:-*\D!W--%6%=.6+4E6'6M@O?EI8Q979V1+8%N5$#P)XUN1"JR: KPZM\@^
M212;B^53]XSE,P\>ZG:8X$$*(*( HD[&:^P20/0TKDZH$U-TQ##0DSEO>56!
M1%%J[.")@CHHJ.,@#%74!JL[G;X$GHZS]P3#YUN%QCINL=U/7R[L'%21S .$
M8)%"7H)"UO'ZD$(^HY"R)368/XD4\I(5LDYU=5+(YQ32T!J,%"*%O&"%E.L
M.X7VO59A=8M"^TY)H<5SU6@><]2.I+4=6G0R_I-3\N"U&7=T3BX^J:>)X@%S
M YV^%'<D-*"),_VU6 %VBW63KMD<&X6W%:$%.X0 B(.1,[(<96AHAFY9UM 4
MG3P$0)$MUU);#P%8.Y@WYVN)CN2&54I>JI1FF)*E/W/D5K!6N IO,'H I^-%
M@=EU?/I\2Z(G>7Z81$^_,R&:L]A+&69C>C*V)E\%*M=J_\5 @,5"DD];3WB
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MCUG% AABFL;^.,,'H2?0)__>GV9>(/"XJQ@G<PS3,A7@G0"-7GF5'QE7OE&
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M",IJ66B9@?+A^]YYL\<@\K&B0NJ5%&"-57@.^IUY8^'MX.IJ("K&#[U7,*6
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MNCB#M0*)NCB#M2*3NCB#M4*=NFBJU8J=ZN0,U@G&ZN0,UHGNZN(,U@H7Z^0
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M%SSPZ@,\42 OSSGW'GDVP*@H+,1I?;4LU#&WVI&%(@UW%J1E<LPIF_A) 0H
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MFPD[X6O1UCLUFCIJ:_#7$NZ^CJA,6F(\OT!B>1VPIRU'EAZ566=O6T98CG/
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M:@]H)D*.O/#34<@C?*3ZP(R0V?^.AA\^O+MZF$SN\&J&^=& HA7^=%1_3()
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M#RO>GA6(@P%(!_K/[%D^>^$LO[%G^<T+9_FM/<MO#\]RSN(C(HH&L-G2LWG
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M<KU.1-LB<LE=*O!PC\EJ%D$@+O](B6_ANPG&)1;C-$ 5V4Z2"YM*"]DZ%CO
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M'94GP=K3?]Z4]_.)I%MX2_"J?_G+_P-02P,$%     @ <(-#2)74CD@.,P
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M"^SMW?.\]D\2392@0XZ WBU.C=D 7#H/3*FHM%54]*RP7UWIGP6&03DT:K6
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MRH$AI&28EM=.B);1]'/\ZJ1>7CJ>-0Q+ZVZ$+].[]2*\18Z@4_&EPF*WO>]
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MN]L9FS.LO7KT-,B=U6]C(RY&0@3J9%?\:VHA<(D^MY?!9T(H3_T 6*=(;"4
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MP5C3[[2D3E&'09?]X*RJ8XVL%NNPVB1)/D$$OVF) C[\O+$IN>A8!%_8E7-
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M (835-PBT9Q2-MGUNR%6Z1FE\>$Q"-.J1JHO4C?EQYQ3V!9#W]'STJW2O@.
M(XCMWDE#N):VO+L7K(RHN)4%DAE*.UJ/'K*21K>%$&HRXOZ[6X]OTZY+SLFZ
MN'+W/CZ90R?UWKB092P/*"L:-4B#KJ/.VI?:623KX#51_6R*.M&7L4 ROP9.
M5]A4NDQL?R[4T9.G<[IMA.<^"9%!*J,A:<,!'0F!FS$/,O!,2;KFB\I7!,D!
M67PE6/PZI:I\\72"#4MJ^>1+D;F>F&SKOM'62R8LAQ2%+^FC#&1T&1*UAC$M
MR^-$5QQ;NB)LCL#J*\'HYWC]N1KR2T>-US%(7?+HM409:..1,H6KUN'.@<M5
MR)XOG-:)1UT1[LYBZI4@[+=YL>'7^)F?WCZL>.\ =1;OGJ&>"<,31VLL>LT9
MW2NPS$N(G#'P3 DP4LFH,JY>T^]F2YTPU15A=7S.7S&@VT)<9_7;H-N<>4+S
MVPATUC5W&BQ5!EA441@B/!/]RI'4B81=.4C[\KA/=D\7&@\4*#^4Y7-&EXWR
M7#%+2P%.F\K+V 9">:AYDZH2J.1<G/T6^;<+K NP=RQ,_>IFZ^Q"*<<S>_-T
MNP+.@]3^'AO#M"$R*U").3 4S91 8]@6\XG<69QU+T29_U6(&HR[5>.WXU5(
M>CC6V(7:[XPX<DFB9]B/7Z58WJFH,LC8Y=CWC'61'/1?YK,WK]/BYK?Y*BU?
MN$]%C$=LM'V?-X%:%;,@0(,MSA;J<6+*M4F1#??$<Z/;;@Z..[G[==9>IG?;
M1\"6S_,+U!UA\JX$TWY#AK_^D*;OTZ^HRMX>\_7/ZK?QN#6AG^HA*U'N7; $
M.?$$.J.5;[RDGKDKCM"?#X'Y9;E9P44Z:4JEW-_K#_.A\+;KKN&22Z>1-BLB
MVE2<<1"JO&^GJ$-;RY:*@E<<=;\LS/HS\2K1A:-WT>JG==@8H9@(7$&.&DT\
MKR/:>5X!)[R<Q3L44K]$[SJQ\RM 6$\V7B/&?IJOCP5W>O77)*L">H<"T(J/
M(*QFD(JN=S1Y:ZS(A/0[.:P3);\\PGIR\2H!AM[@H ##_AH>F9.&9L!UEH%X
M_".:\J9%SL$I*5&]]PONU EM7P' ^G'QN@"VJ;P\+,;N==DHJ1QW'&E$<P)X
MY QRSAX\5X0E;6S4_4S^.L'I2\+L7$:.&MQYX,./'W'Y,N3H(9?[-TD>S^+M
M/9-+C'G!$LX_36:X/GY!_#VX7G/\ANCQADVD66DF#"3K92F]6K*2"6I1(G6F
MCD?:JA7&F7!!63Y,^X\?PW1=GG#_&@][BWJ<UE7#D2,L.@%HJY1W/H4$-% $
MB,AY2MPYK:ZYZ/.0(G]0?6-T5E;8EH\PZ'$(ZYLBN-0UV^'TSAJ97=3&X.;!
MO0'E0D*W/HAR'XZ&:'.YWG1N6&3,G/@1 5:%FY>%V,^+^?)89+>M:4.\4LY:
M"LH@?P5:OL"#YR"2P[_QCOG6S/1+QCPN@YZ^K*M2R>H!%T[;WMJ;-^AB.\I,
M1AJ4@<B4!EI"U$J@Y1Q)BC)<:I_?(Z=SIK^_@\8[W&^D"> H"IUXZM$_W-Q&
M3DXF2ED0UUP18G@A/]C91V+CO05TT6UK=!Y6WKQ&<";;7)_QWC<Z,O;H3N97
MU43&&Z&7 WD@G>ASI[.T"MLR^&X69_/9[I=#24-M[1J54_2)$TBIO*>;2Z''
M9.(V&TI'&:T]]4'QH;:*'>5EG2W?I@U RBI^GE^F95J\/WI]J$/K1K)$7/()
M'.$9B/41/'%("Q,QV!"4#]=8CFT$N3[8'<9@7A7;:D?XW^>+?SR;O5C,0UJ>
MCIG#K1M#%<LD*."V#"\H,CBC+A=.*)++X8:YQDIL%3$S*/-J8N:E^_ K[MB+
MB9N>#IF#C1NEJ31.:+ JX1_%N0DJ"C )>5$6BHW]"B:,Z[]51,R0O!O57KJ_
MKX\?>=^-5\$BVM7J?3;[FT,QX'"W57Y_G*WNU8B]S.ACYT;^@J.\N1?Z&W&(
ML2>SN3E14M[GTTDL+LCG!STWEWD+J[<D7)Z""QZQ;&B\4SWTMV.F='NC1F<9
M=,@1A)(6!+,!N'1HRBL5E;:*"G;J&P"';A;<O)O./R5<(!L'<_J%G'9WH$O;
M)EN6K T.T#-&5]5D!\QKNGOZ-YJH>N; U F>#"6D^?A\JV#>_+!>3LK9[9/Y
MC<=5>.1BS"W+/G5:"F?UVUBE7(B)@\A<0[!) .,NHTWHI8Z*1L/Z&45U4D4'
MAMBE>%H!?AM./0YAL4ZQE[8]UK8)-,2P>2^)2U.BDJS4^.?HB=K(#;..NVM^
M*G$D&(W!MUI002+GMW4AMY=]=O=!VW!RL&$CJ3"JU)'D(7N(.0L0'+4TB=P:
MHK5TM"WC;CS/<VOZ;@F^M7I;_,U]39HL:,ZAY%EZ%T%JJR&AX8"[D.4V1JZ-
M[G<9N>*>/9 (][B9 [&LSNG@UO-I1?U77S8F<N<$S@0=<@>VU-X54AN0D9?'
M<QWW/4M[5CJO&14"Y[*JAN1OWKG)HN#T>>[XQ-G^%HV1GIG,+4AI$PXG,B2N
M$=TJ91-85-ST2S'FWSX2!F-9!43\[":S4AOY^>R5FZ:NJ#C2JG'6$V(8 8UF
M!-J)E@,QR0-13OED$TFJWPVM.K<;1@3&L%RKD7*T+7ZU?1([?'J]<+.EV]Q'
MOYW*]F6LU^[CL>RC[KTT.EI)B IH+Q)T;ZT/X+UA8#657*#KZZZZ*,^(X!F7
MBWVJ3VPF>V^"^_.&#W_<!*DDR5&#UCJ!3,I!5EGOJAH(JF3/7:3.#8(1Q#TH
MLT8\J#@U_#KV049G>D8^Z'BQ*&!8?7HQ=;/R?&%YL/#=S9T81+T1+QCX/DC3
M\9L%QYHUY6$8;9P )F2&[-"6YLI1M*:8(M8I+>5EW@,\2'5;6N[QAHV2EF8B
M"!H"GH.R.%<G%8&@B>9*H/J(UUQ183AASD=F6XUK>VX6CR"A_',C,Z7<:X%,
MB+AGE!?; ^6BW#QD,G"E'.^7PW]A>?<0R]<7Z_JQI\K)QV1:DCU+<B'Z?8OY
M^\U6TYJ1?[1=HXR.,@B<6\X$',=):R8LL$B$U%D+':^YM/2(2!B:;S66?G++
M]'8^/0D?AQLUB?CR3I$!(GD&*3B#J"T#[@6CPO&HW377=AY330S)M K(^-6%
MMY-96GPZQ6@XW*B1R2>F-$=FE;=JS>:PI12*"]'E&$.V_)JK+X^(C$&9UL=7
M+N\WK5=I\6J>5Q_<HE2[_S>WB.7'0Q[SD29-0)J=9>C6Q\C*,\06) ]VFQ)7
M'E'4OI]I6"=,,H*D1V!9C0#;>C&;K-8;2G^:?"P_M5_F.]2FB8KGR,MY+OX'
MCE@*T4H'*GFE<SG?[?F"<YUHRHCK?TB>58!%B6.L%MO*GYLTYS=(;RLPCK1J
MDF3!F&S!,YQ<XI*CYY45A!2=1&D1P<]^,^O;A,:P7*L CCOWONX66<>?IVDC
MG/O5UEL#4GN0--00C3?"4:D)<.)PB27N@'%<8E8K[<K38S+WLT@JG1>/%L.X
M((='# JWA2+'#@(?'+^-L/$N(1X<>>0X]'^LW0(MH>FGSW'PIV[E?I^Y=43(
MQTN-.W9>>K?AQ\9A"Q4CB_YEVFYHFPKB]WZYP)!C"[QUY+%E?9B T<7\/LW6
MZ>L+9&./,[Y ]PTWGH+^:KR1A?8JO=EF">;YXF;<RT /AQI;= =''$]Z!X<<
M>]D_''ALY'Q^"_S%KIQ@Q:&&K#*P_U'S79[#LUFIGE&*7917SDN4?_</^QS?
M<[IK.(_),YU!^B A:VHA,^MWV13,,$K:+N:/Y-]--P.E>'1FFSNLQ_.N3NNH
M25%*5_(1>4*B%*490BG=3+)/3#A/4\][#A4J%50!P=<NW-CLK1!+N+UR]@KW
MODE(^V>RFRC^5&Y-A_F;V>1_4#6DQ60>-QQ]XMY-5FY:_A:=UO71T,)((S9:
M*4.9]& 25>"41YDRHDI)^R"L8$&F?HF#%6HF7 *]UR.'$>,1!S>R$0V20T,>
M>N%^Q"''>Y3IX)"B_I"R_I"J_I"F_I"V_I"C6^T/!CY(BJY(Q-BN0]F$%I^>
MYU<3U.!Y$DHH,H2BKR>S-R_FTTD8L_I&M^%'=TX[47$ES&@%Q%^^+__B$43_
M\D__#U!+ P04    " !P@T-( R*)B4K"  !]F0D %0   &)I:6(M,C Q-3$R
M,S%?9&5F+GAM;.R]:7?C.)8F_'U^1;XYG[,2^]*G:^9@S8J>R'1TA+.JN[_P
M*"3:9I<LNK1$A/O7OZ DTDM((@61%.6L.3V5#AL +YY[ =P-%__Z?[_=3W_X
MDLX763[[\X_P3^#'']+9.)]DL]L___C[IY_4)_/NW8__]__\KW_]_W[ZZ3_T
MQ_<_V'R\ND]GRQ_,/!TMT\D/7[/EW0]_FZ2+O_]P,\_O?_A;/O][]F7TTT^;
M3C^L?YAFL[]_'BW2'[XMLG]9C._2^]'[?#Q:KC][MUP^_,O//W_]^O5/WS[/
MIW_*Y[<_(P#PSU6OO2V*?_U4-ONI^-5/$/V$X9^^+28__A F-ULT&'_;\E^*
MOTZ658?GC>G/FS]638N^+X;^BM=MH93RY_5?JZ:+;%?#,"C\^3]^??]IC<9/
MV6RQ',W&Z8__YW_]\,._SO-I^C&]^:'X[^\?W[WH_SG+;]-9-DG'?QKG]S\7
M37Y6X\"5U;1@R-7R+IV;_/YAGMZELT7V)7T7.'J?OL\7BT!20=F_W,W3FS__
M^#G+/@?,((5H@]C_/G*8Y>-#^N<?%]G]PS1@^'.7E-MT.<JF;4W@U6C]SP.V
M.Q%XAIE<CSY/T[88\G*P=F;QCU6VR(H=I@&1W[=MFX;G/S<6YD;=>Z"T@;@V
MZ]\EK4T%LDGOMNG<XG"=?ENN1M-C:-S=LPWZ3#Z=CC[G\W *?TG5;+,^/Z;3
M]:F\N,L>:K%L/D(_]-:WV**)3Y_9\=_J!X.&>\O1 _5*?>U^<_Q(O=*/6J,?
MG87^AOM4['C]S*79>7#L..W0?G^?+0LK:A&^:/+9,MA;P>[*FI!;V[5C"@_\
MJ?GJ;6/TCN?9>"-M.D(_]#9>ND<.U#'U31=KPP':H7:VR*?9I+!=]&A:&.>?
M[M)TV8#*FHZ=4O=A- _XW*7+;-Q$#(X9I6VZ/RW#_ZZY>75C1HL[/\V_'H7N
MP0$ZI?9[,S::[OU#=3D#%TR,Y6,LT2][=TGG:>"VCZ=-Y]F7M;+P;K98SM>^
MT%J9/=BI,ZH:GF!-^G9-8ZW*T*ASUU0V/%N/&*(SBIN=IPVZMD+A-F80SFP7
MCNSEX[O933Z_7ZO8M20VZ-L&C6XTGP5E8O$AG7^Z"X=?'5W[VG=!2\.%7-.M
M"\J:B=GA7JW0%3KGCVFJTUEZDRT_!$VFGJH#?;JBJ2DGZ[NV0F$C':#]LWXS
M8E,L=C5NG8J&6_NA/NW1U'!5[6C;!@U^E,W_.IJNTE_3T6(U3QMI. <[=495
M0Q%JTK=K&FLUG$:=NZ:RUG'9J'/75#9<K$<,T1G%S99R@ZZM4)C-@H6?C:9'
MF"Z'^G1%4]-E7=^U8PKK%W6#OAW36+^D&_3MF,;:>%R3OAW3N-TQ3F'YZR'Z
MH?@4 7@]1%<4-]PF:WNV0=\OJ]%\-%NF]?1\W[*-[V]\5M>C;_4$[&C:,@4-
MM^+]/;JAIW85'NC2#46UJ^Q EVXHJMU4#W3IAJ*&>EMMQY:I:[;Y[.W0#C63
M]/,RG<S2^B3-76W;IJ'QLM_;I2.*&BS\_7TZHJFQ6-?U;)N^IH*]KT<[]"Q'
ML]LL#*L6BW0=M_TESR=?LVD#P&J[=DQAXV70=(1^Z&VP2!H/T3'%346TX0#M
M4/LE*);YO-8Q^EW#5K_>6/9VM^^"EL8;W<%NK5+65'YV-F^+DL4F)>7=[*^C
M>59\(<AK.@^_7D>L&F1U'35(;U0?(8''CM7&'-Z'@6\;Q1"_;]GN]QL"M;=#
M&]1L;U<\I4%4QG*5#['Y:AV51P_4*_4-H8X=[QQS:;BKGCALKS-KMBM'#M?&
M3#[,\X=TOGPL(JOKU()_K+*'XH-U--=V[)2ZAM+?M'\?M#:4[B.'Z93R.EIJ
MU>O31^YT?LU69\/N;5#Z[ZO1/*@+T\=J ["CY>CWV6@UR<*V4$=IP^X]4-IP
M?1XW2G]T-URK48/U,(MF<GW4(&U0_3$M@A7CY6J>S6Y?_*..U/J>W=+74)P;
M#] +M0V%^-AQNJ6]F>@V[=\.K<%D7H4NBW3^I0EI.YMW0$ECH3S4JSNZ:I6#
MFFX=4-94N YT:H.J3^EMH3X<D?N[OT<W]#04K=J.G5)7*V#U/3NEK^'^V[1_
M-[0V6Q)U_5JAK4B(UJ-%.ODP>FR4D;6_1S?T-%T5=1T[I:Y^5=3V[)2^VO2
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M/MGOCKO^8N*DX=PH)!VAR@0]"6M<'93*117A;+TZRQ]"=B/8$17@VA1/6_A
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M7M<B^GD7\,3E,3Z.ILLL75RG\_O%B[,PS*YT\^SC;+/>"93 "^\H!UP!0@W
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M$)91K1&P3,-@*(/RGA8)TXNK4/*&O>5G!/])'O_UYR?<PWS^OO[=RU]M>[Y
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M"G].  ]Z%F *A5U!<8BE [@DV%D5Y8AHW;'?#;^.GWX/COM=/L:/V>+O->Z
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M"^E4QN7GP>U445F;4X&\ZZ_Y:\I\,+..%)+FHR584R$,H]1YP+W6@NOJ/&4
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ML+)VMD^\()0*AP44P'/$%'>;['U@G2:JSOSJ.OMH3:W>6$#-<XV^ZY4(2CR
M'%&GJ/&6,4SU=II6 S:$9VA/Y,_>3*)3P1AJWM"ZHF/QH>? U>0&[>T3S&F"
M,>8:2X.M],X8ATJ<I9(].;8C\W].8/%KL6D)H!Z4C><4UJ9H?-\XL<X7KQAJ
MKHP.<V$ &UI.B FK!YO#TP*/\H[0>0-L'UI*SB"XW3N7/P45-EVH#_.M7W1-
M;&U9] .]$EW$>"S''A!M#'=:2%RAI?6PLG9.8='K';TU3*(R/=9?_X^&?*SK
MDDA'",=2^4 Y()01IFQ%L(LK?]Y9*+(%)K8,2 P'?W]65_\8-M;U2X0%7E-"
M)02>00>,,[ DO7B9=!#^_[9YV3(J?7CL7E"YO;BY6M[E\YK(\>&.07*QID7N
M8+!I'&16Z"?X!/+#"!EW8YNUBDS'KIIN+Y=5E=I_34=%AL:+N]B]?.R,U\LJ
M>M1BD2Z+PG1EQ#=L]UL:)U>SC\5-V7F18C0KXK_S\I]%]85%$\=/J]])C 9:
M.V055\6#+!)R8=;2R8+(&U9766ZX4-:YEUK[1E)4Q6#AY*9$LK"TB8-;Q9UI
M;!&/*L[7LC/J3#*3#P/RH;J\*CST8_7C7[+T_V?O3=O;QI6TX7_T#O;E(]9^
M,T\ZR9.XS\R9+[@4F[$U8XL>2DJWY]<_H"S22R21@DB(=L_5YV0S :+N*@)5
MA5JJN-Z;AX_%S^*VP__5;X* %(.48^<8!E! [@5M^(7C7S)Y2]-:4>83E7W"
M.B2V&12\G<?BKQ1T^EJ.FB=0HJ1R0D<[4Q#N#"%2M3  ,-VBV4.S>9\4C8CB
MWU:HIN;;>U.R=#X9^K"X7Z^6&SQ@IP_PP*@@(5(400@@TY!*&6TTV9!(C)U&
M3<:1N;=/1DZ&ZTP2@9(D K4>4.^4(XAPS:SGUD::&Q*E(4EI_Z,Y%,\G$6EP
MG4DB<))$X,8!A[4T5A@7-4"@A"-\6TPHDF@\3*JF-9I;\GP2D0973HG0#\]
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MM!(J_"T+6SXP)R5?JJIJ)?NQ1E;]I\\_/J]7E^5=L=SL\O___/IF$-'K\Z)
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M(CTF<=_#UEK'M@03Z;)5(^TG'7E<XX.C=E8Q21*/@ DUDLFXZU%")&;:RI9
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M5^>I;\G6SF7*YSZ[E(R.W(D"X\MUM5G??Q35@=75/^DM+D?/&;! 1$+ "<(
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M$&H9]*YOC[+W?*&=[I2]8T+4*&&=?N*@8C;JF+CV36_)TTI.U_$V ,=>R\#
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ML!7Z'-N!9"PQ7F4PXE]?:LZ \'(9D2U@>9K8XJYU,$0?GRMX,%A$8"U1'$'
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M0$812ZH?.;P6\/>S T0[!.E2DO#+<G&;)@Q/;\9%)()@TFDN2-D7#P&K-[R
M"!J'<M"3/"3CE.(RW5?'GWR9/HUA?7/_^]<(T'HRGSYWW^\&6R99N.5BO9S/
M[B;;UE3U>X=\K9U^I A<:80ED8PP)#!'(H1ZG2B1U*-R>)4B77@N#NDE+1*_
MK:?WC_._S^Z/I2NT>+M@ 5/ W."@.7=8@ %139EYEG0_&5XQ.7\+ZAZK_I*I
M6J47Y9'DU)CF]3__7?Z7LK#^__[7_P-02P,$%     @ <(-#2"=KWFYUS@$
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MS,2,!V")"=O?G@&.[$6-\_+3;?.>J,_)#C!(>Q;SYJ0HLI0CA840H3Z<,WX
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M)ZQC[3UT0T!O$$E::2+Z,. [+M1+4]EU9PCJE%-4GBK6B5-3U<7\)S);;8U
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M:9'7N_8N?G5LS9O^%4E:[ROMC$+I8!7YG=8L]-#9!=)@N<YCBH_*> T:*(^
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MG_M=>@-0<SD>8HBZB[L&%FA[GQS6!(]$^[I$ 8VDO4^N"D11TX#<XU[<'X"
MNKA?^&(HWYAYZ/!/#9P\G)V+E5+Y5R \RK6OG*LG0XZT9?3+I#/G1=<]'\ET
M.5LEFN88.K83QPD]UW.U$%MCN/5B]@)QG-^7?61M0(7RHA^6CX@"@QR@XF2.
M(?S,0!HLP"S)%^2 F7S>. ^4@?EC/#[VHL%GCXM-HT<!?9YJ02FNLW"N#H8E
M$?-=2=N](ED Z4;%'?F=V[RID[RJFR2_;1X_Y-LM[>RZ&^I!@#W?BNS(<0/#
M]X?7*0W-M75F%9:&0+).GRX^A"7-B3KH:,2.>O#HEJ(G_R3PT:[#S[ER)-9)
MP%6^Q?PS97&/N.;3!=>TP%&+''U0R#6<:WF+N4C$$M[Z>!25HZL>SH\BD4MW
M$.I85NRDN$*!2"??QG/K<Q(993PL?:[]:]++ZOMRN[DNHXR>S,^+[,M]6ET$
M_:G*R^JZQ&38;-KMOS"@8=T(?3U.W#A.(M>,Q@"O^0;HN/6R4&<XL/WVO%:@
M9C 2W985^IPW^V]IF^'^C+ZTNP-A6J2;E"YQ; 824$U9>%6'R+\(%_1OI@,;
MH%/,"W<AAI"_-$:9)](OY )HM(ZN3([VH=; 5S,)U)I)_R;^'KL%Z'C\]],]
M> _87QK_!VT1HQ[3#_!+]<?Y*P!J= ,%,B)EJ"@5'*: _&H$=G7[4U76-5UB
MKJ]NZ;HS7M_GV==L\Z[X1#<D-@37]6_9]FL6ED6=K??TVM:'LFCNZY\+XNJK
MA]:$(EN1Q,\.?"M.=%VW3 ),=X>W2PS7M2$G5I> )SV/>I_OB"H1V;JC)HT[
M/-V9I'X+*.VMHPG4PV ?T@VT:TU">VH3D;I.\0K(TNLB+F?(@53W-2SO.60V
M)(UI[6FW6MO[VMTN[& 4>E>@T2S4V86.#$.=9:@U#76VH2OU70[(;U1W/5].
M<^@")V.]O4%^:90W71=8'W6!,Z-^:AXC@?=SN<N2+E8@7UG4_%*1H38U+SD%
MB8M'-GB&%1JN'2<.29@\)_8]S1Z*PAN!;T#>T)T3EG)Y2%H\2LQ 9#F7-_-0
MP*N",H[GZ0:Q9L9$0Y9GIR88"GA8<&+Q\IA=.)_@HQF41TCVI*KY@VRS7\T;
M9N&=\7%3"J?*[^ZRZ@C? 'IE^DZ"G<1S-3/P/$/73&.XYF4X8<Q>GGEJ0Y+/
M2/2*W^$[C0(#1- ;GA-990B^<Q(*"ZB*<0EZ%G4^3GE?1VWC5<_M20P;4$X-
M1J^0<"[ B.).@: AS)120M\"W\TY'),O;]?EN-\S;O?T9U965N)%>ABZAN4G
MEAT9H1%K P!3BSQFJ1?;K&3A[V\5/#PYW7-AQQ[R!K9@#S"$A>7(AP6)[XIW
M\.6:)?B?=*M&B!\@5VD8&;I\AT8TS0K$'DF&/;\U(X<[(4>YWY/HF-6K,(AM
M4_,BTXB#V#>Q10+BN&UK!>QS#T'MS7=,^_P)G@ZJP&._K%PSA)X%:(;%'+49
M%GB,6@+3DP]-<S,NYGATUPCO86@@H0K$$=$600XZ<['%%#FB;%UE:9V]*YZ?
M NJ/5T?[[+J,ZR;?T9('8;FCE1#:7ANE.P*Y7F$=1U'LVEH2^%H8>$D8CQ=
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M^ZW%CL@GVA<LRFV^Z7;9ZM$<^A?SUB#@?$",5Q@G;+,[!#XKH\P?]J4[D.B
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M'8%/RV"LCPT8WJ8 B)@D!S'$A^5] PL</=YV1O5"A32*F5:".4'-\3J,)(<
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M:](IV_*3M%[67;K);V^SBOS(KMRD6WJZ2],"-TP""SN1%[O8MCW-'@NF6%;
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M7EY9JW9?(N!<!B>(-@52.5&6E.([%63.7&6[?$_2Q^P?^[QYS(NO9-[>E4O
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M05R__6/E%P)Y6R@!$>WYY3.4I*QNL_PXQW+B,/%CTPE,U[:BQ(D#-QQ7+9+
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M4VCBVI,>C"C*M]W=6E2-./M1"#C/+)!BAK S.[>P8$/A#<6V#P!1IWHM1)X
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MG=X.QD^X^T3B=M',NP)QPLZ%900^%M58"^#$7HKH1X"T*LJ*<I<7)U*E)U:
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M@WX/_5F>C3?_M:\;"F?EF5H8)['N.9J1N'H<AM&XA!%%IKMJZ-,4$Y8/!&
M+22,<.$9W4/9$#@YD9N3!00!BP8B'#%A^6!F'XA92!A.4CU?34 'W JL*+Q.
M+G1M0:"[U!!LZ5:RK#<(9W7B>NXY/"ML1+KFAG;H.JX=):;I:\: (C&-9+(D
M3VA;LA3W8WU/L[:\0.MTNZ8E'>F8GWIJ59HW)BWKSN((J0N[O04*"/%Y-N&+
MNY/]HK#PBK".;8%7$(M,IPR>U<W+OC7[=#NNS>#$UUTM"#S7"1TJZZXW'FP(
MW"1DV2<3TI#D;;'XF3ZB/_<0&=]7$$,GPZF$.9F$:> +Z[<CB7Q'%B;S"3B^
M,">O?$<9GG?2J2<:7K'YW.F&_X^\=VV2%,>V!?\*7\:FVBRJ#B 0<.:3D$2=
MO+<J,R<SNGO.E(VYD>Y$!-T>$!?<LS+ZUU^)EWL\G)"$!$3/L6-=\4K7VFM+
M:V^]MG11M8*3#MI,*0UT)8TG(+IU%[Y(^_7X[1_9]G!=?LGZY=I/%>8/9.WW
M[3A!F*^IL'3>)J[O$AI@ (<CL3ZUM9V.T(K*<(@XX3H_+,&A:SP?H==-&LY.
M+.8AS>GWU; 8WNQ3=+;P9?!SOU;6N3VKR,[EW:!Z*,.(JU>=T9NT6^8PAT'F
M18-'?*QS_@@\@_*-G]=K"B'U\8I--4@4HP3&@'H$HH!7/0*NZQ& ?<^-!85F
M4AOFM*.'99WC6NSDP1A)(R-;"[?K&*QZ3"D-]#V)B34N"S;2;S-F\6<VQN_3
M;78\Y-MTWU>*\4./^,C%(0P3&Q/'=4,PM!D'D?#,>G)+AO.F,WS6,X 2,\'I
M? I,K6>E4DZD1EA4*=8UG4Z)F?6LM*I-K2?1*S;7?HN%2Y-M;>RM8+:MSY;2
M1/^2?%6^/:907Y=H^[^.>97U,2:K?ZV:6V&V@PE(H.<$KF/[-/$A[IMET_Y8
M[OS8Y.:,GP[#:7UG/9157UR)]8@ZW_'KMF.3*4/<BJ6DLY(JI_@]-#Y'[<!9
M)W175H-OYC?IWV!K)#_51O0Z<E1]YCQ_KEXO3Z):EJ1Y];=T?\Q^S]+ZV![6
M^GM^N/MK47ZKL^H[/Z+UH7@X'NHO&:<HW^?-J/["C_-6W26$^K<\_<9^<WCL
M2^8RN) Z/DPB@.P@A@$$-G^DHH5+8T)EEA(7 VD^0^:;]?RPY1/)M,IO^_QV
M@:4H4T2/Z,/BOEV'KBQ/0[FR,3=Y&0N?#ZGK*BWJFZRJLIVS<2&-4&13%R0!
M!C@F83Q(*7!I**--6ALVK#?7_(C1V5']*M]*'@?22[/RZN$\#$]?3>2;#^>Z
M?@9U\<7%BQS*+39.=\4Z!-B,:6\O1NKB3_C!Y4-Z:,3\TTVS[W!7[EGK-64Y
MY^'Q5!O)=VU"(AI"'T4 !H&=V AX,404X3 6+;JCIS%S8W; U^P7GB'\/ZT6
MXV*[ 4+,C8Q4O<RO8XAJMNGY$[0&&),>E.WSM7'HN0D,O,A!=@AQ&"#;ZQJ)
MP\A.I%XQE_MHPQG(:<"IO1TNR9.D2NFG2%6.EGEQ^PD/(N(B1]C*5$02_"6Y
M4.% 6A=:%>*EPLN"KQ(U[W\&%/B >M@-J.<2-P$@COHV 0R!DDPHM327:ESU
M8?F$3^FYYHF\2LJ*<4KE5$::0K-B\QH[(MHSB=652=$T6RXIDP:&1(7J65/=
M<YX$.Q#$T/%L["9AC"@&9&@K2J2*;:FU8%B8G@\EQ1>!%=D3DR'SQ$V3GX6>
M^WV5EA'=F4;C.O1FH@VESHXEN^7.:^+RMM+BL=O<1P$*XLBF24Q=%Q(4 C?H
M6_+C0/!-Q"DM&-]8;Q=L^V+*Q?:7]O;'L$B1-2Z0W6%7H%)T4]TLA[+[Z!R-
MU<&1/LVC:^?\!26CF^7J!*Y#8B99\&)+?"H;PO+"/-ZLNC8K/_WAH20)@4\
M)'; 5"U);%Y9KVTJB%W!9X\F-6%<8 94*A=:U%@3E!+3=$EJR<!3>XUD(3%Y
MA90Q-9G"X4KD9)()S_5D.A^B@G)VL:-K!\/8#L.$8IIXA"0>1#@>\J+$E:R:
M*?_YY@\!*E^,4R!+3$3,LB2G($]NH2TC'R_H&-$.=>K6(1P3\)>Z.I'D6[^[
M7<[W@-/]YS3??2AP^I"S[+]KTTML@"+BV]@#O@L3XOMX6%\.G41./J:U95Q*
M3O"L!X;OYZ:V38-0\K'=:92*B<Q\7,H)SAF)GSL2.V@+R<\H42-2I(?@=<B2
M)EN>/S*KD2%AN=INC_>\VE2V^W2XRRH^3:NRNZRH\^]9^T).UWY$8L>/2!0'
MQ(MP' 8!'J9LF%!?4KJTM6M>QDY0K9)CY<4#3F#[M[-^VO-GH"2531_[@BJW
M".V2BO<)?[CPFM92DB?*VIC\:6=^)5*HWZ[GLFB(.5&)_)(=TKPX/<K:-183
MZF&8>)@"E[+&7!P,1P42&! Y/51LQ+CX];B&"H1R J?*G9B:S4":G'0-; VE
MGI81K->)&5&GB4RN0XJF&E%J[5UR(G-=-?<S'I],4%TOC#P8>'&"$P0H<4Z+
MY-"!KIS"J+1@?F>L Z6RWJ1$F9BPF.9*3E4&DI9<=7J%DA$]F4+@.L1DD@6E
MONXD^6PQ,ZXL#LQ0]D>W'XI#QOK5H6N2(AO&-@ 0V&[L8.!$=M(WZ261Y$[8
MI*:,"\M3=&R.UL*33%^FT2FF-;/Q*"<ZSPCL<2VD/F,DC<B0%F[7H4=Z3'G^
M"K(^?J3/0O_&<JL/[,MZ QP:V@1![$:8Q)X+HC <,JK(\94.0(M_O.'#A6>W
M 3@FJP&E>M!9@C0Q]3',EYSF2%)E]D#S0,B(ODQ@;QVJ,L6 2^>55;D05Y#G
MU[H^%-O]D9=8_]P6KWGZ,-'K(K>)@AA#FU!($Y\0  , 3NOI(/8V17;+UYP^
M9U5>[IAUU4%4@F;!)S0,HW887C!%>&#&V6U>\$FP%:=[7LQ25K[F\9BHY*W'
M/XHR^?*&ZY4U&&%U5KQ80[^0TLVMKSK8']7D6=V[%AV?U^@7VK\ Y\+QHJG1
M^Z&NC]EN$SL(.C3RO3CR<.01#)*^"0QLVU%7?9E6%M7N*Z47WN18%%1B[9RI
MZ6E78;P%,K,<GE$P)FHJ3*U$FI2@/Q<8=?O%#X^7-_GA-UZCS0D!B0'P(0AP
MX@/J>Q[H&\ 1EEQXE_A@\\MBV:$[KR![1ER<'+&Q;X@5R44N1L>'[O@&A_*7
M=Y-&G>@;40T%CM>A&2K 7YP25[1=5"\NG47@3;)^]>GF.OVQ(;83V!3Z(+$Q
M@I%C(^#W3=LHIGVZ<2V^PJ6E784$Y%I^Z>O3Q=-25U:1-=5Z#ND/.2720[N8
M1LU'M9)ZM?0^P?=<S3ZV+%^/L&Q$GD28&Q$NK<2O0]+TFE0:[*AR,OA[7I15
M,^%KPR#)MGRW,TL8 R2OV]#)7VNX-.O[KW;:N'$#2 //@;;O,K&&+*\+^N/X
MV//A()5B*CD;+ 4EE1/1<[0\_2BT[&S.YS8QJ5V7OW3NF%Y9O2T65P7KB34C
M^:35632O<.ORPXBXS^[J=02 ^<TN%QYB.HZNL#@V@'RE[.8&^RCP,*'(B:,@
M3ESW5*<" Y\Z,GO'9A 8WEYNRLS7>?]F@Y[H8,@74P[$S.D&3;K?0VYU_[7"
MPFLX1/,&L=*G:W0Y:AVJ;=A&H?,X>AF=IL=/@@:O&%^7^WS7X@@C8KLA!:X-
M0M8T=4)[F&# T-:@Q5-:-ZS#S^"8UN))?IBBPW.YP$SN_13P&N1WA$]IZ=7A
MFS7+KA;[A"17'Y-*%T":%SNZ!X1VN.1',@]WY6X30L^)$VI3E]@>TWL:G#)O
M1) CMT:BI4GCZQ^7W^V^LE+^XL[(UHM!IL4T=#Z*-=PLN;(:A%?]<V4[_NY%
M?;!:F M>-[E W(@^:N5]'9*HUZ2Q&RIZ^%(2OG:?OV][8Z,H!K8=AG'H!7X2
M AKV56XQL4DP0>\D6UJ#S*D=W)G$KX+*F2!6B[CUQWQZ: L*VE..1'5,D=D5
MRI>J)6.J-8D=);'ZDAV>*B2Z+X_%80,(=@,O1DD4PPBS%C'I+\Y@FZ6.,O-@
M+0T:GOJVL/KW=\ZEBS]25A]3]HM#:1WN,HL/CG8@6F>"][DJ;ZOT7D<^I^P3
M!:6;PQW3)*]#^"2/8P+8P%Q0_BX0)ZJ#4WE?H2!.-FE,&?7P)74]YS2X=ZC8
M=0#(D3\HV1UD;M1ZXSL.RR,C&T*((GXL*Z&#2F,28KFK?QH;?F^2J7BH6ZNO
MQ"1T,3?)26E;:^$,IY46NUY0K1:JU6+M4\L%+M((\CAVLMR$.]:AL&9,>^WJ
MBQG^I!2W/1M_WF8SC7\6"/+V!#T$) G=.*!.&,1^0.R(N#T.]C^2M?STMV_\
M'#Q'R^_"O%#?8\$Z9?=U^=#LY/!Q/TAS]^0N^S 5J=7K) F]7<P[*J+;@GVN
ML=W:Y+-B.#WH!;17AM.W!-B(?U:DPF;L>TV*#3(Y48_;&/ Z$,_SHL )'(>0
MR'<BOF8Q  E<!VD1Y"D WH4B3TB"-;MKDC3/Y2=]VMPOK:Y9G$=8E5=G'2Y:
MM3QK,5!,G_5QJ2-A;G[WJ=&9FO[(JFW.DOH-H5Y$?.#R5Q=#[&+?Q4/BCMP(
M*MSCT@]"88]*X5*70([6_DF'WQH,T)<P*SII>L)LT#&F$F999\R>,+_*J6+"
M/,T_JU9D'?9)),PZF-22,+\.)$I(3$ <Q%&0(">&)+$'(!'[L?3"L=[F#2\?
M-]!^_M8L2_)K?UE1MZ=.456QOVL7EK\]6N=_]SE];'Z,_DPKI@Z=25>#(M16
M7G3:H3%_5O2>AOS9O.,DI7HAG\V?8VL2=!UN7+6B:S%0)L?6P:7PPS+[AO6L
M;3KFW?F\U],?_,ML VTW(&'LQW$2> YR0M?UAH""DT!&QS4U:5B[GXS]K,5D
M55G[OLRA;)<PNO'_T(Y_R04-7=2+B? "K,L)[P#0NBC!'<B97Y41(FY$-S4S
MOPZMU&W4\\=D3' F_C;@/X[UH1G1U^6%U[ZNTQ_TYB;;'OC5@]=!;L+$CP%*
M;-OW(7$<C#Q*3Q>^',E'2.="97P)F8&TOF5%=I,?VNL^&J1T+H\):NT*724I
MQB<+>+![]KJA=7K=\*HO9<.]&I][]9**S_T,HA97C,G[S,Y>B?[/;?6+1QB7
M8'WFVM>AG0241'Y$D&]'_)(PZ0MS\W=)R-,JJ+00O& Q$SJ%=>ZGA@BK%?L'
M(D6O_W]=*%G46^N0E[F--E,H68YSI4+),+ C:J.0P-@A48Q0Z-E=$\3S/*PJ
M$3)M+#70WSQ'L)I2P*(,KF3P*4$?*P4L9[_H0/BU+'=_YOL]*EC,/[!^DK/!
MB.HZ.]0DK[?[LCY6V77VXQ SZ_ZYB7R'>IX?^FR.& 48!;Y- !N/ONM&KDLD
M'W77W+CY@SL#2*M%V1S/Z:V0FV[I)EYL5K4@XW*3IQYHP_!+WD]@K3\X7*O!
M._/[.7)DCNB<(:^L0PE-&5?.TK/EU)2PD/R=38IX4=+Z4!V;N15#]%_9[I8%
M7;1EOV*SK.P,$OK&_C#='C:$1A$ KH\#/R AC(";.!'P0Y>2 .,("(YPDQ#,
M#?<3:NL,=C/X.^#6"?F3T=^#GWGL3Z!Y1 CF<-XZ5&$62\OYAX8&O?@US0M>
MS3A^[(!]X3MF?"/S+G^(']NUPM,39-R1[)?QXVL?]B6O_WG-YU>;,,;$=1SJ
M^CZBB$;8L<E@ )2K'KDBV(9W,%_7I2N+&]M5'N<'&7J-.C?YBO^B6]@]O?;7
MV]W\]M5/M[CQ+*OAYDN^G;@BOTR)5NOO23J"V]-.]):_YPMB1MB7C7G+=H$5
MA\B%B1&)J&OPG7P CA\_I@<>\7_D]<8%R$X\7BO 9;&>_0=2W#?FXT3JR*5B
M$[,%MB82M<!8-LV@*0<=.0IE X0Q]E3%7((XP^I]3HV0TBIQN3955#/BHH)-
MX$1>;3ZF]QDI[YE2;G#H <_Q*<"1BV 0!(B<FH*NU)/@2@W,J#0<E?5'BTM9
M9F2XDQ490[2I2XP88X;UY<2*D+HHD+@V;5$QX:*R*/,AO)N9[K/Z]^S^6U9M
MB)]0#WFAYWE!#"(:N"#J6@A)3*3D1.9S#:O(E^Q[5AQE'^.6X45,*DQ1(J<0
M#0KKCQ;'S+)PQL#8UJT"3^L0 27DSS=NE:V?LG+()TM-]N+8$&$0\E(/. H\
MZ"/B]4W:43AYK4^XH256Y[KULTDS&15.U1>\C-"I88EJX5G-2X(D5Y&D>5V'
M .DQ16"E1I$?>8G"_%Q7NCU<LW_?)4)^S,0O @E.V/3* 3A \="DB[%4-<1)
M#<TG43TXBZ.;/ M2X516H@S3J2Q1 Y-+3XQ>$B0D41-X79M$33'EHD1-YD=4
MHI*RRO+;@O[8WO%[R7V[7>8& ^)A.\&^"V,?P- !,.C;I#AVY Z[36O+^-FV
M#I[5XQL&F9Q 36143*'FHU).HBYRN-!4;92G$:72P^\ZI$J3+:6)'B@G5A<V
MSMKU:C^*O0 F"8ELZB6>%T/0MXBC4/*:Y)269CB$>^%(Q2+3E1&J1@:8#H+7
M,;RT6%+J[WY:AE:7>P [\EW/)F$880P"FKCVT"8$2:QE< FVM>3P6B39'J5+
M?HA)TKSJ029KB]@P4V)(9:<BCFCDH1@D$8684IBX8=RW$"(02A:"E?ADXX/H
MK=V*E2S,B_*TCE&@A'QD85[.>M$>_NEPEU4?RZ)\R"HVGOA-1C[,NFH;7=-A
MXD<4$!O""!$VFW4(L8<HY@>>7-?7TJ3Q,=&@M/(VO/S450/ZB]SL4@^Y8I/,
MV5F5FVNV=)[CZP\;_]1!_,M"LTX1XD8$2BOOZU NO2:5!ONIQNL+O^5%]H&E
M%O7&#P"T(VS3 -HP@2&-J-LW[L6!5.$S34TNL3'Y_,0W1VLU<'4>\Y>@77W'
MTC#C&O8N5<B>_XS]0)_DSN8$_M>AB+J-DCF7KLJ9%E7\DFW+VR+_5[;[4#3*
MS2OI5-D=T^KF'S32W13<8=]V=3(^9H?A'AI&491X+H#8\6,WP-0'9(",8LG,
M<5&HQC/.K\?[^[1ZY,]L\-?EL@8K_VXWF%VSK^O\MFAJ)J:U====Y,K/+J&6
M1?//6<^NRWV^:_ZT[F?--?^\-JG5*.+&>XD&Z5]3]] ?,$[6\4)M;;+]Q, A
MVV[^_LH:3+4Z6Z\L9NVZ[B=K<IUJL)JKQ[R#$#<;%3*!<5[_Z JG^[2N\YL\
MV_$*=6B[/=X?FP+#G_"'#\6AO A[@V,71(&?$(3M*+9CY 7^<.K)\237'Q>#
M:3R,MD_H6N<VM-4ISZP84\B<F==_S0GYCTYB?WHAF9*K0<OU##WA<Q5=PDCH
M'.LH^,-YC[@4.-<5+54]-2%2&N\<[R-*FJ=!,D+.Y!?MD\T6V(<B>P8-%=T;
MZ?0'K\[8VC7@+[*ZOLYJOJS(;0 V" D!7IQX.(:1 V(R'&QA/TFTK>3-CMSP
M@B"?"MPRVVKKISTS+V,RR00S2ZN"X6OFD#?=V;'ML:JR8OO(?\"?0K&VW=DB
M-E4]9KR0-)^C\JB:G9MJ:/(Y3Z_1/!M=78<Q/3WM0^F9R7TP;4IH=1E<;W8;
ME)\8;G66KS#V:G6KCJGKK-WK?43IA;A1G=PNX$'1>,ZA\M.DK!$>!3X4+ S<
MM\??OI7'PV_Y(;]MOOT]/? X-$R^G1 2#!UJT\1W8Q0@-W2:@H:.3>T$BHJL
ML?;-Z26';)UAYCHXH+92#MLZX;8ZX(NMS*DR/")=QIVV#A4R;V8Y\V"0U(;L
M-MWW316[$[(\JT^538'M1( Z3(MHA .<1#0$?=N)[4HN:^EIT_@:U<D5<HFP
M)DH%M75V+B6%E.,;])$GCD\@+EAI68BY,8'4ROQ*U%"O3<^ESP!CPH>$MVR*
M>]QGGVYP6M_QUME_^!,2W]-]\UA-\V#$  (Y<9R0@#J 4A #$(0>B(#K>M@-
M$?5MR7/$>AN?<Y/[)B]2YB VAM.V2OJ?^>'.NN=5K=JZR>QO]GRR=[A+"RNR
MK5WZR)]5[6:%_*_99'++[&T&?_-%=K)<LO:*9B>*2>R"WI/3VAXH]PGN&6^^
M.$/;506U%M-=.3K'3IV;\<LZE-B4<<_/KIOD4/A=Q^]ION<-)67%#]-_S;:=
MNIQ:#AW73B+?A1 F) *)@P*G;SF(J*0@ZVC1N K_GE;_S)J'C*QZP-=)*S]/
MQ.<%A^PVW[*??<^Z1]<DWV?4P;R8BLY-N9QT#NA^9M.QGVN&SSH!7%PR!;@;
MT4F=S*]#'+5:]/P!0^ULB5\8'48Q'G8$X\?^'OBQR9TYED?"QOTS9;9M+XEA
MR)39=2G"+K9!V$/R;!_*WB<U"&7.]'5[0GR6M/ZG]<IX/VFLG(::=9N8N*[&
M7W*J>P;;.N'F)9#/D%L]=(MC7UR+IU ](M*S>' =ZCV/J2\N)L_&KZC>?\G2
M/=\[ZG>3/A5G()\A2'R/N+X;H2B +G5C%$.O1Q"%KF2Y )TM&U?SSU6YS;)=
MW>XPW[^6%%]9V0^-6;%6QX@)^%(>D=/K'N638P,E/RMPTO&E]5F"R1$Y-N&/
M=:BO$<M*\[U9<KDWNVVJ468/?!>^N!UVT5R;$-<C(  1<;PP#&S@M6_T042A
M0T77!%4_W^#J7PO)&C MMAM]B9RQM;RI?*YC<$TWX_GZG!Y>Y'=):'%@N=#?
M\UW6U1V)'W]/_U%6^%@?RONLJN/' 50'LAW9&\]QP@@[Q(D#2+&-/$@'9-#W
M@52Q^!GP&#ZE>;XHWT'G$YP&O#6@;]Y].8W<W@*U)]MF\:+LWLDZ'*B^H:+?
M=X9W5Y0)%]IR,>_.E2CZG!9?W)R9B^VWXL26'V2L'C=__;KQ0^ &(8$H=@D-
M/0?3).D_F'T7B,U()3[0^$3SK[]\51FK;!KZRVWY_3\Z4_A0!?TW?)2"LU%Z
M,O>50:; Q;)C1 5PJ>QWN4R&'JORH:]4X[H$.2CA!^@P=APO(O8P"'QB^W*K
M)U(?;;S7MFCD$@0Y<L0BO3%6Y$)V"V.A*E7G'(Q$426JUA$.U:"7&KJ*7( B
M=!/' 8KCQ/>2!*,P] /HN_T'QXEH^6*)#S0^U'_-JONT>!0;ZS),C(]P0Q3(
MC>M?Z9??T<?_GBM $SH2H"6(6$> E@%<*CM=\M!/G:>=!(" $A3ZGAO3)&0-
M4!3@O@&>&DB>[1'_8.,CEF.1/)$C08M88#;$A]SPY2 6"LHG^\?.R,B3M(Z
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M15Y6'\M#5E__67[F514^YD7V.6,]KCB08W;])_OO8_N_72KE1S%P<( C!%
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M,PY><S@P9+%0*##)MLXPP %EJ-C]QCRX'_XNJS?0I5YL$S],[  0![,I3C)
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MC-9W#I)?(>+/7S[+DAN1'W)EW6H_W6FZ-']6?QE2_LX&ZV^]/[F3G__9VB+
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M_0RNH)Z(7GM*4WU-3+%V6;YIV_J2W>:\B>+P,;W/-G9 8>B1"!%"8]>S$X1
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M'$0J:9,"A]I4Z0(IHX(TE<BU:-%D.U[(D!YFQ!7H;^7^6!S2JMT@KC<^@'&
M* @="&S,_]\)^W8BUY%,E60_?1[%&5"UIQ8DEE<4.1/5%Y-T*>F*,%/:U.09
M!:,JHDK76M1#&?\+U9C&A,0LJSUJ]B5[**L#2XR^'M+#L=Y$*(DATR40A#!&
MOI<@Y X'5Q. ).=7:HW,-+/JSD@.Z*P6GO2,2I%)X;F4>1+59E&R_.F;/;W*
MR/B\:1J):]&9J6:\G"OIX$5<=3X?O^WS;;(OT\,&4AH&=N@F7AC%3DC"& ?#
M^I$+8CFID?GD>?2E160UD&0U18HG42$Q19&2>@BQHTTQSDP?E0D5BM:B#4K8
M7PB".@/"%5"V=]GNN,\^W<3'.B^RND;;_W7,Z[RI,Q _GGUWG?TXQ,S*?VXB
M0D.'$!O&<1("X#-/QPT4!X:41D)YB5$ AC7E,_OY75IGUH/".\)&"!]7G=5P
M+2=./5S^3F$/V#I'?,5+"9[]P/KC.OW&_IZ#MQKTEXLOF*D'HT#P*Q(XB[]6
M4JG%J(G/RZZ8YU->=[]DV_*VR/^5[3[L6/*7W^39#M5U=FC!5>R[8O=;GG[+
M]PQ95K/?'>^S7=/33R@1FY$&GAT[GN/!T -^0(,>9>(#H97MI;"9S@#K0W[/
MB[);-VE>6=_3_3&KN:;4V4-:L5_L'YE[6O,:^4@;"ZVT,[$I.K(_&<E_SZU4
MU?V9'"X;$M;G:_5H<;+%.AECM=98Z-RO9P99G44KBB):?"(48.;U_MIBS\S6
M7PQ+2WA!J.K7UX<T+]AX^5Q6A^-MNO\]:ZHRLH]U,0DA"NW0\P".,+$CX+H>
M80W;H5"%C"F?;SAR-*@:F>AQ2=3R4J5L7+?G8DM2>U\09?W1@I*I?J;*F$2]
MLQF84ZMPIL*@6'&SUTU^)2CH(&@%!<RF6E#JZRX2 OM[^H^R(KS*4?[MR+A#
M/_)Z@Q/;CP&.81(#ZJ D\:C7M^,@L:1>_=,-BVN#R3H#9?W!8<D(AAII @)K
MG"\Y>5V,*@EE-4Z9FJZ^H&YJK<C_3=Z[=L>-(]N"?P5?9DWU6G(/WX_Y!H)@
MM<[8EJZMZL>M#[G2F93$[A2I)IFVU;_^ GQEZI$I! B0K)YUSSW'+LF,'1O
M1B  !-[R\Y28CN)D 5(Z#G^AJG>,D-&X>& *OHK-T#.")#%\QX]<+S8<8Q#L
MT#&%RC*-^?[T4MH"&Z,0HM1)R*D&UD8+ZG2$C1!5#<0M5%9;3T6%%<C+ J45
MZL$Y<95B0ZSX]\'(59YVT; 9A8EEVU%H44*P8?F1$_1V$O:_A,55ZNN:I?58
M(Q@H2"UO*:X$U%0[33 M?<&0S,)?CBI(F7/=E$F6-3^BKLC3T67,W_#RE(*.
M8F0!^CD.?Z&J;\AIY\V/HK,3T= W#/[U./ (B?BC#+V=.(Y<&>T4__J$VLE
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MK.KP+,1+%R,&]7@%U8I%V3DUT^@@> 'SC1:W"LT=$UBP8LMFN;HYJ=0;PE'
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MLU8?XP,(RW@"!?1Y4NY@(GT,3850C^<3H-:3\BHGV<_X52S;[[E_2KN5T;8
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MVA>U>$(C+9M!]KCFQ>MY0:F*3=?U!_Z$(]HR[U"5;KI_ @OD%36'6, ^?3O
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MH[/@)(D9>4;B&Q3[+C$LA[K,0F+ZGF&&=BRL:,#O:M:T'@U@#$.)$= UC9S
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MC;V%<;J3G]KX5# L%K#OJ<*+0JU8C-LB6GDXHJ[EFJ$3D8 Z_-*<.4SVGA%
M=C_!'Y]D%W3S<E-HW)[0^XS)[04I)6OL'M"\&S^ #1]AUI81T,O#?V>#!\B#
M4-#^ZSK+KW)^%/CJ]@M_&;1:-96 $RMTG,C$46P%U#1Z*Y&5B+\V(_%MD%C
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M7<:2"-;$$R^+M+7M0I9&S+^CO_XA>L!,2R1M/6%9RR14L1ZQS%73<0M,&KE
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M'^_7Y0.^Z^MV!PFU'.I&F!J.A2TK,>)!CBTW$19*^*<UZ^0 ".%? 0H@09&
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M[ZA7MZ]ZW '?*DQ\VPB884P)H5%"K$,6*;*(4+DXU38USS\'F*BX1<7KIZJ
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M1NM>&?F^8\6@ F-V;4TA%L(OH17&3%4<5D-]CYJG>P?<'VZ+\@-O%)%H04N
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M7RM*_8#0+//Y$0P_"GU"N]H[",+$S[S5UV)W4XO.8349E1EJ4WS"(VW$Z8Q
M'9+O<^>7/ZK\:5.R$)VN[1JE6VR*>P&>Y;+&,8(G$-G2FX%T6I0+SWW%J#LS
M#];,O1US8MU.U4:_5SDE;"67"_#'VZY$B:H-KA\>=\5]437EU[Y%WG@$%X=9
MXB9Q#"F;J%,(O"3IROP>\KTLQ()C5+=9<X-U1,I?_7X&<=C\NM3I=TD.SXQ:
M4]&P8_@:\ZY>YIN6&]#M2X!'S/)5^(>"8;O.O_</"TW?%;JN/^7\GM2(CJ#4
M"Q#-(A1&*4PR&(&@1Q=0#Q&YN<]2J(Q/CEI'G/4S'>CVZ"1[4BX6)S%!MC%
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M4.EUZ>5VMGZ^A*_6-4VQ;T8C:800"=,DB&$("$@]3*+!"'$ID5L.2OYPXPM
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MY^> 2&GS1X%T2Y1+JTO"6T#*?(GJW*==_5CL]C\^L<]RCZH-WU-_[)_87L&
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MM7A?K>N'XK>ZX<T2/]Y>Y]]7<4C9>BW$$<0Q=@%"/LH&% G.9-5(LW7S*G4
MW!\C7D\A.]M:]-4S8P$0U+$+,B^I;Q/*N]-<S[ Z'5CG%P[WU_8P);_KS3 O
M?HE*AM!SLF@H-);(I2GO7M_',LBBJ+Q^+O9Y614;FN^JLKIK)JA(<5NNR_V*
MIF[F)V'B48B9=0A(2 ?#GD<D=UPU&#0NH@-&I^A!RBFF#D[%1')A,N5T<61Q
M0.?\,I7*'N"ORZK@VXR=$3Z-=-NA=3H=JHU]FI(M,G9%WCSM?DS6P]"E6803
MZH=1[&>1[Z:I.Q@"60!657''@8DIF((!H4&6=(-LBD7\7&R/:2A]Y7LV[VOV
M_^IXWM\BYZ'<;OD)@[;TU5PY[/\\%NL]RS-;R9U!%7+%I,P4JVJ]- 8ZI_6P
MA5MIO.+CC##-(,\.(9KCP,L^&G.Y4#]]L"(>\8G+_D^4QI[K 9Q@_Z!H6.IQ
M/(4?+S,@E _?#^<-7AXU^)__#_1 _*^:#AR\3:7J00.M+!H[8'#I4P52IPF$
M*;5#;.8X\.;I 4DN1,7F][*J=^TIK.YDU0HG 4T3$L<NCM(HAD$R7B0 <00D
M5V72/][X&NS%Z<>R!R:Y%).G34Q6C/)E0%1.G"5=5F5>DG9&8Y3YM4-AU.'7
MFKZS2YS17\60S;/8_P#?BWT0!"3TDE'Z<)#,F_X8@;3(E.F-*9'%I[6EI@%&
M V3'P%[::2.GLB4YU_6*P@K3+ .(AG$($QBZ,'#]4;MP2I#BG60U8XL,_,E%
MY?'13-FUT7Q:Q:8TBS(J-\4Y_DZ"78\CG%%*;<S:H8'ZW)%\!$&2)^')S_J^
MV#QMBX^WI]\:ON:_NZ(9,YQE21(C/P%12$@<(C]((^12"(-@Q?15^$J)-JM2
M2C8"%%]?]$#YIO79)[F=/UN\IR]$F&9?L")T$>(EUW3:.#<SMQ2E\-ST47L8
M[%!' WZ]G 0:8NXMO;PIRYL5KG>/]2[?%[S5W<%>WPKR]^+AIMBM NCZ(<4@
MHI2FODO\$,2=7>!G+H!BM2E]]HP7JT:4SH;!=)K#^'RKN:DIAL]KX66HE=/
M Z<<WU3SQB=F.HR""4<CN9MZ_<1;*.1\Q649R<^PZ?N _R::8;C7;=X 7I\U
MA'DXDBWT<WC9+&' G]K4US8_*WRHJ^>FO2P+TR#S^9,&&<XRB) [F$8 "S[
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MIQB?BZ]%]51\+M;U754>4ZH8A8GKQGZ0)!G %"'?AX-=$(52K[/,MV985WJ
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M>4&;;/U&E77+1J 6ET2J-?/X4MC4:[<=\39OFKZL'D*:A4$<A0@3X/NA-VH
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MWU?(7!\.*+S8D[U9J]FZ<2$CQ8[-RMK62^L>K*2B:2=<L/Y^0:8E*^X=4F>
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M$86!C[(PQ!X$&<)!ASYSL1=0F5NLMF VG';>5VO>,;OHF_GU8-N^?B-:9SO
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M]7Z%PAC #&!$(B]T<9!ZD=]B\%R"(@S%M-B,;>,:+/E8J$PW1.UQ$%@1730
M<O++F>^Q.@QLURE^?.DS:U_ZG#P/[?PY8)9J2:D]"#+M*"\9#,56E'+#878[
M2DF&3JU$C#%MP:K#G&_U$M^JW&IB[/55[+Z6_3L KQ[M/F#]7.3;\K\[D+1_
MQOGC[?11[U44^0BPU!H2'/DN]A#$M,=)?>01N97&\O@6S8"['F];K)@.=,E[
M&!<(H]@:Q>[XR2700U/+SIEG#V-/_;ERIKGV\QACKN:#5WP1-$VW"U\0T1Z7
M,VN?RWT#=JR++NA_;<MH-)"57B;-4PC=P'=3C&,O26B(79C2$6'FP\Q /M*$
MS'@FPJ\GF_R0;S&1*-,Y25<0-6:C"T3/6!YZOL;[Z1*06"CFIA[- ?^)DHYN
MSU72C1'V11/-^(0HVF[K;_QMFX8MQSX7#4-<-&F^Y;^U LC//.!'+LEB%'A)
MBH,D\4/H4<\#  D6[/3:-)X<^JMF[W;%-N_>D;EA_UQ8)82X.C/^]7)MQ\C6
M[%-M\NN4W-I\>GS<M@VC\BV7A8PAF)3RQU*(YWEA #%./!JX?@9 G*6]==_S
M$ZF^)[IL&CY^U";R3WFY<<C3KJSNVHG:?Q;Y3G*_4A?#@CN4%R!7<D]R@K";
M+7&,S[<BWZZ#F]F"%"/OW*:C9OKMT#_M7KW<6#3"FJ@&OJ^8.A3-GH_U#P6S
MPB8Y$4CC(/2]-,B2% $Z6"%QAF2T3O9G&]:T 8Z<A$D3)"95)KF1DZ0!22OW
M5PX#LZSNO&#BC+ZH<F:'CBBCK_5\.;*ZL*X?BNO\>]$,A@!P(R]&;+J%8()]
M'],,#X827A21D@;I'V]<'3@B9\\AR2J$/%6B(F&4)5F=: EJT5Q.*UX2<E8N
ME-FS13'4'7@E&C.Y$-6-CVRAL/M05_5CVV.WNNLLT^^\ %.,DQDW)4F:IA$%
M*:$923->9^F-1RCS! >()FOF!DT+T)DB=/IQ]$L/\M>+3?C%R#LSP#2S;\>@
MT^U4;?2+E4WJ_)%FOM3HK Y3"5[M)&G"?C8@, R#) 4 #N9PEDFU<E,VLM#T
MWRE;6+(Y7I4YT4R_ &FR^7Z U$O6E?/F"LI0TC_.S=G4/Y-..[1HOANOI@%:
M>)$M+O3JM@H(#0'&D9?"U NC+(:>-UB)DRQ2*2Z(_NREU*7H\*@5&82)DBLR
MF.!(L<A WZ#':(FA-RY08I!ES!:]4$1_HL2@QH*P.CP\YN6.B]''VX,P-2OV
MHQ.4A5[LAHBI4N;%T:A%<8BDMEM4;9A6BQ&64_.7VD9@DK*ARJ"@?"Q GLIR
M:G^?5\YU\?!8[_+=#V="YF]UTQ0-GZB\S:@9I3E.V3G%F4FR)<HSUXN7"J2%
M%>%G>O*RXI_.QXI?KGUA$4(8QR"&*:9I&KL!]H+!(B6)4"] '78,*Q*'YORR
M9>!^?2%)5_P2N^0[/7/X%-.FI:B4TZ>.Q=\&%CDT?N[M8G)TAJ4SDJ2#6SMD
M28LG+Y_ET<:.\)L\]:XH[ZJN"_?ZQ_4NKYI\S3>'!RQI<<O^S'7^?94!"!,
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M#]?O%%2IPJ3/J%)ULJVJ2F7L?^*@>+DJ]0UMHE6J+.NFJN <DWBJU'E\S5;
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M>5=<5>\#6P4>AAY== R@'26)[=MQ.D((TS@0:ZA2.K3V_J@>+5W^*@:\H"&
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MMO8"<P "FC&<-@3MSW<$+B@'O.3/.MXW7HPC\!S!="F'&Q-1J<& 6@Q&DUE
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MT%[<,%B@H8?9Q_>S_W@HUP^ Q*#'LJ(W'("\ \]Y4]:[EIU%:$'WT-2[^P=
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MZ)_@&-: :<+*0-(S">M#F&J.U1WAX%CGD"+F#.@>4F7).T?IU+##FZBD>?M
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M]>30\Y_(K_[]?XR_0_Z'/N?X[__C_P)02P,$%     @ <(-#2%^VC06Y)P$
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M5$A2=1([$1G -D)?QSD7K5BX!^!4_0I,OAU3E?CI\K?B\%E/4]7$!? L]HQ
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M+ZL261W L?N/)=0;"8TG6&B!/!%4A67[$53%C(U\*G.$GJ>!.;@W9\69-#>
M/_8J?.CM]3.9&VZ;[BP?$-:(6Q ,5TN,"_]CWE3=4C;VKND("7E.2N3=:V(
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MIW@H*8.K?RG9@I^Q9?OKY(\/.VCQ],=$,(^5-=Q2JPB4VG#)ZLYK+RYHU>I
M7_F)^ V11BLOTNQF81Y%;+1\=Q5/C ZSIS;6A$]PK#TSI%I@";4ZTMDRRBUY
M=Z3H$-$?$48[CY>9%0820AED1%J-G+&B I$A'DG+$=[3')%A=$8%QNSG3/XN
MH)F7WPT_7&>K#[>3,MUL&)1WZ_GDP.GV,=43!)A"Y:-*F%FG+-5&5;XVXBF]
MI#M8YR% WKM28MCU+BVFI=YN-B.SENKM_2;+W.+F4;SE;T4:;,WBZG:RV*1E
M\-GUZN'-XV74M_>;&HN](4I=?B/A8;Q+5SZUP)GV'GHN:M,64S?4XS5]\K0?
MBN3CT,A927KU9]XT7_;QK81["82'3KB@)$?#^L11#9%@D5D\1F5]OB#2QFOF
MW.3]L/XXW&S[U?<2Q9F!%(5A+JR&WG,I:H-?@-@GH\8W\YZ79WTQ_@15CH;U
MX>=!61]^3FC89"#&G2.H?,.+&JA-!14(6^E+F;HOG/7'JW(\K ^?'':VWWPQ
M<=)P;A22CE!E@H47MM?U(JU<9"+OHP]M?C!_>&5&G3L_IC-=^B#V'V$3744P
MI[/_R+/%JDZDU&!_']E,@KR&$DCN".>:6RJ%JI<RJ>0EF-;C\5OTJYP8UI4;
MC"]'RW:0[./7W@H)L>58U=0*R12T#G)3GWL(#2)O>X[/ONU-B7D/, ]Q^EPF
M6=N"4KXPL_P]/717:%?Q1 ,I@C5!R\ -Y!W77M6C22D:>>8\JEEH$.YT"'+,
M;'*@2_OFDP-5$L2AU\&TM P&J],1H4AU0D&@C(WP/C[L)5]-YB^7$QW#/(Y;
ME%]E__]QC?*)'\QXX'"P3H5PEBM@A'M4)[/42=?D9_IQC7+78:GEVEH.I()0
M*UMN XBO0#7 Q[[9,+Z#YH$YV/\URN,T%Q<Q_#"9KQY*P=+5=C;?V&_EPVA+
M_7 5])L%.CSLB?\\OI&$,0Z49QZ4/U @!),UODA=4+3Y.0F1#Z2>7CFW-Q T
MIIF$R3*X&FC" $:*>D"$K;'#%W"MLD]E1_$I"O@H3T#^,2L_?I7KC6'V=E$E
MT'ZU*/]62W3X-L21S204&62]#JN"0L&0I<BZNF,>@4N(-NU7X?E@X,>PZE&.
M1YE*"9Y+]/BWW_-B=:ONTB*;3EIR[*1&$V0X% (PKBAD4EGG%*@Z+22)],N/
MT-<P!..&5$4__+-9D4Y7G3%O9W,)A\@(YKEPE",O4.@?WG:4!:@CS_['=Q8T
M$LYUH83.V+:%H73O5-*%75+V<1U$.X5V1[2;0.@UTP);[8AGR"%@*YLW6"LR
MTC=_=)ST!?.O/VV\N-N*C#'JE>?8$X^8ETXY474/*?7C?GZ'F].NM?'B;BM"
M0*P!S'L'"/)0A?F]VGTQ;-4%Y6,_7<.M;RL>!VKL;O.('>77,ZBCDF-;KN'&
M"2[*HPI5"6CT8!E>SWL=K;66OMXBGH;F %/$^W*";%A_ZC()Q% PZ:749.-U
MAE"ZFO\<1*99^#YNQ\>N-['H#T6>QENNSTHET%FB (7>0(,YDDCRR@ID#(C(
ME]Q'N(9$:&V7WJ-@&T#S;R:?L[OU7:/NORB7,$4TA89[!)"VQ%@I9=4-YV/O
MD(YR+8G27MX=>$-P(%NTX\#S<@DQA/+-&VWE8_&4$@!,O0(J&FE%CLHGV"D'
M3@#OQTWVG?&D$A )(+&* (DLIGSS1F&E"C*4A^:[,F+.J,"X"/'L[N,ZZ*<4
MXH]%4+"ZVT0]J9LB?4S%=E>FF%B^FSR4N#2'BL>UEW##."W/.9G%T'$+_=.D
M+QP?ZA3XQ<6,MZ9(/KR6^B'DFW1UF^]]A[UM_3+Q"H-665IF>,,<4LWJKF!/
MADIB/T!X<-^Z/HY94?!',6FR2M\565Y<Y9LK.2:_NTN+37#99&>H7XM:B7:6
M8H&"B.%;A "K4.T7DTA<S-7#@5G3)>A1AVR3Y>8X1UT'8^4(MC352[ W#D#C
MI6-.<DV5E+4UK&5LC.<(#VD'Y4O'L,?.+G9=)E+XHNOOTD#C_8O3H4J)]9YI
M@1"ST!JAJ#:@ICFG*')N&>&!ZN!S2U>8C^.>PE="_;BG\.RM:N6H\]Y)1(U7
MP:Z@\C'XARJ.K&J*_/MQ3V'75AAYB1A"QB.N/31$ ""WH H21N/%N+('YF#_
M]Q2.T]P 7K1N'FL05C@'+%9 (PX-@,RBJENALR\_8GP,E&CU6,-QFAB 8.=[
MK,$AX23A2EO"O"0JV!&Z@L("$_G S A)>2(33GRLX3B88RQ[]?'CIVS_8>\W
M91+'(-?,&&P$YYI@"E4M$M1VJ*/>,3[)T%I;>3?@_C@(VNDD-H8R#8$,T[V&
M9617V.94(#+ ASJ*_*X6S#,J,&;6Z^71=!\L840,=<Q[+R ECI!:;&@OX2+6
M>=5]Q+/IQ^GB! KU_VRZYD)1Q 0UUA%%!20*UUVAYI(B*T9#JZZU,@Y7VE7Z
M>;6>S+\4[8=#[9DS Q%((,1(8>45(0AH*;&E1C('-&]*[?W#H;;+I( 8T-*0
M=4A*ZH$!&NH*5*[0C_?3(SG8OT/M.,V]N%M6#DB(M&;6>J<AHD0:5G5/,S]4
MNKT7N4]H38W6MZR.T\:+NV6EG#/>"F3#[DJ&GA(K>=4]ZM4%D>UT#;>^974<
MJ -PIHN'P@10CB-$''"&6D@ EZ[J%#/B$MX7Z5"S;1X*.P[1UC3IX^E @"S@
M%AEIG&+.$ZMM/4:@8)$WL<;HN^I,]='H#3 ?/&X6ZRGQ=:FO4C6'398#M1*#
M,9&<8Z6 I5P[+9[,0T-QI)-IC 09C]'2G3[.1[E&T^5@O<0[P3'PQ@FOD#%4
M F^WW?2:\J%\F_W3KA-=M^-/%+1#7/\,N@J?N0W#RZ:?TGE^7TJ]]8PU7PMM
MKATL0>_+[!W2N]!'@#$3U13O(8M-IO)RV'2LYK^^0MHYQ .PZG6^7)I\4;XB
MD2ZF69E+YO?):OV8H[WZ];X$G\<WDF"*'>>&V6 4&!]&*H6B L!S'&E&?Q]W
MVF,7RM[4,S@_MW(WKIH':B6$J?+XE%.DJ):"&"CJ+CK'(]/DC7"6ZT/M!YEU
M"LXQ9WU_R]/I[7)U.$KFBT*)Y()[JY7$F'O,&;"XVG-Z14GDJS"C5WZD9O*.
M<(R*@)K-LA+FR?Q=D<_6TS!='L@RO;MTXK"@T$) 3?F.'6%!3EJ)*87]<?FX
MP]6F.SUT0Y?#":+WE4\ LY;P()AT6 %,.;2D$I51,E36C)XS09^JI\,ZCX(R
M1NN_IW^J,,>9&0*'5X%O"B9,&>$8ML9Y;Z@US#!<"<>YOX2 R8ZTDW>(XQ '
M1/54Z/ZUSE8/CW=]7RT^I<O59D/VS6_3]/?)75-:KE.:33BR4B!BC),4> (\
M@J ""4L9>=A.QS.IC&@=.H/"!F#U/FD;MT*'*R8:!'N-4@.]8*&S$!@%:UM0
MN<L) QF&#GF/X,<LD!\F=\OUXD9G^3*[R^:3XED*A(.Y*1OJ)=![(1T5@B*M
MPB9 E->;MZ(+;BXGM5Q7*LS[0W> Z6=K.[PM/J3%IVS:M%CN*IX8: Q!"$(/
ML.. 2<&KB=Q;@2.G&C8^RHQH$>Q $<.QJT1E*^?^W5MCG42X,L9<"%Z^_J@!
M0X[6FQAHY>5<%3Y-N;N9<C*>47DLLM7Z\V1Q>$GZHE!"E?8F;$F%1YY@I<,,
M7!_2*'E1J;HZT$S>$8XQROU-_=__\W=U6+?/RR0<$F&=Y$25[[>*TO2JW9.8
MTTC5CC"6HF/%G@#B%WI]"?E^>H*P5_?&GO%Q=9L5LW>3HGS=H_STU9^AWPVI
MXP_523"$0>L""VNAQP@!7JT '$#S]>/JO3F]7Z#Z.X0UZN[:Z[?F2EVYP[K_
MLE2BE39>(2Z=,9H![QR3E5@2Q;Y<.$+74L>Z/@G&J!.*U^_>OWW]ZC\;+O5_
M42K!Q'!L$/ :<:.\8@;S2BP49O2+V3-UK-V38(S1[MMID<ZS_UK?33X>5O W
M!1-A#3),4ZP(E!A9JYROA,-$1XY@_AW,UZ=B&>51>VMA@^^L+I&X,)4HP54@
M'G;0 53.,-AZ!8@S1$8>)HJ+'[[1$,9HU+YY][\.:_2I1&*]H XX"[4@$G)@
MG',5P8B/O?8M+UZCT1!&C=$WO[__W#!(GXHD7'$A,!1<:,6YU;A\,& KD++1
MJ;S Q2LU'L08K;Y.)[/[HKR8<K<_<]:>D@FG6 <3  !KK)8J3!Q 5>)9*F,C
MY<?K%>Q*QR=C&34E9\MI'@R2AW;ZWE,\P<!( +WF9<>A\$PJ5@G*F8N-Y;E\
M5U(W@,9H_NE,K$'GWQ1,(("28QSL?$8X=F&C3D%-2Z1B;VB.,+:\8VV?"N4
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MK$'WP_5^# M/5TS4<7=;6=Y,/F=WZ[N]Q]U'MI,H(32E%EMK('.*<8]L/>2
MC+V1\\,-O^N\NU_E## ?/MZM+O-0ESF:CE]_6]5/%!(H#!#-(59A?"$8NEIW
M6['(A//'IXRY<$[VJ93NYL!E%27RE*EI?_Z%UBTD7++RM5.+R]!)ABR%%-3&
M+"*QEYI_N/M;SWL=J&6 &6\3^O@\M_7AS.*[BB>&"<>DI(AS43H4&>'H:8<>
M>QIY?&Z8"^=:ASJ(.AMX?).ROB+U8?UQN2IO24WF\P<UG]>7[+8%=;K).;<5
M=+EZ>_V/O-B?ZZJCYA..A$9(!FN6$\ZM#=9L;<MJ;F,?T_YQVK#KM.$L.CLU
M$T!DJNW':)*K/_/0R\;GT/KZ7D(P=))[C0D W!F*.:CT1#B-?1GD^.PVWP.]
M1Z+$L_)]"(Z7D&@#A&54:P0LT]!P ZJ;M"1T+S9CV(]3F#YY?;SBGKC\[[\^
MUUGHT3\WO_WZE]O:WVC@8Y;?I(MLED[_$G9WC[K[$MGMM9[WZ?SQ=NYM=K^\
MFGR</\4Q/(J4?EZEBUDZ^[E?.[NXF2RR_]J(4B9-RN=E3'7)UD78(#SU^>VU
MSQ:3Q2:5:9WTK;I1?,@P[Z+]Q"'HI7?!CJ2>0R< AQ +A2FVD.C&)V):3D[?
MO**R34\<+(B[]7RR45)YEUK/#T2Y'=5(8H$@4GJ.C?48$T@QMG7'@H$<Z7H>
MTX7T,S%AS\O.G>LD,AAE-?D<S[&V]1,H,+1 <XPH#TNX5HRZJBL,DL@8@A$Z
M6\Y(KIZ4$1<FM]EW;_R)?X05N\(AG6W.FZL4BNU(%M58 GGYR#FQA&% N5-,
M,5-#B''D6=JHTO&.@'-#Z.;DY&2/%QON-D9,'3;S^"K \MWD82-;2R:>TFKB
M&0U(>B*QL\AK)(6H$1:,#Y5*X>(I.:"28KCY87UW-RD>WEZKL%GYE*T>-A9X
MF?'ZBVPY96+C\NW-R>+A0SG*VE&TD\83)KS61'E-I<4>:VQ(#8)2,#(<9E09
M@D? U'/H:AC"NNSF=O6EG'W1M_%3B3&:8LV8$A1 0(2B4E8 828CMS8C=)R\
M*"IWK;>>'2=W=]FJ<D(%;$LO4!H0/(^OY( X-EM.Y_FRC!)N]HD<U4Z"E+ *
M*2:90\X)QC@@6WU08D33'NZ,4!R:=N(:2H0*IH&7CANJ!5(>,$,K,(1RD4DD
M1^DOZ8DE^8#XGVMR.-2IL%G/YDOX_<P?&A/,@ Q[OC**#5#HZ39='J$$-QX\
M]P3%Y#Y;3>:OTTGY[N"Z#(-_DRW*X+OJ-K-=IV9=E /E$!)'-),H!IT"95)4
M@K2C3F#"*R"X$+$/0H_/(.F)'U_/'/UA/T!\42OI7Y4GI/\GG12'8BN/;"E1
M"EO%)5* 2J- V$=P6$&A"8\-!/E!PS[@'Q$3PS?3KKA8MY4$S*GCPA)OI-=8
M JAU!0>SL>?;HPR1&Q,;8Q4P'C[Z?%UT1,>ZJ802K1 #ECNBO0_RV>HB4E@F
M@(],L3S*&+D1L3$6_Q&1,?O4U=Q8-Y482CTCTD,& +7&A1T.JE<*&9LM?I01
M;6,B8R3^8R'CU6U:I)/KU<Z$X)$M)9!*YH7P830:@P3399JZ1RA8^8+,Q?A2
M1T3%:/C'PL13^9=XY:5S"A-HF8*> .Q4W6V!(IUMH\P',!K6'0GZ*+A6O;KY
M:C&=KV?I[-7B0';H+II-:!"5,N\D,U899;2"I@*)1:>J:)\V0#XR<Y'>;$Y;
MOAN"=J:24?!V>SBWS<KY>[KZZN\GL;>I\21 90P44',@D1:<820KP,IWD^,X
M/,JD ^,@;\<:.=?AQO8$X_LYP "2"Z TE- Q(LJGG#7;G#E!;+G QQY@[,V*
MNR'#^U)C\V<";D*9ROL/Y0-]Y9GZ/'WDV(%^GM9@@@&$V,DR!8&42B((.*DZ
M+!R+S4?R\@\Y6S,A/X,>AK@47=V$.?7<[+B&$HH0@<AQ0BWEP%%CS!,0'%T"
M(8>BRM=WIOM4Q'@8V>H@[>BV$L@14<Y;897@V%N+@:S@L))$NHO']YSC:'D9
MK8M14;/-R5I$:XGT$G ,PT!E1 JM.=2@@@1B-=39VG=-SUAMC(F@;8[:CF\L
M,0Z7*7,Q11XI'<PJ(&KPF:&1Z9Y&=2]B[/2,5<:HV-GB[.WXQA*LF5!4E1>5
M+#+.&\!<!0C%<JBG)[]K=D8J8SSL;'48=W1;B0 (4,<0) 0IC((&GFP=*EBD
M^_GHX[COEYO1NA@/-4\G9,*H@D@KZ2F "GH((%!UURF/?,!B1.=SXR;AD?@/
M0+TO)/VP#H@$^1^!6Y;)K3;]^3B9_O-YTI;R<E!6IDPII_H#K#R]\80S(;4-
M!KBQ7 6S!@E(MX YJ7#DE;#88[M+HNS@RADWFUMXFSIH/<'8:6*L=X XSB!C
MG%3:<M["2+]H^R.\'WSN3CLC)W0;'U4G[2<2:20I80A!"3Q U)AZ'J!,QKX[
MTSXS^0]6=ZF@<?.ZC6NKB^83!%$9CD(H158Q:($"J )-4!Q[^:O]&=8/5G>H
MGY&3NH5'K(OF$Z:Q8]S@L/OU6'M(%/ 5:.'WL<_MMC\ ^T'J#O4S5E*W<J*=
MV'*B(14*:$;+M*&,.RI-%=KAD!>1^8./>+_U!Y6[4<U86=PU=Y/0=48<51Y:
MJZ4UR-?>'P<H[O_YV!^,/44A,1F9GF)&-Q)4OL!RVG]UP(/6NFX"29E1@R @
M$>("D="5ZHS:8<)CT\$>?^<L+T-I+X!1?4'?.7NV7HLH]FSK)D10+PFUR%&!
M>6"_E[;VX!$7>60:\6+L]\.>..B[9T_E'8CC3U4[P4P8*HF%6@E@.6?"U2XS
M*$WLFG;\D=)WQ*!(\#OG4+47CZ)053D)*S#BQB.I=!F>BB$A]2+,,(UET/$O
MNGX_#(K$OGL";?>]<03:5DZ(TQ@QX3'3S '$G*7U3$JL&NXQUN^(0''8=TB@
M@RZ&=A43[Q$!CD &O0-,.:<\KH0WBD3:SA$OJGX/Q(G&O4/2'$F51!!OA R\
MMD)1*@,(7M?G)@2I2((<GP#N>R#(D6B?^3)EF>!R/9E_*=,EWZF$3OI@(3@/
M##%$<NJ%D9@*9 TEJC'14C]0?)C>IK/U/'U[73U@H*;_6F?+;./?T0_/_FV3
ML_@ &L<VE1B&/!%&.,!5& <<AEEL"PACB,6>>H\GEJYGGN2#XA^SBIAU^29+
M^037YIW'U^FG=*X^9WN7D7WE$V2#E0T 148 X3!E1/M*5.O Y5"E/R7FW>/<
M%25L7KX->@PI'FLD.MA 7)&PW$G,PTC!&*"Z\X:P%T^+CK35I/LH.&.T_R'[
M_/'QU< WZ=W'_5N/K\LE%%'G* +*0\@1UT!H6XE&7>Q3OB]!T\?J)N\.QA@-
MEYZ15BK^IF BM09:0"N!QPABI*&%E7"$X-AW/R]<QZ?B&*7D('T[)7]=,&$4
M2F@%EV&G"ITA^MF<Y02.C)\94?+;?I1\(HY1<W7Y D^[V?J;DDF87H!2B+E@
MC;@PYRCD:K/$ ARY,H\HJVP_\_6I0,;H^>TBU6VT_'6YA#)6!G4+:JP,_]6!
M@* 232HVU'71%Z;C$V&,T;";3&_5;+;9-4SF3P+\<7^57_T9 'AH18 CFTFT
M4D)8#X&%W@0\(".NZIB')C)5R(@RJ/;"CWY1CJ'/YKBT%4.^+9D8XJ@!CDC!
ML2'62$?J=<K@V"##L5V8[)H$)P,Y0$C@NR*?K:>KM\6'M/B43=,]CIU#Q1-.
M)9-,$"@51N5!!J"JZA3&ZG(>2^[=K],AS,-QIW2';N5<[G4"-=9)E)4L#"UL
MH<;>:\R=I57WE->1"\V(G /=*'<W4T[&,VI)2:?764!YTK">?%DL\91;"\-H
M*(.AI?*&TGI0"(\CDT",5]&GZ";O#,<H#\%DFLVSU</K4@<EW >\_KO*)HH;
M2CAQ&!&./?*8&U+O;SF.M!M&Y"<8UN/? <9=T."PIW]WZ40;ZI2"P$C" ^D1
MU[SN, XCX,6/^@XT=$C743!&G>U,[CX6V>QF&^1P>&[?63A!CFCL, /<<T L
M8KA>S+B4)#)!VMAU?:R&\HYQC'(/YO-\=;LNFGR#7Q9+, #>\;!2":6Y=\!S
MSBO!@(>1\_J(+/[.%7P:@@,8\SO6K8:]X)X:";9$<L8YL&:SPDG#J^F.*V$B
M3X!&Y#4>?#O8#=)G(E'Y8Y&FC3O#QKJ) 4K3T&5L'#)0 &A,%5/#/4,O?UGI
M3-\M^',*M%&;Q8?E)"QQVSU1PXYQ1]G$6,L\\=B0L+NAK(RGJCM/A7GY82(]
M:"OO%M08O>M-7.FK63K]6WJ7WX>N9PW^@OTU$J8L165"366)AM8Z 44E+J;^
MY=L=/7.@,VBCMI'KN\G][:2X4S<-\09?%TR 1!!)AQ0204 4&J[/R3DV_'+\
M"#WI_51$SV,ZO Z_>+5*[XXT0NMJ"2RG-5;:YRQ,;UIR"G752410Y)(QHK/M
M,5BBL7!'^28"AV_299%.\YM%]E_I;)5_F@2MI1_7 9]L<;/73]%4,7% 2J4T
M4M8"SJCR%-4;,H]CD[J_#/,B0H5YC^ .,-N\7=VFQ5-$_X$)YJN2"4$((,\!
M8 897$Z=#-0^&2"&.NP<XHVI3IG2#9X#+D1!QH_98J.H^K+'*ORTW)S!/.JO
MF(3?;JZ$O"]_>GO]=KV:YG?I<O-6WM^RF]L62U<W'TH<#W8!4]A!#YV@FWQ#
M]>;0V,A$?2_#1CJ=EF=51LQ2^":;I\M5OJ@O#KZ9S%*[+H+$[](BRV?[EL+&
MBHF$X5,(N+ CD,8+:3W#]9 TL6'ZHWK?I+_%L&MXAXCCJ.XFY]N]1H5*NORM
MR)<'XX$:JB90D_!51YD@S#A>CHBZLPS%Q@:-T 3O95;J&-X!N/1;GL_^S.;S
MK;RSAAFI3;4$&Q&,1J@,Y58+)R4'KNXD\)$<&E$(:J\<ZA#:KJX*[MVE[2B;
M6&>4HI@08DSHM%,"U(XIJ7SD79,1Q9[VN#$['<\HE>^_*;W-%]#T!'#[%A*#
M'0,F;"D%]Q 09#FONT-M[(OV(W0)]WO_O%_8!UAX-H$30>K']!WN\WVZ6!Y*
M=+"S?((Q!1"X,!"PM4%'T-?QV=PKK0?R O7^0%4?FLZ[!W@(WF23CYLH#Y\7
M?RRF:;&:9(NKR>=W^=9[VOPH=-LFRHA-07&8=IT" #G/K*T[KYB-]#&.RG<T
M&+OZP3QFN5/3:;%.9UN&+]\N_'I1>CV?4'B?SLM,PU>Y":UET\G\?5!D^-0N
M[]"I32; $VBD(!A9QK& !M?A21Q@'KE[']_CN3V2;& =Q)#N7;X*$F23>97R
M^2NOPY.45_G5;5;,WDV*U8.ZOR_RS]E=$'O^L(]\'32=H#"_8T&M]]X@9I$)
M@W +@'#,1^:4&Y4+:1 2#J^+N)/]4K@G?^E6NC UJ\4B8/"/O)B'/>@L_3U=
M;78BY35(!+97X_:' 9S2:B*L=2K(JK7EDKDPZG 5/"MLL(=?O.=I$ (.JH0.
MN5?>O5S>YO.];O"F>HD/4C,8]DHF[*4"0!"AZLJG4-Y'GJ>,R.MT3O[$PCS(
M['1U.UFYS],TG74_1^UH.R$*&\F]EU!2[(.Y@ 6K() "1FX+1N3A&N=,=;HJ
MGM@X;/+-30S/\DM9+CGI)H4",2&XTUHBQJ!0?)L+R5+A<--2W@\43S%77[RZ
M\NCNJ.RSP+ZO'D7>Z*XDO YB_?, 1)VTGQABI S;7ZZHTQ@#%OY;02=5;,3L
MJ!Q:/7-J;X+.X=0R@!ML3[>^2$T<>F4F]UF9A+D3*A_1>$( Q:7;$$/JL WP
M>>PJP#P&D:= +][-WS&+^]-(STOE8IG/LUGIC=&3>9FG^\-MFJ[.LD1^"'W8
M1 <%;+-%D"7LWBNO9(N5L4WU1%I/'4-02\,YX!9@;QDUTCM./*=-QQ3]=%PM
MEP'R%EW\LF"BF5*6:DFXH-!"C8QE56<L<+&/<8YQB>I6N7F'L ZPQ#S*M_7+
MMZ;)5^432EB8=RQEDDCHB7/$H:I;(,R&%\266(7NY,5I. Y #S-9WI8K7OB'
M^]<Z^Q2V:.4:N#*3HG@(:^ FN/+0EJ)-_40)*A360@O /(8.066VW99:LTN:
M;$[4>]X_O$-,.I\FV;PT7((U4^[Z/Z33=1'FV[3%N6YCW01!+(C27O!@OC,8
MNBAIU5U*9.2;2Z,ZT.V'35U#.P23IM-\7<9\I],TT#_(_GNZ:D&B ]42P8TQ
M5C!3OO/B@8?0X:J31L1>)AG566U/_.D.U1B7LEVG/O3PC\7TV<[C/_)LL:J"
M^/8YC)MK)HQ2 IVRA "N-=3 @YKY'I#(3$FC.COMEA3] #O E/)J\2GT.R\>
M GD/3"'/BR7(.H$0"G,BTL18[S27VTXHB62D0^_H8\V7PXX.4!SJ0N(7'3Y
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MC(;"<8)5!2H!Z))LX0%9.P)5#7(;+B@Y&(6E\L//\W3#@L5,W97.S/_:_/X
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M^=^AQ@9A-CUN?3;N<=]'*82M,X/IU"\+3BDFN?02$H6)(Y9C7@/J,<ZL1C_
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MW<]!M<!6M1W?6MZT*LVFJU#T'^-#@<,'VP7N,,6.&,0=019YC+6LQ<1,9#Y
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MY%Y!S:P'6T!D_.M,^IT<E'QY)EZ7.)<(?9^LE%G=[J[?[GZDWQYZ+=ZL@\
MXE9HJK7G)!J[ B&RG7'&9YYTP.L^_.\$VR*O<>IT;8M/LSUO03Z-?JPK.*:C
MY-WR'6)=.]\0A*<Z>EL 4,HLA$81YQXO2F!N.JI!1DNW2<Q>X/\['G(;AR>
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M"9<D"N.,)\C@[4$]4IWG7"JV"K1]DGT^F*7N0M_.IK/G@SU^%'2X87!$*V@
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MC412.T\LCG!LI6<D\^WWH SO=A3V4ONG@]>UMLT__"%MQQ\'ZGRJN*J051)
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M*IXB4K5A=FL(>@ISTU(,\;#Q?+6_.JQN&]\2V4MFT]OMN(]2:,>G Q.4$8^
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MLZ6T8#;S+9_\59AP#IA=G4C,OGZ=33\N9S?_^O@E0K-X<F5U^'CB0,- C;!
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MA5H'MK==[?D]X^,J^FFFJ\</'UJ@SNHW(&@IMQQ)#+4%PE+MMJNTX3KSNFB
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M_M5QRZQ9!\$3K;@7#CB%G400HDWN7.*\@^)8N?ANA#>CQ9?T?Q=-_>^CR6K
MT]L_1O-_5<M$IH^)9BOJ-5E',GH+'GF-)=54:PY1_(6S+2PIY^\5V5MM$^5E
M)L'.T2^^'FQR+%_SL@ %)4(!*[@3@"'I!8V.,D+$ .KDT4Q17;MNB5"K4L;/
M>-4\G?*!]@$SQZ#2T?KBCDA$M?%H(SI#_(HJO[9-A;TN5WMH%S!R'R%HD 7Y
M]8>#A48RP24 Q$($%('>U0)1*:^GPF'+^IVUC&QQJIC1LKJ?S<?_7NGN:*K0
MXXT#E]H#A+CPS$"N(8K3L!98,78]66?/4?9!WK0 :P$>I8B@:IZ,C/>C;]7\
M*'5V?CYXS92UPA@FC+:80D_H1BS-%2^5];JLR7J^DE\EOCX?VP*4^5!]V\0P
MJOMY51U^>GV\4<!Q2X<J_LNYDX ;9("L!41,ELI/?.'D:0W@ @SZ8S:M?J[=
M,/\PO3W.GMT-@E* $T*=MM)9H2E2BM6"680SEYT!OHGID#>M0%OHX>JCOWZ4
M,;L^'ACA3!E$;/0C"%?$6K852@.:^1CUY-<C%[[2M !M"<-FIV.P#1DX<F9W
MH&6@P%H>A2+1J[!4RXC<5E3.4>8[BP&^%>W6RVH7YD*,>GJ2N#2C^?SG>'J_
MOM(]?O[5K(/ L/;<*@"\$I(1H[6N#SU2\JYK,J9;X\ .;K6.=.\4RZ96<$9Z
M0 !'!GGK".,I=^5&4($<OS)*M:GZDYAU(M!]W1Z\V(VOZ_H <Q]M$$T@D5@;
MBR!22&$2O6A@F?9]UVM4WZ,&TL;I9_./HV=W4(VO$([T$9RG(N5#DEQA"1F-
MBRC=0."$()F!!H,^O&N'$GNO$=I%O(2+/?J?V3R9_HMW=\E@C[ML6K92P>-Z
MY$?N%QKV$ P"!$9+CS E:)1:*5F#ZR2AI4IRE#2'6V/#2U^\$\B'P;:C.7P;
M]Q&8!0P;*8%S&%C,@7PB/BYFS73/N-;Y<#K?LB _*[GG\^,%L\X&U#"UYX&V
M@0B J3.0.>=T$H)"OA8!8@]@J5R_)6S@#O2Z,\5G>W"WR)BWL^DYI'G9/"#O
MH^G@L<#$>Y,R,RA0"Z+@5<4<]\.;,Q'/H<YOLPCG-!F))ZXT1QL&CAVB0 &6
M+EJBRR>8T=O!NZL*\NV8+FUCW191FBXP3=I&UX1S C041'".$ ? NUH$(? U
M74GT0)<SX<YZ_3R;+^]']U64;N6/KI[ZZ-'-OZK;$]>:TWL*CEH##/+2:.>(
M@E!QL16/F&M* =4QFSH'OS-N-5V>LCH+'BL6'5LEC%"<(:;B'*J%C)9>9K#&
MR3F;?A6&G8E_%LFVX?$OI3W"IR/M I5QY<6,F;A;<^F@4$C60V<HM^3&R5F4
MKH$Z[4)=X("HR=E9D[OYD_H)P& JN#-$4(LT ,P]KLB4%(LLNX:CR2Z!+\"_
M_8-N</%TO'&$56&GB/281$&QM=:QC<!$NF+EQ4JL;1TQ8=8QYKV2+(M< 1-J
M))-QQZ>$2,RTE5L!:9S 5T2J-M7=F$DG MSO,G5S\_#U89*J._PVGRT6?T[G
MU6B2TM2D=,NZNIO-JT^C'WFK6+.^ V ""LF1B2!! 9&"IC[2394%,\L<#?(D
MM!<^=J.'@=(V90COBK;/^@[<,*P, P 8H@7A&L#:92(6@,R]N?F)K%S3=EK=
MIZ'^2K0]1P_]TO9K=,Z3!&:VR+0,G_80-.-4,DTYAP@"SJ4%<#MC)<M\USO
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M#78*0F@@W:(N36XHS2"CL(;,R'.4<H'WT0:D:"4;487"IKIKP,!:P/2^N5
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M=MJH"*KC8/Y]!(8S>@V80,$]-=I(1@!"<=%K8+)6YWI"=.$Z7*=RY?E+Y&S
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MA17<\T9@CQ*S8(Z;1$D*/\2>OJ#-R:5_EJM_OUM^6I57Q;H[F0ZW#L!RA)%
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MPA4S9'=JBC7B$K29-4.'^#9#-P^GO)WCT]NZ"$  ;AE3$%+@#%':5]4F'@#
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ME+>WQ>HJMODRBQ_^L8P:_5JL;M<?OYLX.V;?RM6#NF]615&U/VB,Y1Q$X,I
M5)5X\<!#RH@ K)FIT=#)54TIX]GW (0KWXCZTN;$NHCM?L21/A'$E.L(Y)?M
MW5VYVG1G>'*7P4%A!4*,.Z$@AUP+RVN!(;.YC,@I\367,G+$V.^GU==RGXNW
MAJR2Y=MZ?CV/4!;5K%/?O\\7\]GFZ"/OE.Y"A!TZ@*)CSRDT0DA+:O<0&>;
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MK8,0;4RIM68.:NN\U9ZC>D_'3/E$2QM/<WL:!-,L*\_C:X)JP">DD#G4)#!
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M';J!_>9N':##3!M-H,*41Q5!+AOQM/<3#9PX1\\GWSIT@_9-W3I8)#G2""%
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M*U?5]=8)23$.-8EV1/1 $2;64PN4AX#:AP=###@MP(5R8#P;;<>W\.VM U9
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M[S2.9Q=#)!)8::D:<CF36*<\RXUV+,9:3(G0R)IGPOZFN2H@9*B  %FK*V^
M=QA2(+&E1GJ*&#S6T'/PT\'#U_O%]Z+867=/D#Y?:M6@^WKS4[677B_NYN7_
MQ*46RW*Q77^'(.G^OA<4CF)O=-R():0.2V4(K$E+] 7U2AV+!?>?'"9#;813
MPX=YU&A%$ZGYRVX11X*I#XP*PD)I+*3$&*0-9)0@4R]1$IM8AB%#QIR80Q9#
M03(=UQT-JCXX+D"&H=-5Z6GB@ >64*WK90IJ+J>[0R]8M^.?)-*.P$&?(E;Q
M,U_4_,;& ^[]XFLU:_=W)6['"XNU&!T$]EI9! $S0A*FXD'7[Y;,I(=CZ;$Q
M3@,]8;\8FLBCI'K<QW?>_:.8%\O9?9RZNGDHY]4==R3)MV(W^]51#NOTGD 4
M!99SR316V#* F50U&:H[C OR= W#:T.2>QQMMEX^7J\?EW$1)IH/=RU8;/^@
M )Q!Q,9#,8"*0"299;A>8!2L1-V58>C"8)JK'\J.P#H?-W0ZRBS/'PLVDL52
MCHV!F$OED&.\7H26-)$]LDR^'X9!3J#F&/')O1Q'?FD3M=SOET+5W=!##!E!
M7C*%N1&F(64T%$;:!]_;V7%:&,>PZHZL*!H,YGZV6I6WY?87'^:^G,_FU^7L
MOM$=K>JW]?JA@*V6AB"L 43:*XBI034AH55CE>H:);AU*AY\;4E.B> (HK!;
M27'S]D)WEO(!%F_W@N"X=Y9C; U6D$8CR;*GA9/A_=-RR[KSXJZ:Z[#*?"*6
M>5WM=PA@LN'(7XOUU>WGV=\G<V;]HD"\QQ C3J5FVDEG%6PT!% L\;HWRT/W
M67%H(D!G8UB;V==R/;NO?JL>JFB;P0WL'[X85.5RD\;[B)Z'#,CGNV/R"3!#
M!T$FG)\'CDEY$X=$-9ZN[Q]OBIL/\\W\(C%K3]O>;(JTUX6JEQ[SS&)!.8^+
M,Q(VCN*H)!)C 3N[+-:+2/]+9M@10<I%8<>M1A?SXK9<5S&2W8SA?CX0('>4
M VN\EIP1QJ0"HB8< C*1N]NW+GA_QO(DP$T3D#9)P\]<(]*4T;HJ&H&%,R;N
MD0CLTOVAB:S#C^5;_8Q(.^!]A(A5S72=XE0S;TA=\2.25@*46/<YP_"+L5AP
MG(BT3JB-<:%U/YO_.GLHCH2@/7\L6(8L<\Y$RT-+8366NUXTL,J8(!?4TF!:
M'GA]#9:.P8B,=#2J[.6#@3@#X^SC1DXMMU73- %W"R' I-:OSY"9TN#;PP-)
MQ!OS"+!>7/]Y];5"Y7C?R7UC O6:<:$IA  Y(0 3OED>]G LWAC#9Y@*[#Y#
M^T1:IE5G7/Y9K#=?_M>\7.\/J3GP="#<B&C>4ZR4MYYS@KRNIRDAN"0W\8F0
M]T?%%+ _EP_%OXM5-, VX3OE=>5G;@E]F[&! 4>4<X1Q%,^8BD(GFR4 *1/#
MB[/L1=H'(PQ TQ2V,+/5E]^*]?I^8_=L,K_G.W/I"%,<'QFDCC0! G()-#2.
M4^AK4YXX+!+MSNY>R=%,A5,8HG=ZCF%#MF:9(R-"))/FS&H3.=XI;SP4K%&
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MW!,H(%54>DBP%X@W27T>69I8BP&>8WSD@)(P"CBG56BH:TWN"KP>*)O:;F
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M'%LO!"<8-,2'A@U>G$QN96E>W%7.NI^R-"J<9RU+?K&\+<JIQ>F'602A*57
M&,ZYLHH8B43C0I$$)NY.[2,,?TK4M(B>M5#E>'X"0"/.B1,&0QWM;(40KLF/
M-4TL(]$YD'%[?G+SGR(U,J(CW]!OW#6KEU-XW[?Q5$J@K61,PFBK<PYU=6<:
MX<*80W+4@3'T;7RKW!QUOYE76542>LJ^V2KXS?JKB!<=G_FSU>U\S]\,0&%+
MI)084L>\MHYK7I-8$YG81"2KM,2QF7'O??VTV(UA'C1+?9U]%FV;'U7X,Q?V
M\U6_39?-VO7WZD)FHRB[B<V(\PD" \&(4$99R[RU3DM=PU+=;EZ0EVARD<H7
MUU'%[>VEO,A^OEZ7WZ*QE" [J2\/$BMCI"86$^"L D@AV1",\D1!R+!!U>1B
M,!)$XVXAL]67C\O%=5'<K.)&6)3?BILJY?_MH\ J95,XY0O! :,,-M8)P9 2
M5,5C14TZ!]"Q4-'SZ9D[.7>/B5-2;9MFIJ]+E+?6NDGO"1!R!B-U!4&."VVJ
MDG#UTB1&8V5:7AP+CH%&"J.IU>KQ8:O/JU*!'^95^L[.FME.<B,-3S-MQW<G
MOC80SQ T!CDDHF0!C11[1EZ8>)6388WW*=AP7'!.4W^'^K&FJL+N[PS<0PF!
M$!Y:*"03V,63<BV(U"3NS!E6;)]6+0Z.3 HS/IO)8R4-LTYLUVYTT%I#394@
MU &H&=:<VWH9@J4V^LLH.6]*!AL$@Q16.MR9M9L^2WE7H-IZ1A2IRHD*PP02
MKB$?@#91CV58QGP*-AL!D>0ZF:MM"<]-^\&]53M;;J2)[PL86U7]HQ&U5:,D
MJ7ES;")4)S)?]TKAE\E](\$R[ WFX\/#;/G]ZO:W\FY>WI;7LW@"O[Y>/,ZK
MDHP?%_?E=3G-?>:/LVAQ5[E_4#!:*8(X!P1(KRW37&^OC;$5"HIC60?#+/)J
M>3>;E_^S<UK/5W'2-YL_Q/- N;JZ_?@,6OVX*N?%:F6+U?6RW)PFU/SFQQ6W
M\9\-^MT @82"Q!W=8%RU4\%4LIK4UKC$,FD9YB?UP6Z+?)')0//LZAM<@@*"
MS/*J6AV-/P",F(S6AL0($4L8=T<[0 WMJO^X7'PMENO-I=FZJK/[G\?R:[5+
MMJ\Z</@501-C-,&.@+AR!*V2G#0$4/:"LF)[8(*]CO1>B3S&95!$;'-O^X]B
M<;><??T2)?W^2&V O6."\W$E2')M$*<4 ^<=JI?'K$ILHY8A#_4/^ ]M!OJA
M\1@L5-R]GNCQO/Y]8X)F+IKXR,5MF1EI*ZKQ>GF.D,3NU3FRT.D(O^:9GHB:
M=*C^&K\SF]]\7"S7CW>S^[W9\P>>#AP+9*Q@2@!!"*X*/(%ZFO%7%Z0^3D=J
MT3<Y4U#_Y^S_+9;Q<+]>EG\\1BSV;!Q[GPW& ZJQT<QK[*#RGKA&/4*%$_-G
MLTXV[WG#Z(NV?<"_5^T?>#I8*!D0W@-.HNT5[2X"&BZ5!)Y_N8P>$#J$=1(9
M4]!^]LVK>7%8P;_U;(!:>H2QEL@9HP#BFHAZBIZD.MMS1[HK/HM^R7@BTI__
M6K1&NGDV:!=/3J":6-Q^HCXSPM!ZBM;JL>)SSQ/I5#*.8.I_JJ)\CYP.FV<"
M=M&*U=9)J % 4"'/:O7&D99C=08YX\W]5)J.Q1)':V4]>RI 2X'3A"H"B 3Q
MA*,0KI>@@;\<*S\!M;=P3R+;",C_LYR7#X\/1[%_\5RP!D%"J^1U#;2S43^B
M6J=QKI/;M>:8NI&$WJ(_XHW! [._V_' \^>"HH0B2Z+YRZ 5AL<?:@N&0YI:
M>3O+])U>>. $XHU1.7'?GJ>_MR@TVV)TP%YY+I%D%%&D%?56R'K)3*46!<HP
M#V!P0Z)_:D_)8-64C[J:6XP.5@""@+;"20FE-$1:6R]9:7,Y]8U[Q;\M;R43
M>@3>TH^17E7/LF,[V,L'@V?>,"61P<(P"(6C$#:ZW('S]V4,@NJB1YJ.P!S^
M<3DOUX_+JDRM+_^N?CI>%GC_H$#CV@35'#$M("6..MQLW1;(1*;)R"TR!M/T
M1M]1S.-(J'FQ_/Z<!BV,Y;VC B>*(\B]LU+:BFH,N'J)D8Z).U6&/I4A6:@_
M H_ 0U6\[&.D=WO^V3,B&,X=8'$AF""K@<4,@Z?S![T<,WI(WNF'N%-:S;^T
MJ"-^?' @<:MFB$4U&Q=)%95$XR<SD2>6M<DP,W:Z0UDJL4?@KET0W2Y9O%K^
MK\5ZUP;X> #FF\."\-9A97A<%Y=:$:5%XR7%@"06@SLGFSH!\-?M8_HC\%1<
M].MB?IW&2$\CHWIGGA%N)&7(46* )<TV[@%*#'+/TL4X-C<E4SDQV?2Z J)J
M"EC/875U^_N72)_5[+YX'E*QG6R5P/T4FE_EGC7C]MUA]_J1X*F0 '+$"2*
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M\5_-%>&PE@QM"+R<=AH#L$U?5!V!:;9-X?]9K+\L;IZF?=RB/C@N $*I59P
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M2P$"% ,4    " !P@T-(K/TO*H8<! #RL4D $0              @ $
M8FEI8BTR,#$U,3(S,2YX;6Q02P$"% ,4    " !P@T-(H6LTQ:XG  !K^0$
M$0              @ &U' 0 8FEI8BTR,#$U,3(S,2YX<V102P$"% ,4
M" !P@T-(E=2.2 XS  !U/@( %0              @ &21 0 8FEI8BTR,#$U
M,3(S,5]C86PN>&UL4$L! A0#%     @ <(-#2 ,BB8E*P@  ?9D) !4
M         ( !TW<$ &)I:6(M,C Q-3$R,S%?9&5F+GAM;%!+ 0(4 Q0    (
M '"#0T@G:]YN=<X! #(I&  5              "  5 Z!0!B:6EB+3(P,34Q
M,C,Q7VQA8BYX;6Q02P$"% ,4    " !P@T-(7[:-!;DG 0 $]@X %0
M        @ 'X" < 8FEI8BTR,#$U,3(S,5]P<F4N>&UL4$L%!@     &  8
*B@$  .0P"     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
